words,sentence_id,labels
Selective,0,O
costimulation,0,O
modulators,0,O
:,0,O
a,0,O
novel,0,O
approach,0,O
for,0,O
the,0,O
treatment,0,O
of,0,O
rheumatoid,0,O
arthritis,0,O
.,0,O
T,1,O
cells,1,O
have,1,O
a,1,O
central,1,O
role,1,O
in,1,O
the,1,O
orchestration,1,O
of,1,O
the,1,O
immune,1,O
pathways,1,O
that,1,O
contribute,1,O
to,1,O
the,1,O
inflammation,1,O
and,1,O
joint,1,O
destruction,1,O
characteristic,1,O
of,1,O
rheumatoid,1,O
arthritis,1,O
(,1,O
RA,1,O
),1,O
.,1,O
The,2,O
requirement,2,O
for,2,O
a,2,O
dual,2,O
signal,2,O
for,2,O
T-cell,2,O
activation,2,O
and,2,O
the,2,O
construction,2,O
of,2,O
a,2,O
fusion,2,O
protein,2,O
that,2,O
prevents,2,O
engagement,2,O
of,2,O
the,2,O
costimulatory,2,O
molecules,2,O
required,2,O
for,2,O
this,2,O
activation,2,O
has,2,O
led,2,O
to,2,O
a,2,O
new,2,O
approach,2,O
to,2,O
RA,2,O
therapy,2,O
.,2,O
This,3,O
approach,3,O
is,3,O
mechanistically,3,O
distinct,3,O
from,3,O
other,3,O
currently,3,O
used,3,O
therapies,3,O
;,3,O
it,3,O
targets,3,O
events,3,O
early,3,O
rather,3,O
than,3,O
late,3,O
in,3,O
the,3,O
immune,3,O
cascade,3,O
",",3,O
and,3,O
it,3,O
results,3,O
in,3,O
immunomodulation,3,O
rather,3,O
than,3,O
complete,3,O
immunosuppression,3,O
.,3,O
The,4,O
fusion,4,O
protein,4,O
abatacept,4,O
is,4,O
a,4,O
selective,4,O
costimulation,4,O
modulator,4,O
that,4,O
avidly,4,O
binds,4,O
to,4,O
the,4,O
CD80/CD86,4,B-GENE-Y
ligands,4,O
on,4,O
an,4,O
antigen-presenting,4,O
cell,4,O
",",4,O
resulting,4,O
in,4,O
the,4,O
inability,4,O
of,4,O
these,4,O
ligands,4,O
to,4,O
engage,4,O
the,4,O
CD28,4,B-GENE-N
receptor,4,I-GENE-N
on,4,O
the,4,O
T,4,O
cell,4,O
.,4,O
Abatacept,5,O
dose-dependently,5,O
reduces,5,O
T-cell,5,O
proliferation,5,O
",",5,O
serum,5,O
concentrations,5,O
of,5,O
acute-phase,5,O
reactants,5,O
",",5,O
and,5,O
other,5,O
markers,5,O
of,5,O
inflammation,5,O
",",5,O
including,5,O
the,5,O
production,5,O
of,5,O
rheumatoid,5,O
factor,5,O
by,5,O
B,5,O
cells,5,O
.,5,O
Recent,6,O
studies,6,O
have,6,O
provided,6,O
consistent,6,O
evidence,6,O
that,6,O
treatment,6,O
with,6,O
abatacept,6,O
results,6,O
in,6,O
a,6,O
rapid,6,O
onset,6,O
of,6,O
efficacy,6,O
that,6,O
is,6,O
maintained,6,O
over,6,O
the,6,O
course,6,O
of,6,O
treatment,6,O
in,6,O
patients,6,O
with,6,O
inadequate,6,O
response,6,O
to,6,O
methotrexate,6,B-CHEMICAL
and,6,O
anti-tumor,6,O
necrosis,6,I-GENE-N
factor,6,I-GENE-N
therapies,6,O
.,6,O
This,7,O
efficacy,7,O
includes,7,O
patient-centered,7,O
outcomes,7,O
and,7,O
radiographic,7,O
measurement,7,O
of,7,O
disease,7,O
progression,7,O
.,7,O
Abatacept,8,O
has,8,O
also,8,O
demonstrated,8,O
a,8,O
very,8,O
favorable,8,O
safety,8,O
profile,8,O
to,8,O
date,8,O
.,8,O
This,9,O
article,9,O
reviews,9,O
the,9,O
rationale,9,O
for,9,O
this,9,O
therapeutic,9,O
approach,9,O
and,9,O
highlights,9,O
some,9,O
of,9,O
the,9,O
recent,9,O
studies,9,O
that,9,O
demonstrate,9,O
the,9,O
benefits,9,O
obtained,9,O
by,9,O
using,9,O
abatacept,9,O
.,9,O
This,10,O
clinical,10,O
experience,10,O
indicates,10,O
that,10,O
abatacept,10,O
is,10,O
a,10,O
significant,10,O
addition,10,O
to,10,O
the,10,O
therapeutic,10,O
armamentarium,10,O
for,10,O
the,10,O
management,10,O
of,10,O
patients,10,O
with,10,O
RA,10,O
.,10,O
Emerging,11,O
role,11,O
of,11,O
epidermal,11,B-GENE-Y
growth,11,I-GENE-Y
factor,11,I-GENE-Y
receptor,11,I-GENE-Y
inhibition,11,O
in,11,O
therapy,11,O
for,11,O
advanced,11,O
malignancy,11,O
:,11,O
focus,11,O
on,11,O
NSCLC,11,O
.,11,O
Combination,12,O
chemotherapy,12,O
regimens,12,O
have,12,O
emerged,12,O
as,12,O
the,12,O
standard,12,O
approach,12,O
in,12,O
advanced,12,O
non-small-cell,12,O
lung,12,O
cancer,12,O
.,12,O
Meta-analyses,13,O
have,13,O
demonstrated,13,O
a,13,O
2-month,13,O
increase,13,O
in,13,O
median,13,O
survival,13,O
after,13,O
platinum-based,13,B-CHEMICAL
therapy,13,O
vs.,13,O
best,13,O
supportive,13,O
care,13,O
",",13,O
and,13,O
an,13,O
absolute,13,O
10,13,O
%,13,O
improvement,13,O
in,13,O
the,13,O
1-year,13,O
survival,13,O
rate,13,O
.,13,O
Just,14,O
as,14,O
importantly,14,O
",",14,O
cytotoxic,14,O
therapy,14,O
has,14,O
produced,14,O
benefits,14,O
in,14,O
symptom,14,O
control,14,O
and,14,O
quality,14,O
of,14,O
life,14,O
.,14,O
Newer,15,O
agents,15,O
",",15,O
including,15,O
the,15,O
taxanes,15,B-CHEMICAL
",",15,O
vinorelbine,15,B-CHEMICAL
",",15,O
gemcitabine,15,B-CHEMICAL
",",15,O
and,15,O
irinotecan,15,B-CHEMICAL
",",15,O
have,15,O
expanded,15,O
our,15,O
therapeutic,15,O
options,15,O
in,15,O
the,15,O
treatment,15,O
of,15,O
advanced,15,O
non-small-cell,15,O
lung,15,O
cancer,15,O
.,15,O
Despite,16,O
their,16,O
contributions,16,O
",",16,O
we,16,O
have,16,O
reached,16,O
a,16,O
therapeutic,16,O
plateau,16,O
",",16,O
with,16,O
response,16,O
rates,16,O
seldom,16,O
exceeding,16,O
30-40,16,O
%,16,O
in,16,O
cooperative,16,O
group,16,O
studies,16,O
and,16,O
1-year,16,O
survival,16,O
rates,16,O
stable,16,O
between,16,O
30,16,O
%,16,O
and,16,O
40,16,O
%,16,O
.,16,O
It,17,O
is,17,O
doubtful,17,O
that,17,O
substituting,17,O
one,17,O
agent,17,O
for,17,O
another,17,O
in,17,O
various,17,O
combinations,17,O
will,17,O
lead,17,O
to,17,O
any,17,O
further,17,O
improvement,17,O
in,17,O
these,17,O
rates,17,O
.,17,O
The,18,O
thrust,18,O
of,18,O
current,18,O
research,18,O
has,18,O
focused,18,O
on,18,O
targeted,18,O
therapy,18,O
",",18,O
and,18,O
epidermal,18,B-GENE-Y
growth,18,I-GENE-Y
factor,18,I-GENE-Y
receptor,18,I-GENE-Y
inhibition,18,O
is,18,O
one,18,O
of,18,O
the,18,O
most,18,O
promising,18,O
clinical,18,O
strategies,18,O
.,18,O
Epidermal,19,B-GENE-Y
growth,19,I-GENE-Y
factor,19,I-GENE-Y
receptor,19,I-GENE-Y
inhibitors,19,O
currently,19,O
under,19,O
investigation,19,O
include,19,O
the,19,O
small,19,O
molecules,19,O
gefitinib,19,B-CHEMICAL
(,19,O
Iressa,19,B-CHEMICAL
",",19,O
ZD1839,19,B-CHEMICAL
),19,O
and,19,O
erlotinib,19,B-CHEMICAL
(,19,O
Tarceva,19,B-CHEMICAL
",",19,O
OSI-774,19,B-CHEMICAL
),19,O
",",19,O
as,19,O
well,19,O
as,19,O
monoclonal,19,O
antibodies,19,O
such,19,O
as,19,O
cetuximab,19,B-CHEMICAL
(,19,O
IMC-225,19,B-CHEMICAL
",",19,O
Erbitux,19,B-CHEMICAL
),19,O
.,19,O
Agents,20,O
that,20,O
have,20,O
only,20,O
begun,20,O
to,20,O
undergo,20,O
clinical,20,O
evaluation,20,O
include,20,O
CI-1033,20,B-CHEMICAL
",",20,O
an,20,O
irreversible,20,O
pan-erbB,20,O
tyrosine,20,B-GENE-N
kinase,20,I-GENE-N
inhibitor,20,O
",",20,O
and,20,O
PKI166,20,B-CHEMICAL
and,20,O
GW572016,20,B-CHEMICAL
",",20,O
both,20,O
examples,20,O
of,20,O
dual,20,O
kinase,20,B-GENE-N
inhibitors,20,O
(,20,O
inhibiting,20,O
epidermal,20,B-GENE-Y
growth,20,I-GENE-Y
factor,20,I-GENE-Y
receptor,20,I-GENE-Y
and,20,O
Her2,20,B-GENE-Y
),20,O
.,20,O
Preclinical,21,O
models,21,O
have,21,O
demonstrated,21,O
synergy,21,O
for,21,O
all,21,O
these,21,O
agents,21,O
in,21,O
combination,21,O
with,21,O
either,21,O
chemotherapy,21,O
or,21,O
radiotherapy,21,O
",",21,O
leading,21,O
to,21,O
great,21,O
enthusiasm,21,O
regarding,21,O
their,21,O
ultimate,21,O
contribution,21,O
to,21,O
lung,21,O
cancer,21,O
therapy,21,O
.,21,O
However,22,O
",",22,O
serious,22,O
clinical,22,O
challenges,22,O
persist,22,O
.,22,O
These,23,O
include,23,O
the,23,O
identification,23,O
of,23,O
the,23,O
optimal,23,O
dose,23,O
(,23,O
s,23,O
),23,O
;,23,O
the,23,O
proper,23,O
integration,23,O
of,23,O
these,23,O
agents,23,O
into,23,O
popular,23,O
",",23,O
established,23,O
cytotoxic,23,O
regimens,23,O
;,23,O
and,23,O
the,23,O
selection,23,O
of,23,O
the,23,O
optimal,23,O
setting,23,O
(,23,O
s,23,O
),23,O
in,23,O
which,23,O
to,23,O
test,23,O
these,23,O
compounds,23,O
.,23,O
Both,24,O
gefitinib,24,B-CHEMICAL
and,24,O
erlotinib,24,B-CHEMICAL
have,24,O
shown,24,O
clinical,24,O
activity,24,O
in,24,O
pretreated,24,O
",",24,O
advanced,24,O
non-small-cell,24,O
lung,24,O
cancer,24,O
",",24,O
but,24,O
placebo-controlled,24,O
randomized,24,O
Phase,24,O
III,24,O
studies,24,O
evaluating,24,O
gefitinib,24,B-CHEMICAL
in,24,O
combination,24,O
with,24,O
standard,24,O
cytotoxic,24,O
therapy,24,O
",",24,O
to,24,O
our,24,O
chagrin,24,O
",",24,O
have,24,O
failed,24,O
to,24,O
demonstrate,24,O
a,24,O
survival,24,O
advantage,24,O
compared,24,O
with,24,O
chemotherapy,24,O
alone,24,O
.,24,O
Effects,25,O
of,25,O
chronic,25,O
social,25,O
defeat,25,O
stress,25,O
on,25,O
behavior,25,O
and,25,O
choline,25,B-GENE-Y
acetyltransferase,25,I-GENE-Y
",",25,O
78-kDa,25,B-GENE-Y
glucose-regulated,25,I-GENE-Y
protein,25,I-GENE-Y
",",25,O
and,25,O
CCAAT/enhancer-binding,25,B-GENE-Y
protein,25,I-GENE-Y
(,25,I-GENE-Y
C/EBP,25,I-GENE-Y
),25,I-GENE-Y
homologous,25,I-GENE-Y
protein,25,I-GENE-Y
in,25,O
adult,25,O
mice,25,O
.,25,O
RATIONALE,26,O
:,26,O
Social,26,O
defeat,26,O
stress,26,O
induces,26,O
physiological,26,O
and,26,O
behavioral,26,O
symptoms,26,O
",",26,O
including,26,O
anxiety,26,O
",",26,O
anhedonia,26,O
",",26,O
immune,26,O
deficits,26,O
",",26,O
and,26,O
altered,26,O
expression,26,O
of,26,O
key,26,O
brain,26,O
genes,26,O
.,26,O
OBJECTIVES,27,O
:,27,O
The,27,O
present,27,O
study,27,O
investigated,27,O
the,27,O
effects,27,O
of,27,O
social,27,O
defeat,27,O
stress,27,O
on,27,O
the,27,O
behaviors,27,O
and,27,O
expressions,27,O
of,27,O
Chat,27,B-GENE-Y
",",27,O
Grp78,27,B-GENE-Y
",",27,O
and,27,O
chop,27,B-GENE-Y
in,27,O
the,27,O
brains,27,O
of,27,O
adult,27,O
mice,27,O
.,27,O
METHODS,28,O
:,28,O
Adult,28,O
mice,28,O
were,28,O
divided,28,O
into,28,O
susceptible,28,O
and,28,O
unsusceptible,28,O
groups,28,O
after,28,O
10,28,O
days,28,O
of,28,O
social,28,O
defeat,28,O
stress,28,O
.,28,O
In,29,O
experiment,29,O
1,29,O
",",29,O
behavioral,29,O
tests,29,O
were,29,O
conducted,29,O
",",29,O
and,29,O
brains,29,O
were,29,O
processed,29,O
for,29,O
Western,29,O
blotting,29,O
at,29,O
day,29,O
27,29,O
after,29,O
stress,29,O
.,29,O
In,30,O
experiment,30,O
2,30,O
",",30,O
social,30,O
avoidance,30,O
tests,30,O
were,30,O
conducted,30,O
",",30,O
and,30,O
brains,30,O
were,30,O
processed,30,O
for,30,O
Western,30,O
blotting,30,O
at,30,O
day,30,O
12,30,O
after,30,O
stress,30,O
.,30,O
RESULTS,31,O
:,31,O
The,31,O
results,31,O
indicate,31,O
decreased,31,O
and,31,O
increased,31,O
locomotion,31,O
and,31,O
anxiety,31,O
behavior,31,O
in,31,O
all,31,O
defeated,31,O
mice,31,O
.,31,O
Decrease,32,O
in,32,O
social,32,O
interaction,32,O
",",32,O
increased,32,O
immobility,32,O
",",32,O
and,32,O
impaired,32,O
memory,32,O
performance,32,O
were,32,O
only,32,O
observed,32,O
in,32,O
susceptible,32,O
mice,32,O
.,32,O
A,33,O
decrease,33,O
in,33,O
the,33,O
Chat,33,O
level,33,O
at,33,O
days,33,O
12,33,O
and,33,O
27,33,O
was,33,O
noted,33,O
in,33,O
the,33,O
prefrontal,33,O
cortex,33,O
(,33,O
PFC,33,O
),33,O
",",33,O
amygdala,33,O
(,33,O
Amyg,33,O
),33,O
",",33,O
and,33,O
dorsal,33,O
hippocampus,33,O
(,33,O
HIP,33,O
),33,O
in,33,O
defeated,33,O
mice,33,O
.,33,O
The,34,O
expression,34,O
levels,34,O
of,34,O
Grp78,34,B-GENE-Y
and,34,O
chop,34,B-GENE-Y
measured,34,O
on,34,O
days,34,O
12,34,O
and,34,O
27,34,O
were,34,O
significantly,34,O
greater,34,O
in,34,O
the,34,O
Amyg,34,O
of,34,O
susceptible,34,O
mice,34,O
.,34,O
In,35,O
the,35,O
PFC,35,O
and,35,O
HIP,35,O
",",35,O
defeated,35,O
mice,35,O
displayed,35,O
different,35,O
patterns,35,O
in,35,O
the,35,O
levels,35,O
of,35,O
Grp78,35,B-GENE-Y
and,35,O
chop,35,B-GENE-Y
expressions,35,O
measured,35,O
on,35,O
days,35,O
12,35,O
and,35,O
27,35,O
.,35,O
CONCLUSIONS,36,O
:,36,O
The,36,O
present,36,O
study,36,O
demonstrated,36,O
that,36,O
chronic,36,O
social,36,O
defeat,36,O
stress,36,O
in,36,O
mice,36,O
produces,36,O
stress-related,36,O
behaviors,36,O
.,36,O
Different,37,O
response,37,O
patterns,37,O
were,37,O
noted,37,O
for,37,O
Grp78,37,B-GENE-Y
and,37,O
chop,37,B-GENE-Y
expression,37,O
among,37,O
the,37,O
groups,37,O
in,37,O
terms,37,O
of,37,O
brain,37,O
regions,37,O
and,37,O
time-course,37,O
effects,37,O
.,37,O
Hepatocyte,38,B-GENE-Y
growth,38,I-GENE-Y
factor,38,I-GENE-Y
activator,38,I-GENE-Y
inhibitor,38,I-GENE-Y
type,38,I-GENE-Y
2,38,I-GENE-Y
(,38,O
HAI-2,38,B-GENE-Y
),38,O
modulates,38,O
hepcidin,38,B-GENE-Y
expression,38,O
by,38,O
inhibiting,38,O
the,38,O
cell,38,O
surface,38,O
protease,38,B-GENE-N
matriptase-2,38,B-GENE-Y
.,38,O
Matriptase-2,39,B-GENE-Y
",",39,O
a,39,O
recently,39,O
identified,39,O
cell,39,O
surface,39,O
protease,39,B-GENE-N
",",39,O
is,39,O
the,39,O
key,39,O
enzyme,39,O
of,39,O
iron,39,B-CHEMICAL
homoeostasis,39,O
modulating,39,O
the,39,O
expression,39,O
of,39,O
the,39,O
liver,39,O
peptide,39,O
hormone,39,O
hepcidin,39,B-GENE-Y
.,39,O
HAI,40,B-GENE-N
(,40,B-GENE-N
hepatocyte,40,I-GENE-N
growth,40,I-GENE-N
factor,40,I-GENE-N
activator,40,I-GENE-N
inhibitor,40,I-GENE-N
),40,I-GENE-N
types,40,I-GENE-N
1,40,I-GENE-N
and,40,I-GENE-N
2,40,I-GENE-N
(,40,O
HAI-1,40,B-GENE-Y
and,40,O
HAI-2,40,B-GENE-Y
respectively,40,O
),40,O
have,40,O
been,40,O
shown,40,O
to,40,O
inhibit,40,O
the,40,O
close,40,O
homologue,40,O
",",40,O
i.e,40,O
.,40,O
matriptase,41,B-GENE-N
.,41,O
By,42,O
co-expressing,42,O
matriptase-2,42,B-GENE-Y
and,42,O
the,42,O
inhibitor,42,O
HAI-2,42,B-GENE-Y
we,42,O
have,42,O
identified,42,O
HAI-2,42,B-GENE-Y
displaying,42,O
high,42,O
inhibitory,42,O
potential,42,O
against,42,O
matriptase-2,42,B-GENE-N
at,42,O
the,42,O
cell,42,O
surface,42,O
as,42,O
well,42,O
as,42,O
in,42,O
conditioned,42,O
medium,42,O
.,42,O
Accordingly,43,O
",",43,O
complex,43,O
formation,43,O
between,43,O
matriptase-2,43,B-GENE-Y
and,43,O
HAI-2,43,B-GENE-Y
was,43,O
demonstrated,43,O
by,43,O
isolation,43,O
of,43,O
the,43,O
complex,43,O
via,43,O
immobilizing,43,O
either,43,O
HAI-2,43,B-GENE-Y
or,43,O
matriptase-2,43,B-GENE-Y
from,43,O
lysates,43,O
and,43,O
conditioned,43,O
medium,43,O
of,43,O
co-expressing,43,O
cells,43,O
.,43,O
Furthermore,44,O
",",44,O
HAI-2,44,B-GENE-Y
indirectly,44,O
influences,44,O
the,44,O
expression,44,O
of,44,O
the,44,O
hepcidin-encoding,44,B-GENE-Y
gene,44,O
HAMP,44,B-GENE-Y
.,44,O
The,45,O
inhibitor,45,O
abrogates,45,O
the,45,O
matriptase-2-mediated,45,B-GENE-Y
suppression,45,O
of,45,O
HAMP,45,B-GENE-Y
expression,45,O
",",45,O
presumably,45,O
by,45,O
inhibiting,45,O
the,45,O
supposed,45,O
potential,45,O
of,45,O
matriptase-2,45,B-GENE-Y
to,45,O
cleave,45,O
membrane-bound,45,O
HJV,45,O
(,45,O
haemojuvelin,45,O
),45,O
.,45,O
Taken,46,O
together,46,O
",",46,O
the,46,O
results,46,O
of,46,O
the,46,O
present,46,O
study,46,O
have,46,O
characterized,46,O
HAI-2,46,B-GENE-Y
as,46,O
an,46,O
inhibitor,46,O
of,46,O
matriptase-2,46,B-GENE-Y
that,46,O
modulates,46,O
the,46,O
synthesis,46,O
of,46,O
hepcidin,46,B-GENE-Y
and,46,O
provides,46,O
new,46,O
insights,46,O
into,46,O
the,46,O
regulatory,46,O
mechanism,46,O
of,46,O
iron,46,B-CHEMICAL
homoeostasis,46,O
",",46,O
with,46,O
clinical,46,O
importance,46,O
for,46,O
a,46,O
treatment,46,O
of,46,O
iron,46,B-CHEMICAL
overload,46,O
diseases,46,O
.,46,O
Alprenolol,47,B-CHEMICAL
and,47,O
bromoacetylalprenololmenthane,47,B-CHEMICAL
are,47,O
competitive,47,O
slowly,47,O
reversible,47,O
antagonists,47,O
at,47,O
the,47,O
beta,47,B-GENE-Y
1-adrenoceptors,47,I-GENE-Y
of,47,O
rat,47,O
left,47,O
atria,47,O
.,47,O
We,48,O
studied,48,O
the,48,O
effects,48,O
of,48,O
alprenolol,48,B-CHEMICAL
and,48,O
bromoacetylalprenololmenthane,48,B-CHEMICAL
(,48,O
BAAM,48,B-CHEMICAL
),48,O
on,48,O
rat,48,O
left,48,O
atria,48,O
.,48,O
Alprenolol,49,B-CHEMICAL
and,49,O
BAAM,49,B-CHEMICAL
at,49,O
10,49,O
(,49,O
-7,49,O
),49,O
",",49,O
3,49,O
x,49,O
10,49,O
(,49,O
-7,49,O
),49,O
",",49,O
and,49,O
10,49,O
(,49,O
-6,49,O
),49,O
M,49,O
inhibited,49,O
the,49,O
cardiac,49,O
stimulation,49,O
response,49,O
slightly,49,O
",",49,O
which,49,O
is,49,O
indicative,49,O
of,49,O
membrane-stabilizing,49,O
activity,49,O
independent,49,O
of,49,O
beta-adrenoceptor,49,B-GENE-N
blockade,49,O
.,49,O
This,50,O
membrane-stabilizing,50,O
activity,50,O
was,50,O
readily,50,O
reversible,50,O
.,50,O
Alprenolol,51,B-CHEMICAL
and,51,O
BAAM,51,B-CHEMICAL
also,51,O
caused,51,O
surmountable,51,O
antagonism,51,O
of,51,O
isoprenaline,51,B-CHEMICAL
responses,51,O
",",51,O
and,51,O
this,51,O
beta,51,B-GENE-Y
1-adrenoceptor,51,I-GENE-Y
antagonism,51,O
was,51,O
slowly,51,O
reversible,51,O
.,51,O
Inhibition,52,O
of,52,O
the,52,O
isoprenaline,52,B-CHEMICAL
responses,52,O
with,52,O
alprenolol,52,B-CHEMICAL
and,52,O
BAAM,52,B-CHEMICAL
at,52,O
10,52,O
(,52,O
-6,52,O
),52,O
M,52,O
was,52,O
at,52,O
equilibrium,52,O
after,52,O
60,52,O
min,52,O
",",52,O
which,52,O
is,52,O
indicative,52,O
of,52,O
reversible,52,O
antagonism,52,O
.,52,O
We,53,O
conclude,53,O
that,53,O
alprenolol,53,B-CHEMICAL
and,53,O
BAAM,53,B-CHEMICAL
are,53,O
competitive,53,O
slowly,53,O
reversible,53,O
beta,53,B-GENE-Y
1-adrenoceptor,53,I-GENE-Y
antagonists,53,O
on,53,O
rat,53,O
left,53,O
atria,53,O
.,53,O
Covalent,54,O
linkage,54,O
of,54,O
apolipoprotein,54,B-GENE-Y
e,54,I-GENE-Y
to,54,O
albumin,54,B-GENE-Y
nanoparticles,54,O
strongly,54,O
enhances,54,O
drug,54,O
transport,54,O
into,54,O
the,54,O
brain,54,O
.,54,O
Drug,55,O
delivery,55,O
to,55,O
the,55,O
brain,55,O
is,55,O
becoming,55,O
more,55,O
and,55,O
more,55,O
important,55,O
but,55,O
is,55,O
severely,55,O
restricted,55,O
by,55,O
the,55,O
blood-brain,55,O
barrier,55,O
.,55,O
Nanoparticles,56,O
coated,56,O
with,56,O
polysorbates,56,B-CHEMICAL
have,56,O
previously,56,O
been,56,O
shown,56,O
to,56,O
enable,56,O
the,56,O
transport,56,O
of,56,O
several,56,O
drugs,56,O
across,56,O
the,56,O
blood-brain,56,O
barrier,56,O
",",56,O
which,56,O
under,56,O
normal,56,O
circumstances,56,O
is,56,O
impermeable,56,O
to,56,O
these,56,O
compounds,56,O
.,56,O
Apolipoprotein,57,B-GENE-Y
E,57,I-GENE-Y
was,57,O
suggested,57,O
to,57,O
mediate,57,O
this,57,O
drug,57,O
transport,57,O
across,57,O
the,57,O
blood-brain,57,O
barrier,57,O
.,57,O
In,58,O
the,58,O
present,58,O
study,58,O
",",58,O
apolipoprotein,58,B-GENE-Y
E,58,I-GENE-Y
was,58,O
coupled,58,O
by,58,O
chemical,58,O
methods,58,O
to,58,O
nanoparticles,58,O
made,58,O
of,58,O
human,58,B-GENE-Y
serum,58,I-GENE-Y
albumin,58,I-GENE-Y
(,58,O
HSA-NP,58,B-GENE-Y
),58,O
.,58,O
Loperamide,59,B-CHEMICAL
",",59,O
which,59,O
does,59,O
not,59,O
cross,59,O
the,59,O
blood-brain,59,O
barrier,59,O
but,59,O
exerts,59,O
antinociceptive,59,O
effects,59,O
after,59,O
direct,59,O
injection,59,O
into,59,O
the,59,O
brain,59,O
",",59,O
was,59,O
used,59,O
as,59,O
model,59,O
drug,59,O
.,59,O
Apolipoprotein,60,B-GENE-Y
E,60,I-GENE-Y
was,60,O
chemically,60,O
bound,60,O
via,60,O
linkers,60,O
to,60,O
loperamide-loaded,60,B-CHEMICAL
HSA-NP,60,B-GENE-Y
.,60,O
This,61,O
preparation,61,O
induced,61,O
antinociceptive,61,O
effects,61,O
in,61,O
the,61,O
tail-flick,61,O
test,61,O
in,61,O
ICR,61,O
mice,61,O
after,61,O
i.v,61,O
.,61,O
injection,62,O
.,62,O
In,63,O
contrast,63,O
",",63,O
nanoparticles,63,O
linked,63,O
to,63,O
apolipoprotein,63,B-GENE-Y
E,63,I-GENE-Y
variants,63,O
that,63,O
do,63,O
not,63,O
recognize,63,O
lipoprotein,63,B-GENE-N
receptors,63,I-GENE-N
failed,63,O
to,63,O
induce,63,O
these,63,O
effects,63,O
.,63,O
These,64,O
results,64,O
indicate,64,O
that,64,O
apolipoprotein,64,B-GENE-Y
E,64,I-GENE-Y
attached,64,O
to,64,O
the,64,O
surface,64,O
of,64,O
nanoparticles,64,O
facilitates,64,O
transport,64,O
of,64,O
drugs,64,O
across,64,O
the,64,O
blood-brain,64,O
barrier,64,O
",",64,O
probably,64,O
after,64,O
interaction,64,O
with,64,O
lipoprotein,64,B-GENE-N
receptors,64,I-GENE-N
on,64,O
the,64,O
brain,64,O
capillary,64,O
endothelial,64,O
cell,64,O
membranes,64,O
.,64,O
Discovery,65,O
and,65,O
optimization,65,O
of,65,O
anthranilic,65,B-CHEMICAL
acid,65,I-CHEMICAL
sulfonamides,65,I-CHEMICAL
as,65,O
inhibitors,65,O
of,65,O
methionine,65,B-GENE-Y
aminopeptidase-2,65,I-GENE-Y
:,65,O
a,65,O
structural,65,O
basis,65,O
for,65,O
the,65,O
reduction,65,O
of,65,O
albumin,65,B-GENE-Y
binding,65,O
.,65,O
Methionine,66,B-GENE-Y
aminopeptidase-2,66,I-GENE-Y
(,66,O
MetAP2,66,B-GENE-Y
),66,O
is,66,O
a,66,O
novel,66,O
target,66,O
for,66,O
cancer,66,O
therapy,66,O
.,66,O
As,67,O
part,67,O
of,67,O
an,67,O
effort,67,O
to,67,O
discover,67,O
orally,67,O
active,67,O
reversible,67,O
inhibitors,67,O
of,67,O
MetAP2,67,B-GENE-Y
",",67,O
a,67,O
series,67,O
of,67,O
anthranilic,67,B-CHEMICAL
acid,67,I-CHEMICAL
sulfonamides,67,I-CHEMICAL
with,67,O
micromolar,67,O
affinities,67,O
for,67,O
human,67,B-GENE-Y
MetAP2,67,I-GENE-Y
were,67,O
identified,67,O
using,67,O
affinity,67,O
selection,67,O
by,67,O
mass,67,O
spectrometry,67,O
(,67,O
ASMS,67,O
),67,O
screening,67,O
.,67,O
These,68,O
micromolar,68,O
hits,68,O
were,68,O
rapidly,68,O
improved,68,O
to,68,O
nanomolar,68,O
leads,68,O
on,68,O
the,68,O
basis,68,O
of,68,O
insights,68,O
from,68,O
protein,68,O
crystallography,68,O
;,68,O
however,68,O
",",68,O
the,68,O
compounds,68,O
displayed,68,O
extensive,68,O
binding,68,O
to,68,O
human,68,B-GENE-Y
serum,68,I-GENE-Y
albumin,68,I-GENE-Y
and,68,O
had,68,O
limited,68,O
activity,68,O
in,68,O
cellular,68,O
assays,68,O
.,68,O
Modifications,69,O
based,69,O
on,69,O
structural,69,O
information,69,O
on,69,O
the,69,O
binding,69,O
of,69,O
lead,69,O
compounds,69,O
to,69,O
both,69,O
MetAP2,69,B-GENE-Y
and,69,O
domain,69,B-GENE-N
III,69,I-GENE-N
of,69,I-GENE-N
albumin,69,I-GENE-N
allowed,69,O
the,69,O
identification,69,O
of,69,O
compounds,69,O
with,69,O
significant,69,O
improvements,69,O
in,69,O
both,69,O
parameters,69,O
",",69,O
which,69,O
showed,69,O
good,69,O
cellular,69,O
activity,69,O
in,69,O
both,69,O
proliferation,69,O
and,69,O
methionine,69,B-CHEMICAL
processing,69,O
assays,69,O
.,69,O
Keratinocyte,70,B-GENE-Y
growth,70,I-GENE-Y
factor,70,I-GENE-Y
and,70,O
acidic,70,B-GENE-Y
fibroblast,70,I-GENE-Y
growth,70,I-GENE-Y
factor,70,I-GENE-Y
are,70,O
mitogens,70,O
for,70,O
primary,70,O
cultures,70,O
of,70,O
mammary,70,O
epithelium,70,O
.,70,O
Mammary,71,O
epithelial,71,O
cells,71,O
derived,71,O
from,71,O
the,71,O
entire,71,O
mammary,71,O
parenchyma,71,O
or,71,O
only,71,O
end,71,O
buds,71,O
were,71,O
isolated,71,O
by,71,O
collagenase,71,B-GENE-N
digestion,71,O
of,71,O
mammary,71,O
glands,71,O
from,71,O
virgin,71,O
mice,71,O
.,71,O
Cells,72,O
were,72,O
cultured,72,O
within,72,O
collagen,72,O
gels,72,O
in,72,O
serum-free,72,O
medium,72,O
containing,72,O
insulin,72,B-GENE-Y
.,72,O
Keratinocyte,73,B-GENE-Y
growth,73,I-GENE-Y
factor,73,I-GENE-Y
(,73,O
KGF,73,B-GENE-Y
or,73,O
FGF-7,73,B-GENE-Y
),73,O
and,73,O
acidic,73,B-GENE-Y
fibroblast,73,I-GENE-Y
growth,73,I-GENE-Y
factor,73,I-GENE-Y
(,73,O
aFGF,73,B-GENE-Y
or,73,O
FGF-1,73,B-GENE-Y
),73,O
stimulated,73,O
multifold,73,O
proliferation,73,O
when,73,O
added,73,O
alone,73,O
to,73,O
this,73,O
medium,73,O
.,73,O
Growth,74,O
occurred,74,O
as,74,O
three-dimensional,74,O
colonies,74,O
within,74,O
the,74,O
collagen,74,B-GENE-N
gel,74,O
matrix,74,O
.,74,O
KGF,75,B-GENE-Y
stimulated,75,O
growth,75,O
was,75,O
unaffected,75,O
by,75,O
adding,75,O
heparin,75,O
.,75,O
Conversely,76,O
",",76,O
multifold,76,O
growth,76,O
stimulation,76,O
by,76,O
acidic,76,B-GENE-Y
FGF,76,I-GENE-Y
required,76,O
heparin,76,O
.,76,O
Since,77,O
end,77,O
buds,77,O
are,77,O
the,77,O
actively,77,O
proliferating,77,O
cell,77,O
population,77,O
of,77,O
ductal,77,O
glands,77,O
",",77,O
organ,77,O
cultures,77,O
of,77,O
these,77,O
structures,77,O
were,77,O
prepared,77,O
.,77,O
KGF,78,B-GENE-Y
stimulated,78,O
3H-thymidine,78,B-CHEMICAL
incorporation,78,O
in,78,O
these,78,O
end,78,O
buds,78,O
in,78,O
the,78,O
absence,78,O
and,78,O
presence,78,O
of,78,O
epidermal,78,B-GENE-Y
growth,78,I-GENE-Y
factor,78,I-GENE-Y
.,78,O
These,79,O
data,79,O
suggest,79,O
that,79,O
acidic,79,B-GENE-Y
FGF,79,I-GENE-Y
and,79,O
KGF,79,B-GENE-Y
may,79,O
represent,79,O
in,79,O
vivo,79,O
stromal,79,O
factors,79,O
capable,79,O
of,79,O
regulating,79,O
mammary,79,O
gland,79,O
development,79,O
.,79,O
Configuration,80,O
of,80,O
a,80,O
scintillation,80,O
proximity,80,O
assay,80,O
for,80,O
the,80,O
activity,80,O
assessment,80,O
of,80,O
recombinant,80,O
human,80,B-GENE-Y
adenine,80,I-GENE-Y
phosphoribosyltransferase,80,I-GENE-Y
.,80,O
Adenine,81,B-GENE-Y
phosphoribosyltransferase,81,I-GENE-Y
plays,81,O
a,81,O
role,81,O
in,81,O
purine,81,B-CHEMICAL
salvage,81,O
by,81,O
catalyzing,81,O
the,81,O
direct,81,O
conversion,81,O
of,81,O
adenine,81,B-CHEMICAL
to,81,O
adenosine,81,B-CHEMICAL
monophosphate,81,I-CHEMICAL
.,81,O
The,82,O
involvement,82,O
of,82,O
the,82,O
purine,82,B-CHEMICAL
salvage,82,O
pathway,82,O
in,82,O
tumor,82,O
proliferation,82,O
and,82,O
angiogenesis,82,O
makes,82,O
adenine,82,B-GENE-Y
phosphoribosyltransferase,82,I-GENE-Y
a,82,O
potential,82,O
target,82,O
for,82,O
oncology,82,O
drug,82,O
discovery,82,O
.,82,O
We,83,O
have,83,O
expressed,83,O
and,83,O
characterized,83,O
recombinant,83,O
",",83,O
N-terminally,83,B-CHEMICAL
His-tagged,83,B-CHEMICAL
human,83,B-GENE-Y
adenine,83,I-GENE-Y
phosphoribosyltransferase,83,I-GENE-Y
.,83,O
Two,84,O
assay,84,O
formats,84,O
were,84,O
assessed,84,O
for,84,O
use,84,O
in,84,O
a,84,O
high,84,O
throughput,84,O
screen,84,O
:,84,O
a,84,O
spectrophotometric-based,84,O
enzyme-coupled,84,O
assay,84,O
system,84,O
and,84,O
a,84,O
radiometric,84,O
ionic,84,O
capture,84,O
scintillation,84,O
proximity,84,O
bead,84,O
assay,84,O
format,84,O
.,84,O
Ultimately,85,O
",",85,O
the,85,O
scintillation,85,O
proximity,85,O
assay,85,O
format,85,O
was,85,O
chosen,85,O
because,85,O
of,85,O
automated,85,O
screening,85,O
compatibility,85,O
limitations,85,O
of,85,O
the,85,O
coupled,85,O
assay,85,O
.,85,O
We,86,O
describe,86,O
here,86,O
the,86,O
biochemical,86,O
characterization,86,O
of,86,O
adenine,86,B-GENE-Y
phosphoribosyltransferase,86,I-GENE-Y
and,86,O
the,86,O
development,86,O
of,86,O
a,86,O
robust,86,O
",",86,O
homogeneous,86,O
",",86,O
384-well,86,O
assay,86,O
suitable,86,O
for,86,O
high,86,O
throughput,86,O
screening,86,O
.,86,O
Cholinesterase,87,B-GENE-Y
inhibitors,87,O
for,87,O
Alzheimer,87,O
's,87,O
disease,87,O
.,87,O
BACKGROUND,88,O
:,88,O
Since,88,O
the,88,O
introduction,88,O
of,88,O
the,88,O
first,88,O
cholinesterase,88,B-GENE-Y
inhibitor,88,O
(,88,O
ChEI,88,O
),88,O
in,88,O
1997,88,O
",",88,O
most,88,O
clinicians,88,O
and,88,O
probably,88,O
most,88,O
patients,88,O
would,88,O
consider,88,O
the,88,O
cholinergic,88,O
drugs,88,O
",",88,O
donepezil,88,B-CHEMICAL
",",88,O
galantamine,88,B-CHEMICAL
and,88,O
rivastigmine,88,B-CHEMICAL
",",88,O
to,88,O
be,88,O
the,88,O
first,88,O
line,88,O
pharmacotherapy,88,O
for,88,O
mild,88,O
to,88,O
moderate,88,O
Alzheimer,88,O
's,88,O
disease.The,88,O
drugs,88,O
have,88,O
slightly,88,O
different,88,O
pharmacological,88,O
properties,88,O
",",88,O
but,88,O
they,88,O
all,88,O
work,88,O
by,88,O
inhibiting,88,O
the,88,O
breakdown,88,O
of,88,O
acetylcholine,88,B-CHEMICAL
",",88,O
an,88,O
important,88,O
neurotransmitter,88,O
associated,88,O
with,88,O
memory,88,O
",",88,O
by,88,O
blocking,88,O
the,88,O
enzyme,88,O
acetylcholinesterase,88,B-GENE-Y
.,88,O
The,89,O
most,89,O
that,89,O
these,89,O
drugs,89,O
could,89,O
achieve,89,O
is,89,O
to,89,O
modify,89,O
the,89,O
manifestations,89,O
of,89,O
Alzheimer,89,O
's,89,O
disease,89,O
.,89,O
Cochrane,90,O
reviews,90,O
of,90,O
each,90,O
ChEI,90,O
for,90,O
Alzheimer,90,O
's,90,O
disease,90,O
have,90,O
been,90,O
completed,90,O
(,90,O
Birks,90,O
2005,90,O
",",90,O
Birks,90,O
2005b,90,O
and,90,O
Loy,90,O
2005,90,O
),90,O
.,90,O
Despite,91,O
the,91,O
evidence,91,O
from,91,O
the,91,O
clinical,91,O
studies,91,O
and,91,O
the,91,O
intervening,91,O
clinical,91,O
experience,91,O
the,91,O
debate,91,O
on,91,O
whether,91,O
ChEIs,91,O
are,91,O
effective,91,O
continues,91,O
.,91,O
OBJECTIVES,92,O
:,92,O
To,92,O
assess,92,O
the,92,O
effects,92,O
of,92,O
donepezil,92,B-CHEMICAL
",",92,O
galantamine,92,B-CHEMICAL
and,92,O
rivastigmine,92,B-CHEMICAL
in,92,O
people,92,O
with,92,O
mild,92,O
",",92,O
moderate,92,O
or,92,O
severe,92,O
dementia,92,O
due,92,O
to,92,O
Alzheimer,92,O
's,92,O
disease,92,O
.,92,O
SEARCH,93,O
STRATEGY,93,O
:,93,O
The,93,O
Cochrane,93,O
Dementia,93,O
and,93,O
Cognitive,93,O
Improvement,93,O
Group,93,O
's,93,O
Specialized,93,O
Register,93,O
was,93,O
searched,93,O
using,93,O
the,93,O
terms,93,O
'donepezil,93,O
',93,O
",",93,O
'E2020,93,O
',93,O
",",93,O
'Aricept,93,O
',93,O
",",93,O
galanthamin,93,B-CHEMICAL
*,93,O
galantamin,93,B-CHEMICAL
*,93,O
reminyl,93,B-CHEMICAL
",",93,O
rivastigmine,93,B-CHEMICAL
",",93,O
exelon,93,B-CHEMICAL
",",93,O
``,93,O
ENA,93,B-CHEMICAL
713,93,I-CHEMICAL
'',93,O
and,93,O
ENA-713,93,B-CHEMICAL
on,93,O
12,93,O
June,93,O
2005,93,O
.,93,O
This,94,O
Register,94,O
contains,94,O
up-to-date,94,O
records,94,O
of,94,O
all,94,O
major,94,O
health,94,O
care,94,O
databases,94,O
and,94,O
many,94,O
ongoing,94,O
trial,94,O
databases,94,O
.,94,O
SELECTION,95,O
CRITERIA,95,O
:,95,O
All,95,O
unconfounded,95,O
",",95,O
blinded,95,O
",",95,O
randomized,95,O
trials,95,O
in,95,O
which,95,O
treatment,95,O
with,95,O
a,95,O
ChEI,95,O
was,95,O
compared,95,O
with,95,O
placebo,95,O
or,95,O
another,95,O
ChEI,95,O
for,95,O
patients,95,O
with,95,O
mild,95,O
",",95,O
moderate,95,O
or,95,O
severe,95,O
dementia,95,O
due,95,O
to,95,O
Alzheimer,95,O
's,95,O
disease,95,O
.,95,O
DATA,96,O
COLLECTION,96,O
AND,96,O
ANALYSIS,96,O
:,96,O
Data,96,O
were,96,O
extracted,96,O
by,96,O
one,96,O
reviewer,96,O
(,96,O
JSB,96,O
),96,O
",",96,O
pooled,96,O
where,96,O
appropriate,96,O
and,96,O
possible,96,O
",",96,O
and,96,O
the,96,O
pooled,96,O
treatment,96,O
effects,96,O
",",96,O
or,96,O
the,96,O
risks,96,O
and,96,O
benefits,96,O
of,96,O
treatment,96,O
estimated,96,O
.,96,O
MAIN,97,O
RESULTS,97,O
:,97,O
The,97,O
results,97,O
of,97,O
13,97,O
randomized,97,O
",",97,O
double,97,O
blind,97,O
",",97,O
placebo,97,O
controlled,97,O
trials,97,O
demonstrate,97,O
that,97,O
treatment,97,O
for,97,O
periods,97,O
of,97,O
6,97,O
months,97,O
and,97,O
one,97,O
year,97,O
",",97,O
with,97,O
donepezil,97,B-CHEMICAL
",",97,O
galantamine,97,B-CHEMICAL
or,97,O
rivastigmine,97,B-CHEMICAL
at,97,O
the,97,O
recommended,97,O
dose,97,O
for,97,O
people,97,O
with,97,O
mild,97,O
",",97,O
moderate,97,O
or,97,O
severe,97,O
dementia,97,O
due,97,O
to,97,O
Alzheimer,97,O
's,97,O
disease,97,O
produced,97,O
improvements,97,O
in,97,O
cognitive,97,O
function,97,O
",",97,O
on,97,O
average,97,O
-2.7,97,O
points,97,O
(,97,O
95,97,O
%,97,O
CI,97,O
-3.0,97,O
to,97,O
-2.3,97,O
),97,O
",",97,O
in,97,O
the,97,O
midrange,97,O
of,97,O
the,97,O
70,97,O
point,97,O
ADAS-Cog,97,O
Scale,97,O
.,97,O
Study,98,O
clinicians,98,O
blind,98,O
to,98,O
other,98,O
measures,98,O
rated,98,O
global,98,O
clinical,98,O
state,98,O
more,98,O
positively,98,O
in,98,O
treated,98,O
patients,98,O
.,98,O
Benefits,99,O
of,99,O
treatment,99,O
were,99,O
also,99,O
seen,99,O
on,99,O
measures,99,O
of,99,O
activities,99,O
of,99,O
daily,99,O
living,99,O
and,99,O
behaviour,99,O
.,99,O
None,100,O
of,100,O
these,100,O
treatment,100,O
effects,100,O
are,100,O
large,100,O
.,100,O
There,101,O
is,101,O
nothing,101,O
to,101,O
suggest,101,O
the,101,O
effects,101,O
are,101,O
less,101,O
for,101,O
patients,101,O
with,101,O
severe,101,O
dementia,101,O
or,101,O
mild,101,O
dementia,101,O
",",101,O
although,101,O
there,101,O
is,101,O
very,101,O
little,101,O
evidence,101,O
for,101,O
other,101,O
than,101,O
mild,101,O
to,101,O
moderate,101,O
dementia.More,101,O
patients,101,O
leave,101,O
ChEI,101,O
treatment,101,O
groups,101,O
",",101,O
approximately,101,O
29,101,O
%,101,O
",",101,O
on,101,O
account,101,O
of,101,O
adverse,101,O
events,101,O
than,101,O
leave,101,O
the,101,O
placebo,101,O
groups,101,O
(,101,O
18,101,O
%,101,O
),101,O
.,101,O
There,102,O
is,102,O
evidence,102,O
of,102,O
more,102,O
adverse,102,O
events,102,O
in,102,O
total,102,O
in,102,O
the,102,O
patients,102,O
treated,102,O
with,102,O
a,102,O
ChEI,102,O
than,102,O
with,102,O
placebo,102,O
.,102,O
Although,103,O
many,103,O
types,103,O
of,103,O
adverse,103,O
event,103,O
were,103,O
reported,103,O
",",103,O
nausea,103,O
",",103,O
vomiting,103,O
",",103,O
diarrhoea,103,O
",",103,O
were,103,O
significantly,103,O
more,103,O
frequent,103,O
in,103,O
the,103,O
ChEI,103,O
groups,103,O
than,103,O
in,103,O
placebo,103,O
.,103,O
There,104,O
are,104,O
four,104,O
studies,104,O
",",104,O
all,104,O
supported,104,O
by,104,O
one,104,O
of,104,O
the,104,O
pharmaceutical,104,O
companies,104,O
",",104,O
in,104,O
which,104,O
two,104,O
ChEIs,104,O
were,104,O
compared,104,O
",",104,O
two,104,O
studies,104,O
of,104,O
donepezil,104,B-CHEMICAL
compared,104,O
with,104,O
galantamine,104,B-CHEMICAL
",",104,O
and,104,O
two,104,O
of,104,O
donepezil,104,B-CHEMICAL
compared,104,O
with,104,O
rivastigmine,104,B-CHEMICAL
.,104,O
In,105,O
three,105,O
studies,105,O
the,105,O
patients,105,O
were,105,O
not,105,O
blinded,105,O
to,105,O
treatment,105,O
",",105,O
only,105,O
the,105,O
fourth,105,O
",",105,O
DON,105,O
vs,105,O
RIV/Bullock,105,O
is,105,O
double,105,O
blind,105,O
.,105,O
Two,106,O
of,106,O
the,106,O
studies,106,O
provide,106,O
little,106,O
evidence,106,O
",",106,O
they,106,O
are,106,O
of,106,O
12,106,O
weeks,106,O
duration,106,O
",",106,O
which,106,O
is,106,O
barely,106,O
long,106,O
enough,106,O
to,106,O
complete,106,O
the,106,O
drug,106,O
titration,106,O
.,106,O
There,107,O
is,107,O
no,107,O
evidence,107,O
from,107,O
DON,107,O
vs,107,O
GAL/Wilcock,107,O
of,107,O
a,107,O
treatment,107,O
difference,107,O
between,107,O
donepezil,107,B-CHEMICAL
and,107,O
galantamine,107,B-CHEMICAL
at,107,O
52,107,O
weeks,107,O
for,107,O
cognition,107,O
",",107,O
activities,107,O
of,107,O
daily,107,O
living,107,O
",",107,O
the,107,O
numbers,107,O
who,107,O
leave,107,O
the,107,O
trial,107,O
before,107,O
the,107,O
end,107,O
of,107,O
treatment,107,O
",",107,O
the,107,O
number,107,O
who,107,O
suffer,107,O
any,107,O
adverse,107,O
event,107,O
",",107,O
or,107,O
any,107,O
specific,107,O
adverse,107,O
event,107,O
.,107,O
There,108,O
is,108,O
no,108,O
evidence,108,O
from,108,O
DON,108,O
vs,108,O
RIV/Bullock,108,O
of,108,O
a,108,O
difference,108,O
between,108,O
donepezil,108,B-CHEMICAL
and,108,O
rivastigmine,108,B-CHEMICAL
for,108,O
cognitive,108,O
function,108,O
",",108,O
activities,108,O
of,108,O
daily,108,O
living,108,O
and,108,O
behavioural,108,O
disturbance,108,O
at,108,O
two,108,O
years,108,O
.,108,O
Fewer,109,O
patients,109,O
suffer,109,O
adverse,109,O
events,109,O
on,109,O
donepezil,109,B-CHEMICAL
than,109,O
rivastigmine,109,B-CHEMICAL
.,109,O
AUTHORS,110,O
',110,O
CONCLUSIONS,110,O
:,110,O
The,110,O
three,110,O
cholinesterase,110,B-GENE-Y
inhibitors,110,O
are,110,O
efficacious,110,O
for,110,O
mild,110,O
to,110,O
moderate,110,O
Alzheimer,110,O
's,110,O
disease,110,O
.,110,O
It,111,O
is,111,O
not,111,O
possible,111,O
to,111,O
identify,111,O
those,111,O
who,111,O
will,111,O
respond,111,O
to,111,O
treatment,111,O
prior,111,O
to,111,O
treatment,111,O
.,111,O
There,112,O
is,112,O
no,112,O
evidence,112,O
that,112,O
treatment,112,O
with,112,O
a,112,O
ChEI,112,O
is,112,O
not,112,O
cost,112,O
effective,112,O
.,112,O
Despite,113,O
the,113,O
slight,113,O
variations,113,O
in,113,O
the,113,O
mode,113,O
of,113,O
action,113,O
of,113,O
the,113,O
three,113,O
cholinesterase,113,B-GENE-Y
inhibitors,113,O
there,113,O
is,113,O
no,113,O
evidence,113,O
of,113,O
any,113,O
differences,113,O
between,113,O
them,113,O
with,113,O
respect,113,O
to,113,O
efficacy,113,O
.,113,O
There,114,O
appears,114,O
to,114,O
be,114,O
less,114,O
adverse,114,O
effects,114,O
associated,114,O
with,114,O
donepezil,114,B-CHEMICAL
compared,114,O
with,114,O
rivastigmine,114,B-CHEMICAL
.,114,O
It,115,O
may,115,O
be,115,O
that,115,O
galantamine,115,B-CHEMICAL
and,115,O
rivastigmine,115,B-CHEMICAL
match,115,O
donepezil,115,B-CHEMICAL
in,115,O
tolerability,115,O
if,115,O
a,115,O
careful,115,O
and,115,O
gradual,115,O
titration,115,O
routine,115,O
over,115,O
more,115,O
than,115,O
three,115,O
months,115,O
is,115,O
used,115,O
.,115,O
Titration,116,O
with,116,O
donepezil,116,B-CHEMICAL
is,116,O
more,116,O
straightforward,116,O
and,116,O
the,116,O
lower,116,O
dose,116,O
may,116,O
be,116,O
worth,116,O
consideration,116,O
.,116,O
The,117,O
effects,117,O
of,117,O
mitiglinide,117,B-CHEMICAL
(,117,O
KAD-1229,117,B-CHEMICAL
),117,O
",",117,O
a,117,O
new,117,O
anti-diabetic,117,O
drug,117,O
",",117,O
on,117,O
ATP-sensitive,117,B-GENE-N
K+,117,I-GENE-N
channels,117,I-GENE-N
and,117,O
insulin,117,B-GENE-Y
secretion,117,O
:,117,O
comparison,117,O
with,117,O
the,117,O
sulfonylureas,117,B-CHEMICAL
and,117,O
nateglinide,117,B-CHEMICAL
.,117,O
Mitiglinide,118,B-CHEMICAL
(,118,O
KAD-1229,118,B-CHEMICAL
),118,O
",",118,O
a,118,O
new,118,O
anti-diabetic,118,O
drug,118,O
",",118,O
is,118,O
thought,118,O
to,118,O
stimulate,118,O
insulin,118,B-GENE-Y
secretion,118,O
by,118,O
closing,118,O
the,118,O
ATP-sensitive,118,B-GENE-N
K+,118,I-GENE-N
(,118,I-GENE-N
K,118,I-GENE-N
(,118,I-GENE-N
ATP,118,I-GENE-N
),118,I-GENE-N
),118,I-GENE-N
channels,118,I-GENE-N
in,118,O
pancreatic,118,O
beta-cells,118,O
.,118,O
However,119,O
",",119,O
its,119,O
selectivity,119,O
for,119,O
the,119,O
various,119,O
K,119,B-GENE-N
(,119,I-GENE-N
ATP,119,I-GENE-N
),119,I-GENE-N
channels,119,I-GENE-N
is,119,O
not,119,O
known,119,O
.,119,O
In,120,O
this,120,O
study,120,O
",",120,O
we,120,O
examined,120,O
the,120,O
effects,120,O
of,120,O
mitiglinide,120,B-CHEMICAL
on,120,O
various,120,O
cloned,120,O
K,120,B-GENE-N
(,120,I-GENE-N
ATP,120,I-GENE-N
),120,I-GENE-N
channels,120,I-GENE-N
(,120,O
Kir6.2/SUR1,120,B-GENE-Y
",",120,O
Kir6.2/SUR2A,120,B-GENE-Y
",",120,O
and,120,O
Kir6.2/SUR2B,120,B-GENE-Y
),120,O
reconstituted,120,O
in,120,O
COS-1,120,O
cells,120,O
",",120,O
and,120,O
compared,120,O
them,120,O
to,120,O
another,120,O
meglitinide-related,120,B-CHEMICAL
compound,120,O
",",120,O
nateglinide,120,B-CHEMICAL
.,120,O
Patch-clamp,121,O
analysis,121,O
using,121,O
inside-out,121,O
recording,121,O
configuration,121,O
showed,121,O
that,121,O
mitiglinide,121,B-CHEMICAL
inhibits,121,O
the,121,O
Kir6.2/SUR1,121,B-GENE-Y
channel,121,O
currents,121,O
in,121,O
a,121,O
dose-dependent,121,O
manner,121,O
(,121,O
IC50,121,O
value,121,O
",",121,O
100,121,O
nM,121,O
),121,O
but,121,O
does,121,O
not,121,O
significantly,121,O
inhibit,121,O
either,121,O
Kir6.2/SUR2A,121,B-GENE-Y
or,121,O
Kir6.2/SUR2B,121,B-GENE-Y
channel,121,O
currents,121,O
even,121,O
at,121,O
high,121,O
doses,121,O
(,121,O
more,121,O
than,121,O
10,121,O
microM,121,O
),121,O
.,121,O
Nateglinide,122,B-CHEMICAL
inhibits,122,O
Kir6.2/SUR1,122,B-GENE-Y
and,122,O
Kir6.2/SUR2B,122,B-GENE-Y
channels,122,O
at,122,O
100,122,O
nM,122,O
",",122,O
and,122,O
inhibits,122,O
Kir6.2/SUR2A,122,B-GENE-Y
channels,122,O
at,122,O
high,122,O
concentrations,122,O
(,122,O
1,122,O
microM,122,O
),122,O
.,122,O
Binding,123,O
experiments,123,O
on,123,O
mitiglinide,123,B-CHEMICAL
",",123,O
nateglinide,123,B-CHEMICAL
",",123,O
and,123,O
repaglinide,123,B-CHEMICAL
to,123,O
SUR1,123,B-GENE-Y
expressed,123,O
in,123,O
COS-1,123,O
cells,123,O
revealed,123,O
that,123,O
they,123,O
inhibit,123,O
the,123,O
binding,123,O
of,123,O
[,123,B-CHEMICAL
3H,123,I-CHEMICAL
],123,I-CHEMICAL
glibenclamide,123,I-CHEMICAL
to,123,O
SUR1,123,B-GENE-Y
(,123,O
IC50,123,O
values,123,O
:,123,O
mitiglinide,123,B-CHEMICAL
",",123,O
280,123,O
nM,123,O
;,123,O
nateglinide,123,B-CHEMICAL
",",123,O
8,123,O
microM,123,O
;,123,O
repaglinide,123,B-CHEMICAL
",",123,O
1.6,123,O
microM,123,O
),123,O
",",123,O
suggesting,123,O
that,123,O
they,123,O
all,123,O
share,123,O
a,123,O
glibenclamide,123,B-CHEMICAL
binding,123,O
site,123,O
.,123,O
The,124,O
insulin,124,B-GENE-N
responses,124,O
to,124,O
glucose,124,B-CHEMICAL
",",124,O
mitiglinide,124,B-CHEMICAL
",",124,O
tolbutamide,124,B-CHEMICAL
",",124,O
and,124,O
glibenclamide,124,B-CHEMICAL
in,124,O
MIN6,124,O
cells,124,O
after,124,O
chronic,124,O
mitiglinide,124,B-CHEMICAL
",",124,O
nateglinide,124,B-CHEMICAL
",",124,O
or,124,O
repaglinide,124,B-CHEMICAL
treatment,124,O
were,124,O
comparable,124,O
to,124,O
those,124,O
after,124,O
chronic,124,O
tolbutamide,124,B-CHEMICAL
and,124,O
glibenclamide,124,B-CHEMICAL
treatment,124,O
.,124,O
These,125,O
results,125,O
indicate,125,O
that,125,O
",",125,O
similar,125,O
to,125,O
the,125,O
sulfonylureas,125,B-CHEMICAL
",",125,O
mitiglinide,125,B-CHEMICAL
is,125,O
highly,125,O
specific,125,O
to,125,O
the,125,O
Kir6.2/SUR1,125,B-GENE-Y
complex,125,O
",",125,O
i.e.,125,O
",",125,O
the,125,O
pancreatic,125,O
beta-cell,125,O
K,125,B-GENE-N
(,125,I-GENE-N
ATP,125,I-GENE-N
),125,I-GENE-N
channel,125,I-GENE-N
",",125,O
and,125,O
suggest,125,O
that,125,O
mitiglinide,125,B-CHEMICAL
may,125,O
be,125,O
a,125,O
clinically,125,O
useful,125,O
anti-diabetic,125,O
drug,125,O
.,125,O
A,126,O
systematic,126,O
comparison,126,O
of,126,O
the,126,O
properties,126,O
of,126,O
clinically,126,O
used,126,O
angiotensin,126,B-GENE-Y
II,126,I-GENE-Y
type,126,I-GENE-Y
1,126,I-GENE-Y
receptor,126,I-GENE-Y
antagonists,126,O
.,126,O
Angiotensin,127,B-GENE-Y
II,127,I-GENE-Y
type,127,I-GENE-Y
1,127,I-GENE-Y
receptor,127,I-GENE-Y
antagonists,127,O
(,127,O
ARBs,127,O
),127,O
have,127,O
become,127,O
an,127,O
important,127,O
drug,127,O
class,127,O
in,127,O
the,127,O
treatment,127,O
of,127,O
hypertension,127,O
and,127,O
heart,127,O
failure,127,O
and,127,O
the,127,O
protection,127,O
from,127,O
diabetic,127,O
nephropathy,127,O
.,127,O
Eight,128,O
ARBs,128,O
are,128,O
clinically,128,O
available,128,O
[,128,O
azilsartan,128,B-CHEMICAL
",",128,O
candesartan,128,B-CHEMICAL
",",128,O
eprosartan,128,B-CHEMICAL
",",128,O
irbesartan,128,B-CHEMICAL
",",128,O
losartan,128,B-CHEMICAL
",",128,O
olmesartan,128,B-CHEMICAL
",",128,O
telmisartan,128,B-CHEMICAL
",",128,O
valsartan,128,B-CHEMICAL
],128,O
.,128,O
Azilsartan,129,B-CHEMICAL
(,129,O
in,129,O
some,129,O
countries,129,O
),129,O
",",129,O
candesartan,129,B-CHEMICAL
",",129,O
and,129,O
olmesartan,129,B-CHEMICAL
are,129,O
orally,129,O
administered,129,O
as,129,O
prodrugs,129,O
",",129,O
whereas,129,O
the,129,O
blocking,129,O
action,129,O
of,129,O
some,129,O
is,129,O
mediated,129,O
through,129,O
active,129,O
metabolites,129,O
.,129,O
On,130,O
the,130,O
basis,130,O
of,130,O
their,130,O
chemical,130,O
structures,130,O
",",130,O
ARBs,130,O
use,130,O
different,130,O
binding,130,O
pockets,130,O
in,130,O
the,130,O
receptor,130,O
",",130,O
which,130,O
are,130,O
associated,130,O
with,130,O
differences,130,O
in,130,O
dissociation,130,O
times,130,O
and,130,O
",",130,O
in,130,O
most,130,O
cases,130,O
",",130,O
apparently,130,O
insurmountable,130,O
antagonism,130,O
.,130,O
The,131,O
physicochemical,131,O
differences,131,O
between,131,O
ARBs,131,O
also,131,O
manifest,131,O
in,131,O
different,131,O
tissue,131,O
penetration,131,O
",",131,O
including,131,O
passage,131,O
through,131,O
the,131,O
blood-brain,131,O
barrier,131,O
.,131,O
Differences,132,O
in,132,O
binding,132,O
mode,132,O
and,132,O
tissue,132,O
penetration,132,O
are,132,O
also,132,O
associated,132,O
with,132,O
differences,132,O
in,132,O
pharmacokinetic,132,O
profile,132,O
",",132,O
particularly,132,O
duration,132,O
of,132,O
action,132,O
.,132,O
Although,133,O
generally,133,O
highly,133,O
specific,133,O
for,133,O
angiotensin,133,B-GENE-Y
II,133,I-GENE-Y
type,133,I-GENE-Y
1,133,I-GENE-Y
receptors,133,I-GENE-Y
",",133,O
some,133,O
ARBs,133,O
",",133,O
particularly,133,O
telmisartan,133,B-CHEMICAL
",",133,O
are,133,O
partial,133,O
agonists,133,O
at,133,O
peroxisome,133,B-GENE-Y
proliferator-activated,133,I-GENE-Y
receptor-γ,133,I-GENE-Y
.,133,O
All,134,O
of,134,O
these,134,O
properties,134,O
are,134,O
comprehensively,134,O
reviewed,134,O
in,134,O
this,134,O
article,134,O
.,134,O
Although,135,O
there,135,O
is,135,O
general,135,O
consensus,135,O
that,135,O
a,135,O
continuous,135,O
receptor,135,O
blockade,135,O
over,135,O
a,135,O
24-hour,135,O
period,135,O
is,135,O
desirable,135,O
",",135,O
the,135,O
clinical,135,O
relevance,135,O
of,135,O
other,135,O
pharmacological,135,O
differences,135,O
between,135,O
individual,135,O
ARBs,135,O
remains,135,O
to,135,O
be,135,O
assessed,135,O
.,135,O
Diuretic,136,O
effects,136,O
of,136,O
cannabinoids,136,O
.,136,O
In,137,O
vivo,137,O
effects,137,O
of,137,O
cannabinoid,137,O
(,137,O
CB,137,O
),137,O
agonists,137,O
are,137,O
often,137,O
assessed,137,O
using,137,O
four,137,O
well-established,137,O
measures,137,O
:,137,O
locomotor,137,O
activity,137,O
",",137,O
hypothermia,137,O
",",137,O
cataleptic-like,137,O
effects,137,O
",",137,O
and,137,O
analgesia,137,O
.,137,O
The,138,O
present,138,O
studies,138,O
demonstrate,138,O
that,138,O
doses,138,O
of,138,O
CB,138,O
agonists,138,O
that,138,O
produce,138,O
these,138,O
effects,138,O
also,138,O
reliably,138,O
increase,138,O
diuresis,138,O
.,138,O
Diuretic,139,O
effects,139,O
of,139,O
several,139,O
CB,139,O
agonists,139,O
were,139,O
measured,139,O
in,139,O
female,139,O
rats,139,O
over,139,O
2,139,O
hours,139,O
immediately,139,O
after,139,O
drug,139,O
injection,139,O
",",139,O
and,139,O
results,139,O
were,139,O
compared,139,O
with,139,O
hypothermic,139,O
effects,139,O
.,139,O
Direct-acting,140,O
CB1,140,B-GENE-Y
agonists,140,O
",",140,O
including,140,O
Δ,140,B-CHEMICAL
(,140,I-CHEMICAL
9,140,I-CHEMICAL
),140,I-CHEMICAL
-tetrahydrocannabinol,140,I-CHEMICAL
",",140,O
WIN,140,B-CHEMICAL
"55,212",140,I-CHEMICAL
[,140,O
R-,140,B-CHEMICAL
(,140,I-CHEMICAL
1,140,I-CHEMICAL
),140,I-CHEMICAL
-,140,I-CHEMICAL
[,140,I-CHEMICAL
"2,3-dihydro-5-methyl-3-",140,I-CHEMICAL
[,140,I-CHEMICAL
(,140,I-CHEMICAL
morpholinyl,140,I-CHEMICAL
),140,I-CHEMICAL
methyl,140,I-CHEMICAL
],140,I-CHEMICAL
pyrrolo,140,I-CHEMICAL
[,140,I-CHEMICAL
"1,2,3-de",140,I-CHEMICAL
],140,I-CHEMICAL
"-1,4-benzoxazinyl",140,I-CHEMICAL
],140,I-CHEMICAL
-,140,I-CHEMICAL
(,140,I-CHEMICAL
1-naphthalenyl,140,I-CHEMICAL
),140,I-CHEMICAL
methanone,140,I-CHEMICAL
mesylate,140,I-CHEMICAL
],140,O
",",140,O
AM2389,140,B-CHEMICAL
[,140,O
9β-hydroxy-3-,140,B-CHEMICAL
(,140,I-CHEMICAL
1-hexyl-cyclobut-1-yl,140,I-CHEMICAL
),140,I-CHEMICAL
-hexahydrocannabinol,140,I-CHEMICAL
],140,O
",",140,O
and,140,O
AM4054,140,B-CHEMICAL
[,140,O
9β-,140,B-CHEMICAL
(,140,I-CHEMICAL
hydroxymethyl,140,I-CHEMICAL
),140,I-CHEMICAL
-3-,140,I-CHEMICAL
(,140,I-CHEMICAL
1-adamantyl,140,I-CHEMICAL
),140,I-CHEMICAL
-hexahydrocannabinol,140,I-CHEMICAL
],140,O
",",140,O
produced,140,O
dose-dependent,140,O
increases,140,O
in,140,O
diuresis,140,O
and,140,O
decreases,140,O
in,140,O
colonic,140,O
temperature,140,O
",",140,O
with,140,O
slightly,140,O
lower,140,O
ED,140,O
(,140,O
50,140,O
),140,O
values,140,O
for,140,O
diuresis,140,O
than,140,O
for,140,O
hypothermia,140,O
.,140,O
The,141,O
highest,141,O
doses,141,O
of,141,O
cannabinoid,141,O
drugs,141,O
yielded,141,O
",",141,O
on,141,O
average,141,O
",",141,O
26-32,141,O
g/kg,141,O
urine,141,O
;,141,O
comparable,141,O
effects,141,O
were,141,O
obtained,141,O
with,141,O
10,141,O
mg/kg,141,O
furosemide,141,B-CHEMICAL
and,141,O
3.0,141,O
mg/kg,141,O
trans-,141,B-CHEMICAL
(,141,I-CHEMICAL
-,141,I-CHEMICAL
),141,I-CHEMICAL
"-3,4-dichloro-N-methyl-N-",141,I-CHEMICAL
[,141,I-CHEMICAL
2-,141,I-CHEMICAL
(,141,I-CHEMICAL
1-pyrrolidinyl,141,I-CHEMICAL
),141,I-CHEMICAL
cyclohexyl,141,I-CHEMICAL
],141,I-CHEMICAL
benzeneacetamide,141,I-CHEMICAL
(,141,O
U50-488,141,B-CHEMICAL
),141,O
.,141,O
Methanandamide,142,B-CHEMICAL
(,142,O
10.0,142,O
mg/kg,142,O
),142,O
had,142,O
lesser,142,O
effect,142,O
than,142,O
other,142,O
CB,142,O
agonists,142,O
",",142,O
and,142,O
the,142,O
CB2,142,B-GENE-Y
agonist,142,O
AM1241,142,B-CHEMICAL
[,142,O
1-,142,B-CHEMICAL
(,142,I-CHEMICAL
methylpiperidin-2-ylmethyl,142,I-CHEMICAL
),142,I-CHEMICAL
-3-,142,I-CHEMICAL
(,142,I-CHEMICAL
2-iodo-5-nitrobenzoyl,142,I-CHEMICAL
),142,I-CHEMICAL
indole,142,I-CHEMICAL
],142,O
",",142,O
the,142,O
anandamide,142,B-CHEMICAL
transport,142,O
inhibitor,142,O
AM404,142,B-CHEMICAL
",",142,O
and,142,O
the,142,O
CB,142,O
antagonist,142,O
rimonabant,142,B-CHEMICAL
did,142,O
not,142,O
have,142,O
diuretic,142,O
effects,142,O
.,142,O
In,143,O
further,143,O
studies,143,O
",",143,O
the,143,O
diuretic,143,O
effects,143,O
of,143,O
the,143,O
CB1,143,B-GENE-Y
agonist,143,O
AM4054,143,B-CHEMICAL
were,143,O
similar,143,O
in,143,O
male,143,O
and,143,O
female,143,O
rats,143,O
",",143,O
displayed,143,O
a,143,O
relatively,143,O
rapid,143,O
onset,143,O
to,143,O
action,143,O
",",143,O
and,143,O
were,143,O
dose-dependently,143,O
antagonized,143,O
by,143,O
30,143,O
minutes,143,O
pretreatment,143,O
with,143,O
rimonabant,143,B-CHEMICAL
",",143,O
but,143,O
not,143,O
by,143,O
the,143,O
vanilloid,143,B-GENE-Y
receptor,143,I-GENE-Y
type,143,I-GENE-Y
I,143,I-GENE-Y
antagonist,143,O
capsazepine,143,B-CHEMICAL
",",143,O
nor,143,O
were,143,O
the,143,O
effects,143,O
of,143,O
WIN,143,B-CHEMICAL
"55,212",143,I-CHEMICAL
antagonized,143,O
by,143,O
the,143,O
CB2,143,B-GENE-Y
antagonist,143,O
AM630,143,B-CHEMICAL
[,143,O
(,143,B-CHEMICAL
6-iodo-2-methyl-1-,143,I-CHEMICAL
[,143,I-CHEMICAL
2-,143,I-CHEMICAL
(,143,I-CHEMICAL
4-morpholinyl,143,I-CHEMICAL
),143,I-CHEMICAL
ethyl,143,I-CHEMICAL
],143,I-CHEMICAL
-1H-indol-3-yl,143,I-CHEMICAL
],143,I-CHEMICAL
(,143,I-CHEMICAL
4-methoxyphenyl,143,I-CHEMICAL
),143,I-CHEMICAL
methanone,143,I-CHEMICAL
),143,I-CHEMICAL
],143,O
.,143,O
These,144,O
data,144,O
indicate,144,O
that,144,O
cannabinoids,144,O
have,144,O
robust,144,O
diuretic,144,O
effects,144,O
in,144,O
rats,144,O
that,144,O
are,144,O
mediated,144,O
via,144,O
CB1,144,B-GENE-Y
receptor,144,O
mechanisms,144,O
.,144,O
Nonsteroidal,145,O
anti-inflammatory,145,O
drugs,145,O
induce,145,O
apoptosis,145,O
in,145,O
association,145,O
with,145,O
activation,145,O
of,145,O
peroxisome,145,B-GENE-Y
proliferator-activated,145,I-GENE-Y
receptor,145,I-GENE-Y
gamma,145,I-GENE-Y
in,145,O
rheumatoid,145,O
synovial,145,O
cells,145,O
.,145,O
Nonsteroidal,146,O
anti-inflammatory,146,O
drugs,146,O
(,146,O
NSAIDs,146,O
),146,O
have,146,O
been,146,O
reported,146,O
to,146,O
induce,146,O
apoptosis,146,O
in,146,O
a,146,O
variety,146,O
of,146,O
cell,146,O
lines,146,O
.,146,O
In,147,O
this,147,O
study,147,O
",",147,O
we,147,O
examined,147,O
the,147,O
effect,147,O
of,147,O
NSAIDs,147,O
on,147,O
the,147,O
growth,147,O
and,147,O
apoptosis,147,O
of,147,O
synovial,147,O
cells,147,O
from,147,O
patients,147,O
with,147,O
rheumatoid,147,O
arthritis,147,O
and,147,O
analyzed,147,O
the,147,O
activation,147,O
of,147,O
peroxisome,147,B-GENE-Y
proliferator-activated,147,I-GENE-Y
receptor,147,I-GENE-Y
gamma,147,I-GENE-Y
(,147,O
PPARgamma,147,B-GENE-Y
),147,O
as,147,O
a,147,O
possible,147,O
mechanism,147,O
of,147,O
action,147,O
of,147,O
NSAIDs,147,O
.,147,O
Cell,148,O
proliferation,148,O
and,148,O
viability,148,O
were,148,O
assessed,148,O
from,148,O
5-bromo-2'-deoxyuridine,148,B-CHEMICAL
incorporation,148,O
and,148,O
by,148,O
4-,148,B-CHEMICAL
[,148,I-CHEMICAL
3-,148,I-CHEMICAL
(,148,I-CHEMICAL
4-iodophenyl,148,I-CHEMICAL
),148,I-CHEMICAL
-2-,148,I-CHEMICAL
(,148,I-CHEMICAL
4-nitrophenyl,148,I-CHEMICAL
),148,I-CHEMICAL
-2H-5-tetrazolio,148,I-CHEMICAL
],148,I-CHEMICAL
"-1,3-benzene",148,I-CHEMICAL
disulfonate,148,I-CHEMICAL
(,148,O
WST-1,148,B-CHEMICAL
),148,O
assay,148,O
",",148,O
respectively,148,O
.,148,O
The,149,O
apoptosis,149,O
of,149,O
synovial,149,O
cells,149,O
was,149,O
identified,149,O
by,149,O
DNA,149,O
fragmentation,149,O
assay,149,O
and,149,O
terminal,149,O
deoxynucleotidyl,149,O
transferase-mediated,149,O
dUTP,149,O
nick-end,149,O
labeling,149,O
assay,149,O
.,149,O
Indometacin,150,B-CHEMICAL
",",150,O
diclofenac,150,B-CHEMICAL
",",150,O
oxaprozin,150,B-CHEMICAL
",",150,O
and,150,O
zaltoprofen,150,B-CHEMICAL
reduced,150,O
cell,150,O
proliferation,150,O
and,150,O
induced,150,O
apoptotic,150,O
cell,150,O
death,150,O
in,150,O
synovial,150,O
cells,150,O
",",150,O
whereas,150,O
ketoprofen,150,B-CHEMICAL
and,150,O
acetaminophen,150,B-CHEMICAL
did,150,O
not,150,O
.,150,O
N-,151,B-CHEMICAL
[,151,I-CHEMICAL
2-,151,I-CHEMICAL
(,151,I-CHEMICAL
cyclohexyloxyl,151,I-CHEMICAL
),151,I-CHEMICAL
-4-nitrophenyl,151,I-CHEMICAL
],151,I-CHEMICAL
-methanesulfonamide,151,I-CHEMICAL
(,151,O
NS-398,151,B-CHEMICAL
),151,O
",",151,O
a,151,O
selective,151,O
cyclooxygenase-2,151,B-GENE-Y
inhibitor,151,O
",",151,O
also,151,O
inhibited,151,O
cell,151,O
proliferation,151,O
",",151,O
whereas,151,O
it,151,O
did,151,O
not,151,O
cause,151,O
apoptosis,151,O
.,151,O
Rheumatoid,152,O
synovial,152,O
cells,152,O
expressed,152,O
PPARgamma,152,B-GENE-Y
mRNA,152,O
",",152,O
and,152,O
the,152,O
PPARgamma,152,B-GENE-Y
ligands,152,O
15-deoxy-Delta,152,B-CHEMICAL
(,152,I-CHEMICAL
"12,14",152,I-CHEMICAL
),152,I-CHEMICAL
-prostaglandin,152,I-CHEMICAL
J,152,I-CHEMICAL
(,152,I-CHEMICAL
2,152,I-CHEMICAL
),152,I-CHEMICAL
and,152,O
troglitazone,152,B-CHEMICAL
reduced,152,O
the,152,O
proliferation,152,O
and,152,O
induced,152,O
apoptosis,152,O
in,152,O
synovial,152,O
cells,152,O
.,152,O
Luciferase,153,O
reporter,153,O
assay,153,O
demonstrated,153,O
that,153,O
not,153,O
only,153,O
PPARgamma,153,B-GENE-Y
ligands,153,O
but,153,O
also,153,O
NSAIDs,153,O
",",153,O
which,153,O
could,153,O
induce,153,O
apoptosis,153,O
",",153,O
increased,153,O
the,153,O
activation,153,O
of,153,O
PPARgamma,153,B-GENE-Y
in,153,O
synovial,153,O
cells,153,O
.,153,O
Furthermore,154,O
",",154,O
the,154,O
ability,154,O
of,154,O
NSAIDs,154,O
and,154,O
PPARgamma,154,B-GENE-Y
ligands,154,O
to,154,O
stimulate,154,O
the,154,O
activation,154,O
of,154,O
PPARgamma,154,B-GENE-Y
correlated,154,O
with,154,O
their,154,O
ability,154,O
to,154,O
decrease,154,O
cell,154,O
viability,154,O
(,154,O
r,154,O
=,154,O
0.92,154,O
",",154,O
p,154,O
<,154,O
0.01,154,O
),154,O
and,154,O
ability,154,O
to,154,O
induce,154,O
DNA,154,O
fragmentation,154,O
(,154,O
r,154,O
=,154,O
0.97,154,O
",",154,O
p,154,O
<,154,O
0.001,154,O
),154,O
in,154,O
synovial,154,O
cells,154,O
.,154,O
These,155,O
results,155,O
suggest,155,O
that,155,O
PPARgamma,155,B-GENE-Y
is,155,O
an,155,O
attractive,155,O
target,155,O
for,155,O
induction,155,O
of,155,O
apoptosis,155,O
in,155,O
rheumatoid,155,O
synovial,155,O
cells,155,O
and,155,O
that,155,O
the,155,O
activation,155,O
of,155,O
the,155,O
PPARgamma,155,B-GENE-Y
pathway,155,O
is,155,O
associated,155,O
with,155,O
the,155,O
apoptotic,155,O
action,155,O
of,155,O
NSAIDs,155,O
.,155,O
Anisotropy,156,O
of,156,O
chemical,156,O
bonding,156,O
in,156,O
semifluorinated,156,O
graphite,156,B-CHEMICAL
C2F,156,B-CHEMICAL
revealed,156,O
with,156,O
angle-resolved,156,O
X-ray,156,O
absorption,156,O
spectroscopy,156,O
.,156,O
Highly,157,O
oriented,157,O
pyrolytic,157,O
graphite,157,B-CHEMICAL
characterized,157,O
by,157,O
a,157,O
low,157,O
misorientation,157,O
of,157,O
crystallites,157,O
is,157,O
fluorinated,157,O
using,157,O
a,157,O
gaseous,157,O
mixture,157,O
of,157,O
BrF,157,B-CHEMICAL
(,157,I-CHEMICAL
3,157,I-CHEMICAL
),157,I-CHEMICAL
with,157,O
Br,157,B-CHEMICAL
(,157,I-CHEMICAL
2,157,I-CHEMICAL
),157,I-CHEMICAL
at,157,O
room,157,O
temperature,157,O
.,157,O
The,158,O
golden-colored,158,O
product,158,O
",",158,O
easily,158,O
delaminating,158,O
into,158,O
micrometer-size,158,O
transparent,158,O
flakes,158,O
",",158,O
is,158,O
an,158,O
intercalation,158,O
compound,158,O
where,158,O
Br,158,B-CHEMICAL
(,158,I-CHEMICAL
2,158,I-CHEMICAL
),158,I-CHEMICAL
molecules,158,O
are,158,O
hosted,158,O
between,158,O
fluorinated,158,O
graphene,158,B-CHEMICAL
layers,158,O
of,158,O
approximate,158,O
C,158,B-CHEMICAL
(,158,I-CHEMICAL
2,158,I-CHEMICAL
),158,I-CHEMICAL
F,158,I-CHEMICAL
composition,158,O
.,158,O
To,159,O
unravel,159,O
the,159,O
chemical,159,O
bonding,159,O
in,159,O
semifluorinated,159,O
graphite,159,B-CHEMICAL
",",159,O
we,159,O
apply,159,O
angle-resolved,159,O
near-edge,159,O
X-ray,159,O
absorption,159,O
fine,159,O
structure,159,O
(,159,O
NEXAFS,159,O
),159,O
spectroscopy,159,O
and,159,O
quantum-chemical,159,O
modeling,159,O
.,159,O
The,160,O
strong,160,O
angular,160,O
dependence,160,O
of,160,O
the,160,O
CK,160,O
and,160,O
FK,160,O
edge,160,O
NEXAFS,160,O
spectra,160,O
on,160,O
the,160,O
incident,160,O
radiation,160,O
indicates,160,O
that,160,O
room-temperature-produced,160,O
graphite,160,B-CHEMICAL
fluoride,160,I-CHEMICAL
is,160,O
a,160,O
highly,160,O
anisotropic,160,O
material,160,O
",",160,O
where,160,O
half,160,O
of,160,O
the,160,O
carbon,160,B-CHEMICAL
atoms,160,O
are,160,O
covalently,160,O
bonded,160,O
with,160,O
fluorine,160,B-CHEMICAL
",",160,O
while,160,O
the,160,O
rest,160,O
of,160,O
the,160,O
carbon,160,O
atoms,160,O
preserve,160,O
π,160,O
electrons,160,O
.,160,O
Comparison,161,O
of,161,O
the,161,O
experimental,161,O
CK,161,O
edge,161,O
spectrum,161,O
with,161,O
theoretical,161,O
spectra,161,O
plotted,161,O
for,161,O
C,161,B-CHEMICAL
(,161,I-CHEMICAL
2,161,I-CHEMICAL
),161,I-CHEMICAL
F,161,I-CHEMICAL
models,161,O
reveals,161,O
that,161,O
fluorine,161,B-CHEMICAL
atoms,161,O
are,161,O
more,161,O
likely,161,O
to,161,O
form,161,O
chains,161,O
.,161,O
This,162,O
conclusion,162,O
agrees,162,O
with,162,O
the,162,O
atomic,162,O
force,162,O
microscopy,162,O
observation,162,O
of,162,O
a,162,O
chain-like,162,O
pattern,162,O
on,162,O
the,162,O
surface,162,O
of,162,O
graphite,162,B-CHEMICAL
fluoride,162,I-CHEMICAL
layers,162,O
.,162,O
Two,163,O
novel,163,O
mutations,163,O
in,163,O
the,163,O
MEN1,163,B-GENE-Y
gene,163,O
in,163,O
subjects,163,O
with,163,O
multiple,163,O
endocrine,163,O
neoplasia-1,163,O
.,163,O
Multiple,164,O
endocrine,164,O
neoplasia,164,O
type,164,O
1,164,O
(,164,O
MEN1,164,B-GENE-Y
),164,O
is,164,O
characterized,164,O
by,164,O
parathyroid,164,O
",",164,O
enteropancreatic,164,O
endocrine,164,O
and,164,O
pituitary,164,O
adenomas,164,O
as,164,O
well,164,O
as,164,O
germline,164,O
mutation,164,O
of,164,O
the,164,O
MEN1,164,B-GENE-Y
gene,164,O
.,164,O
We,165,O
describe,165,O
2,165,O
families,165,O
with,165,O
MEN1,165,B-GENE-Y
with,165,O
novel,165,O
mutations,165,O
in,165,O
the,165,O
MEN1,165,B-GENE-Y
gene,165,O
.,165,O
One,166,O
family,166,O
was,166,O
of,166,O
Turkish,166,O
origin,166,O
",",166,O
and,166,O
the,166,O
index,166,O
patient,166,O
had,166,O
primary,166,O
hyperparathyroidism,166,O
(,166,O
PHPT,166,O
),166,O
plus,166,O
a,166,O
prolactinoma,166,O
;,166,O
three,166,O
relatives,166,O
had,166,O
PHPT,166,O
only,166,O
.,166,O
The,167,O
index,167,O
patient,167,O
in,167,O
the,167,O
second,167,O
family,167,O
was,167,O
a,167,O
46-yr-old,167,O
woman,167,O
of,167,O
Chinese,167,O
origin,167,O
living,167,O
in,167,O
Taiwan,167,O
.,167,O
This,168,O
patient,168,O
presented,168,O
with,168,O
a,168,O
complaint,168,O
of,168,O
epigastric,168,O
pain,168,O
and,168,O
watery,168,O
diarrhea,168,O
over,168,O
the,168,O
past,168,O
3,168,O
months,168,O
",",168,O
and,168,O
had,168,O
undergone,168,O
subtotal,168,O
parathyroidectomy,168,O
and,168,O
enucleation,168,O
of,168,O
pancreatic,168,O
islet,168,O
cell,168,O
tumor,168,O
about,168,O
10,168,O
yr,168,O
before,168,O
.,168,O
There,169,O
was,169,O
also,169,O
a,169,O
prolactinoma,169,O
.,169,O
Sequence,170,O
analysis,170,O
of,170,O
the,170,O
MEN1,170,B-GENE-Y
gene,170,O
from,170,O
leukocyte,170,O
genomic,170,O
DNA,170,O
revealed,170,O
heterozygous,170,O
mutations,170,O
in,170,O
both,170,O
probands,170,O
.,170,O
The,171,O
Turkish,171,O
patient,171,O
and,171,O
her,171,O
affected,171,O
relatives,171,O
all,171,O
had,171,O
a,171,O
heterozygous,171,O
A,171,B-GENE-N
to,171,I-GENE-N
G,171,I-GENE-N
transition,171,I-GENE-N
at,171,I-GENE-N
codon,171,I-GENE-N
557,171,I-GENE-N
(,171,O
AAG,171,B-GENE-N
--,171,I-GENE-N
>,171,I-GENE-N
GAG,171,I-GENE-N
),171,O
of,171,O
exon,171,O
10,171,O
of,171,O
MEN1,171,B-GENE-Y
that,171,O
results,171,O
in,171,O
a,171,O
replacement,171,O
of,171,O
lysine,171,B-CHEMICAL
by,171,O
glutamic,171,B-CHEMICAL
acid,171,I-CHEMICAL
.,171,O
The,172,O
Chinese,172,O
index,172,O
patient,172,O
and,172,O
one,172,O
of,172,O
her,172,O
siblings,172,O
had,172,O
a,172,O
heterozygous,172,O
mutation,172,O
at,172,O
codon,172,O
418,172,O
of,172,O
exon,172,O
9,172,O
(,172,O
GAC,172,B-GENE-N
--,172,I-GENE-N
>,172,I-GENE-N
TAT,172,I-GENE-N
),172,O
that,172,O
results,172,O
in,172,O
a,172,O
substitution,172,O
of,172,O
aspartic,172,B-CHEMICAL
acid,172,I-CHEMICAL
by,172,O
tyrosine,172,B-CHEMICAL
.,172,O
In,173,O
conclusion,173,O
",",173,O
we,173,O
have,173,O
identified,173,O
2,173,O
novel,173,O
missense,173,O
mutations,173,O
in,173,O
the,173,O
MEN1,173,B-GENE-Y
gene,173,O
.,173,O
Mutation,174,O
of,174,O
arginine,174,B-CHEMICAL
228,174,O
to,174,O
lysine,174,B-CHEMICAL
enhances,174,O
the,174,O
glucosyltransferase,174,B-GENE-N
activity,174,O
of,174,O
bovine,174,B-GENE-Y
"beta-1,4-galactosyltransferase",174,I-GENE-Y
I.,174,O
"Beta-1,4-galactosyltransferase",174,B-GENE-Y
I,174,I-GENE-Y
(,174,O
beta4Gal-T1,174,B-GENE-Y
),174,O
normally,174,O
transfers,174,O
Gal,174,B-CHEMICAL
from,174,O
UDP-Gal,174,B-CHEMICAL
to,174,O
GlcNAc,174,B-CHEMICAL
in,174,O
the,174,O
presence,174,O
of,174,O
Mn,174,B-CHEMICAL
(,174,I-CHEMICAL
2+,174,I-CHEMICAL
),174,I-CHEMICAL
ion,174,O
(,174,O
Gal-T,174,B-GENE-N
activity,174,O
),174,O
and,174,O
also,174,O
transfers,174,O
Glc,174,B-CHEMICAL
from,174,O
UDP-Glc,174,B-CHEMICAL
to,174,O
GlcNAc,174,B-CHEMICAL
(,174,O
Glc-T,174,B-GENE-N
activity,174,O
),174,O
",",174,O
albeit,174,O
at,174,O
only,174,O
0.3,174,O
%,174,O
efficiency,174,O
.,174,O
In,175,O
addition,175,O
",",175,O
alpha-lactalbumin,175,B-GENE-Y
(,175,O
LA,175,B-GENE-Y
),175,O
enhances,175,O
this,175,O
Glc-T,175,B-GENE-N
activity,175,O
more,175,O
than,175,O
25,175,O
times,175,O
.,175,O
Comparison,176,O
of,176,O
the,176,O
crystal,176,O
structures,176,O
of,176,O
UDP-Gal-,176,B-CHEMICAL
and,176,O
UDP-Glc-bound,176,B-CHEMICAL
beta4Gal-T1,176,B-GENE-Y
reveals,176,O
that,176,O
the,176,O
O4,176,B-CHEMICAL
hydroxyl,176,I-CHEMICAL
group,176,O
in,176,O
both,176,O
Gal,176,B-CHEMICAL
and,176,O
Glc,176,B-CHEMICAL
moieties,176,O
forms,176,O
a,176,O
hydrogen,176,B-CHEMICAL
bond,176,O
with,176,O
the,176,O
side,176,O
chain,176,O
carboxylate,176,B-CHEMICAL
group,176,O
of,176,O
Glu317,176,O
.,176,O
The,177,O
orientation,177,O
of,177,O
the,177,O
O4,177,B-CHEMICAL
hydroxyl,177,I-CHEMICAL
of,177,I-CHEMICAL
glucose,177,I-CHEMICAL
causes,177,O
a,177,O
steric,177,O
hindrance,177,O
to,177,O
the,177,O
side,177,O
chain,177,O
carboxylate,177,B-CHEMICAL
group,177,O
of,177,O
Glu317,177,O
",",177,O
accounting,177,O
for,177,O
the,177,O
enzyme,177,O
's,177,O
low,177,O
Glc-T,177,B-GENE-N
activity,177,O
.,177,O
In,178,O
this,178,O
study,178,O
",",178,O
we,178,O
show,178,O
that,178,O
mutation,178,O
of,178,O
Arg228,178,O
",",178,O
a,178,O
residue,178,O
in,178,O
the,178,O
vicinity,178,O
of,178,O
Glu317,178,O
",",178,O
to,178,O
lysine,178,B-CHEMICAL
(,178,O
R228K-Gal-T1,178,B-GENE-N
),178,O
results,178,O
in,178,O
a,178,O
15-fold,178,O
higher,178,O
Glc-T,178,B-GENE-N
activity,178,O
",",178,O
which,178,O
is,178,O
further,178,O
enhanced,178,O
by,178,O
LA,178,O
to,178,O
nearly,178,O
25,178,O
%,178,O
of,178,O
the,178,O
Gal-T,178,B-GENE-N
activity,178,O
of,178,O
the,178,O
wild,178,O
type,178,O
.,178,O
The,179,O
kinetic,179,O
parameters,179,O
indicate,179,O
that,179,O
the,179,O
main,179,O
effect,179,O
of,179,O
the,179,O
mutation,179,O
of,179,O
Arg228,179,O
to,179,O
lysine,179,B-CHEMICAL
is,179,O
on,179,O
the,179,O
k,179,O
(,179,O
cat,179,O
),179,O
of,179,O
Glc-T,179,B-GENE-N
",",179,O
which,179,O
increases,179,O
3-4-fold,179,O
",",179,O
both,179,O
in,179,O
the,179,O
absence,179,O
and,179,O
in,179,O
the,179,O
presence,179,O
of,179,O
LA,179,O
;,179,O
simultaneously,179,O
",",179,O
the,179,O
k,179,O
(,179,O
cat,179,O
),179,O
for,179,O
the,179,O
Gal-T,179,B-GENE-N
reaction,179,O
is,179,O
reduced,179,O
30-fold,179,O
.,179,O
The,180,O
crystal,180,O
structure,180,O
of,180,O
R228K-Gal-T1,180,B-GENE-N
complexed,180,O
with,180,O
LA,180,O
",",180,O
UDP-Gal,180,B-CHEMICAL
",",180,O
and,180,O
Mn,180,B-CHEMICAL
(,180,I-CHEMICAL
2+,180,I-CHEMICAL
),180,I-CHEMICAL
determined,180,O
at,180,O
1.9,180,O
A,180,O
resolution,180,O
shows,180,O
that,180,O
the,180,O
Asp318,180,O
side,180,O
chain,180,O
exhibits,180,O
a,180,O
minor,180,O
alternate,180,O
conformation,180,O
",",180,O
compared,180,O
to,180,O
that,180,O
in,180,O
the,180,O
wild,180,O
type,180,O
.,180,O
This,181,O
alternate,181,O
conformation,181,O
now,181,O
causes,181,O
a,181,O
steric,181,O
hindrance,181,O
to,181,O
the,181,O
O4,181,B-CHEMICAL
hydroxyl,181,I-CHEMICAL
group,181,O
of,181,O
the,181,O
Gal,181,B-CHEMICAL
moiety,181,O
of,181,O
UDP-Gal,181,B-CHEMICAL
",",181,O
probably,181,O
causing,181,O
the,181,O
dissociation,181,O
of,181,O
UDP-Gal,181,B-CHEMICAL
and,181,O
the,181,O
reduced,181,O
k,181,O
(,181,O
cat,181,O
),181,O
of,181,O
the,181,O
Gal-T,181,B-GENE-N
reaction,181,O
.,181,O
Discovery,182,O
of,182,O
novel,182,O
2-hydroxydiarylamide,182,B-CHEMICAL
derivatives,182,O
as,182,O
TMPRSS4,182,B-GENE-Y
inhibitors,182,O
.,182,O
TMPRSS4,183,B-GENE-Y
is,183,O
a,183,O
novel,183,O
type,183,B-GENE-N
II,183,I-GENE-N
transmembrane,183,I-GENE-N
serine,183,I-GENE-N
protease,183,I-GENE-N
that,183,O
has,183,O
been,183,O
implicated,183,O
in,183,O
the,183,O
invasion,183,O
and,183,O
metastasis,183,O
of,183,O
colon,183,O
cancer,183,O
cells,183,O
.,183,O
In,184,O
this,184,O
study,184,O
",",184,O
a,184,O
novel,184,O
series,184,O
of,184,O
2-hydroxydiarylamide,184,B-CHEMICAL
derivatives,184,O
were,184,O
synthesized,184,O
and,184,O
evaluated,184,O
for,184,O
inhibiting,184,O
TMPRSS4,184,B-GENE-Y
serine,184,B-GENE-N
protease,184,I-GENE-N
activity,184,O
and,184,O
suppressing,184,O
cancer,184,O
cell,184,O
invasion,184,O
.,184,O
These,185,O
derivatives,185,O
demonstrated,185,O
good,185,O
inhibitory,185,O
activity,185,O
against,185,O
TMPRSS4,185,B-GENE-Y
serine,185,B-GENE-N
protease,185,I-GENE-N
",",185,O
which,185,O
correlated,185,O
with,185,O
the,185,O
promising,185,O
anti-invasive,185,O
activity,185,O
of,185,O
colon,185,O
cancer,185,O
cells,185,O
overexpressing,185,O
TMPRSS4,185,B-GENE-Y
.,185,O
Conformationally,186,O
restricted,186,O
homotryptamines,186,B-CHEMICAL
.,186,O
Part,187,O
6,187,O
:,187,O
Indole-5-cycloalkyl,187,B-CHEMICAL
methylamines,187,I-CHEMICAL
as,187,O
selective,187,O
serotonin,187,B-CHEMICAL
reuptake,187,O
inhibitors,187,O
.,187,O
Racemic,188,B-CHEMICAL
5-,188,I-CHEMICAL
(,188,I-CHEMICAL
trans-2-aminomethylcyclopropyl,188,I-CHEMICAL
),188,I-CHEMICAL
indoles,188,I-CHEMICAL
",",188,O
5-,188,B-CHEMICAL
(,188,I-CHEMICAL
trans-2-aminomethylcyclopentyl,188,I-CHEMICAL
),188,I-CHEMICAL
indoles,188,I-CHEMICAL
",",188,O
and,188,O
5-,188,B-CHEMICAL
(,188,I-CHEMICAL
cis-2-aminomethylcyclopentyl,188,I-CHEMICAL
),188,I-CHEMICAL
indoles,188,I-CHEMICAL
were,188,O
synthesized,188,O
and,188,O
evaluated,188,O
as,188,O
selective,188,O
serotonin,188,B-CHEMICAL
reuptake,188,O
inhibitors,188,O
.,188,O
These,189,O
analogs,189,O
followed,189,O
SAR,189,O
trends,189,O
similar,189,O
to,189,O
those,189,O
previously,189,O
reported,189,O
for,189,O
3-cycloalkyl,189,B-CHEMICAL
substituted,189,I-CHEMICAL
indoles,189,I-CHEMICAL
.,189,O
The,190,O
most,190,O
potent,190,O
analogs,190,O
exhibited,190,O
single,190,O
digit,190,O
nanomolar,190,O
inhibition,190,O
at,190,O
the,190,O
human,190,B-GENE-Y
serotonin,190,I-GENE-Y
transporter,190,I-GENE-Y
but,190,O
were,190,O
10-fold,190,O
less,190,O
active,190,O
than,190,O
the,190,O
previously,190,O
reported,190,O
compounds,190,O
.,190,O
Beta1,191,B-GENE-Y
adrenergic,191,I-GENE-Y
receptor-mediated,191,O
enhancement,191,O
of,191,O
hippocampal,191,O
CA3,191,O
network,191,O
activity,191,O
.,191,O
Norepinephrine,192,B-CHEMICAL
is,192,O
an,192,O
endogenous,192,O
neurotransmitter,192,O
distributed,192,O
throughout,192,O
the,192,O
mammalian,192,O
brain,192,O
.,192,O
In,193,O
higher,193,O
cortical,193,O
structures,193,O
such,193,O
as,193,O
the,193,O
hippocampus,193,O
",",193,O
norepinephrine,193,B-CHEMICAL
",",193,O
via,193,O
beta,193,B-GENE-N
adrenergic,193,I-GENE-N
receptor,193,I-GENE-N
(,193,O
AR,193,B-GENE-N
),193,O
activation,193,O
",",193,O
has,193,O
been,193,O
shown,193,O
to,193,O
reinforce,193,O
the,193,O
cognitive,193,O
processes,193,O
of,193,O
attention,193,O
and,193,O
memory,193,O
.,193,O
In,194,O
this,194,O
study,194,O
",",194,O
we,194,O
investigated,194,O
the,194,O
effect,194,O
of,194,O
beta1AR,194,B-GENE-Y
activation,194,O
on,194,O
hippocampal,194,O
cornu,194,O
ammonis,194,O
3,194,O
(,194,O
CA3,194,O
),194,O
network,194,O
activity,194,O
.,194,O
AR,195,B-GENE-N
expression,195,O
was,195,O
first,195,O
determined,195,O
using,195,O
immunocytochemistry,195,O
with,195,O
antibodies,195,O
against,195,O
beta1ARs,195,B-GENE-Y
",",195,O
which,195,O
were,195,O
found,195,O
to,195,O
be,195,O
exceptionally,195,O
dense,195,O
in,195,O
hippocampal,195,O
CA3,195,O
pyramidal,195,O
neurons,195,O
.,195,O
CA3,196,O
network,196,O
activity,196,O
was,196,O
then,196,O
examined,196,O
in,196,O
vitro,196,O
using,196,O
field,196,O
potential,196,O
recordings,196,O
in,196,O
rat,196,O
brain,196,O
slices,196,O
.,196,O
The,197,O
selective,197,O
betaAR,197,B-GENE-N
agonist,197,O
isoproterenol,197,B-CHEMICAL
caused,197,O
an,197,O
enhancement,197,O
of,197,O
hippocampal,197,O
CA3,197,O
network,197,O
activity,197,O
",",197,O
as,197,O
measured,197,O
by,197,O
an,197,O
increase,197,O
in,197,O
frequency,197,O
of,197,O
spontaneous,197,O
burst,197,O
discharges,197,O
recorded,197,O
in,197,O
the,197,O
CA3,197,O
region,197,O
.,197,O
In,198,O
the,198,O
presence,198,O
of,198,O
alphaAR,198,B-GENE-N
blockade,198,O
",",198,O
concentration-response,198,O
curves,198,O
for,198,O
isoproterenol,198,B-CHEMICAL
",",198,O
norepinephrine,198,B-CHEMICAL
",",198,O
and,198,O
epinephrine,198,B-CHEMICAL
suggested,198,O
that,198,O
a,198,O
beta1AR,198,B-GENE-Y
was,198,O
involved,198,O
in,198,O
this,198,O
response,198,O
",",198,O
and,198,O
the,198,O
rank,198,O
order,198,O
of,198,O
potency,198,O
was,198,O
isoproterenol,198,B-CHEMICAL
>,198,O
norepinephrine,198,B-CHEMICAL
=,198,O
epinephrine,198,B-CHEMICAL
.,198,O
Finally,199,O
",",199,O
equilibrium,199,O
dissociation,199,O
constants,199,O
(,199,O
pK,199,O
(,199,O
b,199,O
),199,O
),199,O
of,199,O
subtype-selective,199,O
betaAR,199,B-GENE-N
antagonists,199,O
were,199,O
functionally,199,O
determined,199,O
to,199,O
characterize,199,O
the,199,O
AR,199,B-GENE-N
subtype,199,O
modulating,199,O
hippocampal,199,O
CA3,199,O
activity,199,O
.,199,O
The,200,O
selective,200,O
beta1AR,200,B-GENE-Y
antagonists,200,O
atenolol,200,B-CHEMICAL
and,200,O
metoprolol,200,B-CHEMICAL
blocked,200,O
isoproterenol-induced,200,B-CHEMICAL
enhancement,200,O
",",200,O
with,200,O
apparent,200,O
K,200,O
(,200,O
b,200,O
),200,O
values,200,O
of,200,O
85,200,O
+/-,200,O
36,200,O
and,200,O
3.9,200,O
+/-,200,O
1.7,200,O
nM,200,O
",",200,O
respectively,200,O
.,200,O
In,201,O
contrast,201,O
",",201,O
the,201,O
selective,201,O
beta2AR,201,B-GENE-Y
antagonists,201,O
"ICI-118,551",201,B-CHEMICAL
and,201,O
butoxamine,201,B-CHEMICAL
inhibited,201,O
isoproterenol-mediated,201,B-CHEMICAL
enhancement,201,O
with,201,O
apparent,201,O
low,201,O
affinities,201,O
(,201,O
K,201,O
(,201,O
b,201,O
),201,O
of,201,O
222,201,O
+/-,201,O
61,201,O
and,201,O
9268,201,O
+/-,201,O
512,201,O
nM,201,O
",",201,O
respectively,201,O
),201,O
.,201,O
Together,202,O
",",202,O
this,202,O
pharmacological,202,O
profile,202,O
of,202,O
subtype-selective,202,O
betaAR,202,B-GENE-N
antagonists,202,O
indicates,202,O
that,202,O
in,202,O
this,202,O
model,202,O
",",202,O
beta1AR,202,B-GENE-Y
activation,202,O
is,202,O
responsible,202,O
for,202,O
the,202,O
enhanced,202,O
hippocampal,202,O
CA3,202,O
network,202,O
activity,202,O
initiated,202,O
by,202,O
isoproterenol,202,B-CHEMICAL
.,202,O
P2Y,203,B-GENE-Y
(,203,I-GENE-Y
2,203,I-GENE-Y
),203,I-GENE-Y
receptor,203,I-GENE-Y
agonist,203,O
INS37217,203,B-CHEMICAL
enhances,203,O
functional,203,O
recovery,203,O
after,203,O
detachment,203,O
caused,203,O
by,203,O
subretinal,203,O
injection,203,O
in,203,O
normal,203,O
and,203,O
rds,203,O
mice,203,O
.,203,O
PURPOSE,204,O
:,204,O
To,204,O
evaluate,204,O
the,204,O
effects,204,O
of,204,O
INS37217,204,B-CHEMICAL
on,204,O
the,204,O
recovery,204,O
of,204,O
retinal,204,B-CHEMICAL
function,204,O
after,204,O
experimental,204,O
retinal,204,B-CHEMICAL
detachment,204,O
induced,204,O
by,204,O
subretinal,204,O
injection,204,O
.,204,O
METHODS,205,O
:,205,O
Subretinal,205,O
injections,205,O
of,205,O
1,205,O
micro,205,O
L,205,O
of,205,O
fluorescent,205,O
microbeads,205,O
",",205,O
saline,205,O
",",205,O
or,205,O
INS37217,205,B-CHEMICAL
(,205,O
1-200,205,O
micro,205,O
M,205,O
),205,O
were,205,O
made,205,O
by,205,O
the,205,O
transvitreal,205,O
method,205,O
in,205,O
normal,205,O
(,205,O
C57BL/6,205,O
),205,O
mice,205,O
and,205,O
in,205,O
mice,205,O
heterozygous,205,O
for,205,O
the,205,O
retinal,205,B-CHEMICAL
degeneration,205,O
slow,205,O
(,205,O
rds,205,O
),205,O
gene,205,O
.,205,O
Control,206,O
",",206,O
mock-injected,206,O
animals,206,O
underwent,206,O
corneal,206,O
puncture,206,O
without,206,O
injection,206,O
.,206,O
Histologic,207,O
and,207,O
ERG,207,O
evaluations,207,O
were,207,O
made,207,O
at,207,O
0,207,O
to,207,O
1,207,O
and,207,O
8,207,O
hours,207,O
",",207,O
and,207,O
1,207,O
",",207,O
3,207,O
",",207,O
7,207,O
",",207,O
10,207,O
",",207,O
14,207,O
",",207,O
and,207,O
60,207,O
days,207,O
post,207,O
injection,207,O
(,207,O
PI,207,O
),207,O
.,207,O
DNA,208,O
fragmentation,208,O
was,208,O
evaluated,208,O
by,208,O
terminal,208,O
deoxynucleotidyl,208,B-CHEMICAL
transferase-mediated,208,O
uridine,208,B-CHEMICAL
5'-triphosphate-biotin,208,I-CHEMICAL
nick,208,O
end,208,O
labeling,208,O
(,208,O
TUNEL,208,O
),208,O
.,208,O
RESULTS,209,O
:,209,O
A,209,O
single,209,O
subretinal,209,O
injection,209,O
of,209,O
saline,209,O
solution,209,O
containing,209,O
fluorescent,209,O
beads,209,O
caused,209,O
a,209,O
histologically,209,O
evident,209,O
retinal,209,O
detachment,209,O
and,209,O
distributed,209,O
the,209,O
microbeads,209,O
to,209,O
almost,209,O
all,209,O
the,209,O
subretinal,209,O
space,209,O
.,209,O
Spontaneous,210,O
reattachment,210,O
occurred,210,O
within,210,O
24,210,O
hours,210,O
after,210,O
injection,210,O
and,210,O
was,210,O
accompanied,210,O
by,210,O
evident,210,O
retinal,210,B-CHEMICAL
folding,210,O
that,210,O
appeared,210,O
largely,210,O
resolved,210,O
by,210,O
6,210,O
days,210,O
later,210,O
.,210,O
Relative,211,O
to,211,O
controls,211,O
",",211,O
injection,211,O
of,211,O
saline,211,O
resulted,211,O
in,211,O
approximately,211,O
40,211,O
%,211,O
recovery,211,O
of,211,O
dark-adapted,211,O
a-wave,211,O
amplitude,211,O
at,211,O
24,211,O
hours,211,O
PI,211,O
and,211,O
gradually,211,O
improved,211,O
to,211,O
approximately,211,O
90,211,O
%,211,O
of,211,O
controls,211,O
at,211,O
2,211,O
months,211,O
PI,211,O
.,211,O
Subretinal,212,O
injection,212,O
of,212,O
saline,212,O
containing,212,O
INS37217,212,B-CHEMICAL
(,212,O
10,212,O
micro,212,O
M,212,O
),212,O
significantly,212,O
increased,212,O
rod,212,O
and,212,O
cone,212,O
ERG,212,O
of,212,O
normal,212,O
and,212,O
rds,212,O
(,212,O
+/-,212,O
),212,O
mice,212,O
at,212,O
1,212,O
and,212,O
10,212,O
days,212,O
PI,212,O
",",212,O
when,212,O
compared,212,O
with,212,O
injection,212,O
of,212,O
saline,212,O
alone,212,O
.,212,O
Additionally,213,O
",",213,O
INS37217,213,B-CHEMICAL
reduced,213,O
the,213,O
number,213,O
of,213,O
TUNEL-positive,213,O
photoreceptors,213,O
and,213,O
the,213,O
enhanced,213,O
rate,213,O
of,213,O
reattachment,213,O
.,213,O
CONCLUSIONS,214,O
:,214,O
Enhancement,214,O
of,214,O
ERG,214,O
recovery,214,O
by,214,O
INS37217,214,B-CHEMICAL
is,214,O
likely,214,O
due,214,O
to,214,O
reduced,214,O
retinal,214,B-CHEMICAL
folding,214,O
and,214,O
cell,214,O
death,214,O
associated,214,O
with,214,O
detachment,214,O
.,214,O
These,215,O
results,215,O
support,215,O
the,215,O
use,215,O
of,215,O
INS37217,215,B-CHEMICAL
to,215,O
help,215,O
restore,215,O
function,215,O
after,215,O
therapies,215,O
that,215,O
involve,215,O
subretinal,215,O
administration,215,O
of,215,O
drugs,215,O
in,215,O
animal,215,O
models,215,O
of,215,O
retinal,215,B-CHEMICAL
diseases,215,O
.,215,O
Selective,216,O
antagonism,216,O
of,216,O
GluR5,216,B-GENE-Y
kainate-receptor-mediated,216,B-GENE-N
synaptic,216,O
currents,216,O
by,216,O
topiramate,216,B-CHEMICAL
in,216,O
rat,216,O
basolateral,216,O
amygdala,216,O
neurons,216,O
.,216,O
Topiramate,217,B-CHEMICAL
is,217,O
a,217,O
widely,217,O
used,217,O
antiepileptic,217,O
agent,217,O
whose,217,O
mechanism,217,O
of,217,O
action,217,O
is,217,O
poorly,217,O
understood,217,O
.,217,O
The,218,O
drug,218,O
has,218,O
been,218,O
reported,218,O
to,218,O
interact,218,O
with,218,O
various,218,O
ion,218,B-GENE-N
channel,218,I-GENE-N
types,218,O
",",218,O
including,218,O
AMPA/kainate,218,B-GENE-N
receptors,218,I-GENE-N
.,218,O
In,219,O
whole-cell,219,O
voltage-clamp,219,O
recordings,219,O
from,219,O
principal,219,O
neurons,219,O
of,219,O
the,219,O
rat,219,O
basolateral,219,O
amygdala,219,O
",",219,O
topiramate,219,B-CHEMICAL
at,219,O
low,219,O
concentrations,219,O
(,219,O
IC50,219,O
",",219,O
approximately,219,O
0.5,219,O
microm,219,O
),219,O
selectively,219,O
inhibited,219,O
pharmacologically,219,O
isolated,219,O
excitatory,219,O
synaptic,219,O
currents,219,O
mediated,219,O
by,219,O
kainate,219,B-GENE-N
receptors,219,I-GENE-N
containing,219,O
the,219,O
GluR5,219,B-GENE-Y
subunit,219,O
.,219,O
Topiramate,220,B-CHEMICAL
also,220,O
partially,220,O
depressed,220,O
predominantly,220,O
AMPA-receptor-mediated,220,B-GENE-N
EPSCs,220,O
",",220,O
but,220,O
with,220,O
lower,220,O
efficacy,220,O
.,220,O
Topiramate,221,B-CHEMICAL
did,221,O
not,221,O
alter,221,O
the,221,O
degree,221,O
of,221,O
facilitation,221,O
in,221,O
paired-pulse,221,O
experiments,221,O
",",221,O
and,221,O
it,221,O
reduced,221,O
the,221,O
amplitude,221,O
of,221,O
miniature,221,O
EPSCs,221,O
without,221,O
affecting,221,O
their,221,O
frequency,221,O
",",221,O
demonstrating,221,O
that,221,O
the,221,O
block,221,O
of,221,O
synaptic,221,O
responses,221,O
occurs,221,O
postsynaptically,221,O
.,221,O
Inhibition,222,O
of,222,O
GluR5,222,B-GENE-Y
kainate,222,B-GENE-N
receptors,222,I-GENE-N
could,222,O
represent,222,O
a,222,O
key,222,O
mechanism,222,O
underlying,222,O
the,222,O
anticonvulsant,222,O
activity,222,O
of,222,O
topiramate,222,B-CHEMICAL
.,222,O
Moreover,223,O
",",223,O
these,223,O
results,223,O
support,223,O
the,223,O
concept,223,O
that,223,O
GluR5,223,B-GENE-Y
kainate,223,B-GENE-N
receptors,223,I-GENE-N
represent,223,O
a,223,O
novel,223,O
target,223,O
for,223,O
antiepileptic,223,O
drug,223,O
development,223,O
.,223,O
From,224,O
traditional,224,O
European,224,O
medicine,224,O
to,224,O
discovery,224,O
of,224,O
new,224,O
drug,224,O
candidates,224,O
for,224,O
the,224,O
treatment,224,O
of,224,O
dementia,224,O
and,224,O
Alzheimer,224,O
's,224,O
disease,224,O
:,224,O
acetylcholinesterase,224,B-GENE-Y
inhibitors,224,O
.,224,O
The,225,O
leading,225,O
Alzheimer,225,O
's,225,O
disease,225,O
(,225,O
AD,225,O
),225,O
therapeutics,225,O
to,225,O
date,225,O
involves,225,O
inhibitors,225,O
of,225,O
acetylcholinesterase,225,B-GENE-Y
(,225,O
AChE,225,B-GENE-Y
),225,O
",",225,O
which,225,O
should,225,O
",",225,O
in,225,O
principle,225,O
",",225,O
elevate,225,O
cholinergic,225,O
signaling,225,O
and,225,O
limit,225,O
inflammation,225,O
.,225,O
In,226,O
spite,226,O
of,226,O
the,226,O
effectiveness,226,O
in,226,O
20,226,O
%,226,O
-30,226,O
%,226,O
of,226,O
AD,226,O
patients,226,O
",",226,O
more,226,O
attention,226,O
has,226,O
been,226,O
paid,226,O
to,226,O
find,226,O
new,226,O
anti-AChE,226,O
agents,226,O
from,226,O
medicinal,226,O
plants,226,O
.,226,O
Galanthamine,227,B-CHEMICAL
",",227,O
contained,227,O
in,227,O
the,227,O
bulbs,227,O
and,227,O
flowers,227,O
of,227,O
Galanthus,227,O
and,227,O
related,227,O
genera,227,O
like,227,O
Narcissus,227,O
",",227,O
represents,227,O
a,227,O
good,227,O
example,227,O
.,227,O
The,228,O
aim,228,O
of,228,O
this,228,O
study,228,O
is,228,O
to,228,O
review,228,O
the,228,O
role,228,O
of,228,O
possible,228,O
AChE,228,B-GENE-Y
inhibitors,228,O
(,228,O
AChEI,228,O
),228,O
present,228,O
in,228,O
plants,228,O
traditionally,228,O
used,228,O
in,228,O
European,228,O
medicine,228,O
for,228,O
improving,228,O
memory,228,O
.,228,O
Starting,229,O
from,229,O
Galanthamine,229,B-CHEMICAL
",",229,O
properties,229,O
of,229,O
Melissa,229,O
species,229,O
",",229,O
Salvia,229,O
officinalis,229,O
",",229,O
Arnica,229,O
chamissonis,229,O
and,229,O
Ruta,229,O
graveolens,229,O
are,229,O
discussed,229,O
to,229,O
point,229,O
to,229,O
the,229,O
role,229,O
of,229,O
these,229,O
plants,229,O
as,229,O
potential,229,O
sources,229,O
for,229,O
the,229,O
development,229,O
of,229,O
therapeutic,229,O
agents,229,O
for,229,O
AD,229,O
.,229,O
Structure,230,O
of,230,O
acetylcholinesterase,230,B-GENE-Y
complexed,230,O
with,230,O
(,230,B-CHEMICAL
-,230,I-CHEMICAL
),230,I-CHEMICAL
-galanthamine,230,I-CHEMICAL
at,230,O
2.3,230,O
A,230,O
resolution,230,O
.,230,O
(,231,B-CHEMICAL
-,231,I-CHEMICAL
),231,I-CHEMICAL
-Galanthamine,231,I-CHEMICAL
(,231,O
GAL,231,B-CHEMICAL
),231,O
",",231,O
an,231,O
alkaloid,231,O
from,231,O
the,231,O
flower,231,O
",",231,O
the,231,O
common,231,O
snowdrop,231,O
(,231,O
Galanthus,231,O
nivalis,231,O
),231,O
",",231,O
shows,231,O
anticholinesterase,231,O
activity,231,O
.,231,O
This,232,O
property,232,O
has,232,O
made,232,O
GAL,232,O
the,232,O
target,232,O
of,232,O
research,232,O
as,232,O
to,232,O
its,232,O
effectiveness,232,O
in,232,O
the,232,O
treatment,232,O
of,232,O
Alzheimer,232,O
's,232,O
disease,232,O
.,232,O
We,233,O
have,233,O
solved,233,O
the,233,O
X-ray,233,O
crystal,233,O
structure,233,O
of,233,O
GAL,233,O
bound,233,O
in,233,O
the,233,O
active,233,O
site,233,O
of,233,O
Torpedo,233,B-GENE-Y
californica,233,I-GENE-Y
acetylcholinesterase,233,I-GENE-Y
(,233,O
TcAChE,233,B-GENE-Y
),233,O
to,233,O
2.3,233,O
A,233,O
resolution,233,O
.,233,O
The,234,O
inhibitor,234,O
binds,234,O
at,234,O
the,234,O
base,234,O
of,234,O
the,234,O
active,234,O
site,234,O
gorge,234,O
of,234,O
TcAChE,234,B-GENE-Y
",",234,O
interacting,234,O
with,234,O
both,234,O
the,234,O
choline-binding,234,B-GENE-N
site,234,I-GENE-N
(,234,O
Trp-84,234,B-CHEMICAL
),234,O
and,234,O
the,234,O
acyl-binding,234,B-GENE-N
pocket,234,I-GENE-N
(,234,O
Phe-288,234,B-CHEMICAL
",",234,O
Phe-290,234,B-CHEMICAL
),234,O
.,234,O
The,235,O
tertiary,235,B-CHEMICAL
amine,235,I-CHEMICAL
group,235,O
of,235,O
GAL,235,O
does,235,O
not,235,O
interact,235,O
closely,235,O
with,235,O
Trp-84,235,B-CHEMICAL
;,235,O
rather,235,O
",",235,O
the,235,O
double,235,O
bond,235,O
of,235,O
its,235,O
cyclohexene,235,B-CHEMICAL
ring,235,O
stacks,235,O
against,235,O
the,235,O
indole,235,B-CHEMICAL
ring,235,O
.,235,O
The,236,O
tertiary,236,O
amine,236,O
appears,236,O
to,236,O
make,236,O
a,236,O
non-conventional,236,O
hydrogen,236,B-CHEMICAL
bond,236,O
",",236,O
via,236,O
its,236,O
N-methyl,236,B-CHEMICAL
group,236,O
",",236,O
to,236,O
Asp-72,236,B-CHEMICAL
",",236,O
near,236,O
the,236,O
top,236,O
of,236,O
the,236,O
gorge,236,O
.,236,O
The,237,O
hydroxyl,237,B-CHEMICAL
group,237,O
of,237,O
the,237,O
inhibitor,237,O
makes,237,O
a,237,O
strong,237,O
hydrogen,237,B-CHEMICAL
bond,237,O
(,237,O
2.7,237,O
A,237,O
),237,O
with,237,O
Glu-199,237,B-CHEMICAL
.,237,O
The,238,O
relatively,238,O
tight,238,O
binding,238,O
of,238,O
GAL,238,O
to,238,O
TcAChE,238,B-GENE-Y
appears,238,O
to,238,O
arise,238,O
from,238,O
a,238,O
number,238,O
of,238,O
moderate,238,O
to,238,O
weak,238,O
interactions,238,O
with,238,O
the,238,O
protein,238,O
",",238,O
coupled,238,O
to,238,O
a,238,O
low,238,O
entropy,238,O
cost,238,O
for,238,O
binding,238,O
due,238,O
to,238,O
the,238,O
rigid,238,O
nature,238,O
of,238,O
the,238,O
inhibitor,238,O
.,238,O
Methyl,239,B-CHEMICAL
transfer,239,O
in,239,O
glycine,239,B-GENE-Y
N-methyltransferase,239,I-GENE-Y
.,239,O
A,240,O
theoretical,240,O
study,240,O
.,240,O
Density,241,O
functional,241,O
theory,241,O
calculations,241,O
using,241,O
the,241,O
hybrid,241,O
functional,241,O
B3LYP,241,O
have,241,O
been,241,O
performed,241,O
to,241,O
study,241,O
the,241,O
methyl,241,B-CHEMICAL
transfer,241,O
step,241,O
in,241,O
glycine,241,B-GENE-Y
N-methyltransferase,241,I-GENE-Y
(,241,O
GNMT,241,B-GENE-Y
),241,O
.,241,O
This,242,O
enzyme,242,O
catalyzes,242,O
the,242,O
S-adenosyl-L-methionine,242,B-CHEMICAL
(,242,O
SAM,242,B-CHEMICAL
),242,O
-dependent,242,O
methylation,242,O
of,242,O
glycine,242,B-CHEMICAL
to,242,O
form,242,O
sarcosine,242,B-CHEMICAL
.,242,O
The,243,O
starting,243,O
point,243,O
for,243,O
the,243,O
calculations,243,O
is,243,O
the,243,O
recent,243,O
X-ray,243,O
crystal,243,O
structure,243,O
of,243,O
GNMT,243,B-GENE-Y
complexed,243,O
with,243,O
SAM,243,B-CHEMICAL
and,243,O
acetate,243,O
.,243,O
Several,244,O
quantum,244,O
chemical,244,O
models,244,O
with,244,O
different,244,O
sizes,244,O
",",244,O
employing,244,O
up,244,O
to,244,O
98,244,O
atoms,244,O
",",244,O
were,244,O
used,244,O
.,244,O
The,245,O
calculations,245,O
demonstrate,245,O
that,245,O
the,245,O
suggested,245,O
mechanism,245,O
",",245,O
where,245,O
the,245,O
methyl,245,O
group,245,O
is,245,O
transferred,245,O
in,245,O
a,245,O
single,245,O
S,245,O
(,245,O
N,245,O
),245,O
2,245,O
step,245,O
",",245,O
is,245,O
thermodynamically,245,O
plausible,245,O
.,245,O
By,246,O
adding,246,O
or,246,O
eliminating,246,O
various,246,O
groups,246,O
at,246,O
the,246,O
active,246,O
site,246,O
",",246,O
it,246,O
was,246,O
furthermore,246,O
demonstrated,246,O
that,246,O
hydrogen,246,B-CHEMICAL
bonds,246,O
to,246,O
the,246,O
amino,246,B-CHEMICAL
group,246,O
of,246,O
the,246,O
glycine,246,B-CHEMICAL
substrate,246,O
lower,246,O
the,246,O
reaction,246,O
barrier,246,O
",",246,O
while,246,O
hydrogen,246,B-CHEMICAL
bonds,246,O
to,246,O
the,246,O
carboxylate,246,B-CHEMICAL
group,246,O
raise,246,O
the,246,O
barrier,246,O
.,246,O
Water,247,O
extract,247,O
of,247,O
licorice,247,O
had,247,O
anti-viral,247,O
activity,247,O
against,247,O
human,247,O
respiratory,247,O
syncytial,247,O
virus,247,O
in,247,O
human,247,O
respiratory,247,O
tract,247,O
cell,247,O
lines,247,O
.,247,O
ETHNOPHARMACOLOGICAL,248,O
RELEVANCE,248,O
:,248,O
Licorice,248,O
(,248,O
Glycyrrhiza,248,O
uralensis,248,O
Fisch.,248,O
",",248,O
Leguminosae,248,O
),248,O
has,248,O
been,248,O
used,248,O
in,248,O
herbal,248,O
medicine,248,O
and,248,O
food,248,O
supplement,248,O
worldwide,248,O
for,248,O
centuries,248,O
.,248,O
Licorice,249,O
is,249,O
a,249,O
common,249,O
ingredient,249,O
of,249,O
several,249,O
prescriptions,249,O
of,249,O
traditional,249,O
Chinese,249,O
medicine,249,O
which,249,O
have,249,O
been,249,O
proved,249,O
to,249,O
inhibit,249,O
infection,249,O
of,249,O
human,249,O
respiratory,249,O
syncytial,249,O
virus,249,O
(,249,O
HRSV,249,O
),249,O
.,249,O
There,250,O
are,250,O
two,250,O
preparations,250,O
of,250,O
licorice,250,O
",",250,O
Radix,250,O
Glycyrrhizae,250,O
and,250,O
Radix,250,O
Glycyrrhizae,250,O
Preparata,250,O
.,250,O
However,251,O
",",251,O
it,251,O
is,251,O
unknown,251,O
whether,251,O
licorice,251,O
or,251,O
which,251,O
preparation,251,O
of,251,O
licorice,251,O
is,251,O
effective,251,O
against,251,O
HRSV,251,O
",",251,O
nor,251,O
is,251,O
its,251,O
active,251,O
constituent,251,O
.,251,O
AIM,252,O
OF,252,O
THE,252,O
STUDY,252,O
:,252,O
We,252,O
tested,252,O
the,252,O
hypothesis,252,O
that,252,O
Radix,252,O
Glycyrrhizae,252,O
can,252,O
effectively,252,O
decrease,252,O
HRSV-induced,252,O
plaque,252,O
formation,252,O
in,252,O
respiratory,252,O
mucosal,252,O
cell,252,O
lines,252,O
.,252,O
We,253,O
also,253,O
tried,253,O
to,253,O
find,253,O
out,253,O
the,253,O
active,253,O
constituent,253,O
.,253,O
MATERIALS,254,O
AND,254,O
METHODS,254,O
:,254,O
Anti-HRSV,254,O
activities,254,O
of,254,O
hot,254,O
water,254,O
extracts,254,O
of,254,O
preparations,254,O
of,254,O
licorice,254,O
",",254,O
glycyrrhizin,254,B-CHEMICAL
and,254,O
18β-glycyrrhetinic,254,B-CHEMICAL
acid,254,I-CHEMICAL
(,254,O
18β-GA,254,B-CHEMICAL
),254,O
",",254,O
the,254,O
active,254,O
constituents,254,O
of,254,O
licorice,254,O
",",254,O
were,254,O
examined,254,O
by,254,O
plaque,254,O
reduction,254,O
assay,254,O
in,254,O
both,254,O
human,254,O
upper,254,O
(,254,O
HEp-2,254,O
),254,O
and,254,O
low,254,O
(,254,O
A549,254,O
),254,O
respiratory,254,O
tract,254,O
cell,254,O
lines,254,O
.,254,O
Abilities,255,O
of,255,O
crude,255,O
licorice,255,O
to,255,O
inhibit,255,O
viral,255,O
replication,255,O
and,255,O
to,255,O
stimulate,255,O
IFN-β,255,B-GENE-Y
were,255,O
evaluated,255,O
by,255,O
reverse,255,O
transcription,255,O
polymerase,255,O
chain,255,O
reaction,255,O
(,255,O
RT-PCR,255,O
),255,O
and,255,O
enzyme-linked,255,O
immunosorbent,255,O
assay,255,O
(,255,O
ELISA,255,O
),255,O
",",255,O
respectively,255,O
.,255,O
RESULTS,256,O
:,256,O
Radix,256,O
Glycyrrhizae,256,O
and,256,O
Radix,256,O
Glycyrrhizae,256,O
Preparata,256,O
dose-dependently,256,O
inhibited,256,O
HRSV-induced,256,O
plaque,256,O
formation,256,O
in,256,O
both,256,O
HEp-2,256,O
and,256,O
A549,256,O
cell,256,O
lines,256,O
(,256,O
p,256,O
<,256,O
0.0001,256,O
),256,O
.,256,O
The,257,O
effect,257,O
of,257,O
Radix,257,O
Glycyrrhizae,257,O
was,257,O
better,257,O
than,257,O
that,257,O
of,257,O
Radix,257,O
Glycyrrhizae,257,O
Preparata,257,O
on,257,O
HEp-2,257,O
cells,257,O
.,257,O
However,258,O
",",258,O
there,258,O
was,258,O
no,258,O
difference,258,O
of,258,O
their,258,O
anti-HRSV,258,O
effects,258,O
on,258,O
A549,258,O
cells,258,O
.,258,O
Besides,259,O
",",259,O
glycyrrhizin,259,B-CHEMICAL
was,259,O
ineffective,259,O
at,259,O
all,259,O
.,259,O
Nevertheless,260,O
",",260,O
18β-GA,260,B-CHEMICAL
showed,260,O
a,260,O
potent,260,O
anti-HRSV,260,O
activity,260,O
.,260,O
Radix,261,O
Glycyrrhizae,261,O
was,261,O
more,261,O
effective,261,O
when,261,O
given,261,O
before,261,O
viral,261,O
inoculation,261,O
(,261,O
p,261,O
<,261,O
0.0001,261,O
),261,O
which,261,O
may,261,O
be,261,O
due,261,O
to,261,O
its,261,O
inhibition,261,O
of,261,O
viral,261,O
attachment,261,O
on,261,O
(,261,O
p,261,O
<,261,O
0.0001,261,O
),261,O
and,261,O
penetration,261,O
(,261,O
p,261,O
<,261,O
0.0001,261,O
),261,O
into,261,O
the,261,O
host,261,O
cells,261,O
.,261,O
The,262,O
anti-HRSV,262,O
activity,262,O
of,262,O
Radix,262,O
Glycyrrhizae,262,O
was,262,O
further,262,O
confirmed,262,O
by,262,O
RT-PCR,262,O
and,262,O
qRT-PCR,262,O
.,262,O
300μg/ml,263,O
Radix,263,O
Glycyrrhizae,263,O
markedly,263,O
decreased,263,O
the,263,O
viral,263,O
amounts,263,O
within,263,O
the,263,O
cells,263,O
and,263,O
in,263,O
the,263,O
suspension,263,O
.,263,O
Radix,264,O
Glycyrrhizae,264,O
might,264,O
further,264,O
stimulate,264,O
mucosal,264,O
cells,264,O
to,264,O
secrete,264,O
IFN-β,264,B-GENE-Y
to,264,O
counteract,264,O
viral,264,O
infection,264,O
.,264,O
CONCLUSIONS,265,O
:,265,O
Both,265,O
Radix,265,O
Glycyrrhizae,265,O
and,265,O
Radix,265,O
Glycyrrhizae,265,O
Preparata,265,O
are,265,O
effective,265,O
against,265,O
HRSV,265,O
infection,265,O
on,265,O
airway,265,O
epithelial,265,O
cells,265,O
.,265,O
Radix,266,O
Glycyrrhizae,266,O
inhibited,266,O
HRSV,266,O
mainly,266,O
by,266,O
preventing,266,O
viral,266,O
attachment,266,O
",",266,O
internalization,266,O
",",266,O
and,266,O
by,266,O
stimulating,266,O
IFN,266,B-GENE-N
secretion,266,O
.,266,O
18β-GA,267,B-CHEMICAL
may,267,O
be,267,O
one,267,O
of,267,O
its,267,O
active,267,O
constituents,267,O
.,267,O
Parental,268,O
exposure,268,O
to,268,O
natural,268,O
mixtures,268,O
of,268,O
POPs,268,O
reduced,268,O
embryo,268,O
production,268,O
and,268,O
altered,268,O
gene,268,O
transcription,268,O
in,268,O
zebrafish,268,O
embryos,268,O
.,268,O
Determination,269,O
of,269,O
toxicity,269,O
of,269,O
complex,269,O
mixtures,269,O
has,269,O
been,269,O
proposed,269,O
to,269,O
be,269,O
one,269,O
of,269,O
the,269,O
most,269,O
important,269,O
challenges,269,O
for,269,O
modern,269,O
toxicology,269,O
.,269,O
In,270,O
this,270,O
study,270,O
we,270,O
performed,270,O
genome,270,O
wide,270,O
transcriptome,270,O
profiling,270,O
to,270,O
assess,270,O
potential,270,O
toxicant,270,O
induced,270,O
changes,270,O
in,270,O
gene,270,O
regulation,270,O
in,270,O
zebrafish,270,O
embryos,270,O
following,270,O
parental,270,O
exposure,270,O
to,270,O
two,270,O
natural,270,O
mixtures,270,O
of,270,O
persistent,270,O
organic,270,O
pollutants,270,O
(,270,O
POPs,270,O
),270,O
.,270,O
The,271,O
mixtures,271,O
used,271,O
were,271,O
extracted,271,O
from,271,O
burbot,271,O
(,271,O
Lota,271,O
lota,271,O
),271,O
liver,271,O
originating,271,O
from,271,O
two,271,O
lakes,271,O
(,271,O
Lake,271,O
Mjøsa,271,O
and,271,O
Lake,271,O
Losna,271,O
),271,O
belonging,271,O
to,271,O
the,271,O
same,271,O
freshwater,271,O
system,271,O
in,271,O
Norway,271,O
.,271,O
The,272,O
dominating,272,O
groups,272,O
of,272,O
contaminants,272,O
were,272,O
polybrominated,272,B-CHEMICAL
diphenyl,272,I-CHEMICAL
ethers,272,I-CHEMICAL
(,272,O
PBDEs,272,B-CHEMICAL
),272,O
",",272,O
polychlorinated,272,B-CHEMICAL
biphenyls,272,I-CHEMICAL
(,272,O
PCBs,272,B-CHEMICAL
),272,O
and,272,O
dichlorodiphenyltrichloroethane,272,B-CHEMICAL
metabolites,272,O
(,272,O
DDTs,272,O
),272,O
.,272,O
Because,273,O
both,273,O
mixtures,273,O
used,273,O
in,273,O
the,273,O
present,273,O
study,273,O
induced,273,O
similar,273,O
effects,273,O
",",273,O
it,273,O
is,273,O
likely,273,O
that,273,O
the,273,O
same,273,O
toxicants,273,O
are,273,O
involved,273,O
.,273,O
The,274,O
Mjøsa,274,O
mixture,274,O
contains,274,O
high,274,O
levels,274,O
of,274,O
PBDEs,274,B-CHEMICAL
while,274,O
this,274,O
group,274,O
of,274,O
pollutants,274,O
is,274,O
low,274,O
in,274,O
the,274,O
Losna,274,O
mixture,274,O
.,274,O
However,275,O
",",275,O
both,275,O
mixtures,275,O
contain,275,O
substantial,275,O
concentrations,275,O
of,275,O
PCB,275,B-CHEMICAL
and,275,O
DDT,275,B-CHEMICAL
suggesting,275,O
these,275,O
contaminants,275,O
as,275,O
the,275,O
predominant,275,O
contributors,275,O
to,275,O
the,275,O
toxicity,275,O
observed,275,O
.,275,O
The,276,O
observed,276,O
effects,276,O
included,276,O
phenotypic,276,O
traits,276,O
",",276,O
like,276,O
embryo,276,O
production,276,O
and,276,O
survival,276,O
",",276,O
and,276,O
gene,276,O
transcription,276,O
changes,276,O
corresponding,276,O
with,276,O
disease,276,O
and,276,O
biological,276,O
functions,276,O
such,276,O
as,276,O
cancer,276,O
",",276,O
reproductive,276,O
system,276,O
disease,276,O
",",276,O
cardiovascular,276,O
disease,276,O
",",276,O
lipid,276,O
and,276,O
protein,276,O
metabolism,276,O
",",276,O
small,276,O
molecule,276,O
biochemistry,276,O
and,276,O
cell,276,O
cycle,276,O
.,276,O
The,277,O
changes,277,O
in,277,O
gene,277,O
transcription,277,O
included,277,O
genes,277,O
regulated,277,O
by,277,O
HNF4A,277,B-GENE-Y
",",277,O
insulin,277,B-GENE-Y
",",277,O
LH,277,B-GENE-N
",",277,O
FSH,277,B-GENE-N
and,277,O
NF-κB,277,B-GENE-N
which,277,O
are,277,O
known,277,O
to,277,O
be,277,O
central,277,O
regulators,277,O
of,277,O
endocrine,277,O
signaling,277,O
",",277,O
metabolism,277,O
",",277,O
metabolic,277,O
homeostasis,277,O
",",277,O
immune,277,O
functions,277,O
",",277,O
cancer,277,O
development,277,O
and,277,O
reproduction,277,O
.,277,O
The,278,O
results,278,O
suggest,278,O
that,278,O
relative,278,O
low,278,O
concentrations,278,O
of,278,O
the,278,O
natural,278,O
mixtures,278,O
of,278,O
POPs,278,O
used,278,O
in,278,O
the,278,O
present,278,O
study,278,O
might,278,O
pose,278,O
a,278,O
threat,278,O
to,278,O
wild,278,O
freshwater,278,O
fish,278,O
living,278,O
in,278,O
the,278,O
lakes,278,O
from,278,O
which,278,O
the,278,O
POPs,278,O
mixtures,278,O
originated,278,O
.,278,O
Complexities,279,O
of,279,O
androgen,279,B-CHEMICAL
action,279,O
.,279,O
Androgens,280,B-CHEMICAL
mediate,280,O
a,280,O
wide,280,O
range,280,O
of,280,O
processes,280,O
during,280,O
embryogenesis,280,O
and,280,O
in,280,O
the,280,O
adult,280,O
.,280,O
In,281,O
mammals,281,O
",",281,O
the,281,O
principal,281,O
androgens,281,B-CHEMICAL
are,281,O
testosterone,281,B-CHEMICAL
and,281,O
its,281,O
5alpha-reduced,281,O
metabolite,281,O
",",281,O
5alpha-dihydrotestosterone,281,B-CHEMICAL
(,281,O
DHT,281,B-CHEMICAL
),281,O
.,281,O
Although,282,O
these,282,O
androgenic,282,O
hormones,282,O
are,282,O
diverse,282,O
in,282,O
character,282,O
",",282,O
it,282,O
is,282,O
believed,282,O
that,282,O
their,282,O
effects,282,O
are,282,O
mediated,282,O
via,282,O
the,282,O
protein,282,O
products,282,O
of,282,O
a,282,O
single,282,O
androgen,282,B-GENE-Y
receptor,282,I-GENE-Y
gene,282,O
encoded,282,O
on,282,O
the,282,O
X-chromosome,282,O
.,282,O
A,283,O
great,283,O
deal,283,O
of,283,O
information,283,O
has,283,O
now,283,O
accumulated,283,O
pertaining,283,O
to,283,O
the,283,O
mechanisms,283,O
by,283,O
which,283,O
nuclear,283,B-GENE-N
receptors,283,I-GENE-N
",",283,O
such,283,O
as,283,O
the,283,O
androgen,283,B-GENE-Y
receptor,283,I-GENE-Y
",",283,O
modulate,283,O
the,283,O
activity,283,O
of,283,O
responsive,283,O
genes,283,O
.,283,O
The,284,O
studies,284,O
have,284,O
demonstrated,284,O
the,284,O
participation,284,O
of,284,O
a,284,O
number,284,O
of,284,O
ancillary,284,O
proteins,284,O
in,284,O
modulating,284,O
activation,284,O
or,284,O
repression,284,O
by,284,O
nuclear,284,B-GENE-N
receptors,284,I-GENE-N
.,284,O
In,285,O
addition,285,O
to,285,O
studies,285,O
focused,285,O
on,285,O
the,285,O
mechanisms,285,O
of,285,O
nuclear,285,B-GENE-N
receptor,285,I-GENE-N
function,285,O
",",285,O
additional,285,O
work,285,O
has,285,O
illuminated,285,O
the,285,O
mechanism,285,O
by,285,O
which,285,O
androgens,285,B-CHEMICAL
are,285,O
metabolized,285,O
in,285,O
selected,285,O
tissues,285,O
.,285,O
This,286,O
information,286,O
provides,286,O
a,286,O
perspective,286,O
on,286,O
the,286,O
number,286,O
of,286,O
levels,286,O
of,286,O
complexity,286,O
by,286,O
which,286,O
differential,286,O
gene,286,O
regulation,286,O
by,286,O
androgens,286,B-CHEMICAL
may,286,O
occur,286,O
in,286,O
different,286,O
tissues,286,O
and,286,O
in,286,O
different,286,O
cell,286,O
types,286,O
.,286,O
Combining,287,O
QSAR,287,O
classification,287,O
models,287,O
for,287,O
predictive,287,O
modeling,287,O
of,287,O
human,287,B-GENE-N
monoamine,287,I-GENE-N
oxidase,287,I-GENE-N
inhibitors,287,O
.,287,O
Due,288,O
to,288,O
their,288,O
role,288,O
in,288,O
the,288,O
metabolism,288,O
of,288,O
monoamine,288,O
neurotransmitters,288,O
",",288,O
MAO-A,288,B-GENE-Y
and,288,O
MAO-B,288,B-GENE-Y
present,288,O
a,288,O
significant,288,O
pharmacological,288,O
interest,288,O
.,288,O
For,289,O
instance,289,O
the,289,O
inhibitors,289,O
of,289,O
human,289,B-GENE-Y
MAO-B,289,I-GENE-Y
are,289,O
considered,289,O
useful,289,O
tools,289,O
for,289,O
the,289,O
treatment,289,O
of,289,O
Parkinson,289,O
Disease,289,O
.,289,O
Therefore,290,O
",",290,O
the,290,O
rational,290,O
design,290,O
and,290,O
synthesis,290,O
of,290,O
new,290,O
MAOs,290,B-GENE-N
inhibitors,290,O
is,290,O
considered,290,O
of,290,O
great,290,O
importance,290,O
for,290,O
the,290,O
development,290,O
of,290,O
new,290,O
and,290,O
more,290,O
effective,290,O
treatments,290,O
of,290,O
Parkinson,290,O
Disease,290,O
.,290,O
In,291,O
this,291,O
work,291,O
",",291,O
Quantitative,291,O
Structure,291,O
Activity,291,O
Relationships,291,O
(,291,O
QSAR,291,O
),291,O
has,291,O
been,291,O
developed,291,O
to,291,O
predict,291,O
the,291,O
human,291,B-GENE-N
MAO,291,I-GENE-N
inhibitory,291,O
activity,291,O
and,291,O
selectivity,291,O
.,291,O
The,292,O
first,292,O
step,292,O
was,292,O
the,292,O
selection,292,O
of,292,O
a,292,O
suitable,292,O
dataset,292,O
of,292,O
heterocyclic,292,O
compounds,292,O
that,292,O
include,292,O
chromones,292,B-CHEMICAL
",",292,O
coumarins,292,B-CHEMICAL
",",292,O
chalcones,292,B-CHEMICAL
",",292,O
thiazolylhydrazones,292,B-CHEMICAL
",",292,O
etc,292,O
.,292,O
These,293,O
compounds,293,O
were,293,O
previously,293,O
synthesized,293,O
in,293,O
one,293,O
of,293,O
our,293,O
laboratories,293,O
",",293,O
or,293,O
elsewhere,293,O
",",293,O
and,293,O
their,293,O
activities,293,O
measured,293,O
by,293,O
the,293,O
same,293,O
assays,293,O
and,293,O
for,293,O
the,293,O
same,293,O
laboratory,293,O
staff,293,O
.,293,O
Applying,294,O
linear,294,O
discriminant,294,O
analysis,294,O
to,294,O
data,294,O
derived,294,O
from,294,O
a,294,O
variety,294,O
of,294,O
molecular,294,O
representations,294,O
and,294,O
feature,294,O
selection,294,O
algorithms,294,O
",",294,O
reliable,294,O
QSAR,294,O
models,294,O
were,294,O
built,294,O
which,294,O
could,294,O
be,294,O
used,294,O
to,294,O
predict,294,O
for,294,O
test,294,O
compounds,294,O
the,294,O
inhibitory,294,O
activity,294,O
and,294,O
selectivity,294,O
toward,294,O
human,294,B-GENE-N
MAO,294,I-GENE-N
.,294,O
This,295,O
work,295,O
also,295,O
showed,295,O
how,295,O
several,295,O
QSAR,295,O
models,295,O
can,295,O
be,295,O
combined,295,O
to,295,O
make,295,O
better,295,O
predictions,295,O
.,295,O
The,296,O
final,296,O
models,296,O
exhibit,296,O
significant,296,O
statistics,296,O
",",296,O
interpretability,296,O
",",296,O
as,296,O
well,296,O
as,296,O
displaying,296,O
predictive,296,O
power,296,O
on,296,O
an,296,O
external,296,O
validation,296,O
set,296,O
made,296,O
up,296,O
of,296,O
chromone,296,O
derivatives,296,O
with,296,O
unknown,296,O
activity,296,O
(,296,O
that,296,O
are,296,O
being,296,O
reported,296,O
here,296,O
for,296,O
first,296,O
time,296,O
),296,O
synthesized,296,O
by,296,O
our,296,O
group,296,O
",",296,O
and,296,O
coumarins,296,B-CHEMICAL
recently,296,O
reported,296,O
in,296,O
the,296,O
literature,296,O
.,296,O
Dasatinib,297,B-CHEMICAL
(,297,O
BMS-354825,297,B-CHEMICAL
),297,O
inhibits,297,O
KITD816V,297,B-GENE-Y
",",297,O
an,297,O
imatinib-resistant,297,B-CHEMICAL
activating,297,O
mutation,297,O
that,297,O
triggers,297,O
neoplastic,297,O
growth,297,O
in,297,O
most,297,O
patients,297,O
with,297,O
systemic,297,O
mastocytosis,297,O
.,297,O
Mastocytosis,298,O
is,298,O
associated,298,O
with,298,O
an,298,O
activating,298,O
mutation,298,O
in,298,O
the,298,O
KIT,298,B-GENE-Y
oncoprotein,298,O
(,298,O
KITD816V,298,B-GENE-Y
),298,O
that,298,O
results,298,O
in,298,O
autophosphorylation,298,O
of,298,O
the,298,O
KIT,298,B-GENE-Y
receptor,298,O
in,298,O
a,298,O
ligand-independent,298,O
manner,298,O
.,298,O
This,299,O
mutation,299,O
is,299,O
inherently,299,O
resistant,299,O
to,299,O
imatinib,299,B-CHEMICAL
and,299,O
",",299,O
to,299,O
date,299,O
",",299,O
there,299,O
remains,299,O
no,299,O
effective,299,O
curative,299,O
therapy,299,O
for,299,O
systemic,299,O
mastocytosis,299,O
associated,299,O
with,299,O
KITD816V,299,B-GENE-Y
.,299,O
Dasatinib,300,B-CHEMICAL
(,300,O
BMS-354825,300,B-CHEMICAL
),300,O
is,300,O
a,300,O
novel,300,O
orally,300,O
bioavailable,300,O
SRC/ABL,300,B-GENE-Y
inhibitor,300,O
that,300,O
has,300,O
activity,300,O
against,300,O
multiple,300,O
imatinib-resistant,300,B-CHEMICAL
BCR-ABL,300,B-GENE-Y
isoforms,300,O
in,300,O
vitro,300,O
that,300,O
is,300,O
presently,300,O
showing,300,O
considerable,300,O
promise,300,O
in,300,O
early-phase,300,O
clinical,300,O
trials,300,O
of,300,O
chronic,300,O
myeloid,300,O
leukemia,300,O
(,300,O
CML,300,O
),300,O
.,300,O
Pharmacokinetic,301,O
analysis,301,O
suggests,301,O
that,301,O
high,301,O
nanomolar,301,O
concentrations,301,O
of,301,O
dasatinib,301,B-CHEMICAL
can,301,O
be,301,O
achieved,301,O
safely,301,O
in,301,O
humans,301,O
.,301,O
In,302,O
this,302,O
study,302,O
",",302,O
we,302,O
demonstrate,302,O
significant,302,O
inhibitory,302,O
activity,302,O
of,302,O
dasatinib,302,B-CHEMICAL
against,302,O
both,302,O
wild-type,302,O
KIT,302,B-GENE-Y
and,302,O
the,302,O
KITD816V,302,B-GENE-Y
mutation,302,O
in,302,O
the,302,O
nanomolar,302,O
range,302,O
in,302,O
in,302,O
vitro,302,O
and,302,O
cell-based,302,O
kinase,302,B-GENE-N
assays,302,O
.,302,O
Additionally,303,O
",",303,O
dasatinib,303,B-CHEMICAL
leads,303,O
to,303,O
growth,303,O
inhibition,303,O
of,303,O
a,303,O
KITD816V-harboring,303,B-GENE-Y
human,303,O
masto-cytosis,303,O
cell,303,O
line,303,O
.,303,O
Significantly,304,O
",",304,O
dasatinib,304,B-CHEMICAL
selectively,304,O
kills,304,O
primary,304,O
neoplastic,304,O
bone,304,O
marrow,304,O
mast,304,O
cells,304,O
from,304,O
patients,304,O
with,304,O
systemic,304,O
mastocytosis,304,O
while,304,O
sparing,304,O
other,304,O
hematopoietic,304,O
cells,304,O
.,304,O
Computer,305,O
modeling,305,O
suggests,305,O
that,305,O
the,305,O
KITD816V,305,B-GENE-Y
mutation,305,O
destabilizes,305,O
the,305,O
inactive,305,O
conformation,305,O
of,305,O
the,305,O
KIT,305,B-GENE-N
activation,305,I-GENE-N
loop,305,I-GENE-N
to,305,O
which,305,O
imatinib,305,B-CHEMICAL
binds,305,O
",",305,O
but,305,O
it,305,O
is,305,O
not,305,O
predicted,305,O
to,305,O
impair,305,O
binding,305,O
of,305,O
KIT,305,B-GENE-Y
by,305,O
dasatinib,305,B-CHEMICAL
.,305,O
Based,306,O
upon,306,O
our,306,O
results,306,O
",",306,O
further,306,O
evaluation,306,O
of,306,O
dasatinib,306,B-CHEMICAL
for,306,O
the,306,O
treatment,306,O
of,306,O
systemic,306,O
masto-cytosis,306,O
in,306,O
clinical,306,O
trials,306,O
is,306,O
warranted,306,O
.,306,O
Moreover,307,O
",",307,O
dasatinib,307,B-CHEMICAL
may,307,O
be,307,O
of,307,O
clinical,307,O
utility,307,O
in,307,O
other,307,O
disease,307,O
settings,307,O
driven,307,O
by,307,O
activating,307,O
KIT,307,B-GENE-Y
mutations,307,O
.,307,O
A,308,O
water-alcohol,308,O
extract,308,O
of,308,O
Citrus,308,O
grandis,308,O
whole,308,O
fruits,308,O
has,308,O
beneficial,308,O
metabolic,308,O
effects,308,O
in,308,O
the,308,O
obese,308,O
Zucker,308,O
rats,308,O
fed,308,O
with,308,O
high,308,O
fat/high,308,O
cholesterol,308,B-CHEMICAL
diet,308,O
.,308,O
Epidemiological,309,O
studies,309,O
suggest,309,O
that,309,O
citrus,309,O
fruits,309,O
and,309,O
compounds,309,O
such,309,O
as,309,O
flavonoids,309,B-CHEMICAL
",",309,O
limonoids,309,O
and,309,O
pectins,309,O
have,309,O
health,309,O
promoting,309,O
effects,309,O
.,309,O
Our,310,O
aim,310,O
was,310,O
to,310,O
study,310,O
the,310,O
effects,310,O
of,310,O
Citrus,310,O
grandis,310,O
(,310,O
L.,310,O
),310,O
Osbeck,310,O
var,310,O
.,310,O
tomentosa,311,O
hort,311,O
.,311,O
fruit,312,O
extract,312,O
on,312,O
the,312,O
energy,312,O
metabolism,312,O
.,312,O
A,313,O
whole,313,O
fruit,313,O
powder,313,O
from,313,O
dry,313,O
water,313,O
and,313,O
alcohol,313,B-CHEMICAL
extracts,313,O
of,313,O
C.,313,O
grandis,313,O
containing,313,O
19,313,O
%,313,O
naringin,313,B-CHEMICAL
flavonoid,313,O
was,313,O
prepared,313,O
.,313,O
The,314,O
effects,314,O
of,314,O
the,314,O
citrus,314,O
extract,314,O
were,314,O
followed,314,O
in,314,O
the,314,O
obese,314,O
Zucker,314,O
rats,314,O
fed,314,O
with,314,O
the,314,O
HFD,314,O
.,314,O
The,315,O
circulatory,315,O
levels,315,O
of,315,O
GLP-1,315,B-GENE-Y
decreased,315,O
significantly,315,O
by,315,O
the,315,O
extract,315,O
in,315,O
comparison,315,O
to,315,O
the,315,O
HFD,315,O
group,315,O
",",315,O
whereas,315,O
the,315,O
decreased,315,O
ghrelin,315,B-GENE-Y
levels,315,O
were,315,O
reversed,315,O
.,315,O
The,316,O
levels,316,O
of,316,O
PYY,316,B-GENE-Y
were,316,O
decreased,316,O
in,316,O
all,316,O
HFD,316,O
groups,316,O
.,316,O
The,317,O
leptin,317,B-GENE-Y
amounts,317,O
decreased,317,O
but,317,O
not,317,O
significantly,317,O
whereas,317,O
insulin,317,B-GENE-N
and,317,O
amylin,317,B-GENE-Y
were,317,O
unchanged,317,O
.,317,O
The,318,O
cholesterol,318,B-CHEMICAL
and,318,O
glucose,318,B-CHEMICAL
levels,318,O
were,318,O
somewhat,318,O
but,318,O
not,318,O
systematically,318,O
improved,318,O
in,318,O
the,318,O
HFD,318,O
fed,318,O
rats,318,O
.,318,O
Further,319,O
studies,319,O
are,319,O
needed,319,O
to,319,O
identify,319,O
the,319,O
active,319,O
compounds,319,O
and,319,O
their,319,O
mechanisms,319,O
.,319,O
Dopamine,320,B-GENE-Y
D,320,I-GENE-Y
(,320,I-GENE-Y
2,320,I-GENE-Y
),320,I-GENE-Y
receptor-induced,320,O
COX-2-mediated,320,B-GENE-Y
production,320,O
of,320,O
prostaglandin,320,B-CHEMICAL
E,320,I-CHEMICAL
(,320,I-CHEMICAL
2,320,I-CHEMICAL
),320,I-CHEMICAL
in,320,O
D,320,B-GENE-Y
(,320,I-GENE-Y
2,320,I-GENE-Y
),320,I-GENE-Y
-transfected,320,O
Chinese,320,O
hamster,320,O
ovary,320,O
cells,320,O
without,320,O
simultaneous,320,O
administration,320,O
of,320,O
a,320,O
Ca,320,B-CHEMICAL
(,320,I-CHEMICAL
2+,320,I-CHEMICAL
),320,I-CHEMICAL
-mobilizing,320,O
agent,320,O
.,320,O
We,321,O
have,321,O
earlier,321,O
demonstrated,321,O
that,321,O
dopamine,321,O
stimulates,321,O
the,321,O
liberation,321,O
of,321,O
the,321,O
prostaglandin,321,B-CHEMICAL
E,321,I-CHEMICAL
(,321,I-CHEMICAL
2,321,I-CHEMICAL
),321,I-CHEMICAL
(,321,O
PGE,321,B-CHEMICAL
(,321,I-CHEMICAL
2,321,I-CHEMICAL
),321,I-CHEMICAL
),321,O
precursor,321,O
",",321,O
arachidonic,321,B-CHEMICAL
acid,321,I-CHEMICAL
",",321,O
in,321,O
Chinese,321,O
hamster,321,O
ovary,321,O
cells,321,O
transfected,321,O
with,321,O
the,321,O
rat,321,B-GENE-Y
dopamine,321,I-GENE-Y
D,321,I-GENE-Y
(,321,I-GENE-Y
2,321,I-GENE-Y
),321,I-GENE-Y
receptor,321,I-GENE-Y
(,321,I-GENE-Y
long,321,I-GENE-Y
isoform,321,I-GENE-Y
),321,I-GENE-Y
",",321,O
also,321,O
without,321,O
concomitant,321,O
administration,321,O
of,321,O
a,321,O
Ca,321,B-CHEMICAL
(,321,I-CHEMICAL
2+,321,I-CHEMICAL
),321,I-CHEMICAL
-releasing,321,O
agent,321,O
[,321,O
Nilsson,321,O
et,321,O
al.,321,O
",",321,O
Br,321,O
J,321,O
Pharmacol,321,O
1998,321,O
;,321,O
124:1651-8,321,O
],321,O
.,321,O
In,322,O
the,322,O
present,322,O
report,322,O
",",322,O
we,322,O
show,322,O
that,322,O
dopamine,322,B-CHEMICAL
",",322,O
under,322,O
the,322,O
same,322,O
conditions,322,O
",",322,O
also,322,O
induces,322,O
a,322,O
concentration-dependent,322,O
increase,322,O
in,322,O
the,322,O
production,322,O
of,322,O
PGE,322,B-CHEMICAL
(,322,I-CHEMICAL
2,322,I-CHEMICAL
),322,I-CHEMICAL
",",322,O
with,322,O
a,322,O
maximal,322,O
effect,322,O
of,322,O
235,322,O
%,322,O
at,322,O
approximately,322,O
100,322,O
microM,322,O
",",322,O
and,322,O
with,322,O
an,322,O
EC,322,O
(,322,O
50,322,O
),322,O
of,322,O
794,322,O
nM,322,O
.,322,O
The,323,O
effect,323,O
was,323,O
counteracted,323,O
by,323,O
the,323,O
D,323,B-GENE-Y
(,323,I-GENE-Y
2,323,I-GENE-Y
),323,I-GENE-Y
antagonist,323,O
eticlopride,323,B-CHEMICAL
",",323,O
pertussis,323,B-GENE-N
toxin,323,I-GENE-N
",",323,O
the,323,O
inhibitor,323,O
of,323,O
intracellular,323,O
Ca,323,B-CHEMICAL
(,323,I-CHEMICAL
2+,323,I-CHEMICAL
),323,I-CHEMICAL
release,323,O
TMB-8,323,O
",",323,O
incubation,323,O
in,323,O
Ca,323,B-CHEMICAL
(,323,I-CHEMICAL
2+,323,I-CHEMICAL
),323,I-CHEMICAL
-free,323,O
experimental,323,O
medium,323,O
",",323,O
and,323,O
PKC,323,B-GENE-N
desensitization,323,O
obtained,323,O
by,323,O
chronic,323,O
pretreatment,323,O
with,323,O
the,323,O
phorbol,323,O
ester,323,O
TPA,323,O
.,323,O
It,324,O
was,324,O
also,324,O
antagonized,324,O
by,324,O
the,324,O
non-specific,324,O
cyclooxygenase,324,B-GENE-N
(,324,O
COX,324,B-GENE-N
),324,O
inhibitor,324,O
",",324,O
indomethacin,324,B-CHEMICAL
",",324,O
and,324,O
by,324,O
the,324,O
selective,324,O
COX-2,324,B-GENE-Y
inhibitor,324,O
",",324,O
NS-398,324,B-CHEMICAL
",",324,O
but,324,O
not,324,O
by,324,O
the,324,O
specific,324,O
COX-1,324,B-GENE-Y
inhibitor,324,O
",",324,O
valeryl,324,B-CHEMICAL
salicylate,324,I-CHEMICAL
.,324,O
Both,325,O
the,325,O
non-specific,325,O
phospholipase,325,B-GENE-Y
A,325,I-GENE-Y
(,325,I-GENE-Y
2,325,I-GENE-Y
),325,I-GENE-Y
inhibitor,325,O
",",325,O
quinacrine,325,B-CHEMICAL
",",325,O
and,325,O
an,325,O
inhibitor,325,O
of,325,O
cPLA,325,B-GENE-Y
(,325,I-GENE-Y
2,325,I-GENE-Y
),325,I-GENE-Y
and,325,O
iPLA,325,B-GENE-Y
(,325,I-GENE-Y
2,325,I-GENE-Y
),325,I-GENE-Y
",",325,O
AACOF3,325,O
",",325,O
counteracted,325,O
the,325,O
effect,325,O
;,325,O
in,325,O
contrast,325,O
",",325,O
a,325,O
selective,325,O
iPLA,325,B-GENE-Y
(,325,I-GENE-Y
2,325,I-GENE-Y
),325,I-GENE-Y
inhibitor,325,O
",",325,O
BEL,325,O
",",325,O
and,325,O
a,325,O
selective,325,O
sPLA,325,B-GENE-N
(,325,I-GENE-N
2,325,I-GENE-N
),325,I-GENE-N
inhibitor,325,O
",",325,O
TAPC,325,O
",",325,O
were,325,O
ineffective,325,O
.,325,O
No,326,O
effects,326,O
of,326,O
dopamine,326,B-CHEMICAL
were,326,O
obtained,326,O
in,326,O
control,326,O
cells,326,O
mock-transfected,326,O
with,326,O
the,326,O
p3C,326,O
vector,326,O
only,326,O
.,326,O
The,327,O
results,327,O
reinforce,327,O
previous,327,O
assumptions,327,O
that,327,O
dopamine,327,B-CHEMICAL
may,327,O
interact,327,O
with,327,O
eicosanoid,327,B-CHEMICAL
metabolism,327,O
by,327,O
means,327,O
of,327,O
D,327,B-GENE-Y
(,327,I-GENE-Y
2,327,I-GENE-Y
),327,I-GENE-Y
receptor,327,I-GENE-Y
activation,327,O
",",327,O
and,327,O
implicate,327,O
an,327,O
involvement,327,O
of,327,O
cPLA,327,B-GENE-Y
(,327,I-GENE-Y
2,327,I-GENE-Y
),327,I-GENE-Y
and,327,O
COX-2,327,B-GENE-Y
in,327,O
this,327,O
effect,327,O
.,327,O
It,328,O
is,328,O
suggested,328,O
that,328,O
measurement,328,O
of,328,O
dopamine-induced,328,B-CHEMICAL
PGE,328,O
(,328,O
2,328,O
),328,O
production,328,O
may,328,O
serve,328,O
as,328,O
a,328,O
convenient,328,O
way,328,O
to,328,O
study,328,O
D,328,B-GENE-Y
(,328,I-GENE-Y
2,328,I-GENE-Y
),328,I-GENE-Y
receptor,328,I-GENE-Y
function,328,O
in,328,O
vitro,328,O
.,328,O
A,329,O
high,329,O
throughput,329,O
assay,329,O
for,329,O
the,329,O
glucuronidation,329,O
of,329,O
7-hydroxy-4-trifluoromethylcoumarin,329,B-CHEMICAL
by,329,O
recombinant,329,O
human,329,B-GENE-N
UDP-glucuronosyltransferases,329,I-GENE-N
and,329,O
liver,329,O
microsomes,329,O
.,329,O
Abstract,330,O
1,330,O
.,330,O
UDP-glucuronosyltransferases,331,O
(,331,O
UGTs,331,O
),331,I-GENE-N
are,331,O
versatile,331,O
and,331,O
important,331,O
conjugation,331,O
enzymes,331,O
in,331,O
the,331,O
metabolism,331,O
of,331,O
drugs,331,O
and,331,O
other,331,O
xenobiotics,331,O
.,331,O
2,332,O
.,332,O
We,333,O
have,333,O
developed,333,O
a,333,O
convenient,333,O
quantitative,333,O
multi-well,333,O
plate,333,O
assay,333,O
to,333,O
measure,333,O
the,333,O
glucuronidation,333,O
rate,333,O
of,333,O
7-hydroxy-4-trifluoromethylcoumarin,333,O
(,333,I-CHEMICAL
HFC,333,O
),333,I-CHEMICAL
for,333,O
several,333,O
UGTs,333,O
.,333,O
3,334,O
.,334,O
We,335,O
have,335,O
used,335,O
this,335,O
method,335,O
to,335,O
screen,335,O
11,335,O
recombinant,335,O
human,335,O
UGTs,335,I-GENE-N
for,335,O
HFC,335,O
glucuronidation,335,O
activity,335,O
and,335,O
studied,335,O
the,335,O
reaction,335,O
kinetics,335,O
with,335,O
the,335,O
most,335,O
active,335,O
enzymes,335,O
.,335,O
We,336,O
have,336,O
also,336,O
examined,336,O
the,336,O
HFC,336,O
glucuronidation,336,O
activity,336,O
of,336,O
liver,336,O
microsomes,336,O
from,336,O
human,336,O
",",336,O
pig,336,O
",",336,O
rabbit,336,O
and,336,O
rat,336,O
.,336,O
4,337,O
.,337,O
At,338,O
a,338,O
substrate,338,O
concentration,338,O
of,338,O
20,338,O
µM,338,O
",",338,O
the,338,O
most,338,O
active,338,O
HFC,338,O
glucuronidation,338,B-CHEMICAL
catalysts,338,O
were,338,O
UGT1A10,338,O
followed,338,O
by,338,O
UGT1A6,338,O
>,338,I-GENE-Y
UGT1A7,338,O
>,338,I-GENE-Y
UGT2A1,338,O
",",338,I-GENE-Y
whereas,338,O
at,338,O
300,338,O
µM,338,O
UGT1A6,338,O
was,338,I-GENE-Y
about,338,O
10,338,O
times,338,O
better,338,O
catalyst,338,O
than,338,O
the,338,O
other,338,O
recombinant,338,O
UGTs,338,O
.,338,O
The,339,O
activities,339,O
of,339,O
UGTs,339,O
1A3,339,I-GENE-N
",",339,I-GENE-N
1A8,339,I-GENE-N
",",339,I-GENE-N
1A9,339,I-GENE-N
",",339,I-GENE-N
2B4,339,I-GENE-N
and,339,I-GENE-N
2B7,339,I-GENE-N
were,339,O
low,339,O
",",339,O
whereas,339,O
UGT1A1,339,O
and,339,I-GENE-Y
UGT2B17,339,O
exhibited,339,O
no,339,O
HFC,339,O
glucuronidation,339,B-CHEMICAL
activity,339,O
.,339,O
UGT1A6,340,O
exhibited,340,O
a,340,O
significantly,340,O
higher,340,O
Vmax,340,O
and,340,O
Km,340,O
values,340,O
toward,340,O
both,340,O
HFC,340,O
and,340,B-CHEMICAL
UDP-glucuronic,340,O
acid,340,I-CHEMICAL
than,340,O
the,340,O
other,340,O
UGTs,340,O
.,340,O
5,341,O
.,341,O
Human,342,O
",",342,O
pig,342,O
and,342,O
rabbit,342,O
",",342,O
but,342,O
not,342,O
rat,342,O
liver,342,O
microsomes,342,O
",",342,O
catalyzed,342,O
HFC,342,O
glucuronidation,342,O
at,342,O
high,342,O
rates,342,O
.,342,O
6,343,O
.,343,O
This,344,O
new,344,O
method,344,O
is,344,O
particularly,344,O
suitable,344,O
for,344,O
fast,344,O
activity,344,O
screenings,344,O
of,344,O
UGTs,344,O
1A6,344,O
",",344,I-GENE-N
1A7,344,I-GENE-N
",",344,I-GENE-N
1A10,344,I-GENE-N
and,344,I-GENE-N
2A1,344,I-GENE-N
and,344,I-GENE-N
HFC,344,O
glucuronidation,344,O
activity,344,O
determination,344,O
from,344,O
various,344,O
samples,344,O
.,344,O
Influence,345,O
of,345,O
the,345,O
novel,345,O
histamine,345,B-GENE-Y
H3,345,I-GENE-Y
receptor,345,I-GENE-Y
antagonist,345,O
ST1283,345,O
on,345,O
voluntary,345,O
alcohol,345,B-CHEMICAL
consumption,345,O
and,345,O
ethanol-induced,345,B-CHEMICAL
place,345,O
preference,345,O
in,345,O
mice,345,O
.,345,O
RATIONALE,346,O
:,346,O
Growing,346,O
evidence,346,O
supports,346,O
a,346,O
role,346,O
for,346,O
the,346,O
central,346,O
histaminergic,346,O
system,346,O
to,346,O
have,346,O
a,346,O
modulatory,346,O
influence,346,O
on,346,O
drug,346,O
addiction,346,O
in,346,O
general,346,O
and,346,O
alcohol-use,346,B-CHEMICAL
disorders,346,O
in,346,O
particular,346,O
through,346,O
histamine,346,B-GENE-Y
H3,346,I-GENE-Y
receptors,346,I-GENE-Y
(,346,O
H3R,346,B-GENE-Y
),346,O
.,346,O
OBJECTIVE,347,O
:,347,O
In,347,O
the,347,O
present,347,O
study,347,O
",",347,O
the,347,O
effects,347,O
of,347,O
systemic,347,O
injection,347,O
of,347,O
the,347,O
newly,347,O
synthesized,347,O
H3R,347,B-GENE-Y
antagonist,347,O
ST1283,347,O
on,347,O
ethanol,347,B-CHEMICAL
(,347,O
EtOH,347,B-CHEMICAL
),347,O
voluntary,347,O
intake,347,O
and,347,O
EtOH-conditioned,347,B-CHEMICAL
reward,347,O
in,347,O
mice,347,O
have,347,O
been,347,O
investigated,347,O
.,347,O
METHODS,348,O
:,348,O
Oral,348,O
EtOH,348,B-CHEMICAL
",",348,O
saccharin,348,B-CHEMICAL
",",348,O
and,348,O
quinine,348,B-CHEMICAL
intake,348,O
was,348,O
assessed,348,O
in,348,O
a,348,O
two-bottle,348,O
choice,348,O
paradigm,348,O
using,348,O
escalating,348,O
concentrations,348,O
of,348,O
alcohol,348,B-CHEMICAL
or,348,O
tastant,348,O
solutions,348,O
.,348,O
EtOH-induced,349,B-CHEMICAL
place,349,O
preference,349,O
(,349,O
CPP,349,O
),349,O
",",349,O
EtOH-induced,349,B-CHEMICAL
locomotor,349,O
activity,349,O
",",349,O
and,349,O
blood,349,O
ethanol,349,B-CHEMICAL
concentration,349,O
(,349,O
BEC,349,O
),349,O
were,349,O
also,349,O
measured,349,O
.,349,O
RESULTS,350,O
:,350,O
Following,350,O
administration,350,O
of,350,O
the,350,O
H3R,350,B-GENE-Y
antagonist,350,O
(,350,O
2.5,350,O
",",350,O
5,350,O
",",350,O
and,350,O
10,350,O
mg/kg,350,O
",",350,O
i.p,350,O
.,350,O
),351,O
",",351,O
there,351,O
was,351,O
a,351,O
significant,351,O
dose-dependent,351,O
decrease,351,O
in,351,O
alcohol,351,O
consumption,351,O
and,351,O
preference,351,O
.,351,O
Importantly,352,O
",",352,O
vehicle-,352,O
and,352,O
ST1283,352,O
(,352,O
5,352,O
mg/kg,352,O
),352,O
-treated,352,O
mice,352,O
showed,352,O
similar,352,O
consumption,352,O
and,352,O
preference,352,O
to,352,O
increasing,352,O
concentration,352,O
of,352,O
both,352,O
sweet,352,O
and,352,O
bitter,352,O
tastes,352,O
.,352,O
More,353,O
interestingly,353,O
",",353,O
systemic,353,O
administration,353,O
of,353,O
ST1283,353,O
inhibited,353,O
EtOH-CPP,353,O
and,353,O
EtOH-enhanced,353,O
locomotion,353,O
.,353,O
This,354,O
inhibition,354,O
was,354,O
blocked,354,O
when,354,O
mice,354,O
were,354,O
pretreated,354,O
with,354,O
the,354,O
selective,354,O
H3R,354,O
agonist,354,O
R-,354,I-CHEMICAL
(,354,I-CHEMICAL
alpha,354,I-CHEMICAL
),354,I-CHEMICAL
-methyl-histamine,354,O
(,354,O
10,354,O
mg/kg,354,O
),354,O
.,354,O
Finally,355,O
",",355,O
vehicle-,355,O
and,355,O
ST1283-treated,355,O
mice,355,O
had,355,O
similar,355,O
BECs,355,O
.,355,O
CONCLUSION,356,O
:,356,O
Our,356,O
results,356,O
show,356,O
that,356,O
ST1283,356,O
may,356,O
decrease,356,O
voluntary,356,O
EtOH,356,O
consumption,356,O
and,356,O
EtOH-CPP,356,O
by,356,O
altering,356,O
its,356,O
reinforcing,356,O
effects,356,O
",",356,O
suggesting,356,O
a,356,O
novel,356,O
role,356,O
for,356,O
histamine,356,O
signaling,356,O
in,356,O
regulation,356,O
of,356,O
alcoholism,356,O
.,356,O
Lastly,357,O
",",357,O
the,357,O
results,357,O
add,357,O
to,357,O
the,357,O
growing,357,O
literature,357,O
on,357,O
H3R,357,O
modulation,357,O
in,357,O
the,357,O
pharmacotherapy,357,O
of,357,O
EtOH,357,O
addiction,357,O
.,357,O
The,358,O
tricyclic,358,B-CHEMICAL
antidepressant,358,O
clomipramine,358,B-CHEMICAL
increases,358,O
plasma,358,O
glucose,358,B-CHEMICAL
levels,358,O
of,358,O
mice,358,O
.,358,O
Effects,359,O
of,359,O
the,359,O
tricyclic,359,B-CHEMICAL
antidepressant,359,O
clomipramine,359,B-CHEMICAL
on,359,O
plasma,359,O
glucose,359,B-CHEMICAL
levels,359,O
in,359,O
mice,359,O
were,359,O
studied,359,O
.,359,O
Clomipramine,360,B-CHEMICAL
at,360,O
doses,360,O
ranging,360,O
5,360,O
-,360,O
20,360,O
mg/kg,360,O
elicited,360,O
significant,360,O
hyperglycemia,360,O
in,360,O
mice,360,O
.,360,O
Hyperglycemia,361,O
elicited,361,O
by,361,O
clomipramine,361,B-CHEMICAL
was,361,O
not,361,O
reduced,361,O
by,361,O
pretreatment,361,O
with,361,O
the,361,O
5-hydroxytryptamine,361,B-CHEMICAL
(,361,O
5-HT,361,B-CHEMICAL
),361,O
depleter,361,O
p-chlorophenylalanine,361,B-CHEMICAL
.,361,O
The,362,O
5-HT,362,B-GENE-N
(,362,I-GENE-N
1/2/5/7,362,I-GENE-N
),362,I-GENE-N
-receptor,362,I-GENE-N
antagonist,362,O
methysergide,362,O
and,362,O
the,362,O
5-HT,362,B-GENE-N
(,362,I-GENE-N
2A/2B/2C,362,I-GENE-N
),362,I-GENE-N
-receptor,362,I-GENE-N
antagonist,362,O
LY,362,B-CHEMICAL
53857,362,I-CHEMICAL
enhanced,362,O
clomipramine-induced,362,B-CHEMICAL
hyperglycemia,362,O
",",362,O
while,362,O
the,362,O
5-HT,362,B-GENE-N
(,362,I-GENE-N
1A/1B,362,I-GENE-N
),362,I-GENE-N
-receptor,362,I-GENE-N
antagonist,362,O
(,362,B-CHEMICAL
-,362,I-CHEMICAL
),362,I-CHEMICAL
-propranolol,362,I-CHEMICAL
and,362,O
the,362,O
5-HT,362,B-GENE-N
(,362,I-GENE-N
3/4,362,I-GENE-N
),362,I-GENE-N
-receptor,362,I-GENE-N
antagonist,362,O
tropisetron,362,B-CHEMICAL
did,362,O
not,362,O
affect,362,O
it,362,O
.,362,O
The,363,O
5-HT,363,B-GENE-N
(,363,I-GENE-N
2B/2C,363,I-GENE-N
),363,I-GENE-N
-receptor,363,I-GENE-N
antagonist,363,O
SB,363,B-CHEMICAL
206553,363,I-CHEMICAL
facilitated,363,O
hyperglycemia,363,O
induced,363,O
by,363,O
clomipramine,363,B-CHEMICAL
",",363,O
although,363,O
the,363,O
5-HT,363,B-GENE-Y
(,363,I-GENE-Y
2A,363,I-GENE-Y
),363,I-GENE-Y
-receptor,363,O
antagonist,363,O
ketanserin,363,B-CHEMICAL
was,363,O
without,363,O
effect,363,O
.,363,O
Clomipramine-induced,364,B-CHEMICAL
hyperglycemia,364,O
was,364,O
reduced,364,O
by,364,O
prior,364,O
adrenalectomy,364,O
.,364,O
These,365,O
results,365,O
suggest,365,O
that,365,O
clomipramine,365,B-CHEMICAL
induces,365,O
hyperglycemia,365,O
in,365,O
mice,365,O
by,365,O
blocking,365,O
the,365,O
5-HT,365,B-GENE-Y
(,365,I-GENE-Y
2B,365,I-GENE-Y
),365,I-GENE-Y
and/or,365,O
5-HT,365,B-GENE-Y
(,365,I-GENE-Y
2C,365,I-GENE-Y
),365,I-GENE-Y
receptors,365,O
",",365,O
which,365,O
results,365,O
in,365,O
facilitation,365,O
of,365,O
adrenaline,365,B-CHEMICAL
release,365,O
.,365,O
p300-mediated,366,B-GENE-Y
acetylation,366,O
of,366,O
TRF2,366,B-GENE-Y
is,366,O
required,366,O
for,366,O
maintaining,366,O
functional,366,O
telomeres,366,O
.,366,O
The,367,O
human,367,B-GENE-Y
telomeric,367,I-GENE-Y
protein,367,I-GENE-Y
TRF2,367,I-GENE-Y
is,367,O
required,367,O
to,367,O
protect,367,O
chromosome,367,O
ends,367,O
by,367,O
facilitating,367,O
their,367,O
organization,367,O
into,367,O
the,367,O
protective,367,O
capping,367,O
structure,367,O
.,367,O
Post-translational,368,O
modifications,368,O
of,368,O
TRF2,368,B-GENE-Y
such,368,O
as,368,O
phosphorylation,368,O
",",368,O
ubiquitination,368,O
",",368,O
SUMOylation,368,O
",",368,O
methylation,368,O
and,368,O
poly,368,O
(,368,O
ADP-ribosyl,368,B-CHEMICAL
),368,O
ation,368,O
have,368,O
been,368,O
shown,368,O
to,368,O
play,368,O
important,368,O
roles,368,O
in,368,O
telomere,368,O
function,368,O
.,368,O
Here,369,O
we,369,O
show,369,O
that,369,O
TRF2,369,B-GENE-Y
specifically,369,O
interacts,369,O
with,369,O
the,369,O
histone,369,B-GENE-Y
acetyltransferase,369,I-GENE-Y
p300,369,I-GENE-Y
",",369,O
and,369,O
that,369,O
p300,369,B-GENE-Y
acetylates,369,O
the,369,O
lysine,369,B-CHEMICAL
residue,369,O
at,369,O
position,369,O
293,369,O
of,369,O
TRF2,369,B-GENE-Y
.,369,O
We,370,O
also,370,O
report,370,O
that,370,O
p300-mediated,370,B-GENE-Y
acetylation,370,O
stabilizes,370,O
the,370,O
TRF2,370,B-GENE-Y
protein,370,O
by,370,O
inhibiting,370,O
its,370,O
ubiquitin-dependent,370,B-GENE-N
proteolysis,370,O
and,370,O
is,370,O
required,370,O
for,370,O
efficient,370,O
telomere,370,O
binding,370,O
of,370,O
TRF2,370,B-GENE-Y
.,370,O
Furthermore,371,O
",",371,O
overexpression,371,O
of,371,O
the,371,O
acetylation-deficient,371,O
mutant,371,O
",",371,O
K293R,371,B-GENE-N
",",371,O
induces,371,O
DNA-damage,371,O
response,371,O
foci,371,O
at,371,O
telomeres,371,O
",",371,O
thereby,371,O
leading,371,O
to,371,O
induction,371,O
of,371,O
impaired,371,O
cell,371,O
growth,371,O
",",371,O
cellular,371,O
senescence,371,O
and,371,O
altered,371,O
cell,371,O
cycle,371,O
distribution,371,O
.,371,O
A,372,O
small,372,O
but,372,O
significant,372,O
number,372,O
of,372,O
metaphase,372,O
chromosomes,372,O
show,372,O
no,372,O
telomeric,372,O
signals,372,O
at,372,O
chromatid,372,O
ends,372,O
",",372,O
suggesting,372,O
an,372,O
aberrant,372,O
telomere,372,O
structure,372,O
.,372,O
These,373,O
findings,373,O
demonstrate,373,O
that,373,O
acetylation,373,O
of,373,O
TRF2,373,B-GENE-Y
by,373,O
p300,373,B-GENE-Y
plays,373,O
a,373,O
crucial,373,O
role,373,O
in,373,O
the,373,O
maintenance,373,O
of,373,O
functional,373,O
telomeres,373,O
as,373,O
well,373,O
as,373,O
in,373,O
the,373,O
regulation,373,O
of,373,O
the,373,O
telomere-associated,373,O
DNA-damage,373,O
response,373,O
",",373,O
thus,373,O
providing,373,O
a,373,O
new,373,O
route,373,O
for,373,O
modulating,373,O
telomere,373,O
protection,373,O
function,373,O
.,373,O
Externalization,374,O
of,374,O
phosphatidylserine,374,B-CHEMICAL
during,374,O
apoptosis,374,O
does,374,O
not,374,O
specifically,374,O
require,374,O
either,374,O
isoform,374,O
of,374,O
phosphatidylserine,374,B-GENE-N
synthase,374,I-GENE-N
.,374,O
Phosphatidylserine,375,B-CHEMICAL
(,375,O
PtdSer,375,B-CHEMICAL
),375,O
is,375,O
made,375,O
in,375,O
mammalian,375,O
cells,375,O
by,375,O
two,375,O
PtdSer,375,B-GENE-N
synthases,375,I-GENE-N
",",375,O
PSS1,375,B-GENE-N
and,375,O
PSS2,375,B-GENE-N
.,375,O
In,376,O
the,376,O
plasma,376,O
membrane,376,O
PtdSer,376,B-CHEMICAL
is,376,O
normally,376,O
localized,376,O
on,376,O
the,376,O
inner,376,O
leaflet,376,O
but,376,O
undergoes,376,O
transbilayer,376,O
movement,376,O
during,376,O
apoptosis,376,O
and,376,O
becomes,376,O
exposed,376,O
on,376,O
the,376,O
cell,376,O
surface,376,O
.,376,O
We,377,O
induced,377,O
apoptosis,377,O
with,377,O
staurosporine,377,B-CHEMICAL
in,377,O
four,377,O
Chinese,377,O
hamster,377,O
ovary,377,O
(,377,O
CHO,377,O
),377,O
cell,377,O
lines,377,O
that,377,O
are,377,O
deficient,377,O
in,377,O
PSS1,377,B-GENE-Y
and/or,377,O
PSS2,377,B-GENE-Y
to,377,O
determine,377,O
if,377,O
PtdSer,377,B-CHEMICAL
generated,377,O
by,377,O
either,377,O
of,377,O
these,377,O
enzymes,377,O
is,377,O
required,377,O
for,377,O
externalization,377,O
on,377,O
the,377,O
cell,377,O
surface,377,O
during,377,O
apoptosis,377,O
.,377,O
The,378,O
onset,378,O
of,378,O
apoptosis,378,O
was,378,O
confirmed,378,O
by,378,O
the,378,O
appearance,378,O
of,378,O
morphological,378,O
changes,378,O
and,378,O
DNA,378,O
fragmentation,378,O
while,378,O
the,378,O
plasma,378,O
membrane,378,O
remained,378,O
largely,378,O
intact,378,O
.,378,O
In,379,O
all,379,O
cell,379,O
lines,379,O
",",379,O
regardless,379,O
of,379,O
their,379,O
content,379,O
of,379,O
PSS1,379,B-GENE-Y
and/or,379,O
PSS2,379,B-GENE-Y
",",379,O
apoptosis,379,O
occurred,379,O
to,379,O
approximately,379,O
the,379,O
same,379,O
extent,379,O
",",379,O
and,379,O
within,379,O
approximately,379,O
the,379,O
same,379,O
time,379,O
frame,379,O
",",379,O
as,379,O
in,379,O
parental,379,O
CHO-K1,379,O
cells,379,O
.,379,O
The,380,O
exposure,380,O
of,380,O
PtdSer,380,B-CHEMICAL
on,380,O
the,380,O
cell,380,O
surface,380,O
was,380,O
assessed,380,O
by,380,O
annexin,380,O
V,380,O
labeling,380,O
and,380,O
flow,380,O
cytometry,380,O
.,380,O
Cells,381,O
that,381,O
were,381,O
deficient,381,O
in,381,O
either,381,O
PSS1,381,B-GENE-Y
or,381,O
PSS2,381,B-GENE-Y
",",381,O
as,381,O
well,381,O
as,381,O
cells,381,O
that,381,O
were,381,O
deficient,381,O
in,381,O
both,381,O
PSS1,381,B-GENE-Y
and,381,O
PSS2,381,B-GENE-Y
",",381,O
externalized,381,O
normal,381,O
amounts,381,O
of,381,O
PtdSer,381,B-CHEMICAL
.,381,O
Our,382,O
study,382,O
demonstrates,382,O
",",382,O
that,382,O
reduction,382,O
of,382,O
in,382,O
vitro,382,O
serine-exchange,382,B-CHEMICAL
activity,382,O
",",382,O
even,382,O
by,382,O
97,382,O
%,382,O
",",382,O
does,382,O
not,382,O
restrict,382,O
the,382,O
externalization,382,O
of,382,O
PtdSer,382,B-CHEMICAL
during,382,O
apoptosis,382,O
.,382,O
Moreover,383,O
",",383,O
a,383,O
normal,383,O
level,383,O
of,383,O
expression,383,O
of,383,O
PSS1,383,B-GENE-Y
and/or,383,O
PSS2,383,B-GENE-Y
is,383,O
not,383,O
required,383,O
for,383,O
generating,383,O
the,383,O
pool,383,O
of,383,O
PtdSer,383,B-CHEMICAL
externalized,383,O
during,383,O
apoptosis,383,O
.,383,O
Characterization,384,O
of,384,O
the,384,O
interaction,384,O
of,384,O
ingenol,384,B-CHEMICAL
3-angelate,384,I-CHEMICAL
with,384,O
protein,384,B-GENE-N
kinase,384,I-GENE-N
C.,384,O
Ingenol,384,B-CHEMICAL
3-angelate,384,I-CHEMICAL
(,384,O
I3A,384,B-CHEMICAL
),384,O
is,384,O
one,384,O
of,384,O
the,384,O
active,384,O
ingredients,384,O
in,384,O
Euphorbia,384,O
peplus,384,O
",",384,O
which,384,O
has,384,O
been,384,O
used,384,O
in,384,O
traditional,384,O
medicine,384,O
.,384,O
Here,385,O
",",385,O
we,385,O
report,385,O
the,385,O
initial,385,O
characterization,385,O
of,385,O
I3A,385,B-CHEMICAL
as,385,O
a,385,O
protein,385,B-GENE-N
kinase,385,I-GENE-N
C,385,I-GENE-N
(,385,O
PKC,385,B-GENE-N
),385,O
ligand,385,O
.,385,O
I3A,386,B-CHEMICAL
bound,386,O
to,386,O
PKC-alpha,386,B-GENE-Y
in,386,O
the,386,O
presence,386,O
of,386,O
phosphatidylserine,386,B-CHEMICAL
with,386,O
high,386,O
affinity,386,O
;,386,O
however,386,O
",",386,O
under,386,O
these,386,O
assay,386,O
conditions,386,O
",",386,O
little,386,O
PKC,386,B-GENE-N
isoform,386,O
selectivity,386,O
was,386,O
observed,386,O
.,386,O
PKC,387,B-GENE-N
isoforms,387,O
did,387,O
show,387,O
different,387,O
sensitivity,387,O
and,387,O
selectivity,387,O
for,387,O
down-regulation,387,O
by,387,O
I3A,387,B-CHEMICAL
and,387,O
phorbol,387,B-CHEMICAL
12-myristate,387,I-CHEMICAL
13-acetate,387,I-CHEMICAL
(,387,O
PMA,387,B-CHEMICAL
),387,O
in,387,O
WEHI-231,387,O
",",387,O
HOP-92,387,O
",",387,O
and,387,O
Colo-205,387,O
cells,387,O
.,387,O
In,388,O
all,388,O
of,388,O
the,388,O
three,388,O
cell,388,O
types,388,O
",",388,O
I3A,388,B-CHEMICAL
inhibited,388,O
cell,388,O
proliferation,388,O
with,388,O
somewhat,388,O
lower,388,O
potency,388,O
than,388,O
did,388,O
PMA,388,B-CHEMICAL
.,388,O
In,389,O
intact,389,O
CHO-K1,389,O
cells,389,O
",",389,O
I3A,389,B-CHEMICAL
was,389,O
able,389,O
to,389,O
translocate,389,O
different,389,O
green,389,B-GENE-Y
fluorescent,389,I-GENE-Y
protein-tagged,389,O
PKC,389,B-GENE-N
isoforms,389,O
",",389,O
visualized,389,O
by,389,O
confocal,389,O
microscopy,389,O
",",389,O
with,389,O
equal,389,O
or,389,O
higher,389,O
potency,389,O
than,389,O
PMA,389,B-CHEMICAL
.,389,O
PKC-delta,390,B-GENE-Y
in,390,O
particular,390,O
showed,390,O
a,390,O
different,390,O
pattern,390,O
of,390,O
translocation,390,O
in,390,O
response,390,O
to,390,O
I3A,390,B-CHEMICAL
and,390,O
PMA,390,B-CHEMICAL
.,390,O
I3A,391,B-CHEMICAL
induced,391,O
a,391,O
higher,391,O
level,391,O
of,391,O
secretion,391,O
of,391,O
the,391,O
inflammatory,391,O
cytokine,391,B-GENE-N
interleukin,391,B-GENE-Y
6,391,I-GENE-Y
compared,391,O
with,391,O
PMA,391,B-CHEMICAL
in,391,O
the,391,O
WEHI-231,391,O
cells,391,O
and,391,O
displayed,391,O
a,391,O
marked,391,O
biphasic,391,O
dose-response,391,O
curve,391,O
for,391,O
the,391,O
induction,391,O
.,391,O
I3A,392,B-CHEMICAL
was,392,O
unable,392,O
to,392,O
cause,392,O
the,392,O
same,392,O
extent,392,O
of,392,O
association,392,O
of,392,O
the,392,O
C1b,392,B-GENE-N
domain,392,I-GENE-N
of,392,O
PKC-delta,392,B-GENE-Y
with,392,O
lipids,392,O
",",392,O
compared,392,O
with,392,O
PMA,392,B-CHEMICAL
or,392,O
the,392,O
physiological,392,O
regulator,392,O
diacylglycerol,392,B-CHEMICAL
",",392,O
and,392,O
was,392,O
able,392,O
to,392,O
partially,392,O
block,392,O
the,392,O
association,392,O
induced,392,O
by,392,O
these,392,O
agents,392,O
",",392,O
measured,392,O
by,392,O
surface,392,O
plasmon,392,O
resonance,392,O
.,392,O
The,393,O
in,393,O
vitro,393,O
kinase,393,O
activity,393,O
of,393,O
PKC-alpha,393,B-GENE-Y
induced,393,O
by,393,O
I3A,393,B-CHEMICAL
was,393,O
lower,393,O
than,393,O
that,393,O
induced,393,O
by,393,O
PMA,393,B-CHEMICAL
.,393,O
The,394,O
novel,394,O
pattern,394,O
of,394,O
behavior,394,O
of,394,O
I3A,394,B-CHEMICAL
makes,394,O
it,394,O
of,394,O
great,394,O
interest,394,O
for,394,O
further,394,O
evaluation,394,O
.,394,O
In,395,O
ovo,395,O
effects,395,O
of,395,O
two,395,O
organophosphate,395,B-CHEMICAL
flame,395,O
retardants,395,O
",",395,O
TCPP,395,B-CHEMICAL
and,395,O
TDCPP,395,B-CHEMICAL
",",395,O
on,395,O
pipping,395,O
success,395,O
",",395,O
development,395,O
",",395,O
mRNA,395,O
expression,395,O
and,395,O
thyroid,395,O
hormone,395,O
levels,395,O
in,395,O
chicken,395,O
embryos,395,O
.,395,O
Tris,396,B-CHEMICAL
(,396,I-CHEMICAL
1-chloro-2-propyl,396,I-CHEMICAL
),396,I-CHEMICAL
phosphate,396,I-CHEMICAL
(,396,O
TCPP,396,B-CHEMICAL
),396,O
and,396,O
tris,396,B-CHEMICAL
(,396,I-CHEMICAL
"1,3-dichloro-2-propyl",396,I-CHEMICAL
),396,I-CHEMICAL
phosphate,396,I-CHEMICAL
(,396,O
TDCPP,396,B-CHEMICAL
),396,O
are,396,O
organic,396,O
flame,396,O
retardants,396,O
detected,396,O
in,396,O
the,396,O
environment,396,O
and,396,O
biota,396,O
for,396,O
which,396,O
toxicological,396,O
data,396,O
for,396,O
avian,396,O
species,396,O
are,396,O
limited,396,O
.,396,O
In,397,O
this,397,O
study,397,O
",",397,O
domestic,397,O
chicken,397,O
eggs,397,O
were,397,O
injected,397,O
with,397,O
TCPP,397,B-CHEMICAL
or,397,O
TDCPP,397,B-CHEMICAL
(,397,O
maximum,397,O
dose,397,O
=,397,O
51600,397,O
and,397,O
45000,397,O
ng/g,397,O
egg,397,O
",",397,O
respectively,397,O
),397,O
to,397,O
determine,397,O
dose-dependent,397,O
effects,397,O
on,397,O
pipping,397,O
success,397,O
",",397,O
development,397,O
",",397,O
hepatic,397,O
messenger,397,O
RNA,397,O
(,397,O
mRNA,397,O
),397,O
expression,397,O
levels,397,O
of,397,O
genes,397,O
associated,397,O
with,397,O
xenobiotic,397,O
metabolism,397,O
and,397,O
the,397,O
thyroid,397,O
hormone,397,O
(,397,O
TH,397,O
),397,O
pathway,397,O
",",397,O
and,397,O
TH,397,O
levels,397,O
following,397,O
20-22,397,O
days,397,O
of,397,O
incubation,397,O
.,397,O
Neither,398,O
compound,398,O
reduced,398,O
pipping,398,O
success,398,O
;,398,O
however,398,O
",",398,O
TCPP,398,B-CHEMICAL
significantly,398,O
delayed,398,O
pipping,398,O
at,398,O
9240,398,O
and,398,O
51600,398,O
ng/g,398,O
and,398,O
reduced,398,O
tarsus,398,O
length,398,O
at,398,O
51600,398,O
ng/g,398,O
.,398,O
TDCPP,399,B-CHEMICAL
exposure,399,O
resulted,399,O
in,399,O
significant,399,O
decreases,399,O
in,399,O
head,399,O
plus,399,O
bill,399,O
length,399,O
",",399,O
embryo,399,O
mass,399,O
and,399,O
gallbladder,399,O
size,399,O
at,399,O
45000,399,O
ng/g,399,O
and,399,O
reduced,399,O
plasma,399,O
free,399,O
T4,399,O
levels,399,O
at,399,O
7640,399,O
ng/g,399,O
.,399,O
Type,400,B-GENE-Y
I,400,I-GENE-Y
deiodinase,400,I-GENE-Y
",",400,O
liver,400,B-GENE-Y
fatty-acid,400,I-GENE-Y
binding,400,I-GENE-Y
protein,400,I-GENE-Y
and,400,O
cytochrome,400,B-GENE-Y
P450,400,I-GENE-Y
(,400,I-GENE-Y
CYP,400,I-GENE-Y
),400,I-GENE-Y
3A37,400,I-GENE-Y
mRNA,400,O
levels,400,O
were,400,O
significantly,400,O
induced,400,O
by,400,O
TCPP,400,B-CHEMICAL
",",400,O
while,400,O
TDCPP,400,B-CHEMICAL
induced,400,O
CYP3A37,400,B-GENE-Y
and,400,O
CYP2H1,400,B-GENE-Y
.,400,O
Chemical,401,O
analysis,401,O
of,401,O
egg,401,O
contents,401,O
at,401,O
incubation,401,O
days,401,O
0,401,O
",",401,O
5,401,O
",",401,O
11,401,O
",",401,O
18,401,O
",",401,O
and,401,O
19,401,O
revealed,401,O
that,401,O
>,401,O
92,401,O
%,401,O
of,401,O
the,401,O
injected,401,O
TCPP,401,B-CHEMICAL
or,401,O
TDCPP,401,B-CHEMICAL
concentration,401,O
was,401,O
detectable,401,O
up,401,O
to,401,O
day,401,O
5,401,O
;,401,O
however,401,O
",",401,O
<,401,O
1,401,O
%,401,O
was,401,O
detected,401,O
by,401,O
day,401,O
19,401,O
.,401,O
The,402,O
observed,402,O
phenotypic,402,O
responses,402,O
to,402,O
TCPP,402,B-CHEMICAL
and,402,O
TDCPP,402,B-CHEMICAL
exposure,402,O
may,402,O
be,402,O
associated,402,O
with,402,O
disruption,402,O
of,402,O
the,402,O
TH-axis,402,O
",",402,O
which,402,O
is,402,O
critical,402,O
for,402,O
normal,402,O
growth,402,O
and,402,O
development,402,O
in,402,O
birds,402,O
.,402,O
The,403,O
effects,403,O
of,403,O
TDCPP,403,B-CHEMICAL
on,403,O
the,403,O
gallbladder,403,O
indicate,403,O
that,403,O
the,403,O
disturbance,403,O
of,403,O
lipid,403,O
metabolism,403,O
is,403,O
a,403,O
likely,403,O
target,403,O
in,403,O
its,403,O
mechanism,403,O
of,403,O
toxicity,403,O
.,403,O
Insulin-degrading,404,B-GENE-Y
enzyme,404,I-GENE-Y
(,404,O
IDE,404,B-GENE-Y
),404,O
:,404,O
a,404,O
novel,404,O
heat,404,B-GENE-N
shock-like,404,I-GENE-N
protein,404,I-GENE-N
.,404,O
Insulin-degrading,405,B-GENE-Y
enzyme,405,I-GENE-Y
(,405,O
IDE,405,B-GENE-Y
),405,O
is,405,O
a,405,O
highly,405,O
conserved,405,O
zinc,405,B-GENE-N
metallopeptidase,405,I-GENE-N
that,405,O
is,405,O
ubiquitously,405,O
distributed,405,O
in,405,O
human,405,O
tissues,405,O
",",405,O
and,405,O
particularly,405,O
abundant,405,O
in,405,O
the,405,O
brain,405,O
",",405,O
liver,405,O
",",405,O
and,405,O
muscles,405,O
.,405,O
IDE,406,B-GENE-Y
activity,406,O
has,406,O
been,406,O
historically,406,O
associated,406,O
with,406,O
insulin,406,B-GENE-Y
and,406,O
β-amyloid,406,B-GENE-Y
catabolism,406,O
.,406,O
However,407,O
",",407,O
over,407,O
the,407,O
last,407,O
decade,407,O
",",407,O
several,407,O
experimental,407,O
findings,407,O
have,407,O
established,407,O
that,407,O
IDE,407,B-GENE-Y
is,407,O
also,407,O
involved,407,O
in,407,O
a,407,O
wide,407,O
variety,407,O
of,407,O
physiopathological,407,O
processes,407,O
",",407,O
including,407,O
ubiquitin,407,B-GENE-N
clearance,407,O
and,407,O
Varicella,407,O
Zoster,407,O
Virus,407,O
infection,407,O
.,407,O
In,408,O
this,408,O
study,408,O
",",408,O
we,408,O
demonstrate,408,O
that,408,O
normal,408,O
and,408,O
malignant,408,O
cells,408,O
exposed,408,O
to,408,O
different,408,O
stresses,408,O
markedly,408,O
up-regulate,408,O
IDE,408,B-GENE-Y
in,408,O
a,408,O
heat,408,B-GENE-N
shock,408,I-GENE-N
protein,408,I-GENE-N
(,408,O
HSP,408,B-GENE-N
),408,O
-like,408,O
fashion,408,O
.,408,O
Additionally,409,O
",",409,O
we,409,O
focused,409,O
our,409,O
attention,409,O
on,409,O
tumor,409,O
cells,409,O
and,409,O
report,409,O
that,409,O
(,409,O
i,409,O
),409,O
IDE,409,B-GENE-Y
is,409,O
overexpressed,409,O
in,409,O
vivo,409,O
in,409,O
tumors,409,O
of,409,O
the,409,O
central,409,O
nervous,409,O
system,409,O
(,409,O
CNS,409,O
),409,O
;,409,O
(,409,O
ii,409,O
),409,O
IDE-silencing,409,B-GENE-Y
inhibits,409,O
neuroblastoma,409,O
(,409,O
SHSY5Y,409,O
),409,O
cell,409,O
proliferation,409,O
and,409,O
triggers,409,O
cell,409,O
death,409,O
;,409,O
(,409,O
iii,409,O
),409,O
IDE,409,B-GENE-Y
inhibition,409,O
is,409,O
accompanied,409,O
by,409,O
a,409,O
decrease,409,O
of,409,O
the,409,O
poly-ubiquitinated,409,O
protein,409,O
content,409,O
and,409,O
co-immunoprecipitates,409,O
with,409,O
proteasome,409,O
and,409,O
ubiquitin,409,O
in,409,O
SHSY5Y,409,O
cells,409,O
.,409,O
In,410,O
this,410,O
work,410,O
",",410,O
we,410,O
propose,410,O
a,410,O
novel,410,O
role,410,O
for,410,O
IDE,410,B-GENE-Y
as,410,O
a,410,O
heat,410,B-GENE-N
shock,410,I-GENE-N
protein,410,I-GENE-N
with,410,O
implications,410,O
in,410,O
cell,410,O
growth,410,O
regulation,410,O
and,410,O
cancer,410,O
progression,410,O
",",410,O
thus,410,O
opening,410,O
up,410,O
an,410,O
intriguing,410,O
hypothesis,410,O
of,410,O
IDE,410,B-GENE-Y
as,410,O
an,410,O
anticancer,410,O
target,410,O
.,410,O
Development,411,O
of,411,O
a,411,O
cell-based,411,O
high-throughput,411,O
peroxisome,411,B-GENE-N
proliferator-activated,411,I-GENE-N
receptors,411,I-GENE-N
(,411,O
PPARs,411,B-GENE-N
),411,O
screening,411,O
model,411,O
and,411,O
its,411,O
application,411,O
for,411,O
evaluation,411,O
of,411,O
the,411,O
extracts,411,O
from,411,O
Rhizoma,411,O
Coptis,411,O
.,411,O
To,412,O
date,412,O
",",412,O
peroxisome,412,B-GENE-N
proliferator-activated,412,I-GENE-N
receptors,412,I-GENE-N
(,412,O
PPARs,412,B-GENE-N
),412,O
are,412,O
becoming,412,O
the,412,O
new,412,O
therapeutic,412,O
targets,412,O
for,412,O
the,412,O
treatment,412,O
of,412,O
metabolic,412,O
diseases,412,O
",",412,O
such,412,O
as,412,O
Type,412,O
2,412,O
diabetes,412,O
",",412,O
obesity,412,O
",",412,O
and,412,O
cardiovascular,412,O
disease,412,O
.,412,O
In,413,O
this,413,O
study,413,O
",",413,O
a,413,O
cell-based,413,O
high-throughput,413,O
PPARs,413,B-GENE-N
(,413,O
PPARα/β/γ,413,B-GENE-N
),413,O
model,413,O
was,413,O
developed,413,O
for,413,O
the,413,O
screening,413,O
of,413,O
PPARs,413,B-GENE-N
agonists,413,O
.,413,O
The,414,O
screening,414,O
conditions,414,O
were,414,O
evaluated,414,O
through,414,O
analyzing,414,O
the,414,O
expression,414,O
value,414,O
of,414,O
luciferase,414,O
.,414,O
Finally,415,O
",",415,O
24,415,O
h,415,O
of,415,O
drug,415,O
acting,415,O
time,415,O
",",415,O
5,415,O
times,415,O
of,415,O
the,415,O
dilution,415,O
factor,415,O
of,415,O
luciferase,415,O
zymolyte,415,O
",",415,O
and,415,O
about,415,O
2,415,O
×,415,O
10,415,O
(,415,O
4,415,O
),415,O
cells/,415,O
well,415,O
on,415,O
HeLa,415,O
cells,415,O
in,415,O
96-well,415,O
plates,415,O
were,415,O
used,415,O
",",415,O
respectively,415,O
.,415,O
Furthermore,416,O
",",416,O
the,416,O
quality,416,O
of,416,O
high-throughput,416,O
screening,416,O
(,416,O
HTS,416,O
),416,O
in,416,O
stability,416,O
and,416,O
reliability,416,O
was,416,O
evaluated,416,O
by,416,O
the,416,O
Z'-factor,416,O
.,416,O
Additionally,417,O
",",417,O
different,417,O
extracts,417,O
of,417,O
Rhizoma,417,O
Coptis,417,O
and,417,O
berberine,417,B-CHEMICAL
were,417,O
tested,417,O
by,417,O
the,417,O
developed,417,O
method,417,O
.,417,O
The,418,O
results,418,O
suggested,418,O
that,418,O
both,418,O
the,418,O
EtOAc,418,B-CHEMICAL
extract,418,O
and,418,O
berberine,418,B-CHEMICAL
were,418,O
able,418,O
to,418,O
activate,418,O
PPARα/β/γ,418,B-GENE-N
",",418,O
and,418,O
Rhizoma,418,O
Coptis,418,O
contains,418,O
potential,418,O
natural,418,O
agonists,418,O
of,418,O
PPARs,418,B-GENE-N
besides,418,O
berberine,418,B-CHEMICAL
.,418,O
In,419,O
conclusion,419,O
",",419,O
the,419,O
developed,419,O
HTS,419,O
assay,419,O
is,419,O
a,419,O
simple,419,O
",",419,O
rapid,419,O
",",419,O
stable,419,O
",",419,O
and,419,O
specific,419,O
method,419,O
for,419,O
the,419,O
screening,419,O
of,419,O
PPARs,419,B-GENE-N
natural,419,O
agonists,419,O
.,419,O
Synthesis,420,O
of,420,O
2-aminomethyl-4-phenyl-1-azabicyclo,420,B-CHEMICAL
[,420,I-CHEMICAL
2.2.1,420,I-CHEMICAL
],420,I-CHEMICAL
heptanes,420,I-CHEMICAL
via,420,O
LiAlH₄-induced,420,B-CHEMICAL
reductive,420,O
cyclization,420,O
of,420,O
2-,420,B-CHEMICAL
(,420,I-CHEMICAL
4-chloro-2-cyano-2-phenylbutyl,420,I-CHEMICAL
),420,I-CHEMICAL
aziridines,420,I-CHEMICAL
and,420,O
evaluation,420,O
of,420,O
their,420,O
antimalarial,420,O
activity,420,O
.,420,O
2-,421,B-CHEMICAL
(,421,I-CHEMICAL
4-Chloro-2-cyano-2-phenylbutyl,421,I-CHEMICAL
),421,I-CHEMICAL
aziridines,421,I-CHEMICAL
were,421,O
employed,421,O
for,421,O
the,421,O
one-step,421,O
stereoselective,421,O
construction,421,O
of,421,O
both,421,O
endo-,421,B-CHEMICAL
and,421,I-CHEMICAL
exo-2-aminomethyl-4-phenyl-1-azabicyclo,421,I-CHEMICAL
[,421,I-CHEMICAL
2.2.1,421,I-CHEMICAL
],421,I-CHEMICAL
heptanes,421,I-CHEMICAL
as,421,O
new,421,O
azaheterobicyclic,421,B-CHEMICAL
scaffolds,421,O
via,421,O
a,421,O
double,421,O
LiAlH,421,B-CHEMICAL
(,421,I-CHEMICAL
4,421,I-CHEMICAL
),421,I-CHEMICAL
-induced,421,O
reductive,421,O
cyclization,421,O
protocol,421,O
.,421,O
Antiplasmodial,422,O
assessment,422,O
of,422,O
these,422,O
1-azabicyclo,422,B-CHEMICAL
[,422,I-CHEMICAL
2.2.1,422,I-CHEMICAL
],422,I-CHEMICAL
heptanes,422,I-CHEMICAL
revealed,422,O
moderate,422,O
to,422,O
good,422,O
activities,422,O
in,422,O
the,422,O
micromolar,422,O
range,422,O
",",422,O
with,422,O
the,422,O
exo-isomers,422,O
being,422,O
the,422,O
most,422,O
promising,422,O
structures,422,O
.,422,O
Furthermore,423,O
",",423,O
the,423,O
proposed,423,O
mode,423,O
of,423,O
action,423,O
was,423,O
supported,423,O
by,423,O
ligand,423,O
docking,423,O
studies,423,O
",",423,O
pointing,423,O
to,423,O
a,423,O
strong,423,O
binding,423,O
interaction,423,O
with,423,O
the,423,O
enzyme,423,O
plasmepsin,423,B-GENE-Y
II,423,I-GENE-Y
.,423,O
Pretreatment,424,O
renal,424,O
vascular,424,O
tone,424,O
predicts,424,O
the,424,O
effect,424,O
of,424,O
specific,424,O
renin,424,B-GENE-Y
inhibition,424,O
on,424,O
natriuresis,424,O
in,424,O
essential,424,O
hypertension,424,O
.,424,O
BACKGROUND,425,O
:,425,O
In,425,O
essential,425,O
hypertension,425,O
an,425,O
elevated,425,O
renal,425,O
vascular,425,O
resistance,425,O
(,425,O
RVR,425,O
),425,O
may,425,O
be,425,O
a,425,O
marker,425,O
of,425,O
renin-angiotensin-aldosterone,425,B-GENE-Y
system-mediated,425,O
impairment,425,O
of,425,O
renal,425,O
sodium,425,B-CHEMICAL
excretion,425,O
.,425,O
This,426,O
hypothesis,426,O
was,426,O
tested,426,O
by,426,O
investigating,426,O
whether,426,O
",",426,O
in,426,O
subjects,426,O
with,426,O
essential,426,O
hypertension,426,O
",",426,O
the,426,O
natriuretic,426,O
response,426,O
to,426,O
specific,426,O
renin-angiotensin-aldosterone,426,B-GENE-Y
system,426,O
(,426,O
RAAS,426,O
),426,O
blockade,426,O
by,426,O
renin-inhibitor,426,B-GENE-Y
remikiren,426,B-CHEMICAL
could,426,O
be,426,O
predicted,426,O
from,426,O
pretreatment,426,O
renal,426,O
vascular,426,O
tone,426,O
.,426,O
MATERIALS,427,O
AND,427,O
METHODS,427,O
:,427,O
Renal,427,O
hemodynamics,427,O
",",427,O
and,427,O
the,427,O
effects,427,O
of,427,O
single,427,O
(,427,O
n,427,O
=,427,O
17,427,O
),427,O
and,427,O
multiple,427,O
doses,427,O
(,427,O
n,427,O
=,427,O
8,427,O
",",427,O
8,427,O
days,427,O
),427,O
of,427,O
remikiren,427,B-CHEMICAL
(,427,O
600,427,O
mg,427,O
day-1,427,O
),427,O
on,427,O
sodium,427,B-CHEMICAL
excretion,427,O
were,427,O
studied,427,O
under,427,O
conditions,427,O
of,427,O
carefully,427,O
controlled,427,O
sodium,427,B-CHEMICAL
balance,427,O
.,427,O
RESULTS,428,O
:,428,O
Pretreatment,428,O
renal,428,O
vascular,428,O
tone,428,O
showed,428,O
considerable,428,O
individual,428,O
differences,428,O
:,428,O
filtration,428,O
fraction,428,O
(,428,O
FF,428,O
),428,O
ranged,428,O
from,428,O
21.2,428,O
to,428,O
30.3,428,O
%,428,O
and,428,O
RVR,428,O
from,428,O
18.8,428,O
to,428,O
33.5,428,O
10-2,428,O
mmHg,428,O
min,428,O
mL-1,428,O
in,428,O
the,428,O
single,428,O
dose,428,O
study,428,O
",",428,O
and,428,O
FF,428,O
from,428,O
20.8,428,O
to,428,O
24.9,428,O
%,428,O
and,428,O
RVR,428,O
from,428,O
14.8,428,O
to,428,O
28.8,428,O
10-2,428,O
mmHg,428,O
min,428,O
mL-1,428,O
in,428,O
the,428,O
multiple,428,O
dose,428,O
study,428,O
.,428,O
Remikiren,429,B-CHEMICAL
induced,429,O
a,429,O
fall,429,O
in,429,O
blood,429,O
pressure,429,O
",",429,O
FF,429,O
and,429,O
RVR,429,O
",",429,O
with,429,O
considerable,429,O
interindividual,429,O
variability,429,O
in,429,O
natriuretic,429,O
response,429,O
.,429,O
During,430,O
single,430,O
dose,430,O
",",430,O
cumulative,430,O
sodium,430,B-CHEMICAL
loss,430,O
was,430,O
5.1,430,O
mmol,430,O
per,430,O
5,430,O
h,430,O
(,430,O
-8.8,430,O
to,430,O
+24.6,430,O
),430,O
",",430,O
whereas,430,O
after,430,O
8,430,O
days,430,O
treatment,430,O
cumulative,430,O
sodium,430,B-CHEMICAL
loss,430,O
was,430,O
72,430,O
+/-,430,O
30,430,O
mmol,430,O
(,430,O
-46,430,O
to,430,O
+187,430,O
),430,O
.,430,O
The,431,O
natriuretic,431,O
response,431,O
to,431,O
remikiren,431,B-CHEMICAL
during,431,O
single,431,O
as,431,O
well,431,O
as,431,O
multiple,431,O
dose,431,O
significantly,431,O
correlated,431,O
with,431,O
pretreatment,431,O
renal,431,O
vascular,431,O
tone,431,O
(,431,O
estimated,431,O
from,431,O
FF,431,O
and,431,O
RVR,431,O
),431,O
but,431,O
not,431,O
with,431,O
remikiren-induced,431,B-CHEMICAL
changes,431,O
in,431,O
renal,431,O
hemodynamics,431,O
or,431,O
in,431,O
hormonal,431,O
parameters,431,O
.,431,O
Cumulative,432,O
sodium,432,B-CHEMICAL
loss,432,O
was,432,O
largest,432,O
in,432,O
patients,432,O
with,432,O
a,432,O
higher,432,O
pretreatment,432,O
FF,432,O
and,432,O
RVR,432,O
(,432,O
r,432,O
=,432,O
0.74,432,O
",",432,O
P,432,O
<,432,O
0.001,432,O
and,432,O
r,432,O
=,432,O
0.52,432,O
",",432,O
P,432,O
<,432,O
0.05,432,O
",",432,O
respectively,432,O
",",432,O
single,432,O
dose,432,O
;,432,O
and,432,O
r,432,O
=,432,O
0.75,432,O
",",432,O
P,432,O
<,432,O
0.05,432,O
and,432,O
r,432,O
=,432,O
0.73,432,O
",",432,O
P,432,O
<,432,O
0.05,432,O
",",432,O
respectively,432,O
",",432,O
multiple,432,O
dose,432,O
),432,O
.,432,O
CONCLUSION,433,O
:,433,O
These,433,O
data,433,O
support,433,O
the,433,O
hypothesis,433,O
that,433,O
in,433,O
essential,433,O
hypertension,433,O
an,433,O
elevated,433,O
renal,433,O
vascular,433,O
tone,433,O
is,433,O
a,433,O
marker,433,O
of,433,O
RAAS-mediated,433,O
impairment,433,O
of,433,O
sodium,433,B-CHEMICAL
excretion,433,O
.,433,O
Cloning,434,O
",",434,O
functional,434,O
expression,434,O
and,434,O
brain,434,O
localization,434,O
of,434,O
a,434,O
novel,434,O
unconventional,434,O
outward,434,B-GENE-N
rectifier,434,I-GENE-N
K+,434,I-GENE-N
channel,434,I-GENE-N
.,434,O
Human,435,B-GENE-Y
TWIK-1,435,I-GENE-Y
",",435,O
which,435,O
has,435,O
been,435,O
cloned,435,O
recently,435,O
",",435,O
is,435,O
a,435,O
new,435,O
structural,435,O
type,435,O
of,435,O
weak,435,O
inward,435,B-GENE-N
rectifier,435,I-GENE-N
K+,435,I-GENE-N
channel,435,I-GENE-N
.,435,O
Here,436,O
we,436,O
report,436,O
the,436,O
structural,436,O
and,436,O
functional,436,O
properties,436,O
of,436,O
TREK-1,436,B-GENE-Y
",",436,O
a,436,O
mammalian,436,B-GENE-Y
TWIK-1-related,436,I-GENE-Y
K+,436,I-GENE-Y
channel,436,I-GENE-Y
.,436,O
Despite,437,O
a,437,O
low,437,O
amino,437,B-CHEMICAL
acid,437,I-CHEMICAL
identity,437,O
between,437,O
TWIK-1,437,B-GENE-Y
and,437,O
TREK-1,437,B-GENE-Y
(,437,O
approximately,437,O
28,437,O
%,437,O
),437,O
",",437,O
both,437,O
channel,437,O
proteins,437,O
share,437,O
the,437,O
same,437,O
overall,437,O
structural,437,O
arrangement,437,O
consisting,437,O
of,437,O
two,437,O
pore-forming,437,B-GENE-N
domains,437,I-GENE-N
and,437,O
four,437,O
transmembrane,437,O
segments,437,O
(,437,O
TMS,437,O
),437,O
.,437,O
This,438,O
structural,438,O
similarity,438,O
does,438,O
not,438,O
give,438,O
rise,438,O
to,438,O
a,438,O
functional,438,O
analogy,438,O
.,438,O
K+,439,B-CHEMICAL
currents,439,O
generated,439,O
by,439,O
TWIK-1,439,B-GENE-Y
are,439,O
inwardly,439,O
rectifying,439,O
while,439,O
K+,439,B-CHEMICAL
currents,439,O
generated,439,O
by,439,O
TREK-1,439,B-GENE-Y
are,439,O
outwardly,439,O
rectifying,439,O
.,439,O
These,440,O
channels,440,O
have,440,O
a,440,O
conductance,440,O
of,440,O
14,440,O
pS,440,O
.,440,O
TREK-1,441,B-GENE-Y
currents,441,O
are,441,O
insensitive,441,O
to,441,O
pharmacological,441,O
agents,441,O
that,441,O
block,441,O
TWIK-1,441,B-GENE-Y
activity,441,O
such,441,O
as,441,O
quinine,441,B-CHEMICAL
and,441,O
quinidine,441,B-CHEMICAL
.,441,O
Extensive,442,O
inhibitions,442,O
of,442,O
TREK-1,442,B-GENE-Y
activity,442,O
are,442,O
observed,442,O
after,442,O
activation,442,O
of,442,O
protein,442,B-GENE-N
kinases,442,I-GENE-N
A,442,I-GENE-N
and,442,I-GENE-N
C.,442,O
TREK-1,442,B-GENE-Y
currents,442,O
are,442,O
sensitive,442,O
to,442,O
extracellular,442,O
K+,442,B-CHEMICAL
and,442,O
Na+,442,B-CHEMICAL
.,442,O
TREK-1,443,B-GENE-Y
mRNA,443,O
is,443,O
expressed,443,O
in,443,O
most,443,O
tissues,443,O
and,443,O
is,443,O
particularly,443,O
abundant,443,O
in,443,O
the,443,O
lung,443,O
and,443,O
in,443,O
the,443,O
brain,443,O
.,443,O
Its,444,O
localization,444,O
in,444,O
this,444,O
latter,444,O
tissue,444,O
has,444,O
been,444,O
studied,444,O
by,444,O
in,444,O
situ,444,O
hybridization,444,O
.,444,O
TREK-1,445,B-GENE-Y
expression,445,O
is,445,O
high,445,O
in,445,O
the,445,O
olfactory,445,O
bulb,445,O
",",445,O
hippocampus,445,O
and,445,O
cerebellum,445,O
.,445,O
These,446,O
results,446,O
provide,446,O
the,446,O
first,446,O
evidence,446,O
for,446,O
the,446,O
existence,446,O
of,446,O
a,446,O
K+,446,B-GENE-N
channel,446,I-GENE-N
family,446,O
with,446,O
four,446,O
TMS,446,O
and,446,O
two,446,O
pore,446,B-GENE-N
domains,446,I-GENE-N
in,446,O
the,446,O
nervous,446,O
system,446,O
of,446,O
mammals,446,O
.,446,O
They,447,O
also,447,O
show,447,O
that,447,O
different,447,O
members,447,O
in,447,O
this,447,O
structural,447,O
family,447,O
can,447,O
have,447,O
totally,447,O
different,447,O
functional,447,O
properties,447,O
.,447,O
Dopamine,448,B-GENE-Y
D2,448,I-GENE-Y
receptor,448,I-GENE-Y
occupancy,448,O
by,448,O
risperidone,448,B-CHEMICAL
:,448,O
implications,448,O
for,448,O
the,448,O
timing,448,O
and,448,O
magnitude,448,O
of,448,O
clinical,448,O
response,448,O
.,448,O
The,449,O
objective,449,O
of,449,O
the,449,O
study,449,O
is,449,O
to,449,O
investigate,449,O
whether,449,O
dopamine,449,B-GENE-Y
D2,449,I-GENE-Y
receptor,449,I-GENE-Y
occupancy,449,O
by,449,O
risperidone,449,B-CHEMICAL
and,449,O
plasma,449,O
levels,449,O
over,449,O
time,449,O
can,449,O
account,449,O
for,449,O
therapeutic,449,O
efficacy,449,O
and,449,O
the,449,O
latency,449,O
period,449,O
to,449,O
response,449,O
.,449,O
Thirty-eight,450,O
examinations,450,O
with,450,O
(,450,B-CHEMICAL
123,450,I-CHEMICAL
),450,I-CHEMICAL
I-IBZM,450,I-CHEMICAL
single,450,O
photon,450,O
emission,450,O
computed,450,O
tomography,450,O
were,450,O
performed,450,O
on,450,O
22,450,O
patients,450,O
with,450,O
schizophrenia,450,O
",",450,O
at,450,O
diagnosis,450,O
",",450,O
48,450,O
h,450,O
after,450,O
starting,450,O
risperidone,450,B-CHEMICAL
treatment,450,O
and,450,O
at,450,O
a,450,O
stable,450,O
dose,450,O
.,450,O
Risperidone,451,B-CHEMICAL
plasma,451,O
levels,451,O
were,451,O
determined,451,O
and,451,O
psychopathologic,451,O
evaluations,451,O
(,451,O
Brief,451,O
Psychiatric,451,O
Rating,451,O
Scale,451,O
",",451,O
Positive,451,O
and,451,O
Negative,451,O
Syndrome,451,O
Scale,451,O
),451,O
were,451,O
carried,451,O
out,451,O
.,451,O
No,452,O
differences,452,O
in,452,O
the,452,O
striatal/occipital,452,O
(,452,O
S/O,452,O
),452,O
ratio,452,O
or,452,O
plasma,452,O
levels,452,O
were,452,O
found,452,O
between,452,O
examinations,452,O
at,452,O
the,452,O
48-h,452,O
time,452,O
point,452,O
and,452,O
when,452,O
a,452,O
stable,452,O
dose,452,O
level,452,O
had,452,O
been,452,O
established,452,O
",",452,O
so,452,O
these,452,O
parameters,452,O
could,452,O
not,452,O
account,452,O
for,452,O
the,452,O
latency,452,O
period,452,O
required,452,O
for,452,O
clinical,452,O
response,452,O
.,452,O
D2,453,B-GENE-Y
receptor,453,I-GENE-Y
occupancy,453,O
at,453,O
48,453,O
h,453,O
correlated,453,O
positively,453,O
with,453,O
clinical,453,O
improvement,453,O
after,453,O
2,453,O
weeks,453,O
of,453,O
treatment,453,O
.,453,O
Therefore,454,O
",",454,O
if,454,O
these,454,O
results,454,O
are,454,O
confirmed,454,O
",",454,O
D2,454,B-GENE-Y
receptor,454,I-GENE-Y
occupancy,454,O
at,454,O
the,454,O
beginning,454,O
of,454,O
treatment,454,O
with,454,O
risperidone,454,B-CHEMICAL
may,454,O
be,454,O
a,454,O
predictor,454,O
of,454,O
subsequent,454,O
clinical,454,O
response,454,O
.,454,O
Overexpression,455,O
of,455,O
beta,455,B-GENE-Y
1-adrenoceptors,455,I-GENE-Y
in,455,O
adult,455,O
rat,455,O
ventricular,455,O
myocytes,455,O
enhances,455,O
CGP,455,B-CHEMICAL
12177A,455,I-CHEMICAL
cardiostimulation,455,O
:,455,O
implications,455,O
for,455,O
'putative,455,O
',455,O
beta,455,B-GENE-N
4-adrenoceptor,455,I-GENE-N
pharmacology,455,O
.,455,O
1,456,O
.,456,O
CGP,457,B-CHEMICAL
12177A,457,I-CHEMICAL
mediates,457,O
cardiostimulation,457,O
by,457,O
activation,457,O
of,457,O
the,457,O
'putative,457,O
',457,O
beta,457,B-GENE-N
(,457,I-GENE-N
4,457,I-GENE-N
),457,I-GENE-N
-adrenoceptor,457,I-GENE-N
;,457,O
however,457,O
",",457,O
it,457,O
has,457,O
recently,457,O
been,457,O
reported,457,O
that,457,O
disruption,457,O
of,457,O
the,457,O
beta,457,B-GENE-Y
(,457,I-GENE-Y
1,457,I-GENE-Y
),457,I-GENE-Y
-adrenoceptor,457,I-GENE-Y
gene,457,O
abolishes,457,O
this,457,O
effect,457,O
.,457,O
We,458,O
have,458,O
adenovirally,458,O
overexpressed,458,O
beta,458,B-GENE-Y
(,458,I-GENE-Y
1,458,I-GENE-Y
),458,I-GENE-Y
-adrenoceptors,458,I-GENE-Y
in,458,O
isolated,458,O
",",458,O
cultured,458,O
adult,458,O
rat,458,O
ventricular,458,O
cardiomyocytes,458,O
and,458,O
observed,458,O
the,458,O
inotropic,458,O
potency,458,O
of,458,O
isoprenaline,458,B-CHEMICAL
and,458,O
CGP,458,B-CHEMICAL
12177A,458,I-CHEMICAL
(,458,O
in,458,O
the,458,O
presence,458,O
of,458,O
1,458,O
microm,458,O
propranolol,458,B-CHEMICAL
),458,O
.,458,O
2,459,O
.,459,O
Isoprenaline,460,B-CHEMICAL
was,460,O
a,460,O
full,460,O
inotropic,460,O
agonist,460,O
at,460,O
rat,460,O
ventricular,460,O
myocytes,460,O
(,460,O
pD,460,O
(,460,O
2,460,O
),460,O
7.69+/-0.12,460,O
),460,O
.,460,O
CGP,461,B-CHEMICAL
12177A,461,I-CHEMICAL
was,461,O
a,461,O
nonconventional,461,O
partial,461,O
agonist,461,O
(,461,O
pD,461,O
(,461,O
2,461,O
),461,O
6.34+/-0.09,461,O
),461,O
",",461,O
increasing,461,O
inotropy,461,O
and,461,O
lusitropy,461,O
",",461,O
with,461,O
an,461,O
intrinsic,461,O
activity,461,O
of,461,O
0.34,461,O
and,461,O
antagonised,461,O
by,461,O
bupranolol,461,B-CHEMICAL
.,461,O
3.,462,O
beta,462,B-GENE-Y
(,462,I-GENE-Y
1,462,I-GENE-Y
),462,I-GENE-Y
-adrenoceptor,462,I-GENE-Y
overexpression,462,O
enhanced,462,O
the,462,O
inotropic,462,O
potency,462,O
of,462,O
isoprenaline,462,B-CHEMICAL
by,462,O
11.7-fold,462,O
(,462,O
pD,462,O
(,462,O
2,462,O
),462,O
8.76+/-0.14,462,O
),462,O
and,462,O
CGP,462,O
12177A,462,O
by,462,O
5.9-fold,462,O
(,462,O
7.11+/-0.10,462,O
),462,O
",",462,O
respectively,462,O
.,462,O
Green,463,O
fluorescent,463,O
protein,463,O
(,463,O
GFP,463,O
),463,O
overexpression,463,O
did,463,O
not,463,O
alter,463,O
the,463,O
potency,463,O
of,463,O
isoprenaline,463,B-CHEMICAL
or,463,O
CGP,463,O
12177A,463,O
(,463,O
pD,463,O
(,463,O
2,463,O
),463,O
7.41+/-0.24,463,O
and,463,O
pD,463,O
(,463,O
2,463,O
),463,O
6.60+/-0.50,463,O
",",463,O
respectively,463,O
),463,O
.,463,O
4,464,O
.,464,O
The,465,O
cardiostimulant,465,O
effects,465,O
of,465,O
CGP,465,B-CHEMICAL
12177A,465,I-CHEMICAL
were,465,O
enhanced,465,O
by,465,O
IBMX,465,O
(,465,O
phosphodiesterase,465,B-GENE-N
inhibitor,465,O
),465,O
and,465,O
decreased,465,O
by,465,O
Rp-cAMPS,465,B-CHEMICAL
(,465,O
cAMP,465,B-CHEMICAL
antagonist,465,O
),465,O
.,465,O
CGP,466,B-CHEMICAL
12177A,466,I-CHEMICAL
also,466,O
increased,466,O
cAMP,466,B-CHEMICAL
levels,466,O
.,466,O
CGP,467,B-CHEMICAL
12177A,467,I-CHEMICAL
but,467,O
not,467,O
isoprenaline,467,B-CHEMICAL
initiated,467,O
arrhythmias,467,O
at,467,O
lower,467,O
concentrations,467,O
following,467,O
beta,467,B-GENE-Y
(,467,I-GENE-Y
1,467,I-GENE-Y
),467,I-GENE-Y
-adrenoceptor,467,I-GENE-Y
overexpression,467,O
.,467,O
5,468,O
.,468,O
(,469,B-CHEMICAL
125,469,I-CHEMICAL
),469,I-CHEMICAL
I-Cyanopindolol,469,I-CHEMICAL
saturation,469,O
binding,469,O
in,469,O
Adv.beta,469,O
(,469,O
1,469,O
),469,O
myocytes,469,O
demonstrated,469,O
approximately,469,O
18-fold,469,O
increase,469,O
in,469,O
beta,469,B-GENE-Y
(,469,I-GENE-Y
1,469,I-GENE-Y
),469,I-GENE-Y
-adrenoceptors,469,I-GENE-Y
.,469,O
(,470,B-CHEMICAL
3,470,I-CHEMICAL
),470,I-CHEMICAL
H-CGP,470,I-CHEMICAL
12177A,470,I-CHEMICAL
saturation,470,O
binding,470,O
",",470,O
in,470,O
the,470,O
presence,470,O
of,470,O
propranolol,470,B-CHEMICAL
",",470,O
increased,470,O
approximately,470,O
5-fold,470,O
following,470,O
overexpression,470,O
of,470,O
beta,470,B-GENE-Y
(,470,I-GENE-Y
1,470,I-GENE-Y
),470,I-GENE-Y
-adrenoceptors,470,I-GENE-Y
.,470,O
6,471,O
.,471,O
This,472,O
study,472,O
demonstrates,472,O
enhanced,472,O
cardiostimulation,472,O
by,472,O
CGP,472,B-CHEMICAL
12177A,472,I-CHEMICAL
(,472,O
in,472,O
the,472,O
presence,472,O
of,472,O
propranolol,472,B-CHEMICAL
),472,O
in,472,O
rat,472,O
ventricular,472,O
myocytes,472,O
overexpressing,472,O
beta,472,B-GENE-Y
(,472,I-GENE-Y
1,472,I-GENE-Y
),472,I-GENE-Y
-adrenoceptors,472,I-GENE-Y
",",472,O
mediated,472,O
by,472,O
a,472,O
Gs/cAMP,472,B-GENE-N
signalling,472,O
pathway,472,O
.,472,O
'Putative,473,O
',473,O
beta,473,B-GENE-N
(,473,I-GENE-N
4,473,I-GENE-N
),473,I-GENE-N
-adrenoceptor,473,I-GENE-N
pharmacology,473,O
appears,473,O
to,473,O
be,473,O
mediated,473,O
by,473,O
activation,473,O
of,473,O
a,473,O
novel,473,O
affinity,473,O
state,473,O
of,473,O
the,473,O
beta,473,B-GENE-Y
(,473,I-GENE-Y
1,473,I-GENE-Y
),473,I-GENE-Y
-adrenoceptor,473,O
.,473,O
Antithrombin,474,O
binding,474,O
of,474,O
low,474,O
molecular,474,O
weight,474,O
heparins,474,O
and,474,O
inhibition,474,O
of,474,O
factor,474,B-GENE-Y
Xa,474,I-GENE-Y
.,474,O
Fluorescence,475,O
and,475,O
stopped,475,O
flow,475,O
methods,475,O
were,475,O
used,475,O
to,475,O
compare,475,O
clinically,475,O
used,475,O
heparins,475,O
with,475,O
regard,475,O
to,475,O
their,475,O
ability,475,O
to,475,O
bind,475,O
to,475,O
antithrombin,475,B-GENE-Y
and,475,O
to,475,O
accelerate,475,O
the,475,O
inactivation,475,O
of,475,O
factor,475,B-GENE-Y
Xa,475,I-GENE-Y
.,475,O
Titration,476,O
of,476,O
antithrombin,476,B-GENE-Y
with,476,O
both,476,O
low,476,O
molecular,476,O
weight,476,O
heparin,476,O
(,476,O
LMWH,476,O
),476,O
(,476,O
enoxaparin,476,O
",",476,O
fragmin,476,O
and,476,O
ardeparin,476,O
),476,O
and,476,O
unfractionated,476,O
heparin,476,O
(,476,O
UFH,476,O
),476,O
produced,476,O
an,476,O
equivalent,476,O
fluorescence,476,O
increase,476,O
and,476,O
indicates,476,O
similar,476,O
affinity,476,O
of,476,O
all,476,O
heparin,476,O
preparations,476,O
to,476,O
antithrombin,476,B-GENE-Y
.,476,O
However,477,O
",",477,O
relative,477,O
to,477,O
UFH,477,O
enoxaparin,477,O
",",477,O
the,477,O
LMWH,477,O
with,477,O
the,477,O
smallest,477,O
average,477,O
molecular,477,O
mass,477,O
",",477,O
contained,477,O
only,477,O
12,477,O
%,477,O
material,477,O
with,477,O
high,477,O
affinity,477,O
for,477,O
antithrombin,477,B-GENE-Y
.,477,O
The,478,O
rate,478,O
of,478,O
factor,478,B-GENE-Y
Xa,478,I-GENE-Y
inhibition,478,O
by,478,O
antithrombin,478,B-GENE-Y
increased,478,O
with,478,O
the,478,O
concentration,478,O
of,478,O
the,478,O
examined,478,O
heparins,478,O
to,478,O
the,478,O
same,478,O
limiting,478,O
value,478,O
",",478,O
but,478,O
the,478,O
concentration,478,O
required,478,O
for,478,O
maximal,478,O
acceleration,478,O
depended,478,O
on,478,O
the,478,O
preparation,478,O
.,478,O
According,479,O
to,479,O
these,479,O
data,479,O
the,479,O
high,479,O
affinity,479,O
fraction,479,O
of,479,O
the,479,O
heparin,479,O
preparations,479,O
increased,479,O
the,479,O
intrinsic,479,O
fluorescence,479,O
and,479,O
inhibitory,479,O
activity,479,O
equally,479,O
without,479,O
additional,479,O
effects,479,O
by,479,O
variations,479,O
in,479,O
chain,479,O
length,479,O
and,479,O
chemical,479,O
composition,479,O
.,479,O
In,480,O
contrast,480,O
",",480,O
in,480,O
the,480,O
presence,480,O
of,480,O
Ca,480,B-CHEMICAL
UFH,480,O
accelerated,480,O
the,480,O
inhibition,480,O
of,480,O
factor,480,B-GENE-Y
Xa,480,I-GENE-Y
by,480,O
antithrombin,480,B-GENE-Y
10-fold,480,O
more,480,O
efficiently,480,O
than,480,O
comparable,480,O
concentrations,480,O
of,480,O
the,480,O
high,480,O
affinity,480,O
fractions,480,O
of,480,O
enoxaparin,480,O
and,480,O
fragmin,480,O
.,480,O
The,481,O
bell-shaped,481,O
dependence,481,O
of,481,O
this,481,O
accelerating,481,O
effect,481,O
suggests,481,O
simultaneous,481,O
binding,481,O
of,481,O
both,481,O
proteins,481,O
to,481,O
heparin,481,O
.,481,O
In,482,O
conclusion,482,O
",",482,O
under,482,O
physiologic,482,O
conditions,482,O
the,482,O
anti-factor,482,O
Xa,482,I-GENE-Y
activity,482,O
of,482,O
heparin,482,O
results,482,O
from,482,O
a,482,O
composite,482,O
effect,482,O
of,482,O
chain,482,O
length,482,O
and,482,O
the,482,O
content,482,O
of,482,O
material,482,O
with,482,O
high,482,O
affinity,482,O
to,482,O
antithrombin,482,B-GENE-Y
.,482,O
Thus,483,O
",",483,O
the,483,O
reduced,483,O
antithrombotic,483,O
activity,483,O
of,483,O
LMWH,483,O
relative,483,O
to,483,O
UFH,483,O
results,483,O
from,483,O
a,483,O
smaller,483,O
content,483,O
of,483,O
high,483,O
affinity,483,O
material,483,O
and,483,O
the,483,O
absence,483,O
of,483,O
a,483,O
stimulating,483,O
effect,483,O
of,483,O
calcium,483,B-CHEMICAL
.,483,O
Further,484,O
insights,484,O
into,484,O
the,484,O
effect,484,O
of,484,O
quinidine,484,B-CHEMICAL
in,484,O
short,484,O
QT,484,O
syndrome,484,O
caused,484,O
by,484,O
a,484,O
mutation,484,O
in,484,O
HERG,484,B-GENE-Y
.,484,O
INTRODUCTION,485,O
:,485,O
The,485,O
principal,485,O
aim,485,O
of,485,O
this,485,O
study,485,O
was,485,O
to,485,O
assess,485,O
the,485,O
efficacy,485,O
of,485,O
quinidine,485,B-CHEMICAL
in,485,O
suppressing,485,O
IKr,485,B-GENE-N
in,485,O
vitro,485,O
and,485,O
in,485,O
modulating,485,O
the,485,O
rate,485,O
dependence,485,O
of,485,O
the,485,O
QT,485,O
interval,485,O
in,485,O
the,485,O
``,485,O
SQT1,485,O
'',485,O
form,485,O
of,485,O
the,485,O
short,485,O
QT,485,O
syndrome,485,O
.,485,O
METHODS,486,O
AND,486,O
RESULTS,486,O
:,486,O
Graded-intensity,486,O
bicycle,486,O
exercise,486,O
testing,486,O
was,486,O
performed,486,O
off,486,O
drug,486,O
in,486,O
three,486,O
patients,486,O
and,486,O
during,486,O
oral,486,O
quinidine,486,B-CHEMICAL
in,486,O
two,486,O
patients,486,O
with,486,O
short,486,O
QT,486,O
syndrome,486,O
and,486,O
compared,486,O
to,486,O
a,486,O
control,486,O
group,486,O
of,486,O
healthy,486,O
normal,486,O
subjects,486,O
.,486,O
The,487,O
in,487,O
vitro,487,O
effects,487,O
of,487,O
quinidine,487,B-CHEMICAL
on,487,O
currents,487,O
in,487,O
patch,487,O
clamp,487,O
technique,487,O
were,487,O
investigated,487,O
.,487,O
Off,488,O
drugs,488,O
QTpV3/heart,488,O
rate,488,O
correlation,488,O
is,488,O
much,488,O
weaker,488,O
in,488,O
patients,488,O
with,488,O
short,488,O
QT,488,O
syndrome,488,O
",",488,O
and,488,O
QTpV3,488,O
shortens,488,O
less,488,O
with,488,O
heart,488,O
rate,488,O
increase,488,O
compared,488,O
to,488,O
normal,488,O
subjects,488,O
.,488,O
In,489,O
addition,489,O
to,489,O
prolonging,489,O
the,489,O
QT,489,O
interval,489,O
into,489,O
the,489,O
normal,489,O
range,489,O
",",489,O
quinidine,489,B-CHEMICAL
restored,489,O
the,489,O
heart,489,O
rate,489,O
dependence,489,O
of,489,O
the,489,O
QT,489,O
interval,489,O
toward,489,O
a,489,O
range,489,O
of,489,O
adaptation,489,O
reported,489,O
for,489,O
normal,489,O
subjects,489,O
.,489,O
Data,490,O
from,490,O
heterologous,490,O
expression,490,O
of,490,O
wild-type,490,O
and,490,O
mutant,490,O
HERG,490,B-GENE-Y
genes,490,O
indicate,490,O
the,490,O
mutation,490,O
causes,490,O
a,490,O
20-fold,490,O
increase,490,O
in,490,O
IC50,490,O
of,490,O
d-sotalol,490,O
but,490,O
only,490,O
a,490,O
5.8-fold,490,O
increase,490,O
in,490,O
IC50,490,O
of,490,O
quinidine,490,B-CHEMICAL
.,490,O
CONCLUSION,491,O
:,491,O
Oral,491,O
quinidine,491,B-CHEMICAL
is,491,O
effective,491,O
in,491,O
suppressing,491,O
the,491,O
gain,491,O
of,491,O
function,491,O
in,491,O
IKr,491,B-GENE-N
responsible,491,O
for,491,O
some,491,O
cases,491,O
of,491,O
short,491,O
QT,491,O
syndrome,491,O
with,491,O
a,491,O
mutation,491,O
in,491,O
HERG,491,B-GENE-Y
and,491,O
thus,491,O
restoring,491,O
normal,491,O
rate,491,O
dependence,491,O
of,491,O
the,491,O
QT,491,O
interval,491,O
and,491,O
rendering,491,O
ventricular,491,O
tachycardia/ventricular,491,O
fibrillation,491,O
noninducible,491,O
.,491,O
Apoptotic,492,O
cell,492,O
death,492,O
in,492,O
rat,492,O
epididymis,492,O
following,492,O
epichlorohydrin,492,B-CHEMICAL
treatment,492,O
.,492,O
Epichlorohydrin,493,B-CHEMICAL
(,493,O
ECH,493,B-CHEMICAL
),493,O
is,493,O
an,493,O
antifertility,493,O
agent,493,O
that,493,O
acts,493,O
both,493,O
as,493,O
an,493,O
epididymal,493,O
toxicant,493,O
and,493,O
an,493,O
agent,493,O
capable,493,O
of,493,O
directly,493,O
affecting,493,O
sperm,493,O
motility,493,O
.,493,O
This,494,O
study,494,O
identified,494,O
the,494,O
time,494,O
course,494,O
of,494,O
apoptotic,494,O
cell,494,O
death,494,O
in,494,O
rat,494,O
epididymides,494,O
after,494,O
ECH,494,O
treatment,494,O
.,494,O
Rats,495,O
were,495,O
administrated,495,O
with,495,O
a,495,O
single,495,O
oral,495,O
dose,495,O
of,495,O
ECH,495,B-CHEMICAL
(,495,O
50,495,O
mg/kg,495,O
),495,O
.,495,O
ECH-induced,496,B-CHEMICAL
apoptotic,496,O
changes,496,O
were,496,O
evaluated,496,O
by,496,O
terminal,496,B-GENE-Y
deoxynucleotidyl,496,I-GENE-Y
transferase,496,I-GENE-Y
dUTP,496,B-CHEMICAL
nick,496,O
end,496,O
labeling,496,O
(,496,O
TUNEL,496,O
),496,O
assay,496,O
and,496,O
its,496,O
related,496,O
mechanism,496,O
was,496,O
confirmed,496,O
by,496,O
Western,496,O
blot,496,O
analysis,496,O
and,496,O
colorimetric,496,O
assay,496,O
.,496,O
The,497,O
TUNEL,497,O
assay,497,O
showed,497,O
that,497,O
the,497,O
number,497,O
of,497,O
apoptotic,497,O
cells,497,O
increased,497,O
at,497,O
8,497,O
h,497,O
",",497,O
reached,497,O
a,497,O
maximum,497,O
level,497,O
at,497,O
12,497,O
h,497,O
",",497,O
and,497,O
then,497,O
decreased,497,O
progressively,497,O
.,497,O
The,498,O
Western,498,O
blot,498,O
analysis,498,O
demonstrated,498,O
no,498,O
significant,498,O
changes,498,O
in,498,O
proapoptotic,498,O
Bcl-2-associated,498,B-GENE-Y
X,498,I-GENE-Y
(,498,O
Bax,498,B-GENE-Y
),498,O
and,498,O
anti-apoptotic,498,O
Bcl-2,498,B-GENE-Y
expression,498,O
during,498,O
the,498,O
time,498,O
course,498,O
of,498,O
the,498,O
study,498,O
.,498,O
However,499,O
",",499,O
phospho-p38,499,B-GENE-N
mitogen-activated,499,B-GENE-N
protein,499,I-GENE-N
kinase,499,I-GENE-N
(,499,O
p-p38,499,B-GENE-N
MAPK,499,B-GENE-N
),499,O
and,499,O
phospho-c-Jun,499,B-GENE-N
amino-terminal,499,I-GENE-N
kinase,499,I-GENE-N
(,499,O
p-JNK,499,B-GENE-N
),499,O
expression,499,O
increased,499,O
at,499,O
8-24,499,O
h.,499,O
Caspase-3,499,B-GENE-Y
and,499,O
caspase-8,499,B-GENE-Y
activities,499,O
also,499,O
increased,499,O
at,499,O
8-48,499,O
h,499,O
and,499,O
12-48,499,O
h,499,O
",",499,O
respectively,499,O
",",499,O
in,499,O
the,499,O
same,499,O
manner,499,O
as,499,O
p-p38,499,B-GENE-N
MAPK,499,B-GENE-N
and,499,O
p-JNK,499,B-GENE-N
expression,499,O
.,499,O
These,500,O
results,500,O
indicate,500,O
that,500,O
ECH,500,O
induced,500,O
apoptotic,500,O
changes,500,O
in,500,O
rat,500,O
epididymides,500,O
and,500,O
that,500,O
the,500,O
apoptotic,500,O
cell,500,O
death,500,O
may,500,O
be,500,O
related,500,O
more,500,O
to,500,O
the,500,O
MAPK,500,B-GENE-N
pathway,500,O
than,500,O
to,500,O
the,500,O
mitochondrial,500,O
pathway,500,O
.,500,O
Effects,501,O
of,501,O
an,501,O
ethanolic,501,O
salix,501,O
extract,501,O
on,501,O
the,501,O
release,501,O
of,501,O
selected,501,O
inflammatory,501,O
mediators,501,O
in,501,O
vitro,501,O
.,501,O
Salix,502,O
extracts,502,O
are,502,O
in,502,O
current,502,O
use,502,O
for,502,O
the,502,O
treatment,502,O
of,502,O
pain,502,O
and,502,O
inflammation,502,O
.,502,O
In,503,O
order,503,O
to,503,O
obtain,503,O
an,503,O
insight,503,O
into,503,O
the,503,O
mechanism,503,O
(,503,O
s,503,O
),503,O
of,503,O
action,503,O
of,503,O
the,503,O
ethanolic,503,O
Salix,503,O
extract,503,O
1520L,503,O
--,503,O
which,503,O
is,503,O
essentially,503,O
similar,503,O
to,503,O
an,503,O
extract,503,O
for,503,O
which,503,O
clinical,503,O
studies,503,O
have,503,O
demonstrated,503,O
analgesic,503,O
effectiveness,503,O
--,503,O
its,503,O
effects,503,O
were,503,O
evaluated,503,O
in,503,O
an,503,O
established,503,O
in,503,O
vitro,503,O
assay,503,O
test,503,O
system,503,O
using,503,O
primary,503,O
human,503,O
monocytes,503,O
.,503,O
The,504,O
IC50-values,504,O
obtained,504,O
for,504,O
the,504,O
inhibition,504,O
of,504,O
lipopolysaccharide,504,O
(,504,O
LPS,504,O
),504,O
-induced,504,O
release,504,O
of,504,O
prostaglandin,504,B-CHEMICAL
E2,504,I-CHEMICAL
(,504,O
PGE2,504,B-CHEMICAL
),504,O
reflecting,504,O
cyclooxygenase,504,B-GENE-Y
(,504,I-GENE-Y
COX,504,I-GENE-Y
),504,I-GENE-Y
-2-mediated,504,O
PGE2,504,B-CHEMICAL
release,504,O
were,504,O
47,504,O
microg/ml,504,O
and,504,O
0.6,504,O
microg/ml,504,O
",",504,O
for,504,O
the,504,O
Salix,504,O
extract,504,O
1520L,504,O
and,504,O
rofecoxib-like,504,B-CHEMICAL
research,504,O
compound,504,O
L745337,504,B-CHEMICAL
",",504,O
respectively,504,O
.,504,O
There,505,O
was,505,O
no,505,O
effect,505,O
on,505,O
COX-1,505,B-GENE-Y
and,505,O
COX-2,505,B-GENE-Y
activity,505,O
.,505,O
The,506,O
Salix,506,O
extract,506,O
inhibited,506,O
the,506,O
LPS-induced,506,O
release,506,O
of,506,O
tumor,506,B-GENE-Y
necrosis,506,I-GENE-Y
factor-alpha,506,I-GENE-Y
",",506,O
interleukin-1beta,506,B-GENE-Y
and,506,O
interleukin-6,506,B-GENE-Y
with,506,O
IC50-values,506,O
of,506,O
180.0,506,O
",",506,O
33.0,506,O
and,506,O
86.0,506,O
microg/ml,506,O
",",506,O
respectively,506,O
.,506,O
Both,507,O
",",507,O
salicin,507,B-CHEMICAL
and,507,O
salicylate,507,B-CHEMICAL
",",507,O
had,507,O
no,507,O
effect,507,O
in,507,O
any,507,O
of,507,O
the,507,O
parameters,507,O
.,507,O
Our,508,O
results,508,O
indicate,508,O
that,508,O
Salix,508,O
extract,508,O
1520L,508,O
inhibits,508,O
COX-2-mediated,508,B-GENE-Y
PGE2,508,B-CHEMICAL
release,508,O
through,508,O
compounds,508,O
other,508,O
than,508,O
salicin,508,B-CHEMICAL
or,508,O
salicylate,508,B-CHEMICAL
.,508,O
Our,509,O
data,509,O
further,509,O
suggest,509,O
that,509,O
the,509,O
proprietary,509,O
Salix,509,O
extract,509,O
is,509,O
a,509,O
weak,509,O
inhibitor,509,O
of,509,O
proinflammatory,509,O
cytokines,509,B-GENE-N
.,509,O
Mutations,510,O
in,510,O
the,510,O
follicle-stimulating,510,B-GENE-N
hormone-beta,510,I-GENE-N
(,510,O
FSH,510,B-GENE-N
beta,510,I-GENE-N
),510,O
and,510,O
FSH,510,B-GENE-N
receptor,510,I-GENE-N
genes,510,O
in,510,O
mice,510,O
and,510,O
humans,510,O
.,510,O
Follicle-stimulating,511,B-GENE-N
hormone,511,I-GENE-N
(,511,O
FSH,511,B-GENE-N
),511,O
",",511,O
a,511,O
dimeric,511,O
glycoprotein,511,O
synthesized,511,O
in,511,O
the,511,O
anterior,511,O
pituitary,511,O
gland,511,O
",",511,O
is,511,O
important,511,O
for,511,O
the,511,O
production,511,O
of,511,O
sex,511,O
steroids,511,B-CHEMICAL
and,511,O
gametes,511,O
.,511,O
FSH-beta,512,B-GENE-Y
(,512,O
FSH,512,B-GENE-Y
beta,512,I-GENE-Y
),512,O
and,512,O
FSH,512,B-GENE-Y
receptor,512,I-GENE-Y
(,512,O
FSHR,512,B-GENE-Y
),512,O
knockout,512,O
mice,512,O
display,512,O
impaired,512,O
ovarian,512,O
follicular,512,O
development,512,O
and,512,O
infertility,512,O
in,512,O
females,512,O
and,512,O
small,512,O
testes,512,O
",",512,O
oligospermia,512,O
",",512,O
and,512,O
fertility,512,O
in,512,O
males,512,O
.,512,O
Humans,513,O
with,513,O
FSH,513,B-GENE-Y
beta,513,I-GENE-Y
gene,513,O
mutations,513,O
tend,513,O
to,513,O
have,513,O
a,513,O
more,513,O
severe,513,O
phenotype,513,O
than,513,O
those,513,O
with,513,O
FSHR,513,B-GENE-Y
gene,513,O
mutations,513,O
",",513,O
although,513,O
infertility,513,O
and,513,O
varying,513,O
degrees,513,O
of,513,O
impaired,513,O
sex,513,O
steroid,513,B-CHEMICAL
production,513,O
occur,513,O
in,513,O
both,513,O
types,513,O
of,513,O
mutations,513,O
.,513,O
Data,514,O
from,514,O
human,514,O
and,514,O
mouse,514,O
mutations,514,O
in,514,O
the,514,O
FSH,514,B-GENE-N
beta,514,I-GENE-N
and,514,O
FSHR,514,B-GENE-N
genes,514,O
suggest,514,O
that,514,O
FSH,514,B-GENE-N
is,514,O
necessary,514,O
for,514,O
normal,514,O
pubertal,514,O
development,514,O
and,514,O
fertility,514,O
in,514,O
males,514,O
and,514,O
females,514,O
.,514,O
Antipsychotic,515,O
profile,515,O
of,515,O
rolipram,515,B-CHEMICAL
:,515,O
efficacy,515,O
in,515,O
rats,515,O
and,515,O
reduced,515,O
sensitivity,515,O
in,515,O
mice,515,O
deficient,515,O
in,515,O
the,515,O
phosphodiesterase-4B,515,B-GENE-Y
(,515,O
PDE4B,515,B-GENE-Y
),515,O
enzyme,515,O
.,515,O
RATIONALE,516,O
:,516,O
Recent,516,O
studies,516,O
provide,516,O
evidence,516,O
for,516,O
reduced,516,O
phosphodiesterase-4B,516,B-GENE-Y
(,516,O
PDE4B,516,B-GENE-Y
),516,O
as,516,O
a,516,O
genetic,516,O
susceptibility,516,O
factor,516,O
as,516,O
well,516,O
as,516,O
suggesting,516,O
an,516,O
association,516,O
of,516,O
several,516,O
single,516,O
nucleotide,516,B-CHEMICAL
polymorphisms,516,O
(,516,O
SNPs,516,O
),516,O
in,516,O
PDE4B,516,B-GENE-Y
that,516,O
are,516,O
associated,516,O
with,516,O
an,516,O
increased,516,O
incidence,516,O
of,516,O
schizophrenia,516,O
.,516,O
OBJECTIVES,517,O
:,517,O
The,517,O
aim,517,O
of,517,O
the,517,O
current,517,O
study,517,O
was,517,O
to,517,O
assess,517,O
the,517,O
activity,517,O
of,517,O
rolipram,517,B-CHEMICAL
",",517,O
a,517,O
nonsubtype-selective,517,O
PDE4,517,B-GENE-N
inhibitor,517,O
",",517,O
in,517,O
several,517,O
animal,517,O
models,517,O
predictive,517,O
of,517,O
antipsychotic-like,517,O
efficacy,517,O
and,517,O
side-effect,517,O
liability,517,O
and,517,O
to,517,O
use,517,O
PDE4B,517,B-GENE-Y
wild-type,517,O
and,517,O
knockout,517,O
mice,517,O
to,517,O
begin,517,O
to,517,O
understand,517,O
the,517,O
subtypes,517,O
involved,517,O
in,517,O
the,517,O
activity,517,O
of,517,O
rolipram,517,B-CHEMICAL
.,517,O
RESULTS,518,O
:,518,O
In,518,O
rats,518,O
",",518,O
rolipram,518,B-CHEMICAL
antagonized,518,O
both,518,O
phencyclidine,518,B-CHEMICAL
hydrochloride-,518,O
and,518,O
D-amphetamine-induced,518,B-CHEMICAL
hyperactivity,518,O
and,518,O
inhibited,518,O
conditioned,518,O
avoidance,518,O
responding,518,O
(,518,O
CAR,518,O
),518,O
.,518,O
In,519,O
PDE4B,519,B-GENE-Y
wild-type,519,O
mice,519,O
",",519,O
rolipram,519,B-CHEMICAL
dose-dependently,519,O
suppressed,519,O
CAR,519,O
(,519,O
ED,519,O
(,519,O
50,519,O
),519,O
=,519,O
2.4,519,O
mg/kg,519,O
),519,O
;,519,O
however,519,O
",",519,O
in,519,O
knockout,519,O
mice,519,O
",",519,O
their,519,O
sensitivity,519,O
to,519,O
rolipram,519,B-CHEMICAL
at,519,O
the,519,O
higher,519,O
doses,519,O
(,519,O
1.0,519,O
and,519,O
3.2,519,O
mg/kg,519,O
),519,O
was,519,O
reduced,519,O
",",519,O
resulting,519,O
in,519,O
a,519,O
threefold,519,O
shift,519,O
in,519,O
the,519,O
ED,519,O
(,519,O
50,519,O
),519,O
(,519,O
7.3,519,O
mg/kg,519,O
),519,O
",",519,O
suggesting,519,O
PDE4B,519,B-GENE-Y
is,519,O
involved,519,O
",",519,O
at,519,O
least,519,O
in,519,O
part,519,O
",",519,O
with,519,O
the,519,O
activity,519,O
of,519,O
rolipram,519,B-CHEMICAL
.,519,O
Only,520,O
the,520,O
highest,520,O
dose,520,O
of,520,O
rolipram,520,B-CHEMICAL
(,520,O
3.2,520,O
mg/kg,520,O
),520,O
produced,520,O
a,520,O
modest,520,O
but,520,O
significant,520,O
degree,520,O
of,520,O
catalepsy,520,O
.,520,O
CONCLUSIONS,521,O
:,521,O
Rolipram,521,B-CHEMICAL
has,521,O
a,521,O
pharmacologic,521,O
profile,521,O
similar,521,O
to,521,O
that,521,O
of,521,O
the,521,O
atypical,521,O
antipsychotics,521,O
and,521,O
has,521,O
low,521,O
extrapyramidal,521,O
symptom,521,O
liability,521,O
.,521,O
These,522,O
results,522,O
suggest,522,O
that,522,O
PDE4B,522,B-GENE-Y
mediates,522,O
the,522,O
antipsychotic,522,O
effects,522,O
of,522,O
rolipram,522,B-CHEMICAL
in,522,O
CAR,522,O
and,522,O
that,522,O
the,522,O
PDE4B-regulated,522,B-GENE-Y
cyclic,522,B-CHEMICAL
adenosine,522,I-CHEMICAL
monophosphate,522,I-CHEMICAL
signaling,522,O
pathway,522,O
may,522,O
play,522,O
a,522,O
role,522,O
in,522,O
the,522,O
pathophysiology,522,O
and,522,O
pharmacotherapy,522,O
of,522,O
psychosis,522,O
.,522,O
Improving,523,O
the,523,O
tolerability,523,O
of,523,O
anticholinergic,523,O
agents,523,O
in,523,O
the,523,O
treatment,523,O
of,523,O
overactive,523,O
bladder,523,O
.,523,O
Pharmacological,524,O
treatment,524,O
for,524,O
overactive,524,O
bladder,524,O
has,524,O
centred,524,O
around,524,O
the,524,O
interruption,524,O
of,524,O
the,524,O
detrusor,524,O
activity,524,O
that,524,O
is,524,O
central,524,O
to,524,O
urge,524,O
and,524,O
incontinence,524,O
symptoms,524,O
.,524,O
The,525,O
majority,525,O
of,525,O
patients,525,O
with,525,O
this,525,O
disorder,525,O
are,525,O
treated,525,O
with,525,O
antimuscarinic,525,O
agents,525,O
.,525,O
These,526,O
drugs,526,O
have,526,O
been,526,O
demonstrated,526,O
to,526,O
improve,526,O
urgency,526,O
",",526,O
frequency,526,O
of,526,O
micturition,526,O
and,526,O
urge,526,O
incontinence,526,O
",",526,O
all,526,O
of,526,O
which,526,O
are,526,O
primary,526,O
symptoms,526,O
of,526,O
overactive,526,O
bladder,526,O
;,526,O
however,526,O
",",526,O
they,526,O
are,526,O
also,526,O
commonly,526,O
associated,526,O
with,526,O
anticholinergic,526,O
adverse,526,O
effects,526,O
",",526,O
most,526,O
notably,526,O
dry,526,O
mouth,526,O
.,526,O
Attempts,527,O
to,527,O
increase,527,O
tolerability,527,O
have,527,O
included,527,O
the,527,O
development,527,O
of,527,O
advanced,527,O
formulations,527,O
that,527,O
regulate,527,O
release,527,O
of,527,O
the,527,O
active,527,O
ingredient,527,O
and,527,O
the,527,O
development,527,O
of,527,O
pharmacological,527,O
agents,527,O
that,527,O
target,527,O
the,527,O
desired,527,O
bladder,527,O
receptors,527,O
more,527,O
specifically,527,O
and,527,O
accurately,527,O
.,527,O
Although,528,O
all,528,O
agents,528,O
provide,528,O
good,528,O
efficacy,528,O
",",528,O
tolerability,528,O
is,528,O
greatly,528,O
affected,528,O
by,528,O
the,528,O
formulation,528,O
used,528,O
to,528,O
deliver,528,O
the,528,O
active,528,O
pharmacological,528,O
agent,528,O
",",528,O
as,528,O
well,528,O
as,528,O
the,528,O
specificity,528,O
of,528,O
the,528,O
targeted,528,O
receptors,528,O
.,528,O
Clinical,529,O
trials,529,O
involving,529,O
a,529,O
transdermal,529,O
formulation,529,O
of,529,O
oxybutynin,529,B-CHEMICAL
have,529,O
shown,529,O
that,529,O
this,529,O
delivery,529,O
method,529,O
may,529,O
be,529,O
associated,529,O
with,529,O
a,529,O
lower,529,O
incidence,529,O
of,529,O
anticholinergic,529,O
adverse,529,O
events,529,O
compared,529,O
with,529,O
both,529,O
the,529,O
immediate-release,529,O
and,529,O
the,529,O
extended-release,529,O
oral,529,O
formulations,529,O
of,529,O
traditional,529,O
agents,529,O
",",529,O
as,529,O
well,529,O
as,529,O
the,529,O
most,529,O
recently,529,O
approved,529,O
agents,529,O
-,529,O
trospium,529,B-CHEMICAL
chloride,529,I-CHEMICAL
",",529,O
solifenacin,529,B-CHEMICAL
and,529,O
darifenacin,529,B-CHEMICAL
.,529,O
Much,530,O
is,530,O
still,530,O
being,530,O
learned,530,O
about,530,O
the,530,O
function,530,O
and,530,O
specificity,530,O
of,530,O
muscarinic,530,B-GENE-N
receptors,530,I-GENE-N
",",530,O
which,530,O
will,530,O
support,530,O
the,530,O
development,530,O
of,530,O
agents,530,O
with,530,O
sustained,530,O
efficacy,530,O
and,530,O
enhanced,530,O
tolerability,530,O
compared,530,O
with,530,O
the,530,O
available,530,O
formulations,530,O
to,530,O
date,530,O
.,530,O
These,531,O
include,531,O
the,531,O
S-isomer,531,B-CHEMICAL
of,531,I-CHEMICAL
oxybutynin,531,I-CHEMICAL
",",531,O
as,531,O
well,531,O
as,531,O
selective,531,O
muscarinic,531,B-GENE-Y
M2,531,I-GENE-Y
receptor,531,I-GENE-Y
antagonists,531,O
.,531,O
Intradialytic,532,O
parenteral,532,O
nutrition,532,O
:,532,O
comparison,532,O
of,532,O
olive,532,O
oil,532,O
versus,532,O
soybean,532,O
oil-based,532,O
lipid,532,O
emulsions,532,O
.,532,O
Lipid,533,O
",",533,O
oxidative,533,O
and,533,O
inflammatory,533,O
parameters,533,O
are,533,O
frequently,533,O
altered,533,O
in,533,O
dialysis,533,O
patients,533,O
and,533,O
may,533,O
be,533,O
worsened,533,O
by,533,O
intravenous,533,O
lipid,533,O
emulsions,533,O
(,533,O
ILE,533,O
),533,O
.,533,O
We,534,O
assessed,534,O
the,534,O
efficacy,534,O
and,534,O
tolerance,534,O
of,534,O
olive,534,O
as,534,O
compared,534,O
with,534,O
standard,534,O
soybean,534,O
oil-based,534,O
ILE,534,O
during,534,O
intradialytic,534,O
parenteral,534,O
nutrition,534,O
(,534,O
IDPN,534,O
),534,O
.,534,O
IDPN,535,O
mixtures,535,O
containing,535,O
amino,535,B-CHEMICAL
acids,535,I-CHEMICAL
",",535,O
glucose,535,B-CHEMICAL
",",535,O
and,535,O
either,535,O
olive,535,O
oil,535,O
(,535,O
OO,535,O
group,535,O
",",535,O
n,535,O
17,535,O
),535,O
or,535,O
soybean,535,O
oil-based,535,O
ILE,535,O
(,535,O
SO,535,O
group,535,O
",",535,O
n,535,O
18,535,O
),535,O
were,535,O
administered,535,O
in,535,O
a,535,O
5-week,535,O
randomized,535,O
",",535,O
double-blind,535,O
study,535,O
.,535,O
On,536,O
days,536,O
0,536,O
and,536,O
35,536,O
",",536,O
patients,536,O
',536,O
nutritional,536,O
status,536,O
was,536,O
assessed,536,O
by,536,O
BMI,536,O
",",536,O
normalized,536,O
protein,536,O
catabolic,536,O
rate,536,O
",",536,O
predialytic,536,O
creatinine,536,B-CHEMICAL
",",536,O
serum,536,B-GENE-Y
albumin,536,I-GENE-Y
and,536,O
transthyretin,536,B-GENE-Y
;,536,O
lipid,536,O
metabolism,536,O
by,536,O
plasma,536,O
LDL-,536,B-GENE-N
and,536,O
HDL-cholesterol,536,B-GENE-N
",",536,O
triacylglycerols,536,B-CHEMICAL
",",536,O
phospholipids,536,O
",",536,O
apo,536,B-GENE-N
A-I,536,I-GENE-N
",",536,I-GENE-N
A-II,536,I-GENE-N
",",536,I-GENE-N
B,536,I-GENE-N
",",536,I-GENE-N
C-II,536,I-GENE-N
",",536,I-GENE-N
C-III,536,I-GENE-N
",",536,I-GENE-N
E,536,I-GENE-N
and,536,O
lipoprotein,536,B-GENE-Y
(,536,I-GENE-Y
a,536,I-GENE-Y
),536,I-GENE-Y
;,536,O
oxidative,536,O
status,536,O
by,536,O
alpha-tocopherol,536,B-CHEMICAL
",",536,O
retinol,536,B-CHEMICAL
",",536,O
selenium,536,B-CHEMICAL
",",536,O
glutathione,536,B-GENE-N
peroxidase,536,I-GENE-N
",",536,O
malondialdehyde,536,B-CHEMICAL
and,536,O
advanced,536,O
oxidized,536,O
protein,536,O
products,536,O
;,536,O
inflammatory,536,O
status,536,O
by,536,O
serum,536,O
C-reactive,536,B-GENE-Y
protein,536,I-GENE-Y
",",536,O
orosomucoid,536,B-GENE-N
",",536,O
IL-2,536,B-GENE-Y
and,536,O
IL-6,536,B-GENE-Y
.,536,O
No,537,O
serious,537,O
adverse,537,O
event,537,O
was,537,O
observed,537,O
.,537,O
Significant,538,O
changes,538,O
were,538,O
observed,538,O
from,538,O
day,538,O
0,538,O
to,538,O
day,538,O
35,538,O
(,538,O
P,538,O
<,538,O
0.05,538,O
),538,O
:,538,O
nutritional,538,O
criteria,538,O
improved,538,O
(,538,O
albumin,538,B-GENE-Y
in,538,O
OO,538,O
;,538,O
albumin,538,B-GENE-Y
",",538,O
transthyretin,538,B-GENE-Y
and,538,O
creatinine,538,B-CHEMICAL
in,538,O
SO,538,O
),538,O
;,538,O
LDL-cholesterol,538,B-GENE-N
",",538,O
apo,538,B-GENE-N
B,538,I-GENE-N
",",538,I-GENE-N
C-II,538,I-GENE-N
",",538,I-GENE-N
C-III,538,I-GENE-N
and,538,O
apo,538,B-GENE-N
A-I/A-II,538,I-GENE-N
ratio,538,O
increased,538,O
in,538,O
both,538,O
groups,538,O
.,538,O
HDL-cholesterol,539,B-GENE-N
decreased,539,O
in,539,O
OO,539,O
;,539,O
apo,539,B-GENE-Y
E,539,I-GENE-Y
increased,539,O
and,539,O
lipoprotein,539,B-GENE-Y
(,539,I-GENE-Y
a,539,I-GENE-Y
),539,I-GENE-Y
decreased,539,O
in,539,O
SO,539,O
;,539,O
alpha-tocopherol/cholesterol,539,B-CHEMICAL
ratio,539,O
increased,539,O
in,539,O
OO,539,O
;,539,O
malondialdehyde,539,B-CHEMICAL
decreased,539,O
in,539,O
both,539,O
groups,539,O
;,539,O
IL-2,539,B-GENE-Y
increased,539,O
in,539,O
both,539,O
groups,539,O
.,539,O
The,540,O
between-group,540,O
comparison,540,O
only,540,O
showed,540,O
the,540,O
following,540,O
differences,540,O
:,540,O
alpha-tocopherol/cholesterol,540,B-CHEMICAL
increased,540,O
in,540,O
OO,540,O
;,540,O
lipoprotein,540,B-GENE-Y
(,540,I-GENE-Y
a,540,I-GENE-Y
),540,I-GENE-Y
decreased,540,O
in,540,O
SO,540,O
.,540,O
From,541,O
these,541,O
data,541,O
",",541,O
it,541,O
was,541,O
concluded,541,O
that,541,O
OO-,541,O
and,541,O
SO-based,541,O
IDPNs,541,O
similarly,541,O
improved,541,O
nutritional,541,O
status,541,O
and,541,O
influenced,541,O
plasma,541,O
lipid,541,O
",",541,O
oxidative,541,O
",",541,O
inflammatory,541,O
and,541,O
immune,541,O
parameters,541,O
.,541,O
Transcriptional,542,O
control,542,O
of,542,O
the,542,O
arginine/lysine,542,B-GENE-N
transporter,542,I-GENE-N
",",542,O
cat-1,542,B-GENE-Y
",",542,O
by,542,O
physiological,542,O
stress,542,O
.,542,O
Cells,543,O
respond,543,O
to,543,O
physiological,543,O
stress,543,O
by,543,O
phosphorylating,543,O
the,543,O
alpha,543,O
subunit,543,O
of,543,O
the,543,O
translation,543,O
initiation,543,O
factor,543,O
eIF2,543,B-GENE-N
.,543,O
This,544,O
adaptive,544,O
response,544,O
inhibits,544,O
protein,544,O
synthesis,544,O
and,544,O
up-regulates,544,O
genes,544,O
essential,544,O
for,544,O
cell,544,O
survival,544,O
.,544,O
Cat-1,545,B-GENE-Y
",",545,O
the,545,O
transporter,545,O
for,545,O
the,545,O
essential,545,O
amino,545,B-CHEMICAL
acids,545,I-CHEMICAL
",",545,O
arginine,545,B-CHEMICAL
and,545,O
lysine,545,B-CHEMICAL
",",545,O
is,545,O
one,545,O
of,545,O
the,545,O
up-regulated,545,O
genes,545,O
.,545,O
We,546,O
previously,546,O
showed,546,O
that,546,O
stress,546,O
increases,546,O
cat-1,546,B-GENE-Y
expression,546,O
by,546,O
coordinated,546,O
stabilization,546,O
of,546,O
the,546,O
mRNA,546,O
and,546,O
increased,546,O
mRNA,546,O
translation,546,O
.,546,O
This,547,O
induction,547,O
is,547,O
triggered,547,O
by,547,O
amino,547,B-CHEMICAL
acid,547,I-CHEMICAL
depletion,547,O
and,547,O
the,547,O
unfolded,547,B-GENE-N
protein,547,I-GENE-N
response,547,I-GENE-N
(,547,O
UPR,547,B-GENE-N
),547,O
",",547,O
which,547,O
is,547,O
caused,547,O
by,547,O
unfolded,547,O
proteins,547,O
in,547,O
the,547,O
endoplasmic,547,O
reticulum,547,O
.,547,O
We,548,O
show,548,O
here,548,O
that,548,O
cat-1,548,B-GENE-Y
gene,548,O
transcription,548,O
is,548,O
also,548,O
increased,548,O
by,548,O
cellular,548,O
stress,548,O
.,548,O
Our,549,O
studies,549,O
demonstrate,549,O
that,549,O
the,549,O
cat-1,549,B-GENE-N
gene,549,I-GENE-N
promoter/regulatory,549,O
region,549,O
is,549,O
TATA-less,549,B-GENE-N
and,549,O
is,549,O
located,549,O
in,549,O
a,549,O
region,549,O
that,549,O
includes,549,O
94,549,O
bases,549,O
of,549,O
the,549,O
first,549,O
exon,549,O
.,549,O
Transcription,550,O
from,550,O
this,550,O
promoter,550,O
is,550,O
stimulated,550,O
8-fold,550,O
by,550,O
cellular,550,O
stress,550,O
.,550,O
An,551,O
amino,551,B-CHEMICAL
acid,551,I-CHEMICAL
response,551,O
element,551,O
within,551,O
the,551,O
first,551,O
exon,551,O
is,551,O
shown,551,O
to,551,O
be,551,O
required,551,O
for,551,O
the,551,O
response,551,O
to,551,O
amino,551,B-CHEMICAL
acid,551,I-CHEMICAL
depletion,551,O
but,551,O
not,551,O
to,551,O
the,551,O
UPR,551,O
.,551,O
The,552,O
stimulation,552,O
of,552,O
transcription,552,O
by,552,O
amino,552,B-CHEMICAL
acid,552,I-CHEMICAL
depletion,552,O
requires,552,O
activation,552,O
of,552,O
GCN2,552,B-GENE-Y
kinase,552,B-GENE-N
",",552,O
which,552,O
phosphorylates,552,O
eIF2alpha,552,B-GENE-Y
.,552,O
This,553,O
phosphorylation,553,O
also,553,O
induces,553,O
translation,553,O
of,553,O
the,553,O
cat-1,553,B-GENE-Y
mRNA,553,O
",",553,O
demonstrating,553,O
that,553,O
stress-induced,553,O
transcriptional,553,O
and,553,O
translational,553,O
control,553,O
of,553,O
cat-1,553,B-GENE-Y
are,553,O
downstream,553,O
targets,553,O
of,553,O
a,553,O
signaling,553,O
pathway,553,O
initiating,553,O
with,553,O
eIF2alpha,553,B-GENE-Y
phosphorylation,553,O
.,553,O
Our,554,O
studies,554,O
show,554,O
that,554,O
the,554,O
increase,554,O
in,554,O
cat-1,554,B-GENE-Y
gene,554,O
expression,554,O
by,554,O
cellular,554,O
stress,554,O
involves,554,O
at,554,O
least,554,O
three,554,O
types,554,O
of,554,O
coordinate,554,O
regulation,554,O
:,554,O
regulation,554,O
of,554,O
transcription,554,O
",",554,O
regulation,554,O
of,554,O
mRNA,554,O
stability,554,O
",",554,O
and,554,O
regulation,554,O
of,554,O
mRNA,554,O
translation,554,O
.,554,O
Physiological,555,O
oxygenation,555,O
status,555,O
is,555,O
required,555,O
for,555,O
fully,555,O
differentiated,555,O
phenotype,555,O
in,555,O
kidney,555,O
cortex,555,O
proximal,555,O
tubules,555,O
.,555,O
Hypoxia,556,O
has,556,O
been,556,O
suspected,556,O
to,556,O
trigger,556,O
transdifferentiation,556,O
of,556,O
renal,556,O
tubular,556,O
cells,556,O
into,556,O
myofibroblasts,556,O
in,556,O
an,556,O
epithelial-to-mesenchymal,556,O
transition,556,O
(,556,O
EMT,556,O
),556,O
process,556,O
.,556,O
To,557,O
determine,557,O
the,557,O
functional,557,O
networks,557,O
potentially,557,O
altered,557,O
by,557,O
hypoxia,557,O
",",557,O
rat,557,O
renal,557,O
tubule,557,O
suspensions,557,O
were,557,O
incubated,557,O
under,557,O
three,557,O
conditions,557,O
of,557,O
oxygenation,557,O
ranging,557,O
from,557,O
normoxia,557,O
(,557,O
lactate,557,O
uptake,557,O
),557,O
to,557,O
severe,557,O
hypoxia,557,O
(,557,O
lactate,557,O
production,557,O
),557,O
.,557,O
Transcriptome,558,O
changes,558,O
after,558,O
4,558,O
h,558,O
were,558,O
analyzed,558,O
on,558,O
a,558,O
high,558,O
scale,558,O
by,558,O
restriction,558,O
fragment,558,O
differential,558,O
display,558,O
.,558,O
Among,559,O
"1,533",559,O
transcripts,559,O
found,559,O
",",559,O
42,559,O
%,559,O
were,559,O
maximally,559,O
expressed,559,O
under,559,O
severe,559,O
hypoxia,559,O
and,559,O
8,559,O
%,559,O
under,559,O
mild,559,O
hypoxia,559,O
(,559,O
Po,559,O
(,559,O
2,559,O
),559,O
=,559,O
48,559,O
mmHg,559,O
),559,O
",",559,O
suggesting,559,O
two,559,O
different,559,O
levels,559,O
of,559,O
oxygen,559,B-CHEMICAL
sensing,559,O
.,559,O
Normoxia,560,O
was,560,O
required,560,O
for,560,O
full,560,O
expression,560,O
of,560,O
the,560,O
proximal,560,O
tubule-specific,560,O
transcripts,560,O
25-hydroxyvitamin,560,B-GENE-Y
D,560,I-GENE-Y
1-hydroxylase,560,I-GENE-Y
(,560,O
Cyp27b1,560,B-GENE-Y
),560,O
and,560,O
l-pyruvate,560,B-GENE-Y
kinase,560,I-GENE-Y
(,560,O
Pklr,560,B-GENE-Y
),560,O
",",560,O
transcripts,560,O
involved,560,O
in,560,O
tissue,560,O
cohesion,560,O
such,560,O
as,560,O
fibronectin,560,B-GENE-Y
(,560,O
Fn1,560,B-GENE-Y
),560,O
and,560,O
N-cadherin,560,B-GENE-Y
(,560,O
Cdh2,560,B-GENE-Y
),560,O
",",560,O
and,560,O
non-muscle-type,560,B-GENE-N
myosin,560,I-GENE-N
transcripts,560,O
.,560,O
Mild,561,O
hypoxia,561,O
increased,561,O
myogenin,561,B-GENE-Y
transcript,561,O
level,561,O
.,561,O
Conversely,562,O
",",562,O
severe,562,O
hypoxia,562,O
increased,562,O
transcripts,562,O
involved,562,O
in,562,O
extracellular,562,O
matrix,562,O
remodeling,562,O
",",562,O
those,562,O
of,562,O
muscle-type,562,B-GENE-N
myosins,562,I-GENE-N
",",562,O
and,562,O
others,562,O
involved,562,O
in,562,O
creatine,562,O
phosphate,562,B-CHEMICAL
synthesis,562,O
and,562,O
lactate,562,O
transport,562,O
(,562,O
Slc16a7,562,B-GENE-Y
),562,O
.,562,O
Accordingly,563,O
",",563,O
microscopy,563,O
showed,563,O
loss,563,O
of,563,O
tubule,563,O
aggregation,563,O
under,563,O
hypoxia,563,O
",",563,O
without,563,O
tubular,563,O
disruption,563,O
.,563,O
Hypoxia,564,O
also,564,O
increased,564,O
the,564,O
levels,564,O
of,564,O
kidney-specific,564,O
transcripts,564,O
normally,564,O
restricted,564,O
to,564,O
the,564,O
less,564,O
oxygenated,564,O
medullary,564,O
zone,564,O
and,564,O
others,564,O
specific,564,O
for,564,O
the,564,O
distal,564,O
part,564,O
of,564,O
the,564,O
nephron,564,O
.,564,O
We,565,O
conclude,565,O
that,565,O
extensive,565,O
oxygen,565,B-CHEMICAL
supply,565,O
to,565,O
the,565,O
kidney,565,O
tubule,565,O
favors,565,O
expression,565,O
of,565,O
its,565,O
differentiated,565,O
functions,565,O
specifically,565,O
in,565,O
the,565,O
proximal,565,O
tubule,565,O
",",565,O
whose,565,O
embryonic,565,O
origin,565,O
is,565,O
mesenchymal,565,O
.,565,O
The,566,O
phenotype,566,O
changes,566,O
could,566,O
potentially,566,O
permit,566,O
transient,566,O
adaptation,566,O
to,566,O
hypoxia,566,O
but,566,O
also,566,O
favor,566,O
pathological,566,O
processes,566,O
such,566,O
as,566,O
tissue,566,O
invasion,566,O
.,566,O
A,567,O
human,567,O
hemi-cornea,567,O
model,567,O
for,567,O
eye,567,O
irritation,567,O
testing,567,O
:,567,O
quality,567,O
control,567,O
of,567,O
production,567,O
",",567,O
reliability,567,O
and,567,O
predictive,567,O
capacity,567,O
.,567,O
We,568,O
have,568,O
developed,568,O
a,568,O
3-dimensional,568,O
human,568,O
hemi-cornea,568,O
which,568,O
comprises,568,O
an,568,O
immortalized,568,O
epithelial,568,O
cell,568,O
line,568,O
and,568,O
keratocytes,568,O
embedded,568,O
in,568,O
a,568,O
collagen,568,B-GENE-N
stroma,568,O
.,568,O
In,569,O
the,569,O
present,569,O
study,569,O
",",569,O
we,569,O
have,569,O
used,569,O
MTT,569,B-CHEMICAL
reduction,569,O
of,569,O
the,569,O
whole,569,O
tissue,569,O
to,569,O
clarify,569,O
whether,569,O
the,569,O
production,569,O
of,569,O
this,569,O
complex,569,O
3-D-model,569,O
is,569,O
transferable,569,O
into,569,O
other,569,O
laboratories,569,O
and,569,O
whether,569,O
these,569,O
tissues,569,O
can,569,O
be,569,O
constructed,569,O
reproducibly,569,O
.,569,O
Our,570,O
results,570,O
demonstrate,570,O
the,570,O
reproducible,570,O
production,570,O
of,570,O
the,570,O
hemi-cornea,570,O
model,570,O
according,570,O
to,570,O
standard,570,O
operation,570,O
procedures,570,O
using,570,O
15,570,O
independent,570,O
batches,570,O
of,570,O
reconstructed,570,O
hemi-cornea,570,O
models,570,O
in,570,O
two,570,O
independent,570,O
laboratories,570,O
each,570,O
.,570,O
Furthermore,571,O
",",571,O
the,571,O
hemi-cornea,571,O
tissues,571,O
have,571,O
been,571,O
treated,571,O
with,571,O
20,571,O
chemicals,571,O
of,571,O
different,571,O
eye-irritating,571,O
potential,571,O
under,571,O
blind,571,O
conditions,571,O
to,571,O
assess,571,O
the,571,O
performance,571,O
and,571,O
limitations,571,O
of,571,O
our,571,O
test,571,O
system,571,O
comparing,571,O
three,571,O
different,571,O
prediction,571,O
models,571,O
.,571,O
The,572,O
most,572,O
suitable,572,O
prediction,572,O
model,572,O
revealed,572,O
an,572,O
overall,572,O
in,572,O
vitro-in,572,O
vivo,572,O
concordance,572,O
of,572,O
80,572,O
%,572,O
and,572,O
70,572,O
%,572,O
in,572,O
the,572,O
participating,572,O
laboratories,572,O
",",572,O
respectively,572,O
",",572,O
and,572,O
an,572,O
inter-laboratory,572,O
concordance,572,O
of,572,O
80,572,O
%,572,O
.,572,O
Sensitivity,573,O
of,573,O
the,573,O
test,573,O
was,573,O
77,573,O
%,573,O
and,573,O
specificity,573,O
was,573,O
between,573,O
57,573,O
%,573,O
and,573,O
86,573,O
%,573,O
to,573,O
discriminate,573,O
classified,573,O
from,573,O
non-classified,573,O
chemicals,573,O
.,573,O
We,574,O
conclude,574,O
that,574,O
additional,574,O
physiologically,574,O
relevant,574,O
endpoints,574,O
in,574,O
both,574,O
epithelium,574,O
and,574,O
stroma,574,O
have,574,O
to,574,O
be,574,O
developed,574,O
for,574,O
the,574,O
reliable,574,O
prediction,574,O
of,574,O
all,574,O
GHS,574,O
classes,574,O
of,574,O
eye,574,O
irritation,574,O
in,574,O
one,574,O
stand,574,O
alone,574,O
test,574,O
system,574,O
.,574,O
Steroidal,575,B-CHEMICAL
glycosides,575,I-CHEMICAL
from,575,O
the,575,O
bulbs,575,O
of,575,O
Easter,575,O
lily,575,O
(,575,O
Lilium,575,O
longiflorum,575,O
Thunb,575,O
.,575,O
),575,O
promote,576,O
dermal,576,O
fibroblast,576,O
migration,576,O
in,576,O
vitro,576,O
.,576,O
ETHNOPHARMACOLOGICAL,577,O
RELEVANCE,577,O
:,577,O
Preparations,577,O
derived,577,O
from,577,O
bulbs,577,O
of,577,O
various,577,O
Lilium,577,O
species,577,O
have,577,O
been,577,O
used,577,O
to,577,O
promote,577,O
the,577,O
healing,577,O
of,577,O
skin,577,O
abrasions,577,O
",",577,O
sores,577,O
and,577,O
burns,577,O
and,577,O
to,577,O
aid,577,O
in,577,O
healing,577,O
wounds,577,O
in,577,O
Traditional,577,O
Chinese,577,O
and,577,O
Greco-Roman,577,O
Medicine,577,O
.,577,O
AIM,578,O
OF,578,O
THE,578,O
STUDY,578,O
:,578,O
To,578,O
evaluate,578,O
fractionated,578,O
Easter,578,O
lily,578,O
bulb,578,O
extracts,578,O
and,578,O
their,578,O
steroidal,578,B-CHEMICAL
glycosides,578,I-CHEMICAL
(,578,O
1-5,578,O
),578,O
for,578,O
the,578,O
promotion,578,O
of,578,O
dermal,578,O
fibroblast,578,O
migration,578,O
in,578,O
vitro,578,O
",",578,O
as,578,O
a,578,O
model,578,O
for,578,O
the,578,O
early,578,O
events,578,O
in,578,O
wound,578,O
healing,578,O
.,578,O
MATERIALS,579,O
AND,579,O
METHODS,579,O
:,579,O
An,579,O
activity-guided,579,O
screening,579,O
approach,579,O
was,579,O
used,579,O
by,579,O
coupling,579,O
sequential,579,O
solvent,579,O
extraction,579,O
",",579,O
gel,579,O
permeation,579,O
chromatography,579,O
(,579,O
GPC,579,O
),579,O
",",579,O
and,579,O
semi-preparative,579,O
reverse-phase,579,O
high,579,O
performance,579,O
liquid,579,O
chromatography,579,O
(,579,O
RP-HPLC,579,O
),579,O
with,579,O
an,579,O
in,579,O
vitro,579,O
dermal,579,O
fibroblast,579,O
migration,579,O
assay,579,O
.,579,O
Cytotoxicity,580,O
was,580,O
evaluated,580,O
with,580,O
methyl,580,B-CHEMICAL
thiazole,580,I-CHEMICAL
tetrazolium,580,I-CHEMICAL
(,580,O
MTT,580,B-CHEMICAL
),580,O
.,580,O
To,581,O
gain,581,O
insight,581,O
into,581,O
the,581,O
mode,581,O
of,581,O
action,581,O
of,581,O
the,581,O
steroidal,581,B-CHEMICAL
glycosides,581,I-CHEMICAL
",",581,O
nitric,581,B-CHEMICAL
oxide,581,I-CHEMICAL
(,581,O
NO,581,B-CHEMICAL
),581,O
production,581,O
",",581,O
and,581,O
expression,581,O
of,581,O
genes,581,O
for,581,O
transforming,581,B-GENE-Y
growth,581,I-GENE-Y
factor,581,I-GENE-Y
beta-1,581,I-GENE-Y
(,581,O
TGF-β,581,B-GENE-Y
),581,O
and,581,O
its,581,O
receptors,581,O
were,581,O
evaluated,581,O
.,581,O
RESULTS,582,O
:,582,O
Fractionated,582,O
bulb,582,O
extracts,582,O
and,582,O
the,582,O
two,582,O
isolated,582,O
steroidal,582,B-CHEMICAL
glycoalkaloids,582,I-CHEMICAL
(,582,O
1,582,O
),582,O
and,582,O
(,582,O
2,582,O
),582,O
induced,582,O
NO,582,B-CHEMICAL
production,582,O
and,582,O
TGF-β,582,B-GENE-Y
receptor,582,I-GENE-Y
I,582,I-GENE-Y
mRNA,582,O
expression,582,O
in,582,O
fibroblast,582,O
cell,582,O
culture,582,O
.,582,O
In,583,O
a,583,O
cytotoxicity,583,O
assay,583,O
",",583,O
steroidal,583,B-CHEMICAL
glycosides,583,I-CHEMICAL
(,583,O
1,583,O
),583,O
and,583,O
(,583,O
3,583,O
),583,O
had,583,O
IC50,583,O
values,583,O
of,583,O
8.2,583,O
and,583,O
8.7µM,583,O
",",583,O
but,583,O
the,583,O
natural,583,O
acetylation,583,O
of,583,O
the,583,O
C-6″,583,O
',583,O
hydroxy,583,B-CHEMICAL
of,583,O
the,583,O
terminal,583,O
glucose,583,B-CHEMICAL
unit,583,O
in,583,O
(,583,O
2,583,O
),583,O
resulted,583,O
in,583,O
a,583,O
3-fold,583,O
decrease,583,O
in,583,O
cell,583,O
cytotoxicity,583,O
when,583,O
compared,583,O
with,583,O
(,583,O
1,583,O
),583,O
.,583,O
Results,584,O
from,584,O
the,584,O
dermal,584,O
fibroblast,584,O
migration,584,O
assay,584,O
revealed,584,O
that,584,O
the,584,O
steroidal,584,B-CHEMICAL
glycoalkaloids,584,I-CHEMICAL
(,584,O
1,584,O
),584,O
and,584,O
(,584,O
2,584,O
),584,O
",",584,O
and,584,O
the,584,O
furostanol,584,B-CHEMICAL
saponin,584,I-CHEMICAL
(,584,O
3,584,O
),584,O
promoted,584,O
fibroblast,584,O
migration,584,O
from,584,O
the,584,O
range,584,O
of,584,O
23.7±5.7,584,O
to,584,O
37.7±5.1,584,O
%,584,O
",",584,O
as,584,O
compared,584,O
with,584,O
the,584,O
control,584,O
.,584,O
CONCLUSION,585,O
:,585,O
Collectively,585,O
",",585,O
our,585,O
data,585,O
demonstrate,585,O
that,585,O
the,585,O
steroidal,585,B-CHEMICAL
glycosides,585,I-CHEMICAL
present,585,O
in,585,O
Easter,585,O
lily,585,O
bulbs,585,O
induce,585,O
",",585,O
at,585,O
least,585,O
in,585,O
part,585,O
",",585,O
the,585,O
observed,585,O
dermal,585,O
fibroblast,585,O
migration,585,O
activity,585,O
of,585,O
the,585,O
bulb,585,O
extracts,585,O
.,585,O
This,586,O
is,586,O
the,586,O
first,586,O
evidence,586,O
that,586,O
steroidal,586,B-CHEMICAL
glycosides,586,I-CHEMICAL
from,586,O
L.,586,O
longiflorum,586,O
may,586,O
potentially,586,O
play,586,O
a,586,O
role,586,O
in,586,O
the,586,O
wound,586,O
healing,586,O
process,586,O
and,586,O
may,586,O
provide,586,O
a,586,O
scientific,586,O
basis,586,O
for,586,O
the,586,O
historical,586,O
use,586,O
of,586,O
lily,586,O
bulbs,586,O
for,586,O
this,586,O
purpose,586,O
.,586,O
Species-specific,587,O
pharmacological,587,O
properties,587,O
of,587,O
human,587,B-GENE-Y
alpha,587,I-GENE-Y
(,587,I-GENE-Y
2A,587,I-GENE-Y
),587,I-GENE-Y
-adrenoceptors,587,I-GENE-Y
.,587,O
On,588,O
the,588,O
basis,588,O
of,588,O
data,588,O
obtained,588,O
in,588,O
rabbits,588,O
",",588,O
the,588,O
imidazoline,588,B-GENE-N
receptor,588,I-GENE-N
ligand,588,O
rilmenidine,588,B-CHEMICAL
has,588,O
been,588,O
suggested,588,O
to,588,O
decrease,588,O
blood,588,O
pressure,588,O
in,588,O
humans,588,O
by,588,O
activating,588,O
central,588,O
alpha,588,B-GENE-Y
(,588,I-GENE-Y
2A,588,I-GENE-Y
),588,I-GENE-Y
-adrenoceptors,588,I-GENE-Y
.,588,O
A,589,O
prerequisite,589,O
for,589,O
this,589,O
hypothesis,589,O
was,589,O
the,589,O
unproved,589,O
assumption,589,O
that,589,O
rabbit,589,O
and,589,O
human,589,O
alpha,589,B-GENE-N
(,589,I-GENE-N
2A,589,I-GENE-N
),589,I-GENE-N
-adrenoceptors,589,I-GENE-N
are,589,O
equally,589,O
activated,589,O
by,589,O
rilmenidine,589,B-CHEMICAL
.,589,O
Because,590,O
alpha,590,B-GENE-N
(,590,I-GENE-N
2A,590,I-GENE-N
),590,I-GENE-N
-adrenoceptors,590,I-GENE-N
in,590,O
the,590,O
brain,590,O
and,590,O
on,590,O
cardiovascular,590,O
sympathetic,590,O
nerve,590,O
terminals,590,O
are,590,O
identical,590,O
",",590,O
the,590,O
latter,590,O
were,590,O
used,590,O
as,590,O
a,590,O
model,590,O
for,590,O
the,590,O
former,590,O
to,590,O
confirm,590,O
or,590,O
disprove,590,O
this,590,O
assumption,590,O
.,590,O
Human,591,O
atrial,591,O
appendages,591,O
and,591,O
rabbit,591,O
pulmonary,591,O
arteries,591,O
were,591,O
used,591,O
to,591,O
determine,591,O
the,591,O
potencies,591,O
of,591,O
alpha,591,B-GENE-N
(,591,I-GENE-N
2,591,I-GENE-N
),591,I-GENE-N
-adrenoceptor,591,I-GENE-N
agonists,591,O
in,591,O
inhibiting,591,O
the,591,O
electrically,591,O
(,591,O
2,591,O
Hz,591,O
),591,O
evoked,591,O
[,591,B-CHEMICAL
(,591,I-CHEMICAL
3,591,I-CHEMICAL
),591,I-CHEMICAL
H,591,I-CHEMICAL
],591,I-CHEMICAL
norepinephrine,591,I-CHEMICAL
release,591,O
and,591,O
of,591,O
antagonists,591,O
in,591,O
counteracting,591,O
the,591,O
alpha,591,B-GENE-N
(,591,I-GENE-N
2,591,I-GENE-N
),591,I-GENE-N
-adrenoceptor-mediated,591,O
inhibition,591,O
induced,591,O
by,591,O
moxonidine,591,B-CHEMICAL
.,591,O
In,592,O
the,592,O
rabbit,592,O
pulmonary,592,O
artery,592,O
",",592,O
rilmenidine,592,B-CHEMICAL
and,592,O
oxymetazoline,592,B-CHEMICAL
are,592,O
potent,592,O
full,592,O
agonists,592,O
",",592,O
whereas,592,O
in,592,O
the,592,O
human,592,O
atrial,592,O
appendages,592,O
they,592,O
are,592,O
antagonists,592,O
at,592,O
the,592,O
alpha,592,B-GENE-N
(,592,I-GENE-N
2,592,I-GENE-N
),592,I-GENE-N
-autoreceptors,592,I-GENE-N
",",592,O
sharing,592,O
this,592,O
property,592,O
with,592,O
rauwolscine,592,B-CHEMICAL
",",592,O
phentolamine,592,B-CHEMICAL
",",592,O
and,592,O
idazoxan,592,B-CHEMICAL
.,592,O
In,593,O
contrast,593,O
",",593,O
prazosin,593,B-CHEMICAL
is,593,O
ineffective,593,O
.,593,O
In,594,O
addition,594,O
",",594,O
a,594,O
partial,594,O
nucleotide,594,O
and,594,O
amino,594,B-CHEMICAL
acid,594,I-CHEMICAL
sequence,594,O
of,594,O
the,594,O
rabbit,594,B-GENE-Y
alpha,594,I-GENE-Y
(,594,I-GENE-Y
2A,594,I-GENE-Y
),594,I-GENE-Y
-adrenoceptor,594,I-GENE-Y
(,594,O
a,594,O
region,594,O
known,594,O
to,594,O
substantially,594,O
influence,594,O
the,594,O
pharmacological,594,O
characteristics,594,O
of,594,O
the,594,O
alpha,594,B-GENE-N
(,594,I-GENE-N
2,594,I-GENE-N
),594,I-GENE-N
-adrenoceptor,594,I-GENE-N
),594,O
revealed,594,O
marked,594,O
differences,594,O
between,594,O
the,594,O
rabbit,594,O
and,594,O
the,594,O
human,594,O
alpha,594,B-GENE-N
(,594,I-GENE-N
2A,594,I-GENE-N
),594,I-GENE-N
-adrenoceptor,594,I-GENE-N
.,594,O
The,595,O
sympathetic,595,O
nerves,595,O
of,595,O
both,595,O
the,595,O
human,595,O
atrial,595,O
appendages,595,O
and,595,O
rabbit,595,O
pulmonary,595,O
artery,595,O
are,595,O
endowed,595,O
with,595,O
alpha,595,B-GENE-N
(,595,I-GENE-N
2A,595,I-GENE-N
),595,I-GENE-N
-autoreceptors,595,I-GENE-N
",",595,O
at,595,O
which,595,O
",",595,O
however,595,O
",",595,O
both,595,O
rilmenidine,595,B-CHEMICAL
and,595,O
oxymetazoline,595,B-CHEMICAL
exhibit,595,O
different,595,O
properties,595,O
(,595,O
antagonism,595,O
and,595,O
agonism,595,O
",",595,O
respectively,595,O
),595,O
.,595,O
The,596,O
antagonistic,596,O
property,596,O
of,596,O
rilmenidine,596,B-CHEMICAL
at,596,O
human,596,B-GENE-Y
alpha,596,I-GENE-Y
(,596,I-GENE-Y
2A,596,I-GENE-Y
),596,I-GENE-Y
-adrenoceptors,596,I-GENE-Y
indicates,596,O
that,596,O
in,596,O
contrast,596,O
to,596,O
the,596,O
suggestion,596,O
based,596,O
on,596,O
rabbit,596,O
data,596,O
",",596,O
the,596,O
hypotensive,596,O
property,596,O
of,596,O
the,596,O
drug,596,O
in,596,O
humans,596,O
is,596,O
not,596,O
due,596,O
to,596,O
activation,596,O
of,596,O
alpha,596,B-GENE-Y
(,596,I-GENE-Y
2A,596,I-GENE-Y
),596,I-GENE-Y
-adrenoceptors,596,I-GENE-Y
but,596,O
other,596,O
",",596,O
presumably,596,O
I,596,B-GENE-Y
(,596,I-GENE-Y
1,596,I-GENE-Y
),596,I-GENE-Y
-imidazoline,596,I-GENE-Y
receptors,596,I-GENE-Y
",",596,O
are,596,O
probably,596,O
involved,596,O
.,596,O
Gonadotropin-releasing,597,B-GENE-Y
hormone,597,I-GENE-Y
receptor,597,I-GENE-Y
gene,597,O
expression,597,O
during,597,O
pubertal,597,O
development,597,O
of,597,O
male,597,O
rats,597,O
.,597,O
Appropriate,598,O
expression,598,O
of,598,O
the,598,O
GnRH,598,B-GENE-Y
receptor,598,I-GENE-Y
(,598,O
GnRH-R,598,B-GENE-Y
),598,O
in,598,O
gonadotropes,598,O
is,598,O
critical,598,O
for,598,O
GnRH,598,B-GENE-Y
signaling,598,O
and,598,O
hence,598,O
for,598,O
gonadotropin,598,B-GENE-N
secretion,598,O
and,598,O
sexual,598,O
development,598,O
.,598,O
In,599,O
the,599,O
present,599,O
work,599,O
",",599,O
we,599,O
have,599,O
studied,599,O
the,599,O
ontogeny,599,O
of,599,O
the,599,O
steady-state,599,O
GnRH-R,599,B-GENE-Y
mRNA,599,O
levels,599,O
in,599,O
pituitaries,599,O
of,599,O
male,599,O
rats,599,O
from,599,O
Day,599,O
5,599,O
to,599,O
Day,599,O
55,599,O
",",599,O
when,599,O
sexual,599,O
maturity,599,O
is,599,O
attained,599,O
.,599,O
Developmental,600,O
changes,600,O
of,600,O
gonadotropin,600,B-GENE-N
subunit,600,O
(,600,O
alpha,600,O
",",600,O
FSHbeta,600,B-GENE-Y
",",600,O
and,600,O
LHbeta,600,B-GENE-Y
),600,O
mRNA,600,O
levels,600,O
were,600,O
also,600,O
assessed,600,O
.,600,O
In,601,O
addition,601,O
",",601,O
the,601,O
role,601,O
of,601,O
the,601,O
endogenous,601,O
GnRH,601,B-GENE-Y
on,601,O
the,601,O
maturational,601,O
changes,601,O
of,601,O
GnRH-R,601,B-GENE-Y
and,601,O
gonadotropin,601,B-GENE-N
subunit,601,O
gene,601,O
expression,601,O
was,601,O
investigated,601,O
.,601,O
Messenger,602,O
RNA,602,O
levels,602,O
were,602,O
determined,602,O
by,602,O
Northern,602,O
blot,602,O
analysis,602,O
of,602,O
total,602,O
RNA,602,O
from,602,O
anterior,602,O
pituitaries,602,O
.,602,O
Amounts,603,O
of,603,O
the,603,O
most,603,O
abundant,603,O
(,603,O
5.0,603,O
kb,603,O
),603,O
GnRH-R,603,B-GENE-Y
mRNA,603,O
increased,603,O
slowly,603,O
from,603,O
Day,603,O
5,603,O
through,603,O
the,603,O
infantile,603,O
and,603,O
the,603,O
juvenile,603,O
periods,603,O
",",603,O
to,603,O
peak,603,O
at,603,O
Day,603,O
35,603,O
(,603,O
12-fold,603,O
increase,603,O
vs.,603,O
Day,603,O
5,603,O
),603,O
.,603,O
Thereafter,604,O
",",604,O
the,604,O
levels,604,O
of,604,O
the,604,O
GnRH-R,604,B-GENE-Y
mRNA,604,O
decline,604,O
slightly,604,O
until,604,O
Day,604,O
55,604,O
(,604,O
33,604,O
%,604,O
decrease,604,O
vs.,604,O
Day,604,O
35,604,O
),604,O
.,604,O
Parallel,605,O
changes,605,O
were,605,O
observed,605,O
on,605,O
the,605,O
4.5-kb,605,O
transcript,605,O
of,605,O
the,605,O
GnRH-R,605,B-GENE-Y
gene,605,O
.,605,O
Alpha,606,O
subunit,606,O
mRNA,606,O
was,606,O
easily,606,O
detected,606,O
at,606,O
Day,606,O
5,606,O
",",606,O
and,606,O
its,606,O
levels,606,O
increased,606,O
progressively,606,O
through,606,O
the,606,O
infantile,606,O
period,606,O
(,606,O
2.5-fold,606,O
increase,606,O
),606,O
and,606,O
peaked,606,O
at,606,O
Day,606,O
25,606,O
(,606,O
3.3-fold,606,O
increase,606,O
vs.,606,O
Day,606,O
5,606,O
),606,O
with,606,O
a,606,O
smooth,606,O
nonstatistically,606,O
significant,606,O
increment,606,O
until,606,O
Day,606,O
35,606,O
;,606,O
then,606,O
it,606,O
decreased,606,O
by,606,O
41.5,606,O
%,606,O
at,606,O
Day,606,O
55,606,O
.,606,O
FSHbeta,607,B-GENE-Y
and,607,O
LHbeta,607,B-GENE-Y
mRNA,607,O
levels,607,O
rose,607,O
slowly,607,O
until,607,O
Day,607,O
25,607,O
.,607,O
A,608,O
sharp,608,O
rise,608,O
occurred,608,O
thereafter,608,O
to,608,O
reach,608,O
maximum,608,O
levels,608,O
at,608,O
Day,608,O
35,608,O
(,608,O
5.8-fold,608,O
for,608,O
FSHbeta,608,B-GENE-Y
and,608,O
3.8-fold,608,O
for,608,O
LHbeta,608,B-GENE-Y
vs.,608,O
Day,608,O
25,608,O
),608,O
.,608,O
Thereafter,609,O
",",609,O
the,609,O
levels,609,O
of,609,O
both,609,O
mRNAs,609,O
fell,609,O
until,609,O
Day,609,O
55,609,O
(,609,O
44.1,609,O
%,609,O
decrease,609,O
for,609,O
FSHbeta,609,B-GENE-Y
and,609,O
37.1,609,O
%,609,O
decrease,609,O
for,609,O
LHbeta,609,B-GENE-Y
vs.,609,O
Day,609,O
35,609,O
),609,O
.,609,O
To,610,O
ascertain,610,O
whether,610,O
developmental,610,O
activation,610,O
of,610,O
the,610,O
GnRH-R,610,B-GENE-Y
and,610,O
gonadotropin,610,B-GENE-N
subunit,610,O
gene,610,O
expression,610,O
is,610,O
GnRH,610,B-GENE-Y
dependent,610,O
",",610,O
we,610,O
have,610,O
studied,610,O
the,610,O
effect,610,O
of,610,O
blocking,610,O
the,610,O
endogenous,610,O
GnRH,610,B-GENE-Y
action,610,O
by,610,O
treating,610,O
developing,610,O
male,610,O
rats,610,O
with,610,O
the,610,O
specific,610,O
GnRH,610,B-GENE-Y
antagonist,610,O
cetrorelix,610,O
(,610,O
1.5,610,O
mg/kg,610,O
body,610,O
weight/week,610,O
",",610,O
s.c.,610,O
),610,O
through,610,O
the,610,O
infantile,610,O
(,610,O
Days,610,O
5-20,610,O
),610,O
and,610,O
the,610,O
juvenile,610,O
periods,610,O
(,610,O
Days,610,O
20-35,610,O
),610,O
.,610,O
Cetrorelix,611,B-CHEMICAL
completely,611,O
blocked,611,O
the,611,O
rise,611,O
of,611,O
levels,611,O
of,611,O
the,611,O
two,611,O
most,611,O
abundant,611,O
species,611,O
",",611,O
5.0,611,O
kb,611,O
and,611,O
4.5,611,O
kb,611,O
",",611,O
of,611,O
the,611,O
GnRH-R,611,B-GENE-Y
mRNA,611,O
",",611,O
during,611,O
both,611,O
the,611,O
infantile,611,O
and,611,O
the,611,O
juvenile,611,O
periods,611,O
.,611,O
Cetrorelix,612,B-CHEMICAL
also,612,O
abolished,612,O
the,612,O
developmental,612,O
rise,612,O
of,612,O
the,612,O
gonadotropin,612,B-GENE-N
beta,612,I-GENE-N
subunit,612,O
mRNAs,612,O
during,612,O
the,612,O
two,612,O
periods,612,O
of,612,O
the,612,O
study,612,O
.,612,O
In,613,O
contrast,613,O
",",613,O
the,613,O
alpha,613,O
subunit,613,O
gene,613,O
expression,613,O
was,613,O
not,613,O
altered,613,O
by,613,O
cetrorelix,613,O
treatment,613,O
during,613,O
any,613,O
of,613,O
the,613,O
two,613,O
periods,613,O
.,613,O
These,614,O
data,614,O
demonstrate,614,O
that,614,O
sexual,614,O
maturation,614,O
of,614,O
male,614,O
rats,614,O
is,614,O
accompanied,614,O
by,614,O
a,614,O
progressive,614,O
and,614,O
concerted,614,O
induction,614,O
of,614,O
GnRH-R,614,B-GENE-Y
and,614,O
gonadotropin,614,B-GENE-N
subunit,614,O
gene,614,O
expression,614,O
.,614,O
Developmental,615,O
activation,615,O
of,615,O
GnRH-R,615,B-GENE-Y
and,615,O
gonadotropin,615,B-GENE-N
beta,615,I-GENE-N
subunit,615,O
genes,615,O
is,615,O
GnRH,615,B-GENE-Y
dependent,615,O
.,615,O
The,616,O
apparent,616,O
GnRH-independent,616,B-GENE-Y
regulation,616,O
of,616,O
the,616,O
alpha-glycoprotein,616,B-GENE-N
subunit,616,O
mRNA,616,O
levels,616,O
may,616,O
be,616,O
due,616,O
to,616,O
the,616,O
contribution,616,O
of,616,O
thyrotropes,616,O
and,616,O
perhaps,616,O
to,616,O
the,616,O
presence,616,O
of,616,O
exclusive,616,O
regulatory,616,O
signals,616,O
for,616,O
this,616,O
gene,616,O
.,616,O
Nonsedating,617,O
histamine,617,B-GENE-Y
H1-receptor,617,I-GENE-Y
antagonists,617,O
.,617,O
The,618,O
chemistry,618,O
",",618,O
pharmacology,618,O
",",618,O
pharmacokinetics,618,O
",",618,O
clinical,618,O
efficacy,618,O
",",618,O
adverse,618,O
effects,618,O
",",618,O
and,618,O
dosages,618,O
of,618,O
the,618,O
nonsedating,618,O
histamine,618,B-GENE-Y
H1-receptor,618,I-GENE-Y
antagonists,618,O
terfenadine,618,B-CHEMICAL
",",618,O
astemizole,618,B-CHEMICAL
",",618,O
loratadine,618,B-CHEMICAL
",",618,O
and,618,O
acrivastine,618,B-CHEMICAL
are,618,O
reviewed,618,O
.,618,O
Terfenadine,619,B-CHEMICAL
and,619,O
astemizole,619,B-CHEMICAL
are,619,O
chemically,619,O
unrelated,619,O
to,619,O
histamine,619,B-GENE-Y
H1-receptor,619,I-GENE-Y
antagonists,619,O
such,619,O
as,619,O
diphenhydramine,619,B-CHEMICAL
and,619,O
chlorpheniramine,619,B-CHEMICAL
.,619,O
Loratadine,620,B-CHEMICAL
is,620,O
structurally,620,O
related,620,O
to,620,O
the,620,O
antihistamine,620,O
azatadine,620,B-CHEMICAL
",",620,O
and,620,O
acrivastine,620,B-CHEMICAL
is,620,O
a,620,O
side-chain-reduced,620,O
metabolite,620,O
of,620,O
the,620,O
antihistamine,620,O
triprolidine,620,B-CHEMICAL
.,620,O
Like,621,O
other,621,O
histamine,621,B-GENE-Y
H1-receptor,621,I-GENE-Y
antagonists,621,O
",",621,O
they,621,O
competitively,621,O
block,621,O
histamine,621,B-GENE-N
receptor,621,I-GENE-N
sites,621,O
rather,621,O
than,621,O
inhibiting,621,O
histamine,621,B-CHEMICAL
release,621,O
.,621,O
All,622,O
four,622,O
drugs,622,O
have,622,O
relatively,622,O
long,622,O
half-lives,622,O
and,622,O
are,622,O
rapidly,622,O
absorbed,622,O
after,622,O
oral,622,O
administration,622,O
.,622,O
Terfenadine,623,B-CHEMICAL
",",623,O
astemizole,623,B-CHEMICAL
",",623,O
and,623,O
loratadine,623,B-CHEMICAL
are,623,O
metabolized,623,O
extensively,623,O
in,623,O
the,623,O
liver,623,O
;,623,O
terfenadine,623,B-CHEMICAL
and,623,O
astemizole,623,B-CHEMICAL
are,623,O
both,623,O
97,623,O
%,623,O
protein,623,O
bound,623,O
.,623,O
Terfenadine,624,B-CHEMICAL
60,624,O
mg,624,O
twice,624,O
daily,624,O
has,624,O
been,624,O
shown,624,O
to,624,O
be,624,O
as,624,O
effective,624,O
as,624,O
conventional,624,O
antihistamines,624,O
for,624,O
the,624,O
treatment,624,O
of,624,O
seasonal,624,O
allergic,624,O
rhinitis,624,O
.,624,O
In,625,O
clinical,625,O
trials,625,O
",",625,O
astemizole,625,B-CHEMICAL
10,625,O
mg,625,O
daily,625,O
was,625,O
comparable,625,O
to,625,O
or,625,O
better,625,O
than,625,O
chlorpheniramine,625,B-CHEMICAL
for,625,O
treatment,625,O
of,625,O
chronic,625,O
rhinitis,625,O
.,625,O
Both,626,O
terfenadine,626,B-CHEMICAL
and,626,O
astemizole,626,B-CHEMICAL
were,626,O
effective,626,O
for,626,O
treatment,626,O
of,626,O
chronic,626,O
urticaria,626,O
.,626,O
For,627,O
treatment,627,O
of,627,O
seasonal,627,O
allergic,627,O
rhinitis,627,O
",",627,O
loratadine,627,B-CHEMICAL
combined,627,O
with,627,O
pseudoephedrine,627,B-CHEMICAL
may,627,O
be,627,O
preferable,627,O
to,627,O
triprolidine-pseudoephedrine,627,B-CHEMICAL
and,627,O
acrivastine-pseudoephedrine,627,B-CHEMICAL
combinations,627,O
that,627,O
require,627,O
more,627,O
frequent,627,O
dosing,627,O
.,627,O
Acrivastine,628,B-CHEMICAL
must,628,O
be,628,O
administered,628,O
more,628,O
frequently,628,O
than,628,O
the,628,O
other,628,O
nonsedating,628,O
antihistamines,628,O
.,628,O
None,629,O
of,629,O
these,629,O
four,629,O
agents,629,O
impairs,629,O
psychomotor,629,O
activity,629,O
.,629,O
Infrequently,630,O
reported,630,O
adverse,630,O
effects,630,O
include,630,O
dry,630,O
mouth,630,O
",",630,O
skin,630,O
reactions,630,O
",",630,O
and,630,O
weight,630,O
gain,630,O
.,630,O
The,631,O
absence,631,O
of,631,O
substantial,631,O
sedative,631,O
effects,631,O
and,631,O
the,631,O
less-frequent,631,O
dosing,631,O
schedules,631,O
make,631,O
these,631,O
agents,631,O
good,631,O
alternatives,631,O
to,631,O
the,631,O
classic,631,O
antihistamines,631,O
for,631,O
treatment,631,O
of,631,O
seasonal,631,O
and,631,O
chronic,631,O
rhinitis,631,O
and,631,O
chronic,631,O
urticaria,631,O
.,631,O
Anti-inflammatory,632,O
effect,632,O
of,632,O
prunetin,632,B-CHEMICAL
via,632,O
the,632,O
suppression,632,O
of,632,O
NF-κB,632,B-GENE-N
pathway,632,O
.,632,O
Prunetin,633,B-CHEMICAL
is,633,O
an,633,O
O-methylated,633,B-CHEMICAL
isoflavone,633,I-CHEMICAL
",",633,O
which,633,O
is,633,O
found,633,O
in,633,O
Prunus,633,O
yedoensis,633,O
.,633,O
To,634,O
date,634,O
no,634,O
report,634,O
has,634,O
been,634,O
published,634,O
on,634,O
anti-inflammatory,634,O
activities,634,O
of,634,O
prunetin,634,B-CHEMICAL
.,634,O
In,635,O
the,635,O
present,635,O
study,635,O
",",635,O
the,635,O
anti-inflammatory,635,O
effect,635,O
of,635,O
prunetin,635,B-CHEMICAL
on,635,O
LPS-stimulated,635,O
RAW,635,O
264.7,635,O
macrophage,635,O
and,635,O
LPS-induced,635,O
septic,635,O
shock,635,O
model,635,O
were,635,O
investigated,635,O
.,635,O
Inducible,636,B-GENE-Y
nitric,636,I-GENE-Y
oxide,636,I-GENE-Y
synthase,636,I-GENE-Y
(,636,O
iNOS,636,B-GENE-Y
),636,O
",",636,O
cyclooxygenase-2,636,B-GENE-Y
(,636,O
COX-2,636,B-GENE-Y
),636,O
",",636,O
tumor,636,B-GENE-Y
necrosis,636,I-GENE-Y
factor-α,636,I-GENE-Y
(,636,O
TNF-α,636,B-GENE-Y
),636,O
",",636,O
interleukin-6,636,B-GENE-Y
(,636,O
IL-6,636,B-GENE-Y
),636,O
",",636,O
and,636,O
interleukin-1β,636,B-GENE-Y
(,636,O
IL-1β,636,B-GENE-Y
),636,O
expressions,636,O
were,636,O
determined,636,O
by,636,O
western,636,O
blot,636,O
and,636,O
or,636,O
realtime-PCR,636,O
(,636,O
RT-PCR,636,O
),636,O
.,636,O
To,637,O
elucidate,637,O
its,637,O
underlying,637,O
mechanism,637,O
",",637,O
nuclear,637,B-GENE-N
factor-kappa,637,I-GENE-N
B,637,I-GENE-N
(,637,O
NF-κb,637,B-GENE-N
),637,O
activation,637,O
and,637,O
its,637,O
downstream,637,O
pathways,637,O
were,637,O
investigated,637,O
by,637,O
NF-κB,637,B-GENE-N
transcription,637,O
factor,637,O
assay,637,O
",",637,O
reporter,637,O
gene,637,O
expression,637,O
",",637,O
and,637,O
western,637,O
blot,637,O
.,637,O
In,638,O
vivo,638,O
anti-inflammatory,638,O
effects,638,O
of,638,O
prunetin,638,B-CHEMICAL
were,638,O
evaluated,638,O
in,638,O
LPS-induced,638,O
endotoxemia,638,O
.,638,O
Promoter,639,O
assay,639,O
revealed,639,O
that,639,O
prunetin,639,B-CHEMICAL
inhibits,639,O
LPS-induced,639,O
nitric,639,B-CHEMICAL
oxide,639,I-CHEMICAL
and,639,O
prostaglandin,639,B-CHEMICAL
E2,639,I-CHEMICAL
production,639,O
through,639,O
the,639,O
suppression,639,O
of,639,O
iNOS,639,B-GENE-Y
and,639,O
COX-2,639,B-GENE-Y
at,639,O
the,639,O
transcriptional,639,O
level,639,O
.,639,O
In,640,O
addition,640,O
",",640,O
prunetin,640,B-CHEMICAL
inhibits,640,O
NF-κB-dependent,640,B-GENE-N
inflammatory,640,O
responses,640,O
by,640,O
modulating,640,O
IκB,640,B-GENE-N
kinase,640,I-GENE-N
(,640,O
IKK,640,B-GENE-N
),640,O
-inhibitor,640,O
κBα,640,I-GENE-Y
(,640,O
IκBα,640,B-GENE-Y
),640,O
-NF-κB,640,O
signaling,640,O
.,640,O
Consistent,641,O
with,641,O
these,641,O
results,641,O
",",641,O
prunetin,641,B-CHEMICAL
significantly,641,O
reduced,641,O
serum,641,O
levels,641,O
of,641,O
inflammatory,641,O
cytokines,641,B-GENE-N
and,641,O
mortality,641,O
in,641,O
mice,641,O
challenged,641,O
with,641,O
lipopolysaccharide,641,O
.,641,O
These,642,O
findings,642,O
offer,642,O
a,642,O
potential,642,O
mechanism,642,O
for,642,O
the,642,O
anti-inflammatory,642,O
activity,642,O
of,642,O
prunetin,642,B-CHEMICAL
.,642,O
G6PC2,643,B-GENE-Y
:,643,O
A,643,O
Negative,643,O
Regulator,643,O
of,643,O
Basal,643,O
Glucose-Stimulated,643,B-CHEMICAL
Insulin,643,B-GENE-Y
Secretion,643,O
.,643,O
Elevated,644,O
fasting,644,O
blood,644,O
glucose,644,B-CHEMICAL
(,644,O
FBG,644,O
),644,O
is,644,O
associated,644,O
with,644,O
increased,644,O
risk,644,O
for,644,O
the,644,O
development,644,O
of,644,O
type,644,O
2,644,O
diabetes,644,O
and,644,O
cardiovascular-associated,644,O
mortality,644,O
.,644,O
Genome-wide,645,O
association,645,O
studies,645,O
(,645,O
GWAS,645,O
),645,O
have,645,O
linked,645,O
polymorphisms,645,O
in,645,O
G6PC2,645,B-GENE-Y
with,645,O
variations,645,O
in,645,O
FBG,645,O
and,645,O
body,645,O
fat,645,O
",",645,O
although,645,O
not,645,O
insulin,645,B-GENE-Y
sensitivity,645,O
or,645,O
glucose,645,B-CHEMICAL
tolerance,645,O
.,645,O
G6PC2,646,B-GENE-Y
encodes,646,O
an,646,O
islet-specific,646,O
",",646,O
endoplasmic,646,O
reticulum-resident,646,O
glucose-6-phosphatase,646,B-GENE-Y
catalytic,646,I-GENE-Y
subunit,646,I-GENE-Y
.,646,O
A,647,O
combination,647,O
of,647,O
in,647,O
situ,647,O
perfused,647,O
pancreas,647,O
",",647,O
in,647,O
vitro,647,O
isolated,647,O
islet,647,O
",",647,O
and,647,O
in,647,O
vivo,647,O
analyses,647,O
were,647,O
used,647,O
to,647,O
explore,647,O
the,647,O
function,647,O
of,647,O
G6pc2,647,B-GENE-Y
in,647,O
mice,647,O
.,647,O
G6pc2,648,B-GENE-Y
deletion,648,O
had,648,O
little,648,O
effect,648,O
on,648,O
insulin,648,B-GENE-N
sensitivity,648,O
and,648,O
glucose,648,B-CHEMICAL
tolerance,648,O
",",648,O
whereas,648,O
body,648,O
fat,648,O
was,648,O
reduced,648,O
in,648,O
female,648,O
G6pc2,648,B-GENE-Y
knockout,648,O
(,648,O
KO,648,O
),648,O
mice,648,O
on,648,O
both,648,O
a,648,O
chow,648,O
and,648,O
high-fat,648,O
diet,648,O
",",648,O
observations,648,O
that,648,O
are,648,O
all,648,O
consistent,648,O
with,648,O
human,648,O
GWAS,648,O
data,648,O
.,648,O
G6pc2,649,B-GENE-Y
deletion,649,O
resulted,649,O
in,649,O
a,649,O
leftward,649,O
shift,649,O
in,649,O
the,649,O
dose-response,649,O
curve,649,O
for,649,O
glucose-stimulated,649,B-CHEMICAL
insulin,649,B-GENE-N
secretion,649,O
(,649,O
GSIS,649,O
),649,O
.,649,O
As,650,O
a,650,O
consequence,650,O
",",650,O
under,650,O
fasting,650,O
conditions,650,O
in,650,O
which,650,O
plasma,650,O
insulin,650,B-GENE-N
levels,650,O
were,650,O
identical,650,O
",",650,O
blood,650,O
glucose,650,B-CHEMICAL
levels,650,O
were,650,O
reduced,650,O
in,650,O
G6pc2,650,B-GENE-Y
KO,650,O
mice,650,O
",",650,O
again,650,O
consistent,650,O
with,650,O
human,650,O
GWAS,650,O
data,650,O
.,650,O
Glucose-6-phosphatase,651,B-GENE-Y
activity,651,O
was,651,O
reduced,651,O
",",651,O
whereas,651,O
basal,651,O
cytoplasmic,651,O
calcium,651,B-CHEMICAL
levels,651,O
were,651,O
elevated,651,O
in,651,O
islets,651,O
isolated,651,O
from,651,O
G6pc2,651,B-GENE-Y
KO,651,O
mice,651,O
.,651,O
These,652,O
data,652,O
suggest,652,O
that,652,O
G6pc2,652,B-GENE-Y
represents,652,O
a,652,O
novel,652,O
",",652,O
negative,652,O
regulator,652,O
of,652,O
basal,652,O
GSIS,652,O
that,652,O
acts,652,O
by,652,O
hydrolyzing,652,O
glucose-6-phosphate,652,B-CHEMICAL
",",652,O
thereby,652,O
reducing,652,O
glycolytic,652,O
flux,652,O
.,652,O
Transforming,653,B-GENE-Y
growth,653,I-GENE-Y
factor,653,I-GENE-Y
β,653,I-GENE-Y
integrates,653,O
Smad,653,B-GENE-Y
3,653,I-GENE-Y
to,653,O
mechanistic,653,B-GENE-Y
target,653,I-GENE-Y
of,653,I-GENE-Y
rapamycin,653,I-GENE-Y
complexes,653,O
to,653,O
arrest,653,O
deptor,653,B-GENE-Y
abundance,653,O
for,653,O
glomerular,653,O
mesangial,653,O
cell,653,O
hypertrophy,653,O
.,653,O
In,654,O
many,654,O
renal,654,O
diseases,654,O
",",654,O
transforming,654,B-GENE-Y
growth,654,I-GENE-Y
factor,654,I-GENE-Y
β,654,I-GENE-Y
(,654,O
TGFβ,654,B-GENE-Y
),654,O
-stimulated,654,O
canonical,654,O
Smad,654,B-GENE-Y
3,654,I-GENE-Y
and,654,O
noncanonical,654,O
mechanistic,654,B-GENE-Y
target,654,I-GENE-Y
of,654,I-GENE-Y
rapamycin,654,I-GENE-Y
(,654,O
mTOR,654,B-GENE-Y
),654,O
promote,654,O
increased,654,O
protein,654,O
synthesis,654,O
and,654,O
mesangial,654,O
cell,654,O
hypertrophy,654,O
.,654,O
The,655,O
cellular,655,O
underpinnings,655,O
involving,655,O
these,655,O
signaling,655,O
molecules,655,O
to,655,O
regulate,655,O
mesangial,655,O
cell,655,O
hypertrophy,655,O
are,655,O
not,655,O
fully,655,O
understood,655,O
.,655,O
Deptor,656,B-GENE-Y
has,656,O
recently,656,O
been,656,O
identified,656,O
as,656,O
an,656,O
mTOR,656,B-GENE-Y
interacting,656,O
protein,656,O
and,656,O
functions,656,O
as,656,O
an,656,O
endogenous,656,O
inhibitor,656,O
of,656,O
the,656,O
kinase,656,B-GENE-N
activity,656,O
for,656,O
both,656,O
TORC1,656,B-GENE-Y
and,656,O
TORC2,656,B-GENE-Y
.,656,O
Prolonged,657,O
incubation,657,O
of,657,O
mesangial,657,O
cells,657,O
with,657,O
TGFβ,657,B-GENE-Y
reduced,657,O
the,657,O
levels,657,O
of,657,O
deptor,657,B-GENE-Y
concomitant,657,O
with,657,O
an,657,O
increase,657,O
in,657,O
TORC1,657,B-GENE-Y
and,657,O
TORC2,657,B-GENE-Y
activity,657,O
.,657,O
Sustained,658,O
TGFβ,658,B-GENE-Y
activation,658,O
was,658,O
required,658,O
to,658,O
inhibit,658,O
association,658,O
of,658,O
deptor,658,B-GENE-Y
with,658,O
mTOR,658,B-GENE-N
",",658,O
whereas,658,O
rapid,658,O
activation,658,O
had,658,O
no,658,O
effect,658,O
.,658,O
Using,659,O
the,659,O
mTOR,659,B-GENE-Y
inhibitor,659,O
PP242,659,B-CHEMICAL
",",659,I-CHEMICAL
we,659,O
found,659,O
that,659,O
TGFβ-induced,659,B-GENE-Y
both,659,O
early,659,O
and,659,O
sustained,659,O
activation,659,O
of,659,O
TORC1,659,B-GENE-Y
and,659,O
TORC2,659,B-GENE-Y
was,659,O
necessary,659,O
for,659,O
deptor,659,B-GENE-Y
suppression,659,O
.,659,O
PP242-induced,660,B-CHEMICAL
reversal,660,O
of,660,O
deptor,660,B-GENE-Y
suppression,660,O
by,660,O
TGFβ,660,B-GENE-Y
was,660,O
associated,660,O
with,660,O
a,660,O
significant,660,O
inhibition,660,O
of,660,O
TGFβ-stimulated,660,B-GENE-Y
protein,660,O
synthesis,660,O
and,660,O
hypertrophy,660,O
.,660,O
Interestingly,661,O
",",661,O
expression,661,O
of,661,O
siRNA,661,O
against,661,O
Smad,661,B-GENE-Y
3,661,I-GENE-Y
or,661,O
Smad,661,B-GENE-Y
7,661,I-GENE-Y
",",661,O
which,661,O
blocks,661,O
TGFβ,661,B-GENE-N
receptor-specific,661,O
Smad,661,B-GENE-Y
3,661,I-GENE-Y
signaling,661,O
",",661,O
prevented,661,O
TGFβ-induced,661,B-GENE-Y
suppression,661,O
of,661,O
deptor,661,B-GENE-Y
abundance,661,O
and,661,O
TORC1/2,661,B-GENE-N
activities,661,O
.,661,O
Furthermore,662,O
",",662,O
overexpression,662,O
of,662,O
Smad,662,B-GENE-Y
3,662,I-GENE-Y
decreased,662,O
deptor,662,B-GENE-Y
expression,662,O
similar,662,O
to,662,O
TGFβ,662,B-GENE-Y
stimulation,662,O
concomitant,662,O
with,662,O
increased,662,O
TORC1,662,B-GENE-Y
and,662,O
TORC2,662,B-GENE-Y
activities,662,O
.,662,O
Finally,663,O
",",663,O
knockdown,663,O
of,663,O
deptor,663,B-GENE-Y
reversed,663,O
Smad,663,B-GENE-Y
7-mediated,663,O
inhibition,663,O
of,663,O
protein,663,O
synthesis,663,O
and,663,O
mesangial,663,O
cell,663,O
hypertrophy,663,O
induced,663,O
by,663,O
TGFβ,663,B-GENE-Y
.,663,O
These,664,O
data,664,O
reveal,664,O
the,664,O
requirement,664,O
of,664,O
both,664,O
early,664,O
and,664,O
late,664,O
activation,664,O
of,664,O
mTOR,664,B-GENE-Y
for,664,O
TGFβ-induced,664,B-GENE-Y
protein,664,O
synthesis,664,O
.,664,O
Our,665,O
results,665,O
support,665,O
that,665,O
TGFβ-stimulated,665,B-GENE-Y
Smad,665,B-GENE-Y
3,665,I-GENE-Y
acts,665,O
as,665,O
a,665,O
key,665,O
node,665,O
to,665,O
instill,665,O
a,665,O
feedback,665,O
loop,665,O
between,665,O
deptor,665,B-GENE-Y
down-regulation,665,O
and,665,O
TORC1/2,665,B-GENE-N
activation,665,O
in,665,O
driving,665,O
mesangial,665,O
cell,665,O
hypertrophy,665,O
.,665,O
R-modafinil,666,B-CHEMICAL
(,666,O
armodafinil,666,B-CHEMICAL
),666,O
:,666,O
a,666,O
unique,666,O
dopamine,666,B-CHEMICAL
uptake,666,O
inhibitor,666,O
and,666,O
potential,666,O
medication,666,O
for,666,O
psychostimulant,666,O
abuse,666,O
.,666,O
BACKGROUND,667,O
:,667,O
(,667,B-CHEMICAL
+/-,667,I-CHEMICAL
),667,I-CHEMICAL
-Modafinil,667,I-CHEMICAL
has,667,O
piqued,667,O
interest,667,O
as,667,O
a,667,O
treatment,667,O
for,667,O
attention-deficit/hyperactivity,667,O
disorder,667,O
and,667,O
stimulant,667,O
dependence,667,O
.,667,O
The,668,O
R-enantiomer,668,B-CHEMICAL
of,668,I-CHEMICAL
modafinil,668,I-CHEMICAL
might,668,O
have,668,O
unique,668,O
pharmacological,668,O
properties,668,O
that,668,O
should,668,O
be,668,O
further,668,O
investigated,668,O
.,668,O
METHODS,669,O
:,669,O
(,669,B-CHEMICAL
+/-,669,I-CHEMICAL
),669,I-CHEMICAL
-Modafinil,669,I-CHEMICAL
and,669,O
its,669,O
R-,669,O
(,669,O
-,669,O
),669,O
-,669,O
and,669,O
S-,669,O
(,669,O
+,669,O
),669,O
-enantiomers,669,O
were,669,O
synthesized,669,O
and,669,O
tested,669,O
for,669,O
inhibition,669,O
of,669,O
[,669,B-CHEMICAL
(,669,I-CHEMICAL
3,669,I-CHEMICAL
),669,I-CHEMICAL
H,669,I-CHEMICAL
],669,I-CHEMICAL
dopamine,669,I-CHEMICAL
(,669,O
DA,669,B-CHEMICAL
),669,O
uptake,669,O
and,669,O
[,669,B-CHEMICAL
(,669,I-CHEMICAL
3,669,I-CHEMICAL
),669,I-CHEMICAL
H,669,I-CHEMICAL
],669,I-CHEMICAL
WIN,669,I-CHEMICAL
35428,669,I-CHEMICAL
binding,669,O
in,669,O
human,669,B-GENE-Y
dopamine,669,I-GENE-Y
transporter,669,I-GENE-Y
(,669,O
DAT,669,B-GENE-Y
),669,O
wild-type,669,O
and,669,O
mutants,669,O
with,669,O
altered,669,O
conformational,669,O
equilibria,669,O
.,669,O
Data,670,O
were,670,O
compared,670,O
with,670,O
cocaine,670,B-CHEMICAL
and,670,O
the,670,O
atypical,670,O
DA,670,B-CHEMICAL
uptake,670,O
inhibitor,670,O
",",670,O
JHW,670,B-CHEMICAL
007,670,I-CHEMICAL
.,670,O
R-,671,B-CHEMICAL
and,671,I-CHEMICAL
S-modafinil,671,I-CHEMICAL
were,671,O
also,671,O
evaluated,671,O
in,671,O
microdialysis,671,O
studies,671,O
in,671,O
the,671,O
mouse,671,O
nucleus,671,O
accumbens,671,O
shell,671,O
and,671,O
in,671,O
a,671,O
cocaine,671,B-CHEMICAL
discrimination,671,O
procedure,671,O
.,671,O
RESULTS,672,O
:,672,O
(,672,B-CHEMICAL
+/-,672,I-CHEMICAL
),672,I-CHEMICAL
-,672,I-CHEMICAL
",",672,I-CHEMICAL
R-,672,I-CHEMICAL
",",672,I-CHEMICAL
and,672,I-CHEMICAL
S-modafinil,672,I-CHEMICAL
bind,672,O
to,672,O
the,672,O
DAT,672,B-GENE-Y
and,672,O
inhibit,672,O
DA,672,B-CHEMICAL
uptake,672,O
less,672,O
potently,672,O
than,672,O
cocaine,672,B-CHEMICAL
",",672,O
with,672,O
R-modafinil,672,B-CHEMICAL
having,672,O
approximately,672,O
threefold,672,O
higher,672,O
affinity,672,O
than,672,O
its,672,O
S-enantiomer,672,O
.,672,O
Molecular,673,O
docking,673,O
studies,673,O
revealed,673,O
subtle,673,O
differences,673,O
in,673,O
binding,673,O
modes,673,O
for,673,O
the,673,O
enantiomers,673,O
.,673,O
R-modafinil,674,B-CHEMICAL
was,674,O
significantly,674,O
less,674,O
potent,674,O
in,674,O
the,674,O
DAT,674,B-GENE-Y
Y156F,674,B-GENE-N
mutant,674,O
compared,674,O
with,674,O
wild-type,674,O
DAT,674,B-GENE-Y
",",674,O
whereas,674,O
S-modafinil,674,B-CHEMICAL
was,674,O
affected,674,O
less,674,O
.,674,O
Studies,675,O
with,675,O
the,675,O
Y335A,675,B-GENE-N
DAT,675,B-GENE-Y
mutant,675,O
showed,675,O
that,675,O
the,675,O
R-,675,O
and,675,O
S-enantiomers,675,O
tolerated,675,O
the,675,O
inward-facing,675,O
conformation,675,O
better,675,O
than,675,O
cocaine,675,B-CHEMICAL
",",675,O
which,675,O
was,675,O
further,675,O
supported,675,O
by,675,O
[,675,B-CHEMICAL
2-,675,I-CHEMICAL
(,675,I-CHEMICAL
trimethylammonium,675,I-CHEMICAL
),675,I-CHEMICAL
ethyl,675,I-CHEMICAL
],675,I-CHEMICAL
-methanethiosulfonate,675,I-CHEMICAL
reactivity,675,O
on,675,O
the,675,O
DAT,675,B-GENE-Y
E2C,675,B-GENE-N
I159C,675,B-GENE-N
.,675,O
Microdialysis,676,O
studies,676,O
demonstrated,676,O
that,676,O
both,676,O
R-,676,B-CHEMICAL
and,676,I-CHEMICAL
S-modafinil,676,I-CHEMICAL
produced,676,O
increases,676,O
in,676,O
extracellular,676,O
DA,676,B-CHEMICAL
concentrations,676,O
in,676,O
the,676,O
nucleus,676,O
accumbens,676,O
shell,676,O
less,676,O
efficaciously,676,O
than,676,O
cocaine,676,B-CHEMICAL
and,676,O
with,676,O
a,676,O
longer,676,O
duration,676,O
of,676,O
action,676,O
.,676,O
Both,677,O
enantiomers,677,O
fully,677,O
substituted,677,O
in,677,O
mice,677,O
trained,677,O
to,677,O
discriminate,677,O
cocaine,677,B-CHEMICAL
from,677,O
saline,677,O
.,677,O
CONCLUSIONS,678,O
:,678,O
R-modafinil,678,B-CHEMICAL
displays,678,O
an,678,O
in,678,O
vitro,678,O
profile,678,O
different,678,O
from,678,O
cocaine,678,B-CHEMICAL
.,678,O
Future,679,O
trials,679,O
with,679,O
R-modafinil,679,B-CHEMICAL
as,679,O
a,679,O
substitute,679,O
therapy,679,O
with,679,O
the,679,O
potential,679,O
benefit,679,O
of,679,O
cognitive,679,O
enhancement,679,O
for,679,O
psychostimulant,679,O
addiction,679,O
are,679,O
warranted,679,O
.,679,O
Apple,680,O
polyphenols,680,B-CHEMICAL
suppress,680,O
antigen,680,O
presentation,680,O
of,680,O
ovalbumin,680,B-GENE-N
by,680,O
THP-1-derived,680,O
dendritic,680,O
cells,680,O
.,680,O
Apple,681,O
polyphenol,681,B-CHEMICAL
extract,681,O
(,681,O
AP,681,O
),681,O
and,681,O
procyanidin,681,B-CHEMICAL
contained,681,O
in,681,O
AP,681,O
were,681,O
investigated,681,O
for,681,O
their,681,O
immunomodulatory,681,O
effects,681,O
using,681,O
THP-1-derived,681,O
human,681,O
dendritic,681,O
cells,681,O
(,681,O
TDDCs,681,O
),681,O
.,681,O
The,682,O
expression,682,O
levels,682,O
of,682,O
HLA-DR,682,B-GENE-N
(,682,O
MHC,682,B-GENE-N
class,682,I-GENE-N
II,682,I-GENE-N
),682,O
and,682,O
CD86,682,B-GENE-N
(,682,O
costimulatory,682,O
molecule,682,O
),682,O
were,682,O
measured,682,O
as,682,O
an,682,O
indicator,682,O
of,682,O
antigen,682,O
presentation,682,O
in,682,O
TDDCs,682,O
.,682,O
A,683,O
significant,683,O
decrease,683,O
in,683,O
HLA-DR,683,B-GENE-N
expression,683,O
was,683,O
observed,683,O
in,683,O
the,683,O
AP,683,O
and,683,O
fractionated,683,O
procyanidin-treated,683,B-CHEMICAL
cells,683,O
in,683,O
the,683,O
presence,683,O
of,683,O
ovalbumin,683,B-GENE-N
(,683,O
OVA,683,B-GENE-N
),683,O
",",683,O
but,683,O
no,683,O
effect,683,O
on,683,O
CD86,683,B-GENE-N
expression,683,O
was,683,O
observed,683,O
.,683,O
The,684,O
uptake,684,O
of,684,O
OVA,684,B-GENE-N
was,684,O
not,684,O
inhibited,684,O
by,684,O
AP,684,O
treatment,684,O
",",684,O
and,684,O
the,684,O
gene,684,O
expression,684,O
of,684,O
membrane-associated,684,O
RING-CH,684,B-GENE-N
ubiquitin,684,B-GENE-N
E3,684,I-GENE-N
ligase,684,I-GENE-N
",",684,O
MARCH1,684,B-GENE-N
",",684,O
was,684,O
up-regulated,684,O
by,684,O
AP,684,O
treatment,684,O
.,684,O
It,685,O
can,685,O
therefore,685,O
be,685,O
presumed,685,O
that,685,O
AP,685,O
suppresses,685,O
HLA-DR,685,B-GENE-N
expression,685,O
via,685,O
the,685,O
ubiquitin-proteasome,685,B-GENE-N
pathway,685,O
.,685,O
Furthermore,686,O
",",686,O
the,686,O
up-regulation,686,O
of,686,O
IL-12,686,B-GENE-N
and,686,O
TNF-α,686,B-GENE-N
was,686,O
found,686,O
in,686,O
the,686,O
procyanidin,686,B-CHEMICAL
trimers-treated,686,O
cells,686,O
in,686,O
the,686,O
presence,686,O
of,686,O
OVA,686,B-GENE-N
.,686,O
These,687,O
results,687,O
suggest,687,O
that,687,O
apple,687,O
polyphenols,687,B-CHEMICAL
would,687,O
be,687,O
an,687,O
effective,687,O
factor,687,O
for,687,O
the,687,O
development,687,O
of,687,O
immunomodulatory,687,O
agents,687,O
with,687,O
suppressive,687,O
effects,687,O
of,687,O
antigen,687,O
presentation,687,O
.,687,O
Alternariol,688,B-CHEMICAL
induces,688,O
abnormal,688,O
nuclear,688,O
morphology,688,O
and,688,O
cell,688,O
cycle,688,O
arrest,688,O
in,688,O
murine,688,O
RAW,688,O
264.7,688,O
macrophages,688,O
.,688,O
The,689,O
mycotoxin,689,O
alternariol,689,B-CHEMICAL
(,689,O
AOH,689,B-CHEMICAL
),689,O
",",689,O
a,689,O
frequent,689,O
contaminant,689,O
in,689,O
fruit,689,O
and,689,O
cereal,689,O
products,689,O
",",689,O
is,689,O
known,689,O
to,689,O
induce,689,O
DNA,689,O
damage,689,O
with,689,O
subsequent,689,O
cell,689,O
cycle,689,O
arrest,689,O
.,689,O
Here,690,O
we,690,O
elucidated,690,O
the,690,O
effects,690,O
of,690,O
AOH,690,B-CHEMICAL
on,690,O
stages,690,O
of,690,O
cell,690,O
cycle,690,O
progression,690,O
using,690,O
the,690,O
RAW,690,O
264.7,690,O
macrophage,690,O
model,690,O
.,690,O
AOH,691,B-CHEMICAL
resulted,691,O
in,691,O
an,691,O
accumulation,691,O
of,691,O
cells,691,O
in,691,O
the,691,O
G2/M-phase,691,O
(,691,O
4N,691,O
),691,O
.,691,O
Most,692,O
cells,692,O
exhibited,692,O
a,692,O
large,692,O
G2,692,O
nucleus,692,O
whereas,692,O
numbers,692,O
of,692,O
true,692,O
mitotic,692,O
cells,692,O
were,692,O
reduced,692,O
relative,692,O
to,692,O
control,692,O
.,692,O
Both,693,O
cyclin,693,B-GENE-Y
B1,693,I-GENE-Y
and,693,O
p-cdc2,693,B-GENE-Y
levels,693,O
increased,693,O
",",693,O
while,693,O
cyclin,693,B-GENE-Y
B1,693,I-GENE-Y
remained,693,O
in,693,O
the,693,O
cytoplasm,693,O
;,693,O
suggesting,693,O
arrest,693,O
in,693,O
the,693,O
G2/M,693,O
transition,693,O
point,693,O
.,693,O
Remarkably,694,O
",",694,O
after,694,O
exposure,694,O
to,694,O
AOH,694,B-CHEMICAL
for,694,O
24h,694,O
",",694,O
most,694,O
of,694,O
the,694,O
cells,694,O
exhibited,694,O
abnormally,694,O
shaped,694,O
nuclei,694,O
",",694,O
as,694,O
evidenced,694,O
by,694,O
partly,694,O
divided,694,O
nuclei,694,O
",",694,O
nuclear,694,O
blebs,694,O
",",694,O
polyploidy,694,O
and,694,O
micronuclei,694,O
(,694,O
MN,694,O
),694,O
.,694,O
AOH,695,B-CHEMICAL
treatment,695,O
also,695,O
induced,695,O
abnormal,695,O
Aurora,695,B-GENE-Y
B,695,I-GENE-Y
bridges,695,O
",",695,O
suggesting,695,O
that,695,O
cytokinesis,695,O
was,695,O
interfered,695,O
within,695,O
cells,695,O
undergoing,695,O
karyokinesis,695,O
.,695,O
A,696,O
minor,696,O
part,696,O
of,696,O
the,696,O
resultant,696,O
G1,696,O
tetraploid,696,O
(,696,O
4N,696,O
),696,O
cells,696,O
re-entered,696,O
the,696,O
S-phase,696,O
and,696,O
progressed,696,O
to,696,O
8N,696,O
cells,696,O
.,696,O
Long,697,O
acting,697,O
beta-agonists,697,O
versus,697,O
theophylline,697,B-CHEMICAL
for,697,O
maintenance,697,O
treatment,697,O
of,697,O
asthma,697,O
.,697,O
BACKGROUND,698,O
:,698,O
Theophylline,698,B-CHEMICAL
and,698,O
long,698,O
acting,698,O
beta2-agonists,698,O
are,698,O
bronchodilators,698,O
used,698,O
for,698,O
the,698,O
management,698,O
of,698,O
persistent,698,O
asthma,698,O
symptoms,698,O
",",698,O
especially,698,O
nocturnal,698,O
asthma,698,O
.,698,O
They,699,O
represent,699,O
different,699,O
classes,699,O
of,699,O
drug,699,O
with,699,O
differing,699,O
side-effect,699,O
profiles,699,O
.,699,O
OBJECTIVES,700,O
:,700,O
To,700,O
assess,700,O
the,700,O
comparative,700,O
efficacy,700,O
",",700,O
safety,700,O
and,700,O
side-effects,700,O
of,700,O
long-acting,700,O
beta-agonists,700,O
and,700,O
theophylline,700,B-CHEMICAL
in,700,O
the,700,O
maintenance,700,O
treatment,700,O
of,700,O
asthma,700,O
.,700,O
SEARCH,701,O
STRATEGY,701,O
:,701,O
Randomised,701,O
",",701,O
controlled,701,O
trials,701,O
(,701,O
RCTs,701,O
),701,O
were,701,O
identified,701,O
using,701,O
the,701,O
Cochrane,701,O
Airways,701,O
Group,701,O
register,701,O
.,701,O
The,702,O
register,702,O
was,702,O
searched,702,O
using,702,O
the,702,O
following,702,O
terms,702,O
:,702,O
asthma,702,O
and,702,O
theophylline,702,B-CHEMICAL
and,702,O
long,702,O
acting,702,O
beta-agonist,702,O
or,702,O
formoterol,702,B-CHEMICAL
or,702,O
foradile,702,B-CHEMICAL
or,702,O
eformoterol,702,B-CHEMICAL
or,702,O
salmeterol,702,B-CHEMICAL
or,702,O
bambuterol,702,B-CHEMICAL
or,702,O
bitolterol,702,B-CHEMICAL
.,702,O
Titles,703,O
and,703,O
abstracts,703,O
were,703,O
then,703,O
screened,703,O
to,703,O
identify,703,O
potentially,703,O
relevant,703,O
studies,703,O
.,703,O
The,704,O
bibliography,704,O
of,704,O
each,704,O
RCT,704,O
was,704,O
searched,704,O
for,704,O
additional,704,O
RCTs,704,O
.,704,O
Authors,705,O
of,705,O
identified,705,O
RCTs,705,O
were,705,O
contacted,705,O
for,705,O
other,705,O
relevant,705,O
published,705,O
and,705,O
unpublished,705,O
studies,705,O
.,705,O
SELECTION,706,O
CRITERIA,706,O
:,706,O
All,706,O
included,706,O
studies,706,O
were,706,O
RCTs,706,O
involving,706,O
adults,706,O
and,706,O
children,706,O
with,706,O
clinical,706,O
evidence,706,O
of,706,O
asthma,706,O
.,706,O
These,707,O
studies,707,O
must,707,O
have,707,O
compared,707,O
oral,707,O
sustained,707,O
release,707,O
and/or,707,O
dose,707,O
adjusted,707,O
theophylline,707,B-CHEMICAL
with,707,O
an,707,O
inhaled,707,O
long-acting,707,O
beta-agonist,707,O
.,707,O
DATA,708,O
COLLECTION,708,O
AND,708,O
ANALYSIS,708,O
:,708,O
Potentially,708,O
relevant,708,O
trials,708,O
",",708,O
identified,708,O
by,708,O
screening,708,O
titles,708,O
and/or,708,O
abstracts,708,O
",",708,O
were,708,O
obtained,708,O
.,708,O
Two,709,O
reviewers,709,O
independently,709,O
assessed,709,O
full,709,O
text,709,O
versions,709,O
of,709,O
these,709,O
trials,709,O
to,709,O
decided,709,O
whether,709,O
the,709,O
trial,709,O
should,709,O
be,709,O
included,709,O
in,709,O
the,709,O
review,709,O
",",709,O
and,709,O
assessed,709,O
its,709,O
methodological,709,O
quality,709,O
.,709,O
Where,710,O
there,710,O
was,710,O
disagreement,710,O
between,710,O
reviewers,710,O
",",710,O
this,710,O
was,710,O
resolved,710,O
by,710,O
consensus,710,O
",",710,O
or,710,O
reference,710,O
to,710,O
a,710,O
third,710,O
party,710,O
.,710,O
Data,711,O
were,711,O
extracted,711,O
by,711,O
two,711,O
independent,711,O
reviewers,711,O
.,711,O
Inter-rater,712,O
reliability,712,O
was,712,O
assessed,712,O
by,712,O
simple,712,O
agreement,712,O
.,712,O
Study,713,O
authors,713,O
were,713,O
contacted,713,O
to,713,O
clarify,713,O
randomisation,713,O
methods,713,O
",",713,O
provide,713,O
missing,713,O
data,713,O
",",713,O
verify,713,O
the,713,O
data,713,O
extracted,713,O
and,713,O
identify,713,O
unpublished,713,O
studies,713,O
.,713,O
Relevant,714,O
pharmaceutical,714,O
manufacturers,714,O
were,714,O
also,714,O
contacted,714,O
.,714,O
MAIN,715,O
RESULTS,715,O
:,715,O
Six,715,O
trials,715,O
met,715,O
the,715,O
inclusion,715,O
criteria,715,O
.,715,O
Five,716,O
used,716,O
salmeterol,716,B-CHEMICAL
and,716,O
one,716,O
",",716,O
biltoterol,716,B-CHEMICAL
.,716,O
They,717,O
were,717,O
of,717,O
varying,717,O
quality,717,O
.,717,O
There,718,O
was,718,O
a,718,O
trend,718,O
for,718,O
salmeterol,718,B-CHEMICAL
to,718,O
improve,718,O
FEV1,718,O
more,718,O
than,718,O
theophylline,718,B-CHEMICAL
in,718,O
three,718,O
studies,718,O
and,718,O
salmeterol,718,B-CHEMICAL
use,718,O
was,718,O
associated,718,O
with,718,O
more,718,O
symptom,718,O
free,718,O
nights,718,O
.,718,O
Bitolterol,719,B-CHEMICAL
",",719,O
used,719,O
in,719,O
only,719,O
one,719,O
study,719,O
",",719,O
was,719,O
reported,719,O
to,719,O
be,719,O
less,719,O
effective,719,O
than,719,O
theophylline,719,B-CHEMICAL
.,719,O
Subjects,720,O
taking,720,O
salmeterol,720,B-CHEMICAL
experienced,720,O
fewer,720,O
adverse,720,O
events,720,O
than,720,O
those,720,O
using,720,O
theophylline,720,B-CHEMICAL
(,720,O
Relative,720,O
Risk,720,O
0.38,720,O
;,720,O
95,720,O
%,720,O
Confidence,720,O
Intervals,720,O
0.25,720,O
",",720,O
0.57,720,O
),720,O
.,720,O
Significant,721,O
reductions,721,O
were,721,O
reported,721,O
for,721,O
central,721,O
nervous,721,O
system,721,O
adverse,721,O
events,721,O
(,721,O
Relative,721,O
Risk,721,O
0.51,721,O
;,721,O
95,721,O
%,721,O
Confidence,721,O
Intervals,721,O
0.30,721,O
",",721,O
0.88,721,O
),721,O
and,721,O
gastrointestinal,721,O
adverse,721,O
events,721,O
(,721,O
Relative,721,O
Risk,721,O
0.32,721,O
;,721,O
95,721,O
%,721,O
Confidence,721,O
Intervals,721,O
0.17,721,O
",",721,O
0.59,721,O
),721,O
.,721,O
REVIEWER,722,O
'S,722,O
CONCLUSIONS,722,O
:,722,O
Salmeterol,722,B-CHEMICAL
may,722,O
be,722,O
more,722,O
effective,722,O
than,722,O
theophylline,722,B-CHEMICAL
in,722,O
reducing,722,O
asthma,722,O
symptoms,722,O
including,722,O
night,722,O
waking,722,O
and,722,O
improving,722,O
lung,722,O
function,722,O
.,722,O
More,723,O
adverse,723,O
events,723,O
occurred,723,O
in,723,O
subjects,723,O
using,723,O
theophylline,723,B-CHEMICAL
when,723,O
compared,723,O
to,723,O
salmeterol,723,B-CHEMICAL
.,723,O
Prohormone,724,B-GENE-Y
convertase-1,724,I-GENE-Y
will,724,O
process,724,O
prorelaxin,724,B-GENE-N
",",724,O
a,724,O
member,724,O
of,724,O
the,724,O
insulin,724,B-GENE-Y
family,724,O
of,724,O
hormones,724,O
.,724,O
Relaxin,725,B-GENE-N
is,725,O
a,725,O
polypeptide,725,O
hormone,725,O
involved,725,O
in,725,O
remodeling,725,O
of,725,O
the,725,O
birth,725,O
canal,725,O
during,725,O
parturition,725,O
.,725,O
It,726,O
is,726,O
synthesized,726,O
as,726,O
a,726,O
preprohormone,726,O
precursor,726,O
",",726,O
which,726,O
undergoes,726,O
specific,726,O
processing,726,O
to,726,O
form,726,O
the,726,O
mature,726,O
two-chain,726,O
disulfide-linked,726,B-CHEMICAL
active,726,O
species,726,O
that,726,O
is,726,O
secreted,726,O
by,726,O
the,726,O
cell,726,O
.,726,O
A,727,O
major,727,O
part,727,O
of,727,O
this,727,O
processing,727,O
requires,727,O
endoproteolytic,727,O
cleavage,727,O
at,727,O
specific,727,O
pairs,727,O
of,727,O
basic,727,O
amino,727,B-CHEMICAL
acid,727,I-CHEMICAL
residues,727,O
",",727,O
an,727,O
event,727,O
necessary,727,O
for,727,O
the,727,O
maturation,727,O
of,727,O
a,727,O
variety,727,O
of,727,O
important,727,O
biologically,727,O
active,727,O
proteins,727,O
",",727,O
such,727,O
as,727,O
insulin,727,B-GENE-Y
and,727,O
nerve,727,B-GENE-Y
growth,727,I-GENE-Y
factor,727,I-GENE-Y
.,727,O
Human,728,B-GENE-Y
type,728,I-GENE-Y
2,728,I-GENE-Y
preprorelaxin,728,I-GENE-Y
was,728,O
coexpressed,728,O
in,728,O
human,728,O
kidney,728,O
293,728,O
cells,728,O
with,728,O
the,728,O
candidate,728,O
prohormone,728,B-GENE-N
convertase-processing,728,I-GENE-N
enzymes,728,I-GENE-N
mPC1,728,B-GENE-Y
or,728,O
mPC2,728,B-GENE-Y
",",728,O
both,728,O
cloned,728,O
from,728,O
the,728,O
mouse,728,O
pituitary,728,O
tumor,728,O
AtT-20,728,O
cell,728,O
line,728,O
",",728,O
or,728,O
with,728,O
the,728,O
yeast,728,B-GENE-Y
kex2,728,I-GENE-Y
alpha-mating,728,B-GENE-Y
factor-converting,728,I-GENE-Y
enzyme,728,I-GENE-Y
from,728,O
Saccharomyces,728,O
cerevisiae,728,O
.,728,O
Prorelaxin,729,B-GENE-N
expressed,729,O
alone,729,O
in,729,O
293,729,O
cells,729,O
was,729,O
secreted,729,O
into,729,O
the,729,O
culture,729,O
medium,729,O
unprocessed,729,O
.,729,O
Transient,730,O
coexpression,730,O
with,730,O
mPC1,730,B-GENE-Y
or,730,O
kex2,730,B-GENE-Y
",",730,O
but,730,O
not,730,O
with,730,O
mPC2,730,B-GENE-Y
",",730,O
resulted,730,O
in,730,O
the,730,O
secretion,730,O
of,730,O
a,730,O
low,730,O
mol,730,O
wt,730,O
species,730,O
with,730,O
an,730,O
electrophoretic,730,O
mobility,730,O
very,730,O
similar,730,O
",",730,O
if,730,O
not,730,O
identical,730,O
",",730,O
to,730,O
that,730,O
of,730,O
authentic,730,O
mature,730,O
relaxin,730,B-GENE-N
purified,730,O
from,730,O
human,730,O
placenta,730,O
.,730,O
This,731,O
species,731,O
was,731,O
precipitable,731,O
by,731,O
monoclonal,731,O
antibodies,731,O
specific,731,O
for,731,O
relaxin,731,B-GENE-N
and,731,O
had,731,O
a,731,O
retention,731,O
time,731,O
on,731,O
reverse,731,O
phase,731,O
HPLC,731,O
comparable,731,O
to,731,O
that,731,O
of,731,O
relaxin,731,B-GENE-N
.,731,O
Its,732,O
analysis,732,O
by,732,O
both,732,O
electrospray,732,O
and,732,O
fast,732,O
atom,732,O
bombardment,732,O
mass,732,O
spectrometry,732,O
generated,732,O
mass,732,O
data,732,O
that,732,O
were,732,O
consistent,732,O
only,732,O
with,732,O
mature,732,O
relaxin,732,B-GENE-N
.,732,O
The,733,O
basic,733,O
residues,733,O
required,733,O
for,733,O
mPC1-dependent,733,B-GENE-Y
cleavage,733,O
of,733,O
prorelaxin,733,B-GENE-N
are,733,O
defined,733,O
by,733,O
site-directed,733,O
mutagenesis,733,O
.,733,O
Binding,734,O
between,734,O
heparin,734,O
and,734,O
the,734,O
integrin,734,B-GENE-N
VLA-4,734,B-GENE-Y
.,734,O
Heparin,735,O
possesses,735,O
antimetastatic,735,O
effects,735,O
that,735,O
were,735,O
related,735,O
to,735,O
various,735,O
molecular,735,O
mechanisms,735,O
beyond,735,O
anticoagulant,735,O
activities,735,O
.,735,O
The,736,O
ability,736,O
of,736,O
heparin,736,O
to,736,O
interfere,736,O
with,736,O
the,736,O
function,736,O
of,736,O
adhesion,736,B-GENE-N
receptors,736,I-GENE-N
in,736,O
the,736,O
metastatic,736,O
course,736,O
appears,736,O
as,736,O
a,736,O
promising,736,O
therapeutic,736,O
approach,736,O
.,736,O
This,737,O
refers,737,O
to,737,O
numerous,737,O
findings,737,O
that,737,O
heparin,737,O
attenuates,737,O
metastasis,737,O
in,737,O
a,737,O
selectin-dependent,737,O
manner,737,O
.,737,O
We,738,O
recently,738,O
demonstrated,738,O
that,738,O
heparin,738,O
interferes,738,O
with,738,O
the,738,O
integrin,738,B-GENE-N
VLA-4,738,B-GENE-Y
on,738,O
murine,738,O
melanoma,738,O
cells,738,O
binding,738,O
to,738,O
VCAM-1,738,B-GENE-Y
.,738,O
To,739,O
confirm,739,O
this,739,O
activity,739,O
and,739,O
to,739,O
obtain,739,O
further,739,O
insight,739,O
into,739,O
molecular,739,O
recognition,739,O
of,739,O
heparin,739,O
by,739,O
VLA-4,739,B-GENE-Y
",",739,O
we,739,O
investigated,739,O
the,739,O
inhibition,739,O
of,739,O
VLA-4,739,B-GENE-Y
mediated,739,O
binding,739,O
of,739,O
human,739,O
melanoma,739,O
MV3,739,O
cells,739,O
to,739,O
immobilised,739,O
VCAM-1,739,B-GENE-Y
by,739,O
different,739,O
heparins,739,O
.,739,O
The,740,O
size,740,O
of,740,O
heparin,740,O
has,740,O
an,740,O
important,740,O
impact,740,O
on,740,O
inhibition,740,O
.,740,O
Unfractionated,741,O
heparin,741,O
(,741,O
UFH,741,O
),741,O
and,741,O
tinzaparin,741,B-CHEMICAL
",",741,O
a,741,O
low-molecular-weight,741,O
heparin,741,O
(,741,O
LMWH,741,O
),741,O
representing,741,O
a,741,O
mean,741,O
of,741,O
about,741,O
18-20,741,O
monomers,741,O
",",741,O
displayed,741,O
high,741,O
inhibitory,741,O
activity,741,O
.,741,O
Fractionating,742,O
tinzaparin,742,B-CHEMICAL
to,742,O
14-18,742,O
monomers,742,O
reduced,742,O
inhibition,742,O
slightly,742,O
",",742,O
while,742,O
the,742,O
pentasaccharide,742,B-CHEMICAL
fondaparinux,742,I-CHEMICAL
was,742,O
without,742,O
effects,742,O
.,742,O
To,743,O
confirm,743,O
molecular,743,O
recognition,743,O
of,743,O
tinzaparin,743,B-CHEMICAL
by,743,O
VLA-4,743,B-GENE-Y
",",743,O
a,743,O
surface,743,O
acoustic,743,O
wave-biosensor,743,O
was,743,O
applied,743,O
.,743,O
A,744,O
VLA-4,744,B-GENE-Y
containing,744,O
membrane,744,O
preparation,744,O
of,744,O
MV3,744,O
cells,744,O
was,744,O
immobilised,744,O
at,744,O
the,744,O
sensors,744,O
to,744,O
allow,744,O
for,744,O
detection,744,O
of,744,O
kinetic,744,O
binding,744,O
constants,744,O
of,744,O
tinzaparin,744,B-CHEMICAL
compared,744,O
to,744,O
VCAM-1,744,B-GENE-Y
.,744,O
Tinzaparin,745,B-CHEMICAL
binds,745,O
to,745,O
VLA-4,745,B-GENE-Y
with,745,O
affinity,745,O
in,745,O
the,745,O
low,745,O
micromolar,745,O
range,745,O
(,745,O
4.61,745,O
x,745,O
10,745,O
(,745,O
-6,745,O
),745,O
M,745,O
),745,O
",",745,O
which,745,O
clearly,745,O
indicates,745,O
specific,745,O
molecular,745,O
recognition,745,O
.,745,O
Furthermore,746,O
",",746,O
tinzaparin,746,B-CHEMICAL
displays,746,O
a,746,O
nearly,746,O
identical,746,O
k,746,O
(,746,O
off,746,O
),746,O
compared,746,O
to,746,O
VCAM-1,746,B-GENE-Y
(,746,O
5.13,746,O
x,746,O
10,746,O
(,746,O
-3,746,O
),746,O
s,746,O
(,746,O
-1,746,O
),746,O
versus,746,O
3.44,746,O
x,746,O
10,746,O
(,746,O
-3,746,O
),746,O
s,746,O
(,746,O
-1,746,O
),746,O
),746,O
which,746,O
is,746,O
evident,746,O
for,746,O
interference,746,O
with,746,O
the,746,O
ligand,746,O
binding,746,O
.,746,O
The,747,O
data,747,O
provide,747,O
evidence,747,O
for,747,O
a,747,O
direct,747,O
confirmation,747,O
of,747,O
heparin,747,O
binding,747,O
to,747,O
VLA-4,747,B-GENE-Y
and,747,O
thus,747,O
",",747,O
contribute,747,O
to,747,O
understand,747,O
the,747,O
antimetastatic,747,O
activity,747,O
of,747,O
heparin,747,O
.,747,O
Extracellular,748,B-GENE-N
loop,748,I-GENE-N
3,748,I-GENE-N
(,748,O
EL3,748,B-GENE-N
),748,O
and,748,O
EL3-proximal,748,B-GENE-N
transmembrane,748,I-GENE-N
helix,748,I-GENE-N
7,748,I-GENE-N
of,748,O
the,748,O
mammalian,748,B-GENE-N
type,748,I-GENE-N
I,748,I-GENE-N
and,748,I-GENE-N
type,748,I-GENE-N
II,748,I-GENE-N
gonadotropin-releasing,748,I-GENE-N
hormone,748,I-GENE-N
(,748,I-GENE-N
GnRH,748,I-GENE-N
),748,I-GENE-N
receptors,748,I-GENE-N
determine,748,O
differential,748,O
ligand,748,O
selectivity,748,O
to,748,O
GnRH-I,748,B-GENE-Y
and,748,O
GnRH-II,748,B-GENE-Y
.,748,O
Mammalian,749,B-GENE-N
type,749,I-GENE-N
I,749,I-GENE-N
and,749,I-GENE-N
II,749,I-GENE-N
gonadotropin-releasing,749,I-GENE-N
hormone,749,I-GENE-N
(,749,I-GENE-N
GnRH,749,I-GENE-N
),749,I-GENE-N
receptors,749,I-GENE-N
(,749,O
GnRHRs,749,B-GENE-N
),749,O
show,749,O
differential,749,O
ligand,749,O
preference,749,O
for,749,O
GnRH-I,749,B-GENE-Y
and,749,O
GnRH-II,749,B-GENE-Y
",",749,O
respectively,749,O
.,749,O
Using,750,O
a,750,O
variety,750,O
of,750,O
chimeric,750,O
receptors,750,O
based,750,O
on,750,O
green,750,B-GENE-Y
monkey,750,I-GENE-Y
GnRHR-2,750,I-GENE-Y
(,750,O
gmGnRHR-2,750,B-GENE-Y
),750,O
",",750,O
a,750,O
representative,750,O
type,750,B-GENE-Y
II,750,I-GENE-Y
GnRHR,750,I-GENE-Y
",",750,O
and,750,O
rat,750,B-GENE-Y
GnRHR,750,I-GENE-Y
",",750,O
a,750,O
representative,750,O
type,750,B-GENE-Y
I,750,I-GENE-Y
GnRHR,750,I-GENE-Y
",",750,O
this,750,O
study,750,O
elucidated,750,O
specific,750,O
domains,750,O
responsible,750,O
for,750,O
this,750,O
ligand,750,O
selectivity,750,O
.,750,O
A,751,O
chimeric,751,O
gmGnRHR-2,751,B-GENE-Y
with,751,O
the,751,O
extracellular,751,B-GENE-N
loop,751,I-GENE-N
3,751,I-GENE-N
(,751,O
EL3,751,B-GENE-N
),751,O
and,751,O
EL3-proximal,751,B-GENE-N
transmembrane,751,I-GENE-N
helix,751,I-GENE-N
7,751,I-GENE-N
(,751,O
TMH7,751,B-GENE-N
),751,O
of,751,O
rat,751,B-GENE-Y
GnRHR,751,I-GENE-Y
showed,751,O
a,751,O
great,751,O
increase,751,O
in,751,O
ligand,751,O
sensitivity,751,O
to,751,O
GnRH-I,751,B-GENE-Y
but,751,O
not,751,O
to,751,O
GnRH-II,751,B-GENE-Y
.,751,O
Point-mutation,752,O
studies,752,O
indicate,752,O
that,752,O
four,752,O
amino,752,B-CHEMICAL
acids,752,I-CHEMICAL
",",752,O
Leu/Phe,752,B-CHEMICAL
(,752,O
7.38,752,O
),752,O
",",752,O
Leu/Phe,752,B-CHEMICAL
(,752,O
7.43,752,O
),752,O
",",752,O
Ala/Pro,752,B-CHEMICAL
(,752,O
7.46,752,O
),752,O
",",752,O
and,752,O
Pro/Cys,752,B-CHEMICAL
(,752,O
7.47,752,O
),752,O
in,752,O
TMH7,752,B-GENE-N
are,752,O
critical,752,O
for,752,O
ligand,752,O
selectivity,752,O
as,752,O
well,752,O
as,752,O
receptor,752,O
conformation,752,O
.,752,O
Furthermore,753,O
",",753,O
a,753,O
combinatory,753,O
mutation,753,O
(,753,O
Pro,753,B-CHEMICAL
(,753,O
7.31,753,O
),753,O
-Pro,753,O
(,753,O
7.32,753,O
),753,O
-Ser,753,O
(,753,O
7.33,753,O
),753,O
motif,753,O
to,753,O
Ser-Glu-Pro,753,B-CHEMICAL
in,753,O
EL3,753,B-GENE-N
and,753,O
Leu,753,B-CHEMICAL
(,753,O
7.38,753,O
),753,O
",",753,O
Leu,753,B-CHEMICAL
(,753,O
7.43,753,O
),753,O
",",753,O
Ala,753,B-CHEMICAL
(,753,O
7.46,753,O
),753,O
",",753,O
and,753,O
Pro,753,B-CHEMICAL
(,753,O
7.47,753,O
),753,O
to,753,O
those,753,O
of,753,O
rat,753,B-GENE-Y
GnRHR,753,I-GENE-Y
),753,O
in,753,O
gmGnRH-2,753,B-GENE-Y
exhibited,753,O
an,753,O
approximately,753,O
500-fold,753,O
increased,753,O
sensitivity,753,O
to,753,O
GnRH-I,753,B-GENE-Y
",",753,O
indicating,753,O
that,753,O
these,753,O
residues,753,O
are,753,O
critical,753,O
for,753,O
discriminating,753,O
GnRH-II,753,B-GENE-Y
from,753,O
GnRH-I,753,B-GENE-Y
.,753,O
[,754,O
Trp,754,O
(,754,O
7,754,O
),754,O
],754,O
GnRH-I,754,B-GENE-Y
and,754,O
[,754,O
Trp,754,O
(,754,O
8,754,O
),754,O
],754,O
GnRH-I,754,B-GENE-Y
but,754,O
not,754,O
[,754,O
His,754,O
(,754,O
5,754,O
),754,O
],754,O
GnRH-I,754,B-GENE-Y
exhibit,754,O
a,754,O
higher,754,O
potency,754,O
in,754,O
activating,754,O
wild-type,754,O
gmGnRHR-2,754,B-GENE-Y
than,754,O
native,754,O
GnRH-I,754,B-GENE-Y
",",754,O
indicating,754,O
that,754,O
amino,754,B-CHEMICAL
acids,754,I-CHEMICAL
at,754,O
positions,754,O
7,754,O
and,754,O
8,754,O
of,754,O
GnRHs,754,B-GENE-N
are,754,O
more,754,O
important,754,O
than,754,O
position,754,O
5,754,O
for,754,O
differential,754,O
recognition,754,O
by,754,O
type,754,B-GENE-N
I,754,I-GENE-N
and,754,I-GENE-N
type,754,I-GENE-N
II,754,I-GENE-N
GnRHRs,754,I-GENE-N
.,754,O
As,755,O
a,755,O
whole,755,O
",",755,O
these,755,O
data,755,O
suggest,755,O
a,755,O
molecular,755,O
coevolution,755,O
of,755,O
ligands,755,O
and,755,O
their,755,O
receptors,755,O
and,755,O
facilitate,755,O
the,755,O
understanding,755,O
of,755,O
the,755,O
molecular,755,O
interaction,755,O
between,755,O
GnRHs,755,B-GENE-N
and,755,O
their,755,O
cognate,755,O
receptors,755,O
.,755,O
Success,756,O
of,756,O
pyridostigmine,756,B-CHEMICAL
",",756,O
physostigmine,756,B-CHEMICAL
",",756,O
eptastigmine,756,B-CHEMICAL
and,756,O
phosphotriesterase,756,B-GENE-N
treatments,756,O
in,756,O
acute,756,O
sarin,756,B-CHEMICAL
intoxication,756,O
.,756,O
The,757,O
acute,757,O
toxicity,757,O
of,757,O
organophosphorus,757,B-CHEMICAL
(,757,O
OP,757,O
),757,O
compounds,757,O
in,757,O
mammals,757,O
is,757,O
due,757,O
to,757,O
their,757,O
irreversible,757,O
inhibition,757,O
of,757,O
acetylcholinesterase,757,B-GENE-N
(,757,O
AChE,757,B-GENE-N
),757,O
in,757,O
the,757,O
nervous,757,O
system,757,O
",",757,O
which,757,O
leads,757,O
to,757,O
increased,757,O
synaptic,757,O
acetylcholine,757,B-CHEMICAL
levels,757,O
.,757,O
The,758,O
protective,758,O
actions,758,O
of,758,O
intravenously,758,O
(,758,O
i.v,758,O
.,758,O
),758,O
administered,759,O
pyridostigmine,759,B-CHEMICAL
",",759,O
physostigmine,759,B-CHEMICAL
",",759,O
eptastigmine,759,B-CHEMICAL
",",759,O
and,759,O
an,759,O
organophosphate,759,B-GENE-N
hydrolase,759,I-GENE-N
",",759,O
phosphotriesterase,759,B-GENE-N
",",759,O
in,759,O
acute,759,O
sarin,759,B-CHEMICAL
intoxication,759,O
were,759,O
studied,759,O
in,759,O
mice,759,O
.,759,O
The,760,O
acute,760,O
intragastric,760,O
(,760,O
i.g,760,O
.,760,O
),760,O
toxicity,761,O
(,761,O
LD50,761,O
),761,O
of,761,O
sarin,761,B-CHEMICAL
with,761,O
and,761,O
without,761,O
the,761,O
pretreatments,761,O
was,761,O
tested,761,O
by,761,O
the,761,O
up-and-down,761,O
method,761,O
.,761,O
The,762,O
mice,762,O
received,762,O
pyridostigmine,762,B-CHEMICAL
(,762,O
0.06,762,O
mg/kg,762,O
body,762,O
weight,762,O
),762,O
",",762,O
physostigmine,762,B-CHEMICAL
(,762,O
0.09,762,O
mg/kg,762,O
body,762,O
weight,762,O
),762,O
",",762,O
the,762,O
physostigmine,762,B-CHEMICAL
derivative,762,O
eptastigmine,762,B-CHEMICAL
(,762,O
0.90,762,O
mg/kg,762,O
body,762,O
weight,762,O
),762,O
or,762,O
phosphotriesterase,762,B-GENE-N
(,762,O
104,762,O
U/g,762,O
",",762,O
10.7,762,O
microg/g,762,O
body,762,O
weight,762,O
),762,O
10,762,O
min,762,O
prior,762,O
to,762,O
the,762,O
i.g,762,O
.,762,O
administration,763,O
of,763,O
sarin,763,B-CHEMICAL
.,763,O
Physostigmine,764,B-CHEMICAL
was,764,O
also,764,O
administered,764,O
with,764,O
phosphotriesterase,764,B-GENE-N
.,764,O
Phosphotriesterase,765,B-GENE-N
was,765,O
the,765,O
most,765,O
effective,765,O
antidote,765,O
in,765,O
sarin,765,B-CHEMICAL
intoxication,765,O
.,765,O
The,766,O
LD50,766,O
value,766,O
for,766,O
sarin,766,B-CHEMICAL
increased,766,O
3.4-fold,766,O
in,766,O
mice,766,O
receiving,766,O
phosphotriesterase,766,B-GENE-N
.,766,O
Physostigmine,767,B-CHEMICAL
was,767,O
the,767,O
most,767,O
effective,767,O
carbamate,767,B-CHEMICAL
in,767,O
sarin,767,B-CHEMICAL
exposure,767,O
.,767,O
The,768,O
protective,768,O
ratios,768,O
of,768,O
physostigmine,768,B-CHEMICAL
and,768,O
pyridostigmine,768,B-CHEMICAL
were,768,O
1.5-,768,O
and,768,O
1.2-1.3-fold,768,O
",",768,O
respectively,768,O
.,768,O
Eptastigmine,769,B-CHEMICAL
did,769,O
not,769,O
give,769,O
any,769,O
protection,769,O
against,769,O
sarin,769,B-CHEMICAL
toxicity,769,O
.,769,O
Both,770,O
the,770,O
phosphotriesterase,770,B-GENE-N
and,770,O
physostigmine,770,B-CHEMICAL
treatments,770,O
protected,770,O
the,770,O
brain,770,O
AChE,770,B-GENE-Y
activities,770,O
measured,770,O
24,770,O
h,770,O
after,770,O
sarin,770,B-CHEMICAL
exposure,770,O
.,770,O
In,771,O
phosphotriesterase,771,B-GENE-N
and,771,O
physostigmine-treated,771,B-CHEMICAL
mice,771,O
",",771,O
a,771,O
4-,771,O
and,771,O
2-fold,771,O
higher,771,O
sarin,771,B-CHEMICAL
dose,771,O
",",771,O
respectively,771,O
",",771,O
was,771,O
needed,771,O
to,771,O
cause,771,O
a,771,O
50,771,O
%,771,O
inhibition,771,O
of,771,O
brain,771,O
AChE,771,B-GENE-Y
activity,771,O
.,771,O
Moreover,772,O
",",772,O
the,772,O
combination,772,O
of,772,O
phosphotriesterase-physostigmine,772,B-GENE-N
increased,772,O
the,772,O
LD50,772,O
value,772,O
for,772,O
sarin,772,B-CHEMICAL
4.3-fold,772,O
.,772,O
The,773,O
animals,773,O
pretreated,773,O
with,773,O
phosphotriesterase-ephysostigmine,773,B-GENE-N
tolerated,773,O
four,773,O
times,773,O
the,773,O
lethal,773,O
dose,773,O
in,773,O
control,773,O
animals,773,O
",",773,O
furthermore,773,O
their,773,O
survival,773,O
time,773,O
was,773,O
2-3,773,O
h,773,O
in,773,O
comparison,773,O
to,773,O
20,773,O
min,773,O
in,773,O
controls,773,O
.,773,O
In,774,O
conclusion,774,O
",",774,O
phosphotriesterase,774,B-GENE-N
and,774,O
physostigmine,774,B-CHEMICAL
were,774,O
the,774,O
most,774,O
effective,774,O
treatments,774,O
against,774,O
sarin,774,B-CHEMICAL
intoxication,774,O
.,774,O
However,775,O
",",775,O
eptastigmine,775,B-CHEMICAL
did,775,O
not,775,O
provide,775,O
any,775,O
protection,775,O
against,775,O
sarin,775,B-CHEMICAL
toxicity,775,O
.,775,O
Phase,776,O
1,776,O
and,776,O
phase,776,O
2,776,O
drug,776,O
metabolism,776,O
and,776,O
bile,776,B-CHEMICAL
acid,776,I-CHEMICAL
production,776,O
of,776,O
HepaRG,776,O
cells,776,O
in,776,O
a,776,O
bioartificial,776,O
liver,776,O
in,776,O
absence,776,O
of,776,O
dimethyl,776,B-CHEMICAL
sulfoxide,776,I-CHEMICAL
.,776,O
The,777,O
human,777,O
liver,777,O
cell,777,O
line,777,O
HepaRG,777,O
has,777,O
been,777,O
recognized,777,O
as,777,O
a,777,O
promising,777,O
source,777,O
for,777,O
in,777,O
vitro,777,O
testing,777,O
of,777,O
metabolism,777,O
and,777,O
toxicity,777,O
of,777,O
compounds,777,O
.,777,O
However,778,O
",",778,O
currently,778,O
the,778,O
hepatic,778,O
differentiation,778,O
of,778,O
these,778,O
cells,778,O
relies,778,O
on,778,O
exposure,778,O
to,778,O
dimethylsulfoxide,778,B-CHEMICAL
(,778,O
DMSO,778,B-CHEMICAL
),778,O
",",778,O
which,778,O
",",778,O
as,778,O
a,778,O
side,778,O
effect,778,O
",",778,O
has,778,O
a,778,O
cytotoxic,778,O
effect,778,O
and,778,O
represses,778,O
an,778,O
all-round,778,O
hepatic,778,O
functionality,778,O
.,778,O
The,779,O
AMC-bioartificial,779,O
liver,779,O
(,779,O
AMC-BAL,779,O
),779,O
is,779,O
a,779,O
three-dimensional,779,O
bioreactor,779,O
that,779,O
has,779,O
previously,779,O
been,779,O
shown,779,O
to,779,O
upregulate,779,O
various,779,O
liver,779,O
functions,779,O
of,779,O
cultured,779,O
cells,779,O
.,779,O
We,780,O
therefore,780,O
cultured,780,O
HepaRG,780,O
cells,780,O
in,780,O
the,780,O
AMC-BAL,780,O
without,780,O
DMSO,780,B-CHEMICAL
and,780,O
characterized,780,O
the,780,O
drug,780,O
metabolism,780,O
.,780,O
Within,781,O
14,781,O
days,781,O
of,781,O
culture,781,O
",",781,O
the,781,O
HepaRG-AMC-BALs,781,O
contained,781,O
highly,781,O
polarized,781,O
viable,781,O
liver-like,781,O
tissue,781,O
with,781,O
heterogeneous,781,O
expression,781,O
of,781,O
CYP3A4,781,B-GENE-Y
.,781,O
We,782,O
found,782,O
a,782,O
substantial,782,O
metabolism,782,O
of,782,O
the,782,O
tested,782,O
substrates,782,O
",",782,O
ranging,782,O
from,782,O
26,782,O
%,782,O
(,782,O
UDP-glucuronosyltransferase,782,B-GENE-Y
1A1,782,I-GENE-Y
),782,O
",",782,O
47,782,O
%,782,O
(,782,O
CYP3A4,782,B-GENE-Y
),782,O
",",782,O
to,782,O
240,782,O
%,782,O
(,782,O
CYP2C9,782,B-GENE-Y
),782,O
of,782,O
primary,782,O
human,782,O
hepatocytes,782,O
.,782,O
The,783,O
CYP3A4,783,B-GENE-Y
activity,783,O
could,783,O
be,783,O
induced,783,O
2-fold,783,O
by,783,O
rifampicin,783,B-CHEMICAL
",",783,O
whereas,783,O
CYP2C9,783,B-GENE-Y
activity,783,O
remained,783,O
equally,783,O
high,783,O
.,783,O
The,784,O
HepaRG-AMC-BAL,784,O
secreted,784,O
bile,784,B-CHEMICAL
acids,784,I-CHEMICAL
at,784,O
43,784,O
%,784,O
the,784,O
rate,784,O
of,784,O
primary,784,O
human,784,O
hepatocytes,784,O
and,784,O
demonstrated,784,O
hydroxylation,784,O
",",784,O
conjugation,784,O
",",784,O
and,784,O
transport,784,O
of,784,O
bile,784,B-CHEMICAL
salts,784,I-CHEMICAL
.,784,O
Concluding,785,O
",",785,O
culturing,785,O
HepaRG,785,O
cells,785,O
in,785,O
the,785,O
AMC-BAL,785,O
yields,785,O
substantial,785,O
phase,785,O
1,785,O
and,785,O
phase,785,O
2,785,O
drug,785,O
metabolism,785,O
",",785,O
while,785,O
maintaining,785,O
high,785,O
viability,785,O
",",785,O
rendering,785,O
DMSO,785,B-CHEMICAL
addition,785,O
superfluous,785,O
for,785,O
the,785,O
promotion,785,O
of,785,O
drug,785,O
metabolism,785,O
.,785,O
Therefore,786,O
",",786,O
AMC-BAL,786,O
culturing,786,O
makes,786,O
the,786,O
HepaRG,786,O
cells,786,O
more,786,O
suitable,786,O
for,786,O
testing,786,O
metabolism,786,O
and,786,O
toxicity,786,O
of,786,O
drugs,786,O
.,786,O
Dose-dependent,787,O
effects,787,O
of,787,O
vitamin,787,B-CHEMICAL
D,787,I-CHEMICAL
on,787,O
transdifferentiation,787,O
of,787,O
skeletal,787,O
muscle,787,O
cells,787,O
to,787,O
adipose,787,O
cells,787,O
.,787,O
Fat,788,O
infiltration,788,O
within,788,O
muscle,788,O
is,788,O
one,788,O
of,788,O
a,788,O
number,788,O
of,788,O
features,788,O
of,788,O
vitamin,788,B-CHEMICAL
D,788,I-CHEMICAL
deficiency,788,O
",",788,O
which,788,O
leads,788,O
to,788,O
a,788,O
decline,788,O
in,788,O
muscle,788,O
functionality,788,O
.,788,O
The,789,O
origin,789,O
of,789,O
this,789,O
fat,789,O
is,789,O
unclear,789,O
",",789,O
but,789,O
one,789,O
possibility,789,O
is,789,O
that,789,O
it,789,O
forms,789,O
from,789,O
myogenic,789,O
precursor,789,O
cells,789,O
present,789,O
in,789,O
the,789,O
muscle,789,O
",",789,O
which,789,O
transdifferentiate,789,O
into,789,O
mature,789,O
adipocytes,789,O
.,789,O
The,790,O
current,790,O
study,790,O
examined,790,O
the,790,O
effect,790,O
of,790,O
the,790,O
active,790,O
form,790,O
of,790,O
vitamin,790,B-CHEMICAL
D₃,790,I-CHEMICAL
",",790,O
"1,25-dihydroxyvitamin",790,B-CHEMICAL
D₃,790,I-CHEMICAL
(,790,O
"1,25",790,B-CHEMICAL
(,790,I-CHEMICAL
OH,790,I-CHEMICAL
),790,I-CHEMICAL
₂D₃,790,I-CHEMICAL
),790,O
",",790,O
on,790,O
the,790,O
capacity,790,O
of,790,O
the,790,O
C2C12,790,O
muscle,790,O
cell,790,O
line,790,O
to,790,O
differentiate,790,O
towards,790,O
the,790,O
myogenic,790,O
and,790,O
adipogenic,790,O
lineages,790,O
.,790,O
Cells,791,O
were,791,O
cultured,791,O
in,791,O
myogenic,791,O
or,791,O
adipogenic,791,O
differentiation,791,O
media,791,O
containing,791,O
increasing,791,O
concentrations,791,O
(,791,O
0,791,O
",",791,O
10⁻¹³,791,O
",",791,O
10⁻¹¹,791,O
",",791,O
10⁻⁹,791,O
",",791,O
10⁻⁷,791,O
or,791,O
10⁻⁵,791,O
M,791,O
),791,O
of,791,O
"1,25",791,B-CHEMICAL
(,791,I-CHEMICAL
OH,791,I-CHEMICAL
),791,I-CHEMICAL
₂D₃,791,I-CHEMICAL
for,791,O
up,791,O
to,791,O
6,791,O
days,791,O
and,791,O
markers,791,O
of,791,O
muscle,791,O
and,791,O
fat,791,O
development,791,O
measured,791,O
.,791,O
Mature,792,O
myofibres,792,O
were,792,O
formed,792,O
in,792,O
both,792,O
adipogenic,792,O
and,792,O
myogenic,792,O
media,792,O
",",792,O
but,792,O
fat,792,O
droplets,792,O
were,792,O
only,792,O
observed,792,O
in,792,O
adipogenic,792,O
media,792,O
.,792,O
Relative,793,O
to,793,O
controls,793,O
",",793,O
low,793,O
physiological,793,O
concentrations,793,O
(,793,O
10⁻¹³,793,O
and,793,O
10⁻¹¹,793,O
M,793,O
),793,O
of,793,O
"1,25",793,B-CHEMICAL
(,793,I-CHEMICAL
OH,793,I-CHEMICAL
),793,I-CHEMICAL
₂D3,793,I-CHEMICAL
increased,793,O
fat,793,O
droplet,793,O
accumulation,793,O
",",793,O
whereas,793,O
high,793,O
physiological,793,O
(,793,O
10⁻⁹,793,O
M,793,O
),793,O
and,793,O
supraphysiological,793,O
concentrations,793,O
(,793,O
≥10⁻⁷,793,O
M,793,O
),793,O
inhibited,793,O
fat,793,O
accumulation,793,O
.,793,O
This,794,O
increased,794,O
accumulation,794,O
of,794,O
fat,794,O
with,794,O
low,794,O
physiological,794,O
concentrations,794,O
(,794,O
10⁻¹³,794,O
and,794,O
10⁻¹¹,794,O
M,794,O
),794,O
was,794,O
associated,794,O
with,794,O
a,794,O
sequential,794,O
up-regulation,794,O
of,794,O
PPARγ2,794,B-GENE-Y
(,794,O
PPARG,794,B-GENE-Y
),794,O
and,794,O
FABP4,794,B-GENE-Y
mRNA,794,O
",",794,O
indicating,794,O
formation,794,O
of,794,O
adipocytes,794,O
",",794,O
whereas,794,O
higher,794,O
concentrations,794,O
(,794,O
≥10⁻⁹,794,O
M,794,O
),794,O
reduced,794,O
all,794,O
these,794,O
effects,794,O
",",794,O
and,794,O
the,794,O
highest,794,O
concentration,794,O
(,794,O
10⁻⁵,794,O
M,794,O
),794,O
appeared,794,O
to,794,O
have,794,O
toxic,794,O
effects,794,O
.,794,O
This,795,O
is,795,O
the,795,O
first,795,O
study,795,O
to,795,O
demonstrate,795,O
dose-dependent,795,O
effects,795,O
of,795,O
"1,25",795,B-CHEMICAL
(,795,I-CHEMICAL
OH,795,I-CHEMICAL
),795,I-CHEMICAL
₂D₃,795,I-CHEMICAL
on,795,O
the,795,O
transdifferentiation,795,O
of,795,O
muscle,795,O
cells,795,O
into,795,O
adipose,795,O
cells,795,O
.,795,O
Low,796,O
physiological,796,O
concentrations,796,O
(,796,O
possibly,796,O
mimicking,796,O
a,796,O
deficient,796,O
state,796,O
),796,O
induced,796,O
adipogenesis,796,O
",",796,O
whereas,796,O
higher,796,O
(,796,O
physiological,796,O
and,796,O
supraphysiological,796,O
),796,O
concentrations,796,O
attenuated,796,O
this,796,O
effect,796,O
.,796,O
PF-04859989,797,B-CHEMICAL
as,797,O
a,797,O
template,797,O
for,797,O
structure-based,797,O
drug,797,O
design,797,O
:,797,O
identification,797,O
of,797,O
new,797,O
pyrazole,797,B-CHEMICAL
series,797,O
of,797,O
irreversible,797,O
KAT,797,B-GENE-Y
II,797,I-GENE-Y
inhibitors,797,O
with,797,O
improved,797,O
lipophilic,797,O
efficiency,797,O
.,797,O
The,798,O
structure-based,798,O
design,798,O
",",798,O
synthesis,798,O
",",798,O
and,798,O
biological,798,O
evaluation,798,O
of,798,O
a,798,O
new,798,O
pyrazole,798,B-CHEMICAL
series,798,O
of,798,O
irreversible,798,O
KAT,798,B-GENE-Y
II,798,I-GENE-Y
inhibitors,798,O
are,798,O
described,798,O
herein,798,O
.,798,O
The,799,O
modification,799,O
of,799,O
the,799,O
inhibitor,799,O
scaffold,799,O
of,799,O
1,799,O
and,799,O
2,799,O
from,799,O
a,799,O
dihydroquinolinone,799,B-CHEMICAL
core,799,O
to,799,O
a,799,O
tetrahydropyrazolopyridinone,799,B-CHEMICAL
core,799,O
led,799,O
to,799,O
discovery,799,O
of,799,O
a,799,O
new,799,O
series,799,O
of,799,O
potent,799,O
KAT,799,B-GENE-Y
II,799,I-GENE-Y
inhibitors,799,O
with,799,O
excellent,799,O
physicochemical,799,O
properties,799,O
.,799,O
Compound,800,O
20,800,O
is,800,O
the,800,O
most,800,O
potent,800,O
and,800,O
lipophilically,800,O
efficient,800,O
of,800,O
these,800,O
new,800,O
pyrazole,800,B-CHEMICAL
analogs,800,O
",",800,O
with,800,O
a,800,O
k,800,O
(,800,O
inact,800,O
),800,O
/K,800,O
(,800,O
i,800,O
),800,O
value,800,O
of,800,O
"112,000",800,O
M,800,O
(,800,O
-1,800,O
),800,O
s,800,O
(,800,O
-1,800,O
),800,O
and,800,O
lipophilic,800,O
efficiency,800,O
(,800,O
LipE,800,O
),800,O
of,800,O
8.53,800,O
.,800,O
The,801,O
X-ray,801,O
crystal,801,O
structure,801,O
of,801,O
20,801,O
with,801,O
KAT,801,B-GENE-Y
II,801,I-GENE-Y
demonstrates,801,O
key,801,O
features,801,O
that,801,O
contribute,801,O
to,801,O
this,801,O
remarkable,801,O
potency,801,O
and,801,O
binding,801,O
efficiency,801,O
.,801,O
A,802,O
single,802,O
residue,802,O
in,802,O
leucyl-tRNA,802,B-GENE-Y
synthetase,802,I-GENE-Y
affecting,802,O
amino,802,B-CHEMICAL
acid,802,I-CHEMICAL
specificity,802,O
and,802,O
tRNA,802,O
aminoacylation,802,O
.,802,O
Human,803,B-GENE-Y
mitochondrial,803,I-GENE-Y
leucyl-tRNA,803,I-GENE-Y
synthetase,803,I-GENE-Y
(,803,O
hs,803,B-GENE-Y
mt,803,I-GENE-Y
LeuRS,803,I-GENE-Y
),803,O
achieves,803,O
high,803,O
aminoacylation,803,O
fidelity,803,O
without,803,O
a,803,O
functional,803,O
editing,803,O
active,803,O
site,803,O
",",803,O
representing,803,O
a,803,O
rare,803,O
example,803,O
of,803,O
a,803,O
class,803,B-GENE-N
I,803,I-GENE-N
aminoacyl-tRNA,803,I-GENE-N
synthetase,803,I-GENE-N
(,803,O
aaRS,803,B-GENE-N
),803,O
that,803,O
does,803,O
not,803,O
proofread,803,O
its,803,O
products,803,O
.,803,O
Previous,804,O
studies,804,O
demonstrated,804,O
that,804,O
the,804,O
enzyme,804,O
achieves,804,O
high,804,O
selectivity,804,O
by,804,O
using,804,O
a,804,O
more,804,O
specific,804,O
synthetic,804,O
active,804,O
site,804,O
that,804,O
is,804,O
not,804,O
prone,804,O
to,804,O
errors,804,O
under,804,O
physiological,804,O
conditions,804,O
.,804,O
Interestingly,805,O
",",805,O
the,805,O
synthetic,805,O
active,805,O
site,805,O
of,805,O
hs,805,B-GENE-Y
mt,805,I-GENE-Y
LeuRS,805,I-GENE-Y
displays,805,O
a,805,O
high,805,O
degree,805,O
of,805,O
homology,805,O
with,805,O
prokaryotic,805,O
",",805,O
lower,805,O
eukaryotic,805,O
",",805,O
and,805,O
other,805,O
mitochondrial,805,O
LeuRSs,805,B-GENE-Y
that,805,O
are,805,O
less,805,O
specific,805,O
.,805,O
However,806,O
",",806,O
there,806,O
is,806,O
one,806,O
residue,806,O
that,806,O
differs,806,O
between,806,O
hs,806,B-GENE-N
mt,806,I-GENE-N
and,806,I-GENE-N
Escherichia,806,I-GENE-N
coli,806,I-GENE-N
LeuRSs,806,I-GENE-N
located,806,O
on,806,O
a,806,O
flexible,806,O
closing,806,O
loop,806,O
near,806,O
the,806,O
signature,806,O
KMSKS,806,B-GENE-N
motif,806,I-GENE-N
.,806,O
Here,807,O
we,807,O
describe,807,O
studies,807,O
indicating,807,O
that,807,O
this,807,O
particular,807,O
residue,807,O
(,807,O
K600,807,O
in,807,O
hs,807,B-GENE-Y
mt,807,I-GENE-Y
LeuRS,807,I-GENE-Y
and,807,O
L570,807,O
in,807,O
E.,807,B-GENE-Y
coli,807,I-GENE-Y
LeuRS,807,I-GENE-Y
),807,O
strongly,807,O
impacts,807,O
aminoacylation,807,O
in,807,O
two,807,O
ways,807,O
:,807,O
it,807,O
affects,807,O
both,807,O
amino,807,B-CHEMICAL
acid,807,I-CHEMICAL
discrimination,807,O
and,807,O
transfer,807,O
RNA,807,O
(,807,O
tRNA,807,O
),807,O
binding,807,O
.,807,O
While,808,O
this,808,O
residue,808,O
may,808,O
not,808,O
be,808,O
in,808,O
direct,808,O
contact,808,O
with,808,O
the,808,O
amino,808,B-CHEMICAL
acid,808,I-CHEMICAL
or,808,O
tRNA,808,O
substrate,808,O
",",808,O
substitutions,808,O
of,808,O
this,808,O
position,808,O
in,808,O
both,808,O
enzymes,808,O
lead,808,O
to,808,O
altered,808,O
catalytic,808,O
efficiency,808,O
and,808,O
perturbations,808,O
to,808,O
the,808,O
discrimination,808,O
of,808,O
leucine,808,B-CHEMICAL
and,808,O
isoleucine,808,B-CHEMICAL
.,808,O
In,809,O
addition,809,O
",",809,O
tRNA,809,O
recognition,809,O
and,809,O
aminoacylation,809,O
is,809,O
affected,809,O
.,809,O
These,810,O
findings,810,O
indicate,810,O
that,810,O
the,810,O
conformation,810,O
of,810,O
the,810,O
synthetic,810,O
active,810,O
site,810,O
",",810,O
modulated,810,O
by,810,O
this,810,O
residue,810,O
",",810,O
may,810,O
be,810,O
coupled,810,O
to,810,O
specificity,810,O
and,810,O
provide,810,O
new,810,O
insights,810,O
into,810,O
the,810,O
origins,810,O
of,810,O
selectivity,810,O
without,810,O
editing,810,O
.,810,O
Neurochemical,811,O
control,811,O
of,811,O
rapid,811,O
stress-induced,811,O
changes,811,O
in,811,O
brain,811,O
aromatase,811,B-GENE-Y
activity,811,O
.,811,O
In,812,O
the,812,O
male,812,O
brain,812,O
",",812,O
the,812,O
medial,812,O
preoptic,812,O
nucleus,812,O
(,812,O
POM,812,O
),812,O
is,812,O
known,812,O
to,812,O
be,812,O
a,812,O
critical,812,O
relay,812,O
for,812,O
the,812,O
activation,812,O
of,812,O
sexual,812,O
behaviour,812,O
",",812,O
with,812,O
the,812,O
aromatisation,812,O
of,812,O
testosterone,812,B-CHEMICAL
into,812,O
17β-oestradiol,812,B-CHEMICAL
(,812,O
E2,812,O
),812,O
playing,812,O
a,812,O
key,812,O
role,812,O
.,812,O
Acute,813,O
stress,813,O
has,813,O
been,813,O
shown,813,O
to,813,O
differentially,813,O
modulate,813,O
the,813,O
aromatase,813,B-GENE-Y
enzyme,813,O
in,813,O
this,813,O
and,813,O
other,813,O
brain,813,O
nuclei,813,O
in,813,O
a,813,O
sex-specific,813,O
manner,813,O
.,813,O
In,814,O
POM,814,O
specifically,814,O
",",814,O
stress,814,O
induces,814,O
increases,814,O
in,814,O
aromatase,814,B-GENE-Y
activity,814,O
(,814,O
AA,814,O
),814,O
that,814,O
are,814,O
both,814,O
rapid,814,O
and,814,O
reversible,814,O
.,814,O
How,815,O
the,815,O
physiological,815,O
processes,815,O
initiated,815,O
during,815,O
an,815,O
acute,815,O
stress,815,O
response,815,O
mediate,815,O
sex-,815,O
and,815,O
nuclei-,815,O
specific,815,O
changes,815,O
in,815,O
AA,815,O
and,815,O
which,815,O
stress,815,O
response,815,O
hormones,815,O
are,815,O
involved,815,O
remains,815,O
to,815,O
be,815,O
determined,815,O
.,815,O
By,816,O
examining,816,O
the,816,O
relative,816,O
effects,816,O
of,816,O
corticosterone,816,B-CHEMICAL
(,816,O
CORT,816,B-CHEMICAL
),816,O
",",816,O
arginine,816,B-GENE-N
vasotocin,816,I-GENE-N
(,816,O
AVT,816,B-GENE-N
",",816,O
the,816,O
avian,816,O
homologue,816,O
to,816,O
arginine,816,B-GENE-Y
vasopressin,816,I-GENE-Y
),816,O
and,816,O
corticotrophin-releasing,816,B-GENE-Y
factor,816,I-GENE-Y
(,816,O
CRF,816,B-GENE-Y
),816,O
",",816,O
the,816,O
present,816,O
study,816,O
aimed,816,O
to,816,O
define,816,O
the,816,O
hormone,816,O
profile,816,O
regulating,816,O
stress-induced,816,O
increases,816,O
in,816,O
AA,816,O
in,816,O
the,816,O
POM,816,O
.,816,O
We,817,O
found,817,O
that,817,O
CORT,817,B-CHEMICAL
",",817,O
AVT,817,B-GENE-N
and,817,O
CRF,817,B-GENE-Y
all,817,O
appear,817,O
to,817,O
play,817,O
some,817,O
role,817,O
in,817,O
these,817,O
changes,817,O
in,817,O
the,817,O
male,817,O
brain,817,O
.,817,O
In,818,O
addition,818,O
",",818,O
these,818,O
effects,818,O
occur,818,O
in,818,O
a,818,O
targeted,818,O
manner,818,O
",",818,O
such,818,O
that,818,O
modulation,818,O
of,818,O
the,818,O
enzyme,818,O
by,818,O
these,818,O
hormones,818,O
only,818,O
occurs,818,O
in,818,O
the,818,O
POM,818,O
rather,818,O
than,818,O
in,818,O
all,818,O
aromatase-expressing,818,B-GENE-Y
nuclei,818,O
.,818,O
Similarly,819,O
",",819,O
in,819,O
the,819,O
female,819,O
brain,819,O
",",819,O
the,819,O
experimental,819,O
effects,819,O
were,819,O
restricted,819,O
to,819,O
the,819,O
POM,819,O
but,819,O
only,819,O
CRF,819,B-GENE-Y
was,819,O
capable,819,O
of,819,O
inducing,819,O
the,819,O
stress-like,819,O
increases,819,O
in,819,O
AA,819,O
.,819,O
These,820,O
data,820,O
further,820,O
demonstrate,820,O
the,820,O
high,820,O
degree,820,O
of,820,O
specificity,820,O
(,820,O
nuclei-,820,O
",",820,O
sex-,820,O
and,820,O
hormone-specific,820,O
effects,820,O
),820,O
in,820,O
this,820,O
system,820,O
",",820,O
highlighting,820,O
the,820,O
complexity,820,O
of,820,O
the,820,O
stress-aromatase,820,O
link,820,O
and,820,O
suggesting,820,O
modes,820,O
through,820,O
which,820,O
the,820,O
nongenomic,820,O
modulation,820,O
of,820,O
this,820,O
enzyme,820,O
can,820,O
result,820,O
in,820,O
targeted,820,O
",",820,O
rapid,820,O
changes,820,O
in,820,O
local,820,O
oestrogen,820,B-CHEMICAL
concentrations,820,O
.,820,O
Differential,821,O
inhibition,821,O
of,821,O
[,821,B-CHEMICAL
3H,821,I-CHEMICAL
],821,I-CHEMICAL
-oxotremorine-M,821,I-CHEMICAL
and,821,O
[,821,B-CHEMICAL
3H,821,I-CHEMICAL
],821,I-CHEMICAL
-quinuclinidyl,821,I-CHEMICAL
benzilate,821,I-CHEMICAL
binding,821,O
to,821,O
muscarinic,821,B-GENE-N
receptors,821,I-GENE-N
in,821,O
rat,821,O
brain,821,O
membranes,821,O
with,821,O
acetylcholinesterase,821,B-GENE-Y
inhibitors,821,O
.,821,O
The,822,O
potential,822,O
interaction,822,O
of,822,O
acetylcholinesterase,822,B-GENE-Y
inhibitors,822,O
with,822,O
cholinergic,822,B-GENE-N
receptors,822,I-GENE-N
may,822,O
play,822,O
a,822,O
significant,822,O
role,822,O
in,822,O
the,822,O
therapeutic,822,O
and/or,822,O
side-effects,822,O
associated,822,O
with,822,O
this,822,O
class,822,O
of,822,O
compound,822,O
.,822,O
In,823,O
the,823,O
present,823,O
study,823,O
",",823,O
the,823,O
capacity,823,O
of,823,O
acetylcholinesterase,823,B-GENE-Y
inhibitors,823,O
to,823,O
interact,823,O
with,823,O
muscarinic,823,B-GENE-N
receptors,823,I-GENE-N
was,823,O
assessed,823,O
by,823,O
their,823,O
ability,823,O
to,823,O
displace,823,O
both,823,O
[,823,B-CHEMICAL
3H,823,I-CHEMICAL
],823,I-CHEMICAL
-oxotremorine-M,823,I-CHEMICAL
and,823,O
[,823,B-CHEMICAL
3H,823,I-CHEMICAL
],823,I-CHEMICAL
-quinuclinidyl,823,I-CHEMICAL
benzilate,823,I-CHEMICAL
binding,823,O
in,823,O
rat,823,O
brain,823,O
membranes,823,O
.,823,O
The,824,O
[,824,B-CHEMICAL
3H,824,I-CHEMICAL
],824,I-CHEMICAL
-quinuclinidyl,824,I-CHEMICAL
benzilate/,824,O
[,824,B-CHEMICAL
3H,824,I-CHEMICAL
],824,I-CHEMICAL
-oxotremorine-M,824,I-CHEMICAL
affinity,824,O
ratios,824,O
permitted,824,O
predictions,824,O
to,824,O
be,824,O
made,824,O
of,824,O
either,824,O
the,824,O
antagonist,824,O
or,824,O
agonist,824,O
properties,824,O
of,824,O
the,824,O
different,824,O
compounds,824,O
.,824,O
A,825,O
series,825,O
of,825,O
compounds,825,O
",",825,O
representative,825,O
of,825,O
the,825,O
principal,825,O
classes,825,O
of,825,O
acetylcholinesterase,825,B-GENE-Y
inhibitors,825,O
",",825,O
displaced,825,O
[,825,B-CHEMICAL
3H,825,I-CHEMICAL
],825,I-CHEMICAL
-oxotremorine-M,825,I-CHEMICAL
binding,825,O
with,825,O
high-to-moderate,825,O
potency,825,O
(,825,O
ambenonium,825,B-CHEMICAL
>,825,O
neostigmine=pyridostigmine=tacrine,825,B-CHEMICAL
>,825,O
physostigmine,825,B-CHEMICAL
>,825,O
edrophonium=galanthamine,825,B-CHEMICAL
>,825,O
desoxypeganine,825,B-CHEMICAL
),825,O
whereas,825,O
only,825,O
ambenonium,825,B-CHEMICAL
and,825,O
tacrine,825,B-CHEMICAL
displaced,825,O
[,825,B-CHEMICAL
3H,825,I-CHEMICAL
],825,I-CHEMICAL
-quinuclinidyl,825,I-CHEMICAL
benzilate,825,I-CHEMICAL
binding,825,O
.,825,O
Inhibitors,826,O
such,826,O
as,826,O
desoxypeganine,826,B-CHEMICAL
",",826,O
parathion,826,O
and,826,O
gramine,826,O
demonstrated,826,O
negligible,826,O
inhibition,826,O
of,826,O
the,826,O
binding,826,O
of,826,O
both,826,O
radioligands,826,O
.,826,O
Scatchard,827,O
plots,827,O
constructed,827,O
from,827,O
the,827,O
inhibition,827,O
of,827,O
[,827,B-CHEMICAL
3H,827,I-CHEMICAL
],827,I-CHEMICAL
-oxotremorine-M,827,I-CHEMICAL
binding,827,O
in,827,O
the,827,O
absence,827,O
and,827,O
presence,827,O
of,827,O
different,827,O
inhibitors,827,O
showed,827,O
an,827,O
unaltered,827,O
Bmax,827,O
and,827,O
a,827,O
reduced,827,O
affinity,827,O
constant,827,O
",",827,O
indicative,827,O
of,827,O
potential,827,O
competitive,827,O
or,827,O
allosteric,827,O
mechanisms,827,O
.,827,O
The,828,O
capacity,828,O
of,828,O
acetylcholinesterase,828,B-GENE-Y
inhibitors,828,O
",",828,O
with,828,O
the,828,O
exception,828,O
of,828,O
tacrine,828,B-CHEMICAL
and,828,O
ambenonium,828,B-CHEMICAL
",",828,O
to,828,O
displace,828,O
bound,828,O
[,828,B-CHEMICAL
3H,828,I-CHEMICAL
],828,I-CHEMICAL
-oxotremorine-M,828,I-CHEMICAL
in,828,O
preference,828,O
to,828,O
[,828,B-CHEMICAL
3H,828,I-CHEMICAL
],828,I-CHEMICAL
quinuclinidyl,828,I-CHEMICAL
benzilate,828,I-CHEMICAL
predicts,828,O
that,828,O
the,828,O
former,828,O
compounds,828,O
could,828,O
act,828,O
as,828,O
potential,828,O
agonists,828,O
at,828,O
muscarinic,828,B-GENE-N
receptors,828,I-GENE-N
.,828,O
Moreover,829,O
",",829,O
the,829,O
rank,829,O
order,829,O
for,829,O
potency,829,O
in,829,O
inhibiting,829,O
acetylcholinesterase,829,B-GENE-Y
(,829,O
ambenonium,829,B-CHEMICAL
>,829,O
neostigmine=physostigmine,829,B-CHEMICAL
=tacrine,829,O
>,829,O
pyridostigmine=edrophonium=galanthamine,829,B-CHEMICAL
>,829,O
desoxypeganine,829,B-CHEMICAL
>,829,O
parathion,829,B-CHEMICAL
>,829,O
gramine,829,B-CHEMICAL
),829,O
indicated,829,O
that,829,O
the,829,O
most,829,O
effective,829,O
inhibitors,829,O
of,829,O
acetylcholinesterase,829,B-GENE-Y
also,829,O
displaced,829,O
[,829,B-CHEMICAL
3H,829,I-CHEMICAL
],829,I-CHEMICAL
-oxotremorine-M,829,I-CHEMICAL
to,829,O
the,829,O
greatest,829,O
extent,829,O
.,829,O
The,830,O
capacity,830,O
of,830,O
these,830,O
inhibitors,830,O
to,830,O
displace,830,O
[,830,B-CHEMICAL
3H,830,I-CHEMICAL
],830,I-CHEMICAL
-oxotremorine-M,830,O
binding,830,O
preclude,830,O
their,830,O
utilisation,830,O
for,830,O
the,830,O
prevention,830,O
of,830,O
acetylcholine,830,B-CHEMICAL
catabolism,830,O
in,830,O
rat,830,O
brain,830,O
membranes,830,O
",",830,O
the,830,O
latter,830,O
being,830,O
required,830,O
to,830,O
estimate,830,O
the,830,O
binding,830,O
of,830,O
acetylcholine,830,O
to,830,O
[,830,B-CHEMICAL
3H,830,I-CHEMICAL
],830,I-CHEMICAL
-oxotremorine-M-labelled,830,O
muscarinic,830,B-GENE-N
receptors,830,I-GENE-N
.,830,O
However,831,O
",",831,O
fasciculin-2,831,O
",",831,O
a,831,O
potent,831,O
peptide,831,O
inhibitor,831,O
of,831,O
acetylcholinesterase,831,B-GENE-Y
(,831,O
IC50,831,O
24,831,O
nM,831,O
),831,O
",",831,O
did,831,O
prevent,831,O
catabolism,831,O
of,831,O
acetylcholine,831,B-CHEMICAL
in,831,O
rat,831,O
brain,831,O
membranes,831,O
with,831,O
an,831,O
atypical,831,O
inhibition,831,O
isotherm,831,O
of,831,O
[,831,B-CHEMICAL
3H,831,I-CHEMICAL
],831,I-CHEMICAL
-oxotremorine-M,831,I-CHEMICAL
binding,831,O
",",831,O
thus,831,O
permitting,831,O
an,831,O
estimation,831,O
of,831,O
the,831,O
``,831,O
global,831,O
affinity,831,O
'',831,O
of,831,O
acetylcholine,831,B-GENE-Y
(,831,O
Ki,831,O
85,831,O
nM,831,O
),831,O
for,831,O
[,831,B-CHEMICAL
3H,831,I-CHEMICAL
],831,I-CHEMICAL
-oxotremorine-M-labelled,831,O
muscarinic,831,B-GENE-N
receptors,831,I-GENE-N
in,831,O
rat,831,O
brain,831,O
.,831,O
Abnormally,832,O
high,832,O
plasma,832,O
levels,832,O
of,832,O
vitamin,832,B-CHEMICAL
B6,832,I-CHEMICAL
in,832,O
children,832,O
with,832,O
autism,832,O
not,832,O
taking,832,O
supplements,832,O
compared,832,O
to,832,O
controls,832,O
not,832,O
taking,832,O
supplements,832,O
.,832,O
BACKGROUND,833,O
:,833,O
There,833,O
have,833,O
been,833,O
many,833,O
studies,833,O
of,833,O
the,833,O
effect,833,O
of,833,O
high-dose,833,O
supplementation,833,O
of,833,O
vitamin,833,B-CHEMICAL
B6,833,I-CHEMICAL
on,833,O
children,833,O
and,833,O
adults,833,O
with,833,O
autism,833,O
",",833,O
with,833,O
all,833,O
but,833,O
one,833,O
reporting,833,O
benefits,833,O
.,833,O
OBJECTIVE,834,O
:,834,O
The,834,O
aim,834,O
of,834,O
this,834,O
study,834,O
was,834,O
to,834,O
investigate,834,O
the,834,O
biochemical,834,O
basis,834,O
for,834,O
vitamin,834,B-CHEMICAL
B6,834,I-CHEMICAL
therapy,834,O
by,834,O
measuring,834,O
the,834,O
level,834,O
of,834,O
total,834,O
vitamin,834,B-CHEMICAL
B6,834,I-CHEMICAL
in,834,O
the,834,O
plasma,834,O
of,834,O
unsupplemented,834,O
children,834,O
with,834,O
autism,834,O
spectrum,834,O
disorder,834,O
compared,834,O
to,834,O
unsupplemented,834,O
control,834,O
subjects,834,O
.,834,O
PARTICIPANTS,835,O
:,835,O
Children,835,O
with,835,O
autism,835,O
spectrum,835,O
disorders,835,O
(,835,O
n,835,O
=,835,O
35,835,O
",",835,O
age,835,O
3-9,835,O
years,835,O
),835,O
and,835,O
unrelated,835,O
typical,835,O
children,835,O
(,835,O
n,835,O
=,835,O
11,835,O
",",835,O
age,835,O
6-9,835,O
years,835,O
),835,O
",",835,O
all,835,O
from,835,O
Arizona,835,O
",",835,O
were,835,O
studied,835,O
.,835,O
(,836,O
This,836,O
includes,836,O
the,836,O
data,836,O
from,836,O
24,836,O
children,836,O
with,836,O
autism,836,O
from,836,O
our,836,O
previous,836,O
study,836,O
.,836,O
),836,O
METHODOLOGY,837,O
:,837,O
A,837,O
microbiologic,837,O
assay,837,O
was,837,O
used,837,O
to,837,O
measure,837,O
the,837,O
level,837,O
of,837,O
total,837,O
vitamin,837,B-CHEMICAL
B6,837,I-CHEMICAL
(,837,O
including,837,O
phosphorylated,837,O
and,837,O
unphosphorylated,837,O
forms,837,O
),837,O
",",837,O
in,837,O
a,837,O
blinded,837,O
fashion,837,O
.,837,O
RESULTS,838,O
:,838,O
Children,838,O
with,838,O
autism,838,O
had,838,O
a,838,O
75,838,O
%,838,O
higher,838,O
level,838,O
of,838,O
total,838,O
vitamin,838,B-CHEMICAL
B6,838,I-CHEMICAL
than,838,O
the,838,O
controls,838,O
(,838,O
medians,838,O
of,838,O
56,838,O
versus,838,O
32,838,O
ng/mL,838,O
",",838,O
respectively,838,O
",",838,O
p,838,O
=,838,O
0.00002,838,O
),838,O
.,838,O
Most,839,O
of,839,O
the,839,O
autistic,839,O
children,839,O
(,839,O
77,839,O
%,839,O
),839,O
had,839,O
levels,839,O
that,839,O
were,839,O
more,839,O
than,839,O
2,839,O
standard,839,O
deviations,839,O
above,839,O
the,839,O
median,839,O
value,839,O
of,839,O
the,839,O
controls,839,O
.,839,O
The,840,O
autistic,840,O
girls,840,O
(,840,O
n,840,O
=,840,O
5,840,O
),840,O
also,840,O
had,840,O
elevated,840,O
levels,840,O
(,840,O
mean,840,O
of,840,O
54.6,840,O
ng/mL,840,O
",",840,O
median,840,O
of,840,O
60,840,O
ng/mL,840,O
),840,O
.,840,O
DISCUSSION,841,O
:,841,O
These,841,O
results,841,O
are,841,O
consistent,841,O
with,841,O
previous,841,O
studies,841,O
that,841,O
found,841,O
that,841,O
:,841,O
(,841,O
1,841,O
),841,O
pyridoxal,841,B-GENE-Y
kinase,841,I-GENE-Y
had,841,O
a,841,O
very,841,O
low,841,O
activity,841,O
in,841,O
children,841,O
with,841,O
autism,841,O
and,841,O
(,841,O
2,841,O
),841,O
pyridoxal,841,B-CHEMICAL
5,841,I-CHEMICAL
phosphate,841,I-CHEMICAL
(,841,O
PLP,841,B-CHEMICAL
),841,O
levels,841,O
are,841,O
unusually,841,O
low,841,O
in,841,O
children,841,O
with,841,O
autism,841,O
.,841,O
Thus,842,O
",",842,O
it,842,O
appears,842,O
that,842,O
the,842,O
low,842,O
conversion,842,O
of,842,O
pyridoxal,842,B-CHEMICAL
and,842,O
pyridoxine,842,B-CHEMICAL
to,842,O
PLP,842,B-CHEMICAL
results,842,O
in,842,O
low,842,O
levels,842,O
of,842,O
PLP,842,B-CHEMICAL
",",842,O
which,842,O
is,842,O
the,842,O
active,842,O
cofactor,842,O
for,842,O
113,842,O
known,842,O
enzymatic,842,O
reactions,842,O
",",842,O
including,842,O
the,842,O
formation,842,O
of,842,O
many,842,O
key,842,O
neurotransmitters,842,O
.,842,O
CONCLUSIONS,843,O
:,843,O
Total,843,O
vitamin,843,B-CHEMICAL
B6,843,I-CHEMICAL
is,843,O
abnormally,843,O
high,843,O
in,843,O
autism,843,O
",",843,O
consistent,843,O
with,843,O
previous,843,O
reports,843,O
of,843,O
an,843,O
impaired,843,O
pyridoxal,843,B-GENE-Y
kinase,843,I-GENE-Y
for,843,O
the,843,O
conversion,843,O
of,843,O
pyridoxine,843,B-CHEMICAL
and,843,O
pyridoxal,843,B-CHEMICAL
to,843,O
PLP,843,B-CHEMICAL
.,843,O
This,844,O
may,844,O
explain,844,O
the,844,O
many,844,O
published,844,O
studies,844,O
of,844,O
benefits,844,O
of,844,O
high-dose,844,O
vitamin,844,B-CHEMICAL
B6,844,I-CHEMICAL
supplementation,844,O
in,844,O
some,844,O
children,844,O
and,844,O
adults,844,O
with,844,O
autism,844,O
.,844,O
Synthesis,845,O
",",845,O
molecular,845,O
modeling,845,O
and,845,O
evaluation,845,O
of,845,O
novel,845,O
N'-2-,845,B-CHEMICAL
(,845,I-CHEMICAL
4-benzylpiperidin-/piperazin-1-yl,845,I-CHEMICAL
),845,I-CHEMICAL
acylhydrazone,845,I-CHEMICAL
derivatives,845,O
as,845,O
dual,845,O
inhibitors,845,O
for,845,O
cholinesterases,845,B-GENE-Y
and,845,O
Aβ,845,B-GENE-Y
aggregation,845,O
.,845,O
To,846,O
develop,846,O
new,846,O
drugs,846,O
for,846,O
treatment,846,O
of,846,O
Alzheimer,846,O
's,846,O
disease,846,O
",",846,O
a,846,O
group,846,O
of,846,O
N'-2-,846,B-CHEMICAL
(,846,I-CHEMICAL
4-Benzylpiperidin-/piperazin-1-yl,846,I-CHEMICAL
),846,I-CHEMICAL
acylhydrazones,846,I-CHEMICAL
was,846,O
designed,846,O
",",846,O
synthesized,846,O
and,846,O
tested,846,O
for,846,O
their,846,O
ability,846,O
to,846,O
inhibit,846,O
acetylcholinesterase,846,B-GENE-Y
",",846,O
butyrylcholinesterase,846,B-GENE-Y
and,846,O
aggregation,846,O
of,846,O
amyloid,846,B-GENE-N
beta,846,I-GENE-N
peptides,846,I-GENE-N
(,846,I-GENE-N
1-40,846,I-GENE-N
",",846,I-GENE-N
1-42,846,I-GENE-N
and,846,I-GENE-N
1-40_1-42,846,I-GENE-N
),846,I-GENE-N
.,846,O
The,847,O
enzyme,847,O
inhibition,847,O
assay,847,O
results,847,O
indicated,847,O
that,847,O
compounds,847,O
moderately,847,O
inhibit,847,O
both,847,O
acetylcholinesterase,847,B-GENE-Y
and,847,O
butyrylcholinesterase,847,B-GENE-Y
.,847,O
β-Amyloid,848,B-GENE-Y
aggregation,848,O
results,848,O
showed,848,O
that,848,O
all,848,O
compounds,848,O
exhibited,848,O
remarkable,848,O
Aβ,848,B-GENE-Y
fibril,848,O
aggregation,848,O
inhibition,848,O
activity,848,O
with,848,O
a,848,O
nearly,848,O
similar,848,O
potential,848,O
as,848,O
the,848,O
reference,848,O
compound,848,O
rifampicin,848,B-CHEMICAL
",",848,O
which,848,O
makes,848,O
them,848,O
promising,848,O
anti-Alzheimer,848,O
drug,848,O
candidates,848,O
.,848,O
Docking,849,O
experiments,849,O
were,849,O
carried,849,O
out,849,O
with,849,O
the,849,O
aim,849,O
to,849,O
understand,849,O
the,849,O
interactions,849,O
of,849,O
the,849,O
most,849,O
active,849,O
compounds,849,O
with,849,O
the,849,O
active,849,O
site,849,O
of,849,O
the,849,O
cholinesterase,849,B-GENE-Y
enzymes,849,O
.,849,O
Effect,850,O
of,850,O
anabolic-androgenic,850,O
steroids,850,B-CHEMICAL
and,850,O
glucocorticoids,850,O
on,850,O
the,850,O
kinetics,850,O
of,850,O
hAR,850,B-GENE-Y
and,850,O
hGR,850,B-GENE-Y
nucleocytoplasmic,850,O
translocation,850,O
.,850,O
Although,851,O
the,851,O
qualitative,851,O
nucleocytoplasmic,851,O
transport,851,O
of,851,O
nuclear,851,B-GENE-N
hormone,851,I-GENE-N
receptors,851,I-GENE-N
(,851,O
NHRs,851,B-GENE-N
),851,O
has,851,O
been,851,O
studied,851,O
",",851,O
there,851,O
is,851,O
little,851,O
documentation,851,O
of,851,O
the,851,O
cellular,851,O
kinetics,851,O
of,851,O
this,851,O
transport,851,O
.,851,O
Here,852,O
",",852,O
translocation,852,O
studies,852,O
using,852,O
the,852,O
human,852,B-GENE-Y
androgen,852,I-GENE-Y
receptor,852,I-GENE-Y
(,852,O
hAR,852,B-GENE-Y
),852,O
and,852,O
the,852,O
human,852,B-GENE-Y
glucocorticoid,852,I-GENE-Y
receptor,852,I-GENE-Y
(,852,O
hGR,852,B-GENE-Y
),852,O
were,852,O
performed,852,O
to,852,O
aid,852,O
in,852,O
identifying,852,O
the,852,O
mechanism,852,O
by,852,O
which,852,O
anabolic-androgenic,852,O
steroids,852,B-CHEMICAL
(,852,O
AAS,852,O
),852,O
were,852,O
activating,852,O
hAR,852,B-GENE-Y
and,852,O
potentially,852,O
interacting,852,O
with,852,O
hGR,852,B-GENE-Y
and,852,O
how,852,O
glucocorticoid,852,O
ligands,852,O
were,852,O
interacting,852,O
with,852,O
the,852,O
hGR,852,B-GENE-Y
and,852,O
hAR,852,B-GENE-Y
.,852,O
The,853,O
real-time,853,O
analysis,853,O
of,853,O
EGFP-labeled,853,O
hAR,853,B-GENE-Y
and,853,O
hGR,853,B-GENE-Y
ligand-induced,853,O
cytoplasm-to-nucleus,853,O
translocation,853,O
was,853,O
performed,853,O
using,853,O
fluorescence,853,O
microscopy,853,O
to,853,O
better,853,O
understand,853,O
the,853,O
action,853,O
of,853,O
these,853,O
NHRs,853,B-GENE-N
in,853,O
a,853,O
physiologically,853,O
relevant,853,O
cell-based,853,O
model,853,O
.,853,O
After,854,O
transient,854,O
transfection,854,O
",",854,O
the,854,O
hAR,854,B-GENE-Y
and,854,O
hGR,854,B-GENE-Y
individually,854,O
translocate,854,O
as,854,O
expected,854,O
(,854,O
i.e.,854,O
",",854,O
transport,854,O
is,854,O
ligand-induced,854,O
and,854,O
dose-dependent,854,O
),854,O
in,854,O
this,854,O
model,854,O
biological,854,O
system,854,O
.,854,O
Testosterone,855,B-CHEMICAL
(,855,O
TEST,855,B-CHEMICAL
),855,O
had,855,O
the,855,O
fastest,855,O
translocation,855,O
rate,855,O
for,855,O
the,855,O
hAR,855,B-GENE-Y
of,855,O
0.0525,855,O
min,855,O
(,855,O
-1,855,O
),855,O
.,855,O
The,856,O
other,856,O
endogenous,856,O
steroids,856,B-CHEMICAL
",",856,O
androstenedione,856,B-CHEMICAL
(,856,O
ANE,856,B-CHEMICAL
),856,O
and,856,O
dihydrotestosterone,856,B-CHEMICAL
(,856,O
DHT,856,B-CHEMICAL
),856,O
",",856,O
had,856,O
considerably,856,O
lower,856,O
hAR,856,B-GENE-Y
transport,856,O
rates,856,O
.,856,O
The,857,O
rates,857,O
of,857,O
hAR,857,B-GENE-Y
transport,857,O
for,857,O
the,857,O
exogenous,857,O
steroids,857,B-CHEMICAL
methyltrienelone,857,B-CHEMICAL
(,857,O
MET,857,B-CHEMICAL
),857,O
",",857,O
nandrolone,857,B-CHEMICAL
(,857,O
NAN,857,B-CHEMICAL
),857,O
",",857,O
and,857,O
oxandrolone,857,B-CHEMICAL
(,857,O
OXA,857,B-CHEMICAL
),857,O
are,857,O
lower,857,O
than,857,O
that,857,O
of,857,O
testosterone,857,B-CHEMICAL
and,857,O
similar,857,O
to,857,O
those,857,O
of,857,O
the,857,O
endogenous,857,O
steroids,857,B-CHEMICAL
ANE,857,B-CHEMICAL
and,857,O
DHT,857,B-CHEMICAL
.,857,O
The,858,O
hGR,858,B-GENE-Y
transport,858,O
rates,858,O
for,858,O
cortisol,858,O
(,858,O
COR,858,O
),858,O
and,858,O
dexamethasone,858,O
(,858,O
DEX,858,O
),858,O
are,858,O
also,858,O
presented,858,O
.,858,O
The,859,O
synthetic,859,O
GC,859,O
",",859,O
DEX,859,O
",",859,O
had,859,O
a,859,O
more,859,O
rapid,859,O
translocation,859,O
rate,859,O
(,859,O
0.1599,859,O
min,859,O
(,859,O
-1,859,O
),859,O
),859,O
at,859,O
the,859,O
highest,859,O
dose,859,O
of,859,O
100,859,O
nM,859,O
compared,859,O
to,859,O
the,859,O
endogenous,859,O
GC,859,O
COR,859,O
(,859,O
0.0431,859,O
min,859,O
(,859,O
-1,859,O
),859,O
),859,O
.,859,O
The,860,O
data,860,O
obtained,860,O
agrees,860,O
with,860,O
the,860,O
existing,860,O
qualitative,860,O
data,860,O
and,860,O
adds,860,O
an,860,O
important,860,O
ligand-dependent,860,O
kinetic,860,O
component,860,O
to,860,O
hAR,860,B-GENE-Y
and,860,O
hGR,860,B-GENE-Y
transport,860,O
.,860,O
These,861,O
kinetic,861,O
data,861,O
can,861,O
aid,861,O
our,861,O
understanding,861,O
of,861,O
NHR,861,B-GENE-N
action,861,O
and,861,O
interaction,861,O
with,861,O
other,861,O
regulatory,861,O
proteins,861,O
",",861,O
and,861,O
can,861,O
be,861,O
useful,861,O
in,861,O
the,861,O
development,861,O
of,861,O
new,861,O
therapies,861,O
.,861,O
Licofelone,862,B-CHEMICAL
",",862,O
a,862,O
balanced,862,O
inhibitor,862,O
of,862,O
cyclooxygenase,862,B-GENE-N
and,862,O
5-lipoxygenase,862,B-GENE-Y
",",862,O
reduces,862,O
inflammation,862,O
in,862,O
a,862,O
rabbit,862,O
model,862,O
of,862,O
atherosclerosis,862,O
.,862,O
Licofelone,863,B-CHEMICAL
",",863,O
a,863,O
dual,863,O
anti-inflammatory,863,O
drug,863,O
that,863,O
inhibits,863,O
5-lipoxygenase,863,B-GENE-Y
(,863,O
LOX,863,B-GENE-N
),863,O
and,863,O
cyclooxygenase,863,B-GENE-N
(,863,O
COX,863,B-GENE-N
),863,O
enzymes,863,O
",",863,O
may,863,O
have,863,O
a,863,O
better,863,O
cardiovascular,863,O
profile,863,O
that,863,O
cycloxygenase-2,863,B-GENE-Y
inhibitors,863,O
due,863,O
to,863,O
cycloxygenase-1,863,B-GENE-Y
blockade-mediated,863,O
antithrombotic,863,O
effect,863,O
and,863,O
a,863,O
better,863,O
gastrointestinal,863,O
tolerability,863,O
.,863,O
We,864,O
examined,864,O
the,864,O
anti-inflammatory,864,O
effect,864,O
of,864,O
licofelone,864,B-CHEMICAL
on,864,O
atherosclerotic,864,O
lesions,864,O
as,864,O
well,864,O
as,864,O
in,864,O
isolated,864,O
neutrophils,864,O
from,864,O
whole,864,O
blood,864,O
of,864,O
rabbits,864,O
compared,864,O
with,864,O
a,864,O
selective,864,O
inhibitor,864,O
of,864,O
COX-2,864,B-GENE-Y
",",864,O
rofecoxib,864,B-CHEMICAL
.,864,O
We,865,O
also,865,O
assessed,865,O
the,865,O
antithrombotic,865,O
effect,865,O
of,865,O
licofelone,865,B-CHEMICAL
in,865,O
rabbit,865,O
platelet-rich,865,O
plasma,865,O
.,865,O
For,866,O
this,866,O
purpose,866,O
",",866,O
30,866,O
rabbits,866,O
underwent,866,O
injury,866,O
of,866,O
femoral,866,O
arteries,866,O
",",866,O
and,866,O
they,866,O
were,866,O
randomized,866,O
to,866,O
receive,866,O
10,866,O
mg/kg/day,866,O
licofelone,866,B-CHEMICAL
or,866,O
5,866,O
mg/kg/day,866,O
rofecoxib,866,B-CHEMICAL
or,866,O
no,866,O
treatment,866,O
during,866,O
4,866,O
weeks,866,O
with,866,O
atherogenic,866,O
diet,866,O
in,866,O
all,866,O
cases,866,O
.,866,O
Ten,867,O
healthy,867,O
rabbits,867,O
were,867,O
used,867,O
as,867,O
controls,867,O
.,867,O
Neutrophils,868,O
and,868,O
platelets,868,O
were,868,O
isolated,868,O
from,868,O
peripheral,868,O
blood,868,O
of,868,O
rabbits,868,O
for,868,O
ex,868,O
vivo,868,O
studies,868,O
.,868,O
Licofelone,869,B-CHEMICAL
reduced,869,O
intima/media,869,O
ratio,869,O
in,869,O
injured,869,O
arteries,869,O
",",869,O
the,869,O
macrophages,869,O
infiltration,869,O
in,869,O
the,869,O
neointimal,869,O
area,869,O
",",869,O
monocyte,869,B-GENE-Y
chemoattractant,869,I-GENE-Y
protein-1,869,I-GENE-Y
(,869,O
MCP-1,869,B-GENE-Y
),869,O
gene,869,O
expression,869,O
",",869,O
and,869,O
the,869,O
activation,869,O
of,869,O
nuclear,869,B-GENE-N
factor-kappaB,869,I-GENE-N
in,869,O
rabbit,869,O
atheroma,869,O
.,869,O
Moreover,870,O
",",870,O
licofelone,870,B-CHEMICAL
inhibited,870,O
COX-2,870,B-GENE-Y
and,870,O
5-LOX,870,B-GENE-Y
protein,870,O
expression,870,O
in,870,O
vascular,870,O
lesions,870,O
.,870,O
Rofecoxib,871,B-CHEMICAL
only,871,O
diminished,871,O
COX-2,871,B-GENE-Y
protein,871,O
expression,871,O
and,871,O
MCP-1,871,B-GENE-Y
gene,871,O
expression,871,O
in,871,O
vascular,871,O
atheroma,871,O
.,871,O
Prostaglandin,872,B-CHEMICAL
E,872,I-CHEMICAL
(,872,I-CHEMICAL
2,872,I-CHEMICAL
),872,I-CHEMICAL
in,872,O
rabbit,872,O
plasma,872,O
was,872,O
attenuated,872,O
by,872,O
both,872,O
drugs,872,O
.,872,O
Licofelone,873,B-CHEMICAL
almost,873,O
abolished,873,O
5-LOX,873,B-GENE-Y
activity,873,O
by,873,O
inhibiting,873,O
leukotriene,873,B-CHEMICAL
B4,873,I-CHEMICAL
generation,873,O
in,873,O
rabbit,873,O
neutrophils,873,O
and,873,O
prevented,873,O
platelet,873,O
thromboxane,873,B-CHEMICAL
B2,873,I-CHEMICAL
production,873,O
from,873,O
whole,873,O
blood,873,O
.,873,O
Licofelone,874,B-CHEMICAL
reduces,874,O
neointimal,874,O
formation,874,O
and,874,O
inflammation,874,O
in,874,O
an,874,O
atherosclerotic,874,O
rabbit,874,O
model,874,O
more,874,O
markedly,874,O
than,874,O
rofecoxib,874,B-CHEMICAL
.,874,O
This,875,O
effect,875,O
",",875,O
together,875,O
with,875,O
the,875,O
antiplatelet,875,O
activity,875,O
of,875,O
licofelone,875,B-CHEMICAL
",",875,O
suggests,875,O
that,875,O
this,875,O
drug,875,O
may,875,O
have,875,O
a,875,O
favorable,875,O
cardiovascular,875,O
profile,875,O
.,875,O
No,876,O
influence,876,O
of,876,O
moderate,876,O
hepatic,876,O
impairment,876,O
on,876,O
the,876,O
pharmacokinetics,876,O
of,876,O
lumiracoxib,876,B-CHEMICAL
",",876,O
an,876,O
oral,876,O
COX-2,876,B-GENE-Y
selective,876,O
inhibitor,876,O
.,876,O
The,877,O
aim,877,O
of,877,O
this,877,O
study,877,O
was,877,O
to,877,O
evaluate,877,O
the,877,O
influence,877,O
of,877,O
hepatic,877,O
impairment,877,O
on,877,O
the,877,O
pharmacokinetics,877,O
(,877,O
PK,877,O
),877,O
of,877,O
the,877,O
novel,877,O
cyclooxygenase-2,877,B-GENE-Y
(,877,O
COX-2,877,B-GENE-Y
),877,O
selective,877,O
inhibitor,877,O
lumiracoxib,877,B-CHEMICAL
(,877,O
Prexige,877,B-CHEMICAL
),877,O
",",877,O
so,877,O
that,877,O
dose,877,O
recommendations,877,O
for,877,O
clinical,877,O
use,877,O
can,877,O
be,877,O
provided,877,O
.,877,O
This,878,O
was,878,O
an,878,O
open-label,878,O
",",878,O
single,878,O
dose,878,O
",",878,O
case-controlled,878,O
study,878,O
in,878,O
which,878,O
eight,878,O
subjects,878,O
with,878,O
liver,878,O
cirrhosis,878,O
classed,878,O
as,878,O
moderate,878,O
hepatic,878,O
impairment,878,O
(,878,O
Child-Pugh,878,O
score,878,O
:,878,O
7-9,878,O
),878,O
and,878,O
eight,878,O
demographically-matched,878,O
healthy,878,O
subjects,878,O
received,878,O
a,878,O
single,878,O
oral,878,O
400,878,O
mg,878,O
dose,878,O
of,878,O
lumiracoxib,878,B-CHEMICAL
.,878,O
Routine,879,O
safety,879,O
assessments,879,O
were,879,O
made,879,O
and,879,O
blood,879,O
samples,879,O
were,879,O
taken,879,O
for,879,O
determination,879,O
of,879,O
lumiracoxib,879,B-CHEMICAL
concentrations,879,O
for,879,O
96,879,O
h,879,O
post,879,O
dose,879,O
.,879,O
The,880,O
ex,880,O
vivo,880,O
binding,880,O
of,880,O
lumiracoxib,880,B-CHEMICAL
to,880,O
plasma,880,O
proteins,880,O
was,880,O
determined,880,O
pre,880,O
dose,880,O
and,880,O
at,880,O
2,880,O
and,880,O
12,880,O
h,880,O
post,880,O
dose,880,O
.,880,O
An,881,O
analysis,881,O
of,881,O
variance,881,O
was,881,O
used,881,O
to,881,O
detect,881,O
differences,881,O
in,881,O
PK,881,O
parameters,881,O
(,881,O
AUC,881,O
",",881,O
Cmax,881,O
and,881,O
Tmax,881,O
),881,O
between,881,O
the,881,O
treatment,881,O
groups,881,O
.,881,O
There,882,O
were,882,O
no,882,O
significant,882,O
differences,882,O
between,882,O
subjects,882,O
with,882,O
moderate,882,O
hepatic,882,O
insufficiency,882,O
and,882,O
healthy,882,O
subjects,882,O
in,882,O
the,882,O
area,882,O
under,882,O
the,882,O
lumiracoxib,882,B-CHEMICAL
plasma,882,O
concentration-time,882,O
curves,882,O
(,882,O
AUC,882,O
(,882,O
0-infinity,882,O
),882,O
),882,O
:,882,O
29.2,882,O
+/-,882,O
6.7,882,O
microg,882,O
h,882,O
ml,882,O
(,882,O
-1,882,O
),882,O
versus,882,O
28.7,882,O
+/-,882,O
6.3,882,O
mircrog,882,O
h,882,O
ml,882,O
(,882,O
-1,882,O
),882,O
.,882,O
The,883,O
rate,883,O
of,883,O
absorption,883,O
of,883,O
lumiracoxib,883,B-CHEMICAL
was,883,O
not,883,O
significantly,883,O
altered,883,O
by,883,O
hepatic,883,O
impairment,883,O
based,883,O
on,883,O
Cmax,883,O
and,883,O
Tmax,883,O
.,883,O
The,884,O
protein-bound,884,O
fraction,884,O
of,884,O
lumiracoxib,884,B-CHEMICAL
exceeded,884,O
98,884,O
%,884,O
both,884,O
in,884,O
healthy,884,O
control,884,O
subjects,884,O
and,884,O
in,884,O
those,884,O
with,884,O
moderate,884,O
hepatic,884,O
insufficiency,884,O
.,884,O
A,885,O
single,885,O
dose,885,O
of,885,O
400,885,O
mg,885,O
lumiracoxib,885,B-CHEMICAL
was,885,O
well,885,O
tolerated,885,O
.,885,O
In,886,O
conclusion,886,O
",",886,O
no,886,O
dose,886,O
adjustments,886,O
appear,886,O
to,886,O
be,886,O
required,886,O
when,886,O
lumiracoxib,886,B-CHEMICAL
is,886,O
administered,886,O
to,886,O
patients,886,O
with,886,O
either,886,O
mild,886,O
or,886,O
moderate,886,O
hepatic,886,O
impairment,886,O
.,886,O
Alcohol,887,B-CHEMICAL
modulates,887,O
expression,887,O
of,887,O
DNA,887,B-GENE-N
methyltranferases,887,I-GENE-N
and,887,O
methyl,887,B-GENE-N
CpG-/CpG,887,I-GENE-N
domain-binding,887,I-GENE-N
proteins,887,I-GENE-N
in,887,O
murine,887,O
embryonic,887,O
fibroblasts,887,O
.,887,O
Fetal,888,O
alcohol,888,B-CHEMICAL
syndrome,888,O
(,888,O
FAS,888,O
),888,O
",",888,O
presenting,888,O
with,888,O
a,888,O
constellation,888,O
of,888,O
neuro-/psychological,888,O
",",888,O
craniofacial,888,O
and,888,O
cardiac,888,O
abnormalities,888,O
",",888,O
occurs,888,O
frequently,888,O
in,888,O
offspring,888,O
of,888,O
women,888,O
who,888,O
consume,888,O
alcohol,888,B-CHEMICAL
during,888,O
pregnancy,888,O
",",888,O
with,888,O
a,888,O
prevalence,888,O
of,888,O
1-3,888,O
per,888,O
1000,888,O
livebirths,888,O
.,888,O
The,889,O
present,889,O
study,889,O
was,889,O
designed,889,O
to,889,O
test,889,O
the,889,O
hypothesis,889,O
that,889,O
alcohol,889,B-CHEMICAL
alters,889,O
global,889,O
DNA,889,O
methylation,889,O
",",889,O
and,889,O
modulates,889,O
expression,889,O
of,889,O
the,889,O
DNA,889,B-GENE-N
methyltransferases,889,I-GENE-N
(,889,O
DNMTs,889,B-GENE-N
),889,O
and,889,O
various,889,O
methyl,889,B-CHEMICAL
CpG-binding,889,B-GENE-N
proteins,889,I-GENE-N
.,889,O
Murine,890,O
embryonic,890,O
fibroblasts,890,O
(,890,O
MEFs,890,O
),890,O
",",890,O
utilized,890,O
as,890,O
an,890,O
in,890,O
vitro,890,O
embryonic,890,O
model,890,O
system,890,O
",",890,O
demonstrated,890,O
∼5,890,O
%,890,O
reduction,890,O
in,890,O
global,890,O
DNA,890,O
methylation,890,O
following,890,O
exposure,890,O
to,890,O
200mM,890,O
ethanol,890,B-CHEMICAL
.,890,O
In,891,O
addition,891,O
",",891,O
ethanol,891,B-CHEMICAL
induced,891,O
degradation,891,O
of,891,O
DNA,891,B-GENE-N
methyltransferases,891,I-GENE-N
(,891,O
DNMT-1,891,B-GENE-Y
",",891,O
DNMT-3a,891,B-GENE-Y
",",891,O
and,891,O
DNMT-3b,891,B-GENE-Y
),891,O
",",891,O
as,891,O
well,891,O
as,891,O
the,891,O
methyl,891,B-GENE-N
CpG-binding,891,I-GENE-N
proteins,891,I-GENE-N
(,891,O
MeCP-2,891,B-GENE-Y
",",891,O
MBD-2,891,B-GENE-Y
and,891,O
MBD-3,891,B-GENE-Y
),891,O
",",891,O
in,891,O
MEF,891,O
cells,891,O
by,891,O
the,891,O
proteasomal,891,O
pathway,891,O
.,891,O
Such,892,O
degradation,892,O
could,892,O
be,892,O
completely,892,O
rescued,892,O
by,892,O
pretreatment,892,O
of,892,O
MEF,892,O
cells,892,O
with,892,O
the,892,O
proteasomal,892,O
inhibitor,892,O
",",892,O
MG-132,892,B-CHEMICAL
.,892,O
These,893,O
data,893,O
support,893,O
a,893,O
potential,893,O
epigenetic,893,O
molecular,893,O
mechanism,893,O
underlying,893,O
the,893,O
pathogenesis,893,O
of,893,O
FAS,893,O
during,893,O
mammalian,893,O
development,893,O
.,893,O
Clock,894,B-GENE-Y
Gene,894,O
Expression,894,O
in,894,O
the,894,O
Liver,894,O
of,894,O
Streptozotocin-induced,894,B-CHEMICAL
and,894,O
Spontaneous,894,O
Type,894,O
1,894,O
Diabetic,894,O
Rats,894,O
.,894,O
Several,895,O
investigations,895,O
have,895,O
shown,895,O
a,895,O
relation,895,O
between,895,O
diabetes,895,O
and,895,O
alterations,895,O
of,895,O
the,895,O
liver,895,O
circadian,895,O
clock,895,B-GENE-Y
.,895,O
We,896,O
investigated,896,O
the,896,O
diurnal,896,O
expression,896,O
of,896,O
clock,896,B-GENE-Y
genes,896,O
and,896,O
clock-controlled,896,B-GENE-N
genes,896,I-GENE-N
(,896,O
CCGs,896,B-GENE-N
),896,O
in,896,O
3-hour,896,O
intervals,896,O
for,896,O
a,896,O
24-h,896,O
period,896,O
in,896,O
the,896,O
livers,896,O
of,896,O
male,896,O
streptozotocin,896,B-CHEMICAL
(,896,O
STZ,896,B-CHEMICAL
),896,O
-treated,896,O
rats,896,O
",",896,O
male,896,O
spontaneous,896,O
type,896,O
1,896,O
diabetic,896,O
LEW.1AR1-iddm,896,O
(,896,O
Iddm,896,O
),896,O
rats,896,O
",",896,O
and,896,O
Iddm,896,O
rats,896,O
treated,896,O
for,896,O
10,896,O
days,896,O
with,896,O
insulin,896,B-GENE-Y
.,896,O
Hepatic,897,O
mRNA,897,O
was,897,O
extracted,897,O
",",897,O
and,897,O
the,897,O
relative,897,O
expression,897,O
of,897,O
clock,897,B-GENE-Y
genes,897,O
(,897,O
Per1,897,B-GENE-Y
",",897,O
Per2,897,B-GENE-Y
",",897,O
Bmal1,897,B-GENE-Y
",",897,O
Clock,897,B-GENE-Y
",",897,O
Cry1,897,B-GENE-Y
),897,O
",",897,O
as,897,O
well,897,O
as,897,O
CCGs,897,B-GENE-N
(,897,O
Dbp,897,B-GENE-Y
",",897,O
E4bp4,897,B-GENE-Y
",",897,O
RevErbα,897,B-GENE-Y
",",897,O
Rorα,897,B-GENE-N
",",897,O
Pparγ,897,B-GENE-Y
),897,O
",",897,O
was,897,O
analyzed,897,O
by,897,O
reverse,897,O
transcription,897,O
followed,897,O
by,897,O
real-time,897,O
polymerase,897,O
chain,897,O
reaction,897,O
.,897,O
Diabetic,898,O
STZ,898,B-CHEMICAL
and,898,O
Iddm,898,O
rats,898,O
",",898,O
as,898,O
well,898,O
as,898,O
insulin-substituted,898,B-GENE-Y
Iddm,898,O
rats,898,O
",",898,O
exhibited,898,O
a,898,O
significant,898,O
diurnal,898,O
expression,898,O
pattern,898,O
of,898,O
clock,898,B-GENE-Y
genes,898,O
as,898,O
determined,898,O
by,898,O
Cosinor,898,O
analysis,898,O
;,898,O
however,898,O
",",898,O
the,898,O
MESOR,898,O
(,898,O
midline,898,O
estimating,898,O
statistic,898,O
of,898,O
rhythm,898,O
),898,O
of,898,O
Bmal1,898,B-GENE-Y
",",898,O
Per2,898,B-GENE-Y
",",898,O
and,898,O
Clock,898,B-GENE-Y
transcript,898,O
expression,898,O
was,898,O
altered,898,O
in,898,O
Iddm,898,O
and,898,O
insulin-substituted,898,B-GENE-Y
Iddm,898,O
rats,898,O
.,898,O
The,899,O
hepatic,899,O
expression,899,O
of,899,O
the,899,O
CCGs,899,B-GENE-N
Dbp,899,B-GENE-Y
and,899,O
RevErbα,899,B-GENE-Y
revealed,899,O
a,899,O
diurnal,899,O
rhythm,899,O
in,899,O
all,899,O
investigated,899,O
groups,899,O
.,899,O
Insulin,900,B-GENE-Y
administration,900,O
to,900,O
Iddm,900,O
rats,900,O
normalized,900,O
the,900,O
enhanced,900,O
MESOR,900,O
in,900,O
the,900,O
expression,900,O
of,900,O
Dbp,900,B-GENE-Y
",",900,O
RevErbα,900,B-GENE-Y
",",900,O
and,900,O
E4bp4,900,B-GENE-Y
to,900,O
the,900,O
levels,900,O
of,900,O
normoglycemic,900,O
controls,900,O
.,900,O
Cosinor,901,O
analysis,901,O
indicated,901,O
no,901,O
diurnal,901,O
rhythm,901,O
of,901,O
Pparγ,901,B-GENE-Y
expression,901,O
in,901,O
the,901,O
livers,901,O
of,901,O
diabetic,901,O
STZ,901,B-CHEMICAL
or,901,O
Iddm,901,O
rats,901,O
or,901,O
in,901,O
those,901,O
of,901,O
insulin-substituted,901,B-GENE-Y
Iddm,901,O
rats,901,O
.,901,O
Also,902,O
",",902,O
insulin,902,B-GENE-Y
substitution,902,O
could,902,O
not,902,O
reverse,902,O
the,902,O
decreased,902,O
MESOR,902,O
of,902,O
Pparγ,902,B-GENE-Y
expression,902,O
in,902,O
Iddm,902,O
rats,902,O
.,902,O
In,903,O
consequence,903,O
of,903,O
the,903,O
diabetic,903,O
disease,903,O
",",903,O
changes,903,O
in,903,O
the,903,O
expression,903,O
of,903,O
clock,903,B-GENE-Y
genes,903,O
and,903,O
CCGs,903,B-GENE-N
suggest,903,O
alterations,903,O
in,903,O
the,903,O
hepatic,903,O
peripheral,903,O
clock,903,B-GENE-Y
mechanism,903,O
.,903,O
Comparison,904,O
of,904,O
the,904,O
monoamine,904,B-GENE-N
oxidase,904,I-GENE-N
inhibiting,904,O
properties,904,O
of,904,O
two,904,O
reversible,904,O
and,904,O
selective,904,O
monoamine,904,B-GENE-Y
oxidase-A,904,I-GENE-Y
inhibitors,904,O
moclobemide,904,B-CHEMICAL
and,904,O
toloxatone,904,B-CHEMICAL
",",904,O
and,904,O
assessment,904,O
of,904,O
their,904,O
effect,904,O
on,904,O
psychometric,904,O
performance,904,O
in,904,O
healthy,904,O
subjects,904,O
.,904,O
1,905,O
.,905,O
The,906,O
effects,906,O
of,906,O
two,906,O
reversible,906,O
",",906,O
predominantly,906,O
monoamine,906,B-GENE-Y
oxidase-A,906,I-GENE-Y
(,906,O
MAO-A,906,B-GENE-Y
),906,O
inhibitors,906,O
",",906,O
moclobemide,906,B-CHEMICAL
(,906,O
150,906,O
mg,906,O
three,906,O
times,906,O
daily,906,O
),906,O
and,906,O
toloxatone,906,B-CHEMICAL
(,906,O
400-200-400,906,O
mg,906,O
day-1,906,O
),906,O
on,906,O
monoamine,906,B-CHEMICAL
metabolites,906,O
and,906,O
psychometric,906,O
performance,906,O
were,906,O
compared,906,O
in,906,O
a,906,O
double-blind,906,O
placebo,906,O
controlled,906,O
crossover,906,O
study,906,O
in,906,O
12,906,O
healthy,906,O
subjects,906,O
.,906,O
2,907,O
.,907,O
After,908,O
7,908,O
days,908,O
of,908,O
moclobemide/toloxatone/placebo,908,B-CHEMICAL
administration,908,O
subjects,908,O
were,908,O
hospitalized,908,O
for,908,O
24,908,O
h,908,O
on,908,O
day,908,O
8,908,O
.,908,O
Blood,909,O
samples,909,O
were,909,O
drawn,909,O
every,909,O
2,909,O
h,909,O
for,909,O
determination,909,O
of,909,O
plasma,909,O
noradrenaline,909,B-CHEMICAL
(,909,O
NA,909,B-CHEMICAL
),909,O
",",909,O
"3,4-dihydroxyphenylglycol",909,B-CHEMICAL
(,909,O
DHPG,909,B-CHEMICAL
),909,O
",",909,O
homovanillic,909,B-CHEMICAL
acid,909,I-CHEMICAL
(,909,O
HVA,909,B-CHEMICAL
),909,O
and,909,O
5-hydroxyindolacetic,909,B-CHEMICAL
acid,909,I-CHEMICAL
(,909,O
5-HIAA,909,B-CHEMICAL
),909,O
.,909,O
Urine,910,O
was,910,O
collected,910,O
for,910,O
measurements,910,O
of,910,O
normetanephrine,910,B-CHEMICAL
and,910,O
3-methoxytyramine,910,B-CHEMICAL
excretion,910,O
.,910,O
Psychometric,911,O
performance,911,O
(,911,O
short-,911,O
and,911,O
long-term,911,O
memory,911,O
",",911,O
critical,911,O
flicker,911,O
fusion,911,O
frequency,911,O
",",911,O
choice,911,O
reaction,911,O
time,911,O
),911,O
and,911,O
subjective,911,O
feelings,911,O
were,911,O
assessed,911,O
before,911,O
each,911,O
drug,911,O
intake,911,O
(,911,O
in,911,O
the,911,O
morning,911,O
",",911,O
at,911,O
noon,911,O
",",911,O
in,911,O
the,911,O
evening,911,O
),911,O
.,911,O
3,912,O
.,912,O
Compared,913,O
with,913,O
placebo,913,O
",",913,O
both,913,O
reversible,913,O
monoamine,913,B-GENE-N
oxidase,913,I-GENE-N
inhibitors,913,O
decreased,913,O
the,913,O
plasma,913,O
concentration,913,O
of,913,O
DHPG,913,B-CHEMICAL
and,913,O
HVA,913,B-CHEMICAL
.,913,O
The,914,O
overall,914,O
fall,914,O
in,914,O
DHPG,914,B-CHEMICAL
(,914,O
AUC,914,O
from,914,O
0,914,O
to,914,O
24,914,O
h,914,O
),914,O
was,914,O
44,914,O
%,914,O
during,914,O
moclobemide,914,B-CHEMICAL
and,914,O
12,914,O
%,914,O
during,914,O
toloxatone,914,B-CHEMICAL
(,914,O
P,914,O
less,914,O
than,914,O
0.001,914,O
),914,O
and,914,O
the,914,O
overall,914,O
decrease,914,O
in,914,O
HVA,914,B-CHEMICAL
was,914,O
38,914,O
%,914,O
and,914,O
20,914,O
%,914,O
(,914,O
P,914,O
less,914,O
than,914,O
0.005,914,O
),914,O
on,914,O
moclobemide,914,B-CHEMICAL
and,914,O
toloxatone,914,B-CHEMICAL
",",914,O
respectively,914,O
.,914,O
4,915,O
.,915,O
Before,916,O
the,916,O
next,916,O
drug,916,O
intake,916,O
",",916,O
MAO-A,916,B-GENE-Y
inhibition,916,O
",",916,O
as,916,O
judged,916,O
by,916,O
the,916,O
decrease,916,O
of,916,O
plasma,916,O
DHPG,916,B-CHEMICAL
concentration,916,O
",",916,O
was,916,O
significantly,916,O
different,916,O
from,916,O
placebo,916,O
with,916,O
moclobemide,916,B-CHEMICAL
but,916,O
not,916,O
with,916,O
toloxatone,916,B-CHEMICAL
.,916,O
5,917,O
.,917,O
Moclobemide,918,B-CHEMICAL
",",918,O
but,918,O
not,918,O
toloxatone,918,B-CHEMICAL
",",918,O
exerted,918,O
a,918,O
moderate,918,O
",",918,O
but,918,O
significant,918,O
inhibition,918,O
of,918,O
the,918,O
deamination,918,O
of,918,O
5-hydroxytryptamine,918,B-CHEMICAL
(,918,O
5-HT,918,B-CHEMICAL
),918,O
as,918,O
judged,918,O
by,918,O
the,918,O
fall,918,O
in,918,O
plasma,918,O
5-HIAA,918,B-CHEMICAL
concentration,918,O
.,918,O
Neither,919,O
drug,919,O
influenced,919,O
plasma,919,O
NA,919,B-CHEMICAL
concentration,919,O
.,919,O
6,920,O
.,920,O
A,921,O
significant,921,O
rise,921,O
in,921,O
urinary,921,O
excretion,921,O
of,921,O
normetanephrine,921,B-CHEMICAL
was,921,O
observed,921,O
on,921,O
moclobemide,921,B-CHEMICAL
and,921,O
to,921,O
a,921,O
lesser,921,O
extent,921,O
on,921,O
toloxatone,921,B-CHEMICAL
.,921,O
The,922,O
urinary,922,O
excretion,922,O
of,922,O
3-methoxytyramine,922,B-CHEMICAL
was,922,O
significantly,922,O
raised,922,O
by,922,O
moclobemide,922,B-CHEMICAL
but,922,O
not,922,O
by,922,O
toloxatone,922,B-CHEMICAL
.,922,O
7,923,O
.,923,O
Neither,924,O
moclobemide,924,B-CHEMICAL
nor,924,O
toloxatone,924,B-CHEMICAL
altered,924,O
memory,924,O
function,924,O
",",924,O
vigilance,924,O
",",924,O
subjective,924,O
feelings,924,O
or,924,O
sleep,924,O
characteristics,924,O
of,924,O
the,924,O
subjects,924,O
.,924,O
Synthesis,925,O
and,925,O
evaluation,925,O
of,925,O
nicotinamide,925,B-CHEMICAL
derivative,925,O
as,925,O
anti-angiogenic,925,O
agents,925,O
.,925,O
Previously,926,O
",",926,O
we,926,O
have,926,O
found,926,O
that,926,O
BRN-103,926,B-CHEMICAL
",",926,O
a,926,O
nicotinamide,926,B-CHEMICAL
derivative,926,O
",",926,O
inhibits,926,O
vascular,926,B-GENE-Y
endothelial,926,I-GENE-Y
growth,926,I-GENE-Y
factor,926,I-GENE-Y
(,926,O
VEGF,926,B-GENE-Y
),926,O
-mediated,926,O
angiogenesis,926,O
signaling,926,O
in,926,O
human,926,O
endothelial,926,O
cells,926,O
.,926,O
During,927,O
our,927,O
continuous,927,O
efforts,927,O
to,927,O
identify,927,O
more,927,O
potent,927,O
anti-angiogenic,927,O
agents,927,O
",",927,O
we,927,O
synthesized,927,O
various,927,O
nicotinamide,927,B-CHEMICAL
derivatives,927,O
and,927,O
evaluated,927,O
their,927,O
anti-angiogenic,927,O
effects,927,O
.,927,O
We,928,O
found,928,O
that,928,O
2-,928,B-CHEMICAL
{,928,I-CHEMICAL
1-,928,I-CHEMICAL
[,928,I-CHEMICAL
1-,928,I-CHEMICAL
(,928,I-CHEMICAL
6-chloro-5-fluoropyrimidin-4-yl,928,I-CHEMICAL
),928,I-CHEMICAL
ethyl,928,I-CHEMICAL
],928,I-CHEMICAL
piperidin-4-ylamino,928,I-CHEMICAL
},928,I-CHEMICAL
-N-,928,I-CHEMICAL
(,928,I-CHEMICAL
3-chlorophenyl,928,I-CHEMICAL
),928,I-CHEMICAL
pyridine-3-carboxamide,928,I-CHEMICAL
(,928,O
BRN-250,928,B-CHEMICAL
),928,O
significantly,928,O
inhibited,928,O
human,928,O
umbilical,928,O
vascular,928,O
endothelial,928,O
cells,928,O
(,928,O
HUVECs,928,O
),928,O
proliferation,928,O
",",928,O
migration,928,O
",",928,O
tube,928,O
formation,928,O
",",928,O
and,928,O
microvessel,928,O
growth,928,O
in,928,O
a,928,O
concentration,928,O
range,928,O
of,928,O
10-100,928,O
nM,928,O
.,928,O
Furthermore,929,O
",",929,O
BRN-250,929,B-CHEMICAL
inhibited,929,O
the,929,O
VEGF-induced,929,B-GENE-Y
phosphorylation,929,O
and,929,O
intracellular,929,O
tyrosine,929,B-GENE-N
kinase,929,I-GENE-N
activity,929,O
of,929,O
VEGF,929,B-GENE-Y
receptor,929,I-GENE-Y
2,929,I-GENE-Y
(,929,O
VEGFR2,929,B-GENE-Y
),929,O
and,929,O
the,929,O
activation,929,O
of,929,O
its,929,O
downstream,929,O
AKT,929,B-GENE-N
pathway,929,O
.,929,O
Taken,930,O
together,930,O
",",930,O
these,930,O
findings,930,O
suggest,930,O
that,930,O
BRN-250,930,B-CHEMICAL
be,930,O
considered,930,O
a,930,O
potential,930,O
lead,930,O
compound,930,O
for,930,O
cancer,930,O
therapy,930,O
.,930,O
Inhibition,931,O
of,931,O
gelatinase,931,B-GENE-Y
A,931,I-GENE-Y
(,931,O
MMP-2,931,B-GENE-Y
),931,O
by,931,O
batimastat,931,B-CHEMICAL
and,931,O
captopril,931,B-CHEMICAL
reduces,931,O
tumor,931,O
growth,931,O
and,931,O
lung,931,O
metastases,931,O
in,931,O
mice,931,O
bearing,931,O
Lewis,931,O
lung,931,O
carcinoma,931,O
.,931,O
We,932,O
have,932,O
examined,932,O
the,932,O
effects,932,O
of,932,O
the,932,O
synthetic,932,O
matrix,932,B-GENE-N
metalloproteinase,932,I-GENE-N
inhibitor,932,O
",",932,O
batimastat,932,B-CHEMICAL
(,932,O
BB-94,932,B-CHEMICAL
),932,O
and,932,O
the,932,O
angiotensin-converting,932,B-GENE-Y
enzyme,932,I-GENE-Y
inhibitor,932,O
",",932,O
captopril,932,B-CHEMICAL
",",932,O
on,932,O
metalloproteinase,932,B-GENE-N
activity,932,O
of,932,O
murine,932,O
Lewis-lung-carcinoma,932,O
cells,932,O
(,932,O
3LL,932,O
),932,O
in,932,O
vitro,932,O
",",932,O
and,932,O
on,932,O
local,932,O
growth,932,O
and,932,O
lung,932,O
metastasis,932,O
of,932,O
the,932,O
same,932,O
tumor,932,O
implanted,932,O
intramuscularly,932,O
in,932,O
syngeneic,932,O
C57BL/6,932,O
mice,932,O
.,932,O
The,933,O
effect,933,O
of,933,O
BB-94,933,B-CHEMICAL
and,933,O
captopril,933,B-CHEMICAL
on,933,O
the,933,O
survival,933,O
of,933,O
the,933,O
3LL-tumor-bearing,933,O
mice,933,O
was,933,O
also,933,O
examined,933,O
.,933,O
Here,934,O
we,934,O
report,934,O
that,934,O
captopril,934,B-CHEMICAL
treatment,934,O
resulted,934,O
in,934,O
decreased,934,O
transcription,934,O
and,934,O
protein,934,O
levels,934,O
of,934,O
gelatinase,934,B-GENE-Y
A,934,I-GENE-Y
by,934,O
3LL,934,O
cells,934,O
.,934,O
Both,935,O
BB-94,935,B-CHEMICAL
and,935,O
captopril,935,O
also,935,O
prevented,935,O
substrate,935,O
degradation,935,O
by,935,O
gelatinase,935,B-GENE-N
A,935,I-GENE-N
and,935,I-GENE-N
B,935,I-GENE-N
released,935,O
in,935,O
conditioned,935,O
medium,935,O
by,935,O
cultured,935,O
cells,935,O
.,935,O
Treatment,936,O
of,936,O
tumor-bearing,936,O
animals,936,O
with,936,O
BB-94,936,B-CHEMICAL
(,936,O
i.p,936,O
.,936,O
),936,O
or,937,O
captopril,937,B-CHEMICAL
(,937,O
in,937,O
drinking,937,O
water,937,O
),937,O
resulted,937,O
in,937,O
significant,937,O
inhibition,937,O
of,937,O
the,937,O
mean,937,O
tumor,937,O
volume,937,O
(,937,O
25,937,O
and,937,O
33,937,O
%,937,O
respectively,937,O
),937,O
and,937,O
of,937,O
the,937,O
mean,937,O
lung,937,O
metastasis,937,O
number,937,O
(,937,O
26,937,O
and,937,O
29,937,O
%,937,O
respectively,937,O
),937,O
.,937,O
When,938,O
both,938,O
agents,938,O
were,938,O
given,938,O
",",938,O
they,938,O
acted,938,O
in,938,O
synergy,938,O
",",938,O
resulting,938,O
in,938,O
51,938,O
and,938,O
80,938,O
%,938,O
inhibition,938,O
of,938,O
tumor,938,O
growth,938,O
and,938,O
metastasis,938,O
.,938,O
The,939,O
survival,939,O
time,939,O
of,939,O
the,939,O
mice,939,O
treated,939,O
with,939,O
both,939,O
BB-94,939,B-CHEMICAL
and,939,O
captopril,939,B-CHEMICAL
was,939,O
also,939,O
significantly,939,O
longer,939,O
compared,939,O
with,939,O
the,939,O
groups,939,O
treated,939,O
with,939,O
each,939,O
agent,939,O
alone,939,O
or,939,O
with,939,O
the,939,O
vehicle,939,O
.,939,O
Our,940,O
data,940,O
support,940,O
the,940,O
hypothesis,940,O
of,940,O
an,940,O
essential,940,O
role,940,O
of,940,O
metalloproteinase,940,B-GENE-N
(,940,I-GENE-N
s,940,I-GENE-N
),940,I-GENE-N
in,940,O
the,940,O
metastatic,940,O
process,940,O
.,940,O
Moreover,941,O
",",941,O
blockade,941,O
of,941,O
invasion,941,O
",",941,O
angiogenesis,941,O
and,941,O
other,941,O
processes,941,O
mediated,941,O
by,941,O
metalloproteinases,941,B-GENE-N
may,941,O
underlie,941,O
the,941,O
anti-tumor,941,O
and,941,O
anti-metastatic,941,O
effect,941,O
of,941,O
BB-94,941,B-CHEMICAL
and,941,O
captopril,941,B-CHEMICAL
and,941,O
their,941,O
combination,941,O
.,941,O
It,942,O
is,942,O
conceivable,942,O
that,942,O
this,942,O
combination,942,O
could,942,O
be,942,O
tested,942,O
in,942,O
selected,942,O
clinical,942,O
conditions,942,O
as,942,O
an,942,O
adjuvant,942,O
modality,942,O
to,942,O
cytotoxic,942,O
therapy,942,O
.,942,O
Methionine,943,B-GENE-Y
synthase,943,I-GENE-Y
reductase,943,I-GENE-Y
polymorphisms,943,O
are,943,O
associated,943,O
with,943,O
serum,943,O
osteocalcin,943,B-GENE-Y
levels,943,O
in,943,O
postmenopausal,943,O
women,943,O
.,943,O
Homocysteine,944,B-CHEMICAL
(,944,O
Hcy,944,B-CHEMICAL
),944,O
is,944,O
thought,944,O
to,944,O
play,944,O
an,944,O
important,944,O
role,944,O
in,944,O
the,944,O
development,944,O
of,944,O
osteoporosis,944,O
and,944,O
fracture,944,O
.,944,O
Methionine,945,B-GENE-Y
synthase,945,I-GENE-Y
reductase,945,I-GENE-Y
(,945,O
MTRR,945,B-GENE-Y
),945,O
is,945,O
an,945,O
enzyme,945,O
involved,945,O
in,945,O
the,945,O
conversion,945,O
of,945,O
Hcy,945,B-CHEMICAL
to,945,O
methionine,945,B-CHEMICAL
.,945,O
We,946,O
hypothesized,946,O
that,946,O
certain,946,O
genetic,946,O
polymorphisms,946,O
of,946,O
MTRR,946,B-GENE-Y
leading,946,O
to,946,O
reduced,946,O
enzyme,946,O
activity,946,O
may,946,O
cause,946,O
hyperhomocysteinemia,946,O
and,946,O
affect,946,O
bone,946,O
metabolism,946,O
.,946,O
We,947,O
therefore,947,O
examined,947,O
the,947,O
associations,947,O
of,947,O
the,947,O
A66G,947,B-GENE-N
and,947,O
C524T,947,B-GENE-N
polymorphisms,947,O
of,947,O
the,947,O
MTRR,947,B-GENE-Y
gene,947,O
with,947,O
bone,947,O
mineral,947,O
density,947,O
(,947,O
BMD,947,O
),947,O
and,947,O
serum,947,O
osteocalcin,947,B-GENE-Y
levels,947,O
in,947,O
postmenopausal,947,O
women,947,O
.,947,O
Although,948,O
we,948,O
did,948,O
not,948,O
detect,948,O
any,948,O
significant,948,O
associations,948,O
between,948,O
MTRR,948,B-GENE-Y
polymorphisms,948,O
and,948,O
BMD,948,O
or,948,O
serum,948,O
osteocalcin,948,B-GENE-Y
levels,948,O
",",948,O
we,948,O
found,948,O
that,948,O
the,948,O
66G/524C,948,O
haplotype,948,O
",",948,O
which,948,O
has,948,O
reduced,948,O
enzyme,948,O
activity,948,O
",",948,O
was,948,O
significantly,948,O
associated,948,O
with,948,O
serum,948,O
osteocalcin,948,B-GENE-Y
levels,948,O
in,948,O
a,948,O
gene-dose,948,O
dependent,948,O
manner,948,O
(,948,O
P,948,O
=,948,O
0.002,948,O
),948,O
.,948,O
That,949,O
is,949,O
",",949,O
the,949,O
highest,949,O
osteocalcin,949,B-GENE-Y
levels,949,O
(,949,O
34.5,949,O
+/-,949,O
16.8,949,O
ng/ml,949,O
),949,O
were,949,O
observed,949,O
in,949,O
subjects,949,O
bearing,949,O
two,949,O
copies,949,O
",",949,O
intermediate,949,O
osteocalcin,949,B-GENE-Y
levels,949,O
(,949,O
32.6,949,O
+/-,949,O
14.4,949,O
ng/ml,949,O
),949,O
were,949,O
observed,949,O
in,949,O
subjects,949,O
bearing,949,O
one,949,O
copy,949,O
",",949,O
and,949,O
the,949,O
lowest,949,O
levels,949,O
of,949,O
osteocalcin,949,B-GENE-Y
(,949,O
28.8,949,O
+/-,949,O
10.9,949,O
ng/ml,949,O
),949,O
were,949,O
observed,949,O
in,949,O
subjects,949,O
bearing,949,O
no,949,O
copies,949,O
.,949,O
These,950,O
results,950,O
suggest,950,O
that,950,O
the,950,O
66G/524C,950,O
haplotype,950,O
of,950,O
the,950,O
MTRR,950,B-GENE-Y
gene,950,O
affect,950,O
bone,950,O
turn,950,O
over,950,O
rate,950,O
.,950,O
Glutathione,951,B-GENE-N
peroxidases,951,I-GENE-N
and,951,O
redox-regulated,951,O
transcription,951,O
factors,951,O
.,951,O
Analysis,952,O
of,952,O
the,952,O
selenoproteome,952,O
identified,952,O
five,952,O
glutathione,952,B-GENE-N
peroxidases,952,I-GENE-N
(,952,O
GPxs,952,B-GENE-N
),952,O
in,952,O
mammals,952,O
:,952,O
cytosolic,952,B-GENE-N
GPx,952,I-GENE-N
(,952,O
cGPx,952,B-GENE-N
",",952,O
GPx1,952,B-GENE-N
),952,O
",",952,O
phospholipid,952,B-GENE-N
hydroperoxide,952,I-GENE-N
GPx,952,I-GENE-N
(,952,O
PHGPX,952,B-GENE-N
",",952,O
GPx4,952,B-GENE-N
),952,O
",",952,O
plasma,952,B-GENE-N
GPx,952,I-GENE-N
(,952,O
pGPX,952,B-GENE-N
",",952,O
GPx3,952,B-GENE-N
),952,O
",",952,O
gastrointestinal,952,B-GENE-N
GPx,952,I-GENE-N
(,952,O
GI-GPx,952,B-GENE-N
",",952,O
GPx2,952,B-GENE-N
),952,O
and,952,O
",",952,O
in,952,O
humans,952,B-GENE-Y
",",952,I-GENE-Y
GPx6,952,I-GENE-Y
",",952,O
which,952,O
is,952,O
restricted,952,O
to,952,O
the,952,O
olfactory,952,O
system,952,O
.,952,O
GPxs,953,B-GENE-N
reduce,953,O
hydroperoxides,953,O
to,953,O
the,953,O
corresponding,953,O
alcohols,953,B-CHEMICAL
by,953,O
means,953,O
of,953,O
glutathione,953,B-CHEMICAL
(,953,O
GSH,953,B-CHEMICAL
),953,O
.,953,O
They,954,O
have,954,O
long,954,O
been,954,O
considered,954,O
to,954,O
only,954,O
act,954,O
as,954,O
antioxidant,954,O
enzymes,954,O
.,954,O
Increasing,955,O
evidence,955,O
",",955,O
however,955,O
",",955,O
suggests,955,O
that,955,O
nature,955,O
has,955,O
not,955,O
created,955,O
redundant,955,O
GPxs,955,B-GENE-N
just,955,O
to,955,O
detoxify,955,O
hydroperoxides,955,O
.,955,O
cGPx,956,B-GENE-Y
clearly,956,O
acts,956,O
as,956,O
an,956,O
antioxidant,956,O
",",956,O
as,956,O
convincingly,956,O
demonstrated,956,O
in,956,O
GPx1-knockout,956,B-GENE-Y
mice,956,O
.,956,O
PHGPx,957,B-GENE-N
specifically,957,O
interferes,957,O
with,957,O
NF-kappaB,957,B-GENE-N
activation,957,O
by,957,O
interleukin-1,957,B-GENE-N
",",957,O
reduces,957,O
leukotriene,957,B-CHEMICAL
and,957,O
prostanoid,957,B-CHEMICAL
biosynthesis,957,O
",",957,O
prevents,957,O
COX-2,957,B-GENE-Y
expression,957,O
",",957,O
and,957,O
is,957,O
indispensable,957,O
for,957,O
sperm,957,O
maturation,957,O
and,957,O
embryogenesis,957,O
.,957,O
GI-GPx,958,B-GENE-N
",",958,O
which,958,O
is,958,O
not,958,O
exclusively,958,O
expressed,958,O
in,958,O
the,958,O
gastrointestinal,958,O
system,958,O
",",958,O
is,958,O
upregulated,958,O
in,958,O
colon,958,O
and,958,O
skin,958,O
cancers,958,O
and,958,O
in,958,O
certain,958,O
cultured,958,O
cancer,958,O
cells,958,O
.,958,O
GI-GPx,959,B-GENE-N
is,959,O
a,959,O
target,959,O
for,959,O
Nrf2,959,B-GENE-Y
",",959,O
and,959,O
thus,959,O
is,959,O
part,959,O
of,959,O
the,959,O
adaptive,959,O
response,959,O
by,959,O
itself,959,O
",",959,O
while,959,O
PHGPx,959,B-GENE-N
might,959,O
prevent,959,O
cancer,959,O
by,959,O
interfering,959,O
with,959,O
inflammatory,959,O
pathways,959,O
.,959,O
In,960,O
conclusion,960,O
",",960,O
cGPx,960,B-GENE-Y
",",960,O
PHGPx,960,B-GENE-N
and,960,O
GI-GPx,960,B-GENE-N
have,960,O
distinct,960,O
roles,960,O
",",960,O
particularly,960,O
in,960,O
cellular,960,O
defence,960,O
mechanisms,960,O
.,960,O
Redox,961,O
sensing,961,O
and,961,O
redox,961,O
regulation,961,O
of,961,O
metabolic,961,O
events,961,O
have,961,O
become,961,O
attractive,961,O
paradigms,961,O
to,961,O
unravel,961,O
the,961,O
specific,961,O
and,961,O
in,961,O
part,961,O
still,961,O
enigmatic,961,O
roles,961,O
of,961,O
GPxs,961,B-GENE-N
.,961,O
Efficacy,962,O
and,962,O
long-term,962,O
safety,962,O
of,962,O
alipogene,962,O
tiparvovec,962,O
(,962,O
AAV1-LPL,962,O
(,962,O
S447X,962,B-GENE-N
),962,O
),962,O
gene,962,O
therapy,962,O
for,962,O
lipoprotein,962,B-GENE-Y
lipase,962,I-GENE-Y
deficiency,962,O
:,962,O
an,962,O
open-label,962,O
trial,962,O
.,962,O
We,963,O
describe,963,O
the,963,O
2-year,963,O
follow-up,963,O
of,963,O
an,963,O
open-label,963,O
trial,963,O
(,963,O
CT-AMT-011-01,963,O
),963,O
of,963,O
AAV1-LPL,963,O
(,963,O
S447X,963,B-GENE-N
),963,O
gene,963,O
therapy,963,O
for,963,O
lipoprotein,963,B-GENE-Y
lipase,963,I-GENE-Y
(,963,O
LPL,963,B-GENE-Y
),963,O
deficiency,963,O
(,963,O
LPLD,963,O
),963,O
",",963,O
an,963,O
orphan,963,O
disease,963,O
associated,963,O
with,963,O
chylomicronemia,963,O
",",963,O
severe,963,O
hypertriglyceridemia,963,O
",",963,O
metabolic,963,O
complications,963,O
and,963,O
potentially,963,O
life-threatening,963,O
pancreatitis,963,O
.,963,O
The,964,O
LPL,964,B-GENE-Y
(,964,O
S447X,964,B-GENE-N
),964,O
gene,964,O
variant,964,O
",",964,O
in,964,O
an,964,O
adeno-associated,964,O
viral,964,O
vector,964,O
of,964,O
serotype,964,O
1,964,O
(,964,O
alipogene,964,O
tiparvovec,964,O
),964,O
",",964,O
was,964,O
administered,964,O
to,964,O
14,964,O
adult,964,O
LPLD,964,O
patients,964,O
with,964,O
a,964,O
prior,964,O
history,964,O
of,964,O
pancreatitis,964,O
.,964,O
Primary,965,O
objectives,965,O
were,965,O
to,965,O
assess,965,O
the,965,O
long-term,965,O
safety,965,O
of,965,O
alipogene,965,O
tiparvovec,965,O
and,965,O
achieve,965,O
a,965,O
40,965,O
%,965,O
reduction,965,O
in,965,O
fasting,965,O
median,965,O
plasma,965,O
triglyceride,965,B-CHEMICAL
(,965,O
TG,965,O
),965,O
at,965,O
3-12,965,O
weeks,965,O
compared,965,O
with,965,O
baseline,965,O
.,965,O
Cohorts,966,O
1,966,O
(,966,O
n=2,966,O
),966,O
and,966,O
2,966,O
(,966,O
n=4,966,O
),966,O
received,966,O
3,966,O
×,966,O
10,966,O
(,966,O
11,966,O
),966,O
gc,966,O
kg,966,O
(,966,O
-1,966,O
),966,O
",",966,O
and,966,O
cohort,966,O
3,966,O
(,966,O
n=8,966,O
),966,O
received,966,O
1,966,O
×,966,O
10,966,O
(,966,O
12,966,O
),966,O
gc,966,O
kg,966,O
(,966,O
-1,966,O
),966,O
.,966,O
Cohorts,967,O
2,967,O
and,967,O
3,967,O
also,967,O
received,967,O
immunosuppressants,967,O
from,967,O
the,967,O
time,967,O
of,967,O
alipogene,967,O
tiparvovec,967,O
administration,967,O
and,967,O
continued,967,O
for,967,O
12,967,O
weeks,967,O
.,967,O
Alipogene,968,O
tiparvovec,968,O
was,968,O
well,968,O
tolerated,968,O
",",968,O
without,968,O
emerging,968,O
safety,968,O
concerns,968,O
for,968,O
2,968,O
years,968,O
.,968,O
Half,969,O
of,969,O
the,969,O
patients,969,O
demonstrated,969,O
a,969,O
40,969,O
%,969,O
reduction,969,O
in,969,O
fasting,969,O
TG,969,O
between,969,O
3,969,O
and,969,O
12,969,O
weeks,969,O
.,969,O
TG,970,O
subsequently,970,O
returned,970,O
to,970,O
baseline,970,O
",",970,O
although,970,O
sustained,970,O
LPL,970,B-GENE-Y
(,970,O
S447X,970,B-GENE-N
),970,O
expression,970,O
and,970,O
long-term,970,O
changes,970,O
in,970,O
TG-rich,970,O
lipoprotein,970,O
characteristics,970,O
were,970,O
noted,970,O
independently,970,O
of,970,O
the,970,O
effect,970,O
on,970,O
fasting,970,O
plasma,970,O
TG,970,O
.,970,O
"2,3,7,8-Tetrachlorodibenzo-p-dioxin-mediated",971,B-CHEMICAL
production,971,O
of,971,O
reactive,971,O
oxygen,971,B-CHEMICAL
species,971,O
is,971,O
an,971,O
essential,971,O
step,971,O
in,971,O
the,971,O
mechanism,971,O
of,971,O
action,971,O
to,971,O
accelerate,971,O
human,971,O
keratinocyte,971,O
differentiation,971,O
.,971,O
Chloracne,972,O
is,972,O
commonly,972,O
observed,972,O
in,972,O
humans,972,O
exposed,972,O
to,972,O
"2,3,7,8-tetrachlorodibenzo-p-dioxin",972,B-CHEMICAL
(,972,O
TCDD,972,B-CHEMICAL
),972,O
;,972,O
yet,972,O
",",972,O
the,972,O
mechanism,972,O
of,972,O
toxicity,972,O
is,972,O
not,972,O
well,972,O
understood,972,O
.,972,O
Using,973,O
normal,973,O
human,973,O
epidermal,973,O
keratinocytes,973,O
",",973,O
we,973,O
investigated,973,O
the,973,O
mechanism,973,O
of,973,O
TCDD-mediated,973,B-CHEMICAL
enhancement,973,O
of,973,O
epidermal,973,O
differentiation,973,O
by,973,O
integrating,973,O
functional,973,O
genomic,973,O
",",973,O
metabolomic,973,O
",",973,O
and,973,O
biochemical,973,O
analyses,973,O
.,973,O
TCDD,974,B-CHEMICAL
increased,974,O
the,974,O
expression,974,O
of,974,O
40,974,O
%,974,O
of,974,O
the,974,O
genes,974,O
of,974,O
the,974,O
epidermal,974,O
differentiation,974,O
complex,974,O
found,974,O
on,974,O
chromosome,974,O
1q21,974,O
and,974,O
75,974,O
%,974,O
of,974,O
the,974,O
genes,974,O
required,974,O
for,974,O
de,974,O
novo,974,O
ceramide,974,B-CHEMICAL
biosynthesis,974,O
.,974,O
Lipid,975,O
analysis,975,O
demonstrated,975,O
that,975,O
eight,975,O
of,975,O
the,975,O
nine,975,O
classes,975,O
of,975,O
ceramides,975,B-CHEMICAL
were,975,O
increased,975,O
by,975,O
TCDD,975,B-CHEMICAL
",",975,O
altering,975,O
the,975,O
ratio,975,O
of,975,O
ceramides,975,B-CHEMICAL
to,975,O
free,975,O
fatty,975,B-CHEMICAL
acids,975,I-CHEMICAL
.,975,O
TCDD,976,B-CHEMICAL
decreased,976,O
the,976,O
expression,976,O
of,976,O
the,976,O
glucose,976,B-GENE-N
transporter,976,I-GENE-N
",",976,O
SLC2A1,976,B-GENE-Y
",",976,O
and,976,O
most,976,O
of,976,O
the,976,O
glycolytic,976,O
transcripts,976,O
",",976,O
followed,976,O
by,976,O
decreases,976,O
in,976,O
glycolytic,976,O
intermediates,976,O
",",976,O
including,976,O
pyruvate,976,B-CHEMICAL
.,976,O
NADH,977,B-CHEMICAL
and,977,O
Krebs,977,O
cycle,977,O
intermediates,977,O
were,977,O
decreased,977,O
",",977,O
whereas,977,O
NAD,977,B-CHEMICAL
(,977,I-CHEMICAL
+,977,I-CHEMICAL
),977,I-CHEMICAL
was,977,O
increased,977,O
.,977,O
Mitochondrial,978,O
glutathione,978,B-GENE-N
(,978,I-GENE-N
GSH,978,I-GENE-N
),978,I-GENE-N
reductase,978,I-GENE-N
activity,978,O
and,978,O
the,978,O
GSH/glutathione,978,B-CHEMICAL
disulfide,978,I-CHEMICAL
ratio,978,O
were,978,O
decreased,978,O
by,978,O
TCDD,978,B-CHEMICAL
",",978,O
ultimately,978,O
leading,978,O
to,978,O
mitochondrial,978,O
dysfunction,978,O
",",978,O
characterized,978,O
by,978,O
decreased,978,O
inner,978,O
mitochondrial,978,O
membrane,978,O
potential,978,O
and,978,O
ATP,978,B-CHEMICAL
production,978,O
",",978,O
and,978,O
increased,978,O
production,978,O
of,978,O
the,978,O
reactive,978,O
oxygen,978,B-CHEMICAL
species,978,O
(,978,O
ROS,978,O
),978,O
",",978,O
hydrogen,978,B-CHEMICAL
peroxide,978,I-CHEMICAL
.,978,O
Aryl,979,B-GENE-Y
hydrocarbon,979,I-GENE-Y
receptor,979,I-GENE-Y
(,979,O
AHR,979,B-GENE-Y
),979,O
antagonists,979,O
blocked,979,O
the,979,O
response,979,O
of,979,O
many,979,O
transcripts,979,O
to,979,O
TCDD,979,B-CHEMICAL
",",979,O
and,979,O
the,979,O
endpoints,979,O
of,979,O
decreased,979,O
ATP,979,B-CHEMICAL
production,979,O
and,979,O
differentiation,979,O
",",979,O
suggesting,979,O
regulation,979,O
by,979,O
the,979,O
AHR,979,B-GENE-Y
.,979,O
Cotreatment,980,O
of,980,O
cells,980,O
with,980,O
chemical,980,O
antioxidants,980,O
or,980,O
the,980,O
enzyme,980,O
catalase,980,B-GENE-Y
blocked,980,O
the,980,O
TCDD-mediated,980,B-CHEMICAL
acceleration,980,O
of,980,O
keratinocyte,980,O
cornified,980,O
envelope,980,O
formation,980,O
",",980,O
an,980,O
endpoint,980,O
of,980,O
terminal,980,O
differentiation,980,O
.,980,O
Thus,981,O
",",981,O
TCDD-mediated,981,B-CHEMICAL
ROS,981,O
production,981,O
is,981,O
a,981,O
critical,981,O
step,981,O
in,981,O
the,981,O
mechanism,981,O
of,981,O
this,981,O
chemical,981,O
to,981,O
accelerate,981,O
keratinocyte,981,O
differentiation,981,O
.,981,O
ATP-binding,982,B-GENE-Y
cassette,982,I-GENE-Y
transporter,982,I-GENE-Y
A1,982,I-GENE-Y
is,982,O
involved,982,O
in,982,O
hepatic,982,O
alpha-tocopherol,982,B-CHEMICAL
secretion,982,O
.,982,O
Vitamin,983,B-CHEMICAL
E,983,I-CHEMICAL
(,983,O
alpha-tocopherol,983,B-CHEMICAL
),983,O
is,983,O
an,983,O
essential,983,O
fat-soluble,983,O
nutrient,983,O
with,983,O
antioxidant,983,O
properties,983,O
.,983,O
alpha-Tocopherol,984,B-GENE-Y
transfer,984,I-GENE-Y
protein,984,I-GENE-Y
(,984,O
alpha-TTP,984,B-GENE-Y
),984,O
",",984,O
the,984,O
product,984,O
of,984,O
the,984,O
gene,984,O
responsible,984,O
for,984,O
familial,984,O
isolated,984,O
vitamin,984,B-CHEMICAL
E,984,I-CHEMICAL
deficiency,984,O
",",984,O
plays,984,O
an,984,O
important,984,O
role,984,O
in,984,O
maintaining,984,O
the,984,O
plasma,984,O
alpha-tocopherol,984,B-CHEMICAL
level,984,O
by,984,O
mediating,984,O
the,984,O
secretion,984,O
of,984,O
alpha-tocopherol,984,B-CHEMICAL
by,984,O
the,984,O
liver,984,O
.,984,O
However,985,O
",",985,O
the,985,O
mechanisms,985,O
underlying,985,O
hepatic,985,O
alpha-tocopherol,985,B-CHEMICAL
secretion,985,O
are,985,O
not,985,O
fully,985,O
understood,985,O
.,985,O
This,986,O
study,986,O
was,986,O
undertaken,986,O
to,986,O
elucidate,986,O
the,986,O
mechanism,986,O
of,986,O
alpha-tocopherol,986,B-CHEMICAL
re-efflux,986,O
from,986,O
hepatocytes,986,O
",",986,O
the,986,O
cells,986,O
that,986,O
have,986,O
the,986,O
most,986,O
important,986,O
role,986,O
in,986,O
regulating,986,O
plasma-alpha-tocopherol,986,O
concentrations,986,O
.,986,O
From,987,O
in,987,O
vitro,987,O
experiments,987,O
using,987,O
[,987,B-CHEMICAL
(,987,I-CHEMICAL
3,987,I-CHEMICAL
),987,I-CHEMICAL
H,987,I-CHEMICAL
],987,I-CHEMICAL
alpha-tocopheryl,987,I-CHEMICAL
acetate,987,I-CHEMICAL
and,987,O
McARH7777,987,O
cells,987,O
that,987,O
stably,987,O
express,987,O
alpha-tocopherol,987,B-GENE-Y
transfer,987,I-GENE-Y
protein,987,I-GENE-Y
(,987,O
alpha-TTP,987,B-GENE-Y
),987,O
",",987,O
the,987,O
following,987,O
results,987,O
were,987,O
obtained,987,O
.,987,O
First,988,O
",",988,O
addition,988,O
of,988,O
apolipoprotein,988,B-GENE-Y
A-I,988,I-GENE-Y
(,988,O
apoA-I,988,B-GENE-Y
),988,O
",",988,O
a,988,O
direct,988,O
acceptor,988,O
of,988,O
the,988,O
ATP-binding,988,B-GENE-Y
cassette,988,I-GENE-Y
transporter,988,I-GENE-Y
A1,988,I-GENE-Y
(,988,O
ABCA1,988,B-GENE-Y
),988,O
-secreted,988,O
lipids,988,O
",",988,O
increased,988,O
alpha-tocopherol,988,B-CHEMICAL
secretion,988,O
in,988,O
a,988,O
dose-dependent,988,O
manner,988,O
.,988,O
Second,989,O
",",989,O
probucol,989,B-CHEMICAL
",",989,O
an,989,O
antiatherogenic,989,O
compound,989,O
reported,989,O
to,989,O
be,989,O
an,989,O
inactivator,989,O
of,989,O
ABCA1,989,B-GENE-Y
reduced,989,O
hepatic,989,O
alpha-tocopherol,989,B-CHEMICAL
secretion,989,O
.,989,O
Third,990,O
",",990,O
ABCA1-RNAi,990,B-GENE-Y
suppressed,990,O
hepatic,990,O
alpha-tocopherol,990,B-CHEMICAL
secretion,990,O
.,990,O
In,991,O
a,991,O
mouse,991,O
in,991,O
vivo,991,O
experiment,991,O
",",991,O
addition,991,O
of,991,O
1,991,O
%,991,O
probucol,991,B-CHEMICAL
to,991,O
the,991,O
diet,991,O
decreased,991,O
plasma,991,O
alpha-tocopherol,991,B-CHEMICAL
concentrations,991,O
.,991,O
These,992,O
results,992,O
strongly,992,O
suggest,992,O
that,992,O
ABCA1,992,B-GENE-Y
is,992,O
substantially,992,O
involved,992,O
in,992,O
hepatic,992,O
alpha-tocopherol,992,B-CHEMICAL
secretion,992,O
.,992,O
Crystal,993,O
structures,993,O
of,993,O
protein,993,B-GENE-N
phosphatase-1,993,I-GENE-N
bound,993,O
to,993,O
motuporin,993,B-CHEMICAL
and,993,O
dihydromicrocystin-LA,993,B-CHEMICAL
:,993,O
elucidation,993,O
of,993,O
the,993,O
mechanism,993,O
of,993,O
enzyme,993,O
inhibition,993,O
by,993,O
cyanobacterial,993,O
toxins,993,O
.,993,O
The,994,O
microcystins,994,B-CHEMICAL
and,994,O
nodularins,994,B-CHEMICAL
are,994,O
tumour,994,O
promoting,994,O
hepatotoxins,994,O
that,994,O
are,994,O
responsible,994,O
for,994,O
global,994,O
adverse,994,O
human,994,O
health,994,O
effects,994,O
and,994,O
wildlife,994,O
fatalities,994,O
in,994,O
countries,994,O
where,994,O
drinking,994,O
water,994,O
supplies,994,O
contain,994,O
cyanobacteria,994,O
.,994,O
The,995,O
toxins,995,O
function,995,O
by,995,O
inhibiting,995,O
broad,995,O
specificity,995,O
Ser/Thr,995,B-GENE-N
protein,995,I-GENE-N
phosphatases,995,I-GENE-N
in,995,O
the,995,O
host,995,O
cells,995,O
",",995,O
thereby,995,O
disrupting,995,O
signal,995,O
transduction,995,O
pathways,995,O
.,995,O
A,996,O
previous,996,O
crystal,996,O
structure,996,O
of,996,O
a,996,O
microcystin,996,B-CHEMICAL
bound,996,O
to,996,O
the,996,O
catalytic,996,O
subunit,996,O
of,996,O
protein,996,B-GENE-N
phosphatase-1,996,I-GENE-N
(,996,O
PP-1c,996,B-GENE-N
),996,O
showed,996,O
distinct,996,O
changes,996,O
in,996,O
the,996,O
active,996,O
site,996,O
region,996,O
when,996,O
compared,996,O
with,996,O
protein,996,B-GENE-N
phosphatase-1,996,I-GENE-N
structures,996,O
bound,996,O
to,996,O
other,996,O
toxins,996,O
.,996,O
We,997,O
have,997,O
elucidated,997,O
the,997,O
crystal,997,O
structures,997,O
of,997,O
the,997,O
cyanotoxins,997,B-GENE-N
",",997,O
motuporin,997,B-CHEMICAL
(,997,O
nodularin-V,997,B-CHEMICAL
),997,O
and,997,O
dihydromicrocystin-LA,997,B-CHEMICAL
bound,997,O
to,997,O
human,997,B-GENE-Y
protein,997,I-GENE-Y
phosphatase-1c,997,I-GENE-Y
(,997,I-GENE-Y
gamma,997,I-GENE-Y
isoform,997,I-GENE-Y
),997,I-GENE-Y
.,997,O
The,998,O
atomic,998,O
structures,998,O
of,998,O
these,998,O
complexes,998,O
reveal,998,O
the,998,O
structural,998,O
basis,998,O
for,998,O
inhibition,998,O
of,998,O
protein,998,B-GENE-N
phosphatases,998,I-GENE-N
by,998,O
these,998,O
toxins,998,O
.,998,O
Comparisons,999,O
of,999,O
the,999,O
structures,999,O
of,999,O
the,999,O
cyanobacterial,999,B-GENE-N
toxin,999,I-GENE-N
:,999,O
phosphatase,999,B-GENE-N
complexes,999,O
explain,999,O
the,999,O
biochemical,999,O
mechanism,999,O
by,999,O
which,999,O
microcystins,999,B-CHEMICAL
but,999,O
not,999,O
nodularins,999,B-CHEMICAL
permanently,999,O
modify,999,O
their,999,O
protein,999,B-GENE-N
phosphatase,999,I-GENE-N
targets,999,O
by,999,O
covalent,999,O
addition,999,O
to,999,O
an,999,O
active,999,O
site,999,O
cysteine,999,B-CHEMICAL
residue,999,O
.,999,O
A,1000,O
cocaine-sensitive,1000,B-CHEMICAL
Drosophila,1000,B-GENE-Y
serotonin,1000,I-GENE-Y
transporter,1000,I-GENE-Y
:,1000,O
cloning,1000,O
",",1000,O
expression,1000,O
",",1000,O
and,1000,O
electrophysiological,1000,O
characterization,1000,O
.,1000,O
A,1001,O
cocaine-sensitive,1001,B-CHEMICAL
",",1001,O
high-affinity,1001,O
Drosophila,1001,B-GENE-Y
serotonin,1001,I-GENE-Y
(,1001,I-GENE-Y
5-hydroxytryptamine,1001,I-GENE-Y
;,1001,I-GENE-Y
5HT,1001,I-GENE-Y
),1001,I-GENE-Y
transporter,1001,I-GENE-Y
cDNA,1001,O
",",1001,O
denoted,1001,O
dSERT1,1001,B-GENE-Y
",",1001,O
was,1001,O
isolated,1001,O
and,1001,O
characterized,1001,O
in,1001,O
oocytes,1001,O
.,1001,O
dSERT1,1002,B-GENE-Y
shows,1002,O
little,1002,O
transport,1002,O
of,1002,O
other,1002,O
monoamines,1002,B-CHEMICAL
and,1002,O
is,1002,O
Na+,1002,B-CHEMICAL
and,1002,O
Cl-,1002,B-CHEMICAL
dependent,1002,O
.,1002,O
Sequence,1003,O
analysis,1003,O
indicates,1003,O
12,1003,O
putative,1003,O
transmembrane,1003,O
domains,1003,O
and,1003,O
strong,1003,O
homologies,1003,O
(,1003,O
approximately,1003,O
50,1003,O
%,1003,O
),1003,O
among,1003,O
dSERT1,1003,B-GENE-Y
and,1003,O
mammalian,1003,B-GENE-N
5HT,1003,I-GENE-N
",",1003,I-GENE-N
norepinephrine,1003,I-GENE-N
",",1003,I-GENE-N
and,1003,I-GENE-N
dopamine,1003,I-GENE-N
transporters,1003,I-GENE-N
.,1003,O
Interestingly,1004,O
",",1004,O
the,1004,O
pharmacological,1004,O
properties,1004,O
of,1004,O
dSERT1,1004,B-GENE-Y
",",1004,O
including,1004,O
sensitivity,1004,O
to,1004,O
antidepressants,1004,O
",",1004,O
are,1004,O
more,1004,O
similar,1004,O
to,1004,O
those,1004,O
of,1004,O
mammalian,1004,B-GENE-N
catecholamine,1004,I-GENE-N
transporters,1004,I-GENE-N
than,1004,O
to,1004,O
mammalian,1004,B-GENE-N
5HT,1004,I-GENE-N
transporters,1004,I-GENE-N
.,1004,O
Two-electrode,1005,O
voltage-clamp,1005,O
analysis,1005,O
demonstrated,1005,O
5HT-induced,1005,B-CHEMICAL
",",1005,O
voltage-dependent,1005,O
currents,1005,O
.,1005,O
Cloning,1006,O
and,1006,O
characterization,1006,O
of,1006,O
dSERT1,1006,B-GENE-Y
adds,1006,O
significantly,1006,O
to,1006,O
our,1006,O
knowledge,1006,O
of,1006,O
the,1006,O
diversity,1006,O
of,1006,O
5HT,1006,B-GENE-Y
transporters,1006,I-GENE-Y
with,1006,O
regard,1006,O
to,1006,O
primary,1006,O
sequence,1006,O
",",1006,O
pharmacological,1006,O
profile,1006,O
",",1006,O
and,1006,O
permeation,1006,O
properties,1006,O
.,1006,O
Formation,1007,O
of,1007,O
mainstream,1007,O
cigarette,1007,O
smoke,1007,O
constituents,1007,O
prioritized,1007,O
by,1007,O
the,1007,O
World,1007,O
Health,1007,O
Organization,1007,O
--,1007,O
yield,1007,O
patterns,1007,O
observed,1007,O
in,1007,O
market,1007,O
surveys,1007,O
",",1007,O
clustering,1007,O
and,1007,O
inverse,1007,O
correlations,1007,O
.,1007,O
The,1008,O
WHO,1008,O
TobReg,1008,O
proposed,1008,O
mandating,1008,O
ceilings,1008,O
on,1008,O
selected,1008,O
smoke,1008,O
constituents,1008,O
determined,1008,O
from,1008,O
the,1008,O
market-specific,1008,O
median,1008,O
of,1008,O
nicotine-normalized,1008,B-CHEMICAL
yield,1008,O
distributions,1008,O
.,1008,O
Data,1009,O
validating,1009,O
this,1009,O
regulatory,1009,O
concept,1009,O
were,1009,O
obtained,1009,O
from,1009,O
essentially,1009,O
single-blend,1009,O
surveys,1009,O
.,1009,O
This,1010,O
process,1010,O
is,1010,O
strongly,1010,O
impacted,1010,O
by,1010,O
inverse,1010,O
correlations,1010,O
among,1010,O
yields,1010,O
.,1010,O
In,1011,O
the,1011,O
present,1011,O
study,1011,O
",",1011,O
18,1011,O
priority,1011,O
WHO,1011,O
smoke,1011,O
constituent,1011,O
yields,1011,O
(,1011,O
nicotine-normalized,1011,B-CHEMICAL
),1011,O
were,1011,O
determined,1011,O
(,1011,O
using,1011,O
two,1011,O
smoking,1011,O
regimens,1011,O
),1011,O
from,1011,O
262,1011,O
commercial,1011,O
brands,1011,O
including,1011,O
American,1011,O
",",1011,O
Virginia,1011,O
and,1011,O
local,1011,O
blends,1011,O
from,1011,O
13,1011,O
countries,1011,O
.,1011,O
Principal,1012,O
Component,1012,O
Analysis,1012,O
was,1012,O
used,1012,O
to,1012,O
identify,1012,O
yields,1012,O
patterns,1012,O
",",1012,O
clustering,1012,O
of,1012,O
blend,1012,O
types,1012,O
and,1012,O
the,1012,O
inverse,1012,O
correlations,1012,O
causing,1012,O
these,1012,O
clusters,1012,O
.,1012,O
Three,1013,O
principal,1013,O
components,1013,O
explain,1013,O
about,1013,O
75,1013,O
%,1013,O
of,1013,O
total,1013,O
data,1013,O
variability,1013,O
.,1013,O
PC1,1014,O
was,1014,O
sensitive,1014,O
to,1014,O
the,1014,O
relative,1014,O
levels,1014,O
of,1014,O
gas-,1014,O
and,1014,O
particle-phase,1014,O
compounds,1014,O
.,1014,O
PC2,1015,O
and,1015,O
PC3,1015,O
cluster,1015,O
American-,1015,O
and,1015,O
Virginia-blends,1015,O
",",1015,O
revealing,1015,O
inverse,1015,O
correlations,1015,O
:,1015,O
Nitrogen,1015,B-CHEMICAL
oxides,1015,I-CHEMICAL
and,1015,O
amino-,1015,B-CHEMICAL
or,1015,O
nitroso-aromatic,1015,B-CHEMICAL
compounds,1015,O
inversely,1015,O
correlate,1015,O
to,1015,O
either,1015,O
formaldehyde,1015,B-CHEMICAL
and,1015,O
acrolein,1015,B-CHEMICAL
",",1015,O
or,1015,O
benzo,1015,B-CHEMICAL
(,1015,I-CHEMICAL
a,1015,I-CHEMICAL
),1015,I-CHEMICAL
pyrene,1015,I-CHEMICAL
and,1015,O
di-hydroxybenzenes,1015,B-CHEMICAL
.,1015,O
These,1016,O
results,1016,O
can,1016,O
be,1016,O
explained,1016,O
by,1016,O
reviewing,1016,O
the,1016,O
processes,1016,O
determining,1016,O
each,1016,O
components,1016,O
smoke,1016,O
delivery,1016,O
.,1016,O
Regulatory,1017,O
initiatives,1017,O
simultaneously,1017,O
targeting,1017,O
selected,1017,O
smoke,1017,O
constituents,1017,O
in,1017,O
markets,1017,O
with,1017,O
mixed,1017,O
blend,1017,O
styles,1017,O
will,1017,O
be,1017,O
strongly,1017,O
impacted,1017,O
by,1017,O
the,1017,O
inverse,1017,O
correlations,1017,O
described,1017,O
.,1017,O
It,1018,O
is,1018,O
difficult,1018,O
to,1018,O
predict,1018,O
the,1018,O
ultimate,1018,O
impact,1018,O
of,1018,O
such,1018,O
regulations,1018,O
on,1018,O
public,1018,O
health,1018,O
",",1018,O
considering,1018,O
the,1018,O
complex,1018,O
chemistry,1018,O
of,1018,O
cigarette,1018,O
smoke,1018,O
formation,1018,O
.,1018,O
Atypical,1019,O
neuroleptics,1019,O
have,1019,O
low,1019,O
affinity,1019,O
for,1019,O
dopamine,1019,B-GENE-Y
D2,1019,I-GENE-Y
receptors,1019,I-GENE-Y
or,1019,O
are,1019,O
selective,1019,O
for,1019,O
D4,1019,B-GENE-Y
receptors,1019,I-GENE-Y
.,1019,O
This,1020,O
review,1020,O
examines,1020,O
the,1020,O
possible,1020,O
receptor,1020,O
basis,1020,O
of,1020,O
the,1020,O
atypical,1020,O
action,1020,O
of,1020,O
those,1020,O
atypical,1020,O
antipsychotic,1020,O
drugs,1020,O
that,1020,O
elicit,1020,O
low,1020,O
levels,1020,O
of,1020,O
Parkinsonism,1020,O
.,1020,O
Such,1021,O
an,1021,O
examination,1021,O
requires,1021,O
consistent,1021,O
and,1021,O
accurate,1021,O
dissociation,1021,O
constants,1021,O
for,1021,O
the,1021,O
antipsychotic,1021,O
drugs,1021,O
at,1021,O
the,1021,O
relevant,1021,O
dopamine,1021,B-GENE-N
and,1021,I-GENE-N
serotonin,1021,I-GENE-N
receptors,1021,I-GENE-N
.,1021,O
It,1022,O
has,1022,O
long,1022,O
been,1022,O
known,1022,O
",",1022,O
however,1022,O
",",1022,O
that,1022,O
the,1022,O
dissociation,1022,O
constant,1022,O
of,1022,O
a,1022,O
given,1022,O
antipsychotic,1022,O
drug,1022,O
at,1022,O
the,1022,O
dopamine,1022,B-GENE-Y
D2,1022,I-GENE-Y
receptor,1022,I-GENE-Y
varies,1022,O
between,1022,O
laboratories,1022,O
.,1022,O
Although,1023,O
such,1023,O
variation,1023,O
depends,1023,O
on,1023,O
several,1023,O
factors,1023,O
",",1023,O
it,1023,O
has,1023,O
recently,1023,O
been,1023,O
recognized,1023,O
that,1023,O
the,1023,O
radioligand,1023,O
used,1023,O
to,1023,O
measure,1023,O
the,1023,O
competition,1023,O
between,1023,O
the,1023,O
antipsychotic,1023,O
drug,1023,O
and,1023,O
the,1023,O
radioligand,1023,O
is,1023,O
an,1023,O
important,1023,O
variable,1023,O
.,1023,O
The,1024,O
present,1024,O
review,1024,O
summarizes,1024,O
information,1024,O
on,1024,O
this,1024,O
radioligand,1024,O
dependence,1024,O
.,1024,O
In,1025,O
general,1025,O
",",1025,O
a,1025,O
radioligand,1025,O
of,1025,O
low,1025,O
solubility,1025,O
in,1025,O
the,1025,O
membrane,1025,O
(,1025,O
i.e.,1025,O
",",1025,O
low,1025,O
tissue,1025,O
:,1025,O
buffer,1025,O
partition,1025,O
),1025,O
results,1025,O
in,1025,O
a,1025,O
low,1025,O
value,1025,O
for,1025,O
the,1025,O
antipsychotic,1025,O
dissociation,1025,O
constant,1025,O
when,1025,O
the,1025,O
drug,1025,O
competes,1025,O
with,1025,O
the,1025,O
radioligand,1025,O
.,1025,O
Hence,1026,O
",",1026,O
by,1026,O
first,1026,O
obtaining,1026,O
the,1026,O
antipsychotic,1026,O
dissociation,1026,O
constants,1026,O
using,1026,O
different,1026,O
radioligands,1026,O
of,1026,O
different,1026,O
solubility,1026,O
in,1026,O
the,1026,O
membrane,1026,O
",",1026,O
one,1026,O
can,1026,O
then,1026,O
extrapolate,1026,O
the,1026,O
data,1026,O
to,1026,O
low,1026,O
or,1026,O
``,1026,O
zero,1026,O
'',1026,O
ligand,1026,O
solubility,1026,O
.,1026,O
The,1027,O
extrapolated,1027,O
value,1027,O
represents,1027,O
the,1027,O
radioligand-independent,1027,O
dissociation,1027,O
constant,1027,O
of,1027,O
the,1027,O
antipsychotic,1027,O
.,1027,O
These,1028,O
values,1028,O
are,1028,O
here,1028,O
given,1028,O
for,1028,O
dopamine,1028,B-GENE-N
D2,1028,I-GENE-N
and,1028,I-GENE-N
D4,1028,I-GENE-N
receptors,1028,I-GENE-N
",",1028,O
as,1028,O
well,1028,O
as,1028,O
for,1028,O
serotonin,1028,B-GENE-Y
5-HT2A,1028,I-GENE-Y
receptors,1028,I-GENE-Y
.,1028,O
These,1029,O
values,1029,O
",",1029,O
moreover,1029,O
",",1029,O
agree,1029,O
with,1029,O
the,1029,O
dissociation,1029,O
constant,1029,O
directly,1029,O
obtained,1029,O
with,1029,O
the,1029,O
radioactive,1029,O
antipsychotic,1029,O
itself,1029,O
.,1029,O
For,1030,O
example,1030,O
",",1030,O
clozapine,1030,B-CHEMICAL
revealed,1030,O
a,1030,O
radioligand-independent,1030,O
value,1030,O
of,1030,O
1.6,1030,O
nM,1030,O
at,1030,O
the,1030,O
dopamine,1030,B-GENE-Y
D4,1030,I-GENE-Y
receptor,1030,I-GENE-Y
",",1030,O
agreeing,1030,O
with,1030,O
the,1030,O
value,1030,O
directly,1030,O
measured,1030,O
with,1030,O
[,1030,B-CHEMICAL
3H,1030,I-CHEMICAL
],1030,I-CHEMICAL
-clozapine,1030,I-CHEMICAL
at,1030,O
D4,1030,B-GENE-Y
.,1030,O
However,1031,O
",",1031,O
because,1031,O
clozapine,1031,B-CHEMICAL
competes,1031,O
with,1031,O
endogenous,1031,O
dopamine,1031,B-CHEMICAL
",",1031,O
the,1031,O
in,1031,O
vivo,1031,O
concentration,1031,O
of,1031,O
clozapine,1031,B-CHEMICAL
(,1031,O
to,1031,O
occupy,1031,O
dopamine,1031,B-GENE-Y
D4,1031,I-GENE-Y
receptors,1031,I-GENE-Y
),1031,O
can,1031,O
be,1031,O
derived,1031,O
to,1031,O
be,1031,O
about,1031,O
13,1031,O
nM,1031,O
",",1031,O
agreeing,1031,O
with,1031,O
the,1031,O
value,1031,O
of,1031,O
12,1031,O
to,1031,O
20,1031,O
nM,1031,O
in,1031,O
the,1031,O
plasma,1031,O
water,1031,O
or,1031,O
spinal,1031,O
fluid,1031,O
observed,1031,O
in,1031,O
treated,1031,O
patients,1031,O
.,1031,O
The,1032,O
atypical,1032,O
neuroleptics,1032,O
remoxipride,1032,B-CHEMICAL
",",1032,O
clozapine,1032,B-CHEMICAL
",",1032,O
perlapine,1032,B-CHEMICAL
",",1032,O
seroquel,1032,B-CHEMICAL
",",1032,O
and,1032,O
melperone,1032,B-CHEMICAL
had,1032,O
low,1032,O
affinity,1032,O
for,1032,O
the,1032,O
dopamine,1032,B-CHEMICAL
D2,1032,B-GENE-Y
receptor,1032,I-GENE-Y
(,1032,O
radioligand-independent,1032,O
dissociation,1032,O
constants,1032,O
of,1032,O
30,1032,O
to,1032,O
90,1032,O
nM,1032,O
),1032,O
.,1032,O
Such,1033,O
low,1033,O
affinity,1033,O
makes,1033,O
these,1033,O
latter,1033,O
five,1033,O
drugs,1033,O
readily,1033,O
displaceable,1033,O
by,1033,O
high,1033,O
levels,1033,O
of,1033,O
endogenous,1033,O
dopamine,1033,B-CHEMICAL
in,1033,O
the,1033,O
caudate,1033,O
or,1033,O
putamen,1033,O
.,1033,O
Most,1034,O
typical,1034,O
neuroleptics,1034,O
have,1034,O
radioligand-independent,1034,O
values,1034,O
of,1034,O
0.3,1034,O
to,1034,O
5,1034,O
nM,1034,O
at,1034,O
dopamine,1034,B-GENE-Y
D2,1034,I-GENE-Y
receptors,1034,I-GENE-Y
",",1034,O
making,1034,O
them,1034,O
more,1034,O
resistant,1034,O
to,1034,O
displacement,1034,O
by,1034,O
endogenous,1034,O
dopamine,1034,B-CHEMICAL
.,1034,O
Finally,1035,O
",",1035,O
a,1035,O
relation,1035,O
was,1035,O
found,1035,O
between,1035,O
the,1035,O
neuroleptic,1035,O
doses,1035,O
for,1035,O
rat,1035,O
catalepsy,1035,O
and,1035,O
the,1035,O
D2,1035,B-GENE-Y
:,1035,O
D4,1035,B-GENE-Y
ratio,1035,O
of,1035,O
the,1035,O
radioligand-independent,1035,O
K,1035,O
values,1035,O
for,1035,O
these,1035,O
two,1035,O
receptors,1035,O
.,1035,O
Thus,1036,O
",",1036,O
the,1036,O
atypical,1036,O
neuroleptics,1036,O
appear,1036,O
to,1036,O
fall,1036,O
into,1036,O
two,1036,O
groups,1036,O
",",1036,O
those,1036,O
that,1036,O
have,1036,O
a,1036,O
low,1036,O
affinity,1036,O
for,1036,O
dopamine,1036,B-GENE-Y
D2,1036,I-GENE-Y
receptors,1036,I-GENE-Y
and,1036,O
those,1036,O
that,1036,O
are,1036,O
selective,1036,O
for,1036,O
dopamine,1036,B-GENE-Y
D4,1036,I-GENE-Y
receptors,1036,I-GENE-Y
.,1036,O
alpha7,1037,B-GENE-N
nicotinic,1037,I-GENE-N
receptor,1037,I-GENE-N
gene,1037,I-GENE-N
promoter,1037,I-GENE-N
polymorphisms,1037,O
in,1037,O
inbred,1037,O
mice,1037,O
affect,1037,O
expression,1037,O
in,1037,O
a,1037,O
cell,1037,O
type-specific,1037,O
fashion,1037,O
.,1037,O
Inbred,1038,O
mouse,1038,O
strains,1038,O
display,1038,O
significant,1038,O
differences,1038,O
in,1038,O
their,1038,O
levels,1038,O
of,1038,O
brain,1038,O
alpha7,1038,B-GENE-Y
nicotinic,1038,I-GENE-Y
acetylcholine,1038,I-GENE-Y
receptor,1038,I-GENE-Y
(,1038,O
alpha7,1038,B-GENE-Y
nAChR,1038,I-GENE-Y
),1038,O
expression,1038,O
",",1038,O
as,1038,O
measured,1038,O
by,1038,O
binding,1038,O
of,1038,O
the,1038,O
alpha7-selective,1038,O
antagonist,1038,O
alpha-bungarotoxin,1038,O
.,1038,O
Variations,1039,O
in,1039,O
alpha-bungarotoxin,1039,B-GENE-Y
binding,1039,O
have,1039,O
been,1039,O
shown,1039,O
to,1039,O
correlate,1039,O
with,1039,O
an,1039,O
animal,1039,O
's,1039,O
sensitivity,1039,O
to,1039,O
nicotine-induced,1039,B-CHEMICAL
seizures,1039,O
and,1039,O
sensory,1039,O
gating,1039,O
.,1039,O
In,1040,O
two,1040,O
inbred,1040,O
mouse,1040,O
strains,1040,O
",",1040,O
C3H/2Ibg,1040,O
(,1040,O
C3H,1040,O
),1040,O
and,1040,O
DBA/2Ibg,1040,O
(,1040,O
DBA/2,1040,O
),1040,O
",",1040,O
the,1040,O
inter-strain,1040,O
binding,1040,O
differences,1040,O
are,1040,O
linked,1040,O
to,1040,O
a,1040,O
restriction,1040,O
length,1040,O
polymorphism,1040,O
in,1040,O
the,1040,O
alpha7,1040,B-GENE-Y
nAChR,1040,I-GENE-Y
gene,1040,O
",",1040,O
Chrna7,1040,B-GENE-Y
.,1040,O
Despite,1041,O
this,1041,O
finding,1041,O
",",1041,O
the,1041,O
molecular,1041,O
mechanism,1041,O
(,1041,O
s,1041,O
),1041,O
through,1041,O
which,1041,O
genetic,1041,O
variability,1041,O
in,1041,O
Chrna7,1041,B-GENE-Y
may,1041,O
contribute,1041,O
to,1041,O
alpha7,1041,B-GENE-Y
nAChR,1041,I-GENE-Y
expression,1041,O
differences,1041,O
remains,1041,O
unknown,1041,O
.,1041,O
However,1042,O
",",1042,O
studies,1042,O
of,1042,O
the,1042,O
human,1042,B-GENE-Y
alpha7,1042,I-GENE-Y
nAChR,1042,I-GENE-Y
gene,1042,O
(,1042,O
CHRNA7,1042,B-GENE-Y
),1042,O
previously,1042,O
have,1042,O
demonstrated,1042,O
that,1042,O
CHRNA7,1042,B-GENE-N
promoter,1042,I-GENE-N
polymorphisms,1042,O
are,1042,O
associated,1042,O
with,1042,O
differences,1042,O
in,1042,O
promoter,1042,O
activity,1042,O
as,1042,O
well,1042,O
as,1042,O
differences,1042,O
in,1042,O
sensory,1042,O
processing,1042,O
.,1042,O
In,1043,O
the,1043,O
present,1043,O
study,1043,O
",",1043,O
a,1043,O
947-base,1043,O
pair,1043,O
region,1043,O
of,1043,O
the,1043,O
Chrna7,1043,B-GENE-N
promoter,1043,I-GENE-N
was,1043,O
cloned,1043,O
from,1043,O
both,1043,O
the,1043,O
C3H,1043,O
and,1043,O
DBA/2,1043,O
inbred,1043,O
mouse,1043,O
strains,1043,O
in,1043,O
an,1043,O
attempt,1043,O
to,1043,O
identify,1043,O
polymorphisms,1043,O
that,1043,O
may,1043,O
underlie,1043,O
alpha7,1043,B-GENE-Y
nAChR,1043,I-GENE-Y
differential,1043,O
expression,1043,O
.,1043,O
Sequence,1044,O
analysis,1044,O
of,1044,O
these,1044,O
fragments,1044,O
identified,1044,O
14,1044,O
single,1044,O
nucleotide,1044,B-CHEMICAL
polymorphisms,1044,O
(,1044,O
SNPs,1044,O
),1044,O
.,1044,O
A,1045,O
combination,1045,O
of,1045,O
two,1045,O
of,1045,O
these,1045,O
SNPs,1045,O
affects,1045,O
promoter,1045,O
activity,1045,O
in,1045,O
an,1045,O
in,1045,O
vitro,1045,O
luciferase,1045,O
reporter,1045,O
assay,1045,O
.,1045,O
These,1046,O
results,1046,O
suggest,1046,O
a,1046,O
mechanism,1046,O
through,1046,O
which,1046,O
the,1046,O
Chrna7,1046,B-GENE-N
promoter,1046,I-GENE-N
genotype,1046,O
may,1046,O
influence,1046,O
interstrain,1046,O
variations,1046,O
in,1046,O
alpha7,1046,B-GENE-Y
nAChR,1046,I-GENE-Y
expression,1046,O
.,1046,O
Synthesis,1047,O
and,1047,O
in,1047,O
vitro,1047,O
pharmacology,1047,O
at,1047,O
AMPA,1047,B-CHEMICAL
and,1047,O
kainate,1047,B-CHEMICAL
preferring,1047,O
glutamate,1047,B-GENE-N
receptors,1047,I-GENE-N
of,1047,O
4-heteroarylmethylidene,1047,B-CHEMICAL
glutamate,1047,I-CHEMICAL
analogues,1047,O
.,1047,O
2-Amino-3-,1048,B-CHEMICAL
[,1048,I-CHEMICAL
3-hydroxy-5-,1048,I-CHEMICAL
(,1048,I-CHEMICAL
2-thiazolyl,1048,I-CHEMICAL
),1048,I-CHEMICAL
-4-isoxazolyl,1048,I-CHEMICAL
],1048,I-CHEMICAL
propionic,1048,I-CHEMICAL
acid,1048,I-CHEMICAL
(,1048,O
1,1048,O
),1048,O
is,1048,O
a,1048,O
potent,1048,O
AMPA,1048,B-GENE-N
receptor,1048,I-GENE-N
agonist,1048,O
with,1048,O
moderate,1048,O
affinity,1048,O
for,1048,O
native,1048,O
kainic,1048,B-GENE-N
acid,1048,I-GENE-N
(,1048,I-GENE-N
KA,1048,I-GENE-N
),1048,I-GENE-N
receptors,1048,I-GENE-N
",",1048,O
whereas,1048,O
(,1048,B-CHEMICAL
S,1048,I-CHEMICAL
),1048,I-CHEMICAL
-E-4-,1048,I-CHEMICAL
(,1048,I-CHEMICAL
"2,2-dimethylpropylidene",1048,I-CHEMICAL
),1048,I-CHEMICAL
glutamic,1048,I-CHEMICAL
acid,1048,I-CHEMICAL
(,1048,O
3,1048,O
),1048,O
show,1048,O
high,1048,O
affinity,1048,O
for,1048,O
the,1048,O
GluR5,1048,B-GENE-Y
subtype,1048,O
of,1048,O
KA,1048,B-GENE-N
receptors,1048,I-GENE-N
and,1048,O
much,1048,O
lower,1048,O
affinity,1048,O
for,1048,O
the,1048,O
GluR2,1048,B-GENE-Y
subtype,1048,O
of,1048,O
AMPA,1048,B-GENE-N
receptors,1048,I-GENE-N
.,1048,O
As,1049,O
an,1049,O
attempt,1049,O
to,1049,O
develop,1049,O
new,1049,O
pharmacological,1049,O
tools,1049,O
for,1049,O
studies,1049,O
of,1049,O
GluR5,1049,B-GENE-Y
receptors,1049,O
",",1049,O
(,1049,B-CHEMICAL
S,1049,I-CHEMICAL
),1049,I-CHEMICAL
-E-4-,1049,I-CHEMICAL
(,1049,I-CHEMICAL
2-thiazolylmethylene,1049,I-CHEMICAL
),1049,I-CHEMICAL
glutamic,1049,I-CHEMICAL
acid,1049,I-CHEMICAL
(,1049,O
4a,1049,O
),1049,O
was,1049,O
designed,1049,O
as,1049,O
a,1049,O
structural,1049,O
hybrid,1049,O
between,1049,O
1,1049,O
and,1049,O
3,1049,O
.,1049,O
4a,1050,O
was,1050,O
shown,1050,O
to,1050,O
be,1050,O
a,1050,O
potent,1050,O
GluR5,1050,B-GENE-Y
agonist,1050,O
and,1050,O
a,1050,O
high,1050,O
affinity,1050,O
ligand,1050,O
and,1050,O
to,1050,O
indiscriminately,1050,O
bind,1050,O
to,1050,O
the,1050,O
AMPA,1050,B-GENE-N
receptor,1050,I-GENE-N
subtypes,1050,O
GluR1-4,1050,B-GENE-N
with,1050,O
lower,1050,O
affinities,1050,O
.,1050,O
Compounds,1051,O
4b-h,1051,O
",",1051,O
in,1051,O
which,1051,O
the,1051,O
2-thiazolyl,1051,B-CHEMICAL
substituent,1051,O
of,1051,O
4a,1051,O
was,1051,O
replaced,1051,O
by,1051,O
other,1051,O
heterocyclic,1051,B-CHEMICAL
rings,1051,O
",",1051,O
which,1051,O
have,1051,O
previously,1051,O
been,1051,O
incorporated,1051,O
as,1051,O
5-substituents,1051,O
in,1051,O
AMPA,1051,B-CHEMICAL
analogues,1051,O
",",1051,O
as,1051,O
exemplified,1051,O
by,1051,O
1,1051,O
were,1051,O
also,1051,O
synthesized,1051,O
.,1051,O
Compounds,1052,O
4b-h,1052,O
were,1052,O
either,1052,O
inactive,1052,O
(,1052,O
4e,1052,O
",",1052,O
f,1052,O
),1052,O
or,1052,O
weaker,1052,O
than,1052,O
4a,1052,O
as,1052,O
affinity,1052,O
ligands,1052,O
for,1052,O
GluR1-4,1052,B-GENE-N
and,1052,O
GluR5,1052,B-GENE-Y
with,1052,O
relative,1052,O
potencies,1052,O
comparable,1052,O
with,1052,O
those,1052,O
of,1052,O
the,1052,O
corresponding,1052,O
AMPA,1052,B-CHEMICAL
analogues,1052,O
as,1052,O
AMPA,1052,B-GENE-N
receptor,1052,I-GENE-N
agonists,1052,O
.,1052,O
Compounds,1053,O
4a-h,1053,O
may,1053,O
be,1053,O
useful,1053,O
tools,1053,O
for,1053,O
the,1053,O
progressing,1053,O
pharmacophore,1053,O
mapping,1053,O
of,1053,O
the,1053,O
GluR5,1053,B-GENE-Y
agonist,1053,O
binding,1053,O
site,1053,O
.,1053,O
Pranlukast,1054,B-CHEMICAL
",",1054,O
a,1054,O
leukotriene,1054,B-GENE-N
receptor,1054,I-GENE-N
antagonist,1054,O
",",1054,O
inhibits,1054,O
interleukin-5,1054,B-GENE-Y
production,1054,O
via,1054,O
a,1054,O
mechanism,1054,O
distinct,1054,O
from,1054,O
leukotriene,1054,B-GENE-N
receptor,1054,I-GENE-N
antagonism,1054,O
.,1054,O
BACKGROUND,1055,O
:,1055,O
Pranlukast,1055,B-CHEMICAL
",",1055,O
a,1055,O
cysteinyl,1055,B-GENE-Y
leukotriene,1055,I-GENE-Y
receptor,1055,I-GENE-Y
1,1055,I-GENE-Y
(,1055,O
CysLTR1,1055,B-GENE-Y
),1055,O
antagonist,1055,O
",",1055,O
inhibits,1055,O
not,1055,O
only,1055,O
airway,1055,O
smooth,1055,O
muscle,1055,O
contraction,1055,O
",",1055,O
but,1055,O
also,1055,O
allergic,1055,O
inflammation,1055,O
.,1055,O
The,1056,O
aim,1056,O
of,1056,O
this,1056,O
study,1056,O
was,1056,O
to,1056,O
determine,1056,O
the,1056,O
mechanism,1056,O
of,1056,O
pranlukast-induced,1056,B-CHEMICAL
interleukin-5,1056,B-GENE-Y
(,1056,O
IL-5,1056,B-GENE-Y
),1056,O
inhibition,1056,O
in,1056,O
allergic,1056,O
inflammation,1056,O
.,1056,O
METHODS,1057,O
:,1057,O
Surgically,1057,O
resected,1057,O
human,1057,O
lung,1057,O
tissue,1057,O
was,1057,O
passively,1057,O
sensitized,1057,O
in,1057,O
vitro,1057,O
with,1057,O
mite-allergen-sensitized,1057,O
sera,1057,O
",",1057,O
followed,1057,O
by,1057,O
stimulation,1057,O
with,1057,O
mite,1057,O
allergen,1057,O
after,1057,O
pretreatment,1057,O
of,1057,O
the,1057,O
tissue,1057,O
with,1057,O
pranlukast,1057,B-CHEMICAL
",",1057,O
dexamethasone,1057,B-CHEMICAL
",",1057,O
or,1057,O
both,1057,O
.,1057,O
The,1058,O
IL-5,1058,B-GENE-Y
protein,1058,O
level,1058,O
in,1058,O
the,1058,O
culture,1058,O
medium,1058,O
was,1058,O
measured,1058,O
",",1058,O
and,1058,O
in,1058,O
situ,1058,O
hybridization,1058,O
of,1058,O
IL-5,1058,B-GENE-Y
and,1058,O
CysLTR1,1058,B-GENE-Y
mRNA,1058,O
was,1058,O
performed,1058,O
using,1058,O
lung,1058,O
tissues,1058,O
.,1058,O
RESULTS,1059,O
:,1059,O
Pretreatment,1059,O
of,1059,O
lung,1059,O
tissues,1059,O
with,1059,O
pranlukast,1059,B-CHEMICAL
alone,1059,O
significantly,1059,O
decreased,1059,O
the,1059,O
amount,1059,O
of,1059,O
IL-5,1059,B-GENE-Y
protein,1059,O
in,1059,O
the,1059,O
culture,1059,O
medium,1059,O
by,1059,O
40,1059,O
%,1059,O
.,1059,O
The,1060,O
combination,1060,O
of,1060,O
pranlukast,1060,B-CHEMICAL
and,1060,O
dexamethasone,1060,B-CHEMICAL
synergistically,1060,O
enhanced,1060,O
this,1060,O
effect,1060,O
.,1060,O
Quantitative,1061,O
in,1061,O
situ,1061,O
hybridization,1061,O
with,1061,O
image,1061,O
analysis,1061,O
revealed,1061,O
abundant,1061,O
expression,1061,O
of,1061,O
IL-5,1061,B-GENE-Y
mRNA,1061,O
in,1061,O
eosinophils,1061,O
",",1061,O
lymphocytes,1061,O
",",1061,O
and,1061,O
mast,1061,O
cells,1061,O
in,1061,O
sensitized,1061,O
and,1061,O
allergen-stimulated,1061,O
lung,1061,O
tissues,1061,O
.,1061,O
CysLTR1,1062,B-GENE-Y
mRNA,1062,O
was,1062,O
detected,1062,O
in,1062,O
macrophages,1062,O
",",1062,O
smooth,1062,O
muscle,1062,O
cells,1062,O
",",1062,O
eosinophils,1062,O
",",1062,O
and,1062,O
mast,1062,O
cells,1062,O
",",1062,O
but,1062,O
was,1062,O
less,1062,O
expressed,1062,O
in,1062,O
lymphocytes,1062,O
.,1062,O
Pranlukast-induced,1063,B-CHEMICAL
inhibition,1063,O
of,1063,O
IL-5,1063,B-GENE-Y
mRNA,1063,O
expression,1063,O
was,1063,O
noted,1063,O
in,1063,O
various,1063,O
cells,1063,O
",",1063,O
irrespective,1063,O
of,1063,O
their,1063,O
CysLTR1,1063,B-GENE-Y
mRNA,1063,O
expression,1063,O
status,1063,O
.,1063,O
In,1064,O
addition,1064,O
",",1064,O
cysteinyl,1064,B-CHEMICAL
leukotrienes,1064,I-CHEMICAL
per,1064,O
se,1064,O
failed,1064,O
to,1064,O
upregulate,1064,O
the,1064,O
IL-5,1064,B-GENE-Y
production,1064,O
.,1064,O
CONCLUSION,1065,O
:,1065,O
Our,1065,O
results,1065,O
indicate,1065,O
that,1065,O
pranlukast,1065,B-CHEMICAL
inhibits,1065,O
IL-5,1065,B-GENE-Y
synthesis,1065,O
via,1065,O
a,1065,O
mechanism,1065,O
distinct,1065,O
from,1065,O
CysLTR1,1065,B-GENE-Y
antagonism,1065,O
.,1065,O
The,1066,O
platelet,1066,B-GENE-N
P2,1066,I-GENE-N
receptors,1066,I-GENE-N
as,1066,O
molecular,1066,O
targets,1066,O
for,1066,O
old,1066,O
and,1066,O
new,1066,O
antiplatelet,1066,O
drugs,1066,O
.,1066,O
Platelet,1067,O
activation,1067,O
by,1067,O
ADP,1067,B-CHEMICAL
and,1067,O
ATP,1067,B-CHEMICAL
plays,1067,O
a,1067,O
crucial,1067,O
role,1067,O
in,1067,O
haemostasis,1067,O
and,1067,O
thrombosis,1067,O
",",1067,O
and,1067,O
their,1067,O
so-called,1067,O
P2,1067,B-GENE-N
receptors,1067,I-GENE-N
are,1067,O
potential,1067,O
targets,1067,O
for,1067,O
antithrombotic,1067,O
drugs,1067,O
.,1067,O
The,1068,O
ATP-gated,1068,B-GENE-Y
channel,1068,I-GENE-Y
P2X1,1068,I-GENE-Y
and,1068,O
the,1068,O
2,1068,O
G,1068,B-GENE-Y
protein-coupled,1068,I-GENE-Y
P2Y1,1068,I-GENE-Y
and,1068,O
P2Y12,1068,B-GENE-Y
ADP,1068,B-GENE-N
receptors,1068,I-GENE-N
selectively,1068,O
contribute,1068,O
to,1068,O
platelet,1068,O
aggregation,1068,O
.,1068,O
The,1069,O
P2Y1,1069,B-GENE-Y
receptor,1069,O
is,1069,O
responsible,1069,O
for,1069,O
ADP-induced,1069,B-CHEMICAL
shape,1069,O
change,1069,O
and,1069,O
weak,1069,O
and,1069,O
transient,1069,O
aggregation,1069,O
",",1069,O
while,1069,O
the,1069,O
P2Y12,1069,B-GENE-Y
receptor,1069,O
is,1069,O
responsible,1069,O
for,1069,O
the,1069,O
completion,1069,O
and,1069,O
amplification,1069,O
of,1069,O
the,1069,O
response,1069,O
to,1069,O
ADP,1069,B-CHEMICAL
and,1069,O
to,1069,O
all,1069,O
platelet,1069,O
agonists,1069,O
",",1069,O
including,1069,O
thromboxane,1069,B-CHEMICAL
A2,1069,I-CHEMICAL
(,1069,O
TXA2,1069,B-CHEMICAL
),1069,O
",",1069,O
thrombin,1069,B-GENE-Y
",",1069,O
and,1069,O
collagen,1069,B-GENE-N
.,1069,O
The,1070,O
P2X1,1070,B-GENE-Y
receptor,1070,O
is,1070,O
involved,1070,O
in,1070,O
platelet,1070,O
shape,1070,O
change,1070,O
and,1070,O
in,1070,O
activation,1070,O
by,1070,O
collagen,1070,B-GENE-N
under,1070,O
shear,1070,O
conditions,1070,O
.,1070,O
Due,1071,O
to,1071,O
its,1071,O
central,1071,O
role,1071,O
in,1071,O
the,1071,O
formation,1071,O
and,1071,O
stabilization,1071,O
of,1071,O
a,1071,O
thrombus,1071,O
",",1071,O
the,1071,O
P2Y12,1071,B-GENE-Y
receptor,1071,O
is,1071,O
a,1071,O
well-established,1071,O
target,1071,O
of,1071,O
antithrombotic,1071,O
drugs,1071,O
like,1071,O
ticlopidine,1071,B-CHEMICAL
or,1071,O
clopidogrel,1071,B-CHEMICAL
",",1071,O
which,1071,O
have,1071,O
proved,1071,O
efficacy,1071,O
in,1071,O
many,1071,O
clinical,1071,O
trials,1071,O
and,1071,O
experimental,1071,O
models,1071,O
of,1071,O
thrombosis,1071,O
.,1071,O
Competitive,1072,O
P2Y12,1072,B-GENE-Y
antagonists,1072,O
have,1072,O
also,1072,O
been,1072,O
shown,1072,O
to,1072,O
be,1072,O
effective,1072,O
in,1072,O
experimental,1072,O
thrombosis,1072,O
as,1072,O
well,1072,O
as,1072,O
in,1072,O
several,1072,O
clinical,1072,O
trials,1072,O
.,1072,O
Studies,1073,O
in,1073,O
P2Y1,1073,B-GENE-Y
and,1073,O
P2X1,1073,B-GENE-Y
knockout,1073,O
mice,1073,O
and,1073,O
experimental,1073,O
thrombosis,1073,O
models,1073,O
using,1073,O
selective,1073,O
P2Y1,1073,B-GENE-Y
and,1073,O
P2X1,1073,B-GENE-Y
antagonists,1073,O
have,1073,O
shown,1073,O
that,1073,O
",",1073,O
depending,1073,O
on,1073,O
the,1073,O
conditions,1073,O
",",1073,O
these,1073,O
receptors,1073,O
could,1073,O
also,1073,O
be,1073,O
potential,1073,O
targets,1073,O
for,1073,O
new,1073,O
antithrombotic,1073,O
drugs,1073,O
.,1073,O
Effect,1074,O
of,1074,O
thiazolidinediones,1074,B-CHEMICAL
on,1074,O
equilibrative,1074,B-GENE-Y
nucleoside,1074,I-GENE-Y
transporter-1,1074,I-GENE-Y
in,1074,O
human,1074,O
aortic,1074,O
smooth,1074,O
muscle,1074,O
cells,1074,O
.,1074,O
Thiazolidinediones,1075,B-CHEMICAL
are,1075,O
a,1075,O
new,1075,O
class,1075,O
of,1075,O
anti-diabetic,1075,O
agents,1075,O
which,1075,O
increase,1075,O
insulin,1075,B-GENE-Y
sensitivity,1075,O
by,1075,O
binding,1075,O
to,1075,O
the,1075,O
peroxisome,1075,B-GENE-Y
proliferator-activated,1075,I-GENE-Y
receptor,1075,I-GENE-Y
gamma,1075,I-GENE-Y
(,1075,O
PPAR,1075,B-GENE-Y
(,1075,I-GENE-Y
gamma,1075,I-GENE-Y
),1075,I-GENE-Y
),1075,O
and,1075,O
stimulating,1075,O
the,1075,O
expression,1075,O
of,1075,O
insulin-responsive,1075,B-GENE-Y
genes,1075,O
involved,1075,O
in,1075,O
glucose,1075,B-CHEMICAL
and,1075,O
lipid,1075,O
metabolism,1075,O
.,1075,O
These,1076,O
drugs,1076,O
also,1076,O
have,1076,O
vasodilatory,1076,O
and,1076,O
anti-proliferative,1076,O
effects,1076,O
on,1076,O
vascular,1076,O
smooth,1076,O
muscle,1076,O
cells,1076,O
.,1076,O
However,1077,O
the,1077,O
mechanisms,1077,O
for,1077,O
these,1077,O
actions,1077,O
are,1077,O
not,1077,O
fully,1077,O
understood,1077,O
.,1077,O
Adenosine,1078,O
is,1078,O
a,1078,O
vasodilator,1078,O
and,1078,O
a,1078,O
substrate,1078,O
of,1078,O
equilibrative,1078,B-GENE-N
nucleoside,1078,I-GENE-N
transporters,1078,I-GENE-N
(,1078,O
ENT,1078,B-GENE-N
),1078,O
.,1078,O
The,1079,O
present,1079,O
study,1079,O
studied,1079,O
the,1079,O
effects,1079,O
of,1079,O
three,1079,O
thiazolidinediones,1079,B-CHEMICAL
",",1079,O
troglitazone,1079,B-CHEMICAL
",",1079,O
pioglitazone,1079,B-CHEMICAL
and,1079,O
ciglitazone,1079,B-CHEMICAL
",",1079,O
on,1079,O
ENT1,1079,B-GENE-Y
in,1079,O
the,1079,O
human,1079,O
aortic,1079,O
smooth,1079,O
muscle,1079,O
cells,1079,O
(,1079,O
HASMCs,1079,O
),1079,O
.,1079,O
Although,1080,O
incubating,1080,O
HASMCs,1080,O
for,1080,O
48h,1080,O
with,1080,O
thiazolidinediones,1080,B-CHEMICAL
had,1080,O
no,1080,O
effect,1080,O
on,1080,O
ENT1,1080,B-GENE-Y
mRNA,1080,O
and,1080,O
protein,1080,O
levels,1080,O
",",1080,O
troglitazone,1080,B-CHEMICAL
acutely,1080,O
inhibited,1080,O
[,1080,B-CHEMICAL
3H,1080,I-CHEMICAL
],1080,I-CHEMICAL
adenosine,1080,I-CHEMICAL
uptake,1080,O
and,1080,O
[,1080,B-CHEMICAL
3H,1080,I-CHEMICAL
],1080,I-CHEMICAL
NBMPR,1080,I-CHEMICAL
binding,1080,O
of,1080,O
HASMCs,1080,O
with,1080,O
IC50,1080,O
values,1080,O
of,1080,O
2.35+/-0.35,1080,O
and,1080,O
3.99+/-0.57microM,1080,O
",",1080,O
respectively,1080,O
.,1080,O
The,1081,O
effect,1081,O
of,1081,O
troglitazone,1081,B-CHEMICAL
on,1081,O
ENT1,1081,B-GENE-Y
was,1081,O
PPAR,1081,B-GENE-Y
(,1081,I-GENE-Y
gamma,1081,I-GENE-Y
),1081,I-GENE-Y
-independent,1081,O
and,1081,O
kinetic,1081,O
studies,1081,O
revealed,1081,O
that,1081,O
troglitazone,1081,B-CHEMICAL
was,1081,O
a,1081,O
competitive,1081,O
inhibitor,1081,O
of,1081,O
ENT1,1081,B-GENE-Y
.,1081,O
In,1082,O
contrast,1082,O
",",1082,O
pioglitazone,1082,B-CHEMICAL
and,1082,O
ciglitazone,1082,B-CHEMICAL
had,1082,O
minimal,1082,O
effects,1082,O
on,1082,O
[,1082,B-CHEMICAL
3H,1082,I-CHEMICAL
],1082,I-CHEMICAL
adenosine,1082,I-CHEMICAL
uptake,1082,O
by,1082,O
HASMCs,1082,O
.,1082,O
Troglitazone,1083,B-CHEMICAL
differs,1083,O
from,1083,O
pioglitazone,1083,B-CHEMICAL
and,1083,O
ciglitazone,1083,B-CHEMICAL
in,1083,O
that,1083,O
its,1083,O
side-chain,1083,O
contains,1083,O
a,1083,O
Vitamin,1083,B-CHEMICAL
E,1083,I-CHEMICAL
moiety,1083,O
.,1083,O
The,1084,O
difference,1084,O
in,1084,O
structure,1084,O
of,1084,O
troglitazone,1084,B-CHEMICAL
did,1084,O
not,1084,O
account,1084,O
for,1084,O
its,1084,O
inhibitory,1084,O
effect,1084,O
on,1084,O
ENT1,1084,B-GENE-Y
because,1084,O
Vitamin,1084,B-CHEMICAL
E,1084,I-CHEMICAL
did,1084,O
not,1084,O
inhibit,1084,O
[,1084,B-CHEMICAL
3H,1084,I-CHEMICAL
],1084,I-CHEMICAL
adenosine,1084,I-CHEMICAL
uptake,1084,O
by,1084,O
HASMCs,1084,O
.,1084,O
Using,1085,O
the,1085,O
nucleoside,1085,B-GENE-N
transporter,1085,I-GENE-N
deficient,1085,O
PK15NTD,1085,O
cells,1085,O
stably,1085,O
expressing,1085,O
ENT1,1085,B-GENE-Y
and,1085,O
ENT2,1085,B-GENE-Y
",",1085,O
it,1085,O
was,1085,O
found,1085,O
that,1085,O
troglitazone,1085,B-CHEMICAL
inhibited,1085,O
ENT1,1085,B-GENE-Y
but,1085,O
had,1085,O
no,1085,O
effect,1085,O
on,1085,O
ENT2,1085,B-GENE-Y
.,1085,O
From,1086,O
these,1086,O
results,1086,O
",",1086,O
it,1086,O
is,1086,O
suggested,1086,O
that,1086,O
troglitazone,1086,B-CHEMICAL
may,1086,O
enhance,1086,O
the,1086,O
vasodilatory,1086,O
effect,1086,O
of,1086,O
adenosine,1086,B-CHEMICAL
by,1086,O
inhibiting,1086,O
ENT1,1086,B-GENE-Y
.,1086,O
Pharmacologically,1087,O
",",1087,O
troglitazone,1087,B-CHEMICAL
is,1087,O
a,1087,O
novel,1087,O
inhibitor,1087,O
of,1087,O
ENT1,1087,B-GENE-Y
.,1087,O
Genetic,1088,O
predictors,1088,O
of,1088,O
the,1088,O
maximum,1088,O
doses,1088,O
patients,1088,O
receive,1088,O
during,1088,O
clinical,1088,O
use,1088,O
of,1088,O
the,1088,O
anti-epileptic,1088,O
drugs,1088,O
carbamazepine,1088,B-CHEMICAL
and,1088,O
phenytoin,1088,B-CHEMICAL
.,1088,O
Phenytoin,1089,B-CHEMICAL
and,1089,O
carbamazepine,1089,B-CHEMICAL
are,1089,O
effective,1089,O
and,1089,O
inexpensive,1089,O
anti-epileptic,1089,O
drugs,1089,O
(,1089,O
AEDs,1089,O
),1089,O
.,1089,O
As,1090,O
with,1090,O
many,1090,O
AEDs,1090,O
",",1090,O
a,1090,O
broad,1090,O
range,1090,O
of,1090,O
doses,1090,O
is,1090,O
used,1090,O
",",1090,O
with,1090,O
the,1090,O
final,1090,O
``,1090,O
maintenance,1090,O
'',1090,O
dose,1090,O
normally,1090,O
determined,1090,O
by,1090,O
trial,1090,O
and,1090,O
error,1090,O
.,1090,O
Although,1091,O
many,1091,O
genes,1091,O
could,1091,O
influence,1091,O
response,1091,O
to,1091,O
these,1091,O
medicines,1091,O
",",1091,O
there,1091,O
are,1091,O
obvious,1091,O
candidates,1091,O
.,1091,O
Both,1092,O
drugs,1092,O
target,1092,O
the,1092,O
alpha-subunit,1092,B-GENE-N
of,1092,I-GENE-N
the,1092,I-GENE-N
sodium,1092,I-GENE-N
channel,1092,I-GENE-N
",",1092,O
encoded,1092,O
by,1092,O
the,1092,O
SCN,1092,B-GENE-N
family,1092,O
of,1092,O
genes,1092,O
.,1092,O
Phenytoin,1093,B-CHEMICAL
is,1093,O
principally,1093,O
metabolized,1093,O
by,1093,O
CYP2C9,1093,B-GENE-Y
",",1093,O
and,1093,O
both,1093,O
are,1093,O
probable,1093,O
substrates,1093,O
of,1093,O
the,1093,O
drug,1093,B-GENE-N
transporter,1093,I-GENE-N
P-glycoprotein,1093,B-GENE-N
.,1093,O
We,1094,O
therefore,1094,O
assessed,1094,O
whether,1094,O
variation,1094,O
in,1094,O
these,1094,O
genes,1094,O
associates,1094,O
with,1094,O
the,1094,O
clinical,1094,O
use,1094,O
of,1094,O
carbamazepine,1094,B-CHEMICAL
and,1094,O
phenytoin,1094,B-CHEMICAL
in,1094,O
cohorts,1094,O
of,1094,O
425,1094,O
and,1094,O
281,1094,O
patients,1094,O
",",1094,O
respectively,1094,O
.,1094,O
We,1095,O
report,1095,O
that,1095,O
a,1095,O
known,1095,O
functional,1095,O
polymorphism,1095,O
in,1095,O
CYP2C9,1095,B-GENE-Y
is,1095,O
highly,1095,O
associated,1095,O
with,1095,O
the,1095,O
maximum,1095,O
dose,1095,O
of,1095,O
phenytoin,1095,B-CHEMICAL
(,1095,O
P,1095,O
=,1095,O
0.0066,1095,O
),1095,O
.,1095,O
We,1096,O
also,1096,O
show,1096,O
that,1096,O
an,1096,O
intronic,1096,O
polymorphism,1096,O
in,1096,O
the,1096,O
SCN1A,1096,B-GENE-Y
gene,1096,O
shows,1096,O
significant,1096,O
association,1096,O
with,1096,O
maximum,1096,O
doses,1096,O
in,1096,O
regular,1096,O
usage,1096,O
of,1096,O
both,1096,O
carbamazepine,1096,B-CHEMICAL
and,1096,O
phenytoin,1096,B-CHEMICAL
(,1096,O
P,1096,O
=,1096,O
0.0051,1096,O
and,1096,O
P,1096,O
=,1096,O
0.014,1096,O
",",1096,O
respectively,1096,O
),1096,O
.,1096,O
This,1097,O
polymorphism,1097,O
disrupts,1097,O
the,1097,O
consensus,1097,O
sequence,1097,O
of,1097,O
the,1097,O
5,1097,O
',1097,O
splice,1097,O
donor,1097,O
site,1097,O
of,1097,O
a,1097,O
highly,1097,O
conserved,1097,O
alternative,1097,O
exon,1097,O
(,1097,O
5N,1097,O
),1097,O
",",1097,O
and,1097,O
it,1097,O
significantly,1097,O
affects,1097,O
the,1097,O
proportions,1097,O
of,1097,O
the,1097,O
alternative,1097,O
transcripts,1097,O
in,1097,O
individuals,1097,O
with,1097,O
a,1097,O
history,1097,O
of,1097,O
epilepsy,1097,O
.,1097,O
These,1098,O
results,1098,O
provide,1098,O
evidence,1098,O
of,1098,O
a,1098,O
drug,1098,O
target,1098,O
polymorphism,1098,O
associated,1098,O
with,1098,O
the,1098,O
clinical,1098,O
use,1098,O
of,1098,O
AEDs,1098,O
and,1098,O
set,1098,O
the,1098,O
stage,1098,O
for,1098,O
a,1098,O
prospective,1098,O
evaluation,1098,O
of,1098,O
how,1098,O
pharmacogenetic,1098,O
diagnostics,1098,O
can,1098,O
be,1098,O
used,1098,O
to,1098,O
improve,1098,O
dosing,1098,O
decisions,1098,O
in,1098,O
the,1098,O
use,1098,O
of,1098,O
phenytoin,1098,B-CHEMICAL
and,1098,O
carbamazepine,1098,B-CHEMICAL
.,1098,O
Although,1099,O
the,1099,O
case,1099,O
made,1099,O
here,1099,O
is,1099,O
compelling,1099,O
",",1099,O
our,1099,O
results,1099,O
can,1099,O
not,1099,O
be,1099,O
considered,1099,O
definitive,1099,O
or,1099,O
ready,1099,O
for,1099,O
clinical,1099,O
application,1099,O
until,1099,O
they,1099,O
are,1099,O
confirmed,1099,O
by,1099,O
independent,1099,O
replication,1099,O
.,1099,O
Fisetin,1100,B-CHEMICAL
regulates,1100,O
obesity,1100,O
by,1100,O
targeting,1100,O
mTORC1,1100,B-GENE-N
signaling,1100,O
.,1100,O
Fisetin,1101,B-CHEMICAL
",",1101,O
a,1101,O
flavonol,1101,B-CHEMICAL
present,1101,O
in,1101,O
vegetables,1101,O
and,1101,O
fruits,1101,O
",",1101,O
possesses,1101,O
antioxidative,1101,O
and,1101,O
anti-inflammatory,1101,O
properties,1101,O
.,1101,O
In,1102,O
this,1102,O
study,1102,O
",",1102,O
we,1102,O
have,1102,O
demonstrated,1102,O
that,1102,O
fisetin,1102,B-CHEMICAL
prevents,1102,O
diet-induced,1102,O
obesity,1102,O
through,1102,O
regulation,1102,O
of,1102,O
the,1102,O
signaling,1102,O
of,1102,O
mammalian,1102,B-GENE-N
target,1102,I-GENE-N
of,1102,I-GENE-N
rapamycin,1102,I-GENE-N
complex,1102,I-GENE-N
1,1102,I-GENE-N
(,1102,O
mTORC1,1102,B-GENE-N
),1102,O
",",1102,O
a,1102,O
central,1102,O
mediator,1102,O
of,1102,O
cellular,1102,O
growth,1102,O
",",1102,O
cellular,1102,O
proliferation,1102,O
and,1102,O
lipid,1102,O
biosynthesis,1102,O
.,1102,O
To,1103,O
evaluate,1103,O
whether,1103,O
fisetin,1103,B-CHEMICAL
regulates,1103,O
mTORC1,1103,B-GENE-N
signaling,1103,O
",",1103,O
we,1103,O
investigated,1103,O
the,1103,O
phosphorylation,1103,O
and,1103,O
kinase,1103,B-GENE-N
activity,1103,O
of,1103,O
the,1103,O
70-kDa,1103,B-GENE-Y
ribosomal,1103,I-GENE-Y
protein,1103,I-GENE-Y
S6,1103,I-GENE-Y
kinase,1103,I-GENE-Y
1,1103,I-GENE-Y
(,1103,O
S6K1,1103,B-GENE-Y
),1103,O
and,1103,O
mTORC1,1103,B-GENE-N
in,1103,O
3T3-L1,1103,O
preadipocytes,1103,O
.,1103,O
Fisetin,1104,B-CHEMICAL
treatment,1104,O
of,1104,O
preadipocytes,1104,O
reduced,1104,O
the,1104,O
phosphorylation,1104,O
of,1104,O
S6K1,1104,B-GENE-Y
and,1104,O
mTORC1,1104,B-GENE-N
in,1104,O
a,1104,O
time-,1104,O
and,1104,O
concentration-dependent,1104,O
manner,1104,O
.,1104,O
To,1105,O
further,1105,O
our,1105,O
understanding,1105,O
of,1105,O
how,1105,O
fisetin,1105,B-CHEMICAL
negatively,1105,O
regulates,1105,O
mTORC1,1105,B-GENE-N
signaling,1105,O
",",1105,O
we,1105,O
analyzed,1105,O
the,1105,O
phosphorylation,1105,O
of,1105,O
S6K1,1105,B-GENE-Y
",",1105,O
mTOR,1105,B-GENE-Y
and,1105,O
Akt,1105,B-GENE-N
in,1105,O
fisetin-treated,1105,B-CHEMICAL
TSC2-knockdown,1105,B-GENE-Y
cells,1105,O
.,1105,O
The,1106,O
results,1106,O
suggested,1106,O
that,1106,O
fisetin,1106,B-CHEMICAL
treatment,1106,O
inhibits,1106,O
mTORC1,1106,B-GENE-N
activity,1106,O
in,1106,O
an,1106,O
Akt-dependent,1106,B-GENE-N
manner,1106,O
.,1106,O
Recent,1107,O
studies,1107,O
have,1107,O
shown,1107,O
that,1107,O
adipocyte,1107,O
differentiation,1107,O
is,1107,O
dependent,1107,O
on,1107,O
mTORC1,1107,B-GENE-N
activity,1107,O
.,1107,O
Fisetin,1108,B-CHEMICAL
treatment,1108,O
inhibited,1108,O
adipocyte,1108,O
differentiation,1108,O
",",1108,O
consistent,1108,O
with,1108,O
the,1108,O
negative,1108,O
effect,1108,O
of,1108,O
fisetin,1108,B-CHEMICAL
on,1108,O
mTOR,1108,B-GENE-Y
.,1108,O
The,1109,O
inhibitory,1109,O
effect,1109,O
of,1109,O
fisetin,1109,B-CHEMICAL
on,1109,O
adipogenesis,1109,O
is,1109,O
dependent,1109,O
of,1109,O
mTOR,1109,B-GENE-Y
activity,1109,O
",",1109,O
suggesting,1109,O
that,1109,O
fisetin,1109,B-CHEMICAL
inhibits,1109,O
adipogenesis,1109,O
and,1109,O
the,1109,O
accumulation,1109,O
of,1109,O
intracellular,1109,O
triglycerides,1109,B-CHEMICAL
during,1109,O
adipocyte,1109,O
differentiation,1109,O
by,1109,O
targeting,1109,O
mTORC1,1109,B-GENE-N
signaling,1109,O
.,1109,O
Fisetin,1110,B-CHEMICAL
supplementation,1110,O
in,1110,O
mice,1110,O
fed,1110,O
a,1110,O
high-fat,1110,O
diet,1110,O
(,1110,O
HFD,1110,O
),1110,O
significantly,1110,O
attenuated,1110,O
HFD-induced,1110,O
increases,1110,O
in,1110,O
body,1110,O
weight,1110,O
and,1110,O
white,1110,O
adipose,1110,O
tissue,1110,O
.,1110,O
We,1111,O
also,1111,O
observed,1111,O
that,1111,O
fisetin,1111,B-CHEMICAL
efficiently,1111,O
suppressed,1111,O
the,1111,O
phosphorylation,1111,O
of,1111,O
Akt,1111,B-GENE-N
",",1111,O
S6K1,1111,B-GENE-Y
and,1111,O
mTORC1,1111,B-GENE-N
in,1111,O
adipose,1111,O
tissue,1111,O
.,1111,O
Collectively,1112,O
",",1112,O
these,1112,O
results,1112,O
suggest,1112,O
that,1112,O
inhibition,1112,O
of,1112,O
mTORC1,1112,B-GENE-N
signaling,1112,O
by,1112,O
fisetin,1112,B-CHEMICAL
prevents,1112,O
adipocyte,1112,O
differentiation,1112,O
of,1112,O
3T3-L1,1112,O
preadipocytes,1112,O
and,1112,O
obesity,1112,O
in,1112,O
HFD-fed,1112,O
mice,1112,O
.,1112,O
Therefore,1113,O
",",1113,O
fisetin,1113,B-CHEMICAL
may,1113,O
be,1113,O
a,1113,O
useful,1113,O
phytochemical,1113,O
agent,1113,O
for,1113,O
attenuating,1113,O
diet-induced,1113,O
obesity,1113,O
.,1113,O
Cyclin,1114,B-GENE-Y
E-cdk2,1114,O
activation,1114,O
is,1114,O
associated,1114,O
with,1114,O
cell,1114,O
cycle,1114,O
arrest,1114,O
and,1114,O
inhibition,1114,O
of,1114,O
DNA,1114,O
replication,1114,O
induced,1114,O
by,1114,O
the,1114,O
thymidylate,1114,B-GENE-Y
synthase,1114,I-GENE-Y
inhibitor,1114,O
Tomudex,1114,B-CHEMICAL
.,1114,O
Tomudex,1115,B-CHEMICAL
(,1115,O
ZD1694,1115,B-CHEMICAL
),1115,O
is,1115,O
a,1115,O
specific,1115,O
antifolate-based,1115,O
thymidylate,1115,B-GENE-Y
synthase,1115,I-GENE-Y
inhibitor,1115,O
active,1115,O
in,1115,O
a,1115,O
variety,1115,O
of,1115,O
solid,1115,O
tumor,1115,O
malignancies,1115,O
.,1115,O
Studies,1116,O
were,1116,O
carried,1116,O
out,1116,O
in,1116,O
vitro,1116,O
to,1116,O
evaluate,1116,O
downstream,1116,O
molecular,1116,O
alterations,1116,O
induced,1116,O
as,1116,O
a,1116,O
consequence,1116,O
of,1116,O
the,1116,O
potent,1116,O
and,1116,O
sustained,1116,O
inhibition,1116,O
of,1116,O
thymidylate,1116,B-GENE-Y
synthase,1116,I-GENE-Y
by,1116,O
Tomudex,1116,B-CHEMICAL
.,1116,O
Twenty-four,1117,O
hours,1117,O
following,1117,O
the,1117,O
initial,1117,O
2-h,1117,O
treatment,1117,O
with,1117,O
Tomudex,1117,B-CHEMICAL
",",1117,O
human,1117,O
A253,1117,O
head,1117,O
and,1117,O
neck,1117,O
squamous,1117,O
carcinoma,1117,O
cells,1117,O
",",1117,O
not,1117,O
expressing,1117,O
p53,1117,B-GENE-Y
and,1117,O
p21,1117,B-GENE-Y
(,1117,O
WAF1,1117,B-GENE-Y
),1117,O
",",1117,O
were,1117,O
accumulated,1117,O
with,1117,O
DNA,1117,O
content,1117,O
characteristic,1117,O
of,1117,O
early,1117,O
S,1117,O
phase,1117,O
of,1117,O
the,1117,O
cell,1117,O
cycle,1117,O
with,1117,O
a,1117,O
concomitant,1117,O
reduction,1117,O
of,1117,O
cells,1117,O
in,1117,O
G1,1117,O
and,1117,O
G2/M,1117,O
phases,1117,O
.,1117,O
The,1118,O
changes,1118,O
in,1118,O
cyclin,1118,B-GENE-N
and,1118,O
cdk,1118,B-GENE-N
protein,1118,O
expression,1118,O
and,1118,O
their,1118,O
kinase,1118,B-GENE-N
activities,1118,O
were,1118,O
examined,1118,O
in,1118,O
control,1118,O
and,1118,O
drug-treated,1118,O
A253,1118,O
cells,1118,O
.,1118,O
Tomudex,1119,B-CHEMICAL
treatment,1119,O
resulted,1119,O
in,1119,O
the,1119,O
decrease,1119,O
in,1119,O
p27,1119,B-GENE-Y
(,1119,I-GENE-Y
kip1,1119,I-GENE-Y
),1119,I-GENE-Y
expression,1119,O
",",1119,O
with,1119,O
an,1119,O
increase,1119,O
in,1119,O
cyclin,1119,B-GENE-Y
E,1119,I-GENE-Y
and,1119,O
cdk2,1119,B-GENE-Y
protein,1119,O
expression,1119,O
and,1119,O
kinase,1119,B-GENE-N
activities,1119,O
24,1119,O
h,1119,O
after,1119,O
a,1119,O
2-h,1119,O
exposure,1119,O
.,1119,O
Although,1120,O
cyclin,1120,B-GENE-Y
A,1120,I-GENE-Y
protein,1120,O
expression,1120,O
was,1120,O
markedly,1120,O
increased,1120,O
",",1120,O
cyclin,1120,B-GENE-Y
A,1120,I-GENE-Y
kinase,1120,B-GENE-N
activity,1120,O
was,1120,O
only,1120,O
slightly,1120,O
increased,1120,O
.,1120,O
Cyclin,1121,B-GENE-Y
D1,1121,I-GENE-Y
",",1121,O
cyclin,1121,B-GENE-Y
B,1121,I-GENE-Y
",",1121,O
cdk4,1121,B-GENE-Y
",",1121,O
and,1121,O
cdc2,1121,B-GENE-Y
protein,1121,O
expression,1121,O
and,1121,O
kinase,1121,B-GENE-N
activities,1121,O
remain,1121,O
constant,1121,O
.,1121,O
Lack,1122,O
of,1122,O
activation,1122,O
of,1122,O
cyclin,1122,B-GENE-N
A-,1122,I-GENE-N
and,1122,I-GENE-N
B-cdc2,1122,O
was,1122,O
associated,1122,O
with,1122,O
a,1122,O
reduced,1122,O
proportion,1122,O
of,1122,O
cells,1122,O
in,1122,O
G2/M,1122,O
phases,1122,O
.,1122,O
Increased,1123,O
cyclin,1123,B-GENE-Y
E-cdk2,1123,O
protein,1123,O
expression,1123,O
was,1123,O
accompanied,1123,O
by,1123,O
the,1123,O
inhibition,1123,O
of,1123,O
DNA,1123,O
synthesis,1123,O
",",1123,O
with,1123,O
a,1123,O
decrease,1123,O
in,1123,O
E2F-1,1123,B-GENE-Y
expression,1123,O
.,1123,O
These,1124,O
results,1124,O
propose,1124,O
that,1124,O
cyclin,1124,B-GENE-Y
E-cdk2,1124,O
kinase,1124,B-GENE-N
can,1124,O
negatively,1124,O
regulate,1124,O
DNA,1124,O
replication,1124,O
.,1124,O
The,1125,O
studies,1125,O
with,1125,O
dThyd,1125,O
rescue,1125,O
from,1125,O
cyclin,1125,B-GENE-Y
E-cdk2,1125,O
protein,1125,O
overexpression,1125,O
and,1125,O
growth,1125,O
inhibition,1125,O
by,1125,O
Tomudex,1125,B-CHEMICAL
indicate,1125,O
that,1125,O
increased,1125,O
cyclin,1125,B-GENE-Y
E-cdk2,1125,O
protein,1125,O
expression,1125,O
is,1125,O
associated,1125,O
with,1125,O
effective,1125,O
inhibition,1125,O
of,1125,O
thymidylate,1125,B-GENE-Y
synthase,1125,I-GENE-Y
and,1125,O
resultant,1125,O
dNTP,1125,O
pool,1125,O
imbalance,1125,O
.,1125,O
Provision,1126,O
of,1126,O
dThyd,1126,O
more,1126,O
than,1126,O
24,1126,O
h,1126,O
after,1126,O
exposure,1126,O
to,1126,O
Tomudex,1126,B-CHEMICAL
allowed,1126,O
cells,1126,O
to,1126,O
replicate,1126,O
DNA,1126,O
for,1126,O
a,1126,O
single,1126,O
cycle,1126,O
back,1126,O
to,1126,O
G1,1126,O
",",1126,O
but,1126,O
did,1126,O
not,1126,O
prevent,1126,O
the,1126,O
profound,1126,O
growth-inhibitory,1126,O
effect,1126,O
manifested,1126,O
in,1126,O
the,1126,O
following,1126,O
5,1126,O
days,1126,O
.,1126,O
Tomudex,1127,B-CHEMICAL
treatment,1127,O
resulted,1127,O
in,1127,O
a,1127,O
time-dependent,1127,O
induction,1127,O
of,1127,O
the,1127,O
megabase,1127,O
DNA,1127,O
fragments,1127,O
",",1127,O
followed,1127,O
by,1127,O
secondary,1127,O
50-,1127,O
to,1127,O
300-kb,1127,O
DNA,1127,O
fragmentation,1127,O
.,1127,O
The,1128,O
50-,1128,O
to,1128,O
300-kb,1128,O
DNA,1128,O
fragmentation,1128,O
may,1128,O
be,1128,O
derived,1128,O
from,1128,O
the,1128,O
inhibition,1128,O
of,1128,O
DNA,1128,O
synthesis,1128,O
associated,1128,O
with,1128,O
cyclin,1128,B-GENE-Y
E-cdk2,1128,O
activation,1128,O
.,1128,O
These,1129,O
results,1129,O
suggest,1129,O
that,1129,O
the,1129,O
megabase,1129,O
DNA,1129,O
fragmentation,1129,O
is,1129,O
induced,1129,O
as,1129,O
a,1129,O
consequence,1129,O
of,1129,O
inhibition,1129,O
of,1129,O
thymidylate,1129,B-GENE-Y
synthase,1129,I-GENE-Y
by,1129,O
Tomudex,1129,B-CHEMICAL
and,1129,O
kilobase,1129,O
DNA,1129,O
fragmentation,1129,O
may,1129,O
correlate,1129,O
with,1129,O
the,1129,O
reduction,1129,O
of,1129,O
p27,1129,B-GENE-Y
(,1129,I-GENE-Y
kip1,1129,I-GENE-Y
),1129,I-GENE-Y
expression,1129,O
and,1129,O
the,1129,O
increase,1129,O
in,1129,O
cyclin,1129,B-GENE-Y
E,1129,I-GENE-Y
and,1129,O
cdk2,1129,B-GENE-Y
kinase,1129,B-GENE-N
activities,1129,O
.,1129,O
Activation,1130,O
of,1130,O
cyclin,1130,B-GENE-Y
E,1130,I-GENE-Y
and,1130,O
cdk2,1130,B-GENE-Y
kinases,1130,B-GENE-N
allows,1130,O
cells,1130,O
to,1130,O
transit,1130,O
from,1130,O
G1,1130,O
to,1130,O
S,1130,O
phase,1130,O
accompanied,1130,O
by,1130,O
the,1130,O
inhibition,1130,O
of,1130,O
DNA,1130,O
synthesis,1130,O
.,1130,O
The,1131,O
changes,1131,O
in,1131,O
cell,1131,O
cycle,1131,O
regulatory,1131,O
proteins,1131,O
associated,1131,O
with,1131,O
growth,1131,O
inhibition,1131,O
and,1131,O
DNA,1131,O
damage,1131,O
by,1131,O
Tomudex,1131,B-CHEMICAL
are,1131,O
not,1131,O
p53,1131,B-GENE-Y
dependent,1131,O
.,1131,O
Modulation,1132,O
of,1132,O
cellular,1132,O
insulin,1132,B-GENE-N
signaling,1132,O
and,1132,O
PTP1B,1132,B-GENE-Y
effects,1132,O
by,1132,O
lipid,1132,O
metabolites,1132,O
in,1132,O
skeletal,1132,O
muscle,1132,O
cells,1132,O
.,1132,O
Normal,1133,O
glucose,1133,B-CHEMICAL
regulation,1133,O
is,1133,O
achieved,1133,O
by,1133,O
having,1133,O
adequate,1133,O
insulin,1133,B-GENE-Y
secretion,1133,O
and,1133,O
effective,1133,O
glucose,1133,B-CHEMICAL
uptake/disposal,1133,O
.,1133,O
Excess,1134,O
lipids,1134,O
in,1134,O
peripheral,1134,O
tissues,1134,O
-,1134,O
skeletal,1134,O
muscle,1134,O
",",1134,O
liver,1134,O
and,1134,O
adipose,1134,O
tissue,1134,O
-,1134,O
may,1134,O
attenuate,1134,O
insulin,1134,B-GENE-Y
signaling,1134,O
through,1134,O
the,1134,O
protein,1134,B-GENE-N
kinase,1134,I-GENE-N
B,1134,I-GENE-N
(,1134,O
AKt,1134,B-GENE-N
),1134,O
pathway,1134,O
and,1134,O
up-regulate,1134,O
protein,1134,B-GENE-Y
tyrosine,1134,I-GENE-Y
phosphatase,1134,I-GENE-Y
1B,1134,I-GENE-Y
(,1134,O
PTP1B,1134,B-GENE-Y
),1134,O
",",1134,O
a,1134,O
negative,1134,O
regulator,1134,O
of,1134,O
insulin,1134,B-GENE-Y
signaling,1134,O
.,1134,O
We,1135,O
studied,1135,O
accumulation,1135,O
of,1135,O
lipid,1135,O
metabolites,1135,O
[,1135,O
triglycerides,1135,B-CHEMICAL
(,1135,O
TAGs,1135,B-CHEMICAL
),1135,O
",",1135,O
diglycerides,1135,B-CHEMICAL
(,1135,O
DAGs,1135,B-CHEMICAL
),1135,O
],1135,O
and,1135,O
ceramides,1135,B-CHEMICAL
in,1135,O
relation,1135,O
to,1135,O
insulin,1135,B-GENE-N
signaling,1135,O
and,1135,O
expression,1135,O
and,1135,O
phosphorylation,1135,O
of,1135,O
PTP1B,1135,B-GENE-Y
by,1135,O
preincubating,1135,O
rat,1135,O
skeletal,1135,O
muscle,1135,O
cells,1135,O
(,1135,O
L6,1135,O
myotubes,1135,O
),1135,O
with,1135,O
three,1135,O
saturated,1135,O
and,1135,O
three,1135,O
unsaturated,1135,O
free,1135,O
fatty,1135,B-CHEMICAL
acids,1135,I-CHEMICAL
(,1135,O
FFAs,1135,O
),1135,O
(,1135,O
200,1135,O
μM,1135,O
),1135,O
.,1135,O
Cells,1136,O
were,1136,O
also,1136,O
evaluated,1136,O
in,1136,O
the,1136,O
presence,1136,O
of,1136,O
wortmannin,1136,B-CHEMICAL
",",1136,O
an,1136,O
inhibitor,1136,O
of,1136,O
phosphatidylinositol,1136,B-GENE-N
3-kinases,1136,I-GENE-N
and,1136,O
thus,1136,O
AKt,1136,B-GENE-N
(,1136,O
0-100,1136,O
nM,1136,O
),1136,O
.,1136,O
Unsaturated,1137,O
FFAs,1137,O
increased,1137,O
DAGs,1137,B-CHEMICAL
",",1137,O
TAGs,1137,B-CHEMICAL
and,1137,O
PTP1B,1137,B-GENE-Y
expression,1137,O
significantly,1137,O
",",1137,O
but,1137,O
cells,1137,O
remained,1137,O
insulin,1137,B-GENE-N
sensitive,1137,O
as,1137,O
assessed,1137,O
by,1137,O
robust,1137,O
AKt,1137,B-GENE-N
and,1137,O
PTP1B,1137,B-GENE-Y
phosphorylation,1137,O
at,1137,O
serine,1137,B-CHEMICAL
(,1137,O
Ser,1137,B-CHEMICAL
),1137,O
50,1137,O
",",1137,O
Ser,1137,B-CHEMICAL
398,1137,O
and,1137,O
tyrosine,1137,B-CHEMICAL
152,1137,O
.,1137,O
Saturated,1138,O
palmitic,1138,B-CHEMICAL
and,1138,I-CHEMICAL
stearic,1138,I-CHEMICAL
acids,1138,I-CHEMICAL
increased,1138,O
ceramides,1138,B-CHEMICAL
",",1138,O
up-regulated,1138,O
PTP1B,1138,B-GENE-Y
",",1138,O
and,1138,O
had,1138,O
AKt,1138,B-GENE-N
and,1138,O
PTP1B,1138,B-GENE-Y
phosphorylation,1138,O
at,1138,O
Ser,1138,B-CHEMICAL
50,1138,O
impaired,1138,O
.,1138,O
We,1139,O
show,1139,O
a,1139,O
significant,1139,O
correlation,1139,O
between,1139,O
phosphorylation,1139,O
levels,1139,O
of,1139,O
AKt,1139,B-GENE-N
and,1139,O
of,1139,O
PTP1B,1139,B-GENE-Y
at,1139,O
Ser,1139,O
50,1139,O
(,1139,O
R,1139,O
(,1139,O
2,1139,O
),1139,O
=0.84,1139,O
",",1139,O
P,1139,O
<,1139,O
.05,1139,O
),1139,O
.,1139,O
The,1140,O
same,1140,O
was,1140,O
observed,1140,O
with,1140,O
increasing,1140,O
wortmannin,1140,B-CHEMICAL
dose,1140,O
(,1140,O
R,1140,O
(,1140,O
2,1140,O
),1140,O
=0.73,1140,O
",",1140,O
P,1140,O
<,1140,O
.05,1140,O
),1140,O
.,1140,O
Only,1141,O
FFAs,1141,O
that,1141,O
increased,1141,O
ceramides,1141,B-CHEMICAL
caused,1141,O
impairment,1141,O
of,1141,O
AKt,1141,B-GENE-N
and,1141,O
PTP1B,1141,B-GENE-Y
phosphorylation,1141,O
at,1141,O
Ser,1141,B-CHEMICAL
50,1141,O
.,1141,O
PTP1B,1142,B-GENE-Y
overexpression,1142,O
in,1142,O
the,1142,O
presence,1142,O
of,1142,O
excess,1142,O
lipids,1142,O
may,1142,O
not,1142,O
directly,1142,O
cause,1142,O
insulin,1142,B-GENE-N
resistance,1142,O
unless,1142,O
it,1142,O
is,1142,O
accompanied,1142,O
by,1142,O
decreased,1142,O
PTP1B,1142,B-GENE-Y
phosphorylation,1142,O
.,1142,O
A,1143,O
clear,1143,O
relationship,1143,O
between,1143,O
PTP1B,1143,B-GENE-Y
phosphorylation,1143,O
levels,1143,O
at,1143,O
Ser,1143,B-CHEMICAL
50,1143,O
and,1143,O
its,1143,O
negative,1143,O
effect,1143,O
on,1143,O
insulin,1143,B-GENE-N
signaling,1143,O
is,1143,O
shown,1143,O
.,1143,O
Functional,1144,O
analyses,1144,O
of,1144,O
glycyl-tRNA,1144,B-GENE-Y
synthetase,1144,I-GENE-Y
mutations,1144,O
suggest,1144,O
a,1144,O
key,1144,O
role,1144,O
for,1144,O
tRNA-charging,1144,B-GENE-N
enzymes,1144,I-GENE-N
in,1144,O
peripheral,1144,O
axons,1144,O
.,1144,O
Charcot-Marie-Tooth,1145,O
disease,1145,O
type,1145,O
2D,1145,O
(,1145,O
CMT2D,1145,O
),1145,O
and,1145,O
distal,1145,O
spinal,1145,O
muscular,1145,O
atrophy,1145,O
type,1145,O
V,1145,O
(,1145,O
dSMA-V,1145,O
),1145,O
are,1145,O
axonal,1145,O
neuropathies,1145,O
characterized,1145,O
by,1145,O
a,1145,O
phenotype,1145,O
that,1145,O
is,1145,O
more,1145,O
severe,1145,O
in,1145,O
the,1145,O
upper,1145,O
extremities,1145,O
.,1145,O
We,1146,O
previously,1146,O
implicated,1146,O
mutations,1146,O
in,1146,O
the,1146,O
gene,1146,O
encoding,1146,O
glycyl-tRNA,1146,B-GENE-Y
synthetase,1146,I-GENE-Y
(,1146,O
GARS,1146,B-GENE-Y
),1146,O
as,1146,O
the,1146,O
cause,1146,O
of,1146,O
CMT2D,1146,O
and,1146,O
dSMA-V.,1146,O
GARS,1146,B-GENE-Y
is,1146,O
a,1146,O
member,1146,O
of,1146,O
the,1146,O
family,1146,O
of,1146,O
aminoacyl-tRNA,1146,B-GENE-N
synthetases,1146,I-GENE-N
responsible,1146,O
for,1146,O
charging,1146,O
tRNA,1146,O
with,1146,O
cognate,1146,O
amino,1146,B-CHEMICAL
acids,1146,I-CHEMICAL
;,1146,O
GARS,1146,B-GENE-Y
ligates,1146,O
glycine,1146,B-CHEMICAL
to,1146,O
tRNA,1146,O
(,1146,O
Gly,1146,O
),1146,O
.,1146,O
Here,1147,O
",",1147,O
we,1147,O
present,1147,O
functional,1147,O
analyses,1147,O
of,1147,O
disease-associated,1147,O
GARS,1147,B-GENE-Y
mutations,1147,O
and,1147,O
show,1147,O
that,1147,O
there,1147,O
are,1147,O
not,1147,O
any,1147,O
significant,1147,O
mutation-associated,1147,O
changes,1147,O
in,1147,O
GARS,1147,B-GENE-Y
expression,1147,O
levels,1147,O
;,1147,O
that,1147,O
the,1147,O
majority,1147,O
of,1147,O
identified,1147,O
GARS,1147,B-GENE-Y
mutations,1147,O
modeled,1147,O
in,1147,O
yeast,1147,O
severely,1147,O
impair,1147,O
viability,1147,O
;,1147,O
and,1147,O
that,1147,O
",",1147,O
in,1147,O
most,1147,O
cases,1147,O
",",1147,O
mutant,1147,O
GARS,1147,B-GENE-Y
protein,1147,O
mislocalizes,1147,O
in,1147,O
neuronal,1147,O
cells,1147,O
.,1147,O
Indeed,1148,O
",",1148,O
four,1148,O
of,1148,O
the,1148,O
five,1148,O
mutations,1148,O
studied,1148,O
show,1148,O
loss-of-function,1148,O
features,1148,O
in,1148,O
at,1148,O
least,1148,O
one,1148,O
assay,1148,O
",",1148,O
suggesting,1148,O
that,1148,O
tRNA-charging,1148,O
deficits,1148,O
play,1148,O
a,1148,O
role,1148,O
in,1148,O
disease,1148,O
pathogenesis,1148,O
.,1148,O
Finally,1149,O
",",1149,O
we,1149,O
detected,1149,O
endogenous,1149,O
GARS-associated,1149,B-GENE-Y
granules,1149,O
in,1149,O
the,1149,O
neurite,1149,O
projections,1149,O
of,1149,O
cultured,1149,O
neurons,1149,O
and,1149,O
in,1149,O
the,1149,O
peripheral,1149,O
nerve,1149,O
axons,1149,O
of,1149,O
normal,1149,O
human,1149,O
tissue,1149,O
.,1149,O
These,1150,O
data,1150,O
are,1150,O
particularly,1150,O
important,1150,O
in,1150,O
light,1150,O
of,1150,O
the,1150,O
recent,1150,O
identification,1150,O
of,1150,O
CMT-associated,1150,O
mutations,1150,O
in,1150,O
another,1150,O
tRNA,1150,B-GENE-N
synthetase,1150,I-GENE-N
gene,1150,O
[,1150,O
YARS,1150,B-GENE-Y
(,1150,O
tyrosyl-tRNA,1150,B-GENE-Y
synthetase,1150,I-GENE-Y
gene,1150,O
),1150,O
],1150,O
.,1150,O
Together,1151,O
",",1151,O
these,1151,O
findings,1151,O
suggest,1151,O
that,1151,O
tRNA-charging,1151,B-GENE-N
enzymes,1151,I-GENE-N
play,1151,O
a,1151,O
key,1151,O
role,1151,O
in,1151,O
maintaining,1151,O
peripheral,1151,O
axons,1151,O
.,1151,O
IFN-gamma-induced,1152,B-GENE-Y
IDO,1152,B-GENE-Y
and,1152,O
WRS,1152,B-GENE-Y
expression,1152,O
in,1152,O
microglia,1152,O
is,1152,O
differentially,1152,O
regulated,1152,O
by,1152,O
IL-4,1152,B-GENE-Y
.,1152,O
Indoleamine,1153,B-GENE-Y
"2,3-dioxygenase",1153,I-GENE-Y
(,1153,O
IDO,1153,B-GENE-Y
),1153,O
",",1153,O
a,1153,O
tryptophan,1153,B-CHEMICAL
catabolizing,1153,O
enzyme,1153,O
",",1153,O
has,1153,O
been,1153,O
implicated,1153,O
in,1153,O
the,1153,O
pathogenesis,1153,O
of,1153,O
various,1153,O
neurological,1153,O
disorders,1153,O
.,1153,O
IDO,1154,B-GENE-Y
expression,1154,O
is,1154,O
induced,1154,O
by,1154,O
IFN-gamma,1154,B-GENE-Y
and,1154,O
leads,1154,O
to,1154,O
neurotoxicity,1154,O
by,1154,O
generating,1154,O
quinolinic,1154,B-CHEMICAL
acid,1154,I-CHEMICAL
.,1154,O
Additionally,1155,O
",",1155,O
it,1155,O
inhibits,1155,O
the,1155,O
immune,1155,O
response,1155,O
through,1155,O
both,1155,O
tryptophan,1155,B-CHEMICAL
depletion,1155,O
and,1155,O
generating,1155,O
other,1155,O
tryptophan,1155,B-CHEMICAL
catabolites,1155,O
.,1155,O
IL-4,1156,B-GENE-Y
and,1156,O
IL-13,1156,B-GENE-Y
have,1156,O
been,1156,O
shown,1156,O
to,1156,O
control,1156,O
IDO,1156,B-GENE-Y
expression,1156,O
by,1156,O
antagonizing,1156,O
the,1156,O
effects,1156,O
of,1156,O
IFN-gamma,1156,B-GENE-Y
in,1156,O
different,1156,O
cell,1156,O
types,1156,O
.,1156,O
Here,1157,O
",",1157,O
we,1157,O
investigated,1157,O
the,1157,O
effects,1157,O
of,1157,O
these,1157,O
cytokines,1157,B-GENE-N
on,1157,O
IDO,1157,B-GENE-Y
expression,1157,O
in,1157,O
microglia,1157,O
.,1157,O
Interestingly,1158,O
",",1158,O
we,1158,O
observed,1158,O
that,1158,O
both,1158,O
IL-4,1158,B-GENE-Y
and,1158,O
IL-13,1158,B-GENE-Y
greatly,1158,O
enhanced,1158,O
IFN-gamma-induced,1158,B-GENE-Y
IDO,1158,B-GENE-Y
expression,1158,O
.,1158,O
However,1159,O
",",1159,O
tryptophanyl-tRNA,1159,B-GENE-Y
synthetase,1159,I-GENE-Y
(,1159,O
WRS,1159,B-GENE-Y
),1159,O
",",1159,O
which,1159,O
is,1159,O
coinduced,1159,O
with,1159,O
IDO,1159,B-GENE-Y
by,1159,O
IFN-gamma,1159,B-GENE-Y
",",1159,O
is,1159,O
downregulated,1159,O
by,1159,O
IL-4,1159,B-GENE-Y
and,1159,O
IL-13,1159,B-GENE-Y
.,1159,O
The,1160,O
effect,1160,O
of,1160,O
IL-4,1160,B-GENE-Y
and,1160,O
IL-13,1160,B-GENE-Y
was,1160,O
independent,1160,O
of,1160,O
STAT-6,1160,B-GENE-Y
.,1160,O
Modulation,1161,O
of,1161,O
IDO,1161,B-GENE-Y
but,1161,O
not,1161,O
WRS,1161,B-GENE-Y
was,1161,O
eliminated,1161,O
by,1161,O
inhibition,1161,O
of,1161,O
protein,1161,B-GENE-N
phosphatase,1161,I-GENE-N
2A,1161,I-GENE-N
(,1161,O
PP2A,1161,B-GENE-N
),1161,O
activity,1161,O
.,1161,O
The,1162,O
phosphatidylinositol,1162,B-GENE-N
3-kinase,1162,I-GENE-N
(,1162,O
PI3K,1162,B-GENE-N
),1162,O
pathway,1162,O
further,1162,O
differentiated,1162,O
the,1162,O
regulation,1162,O
of,1162,O
these,1162,O
two,1162,O
enzymes,1162,O
",",1162,O
as,1162,O
inhibiting,1162,O
the,1162,O
PI3K,1162,B-GENE-N
pathway,1162,O
eliminated,1162,O
IFN-gamma,1162,B-GENE-Y
induction,1162,O
of,1162,O
IDO,1162,B-GENE-Y
",",1162,O
whereas,1162,O
such,1162,O
inhibition,1162,O
greatly,1162,O
enhanced,1162,O
WRS,1162,B-GENE-Y
expression,1162,O
.,1162,O
These,1163,O
findings,1163,O
show,1163,O
discordance,1163,O
between,1163,O
modulations,1163,O
of,1163,O
expression,1163,O
of,1163,O
two,1163,O
distinct,1163,O
enzymes,1163,O
utilizing,1163,O
tryptophan,1163,B-CHEMICAL
as,1163,O
a,1163,O
common,1163,O
substrate,1163,O
",",1163,O
and,1163,O
raise,1163,O
the,1163,O
possibility,1163,O
of,1163,O
their,1163,O
involvement,1163,O
in,1163,O
regulating,1163,O
immune,1163,O
responses,1163,O
in,1163,O
various,1163,O
neurological,1163,O
disorders,1163,O
.,1163,O
SIRT1,1164,B-GENE-Y
inhibits,1164,O
NADPH,1164,B-GENE-N
oxidase,1164,I-GENE-N
activation,1164,O
and,1164,O
protects,1164,O
endothelial,1164,O
function,1164,O
in,1164,O
the,1164,O
rat,1164,O
aorta,1164,O
:,1164,O
Implications,1164,O
for,1164,O
vascular,1164,O
aging,1164,O
.,1164,O
Vascular,1165,O
aging,1165,O
is,1165,O
characterized,1165,O
by,1165,O
up-regulation,1165,O
of,1165,O
NADPH,1165,B-GENE-N
oxidase,1165,I-GENE-N
",",1165,O
oxidative,1165,O
stress,1165,O
and,1165,O
endothelial,1165,O
dysfunction,1165,O
.,1165,O
Previous,1166,O
studies,1166,O
demonstrate,1166,O
that,1166,O
the,1166,O
activity,1166,O
of,1166,O
the,1166,O
evolutionarily,1166,O
conserved,1166,O
NAD,1166,B-GENE-Y
(,1166,I-GENE-Y
+,1166,I-GENE-Y
),1166,I-GENE-Y
-dependent,1166,I-GENE-Y
deacetylase,1166,I-GENE-Y
SIRT1,1166,I-GENE-Y
declines,1166,O
with,1166,O
age,1166,O
and,1166,O
that,1166,O
pharmacological,1166,O
activators,1166,O
of,1166,O
SIRT1,1166,B-GENE-Y
confer,1166,O
significant,1166,O
anti-aging,1166,O
cardiovascular,1166,O
effects,1166,O
.,1166,O
To,1167,O
determine,1167,O
whether,1167,O
dysregulation,1167,O
of,1167,O
SIRT1,1167,B-GENE-Y
promotes,1167,O
NADPH,1167,B-GENE-N
oxidase-dependent,1167,O
production,1167,O
of,1167,O
reactive,1167,O
oxygen,1167,B-CHEMICAL
species,1167,O
(,1167,O
ROS,1167,O
),1167,O
and,1167,O
impairs,1167,O
endothelial,1167,O
function,1167,O
we,1167,O
assessed,1167,O
the,1167,O
effects,1167,O
of,1167,O
three,1167,O
structurally,1167,O
different,1167,O
inhibitors,1167,O
of,1167,O
SIRT1,1167,B-GENE-Y
(,1167,O
nicotinamide,1167,B-CHEMICAL
",",1167,O
sirtinol,1167,B-CHEMICAL
",",1167,O
EX527,1167,B-CHEMICAL
),1167,O
in,1167,O
aorta,1167,O
segments,1167,O
isolated,1167,O
from,1167,O
young,1167,O
Wistar,1167,O
rats,1167,O
.,1167,O
Inhibition,1168,O
of,1168,O
SIRT1,1168,B-GENE-Y
induced,1168,O
endothelial,1168,O
dysfunction,1168,O
",",1168,O
as,1168,O
shown,1168,O
by,1168,O
the,1168,O
significantly,1168,O
reduced,1168,O
relaxation,1168,O
to,1168,O
the,1168,O
endothelium-dependent,1168,O
vasodilators,1168,O
acetylcholine,1168,B-CHEMICAL
and,1168,O
the,1168,O
calcium,1168,B-CHEMICAL
ionophore,1168,O
A23187,1168,B-CHEMICAL
.,1168,O
Endothelial,1169,O
dysfunction,1169,O
induced,1169,O
by,1169,O
SIRT1,1169,B-GENE-Y
inhibition,1169,O
was,1169,O
prevented,1169,O
by,1169,O
treatment,1169,O
of,1169,O
the,1169,O
vessels,1169,O
with,1169,O
the,1169,O
NADPH,1169,B-GENE-N
oxidase,1169,I-GENE-N
inhibitor,1169,O
apocynin,1169,B-CHEMICAL
or,1169,O
superoxide,1169,B-GENE-N
dismutase,1169,I-GENE-N
.,1169,O
Inhibition,1170,O
of,1170,O
SIRT1,1170,B-GENE-Y
significantly,1170,O
increased,1170,O
vascular,1170,O
superoxide,1170,B-CHEMICAL
production,1170,O
",",1170,O
enhanced,1170,O
NADPH,1170,B-GENE-N
oxidase,1170,I-GENE-N
activity,1170,O
",",1170,O
and,1170,O
mRNA,1170,O
expression,1170,O
of,1170,O
its,1170,O
subunits,1170,O
p22,1170,B-GENE-Y
(,1170,I-GENE-Y
phox,1170,I-GENE-Y
),1170,I-GENE-Y
and,1170,O
NOX4,1170,B-GENE-Y
",",1170,O
which,1170,O
were,1170,O
prevented,1170,O
by,1170,O
resveratrol,1170,B-CHEMICAL
.,1170,O
Peroxisome,1171,B-GENE-Y
proliferator-activated,1171,I-GENE-Y
receptor-α,1171,I-GENE-Y
(,1171,O
PPARα,1171,B-GENE-Y
),1171,O
activation,1171,O
mimicked,1171,O
the,1171,O
effects,1171,O
of,1171,O
resveratrol,1171,B-CHEMICAL
while,1171,O
PPARα,1171,B-GENE-Y
inhibition,1171,O
prevented,1171,O
the,1171,O
effects,1171,O
of,1171,O
this,1171,O
SIRT1,1171,B-GENE-Y
activator,1171,O
.,1171,O
SIRT1,1172,B-GENE-Y
co-precipitated,1172,O
with,1172,O
PPARα,1172,B-GENE-Y
and,1172,O
nicotinamide,1172,B-CHEMICAL
increased,1172,O
the,1172,O
acetylation,1172,O
of,1172,O
the,1172,O
PPARα,1172,B-GENE-Y
coactivator,1172,O
PGC-1α,1172,B-GENE-Y
",",1172,O
which,1172,O
was,1172,O
suppressed,1172,O
by,1172,O
resveratrol,1172,B-CHEMICAL
.,1172,O
In,1173,O
conclusion,1173,O
",",1173,O
impaired,1173,O
activity,1173,O
of,1173,O
SIRT1,1173,B-GENE-Y
induces,1173,O
endothelial,1173,O
dysfunction,1173,O
and,1173,O
up-regulates,1173,O
NADPH,1173,B-GENE-N
oxidase-derived,1173,O
ROS,1173,O
production,1173,O
in,1173,O
the,1173,O
vascular,1173,O
wall,1173,O
",",1173,O
mimicking,1173,O
the,1173,O
vascular,1173,O
aging,1173,O
phenotype,1173,O
.,1173,O
Moreover,1174,O
",",1174,O
a,1174,O
new,1174,O
mechanism,1174,O
for,1174,O
controlling,1174,O
endothelial,1174,O
function,1174,O
after,1174,O
SIRT1,1174,B-GENE-Y
activation,1174,O
involves,1174,O
a,1174,O
decreased,1174,O
PGC-1α,1174,B-GENE-Y
acetylation,1174,O
and,1174,O
the,1174,O
subsequent,1174,O
PPARα,1174,B-GENE-Y
activation,1174,O
",",1174,O
resulting,1174,O
in,1174,O
both,1174,O
decreased,1174,O
NADPH,1174,B-GENE-N
oxidase-driven,1174,O
ROS,1174,O
production,1174,O
and,1174,O
NO,1174,B-CHEMICAL
inactivation,1174,O
.,1174,O
EROD,1175,B-GENE-N
activity,1175,O
induction,1175,O
in,1175,O
peripheral,1175,O
blood,1175,O
lymphocytes,1175,O
",",1175,O
liver,1175,O
and,1175,O
brain,1175,O
tissues,1175,O
of,1175,O
rats,1175,O
orally,1175,O
exposed,1175,O
to,1175,O
polycyclic,1175,B-CHEMICAL
aromatic,1175,I-CHEMICAL
hydrocarbons,1175,I-CHEMICAL
.,1175,O
Little,1176,O
is,1176,O
known,1176,O
in,1176,O
terms,1176,O
of,1176,O
multi-matrix,1176,O
cytochrome,1176,B-GENE-N
P450,1176,I-GENE-N
activity,1176,O
induction,1176,O
under,1176,O
repeated,1176,O
oral,1176,O
exposure,1176,O
to,1176,O
planar,1176,O
halogenated,1176,B-CHEMICAL
and,1176,I-CHEMICAL
polycyclic,1176,I-CHEMICAL
aromatic,1176,I-CHEMICAL
hydrocarbons,1176,I-CHEMICAL
(,1176,O
PHH,1176,O
",",1176,O
PAH,1176,B-CHEMICAL
),1176,O
.,1176,O
In,1177,O
the,1177,O
present,1177,O
study,1177,O
",",1177,O
60,1177,O
rats,1177,O
were,1177,O
daily,1177,O
exposed,1177,O
",",1177,O
during,1177,O
28days,1177,O
",",1177,O
to,1177,O
oral,1177,O
ingestion,1177,O
of,1177,O
a,1177,O
mixture,1177,O
consisting,1177,O
of,1177,O
phenanthrene,1177,B-CHEMICAL
",",1177,O
pyrene,1177,B-CHEMICAL
and,1177,O
benzo,1177,B-CHEMICAL
(,1177,I-CHEMICAL
a,1177,I-CHEMICAL
),1177,I-CHEMICAL
pyrene,1177,I-CHEMICAL
at,1177,O
0,1177,O
",",1177,O
6,1177,O
or,1177,O
600μg/day,1177,O
.,1177,O
EROD,1178,B-GENE-N
activity,1178,O
",",1178,O
reflecting,1178,O
almost,1178,O
exclusively,1178,O
CYP1A1,1178,B-GENE-Y
and,1178,O
CYP1B1,1178,B-GENE-Y
activities,1178,O
",",1178,O
was,1178,O
measured,1178,O
in,1178,O
brain,1178,O
and,1178,O
liver,1178,O
microsomes,1178,O
as,1178,O
well,1178,O
as,1178,O
in,1178,O
peripheral,1178,O
blood,1178,O
lymphocytes,1178,O
(,1178,O
PBLs,1178,O
),1178,O
.,1178,O
All,1179,O
induction,1179,O
kinetics,1179,O
could,1179,O
be,1179,O
appropriately,1179,O
fitted,1179,O
using,1179,O
logistic-like,1179,O
models,1179,O
.,1179,O
After,1180,O
28days,1180,O
of,1180,O
exposure,1180,O
to,1180,O
a,1180,O
6μg/day,1180,O
dose,1180,O
",",1180,O
EROD,1180,B-GENE-N
activity,1180,O
was,1180,O
found,1180,O
to,1180,O
be,1180,O
91,1180,O
",",1180,O
152,1180,O
and,1180,O
94-fold,1180,O
increased,1180,O
in,1180,O
lymphocytes,1180,O
",",1180,O
liver,1180,O
and,1180,O
brain,1180,O
",",1180,O
respectively,1180,O
",",1180,O
compared,1180,O
to,1180,O
day,1180,O
0,1180,O
.,1180,O
Plateau,1181,O
activities,1181,O
could,1181,O
be,1181,O
appropriately,1181,O
fitted,1181,O
versus,1181,O
ingested,1181,O
doses,1181,O
using,1181,O
Hill,1181,O
or,1181,O
Michaelis-Menten,1181,O
models,1181,O
.,1181,O
Correlations,1182,O
between,1182,O
matrices,1182,O
made,1182,O
it,1182,O
possible,1182,O
to,1182,O
conclude,1182,O
that,1182,O
EROD,1182,B-GENE-N
activity,1182,O
in,1182,O
PBL,1182,O
should,1182,O
be,1182,O
considered,1182,O
as,1182,O
a,1182,O
sensitive,1182,O
",",1182,O
convenient,1182,O
and,1182,O
non-destructive,1182,O
approach,1182,O
for,1182,O
(,1182,O
i,1182,O
),1182,O
evaluating,1182,O
EROD,1182,B-GENE-N
activity,1182,O
in,1182,O
liver,1182,O
",",1182,O
which,1182,O
was,1182,O
found,1182,O
to,1182,O
represent,1182,O
98,1182,O
%,1182,O
of,1182,O
the,1182,O
observed,1182,O
EROD,1182,B-GENE-N
activities,1182,O
in,1182,O
the,1182,O
three,1182,O
tested,1182,O
matrices,1182,O
and,1182,O
(,1182,O
ii,1182,O
),1182,O
evaluating,1182,O
oral,1182,O
exposure,1182,O
of,1182,O
homogeneous,1182,O
groups,1182,O
of,1182,O
farm,1182,O
animals,1182,O
(,1182,O
race,1182,O
",",1182,O
diet,1182,O
),1182,O
to,1182,O
CYP,1182,B-GENE-N
inducing,1182,O
PAH,1182,O
and,1182,O
PHH,1182,B-CHEMICAL
.,1182,O
Genome-wide,1183,O
screen,1183,O
for,1183,O
modulation,1183,O
of,1183,O
hepatic,1183,O
apolipoprotein,1183,B-GENE-Y
A-I,1183,I-GENE-Y
(,1183,O
ApoA-I,1183,B-GENE-Y
),1183,O
secretion,1183,O
.,1183,O
Control,1184,O
of,1184,O
plasma,1184,O
cholesterol,1184,B-CHEMICAL
levels,1184,O
is,1184,O
a,1184,O
major,1184,O
therapeutic,1184,O
strategy,1184,O
for,1184,O
management,1184,O
of,1184,O
coronary,1184,O
artery,1184,O
disease,1184,O
(,1184,O
CAD,1184,O
),1184,O
.,1184,O
Although,1185,O
reducing,1185,O
LDL,1185,B-GENE-N
cholesterol,1185,B-CHEMICAL
(,1185,O
LDL-c,1185,B-GENE-N
),1185,O
levels,1185,O
decreases,1185,O
morbidity,1185,O
and,1185,O
mortality,1185,O
",",1185,O
this,1185,O
therapeutic,1185,O
intervention,1185,O
only,1185,O
translates,1185,O
into,1185,O
a,1185,O
25-40,1185,O
%,1185,O
reduction,1185,O
in,1185,O
cardiovascular,1185,O
events,1185,O
.,1185,O
Epidemiological,1186,O
studies,1186,O
have,1186,O
shown,1186,O
that,1186,O
a,1186,O
high,1186,O
LDL-c,1186,B-GENE-N
level,1186,O
is,1186,O
not,1186,O
the,1186,O
only,1186,O
risk,1186,O
factor,1186,O
for,1186,O
CAD,1186,O
;,1186,O
low,1186,O
HDL,1186,B-GENE-N
cholesterol,1186,B-CHEMICAL
(,1186,O
HDL-c,1186,B-GENE-N
),1186,O
is,1186,O
an,1186,O
independent,1186,O
risk,1186,O
factor,1186,O
for,1186,O
CAD,1186,O
.,1186,O
Apolipoprotein,1187,B-GENE-Y
A-I,1187,O
(,1187,O
ApoA-I,1187,B-GENE-Y
),1187,O
is,1187,O
the,1187,O
major,1187,O
protein,1187,O
component,1187,O
of,1187,O
HDL-c,1187,B-GENE-N
that,1187,O
mediates,1187,O
reverse,1187,O
cholesterol,1187,B-CHEMICAL
transport,1187,O
from,1187,O
tissues,1187,O
to,1187,O
the,1187,O
liver,1187,O
for,1187,O
excretion,1187,O
.,1187,O
Therefore,1188,O
",",1188,O
increasing,1188,O
ApoA-I,1188,B-GENE-Y
levels,1188,O
is,1188,O
an,1188,O
attractive,1188,O
strategy,1188,O
for,1188,O
HDL-c,1188,B-GENE-N
elevation,1188,O
.,1188,O
Using,1189,O
genome-wide,1189,O
siRNA,1189,O
screening,1189,O
",",1189,O
targets,1189,O
that,1189,O
regulate,1189,O
hepatocyte,1189,O
ApoA-I,1189,B-GENE-Y
secretion,1189,O
were,1189,O
identified,1189,O
through,1189,O
transfection,1189,O
of,1189,O
"21,789",1189,O
siRNAs,1189,O
into,1189,O
hepatocytes,1189,O
whereby,1189,O
cell,1189,O
supernatants,1189,O
were,1189,O
assayed,1189,O
for,1189,O
ApoA-I,1189,B-GENE-Y
.,1189,O
Approximately,1190,O
800,1190,O
genes,1190,O
were,1190,O
identified,1190,O
and,1190,O
triaged,1190,O
using,1190,O
a,1190,O
convergence,1190,O
of,1190,O
information,1190,O
",",1190,O
including,1190,O
genetic,1190,O
associations,1190,O
with,1190,O
HDL-c,1190,B-GENE-N
levels,1190,O
",",1190,O
tissue-specific,1190,O
gene,1190,O
expression,1190,O
",",1190,O
druggability,1190,O
assessments,1190,O
",",1190,O
and,1190,O
pathway,1190,O
analysis,1190,O
.,1190,O
Fifty-nine,1191,O
genes,1191,O
were,1191,O
selected,1191,O
for,1191,O
reconfirmation,1191,O
;,1191,O
40,1191,O
genes,1191,O
were,1191,O
confirmed,1191,O
.,1191,O
Here,1192,O
we,1192,O
describe,1192,O
the,1192,O
siRNA,1192,O
screening,1192,O
strategy,1192,O
",",1192,O
assay,1192,O
implementation,1192,O
and,1192,O
validation,1192,O
",",1192,O
data,1192,O
triaging,1192,O
",",1192,O
and,1192,O
example,1192,O
genes,1192,O
of,1192,O
interest,1192,O
.,1192,O
The,1193,O
genes,1193,O
of,1193,O
interest,1193,O
include,1193,O
known,1193,O
and,1193,O
novel,1193,O
genes,1193,O
encoding,1193,O
secreted,1193,O
enzymes,1193,O
",",1193,O
proteases,1193,O
",",1193,O
G-protein-coupled,1193,B-GENE-N
receptors,1193,I-GENE-N
",",1193,O
metabolic,1193,O
enzymes,1193,O
",",1193,O
ion,1193,B-GENE-N
transporters,1193,I-GENE-N
",",1193,O
and,1193,O
proteins,1193,O
of,1193,O
unknown,1193,O
function,1193,O
.,1193,O
Repression,1194,O
of,1194,O
farnesyltransferase,1194,B-GENE-Y
(,1194,O
FNTA,1194,B-GENE-Y
),1194,O
by,1194,O
siRNA,1194,O
and,1194,O
the,1194,O
enzyme,1194,O
inhibitor,1194,O
manumycin,1194,B-CHEMICAL
A,1194,I-CHEMICAL
caused,1194,O
elevation,1194,O
of,1194,O
ApoA-I,1194,B-GENE-Y
secretion,1194,O
from,1194,O
hepatocytes,1194,O
and,1194,O
from,1194,O
transgenic,1194,O
mice,1194,O
expressing,1194,O
hApoA-I,1194,B-GENE-Y
and,1194,O
cholesterol,1194,B-CHEMICAL
ester,1194,I-CHEMICAL
transfer,1194,O
protein,1194,O
transgenes,1194,O
.,1194,O
In,1195,O
total,1195,O
",",1195,O
this,1195,O
work,1195,O
underscores,1195,O
the,1195,O
power,1195,O
of,1195,O
functional,1195,O
genetic,1195,O
assessment,1195,O
to,1195,O
identify,1195,O
new,1195,O
therapeutic,1195,O
targets,1195,O
.,1195,O
Update,1196,O
on,1196,O
the,1196,O
use,1196,O
of,1196,O
aromatase,1196,B-GENE-Y
inhibitors,1196,O
in,1196,O
breast,1196,O
cancer,1196,O
.,1196,O
Estrogens,1197,B-CHEMICAL
are,1197,O
biosynthesised,1197,O
from,1197,O
androgens,1197,B-CHEMICAL
by,1197,O
the,1197,O
CYP450,1197,B-GENE-N
enzyme,1197,O
complex,1197,O
called,1197,O
aromatase,1197,B-GENE-Y
.,1197,O
Aromatase,1198,B-GENE-Y
is,1198,O
expressed,1198,O
in,1198,O
the,1198,O
ovary,1198,O
",",1198,O
placenta,1198,O
",",1198,O
brain,1198,O
",",1198,O
bone,1198,O
",",1198,O
adipose,1198,O
tissue,1198,O
and,1198,O
breast,1198,O
tissue,1198,O
.,1198,O
In,1199,O
breast,1199,O
cancer,1199,O
",",1199,O
intratumoural,1199,O
aromatase,1199,B-GENE-Y
is,1199,O
the,1199,O
source,1199,O
for,1199,O
local,1199,O
estrogen,1199,B-CHEMICAL
production,1199,O
in,1199,O
the,1199,O
tissue,1199,O
.,1199,O
Inhibition,1200,O
of,1200,O
aromatase,1200,B-GENE-Y
is,1200,O
an,1200,O
important,1200,O
approach,1200,O
for,1200,O
reducing,1200,O
growth,1200,O
stimulatory,1200,O
effects,1200,O
of,1200,O
estrogens,1200,B-CHEMICAL
in,1200,O
estrogen-dependent,1200,B-CHEMICAL
breast,1200,O
cancer,1200,O
.,1200,O
The,1201,O
potent,1201,O
and,1201,O
selective,1201,O
third-generation,1201,O
aromatase,1201,B-GENE-Y
inhibitors,1201,O
anastrozole,1201,B-CHEMICAL
",",1201,O
letrozole,1201,B-CHEMICAL
and,1201,O
exemestane,1201,O
were,1201,O
introduced,1201,O
to,1201,O
the,1201,O
market,1201,O
as,1201,O
endocrine,1201,O
therapy,1201,O
in,1201,O
postmenopausal,1201,O
patients,1201,O
failing,1201,O
anti-estrogen,1201,O
therapy,1201,O
alone,1201,O
",",1201,O
or,1201,O
multiple,1201,O
hormonal,1201,O
therapies,1201,O
.,1201,O
Anastrozole,1202,B-CHEMICAL
and,1202,O
letrozole,1202,B-CHEMICAL
are,1202,O
both,1202,O
non-steroidal,1202,O
aromatase,1202,B-GENE-Y
inhibitors,1202,O
that,1202,O
compete,1202,O
with,1202,O
the,1202,O
substrate,1202,O
for,1202,O
binding,1202,O
to,1202,O
the,1202,O
enzyme,1202,O
active,1202,O
site,1202,O
.,1202,O
Exemestane,1203,O
is,1203,O
a,1203,O
mechanism-based,1203,O
steroidal,1203,B-CHEMICAL
inhibitor,1203,O
that,1203,O
mimics,1203,O
the,1203,O
substrate,1203,O
",",1203,O
is,1203,O
converted,1203,O
by,1203,O
the,1203,O
enzyme,1203,O
to,1203,O
a,1203,O
reactive,1203,O
intermediate,1203,O
",",1203,O
and,1203,O
results,1203,O
in,1203,O
inactivation,1203,O
of,1203,O
aromatase,1203,B-GENE-Y
.,1203,O
These,1204,O
third-generation,1204,O
aromatase,1204,B-GENE-Y
inhibitors,1204,O
are,1204,O
currently,1204,O
approved,1204,O
as,1204,O
first-line,1204,O
therapy,1204,O
for,1204,O
the,1204,O
treatment,1204,O
of,1204,O
postmenopausal,1204,O
women,1204,O
with,1204,O
metastatic,1204,O
estrogen-dependent,1204,B-CHEMICAL
breast,1204,O
cancer,1204,O
.,1204,O
The,1205,O
use,1205,O
of,1205,O
an,1205,O
aromatase,1205,B-GENE-Y
inhibitor,1205,O
as,1205,O
initial,1205,O
therapy,1205,O
",",1205,O
or,1205,O
after,1205,O
treatment,1205,O
with,1205,O
tamoxifen,1205,B-CHEMICAL
",",1205,O
is,1205,O
now,1205,O
recommended,1205,O
as,1205,O
adjuvant,1205,O
hormonal,1205,O
therapy,1205,O
for,1205,O
postmenopausal,1205,O
women,1205,O
with,1205,O
hormone-dependent,1205,O
breast,1205,O
cancer,1205,O
.,1205,O
Several,1206,O
clinical,1206,O
studies,1206,O
of,1206,O
aromatase,1206,B-GENE-Y
inhibitors,1206,O
focus,1206,O
on,1206,O
the,1206,O
use,1206,O
of,1206,O
these,1206,O
agents,1206,O
in,1206,O
the,1206,O
adjuvant,1206,O
setting,1206,O
",",1206,O
for,1206,O
the,1206,O
treatment,1206,O
of,1206,O
early,1206,O
breast,1206,O
cancer,1206,O
.,1206,O
Recently,1207,O
published,1207,O
results,1207,O
show,1207,O
improved,1207,O
responses,1207,O
with,1207,O
these,1207,O
agents,1207,O
compared,1207,O
with,1207,O
tamoxifen,1207,B-CHEMICAL
.,1207,O
High,1208,B-GENE-N
density,1208,I-GENE-N
lipoprotein,1208,I-GENE-N
as,1208,O
a,1208,O
source,1208,O
of,1208,O
cholesterol,1208,B-CHEMICAL
for,1208,O
adrenal,1208,O
steroidogenesis,1208,O
:,1208,O
a,1208,O
study,1208,O
in,1208,O
individuals,1208,O
with,1208,O
low,1208,O
plasma,1208,O
HDL-C.,1208,B-GENE-N
Few,1208,O
studies,1208,O
have,1208,O
addressed,1208,O
the,1208,O
delivery,1208,O
of,1208,O
lipoprotein-derived,1208,B-GENE-N
cholesterol,1208,B-CHEMICAL
to,1208,O
the,1208,O
adrenals,1208,O
for,1208,O
steroid,1208,B-CHEMICAL
production,1208,O
in,1208,O
humans,1208,O
.,1208,O
While,1209,O
there,1209,O
is,1209,O
evidence,1209,O
against,1209,O
a,1209,O
role,1209,O
for,1209,O
low-density,1209,B-GENE-N
lipoprotein,1209,I-GENE-N
(,1209,O
LDL,1209,B-GENE-N
),1209,O
",",1209,O
it,1209,O
is,1209,O
unresolved,1209,O
whether,1209,O
high,1209,B-GENE-N
density,1209,I-GENE-N
lipoprotein,1209,I-GENE-N
(,1209,O
HDL,1209,B-GENE-N
),1209,O
contributes,1209,O
to,1209,O
adrenal,1209,O
steroidogenesis,1209,O
.,1209,O
To,1210,O
study,1210,O
this,1210,O
",",1210,O
steroid,1210,B-CHEMICAL
hormone,1210,I-CHEMICAL
profiles,1210,O
in,1210,O
urine,1210,O
were,1210,O
assessed,1210,O
in,1210,O
male,1210,O
subjects,1210,O
suffering,1210,O
from,1210,O
functional,1210,O
mutations,1210,O
in,1210,O
ATP,1210,B-GENE-Y
binding,1210,I-GENE-Y
cassette,1210,I-GENE-Y
transporter,1210,I-GENE-Y
A1,1210,I-GENE-Y
(,1210,O
ABCA1,1210,B-GENE-Y
),1210,O
(,1210,O
n,1210,O
=,1210,O
24,1210,O
),1210,O
",",1210,O
lecithin,1210,B-GENE-Y
:,1210,I-GENE-Y
cholesterol,1210,I-GENE-Y
acyltransferase,1210,I-GENE-Y
(,1210,O
LCAT,1210,B-GENE-Y
),1210,O
(,1210,O
n,1210,O
=,1210,O
40,1210,O
),1210,O
",",1210,O
as,1210,O
well,1210,O
as,1210,O
in,1210,O
11,1210,O
subjects,1210,O
with,1210,O
low,1210,O
HDL,1210,B-GENE-N
cholesterol,1210,B-CHEMICAL
(,1210,O
HDL-C,1210,B-GENE-N
),1210,O
without,1210,O
ABCA1/LCAT,1210,B-GENE-Y
mutations,1210,O
.,1210,O
HDL-C,1211,B-GENE-N
levels,1211,O
were,1211,O
39,1211,O
%,1211,O
lower,1211,O
in,1211,O
the,1211,O
ABCA1,1211,B-GENE-Y
",",1211,O
LCAT,1211,B-GENE-Y
",",1211,O
and,1211,O
low,1211,O
HDL-C,1211,B-GENE-N
groups,1211,O
compared,1211,O
with,1211,O
controls,1211,O
(,1211,O
all,1211,O
P,1211,O
<,1211,O
0.001,1211,O
),1211,O
.,1211,O
In,1212,O
all,1212,O
groups,1212,O
with,1212,O
low,1212,O
HDL-C,1212,B-GENE-N
levels,1212,O
",",1212,O
urinary,1212,O
excretion,1212,O
of,1212,O
17-ketogenic,1212,B-CHEMICAL
steroids,1212,I-CHEMICAL
was,1212,O
reduced,1212,O
by,1212,O
33,1212,O
%,1212,O
",",1212,O
27,1212,O
%,1212,O
",",1212,O
and,1212,O
32,1212,O
%,1212,O
compared,1212,O
with,1212,O
controls,1212,O
(,1212,O
all,1212,O
P,1212,O
<,1212,O
0.04,1212,O
),1212,O
.,1212,O
In,1213,O
seven,1213,O
carriers,1213,O
of,1213,O
either,1213,O
type,1213,O
of,1213,O
mutation,1213,O
",",1213,O
adrenocorticotropic,1213,B-GENE-Y
hormone,1213,I-GENE-Y
(,1213,O
ACTH,1213,B-GENE-Y
),1213,O
stimulation,1213,O
did,1213,O
not,1213,O
reveal,1213,O
differences,1213,O
from,1213,O
normolipidemic,1213,O
controls,1213,O
.,1213,O
In,1214,O
conclusion,1214,O
",",1214,O
this,1214,O
study,1214,O
shows,1214,O
that,1214,O
basal,1214,O
but,1214,O
not,1214,O
stimulated,1214,O
corticosteroid,1214,O
metabolism,1214,O
is,1214,O
attenuated,1214,O
in,1214,O
subjects,1214,O
with,1214,O
low,1214,O
HDL-C,1214,B-GENE-N
",",1214,O
irrespective,1214,O
of,1214,O
its,1214,O
molecular,1214,O
origin,1214,O
.,1214,O
These,1215,O
findings,1215,O
lend,1215,O
support,1215,O
to,1215,O
a,1215,O
role,1215,O
for,1215,O
HDL,1215,B-GENE-N
as,1215,O
a,1215,O
cholesterol,1215,B-CHEMICAL
donor,1215,O
for,1215,O
basal,1215,O
adrenal,1215,O
steroidogenesis,1215,O
in,1215,O
humans,1215,O
.,1215,O
Neural,1216,O
tube,1216,O
defects,1216,O
and,1216,O
folate,1216,B-CHEMICAL
pathway,1216,O
genes,1216,O
:,1216,O
family-based,1216,O
association,1216,O
tests,1216,O
of,1216,O
gene-gene,1216,O
and,1216,O
gene-environment,1216,O
interactions,1216,O
.,1216,O
BACKGROUND,1217,O
:,1217,O
Folate,1217,B-CHEMICAL
metabolism,1217,O
pathway,1217,O
genes,1217,O
have,1217,O
been,1217,O
examined,1217,O
for,1217,O
association,1217,O
with,1217,O
neural,1217,O
tube,1217,O
defects,1217,O
(,1217,O
NTDs,1217,O
),1217,O
because,1217,O
folic,1217,B-CHEMICAL
acid,1217,I-CHEMICAL
supplementation,1217,O
reduces,1217,O
the,1217,O
risk,1217,O
of,1217,O
this,1217,O
debilitating,1217,O
birth,1217,O
defect,1217,O
.,1217,O
Most,1218,O
studies,1218,O
addressed,1218,O
these,1218,O
genes,1218,O
individually,1218,O
",",1218,O
often,1218,O
with,1218,O
different,1218,O
populations,1218,O
providing,1218,O
conflicting,1218,O
results,1218,O
.,1218,O
OBJECTIVES,1219,O
:,1219,O
Our,1219,O
study,1219,O
evaluates,1219,O
several,1219,O
folate,1219,B-CHEMICAL
pathway,1219,O
genes,1219,O
for,1219,O
association,1219,O
with,1219,O
human,1219,O
NTDs,1219,O
",",1219,O
incorporating,1219,O
an,1219,O
environmental,1219,O
cofactor,1219,O
:,1219,O
maternal,1219,O
folate,1219,B-CHEMICAL
supplementation,1219,O
.,1219,O
METHODS,1220,O
:,1220,O
In,1220,O
304,1220,O
Caucasian,1220,O
American,1220,O
NTD,1220,O
families,1220,O
with,1220,O
myelomeningocele,1220,O
or,1220,O
anencephaly,1220,O
",",1220,O
we,1220,O
examined,1220,O
28,1220,O
polymorphisms,1220,O
in,1220,O
11,1220,O
genes,1220,O
:,1220,O
folate,1220,B-GENE-Y
receptor,1220,I-GENE-Y
1,1220,I-GENE-Y
",",1220,O
folate,1220,B-GENE-Y
receptor,1220,I-GENE-Y
2,1220,I-GENE-Y
",",1220,O
solute,1220,B-GENE-Y
carrier,1220,I-GENE-Y
family,1220,I-GENE-Y
19,1220,I-GENE-Y
member,1220,I-GENE-Y
1,1220,I-GENE-Y
",",1220,O
transcobalamin,1220,B-GENE-Y
II,1220,I-GENE-Y
",",1220,O
methylenetetrahydrofolate,1220,B-GENE-Y
dehydrogenase,1220,I-GENE-Y
1,1220,I-GENE-Y
",",1220,O
serine,1220,B-GENE-Y
hydroxymethyl-transferase,1220,I-GENE-Y
1,1220,I-GENE-Y
",",1220,I-CHEMICAL
"5,10-methylenetetrahydrofolate",1220,B-GENE-Y
reductase,1220,I-GENE-Y
(,1220,O
MTHFR,1220,B-GENE-Y
),1220,O
",",1220,O
5-methyltetrahydrofolate-homo-cysteine,1220,B-GENE-Y
methyltransferase,1220,I-GENE-Y
",",1220,O
5-methyltetrahydrofolate-homocysteine,1220,B-GENE-Y
methyltransferase,1220,I-GENE-Y
reductase,1220,I-GENE-Y
",",1220,O
betaine-homocysteine,1220,B-GENE-Y
methyltransferase,1220,I-GENE-Y
(,1220,O
BHMT,1220,B-GENE-Y
),1220,O
",",1220,O
and,1220,O
cystathionine-beta-synthase,1220,B-GENE-Y
.,1220,O
RESULTS,1221,O
:,1221,O
Only,1221,O
single,1221,O
nucleotide,1221,B-CHEMICAL
polymorphisms,1221,O
(,1221,O
SNPs,1221,O
),1221,O
in,1221,O
BHMT,1221,B-GENE-Y
were,1221,O
significantly,1221,O
associated,1221,O
in,1221,O
the,1221,O
overall,1221,O
data,1221,O
set,1221,O
;,1221,O
this,1221,O
significance,1221,O
was,1221,O
strongest,1221,O
when,1221,O
mothers,1221,O
took,1221,O
folate-containing,1221,B-CHEMICAL
nutritional,1221,O
supplements,1221,O
before,1221,O
conception,1221,O
.,1221,O
The,1222,O
BHMT,1222,B-GENE-Y
SNP,1222,O
rs3733890,1222,O
was,1222,O
more,1222,O
significant,1222,O
when,1222,O
the,1222,O
data,1222,O
were,1222,O
stratified,1222,O
by,1222,O
preferential,1222,O
transmission,1222,O
of,1222,O
the,1222,O
MTHFR,1222,B-GENE-Y
rs1801133,1222,O
thermolabile,1222,O
T,1222,O
allele,1222,O
from,1222,O
parent,1222,O
to,1222,O
offspring,1222,O
.,1222,O
Other,1223,O
SNPs,1223,O
in,1223,O
folate,1223,B-CHEMICAL
pathway,1223,O
genes,1223,O
were,1223,O
marginally,1223,O
significant,1223,O
in,1223,O
some,1223,O
analyses,1223,O
when,1223,O
stratified,1223,O
by,1223,O
maternal,1223,O
supplementation,1223,O
",",1223,O
MTHFR,1223,B-GENE-Y
",",1223,O
or,1223,O
BHMT,1223,B-GENE-Y
allele,1223,O
transmission,1223,O
.,1223,O
CONCLUSIONS,1224,O
:,1224,O
BHMT,1224,B-GENE-Y
rs3733890,1224,O
is,1224,O
significantly,1224,O
associated,1224,O
in,1224,O
our,1224,O
data,1224,O
set,1224,O
",",1224,O
whereas,1224,O
MTHFR,1224,B-GENE-Y
rs1801133,1224,O
is,1224,O
not,1224,O
a,1224,O
major,1224,O
risk,1224,O
factor,1224,O
.,1224,O
Further,1225,O
investigation,1225,O
of,1225,O
folate,1225,B-CHEMICAL
and,1225,O
methionine,1225,B-CHEMICAL
cycle,1225,O
genes,1225,O
will,1225,O
require,1225,O
extensive,1225,O
SNP,1225,O
genotyping,1225,O
and/or,1225,O
resequencing,1225,O
to,1225,O
identify,1225,O
novel,1225,O
variants,1225,O
",",1225,O
inclusion,1225,O
of,1225,O
environmental,1225,O
factors,1225,O
",",1225,O
and,1225,O
investigation,1225,O
of,1225,O
gene-gene,1225,O
interactions,1225,O
in,1225,O
large,1225,O
data,1225,O
sets,1225,O
.,1225,O
Identification,1226,O
and,1226,O
synthesis,1226,O
of,1226,O
N-,1226,B-CHEMICAL
(,1226,I-CHEMICAL
thiophen-2-yl,1226,I-CHEMICAL
),1226,I-CHEMICAL
benzamide,1226,I-CHEMICAL
derivatives,1226,O
as,1226,O
BRAF,1226,B-GENE-Y
(,1226,O
V600E,1226,B-GENE-N
),1226,O
inhibitors,1226,O
.,1226,O
The,1227,O
V600E,1227,B-GENE-N
BRAF,1227,B-GENE-Y
kinase,1227,B-GENE-N
mutation,1227,O
",",1227,O
which,1227,O
activates,1227,O
the,1227,O
downstream,1227,O
MAPK,1227,B-GENE-N
signaling,1227,O
pathway,1227,O
",",1227,O
commonly,1227,O
occurs,1227,O
in,1227,O
about,1227,O
8,1227,O
%,1227,O
of,1227,O
all,1227,O
human,1227,O
malignancies,1227,O
and,1227,O
about,1227,O
50,1227,O
%,1227,O
of,1227,O
all,1227,O
melanomas,1227,O
.,1227,O
In,1228,O
this,1228,O
study,1228,O
",",1228,O
we,1228,O
employed,1228,O
virtual,1228,O
screening,1228,O
and,1228,O
chemical,1228,O
synthesis,1228,O
to,1228,O
identify,1228,O
a,1228,O
series,1228,O
of,1228,O
N-,1228,B-CHEMICAL
(,1228,I-CHEMICAL
thiophen-2-yl,1228,I-CHEMICAL
),1228,I-CHEMICAL
benzamide,1228,I-CHEMICAL
derivatives,1228,O
as,1228,O
potent,1228,O
BRAF,1228,B-GENE-Y
(,1228,O
V600E,1228,B-GENE-N
),1228,O
inhibitors,1228,O
.,1228,O
Structure-activity,1229,O
relationship,1229,O
studies,1229,O
of,1229,O
these,1229,O
derivatives,1229,O
revealed,1229,O
that,1229,O
compounds,1229,O
b40,1229,O
and,1229,O
b47,1229,O
are,1229,O
the,1229,O
two,1229,O
most,1229,O
potent,1229,O
BRAF,1229,B-GENE-Y
(,1229,O
V600E,1229,B-GENE-N
),1229,O
inhibitors,1229,O
in,1229,O
this,1229,O
series,1229,O
.,1229,O
Robust,1230,O
array-based,1230,O
coregulator,1230,O
binding,1230,O
assay,1230,O
predicting,1230,O
ERα-agonist,1230,B-GENE-Y
potency,1230,O
and,1230,O
generating,1230,O
binding,1230,O
profiles,1230,O
reflecting,1230,O
ligand,1230,O
structure,1230,O
.,1230,O
Testing,1231,O
chemicals,1231,O
for,1231,O
their,1231,O
endocrine-disrupting,1231,O
potential,1231,O
",",1231,O
including,1231,O
interference,1231,O
with,1231,O
estrogen,1231,B-GENE-Y
receptor,1231,I-GENE-Y
(,1231,O
ER,1231,B-GENE-Y
),1231,O
signaling,1231,O
",",1231,O
is,1231,O
an,1231,O
important,1231,O
aspect,1231,O
of,1231,O
chemical,1231,O
safety,1231,O
testing,1231,O
.,1231,O
Because,1232,O
of,1232,O
the,1232,O
practical,1232,O
drawbacks,1232,O
of,1232,O
animal,1232,O
testing,1232,O
",",1232,O
the,1232,O
development,1232,O
of,1232,O
in,1232,O
vitro,1232,O
alternatives,1232,O
for,1232,O
the,1232,O
uterotrophic,1232,O
assay,1232,O
and,1232,O
other,1232,O
in,1232,O
vivo,1232,O
(,1232,O
anti,1232,O
),1232,O
estrogenicity,1232,O
tests,1232,O
has,1232,O
high,1232,O
priority,1232,O
.,1232,O
It,1233,O
was,1233,O
previously,1233,O
demonstrated,1233,O
that,1233,O
an,1233,O
in,1233,O
vitro,1233,O
assay,1233,O
that,1233,O
profiles,1233,O
ligand-induced,1233,O
binding,1233,O
of,1233,O
ERα,1233,B-GENE-Y
to,1233,O
a,1233,O
microarray,1233,O
of,1233,O
coregulator-derived,1233,O
peptides,1233,O
might,1233,O
be,1233,O
a,1233,O
valuable,1233,O
candidate,1233,O
for,1233,O
a,1233,O
panel,1233,O
of,1233,O
in,1233,O
vitro,1233,O
assays,1233,O
aiming,1233,O
at,1233,O
an,1233,O
ultimate,1233,O
replacement,1233,O
of,1233,O
the,1233,O
uterotrophic,1233,O
assay,1233,O
.,1233,O
In,1234,O
the,1234,O
present,1234,O
study,1234,O
",",1234,O
the,1234,O
reproducibility,1234,O
and,1234,O
robustness,1234,O
of,1234,O
this,1234,O
coregulator,1234,O
binding,1234,O
assay,1234,O
was,1234,O
determined,1234,O
by,1234,O
measuring,1234,O
the,1234,O
binding,1234,O
profiles,1234,O
of,1234,O
14,1234,O
model,1234,O
compounds,1234,O
that,1234,O
are,1234,O
recommended,1234,O
by,1234,O
the,1234,O
Office,1234,O
of,1234,O
Prevention,1234,O
",",1234,O
Pesticides,1234,O
and,1234,O
Toxic,1234,O
Substances,1234,O
for,1234,O
testing,1234,O
laboratory,1234,O
proficiency,1234,O
in,1234,O
estrogen,1234,B-GENE-Y
receptor,1234,I-GENE-Y
transactivation,1234,O
assays,1234,O
.,1234,O
With,1235,O
a,1235,O
median,1235,O
coefficient,1235,O
of,1235,O
variation,1235,O
of,1235,O
5.0,1235,O
%,1235,O
and,1235,O
excellent,1235,O
correlation,1235,O
(,1235,O
R,1235,O
(,1235,O
2,1235,O
),1235,O
=,1235,O
0.993,1235,O
),1235,O
between,1235,O
duplicate,1235,O
measurements,1235,O
",",1235,O
the,1235,O
reproducibility,1235,O
of,1235,O
the,1235,O
ERα-coregulator,1235,B-GENE-Y
binding,1235,O
assay,1235,O
was,1235,O
better,1235,O
than,1235,O
the,1235,O
reproducibility,1235,O
of,1235,O
other,1235,O
commonly,1235,O
used,1235,O
in,1235,O
vitro,1235,O
ER,1235,B-GENE-Y
functional,1235,O
assays,1235,O
.,1235,O
In,1236,O
addition,1236,O
",",1236,O
the,1236,O
coregulator,1236,O
binding,1236,O
assay,1236,O
is,1236,O
correctly,1236,O
predicting,1236,O
the,1236,O
estrogenicity,1236,O
for,1236,O
13,1236,O
out,1236,O
of,1236,O
14,1236,O
compounds,1236,O
tested,1236,O
.,1236,O
When,1237,O
the,1237,O
potency,1237,O
of,1237,O
the,1237,O
ER-agonists,1237,B-GENE-Y
to,1237,O
induce,1237,O
ERα-coregulator,1237,B-GENE-Y
binding,1237,O
was,1237,O
compared,1237,O
to,1237,O
their,1237,O
ER,1237,B-GENE-Y
binding,1237,O
affinity,1237,O
",",1237,O
their,1237,O
ranking,1237,O
was,1237,O
similar,1237,O
",",1237,O
and,1237,O
the,1237,O
correlation,1237,O
between,1237,O
the,1237,O
EC50,1237,O
values,1237,O
was,1237,O
excellent,1237,O
(,1237,O
R,1237,O
(,1237,O
2,1237,O
),1237,O
=,1237,O
0.96,1237,O
),1237,O
",",1237,O
as,1237,O
was,1237,O
the,1237,O
correlation,1237,O
with,1237,O
their,1237,O
potency,1237,O
in,1237,O
a,1237,O
transactivation,1237,O
assay,1237,O
(,1237,O
R,1237,O
(,1237,O
2,1237,O
),1237,O
=,1237,O
0.94,1237,O
),1237,O
.,1237,O
Moreover,1238,O
",",1238,O
when,1238,O
the,1238,O
ERα-coregulator,1238,B-GENE-Y
binding,1238,O
profiles,1238,O
were,1238,O
hierarchically,1238,O
clustered,1238,O
using,1238,O
Euclidian,1238,O
cluster,1238,O
distance,1238,O
",",1238,O
the,1238,O
structurally,1238,O
related,1238,O
compounds,1238,O
were,1238,O
found,1238,O
to,1238,O
cluster,1238,O
together,1238,O
",",1238,O
whereas,1238,O
the,1238,O
steroid,1238,B-CHEMICAL
test,1238,O
compounds,1238,O
having,1238,O
an,1238,O
aromatic,1238,O
A-ring,1238,O
were,1238,O
separated,1238,O
from,1238,O
those,1238,O
with,1238,O
a,1238,O
cyclohexene,1238,B-CHEMICAL
A-ring,1238,O
.,1238,O
We,1239,O
concluded,1239,O
that,1239,O
this,1239,O
assay,1239,O
is,1239,O
capable,1239,O
of,1239,O
distinguishing,1239,O
ERα,1239,B-GENE-Y
agonists,1239,O
and,1239,O
antagonists,1239,O
and,1239,O
that,1239,O
it,1239,O
even,1239,O
reflects,1239,O
the,1239,O
structural,1239,O
similarity,1239,O
of,1239,O
ERα,1239,B-GENE-Y
agonists,1239,O
",",1239,O
indicating,1239,O
a,1239,O
potential,1239,O
to,1239,O
achieve,1239,O
identification,1239,O
and,1239,O
classification,1239,O
of,1239,O
ERα,1239,B-GENE-Y
endocrine,1239,O
disruptors,1239,O
with,1239,O
high,1239,O
fidelity,1239,O
.,1239,O
Rapid,1240,O
and,1240,O
specific,1240,O
purification,1240,O
of,1240,O
Argonaute-small,1240,B-GENE-N
RNA,1240,O
complexes,1240,O
from,1240,O
crude,1240,O
cell,1240,O
lysates,1240,O
.,1240,O
Small,1241,O
interfering,1241,O
RNAs,1241,O
(,1241,O
siRNAs,1241,O
),1241,O
direct,1241,O
Argonaute,1241,B-GENE-N
proteins,1241,O
",",1241,O
the,1241,O
core,1241,O
components,1241,O
of,1241,O
the,1241,O
RNA-induced,1241,B-GENE-N
silencing,1241,I-GENE-N
complex,1241,I-GENE-N
(,1241,O
RISC,1241,B-GENE-N
),1241,O
",",1241,O
to,1241,O
cleave,1241,O
complementary,1241,O
target,1241,O
RNAs,1241,O
.,1241,O
Here,1242,O
",",1242,O
we,1242,O
describe,1242,O
a,1242,O
method,1242,O
to,1242,O
purify,1242,O
active,1242,O
RISC,1242,B-GENE-N
containing,1242,O
a,1242,O
single,1242,O
",",1242,O
unique,1242,O
small,1242,O
RNA,1242,O
guide,1242,O
sequence,1242,O
.,1242,O
We,1243,O
begin,1243,O
by,1243,O
capturing,1243,O
RISC,1243,B-GENE-N
using,1243,O
a,1243,O
complementary,1243,O
2'-O-methyl,1243,B-CHEMICAL
oligonucleotide,1243,O
tethered,1243,O
to,1243,O
beads,1243,O
.,1243,O
Unlike,1244,O
other,1244,O
methods,1244,O
that,1244,O
capture,1244,O
RISC,1244,B-GENE-N
but,1244,O
do,1244,O
not,1244,O
allow,1244,O
its,1244,O
recovery,1244,O
",",1244,O
our,1244,O
strategy,1244,O
purifies,1244,O
active,1244,O
",",1244,O
soluble,1244,O
RISC,1244,B-GENE-N
in,1244,O
good,1244,O
yield,1244,O
.,1244,O
The,1245,O
method,1245,O
takes,1245,O
advantage,1245,O
of,1245,O
the,1245,O
finding,1245,O
that,1245,O
RISC,1245,O
partially,1245,O
paired,1245,O
to,1245,O
a,1245,O
target,1245,O
through,1245,O
its,1245,O
siRNA,1245,O
guide,1245,O
dissociates,1245,O
more,1245,O
than,1245,O
300,1245,O
times,1245,O
faster,1245,O
than,1245,O
a,1245,O
fully,1245,O
paired,1245,O
siRNA,1245,O
in,1245,O
RISC,1245,B-GENE-N
.,1245,O
We,1246,O
use,1246,O
this,1246,O
strategy,1246,O
to,1246,O
purify,1246,O
fly,1246,B-GENE-Y
Ago1-,1246,O
and,1246,O
Ago2-RISC,1246,B-GENE-Y
",",1246,O
as,1246,O
well,1246,O
as,1246,O
mouse,1246,B-GENE-Y
AGO2-RISC,1246,I-GENE-Y
.,1246,O
The,1247,O
method,1247,O
can,1247,O
discriminate,1247,O
among,1247,O
RISCs,1247,B-GENE-N
programmed,1247,O
with,1247,O
different,1247,O
guide,1247,O
strands,1247,O
",",1247,O
making,1247,O
it,1247,O
possible,1247,O
to,1247,O
deplete,1247,O
and,1247,O
recover,1247,O
specific,1247,O
RISC,1247,B-GENE-N
populations,1247,O
.,1247,O
Endogenous,1248,O
microRNA,1248,O
:,1248,O
Argonaute,1248,B-GENE-N
complexes,1248,O
can,1248,O
also,1248,O
be,1248,O
purified,1248,O
from,1248,O
cell,1248,O
lysates,1248,O
.,1248,O
Our,1249,O
method,1249,O
scales,1249,O
readily,1249,O
and,1249,O
takes,1249,O
less,1249,O
than,1249,O
a,1249,O
day,1249,O
to,1249,O
complete,1249,O
.,1249,O
Sodium,1250,B-CHEMICAL
fluoride,1250,I-CHEMICAL
induces,1250,O
apoptosis,1250,O
in,1250,O
odontoblasts,1250,O
via,1250,O
a,1250,O
JNK-dependent,1250,B-GENE-N
mechanism,1250,O
.,1250,O
Sodium,1251,B-CHEMICAL
fluoride,1251,I-CHEMICAL
(,1251,O
NaF,1251,B-CHEMICAL
),1251,O
is,1251,O
widely,1251,O
used,1251,O
for,1251,O
the,1251,O
treatment,1251,O
of,1251,O
dental,1251,O
caries,1251,O
and,1251,O
dentin,1251,O
hypersensitivity,1251,O
.,1251,O
However,1252,O
",",1252,O
its,1252,O
pro-apoptotic,1252,O
effect,1252,O
on,1252,O
odontoblasts,1252,O
may,1252,O
lead,1252,O
to,1252,O
harmful,1252,O
side-effects,1252,O
.,1252,O
The,1253,O
purpose,1253,O
of,1253,O
this,1253,O
study,1253,O
was,1253,O
to,1253,O
evaluate,1253,O
the,1253,O
pro-apoptotic,1253,O
effects,1253,O
of,1253,O
NaF,1253,B-CHEMICAL
in,1253,O
odontoblasts,1253,O
and,1253,O
elucidate,1253,O
the,1253,O
possible,1253,O
underlying,1253,O
molecular,1253,O
mechanisms,1253,O
.,1253,O
NaF,1254,B-CHEMICAL
generated,1254,O
cytotoxic,1254,O
effects,1254,O
in,1254,O
odontoblast-lineage,1254,O
cell,1254,O
(,1254,O
OLC,1254,O
),1254,O
in,1254,O
a,1254,O
dose-,1254,O
and,1254,O
time-dependent,1254,O
manner,1254,O
.,1254,O
Exposure,1255,O
of,1255,O
cells,1255,O
to,1255,O
4mM,1255,O
NaF,1255,B-CHEMICAL
for,1255,O
24h,1255,O
induced,1255,O
caspase-3,1255,B-GENE-Y
activation,1255,O
",",1255,O
ultrastructural,1255,O
alterations,1255,O
",",1255,O
and,1255,O
resulted,1255,O
in,1255,O
the,1255,O
translocation,1255,O
of,1255,O
Bax,1255,B-GENE-Y
to,1255,O
the,1255,O
mitochondria,1255,O
and,1255,O
the,1255,O
release,1255,O
of,1255,O
cytochrome,1255,B-GENE-Y
c,1255,I-GENE-Y
from,1255,O
the,1255,O
mitochondrial,1255,O
inter-membrane,1255,O
space,1255,O
into,1255,O
the,1255,O
cytosol,1255,O
",",1255,O
indicating,1255,O
that,1255,O
fluoride-mediated,1255,B-CHEMICAL
apoptosis,1255,O
is,1255,O
mitochondria-dependent,1255,O
.,1255,O
Fluoride,1256,B-CHEMICAL
treatment,1256,O
also,1256,O
increased,1256,O
phosphorylation,1256,O
of,1256,O
JNK,1256,B-GENE-N
and,1256,O
ERK,1256,B-GENE-N
",",1256,O
but,1256,O
not,1256,O
p38,1256,B-GENE-N
",",1256,O
and,1256,O
apoptosis,1256,O
induced,1256,O
by,1256,O
fluoride,1256,B-CHEMICAL
was,1256,O
notably,1256,O
or,1256,O
partly,1256,O
suppressed,1256,O
by,1256,O
treatment,1256,O
with,1256,O
JNK,1256,B-GENE-N
or,1256,O
ERK,1256,B-GENE-N
inhibitors,1256,O
",",1256,O
respectively,1256,O
.,1256,O
Taken,1257,O
together,1257,O
",",1257,O
these,1257,O
findings,1257,O
suggest,1257,O
that,1257,O
NaF,1257,B-CHEMICAL
induces,1257,O
apoptosis,1257,O
in,1257,O
OLC,1257,O
odontoblasts,1257,O
through,1257,O
a,1257,O
JNK-dependent,1257,B-GENE-N
mitochondrial,1257,O
pathway,1257,O
.,1257,O
The,1258,O
potassium,1258,B-GENE-Y
channel,1258,I-GENE-Y
subunit,1258,I-GENE-Y
Kvbeta3,1258,I-GENE-Y
interacts,1258,O
with,1258,O
pannexin,1258,B-GENE-Y
1,1258,I-GENE-Y
and,1258,O
attenuates,1258,O
its,1258,O
sensitivity,1258,O
to,1258,O
changes,1258,O
in,1258,O
redox,1258,O
potentials,1258,O
.,1258,O
Pannexin,1259,B-GENE-Y
1,1259,I-GENE-Y
(,1259,O
Panx1,1259,B-GENE-Y
),1259,O
",",1259,O
a,1259,O
member,1259,O
of,1259,O
the,1259,O
second,1259,O
gap,1259,B-GENE-N
junction,1259,I-GENE-N
protein,1259,I-GENE-N
family,1259,O
identified,1259,O
in,1259,O
vertebrates,1259,O
",",1259,O
appears,1259,O
to,1259,O
preferentially,1259,O
form,1259,O
non-junctional,1259,O
membrane,1259,O
channels,1259,O
.,1259,O
A,1260,O
candidate,1260,O
regulatory,1260,O
protein,1260,O
of,1260,O
Panx1,1260,B-GENE-Y
is,1260,O
the,1260,O
potassium,1260,B-GENE-Y
channel,1260,I-GENE-Y
subunit,1260,I-GENE-Y
Kvbeta3,1260,I-GENE-Y
",",1260,O
previously,1260,O
identified,1260,O
by,1260,O
bacterial,1260,O
two-hybrid,1260,O
strategies,1260,O
.,1260,O
Here,1261,O
",",1261,O
we,1261,O
report,1261,O
on,1261,O
the,1261,O
physical,1261,O
association,1261,O
of,1261,O
Panx1,1261,B-GENE-Y
with,1261,O
Kvbeta3,1261,B-GENE-Y
by,1261,O
immunoprecipitation,1261,O
when,1261,O
co-expressed,1261,O
in,1261,O
a,1261,O
neuroblastoma,1261,O
cell,1261,O
line,1261,O
(,1261,O
Neuro2A,1261,O
),1261,O
.,1261,O
Furthermore,1262,O
",",1262,O
in,1262,O
vivo,1262,O
co-expression,1262,O
of,1262,O
Panx1,1262,B-GENE-Y
and,1262,O
Kvbeta3,1262,B-GENE-Y
was,1262,O
shown,1262,O
to,1262,O
occur,1262,O
in,1262,O
murine,1262,O
hippocampus,1262,O
and,1262,O
cerebellum,1262,O
.,1262,O
Kvbeta3,1263,B-GENE-Y
is,1263,O
known,1263,O
to,1263,O
accelerate,1263,O
inactivation,1263,O
of,1263,O
otherwise,1263,O
slowly,1263,O
inactivating,1263,O
potassium,1263,B-GENE-N
channels,1263,I-GENE-N
under,1263,O
reducing,1263,O
conditions,1263,O
.,1263,O
We,1264,O
subsequently,1264,O
found,1264,O
that,1264,O
Panx1,1264,B-GENE-Y
channel,1264,O
currents,1264,O
exhibit,1264,O
a,1264,O
significant,1264,O
reduction,1264,O
when,1264,O
exposed,1264,O
to,1264,O
reducing,1264,O
agents,1264,O
",",1264,O
and,1264,O
that,1264,O
this,1264,O
effect,1264,O
is,1264,O
attenuated,1264,O
in,1264,O
the,1264,O
presence,1264,O
of,1264,O
Kvbeta3,1264,B-GENE-Y
.,1264,O
Apparently,1265,O
",",1265,O
Kvbeta3,1265,B-GENE-Y
is,1265,O
involved,1265,O
in,1265,O
regulating,1265,O
the,1265,O
susceptibility,1265,O
of,1265,O
Panx1,1265,B-GENE-Y
channels,1265,O
to,1265,O
redox,1265,O
potential,1265,O
.,1265,O
Furthermore,1266,O
",",1266,O
the,1266,O
Panx1,1266,B-GENE-Y
channel,1266,O
blockers,1266,O
carbenoxolone,1266,B-CHEMICAL
and,1266,O
Probenecid,1266,B-CHEMICAL
were,1266,O
less,1266,O
effective,1266,O
in,1266,O
inhibiting,1266,O
Panx1,1266,B-GENE-Y
currents,1266,O
when,1266,O
Kvbeta3,1266,B-GENE-Y
was,1266,O
co-expressed,1266,O
.,1266,O
The,1267,O
influence,1267,O
of,1267,O
Kvbeta3,1267,B-GENE-Y
on,1267,O
Panx1,1267,B-GENE-Y
is,1267,O
the,1267,O
first,1267,O
example,1267,O
of,1267,O
modulation,1267,O
of,1267,O
Panx1,1267,B-GENE-Y
channel,1267,O
function,1267,O
(,1267,O
s,1267,O
),1267,O
by,1267,O
interacting,1267,O
proteins,1267,O
",",1267,O
and,1267,O
suggests,1267,O
the,1267,O
physiological,1267,O
importance,1267,O
of,1267,O
sensing,1267,O
changes,1267,O
in,1267,O
redox,1267,O
potentials,1267,O
.,1267,O
Optoelectronic,1268,O
Processes,1268,O
in,1268,O
Squaraine,1268,B-CHEMICAL
Dye-Doped,1268,O
OLEDs,1268,O
for,1268,O
Emission,1268,O
in,1268,O
the,1268,O
Near-Infrared,1268,O
.,1268,O
A,1269,O
novel,1269,O
all-organic,1269,O
host-guest,1269,O
system,1269,O
for,1269,O
emission,1269,O
in,1269,O
the,1269,O
NIR,1269,O
is,1269,O
introduced,1269,O
and,1269,O
investigated,1269,O
with,1269,O
respect,1269,O
to,1269,O
its,1269,O
opto-electronic,1269,O
processes,1269,O
.,1269,O
The,1270,O
good,1270,O
agreement,1270,O
between,1270,O
theoretical,1270,O
and,1270,O
experimental,1270,O
results,1270,O
highlights,1270,O
the,1270,O
model,1270,O
character,1270,O
of,1270,O
this,1270,O
system,1270,O
and,1270,O
its,1270,O
potential,1270,O
for,1270,O
electroluminescent,1270,O
application,1270,O
.,1270,O
Comparative,1271,O
measurements,1271,O
provide,1271,O
access,1271,O
to,1271,O
the,1271,O
recombination,1271,O
mechanisms,1271,O
on,1271,O
molecular,1271,O
length,1271,O
scale,1271,O
and,1271,O
show,1271,O
that,1271,O
the,1271,O
emission,1271,O
behavior,1271,O
of,1271,O
the,1271,O
device,1271,O
under,1271,O
operation,1271,O
is,1271,O
controlled,1271,O
by,1271,O
charge,1271,O
carrier,1271,O
dynamics,1271,O
.,1271,O
Phosphodiesterase,1272,B-GENE-N
inhibitors,1272,O
.,1272,O
Part,1273,O
5,1273,O
:,1273,O
hybrid,1273,O
PDE3/4,1273,B-GENE-N
inhibitors,1273,O
as,1273,O
dual,1273,O
bronchorelaxant/anti-inflammatory,1273,O
agents,1273,O
for,1273,O
inhaled,1273,O
administration,1273,O
.,1273,O
(,1274,B-CHEMICAL
-,1274,I-CHEMICAL
),1274,I-CHEMICAL
-6-,1274,I-CHEMICAL
(,1274,I-CHEMICAL
7-Methoxy-2-,1274,I-CHEMICAL
(,1274,I-CHEMICAL
trifluoromethyl,1274,I-CHEMICAL
),1274,I-CHEMICAL
pyrazolo,1274,I-CHEMICAL
[,1274,I-CHEMICAL
"1,5-a",1274,I-CHEMICAL
],1274,I-CHEMICAL
pyridin-4-yl,1274,I-CHEMICAL
),1274,I-CHEMICAL
"-5-methyl-4,5-dihydropyridazin-3",1274,I-CHEMICAL
(,1274,I-CHEMICAL
2H,1274,I-CHEMICAL
),1274,I-CHEMICAL
-one,1274,I-CHEMICAL
(,1274,O
KCA-1490,1274,B-CHEMICAL
),1274,O
exhibits,1274,O
moderate,1274,O
dual,1274,O
PDE3/4-inhibitory,1274,B-GENE-N
activity,1274,O
and,1274,O
promises,1274,O
as,1274,O
a,1274,O
combined,1274,O
bronchodilatory/anti-inflammatory,1274,O
agent,1274,O
.,1274,O
N-alkylation,1275,B-CHEMICAL
of,1275,O
the,1275,O
pyridazinone,1275,B-CHEMICAL
ring,1275,O
markedly,1275,O
enhances,1275,O
potency,1275,O
against,1275,O
PDE4,1275,B-GENE-N
but,1275,O
suppresses,1275,O
PDE3,1275,B-GENE-N
inhibition,1275,O
.,1275,O
Addition,1276,O
of,1276,O
a,1276,O
"6-aryl-4,5-dihydropyridazin-3",1276,B-CHEMICAL
(,1276,I-CHEMICAL
2H,1276,I-CHEMICAL
),1276,I-CHEMICAL
-one,1276,I-CHEMICAL
extension,1276,O
to,1276,O
the,1276,O
N-alkyl,1276,B-CHEMICAL
group,1276,O
facilitates,1276,O
both,1276,O
enhancement,1276,O
of,1276,O
PDE4-inhibitory,1276,B-GENE-N
activity,1276,O
and,1276,O
restoration,1276,O
of,1276,O
potent,1276,O
PDE3,1276,B-GENE-N
inhibition,1276,O
.,1276,O
Both,1277,O
dihydropyridazinone,1277,B-CHEMICAL
rings,1277,O
",",1277,O
in,1277,O
the,1277,O
core,1277,O
and,1277,O
extension,1277,O
",",1277,O
can,1277,O
be,1277,O
replaced,1277,O
by,1277,O
achiral,1277,O
"4,4-dimethylpyrazolone",1277,B-CHEMICAL
subunits,1277,O
and,1277,O
the,1277,O
core,1277,O
pyrazolopyridine,1277,B-CHEMICAL
by,1277,O
isosteric,1277,O
bicyclic,1277,O
heteroaromatics,1277,O
.,1277,O
In,1278,O
combination,1278,O
",",1278,O
these,1278,O
modifications,1278,O
afford,1278,O
potent,1278,O
dual,1278,O
PDE3/4,1278,B-GENE-N
inhibitors,1278,O
that,1278,O
suppress,1278,O
histamine-induced,1278,B-CHEMICAL
bronchoconstriction,1278,O
in,1278,O
vivo,1278,O
and,1278,O
exhibit,1278,O
promising,1278,O
anti-inflammatory,1278,O
activity,1278,O
via,1278,O
intratracheal,1278,O
administration,1278,O
.,1278,O
Using,1279,O
a,1279,O
fragment-based,1279,O
approach,1279,O
to,1279,O
target,1279,O
protein-protein,1279,O
interactions,1279,O
.,1279,O
The,1280,O
ability,1280,O
to,1280,O
identify,1280,O
inhibitors,1280,O
of,1280,O
protein-protein,1280,O
interactions,1280,O
represents,1280,O
a,1280,O
major,1280,O
challenge,1280,O
in,1280,O
modern,1280,O
drug,1280,O
discovery,1280,O
and,1280,O
in,1280,O
the,1280,O
development,1280,O
of,1280,O
tools,1280,O
for,1280,O
chemical,1280,O
biology,1280,O
.,1280,O
In,1281,O
recent,1281,O
years,1281,O
",",1281,O
fragment-based,1281,O
approaches,1281,O
have,1281,O
emerged,1281,O
as,1281,O
a,1281,O
new,1281,O
methodology,1281,O
in,1281,O
drug,1281,O
discovery,1281,O
;,1281,O
however,1281,O
",",1281,O
few,1281,O
examples,1281,O
of,1281,O
small,1281,O
molecules,1281,O
that,1281,O
are,1281,O
active,1281,O
against,1281,O
chemotherapeutic,1281,O
targets,1281,O
have,1281,O
been,1281,O
published,1281,O
.,1281,O
Herein,1282,O
",",1282,O
we,1282,O
describe,1282,O
the,1282,O
fragment-based,1282,O
approach,1282,O
of,1282,O
targeting,1282,O
the,1282,O
interaction,1282,O
between,1282,O
the,1282,O
tumour,1282,O
suppressor,1282,O
BRCA2,1282,B-GENE-Y
and,1282,O
the,1282,O
recombination,1282,O
enzyme,1282,O
RAD51,1282,B-GENE-Y
;,1282,O
it,1282,O
makes,1282,O
use,1282,O
of,1282,O
a,1282,O
screening,1282,O
pipeline,1282,O
of,1282,O
biophysical,1282,O
techniques,1282,O
that,1282,O
we,1282,O
expect,1282,O
to,1282,O
be,1282,O
more,1282,O
generally,1282,O
applicable,1282,O
to,1282,O
similar,1282,O
targets,1282,O
.,1282,O
Disruption,1283,O
of,1283,O
this,1283,O
interaction,1283,O
in,1283,O
vivo,1283,O
is,1283,O
hypothesised,1283,O
to,1283,O
give,1283,O
rise,1283,O
to,1283,O
cellular,1283,O
hypersensitivity,1283,O
to,1283,O
radiation,1283,O
and,1283,O
genotoxic,1283,O
drugs,1283,O
.,1283,O
We,1284,O
have,1284,O
used,1284,O
protein,1284,O
engineering,1284,O
to,1284,O
create,1284,O
a,1284,O
monomeric,1284,O
form,1284,O
of,1284,O
RAD51,1284,B-GENE-Y
by,1284,O
humanising,1284,O
a,1284,O
thermostable,1284,O
archaeal,1284,O
orthologue,1284,O
",",1284,O
RadA,1284,B-GENE-N
",",1284,O
and,1284,O
used,1284,O
this,1284,O
protein,1284,O
for,1284,O
fragment,1284,O
screening,1284,O
.,1284,O
The,1285,O
initial,1285,O
fragment,1285,O
hits,1285,O
were,1285,O
thoroughly,1285,O
validated,1285,O
biophysically,1285,O
by,1285,O
isothermal,1285,O
titration,1285,O
calorimetry,1285,O
(,1285,O
ITC,1285,O
),1285,O
and,1285,O
NMR,1285,O
techniques,1285,O
and,1285,O
observed,1285,O
by,1285,O
X-ray,1285,O
crystallography,1285,O
to,1285,O
bind,1285,O
in,1285,O
a,1285,O
shallow,1285,O
surface,1285,O
pocket,1285,O
that,1285,O
is,1285,O
occupied,1285,O
in,1285,O
the,1285,O
native,1285,O
complex,1285,O
by,1285,O
the,1285,O
side,1285,O
chain,1285,O
of,1285,O
a,1285,O
phenylalanine,1285,B-CHEMICAL
from,1285,O
the,1285,O
conserved,1285,O
FxxA,1285,B-GENE-N
interaction,1285,I-GENE-N
motif,1285,I-GENE-N
found,1285,O
in,1285,O
BRCA2,1285,B-GENE-Y
.,1285,O
This,1286,O
represents,1286,O
the,1286,O
first,1286,O
report,1286,O
of,1286,O
fragments,1286,O
or,1286,O
any,1286,O
small,1286,O
molecule,1286,O
binding,1286,O
at,1286,O
this,1286,O
protein-protein,1286,O
interaction,1286,O
site,1286,O
.,1286,O
Fumarate,1287,B-GENE-N
reductase,1287,I-GENE-N
is,1287,O
essential,1287,O
for,1287,O
Helicobacter,1287,O
pylori,1287,O
colonization,1287,O
of,1287,O
the,1287,O
mouse,1287,O
stomach,1287,O
.,1287,O
Fumarate,1288,B-GENE-N
reductase,1288,I-GENE-N
(,1288,O
FRD,1288,B-GENE-N
),1288,O
is,1288,O
the,1288,O
key,1288,O
enzyme,1288,O
in,1288,O
fumarate,1288,B-CHEMICAL
respiration,1288,O
induced,1288,O
by,1288,O
anaerobic,1288,O
growth,1288,O
of,1288,O
bacteria,1288,O
.,1288,O
In,1289,O
Helicobacter,1289,O
pylori,1289,O
",",1289,O
this,1289,O
enzyme,1289,O
appears,1289,O
to,1289,O
be,1289,O
constitutively,1289,O
expressed,1289,O
under,1289,O
microaerobic,1289,O
conditions,1289,O
and,1289,O
is,1289,O
not,1289,O
essential,1289,O
for,1289,O
its,1289,O
survival,1289,O
in,1289,O
vitro,1289,O
.,1289,O
In,1290,O
this,1290,O
study,1290,O
",",1290,O
the,1290,O
role,1290,O
of,1290,O
FRD,1290,B-GENE-N
in,1290,O
the,1290,O
colonization,1290,O
of,1290,O
H.,1290,O
pylori,1290,O
was,1290,O
investigated,1290,O
using,1290,O
a,1290,O
mouse,1290,O
model,1290,O
.,1290,O
The,1291,O
frdA,1291,B-GENE-Y
gene,1291,O
coding,1291,O
for,1291,O
subunit,1291,B-GENE-Y
A,1291,I-GENE-Y
of,1291,I-GENE-Y
FRD,1291,I-GENE-Y
",",1291,O
and,1291,O
two,1291,O
control,1291,O
genes,1291,O
",",1291,O
copA,1291,B-GENE-Y
and,1291,O
copP,1291,B-GENE-Y
associated,1291,O
with,1291,O
the,1291,O
export,1291,O
of,1291,O
copper,1291,B-CHEMICAL
out,1291,O
of,1291,O
H.,1291,O
pylori,1291,O
",",1291,O
were,1291,O
inactivated,1291,O
by,1291,O
insertion,1291,O
of,1291,O
the,1291,O
chloramphenicol,1291,B-CHEMICAL
acetyltransferase,1291,O
cassette,1291,O
into,1291,O
these,1291,O
individual,1291,O
genes,1291,O
.,1291,O
The,1292,O
isogenic,1292,O
mutants,1292,O
of,1292,O
H.,1292,O
pylori,1292,O
strain,1292,O
AH244,1292,O
were,1292,O
obtained,1292,O
by,1292,O
natural,1292,O
transformation,1292,O
.,1292,O
Seventy-five,1293,O
ICR,1293,O
mice,1293,O
(,1293,O
15,1293,O
mice/group,1293,O
),1293,O
were,1293,O
orogastrically,1293,O
dosed,1293,O
with,1293,O
either,1293,O
the,1293,O
wild,1293,O
type,1293,O
H.,1293,O
pylori,1293,O
strain,1293,O
AH244,1293,O
",",1293,O
its,1293,O
isogenic,1293,O
mutants,1293,O
",",1293,O
or,1293,O
Brucella,1293,O
broth,1293,O
(,1293,O
negative,1293,O
control,1293,O
),1293,O
.,1293,O
Five,1294,O
mice,1294,O
from,1294,O
each,1294,O
group,1294,O
were,1294,O
killed,1294,O
at,1294,O
2,1294,O
",",1294,O
4,1294,O
and,1294,O
8,1294,O
weeks,1294,O
post-inoculation,1294,O
(,1294,O
WPI,1294,O
),1294,O
",",1294,O
respectively,1294,O
.,1294,O
H.,1295,O
pylori,1295,O
colonization,1295,O
was,1295,O
not,1295,O
detected,1295,O
in,1295,O
mouse,1295,O
gastric,1295,O
mucosa,1295,O
infected,1295,O
with,1295,O
the,1295,O
frdA,1295,B-GENE-Y
mutant,1295,O
at,1295,O
any,1295,O
time,1295,O
point,1295,O
in,1295,O
the,1295,O
study,1295,O
by,1295,O
both,1295,O
quantitative,1295,O
culture,1295,O
and,1295,O
PCR,1295,O
.,1295,O
In,1296,O
contrast,1296,O
",",1296,O
the,1296,O
mice,1296,O
inoculated,1296,O
with,1296,O
either,1296,O
wild,1296,O
type,1296,O
AH244,1296,O
",",1296,O
copA,1296,B-GENE-Y
or,1296,O
copPH,1296,B-GENE-Y
.,1296,O
pylori,1297,O
mutants,1297,O
became,1297,O
readily,1297,O
infected,1297,O
.,1297,O
These,1298,O
data,1298,O
indicate,1298,O
that,1298,O
FRD,1298,B-GENE-N
plays,1298,O
a,1298,O
crucial,1298,O
role,1298,O
in,1298,O
H.,1298,O
pylori,1298,O
survival,1298,O
in,1298,O
the,1298,O
gastric,1298,O
mucosa,1298,O
of,1298,O
mice,1298,O
.,1298,O
Given,1299,O
that,1299,O
FRD,1299,B-GENE-N
",",1299,O
present,1299,O
in,1299,O
all,1299,O
H.,1299,O
pylori,1299,O
strains,1299,O
",",1299,O
is,1299,O
immunogenic,1299,O
in,1299,O
H.,1299,O
pylori,1299,O
-infected,1299,O
patients,1299,O
and,1299,O
H.,1299,O
pylori,1299,O
growth,1299,O
in,1299,O
vitro,1299,O
can,1299,O
be,1299,O
inhibited,1299,O
by,1299,O
three,1299,O
anthelmintics,1299,O
(,1299,O
morantel,1299,B-CHEMICAL
",",1299,O
oxantel,1299,B-CHEMICAL
and,1299,O
thiabendazole,1299,B-CHEMICAL
),1299,O
",",1299,O
this,1299,O
enzyme,1299,O
could,1299,O
potentially,1299,O
be,1299,O
used,1299,O
both,1299,O
as,1299,O
a,1299,O
novel,1299,O
drug,1299,O
target,1299,O
as,1299,O
well,1299,O
as,1299,O
in,1299,O
the,1299,O
development,1299,O
of,1299,O
vaccines,1299,O
for,1299,O
H.,1299,O
pylori,1299,O
prevention,1299,O
and,1299,O
eradication,1299,O
.,1299,O
Tryptophan,1300,B-GENE-Y
hydroxylase,1300,I-GENE-Y
mRNA,1300,O
levels,1300,O
are,1300,O
elevated,1300,O
by,1300,O
repeated,1300,O
immobilization,1300,O
stress,1300,O
in,1300,O
rat,1300,O
raphe,1300,O
nuclei,1300,O
but,1300,O
not,1300,O
in,1300,O
pineal,1300,O
gland,1300,O
.,1300,O
Repeated,1301,O
stress,1301,O
triggers,1301,O
a,1301,O
wide,1301,O
range,1301,O
of,1301,O
adaptive,1301,O
changes,1301,O
in,1301,O
the,1301,O
central,1301,O
nervous,1301,O
system,1301,O
including,1301,O
the,1301,O
elevation,1301,O
of,1301,O
serotonin,1301,B-CHEMICAL
(,1301,O
5-HT,1301,B-CHEMICAL
),1301,O
metabolism,1301,O
and,1301,O
an,1301,O
increased,1301,O
susceptibility,1301,O
to,1301,O
affective,1301,O
disorders,1301,O
.,1301,O
To,1302,O
begin,1302,O
to,1302,O
examine,1302,O
whether,1302,O
these,1302,O
changes,1302,O
are,1302,O
mediated,1302,O
by,1302,O
alterations,1302,O
in,1302,O
gene,1302,O
expression,1302,O
for,1302,O
tryptophan,1302,B-GENE-Y
hydroxylase,1302,I-GENE-Y
(,1302,O
TPH,1302,B-GENE-Y
),1302,O
",",1302,O
the,1302,O
rate-limiting,1302,O
enzyme,1302,O
in,1302,O
5-HT,1302,B-CHEMICAL
biosynthesis,1302,O
",",1302,O
we,1302,O
quantitated,1302,O
its,1302,O
mRNA,1302,O
levels,1302,O
by,1302,O
competitive,1302,O
reverse,1302,O
transcription-polymerase,1302,O
chain,1302,O
reaction,1302,O
(,1302,O
RT-PCR,1302,O
),1302,O
.,1302,O
Repeated,1303,O
immobilization,1303,O
stress,1303,O
(,1303,O
2,1303,O
h,1303,O
",",1303,O
7,1303,O
days,1303,O
),1303,O
elicited,1303,O
a,1303,O
six-,1303,O
or,1303,O
ten-fold,1303,O
rise,1303,O
in,1303,O
TPH,1303,B-GENE-Y
mRNA,1303,O
in,1303,O
median,1303,O
raphe,1303,O
nucleus,1303,O
(,1303,O
MRN,1303,O
),1303,O
and,1303,O
dorsal,1303,O
raphe,1303,O
nucleus,1303,O
(,1303,O
DRN,1303,O
),1303,O
",",1303,O
respectively,1303,O
",",1303,O
without,1303,O
significantly,1303,O
altering,1303,O
TPH,1303,B-GENE-Y
mRNA,1303,O
levels,1303,O
in,1303,O
the,1303,O
pineal,1303,O
gland,1303,O
.,1303,O
In,1304,O
contrast,1304,O
",",1304,O
there,1304,O
was,1304,O
little,1304,O
change,1304,O
in,1304,O
mRNA,1304,O
levels,1304,O
for,1304,O
GTP,1304,B-GENE-Y
cyclohydrolase,1304,I-GENE-Y
I,1304,I-GENE-Y
(,1304,O
GTPCH,1304,B-GENE-Y
),1304,O
",",1304,O
the,1304,O
rate,1304,O
limiting,1304,O
enzyme,1304,O
in,1304,O
synthesis,1304,O
of,1304,O
the,1304,O
tetrahydrobiopterin,1304,B-CHEMICAL
(,1304,O
BH4,1304,B-CHEMICAL
),1304,O
",",1304,O
the,1304,O
obligate,1304,O
cofactor,1304,O
for,1304,O
TPH,1304,B-GENE-Y
.,1304,O
This,1305,O
is,1305,O
the,1305,O
first,1305,O
study,1305,O
to,1305,O
reveal,1305,O
stress-elicited,1305,O
activation,1305,O
of,1305,O
TPH,1305,B-GENE-Y
gene,1305,O
expression,1305,O
.,1305,O
Iron,1306,B-CHEMICAL
and,1306,O
zinc,1306,B-CHEMICAL
bioavailability,1306,O
in,1306,O
Caco-2,1306,O
cells,1306,O
:,1306,O
influence,1306,O
of,1306,O
caseinophosphopeptides,1306,B-GENE-N
.,1306,O
A,1307,O
study,1307,O
has,1307,O
been,1307,O
made,1307,O
of,1307,O
the,1307,O
influence,1307,O
of,1307,O
two,1307,O
pools,1307,O
of,1307,O
caseinophosphopeptides,1307,B-GENE-N
(,1307,O
CPPs,1307,B-GENE-N
),1307,O
obtained,1307,O
from,1307,O
α,1307,B-GENE-N
(,1307,I-GENE-N
s,1307,I-GENE-N
),1307,I-GENE-N
-,1307,I-GENE-N
and,1307,I-GENE-N
β-casein,1307,I-GENE-N
(,1307,O
CN,1307,B-GENE-N
),1307,O
fractions,1307,O
",",1307,O
and,1307,O
of,1307,O
three,1307,O
specific,1307,O
CPPs,1307,B-GENE-N
(,1307,O
β-CN,1307,B-GENE-Y
(,1307,O
1-25,1307,O
),1307,O
4P,1307,O
",",1307,O
α,1307,B-GENE-Y
(,1307,I-GENE-Y
s1,1307,I-GENE-Y
),1307,I-GENE-Y
-CN,1307,I-GENE-Y
(,1307,O
64-74,1307,O
),1307,O
4P,1307,O
and,1307,O
α,1307,B-GENE-N
(,1307,I-GENE-N
s2,1307,I-GENE-N
),1307,I-GENE-N
-CN,1307,I-GENE-N
(,1307,O
1-19,1307,O
),1307,O
4P,1307,O
),1307,O
",",1307,O
on,1307,O
iron,1307,B-CHEMICAL
bioavailability,1307,O
(,1307,O
ferritin,1307,B-GENE-Y
synthesis,1307,O
),1307,O
and,1307,O
zinc,1307,B-CHEMICAL
bioavailability,1307,O
(,1307,O
retention,1307,O
",",1307,O
transport,1307,O
and,1307,O
uptake,1307,O
of,1307,O
zinc,1307,B-CHEMICAL
),1307,O
in,1307,O
Caco-2,1307,O
cells,1307,O
.,1307,O
α-CPP,1308,B-GENE-N
and,1308,O
β-CPP,1308,B-GENE-N
pools,1308,O
did,1308,O
not,1308,O
improve,1308,O
ferritin,1308,B-GENE-Y
synthesis,1308,O
",",1308,O
but,1308,O
the,1308,O
three,1308,O
specific,1308,O
CPPs,1308,B-GENE-N
showed,1308,O
an,1308,O
increase,1308,O
in,1308,O
ferritin,1308,B-GENE-Y
synthesis,1308,O
in,1308,O
Caco-2,1308,O
cells,1308,O
versus,1308,O
iron,1308,B-CHEMICAL
sulphate,1308,I-CHEMICAL
",",1308,O
β-CN,1308,B-GENE-Y
(,1308,O
1-25,1308,O
),1308,O
4P,1308,O
being,1308,O
the,1308,O
most,1308,O
effective,1308,O
.,1308,O
In,1309,O
relation,1309,O
to,1309,O
zinc,1309,B-CHEMICAL
bioavailability,1309,O
",",1309,O
α-CPPs,1309,B-GENE-N
",",1309,O
β-CPPs,1309,B-GENE-N
",",1309,O
α,1309,B-GENE-Y
(,1309,I-GENE-Y
s1,1309,I-GENE-Y
),1309,I-GENE-Y
-CN,1309,I-GENE-Y
(,1309,O
64-74,1309,O
),1309,O
4P,1309,O
and,1309,O
β-CN,1309,B-GENE-Y
(,1309,O
1-25,1309,O
),1309,O
4P,1309,O
increased,1309,O
zinc,1309,B-CHEMICAL
uptake,1309,O
.,1309,O
However,1310,O
",",1310,O
this,1310,O
increase,1310,O
was,1310,O
of,1310,O
the,1310,O
same,1310,O
order,1310,O
as,1310,O
the,1310,O
increase,1310,O
due,1310,O
to,1310,O
the,1310,O
presence,1310,O
of,1310,O
zinc,1310,B-CHEMICAL
sulphate,1310,I-CHEMICAL
.,1310,O
An,1311,O
overview,1311,O
on,1311,O
the,1311,O
marine,1311,O
neurotoxin,1311,O
",",1311,O
saxitoxin,1311,B-CHEMICAL
:,1311,O
genetics,1311,O
",",1311,O
molecular,1311,O
targets,1311,O
",",1311,O
methods,1311,O
of,1311,O
detection,1311,O
and,1311,O
ecological,1311,O
functions,1311,O
.,1311,O
Marine,1312,O
neurotoxins,1312,O
are,1312,O
natural,1312,O
products,1312,O
produced,1312,O
by,1312,O
phytoplankton,1312,O
and,1312,O
select,1312,O
species,1312,O
of,1312,O
invertebrates,1312,O
and,1312,O
fish,1312,O
.,1312,O
These,1313,O
compounds,1313,O
interact,1313,O
with,1313,O
voltage-gated,1313,B-GENE-N
sodium,1313,I-GENE-N
",",1313,I-GENE-N
potassium,1313,I-GENE-N
and,1313,I-GENE-N
calcium,1313,I-GENE-N
channels,1313,I-GENE-N
and,1313,O
modulate,1313,O
the,1313,O
flux,1313,O
of,1313,O
these,1313,O
ions,1313,O
into,1313,O
various,1313,O
cell,1313,O
types,1313,O
.,1313,O
This,1314,O
review,1314,O
provides,1314,O
a,1314,O
summary,1314,O
of,1314,O
marine,1314,O
neurotoxins,1314,O
",",1314,O
including,1314,O
their,1314,O
structures,1314,O
",",1314,O
molecular,1314,O
targets,1314,O
and,1314,O
pharmacologies,1314,O
.,1314,O
Saxitoxin,1315,B-CHEMICAL
and,1315,O
its,1315,O
derivatives,1315,O
",",1315,O
collectively,1315,O
referred,1315,O
to,1315,O
as,1315,O
paralytic,1315,O
shellfish,1315,O
toxins,1315,O
(,1315,O
PSTs,1315,O
),1315,O
",",1315,O
are,1315,O
unique,1315,O
among,1315,O
neurotoxins,1315,O
in,1315,O
that,1315,O
they,1315,O
are,1315,O
found,1315,O
in,1315,O
both,1315,O
marine,1315,O
and,1315,O
freshwater,1315,O
environments,1315,O
by,1315,O
organisms,1315,O
inhabiting,1315,O
two,1315,O
kingdoms,1315,O
of,1315,O
life,1315,O
.,1315,O
Prokaryotic,1316,O
cyanobacteria,1316,O
are,1316,O
responsible,1316,O
for,1316,O
PST,1316,O
production,1316,O
in,1316,O
freshwater,1316,O
systems,1316,O
",",1316,O
while,1316,O
eukaryotic,1316,O
dinoflagellates,1316,O
are,1316,O
the,1316,O
main,1316,O
producers,1316,O
in,1316,O
marine,1316,O
waters,1316,O
.,1316,O
Bioaccumulation,1317,O
by,1317,O
filter-feeding,1317,O
bivalves,1317,O
and,1317,O
fish,1317,O
and,1317,O
subsequent,1317,O
transfer,1317,O
through,1317,O
the,1317,O
food,1317,O
web,1317,O
results,1317,O
in,1317,O
the,1317,O
potentially,1317,O
fatal,1317,O
human,1317,O
illnesses,1317,O
",",1317,O
paralytic,1317,O
shellfish,1317,O
poisoning,1317,O
and,1317,O
saxitoxin,1317,B-CHEMICAL
pufferfish,1317,O
poisoning,1317,O
.,1317,O
These,1318,O
illnesses,1318,O
are,1318,O
a,1318,O
result,1318,O
of,1318,O
saxitoxin,1318,B-CHEMICAL
's,1318,O
ability,1318,O
to,1318,O
bind,1318,O
to,1318,O
the,1318,O
voltage-gated,1318,B-GENE-N
sodium,1318,I-GENE-N
channel,1318,I-GENE-N
",",1318,O
blocking,1318,O
the,1318,O
passage,1318,O
of,1318,O
nerve,1318,O
impulses,1318,O
and,1318,O
leading,1318,O
to,1318,O
death,1318,O
via,1318,O
respiratory,1318,O
paralysis,1318,O
.,1318,O
Recent,1319,O
advances,1319,O
in,1319,O
saxitoxin,1319,B-CHEMICAL
research,1319,O
are,1319,O
discussed,1319,O
",",1319,O
including,1319,O
the,1319,O
molecular,1319,O
biology,1319,O
of,1319,O
toxin,1319,O
synthesis,1319,O
",",1319,O
new,1319,O
protein,1319,O
targets,1319,O
",",1319,O
association,1319,O
with,1319,O
metal-binding,1319,B-GENE-N
motifs,1319,I-GENE-N
and,1319,O
methods,1319,O
of,1319,O
detection,1319,O
.,1319,O
The,1320,O
eco-evolutionary,1320,O
role,1320,O
(,1320,O
s,1320,O
),1320,O
PSTs,1320,O
may,1320,O
serve,1320,O
for,1320,O
phytoplankton,1320,O
species,1320,O
that,1320,O
produce,1320,O
them,1320,O
are,1320,O
also,1320,O
discussed,1320,O
.,1320,O
Pulmonary,1321,O
delivery,1321,O
of,1321,O
an,1321,O
aerosolized,1321,O
recombinant,1321,O
human,1321,B-GENE-Y
butyrylcholinesterase,1321,I-GENE-Y
pretreatment,1321,O
protects,1321,O
against,1321,O
aerosolized,1321,O
paraoxon,1321,B-CHEMICAL
in,1321,O
macaques,1321,O
.,1321,O
Butyrylcholinesterase,1322,B-GENE-Y
(,1322,O
BChE,1322,B-GENE-Y
),1322,O
is,1322,O
the,1322,O
leading,1322,O
pretreatment,1322,O
candidate,1322,O
against,1322,O
exposure,1322,O
to,1322,O
organophosphates,1322,B-CHEMICAL
(,1322,O
OPs,1322,O
),1322,O
",",1322,O
which,1322,O
pose,1322,O
an,1322,O
ever,1322,O
increasing,1322,O
public,1322,O
and,1322,O
military,1322,O
health,1322,O
.,1322,O
Since,1323,O
respiratory,1323,O
failure,1323,O
is,1323,O
the,1323,O
primary,1323,O
cause,1323,O
of,1323,O
death,1323,O
following,1323,O
acute,1323,O
OP,1323,O
poisoning,1323,O
",",1323,O
an,1323,O
inhaled,1323,O
BChE,1323,B-GENE-Y
therapeutic,1323,O
could,1323,O
prove,1323,O
highly,1323,O
efficacious,1323,O
in,1323,O
preventing,1323,O
acute,1323,O
toxicity,1323,O
as,1323,O
well,1323,O
as,1323,O
the,1323,O
associated,1323,O
delayed,1323,O
neuropathy,1323,O
.,1323,O
To,1324,O
address,1324,O
this,1324,O
",",1324,O
studies,1324,O
have,1324,O
been,1324,O
performed,1324,O
in,1324,O
mice,1324,O
and,1324,O
macaques,1324,O
using,1324,O
Chinese,1324,O
Hamster,1324,O
Ovary,1324,O
cells,1324,O
(,1324,O
CHO,1324,O
),1324,O
-derived,1324,O
recombinant,1324,O
(,1324,O
r,1324,O
),1324,O
BChE,1324,B-GENE-Y
delivered,1324,O
by,1324,O
the,1324,O
pulmonary,1324,O
route,1324,O
",",1324,O
to,1324,O
examine,1324,O
whether,1324,O
the,1324,O
deposition,1324,O
of,1324,O
both,1324,O
macaque,1324,O
(,1324,O
Ma,1324,O
),1324,O
and,1324,O
human,1324,O
(,1324,O
Hu,1324,O
),1324,O
rBChE,1324,B-GENE-Y
administered,1324,O
as,1324,O
aerosols,1324,O
(,1324,O
aer,1324,O
),1324,O
favored,1324,O
the,1324,O
creation,1324,O
and,1324,O
retention,1324,O
of,1324,O
an,1324,O
efficient,1324,O
protective,1324,O
``,1324,O
pulmonary,1324,O
bioshield,1324,O
'',1324,O
that,1324,O
could,1324,O
scavenge,1324,O
incoming,1324,O
(,1324,O
inhaled,1324,O
),1324,O
OPs,1324,O
in,1324,O
situ,1324,O
thereby,1324,O
preventing,1324,O
entry,1324,O
into,1324,O
the,1324,O
circulation,1324,O
and,1324,O
inhibition,1324,O
of,1324,O
plasma,1324,O
BChE,1324,B-GENE-Y
and,1324,O
AChE,1324,B-GENE-Y
on,1324,O
red,1324,O
blood,1324,O
cells,1324,O
(,1324,O
RBC-AChE,1324,O
),1324,O
and,1324,O
in,1324,O
cholinergic,1324,O
synapses,1324,O
.,1324,O
In,1325,O
contrast,1325,O
to,1325,O
parenteral,1325,O
delivery,1325,O
of,1325,O
rBChE,1325,B-GENE-Y
",",1325,O
which,1325,O
currently,1325,O
requires,1325,O
posttranslational,1325,O
modification,1325,O
for,1325,O
good,1325,O
plasma,1325,O
stability,1325,O
",",1325,O
an,1325,O
unmodified,1325,O
aer-rBChE,1325,O
pretreatment,1325,O
given,1325,O
1-40h,1325,O
prior,1325,O
to,1325,O
>,1325,O
1,1325,O
LD50,1325,O
of,1325,O
aer-paraoxon,1325,O
(,1325,O
Px,1325,O
),1325,O
was,1325,O
able,1325,O
to,1325,O
prevent,1325,O
inhibition,1325,O
of,1325,O
circulating,1325,O
cholinesterase,1325,B-GENE-Y
in,1325,O
a,1325,O
dose-dependent,1325,O
manner,1325,O
.,1325,O
These,1326,O
studies,1326,O
are,1326,O
the,1326,O
first,1326,O
to,1326,O
show,1326,O
protection,1326,O
by,1326,O
rBChE,1326,B-GENE-Y
against,1326,O
a,1326,O
pesticide,1326,O
such,1326,O
as,1326,O
paraoxon,1326,B-CHEMICAL
when,1326,O
delivered,1326,O
directly,1326,O
into,1326,O
the,1326,O
lung,1326,O
and,1326,O
bode,1326,O
well,1326,O
for,1326,O
the,1326,O
use,1326,O
of,1326,O
a,1326,O
non-invasive,1326,O
and,1326,O
consumer,1326,O
friendly,1326,O
method,1326,O
of,1326,O
rHuBChE,1326,B-GENE-Y
delivery,1326,O
as,1326,O
a,1326,O
human,1326,O
treatment,1326,O
to,1326,O
counteract,1326,O
OP,1326,O
toxicity,1326,O
.,1326,O
Anti-diabetic,1327,O
property,1327,O
of,1327,O
Tinospora,1327,O
cordifolia,1327,O
and,1327,O
its,1327,O
active,1327,O
compound,1327,O
is,1327,O
mediated,1327,O
through,1327,O
the,1327,O
expression,1327,O
of,1327,O
Glut-4,1327,B-GENE-Y
in,1327,O
L6,1327,O
myotubes,1327,O
.,1327,O
Tinospora,1328,O
cordifolia,1328,O
is,1328,O
a,1328,O
well,1328,O
reported,1328,O
plant,1328,O
possessing,1328,O
numerous,1328,O
medicinal,1328,O
values,1328,O
including,1328,O
anti-diabetic,1328,O
property,1328,O
.,1328,O
Aim,1329,O
of,1329,O
the,1329,O
present,1329,O
study,1329,O
is,1329,O
to,1329,O
study,1329,O
the,1329,O
mechanism,1329,O
of,1329,O
action,1329,O
of,1329,O
Tinospora,1329,O
cordifolia,1329,O
and,1329,O
its,1329,O
active,1329,O
compound,1329,O
in,1329,O
differentiated,1329,O
myocytes,1329,O
",",1329,O
L6,1329,O
cells,1329,O
.,1329,O
Key,1330,O
marker,1330,O
of,1330,O
diabetes,1330,O
in,1330,O
cells,1330,O
is,1330,O
the,1330,O
insulin,1330,B-GENE-Y
dependent,1330,I-GENE-Y
glucose,1330,I-GENE-Y
transporter-4,1330,I-GENE-Y
(,1330,O
Glut-4,1330,B-GENE-Y
),1330,O
which,1330,O
also,1330,O
responds,1330,O
to,1330,O
exogenous,1330,O
chemicals,1330,O
",",1330,O
and,1330,O
is,1330,O
over,1330,O
expressed,1330,O
up,1330,O
to,1330,O
5-,1330,O
and,1330,O
4-fold,1330,O
",",1330,O
by,1330,O
Tinospora,1330,O
cordifolia,1330,O
and,1330,O
palmatine,1330,B-CHEMICAL
",",1330,O
respectively,1330,O
.,1330,O
Next,1331,O
to,1331,O
Glut-4,1331,B-GENE-Y
",",1331,O
the,1331,O
predominant,1331,O
protein,1331,O
influencing,1331,O
glucose,1331,B-CHEMICAL
metabolism,1331,O
is,1331,O
PPARα,1331,B-GENE-N
and,1331,I-GENE-N
γ,1331,I-GENE-N
whose,1331,O
expressions,1331,O
were,1331,O
also,1331,O
positively,1331,O
modulated,1331,O
.,1331,O
Further,1332,O
",",1332,O
the,1332,O
inhibitors,1332,O
of,1332,O
insulin,1332,B-GENE-N
pathway,1332,O
prevented,1332,O
glucose,1332,B-CHEMICAL
uptake,1332,O
mediated,1332,O
by,1332,O
Tinospora,1332,O
cordifolia,1332,O
and,1332,O
palmatine,1332,B-CHEMICAL
which,1332,O
shows,1332,O
that,1332,O
the,1332,O
activity,1332,O
is,1332,O
majorly,1332,O
mediated,1332,O
through,1332,O
insulin,1332,B-GENE-N
pathway,1332,O
.,1332,O
Differential,1333,O
IL-2,1333,B-GENE-N
receptor,1333,I-GENE-N
expression,1333,O
in,1333,O
renal,1333,O
allograft,1333,O
recipients,1333,O
treated,1333,O
with,1333,O
an,1333,O
anti-IL-2-receptor,1333,O
antibody,1333,O
.,1333,O
Patients,1334,O
were,1334,O
entered,1334,O
into,1334,O
a,1334,O
randomized,1334,O
trial,1334,O
of,1334,O
prophylaxis,1334,O
for,1334,O
renal,1334,O
allograft,1334,O
rejection,1334,O
by,1334,O
the,1334,O
administration,1334,O
of,1334,O
an,1334,O
anti-human,1334,O
IL-2,1334,I-GENE-N
receptor,1334,I-GENE-N
antibody,1334,O
",",1334,O
anti-Tac,1334,O
",",1334,O
during,1334,O
the,1334,O
first,1334,O
ten,1334,O
days,1334,O
posttransplant,1334,O
.,1334,O
Interleukin-2,1335,B-GENE-N
receptor,1335,I-GENE-N
(,1335,O
IL-2,1335,B-GENE-N
R,1335,I-GENE-N
),1335,O
expression,1335,O
was,1335,O
measured,1335,O
using,1335,O
two,1335,O
anti-IL-2,1335,O
R,1335,I-GENE-N
monoclonal,1335,O
antibodies,1335,O
(,1335,O
moAbs,1335,O
),1335,O
",",1335,O
anti-Tac,1335,O
and,1335,O
1HT4-4H3,1335,O
.,1335,O
These,1336,O
two,1336,O
antibodies,1336,O
recognize,1336,O
closely,1336,O
spaced,1336,O
epitopes,1336,O
on,1336,O
the,1336,O
55,1336,O
kD,1336,O
chain,1336,O
of,1336,O
the,1336,O
IL-2,1336,B-GENE-N
R.,1336,O
IL-2,1336,B-GENE-N
R,1336,I-GENE-N
expression,1336,O
was,1336,O
examined,1336,O
on,1336,O
peripheral,1336,O
blood,1336,O
small,1336,O
lymphocytes,1336,O
in,1336,O
three,1336,O
groups,1336,O
of,1336,O
patients,1336,O
who,1336,O
received,1336,O
:,1336,O
(,1336,B-CHEMICAL
A,1336,I-CHEMICAL
),1336,I-CHEMICAL
cyclosporine,1336,I-CHEMICAL
CsA,1336,B-CHEMICAL
and,1336,O
prednisone,1336,B-CHEMICAL
for,1336,O
baseline,1336,O
immunosuppression,1336,O
(,1336,O
n,1336,O
=,1336,O
9,1336,O
),1336,O
;,1336,O
(,1336,O
B,1336,O
),1336,O
anti-Tac,1336,O
with,1336,O
CsA,1336,B-CHEMICAL
and,1336,O
prednisone,1336,B-CHEMICAL
as,1336,O
baseline,1336,O
immunosuppression,1336,O
(,1336,O
n,1336,O
=,1336,O
12,1336,O
),1336,O
;,1336,O
and,1336,O
(,1336,O
C,1336,O
),1336,O
anti-Tac,1336,O
with,1336,O
azathioprine,1336,B-CHEMICAL
and,1336,O
prednisone,1336,B-CHEMICAL
as,1336,O
baseline,1336,O
immunosuppression,1336,O
(,1336,O
n,1336,O
=,1336,O
5,1336,O
),1336,O
.,1336,O
We,1337,O
found,1337,O
that,1337,O
large,1337,O
numbers,1337,O
of,1337,O
T,1337,O
cells,1337,O
express,1337,O
IL-2,1337,B-GENE-N
receptors,1337,I-GENE-N
despite,1337,O
the,1337,O
presence,1337,O
of,1337,O
anti-Tac,1337,O
(,1337,O
average,1337,O
of,1337,O
IL-2,1337,B-GENE-N
R-positive,1337,O
cells,1337,O
at,1337,O
day,1337,O
of,1337,O
peak,1337,O
IL-2,1337,B-GENE-N
R,1337,I-GENE-N
expression,1337,O
56.0,1337,O
+/-,1337,O
20.8,1337,O
%,1337,O
in,1337,O
group,1337,O
A,1337,O
",",1337,O
65.2,1337,O
+/-,1337,O
26.6,1337,O
%,1337,O
in,1337,O
group,1337,O
B,1337,O
",",1337,O
21.0,1337,O
+/-,1337,O
7.4,1337,O
%,1337,O
in,1337,O
group,1337,O
C,1337,O
),1337,O
.,1337,O
IL-2,1338,B-GENE-N
R,1338,I-GENE-N
expression,1338,O
did,1338,O
not,1338,O
correlate,1338,O
with,1338,O
clinical,1338,O
activity,1338,O
",",1338,O
and,1338,O
the,1338,O
presence,1338,O
or,1338,O
accessibility,1338,O
of,1338,O
epitopes,1338,O
on,1338,O
the,1338,O
same,1338,O
55,1338,O
kD,1338,O
chain,1338,O
varied,1338,O
dramatically,1338,O
from,1338,O
patient,1338,O
to,1338,O
patient,1338,O
.,1338,O
Medical,1339,O
therapy,1339,O
and,1339,O
quality,1339,O
of,1339,O
life,1339,O
.,1339,O
The,1340,O
risk,1340,O
of,1340,O
mortality,1340,O
and,1340,O
long-term,1340,O
morbidity,1340,O
",",1340,O
including,1340,O
loss,1340,O
of,1340,O
sexual,1340,O
function,1340,O
",",1340,O
associated,1340,O
with,1340,O
surgical,1340,O
procedures,1340,O
for,1340,O
symptomatic,1340,O
benign,1340,O
prostatic,1340,O
hyperplasia,1340,O
(,1340,O
BPH,1340,O
),1340,O
has,1340,O
prompted,1340,O
research,1340,O
into,1340,O
alternative,1340,O
medical,1340,O
therapies,1340,O
.,1340,O
Phytotherapy,1341,O
involves,1341,O
the,1341,O
use,1341,O
of,1341,O
herbal,1341,O
formulations,1341,O
",",1341,O
where,1341,O
the,1341,O
mechanisms,1341,O
of,1341,O
action,1341,O
are,1341,O
usually,1341,O
obscure,1341,O
and,1341,O
although,1341,O
studies,1341,O
have,1341,O
confirmed,1341,O
their,1341,O
effectiveness,1341,O
in,1341,O
symptom,1341,O
relief,1341,O
and,1341,O
improving,1341,O
quality,1341,O
of,1341,O
life,1341,O
(,1341,O
QOL,1341,O
),1341,O
",",1341,O
few,1341,O
placebo-controlled,1341,O
trials,1341,O
exist,1341,O
.,1341,O
Both,1342,O
the,1342,O
5,1342,B-GENE-N
alpha-reductase,1342,I-GENE-N
inhibitor,1342,O
finasteride,1342,B-CHEMICAL
and,1342,O
alpha,1342,B-GENE-N
1-adrenoceptor,1342,I-GENE-N
antagonists,1342,O
(,1342,O
e.g,1342,O
.,1342,O
alfuzosin,1343,B-CHEMICAL
",",1343,O
doxazosin,1343,B-CHEMICAL
",",1343,O
prazosin,1343,B-CHEMICAL
",",1343,O
tamsulosin,1343,B-CHEMICAL
and,1343,O
terazosin,1343,B-CHEMICAL
),1343,O
have,1343,O
been,1343,O
recommended,1343,O
as,1343,O
appropriate,1343,O
treatment,1343,O
options,1343,O
for,1343,O
patients,1343,O
with,1343,O
lower,1343,O
urinary,1343,O
tract,1343,O
symptoms,1343,O
(,1343,O
LUTS,1343,O
),1343,O
associated,1343,O
with,1343,O
benign,1343,O
prostatic,1343,O
obstruction,1343,O
(,1343,O
BPO,1343,O
),1343,O
",",1343,O
and,1343,O
their,1343,O
efficacy,1343,O
has,1343,O
been,1343,O
proven,1343,O
in,1343,O
several,1343,O
placebo-controlled,1343,O
trials,1343,O
.,1343,O
Finasteride,1344,B-CHEMICAL
reduces,1344,O
the,1344,O
static,1344,O
component,1344,O
of,1344,O
BPO,1344,O
--,1344,O
by,1344,O
reducing,1344,O
the,1344,O
size,1344,O
of,1344,O
the,1344,O
prostate,1344,O
--,1344,O
and,1344,O
",",1344,O
as,1344,O
a,1344,O
result,1344,O
",",1344,O
symptom,1344,O
relief,1344,O
is,1344,O
slow,1344,O
(,1344,O
6-12,1344,O
months,1344,O
),1344,O
and,1344,O
is,1344,O
predominantly,1344,O
restricted,1344,O
to,1344,O
patients,1344,O
with,1344,O
large,1344,O
prostates,1344,O
(,1344,O
>,1344,O
40,1344,O
g,1344,O
),1344,O
.,1344,O
The,1345,O
alpha,1345,B-GENE-N
1-adrenoceptor,1345,I-GENE-N
antagonists,1345,O
",",1345,O
on,1345,O
the,1345,O
other,1345,O
hand,1345,O
",",1345,O
reduce,1345,O
the,1345,O
dynamic,1345,O
component,1345,O
of,1345,O
obstruction,1345,O
--,1345,O
relaxation,1345,O
of,1345,O
smooth,1345,O
muscle,1345,O
in,1345,O
the,1345,O
prostate,1345,O
",",1345,O
urethra,1345,O
and,1345,O
bladder,1345,O
neck,1345,O
--,1345,O
and,1345,O
provide,1345,O
rapid,1345,O
symptom,1345,O
relief,1345,O
after,1345,O
only,1345,O
a,1345,O
few,1345,O
doses,1345,O
",",1345,O
relieving,1345,O
LUTS,1345,O
more,1345,O
effectively,1345,O
than,1345,O
finasteride,1345,B-CHEMICAL
and,1345,O
irrespective,1345,O
of,1345,O
prostate,1345,O
size,1345,O
.,1345,O
All,1346,O
of,1346,O
the,1346,O
various,1346,O
alpha,1346,B-GENE-N
1-adrenoceptor,1346,I-GENE-N
antagonists,1346,O
provide,1346,O
effective,1346,O
and,1346,O
comparable,1346,O
relief,1346,O
of,1346,O
LUTS,1346,O
",",1346,O
and,1346,O
an,1346,O
improvement,1346,O
in,1346,O
bothersomeness,1346,O
and,1346,O
symptom-related,1346,O
QOL,1346,O
.,1346,O
However,1347,O
",",1347,O
it,1347,O
is,1347,O
also,1347,O
important,1347,O
that,1347,O
the,1347,O
therapy,1347,O
is,1347,O
fast,1347,O
acting,1347,O
and,1347,O
acceptable,1347,O
to,1347,O
the,1347,O
patient,1347,O
",",1347,O
in,1347,O
that,1347,O
it,1347,O
does,1347,O
not,1347,O
interfere,1347,O
with,1347,O
other,1347,O
medication,1347,O
or,1347,O
produce,1347,O
unpleasant,1347,O
side,1347,O
effects,1347,O
.,1347,O
These,1348,O
documented,1348,O
properties,1348,O
of,1348,O
the,1348,O
alpha,1348,B-GENE-Y
1A-adrenoceptor,1348,I-GENE-Y
antagonists,1348,O
make,1348,O
them,1348,O
an,1348,O
ideal,1348,O
choice,1348,O
for,1348,O
the,1348,O
medical,1348,O
treatment,1348,O
of,1348,O
symptomatic,1348,O
BPH,1348,O
.,1348,O
Bioinspired,1349,O
Water-Enhanced,1349,O
Mechanical,1349,O
Gradient,1349,O
Nanocomposite,1349,O
Films,1349,O
That,1349,O
Mimic,1349,O
the,1349,O
Architecture,1349,O
and,1349,O
Properties,1349,O
of,1349,O
the,1349,O
Squid,1349,O
Beak,1349,O
.,1349,O
Inspired,1350,O
by,1350,O
the,1350,O
water-enhanced,1350,O
mechanical,1350,O
gradient,1350,O
character,1350,O
of,1350,O
the,1350,O
squid,1350,O
beak,1350,O
",",1350,O
we,1350,O
herein,1350,O
report,1350,O
a,1350,O
nanocomposite,1350,O
that,1350,O
mimics,1350,O
both,1350,O
the,1350,O
architecture,1350,O
and,1350,O
properties,1350,O
of,1350,O
this,1350,O
interesting,1350,O
natural,1350,O
material,1350,O
.,1350,O
Similar,1351,O
to,1351,O
the,1351,O
squid,1351,O
beak,1351,O
",",1351,O
we,1351,O
have,1351,O
developed,1351,O
nanocomposites,1351,O
where,1351,O
the,1351,O
degree,1351,O
of,1351,O
cross-linking,1351,O
is,1351,O
controlled,1351,O
along,1351,O
the,1351,O
length,1351,O
of,1351,O
the,1351,O
film,1351,O
.,1351,O
In,1352,O
this,1352,O
study,1352,O
",",1352,O
we,1352,O
utilized,1352,O
tunicate,1352,O
cellulose,1352,O
nanocrystals,1352,O
as,1352,O
the,1352,O
nanofiller,1352,O
that,1352,O
are,1352,O
functionalized,1352,O
with,1352,O
allyl,1352,B-CHEMICAL
moieties,1352,O
.,1352,O
Using,1353,O
photoinduced,1353,O
thiol-ene,1353,B-CHEMICAL
chemistry,1353,O
",",1353,O
we,1353,O
have,1353,O
been,1353,O
able,1353,O
to,1353,O
cross-link,1353,O
the,1353,O
CNC,1353,O
nanofiller,1353,O
.,1353,O
In,1354,O
the,1354,O
dry,1354,O
state,1354,O
where,1354,O
strong,1354,O
CNC,1354,O
interactions,1354,O
can,1354,O
occur,1354,O
",",1354,O
only,1354,O
a,1354,O
small,1354,O
mechanical,1354,O
contrast,1354,O
is,1354,O
observed,1354,O
between,1354,O
the,1354,O
cross-linked,1354,O
and,1354,O
uncross-linked,1354,O
samples,1354,O
.,1354,O
However,1355,O
",",1355,O
when,1355,O
the,1355,O
films,1355,O
are,1355,O
exposed,1355,O
to,1355,O
water,1355,O
",",1355,O
which,1355,O
``,1355,O
switches,1355,O
off,1355,O
'',1355,O
the,1355,O
noncovalent,1355,O
CNC,1355,O
interactions,1355,O
",",1355,O
a,1355,O
significant,1355,O
mechanical,1355,O
contrast,1355,O
is,1355,O
observed,1355,O
between,1355,O
the,1355,O
same,1355,O
films,1355,O
.,1355,O
For,1356,O
example,1356,O
",",1356,O
at,1356,O
20,1356,O
wt,1356,O
%,1356,O
CNC,1356,O
(,1356,O
in,1356,O
the,1356,O
dry,1356,O
film,1356,O
),1356,O
",",1356,O
an,1356,O
increase,1356,O
in,1356,O
wet,1356,O
modulus,1356,O
from,1356,O
60,1356,O
to,1356,O
300,1356,O
MPa,1356,O
(,1356,O
∼500,1356,O
%,1356,O
increase,1356,O
),1356,O
is,1356,O
observed,1356,O
after,1356,O
photoirradiation,1356,O
.,1356,O
Furthermore,1357,O
",",1357,O
we,1357,O
show,1357,O
that,1357,O
the,1357,O
wet,1357,O
modulus,1357,O
can,1357,O
be,1357,O
controlled,1357,O
by,1357,O
altering,1357,O
the,1357,O
UV,1357,O
exposure,1357,O
time,1357,O
which,1357,O
allows,1357,O
access,1357,O
to,1357,O
mechanical,1357,O
gradient,1357,O
films,1357,O
.,1357,O
Wired,1358,O
Enzyme,1358,O
Electrodes-A,1358,O
Retroperspective,1358,O
Story,1358,O
about,1358,O
an,1358,O
Exciting,1358,O
Time,1358,O
at,1358,O
University,1358,O
of,1358,O
Texas,1358,O
at,1358,O
Austin,1358,O
and,1358,O
Its,1358,O
Impact,1358,O
on,1358,O
My,1358,O
Scientific,1358,O
Career,1358,O
.,1358,O
The,1359,O
present,1359,O
paper,1359,O
features,1359,O
an,1359,O
exciting,1359,O
time,1359,O
in,1359,O
the,1359,O
late,1359,O
1980s,1359,O
when,1359,O
I,1359,O
",",1359,O
as,1359,O
a,1359,O
visiting,1359,O
scientist,1359,O
",",1359,O
had,1359,O
the,1359,O
privilege,1359,O
to,1359,O
participate,1359,O
in,1359,O
the,1359,O
early,1359,O
and,1359,O
very,1359,O
exciting,1359,O
development,1359,O
of,1359,O
the,1359,O
in,1359,O
vivo,1359,O
redox-polymer-wired,1359,O
glucose,1359,B-CHEMICAL
sensor,1359,O
in,1359,O
Professor,1359,O
Adam,1359,O
Heller,1359,O
's,1359,O
laboratory,1359,O
at,1359,O
the,1359,O
Department,1359,O
of,1359,O
Chemical,1359,O
Engineering,1359,O
at,1359,O
University,1359,O
of,1359,O
Texas,1359,O
at,1359,O
Austin,1359,O
.,1359,O
This,1360,O
story,1360,O
is,1360,O
followed,1360,O
by,1360,O
an,1360,O
overview,1360,O
of,1360,O
the,1360,O
research,1360,O
my,1360,O
visit,1360,O
initiated,1360,O
at,1360,O
Uppsala,1360,O
University,1360,O
.,1360,O
In,1361,O
collaboration,1361,O
with,1361,O
Swedish,1361,O
colleagues,1361,O
",",1361,O
we,1361,O
explored,1361,O
a,1361,O
few,1361,O
of,1361,O
the,1361,O
many,1361,O
possibilities,1361,O
to,1361,O
form,1361,O
new,1361,O
biosensors,1361,O
by,1361,O
utilizing,1361,O
Prof.,1361,O
Heller,1361,O
's,1361,O
concept,1361,O
of,1361,O
cross-linked,1361,O
redox-polymer/redox-enzyme,1361,O
electrodes,1361,O
.,1361,O
Antithrombotic,1362,O
activity,1362,O
of,1362,O
a,1362,O
newly,1362,O
synthesized,1362,O
coumarin,1362,B-CHEMICAL
derivative,1362,O
3-,1362,B-CHEMICAL
(,1362,I-CHEMICAL
"5-hydroxy-2,2-dimethyl-chroman-6-yl",1362,I-CHEMICAL
),1362,I-CHEMICAL
-N-,1362,I-CHEMICAL
{,1362,I-CHEMICAL
2-,1362,I-CHEMICAL
[,1362,I-CHEMICAL
3-,1362,I-CHEMICAL
(,1362,I-CHEMICAL
"5-hydroxy-2,2-dimethyl-chroman-6-yl",1362,I-CHEMICAL
),1362,I-CHEMICAL
-propionylamino,1362,I-CHEMICAL
],1362,I-CHEMICAL
-ethyl,1362,I-CHEMICAL
},1362,I-CHEMICAL
-propionamide,1362,I-CHEMICAL
.,1362,O
Anti-platelet,1363,O
therapy,1363,O
is,1363,O
a,1363,O
useful,1363,O
strategy,1363,O
to,1363,O
prevent,1363,O
acute,1363,O
thromboembolic,1363,O
artery,1363,O
occlusions,1363,O
.,1363,O
This,1364,O
study,1364,O
was,1364,O
designed,1364,O
to,1364,O
assess,1364,O
the,1364,O
efficacy,1364,O
of,1364,O
seselin,1364,B-CHEMICAL
derivatives,1364,O
against,1364,O
murine,1364,O
pulmonary,1364,O
thromboembolism,1364,O
",",1364,O
bleeding,1364,O
time,1364,O
",",1364,O
platelet,1364,O
activation,1364,O
and,1364,O
thrombosis,1364,O
.,1364,O
Administration,1365,O
of,1365,O
C3,1365,O
(,1365,O
16,1365,O
mg/kg,1365,O
),1365,O
offered,1365,O
70,1365,O
%,1365,O
protection,1365,O
against,1365,O
collagen-,1365,B-GENE-N
and,1365,O
epinephrine-induced,1365,B-CHEMICAL
pulmonary,1365,O
thromboembolism,1365,O
and,1365,O
30,1365,O
%,1365,O
protection,1365,O
against,1365,O
arachidonic,1365,B-CHEMICAL
acid-induced,1365,O
death,1365,O
in,1365,O
mice,1365,O
",",1365,O
without,1365,O
adversely,1365,O
affecting,1365,O
bleeding,1365,O
time,1365,O
.,1365,O
No,1366,O
significant,1366,O
difference,1366,O
was,1366,O
observed,1366,O
by,1366,O
C3,1366,O
in,1366,O
ferric,1366,B-CHEMICAL
chloride-induced,1366,O
arterial,1366,O
thrombosis,1366,O
in,1366,O
rats,1366,O
.,1366,O
Significant,1367,O
reduction,1367,O
in,1367,O
thrombus,1367,O
weight,1367,O
was,1367,O
observed,1367,O
in,1367,O
arteriovenous,1367,O
shunt,1367,O
model,1367,O
.,1367,O
In,1368,O
rat,1368,O
PRP,1368,O
",",1368,O
C3,1368,O
reduced,1368,O
ADP,1368,B-CHEMICAL
and,1368,O
collagen-induced,1368,B-GENE-N
platelet,1368,O
aggregation,1368,O
.,1368,O
In,1369,O
chronic,1369,O
hamster,1369,O
model,1369,O
of,1369,O
dyslipidemia,1369,O
",",1369,O
administration,1369,O
of,1369,O
C3,1369,O
(,1369,O
16,1369,O
mg/kg,1369,O
p.o,1369,O
.,1369,O
for,1370,O
90,1370,O
days,1370,O
),1370,O
had,1370,O
no,1370,O
effect,1370,O
on,1370,O
plasma,1370,O
lipids,1370,O
",",1370,O
vasoreactivity,1370,O
and,1370,O
platelet,1370,O
adhesion,1370,O
.,1370,O
C3,1371,O
fed,1371,O
hamsters,1371,O
showed,1371,O
reduced,1371,O
whole-blood,1371,O
aggregation,1371,O
response,1371,O
to,1371,O
ADP,1371,B-CHEMICAL
and,1371,O
collagen,1371,B-GENE-N
compared,1371,O
to,1371,O
HC-fed,1371,O
hamsters,1371,O
.,1371,O
In,1372,O
addition,1372,O
",",1372,O
C3,1372,O
augmented,1372,O
thrombin,1372,O
time,1372,O
;,1372,O
however,1372,O
",",1372,O
time,1372,O
to,1372,O
occlusion,1372,O
was,1372,O
not,1372,O
increased,1372,O
.,1372,O
These,1373,O
results,1373,O
convincingly,1373,O
demonstrated,1373,O
that,1373,O
C3,1373,O
is,1373,O
a,1373,O
novel,1373,O
molecule,1373,O
that,1373,O
reduces,1373,O
the,1373,O
risk,1373,O
of,1373,O
thrombosis,1373,O
and,1373,O
alleviates,1373,O
prothrombotic,1373,O
state,1373,O
associated,1373,O
with,1373,O
hyperlipidemia,1373,O
without,1373,O
any,1373,O
adverse,1373,O
effect,1373,O
on,1373,O
bleeding,1373,O
time,1373,O
.,1373,O
The,1374,O
high,1374,O
benefit/risk,1374,O
ratio,1374,O
of,1374,O
this,1374,O
compound,1374,O
makes,1374,O
it,1374,O
a,1374,O
suitable,1374,O
candidate,1374,O
for,1374,O
future,1374,O
valid,1374,O
studies,1374,O
.,1374,O
Central,1375,O
5-HT3,1375,B-GENE-Y
receptor,1375,O
stimulation,1375,O
by,1375,O
m-CPBG,1375,B-CHEMICAL
increases,1375,O
blood,1375,O
glucose,1375,B-CHEMICAL
in,1375,O
rats,1375,O
.,1375,O
The,1376,O
aim,1376,O
of,1376,O
the,1376,O
present,1376,O
study,1376,O
was,1376,O
to,1376,O
investigate,1376,O
the,1376,O
role,1376,O
of,1376,O
central,1376,O
5-HT3,1376,B-GENE-Y
receptors,1376,O
on,1376,O
the,1376,O
control,1376,O
of,1376,O
blood,1376,O
glucose,1376,B-CHEMICAL
in,1376,O
stressed,1376,O
and,1376,O
non-stressed,1376,O
rats,1376,O
in,1376,O
both,1376,O
fasted,1376,O
and,1376,O
fed,1376,O
states,1376,O
.,1376,O
Adult,1377,O
Wistar,1377,O
male,1377,O
rats,1377,O
had,1377,O
each,1377,O
their,1377,O
third,1377,O
ventricle,1377,O
cannulated,1377,O
7,1377,O
days,1377,O
before,1377,O
the,1377,O
experiments,1377,O
.,1377,O
Injections,1378,O
of,1378,O
m-CPBG,1378,B-CHEMICAL
",",1378,O
a,1378,O
selective,1378,O
5-HT3,1378,B-GENE-Y
receptor,1378,O
agonist,1378,O
",",1378,O
induced,1378,O
a,1378,O
significant,1378,O
increase,1378,O
in,1378,O
blood,1378,O
glucose,1378,B-CHEMICAL
in,1378,O
non-stressed,1378,O
rats,1378,O
in,1378,O
both,1378,O
fasted,1378,O
and,1378,O
in,1378,O
fed,1378,O
states,1378,O
.,1378,O
The,1379,O
same,1379,O
procedure,1379,O
was,1379,O
unable,1379,O
to,1379,O
modify,1379,O
stress-induced,1379,O
hyperglycemia,1379,O
.,1379,O
The,1380,O
hyperglycemic,1380,O
effect,1380,O
of,1380,O
m-CPBG,1380,B-CHEMICAL
central,1380,O
administration,1380,O
was,1380,O
blocked,1380,O
by,1380,O
pretreatment,1380,O
with,1380,O
ondansetron,1380,O
",",1380,O
a,1380,O
specific,1380,O
5-HT3,1380,B-GENE-Y
receptor,1380,O
antagonist,1380,O
",",1380,O
indicating,1380,O
that,1380,O
the,1380,O
effects,1380,O
here,1380,O
obtained,1380,O
with,1380,O
m-CPBG,1380,B-CHEMICAL
were,1380,O
a,1380,O
result,1380,O
of,1380,O
its,1380,O
interaction,1380,O
with,1380,O
5-HT3,1380,B-GENE-Y
receptors,1380,O
.,1380,O
Third,1381,O
ventricle,1381,O
injections,1381,O
of,1381,O
ondansetron,1381,B-CHEMICAL
alone,1381,O
were,1381,O
not,1381,O
able,1381,O
to,1381,O
modify,1381,O
blood,1381,O
glucose,1381,B-CHEMICAL
in,1381,O
non-stressed,1381,O
animals,1381,O
and,1381,O
did,1381,O
not,1381,O
change,1381,O
the,1381,O
hyperglycemic,1381,O
responses,1381,O
observed,1381,O
after,1381,O
immobilization,1381,O
stress,1381,O
.,1381,O
We,1382,O
conclude,1382,O
that,1382,O
pharmacological,1382,O
activation,1382,O
of,1382,O
the,1382,O
central,1382,O
5-HT3,1382,B-GENE-Y
receptor,1382,O
induces,1382,O
a,1382,O
hyperglycemic,1382,O
effect,1382,O
in,1382,O
non-stressed,1382,O
animals,1382,O
.,1382,O
3'-R/S-Hydroxyvoacamine,1383,B-CHEMICAL
",",1383,O
a,1383,O
potent,1383,O
acetylcholinesterase,1383,B-GENE-Y
inhibitor,1383,O
from,1383,O
Tabernaemontana,1383,O
divaricata,1383,O
.,1383,O
Guided,1384,O
by,1384,O
the,1384,O
acetylcholinesterase,1384,B-GENE-Y
inhibiting,1384,O
activity,1384,O
",",1384,O
the,1384,O
bisindole,1384,B-CHEMICAL
alkaloid,1384,I-CHEMICAL
3'-R/S-hydroxyvoacamine,1384,B-CHEMICAL
was,1384,O
isolated,1384,O
from,1384,O
a,1384,O
stem,1384,O
extract,1384,O
of,1384,O
Tabernaemontana,1384,O
divaricata,1384,O
",",1384,O
a,1384,O
plant,1384,O
used,1384,O
in,1384,O
Thailand,1384,O
in,1384,O
traditional,1384,O
rejuvenation,1384,O
remedies,1384,O
for,1384,O
improving,1384,O
the,1384,O
memory,1384,O
.,1384,O
The,1385,O
structure,1385,O
of,1385,O
the,1385,O
alkaloid,1385,O
was,1385,O
elucidated,1385,O
by,1385,O
extensive,1385,O
use,1385,O
of,1385,O
NMR,1385,O
spectroscopy,1385,O
and,1385,O
the,1385,O
complete,1385,O
assignment,1385,O
of,1385,O
the,1385,O
(,1385,B-CHEMICAL
1,1385,I-CHEMICAL
),1385,I-CHEMICAL
H,1385,I-CHEMICAL
and,1385,O
(,1385,B-CHEMICAL
13,1385,I-CHEMICAL
),1385,I-CHEMICAL
C,1385,I-CHEMICAL
NMR,1385,O
spectra,1385,O
is,1385,O
reported,1385,O
.,1385,O
The,1386,O
alkaloid,1386,O
acted,1386,O
as,1386,O
a,1386,O
non-competitive,1386,O
inhibitor,1386,O
against,1386,O
AChE,1386,B-GENE-Y
with,1386,O
an,1386,O
IC50,1386,O
value,1386,O
of,1386,O
7.00±1.99μM,1386,O
.,1386,O
An,1387,O
HPLC,1387,O
method,1387,O
was,1387,O
developed,1387,O
for,1387,O
the,1387,O
quantitative,1387,O
analysis,1387,O
of,1387,O
the,1387,O
AChE,1387,B-GENE-Y
inhibitor,1387,O
.,1387,O
It,1388,O
suggested,1388,O
that,1388,O
there,1388,O
was,1388,O
12.4,1388,O
%,1388,O
(,1388,O
w/w,1388,O
),1388,O
of,1388,O
3'-R/S-hydroxyvoacamine,1388,B-CHEMICAL
in,1388,O
the,1388,O
alkaloid,1388,O
enriched,1388,O
fraction,1388,O
of,1388,O
T.,1388,O
divaricata,1388,O
stem,1388,O
.,1388,O
TCF7L2,1389,B-GENE-Y
Variation,1389,O
and,1389,O
Proliferative,1389,O
Diabetic,1389,O
Retinopathy,1389,O
.,1389,O
Proliferative,1390,O
diabetic,1390,O
retinopathy,1390,O
(,1390,O
PDR,1390,O
),1390,O
is,1390,O
the,1390,O
most,1390,O
severe,1390,O
vision-threatening,1390,O
complication,1390,O
of,1390,O
diabetes,1390,O
.,1390,O
To,1391,O
investigated,1391,O
genetic,1391,O
association,1391,O
between,1391,O
TCF7L2,1391,B-GENE-Y
and,1391,O
PDR,1391,O
in,1391,O
Caucasian,1391,O
type,1391,O
2,1391,O
diabetes,1391,O
mellitus,1391,O
(,1391,O
T2DM,1391,O
),1391,O
and,1391,O
its,1391,O
functional,1391,O
consequences,1391,O
",",1391,O
383,1391,O
T2DM,1391,O
patients,1391,O
with,1391,O
PDR,1391,O
(,1391,O
T2DM-PDR,1391,O
),1391,O
and,1391,O
756,1391,O
T2DM,1391,O
patients,1391,O
without,1391,O
diabetic,1391,O
retinopathy,1391,O
(,1391,O
T2DM-no,1391,O
DR,1391,O
),1391,O
were,1391,O
genotyped,1391,O
with,1391,O
rs7903146,1391,O
in,1391,O
TCF7L2,1391,B-GENE-Y
.,1391,O
We,1392,O
found,1392,O
that,1392,O
risk,1392,O
allele,1392,O
(,1392,O
T,1392,O
),1392,O
frequency,1392,O
of,1392,O
rs7903146,1392,O
was,1392,O
significantly,1392,O
higher,1392,O
in,1392,O
T2DM-PDR,1392,O
patients,1392,O
(,1392,O
allelic,1392,O
P,1392,O
=,1392,O
2.52E-04,1392,O
),1392,O
.,1392,O
In,1393,O
lymphoblastoid,1393,O
cells,1393,O
induced,1393,O
to,1393,O
undergo,1393,O
endoplasmic,1393,O
reticulum,1393,O
(,1393,O
ER,1393,O
),1393,O
stress,1393,O
by,1393,O
treatment,1393,O
of,1393,O
tunicamycin,1393,B-CHEMICAL
",",1393,O
higher,1393,O
fold,1393,O
change,1393,O
of,1393,O
TCF7L2,1393,B-GENE-Y
and,1393,O
VEGFA,1393,B-GENE-Y
mRNA,1393,O
levels,1393,O
were,1393,O
observed,1393,O
in,1393,O
rs7903146-TT,1393,O
cells,1393,O
than,1393,O
that,1393,O
in,1393,O
rs7903146-CC,1393,O
cells,1393,O
(,1393,O
P,1393,O
=,1393,O
0.02,1393,O
for,1393,O
TCF7L2,1393,B-GENE-Y
;,1393,O
P,1393,O
=,1393,O
0.004,1393,O
for,1393,O
VEGFA,1393,B-GENE-Y
),1393,O
",",1393,O
suggesting,1393,O
ER,1393,O
stress,1393,O
plays,1393,O
a,1393,O
role,1393,O
in,1393,O
PDR,1393,O
pathogenesis,1393,O
.,1393,O
Silencing,1394,O
TCF7L2,1394,B-GENE-Y
resulted,1394,O
in,1394,O
decreased,1394,O
mRNA,1394,O
levels,1394,O
of,1394,O
both,1394,O
TCF7L2,1394,B-GENE-Y
and,1394,O
VEGFA,1394,B-GENE-Y
(,1394,O
P,1394,O
<,1394,O
0.001,1394,O
),1394,O
.,1394,O
Retinas,1395,O
of,1395,O
oxygen-induced,1395,B-CHEMICAL
retinopathy,1395,O
(,1395,O
OIR,1395,O
),1395,O
mice,1395,O
(,1395,O
a,1395,O
model,1395,O
for,1395,O
PDR,1395,O
),1395,O
had,1395,O
higher,1395,O
TCF7L2,1395,B-GENE-Y
and,1395,O
VEGFA,1395,B-GENE-Y
mRNA,1395,O
levels,1395,O
than,1395,O
controls,1395,O
(,1395,O
P,1395,O
=,1395,O
2.9E-04,1395,O
for,1395,O
TCF7L2,1395,B-GENE-Y
;,1395,O
P,1395,O
=,1395,O
1.9E-07,1395,O
for,1395,O
VEGFA,1395,B-GENE-Y
),1395,O
.,1395,O
Together,1396,O
",",1396,O
our,1396,O
study,1396,O
showed,1396,O
that,1396,O
TCF7L2-rs7903146,1396,B-GENE-Y
is,1396,O
associated,1396,O
with,1396,O
PDR,1396,O
in,1396,O
Caucasian,1396,O
T2DM,1396,O
and,1396,O
suggested,1396,O
TCF7L2,1396,B-GENE-Y
promoted,1396,O
pathological,1396,O
retinal,1396,O
neovascularization,1396,O
via,1396,O
ER,1396,O
stress-dependent,1396,O
upregulation,1396,O
of,1396,O
VEGFA,1396,B-GENE-Y
.,1396,O
α-Amino-α´-Halomethylketones,1397,B-CHEMICAL
:,1397,O
Synthetic,1397,O
Methodologies,1397,O
and,1397,O
Pharmaceutical,1397,O
Applications,1397,O
as,1397,O
Serine,1397,B-GENE-N
and,1397,I-GENE-N
Cysteine,1397,I-GENE-N
Protease,1397,I-GENE-N
Inhibitors,1397,O
.,1397,O
α-Amino-α´-halomethylketones,1398,B-CHEMICAL
are,1398,O
interesting,1398,O
scaffolds,1398,O
bearing,1398,O
(,1398,O
at,1398,O
least,1398,O
),1398,O
two,1398,O
sequential,1398,O
electrophilic,1398,O
carbons,1398,B-CHEMICAL
that,1398,O
by,1398,O
interacting,1398,O
with,1398,O
the,1398,O
nucleophilic,1398,O
moieties,1398,O
of,1398,O
several,1398,O
enzymes,1398,O
",",1398,O
represent,1398,O
the,1398,O
ideal,1398,O
candidates,1398,O
for,1398,O
in,1398,O
vivo,1398,O
and,1398,O
in,1398,O
vitro,1398,O
inhibition,1398,O
studies,1398,O
.,1398,O
In,1399,O
this,1399,O
work,1399,O
a,1399,O
summary,1399,O
of,1399,O
their,1399,O
use,1399,O
as,1399,O
optimal,1399,O
inhibitors,1399,O
of,1399,O
physiologically,1399,O
relevant,1399,O
serine,1399,B-GENE-N
and,1399,I-GENE-N
cysteine,1399,I-GENE-N
proteases,1399,I-GENE-N
is,1399,O
given,1399,O
with,1399,O
a,1399,O
particular,1399,O
emphasis,1399,O
on,1399,O
recently,1399,O
established,1399,O
SAR,1399,O
studies,1399,O
.,1399,O
A,1400,O
brief,1400,O
survey,1400,O
of,1400,O
the,1400,O
most,1400,O
relevant,1400,O
synthetic,1400,O
processes,1400,O
for,1400,O
their,1400,O
obtainment,1400,O
and,1400,O
the,1400,O
importance,1400,O
they,1400,O
possess,1400,O
in,1400,O
synthetic,1400,O
medicinal,1400,O
chemistry,1400,O
is,1400,O
reported,1400,O
.,1400,O
5-Lipoxygenase,1401,B-GENE-Y
inhibitors,1401,O
:,1401,O
a,1401,O
review,1401,O
of,1401,O
recent,1401,O
patents,1401,O
(,1401,O
2010,1401,O
-,1401,O
2012,1401,O
),1401,O
.,1401,O
Introduction,1402,O
:,1402,O
5-Lipoxygenase,1402,B-GENE-Y
(,1402,O
5-LO,1402,B-GENE-Y
),1402,O
is,1402,O
a,1402,O
crucial,1402,O
enzyme,1402,O
of,1402,O
the,1402,O
arachidonic,1402,B-CHEMICAL
acid,1402,I-CHEMICAL
(,1402,O
AA,1402,O
),1402,O
cascade,1402,O
and,1402,O
catalyzes,1402,O
the,1402,O
formation,1402,O
of,1402,O
bioactive,1402,O
leukotrienes,1402,O
(,1402,O
LTs,1402,O
),1402,O
with,1402,O
the,1402,O
help,1402,O
of,1402,O
FLAP,1402,B-GENE-Y
",",1402,O
the,1402,O
5-LO-activating,1402,B-GENE-Y
protein,1402,I-GENE-Y
.,1402,O
LTs,1403,O
are,1403,O
inflammatory,1403,O
mediators,1403,O
playing,1403,O
a,1403,O
pathophysiological,1403,O
role,1403,O
in,1403,O
different,1403,O
diseases,1403,O
like,1403,O
asthma,1403,O
",",1403,O
allergic,1403,O
rhinitis,1403,O
as,1403,O
well,1403,O
as,1403,O
cardiovascular,1403,O
diseases,1403,O
and,1403,O
certain,1403,O
types,1403,O
of,1403,O
cancer,1403,O
.,1403,O
With,1404,O
the,1404,O
rising,1404,O
number,1404,O
of,1404,O
indications,1404,O
for,1404,O
anti-LT,1404,O
therapy,1404,O
",",1404,O
5-LO,1404,B-GENE-Y
inhibitor,1404,O
drug,1404,O
development,1404,O
becomes,1404,O
increasingly,1404,O
important,1404,O
.,1404,O
Areas,1405,O
covered,1405,O
:,1405,O
Here,1405,O
",",1405,O
both,1405,O
recent,1405,O
findings,1405,O
regarding,1405,O
the,1405,O
pathophysiological,1405,O
role,1405,O
of,1405,O
5-LO,1405,B-GENE-Y
and,1405,O
the,1405,O
patents,1405,O
claimed,1405,O
for,1405,O
5-LO,1405,B-GENE-Y
inhibitors,1405,O
are,1405,O
discussed,1405,O
.,1405,O
Focusing,1406,O
on,1406,O
direct,1406,O
inhibitors,1406,O
",",1406,O
several,1406,O
patents,1406,O
disclosing,1406,O
FLAP,1406,B-GENE-Y
antagonists,1406,O
are,1406,O
also,1406,O
subject,1406,O
of,1406,O
this,1406,O
review,1406,O
.,1406,O
Novel,1407,O
compounds,1407,O
include,1407,O
"1,5-diarylpyrazoles",1407,B-CHEMICAL
",",1407,O
indolizines,1407,B-CHEMICAL
and,1407,O
indoles,1407,B-CHEMICAL
and,1407,O
several,1407,O
natural,1407,O
product,1407,O
extracts,1407,O
.,1407,O
Expert,1408,O
opinion,1408,O
:,1408,O
Evaluation,1408,O
of,1408,O
the,1408,O
patent,1408,O
activities,1408,O
revealed,1408,O
only,1408,O
quite,1408,O
moderate,1408,O
action,1408,O
.,1408,O
Nevertheless,1409,O
",",1409,O
several,1409,O
auspicious,1409,O
drug-like,1409,O
molecules,1409,O
were,1409,O
disclosed,1409,O
.,1409,O
It,1410,O
seems,1410,O
that,1410,O
in,1410,O
the,1410,O
near,1410,O
future,1410,O
",",1410,O
FLAP,1410,B-GENE-Y
inhibitors,1410,O
can,1410,O
be,1410,O
expected,1410,O
to,1410,O
enter,1410,O
the,1410,O
market,1410,O
for,1410,O
the,1410,O
treatment,1410,O
of,1410,O
asthma,1410,O
.,1410,O
With,1411,O
the,1411,O
resolved,1411,O
structure,1411,O
of,1411,O
5-LO,1411,B-GENE-Y
",",1411,O
structure-based,1411,O
drug,1411,O
design,1411,O
is,1411,O
now,1411,O
applicable,1411,O
.,1411,O
Together,1412,O
with,1412,O
the,1412,O
identification,1412,O
of,1412,O
downstream,1412,O
enzyme,1412,O
inhibitors,1412,O
and,1412,O
dual-targeting,1412,O
drugs,1412,O
within,1412,O
the,1412,O
AA,1412,O
cascade,1412,O
",",1412,O
several,1412,O
tools,1412,O
are,1412,O
at,1412,O
hand,1412,O
to,1412,O
cope,1412,O
with,1412,O
5-LOs,1412,B-GENE-Y
increasing,1412,O
pathophysiological,1412,O
roles,1412,O
.,1412,O
Super-stable,1413,O
ultrafine,1413,O
beta-tungsten,1413,B-CHEMICAL
nanocrystals,1413,O
with,1413,O
metastable,1413,O
phase,1413,O
and,1413,O
related,1413,O
magnetism,1413,O
.,1413,O
Ultrafine,1414,O
tungsten,1414,B-CHEMICAL
nanocrystals,1414,O
(,1414,O
average,1414,O
size,1414,O
of,1414,O
3,1414,O
nm,1414,O
),1414,O
with,1414,O
a,1414,O
metastable,1414,O
phase,1414,O
(,1414,O
beta-tungsten,1414,B-CHEMICAL
with,1414,O
A15,1414,O
structure,1414,O
",",1414,O
β-W,1414,O
),1414,O
have,1414,O
been,1414,O
prepared,1414,O
by,1414,O
laser,1414,O
ablation,1414,O
of,1414,O
tungsten,1414,B-CHEMICAL
in,1414,O
liquid,1414,O
nitrogen,1414,B-CHEMICAL
.,1414,O
The,1415,O
as-prepared,1415,O
metastable,1415,O
nanocrystals,1415,O
exhibited,1415,O
super-stablity,1415,O
",",1415,O
and,1415,O
can,1415,O
keep,1415,O
the,1415,O
same,1415,O
metastable,1415,O
structure,1415,O
over,1415,O
a,1415,O
period,1415,O
of,1415,O
6,1415,O
months,1415,O
at,1415,O
room,1415,O
temperature,1415,O
.,1415,O
This,1416,O
super-stability,1416,O
is,1416,O
attributed,1416,O
to,1416,O
the,1416,O
nanosized,1416,O
confinement,1416,O
effect,1416,O
of,1416,O
ultrafine,1416,O
nanocrystals,1416,O
.,1416,O
The,1417,O
magnetism,1417,O
measurements,1417,O
showed,1417,O
that,1417,O
the,1417,O
β-W,1417,O
nanocrystals,1417,O
have,1417,O
weak,1417,O
ferromagnetic,1417,O
properties,1417,O
at,1417,O
2,1417,O
K,1417,O
",",1417,O
which,1417,O
may,1417,O
arise,1417,O
from,1417,O
surface,1417,O
defects,1417,O
and,1417,O
unpaired,1417,O
electrons,1417,O
on,1417,O
the,1417,O
surface,1417,O
of,1417,O
the,1417,O
ultrafine,1417,O
nanocrystals,1417,O
.,1417,O
These,1418,O
findings,1418,O
provided,1418,O
useful,1418,O
information,1418,O
for,1418,O
the,1418,O
application,1418,O
of,1418,O
ultrafine,1418,O
β-W,1418,O
nanocrystals,1418,O
in,1418,O
microelectronics,1418,O
and,1418,O
spintronics,1418,O
.,1418,O
Transport,1419,O
Function,1419,O
and,1419,O
Transcriptional,1419,O
Regulation,1419,O
of,1419,O
a,1419,O
Liver-Enriched,1419,O
Human,1419,B-GENE-Y
Organic,1419,I-GENE-Y
Anion,1419,I-GENE-Y
Transporting,1419,I-GENE-Y
Polypeptide,1419,I-GENE-Y
2B1,1419,I-GENE-Y
Transcriptional,1419,O
Start,1419,O
Site,1419,O
Variant,1419,O
.,1419,O
Human,1420,B-GENE-Y
Organic,1420,I-GENE-Y
Anion,1420,I-GENE-Y
Transporting,1420,I-GENE-Y
Polypeptide,1420,I-GENE-Y
2B1,1420,I-GENE-Y
(,1420,O
OATP2B1,1420,B-GENE-Y
),1420,O
is,1420,O
a,1420,O
membrane,1420,O
transporter,1420,O
that,1420,O
facilitates,1420,O
the,1420,O
cellular,1420,O
uptake,1420,O
of,1420,O
a,1420,O
number,1420,O
of,1420,O
endogenous,1420,O
compounds,1420,O
and,1420,O
drugs,1420,O
.,1420,O
OATP2B1,1421,B-GENE-Y
is,1421,O
widely,1421,O
expressed,1421,O
in,1421,O
tissues,1421,O
including,1421,O
the,1421,O
small,1421,O
intestine,1421,O
",",1421,O
liver,1421,O
",",1421,O
kidney,1421,O
",",1421,O
placenta,1421,O
",",1421,O
heart,1421,O
",",1421,O
skeletal,1421,O
muscle,1421,O
and,1421,O
platelets,1421,O
.,1421,O
Recently,1422,O
",",1422,O
it,1422,O
has,1422,O
been,1422,O
shown,1422,O
that,1422,O
differential,1422,O
promoter,1422,O
usage,1422,O
in,1422,O
tissues,1422,O
results,1422,O
in,1422,O
expression,1422,O
of,1422,O
five,1422,O
OATP2B1,1422,B-GENE-Y
transcriptional,1422,O
start,1422,O
site,1422,O
variants,1422,O
which,1422,O
utilize,1422,O
distinct,1422,O
first,1422,O
exons,1422,O
but,1422,O
share,1422,O
common,1422,O
subsequent,1422,O
exons,1422,O
.,1422,O
These,1423,O
variants,1423,O
are,1423,O
expected,1423,O
to,1423,O
encode,1423,O
either,1423,O
a,1423,O
full,1423,O
length,1423,O
(,1423,O
OATP2B1-FL,1423,B-GENE-Y
),1423,O
or,1423,O
shortened,1423,O
protein,1423,O
lacking,1423,O
22,1423,O
N-terminus,1423,B-CHEMICAL
amino,1423,B-CHEMICAL
acids,1423,I-CHEMICAL
(,1423,O
OATP2B-Short,1423,B-GENE-Y
),1423,O
.,1423,O
Little,1424,O
is,1424,O
known,1424,O
regarding,1424,O
the,1424,O
transport,1424,O
activity,1424,O
and,1424,O
regulation,1424,O
of,1424,O
OATP2B1,1424,B-GENE-Y
variants,1424,O
with,1424,O
N-terminus,1424,B-CHEMICAL
truncation,1424,O
.,1424,O
Here,1425,O
",",1425,O
using,1425,O
absolute,1425,O
quantitative,1425,O
polymerase,1425,O
chain,1425,O
reaction,1425,O
we,1425,O
find,1425,O
the,1425,O
full,1425,O
length,1425,O
variant,1425,O
is,1425,O
the,1425,O
major,1425,O
form,1425,O
expressed,1425,O
in,1425,O
duodenum,1425,O
but,1425,O
the,1425,O
short,1425,O
variant,1425,O
predominates,1425,O
in,1425,O
liver,1425,O
.,1425,O
Using,1426,O
a,1426,O
transient,1426,O
heterologous,1426,O
cell,1426,O
expression,1426,O
system,1426,O
",",1426,O
we,1426,O
find,1426,O
that,1426,O
the,1426,O
transport,1426,O
activities,1426,O
of,1426,O
the,1426,O
short,1426,B-GENE-Y
OATP2B1,1426,I-GENE-Y
variant,1426,O
towards,1426,O
substrates,1426,O
estrone,1426,B-CHEMICAL
sulfate,1426,I-CHEMICAL
and,1426,O
rosuvastatin,1426,B-CHEMICAL
are,1426,O
similar,1426,O
to,1426,O
the,1426,O
well-characterized,1426,O
full,1426,O
length,1426,O
variant,1426,O
.,1426,O
Transcriptional,1427,O
activity,1427,O
screening,1427,O
of,1427,O
the,1427,O
liver,1427,O
enriched,1427,O
OATP2B1,1427,B-GENE-N
variant,1427,I-GENE-N
promoter,1427,I-GENE-N
identified,1427,O
hepatocyte,1427,B-GENE-Y
nuclear,1427,I-GENE-Y
factor,1427,I-GENE-Y
4,1427,I-GENE-Y
alpha,1427,I-GENE-Y
(,1427,O
HNF4α,1427,B-GENE-Y
),1427,O
as,1427,O
a,1427,O
novel,1427,O
transacting,1427,O
factor,1427,O
.,1427,O
With,1428,O
a,1428,O
combination,1428,O
of,1428,O
in,1428,O
silico,1428,O
screening,1428,O
",",1428,O
promoter,1428,O
mutation,1428,O
in,1428,O
cell-based,1428,O
reporter,1428,O
assays,1428,O
",",1428,O
siRNA,1428,O
knockdown,1428,O
and,1428,O
chromatin,1428,O
immunoprecipitation,1428,O
studies,1428,O
",",1428,O
we,1428,O
identified,1428,O
a,1428,O
functional,1428,O
HNF4α,1428,B-GENE-Y
binding,1428,O
site,1428,O
close,1428,O
to,1428,O
the,1428,O
transcription,1428,O
start,1428,O
site,1428,O
(,1428,O
-17,1428,O
to,1428,O
-4,1428,O
bp,1428,O
),1428,O
.,1428,O
We,1429,O
conclude,1429,O
that,1429,O
the,1429,O
major,1429,O
OATP2B1,1429,B-GENE-Y
protein,1429,O
form,1429,O
in,1429,O
liver,1429,O
is,1429,O
transport,1429,O
competent,1429,O
and,1429,O
its,1429,O
hepatic,1429,O
expression,1429,O
is,1429,O
regulated,1429,O
by,1429,O
HNF4α,1429,B-GENE-Y
.,1429,O
TLR4,1430,B-GENE-Y
antagonist,1430,O
reduces,1430,O
early-stage,1430,O
atherosclerosis,1430,O
in,1430,O
diabetic,1430,O
apolipoprotein,1430,B-GENE-Y
E-deficient,1430,O
mice,1430,O
.,1430,O
Although,1431,O
it,1431,O
has,1431,O
been,1431,O
reported,1431,O
that,1431,O
deficiency,1431,O
of,1431,O
toll-like,1431,B-GENE-Y
receptor,1431,I-GENE-Y
4,1431,I-GENE-Y
(,1431,O
TLR4,1431,B-GENE-Y
),1431,O
is,1431,O
associated,1431,O
with,1431,O
reduced,1431,O
atherosclerosis,1431,O
in,1431,O
atherosclerosis-prone,1431,O
mice,1431,O
and,1431,O
attenuated,1431,O
pro-inflammatory,1431,O
state,1431,O
in,1431,O
diabetic,1431,O
mice,1431,O
",",1431,O
it,1431,O
remains,1431,O
undetermined,1431,O
whether,1431,O
treatment,1431,O
with,1431,O
a,1431,O
TLR4,1431,B-GENE-Y
antagonist,1431,O
reduces,1431,O
atherosclerosis,1431,O
in,1431,O
nondiabetic,1431,O
or,1431,O
diabetic,1431,O
mice,1431,O
that,1431,O
have,1431,O
TLR4,1431,B-GENE-Y
expression,1431,O
.,1431,O
In,1432,O
this,1432,O
study,1432,O
",",1432,O
we,1432,O
determined,1432,O
the,1432,O
effect,1432,O
of,1432,O
Rhodobacter,1432,O
sphaeroides,1432,O
lipopolysaccharide,1432,O
(,1432,O
Rs-LPS,1432,O
),1432,O
",",1432,O
an,1432,O
established,1432,O
TLR4,1432,B-GENE-Y
antagonist,1432,O
",",1432,O
on,1432,O
early-stage,1432,O
atherosclerosis,1432,O
in,1432,O
nondiabetic,1432,O
and,1432,O
streptozotocin-induced,1432,B-CHEMICAL
diabetic,1432,O
apolipoprotein,1432,B-GENE-Y
E-deficient,1432,O
(,1432,O
Apoe,1432,B-GENE-Y
(,1432,O
-/-,1432,O
),1432,O
),1432,O
mice,1432,O
.,1432,O
Analysis,1433,O
of,1433,O
atherosclerotic,1433,O
lesions,1433,O
of,1433,O
both,1433,O
en,1433,O
face,1433,O
aortas,1433,O
and,1433,O
cross,1433,O
sections,1433,O
of,1433,O
aortic,1433,O
roots,1433,O
showed,1433,O
that,1433,O
administration,1433,O
of,1433,O
Rs-LPS,1433,O
in,1433,O
14-week-old,1433,O
diabetic,1433,O
Apoe,1433,B-GENE-Y
(,1433,O
-/-,1433,O
),1433,O
mice,1433,O
for,1433,O
10,1433,O
weeks,1433,O
significantly,1433,O
reduced,1433,O
atherosclerotic,1433,O
lesions,1433,O
.,1433,O
Although,1434,O
atherosclerotic,1434,O
lesions,1434,O
in,1434,O
nondiabetic,1434,O
Apoe,1434,B-GENE-Y
(,1434,O
-/-,1434,O
),1434,O
mice,1434,O
appeared,1434,O
to,1434,O
be,1434,O
decreased,1434,O
by,1434,O
Rs-LPS,1434,O
treatment,1434,O
",",1434,O
the,1434,O
difference,1434,O
was,1434,O
not,1434,O
statistically,1434,O
significant,1434,O
.,1434,O
Metabolic,1435,O
study,1435,O
showed,1435,O
that,1435,O
Rs-LPS,1435,O
significantly,1435,O
lowered,1435,O
serum,1435,O
levels,1435,O
of,1435,O
cholesterol,1435,B-CHEMICAL
and,1435,O
triglycerides,1435,B-CHEMICAL
in,1435,O
nondiabetic,1435,O
mice,1435,O
but,1435,O
not,1435,O
in,1435,O
diabetic,1435,O
mice,1435,O
.,1435,O
Furthermore,1436,O
",",1436,O
immunohistochemistry,1436,O
studies,1436,O
showed,1436,O
that,1436,O
Rs-LPS,1436,O
inhibited,1436,O
the,1436,O
expression,1436,O
of,1436,O
interleukin,1436,B-GENE-Y
6,1436,I-GENE-Y
and,1436,O
matrix,1436,B-GENE-Y
metalloproteinase-9,1436,I-GENE-Y
and,1436,O
reduced,1436,O
the,1436,O
content,1436,O
of,1436,O
monocytes,1436,O
and,1436,O
macrophages,1436,O
in,1436,O
atherosclerotic,1436,O
plaques,1436,O
.,1436,O
Taken,1437,O
together,1437,O
",",1437,O
this,1437,O
study,1437,O
demonstrated,1437,O
for,1437,O
the,1437,O
first,1437,O
time,1437,O
that,1437,O
TLR4,1437,B-GENE-Y
antagonist,1437,O
inhibited,1437,O
vascular,1437,O
inflammation,1437,O
and,1437,O
atherogenesis,1437,O
in,1437,O
diabetic,1437,O
Apoe,1437,B-GENE-Y
(,1437,O
-/-,1437,O
),1437,O
mice,1437,O
and,1437,O
lowered,1437,O
serum,1437,O
cholesterol,1437,B-CHEMICAL
and,1437,O
triglyceride,1437,B-CHEMICAL
levels,1437,O
in,1437,O
nondiabetic,1437,O
Apoe,1437,B-GENE-Y
(,1437,O
-/-,1437,O
),1437,O
mice,1437,O
.,1437,O
The,1438,O
neuropharmacological,1438,O
basis,1438,O
for,1438,O
the,1438,O
use,1438,O
of,1438,O
memantine,1438,B-CHEMICAL
in,1438,O
the,1438,O
treatment,1438,O
of,1438,O
Alzheimer,1438,O
's,1438,O
disease,1438,O
.,1438,O
Memantine,1439,B-CHEMICAL
has,1439,O
been,1439,O
demonstrated,1439,O
to,1439,O
be,1439,O
safe,1439,O
and,1439,O
effective,1439,O
in,1439,O
the,1439,O
symptomatic,1439,O
treatment,1439,O
of,1439,O
Alzheimer,1439,O
's,1439,O
disease,1439,O
(,1439,O
AD,1439,O
),1439,O
.,1439,O
While,1440,O
the,1440,O
neurobiological,1440,O
basis,1440,O
for,1440,O
the,1440,O
therapeutic,1440,O
activity,1440,O
of,1440,O
memantine,1440,B-CHEMICAL
is,1440,O
not,1440,O
fully,1440,O
understood,1440,O
",",1440,O
the,1440,O
drug,1440,O
is,1440,O
not,1440,O
a,1440,O
cholinesterase,1440,B-GENE-Y
inhibitor,1440,O
and,1440,O
",",1440,O
therefore,1440,O
",",1440,O
acts,1440,O
differently,1440,O
from,1440,O
current,1440,O
AD,1440,O
therapies,1440,O
.,1440,O
Memantine,1441,B-CHEMICAL
can,1441,O
interact,1441,O
with,1441,O
a,1441,O
variety,1441,O
of,1441,O
ligand-gated,1441,B-GENE-N
ion,1441,I-GENE-N
channels,1441,I-GENE-N
.,1441,O
However,1442,O
",",1442,O
NMDA,1442,B-GENE-N
receptors,1442,I-GENE-N
appear,1442,O
to,1442,O
be,1442,O
a,1442,O
key,1442,O
target,1442,O
of,1442,O
memantine,1442,B-CHEMICAL
at,1442,O
therapeutic,1442,O
concentrations,1442,O
.,1442,O
Memantine,1443,B-CHEMICAL
is,1443,O
an,1443,O
uncompetitive,1443,O
(,1443,O
channel,1443,O
blocking,1443,O
),1443,O
NMDA,1443,B-GENE-N
receptor,1443,I-GENE-N
antagonist,1443,O
.,1443,O
Like,1444,O
other,1444,O
NMDA,1444,B-GENE-N
receptor,1444,I-GENE-N
antagonists,1444,O
",",1444,O
memantine,1444,B-CHEMICAL
at,1444,O
high,1444,O
concentrations,1444,O
can,1444,O
inhibit,1444,O
mechanisms,1444,O
of,1444,O
synaptic,1444,O
plasticity,1444,O
that,1444,O
are,1444,O
believed,1444,O
to,1444,O
underlie,1444,O
learning,1444,O
and,1444,O
memory,1444,O
.,1444,O
However,1445,O
",",1445,O
at,1445,O
lower,1445,O
",",1445,O
clinically,1445,O
relevant,1445,O
concentrations,1445,O
memantine,1445,B-CHEMICAL
can,1445,O
under,1445,O
some,1445,O
circumstances,1445,O
promote,1445,O
synaptic,1445,O
plasticity,1445,O
and,1445,O
preserve,1445,O
or,1445,O
enhance,1445,O
memory,1445,O
in,1445,O
animal,1445,O
models,1445,O
of,1445,O
AD,1445,O
.,1445,O
In,1446,O
addition,1446,O
",",1446,O
memantine,1446,B-CHEMICAL
can,1446,O
protect,1446,O
against,1446,O
the,1446,O
excitotoxic,1446,O
destruction,1446,O
of,1446,O
cholinergic,1446,O
neurons,1446,O
.,1446,O
Blockade,1447,O
of,1447,O
NMDA,1447,B-GENE-N
receptors,1447,I-GENE-N
by,1447,O
memantine,1447,B-CHEMICAL
could,1447,O
theoretically,1447,O
confer,1447,O
disease-modifying,1447,O
activity,1447,O
in,1447,O
AD,1447,O
by,1447,O
inhibiting,1447,O
the,1447,O
``,1447,O
weak,1447,O
'',1447,O
NMDA,1447,B-GENE-N
receptor-dependent,1447,O
excitotoxicity,1447,O
that,1447,O
has,1447,O
been,1447,O
hypothesized,1447,O
to,1447,O
play,1447,O
a,1447,O
role,1447,O
in,1447,O
the,1447,O
progressive,1447,O
neuronal,1447,O
loss,1447,O
that,1447,O
underlies,1447,O
the,1447,O
evolving,1447,O
dementia,1447,O
.,1447,O
Moreover,1448,O
",",1448,O
recent,1448,O
in,1448,O
vitro,1448,O
studies,1448,O
suggest,1448,O
that,1448,O
memantine,1448,B-CHEMICAL
abrogates,1448,O
beta-amyloid,1448,B-GENE-Y
(,1448,O
Abeta,1448,B-GENE-Y
),1448,O
toxicity,1448,O
and,1448,O
possibly,1448,O
inhibits,1448,O
Abeta,1448,B-GENE-Y
production,1448,O
.,1448,O
Considerable,1449,O
attention,1449,O
has,1449,O
focused,1449,O
on,1449,O
the,1449,O
investigation,1449,O
of,1449,O
theories,1449,O
to,1449,O
explain,1449,O
the,1449,O
better,1449,O
tolerability,1449,O
of,1449,O
memantine,1449,B-CHEMICAL
over,1449,O
other,1449,O
NMDA,1449,B-GENE-N
receptor,1449,I-GENE-N
antagonists,1449,O
",",1449,O
particularly,1449,O
those,1449,O
that,1449,O
act,1449,O
by,1449,O
a,1449,O
similar,1449,O
channel,1449,O
blocking,1449,O
mechanism,1449,O
such,1449,O
as,1449,O
dissociative,1449,O
anesthetic-like,1449,O
agents,1449,O
(,1449,O
phencyclidine,1449,B-CHEMICAL
",",1449,O
ketamine,1449,B-CHEMICAL
",",1449,O
MK-801,1449,B-CHEMICAL
),1449,O
.,1449,O
A,1450,O
variety,1450,O
of,1450,O
channel-level,1450,O
factors,1450,O
could,1450,O
be,1450,O
relevant,1450,O
",",1450,O
including,1450,O
fast,1450,O
channel-blocking,1450,O
kinetics,1450,O
and,1450,O
strong,1450,O
voltage-dependence,1450,O
(,1450,O
allowing,1450,O
rapid,1450,O
relief,1450,O
of,1450,O
block,1450,O
during,1450,O
synaptic,1450,O
activity,1450,O
),1450,O
",",1450,O
as,1450,O
well,1450,O
as,1450,O
reduced,1450,O
trapping,1450,O
(,1450,O
permitting,1450,O
egress,1450,O
from,1450,O
closed,1450,O
channels,1450,O
),1450,O
.,1450,O
These,1451,O
factors,1451,O
may,1451,O
allow,1451,O
memantine,1451,B-CHEMICAL
to,1451,O
block,1451,O
channel,1451,O
activity,1451,O
induced,1451,O
by,1451,O
low,1451,O
",",1451,O
tonic,1451,O
levels,1451,O
of,1451,O
glutamate,1451,B-CHEMICAL
--,1451,O
an,1451,O
action,1451,O
that,1451,O
might,1451,O
contribute,1451,O
to,1451,O
symptomatic,1451,O
improvement,1451,O
and,1451,O
could,1451,O
theoretically,1451,O
protect,1451,O
against,1451,O
weak,1451,O
excitotoxicity,1451,O
--,1451,O
while,1451,O
sparing,1451,O
synaptic,1451,O
responses,1451,O
required,1451,O
for,1451,O
normal,1451,O
behavioral,1451,O
functioning,1451,O
",",1451,O
cognition,1451,O
and,1451,O
memory,1451,O
.,1451,O
Expansion,1452,O
of,1452,O
the,1452,O
Homeostasis,1452,O
Model,1452,O
Assessment,1452,O
of,1452,O
β-Cell,1452,O
Function,1452,O
and,1452,O
Insulin,1452,B-GENE-Y
Resistance,1452,O
to,1452,O
Enable,1452,O
Clinical,1452,O
Trial,1452,O
Outcome,1452,O
Modeling,1452,O
Through,1452,O
the,1452,O
Interactive,1452,O
Adjustment,1452,O
of,1452,O
Physiology,1452,O
and,1452,O
Treatment,1452,O
Effects,1452,O
--,1452,O
iHOMA2,1452,O
.,1452,O
OBJECTIVETo,1453,O
describe,1453,O
and,1453,O
make,1453,O
available,1453,O
an,1453,O
interactive,1453,O
",",1453,O
24-variable,1453,O
homeostasis,1453,O
model,1453,O
assessment,1453,O
(,1453,O
iHOMA2,1453,O
),1453,O
that,1453,O
extends,1453,O
the,1453,O
HOMA2,1453,O
model,1453,O
",",1453,O
enabling,1453,O
the,1453,O
modeling,1453,O
of,1453,O
physiology,1453,O
and,1453,O
treatment,1453,O
effects,1453,O
",",1453,O
to,1453,O
present,1453,O
equations,1453,O
of,1453,O
the,1453,O
HOMA2,1453,O
and,1453,O
iHOMA2,1453,O
models,1453,O
",",1453,O
and,1453,O
to,1453,O
exemplify,1453,O
iHOMA2,1453,O
in,1453,O
two,1453,O
widely,1453,O
differing,1453,O
scenarios,1453,O
:,1453,O
changes,1453,O
in,1453,O
insulin,1453,B-GENE-N
sensitivity,1453,O
with,1453,O
thiazolidinediones,1453,B-CHEMICAL
and,1453,O
changes,1453,O
in,1453,O
renal,1453,O
threshold,1453,O
with,1453,O
sodium,1453,B-GENE-N
glucose,1453,I-GENE-N
transporter,1453,I-GENE-N
(,1453,O
SGLT2,1453,B-GENE-Y
),1453,O
inhibition.RESEARCH,1453,O
DESIGN,1453,O
AND,1453,O
METHODSiHOMA2,1453,O
enables,1453,O
a,1453,O
user,1453,O
of,1453,O
the,1453,O
available,1453,O
software,1453,O
to,1453,O
examine,1453,O
and,1453,O
modify,1453,O
the,1453,O
mathematical,1453,O
functions,1453,O
describing,1453,O
the,1453,O
organs,1453,O
and,1453,O
tissues,1453,O
involved,1453,O
in,1453,O
the,1453,O
glucose,1453,B-CHEMICAL
and,1453,O
hormonal,1453,O
compartments,1453,O
.,1453,O
We,1454,O
exemplify,1454,O
this,1454,O
with,1454,O
SGLT2,1454,B-GENE-Y
inhibition,1454,O
modeling,1454,O
(,1454,O
by,1454,O
changing,1454,O
the,1454,O
renal,1454,O
threshold,1454,O
parameters,1454,O
),1454,O
using,1454,O
published,1454,O
data,1454,O
of,1454,O
renal,1454,O
effect,1454,O
",",1454,O
showing,1454,O
that,1454,O
the,1454,O
modeled,1454,O
effect,1454,O
is,1454,O
concordant,1454,O
with,1454,O
the,1454,O
effects,1454,O
on,1454,O
fasting,1454,O
glucose,1454,B-CHEMICAL
from,1454,O
independent,1454,O
data.RESULTSiHOMA2,1454,O
modeling,1454,O
of,1454,O
thiazolidinediones,1454,B-CHEMICAL
effect,1454,O
suggested,1454,O
that,1454,O
changes,1454,O
in,1454,O
insulin,1454,O
sensitivity,1454,O
in,1454,O
the,1454,O
fasting,1454,O
state,1454,O
are,1454,O
predominantly,1454,O
hepatic,1454,O
.,1454,O
SGLT2,1455,B-GENE-Y
inhibition,1455,O
modeled,1455,O
by,1455,O
iHOMA2,1455,O
resulted,1455,O
in,1455,O
a,1455,O
decrease,1455,O
in,1455,O
mean,1455,O
glucose,1455,B-CHEMICAL
of,1455,O
1.1,1455,O
mmol/L,1455,O
.,1455,O
Observed,1456,O
data,1456,O
showed,1456,O
a,1456,O
decrease,1456,O
in,1456,O
glucose,1456,B-CHEMICAL
of,1456,O
0.9,1456,O
mmol/L,1456,O
.,1456,O
There,1457,O
was,1457,O
no,1457,O
significant,1457,O
difference,1457,O
between,1457,O
the,1457,O
model,1457,O
and,1457,O
the,1457,O
independent,1457,O
data,1457,O
.,1457,O
Manipulation,1458,O
of,1458,O
iHOMA2s,1458,O
renal,1458,O
excretion,1458,O
threshold,1458,O
variable,1458,O
suggested,1458,O
that,1458,O
a,1458,O
decrease,1458,O
of,1458,O
17,1458,O
%,1458,O
was,1458,O
required,1458,O
to,1458,O
obtain,1458,O
a,1458,O
0.9,1458,O
mmol/L,1458,O
decrease,1458,O
in,1458,O
mean,1458,O
glucose.CONCLUSIONSiHOMA2,1458,B-CHEMICAL
is,1458,O
an,1458,O
extended,1458,O
mathematical,1458,O
model,1458,O
for,1458,O
the,1458,O
assessment,1458,O
of,1458,O
insulin,1458,B-GENE-Y
resistance,1458,O
and,1458,O
β-cell,1458,O
function,1458,O
.,1458,O
The,1459,O
model,1459,O
can,1459,O
be,1459,O
used,1459,O
to,1459,O
evaluate,1459,O
therapeutic,1459,O
agents,1459,O
and,1459,O
predict,1459,O
effects,1459,O
on,1459,O
fasting,1459,O
glucose,1459,B-CHEMICAL
and,1459,O
insulin,1459,O
and,1459,O
on,1459,O
β-cell,1459,O
function,1459,O
and,1459,O
insulin,1459,B-GENE-Y
sensitivity,1459,O
.,1459,O
Roles,1460,O
of,1460,O
rifampicin,1460,B-CHEMICAL
in,1460,O
drug-drug,1460,O
interactions,1460,O
:,1460,O
underlying,1460,O
molecular,1460,O
mechanisms,1460,O
involving,1460,O
the,1460,O
nuclear,1460,B-GENE-Y
pregnane,1460,I-GENE-Y
X,1460,I-GENE-Y
receptor,1460,I-GENE-Y
.,1460,O
Rifampicin,1461,B-CHEMICAL
",",1461,O
an,1461,O
important,1461,O
drug,1461,O
in,1461,O
the,1461,O
treatment,1461,O
of,1461,O
tuberculosis,1461,O
",",1461,O
is,1461,O
used,1461,O
extensively,1461,O
despite,1461,O
its,1461,O
broad,1461,O
effects,1461,O
on,1461,O
drug-drug,1461,O
interactions,1461,O
",",1461,O
creating,1461,O
serious,1461,O
problems,1461,O
.,1461,O
The,1462,O
clinical,1462,O
importance,1462,O
of,1462,O
such,1462,O
interactions,1462,O
includes,1462,O
autoinduction,1462,O
leading,1462,O
to,1462,O
suboptimal,1462,O
or,1462,O
failed,1462,O
treatment,1462,O
.,1462,O
The,1463,O
concomitantly,1463,O
administered,1463,O
effects,1463,O
of,1463,O
rifampicin,1463,B-CHEMICAL
on,1463,O
other,1463,O
drugs,1463,O
can,1463,O
result,1463,O
in,1463,O
their,1463,O
altered,1463,O
metabolism,1463,O
or,1463,O
transportation,1463,O
that,1463,O
are,1463,O
metabolised,1463,O
by,1463,O
cytochromes,1463,B-GENE-N
P450,1463,I-GENE-N
or,1463,O
transported,1463,O
by,1463,O
p-glycoprotein,1463,B-GENE-N
in,1463,O
the,1463,O
gastrointestinal,1463,O
tract,1463,O
and,1463,O
liver,1463,O
.,1463,O
This,1464,O
review,1464,O
paper,1464,O
summarises,1464,O
recent,1464,O
findings,1464,O
with,1464,O
emphases,1464,O
on,1464,O
the,1464,O
molecular,1464,O
mechanisms,1464,O
used,1464,O
to,1464,O
explain,1464,O
these,1464,O
broad,1464,O
drug-drug,1464,O
interactions,1464,O
.,1464,O
In,1465,O
general,1465,O
",",1465,O
rifampicin,1465,B-CHEMICAL
can,1465,O
act,1465,O
on,1465,O
a,1465,O
pattern,1465,O
:,1465,O
rifampicin,1465,B-CHEMICAL
activates,1465,O
the,1465,O
nuclear,1465,B-GENE-Y
pregnane,1465,I-GENE-Y
X,1465,I-GENE-Y
receptor,1465,I-GENE-Y
that,1465,O
in,1465,O
turn,1465,O
affects,1465,O
cytochromes,1465,B-GENE-N
P450,1465,I-GENE-N
",",1465,O
glucuronosyltransferases,1465,B-GENE-N
and,1465,O
p-glycoprotein,1465,B-GENE-N
activities,1465,O
.,1465,O
This,1466,O
pattern,1466,O
of,1466,O
action,1466,O
may,1466,O
explain,1466,O
many,1466,O
of,1466,O
the,1466,O
rifampicin,1466,B-CHEMICAL
inducing,1466,O
drug-drug,1466,O
interactions,1466,O
.,1466,O
However,1467,O
",",1467,O
effects,1467,O
through,1467,O
other,1467,O
mechanisms,1467,O
have,1467,O
also,1467,O
been,1467,O
reported,1467,O
and,1467,O
these,1467,O
make,1467,O
any,1467,O
explanation,1467,O
of,1467,O
such,1467,O
drug-drug,1467,O
interactions,1467,O
more,1467,O
complex,1467,O
.,1467,O
Screening,1468,O
for,1468,O
(,1468,O
anti,1468,O
),1468,O
androgenic,1468,O
properties,1468,O
using,1468,O
a,1468,O
standard,1468,O
operation,1468,O
protocol,1468,O
based,1468,O
on,1468,O
the,1468,O
human,1468,O
stably,1468,O
transfected,1468,O
androgen,1468,B-CHEMICAL
sensitive,1468,O
PALM,1468,O
cell,1468,O
line,1468,O
.,1468,O
First,1469,O
steps,1469,O
towards,1469,O
validation,1469,O
.,1469,O
Despite,1470,O
more,1470,O
than,1470,O
a,1470,O
decade,1470,O
of,1470,O
research,1470,O
in,1470,O
the,1470,O
field,1470,O
of,1470,O
endocrine,1470,O
active,1470,O
compounds,1470,O
targeting,1470,O
the,1470,O
androgen,1470,B-GENE-Y
receptor,1470,I-GENE-Y
(,1470,O
AR,1470,B-GENE-Y
),1470,O
",",1470,O
and,1470,O
although,1470,O
suitable,1470,O
cell,1470,O
lines,1470,O
can,1470,O
be,1470,O
obtained,1470,O
",",1470,O
no,1470,O
validated,1470,O
human,1470,O
stably,1470,O
transfected,1470,O
androgen,1470,B-CHEMICAL
sensitive,1470,O
transactivation,1470,O
assay,1470,O
is,1470,O
available,1470,O
.,1470,O
Bayer,1471,O
Schering,1471,O
Pharma,1471,O
(,1471,O
BSP,1471,O
),1471,O
and,1471,O
the,1471,O
Flemish,1471,O
Institute,1471,O
for,1471,O
Technological,1471,O
Research,1471,O
(,1471,O
VITO,1471,O
),1471,O
",",1471,O
partners,1471,O
within,1471,O
the,1471,O
EU-sponsored,1471,O
6th,1471,O
framework,1471,O
project,1471,O
ReProTect,1471,O
",",1471,O
made,1471,O
first,1471,O
steps,1471,O
towards,1471,O
such,1471,O
a,1471,O
validation,1471,O
.,1471,O
A,1472,O
standard,1472,O
operation,1472,O
protocol,1472,O
(,1472,O
SOP,1472,O
),1472,O
developed,1472,O
at,1472,O
BSP,1472,O
based,1472,O
on,1472,O
the,1472,O
androgen,1472,B-CHEMICAL
sensitive,1472,O
PALM,1472,O
cell,1472,O
line,1472,O
was,1472,O
transferred,1472,O
to,1472,O
VITO,1472,O
and,1472,O
its,1472,O
performance,1472,O
and,1472,O
transferability,1472,O
were,1472,O
thoroughly,1472,O
studied,1472,O
.,1472,O
The,1473,O
investigation,1473,O
followed,1473,O
a,1473,O
generic,1473,O
protocol,1473,O
prepared,1473,O
for,1473,O
all,1473,O
reporter,1473,O
gene,1473,O
assays,1473,O
evaluated,1473,O
within,1473,O
ReProTect,1473,O
",",1473,O
and,1473,O
in,1473,O
both,1473,O
laboratories,1473,O
at,1473,O
least,1473,O
three,1473,O
independent,1473,O
experiments,1473,O
were,1473,O
performed,1473,O
.,1473,O
The,1474,O
highest,1474,O
concentration,1474,O
to,1474,O
be,1474,O
tested,1474,O
was,1474,O
limited,1474,O
to,1474,O
10,1474,O
microM,1474,O
",",1474,O
if,1474,O
needed,1474,O
.,1474,O
A,1475,O
few,1475,O
compounds,1475,O
",",1475,O
17alpha-methyltestosterone,1475,B-CHEMICAL
(,1475,O
17alpha-MT,1475,B-CHEMICAL
),1475,O
",",1475,O
vinclozolin,1475,B-CHEMICAL
and,1475,O
linuron,1475,B-CHEMICAL
",",1475,O
were,1475,O
studied,1475,O
using,1475,O
a,1475,O
real,1475,O
world,1475,O
scenario,1475,O
",",1475,O
i.e.,1475,O
",",1475,O
assuming,1475,O
that,1475,O
their,1475,O
interaction,1475,O
with,1475,O
the,1475,O
AR,1475,B-GENE-Y
was,1475,O
not,1475,O
known,1475,O
:,1475,O
A,1475,O
prescreening,1475,O
for,1475,O
agonism,1475,O
and,1475,O
true,1475,O
",",1475,O
competitive,1475,O
antagonism,1475,O
was,1475,O
used,1475,O
to,1475,O
select,1475,O
conditions,1475,O
such,1475,O
as,1475,O
the,1475,O
appropriate,1475,O
mode,1475,O
of,1475,O
action,1475,O
",",1475,O
and,1475,O
the,1475,O
working,1475,O
range,1475,O
excluding,1475,O
cytotoxicity,1475,O
for,1475,O
the,1475,O
final,1475,O
screening,1475,O
.,1475,O
All,1476,O
other,1476,O
compounds,1476,O
were,1476,O
tested,1476,O
according,1476,O
to,1476,O
the,1476,O
generic,1476,O
protocol,1476,O
:,1476,O
Compounds,1476,O
screened,1476,O
for,1476,O
agonism,1476,O
were,1476,O
the,1476,O
reference,1476,O
androgen,1476,B-CHEMICAL
17alpha-methyldihydrotestosterone,1476,B-CHEMICAL
(,1476,O
MDHT,1476,B-CHEMICAL
),1476,O
",",1476,O
levonorgestrel,1476,B-CHEMICAL
",",1476,O
norethynodrel,1476,B-CHEMICAL
",",1476,O
progesterone,1476,B-CHEMICAL
",",1476,O
o,1476,B-CHEMICAL
",",1476,I-CHEMICAL
p'-DDT,1476,I-CHEMICAL
",",1476,O
and,1476,O
dibutylphthalate,1476,B-CHEMICAL
(,1476,O
DBP,1476,B-CHEMICAL
),1476,O
",",1476,O
while,1476,O
compounds,1476,O
screened,1476,O
for,1476,O
antagonism,1476,O
were,1476,O
the,1476,O
reference,1476,O
anti-androgen,1476,B-CHEMICAL
flutamide,1476,B-CHEMICAL
",",1476,O
prochloraz,1476,B-CHEMICAL
",",1476,O
o,1476,B-CHEMICAL
",",1476,I-CHEMICAL
p'-DDT,1476,I-CHEMICAL
",",1476,O
progesterone,1476,B-CHEMICAL
",",1476,O
norethynodrel,1476,B-CHEMICAL
",",1476,O
and,1476,O
DBP,1476,B-CHEMICAL
.,1476,O
Cytotoxicity,1477,O
was,1477,O
assessed,1477,O
in,1477,O
parallel,1477,O
as,1477,O
lactate,1477,B-GENE-N
dehydrogenase,1477,I-GENE-N
release,1477,O
.,1477,O
The,1478,O
prescreen,1478,O
classified,1478,O
17alpha-MT,1478,B-CHEMICAL
as,1478,O
androgenic,1478,O
",",1478,O
vinclozolin,1478,B-CHEMICAL
and,1478,O
linuron,1478,O
as,1478,O
anti-androgenic,1478,O
and,1478,O
compounds,1478,O
were,1478,O
tested,1478,O
accordingly,1478,O
.,1478,O
In,1479,O
the,1479,O
absence,1479,O
of,1479,O
cytotoxicity,1479,O
",",1479,O
appropriate,1479,O
androgenic,1479,O
properties,1479,O
of,1479,O
reference,1479,O
and,1479,O
test,1479,O
compounds,1479,O
were,1479,O
detected,1479,O
by,1479,O
both,1479,O
laboratories,1479,O
",",1479,O
o,1479,B-CHEMICAL
",",1479,I-CHEMICAL
p'-DDT,1479,I-CHEMICAL
and,1479,O
DBP,1479,B-CHEMICAL
had,1479,O
no,1479,O
androgenic,1479,O
activity,1479,O
.,1479,O
Across,1480,O
the,1480,O
two,1480,O
laboratories,1480,O
EC,1480,O
(,1480,O
50,1480,O
),1480,O
-values,1480,O
for,1480,O
MDHT,1480,B-CHEMICAL
",",1480,O
17alpha-MT,1480,B-CHEMICAL
",",1480,O
and,1480,O
levonorgestrel,1480,B-CHEMICAL
varied,1480,O
by,1480,O
not,1480,O
more,1480,O
than,1480,O
a,1480,O
factor,1480,O
of,1480,O
3.4,1480,O
",",1480,O
for,1480,O
norethynodrel,1480,B-CHEMICAL
by,1480,O
a,1480,O
factor,1480,O
of,1480,O
9.7,1480,O
.,1480,O
Progesterone,1481,B-CHEMICAL
effects,1481,O
could,1481,O
not,1481,O
fully,1481,O
be,1481,O
evaluated,1481,O
",",1481,O
as,1481,O
frequently,1481,O
concentration,1481,O
response,1481,O
curves,1481,O
were,1481,O
incomplete,1481,O
.,1481,O
In,1482,O
the,1482,O
absence,1482,O
of,1482,O
cytotoxicity,1482,O
anti-androgenic,1482,O
properties,1482,O
of,1482,O
reference,1482,O
and,1482,O
test,1482,O
compounds,1482,O
were,1482,O
also,1482,O
detected,1482,O
in,1482,O
both,1482,O
laboratories,1482,O
.,1482,O
DBP,1483,B-CHEMICAL
",",1483,O
the,1483,O
putative,1483,O
negative,1483,O
reference,1483,O
compound,1483,O
",",1483,O
was,1483,O
inactive,1483,O
",",1483,O
norethynodrel,1483,B-CHEMICAL
rather,1483,O
showed,1483,O
agonistic,1483,O
properties,1483,O
.,1483,O
Progesterone,1484,B-CHEMICAL
was,1484,O
an,1484,O
antagonist,1484,O
at,1484,O
low,1484,O
concentrations,1484,O
",",1484,O
but,1484,O
agonistic,1484,O
properties,1484,O
were,1484,O
observed,1484,O
in,1484,O
one,1484,O
laboratory,1484,O
at,1484,O
high,1484,O
concentrations,1484,O
.,1484,O
Since,1485,O
the,1485,O
highest,1485,O
test,1485,O
concentration,1485,O
was,1485,O
limited,1485,O
to,1485,O
10,1485,O
microM,1485,O
",",1485,O
for,1485,O
some,1485,O
compounds,1485,O
no,1485,O
complete,1485,O
concentration,1485,O
response,1485,O
curves,1485,O
were,1485,O
obtained,1485,O
and,1485,O
estimation,1485,O
of,1485,O
EC,1485,O
(,1485,O
50,1485,O
),1485,O
-values,1485,O
was,1485,O
less,1485,O
robust,1485,O
.,1485,O
Our,1486,O
data,1486,O
demonstrated,1486,O
that,1486,O
the,1486,O
SOP,1486,O
was,1486,O
transferable,1486,O
",",1486,O
and,1486,O
that,1486,O
the,1486,O
assay,1486,O
was,1486,O
able,1486,O
to,1486,O
rank,1486,O
compounds,1486,O
with,1486,O
strong,1486,O
",",1486,O
weak,1486,O
",",1486,O
and,1486,O
without,1486,O
affinity,1486,O
for,1486,O
the,1486,O
AR,1486,B-GENE-Y
and,1486,O
to,1486,O
discriminate,1486,O
agonists,1486,O
and,1486,O
antagonists,1486,O
.,1486,O
The,1487,O
sensitivity,1487,O
of,1487,O
the,1487,O
assay,1487,O
could,1487,O
be,1487,O
improved,1487,O
further,1487,O
",",1487,O
if,1487,O
the,1487,O
limit,1487,O
of,1487,O
solubility,1487,O
or,1487,O
beginning,1487,O
cytotoxicity,1487,O
was,1487,O
chosen,1487,O
as,1487,O
the,1487,O
highest,1487,O
test,1487,O
concentration,1487,O
.,1487,O
The,1488,O
assay,1488,O
avoids,1488,O
the,1488,O
use,1488,O
of,1488,O
tissues,1488,O
from,1488,O
laboratory,1488,O
animals,1488,O
",",1488,O
and,1488,O
thus,1488,O
contributes,1488,O
to,1488,O
the,1488,O
3R,1488,O
concept,1488,O
.,1488,O
Furthermore,1489,O
",",1489,O
it,1489,O
could,1489,O
be,1489,O
adjusted,1489,O
to,1489,O
an,1489,O
intermediate/high,1489,O
throughput,1489,O
format,1489,O
.,1489,O
On,1490,O
the,1490,O
whole,1490,O
",",1490,O
this,1490,O
PALM,1490,O
assay,1490,O
is,1490,O
a,1490,O
promising,1490,O
candidate,1490,O
for,1490,O
further,1490,O
validation,1490,O
.,1490,O
Evidence,1491,O
for,1491,O
a,1491,O
new,1491,O
binding,1491,O
mode,1491,O
to,1491,O
GSK-3,1491,B-GENE-N
:,1491,O
allosteric,1491,O
regulation,1491,O
by,1491,O
the,1491,O
marine,1491,O
compound,1491,O
palinurin,1491,B-CHEMICAL
.,1491,O
Glycogen,1492,B-GENE-Y
synthase,1492,I-GENE-Y
kinase,1492,I-GENE-Y
3β,1492,I-GENE-Y
(,1492,O
GSK-3β,1492,B-GENE-Y
),1492,O
is,1492,O
widely,1492,O
recognised,1492,O
as,1492,O
a,1492,O
relevant,1492,O
player,1492,O
in,1492,O
the,1492,O
pathogenesis,1492,O
of,1492,O
several,1492,O
highly,1492,O
prevalent,1492,O
disorders,1492,O
such,1492,O
as,1492,O
Alzheimer,1492,O
's,1492,O
disease,1492,O
",",1492,O
mood,1492,O
disorders,1492,O
",",1492,O
diabetes,1492,O
and,1492,O
cancer,1492,O
.,1492,O
Therefore,1493,O
",",1493,O
this,1493,O
enzyme,1493,O
constitutes,1493,O
a,1493,O
highly,1493,O
attractive,1493,O
therapeutic,1493,O
target,1493,O
for,1493,O
the,1493,O
development,1493,O
of,1493,O
selective,1493,O
inhibitors,1493,O
as,1493,O
new,1493,O
promising,1493,O
drugs,1493,O
for,1493,O
the,1493,O
treatment,1493,O
of,1493,O
these,1493,O
pathologies,1493,O
.,1493,O
We,1494,O
describe,1494,O
here,1494,O
the,1494,O
isolation,1494,O
and,1494,O
biochemical,1494,O
characterization,1494,O
of,1494,O
the,1494,O
marine,1494,O
natural,1494,O
sesquiterpene,1494,B-CHEMICAL
palinurin,1494,B-CHEMICAL
as,1494,O
a,1494,O
GSK-3β,1494,B-GENE-Y
inhibitor,1494,O
.,1494,O
Experimental,1495,O
studies,1495,O
performed,1495,O
for,1495,O
characterizing,1495,O
the,1495,O
inhibitory,1495,O
mechanism,1495,O
indicate,1495,O
that,1495,O
GSK-3β,1495,B-GENE-Y
inhibition,1495,O
by,1495,O
palinurin,1495,B-CHEMICAL
can,1495,O
not,1495,O
be,1495,O
competed,1495,O
out,1495,O
by,1495,O
ATP,1495,B-CHEMICAL
nor,1495,O
peptide,1495,O
substrate,1495,O
.,1495,O
Molecular,1496,O
modelling,1496,O
techniques,1496,O
have,1496,O
enabled,1496,O
us,1496,O
to,1496,O
propose,1496,O
an,1496,O
unconventional,1496,O
binding,1496,O
mode,1496,O
to,1496,O
GSK-3β,1496,B-GENE-Y
.,1496,O
Moreover,1497,O
",",1497,O
molecular,1497,O
dynamics,1497,O
simulations,1497,O
have,1497,O
identified,1497,O
an,1497,O
allosteric,1497,O
mechanism,1497,O
by,1497,O
which,1497,O
binding,1497,O
of,1497,O
palinurin,1497,B-CHEMICAL
leads,1497,O
to,1497,O
GSK-3β,1497,B-GENE-Y
inhibition,1497,O
.,1497,O
The,1498,O
inhibitory,1498,O
activities,1498,O
determined,1498,O
for,1498,O
a,1498,O
series,1498,O
of,1498,O
structurally,1498,O
related,1498,O
analogues,1498,O
support,1498,O
the,1498,O
proposed,1498,O
binding,1498,O
mode,1498,O
of,1498,O
palinurin,1498,B-CHEMICAL
",",1498,O
which,1498,O
is,1498,O
the,1498,O
first,1498,O
compound,1498,O
described,1498,O
to,1498,O
target,1498,O
this,1498,O
allosteric,1498,O
site,1498,O
.,1498,O
The,1499,O
results,1499,O
offer,1499,O
new,1499,O
opportunities,1499,O
for,1499,O
designing,1499,O
and,1499,O
developing,1499,O
selective,1499,O
inhibitors,1499,O
with,1499,O
novel,1499,O
mechanisms,1499,O
of,1499,O
action,1499,O
.,1499,O
Pharmacological,1500,O
Inhibition,1500,O
of,1500,O
Platelet-tumor,1500,O
Cell,1500,O
Cross-talk,1500,O
Prevents,1500,O
Platelet-induced,1500,O
Overexpression,1500,O
of,1500,O
Cyclooxygenase-2,1500,B-GENE-Y
in,1500,O
HT29,1500,O
Human,1500,O
Colon,1500,O
Carcinoma,1500,O
Cells,1500,O
.,1500,O
Cyclooxygenase,1501,B-GENE-Y
(,1501,I-GENE-Y
COX,1501,I-GENE-Y
),1501,I-GENE-Y
-2-derived,1501,O
prostanoids,1501,B-CHEMICAL
can,1501,O
influence,1501,O
several,1501,O
processes,1501,O
that,1501,O
are,1501,O
linked,1501,O
to,1501,O
carcinogenesis,1501,O
.,1501,O
We,1502,O
aimed,1502,O
to,1502,O
address,1502,O
the,1502,O
hypothesis,1502,O
that,1502,O
platelets,1502,O
contribute,1502,O
to,1502,O
aberrant,1502,O
COX-2,1502,B-GENE-Y
expression,1502,O
in,1502,O
HT29,1502,O
colon,1502,O
carcinoma,1502,O
cells,1502,O
and,1502,O
to,1502,O
reveal,1502,O
the,1502,O
role,1502,O
of,1502,O
platelet-induced,1502,O
COX-2,1502,B-GENE-Y
on,1502,O
the,1502,O
expression,1502,O
of,1502,O
proteins,1502,O
involved,1502,O
in,1502,O
malignancy,1502,O
and,1502,O
marker,1502,O
genes,1502,O
of,1502,O
epithelial-mesenchymal,1502,O
transition,1502,O
(,1502,O
EMT,1502,O
),1502,O
.,1502,O
Human,1503,O
platelets,1503,O
co-cultured,1503,O
with,1503,O
HT29,1503,O
cells,1503,O
rapidly,1503,O
adhered,1503,O
to,1503,O
cancer,1503,O
cells,1503,O
and,1503,O
induced,1503,O
COX-2,1503,B-GENE-Y
mRNA,1503,O
expression,1503,O
",",1503,O
but,1503,O
not,1503,O
protein,1503,O
synthesis,1503,O
which,1503,O
required,1503,O
the,1503,O
late,1503,O
release,1503,O
of,1503,O
platelet,1503,O
PDGF,1503,B-GENE-N
and,1503,O
COX-2,1503,B-GENE-Y
mRNA,1503,O
stabilization,1503,O
.,1503,O
Platelet-induced,1504,O
COX-2-dependent,1504,B-GENE-Y
PGE2,1504,B-CHEMICAL
synthesis,1504,O
in,1504,O
HT29,1504,O
cells,1504,O
was,1504,O
involved,1504,O
in,1504,O
downregulation,1504,O
of,1504,O
p21,1504,B-GENE-Y
(,1504,O
WAF1/CIP1,1504,B-GENE-Y
),1504,O
and,1504,O
upregulation,1504,O
of,1504,O
cyclinB1,1504,B-GENE-Y
",",1504,O
since,1504,O
these,1504,O
effects,1504,O
were,1504,O
prevented,1504,O
by,1504,O
rofecoxib,1504,B-CHEMICAL
(,1504,O
a,1504,O
selective,1504,O
COX-2,1504,B-GENE-Y
inhibitor,1504,O
),1504,O
and,1504,O
rescued,1504,O
by,1504,O
exogenous,1504,O
PGE2,1504,B-CHEMICAL
.,1504,O
Galectin-3,1505,B-GENE-Y
",",1505,O
highly,1505,O
expressed,1505,O
in,1505,O
HT29,1505,O
cells,1505,O
",",1505,O
is,1505,O
unique,1505,O
among,1505,O
galectins,1505,O
because,1505,O
it,1505,O
contains,1505,O
a,1505,O
collagen-like,1505,B-GENE-N
domain,1505,I-GENE-N
.,1505,O
Thus,1506,O
",",1506,O
we,1506,O
studied,1506,O
the,1506,O
role,1506,O
of,1506,O
galectin-3,1506,B-GENE-Y
and,1506,O
platelet,1506,B-GENE-Y
collagen,1506,I-GENE-Y
receptors,1506,I-GENE-Y
in,1506,O
platelet-induced,1506,O
COX-2,1506,B-GENE-Y
overexpression,1506,O
.,1506,O
Inhibitors,1507,O
of,1507,O
galectin-3,1507,B-GENE-Y
function,1507,O
(,1507,O
β-lactose,1507,B-CHEMICAL
",",1507,O
a,1507,O
dominant-negative,1507,O
form,1507,O
of,1507,O
galectin-3,1507,B-GENE-Y
",",1507,O
Gal-3C,1507,B-GENE-Y
",",1507,O
and,1507,O
anti-galectin-3,1507,O
antibody,1507,O
M3/38,1507,O
),1507,O
or,1507,O
collagen,1507,B-GENE-Y
receptor-mediated,1507,O
platelet,1507,O
adhesion,1507,O
(,1507,O
revacept,1507,O
",",1507,O
a,1507,O
dimeric,1507,O
collagen,1507,B-GENE-Y
receptor,1507,I-GENE-Y
GPVI-Fc,1507,B-GENE-Y
),1507,O
prevented,1507,O
aberrant,1507,O
COX-2,1507,B-GENE-Y
expression,1507,O
.,1507,O
Inhibition,1508,O
of,1508,O
platelet-cancer,1508,O
cell,1508,O
interaction,1508,O
by,1508,O
revacept,1508,O
was,1508,O
more,1508,O
effective,1508,O
than,1508,O
rofecoxib,1508,B-CHEMICAL
in,1508,O
preventing,1508,O
platelet-induced,1508,O
mRNA,1508,O
changes,1508,O
of,1508,O
EMT,1508,O
markers,1508,O
suggesting,1508,O
that,1508,O
direct,1508,O
cell-cell,1508,O
contact,1508,O
and,1508,O
aberrant,1508,O
COX-2,1508,B-GENE-Y
expression,1508,O
synergistically,1508,O
induced,1508,O
gene,1508,O
expression,1508,O
modifications,1508,O
associated,1508,O
with,1508,O
EMT,1508,O
.,1508,O
In,1509,O
conclusion,1509,O
",",1509,O
our,1509,O
findings,1509,O
provide,1509,O
the,1509,O
rationale,1509,O
for,1509,O
testing,1509,O
blockers,1509,O
of,1509,O
collagen,1509,B-GENE-N
binding,1509,I-GENE-N
sites,1509,I-GENE-N
",",1509,O
such,1509,O
as,1509,O
revacept,1509,O
",",1509,O
and,1509,O
galectin-3,1509,B-GENE-Y
inhibitors,1509,O
in,1509,O
the,1509,O
prevention,1509,O
of,1509,O
colon,1509,O
cancer,1509,O
metastasis,1509,O
in,1509,O
animal,1509,O
models,1509,O
followed,1509,O
by,1509,O
studies,1509,O
in,1509,O
patients,1509,O
.,1509,O
Targeting,1510,O
protein-protein,1510,O
interactions,1510,O
within,1510,O
the,1510,O
cyclic,1510,B-CHEMICAL
AMP,1510,I-CHEMICAL
signaling,1510,O
system,1510,O
as,1510,O
a,1510,O
therapeutic,1510,O
strategy,1510,O
for,1510,O
cardiovascular,1510,O
disease,1510,O
.,1510,O
The,1511,O
cAMP,1511,B-CHEMICAL
signaling,1511,O
system,1511,O
can,1511,O
trigger,1511,O
precise,1511,O
physiological,1511,O
cellular,1511,O
responses,1511,O
that,1511,O
depend,1511,O
on,1511,O
the,1511,O
fidelity,1511,O
of,1511,O
many,1511,O
protein-protein,1511,O
interactions,1511,O
",",1511,O
which,1511,O
act,1511,O
to,1511,O
bring,1511,O
together,1511,O
signaling,1511,O
intermediates,1511,O
at,1511,O
defined,1511,O
locations,1511,O
within,1511,O
cells,1511,O
.,1511,O
In,1512,O
the,1512,O
heart,1512,O
",",1512,O
cAMP,1512,B-CHEMICAL
participates,1512,O
in,1512,O
the,1512,O
fine,1512,O
control,1512,O
of,1512,O
excitation-contraction,1512,O
coupling,1512,O
",",1512,O
hence,1512,O
",",1512,O
any,1512,O
disregulation,1512,O
of,1512,O
this,1512,O
signaling,1512,O
cascade,1512,O
can,1512,O
lead,1512,O
to,1512,O
cardiac,1512,O
disease,1512,O
.,1512,O
Due,1513,O
to,1513,O
the,1513,O
ubiquitous,1513,O
nature,1513,O
of,1513,O
the,1513,O
cAMP,1513,B-CHEMICAL
pathway,1513,O
",",1513,O
general,1513,O
inhibitors,1513,O
of,1513,O
cAMP,1513,B-CHEMICAL
signaling,1513,O
proteins,1513,O
such,1513,O
as,1513,O
PKA,1513,B-GENE-N
",",1513,O
EPAC,1513,B-GENE-Y
and,1513,O
PDEs,1513,B-GENE-N
would,1513,O
act,1513,O
non-specifically,1513,O
and,1513,O
universally,1513,O
",",1513,O
increasing,1513,O
the,1513,O
likelihood,1513,O
of,1513,O
serious,1513,O
'off,1513,O
target,1513,O
',1513,O
effects,1513,O
.,1513,O
Recent,1514,O
advances,1514,O
in,1514,O
the,1514,O
discovery,1514,O
of,1514,O
peptides,1514,O
and,1514,O
small,1514,O
molecules,1514,O
that,1514,O
disrupt,1514,O
the,1514,O
protein-protein,1514,O
interactions,1514,O
that,1514,O
underpin,1514,O
cellular,1514,O
targeting,1514,O
of,1514,O
cAMP,1514,B-CHEMICAL
signaling,1514,O
proteins,1514,O
are,1514,O
described,1514,O
and,1514,O
discussed,1514,O
.,1514,O
Anxiolytic-,1515,O
but,1515,O
not,1515,O
antidepressant-like,1515,O
activity,1515,O
of,1515,O
Lu,1515,B-CHEMICAL
AF21934,1515,I-CHEMICAL
",",1515,O
a,1515,O
novel,1515,O
",",1515,O
selective,1515,O
positive,1515,O
allosteric,1515,O
modulator,1515,O
of,1515,O
the,1515,O
mGlu₄,1515,B-GENE-Y
receptor,1515,O
.,1515,O
Previous,1516,O
studies,1516,O
demonstrated,1516,O
that,1516,O
the,1516,O
Group,1516,B-GENE-N
III,1516,I-GENE-N
mGlu,1516,I-GENE-N
receptor-selective,1516,O
orthosteric,1516,O
agonist,1516,O
",",1516,O
LSP1-2111,1516,B-CHEMICAL
produced,1516,O
anxiolytic-,1516,O
but,1516,O
not,1516,O
antidepressant-like,1516,O
effects,1516,O
upon,1516,O
peripheral,1516,O
administration,1516,O
.,1516,O
Herein,1517,O
",",1517,O
we,1517,O
report,1517,O
the,1517,O
pharmacological,1517,O
actions,1517,O
of,1517,O
Lu,1517,B-CHEMICAL
AF21934,1517,I-CHEMICAL
",",1517,O
a,1517,O
novel,1517,O
",",1517,O
selective,1517,O
",",1517,O
and,1517,O
brain-penetrant,1517,O
positive,1517,O
allosteric,1517,O
modulator,1517,O
(,1517,O
PAM,1517,O
),1517,O
of,1517,O
the,1517,O
mGlu,1517,B-GENE-Y
(,1517,I-GENE-Y
4,1517,I-GENE-Y
),1517,I-GENE-Y
receptor,1517,O
in,1517,O
the,1517,O
stress-induced,1517,O
hyperthermia,1517,O
(,1517,O
SIH,1517,O
),1517,O
",",1517,O
four-plate,1517,O
",",1517,O
marble-burying,1517,O
and,1517,O
Vogel,1517,O
's,1517,O
conflict,1517,O
tests,1517,O
.,1517,O
In,1518,O
all,1518,O
models,1518,O
",",1518,O
except,1518,O
Vogel,1518,O
's,1518,O
conflict,1518,O
test,1518,O
",",1518,O
a,1518,O
dose-dependent,1518,O
anxiolytic-like,1518,O
effect,1518,O
was,1518,O
seen,1518,O
.,1518,O
The,1519,O
anti-hyperthermic,1519,O
effect,1519,O
of,1519,O
Lu,1519,B-CHEMICAL
AF21934,1519,I-CHEMICAL
(,1519,O
5,1519,O
mg/kg,1519,O
),1519,O
in,1519,O
the,1519,O
SIH,1519,O
test,1519,O
was,1519,O
inhibited,1519,O
by,1519,O
the,1519,O
benzodiazepine,1519,B-GENE-Y
receptor,1519,I-GENE-Y
antagonist,1519,O
flumazenil,1519,B-CHEMICAL
(,1519,O
10,1519,O
mg/kg,1519,O
),1519,O
and,1519,O
was,1519,O
not,1519,O
serotonin-dependent,1519,B-CHEMICAL
",",1519,O
as,1519,O
it,1519,O
persisted,1519,O
in,1519,O
serotonin-deficient,1519,B-CHEMICAL
mice,1519,O
and,1519,O
upon,1519,O
blockade,1519,O
of,1519,O
either,1519,O
5-HT,1519,B-GENE-Y
(,1519,I-GENE-Y
1A,1519,I-GENE-Y
),1519,I-GENE-Y
receptors,1519,O
by,1519,O
WAY100635,1519,B-CHEMICAL
",",1519,O
or,1519,O
5-HT,1519,B-GENE-N
(,1519,I-GENE-N
2A/2C,1519,I-GENE-N
),1519,I-GENE-N
receptors,1519,O
by,1519,O
ritanserin,1519,B-CHEMICAL
.,1519,O
These,1520,O
results,1520,O
suggest,1520,O
that,1520,O
the,1520,O
GABAergic,1520,O
system,1520,O
",",1520,O
but,1520,O
not,1520,O
the,1520,O
serotonergic,1520,O
system,1520,O
",",1520,O
is,1520,O
involved,1520,O
in,1520,O
the,1520,O
mechanism,1520,O
of,1520,O
the,1520,O
anxiolytic-like,1520,O
phenotype,1520,O
of,1520,O
Lu,1520,B-CHEMICAL
AF21934,1520,I-CHEMICAL
in,1520,O
rodents,1520,O
.,1520,O
Lu,1521,B-CHEMICAL
AF21934,1521,I-CHEMICAL
did,1521,O
not,1521,O
produce,1521,O
antidepressant-like,1521,O
effects,1521,O
in,1521,O
the,1521,O
tail,1521,O
suspension,1521,O
test,1521,O
(,1521,O
TST,1521,O
),1521,O
in,1521,O
mice,1521,O
;,1521,O
however,1521,O
",",1521,O
it,1521,O
decreased,1521,O
the,1521,O
basal,1521,O
locomotor,1521,O
activity,1521,O
of,1521,O
mice,1521,O
that,1521,O
were,1521,O
not,1521,O
habituated,1521,O
to,1521,O
activity,1521,O
cages,1521,O
.,1521,O
This,1522,O
article,1522,O
is,1522,O
part,1522,O
of,1522,O
a,1522,O
Special,1522,O
Issue,1522,O
entitled,1522,O
'Metabotropic,1522,O
Glutamate,1522,I-GENE-N
Receptors,1522,I-GENE-N
',1522,O
.,1522,O
Lead-induced,1523,O
ER,1523,O
calcium,1523,B-CHEMICAL
release,1523,O
and,1523,O
inhibitory,1523,O
effects,1523,O
of,1523,O
methionine,1523,B-CHEMICAL
choline,1523,I-CHEMICAL
in,1523,O
cultured,1523,O
rat,1523,O
hippocampal,1523,O
neurons,1523,O
.,1523,O
Lead,1524,O
",",1524,O
a,1524,O
ubiquitous,1524,O
neurotoxicant,1524,O
",",1524,O
can,1524,O
result,1524,O
in,1524,O
learning,1524,O
and,1524,O
memory,1524,O
dysfunction,1524,O
.,1524,O
Long,1525,O
term,1525,O
potentiation,1525,O
in,1525,O
the,1525,O
hippocampus,1525,O
",",1525,O
a,1525,O
potential,1525,O
neural,1525,O
substrate,1525,O
for,1525,O
learning,1525,O
and,1525,O
memory,1525,O
",",1525,O
is,1525,O
thought,1525,O
to,1525,O
be,1525,O
linked,1525,O
to,1525,O
calcium-triggered,1525,B-CHEMICAL
intracellular,1525,O
events,1525,O
.,1525,O
In,1526,O
this,1526,O
study,1526,O
",",1526,O
laser,1526,O
scanning,1526,O
confocal,1526,O
microscopy,1526,O
was,1526,O
used,1526,O
to,1526,O
examine,1526,O
the,1526,O
effects,1526,O
of,1526,O
Pb,1526,B-CHEMICAL
(,1526,I-CHEMICAL
2+,1526,I-CHEMICAL
),1526,I-CHEMICAL
on,1526,O
intracellular,1526,O
and,1526,O
endoplasmic,1526,O
reticulum,1526,O
free,1526,O
calcium,1526,B-CHEMICAL
concentration,1526,O
(,1526,O
[,1526,O
Ca,1526,B-CHEMICAL
(,1526,I-CHEMICAL
2+,1526,I-CHEMICAL
),1526,I-CHEMICAL
],1526,O
(,1526,O
i,1526,O
),1526,O
and,1526,O
[,1526,O
Ca,1526,B-CHEMICAL
(,1526,I-CHEMICAL
2+,1526,I-CHEMICAL
),1526,I-CHEMICAL
],1526,O
(,1526,O
ER,1526,O
),1526,O
),1526,O
in,1526,O
cultured,1526,O
neonatal,1526,O
rat,1526,O
hippocampal,1526,O
neurons,1526,O
and,1526,O
their,1526,O
possible,1526,O
antagonism,1526,O
by,1526,O
methionine,1526,B-CHEMICAL
choline,1526,I-CHEMICAL
;,1526,O
understanding,1526,O
these,1526,O
effects,1526,O
would,1526,O
help,1526,O
explain,1526,O
the,1526,O
lead-induced,1526,O
cognitive,1526,O
and,1526,O
learning,1526,O
dysfunction,1526,O
and,1526,O
explore,1526,O
efficient,1526,O
safety,1526,O
and,1526,O
relief,1526,O
strategies,1526,O
.,1526,O
The,1527,O
results,1527,O
showed,1527,O
that,1527,O
Pb,1527,B-CHEMICAL
(,1527,I-CHEMICAL
2+,1527,I-CHEMICAL
),1527,I-CHEMICAL
increased,1527,O
[,1527,O
Ca,1527,B-CHEMICAL
(,1527,I-CHEMICAL
2+,1527,I-CHEMICAL
),1527,I-CHEMICAL
],1527,O
(,1527,O
i,1527,O
),1527,O
and,1527,O
decreased,1527,O
[,1527,O
Ca,1527,B-CHEMICAL
(,1527,I-CHEMICAL
2+,1527,I-CHEMICAL
),1527,I-CHEMICAL
],1527,O
(,1527,O
ER,1527,O
),1527,O
linearly,1527,O
in,1527,O
a,1527,O
time-,1527,O
and,1527,O
concentration-dependant,1527,O
manner,1527,O
",",1527,O
and,1527,O
Pb,1527,B-CHEMICAL
(,1527,I-CHEMICAL
2+,1527,I-CHEMICAL
),1527,I-CHEMICAL
addition,1527,O
after,1527,O
the,1527,O
applying,1527,O
of,1527,O
a,1527,O
ryanodine,1527,B-GENE-N
receptor,1527,I-GENE-N
(,1527,O
RyR,1527,B-GENE-N
),1527,O
antagonist,1527,O
and,1527,O
an,1527,O
"inositol-1,4,5-triphosphate",1527,B-GENE-N
receptor,1527,I-GENE-N
(,1527,O
IP,1527,B-GENE-N
(,1527,I-GENE-N
3,1527,I-GENE-N
),1527,I-GENE-N
R,1527,I-GENE-N
),1527,O
antagonist,1527,O
did,1527,O
not,1527,O
increase,1527,O
[,1527,O
Ca,1527,B-CHEMICAL
(,1527,I-CHEMICAL
2+,1527,I-CHEMICAL
),1527,I-CHEMICAL
],1527,O
(,1527,O
i,1527,O
),1527,O
.,1527,O
The,1528,O
addition,1528,O
of,1528,O
10,1528,O
",",1528,O
20,1528,O
",",1528,O
or,1528,O
40,1528,O
mmol/L,1528,O
methionine,1528,B-CHEMICAL
choline,1528,I-CHEMICAL
simultaneously,1528,O
with,1528,O
addition,1528,O
of,1528,O
10,1528,O
μmol/L,1528,O
Pb,1528,B-CHEMICAL
(,1528,I-CHEMICAL
2+,1528,I-CHEMICAL
),1528,I-CHEMICAL
decreased,1528,O
[,1528,O
Ca,1528,B-CHEMICAL
(,1528,I-CHEMICAL
2+,1528,I-CHEMICAL
),1528,I-CHEMICAL
],1528,O
(,1528,O
i,1528,O
),1528,O
in,1528,O
Ca,1528,B-CHEMICAL
(,1528,I-CHEMICAL
2+,1528,I-CHEMICAL
),1528,I-CHEMICAL
-free,1528,O
culture,1528,O
medium,1528,O
by,1528,O
39.0,1528,O
%,1528,O
",",1528,O
66.0,1528,O
%,1528,O
",",1528,O
and,1528,O
61.6,1528,O
%,1528,O
",",1528,O
respectively,1528,O
",",1528,O
in,1528,O
a,1528,O
concentration-dependant,1528,O
manner,1528,O
in,1528,O
a,1528,O
certain,1528,O
dose,1528,O
range,1528,O
.,1528,O
Our,1529,O
results,1529,O
suggest,1529,O
that,1529,O
Pb,1529,B-CHEMICAL
(,1529,I-CHEMICAL
2+,1529,I-CHEMICAL
),1529,I-CHEMICAL
induces,1529,O
ER,1529,O
calcium,1529,B-CHEMICAL
release,1529,O
to,1529,O
increase,1529,O
the,1529,O
resting,1529,O
[,1529,O
Ca,1529,B-CHEMICAL
(,1529,I-CHEMICAL
2+,1529,I-CHEMICAL
),1529,I-CHEMICAL
],1529,O
(,1529,O
i,1529,O
),1529,O
;,1529,O
and,1529,O
methionine,1529,B-CHEMICAL
choline,1529,I-CHEMICAL
inhibit,1529,O
this,1529,O
increase,1529,O
in,1529,O
[,1529,O
Ca,1529,B-CHEMICAL
(,1529,I-CHEMICAL
2+,1529,I-CHEMICAL
),1529,I-CHEMICAL
],1529,O
(,1529,O
i,1529,O
),1529,O
.,1529,O
Critical,1530,O
amino,1530,B-CHEMICAL
acids,1530,I-CHEMICAL
in,1530,O
phosphodiesterase-5,1530,B-GENE-Y
catalytic,1530,O
site,1530,O
that,1530,O
provide,1530,O
for,1530,O
high-affinity,1530,O
interaction,1530,O
with,1530,O
cyclic,1530,B-CHEMICAL
guanosine,1530,I-CHEMICAL
monophosphate,1530,I-CHEMICAL
and,1530,O
inhibitors,1530,O
.,1530,O
The,1531,O
molecular,1531,O
bases,1531,O
for,1531,O
phosphodiesterase,1531,B-GENE-Y
5,1531,I-GENE-Y
(,1531,O
PDE5,1531,B-GENE-Y
),1531,O
catalytic-site,1531,O
affinity,1531,O
for,1531,O
cyclic,1531,B-CHEMICAL
guanosine,1531,I-CHEMICAL
monophosphate,1531,I-CHEMICAL
(,1531,O
cGMP,1531,B-CHEMICAL
),1531,O
and,1531,O
potency,1531,O
of,1531,O
inhibitors,1531,O
are,1531,O
poorly,1531,O
understood,1531,O
.,1531,O
Cocrystal,1532,O
structures,1532,O
of,1532,O
PDE5,1532,B-GENE-N
catalytic,1532,I-GENE-N
(,1532,I-GENE-N
C,1532,I-GENE-N
),1532,I-GENE-N
domain,1532,I-GENE-N
with,1532,O
inhibitors,1532,O
reveal,1532,O
a,1532,O
hydrogen,1532,B-CHEMICAL
bond,1532,O
and,1532,O
hydrophobic,1532,O
interactions,1532,O
with,1532,O
Tyr-612,1532,B-CHEMICAL
",",1532,O
hydrogen,1532,B-CHEMICAL
bonds,1532,O
with,1532,O
Gln-817,1532,B-CHEMICAL
",",1532,O
a,1532,O
hydrophobic,1532,O
clamp,1532,O
formed,1532,O
by,1532,O
Phe-820,1532,B-CHEMICAL
and,1532,O
Val-782,1532,B-CHEMICAL
",",1532,O
and,1532,O
contacts,1532,O
with,1532,O
His-613,1532,B-CHEMICAL
",",1532,O
Leu-765,1532,B-CHEMICAL
",",1532,O
and,1532,O
Phe-786,1532,B-CHEMICAL
[,1532,O
Sung,1532,O
et,1532,O
al,1532,O
.,1532,O
(,1533,O
2003,1533,O
),1533,O
Nature,1533,O
425,1533,O
",",1533,O
98-102,1533,O
;,1533,O
Huai,1533,O
et,1533,O
al,1533,O
.,1533,O
(,1534,O
2004,1534,O
),1534,O
J.,1534,O
Biol,1534,O
.,1534,O
Chem,1535,O
.,1535,O
279,1536,O
",",1536,O
13095-13101,1536,O
],1536,O
.,1536,O
Present,1537,O
results,1537,O
of,1537,O
point,1537,O
mutations,1537,O
of,1537,O
full-length,1537,O
PDE5,1537,B-GENE-Y
showed,1537,O
that,1537,O
maximum,1537,O
catalysis,1537,O
was,1537,O
decreased,1537,O
2650-fold,1537,O
in,1537,O
H613A,1537,B-GENE-N
and,1537,O
55-fold,1537,O
in,1537,O
F820A,1537,B-GENE-N
.,1537,O
Catalytic-site,1538,O
affinities,1538,O
for,1538,O
cGMP,1538,B-CHEMICAL
",",1538,O
vardenafil,1538,B-CHEMICAL
",",1538,O
sildenafil,1538,B-CHEMICAL
",",1538,O
tadalafil,1538,B-CHEMICAL
",",1538,O
or,1538,O
3-isobutyl-1-methylxanthine,1538,B-CHEMICAL
(,1538,O
IBMX,1538,B-CHEMICAL
),1538,O
were,1538,O
respectively,1538,O
weakened,1538,O
14-,1538,O
",",1538,O
123-,1538,O
",",1538,O
30-,1538,O
",",1538,O
51-,1538,O
",",1538,O
and,1538,O
43-fold,1538,O
for,1538,O
Y612A,1538,B-GENE-N
;,1538,O
63-,1538,O
",",1538,O
511-,1538,O
",",1538,O
43-,1538,O
",",1538,O
95-,1538,O
and,1538,O
61-fold,1538,O
for,1538,O
Q817A,1538,B-GENE-N
;,1538,O
and,1538,O
59-,1538,O
",",1538,O
448-,1538,O
",",1538,O
71-,1538,O
",",1538,O
137-,1538,O
",",1538,O
and,1538,O
93-fold,1538,O
for,1538,O
F820A,1538,B-GENE-N
.,1538,O
The,1539,O
data,1539,O
indicate,1539,O
that,1539,O
these,1539,O
three,1539,O
amino,1539,B-CHEMICAL
acids,1539,I-CHEMICAL
are,1539,O
major,1539,O
determinants,1539,O
of,1539,O
affinity,1539,O
for,1539,O
cGMP,1539,B-CHEMICAL
and,1539,O
potency,1539,O
of,1539,O
selective,1539,O
and,1539,O
nonselective,1539,O
inhibitors,1539,O
",",1539,O
and,1539,O
that,1539,O
higher,1539,O
vardenafil,1539,B-CHEMICAL
potency,1539,O
over,1539,O
sildenafil,1539,B-CHEMICAL
and,1539,O
tadalafil,1539,B-CHEMICAL
results,1539,O
from,1539,O
stronger,1539,O
contacts,1539,O
with,1539,O
Tyr-612,1539,B-CHEMICAL
",",1539,O
Gln-817,1539,B-CHEMICAL
",",1539,O
and,1539,O
Phe-820,1539,B-CHEMICAL
.,1539,O
Affinity,1540,O
of,1540,O
V782A,1540,B-GENE-N
for,1540,O
cGMP,1540,B-CHEMICAL
",",1540,O
vardenafil,1540,B-CHEMICAL
",",1540,O
sildenafil,1540,B-CHEMICAL
",",1540,O
tadalafil,1540,B-CHEMICAL
",",1540,O
or,1540,O
IBMX,1540,B-CHEMICAL
was,1540,O
reduced,1540,O
5.5-,1540,O
",",1540,O
23-,1540,O
",",1540,O
10-,1540,O
",",1540,O
3-,1540,O
",",1540,O
and,1540,O
12-fold,1540,O
",",1540,O
respectively,1540,O
.,1540,O
Change,1541,O
in,1541,O
affinity,1541,O
for,1541,O
cGMP,1541,B-CHEMICAL
",",1541,O
vardenafil,1541,B-CHEMICAL
",",1541,O
sildenafil,1541,B-CHEMICAL
",",1541,O
or,1541,O
IBMX,1541,B-CHEMICAL
in,1541,O
Y612F,1541,B-GENE-N
",",1541,O
H613A,1541,B-GENE-N
",",1541,O
L765A,1541,B-GENE-N
",",1541,O
or,1541,O
F786A,1541,B-GENE-N
was,1541,O
less,1541,O
",",1541,O
but,1541,O
affinity,1541,O
of,1541,O
H613A,1541,B-GENE-N
or,1541,O
F786A,1541,B-GENE-N
for,1541,O
tadalafil,1541,B-CHEMICAL
was,1541,O
weakened,1541,O
37-,1541,O
and,1541,O
17-fold,1541,O
",",1541,O
respectively,1541,O
.,1541,O
The,1542,O
results,1542,O
quantify,1542,O
the,1542,O
role,1542,O
of,1542,O
PDE5,1542,B-GENE-Y
catalytic-site,1542,O
residues,1542,O
for,1542,O
cGMP,1542,B-CHEMICAL
and,1542,O
inhibitors,1542,O
",",1542,O
indicate,1542,O
that,1542,O
Tyr-612,1542,B-CHEMICAL
",",1542,O
Gln-817,1542,B-CHEMICAL
",",1542,O
and,1542,O
Phe-820,1542,B-CHEMICAL
are,1542,O
the,1542,O
most,1542,O
important,1542,O
cGMP,1542,B-CHEMICAL
or,1542,O
inhibitor,1542,O
contacts,1542,O
studied,1542,O
",",1542,O
and,1542,O
identify,1542,O
residues,1542,O
that,1542,O
contribute,1542,O
to,1542,O
selectivity,1542,O
among,1542,O
different,1542,O
classes,1542,O
of,1542,O
inhibitors,1542,O
.,1542,O
Alteration,1543,O
of,1543,O
α-tocopherol-associated,1543,B-GENE-Y
protein,1543,I-GENE-Y
(,1543,O
TAP,1543,B-GENE-Y
),1543,O
expression,1543,O
in,1543,O
human,1543,O
breast,1543,O
epithelial,1543,O
cells,1543,O
during,1543,O
breast,1543,O
cancer,1543,O
development,1543,O
.,1543,O
Breast,1544,O
cancer,1544,O
is,1544,O
the,1544,O
most,1544,O
common,1544,O
malignancy,1544,O
among,1544,O
women,1544,O
and,1544,O
has,1544,O
an,1544,O
age-specific,1544,O
incidence,1544,O
profile,1544,O
.,1544,O
Over,1545,O
the,1545,O
last,1545,O
decade,1545,O
",",1545,O
many,1545,O
studies,1545,O
have,1545,O
demonstrated,1545,O
the,1545,O
anticancer,1545,O
activity,1545,O
of,1545,O
α-tocopherol,1545,B-CHEMICAL
",",1545,O
the,1545,O
main,1545,O
and,1545,O
most,1545,O
active,1545,O
form,1545,O
of,1545,O
natural,1545,O
vitamin,1545,B-CHEMICAL
E.,1545,O
α-Tocopherol-associated,1545,B-GENE-Y
protein,1545,I-GENE-Y
(,1545,O
TAP,1545,B-GENE-Y
),1545,O
was,1545,O
found,1545,O
to,1545,O
be,1545,O
one,1545,O
of,1545,O
the,1545,O
major,1545,O
α-tocopherol,1545,B-GENE-N
binding,1545,I-GENE-N
proteins,1545,I-GENE-N
in,1545,O
human,1545,O
serum,1545,O
and,1545,O
in,1545,O
liver,1545,O
",",1545,O
brain,1545,O
",",1545,O
and,1545,O
prostate,1545,O
tissues,1545,O
.,1545,O
In,1546,O
this,1546,O
study,1546,O
",",1546,O
we,1546,O
found,1546,O
that,1546,O
reduced,1546,O
TAP,1546,B-GENE-Y
expression,1546,O
was,1546,O
significantly,1546,O
correlated,1546,O
with,1546,O
Her2/neu,1546,B-GENE-Y
receptor,1546,O
expression,1546,O
",",1546,O
breast,1546,O
cancer,1546,O
stage,1546,O
and,1546,O
nodal,1546,O
stage,1546,O
in,1546,O
paired,1546,O
normal,1546,O
and,1546,O
cancerous,1546,O
breast,1546,O
tissue,1546,O
samples,1546,O
from,1546,O
93,1546,O
patients,1546,O
using,1546,O
real-time,1546,O
PCR,1546,O
analysis,1546,O
.,1546,O
A,1547,O
cell,1547,O
viability,1547,O
assay,1547,O
showed,1547,O
that,1547,O
α-tocopheryl,1547,B-CHEMICAL
succinate,1547,I-CHEMICAL
(,1547,O
α-TOS,1547,B-CHEMICAL
),1547,O
",",1547,O
a,1547,O
synthetic,1547,O
derivative,1547,O
of,1547,O
α-tocopherol,1547,B-CHEMICAL
",",1547,O
enhanced,1547,O
the,1547,O
cells,1547,O
',1547,O
sensitivity,1547,O
to,1547,O
doxorubicin,1547,B-CHEMICAL
and,1547,O
resulted,1547,O
in,1547,O
a,1547,O
reduction,1547,O
in,1547,O
cell,1547,O
viability,1547,O
in,1547,O
breast,1547,O
cancers,1547,O
.,1547,O
Taken,1548,O
together,1548,O
",",1548,O
these,1548,O
data,1548,O
suggest,1548,O
that,1548,O
the,1548,O
use,1548,O
of,1548,O
vitamin,1548,B-CHEMICAL
E,1548,I-CHEMICAL
or,1548,O
its,1548,O
analogue,1548,O
as,1548,O
a,1548,O
dietary,1548,O
supplement,1548,O
may,1548,O
be,1548,O
beneficial,1548,O
for,1548,O
the,1548,O
treatment,1548,O
of,1548,O
cancer,1548,O
.,1548,O
International,1549,O
Union,1549,O
of,1549,O
Pharmacology,1549,O
.,1549,O
LXXXVII,1550,O
.,1550,O
Complement,1551,B-GENE-N
peptide,1551,I-GENE-N
C5a,1551,I-GENE-N
",",1551,I-GENE-N
C4a,1551,I-GENE-N
",",1551,I-GENE-N
and,1551,I-GENE-N
C3a,1551,I-GENE-N
receptors,1551,I-GENE-N
.,1551,O
The,1552,O
activation,1552,O
of,1552,O
the,1552,O
complement,1552,B-GENE-N
cascade,1552,O
",",1552,O
a,1552,O
cornerstone,1552,O
of,1552,O
the,1552,O
innate,1552,O
immune,1552,O
response,1552,O
",",1552,O
produces,1552,O
a,1552,O
number,1552,O
of,1552,O
small,1552,O
(,1552,O
74-77,1552,O
amino,1552,B-CHEMICAL
acid,1552,I-CHEMICAL
),1552,O
fragments,1552,O
",",1552,O
originally,1552,O
termed,1552,O
anaphylatoxins,1552,B-GENE-N
",",1552,O
that,1552,O
are,1552,O
potent,1552,O
chemoattractants,1552,O
and,1552,O
secretagogues,1552,O
that,1552,O
act,1552,O
on,1552,O
a,1552,O
wide,1552,O
variety,1552,O
of,1552,O
cell,1552,O
types,1552,O
.,1552,O
These,1553,O
fragments,1553,O
",",1553,O
C5a,1553,B-GENE-Y
",",1553,O
C4a,1553,B-GENE-Y
",",1553,O
and,1553,O
C3a,1553,B-GENE-Y
",",1553,O
participate,1553,O
at,1553,O
all,1553,O
levels,1553,O
of,1553,O
the,1553,O
immune,1553,O
response,1553,O
and,1553,O
are,1553,O
also,1553,O
involved,1553,O
in,1553,O
other,1553,O
processes,1553,O
such,1553,O
as,1553,O
neural,1553,O
development,1553,O
and,1553,O
organ,1553,O
regeneration,1553,O
.,1553,O
Their,1554,O
primary,1554,O
function,1554,O
",",1554,O
however,1554,O
",",1554,O
is,1554,O
in,1554,O
inflammation,1554,O
",",1554,O
so,1554,O
they,1554,O
are,1554,O
important,1554,O
targets,1554,O
for,1554,O
the,1554,O
development,1554,O
of,1554,O
antiinflammatory,1554,O
therapies,1554,O
.,1554,O
Only,1555,O
three,1555,O
receptors,1555,O
for,1555,O
complement,1555,O
peptides,1555,O
have,1555,O
been,1555,O
found,1555,O
",",1555,O
but,1555,O
there,1555,O
are,1555,O
no,1555,O
satisfactory,1555,O
antagonists,1555,O
as,1555,O
yet,1555,O
",",1555,O
despite,1555,O
intensive,1555,O
investigation,1555,O
.,1555,O
In,1556,O
humans,1556,O
",",1556,O
there,1556,O
is,1556,O
a,1556,O
single,1556,O
receptor,1556,O
for,1556,O
C3a,1556,B-GENE-Y
(,1556,O
C3a,1556,B-GENE-Y
receptor,1556,I-GENE-Y
),1556,O
",",1556,O
no,1556,O
known,1556,O
receptor,1556,O
for,1556,O
C4a,1556,B-GENE-Y
",",1556,O
and,1556,O
two,1556,O
receptors,1556,O
for,1556,O
C5a,1556,B-GENE-Y
(,1556,O
C5a₁,1556,B-GENE-Y
receptor,1556,I-GENE-Y
and,1556,O
C5a₂,1556,B-GENE-Y
receptor,1556,I-GENE-Y
),1556,O
.,1556,O
The,1557,O
most,1557,O
recently,1557,O
characterized,1557,O
receptor,1557,O
",",1557,O
the,1557,O
C5a₂,1557,B-GENE-Y
receptor,1557,O
(,1557,O
previously,1557,O
known,1557,O
as,1557,O
C5L2,1557,B-GENE-Y
or,1557,O
GPR77,1557,B-GENE-Y
),1557,O
",",1557,O
has,1557,O
been,1557,O
regarded,1557,O
as,1557,O
a,1557,O
passive,1557,O
binding,1557,O
protein,1557,O
",",1557,O
but,1557,O
signaling,1557,O
activities,1557,O
are,1557,O
now,1557,O
ascribed,1557,O
to,1557,O
it,1557,O
",",1557,O
so,1557,O
we,1557,O
propose,1557,O
that,1557,O
it,1557,O
be,1557,O
formally,1557,O
identified,1557,O
as,1557,O
a,1557,O
receptor,1557,O
and,1557,O
be,1557,O
given,1557,O
a,1557,O
name,1557,O
to,1557,O
reflect,1557,O
this,1557,O
.,1557,O
Here,1558,O
",",1558,O
we,1558,O
describe,1558,O
the,1558,O
complex,1558,O
biology,1558,O
of,1558,O
the,1558,O
complement,1558,O
peptides,1558,O
",",1558,O
introduce,1558,O
a,1558,O
new,1558,O
suggested,1558,O
nomenclature,1558,O
",",1558,O
and,1558,O
review,1558,O
our,1558,O
current,1558,O
knowledge,1558,O
of,1558,O
receptor,1558,O
pharmacology,1558,O
.,1558,O
Short-term,1559,O
heating,1559,O
reduces,1559,O
the,1559,O
anti-inflammatory,1559,O
effects,1559,O
of,1559,O
fresh,1559,O
raw,1559,O
garlic,1559,O
extracts,1559,O
on,1559,O
the,1559,O
LPS-induced,1559,O
production,1559,O
of,1559,O
NO,1559,B-CHEMICAL
and,1559,O
pro-inflammatory,1559,O
cytokines,1559,B-GENE-N
by,1559,O
downregulating,1559,O
allicin,1559,B-CHEMICAL
activity,1559,O
in,1559,O
RAW,1559,O
264.7,1559,O
macrophages,1559,O
.,1559,O
Garlic,1560,O
has,1560,O
a,1560,O
variety,1560,O
of,1560,O
biologic,1560,O
activities,1560,O
",",1560,O
including,1560,O
anti-inflammatory,1560,O
properties,1560,O
.,1560,O
Although,1561,O
garlic,1561,O
has,1561,O
several,1561,O
biologic,1561,O
activities,1561,O
",",1561,O
some,1561,O
people,1561,O
dislike,1561,O
eating,1561,O
fresh,1561,O
raw,1561,O
garlic,1561,O
because,1561,O
of,1561,O
its,1561,O
strong,1561,O
taste,1561,O
and,1561,O
smell,1561,O
.,1561,O
Therefore,1562,O
",",1562,O
garlic,1562,O
formulations,1562,O
involving,1562,O
heating,1562,O
procedures,1562,O
have,1562,O
been,1562,O
developed,1562,O
.,1562,O
In,1563,O
this,1563,O
study,1563,O
",",1563,O
we,1563,O
investigated,1563,O
whether,1563,O
short-term,1563,O
heating,1563,O
affects,1563,O
the,1563,O
anti-inflammatory,1563,O
properties,1563,O
of,1563,O
garlic,1563,O
.,1563,O
Fresh,1564,O
and,1564,O
heated,1564,O
raw,1564,O
garlic,1564,O
extracts,1564,O
(,1564,O
FRGE,1564,O
and,1564,O
HRGE,1564,O
),1564,O
were,1564,O
prepared,1564,O
with,1564,O
incubation,1564,O
at,1564,O
25°C,1564,O
and,1564,O
95°C,1564,O
",",1564,O
respectively,1564,O
",",1564,O
for,1564,O
2h,1564,O
.,1564,O
Treatment,1565,O
with,1565,O
FRGE,1565,O
and,1565,O
HRGE,1565,O
significantly,1565,O
reduced,1565,O
the,1565,O
LPS-induced,1565,O
increase,1565,O
in,1565,O
the,1565,O
pro-inflammatory,1565,O
cytokine,1565,B-GENE-N
concentration,1565,O
(,1565,O
TNF-α,1565,B-GENE-Y
",",1565,O
IL-1β,1565,B-GENE-Y
",",1565,O
and,1565,O
IL-6,1565,B-GENE-Y
),1565,O
and,1565,O
NO,1565,B-CHEMICAL
through,1565,O
HO-1,1565,B-GENE-Y
upregulation,1565,O
in,1565,O
RAW,1565,O
264.7,1565,O
macrophages,1565,O
.,1565,O
The,1566,O
anti-inflammatory,1566,O
effect,1566,O
was,1566,O
greater,1566,O
in,1566,O
FRGE,1566,O
than,1566,O
in,1566,O
HRGE,1566,O
.,1566,O
The,1567,O
allicin,1567,B-CHEMICAL
concentration,1567,O
was,1567,O
higher,1567,O
in,1567,O
FRGE,1567,O
than,1567,O
in,1567,O
HRGE,1567,O
.,1567,O
Allicin,1568,B-CHEMICAL
treatment,1568,O
showed,1568,O
reduced,1568,O
production,1568,O
of,1568,O
pro-inflammatory,1568,O
cytokines,1568,B-GENE-N
and,1568,O
NO,1568,B-CHEMICAL
and,1568,O
increased,1568,O
HO-1,1568,B-GENE-Y
activity,1568,O
.,1568,O
The,1569,O
results,1569,O
show,1569,O
that,1569,O
the,1569,O
decrease,1569,O
in,1569,O
LPS-induced,1569,O
NO,1569,B-CHEMICAL
and,1569,O
pro-inflammatory,1569,O
cytokines,1569,B-GENE-N
in,1569,O
RAW,1569,O
264.7,1569,O
macrophages,1569,O
through,1569,O
HO-1,1569,B-GENE-Y
induction,1569,O
was,1569,O
greater,1569,O
for,1569,O
FRGE,1569,O
compared,1569,O
with,1569,O
HRGE,1569,O
.,1569,O
Additionally,1570,O
",",1570,O
the,1570,O
results,1570,O
indicate,1570,O
that,1570,O
allicin,1570,B-CHEMICAL
is,1570,O
responsible,1570,O
for,1570,O
the,1570,O
anti-inflammatory,1570,O
effect,1570,O
of,1570,O
FRGE,1570,O
.,1570,O
Our,1571,O
results,1571,O
suggest,1571,O
a,1571,O
potential,1571,O
therapeutic,1571,O
use,1571,O
of,1571,O
allicin,1571,B-CHEMICAL
in,1571,O
the,1571,O
treatment,1571,O
of,1571,O
chronic,1571,O
inflammatory,1571,O
disease,1571,O
.,1571,O
MORAb-003,1572,O
",",1572,O
a,1572,O
fully,1572,O
humanized,1572,O
monoclonal,1572,O
antibody,1572,O
against,1572,O
the,1572,O
folate,1572,B-GENE-Y
receptor,1572,I-GENE-Y
alpha,1572,I-GENE-Y
",",1572,O
for,1572,O
the,1572,O
potential,1572,O
treatment,1572,O
of,1572,O
epithelial,1572,O
ovarian,1572,O
cancer,1572,O
.,1572,O
Morphotek,1573,O
Inc,1573,O
is,1573,O
developing,1573,O
MORAb-003,1573,O
",",1573,O
a,1573,O
humanized,1573,O
monoclonal,1573,O
antibody,1573,O
directed,1573,O
against,1573,O
folate,1573,B-GENE-Y
receptor,1573,I-GENE-Y
alpha,1573,I-GENE-Y
",",1573,O
for,1573,O
the,1573,O
potential,1573,O
treatment,1573,O
of,1573,O
ovarian,1573,O
cancer,1573,O
.,1573,O
Phase,1574,O
II,1574,O
clinical,1574,O
trialsof,1574,O
MORAb-003,1574,O
",",1574,O
either,1574,O
alone,1574,O
or,1574,O
in,1574,O
combination,1574,O
with,1574,O
platinum/taxane,1574,B-CHEMICAL
chemotherapy,1574,O
",",1574,O
are,1574,O
underway,1574,O
in,1574,O
ovarian,1574,O
cancer,1574,O
patients,1574,O
experiencing,1574,O
their,1574,O
first,1574,O
disease,1574,O
recurrence,1574,O
.,1574,O
Artificial,1575,O
sweeteners,1575,O
and,1575,O
salts,1575,O
producing,1575,O
a,1575,O
metallic,1575,O
taste,1575,O
sensation,1575,O
activate,1575,O
TRPV1,1575,B-GENE-Y
receptors,1575,O
.,1575,O
Throughout,1576,O
the,1576,O
world,1576,O
many,1576,O
people,1576,O
use,1576,O
artificial,1576,O
sweeteners,1576,O
(,1576,O
AS,1576,O
),1576,O
for,1576,O
the,1576,O
purpose,1576,O
of,1576,O
reducing,1576,O
caloric,1576,O
intake,1576,O
.,1576,O
The,1577,O
most,1577,O
prominently,1577,O
used,1577,O
of,1577,O
these,1577,O
molecules,1577,O
include,1577,O
saccharin,1577,B-CHEMICAL
",",1577,O
aspartame,1577,B-CHEMICAL
(,1577,O
Nutrasweet,1577,B-CHEMICAL
),1577,O
",",1577,O
acesulfame-K,1577,B-CHEMICAL
",",1577,O
and,1577,O
cyclamate,1577,B-CHEMICAL
.,1577,O
Despite,1578,O
the,1578,O
caloric,1578,O
advantage,1578,O
they,1578,O
provide,1578,O
",",1578,O
one,1578,O
key,1578,O
concern,1578,O
in,1578,O
their,1578,O
use,1578,O
is,1578,O
their,1578,O
aversive,1578,O
aftertaste,1578,O
that,1578,O
has,1578,O
been,1578,O
characterized,1578,O
on,1578,O
a,1578,O
sensory,1578,O
level,1578,O
as,1578,O
bitter,1578,O
and/or,1578,O
metallic,1578,O
.,1578,O
Recently,1579,O
",",1579,O
it,1579,O
has,1579,O
been,1579,O
shown,1579,O
that,1579,O
the,1579,O
activation,1579,O
of,1579,O
particular,1579,O
T2R,1579,B-GENE-N
bitter,1579,O
taste,1579,O
receptors,1579,O
is,1579,O
partially,1579,O
involved,1579,O
with,1579,O
the,1579,O
bitter,1579,O
aftertaste,1579,O
sensation,1579,O
of,1579,O
saccharin,1579,B-CHEMICAL
and,1579,O
acesulfame-K.,1579,B-CHEMICAL
To,1579,O
more,1579,O
fully,1579,O
understand,1579,O
the,1579,O
biology,1579,O
behind,1579,O
these,1579,O
phenomena,1579,O
we,1579,O
have,1579,O
addressed,1579,O
the,1579,O
question,1579,O
of,1579,O
whether,1579,O
AS,1579,O
could,1579,O
stimulate,1579,O
transient,1579,B-GENE-Y
receptor,1579,I-GENE-Y
potential,1579,I-GENE-Y
vanilloid-1,1579,I-GENE-Y
(,1579,I-GENE-Y
TRPV1,1579,I-GENE-Y
),1579,I-GENE-Y
receptors,1579,I-GENE-Y
",",1579,O
as,1579,O
these,1579,O
receptors,1579,O
are,1579,O
activated,1579,O
by,1579,O
a,1579,O
large,1579,O
range,1579,O
of,1579,O
structurally,1579,O
different,1579,O
chemicals,1579,O
.,1579,O
Moreover,1580,O
",",1580,O
TRPV1,1580,B-GENE-Y
receptors,1580,O
and/or,1580,O
their,1580,O
variants,1580,O
are,1580,O
found,1580,O
in,1580,O
taste,1580,O
receptor,1580,O
cells,1580,O
and,1580,O
in,1580,O
nerve,1580,O
terminals,1580,O
throughout,1580,O
the,1580,O
oral,1580,O
cavity,1580,O
.,1580,O
Hence,1581,O
",",1581,O
TRPV1,1581,B-GENE-Y
activation,1581,O
could,1581,O
be,1581,O
involved,1581,O
in,1581,O
the,1581,O
AS,1581,O
aftertaste,1581,O
or,1581,O
even,1581,O
contribute,1581,O
to,1581,O
the,1581,O
poorly,1581,O
understood,1581,O
metallic,1581,O
taste,1581,O
sensation,1581,O
.,1581,O
Using,1582,O
Ca,1582,B-CHEMICAL
(,1582,I-CHEMICAL
2+,1582,I-CHEMICAL
),1582,I-CHEMICAL
imaging,1582,O
on,1582,O
TRPV1,1582,B-GENE-Y
receptors,1582,O
heterologously,1582,O
expressed,1582,O
in,1582,O
the,1582,O
human,1582,O
embryonic,1582,O
kidney,1582,O
(,1582,O
HEK,1582,O
),1582,O
293,1582,O
cells,1582,O
and,1582,O
on,1582,O
dissociated,1582,O
primary,1582,O
sensory,1582,O
neurons,1582,O
",",1582,O
we,1582,O
find,1582,O
that,1582,O
in,1582,O
both,1582,O
systems,1582,O
",",1582,O
AS,1582,O
activate,1582,O
TRPV1,1582,B-GENE-Y
receptors,1582,O
",",1582,O
and,1582,O
",",1582,O
moreover,1582,O
",",1582,O
they,1582,O
sensitize,1582,O
these,1582,O
channels,1582,O
to,1582,O
acid,1582,O
and,1582,O
heat,1582,O
.,1582,O
We,1583,O
also,1583,O
found,1583,O
that,1583,O
TRPV1,1583,B-GENE-Y
receptors,1583,O
are,1583,O
activated,1583,O
by,1583,O
CuSO,1583,B-CHEMICAL
(,1583,I-CHEMICAL
4,1583,I-CHEMICAL
),1583,I-CHEMICAL
",",1583,O
ZnSO,1583,B-CHEMICAL
(,1583,I-CHEMICAL
4,1583,I-CHEMICAL
),1583,I-CHEMICAL
",",1583,O
and,1583,O
FeSO,1583,B-CHEMICAL
(,1583,I-CHEMICAL
4,1583,I-CHEMICAL
),1583,I-CHEMICAL
",",1583,O
three,1583,O
salts,1583,O
known,1583,O
to,1583,O
produce,1583,O
a,1583,O
metallic,1583,O
taste,1583,O
sensation,1583,O
.,1583,O
In,1584,O
summary,1584,O
",",1584,O
our,1584,O
results,1584,O
identify,1584,O
a,1584,O
novel,1584,O
group,1584,O
of,1584,O
compounds,1584,O
that,1584,O
activate,1584,O
TRPV1,1584,B-GENE-Y
and,1584,O
",",1584,O
consequently,1584,O
",",1584,O
provide,1584,O
a,1584,O
molecular,1584,O
mechanism,1584,O
that,1584,O
may,1584,O
account,1584,O
for,1584,O
off,1584,O
tastes,1584,O
of,1584,O
sweeteners,1584,O
and,1584,O
metallic,1584,O
tasting,1584,O
salts,1584,O
.,1584,O
Molecular,1585,O
mechanisms,1585,O
of,1585,O
fibrosis-associated,1585,O
promotion,1585,O
of,1585,O
liver,1585,O
carcinogenesis,1585,O
.,1585,O
Hepatocellular,1586,O
carcinoma,1586,O
(,1586,O
HCC,1586,O
),1586,O
mostly,1586,O
develops,1586,O
in,1586,O
patients,1586,O
with,1586,O
advanced,1586,O
fibrosis,1586,O
;,1586,O
however,1586,O
",",1586,O
the,1586,O
mechanisms,1586,O
of,1586,O
interaction,1586,O
between,1586,O
a,1586,O
genotoxic,1586,O
insult,1586,O
and,1586,O
fibrogenesis,1586,O
are,1586,O
not,1586,O
well,1586,O
understood,1586,O
.,1586,O
This,1587,O
study,1587,O
tested,1587,O
a,1587,O
hypothesis,1587,O
that,1587,O
fibrosis,1587,O
promotes,1587,O
HCC,1587,O
via,1587,O
a,1587,O
mechanism,1587,O
that,1587,O
involves,1587,O
activation,1587,O
of,1587,O
liver,1587,O
stem,1587,O
cells,1587,O
.,1587,O
First,1588,O
",",1588,O
B6C3F1,1588,O
mice,1588,O
were,1588,O
administered,1588,O
diethylnitrosamine,1588,B-CHEMICAL
(,1588,O
DEN,1588,B-CHEMICAL
;,1588,O
single,1588,O
ip,1588,O
injection,1588,O
of,1588,O
1mg/kg,1588,O
at,1588,O
14,1588,O
days,1588,O
of,1588,O
age,1588,O
),1588,O
.,1588,O
Second,1589,O
",",1589,O
carbon,1589,B-CHEMICAL
tetrachloride,1589,I-CHEMICAL
(,1589,O
CCl,1589,B-CHEMICAL
(,1589,I-CHEMICAL
4,1589,I-CHEMICAL
),1589,I-CHEMICAL
;,1589,O
0.2ml/kg,1589,O
",",1589,O
2/week,1589,O
ip,1589,O
starting,1589,O
at,1589,O
8,1589,O
weeks,1589,O
of,1589,O
age,1589,O
),1589,O
was,1589,O
administered,1589,O
for,1589,O
9,1589,O
or,1589,O
14,1589,O
weeks,1589,O
to,1589,O
develop,1589,O
advanced,1589,O
liver,1589,O
fibrosis,1589,O
.,1589,O
In,1590,O
animals,1590,O
treated,1590,O
with,1590,O
DEN,1590,B-CHEMICAL
as,1590,O
neonates,1590,O
",",1590,O
presence,1590,O
of,1590,O
liver,1590,O
fibrosis,1590,O
led,1590,O
to,1590,O
more,1590,O
than,1590,O
doubling,1590,O
(,1590,O
to,1590,O
100,1590,O
%,1590,O
),1590,O
of,1590,O
the,1590,O
liver,1590,O
tumor,1590,O
incidence,1590,O
as,1590,O
early,1590,O
as,1590,O
5,1590,O
months,1590,O
of,1590,O
age,1590,O
.,1590,O
This,1591,O
effect,1591,O
was,1591,O
associated,1591,O
with,1591,O
activation,1591,O
of,1591,O
cells,1591,O
with,1591,O
progenitor,1591,O
features,1591,O
in,1591,O
noncancerous,1591,O
liver,1591,O
tissue,1591,O
",",1591,O
including,1591,O
markers,1591,O
of,1591,O
replicative,1591,O
senescence,1591,O
(,1591,O
p16,1591,B-GENE-Y
),1591,O
",",1591,O
oncofetal,1591,O
transformation,1591,O
(,1591,O
Afp,1591,B-GENE-Y
",",1591,O
H19,1591,B-GENE-Y
",",1591,O
and,1591,O
Bex1,1591,B-GENE-Y
),1591,O
",",1591,O
and,1591,O
increased,1591,O
``,1591,O
stemness,1591,O
'',1591,O
(,1591,O
Prom1,1591,B-GENE-Y
and,1591,O
Epcam,1591,B-GENE-Y
),1591,O
.,1591,O
In,1592,O
contrast,1592,O
",",1592,O
the,1592,O
dose,1592,O
of,1592,O
DEN,1592,B-CHEMICAL
used,1592,O
did,1592,O
not,1592,O
modify,1592,O
the,1592,O
extent,1592,O
of,1592,O
liver,1592,O
inflammation,1592,O
",",1592,O
fibrogenesis,1592,O
",",1592,O
oxidative,1592,O
stress,1592,O
",",1592,O
proliferation,1592,O
",",1592,O
or,1592,O
apoptosis,1592,O
induced,1592,O
by,1592,O
subchronic,1592,O
CCl,1592,B-CHEMICAL
(,1592,I-CHEMICAL
4,1592,I-CHEMICAL
),1592,I-CHEMICAL
administration,1592,O
.,1592,O
This,1593,O
study,1593,O
demonstrates,1593,O
the,1593,O
potential,1593,O
role,1593,O
of,1593,O
liver,1593,O
stem-like,1593,O
cells,1593,O
in,1593,O
the,1593,O
mechanisms,1593,O
of,1593,O
chemical-induced,1593,O
",",1593,O
fibrosis-promoted,1593,O
HCC,1593,O
.,1593,O
We,1594,O
posit,1594,O
that,1594,O
the,1594,O
combination,1594,O
of,1594,O
genotoxic,1594,O
and,1594,O
fibrogenic,1594,O
insults,1594,O
is,1594,O
a,1594,O
sensible,1594,O
approach,1594,O
to,1594,O
model,1594,O
liver,1594,O
carcinogenesis,1594,O
in,1594,O
experimental,1594,O
animals,1594,O
.,1594,O
These,1595,O
results,1595,O
may,1595,O
contribute,1595,O
to,1595,O
identification,1595,O
of,1595,O
cirrhotic,1595,O
patients,1595,O
predisposed,1595,O
to,1595,O
HCC,1595,O
by,1595,O
analyzing,1595,O
the,1595,O
expression,1595,O
of,1595,O
hepatic,1595,O
progenitor,1595,O
cell,1595,O
markers,1595,O
in,1595,O
the,1595,O
noncancerous,1595,O
liver,1595,O
tissue,1595,O
.,1595,O
2-Arylpropionic,1596,B-CHEMICAL
CXC,1596,B-GENE-Y
chemokine,1596,I-GENE-Y
receptor,1596,I-GENE-Y
1,1596,I-GENE-Y
(,1596,O
CXCR1,1596,B-GENE-Y
),1596,O
ligands,1596,O
as,1596,O
novel,1596,O
noncompetitive,1596,O
CXCL8,1596,B-GENE-Y
inhibitors,1596,O
.,1596,O
The,1597,O
CXC,1597,B-GENE-N
chemokine,1597,I-GENE-N
CXCL8/IL-8,1597,B-GENE-Y
plays,1597,O
a,1597,O
major,1597,O
role,1597,O
in,1597,O
the,1597,O
activation,1597,O
and,1597,O
recruitment,1597,O
of,1597,O
polymorphonuclear,1597,O
(,1597,O
PMN,1597,O
),1597,O
cells,1597,O
at,1597,O
inflammatory,1597,O
sites,1597,O
.,1597,O
CXCL8,1598,B-GENE-Y
activates,1598,O
PMNs,1598,O
by,1598,O
binding,1598,O
the,1598,O
seven-transmembrane,1598,B-GENE-N
(,1598,I-GENE-N
7-TM,1598,I-GENE-N
),1598,I-GENE-N
G-protein-coupled,1598,I-GENE-N
receptors,1598,I-GENE-N
CXC,1598,B-GENE-Y
chemokine,1598,I-GENE-Y
receptor,1598,I-GENE-Y
1,1598,I-GENE-Y
(,1598,O
CXCR1,1598,B-GENE-Y
),1598,O
and,1598,O
CXC,1598,B-GENE-Y
chemokine,1598,I-GENE-Y
receptor,1598,I-GENE-Y
2,1598,I-GENE-Y
(,1598,O
CXCR2,1598,B-GENE-Y
),1598,O
.,1598,O
(,1599,B-CHEMICAL
R,1599,I-CHEMICAL
),1599,I-CHEMICAL
-Ketoprofen,1599,I-CHEMICAL
(,1599,O
1,1599,O
),1599,O
was,1599,O
previously,1599,O
reported,1599,O
to,1599,O
be,1599,O
a,1599,O
potent,1599,O
and,1599,O
specific,1599,O
noncompetitive,1599,O
inhibitor,1599,O
of,1599,O
CXCL8-induced,1599,B-GENE-Y
human,1599,O
PMNs,1599,O
chemotaxis,1599,O
.,1599,O
We,1600,O
report,1600,O
here,1600,O
molecular,1600,O
modeling,1600,O
studies,1600,O
showing,1600,O
a,1600,O
putative,1600,O
interaction,1600,O
site,1600,O
of,1600,O
1,1600,O
in,1600,O
the,1600,O
TM,1600,O
region,1600,O
of,1600,O
CXCR1,1600,B-GENE-Y
.,1600,O
The,1601,O
binding,1601,O
model,1601,O
was,1601,O
confirmed,1601,O
by,1601,O
alanine,1601,B-CHEMICAL
scanning,1601,O
mutagenesis,1601,O
and,1601,O
photoaffinity,1601,O
labeling,1601,O
experiments,1601,O
.,1601,O
The,1602,O
molecular,1602,O
model,1602,O
driven,1602,O
medicinal,1602,O
chemistry,1602,O
optimization,1602,O
of,1602,O
1,1602,O
led,1602,O
to,1602,O
a,1602,O
new,1602,O
class,1602,O
of,1602,O
potent,1602,O
and,1602,O
specific,1602,O
inhibitors,1602,O
of,1602,O
CXCL8,1602,B-GENE-Y
biological,1602,O
activity,1602,O
.,1602,O
Among,1603,O
these,1603,O
",",1603,O
repertaxin,1603,B-CHEMICAL
(,1603,O
13,1603,O
),1603,O
was,1603,O
selected,1603,O
as,1603,O
a,1603,O
clinical,1603,O
candidate,1603,O
drug,1603,O
for,1603,O
prevention,1603,O
of,1603,O
post-ischemia,1603,O
reperfusion,1603,O
injury,1603,O
.,1603,O
Role,1604,O
of,1604,O
organic,1604,B-GENE-Y
cation/carnitine,1604,I-GENE-Y
transporter,1604,I-GENE-Y
1,1604,I-GENE-Y
in,1604,O
uptake,1604,O
of,1604,O
phenformin,1604,B-CHEMICAL
and,1604,O
inhibitory,1604,O
effect,1604,O
on,1604,O
complex,1604,B-GENE-N
I,1604,I-GENE-N
respiration,1604,O
in,1604,O
mitochondria,1604,O
.,1604,O
Phenformin,1605,B-CHEMICAL
causes,1605,O
lactic,1605,O
acidosis,1605,O
in,1605,O
clinical,1605,O
situations,1605,O
due,1605,O
to,1605,O
inhibition,1605,O
of,1605,O
mitochondrial,1605,B-GENE-N
respiratory,1605,I-GENE-N
chain,1605,I-GENE-N
complex,1605,I-GENE-N
I,1605,I-GENE-N
.,1605,O
It,1606,O
is,1606,O
reportedly,1606,O
taken,1606,O
up,1606,O
by,1606,O
hepatocytes,1606,O
and,1606,O
exhibits,1606,O
mitochondrial,1606,O
toxicity,1606,O
in,1606,O
the,1606,O
liver,1606,O
.,1606,O
In,1607,O
this,1607,O
study,1607,O
",",1607,O
uptake,1607,O
of,1607,O
phenformin,1607,B-CHEMICAL
and,1607,O
[,1607,B-CHEMICAL
(,1607,I-CHEMICAL
14,1607,I-CHEMICAL
),1607,I-CHEMICAL
C,1607,I-CHEMICAL
],1607,I-CHEMICAL
tetraethylammonium,1607,I-CHEMICAL
(,1607,O
TEA,1607,B-CHEMICAL
),1607,O
and,1607,O
complex,1607,B-GENE-N
I,1607,I-GENE-N
inhibition,1607,O
by,1607,O
phenformin,1607,B-CHEMICAL
were,1607,O
examined,1607,O
in,1607,O
isolated,1607,O
liver,1607,O
and,1607,O
heart,1607,O
mitochondria,1607,O
.,1607,O
Uptake,1608,O
of,1608,O
phenformin,1608,B-CHEMICAL
into,1608,O
isolated,1608,O
rat,1608,O
liver,1608,O
mitochondria,1608,O
was,1608,O
higher,1608,O
than,1608,O
that,1608,O
into,1608,O
heart,1608,O
mitochondria,1608,O
.,1608,O
It,1609,O
was,1609,O
inhibited,1609,O
by,1609,O
several,1609,O
cat,1609,O
ionic,1609,O
compounds,1609,O
",",1609,O
which,1609,O
suggests,1609,O
the,1609,O
involvement,1609,O
of,1609,O
multispecific,1609,O
transport,1609,O
system,1609,O
(,1609,O
s,1609,O
),1609,O
.,1609,O
Similar,1610,O
characteristics,1610,O
were,1610,O
also,1610,O
observed,1610,O
for,1610,O
uptake,1610,O
of,1610,O
TEA,1610,B-CHEMICAL
;,1610,O
however,1610,O
",",1610,O
uptake,1610,O
of,1610,O
phenformin,1610,B-CHEMICAL
into,1610,O
mitochondria,1610,O
of,1610,O
organic,1610,B-GENE-Y
cation/carnitine,1610,I-GENE-Y
transporter,1610,I-GENE-Y
1,1610,I-GENE-Y
(,1610,O
OCTN1,1610,B-GENE-Y
),1610,O
knockout,1610,O
mice,1610,O
was,1610,O
lower,1610,O
than,1610,O
that,1610,O
in,1610,O
wild-type,1610,O
mice,1610,O
",",1610,O
whereas,1610,O
uptake,1610,O
of,1610,O
TEA,1610,B-CHEMICAL
was,1610,O
comparable,1610,O
between,1610,O
the,1610,O
two,1610,O
strains,1610,O
",",1610,O
suggesting,1610,O
the,1610,O
involvement,1610,O
of,1610,O
distinct,1610,O
transport,1610,O
mechanisms,1610,O
for,1610,O
these,1610,O
two,1610,O
cations,1610,O
in,1610,O
mitochondria,1610,O
.,1610,O
Inhibition,1611,O
by,1611,O
phenformin,1611,B-CHEMICAL
of,1611,O
oxygen,1611,B-CHEMICAL
consumption,1611,O
via,1611,O
complex,1611,B-GENE-N
I,1611,I-GENE-N
respiration,1611,O
in,1611,O
isolated,1611,O
rat,1611,O
liver,1611,O
mitochondria,1611,O
was,1611,O
greater,1611,O
than,1611,O
that,1611,O
in,1611,O
heart,1611,O
mitochondria,1611,O
",",1611,O
whereas,1611,O
inhibitory,1611,O
effect,1611,O
of,1611,O
phenformin,1611,B-CHEMICAL
on,1611,O
complex,1611,B-GENE-N
I,1611,I-GENE-N
respiration,1611,O
was,1611,O
similar,1611,O
in,1611,O
inside-out,1611,O
structured,1611,O
submitochondrial,1611,O
particles,1611,O
prepared,1611,O
from,1611,O
rat,1611,O
livers,1611,O
and,1611,O
hearts,1611,O
.,1611,O
Lactic,1612,O
acidosis,1612,O
provoked,1612,O
by,1612,O
iv,1612,O
infusion,1612,O
of,1612,O
phenformin,1612,B-CHEMICAL
was,1612,O
weaker,1612,O
in,1612,O
octn1,1612,B-GENE-Y
(,1612,O
-/-,1612,O
),1612,O
mice,1612,O
than,1612,O
that,1612,O
in,1612,O
wild-type,1612,O
mice,1612,O
.,1612,O
These,1613,O
observations,1613,O
suggest,1613,O
that,1613,O
uptake,1613,O
of,1613,O
phenformin,1613,B-CHEMICAL
into,1613,O
liver,1613,O
mitochondria,1613,O
is,1613,O
at,1613,O
least,1613,O
partly,1613,O
mediated,1613,O
by,1613,O
OCTN1,1613,B-GENE-Y
and,1613,O
functionally,1613,O
relevant,1613,O
to,1613,O
its,1613,O
inhibition,1613,O
potential,1613,O
of,1613,O
complex,1613,B-GENE-N
I,1613,I-GENE-N
respiration,1613,O
.,1613,O
This,1614,O
study,1614,O
was,1614,O
",",1614,O
thus,1614,O
",",1614,O
the,1614,O
first,1614,O
to,1614,O
demonstrate,1614,O
OCTN1-mediated,1614,B-GENE-Y
mitochondrial,1614,O
transport,1614,O
and,1614,O
toxicity,1614,O
of,1614,O
biguanide,1614,O
in,1614,O
vivo,1614,O
in,1614,O
rodents,1614,O
.,1614,O
Synthesis,1615,O
and,1615,O
biological,1615,O
evaluation,1615,O
of,1615,O
xanthine,1615,B-CHEMICAL
derivatives,1615,O
on,1615,O
dipeptidyl,1615,B-GENE-Y
peptidase,1615,I-GENE-Y
4,1615,I-GENE-Y
.,1615,O
A,1616,O
series,1616,O
of,1616,O
xanthine,1616,B-CHEMICAL
derivatives,1616,O
in,1616,O
which,1616,O
a,1616,O
methylene,1616,B-CHEMICAL
was,1616,O
inserted,1616,O
at,1616,O
position,1616,O
8,1616,O
of,1616,O
xanthine,1616,B-CHEMICAL
scaffold,1616,O
was,1616,O
synthesized,1616,O
and,1616,O
evaluated,1616,O
as,1616,O
inhibitors,1616,O
of,1616,O
dipeptidyl,1616,B-GENE-Y
peptidase,1616,I-GENE-Y
4,1616,I-GENE-Y
(,1616,O
DPP-4,1616,B-GENE-Y
),1616,O
for,1616,O
the,1616,O
treatment,1616,O
of,1616,O
type,1616,O
2,1616,O
diabetes,1616,O
.,1616,O
As,1617,O
the,1617,O
results,1617,O
of,1617,O
structure-activity,1617,O
relationship,1617,O
(,1617,O
SAR,1617,O
),1617,O
study,1617,O
of,1617,O
the,1617,O
series,1617,O
",",1617,O
the,1617,O
compounds,1617,O
with,1617,O
4-methyl-quinazoline-2-yl-methyl,1617,B-CHEMICAL
group,1617,O
at,1617,O
N-1,1617,O
position,1617,O
and,1617,O
2-aminoethylaminomethyl,1617,B-CHEMICAL
group,1617,O
gave,1617,O
better,1617,O
activities,1617,O
.,1617,O
Compounds,1618,O
H4,1618,O
and,1618,O
H9,1618,O
showed,1618,O
good,1618,O
DPP-4,1618,B-GENE-Y
inhibition,1618,O
and,1618,O
more,1618,O
than,1618,O
100-fold,1618,O
selectivity,1618,O
over,1618,O
DPP-7,1618,B-GENE-Y
and,1618,O
DPP-8,1618,B-GENE-Y
.,1618,O
5-HT1B,1619,B-GENE-Y
receptors,1619,O
",",1619,O
alpha2A/2C-,1619,O
and,1619,O
",",1619,O
to,1619,O
a,1619,O
lesser,1619,O
extent,1619,O
",",1619,O
alpha1-adrenoceptors,1619,B-GENE-N
mediate,1619,O
the,1619,O
external,1619,O
carotid,1619,O
vasoconstriction,1619,O
to,1619,O
ergotamine,1619,B-CHEMICAL
in,1619,O
vagosympathectomised,1619,O
dogs,1619,O
.,1619,O
It,1620,O
has,1620,O
previously,1620,O
been,1620,O
suggested,1620,O
that,1620,O
ergotamine,1620,B-CHEMICAL
produces,1620,O
external,1620,O
carotid,1620,O
vasoconstriction,1620,O
in,1620,O
vagosympathectomised,1620,O
dogs,1620,O
via,1620,O
5-HT1B/1D,1620,B-GENE-N
receptors,1620,O
and,1620,O
alpha2-adrenoceptors,1620,B-GENE-N
.,1620,O
The,1621,O
present,1621,O
study,1621,O
has,1621,O
reanalysed,1621,O
this,1621,O
suggestion,1621,O
by,1621,O
using,1621,O
more,1621,O
selective,1621,O
antagonists,1621,O
alone,1621,O
and,1621,O
in,1621,O
combination,1621,O
.,1621,O
Fifty-two,1622,O
anaesthetised,1622,O
dogs,1622,O
were,1622,O
prepared,1622,O
for,1622,O
ultrasonic,1622,O
measurements,1622,O
of,1622,O
external,1622,O
carotid,1622,O
blood,1622,O
flow,1622,O
.,1622,O
The,1623,O
animals,1623,O
were,1623,O
divided,1623,O
into,1623,O
thirteen,1623,O
groups,1623,O
(,1623,O
n=4,1623,O
each,1623,O
),1623,O
receiving,1623,O
an,1623,O
i.v,1623,O
.,1623,O
bolus,1624,O
injection,1624,O
of,1624,O
",",1624,O
either,1624,O
physiological,1624,O
saline,1624,O
(,1624,O
0.3,1624,O
ml/kg,1624,O
;,1624,O
control,1624,O
),1624,O
",",1624,O
or,1624,O
the,1624,O
antagonists,1624,O
SB224289,1624,B-CHEMICAL
(,1624,O
300,1624,O
microg/kg,1624,O
;,1624,O
5-HT1B,1624,B-GENE-Y
),1624,O
",",1624,O
BRL15572,1624,B-CHEMICAL
(,1624,O
300,1624,O
microg/kg,1624,O
;,1624,O
5-HT1D,1624,B-GENE-Y
),1624,O
",",1624,O
rauwolscine,1624,B-CHEMICAL
(,1624,O
300,1624,O
microg/kg,1624,O
;,1624,O
alpha2,1624,O
),1624,O
",",1624,O
SB224289,1624,B-CHEMICAL
+,1624,O
BRL15572,1624,B-CHEMICAL
(,1624,O
300,1624,O
microg/kg,1624,O
each,1624,O
),1624,O
",",1624,O
SB224289,1624,B-CHEMICAL
+,1624,O
rauwolscine,1624,B-CHEMICAL
(,1624,O
300,1624,O
microg/kg,1624,O
each,1624,O
),1624,O
",",1624,O
BRL15572,1624,B-CHEMICAL
+,1624,O
rauwolscine,1624,B-CHEMICAL
(,1624,O
300,1624,O
microg/kg,1624,O
each,1624,O
),1624,O
",",1624,O
rauwolscine,1624,B-CHEMICAL
(,1624,O
300,1624,O
microg/kg,1624,O
),1624,O
+,1624,O
prazosin,1624,B-CHEMICAL
(,1624,O
100,1624,O
microg/kg,1624,O
;,1624,O
alpha1,1624,O
),1624,O
",",1624,O
SB224289,1624,B-CHEMICAL
(,1624,O
300,1624,O
microg/kg,1624,O
),1624,O
+,1624,O
prazosin,1624,B-CHEMICAL
(,1624,O
100,1624,O
microg/kg,1624,O
),1624,O
",",1624,O
SB224289,1624,B-CHEMICAL
(,1624,O
300,1624,O
microg/kg,1624,O
),1624,O
+,1624,O
rauwolscine,1624,B-CHEMICAL
(,1624,O
300,1624,O
microg/kg,1624,O
),1624,O
+,1624,O
prazosin,1624,B-CHEMICAL
(,1624,O
100,1624,O
microg/kg,1624,O
),1624,O
",",1624,O
SB224289,1624,B-CHEMICAL
(,1624,O
300,1624,O
microg/kg,1624,O
),1624,O
+,1624,O
prazosin,1624,B-CHEMICAL
(,1624,O
100,1624,O
microg/kg,1624,O
),1624,O
+,1624,O
BRL44408,1624,B-CHEMICAL
(,1624,O
"1,000",1624,O
microg/kg,1624,O
;,1624,O
alpha2A,1624,O
),1624,O
",",1624,O
SB224289,1624,B-CHEMICAL
(,1624,O
300,1624,O
microg/kg,1624,O
),1624,O
+,1624,O
prazosin,1624,B-CHEMICAL
(,1624,O
100,1624,O
microg/kg,1624,O
),1624,O
+,1624,O
imiloxan,1624,B-CHEMICAL
(,1624,O
"1,000",1624,O
microg/kg,1624,O
;,1624,O
alpha2B,1624,O
),1624,O
",",1624,O
or,1624,O
SB224289,1624,B-CHEMICAL
(,1624,O
300,1624,O
microg/kg,1624,O
),1624,O
+,1624,O
prazosin,1624,B-CHEMICAL
(,1624,O
100,1624,O
microg/kg,1624,O
),1624,O
+,1624,O
MK912,1624,B-CHEMICAL
(,1624,O
300,1624,O
microg/kg,1624,O
;,1624,O
alpha2C,1624,O
),1624,O
.,1624,O
Each,1625,O
group,1625,O
received,1625,O
consecutive,1625,O
1-min,1625,O
intracarotid,1625,O
infusions,1625,O
of,1625,O
ergotamine,1625,B-CHEMICAL
(,1625,O
0.56,1625,O
",",1625,O
1,1625,O
",",1625,O
1.8,1625,O
",",1625,O
3.1,1625,O
",",1625,O
5.6,1625,O
",",1625,O
10,1625,O
and,1625,O
18,1625,O
microg/min,1625,O
),1625,O
",",1625,O
following,1625,O
a,1625,O
cumulative,1625,O
schedule,1625,O
.,1625,O
In,1626,O
saline-pretreated,1626,O
animals,1626,O
",",1626,O
ergotamine,1626,B-CHEMICAL
induced,1626,O
dose-dependent,1626,O
decreases,1626,O
in,1626,O
external,1626,O
carotid,1626,O
blood,1626,O
flow,1626,O
without,1626,O
affecting,1626,O
arterial,1626,O
blood,1626,O
pressure,1626,O
or,1626,O
heart,1626,O
rate,1626,O
.,1626,O
These,1627,O
control,1627,O
responses,1627,O
were,1627,O
:,1627,O
unaffected,1627,O
by,1627,O
SB224289,1627,B-CHEMICAL
",",1627,O
BRL15572,1627,B-CHEMICAL
",",1627,O
rauwolscine,1627,B-CHEMICAL
or,1627,O
the,1627,O
combinations,1627,O
of,1627,O
SB224289,1627,B-CHEMICAL
+,1627,O
BRL15572,1627,B-CHEMICAL
",",1627,O
BRL15572,1627,B-CHEMICAL
+,1627,O
rauwolscine,1627,B-CHEMICAL
",",1627,O
rauwolscine,1627,B-CHEMICAL
+,1627,O
prazosin,1627,B-CHEMICAL
",",1627,O
SB224289,1627,B-CHEMICAL
+,1627,O
prazosin,1627,B-CHEMICAL
",",1627,O
or,1627,O
SB224289,1627,B-CHEMICAL
+,1627,O
prazosin,1627,B-CHEMICAL
+,1627,O
imiloxan,1627,B-CHEMICAL
;,1627,O
slightly,1627,O
blocked,1627,O
by,1627,O
SB224289,1627,B-CHEMICAL
+,1627,O
rauwolscine,1627,B-CHEMICAL
;,1627,O
and,1627,O
markedly,1627,O
blocked,1627,O
by,1627,O
SB224289,1627,B-CHEMICAL
+,1627,O
rauwolscine,1627,B-CHEMICAL
+,1627,O
prazosin,1627,B-CHEMICAL
",",1627,O
SB224289,1627,B-CHEMICAL
+,1627,O
prazosin,1627,B-CHEMICAL
+,1627,O
BRL44408,1627,B-CHEMICAL
or,1627,O
SB224289,1627,B-CHEMICAL
+,1627,O
prazosin,1627,B-CHEMICAL
+,1627,O
MK912,1627,B-CHEMICAL
.,1627,O
Thus,1628,O
",",1628,O
the,1628,O
cranio-selective,1628,O
vasoconstriction,1628,O
elicited,1628,O
by,1628,O
ergotamine,1628,B-CHEMICAL
in,1628,O
dogs,1628,O
is,1628,O
predominantly,1628,O
mediated,1628,O
by,1628,O
5-HT1B,1628,B-GENE-Y
receptors,1628,O
as,1628,O
well,1628,O
as,1628,O
alpha2A/2C-adrenoceptor,1628,B-GENE-N
subtypes,1628,O
and,1628,O
",",1628,O
to,1628,O
a,1628,O
lesser,1628,O
extent,1628,O
",",1628,O
by,1628,O
alpha1-adrenoceptors,1628,B-GENE-N
.,1628,O
Influence,1629,O
of,1629,O
the,1629,O
dopamine,1629,B-GENE-N
D2,1629,I-GENE-N
receptor,1629,I-GENE-N
(,1629,I-GENE-N
DRD2,1629,I-GENE-N
),1629,I-GENE-N
exon,1629,I-GENE-N
8,1629,I-GENE-N
genotype,1629,O
on,1629,O
efficacy,1629,O
of,1629,O
tiapride,1629,B-CHEMICAL
and,1629,O
clinical,1629,O
outcome,1629,O
of,1629,O
alcohol,1629,B-CHEMICAL
withdrawal,1629,O
.,1629,O
We,1630,O
tested,1630,O
the,1630,O
hypothesis,1630,O
that,1630,O
allelic,1630,O
variants,1630,O
of,1630,O
the,1630,O
human,1630,B-GENE-N
dopamine,1630,I-GENE-N
D2,1630,I-GENE-N
receptor,1630,I-GENE-N
E8,1630,I-GENE-N
genotype,1630,O
are,1630,O
associated,1630,O
with,1630,O
(,1630,O
i,1630,O
),1630,O
dopamine,1630,B-GENE-Y
D2,1630,I-GENE-Y
antagonist,1630,O
tiapride,1630,O
dose,1630,O
in,1630,O
treatment,1630,O
of,1630,O
alcohol,1630,B-CHEMICAL
withdrawal,1630,O
(,1630,O
n,1630,O
=,1630,O
50,1630,O
),1630,O
and,1630,O
(,1630,O
ii,1630,O
),1630,O
with,1630,O
anxiety,1630,O
and,1630,O
depression,1630,O
in,1630,O
patients,1630,O
during,1630,O
alcoholism,1630,O
detoxification,1630,O
therapy,1630,O
(,1630,O
admission,1630,O
n,1630,O
=,1630,O
87,1630,O
;,1630,O
discharge,1630,O
n,1630,O
=,1630,O
50,1630,O
),1630,O
.,1630,O
DRD2,1631,B-GENE-N
E8,1631,I-GENE-N
A/A,1631,O
genotype,1631,O
was,1631,O
associated,1631,O
with,1631,O
increased,1631,O
dose,1631,O
of,1631,O
tiapride,1631,B-CHEMICAL
during,1631,O
a,1631,O
9-day,1631,O
detoxification,1631,O
therapy,1631,O
and,1631,O
with,1631,O
increased,1631,O
anxiety,1631,O
and,1631,O
depression,1631,O
scores,1631,O
on,1631,O
admission,1631,O
and,1631,O
2,1631,O
weeks,1631,O
later,1631,O
.,1631,O
The,1632,O
findings,1632,O
suggest,1632,O
a,1632,O
pharmacogenetic,1632,O
influence,1632,O
of,1632,O
DRD2,1632,B-GENE-N
E8,1632,I-GENE-N
genotype,1632,O
on,1632,O
tiapride,1632,O
efficacy,1632,O
in,1632,O
alcohol,1632,O
withdrawal,1632,O
.,1632,O
In,1633,O
an,1633,O
earlier,1633,O
report,1633,O
",",1633,O
DRD2,1633,B-GENE-Y
E8,1633,O
A/A,1633,O
genotype,1633,O
was,1633,O
associated,1633,O
with,1633,O
reduced,1633,O
responsiveness,1633,O
to,1633,O
the,1633,O
dopamine,1633,B-GENE-Y
D2,1633,I-GENE-Y
agonist,1633,O
apomorphine,1633,B-CHEMICAL
;,1633,O
however,1633,O
",",1633,O
it,1633,O
is,1633,O
not,1633,O
clear,1633,O
whether,1633,O
both,1633,O
findings,1633,O
share,1633,O
the,1633,O
same,1633,O
biological,1633,O
basis,1633,O
.,1633,O
Earlier,1634,O
findings,1634,O
concerning,1634,O
association,1634,O
of,1634,O
DRD2,1634,B-GENE-N
E8,1634,I-GENE-N
A/A,1634,O
with,1634,O
increased,1634,O
anxiety,1634,O
and,1634,O
depression,1634,O
are,1634,O
replicated,1634,O
for,1634,O
the,1634,O
first,1634,O
time,1634,O
.,1634,O
Peroxynitrite,1635,B-CHEMICAL
mediates,1635,O
testosterone-induced,1635,B-CHEMICAL
vasodilation,1635,O
of,1635,O
microvascular,1635,O
resistance,1635,O
vessels,1635,O
.,1635,O
Our,1636,O
knowledge,1636,O
of,1636,O
how,1636,O
androgens,1636,B-CHEMICAL
influence,1636,O
the,1636,O
cardiovascular,1636,O
system,1636,O
is,1636,O
far,1636,O
from,1636,O
complete,1636,O
",",1636,O
and,1636,O
this,1636,O
lack,1636,O
of,1636,O
understanding,1636,O
is,1636,O
especially,1636,O
true,1636,O
of,1636,O
how,1636,O
androgens,1636,B-CHEMICAL
affect,1636,O
resistance,1636,O
vessels,1636,O
.,1636,O
Our,1637,O
aim,1637,O
was,1637,O
to,1637,O
identify,1637,O
the,1637,O
signaling,1637,O
mechanisms,1637,O
stimulated,1637,O
by,1637,O
testosterone,1637,B-CHEMICAL
(,1637,O
TES,1637,B-CHEMICAL
),1637,O
in,1637,O
microvascular,1637,O
arteries,1637,O
and,1637,O
to,1637,O
understand,1637,O
how,1637,O
these,1637,O
mechanisms,1637,O
mediate,1637,O
TES-induced,1637,B-CHEMICAL
vasodilation,1637,O
.,1637,O
Mesenteric,1638,O
microvessels,1638,O
were,1638,O
isolated,1638,O
from,1638,O
male,1638,O
Sprague-Dawley,1638,O
rats,1638,O
.,1638,O
Tension,1639,O
studies,1639,O
demonstrated,1639,O
a,1639,O
rapid,1639,O
",",1639,O
concentration-dependent,1639,O
",",1639,O
vasodilatory,1639,O
response,1639,O
to,1639,O
TES,1639,B-CHEMICAL
that,1639,O
did,1639,O
not,1639,O
involve,1639,O
protein,1639,O
synthesis,1639,O
or,1639,O
aromatization,1639,O
to,1639,O
17β-estradiol,1639,B-CHEMICAL
.,1639,O
Dichlorofluorescein,1640,B-CHEMICAL
fluorescence,1640,O
and,1640,O
nitrotyrosine,1640,B-CHEMICAL
immunoblot,1640,O
experiments,1640,O
indicated,1640,O
that,1640,O
TES,1640,B-CHEMICAL
stimulated,1640,O
peroxynitrite,1640,B-CHEMICAL
formation,1640,O
in,1640,O
microvessels,1640,O
",",1640,O
and,1640,O
functional,1640,O
studies,1640,O
demonstrated,1640,O
that,1640,O
TES-induced,1640,B-CHEMICAL
vasodilation,1640,O
was,1640,O
inhibited,1640,O
by,1640,O
scavenging,1640,O
peroxynitrite,1640,B-CHEMICAL
.,1640,O
As,1641,O
predicted,1641,O
",",1641,O
TES,1641,B-CHEMICAL
enhanced,1641,O
the,1641,O
production,1641,O
of,1641,O
both,1641,O
peroxynitrite,1641,B-CHEMICAL
precursors,1641,O
(,1641,O
i.e.,1641,O
",",1641,O
superoxide,1641,B-CHEMICAL
and,1641,O
nitic,1641,B-CHEMICAL
oxide,1641,I-CHEMICAL
),1641,O
",",1641,O
and,1641,O
xanthine,1641,B-GENE-Y
oxidase,1641,I-GENE-Y
was,1641,O
identified,1641,O
as,1641,O
the,1641,O
likely,1641,O
source,1641,O
of,1641,O
TES-stimulated,1641,B-CHEMICAL
superoxide,1641,B-CHEMICAL
production,1641,O
.,1641,O
Functional,1642,O
and,1642,O
biochemical,1642,O
studies,1642,O
indicated,1642,O
that,1642,O
TES,1642,B-CHEMICAL
signaling,1642,O
involved,1642,O
activity,1642,O
of,1642,O
the,1642,O
phosphoinositide,1642,B-GENE-N
3,1642,I-GENE-N
(,1642,I-GENE-N
PI3,1642,I-GENE-N
),1642,I-GENE-N
kinase-protein,1642,O
kinase,1642,I-GENE-Y
B,1642,I-GENE-Y
(,1642,O
Akt,1642,B-GENE-Y
),1642,O
cascade,1642,O
initiated,1642,O
by,1642,O
activation,1642,O
of,1642,O
the,1642,O
androgen,1642,B-GENE-Y
receptor,1642,I-GENE-Y
and,1642,O
culminated,1642,O
in,1642,O
enhanced,1642,O
production,1642,O
of,1642,O
cGMP,1642,B-CHEMICAL
and,1642,O
microvascular,1642,O
vasodilation,1642,O
.,1642,O
These,1643,O
findings,1643,O
",",1643,O
derived,1643,O
from,1643,O
a,1643,O
variety,1643,O
of,1643,O
analytical,1643,O
and,1643,O
functional,1643,O
approaches,1643,O
",",1643,O
provide,1643,O
evidence,1643,O
for,1643,O
a,1643,O
novel,1643,O
nongenomic,1643,O
signaling,1643,O
mechanism,1643,O
for,1643,O
androgen,1643,B-CHEMICAL
action,1643,O
in,1643,O
the,1643,O
microvasculature,1643,O
:,1643,O
TES-stimulated,1643,B-CHEMICAL
vasodilation,1643,O
mediated,1643,O
primarily,1643,O
by,1643,O
peroxynitrite,1643,B-CHEMICAL
formed,1643,O
from,1643,O
xanthine,1643,B-GENE-Y
oxidase-generated,1643,O
superoxide,1643,B-CHEMICAL
and,1643,O
NO,1643,B-CHEMICAL
.,1643,O
This,1644,O
response,1644,O
was,1644,O
associated,1644,O
with,1644,O
activation,1644,O
of,1644,O
the,1644,O
PI3,1644,B-GENE-N
kinase-Akt,1644,O
signaling,1644,O
cascade,1644,O
initiated,1644,O
by,1644,O
activation,1644,O
of,1644,O
the,1644,O
androgen,1644,B-GENE-Y
receptor,1644,I-GENE-Y
.,1644,O
We,1645,O
propose,1645,O
this,1645,O
mechanism,1645,O
could,1645,O
account,1645,O
for,1645,O
TES-stimulated,1645,B-CHEMICAL
cGMP,1645,B-CHEMICAL
production,1645,O
in,1645,O
microvessels,1645,O
and,1645,O
",",1645,O
ultimately,1645,O
",",1645,O
vasodilation,1645,O
.,1645,O
Mouse,1646,B-GENE-Y
brain,1646,I-GENE-Y
serine,1646,I-GENE-Y
racemase,1646,I-GENE-Y
catalyzes,1646,O
specific,1646,O
elimination,1646,O
of,1646,O
L-serine,1646,B-CHEMICAL
to,1646,O
pyruvate,1646,B-CHEMICAL
.,1646,O
D-Serine,1647,B-CHEMICAL
was,1647,O
previously,1647,O
identified,1647,O
in,1647,O
mammalian,1647,O
brain,1647,O
and,1647,O
was,1647,O
shown,1647,O
to,1647,O
be,1647,O
a,1647,O
co-agonist,1647,O
at,1647,O
the,1647,O
'glycine,1647,O
',1647,O
site,1647,O
of,1647,O
the,1647,O
N-methyl-D-aspartate,1647,B-GENE-N
(,1647,I-GENE-N
NMDA,1647,I-GENE-N
),1647,I-GENE-N
-type,1647,I-GENE-N
receptors,1647,I-GENE-N
.,1647,O
Racemization,1648,O
of,1648,O
serine,1648,B-CHEMICAL
is,1648,O
catalyzed,1648,O
by,1648,O
serine,1648,B-GENE-Y
racemase,1648,I-GENE-Y
",",1648,O
a,1648,O
pyridoxal,1648,B-CHEMICAL
5'-phosphate-dependent,1648,O
enzyme,1648,O
expressed,1648,O
mainly,1648,O
in,1648,O
brain,1648,O
and,1648,O
liver,1648,O
.,1648,O
NMDA,1649,B-GENE-N
receptor,1649,I-GENE-N
overactivation,1649,O
has,1649,O
been,1649,O
implicated,1649,O
in,1649,O
a,1649,O
number,1649,O
of,1649,O
pathological,1649,O
conditions,1649,O
and,1649,O
inhibitors,1649,O
of,1649,O
serine,1649,B-GENE-Y
racemase,1649,I-GENE-Y
are,1649,O
thus,1649,O
potentially,1649,O
interesting,1649,O
targets,1649,O
for,1649,O
therapy,1649,O
.,1649,O
We,1650,O
expressed,1650,O
recombinant,1650,O
mouse,1650,B-GENE-Y
serine,1650,I-GENE-Y
racemase,1650,I-GENE-Y
in,1650,O
insect,1650,O
cells,1650,O
and,1650,O
purified,1650,O
it,1650,O
to,1650,O
near,1650,O
homogeneity,1650,O
.,1650,O
The,1651,O
enzyme,1651,O
is,1651,O
a,1651,O
non-covalent,1651,O
homodimer,1651,O
in,1651,O
solution,1651,O
and,1651,O
requires,1651,O
divalent,1651,O
cations,1651,O
Mg,1651,B-CHEMICAL
(,1651,I-CHEMICAL
2+,1651,I-CHEMICAL
),1651,I-CHEMICAL
",",1651,O
Ca,1651,B-CHEMICAL
(,1651,I-CHEMICAL
2+,1651,I-CHEMICAL
),1651,I-CHEMICAL
or,1651,O
Mn,1651,B-CHEMICAL
(,1651,I-CHEMICAL
2+,1651,I-CHEMICAL
),1651,I-CHEMICAL
for,1651,O
activity,1651,O
but,1651,O
not,1651,O
for,1651,O
dimerization,1651,O
.,1651,O
In,1652,O
addition,1652,O
to,1652,O
the,1652,O
racemization,1652,O
it,1652,O
also,1652,O
catalyzes,1652,O
specific,1652,O
elimination,1652,O
of,1652,O
L-Ser,1652,B-CHEMICAL
to,1652,O
pyruvate,1652,B-CHEMICAL
.,1652,O
D-Serine,1653,B-CHEMICAL
is,1653,O
eliminated,1653,O
much,1653,O
less,1653,O
efficiently,1653,O
.,1653,O
Both,1654,O
L-serine,1654,B-CHEMICAL
racemization,1654,O
and,1654,O
elimination,1654,O
activities,1654,O
of,1654,O
serine,1654,B-CHEMICAL
racemase,1654,O
are,1654,O
of,1654,O
comparable,1654,O
magnitude,1654,O
",",1654,O
display,1654,O
alkaline,1654,B-CHEMICAL
pH,1654,O
optimum,1654,O
and,1654,O
are,1654,O
negligible,1654,O
below,1654,O
pH,1654,O
6.5,1654,O
.,1654,O
Ankyrin,1655,B-GENE-N
repeat,1655,O
and,1655,O
suppressors,1655,O
of,1655,O
cytokine,1655,B-GENE-N
signaling,1655,I-GENE-N
box,1655,I-GENE-N
protein,1655,I-GENE-N
asb-9,1655,B-GENE-Y
targets,1655,O
creatine,1655,B-GENE-Y
kinase,1655,I-GENE-Y
B,1655,I-GENE-Y
for,1655,O
degradation,1655,O
.,1655,O
The,1656,O
suppressors,1656,B-GENE-N
of,1656,I-GENE-N
cytokine,1656,I-GENE-N
signaling,1656,I-GENE-N
(,1656,I-GENE-N
SOCS,1656,I-GENE-N
),1656,I-GENE-N
proteins,1656,I-GENE-N
inhibit,1656,O
cytokine,1656,B-GENE-N
action,1656,O
by,1656,O
direct,1656,O
interaction,1656,O
with,1656,O
Janus,1656,B-GENE-N
kinases,1656,I-GENE-N
or,1656,O
activated,1656,O
cytokine,1656,B-GENE-N
receptors,1656,I-GENE-N
.,1656,O
In,1657,O
addition,1657,O
to,1657,O
the,1657,O
N-terminal,1657,B-CHEMICAL
and,1657,O
Src,1657,B-GENE-N
homology,1657,I-GENE-N
2,1657,I-GENE-N
domains,1657,I-GENE-N
that,1657,O
mediate,1657,O
these,1657,O
interactions,1657,O
",",1657,O
SOCS,1657,B-GENE-N
proteins,1657,O
contain,1657,O
a,1657,O
C-terminal,1657,B-CHEMICAL
SOCS,1657,B-GENE-N
box,1657,I-GENE-N
.,1657,O
DNA,1658,O
data,1658,O
base,1658,O
searches,1658,O
have,1658,O
identified,1658,O
a,1658,O
number,1658,O
of,1658,O
other,1658,O
protein,1658,O
families,1658,O
that,1658,O
possess,1658,O
a,1658,O
SOCS,1658,B-GENE-N
box,1658,I-GENE-N
",",1658,O
of,1658,O
which,1658,O
the,1658,O
ankyrin,1658,B-GENE-N
repeat,1658,O
and,1658,O
SOCS,1658,B-GENE-N
box-containing,1658,O
(,1658,O
Asb,1658,B-GENE-N
),1658,O
proteins,1658,O
constitute,1658,O
the,1658,O
largest,1658,O
.,1658,O
Although,1659,O
it,1659,O
is,1659,O
known,1659,O
that,1659,O
the,1659,O
SOCS,1659,B-GENE-N
proteins,1659,O
are,1659,O
involved,1659,O
in,1659,O
the,1659,O
negative,1659,O
regulation,1659,O
of,1659,O
cytokine,1659,B-GENE-N
signaling,1659,O
",",1659,O
the,1659,O
biological,1659,O
and,1659,O
biochemical,1659,O
functions,1659,O
of,1659,O
the,1659,O
Asbs,1659,B-GENE-N
are,1659,O
largely,1659,O
undefined,1659,O
.,1659,O
Using,1660,O
a,1660,O
proteomics,1660,O
approach,1660,O
",",1660,O
we,1660,O
demonstrate,1660,O
that,1660,O
creatine,1660,B-GENE-Y
kinase,1660,I-GENE-Y
B,1660,I-GENE-Y
(,1660,O
CKB,1660,B-GENE-Y
),1660,O
interacts,1660,O
with,1660,O
Asb-9,1660,B-GENE-Y
in,1660,O
a,1660,O
specific,1660,O
",",1660,O
SOCS,1660,B-GENE-N
box-independent,1660,O
manner,1660,O
.,1660,O
This,1661,O
interaction,1661,O
increases,1661,O
the,1661,O
polyubiquitylation,1661,O
of,1661,O
CKB,1661,B-GENE-Y
and,1661,O
decreases,1661,O
total,1661,O
CKB,1661,B-GENE-Y
levels,1661,O
within,1661,O
the,1661,O
cell,1661,O
.,1661,O
The,1662,O
targeting,1662,O
of,1662,O
CKB,1662,B-GENE-Y
for,1662,O
degradation,1662,O
by,1662,O
Asb-9,1662,B-GENE-Y
was,1662,O
primarily,1662,O
SOCS,1662,B-GENE-N
box-dependent,1662,O
and,1662,O
suggests,1662,O
that,1662,O
Asb-9,1662,B-GENE-Y
acts,1662,O
as,1662,O
a,1662,O
specific,1662,O
ubiquitin,1662,B-GENE-N
ligase,1662,I-GENE-N
regulating,1662,O
levels,1662,O
of,1662,O
this,1662,O
evolutionarily,1662,O
conserved,1662,O
enzyme,1662,O
.,1662,O
Tamoxifen,1663,B-CHEMICAL
and,1663,O
fluoxymesterone,1663,B-CHEMICAL
versus,1663,O
tamoxifen,1663,B-CHEMICAL
and,1663,O
danazol,1663,B-CHEMICAL
in,1663,O
metastatic,1663,O
breast,1663,O
cancer,1663,O
--,1663,O
a,1663,O
randomized,1663,O
study,1663,O
.,1663,O
A,1664,O
prospective,1664,O
randomized,1664,O
trial,1664,O
of,1664,O
tamoxifen,1664,B-CHEMICAL
and,1664,O
fluoxymesterone,1664,B-CHEMICAL
versus,1664,O
tamoxifen,1664,B-CHEMICAL
and,1664,O
danazol,1664,B-CHEMICAL
in,1664,O
metastatic,1664,O
breast,1664,O
cancer,1664,O
was,1664,O
conducted,1664,O
from,1664,O
December,1664,O
1980,1664,O
to,1664,O
September,1664,O
1985,1664,O
.,1664,O
Patients,1665,O
were,1665,O
eligible,1665,O
regardless,1665,O
of,1665,O
site,1665,O
of,1665,O
disease,1665,O
",",1665,O
estrogen,1665,B-GENE-Y
receptor,1665,I-GENE-Y
status,1665,O
",",1665,O
or,1665,O
age,1665,O
.,1665,O
Sixty-two,1666,O
of,1666,O
sixty-three,1666,O
randomized,1666,O
patients,1666,O
were,1666,O
evaluable,1666,O
for,1666,O
response,1666,O
.,1666,O
Overall,1667,O
response,1667,O
for,1667,O
tamoxifen,1667,B-CHEMICAL
and,1667,O
fluoxymesterone,1667,B-CHEMICAL
was,1667,O
11,1667,O
%,1667,O
with,1667,O
61,1667,O
%,1667,O
stabilization,1667,O
of,1667,O
disease,1667,O
",",1667,O
versus,1667,O
12,1667,O
%,1667,O
response,1667,O
rate,1667,O
for,1667,O
tamoxifen,1667,B-CHEMICAL
and,1667,O
danazol,1667,B-CHEMICAL
with,1667,O
59,1667,O
%,1667,O
stabilization,1667,O
.,1667,O
Toxicities,1668,O
with,1668,O
tamoxifen,1668,B-CHEMICAL
and,1668,O
fluoxymesterone,1668,B-CHEMICAL
were,1668,O
greater,1668,O
with,1668,O
an,1668,O
increase,1668,O
in,1668,O
masculinization,1668,O
.,1668,O
We,1669,O
conclude,1669,O
that,1669,O
the,1669,O
response,1669,O
rates,1669,O
to,1669,O
the,1669,O
combinations,1669,O
of,1669,O
tamoxifen,1669,B-CHEMICAL
and,1669,O
fluoxymesterone,1669,B-CHEMICAL
or,1669,O
tamoxifen,1669,B-CHEMICAL
and,1669,O
danazol,1669,B-CHEMICAL
reported,1669,O
are,1669,O
equivalent,1669,O
in,1669,O
this,1669,O
study,1669,O
but,1669,O
that,1669,O
the,1669,O
increased,1669,O
toxicity,1669,O
with,1669,O
tamoxifen,1669,B-CHEMICAL
and,1669,O
fluoxymesterone,1669,B-CHEMICAL
would,1669,O
make,1669,O
tamoxifen,1669,B-CHEMICAL
and,1669,O
danazol,1669,B-CHEMICAL
the,1669,O
treatment,1669,O
of,1669,O
choice,1669,O
if,1669,O
a,1669,O
combination,1669,O
were,1669,O
to,1669,O
be,1669,O
used,1669,O
.,1669,O
Effect,1670,O
of,1670,O
quercetin-rich,1670,B-CHEMICAL
onion,1670,O
peel,1670,O
extracts,1670,O
on,1670,O
arterial,1670,O
thrombosis,1670,O
in,1670,O
rats,1670,O
.,1670,O
The,1671,O
aim,1671,O
of,1671,O
this,1671,O
study,1671,O
was,1671,O
to,1671,O
examine,1671,O
whether,1671,O
oral,1671,O
supplementation,1671,O
of,1671,O
quercetin-rich,1671,B-CHEMICAL
onion,1671,O
peel,1671,O
extract,1671,O
(,1671,O
OPE,1671,O
),1671,O
influences,1671,O
blood,1671,O
coagulation,1671,O
and,1671,O
arterial,1671,O
thrombosis,1671,O
in,1671,O
Sprague-Dawley,1671,O
(,1671,O
SD,1671,O
),1671,O
rats,1671,O
.,1671,O
24,1672,O
male,1672,O
rats,1672,O
",",1672,O
5weeks,1672,O
old,1672,O
",",1672,O
were,1672,O
divided,1672,O
into,1672,O
three,1672,O
groups,1672,O
with,1672,O
different,1672,O
diets,1672,O
(,1672,O
C,1672,O
:,1672,O
control,1672,O
",",1672,O
2mg,1672,O
OPE,1672,O
:,1672,O
chow,1672,O
diet,1672,O
with,1672,O
2mg,1672,O
OPE,1672,O
supplementation,1672,O
",",1672,O
10mg,1672,O
OPE,1672,O
:,1672,O
chow,1672,O
diet,1672,O
with,1672,O
10mg,1672,O
OPE,1672,O
supplementation,1672,O
),1672,O
for,1672,O
6weeks,1672,O
.,1672,O
Blood,1673,O
coagulation,1673,O
parameters,1673,O
including,1673,O
prothrombin,1673,B-GENE-Y
time,1673,O
(,1673,O
PT,1673,O
),1673,O
",",1673,O
activated,1673,O
partial,1673,O
thromboplastin,1673,B-GENE-Y
time,1673,O
(,1673,O
aPTT,1673,O
),1673,O
and,1673,O
platelet,1673,O
aggregation,1673,O
were,1673,O
examined,1673,O
.,1673,O
The,1674,O
OPE,1674,O
did,1674,O
not,1674,O
affect,1674,O
blood,1674,O
cholesterol,1674,B-CHEMICAL
levels,1674,O
but,1674,O
significantly,1674,O
decreased,1674,O
blood,1674,O
triglyceride,1674,B-CHEMICAL
and,1674,O
glucose,1674,B-CHEMICAL
levels,1674,O
.,1674,O
PT,1675,O
",",1675,O
aPTT,1675,O
and,1675,O
platelet,1675,O
aggregation,1675,O
were,1675,O
not,1675,O
significantly,1675,O
different,1675,O
among,1675,O
all,1675,O
tested,1675,O
groups,1675,O
.,1675,O
However,1676,O
",",1676,O
in,1676,O
vivo,1676,O
arterial,1676,O
thrombosis,1676,O
was,1676,O
significantly,1676,O
delayed,1676,O
in,1676,O
groups,1676,O
that,1676,O
were,1676,O
fed,1676,O
2mg,1676,O
and,1676,O
10mg,1676,O
OPE,1676,O
diets,1676,O
compared,1676,O
to,1676,O
the,1676,O
control,1676,O
group,1676,O
.,1676,O
In,1677,O
addition,1677,O
",",1677,O
the,1677,O
OPE,1677,O
greatly,1677,O
diminished,1677,O
thrombin-induced,1677,B-GENE-Y
expression,1677,O
of,1677,O
tissue,1677,B-GENE-Y
factor,1677,I-GENE-Y
in,1677,O
human,1677,O
umbilical,1677,O
vein,1677,O
endothelial,1677,O
cells,1677,O
(,1677,O
HUVECs,1677,O
),1677,O
",",1677,O
a,1677,O
coagulation,1677,O
initiator,1677,O
.,1677,O
In,1678,O
addition,1678,O
",",1678,O
extracellular,1678,B-GENE-N
signal-regulated,1678,I-GENE-N
kinase,1678,I-GENE-N
(,1678,O
ERK,1678,B-GENE-N
),1678,O
and,1678,O
c-Jun,1678,B-GENE-Y
N-terminal,1678,I-GENE-Y
kinase,1678,I-GENE-Y
(,1678,O
JNK,1678,B-GENE-Y
),1678,O
signaling,1678,O
pathways,1678,O
activated,1678,O
by,1678,O
thrombin,1678,B-GENE-Y
treatment,1678,O
were,1678,O
prevented,1678,O
by,1678,O
the,1678,O
OPE,1678,O
pre-treatment,1678,O
.,1678,O
These,1679,O
results,1679,O
indicate,1679,O
that,1679,O
OPE,1679,O
may,1679,O
have,1679,O
anti-thrombotic,1679,O
effects,1679,O
through,1679,O
restricting,1679,O
the,1679,O
induced,1679,O
expression,1679,O
of,1679,O
tissue,1679,B-GENE-Y
factor,1679,I-GENE-Y
via,1679,O
down-regulating,1679,O
mitogen-activated,1679,B-GENE-N
protein,1679,I-GENE-N
kinase,1679,I-GENE-N
(,1679,O
MAPK,1679,B-GENE-N
),1679,O
activation,1679,O
upon,1679,O
coagulation,1679,O
stimulus,1679,O
",",1679,O
leading,1679,O
to,1679,O
the,1679,O
prolongation,1679,O
of,1679,O
time,1679,O
for,1679,O
arterial,1679,O
thrombosis,1679,O
.,1679,O
Thyroid,1680,B-GENE-N
hormone,1680,I-GENE-N
receptors/THR,1680,O
genes,1680,O
in,1680,O
human,1680,O
cancer,1680,O
.,1680,O
Thyroid,1681,B-CHEMICAL
hormone,1681,I-CHEMICAL
(,1681,O
triiodothyronine,1681,B-CHEMICAL
",",1681,O
T3,1681,O
),1681,O
is,1681,O
a,1681,O
pleiotropic,1681,O
regulator,1681,O
of,1681,O
growth,1681,O
",",1681,O
differentiation,1681,O
and,1681,O
tissue,1681,O
homeostasis,1681,O
in,1681,O
higher,1681,O
organisms,1681,O
that,1681,O
acts,1681,O
through,1681,O
the,1681,O
control,1681,O
of,1681,O
target,1681,O
gene,1681,O
expression,1681,O
.,1681,O
Most,1682,O
",",1682,O
if,1682,O
not,1682,O
all,1682,O
",",1682,O
major,1682,O
T3,1682,O
actions,1682,O
are,1682,O
mediated,1682,O
by,1682,O
specific,1682,O
high,1682,O
affinity,1682,O
nuclear,1682,B-GENE-N
receptors,1682,I-GENE-N
(,1682,O
TR,1682,B-GENE-N
),1682,O
which,1682,O
are,1682,O
encoded,1682,O
by,1682,O
two,1682,O
genes,1682,O
",",1682,O
THRA,1682,B-GENE-Y
and,1682,O
THRB,1682,B-GENE-Y
.,1682,O
Several,1683,O
TRalpha,1683,B-GENE-Y
and,1683,O
TRbeta,1683,B-GENE-Y
receptor,1683,O
isoforms,1683,O
are,1683,O
expressed,1683,O
.,1683,O
Abundant,1684,O
and,1684,O
contradictory,1684,O
literature,1684,O
exists,1684,O
on,1684,O
the,1684,O
relationship,1684,O
between,1684,O
circulating,1684,O
thyroid,1684,B-CHEMICAL
hormone,1684,I-CHEMICAL
levels,1684,O
",",1684,O
thyroid,1684,O
diseases,1684,O
and,1684,O
human,1684,O
cancer,1684,O
.,1684,O
In,1685,O
1986,1685,O
",",1685,O
a,1685,O
connection,1685,O
between,1685,O
TR,1685,B-GENE-N
and,1685,O
cancer,1685,O
became,1685,O
evident,1685,O
when,1685,O
the,1685,O
chicken,1685,B-GENE-Y
TRalpha1,1685,I-GENE-Y
was,1685,O
characterized,1685,O
as,1685,O
the,1685,O
c-erbA,1685,B-GENE-Y
proto-oncogene,1685,O
",",1685,O
the,1685,O
cellular,1685,O
counterpart,1685,O
of,1685,O
the,1685,O
retroviral,1685,O
v-erbA,1685,B-GENE-N
oncogene,1685,O
.,1685,O
V-erbA,1686,B-GENE-N
causes,1686,O
erythroleukemias,1686,O
and,1686,O
sarcomas,1686,O
in,1686,O
birds,1686,O
",",1686,O
and,1686,O
hepatocellular,1686,O
carcinomas,1686,O
in,1686,O
transgenic,1686,O
mice,1686,O
.,1686,O
In,1687,O
recent,1687,O
years,1687,O
",",1687,O
many,1687,O
studies,1687,O
have,1687,O
analyzed,1687,O
the,1687,O
presence,1687,O
of,1687,O
quantitative,1687,O
(,1687,O
abnormal,1687,O
levels,1687,O
),1687,O
or,1687,O
qualitative,1687,O
(,1687,O
mutations,1687,O
),1687,O
alterations,1687,O
in,1687,O
the,1687,O
expression,1687,O
of,1687,O
THR,1687,B-GENE-N
genes,1687,O
in,1687,O
different,1687,O
types,1687,O
of,1687,O
human,1687,O
neoplasias,1687,O
.,1687,O
While,1688,O
their,1688,O
role,1688,O
in,1688,O
tumor,1688,O
generation,1688,O
or,1688,O
progression,1688,O
is,1688,O
currently,1688,O
unclear,1688,O
",",1688,O
both,1688,O
gross,1688,O
chromosomal,1688,O
and,1688,O
minor,1688,O
mutations,1688,O
(,1688,O
deletions,1688,O
",",1688,O
aberrant,1688,O
splicing,1688,O
",",1688,O
point,1688,O
mutations,1688,O
),1688,O
and,1688,O
changes,1688,O
in,1688,O
the,1688,O
level,1688,O
of,1688,O
expression,1688,O
of,1688,O
THRA,1688,B-GENE-Y
and,1688,O
THRB,1688,B-GENE-Y
genes,1688,O
have,1688,O
been,1688,O
found,1688,O
.,1688,O
Together,1689,O
with,1689,O
other,1689,O
in,1689,O
vitro,1689,O
data,1689,O
indicating,1689,O
connections,1689,O
between,1689,O
TR,1689,B-GENE-N
and,1689,O
p53,1689,B-GENE-Y
",",1689,O
Rb,1689,B-GENE-Y
",",1689,O
cyclin,1689,B-GENE-N
D,1689,I-GENE-N
and,1689,O
other,1689,O
cell,1689,O
cycle,1689,O
regulators,1689,O
and,1689,O
oncogenes,1689,O
",",1689,O
these,1689,O
results,1689,O
suggest,1689,O
that,1689,O
THRA,1689,B-GENE-Y
and,1689,O
THRB,1689,B-GENE-Y
may,1689,O
be,1689,O
involved,1689,O
in,1689,O
human,1689,O
cancer,1689,O
.,1689,O
Warfarin,1690,B-CHEMICAL
dose,1690,O
and,1690,O
the,1690,O
pharmacogenomics,1690,O
of,1690,O
CYP2C9,1690,B-GENE-Y
and,1690,O
VKORC1,1690,B-GENE-Y
-,1690,O
rationale,1690,O
and,1690,O
perspectives,1690,O
.,1690,O
Warfarin,1691,B-CHEMICAL
is,1691,O
the,1691,O
most,1691,O
widely,1691,O
prescribed,1691,O
oral,1691,O
anticoagulant,1691,O
",",1691,O
but,1691,O
there,1691,O
is,1691,O
greater,1691,O
than,1691,O
10-fold,1691,O
interindividual,1691,O
variability,1691,O
in,1691,O
the,1691,O
dose,1691,O
required,1691,O
to,1691,O
attain,1691,O
a,1691,O
therapeutic,1691,O
response,1691,O
.,1691,O
Information,1692,O
from,1692,O
pharmacogenomics,1692,O
",",1692,O
the,1692,O
study,1692,O
of,1692,O
the,1692,O
interaction,1692,O
of,1692,O
an,1692,O
individual,1692,O
's,1692,O
genotype,1692,O
and,1692,O
drug,1692,O
response,1692,O
",",1692,O
can,1692,O
help,1692,O
optimize,1692,O
drug,1692,O
efficacy,1692,O
while,1692,O
minimizing,1692,O
adverse,1692,O
drug,1692,O
reactions,1692,O
.,1692,O
Pharmacogenetic,1693,O
analysis,1693,O
of,1693,O
two,1693,O
genes,1693,O
",",1693,O
the,1693,O
warfarin,1693,B-CHEMICAL
metabolic,1693,O
enzyme,1693,O
CYP2C9,1693,B-GENE-Y
and,1693,O
warfarin,1693,B-CHEMICAL
target,1693,O
enzyme,1693,O
",",1693,O
vitamin,1693,B-GENE-Y
K,1693,I-GENE-Y
epoxide,1693,I-GENE-Y
reductase,1693,I-GENE-Y
complex,1693,I-GENE-Y
1,1693,I-GENE-Y
VKORC1,1693,B-GENE-Y
",",1693,O
confirmed,1693,O
their,1693,O
influence,1693,O
on,1693,O
warfarin,1693,B-CHEMICAL
maintenance,1693,O
dose,1693,O
.,1693,O
Possession,1694,O
of,1694,O
CYP2C9,1694,B-GENE-Y
*,1694,O
2,1694,O
or,1694,O
CYP2C9,1694,B-GENE-Y
*,1694,O
3,1694,O
variant,1694,O
alleles,1694,O
",",1694,O
which,1694,O
result,1694,O
in,1694,O
decreased,1694,O
enzyme,1694,O
activity,1694,O
",",1694,O
is,1694,O
associated,1694,O
with,1694,O
a,1694,O
significant,1694,O
decrease,1694,O
in,1694,O
the,1694,O
mean,1694,O
warfarin,1694,B-CHEMICAL
dose,1694,O
.,1694,O
Several,1695,O
single,1695,O
nucleotide,1695,B-CHEMICAL
polymorphisms,1695,O
(,1695,O
SNPs,1695,O
),1695,O
in,1695,O
VKORC1,1695,B-GENE-Y
are,1695,O
associated,1695,O
with,1695,O
warfarin,1695,B-CHEMICAL
dose,1695,O
across,1695,O
the,1695,O
normal,1695,O
dose,1695,O
range,1695,O
.,1695,O
Haplotypes,1696,O
based,1696,O
on,1696,O
these,1696,O
SNPs,1696,O
explain,1696,O
a,1696,O
large,1696,O
fraction,1696,O
of,1696,O
the,1696,O
interindividual,1696,O
variation,1696,O
in,1696,O
warfarin,1696,B-CHEMICAL
dose,1696,O
",",1696,O
and,1696,O
VKORC1,1696,B-GENE-Y
has,1696,O
an,1696,O
approximately,1696,O
three-fold,1696,O
greater,1696,O
effect,1696,O
than,1696,O
CYP2C9,1696,B-GENE-Y
.,1696,O
Algorithms,1697,O
incorporating,1697,O
genetic,1697,O
(,1697,O
CYP2C9,1697,B-GENE-Y
and,1697,O
VKORC1,1697,B-GENE-Y
),1697,O
",",1697,O
demographic,1697,O
",",1697,O
and,1697,O
clinical,1697,O
factors,1697,O
to,1697,O
estimate,1697,O
the,1697,O
warfarin,1697,B-CHEMICAL
dosage,1697,O
",",1697,O
could,1697,O
potentially,1697,O
minimize,1697,O
the,1697,O
risk,1697,O
of,1697,O
over,1697,O
dose,1697,O
during,1697,O
warfarin,1697,B-CHEMICAL
induction,1697,O
.,1697,O
Pseudoephedrine,1698,B-CHEMICAL
inhibits,1698,O
T-cell,1698,O
activation,1698,O
by,1698,O
targeting,1698,O
NF-kappaB,1698,B-GENE-N
",",1698,O
NFAT,1698,B-GENE-N
and,1698,O
AP-1,1698,B-GENE-Y
signaling,1698,O
pathways,1698,O
.,1698,O
Pseudoephedrine,1699,B-CHEMICAL
(,1699,O
PSE,1699,B-CHEMICAL
),1699,O
is,1699,O
a,1699,O
stereoisomer,1699,O
of,1699,O
ephedrine,1699,B-CHEMICAL
that,1699,O
is,1699,O
commonly,1699,O
used,1699,O
as,1699,O
a,1699,O
nasal,1699,O
decongestant,1699,O
in,1699,O
combination,1699,O
with,1699,O
other,1699,O
anti-inflammatory,1699,O
drugs,1699,O
for,1699,O
the,1699,O
symptomatic,1699,O
treatment,1699,O
of,1699,O
some,1699,O
common,1699,O
pathologies,1699,O
such,1699,O
as,1699,O
common,1699,O
cold,1699,O
.,1699,O
Herein,1700,O
",",1700,O
we,1700,O
describe,1700,O
for,1700,O
the,1700,O
first,1700,O
time,1700,O
the,1700,O
effects,1700,O
of,1700,O
PSE,1700,B-CHEMICAL
on,1700,O
T-cell,1700,O
activation,1700,O
events,1700,O
.,1700,O
We,1701,O
found,1701,O
that,1701,O
PSE,1701,B-CHEMICAL
inhibits,1701,O
interleukin-2,1701,B-GENE-Y
(,1701,O
IL-2,1701,B-GENE-Y
),1701,O
and,1701,O
tumor,1701,B-GENE-Y
necrosis,1701,I-GENE-Y
factor,1701,I-GENE-Y
(,1701,I-GENE-Y
TNF,1701,I-GENE-Y
),1701,I-GENE-Y
alpha-gene,1701,O
transcription,1701,O
in,1701,O
stimulated,1701,O
Jurkat,1701,O
cells,1701,O
",",1701,O
a,1701,O
human,1701,O
T-cell,1701,O
leukemia,1701,O
cell,1701,O
line,1701,O
.,1701,O
To,1702,O
further,1702,O
characterize,1702,O
the,1702,O
inhibitory,1702,O
mechanisms,1702,O
of,1702,O
PSE,1702,B-CHEMICAL
at,1702,O
the,1702,O
transcriptional,1702,O
level,1702,O
",",1702,O
we,1702,O
examined,1702,O
the,1702,O
transcriptional,1702,O
activities,1702,O
of,1702,O
nuclear,1702,B-GENE-N
factor,1702,I-GENE-N
kappa,1702,I-GENE-N
B,1702,I-GENE-N
(,1702,O
NF-kappaB,1702,B-GENE-N
),1702,O
",",1702,O
nuclear,1702,B-GENE-N
factor,1702,I-GENE-N
of,1702,I-GENE-N
activated,1702,I-GENE-N
T,1702,I-GENE-N
cells,1702,I-GENE-N
(,1702,O
NFAT,1702,B-GENE-N
),1702,O
",",1702,O
and,1702,O
activator,1702,B-GENE-Y
protein-1,1702,I-GENE-Y
(,1702,O
AP-1,1702,B-GENE-Y
),1702,O
transcription,1702,O
factors,1702,O
and,1702,O
found,1702,O
that,1702,O
PSE,1702,B-CHEMICAL
inhibited,1702,O
NF-kappaB-dependent,1702,B-GENE-N
transcriptional,1702,O
activity,1702,O
without,1702,O
affecting,1702,O
either,1702,O
the,1702,O
phosphorylation,1702,O
",",1702,O
the,1702,O
degradation,1702,O
of,1702,O
the,1702,O
cytoplasmic,1702,O
NF-kappaB,1702,B-GENE-Y
inhibitory,1702,I-GENE-Y
protein,1702,I-GENE-Y
",",1702,O
IkappaBalpha,1702,B-GENE-Y
or,1702,O
the,1702,O
DNA-binding,1702,O
activity,1702,O
.,1702,O
However,1703,O
",",1703,O
phosphorylation,1703,O
of,1703,O
the,1703,O
p65/RelA,1703,B-GENE-Y
subunit,1703,O
was,1703,O
clearly,1703,O
inhibited,1703,O
by,1703,O
PSE,1703,B-CHEMICAL
in,1703,O
stimulated,1703,O
cells,1703,O
.,1703,O
In,1704,O
addition,1704,O
",",1704,O
PSE,1704,B-CHEMICAL
inhibited,1704,O
the,1704,O
transcriptional,1704,O
activity,1704,O
of,1704,O
NFAT,1704,B-GENE-N
without,1704,O
interfering,1704,O
with,1704,O
the,1704,O
calcium-induced,1704,B-CHEMICAL
NFAT,1704,B-GENE-N
dephosphorylation,1704,O
event,1704,O
",",1704,O
which,1704,O
represents,1704,O
the,1704,O
major,1704,O
signaling,1704,O
pathway,1704,O
for,1704,O
its,1704,O
activation,1704,O
.,1704,O
NFAT,1705,B-GENE-N
cooperates,1705,O
with,1705,O
c-Jun,1705,B-GENE-Y
",",1705,O
a,1705,O
compound,1705,O
of,1705,O
the,1705,O
AP-1,1705,B-GENE-Y
complex,1705,O
",",1705,O
to,1705,O
activate,1705,O
target,1705,O
genes,1705,O
",",1705,O
and,1705,O
we,1705,O
also,1705,O
found,1705,O
that,1705,O
PSE,1705,B-CHEMICAL
inhibited,1705,O
both,1705,O
JNK,1705,B-GENE-N
activation,1705,O
and,1705,O
AP-1,1705,B-GENE-Y
transcriptional,1705,O
activity,1705,O
.,1705,O
These,1706,O
findings,1706,O
provide,1706,O
new,1706,O
mechanistic,1706,O
insights,1706,O
into,1706,O
the,1706,O
potential,1706,O
immunomodulatory,1706,O
activities,1706,O
of,1706,O
PSE,1706,B-CHEMICAL
and,1706,O
highlight,1706,O
their,1706,O
potential,1706,O
in,1706,O
designing,1706,O
novel,1706,O
therapeutic,1706,O
strategies,1706,O
to,1706,O
manage,1706,O
inflammatory,1706,O
diseases,1706,O
.,1706,O
Diethylcarbamazine,1707,B-CHEMICAL
activity,1707,O
against,1707,O
Brugia,1707,O
malayi,1707,O
microfilariae,1707,O
is,1707,O
dependent,1707,O
on,1707,O
inducible,1707,B-GENE-Y
nitric-oxide,1707,I-GENE-Y
synthase,1707,I-GENE-Y
and,1707,O
the,1707,O
cyclooxygenase,1707,B-GENE-N
pathway,1707,O
.,1707,O
BACKGROUND,1708,O
:,1708,O
Diethylcarbamazine,1708,B-CHEMICAL
(,1708,O
DEC,1708,B-CHEMICAL
),1708,O
has,1708,O
been,1708,O
used,1708,O
for,1708,O
many,1708,O
years,1708,O
in,1708,O
the,1708,O
treatment,1708,O
of,1708,O
human,1708,O
lymphatic,1708,O
filariasis,1708,O
.,1708,O
Its,1709,O
mode,1709,O
of,1709,O
action,1709,O
is,1709,O
not,1709,O
well,1709,O
understood,1709,O
",",1709,O
but,1709,O
it,1709,O
is,1709,O
known,1709,O
to,1709,O
interact,1709,O
with,1709,O
the,1709,O
arachidonic,1709,B-CHEMICAL
acid,1709,I-CHEMICAL
pathway,1709,O
.,1709,O
Here,1710,O
we,1710,O
have,1710,O
investigated,1710,O
the,1710,O
contribution,1710,O
of,1710,O
the,1710,O
nitric,1710,B-CHEMICAL
oxide,1710,I-CHEMICAL
and,1710,O
cyclooxygenase,1710,B-GENE-N
(,1710,O
COX,1710,B-GENE-N
),1710,O
pathways,1710,O
to,1710,O
the,1710,O
activity,1710,O
of,1710,O
DEC,1710,B-CHEMICAL
against,1710,O
B.,1710,O
malayi,1710,O
microfilariae,1710,O
in,1710,O
mice,1710,O
.,1710,O
METHODS,1711,O
:,1711,O
B.,1711,O
malayi,1711,O
microfilariae,1711,O
were,1711,O
injected,1711,O
intravenously,1711,O
into,1711,O
mice,1711,O
and,1711,O
parasitaemia,1711,O
was,1711,O
measured,1711,O
24,1711,O
hours,1711,O
later,1711,O
.,1711,O
DEC,1712,B-CHEMICAL
was,1712,O
then,1712,O
administered,1712,O
to,1712,O
BALB/c,1712,O
mice,1712,O
with,1712,O
and,1712,O
without,1712,O
pre-treatment,1712,O
with,1712,O
indomethacin,1712,B-CHEMICAL
or,1712,O
dexamethasone,1712,B-CHEMICAL
and,1712,O
the,1712,O
parasitaemia,1712,O
monitored,1712,O
.,1712,O
To,1713,O
investigate,1713,O
a,1713,O
role,1713,O
for,1713,O
inducible,1713,O
nitric,1713,B-CHEMICAL
oxide,1713,I-CHEMICAL
in,1713,O
DEC,1713,O
's,1713,O
activity,1713,O
",",1713,O
DEC,1713,B-CHEMICAL
and,1713,O
ivermectin,1713,B-CHEMICAL
were,1713,O
administered,1713,O
to,1713,O
microfilaraemic,1713,O
iNOS-/-,1713,B-GENE-Y
mice,1713,O
and,1713,O
their,1713,O
background,1713,O
strain,1713,O
(,1713,O
129/SV,1713,O
),1713,O
.,1713,O
Western,1714,O
blot,1714,O
analysis,1714,O
was,1714,O
used,1714,O
to,1714,O
determine,1714,O
any,1714,O
effect,1714,O
of,1714,O
DEC,1714,B-CHEMICAL
on,1714,O
the,1714,O
production,1714,O
of,1714,O
COX,1714,B-GENE-N
and,1714,O
inducible,1714,O
nitric-oxide,1714,B-GENE-Y
synthase,1714,I-GENE-Y
(,1714,O
iNOS,1714,B-GENE-Y
),1714,O
proteins,1714,O
.,1714,O
RESULTS,1715,O
:,1715,O
DEC,1715,O
administered,1715,O
alone,1715,O
to,1715,O
BALB/c,1715,O
mice,1715,O
resulted,1715,O
in,1715,O
a,1715,O
rapid,1715,O
and,1715,O
profound,1715,O
reduction,1715,O
in,1715,O
circulating,1715,O
microfilariae,1715,O
within,1715,O
five,1715,O
minutes,1715,O
of,1715,O
treatment,1715,O
.,1715,O
Microfilarial,1716,O
levels,1716,O
began,1716,O
to,1716,O
recover,1716,O
after,1716,O
24,1716,O
hours,1716,O
and,1716,O
returned,1716,O
to,1716,O
near,1716,O
pre-treatment,1716,O
levels,1716,O
two,1716,O
weeks,1716,O
later,1716,O
",",1716,O
suggesting,1716,O
that,1716,O
the,1716,O
sequestration,1716,O
of,1716,O
microfilariae,1716,O
occurs,1716,O
independently,1716,O
of,1716,O
parasite,1716,O
killing,1716,O
.,1716,O
Pre-treatment,1717,O
of,1717,O
animals,1717,O
with,1717,O
dexamethasone,1717,B-CHEMICAL
or,1717,O
indomethacin,1717,B-CHEMICAL
reduced,1717,O
DEC,1717,O
's,1717,O
efficacy,1717,O
by,1717,O
almost,1717,O
90,1717,O
%,1717,O
or,1717,O
56,1717,O
%,1717,O
",",1717,O
respectively,1717,O
",",1717,O
supporting,1717,O
a,1717,O
role,1717,O
for,1717,O
the,1717,O
arachidonic,1717,B-CHEMICAL
acid,1717,I-CHEMICAL
and,1717,O
cyclooxygenase,1717,B-GENE-N
pathways,1717,O
in,1717,O
vivo,1717,O
.,1717,O
Furthermore,1718,O
",",1718,O
experiments,1718,O
showed,1718,O
that,1718,O
treatment,1718,O
with,1718,O
DEC,1718,B-CHEMICAL
results,1718,O
in,1718,O
a,1718,O
reduction,1718,O
in,1718,O
the,1718,O
amount,1718,O
of,1718,O
COX-1,1718,B-GENE-Y
protein,1718,O
in,1718,O
peritoneal,1718,O
exudate,1718,O
cells,1718,O
.,1718,O
Additionally,1719,O
",",1719,O
in,1719,O
iNOS-/-,1719,B-GENE-Y
mice,1719,O
infected,1719,O
with,1719,O
B.,1719,O
malayi,1719,O
microfilariae,1719,O
",",1719,O
DEC,1719,B-CHEMICAL
showed,1719,O
no,1719,O
activity,1719,O
",",1719,O
whereas,1719,O
the,1719,O
efficacy,1719,O
of,1719,O
another,1719,O
antifilarial,1719,O
drug,1719,O
",",1719,O
ivermectin,1719,B-CHEMICAL
",",1719,O
was,1719,O
unaffected,1719,O
.,1719,O
CONCLUSION,1720,O
:,1720,O
These,1720,O
results,1720,O
confirm,1720,O
the,1720,O
important,1720,O
role,1720,O
of,1720,O
the,1720,O
arachidonic,1720,B-CHEMICAL
acid,1720,I-CHEMICAL
metabolic,1720,O
pathway,1720,O
in,1720,O
DEC,1720,O
's,1720,O
mechanism,1720,O
of,1720,O
action,1720,O
in,1720,O
vivo,1720,O
and,1720,O
show,1720,O
that,1720,O
in,1720,O
addition,1720,O
to,1720,O
its,1720,O
effects,1720,O
on,1720,O
the,1720,O
5-lipoxygenase,1720,B-GENE-Y
pathway,1720,O
",",1720,O
it,1720,O
targets,1720,O
the,1720,O
cyclooxygenase,1720,B-GENE-N
pathway,1720,O
and,1720,O
COX-1,1720,B-GENE-Y
.,1720,O
Moreover,1721,O
",",1721,O
we,1721,O
show,1721,O
for,1721,O
the,1721,O
first,1721,O
time,1721,O
that,1721,O
inducible,1721,O
nitric,1721,B-CHEMICAL
oxide,1721,I-CHEMICAL
is,1721,O
essential,1721,O
for,1721,O
the,1721,O
rapid,1721,O
sequestration,1721,O
of,1721,O
microfilariae,1721,O
by,1721,O
DEC,1721,B-CHEMICAL
.,1721,O
SUR-dependent,1722,B-GENE-Y
modulation,1722,O
of,1722,O
KATP,1722,B-GENE-N
channels,1722,I-GENE-N
by,1722,O
an,1722,O
N-terminal,1722,B-CHEMICAL
KIR6.2,1722,B-GENE-Y
peptide,1722,O
.,1722,O
Defining,1723,O
intersubunit,1723,O
gating,1723,O
interactions,1723,O
.,1723,O
Ntp,1724,O
and,1724,O
Ctp,1724,O
",",1724,O
synthetic,1724,O
peptides,1724,O
based,1724,O
on,1724,O
the,1724,O
N-,1724,B-CHEMICAL
and,1724,O
C-terminal,1724,B-CHEMICAL
sequences,1724,O
of,1724,O
K,1724,B-GENE-Y
(,1724,I-GENE-Y
IR,1724,I-GENE-Y
),1724,I-GENE-Y
6.0,1724,I-GENE-Y
",",1724,O
respectively,1724,O
",",1724,O
were,1724,O
used,1724,O
to,1724,O
probe,1724,O
gating,1724,O
of,1724,O
K,1724,B-GENE-Y
(,1724,I-GENE-Y
IR,1724,I-GENE-Y
),1724,I-GENE-Y
6.0/SUR,1724,O
K,1724,B-GENE-N
(,1724,I-GENE-N
ATP,1724,I-GENE-N
),1724,I-GENE-N
channels,1724,I-GENE-N
.,1724,O
Micromolar,1725,O
Ntp,1725,O
dose-dependently,1725,O
increased,1725,O
the,1725,O
mean,1725,O
open,1725,O
channel,1725,O
probability,1725,O
in,1725,O
ligand-free,1725,O
solution,1725,O
(,1725,O
P,1725,O
(,1725,O
O,1725,O
(,1725,O
max,1725,O
),1725,O
),1725,O
),1725,O
and,1725,O
attenuated,1725,O
the,1725,O
ATP,1725,B-CHEMICAL
inhibition,1725,O
of,1725,O
K,1725,B-GENE-Y
(,1725,I-GENE-Y
IR,1725,I-GENE-Y
),1725,I-GENE-Y
6.2/SUR1,1725,O
",",1725,O
but,1725,O
had,1725,O
no,1725,O
effect,1725,O
on,1725,O
homomeric,1725,O
K,1725,B-GENE-Y
(,1725,I-GENE-Y
IR,1725,I-GENE-Y
),1725,I-GENE-Y
6.2,1725,I-GENE-Y
channels,1725,O
.,1725,O
Ntp,1726,O
(,1726,O
up,1726,O
to,1726,O
approximately,1726,O
10,1726,O
(,1726,O
-4,1726,O
),1726,O
m,1726,O
),1726,O
did,1726,O
not,1726,O
affect,1726,O
significantly,1726,O
the,1726,O
mean,1726,O
open,1726,O
or,1726,O
``,1726,O
fast,1726,O
",",1726,O
'',1726,O
K,1726,B-CHEMICAL
(,1726,I-CHEMICAL
+,1726,I-CHEMICAL
),1726,I-CHEMICAL
driving,1726,O
force-dependent,1726,O
",",1726,O
intraburst,1726,O
closed,1726,O
times,1726,O
",",1726,O
verifying,1726,O
that,1726,O
Ntp,1726,O
selectively,1726,O
modulates,1726,O
the,1726,O
ratio,1726,O
of,1726,O
mean,1726,O
burst,1726,O
to,1726,O
interburst,1726,O
times,1726,O
.,1726,O
Ctp,1727,O
and,1727,O
Rnp,1727,O
",",1727,O
a,1727,O
randomized,1727,O
Ntp,1727,O
",",1727,O
had,1727,O
no,1727,O
effect,1727,O
",",1727,O
indicating,1727,O
that,1727,O
the,1727,O
effects,1727,O
of,1727,O
Ntp,1727,O
are,1727,O
structure,1727,O
specific,1727,O
.,1727,O
Ntp,1728,O
opened,1728,O
K,1728,B-GENE-Y
(,1728,I-GENE-Y
IR,1728,I-GENE-Y
),1728,I-GENE-Y
6.1/SUR1,1728,O
channels,1728,O
normally,1728,O
silent,1728,O
in,1728,O
the,1728,O
absence,1728,O
of,1728,O
stimulatory,1728,O
Mg,1728,O
(,1728,O
-,1728,O
),1728,O
nucleotide,1728,B-CHEMICAL
(,1728,I-CHEMICAL
s,1728,I-CHEMICAL
),1728,I-CHEMICAL
and,1728,O
attenuated,1728,O
the,1728,O
coupling,1728,O
of,1728,O
high-affinity,1728,O
sulfonylurea,1728,B-CHEMICAL
binding,1728,O
with,1728,O
K,1728,B-GENE-N
(,1728,I-GENE-N
ATP,1728,I-GENE-N
),1728,I-GENE-N
pore,1728,O
closure,1728,O
.,1728,O
These,1729,O
effects,1729,O
resemble,1729,O
those,1729,O
seen,1729,O
with,1729,O
N-terminal,1729,B-CHEMICAL
deletions,1729,O
(,1729,O
DeltaN,1729,O
),1729,O
of,1729,O
K,1729,B-GENE-Y
(,1729,I-GENE-Y
IR,1729,I-GENE-Y
),1729,I-GENE-Y
6.0,1729,I-GENE-Y
",",1729,O
and,1729,O
application,1729,O
of,1729,O
Ntp,1729,O
to,1729,O
DeltaNK,1729,B-GENE-N
(,1729,I-GENE-N
ATP,1729,I-GENE-N
),1729,I-GENE-N
channels,1729,I-GENE-N
decreased,1729,O
their,1729,O
P,1729,O
(,1729,O
O,1729,O
(,1729,O
max,1729,O
),1729,O
),1729,O
and,1729,O
apparent,1729,O
IC,1729,O
(,1729,O
50,1729,O
),1729,O
for,1729,O
ATP,1729,B-CHEMICAL
in,1729,O
the,1729,O
absence,1729,O
of,1729,O
Mg,1729,B-CHEMICAL
(,1729,I-CHEMICAL
2+,1729,I-CHEMICAL
),1729,I-CHEMICAL
.,1729,O
The,1730,O
results,1730,O
are,1730,O
consistent,1730,O
with,1730,O
a,1730,O
competition,1730,O
between,1730,O
Ntp,1730,O
and,1730,O
the,1730,O
endogenous,1730,O
N,1730,B-CHEMICAL
terminus,1730,O
for,1730,O
a,1730,O
site,1730,O
of,1730,O
interaction,1730,O
on,1730,O
the,1730,O
cytoplasmic,1730,O
face,1730,O
of,1730,O
the,1730,O
channel,1730,O
or,1730,O
with,1730,O
partial,1730,O
replacement,1730,O
of,1730,O
the,1730,O
deleted,1730,O
N,1730,B-CHEMICAL
terminus,1730,O
by,1730,O
Ntp,1730,O
",",1730,O
respectively,1730,O
.,1730,O
The,1731,O
K,1731,B-GENE-Y
(,1731,I-GENE-Y
IR,1731,I-GENE-Y
),1731,I-GENE-Y
N,1731,B-CHEMICAL
terminus,1731,O
and,1731,O
the,1731,O
TMD0-L0,1731,O
segment,1731,O
of,1731,O
SUR1,1731,B-GENE-Y
are,1731,O
known,1731,O
to,1731,O
control,1731,O
the,1731,O
P,1731,O
(,1731,O
O,1731,O
(,1731,O
max,1731,O
),1731,O
),1731,O
.,1731,O
The,1732,O
L0,1732,O
linker,1732,O
has,1732,O
been,1732,O
reported,1732,O
to,1732,O
be,1732,O
required,1732,O
for,1732,O
glibenclamide,1732,B-CHEMICAL
binding,1732,O
",",1732,O
and,1732,O
DeltaNK,1732,B-GENE-Y
(,1732,I-GENE-Y
IR,1732,I-GENE-Y
),1732,I-GENE-Y
6.2/SUR1,1732,O
channels,1732,O
exhibit,1732,O
reduced,1732,O
labeling,1732,O
of,1732,O
K,1732,B-GENE-Y
(,1732,I-GENE-Y
IR,1732,I-GENE-Y
),1732,I-GENE-Y
with,1732,O
(,1732,B-CHEMICAL
125,1732,I-CHEMICAL
),1732,I-CHEMICAL
I-azidoglibenclamide,1732,I-CHEMICAL
",",1732,O
implying,1732,O
that,1732,O
the,1732,O
K,1732,B-GENE-Y
(,1732,I-GENE-Y
IR,1732,I-GENE-Y
),1732,I-GENE-Y
N,1732,B-CHEMICAL
terminus,1732,O
and,1732,O
L0,1732,O
of,1732,O
SUR1,1732,B-GENE-Y
are,1732,O
in,1732,O
proximity,1732,O
.,1732,O
We,1733,O
hypothesize,1733,O
that,1733,O
L0,1733,O
interacts,1733,O
with,1733,O
the,1733,O
K,1733,B-GENE-Y
(,1733,I-GENE-Y
IR,1733,I-GENE-Y
),1733,I-GENE-Y
N,1733,B-CHEMICAL
terminus,1733,O
in,1733,O
ligand-inhibited,1733,O
K,1733,B-GENE-N
(,1733,I-GENE-N
ATP,1733,I-GENE-N
),1733,I-GENE-N
channels,1733,I-GENE-N
and,1733,O
put,1733,O
forward,1733,O
a,1733,O
model,1733,O
",",1733,O
based,1733,O
on,1733,O
the,1733,O
architecture,1733,O
of,1733,O
BtuCD,1733,B-GENE-N
",",1733,O
MsbA,1733,B-GENE-N
",",1733,O
and,1733,O
the,1733,O
KcsA,1733,B-GENE-N
channel,1733,O
",",1733,O
in,1733,O
which,1733,O
TMD0-L0,1733,O
links,1733,O
the,1733,O
MDR-like,1733,B-GENE-N
core,1733,O
of,1733,O
SUR,1733,B-GENE-Y
with,1733,O
the,1733,O
K,1733,B-GENE-Y
(,1733,I-GENE-Y
IR,1733,I-GENE-Y
),1733,I-GENE-Y
pore,1733,O
.,1733,O
Monocarboxylate,1734,B-GENE-N
transporters,1734,I-GENE-N
in,1734,O
the,1734,O
central,1734,O
nervous,1734,O
system,1734,O
:,1734,O
distribution,1734,O
",",1734,O
regulation,1734,O
and,1734,O
function,1734,O
.,1734,O
Monocarboxylate,1735,B-GENE-N
transporters,1735,I-GENE-N
(,1735,O
MCTs,1735,B-GENE-N
),1735,O
are,1735,O
proton-linked,1735,O
membrane,1735,O
carriers,1735,O
involved,1735,O
in,1735,O
the,1735,O
transport,1735,O
of,1735,O
monocarboxylates,1735,B-CHEMICAL
such,1735,O
as,1735,O
lactate,1735,B-CHEMICAL
",",1735,O
pyruvate,1735,B-CHEMICAL
",",1735,O
as,1735,O
well,1735,O
as,1735,O
ketone,1735,B-CHEMICAL
bodies,1735,O
.,1735,O
They,1736,O
belong,1736,O
to,1736,O
a,1736,O
larger,1736,O
family,1736,O
of,1736,O
transporters,1736,O
composed,1736,O
of,1736,O
14,1736,O
members,1736,O
in,1736,O
mammals,1736,O
based,1736,O
on,1736,O
sequence,1736,O
homologies,1736,O
.,1736,O
MCTs,1737,B-GENE-N
are,1737,O
found,1737,O
in,1737,O
various,1737,O
tissues,1737,O
including,1737,O
the,1737,O
brain,1737,O
where,1737,O
three,1737,O
isoforms,1737,O
",",1737,O
MCT1,1737,B-GENE-Y
",",1737,O
MCT2,1737,B-GENE-Y
and,1737,O
MCT4,1737,B-GENE-Y
",",1737,O
have,1737,O
been,1737,O
described,1737,O
.,1737,O
Each,1738,O
of,1738,O
these,1738,O
isoforms,1738,O
exhibits,1738,O
a,1738,O
distinct,1738,O
regional,1738,O
and,1738,O
cellular,1738,O
distribution,1738,O
in,1738,O
rodent,1738,O
brain,1738,O
.,1738,O
At,1739,O
the,1739,O
cellular,1739,O
level,1739,O
",",1739,O
MCT1,1739,B-GENE-Y
is,1739,O
expressed,1739,O
by,1739,O
endothelial,1739,O
cells,1739,O
of,1739,O
microvessels,1739,O
",",1739,O
by,1739,O
ependymocytes,1739,O
as,1739,O
well,1739,O
as,1739,O
by,1739,O
astrocytes,1739,O
.,1739,O
MCT4,1740,B-GENE-Y
expression,1740,O
appears,1740,O
to,1740,O
be,1740,O
specific,1740,O
for,1740,O
astrocytes,1740,O
.,1740,O
By,1741,O
contrast,1741,O
",",1741,O
the,1741,O
predominant,1741,O
neuronal,1741,O
monocarboxylate,1741,B-GENE-N
transporter,1741,I-GENE-N
is,1741,O
MCT2,1741,B-GENE-Y
.,1741,O
Interestingly,1742,O
",",1742,O
part,1742,O
of,1742,O
MCT2,1742,B-GENE-Y
immunoreactivity,1742,O
is,1742,O
located,1742,O
at,1742,O
postsynaptic,1742,O
sites,1742,O
",",1742,O
suggesting,1742,O
a,1742,O
particular,1742,O
role,1742,O
of,1742,O
monocarboxylates,1742,B-CHEMICAL
and,1742,O
their,1742,O
transporters,1742,O
in,1742,O
synaptic,1742,O
transmission,1742,O
.,1742,O
In,1743,O
addition,1743,O
to,1743,O
variation,1743,O
in,1743,O
expression,1743,O
during,1743,O
development,1743,O
and,1743,O
upon,1743,O
nutritional,1743,O
modifications,1743,O
",",1743,O
new,1743,O
data,1743,O
indicate,1743,O
that,1743,O
MCT,1743,B-GENE-N
expression,1743,O
is,1743,O
regulated,1743,O
at,1743,O
the,1743,O
translational,1743,O
level,1743,O
by,1743,O
neurotransmitters,1743,O
.,1743,O
Understanding,1744,O
how,1744,O
transport,1744,O
of,1744,O
monocarboxylates,1744,B-CHEMICAL
is,1744,O
regulated,1744,O
could,1744,O
be,1744,O
of,1744,O
particular,1744,O
importance,1744,O
not,1744,O
only,1744,O
for,1744,O
neuroenergetics,1744,O
but,1744,O
also,1744,O
for,1744,O
areas,1744,O
such,1744,O
as,1744,O
functional,1744,O
brain,1744,O
imaging,1744,O
",",1744,O
regulation,1744,O
of,1744,O
food,1744,O
intake,1744,O
and,1744,O
glucose,1744,B-CHEMICAL
homeostasis,1744,O
",",1744,O
or,1744,O
for,1744,O
central,1744,O
nervous,1744,O
system,1744,O
disorders,1744,O
such,1744,O
as,1744,O
ischaemia,1744,O
and,1744,O
neurodegenerative,1744,O
diseases,1744,O
.,1744,O
Lysine,1745,B-CHEMICAL
48-linked,1745,O
polyubiquitination,1745,O
of,1745,O
organic,1745,B-GENE-Y
anion,1745,I-GENE-Y
transporter-1,1745,I-GENE-Y
is,1745,O
essential,1745,O
for,1745,O
its,1745,O
protein,1745,B-GENE-N
kinase,1745,I-GENE-N
C-regulated,1745,O
endocytosis,1745,O
.,1745,O
Organic,1746,B-GENE-Y
anion,1746,I-GENE-Y
transporter-1,1746,I-GENE-Y
(,1746,O
OAT1,1746,B-GENE-Y
),1746,O
mediates,1746,O
the,1746,O
body,1746,O
's,1746,O
disposition,1746,O
of,1746,O
a,1746,O
diverse,1746,O
array,1746,O
of,1746,O
environmental,1746,O
toxins,1746,O
and,1746,O
clinically,1746,O
important,1746,O
drugs,1746,O
.,1746,O
Therefore,1747,O
",",1747,O
understanding,1747,O
the,1747,O
regulation,1747,O
of,1747,O
this,1747,O
transporter,1747,O
has,1747,O
profound,1747,O
clinical,1747,O
significance,1747,O
.,1747,O
We,1748,O
had,1748,O
previously,1748,O
established,1748,O
that,1748,O
OAT1,1748,B-GENE-Y
undergoes,1748,O
constitutive,1748,O
internalization,1748,O
from,1748,O
and,1748,O
recycling,1748,O
back,1748,O
to,1748,O
the,1748,O
cell,1748,O
surface,1748,O
and,1748,O
that,1748,O
acute,1748,O
activation,1748,O
of,1748,O
protein,1748,B-GENE-N
kinase,1748,I-GENE-N
C,1748,I-GENE-N
(,1748,O
PKC,1748,B-GENE-N
),1748,O
inhibits,1748,O
OAT1,1748,B-GENE-Y
activity,1748,O
by,1748,O
reducing,1748,O
OAT1,1748,B-GENE-Y
cell-surface,1748,O
expression,1748,O
through,1748,O
accelerating,1748,O
its,1748,O
internalization,1748,O
from,1748,O
cell,1748,O
surface,1748,O
to,1748,O
intracellular,1748,O
compartments,1748,O
.,1748,O
However,1749,O
",",1749,O
the,1749,O
underlying,1749,O
mechanisms,1749,O
are,1749,O
poorly,1749,O
understood,1749,O
.,1749,O
In,1750,O
the,1750,O
current,1750,O
study,1750,O
",",1750,O
we,1750,O
provide,1750,O
novel,1750,O
evidence,1750,O
that,1750,O
acute,1750,O
activation,1750,O
of,1750,O
PKC,1750,B-GENE-N
significantly,1750,O
enhances,1750,O
OAT1,1750,B-GENE-Y
ubiquitination,1750,O
both,1750,O
in,1750,O
vitro,1750,O
and,1750,O
ex,1750,O
vivo,1750,O
.,1750,O
We,1751,O
further,1751,O
show,1751,O
that,1751,O
ubiquitination,1751,O
of,1751,O
cell-surface,1751,O
OAT1,1751,B-GENE-Y
increases,1751,O
in,1751,O
cells,1751,O
transfected,1751,O
with,1751,O
dominant,1751,O
negative,1751,O
mutant,1751,O
of,1751,O
dynamin-2,1751,B-GENE-Y
",",1751,O
a,1751,O
maneuver,1751,O
blocking,1751,O
OAT1,1751,B-GENE-Y
internalization,1751,O
",",1751,O
which,1751,O
suggests,1751,O
that,1751,O
OAT1,1751,B-GENE-Y
ubiquitination,1751,O
proceeds,1751,O
before,1751,O
OAT1,1751,B-GENE-Y
internalization,1751,O
.,1751,O
Mass,1752,O
spectroscopy,1752,O
has,1752,O
revealed,1752,O
that,1752,O
ubiquitination,1752,O
of,1752,O
OAT1,1752,B-GENE-Y
consists,1752,O
of,1752,O
polyubiquitin,1752,O
chains,1752,O
",",1752,O
primarily,1752,O
through,1752,O
lysine,1752,B-CHEMICAL
48,1752,O
linkage,1752,O
.,1752,O
Transfection,1753,O
of,1753,O
cells,1753,O
with,1753,O
the,1753,O
dominant,1753,O
negative,1753,O
mutant,1753,O
of,1753,O
ubiquitin,1753,O
Ub-K48R,1753,O
",",1753,O
which,1753,O
prevents,1753,O
the,1753,O
formation,1753,O
of,1753,O
Lys48-linked,1753,B-CHEMICAL
polyubiquitin,1753,O
chains,1753,O
",",1753,O
abolishes,1753,O
PKC-stimulated,1753,B-GENE-N
OAT1,1753,B-GENE-Y
ubiquitination,1753,O
and,1753,O
internalization,1753,O
.,1753,O
Together,1754,O
",",1754,O
our,1754,O
findings,1754,O
demonstrate,1754,O
for,1754,O
the,1754,O
first,1754,O
time,1754,O
that,1754,O
Lys48-linked,1754,B-CHEMICAL
polyubiquitination,1754,O
is,1754,O
essential,1754,O
for,1754,O
PKC-regulated,1754,B-GENE-N
OAT1,1754,B-GENE-Y
trafficking,1754,O
.,1754,O
Differentiating,1755,O
the,1755,O
roles,1755,O
of,1755,O
mGlu2,1755,B-GENE-Y
and,1755,O
mGlu3,1755,B-GENE-Y
receptors,1755,O
using,1755,O
LY541850,1755,B-CHEMICAL
",",1755,O
an,1755,O
mGlu2,1755,B-GENE-Y
agonist/mGlu3,1755,O
antagonist,1755,O
.,1755,O
Despite,1756,O
the,1756,O
potential,1756,O
therapeutic,1756,O
relevance,1756,O
of,1756,O
group,1756,B-GENE-N
II,1756,I-GENE-N
metabotropic,1756,I-GENE-N
glutamate,1756,I-GENE-N
(,1756,I-GENE-N
mGlu,1756,I-GENE-N
),1756,I-GENE-N
receptors,1756,I-GENE-N
",",1756,O
there,1756,O
has,1756,O
been,1756,O
a,1756,O
lack,1756,O
of,1756,O
pharmacological,1756,O
tools,1756,O
for,1756,O
separating,1756,O
the,1756,O
roles,1756,O
of,1756,O
mGlu2,1756,B-GENE-Y
and,1756,O
mGlu3,1756,B-GENE-Y
receptor,1756,O
subtypes,1756,O
.,1756,O
LY541850,1757,B-CHEMICAL
was,1757,O
claimed,1757,O
from,1757,O
human,1757,B-GENE-N
mGlu,1757,I-GENE-N
receptors,1757,I-GENE-N
expressed,1757,O
in,1757,O
non-neuronal,1757,O
cells,1757,O
to,1757,O
be,1757,O
a,1757,O
selective,1757,O
orthosteric,1757,O
mGlu2,1757,B-GENE-Y
agonist,1757,O
and,1757,O
mGlu3,1757,B-GENE-Y
antagonist,1757,O
.,1757,O
We,1758,O
have,1758,O
verified,1758,O
this,1758,O
pharmacological,1758,O
profile,1758,O
of,1758,O
LY541850,1758,B-CHEMICAL
in,1758,O
hippocampal,1758,O
slices,1758,O
.,1758,O
Field,1759,O
excitatory,1759,O
post-synaptic,1759,O
potentials,1759,O
(,1759,O
fEPSPs,1759,O
),1759,O
evoked,1759,O
by,1759,O
stimulation,1759,O
of,1759,O
the,1759,O
temporo-ammonic,1759,O
path,1759,O
(,1759,O
TAP,1759,O
),1759,O
input,1759,O
to,1759,O
CA1,1759,O
stratum,1759,O
lacunosum,1759,O
moleculare,1759,O
(,1759,O
SLM,1759,O
),1759,O
were,1759,O
inhibited,1759,O
by,1759,O
LY541850,1759,B-CHEMICAL
in,1759,O
mGlu3-/-,1759,B-GENE-Y
mice,1759,O
(,1759,O
EC,1759,O
(,1759,O
50,1759,O
),1759,O
38,1759,O
nM,1759,O
),1759,O
and,1759,O
wild-type,1759,O
littermates,1759,O
(,1759,O
EC,1759,O
(,1759,O
50,1759,O
),1759,O
42,1759,O
nM,1759,O
),1759,O
to,1759,O
a,1759,O
similar,1759,O
extent,1759,O
but,1759,O
were,1759,O
not,1759,O
significantly,1759,O
affected,1759,O
in,1759,O
mGlu2-/-,1759,B-GENE-Y
mice,1759,O
.,1759,O
The,1760,O
group,1760,O
II,1760,O
agonist,1760,O
",",1760,O
DCG-IV,1760,O
",",1760,O
inhibited,1760,O
the,1760,O
fEPSP,1760,O
in,1760,O
all,1760,O
three,1760,O
genotypes,1760,O
.,1760,O
Co-application,1761,O
of,1761,O
DCG-IV,1761,O
and,1761,O
LY541850,1761,B-CHEMICAL
in,1761,O
mGlu3-/-,1761,B-GENE-Y
and,1761,O
wild-type,1761,O
littermates,1761,O
resulted,1761,O
in,1761,O
an,1761,O
additive,1761,O
effect,1761,O
",",1761,O
whereas,1761,O
in,1761,O
mGlu2-/-,1761,B-GENE-Y
mice,1761,O
",",1761,O
LY541850,1761,B-CHEMICAL
reversed,1761,O
the,1761,O
inhibitory,1761,O
action,1761,O
of,1761,O
DCG-IV,1761,O
.,1761,O
These,1762,O
results,1762,O
confirm,1762,O
the,1762,O
selective,1762,O
mGlu2,1762,B-GENE-Y
agonist,1762,O
and,1762,O
mGlu3,1762,B-GENE-Y
antagonist,1762,O
actions,1762,O
of,1762,O
LY541850,1762,B-CHEMICAL
.,1762,O
A,1763,O
similar,1763,O
profile,1763,O
of,1763,O
activity,1763,O
was,1763,O
seen,1763,O
in,1763,O
medial,1763,O
perforant,1763,O
path,1763,O
synapse,1763,O
to,1763,O
the,1763,O
dentate,1763,O
gyrus,1763,O
.,1763,O
Systemic,1764,O
administration,1764,O
of,1764,O
LY541850,1764,B-CHEMICAL
to,1764,O
wild-type,1764,O
mice,1764,O
",",1764,O
reduced,1764,O
the,1764,O
increase,1764,O
in,1764,O
locomotor,1764,O
activity,1764,O
following,1764,O
both,1764,O
phencyclidine,1764,B-CHEMICAL
and,1764,O
amphetamine,1764,B-CHEMICAL
administration,1764,O
.,1764,O
These,1765,O
data,1765,O
support,1765,O
the,1765,O
hypothesis,1765,O
that,1765,O
mGlu2,1765,B-GENE-Y
receptors,1765,O
mediate,1765,O
the,1765,O
antipsychotic,1765,O
effects,1765,O
of,1765,O
mixed,1765,O
group,1765,O
II,1765,O
agonists,1765,O
.,1765,O
This,1766,O
article,1766,O
is,1766,O
part,1766,O
of,1766,O
a,1766,O
Special,1766,O
Issue,1766,O
entitled,1766,O
'Metabotropic,1766,O
Glutamate,1766,I-GENE-N
Receptors,1766,I-GENE-N
',1766,O
.,1766,O
Characterization,1767,O
of,1767,O
rat,1767,B-GENE-Y
brain,1767,I-GENE-Y
aldosterone,1767,I-GENE-Y
receptors,1767,I-GENE-Y
reveals,1767,O
high,1767,O
affinity,1767,O
for,1767,O
corticosterone,1767,B-CHEMICAL
.,1767,O
The,1768,O
two,1768,O
[,1768,B-CHEMICAL
3H,1768,I-CHEMICAL
],1768,I-CHEMICAL
aldosterone-binding,1768,O
proteins,1768,O
of,1768,O
rat,1768,O
brain,1768,O
cytosol,1768,O
were,1768,O
characterized,1768,O
by,1768,O
a,1768,O
dextran-coated,1768,O
charcoal,1768,O
method,1768,O
.,1768,O
With,1769,O
molybdate,1769,B-CHEMICAL
present,1769,O
to,1769,O
stabilize,1769,O
receptors,1769,O
",",1769,O
the,1769,O
affinities,1769,O
of,1769,O
the,1769,O
two,1769,O
sites,1769,O
for,1769,O
[,1769,B-CHEMICAL
3H,1769,I-CHEMICAL
],1769,I-CHEMICAL
aldosterone,1769,I-CHEMICAL
in,1769,O
adrenalectomized,1769,O
perfused,1769,O
rat,1769,O
brain,1769,O
cytosols,1769,O
were,1769,O
0.28,1769,O
and,1769,O
18.0,1769,O
nM,1769,O
at,1769,O
4,1769,O
C.,1769,O
High,1769,O
affinity,1769,O
sites,1769,O
comprised,1769,O
15,1769,O
%,1769,O
of,1769,O
the,1769,O
total,1769,O
receptor,1769,O
number,1769,O
.,1769,O
A,1770,O
small,1770,O
contamination,1770,O
of,1770,O
perfused,1770,O
brain,1770,O
cytosol,1770,O
preparations,1770,O
with,1770,O
corticosteroid-binding,1770,B-GENE-Y
globulin,1770,I-GENE-Y
(,1770,O
CBG,1770,B-GENE-Y
),1770,O
was,1770,O
found,1770,O
.,1770,O
However,1771,O
",",1771,O
due,1771,O
to,1771,O
the,1771,O
very,1771,O
high,1771,O
affinity,1771,O
of,1771,O
CBG,1771,B-GENE-Y
for,1771,O
corticosterone,1771,B-CHEMICAL
at,1771,O
4,1771,O
C,1771,O
",",1771,O
this,1771,O
slight,1771,O
contamination,1771,O
resulted,1771,O
in,1771,O
significant,1771,O
alterations,1771,O
in,1771,O
the,1771,O
apparent,1771,O
affinity,1771,O
of,1771,O
steroids,1771,B-CHEMICAL
competing,1771,O
for,1771,O
aldosterone-binding,1771,B-CHEMICAL
sites,1771,O
.,1771,O
Selective,1772,O
precipitation,1772,O
of,1772,O
cytosol,1772,O
receptors,1772,O
with,1772,O
36,1772,O
%,1772,O
(,1772,B-CHEMICAL
NH4,1772,I-CHEMICAL
),1772,I-CHEMICAL
2SO4,1772,I-CHEMICAL
reduced,1772,O
CBG,1772,B-GENE-Y
concentrations,1772,O
to,1772,O
negligible,1772,O
levels,1772,O
.,1772,O
After,1773,O
blockade,1773,O
of,1773,O
low,1773,O
affinity,1773,O
sites,1773,O
with,1773,O
a,1773,O
highly,1773,O
selective,1773,O
glucocorticoid,1773,O
(,1773,O
RU,1773,B-CHEMICAL
26988,1773,I-CHEMICAL
),1773,O
",",1773,O
the,1773,O
order,1773,O
of,1773,O
steroids,1773,B-CHEMICAL
in,1773,O
competing,1773,O
for,1773,O
the,1773,O
high,1773,O
affinity,1773,O
receptor,1773,O
was,1773,O
desoxycorticosterone,1773,B-CHEMICAL
greater,1773,O
than,1773,O
fludrocortisone,1773,B-CHEMICAL
greater,1773,O
than,1773,O
corticosterone,1773,B-CHEMICAL
greater,1773,O
than,1773,O
aldosterone,1773,B-CHEMICAL
greater,1773,O
than,1773,O
progesterone,1773,B-CHEMICAL
greater,1773,O
than,1773,O
dexamethasone,1773,B-CHEMICAL
.,1773,O
Readdition,1774,O
of,1774,O
a,1774,O
small,1774,O
quantity,1774,O
of,1774,O
dialyzed,1774,O
serum,1774,O
to,1774,O
cytosol,1774,O
preparations,1774,O
yielded,1774,O
a,1774,O
profile,1774,O
of,1774,O
steroid,1774,B-CHEMICAL
binding,1774,O
similar,1774,O
to,1774,O
that,1774,O
of,1774,O
the,1774,O
kidney,1774,O
mineralocorticoid,1774,B-GENE-Y
receptor,1774,I-GENE-Y
(,1774,O
aldosterone,1774,B-CHEMICAL
greater,1774,O
than,1774,O
desoxycorticosterone,1774,B-CHEMICAL
greater,1774,O
than,1774,O
corticosterone,1774,B-CHEMICAL
),1774,O
.,1774,O
The,1775,O
distribution,1775,O
of,1775,O
both,1775,O
receptors,1775,O
in,1775,O
brain,1775,O
regions,1775,O
of,1775,O
adrenalectomized,1775,O
rats,1775,O
was,1775,O
determined,1775,O
.,1775,O
Both,1776,O
receptors,1776,O
were,1776,O
at,1776,O
greatest,1776,O
density,1776,O
in,1776,O
the,1776,O
hippocampus,1776,O
and,1776,O
lowest,1776,O
density,1776,O
in,1776,O
the,1776,O
hypothalamus,1776,O
.,1776,O
The,1777,O
high,1777,O
affinity,1777,O
site,1777,O
was,1777,O
at,1777,O
greatest,1777,O
density,1777,O
in,1777,O
limbic,1777,O
regions,1777,O
",",1777,O
whereas,1777,O
the,1777,O
low,1777,O
affinity,1777,O
receptor,1777,O
",",1777,O
apparently,1777,O
identical,1777,O
to,1777,O
the,1777,O
glucocorticoid,1777,B-GENE-N
type,1777,I-GENE-N
II,1777,I-GENE-N
receptor,1777,I-GENE-N
",",1777,O
was,1777,O
at,1777,O
greatest,1777,O
density,1777,O
in,1777,O
cortex,1777,O
and,1777,O
cerebellum,1777,O
.,1777,O
It,1778,O
is,1778,O
concluded,1778,O
that,1778,O
the,1778,O
high,1778,O
affinity,1778,O
aldosterone,1778,B-GENE-Y
receptor,1778,I-GENE-Y
of,1778,O
rat,1778,O
brain,1778,O
",",1778,O
which,1778,O
had,1778,O
been,1778,O
identified,1778,O
in,1778,O
preliminary,1778,O
studies,1778,O
as,1778,O
a,1778,O
mineralocorticoid,1778,B-GENE-Y
receptor,1778,I-GENE-Y
",",1778,O
may,1778,O
bind,1778,O
either,1778,O
corticosterone,1778,B-CHEMICAL
or,1778,O
aldosterone,1778,B-CHEMICAL
in,1778,O
vivo,1778,O
.,1778,O
Acromegaly,1779,O
:,1779,O
molecular,1779,O
expression,1779,O
of,1779,O
somatostatin,1779,B-GENE-N
receptor,1779,I-GENE-N
subtypes,1779,O
and,1779,O
treatment,1779,O
outcome,1779,O
.,1779,O
About,1780,O
a,1780,O
third,1780,O
of,1780,O
acromegalic,1780,O
patients,1780,O
are,1780,O
resistant,1780,O
to,1780,O
the,1780,O
currently,1780,O
commercially,1780,O
available,1780,O
somatostatin,1780,B-CHEMICAL
analogs,1780,O
(,1780,O
SA,1780,O
),1780,O
octreotide,1780,B-CHEMICAL
and,1780,O
lanreotide,1780,B-CHEMICAL
.,1780,O
Such,1781,O
resistance,1781,O
is,1781,O
related,1781,O
to,1781,O
an,1781,O
overall,1781,O
reduction,1781,O
of,1781,O
somatostatin,1781,B-GENE-N
receptor,1781,I-GENE-N
(,1781,O
SSTR,1781,B-GENE-N
),1781,O
density,1781,O
or,1781,O
to,1781,O
a,1781,O
differentiated,1781,O
expression,1781,O
of,1781,O
SSTR,1781,B-GENE-N
subtypes,1781,O
.,1781,O
There,1782,O
are,1782,O
five,1782,O
known,1782,O
SSTR,1782,B-GENE-N
subtypes,1782,O
.,1782,O
SSTR2,1783,B-GENE-Y
and,1783,O
SSTR5,1783,B-GENE-Y
are,1783,O
usually,1783,O
expressed,1783,O
in,1783,O
GH-secreting,1783,B-GENE-Y
pituitary,1783,O
tumors,1783,O
",",1783,O
and,1783,O
both,1783,O
octreotide,1783,B-CHEMICAL
and,1783,O
lanreotide,1783,B-CHEMICAL
bind,1783,O
preferentially,1783,O
to,1783,O
SSTR2,1783,B-GENE-Y
and,1783,O
",",1783,O
to,1783,O
a,1783,O
lesser,1783,O
extent,1783,O
",",1783,O
to,1783,O
SSTR5,1783,B-GENE-Y
.,1783,O
SA,1784,O
inhibitory,1784,O
effects,1784,O
on,1784,O
GH,1784,B-GENE-Y
secretion,1784,O
and,1784,O
tumor,1784,O
cell,1784,O
proliferation,1784,O
can,1784,O
occur,1784,O
together,1784,O
or,1784,O
be,1784,O
dissociated,1784,O
events,1784,O
",",1784,O
depending,1784,O
on,1784,O
the,1784,O
tumor,1784,O
expression,1784,O
of,1784,O
SSTR,1784,B-GENE-N
subtypes,1784,O
involved,1784,O
in,1784,O
each,1784,O
mechanism,1784,O
.,1784,O
The,1785,O
development,1785,O
of,1785,O
specific,1785,O
somatostatin,1785,B-CHEMICAL
subtypes,1785,O
analogs,1785,O
",",1785,O
mainly,1785,O
for,1785,O
SSTR5,1785,B-GENE-Y
",",1785,O
of,1785,O
a,1785,O
SSTR2-SSTR5,1785,B-GENE-Y
bispecific,1785,O
compound,1785,O
",",1785,O
and,1785,O
of,1785,O
a,1785,O
``,1785,O
universal,1785,O
'',1785,O
analog,1785,O
with,1785,O
high,1785,O
affinity,1785,O
to,1785,O
SSTR1,1785,B-GENE-N
",",1785,I-GENE-N
2,1785,I-GENE-N
",",1785,I-GENE-N
3,1785,I-GENE-N
",",1785,I-GENE-N
and,1785,I-GENE-N
5,1785,I-GENE-N
showed,1785,O
preliminary,1785,O
",",1785,O
albeit,1785,O
promising,1785,O
results,1785,O
for,1785,O
the,1785,O
treatment,1785,O
of,1785,O
resistant,1785,O
somatotropic,1785,O
adenomas,1785,O
.,1785,O
REMNANT,1786,O
UPTAKE,1786,O
AS,1786,O
A,1786,O
POSTOPERATIVE,1786,O
ONCOLOGIC,1786,O
QUALITY,1786,O
INDICATOR,1786,O
.,1786,O
BACKGROUND,1787,O
:,1787,O
The,1787,O
purpose,1787,O
of,1787,O
this,1787,O
study,1787,O
was,1787,O
to,1787,O
examine,1787,O
the,1787,O
utility,1787,O
of,1787,O
remnant,1787,O
uptake,1787,O
on,1787,O
postoperative,1787,O
radioiodine,1787,B-CHEMICAL
scans,1787,O
as,1787,O
an,1787,O
oncologic,1787,O
indicator,1787,O
after,1787,O
thyroidectomy,1787,O
for,1787,O
differentiated,1787,O
thyroid,1787,O
cancer,1787,O
(,1787,O
DTC,1787,O
),1787,O
.,1787,O
METHODS,1788,O
:,1788,O
We,1788,O
conducted,1788,O
a,1788,O
retrospective,1788,O
review,1788,O
of,1788,O
patients,1788,O
undergoing,1788,O
total,1788,O
thyroidectomy,1788,O
for,1788,O
DTC,1788,O
and,1788,O
subsequent,1788,O
radioactive,1788,O
iodine,1788,B-CHEMICAL
(,1788,O
RAI,1788,O
),1788,O
treatment,1788,O
.,1788,O
Of,1789,O
the,1789,O
eight,1789,O
surgeons,1789,O
included,1789,O
",",1789,O
three,1789,O
were,1789,O
considered,1789,O
high,1789,O
volume,1789,O
",",1789,O
performing,1789,O
at,1789,O
least,1789,O
20,1789,O
thyroidectomies,1789,O
per,1789,O
year,1789,O
.,1789,O
Patients,1790,O
with,1790,O
distant,1790,O
metastases,1790,O
at,1790,O
diagnosis,1790,O
or,1790,O
poorly,1790,O
differentiated,1790,O
variants,1790,O
were,1790,O
excluded,1790,O
.,1790,O
To,1791,O
control,1791,O
for,1791,O
the,1791,O
effect,1791,O
of,1791,O
varying,1791,O
RAI,1791,O
doses,1791,O
",",1791,O
the,1791,O
remnant,1791,O
uptake,1791,O
was,1791,O
analyzed,1791,O
as,1791,O
a,1791,O
ratio,1791,O
of,1791,O
the,1791,O
percentage,1791,O
uptake,1791,O
to,1791,O
the,1791,O
dose,1791,O
received,1791,O
(,1791,O
uptake,1791,O
to,1791,O
dose,1791,O
ratio,1791,O
",",1791,O
UDR,1791,O
),1791,O
.,1791,O
Multivariate,1792,O
logistic,1792,O
regression,1792,O
was,1792,O
used,1792,O
to,1792,O
determine,1792,O
the,1792,O
influence,1792,O
of,1792,O
UDR,1792,O
on,1792,O
recurrence,1792,O
.,1792,O
RESULTS,1793,O
:,1793,O
Of,1793,O
the,1793,O
223,1793,O
patients,1793,O
who,1793,O
met,1793,O
inclusion,1793,O
criteria,1793,O
",",1793,O
21,1793,O
patients,1793,O
(,1793,O
9.42,1793,O
%,1793,O
),1793,O
experienced,1793,O
a,1793,O
recurrence,1793,O
.,1793,O
Those,1794,O
who,1794,O
recurred,1794,O
had,1794,O
a,1794,O
ten-fold,1794,O
higher,1794,O
UDR,1794,O
compared,1794,O
to,1794,O
those,1794,O
who,1794,O
did,1794,O
not,1794,O
recur,1794,O
(,1794,O
0.030,1794,O
vs.,1794,O
0.003,1794,O
",",1794,O
p,1794,O
=,1794,O
0.001,1794,O
),1794,O
.,1794,O
Similarly,1795,O
",",1795,O
patients,1795,O
with,1795,O
increasing,1795,O
postoperative,1795,O
thyroglobulin,1795,B-GENE-Y
measurements,1795,O
(,1795,O
0.339,1795,O
vs.,1795,O
0.003,1795,O
",",1795,O
p,1795,O
<,1795,O
0.001,1795,O
),1795,O
also,1795,O
had,1795,O
significantly,1795,O
greater,1795,O
UDRs,1795,O
compared,1795,O
to,1795,O
those,1795,O
with,1795,O
stable,1795,O
thyroglobulin,1795,B-GENE-Y
.,1795,O
The,1796,O
UDRs,1796,O
of,1796,O
high,1796,O
volume,1796,O
surgeons,1796,O
were,1796,O
significantly,1796,O
smaller,1796,O
than,1796,O
low,1796,O
volume,1796,O
surgeons,1796,O
(,1796,O
0.003,1796,O
vs.,1796,O
0.025,1796,O
",",1796,O
p,1796,O
=,1796,O
0.002,1796,O
),1796,O
.,1796,O
When,1797,O
combined,1797,O
with,1797,O
other,1797,O
known,1797,O
predictors,1797,O
for,1797,O
recurrence,1797,O
",",1797,O
UDR,1797,O
(,1797,O
OR,1797,O
3.71,1797,O
",",1797,O
C.I,1797,O
1.05,1797,O
-,1797,O
13.10,1797,O
",",1797,O
p,1797,O
=,1797,O
0.041,1797,O
),1797,O
was,1797,O
significantly,1797,O
associated,1797,O
with,1797,O
recurrence,1797,O
.,1797,O
High,1798,O
volume,1798,O
surgeons,1798,O
maintained,1798,O
a,1798,O
low,1798,O
level,1798,O
of,1798,O
permanent,1798,O
complications,1798,O
across,1798,O
all,1798,O
UDRs,1798,O
whereas,1798,O
low,1798,O
volume,1798,O
surgeons,1798,O
had,1798,O
greater,1798,O
permanent,1798,O
complications,1798,O
associated,1798,O
with,1798,O
higher,1798,O
uptake,1798,O
.,1798,O
Bioactivation,1799,O
of,1799,O
the,1799,O
nasal,1799,O
toxicant,1799,O
"2,6-dichlorobenzonitrile",1799,B-CHEMICAL
:,1799,O
an,1799,O
assessment,1799,O
of,1799,O
metabolic,1799,O
activity,1799,O
in,1799,O
human,1799,O
nasal,1799,O
mucosa,1799,O
and,1799,O
identification,1799,O
of,1799,O
indicators,1799,O
of,1799,O
exposure,1799,O
and,1799,O
potential,1799,O
toxicity,1799,O
.,1799,O
The,1800,O
herbicide,1800,O
"2,6-dichlorobenzonitrile",1800,B-CHEMICAL
(,1800,O
DCBN,1800,B-CHEMICAL
),1800,O
is,1800,O
a,1800,O
potent,1800,O
nasal,1800,O
toxicant,1800,O
in,1800,O
rodents,1800,O
;,1800,O
however,1800,O
",",1800,O
it,1800,O
is,1800,O
not,1800,O
known,1800,O
whether,1800,O
DCBN,1800,B-CHEMICAL
causes,1800,O
similar,1800,O
nasal,1800,O
toxicity,1800,O
in,1800,O
humans,1800,O
.,1800,O
The,1801,O
tissue-selective,1801,O
toxicity,1801,O
of,1801,O
DCBN,1801,B-CHEMICAL
in,1801,O
mouse,1801,O
nasal,1801,O
mucosa,1801,O
is,1801,O
largely,1801,O
dependent,1801,O
on,1801,O
target,1801,O
tissue,1801,O
bioactivation,1801,O
by,1801,O
CYP2A5,1801,B-GENE-Y
.,1801,O
The,1802,O
human,1802,O
orthologues,1802,O
of,1802,O
CYP2A5,1802,B-GENE-Y
",",1802,O
CYP2A6,1802,B-GENE-Y
and,1802,O
CYP2A13,1802,B-GENE-Y
",",1802,O
are,1802,O
both,1802,O
expressed,1802,O
in,1802,O
nasal,1802,O
mucosa,1802,O
and,1802,O
are,1802,O
capable,1802,O
of,1802,O
activating,1802,O
DCBN,1802,B-CHEMICAL
.,1802,O
In,1803,O
this,1803,O
study,1803,O
",",1803,O
we,1803,O
directly,1803,O
determined,1803,O
the,1803,O
ability,1803,O
of,1803,O
human,1803,O
nasal,1803,O
mucosa,1803,O
to,1803,O
bioactivate,1803,O
DCBN,1803,B-CHEMICAL
.,1803,O
We,1804,O
also,1804,O
tested,1804,O
the,1804,O
suitability,1804,O
of,1804,O
a,1804,O
glutathione,1804,B-CHEMICAL
conjugate,1804,O
of,1804,O
DCBN,1804,B-CHEMICAL
(,1804,O
GS-DCBN,1804,O
),1804,O
or,1804,O
its,1804,O
derivatives,1804,O
as,1804,O
biomarkers,1804,O
of,1804,O
DCBN,1804,B-CHEMICAL
exposure,1804,O
and,1804,O
nasal,1804,O
toxicity,1804,O
in,1804,O
mouse,1804,O
models,1804,O
.,1804,O
We,1805,O
found,1805,O
that,1805,O
human,1805,O
fetal,1805,O
nasal,1805,O
mucosa,1805,O
microsomes,1805,O
catalyze,1805,O
the,1805,O
formation,1805,O
of,1805,O
GS-DCBN,1805,O
",",1805,O
with,1805,O
a,1805,O
Km,1805,O
value,1805,O
comparable,1805,O
to,1805,O
that,1805,O
of,1805,O
adult,1805,O
mouse,1805,O
nasal,1805,O
mucosa,1805,O
microsomes,1805,O
.,1805,O
The,1806,O
activity,1806,O
of,1806,O
the,1806,O
human,1806,O
nasal,1806,O
mucosa,1806,O
microsomes,1806,O
was,1806,O
inhibited,1806,O
by,1806,O
8-methoxypsoralen,1806,B-CHEMICAL
",",1806,O
a,1806,O
known,1806,O
CYP2A,1806,B-GENE-N
inhibitor,1806,O
.,1806,O
GS-DCBN,1807,O
and,1807,O
its,1807,O
metabolites,1807,O
were,1807,O
detected,1807,O
in,1807,O
the,1807,O
nasal,1807,O
mucosa,1807,O
and,1807,O
nasal-wash,1807,O
fluid,1807,O
obtained,1807,O
from,1807,O
DCBN-treated,1807,B-CHEMICAL
mice,1807,O
",",1807,O
in,1807,O
amounts,1807,O
that,1807,O
increased,1807,O
with,1807,O
escalations,1807,O
in,1807,O
DCBN,1807,B-CHEMICAL
dose,1807,O
",",1807,O
and,1807,O
they,1807,O
were,1807,O
all,1807,O
still,1807,O
detectable,1807,O
at,1807,O
24,1807,O
h,1807,O
after,1807,O
a,1807,O
DCBN,1807,B-CHEMICAL
treatment,1807,O
(,1807,O
at,1807,O
10,1807,O
mg/kg,1807,O
),1807,O
.,1807,O
Further,1808,O
studies,1808,O
in,1808,O
Cyp2a5-null,1808,B-GENE-Y
mice,1808,O
indicated,1808,O
that,1808,O
GS-DCBN,1808,O
and,1808,O
its,1808,O
metabolites,1808,O
in,1808,O
nasal-wash,1808,O
fluid,1808,O
were,1808,O
generated,1808,O
in,1808,O
the,1808,O
nasal,1808,O
mucosa,1808,O
",",1808,O
rather,1808,O
than,1808,O
in,1808,O
other,1808,O
organs,1808,O
.,1808,O
Thus,1809,O
",",1809,O
our,1809,O
data,1809,O
indicate,1809,O
for,1809,O
the,1809,O
first,1809,O
time,1809,O
that,1809,O
the,1809,O
human,1809,O
nasal,1809,O
mucosa,1809,O
is,1809,O
capable,1809,O
of,1809,O
bioactivating,1809,O
DCBN,1809,B-CHEMICAL
and,1809,O
that,1809,O
GS-DCBN,1809,O
and,1809,O
its,1809,O
metabolites,1809,O
in,1809,O
nasal-wash,1809,O
fluid,1809,O
may,1809,O
collectively,1809,O
serve,1809,O
as,1809,O
indicators,1809,O
of,1809,O
DCBN,1809,B-CHEMICAL
exposure,1809,O
and,1809,O
potential,1809,O
nasal,1809,O
toxicity,1809,O
in,1809,O
humans,1809,O
.,1809,O
Effects,1810,O
of,1810,O
some,1810,O
mono-,1810,B-CHEMICAL
and,1810,I-CHEMICAL
bisquaternary,1810,I-CHEMICAL
ammonium,1810,I-CHEMICAL
compounds,1810,O
on,1810,O
the,1810,O
reactivatability,1810,O
of,1810,O
soman-inhibited,1810,B-CHEMICAL
human,1810,B-GENE-Y
acetylcholinesterase,1810,I-GENE-Y
in,1810,O
vitro,1810,O
.,1810,O
Acetylcholinesterase,1811,B-GENE-Y
(,1811,O
AChE,1811,B-GENE-Y
),1811,O
inhibited,1811,O
by,1811,O
the,1811,O
organophosphate,1811,B-CHEMICAL
soman,1811,B-CHEMICAL
(,1811,O
"1,2,2-trimethyl-propylmethylphosphonofluoridate",1811,B-CHEMICAL
),1811,O
rapidly,1811,O
becomes,1811,O
resistant,1811,O
to,1811,O
reactivation,1811,O
by,1811,O
oximes,1811,B-CHEMICAL
due,1811,O
to,1811,O
dealkylation,1811,O
of,1811,O
the,1811,O
soman-enzyme,1811,B-CHEMICAL
complex,1811,O
.,1811,O
This,1812,O
reaction,1812,O
is,1812,O
called,1812,O
aging,1812,O
.,1812,O
The,1813,O
effect,1813,O
of,1813,O
the,1813,O
four,1813,O
mono-,1813,B-CHEMICAL
and,1813,I-CHEMICAL
bisquaternary,1813,I-CHEMICAL
ammonium,1813,I-CHEMICAL
compounds,1813,O
tetramethylammonium,1813,B-CHEMICAL
(,1813,O
TMA,1813,B-CHEMICAL
),1813,O
",",1813,O
hexamethonium,1813,B-CHEMICAL
",",1813,O
decamethonium,1813,B-CHEMICAL
and,1813,O
suxamethonium,1813,B-CHEMICAL
on,1813,O
the,1813,O
reactivatability,1813,O
of,1813,O
soman-inhibited,1813,B-CHEMICAL
",",1813,O
solubilized,1813,O
AChE,1813,B-GENE-Y
from,1813,O
human,1813,O
erythrocytes,1813,O
was,1813,O
investigated,1813,O
in,1813,O
vitro,1813,O
.,1813,O
All,1814,O
compounds,1814,O
were,1814,O
reversible,1814,O
inhibitors,1814,O
of,1814,O
AChE,1814,B-GENE-Y
;,1814,O
the,1814,O
respective,1814,O
dissociation,1814,O
constants,1814,O
and,1814,O
the,1814,O
type,1814,O
of,1814,O
inhibition,1814,O
exhibited,1814,O
considerable,1814,O
differences,1814,O
.,1814,O
The,1815,O
affinities,1815,O
to,1815,O
both,1815,O
the,1815,O
active,1815,O
and,1815,O
the,1815,O
allosteric,1815,O
site,1815,O
were,1815,O
considerably,1815,O
higher,1815,O
for,1815,O
suxamethonium,1815,B-CHEMICAL
(,1815,O
Kii,1815,O
81.3,1815,O
microM,1815,O
;,1815,O
Ki,1815,O
15.9,1815,O
microM,1815,O
),1815,O
and,1815,O
decamethonium,1815,B-CHEMICAL
(,1815,O
Kii,1815,O
15.4,1815,O
microM,1815,O
;,1815,O
Ki,1815,O
4.4,1815,O
microM,1815,O
),1815,O
than,1815,O
for,1815,O
TMA,1815,B-CHEMICAL
(,1815,O
Kii,1815,O
1,1815,O
mM,1815,O
;,1815,O
Ki,1815,O
289.6,1815,O
microM,1815,O
),1815,O
and,1815,O
hexamethonium,1815,B-CHEMICAL
(,1815,O
Kii,1815,O
4.5,1815,O
mM,1815,O
;,1815,O
Ki,1815,O
331.8,1815,O
microM,1815,O
),1815,O
.,1815,O
The,1816,O
reactivation,1816,O
experiments,1816,O
were,1816,O
performed,1816,O
in,1816,O
a,1816,O
four-step,1816,O
procedure,1816,O
(,1816,O
soman-inhibition,1816,B-CHEMICAL
at,1816,O
0,1816,O
degree,1816,O
and,1816,O
pH,1816,O
10,1816,O
",",1816,O
aging,1816,O
at,1816,O
37,1816,O
degrees,1816,O
and,1816,O
pH,1816,O
7.3,1816,O
",",1816,O
reactivation,1816,O
by,1816,O
the,1816,O
oxime,1816,B-CHEMICAL
HI,1816,O
6,1816,O
at,1816,O
37,1816,O
degrees,1816,O
and,1816,O
pH,1816,O
7.3,1816,O
followed,1816,O
by,1816,O
AChE,1816,B-GENE-Y
assay,1816,O
),1816,O
.,1816,O
After,1817,O
these,1817,O
four,1817,O
steps,1817,O
(,1817,O
total,1817,O
duration,1817,O
55,1817,O
min,1817,O
),1817,O
",",1817,O
AChE,1817,B-GENE-Y
was,1817,O
inhibited,1817,O
by,1817,O
soman,1817,O
to,1817,O
95-100,1817,O
%,1817,O
.,1817,O
HI,1818,O
6,1818,O
could,1818,O
reactivate,1818,O
about,1818,O
20,1818,O
%,1818,O
of,1818,O
the,1818,O
inhibited,1818,O
enzyme,1818,O
.,1818,O
All,1819,O
effectors,1819,O
increased,1819,O
the,1819,O
AChE,1819,B-GENE-Y
reactivatability,1819,O
by,1819,O
HI,1819,O
6,1819,O
when,1819,O
added,1819,O
before,1819,O
aging,1819,O
was,1819,O
started,1819,O
.,1819,O
The,1820,O
maximal,1820,O
increase,1820,O
in,1820,O
reactivatability,1820,O
was,1820,O
higher,1820,O
in,1820,O
the,1820,O
presence,1820,O
of,1820,O
1.6,1820,O
mM,1820,O
suxamethonium,1820,B-CHEMICAL
(,1820,O
+35.8,1820,O
%,1820,O
),1820,O
and,1820,O
150,1820,O
microM,1820,O
decamethonium,1820,B-CHEMICAL
(,1820,O
+40,1820,O
%,1820,O
),1820,O
than,1820,O
of,1820,O
22,1820,O
mM,1820,O
TMA,1820,B-CHEMICAL
(,1820,O
+22.5,1820,O
%,1820,O
),1820,O
and,1820,O
8.3,1820,O
mM,1820,O
hexamethonium,1820,B-CHEMICAL
(,1820,O
+19.2,1820,O
%,1820,O
),1820,O
.,1820,O
If,1821,O
the,1821,O
effectors,1821,O
were,1821,O
added,1821,O
after,1821,O
5,1821,O
min,1821,O
of,1821,O
aging,1821,O
they,1821,O
increased,1821,O
the,1821,O
activity,1821,O
of,1821,O
soman-inhibited,1821,B-CHEMICAL
AChE,1821,B-GENE-Y
",",1821,O
but,1821,O
to,1821,O
a,1821,O
considerably,1821,O
smaller,1821,O
extent,1821,O
than,1821,O
HI,1821,O
6,1821,O
.,1821,O
A,1822,O
good,1822,O
correlation,1822,O
of,1822,O
the,1822,O
respective,1822,O
Kii,1822,O
values,1822,O
and,1822,O
the,1822,O
effective,1822,O
concentrations,1822,O
of,1822,O
these,1822,O
drugs,1822,O
was,1822,O
observed,1822,O
",",1822,O
indicating,1822,O
that,1822,O
an,1822,O
allosteric,1822,O
binding,1822,O
site,1822,O
of,1822,O
AChE,1822,B-GENE-Y
might,1822,O
be,1822,O
involved,1822,O
in,1822,O
the,1822,O
protective,1822,O
effect,1822,O
of,1822,O
these,1822,O
drugs,1822,O
.,1822,O
Atp-bound,1823,O
topoisomerase,1823,B-GENE-Y
ii,1823,I-GENE-Y
as,1823,O
a,1823,O
target,1823,O
for,1823,O
antitumor,1823,O
drugs,1823,O
.,1823,O
Topoisomerase,1824,B-GENE-Y
II,1824,I-GENE-Y
(,1824,O
TOP2,1824,B-GENE-Y
),1824,O
poisons,1824,O
interfere,1824,O
with,1824,O
the,1824,O
breakage/reunion,1824,O
reaction,1824,O
of,1824,O
TOP2,1824,B-GENE-Y
resulting,1824,O
in,1824,O
DNA,1824,O
cleavage,1824,O
.,1824,O
In,1825,O
the,1825,O
current,1825,O
studies,1825,O
",",1825,O
we,1825,O
show,1825,O
that,1825,O
two,1825,O
different,1825,O
classes,1825,O
(,1825,O
ATP-sensitive,1825,B-CHEMICAL
and,1825,O
-insensitive,1825,O
),1825,O
of,1825,O
TOP2,1825,B-GENE-Y
poisons,1825,O
can,1825,O
be,1825,O
identified,1825,O
based,1825,O
on,1825,O
their,1825,O
differential,1825,O
sensitivity,1825,O
to,1825,O
the,1825,O
ATP-bound,1825,B-CHEMICAL
conformation,1825,O
of,1825,O
TOP2,1825,B-GENE-Y
.,1825,O
First,1826,O
",",1826,O
in,1826,O
the,1826,O
presence,1826,O
of,1826,O
1,1826,O
mm,1826,O
ATP,1826,B-CHEMICAL
or,1826,O
the,1826,O
nonhydrolyzable,1826,O
analog,1826,O
adenosine,1826,B-CHEMICAL
5'-,1826,I-CHEMICAL
(,1826,I-CHEMICAL
beta,1826,I-CHEMICAL
",",1826,I-CHEMICAL
gamma-imino,1826,I-CHEMICAL
),1826,I-CHEMICAL
triphosphate,1826,I-CHEMICAL
",",1826,O
TOP2-mediated,1826,B-GENE-Y
DNA,1826,O
cleavage,1826,O
induced,1826,O
by,1826,O
ATP-sensitive,1826,B-CHEMICAL
TOP2,1826,B-GENE-Y
poisons,1826,O
(,1826,O
e.g,1826,O
.,1826,O
doxorubicin,1827,B-CHEMICAL
",",1827,O
etoposide,1827,B-CHEMICAL
",",1827,O
mitoxantrone,1827,B-CHEMICAL
",",1827,O
and,1827,O
4'-,1827,B-CHEMICAL
(,1827,I-CHEMICAL
9-acridinylamino,1827,I-CHEMICAL
),1827,I-CHEMICAL
methanesulfon-m-anisidide,1827,I-CHEMICAL
),1827,O
was,1827,O
30-100-fold,1827,O
stimulated,1827,O
",",1827,O
whereas,1827,O
DNA,1827,O
cleavage,1827,O
induced,1827,O
by,1827,O
ATP-insensitive,1827,B-CHEMICAL
TOP2,1827,B-GENE-Y
poisons,1827,O
(,1827,O
e.g,1827,O
.,1827,O
amonafide,1828,B-CHEMICAL
",",1828,O
batracylin,1828,B-CHEMICAL
",",1828,O
and,1828,O
menadione,1828,B-CHEMICAL
),1828,O
was,1828,O
only,1828,O
slightly,1828,O
(,1828,O
less,1828,O
than,1828,O
3-fold,1828,O
),1828,O
affected,1828,O
.,1828,O
In,1829,O
addition,1829,O
",",1829,O
ADP,1829,B-CHEMICAL
was,1829,O
shown,1829,O
to,1829,O
strongly,1829,O
antagonize,1829,O
TOP2-mediated,1829,B-GENE-Y
DNA,1829,O
cleavage,1829,O
induced,1829,O
by,1829,O
ATP-sensitive,1829,B-CHEMICAL
but,1829,O
not,1829,O
ATP-insensitive,1829,B-CHEMICAL
TOP2,1829,B-GENE-Y
poisons,1829,O
.,1829,O
Second,1830,O
",",1830,O
C427A,1830,B-GENE-N
mutant,1830,O
human,1830,B-GENE-Y
TOP2alpha,1830,I-GENE-Y
",",1830,O
which,1830,O
exhibits,1830,O
reduced,1830,O
ATPase,1830,B-GENE-N
activity,1830,O
",",1830,O
was,1830,O
shown,1830,O
to,1830,O
exhibit,1830,O
cross-resistance,1830,O
to,1830,O
all,1830,O
ATP-sensitive,1830,B-CHEMICAL
but,1830,O
not,1830,O
ATP-insensitive,1830,B-CHEMICAL
TOP2,1830,B-GENE-Y
poisons,1830,O
.,1830,O
Third,1831,O
",",1831,O
using,1831,O
ciprofloxacin,1831,B-CHEMICAL
competition,1831,O
assay,1831,O
",",1831,O
TOP2-mediated,1831,B-GENE-Y
DNA,1831,O
cleavage,1831,O
induced,1831,O
by,1831,O
ATP-sensitive,1831,B-CHEMICAL
but,1831,O
not,1831,O
ATP-insensitive,1831,B-CHEMICAL
poisons,1831,O
was,1831,O
shown,1831,O
to,1831,O
be,1831,O
antagonized,1831,O
by,1831,O
ciprofloxacin,1831,B-CHEMICAL
.,1831,O
These,1832,O
results,1832,O
suggest,1832,O
that,1832,O
ATP-bound,1832,B-CHEMICAL
TOP2,1832,B-GENE-Y
may,1832,O
be,1832,O
the,1832,O
specific,1832,O
target,1832,O
of,1832,O
ATP-sensitive,1832,B-CHEMICAL
TOP2,1832,B-GENE-Y
poisons,1832,O
.,1832,O
Using,1833,O
Lac,1833,B-GENE-N
repressor-operator,1833,I-GENE-N
complexes,1833,I-GENE-N
as,1833,O
roadblocks,1833,O
",",1833,O
we,1833,O
show,1833,O
that,1833,O
ATP-bound,1833,B-CHEMICAL
TOP2,1833,B-GENE-Y
acts,1833,O
as,1833,O
a,1833,O
circular,1833,O
clamp,1833,O
capable,1833,O
of,1833,O
entering,1833,O
DNA,1833,O
ends,1833,O
and,1833,O
sliding,1833,O
on,1833,O
unobstructed,1833,O
duplex,1833,O
DNA,1833,O
.,1833,O
Tunable,1834,O
morphology,1834,O
and,1834,O
mesophase,1834,O
formation,1834,O
by,1834,O
naphthalene-containing,1834,B-CHEMICAL
poly,1834,B-CHEMICAL
(,1834,I-CHEMICAL
aryl,1834,I-CHEMICAL
ether,1834,I-CHEMICAL
),1834,I-CHEMICAL
dendron-based,1834,O
low-molecular-weight,1834,O
fluorescent,1834,O
gels,1834,O
.,1834,O
Novel,1835,O
poly,1835,B-CHEMICAL
(,1835,I-CHEMICAL
aryl,1835,I-CHEMICAL
ether,1835,I-CHEMICAL
),1835,I-CHEMICAL
dendron-based,1835,O
low-molecular-weight,1835,O
organogelaters,1835,O
(,1835,O
LMWG,1835,O
),1835,O
containing,1835,O
naphthalene,1835,B-CHEMICAL
units,1835,O
at,1835,O
the,1835,O
core,1835,O
have,1835,O
been,1835,O
synthesized,1835,O
",",1835,O
and,1835,O
the,1835,O
self-assembly,1835,O
of,1835,O
the,1835,O
system,1835,O
has,1835,O
been,1835,O
examined,1835,O
in,1835,O
a,1835,O
variety,1835,O
of,1835,O
solvents,1835,O
and,1835,O
solvent,1835,O
mixtures,1835,O
.,1835,O
The,1836,O
compounds,1836,O
readily,1836,O
form,1836,O
gels,1836,O
with,1836,O
attractive,1836,O
critical,1836,O
gel,1836,O
concentration,1836,O
values,1836,O
associated,1836,O
with,1836,O
gelation-induced,1836,O
enhanced,1836,O
emission,1836,O
(,1836,O
GIEE,1836,O
),1836,O
.,1836,O
In,1837,O
addition,1837,O
to,1837,O
the,1837,O
remarkable,1837,O
properties,1837,O
of,1837,O
the,1837,O
previously,1837,O
reported,1837,O
anthracene,1837,B-CHEMICAL
and,1837,O
pyrene,1837,B-CHEMICAL
analogues,1837,O
(,1837,O
Rajamalli,1837,O
",",1837,O
P.,1837,O
;,1837,O
Prasad,1837,O
",",1837,O
E.,1837,O
Org,1837,O
.,1837,O
Lett.2011,1838,O
",",1838,O
13,1838,O
",",1838,O
3714,1838,O
and,1838,O
Rajamalli,1838,O
",",1838,O
P.,1838,O
;,1838,O
Prasad,1838,O
",",1838,O
E.,1838,O
Soft,1838,O
Matter2012,1838,O
",",1838,O
8,1838,O
",",1838,O
8896,1838,O
),1838,O
",",1838,O
the,1838,O
self-assembled,1838,O
systems,1838,O
exhibit,1838,O
distinctly,1838,O
different,1838,O
structure-property,1838,O
relationships,1838,O
.,1838,O
Unlike,1839,O
the,1839,O
reported,1839,O
ones,1839,O
",",1839,O
the,1839,O
present,1839,O
system,1839,O
forms,1839,O
sheetlike,1839,O
morphology,1839,O
in,1839,O
nonpolar,1839,O
solvent,1839,O
mixtures,1839,O
",",1839,O
giant,1839,O
vesicles,1839,O
in,1839,O
polar,1839,O
solvent,1839,O
mixtures,1839,O
",",1839,O
and,1839,O
lamellar,1839,O
or,1839,O
hexagonal,1839,O
columnar,1839,O
phases,1839,O
in,1839,O
single,1839,O
solvents,1839,O
.,1839,O
The,1840,O
unique,1840,O
properties,1840,O
of,1840,O
the,1840,O
self-assembled,1840,O
systems,1840,O
",",1840,O
which,1840,O
were,1840,O
analyzed,1840,O
through,1840,O
electron,1840,O
microscopic,1840,O
(,1840,O
SEM,1840,O
",",1840,O
TEM,1840,O
",",1840,O
AFM,1840,O
),1840,O
and,1840,O
spectroscopic,1840,O
techniques,1840,O
(,1840,O
POM,1840,O
",",1840,O
fluorescence,1840,O
),1840,O
",",1840,O
are,1840,O
attributed,1840,O
to,1840,O
the,1840,O
replacement,1840,O
of,1840,O
anthracene/pyrene,1840,B-CHEMICAL
units,1840,O
by,1840,O
naphthalene,1840,B-CHEMICAL
units,1840,O
.,1840,O
The,1841,O
present,1841,O
work,1841,O
unravels,1841,O
the,1841,O
subtle,1841,O
role,1841,O
of,1841,O
minute,1841,O
structural,1841,O
change,1841,O
in,1841,O
altering,1841,O
the,1841,O
properties,1841,O
of,1841,O
LMWGs,1841,O
based,1841,O
on,1841,O
poly,1841,B-CHEMICAL
(,1841,I-CHEMICAL
aryl,1841,I-CHEMICAL
ether,1841,I-CHEMICAL
),1841,I-CHEMICAL
dendrons,1841,O
.,1841,O
Turnover,1842,O
of,1842,O
type,1842,B-GENE-N
II,1842,I-GENE-N
collagen,1842,I-GENE-N
and,1842,O
aggrecan,1842,B-GENE-Y
in,1842,O
cartilage,1842,O
matrix,1842,O
at,1842,O
the,1842,O
onset,1842,O
of,1842,O
inflammatory,1842,O
arthritis,1842,O
in,1842,O
humans,1842,O
:,1842,O
relationship,1842,O
to,1842,O
mediators,1842,O
of,1842,O
systemic,1842,O
and,1842,O
local,1842,O
inflammation,1842,O
.,1842,O
OBJECTIVE,1843,O
:,1843,O
To,1843,O
determine,1843,O
in,1843,O
vivo,1843,O
the,1843,O
extent,1843,O
of,1843,O
damage,1843,O
to,1843,O
",",1843,O
and,1843,O
changes,1843,O
in,1843,O
turnover,1843,O
of,1843,O
",",1843,O
articular,1843,O
cartilage,1843,O
type,1843,B-GENE-N
II,1843,I-GENE-N
collagen,1843,I-GENE-N
(,1843,O
CII,1843,B-GENE-N
),1843,O
and,1843,O
the,1843,O
proteoglycan,1843,B-GENE-N
aggrecan,1843,B-GENE-Y
following,1843,O
the,1843,O
onset,1843,O
of,1843,O
inflammatory,1843,O
arthritis,1843,O
in,1843,O
humans,1843,O
",",1843,O
and,1843,O
to,1843,O
examine,1843,O
the,1843,O
hypothesis,1843,O
that,1843,O
there,1843,O
are,1843,O
direct,1843,O
relationships,1843,O
between,1843,O
cartilage,1843,O
biomarkers,1843,O
of,1843,O
damage/turnover,1843,O
and,1843,O
clinical,1843,O
",",1843,O
histologic,1843,O
",",1843,O
and,1843,O
molecular,1843,O
markers,1843,O
of,1843,O
inflammation,1843,O
.,1843,O
METHODS,1844,O
:,1844,O
Synovial,1844,O
fluid,1844,O
(,1844,O
SF,1844,O
),1844,O
and,1844,O
synovial,1844,O
membrane,1844,O
(,1844,O
SM,1844,O
),1844,O
were,1844,O
obtained,1844,O
by,1844,O
arthroscopy,1844,O
",",1844,O
and,1844,O
a,1844,O
synovitis,1844,O
score,1844,O
was,1844,O
determined,1844,O
",",1844,O
in,1844,O
32,1844,O
patients,1844,O
with,1844,O
rheumatoid,1844,O
arthritis,1844,O
(,1844,O
RA,1844,O
),1844,O
(,1844,O
13,1844,O
with,1844,O
early,1844,O
untreated,1844,O
disease,1844,O
",",1844,O
19,1844,O
with,1844,O
established,1844,O
disease,1844,O
),1844,O
",",1844,O
18,1844,O
with,1844,O
psoriatic,1844,O
arthritis,1844,O
(,1844,O
PsA,1844,O
),1844,O
",",1844,O
and,1844,O
10,1844,O
with,1844,O
osteoarthritis,1844,O
(,1844,O
OA,1844,O
),1844,O
.,1844,O
Systemic,1845,O
disease,1845,O
activity,1845,O
markers,1845,O
were,1845,O
recorded,1845,O
",",1845,O
and,1845,O
SM,1845,O
CD3+,1845,O
T,1845,O
cells,1845,O
",",1845,O
CD4+,1845,O
T,1845,O
cells,1845,O
",",1845,O
CD68+,1845,O
macrophages,1845,O
",",1845,O
and,1845,O
lining,1845,O
layer,1845,O
hyperplasia,1845,O
were,1845,O
quantified,1845,O
.,1845,O
SF,1846,O
levels,1846,O
of,1846,O
tumor,1846,B-GENE-Y
necrosis,1846,I-GENE-Y
factor,1846,I-GENE-Y
alpha,1846,I-GENE-Y
(,1846,O
TNFalpha,1846,B-GENE-Y
),1846,O
",",1846,O
interleukin-10,1846,B-GENE-Y
(,1846,O
IL-10,1846,B-GENE-Y
),1846,O
",",1846,O
matrix,1846,B-GENE-Y
metalloproteinase,1846,I-GENE-Y
1,1846,I-GENE-Y
(,1846,O
MMP-1,1846,B-GENE-Y
),1846,O
",",1846,O
MMP-3,1846,B-GENE-Y
",",1846,O
Col2-3/4C,1846,B-GENE-N
(,1846,I-GENE-N
Long,1846,I-GENE-N
mono,1846,I-GENE-N
),1846,I-GENE-N
neoepitope,1846,I-GENE-N
(,1846,O
C2C,1846,B-GENE-N
),1846,O
(,1846,O
reflecting,1846,O
collagenase,1846,B-GENE-N
cleavage,1846,O
of,1846,O
cartilage,1846,O
CII,1846,B-GENE-N
),1846,O
",",1846,O
C-propeptide,1846,B-GENE-N
of,1846,I-GENE-N
type,1846,I-GENE-N
II,1846,I-GENE-N
procollagen,1846,I-GENE-N
(,1846,O
PIICP,1846,B-GENE-N
),1846,O
(,1846,O
a,1846,O
biosynthesis,1846,O
marker,1846,O
),1846,O
",",1846,O
keratan,1846,O
sulfate,1846,B-CHEMICAL
(,1846,O
KS,1846,O
),1846,O
",",1846,O
and,1846,O
the,1846,O
846,1846,O
epitope,1846,O
of,1846,O
aggrecan,1846,B-GENE-Y
(,1846,O
turnover,1846,O
),1846,O
were,1846,O
measured,1846,O
by,1846,O
enzyme-linked,1846,O
immunosorbent,1846,O
assay,1846,O
or,1846,O
radioimmunoassay,1846,O
.,1846,O
RESULTS,1847,O
:,1847,O
Levels,1847,O
of,1847,O
cartilage,1847,O
degradation,1847,O
products,1847,O
in,1847,O
early,1847,O
RA,1847,O
or,1847,O
early,1847,O
PsA,1847,O
were,1847,O
not,1847,O
elevated,1847,O
above,1847,O
levels,1847,O
in,1847,O
OA,1847,O
",",1847,O
although,1847,O
in,1847,O
early,1847,O
inflammatory,1847,O
arthritis,1847,O
",",1847,O
TNFalpha,1847,B-GENE-Y
and,1847,O
MMP-1,1847,B-GENE-Y
levels,1847,O
were,1847,O
similar,1847,O
to,1847,O
those,1847,O
observed,1847,O
in,1847,O
late,1847,O
inflammatory,1847,O
disease,1847,O
and,1847,O
higher,1847,O
than,1847,O
those,1847,O
in,1847,O
OA,1847,O
.,1847,O
PIICP,1848,B-GENE-N
was,1848,O
reduced,1848,O
in,1848,O
early,1848,O
RA,1848,O
.,1848,O
Correlations,1849,O
were,1849,O
observed,1849,O
between,1849,O
the,1849,O
SF,1849,O
C2C,1849,B-GENE-N
neoepitope,1849,I-GENE-N
level,1849,O
and,1849,O
the,1849,O
Health,1849,O
Assessment,1849,O
Questionnaire,1849,O
score,1849,O
",",1849,O
C-reactive,1849,B-GENE-Y
protein,1849,I-GENE-Y
level,1849,O
",",1849,O
plasma,1849,O
viscosity,1849,O
",",1849,O
synovitis,1849,O
score,1849,O
",",1849,O
and,1849,O
SF,1849,O
TNFalpha,1849,B-GENE-Y
and,1849,O
MMP-1,1849,B-GENE-Y
levels,1849,O
.,1849,O
KS,1850,O
epitope,1850,O
content,1850,O
was,1850,O
reduced,1850,O
in,1850,O
direct,1850,O
relation,1850,O
to,1850,O
SM,1850,O
macrophage,1850,O
infiltration,1850,O
in,1850,O
the,1850,O
sublining,1850,O
and,1850,O
lining,1850,O
layers,1850,O
and,1850,O
in,1850,O
the,1850,O
presence,1850,O
of,1850,O
elevated,1850,O
SF,1850,O
MMP-3,1850,B-GENE-Y
.,1850,O
Both,1851,O
SF,1851,O
MMP-1,1851,B-GENE-Y
and,1851,O
SF,1851,O
MMP-3,1851,B-GENE-Y
levels,1851,O
correlated,1851,O
with,1851,O
CD4+,1851,O
T,1851,O
cell,1851,O
infiltration,1851,O
and,1851,O
lining,1851,O
layer,1851,O
hyperplasia,1851,O
in,1851,O
the,1851,O
SM,1851,O
",",1851,O
and,1851,O
MMP-1,1851,B-GENE-Y
levels,1851,O
correlated,1851,O
with,1851,O
lining,1851,O
layer,1851,O
CD68,1851,B-GENE-Y
levels,1851,O
",",1851,O
but,1851,O
TNFalpha,1851,B-GENE-Y
and,1851,O
IL-10,1851,B-GENE-Y
levels,1851,O
did,1851,O
not,1851,O
.,1851,O
CONCLUSION,1852,O
:,1852,O
Except,1852,O
for,1852,O
CII,1852,B-GENE-N
synthesis,1852,O
",",1852,O
there,1852,O
were,1852,O
no,1852,O
significant,1852,O
changes,1852,O
in,1852,O
extracellular,1852,O
matrix,1852,O
turnover,1852,O
of,1852,O
aggrecan,1852,B-GENE-Y
or,1852,O
CII,1852,B-GENE-N
in,1852,O
the,1852,O
early,1852,O
stages,1852,O
of,1852,O
human,1852,O
inflammatory,1852,O
arthritis,1852,O
.,1852,O
However,1853,O
",",1853,O
the,1853,O
direct,1853,O
correlation,1853,O
between,1853,O
the,1853,O
increases,1853,O
in,1853,O
TNFalpha,1853,B-GENE-Y
and,1853,O
MMP-1,1853,B-GENE-Y
production,1853,O
and,1853,O
collagen,1853,B-GENE-N
degradation,1853,O
suggests,1853,O
that,1853,O
collagenase,1853,B-GENE-N
cleavage,1853,O
of,1853,O
cartilage,1853,O
collagen,1853,B-GENE-N
is,1853,O
related,1853,O
to,1853,O
the,1853,O
activities,1853,O
of,1853,O
TNFalpha,1853,B-GENE-Y
and,1853,O
MMP-1,1853,B-GENE-Y
.,1853,O
The,1854,O
reduction,1854,O
in,1854,O
CII,1854,B-GENE-N
synthesis,1854,O
in,1854,O
early,1854,O
RA,1854,O
may,1854,O
contribute,1854,O
to,1854,O
the,1854,O
developing,1854,O
pathology,1854,O
",",1854,O
since,1854,O
a,1854,O
lack,1854,O
of,1854,O
synthesis,1854,O
of,1854,O
this,1854,O
molecule,1854,O
would,1854,O
inhibit,1854,O
maintenance,1854,O
of,1854,O
cartilage,1854,O
matrix,1854,O
.,1854,O
Activation,1855,O
of,1855,O
ALDH2,1855,B-GENE-Y
with,1855,O
ethanol,1855,B-CHEMICAL
attenuates,1855,O
diabetes,1855,O
induced,1855,O
myocardial,1855,O
injury,1855,O
in,1855,O
rats,1855,O
.,1855,O
This,1856,O
study,1856,O
assessed,1856,O
changes,1856,O
in,1856,O
myocardial,1856,O
ALDH2,1856,B-GENE-Y
expression,1856,O
in,1856,O
the,1856,O
diabetic,1856,O
rat,1856,O
",",1856,O
in,1856,O
particular,1856,O
the,1856,O
diabetic,1856,O
rat,1856,O
pretreated,1856,O
with,1856,O
ALDH2,1856,B-GENE-Y
activator,1856,O
ethanol,1856,B-CHEMICAL
(,1856,O
EtOH,1856,B-CHEMICAL
),1856,O
.,1856,O
The,1857,O
rats,1857,O
were,1857,O
divided,1857,O
into,1857,O
six,1857,O
groups,1857,O
:,1857,O
control,1857,O
",",1857,O
EtOH,1857,B-CHEMICAL
control,1857,O
",",1857,O
diabetic,1857,O
rat,1857,O
at,1857,O
4th,1857,O
week,1857,O
(,1857,O
DM4W,1857,O
),1857,O
",",1857,O
8th,1857,O
week,1857,O
(,1857,O
DM8W,1857,O
),1857,O
",",1857,O
12th,1857,O
week,1857,O
(,1857,O
DM12W,1857,O
),1857,O
and,1857,O
EtOH+DM8W,1857,B-CHEMICAL
groups,1857,O
.,1857,O
Compared,1858,O
with,1858,O
control,1858,O
group,1858,O
",",1858,O
fasting,1858,O
blood,1858,O
glucose,1858,B-CHEMICAL
(,1858,O
FBG,1858,O
),1858,O
and,1858,O
glycosylated,1858,B-GENE-N
hemoglobin,1858,I-GENE-N
(,1858,O
HbA1c,1858,B-GENE-N
),1858,O
levels,1858,O
were,1858,O
increased,1858,O
in,1858,O
DM,1858,O
groups,1858,O
.,1858,O
HbA1c,1859,B-GENE-N
level,1859,O
in,1859,O
DM12W,1859,O
group,1859,O
was,1859,O
higher,1859,O
than,1859,O
in,1859,O
DM4W,1859,O
group,1859,O
",",1859,O
HbA1c,1859,B-GENE-N
level,1859,O
in,1859,O
EtOH+DM8W,1859,B-CHEMICAL
group,1859,O
was,1859,O
lower,1859,O
than,1859,O
in,1859,O
DM8W,1859,O
group,1859,O
.,1859,O
Compared,1860,O
with,1860,O
control,1860,O
group,1860,O
",",1860,O
there,1860,O
were,1860,O
no,1860,O
changes,1860,O
of,1860,O
LVDP,1860,O
",",1860,O
HR,1860,O
and,1860,O
±dp/dtmax,1860,O
in,1860,O
DM4W,1860,O
group,1860,O
",",1860,O
but,1860,O
there,1860,O
were,1860,O
decreased,1860,O
in,1860,O
DM8W,1860,O
and,1860,O
DM12W,1860,O
groups,1860,O
",",1860,O
and,1860,O
increased,1860,O
in,1860,O
the,1860,O
EtOH+DM8W,1860,B-CHEMICAL
group,1860,O
.,1860,O
In,1861,O
DM,1861,O
groups,1861,O
",",1861,O
SOD,1861,B-GENE-N
activity,1861,O
",",1861,O
ALDH2,1861,B-GENE-Y
mRNA,1861,O
and,1861,O
protein,1861,O
levels,1861,O
were,1861,O
reduced,1861,O
",",1861,O
MDA,1861,B-CHEMICAL
content,1861,O
was,1861,O
increased,1861,O
compared,1861,O
with,1861,O
control,1861,O
group,1861,O
;,1861,O
which,1861,O
decreased,1861,O
further,1861,O
as,1861,O
diabetes,1861,O
progressed,1861,O
.,1861,O
Compared,1862,O
with,1862,O
DM8W,1862,O
group,1862,O
",",1862,O
SOD,1862,B-GENE-N
and,1862,O
ALDH2,1862,B-GENE-Y
in,1862,O
EtOH+DM8W,1862,B-CHEMICAL
group,1862,O
was,1862,O
increased,1862,O
",",1862,O
MDA,1862,B-CHEMICAL
was,1862,O
decreased,1862,O
.,1862,O
Our,1863,O
results,1863,O
indicated,1863,O
with,1863,O
the,1863,O
development,1863,O
of,1863,O
diabetes,1863,O
",",1863,O
myocardial,1863,O
ALDH2,1863,B-GENE-Y
expression,1863,O
was,1863,O
further,1863,O
decreased,1863,O
accompanying,1863,O
decreased,1863,O
ventricular,1863,O
function,1863,O
.,1863,O
However,1864,O
",",1864,O
activation,1864,O
of,1864,O
ALDH2,1864,B-GENE-Y
can,1864,O
decrease,1864,O
diabetes,1864,O
induced,1864,O
myocardial,1864,O
injury,1864,O
.,1864,O
ALDH2,1865,B-GENE-Y
may,1865,O
be,1865,O
one,1865,O
key,1865,O
endogenous,1865,O
cardiac,1865,O
protective,1865,O
factor,1865,O
in,1865,O
diabetic,1865,O
individuals,1865,O
.,1865,O
Kinetic,1866,O
mechanism,1866,O
of,1866,O
quinone,1866,B-GENE-Y
oxidoreductase,1866,I-GENE-Y
2,1866,I-GENE-Y
and,1866,O
its,1866,O
inhibition,1866,O
by,1866,O
the,1866,O
antimalarial,1866,O
quinolines,1866,B-CHEMICAL
.,1866,O
Quinone,1867,B-GENE-Y
oxidoreductase,1867,I-GENE-Y
2,1867,I-GENE-Y
(,1867,O
QR2,1867,B-GENE-Y
),1867,O
purified,1867,O
from,1867,O
human,1867,O
red,1867,O
blood,1867,O
cells,1867,O
was,1867,O
recently,1867,O
shown,1867,O
to,1867,O
be,1867,O
a,1867,O
potential,1867,O
target,1867,O
of,1867,O
the,1867,O
quinoline,1867,B-CHEMICAL
antimalarial,1867,O
compounds,1867,O
[,1867,O
Graves,1867,O
et,1867,O
al.,1867,O
",",1867,O
(,1867,O
2002,1867,O
),1867,O
Mol,1867,O
.,1867,O
Pharmacol,1868,O
.,1868,O
62,1869,O
",",1869,O
1364,1869,O
],1869,O
.,1869,O
QR2,1870,B-GENE-Y
catalyzes,1870,O
the,1870,O
two-electron,1870,O
reduction,1870,O
of,1870,O
menadione,1870,B-CHEMICAL
via,1870,O
the,1870,O
oxidation,1870,O
of,1870,O
N-alkylated,1870,B-CHEMICAL
or,1870,O
N-ribosylated,1870,B-CHEMICAL
nicotinamides,1870,I-CHEMICAL
.,1870,O
To,1871,O
investigate,1871,O
the,1871,O
mechanism,1871,O
and,1871,O
consequences,1871,O
of,1871,O
inhibition,1871,O
of,1871,O
QR2,1871,B-GENE-Y
by,1871,O
the,1871,O
quinolines,1871,B-CHEMICAL
further,1871,O
",",1871,O
we,1871,O
have,1871,O
used,1871,O
steady-state,1871,O
and,1871,O
transient-state,1871,O
kinetics,1871,O
to,1871,O
define,1871,O
the,1871,O
mechanism,1871,O
of,1871,O
QR2,1871,B-GENE-Y
.,1871,O
Importantly,1872,O
",",1872,O
we,1872,O
have,1872,O
shown,1872,O
that,1872,O
QR2,1872,B-GENE-Y
when,1872,O
isolated,1872,O
from,1872,O
an,1872,O
overproducing,1872,O
strain,1872,O
of,1872,O
E.,1872,O
coli,1872,O
is,1872,O
kinetically,1872,O
equivalent,1872,O
to,1872,O
the,1872,O
enzyme,1872,O
from,1872,O
the,1872,O
native,1872,O
human,1872,O
red,1872,O
blood,1872,O
cell,1872,O
source,1872,O
.,1872,O
We,1873,O
observe,1873,O
ping-pong,1873,O
kinetics,1873,O
consistent,1873,O
with,1873,O
one,1873,O
substrate/inhibitor,1873,O
binding,1873,O
site,1873,O
that,1873,O
shows,1873,O
selectivity,1873,O
for,1873,O
the,1873,O
oxidation,1873,O
state,1873,O
of,1873,O
the,1873,O
FAD,1873,O
cofactor,1873,O
",",1873,O
suggesting,1873,O
that,1873,O
selective,1873,O
inhibition,1873,O
of,1873,O
the,1873,O
liver,1873,O
versus,1873,O
red,1873,O
blood,1873,O
cell,1873,O
forms,1873,O
of,1873,O
malaria,1873,O
may,1873,O
be,1873,O
possible,1873,O
.,1873,O
The,1874,O
reductant,1874,O
N-methyldihydronicotinamide,1874,B-CHEMICAL
and,1874,O
the,1874,O
inhibitor,1874,O
primaquine,1874,B-CHEMICAL
bind,1874,O
exclusively,1874,O
to,1874,O
the,1874,O
oxidized,1874,O
enzyme,1874,O
.,1874,O
In,1875,O
contrast,1875,O
",",1875,O
the,1875,O
inhibitors,1875,O
quinacrine,1875,B-CHEMICAL
and,1875,O
chloroquine,1875,B-CHEMICAL
bind,1875,O
exclusively,1875,O
to,1875,O
the,1875,O
reduced,1875,O
enzyme,1875,O
.,1875,O
The,1876,O
quinone,1876,B-CHEMICAL
substrate,1876,O
menadione,1876,B-CHEMICAL
",",1876,O
on,1876,O
the,1876,O
other,1876,O
hand,1876,O
",",1876,O
binds,1876,O
nonspecifically,1876,O
to,1876,O
both,1876,O
forms,1876,O
of,1876,O
the,1876,O
enzyme,1876,O
.,1876,O
Single-turnover,1877,O
kinetics,1877,O
of,1877,O
the,1877,O
reductive,1877,O
half-reaction,1877,O
are,1877,O
chemically,1877,O
and,1877,O
kinetically,1877,O
competent,1877,O
and,1877,O
confirm,1877,O
the,1877,O
inhibitor,1877,O
selectivity,1877,O
seen,1877,O
in,1877,O
the,1877,O
steady-state,1877,O
experiments,1877,O
.,1877,O
Our,1878,O
studies,1878,O
shed,1878,O
light,1878,O
on,1878,O
the,1878,O
possible,1878,O
in,1878,O
vivo,1878,O
potency,1878,O
of,1878,O
the,1878,O
quinolines,1878,B-CHEMICAL
and,1878,O
provide,1878,O
a,1878,O
foundation,1878,O
for,1878,O
future,1878,O
studies,1878,O
aimed,1878,O
at,1878,O
creating,1878,O
more,1878,O
potent,1878,O
QR2,1878,B-GENE-Y
inhibitors,1878,O
and,1878,O
at,1878,O
understanding,1878,O
the,1878,O
physiological,1878,O
significance,1878,O
of,1878,O
QR2,1878,B-GENE-Y
.,1878,O
HISTONE,1879,B-GENE-N
DEACETYLASE,1879,I-GENE-N
INHIBITION,1879,O
AFFECTS,1879,O
SODIUM,1879,B-GENE-Y
IODIDE,1879,I-GENE-Y
SYMPORTER,1879,I-GENE-Y
(,1879,O
NIS,1879,B-GENE-Y
),1879,O
EXPRESSION,1879,O
AND,1879,O
INDUCES,1879,O
¹³¹I,1879,B-CHEMICAL
CYTOTOXICITY,1879,O
IN,1879,O
ANAPLASTIC,1879,O
THYROID,1879,O
CANCER,1879,O
CELLS,1879,O
.,1879,O
Background,1880,O
:,1880,O
Anaplastic,1880,O
thyroid,1880,O
cancers,1880,O
(,1880,O
ATC,1880,O
),1880,O
represent,1880,O
only,1880,O
1-2,1880,O
%,1880,O
of,1880,O
all,1880,O
thyroid,1880,O
tumors,1880,O
",",1880,O
but,1880,O
they,1880,O
account,1880,O
for,1880,O
up,1880,O
to,1880,O
50,1880,O
%,1880,O
of,1880,O
the,1880,O
mortality,1880,O
.,1880,O
Treatment,1881,O
of,1881,O
differentiated,1881,O
thyroid,1881,O
carcinomas,1881,O
is,1881,O
well,1881,O
standardized,1881,O
and,1881,O
the,1881,O
use,1881,O
of,1881,O
radioiodine,1881,B-CHEMICAL
represents,1881,O
an,1881,O
essential,1881,O
step,1881,O
;,1881,O
in,1881,O
contrast,1881,O
",",1881,O
there,1881,O
is,1881,O
no,1881,O
standardized,1881,O
therapeutic,1881,O
approach,1881,O
for,1881,O
anaplastic,1881,O
tumors,1881,O
and,1881,O
their,1881,O
prognosis,1881,O
is,1881,O
poor,1881,O
.,1881,O
The,1882,O
resistance,1882,O
of,1882,O
anaplastic,1882,O
thyroid,1882,O
cancer,1882,O
to,1882,O
radioiodine,1882,B-CHEMICAL
treatment,1882,O
is,1882,O
principally,1882,O
due,1882,O
to,1882,O
the,1882,O
absence,1882,O
of,1882,O
expression,1882,O
of,1882,O
the,1882,O
sodium,1882,B-GENE-Y
iodide,1882,I-GENE-Y
symporter,1882,I-GENE-Y
(,1882,O
NIS,1882,B-GENE-Y
),1882,O
",",1882,O
mainly,1882,O
due,1882,O
to,1882,O
epigenetic,1882,O
silencing,1882,O
.,1882,O
The,1883,O
acetylation,1883,O
status,1883,O
of,1883,O
histones,1883,B-GENE-N
is,1883,O
involved,1883,O
in,1883,O
the,1883,O
epigenetic,1883,O
control,1883,O
of,1883,O
gene,1883,O
expression,1883,O
and,1883,O
is,1883,O
usually,1883,O
disrupted,1883,O
in,1883,O
advanced,1883,O
thyroid,1883,O
cancer,1883,O
.,1883,O
Histone,1884,B-GENE-N
deacetylase,1884,I-GENE-N
inhibitors,1884,O
have,1884,O
been,1884,O
demonstrated,1884,O
as,1884,O
potent,1884,O
anticancer,1884,O
drugs,1884,O
with,1884,O
several,1884,O
different,1884,O
effects,1884,O
on,1884,O
cell,1884,O
viability,1884,O
and,1884,O
differentiation,1884,O
.,1884,O
Methods,1885,O
:,1885,O
Stabilized,1885,O
anaplastic,1885,O
thyroid,1885,O
cancer,1885,O
cell,1885,O
lines,1885,O
(,1885,O
BHT-101,1885,O
and,1885,O
CAL-62,1885,O
),1885,O
and,1885,O
primary,1885,O
cultures,1885,O
from,1885,O
patients,1885,O
who,1885,O
underwent,1885,O
thyroidectomy,1885,O
for,1885,O
anaplastic,1885,O
thyroid,1885,O
cancer,1885,O
were,1885,O
treated,1885,O
with,1885,O
the,1885,O
histone,1885,B-GENE-N
deacetylase,1885,I-GENE-N
inhibitor,1885,O
LBH589,1885,B-CHEMICAL
.,1885,O
After,1886,O
treatment,1886,O
",",1886,O
we,1886,O
evaluated,1886,O
the,1886,O
expression,1886,O
and,1886,O
function,1886,O
of,1886,O
NIS,1886,B-GENE-Y
.,1886,O
Gene,1887,O
expression,1887,O
was,1887,O
evaluated,1887,O
by,1887,O
real-time,1887,O
PCR,1887,O
(,1887,O
RT-PCR,1887,O
),1887,O
;,1887,O
NIS,1887,B-GENE-N
promoter,1887,I-GENE-N
activity,1887,O
was,1887,O
determined,1887,O
with,1887,O
a,1887,O
luciferase,1887,O
reporter,1887,O
assay,1887,O
;,1887,O
and,1887,O
protein,1887,O
expression,1887,O
was,1887,O
assessed,1887,O
through,1887,O
immunofluorescence,1887,O
.,1887,O
We,1888,O
tested,1888,O
the,1888,O
protein,1888,O
function,1888,O
by,1888,O
125I,1888,B-CHEMICAL
uptake,1888,O
and,1888,O
efflux,1888,O
experiments,1888,O
;,1888,O
finally,1888,O
the,1888,O
cytotoxic,1888,O
effect,1888,O
of,1888,O
131I,1888,B-CHEMICAL
was,1888,O
determined,1888,O
with,1888,O
a,1888,O
clonogenic,1888,O
assay,1888,O
.,1888,O
Results,1889,O
:,1889,O
Our,1889,O
results,1889,O
demonstrate,1889,O
that,1889,O
treatment,1889,O
with,1889,O
LBH589,1889,B-CHEMICAL
leads,1889,O
to,1889,O
NIS,1889,B-GENE-Y
RNA,1889,O
expression,1889,O
as,1889,O
shown,1889,O
by,1889,O
RT-PCR,1889,O
and,1889,O
luciferase,1889,O
assay,1889,O
",",1889,O
and,1889,O
to,1889,O
protein,1889,O
expression,1889,O
as,1889,O
determined,1889,O
by,1889,O
immunofluorescence,1889,O
in,1889,O
vitro,1889,O
and,1889,O
by,1889,O
immunohistochemistry,1889,O
in,1889,O
xenograft,1889,O
tumors,1889,O
.,1889,O
Moreover,1890,O
",",1890,O
125I,1890,B-CHEMICAL
uptake,1890,O
and,1890,O
efflux,1890,O
experiments,1890,O
show,1890,O
the,1890,O
correct,1890,O
protein,1890,O
function,1890,O
and,1890,O
iodine,1890,B-CHEMICAL
retention,1890,O
",",1890,O
that,1890,O
translate,1890,O
into,1890,O
cytotoxicity,1890,O
effects,1890,O
",",1890,O
as,1890,O
demonstrated,1890,O
by,1890,O
a,1890,O
clonogenic,1890,O
assay,1890,O
with,1890,O
131I,1890,B-CHEMICAL
.,1890,O
Conclusions,1891,O
:,1891,O
This,1891,O
study,1891,O
supplies,1891,O
a,1891,O
new,1891,O
potential,1891,O
strategy,1891,O
for,1891,O
the,1891,O
treatment,1891,O
of,1891,O
ATC,1891,O
by,1891,O
modifying,1891,O
gene,1891,O
expression,1891,O
with,1891,O
the,1891,O
aim,1891,O
of,1891,O
inducing,1891,O
responsiveness,1891,O
towards,1891,O
radioiodine,1891,B-CHEMICAL
therapy,1891,O
.,1891,O
EphB4,1892,B-GENE-Y
enhances,1892,O
the,1892,O
process,1892,O
of,1892,O
endochondral,1892,O
ossification,1892,O
and,1892,O
inhibits,1892,O
remodeling,1892,O
during,1892,O
bone,1892,O
fracture,1892,O
repair,1892,O
.,1892,O
Previous,1893,O
reports,1893,O
have,1893,O
identified,1893,O
a,1893,O
role,1893,O
for,1893,O
the,1893,O
tyrosine,1893,B-GENE-N
kinase,1893,I-GENE-N
receptor,1893,I-GENE-N
EphB4,1893,B-GENE-Y
and,1893,O
its,1893,O
ligand,1893,O
",",1893,O
ephrinB2,1893,B-GENE-Y
",",1893,O
as,1893,O
potential,1893,O
mediators,1893,O
of,1893,O
both,1893,O
bone,1893,O
formation,1893,O
by,1893,O
osteoblasts,1893,O
and,1893,O
bone,1893,O
resorption,1893,O
by,1893,O
osteoclasts,1893,O
.,1893,O
In,1894,O
the,1894,O
present,1894,O
study,1894,O
",",1894,O
we,1894,O
examined,1894,O
the,1894,O
role,1894,O
of,1894,O
EphB4,1894,B-GENE-Y
during,1894,O
bone,1894,O
repair,1894,O
after,1894,O
traumatic,1894,O
injury,1894,O
.,1894,O
We,1895,O
performed,1895,O
femoral,1895,O
fractures,1895,O
with,1895,O
internal,1895,O
fixation,1895,O
in,1895,O
transgenic,1895,O
mice,1895,O
that,1895,O
overexpress,1895,O
EphB4,1895,B-GENE-Y
under,1895,O
the,1895,O
collagen,1895,B-GENE-N
type,1895,I-GENE-N
1,1895,I-GENE-N
promoter,1895,I-GENE-N
(,1895,O
Col1-EphB4,1895,B-GENE-N
),1895,O
and,1895,O
investigated,1895,O
the,1895,O
bone,1895,O
repair,1895,O
process,1895,O
up,1895,O
to,1895,O
12,1895,O
weeks,1895,O
postfracture,1895,O
.,1895,O
The,1896,O
data,1896,O
indicated,1896,O
that,1896,O
Col1-EphB4,1896,B-GENE-N
mice,1896,O
exhibited,1896,O
stiffer,1896,O
and,1896,O
stronger,1896,O
bones,1896,O
after,1896,O
fracture,1896,O
compared,1896,O
with,1896,O
wild-type,1896,O
mice,1896,O
.,1896,O
The,1897,O
fractured,1897,O
bones,1897,O
of,1897,O
Col1-EphB4,1897,B-GENE-N
transgenic,1897,O
mice,1897,O
displayed,1897,O
significantly,1897,O
greater,1897,O
tissue,1897,O
and,1897,O
bone,1897,O
volume,1897,O
2,1897,O
weeks,1897,O
postfracture,1897,O
compared,1897,O
with,1897,O
that,1897,O
of,1897,O
wild-type,1897,O
mice,1897,O
.,1897,O
These,1898,O
findings,1898,O
correlated,1898,O
with,1898,O
increased,1898,O
chondrogenesis,1898,O
and,1898,O
mineral,1898,O
formation,1898,O
within,1898,O
the,1898,O
callus,1898,O
site,1898,O
at,1898,O
2,1898,O
weeks,1898,O
postfracture,1898,O
",",1898,O
as,1898,O
demonstrated,1898,O
by,1898,O
increased,1898,O
safranin,1898,B-CHEMICAL
O,1898,I-CHEMICAL
and,1898,O
von,1898,O
Kossa,1898,O
staining,1898,O
",",1898,O
respectively,1898,O
.,1898,O
Interestingly,1899,O
",",1899,O
Col1-EphB4,1899,B-GENE-N
mice,1899,O
were,1899,O
found,1899,O
to,1899,O
possess,1899,O
significantly,1899,O
greater,1899,O
numbers,1899,O
of,1899,O
clonogenic,1899,O
mesenchymal,1899,O
stromal,1899,O
progenitor,1899,O
cells,1899,O
(,1899,O
CFU-F,1899,O
),1899,O
",",1899,O
with,1899,O
an,1899,O
increased,1899,O
capacity,1899,O
to,1899,O
form,1899,O
mineralized,1899,O
nodules,1899,O
in,1899,O
vitro,1899,O
under,1899,O
osteogenic,1899,O
conditions,1899,O
",",1899,O
when,1899,O
compared,1899,O
with,1899,O
those,1899,O
of,1899,O
the,1899,O
wild-type,1899,O
control,1899,O
mice,1899,O
.,1899,O
Furthermore,1900,O
",",1900,O
Col1-EphB4,1900,B-GENE-N
mice,1900,O
had,1900,O
significantly,1900,O
lower,1900,O
numbers,1900,O
of,1900,O
TRAP-positive,1900,B-GENE-Y
multinucleated,1900,O
osteoclasts,1900,O
within,1900,O
the,1900,O
callus,1900,O
site,1900,O
.,1900,O
Taken,1901,O
together,1901,O
",",1901,O
these,1901,O
observations,1901,O
suggest,1901,O
that,1901,O
EphB4,1901,B-GENE-Y
promotes,1901,O
endochondral,1901,O
ossification,1901,O
while,1901,O
inhibiting,1901,O
osteoclast,1901,O
development,1901,O
during,1901,O
callus,1901,O
formation,1901,O
and,1901,O
may,1901,O
represent,1901,O
a,1901,O
novel,1901,O
drug,1901,O
target,1901,O
for,1901,O
the,1901,O
repair,1901,O
of,1901,O
fractured,1901,O
bones,1901,O
.,1901,O
Inverted,1902,O
CdSe/CdS/ZnS,1902,B-CHEMICAL
quantum,1902,O
dot,1902,O
light,1902,O
emitting,1902,O
devices,1902,O
with,1902,O
titanium,1902,B-CHEMICAL
dioxide,1902,I-CHEMICAL
as,1902,O
an,1902,O
electron-injection,1902,O
contact,1902,O
.,1902,O
We,1903,O
demonstrated,1903,O
the,1903,O
fabrication,1903,O
of,1903,O
inverted,1903,O
CdSe/CdS/ZnS,1903,B-CHEMICAL
quantum,1903,O
dot,1903,O
light,1903,O
emitting,1903,O
devices,1903,O
(,1903,O
QD-LEDs,1903,O
),1903,O
using,1903,O
titanium,1903,B-CHEMICAL
dioxide,1903,I-CHEMICAL
(,1903,O
TiO2,1903,B-CHEMICAL
),1903,O
as,1903,O
an,1903,O
electron-injection,1903,O
layer,1903,O
and,1903,O
investigated,1903,O
the,1903,O
operating,1903,O
mechanism,1903,O
by,1903,O
utilizing,1903,O
different,1903,O
hole-transport,1903,O
materials,1903,O
",",1903,O
"4,4-N",1903,B-CHEMICAL
",",1903,I-CHEMICAL
N-dicarbazole-biphenyl,1903,I-CHEMICAL
(,1903,O
CBP,1903,B-CHEMICAL
),1903,O
and,1903,O
"4,4',4",1903,B-CHEMICAL
'',1903,I-CHEMICAL
-tris,1903,I-CHEMICAL
(,1903,I-CHEMICAL
carbazol-9-yl,1903,I-CHEMICAL
),1903,I-CHEMICAL
-triphenylamine,1903,I-CHEMICAL
(,1903,O
TCTA,1903,B-CHEMICAL
),1903,O
.,1903,O
A,1904,O
more,1904,O
efficient,1904,O
device,1904,O
with,1904,O
CBP,1904,O
as,1904,O
the,1904,O
hole-transport,1904,O
layer,1904,O
(,1904,O
HTL,1904,O
),1904,O
was,1904,O
obtained,1904,O
compared,1904,O
with,1904,O
the,1904,O
TCTA,1904,B-CHEMICAL
based,1904,O
device,1904,O
.,1904,O
The,1905,O
peak,1905,O
efficiency,1905,O
of,1905,O
6.70,1905,O
cd,1905,O
A,1905,O
(,1905,O
-1,1905,O
),1905,O
for,1905,O
the,1905,O
CBP,1905,O
based,1905,O
device,1905,O
was,1905,O
found,1905,O
to,1905,O
be,1905,O
about,1905,O
74.5,1905,O
%,1905,O
higher,1905,O
than,1905,O
the,1905,O
TCTA,1905,B-CHEMICAL
based,1905,O
device,1905,O
(,1905,O
3.84,1905,O
cd,1905,O
A,1905,O
(,1905,O
-1,1905,O
),1905,O
),1905,O
.,1905,O
The,1906,O
studies,1906,O
on,1906,O
the,1906,O
time-resolved,1906,O
photoluminescence,1906,O
spectra,1906,O
of,1906,O
the,1906,O
QD-HTL,1906,O
composite,1906,O
structures,1906,O
showed,1906,O
that,1906,O
the,1906,O
energy,1906,O
transfer,1906,O
(,1906,O
ET,1906,O
),1906,O
efficiencies,1906,O
from,1906,O
the,1906,O
two,1906,O
HTLs,1906,O
to,1906,O
the,1906,O
QD,1906,O
layer,1906,O
were,1906,O
similar,1906,O
and,1906,O
the,1906,O
charge,1906,O
separation,1906,O
between,1906,O
QDs,1906,O
and,1906,O
HTLs,1906,O
could,1906,O
be,1906,O
neglected,1906,O
.,1906,O
The,1907,O
enhancement,1907,O
in,1907,O
the,1907,O
performance,1907,O
of,1907,O
the,1907,O
CBP,1907,O
based,1907,O
device,1907,O
was,1907,O
attributed,1907,O
to,1907,O
the,1907,O
more,1907,O
efficient,1907,O
hole-injection,1907,O
from,1907,O
CBP,1907,O
to,1907,O
QDs,1907,O
.,1907,O
Pharmacokinetic,1908,O
Interactions,1908,O
between,1908,O
Monoamine,1908,B-GENE-Y
Oxidase,1908,I-GENE-Y
A,1908,I-GENE-Y
Inhibitor,1908,O
Harmaline,1908,B-CHEMICAL
and,1908,O
5-Methoxy-N,1908,B-CHEMICAL
",",1908,I-CHEMICAL
N-Dimethyltryptamine,1908,I-CHEMICAL
",",1908,O
and,1908,O
the,1908,O
Impact,1908,O
of,1908,O
CYP2D6,1908,B-GENE-Y
Status,1908,O
.,1908,O
5-Methoxy-N,1909,B-CHEMICAL
",",1909,I-CHEMICAL
N-dimethyltryptamine,1909,I-CHEMICAL
(,1909,O
5-MeO-DMT,1909,B-CHEMICAL
or,1909,O
street,1909,O
name,1909,O
``,1909,O
5-MEO,1909,B-CHEMICAL
'',1909,O
),1909,O
is,1909,O
a,1909,O
newer,1909,O
designer,1909,O
drug,1909,O
belonging,1909,O
to,1909,O
a,1909,O
group,1909,O
of,1909,O
naturally,1909,O
occurring,1909,O
indolealkylamines,1909,B-CHEMICAL
.,1909,O
Our,1910,O
recent,1910,O
study,1910,O
has,1910,O
demonstrated,1910,O
that,1910,O
coadministration,1910,O
of,1910,O
monoamine,1910,B-GENE-Y
oxidase,1910,I-GENE-Y
A,1910,I-GENE-Y
(,1910,O
MAO-A,1910,B-GENE-Y
),1910,O
inhibitor,1910,O
harmaline,1910,B-CHEMICAL
(,1910,O
5,1910,O
mg/kg,1910,O
),1910,O
increases,1910,O
systemic,1910,O
exposure,1910,O
to,1910,O
5-MeO-DMT,1910,B-CHEMICAL
(,1910,O
2,1910,O
mg/kg,1910,O
),1910,O
and,1910,O
active,1910,O
metabolite,1910,O
bufotenine,1910,O
.,1910,O
This,1911,O
study,1911,O
is,1911,O
aimed,1911,O
at,1911,O
delineating,1911,O
harmaline,1911,B-CHEMICAL
and,1911,O
5-MeO-DMT,1911,B-CHEMICAL
pharmacokinetic,1911,O
(,1911,O
PK,1911,O
),1911,O
interactions,1911,O
at,1911,O
multiple,1911,O
dose,1911,O
levels,1911,O
",",1911,O
as,1911,O
well,1911,O
as,1911,O
the,1911,O
impact,1911,O
of,1911,O
CYP2D6,1911,B-GENE-Y
that,1911,O
affects,1911,O
harmaline,1911,B-CHEMICAL
PK,1911,O
and,1911,O
determines,1911,O
5-MeO-DMT,1911,B-CHEMICAL
O-demethylation,1911,B-CHEMICAL
to,1911,O
produce,1911,O
bufotenine,1911,B-CHEMICAL
.,1911,O
Our,1912,O
data,1912,O
revealed,1912,O
that,1912,O
inhibition,1912,O
of,1912,O
MAO-A-mediated,1912,B-GENE-Y
metabolic,1912,O
elimination,1912,O
by,1912,O
harmaline,1912,B-CHEMICAL
(,1912,O
2,1912,O
",",1912,O
5,1912,O
",",1912,O
and,1912,O
15,1912,O
mg/kg,1912,O
),1912,O
led,1912,O
to,1912,O
a,1912,O
sharp,1912,O
increase,1912,O
in,1912,O
systemic,1912,O
and,1912,O
cerebral,1912,O
exposure,1912,O
to,1912,O
5-MeO-DMT,1912,B-CHEMICAL
(,1912,O
2,1912,O
and,1912,O
10,1912,O
mg/kg,1912,O
),1912,O
at,1912,O
all,1912,O
dose,1912,O
combinations,1912,O
.,1912,O
A,1913,O
more,1913,O
pronounced,1913,O
effect,1913,O
on,1913,O
5-MeO-DMT,1913,B-CHEMICAL
PK,1913,O
was,1913,O
associated,1913,O
with,1913,O
greater,1913,O
exposure,1913,O
to,1913,O
harmaline,1913,B-CHEMICAL
in,1913,O
wild-type,1913,O
mice,1913,O
than,1913,O
CYP2D6-humanized,1913,B-GENE-Y
(,1913,O
Tg-CYP2D6,1913,O
),1913,O
mice,1913,O
.,1913,O
Harmaline,1914,B-CHEMICAL
(,1914,O
5,1914,O
mg/kg,1914,O
),1914,O
also,1914,O
increased,1914,O
blood,1914,O
and,1914,O
brain,1914,O
bufotenine,1914,B-CHEMICAL
concentrations,1914,O
that,1914,O
were,1914,O
generally,1914,O
higher,1914,O
in,1914,O
Tg-CYP2D6,1914,O
mice,1914,O
.,1914,O
Surprisingly,1915,O
",",1915,O
greater,1915,O
harmaline,1915,B-CHEMICAL
dose,1915,O
(,1915,O
15,1915,O
mg/kg,1915,O
),1915,O
reduced,1915,O
bufotenine,1915,B-CHEMICAL
levels,1915,O
.,1915,O
The,1916,O
in,1916,O
vivo,1916,O
inhibitory,1916,O
effect,1916,O
of,1916,O
harmaline,1916,B-CHEMICAL
on,1916,O
CYP2D6-catalyzed,1916,B-GENE-Y
bufotenine,1916,B-CHEMICAL
formation,1916,O
was,1916,O
confirmed,1916,O
by,1916,O
in,1916,O
vitro,1916,O
study,1916,O
using,1916,O
purified,1916,O
CYP2D6,1916,B-GENE-Y
.,1916,O
Given,1917,O
these,1917,O
findings,1917,O
",",1917,O
a,1917,O
unified,1917,O
PK,1917,O
model,1917,O
including,1917,O
the,1917,O
inhibition,1917,O
of,1917,O
MAO-A-,1917,B-GENE-Y
and,1917,O
CYP2D6-catalyzed,1917,B-GENE-Y
5-MeO-DMT,1917,B-CHEMICAL
metabolism,1917,O
by,1917,O
harmaline,1917,B-CHEMICAL
was,1917,O
developed,1917,O
to,1917,O
describe,1917,O
blood,1917,O
harmaline,1917,B-CHEMICAL
",",1917,O
5-MeO-DMT,1917,B-CHEMICAL
",",1917,O
and,1917,O
bufotenine,1917,B-CHEMICAL
PK,1917,O
profiles,1917,O
in,1917,O
both,1917,O
wild-type,1917,O
and,1917,O
Tg-CYP2D6,1917,O
mouse,1917,O
models,1917,O
.,1917,O
This,1918,O
PK,1918,O
model,1918,O
may,1918,O
be,1918,O
further,1918,O
employed,1918,O
to,1918,O
predict,1918,O
harmaline,1918,B-CHEMICAL
and,1918,O
5-MeO-DMT,1918,B-CHEMICAL
PK,1918,O
interactions,1918,O
at,1918,O
various,1918,O
doses,1918,O
",",1918,O
define,1918,O
the,1918,O
impact,1918,O
of,1918,O
CYP2D6,1918,B-GENE-Y
status,1918,O
",",1918,O
and,1918,O
drive,1918,O
harmaline-5-MeO-DMT,1918,B-CHEMICAL
pharmacodynamics,1918,O
.,1918,O
Iodine-129,1919,B-CHEMICAL
microdosing,1919,O
for,1919,O
protein,1919,O
and,1919,O
peptide,1919,O
drug,1919,O
development,1919,O
:,1919,O
erythropoietin,1919,B-GENE-Y
as,1919,O
a,1919,O
case,1919,O
study,1919,O
.,1919,O
BACKGROUND,1920,O
:,1920,O
Microdosing,1920,O
is,1920,O
a,1920,O
technique,1920,O
for,1920,O
studying,1920,O
the,1920,O
behavior,1920,O
of,1920,O
compounds,1920,O
in,1920,O
vivo,1920,O
at,1920,O
1/100th,1920,O
of,1920,O
the,1920,O
dose,1920,O
of,1920,O
a,1920,O
test,1920,O
substance,1920,O
calculated,1920,O
",",1920,O
based,1920,O
on,1920,O
animal,1920,O
data,1920,O
",",1920,O
to,1920,O
yield,1920,O
a,1920,O
pharmacologic,1920,O
effect,1920,O
.,1920,O
In,1921,O
microdosing,1921,O
",",1921,O
use,1921,O
is,1921,O
made,1921,O
of,1921,O
accelerator,1921,O
MS,1921,O
(,1921,O
AMS,1921,O
),1921,O
.,1921,O
In,1922,O
this,1922,O
study,1922,O
",",1922,O
we,1922,O
investigated,1922,O
whether,1922,O
(,1922,B-CHEMICAL
129,1922,I-CHEMICAL
),1922,I-CHEMICAL
I-labeling,1922,O
of,1922,O
proteins,1922,O
with,1922,O
subsequent,1922,O
AMS,1922,O
measurements,1922,O
is,1922,O
a,1922,O
suitable,1922,O
method,1922,O
to,1922,O
perform,1922,O
microdose,1922,O
studies,1922,O
with,1922,O
therapeutic,1922,O
proteins,1922,O
.,1922,O
We,1923,O
used,1923,O
erythropoietin,1923,B-GENE-Y
(,1923,O
EPO,1923,B-GENE-Y
),1923,O
as,1923,O
a,1923,O
case,1923,O
study,1923,O
.,1923,O
RESULTS,1924,O
:,1924,O
In,1924,O
an,1924,O
animal,1924,O
study,1924,O
with,1924,O
(,1924,B-CHEMICAL
129,1924,I-CHEMICAL
),1924,I-CHEMICAL
I-labeled,1924,O
EPO,1924,B-GENE-Y
in,1924,O
Han-Wistar,1924,O
rats,1924,O
",",1924,O
an,1924,O
increase,1924,O
of,1924,O
(,1924,B-CHEMICAL
129,1924,I-CHEMICAL
),1924,I-CHEMICAL
I-EPO,1924,O
is,1924,O
observed,1924,O
after,1924,O
dose,1924,O
administration,1924,O
.,1924,O
The,1925,O
half-life,1925,O
was,1925,O
found,1925,O
to,1925,O
be,1925,O
2,1925,O
and,1925,O
5.5,1925,O
h,1925,O
for,1925,O
two,1925,O
different,1925,O
EPOs,1925,B-GENE-Y
.,1925,O
These,1926,O
results,1926,O
are,1926,O
in,1926,O
accordance,1926,O
with,1926,O
expected,1926,O
values,1926,O
.,1926,O
CoNCLUSION,1927,O
:,1927,O
Although,1927,O
further,1927,O
research,1927,O
is,1927,O
required,1927,O
",",1927,O
(,1927,B-CHEMICAL
129,1927,I-CHEMICAL
),1927,I-CHEMICAL
I-labeling,1927,O
of,1927,O
proteins,1927,O
seems,1927,O
a,1927,O
feasible,1927,O
method,1927,O
for,1927,O
AMS,1927,O
microdose,1927,O
studies,1927,O
with,1927,O
peptide,1927,O
and,1927,O
protein,1927,O
drugs,1927,O
",",1927,O
such,1927,O
as,1927,O
biosimilars,1927,O
.,1927,O
Compared,1928,O
pharmacological,1928,O
characteristics,1928,O
in,1928,O
humans,1928,O
of,1928,O
racemic,1928,O
cetirizine,1928,B-CHEMICAL
and,1928,O
levocetirizine,1928,B-CHEMICAL
",",1928,O
two,1928,O
histamine,1928,B-GENE-Y
H1-receptor,1928,I-GENE-Y
antagonists,1928,O
.,1928,O
The,1929,O
potent,1929,O
histamine,1929,B-GENE-Y
H,1929,I-GENE-Y
(,1929,I-GENE-Y
1,1929,I-GENE-Y
),1929,I-GENE-Y
-receptor,1929,I-GENE-Y
antagonist,1929,O
cetirizine,1929,B-CHEMICAL
(,1929,O
Zyrtec,1929,B-CHEMICAL
),1929,O
is,1929,O
a,1929,O
racemic,1929,O
mixture,1929,O
of,1929,O
levocetirizine,1929,B-CHEMICAL
(,1929,O
now,1929,O
available,1929,O
under,1929,O
the,1929,O
trademark,1929,O
Xyzal,1929,B-CHEMICAL
and,1929,O
dextrocetirizine,1929,B-CHEMICAL
.,1929,O
In,1930,O
this,1930,O
Commentary,1930,O
",",1930,O
we,1930,O
examine,1930,O
some,1930,O
biological,1930,O
properties,1930,O
of,1930,O
cetirizine,1930,B-CHEMICAL
and,1930,O
levocetirizine,1930,B-CHEMICAL
",",1930,O
namely,1930,O
enantioselectivity,1930,O
in,1930,O
pharmacological,1930,O
activity,1930,O
and,1930,O
pharmacokinetic,1930,O
properties,1930,O
",",1930,O
with,1930,O
emphasis,1930,O
on,1930,O
the,1930,O
possibility,1930,O
of,1930,O
racemization,1930,O
",",1930,O
the,1930,O
compared,1930,O
behavior,1930,O
of,1930,O
the,1930,O
two,1930,O
enantiomers,1930,O
",",1930,O
and,1930,O
the,1930,O
potential,1930,O
for,1930,O
interactions,1930,O
with,1930,O
other,1930,O
drugs,1930,O
.,1930,O
Recent,1931,O
data,1931,O
demonstrate,1931,O
that,1931,O
the,1931,O
antihistaminergic,1931,O
activity,1931,O
of,1931,O
the,1931,O
racemate,1931,O
is,1931,O
primarily,1931,O
due,1931,O
to,1931,O
levocetirizine,1931,B-CHEMICAL
.,1931,O
Levocetirizine,1932,B-CHEMICAL
is,1932,O
rapidly,1932,O
and,1932,O
extensively,1932,O
absorbed,1932,O
",",1932,O
poorly,1932,O
metabolized,1932,O
",",1932,O
and,1932,O
not,1932,O
subject,1932,O
to,1932,O
racemization,1932,O
.,1932,O
Its,1933,O
pharmacokinetic,1933,O
characteristics,1933,O
are,1933,O
comparable,1933,O
after,1933,O
administration,1933,O
alone,1933,O
or,1933,O
in,1933,O
the,1933,O
racemate,1933,O
.,1933,O
Its,1934,O
apparent,1934,O
volume,1934,O
of,1934,O
distribution,1934,O
is,1934,O
smaller,1934,O
than,1934,O
that,1934,O
of,1934,O
dextrocetirizine,1934,B-CHEMICAL
(,1934,O
0.41,1934,O
L,1934,O
kg,1934,O
(,1934,O
-1,1934,O
),1934,O
vs.,1934,O
0.60,1934,O
L,1934,O
kg,1934,O
(,1934,O
-1,1934,O
),1934,O
),1934,O
.,1934,O
Moreover,1935,O
",",1935,O
the,1935,O
non-renal,1935,O
(,1935,O
mostly,1935,O
hepatic,1935,O
),1935,O
clearance,1935,O
of,1935,O
levocetirizine,1935,B-CHEMICAL
is,1935,O
also,1935,O
significantly,1935,O
lower,1935,O
than,1935,O
that,1935,O
of,1935,O
dextrocetirizine,1935,B-CHEMICAL
(,1935,O
11.8,1935,O
mL,1935,O
min,1935,O
(,1935,O
-1,1935,O
),1935,O
vs.,1935,O
29.2,1935,O
mL,1935,O
min,1935,O
(,1935,O
-1,1935,O
),1935,O
),1935,O
.,1935,O
Our,1936,O
conclusion,1936,O
is,1936,O
that,1936,O
levocetirizine,1936,B-CHEMICAL
is,1936,O
indeed,1936,O
the,1936,O
eutomer,1936,O
of,1936,O
cetirizine,1936,B-CHEMICAL
.,1936,O
The,1937,O
evidence,1937,O
reviewed,1937,O
here,1937,O
confirms,1937,O
preclinical,1937,O
findings,1937,O
and,1937,O
offers,1937,O
a,1937,O
rationale,1937,O
for,1937,O
the,1937,O
chiral,1937,O
switch,1937,O
from,1937,O
the,1937,O
racemate,1937,O
to,1937,O
levocetirizine,1937,B-CHEMICAL
.,1937,O
Vegfrecine,1938,B-CHEMICAL
",",1938,O
an,1938,O
Inhibitor,1938,O
of,1938,O
VEGF,1938,B-GENE-N
Receptor,1938,I-GENE-N
Tyrosine,1938,I-GENE-N
Kinases,1938,I-GENE-N
Isolated,1938,O
from,1938,O
the,1938,O
Culture,1938,O
Broth,1938,O
of,1938,O
Streptomyces,1938,O
sp,1938,O
.,1938,O
A,1939,O
new,1939,O
inhibitor,1939,O
of,1939,O
VEGF,1939,B-GENE-N
receptor,1939,I-GENE-N
tyrosine,1939,I-GENE-N
kinases,1939,I-GENE-N
",",1939,O
vegfrecine,1939,B-CHEMICAL
(,1939,O
1,1939,O
),1939,O
",",1939,O
was,1939,O
isolated,1939,O
from,1939,O
the,1939,O
culture,1939,O
broth,1939,O
of,1939,O
Streptomyces,1939,O
sp,1939,O
.,1939,O
MK931-CF8,1940,O
.,1940,O
The,1941,O
molecular,1941,O
structure,1941,O
of,1941,O
1,1941,O
was,1941,O
determined,1941,O
by,1941,O
NMR,1941,O
and,1941,O
MS,1941,O
analysis,1941,O
combined,1941,O
with,1941,O
synthesis,1941,O
.,1941,O
Compound,1942,O
1,1942,O
showed,1942,O
potent,1942,O
inhibitory,1942,O
activity,1942,O
against,1942,O
vascular,1942,B-GENE-N
endothelial,1942,I-GENE-N
growth,1942,I-GENE-N
factor,1942,I-GENE-N
receptor,1942,I-GENE-N
(,1942,O
VEGFR,1942,B-GENE-N
),1942,O
tyrosine,1942,B-GENE-N
kinases,1942,I-GENE-N
in,1942,O
in,1942,O
vitro,1942,O
enzyme,1942,O
assays,1942,O
",",1942,O
but,1942,O
platelet-derived,1942,B-GENE-N
growth,1942,I-GENE-N
factor,1942,I-GENE-N
receptors,1942,I-GENE-N
(,1942,O
PDGFRs,1942,B-GENE-N
),1942,O
",",1942,O
fibroblast,1942,B-GENE-N
growth,1942,I-GENE-N
factor,1942,I-GENE-N
receptor,1942,I-GENE-N
(,1942,O
FGFR,1942,B-GENE-N
),1942,O
",",1942,O
and,1942,O
epidermal,1942,B-GENE-Y
growth,1942,I-GENE-Y
factor,1942,I-GENE-Y
receptor,1942,I-GENE-Y
(,1942,O
EGFR,1942,B-GENE-Y
),1942,O
responded,1942,O
only,1942,O
weakly,1942,O
.,1942,O
Compound,1943,O
1,1943,O
is,1943,O
a,1943,O
promising,1943,O
new,1943,O
selective,1943,O
VEGFR,1943,B-GENE-N
inhibitor,1943,O
for,1943,O
investigating,1943,O
new,1943,O
treatments,1943,O
of,1943,O
cancer,1943,O
and,1943,O
inflammatory,1943,O
diseases,1943,O
.,1943,O
Substrate,1944,O
specificity,1944,O
of,1944,O
the,1944,O
human,1944,B-GENE-N
renal,1944,I-GENE-N
sodium,1944,I-GENE-N
dicarboxylate,1944,I-GENE-N
cotransporter,1944,I-GENE-N
",",1944,O
hNaDC-3,1944,B-GENE-Y
",",1944,O
under,1944,O
voltage-clamp,1944,O
conditions,1944,O
.,1944,O
Proximal,1945,O
tubule,1945,O
cells,1945,O
extract,1945,O
dicarboxylates,1945,O
from,1945,O
filtrate,1945,O
and,1945,O
blood,1945,O
",",1945,O
using,1945,O
cotransporters,1945,O
located,1945,O
in,1945,O
the,1945,O
brush,1945,O
border,1945,O
[,1945,O
sodium,1945,B-GENE-N
dicarboxylate,1945,I-GENE-N
cotransporter,1945,I-GENE-N
(,1945,O
NaDC-1,1945,B-GENE-Y
),1945,O
],1945,O
and,1945,O
basolateral,1945,O
cell,1945,O
membrane,1945,O
(,1945,O
NaDC-3,1945,B-GENE-Y
),1945,O
.,1945,O
We,1946,O
expressed,1946,O
the,1946,O
human,1946,B-GENE-Y
NaDC-3,1946,I-GENE-Y
(,1946,O
hNaDC-3,1946,B-GENE-Y
),1946,O
in,1946,O
Xenopus,1946,O
laevis,1946,O
oocytes,1946,O
and,1946,O
characterized,1946,O
it,1946,O
by,1946,O
the,1946,O
two-electrode,1946,O
voltage-clamp,1946,O
technique,1946,O
.,1946,O
At,1947,O
-60,1947,O
mV,1947,O
",",1947,O
succinate,1947,B-CHEMICAL
(,1947,O
4,1947,O
carbons,1947,B-CHEMICAL
),1947,O
and,1947,O
glutarate,1947,B-CHEMICAL
(,1947,O
5,1947,O
carbons,1947,B-CHEMICAL
),1947,O
generated,1947,O
inward,1947,O
currents,1947,O
due,1947,O
to,1947,O
translocation,1947,O
of,1947,O
three,1947,O
sodium,1947,B-CHEMICAL
ions,1947,O
and,1947,O
one,1947,O
divalent,1947,O
dicarboxylate,1947,O
",",1947,O
whereas,1947,O
oxalate,1947,B-CHEMICAL
(,1947,O
2,1947,O
carbons,1947,B-CHEMICAL
),1947,O
and,1947,O
malonate,1947,B-CHEMICAL
(,1947,O
3,1947,O
carbons,1947,B-CHEMICAL
),1947,O
did,1947,O
not,1947,O
.,1947,O
The,1948,O
cis-dicarboxylate,1948,B-CHEMICAL
maleate,1948,I-CHEMICAL
produced,1948,O
currents,1948,O
smaller,1948,O
in,1948,O
magnitude,1948,O
",",1948,O
whereas,1948,O
the,1948,O
trans-dicarboxylate,1948,B-CHEMICAL
fumarate,1948,I-CHEMICAL
generated,1948,O
currents,1948,O
similar,1948,O
to,1948,O
succinate,1948,B-CHEMICAL
.,1948,O
The,1949,O
substituted,1949,O
succinate,1949,B-CHEMICAL
derivatives,1949,O
",",1949,O
malate,1949,B-CHEMICAL
",",1949,O
"2,2-",1949,B-CHEMICAL
and,1949,I-CHEMICAL
"2,3-dimethylsuccinate",1949,I-CHEMICAL
",",1949,O
and,1949,O
"2,3-dimercaptosuccinate",1949,B-CHEMICAL
elicited,1949,O
inward,1949,O
currents,1949,O
",",1949,O
whereas,1949,O
aspartate,1949,B-CHEMICAL
and,1949,O
guanidinosuccinate,1949,B-CHEMICAL
showed,1949,O
hardly,1949,O
detectable,1949,O
currents,1949,O
.,1949,O
The,1950,O
C-5,1950,B-CHEMICAL
dicarboxylates,1950,I-CHEMICAL
glutarate,1950,I-CHEMICAL
and,1950,O
alpha-ketoglutarate,1950,B-CHEMICAL
produced,1950,O
larger,1950,O
currents,1950,O
than,1950,O
succinate,1950,B-CHEMICAL
;,1950,O
glutamate,1950,B-CHEMICAL
and,1950,O
folate,1950,B-CHEMICAL
failed,1950,O
to,1950,O
cause,1950,O
inward,1950,O
currents,1950,O
.,1950,O
Kinetic,1951,O
analysis,1951,O
revealed,1951,O
",",1951,O
at,1951,O
-60,1951,O
mV,1951,O
",",1951,O
K,1951,O
(,1951,O
0.5,1951,O
),1951,O
values,1951,O
of,1951,O
25,1951,O
+/-,1951,O
12,1951,O
microM,1951,O
for,1951,O
succinate,1951,B-CHEMICAL
and,1951,O
45,1951,O
+/-,1951,O
13,1951,O
microM,1951,O
for,1951,O
alpha-ketoglutarate,1951,B-CHEMICAL
",",1951,O
values,1951,O
close,1951,O
to,1951,O
the,1951,O
plasma,1951,O
concentration,1951,O
of,1951,O
these,1951,O
compounds,1951,O
.,1951,O
For,1952,O
both,1952,O
compounds,1952,O
",",1952,O
the,1952,O
K,1952,O
(,1952,O
0.5,1952,O
),1952,O
was,1952,O
independent,1952,O
of,1952,O
voltage,1952,O
",",1952,O
whereas,1952,O
the,1952,O
maximal,1952,O
current,1952,O
increased,1952,O
with,1952,O
hyperpolarization,1952,O
.,1952,O
As,1953,O
opposed,1953,O
to,1953,O
the,1953,O
rat,1953,O
and,1953,O
flounder,1953,O
orthologs,1953,O
",",1953,O
hNaDC-3,1953,B-GENE-Y
was,1953,O
hardly,1953,O
inhibited,1953,O
by,1953,O
lithium,1953,B-CHEMICAL
concentrations,1953,O
up,1953,O
to,1953,O
5,1953,O
mM,1953,O
.,1953,O
In,1954,O
the,1954,O
absence,1954,O
of,1954,O
sodium,1954,B-CHEMICAL
",",1954,O
however,1954,O
",",1954,O
lithium,1954,B-CHEMICAL
can,1954,O
mediate,1954,O
succinate-dependent,1954,B-CHEMICAL
currents,1954,O
.,1954,O
The,1955,O
narrow,1955,O
substrate,1955,O
specificity,1955,O
prevents,1955,O
interaction,1955,O
of,1955,O
drugs,1955,O
with,1955,O
dicarboxylate-like,1955,O
structure,1955,O
with,1955,O
hNaDC-3,1955,B-GENE-Y
and,1955,O
ensures,1955,O
sufficient,1955,O
support,1955,O
of,1955,O
the,1955,O
proximal,1955,O
tubule,1955,O
cells,1955,O
with,1955,O
alpha-ketoglutarate,1955,B-CHEMICAL
for,1955,O
anion,1955,O
secretion,1955,O
via,1955,O
organic,1955,B-GENE-N
anion,1955,I-GENE-N
transporter,1955,I-GENE-N
1,1955,I-GENE-N
or,1955,I-GENE-N
3,1955,I-GENE-N
.,1955,O
Effects,1956,O
of,1956,O
inhibition,1956,O
of,1956,O
urokinase-type,1956,B-GENE-Y
plasminogen,1956,I-GENE-Y
activator,1956,I-GENE-Y
(,1956,O
u-PA,1956,B-GENE-Y
),1956,O
by,1956,O
amiloride,1956,B-CHEMICAL
in,1956,O
the,1956,O
cornea,1956,O
and,1956,O
tear,1956,O
fluid,1956,O
of,1956,O
eyes,1956,O
irradiated,1956,O
with,1956,O
UVB,1956,O
.,1956,O
The,1957,O
purpose,1957,O
of,1957,O
the,1957,O
present,1957,O
study,1957,O
was,1957,O
to,1957,O
test,1957,O
our,1957,O
hypothesis,1957,O
that,1957,O
amiloride,1957,B-CHEMICAL
",",1957,O
a,1957,O
specific,1957,O
u-PA,1957,B-GENE-Y
inhibitor,1957,O
",",1957,O
effectively,1957,O
decreases,1957,O
u-PA,1957,B-GENE-Y
activity,1957,O
in,1957,O
cornea,1957,O
as,1957,O
well,1957,O
as,1957,O
in,1957,O
tear,1957,O
fluid,1957,O
and,1957,O
favourably,1957,O
affects,1957,O
corneal,1957,O
healing,1957,O
.,1957,O
Therefore,1958,O
",",1958,O
comparative,1958,O
histochemical,1958,O
and,1958,O
biochemical,1958,O
studies,1958,O
of,1958,O
u-PA,1958,B-GENE-Y
and,1958,O
the,1958,O
effects,1958,O
of,1958,O
amiloride,1958,B-CHEMICAL
were,1958,O
performed,1958,O
on,1958,O
rabbit,1958,O
corneas,1958,O
and,1958,O
tear,1958,O
fluid,1958,O
using,1958,O
the,1958,O
sensitive,1958,O
fluorogenic,1958,O
substrate,1958,O
Z-Gly-Gly-Arg-7-amino-4-trifluoromethylcoumarin,1958,B-CHEMICAL
.,1958,O
Rabbit,1959,O
eyes,1959,O
were,1959,O
repeatedly,1959,O
irradiated,1959,O
with,1959,O
UVB,1959,O
for,1959,O
9,1959,O
days,1959,O
and,1959,O
during,1959,O
the,1959,O
irradiation,1959,O
topically,1959,O
treated,1959,O
with,1959,O
amiloride,1959,B-CHEMICAL
(,1959,O
1,1959,O
mg/ml,1959,O
saline,1959,O
),1959,O
or,1959,O
placebo,1959,O
(,1959,O
saline,1959,O
),1959,O
(,1959,O
dropwise,1959,O
",",1959,O
5,1959,O
times,1959,O
daily,1959,O
),1959,O
.,1959,O
Results,1960,O
show,1960,O
that,1960,O
in,1960,O
placebo-treated,1960,O
eyes,1960,O
",",1960,O
UVB,1960,O
evoked,1960,O
the,1960,O
appearance,1960,O
of,1960,O
u-PA,1960,B-GENE-Y
activity,1960,O
in,1960,O
cornea,1960,O
and,1960,O
tear,1960,O
fluid,1960,O
in,1960,O
early,1960,O
stages,1960,O
of,1960,O
irradiation,1960,O
",",1960,O
and,1960,O
u-PA,1960,B-GENE-Y
levels,1960,O
increased,1960,O
during,1960,O
irradiation,1960,O
.,1960,O
Corneal,1961,O
epithelium,1961,O
was,1961,O
gradually,1961,O
lost,1961,O
and,1961,O
remnants,1961,O
of,1961,O
the,1961,O
epithelium,1961,O
as,1961,O
well,1961,O
as,1961,O
keratocytes,1961,O
in,1961,O
the,1961,O
upper,1961,O
part,1961,O
of,1961,O
corneal,1961,O
stroma,1961,O
showed,1961,O
high,1961,O
u-PA,1961,B-GENE-Y
activity,1961,O
.,1961,O
Finally,1962,O
",",1962,O
corneas,1962,O
lost,1962,O
their,1962,O
epithelium,1962,O
completely,1962,O
.,1962,O
In,1963,O
corneal,1963,O
stroma,1963,O
",",1963,O
numerous,1963,O
u-PA-containing,1963,B-GENE-Y
inflammatory,1963,O
cells,1963,O
were,1963,O
present,1963,O
.,1963,O
Corneas,1964,O
were,1964,O
vascularized,1964,O
.,1964,O
When,1965,O
amiloride,1965,B-CHEMICAL
was,1965,O
dropped,1965,O
on,1965,O
the,1965,O
eye,1965,O
surface,1965,O
on,1965,O
the,1965,O
first,1965,O
day,1965,O
of,1965,O
irradiation,1965,O
and,1965,O
subsequently,1965,O
daily,1965,O
until,1965,O
the,1965,O
end,1965,O
of,1965,O
the,1965,O
experiment,1965,O
",",1965,O
u-PA,1965,B-GENE-Y
activity,1965,O
in,1965,O
both,1965,O
cornea,1965,O
and,1965,O
tear,1965,O
fluid,1965,O
was,1965,O
strongly,1965,O
inhibited,1965,O
.,1965,O
Corneas,1966,O
were,1966,O
covered,1966,O
with,1966,O
a,1966,O
continuous,1966,O
epithelium,1966,O
until,1966,O
the,1966,O
end,1966,O
of,1966,O
the,1966,O
experiment,1966,O
.,1966,O
The,1967,O
number,1967,O
of,1967,O
inflammatory,1967,O
cells,1967,O
was,1967,O
significantly,1967,O
decreased,1967,O
.,1967,O
Corneal,1968,O
vascularization,1968,O
was,1968,O
reduced,1968,O
by,1968,O
50,1968,O
%,1968,O
.,1968,O
In,1969,O
conclusion,1969,O
",",1969,O
early,1969,O
application,1969,O
of,1969,O
amiloride,1969,B-CHEMICAL
inhibited,1969,O
u-PA,1969,B-GENE-Y
activity,1969,O
in,1969,O
UVB-irradiated,1969,O
corneas,1969,O
as,1969,O
well,1969,O
as,1969,O
in,1969,O
tear,1969,O
fluid,1969,O
and,1969,O
diminished,1969,O
the,1969,O
development,1969,O
of,1969,O
corneal,1969,O
pathology,1969,O
.,1969,O
Rapid,1970,O
glucocorticoid,1970,B-GENE-Y
receptor-mediated,1970,O
inhibition,1970,O
of,1970,O
hypothalamic-pituitary-adrenal,1970,O
ultradian,1970,O
activity,1970,O
in,1970,O
healthy,1970,O
males,1970,O
.,1970,O
A,1971,O
complex,1971,O
dynamic,1971,O
ultradian,1971,O
rhythm,1971,O
underlies,1971,O
the,1971,O
hypothalamic-pituitary-adrenal,1971,O
(,1971,O
HPA,1971,O
),1971,O
circadian,1971,O
rhythm,1971,O
.,1971,O
We,1972,O
have,1972,O
investigated,1972,O
in,1972,O
normal,1972,O
human,1972,O
male,1972,O
subjects,1972,O
the,1972,O
importance,1972,O
",",1972,O
site,1972,O
of,1972,O
action,1972,O
",",1972,O
and,1972,O
receptor-mediated,1972,O
processes,1972,O
involved,1972,O
in,1972,O
rapid,1972,O
basal,1972,O
corticosteroid,1972,B-CHEMICAL
feedback,1972,O
and,1972,O
its,1972,O
interaction,1972,O
with,1972,O
corticotrophin,1972,B-GENE-Y
releasing,1972,I-GENE-Y
hormone,1972,I-GENE-Y
(,1972,O
CRH,1972,B-GENE-Y
),1972,O
drive,1972,O
.,1972,O
Pro-opiomelanocortin,1973,B-GENE-Y
(,1973,O
POMC,1973,B-GENE-Y
),1973,O
",",1973,O
ACTH,1973,O
",",1973,O
and,1973,O
cortisol,1973,O
were,1973,O
measured,1973,O
every,1973,O
10,1973,O
min,1973,O
from,1973,O
healthy,1973,O
males,1973,O
during,1973,O
the,1973,O
awakening,1973,O
period,1973,O
or,1973,O
late,1973,O
afternoon,1973,O
using,1973,O
an,1973,O
automated,1973,O
blood,1973,O
sampling,1973,O
system,1973,O
.,1973,O
Mathematical,1974,O
modeling,1974,O
into,1974,O
discrete,1974,O
pulses,1974,O
of,1974,O
activity,1974,O
revealed,1974,O
that,1974,O
intravenous,1974,O
infusion,1974,O
of,1974,O
the,1974,O
synthetic,1974,O
mixed,1974,O
glucocorticoid/mineralocorticoid,1974,O
agonist,1974,O
prednisolone,1974,B-CHEMICAL
produced,1974,O
rapid,1974,O
inhibition,1974,O
of,1974,O
ACTH,1974,O
and,1974,O
cortisol,1974,B-CHEMICAL
pulsatility,1974,O
within,1974,O
30,1974,O
min,1974,O
in,1974,O
the,1974,O
morning,1974,O
and,1974,O
afternoon,1974,O
.,1974,O
Any,1975,O
pulse,1975,O
that,1975,O
had,1975,O
commenced,1975,O
at,1975,O
the,1975,O
time,1975,O
of,1975,O
injection,1975,O
was,1975,O
unaffected,1975,O
",",1975,O
and,1975,O
subsequent,1975,O
pulsatility,1975,O
was,1975,O
inhibited,1975,O
.,1975,O
Prednisolone,1976,B-CHEMICAL
also,1976,O
inhibited,1976,O
ACTH,1976,O
and,1976,O
cortisol,1976,B-CHEMICAL
secretion,1976,O
in,1976,O
response,1976,O
to,1976,O
exogenous,1976,O
CRH,1976,B-GENE-Y
stimulation,1976,O
",",1976,O
inferring,1976,O
rapid,1976,O
feedback,1976,O
inhibition,1976,O
at,1976,O
the,1976,O
anterior,1976,O
pituitary,1976,O
.,1976,O
Circulating,1977,O
POMC,1977,B-GENE-Y
peptide,1977,O
concentrations,1977,O
were,1977,O
unaffected,1977,O
",",1977,O
suggesting,1977,O
that,1977,O
the,1977,O
rapid,1977,O
corticosteroid,1977,B-CHEMICAL
inhibitory,1977,O
effect,1977,O
specifically,1977,O
targeted,1977,O
ACTH,1977,O
secretion,1977,O
from,1977,O
pituitary,1977,O
corticotrophs,1977,O
.,1977,O
Prednisolone,1978,B-CHEMICAL
fast,1978,O
feedback,1978,O
was,1978,O
only,1978,O
reduced,1978,O
by,1978,O
glucocorticoid,1978,B-GENE-Y
receptor,1978,I-GENE-Y
antagonist,1978,O
pretreatment,1978,O
and,1978,O
not,1978,O
by,1978,O
mineralocorticoid,1978,B-GENE-Y
receptor,1978,I-GENE-Y
antagonism,1978,O
",",1978,O
suggesting,1978,O
a,1978,O
glucocorticoid,1978,B-GENE-Y
receptor-mediated,1978,O
pathway,1978,O
.,1978,O
The,1979,O
intravenous,1979,O
prednisolone,1979,B-CHEMICAL
suppression,1979,O
test,1979,O
provides,1979,O
a,1979,O
powerful,1979,O
new,1979,O
tool,1979,O
to,1979,O
investigate,1979,O
HPA,1979,O
abnormalities,1979,O
underlying,1979,O
metabolic,1979,O
and,1979,O
psychiatric,1979,O
disease,1979,O
states,1979,O
.,1979,O
Localization,1980,O
of,1980,O
L-glutamate,1980,B-GENE-N
decarboxylase,1980,I-GENE-N
and,1980,O
GABA,1980,B-GENE-Y
transaminase,1980,I-GENE-Y
immunoreactivity,1980,O
in,1980,O
the,1980,O
sympathetic,1980,O
ganglia,1980,O
of,1980,O
the,1980,O
rat,1980,O
.,1980,O
The,1981,O
location,1981,O
of,1981,O
L-glutamate,1981,B-GENE-N
decarboxylase,1981,I-GENE-N
and,1981,O
gamma-aminobutyrate,1981,B-GENE-Y
(,1981,I-GENE-Y
GABA,1981,I-GENE-Y
),1981,I-GENE-Y
-transaminase,1981,I-GENE-Y
immunoreactivity,1981,O
in,1981,O
the,1981,O
superior,1981,O
cervical,1981,O
ganglion,1981,O
and,1981,O
in,1981,O
the,1981,O
coeliac-superior,1981,O
mesenteric,1981,O
ganglion,1981,O
complex,1981,O
of,1981,O
the,1981,O
rat,1981,O
was,1981,O
studied,1981,O
by,1981,O
an,1981,O
indirect,1981,O
immunofluorescence,1981,O
method,1981,O
and,1981,O
by,1981,O
immunoelectron,1981,O
microscopy,1981,O
",",1981,O
with,1981,O
specific,1981,O
antisera,1981,O
raised,1981,O
in,1981,O
rabbits,1981,O
against,1981,O
the,1981,O
corresponding,1981,O
enzymes,1981,O
.,1981,O
In,1982,O
light,1982,O
microscopy,1982,O
",",1982,O
several,1982,O
glutamate,1982,B-GENE-N
decarboxylase-,1982,O
or,1982,O
GABA-transaminase-immunoreactive,1982,B-GENE-Y
principal,1982,O
nerve,1982,O
cells,1982,O
were,1982,O
detected,1982,O
in,1982,O
the,1982,O
superior,1982,O
cervical,1982,O
ganglion,1982,O
and,1982,O
coeliac-superior,1982,O
mesenteric,1982,O
ganglion,1982,O
complex,1982,O
.,1982,O
In,1983,O
addition,1983,O
",",1983,O
numerous,1983,O
small,1983,O
cells,1983,O
in,1983,O
both,1983,O
the,1983,O
superior,1983,O
cervical,1983,O
ganglion,1983,O
and,1983,O
coeliac-superior,1983,O
mesenteric,1983,O
ganglion,1983,O
complex,1983,O
showed,1983,O
intense,1983,O
immunoreactivity,1983,O
to,1983,O
glutamate,1983,B-GENE-N
decarboxylase,1983,I-GENE-N
or,1983,O
GABA-transaminase,1983,B-GENE-Y
.,1983,O
The,1984,O
small,1984,O
cells,1984,O
were,1984,O
10-20,1984,O
micron,1984,O
in,1984,O
diameter,1984,O
and,1984,O
resembled,1984,O
in,1984,O
size,1984,O
and,1984,O
morphology,1984,O
the,1984,O
small,1984,O
intensely,1984,O
fluorescent,1984,O
cells,1984,O
.,1984,O
In,1985,O
consecutive,1985,O
sections,1985,O
",",1985,O
the,1985,O
small,1985,O
glutamate,1985,B-GENE-N
decarboxylase-immunoreactive,1985,O
cell,1985,O
clusters,1985,O
also,1985,O
showed,1985,O
immunoreactivity,1985,O
to,1985,O
tyrosine,1985,B-GENE-Y
hydroxylase,1985,I-GENE-Y
",",1985,O
suggesting,1985,O
that,1985,O
these,1985,O
cells,1985,O
contain,1985,O
the,1985,O
enzymes,1985,O
for,1985,O
both,1985,O
GABA,1985,B-CHEMICAL
and,1985,O
catecholamine,1985,B-CHEMICAL
synthesis,1985,O
.,1985,O
In,1986,O
the,1986,O
superior,1986,O
cervical,1986,O
ganglion,1986,O
and,1986,O
in,1986,O
the,1986,O
coeliac-superior,1986,O
mesenteric,1986,O
ganglion,1986,O
complex,1986,O
",",1986,O
GABA-transaminase,1986,B-GENE-Y
immunoreactivity,1986,O
was,1986,O
also,1986,O
localized,1986,O
in,1986,O
fibre-like,1986,O
processes,1986,O
around,1986,O
and,1986,O
between,1986,O
the,1986,O
principal,1986,O
nerve,1986,O
cells,1986,O
",",1986,O
in,1986,O
nerve,1986,O
trunks,1986,O
traversing,1986,O
the,1986,O
ganglia,1986,O
",",1986,O
and,1986,O
around,1986,O
or,1986,O
in,1986,O
close,1986,O
contact,1986,O
with,1986,O
ganglionic,1986,O
blood,1986,O
vessels,1986,O
.,1986,O
Furthermore,1987,O
",",1987,O
GABA-transaminase,1987,B-GENE-Y
immunoreactivity,1987,O
was,1987,O
observed,1987,O
in,1987,O
fibre-like,1987,O
structures,1987,O
close,1987,O
to,1987,O
the,1987,O
capsule,1987,O
of,1987,O
the,1987,O
ganglia,1987,O
.,1987,O
Division,1988,O
of,1988,O
the,1988,O
preganglionic,1988,O
nerve,1988,O
trunk,1988,O
of,1988,O
the,1988,O
superior,1988,O
cervical,1988,O
ganglion,1988,O
caused,1988,O
no,1988,O
detectable,1988,O
change,1988,O
in,1988,O
GABA-transaminase,1988,B-GENE-Y
immunoreactivity,1988,O
in,1988,O
the,1988,O
ganglion,1988,O
.,1988,O
In,1989,O
immunoelectron,1989,O
microscopy,1989,O
of,1989,O
the,1989,O
superior,1989,O
cervical,1989,O
ganglion,1989,O
",",1989,O
GABA-transaminase,1989,B-GENE-Y
immunoreactivity,1989,O
was,1989,O
localized,1989,O
in,1989,O
nerve,1989,O
fibres,1989,O
in,1989,O
association,1989,O
with,1989,O
neurotubules,1989,O
.,1989,O
A,1990,O
large,1990,O
number,1990,O
of,1990,O
GABA-transaminase,1990,B-GENE-Y
labelled,1990,O
principal,1990,O
nerve,1990,O
cells,1990,O
were,1990,O
detected,1990,O
",",1990,O
containing,1990,O
immunoreactivity,1990,O
evenly,1990,O
distributed,1990,O
in,1990,O
their,1990,O
cytoplasm,1990,O
.,1990,O
GABA-transaminase,1991,B-GENE-Y
immunoreactivity,1991,O
was,1991,O
also,1991,O
observed,1991,O
in,1991,O
satellite,1991,O
cells,1991,O
and,1991,O
their,1991,O
processes,1991,O
in,1991,O
the,1991,O
superior,1991,O
cervical,1991,O
ganglion,1991,O
.,1991,O
The,1992,O
present,1992,O
immunocytochemical,1992,O
results,1992,O
provide,1992,O
evidence,1992,O
that,1992,O
the,1992,O
rat,1992,O
sympathetic,1992,O
ganglia,1992,O
contain,1992,O
an,1992,O
intrinsic,1992,O
neuronal,1992,O
system,1992,O
showing,1992,O
histochemical,1992,O
markers,1992,O
for,1992,O
GABA,1992,B-CHEMICAL
synthesis,1992,O
and,1992,O
inactivation,1992,O
",",1992,O
but,1992,O
its,1992,O
functional,1992,O
role,1992,O
in,1992,O
the,1992,O
modulation,1992,O
of,1992,O
ganglionic,1992,O
neurotransmission,1992,O
remains,1992,O
to,1992,O
be,1992,O
established,1992,O
.,1992,O
Albiglutide,1993,O
:,1993,O
a,1993,O
new,1993,O
GLP-1,1993,B-GENE-Y
receptor,1993,I-GENE-Y
agonist,1993,O
for,1993,O
the,1993,O
treatment,1993,O
of,1993,O
type,1993,O
2,1993,O
diabetes,1993,O
.,1993,O
OBJECTIVE,1994,O
:,1994,O
To,1994,O
review,1994,O
the,1994,O
pharmacology,1994,O
",",1994,O
pharmacokinetics,1994,O
",",1994,O
safety,1994,O
",",1994,O
and,1994,O
efficacy,1994,O
of,1994,O
albiglutide,1994,O
",",1994,O
a,1994,O
glucagon-like,1994,B-GENE-Y
peptide-1,1994,I-GENE-Y
receptor,1994,I-GENE-Y
agonist,1994,O
(,1994,O
GLP-1,1994,B-GENE-Y
RA,1994,O
),1994,O
in,1994,O
type,1994,O
2,1994,O
diabetes,1994,O
(,1994,O
T2D,1994,O
),1994,O
.,1994,O
DATA,1995,O
SOURCES,1995,O
:,1995,O
A,1995,O
MEDLINE,1995,O
search,1995,O
(,1995,O
1950-June,1995,O
2014,1995,O
),1995,O
was,1995,O
conducted,1995,O
using,1995,O
the,1995,O
keyword,1995,O
albiglutide,1995,O
.,1995,O
References,1996,O
were,1996,O
reviewed,1996,O
to,1996,O
identify,1996,O
additional,1996,O
sources,1996,O
.,1996,O
STUDY,1997,O
SELECTION,1997,O
AND,1997,O
DATA,1997,O
EXTRACTION,1997,O
:,1997,O
Articles,1997,O
evaluating,1997,O
pharmacokinetics,1997,O
",",1997,O
pharmacodynamics,1997,O
",",1997,O
safety,1997,O
",",1997,O
or,1997,O
efficacy,1997,O
of,1997,O
albiglutide,1997,O
were,1997,O
included,1997,O
.,1997,O
DATA,1998,O
SYNTHESIS,1998,O
:,1998,O
Albiglutide,1998,O
is,1998,O
a,1998,O
long-acting,1998,O
GLP-1,1998,B-GENE-Y
RA,1998,O
that,1998,O
lowers,1998,O
glycosylated,1998,B-GENE-Y
hemoglobin,1998,I-GENE-Y
(,1998,O
A1C,1998,B-GENE-Y
),1998,O
and,1998,O
reduces,1998,O
weight,1998,O
by,1998,O
stimulating,1998,O
glucose-dependent,1998,B-CHEMICAL
insulin,1998,B-GENE-Y
secretion,1998,O
",",1998,O
suppressing,1998,O
glucagon,1998,B-GENE-Y
secretion,1998,O
",",1998,O
delaying,1998,O
gastric,1998,O
emptying,1998,O
",",1998,O
and,1998,O
promoting,1998,O
satiety,1998,O
.,1998,O
Albiglutide,1999,O
has,1999,O
a,1999,O
long,1999,O
half-life,1999,O
as,1999,O
a,1999,O
result,1999,O
of,1999,O
resistance,1999,O
to,1999,O
degradation,1999,O
by,1999,O
dipeptidyl,1999,B-GENE-Y
peptidase-4,1999,I-GENE-Y
and,1999,O
fusion,1999,O
to,1999,O
albumin,1999,B-GENE-Y
",",1999,O
thus,1999,O
allowing,1999,O
once-weekly,1999,O
dosing,1999,O
.,1999,O
Albiglutide,2000,O
has,2000,O
been,2000,O
studied,2000,O
as,2000,O
monotherapy,2000,O
and,2000,O
add-on,2000,O
therapy,2000,O
to,2000,O
metformin,2000,B-CHEMICAL
",",2000,O
sulfonylureas,2000,B-CHEMICAL
",",2000,O
thiazolidinediones,2000,B-CHEMICAL
",",2000,O
insulin,2000,B-GENE-Y
glargine,2000,O
",",2000,O
and,2000,O
varying,2000,O
combinations,2000,O
of,2000,O
these,2000,O
agents,2000,O
.,2000,O
Clinical,2001,O
studies,2001,O
have,2001,O
shown,2001,O
albiglutide,2001,O
to,2001,O
be,2001,O
superior,2001,O
to,2001,O
placebo,2001,O
",",2001,O
sitagliptin,2001,B-CHEMICAL
",",2001,O
and,2001,O
glimepiride,2001,B-CHEMICAL
and,2001,O
noninferior,2001,O
to,2001,O
insulin,2001,B-GENE-Y
glargine,2001,O
and,2001,O
insulin,2001,B-GENE-Y
lispro,2001,O
at,2001,O
reducing,2001,O
A1C,2001,B-GENE-Y
in,2001,O
T2D,2001,O
patients,2001,O
",",2001,O
with,2001,O
A1C,2001,B-GENE-Y
changes,2001,O
from,2001,O
baseline,2001,O
ranging,2001,O
from,2001,O
-0.55,2001,O
%,2001,O
to,2001,O
-0.9,2001,O
%,2001,O
.,2001,O
Noninferiority,2002,O
was,2002,O
not,2002,O
achieved,2002,O
when,2002,O
compared,2002,O
to,2002,O
liraglutide,2002,O
and,2002,O
pioglitazone,2002,B-CHEMICAL
.,2002,O
Weight,2003,O
changes,2003,O
ranged,2003,O
from,2003,O
+0.28,2003,O
to,2003,O
-1.21,2003,O
kg,2003,O
.,2003,O
The,2004,O
most,2004,O
common,2004,O
side,2004,O
effects,2004,O
are,2004,O
upper-respiratory-tract,2004,O
infections,2004,O
",",2004,O
diarrhea,2004,O
",",2004,O
nausea,2004,O
",",2004,O
and,2004,O
injection-site,2004,O
reactions,2004,O
.,2004,O
CONCLUSION,2005,O
:,2005,O
Albiglutide,2005,O
is,2005,O
the,2005,O
fourth,2005,O
GLP-1,2005,B-GENE-Y
RA,2005,O
approved,2005,O
in,2005,O
the,2005,O
United,2005,O
States,2005,O
.,2005,O
Advantages,2006,O
include,2006,O
once-weekly,2006,O
dosing,2006,O
and,2006,O
fewer,2006,O
gastrointestinal,2006,O
side,2006,O
effects,2006,O
compared,2006,O
with,2006,O
liraglutide,2006,O
",",2006,O
but,2006,O
it,2006,O
is,2006,O
less,2006,O
effective,2006,O
at,2006,O
reducing,2006,O
A1C,2006,B-GENE-Y
and,2006,O
weight,2006,O
compared,2006,O
to,2006,O
liraglutide,2006,O
.,2006,O
It,2007,O
has,2007,O
not,2007,O
been,2007,O
compared,2007,O
head,2007,O
to,2007,O
head,2007,O
with,2007,O
other,2007,O
GLP-1,2007,B-GENE-Y
RAs,2007,O
.,2007,O
Pharmacophore,2008,O
identification,2008,O
of,2008,O
c-Myc,2008,B-GENE-Y
inhibitor,2008,O
10074-G5,2008,B-CHEMICAL
.,2008,O
A,2009,O
structure-activity,2009,O
relationship,2009,O
(,2009,O
SAR,2009,O
),2009,O
study,2009,O
of,2009,O
the,2009,O
c-Myc,2009,B-GENE-Y
(,2009,O
Myc,2009,B-GENE-Y
),2009,O
inhibitor,2009,O
10074-G5,2009,B-CHEMICAL
(,2009,O
N-,2009,B-CHEMICAL
(,2009,I-CHEMICAL
[,2009,I-CHEMICAL
"1,1'-biphenyl",2009,I-CHEMICAL
],2009,I-CHEMICAL
-2-yl,2009,I-CHEMICAL
),2009,I-CHEMICAL
-7-nitrobenzo,2009,I-CHEMICAL
[,2009,I-CHEMICAL
c,2009,I-CHEMICAL
],2009,I-CHEMICAL
[,2009,I-CHEMICAL
"1,2,5",2009,I-CHEMICAL
],2009,I-CHEMICAL
oxadiazol-4-amine,2009,I-CHEMICAL
",",2009,O
1,2009,O
),2009,O
-,2009,O
which,2009,O
targets,2009,O
a,2009,O
hydrophobic,2009,O
domain,2009,O
of,2009,O
the,2009,O
Myc,2009,B-GENE-Y
oncoprotein,2009,O
that,2009,O
is,2009,O
flanked,2009,O
by,2009,O
arginine,2009,B-CHEMICAL
residues,2009,O
-,2009,O
was,2009,O
executed,2009,O
in,2009,O
order,2009,O
to,2009,O
determine,2009,O
its,2009,O
pharmacophore,2009,O
.,2009,O
Whilst,2010,O
the,2010,O
7-nitrobenzofurazan,2010,B-CHEMICAL
was,2010,O
found,2010,O
to,2010,O
be,2010,O
critical,2010,O
for,2010,O
inhibitory,2010,O
activity,2010,O
",",2010,O
the,2010,O
ortho-biphenyl,2010,B-CHEMICAL
could,2010,O
be,2010,O
replaced,2010,O
with,2010,O
a,2010,O
para-carboxyphenyl,2010,B-CHEMICAL
group,2010,O
to,2010,O
furnish,2010,O
the,2010,O
new,2010,O
inhibitor,2010,O
JY-3-094,2010,B-CHEMICAL
(,2010,O
3q,2010,O
),2010,O
.,2010,O
Around,2011,O
five,2011,O
times,2011,O
as,2011,O
potent,2011,O
as,2011,O
the,2011,O
lead,2011,O
with,2011,O
an,2011,O
IC,2011,O
(,2011,O
50,2011,O
),2011,O
of,2011,O
33,2011,O
μM,2011,O
for,2011,O
disruption,2011,O
of,2011,O
the,2011,O
Myc-Max,2011,B-GENE-Y
heterodimer,2011,O
",",2011,O
JY-3-094,2011,B-CHEMICAL
demonstrated,2011,O
excellent,2011,O
selectivity,2011,O
over,2011,O
Max-Max,2011,B-GENE-Y
homodimers,2011,O
",",2011,O
with,2011,O
no,2011,O
apparent,2011,O
effect,2011,O
at,2011,O
100,2011,O
μM,2011,O
.,2011,O
Importantly,2012,O
",",2012,O
the,2012,O
carboxylic,2012,O
acid,2012,O
of,2012,O
JY-3-094,2012,B-CHEMICAL
improves,2012,O
the,2012,O
physicochemical,2012,O
properties,2012,O
of,2012,O
the,2012,O
lead,2012,O
compound,2012,O
",",2012,O
which,2012,O
will,2012,O
facilitate,2012,O
the,2012,O
incorporation,2012,O
of,2012,O
additional,2012,O
hydrophobicity,2012,O
that,2012,O
might,2012,O
enhance,2012,O
Myc,2012,B-GENE-Y
inhibitory,2012,O
activity,2012,O
further,2012,O
still,2012,O
.,2012,O
Treatment,2013,O
of,2013,O
Niemann-Pick,2013,O
disease,2013,O
type,2013,O
C,2013,O
in,2013,O
two,2013,O
children,2013,O
with,2013,O
miglustat,2013,B-CHEMICAL
:,2013,O
initial,2013,O
responses,2013,O
and,2013,O
maintenance,2013,O
of,2013,O
effects,2013,O
over,2013,O
1,2013,O
year,2013,O
.,2013,O
Niemann-Pick,2014,O
disease,2014,O
type,2014,O
C,2014,O
(,2014,O
NP-C,2014,O
),2014,O
is,2014,O
a,2014,O
lipid,2014,O
storage,2014,O
disorder,2014,O
characterized,2014,O
by,2014,O
the,2014,O
accumulation,2014,O
of,2014,O
unesterified,2014,O
cholesterol,2014,B-CHEMICAL
and,2014,O
glycolipids,2014,O
in,2014,O
the,2014,O
lysosomal/late,2014,O
endosomal,2014,O
system,2014,O
of,2014,O
certain,2014,O
cells,2014,O
in,2014,O
the,2014,O
central,2014,O
nervous,2014,O
system,2014,O
(,2014,O
CNS,2014,O
),2014,O
and,2014,O
visceral,2014,O
organs,2014,O
.,2014,O
Clinical,2015,O
symptoms,2015,O
include,2015,O
progressive,2015,O
neurological,2015,O
deterioration,2015,O
and,2015,O
visceral,2015,O
organomegaly,2015,O
.,2015,O
Miglustat,2016,B-CHEMICAL
",",2016,O
a,2016,O
small,2016,O
iminosugar,2016,O
molecule,2016,O
approved,2016,O
for,2016,O
the,2016,O
treatment,2016,O
of,2016,O
Gaucher,2016,O
disease,2016,O
",",2016,O
reversibly,2016,O
inhibits,2016,O
glucosylceramide,2016,B-GENE-Y
synthase,2016,I-GENE-Y
",",2016,O
which,2016,O
catalyses,2016,O
the,2016,O
first,2016,O
committed,2016,O
step,2016,O
in,2016,O
glycosphingolipid,2016,O
synthesis,2016,O
.,2016,O
The,2017,O
physicochemical,2017,O
properties,2017,O
of,2017,O
miglustat,2017,O
allow,2017,O
it,2017,O
to,2017,O
cross,2017,O
the,2017,O
blood-brain,2017,O
barrier,2017,O
and,2017,O
suggest,2017,O
possible,2017,O
benefits,2017,O
in,2017,O
lysosomal,2017,O
storage,2017,O
diseases,2017,O
affecting,2017,O
the,2017,O
CNS,2017,O
.,2017,O
Here,2018,O
",",2018,O
we,2018,O
present,2018,O
findings,2018,O
in,2018,O
two,2018,O
children,2018,O
with,2018,O
NP-C,2018,O
",",2018,O
aged,2018,O
14,2018,O
years,2018,O
(,2018,O
patient,2018,O
1,2018,O
),2018,O
and,2018,O
9,2018,O
years,2018,O
(,2018,O
patient,2018,O
2,2018,O
),2018,O
",",2018,O
treated,2018,O
with,2018,O
miglustat,2018,B-CHEMICAL
for,2018,O
1,2018,O
year,2018,O
.,2018,O
Before,2019,O
treatment,2019,O
",",2019,O
patient,2019,O
1,2019,O
presented,2019,O
with,2019,O
severe,2019,O
difficulties,2019,O
in,2019,O
swallowing,2019,O
and,2019,O
walking,2019,O
",",2019,O
and,2019,O
patient,2019,O
2,2019,O
with,2019,O
problems,2019,O
mostly,2019,O
affecting,2019,O
communication,2019,O
and,2019,O
social,2019,O
interaction,2019,O
.,2019,O
Videofluoroscopic,2020,O
studies,2020,O
in,2020,O
patient,2020,O
1,2020,O
demonstrated,2020,O
a,2020,O
substantial,2020,O
improvement,2020,O
in,2020,O
swallowing,2020,O
by,2020,O
month,2020,O
6,2020,O
of,2020,O
treatment,2020,O
",",2020,O
and,2020,O
ambulation,2020,O
index,2020,O
measurements,2020,O
indicated,2020,O
improved,2020,O
walking,2020,O
.,2020,O
Mini,2021,O
Mental-State,2021,O
Examination,2021,O
(,2021,O
MMSE,2021,O
),2021,O
assessments,2021,O
in,2021,O
patient,2021,O
2,2021,O
showed,2021,O
cognitive,2021,O
improvement,2021,O
by,2021,O
month,2021,O
6,2021,O
",",2021,O
which,2021,O
was,2021,O
sustained,2021,O
up,2021,O
to,2021,O
month,2021,O
12,2021,O
.,2021,O
Liver/spleen,2022,O
volume,2022,O
and,2022,O
plasma,2022,O
chitotriosidase,2022,B-GENE-Y
activities,2022,O
were,2022,O
stabilized,2022,O
in,2022,O
both,2022,O
cases,2022,O
.,2022,O
There,2023,O
was,2023,O
no,2023,O
weight,2023,O
loss,2023,O
during,2023,O
treatment,2023,O
.,2023,O
Patient,2024,O
1,2024,O
experienced,2024,O
severe,2024,O
but,2024,O
self-limiting,2024,O
paresthesia,2024,O
",",2024,O
which,2024,O
was,2024,O
not,2024,O
associated,2024,O
with,2024,O
peripheral,2024,O
neuropathy,2024,O
.,2024,O
We,2025,O
conclude,2025,O
that,2025,O
miglustat,2025,B-CHEMICAL
can,2025,O
provide,2025,O
therapeutic,2025,O
benefits,2025,O
in,2025,O
CNS,2025,O
symptoms,2025,O
and,2025,O
allows,2025,O
stabilization,2025,O
of,2025,O
systemic,2025,O
disease,2025,O
in,2025,O
childhood-onset,2025,O
NP-C.,2025,O
Further,2025,O
follow-up,2025,O
is,2025,O
crucial,2025,O
to,2025,O
determine,2025,O
the,2025,O
long-term,2025,O
maintenance,2025,O
of,2025,O
these,2025,O
effects,2025,O
.,2025,O
"Safrole-2',3'-oxide",2026,B-CHEMICAL
induces,2026,O
atherosclerotic,2026,O
plaque,2026,O
vulnerability,2026,O
in,2026,O
apolipoprotein,2026,B-GENE-Y
E-knockout,2026,O
mice,2026,O
.,2026,O
"Safrole-2',3'-oxide",2027,B-CHEMICAL
(,2027,O
SFO,2027,B-CHEMICAL
),2027,O
is,2027,O
the,2027,O
major,2027,O
electrophilic,2027,O
metabolite,2027,O
of,2027,O
safrole,2027,B-CHEMICAL
(,2027,O
4-allyl-1,2027,B-CHEMICAL
",",2027,I-CHEMICAL
2-methylenedioxybenzene,2027,I-CHEMICAL
),2027,O
",",2027,O
a,2027,O
natural,2027,O
plant,2027,O
constituent,2027,O
found,2027,O
in,2027,O
essential,2027,O
oils,2027,O
of,2027,O
numerous,2027,O
edible,2027,O
herbs,2027,O
and,2027,O
spices,2027,O
and,2027,O
in,2027,O
food,2027,O
containing,2027,O
these,2027,O
herbs,2027,O
",",2027,O
such,2027,O
as,2027,O
pesto,2027,O
sauce,2027,O
",",2027,O
cola,2027,O
beverages,2027,O
and,2027,O
bologna,2027,O
sausages,2027,O
.,2027,O
The,2028,O
effects,2028,O
of,2028,O
SFO,2028,B-CHEMICAL
in,2028,O
mammalian,2028,O
systems,2028,O
",",2028,O
especially,2028,O
the,2028,O
cardiovascular,2028,O
system,2028,O
",",2028,O
are,2028,O
little,2028,O
known,2028,O
.,2028,O
Disruption,2029,O
of,2029,O
vulnerable,2029,O
atherosclerotic,2029,O
plaques,2029,O
in,2029,O
atherosclerosis,2029,O
",",2029,O
a,2029,O
chronic,2029,O
inflammatory,2029,O
disease,2029,O
",",2029,O
is,2029,O
the,2029,O
main,2029,O
cause,2029,O
of,2029,O
cardiovascular,2029,O
events,2029,O
.,2029,O
In,2030,O
this,2030,O
study,2030,O
",",2030,O
we,2030,O
investigated,2030,O
SFO-induced,2030,B-CHEMICAL
atherosclerotic,2030,O
plaque,2030,O
vulnerability,2030,O
(,2030,O
possibility,2030,O
of,2030,O
rupture,2030,O
),2030,O
in,2030,O
apolipoprotein,2030,B-GENE-Y
E-knockout,2030,O
(,2030,O
apoE,2030,B-GENE-Y
(,2030,O
-/-,2030,O
),2030,O
),2030,O
mice,2030,O
.,2030,O
Lipid,2031,O
area,2031,O
in,2031,O
vessel,2031,O
wall,2031,O
reached,2031,O
59.8,2031,O
%,2031,O
in,2031,O
high,2031,O
dose,2031,O
SFO,2031,B-CHEMICAL
(,2031,O
SFO-HD,2031,B-CHEMICAL
),2031,O
treated,2031,O
group,2031,O
",",2031,O
which,2031,O
is,2031,O
only,2031,O
31.2,2031,O
%,2031,O
in,2031,O
control,2031,O
group,2031,O
.,2031,O
SFO,2032,B-CHEMICAL
treatment,2032,O
changed,2032,O
the,2032,O
lesion,2032,O
composition,2032,O
to,2032,O
an,2032,O
unstable,2032,O
phenotype,2032,O
",",2032,O
increased,2032,O
the,2032,O
number,2032,O
of,2032,O
apoptotic,2032,O
cells,2032,O
in,2032,O
plaque,2032,O
and,2032,O
the,2032,O
endothelium,2032,O
in,2032,O
plaques,2032,O
was,2032,O
damaged,2032,O
after,2032,O
SFO,2032,B-CHEMICAL
treatment,2032,O
.,2032,O
Furthermore,2033,O
",",2033,O
compared,2033,O
with,2033,O
control,2033,O
groups,2033,O
",",2033,O
the,2033,O
plaque,2033,O
endothelium,2033,O
level,2033,O
of,2033,O
p75,2033,B-GENE-Y
(,2033,I-GENE-Y
NTR,2033,I-GENE-Y
),2033,I-GENE-Y
was,2033,O
3-fold,2033,O
increased,2033,O
and,2033,O
the,2033,O
liver,2033,O
level,2033,O
of,2033,O
p75,2033,B-GENE-Y
(,2033,I-GENE-Y
NTR,2033,I-GENE-Y
),2033,I-GENE-Y
was,2033,O
17.4-fold,2033,O
increased,2033,O
by,2033,O
SFO-HD,2033,B-CHEMICAL
.,2033,O
Meanwhile,2034,O
",",2034,O
the,2034,O
serum,2034,O
level,2034,O
of,2034,O
KC,2034,O
(,2034,O
a,2034,O
functional,2034,O
homolog,2034,O
of,2034,O
IL-8,2034,B-GENE-N
and,2034,O
the,2034,O
main,2034,O
proinflammatory,2034,O
alpha,2034,B-GENE-N
chemokine,2034,I-GENE-N
in,2034,O
mice,2034,O
),2034,O
in,2034,O
apoE,2034,B-GENE-Y
(,2034,O
-/-,2034,O
),2034,O
mice,2034,O
was,2034,O
up,2034,O
to,2034,O
357pg/ml,2034,O
in,2034,O
SFO-HD,2034,B-CHEMICAL
treated,2034,O
group,2034,O
.,2034,O
Thus,2035,O
",",2035,O
SFO,2035,B-CHEMICAL
contributes,2035,O
to,2035,O
the,2035,O
instability,2035,O
of,2035,O
atherosclerotic,2035,O
plaque,2035,O
in,2035,O
apoE,2035,B-GENE-Y
(,2035,O
-/-,2035,O
),2035,O
mice,2035,O
through,2035,O
activating,2035,O
p75,2035,B-GENE-Y
(,2035,I-GENE-Y
NTR,2035,I-GENE-Y
),2035,I-GENE-Y
and,2035,O
IL-8,2035,B-GENE-N
and,2035,O
cell,2035,O
apoptosis,2035,O
in,2035,O
plaque,2035,O
.,2035,O
Mechanism,2036,O
of,2036,O
action,2036,O
of,2036,O
dopaminergic,2036,O
agents,2036,O
in,2036,O
Parkinson,2036,O
's,2036,O
disease,2036,O
.,2036,O
As,2037,O
the,2037,O
substantia,2037,O
nigra,2037,O
degenerates,2037,O
in,2037,O
Parkinson,2037,O
's,2037,O
disease,2037,O
(,2037,O
PD,2037,O
),2037,O
",",2037,O
the,2037,O
nigrostriatal,2037,O
pathway,2037,O
is,2037,O
disrupted,2037,O
",",2037,O
reducing,2037,O
striatal,2037,O
dopamine,2037,B-CHEMICAL
and,2037,O
producing,2037,O
PD,2037,O
symptoms,2037,O
.,2037,O
Although,2038,O
dopamine,2038,B-CHEMICAL
does,2038,O
not,2038,O
readily,2038,O
cross,2038,O
the,2038,O
blood-brain,2038,O
barrier,2038,O
",",2038,O
its,2038,O
precursor,2038,O
",",2038,O
levodopa,2038,B-CHEMICAL
",",2038,O
does,2038,O
.,2038,O
Levodopa,2039,B-CHEMICAL
is,2039,O
absorbed,2039,O
in,2039,O
the,2039,O
small,2039,O
bowel,2039,O
and,2039,O
is,2039,O
rapidly,2039,O
catabolized,2039,O
by,2039,O
aromatic-L-amino-acid,2039,B-GENE-Y
decarboxylase,2039,I-GENE-Y
(,2039,O
AADC,2039,B-GENE-Y
),2039,O
and,2039,O
catechol-O-methyltransferase,2039,B-GENE-Y
(,2039,O
COMT,2039,B-GENE-Y
),2039,O
.,2039,O
Because,2040,O
gastric,2040,O
AADC,2040,B-GENE-Y
and,2040,O
COMT,2040,B-GENE-Y
degrade,2040,O
levodopa,2040,B-CHEMICAL
",",2040,O
the,2040,O
drug,2040,O
is,2040,O
given,2040,O
with,2040,O
inhibitors,2040,O
of,2040,O
AADC,2040,B-GENE-Y
(,2040,O
carbidopa,2040,B-CHEMICAL
or,2040,O
benserazide,2040,B-CHEMICAL
),2040,O
",",2040,O
and,2040,O
inhibitors,2040,O
of,2040,O
COMT,2040,B-GENE-Y
will,2040,O
also,2040,O
enter,2040,O
clinical,2040,O
use,2040,O
.,2040,O
Although,2041,O
the,2041,O
exact,2041,O
site,2041,O
of,2041,O
decarboxylation,2041,O
of,2041,O
exogenous,2041,O
levodopa,2041,B-CHEMICAL
to,2041,O
dopamine,2041,B-CHEMICAL
in,2041,O
the,2041,O
brain,2041,O
is,2041,O
unknown,2041,O
",",2041,O
most,2041,O
striatal,2041,O
AADC,2041,B-GENE-Y
is,2041,O
located,2041,O
in,2041,O
nigrostriatal,2041,O
dopaminergic,2041,O
nerve,2041,O
terminals,2041,O
.,2041,O
Newly,2042,O
synthesized,2042,O
dopamine,2042,O
is,2042,O
stored,2042,O
in,2042,O
the,2042,O
terminals,2042,O
and,2042,O
then,2042,O
released,2042,O
",",2042,O
stimulating,2042,O
postsynaptic,2042,O
dopamine,2042,B-GENE-N
receptors,2042,I-GENE-N
and,2042,O
mediating,2042,O
the,2042,O
antiparkinsonian,2042,O
action,2042,O
of,2042,O
levodopa,2042,B-CHEMICAL
.,2042,O
Dopamine,2043,B-CHEMICAL
agonists,2043,O
act,2043,O
directly,2043,O
on,2043,O
postsynaptic,2043,O
dopamine,2043,B-GENE-N
receptors,2043,I-GENE-N
",",2043,O
thus,2043,O
obviating,2043,O
the,2043,O
need,2043,O
for,2043,O
metabolic,2043,O
conversion,2043,O
",",2043,O
storage,2043,O
",",2043,O
and,2043,O
release,2043,O
.,2043,O
How,2044,O
the,2044,O
actions,2044,O
of,2044,O
dopaminergic,2044,O
drugs,2044,O
produce,2044,O
side,2044,O
effects,2044,O
and,2044,O
how,2044,O
these,2044,O
side,2044,O
effects,2044,O
should,2044,O
be,2044,O
managed,2044,O
are,2044,O
discussed,2044,O
.,2044,O
Soy,2045,O
protein,2045,O
suppresses,2045,O
gene,2045,O
expression,2045,O
of,2045,O
acetyl-coA,2045,B-GENE-Y
carboxylase,2045,I-GENE-Y
alpha,2045,I-GENE-Y
from,2045,O
promoter,2045,B-GENE-N
PI,2045,I-GENE-N
in,2045,O
rat,2045,O
liver,2045,O
.,2045,O
Dietary,2046,O
soy,2046,O
protein,2046,O
isolate,2046,O
(,2046,O
SPI,2046,O
),2046,O
reduces,2046,O
hepatic,2046,O
lipogenesis,2046,O
by,2046,O
suppressing,2046,O
gene,2046,O
expression,2046,O
of,2046,O
lipogenic,2046,O
enzymes,2046,O
",",2046,O
including,2046,O
acetyl-CoA,2046,B-GENE-N
carboxylase,2046,I-GENE-N
(,2046,O
ACC,2046,B-GENE-N
),2046,O
.,2046,O
In,2047,O
order,2047,O
to,2047,O
elucidate,2047,O
the,2047,O
mechanism,2047,O
of,2047,O
this,2047,O
regulation,2047,O
",",2047,O
the,2047,O
effect,2047,O
of,2047,O
dietary,2047,O
SPI,2047,O
on,2047,O
promoter,2047,B-GENE-N
(,2047,I-GENE-N
PI,2047,I-GENE-N
and,2047,I-GENE-N
PII,2047,I-GENE-N
),2047,I-GENE-N
specific,2047,O
gene,2047,O
expression,2047,O
of,2047,O
ACC,2047,B-GENE-Y
alpha,2047,I-GENE-Y
was,2047,O
investigated,2047,O
.,2047,O
Rats,2048,O
were,2048,O
fed,2048,O
experimental,2048,O
diets,2048,O
containing,2048,O
SPI,2048,O
or,2048,O
casein,2048,B-GENE-N
as,2048,O
a,2048,O
nitrogen,2048,B-CHEMICAL
source,2048,O
.,2048,O
SPI,2049,O
feeding,2049,O
decreased,2049,O
the,2049,O
hepatic,2049,O
contents,2049,O
of,2049,O
total,2049,O
ACC,2049,B-GENE-N
mRNA,2049,O
as,2049,O
well,2049,O
as,2049,O
triglyceride,2049,B-CHEMICAL
(,2049,O
TG,2049,B-CHEMICAL
),2049,O
content,2049,O
",",2049,O
but,2049,O
dietary,2049,O
SPI,2049,O
affected,2049,O
the,2049,O
amount,2049,O
of,2049,O
sterol-regulatory,2049,B-GENE-Y
element,2049,I-GENE-Y
binding,2049,I-GENE-Y
protein,2049,I-GENE-Y
(,2049,I-GENE-Y
SREBP,2049,I-GENE-Y
),2049,I-GENE-Y
-1,2049,I-GENE-Y
mRNA,2049,O
and,2049,O
protein,2049,O
very,2049,O
little,2049,O
.,2049,O
The,2050,O
amount,2050,O
of,2050,O
ACC,2050,B-GENE-N
mRNA,2050,O
transcribed,2050,O
from,2050,O
PII,2050,B-GENE-N
promoter,2050,I-GENE-N
containing,2050,O
SRE,2050,B-GENE-N
was,2050,O
not,2050,O
significantly,2050,O
affected,2050,O
by,2050,O
dietary,2050,O
protein,2050,O
",",2050,O
while,2050,O
a,2050,O
significant,2050,O
decrease,2050,O
in,2050,O
PI-generated,2050,B-GENE-N
ACC,2050,B-GENE-N
mRNA,2050,O
content,2050,O
was,2050,O
observed,2050,O
in,2050,O
rats,2050,O
fed,2050,O
the,2050,O
SPI,2050,O
diet,2050,O
.,2050,O
These,2051,O
data,2051,O
suggest,2051,O
that,2051,O
SPI,2051,O
feeding,2051,O
decreased,2051,O
the,2051,O
hepatic,2051,O
contents,2051,O
of,2051,O
ACC,2051,B-GENE-Y
alpha,2051,I-GENE-Y
mRNA,2051,O
mainly,2051,O
by,2051,O
regulating,2051,O
PI,2051,B-GENE-N
promoter,2051,I-GENE-N
via,2051,O
a,2051,O
nuclear,2051,O
factor,2051,O
(,2051,O
s,2051,O
),2051,O
other,2051,O
than,2051,O
SREBP-1,2051,B-GENE-Y
.,2051,O
Polymethoxyflavones,2052,B-CHEMICAL
as,2052,O
agents,2052,O
that,2052,O
prevent,2052,O
formation,2052,O
of,2052,O
cataract,2052,O
:,2052,O
nobiletin,2052,B-CHEMICAL
congeners,2052,O
show,2052,O
potent,2052,O
growth,2052,O
inhibitory,2052,O
effects,2052,O
in,2052,O
human,2052,O
lens,2052,O
epithelial,2052,O
cells,2052,O
.,2052,O
Posterior,2053,O
capsular,2053,O
opacification,2053,O
(,2053,O
PCO,2053,O
),2053,O
is,2053,O
the,2053,O
most,2053,O
frequent,2053,O
complication,2053,O
and,2053,O
the,2053,O
primary,2053,O
reason,2053,O
for,2053,O
visual,2053,O
decrease,2053,O
after,2053,O
extracapsular,2053,O
cataract,2053,O
surgery,2053,O
.,2053,O
The,2054,O
proliferation,2054,O
and,2054,O
migration,2054,O
of,2054,O
leftover,2054,O
lens,2054,O
epithelial,2054,O
cells,2054,O
(,2054,O
LECs,2054,O
),2054,O
after,2054,O
surgery,2054,O
may,2054,O
contribute,2054,O
to,2054,O
the,2054,O
development,2054,O
of,2054,O
PCO,2054,O
.,2054,O
To,2055,O
prevent,2055,O
PCO,2055,O
",",2055,O
a,2055,O
rational,2055,O
approach,2055,O
would,2055,O
be,2055,O
to,2055,O
inhibit,2055,O
both,2055,O
the,2055,O
proliferation,2055,O
and,2055,O
the,2055,O
migration,2055,O
of,2055,O
LECs,2055,O
using,2055,O
nontoxic,2055,O
xenobiotics,2055,O
.,2055,O
Nobiletin,2056,B-CHEMICAL
",",2056,O
one,2056,O
of,2056,O
the,2056,O
most,2056,O
abundant,2056,O
polymethoxyflavones,2056,B-CHEMICAL
(,2056,O
PMFs,2056,B-CHEMICAL
),2056,O
in,2056,O
citrus,2056,O
peel,2056,O
",",2056,O
and,2056,O
its,2056,O
synthetic,2056,O
congeners,2056,O
displayed,2056,O
a,2056,O
potent,2056,O
inhibition,2056,O
of,2056,O
LEC,2056,O
proliferation,2056,O
.,2056,O
Structural,2057,O
features,2057,O
which,2057,O
enhance,2057,O
anti-proliferative,2057,O
activity,2057,O
have,2057,O
also,2057,O
been,2057,O
discussed,2057,O
.,2057,O
The,2058,O
in,2058,O
vivo,2058,O
antioxidant,2058,O
and,2058,O
antifibrotic,2058,O
properties,2058,O
of,2058,O
green,2058,O
tea,2058,O
(,2058,O
Camellia,2058,O
sinensis,2058,O
",",2058,O
Theaceae,2058,O
),2058,O
.,2058,O
The,2059,O
in,2059,O
vivo,2059,O
antioxidant,2059,O
and,2059,O
antifibrotic,2059,O
properties,2059,O
of,2059,O
green,2059,O
tea,2059,O
(,2059,O
Camellia,2059,O
sinensis,2059,O
",",2059,O
Theaceae,2059,O
),2059,O
were,2059,O
investigated,2059,O
with,2059,O
a,2059,O
study,2059,O
of,2059,O
carbon,2059,B-CHEMICAL
tetrachloride,2059,I-CHEMICAL
(,2059,O
CCl,2059,B-CHEMICAL
(,2059,I-CHEMICAL
4,2059,I-CHEMICAL
),2059,I-CHEMICAL
),2059,O
-induced,2059,O
oxidative,2059,O
stress,2059,O
and,2059,O
hepatic,2059,O
fibrosis,2059,O
in,2059,O
male,2059,O
ICR,2059,O
mice,2059,O
.,2059,O
Oral,2060,O
administration,2060,O
of,2060,O
green,2060,O
tea,2060,O
extract,2060,O
at,2060,O
doses,2060,O
of,2060,O
125,2060,O
",",2060,O
625,2060,O
and,2060,O
1250,2060,O
mg/kg,2060,O
for,2060,O
8,2060,O
weeks,2060,O
significantly,2060,O
reduced,2060,O
(,2060,O
p,2060,O
<,2060,O
0.05,2060,O
),2060,O
the,2060,O
levels,2060,O
of,2060,O
thiobarbituric,2060,B-CHEMICAL
acid-reactive,2060,O
substances,2060,O
(,2060,O
TBARS,2060,O
),2060,O
and,2060,O
protein,2060,O
carbonyls,2060,B-CHEMICAL
in,2060,O
the,2060,O
liver,2060,O
by,2060,O
at,2060,O
least,2060,O
28,2060,O
%,2060,O
compared,2060,O
with,2060,O
that,2060,O
was,2060,O
induced,2060,O
by,2060,O
CCl,2060,B-CHEMICAL
(,2060,I-CHEMICAL
4,2060,I-CHEMICAL
),2060,I-CHEMICAL
(,2060,O
1,2060,O
mL/kg,2060,O
),2060,O
in,2060,O
mice,2060,O
.,2060,O
Moreover,2061,O
",",2061,O
green,2061,O
tea,2061,O
extract,2061,O
administration,2061,O
significantly,2061,O
increased,2061,O
(,2061,O
p,2061,O
<,2061,O
0.05,2061,O
),2061,O
the,2061,O
activities,2061,O
of,2061,O
catalase,2061,B-GENE-Y
",",2061,O
glutathione,2061,B-GENE-N
peroxidase,2061,I-GENE-N
(,2061,O
GSH-Px,2061,B-GENE-N
),2061,O
and,2061,O
glutathione,2061,B-GENE-Y
reductase,2061,I-GENE-Y
(,2061,O
GSH-Rd,2061,B-GENE-Y
),2061,O
in,2061,O
the,2061,O
liver,2061,O
.,2061,O
Our,2062,O
study,2062,O
found,2062,O
that,2062,O
oral,2062,O
administration,2062,O
of,2062,O
green,2062,O
tea,2062,O
extract,2062,O
prevented,2062,O
CCl,2062,B-CHEMICAL
(,2062,I-CHEMICAL
4,2062,I-CHEMICAL
),2062,I-CHEMICAL
-induced,2062,O
hepatic,2062,O
fibrosis,2062,O
",",2062,O
as,2062,O
evidenced,2062,O
by,2062,O
a,2062,O
decreased,2062,O
hydroxyproline,2062,B-CHEMICAL
level,2062,O
in,2062,O
the,2062,O
liver,2062,O
and,2062,O
a,2062,O
reduced,2062,O
incidence,2062,O
of,2062,O
hepatic,2062,O
fibrosis,2062,O
by,2062,O
histological,2062,O
observations,2062,O
.,2062,O
These,2063,O
results,2063,O
indicate,2063,O
that,2063,O
green,2063,O
tea,2063,O
exhibits,2063,O
potent,2063,O
protective,2063,O
effects,2063,O
against,2063,O
CCl,2063,B-CHEMICAL
(,2063,I-CHEMICAL
4,2063,I-CHEMICAL
),2063,I-CHEMICAL
-induced,2063,O
oxidative,2063,O
stress,2063,O
and,2063,O
hepatic,2063,O
fibrosis,2063,O
in,2063,O
mice,2063,O
by,2063,O
inhibiting,2063,O
oxidative,2063,O
damage,2063,O
and,2063,O
increasing,2063,O
antioxidant,2063,O
enzyme,2063,O
activities,2063,O
.,2063,O
Comparison,2064,O
of,2064,O
vaginal,2064,B-GENE-N
aminopeptidase,2064,I-GENE-N
enzymatic,2064,O
activities,2064,O
in,2064,O
various,2064,O
animals,2064,O
and,2064,O
in,2064,O
humans,2064,O
.,2064,O
The,2065,O
specific,2065,O
enzymatic,2065,O
activity,2065,O
of,2065,O
four,2065,O
different,2065,O
aminopeptidases,2065,B-GENE-N
(,2065,O
aminopeptidase,2065,B-GENE-N
N,2065,I-GENE-N
",",2065,O
leucine,2065,B-GENE-N
aminopeptidase,2065,I-GENE-N
",",2065,O
aminopeptidase,2065,B-GENE-N
A,2065,I-GENE-N
and,2065,O
aminopeptidase,2065,B-GENE-N
B,2065,I-GENE-N
),2065,O
in,2065,O
vaginal,2065,O
homogenates,2065,O
from,2065,O
rabbit,2065,O
",",2065,O
rat,2065,O
",",2065,O
guinea-pig,2065,O
",",2065,O
sheep,2065,O
and,2065,O
humans,2065,O
was,2065,O
compared,2065,O
.,2065,O
The,2066,O
purpose,2066,O
of,2066,O
the,2066,O
study,2066,O
was,2066,O
to,2066,O
find,2066,O
an,2066,O
appropriate,2066,O
animal,2066,O
model,2066,O
that,2066,O
can,2066,O
be,2066,O
used,2066,O
in,2066,O
degradation,2066,O
studies,2066,O
of,2066,O
protein,2066,O
and,2066,O
peptide,2066,O
drugs,2066,O
.,2066,O
Different,2067,O
substrates,2067,O
were,2067,O
used,2067,O
as,2067,O
the,2067,O
relative,2067,O
specific,2067,O
substrates,2067,O
for,2067,O
the,2067,O
determination,2067,O
of,2067,O
aminopeptidase,2067,B-GENE-N
enzymatic,2067,O
activity,2067,O
:,2067,O
4-methoxy-2-naphthylamide,2067,B-CHEMICAL
of,2067,O
L-alanine,2067,B-CHEMICAL
for,2067,O
aminopeptidase,2067,B-GENE-N
N,2067,I-GENE-N
",",2067,O
4-methoxy-2-naphthylamide,2067,B-CHEMICAL
of,2067,O
L-leucine,2067,B-CHEMICAL
for,2067,O
leucine,2067,B-GENE-N
aminopeptidase,2067,I-GENE-N
",",2067,O
4-methoxy-2-naphthylamide,2067,B-CHEMICAL
of,2067,O
L-glutamic,2067,B-CHEMICAL
acid,2067,I-CHEMICAL
for,2067,O
aminopeptidase,2067,B-GENE-N
A,2067,I-GENE-N
and,2067,O
4-methoxy-2-naphthylamide,2067,B-CHEMICAL
of,2067,O
L-arginine,2067,B-CHEMICAL
for,2067,O
aminopeptidase,2067,B-GENE-N
B,2067,I-GENE-N
.,2067,O
The,2068,O
vaginal,2068,B-GENE-N
aminopeptidase,2068,I-GENE-N
enzymatic,2068,O
activity,2068,O
of,2068,O
different,2068,O
species,2068,O
was,2068,O
determined,2068,O
spectrofluorometrically,2068,O
.,2068,O
The,2069,O
inhibition,2069,O
of,2069,O
aminopeptidase,2069,B-GENE-N
activity,2069,O
in,2069,O
the,2069,O
presence,2069,O
of,2069,O
bestatin,2069,B-CHEMICAL
and,2069,O
puromycin,2069,B-CHEMICAL
inhibitors,2069,O
was,2069,O
also,2069,O
investigated,2069,O
.,2069,O
The,2070,O
results,2070,O
showed,2070,O
the,2070,O
presence,2070,O
of,2070,O
aminopeptidase,2070,B-GENE-N
enzymatic,2070,O
activity,2070,O
in,2070,O
all,2070,O
vaginal,2070,O
homogenates,2070,O
in,2070,O
the,2070,O
order,2070,O
:,2070,O
sheep,2070,O
>,2070,O
guinea-pig,2070,O
>,2070,O
rabbit,2070,O
>,2070,O
or,2070,O
=,2070,O
human,2070,O
>,2070,O
or,2070,O
=,2070,O
rat,2070,O
.,2070,O
Based,2071,O
on,2071,O
the,2071,O
results,2071,O
of,2071,O
the,2071,O
hydrolysis,2071,O
and,2071,O
inhibition,2071,O
of,2071,O
the,2071,O
4-methoxy-2-naphthylamide,2071,B-CHEMICAL
substrates,2071,O
",",2071,O
it,2071,O
was,2071,O
difficult,2071,O
to,2071,O
have,2071,O
an,2071,O
exact,2071,O
decision,2071,O
on,2071,O
the,2071,O
aminopeptidase,2071,B-GENE-N
type,2071,O
in,2071,O
the,2071,O
vaginal,2071,O
homogenates,2071,O
from,2071,O
the,2071,O
species,2071,O
studied,2071,O
.,2071,O
It,2072,O
was,2072,O
found,2072,O
that,2072,O
the,2072,O
aminopeptidase,2072,B-GENE-N
activity,2072,O
in,2072,O
rat,2072,O
",",2072,O
rabbit,2072,O
and,2072,O
humans,2072,O
was,2072,O
not,2072,O
statistically,2072,O
different,2072,O
.,2072,O
Therefore,2073,O
",",2073,O
we,2073,O
suggest,2073,O
that,2073,O
rats,2073,O
and,2073,O
rabbits,2073,O
could,2073,O
be,2073,O
used,2073,O
as,2073,O
model,2073,O
animals,2073,O
for,2073,O
vaginal,2073,O
enzymatic,2073,O
activity,2073,O
studies,2073,O
and,2073,O
for,2073,O
determination,2073,O
of,2073,O
the,2073,O
degradation,2073,O
of,2073,O
protein,2073,O
and,2073,O
peptide,2073,O
drugs,2073,O
in,2073,O
the,2073,O
vagina,2073,O
.,2073,O
In,2074,O
silico,2074,O
identification,2074,O
of,2074,O
poly,2074,B-GENE-Y
(,2074,I-GENE-Y
ADP-ribose,2074,I-GENE-Y
),2074,I-GENE-Y
polymerase-1,2074,I-GENE-Y
inhibitors,2074,O
and,2074,O
their,2074,O
chemosensitizing,2074,O
effects,2074,O
against,2074,O
cisplatin-resistant,2074,B-CHEMICAL
human,2074,O
gastric,2074,O
cancer,2074,O
cells,2074,O
.,2074,O
Poly,2075,B-GENE-Y
(,2075,I-GENE-Y
ADP-ribose,2075,I-GENE-Y
),2075,I-GENE-Y
polymerase-1,2075,I-GENE-Y
(,2075,O
PARP-1,2075,B-GENE-Y
),2075,O
enzyme,2075,O
is,2075,O
involved,2075,O
in,2075,O
the,2075,O
repair,2075,O
of,2075,O
DNA,2075,O
damages,2075,O
made,2075,O
by,2075,O
certain,2075,O
anticancer,2075,O
agents,2075,O
.,2075,O
It,2076,O
is,2076,O
suggested,2076,O
that,2076,O
PARP-1,2076,B-GENE-Y
inhibitors,2076,O
potentiate,2076,O
the,2076,O
cytotoxic,2076,O
effects,2076,O
and,2076,O
circumvent,2076,O
the,2076,O
resistance,2076,O
of,2076,O
DNA-modifying,2076,O
anticancer,2076,O
agents,2076,O
such,2076,O
as,2076,O
cisplatin,2076,B-CHEMICAL
.,2076,O
In,2077,O
this,2077,O
study,2077,O
",",2077,O
we,2077,O
conducted,2077,O
virtual,2077,O
screening,2077,O
of,2077,O
Korea,2077,O
Chemical,2077,O
Bank,2077,O
database,2077,O
targeting,2077,O
PARP-1,2077,B-GENE-Y
and,2077,O
identified,2077,O
several,2077,O
potent,2077,O
PARP-1,2077,B-GENE-Y
inhibitors,2077,O
with,2077,O
submicromolar,2077,O
IC50,2077,O
values,2077,O
(,2077,O
77-79nM,2077,O
),2077,O
.,2077,O
We,2078,O
then,2078,O
examined,2078,O
the,2078,O
chemosensitization,2078,O
of,2078,O
cisplatin,2078,B-CHEMICAL
by,2078,O
pre-treatment,2078,O
of,2078,O
PARP-1,2078,B-GENE-Y
inhibitors,2078,O
in,2078,O
cisplatin-resistant,2078,B-CHEMICAL
human,2078,O
gastric,2078,O
cancer,2078,O
cells,2078,O
.,2078,O
Our,2079,O
results,2079,O
show,2079,O
that,2079,O
PARP-1,2079,B-GENE-Y
inhibitors,2079,O
suppress,2079,O
the,2079,O
formation,2079,O
of,2079,O
poly,2079,B-CHEMICAL
(,2079,I-CHEMICAL
ADP-ribose,2079,I-CHEMICAL
),2079,I-CHEMICAL
and,2079,O
enhance,2079,O
the,2079,O
cytotoxicity,2079,O
of,2079,O
cisplatin,2079,B-CHEMICAL
.,2079,O
Peptidyl-prolyl,2080,B-GENE-Y
cis/trans-isomerase,2080,I-GENE-Y
A1,2080,I-GENE-Y
(,2080,O
Pin1,2080,B-GENE-Y
),2080,O
is,2080,O
a,2080,O
target,2080,O
for,2080,O
modification,2080,O
by,2080,O
lipid,2080,O
electrophiles,2080,O
.,2080,O
Oxidation,2081,O
of,2081,O
membrane,2081,O
phospholipids,2081,O
is,2081,O
associated,2081,O
with,2081,O
inflammation,2081,O
",",2081,O
neurodegenerative,2081,O
disease,2081,O
",",2081,O
and,2081,O
cancer,2081,O
.,2081,O
Oxyradical,2082,O
damage,2082,O
to,2082,O
phospholipids,2082,O
results,2082,O
in,2082,O
the,2082,O
production,2082,O
of,2082,O
reactive,2082,O
aldehydes,2082,B-CHEMICAL
that,2082,O
adduct,2082,O
proteins,2082,O
and,2082,O
modulate,2082,O
their,2082,O
function,2082,O
.,2082,O
4-Hydroxynonenal,2083,B-CHEMICAL
(,2083,O
HNE,2083,B-CHEMICAL
),2083,O
",",2083,O
a,2083,O
common,2083,O
product,2083,O
of,2083,O
oxidative,2083,O
damage,2083,O
to,2083,O
lipids,2083,O
",",2083,O
adducts,2083,O
proteins,2083,O
at,2083,O
exposed,2083,O
Cys,2083,B-CHEMICAL
",",2083,O
His,2083,B-CHEMICAL
",",2083,O
or,2083,O
Lys,2083,B-CHEMICAL
residues,2083,O
.,2083,O
Here,2084,O
",",2084,O
we,2084,O
demonstrate,2084,O
that,2084,O
peptidyl-prolyl,2084,B-GENE-Y
cis/trans-isomerase,2084,I-GENE-Y
A1,2084,I-GENE-Y
(,2084,O
Pin1,2084,B-GENE-Y
),2084,O
",",2084,O
an,2084,O
enzyme,2084,O
that,2084,O
catalyzes,2084,O
the,2084,O
conversion,2084,O
of,2084,O
the,2084,O
peptide,2084,O
bond,2084,O
of,2084,O
pSer/pThr-Pro,2084,B-CHEMICAL
moieties,2084,O
in,2084,O
signaling,2084,O
proteins,2084,O
from,2084,O
cis,2084,O
to,2084,O
trans,2084,O
",",2084,O
is,2084,O
highly,2084,O
susceptible,2084,O
to,2084,O
HNE,2084,B-CHEMICAL
modification,2084,O
.,2084,O
Incubation,2085,O
of,2085,O
purified,2085,O
Pin1,2085,B-GENE-Y
with,2085,O
HNE,2085,B-CHEMICAL
followed,2085,O
by,2085,O
MALDI-TOF/TOF,2085,O
mass,2085,O
spectrometry,2085,O
resulted,2085,O
in,2085,O
detection,2085,O
of,2085,O
Michael,2085,O
adducts,2085,O
at,2085,O
the,2085,O
active,2085,O
site,2085,O
residues,2085,O
His-157,2085,B-CHEMICAL
and,2085,O
Cys-113,2085,B-CHEMICAL
.,2085,O
Time,2086,O
and,2086,O
concentration,2086,O
dependencies,2086,O
indicate,2086,O
that,2086,O
Cys-113,2086,B-CHEMICAL
is,2086,O
the,2086,O
primary,2086,O
site,2086,O
of,2086,O
HNE,2086,B-CHEMICAL
modification,2086,O
.,2086,O
Pin1,2087,B-GENE-Y
was,2087,O
adducted,2087,O
in,2087,O
MDA-MB-231,2087,O
breast,2087,O
cancer,2087,O
cells,2087,O
treated,2087,O
with,2087,O
8-alkynyl-HNE,2087,B-CHEMICAL
as,2087,O
judged,2087,O
by,2087,O
click,2087,O
chemistry,2087,O
conjugation,2087,O
with,2087,O
biotin,2087,B-CHEMICAL
followed,2087,O
by,2087,O
streptavidin-based,2087,O
pulldown,2087,O
and,2087,O
Western,2087,O
blotting,2087,O
with,2087,O
anti-Pin1,2087,O
antibody,2087,O
.,2087,O
Furthermore,2088,O
",",2088,O
orbitrap,2088,O
MS,2088,O
data,2088,O
support,2088,O
the,2088,O
adduction,2088,O
of,2088,O
Cys-113,2088,B-CHEMICAL
in,2088,O
the,2088,O
Pin1,2088,B-GENE-Y
active,2088,O
site,2088,O
upon,2088,O
HNE,2088,B-CHEMICAL
treatment,2088,O
of,2088,O
MDA-MB-231,2088,O
cells,2088,O
.,2088,O
siRNA,2089,O
knockdown,2089,O
of,2089,O
Pin1,2089,B-GENE-Y
in,2089,O
MDA-MB-231,2089,O
cells,2089,O
partially,2089,O
protected,2089,O
the,2089,O
cells,2089,O
from,2089,O
HNE-induced,2089,B-CHEMICAL
toxicity,2089,O
.,2089,O
Recent,2090,O
studies,2090,O
indicate,2090,O
that,2090,O
Pin1,2090,B-GENE-Y
is,2090,O
an,2090,O
important,2090,O
molecular,2090,O
target,2090,O
for,2090,O
the,2090,O
chemopreventive,2090,O
effects,2090,O
of,2090,O
green,2090,O
tea,2090,O
polyphenols,2090,B-CHEMICAL
.,2090,O
The,2091,O
present,2091,O
study,2091,O
establishes,2091,O
that,2091,O
it,2091,O
is,2091,O
also,2091,O
a,2091,O
target,2091,O
for,2091,O
electrophilic,2091,O
modification,2091,O
by,2091,O
products,2091,O
of,2091,O
lipid,2091,O
peroxidation,2091,O
.,2091,O
Withdrawal,2092,O
from,2092,O
free-choice,2092,O
ethanol,2092,B-CHEMICAL
consumption,2092,O
results,2092,O
in,2092,O
increased,2092,O
packing,2092,O
density,2092,O
of,2092,O
glutamine,2092,B-GENE-Y
synthetase-immunoreactive,2092,O
astrocytes,2092,O
in,2092,O
the,2092,O
prelimbic,2092,O
cortex,2092,O
of,2092,O
alcohol-preferring,2092,B-CHEMICAL
rats,2092,O
.,2092,O
Excess,2093,O
activation,2093,O
of,2093,O
glutamatergic,2093,O
neurotransmission,2093,O
in,2093,O
the,2093,O
cerebral,2093,O
cortex,2093,O
following,2093,O
ethanol,2093,B-CHEMICAL
withdrawal,2093,O
is,2093,O
considered,2093,O
to,2093,O
contribute,2093,O
to,2093,O
significant,2093,O
behavioural,2093,O
disturbances,2093,O
",",2093,O
and,2093,O
to,2093,O
alcohol,2093,B-CHEMICAL
craving,2093,O
.,2093,O
Astrocytes,2094,O
may,2094,O
play,2094,O
a,2094,O
role,2094,O
in,2094,O
these,2094,O
manifestations,2094,O
because,2094,O
astrocytes,2094,O
are,2094,O
essential,2094,O
in,2094,O
the,2094,O
regulation,2094,O
of,2094,O
released,2094,O
glutamate,2094,B-CHEMICAL
and,2094,O
its,2094,O
conversion,2094,O
to,2094,O
glutamine,2094,B-CHEMICAL
through,2094,O
the,2094,O
enzyme,2094,O
glutamine,2094,B-GENE-Y
synthetase,2094,I-GENE-Y
(,2094,O
GS,2094,B-GENE-Y
),2094,O
.,2094,O
However,2095,O
",",2095,O
it,2095,O
is,2095,O
unclear,2095,O
if,2095,O
withdrawal,2095,O
from,2095,O
free-choice,2095,O
ethanol,2095,B-CHEMICAL
drinking,2095,O
causes,2095,O
changes,2095,O
in,2095,O
the,2095,O
numbers,2095,O
of,2095,O
astrocytes,2095,O
expressing,2095,O
GS,2095,B-GENE-Y
or,2095,O
the,2095,O
cytoskeletal,2095,O
protein,2095,O
of,2095,O
astrocytes,2095,O
glial,2095,B-GENE-Y
fibrillary,2095,I-GENE-Y
acidic,2095,I-GENE-Y
protein,2095,I-GENE-Y
(,2095,O
GFAP,2095,B-GENE-Y
),2095,O
.,2095,O
Alcohol-preferring,2096,B-CHEMICAL
(,2096,O
P,2096,O
),2096,O
rats,2096,O
exposed,2096,O
to,2096,O
free-choice,2096,O
ethanol,2096,B-CHEMICAL
drinking,2096,O
were,2096,O
either,2096,O
maintained,2096,O
without,2096,O
forced,2096,O
interruption,2096,O
of,2096,O
ethanol,2096,B-CHEMICAL
drinking,2096,O
",",2096,O
subjected,2096,O
to,2096,O
a,2096,O
3-day,2096,O
withdrawal,2096,O
period,2096,O
at,2096,O
the,2096,O
end,2096,O
of,2096,O
2,2096,O
months,2096,O
",",2096,O
or,2096,O
subjected,2096,O
to,2096,O
three,2096,O
3-day,2096,O
withdrawal,2096,O
periods,2096,O
along,2096,O
6,2096,O
months,2096,O
.,2096,O
At,2097,O
2,2097,O
months,2097,O
",",2097,O
P,2097,O
rats,2097,O
were,2097,O
also,2097,O
compared,2097,O
with,2097,O
alcohol-naive,2097,B-CHEMICAL
alcohol,2097,B-CHEMICAL
non-preferring,2097,O
rats,2097,O
(,2097,O
NP,2097,O
),2097,O
rats,2097,O
.,2097,O
Packing,2098,O
density,2098,O
of,2098,O
GS,2098,B-GENE-Y
and,2098,O
GFAP-immunoreactive,2098,B-GENE-Y
(,2098,O
IR,2098,O
),2098,O
astrocytes,2098,O
was,2098,O
measured,2098,O
in,2098,O
sections,2098,O
from,2098,O
the,2098,O
prelimbic,2098,O
cortex,2098,O
(,2098,O
PLC,2098,O
),2098,O
using,2098,O
the,2098,O
optical,2098,O
disector,2098,O
probe,2098,O
.,2098,O
An,2099,O
alcohol,2099,B-CHEMICAL
deprivation,2099,O
effect,2099,O
was,2099,O
observed,2099,O
in,2099,O
P,2099,O
rats,2099,O
with,2099,O
withdrawals,2099,O
during,2099,O
a,2099,O
6-month,2099,O
ethanol,2099,O
drinking,2099,O
period,2099,O
.,2099,O
Ethanol,2100,B-CHEMICAL
withdrawal,2100,O
significantly,2100,O
increased,2100,O
the,2100,O
packing,2100,O
density,2100,O
of,2100,O
GS-,2100,B-GENE-Y
and,2100,O
GFAP-IR,2100,B-GENE-Y
astrocytes,2100,O
in,2100,O
the,2100,O
PLC,2100,O
of,2100,O
P,2100,O
rats,2100,O
as,2100,O
compared,2100,O
with,2100,O
P,2100,O
rats,2100,O
with,2100,O
continuous,2100,O
access,2100,O
to,2100,O
ethanol,2100,O
.,2100,O
In,2101,O
addition,2101,O
",",2101,O
there,2101,O
was,2101,O
a,2101,O
positive,2101,O
correlation,2101,O
between,2101,O
the,2101,O
pre-withdrawal,2101,O
ethanol,2101,B-CHEMICAL
consumption,2101,O
and,2101,O
the,2101,O
packing,2101,O
density,2101,O
of,2101,O
GS-IR,2101,B-GENE-Y
astrocytes,2101,O
.,2101,O
The,2102,O
present,2102,O
results,2102,O
suggest,2102,O
the,2102,O
involvement,2102,O
of,2102,O
astrocytes,2102,O
in,2102,O
the,2102,O
regulation,2102,O
of,2102,O
the,2102,O
glutamatergic,2102,O
activation,2102,O
associated,2102,O
with,2102,O
withdrawal,2102,O
from,2102,O
free-choice,2102,O
ethanol,2102,B-CHEMICAL
consumption,2102,O
and,2102,O
point,2102,O
to,2102,O
differential,2102,O
adaptations,2102,O
of,2102,O
GS,2102,B-GENE-Y
and,2102,O
GFAP,2102,B-GENE-Y
to,2102,O
prolonged,2102,O
alcohol,2102,B-CHEMICAL
drinking,2102,O
in,2102,O
the,2102,O
PLC,2102,O
of,2102,O
P,2102,O
rats,2102,O
.,2102,O
Fetal,2103,O
PGC-1α,2103,B-GENE-Y
overexpression,2103,O
programs,2103,O
adult,2103,O
pancreatic,2103,O
β-cell,2103,O
dysfunction,2103,O
.,2103,O
Adult,2104,O
β-cell,2104,O
dysfunction,2104,O
",",2104,O
a,2104,O
hallmark,2104,O
of,2104,O
type,2104,O
2,2104,O
diabetes,2104,O
",",2104,O
can,2104,O
be,2104,O
programmed,2104,O
by,2104,O
adverse,2104,O
fetal,2104,O
environment,2104,O
.,2104,O
We,2105,O
have,2105,O
shown,2105,O
that,2105,O
fetal,2105,O
glucocorticoids,2105,O
(,2105,O
GCs,2105,O
),2105,O
participate,2105,O
in,2105,O
this,2105,O
programming,2105,O
through,2105,O
inhibition,2105,O
of,2105,O
β-cell,2105,O
development,2105,O
.,2105,O
Here,2106,O
we,2106,O
have,2106,O
investigated,2106,O
the,2106,O
molecular,2106,O
mechanisms,2106,O
underlying,2106,O
this,2106,O
regulation,2106,O
.,2106,O
We,2107,O
showed,2107,O
that,2107,O
GCs,2107,O
stimulate,2107,O
the,2107,O
expression,2107,O
of,2107,O
peroxisome,2107,B-GENE-Y
proliferator-activated,2107,I-GENE-Y
receptor-γ,2107,I-GENE-Y
coactivator-1α,2107,I-GENE-Y
(,2107,O
PGC-1α,2107,B-GENE-Y
),2107,O
",",2107,O
a,2107,O
coregulator,2107,O
of,2107,O
the,2107,O
GCs,2107,B-GENE-Y
receptor,2107,I-GENE-Y
(,2107,O
GR,2107,B-GENE-Y
),2107,O
",",2107,O
and,2107,O
that,2107,O
the,2107,O
overexpression,2107,O
of,2107,O
PGC-1α,2107,B-GENE-Y
represses,2107,O
genes,2107,O
important,2107,O
for,2107,O
β-cell,2107,O
development,2107,O
and,2107,O
function,2107,O
.,2107,O
More,2108,O
precisely,2108,O
",",2108,O
PGC-1α,2108,B-GENE-Y
inhibited,2108,O
the,2108,O
expression,2108,O
of,2108,O
the,2108,O
key,2108,O
β-cell,2108,O
transcription,2108,O
factor,2108,O
pancreatic,2108,B-GENE-Y
duodenal,2108,I-GENE-Y
homeobox,2108,I-GENE-Y
1,2108,I-GENE-Y
(,2108,O
Pdx1,2108,B-GENE-Y
),2108,O
.,2108,O
This,2109,O
repression,2109,O
required,2109,O
the,2109,O
GR,2109,B-GENE-Y
and,2109,O
was,2109,O
mediated,2109,O
through,2109,O
binding,2109,O
of,2109,O
a,2109,O
GR/PGC-1α,2109,B-GENE-Y
complex,2109,O
to,2109,O
the,2109,O
Pdx1,2109,B-GENE-N
promoter,2109,I-GENE-N
.,2109,O
To,2110,O
explore,2110,O
PGC-1α,2110,B-GENE-Y
function,2110,O
",",2110,O
we,2110,O
generated,2110,O
mice,2110,O
with,2110,O
inducible,2110,O
β-cell,2110,O
PGC-1α,2110,B-GENE-Y
overexpression,2110,O
.,2110,O
Mice,2111,O
overexpressing,2111,O
PGC-1α,2111,B-GENE-Y
exhibited,2111,O
at,2111,O
adult,2111,O
age,2111,O
impaired,2111,O
glucose,2111,B-CHEMICAL
tolerance,2111,O
associated,2111,O
with,2111,O
reduced,2111,O
insulin,2111,O
secretion,2111,O
",",2111,O
decreased,2111,O
β-cell,2111,O
mass,2111,O
",",2111,O
and,2111,O
β-cell,2111,O
hypotrophy,2111,O
.,2111,O
Interestingly,2112,O
",",2112,O
PGC-1α,2112,B-GENE-Y
expression,2112,O
in,2112,O
fetal,2112,O
life,2112,O
only,2112,O
was,2112,O
sufficient,2112,O
to,2112,O
impair,2112,O
adult,2112,O
β-cell,2112,O
function,2112,O
whereas,2112,O
β-cell,2112,O
PGC-1α,2112,B-GENE-Y
overexpression,2112,O
from,2112,O
adult,2112,O
age,2112,O
had,2112,O
no,2112,O
consequence,2112,O
on,2112,O
β-cell,2112,O
function,2112,O
.,2112,O
Altogether,2113,O
",",2113,O
our,2113,O
results,2113,O
demonstrate,2113,O
that,2113,O
the,2113,O
GR,2113,B-GENE-Y
and,2113,O
PGC-1α,2113,B-GENE-Y
participate,2113,O
in,2113,O
the,2113,O
fetal,2113,O
programming,2113,O
of,2113,O
adult,2113,O
β-cell,2113,O
function,2113,O
through,2113,O
inhibition,2113,O
of,2113,O
Pdx1,2113,B-GENE-Y
expression,2113,O
.,2113,O
Rufinamide,2114,B-CHEMICAL
attenuates,2114,O
mechanical,2114,O
allodynia,2114,O
in,2114,O
a,2114,O
model,2114,O
of,2114,O
neuropathic,2114,O
pain,2114,O
in,2114,O
the,2114,O
mouse,2114,O
and,2114,O
stabilizes,2114,O
voltage-gated,2114,B-GENE-N
sodium,2114,I-GENE-N
channel,2114,I-GENE-N
inactivated,2114,O
state,2114,O
.,2114,O
BACKGROUND,2115,O
:,2115,O
Voltage-gated,2115,B-GENE-N
sodium,2115,I-GENE-N
channels,2115,I-GENE-N
dysregulation,2115,O
is,2115,O
important,2115,O
for,2115,O
hyperexcitability,2115,O
leading,2115,O
to,2115,O
pain,2115,O
persistence,2115,O
.,2115,O
Sodium,2116,B-GENE-N
channel,2116,I-GENE-N
blockers,2116,O
currently,2116,O
used,2116,O
to,2116,O
treat,2116,O
neuropathic,2116,O
pain,2116,O
are,2116,O
poorly,2116,O
tolerated,2116,O
.,2116,O
Getting,2117,O
new,2117,O
molecules,2117,O
to,2117,O
clinical,2117,O
use,2117,O
is,2117,O
laborious,2117,O
.,2117,O
We,2118,O
here,2118,O
propose,2118,O
a,2118,O
drug,2118,O
already,2118,O
marketed,2118,O
as,2118,O
anticonvulsant,2118,O
",",2118,O
rufinamide,2118,B-CHEMICAL
.,2118,O
METHODS,2119,O
:,2119,O
We,2119,O
compared,2119,O
the,2119,O
behavioral,2119,O
effect,2119,O
of,2119,O
rufinamide,2119,B-CHEMICAL
to,2119,O
amitriptyline,2119,B-CHEMICAL
using,2119,O
the,2119,O
Spared,2119,O
Nerve,2119,O
Injury,2119,O
neuropathic,2119,O
pain,2119,O
model,2119,O
in,2119,O
mice,2119,O
.,2119,O
We,2120,O
compared,2120,O
the,2120,O
effect,2120,O
of,2120,O
rufinamide,2120,B-CHEMICAL
on,2120,O
sodium,2120,B-CHEMICAL
currents,2120,O
using,2120,O
in,2120,O
vitro,2120,O
patch,2120,O
clamp,2120,O
in,2120,O
cells,2120,O
expressing,2120,O
the,2120,O
voltage-gated,2120,B-GENE-N
sodium,2120,I-GENE-N
channel,2120,I-GENE-N
Nav1.7,2120,B-GENE-Y
isoform,2120,O
and,2120,O
on,2120,O
dissociated,2120,O
dorsal,2120,O
root,2120,O
ganglion,2120,O
neurons,2120,O
to,2120,O
amitriptyline,2120,B-CHEMICAL
and,2120,O
mexiletine,2120,B-CHEMICAL
.,2120,O
RESULTS,2121,O
:,2121,O
In,2121,O
naive,2121,O
mice,2121,O
",",2121,O
amitriptyline,2121,B-CHEMICAL
(,2121,O
20,2121,O
mg/kg,2121,O
),2121,O
increased,2121,O
withdrawal,2121,O
threshold,2121,O
to,2121,O
mechanical,2121,O
stimulation,2121,O
from,2121,O
1.3,2121,O
(,2121,O
0.6-1.9,2121,O
),2121,O
(,2121,O
median,2121,O
[,2121,O
95,2121,O
%,2121,O
CI,2121,O
],2121,O
),2121,O
to,2121,O
2.3,2121,O
g,2121,O
(,2121,O
2.2-2.5,2121,O
),2121,O
and,2121,O
latency,2121,O
of,2121,O
withdrawal,2121,O
to,2121,O
heat,2121,O
stimulation,2121,O
from,2121,O
13.1,2121,O
(,2121,O
10.4-15.5,2121,O
),2121,O
to,2121,O
30.0,2121,O
s,2121,O
(,2121,O
21.8-31.9,2121,O
),2121,O
",",2121,O
whereas,2121,O
rufinamide,2121,B-CHEMICAL
had,2121,O
no,2121,O
effect,2121,O
.,2121,O
Rufinamide,2122,B-CHEMICAL
and,2122,O
amitriptyline,2122,B-CHEMICAL
alleviated,2122,O
injury-induced,2122,O
mechanical,2122,O
allodynia,2122,O
for,2122,O
4,2122,O
h,2122,O
(,2122,O
maximal,2122,O
effect,2122,O
:,2122,O
0.10,2122,O
+/-,2122,O
0.03,2122,O
g,2122,O
(,2122,O
mean,2122,O
+/-,2122,O
SD,2122,O
),2122,O
to,2122,O
1.99,2122,O
+/-,2122,O
0.26,2122,O
g,2122,O
for,2122,O
rufinamide,2122,B-CHEMICAL
and,2122,O
0.25,2122,O
+/-,2122,O
0.22,2122,O
g,2122,O
to,2122,O
1.92,2122,O
+/-,2122,O
0.85,2122,O
g,2122,O
for,2122,O
amitriptyline,2122,B-CHEMICAL
),2122,O
.,2122,O
All,2123,O
drugs,2123,O
reduced,2123,O
peak,2123,O
current,2123,O
and,2123,O
stabilized,2123,O
the,2123,O
inactivated,2123,O
state,2123,O
of,2123,O
voltage-gated,2123,B-GENE-N
sodium,2123,I-GENE-N
channel,2123,I-GENE-N
Nav1.7,2123,B-GENE-Y
",",2123,O
with,2123,O
similar,2123,O
effects,2123,O
in,2123,O
dorsal,2123,O
root,2123,O
ganglion,2123,O
neurons,2123,O
.,2123,O
CONCLUSIONS,2124,O
:,2124,O
At,2124,O
doses,2124,O
alleviating,2124,O
neuropathic,2124,O
pain,2124,O
",",2124,O
amitriptyline,2124,B-CHEMICAL
showed,2124,O
alteration,2124,O
of,2124,O
behavioral,2124,O
response,2124,O
possibly,2124,O
related,2124,O
to,2124,O
either,2124,O
alteration,2124,O
of,2124,O
basal,2124,O
pain,2124,O
sensitivity,2124,O
or,2124,O
sedative,2124,O
effect,2124,O
or,2124,O
both,2124,O
.,2124,O
Side-effects,2125,O
and,2125,O
drug,2125,O
tolerance/compliance,2125,O
are,2125,O
major,2125,O
problems,2125,O
with,2125,O
drugs,2125,O
such,2125,O
as,2125,O
amitriptyline,2125,B-CHEMICAL
.,2125,O
Rufinamide,2126,B-CHEMICAL
seems,2126,O
to,2126,O
have,2126,O
a,2126,O
better,2126,O
tolerability,2126,O
profile,2126,O
and,2126,O
could,2126,O
be,2126,O
a,2126,O
new,2126,O
alternative,2126,O
to,2126,O
explore,2126,O
for,2126,O
the,2126,O
treatment,2126,O
of,2126,O
neuropathic,2126,O
pain,2126,O
.,2126,O
All-trans,2127,B-CHEMICAL
retinoic,2127,I-CHEMICAL
acid,2127,I-CHEMICAL
protects,2127,O
hepatocellular,2127,O
carcinoma,2127,O
cells,2127,O
against,2127,O
serum-starvation-induced,2127,O
cell,2127,O
death,2127,O
by,2127,O
upregulating,2127,O
collagen,2127,B-GENE-Y
8A2,2127,I-GENE-Y
.,2127,O
As,2128,O
a,2128,O
therapeutic,2128,O
or,2128,O
chemopreventative,2128,O
agent,2128,O
for,2128,O
various,2128,O
cancers,2128,O
",",2128,O
all-trans,2128,B-CHEMICAL
retinoic,2128,I-CHEMICAL
acid,2128,I-CHEMICAL
(,2128,O
atRA,2128,B-CHEMICAL
),2128,O
has,2128,O
been,2128,O
reported,2128,O
to,2128,O
inhibit,2128,O
growth,2128,O
",",2128,O
induce,2128,O
apoptosis,2128,O
or,2128,O
cause,2128,O
differentiation,2128,O
.,2128,O
It,2129,O
was,2129,O
found,2129,O
that,2129,O
atRA,2129,B-CHEMICAL
could,2129,O
protect,2129,O
hepatocellular,2129,O
carcinoma,2129,O
(,2129,O
HCC,2129,O
),2129,O
cells,2129,O
against,2129,O
cell,2129,O
death,2129,O
induced,2129,O
by,2129,O
serum,2129,O
starvation,2129,O
.,2129,O
Furthermore,2130,O
",",2130,O
it,2130,O
was,2130,O
found,2130,O
that,2130,O
atRA,2130,B-CHEMICAL
could,2130,O
enhance,2130,O
cell,2130,O
adhesion,2130,O
",",2130,O
but,2130,O
had,2130,O
no,2130,O
effect,2130,O
on,2130,O
the,2130,O
cell,2130,O
cycle,2130,O
and,2130,O
apoptosis,2130,O
.,2130,O
Using,2131,O
an,2131,O
Illumina,2131,O
Human,2131,O
HT-12,2131,O
v4,2131,O
expression,2131,O
microarray,2131,O
",",2131,O
207,2131,O
upregulated,2131,O
and,2131,O
173,2131,O
downregulated,2131,O
genes,2131,O
were,2131,O
identified,2131,O
in,2131,O
HepG2,2131,O
cells,2131,O
treated,2131,O
with,2131,O
atRA,2131,B-CHEMICAL
.,2131,O
The,2132,O
most,2132,O
upregulated,2132,O
genes,2132,O
are,2132,O
cytochrome,2132,B-GENE-Y
P450,2132,I-GENE-Y
family,2132,I-GENE-Y
26,2132,I-GENE-Y
subfamily,2132,I-GENE-Y
A,2132,I-GENE-Y
polypeptide,2132,I-GENE-Y
1,2132,I-GENE-Y
(,2132,O
CYP26A1,2132,B-GENE-Y
),2132,O
",",2132,O
histidine,2132,B-GENE-Y
triad,2132,I-GENE-Y
nucleotide,2132,I-GENE-Y
binding,2132,I-GENE-Y
protein,2132,I-GENE-Y
3,2132,I-GENE-Y
(,2132,O
HINT3,2132,B-GENE-Y
),2132,O
",",2132,O
miR-1282,2132,B-GENE-Y
and,2132,O
cytochrome,2132,B-GENE-Y
P450,2132,I-GENE-Y
family,2132,I-GENE-Y
26,2132,I-GENE-Y
subfamily,2132,I-GENE-Y
B,2132,I-GENE-Y
polypeptide,2132,I-GENE-Y
1,2132,I-GENE-Y
(,2132,O
CYP26B1,2132,B-GENE-Y
),2132,O
",",2132,O
which,2132,O
showed,2132,O
more,2132,O
than,2132,O
fivefold,2132,O
greater,2132,O
expression,2132,O
.,2132,O
Using,2133,O
Gene,2133,O
Ontology,2133,O
analysis,2133,O
",",2133,O
the,2133,O
greatest,2133,O
significance,2133,O
was,2133,O
found,2133,O
in,2133,O
extracellular-matrix-related,2133,O
molecular,2133,O
functions,2133,O
and,2133,O
the,2133,O
cellular,2133,O
component,2133,O
in,2133,O
upregulated,2133,O
genes,2133,O
.,2133,O
The,2134,O
upregulation,2134,O
of,2134,O
collagen,2134,B-GENE-Y
8A2,2134,I-GENE-Y
(,2134,O
COL8A2,2134,B-GENE-Y
),2134,O
was,2134,O
further,2134,O
confirmed,2134,O
using,2134,O
quantitative,2134,O
RT-PCR,2134,O
and,2134,O
western,2134,O
blotting,2134,O
.,2134,O
Knockdown,2135,O
of,2135,O
COL8A2,2135,B-GENE-Y
blocked,2135,O
enhancement,2135,O
in,2135,O
the,2135,O
early,2135,O
stage,2135,O
of,2135,O
cell,2135,O
adhesion,2135,O
by,2135,O
atRA,2135,B-CHEMICAL
treatment,2135,O
.,2135,O
Re-expression,2136,O
of,2136,O
COL8A2,2136,B-GENE-Y
in,2136,O
COL8A2-knocked-down,2136,B-GENE-Y
HCC,2136,O
cells,2136,O
reversed,2136,O
the,2136,O
effect,2136,O
of,2136,O
small,2136,O
interfering,2136,O
RNA-COL8A2,2136,O
.,2136,O
In,2137,O
addition,2137,O
",",2137,O
COL8A2,2137,B-GENE-Y
could,2137,O
increase,2137,O
HCC,2137,O
cell,2137,O
migration,2137,O
and,2137,O
invasion,2137,O
.,2137,O
Thus,2138,O
",",2138,O
COL8A2,2138,B-GENE-Y
was,2138,O
identified,2138,O
as,2138,O
the,2138,O
key,2138,O
protein,2138,O
involved,2138,O
in,2138,O
the,2138,O
enhancement,2138,O
of,2138,O
cell,2138,O
adhesion,2138,O
of,2138,O
atRA,2138,B-CHEMICAL
under,2138,O
serum-free,2138,O
conditions,2138,O
.,2138,O
In,2139,O
conclusion,2139,O
",",2139,O
atRA,2139,B-CHEMICAL
protects,2139,O
HCC,2139,O
cells,2139,O
against,2139,O
serum-starvation-induced,2139,O
cell,2139,O
death,2139,O
by,2139,O
enhancing,2139,O
cell,2139,O
adhesion,2139,O
",",2139,O
and,2139,O
COL8A2,2139,B-GENE-Y
plays,2139,O
an,2139,O
important,2139,O
role,2139,O
in,2139,O
HCC,2139,O
cell,2139,O
migration,2139,O
and,2139,O
invasion,2139,O
.,2139,O
Cloning,2140,O
and,2140,O
expression,2140,O
of,2140,O
a,2140,O
heme,2140,B-GENE-N
binding,2140,I-GENE-N
protein,2140,I-GENE-N
from,2140,O
the,2140,O
genome,2140,O
of,2140,O
Saccharomyces,2140,O
cerevisiae,2140,O
.,2140,O
The,2141,O
YLR205c,2141,B-GENE-Y
gene,2141,O
of,2141,O
Saccharomyces,2141,O
cerevisiae,2141,O
does,2141,O
not,2141,O
show,2141,O
significant,2141,O
sequence,2141,O
identity,2141,O
to,2141,O
any,2141,O
known,2141,O
gene,2141,O
",",2141,O
except,2141,O
for,2141,O
heme,2141,B-GENE-N
oxygenase,2141,I-GENE-N
(,2141,O
22,2141,O
%,2141,O
to,2141,O
human,2141,B-GENE-Y
HO-1,2141,I-GENE-Y
),2141,O
.,2141,O
The,2142,O
YLR205,2142,B-GENE-N
ORF,2142,I-GENE-N
was,2142,O
cloned,2142,O
and,2142,O
overexpressed,2142,O
in,2142,O
both,2142,O
Escherichia,2142,O
coli,2142,O
and,2142,O
S.,2142,O
cerevisiae,2142,O
.,2142,O
Both,2143,O
expression,2143,O
systems,2143,O
yielded,2143,O
proteins,2143,O
that,2143,O
bound,2143,O
heme,2143,O
tightly,2143,O
.,2143,O
The,2144,O
isolated,2144,O
YLR205c,2144,B-GENE-Y
protein,2144,O
underwent,2144,O
reduction,2144,O
in,2144,O
the,2144,O
presence,2144,O
of,2144,O
either,2144,O
NADPH-cytochrome,2144,B-GENE-Y
P450,2144,I-GENE-Y
reductase,2144,I-GENE-Y
or,2144,O
NADH-putidaredoxin-putidaredoxin,2144,B-GENE-N
reductase,2144,I-GENE-N
but,2144,O
did,2144,O
not,2144,O
exhibit,2144,O
heme,2144,B-GENE-N
oxygenase,2144,I-GENE-N
activity,2144,O
.,2144,O
The,2145,O
protein,2145,O
exhibited,2145,O
modest,2145,O
H,2145,B-CHEMICAL
(,2145,I-CHEMICAL
2,2145,I-CHEMICAL
),2145,I-CHEMICAL
O,2145,I-CHEMICAL
(,2145,I-CHEMICAL
2,2145,I-CHEMICAL
),2145,I-CHEMICAL
-dependent,2145,O
peroxidase,2145,B-GENE-N
activities,2145,O
with,2145,O
guaiacol,2145,B-CHEMICAL
",",2145,O
potassium,2145,B-CHEMICAL
iodide,2145,I-CHEMICAL
",",2145,O
and,2145,O
"2,2",2145,B-CHEMICAL
(,2145,I-CHEMICAL
',2145,I-CHEMICAL
),2145,I-CHEMICAL
-azino-bis,2145,I-CHEMICAL
(,2145,I-CHEMICAL
3-ethylbenzothiazoline-6-sulfonic,2145,I-CHEMICAL
acid,2145,I-CHEMICAL
(,2145,O
ABTS,2145,B-CHEMICAL
),2145,O
.,2145,O
Thus,2146,O
",",2146,O
YLR205c,2146,B-GENE-Y
codes,2146,O
for,2146,O
a,2146,O
hemoprotein,2146,B-GENE-N
of,2146,O
unknown,2146,O
physiological,2146,O
function,2146,O
that,2146,O
exhibits,2146,O
peroxidase,2146,B-GENE-N
activity,2146,O
.,2146,O
Transcriptional,2147,O
regulation,2147,O
of,2147,O
human,2147,B-GENE-Y
ferredoxin,2147,I-GENE-Y
1,2147,I-GENE-Y
in,2147,O
ovarian,2147,O
granulosa,2147,O
cells,2147,O
.,2147,O
Ferredoxin,2148,B-GENE-Y
1,2148,I-GENE-Y
(,2148,O
FDX1,2148,B-GENE-Y
;,2148,O
adrenodoxin,2148,B-GENE-Y
),2148,O
is,2148,O
an,2148,O
iron-sulfur,2148,B-CHEMICAL
protein,2148,O
that,2148,O
is,2148,O
involved,2148,O
in,2148,O
various,2148,O
metabolic,2148,O
processes,2148,O
",",2148,O
including,2148,O
steroid,2148,B-CHEMICAL
hormone,2148,I-CHEMICAL
synthesis,2148,O
in,2148,O
mammalian,2148,O
tissues,2148,O
.,2148,O
We,2149,O
investigated,2149,O
the,2149,O
transcriptional,2149,O
regulation,2149,O
of,2149,O
FDX1,2149,B-GENE-Y
in,2149,O
ovarian,2149,O
granulosa,2149,O
cells,2149,O
.,2149,O
Previously,2150,O
",",2150,O
we,2150,O
reported,2150,O
that,2150,O
the,2150,O
NR5A,2150,B-GENE-N
family,2150,O
",",2150,O
including,2150,O
steroidogenic,2150,B-GENE-Y
factor-1,2150,I-GENE-Y
(,2150,O
SF-1,2150,B-GENE-Y
),2150,O
and,2150,O
liver,2150,B-GENE-Y
receptor,2150,I-GENE-Y
homolog-1,2150,I-GENE-Y
could,2150,O
induce,2150,O
differentiation,2150,O
of,2150,O
human,2150,O
mesenchymal,2150,O
stem,2150,O
cells,2150,O
(,2150,O
hMSCs,2150,O
),2150,O
into,2150,O
steroidogenic,2150,O
cells,2150,O
.,2150,O
A,2151,O
ChIP,2151,O
assay,2151,O
showed,2151,O
that,2151,O
SF-1,2151,B-GENE-Y
could,2151,O
bind,2151,O
to,2151,O
the,2151,O
FDX1,2151,B-GENE-N
promoter,2151,I-GENE-N
in,2151,O
differentiated,2151,O
hMSCs,2151,O
.,2151,O
Luciferase,2152,O
reporter,2152,O
assays,2152,O
showed,2152,O
that,2152,O
transcription,2152,O
of,2152,O
FDX1,2152,B-GENE-Y
was,2152,O
synergistically,2152,O
activated,2152,O
by,2152,O
the,2152,O
NR5A,2152,B-GENE-N
family,2152,O
and,2152,O
8Br-cAMP,2152,B-CHEMICAL
treatment,2152,O
through,2152,O
two,2152,O
SF-1,2152,B-GENE-Y
binding,2152,O
sites,2152,O
and,2152,O
a,2152,O
CRE-like,2152,B-GENE-N
sequence,2152,O
in,2152,O
a,2152,O
human,2152,O
ovarian,2152,O
granulosa,2152,O
cell,2152,O
line,2152,O
",",2152,O
KGN,2152,O
.,2152,O
Knockdown,2153,O
of,2153,O
FDX1,2153,B-GENE-Y
attenuated,2153,O
progesterone,2153,B-CHEMICAL
production,2153,O
in,2153,O
KGN,2153,O
cells,2153,O
.,2153,O
These,2154,O
results,2154,O
indicate,2154,O
transcription,2154,O
of,2154,O
FDX1,2154,B-GENE-Y
is,2154,O
regulated,2154,O
by,2154,O
the,2154,O
NR5A,2154,B-GENE-N
family,2154,O
and,2154,O
cAMP,2154,B-CHEMICAL
signaling,2154,O
",",2154,O
and,2154,O
participates,2154,O
in,2154,O
steroid,2154,B-CHEMICAL
hormone,2154,O
production,2154,O
in,2154,O
ovarian,2154,O
granulosa,2154,O
cells,2154,O
.,2154,O
Evaluation,2155,O
of,2155,O
flutamide,2155,B-CHEMICAL
genotoxicity,2155,O
in,2155,O
rats,2155,O
and,2155,O
in,2155,O
primary,2155,O
human,2155,O
hepatocytes,2155,O
.,2155,O
Flutamide,2156,B-CHEMICAL
",",2156,O
an,2156,O
effective,2156,O
competitive,2156,O
inhibitor,2156,O
of,2156,O
the,2156,O
androgen,2156,B-GENE-Y
receptor,2156,I-GENE-Y
used,2156,O
orally,2156,O
for,2156,O
palliative,2156,O
treatment,2156,O
of,2156,O
prostatic,2156,O
carcinoma,2156,O
and,2156,O
regulation,2156,O
of,2156,O
prostatic,2156,O
hyperplasia,2156,O
was,2156,O
evaluated,2156,O
for,2156,O
its,2156,O
genotoxic,2156,O
effects,2156,O
in,2156,O
the,2156,O
intact,2156,O
rat,2156,O
and,2156,O
in,2156,O
primary,2156,O
cultures,2156,O
of,2156,O
human,2156,O
hepatocytes,2156,O
.,2156,O
Negative,2157,O
responses,2157,O
were,2157,O
obtained,2157,O
in,2157,O
all,2157,O
the,2157,O
in,2157,O
vivo,2157,O
assays,2157,O
as,2157,O
well,2157,O
as,2157,O
in,2157,O
the,2157,O
in,2157,O
vitro,2157,O
assay,2157,O
.,2157,O
In,2158,O
rats,2158,O
given,2158,O
a,2158,O
single,2158,O
oral,2158,O
dose,2158,O
of,2158,O
500,2158,O
mg/kg,2158,O
flutamide,2158,B-CHEMICAL
",",2158,O
fragmentation,2158,O
and,2158,O
repair,2158,O
of,2158,O
liver,2158,O
DNA,2158,O
were,2158,O
absent,2158,O
",",2158,O
and,2158,O
no,2158,O
increase,2158,O
was,2158,O
observed,2158,O
in,2158,O
the,2158,O
frequency,2158,O
of,2158,O
micronucleated,2158,O
hepatocytes,2158,O
.,2158,O
In,2159,O
the,2159,O
liver,2159,O
of,2159,O
rats,2159,O
given,2159,O
flutamide,2159,B-CHEMICAL
as,2159,O
initiating,2159,O
agent,2159,O
at,2159,O
the,2159,O
dose,2159,O
of,2159,O
500,2159,O
mg/kg/week,2159,O
for,2159,O
6,2159,O
successive,2159,O
weeks,2159,O
",",2159,O
gamma-glutamyltraspeptidase-positive,2159,B-GENE-N
foci,2159,O
were,2159,O
detected,2159,O
only,2159,O
in,2159,O
3,2159,O
of,2159,O
10,2159,O
rats,2159,O
.,2159,O
There,2160,O
was,2160,O
no,2160,O
evidence,2160,O
of,2160,O
a,2160,O
promoting,2160,O
effect,2160,O
on,2160,O
the,2160,O
development,2160,O
of,2160,O
aberrant,2160,O
crypt,2160,O
foci,2160,O
in,2160,O
rats,2160,O
given,2160,O
100,2160,O
mg/kg,2160,O
flutamide,2160,B-CHEMICAL
on,2160,O
alternate,2160,O
days,2160,O
for,2160,O
8,2160,O
successive,2160,O
weeks,2160,O
.,2160,O
In,2161,O
primary,2161,O
cultures,2161,O
of,2161,O
human,2161,O
hepatocytes,2161,O
from,2161,O
one,2161,O
male,2161,O
and,2161,O
one,2161,O
female,2161,O
donor,2161,O
DNA,2161,O
fragmentation,2161,O
as,2161,O
measured,2161,O
by,2161,O
the,2161,O
Comet,2161,O
assays,2161,O
",",2161,O
and,2161,O
DNA,2161,O
repair,2161,O
synthesis,2161,O
as,2161,O
revealed,2161,O
by,2161,O
quantitative,2161,O
autoradiography,2161,O
",",2161,O
were,2161,O
absent,2161,O
after,2161,O
a,2161,O
20,2161,O
hr,2161,O
exposure,2161,O
to,2161,O
flutamide,2161,B-CHEMICAL
concentrations,2161,O
ranging,2161,O
from,2161,O
18,2161,O
to,2161,O
56,2161,O
microM,2161,O
.,2161,O
Taken,2162,O
as,2162,O
a,2162,O
whole,2162,O
",",2162,O
our,2162,O
results,2162,O
seem,2162,O
to,2162,O
indicate,2162,O
that,2162,O
flutamide,2162,B-CHEMICAL
is,2162,O
a,2162,O
non-genotoxic,2162,O
drug,2162,O
.,2162,O
Novel,2163,O
non-canonical,2163,O
TGF-β,2163,B-GENE-N
signaling,2163,O
networks,2163,O
:,2163,O
emerging,2163,O
roles,2163,O
in,2163,O
airway,2163,O
smooth,2163,O
muscle,2163,O
phenotype,2163,O
and,2163,O
function,2163,O
.,2163,O
The,2164,O
airway,2164,O
smooth,2164,O
muscle,2164,O
(,2164,O
ASM,2164,O
),2164,O
plays,2164,O
an,2164,O
important,2164,O
role,2164,O
in,2164,O
the,2164,O
pathophysiology,2164,O
of,2164,O
asthma,2164,O
and,2164,O
chronic,2164,O
obstructive,2164,O
pulmonary,2164,O
disease,2164,O
(,2164,O
COPD,2164,O
),2164,O
.,2164,O
ASM,2165,O
cells,2165,O
express,2165,O
a,2165,O
wide,2165,O
range,2165,O
of,2165,O
receptors,2165,O
involved,2165,O
in,2165,O
contraction,2165,O
",",2165,O
growth,2165,O
",",2165,O
matrix,2165,O
protein,2165,O
production,2165,O
and,2165,O
the,2165,O
secretion,2165,O
of,2165,O
cytokines,2165,B-GENE-N
and,2165,O
chemokines,2165,B-GENE-N
.,2165,O
Transforming,2166,B-GENE-N
growth,2166,I-GENE-N
factor,2166,I-GENE-N
beta,2166,I-GENE-N
(,2166,O
TGF-β,2166,B-GENE-N
),2166,O
is,2166,O
one,2166,O
of,2166,O
the,2166,O
major,2166,O
players,2166,O
in,2166,O
determining,2166,O
the,2166,O
structural,2166,O
and,2166,O
functional,2166,O
abnormalities,2166,O
of,2166,O
the,2166,O
ASM,2166,O
in,2166,O
asthma,2166,O
and,2166,O
COPD,2166,O
.,2166,O
It,2167,O
is,2167,O
increasingly,2167,O
evident,2167,O
that,2167,O
TGF-β,2167,B-GENE-N
functions,2167,O
as,2167,O
a,2167,O
master,2167,O
switch,2167,O
",",2167,O
controlling,2167,O
a,2167,O
network,2167,O
of,2167,O
intracellular,2167,O
and,2167,O
autocrine,2167,O
signaling,2167,O
loops,2167,O
that,2167,O
effect,2167,O
ASM,2167,O
phenotype,2167,O
and,2167,O
function,2167,O
.,2167,O
In,2168,O
this,2168,O
review,2168,O
",",2168,O
the,2168,O
various,2168,O
elements,2168,O
that,2168,O
participate,2168,O
in,2168,O
non-canonical,2168,O
TGF-β,2168,B-GENE-N
signaling,2168,O
",",2168,O
including,2168,O
MAPK,2168,B-GENE-N
",",2168,O
PI3K,2168,B-GENE-N
",",2168,O
WNT/β-catenin,2168,B-GENE-N
",",2168,O
and,2168,O
Ca,2168,B-CHEMICAL
(,2168,I-CHEMICAL
2+,2168,I-CHEMICAL
),2168,I-CHEMICAL
",",2168,O
are,2168,O
discussed,2168,O
",",2168,O
focusing,2168,O
on,2168,O
their,2168,O
effect,2168,O
on,2168,O
ASM,2168,O
phenotype,2168,O
and,2168,O
function,2168,O
.,2168,O
In,2169,O
addition,2169,O
",",2169,O
new,2169,O
aspects,2169,O
of,2169,O
ASM,2169,O
biology,2169,O
and,2169,O
their,2169,O
possible,2169,O
association,2169,O
with,2169,O
non-canonical,2169,O
TGF-β,2169,B-GENE-N
signaling,2169,O
will,2169,O
be,2169,O
discussed,2169,O
.,2169,O
Oxidative,2170,O
status,2170,O
in,2170,O
ICU,2170,O
patients,2170,O
with,2170,O
septic,2170,O
shock,2170,O
.,2170,O
The,2171,O
aim,2171,O
of,2171,O
this,2171,O
pilot,2171,O
study,2171,O
was,2171,O
to,2171,O
investigate,2171,O
variability,2171,O
of,2171,O
oxidative,2171,O
stress,2171,O
during,2171,O
sepsis,2171,O
evolution,2171,O
.,2171,O
ICU,2172,O
patients,2172,O
with,2172,O
the,2172,O
diagnosis,2172,O
of,2172,O
septic,2172,O
shock,2172,O
were,2172,O
included,2172,O
.,2172,O
Thiobarbituric-acid,2173,B-CHEMICAL
reactive,2173,O
substances,2173,O
",",2173,O
total,2173,O
antioxidant,2173,O
capacity,2173,O
",",2173,O
protein,2173,O
carbonyls,2173,B-CHEMICAL
in,2173,O
plasma,2173,O
",",2173,O
reduced,2173,O
",",2173,O
oxidized,2173,O
glutathione,2173,B-CHEMICAL
and,2173,O
catalase,2173,O
activity,2173,O
in,2173,O
erythrocyte,2173,O
lysate,2173,O
were,2173,O
assessed,2173,O
in,2173,O
the,2173,O
1st,2173,O
",",2173,O
3rd,2173,O
",",2173,O
5th,2173,O
and,2173,O
8thday,2173,O
after,2173,O
sepsis,2173,O
appearance,2173,O
.,2173,O
A,2174,O
total,2174,O
of,2174,O
17,2174,O
patients,2174,O
were,2174,O
divided,2174,O
in,2174,O
two,2174,O
groups,2174,O
:,2174,O
survivors,2174,O
(,2174,O
n=7,2174,O
),2174,O
and,2174,O
non-survivors,2174,O
(,2174,O
n=10,2174,O
),2174,O
.,2174,O
APACHE,2175,O
II,2175,O
was,2175,O
11.5±5.4,2175,O
and,2175,O
19.9±4.97,2175,O
in,2175,O
survivors,2175,O
and,2175,O
non-survivors,2175,O
respectively,2175,O
(,2175,O
p=0.005,2175,O
),2175,O
",",2175,O
while,2175,O
mean,2175,O
age,2175,O
and,2175,O
SOFA,2175,O
score,2175,O
at,2175,O
sepsis,2175,O
diagnosis,2175,O
",",2175,O
were,2175,O
similar,2175,O
between,2175,O
the,2175,O
two,2175,O
groups,2175,O
.,2175,O
GSH,2176,B-CHEMICAL
levels,2176,O
",",2176,O
catalase,2176,O
activity,2176,O
and,2176,O
protein,2176,O
carbonyls,2176,B-CHEMICAL
presented,2176,O
significant,2176,O
different,2176,O
course,2176,O
in,2176,O
time,2176,O
between,2176,O
survivors,2176,O
and,2176,O
non-survivors,2176,O
(,2176,O
p,2176,O
<,2176,O
0.05,2176,O
),2176,O
.,2176,O
Catalase,2177,B-GENE-Y
activity,2177,O
was,2177,O
significantly,2177,O
higher,2177,O
in,2177,O
survivors,2177,O
(,2177,O
238.8±51.5,2177,O
),2177,O
than,2177,O
non-survivors,2177,O
(,2177,O
166.4±40.2,2177,O
;,2177,O
p=0.005,2177,O
),2177,O
",",2177,O
while,2177,O
protein,2177,O
carbonyls,2177,B-CHEMICAL
levels,2177,O
were,2177,O
significantly,2177,O
lower,2177,O
in,2177,O
survivors,2177,O
(,2177,O
0.32±0.09,2177,O
),2177,O
than,2177,O
non-survivors,2177,O
(,2177,O
0.48±0.16,2177,O
;,2177,O
p=0.036,2177,O
),2177,O
on,2177,O
the,2177,O
1stday,2177,O
.,2177,O
Yet,2178,O
",",2178,O
non-survivors,2178,O
exhibited,2178,O
a,2178,O
declining,2178,O
course,2178,O
in,2178,O
GSH,2178,B-CHEMICAL
levels,2178,O
during,2178,O
time,2178,O
",",2178,O
while,2178,O
GSH,2178,B-CHEMICAL
levels,2178,O
were,2178,O
maintained,2178,O
in,2178,O
survivors,2178,O
.,2178,O
Conclusively,2179,O
",",2179,O
a,2179,O
longstanding,2179,O
antioxidant,2179,O
deficiency,2179,O
in,2179,O
non-surviving,2179,O
patients,2179,O
was,2179,O
noted,2179,O
.,2179,O
This,2180,O
phenomenon,2180,O
was,2180,O
clearly,2180,O
prominent,2180,O
in,2180,O
patients,2180,O
',2180,O
erythrocytes,2180,O
.,2180,O
NADPH,2181,B-GENE-Y
Oxidase,2181,I-GENE-Y
NOX5-S,2181,I-GENE-Y
and,2181,O
Nuclear,2181,B-GENE-Y
Factor,2181,I-GENE-Y
κB1,2181,I-GENE-Y
Mediate,2181,O
Acid-Induced,2181,O
Microsomal,2181,B-GENE-Y
Prostaglandin,2181,I-GENE-Y
E,2181,I-GENE-Y
Synthase-1,2181,I-GENE-Y
Expression,2181,O
in,2181,O
Barrett,2181,O
's,2181,O
Esophageal,2181,O
Adenocarcinoma,2181,O
Cells,2181,O
.,2181,O
The,2182,O
mechanisms,2182,O
of,2182,O
progression,2182,O
from,2182,O
Barrett,2182,O
's,2182,O
esophagus,2182,O
(,2182,O
BE,2182,O
),2182,O
to,2182,O
esophageal,2182,O
adenocarcinoma,2182,O
(,2182,O
EA,2182,O
),2182,O
are,2182,O
not,2182,O
known,2182,O
.,2182,O
Cycloxygenase-2,2183,B-GENE-Y
(,2183,O
COX-2,2183,B-GENE-Y
),2183,O
-derived,2183,O
prostaglandin,2183,B-CHEMICAL
E2,2183,I-CHEMICAL
(,2183,O
PGE2,2183,B-CHEMICAL
),2183,O
has,2183,O
been,2183,O
shown,2183,O
to,2183,O
be,2183,O
important,2183,O
in,2183,O
esophageal,2183,O
tumorigenesis,2183,O
.,2183,O
We,2184,O
have,2184,O
shown,2184,O
that,2184,O
COX-2,2184,B-GENE-Y
mediates,2184,O
acid-induced,2184,O
PGE2,2184,B-CHEMICAL
production,2184,O
.,2184,O
The,2185,O
prostaglandin,2185,B-GENE-Y
E,2185,I-GENE-Y
synthase,2185,I-GENE-Y
(,2185,O
PGES,2185,B-GENE-Y
),2185,O
responsible,2185,O
for,2185,O
acid-induced,2185,O
PGE2,2185,B-CHEMICAL
production,2185,O
in,2185,O
BE,2185,O
",",2185,O
however,2185,O
",",2185,O
is,2185,O
not,2185,O
known,2185,O
.,2185,O
We,2186,O
found,2186,O
that,2186,O
microsomal,2186,B-GENE-Y
PGES1,2186,I-GENE-Y
(,2186,O
mPGES1,2186,B-GENE-Y
),2186,O
",",2186,O
mPGES2,2186,B-GENE-Y
",",2186,O
and,2186,O
cytosolic,2186,B-GENE-Y
PGES,2186,I-GENE-Y
(,2186,O
cPGES,2186,B-GENE-Y
),2186,O
were,2186,O
present,2186,O
in,2186,O
FLO,2186,O
EA,2186,O
cells,2186,O
.,2186,O
Pulsed,2187,O
acid,2187,O
treatment,2187,O
significantly,2187,O
increased,2187,O
mPGES1,2187,B-GENE-Y
mRNA,2187,O
and,2187,O
protein,2187,O
levels,2187,O
but,2187,O
had,2187,O
little,2187,O
or,2187,O
no,2187,O
effect,2187,O
on,2187,O
mPGES2,2187,B-GENE-Y
or,2187,O
cPGES,2187,B-GENE-Y
mRNA,2187,O
.,2187,O
Knockdown,2188,O
of,2188,O
mPGES1,2188,B-GENE-Y
by,2188,O
mPGES1,2188,B-GENE-Y
small,2188,O
interfering,2188,O
RNA,2188,O
(,2188,O
siRNA,2188,O
),2188,O
blocked,2188,O
acid-induced,2188,O
increase,2188,O
in,2188,O
PGE2,2188,B-CHEMICAL
production,2188,O
and,2188,O
thymidine,2188,B-CHEMICAL
incorporation,2188,O
.,2188,O
Knockdown,2189,O
of,2189,O
NADPH,2189,B-GENE-N
oxidase,2189,I-GENE-N
",",2189,O
NOX5-S,2189,B-GENE-Y
",",2189,O
a,2189,O
variant,2189,O
lacking,2189,O
calcium-binding,2189,B-GENE-N
domains,2189,I-GENE-N
",",2189,O
by,2189,O
NOX5,2189,B-GENE-Y
siRNA,2189,O
significantly,2189,O
inhibited,2189,O
acid-induced,2189,O
increase,2189,O
in,2189,O
mPGES1,2189,B-GENE-Y
expression,2189,O
",",2189,O
thymidine,2189,B-CHEMICAL
incorporation,2189,O
",",2189,O
and,2189,O
PGE2,2189,B-CHEMICAL
production,2189,O
.,2189,O
Overexpression,2190,O
of,2190,O
NOX5-S,2190,B-GENE-Y
significantly,2190,O
increased,2190,O
the,2190,O
luciferase,2190,O
activity,2190,O
in,2190,O
FLO,2190,O
cells,2190,O
transfected,2190,O
with,2190,O
a,2190,O
nuclear,2190,B-GENE-N
factor,2190,I-GENE-N
κB,2190,I-GENE-N
(,2190,O
NF-κB,2190,B-GENE-N
),2190,O
in,2190,O
vivo,2190,O
activation,2190,O
reporter,2190,O
plasmid,2190,O
pNF-κB-Luc,2190,O
.,2190,O
Knockdown,2191,O
of,2191,O
NF-κB1,2191,B-GENE-Y
p50,2191,B-GENE-Y
by,2191,O
p50,2191,B-GENE-Y
siRNA,2191,O
significantly,2191,O
decreased,2191,O
acid-induced,2191,O
increase,2191,O
in,2191,O
mPGES1,2191,B-GENE-Y
expression,2191,O
",",2191,O
thymidine,2191,B-CHEMICAL
incorporation,2191,O
",",2191,O
and,2191,O
PGE2,2191,B-CHEMICAL
production,2191,O
.,2191,O
Two,2192,O
novel,2192,O
NF-κB,2192,B-GENE-N
binding,2192,I-GENE-N
elements,2192,I-GENE-N
",",2192,O
GGAGTCTCCC,2192,B-GENE-N
and,2192,O
CGGGACACCC,2192,B-GENE-N
",",2192,O
were,2192,O
identified,2192,O
in,2192,O
the,2192,O
mPGES1,2192,B-GENE-N
gene,2192,I-GENE-N
promoter,2192,I-GENE-N
.,2192,O
We,2193,O
conclude,2193,O
that,2193,O
mPGES1,2193,B-GENE-Y
mediates,2193,O
acid-induced,2193,O
increase,2193,O
in,2193,O
PGE2,2193,B-CHEMICAL
production,2193,O
and,2193,O
cell,2193,O
proliferation,2193,O
.,2193,O
Acid-induced,2194,O
mPGES1,2194,B-GENE-Y
expression,2194,O
depends,2194,O
on,2194,O
activation,2194,O
of,2194,O
NOX5-S,2194,B-GENE-Y
and,2194,O
NF-κB1,2194,B-GENE-Y
p50,2194,B-GENE-Y
.,2194,O
Microsomal,2195,B-GENE-Y
PGES1,2195,I-GENE-Y
may,2195,O
be,2195,O
a,2195,O
potential,2195,O
target,2195,O
to,2195,O
prevent,2195,O
or,2195,O
treat,2195,O
EA,2195,O
.,2195,O
Butein,2196,B-CHEMICAL
protects,2196,O
human,2196,O
dental,2196,O
pulp,2196,O
cells,2196,O
from,2196,O
hydrogen,2196,B-CHEMICAL
peroxide-induced,2196,O
oxidative,2196,O
toxicity,2196,O
via,2196,O
Nrf2,2196,B-GENE-Y
pathway-dependent,2196,O
heme,2196,B-GENE-Y
oxygenase-1,2196,I-GENE-Y
expressions,2196,O
.,2196,O
Rhus,2197,O
verniciflua,2197,O
Stokes,2197,O
is,2197,O
a,2197,O
plant,2197,O
that,2197,O
is,2197,O
native,2197,O
to,2197,O
East,2197,O
Asian,2197,O
countries,2197,O
",",2197,O
such,2197,O
as,2197,O
Korea,2197,O
",",2197,O
China,2197,O
",",2197,O
and,2197,O
Japan,2197,O
.,2197,O
Butein,2198,B-CHEMICAL
",",2198,O
a,2198,O
plant,2198,O
polyphenol,2198,B-CHEMICAL
",",2198,O
is,2198,O
one,2198,O
of,2198,O
the,2198,O
major,2198,O
active,2198,O
components,2198,O
of,2198,O
R.,2198,O
verniciflua,2198,O
.,2198,O
Reactive,2199,O
oxygen,2199,B-CHEMICAL
species,2199,O
(,2199,O
ROS,2199,O
),2199,O
",",2199,O
produced,2199,O
via,2199,O
dental,2199,O
adhesive,2199,O
bleaching,2199,O
agents,2199,O
and,2199,O
pulpal,2199,O
disease,2199,O
",",2199,O
can,2199,O
cause,2199,O
oxidative,2199,O
stress,2199,O
.,2199,O
Here,2200,O
",",2200,O
we,2200,O
found,2200,O
that,2200,O
butein,2200,B-CHEMICAL
possesses,2200,O
cytoprotective,2200,O
effects,2200,O
on,2200,O
hydrogen,2200,B-CHEMICAL
peroxide,2200,I-CHEMICAL
(,2200,O
H2O2,2200,B-CHEMICAL
),2200,O
-induced,2200,O
dental,2200,O
cell,2200,O
death,2200,O
.,2200,O
H2O2,2201,B-CHEMICAL
is,2201,O
a,2201,O
representative,2201,O
ROS,2201,O
and,2201,O
causes,2201,O
cell,2201,O
death,2201,O
through,2201,O
necrosis,2201,O
in,2201,O
human,2201,O
dental,2201,O
pulp,2201,O
(,2201,O
HDP,2201,O
),2201,O
cells,2201,O
.,2201,O
H2O2-induced,2202,B-CHEMICAL
cytotoxicity,2202,O
and,2202,O
production,2202,O
of,2202,O
ROS,2202,O
were,2202,O
blocked,2202,O
in,2202,O
the,2202,O
presence,2202,O
of,2202,O
butein,2202,B-CHEMICAL
",",2202,O
and,2202,O
these,2202,O
effects,2202,O
were,2202,O
dose,2202,O
dependent,2202,O
.,2202,O
Butein,2203,B-CHEMICAL
also,2203,O
increased,2203,O
heme,2203,B-GENE-Y
oxygenase-1,2203,I-GENE-Y
(,2203,O
HO-1,2203,B-GENE-Y
),2203,O
protein,2203,O
expression,2203,O
and,2203,O
HO,2203,B-GENE-Y
activity,2203,O
.,2203,O
In,2204,O
addition,2204,O
",",2204,O
butein-dependent,2204,B-CHEMICAL
HO-1,2204,B-GENE-Y
expression,2204,O
was,2204,O
required,2204,O
for,2204,O
the,2204,O
inhibition,2204,O
of,2204,O
H2O2-induced,2204,B-CHEMICAL
cell,2204,O
death,2204,O
and,2204,O
ROS,2204,O
generation,2204,O
.,2204,O
Furthermore,2205,O
",",2205,O
butein,2205,B-CHEMICAL
treatment,2205,O
caused,2205,O
nuclear,2205,O
accumulation,2205,O
of,2205,O
nuclear,2205,B-GENE-Y
factor-E2-related,2205,I-GENE-Y
factor,2205,I-GENE-Y
2,2205,I-GENE-Y
(,2205,O
Nrf2,2205,B-GENE-Y
),2205,O
and,2205,O
increased,2205,O
the,2205,O
promoter,2205,O
activity,2205,O
of,2205,O
antioxidant,2205,B-GENE-N
response,2205,I-GENE-N
elements,2205,I-GENE-N
(,2205,O
AREs,2205,B-GENE-N
),2205,O
.,2205,O
Treatment,2206,O
of,2206,O
HDP,2206,O
cells,2206,O
with,2206,O
a,2206,O
c-Jun,2206,B-GENE-N
NH2-terminal,2206,I-GENE-N
kinase,2206,I-GENE-N
(,2206,O
JNK,2206,B-GENE-N
),2206,O
inhibitor,2206,O
also,2206,O
reduced,2206,O
butein-induced,2206,B-CHEMICAL
HO-1,2206,B-GENE-Y
expression,2206,O
",",2206,O
and,2206,O
butein,2206,B-CHEMICAL
treatment,2206,O
led,2206,O
to,2206,O
increased,2206,O
JNK,2206,B-GENE-N
phosphorylation,2206,O
.,2206,O
These,2207,O
results,2207,O
indicate,2207,O
that,2207,O
butein,2207,B-CHEMICAL
may,2207,O
be,2207,O
used,2207,O
to,2207,O
prevent,2207,O
functional,2207,O
dental,2207,O
cell,2207,O
death,2207,O
and,2207,O
thus,2207,O
may,2207,O
be,2207,O
useful,2207,O
as,2207,O
a,2207,O
pulpal,2207,O
disease,2207,O
agent,2207,O
.,2207,O
Folding,2208,O
pathway,2208,O
of,2208,O
guanidine-denatured,2208,B-CHEMICAL
disulfide-intact,2208,B-CHEMICAL
wild-type,2208,O
and,2208,O
mutant,2208,O
bovine,2208,B-GENE-Y
pancreatic,2208,I-GENE-Y
ribonuclease,2208,I-GENE-Y
A,2208,I-GENE-Y
.,2208,O
The,2209,O
refolding,2209,O
kinetics,2209,O
of,2209,O
guanidine-denatured,2209,B-CHEMICAL
disulfide-intact,2209,B-CHEMICAL
bovine,2209,B-GENE-Y
pancreatic,2209,I-GENE-Y
ribonuclease,2209,I-GENE-Y
A,2209,I-GENE-Y
(,2209,O
RNase,2209,B-GENE-Y
A,2209,I-GENE-Y
),2209,O
and,2209,O
its,2209,O
proline-42-to-alanine,2209,B-GENE-N
mutant,2209,O
(,2209,O
Pro42Ala,2209,B-GENE-N
),2209,O
have,2209,O
been,2209,O
studied,2209,O
by,2209,O
monitoring,2209,O
tyrosine,2209,B-CHEMICAL
burial,2209,O
and,2209,O
2'-cytidine,2209,B-CHEMICAL
monophosphate,2209,I-CHEMICAL
(,2209,O
2'CMP,2209,B-CHEMICAL
),2209,O
inhibitor,2209,O
binding,2209,O
.,2209,O
The,2210,O
folding,2210,O
rate,2210,O
for,2210,O
wild-type,2210,O
RNase,2210,B-GENE-Y
A,2210,I-GENE-Y
is,2210,O
faster,2210,O
in,2210,O
the,2210,O
presence,2210,O
of,2210,O
the,2210,O
inhibitor,2210,O
2'CMP,2210,B-CHEMICAL
than,2210,O
in,2210,O
its,2210,O
absence,2210,O
",",2210,O
indicating,2210,O
that,2210,O
the,2210,O
transition-state,2210,O
structure,2210,O
in,2210,O
the,2210,O
rate-determining,2210,O
step,2210,O
is,2210,O
stabilized,2210,O
by,2210,O
2'CMP,2210,B-CHEMICAL
.,2210,O
The,2211,O
folding,2211,O
rate,2211,O
monitored,2211,O
by,2211,O
2'CMP,2211,B-CHEMICAL
binding,2211,O
to,2211,O
the,2211,O
major,2211,O
slow-folding,2211,O
species,2211,O
of,2211,O
Pro42Ala,2211,B-GENE-N
RNase,2211,B-GENE-Y
A,2211,I-GENE-Y
is,2211,O
faster,2211,O
than,2211,O
the,2211,O
folding,2211,O
rate,2211,O
monitored,2211,O
by,2211,O
tyrosine,2211,B-CHEMICAL
burial,2211,O
;,2211,O
however,2211,O
",",2211,O
the,2211,O
folding,2211,O
rate,2211,O
monitored,2211,O
by,2211,O
inhibitor,2211,O
binding,2211,O
to,2211,O
the,2211,O
minor,2211,O
slow-folding,2211,O
species,2211,O
is,2211,O
decreased,2211,O
significantly,2211,O
over,2211,O
the,2211,O
folding,2211,O
rate,2211,O
monitored,2211,O
by,2211,O
tyrosine,2211,B-CHEMICAL
burial,2211,O
",",2211,O
indicating,2211,O
that,2211,O
the,2211,O
major,2211,O
and,2211,O
minor,2211,O
slow-folding,2211,O
species,2211,O
of,2211,O
Pro42Ala,2211,B-GENE-N
fold,2211,O
to,2211,O
the,2211,O
native,2211,O
state,2211,O
with,2211,O
different,2211,O
transition-state,2211,O
conformations,2211,O
in,2211,O
the,2211,O
rate-determining,2211,O
step,2211,O
.,2211,O
Nutrient,2212,O
signaling,2212,O
in,2212,O
protein,2212,O
homeostasis,2212,O
:,2212,O
an,2212,O
increase,2212,O
in,2212,O
quantity,2212,O
at,2212,O
the,2212,O
expense,2212,O
of,2212,O
quality,2212,O
.,2212,O
The,2213,O
discovery,2213,O
that,2213,O
rapamycin,2213,B-CHEMICAL
extends,2213,O
the,2213,O
life,2213,O
span,2213,O
of,2213,O
diverse,2213,O
organisms,2213,O
has,2213,O
triggered,2213,O
many,2213,O
studies,2213,O
aimed,2213,O
at,2213,O
identifying,2213,O
the,2213,O
underlying,2213,O
molecular,2213,O
mechanisms,2213,O
.,2213,O
Mammalian,2214,B-GENE-N
target,2214,I-GENE-N
of,2214,I-GENE-N
rapamycin,2214,I-GENE-N
complex,2214,I-GENE-N
1,2214,I-GENE-N
(,2214,O
mTORC1,2214,B-GENE-N
),2214,O
regulates,2214,O
cell,2214,O
growth,2214,O
and,2214,O
may,2214,O
regulate,2214,O
organismal,2214,O
aging,2214,O
by,2214,O
controlling,2214,O
mRNA,2214,O
translation,2214,O
.,2214,O
However,2215,O
",",2215,O
how,2215,O
inhibiting,2215,O
mTORC1,2215,B-GENE-N
and,2215,O
decreasing,2215,O
protein,2215,O
synthesis,2215,O
can,2215,O
extend,2215,O
life,2215,O
span,2215,O
remains,2215,O
an,2215,O
unresolved,2215,O
issue,2215,O
.,2215,O
We,2216,O
showed,2216,O
that,2216,O
constitutively,2216,O
active,2216,O
mTORC1,2216,B-GENE-N
signaling,2216,O
increased,2216,O
general,2216,O
protein,2216,O
synthesis,2216,O
but,2216,O
unexpectedly,2216,O
reduced,2216,O
the,2216,O
quality,2216,O
of,2216,O
newly,2216,O
synthesized,2216,O
polypeptides,2216,O
.,2216,O
We,2217,O
demonstrated,2217,O
that,2217,O
constitutively,2217,O
active,2217,O
mTORC1,2217,B-GENE-N
decreased,2217,O
translation,2217,O
fidelity,2217,O
by,2217,O
increasing,2217,O
the,2217,O
speed,2217,O
of,2217,O
ribosomal,2217,O
elongation,2217,O
.,2217,O
Conversely,2218,O
",",2218,O
rapamycin,2218,B-CHEMICAL
treatment,2218,O
restored,2218,O
the,2218,O
quality,2218,O
of,2218,O
newly,2218,O
synthesized,2218,O
polypeptides,2218,O
mainly,2218,O
by,2218,O
slowing,2218,O
the,2218,O
rate,2218,O
of,2218,O
ribosomal,2218,O
elongation,2218,O
.,2218,O
We,2219,O
also,2219,O
found,2219,O
distinct,2219,O
roles,2219,O
for,2219,O
mTORC1,2219,B-GENE-N
downstream,2219,O
targets,2219,O
in,2219,O
maintaining,2219,O
protein,2219,O
homeostasis,2219,O
.,2219,O
Loss,2220,O
of,2220,O
S6,2220,B-GENE-N
kinases,2220,I-GENE-N
",",2220,O
but,2220,O
not,2220,O
4E-BP,2220,B-GENE-N
family,2220,O
proteins,2220,O
",",2220,O
which,2220,O
are,2220,O
both,2220,O
involved,2220,O
in,2220,O
regulation,2220,O
of,2220,O
translation,2220,O
",",2220,O
attenuated,2220,O
the,2220,O
effects,2220,O
of,2220,O
rapamycin,2220,B-CHEMICAL
on,2220,O
the,2220,O
quality,2220,O
of,2220,O
newly,2220,O
translated,2220,O
proteins,2220,O
.,2220,O
Our,2221,O
results,2221,O
reveal,2221,O
a,2221,O
mechanistic,2221,O
connection,2221,O
between,2221,O
mTORC1,2221,B-GENE-N
and,2221,O
protein,2221,O
quality,2221,O
",",2221,O
highlighting,2221,O
the,2221,O
central,2221,O
role,2221,O
of,2221,O
nutrient,2221,O
signaling,2221,O
in,2221,O
growth,2221,O
and,2221,O
aging,2221,O
.,2221,O
Cortisol,2222,B-CHEMICAL
and,2222,O
interferon,2222,O
tau,2222,O
regulation,2222,O
of,2222,O
endometrial,2222,O
function,2222,O
and,2222,O
conceptus,2222,O
development,2222,O
in,2222,O
female,2222,O
sheep,2222,O
.,2222,O
During,2223,O
early,2223,O
pregnancy,2223,O
in,2223,O
sheep,2223,O
",",2223,O
the,2223,O
elongating,2223,O
conceptus,2223,O
secretes,2223,O
interferon-τ,2223,B-GENE-N
(,2223,O
IFNT,2223,B-GENE-N
),2223,O
and,2223,O
the,2223,O
conceptus,2223,O
as,2223,O
well,2223,O
as,2223,O
endometrial,2223,O
epithelia,2223,O
produce,2223,O
prostaglandins,2223,B-CHEMICAL
(,2223,O
PG,2223,O
),2223,O
via,2223,O
PG,2223,B-GENE-Y
synthase,2223,I-GENE-Y
2,2223,I-GENE-Y
(,2223,O
PTGS2,2223,B-GENE-Y
),2223,O
and,2223,O
cortisol,2223,B-CHEMICAL
via,2223,O
hydroxysteroid,2223,B-GENE-Y
(,2223,I-GENE-Y
11-β,2223,I-GENE-Y
),2223,I-GENE-Y
dehydrogenase,2223,I-GENE-Y
1,2223,I-GENE-Y
(,2223,O
HSD11B1,2223,B-GENE-Y
),2223,O
.,2223,O
Ovarian,2224,O
progesterone,2224,B-CHEMICAL
induces,2224,O
and,2224,O
PG,2224,O
and,2224,O
IFNT,2224,B-GENE-N
stimulates,2224,O
endometrial,2224,O
HSD11B1,2224,B-GENE-Y
expression,2224,O
and,2224,O
keto-reductase,2224,B-GENE-N
activity,2224,O
as,2224,O
well,2224,O
as,2224,O
many,2224,O
epithelial,2224,O
genes,2224,O
that,2224,O
govern,2224,O
trophectoderm,2224,O
proliferation,2224,O
",",2224,O
migration,2224,O
",",2224,O
and,2224,O
attachment,2224,O
during,2224,O
elongation,2224,O
.,2224,O
The,2225,O
primary,2225,O
aim,2225,O
of,2225,O
these,2225,O
studies,2225,O
was,2225,O
to,2225,O
test,2225,O
the,2225,O
hypothesis,2225,O
that,2225,O
HSD11B1-derived,2225,B-GENE-Y
cortisol,2225,B-CHEMICAL
has,2225,O
a,2225,O
biological,2225,O
role,2225,O
in,2225,O
endometrial,2225,O
function,2225,O
and,2225,O
conceptus,2225,O
development,2225,O
during,2225,O
early,2225,O
pregnancy,2225,O
in,2225,O
sheep,2225,O
.,2225,O
In,2226,O
study,2226,O
1,2226,O
",",2226,O
cyclic,2226,O
ewes,2226,O
received,2226,O
vehicle,2226,O
",",2226,O
cortisol,2226,B-CHEMICAL
",",2226,O
PF,2226,B-CHEMICAL
915275,2226,I-CHEMICAL
(,2226,O
PF,2226,O
;,2226,O
a,2226,O
selective,2226,O
inhibitor,2226,O
of,2226,O
HSD11B1,2226,B-GENE-Y
),2226,O
",",2226,O
cortisol,2226,B-CHEMICAL
and,2226,O
PF,2226,O
",",2226,O
meloxicam,2226,B-CHEMICAL
(,2226,O
a,2226,O
selective,2226,O
inhibitor,2226,O
of,2226,O
PTGS2,2226,B-GENE-Y
),2226,O
",",2226,O
cortisol,2226,B-CHEMICAL
and,2226,O
meloxicam,2226,B-CHEMICAL
",",2226,O
recombinant,2226,O
ovine,2226,B-GENE-N
IFNT,2226,I-GENE-N
",",2226,O
or,2226,O
IFNT,2226,B-GENE-N
and,2226,O
PF,2226,O
into,2226,O
the,2226,O
uterus,2226,O
from,2226,O
day,2226,O
10,2226,O
to,2226,O
day14,2226,O
after,2226,O
estrus,2226,O
.,2226,O
Cortisol,2227,B-CHEMICAL
and,2227,O
IFNT,2227,B-GENE-N
stimulated,2227,O
endometrial,2227,O
HSD11B1,2227,B-GENE-Y
expression,2227,O
and,2227,O
activity,2227,O
",",2227,O
increased,2227,O
endometrial,2227,O
PTGS2,2227,B-GENE-Y
activity,2227,O
and,2227,O
the,2227,O
amount,2227,O
of,2227,O
PG,2227,O
in,2227,O
the,2227,O
uterine,2227,O
lumen,2227,O
",",2227,O
and,2227,O
up-regulated,2227,O
many,2227,O
conceptus,2227,O
elongation-related,2227,O
genes,2227,O
in,2227,O
the,2227,O
endometrium,2227,O
.,2227,O
Some,2228,O
effects,2228,O
of,2228,O
cortisol,2228,B-CHEMICAL
and,2228,O
IFNT,2228,B-GENE-N
were,2228,O
mediated,2228,O
by,2228,O
PTGS2-derived,2228,B-GENE-Y
PG,2228,O
.,2228,O
In,2229,O
study,2229,O
2,2229,O
",",2229,O
bred,2229,O
ewes,2229,O
received,2229,O
PF,2229,B-CHEMICAL
915275,2229,I-CHEMICAL
or,2229,O
recombinant,2229,O
ovine,2229,B-GENE-N
IFNT,2229,I-GENE-N
and,2229,O
into,2229,O
the,2229,O
uterus,2229,O
from,2229,O
day,2229,O
10,2229,O
to,2229,O
day,2229,O
14,2229,O
after,2229,O
mating,2229,O
.,2229,O
Inhibition,2230,O
of,2230,O
HSD11B1,2230,B-GENE-Y
activity,2230,O
in,2230,O
utero,2230,O
prevented,2230,O
conceptus,2230,O
elongation,2230,O
",",2230,O
whereas,2230,O
IFNT,2230,B-GENE-N
rescued,2230,O
conceptus,2230,O
elongation,2230,O
in,2230,O
PF-infused,2230,O
ewes,2230,O
.,2230,O
These,2231,O
results,2231,O
suggest,2231,O
that,2231,O
HSD11B1-derived,2231,B-GENE-Y
cortisol,2231,B-CHEMICAL
mediates,2231,O
",",2231,O
in,2231,O
part,2231,O
",",2231,O
actions,2231,O
of,2231,O
ovarian,2231,O
progesterone,2231,B-CHEMICAL
and,2231,O
the,2231,O
conceptus,2231,O
on,2231,O
endometrial,2231,O
function,2231,O
and,2231,O
support,2231,O
the,2231,O
hypothesis,2231,O
that,2231,O
IFNT,2231,B-GENE-N
",",2231,O
PG,2231,O
",",2231,O
and,2231,O
cortisol,2231,B-CHEMICAL
coordinately,2231,O
regulate,2231,O
endometrial,2231,O
functions,2231,O
important,2231,O
for,2231,O
conceptus,2231,O
elongation,2231,O
and,2231,O
implantation,2231,O
during,2231,O
early,2231,O
pregnancy,2231,O
in,2231,O
sheep,2231,O
.,2231,O
2-,2232,B-CHEMICAL
(,2232,I-CHEMICAL
2-Aminoethyl,2232,I-CHEMICAL
),2232,I-CHEMICAL
-quinoline,2232,I-CHEMICAL
(,2232,O
D-1997,2232,B-CHEMICAL
),2232,O
:,2232,O
a,2232,O
novel,2232,O
agonist,2232,O
at,2232,O
5-hydroxytryptamine1-like,2232,B-GENE-N
receptors,2232,I-GENE-N
in,2232,O
the,2232,O
canine,2232,O
basilar,2232,O
artery,2232,O
.,2232,O
This,2233,O
study,2233,O
aimed,2233,O
to,2233,O
investigate,2233,O
the,2233,O
mechanisms,2233,O
involved,2233,O
in,2233,O
the,2233,O
contractile,2233,O
effects,2233,O
produced,2233,O
by,2233,O
the,2233,O
novel,2233,O
quinoline,2233,B-CHEMICAL
derivative,2233,O
",",2233,O
2-,2233,B-CHEMICAL
(,2233,I-CHEMICAL
2-aminoethyl,2233,I-CHEMICAL
),2233,I-CHEMICAL
-quinoline,2233,I-CHEMICAL
(,2233,O
D-1997,2233,B-CHEMICAL
),2233,O
",",2233,O
in,2233,O
the,2233,O
canine,2233,O
isolated,2233,O
basilar,2233,O
artery,2233,O
.,2233,O
For,2234,O
comparison,2234,O
",",2234,O
the,2234,O
effects,2234,O
of,2234,O
D-1997,2234,B-CHEMICAL
were,2234,O
also,2234,O
evaluated,2234,O
on,2234,O
rat,2234,O
aorta,2234,O
.,2234,O
Canine,2235,O
basilar,2235,O
artery,2235,O
and,2235,O
rat,2235,O
aortic,2235,O
rings,2235,O
were,2235,O
prepared,2235,O
and,2235,O
mounted,2235,O
in,2235,O
organ,2235,O
baths,2235,O
to,2235,O
record,2235,O
isometric,2235,O
tension,2235,O
changes,2235,O
.,2235,O
The,2236,O
contractile,2236,O
effects,2236,O
of,2236,O
D-1997,2236,B-CHEMICAL
in,2236,O
the,2236,O
basilar,2236,O
artery,2236,O
were,2236,O
compared,2236,O
with,2236,O
those,2236,O
produced,2236,O
by,2236,O
5-hydroxytryptamine,2236,B-CHEMICAL
(,2236,O
5-HT,2236,B-CHEMICAL
),2236,O
and,2236,O
the,2236,O
5-HT,2236,B-GENE-N
receptor,2236,I-GENE-N
agonist,2236,O
quipazine,2236,B-CHEMICAL
.,2236,O
Thus,2237,O
",",2237,O
4-HT,2237,B-CHEMICAL
(,2237,O
10,2237,O
(,2237,O
-10,2237,O
),2237,O
-10,2237,O
(,2237,O
-6,2237,O
),2237,O
M,2237,O
),2237,O
",",2237,O
D-1997,2237,B-CHEMICAL
(,2237,O
3.1,2237,O
x,2237,O
10,2237,O
(,2237,O
-8,2237,O
),2237,O
-10,2237,O
(,2237,O
-4,2237,O
),2237,O
M,2237,O
),2237,O
and,2237,O
quipazine,2237,B-CHEMICAL
(,2237,O
3.1,2237,O
x,2237,O
10,2237,O
(,2237,O
-7,2237,O
),2237,O
-10,2237,O
(,2237,O
-4,2237,O
),2237,O
M,2237,O
),2237,O
each,2237,O
caused,2237,O
concentration-dependent,2237,O
contractions,2237,O
of,2237,O
the,2237,O
canine,2237,O
basilar,2237,O
artery,2237,O
with,2237,O
a,2237,O
rank,2237,O
order,2237,O
of,2237,O
agonist,2237,O
potency,2237,O
of,2237,O
5-HT,2237,B-CHEMICAL
>,2237,O
D-1997,2237,B-CHEMICAL
>,2237,O
quipazine,2237,B-CHEMICAL
.,2237,O
5-HT,2238,B-CHEMICAL
and,2238,O
D-1997,2238,B-CHEMICAL
exhibited,2238,O
similar,2238,O
maximum,2238,O
effects,2238,O
which,2238,O
were,2238,O
higher,2238,O
than,2238,O
that,2238,O
of,2238,O
quipazine,2238,B-CHEMICAL
.,2238,O
Similar,2239,O
concentrations,2239,O
of,2239,O
D-1997,2239,B-CHEMICAL
failed,2239,O
to,2239,O
produce,2239,O
contraction,2239,O
in,2239,O
rat,2239,O
aorta,2239,O
.,2239,O
The,2240,O
effects,2240,O
of,2240,O
D-1997,2240,B-CHEMICAL
in,2240,O
the,2240,O
basilar,2240,O
artery,2240,O
were,2240,O
not,2240,O
modified,2240,O
by,2240,O
incubation,2240,O
with,2240,O
either,2240,O
the,2240,O
5-HT2,2240,B-GENE-N
receptor,2240,I-GENE-N
antagonist,2240,O
ketanserin,2240,B-CHEMICAL
(,2240,O
0.01-1,2240,O
microM,2240,O
),2240,O
",",2240,O
the,2240,O
5-HT3,2240,B-GENE-N
and,2240,O
5-HT4,2240,B-GENE-Y
receptor,2240,O
antagonist,2240,O
ICS205930,2240,O
(,2240,O
tropisetron,2240,B-CHEMICAL
;,2240,O
0.1-10,2240,O
microM,2240,O
),2240,O
",",2240,O
the,2240,O
5-HT1A,2240,B-GENE-Y
receptor,2240,O
antagonist,2240,O
spiroxatrine,2240,B-CHEMICAL
(,2240,O
0.01-1,2240,O
microM,2240,O
),2240,O
",",2240,O
the,2240,O
beta-adrenoceptor,2240,B-GENE-N
blocker,2240,O
with,2240,O
high,2240,O
affinity,2240,O
for,2240,O
5-HT1A,2240,B-GENE-Y
and,2240,O
5-HT1B,2240,B-GENE-Y
binding,2240,O
sites,2240,O
(,2240,B-CHEMICAL
+/-,2240,I-CHEMICAL
),2240,I-CHEMICAL
-pindolol,2240,I-CHEMICAL
(,2240,O
0.01-1,2240,O
microM,2240,O
),2240,O
",",2240,O
or,2240,O
the,2240,O
alpha,2240,B-GENE-N
1-adrenoceptor,2240,I-GENE-N
antagonist,2240,O
prazosin,2240,B-CHEMICAL
(,2240,O
0.01-1,2240,O
microM,2240,O
),2240,O
.,2240,O
In,2241,O
contrast,2241,O
",",2241,O
the,2241,O
D-1997-induced,2241,B-CHEMICAL
responses,2241,O
were,2241,O
potently,2241,O
and,2241,O
concentration-dependently,2241,O
antagonized,2241,O
by,2241,O
the,2241,O
mixed,2241,O
5-HT1-like,2241,B-GENE-N
and,2241,O
5-HT2,2241,B-GENE-N
receptor,2241,I-GENE-N
antagonist,2241,O
methiothepin,2241,B-CHEMICAL
(,2241,O
0.01-1,2241,O
microM,2241,O
),2241,O
.,2241,O
It,2242,O
is,2242,O
concluded,2242,O
that,2242,O
D-1997,2242,B-CHEMICAL
contracts,2242,O
the,2242,O
canine,2242,O
basilar,2242,O
artery,2242,O
by,2242,O
stimulating,2242,O
5-HT1-like,2242,B-GENE-N
receptors,2242,I-GENE-N
unrelated,2242,O
to,2242,O
either,2242,O
the,2242,O
5-HT1A,2242,B-GENE-Y
or,2242,O
5-HT1B,2242,B-GENE-Y
receptor,2242,O
subtypes,2242,O
.,2242,O
The,2243,O
compound,2243,O
seems,2243,O
to,2243,O
be,2243,O
devoid,2243,O
of,2243,O
5-HT2,2243,B-GENE-N
receptor,2243,I-GENE-N
agonist,2243,O
properties,2243,O
in,2243,O
rat,2243,O
aorta,2243,O
.,2243,O
Vitamin,2244,B-CHEMICAL
K2,2244,I-CHEMICAL
covalently,2244,O
binds,2244,O
to,2244,O
Bak,2244,B-GENE-Y
and,2244,O
induces,2244,O
Bak-mediated,2244,B-GENE-Y
apoptosis,2244,O
.,2244,O
Vitamin,2245,B-CHEMICAL
K2,2245,I-CHEMICAL
(,2245,O
VK2,2245,B-CHEMICAL
",",2245,O
menaquinone,2245,B-CHEMICAL
),2245,O
is,2245,O
known,2245,O
to,2245,O
have,2245,O
anticancer,2245,O
activity,2245,O
in,2245,O
vitro,2245,O
and,2245,O
in,2245,O
vivo,2245,O
.,2245,O
Although,2246,O
its,2246,O
effect,2246,O
is,2246,O
thought,2246,O
to,2246,O
be,2246,O
mediated,2246,O
",",2246,O
at,2246,O
least,2246,O
in,2246,O
part,2246,O
",",2246,O
by,2246,O
the,2246,O
induction,2246,O
of,2246,O
apoptosis,2246,O
",",2246,O
the,2246,O
underlying,2246,O
molecular,2246,O
mechanism,2246,O
remains,2246,O
elusive,2246,O
.,2246,O
Here,2247,O
",",2247,O
we,2247,O
identified,2247,O
Bcl-2,2247,B-GENE-Y
antagonist,2247,O
killer,2247,O
1,2247,O
(,2247,O
Bak,2247,B-GENE-Y
),2247,O
as,2247,O
a,2247,O
molecular,2247,O
target,2247,O
of,2247,O
VK2-induced,2247,B-CHEMICAL
apoptosis,2247,O
.,2247,O
VK2,2248,B-CHEMICAL
directly,2248,O
interacts,2248,O
with,2248,O
Bak,2248,B-GENE-Y
and,2248,O
induces,2248,O
mitochondrial-mediated,2248,O
apoptosis,2248,O
.,2248,O
Although,2249,O
Bak,2249,B-GENE-Y
and,2249,O
Bcl-2-associated,2249,B-GENE-Y
X,2249,I-GENE-Y
protein,2249,I-GENE-Y
(,2249,O
Bax,2249,B-GENE-Y
),2249,O
",",2249,O
another,2249,O
member,2249,O
of,2249,O
the,2249,O
Bcl-2,2249,B-GENE-Y
family,2249,O
",",2249,O
are,2249,O
generally,2249,O
thought,2249,O
to,2249,O
be,2249,O
functionally,2249,O
redundant,2249,O
",",2249,O
only,2249,O
Bak,2249,B-GENE-Y
is,2249,O
necessary,2249,O
and,2249,O
sufficient,2249,O
for,2249,O
VK2-induced,2249,B-CHEMICAL
cytochrome,2249,B-GENE-Y
c,2249,I-GENE-Y
(,2249,O
cyt,2249,B-GENE-Y
c,2249,I-GENE-Y
),2249,O
release,2249,O
and,2249,O
cell,2249,O
death,2249,O
.,2249,O
Moreover,2250,O
",",2250,O
"VK2-2,3",2250,B-CHEMICAL
epoxide,2250,I-CHEMICAL
",",2250,O
an,2250,O
intracellular,2250,O
metabolite,2250,O
of,2250,O
VK2,2250,B-CHEMICAL
",",2250,O
was,2250,O
shown,2250,O
to,2250,O
covalently,2250,O
bind,2250,O
to,2250,O
the,2250,O
cysteine-166,2250,B-CHEMICAL
residue,2250,O
of,2250,O
Bak,2250,B-GENE-Y
.,2250,O
Several,2251,O
lines,2251,O
of,2251,O
evidence,2251,O
suggested,2251,O
that,2251,O
the,2251,O
covalent,2251,O
attachment,2251,O
of,2251,O
VK2,2251,B-CHEMICAL
is,2251,O
critical,2251,O
for,2251,O
apoptosis,2251,O
induction,2251,O
.,2251,O
Thus,2252,O
this,2252,O
study,2252,O
reveals,2252,O
a,2252,O
specific,2252,O
role,2252,O
for,2252,O
Bak,2252,B-GENE-Y
in,2252,O
mitochondria-mediated,2252,O
apoptosis,2252,O
.,2252,O
This,2253,O
study,2253,O
also,2253,O
provides,2253,O
insight,2253,O
into,2253,O
the,2253,O
anticancer,2253,O
effects,2253,O
of,2253,O
VK2,2253,B-CHEMICAL
and,2253,O
suggests,2253,O
that,2253,O
Bak,2253,B-GENE-Y
may,2253,O
be,2253,O
a,2253,O
potential,2253,O
target,2253,O
of,2253,O
cancer,2253,O
therapy,2253,O
.,2253,O
Effect,2254,O
of,2254,O
developmental,2254,O
dioxin,2254,B-CHEMICAL
exposure,2254,O
on,2254,O
methylation,2254,O
and,2254,O
expression,2254,O
of,2254,O
specific,2254,O
imprinted,2254,O
genes,2254,O
in,2254,O
mice,2254,O
.,2254,O
"2,3,7,8-Tetrachlorodibenzo-p-dioxin",2255,B-CHEMICAL
(,2255,O
TCDD,2255,B-CHEMICAL
),2255,O
is,2255,O
an,2255,O
endocrine,2255,O
disruptor,2255,O
affecting,2255,O
the,2255,O
reproductive,2255,O
system,2255,O
in,2255,O
humans,2255,O
.,2255,O
The,2256,O
aim,2256,O
of,2256,O
this,2256,O
study,2256,O
was,2256,O
to,2256,O
evaluate,2256,O
the,2256,O
effects,2256,O
of,2256,O
TCDD,2256,B-CHEMICAL
administered,2256,O
to,2256,O
pregnant,2256,O
mice,2256,O
at,2256,O
two,2256,O
different,2256,O
doses,2256,O
(,2256,O
2-10,2256,O
ng/kg/day,2256,O
),2256,O
",",2256,O
on,2256,O
imprinted,2256,O
genes,2256,O
in,2256,O
the,2256,O
male,2256,O
offspring,2256,O
.,2256,O
The,2257,O
degree,2257,O
of,2257,O
methylation,2257,O
and,2257,O
the,2257,O
mRNA,2257,O
expression,2257,O
of,2257,O
Snrpn,2257,B-GENE-Y
",",2257,O
Peg3,2257,B-GENE-Y
and,2257,O
Igf2r,2257,B-GENE-Y
were,2257,O
analyzed,2257,O
in,2257,O
the,2257,O
sperm,2257,O
",",2257,O
skeletal,2257,O
muscle,2257,O
and,2257,O
liver,2257,O
.,2257,O
TCDD,2258,B-CHEMICAL
administration,2258,O
(,2258,O
10,2258,O
ng/kg/day,2258,O
),2258,O
decreased,2258,O
the,2258,O
sperm,2258,O
count,2258,O
in,2258,O
the,2258,O
male,2258,O
offspring,2258,O
.,2258,O
It,2259,O
did,2259,O
not,2259,O
affect,2259,O
methylation,2259,O
but,2259,O
increased,2259,O
mRNA,2259,O
expression,2259,O
of,2259,O
Snrpn,2259,B-GENE-Y
",",2259,O
Peg3,2259,B-GENE-Y
",",2259,O
Igf2r,2259,B-GENE-Y
and,2259,O
Air,2259,B-GENE-Y
ncRNA,2259,I-GENE-Y
.,2259,O
In,2260,O
muscle,2260,O
and,2260,O
liver,2260,O
",",2260,O
TCDD,2260,B-CHEMICAL
(,2260,O
10,2260,O
ng/kg/day,2260,O
),2260,O
induced,2260,O
increases,2260,O
in,2260,O
methylation,2260,O
and,2260,O
decreases,2260,O
in,2260,O
mRNA,2260,O
expression,2260,O
of,2260,O
Igf2r,2260,B-GENE-Y
.,2260,O
These,2261,O
results,2261,O
show,2261,O
that,2261,O
the,2261,O
robust,2261,O
effects,2261,O
of,2261,O
TCDD,2261,B-CHEMICAL
on,2261,O
the,2261,O
mRNA,2261,O
expression,2261,O
of,2261,O
Snrpn,2261,B-GENE-Y
",",2261,O
Peg3,2261,B-GENE-Y
and,2261,O
Igf2r,2261,B-GENE-Y
genes,2261,O
in,2261,O
the,2261,O
sperm,2261,O
and,2261,O
of,2261,O
Igf2r,2261,B-GENE-Y
in,2261,O
the,2261,O
muscle,2261,O
and,2261,O
liver,2261,O
are,2261,O
unrelated,2261,O
to,2261,O
changes,2261,O
in,2261,O
methylation,2261,O
in,2261,O
their,2261,O
respective,2261,O
genes,2261,O
.,2261,O
Rasagiline,2262,B-CHEMICAL
protects,2262,O
against,2262,O
alpha-synuclein,2262,B-GENE-Y
induced,2262,O
sensitivity,2262,O
to,2262,O
oxidative,2262,O
stress,2262,O
in,2262,O
dopaminergic,2262,O
cells,2262,O
.,2262,O
Rasagiline,2263,B-CHEMICAL
is,2263,O
a,2263,O
propargylamine,2263,B-CHEMICAL
and,2263,O
irreversible,2263,O
monoamine,2263,B-GENE-Y
oxidase,2263,I-GENE-Y
(,2263,I-GENE-Y
MAO,2263,I-GENE-Y
),2263,I-GENE-Y
B,2263,I-GENE-Y
inhibitor,2263,O
used,2263,O
for,2263,O
the,2263,O
treatment,2263,O
of,2263,O
Parkinson,2263,O
's,2263,O
disease,2263,O
(,2263,O
PD,2263,O
),2263,O
.,2263,O
It,2264,O
has,2264,O
demonstrated,2264,O
neuroprotective,2264,O
properties,2264,O
in,2264,O
laboratory,2264,O
studies,2264,O
.,2264,O
Current,2265,O
concepts,2265,O
of,2265,O
PD,2265,O
aetiopathogenesis,2265,O
include,2265,O
the,2265,O
role,2265,O
of,2265,O
alpha-synuclein,2265,B-GENE-Y
",",2265,O
protein,2265,O
aggregation,2265,O
",",2265,O
free,2265,O
radical,2265,O
metabolism,2265,O
and,2265,O
mitochondrial,2265,O
dysfunction,2265,O
in,2265,O
contributing,2265,O
to,2265,O
cell,2265,O
death,2265,O
.,2265,O
We,2266,O
have,2266,O
used,2266,O
a,2266,O
combination,2266,O
of,2266,O
alpha-synuclein,2266,B-GENE-Y
and,2266,O
free,2266,O
radical,2266,O
mediated,2266,O
toxicity,2266,O
in,2266,O
a,2266,O
dopaminergic,2266,O
cell,2266,O
line,2266,O
to,2266,O
provide,2266,O
a,2266,O
model,2266,O
of,2266,O
nigral,2266,O
toxicity,2266,O
in,2266,O
order,2266,O
to,2266,O
investigate,2266,O
the,2266,O
potential,2266,O
molecular,2266,O
mechanisms,2266,O
that,2266,O
mediate,2266,O
rasagiline,2266,B-CHEMICAL
protection,2266,O
.,2266,O
We,2267,O
demonstrate,2267,O
that,2267,O
rasagiline,2267,B-CHEMICAL
protects,2267,O
against,2267,O
cell,2267,O
death,2267,O
induced,2267,O
by,2267,O
the,2267,O
combination,2267,O
of,2267,O
free,2267,O
radicals,2267,O
generated,2267,O
by,2267,O
paraquat,2267,B-CHEMICAL
and,2267,O
either,2267,O
wild-type,2267,O
or,2267,O
A53T,2267,B-GENE-N
mutant,2267,O
alpha-synuclein,2267,B-GENE-Y
over-expression,2267,O
.,2267,O
This,2268,O
protection,2268,O
was,2268,O
associated,2268,O
with,2268,O
a,2268,O
reduction,2268,O
in,2268,O
caspase,2268,B-GENE-Y
3,2268,I-GENE-Y
activation,2268,O
",",2268,O
a,2268,O
reduction,2268,O
in,2268,O
superoxide,2268,B-CHEMICAL
generation,2268,O
and,2268,O
a,2268,O
trend,2268,O
to,2268,O
ameliorate,2268,O
the,2268,O
fall,2268,O
in,2268,O
mitochondrial,2268,O
membrane,2268,O
potential,2268,O
.,2268,O
Rasagiline,2269,B-CHEMICAL
induced,2269,O
an,2269,O
increase,2269,O
in,2269,O
cellular,2269,O
glutathione,2269,B-CHEMICAL
levels,2269,O
.,2269,O
The,2270,O
results,2270,O
support,2270,O
a,2270,O
role,2270,O
for,2270,O
rasagiline,2270,B-CHEMICAL
in,2270,O
protecting,2270,O
dopaminergic,2270,O
cells,2270,O
against,2270,O
free,2270,O
radical,2270,O
mediated,2270,O
damage,2270,O
and,2270,O
apoptosis,2270,O
in,2270,O
the,2270,O
presence,2270,O
of,2270,O
alpha-synuclein,2270,B-GENE-Y
over-expression,2270,O
.,2270,O
The,2271,O
data,2271,O
are,2271,O
of,2271,O
relevance,2271,O
to,2271,O
the,2271,O
interpretation,2271,O
of,2271,O
the,2271,O
potential,2271,O
mechanisms,2271,O
of,2271,O
action,2271,O
of,2271,O
rasagiline,2271,B-CHEMICAL
in,2271,O
explaining,2271,O
the,2271,O
results,2271,O
of,2271,O
disease,2271,O
modification,2271,O
trials,2271,O
in,2271,O
PD,2271,O
.,2271,O
Tolvaptan,2272,B-CHEMICAL
and,2272,O
its,2272,O
potential,2272,O
in,2272,O
the,2272,O
treatment,2272,O
of,2272,O
hyponatremia,2272,O
.,2272,O
Tolvaptan,2273,B-CHEMICAL
is,2273,O
a,2273,O
selective,2273,O
arginine,2273,B-GENE-Y
vasopressin,2273,I-GENE-Y
(,2273,I-GENE-Y
AVP,2273,I-GENE-Y
),2273,I-GENE-Y
V,2273,I-GENE-Y
(,2273,I-GENE-Y
2,2273,I-GENE-Y
),2273,I-GENE-Y
receptor,2273,I-GENE-Y
blocker,2273,O
used,2273,O
to,2273,O
induce,2273,O
free,2273,O
water,2273,O
diuresis,2273,O
in,2273,O
the,2273,O
treatment,2273,O
of,2273,O
euvolemic,2273,O
or,2273,O
hypervolemic,2273,O
hyponatremia,2273,O
.,2273,O
Currently,2274,O
the,2274,O
orally,2274,O
active,2274,O
medication,2274,O
is,2274,O
in,2274,O
the,2274,O
final,2274,O
stages,2274,O
prior,2274,O
to,2274,O
approval,2274,O
by,2274,O
the,2274,O
FDA,2274,O
for,2274,O
outpatient,2274,O
therapy,2274,O
.,2274,O
It,2275,O
appears,2275,O
to,2275,O
be,2275,O
safe,2275,O
and,2275,O
effective,2275,O
at,2275,O
promoting,2275,O
aquaresis,2275,O
and,2275,O
raising,2275,O
serum,2275,O
sodium,2275,B-CHEMICAL
levels,2275,O
in,2275,O
both,2275,O
short-,2275,O
and,2275,O
long-term,2275,O
studies,2275,O
.,2275,O
Tolvaptan,2276,B-CHEMICAL
is,2276,O
also,2276,O
effective,2276,O
for,2276,O
treatment,2276,O
of,2276,O
congestive,2276,O
heart,2276,O
failure,2276,O
(,2276,O
CHF,2276,O
),2276,O
exacerbation,2276,O
",",2276,O
but,2276,O
whether,2276,O
there,2276,O
are,2276,O
long,2276,O
standing,2276,O
beneficial,2276,O
effects,2276,O
on,2276,O
CHF,2276,O
is,2276,O
still,2276,O
controversial,2276,O
.,2276,O
Prolonged,2277,O
use,2277,O
of,2277,O
tolvaptan,2277,B-CHEMICAL
leads,2277,O
to,2277,O
increased,2277,O
endogenous,2277,O
levels,2277,O
of,2277,O
AVP,2277,B-GENE-Y
and,2277,O
perhaps,2277,O
over-stimulation,2277,O
of,2277,O
V,2277,B-GENE-Y
(,2277,I-GENE-Y
1A,2277,I-GENE-Y
),2277,I-GENE-Y
receptors,2277,I-GENE-Y
.,2277,O
Theoretically,2278,O
this,2278,O
activation,2278,O
could,2278,O
lead,2278,O
to,2278,O
increased,2278,O
afterload,2278,O
and,2278,O
cardiac,2278,O
myocyte,2278,O
fibrosis,2278,O
",",2278,O
causing,2278,O
progression,2278,O
of,2278,O
CHF,2278,O
.,2278,O
However,2279,O
",",2279,O
after,2279,O
52,2279,O
weeks,2279,O
of,2279,O
tolvaptan,2279,B-CHEMICAL
therapy,2279,O
there,2279,O
was,2279,O
no,2279,O
worsening,2279,O
of,2279,O
left,2279,O
ventricular,2279,O
dilatation,2279,O
.,2279,O
In,2280,O
addition,2280,O
",",2280,O
tolvaptan,2280,B-CHEMICAL
is,2280,O
metabolized,2280,O
by,2280,O
the,2280,O
CYP3A4,2280,B-GENE-Y
system,2280,O
;,2280,O
thus,2280,O
physicians,2280,O
should,2280,O
be,2280,O
aware,2280,O
of,2280,O
the,2280,O
potential,2280,O
for,2280,O
increased,2280,O
interactions,2280,O
with,2280,O
other,2280,O
medications,2280,O
.,2280,O
Tolvaptan,2281,B-CHEMICAL
is,2281,O
a,2281,O
breakthrough,2281,O
in,2281,O
the,2281,O
therapy,2281,O
of,2281,O
hyponatremia,2281,O
as,2281,O
it,2281,O
directly,2281,O
combats,2281,O
elevated,2281,O
AVP,2281,B-GENE-Y
levels,2281,O
associated,2281,O
with,2281,O
the,2281,O
syndrome,2281,O
of,2281,O
inappropriate,2281,O
secretion,2281,O
of,2281,O
antidiuretic,2281,B-GENE-Y
hormone,2281,I-GENE-Y
",",2281,O
congestive,2281,O
heart,2281,O
failure,2281,O
",",2281,O
and,2281,O
cirrhosis,2281,O
of,2281,O
the,2281,O
liver,2281,O
.,2281,O
alpha,2282,B-GENE-Y
(,2282,I-GENE-Y
1B,2282,I-GENE-Y
),2282,I-GENE-Y
adrenergic,2282,I-GENE-Y
receptors,2282,I-GENE-Y
in,2282,O
gonadotrophin-releasing,2282,B-GENE-Y
hormone,2282,I-GENE-Y
neurones,2282,O
:,2282,O
relation,2282,O
to,2282,O
Transport-P.,2282,O
1,2282,O
.,2282,O
Peptidergic,2283,O
neurones,2283,O
accumulate,2283,O
amines,2283,B-CHEMICAL
via,2283,O
an,2283,O
unusual,2283,O
uptake,2283,O
process,2283,O
",",2283,O
designated,2283,O
Transport-P.,2283,O
[,2283,B-CHEMICAL
(,2283,I-CHEMICAL
3,2283,I-CHEMICAL
),2283,I-CHEMICAL
H,2283,I-CHEMICAL
],2283,I-CHEMICAL
-prazosin,2283,I-CHEMICAL
binds,2283,O
to,2283,O
alpha,2283,B-GENE-N
(,2283,I-GENE-N
1,2283,I-GENE-N
),2283,I-GENE-N
adrenoceptors,2283,I-GENE-N
on,2283,O
these,2283,O
cells,2283,O
and,2283,O
is,2283,O
displaceable,2283,O
by,2283,O
unlabelled,2283,O
prazosin,2283,B-CHEMICAL
in,2283,O
concentrations,2283,O
up,2283,O
to,2283,O
10,2283,O
(,2283,O
-7,2283,O
),2283,O
M.,2283,O
However,2283,O
",",2283,O
at,2283,O
greater,2283,O
concentrations,2283,O
of,2283,O
prazosin,2283,B-CHEMICAL
",",2283,O
there,2283,O
is,2283,O
a,2283,O
paradoxical,2283,O
accumulation,2283,O
of,2283,O
[,2283,B-CHEMICAL
(,2283,I-CHEMICAL
3,2283,I-CHEMICAL
),2283,I-CHEMICAL
H,2283,I-CHEMICAL
],2283,I-CHEMICAL
-prazosin,2283,I-CHEMICAL
which,2283,O
we,2283,O
have,2283,O
attributed,2283,O
to,2283,O
Transport-P.,2283,O
Uptake,2283,O
of,2283,O
prazosin,2283,B-CHEMICAL
via,2283,O
Transport-P,2283,O
is,2283,O
detectable,2283,O
at,2283,O
10,2283,O
(,2283,O
-10,2283,O
),2283,O
M,2283,O
prazosin,2283,B-CHEMICAL
concentration,2283,O
",",2283,O
is,2283,O
linear,2283,O
up,2283,O
to,2283,O
10,2283,O
(,2283,O
-7,2283,O
),2283,O
M,2283,O
and,2283,O
at,2283,O
greater,2283,O
concentrations,2283,O
becomes,2283,O
non-linear,2283,O
.,2283,O
In,2284,O
contrast,2284,O
",",2284,O
in,2284,O
noradrenergic,2284,O
neurones,2284,O
",",2284,O
noradrenaline,2284,B-CHEMICAL
uptake,2284,O
is,2284,O
linear,2284,O
and,2284,O
saturates,2284,O
above,2284,O
10,2284,O
(,2284,O
-7,2284,O
),2284,O
M.,2284,O
In,2284,O
noradrenergic,2284,O
neurones,2284,O
and,2284,O
in,2284,O
non-neuronal,2284,O
cells,2284,O
",",2284,O
there,2284,O
is,2284,O
no,2284,O
uptake,2284,O
of,2284,O
prazosin,2284,B-CHEMICAL
in,2284,O
concentrations,2284,O
up,2284,O
to,2284,O
10,2284,O
(,2284,O
-6,2284,O
),2284,O
M,2284,O
",",2284,O
suggesting,2284,O
that,2284,O
Transport-P,2284,O
is,2284,O
a,2284,O
specialised,2284,O
function,2284,O
of,2284,O
peptidergic,2284,O
neurones,2284,O
.,2284,O
2,2285,O
.,2285,O
Using,2286,O
a,2286,O
mouse,2286,O
peptidergic,2286,O
(,2286,O
gonadotrophin-releasing,2286,B-GENE-Y
hormone,2286,I-GENE-Y
",",2286,O
GnRH,2286,B-GENE-Y
),2286,O
neuronal,2286,O
cell,2286,O
line,2286,O
which,2286,O
possesses,2286,O
Transport-P,2286,O
",",2286,O
we,2286,O
have,2286,O
studied,2286,O
the,2286,O
interaction,2286,O
of,2286,O
alpha,2286,B-GENE-N
(,2286,I-GENE-N
1,2286,I-GENE-N
),2286,I-GENE-N
adrenoceptors,2286,I-GENE-N
with,2286,O
Transport-P.,2286,O
Polymerase,2286,O
chain,2286,O
reactions,2286,O
and,2286,O
DNA,2286,O
sequencing,2286,O
of,2286,O
the,2286,O
products,2286,O
demonstrated,2286,O
that,2286,O
only,2286,O
the,2286,O
alpha,2286,B-GENE-Y
(,2286,I-GENE-Y
1B,2286,I-GENE-Y
),2286,I-GENE-Y
sub-type,2286,I-GENE-Y
of,2286,I-GENE-Y
adrenoceptors,2286,I-GENE-Y
is,2286,O
present,2286,O
in,2286,O
GnRH,2286,B-GENE-Y
cells,2286,O
.,2286,O
3,2287,O
.,2287,O
In,2288,O
COS,2288,O
cells,2288,O
transfected,2288,O
with,2288,O
alpha,2288,B-GENE-Y
(,2288,I-GENE-Y
1b,2288,I-GENE-Y
),2288,I-GENE-Y
adrenoceptor,2288,I-GENE-Y
cDNA,2288,O
and,2288,O
in,2288,O
DDT,2288,O
(,2288,O
1,2288,O
),2288,O
MF-2,2288,O
cells,2288,O
which,2288,O
express,2288,O
native,2288,O
alpha,2288,B-GENE-Y
(,2288,I-GENE-Y
1B,2288,I-GENE-Y
),2288,I-GENE-Y
adrenoceptors,2288,I-GENE-Y
",",2288,O
[,2288,B-CHEMICAL
(,2288,I-CHEMICAL
3,2288,I-CHEMICAL
),2288,I-CHEMICAL
H,2288,I-CHEMICAL
],2288,I-CHEMICAL
-prazosin,2288,I-CHEMICAL
was,2288,O
displaced,2288,O
by,2288,O
unlabelled,2288,O
prazosin,2288,B-CHEMICAL
in,2288,O
a,2288,O
normal,2288,O
equilibrium,2288,O
process,2288,O
",",2288,O
with,2288,O
no,2288,O
prazosin,2288,B-CHEMICAL
paradox,2288,O
in,2288,O
concentrations,2288,O
up,2288,O
to,2288,O
10,2288,O
(,2288,O
-6,2288,O
),2288,O
M.,2288,O
In,2288,O
DDT,2288,O
(,2288,O
1,2288,O
),2288,O
MF-2,2288,O
cells,2288,O
",",2288,O
[,2288,B-CHEMICAL
(,2288,I-CHEMICAL
3,2288,I-CHEMICAL
),2288,I-CHEMICAL
H,2288,I-CHEMICAL
],2288,I-CHEMICAL
-prazosin,2288,I-CHEMICAL
was,2288,O
displaced,2288,O
likewise,2288,O
by,2288,O
a,2288,O
series,2288,O
of,2288,O
alpha,2288,B-GENE-N
(,2288,I-GENE-N
1,2288,I-GENE-N
),2288,I-GENE-N
adrenergic,2288,O
agonists,2288,O
",",2288,O
none,2288,O
of,2288,O
which,2288,O
increased,2288,O
the,2288,O
binding,2288,O
of,2288,O
[,2288,B-CHEMICAL
(,2288,I-CHEMICAL
3,2288,I-CHEMICAL
),2288,I-CHEMICAL
H,2288,I-CHEMICAL
],2288,I-CHEMICAL
-prazosin,2288,I-CHEMICAL
.,2288,O
Hence,2289,O
",",2289,O
the,2289,O
prazosin,2289,B-CHEMICAL
paradox,2289,O
is,2289,O
not,2289,O
due,2289,O
to,2289,O
some,2289,O
function,2289,O
of,2289,O
alpha,2289,B-GENE-N
(,2289,I-GENE-N
1,2289,I-GENE-N
),2289,I-GENE-N
adrenoceptors,2289,I-GENE-N
",",2289,O
such,2289,O
as,2289,O
internalization,2289,O
of,2289,O
ligand-receptor,2289,O
complexes,2289,O
.,2289,O
4,2290,O
.,2290,O
In,2291,O
neurones,2291,O
which,2291,O
possess,2291,O
Transport-P,2291,O
",",2291,O
transfection,2291,O
with,2291,O
alpha,2291,B-GENE-Y
(,2291,I-GENE-Y
1b,2291,I-GENE-Y
),2291,I-GENE-Y
adrenoceptor,2291,I-GENE-Y
cDNA,2291,O
resulted,2291,O
in,2291,O
over-expression,2291,O
of,2291,O
alpha,2291,B-GENE-Y
(,2291,I-GENE-Y
1B,2291,I-GENE-Y
),2291,I-GENE-Y
adrenoceptors,2291,I-GENE-Y
",",2291,O
but,2291,O
the,2291,O
prazosin,2291,B-CHEMICAL
paradox,2291,O
was,2291,O
unaltered,2291,O
.,2291,O
Thus,2292,O
",",2292,O
alpha,2292,B-GENE-N
(,2292,I-GENE-N
1,2292,I-GENE-N
),2292,I-GENE-N
adrenoceptors,2292,I-GENE-N
and,2292,O
Transport-P,2292,O
mediate,2292,O
distinct,2292,O
functions,2292,O
in,2292,O
peptidergic,2292,O
neurones,2292,O
.,2292,O
Fisetin,2293,B-CHEMICAL
averts,2293,O
oxidative,2293,O
stress,2293,O
in,2293,O
pancreatic,2293,O
tissues,2293,O
of,2293,O
streptozotocin-induced,2293,B-CHEMICAL
diabetic,2293,O
rats,2293,O
.,2293,O
Persistent,2294,O
hyperglycemia,2294,O
is,2294,O
associated,2294,O
with,2294,O
chronic,2294,O
oxidative,2294,O
stress,2294,O
which,2294,O
contributes,2294,O
to,2294,O
the,2294,O
development,2294,O
and,2294,O
progression,2294,O
of,2294,O
diabetes-associated,2294,O
complications,2294,O
.,2294,O
The,2295,O
sensitivity,2295,O
of,2295,O
pancreatic,2295,O
β-cells,2295,O
to,2295,O
oxidative,2295,O
stress,2295,O
has,2295,O
been,2295,O
attributed,2295,O
to,2295,O
their,2295,O
low,2295,O
content,2295,O
of,2295,O
antioxidants,2295,O
compared,2295,O
with,2295,O
other,2295,O
tissues,2295,O
.,2295,O
Bioactive,2296,O
compounds,2296,O
with,2296,O
potent,2296,O
antidiabetic,2296,O
properties,2296,O
have,2296,O
been,2296,O
shown,2296,O
to,2296,O
ameliorate,2296,O
hyperglycemia,2296,O
mediated,2296,O
oxidative,2296,O
stress,2296,O
.,2296,O
Recently,2297,O
",",2297,O
we,2297,O
have,2297,O
reported,2297,O
that,2297,O
oral,2297,O
administration,2297,O
of,2297,O
fisetin,2297,B-CHEMICAL
(,2297,O
10,2297,O
mg/Kg,2297,O
b.w,2297,O
.,2297,O
),2298,O
",",2298,O
a,2298,O
bioflavonoid,2298,O
found,2298,O
to,2298,O
be,2298,O
present,2298,O
in,2298,O
strawberries,2298,O
",",2298,O
persimmon,2298,O
",",2298,O
to,2298,O
STZ-induced,2298,O
experimental,2298,O
diabetic,2298,O
rats,2298,O
significantly,2298,O
improved,2298,O
normoglycemia,2298,O
.,2298,O
The,2299,O
present,2299,O
study,2299,O
was,2299,O
aimed,2299,O
to,2299,O
evaluate,2299,O
the,2299,O
antioxidant,2299,O
potential,2299,O
of,2299,O
fisetin,2299,O
in,2299,O
both,2299,O
in,2299,O
vitro,2299,O
and,2299,O
in,2299,O
vivo,2299,O
.,2299,O
Diabetes,2300,O
was,2300,O
induced,2300,O
by,2300,O
single,2300,O
intraperitoneal,2300,O
injection,2300,O
of,2300,O
streptozotocin,2300,O
(,2300,O
50,2300,O
mg/kg,2300,O
body,2300,O
weight,2300,O
),2300,O
.,2300,O
Fisetin,2301,O
was,2301,O
administered,2301,O
orally,2301,O
for,2301,O
30,2301,O
days,2301,O
.,2301,O
At,2302,O
the,2302,O
end,2302,O
of,2302,O
the,2302,O
study,2302,O
",",2302,O
all,2302,O
animals,2302,O
were,2302,O
killed,2302,O
.,2302,O
Blood,2303,O
samples,2303,O
were,2303,O
collected,2303,O
for,2303,O
the,2303,O
biochemical,2303,O
estimations,2303,O
.,2303,O
The,2304,O
antioxidant,2304,O
status,2304,O
was,2304,O
evaluated,2304,O
.,2304,O
Histological,2305,O
examinations,2305,O
were,2305,O
performed,2305,O
on,2305,O
pancreatic,2305,O
tissues,2305,O
.,2305,O
Fisetin,2306,O
treatment,2306,O
showed,2306,O
a,2306,O
significant,2306,O
decline,2306,O
in,2306,O
the,2306,O
levels,2306,O
of,2306,O
blood,2306,O
glucose,2306,O
",",2306,O
glycosylated,2306,I-GENE-N
hemoglobin,2306,O
(,2306,B-GENE-N
HbA1c,2306,O
),2306,O
",",2306,O
NF-kB,2306,O
p65,2306,O
unit,2306,O
(,2306,O
in,2306,O
pancreas,2306,O
),2306,O
and,2306,O
IL-1β,2306,O
(,2306,O
plasma,2306,O
),2306,O
",",2306,O
serum,2306,O
nitric,2306,I-CHEMICAL
oxide,2306,O
(,2306,B-CHEMICAL
NO,2306,O
),2306,O
with,2306,O
an,2306,O
elevation,2306,O
in,2306,O
plasma,2306,O
insulin,2306,O
.,2306,O
The,2307,O
treatment,2307,O
also,2307,O
improved,2307,O
the,2307,O
antioxidant,2307,O
status,2307,O
in,2307,O
pancreas,2307,O
as,2307,O
well,2307,O
as,2307,O
plasma,2307,O
of,2307,O
diabetic,2307,O
rats,2307,O
indicating,2307,O
the,2307,O
antioxidant,2307,O
potential,2307,O
of,2307,O
fisetin,2307,O
.,2307,O
In,2308,O
addition,2308,O
",",2308,O
the,2308,O
results,2308,O
of,2308,O
DPPH,2308,O
and,2308,O
ABTS,2308,O
assays,2308,O
substantiate,2308,O
the,2308,O
free,2308,O
radical,2308,O
scavenging,2308,O
activity,2308,O
of,2308,O
fisetin,2308,O
.,2308,O
Histological,2309,O
studies,2309,O
of,2309,O
the,2309,O
pancreas,2309,O
also,2309,O
evidenced,2309,O
the,2309,O
tissue,2309,O
protective,2309,O
nature,2309,O
of,2309,O
fisetin,2309,O
.,2309,O
It,2310,O
is,2310,O
concluded,2310,O
that,2310,O
",",2310,O
fisetin,2310,O
possesses,2310,O
antioxidant,2310,O
and,2310,O
anti-inflammatory,2310,O
property,2310,O
and,2310,O
may,2310,O
be,2310,O
considered,2310,O
as,2310,O
an,2310,O
adjunct,2310,O
for,2310,O
the,2310,O
treatment,2310,O
of,2310,O
diabetes,2310,O
.,2310,O
Inhibition,2311,O
of,2311,O
the,2311,O
uterotropic,2311,O
activity,2311,O
of,2311,O
estrogens,2311,O
and,2311,O
antiestrogens,2311,O
by,2311,O
the,2311,O
short,2311,O
acting,2311,O
antiestrogen,2311,O
LY117018,2311,B-CHEMICAL
.,2311,O
The,2312,O
aim,2312,O
of,2312,O
the,2312,O
study,2312,O
was,2312,O
to,2312,O
determine,2312,O
whether,2312,O
the,2312,O
dihydroxylated,2312,O
antiestrogen,2312,O
LY117018,2312,B-CHEMICAL
",",2312,O
with,2312,O
a,2312,O
high,2312,O
affinity,2312,O
for,2312,O
the,2312,O
estrogen,2312,B-GENE-Y
receptor,2312,I-GENE-Y
and,2312,O
low,2312,O
intrinsic,2312,O
estrogenic,2312,O
activity,2312,O
",",2312,O
could,2312,O
inhibit,2312,O
the,2312,O
uterotropic,2312,O
actions,2312,O
of,2312,O
steroidal,2312,O
[,2312,O
estradiol-17,2312,B-CHEMICAL
beta,2312,I-CHEMICAL
(,2312,O
E2,2312,B-CHEMICAL
),2312,O
],2312,O
and,2312,O
nonsteroidal,2312,O
[,2312,O
ICI,2312,O
3188,2312,O
and,2312,O
trianisylchloroethylene,2312,B-CHEMICAL
(,2312,O
TACE,2312,B-CHEMICAL
),2312,O
],2312,O
estrogens,2312,O
in,2312,O
immature,2312,O
rats,2312,O
and,2312,O
also,2312,O
the,2312,O
uterotropic,2312,O
actions,2312,O
of,2312,O
tamoxifen,2312,B-CHEMICAL
and,2312,O
monohydroxytamoxifen,2312,B-CHEMICAL
in,2312,O
the,2312,O
ovariectomized,2312,O
mouse,2312,O
and,2312,O
immature,2312,O
rat,2312,O
.,2312,O
In,2313,O
the,2313,O
first,2313,O
series,2313,O
of,2313,O
experiments,2313,O
",",2313,O
LY117018,2313,B-CHEMICAL
was,2313,O
compared,2313,O
with,2313,O
monohydroxytamoxifen,2313,B-CHEMICAL
.,2313,O
Both,2314,O
antiestrogens,2314,O
inhibited,2314,O
the,2314,O
uterotropic,2314,O
actions,2314,O
of,2314,O
E2,2314,B-CHEMICAL
(,2314,O
0.32,2314,O
micrograms,2314,O
daily,2314,O
),2314,O
",",2314,O
ICI,2314,O
3188,2314,O
(,2314,O
5,2314,O
micrograms,2314,O
daily,2314,O
),2314,O
",",2314,O
and,2314,O
TACE,2314,O
(,2314,O
40,2314,O
and,2314,O
160,2314,O
micrograms,2314,O
daily,2314,O
),2314,O
in,2314,O
a,2314,O
dose-related,2314,O
manner,2314,O
(,2314,O
0.32-82,2314,O
micrograms,2314,O
daily,2314,O
),2314,O
.,2314,O
The,2315,O
potency,2315,O
of,2315,O
the,2315,O
antiestrogens,2315,O
against,2315,O
E2,2315,O
and,2315,O
ICI,2315,O
3188,2315,O
was,2315,O
similar,2315,O
",",2315,O
however,2315,O
",",2315,O
at,2315,O
higher,2315,O
doses,2315,O
(,2315,O
20.48,2315,O
and,2315,O
82,2315,O
micrograms,2315,O
daily,2315,O
),2315,O
LY117018,2315,B-CHEMICAL
reduced,2315,O
uterine,2315,O
weights,2315,O
to,2315,O
below,2315,O
the,2315,O
lowest,2315,O
level,2315,O
achieved,2315,O
by,2315,O
monohydroxytamoxifen,2315,B-CHEMICAL
.,2315,O
In,2316,O
contrast,2316,O
",",2316,O
LY117018,2316,B-CHEMICAL
was,2316,O
less,2316,O
effective,2316,O
against,2316,O
the,2316,O
long,2316,O
acting,2316,O
estrogen,2316,O
TACE,2316,O
.,2316,O
The,2317,O
competitive,2317,O
interaction,2317,O
of,2317,O
LY117018,2317,B-CHEMICAL
with,2317,O
tamoxifen,2317,B-CHEMICAL
and,2317,O
monohydroxytamoxifen,2317,B-CHEMICAL
was,2317,O
compared,2317,O
in,2317,O
3-day,2317,O
ovariectomized,2317,O
mouse,2317,O
and,2317,O
immature,2317,O
rat,2317,O
uterine,2317,O
weight,2317,O
tests,2317,O
.,2317,O
Tamoxifen,2318,B-CHEMICAL
and,2318,O
monohydroxytamoxifen,2318,B-CHEMICAL
were,2318,O
fully,2318,O
estrogenic,2318,O
in,2318,O
the,2318,O
mouse,2318,O
(,2318,O
5,2318,O
micrograms,2318,O
daily,2318,O
),2318,O
and,2318,O
partially,2318,O
estrogenic,2318,O
in,2318,O
the,2318,O
rat,2318,O
(,2318,O
1.5-20,2318,O
micrograms,2318,O
daily,2318,O
),2318,O
.,2318,O
LY117018,2319,B-CHEMICAL
was,2319,O
a,2319,O
partial,2319,O
estrogen,2319,O
in,2319,O
the,2319,O
mouse,2319,O
and,2319,O
a,2319,O
weekly,2319,O
active,2319,O
partial,2319,O
estrogen,2319,O
in,2319,O
the,2319,O
rat,2319,O
(,2319,O
2.5-120,2319,O
micrograms,2319,O
daily,2319,O
),2319,O
.,2319,O
LY117018,2320,B-CHEMICAL
produced,2320,O
dose-related,2320,O
decreases,2320,O
in,2320,O
the,2320,O
uterine,2320,O
weight,2320,O
increases,2320,O
induced,2320,O
by,2320,O
tamoxifen,2320,B-CHEMICAL
and,2320,O
monohydroxytamoxifen,2320,B-CHEMICAL
in,2320,O
both,2320,O
species,2320,O
.,2320,O
However,2321,O
",",2321,O
in,2321,O
the,2321,O
rat,2321,O
",",2321,O
LY117018,2321,B-CHEMICAL
was,2321,O
more,2321,O
effective,2321,O
against,2321,O
the,2321,O
less,2321,O
potent,2321,O
compound,2321,O
tamoxifen,2321,B-CHEMICAL
",",2321,O
at,2321,O
a,2321,O
6:1,2321,O
dosage,2321,O
ratio,2321,O
compared,2321,O
with,2321,O
a,2321,O
24:1,2321,O
dosage,2321,O
ratio,2321,O
required,2321,O
for,2321,O
the,2321,O
potent,2321,O
compound,2321,O
monohydroxytamoxifen,2321,B-CHEMICAL
.,2321,O
LY117018,2322,B-CHEMICAL
had,2322,O
a,2322,O
short,2322,O
duration,2322,O
of,2322,O
action,2322,O
as,2322,O
an,2322,O
antiestrogen,2322,O
when,2322,O
compared,2322,O
with,2322,O
monohydroxytamoxifen,2322,B-CHEMICAL
.,2322,O
LY117018,2323,B-CHEMICAL
(,2323,O
120,2323,O
micrograms,2323,O
),2323,O
was,2323,O
only,2323,O
completely,2323,O
effective,2323,O
as,2323,O
an,2323,O
antiestrogen,2323,O
if,2323,O
administered,2323,O
repeatedly,2323,O
with,2323,O
E2,2323,B-CHEMICAL
whereas,2323,O
a,2323,O
single,2323,O
injection,2323,O
of,2323,O
monohydroxytamoxifen,2323,B-CHEMICAL
(,2323,O
120,2323,O
micrograms,2323,O
),2323,O
was,2323,O
sufficient,2323,O
to,2323,O
inhibit,2323,O
fully,2323,O
E2,2323,B-CHEMICAL
action,2323,O
in,2323,O
the,2323,O
uterus,2323,O
for,2323,O
up,2323,O
to,2323,O
4,2323,O
days,2323,O
.,2323,O
Because,2324,O
LY117018,2324,B-CHEMICAL
has,2324,O
a,2324,O
shorter,2324,O
duration,2324,O
of,2324,O
action,2324,O
than,2324,O
monohydroxytamoxifen,2324,B-CHEMICAL
",",2324,O
a,2324,O
high,2324,O
dosage,2324,O
ratio,2324,O
of,2324,O
LY117018,2324,B-CHEMICAL
over,2324,O
monohydroxytamoxifen,2324,B-CHEMICAL
is,2324,O
required,2324,O
to,2324,O
maintain,2324,O
effective,2324,O
competitive,2324,O
antagonism,2324,O
in,2324,O
the,2324,O
uterus,2324,O
.,2324,O
Overall,2325,O
",",2325,O
these,2325,O
findings,2325,O
suggest,2325,O
that,2325,O
monohydroxytamoxifen,2325,B-CHEMICAL
and,2325,O
LY117018,2325,B-CHEMICAL
probably,2325,O
act,2325,O
through,2325,O
the,2325,O
same,2325,O
mechanism,2325,O
of,2325,O
action,2325,O
via,2325,O
the,2325,O
estrogen,2325,B-GENE-Y
receptor,2325,I-GENE-Y
.,2325,O
High-glucose,2326,O
environment,2326,O
enhanced,2326,O
oxidative,2326,O
stress,2326,O
and,2326,O
increased,2326,O
interleukin-8,2326,B-GENE-Y
secretion,2326,O
from,2326,O
keratinocytes,2326,O
:,2326,O
New,2326,O
insights,2326,O
on,2326,O
impaired,2326,O
diabetic,2326,O
wound,2326,O
healing,2326,O
.,2326,O
Impaired,2327,O
wound,2327,O
healing,2327,O
frequently,2327,O
occurs,2327,O
in,2327,O
patients,2327,O
with,2327,O
diabetes,2327,O
.,2327,O
Interluekin-8,2328,B-GENE-Y
(,2328,O
IL-8,2328,B-GENE-Y
),2328,O
production,2328,O
by,2328,O
keratinocyte,2328,O
is,2328,O
responsible,2328,O
for,2328,O
recruiting,2328,O
neutrophils,2328,O
during,2328,O
healing,2328,O
.,2328,O
Intense,2329,O
inflammation,2329,O
is,2329,O
associated,2329,O
with,2329,O
diabetic,2329,O
wounds,2329,O
while,2329,O
reduction,2329,O
of,2329,O
neutrophil,2329,O
infiltration,2329,O
is,2329,O
associated,2329,O
with,2329,O
enhanced,2329,O
healing,2329,O
.,2329,O
We,2330,O
hypothesized,2330,O
that,2330,O
increased,2330,O
neutrophil,2330,O
recruitment,2330,O
by,2330,O
keratinocytes,2330,O
may,2330,O
contribute,2330,O
to,2330,O
the,2330,O
delayed,2330,O
healing,2330,O
of,2330,O
diabetic,2330,O
wound,2330,O
.,2330,O
Using,2331,O
cultured,2331,O
human,2331,O
keratinocytes,2331,O
and,2331,O
diabetic,2331,O
rat,2331,O
model,2331,O
",",2331,O
the,2331,O
current,2331,O
study,2331,O
showed,2331,O
that,2331,O
high-glucose,2331,O
environment,2331,O
enhanced,2331,O
IL-8,2331,B-GENE-Y
production,2331,O
via,2331,O
epidermal,2331,B-GENE-Y
growth,2331,I-GENE-Y
factor,2331,I-GENE-Y
receptor,2331,I-GENE-Y
(,2331,O
EGFR,2331,B-GENE-Y
),2331,O
-extracelluar,2331,O
signal-regulated,2331,I-GENE-N
kinase,2331,I-GENE-N
(,2331,O
ERK,2331,B-GENE-N
),2331,O
pathway,2331,O
in,2331,O
a,2331,O
reactive,2331,O
oxygen,2331,B-CHEMICAL
species,2331,O
(,2331,O
ROS,2331,O
),2331,O
-dependent,2331,O
manner,2331,O
in,2331,O
keratinocytes,2331,O
.,2331,O
In,2332,O
addition,2332,O
",",2332,O
diabetic,2332,O
rat,2332,O
skin,2332,O
showed,2332,O
enhanced,2332,O
EGFR,2332,B-GENE-Y
",",2332,O
ERK,2332,B-GENE-N
and,2332,O
IL-8,2332,B-GENE-N
expression,2332,O
as,2332,O
compared,2332,O
to,2332,O
control,2332,O
rats,2332,O
.,2332,O
The,2333,O
dermal,2333,O
neutrophil,2333,O
infiltration,2333,O
of,2333,O
the,2333,O
wound,2333,O
",",2333,O
as,2333,O
represented,2333,O
by,2333,O
expression,2333,O
of,2333,O
myeloperoxidase,2333,B-GENE-Y
level,2333,O
",",2333,O
was,2333,O
also,2333,O
significantly,2333,O
higher,2333,O
in,2333,O
diabetic,2333,O
rats,2333,O
.,2333,O
Treating,2334,O
diabetic,2334,O
rats,2334,O
with,2334,O
dapsone,2334,B-CHEMICAL
",",2334,O
an,2334,O
agent,2334,O
known,2334,O
to,2334,O
inhibit,2334,O
neutrophil,2334,O
function,2334,O
",",2334,O
was,2334,O
associated,2334,O
with,2334,O
improved,2334,O
healing,2334,O
.,2334,O
In,2335,O
conclusion,2335,O
",",2335,O
IL-8,2335,B-GENE-Y
production,2335,O
and,2335,O
neutrophil,2335,O
infiltration,2335,O
are,2335,O
increased,2335,O
in,2335,O
high-glucose,2335,O
environment,2335,O
due,2335,O
to,2335,O
elevated,2335,O
ROS,2335,O
level,2335,O
and,2335,O
contributed,2335,O
to,2335,O
impaired,2335,O
wound,2335,O
healing,2335,O
in,2335,O
diabetic,2335,O
skin,2335,O
.,2335,O
Targeting,2336,O
these,2336,O
dysfunctions,2336,O
may,2336,O
present,2336,O
novel,2336,O
therapeutic,2336,O
approaches,2336,O
.,2336,O
Effects,2337,O
of,2337,O
2-amino-1-methyl-6-phenylimidazo,2337,B-CHEMICAL
[,2337,I-CHEMICAL
4,2337,I-CHEMICAL
",",2337,I-CHEMICAL
5-b,2337,I-CHEMICAL
],2337,I-CHEMICAL
pyridine,2337,I-CHEMICAL
(,2337,O
PhIP,2337,B-CHEMICAL
),2337,O
on,2337,O
histopathology,2337,O
",",2337,O
oxidative,2337,O
stress,2337,O
",",2337,O
and,2337,O
expression,2337,O
of,2337,O
c-fos,2337,B-GENE-Y
",",2337,O
c-jun,2337,B-GENE-Y
and,2337,O
p16,2337,B-GENE-Y
in,2337,O
rat,2337,O
stomachs,2337,O
.,2337,O
2-Amino-1-methyl-6-phenylimidazo,2338,B-CHEMICAL
[,2338,I-CHEMICAL
4,2338,I-CHEMICAL
",",2338,I-CHEMICAL
5-b,2338,I-CHEMICAL
],2338,I-CHEMICAL
pyridine,2338,I-CHEMICAL
(,2338,O
PhIP,2338,B-CHEMICAL
),2338,O
is,2338,O
one,2338,O
of,2338,O
the,2338,O
most,2338,O
abundant,2338,O
heterocyclic,2338,B-CHEMICAL
amines,2338,I-CHEMICAL
(,2338,O
HCAs,2338,B-CHEMICAL
),2338,O
generated,2338,O
from,2338,O
overcooking,2338,O
meat,2338,O
at,2338,O
high,2338,O
temperatures,2338,O
.,2338,O
To,2339,O
understand,2339,O
the,2339,O
possible,2339,O
mechanism,2339,O
of,2339,O
PhIP-associated,2339,B-CHEMICAL
stomach,2339,O
cancer,2339,O
",",2339,O
the,2339,O
effects,2339,O
of,2339,O
PhIP,2339,B-CHEMICAL
on,2339,O
morphology,2339,O
",",2339,O
oxidative,2339,O
stress,2339,O
",",2339,O
gene,2339,O
expression,2339,O
of,2339,O
c-fos,2339,B-GENE-Y
",",2339,O
c-jun,2339,B-GENE-Y
and,2339,O
p16,2339,B-GENE-Y
in,2339,O
rat,2339,O
stomachs,2339,O
were,2339,O
investigated,2339,O
.,2339,O
The,2340,O
results,2340,O
showed,2340,O
that,2340,O
(,2340,O
1,2340,O
),2340,O
15mg/kg,2340,O
body,2340,O
weight,2340,O
PhIP,2340,B-CHEMICAL
induced,2340,O
obvious,2340,O
histopathological,2340,O
changes,2340,O
in,2340,O
gastric,2340,O
mucosa,2340,O
;,2340,O
(,2340,O
2,2340,O
),2340,O
PhIP,2340,B-CHEMICAL
(,2340,O
10,2340,O
and/or,2340,O
15mg/kg,2340,O
),2340,O
significantly,2340,O
decreased,2340,O
superoxide,2340,B-GENE-N
dismutase,2340,I-GENE-N
(,2340,O
SOD,2340,B-GENE-N
),2340,O
and,2340,O
glutathioneperoxidase,2340,B-GENE-N
(,2340,O
GPx,2340,B-GENE-N
),2340,O
activities,2340,O
",",2340,O
while,2340,O
increased,2340,O
catalase,2340,B-GENE-Y
(,2340,O
CAT,2340,B-GENE-Y
),2340,O
activity,2340,O
compared,2340,O
with,2340,O
the,2340,O
control,2340,O
.,2340,O
With,2341,O
the,2341,O
elevated,2341,O
doses,2341,O
of,2341,O
PhIP,2341,B-CHEMICAL
",",2341,O
malondialdehyde,2341,B-CHEMICAL
(,2341,O
MDA,2341,B-CHEMICAL
),2341,O
contents,2341,O
",",2341,O
protein,2341,O
carbonyl,2341,B-CHEMICAL
(,2341,O
PCO,2341,O
),2341,O
contents,2341,O
and,2341,O
DNA-protein,2341,O
crosslinks,2341,O
(,2341,O
DPC,2341,O
),2341,O
coefficients,2341,O
were,2341,O
significantly,2341,O
raised,2341,O
in,2341,O
a,2341,O
dose-dependent,2341,O
manner,2341,O
;,2341,O
(,2341,O
3,2341,O
),2341,O
PhIP,2341,B-CHEMICAL
at,2341,O
the,2341,O
doses,2341,O
of,2341,O
10mg/kg,2341,O
and/or,2341,O
15mg/kg,2341,O
significantly,2341,O
inhibited,2341,O
p16,2341,B-GENE-Y
mRNA,2341,O
and,2341,O
protein,2341,O
expression,2341,O
",",2341,O
whereas,2341,O
enhanced,2341,O
c-fos,2341,B-GENE-Y
and,2341,O
c-jun,2341,B-GENE-Y
expression,2341,O
relative,2341,O
to,2341,O
control,2341,O
.,2341,O
The,2342,O
data,2342,O
indicated,2342,O
that,2342,O
PhIP,2342,B-CHEMICAL
could,2342,O
cause,2342,O
stomach,2342,O
injury,2342,O
",",2342,O
oxidative,2342,O
stress,2342,O
in,2342,O
rat,2342,O
stomachs,2342,O
as,2342,O
well,2342,O
as,2342,O
the,2342,O
activation,2342,O
of,2342,O
c-fos,2342,B-GENE-Y
and,2342,O
c-jun,2342,B-GENE-Y
and,2342,O
inactivation,2342,O
of,2342,O
p16,2342,B-GENE-Y
",",2342,O
which,2342,O
may,2342,O
play,2342,O
a,2342,O
role,2342,O
in,2342,O
the,2342,O
pathogenesis,2342,O
of,2342,O
PhIP-associated,2342,B-CHEMICAL
stomach,2342,O
cancer,2342,O
.,2342,O
A,2343,O
novel,2343,O
method,2343,O
for,2343,O
preparing,2343,O
complete,2343,O
antigens,2343,O
of,2343,O
gonyautoxin,2343,B-CHEMICAL
"2,3",2343,I-CHEMICAL
and,2343,O
their,2343,O
feature,2343,O
of,2343,O
immunogenicity,2343,O
.,2343,O
In,2344,O
this,2344,O
paper,2344,O
",",2344,O
a,2344,O
novel,2344,O
method,2344,O
was,2344,O
proposed,2344,O
to,2344,O
prepare,2344,O
artificial,2344,O
antigens,2344,O
of,2344,O
gonyaulax,2344,O
parlaytic,2344,O
shellfish,2344,O
toxin,2344,O
2,2344,O
and,2344,O
3,2344,O
(,2344,O
"GTX2,3",2344,B-CHEMICAL
),2344,O
.,2344,O
An,2345,O
intermediate,2345,O
"GTX2,3-aldehyde",2345,B-CHEMICAL
was,2345,O
first,2345,O
synthesized,2345,O
by,2345,O
activating,2345,O
the,2345,O
NH2,2345,B-CHEMICAL
group,2345,O
of,2345,O
the,2345,O
2nd,2345,O
and,2345,O
8th,2345,O
amino,2345,B-CHEMICAL
acid,2345,I-CHEMICAL
residues,2345,O
with,2345,O
three,2345,O
different,2345,O
aldehydes,2345,B-CHEMICAL
and,2345,O
two,2345,O
artificial,2345,O
complete,2345,O
antigens,2345,O
"GTX2,3-aldehyde-bovine",2345,B-CHEMICAL
serum,2345,I-GENE-Y
albumin,2345,I-GENE-Y
(,2345,O
BSA,2345,B-GENE-Y
),2345,O
and,2345,O
"GTX2,3-aldehyde-",2345,B-CHEMICAL
keyhole,2345,B-GENE-N
limpet,2345,I-GENE-N
hemocyanin,2345,I-GENE-N
(,2345,O
KLH,2345,B-GENE-N
),2345,O
were,2345,O
then,2345,O
prepared,2345,O
by,2345,O
cross-linking,2345,O
the,2345,O
intermediate,2345,O
with,2345,O
BSA,2345,B-GENE-Y
or,2345,O
KLH,2345,B-GENE-N
.,2345,O
The,2346,O
successful,2346,O
preparation,2346,O
of,2346,O
the,2346,O
two,2346,O
complete,2346,O
antigens,2346,O
was,2346,O
confirmed,2346,O
by,2346,O
UV,2346,O
spectral,2346,O
scanning,2346,O
",",2346,O
HPLC,2346,O
",",2346,O
production,2346,O
of,2346,O
antibodies,2346,O
with,2346,O
titer,2346,O
of,2346,O
1.28,2346,O
×,2346,O
10,2346,O
(,2346,O
4,2346,O
),2346,O
from,2346,O
mice,2346,O
immunized,2346,O
with,2346,O
the,2346,O
two,2346,O
complete,2346,O
antigens,2346,O
",",2346,O
indirect,2346,O
ELISA,2346,O
and,2346,O
Western-blot,2346,O
.,2346,O
In,2347,O
conclusion,2347,O
",",2347,O
the,2347,O
synthesized,2347,O
complete,2347,O
antigens,2347,O
have,2347,O
strong,2347,O
immunogenicity,2347,O
",",2347,O
which,2347,O
provides,2347,O
a,2347,O
solid,2347,O
foundation,2347,O
for,2347,O
preparing,2347,O
"GTX2,3",2347,B-CHEMICAL
monoclonal,2347,O
antibody,2347,O
and,2347,O
rapid,2347,O
detection,2347,O
kit,2347,O
.,2347,O
Tetrahydrobiopterin,2348,B-CHEMICAL
in,2348,O
nitric,2348,B-CHEMICAL
oxide,2348,I-CHEMICAL
synthesis,2348,O
:,2348,O
a,2348,O
novel,2348,O
biological,2348,O
role,2348,O
for,2348,O
pteridines,2348,B-CHEMICAL
.,2348,O
Ever,2349,O
since,2349,O
the,2349,O
discovery,2349,O
that,2349,O
(,2349,B-CHEMICAL
6R,2349,I-CHEMICAL
),2349,I-CHEMICAL
"-5,6,7,8-tetrahydro-L-biopterin",2349,I-CHEMICAL
(,2349,O
BH4,2349,B-CHEMICAL
),2349,O
is,2349,O
a,2349,O
cofactor,2349,O
of,2349,O
NOS,2349,B-GENE-N
",",2349,O
its,2349,O
function,2349,O
has,2349,O
been,2349,O
the,2349,O
object,2349,O
of,2349,O
intense,2349,O
research,2349,O
and,2349,O
occasional,2349,O
controversy,2349,O
.,2349,O
Only,2350,O
in,2350,O
the,2350,O
last,2350,O
couple,2350,O
of,2350,O
years,2350,O
a,2350,O
consensus,2350,O
has,2350,O
been,2350,O
reached,2350,O
on,2350,O
what,2350,O
constitutes,2350,O
the,2350,O
main,2350,O
role,2350,O
of,2350,O
BH4,2350,B-CHEMICAL
in,2350,O
NO,2350,B-CHEMICAL
synthesis,2350,O
.,2350,O
In,2351,O
this,2351,O
review,2351,O
we,2351,O
aim,2351,O
to,2351,O
provide,2351,O
an,2351,O
outline,2351,O
of,2351,O
the,2351,O
various,2351,O
ways,2351,O
in,2351,O
which,2351,O
BH4,2351,B-CHEMICAL
affects,2351,O
NOS,2351,B-GENE-N
catalysis,2351,O
.,2351,O
First,2352,O
we,2352,O
give,2352,O
a,2352,O
brief,2352,O
general,2352,O
description,2352,O
of,2352,O
the,2352,O
structure,2352,O
and,2352,O
catalytic,2352,O
mechanism,2352,O
of,2352,O
NOS,2352,B-GENE-N
",",2352,O
with,2352,O
special,2352,O
emphasis,2352,O
on,2352,O
those,2352,O
aspects,2352,O
of,2352,O
catalysis,2352,O
that,2352,O
are,2352,O
actively,2352,O
debated,2352,O
",",2352,O
and,2352,O
that,2352,O
directly,2352,O
or,2352,O
indirectly,2352,O
involve,2352,O
BH4,2352,B-CHEMICAL
.,2352,O
Foremost,2353,O
among,2353,O
those,2353,O
issues,2353,O
is,2353,O
uncoupled,2353,O
catalysis,2353,O
",",2353,O
i.e,2353,O
.,2353,O
the,2354,O
NOS-catalyzed,2354,B-GENE-N
oxidation,2354,O
of,2354,O
NADPH,2354,B-CHEMICAL
in,2354,O
the,2354,O
absence,2354,O
of,2354,O
substrate,2354,O
or,2354,O
pterin,2354,O
that,2354,O
does,2354,O
not,2354,O
result,2354,O
in,2354,O
NO,2354,B-CHEMICAL
production,2354,O
.,2354,O
We,2355,O
also,2355,O
shortly,2355,O
discuss,2355,O
the,2355,O
ongoing,2355,O
debate,2355,O
on,2355,O
whether,2355,O
NO,2355,B-CHEMICAL
is,2355,O
the,2355,O
actual,2355,O
reaction,2355,O
product,2355,O
of,2355,O
NOS,2355,B-GENE-N
catalysis,2355,O
",",2355,O
as,2355,O
well,2355,O
as,2355,O
the,2355,O
phenomenon,2355,O
of,2355,O
NO-mediated,2355,B-CHEMICAL
autoinhibition,2355,O
.,2355,O
We,2356,O
describe,2356,O
the,2356,O
function,2356,O
of,2356,O
BH4,2356,B-CHEMICAL
in,2356,O
aromatic,2356,B-CHEMICAL
amino,2356,I-CHEMICAL
acid,2356,I-CHEMICAL
hydroxylation,2356,O
",",2356,O
and,2356,O
discuss,2356,O
the,2356,O
allosteric,2356,O
and,2356,O
structural,2356,O
effects,2356,O
that,2356,O
BH4,2356,B-CHEMICAL
exerts,2356,O
on,2356,O
NOS,2356,B-GENE-N
.,2356,O
Next,2357,O
we,2357,O
turn,2357,O
our,2357,O
attention,2357,O
to,2357,O
what,2357,O
is,2357,O
now,2357,O
becoming,2357,O
accepted,2357,O
as,2357,O
the,2357,O
central,2357,O
function,2357,O
of,2357,O
BH4,2357,B-CHEMICAL
:,2357,O
its,2357,O
capacity,2357,O
to,2357,O
act,2357,O
as,2357,O
a,2357,O
1-electron,2357,O
donor,2357,O
during,2357,O
reductive,2357,O
activation,2357,O
of,2357,O
the,2357,O
oxyferrous,2357,B-CHEMICAL
complex,2357,O
of,2357,O
the,2357,O
heme,2357,O
.,2357,O
Finally,2358,O
",",2358,O
we,2358,O
illustrate,2358,O
how,2358,O
BH4,2358,B-CHEMICAL
might,2358,O
transform,2358,O
the,2358,O
NOS,2358,B-GENE-N
dimer,2358,O
into,2358,O
an,2358,O
efficient,2358,O
S-nitrosoglutathione,2358,B-GENE-N
synthase,2358,I-GENE-N
",",2358,O
and,2358,O
briefly,2358,O
touch,2358,O
on,2358,O
some,2358,O
more,2358,O
speculative,2358,O
aspects,2358,O
of,2358,O
the,2358,O
role,2358,O
of,2358,O
BH4,2358,B-CHEMICAL
in,2358,O
NO,2358,B-CHEMICAL
synthesis,2358,O
.,2358,O
Prostacyclin,2359,B-CHEMICAL
analogues,2359,O
inhibit,2359,O
tissue,2359,B-GENE-Y
factor,2359,I-GENE-Y
expression,2359,O
in,2359,O
the,2359,O
human,2359,O
monocytic,2359,O
cell,2359,O
line,2359,O
THP-1,2359,O
via,2359,O
a,2359,O
cyclic,2359,B-CHEMICAL
AMP-dependent,2359,O
mechanism,2359,O
.,2359,O
Increased,2360,O
expression,2360,O
of,2360,O
tissue,2360,B-GENE-Y
factor,2360,I-GENE-Y
procoagulant,2360,O
by,2360,O
peripheral,2360,O
blood,2360,O
monocytes,2360,O
has,2360,O
been,2360,O
implicated,2360,O
in,2360,O
a,2360,O
number,2360,O
of,2360,O
thrombotic,2360,O
disorders,2360,O
.,2360,O
The,2361,O
present,2361,O
studies,2361,O
were,2361,O
undertaken,2361,O
to,2361,O
determine,2361,O
whether,2361,O
stable,2361,O
analogues,2361,O
of,2361,O
prostacyclin,2361,B-CHEMICAL
",",2361,O
a,2361,O
potent,2361,O
endothelium-derived,2361,O
platelet,2361,O
inhibitor,2361,O
and,2361,O
vasodilator,2361,O
",",2361,O
could,2361,O
inhibit,2361,O
tissue,2361,B-GENE-Y
factor,2361,I-GENE-Y
expression,2361,O
by,2361,O
human,2361,O
monocytic,2361,O
cells,2361,O
.,2361,O
Exposure,2362,O
of,2362,O
monocytic,2362,O
tumor,2362,O
THP-1,2362,O
cells,2362,O
to,2362,O
100,2362,O
ng/ml,2362,O
endotoxin,2362,O
",",2362,O
2,2362,O
units/ml,2362,O
interleukin-1,2362,B-GENE-Y
beta,2362,I-GENE-Y
",",2362,O
or,2362,O
5,2362,O
ng/ml,2362,O
tumor,2362,B-GENE-Y
necrosis,2362,I-GENE-Y
factor-alpha,2362,I-GENE-Y
for,2362,O
4,2362,O
hours,2362,O
led,2362,O
to,2362,O
increased,2362,O
tissue,2362,B-GENE-Y
factor,2362,I-GENE-Y
procoagulant,2362,O
activity,2362,O
.,2362,O
Preincubation,2363,O
for,2363,O
30,2363,O
minutes,2363,O
with,2363,O
iloprost,2363,B-CHEMICAL
",",2363,O
ciprostene,2363,B-CHEMICAL
",",2363,O
and,2363,O
carbacyclin,2363,B-CHEMICAL
led,2363,O
to,2363,O
a,2363,O
dose-dependent,2363,O
inhibition,2363,O
of,2363,O
tissue,2363,B-GENE-Y
factor,2363,I-GENE-Y
expression,2363,O
induced,2363,O
by,2363,O
all,2363,O
three,2363,O
challenging,2363,O
agents,2363,O
.,2363,O
Iloprost,2364,B-CHEMICAL
was,2364,O
the,2364,O
most,2364,O
potent,2364,O
:,2364,O
50,2364,O
%,2364,O
inhibition,2364,O
occurred,2364,O
at,2364,O
5,2364,O
nM,2364,O
",",2364,O
a,2364,O
concentration,2364,O
close,2364,O
to,2364,O
the,2364,O
reported,2364,O
dissociation,2364,O
constant,2364,O
for,2364,O
iloprost,2364,B-CHEMICAL
binding,2364,O
to,2364,O
the,2364,O
platelet,2364,O
prostacyclin,2364,B-GENE-Y
receptor,2364,I-GENE-Y
.,2364,O
An,2365,O
orally,2365,O
active,2365,O
analogue,2365,O
",",2365,O
cicaprost,2365,B-CHEMICAL
",",2365,O
was,2365,O
equally,2365,O
effective,2365,O
against,2365,O
endotoxin-induced,2365,O
tissue,2365,B-GENE-Y
factor,2365,I-GENE-Y
expression,2365,O
.,2365,O
Carbacyclin,2366,B-CHEMICAL
and,2366,O
ciprostene,2366,B-CHEMICAL
were,2366,O
100,2366,O
times,2366,O
less,2366,O
potent,2366,O
.,2366,O
Iloprost,2367,O
prevented,2367,O
the,2367,O
endotoxin-induced,2367,O
expression,2367,O
of,2367,O
tissue,2367,B-GENE-Y
factor,2367,I-GENE-Y
antigen,2367,O
on,2367,O
the,2367,O
surface,2367,O
of,2367,O
THP-1,2367,O
cells,2367,O
",",2367,O
as,2367,O
determined,2367,O
by,2367,O
flow,2367,O
cytometry,2367,O
.,2367,O
Iloprost,2368,B-CHEMICAL
(,2368,O
500,2368,O
pM-50,2368,O
nM,2368,O
),2368,O
increased,2368,O
intracellular,2368,O
levels,2368,O
of,2368,O
cyclic,2368,B-CHEMICAL
AMP,2368,I-CHEMICAL
.,2368,O
This,2369,O
effect,2369,O
was,2369,O
potentiated,2369,O
by,2369,O
isobutylmethylxanthine,2369,B-CHEMICAL
",",2369,O
an,2369,O
inhibitor,2369,O
of,2369,O
phosphodiesterase,2369,B-GENE-N
.,2369,O
The,2370,O
inhibitory,2370,O
effects,2370,O
of,2370,O
iloprost,2370,O
on,2370,O
tissue,2370,B-GENE-Y
factor,2370,I-GENE-Y
expression,2370,O
were,2370,O
also,2370,O
potentiated,2370,O
by,2370,O
isobutylmethylxanthine,2370,B-CHEMICAL
and,2370,O
mimicked,2370,O
by,2370,O
forskolin,2370,B-CHEMICAL
and,2370,O
dibutyryl,2370,O
cyclic,2370,I-CHEMICAL
AMP,2370,I-CHEMICAL
but,2370,O
not,2370,O
dibutyryl,2370,B-CHEMICAL
cyclic,2370,I-CHEMICAL
GMP,2370,I-CHEMICAL
.,2370,O
These,2371,O
results,2371,O
suggest,2371,O
that,2371,O
prostacyclin,2371,B-CHEMICAL
may,2371,O
play,2371,O
a,2371,O
role,2371,O
in,2371,O
downregulating,2371,O
tissue,2371,B-GENE-Y
factor,2371,I-GENE-Y
expression,2371,O
in,2371,O
monocytes,2371,O
",",2371,O
at,2371,O
least,2371,O
in,2371,O
part,2371,O
via,2371,O
elevation,2371,O
of,2371,O
intracellular,2371,O
levels,2371,O
of,2371,O
cyclic,2371,B-CHEMICAL
AMP,2371,I-CHEMICAL
.,2371,O
Amphetamine-type,2372,B-CHEMICAL
central,2372,O
nervous,2372,O
system,2372,O
stimulants,2372,O
release,2372,O
norepinephrine,2372,B-CHEMICAL
more,2372,O
potently,2372,O
than,2372,O
they,2372,O
release,2372,O
dopamine,2372,B-CHEMICAL
and,2372,O
serotonin,2372,B-CHEMICAL
.,2372,O
A,2373,O
large,2373,O
body,2373,O
of,2373,O
evidence,2373,O
supports,2373,O
the,2373,O
hypothesis,2373,O
that,2373,O
mesolimbic,2373,O
dopamine,2373,B-CHEMICAL
(,2373,O
DA,2373,B-CHEMICAL
),2373,O
mediates,2373,O
",",2373,O
in,2373,O
animal,2373,O
models,2373,O
",",2373,O
the,2373,O
reinforcing,2373,O
effects,2373,O
of,2373,O
central,2373,O
nervous,2373,O
system,2373,O
stimulants,2373,O
such,2373,O
as,2373,O
cocaine,2373,B-CHEMICAL
and,2373,O
amphetamine,2373,B-CHEMICAL
.,2373,O
The,2374,O
role,2374,O
DA,2374,B-CHEMICAL
plays,2374,O
in,2374,O
mediating,2374,O
amphetamine-type,2374,B-CHEMICAL
subjective,2374,O
effects,2374,O
of,2374,O
stimulants,2374,O
in,2374,O
humans,2374,O
remains,2374,O
to,2374,O
be,2374,O
established,2374,O
.,2374,O
Both,2375,O
amphetamine,2375,B-CHEMICAL
and,2375,O
cocaine,2375,B-CHEMICAL
increase,2375,O
norepinephrine,2375,B-CHEMICAL
(,2375,O
NE,2375,B-CHEMICAL
),2375,O
via,2375,O
stimulation,2375,O
of,2375,O
release,2375,O
and,2375,O
inhibition,2375,O
of,2375,O
reuptake,2375,O
",",2375,O
respectively,2375,O
.,2375,O
If,2376,O
increases,2376,O
in,2376,O
NE,2376,B-CHEMICAL
mediate,2376,O
amphetamine-type,2376,B-CHEMICAL
subjective,2376,O
effects,2376,O
of,2376,O
stimulants,2376,O
in,2376,O
humans,2376,O
",",2376,O
then,2376,O
one,2376,O
would,2376,O
predict,2376,O
that,2376,O
stimulant,2376,O
medications,2376,O
that,2376,O
produce,2376,O
amphetamine-type,2376,B-CHEMICAL
subjective,2376,O
effects,2376,O
in,2376,O
humans,2376,O
should,2376,O
share,2376,O
the,2376,O
ability,2376,O
to,2376,O
increase,2376,O
NE,2376,B-CHEMICAL
.,2376,O
To,2377,O
test,2377,O
this,2377,O
hypothesis,2377,O
",",2377,O
we,2377,O
determined,2377,O
",",2377,O
using,2377,O
in,2377,O
vitro,2377,O
methods,2377,O
",",2377,O
the,2377,O
neurochemical,2377,O
mechanism,2377,O
of,2377,O
action,2377,O
of,2377,O
amphetamine,2377,B-CHEMICAL
",",2377,O
"3,4-methylenedioxymethamphetamine",2377,B-CHEMICAL
(,2377,O
MDMA,2377,B-CHEMICAL
),2377,O
",",2377,O
(,2377,B-CHEMICAL
+,2377,I-CHEMICAL
),2377,I-CHEMICAL
-methamphetamine,2377,I-CHEMICAL
",",2377,O
ephedrine,2377,B-CHEMICAL
",",2377,O
phentermine,2377,B-CHEMICAL
",",2377,O
and,2377,O
aminorex,2377,B-CHEMICAL
.,2377,O
As,2378,O
expected,2378,O
",",2378,O
their,2378,O
rank,2378,O
order,2378,O
of,2378,O
potency,2378,O
for,2378,O
DA,2378,B-CHEMICAL
release,2378,O
was,2378,O
similar,2378,O
to,2378,O
their,2378,O
rank,2378,O
order,2378,O
of,2378,O
potency,2378,O
in,2378,O
published,2378,O
self-administration,2378,O
studies,2378,O
.,2378,O
Interestingly,2379,O
",",2379,O
the,2379,O
results,2379,O
demonstrated,2379,O
that,2379,O
the,2379,O
most,2379,O
potent,2379,O
effect,2379,O
of,2379,O
these,2379,O
stimulants,2379,O
is,2379,O
to,2379,O
release,2379,O
NE,2379,B-CHEMICAL
.,2379,O
Importantly,2380,O
",",2380,O
the,2380,O
oral,2380,O
dose,2380,O
of,2380,O
these,2380,O
stimulants,2380,O
",",2380,O
which,2380,O
produce,2380,O
amphetamine-type,2380,B-CHEMICAL
subjective,2380,O
effects,2380,O
in,2380,O
humans,2380,O
",",2380,O
correlated,2380,O
with,2380,O
the,2380,O
their,2380,O
potency,2380,O
in,2380,O
releasing,2380,O
NE,2380,B-CHEMICAL
",",2380,O
not,2380,O
DA,2380,B-CHEMICAL
",",2380,O
and,2380,O
did,2380,O
not,2380,O
decrease,2380,O
plasma,2380,O
prolactin,2380,B-GENE-Y
",",2380,O
an,2380,O
effect,2380,O
mediated,2380,O
by,2380,O
DA,2380,B-CHEMICAL
release,2380,O
.,2380,O
These,2381,O
results,2381,O
suggest,2381,O
that,2381,O
NE,2381,B-CHEMICAL
may,2381,O
contribute,2381,O
to,2381,O
the,2381,O
amphetamine-type,2381,B-CHEMICAL
subjective,2381,O
effects,2381,O
of,2381,O
stimulants,2381,O
in,2381,O
humans,2381,O
.,2381,O
Genetic,2382,O
risk,2382,O
factors,2382,O
for,2382,O
infection,2382,O
in,2382,O
patients,2382,O
with,2382,O
early,2382,O
rheumatoid,2382,O
arthritis,2382,O
.,2382,O
We,2383,O
analyzed,2383,O
clinical,2383,O
and,2383,O
genetic,2383,O
factors,2383,O
contributing,2383,O
to,2383,O
infections,2383,O
in,2383,O
457,2383,O
subjects,2383,O
with,2383,O
early,2383,O
rheumatoid,2383,O
arthritis,2383,O
(,2383,O
RA,2383,O
),2383,O
enrolled,2383,O
in,2383,O
a,2383,O
prospective,2383,O
",",2383,O
1-year,2383,O
clinical,2383,O
trial,2383,O
of,2383,O
methotrexate,2383,B-CHEMICAL
and,2383,O
the,2383,O
TNF,2383,B-GENE-Y
inhibitor,2383,O
etanercept,2383,O
.,2383,O
Subjects,2384,O
were,2384,O
genotyped,2384,O
for,2384,O
the,2384,O
following,2384,O
single,2384,O
nucleotide,2384,B-CHEMICAL
polymorphisms,2384,O
(,2384,O
SNPs,2384,O
),2384,O
:,2384,O
(,2384,O
TNF,2384,B-GENE-Y
-308,2384,O
",",2384,O
-238,2384,O
",",2384,O
and,2384,O
+,2384,O
488,2384,O
),2384,O
;,2384,O
lymphotoxin-alpha,2384,B-GENE-Y
(,2384,O
LTA,2384,B-GENE-Y
),2384,O
(,2384,O
LTA,2384,B-GENE-Y
+,2384,O
249,2384,O
",",2384,O
+,2384,O
365,2384,O
",",2384,O
and,2384,O
+,2384,O
720,2384,O
),2384,O
;,2384,O
and,2384,O
Fc,2384,B-GENE-N
gamma,2384,I-GENE-N
receptors,2384,I-GENE-N
FCGR2A,2384,B-GENE-Y
131,2384,O
H/R,2384,O
;,2384,O
FCGR3A,2384,B-GENE-Y
176,2384,O
F/V,2384,O
;,2384,O
and,2384,O
FCGR3B,2384,B-GENE-Y
NA,2384,O
1/2,2384,O
and,2384,O
genotypes,2384,O
were,2384,O
correlated,2384,O
with,2384,O
infections,2384,O
.,2384,O
At,2385,O
least,2385,O
one,2385,O
URI,2385,O
was,2385,O
noted,2385,O
in,2385,O
52,2385,O
%,2385,O
of,2385,O
subjects,2385,O
(,2385,O
99/191,2385,O
),2385,O
with,2385,O
the,2385,O
NA2/NA2,2385,O
genotype,2385,O
of,2385,O
the,2385,O
neutrophil-specific,2385,O
FCGR3B,2385,B-GENE-Y
gene,2385,O
",",2385,O
compared,2385,O
to,2385,O
42,2385,O
%,2385,O
(,2385,O
77/181,2385,O
),2385,O
of,2385,O
those,2385,O
with,2385,O
the,2385,O
NA1/NA2,2385,O
genotype,2385,O
and,2385,O
39,2385,O
%,2385,O
(,2385,O
23/59,2385,O
),2385,O
of,2385,O
those,2385,O
with,2385,O
the,2385,O
NA1/NA1,2385,O
genotype,2385,O
(,2385,O
P,2385,O
=,2385,O
0.038,2385,O
),2385,O
.,2385,O
Urinary,2386,O
tract,2386,O
infection,2386,O
(,2386,O
UTI,2386,O
),2386,O
was,2386,O
associated,2386,O
with,2386,O
the,2386,O
TNF,2386,B-GENE-Y
-238,2386,O
A,2386,O
(,2386,O
odds,2386,O
ratio,2386,O
(,2386,O
OR,2386,O
),2386,O
2.56,2386,O
",",2386,O
95,2386,O
%,2386,O
confidence,2386,O
interval,2386,O
(,2386,O
CI,2386,O
),2386,O
1.05-6.25,2386,O
),2386,O
and,2386,O
LTA,2386,B-GENE-Y
+365,2386,O
C,2386,O
(,2386,O
OR,2386,O
1.73,2386,O
",",2386,O
95,2386,O
%,2386,O
CI,2386,O
1.07-2.79,2386,O
),2386,O
alleles,2386,O
",",2386,O
and,2386,O
marginally,2386,O
with,2386,O
the,2386,O
FCGR3A,2386,B-GENE-Y
F,2386,O
allele,2386,O
(,2386,O
OR,2386,O
1.72,2386,O
",",2386,O
95,2386,O
%,2386,O
CI,2386,O
0.99-3.00,2386,O
),2386,O
.,2386,O
There,2387,O
was,2387,O
a,2387,O
striking,2387,O
linear,2387,O
correlation,2387,O
between,2387,O
UTI,2387,O
and,2387,O
the,2387,O
number,2387,O
of,2387,O
risk,2387,O
alleles,2387,O
defined,2387,O
by,2387,O
these,2387,O
three,2387,O
SNPs,2387,O
(,2387,O
P,2387,O
<,2387,O
0.001,2387,O
),2387,O
",",2387,O
suggesting,2387,O
an,2387,O
additive,2387,O
effect,2387,O
on,2387,O
susceptibility,2387,O
.,2387,O
These,2388,O
findings,2388,O
have,2388,O
important,2388,O
implications,2388,O
for,2388,O
the,2388,O
role,2388,O
of,2388,O
genetics,2388,O
in,2388,O
susceptibility,2388,O
to,2388,O
bacterial,2388,O
and,2388,O
viral,2388,O
infections,2388,O
.,2388,O
Design,2389,O
",",2389,O
synthesis,2389,O
",",2389,O
and,2389,O
structure-activity,2389,O
relationship,2389,O
studies,2389,O
of,2389,O
tryptanthrins,2389,B-CHEMICAL
as,2389,O
antitubercular,2389,O
agents,2389,O
.,2389,O
The,2390,O
natural,2390,O
product,2390,O
tryptanthrin,2390,B-CHEMICAL
(,2390,O
1a,2390,O
),2390,O
represents,2390,O
a,2390,O
potential,2390,O
lead,2390,O
for,2390,O
new,2390,O
tuberculosis,2390,O
(,2390,O
TB,2390,O
),2390,O
drugs,2390,O
since,2390,O
tryptanthrin,2390,B-CHEMICAL
and,2390,O
its,2390,O
synthetic,2390,O
analogues,2390,O
possess,2390,O
potent,2390,O
in,2390,O
vitro,2390,O
activity,2390,O
against,2390,O
Mycobacterium,2390,O
tuberculosis,2390,O
(,2390,O
Mtb,2390,O
),2390,O
.,2390,O
However,2391,O
",",2391,O
in,2391,O
spite,2391,O
of,2391,O
their,2391,O
in,2391,O
vitro,2391,O
activity,2391,O
",",2391,O
none,2391,O
of,2391,O
these,2391,O
agents,2391,O
have,2391,O
been,2391,O
shown,2391,O
to,2391,O
be,2391,O
efficacious,2391,O
in,2391,O
vivo,2391,O
against,2391,O
animal,2391,O
models,2391,O
of,2391,O
TB,2391,O
.,2391,O
Described,2392,O
herein,2392,O
are,2392,O
syntheses,2392,O
of,2392,O
new,2392,O
tryptanthrin,2392,B-CHEMICAL
analogues,2392,O
together,2392,O
with,2392,O
a,2392,O
systematic,2392,O
investigation,2392,O
of,2392,O
their,2392,O
in,2392,O
vitro,2392,O
antitubercular,2392,O
activity,2392,O
and,2392,O
ADME,2392,O
properties,2392,O
followed,2392,O
by,2392,O
pharmacokinetic,2392,O
characterization,2392,O
in,2392,O
rodents,2392,O
for,2392,O
the,2392,O
most,2392,O
promising,2392,O
compounds,2392,O
.,2392,O
Those,2393,O
with,2393,O
the,2393,O
best,2393,O
potency,2393,O
and,2393,O
oral,2393,O
bioavailability,2393,O
were,2393,O
progressed,2393,O
to,2393,O
evaluations,2393,O
of,2393,O
efficacy,2393,O
against,2393,O
acute,2393,O
murine,2393,O
TB,2393,O
.,2393,O
The,2394,O
work,2394,O
aimed,2394,O
to,2394,O
prove,2394,O
the,2394,O
concept,2394,O
that,2394,O
this,2394,O
compound,2394,O
class,2394,O
can,2394,O
limit,2394,O
growth,2394,O
of,2394,O
Mtb,2394,O
during,2394,O
infection,2394,O
as,2394,O
well,2394,O
as,2394,O
to,2394,O
establish,2394,O
the,2394,O
SAR,2394,O
for,2394,O
in,2394,O
vitro,2394,O
activity,2394,O
against,2394,O
Mtb,2394,O
and,2394,O
the,2394,O
range,2394,O
of,2394,O
in,2394,O
vitro,2394,O
ADME,2394,O
parameters,2394,O
for,2394,O
this,2394,O
class,2394,O
of,2394,O
natural,2394,O
products,2394,O
.,2394,O
Novel,2395,O
C-11-deoxy,2395,O
(,2395,O
5b,2395,O
),2395,O
and,2395,O
A-ring-saturated,2395,O
(,2395,O
6,2395,O
),2395,O
tryptanthrin,2395,B-CHEMICAL
analogues,2395,O
were,2395,O
discovered,2395,O
that,2395,O
maintained,2395,O
activity,2395,O
against,2395,O
Mtb,2395,O
and,2395,O
showed,2395,O
improved,2395,O
solubility,2395,O
compared,2395,O
to,2395,O
tryptanthrin,2395,B-CHEMICAL
as,2395,O
well,2395,O
as,2395,O
evidence,2395,O
of,2395,O
oral,2395,O
bioavailability,2395,O
in,2395,O
rodents,2395,O
.,2395,O
However,2396,O
",",2396,O
neither,2396,O
5b,2396,O
nor,2396,O
6,2396,O
demonstrated,2396,O
efficacy,2396,O
against,2396,O
acute,2396,O
murine,2396,O
TB,2396,O
following,2396,O
administration,2396,O
at,2396,O
doses,2396,O
up,2396,O
to,2396,O
400,2396,O
mg/kg,2396,O
daily,2396,O
for,2396,O
4,2396,O
weeks,2396,O
.,2396,O
Although,2397,O
5b,2397,O
and,2397,O
6,2397,O
failed,2397,O
to,2397,O
inhibit,2397,O
replication,2397,O
or,2397,O
kill,2397,O
Mtb,2397,O
in,2397,O
vivo,2397,O
",",2397,O
they,2397,O
illuminate,2397,O
a,2397,O
path,2397,O
to,2397,O
new,2397,O
structural,2397,O
variations,2397,O
of,2397,O
the,2397,O
tryptanthrin,2397,B-CHEMICAL
scaffold,2397,O
that,2397,O
may,2397,O
maximize,2397,O
the,2397,O
potential,2397,O
of,2397,O
this,2397,O
class,2397,O
of,2397,O
compounds,2397,O
against,2397,O
TB,2397,O
.,2397,O
Serotonin-glutamate,2398,B-CHEMICAL
and,2398,O
serotonin-dopamine,2398,B-CHEMICAL
reciprocal,2398,O
interactions,2398,O
as,2398,O
putative,2398,O
molecular,2398,O
targets,2398,O
for,2398,O
novel,2398,O
antipsychotic,2398,O
treatments,2398,O
:,2398,O
from,2398,O
receptor,2398,O
heterodimers,2398,O
to,2398,O
postsynaptic,2398,O
scaffolding,2398,O
and,2398,O
effector,2398,O
proteins,2398,O
.,2398,O
The,2399,O
physical,2399,O
and,2399,O
functional,2399,O
interactions,2399,O
between,2399,O
serotonin-glutamate,2399,B-CHEMICAL
and,2399,O
serotonin-dopamine,2399,B-CHEMICAL
signaling,2399,O
have,2399,O
been,2399,O
suggested,2399,O
to,2399,O
be,2399,O
involved,2399,O
in,2399,O
psychosis,2399,O
pathophysiology,2399,O
and,2399,O
are,2399,O
supposed,2399,O
to,2399,O
be,2399,O
relevant,2399,O
for,2399,O
antipsychotic,2399,O
treatment,2399,O
.,2399,O
Type,2400,B-GENE-Y
II,2400,I-GENE-Y
metabotropic,2400,I-GENE-Y
glutamate,2400,I-GENE-Y
receptors,2400,I-GENE-Y
(,2400,O
mGluRs,2400,B-GENE-N
),2400,O
and,2400,O
serotonin,2400,B-CHEMICAL
5-HT,2400,B-GENE-Y
(,2400,I-GENE-Y
2A,2400,I-GENE-Y
),2400,I-GENE-Y
receptors,2400,O
have,2400,O
been,2400,O
reported,2400,O
to,2400,O
form,2400,O
heterodimers,2400,O
that,2400,O
modulate,2400,O
G-protein-mediated,2400,B-GENE-N
intracellular,2400,O
signaling,2400,O
differentially,2400,O
compared,2400,O
to,2400,O
mGluR2,2400,B-GENE-Y
and,2400,O
5-HT,2400,B-GENE-Y
(,2400,I-GENE-Y
2A,2400,I-GENE-Y
),2400,I-GENE-Y
homomers,2400,O
.,2400,O
Additionally,2401,O
",",2401,O
direct,2401,O
evidence,2401,O
has,2401,O
been,2401,O
provided,2401,O
that,2401,O
D,2401,B-GENE-N
(,2401,I-GENE-N
2,2401,I-GENE-N
),2401,I-GENE-N
and,2401,I-GENE-N
5-HT,2401,I-GENE-N
(,2401,I-GENE-N
2A,2401,I-GENE-N
),2401,I-GENE-N
receptors,2401,I-GENE-N
form,2401,O
physical,2401,O
heterocomplexes,2401,O
which,2401,O
exert,2401,O
a,2401,O
functional,2401,O
cross-talk,2401,O
",",2401,O
as,2401,O
demonstrated,2401,O
by,2401,O
studies,2401,O
on,2401,O
hallucinogen-induced,2401,O
signaling,2401,O
.,2401,O
Moving,2402,O
from,2402,O
receptors,2402,O
to,2402,O
postsynaptic,2402,O
density,2402,O
(,2402,O
PSD,2402,O
),2402,O
scenario,2402,O
",",2402,O
the,2402,O
scaffolding,2402,O
protein,2402,O
PSD-95,2402,O
is,2402,O
known,2402,O
to,2402,O
interact,2402,O
with,2402,O
N-methyl-D-aspartate,2402,B-GENE-N
(,2402,I-GENE-N
NMDA,2402,I-GENE-N
),2402,I-GENE-N
",",2402,I-GENE-N
D,2402,I-GENE-N
(,2402,I-GENE-N
2,2402,I-GENE-N
),2402,I-GENE-N
and,2402,I-GENE-N
5-HT,2402,I-GENE-N
(,2402,I-GENE-N
2,2402,I-GENE-N
),2402,I-GENE-N
receptors,2402,I-GENE-N
",",2402,O
regulating,2402,O
their,2402,O
activation,2402,O
state,2402,O
.,2402,O
Homer1a,2403,O
",",2403,O
the,2403,O
inducible,2403,O
member,2403,O
of,2403,O
the,2403,O
Homer,2403,B-GENE-N
family,2403,O
of,2403,O
PSD,2403,O
proteins,2403,O
that,2403,O
is,2403,O
implicated,2403,O
in,2403,O
glutamatergic,2403,O
signal,2403,O
transduction,2403,O
",",2403,O
is,2403,O
induced,2403,O
in,2403,O
striatum,2403,O
by,2403,O
antipsychotics,2403,O
with,2403,O
high,2403,O
dopamine,2403,B-CHEMICAL
receptor,2403,O
affinity,2403,O
and,2403,O
in,2403,O
the,2403,O
cortex,2403,O
by,2403,O
antipsychotics,2403,O
with,2403,O
mixed,2403,O
serotonergic/dopaminergic,2403,O
profile,2403,O
.,2403,O
Signaling,2404,O
molecules,2404,O
",",2404,O
such,2404,O
as,2404,O
Akt,2404,B-GENE-N
and,2404,O
glycogen-synthase-kinase-3,2404,B-GENE-N
(,2404,O
GSK-3,2404,B-GENE-N
),2404,O
",",2404,O
could,2404,O
be,2404,O
involved,2404,O
in,2404,O
the,2404,O
mechanism,2404,O
of,2404,O
action,2404,O
of,2404,O
antipsychotics,2404,O
",",2404,O
targeting,2404,O
dopamine,2404,B-CHEMICAL
",",2404,O
serotonin,2404,B-CHEMICAL
",",2404,O
and,2404,O
glutamate,2404,B-CHEMICAL
neurotransmission,2404,O
.,2404,O
Altogether,2405,O
",",2405,O
these,2405,O
proteins,2405,O
stand,2405,O
at,2405,O
the,2405,O
crossroad,2405,O
of,2405,O
glutamate-dopamine-serotonin,2405,B-CHEMICAL
signaling,2405,O
pathways,2405,O
and,2405,O
may,2405,O
be,2405,O
considered,2405,O
as,2405,O
valuable,2405,O
molecular,2405,O
targets,2405,O
for,2405,O
current,2405,O
and,2405,O
new,2405,O
antipsychotics,2405,O
.,2405,O
The,2406,O
aim,2406,O
of,2406,O
this,2406,O
review,2406,O
is,2406,O
to,2406,O
provide,2406,O
a,2406,O
critical,2406,O
appraisal,2406,O
on,2406,O
serotonin-glutamate,2406,B-CHEMICAL
and,2406,O
serotonin-dopamine,2406,B-CHEMICAL
interplay,2406,O
to,2406,O
support,2406,O
the,2406,O
idea,2406,O
that,2406,O
next,2406,O
generation,2406,O
schizophrenia,2406,O
pharmacotherapy,2406,O
should,2406,O
not,2406,O
exclusively,2406,O
rely,2406,O
on,2406,O
receptor,2406,O
targeting,2406,O
strategies,2406,O
.,2406,O
The,2407,O
serotonin,2407,B-GENE-Y
transporter,2407,I-GENE-Y
polymorphism,2407,O
",",2407,O
5HTTLPR,2407,B-GENE-Y
",",2407,O
is,2407,O
associated,2407,O
with,2407,O
a,2407,O
faster,2407,O
response,2407,O
time,2407,O
to,2407,O
sertraline,2407,B-CHEMICAL
in,2407,O
an,2407,O
elderly,2407,O
population,2407,O
with,2407,O
major,2407,O
depressive,2407,O
disorder,2407,O
.,2407,O
RATIONALE,2408,O
:,2408,O
A,2408,O
common,2408,O
polymorphism,2408,O
(,2408,O
5HTTLPR,2408,B-GENE-Y
),2408,O
within,2408,O
the,2408,O
promoter,2408,O
region,2408,O
of,2408,O
the,2408,O
serotonin,2408,B-GENE-Y
transporter,2408,I-GENE-Y
gene,2408,O
(,2408,O
LSC6A4,2408,B-GENE-Y
),2408,O
has,2408,O
been,2408,O
shown,2408,O
to,2408,O
influence,2408,O
response,2408,O
time,2408,O
as,2408,O
well,2408,O
as,2408,O
overall,2408,O
response,2408,O
to,2408,O
selective,2408,O
serotonin,2408,B-CHEMICAL
reuptake,2408,O
inhibitors,2408,O
(,2408,O
SSRIs,2408,O
),2408,O
in,2408,O
subjects,2408,O
with,2408,O
major,2408,O
depressive,2408,O
disorder,2408,O
.,2408,O
We,2409,O
hypothesized,2409,O
that,2409,O
a,2409,O
similar,2409,O
effect,2409,O
in,2409,O
response,2409,O
time,2409,O
to,2409,O
sertraline,2409,B-CHEMICAL
would,2409,O
be,2409,O
observed,2409,O
and,2409,O
that,2409,O
no,2409,O
effect,2409,O
on,2409,O
response,2409,O
time,2409,O
would,2409,O
be,2409,O
seen,2409,O
in,2409,O
a,2409,O
placebo,2409,O
arm,2409,O
.,2409,O
OBJECTIVES,2410,O
:,2410,O
We,2410,O
tested,2410,O
the,2410,O
hypothesis,2410,O
that,2410,O
subjects,2410,O
homozygous,2410,O
for,2410,O
the,2410,O
long,2410,O
allele,2410,O
at,2410,O
the,2410,O
5HTTLPR,2410,B-GENE-Y
polymorphism,2410,O
would,2410,O
respond,2410,O
more,2410,O
rapidly,2410,O
to,2410,O
sertraline,2410,B-CHEMICAL
than,2410,O
subjects,2410,O
carrying,2410,O
one,2410,O
or,2410,O
two,2410,O
copies,2410,O
of,2410,O
the,2410,O
short,2410,O
allele,2410,O
.,2410,O
METHODS,2411,O
:,2411,O
HAM-D,2411,O
and,2411,O
CGI-I,2411,O
responses,2411,O
to,2411,O
sertraline,2411,B-CHEMICAL
and,2411,O
placebo,2411,O
were,2411,O
measured,2411,O
weekly,2411,O
in,2411,O
the,2411,O
context,2411,O
of,2411,O
an,2411,O
8-week,2411,O
",",2411,O
placebo-controlled,2411,O
study,2411,O
in,2411,O
elderly,2411,O
depressed,2411,O
subjects,2411,O
.,2411,O
Genotyping,2412,O
of,2412,O
the,2412,O
5HTTLPR,2412,B-GENE-Y
polymorphism,2412,O
was,2412,O
performed,2412,O
to,2412,O
test,2412,O
for,2412,O
correlations,2412,O
with,2412,O
response,2412,O
at,2412,O
each,2412,O
week,2412,O
in,2412,O
the,2412,O
sertraline,2412,B-CHEMICAL
and,2412,O
placebo,2412,O
groups,2412,O
(,2412,O
n=206,2412,O
),2412,O
.,2412,O
RESULTS,2413,O
:,2413,O
Subjects,2413,O
homozygous,2413,O
for,2413,O
the,2413,O
long,2413,O
allele,2413,O
of,2413,O
5HTTLPR,2413,B-GENE-Y
showed,2413,O
a,2413,O
significant,2413,O
increase,2413,O
in,2413,O
response,2413,O
at,2413,O
week,2413,O
1,2413,O
and,2413,O
week,2413,O
2,2413,O
",",2413,O
as,2413,O
assessed,2413,O
by,2413,O
the,2413,O
CGI-I,2413,O
scale,2413,O
compared,2413,O
with,2413,O
subjects,2413,O
carrying,2413,O
one,2413,O
or,2413,O
two,2413,O
copies,2413,O
of,2413,O
the,2413,O
short,2413,O
allele,2413,O
(,2413,O
P=0.01,2413,O
at,2413,O
both,2413,O
weeks,2413,O
),2413,O
.,2413,O
No,2414,O
significant,2414,O
difference,2414,O
was,2414,O
observed,2414,O
in,2414,O
the,2414,O
placebo,2414,O
group,2414,O
.,2414,O
CONCLUSIONS,2415,O
:,2415,O
These,2415,O
results,2415,O
suggest,2415,O
that,2415,O
genetic,2415,O
variation,2415,O
in,2415,O
the,2415,O
serotonin,2415,B-GENE-Y
transporter,2415,I-GENE-Y
gene,2415,O
effects,2415,O
the,2415,O
response,2415,O
time,2415,O
to,2415,O
sertraline,2415,B-CHEMICAL
and,2415,O
provides,2415,O
complementing,2415,O
evidence,2415,O
to,2415,O
previous,2415,O
reports,2415,O
that,2415,O
this,2415,O
polymorphism,2415,O
affects,2415,O
response,2415,O
time,2415,O
to,2415,O
other,2415,O
SSRIs,2415,O
.,2415,O
Histone,2416,B-GENE-Y
deacetylase,2416,I-GENE-Y
3,2416,I-GENE-Y
is,2416,O
required,2416,O
for,2416,O
maintenance,2416,O
of,2416,O
bone,2416,O
mass,2416,O
during,2416,O
aging,2416,O
.,2416,O
Histone,2417,B-GENE-Y
deacetylase,2417,I-GENE-Y
3,2417,I-GENE-Y
(,2417,O
Hdac3,2417,B-GENE-Y
),2417,O
is,2417,O
a,2417,O
nuclear,2417,O
enzyme,2417,O
that,2417,O
removes,2417,O
acetyl,2417,B-CHEMICAL
groups,2417,O
from,2417,O
lysine,2417,B-CHEMICAL
residues,2417,O
in,2417,O
histones,2417,B-GENE-N
and,2417,O
other,2417,O
proteins,2417,O
to,2417,O
epigenetically,2417,O
regulate,2417,O
gene,2417,O
expression,2417,O
.,2417,O
Hdac3,2418,B-GENE-Y
interacts,2418,O
with,2418,O
bone-related,2418,O
transcription,2418,O
factors,2418,O
and,2418,O
co-factors,2418,O
such,2418,O
as,2418,O
Runx2,2418,B-GENE-Y
and,2418,O
Zfp521,2418,B-GENE-Y
",",2418,O
and,2418,O
thus,2418,O
is,2418,O
poised,2418,O
to,2418,O
play,2418,O
a,2418,O
key,2418,O
role,2418,O
in,2418,O
the,2418,O
skeletal,2418,O
system,2418,O
.,2418,O
To,2419,O
understand,2419,O
the,2419,O
role,2419,O
of,2419,O
Hdac3,2419,B-GENE-Y
in,2419,O
osteoblasts,2419,O
and,2419,O
osteocytes,2419,O
",",2419,O
Hdac3,2419,B-GENE-Y
conditional,2419,O
knockout,2419,O
(,2419,O
CKO,2419,O
),2419,O
mice,2419,O
were,2419,O
created,2419,O
with,2419,O
the,2419,O
osteocalcin,2419,B-GENE-N
(,2419,I-GENE-N
OCN,2419,I-GENE-N
),2419,I-GENE-N
promoter,2419,I-GENE-N
driving,2419,O
Cre,2419,B-GENE-N
expression,2419,O
.,2419,O
Hdac3,2420,B-GENE-Y
CKO,2420,O
(,2420,O
OCN,2420,B-GENE-Y
),2420,O
mice,2420,O
were,2420,O
of,2420,O
normal,2420,O
size,2420,O
and,2420,O
weight,2420,O
",",2420,O
but,2420,O
progressively,2420,O
lost,2420,O
trabecular,2420,O
and,2420,O
cortical,2420,O
bone,2420,O
mass,2420,O
with,2420,O
age,2420,O
.,2420,O
The,2421,O
Hdac3,2421,B-GENE-Y
CKO,2421,O
(,2421,O
OCN,2421,B-GENE-Y
),2421,O
mice,2421,O
exhibited,2421,O
reduced,2421,O
cortical,2421,O
bone,2421,O
mineralization,2421,O
and,2421,O
material,2421,O
properties,2421,O
and,2421,O
suffered,2421,O
frequent,2421,O
fractures,2421,O
.,2421,O
Bone,2422,O
resorption,2422,O
was,2422,O
lower,2422,O
",",2422,O
not,2422,O
higher,2422,O
",",2422,O
in,2422,O
the,2422,O
Hdac3,2422,B-GENE-Y
CKO,2422,O
(,2422,O
OCN,2422,B-GENE-Y
),2422,O
mice,2422,O
",",2422,O
suggesting,2422,O
that,2422,O
primary,2422,O
defects,2422,O
in,2422,O
osteoblasts,2422,O
caused,2422,O
the,2422,O
reduced,2422,O
bone,2422,O
mass,2422,O
.,2422,O
Indeed,2423,O
",",2423,O
reductions,2423,O
in,2423,O
bone,2423,O
formation,2423,O
were,2423,O
observed,2423,O
.,2423,O
Osteoblasts,2424,O
and,2424,O
osteocytes,2424,O
from,2424,O
Hdac3,2424,B-GENE-Y
CKO,2424,O
(,2424,O
OCN,2424,B-GENE-Y
),2424,O
mice,2424,O
showed,2424,O
increased,2424,O
DNA,2424,O
damage,2424,O
and,2424,O
reduced,2424,O
functional,2424,O
activity,2424,O
in,2424,O
vivo,2424,O
and,2424,O
in,2424,O
vitro,2424,O
.,2424,O
Thus,2425,O
",",2425,O
Hdac3,2425,B-GENE-Y
expression,2425,O
in,2425,O
osteoblasts,2425,O
and,2425,O
osteocytes,2425,O
is,2425,O
essential,2425,O
for,2425,O
bone,2425,O
maintenance,2425,O
during,2425,O
aging,2425,O
.,2425,O
Enzyme,2426,O
expression,2426,O
profiles,2426,O
suggest,2426,O
the,2426,O
novel,2426,O
tumor-activated,2426,O
fluoropyrimidine,2426,B-CHEMICAL
carbamate,2426,I-CHEMICAL
capecitabine,2426,B-CHEMICAL
(,2426,O
Xeloda,2426,B-CHEMICAL
),2426,O
might,2426,O
be,2426,O
effective,2426,O
against,2426,O
papillary,2426,O
thyroid,2426,O
cancers,2426,O
of,2426,O
children,2426,O
and,2426,O
young,2426,O
adults,2426,O
.,2426,O
PURPOSE,2427,O
:,2427,O
The,2427,O
fluoropyrimidine,2427,B-CHEMICAL
carbamate,2427,I-CHEMICAL
(,2427,O
capecitabine,2427,B-CHEMICAL
),2427,O
is,2427,O
converted,2427,O
to,2427,O
5-fluorouracil,2427,B-CHEMICAL
(,2427,O
5-FU,2427,B-CHEMICAL
),2427,O
by,2427,O
thymidine,2427,B-GENE-Y
phosphorylase,2427,I-GENE-Y
(,2427,O
TP,2427,B-GENE-Y
),2427,O
inside,2427,O
target,2427,O
tissues,2427,O
.,2427,O
5-FU,2428,B-CHEMICAL
interferes,2428,O
with,2428,O
DNA,2428,O
synthesis,2428,O
by,2428,O
blocking,2428,O
thymidylate,2428,B-GENE-Y
synthase,2428,I-GENE-Y
(,2428,O
TS,2428,B-GENE-Y
),2428,O
but,2428,O
is,2428,O
inactivated,2428,O
by,2428,O
dihydropyrimidine,2428,B-GENE-Y
dehydrogenase,2428,I-GENE-Y
(,2428,O
DPD,2428,B-GENE-Y
),2428,O
.,2428,O
Favorable,2429,O
enzyme,2429,O
profiles,2429,O
(,2429,O
high,2429,O
TP,2429,B-GENE-Y
and,2429,O
low,2429,O
DPD,2429,B-GENE-Y
),2429,O
generate,2429,O
high,2429,O
intratumor,2429,O
levels,2429,O
of,2429,O
5-FU,2429,B-CHEMICAL
that,2429,O
are,2429,O
effective,2429,O
against,2429,O
many,2429,O
tumors,2429,O
",",2429,O
especially,2429,O
those,2429,O
with,2429,O
low,2429,O
TS,2429,B-GENE-Y
.,2429,O
Capecitabine,2430,B-CHEMICAL
has,2430,O
not,2430,O
been,2430,O
tested,2430,O
against,2430,O
thyroid,2430,O
cancers,2430,O
",",2430,O
and,2430,O
it,2430,O
is,2430,O
not,2430,O
known,2430,O
to,2430,O
what,2430,O
extent,2430,O
thyroid,2430,O
cancers,2430,O
express,2430,O
TP,2430,B-GENE-Y
",",2430,O
TS,2430,B-GENE-Y
or,2430,O
DPD,2430,B-GENE-Y
.,2430,O
METHODS,2431,O
:,2431,O
To,2431,O
test,2431,O
this,2431,O
",",2431,O
we,2431,O
determined,2431,O
TP,2431,B-GENE-Y
",",2431,O
TS,2431,B-GENE-Y
and,2431,O
DPD,2431,B-GENE-Y
in,2431,O
19,2431,O
thyroid,2431,O
cancers,2431,O
from,2431,O
young,2431,O
patients,2431,O
(,2431,O
14,2431,O
papillary,2431,O
",",2431,O
4,2431,O
follicular,2431,O
",",2431,O
1,2431,O
medullary,2431,O
),2431,O
by,2431,O
immunohistochemistry,2431,O
.,2431,O
After,2432,O
approval,2432,O
by,2432,O
the,2432,O
Human,2432,O
Use,2432,O
Committee,2432,O
",",2432,O
the,2432,O
intensity,2432,O
of,2432,O
TP,2432,B-GENE-Y
",",2432,O
TS,2432,B-GENE-Y
",",2432,O
and,2432,O
DPD,2432,B-GENE-Y
staining,2432,O
was,2432,O
determined,2432,O
by,2432,O
two,2432,O
independent,2432,O
examiners,2432,O
and,2432,O
graded,2432,O
(,2432,O
absent=0,2432,O
to,2432,O
intense=3,2432,O
),2432,O
with,2432,O
>,2432,O
90,2432,O
%,2432,O
concordance,2432,O
.,2432,O
RESULTS,2433,O
:,2433,O
TS,2433,B-GENE-Y
was,2433,O
detected,2433,O
in,2433,O
7/19,2433,O
cancers,2433,O
(,2433,O
37,2433,O
%,2433,O
),2433,O
",",2433,O
TP,2433,B-GENE-Y
in,2433,O
14/19,2433,O
cancers,2433,O
(,2433,O
74,2433,O
%,2433,O
),2433,O
and,2433,O
DPD,2433,B-GENE-Y
in,2433,O
14/19,2433,O
cancers,2433,O
(,2433,O
74,2433,O
%,2433,O
),2433,O
.,2433,O
In,2434,O
six,2434,O
tumors,2434,O
",",2434,O
TP,2434,B-GENE-Y
was,2434,O
more,2434,O
intense,2434,O
that,2434,O
DPD,2434,B-GENE-Y
",",2434,O
suggesting,2434,O
capecitabine,2434,O
sensitivity,2434,O
.,2434,O
Only,2435,O
five,2435,O
tumors,2435,O
failed,2435,O
to,2435,O
express,2435,O
TP,2435,B-GENE-Y
but,2435,O
four,2435,O
of,2435,O
these,2435,O
expressed,2435,O
DPD,2435,B-GENE-Y
",",2435,O
suggesting,2435,O
capecitabine,2435,B-CHEMICAL
resistance,2435,O
.,2435,O
Overall,2436,O
",",2436,O
6/19,2436,O
tumors,2436,O
(,2436,O
32,2436,O
%,2436,O
of,2436,O
the,2436,O
total,2436,O
),2436,O
had,2436,O
a,2436,O
favorable,2436,O
expression,2436,O
profile,2436,O
",",2436,O
and,2436,O
all,2436,O
of,2436,O
them,2436,O
were,2436,O
papillary,2436,O
cancers,2436,O
.,2436,O
CONCLUSIONS,2437,O
:,2437,O
We,2437,O
conclude,2437,O
that,2437,O
the,2437,O
majority,2437,O
of,2437,O
differentiated,2437,O
thyroid,2437,O
cancers,2437,O
(,2437,O
74,2437,O
%,2437,O
),2437,O
express,2437,O
TP,2437,B-GENE-Y
and,2437,O
low,2437,O
levels,2437,O
of,2437,O
TS,2437,B-GENE-Y
(,2437,O
63,2437,O
%,2437,O
undetectable,2437,O
),2437,O
.,2437,O
The,2438,O
results,2438,O
support,2438,O
the,2438,O
hypothesis,2438,O
that,2438,O
capecitabine,2438,B-CHEMICAL
is,2438,O
activated,2438,O
in,2438,O
the,2438,O
majority,2438,O
of,2438,O
differentiated,2438,O
thyroid,2438,O
cancers,2438,O
and,2438,O
that,2438,O
32,2438,O
%,2438,O
have,2438,O
favorable,2438,O
expression,2438,O
of,2438,O
all,2438,O
three,2438,O
enzymes,2438,O
(,2438,O
TP,2438,B-GENE-Y
",",2438,O
TS,2438,B-GENE-Y
",",2438,O
and,2438,O
DPD,2438,B-GENE-Y
),2438,O
.,2438,O
Nonsteroidal,2439,O
anti-inflammatory,2439,O
drugs,2439,O
activate,2439,O
carbonic,2439,B-GENE-N
anhydrase,2439,I-GENE-N
by,2439,O
a,2439,O
direct,2439,O
mechanism,2439,O
of,2439,O
action,2439,O
.,2439,O
Previous,2440,O
studies,2440,O
by,2440,O
this,2440,O
research,2440,O
team,2440,O
proved,2440,O
that,2440,O
vasodilating,2440,O
prostaglandins,2440,B-CHEMICAL
(,2440,O
PGs,2440,B-CHEMICAL
),2440,O
E1,2440,O
",",2440,O
E2,2440,O
and,2440,O
I2,2440,O
inhibit,2440,O
carbonic,2440,B-GENE-N
anhydrase,2440,I-GENE-N
(,2440,O
CA,2440,B-GENE-N
),2440,O
in,2440,O
vitro,2440,O
and,2440,O
in,2440,O
vivo,2440,O
",",2440,O
which,2440,O
suggested,2440,O
involvement,2440,O
of,2440,O
CA,2440,B-GENE-N
in,2440,O
gastric,2440,O
acid,2440,O
secretion,2440,O
inhibition,2440,O
and,2440,O
the,2440,O
increase,2440,O
of,2440,O
gastric,2440,O
mucosa,2440,O
blood,2440,O
flow,2440,O
produced,2440,O
by,2440,O
this,2440,O
group,2440,O
of,2440,O
PGs,2440,B-CHEMICAL
.,2440,O
Relying,2441,O
on,2441,O
these,2441,O
findings,2441,O
",",2441,O
as,2441,O
well,2441,O
as,2441,O
on,2441,O
our,2441,O
clinical,2441,O
observations,2441,O
",",2441,O
we,2441,O
studied,2441,O
in,2441,O
vitro,2441,O
and,2441,O
in,2441,O
vivo,2441,O
the,2441,O
effects,2441,O
of,2441,O
nonsteroidal,2441,O
anti-inflammatory,2441,O
drugs,2441,O
(,2441,O
NSAIDs,2441,O
),2441,O
on,2441,O
CA,2441,B-GENE-Y
I,2441,I-GENE-Y
and,2441,O
CA,2441,B-GENE-Y
II,2441,I-GENE-Y
.,2441,O
We,2442,O
also,2442,O
followed,2442,O
in,2442,O
vitro,2442,O
the,2442,O
effects,2442,O
on,2442,O
these,2442,O
isozymes,2442,O
of,2442,O
NSAIDs,2442,O
associated,2442,O
to,2442,O
histamine,2442,B-CHEMICAL
",",2442,O
Ca,2442,B-CHEMICAL
",",2442,O
PGE2,2442,O
and,2442,O
acetazolamide,2442,B-CHEMICAL
.,2442,O
The,2443,O
results,2443,O
show,2443,O
that,2443,O
the,2443,O
NSAIDs,2443,O
used,2443,O
here,2443,O
",",2443,O
which,2443,O
reduce,2443,O
the,2443,O
activity,2443,O
of,2443,O
cyclooxygenase,2443,B-GENE-N
and,2443,O
PG,2443,B-CHEMICAL
production,2443,O
",",2443,O
activated,2443,O
CA,2443,B-GENE-Y
I,2443,I-GENE-Y
and,2443,O
CA,2443,B-GENE-Y
II,2443,I-GENE-Y
in,2443,O
a,2443,O
dose-dependent,2443,O
manner,2443,O
by,2443,O
a,2443,O
mechanism,2443,O
of,2443,O
the,2443,O
noncompetitive,2443,O
type,2443,O
.,2443,O
Histamine,2444,B-CHEMICAL
and,2444,O
Ca,2444,B-CHEMICAL
added,2444,O
to,2444,O
NSAIDs,2444,O
amplified,2444,O
the,2444,O
activating,2444,O
effect,2444,O
of,2444,O
the,2444,O
latter,2444,O
on,2444,O
CA,2444,B-GENE-Y
II,2444,I-GENE-Y
.,2444,O
Association,2445,O
of,2445,O
PGE2,2445,O
or,2445,O
acetazolamide,2445,B-CHEMICAL
to,2445,O
NSAIDs,2445,O
reduced,2445,O
NSAID-induced,2445,O
activation,2445,O
of,2445,O
CA,2445,B-GENE-Y
I,2445,I-GENE-Y
and,2445,O
CA,2445,B-GENE-Y
II,2445,I-GENE-Y
.,2445,O
Indomethacin,2446,B-CHEMICAL
abolished,2446,O
the,2446,O
inhibitory,2446,O
effect,2446,O
of,2446,O
acetazolamide,2446,B-CHEMICAL
on,2446,O
CA,2446,B-GENE-Y
I,2446,I-GENE-Y
and,2446,O
CA,2446,B-GENE-Y
II,2446,I-GENE-Y
.,2446,O
Our,2447,O
data,2447,O
imply,2447,O
that,2447,O
between,2447,O
CA,2447,B-GENE-N
and,2447,O
cyclooxygenase,2447,B-GENE-N
there,2447,O
is,2447,O
an,2447,O
inverse,2447,O
relationship,2447,O
",",2447,O
CA,2447,B-GENE-N
activation,2447,O
being,2447,O
accompanied,2447,O
by,2447,O
reduction,2447,O
of,2447,O
cyclooxygenase,2447,B-GENE-N
activity,2447,O
",",2447,O
a,2447,O
reduction,2447,O
achieved,2447,O
by,2447,O
the,2447,O
pH,2447,O
modifications,2447,O
induced,2447,O
by,2447,O
CA,2447,B-GENE-N
activation,2447,O
.,2447,O
In,2448,O
this,2448,O
way,2448,O
",",2448,O
cyclooxygenase,2448,B-GENE-N
",",2448,O
inhibition,2448,O
occurs,2448,O
``,2448,O
via,2448,O
CA,2448,B-GENE-N
",",2448,O
'',2448,O
with,2448,O
the,2448,O
pH,2448,O
variations,2448,O
it,2448,O
brings,2448,O
about,2448,O
.,2448,O
Surface-modified,2449,O
HK,2449,O
:,2449,O
siRNA,2449,O
nanoplexes,2449,O
with,2449,O
enhanced,2449,O
pharmacokinetics,2449,O
and,2449,O
tumor,2449,O
growth,2449,O
inhibition,2449,O
.,2449,O
We,2450,O
characterized,2450,O
in,2450,O
this,2450,O
study,2450,O
the,2450,O
pharmacokinetics,2450,O
and,2450,O
antitumor,2450,O
efficacy,2450,O
of,2450,O
histidine-lysine,2450,B-CHEMICAL
(,2450,O
HK,2450,O
),2450,O
:,2450,O
siRNA,2450,O
nanoplexes,2450,O
modified,2450,O
with,2450,O
PEG,2450,B-CHEMICAL
and,2450,O
a,2450,O
cyclic,2450,O
RGD,2450,B-GENE-N
(,2450,O
cRGD,2450,B-GENE-N
),2450,O
ligand,2450,O
targeting,2450,O
αvβ3,2450,B-GENE-Y
and,2450,O
αvβ5,2450,B-GENE-Y
integrins,2450,I-GENE-Y
.,2450,O
With,2451,O
noninvasive,2451,O
imaging,2451,O
",",2451,O
systemically,2451,O
administered,2451,O
surface-modified,2451,O
HK,2451,O
:,2451,O
siRNA,2451,O
nanoplexes,2451,O
showed,2451,O
nearly,2451,O
4-fold,2451,O
greater,2451,O
blood,2451,O
levels,2451,O
",",2451,O
40,2451,O
%,2451,O
higher,2451,O
accumulation,2451,O
in,2451,O
tumor,2451,O
tissue,2451,O
",",2451,O
and,2451,O
60,2451,O
%,2451,O
lower,2451,O
luciferase,2451,O
activity,2451,O
than,2451,O
unmodified,2451,O
HK,2451,O
:,2451,O
siRNA,2451,O
nanoplexes,2451,O
.,2451,O
We,2452,O
then,2452,O
determined,2452,O
whether,2452,O
the,2452,O
surface-modified,2452,O
HK,2452,O
:,2452,O
siRNA,2452,O
nanoplex,2452,O
carrier,2452,O
was,2452,O
more,2452,O
effective,2452,O
in,2452,O
reducing,2452,O
MDA-MB-435,2452,O
tumor,2452,O
growth,2452,O
with,2452,O
an,2452,O
siRNA,2452,O
targeting,2452,O
Raf-1,2452,B-GENE-Y
.,2452,O
Repeated,2453,O
systemic,2453,O
administration,2453,O
of,2453,O
the,2453,O
selected,2453,O
surface,2453,O
modified,2453,O
HK,2453,O
:,2453,O
siRNA,2453,O
nanoplexes,2453,O
targeting,2453,O
Raf-1,2453,B-GENE-Y
showed,2453,O
35,2453,O
%,2453,O
greater,2453,O
inhibition,2453,O
of,2453,O
tumor,2453,O
growth,2453,O
than,2453,O
unmodified,2453,O
HK,2453,O
:,2453,O
siRNA,2453,O
nanoplexes,2453,O
and,2453,O
60,2453,O
%,2453,O
greater,2453,O
inhibition,2453,O
of,2453,O
tumor,2453,O
growth,2453,O
than,2453,O
untreated,2453,O
mice,2453,O
.,2453,O
The,2454,O
improved,2454,O
blood,2454,O
pharmacokinetic,2454,O
results,2454,O
and,2454,O
tumor,2454,O
localization,2454,O
observed,2454,O
with,2454,O
the,2454,O
integrin-targeting,2454,B-GENE-N
surface,2454,O
modification,2454,O
of,2454,O
HK,2454,O
:,2454,O
siRNA,2454,O
nanoplexes,2454,O
correlated,2454,O
with,2454,O
greater,2454,O
tumor,2454,O
growth,2454,O
inhibition,2454,O
.,2454,O
This,2455,O
investigation,2455,O
reveals,2455,O
that,2455,O
through,2455,O
control,2455,O
of,2455,O
targeting,2455,O
ligand,2455,O
surface,2455,O
display,2455,O
in,2455,O
association,2455,O
with,2455,O
a,2455,O
steric,2455,O
PEG,2455,B-CHEMICAL
layer,2455,O
",",2455,O
modified,2455,O
HK,2455,O
:,2455,O
siRNA,2455,O
nanoplexes,2455,O
show,2455,O
promise,2455,O
to,2455,O
advance,2455,O
RNAi,2455,O
therapeutics,2455,O
in,2455,O
oncology,2455,O
and,2455,O
potentially,2455,O
other,2455,O
critical,2455,O
diseases,2455,O
.,2455,O
Inhibition,2456,O
of,2456,O
platelet,2456,B-GENE-N
receptors,2456,I-GENE-N
involved,2456,O
in,2456,O
neutrophil-platelet,2456,O
interaction,2456,O
in,2456,O
model,2456,O
cardiopulmonary,2456,O
bypass,2456,O
.,2456,O
We,2457,O
investigated,2457,O
the,2457,O
interactions,2457,O
between,2457,O
neutrophils,2457,O
",",2457,O
platelets,2457,O
",",2457,O
and,2457,O
artificial,2457,O
surfaces,2457,O
",",2457,O
and,2457,O
whether,2457,O
blocking,2457,O
of,2457,O
relevant,2457,O
receptors,2457,O
on,2457,O
platelets,2457,O
reduced,2457,O
unwanted,2457,O
activation,2457,O
responses,2457,O
in,2457,O
model,2457,O
cardiopulmonary,2457,O
bypass,2457,O
.,2457,O
Isolated,2458,O
neutrophils,2458,O
and,2458,O
platelets,2458,O
resuspended,2458,O
in,2458,O
heparin-anticoagulated,2458,O
plasma,2458,O
were,2458,O
recirculated,2458,O
with,2458,O
and,2458,O
without,2458,O
blocking,2458,O
antibodies,2458,O
to,2458,O
CD62P,2458,B-GENE-Y
",",2458,O
CD42b,2458,B-GENE-Y
",",2458,O
or,2458,O
junctional,2458,B-GENE-Y
adhesion,2458,I-GENE-Y
molecule,2458,I-GENE-Y
C,2458,I-GENE-Y
(,2458,O
JAM-C,2458,B-GENE-Y
),2458,O
in,2458,O
polyvinyl,2458,B-CHEMICAL
chloride,2458,I-CHEMICAL
tubing,2458,O
using,2458,O
a,2458,O
roller,2458,O
pump,2458,O
.,2458,O
Platelet,2459,O
adhesion,2459,O
to,2459,O
the,2459,O
tubing,2459,O
was,2459,O
inhibited,2459,O
by,2459,O
anti-CD42b,2459,O
and,2459,O
anti-CD62P,2459,O
",",2459,O
and,2459,O
adhesion,2459,O
of,2459,O
neutrophils,2459,O
by,2459,O
anti-JAM-C,2459,O
.,2459,O
Formation,2460,O
of,2460,O
platelet-neutrophil,2460,O
and,2460,O
platelet,2460,O
aggregates,2460,O
was,2460,O
reduced,2460,O
by,2460,O
anti-CD62P,2460,O
.,2460,O
Anti-JAM-C,2461,O
decreased,2461,O
platelet-neutrophil,2461,O
aggregation,2461,O
at,2461,O
low,2461,O
concentrations,2461,O
and,2461,O
platelet,2461,O
macroaggregates,2461,O
at,2461,O
high,2461,O
concentrations,2461,O
.,2461,O
Anti-CD62P,2462,O
increased,2462,O
neutrophil,2462,O
CD11b,2462,B-GENE-Y
expression,2462,O
but,2462,O
not,2462,O
degranulation,2462,O
.,2462,O
Anti-JAM-C,2463,O
substantially,2463,O
increased,2463,O
neutrophil,2463,O
degranulation,2463,O
and,2463,O
slightly,2463,O
increased,2463,O
CD11b,2463,B-GENE-Y
expression,2463,O
.,2463,O
Platelet,2464,O
activation,2464,O
increased,2464,O
when,2464,O
CD62P,2464,B-GENE-Y
was,2464,O
blocked,2464,O
and,2464,O
decreased,2464,O
with,2464,O
anti-CD42b,2464,O
antibody,2464,O
.,2464,O
High-dose,2465,O
anti-JAM-C,2465,O
reduced,2465,O
platelet,2465,O
activation,2465,O
.,2465,O
In,2466,O
conclusion,2466,O
",",2466,O
inhibiting,2466,O
platelet,2466,O
and,2466,O
neutrophil-platelet,2466,O
interactions,2466,O
had,2466,O
useful,2466,O
effects,2466,O
but,2466,O
no,2466,O
single,2466,O
blocking,2466,O
antibody,2466,O
seemed,2466,O
capable,2466,O
of,2466,O
inducing,2466,O
only,2466,O
beneficial,2466,O
effects,2466,O
.,2466,O
A,2467,O
comparison,2467,O
of,2467,O
the,2467,O
effects,2467,O
of,2467,O
nabumetone,2467,B-CHEMICAL
vs,2467,O
meloxicam,2467,B-CHEMICAL
on,2467,O
serum,2467,O
thromboxane,2467,B-CHEMICAL
B2,2467,I-CHEMICAL
and,2467,O
platelet,2467,O
function,2467,O
in,2467,O
healthy,2467,O
volunteers,2467,O
.,2467,O
AIMS,2468,O
:,2468,O
To,2468,O
compare,2468,O
the,2468,O
effects,2468,O
of,2468,O
nabumetone,2468,B-CHEMICAL
and,2468,O
meloxicam,2468,B-CHEMICAL
",",2468,O
two,2468,O
cyclo-oxygenase-2,2468,B-GENE-Y
(,2468,O
COX-2,2468,B-GENE-Y
),2468,O
preferential,2468,O
nonsteroidal,2468,O
anti-inflammatory,2468,O
drugs,2468,O
(,2468,O
NSAIDs,2468,O
),2468,O
",",2468,O
on,2468,O
platelet,2468,O
COX-1,2468,B-GENE-Y
activity,2468,O
and,2468,O
platelet,2468,O
function,2468,O
.,2468,O
METHODS,2469,O
:,2469,O
Twelve,2469,O
healthy,2469,O
volunteers,2469,O
(,2469,O
3,2469,O
male,2469,O
",",2469,O
9,2469,O
female,2469,O
",",2469,O
median,2469,O
age,2469,O
22,2469,O
years,2469,O
),2469,O
participated,2469,O
in,2469,O
an,2469,O
open,2469,O
",",2469,O
randomized,2469,O
",",2469,O
cross-over,2469,O
trial,2469,O
of,2469,O
nabumetone,2469,B-CHEMICAL
1000,2469,O
mg,2469,O
twice,2469,O
daily,2469,O
vs,2469,O
meloxicam,2469,B-CHEMICAL
7.5,2469,O
mg,2469,O
twice,2469,O
daily,2469,O
during,2469,O
1,2469,O
week,2469,O
with,2469,O
2,2469,O
weeks,2469,O
wash-out,2469,O
.,2469,O
After,2470,O
a,2470,O
second,2470,O
2,2470,O
week,2470,O
wash-out,2470,O
period,2470,O
",",2470,O
one,2470,O
dose,2470,O
of,2470,O
indomethacin,2470,B-CHEMICAL
50,2470,O
mg,2470,O
was,2470,O
given,2470,O
as,2470,O
a,2470,O
positive,2470,O
control,2470,O
to,2470,O
check,2470,O
for,2470,O
NSAID,2470,O
induced,2470,O
inhibition,2470,O
of,2470,O
platelet,2470,O
function,2470,O
.,2470,O
COX-1,2471,B-GENE-Y
inhibition,2471,O
was,2471,O
measured,2471,O
as,2471,O
percentage,2471,O
inhibition,2471,O
of,2471,O
serum,2471,O
TXB2,2471,B-CHEMICAL
generation,2471,O
in,2471,O
clotting,2471,O
whole,2471,O
blood,2471,O
",",2471,O
and,2471,O
as,2471,O
closure,2471,O
time,2471,O
with,2471,O
use,2471,O
of,2471,O
the,2471,O
platelet,2471,O
function,2471,O
analyser,2471,O
PFA-100,2471,O
.,2471,O
Data,2472,O
are,2472,O
reported,2472,O
as,2472,O
median,2472,O
with,2472,O
range,2472,O
.,2472,O
Paired,2473,O
variables,2473,O
were,2473,O
analysed,2473,O
using,2473,O
Wilcoxons,2473,O
signed,2473,O
rank,2473,O
test,2473,O
.,2473,O
RESULTS,2474,O
:,2474,O
TXB2,2474,B-CHEMICAL
levels,2474,O
decreased,2474,O
significantly,2474,O
after,2474,O
all,2474,O
three,2474,O
medications,2474,O
",",2474,O
but,2474,O
percentage,2474,O
inhibition,2474,O
after,2474,O
nabumetone,2474,B-CHEMICAL
and,2474,O
indomethacin,2474,B-CHEMICAL
(,2474,O
88,2474,O
%,2474,O
and,2474,O
97,2474,O
%,2474,O
",",2474,O
respectively,2474,O
),2474,O
was,2474,O
significantly,2474,O
higher,2474,O
than,2474,O
after,2474,O
meloxicam,2474,B-CHEMICAL
(,2474,O
63,2474,O
%,2474,O
),2474,O
(,2474,O
P,2474,O
<,2474,O
0.05,2474,O
),2474,O
.,2474,O
Closure,2475,O
times,2475,O
increased,2475,O
significantly,2475,O
after,2475,O
administration,2475,O
of,2475,O
all,2475,O
three,2475,O
medications,2475,O
(,2475,O
P,2475,O
<,2475,O
0.05,2475,O
),2475,O
.,2475,O
Increases,2476,O
in,2476,O
closure,2476,O
time,2476,O
after,2476,O
administration,2476,O
did,2476,O
not,2476,O
differ,2476,O
between,2476,O
nabumetone,2476,B-CHEMICAL
and,2476,O
meloxicam,2476,B-CHEMICAL
(,2476,O
24,2476,O
%,2476,O
and,2476,O
14,2476,O
%,2476,O
",",2476,O
respectively,2476,O
),2476,O
",",2476,O
but,2476,O
were,2476,O
significantly,2476,O
larger,2476,O
after,2476,O
indomethacin,2476,B-CHEMICAL
administration,2476,O
(,2476,O
63,2476,O
%,2476,O
),2476,O
(,2476,O
P,2476,O
<,2476,O
0.01,2476,O
),2476,O
.,2476,O
CONCLUSIONS,2477,O
:,2477,O
In,2477,O
the,2477,O
maximum,2477,O
registered,2477,O
dosage,2477,O
",",2477,O
nabumetone,2477,B-CHEMICAL
inhibits,2477,O
thromboxane,2477,B-CHEMICAL
production,2477,O
much,2477,O
more,2477,O
than,2477,O
meloxicam,2477,O
",",2477,O
signifying,2477,O
less,2477,O
COX-2,2477,B-GENE-Y
selectivity,2477,O
of,2477,O
the,2477,O
former,2477,O
.,2477,O
However,2478,O
",",2478,O
both,2478,O
nabumetone,2478,B-CHEMICAL
and,2478,O
meloxicam,2478,B-CHEMICAL
cause,2478,O
only,2478,O
minor,2478,O
impairment,2478,O
in,2478,O
platelet,2478,O
function,2478,O
in,2478,O
comparison,2478,O
with,2478,O
indomethacin,2478,B-CHEMICAL
and,2478,O
the,2478,O
difference,2478,O
between,2478,O
them,2478,O
is,2478,O
not,2478,O
significant,2478,O
.,2478,O
Diclofenac,2479,B-CHEMICAL
inhibits,2479,O
proliferation,2479,O
and,2479,O
differentiation,2479,O
of,2479,O
neural,2479,O
stem,2479,O
cells,2479,O
.,2479,O
Nonsteroidal,2480,O
anti-inflammatory,2480,O
drugs,2480,O
(,2480,O
NSAIDs,2480,O
),2480,O
are,2480,O
widely,2480,O
used,2480,O
in,2480,O
clinical,2480,O
situations,2480,O
as,2480,O
anti-inflammatory,2480,O
",",2480,O
analgesic,2480,O
and,2480,O
antipyretic,2480,O
drugs,2480,O
.,2480,O
However,2481,O
",",2481,O
it,2481,O
is,2481,O
still,2481,O
unknown,2481,O
whether,2481,O
NSAIDs,2481,O
have,2481,O
effects,2481,O
on,2481,O
the,2481,O
development,2481,O
of,2481,O
the,2481,O
central,2481,O
nervous,2481,O
system,2481,O
.,2481,O
In,2482,O
the,2482,O
present,2482,O
study,2482,O
",",2482,O
we,2482,O
investigated,2482,O
the,2482,O
effects,2482,O
of,2482,O
NSAIDs,2482,O
on,2482,O
neural,2482,O
stem,2482,O
cell,2482,O
(,2482,O
NSC,2482,O
),2482,O
proliferation,2482,O
and,2482,O
differentiation,2482,O
into,2482,O
neurons,2482,O
.,2482,O
In,2483,O
contrast,2483,O
to,2483,O
aspirin,2483,B-CHEMICAL
",",2483,O
naproxen,2483,B-CHEMICAL
",",2483,O
indomethacin,2483,B-CHEMICAL
and,2483,O
ibuprofen,2483,B-CHEMICAL
",",2483,O
treatment,2483,O
with,2483,O
diclofenac,2483,B-CHEMICAL
(,2483,O
10,2483,O
microM,2483,O
),2483,O
for,2483,O
2,2483,O
days,2483,O
induced,2483,O
the,2483,O
death,2483,O
of,2483,O
NSCs,2483,O
in,2483,O
a,2483,O
concentration-dependent,2483,O
manner,2483,O
.,2483,O
Diclofenac,2484,B-CHEMICAL
also,2484,O
inhibited,2484,O
the,2484,O
proliferation,2484,O
of,2484,O
NSCs,2484,O
and,2484,O
their,2484,O
differentiation,2484,O
into,2484,O
neurons,2484,O
.,2484,O
Treatment,2485,O
with,2485,O
diclofenac,2485,B-CHEMICAL
resulted,2485,O
in,2485,O
nuclear,2485,O
condensation,2485,O
(,2485,O
a,2485,O
morphological,2485,O
change,2485,O
due,2485,O
to,2485,O
apoptosis,2485,O
of,2485,O
NSCs,2485,O
),2485,O
24hr,2485,O
after,2485,O
the,2485,O
treatment,2485,O
and,2485,O
activated,2485,O
caspase-3,2485,B-GENE-Y
after,2485,O
6,2485,O
hr,2485,O
",",2485,O
indicating,2485,O
that,2485,O
diclofenac,2485,B-CHEMICAL
may,2485,O
cause,2485,O
apoptosis,2485,O
of,2485,O
neuronal,2485,O
cells,2485,O
via,2485,O
activation,2485,O
of,2485,O
the,2485,O
caspase,2485,B-GENE-N
cascade,2485,O
.,2485,O
These,2486,O
results,2486,O
suggest,2486,O
that,2486,O
diclofenac,2486,B-CHEMICAL
may,2486,O
affect,2486,O
the,2486,O
development,2486,O
of,2486,O
the,2486,O
central,2486,O
nervous,2486,O
system,2486,O
.,2486,O
Correlation,2487,O
between,2487,O
activation,2487,O
of,2487,O
PPARγ,2487,B-GENE-Y
and,2487,O
resistin,2487,B-GENE-Y
downregulation,2487,O
in,2487,O
a,2487,O
mouse,2487,O
adipocyte,2487,O
cell,2487,O
line,2487,O
by,2487,O
a,2487,O
series,2487,O
of,2487,O
thiazolidinediones,2487,B-CHEMICAL
.,2487,O
The,2488,O
present,2488,O
study,2488,O
shows,2488,O
significant,2488,O
correlations,2488,O
between,2488,O
the,2488,O
EC50,2488,O
for,2488,O
PPARγ,2488,B-GENE-Y
activation,2488,O
in,2488,O
a,2488,O
reporter,2488,O
gene,2488,O
cell,2488,O
line,2488,O
and,2488,O
resistin,2488,B-GENE-Y
downregulation,2488,O
in,2488,O
mouse,2488,O
adipocytes,2488,O
",",2488,O
and,2488,O
between,2488,O
the,2488,O
IC50,2488,O
for,2488,O
resistin,2488,B-GENE-Y
downregulation,2488,O
and,2488,O
the,2488,O
already,2488,O
published,2488,O
minimum,2488,O
effective,2488,O
dose,2488,O
for,2488,O
antihyperglycemic,2488,O
activity,2488,O
in,2488,O
a,2488,O
mouse,2488,O
model,2488,O
.,2488,O
These,2489,O
correlations,2489,O
indicate,2489,O
that,2489,O
PPARγ,2489,B-GENE-Y
mediated,2489,O
downregulation,2489,O
of,2489,O
resistin,2489,O
might,2489,O
promote,2489,O
insulin,2489,B-GENE-N
sensitivity,2489,O
and,2489,O
that,2489,O
downregulation,2489,O
of,2489,O
resistin,2489,B-GENE-Y
in,2489,O
mouse,2489,O
adipocytes,2489,O
provides,2489,O
an,2489,O
adequate,2489,O
and,2489,O
possibly,2489,O
more,2489,O
direct,2489,O
bioassay,2489,O
for,2489,O
screening,2489,O
of,2489,O
newly,2489,O
developed,2489,O
antihyperglycemic,2489,O
compounds,2489,O
.,2489,O
Because,2490,O
of,2490,O
the,2490,O
higher,2490,O
throughput,2490,O
of,2490,O
the,2490,O
PPARγ,2490,B-GENE-Y
the,2490,O
resistin,2490,B-GENE-Y
downregulation,2490,O
assays,2490,O
seems,2490,O
most,2490,O
suitable,2490,O
to,2490,O
be,2490,O
used,2490,O
as,2490,O
a,2490,O
second,2490,O
tier,2490,O
in,2490,O
a,2490,O
tiered,2490,O
screening,2490,O
strategy,2490,O
.,2490,O
Identification,2491,O
of,2491,O
aldo-keto,2491,B-GENE-N
reductases,2491,I-GENE-N
as,2491,O
NRF2-target,2491,B-GENE-Y
marker,2491,O
genes,2491,O
in,2491,O
human,2491,O
cells,2491,O
.,2491,O
Transcription,2492,O
factor,2492,O
NF-E2-related,2492,B-GENE-Y
factor,2492,I-GENE-Y
2,2492,I-GENE-Y
(,2492,O
NRF2,2492,B-GENE-Y
),2492,O
plays,2492,O
a,2492,O
crucial,2492,O
role,2492,O
in,2492,O
the,2492,O
cellular,2492,O
defense,2492,O
against,2492,O
oxidative/electrophilic,2492,O
stress,2492,O
by,2492,O
up-regulating,2492,O
multiple,2492,O
antioxidant,2492,O
genes,2492,O
.,2492,O
Numerous,2493,O
studies,2493,O
with,2493,O
genetically,2493,O
modified,2493,O
animals,2493,O
have,2493,O
demonstrated,2493,O
that,2493,O
Nrf2,2493,B-GENE-Y
is,2493,O
a,2493,O
sensitivity,2493,O
determining,2493,O
factor,2493,O
upon,2493,O
the,2493,O
exposure,2493,O
to,2493,O
environmental,2493,O
chemicals,2493,O
including,2493,O
carcinogens,2493,O
.,2493,O
Moreover,2494,O
",",2494,O
recent,2494,O
studies,2494,O
have,2494,O
demonstrated,2494,O
that,2494,O
polymorphism,2494,O
in,2494,O
the,2494,O
human,2494,B-GENE-N
NRF2,2494,I-GENE-N
promoter,2494,I-GENE-N
is,2494,O
associated,2494,O
with,2494,O
higher,2494,O
risks,2494,O
for,2494,O
developing,2494,O
acute,2494,O
lung,2494,O
injury,2494,O
",",2494,O
gastric,2494,O
mucosal,2494,O
inflammation,2494,O
",",2494,O
and,2494,O
nephritis,2494,O
.,2494,O
Therefore,2495,O
",",2495,O
the,2495,O
identification,2495,O
of,2495,O
reliable,2495,O
and,2495,O
effective,2495,O
human,2495,O
target,2495,O
genes,2495,O
of,2495,O
NRF2,2495,B-GENE-Y
may,2495,O
allow,2495,O
the,2495,O
monitoring,2495,O
of,2495,O
NRF2,2495,B-GENE-Y
activity,2495,O
and,2495,O
to,2495,O
predict,2495,O
individual,2495,O
sensitivity,2495,O
to,2495,O
environmental,2495,O
stress-induced,2495,O
damage,2495,O
.,2495,O
For,2496,O
this,2496,O
purpose,2496,O
",",2496,O
we,2496,O
investigated,2496,O
genes,2496,O
that,2496,O
are,2496,O
tightly,2496,O
controlled,2496,O
by,2496,O
NRF2,2496,B-GENE-Y
to,2496,O
establish,2496,O
markers,2496,O
for,2496,O
NRF2,2496,B-GENE-Y
activity,2496,O
in,2496,O
human,2496,O
cells,2496,O
.,2496,O
Firstly,2497,O
",",2497,O
in,2497,O
the,2497,O
normal,2497,O
human,2497,O
renal,2497,O
epithelial,2497,O
HK-2,2497,O
cells,2497,O
",",2497,O
the,2497,O
measurement,2497,O
of,2497,O
the,2497,O
expression,2497,O
of,2497,O
30,2497,O
previously,2497,O
reported,2497,O
NRF2,2497,B-GENE-Y
target,2497,O
genes,2497,O
in,2497,O
response,2497,O
to,2497,O
NRF2,2497,B-GENE-Y
inducers,2497,O
(,2497,O
sulforaphane,2497,B-CHEMICAL
",",2497,O
tert-butylhydroquinone,2497,B-CHEMICAL
",",2497,O
cinnamic,2497,B-CHEMICAL
aldehyde,2497,I-CHEMICAL
",",2497,O
and,2497,O
hydrogen,2497,B-CHEMICAL
peroxide,2497,I-CHEMICAL
),2497,O
showed,2497,O
that,2497,O
the,2497,O
aldo-keto,2497,B-GENE-Y
reductase,2497,I-GENE-Y
(,2497,I-GENE-Y
AKR,2497,I-GENE-Y
),2497,I-GENE-Y
1C1,2497,I-GENE-Y
is,2497,O
highly,2497,O
inducible,2497,O
by,2497,O
all,2497,O
treatments,2497,O
.,2497,O
Accordantly,2498,O
",",2498,O
the,2498,O
basal,2498,O
and,2498,O
inducible,2498,O
expressions,2498,O
of,2498,O
AKRs,2498,B-GENE-N
were,2498,O
significantly,2498,O
attenuated,2498,O
in,2498,O
NRF2-silenced,2498,B-GENE-Y
HK-2,2498,O
cells,2498,O
.,2498,O
Whereas,2499,O
",",2499,O
cells,2499,O
with,2499,O
stable,2499,O
KEAP1,2499,B-GENE-Y
knockdown,2499,O
",",2499,O
which,2499,O
causes,2499,O
a,2499,O
modest,2499,O
NRF2,2499,B-GENE-Y
activation,2499,O
",",2499,O
demonstrated,2499,O
substantially,2499,O
increased,2499,O
levels,2499,O
of,2499,O
AKR1A1,2499,B-GENE-N
",",2499,I-GENE-N
1B1,2499,I-GENE-N
",",2499,I-GENE-N
1B10,2499,I-GENE-N
",",2499,I-GENE-N
1C1,2499,I-GENE-N
",",2499,I-GENE-N
1C2,2499,I-GENE-N
",",2499,I-GENE-N
and,2499,I-GENE-N
1C3,2499,I-GENE-N
.,2499,O
Secondly,2500,O
",",2500,O
the,2500,O
linkage,2500,O
between,2500,O
NRF2,2500,B-GENE-Y
and,2500,O
the,2500,O
AKRs,2500,B-GENE-N
was,2500,O
confirmed,2500,O
in,2500,O
human,2500,O
monocytic,2500,O
leukemia,2500,O
cell,2500,O
line,2500,O
U937,2500,O
",",2500,O
which,2500,O
can,2500,O
be,2500,O
a,2500,O
model,2500,O
of,2500,O
peripherally,2500,O
available,2500,O
blood,2500,O
cells,2500,O
.,2500,O
The,2501,O
treatment,2501,O
of,2501,O
U937,2501,O
cells,2501,O
with,2501,O
NRF2,2501,B-GENE-Y
inducers,2501,O
including,2501,O
sulforaphane,2501,B-CHEMICAL
effectively,2501,O
elevated,2501,O
the,2501,O
expression,2501,O
of,2501,O
AKR1B1,2501,B-GENE-N
",",2501,I-GENE-N
1B10,2501,I-GENE-N
",",2501,I-GENE-N
1C1,2501,I-GENE-N
",",2501,I-GENE-N
1C2,2501,I-GENE-N
",",2501,I-GENE-N
and,2501,I-GENE-N
1C3,2501,I-GENE-N
.,2501,O
Whereas,2502,O
",",2502,O
the,2502,O
levels,2502,O
of,2502,O
both,2502,O
the,2502,O
basal,2502,O
and,2502,O
sulforaphane-inducible,2502,B-CHEMICAL
expression,2502,O
of,2502,O
AKR1C1,2502,B-GENE-Y
were,2502,O
significantly,2502,O
reduced,2502,O
in,2502,O
NRF2-silenced,2502,B-GENE-Y
stable,2502,O
U937,2502,O
cells,2502,O
compared,2502,O
to,2502,O
the,2502,O
control,2502,O
cells,2502,O
.,2502,O
Similarly,2503,O
",",2503,O
the,2503,O
inducible,2503,O
expression,2503,O
of,2503,O
AKR1C1,2503,B-GENE-Y
was,2503,O
observed,2503,O
in,2503,O
another,2503,O
human,2503,O
monocytic,2503,O
leukemia,2503,O
cell,2503,O
line,2503,O
THP-1,2503,O
as,2503,O
well,2503,O
as,2503,O
in,2503,O
human,2503,O
primary,2503,O
blood,2503,O
CD14,2503,O
(,2503,O
+,2503,O
),2503,O
monocytes,2503,O
.,2503,O
In,2504,O
conclusion,2504,O
",",2504,O
together,2504,O
with,2504,O
the,2504,O
high,2504,O
inducibility,2504,O
and,2504,O
NRF2,2504,B-GENE-Y
dependency,2504,O
shown,2504,O
in,2504,O
renal,2504,O
epithelial,2504,O
cells,2504,O
as,2504,O
well,2504,O
as,2504,O
in,2504,O
peripherally,2504,O
available,2504,O
blood,2504,O
cells,2504,O
",",2504,O
current,2504,O
findings,2504,O
suggest,2504,O
that,2504,O
AKRs,2504,B-GENE-N
can,2504,O
be,2504,O
utilized,2504,O
as,2504,O
a,2504,O
marker,2504,O
of,2504,O
NRF2,2504,B-GENE-Y
activity,2504,O
in,2504,O
human,2504,O
cells,2504,O
.,2504,O
Cellular,2505,O
mechanisms,2505,O
of,2505,O
insulin,2505,B-GENE-Y
resistance,2505,O
:,2505,O
role,2505,O
of,2505,O
stress-regulated,2505,B-GENE-N
serine,2505,I-GENE-N
kinases,2505,I-GENE-N
and,2505,O
insulin,2505,B-GENE-N
receptor,2505,I-GENE-N
substrates,2505,I-GENE-N
(,2505,O
IRS,2505,B-GENE-N
),2505,O
serine,2505,B-CHEMICAL
phosphorylation,2505,O
.,2505,O
Insulin,2506,B-GENE-N
receptor,2506,I-GENE-N
substrates,2506,I-GENE-N
(,2506,O
IRS,2506,B-GENE-N
),2506,O
serine,2506,B-CHEMICAL
phosphorylation,2506,O
is,2506,O
a,2506,O
time-controlled,2506,O
physiological,2506,O
feedback,2506,O
mechanism,2506,O
in,2506,O
insulin,2506,B-GENE-Y
signaling,2506,O
that,2506,O
is,2506,O
hijacked,2506,O
by,2506,O
metabolic,2506,O
and,2506,O
inflammatory,2506,O
stresses,2506,O
to,2506,O
promote,2506,O
insulin,2506,B-GENE-Y
resistance,2506,O
.,2506,O
Kinases,2507,B-GENE-N
",",2507,O
including,2507,O
IKKbeta,2507,B-GENE-Y
",",2507,O
JNK,2507,B-GENE-N
",",2507,O
ERK,2507,B-GENE-N
",",2507,O
mTOR,2507,B-GENE-Y
",",2507,O
and,2507,O
S6K,2507,B-GENE-N
",",2507,O
activated,2507,O
by,2507,O
the,2507,O
inducers,2507,O
of,2507,O
insulin,2507,B-GENE-Y
resistance,2507,O
induce,2507,O
uncontrolled,2507,O
IRS,2507,B-GENE-N
serine,2507,B-CHEMICAL
phosphorylation,2507,O
.,2507,O
Studies,2508,O
with,2508,O
genetically,2508,O
modified,2508,O
mice,2508,O
reveal,2508,O
that,2508,O
these,2508,O
kinases,2508,B-GENE-N
integrate,2508,O
signals,2508,O
from,2508,O
metabolic,2508,O
and,2508,O
inflammatory,2508,O
stresses,2508,O
in,2508,O
adipose,2508,O
tissue,2508,O
",",2508,O
liver,2508,O
",",2508,O
and,2508,O
hypothalamus,2508,O
leading,2508,O
to,2508,O
peripheral,2508,O
and,2508,O
central,2508,O
insulin,2508,B-GENE-N
resistance,2508,O
.,2508,O
Moreover,2509,O
",",2509,O
IKKbeta/NF-kappaB,2509,B-GENE-Y
and,2509,O
JNK1,2509,B-GENE-Y
pathways,2509,O
in,2509,O
myeloid,2509,O
cells,2509,O
represent,2509,O
a,2509,O
core,2509,O
mechanism,2509,O
involved,2509,O
in,2509,O
inflammation,2509,O
linked,2509,O
to,2509,O
obesity,2509,O
.,2509,O
These,2510,O
kinases,2510,B-GENE-N
are,2510,O
thus,2510,O
potential,2510,O
drug,2510,O
targets,2510,O
against,2510,O
insulin,2510,B-GENE-N
resistance,2510,O
and,2510,O
the,2510,O
targeting,2510,O
of,2510,O
the,2510,O
IKKbeta/NF-kappaB,2510,B-GENE-Y
or,2510,O
the,2510,O
JNK,2510,B-GENE-N
pathway,2510,O
may,2510,O
evolve,2510,O
into,2510,O
future,2510,O
diabetes,2510,O
medication,2510,O
.,2510,O
Angiotensin-converting,2511,B-GENE-Y
enzyme,2511,I-GENE-Y
inhibition,2511,O
and,2511,O
AT1,2511,B-GENE-N
receptor,2511,O
blockade,2511,O
modify,2511,O
the,2511,O
pressure-natriuresis,2511,O
relationship,2511,O
by,2511,O
additive,2511,O
mechanisms,2511,O
in,2511,O
rats,2511,O
with,2511,O
human,2511,B-GENE-Y
renin,2511,I-GENE-Y
and,2511,O
angiotensinogen,2511,B-GENE-Y
genes,2511,O
.,2511,O
The,2512,O
intrarenal,2512,O
factors,2512,O
responsible,2512,O
for,2512,O
hypertension,2512,O
in,2512,O
double-transgenic,2512,O
rats,2512,O
(,2512,O
dTGR,2512,O
),2512,O
harboring,2512,O
human,2512,B-GENE-Y
renin,2512,I-GENE-Y
and,2512,O
human,2512,B-GENE-Y
angiotensinogen,2512,I-GENE-Y
genes,2512,O
are,2512,O
unclear,2512,O
.,2512,O
The,2513,O
pressure-natriuresis,2513,O
and,2513,O
-diuresis,2513,O
relationships,2513,O
in,2513,O
response,2513,O
to,2513,O
chronic,2513,O
angiotensin-converting,2513,B-GENE-Y
enzyme,2513,I-GENE-Y
(,2513,O
ACE,2513,B-GENE-Y
),2513,O
inhibition,2513,O
and,2513,O
AT1,2513,B-GENE-N
receptor,2513,O
blockade,2513,O
were,2513,O
evaluated,2513,O
.,2513,O
Renal,2514,B-GENE-Y
renin-angiotensin,2514,O
and,2514,O
nitric,2514,B-CHEMICAL
oxide,2514,I-CHEMICAL
(,2514,O
NO,2514,B-CHEMICAL
),2514,O
system,2514,O
gene,2514,O
expression,2514,O
was,2514,O
also,2514,O
investigated,2514,O
.,2514,O
Six-week-old,2515,O
dTGR,2515,O
were,2515,O
treated,2515,O
for,2515,O
3,2515,O
wk,2515,O
with,2515,O
submaximal,2515,O
doses,2515,O
of,2515,O
cilazapril,2515,B-CHEMICAL
(,2515,O
10,2515,O
mg/kg,2515,O
",",2515,O
orally,2515,O
),2515,O
or,2515,O
losartan,2515,B-CHEMICAL
(,2515,O
10,2515,O
mg/kg,2515,O
",",2515,O
orally,2515,O
),2515,O
or,2515,O
with,2515,O
the,2515,O
drug,2515,O
combination,2515,O
.,2515,O
In,2516,O
untreated,2516,O
dTGR,2516,O
",",2516,O
pressure-natriuresis,2516,O
relationships,2516,O
were,2516,O
maximally,2516,O
shifted,2516,O
rightward,2516,O
by,2516,O
approximately,2516,O
70,2516,O
to,2516,O
80,2516,O
mmHg,2516,O
",",2516,O
and,2516,O
both,2516,O
renal,2516,O
blood,2516,O
flow,2516,O
(,2516,O
RBF,2516,O
),2516,O
and,2516,O
GFR,2516,O
were,2516,O
markedly,2516,O
decreased,2516,O
.,2516,O
Submaximal,2517,O
cilazapril,2517,B-CHEMICAL
and,2517,O
losartan,2517,B-CHEMICAL
dosages,2517,O
both,2517,O
decreased,2517,O
systolic,2517,O
BP,2517,O
by,2517,O
30,2517,O
mmHg,2517,O
and,2517,O
shifted,2517,O
the,2517,O
pressure-natriuresis,2517,O
curves,2517,O
leftward,2517,O
by,2517,O
25,2517,O
to,2517,O
30,2517,O
mmHg,2517,O
.,2517,O
Cilazapril,2518,B-CHEMICAL
increased,2518,O
RBF,2518,O
and,2518,O
GFR,2518,O
to,2518,O
values,2518,O
observed,2518,O
in,2518,O
normotensive,2518,O
control,2518,O
animals,2518,O
but,2518,O
did,2518,O
not,2518,O
significantly,2518,O
affect,2518,O
fractional,2518,O
sodium,2518,B-CHEMICAL
excretion,2518,O
(,2518,O
FENa,2518,O
),2518,O
or,2518,O
fractional,2518,O
water,2518,O
excretion,2518,O
(,2518,O
FEH2O,2518,O
),2518,O
curves,2518,O
.,2518,O
In,2519,O
contrast,2519,O
",",2519,O
losartan,2519,B-CHEMICAL
had,2519,O
no,2519,O
significant,2519,O
effect,2519,O
on,2519,O
RBF,2519,O
or,2519,O
GFR,2519,O
but,2519,O
shifted,2519,O
the,2519,O
FENa,2519,O
and,2519,O
FEH2O,2519,O
curves,2519,O
leftward,2519,O
.,2519,O
The,2520,O
cilazapril,2520,B-CHEMICAL
and,2520,O
losartan,2520,B-CHEMICAL
combination,2520,O
completely,2520,O
normalized,2520,O
BP,2520,O
and,2520,O
shifted,2520,O
the,2520,O
pressure-natriuresis,2520,O
curves,2520,O
leftward,2520,O
more,2520,O
than,2520,O
did,2520,O
either,2520,O
drug,2520,O
alone,2520,O
.,2520,O
When,2521,O
cilazapril,2521,B-CHEMICAL
and,2521,O
losartan,2521,B-CHEMICAL
were,2521,O
administered,2521,O
at,2521,O
higher,2521,O
doses,2521,O
(,2521,O
30,2521,O
mg/kg,2521,O
",",2521,O
orally,2521,O
),2521,O
",",2521,O
the,2521,O
two,2521,O
drugs,2521,O
equally,2521,O
shifted,2521,O
the,2521,O
pressure-natriuresis,2521,O
curves,2521,O
leftward,2521,O
",",2521,O
by,2521,O
50,2521,O
mmHg,2521,O
.,2521,O
Both,2522,O
drugs,2522,O
increased,2522,O
RBF,2522,O
and,2522,O
GFR,2522,O
;,2522,O
however,2522,O
",",2522,O
only,2522,O
losartan,2522,B-CHEMICAL
shifted,2522,O
FENa,2522,O
and,2522,O
FEH2O,2522,O
curves,2522,O
leftward,2522,O
.,2522,O
Human,2523,B-GENE-N
and,2523,I-GENE-N
rat,2523,I-GENE-N
renin,2523,I-GENE-N
and,2523,O
angiotensinogen,2523,B-GENE-N
genes,2523,O
were,2523,O
downregulated,2523,O
in,2523,O
dTGR,2523,O
and,2523,O
were,2523,O
increased,2523,O
by,2523,O
losartan,2523,B-CHEMICAL
and,2523,O
cilazapril,2523,B-CHEMICAL
treatments,2523,O
",",2523,O
whereas,2523,O
no,2523,O
changes,2523,O
in,2523,O
the,2523,O
expression,2523,O
of,2523,O
rat,2523,B-GENE-Y
ACE,2523,I-GENE-Y
and,2523,O
AT1A,2523,B-GENE-Y
receptor,2523,O
genes,2523,O
were,2523,O
observed,2523,O
.,2523,O
Endothelial,2524,B-GENE-Y
NO,2524,I-GENE-Y
synthase,2524,I-GENE-Y
expression,2524,O
was,2524,O
increased,2524,O
by,2524,O
cilazapril,2524,B-CHEMICAL
but,2524,O
not,2524,O
by,2524,O
losartan,2524,B-CHEMICAL
.,2524,O
Neither,2525,O
inducible,2525,B-GENE-Y
NO,2525,I-GENE-Y
synthase,2525,I-GENE-Y
nor,2525,O
neural,2525,B-GENE-Y
NO,2525,I-GENE-Y
synthase,2525,I-GENE-Y
gene,2525,O
expression,2525,O
was,2525,O
affected,2525,O
by,2525,O
drug,2525,O
treatments,2525,O
.,2525,O
Therefore,2526,O
",",2526,O
submaximal,2526,O
ACE,2526,B-GENE-Y
inhibition,2526,O
enhanced,2526,O
sodium,2526,B-CHEMICAL
excretion,2526,O
mainly,2526,O
by,2526,O
increasing,2526,O
RBF,2526,O
and,2526,O
GFR,2526,O
",",2526,O
whereas,2526,O
submaximal,2526,O
AT1,2526,B-GENE-N
receptor,2526,O
blockade,2526,O
decreased,2526,O
tubular,2526,O
sodium,2526,B-CHEMICAL
and,2526,O
water,2526,O
reabsorption,2526,O
.,2526,O
The,2527,O
combination,2527,O
of,2527,O
the,2527,O
two,2527,O
drugs,2527,O
produced,2527,O
an,2527,O
additive,2527,O
effect,2527,O
.,2527,O
The,2528,O
ACE,2528,B-GENE-Y
inhibitor,2528,O
effects,2528,O
may,2528,O
involve,2528,O
increased,2528,O
endothelial,2528,B-GENE-Y
NO,2528,I-GENE-Y
synthase,2528,I-GENE-Y
expression,2528,O
",",2528,O
perhaps,2528,O
related,2528,O
to,2528,O
the,2528,O
inhibition,2528,O
of,2528,O
bradykinin,2528,B-GENE-Y
degradation,2528,O
.,2528,O
A,2529,O
novel,2529,O
SCN5A,2529,B-GENE-Y
arrhythmia,2529,O
mutation,2529,O
",",2529,O
M1766L,2529,B-GENE-N
",",2529,O
with,2529,O
expression,2529,O
defect,2529,O
rescued,2529,O
by,2529,O
mexiletine,2529,B-CHEMICAL
.,2529,O
OBJECTIVE,2530,O
:,2530,O
Mutations,2530,O
in,2530,O
the,2530,O
cardiac,2530,O
sodium,2530,B-CHEMICAL
channel,2530,O
gene,2530,O
",",2530,O
SCN5A,2530,B-GENE-Y
",",2530,O
cause,2530,O
congenital,2530,O
long,2530,O
QT,2530,O
syndrome,2530,O
(,2530,O
LQT3,2530,O
),2530,O
",",2530,O
Brugada,2530,O
syndrome,2530,O
",",2530,O
idiopathic,2530,O
ventricular,2530,O
fibrillation,2530,O
",",2530,O
and,2530,O
conduction,2530,O
disease,2530,O
by,2530,O
distinct,2530,O
cellular,2530,O
and,2530,O
clinical,2530,O
electrophysiological,2530,O
phenotypes,2530,O
.,2530,O
METHODS,2531,O
:,2531,O
Postmortem,2531,O
molecular,2531,O
analysis,2531,O
of,2531,O
SCN5A,2531,B-GENE-Y
was,2531,O
conducted,2531,O
on,2531,O
an,2531,O
infant,2531,O
who,2531,O
presented,2531,O
shortly,2531,O
after,2531,O
birth,2531,O
with,2531,O
self-terminating,2531,O
torsades,2531,O
de,2531,O
pointes,2531,O
.,2531,O
The,2532,O
infant,2532,O
was,2532,O
treated,2532,O
with,2532,O
lidocaine,2532,B-CHEMICAL
",",2532,O
propranolol,2532,B-CHEMICAL
",",2532,O
and,2532,O
mexiletine,2532,B-CHEMICAL
and,2532,O
was,2532,O
stable,2532,O
for,2532,O
16,2532,O
months,2532,O
manifesting,2532,O
only,2532,O
a,2532,O
prolonged,2532,O
QT,2532,O
interval,2532,O
.,2532,O
The,2533,O
infant,2533,O
collapsed,2533,O
suddenly,2533,O
following,2533,O
presumed,2533,O
viral,2533,O
gastroenteritis,2533,O
",",2533,O
was,2533,O
found,2533,O
in,2533,O
2:1,2533,O
AV,2533,O
block,2533,O
",",2533,O
and,2533,O
was,2533,O
subsequently,2533,O
declared,2533,O
brain,2533,O
dead,2533,O
.,2533,O
Genomic,2534,O
DNA,2534,O
was,2534,O
subjected,2534,O
to,2534,O
SCN5A,2534,B-GENE-Y
mutational,2534,O
analyses,2534,O
and,2534,O
DNA,2534,O
sequencing,2534,O
revealing,2534,O
a,2534,O
novel,2534,O
",",2534,O
spontaneous,2534,O
germline,2534,O
missense,2534,O
mutation,2534,O
",",2534,O
M1766L,2534,B-GENE-N
.,2534,O
The,2535,O
M1766L,2535,B-GENE-N
mutation,2535,O
was,2535,O
engineered,2535,O
into,2535,O
the,2535,O
hH1a,2535,O
clone,2535,O
by,2535,O
site-directed,2535,O
mutagenesis,2535,O
",",2535,O
transfected,2535,O
into,2535,O
embryonic,2535,O
kidney,2535,O
cells,2535,O
(,2535,O
HEK-293,2535,O
),2535,O
",",2535,O
and,2535,O
studied,2535,O
by,2535,O
voltage,2535,O
clamp,2535,O
.,2535,O
RESULTS,2536,O
:,2536,O
The,2536,O
M1766L,2536,B-GENE-N
mutation,2536,O
caused,2536,O
a,2536,O
significant,2536,O
decrease,2536,O
in,2536,O
the,2536,O
sodium,2536,B-CHEMICAL
channel,2536,O
expression,2536,O
.,2536,O
Co-expression,2537,O
with,2537,O
beta1,2537,O
subunit,2537,O
",",2537,O
incubation,2537,O
at,2537,O
low,2537,O
temperature,2537,O
",",2537,O
and,2537,O
most,2537,O
effectively,2537,O
incubation,2537,O
with,2537,O
mexiletine,2537,B-CHEMICAL
partially,2537,O
'rescued,2537,O
',2537,O
the,2537,O
defective,2537,O
expression,2537,O
.,2537,O
In,2538,O
addition,2538,O
to,2538,O
this,2538,O
pronounced,2538,O
loss,2538,O
of,2538,O
function,2538,O
",",2538,O
M1766L,2538,B-GENE-N
also,2538,O
showed,2538,O
a,2538,O
10-fold,2538,O
increase,2538,O
in,2538,O
the,2538,O
persistent,2538,O
late,2538,O
sodium,2538,B-CHEMICAL
current,2538,O
.,2538,O
CONCLUSIONS,2539,O
:,2539,O
These,2539,O
findings,2539,O
suggest,2539,O
that,2539,O
M1766L-SCN5A,2539,B-GENE-N
channel,2539,O
dysfunction,2539,O
may,2539,O
contribute,2539,O
to,2539,O
the,2539,O
basis,2539,O
of,2539,O
lethal,2539,O
arrhythmias,2539,O
",",2539,O
displays,2539,O
an,2539,O
overlapping,2539,O
electrophysiological,2539,O
phenotype,2539,O
",",2539,O
and,2539,O
represents,2539,O
the,2539,O
first,2539,O
sodium,2539,B-CHEMICAL
channelopathy,2539,O
rescued,2539,O
by,2539,O
drug,2539,O
.,2539,O
Neuroprotective,2540,O
effects,2540,O
of,2540,O
oxymatrine,2540,B-CHEMICAL
against,2540,O
excitotoxicity,2540,O
partially,2540,O
through,2540,O
down-regulation,2540,O
of,2540,O
NR2B-containing,2540,B-GENE-Y
NMDA,2540,B-GENE-N
receptors,2540,I-GENE-N
.,2540,O
Oxymatrine,2541,B-CHEMICAL
(,2541,O
OMT,2541,B-CHEMICAL
),2541,O
is,2541,O
a,2541,O
major,2541,O
bioactive,2541,O
component,2541,O
derived,2541,O
from,2541,O
Sophora,2541,O
flavescens,2541,O
Ait,2541,O
(,2541,O
kushen,2541,O
),2541,O
",",2541,O
which,2541,O
is,2541,O
widely,2541,O
used,2541,O
in,2541,O
Chinese,2541,O
medicine,2541,O
.,2541,O
Recent,2542,O
studies,2542,O
have,2542,O
shown,2542,O
that,2542,O
it,2542,O
has,2542,O
neuroprotective,2542,O
effects,2542,O
;,2542,O
however,2542,O
",",2542,O
its,2542,O
underlying,2542,O
mechanisms,2542,O
remain,2542,O
unclear,2542,O
.,2542,O
We,2543,O
focus,2543,O
on,2543,O
the,2543,O
mechanisms,2543,O
of,2543,O
pharmacologic,2543,O
action,2543,O
in,2543,O
OMT,2543,B-CHEMICAL
by,2543,O
detecting,2543,O
its,2543,O
pharmacological,2543,O
properties,2543,O
against,2543,O
focal,2543,O
cerebral,2543,O
ischemia,2543,O
in,2543,O
vivo,2543,O
and,2543,O
NMDA-induced,2543,B-CHEMICAL
neurotoxicity,2543,O
in,2543,O
vitro,2543,O
.,2543,O
OMT,2544,B-CHEMICAL
prevented,2544,O
cerebral,2544,O
ischemic,2544,O
injury,2544,O
in,2544,O
mice,2544,O
induced,2544,O
via,2544,O
a,2544,O
2,2544,O
h,2544,O
middle,2544,O
cerebral,2544,O
artery,2544,O
occlusion,2544,O
and,2544,O
a,2544,O
24,2544,O
h,2544,O
reperfusion,2544,O
",",2544,O
in,2544,O
vivo,2544,O
.,2544,O
In,2545,O
vitro,2545,O
cultured,2545,O
neurons,2545,O
challenged,2545,O
with,2545,O
N-methyl-D-aspartate,2545,B-CHEMICAL
(,2545,O
NMDA,2545,B-CHEMICAL
",",2545,O
200,2545,O
μM,2545,O
),2545,O
for,2545,O
30,2545,O
min,2545,O
showed,2545,O
significant,2545,O
decrease,2545,O
in,2545,O
the,2545,O
viability,2545,O
of,2545,O
neurons,2545,O
;,2545,O
however,2545,O
",",2545,O
OMT,2545,B-CHEMICAL
was,2545,O
able,2545,O
to,2545,O
protect,2545,O
neurons,2545,O
against,2545,O
induced,2545,O
neurotoxicity,2545,O
via,2545,O
NMDA,2545,B-CHEMICAL
exposure,2545,O
.,2545,O
Western,2546,O
blot,2546,O
analysis,2546,O
revealed,2546,O
that,2546,O
OMT,2546,B-CHEMICAL
decreased,2546,O
the,2546,O
expression,2546,O
of,2546,O
Bax,2546,B-GENE-Y
and,2546,O
repaired,2546,O
the,2546,O
balance,2546,O
of,2546,O
pro-,2546,O
and,2546,O
anti-apoptotic,2546,O
proteins,2546,O
.,2546,O
Furthermore,2547,O
",",2547,O
OMT,2547,B-CHEMICAL
significantly,2547,O
reversed,2547,O
the,2547,O
up-regulation,2547,O
of,2547,O
NR2B,2547,B-GENE-Y
and,2547,O
inhibited,2547,O
the,2547,O
calcium,2547,B-CHEMICAL
overload,2547,O
in,2547,O
the,2547,O
cultured,2547,O
neurons,2547,O
after,2547,O
challenging,2547,O
the,2547,O
NMDA,2547,B-CHEMICAL
.,2547,O
OMT,2548,B-CHEMICAL
showed,2548,O
partial,2548,O
protection,2548,O
in,2548,O
the,2548,O
cortical,2548,O
neurons,2548,O
via,2548,O
down-regulation,2548,O
of,2548,O
NR2B,2548,B-GENE-Y
containing,2548,O
NMDA,2548,B-GENE-N
receptors,2548,I-GENE-N
and,2548,O
up-regulation,2548,O
of,2548,O
Bcl-2,2548,B-GENE-Y
family,2548,O
.,2548,O
Our,2549,O
results,2549,O
provide,2549,O
new,2549,O
insights,2549,O
into,2549,O
the,2549,O
development,2549,O
of,2549,O
natural,2549,O
therapeutic,2549,O
anti-oxidants,2549,O
against,2549,O
ischemia,2549,O
.,2549,O
Phenotypic,2550,O
analysis,2550,O
of,2550,O
ovine,2550,O
antigen,2550,O
presenting,2550,O
cells,2550,O
loaded,2550,O
with,2550,O
nanoparticles,2550,O
migrating,2550,O
from,2550,O
the,2550,O
site,2550,O
of,2550,O
vaccination,2550,O
.,2550,O
Virus-sized,2551,O
particulate,2551,O
adjuvants,2551,O
such,2551,O
as,2551,O
ISCOMs,2551,O
",",2551,O
polystyrene,2551,B-CHEMICAL
nanoparticles,2551,O
and,2551,O
virus-like,2551,O
particles,2551,O
have,2551,O
been,2551,O
shown,2551,O
to,2551,O
target,2551,O
dendritic,2551,O
cells,2551,O
",",2551,O
resulting,2551,O
in,2551,O
the,2551,O
activation,2551,O
of,2551,O
T,2551,O
and,2551,O
B,2551,O
cells,2551,O
in,2551,O
vivo,2551,O
.,2551,O
Using,2552,O
an,2552,O
ovine,2552,O
pseudo-afferent,2552,O
lymph,2552,O
cannulation,2552,O
model,2552,O
to,2552,O
capture,2552,O
APC,2552,O
that,2552,O
traffic,2552,O
from,2552,O
the,2552,O
site,2552,O
of,2552,O
injection,2552,O
to,2552,O
the,2552,O
local,2552,O
lymph,2552,O
node,2552,O
",",2552,O
we,2552,O
show,2552,O
that,2552,O
40-50nm,2552,O
nanoparticles,2552,O
are,2552,O
taken,2552,O
up,2552,O
at,2552,O
the,2552,O
site,2552,O
of,2552,O
injection,2552,O
by,2552,O
dendritic,2552,O
cells,2552,O
(,2552,O
DCs,2552,O
),2552,O
migrating,2552,O
to,2552,O
the,2552,O
draining,2552,O
lymph,2552,O
node,2552,O
.,2552,O
These,2553,O
DCs,2553,O
can,2553,O
express,2553,O
CD11c,2553,B-GENE-Y
",",2553,O
CD1b,2553,B-GENE-Y
",",2553,O
CD5,2553,B-GENE-Y
",",2553,O
MHC,2553,B-GENE-N
class,2553,I-GENE-N
II,2553,I-GENE-N
and,2553,O
CD8,2553,B-GENE-N
.,2553,O
Nanoparticles,2554,O
transported,2554,O
by,2554,O
DCs,2554,O
migrating,2554,O
from,2554,O
the,2554,O
site,2554,O
of,2554,O
injection,2554,O
to,2554,O
the,2554,O
local,2554,O
lymph,2554,O
node,2554,O
therefore,2554,O
needs,2554,O
to,2554,O
be,2554,O
considered,2554,O
as,2554,O
a,2554,O
new,2554,O
mechanism,2554,O
underlying,2554,O
the,2554,O
immunogenicity,2554,O
of,2554,O
virus-sized,2554,O
vaccine,2554,O
delivery,2554,O
systems,2554,O
.,2554,O
Emodin-6-O-β-D-glucoside,2555,B-CHEMICAL
inhibits,2555,O
HMGB1-induced,2555,B-GENE-Y
inflammatory,2555,O
responses,2555,O
in,2555,O
vitro,2555,O
and,2555,O
in,2555,O
vivo,2555,O
.,2555,O
High,2556,B-GENE-Y
mobility,2556,I-GENE-Y
group,2556,I-GENE-Y
box,2556,I-GENE-Y
1,2556,I-GENE-Y
(,2556,O
HMGB1,2556,B-GENE-Y
),2556,O
protein,2556,O
acts,2556,O
as,2556,O
a,2556,O
potent,2556,O
proinflammatory,2556,O
cytokine,2556,B-GENE-N
and,2556,O
is,2556,O
involved,2556,O
in,2556,O
the,2556,O
pathogenesis,2556,O
of,2556,O
several,2556,O
vascular,2556,O
diseases,2556,O
",",2556,O
such,2556,O
as,2556,O
",",2556,O
systemic,2556,O
vasculitis,2556,O
and,2556,O
sepsis,2556,O
.,2556,O
Emodin-6-O-β-D-glucoside,2557,B-CHEMICAL
(,2557,O
EG,2557,O
),2557,O
is,2557,O
a,2557,O
new,2557,O
active,2557,O
compound,2557,O
from,2557,O
Reynoutria,2557,O
japonica,2557,O
",",2557,O
and,2557,O
its,2557,O
biologic,2557,O
activities,2557,O
have,2557,O
not,2557,O
been,2557,O
previously,2557,O
investigated,2557,O
.,2557,O
In,2558,O
this,2558,O
study,2558,O
",",2558,O
we,2558,O
first,2558,O
investigated,2558,O
the,2558,O
antiinflammatory,2558,O
activities,2558,O
of,2558,O
EG,2558,O
on,2558,O
HMGB1-mediated,2558,B-GENE-Y
proinflammatory,2558,O
responses,2558,O
in,2558,O
human,2558,O
umbilical,2558,O
vein,2558,O
endothelial,2558,O
cells,2558,O
(,2558,O
HUVECs,2558,O
),2558,O
and,2558,O
in,2558,O
a,2558,O
murine,2558,O
cecal,2558,O
ligation,2558,O
and,2558,O
puncture,2558,O
(,2558,O
CLP,2558,O
),2558,O
-model,2558,O
of,2558,O
sepsis,2558,O
in,2558,O
mice,2558,O
.,2558,O
EG,2559,O
was,2559,O
found,2559,O
to,2559,O
suppress,2559,O
the,2559,O
release,2559,O
of,2559,O
HMGB1,2559,B-GENE-Y
",",2559,O
the,2559,O
production,2559,O
of,2559,O
tumor,2559,B-GENE-Y
necrosis,2559,I-GENE-Y
factor,2559,I-GENE-Y
(,2559,I-GENE-Y
TNF,2559,I-GENE-Y
),2559,I-GENE-Y
-α,2559,I-GENE-Y
",",2559,O
and,2559,O
the,2559,O
activation,2559,O
of,2559,O
nuclear,2559,B-GENE-N
factor-κB,2559,I-GENE-N
(,2559,O
NF-κB,2559,B-GENE-N
),2559,O
by,2559,O
HMGB1,2559,B-GENE-Y
in,2559,O
HUVECs,2559,O
",",2559,O
and,2559,O
to,2559,O
inhibit,2559,O
HMGB1-mediated,2559,B-GENE-Y
hyperpermeability,2559,O
and,2559,O
leukocyte,2559,O
migration,2559,O
in,2559,O
mice,2559,O
.,2559,O
In,2560,O
the,2560,O
CLP,2560,O
model,2560,O
",",2560,O
HMGB1,2560,B-GENE-Y
was,2560,O
highly,2560,O
released,2560,O
",",2560,O
but,2560,O
this,2560,O
release,2560,O
was,2560,O
prevented,2560,O
by,2560,O
EG,2560,O
.,2560,O
Furthermore,2561,O
",",2561,O
EG,2561,O
also,2561,O
increased,2561,O
the,2561,O
survival,2561,O
times,2561,O
of,2561,O
CLP,2561,O
administered,2561,O
mice,2561,O
.,2561,O
Collectively,2562,O
",",2562,O
this,2562,O
study,2562,O
shows,2562,O
EG,2562,O
can,2562,O
protect,2562,O
barrier,2562,O
integrity,2562,O
and,2562,O
inhibit,2562,O
HMGB1-mediated,2562,B-GENE-Y
inflammatory,2562,O
responses,2562,O
",",2562,O
which,2562,O
suggests,2562,O
a,2562,O
potential,2562,O
use,2562,O
as,2562,O
a,2562,O
therapy,2562,O
for,2562,O
sepsis,2562,O
or,2562,O
septic,2562,O
shock,2562,O
.,2562,O
Copy,2563,O
number,2563,O
variations,2563,O
of,2563,O
the,2563,O
human,2563,B-GENE-Y
histamine,2563,I-GENE-Y
H4,2563,I-GENE-Y
receptor,2563,I-GENE-Y
gene,2563,O
are,2563,O
associated,2563,O
with,2563,O
systemic,2563,O
lupus,2563,O
erythematosus,2563,O
.,2563,O
BACKGROUND,2564,O
:,2564,O
Systemic,2564,O
lupus,2564,O
erythematosus,2564,O
(,2564,O
SLE,2564,O
),2564,O
is,2564,O
a,2564,O
complex,2564,O
genetic,2564,O
disease,2564,O
;,2564,O
the,2564,O
histamine,2564,B-GENE-Y
H4,2564,I-GENE-Y
receptor,2564,I-GENE-Y
(,2564,O
HRH4,2564,B-GENE-Y
),2564,O
has,2564,O
been,2564,O
shown,2564,O
to,2564,O
be,2564,O
related,2564,O
to,2564,O
different,2564,O
kinds,2564,O
of,2564,O
autoimmune,2564,O
disorders,2564,O
;,2564,O
and,2564,O
copy,2564,O
number,2564,O
variations,2564,O
(,2564,O
CNVs,2564,O
),2564,O
have,2564,O
been,2564,O
found,2564,O
to,2564,O
be,2564,O
associated,2564,O
with,2564,O
various,2564,O
types,2564,O
of,2564,O
diseases,2564,O
.,2564,O
OBJECTIVES,2565,O
:,2565,O
To,2565,O
explore,2565,O
a,2565,O
possible,2565,O
association,2565,O
between,2565,O
HRH4,2565,B-GENE-Y
(,2565,O
formerly,2565,O
H4R,2565,B-GENE-Y
),2565,O
CNVs,2565,O
and,2565,O
the,2565,O
risk,2565,O
of,2565,O
SLE,2565,O
.,2565,O
METHODS,2566,O
:,2566,O
Genomic,2566,O
DNA,2566,O
and,2566,O
RNA,2566,O
from,2566,O
340,2566,O
patients,2566,O
with,2566,O
SLE,2566,O
and,2566,O
392,2566,O
healthy,2566,O
controls,2566,O
were,2566,O
extracted,2566,O
",",2566,O
and,2566,O
CNVs,2566,O
and,2566,O
mRNA,2566,O
levels,2566,O
of,2566,O
HRH4,2566,B-GENE-Y
were,2566,O
examined,2566,O
.,2566,O
RESULTS,2567,O
:,2567,O
The,2567,O
expression,2567,O
of,2567,O
HRH4,2567,B-GENE-Y
mRNA,2567,O
was,2567,O
significantly,2567,O
increased,2567,O
in,2567,O
patients,2567,O
with,2567,O
SLE,2567,O
compared,2567,O
with,2567,O
controls,2567,O
.,2567,O
Amplification,2568,O
of,2568,O
HRH4,2568,B-GENE-Y
copy,2568,O
numbers,2568,O
significantly,2568,O
increased,2568,O
the,2568,O
risk,2568,O
of,2568,O
SLE,2568,O
[,2568,O
P,2568,O
<,2568,O
0.001,2568,O
",",2568,O
odds,2568,O
ratio,2568,O
(,2568,O
OR,2568,O
),2568,O
2.26,2568,O
",",2568,O
95,2568,O
%,2568,O
confidence,2568,O
interval,2568,O
(,2568,O
CI,2568,O
),2568,O
1.50-3.40,2568,O
],2568,O
.,2568,O
HRH4,2569,B-GENE-Y
amplifications,2569,O
also,2569,O
positively,2569,O
correlated,2569,O
with,2569,O
the,2569,O
incidence,2569,O
of,2569,O
arthritis,2569,O
(,2569,O
P,2569,O
=,2569,O
0.019,2569,O
",",2569,O
OR,2569,O
1.96,2569,O
",",2569,O
95,2569,O
%,2569,O
CI,2569,O
1.11-3.47,2569,O
),2569,O
",",2569,O
and,2569,O
proteinuria,2569,O
(,2569,O
P,2569,O
<,2569,O
0.001,2569,O
",",2569,O
OR,2569,O
2.95,2569,O
",",2569,O
95,2569,O
%,2569,O
CI,2569,O
1.73-5.00,2569,O
),2569,O
and,2569,O
antinuclear,2569,O
antibody,2569,O
abnormalities,2569,O
(,2569,O
P,2569,O
<,2569,O
0.001,2569,O
",",2569,O
OR,2569,O
2.97,2569,O
",",2569,O
95,2569,O
%,2569,O
CI,2569,O
1.66-5.33,2569,O
),2569,O
.,2569,O
Deletions,2570,O
of,2570,O
HRH4,2570,B-GENE-Y
copy,2570,O
numbers,2570,O
were,2570,O
protective,2570,O
against,2570,O
proteinuria,2570,O
(,2570,O
P,2570,O
=,2570,O
0.03,2570,O
",",2570,O
OR,2570,O
0.50,2570,O
",",2570,O
95,2570,O
%,2570,O
CI,2570,O
0.26-0.94,2570,O
),2570,O
.,2570,O
CONCLUSION,2571,O
:,2571,O
CNVs,2571,O
of,2571,O
the,2571,O
HRH4,2571,B-GENE-Y
gene,2571,O
are,2571,O
associated,2571,O
with,2571,O
SLE,2571,O
.,2571,O
Pharmacology,2572,O
of,2572,O
ramelteon,2572,B-CHEMICAL
",",2572,O
a,2572,O
selective,2572,O
MT1/MT2,2572,B-GENE-Y
receptor,2572,O
agonist,2572,O
:,2572,O
a,2572,O
novel,2572,O
therapeutic,2572,O
drug,2572,O
for,2572,O
sleep,2572,O
disorders,2572,O
.,2572,O
An,2573,O
estimated,2573,O
one-third,2573,O
of,2573,O
the,2573,O
general,2573,O
population,2573,O
is,2573,O
affected,2573,O
by,2573,O
insomnia,2573,O
",",2573,O
and,2573,O
this,2573,O
number,2573,O
is,2573,O
increasing,2573,O
due,2573,O
to,2573,O
more,2573,O
stressful,2573,O
working,2573,O
conditions,2573,O
and,2573,O
the,2573,O
progressive,2573,O
aging,2573,O
of,2573,O
society,2573,O
.,2573,O
However,2574,O
",",2574,O
current,2574,O
treatment,2574,O
of,2574,O
insomnia,2574,O
with,2574,O
hypnotics,2574,O
",",2574,O
gamma-aminobutyric,2574,B-GENE-N
acid,2574,I-GENE-N
A,2574,I-GENE-N
(,2574,I-GENE-N
GABA,2574,I-GENE-N
(,2574,I-GENE-N
A,2574,I-GENE-N
),2574,I-GENE-N
),2574,I-GENE-N
receptor,2574,I-GENE-N
modulators,2574,O
",",2574,O
induces,2574,O
various,2574,O
side,2574,O
effects,2574,O
",",2574,O
including,2574,O
cognitive,2574,O
impairment,2574,O
",",2574,O
motor,2574,O
disturbance,2574,O
",",2574,O
dependence,2574,O
",",2574,O
tolerance,2574,O
",",2574,O
hangover,2574,O
",",2574,O
and,2574,O
rebound,2574,O
insomnia,2574,O
.,2574,O
Ramelteon,2575,B-CHEMICAL
(,2575,O
Rozerem,2575,B-CHEMICAL
;,2575,O
Takeda,2575,O
Pharmaceutical,2575,O
Company,2575,O
Limited,2575,O
",",2575,O
Osaka,2575,O
",",2575,O
Japan,2575,O
),2575,O
is,2575,O
an,2575,O
orally,2575,O
active,2575,O
",",2575,O
highly,2575,O
selective,2575,O
melatonin,2575,B-CHEMICAL
MT,2575,B-GENE-Y
(,2575,I-GENE-Y
1,2575,I-GENE-Y
),2575,I-GENE-Y
/MT,2575,O
(,2575,I-GENE-Y
2,2575,I-GENE-Y
),2575,I-GENE-Y
receptor,2575,O
agonist,2575,O
.,2575,O
Unlike,2576,O
the,2576,O
sedative,2576,O
hypnotics,2576,O
that,2576,O
target,2576,O
GABA,2576,B-GENE-N
(,2576,I-GENE-N
A,2576,I-GENE-N
),2576,I-GENE-N
receptor,2576,I-GENE-N
complexes,2576,O
",",2576,O
ramelteon,2576,B-CHEMICAL
is,2576,O
a,2576,O
chronohypnotic,2576,O
that,2576,O
acts,2576,O
on,2576,O
the,2576,O
melatonin,2576,B-CHEMICAL
MT,2576,B-GENE-Y
(,2576,I-GENE-Y
1,2576,I-GENE-Y
),2576,I-GENE-Y
and,2576,O
MT,2576,B-GENE-Y
(,2576,I-GENE-Y
2,2576,I-GENE-Y
),2576,I-GENE-Y
receptors,2576,O
",",2576,O
which,2576,O
are,2576,O
primarily,2576,O
located,2576,O
in,2576,O
the,2576,O
suprachiasmatic,2576,O
nucleus,2576,O
",",2576,O
the,2576,O
body,2576,O
's,2576,O
``,2576,O
master,2576,O
clock,2576,O
.,2576,O
'',2576,O
As,2577,O
such,2577,O
",",2577,O
ramelteon,2577,B-CHEMICAL
possesses,2577,O
the,2577,O
first,2577,O
new,2577,O
therapeutic,2577,O
mechanism,2577,O
of,2577,O
action,2577,O
for,2577,O
a,2577,O
prescription,2577,O
insomnia,2577,O
medication,2577,O
in,2577,O
over,2577,O
three,2577,O
decades,2577,O
.,2577,O
Ramelteon,2578,B-CHEMICAL
has,2578,O
demonstrated,2578,O
sleep-promoting,2578,O
effects,2578,O
in,2578,O
clinical,2578,O
trials,2578,O
",",2578,O
and,2578,O
coupled,2578,O
with,2578,O
its,2578,O
favorable,2578,O
safety,2578,O
profile,2578,O
and,2578,O
lack,2578,O
of,2578,O
abuse,2578,O
potential,2578,O
or,2578,O
dependence,2578,O
",",2578,O
this,2578,O
chronohypnotic,2578,O
provides,2578,O
an,2578,O
important,2578,O
treatment,2578,O
option,2578,O
for,2578,O
insomnia,2578,O
.,2578,O
Antimyeloma,2579,O
effects,2579,O
of,2579,O
a,2579,O
novel,2579,O
synthetic,2579,O
retinoid,2579,B-CHEMICAL
Am80,2579,B-CHEMICAL
(,2579,O
Tamibarotene,2579,B-CHEMICAL
),2579,O
through,2579,O
inhibition,2579,O
of,2579,O
angiogenesis,2579,O
.,2579,O
In,2580,O
multiple,2580,O
myeloma,2580,O
(,2580,O
MM,2580,O
),2580,O
",",2580,O
the,2580,O
interaction,2580,O
between,2580,O
myeloma,2580,O
cells,2580,O
and,2580,O
bone,2580,O
marrow,2580,O
microenvironment,2580,O
has,2580,O
an,2580,O
important,2580,O
role,2580,O
in,2580,O
the,2580,O
pathogenesis,2580,O
of,2580,O
MM,2580,O
.,2580,O
We,2581,O
first,2581,O
examined,2581,O
the,2581,O
inducing,2581,O
effect,2581,O
of,2581,O
myeloma,2581,O
cells,2581,O
on,2581,O
migration,2581,O
of,2581,O
human,2581,O
umbilical,2581,O
vein,2581,O
vascular,2581,O
endothelial,2581,O
cells,2581,O
(,2581,O
HUVECs,2581,O
),2581,O
.,2581,O
Five,2582,O
myeloma,2582,O
cell,2582,O
lines,2582,O
produced,2582,O
varying,2582,O
amounts,2582,O
of,2582,O
VEGF,2582,B-GENE-Y
",",2582,O
and,2582,O
migration,2582,O
of,2582,O
HUVECs,2582,O
was,2582,O
induced,2582,O
by,2582,O
coculture,2582,O
with,2582,O
myeloma,2582,O
cells,2582,O
.,2582,O
We,2583,O
next,2583,O
examined,2583,O
the,2583,O
inhibitory,2583,O
effect,2583,O
of,2583,O
a,2583,O
novel,2583,O
synthetic,2583,O
retinoid,2583,B-CHEMICAL
Am80,2583,B-CHEMICAL
(,2583,O
Tamibarotene,2583,B-CHEMICAL
),2583,O
on,2583,O
both,2583,O
myeloma,2583,O
cells,2583,O
and,2583,O
HUVECs,2583,O
.,2583,O
Am80,2584,B-CHEMICAL
is,2584,O
specific,2584,O
for,2584,O
the,2584,O
retinoic-acid,2584,B-GENE-N
receptor-alpha/beta,2584,I-GENE-N
",",2584,O
and,2584,O
has,2584,O
therapeutic,2584,O
effects,2584,O
in,2584,O
all-trans,2584,B-CHEMICAL
retinoic,2584,I-CHEMICAL
acid,2584,I-CHEMICAL
resistant,2584,O
acute,2584,O
promyelocytic,2584,O
leukemia,2584,O
.,2584,O
Am80,2585,B-CHEMICAL
slightly,2585,O
inhibited,2585,O
the,2585,O
growth,2585,O
of,2585,O
both,2585,O
myeloma,2585,O
cells,2585,O
and,2585,O
HUVECs,2585,O
",",2585,O
and,2585,O
remarkably,2585,O
inhibited,2585,O
the,2585,O
growth,2585,O
of,2585,O
HUVECs,2585,O
stimulated,2585,O
by,2585,O
VEGF,2585,B-GENE-Y
.,2585,O
Am80,2586,B-CHEMICAL
showed,2586,O
little,2586,O
growth,2586,O
inhibition,2586,O
of,2586,O
bone,2586,O
marrow,2586,O
stromal,2586,O
cells,2586,O
(,2586,O
BMSCs,2586,O
),2586,O
",",2586,O
but,2586,O
it,2586,O
markedly,2586,O
inhibited,2586,O
migration,2586,O
of,2586,O
HUVECs,2586,O
by,2586,O
cocultured,2586,O
myeloma,2586,O
cells,2586,O
.,2586,O
Am80,2587,B-CHEMICAL
inhibited,2587,O
VEGF-induced,2587,B-GENE-Y
phosphorylation,2587,O
of,2587,O
VEGF,2587,B-GENE-N
receptor,2587,I-GENE-N
.,2587,O
In,2588,O
addition,2588,O
",",2588,O
VEGF-induced,2588,B-GENE-Y
formation,2588,O
of,2588,O
tube-like,2588,O
structures,2588,O
in,2588,O
vitro,2588,O
and,2588,O
neovascularization,2588,O
in,2588,O
mouse,2588,O
corneas,2588,O
were,2588,O
significantly,2588,O
inhibited,2588,O
by,2588,O
Am80,2588,B-CHEMICAL
.,2588,O
These,2589,O
findings,2589,O
clearly,2589,O
demonstrate,2589,O
that,2589,O
Am80,2589,B-CHEMICAL
is,2589,O
a,2589,O
potential,2589,O
inhibitor,2589,O
of,2589,O
angiogenesis,2589,O
caused,2589,O
by,2589,O
the,2589,O
interaction,2589,O
between,2589,O
vascular,2589,O
endothelial,2589,O
cells,2589,O
and,2589,O
myeloma,2589,O
cells,2589,O
",",2589,O
and,2589,O
might,2589,O
be,2589,O
a,2589,O
useful,2589,O
therapeutic,2589,O
agent,2589,O
against,2589,O
MM,2589,O
.,2589,O
Mechanisms,2590,O
of,2590,O
inhibition,2590,O
of,2590,O
calmodulin-stimulated,2590,B-GENE-N
cyclic,2590,I-GENE-N
nucleotide,2590,I-GENE-N
phosphodiesterase,2590,I-GENE-N
by,2590,O
dihydropyridine,2590,O
calcium,2590,O
antagonists,2590,O
.,2590,O
Calmodulin-dependent,2591,B-GENE-N
cyclic,2591,I-GENE-N
nucleotide,2591,I-GENE-N
phosphodiesterase,2591,I-GENE-N
(,2591,O
CaMPDE,2591,B-GENE-N
),2591,O
is,2591,O
one,2591,O
of,2591,O
the,2591,O
key,2591,O
enzymes,2591,O
involved,2591,O
in,2591,O
the,2591,O
complex,2591,O
interaction,2591,O
between,2591,O
the,2591,O
cyclic,2591,O
nucleotide,2591,B-CHEMICAL
and,2591,O
Ca2+,2591,B-CHEMICAL
second-messenger,2591,O
systems,2591,O
.,2591,O
CaMPDE,2592,B-GENE-N
exists,2592,O
as,2592,O
tissue-specific,2592,O
isozymes,2592,O
",",2592,O
and,2592,O
initially,2592,O
these,2592,O
isozymes,2592,O
were,2592,O
designated,2592,O
according,2592,O
to,2592,O
their,2592,O
respective,2592,O
subunit,2592,O
molecular,2592,O
mass,2592,O
.,2592,O
A,2593,O
variety,2593,O
of,2593,O
pharmacological,2593,O
agents,2593,O
have,2593,O
been,2593,O
used,2593,O
to,2593,O
inhibit,2593,O
CaMPDE,2593,B-GENE-N
",",2593,O
and,2593,O
this,2593,O
inhibition,2593,O
occurs,2593,O
mostly,2593,O
via,2593,O
Ca2+-dependent,2593,B-CHEMICAL
association,2593,O
with,2593,O
the,2593,O
proteins,2593,O
.,2593,O
We,2594,O
have,2594,O
examined,2594,O
the,2594,O
effect,2594,O
of,2594,O
dihydropyridine,2594,B-CHEMICAL
Ca2+-channel,2594,B-GENE-N
blockers,2594,O
felodipine,2594,B-CHEMICAL
and,2594,O
nicardipine,2594,B-CHEMICAL
on,2594,O
CaMPDE,2594,B-GENE-N
.,2594,O
The,2595,O
results,2595,O
suggest,2595,O
that,2595,O
the,2595,O
63-kDa,2595,O
(,2595,O
PDE,2595,B-GENE-Y
1B1,2595,I-GENE-Y
),2595,O
and,2595,O
60-kDa,2595,O
(,2595,O
PDE,2595,B-GENE-Y
1A2,2595,I-GENE-Y
),2595,O
CaMPDE,2595,B-GENE-N
isozymes,2595,O
are,2595,O
inhibited,2595,O
by,2595,O
felodipine,2595,B-CHEMICAL
and,2595,O
nicardipine,2595,B-CHEMICAL
by,2595,O
partial,2595,O
competitive,2595,O
inhibition,2595,O
and,2595,O
that,2595,O
these,2595,O
two,2595,O
Ca2+,2595,B-CHEMICAL
antagonists,2595,O
appear,2595,O
to,2595,O
counteract,2595,O
each,2595,O
other,2595,O
.,2595,O
This,2596,O
study,2596,O
further,2596,O
demonstrates,2596,O
the,2596,O
existence,2596,O
of,2596,O
a,2596,O
specific,2596,O
site,2596,O
",",2596,O
distinct,2596,O
from,2596,O
the,2596,O
active,2596,O
site,2596,O
on,2596,O
CaMPDE,2596,B-GENE-N
",",2596,O
that,2596,O
exhibits,2596,O
high-affinity,2596,O
binding,2596,O
of,2596,O
these,2596,O
drugs,2596,O
.,2596,O
Felodipine,2597,B-CHEMICAL
and,2597,O
nicardipine,2597,B-CHEMICAL
have,2597,O
similar,2597,O
affinities,2597,O
for,2597,O
60-kDa,2597,O
CaMPDE,2597,B-GENE-N
isozymes,2597,O
but,2597,O
bring,2597,O
about,2597,O
different,2597,O
levels,2597,O
of,2597,O
enzyme,2597,O
inhibition,2597,O
",",2597,O
suggesting,2597,O
the,2597,O
possibility,2597,O
of,2597,O
designing,2597,O
specific,2597,O
drugs,2597,O
that,2597,O
can,2597,O
protect,2597,O
the,2597,O
enzyme,2597,O
from,2597,O
inhibition,2597,O
by,2597,O
dihydropyridine,2597,B-CHEMICAL
Ca2+-channel,2597,B-GENE-N
blockers,2597,O
.,2597,O
Efficient,2598,O
MRI,2598,O
labeling,2598,O
of,2598,O
endothelial,2598,O
progenitor,2598,O
cells,2598,O
:,2598,O
Design,2598,O
of,2598,O
thiolated,2598,O
surface,2598,O
stabilized,2598,O
superparamagnetic,2598,O
iron,2598,B-CHEMICAL
oxide,2598,I-CHEMICAL
nanoparticles,2598,O
.,2598,O
The,2599,O
aim,2599,O
of,2599,O
this,2599,O
study,2599,O
was,2599,O
to,2599,O
design,2599,O
thiolated,2599,O
surface,2599,O
stabilized,2599,O
superparamagnetic,2599,O
iron,2599,B-CHEMICAL
oxide,2599,I-CHEMICAL
nanoparticles,2599,O
(,2599,O
TSS-SPIONs,2599,O
),2599,O
for,2599,O
efficient,2599,O
internalization,2599,O
with,2599,O
high,2599,O
MRI,2599,O
sensitivity,2599,O
.,2599,O
TSS-SPIONs,2600,O
were,2600,O
developed,2600,O
by,2600,O
chelation,2600,O
between,2600,O
thiolated,2600,O
chitosan-thioglycolic,2600,O
acid,2600,I-CHEMICAL
(,2600,O
chitosan-TGA,2600,O
),2600,O
hydrogel,2600,O
and,2600,O
iron,2600,B-CHEMICAL
ions,2600,O
(,2600,O
Fe,2600,B-CHEMICAL
(,2600,I-CHEMICAL
2+,2600,I-CHEMICAL
),2600,I-CHEMICAL
/Fe,2600,O
(,2600,I-CHEMICAL
3+,2600,I-CHEMICAL
),2600,I-CHEMICAL
),2600,O
.,2600,O
Likely,2601,O
",",2601,O
unmodified,2601,O
chitosan,2601,O
hydrogel,2601,O
SPIONs,2601,O
(,2601,O
UC-SPIONs,2601,O
),2601,O
and,2601,O
uncoated,2601,O
SPIONs,2601,O
were,2601,O
used,2601,O
as,2601,O
control,2601,O
.,2601,O
Moreover,2602,O
",",2602,O
TSS-SPIONs,2602,O
were,2602,O
investigated,2602,O
regarding,2602,O
to,2602,O
their,2602,O
iron,2602,B-CHEMICAL
core,2602,O
size,2602,O
",",2602,O
hydrodynamic,2602,O
diameter,2602,O
",",2602,O
zeta,2602,O
potential,2602,O
",",2602,O
iron,2602,B-CHEMICAL
contents,2602,O
",",2602,O
molar,2602,O
relaxivities,2602,O
(,2602,O
r1,2602,O
and,2602,O
r2,2602,O
),2602,O
",",2602,O
and,2602,O
cellular,2602,O
internalization,2602,O
.,2602,O
TSS-SPIONs,2603,O
demonstrated,2603,O
an,2603,O
iron,2603,B-CHEMICAL
oxide,2603,I-CHEMICAL
core,2603,O
diameter,2603,O
(,2603,O
crystallite,2603,O
size,2603,O
by,2603,O
XRD,2603,O
),2603,O
of,2603,O
3.1±0.02nm,2603,O
",",2603,O
a,2603,O
hydrodynamic,2603,O
diameter,2603,O
of,2603,O
94±20nm,2603,O
",",2603,O
a,2603,O
zeta,2603,O
potential,2603,O
of,2603,O
+21±5mV,2603,O
",",2603,O
and,2603,O
an,2603,O
iron,2603,B-CHEMICAL
content,2603,O
of,2603,O
3.6±0.9mg/mL,2603,O
.,2603,O
In,2604,O
addition,2604,O
",",2604,O
internalization,2604,O
of,2604,O
TSS-SPIONs,2604,O
into,2604,O
human,2604,O
endothelial,2604,O
progenitor,2604,O
cells,2604,O
(,2604,O
EPC,2604,O
),2604,O
from,2604,O
umbilical,2604,O
cord,2604,O
blood,2604,O
was,2604,O
more,2604,O
than,2604,O
threefold,2604,O
and,2604,O
17-fold,2604,O
higher,2604,O
in,2604,O
contrast,2604,O
to,2604,O
UC-SPIONs,2604,O
and,2604,O
SPIONs,2604,O
",",2604,O
respectively,2604,O
.,2604,O
With,2605,O
twofold,2605,O
lower,2605,O
incubation,2605,O
iron,2605,B-CHEMICAL
concentration,2605,O
of,2605,O
TSS-SPIONs,2605,O
",",2605,O
more,2605,O
than,2605,O
threefold,2605,O
higher,2605,O
internalization,2605,O
was,2605,O
achieved,2605,O
as,2605,O
compared,2605,O
to,2605,O
Resovist®,2605,O
.,2605,O
Also,2606,O
",",2606,O
cell,2606,O
viability,2606,O
of,2606,O
more,2606,O
than,2606,O
90,2606,O
%,2606,O
was,2606,O
observed,2606,O
in,2606,O
the,2606,O
presence,2606,O
of,2606,O
TSS-SPIONs,2606,O
after,2606,O
24h,2606,O
.,2606,O
The,2607,O
molar,2607,O
MR,2607,O
relaxivities,2607,O
(,2607,O
r2,2607,O
),2607,O
value,2607,O
at,2607,O
1.5T,2607,O
was,2607,O
threefold,2607,O
higher,2607,O
than,2607,O
that,2607,O
of,2607,O
Resovist®,2607,O
and,2607,O
demonstrated,2607,O
that,2607,O
TSS-SPIONs,2607,O
have,2607,O
the,2607,O
potential,2607,O
as,2607,O
very,2607,O
effective,2607,O
T2,2607,O
contrast-enhancement,2607,O
agent,2607,O
.,2607,O
According,2608,O
to,2608,O
these,2608,O
findings,2608,O
",",2608,O
TSS-SPIONs,2608,O
with,2608,O
efficient,2608,O
internalization,2608,O
",",2608,O
lower,2608,O
cytotoxicity,2608,O
",",2608,O
and,2608,O
high,2608,O
MRI,2608,O
sensitivity,2608,O
seem,2608,O
to,2608,O
be,2608,O
promising,2608,O
for,2608,O
cell,2608,O
tracking,2608,O
.,2608,O
Selective,2609,O
inhibitors,2609,O
and,2609,O
tailored,2609,O
activity,2609,O
probes,2609,O
for,2609,O
lipoprotein-associated,2609,B-GENE-Y
phospholipase,2609,I-GENE-Y
A,2609,I-GENE-Y
(,2609,I-GENE-Y
2,2609,I-GENE-Y
),2609,I-GENE-Y
.,2609,O
Lipoprotein-associated,2610,B-GENE-Y
phospholipase,2610,I-GENE-Y
A,2610,I-GENE-Y
(,2610,I-GENE-Y
2,2610,I-GENE-Y
),2610,I-GENE-Y
(,2610,O
Lp-PLA,2610,B-GENE-Y
(,2610,I-GENE-Y
2,2610,I-GENE-Y
),2610,I-GENE-Y
or,2610,O
PLA,2610,B-GENE-Y
(,2610,I-GENE-Y
2,2610,I-GENE-Y
),2610,I-GENE-Y
G7,2610,I-GENE-Y
),2610,I-GENE-Y
binds,2610,O
to,2610,O
low-density,2610,B-GENE-N
lipoprotein,2610,I-GENE-N
(,2610,O
LDL,2610,B-GENE-N
),2610,O
particles,2610,O
",",2610,O
where,2610,O
it,2610,O
is,2610,O
thought,2610,O
to,2610,O
hydrolyze,2610,O
oxidatively,2610,O
truncated,2610,O
phospholipids,2610,O
.,2610,O
Lp-PLA,2611,B-GENE-Y
(,2611,I-GENE-Y
2,2611,I-GENE-Y
),2611,I-GENE-Y
has,2611,O
also,2611,O
been,2611,O
implicated,2611,O
as,2611,O
a,2611,O
pro-tumorigenic,2611,O
enzyme,2611,O
in,2611,O
human,2611,O
prostate,2611,O
cancer,2611,O
.,2611,O
Several,2612,O
inhibitors,2612,O
of,2612,O
Lp-PLA,2612,B-GENE-Y
(,2612,I-GENE-Y
2,2612,I-GENE-Y
),2612,I-GENE-Y
have,2612,O
been,2612,O
described,2612,O
",",2612,O
including,2612,O
darapladib,2612,B-CHEMICAL
",",2612,O
which,2612,O
is,2612,O
currently,2612,O
in,2612,O
phase,2612,O
3,2612,O
clinical,2612,O
development,2612,O
for,2612,O
the,2612,O
treatment,2612,O
of,2612,O
atherosclerosis,2612,O
.,2612,O
The,2613,O
selectivity,2613,O
that,2613,O
darapladib,2613,B-CHEMICAL
and,2613,O
other,2613,O
Lp-PLA,2613,B-GENE-Y
(,2613,I-GENE-Y
2,2613,I-GENE-Y
),2613,I-GENE-Y
inhibitors,2613,O
display,2613,O
across,2613,O
the,2613,O
larger,2613,O
serine,2613,B-GENE-N
hydrolase,2613,I-GENE-N
family,2613,O
has,2613,O
not,2613,O
",",2613,O
however,2613,O
",",2613,O
been,2613,O
reported,2613,O
.,2613,O
Here,2614,O
",",2614,O
we,2614,O
describe,2614,O
the,2614,O
use,2614,O
of,2614,O
both,2614,O
general,2614,O
and,2614,O
tailored,2614,O
activity-based,2614,O
probes,2614,O
for,2614,O
profiling,2614,O
Lp-PLA,2614,B-GENE-Y
(,2614,I-GENE-Y
2,2614,I-GENE-Y
),2614,I-GENE-Y
and,2614,O
inhibitors,2614,O
of,2614,O
this,2614,O
enzyme,2614,O
in,2614,O
native,2614,O
biological,2614,O
systems,2614,O
.,2614,O
We,2615,O
show,2615,O
that,2615,O
both,2615,O
darapladib,2615,B-CHEMICAL
and,2615,O
a,2615,O
novel,2615,O
class,2615,O
of,2615,O
structurally,2615,O
distinct,2615,O
carbamate,2615,B-CHEMICAL
inhibitors,2615,O
inactivate,2615,O
Lp-PLA,2615,B-GENE-Y
(,2615,I-GENE-Y
2,2615,I-GENE-Y
),2615,I-GENE-Y
in,2615,O
mouse,2615,O
tissues,2615,O
and,2615,O
human,2615,O
cell,2615,O
lines,2615,O
with,2615,O
high,2615,O
selectivity,2615,O
.,2615,O
Our,2616,O
findings,2616,O
thus,2616,O
identify,2616,O
both,2616,O
inhibitors,2616,O
and,2616,O
chemoproteomic,2616,O
probes,2616,O
that,2616,O
are,2616,O
suitable,2616,O
for,2616,O
investigating,2616,O
Lp-PLA,2616,B-GENE-Y
(,2616,I-GENE-Y
2,2616,I-GENE-Y
),2616,I-GENE-Y
function,2616,O
in,2616,O
biological,2616,O
systems,2616,O
.,2616,O
Arformoterol,2617,B-CHEMICAL
:,2617,O
(,2617,B-CHEMICAL
R,2617,I-CHEMICAL
",",2617,I-CHEMICAL
R,2617,I-CHEMICAL
),2617,I-CHEMICAL
-eformoterol,2617,I-CHEMICAL
",",2617,O
(,2617,B-CHEMICAL
R,2617,I-CHEMICAL
",",2617,I-CHEMICAL
R,2617,I-CHEMICAL
),2617,I-CHEMICAL
-formoterol,2617,I-CHEMICAL
",",2617,O
arformoterol,2617,B-CHEMICAL
tartrate,2617,I-CHEMICAL
",",2617,O
eformoterol-sepracor,2617,B-CHEMICAL
",",2617,O
formoterol-sepracor,2617,B-CHEMICAL
",",2617,O
R,2617,B-CHEMICAL
",",2617,I-CHEMICAL
R-eformoterol,2617,I-CHEMICAL
",",2617,O
R,2617,B-CHEMICAL
",",2617,I-CHEMICAL
R-formoterol,2617,I-CHEMICAL
.,2617,O
Sepracor,2618,O
in,2618,O
the,2618,O
US,2618,O
is,2618,O
developing,2618,O
arformoterol,2618,B-CHEMICAL
[,2618,O
R,2618,B-CHEMICAL
",",2618,I-CHEMICAL
R-formoterol,2618,I-CHEMICAL
],2618,O
",",2618,O
a,2618,O
single,2618,O
isomer,2618,O
form,2618,O
of,2618,O
the,2618,O
beta,2618,B-GENE-Y
(,2618,I-GENE-Y
2,2618,I-GENE-Y
),2618,I-GENE-Y
-adrenoceptor,2618,I-GENE-Y
agonist,2618,O
formoterol,2618,B-CHEMICAL
[,2618,O
eformoterol,2618,B-CHEMICAL
],2618,O
.,2618,O
This,2619,O
isomer,2619,O
contains,2619,O
two,2619,O
chiral,2619,O
centres,2619,O
and,2619,O
is,2619,O
being,2619,O
developed,2619,O
as,2619,O
an,2619,O
inhaled,2619,O
preparation,2619,O
for,2619,O
the,2619,O
treatment,2619,O
of,2619,O
respiratory,2619,O
disorders,2619,O
.,2619,O
Sepracor,2620,O
believes,2620,O
that,2620,O
arformoterol,2620,B-CHEMICAL
has,2620,O
the,2620,O
potential,2620,O
to,2620,O
be,2620,O
a,2620,O
once-daily,2620,O
therapy,2620,O
with,2620,O
a,2620,O
rapid,2620,O
onset,2620,O
of,2620,O
action,2620,O
and,2620,O
a,2620,O
duration,2620,O
of,2620,O
effect,2620,O
exceeding,2620,O
12,2620,O
hours,2620,O
.,2620,O
In,2621,O
1995,2621,O
",",2621,O
Sepracor,2621,O
acquired,2621,O
New,2621,O
England,2621,O
Pharmaceuticals,2621,O
",",2621,O
a,2621,O
manufacturer,2621,O
of,2621,O
metered-dose,2621,O
and,2621,O
dry,2621,O
powder,2621,O
inhalers,2621,O
",",2621,O
for,2621,O
the,2621,O
purpose,2621,O
of,2621,O
preparing,2621,O
formulations,2621,O
of,2621,O
levosalbutamol,2621,B-CHEMICAL
and,2621,O
arformoterol,2621,B-CHEMICAL
.,2621,O
Phase,2622,O
II,2622,O
dose-ranging,2622,O
clinical,2622,O
studies,2622,O
of,2622,O
arformoterol,2622,B-CHEMICAL
as,2622,O
a,2622,O
longer-acting,2622,O
",",2622,O
complementary,2622,O
bronchodilator,2622,O
were,2622,O
completed,2622,O
successfully,2622,O
in,2622,O
the,2622,O
fourth,2622,O
quarter,2622,O
of,2622,O
2000,2622,O
.,2622,O
Phase,2623,O
III,2623,O
trials,2623,O
of,2623,O
arformoterol,2623,B-CHEMICAL
began,2623,O
in,2623,O
September,2623,O
2001,2623,O
.,2623,O
The,2624,O
indications,2624,O
for,2624,O
the,2624,O
drug,2624,O
appeared,2624,O
to,2624,O
be,2624,O
asthma,2624,O
and,2624,O
chronic,2624,O
obstructive,2624,O
pulmonary,2624,O
disease,2624,O
(,2624,O
COPD,2624,O
),2624,O
.,2624,O
However,2625,O
",",2625,O
an,2625,O
update,2625,O
of,2625,O
the,2625,O
pharmaceutical,2625,O
product,2625,O
information,2625,O
on,2625,O
the,2625,O
Sepracor,2625,O
website,2625,O
in,2625,O
September,2625,O
2003,2625,O
listed,2625,O
COPD,2625,O
maintenance,2625,O
therapy,2625,O
as,2625,O
the,2625,O
only,2625,O
indication,2625,O
for,2625,O
arformoterol,2625,B-CHEMICAL
.,2625,O
In,2626,O
October,2626,O
2002,2626,O
",",2626,O
Sepracor,2626,O
stated,2626,O
that,2626,O
two,2626,O
pivotal,2626,O
phase,2626,O
III,2626,O
studies,2626,O
were,2626,O
ongoing,2626,O
in,2626,O
1600,2626,O
patients,2626,O
.,2626,O
Sepracor,2627,O
estimates,2627,O
that,2627,O
its,2627,O
NDA,2627,O
submission,2627,O
for,2627,O
arformoterol,2627,B-CHEMICAL
",",2627,O
which,2627,O
is,2627,O
projected,2627,O
for,2627,O
the,2627,O
first,2627,O
half,2627,O
of,2627,O
2004,2627,O
",",2627,O
will,2627,O
include,2627,O
approximately,2627,O
3000,2627,O
adult,2627,O
subjects,2627,O
.,2627,O
Sepracor,2628,O
stated,2628,O
in,2628,O
July,2628,O
2003,2628,O
that,2628,O
it,2628,O
had,2628,O
completed,2628,O
more,2628,O
than,2628,O
100,2628,O
preclinical,2628,O
studies,2628,O
and,2628,O
initiated,2628,O
or,2628,O
completed,2628,O
15,2628,O
clinical,2628,O
studies,2628,O
for,2628,O
arformoterol,2628,B-CHEMICAL
inhalation,2628,O
solution,2628,O
for,2628,O
the,2628,O
treatment,2628,O
of,2628,O
bronchospasm,2628,O
in,2628,O
patients,2628,O
with,2628,O
COPD,2628,O
.,2628,O
In,2629,O
addition,2629,O
",",2629,O
Sepracor,2629,O
stated,2629,O
that,2629,O
the,2629,O
two,2629,O
pivotal,2629,O
phase,2629,O
III,2629,O
studies,2629,O
in,2629,O
1600,2629,O
patients,2629,O
were,2629,O
still,2629,O
progressing,2629,O
.,2629,O
In,2630,O
1995,2630,O
",",2630,O
European,2630,O
patents,2630,O
were,2630,O
granted,2630,O
to,2630,O
Sepracor,2630,O
for,2630,O
the,2630,O
use,2630,O
of,2630,O
arformoterol,2630,B-CHEMICAL
in,2630,O
the,2630,O
treatment,2630,O
of,2630,O
asthma,2630,O
",",2630,O
and,2630,O
the,2630,O
US,2630,O
patent,2630,O
application,2630,O
was,2630,O
pending,2630,O
.,2630,O
Role,2631,O
of,2631,O
nitric,2631,B-CHEMICAL
oxide,2631,I-CHEMICAL
in,2631,O
the,2631,O
chemistry,2631,O
and,2631,O
anticancer,2631,O
activity,2631,O
of,2631,O
etoposide,2631,B-CHEMICAL
(,2631,O
"VP-16,213",2631,B-CHEMICAL
),2631,O
.,2631,O
Originally,2632,O
identified,2632,O
as,2632,O
an,2632,O
innate,2632,O
cytotoxin,2632,O
",",2632,O
nitric,2632,B-CHEMICAL
oxide,2632,I-CHEMICAL
(,2632,O
(,2632,B-CHEMICAL
·,2632,I-CHEMICAL
),2632,I-CHEMICAL
NO,2632,I-CHEMICAL
),2632,O
formation,2632,O
in,2632,O
tumors,2632,O
can,2632,O
influence,2632,O
chemotherapy,2632,O
and,2632,O
exacerbate,2632,O
cancer,2632,O
progression,2632,O
.,2632,O
Here,2633,O
",",2633,O
we,2633,O
examined,2633,O
the,2633,O
hypothesis,2633,O
that,2633,O
(,2633,B-CHEMICAL
·,2633,I-CHEMICAL
),2633,I-CHEMICAL
NO,2633,I-CHEMICAL
generation,2633,O
contributes,2633,O
to,2633,O
cancer,2633,O
cell,2633,O
drug,2633,O
resistance,2633,O
toward,2633,O
the,2633,O
widely,2633,O
used,2633,O
anticancer,2633,O
drug,2633,O
Etoposide,2633,B-CHEMICAL
(,2633,O
VP-16,2633,B-CHEMICAL
),2633,O
.,2633,O
The,2634,O
UV-vis,2634,O
spectrum,2634,O
of,2634,O
VP-16,2634,B-CHEMICAL
was,2634,O
not,2634,O
changed,2634,O
by,2634,O
exposure,2634,O
of,2634,O
VP-16,2634,B-CHEMICAL
to,2634,O
(,2634,B-CHEMICAL
·,2634,I-CHEMICAL
),2634,I-CHEMICAL
NO,2634,I-CHEMICAL
in,2634,O
aqueous,2634,O
buffer,2634,O
.,2634,O
In,2635,O
contrast,2635,O
",",2635,O
reddish-orange,2635,O
compound,2635,O
(,2635,O
s,2635,O
),2635,O
characteristic,2635,O
of,2635,O
o-quinone-,2635,B-CHEMICAL
and,2635,I-CHEMICAL
nitroso-VP-16,2635,I-CHEMICAL
were,2635,O
readily,2635,O
generated,2635,O
in,2635,O
a,2635,O
hydrophobic,2635,O
medium,2635,O
(,2635,O
chloroform,2635,B-CHEMICAL
),2635,O
in,2635,O
an,2635,O
oxygen-dependent,2635,B-CHEMICAL
manner,2635,O
.,2635,O
Similar,2636,O
products,2636,O
were,2636,O
also,2636,O
formed,2636,O
when,2636,O
the,2636,O
VP-16,2636,B-CHEMICAL
radical,2636,O
",",2636,O
generated,2636,O
from,2636,O
VP-16,2636,B-CHEMICAL
and,2636,O
horseradish,2636,O
peroxidase/H2O2,2636,O
",",2636,O
was,2636,O
exposed,2636,O
directly,2636,O
to,2636,O
(,2636,B-CHEMICAL
·,2636,I-CHEMICAL
),2636,I-CHEMICAL
NO,2636,I-CHEMICAL
in,2636,O
chloroform,2636,B-CHEMICAL
in,2636,O
the,2636,O
presence,2636,O
of,2636,O
oxygen,2636,B-CHEMICAL
.,2636,O
Separation,2637,O
and,2637,O
spectral,2637,O
analysis,2637,O
of,2637,O
VP-16,2637,B-CHEMICAL
reaction,2637,O
extracts,2637,O
by,2637,O
electron,2637,O
spin,2637,O
resonance,2637,O
and,2637,O
UV-vis,2637,O
indicated,2637,O
the,2637,O
generation,2637,O
of,2637,O
the,2637,O
phenoxy,2637,B-CHEMICAL
radical,2637,O
and,2637,O
the,2637,O
o-quinone,2637,B-CHEMICAL
of,2637,O
VP-16,2637,B-CHEMICAL
",",2637,O
as,2637,O
well,2637,O
as,2637,O
putative,2637,O
nitroxide,2637,B-CHEMICAL
",",2637,O
iminoxyl,2637,B-CHEMICAL
",",2637,O
and,2637,O
other,2637,O
nitrogen,2637,B-CHEMICAL
oxide,2637,I-CHEMICAL
intermediates,2637,O
.,2637,O
Nitric,2638,B-CHEMICAL
oxide,2638,I-CHEMICAL
products,2638,O
of,2638,O
VP-16,2638,B-CHEMICAL
displayed,2638,O
significantly,2638,O
diminished,2638,O
topoisomerase,2638,B-GENE-Y
II-dependent,2638,O
cleavage,2638,O
of,2638,O
DNA,2638,O
and,2638,O
cytotoxicity,2638,O
to,2638,O
human,2638,O
HL-60,2638,O
leukemia,2638,O
cells,2638,O
.,2638,O
LPS-mediated,2639,O
induction,2639,O
of,2639,O
nitric,2639,B-GENE-N
oxide,2639,I-GENE-N
synthase,2639,I-GENE-N
in,2639,O
murine,2639,O
macrophages,2639,O
resulted,2639,O
in,2639,O
VP-16,2639,B-CHEMICAL
resistance,2639,O
compared,2639,O
to,2639,O
Raw,2639,O
cells,2639,O
.,2639,O
Furthermore,2640,O
",",2640,O
(,2640,B-CHEMICAL
·,2640,I-CHEMICAL
),2640,I-CHEMICAL
NO,2640,I-CHEMICAL
products,2640,O
derived,2640,O
from,2640,O
iNOS,2640,B-GENE-Y
rapidly,2640,O
reacted,2640,O
with,2640,O
VP-16,2640,B-CHEMICAL
leading,2640,O
to,2640,O
decreased,2640,O
DNA,2640,O
damage,2640,O
and,2640,O
cytotoxicity,2640,O
.,2640,O
Together,2641,O
",",2641,O
these,2641,O
observations,2641,O
suggest,2641,O
that,2641,O
the,2641,O
formation,2641,O
of,2641,O
(,2641,B-CHEMICAL
·,2641,I-CHEMICAL
),2641,I-CHEMICAL
NO,2641,I-CHEMICAL
in,2641,O
tumors,2641,O
(,2641,O
associated,2641,O
macrophages,2641,O
),2641,O
can,2641,O
contribute,2641,O
to,2641,O
VP-16,2641,B-CHEMICAL
resistance,2641,O
via,2641,O
the,2641,O
detoxification,2641,O
of,2641,O
VP-16,2641,B-CHEMICAL
.,2641,O
Acyl-CoA,2642,B-GENE-N
synthetase,2642,I-GENE-N
isoforms,2642,I-GENE-N
1,2642,I-GENE-N
",",2642,I-GENE-N
4,2642,I-GENE-N
",",2642,I-GENE-N
and,2642,I-GENE-N
5,2642,I-GENE-N
are,2642,O
present,2642,O
in,2642,O
different,2642,O
subcellular,2642,O
membranes,2642,O
in,2642,O
rat,2642,O
liver,2642,O
and,2642,O
can,2642,O
be,2642,O
inhibited,2642,O
independently,2642,O
.,2642,O
Inhibition,2643,O
studies,2643,O
have,2643,O
suggested,2643,O
that,2643,O
acyl-CoA,2643,B-GENE-N
synthetase,2643,I-GENE-N
(,2643,O
ACS,2643,B-GENE-N
",",2643,O
EC,2643,O
),2643,O
isoforms,2643,O
might,2643,O
regulate,2643,O
the,2643,O
use,2643,O
of,2643,O
acyl-CoAs,2643,B-CHEMICAL
by,2643,O
different,2643,O
metabolic,2643,O
pathways,2643,O
.,2643,O
In,2644,O
order,2644,O
to,2644,O
determine,2644,O
whether,2644,O
the,2644,O
subcellular,2644,O
locations,2644,O
differed,2644,O
for,2644,O
each,2644,O
of,2644,O
the,2644,O
three,2644,O
ACSs,2644,B-GENE-N
present,2644,O
in,2644,O
liver,2644,O
and,2644,O
whether,2644,O
these,2644,O
isoforms,2644,O
were,2644,O
regulated,2644,O
independently,2644,O
",",2644,O
non-cross-reacting,2644,O
peptide,2644,O
antibodies,2644,O
were,2644,O
raised,2644,O
against,2644,O
ACS1,2644,B-GENE-Y
",",2644,O
ACS4,2644,B-GENE-Y
",",2644,O
and,2644,O
ACS5,2644,B-GENE-Y
.,2644,O
ACS1,2645,B-GENE-Y
was,2645,O
identified,2645,O
in,2645,O
endoplasmic,2645,O
reticulum,2645,O
",",2645,O
mitochondria-associated,2645,O
membrane,2645,O
(,2645,O
MAM,2645,O
),2645,O
",",2645,O
and,2645,O
cytosol,2645,O
",",2645,O
but,2645,O
not,2645,O
in,2645,O
mitochondria,2645,O
.,2645,O
ACS4,2646,B-GENE-Y
was,2646,O
present,2646,O
primarily,2646,O
in,2646,O
MAM,2646,O
",",2646,O
and,2646,O
the,2646,O
76-kDa,2646,O
ACS5,2646,B-GENE-Y
protein,2646,O
was,2646,O
located,2646,O
in,2646,O
mitochondrial,2646,O
membrane,2646,O
.,2646,O
Consistent,2647,O
with,2647,O
these,2647,O
locations,2647,O
",",2647,O
N-ethylmaleimide,2647,B-CHEMICAL
",",2647,O
an,2647,O
inhibitor,2647,O
of,2647,O
ACS4,2647,B-GENE-Y
",",2647,O
inhibited,2647,O
ACS,2647,B-GENE-N
activity,2647,O
47,2647,O
%,2647,O
in,2647,O
MAM,2647,O
and,2647,O
28,2647,O
%,2647,O
in,2647,O
endoplasmic,2647,O
reticulum,2647,O
.,2647,O
Troglitazone,2648,B-CHEMICAL
",",2648,O
a,2648,O
second,2648,O
ACS4,2648,B-GENE-Y
inhibitor,2648,O
",",2648,O
inhibited,2648,O
ACS,2648,B-GENE-N
activity,2648,O
<,2648,O
10,2648,O
%,2648,O
in,2648,O
microsomes,2648,O
and,2648,O
mitochondria,2648,O
and,2648,O
45,2648,O
%,2648,O
in,2648,O
MAM,2648,O
.,2648,O
Triacsin,2649,B-CHEMICAL
C,2649,I-CHEMICAL
",",2649,O
a,2649,O
competitive,2649,O
inhibitor,2649,O
of,2649,O
both,2649,O
ACS1,2649,B-GENE-Y
and,2649,O
ACS4,2649,B-GENE-Y
",",2649,O
inhibited,2649,O
ACS,2649,B-GENE-N
activity,2649,O
similarly,2649,O
in,2649,O
endoplasmic,2649,O
reticulum,2649,O
",",2649,O
MAM,2649,O
",",2649,O
and,2649,O
mitochondria,2649,O
",",2649,O
suggesting,2649,O
that,2649,O
a,2649,O
hitherto,2649,O
unidentified,2649,O
triacsin-sensitive,2649,B-CHEMICAL
ACS,2649,B-GENE-N
is,2649,O
present,2649,O
in,2649,O
mitochondria,2649,O
.,2649,O
ACS1,2650,B-GENE-Y
",",2650,O
ACS4,2650,B-GENE-Y
",",2650,O
and,2650,O
ACS5,2650,B-GENE-Y
were,2650,O
regulated,2650,O
independently,2650,O
by,2650,O
fasting,2650,O
and,2650,O
re-feeding,2650,O
.,2650,O
Fasting,2651,O
rats,2651,O
for,2651,O
48,2651,O
h,2651,O
resulted,2651,O
in,2651,O
a,2651,O
decrease,2651,O
in,2651,O
ACS4,2651,B-GENE-Y
protein,2651,O
",",2651,O
and,2651,O
an,2651,O
increase,2651,O
in,2651,O
ACS5,2651,B-GENE-Y
.,2651,O
Re-feeding,2652,O
normal,2652,O
chow,2652,O
or,2652,O
a,2652,O
high,2652,O
sucrose,2652,B-CHEMICAL
diet,2652,O
for,2652,O
24,2652,O
h,2652,O
after,2652,O
a,2652,O
48-h,2652,O
fast,2652,O
increased,2652,O
both,2652,O
ACS1,2652,B-GENE-Y
and,2652,O
ACS4,2652,B-GENE-Y
protein,2652,O
expression,2652,O
1.5-2.0-fold,2652,O
",",2652,O
consistent,2652,O
with,2652,O
inhibition,2652,O
studies,2652,O
.,2652,O
These,2653,O
results,2653,O
suggest,2653,O
that,2653,O
ACS1,2653,B-GENE-Y
and,2653,O
ACS4,2653,B-GENE-Y
may,2653,O
be,2653,O
linked,2653,O
to,2653,O
triacylglycerol,2653,B-CHEMICAL
synthesis,2653,O
.,2653,O
Taken,2654,O
together,2654,O
",",2654,O
the,2654,O
data,2654,O
suggest,2654,O
that,2654,O
acyl-CoAs,2654,B-CHEMICAL
may,2654,O
be,2654,O
functionally,2654,O
channeled,2654,O
to,2654,O
specific,2654,O
metabolic,2654,O
pathways,2654,O
through,2654,O
different,2654,O
ACS,2654,B-GENE-N
isoforms,2654,O
in,2654,O
unique,2654,O
subcellular,2654,O
locations,2654,O
.,2654,O
The,2655,O
tyrosine,2655,B-GENE-N
kinase,2655,I-GENE-N
inhibitor,2655,O
ZD1839,2655,B-CHEMICAL
(,2655,O
``,2655,O
Iressa,2655,B-CHEMICAL
'',2655,O
),2655,O
inhibits,2655,O
HER2-driven,2655,B-GENE-Y
signaling,2655,O
and,2655,O
suppresses,2655,O
the,2655,O
growth,2655,O
of,2655,O
HER2-overexpressing,2655,B-GENE-Y
tumor,2655,O
cells,2655,O
.,2655,O
The,2656,O
epidermal,2656,B-GENE-Y
growth,2656,I-GENE-Y
factor,2656,I-GENE-Y
receptor,2656,I-GENE-Y
(,2656,O
EGFR,2656,B-GENE-Y
),2656,O
is,2656,O
commonly,2656,O
overexpressed,2656,O
in,2656,O
many,2656,O
human,2656,O
tumors,2656,O
and,2656,O
provides,2656,O
a,2656,O
new,2656,O
target,2656,O
for,2656,O
anticancer,2656,O
drug,2656,O
development,2656,O
.,2656,O
ZD1839,2657,B-CHEMICAL
(,2657,O
``,2657,O
Iressa,2657,B-CHEMICAL
'',2657,O
),2657,O
",",2657,O
a,2657,O
quinazoline,2657,B-CHEMICAL
tyrosine,2657,B-GENE-N
kinase,2657,I-GENE-N
inhibitor,2657,O
selective,2657,O
for,2657,O
the,2657,O
EGFR,2657,B-GENE-Y
",",2657,O
has,2657,O
shown,2657,O
good,2657,O
activity,2657,O
in,2657,O
preclinical,2657,O
studies,2657,O
and,2657,O
in,2657,O
the,2657,O
early,2657,O
phase,2657,O
of,2657,O
clinical,2657,O
trials,2657,O
.,2657,O
However,2658,O
",",2658,O
because,2658,O
it,2658,O
remains,2658,O
unclear,2658,O
which,2658,O
tumor,2658,O
types,2658,O
are,2658,O
the,2658,O
best,2658,O
targets,2658,O
for,2658,O
treatment,2658,O
with,2658,O
this,2658,O
agent,2658,O
",",2658,O
the,2658,O
molecular,2658,O
characteristics,2658,O
that,2658,O
correlate,2658,O
with,2658,O
tumor,2658,O
sensitivity,2658,O
to,2658,O
ZD1839,2658,B-CHEMICAL
have,2658,O
been,2658,O
studied,2658,O
.,2658,O
In,2659,O
a,2659,O
panel,2659,O
of,2659,O
human,2659,O
breast,2659,O
cancer,2659,O
and,2659,O
other,2659,O
epithelial,2659,O
tumor,2659,O
cell,2659,O
lines,2659,O
",",2659,O
HER2-overexpressing,2659,B-GENE-Y
tumors,2659,O
were,2659,O
particularly,2659,O
sensitive,2659,O
to,2659,O
ZD1839,2659,B-CHEMICAL
.,2659,O
Growth,2660,O
inhibition,2660,O
of,2660,O
these,2660,O
tumor,2660,O
cell,2660,O
lines,2660,O
was,2660,O
associated,2660,O
with,2660,O
the,2660,O
dephosphorylation,2660,O
of,2660,O
EGFR,2660,B-GENE-Y
",",2660,O
HER2,2660,B-GENE-Y
",",2660,O
and,2660,O
HER3,2660,B-GENE-Y
",",2660,O
accompanied,2660,O
by,2660,O
the,2660,O
loss,2660,O
of,2660,O
association,2660,O
of,2660,O
HER3,2660,O
with,2660,O
phosphatidylinositol,2660,B-GENE-N
3-kinase,2660,I-GENE-N
",",2660,O
and,2660,O
down-regulation,2660,O
of,2660,O
Akt,2660,B-GENE-N
activity,2660,O
.,2660,O
These,2661,O
studies,2661,O
suggest,2661,O
that,2661,O
HER2-overexpressing,2661,B-GENE-Y
tumors,2661,O
are,2661,O
particularly,2661,O
susceptible,2661,O
to,2661,O
the,2661,O
inhibition,2661,O
of,2661,O
HER,2661,B-GENE-N
family,2661,O
tyrosine,2661,B-GENE-N
kinase,2661,I-GENE-N
signaling,2661,O
and,2661,O
suggest,2661,O
novel,2661,O
strategies,2661,O
to,2661,O
treat,2661,O
these,2661,O
particularly,2661,O
aggressive,2661,O
tumors,2661,O
.,2661,O
Integrated,2662,O
chemical,2662,O
and,2662,O
biological,2662,O
analysis,2662,O
to,2662,O
explain,2662,O
estrogenic,2662,O
potency,2662,O
in,2662,O
bile,2662,O
extracts,2662,O
of,2662,O
red,2662,O
mullet,2662,O
(,2662,O
Mullus,2662,O
barbatus,2662,O
),2662,O
.,2662,O
A,2663,O
biological,2663,O
screening,2663,O
was,2663,O
performed,2663,O
to,2663,O
establish,2663,O
the,2663,O
total,2663,O
exposure,2663,O
to,2663,O
estrogenic,2663,O
compounds,2663,O
of,2663,O
red,2663,O
mullet,2663,O
(,2663,O
Mullus,2663,O
barbatus,2663,O
),2663,O
collected,2663,O
at,2663,O
several,2663,O
sites,2663,O
along,2663,O
the,2663,O
Spanish,2663,O
Mediterranean,2663,O
coast,2663,O
by,2663,O
testing,2663,O
male,2663,O
fish,2663,O
bile,2663,O
extracts,2663,O
using,2663,O
the,2663,O
in,2663,O
vitro,2663,O
ER-LUC,2663,B-GENE-Y
reporter,2663,O
gene,2663,O
assay,2663,O
.,2663,O
In,2664,O
addition,2664,O
",",2664,O
major,2664,O
metabolites,2664,O
were,2664,O
identified,2664,O
and,2664,O
measurements,2664,O
of,2664,O
OH-PAHs,2664,B-CHEMICAL
(,2664,O
1-naphthol,2664,B-CHEMICAL
",",2664,O
9-phenantrol,2664,B-CHEMICAL
",",2664,O
9-fluorenol,2664,B-CHEMICAL
",",2664,O
1-pyrenol,2664,B-CHEMICAL
",",2664,O
1OH-BaP,2664,B-CHEMICAL
and,2664,O
3OH-BaP,2664,B-CHEMICAL
),2664,O
and,2664,O
alkylphenols,2664,B-CHEMICAL
(,2664,O
4-n-nonylphenol,2664,B-CHEMICAL
(,2664,O
4-n-NP,2664,B-CHEMICAL
),2664,O
and,2664,O
4-tertoctylphenol,2664,B-CHEMICAL
(,2664,O
4-tert-OP,2664,B-CHEMICAL
),2664,O
),2664,O
in,2664,O
the,2664,O
same,2664,O
fish,2664,O
bile,2664,O
extracts,2664,O
were,2664,O
taken,2664,O
by,2664,O
gas,2664,O
chromatography-mass,2664,O
spectrometry,2664,O
in,2664,O
electron,2664,O
ionization,2664,O
mode,2664,O
(,2664,O
GC-EI-MS,2664,O
),2664,O
.,2664,O
Relative,2665,O
in,2665,O
vitro,2665,O
estrogenic,2665,O
potencies,2665,O
of,2665,O
the,2665,O
chemically,2665,O
quantified,2665,O
compounds,2665,O
were,2665,O
also,2665,O
tested,2665,O
.,2665,O
The,2666,O
highest,2666,O
biliary,2666,O
concentrations,2666,O
of,2666,O
1-pyrenol,2666,B-CHEMICAL
",",2666,O
9-fluorenol,2666,B-CHEMICAL
and,2666,O
4-n-NP,2666,B-CHEMICAL
were,2666,O
found,2666,O
in,2666,O
fish,2666,O
from,2666,O
Barcelona,2666,O
and,2666,O
from,2666,O
the,2666,O
Mar,2666,O
Menor,2666,O
coastal,2666,O
lagoon,2666,O
.,2666,O
However,2667,O
",",2667,O
these,2667,O
concentrations,2667,O
can,2667,O
be,2667,O
considered,2667,O
relatively,2667,O
low,2667,O
compared,2667,O
to,2667,O
values,2667,O
reported,2667,O
in,2667,O
red,2667,O
mullet,2667,O
from,2667,O
other,2667,O
polluted,2667,O
waters,2667,O
in,2667,O
the,2667,O
Mediterranean,2667,O
Sea,2667,O
.,2667,O
The,2668,O
contribution,2668,O
of,2668,O
1-pyrenol,2668,B-CHEMICAL
",",2668,O
4-n-NP,2668,B-CHEMICAL
and,2668,O
4-tert-OP,2668,B-CHEMICAL
to,2668,O
the,2668,O
total,2668,O
estrogenic,2668,O
potency,2668,O
measured,2668,O
in,2668,O
male,2668,O
fish,2668,O
bile,2668,O
was,2668,O
found,2668,O
to,2668,O
be,2668,O
negligible,2668,O
",",2668,O
indicating,2668,O
the,2668,O
presence,2668,O
of,2668,O
other,2668,O
estrogenic,2668,O
compounds,2668,O
in,2668,O
red,2668,O
mullet,2668,O
bile,2668,O
.,2668,O
Estrogenic,2669,O
potency,2669,O
in,2669,O
bile,2669,O
from,2669,O
male,2669,O
fish,2669,O
was,2669,O
markedly,2669,O
elevated,2669,O
in,2669,O
Mar,2669,O
Menor,2669,O
lagoon,2669,O
(,2669,O
234.8±5.7pgE2EQ/μl,2669,O
),2669,O
",",2669,O
and,2669,O
further,2669,O
research,2669,O
will,2669,O
be,2669,O
necessary,2669,O
to,2669,O
explain,2669,O
whether,2669,O
the,2669,O
presence,2669,O
of,2669,O
natural,2669,O
and,2669,O
synthetic-hormones,2669,O
in,2669,O
the,2669,O
lagoon,2669,O
contributed,2669,O
to,2669,O
this,2669,O
finding,2669,O
.,2669,O
Values,2670,O
of,2670,O
approximately,2670,O
15-16E2EQpg/mg,2670,O
bile,2670,O
can,2670,O
be,2670,O
regarded,2670,O
as,2670,O
preliminary,2670,O
baseline,2670,O
levels,2670,O
of,2670,O
bile,2670,O
estrogenicity,2670,O
in,2670,O
male,2670,O
red,2670,O
mullet,2670,O
from,2670,O
the,2670,O
western,2670,O
Mediterranean,2670,O
Sea,2670,O
.,2670,O
[,2671,O
Pharmacological,2671,O
effects,2671,O
of,2671,O
a,2671,O
mu-opioid,2671,B-GENE-Y
receptor,2671,I-GENE-Y
antagonist,2671,O
naltrexone,2671,B-CHEMICAL
on,2671,O
alcohol,2671,B-CHEMICAL
dependence,2671,O
],2671,O
.,2671,O
Alcohol,2672,B-CHEMICAL
is,2672,O
one,2672,O
of,2672,O
the,2672,O
most,2672,O
commonly,2672,O
abused,2672,O
substances,2672,O
",",2672,O
and,2672,O
its,2672,O
chronic,2672,O
intake,2672,O
leads,2672,O
to,2672,O
the,2672,O
development,2672,O
of,2672,O
ethanol,2672,B-CHEMICAL
dependence,2672,O
in,2672,O
both,2672,O
humans,2672,O
and,2672,O
laboratory,2672,O
animals,2672,O
.,2672,O
In,2673,O
many,2673,O
countries,2673,O
",",2673,O
a,2673,O
mu-opioid,2673,B-GENE-Y
receptor,2673,I-GENE-Y
antagonist,2673,O
naltrexone,2673,B-CHEMICAL
has,2673,O
been,2673,O
used,2673,O
in,2673,O
the,2673,O
treatment,2673,O
of,2673,O
alcohol,2673,B-CHEMICAL
dependence,2673,O
.,2673,O
The,2674,O
introduction,2674,O
of,2674,O
naltrexone,2674,B-CHEMICAL
for,2674,O
the,2674,O
treatment,2674,O
of,2674,O
alcohol,2674,B-CHEMICAL
dependence,2674,O
has,2674,O
been,2674,O
mainly,2674,O
based,2674,O
on,2674,O
behavioral,2674,O
animal,2674,O
models,2674,O
that,2674,O
provide,2674,O
evidence,2674,O
of,2674,O
the,2674,O
involvement,2674,O
of,2674,O
the,2674,O
endogenous,2674,O
opioid,2674,O
system,2674,O
in,2674,O
alcohol,2674,B-CHEMICAL
drinking,2674,O
and,2674,O
dependence,2674,O
.,2674,O
It,2675,O
has,2675,O
been,2675,O
well,2675,O
known,2675,O
that,2675,O
alcohol,2675,B-CHEMICAL
leads,2675,O
to,2675,O
the,2675,O
activation,2675,O
of,2675,O
the,2675,O
endogenous,2675,O
opioid,2675,O
system,2675,O
.,2675,O
The,2676,O
endogenous,2676,O
opioid,2676,O
agonists,2676,O
",",2676,O
such,2676,O
as,2676,O
beta-endorphin,2676,B-GENE-Y
",",2676,O
increase,2676,O
the,2676,O
activity,2676,O
of,2676,O
the,2676,O
mesolimbic,2676,O
dopaminergic,2676,O
system,2676,O
through,2676,O
the,2676,O
inhibition,2676,O
of,2676,O
the,2676,O
gamma-aminobutyric,2676,B-CHEMICAL
acid,2676,I-CHEMICAL
(,2676,O
GABA,2676,B-CHEMICAL
),2676,O
-containing,2676,O
inhibitory,2676,O
interneurons,2676,O
in,2676,O
the,2676,O
ventral,2676,O
tegmental,2676,O
area,2676,O
",",2676,O
resulting,2676,O
in,2676,O
the,2676,O
expression,2676,O
of,2676,O
alcohol,2676,B-CHEMICAL
reinforcement,2676,O
and/or,2676,O
rewarding,2676,O
effect,2676,O
.,2676,O
Therefore,2677,O
",",2677,O
naltrexone,2677,B-CHEMICAL
",",2677,O
which,2677,O
is,2677,O
useful,2677,O
for,2677,O
alcohol,2677,B-CHEMICAL
dependence,2677,O
therapy,2677,O
",",2677,O
may,2677,O
attenuate,2677,O
the,2677,O
rewarding,2677,O
effect,2677,O
of,2677,O
ethanol,2677,B-CHEMICAL
by,2677,O
interfering,2677,O
with,2677,O
the,2677,O
ethanol-induced,2677,B-CHEMICAL
stimulation,2677,O
of,2677,O
the,2677,O
mesolimbic,2677,O
dopaminergic,2677,O
system,2677,O
.,2677,O
The,2678,O
following,2678,O
review,2678,O
provides,2678,O
a,2678,O
summary,2678,O
of,2678,O
the,2678,O
interactions,2678,O
between,2678,O
endogenous,2678,O
opioid,2678,O
system,2678,O
and,2678,O
mesolimbic,2678,O
dopaminergic,2678,O
system,2678,O
in,2678,O
alcohol,2678,B-CHEMICAL
dependence,2678,O
.,2678,O
Re-evaluation,2679,O
of,2679,O
lisuride,2679,B-CHEMICAL
pharmacology,2679,O
:,2679,O
5-hydroxytryptamine1A,2679,B-GENE-Y
receptor-mediated,2679,O
behavioral,2679,O
effects,2679,O
overlap,2679,O
its,2679,O
other,2679,O
properties,2679,O
in,2679,O
rats,2679,O
.,2679,O
RATIONALE,2680,O
:,2680,O
There,2680,O
is,2680,O
substantial,2680,O
evidence,2680,O
that,2680,O
lisuride,2680,B-CHEMICAL
can,2680,O
produce,2680,O
effects,2680,O
linked,2680,O
to,2680,O
5-HT,2680,B-GENE-Y
(,2680,I-GENE-Y
1A,2680,I-GENE-Y
),2680,I-GENE-Y
receptor,2680,O
occupancy,2680,O
.,2680,O
Nevertheless,2681,O
",",2681,O
this,2681,O
action,2681,O
has,2681,O
generally,2681,O
been,2681,O
ignored,2681,O
in,2681,O
the,2681,O
mechanism,2681,O
of,2681,O
action,2681,O
of,2681,O
lisuride,2681,B-CHEMICAL
",",2681,O
in,2681,O
favor,2681,O
of,2681,O
an,2681,O
exclusive,2681,O
role,2681,O
for,2681,O
dopamine,2681,B-GENE-N
receptors,2681,I-GENE-N
in,2681,O
considering,2681,O
its,2681,O
antiparkinsonian,2681,O
effects,2681,O
",",2681,O
or,2681,O
an,2681,O
exclusive,2681,O
role,2681,O
of,2681,O
5-HT,2681,B-GENE-N
(,2681,I-GENE-N
2A/2C,2681,I-GENE-N
),2681,I-GENE-N
receptor,2681,O
activation,2681,O
in,2681,O
hallucinogenesis,2681,O
.,2681,O
These,2682,O
conclusions,2682,O
are,2682,O
surprising,2682,O
when,2682,O
one,2682,O
considers,2682,O
that,2682,O
the,2682,O
potent,2682,O
interaction,2682,O
of,2682,O
lisuride,2682,B-CHEMICAL
with,2682,O
5-HT,2682,B-GENE-Y
(,2682,I-GENE-Y
1A,2682,I-GENE-Y
),2682,I-GENE-Y
receptors,2682,O
has,2682,O
been,2682,O
demonstrated,2682,O
in,2682,O
several,2682,O
different,2682,O
laboratories,2682,O
and,2682,O
that,2682,O
activation,2682,O
of,2682,O
5-HT,2682,B-GENE-Y
(,2682,I-GENE-Y
1A,2682,I-GENE-Y
),2682,I-GENE-Y
and,2682,O
5-HT,2682,B-GENE-Y
(,2682,I-GENE-Y
1B,2682,I-GENE-Y
),2682,I-GENE-Y
receptors,2682,O
can,2682,O
modulate,2682,O
dopaminergically,2682,O
mediated,2682,O
responses,2682,O
.,2682,O
OBJECTIVE,2683,O
:,2683,O
The,2683,O
lack,2683,O
of,2683,O
full,2683,O
substitution,2683,O
of,2683,O
lisuride,2683,B-CHEMICAL
for,2683,O
lysergic,2683,B-CHEMICAL
acid,2683,I-CHEMICAL
diethylamide,2683,I-CHEMICAL
(,2683,O
LSD,2683,B-CHEMICAL
),2683,O
in,2683,O
drug,2683,O
discrimination,2683,O
experiments,2683,O
and,2683,O
induction,2683,O
of,2683,O
a,2683,O
pronounced,2683,O
5-HT,2683,B-CHEMICAL
syndrome,2683,O
by,2683,O
this,2683,O
compound,2683,O
at,2683,O
relatively,2683,O
low,2683,O
doses,2683,O
convinced,2683,O
us,2683,O
to,2683,O
execute,2683,O
two,2683,O
series,2683,O
of,2683,O
experiments,2683,O
that,2683,O
might,2683,O
explain,2683,O
the,2683,O
primary,2683,O
mechanism,2683,O
responsible,2683,O
for,2683,O
lisuride-mediated,2683,B-CHEMICAL
biological,2683,O
effects,2683,O
and,2683,O
its,2683,O
paradoxical,2683,O
classification,2683,O
as,2683,O
a,2683,O
dopamine,2683,B-CHEMICAL
agonist,2683,O
in,2683,O
the,2683,O
literature,2683,O
.,2683,O
RESULTS,2684,O
:,2684,O
In,2684,O
drug,2684,O
discrimination,2684,O
studies,2684,O
",",2684,O
lisuride,2684,B-CHEMICAL
fully,2684,O
mimicked,2684,O
the,2684,O
5-HT,2684,B-GENE-Y
(,2684,I-GENE-Y
1A,2684,I-GENE-Y
),2684,I-GENE-Y
agonist,2684,O
LY,2684,B-CHEMICAL
293284,2684,I-CHEMICAL
",",2684,O
only,2684,O
partially,2684,O
substituted,2684,O
for,2684,O
LSD,2684,B-CHEMICAL
and,2684,O
DOI,2684,B-CHEMICAL
",",2684,O
and,2684,O
failed,2684,O
to,2684,O
substitute,2684,O
for,2684,O
(,2684,B-CHEMICAL
+,2684,I-CHEMICAL
),2684,I-CHEMICAL
-amphetamine,2684,I-CHEMICAL
.,2684,O
Lisuride,2685,B-CHEMICAL
produced,2685,O
a,2685,O
significant,2685,O
dose-related,2685,O
increase,2685,O
in,2685,O
flat,2685,O
body,2685,O
posture,2685,O
",",2685,O
forepaw,2685,O
treading,2685,O
",",2685,O
and,2685,O
lower-lip,2685,O
retraction,2685,O
which,2685,O
reflect,2685,O
a,2685,O
modulation,2685,O
of,2685,O
behavior,2685,O
by,2685,O
action,2685,O
at,2685,O
central,2685,O
5-HT,2685,B-GENE-Y
(,2685,I-GENE-Y
1A,2685,I-GENE-Y
),2685,I-GENE-Y
receptors,2685,O
.,2685,O
Only,2686,O
pMPPI,2686,O
[,2686,O
4-iodo-N-,2686,B-CHEMICAL
[,2686,I-CHEMICAL
2-,2686,I-CHEMICAL
[,2686,I-CHEMICAL
4-,2686,I-CHEMICAL
(,2686,I-CHEMICAL
methoxyphenyl,2686,I-CHEMICAL
),2686,I-CHEMICAL
-1-piperazinyl,2686,I-CHEMICAL
],2686,I-CHEMICAL
ethyl,2686,I-CHEMICAL
],2686,I-CHEMICAL
-N-2-pyridynyl-benzamide,2686,I-CHEMICAL
hydrochloride,2686,I-CHEMICAL
],2686,O
",",2686,O
a,2686,O
selective,2686,O
5-HT,2686,B-GENE-Y
(,2686,I-GENE-Y
1A,2686,I-GENE-Y
),2686,I-GENE-Y
antagonist,2686,O
",",2686,O
was,2686,O
effective,2686,O
in,2686,O
inhibiting,2686,O
all,2686,O
5-HT,2686,B-CHEMICAL
syndrome,2686,O
behaviors,2686,O
produced,2686,O
by,2686,O
lisuride,2686,B-CHEMICAL
",",2686,O
whereas,2686,O
pMPPI,2686,O
was,2686,O
without,2686,O
effect,2686,O
on,2686,O
any,2686,O
behavior,2686,O
induced,2686,O
by,2686,O
LSD,2686,B-CHEMICAL
.,2686,O
Lisuride,2687,O
dose,2687,O
dependently,2687,O
decreased,2687,O
body,2687,O
temperature,2687,O
in,2687,O
rats,2687,O
with,2687,O
a,2687,O
potency,2687,O
similar,2687,O
to,2687,O
that,2687,O
of,2687,O
the,2687,O
selective,2687,O
5-HT,2687,B-GENE-Y
(,2687,I-GENE-Y
1A,2687,I-GENE-Y
),2687,I-GENE-Y
agonist,2687,O
LY,2687,B-CHEMICAL
293284,2687,I-CHEMICAL
.,2687,O
The,2688,O
hypothermic,2688,O
effect,2688,O
of,2688,O
lisuride,2688,B-CHEMICAL
was,2688,O
prevented,2688,O
by,2688,O
pre-injection,2688,O
of,2688,O
pMPPI,2688,O
",",2688,O
but,2688,O
not,2688,O
by,2688,O
ketanserin,2688,B-CHEMICAL
or,2688,O
haloperidol,2688,B-CHEMICAL
.,2688,O
CONCLUSION,2689,O
:,2689,O
We,2689,O
have,2689,O
demonstrated,2689,O
that,2689,O
the,2689,O
behavioral,2689,O
effects,2689,O
of,2689,O
low,2689,O
doses,2689,O
of,2689,O
lisuride,2689,B-CHEMICAL
are,2689,O
clearly,2689,O
mediated,2689,O
by,2689,O
stimulation,2689,O
of,2689,O
5-HT,2689,B-GENE-Y
(,2689,I-GENE-Y
1A,2689,I-GENE-Y
),2689,I-GENE-Y
receptors,2689,O
.,2689,O
Bupropion,2690,B-CHEMICAL
inhibits,2690,O
nicotine-evoked,2690,B-CHEMICAL
[,2690,O
(,2690,B-CHEMICAL
3,2690,I-CHEMICAL
),2690,I-CHEMICAL
H,2690,I-CHEMICAL
],2690,O
overflow,2690,O
from,2690,O
rat,2690,O
striatal,2690,O
slices,2690,O
preloaded,2690,O
with,2690,O
[,2690,B-CHEMICAL
(,2690,I-CHEMICAL
3,2690,I-CHEMICAL
),2690,I-CHEMICAL
H,2690,I-CHEMICAL
],2690,I-CHEMICAL
dopamine,2690,I-CHEMICAL
and,2690,O
from,2690,O
rat,2690,O
hippocampal,2690,O
slices,2690,O
preloaded,2690,O
with,2690,O
[,2690,B-CHEMICAL
(,2690,I-CHEMICAL
3,2690,I-CHEMICAL
),2690,I-CHEMICAL
H,2690,I-CHEMICAL
],2690,I-CHEMICAL
norepinephrine,2690,I-CHEMICAL
.,2690,O
Bupropion,2691,B-CHEMICAL
",",2691,O
an,2691,O
efficacious,2691,O
antidepressant,2691,O
and,2691,O
smoking,2691,O
cessation,2691,O
agent,2691,O
",",2691,O
inhibits,2691,O
dopamine,2691,B-GENE-N
and,2691,I-GENE-N
norepinephrine,2691,I-GENE-N
transporters,2691,I-GENE-N
(,2691,O
DAT,2691,B-GENE-Y
and,2691,O
NET,2691,B-GENE-Y
",",2691,O
respectively,2691,O
),2691,O
.,2691,O
Recently,2692,O
",",2692,O
bupropion,2692,B-CHEMICAL
has,2692,O
been,2692,O
reported,2692,O
to,2692,O
noncompetitively,2692,O
inhibit,2692,O
alpha3beta2,2692,B-GENE-N
",",2692,I-GENE-N
alpha3beta4,2692,I-GENE-N
",",2692,I-GENE-N
and,2692,I-GENE-N
alpha4beta2,2692,I-GENE-N
nicotinic,2692,I-GENE-N
acetylcholine,2692,I-GENE-N
receptors,2692,I-GENE-N
(,2692,I-GENE-N
nAChRs,2692,I-GENE-N
),2692,I-GENE-N
expressed,2692,O
in,2692,O
Xenopus,2692,O
oocytes,2692,O
or,2692,O
established,2692,O
cell,2692,O
lines,2692,O
.,2692,O
The,2693,O
present,2693,O
study,2693,O
evaluated,2693,O
bupropion-induced,2693,B-CHEMICAL
inhibition,2693,O
of,2693,O
native,2693,O
alpha3beta2,2693,B-GENE-N
*,2693,I-GENE-N
and,2693,I-GENE-N
alpha3beta4,2693,I-GENE-N
*,2693,I-GENE-N
nAChRs,2693,I-GENE-N
using,2693,O
functional,2693,O
neurotransmitter,2693,O
release,2693,O
assays,2693,O
",",2693,O
nicotine-evoked,2693,B-CHEMICAL
[,2693,O
(,2693,B-CHEMICAL
3,2693,I-CHEMICAL
),2693,I-CHEMICAL
H,2693,I-CHEMICAL
],2693,O
overflow,2693,O
from,2693,O
superfused,2693,O
rat,2693,O
striatal,2693,O
slices,2693,O
preloaded,2693,O
with,2693,O
[,2693,B-CHEMICAL
(,2693,I-CHEMICAL
3,2693,I-CHEMICAL
),2693,I-CHEMICAL
H,2693,I-CHEMICAL
],2693,I-CHEMICAL
dopamine,2693,I-CHEMICAL
(,2693,O
[,2693,B-CHEMICAL
(,2693,I-CHEMICAL
3,2693,I-CHEMICAL
),2693,I-CHEMICAL
H,2693,I-CHEMICAL
],2693,I-CHEMICAL
DA,2693,I-CHEMICAL
),2693,O
",",2693,O
and,2693,O
nicotine-evoked,2693,B-CHEMICAL
[,2693,O
(,2693,B-CHEMICAL
3,2693,I-CHEMICAL
),2693,I-CHEMICAL
H,2693,I-CHEMICAL
],2693,O
overflow,2693,O
from,2693,O
hippocampal,2693,O
slices,2693,O
preloaded,2693,O
with,2693,O
[,2693,B-CHEMICAL
(,2693,I-CHEMICAL
3,2693,I-CHEMICAL
),2693,I-CHEMICAL
H,2693,I-CHEMICAL
],2693,I-CHEMICAL
norepinephrine,2693,I-CHEMICAL
(,2693,O
[,2693,B-CHEMICAL
(,2693,I-CHEMICAL
3,2693,I-CHEMICAL
),2693,I-CHEMICAL
H,2693,I-CHEMICAL
],2693,I-CHEMICAL
NE,2693,I-CHEMICAL
),2693,O
.,2693,O
The,2694,O
mechanism,2694,O
of,2694,O
inhibition,2694,O
was,2694,O
evaluated,2694,O
using,2694,O
Schild,2694,O
analysis,2694,O
.,2694,O
To,2695,O
eliminate,2695,O
the,2695,O
interaction,2695,O
of,2695,O
bupropion,2695,B-CHEMICAL
with,2695,O
DAT,2695,B-GENE-Y
or,2695,O
NET,2695,B-GENE-Y
",",2695,O
nomifensine,2695,B-CHEMICAL
or,2695,O
desipramine,2695,B-CHEMICAL
",",2695,O
respectively,2695,O
",",2695,O
was,2695,O
included,2695,O
in,2695,O
the,2695,O
superfusion,2695,O
buffer,2695,O
.,2695,O
A,2696,O
high,2696,O
bupropion,2696,B-CHEMICAL
concentration,2696,O
(,2696,O
100,2696,O
microM,2696,O
),2696,O
elicited,2696,O
intrinsic,2696,O
activity,2696,O
in,2696,O
the,2696,O
[,2696,B-CHEMICAL
(,2696,I-CHEMICAL
3,2696,I-CHEMICAL
),2696,I-CHEMICAL
H,2696,I-CHEMICAL
],2696,I-CHEMICAL
DA,2696,I-CHEMICAL
release,2696,O
assay,2696,O
.,2696,O
However,2697,O
",",2697,O
none,2697,O
of,2697,O
the,2697,O
concentrations,2697,O
(,2697,O
1,2697,O
nM-100,2697,O
microM,2697,O
),2697,O
examined,2697,O
evoked,2697,O
[,2697,B-CHEMICAL
(,2697,I-CHEMICAL
3,2697,I-CHEMICAL
),2697,I-CHEMICAL
H,2697,I-CHEMICAL
],2697,I-CHEMICAL
NE,2697,I-CHEMICAL
overflow,2697,O
and,2697,O
",",2697,O
thus,2697,O
",",2697,O
were,2697,O
without,2697,O
intrinsic,2697,O
activity,2697,O
in,2697,O
this,2697,O
assay,2697,O
.,2697,O
Moreover,2698,O
",",2698,O
bupropion,2698,B-CHEMICAL
inhibited,2698,O
both,2698,O
nicotine-evoked,2698,B-CHEMICAL
[,2698,B-CHEMICAL
(,2698,I-CHEMICAL
3,2698,I-CHEMICAL
),2698,I-CHEMICAL
H,2698,I-CHEMICAL
],2698,I-CHEMICAL
DA,2698,I-CHEMICAL
overflow,2698,O
(,2698,O
IC,2698,O
(,2698,O
50,2698,O
),2698,O
=,2698,O
1.27,2698,O
microM,2698,O
),2698,O
and,2698,O
nicotine-evoked,2698,B-CHEMICAL
[,2698,B-CHEMICAL
(,2698,I-CHEMICAL
3,2698,I-CHEMICAL
),2698,I-CHEMICAL
H,2698,I-CHEMICAL
],2698,I-CHEMICAL
NE,2698,I-CHEMICAL
overflow,2698,O
(,2698,O
IC,2698,O
(,2698,O
50,2698,O
),2698,O
=,2698,O
323,2698,O
nM,2698,O
),2698,O
at,2698,O
bupropion,2698,B-CHEMICAL
concentrations,2698,O
well,2698,O
below,2698,O
those,2698,O
eliciting,2698,O
intrinsic,2698,O
activity,2698,O
.,2698,O
Results,2699,O
from,2699,O
Schild,2699,O
analyses,2699,O
suggest,2699,O
that,2699,O
bupropion,2699,B-CHEMICAL
competitively,2699,O
inhibits,2699,O
nicotine-evoked,2699,B-CHEMICAL
[,2699,B-CHEMICAL
(,2699,I-CHEMICAL
3,2699,I-CHEMICAL
),2699,I-CHEMICAL
H,2699,I-CHEMICAL
],2699,I-CHEMICAL
DA,2699,I-CHEMICAL
overflow,2699,O
",",2699,O
whereas,2699,O
evidence,2699,O
for,2699,O
receptor,2699,O
reserve,2699,O
was,2699,O
obtained,2699,O
upon,2699,O
assessment,2699,O
of,2699,O
bupropion,2699,B-CHEMICAL
inhibition,2699,O
of,2699,O
nicotine-evoked,2699,B-CHEMICAL
[,2699,B-CHEMICAL
(,2699,I-CHEMICAL
3,2699,I-CHEMICAL
),2699,I-CHEMICAL
H,2699,I-CHEMICAL
],2699,I-CHEMICAL
NE,2699,I-CHEMICAL
overflow,2699,O
.,2699,O
Thus,2700,O
",",2700,O
bupropion,2700,B-CHEMICAL
acts,2700,O
as,2700,O
an,2700,O
antagonist,2700,O
at,2700,O
alpha3beta2,2700,B-GENE-N
*,2700,I-GENE-N
and,2700,I-GENE-N
alpha3beta4,2700,I-GENE-N
*,2700,I-GENE-N
nAChRs,2700,I-GENE-N
in,2700,O
rat,2700,O
striatum,2700,O
and,2700,O
hippocampus,2700,O
",",2700,O
respectively,2700,O
",",2700,O
across,2700,O
the,2700,O
same,2700,O
concentration,2700,O
range,2700,O
that,2700,O
inhibits,2700,O
DAT,2700,B-GENE-Y
and,2700,O
NET,2700,B-GENE-Y
function,2700,O
.,2700,O
The,2701,O
combination,2701,O
of,2701,O
nAChR,2701,B-GENE-N
and,2701,O
transporter,2701,O
inhibition,2701,O
produced,2701,O
by,2701,O
bupropion,2701,B-CHEMICAL
may,2701,O
contribute,2701,O
to,2701,O
its,2701,O
clinical,2701,O
efficacy,2701,O
as,2701,O
a,2701,O
smoking,2701,O
cessation,2701,O
agent,2701,O
.,2701,O
Nitrogen-containing,2702,B-CHEMICAL
bisphosphonates,2702,B-CHEMICAL
induce,2702,O
apoptosis,2702,O
of,2702,O
hematopoietic,2702,O
tumor,2702,O
cells,2702,O
via,2702,O
inhibition,2702,O
of,2702,O
Ras,2702,B-GENE-N
signaling,2702,O
pathways,2702,O
and,2702,O
Bim-mediated,2702,B-GENE-Y
activation,2702,O
of,2702,O
the,2702,O
intrinsic,2702,O
apoptotic,2702,O
pathway,2702,O
.,2702,O
Nitrogen-containing,2703,B-CHEMICAL
bisphosphonates,2703,B-CHEMICAL
(,2703,O
N-BPs,2703,B-CHEMICAL
),2703,O
induce,2703,O
apoptosis,2703,O
in,2703,O
tumor,2703,O
cells,2703,O
by,2703,O
inhibiting,2703,O
the,2703,O
prenylation,2703,O
of,2703,O
small,2703,O
G-proteins,2703,B-GENE-N
.,2703,O
However,2704,O
",",2704,O
the,2704,O
details,2704,O
of,2704,O
the,2704,O
apoptosis-inducing,2704,O
mechanism,2704,O
remain,2704,O
obscure,2704,O
.,2704,O
The,2705,O
present,2705,O
study,2705,O
showed,2705,O
that,2705,O
the,2705,O
induction,2705,O
of,2705,O
apoptosis,2705,O
by,2705,O
N-BPs,2705,B-CHEMICAL
in,2705,O
hematopoietic,2705,O
tumor,2705,O
cells,2705,O
is,2705,O
mediated,2705,O
by,2705,O
mitochondrial,2705,O
apoptotic,2705,O
signaling,2705,O
pathways,2705,O
",",2705,O
which,2705,O
are,2705,O
activated,2705,O
by,2705,O
the,2705,O
suppression,2705,O
of,2705,O
geranylgeranyl,2705,B-CHEMICAL
pyrophosphate,2705,I-CHEMICAL
(,2705,O
GGPP,2705,B-CHEMICAL
),2705,O
biosynthesis,2705,O
.,2705,O
Furthermore,2706,O
",",2706,O
N-BPs,2706,B-CHEMICAL
decreased,2706,O
the,2706,O
levels,2706,O
of,2706,O
phosphorylated,2706,B-GENE-N
extracellular,2706,I-GENE-N
signal-regulated,2706,I-GENE-N
kinase,2706,I-GENE-N
(,2706,O
ERK,2706,B-GENE-N
),2706,O
and,2706,O
mTOR,2706,B-GENE-Y
via,2706,O
suppression,2706,O
of,2706,O
Ras,2706,B-GENE-N
prenylation,2706,O
and,2706,O
enhanced,2706,O
Bim,2706,B-GENE-Y
expression,2706,O
.,2706,O
The,2707,O
present,2707,O
results,2707,O
indicated,2707,O
that,2707,O
N-BPs,2707,B-CHEMICAL
induce,2707,O
apoptosis,2707,O
by,2707,O
decreasing,2707,O
the,2707,O
mitochondrial,2707,O
transmembrane,2707,O
potential,2707,O
",",2707,O
increasing,2707,O
the,2707,O
activation,2707,O
of,2707,O
caspase-9,2707,B-GENE-Y
and,2707,O
caspase-3,2707,B-GENE-Y
",",2707,O
and,2707,O
enhancing,2707,O
Bim,2707,B-GENE-Y
expression,2707,O
through,2707,O
inhibition,2707,O
of,2707,O
the,2707,O
Ras/MEK/ERK,2707,B-GENE-N
and,2707,O
Ras/mTOR,2707,B-GENE-N
pathways,2707,O
.,2707,O
The,2708,O
accumulation,2708,O
of,2708,O
N-BPs,2708,B-CHEMICAL
in,2708,O
bones,2708,O
suggests,2708,O
that,2708,O
they,2708,O
may,2708,O
act,2708,O
more,2708,O
effectively,2708,O
on,2708,O
tumors,2708,O
that,2708,O
have,2708,O
spread,2708,O
to,2708,O
bones,2708,O
or,2708,O
on,2708,O
Ras-variable,2708,B-GENE-N
tumors,2708,O
.,2708,O
This,2709,O
is,2709,O
the,2709,O
first,2709,O
study,2709,O
to,2709,O
show,2709,O
that,2709,O
the,2709,O
specific,2709,O
molecular,2709,O
pathways,2709,O
of,2709,O
N-BP-induced,2709,B-CHEMICAL
apoptosis,2709,O
.,2709,O
CASK,2710,B-GENE-Y
is,2710,O
a,2710,O
new,2710,O
intracellular,2710,O
modulator,2710,O
of,2710,O
P2X3,2710,B-GENE-Y
receptors,2710,I-GENE-Y
.,2710,O
ATP-gated,2711,B-GENE-Y
P2X3,2711,I-GENE-Y
receptors,2711,I-GENE-Y
of,2711,O
sensory,2711,O
ganglion,2711,O
neurons,2711,O
are,2711,O
important,2711,O
transducers,2711,O
of,2711,O
painful,2711,O
stimuli,2711,O
and,2711,O
are,2711,O
modulated,2711,O
by,2711,O
extracellular,2711,O
algogenic,2711,O
substances,2711,O
",",2711,O
via,2711,O
changes,2711,O
in,2711,O
the,2711,O
receptor,2711,O
phosphorylation,2711,O
state,2711,O
.,2711,O
The,2712,O
present,2712,O
study,2712,O
investigated,2712,O
the,2712,O
role,2712,O
of,2712,O
calcium/calmodulin-dependent,2712,B-GENE-Y
serine,2712,I-GENE-Y
protein,2712,I-GENE-Y
kinase,2712,I-GENE-Y
CASK,2712,B-GENE-Y
in,2712,O
interacting,2712,O
and,2712,O
controlling,2712,O
P2X3,2712,B-GENE-Y
receptor,2712,I-GENE-Y
expression,2712,O
and,2712,O
function,2712,O
in,2712,O
mouse,2712,O
trigeminal,2712,O
ganglia,2712,O
.,2712,O
Most,2713,O
ganglion,2713,O
neurons,2713,O
in,2713,O
situ,2713,O
or,2713,O
in,2713,O
culture,2713,O
co-expressed,2713,O
P2X3,2713,B-GENE-Y
and,2713,O
CASK,2713,B-GENE-Y
.,2713,O
CASK,2714,B-GENE-Y
was,2714,O
immunoprecipitated,2714,O
with,2714,O
P2X3,2714,B-GENE-Y
receptors,2714,O
from,2714,O
trigeminal,2714,O
ganglia,2714,O
and,2714,O
from,2714,O
P2X3/CASK-cotransfected,2714,B-GENE-Y
HEK,2714,O
cells,2714,O
.,2714,O
Recombinant,2715,O
P2X3/CASK,2715,B-GENE-Y
expression,2715,O
in,2715,O
HEK,2715,O
cells,2715,O
increased,2715,O
serine,2715,B-CHEMICAL
phosphorylation,2715,O
of,2715,O
P2X3,2715,B-GENE-Y
receptors,2715,O
",",2715,O
typically,2715,O
associated,2715,O
with,2715,O
receptor,2715,O
upregulation,2715,O
.,2715,O
CASK,2716,B-GENE-Y
deletion,2716,O
mutants,2716,O
also,2716,O
enhanced,2716,O
P2X3,2716,B-GENE-Y
subunit,2716,O
expression,2716,O
.,2716,O
After,2717,O
silencing,2717,O
CASK,2717,B-GENE-Y
",",2717,O
cell,2717,O
surface,2717,O
P2X3,2717,B-GENE-Y
receptor,2717,O
expression,2717,O
was,2717,O
decreased,2717,O
",",2717,O
which,2717,O
is,2717,O
consistent,2717,O
with,2717,O
depressed,2717,O
P2X3,2717,B-GENE-Y
currents,2717,O
.,2717,O
The,2718,O
reduction,2718,O
of,2718,O
P2X3,2718,B-GENE-Y
expression,2718,O
levels,2718,O
was,2718,O
reversed,2718,O
by,2718,O
the,2718,O
proteasomal,2718,O
inhibitor,2718,O
MG-132,2718,B-CHEMICAL
.,2718,O
Moreover,2719,O
",",2719,O
neuronal,2719,O
CASK/P2X3,2719,B-GENE-Y
interaction,2719,O
was,2719,O
upregulated,2719,O
by,2719,O
NGF,2719,B-GENE-Y
signaling,2719,O
and,2719,O
downregulated,2719,O
by,2719,O
P2X3,2719,B-GENE-Y
agonist-induced,2719,O
desensitization,2719,O
.,2719,O
These,2720,O
data,2720,O
suggest,2720,O
a,2720,O
novel,2720,O
interaction,2720,O
between,2720,O
CASK,2720,B-GENE-Y
and,2720,O
P2X3,2720,B-GENE-Y
receptors,2720,O
with,2720,O
positive,2720,O
outcome,2720,O
for,2720,O
receptor,2720,O
stability,2720,O
and,2720,O
function,2720,O
.,2720,O
As,2721,O
CASK-mediated,2721,B-GENE-Y
control,2721,O
of,2721,O
P2X3,2721,B-GENE-Y
receptors,2721,O
was,2721,O
dependent,2721,O
on,2721,O
the,2721,O
receptor,2721,O
activation,2721,O
state,2721,O
",",2721,O
CASK,2721,B-GENE-Y
represents,2721,O
an,2721,O
intracellular,2721,O
gateway,2721,O
to,2721,O
regulate,2721,O
purinergic,2721,O
nociceptive,2721,O
signaling,2721,O
.,2721,O
This,2722,O
article,2722,O
is,2722,O
protected,2722,O
by,2722,O
copyright,2722,O
.,2722,O
All,2723,O
rights,2723,O
reserved,2723,O
.,2723,O
Bile,2724,O
acids,2724,O
induce,2724,O
cdx2,2724,B-GENE-Y
expression,2724,O
through,2724,O
the,2724,O
farnesoid,2724,B-GENE-Y
x,2724,I-GENE-Y
receptor,2724,I-GENE-Y
in,2724,O
gastric,2724,O
epithelial,2724,O
cells,2724,O
.,2724,O
Clinical,2725,O
and,2725,O
experimental,2725,O
studies,2725,O
showed,2725,O
that,2725,O
the,2725,O
reflux,2725,O
of,2725,O
bile,2725,O
into,2725,O
the,2725,O
stomach,2725,O
contributes,2725,O
to,2725,O
the,2725,O
induction,2725,O
of,2725,O
intestinal,2725,O
metaplasia,2725,O
of,2725,O
the,2725,O
stomach,2725,O
and,2725,O
gastric,2725,O
carcinogenesis,2725,O
.,2725,O
Caudal-type,2726,B-GENE-Y
homeobox,2726,I-GENE-Y
2,2726,I-GENE-Y
(,2726,O
Cdx2,2726,B-GENE-Y
),2726,O
plays,2726,O
a,2726,O
key,2726,O
role,2726,O
in,2726,O
the,2726,O
exhibition,2726,O
of,2726,O
intestinal,2726,O
phenotypes,2726,O
by,2726,O
regulating,2726,O
the,2726,O
expression,2726,O
of,2726,O
intestine-specific,2726,O
genes,2726,O
such,2726,O
as,2726,O
goblet-specific,2726,O
gene,2726,O
mucin,2726,B-GENE-Y
2,2726,I-GENE-Y
(,2726,O
MUC2,2726,B-GENE-Y
),2726,O
.,2726,O
We,2727,O
investigated,2727,O
the,2727,O
involvement,2727,O
of,2727,O
the,2727,O
farnesoid,2727,B-GENE-Y
X,2727,I-GENE-Y
receptor,2727,I-GENE-Y
(,2727,O
FXR,2727,B-GENE-Y
),2727,O
",",2727,O
a,2727,O
nuclear,2727,B-GENE-N
receptor,2727,I-GENE-N
for,2727,O
bile,2727,O
acids,2727,O
",",2727,O
in,2727,O
the,2727,O
chenodeoxycholic,2727,B-CHEMICAL
acid,2727,I-CHEMICAL
(,2727,O
CDCA,2727,B-CHEMICAL
),2727,O
-induced,2727,O
expression,2727,O
of,2727,O
Cdx2,2727,B-GENE-Y
and,2727,O
MUC2,2727,B-GENE-Y
in,2727,O
normal,2727,O
rat,2727,O
gastric,2727,O
epithelial,2727,O
cells,2727,O
(,2727,O
RGM-1,2727,O
cells,2727,O
),2727,O
.,2727,O
RGM-1,2728,O
cells,2728,O
were,2728,O
treated,2728,O
with,2728,O
CDCA,2728,B-CHEMICAL
or,2728,O
GW4064,2728,B-CHEMICAL
",",2728,O
an,2728,O
FXR,2728,B-GENE-Y
agonist,2728,O
",",2728,O
in,2728,O
the,2728,O
presence,2728,O
or,2728,O
absence,2728,O
of,2728,O
guggulsterone,2728,B-CHEMICAL
",",2728,O
an,2728,O
FXR,2728,B-GENE-Y
antagonist,2728,O
.,2728,O
CDCA,2729,B-CHEMICAL
induced,2729,O
dose-dependent,2729,O
expression,2729,O
of,2729,O
Cdx2,2729,B-GENE-Y
and,2729,O
MUC2,2729,B-GENE-Y
at,2729,O
both,2729,O
the,2729,O
mRNA,2729,O
and,2729,O
protein,2729,O
levels,2729,O
.,2729,O
The,2730,O
maximum,2730,O
stimulation,2730,O
of,2730,O
Cdx2,2730,B-GENE-Y
and,2730,O
MUC2,2730,B-GENE-Y
mRNA,2730,O
induced,2730,O
by,2730,O
CDCA,2730,B-CHEMICAL
was,2730,O
observed,2730,O
at,2730,O
3,2730,O
h,2730,O
and,2730,O
by,2730,O
6,2730,O
h,2730,O
",",2730,O
respectively,2730,O
.,2730,O
GW4064,2731,B-CHEMICAL
also,2731,O
induced,2731,O
expression,2731,O
of,2731,O
these,2731,O
molecules,2731,O
.,2731,O
The,2732,O
effects,2732,O
of,2732,O
CDCA,2732,B-CHEMICAL
and,2732,O
GW4064,2732,B-CHEMICAL
on,2732,O
expression,2732,O
of,2732,O
Cdx2,2732,B-GENE-Y
and,2732,O
MUC2,2732,B-GENE-Y
were,2732,O
abolished,2732,O
by,2732,O
guggulsterone,2732,B-CHEMICAL
.,2732,O
These,2733,O
findings,2733,O
suggest,2733,O
that,2733,O
bile,2733,O
acids,2733,O
may,2733,O
induce,2733,O
gastric,2733,O
intestinal,2733,O
metaplasia,2733,O
and,2733,O
carcinogenesis,2733,O
through,2733,O
the,2733,O
FXR,2733,B-GENE-Y
.,2733,O
Mazindol,2734,B-CHEMICAL
analogues,2734,O
as,2734,O
potential,2734,O
inhibitors,2734,O
of,2734,O
the,2734,O
cocaine,2734,B-GENE-N
binding,2734,I-GENE-N
site,2734,I-GENE-N
at,2734,O
the,2734,O
dopamine,2734,B-GENE-Y
transporter,2734,I-GENE-Y
.,2734,O
A,2735,O
series,2735,O
of,2735,O
mazindol,2735,B-CHEMICAL
(,2735,O
2,2735,O
),2735,O
and,2735,O
homomazindol,2735,B-CHEMICAL
(,2735,O
3,2735,O
),2735,O
analogues,2735,O
with,2735,O
a,2735,O
variety,2735,O
of,2735,O
electron-donating,2735,O
and,2735,O
electron-withdrawing,2735,O
groups,2735,O
in,2735,O
the,2735,O
pendant,2735,O
aryl,2735,B-CHEMICAL
group,2735,O
and,2735,O
the,2735,O
benzo,2735,B-CHEMICAL
ring,2735,O
C,2735,O
",",2735,O
as,2735,O
well,2735,O
as,2735,O
H,2735,O
",",2735,O
methoxy,2735,B-CHEMICAL
",",2735,O
and,2735,O
alkyl,2735,B-CHEMICAL
groups,2735,O
replacing,2735,O
the,2735,O
hydroxyl,2735,B-CHEMICAL
group,2735,O
were,2735,O
synthesized,2735,O
",",2735,O
and,2735,O
their,2735,O
binding,2735,O
affinities,2735,O
at,2735,O
the,2735,O
dopamine,2735,B-GENE-N
transporter,2735,I-GENE-N
(,2735,O
DAT,2735,B-GENE-N
),2735,O
on,2735,O
rat,2735,O
or,2735,O
guinea,2735,O
pig,2735,O
striatal,2735,O
membranes,2735,O
were,2735,O
determined,2735,O
.,2735,O
Several,2736,O
active,2736,O
analogues,2736,O
were,2736,O
also,2736,O
evaluated,2736,O
for,2736,O
their,2736,O
ability,2736,O
to,2736,O
block,2736,O
uptake,2736,O
of,2736,O
DA,2736,B-CHEMICAL
",",2736,O
5-HT,2736,B-CHEMICAL
",",2736,O
and,2736,O
NE,2736,B-CHEMICAL
and,2736,O
inhibit,2736,O
binding,2736,O
of,2736,O
[,2736,B-CHEMICAL
(,2736,I-CHEMICAL
125,2736,I-CHEMICAL
),2736,I-CHEMICAL
I,2736,I-CHEMICAL
],2736,I-CHEMICAL
RTI-55,2736,I-CHEMICAL
at,2736,O
HEK-hDAT,2736,O
",",2736,O
HEK-hSERT,2736,O
",",2736,O
and,2736,O
HEK-hNET,2736,O
cells,2736,O
.,2736,O
Mazindane,2737,B-CHEMICAL
(,2737,O
26,2737,O
),2737,O
was,2737,O
found,2737,O
to,2737,O
be,2737,O
a,2737,O
pro-drug,2737,O
",",2737,O
oxidizing,2737,O
(,2737,O
5-H,2737,B-CHEMICAL
--,2737,O
>,2737,O
5-OH,2737,B-CHEMICAL
),2737,O
to,2737,O
mazindol,2737,B-CHEMICAL
on,2737,O
rat,2737,O
striatal,2737,O
membranes,2737,O
and,2737,O
HEK-hDAT,2737,O
cells,2737,O
.,2737,O
The,2738,O
"4',7,8-trichloro",2738,B-CHEMICAL
analogue,2738,O
(,2738,O
38,2738,O
),2738,O
of,2738,O
mazindol,2738,B-CHEMICAL
was,2738,O
the,2738,O
most,2738,O
potent,2738,O
and,2738,O
selective,2738,O
ligand,2738,O
for,2738,O
HEK-hDAT,2738,O
cells,2738,O
(,2738,O
DAT,2738,B-GENE-Y
K,2738,O
(,2738,O
i,2738,O
),2738,O
=,2738,O
1.1,2738,O
nM,2738,O
;,2738,O
SERT/DAT,2738,B-GENE-Y
=,2738,O
1283,2738,O
and,2738,O
NET/DAT,2738,B-GENE-Y
=,2738,O
38,2738,O
),2738,O
.,2738,O
Experimental,2739,O
results,2739,O
strongly,2739,O
favor,2739,O
the,2739,O
cyclic,2739,O
or,2739,O
ol,2739,O
tautomers,2739,O
of,2739,O
2,2739,O
and,2739,O
3,2739,O
to,2739,O
bind,2739,O
more,2739,O
tightly,2739,O
at,2739,O
the,2739,O
DAT,2739,B-GENE-Y
than,2739,O
the,2739,O
corresponding,2739,O
keto,2739,O
tautomers,2739,O
.,2739,O
Herbicidal,2740,O
inhibitors,2740,O
of,2740,O
amino,2740,B-CHEMICAL
acid,2740,I-CHEMICAL
biosynthesis,2740,O
and,2740,O
herbicide-tolerant,2740,O
crops,2740,O
.,2740,O
Acetohydroxyacid,2741,B-GENE-N
synthase,2741,I-GENE-N
(,2741,O
AHAS,2741,B-GENE-N
),2741,O
inhibitors,2741,O
interfere,2741,O
with,2741,O
branched-chain,2741,B-CHEMICAL
amino,2741,I-CHEMICAL
acid,2741,I-CHEMICAL
biosynthesis,2741,O
by,2741,O
inhibiting,2741,O
AHAS,2741,B-GENE-N
.,2741,O
Glyphosate,2742,B-CHEMICAL
affects,2742,O
aromatic,2742,B-CHEMICAL
amino,2742,I-CHEMICAL
acid,2742,I-CHEMICAL
biosynthesis,2742,O
by,2742,O
inhibiting,2742,O
5-enolpyruvylshikimate-3-phosphate,2742,B-GENE-N
synthase,2742,I-GENE-N
(,2742,O
EPSPS,2742,B-GENE-N
),2742,O
.,2742,O
Glufosinate,2743,B-CHEMICAL
inhibits,2743,O
glutamine,2743,B-GENE-N
synthetase,2743,I-GENE-N
and,2743,O
blocks,2743,O
biosynthesis,2743,O
of,2743,O
glutamine,2743,B-CHEMICAL
.,2743,O
AHAS,2744,B-GENE-N
gene,2744,O
variants,2744,O
that,2744,O
confer,2744,O
tolerance,2744,O
to,2744,O
AHAS,2744,B-GENE-N
inhibitors,2744,O
have,2744,O
been,2744,O
discovered,2744,O
in,2744,O
plants,2744,O
through,2744,O
selection,2744,O
or,2744,O
mutagenesis,2744,O
.,2744,O
Imidazolinone-tolerant,2745,B-CHEMICAL
crops,2745,O
have,2745,O
been,2745,O
commercialized,2745,O
based,2745,O
on,2745,O
these,2745,O
AHAS,2745,B-GENE-N
gene,2745,O
variants,2745,O
.,2745,O
A,2746,O
modified,2746,O
maize,2746,B-GENE-Y
EPSPS,2746,I-GENE-Y
gene,2746,O
and,2746,O
CP4-EPSPS,2746,O
gene,2746,O
from,2746,O
Agrobacterium,2746,O
sp,2746,O
.,2746,O
have,2747,O
been,2747,O
used,2747,O
to,2747,O
transform,2747,O
plants,2747,O
for,2747,O
target-based,2747,O
tolerance,2747,O
to,2747,O
glyphosate,2747,B-CHEMICAL
.,2747,O
A,2748,O
gox,2748,B-GENE-N
gene,2748,O
isolated,2748,O
from,2748,O
Ochrobactrum,2748,O
anthropi,2748,O
has,2748,O
also,2748,O
been,2748,O
employed,2748,O
to,2748,O
encode,2748,O
glyphosate,2748,B-GENE-N
oxidoreductase,2748,I-GENE-N
to,2748,O
detoxify,2748,O
glyphosate,2748,B-CHEMICAL
in,2748,O
plants,2748,O
.,2748,O
Glyphosate-tolerant,2749,B-CHEMICAL
crops,2749,O
with,2749,O
EPSPS,2749,B-GENE-N
transgene,2749,O
alone,2749,O
or,2749,O
both,2749,O
EPSPS,2749,B-GENE-N
and,2749,O
gox,2749,B-GENE-N
transgenes,2749,O
have,2749,O
been,2749,O
commercialized,2749,O
.,2749,O
Similarly,2750,O
",",2750,O
bar,2750,B-GENE-Y
and,2750,O
pat,2750,B-GENE-Y
genes,2750,O
isolated,2750,O
from,2750,O
Streptomyces,2750,O
hygroscopicus,2750,O
and,2750,O
S.,2750,O
viridochromogenes,2750,O
",",2750,O
respectively,2750,O
",",2750,O
have,2750,O
been,2750,O
inserted,2750,O
into,2750,O
plants,2750,O
to,2750,O
encode,2750,O
phosphinothricin,2750,B-GENE-N
N-acetyltransferase,2750,I-GENE-N
to,2750,O
detoxify,2750,O
glufosinate,2750,B-CHEMICAL
.,2750,O
Glufosinate-tolerant,2751,B-CHEMICAL
crops,2751,O
have,2751,O
been,2751,O
commercialized,2751,O
using,2751,O
one,2751,O
of,2751,O
these,2751,O
two,2751,O
transgenes,2751,O
.,2751,O
Mechanisms,2752,O
of,2752,O
Glucose,2752,B-CHEMICAL
Lowering,2752,O
of,2752,O
Dipeptidyl,2752,B-GENE-Y
Peptidase-4,2752,I-GENE-Y
Inhibitor,2752,O
Sitagliptin,2752,B-CHEMICAL
When,2752,O
Used,2752,O
Alone,2752,O
or,2752,O
With,2752,O
Metformin,2752,B-CHEMICAL
in,2752,O
Type,2752,O
2,2752,O
Diabetes,2752,O
:,2752,O
A,2752,O
double-tracer,2752,O
study,2752,O
.,2752,O
OBJECTIVETo,2753,O
assess,2753,O
glucose-lowering,2753,B-CHEMICAL
mechanisms,2753,O
of,2753,O
sitagliptin,2753,B-CHEMICAL
(,2753,O
S,2753,O
),2753,O
",",2753,O
metformin,2753,B-CHEMICAL
(,2753,O
M,2753,O
),2753,O
",",2753,O
and,2753,O
the,2753,O
two,2753,O
combined,2753,O
(,2753,O
M+S,2753,O
),2753,O
.RESEARCH,2753,O
DESIGN,2753,O
AND,2753,O
METHODSWe,2753,O
randomized,2753,O
16,2753,O
patients,2753,O
with,2753,O
type,2753,O
2,2753,O
diabetes,2753,O
mellitus,2753,O
(,2753,O
T2DM,2753,O
),2753,O
to,2753,O
four,2753,O
6-week,2753,O
treatments,2753,O
with,2753,O
placebo,2753,O
(,2753,O
P,2753,O
),2753,O
",",2753,O
M,2753,O
",",2753,O
S,2753,O
",",2753,O
and,2753,O
M+S,2753,O
.,2753,O
After,2754,O
each,2754,O
period,2754,O
",",2754,O
subjects,2754,O
received,2754,O
a,2754,O
6-h,2754,O
meal,2754,O
tolerance,2754,O
test,2754,O
(,2754,O
MTT,2754,B-CHEMICAL
),2754,O
with,2754,O
[,2754,B-CHEMICAL
(,2754,I-CHEMICAL
14,2754,I-CHEMICAL
),2754,I-CHEMICAL
C,2754,I-CHEMICAL
],2754,I-CHEMICAL
glucose,2754,I-CHEMICAL
to,2754,O
calculate,2754,O
glucose,2754,B-CHEMICAL
kinetics,2754,O
.,2754,O
Fasting,2755,O
plasma,2755,O
glucose,2755,B-CHEMICAL
(,2755,O
FPG,2755,O
),2755,O
",",2755,O
fasting,2755,O
plasma,2755,O
insulin,2755,B-GENE-Y
",",2755,O
C-peptide,2755,B-GENE-Y
(,2755,O
insulin,2755,B-GENE-Y
secretory,2755,O
rate,2755,O
[,2755,O
ISR,2755,O
],2755,O
),2755,O
",",2755,O
fasting,2755,O
plasma,2755,O
glucagon,2755,B-GENE-Y
",",2755,O
and,2755,O
bioactive,2755,O
glucagon-like,2755,B-GENE-Y
peptide,2755,I-GENE-Y
(,2755,O
GLP-1,2755,B-GENE-Y
),2755,O
and,2755,O
gastrointestinal,2755,B-GENE-Y
insulinotropic,2755,I-GENE-Y
peptide,2755,I-GENE-Y
(,2755,O
GIP,2755,B-GENE-Y
),2755,O
was,2755,O
measured.RESULTSFPG,2755,O
decreased,2755,O
from,2755,O
P,2755,O
",",2755,O
160,2755,O
±,2755,O
4,2755,O
to,2755,O
M,2755,O
",",2755,O
150,2755,O
±,2755,O
4,2755,O
;,2755,O
S,2755,O
",",2755,O
154,2755,O
±,2755,O
4,2755,O
;,2755,O
and,2755,O
M+S,2755,O
",",2755,O
125,2755,O
±,2755,O
3,2755,O
mg/dL,2755,O
.,2755,O
Mean,2756,O
post-MTT,2756,O
PG,2756,O
decreased,2756,O
from,2756,O
P,2756,O
",",2756,O
207,2756,O
±,2756,O
5,2756,O
to,2756,O
M,2756,O
",",2756,O
191,2756,O
±,2756,O
4,2756,O
;,2756,O
S,2756,O
",",2756,O
195,2756,O
±,2756,O
4,2756,O
;,2756,O
and,2756,O
M+S,2756,O
",",2756,O
161,2756,O
±,2756,O
3,2756,O
mg/dL,2756,O
(,2756,O
P,2756,O
<,2756,O
0.01,2756,O
],2756,O
.,2756,O
The,2757,O
increase,2757,O
in,2757,O
mean,2757,O
post-MTT,2757,O
plasma,2757,O
insulin,2757,B-GENE-Y
and,2757,O
in,2757,O
ISR,2757,O
was,2757,O
similar,2757,O
in,2757,O
P,2757,O
",",2757,O
M,2757,O
",",2757,O
and,2757,O
S,2757,O
and,2757,O
slightly,2757,O
greater,2757,O
in,2757,O
M+S,2757,O
.,2757,O
Fasting,2758,O
plasma,2758,O
glucagon,2758,B-GENE-Y
was,2758,O
equal,2758,O
(,2758,O
∼65-75,2758,O
pg/mL,2758,O
),2758,O
with,2758,O
all,2758,O
treatments,2758,O
",",2758,O
but,2758,O
there,2758,O
was,2758,O
a,2758,O
significant,2758,O
drop,2758,O
during,2758,O
the,2758,O
initial,2758,O
120,2758,O
min,2758,O
with,2758,O
S,2758,O
24,2758,O
%,2758,O
and,2758,O
M+S,2758,O
34,2758,O
%,2758,O
(,2758,O
both,2758,O
P,2758,O
<,2758,O
0.05,2758,O
),2758,O
vs.,2758,O
P,2758,O
17,2758,O
%,2758,O
and,2758,O
M,2758,O
16,2758,O
%,2758,O
.,2758,O
Fasting,2759,O
and,2759,O
mean,2759,O
post-MTT,2759,O
plasma,2759,O
bioactive,2759,O
GLP-1,2759,B-GENE-Y
were,2759,O
higher,2759,O
(,2759,O
P,2759,O
<,2759,O
0.01,2759,O
),2759,O
after,2759,O
S,2759,O
and,2759,O
M+S,2759,O
vs.,2759,O
M,2759,O
and,2759,O
P.,2759,O
Basal,2759,O
endogenous,2759,O
glucose,2759,B-CHEMICAL
production,2759,O
(,2759,O
EGP,2759,O
),2759,O
fell,2759,O
from,2759,O
P,2759,O
2.0,2759,O
±,2759,O
0.1,2759,O
to,2759,O
S,2759,O
1.8,2759,O
±,2759,O
0.1,2759,O
mg/kg,2759,O
⋅,2759,O
min,2759,O
",",2759,O
M,2759,O
1.8,2759,O
±,2759,O
0.2,2759,O
mg/kg,2759,O
⋅,2759,O
min,2759,O
[,2759,O
both,2759,O
P,2759,O
<,2759,O
0.05,2759,O
vs.,2759,O
P,2759,O
),2759,O
",",2759,O
and,2759,O
M+S,2759,O
1.5,2759,O
±,2759,O
0.1,2759,O
mg/kg,2759,O
⋅,2759,O
min,2759,O
(,2759,O
P,2759,O
<,2759,O
0.01,2759,O
vs.,2759,O
P,2759,O
),2759,O
.,2759,O
Although,2760,O
the,2760,O
EGP,2760,O
slope,2760,O
of,2760,O
decline,2760,O
was,2760,O
faster,2760,O
in,2760,O
M,2760,O
and,2760,O
M+S,2760,O
vs.,2760,O
S,2760,O
",",2760,O
all,2760,O
had,2760,O
comparable,2760,O
greater,2760,O
post-MTT,2760,O
EGP,2760,O
inhibition,2760,O
vs.,2760,O
P,2760,O
(,2760,O
P,2760,O
<,2760,O
0.05,2760,O
),2760,O
.CONCLUSIONSM+S,2760,O
combined,2760,O
produce,2760,O
additive,2760,O
effects,2760,O
to,2760,O
1,2760,O
),2760,O
reduce,2760,O
FPG,2760,O
and,2760,O
postmeal,2760,O
PG,2760,O
",",2760,O
2,2760,O
),2760,O
augment,2760,O
GLP-1,2760,B-GENE-Y
secretion,2760,O
and,2760,O
β-cell,2760,O
function,2760,O
",",2760,O
3,2760,O
),2760,O
decrease,2760,O
plasma,2760,O
glucagon,2760,B-GENE-Y
",",2760,O
and,2760,O
4,2760,O
),2760,O
inhibit,2760,O
fasting,2760,O
and,2760,O
postmeal,2760,O
EGP,2760,O
compared,2760,O
with,2760,O
M,2760,O
or,2760,O
S,2760,O
monotherapy,2760,O
.,2760,O
Modulation,2761,O
of,2761,O
cytochrome,2761,B-GENE-N
P450,2761,I-GENE-N
1,2761,I-GENE-N
(,2761,O
Cyp1,2761,B-GENE-N
),2761,O
by,2761,O
vanadium,2761,B-CHEMICAL
in,2761,O
hepatic,2761,O
tissue,2761,O
and,2761,O
isolated,2761,O
hepatocyte,2761,O
of,2761,O
C57BL/6,2761,O
mice,2761,O
.,2761,O
The,2762,O
objective,2762,O
of,2762,O
the,2762,O
current,2762,O
study,2762,O
was,2762,O
to,2762,O
investigate,2762,O
the,2762,O
effect,2762,O
of,2762,O
vanadium,2762,B-CHEMICAL
(,2762,O
V,2762,B-CHEMICAL
(,2762,I-CHEMICAL
5+,2762,I-CHEMICAL
),2762,I-CHEMICAL
),2762,O
on,2762,O
Cyp1,2762,B-GENE-N
expression,2762,O
and,2762,O
activity,2762,O
in,2762,O
C57BL/6,2762,O
mice,2762,O
liver,2762,O
and,2762,O
isolated,2762,O
hepatocytes,2762,O
.,2762,O
For,2763,O
this,2763,O
purpose,2763,O
",",2763,O
C57BL6,2763,O
mice,2763,O
were,2763,O
injected,2763,O
intraperitoneally,2763,O
with,2763,O
V,2763,B-CHEMICAL
(,2763,I-CHEMICAL
5+,2763,I-CHEMICAL
),2763,I-CHEMICAL
(,2763,O
5,2763,O
mg/kg,2763,O
),2763,O
in,2763,O
the,2763,O
absence,2763,O
and,2763,O
presence,2763,O
of,2763,O
"2,3,7,8-tetrachlorodibenzo-p-dioxin",2763,B-CHEMICAL
(,2763,O
TCDD,2763,B-CHEMICAL
),2763,O
(,2763,O
15,2763,O
μg/kg,2763,O
),2763,O
for,2763,O
6,2763,O
and,2763,O
24,2763,O
h.,2763,O
Furthermore,2763,O
",",2763,O
isolated,2763,O
hepatocytes,2763,O
from,2763,O
C57BL6,2763,O
mice,2763,O
were,2763,O
treated,2763,O
with,2763,O
V,2763,B-CHEMICAL
(,2763,I-CHEMICAL
5+,2763,I-CHEMICAL
),2763,I-CHEMICAL
(,2763,O
5,2763,O
",",2763,O
10,2763,O
",",2763,O
and,2763,O
20,2763,O
μM,2763,O
),2763,O
in,2763,O
the,2763,O
absence,2763,O
and,2763,O
presence,2763,O
of,2763,O
TCDD,2763,B-CHEMICAL
(,2763,O
1,2763,O
nM,2763,O
),2763,O
for,2763,O
3,2763,O
",",2763,O
6,2763,O
",",2763,O
12,2763,O
",",2763,O
and,2763,O
24,2763,O
h.,2763,O
In,2763,O
vivo,2763,O
",",2763,O
V,2763,B-CHEMICAL
(,2763,I-CHEMICAL
5+,2763,I-CHEMICAL
),2763,I-CHEMICAL
alone,2763,O
did,2763,O
not,2763,O
significantly,2763,O
alter,2763,O
Cyp1a1,2763,B-GENE-Y
",",2763,O
Cyp1a2,2763,B-GENE-Y
",",2763,O
or,2763,O
Cyp1b1,2763,B-GENE-Y
mRNA,2763,O
",",2763,O
protein,2763,O
",",2763,O
or,2763,O
catalytic,2763,O
activity,2763,O
levels,2763,O
.,2763,O
Upon,2764,O
co-exposure,2764,O
to,2764,O
V,2764,B-CHEMICAL
(,2764,I-CHEMICAL
5+,2764,I-CHEMICAL
),2764,I-CHEMICAL
and,2764,O
TCDD,2764,B-CHEMICAL
",",2764,O
V,2764,B-CHEMICAL
(,2764,I-CHEMICAL
5+,2764,I-CHEMICAL
),2764,I-CHEMICAL
significantly,2764,O
potentiated,2764,O
the,2764,O
TCDD-mediated,2764,B-CHEMICAL
induction,2764,O
of,2764,O
the,2764,O
Cyp1a1,2764,B-GENE-Y
",",2764,O
Cyp1a2,2764,B-GENE-Y
",",2764,O
and,2764,O
Cyp1b1,2764,B-GENE-Y
mRNA,2764,O
",",2764,O
protein,2764,O
",",2764,O
and,2764,O
catalytic,2764,O
activity,2764,O
levels,2764,O
at,2764,O
24,2764,O
h.,2764,O
In,2764,O
vitro,2764,O
",",2764,O
V,2764,B-CHEMICAL
(,2764,I-CHEMICAL
5+,2764,I-CHEMICAL
),2764,I-CHEMICAL
decreased,2764,O
the,2764,O
TCDD-mediated,2764,B-CHEMICAL
induction,2764,O
of,2764,O
Cyp1a1,2764,B-GENE-Y
mRNA,2764,O
",",2764,O
protein,2764,O
",",2764,O
and,2764,O
catalytic,2764,O
activity,2764,O
levels,2764,O
.,2764,O
Furthermore,2765,O
",",2765,O
V,2765,B-CHEMICAL
(,2765,I-CHEMICAL
5+,2765,I-CHEMICAL
),2765,I-CHEMICAL
significantly,2765,O
inhibited,2765,O
the,2765,O
TCDD-induced,2765,B-CHEMICAL
AhR-dependent,2765,B-GENE-Y
luciferase,2765,O
activity,2765,O
.,2765,O
V,2766,B-CHEMICAL
(,2766,I-CHEMICAL
5+,2766,I-CHEMICAL
),2766,I-CHEMICAL
also,2766,O
increased,2766,O
serum,2766,B-GENE-N
hemoglobin,2766,I-GENE-N
(,2766,O
Hb,2766,B-GENE-N
),2766,O
levels,2766,O
in,2766,O
animals,2766,O
treated,2766,O
for,2766,O
24,2766,O
h.,2766,O
Upon,2766,O
treatment,2766,O
of,2766,O
isolated,2766,O
hepatocytes,2766,O
with,2766,O
Hb,2766,B-GENE-N
alone,2766,O
or,2766,O
in,2766,O
the,2766,O
presence,2766,O
of,2766,O
TCDD,2766,B-CHEMICAL
",",2766,O
there,2766,O
was,2766,O
an,2766,O
increase,2766,O
in,2766,O
the,2766,O
AhR-dependent,2766,B-GENE-Y
luciferase,2766,O
activity,2766,O
.,2766,O
When,2767,O
isolated,2767,O
hepatocytes,2767,O
were,2767,O
treated,2767,O
for,2767,O
2,2767,O
h,2767,O
with,2767,O
V,2767,B-CHEMICAL
(,2767,I-CHEMICAL
5+,2767,I-CHEMICAL
),2767,I-CHEMICAL
in,2767,O
the,2767,O
presence,2767,O
of,2767,O
TCDD,2767,B-CHEMICAL
",",2767,O
followed,2767,O
by,2767,O
replacement,2767,O
of,2767,O
the,2767,O
medium,2767,O
with,2767,O
new,2767,O
medium,2767,O
containing,2767,O
Hb,2767,B-GENE-N
",",2767,O
there,2767,O
was,2767,O
further,2767,O
potentiation,2767,O
to,2767,O
the,2767,O
TCDD-mediated,2767,B-CHEMICAL
effect,2767,O
.,2767,O
The,2768,O
present,2768,O
study,2768,O
demonstrates,2768,O
that,2768,O
there,2768,O
is,2768,O
a,2768,O
differential,2768,O
modulation,2768,O
of,2768,O
Cyp1a1,2768,B-GENE-Y
by,2768,O
V,2768,B-CHEMICAL
(,2768,I-CHEMICAL
5+,2768,I-CHEMICAL
),2768,I-CHEMICAL
in,2768,O
C57BL/6,2768,O
mice,2768,O
livers,2768,O
and,2768,O
isolated,2768,O
hepatocytes,2768,O
and,2768,O
demonstrates,2768,O
Hb,2768,B-GENE-N
as,2768,O
an,2768,O
in,2768,O
vivo,2768,O
specific,2768,O
modulator,2768,O
.,2768,O
Glucocorticosteroids,2769,O
affect,2769,O
functions,2769,O
of,2769,O
airway-,2769,O
and,2769,O
blood-derived,2769,O
human,2769,O
T-cell,2769,O
clones,2769,O
",",2769,O
favoring,2769,O
the,2769,O
Th1,2769,O
profile,2769,O
through,2769,O
two,2769,O
mechanisms,2769,O
.,2769,O
Glucocorticosteroids,2770,O
(,2770,O
GCS,2770,B-CHEMICAL
),2770,O
are,2770,O
beneficial,2770,O
in,2770,O
allergic,2770,O
asthma,2770,O
.,2770,O
GCS,2771,B-CHEMICAL
therapy,2771,O
results,2771,O
in,2771,O
reduced,2771,O
mRNA,2771,O
expression,2771,O
of,2771,O
interleukin-4,2771,B-GENE-Y
(,2771,O
IL-4,2771,B-GENE-Y
),2771,O
and,2771,O
IL-5,2771,B-GENE-Y
in,2771,O
cells,2771,O
from,2771,O
bronchoalveolar,2771,O
lavage,2771,O
(,2771,O
BAL,2771,O
),2771,O
but,2771,O
not,2771,O
of,2771,O
IFN-gamma,2771,B-GENE-Y
.,2771,O
In,2772,O
vitro,2772,O
studies,2772,O
with,2772,O
blood-derived,2772,O
T,2772,O
cells,2772,O
",",2772,O
however,2772,O
",",2772,O
show,2772,O
inhibition,2772,O
of,2772,O
all,2772,O
three,2772,O
cytokines,2772,B-GENE-N
by,2772,O
GCS,2772,B-CHEMICAL
.,2772,O
We,2773,O
studied,2773,O
the,2773,O
effects,2773,O
of,2773,O
GCS,2773,B-CHEMICAL
on,2773,O
T,2773,O
cells,2773,O
from,2773,O
BAL,2773,O
in,2773,O
vitro,2773,O
",",2773,O
namely,2773,O
Th0-,2773,O
",",2773,O
Th1,2773,O
",",2773,O
and,2773,O
Th2-like,2773,O
clones,2773,O
;,2773,O
and,2773,O
we,2773,O
compared,2773,O
BAL-,2773,O
with,2773,O
blood-derived,2773,O
clones,2773,O
.,2773,O
Dexamethasone,2774,B-CHEMICAL
(,2774,O
DEX,2774,B-CHEMICAL
),2774,O
inhibited,2774,O
the,2774,O
anti-CD3-induced,2774,O
production,2774,O
of,2774,O
IL-4,2774,B-GENE-Y
",",2774,O
IL-5,2774,B-GENE-Y
and,2774,O
IFN-gamma,2774,B-GENE-Y
in,2774,O
all,2774,O
20,2774,O
clones,2774,O
tested,2774,O
.,2774,O
IFN-gamma,2775,B-GENE-Y
production,2775,O
was,2775,O
inhibited,2775,O
significantly,2775,O
less,2775,O
than,2775,O
IL-4,2775,B-GENE-Y
and,2775,O
IL-5,2775,B-GENE-Y
.,2775,O
DEX,2776,B-CHEMICAL
enhanced,2776,O
the,2776,O
ratio,2776,O
IFN-gamma/IL-4,2776,B-GENE-Y
(,2776,O
mean,2776,O
+/-,2776,O
SEM,2776,O
:,2776,O
control,2776,O
",",2776,O
28.7,2776,O
+/-,2776,O
17.6,2776,O
;,2776,O
with,2776,O
10-7,2776,O
M,2776,O
DEX,2776,O
",",2776,O
55.0,2776,O
+/-,2776,O
27.5,2776,O
",",2776,O
P,2776,O
<,2776,O
0.005,2776,O
),2776,O
.,2776,O
Interestingly,2777,O
",",2777,O
two,2777,O
categories,2777,O
of,2777,O
clones,2777,O
were,2777,O
distinguished,2777,O
based,2777,O
on,2777,O
the,2777,O
effects,2777,O
of,2777,O
GCS,2777,B-CHEMICAL
on,2777,O
IL-2,2777,B-GENE-Y
production,2777,O
and,2777,O
IL-2R,2777,B-GENE-Y
alpha,2777,I-GENE-Y
expression,2777,O
and,2777,O
proliferation,2777,O
;,2777,O
1,2777,O
),2777,O
In,2777,O
low,2777,O
IL-2,2777,B-GENE-Y
producers,2777,O
DEX,2777,B-CHEMICAL
blocked,2777,O
IL-2,2777,B-GENE-Y
production,2777,O
and,2777,O
decreased,2777,O
IL-2R,2777,B-GENE-Y
alpha,2777,I-GENE-Y
expression,2777,O
and,2777,O
proliferation,2777,O
;,2777,O
2,2777,O
),2777,O
In,2777,O
high,2777,O
IL-2,2777,B-GENE-Y
producers,2777,O
DEX,2777,B-CHEMICAL
inhibited,2777,O
IL-2,2777,B-GENE-Y
production,2777,O
partially,2777,O
and,2777,O
enhanced,2777,O
IL-2R,2777,B-GENE-Y
alpha,2777,I-GENE-Y
expression,2777,O
and,2777,O
proliferation,2777,O
.,2777,O
Anti-IL-2,2778,O
and,2778,O
anti-IL2R,2778,O
alpha,2778,I-GENE-Y
blocked,2778,O
the,2778,O
DEX-induced,2778,B-CHEMICAL
increase,2778,O
in,2778,O
proliferation,2778,O
.,2778,O
High,2779,O
levels,2779,O
of,2779,O
added,2779,O
IL-2,2779,B-GENE-Y
induced,2779,O
the,2779,O
second,2779,O
type,2779,O
of,2779,O
response,2779,O
.,2779,O
In,2780,O
conclusion,2780,O
",",2780,O
the,2780,O
production,2780,O
of,2780,O
IL-4,2780,B-GENE-Y
and,2780,O
IL-5,2780,B-GENE-Y
by,2780,O
T-cell,2780,O
clones,2780,O
(,2780,O
derived,2780,O
either,2780,O
from,2780,O
BAL,2780,O
or,2780,O
blood,2780,O
),2780,O
was,2780,O
more,2780,O
sensitive,2780,O
to,2780,O
inhibition,2780,O
by,2780,O
DEX,2780,B-CHEMICAL
than,2780,O
that,2780,O
of,2780,O
IFN-gamma,2780,B-GENE-Y
",",2780,O
which,2780,O
may,2780,O
account,2780,O
for,2780,O
the,2780,O
therapeutic,2780,O
effects,2780,O
of,2780,O
glucocorticosteroids,2780,O
in,2780,O
patients,2780,O
with,2780,O
asthma,2780,O
.,2780,O
The,2781,O
differential,2781,O
effects,2781,O
of,2781,O
DEX,2781,B-CHEMICAL
on,2781,O
the,2781,O
proliferation,2781,O
of,2781,O
high,2781,O
and,2781,O
low,2781,O
IL-2,2781,B-GENE-Y
producers,2781,O
in,2781,O
vitro,2781,O
may,2781,O
implicate,2781,O
a,2781,O
selective,2781,O
outgrowth,2781,O
of,2781,O
Th1-like,2781,O
T,2781,O
cells,2781,O
in,2781,O
vivo,2781,O
in,2781,O
patients,2781,O
treated,2781,O
with,2781,O
steroids,2781,B-CHEMICAL
.,2781,O
Pregnane,2782,B-GENE-Y
X,2782,I-GENE-Y
Receptor,2782,I-GENE-Y
Mediates,2782,O
Dyslipidemia,2782,O
Induced,2782,O
by,2782,O
the,2782,O
HIV,2782,B-GENE-N
Protease,2782,I-GENE-N
Inhibitor,2782,O
Amprenavir,2782,B-CHEMICAL
in,2782,O
Mice,2782,O
.,2782,O
HIV,2783,B-GENE-Y
protease,2783,I-GENE-Y
inhibitors,2783,O
(,2783,O
PIs,2783,O
),2783,O
have,2783,O
been,2783,O
used,2783,O
successfully,2783,O
in,2783,O
extending,2783,O
the,2783,O
lifespan,2783,O
of,2783,O
people,2783,O
infected,2783,O
with,2783,O
HIV,2783,O
.,2783,O
The,2784,O
use,2784,O
of,2784,O
PIs,2784,O
has,2784,O
also,2784,O
been,2784,O
associated,2784,O
with,2784,O
dyslipidemia,2784,O
and,2784,O
an,2784,O
increased,2784,O
risk,2784,O
of,2784,O
cardiovascular,2784,O
disease,2784,O
but,2784,O
the,2784,O
underlying,2784,O
mechanisms,2784,O
remain,2784,O
elusive,2784,O
.,2784,O
Several,2785,O
PIs,2785,O
have,2785,O
been,2785,O
implicated,2785,O
to,2785,O
activate,2785,O
the,2785,O
nuclear,2785,O
receptor,2785,O
pregnane,2785,B-GENE-Y
X,2785,I-GENE-Y
receptor,2785,I-GENE-Y
(,2785,O
PXR,2785,B-GENE-Y
),2785,O
",",2785,O
which,2785,O
acts,2785,O
as,2785,O
a,2785,O
xenobiotic,2785,O
sensor,2785,O
to,2785,O
regulate,2785,O
xenobiotic,2785,O
metabolism,2785,O
in,2785,O
the,2785,O
liver,2785,O
and,2785,O
intestine,2785,O
.,2785,O
Recent,2786,O
studies,2786,O
indicate,2786,O
that,2786,O
PXR,2786,B-GENE-Y
may,2786,O
also,2786,O
play,2786,O
an,2786,O
important,2786,O
role,2786,O
in,2786,O
the,2786,O
regulation,2786,O
of,2786,O
lipid,2786,O
homeostasis,2786,O
.,2786,O
In,2787,O
the,2787,O
present,2787,O
study,2787,O
",",2787,O
we,2787,O
identified,2787,O
amprenavir,2787,B-CHEMICAL
",",2787,O
a,2787,O
widely,2787,O
used,2787,O
HIV,2787,O
PI,2787,O
",",2787,O
as,2787,O
a,2787,O
potent,2787,O
PXR-selective,2787,B-GENE-Y
agonist,2787,O
.,2787,O
Computational,2788,O
docking,2788,O
studies,2788,O
combined,2788,O
with,2788,O
site-direct,2788,O
mutagenesis,2788,O
identified,2788,O
several,2788,O
key,2788,O
residues,2788,O
within,2788,O
the,2788,O
ligand,2788,O
binding,2788,O
pocket,2788,O
of,2788,O
PXR,2788,B-GENE-Y
that,2788,O
constitute,2788,O
points,2788,O
of,2788,O
interaction,2788,O
with,2788,O
amprenavir,2788,B-CHEMICAL
.,2788,O
Amprenavir,2789,B-CHEMICAL
efficiently,2789,O
activated,2789,O
PXR,2789,B-GENE-Y
and,2789,O
induced,2789,O
PXR,2789,B-GENE-Y
target,2789,O
gene,2789,O
expression,2789,O
in,2789,O
vitro,2789,O
and,2789,O
in,2789,O
vivo,2789,O
.,2789,O
Short-term,2790,O
exposure,2790,O
to,2790,O
amprenavir,2790,B-CHEMICAL
significantly,2790,O
increased,2790,O
plasma,2790,O
total,2790,O
cholesterol,2790,B-CHEMICAL
and,2790,O
atherogenic,2790,O
low-density,2790,O
lipoprotein,2790,O
cholesterol,2790,B-CHEMICAL
levels,2790,O
in,2790,O
wild-type,2790,O
mice,2790,O
",",2790,O
but,2790,O
not,2790,O
in,2790,O
PXR-deficient,2790,B-GENE-Y
mice,2790,O
.,2790,O
Amprenavir-mediated,2791,B-CHEMICAL
PXR,2791,B-GENE-Y
activation,2791,O
stimulated,2791,O
the,2791,O
expression,2791,O
of,2791,O
several,2791,O
key,2791,O
intestinal,2791,O
genes,2791,O
involved,2791,O
in,2791,O
lipid,2791,O
homeostasis,2791,O
.,2791,O
These,2792,O
findings,2792,O
provide,2792,O
critical,2792,O
mechanistic,2792,O
insight,2792,O
for,2792,O
understanding,2792,O
the,2792,O
impact,2792,O
of,2792,O
PIs,2792,O
on,2792,O
cardiovascular,2792,O
disease,2792,O
and,2792,O
demonstrate,2792,O
a,2792,O
potential,2792,O
role,2792,O
of,2792,O
PXR,2792,B-GENE-Y
in,2792,O
mediating,2792,O
adverse,2792,O
effects,2792,O
of,2792,O
HIV,2792,O
PIs,2792,O
in,2792,O
humans,2792,O
.,2792,O
Charge,2793,O
screening,2793,O
between,2793,O
anionic,2793,O
and,2793,O
cationic,2793,O
surfactants,2793,O
in,2793,O
ionic,2793,O
liquids,2793,O
.,2793,O
The,2794,O
aggregation,2794,O
and,2794,O
interfacial,2794,O
behavior,2794,O
of,2794,O
mixtures,2794,O
of,2794,O
anionic,2794,O
(,2794,O
sodium,2794,B-CHEMICAL
dodecylsulfate,2794,I-CHEMICAL
",",2794,O
SDS,2794,B-CHEMICAL
),2794,O
and,2794,O
cationic,2794,O
(,2794,O
dodecylammonium,2794,B-CHEMICAL
bromide,2794,I-CHEMICAL
",",2794,O
DTAB,2794,B-CHEMICAL
),2794,O
surfactants,2794,O
were,2794,O
investigated,2794,O
.,2794,O
A,2795,O
room-temperature,2795,O
ionic,2795,O
liquid,2795,O
(,2795,O
IL,2795,O
),2795,O
was,2795,O
explored,2795,O
as,2795,O
a,2795,O
solvent,2795,O
for,2795,O
the,2795,O
SDS/DTAB,2795,B-CHEMICAL
system,2795,O
and,2795,O
compared,2795,O
to,2795,O
water,2795,O
.,2795,O
The,2796,O
critical,2796,O
micelle,2796,O
concentration,2796,O
(,2796,O
cmc,2796,O
),2796,O
and,2796,O
composition,2796,O
in,2796,O
mixed,2796,O
micelles,2796,O
were,2796,O
determined,2796,O
for,2796,O
both,2796,O
solvents,2796,O
.,2796,O
Our,2797,O
experiments,2797,O
showed,2797,O
nearly,2797,O
ideal,2797,O
mixing,2797,O
of,2797,O
SDS/DTAB,2797,B-CHEMICAL
over,2797,O
the,2797,O
entire,2797,O
composition,2797,O
range,2797,O
and,2797,O
suggest,2797,O
that,2797,O
charge,2797,O
screening,2797,O
is,2797,O
prominent,2797,O
in,2797,O
ILs,2797,O
.,2797,O
This,2798,O
behavior,2798,O
is,2798,O
in,2798,O
sharp,2798,O
contrast,2798,O
to,2798,O
the,2798,O
strong,2798,O
electrostatic,2798,O
attraction,2798,O
and,2798,O
a,2798,O
multiphase,2798,O
composition,2798,O
gap,2798,O
in,2798,O
water,2798,O
.,2798,O
Two,2799,O
models,2799,O
by,2799,O
Clint,2799,O
and,2799,O
Rubingh,2799,O
",",2799,O
which,2799,O
describe,2799,O
ideal,2799,O
and,2799,O
nonideal,2799,O
micellar,2799,O
behavior,2799,O
",",2799,O
respectively,2799,O
",",2799,O
are,2799,O
discussed,2799,O
on,2799,O
the,2799,O
basis,2799,O
of,2799,O
our,2799,O
results,2799,O
.,2799,O
According,2800,O
to,2800,O
Rubingh,2800,O
's,2800,O
model,2800,O
",",2800,O
the,2800,O
composition,2800,O
of,2800,O
mixed,2800,O
micelles,2800,O
is,2800,O
gradually,2800,O
changing,2800,O
with,2800,O
the,2800,O
bulk,2800,O
composition,2800,O
in,2800,O
ILs,2800,O
but,2800,O
tends,2800,O
to,2800,O
be,2800,O
a,2800,O
1:1,2800,O
ratio,2800,O
in,2800,O
water,2800,O
.,2800,O
The,2801,O
results,2801,O
here,2801,O
are,2801,O
further,2801,O
support,2801,O
of,2801,O
the,2801,O
strong,2801,O
charge,2801,O
screening,2801,O
in,2801,O
ionic,2801,O
liquids,2801,O
.,2801,O
Anti-diabetic,2802,O
Activity,2802,O
of,2802,O
Swertiamarin,2802,B-CHEMICAL
is,2802,O
due,2802,O
to,2802,O
an,2802,O
Active,2802,O
Metabolite,2802,O
",",2802,O
Gentianine,2802,B-CHEMICAL
",",2802,O
that,2802,O
Upregulates,2802,O
PPAR-γ,2802,B-GENE-Y
Gene,2802,O
Expression,2802,O
in,2802,O
3T3-L1,2802,O
cells,2802,O
.,2802,O
We,2803,O
have,2803,O
previously,2803,O
shown,2803,O
the,2803,O
anti-diabetic,2803,O
effects,2803,O
of,2803,O
swertiamarin,2803,B-CHEMICAL
;,2803,O
however,2803,O
",",2803,O
pharmacokinetic,2803,O
analysis,2803,O
showed,2803,O
that,2803,O
swertiamarin,2803,B-CHEMICAL
had,2803,O
a,2803,O
plasma,2803,O
half-life,2803,O
of,2803,O
1.3,2803,O
h.,2803,O
Gentianine,2803,B-CHEMICAL
is,2803,O
an,2803,O
active,2803,O
metabolite,2803,O
of,2803,O
swertiamarin,2803,B-CHEMICAL
that,2803,O
possesses,2803,O
a,2803,O
pharmacophoric,2803,O
moiety,2803,O
.,2803,O
The,2804,O
aim,2804,O
of,2804,O
this,2804,O
study,2804,O
was,2804,O
to,2804,O
explore,2804,O
the,2804,O
possibility,2804,O
whether,2804,O
the,2804,O
anti-diabetic,2804,O
effect,2804,O
of,2804,O
swertiamarin,2804,B-CHEMICAL
is,2804,O
due,2804,O
to,2804,O
gentianine,2804,B-CHEMICAL
.,2804,O
Swertiamarin,2805,B-CHEMICAL
treatment,2805,O
had,2805,O
no,2805,O
significant,2805,O
effect,2805,O
on,2805,O
adipogenesis,2805,O
",",2805,O
or,2805,O
the,2805,O
mRNA,2805,O
expression,2805,O
of,2805,O
PPAR-γ,2805,B-GENE-Y
and,2805,O
GLUT-4,2805,B-GENE-Y
;,2805,O
however,2805,O
",",2805,O
there,2805,O
was,2805,O
a,2805,O
significant,2805,O
increase,2805,O
in,2805,O
the,2805,O
mRNA,2805,O
expression,2805,O
of,2805,O
adiponectin,2805,B-GENE-Y
.,2805,O
On,2806,O
the,2806,O
other,2806,O
hand,2806,O
",",2806,O
treatment,2806,O
with,2806,O
gentianine,2806,B-CHEMICAL
significantly,2806,O
increased,2806,O
adipogenesis,2806,O
",",2806,O
which,2806,O
was,2806,O
associated,2806,O
with,2806,O
a,2806,O
significant,2806,O
increase,2806,O
in,2806,O
the,2806,O
mRNA,2806,O
expression,2806,O
of,2806,O
PPAR-γ,2806,B-GENE-Y
",",2806,O
GLUT-4,2806,B-GENE-Y
and,2806,O
adiponectin,2806,B-GENE-Y
.,2806,O
These,2807,O
findings,2807,O
suggest,2807,O
",",2807,O
for,2807,O
the,2807,O
first,2807,O
time,2807,O
",",2807,O
that,2807,O
the,2807,O
anti-diabetic,2807,O
effect,2807,O
of,2807,O
swertiamarin,2807,B-CHEMICAL
is,2807,O
due,2807,O
to,2807,O
gentianine,2807,B-CHEMICAL
",",2807,O
an,2807,O
active,2807,O
metabolite,2807,O
of,2807,O
swertiamarin,2807,B-CHEMICAL
.,2807,O
Copyright,2808,O
©,2808,O
2012,2808,O
John,2808,O
Wiley,2808,O
&,2808,O
Sons,2808,O
",",2808,O
Ltd,2808,O
.,2808,O
[,2809,O
Brugada,2809,O
syndrome,2809,O
],2809,O
.,2809,O
In,2810,O
1992,2810,O
we,2810,O
described,2810,O
a,2810,O
new,2810,O
syndrome,2810,O
consisting,2810,O
of,2810,O
syncopal,2810,O
episodes,2810,O
and/or,2810,O
sudden,2810,O
death,2810,O
in,2810,O
patients,2810,O
with,2810,O
a,2810,O
structurally,2810,O
normal,2810,O
heart,2810,O
and,2810,O
a,2810,O
characteristic,2810,O
electrocardiogram,2810,O
displaying,2810,O
a,2810,O
pattern,2810,O
resembling,2810,O
right,2810,O
bundle,2810,O
branch,2810,O
block,2810,O
with,2810,O
an,2810,O
ST,2810,O
segment,2810,O
elevation,2810,O
in,2810,O
leads,2810,O
V1,2810,O
to,2810,O
V3,2810,O
.,2810,O
In,2811,O
1998,2811,O
it,2811,O
was,2811,O
described,2811,O
that,2811,O
the,2811,O
disease,2811,O
is,2811,O
genetically,2811,O
determined,2811,O
with,2811,O
an,2811,O
autosomal,2811,O
dominant,2811,O
pattern,2811,O
of,2811,O
transmission,2811,O
.,2811,O
Three,2812,O
different,2812,O
mutations,2812,O
have,2812,O
been,2812,O
identified,2812,O
.,2812,O
All,2813,O
three,2813,O
mutations,2813,O
affect,2813,O
the,2813,O
structure,2813,O
and,2813,O
the,2813,O
function,2813,O
of,2813,O
the,2813,O
sodium,2813,B-GENE-N
channel,2813,I-GENE-N
SCN5A,2813,B-GENE-Y
.,2813,O
Two,2814,O
mutations,2814,O
result,2814,O
in,2814,O
total,2814,O
loss,2814,O
of,2814,O
function,2814,O
of,2814,O
the,2814,O
sodium,2814,B-GENE-N
channel,2814,I-GENE-N
.,2814,O
The,2815,O
other,2815,O
mutation,2815,O
results,2815,O
in,2815,O
acceleration,2815,O
of,2815,O
the,2815,O
recovery,2815,O
of,2815,O
the,2815,O
sodium,2815,B-GENE-N
channel,2815,I-GENE-N
from,2815,O
inactivation,2815,O
.,2815,O
The,2816,O
disease,2816,O
causes,2816,O
4,2816,O
to,2816,O
10,2816,O
sudden,2816,O
deaths,2816,O
per,2816,O
"10,000",2816,O
inhabitants,2816,O
per,2816,O
year,2816,O
in,2816,O
areas,2816,O
like,2816,O
Thailand,2816,O
and,2816,O
Laos,2816,O
.,2816,O
Up,2817,O
to,2817,O
50,2817,O
%,2817,O
of,2817,O
the,2817,O
yearly,2817,O
sudden,2817,O
deaths,2817,O
in,2817,O
patients,2817,O
with,2817,O
a,2817,O
normal,2817,O
heart,2817,O
might,2817,O
be,2817,O
caused,2817,O
by,2817,O
this,2817,O
syndrome,2817,O
.,2817,O
The,2818,O
diagnosis,2818,O
is,2818,O
easily,2818,O
made,2818,O
by,2818,O
means,2818,O
of,2818,O
the,2818,O
electrocardiogram,2818,O
(,2818,O
ECG,2818,O
),2818,O
.,2818,O
The,2819,O
presence,2819,O
of,2819,O
concealed,2819,O
and,2819,O
intermittent,2819,O
forms,2819,O
",",2819,O
however,2819,O
",",2819,O
makes,2819,O
the,2819,O
diagnosis,2819,O
difficult,2819,O
in,2819,O
some,2819,O
patients,2819,O
.,2819,O
The,2820,O
ECG,2820,O
can,2820,O
be,2820,O
modulated,2820,O
by,2820,O
changes,2820,O
in,2820,O
autonomic,2820,O
balance,2820,O
and,2820,O
the,2820,O
administration,2820,O
of,2820,O
antiarrhythmic,2820,O
drugs,2820,O
.,2820,O
Beta-adrenergic,2821,O
stimulation,2821,O
normalises,2821,O
the,2821,O
ECG,2821,O
",",2821,O
while,2821,O
i.v,2821,O
.,2821,O
ajmaline,2822,B-CHEMICAL
",",2822,O
flecainide,2822,B-CHEMICAL
or,2822,O
procainamide,2822,B-CHEMICAL
accentuate,2822,O
the,2822,O
ST,2822,O
segment,2822,O
elevation,2822,O
and,2822,O
are,2822,O
capable,2822,O
of,2822,O
unmasking,2822,O
concealed,2822,O
and,2822,O
intermittent,2822,O
forms,2822,O
of,2822,O
the,2822,O
disease,2822,O
.,2822,O
The,2823,O
prognosis,2823,O
is,2823,O
poor,2823,O
for,2823,O
patients,2823,O
who,2823,O
do,2823,O
not,2823,O
receive,2823,O
an,2823,O
implantable,2823,O
cardioverter-defibrillator,2823,O
.,2823,O
Antiarrhythmic,2824,O
drugs,2824,O
like,2824,O
amiodarone,2824,B-CHEMICAL
or,2824,O
beta-blockers,2824,O
do,2824,O
not,2824,O
prevent,2824,O
sudden,2824,O
death,2824,O
in,2824,O
symptomatic,2824,O
or,2824,O
asymptomatic,2824,O
individuals,2824,O
.,2824,O
The,2825,O
effects,2825,O
of,2825,O
jaspamide,2825,B-CHEMICAL
on,2825,O
human,2825,O
cardiomyocyte,2825,O
function,2825,O
and,2825,O
cardiac,2825,B-GENE-N
ion,2825,I-GENE-N
channel,2825,I-GENE-N
activity,2825,O
.,2825,O
Jaspamide,2826,B-CHEMICAL
(,2826,O
jasplakinolide,2826,B-CHEMICAL
;,2826,O
NSC-613009,2826,B-CHEMICAL
),2826,O
is,2826,O
a,2826,O
cyclodepsipeptide,2826,B-CHEMICAL
that,2826,O
has,2826,O
antitumor,2826,O
activity,2826,O
.,2826,O
A,2827,O
narrow,2827,O
margin,2827,O
of,2827,O
safety,2827,O
was,2827,O
observed,2827,O
between,2827,O
doses,2827,O
required,2827,O
for,2827,O
efficacy,2827,O
in,2827,O
mouse,2827,O
tumor,2827,O
models,2827,O
and,2827,O
doses,2827,O
that,2827,O
caused,2827,O
severe,2827,O
acute,2827,O
toxicity,2827,O
in,2827,O
rats,2827,O
and,2827,O
dogs,2827,O
.,2827,O
We,2828,O
explored,2828,O
the,2828,O
hypothesis,2828,O
that,2828,O
the,2828,O
observed,2828,O
toxicity,2828,O
was,2828,O
due,2828,O
to,2828,O
cardiotoxicity,2828,O
.,2828,O
Jaspamide,2829,B-CHEMICAL
was,2829,O
tested,2829,O
in,2829,O
a,2829,O
patch,2829,O
clamp,2829,O
assay,2829,O
to,2829,O
determine,2829,O
its,2829,O
effect,2829,O
on,2829,O
selected,2829,O
cardiac,2829,B-GENE-N
ion,2829,I-GENE-N
channels,2829,I-GENE-N
.,2829,O
Jaspamide,2830,B-CHEMICAL
(,2830,O
10,2830,O
μM,2830,O
),2830,O
inhibited,2830,O
Kv1.5,2830,O
activity,2830,O
by,2830,O
98.5,2830,O
%,2830,O
.,2830,O
Jaspamide,2831,B-CHEMICAL
also,2831,O
inhibited,2831,O
other,2831,O
channels,2831,O
including,2831,O
Cav1.2,2831,B-GENE-N
",",2831,O
Cav3.2,2831,B-GENE-N
",",2831,O
and,2831,O
HCN2,2831,B-GENE-N
;,2831,O
however,2831,O
",",2831,O
the,2831,O
Kv11.1,2831,B-GENE-Y
(,2831,O
hERG,2831,B-GENE-Y
),2831,O
channel,2831,O
was,2831,O
minimally,2831,O
affected,2831,O
.,2831,O
Using,2832,O
spontaneously,2832,O
contracting,2832,O
human,2832,O
cardiomyocytes,2832,O
derived,2832,O
from,2832,O
induced,2832,O
pluripotent,2832,O
stem,2832,O
cells,2832,O
",",2832,O
effects,2832,O
on,2832,O
cardiomyocyte,2832,O
contraction,2832,O
and,2832,O
viability,2832,O
were,2832,O
also,2832,O
examined,2832,O
.,2832,O
Jaspamide,2833,B-CHEMICAL
(,2833,O
30,2833,O
nM,2833,O
to,2833,O
30,2833,O
μM,2833,O
),2833,O
decreased,2833,O
cardiomyocyte,2833,O
cell,2833,O
indices,2833,O
and,2833,O
beat,2833,O
amplitude,2833,O
",",2833,O
putative,2833,O
measurements,2833,O
of,2833,O
cell,2833,O
viability,2833,O
and,2833,O
cardiac,2833,O
contractility,2833,O
",",2833,O
respectively,2833,O
.,2833,O
Concentration-dependent,2834,O
increases,2834,O
in,2834,O
rhythmic,2834,O
beating,2834,O
rate,2834,O
were,2834,O
noted,2834,O
at,2834,O
≤,2834,O
6,2834,O
h,2834,O
of,2834,O
treatment,2834,O
",",2834,O
followed,2834,O
by,2834,O
dose-dependent,2834,O
decreases,2834,O
after,2834,O
6,2834,O
and,2834,O
72,2834,O
h,2834,O
exposure,2834,O
.,2834,O
The,2835,O
toxic,2835,O
effects,2835,O
of,2835,O
jaspamide,2835,B-CHEMICAL
were,2835,O
compared,2835,O
with,2835,O
that,2835,O
of,2835,O
the,2835,O
known,2835,O
cardiotoxicant,2835,O
mitoxantrone,2835,B-CHEMICAL
",",2835,O
and,2835,O
confirmed,2835,O
by,2835,O
multiparameter,2835,O
fluorescence,2835,O
imaging,2835,O
analysis,2835,O
.,2835,O
These,2836,O
results,2836,O
support,2836,O
the,2836,O
hypothesis,2836,O
that,2836,O
the,2836,O
toxicity,2836,O
observed,2836,O
in,2836,O
rats,2836,O
and,2836,O
dogs,2836,O
is,2836,O
due,2836,O
to,2836,O
toxic,2836,O
effects,2836,O
of,2836,O
jaspamide,2836,B-CHEMICAL
on,2836,O
cardiomyocytes,2836,O
.,2836,O
Carvedilol,2837,B-CHEMICAL
modulates,2837,O
the,2837,O
expression,2837,O
of,2837,O
hypoxia-inducible,2837,B-GENE-Y
factor-1alpha,2837,I-GENE-Y
and,2837,O
vascular,2837,B-GENE-Y
endothelial,2837,I-GENE-Y
growth,2837,I-GENE-Y
factor,2837,I-GENE-Y
in,2837,O
a,2837,O
rat,2837,O
model,2837,O
of,2837,O
volume-overload,2837,O
heart,2837,O
failure,2837,O
.,2837,O
BACKGROUND,2838,O
:,2838,O
The,2838,O
use,2838,O
of,2838,O
beta-blockers,2838,O
has,2838,O
emerged,2838,O
as,2838,O
a,2838,O
beneficial,2838,O
treatment,2838,O
for,2838,O
congestive,2838,O
heart,2838,O
failure,2838,O
.,2838,O
Hypoxia-inducible,2839,B-GENE-Y
factor-1alpha,2839,I-GENE-Y
(,2839,O
HIF-1alpha,2839,B-GENE-Y
),2839,O
is,2839,O
tightly,2839,O
regulated,2839,O
in,2839,O
the,2839,O
ventricular,2839,O
myocardium,2839,O
.,2839,O
However,2840,O
",",2840,O
the,2840,O
expression,2840,O
of,2840,O
HIF-1alpha,2840,B-GENE-Y
in,2840,O
chronic,2840,O
heart,2840,O
failure,2840,O
resulting,2840,O
from,2840,O
volume,2840,O
overload,2840,O
and,2840,O
after,2840,O
treatment,2840,O
with,2840,O
beta-blocker,2840,O
is,2840,O
little,2840,O
known,2840,O
.,2840,O
METHODS,2841,O
AND,2841,O
RESULTS,2841,O
:,2841,O
To,2841,O
test,2841,O
the,2841,O
hypothesis,2841,O
that,2841,O
HIF-1alpha,2841,B-GENE-Y
plays,2841,O
a,2841,O
role,2841,O
in,2841,O
the,2841,O
failing,2841,O
myocardium,2841,O
because,2841,O
of,2841,O
volume,2841,O
overload,2841,O
",",2841,O
an,2841,O
aorta-caval,2841,O
shunt,2841,O
was,2841,O
created,2841,O
for,2841,O
4,2841,O
weeks,2841,O
in,2841,O
adult,2841,O
Sprague-Dawley,2841,O
rats,2841,O
to,2841,O
induce,2841,O
volume-overload,2841,O
heart,2841,O
failure,2841,O
.,2841,O
Carvedilol,2842,B-CHEMICAL
at,2842,O
50,2842,O
mg/kg,2842,O
body,2842,O
weight,2842,O
per,2842,O
day,2842,O
after,2842,O
surgery,2842,O
was,2842,O
given,2842,O
.,2842,O
The,2843,O
heart,2843,O
weight,2843,O
and,2843,O
body,2843,O
weight,2843,O
ratio,2843,O
increased,2843,O
from,2843,O
2.6,2843,O
+/-,2843,O
0.3,2843,O
in,2843,O
the,2843,O
sham,2843,O
group,2843,O
to,2843,O
3.9,2843,O
+/-,2843,O
0.7,2843,O
(,2843,O
P,2843,O
<,2843,O
.001,2843,O
),2843,O
in,2843,O
the,2843,O
shunt,2843,O
group,2843,O
.,2843,O
Left,2844,O
ventricular,2844,O
end-diastolic,2844,O
dimension,2844,O
increased,2844,O
from,2844,O
6.5,2844,O
+/-,2844,O
0.5,2844,O
mm,2844,O
to,2844,O
8.7,2844,O
+/-,2844,O
0.6,2844,O
mm,2844,O
(,2844,O
P,2844,O
<,2844,O
.001,2844,O
),2844,O
.,2844,O
Treatment,2845,O
with,2845,O
carvedilol,2845,B-CHEMICAL
in,2845,O
the,2845,O
shunt,2845,O
group,2845,O
reversed,2845,O
the,2845,O
heart,2845,O
weight,2845,O
and,2845,O
ventricular,2845,O
dimension,2845,O
to,2845,O
the,2845,O
baseline,2845,O
values,2845,O
.,2845,O
Western,2846,O
blot,2846,O
showed,2846,O
that,2846,O
HIF-1alpha,2846,B-GENE-Y
",",2846,O
vascular,2846,B-GENE-Y
endothelial,2846,I-GENE-Y
growth,2846,I-GENE-Y
factor,2846,I-GENE-Y
(,2846,O
VEGF,2846,B-GENE-Y
),2846,O
",",2846,O
and,2846,O
brain,2846,B-GENE-Y
natriuretic,2846,I-GENE-Y
peptide,2846,I-GENE-Y
(,2846,O
BNP,2846,B-GENE-Y
),2846,O
proteins,2846,O
were,2846,O
upregulated,2846,O
and,2846,O
nerve,2846,B-GENE-Y
growth,2846,I-GENE-Y
factor-beta,2846,I-GENE-Y
(,2846,O
NGF-beta,2846,B-GENE-Y
),2846,O
downregulated,2846,O
in,2846,O
the,2846,O
shunt,2846,O
group,2846,O
.,2846,O
Real-time,2847,O
polymerase,2847,O
chain,2847,O
reaction,2847,O
showed,2847,O
that,2847,O
mRNA,2847,O
of,2847,O
HIF-1alpha,2847,B-GENE-Y
",",2847,O
VEGF,2847,B-GENE-Y
",",2847,O
and,2847,O
BNP,2847,B-GENE-Y
increased,2847,O
and,2847,O
mRNA,2847,O
of,2847,O
NGF-beta,2847,B-GENE-Y
decreased,2847,O
in,2847,O
the,2847,O
shunt,2847,O
group,2847,O
.,2847,O
Treatment,2848,O
with,2848,O
carvedilol,2848,B-CHEMICAL
reversed,2848,O
both,2848,O
protein,2848,O
and,2848,O
mRNA,2848,O
of,2848,O
HIF-1alpha,2848,B-GENE-Y
",",2848,O
VEGF,2848,B-GENE-Y
",",2848,O
BNP,2848,B-GENE-Y
",",2848,O
and,2848,O
NGF-beta,2848,B-GENE-Y
to,2848,O
the,2848,O
baseline,2848,O
values,2848,O
.,2848,O
Increased,2849,O
immunohistochemical,2849,O
labeling,2849,O
of,2849,O
HIF-1alpha,2849,B-GENE-Y
",",2849,O
VEGF,2849,B-GENE-Y
",",2849,O
and,2849,O
BNP,2849,B-GENE-Y
in,2849,O
the,2849,O
ventricular,2849,O
myocardium,2849,O
was,2849,O
observed,2849,O
in,2849,O
the,2849,O
shunt,2849,O
group,2849,O
and,2849,O
carvedilol,2849,B-CHEMICAL
again,2849,O
normalized,2849,O
the,2849,O
labeling,2849,O
.,2849,O
CONCLUSION,2850,O
:,2850,O
HIF-1alpha,2850,B-GENE-Y
and,2850,O
VEGF,2850,B-GENE-Y
mRNA,2850,O
and,2850,O
protein,2850,O
expression,2850,O
were,2850,O
upregulated,2850,O
in,2850,O
the,2850,O
rat,2850,O
model,2850,O
of,2850,O
volume-overload,2850,O
heart,2850,O
failure,2850,O
.,2850,O
Treatment,2851,O
with,2851,O
carvedilol,2851,B-CHEMICAL
is,2851,O
associated,2851,O
with,2851,O
a,2851,O
reversal,2851,O
of,2851,O
abnormal,2851,O
regulation,2851,O
of,2851,O
HIF-1alpha,2851,B-GENE-Y
and,2851,O
VEGF,2851,B-GENE-Y
in,2851,O
the,2851,O
failing,2851,O
ventricular,2851,O
myocardium,2851,O
.,2851,O
Apoptosis,2852,O
induced,2852,O
by,2852,O
oxidized,2852,O
lipids,2852,O
is,2852,O
associated,2852,O
with,2852,O
up-regulation,2852,O
of,2852,O
p66Shc,2852,B-GENE-Y
in,2852,O
intestinal,2852,O
Caco-2,2852,O
cells,2852,O
:,2852,O
protective,2852,O
effects,2852,O
of,2852,O
phenolic,2852,B-CHEMICAL
compounds,2852,O
.,2852,O
In,2853,O
this,2853,O
study,2853,O
",",2853,O
we,2853,O
investigated,2853,O
the,2853,O
alterations,2853,O
of,2853,O
the,2853,O
redox,2853,O
balance,2853,O
induced,2853,O
by,2853,O
the,2853,O
lipid,2853,O
fraction,2853,O
of,2853,O
oxLDL,2853,B-GENE-N
in,2853,O
Caco-2,2853,O
intestinal,2853,O
cells,2853,O
",",2853,O
and,2853,O
the,2853,O
effects,2853,O
of,2853,O
tyrosol,2853,B-CHEMICAL
and,2853,O
protocatechuic,2853,B-CHEMICAL
acid,2853,I-CHEMICAL
",",2853,O
two,2853,O
dietary,2853,O
phenolic,2853,B-CHEMICAL
compounds,2853,O
.,2853,O
We,2854,O
found,2854,O
that,2854,O
oxidized,2854,O
lipids,2854,O
extracted,2854,O
from,2854,O
oxLDL,2854,B-GENE-N
(,2854,O
LipE,2854,B-GENE-Y
),2854,O
induced,2854,O
oxidative,2854,O
stress,2854,O
by,2854,O
determining,2854,O
",",2854,O
6,2854,O
h,2854,O
after,2854,O
treatment,2854,O
",",2854,O
ROS,2854,O
overproduction,2854,O
(,2854,O
about,2854,O
a,2854,O
100,2854,O
%,2854,O
and,2854,O
a,2854,O
43,2854,O
%,2854,O
increase,2854,O
of,2854,O
O,2854,B-CHEMICAL
*,2854,I-CHEMICAL
2,2854,I-CHEMICAL
and,2854,O
H2O2,2854,B-CHEMICAL
production,2854,O
",",2854,O
respectively,2854,O
",",2854,O
P,2854,O
<,2854,O
.05,2854,O
:,2854,O
LipE,2854,B-GENE-Y
vs.,2854,O
control,2854,O
),2854,O
and,2854,O
",",2854,O
12,2854,O
h,2854,O
after,2854,O
treatment,2854,O
",",2854,O
GSH,2854,O
depletion,2854,O
(,2854,O
about,2854,O
a,2854,O
26,2854,O
%,2854,O
decrease,2854,O
",",2854,O
P,2854,O
<,2854,O
.05,2854,O
:,2854,O
LipE,2854,B-GENE-Y
vs.,2854,O
control,2854,O
),2854,O
",",2854,O
and,2854,O
by,2854,O
impairing,2854,O
the,2854,O
activities,2854,O
of,2854,O
superoxide,2854,B-GENE-N
dismutase,2854,I-GENE-N
",",2854,O
catalase,2854,B-GENE-Y
and,2854,O
glutathione,2854,B-GENE-N
peroxidase,2854,I-GENE-N
.,2854,O
In,2855,O
response,2855,O
to,2855,O
the,2855,O
induced,2855,O
oxidative,2855,O
stress,2855,O
",",2855,O
we,2855,O
observed,2855,O
significant,2855,O
overexpression,2855,O
of,2855,O
glutathione,2855,B-GENE-N
peroxidase,2855,I-GENE-N
(,2855,O
6,2855,O
h,2855,O
after,2855,O
treatment,2855,O
:,2855,O
P,2855,O
<,2855,O
.05,2855,O
),2855,O
",",2855,O
glutathione,2855,B-GENE-N
reductase,2855,I-GENE-N
and,2855,O
gamma-glutamylcysteine,2855,B-GENE-Y
synthetase,2855,I-GENE-Y
(,2855,O
12,2855,O
h,2855,O
after,2855,O
treatment,2855,O
:,2855,O
P,2855,O
<,2855,O
.05,2855,O
),2855,O
.,2855,O
Notably,2856,O
",",2856,O
when,2856,O
GSH,2856,O
depletion,2856,O
occurred,2856,O
",",2856,O
p66Shc,2856,B-GENE-Y
protein,2856,O
expression,2856,O
increased,2856,O
by,2856,O
about,2856,O
300,2856,O
%,2856,O
with,2856,O
respect,2856,O
to,2856,O
control,2856,O
(,2856,O
P,2856,O
<,2856,O
.001,2856,O
;,2856,O
LipE,2856,B-GENE-Y
vs.,2856,O
control,2856,O
),2856,O
.,2856,O
These,2857,O
effects,2857,O
were,2857,O
fully,2857,O
counteracted,2857,O
by,2857,O
dietary,2857,O
phenolics,2857,B-CHEMICAL
which,2857,O
inhibited,2857,O
ROS,2857,O
overproduction,2857,O
and,2857,O
GSH,2857,O
consumption,2857,O
",",2857,O
rendered,2857,O
the,2857,O
reactive,2857,O
transcription,2857,O
of,2857,O
glutathione-associated,2857,B-CHEMICAL
enzymes,2857,O
unnecessary,2857,O
and,2857,O
blocked,2857,O
the,2857,O
intracellular,2857,O
signals,2857,O
leading,2857,O
to,2857,O
the,2857,O
overexpression,2857,O
and,2857,O
rearrangement,2857,O
of,2857,O
p66Shc,2857,B-GENE-Y
signalling,2857,O
molecule,2857,O
.,2857,O
Altogether,2858,O
",",2858,O
these,2858,O
results,2858,O
suggest,2858,O
that,2858,O
the,2858,O
impairment,2858,O
of,2858,O
the,2858,O
antioxidant,2858,O
system,2858,O
hijacks,2858,O
intestinal,2858,O
cells,2858,O
towards,2858,O
an,2858,O
apoptotic-prone,2858,O
phenotype,2858,O
via,2858,O
the,2858,O
activation,2858,O
of,2858,O
p66Shc,2858,B-GENE-Y
molecule,2858,O
.,2858,O
They,2859,O
also,2859,O
propose,2859,O
a,2859,O
reappraisal,2859,O
of,2859,O
dietary,2859,O
polyphenols,2859,B-CHEMICAL
as,2859,O
intestinal,2859,O
protecting,2859,O
agents,2859,O
",",2859,O
indicating,2859,O
the,2859,O
antiapoptotic,2859,O
effect,2859,O
as,2859,O
a,2859,O
further,2859,O
mechanism,2859,O
of,2859,O
action,2859,O
of,2859,O
these,2859,O
antioxidant,2859,O
compounds,2859,O
.,2859,O
Serine,2860,B-GENE-N
racemases,2860,I-GENE-N
from,2860,O
barley,2860,O
",",2860,O
Hordeum,2860,O
vulgare,2860,O
L.,2860,O
",",2860,O
and,2860,O
other,2860,O
plant,2860,O
species,2860,O
represent,2860,O
a,2860,O
distinct,2860,O
eukaryotic,2860,O
group,2860,O
:,2860,O
gene,2860,O
cloning,2860,O
and,2860,O
recombinant,2860,O
protein,2860,O
characterization,2860,O
.,2860,O
Several,2861,O
d-amino,2861,B-CHEMICAL
acids,2861,I-CHEMICAL
have,2861,O
been,2861,O
identified,2861,O
in,2861,O
plants,2861,O
.,2861,O
However,2862,O
",",2862,O
the,2862,O
biosynthetic,2862,O
pathway,2862,O
to,2862,O
them,2862,O
is,2862,O
unclear,2862,O
.,2862,O
In,2863,O
this,2863,O
study,2863,O
",",2863,O
we,2863,O
cloned,2863,O
and,2863,O
sequenced,2863,O
a,2863,O
cDNA,2863,O
encoding,2863,O
a,2863,O
serine,2863,B-GENE-Y
racemase,2863,I-GENE-Y
from,2863,O
barley,2863,O
which,2863,O
contained,2863,O
an,2863,O
open,2863,O
reading,2863,O
frame,2863,O
encoding,2863,O
337,2863,O
amino,2863,B-CHEMICAL
acid,2863,I-CHEMICAL
residues,2863,O
.,2863,O
The,2864,O
deduced,2864,O
amino,2864,B-CHEMICAL
acid,2864,I-CHEMICAL
sequence,2864,O
showed,2864,O
significant,2864,O
identity,2864,O
to,2864,O
plant,2864,O
and,2864,O
mammalian,2864,O
serine,2864,B-GENE-N
racemases,2864,I-GENE-N
and,2864,O
contained,2864,O
conserved,2864,O
pyridoxal,2864,B-CHEMICAL
5-phosphate,2864,I-CHEMICAL
(,2864,O
PLP,2864,B-CHEMICAL
),2864,O
-binding,2864,O
lysine,2864,B-CHEMICAL
and,2864,O
PLP-interacting,2864,B-CHEMICAL
amino,2864,B-CHEMICAL
acid,2864,I-CHEMICAL
residues,2864,O
.,2864,O
The,2865,O
purified,2865,O
gene,2865,O
product,2865,O
catalyzed,2865,O
not,2865,O
only,2865,O
racemization,2865,O
of,2865,O
serine,2865,B-CHEMICAL
but,2865,O
also,2865,O
dehydration,2865,O
of,2865,O
serine,2865,B-CHEMICAL
to,2865,O
pyruvate,2865,B-CHEMICAL
.,2865,O
The,2866,O
enzyme,2866,O
requires,2866,O
PLP,2866,B-CHEMICAL
and,2866,O
divalent,2866,O
cations,2866,O
such,2866,O
as,2866,O
Ca,2866,B-CHEMICAL
(,2866,I-CHEMICAL
2+,2866,I-CHEMICAL
),2866,I-CHEMICAL
",",2866,O
Mg,2866,B-CHEMICAL
(,2866,I-CHEMICAL
2+,2866,I-CHEMICAL
),2866,I-CHEMICAL
",",2866,O
or,2866,O
Mn,2866,B-CHEMICAL
(,2866,I-CHEMICAL
2+,2866,I-CHEMICAL
),2866,I-CHEMICAL
",",2866,O
but,2866,O
not,2866,O
ATP,2866,B-CHEMICAL
",",2866,O
whereas,2866,O
mammalian,2866,O
serine,2866,B-GENE-N
racemase,2866,I-GENE-N
activity,2866,O
is,2866,O
increased,2866,O
by,2866,O
ATP,2866,B-CHEMICAL
.,2866,O
In,2867,O
addition,2867,O
to,2867,O
the,2867,O
results,2867,O
regarding,2867,O
the,2867,O
effect,2867,O
of,2867,O
ATP,2867,B-CHEMICAL
on,2867,O
enzyme,2867,O
activity,2867,O
and,2867,O
the,2867,O
phylogenetic,2867,O
analysis,2867,O
of,2867,O
eukaryotic,2867,O
serine,2867,B-GENE-N
racemases,2867,I-GENE-N
",",2867,O
the,2867,O
antiserum,2867,O
against,2867,O
Arabidopsis,2867,B-GENE-Y
serine,2867,I-GENE-Y
racemase,2867,I-GENE-Y
did,2867,O
not,2867,O
form,2867,O
a,2867,O
precipitate,2867,O
with,2867,O
barley,2867,O
and,2867,O
rice,2867,O
serine,2867,B-GENE-N
racemases,2867,I-GENE-N
.,2867,O
This,2868,O
suggests,2868,O
that,2868,O
plant,2868,O
serine,2868,B-GENE-N
racemases,2868,I-GENE-N
represent,2868,O
a,2868,O
distinct,2868,O
group,2868,O
in,2868,O
the,2868,O
eukaryotic,2868,O
serine,2868,B-GENE-N
racemase,2868,I-GENE-N
family,2868,O
and,2868,O
can,2868,O
be,2868,O
clustered,2868,O
into,2868,O
monocot,2868,O
and,2868,O
dicot,2868,O
types,2868,O
.,2868,O
Characterization,2869,O
of,2869,O
renal,2869,O
ecto-phosphodiesterase,2869,O
.,2869,O
In,2870,O
kidneys,2870,O
",",2870,O
stimulation,2870,O
of,2870,O
adenylyl,2870,B-GENE-N
cyclase,2870,I-GENE-N
causes,2870,O
egress,2870,O
of,2870,O
cAMP,2870,B-CHEMICAL
",",2870,O
conversion,2870,O
of,2870,O
cAMP,2870,B-CHEMICAL
to,2870,O
AMP,2870,B-CHEMICAL
by,2870,O
ecto-phosphodiesterase,2870,O
",",2870,O
and,2870,O
metabolism,2870,O
of,2870,O
AMP,2870,B-CHEMICAL
to,2870,O
adenosine,2870,B-CHEMICAL
by,2870,O
ecto-5'-nucleotidase,2870,B-GENE-Y
.,2870,O
Although,2871,O
much,2871,O
is,2871,O
known,2871,O
about,2871,O
ecto-5'-nucleotidase,2871,B-GENE-Y
",",2871,O
the,2871,O
renal,2871,O
ecto-phosphodiesterase,2871,O
remains,2871,O
uncharacterized,2871,O
.,2871,O
We,2872,O
administered,2872,O
cAMP,2872,B-CHEMICAL
(,2872,O
10,2872,O
microM,2872,O
in,2872,O
the,2872,O
perfusate,2872,O
),2872,O
to,2872,O
12,2872,O
different,2872,O
groups,2872,O
of,2872,O
perfused,2872,O
kidneys,2872,O
.,2872,O
AMP,2873,B-CHEMICAL
was,2873,O
measured,2873,O
in,2873,O
perfusate,2873,O
using,2873,O
ion,2873,O
trap,2873,O
mass,2873,O
spectrometry,2873,O
.,2873,O
In,2874,O
control,2874,O
kidneys,2874,O
(,2874,O
n=19,2874,O
),2874,O
",",2874,O
basal,2874,O
renal,2874,O
secretion,2874,O
rate,2874,O
of,2874,O
AMP,2874,B-CHEMICAL
was,2874,O
0.49+/-0.08,2874,O
and,2874,O
increased,2874,O
to,2874,O
3.0+/-0.2,2874,O
nmol,2874,O
AMP/g,2874,B-CHEMICAL
kidney,2874,O
weight/min,2874,O
during,2874,O
administration,2874,O
of,2874,O
cAMP,2874,B-CHEMICAL
.,2874,O
A,2875,O
broad-spectrum,2875,O
phosphodiesterase,2875,B-GENE-N
(,2875,O
PDE,2875,B-GENE-N
),2875,O
inhibitor,2875,O
(,2875,O
"1,3-isobutyl-1-methylxanthine",2875,B-CHEMICAL
",",2875,O
300,2875,O
microM,2875,O
",",2875,O
n=6,2875,O
),2875,O
and,2875,O
an,2875,O
ecto-phosphodiesterase,2875,O
inhibitor,2875,O
(,2875,O
"1,3-dipropyl-8-p-sulfophenylxanthine",2875,B-CHEMICAL
",",2875,O
1,2875,O
mM,2875,O
",",2875,O
n=6,2875,O
),2875,O
significantly,2875,O
attenuated,2875,O
cAMP-induced,2875,B-CHEMICAL
AMP,2875,B-CHEMICAL
secretion,2875,O
by,2875,O
60,2875,O
and,2875,O
74,2875,O
%,2875,O
",",2875,O
respectively,2875,O
.,2875,O
Blockade,2876,O
of,2876,O
PDE1,2876,B-GENE-N
(,2876,O
8-methoxymethyl-3-isobutyl-1-methylxanthine,2876,B-CHEMICAL
",",2876,O
100,2876,O
microM,2876,O
),2876,O
",",2876,O
PDE2,2876,B-GENE-N
[,2876,O
erythro-9-,2876,B-CHEMICAL
(,2876,I-CHEMICAL
2-hydroxy-3-nonyl,2876,I-CHEMICAL
),2876,I-CHEMICAL
adenine,2876,I-CHEMICAL
",",2876,O
30,2876,O
microM,2876,O
],2876,O
",",2876,O
PDE3,2876,B-GENE-N
(,2876,O
milrinone,2876,B-CHEMICAL
",",2876,O
10,2876,O
microM,2876,O
;,2876,O
cGMP,2876,O
",",2876,O
10,2876,O
microM,2876,O
),2876,O
",",2876,O
PDE4,2876,B-GENE-N
(,2876,O
Ro,2876,O
20-1724,2876,O
[,2876,O
4-,2876,B-CHEMICAL
(,2876,I-CHEMICAL
3-butoxy-4-methoxybenzyl,2876,I-CHEMICAL
),2876,I-CHEMICAL
imidazolidin-2-one,2876,I-CHEMICAL
],2876,O
",",2876,O
100,2876,O
microM,2876,O
),2876,O
",",2876,O
PDE5,2876,B-GENE-Y
and,2876,O
PDE6,2876,B-GENE-N
(,2876,O
zaprinast,2876,B-CHEMICAL
",",2876,O
30,2876,O
microM,2876,O
),2876,O
",",2876,O
and,2876,O
PDE7,2876,B-GENE-N
[,2876,O
BRL-50481,2876,B-CHEMICAL
(,2876,O
5-nitro-2,2876,B-CHEMICAL
",",2876,I-CHEMICAL
N,2876,I-CHEMICAL
",",2876,I-CHEMICAL
N-trimethylbenzenesulfonamide,2876,I-CHEMICAL
),2876,O
",",2876,O
10,2876,O
microM,2876,O
],2876,O
did,2876,O
not,2876,O
alter,2876,O
renal,2876,O
ecto-phosphodiesterase,2876,O
activity,2876,O
.,2876,O
Administration,2877,O
of,2877,O
a,2877,O
concentration,2877,O
(,2877,O
100,2877,O
microM,2877,O
),2877,O
of,2877,O
dipyridamole,2877,B-CHEMICAL
that,2877,O
blocks,2877,O
PDE8,2877,B-GENE-N
inhibited,2877,O
ecto-phosphodiesterase,2877,O
activity,2877,O
(,2877,O
by,2877,O
44,2877,O
%,2877,O
),2877,O
.,2877,O
However,2878,O
",",2878,O
a,2878,O
lower,2878,O
concentration,2878,O
of,2878,O
dipyridamole,2878,B-CHEMICAL
(,2878,O
3,2878,O
microM,2878,O
),2878,O
that,2878,O
blocks,2878,O
PDE9,2878,B-GENE-N
",",2878,O
PDE10,2878,B-GENE-Y
",",2878,O
and,2878,O
PDE11,2878,B-GENE-Y
",",2878,O
but,2878,O
not,2878,O
PDE8,2878,B-GENE-N
",",2878,O
did,2878,O
not,2878,O
inhibit,2878,O
ecto-phosphodiesterase,2878,O
activity,2878,O
.,2878,O
These,2879,O
data,2879,O
support,2879,O
the,2879,O
conclusion,2879,O
that,2879,O
renal,2879,O
ecto-phosphodiesterase,2879,O
activity,2879,O
is,2879,O
not,2879,O
mediated,2879,O
by,2879,O
PDE1,2879,B-GENE-N
",",2879,O
PDE2,2879,B-GENE-N
",",2879,O
PDE3,2879,B-GENE-N
",",2879,O
PDE4,2879,B-GENE-N
",",2879,O
PDE5,2879,B-GENE-Y
",",2879,O
PDE6,2879,B-GENE-N
",",2879,O
PDE7,2879,B-GENE-N
",",2879,O
PDE9,2879,B-GENE-N
",",2879,O
PDE10,2879,B-GENE-Y
",",2879,O
or,2879,O
PDE11,2879,B-GENE-Y
and,2879,O
is,2879,O
inhibited,2879,O
by,2879,O
high,2879,O
concentrations,2879,O
of,2879,O
dipyridamole,2879,B-CHEMICAL
.,2879,O
Ecto-phosphodiesterase,2880,O
has,2880,O
some,2880,O
pharmacological,2880,O
characteristics,2880,O
similar,2880,O
to,2880,O
PDE8,2880,O
.,2880,O
Hyperglycemia,2881,O
slows,2881,O
embryonic,2881,O
growth,2881,O
and,2881,O
suppresses,2881,O
cell,2881,O
cycle,2881,O
via,2881,O
cyclin,2881,B-GENE-Y
D1,2881,I-GENE-Y
and,2881,O
p21,2881,B-GENE-Y
.,2881,O
In,2882,O
pregnant,2882,O
women,2882,O
",",2882,O
the,2882,O
diabetic,2882,O
condition,2882,O
results,2882,O
in,2882,O
a,2882,O
three-,2882,O
to,2882,O
fivefold,2882,O
increased,2882,O
risk,2882,O
for,2882,O
fetal,2882,O
cardiac,2882,O
malformations,2882,O
as,2882,O
a,2882,O
result,2882,O
of,2882,O
elevated,2882,O
glucose,2882,B-CHEMICAL
concentrations,2882,O
and,2882,O
the,2882,O
resultant,2882,O
osmotic,2882,O
stress,2882,O
in,2882,O
the,2882,O
developing,2882,O
embryo,2882,O
and,2882,O
fetus,2882,O
.,2882,O
Heart,2883,O
development,2883,O
before,2883,O
septation,2883,O
in,2883,O
the,2883,O
chick,2883,O
embryo,2883,O
was,2883,O
studied,2883,O
under,2883,O
two,2883,O
hyperglycemic,2883,O
conditions,2883,O
.,2883,O
Pulsed,2884,O
hyperglycemia,2884,O
induced,2884,O
by,2884,O
daily,2884,O
administration,2884,O
of,2884,O
glucose,2884,B-CHEMICAL
during,2884,O
3,2884,O
days,2884,O
of,2884,O
development,2884,O
caused,2884,O
daily,2884,O
spikes,2884,O
in,2884,O
plasma,2884,O
glucose,2884,B-CHEMICAL
concentration,2884,O
.,2884,O
In,2885,O
a,2885,O
second,2885,O
model,2885,O
",",2885,O
sustained,2885,O
hyperglycemia,2885,O
was,2885,O
induced,2885,O
with,2885,O
a,2885,O
single,2885,O
injection,2885,O
of,2885,O
glucose,2885,B-CHEMICAL
into,2885,O
the,2885,O
yolk,2885,O
on,2885,O
day,2885,O
0,2885,O
.,2885,O
The,2886,O
sustained,2886,O
model,2886,O
raised,2886,O
the,2886,O
average,2886,O
plasma,2886,O
glucose,2886,B-CHEMICAL
concentration,2886,O
from,2886,O
70,2886,O
mg/dL,2886,O
to,2886,O
180,2886,O
mg/dL,2886,O
and,2886,O
led,2886,O
to,2886,O
decreased,2886,O
gene,2886,O
expression,2886,O
of,2886,O
glucose,2886,B-GENE-N
transporter,2886,I-GENE-N
GLUT1,2886,B-GENE-Y
.,2886,O
Both,2887,O
models,2887,O
of,2887,O
hyperglycemia,2887,O
reduced,2887,O
embryo,2887,O
size,2887,O
",",2887,O
increased,2887,O
mortality,2887,O
",",2887,O
and,2887,O
delayed,2887,O
development,2887,O
.,2887,O
Within,2888,O
the,2888,O
heart,2888,O
outflow,2888,O
tract,2888,O
",",2888,O
reduced,2888,O
proliferation,2888,O
of,2888,O
myocardial,2888,O
and,2888,O
endocardial,2888,O
cells,2888,O
resulted,2888,O
from,2888,O
the,2888,O
sustained,2888,O
hyperglycemia,2888,O
and,2888,O
hyperosmolarity,2888,O
.,2888,O
The,2889,O
cell,2889,O
cycle,2889,O
inhibitor,2889,O
p21,2889,B-GENE-Y
was,2889,O
significantly,2889,O
increased,2889,O
",",2889,O
whereas,2889,O
cyclin,2889,B-GENE-Y
D1,2889,I-GENE-Y
",",2889,O
a,2889,O
cell,2889,O
cycle,2889,O
promoter,2889,O
",",2889,O
decreased,2889,O
in,2889,O
sustained,2889,O
hyperglycemia,2889,O
compared,2889,O
with,2889,O
controls,2889,O
.,2889,O
The,2890,O
evidence,2890,O
suggests,2890,O
that,2890,O
hyperglycemia-induced,2890,O
developmental,2890,O
delays,2890,O
are,2890,O
associated,2890,O
with,2890,O
slowed,2890,O
cell,2890,O
cycle,2890,O
progression,2890,O
",",2890,O
leading,2890,O
to,2890,O
reduced,2890,O
cellular,2890,O
proliferation,2890,O
.,2890,O
The,2891,O
suppression,2891,O
of,2891,O
critical,2891,O
developmental,2891,O
steps,2891,O
may,2891,O
underlie,2891,O
the,2891,O
cardiac,2891,O
defects,2891,O
observed,2891,O
during,2891,O
late,2891,O
gestation,2891,O
under,2891,O
hyperglycemic,2891,O
conditions,2891,O
.,2891,O
Effect,2892,O
of,2892,O
ketoconazole,2892,B-CHEMICAL
on,2892,O
the,2892,O
pharmacokinetic,2892,O
profile,2892,O
of,2892,O
ambrisentan,2892,B-CHEMICAL
.,2892,O
Ambrisentan,2893,B-CHEMICAL
is,2893,O
an,2893,O
endothelin,2893,B-GENE-Y
type,2893,I-GENE-Y
A,2893,I-GENE-Y
(,2893,I-GENE-Y
ET,2893,I-GENE-Y
(,2893,I-GENE-Y
A,2893,I-GENE-Y
),2893,I-GENE-Y
),2893,I-GENE-Y
-selective,2893,I-GENE-Y
receptor,2893,I-GENE-Y
antagonist,2893,O
that,2893,O
is,2893,O
metabolized,2893,O
primarily,2893,O
by,2893,O
glucuronidation,2893,O
but,2893,O
also,2893,O
undergoes,2893,O
oxidative,2893,O
metabolism,2893,O
by,2893,O
CYP3A4,2893,B-GENE-Y
.,2893,O
The,2894,O
potential,2894,O
for,2894,O
ketoconazole,2894,B-CHEMICAL
",",2894,O
the,2894,O
archetypal,2894,O
strong,2894,O
inhibitor,2894,O
of,2894,O
CYP3A4,2894,B-GENE-Y
",",2894,O
to,2894,O
alter,2894,O
the,2894,O
pharmacokinetic,2894,O
profile,2894,O
of,2894,O
ambrisentan,2894,B-CHEMICAL
and,2894,O
its,2894,O
oxidative,2894,O
metabolite,2894,O
",",2894,O
4-hydroxymethyl,2894,B-CHEMICAL
ambrisentan,2894,I-CHEMICAL
",",2894,O
was,2894,O
assessed,2894,O
in,2894,O
an,2894,O
open-label,2894,O
",",2894,O
nonrandomized,2894,O
",",2894,O
2-period,2894,O
",",2894,O
single-sequence,2894,O
study,2894,O
in,2894,O
16,2894,O
healthy,2894,O
men,2894,O
.,2894,O
Participants,2895,O
received,2895,O
a,2895,O
single,2895,O
dose,2895,O
of,2895,O
ambrisentan,2895,B-CHEMICAL
10,2895,O
mg,2895,O
alone,2895,O
and,2895,O
after,2895,O
4,2895,O
days,2895,O
of,2895,O
ketoconazole,2895,B-CHEMICAL
400,2895,O
mg,2895,O
administered,2895,O
once,2895,O
daily,2895,O
.,2895,O
In,2896,O
the,2896,O
presence,2896,O
of,2896,O
multiple,2896,O
doses,2896,O
of,2896,O
ketoconazole,2896,B-CHEMICAL
",",2896,O
single-dose,2896,O
ambrisentan,2896,B-CHEMICAL
AUC,2896,O
(,2896,O
0-infinity,2896,O
),2896,O
estimate,2896,O
was,2896,O
increased,2896,O
by,2896,O
35.3,2896,O
%,2896,O
",",2896,O
whereas,2896,O
C,2896,O
(,2896,O
max,2896,O
),2896,O
was,2896,O
increased,2896,O
by,2896,O
20.0,2896,O
%,2896,O
.,2896,O
For,2897,O
the,2897,O
4-hydroxymethyl,2897,B-CHEMICAL
ambrisentan,2897,I-CHEMICAL
metabolite,2897,O
",",2897,O
AUC,2897,O
(,2897,O
0-infinity,2897,O
),2897,O
estimate,2897,O
was,2897,O
decreased,2897,O
by,2897,O
4.0,2897,O
%,2897,O
",",2897,O
whereas,2897,O
C,2897,O
(,2897,O
max,2897,O
),2897,O
was,2897,O
decreased,2897,O
by,2897,O
16.5,2897,O
%,2897,O
.,2897,O
Concomitant,2898,O
administration,2898,O
of,2898,O
ambrisentan,2898,B-CHEMICAL
and,2898,O
ketoconazole,2898,B-CHEMICAL
was,2898,O
well,2898,O
tolerated,2898,O
.,2898,O
In,2899,O
summary,2899,O
",",2899,O
ketoconazole,2899,B-CHEMICAL
had,2899,O
no,2899,O
clinically,2899,O
significant,2899,O
effect,2899,O
on,2899,O
the,2899,O
pharmacokinetics,2899,O
or,2899,O
safety,2899,O
profile,2899,O
of,2899,O
ambrisentan,2899,B-CHEMICAL
;,2899,O
therefore,2899,O
",",2899,O
no,2899,O
changes,2899,O
in,2899,O
ambrisentan,2899,B-CHEMICAL
dose,2899,O
should,2899,O
be,2899,O
necessary,2899,O
when,2899,O
the,2899,O
drug,2899,O
is,2899,O
administered,2899,O
concomitantly,2899,O
with,2899,O
known,2899,O
CYP3A4,2899,B-GENE-Y
inhibitors,2899,O
.,2899,O
A,2900,O
Model-Based,2900,O
Approach,2900,O
to,2900,O
Predict,2900,O
Longitudinal,2900,O
HbA1c,2900,B-GENE-Y
",",2900,O
Using,2900,O
Early,2900,O
Phase,2900,O
Glucose,2900,B-CHEMICAL
Data,2900,O
From,2900,O
Type,2900,O
2,2900,O
Diabetes,2900,O
Mellitus,2900,O
Patients,2900,O
After,2900,O
Anti-Diabetic,2900,O
Treatment,2900,O
.,2900,O
Predicting,2901,O
late,2901,O
phase,2901,O
outcomes,2901,O
from,2901,O
early-phase,2901,O
findings,2901,O
can,2901,O
help,2901,O
inform,2901,O
decisions,2901,O
in,2901,O
drug,2901,O
development,2901,O
.,2901,O
If,2902,O
the,2902,O
measurements,2902,O
in,2902,O
early-phase,2902,O
differ,2902,O
from,2902,O
those,2902,O
in,2902,O
late,2902,O
phase,2902,O
",",2902,O
forecasting,2902,O
is,2902,O
more,2902,O
challenging,2902,O
.,2902,O
In,2903,O
this,2903,O
paper,2903,O
",",2903,O
we,2903,O
present,2903,O
a,2903,O
model-based,2903,O
approach,2903,O
for,2903,O
predicting,2903,O
glycosylated,2903,B-GENE-Y
hemoglobin,2903,I-GENE-Y
(,2903,O
HbA1c,2903,B-GENE-Y
),2903,O
in,2903,O
late,2903,O
phase,2903,O
using,2903,O
glucose,2903,B-CHEMICAL
and,2903,O
insulin,2903,B-GENE-Y
concentrations,2903,O
from,2903,O
an,2903,O
early-phase,2903,O
study,2903,O
",",2903,O
investigating,2903,O
an,2903,O
anti-diabetic,2903,O
treatment,2903,O
.,2903,O
Two,2904,O
previously,2904,O
published,2904,O
models,2904,O
were,2904,O
used,2904,O
;,2904,O
an,2904,O
integrated,2904,O
glucose,2904,B-CHEMICAL
and,2904,O
insulin,2904,B-GENE-Y
(,2904,O
IGI,2904,O
),2904,O
model,2904,O
for,2904,O
meal,2904,O
tolerance,2904,O
tests,2904,O
and,2904,O
an,2904,O
integrated,2904,O
glucose-red,2904,B-CHEMICAL
blood,2904,O
cell-HbA1c,2904,O
(,2904,O
IGRH,2904,O
),2904,O
model,2904,O
predicting,2904,O
the,2904,O
formation,2904,O
of,2904,O
HbA1c,2904,B-GENE-Y
from,2904,O
the,2904,O
average,2904,O
glucose,2904,B-CHEMICAL
concentration,2904,O
(,2904,O
Cg,2904,O
",",2904,O
av,2904,O
),2904,O
.,2904,O
Output,2905,O
from,2905,O
the,2905,O
IGI,2905,O
model,2905,O
was,2905,O
used,2905,O
as,2905,O
input,2905,O
to,2905,O
the,2905,O
IGRH,2905,O
model,2905,O
.,2905,O
Parameters,2906,O
of,2906,O
the,2906,O
IGI,2906,O
model,2906,O
and,2906,O
drug,2906,O
effects,2906,O
were,2906,O
estimated,2906,O
using,2906,O
data,2906,O
from,2906,O
a,2906,O
phase1,2906,O
study,2906,O
in,2906,O
59,2906,O
diabetic,2906,O
patients,2906,O
receiving,2906,O
various,2906,O
doses,2906,O
of,2906,O
a,2906,O
glucokinase,2906,B-GENE-Y
activator,2906,O
.,2906,O
Cg,2907,O
",",2907,O
av,2907,O
values,2907,O
were,2907,O
simulated,2907,O
according,2907,O
to,2907,O
a,2907,O
Phase,2907,O
2,2907,O
study,2907,O
design,2907,O
and,2907,O
used,2907,O
in,2907,O
the,2907,O
IGRH,2907,O
model,2907,O
for,2907,O
predictions,2907,O
of,2907,O
HbA1c,2907,B-GENE-Y
.,2907,O
The,2908,O
performance,2908,O
of,2908,O
the,2908,O
model-based,2908,O
approach,2908,O
was,2908,O
assessed,2908,O
by,2908,O
comparing,2908,O
the,2908,O
predicted,2908,O
to,2908,O
the,2908,O
actual,2908,O
outcome,2908,O
of,2908,O
the,2908,O
Phase,2908,O
2,2908,O
study,2908,O
.,2908,O
We,2909,O
have,2909,O
shown,2909,O
that,2909,O
this,2909,O
approach,2909,O
well,2909,O
predicts,2909,O
the,2909,O
longitudinal,2909,O
HbA1c,2909,B-GENE-Y
response,2909,O
in,2909,O
a,2909,O
12-week,2909,O
study,2909,O
using,2909,O
only,2909,O
information,2909,O
from,2909,O
a,2909,O
1-week,2909,O
study,2909,O
where,2909,O
glucose,2909,B-CHEMICAL
and,2909,O
insulin,2909,B-GENE-Y
concentrations,2909,O
were,2909,O
measured,2909,O
.,2909,O
Reduction,2910,O
of,2910,O
dimethylarsinic,2910,B-CHEMICAL
acid,2910,I-CHEMICAL
to,2910,O
the,2910,O
highly,2910,O
toxic,2910,O
dimethylarsinous,2910,B-CHEMICAL
acid,2910,I-CHEMICAL
by,2910,O
rats,2910,O
and,2910,O
rat,2910,O
liver,2910,O
cytosol,2910,O
.,2910,O
Dimethylarsinic,2911,B-CHEMICAL
acid,2911,I-CHEMICAL
(,2911,O
DMAs,2911,B-CHEMICAL
(,2911,I-CHEMICAL
V,2911,I-CHEMICAL
),2911,I-CHEMICAL
),2911,O
",",2911,O
the,2911,O
major,2911,O
urinary,2911,O
metabolite,2911,O
of,2911,O
inorganic,2911,O
arsenic,2911,B-CHEMICAL
",",2911,O
is,2911,O
weakly,2911,O
cytotoxic,2911,O
",",2911,O
whereas,2911,O
its,2911,O
reduced,2911,O
form,2911,O
",",2911,O
dimethylarsinous,2911,B-CHEMICAL
acid,2911,I-CHEMICAL
(,2911,O
DMAs,2911,B-CHEMICAL
(,2911,I-CHEMICAL
III,2911,I-CHEMICAL
),2911,I-CHEMICAL
),2911,O
",",2911,O
is,2911,O
highly,2911,O
toxic,2911,O
.,2911,O
Although,2912,O
glutathione,2912,B-GENE-Y
S-transferase,2912,I-GENE-Y
omega,2912,I-GENE-Y
1,2912,I-GENE-Y
(,2912,O
GSTO1,2912,B-GENE-Y
),2912,O
and,2912,O
arsenic,2912,B-GENE-Y
methyltransferase,2912,I-GENE-Y
have,2912,O
been,2912,O
shown,2912,O
or,2912,O
thought,2912,O
to,2912,O
catalyze,2912,O
DMAs,2912,B-CHEMICAL
(,2912,I-CHEMICAL
V,2912,I-CHEMICAL
),2912,I-CHEMICAL
reduction,2912,O
",",2912,O
their,2912,O
role,2912,O
in,2912,O
DMAs,2912,B-CHEMICAL
(,2912,I-CHEMICAL
V,2912,I-CHEMICAL
),2912,I-CHEMICAL
reduction,2912,O
in,2912,O
vivo,2912,O
",",2912,O
or,2912,O
in,2912,O
cell,2912,O
extracts,2912,O
is,2912,O
uncertain,2912,O
.,2912,O
Therefore,2913,O
",",2913,O
the,2913,O
reduction,2913,O
of,2913,O
DMAs,2913,B-CHEMICAL
(,2913,I-CHEMICAL
V,2913,I-CHEMICAL
),2913,I-CHEMICAL
to,2913,O
DMAs,2913,B-CHEMICAL
(,2913,I-CHEMICAL
III,2913,I-CHEMICAL
),2913,I-CHEMICAL
in,2913,O
rats,2913,O
and,2913,O
in,2913,O
rat,2913,O
liver,2913,O
cytosol,2913,O
was,2913,O
studied,2913,O
to,2913,O
better,2913,O
understand,2913,O
its,2913,O
mechanism,2913,O
.,2913,O
To,2914,O
assess,2914,O
DMAs,2914,B-CHEMICAL
(,2914,I-CHEMICAL
V,2914,I-CHEMICAL
),2914,I-CHEMICAL
reduction,2914,O
in,2914,O
rats,2914,O
",",2914,O
a,2914,O
novel,2914,O
procedure,2914,O
was,2914,O
devised,2914,O
based,2914,O
on,2914,O
following,2914,O
the,2914,O
accumulation,2914,O
of,2914,O
red,2914,O
blood,2914,O
cell,2914,O
(,2914,O
RBC,2914,O
),2914,O
-bound,2914,O
dimethylarsenic,2914,B-CHEMICAL
(,2914,O
DMAs,2914,B-CHEMICAL
),2914,O
",",2914,O
which,2914,O
represents,2914,O
DMAs,2914,B-CHEMICAL
(,2914,I-CHEMICAL
III,2914,I-CHEMICAL
),2914,I-CHEMICAL
",",2914,O
in,2914,O
the,2914,O
blood,2914,O
of,2914,O
DMAs,2914,B-CHEMICAL
(,2914,I-CHEMICAL
V,2914,I-CHEMICAL
),2914,I-CHEMICAL
-injected,2914,O
anesthetized,2914,O
rats,2914,O
.,2914,O
These,2915,O
studies,2915,O
indicated,2915,O
that,2915,O
rats,2915,O
reduced,2915,O
DMAs,2915,B-CHEMICAL
(,2915,I-CHEMICAL
V,2915,I-CHEMICAL
),2915,I-CHEMICAL
to,2915,O
DMAs,2915,B-CHEMICAL
(,2915,I-CHEMICAL
III,2915,I-CHEMICAL
),2915,I-CHEMICAL
to,2915,O
a,2915,O
significant,2915,O
extent,2915,O
",",2915,O
as,2915,O
in,2915,O
90,2915,O
min,2915,O
31,2915,O
%,2915,O
of,2915,O
the,2915,O
injected,2915,O
50,2915,O
μmol/kg,2915,O
DMAs,2915,B-CHEMICAL
(,2915,I-CHEMICAL
V,2915,I-CHEMICAL
),2915,I-CHEMICAL
dose,2915,O
was,2915,O
converted,2915,O
to,2915,O
DMAs,2915,B-CHEMICAL
(,2915,I-CHEMICAL
III,2915,I-CHEMICAL
),2915,I-CHEMICAL
that,2915,O
was,2915,O
sequestered,2915,O
by,2915,O
the,2915,O
circulating,2915,O
erythrocytes,2915,O
.,2915,O
Pretreatment,2916,O
of,2916,O
rats,2916,O
with,2916,O
glutathione,2916,B-CHEMICAL
(,2916,O
GSH,2916,B-CHEMICAL
),2916,O
depletors,2916,O
(,2916,O
phorone,2916,B-CHEMICAL
or,2916,O
BSO,2916,B-CHEMICAL
),2916,O
delayed,2916,O
the,2916,O
elimination,2916,O
of,2916,O
DMAs,2916,B-CHEMICAL
(,2916,I-CHEMICAL
V,2916,I-CHEMICAL
),2916,I-CHEMICAL
and,2916,O
the,2916,O
accumulation,2916,O
of,2916,O
RBC-bound,2916,O
DMAs,2916,B-CHEMICAL
",",2916,O
whereas,2916,O
the,2916,O
indirect,2916,O
methyltransferase,2916,B-GENE-N
inhibitor,2916,O
periodate-oxidized,2916,B-CHEMICAL
adenosine,2916,B-CHEMICAL
was,2916,O
without,2916,O
effect,2916,O
.,2916,O
Assessment,2917,O
of,2917,O
DMAs,2917,B-CHEMICAL
(,2917,I-CHEMICAL
V,2917,I-CHEMICAL
),2917,I-CHEMICAL
-reducing,2917,O
activity,2917,O
of,2917,O
rat,2917,O
liver,2917,O
cytosol,2917,O
revealed,2917,O
that,2917,O
reduction,2917,O
of,2917,O
DMAs,2917,B-CHEMICAL
(,2917,I-CHEMICAL
V,2917,I-CHEMICAL
),2917,I-CHEMICAL
required,2917,O
cytosolic,2917,O
protein,2917,O
and,2917,O
GSH,2917,B-CHEMICAL
and,2917,O
was,2917,O
inhibited,2917,O
by,2917,O
thiol,2917,B-CHEMICAL
reagents,2917,O
",",2917,O
GSSG,2917,B-CHEMICAL
and,2917,O
dehydroascorbate,2917,B-CHEMICAL
.,2917,O
Although,2918,O
thioredoxin,2918,B-GENE-N
reductase,2918,I-GENE-N
(,2918,O
TRR,2918,B-GENE-N
),2918,O
inhibitors,2918,O
(,2918,O
aurothioglucose,2918,B-CHEMICAL
and,2918,O
Sb,2918,B-CHEMICAL
(,2918,I-CHEMICAL
III,2918,I-CHEMICAL
),2918,I-CHEMICAL
),2918,O
inhibited,2918,O
cytosolic,2918,O
DMAs,2918,B-CHEMICAL
(,2918,I-CHEMICAL
V,2918,I-CHEMICAL
),2918,I-CHEMICAL
reduction,2918,O
",",2918,O
recombinant,2918,O
rat,2918,B-GENE-N
TRR,2918,I-GENE-N
plus,2918,O
NADPH,2918,B-CHEMICAL
",",2918,O
alone,2918,O
or,2918,O
when,2918,O
added,2918,O
to,2918,O
the,2918,O
cytosol,2918,O
",",2918,O
failed,2918,O
to,2918,O
support,2918,O
DMAs,2918,B-CHEMICAL
(,2918,I-CHEMICAL
V,2918,I-CHEMICAL
),2918,I-CHEMICAL
reduction,2918,O
.,2918,O
On,2919,O
ultrafiltration,2919,O
of,2919,O
the,2919,O
cytosol,2919,O
through,2919,O
a,2919,O
3,2919,O
kDa,2919,O
filter,2919,O
",",2919,O
the,2919,O
reducing,2919,O
activity,2919,O
in,2919,O
the,2919,O
retentate,2919,O
was,2919,O
lost,2919,O
but,2919,O
was,2919,O
largely,2919,O
restored,2919,O
by,2919,O
NADPH,2919,B-CHEMICAL
.,2919,O
Such,2920,O
experiments,2920,O
also,2920,O
suggested,2920,O
that,2920,O
the,2920,O
reducing,2920,O
enzyme,2920,O
was,2920,O
larger,2920,O
than,2920,O
100,2920,O
kDa,2920,O
and,2920,O
was,2920,O
not,2920,O
GSTO1,2920,B-GENE-Y
.,2920,O
In,2921,O
summary,2921,O
",",2921,O
reduction,2921,O
of,2921,O
DMAs,2921,B-CHEMICAL
(,2921,I-CHEMICAL
V,2921,I-CHEMICAL
),2921,I-CHEMICAL
to,2921,O
the,2921,O
highly,2921,O
toxic,2921,O
DMAs,2921,B-CHEMICAL
(,2921,I-CHEMICAL
III,2921,I-CHEMICAL
),2921,I-CHEMICAL
in,2921,O
rats,2921,O
and,2921,O
rat,2921,O
liver,2921,O
cytosol,2921,O
is,2921,O
a,2921,O
GSH-dependent,2921,B-CHEMICAL
enzymatic,2921,O
process,2921,O
",",2921,O
yet,2921,O
its,2921,O
mechanism,2921,O
remains,2921,O
uncertain,2921,O
.,2921,O
Effect,2922,O
of,2922,O
thiazinotrienomycin,2922,B-CHEMICAL
B,2922,I-CHEMICAL
",",2922,O
an,2922,O
ansamycin,2922,B-CHEMICAL
antibiotic,2922,O
",",2922,O
on,2922,O
the,2922,O
function,2922,O
of,2922,O
epidermal,2922,B-GENE-Y
growth,2922,I-GENE-Y
factor,2922,I-GENE-Y
receptor,2922,I-GENE-Y
in,2922,O
human,2922,O
stomach,2922,O
tumor,2922,O
cells,2922,O
.,2922,O
Thiazinotrienomycin,2923,B-CHEMICAL
B,2923,I-CHEMICAL
(,2923,O
TT-B,2923,B-CHEMICAL
),2923,O
",",2923,O
an,2923,O
ansamycin,2923,B-CHEMICAL
isolated,2923,O
from,2923,O
fermentation,2923,O
broths,2923,O
of,2923,O
Streptomyces,2923,O
sp,2923,O
.,2923,O
MJ672-m3,2924,O
",",2924,O
inhibited,2924,O
the,2924,O
growth,2924,O
in,2924,O
vitro,2924,O
of,2924,O
human,2924,O
stomach,2924,O
tumor,2924,O
SC-6,2924,O
cells,2924,O
over,2924,O
10,2924,O
times,2924,O
more,2924,O
strongly,2924,O
than,2924,O
the,2924,O
growth,2924,O
of,2924,O
other,2924,O
human,2924,O
tumor,2924,O
cells,2924,O
",",2924,O
such,2924,O
as,2924,O
HeLa,2924,O
(,2924,O
cervix,2924,O
),2924,O
",",2924,O
T24,2924,O
(,2924,O
bladder,2924,O
),2924,O
and,2924,O
LX-1,2924,O
(,2924,O
lung,2924,O
),2924,O
.,2924,O
The,2925,O
extent,2925,O
of,2925,O
growth,2925,O
inhibition,2925,O
by,2925,O
TT-B,2925,O
of,2925,O
SC-6,2925,O
",",2925,O
but,2925,O
not,2925,O
of,2925,O
LX-1,2925,O
nor,2925,O
T24,2925,O
",",2925,O
was,2925,O
lowered,2925,O
in,2925,O
a,2925,O
competitive,2925,O
manner,2925,O
by,2925,O
raising,2925,O
serum,2925,O
concentrations,2925,O
in,2925,O
the,2925,O
culture,2925,O
medium,2925,O
.,2925,O
TT-B,2926,B-CHEMICAL
inhibited,2926,O
the,2926,O
cell,2926,O
cycle,2926,O
progression,2926,O
of,2926,O
SC-6,2926,O
at,2926,O
an,2926,O
early,2926,O
stage,2926,O
of,2926,O
the,2926,O
progression,2926,O
from,2926,O
G0/G1,2926,O
to,2926,O
S.,2926,O
The,2926,O
inhibition,2926,O
was,2926,O
again,2926,O
competitive,2926,O
with,2926,O
serum,2926,O
concentrations,2926,O
in,2926,O
the,2926,O
culture,2926,O
medium,2926,O
.,2926,O
No,2927,O
direct,2927,O
inhibition,2927,O
of,2927,O
DNA,2927,O
synthesis,2927,O
was,2927,O
observed,2927,O
at,2927,O
the,2927,O
concentration,2927,O
range,2927,O
which,2927,O
caused,2927,O
the,2927,O
cell,2927,O
cycle,2927,O
arrest,2927,O
.,2927,O
TT-B,2928,B-CHEMICAL
and,2928,O
anti-epidermal,2928,O
growth,2928,I-GENE-Y
factor,2928,I-GENE-Y
receptor,2928,I-GENE-Y
(,2928,O
anti-EGFR,2928,O
),2928,O
were,2928,O
antagonistic,2928,O
to,2928,O
each,2928,O
other,2928,O
in,2928,O
inhibiting,2928,O
the,2928,O
cell,2928,O
cycle,2928,O
progression,2928,O
of,2928,O
SC-6,2928,O
from,2928,O
G0/G1,2928,O
to,2928,O
S,2928,O
",",2928,O
suggesting,2928,O
that,2928,O
the,2928,O
two,2928,O
compounds,2928,O
share,2928,O
the,2928,O
same,2928,O
target,2928,O
",",2928,O
EGFR,2928,B-GENE-Y
.,2928,O
The,2929,O
kinase,2929,B-GENE-N
activity,2929,O
of,2929,O
EGFR,2929,B-GENE-Y
was,2929,O
little,2929,O
inhibited,2929,O
by,2929,O
TT-B,2929,B-CHEMICAL
in,2929,O
a,2929,O
cell-free,2929,O
system,2929,O
.,2929,O
Vapreotide,2930,B-CHEMICAL
:,2930,O
a,2930,O
somatostatin,2930,B-GENE-Y
analog,2930,O
for,2930,O
the,2930,O
treatment,2930,O
of,2930,O
acute,2930,O
variceal,2930,O
bleeding,2930,O
.,2930,O
BACKGROUND,2931,O
:,2931,O
Portal,2931,O
hypertension,2931,O
is,2931,O
a,2931,O
clinically,2931,O
important,2931,O
consequence,2931,O
of,2931,O
cirrhosis,2931,O
that,2931,O
can,2931,O
lead,2931,O
to,2931,O
morbidities,2931,O
such,2931,O
as,2931,O
variceal,2931,O
bleeding,2931,O
",",2931,O
hepatic,2931,O
encephalopathy,2931,O
and,2931,O
ascites,2931,O
.,2931,O
All,2932,O
of,2932,O
these,2932,O
outcomes,2932,O
carry,2932,O
high,2932,O
mortality,2932,O
rates,2932,O
.,2932,O
There,2933,O
have,2933,O
been,2933,O
several,2933,O
drugs,2933,O
created,2933,O
to,2933,O
assist,2933,O
with,2933,O
endoscopic,2933,O
therapy,2933,O
for,2933,O
the,2933,O
treatment,2933,O
of,2933,O
acute,2933,O
variceal,2933,O
bleeding,2933,O
.,2933,O
Recently,2934,O
",",2934,O
vapreotide,2934,B-CHEMICAL
has,2934,O
been,2934,O
studied,2934,O
in,2934,O
patients,2934,O
to,2934,O
evaluate,2934,O
its,2934,O
efficacy,2934,O
as,2934,O
treatment,2934,O
for,2934,O
acute,2934,O
variceal,2934,O
hemorrhage,2934,O
.,2934,O
Although,2935,O
no,2935,O
comparisons,2935,O
have,2935,O
been,2935,O
made,2935,O
between,2935,O
vapreotide,2935,B-CHEMICAL
and,2935,O
other,2935,O
somatostatin,2935,B-GENE-Y
analogues,2935,O
",",2935,O
this,2935,O
drug,2935,O
has,2935,O
been,2935,O
shown,2935,O
to,2935,O
have,2935,O
efficacy,2935,O
in,2935,O
the,2935,O
control,2935,O
of,2935,O
acute,2935,O
variceal,2935,O
bleeding,2935,O
as,2935,O
well,2935,O
as,2935,O
reducing,2935,O
the,2935,O
risk,2935,O
of,2935,O
recurrent,2935,O
bleeding,2935,O
and,2935,O
death,2935,O
",",2935,O
especially,2935,O
when,2935,O
started,2935,O
prior,2935,O
to,2935,O
endoscopy,2935,O
.,2935,O
OBJECTIVE,2936,O
:,2936,O
This,2936,O
paper,2936,O
reviews,2936,O
the,2936,O
literature,2936,O
regarding,2936,O
the,2936,O
basic,2936,O
science,2936,O
and,2936,O
clinical,2936,O
efficacy,2936,O
of,2936,O
vapreotide,2936,B-CHEMICAL
in,2936,O
acute,2936,O
variceal,2936,O
bleeding,2936,O
.,2936,O
METHODS,2937,O
:,2937,O
We,2937,O
used,2937,O
a,2937,O
PubMed/Medline,2937,O
search,2937,O
in,2937,O
order,2937,O
to,2937,O
review,2937,O
the,2937,O
literature,2937,O
regarding,2937,O
the,2937,O
drug,2937,O
",",2937,O
vapreotide,2937,B-CHEMICAL
.,2937,O
RESULTS/CONCLUSIONS,2938,O
:,2938,O
Vapreotide,2938,B-CHEMICAL
appears,2938,O
to,2938,O
have,2938,O
benefit,2938,O
in,2938,O
the,2938,O
control,2938,O
of,2938,O
acute,2938,O
variceal,2938,O
bleeding,2938,O
.,2938,O
It,2939,O
is,2939,O
easy,2939,O
to,2939,O
administer,2939,O
and,2939,O
has,2939,O
few,2939,O
side,2939,O
effects,2939,O
",",2939,O
which,2939,O
are,2939,O
minor,2939,O
.,2939,O
These,2940,O
findings,2940,O
endorse,2940,O
the,2940,O
need,2940,O
for,2940,O
future,2940,O
trials,2940,O
to,2940,O
evaluate,2940,O
vapreotide,2940,B-CHEMICAL
and,2940,O
its,2940,O
use,2940,O
in,2940,O
acute,2940,O
variceal,2940,O
hemorrhage,2940,O
",",2940,O
a,2940,O
morbidity,2940,O
among,2940,O
patients,2940,O
with,2940,O
cirrhosis,2940,O
.,2940,O
Sorafenib,2941,B-CHEMICAL
(,2941,O
BAY,2941,B-CHEMICAL
43-9006,2941,I-CHEMICAL
",",2941,O
Nexavar,2941,B-CHEMICAL
),2941,O
",",2941,O
a,2941,O
dual-action,2941,O
inhibitor,2941,O
that,2941,O
targets,2941,O
RAF/MEK/ERK,2941,B-GENE-N
pathway,2941,O
in,2941,O
tumor,2941,O
cells,2941,O
and,2941,O
tyrosine,2941,B-GENE-N
kinases,2941,I-GENE-N
VEGFR/PDGFR,2941,B-GENE-N
in,2941,O
tumor,2941,O
vasculature,2941,O
.,2941,O
Activating,2942,O
mutations,2942,O
in,2942,O
Ras,2942,B-GENE-N
and,2942,O
B-RAF,2942,B-GENE-Y
were,2942,O
identified,2942,O
in,2942,O
several,2942,O
human,2942,O
cancers,2942,O
.,2942,O
In,2943,O
addition,2943,O
",",2943,O
several,2943,O
receptor,2943,B-GENE-N
tyrosine,2943,I-GENE-N
kinases,2943,I-GENE-N
",",2943,O
acting,2943,O
upstream,2943,O
of,2943,O
Ras,2943,B-GENE-N
",",2943,O
were,2943,O
found,2943,O
either,2943,O
mutated,2943,O
or,2943,O
overexpressed,2943,O
in,2943,O
human,2943,O
tumors,2943,O
.,2943,O
Because,2944,O
oncogenic,2944,O
activation,2944,O
of,2944,O
the,2944,O
Ras/RAF,2944,B-GENE-N
pathway,2944,O
may,2944,O
lead,2944,O
to,2944,O
a,2944,O
sustained,2944,O
proliferative,2944,O
signal,2944,O
resulting,2944,O
in,2944,O
tumor,2944,O
growth,2944,O
and,2944,O
progression,2944,O
",",2944,O
inhibition,2944,O
of,2944,O
this,2944,O
pathway,2944,O
represents,2944,O
an,2944,O
attractive,2944,O
approach,2944,O
for,2944,O
cancer,2944,O
drug,2944,O
discovery,2944,O
.,2944,O
A,2945,O
novel,2945,O
class,2945,O
of,2945,O
biaryl,2945,B-CHEMICAL
urea,2945,I-CHEMICAL
that,2945,O
inhibits,2945,O
C-RAF,2945,B-GENE-Y
kinase,2945,B-GENE-N
was,2945,O
discovered,2945,O
using,2945,O
a,2945,O
combination,2945,O
of,2945,O
medicinal,2945,O
and,2945,O
combinatorial,2945,O
chemistry,2945,O
approaches,2945,O
.,2945,O
This,2946,O
effort,2946,O
culminated,2946,O
in,2946,O
the,2946,O
identification,2946,O
of,2946,O
the,2946,O
clinical,2946,O
candidate,2946,O
BAY,2946,B-CHEMICAL
43-9006,2946,I-CHEMICAL
(,2946,O
Sorafenib,2946,B-CHEMICAL
",",2946,O
Nexavar,2946,B-CHEMICAL
),2946,O
",",2946,O
which,2946,O
has,2946,O
recently,2946,O
been,2946,O
approved,2946,O
by,2946,O
the,2946,O
FDA,2946,O
for,2946,O
advanced,2946,O
renal,2946,O
cell,2946,O
carcinoma,2946,O
in,2946,O
phase,2946,O
III,2946,O
clinical,2946,O
trials,2946,O
.,2946,O
Sorafenib,2947,B-CHEMICAL
inhibited,2947,O
the,2947,O
kinase,2947,B-GENE-N
activity,2947,O
of,2947,O
both,2947,O
C-RAF,2947,B-GENE-Y
and,2947,O
B-RAF,2947,B-GENE-Y
(,2947,O
wild,2947,O
type,2947,O
and,2947,O
V600E,2947,B-GENE-N
mutant,2947,O
),2947,O
.,2947,O
It,2948,O
inhibited,2948,O
MEK,2948,B-GENE-N
and,2948,O
ERK,2948,B-GENE-N
phosphorylation,2948,O
in,2948,O
various,2948,O
cancer,2948,O
cell,2948,O
lines,2948,O
and,2948,O
tumor,2948,O
xenografts,2948,O
and,2948,O
exhibited,2948,O
potent,2948,O
oral,2948,O
antitumor,2948,O
activity,2948,O
in,2948,O
a,2948,O
broad,2948,O
spectrum,2948,O
of,2948,O
human,2948,O
tumor,2948,O
xenograft,2948,O
models,2948,O
.,2948,O
Further,2949,O
characterization,2949,O
of,2949,O
sorafenib,2949,B-CHEMICAL
revealed,2949,O
that,2949,O
this,2949,O
molecule,2949,O
was,2949,O
a,2949,O
multikinase,2949,O
inhibitor,2949,O
that,2949,O
targeted,2949,O
the,2949,O
vascular,2949,B-GENE-N
endothelial,2949,I-GENE-N
growth,2949,I-GENE-N
factor,2949,I-GENE-N
receptor,2949,I-GENE-N
family,2949,O
(,2949,O
VEGFR-2,2949,B-GENE-Y
and,2949,O
VEGFR-3,2949,B-GENE-Y
),2949,O
and,2949,O
platelet-derived,2949,B-GENE-N
growth,2949,I-GENE-N
factor,2949,I-GENE-N
receptor,2949,I-GENE-N
family,2949,O
(,2949,O
PDGFR-beta,2949,B-GENE-Y
and,2949,O
Kit,2949,B-GENE-Y
),2949,O
",",2949,O
which,2949,O
play,2949,O
key,2949,O
roles,2949,O
in,2949,O
tumor,2949,O
progression,2949,O
and,2949,O
angiogenesis,2949,O
.,2949,O
Thus,2950,O
",",2950,O
sorafenib,2950,B-CHEMICAL
may,2950,O
inhibit,2950,O
tumor,2950,O
growth,2950,O
by,2950,O
a,2950,O
dual,2950,O
mechanism,2950,O
",",2950,O
acting,2950,O
either,2950,O
directly,2950,O
on,2950,O
the,2950,O
tumor,2950,O
(,2950,O
through,2950,O
inhibition,2950,O
of,2950,O
Raf,2950,B-GENE-N
and,2950,O
Kit,2950,B-GENE-Y
signaling,2950,O
),2950,O
and/or,2950,O
on,2950,O
tumor,2950,O
angiogenesis,2950,O
(,2950,O
through,2950,O
inhibition,2950,O
of,2950,O
VEGFR,2950,B-GENE-N
and,2950,O
PDGFR,2950,B-GENE-N
signaling,2950,O
),2950,O
.,2950,O
In,2951,O
phase,2951,O
I,2951,O
and,2951,O
phase,2951,O
II,2951,O
clinical,2951,O
trials,2951,O
",",2951,O
sorafenib,2951,B-CHEMICAL
showed,2951,O
limited,2951,O
side,2951,O
effects,2951,O
and,2951,O
",",2951,O
more,2951,O
importantly,2951,O
",",2951,O
disease,2951,O
stabilization,2951,O
.,2951,O
This,2952,O
agent,2952,O
is,2952,O
currently,2952,O
being,2952,O
evaluated,2952,O
in,2952,O
phase,2952,O
III,2952,O
clinical,2952,O
trials,2952,O
in,2952,O
renal,2952,O
cell,2952,O
and,2952,O
hepatocellular,2952,O
carcinomas,2952,O
.,2952,O
Treatment-related,2953,O
osteoporosis,2953,O
in,2953,O
men,2953,O
with,2953,O
prostate,2953,O
cancer,2953,O
.,2953,O
The,2954,O
intended,2954,O
therapeutic,2954,O
effect,2954,O
of,2954,O
gonadotropin-releasing,2954,B-GENE-Y
hormone,2954,I-GENE-Y
(,2954,O
GnRH,2954,B-GENE-Y
),2954,O
agonists,2954,O
is,2954,O
hypogonadism,2954,O
",",2954,O
a,2954,O
major,2954,O
cause,2954,O
of,2954,O
acquired,2954,O
osteoporosis,2954,O
in,2954,O
men,2954,O
.,2954,O
Consistent,2955,O
with,2955,O
this,2955,O
observation,2955,O
",",2955,O
GnRH,2955,B-GENE-Y
agonists,2955,O
increase,2955,O
bone,2955,O
turnover,2955,O
and,2955,O
decrease,2955,O
bone,2955,O
mineral,2955,O
density,2955,O
",",2955,O
a,2955,O
surrogate,2955,O
for,2955,O
fracture,2955,O
risk,2955,O
.,2955,O
Large,2956,O
claims-based,2956,O
analyses,2956,O
and,2956,O
other,2956,O
retrospective,2956,O
studies,2956,O
provide,2956,O
compelling,2956,O
evidence,2956,O
that,2956,O
GnRH,2956,B-GENE-Y
agonists,2956,O
increase,2956,O
risk,2956,O
of,2956,O
clinical,2956,O
fractures,2956,O
.,2956,O
Estrogens,2957,B-CHEMICAL
play,2957,O
a,2957,O
central,2957,O
role,2957,O
in,2957,O
homeostasis,2957,O
of,2957,O
the,2957,O
normal,2957,O
male,2957,O
skeleton,2957,O
",",2957,O
and,2957,O
estrogen,2957,B-CHEMICAL
deficiency,2957,O
rather,2957,O
than,2957,O
testosterone,2957,B-CHEMICAL
deficiency,2957,O
seems,2957,O
to,2957,O
be,2957,O
primarily,2957,O
responsible,2957,O
for,2957,O
the,2957,O
adverse,2957,O
skeletal,2957,O
effects,2957,O
of,2957,O
GnRH,2957,B-GENE-Y
agonists,2957,O
.,2957,O
In,2958,O
randomized,2958,O
controlled,2958,O
trials,2958,O
",",2958,O
bisphosphonates,2958,B-CHEMICAL
(,2958,O
pamidronate,2958,B-CHEMICAL
and,2958,O
zoledronic,2958,B-CHEMICAL
acid,2958,I-CHEMICAL
),2958,O
and,2958,O
selective,2958,O
estrogen,2958,B-GENE-Y
receptor,2958,I-GENE-Y
modulators,2958,O
(,2958,O
raloxifene,2958,B-CHEMICAL
and,2958,O
toremifene,2958,B-CHEMICAL
),2958,O
increased,2958,O
bone,2958,O
mineral,2958,O
density,2958,O
in,2958,O
GnRH,2958,B-GENE-Y
agonist-treated,2958,O
men,2958,O
.,2958,O
Two,2959,O
ongoing,2959,O
large,2959,O
randomized,2959,O
placebo-controlled,2959,O
studies,2959,O
will,2959,O
prospectively,2959,O
define,2959,O
fracture,2959,O
outcomes,2959,O
in,2959,O
men,2959,O
with,2959,O
prostate,2959,O
cancer,2959,O
and,2959,O
assess,2959,O
the,2959,O
efficacy,2959,O
of,2959,O
novel,2959,O
pharmacologic,2959,O
interventions,2959,O
(,2959,O
AMG162,2959,O
",",2959,O
toremifene,2959,B-CHEMICAL
),2959,O
during,2959,O
GnRH,2959,B-GENE-Y
agonist,2959,O
treatment,2959,O
.,2959,O
Rapamycin,2960,B-CHEMICAL
allosterically,2960,O
inhibits,2960,O
the,2960,O
proteasome,2960,B-GENE-N
.,2960,O
Rapamycin,2961,B-CHEMICAL
is,2961,O
a,2961,O
canonical,2961,O
allosteric,2961,O
inhibitor,2961,O
of,2961,O
the,2961,O
mTOR,2961,B-GENE-Y
kinase,2961,B-GENE-N
with,2961,O
immunosuppressive,2961,O
and,2961,O
pro-apoptotic,2961,O
activities,2961,O
.,2961,O
We,2962,O
found,2962,O
that,2962,O
in,2962,O
vitro,2962,O
rapamycin,2962,B-CHEMICAL
also,2962,O
regulates,2962,O
the,2962,O
proteasome,2962,B-GENE-N
",",2962,O
an,2962,O
essential,2962,O
intracellular,2962,O
protease,2962,O
of,2962,O
the,2962,O
ubiquitin-proteasome,2962,B-GENE-N
pathway,2962,O
.,2962,O
Rapamycin,2963,B-CHEMICAL
inhibits,2963,O
proteinase,2963,B-GENE-N
and,2963,O
selected,2963,O
peptidase,2963,B-GENE-N
activities,2963,O
of,2963,O
the,2963,O
catalytic,2963,O
core,2963,O
proteasome,2963,B-GENE-N
at,2963,O
low,2963,O
micromolar,2963,O
concentrations,2963,O
.,2963,O
Moreover,2964,O
",",2964,O
the,2964,O
drug,2964,O
interferes,2964,O
with,2964,O
binding,2964,O
of,2964,O
the,2964,O
19S,2964,O
cap,2964,O
essential,2964,O
for,2964,O
processing,2964,O
of,2964,O
polyubiquitinylated,2964,O
substrates,2964,O
",",2964,O
and,2964,O
the,2964,O
PA200,2964,B-GENE-Y
activator,2964,O
to,2964,O
the,2964,O
20S,2964,B-GENE-N
catalytic,2964,I-GENE-N
core,2964,I-GENE-N
proteasome,2964,I-GENE-N
.,2964,O
These,2965,O
protein,2965,O
complexes,2965,O
are,2965,O
known,2965,O
to,2965,O
bind,2965,O
to,2965,O
specific,2965,O
grooves,2965,O
on,2965,O
the,2965,O
α,2965,O
face,2965,O
region,2965,O
of,2965,O
the,2965,O
20S,2965,O
core,2965,O
.,2965,O
A,2966,O
treatment,2966,O
with,2966,O
rapamycin,2966,B-CHEMICAL
affects,2966,O
conformational,2966,O
dynamics,2966,O
of,2966,O
the,2966,O
proteasomal,2966,O
gate,2966,O
",",2966,O
a,2966,O
centrally,2966,O
positioned,2966,O
within,2966,O
the,2966,O
α,2966,O
face,2966,O
and,2966,O
allosterically,2966,O
regulated,2966,O
element,2966,O
responsible,2966,O
for,2966,O
the,2966,O
intake,2966,O
of,2966,O
substrates,2966,O
.,2966,O
Interestingly,2967,O
",",2967,O
we,2967,O
showed,2967,O
that,2967,O
rapamycin,2967,B-CHEMICAL
shares,2967,O
all,2967,O
the,2967,O
proteasome,2967,B-GENE-N
targeting,2967,O
properties,2967,O
not,2967,O
only,2967,O
with,2967,O
other,2967,O
two-domain,2967,O
",",2967,O
closed-ring,2967,O
analogs,2967,O
(,2967,O
rapalogs,2967,O
),2967,O
",",2967,O
but,2967,O
also,2967,O
with,2967,O
its,2967,O
single,2967,O
domain,2967,O
mimics,2967,O
",",2967,O
and,2967,O
with,2967,O
seco-rapamycin,2967,B-CHEMICAL
.,2967,O
The,2968,O
latter,2968,O
is,2968,O
the,2968,O
first,2968,O
in,2968,O
vivo,2968,O
open-ring,2968,O
metabolite,2968,O
of,2968,O
rapamycin,2968,B-CHEMICAL
that,2968,O
does,2968,O
not,2968,O
affect,2968,O
mTOR,2968,B-GENE-Y
.,2968,O
We,2969,O
hypothesize,2969,O
that,2969,O
the,2969,O
rapamycin,2969,B-CHEMICAL
and,2969,O
related,2969,O
compounds,2969,O
bind,2969,O
to,2969,O
the,2969,O
α,2969,O
face,2969,O
and,2969,O
allosterically,2969,O
impact,2969,O
the,2969,O
proteasome,2969,B-GENE-N
function,2969,O
.,2969,O
The,2970,O
implications,2970,O
of,2970,O
our,2970,O
finding,2970,O
for,2970,O
mechanism,2970,O
of,2970,O
in,2970,O
vivo,2970,O
actions,2970,O
of,2970,O
rapamycin,2970,B-CHEMICAL
and,2970,O
for,2970,O
design,2970,O
of,2970,O
novel,2970,O
allosteric,2970,O
drugs,2970,O
targeting,2970,O
the,2970,O
proteasome,2970,B-GENE-N
are,2970,O
discussed,2970,O
.,2970,O
Effect,2971,O
of,2971,O
MELANOTAN,2971,B-CHEMICAL
",",2971,O
[,2971,B-CHEMICAL
Nle,2971,I-CHEMICAL
(,2971,I-CHEMICAL
4,2971,I-CHEMICAL
),2971,I-CHEMICAL
",",2971,I-CHEMICAL
D-Phe,2971,I-CHEMICAL
(,2971,I-CHEMICAL
7,2971,I-CHEMICAL
),2971,I-CHEMICAL
],2971,I-CHEMICAL
-alpha-MSH,2971,I-CHEMICAL
",",2971,O
on,2971,O
melanin,2971,O
synthesis,2971,O
in,2971,O
humans,2971,O
with,2971,O
MC1R,2971,B-GENE-Y
variant,2971,O
alleles,2971,O
.,2971,O
MELANOTAN,2972,B-CHEMICAL
(,2972,O
NDP-MSH,2972,B-CHEMICAL
),2972,O
binds,2972,O
the,2972,O
MC1,2972,B-GENE-Y
receptor,2972,I-GENE-Y
to,2972,O
significantly,2972,O
increase,2972,O
the,2972,O
eumelanin,2972,O
content,2972,O
of,2972,O
human,2972,O
skin,2972,O
cells,2972,O
.,2972,O
In,2973,O
this,2973,O
study,2973,O
of,2973,O
77,2973,O
Caucasian,2973,O
individuals,2973,O
",",2973,O
we,2973,O
investigated,2973,O
the,2973,O
effects,2973,O
of,2973,O
MELANOTAN,2973,B-CHEMICAL
in,2973,O
individuals,2973,O
with,2973,O
variant,2973,O
MC1R,2973,B-GENE-Y
genotypes,2973,O
",",2973,O
as,2973,O
it,2973,O
has,2973,O
been,2973,O
suggested,2973,O
through,2973,O
in,2973,O
vitro,2973,O
studies,2973,O
that,2973,O
variant,2973,O
alleles,2973,O
decrease,2973,O
MELANOTAN,2973,B-CHEMICAL
binding,2973,O
efficacy,2973,O
",",2973,O
which,2973,O
would,2973,O
subsequently,2973,O
affect,2973,O
the,2973,O
synthesis,2973,O
of,2973,O
melanin,2973,O
.,2973,O
Administration,2974,O
of,2974,O
MELANOTAN,2974,B-CHEMICAL
produced,2974,O
a,2974,O
significant,2974,O
(,2974,O
p,2974,O
<,2974,O
0.001,2974,O
),2974,O
increase,2974,O
in,2974,O
melanin,2974,O
density,2974,O
in,2974,O
treated,2974,O
",",2974,O
compared,2974,O
to,2974,O
placebo,2974,O
",",2974,O
individuals,2974,O
.,2974,O
Importantly,2975,O
",",2975,O
MELANOTAN,2975,B-CHEMICAL
increased,2975,O
the,2975,O
melanin,2975,O
density,2975,O
to,2975,O
a,2975,O
greater,2975,O
extent,2975,O
in,2975,O
individuals,2975,O
carrying,2975,O
the,2975,O
variant,2975,O
alleles,2975,O
Val60Leu,2975,O
",",2975,O
Asp84Glu,2975,O
",",2975,O
Val92Met,2975,O
",",2975,O
Arg142His,2975,O
",",2975,O
Arg151Cys,2975,O
",",2975,O
and,2975,O
Arg160Trp,2975,O
than,2975,O
in,2975,O
individuals,2975,O
with,2975,O
no,2975,O
variant,2975,O
alleles,2975,O
.,2975,O
This,2976,O
study,2976,O
demonstrates,2976,O
that,2976,O
MELANOTAN,2976,B-CHEMICAL
effectively,2976,O
increases,2976,O
the,2976,O
melanin,2976,O
content,2976,O
of,2976,O
skin,2976,O
in,2976,O
those,2976,O
individuals,2976,O
with,2976,O
MC1R,2976,B-GENE-Y
variant,2976,O
alleles,2976,O
and,2976,O
therefore,2976,O
",",2976,O
those,2976,O
most,2976,O
in,2976,O
need,2976,O
of,2976,O
photoprotection,2976,O
.,2976,O
In,2977,O
vitro,2977,O
simulation,2977,O
of,2977,O
therapeutic,2977,O
plasmatic,2977,O
fibrinolysis,2977,O
.,2977,O
One,2978,O
type,2978,O
of,2978,O
therapy,2978,O
for,2978,O
thromboembolism,2978,O
is,2978,O
plasmatic,2978,O
thrombolysis,2978,O
.,2978,O
Several,2979,O
plasminogen,2979,B-GENE-N
activators,2979,I-GENE-N
(,2979,O
PA,2979,B-GENE-N
),2979,O
are,2979,O
clinically,2979,O
available,2979,O
",",2979,O
including,2979,O
urokinase,2979,B-GENE-N
(,2979,O
u-PA,2979,B-GENE-Y
),2979,O
",",2979,O
tissue,2979,B-GENE-Y
plasminogen,2979,I-GENE-Y
activator,2979,I-GENE-Y
(,2979,O
t-PA,2979,B-GENE-Y
),2979,O
",",2979,O
streptokinase,2979,B-GENE-N
(,2979,O
SK,2979,B-GENE-N
),2979,O
",",2979,O
plasminogen-streptokinase-activator-complex,2979,B-GENE-N
(,2979,O
PSAC,2979,B-GENE-N
),2979,O
",",2979,O
or,2979,O
mutants,2979,O
of,2979,O
t-PA,2979,B-GENE-Y
such,2979,O
as,2979,O
reteplase,2979,O
(,2979,O
RP,2979,O
),2979,O
or,2979,O
tenecteplase,2979,O
(,2979,O
TP,2979,O
),2979,O
.,2979,O
Therapeutic,2980,O
plasmatic,2980,O
fibrinolysis,2980,O
was,2980,O
simulated,2980,O
",",2980,O
using,2980,O
the,2980,O
PA,2980,B-GENE-N
at,2980,O
relevant,2980,O
plasma,2980,O
concentrations,2980,O
",",2980,O
and,2980,O
plasmin,2980,B-GENE-Y
(,2980,O
Pli,2980,B-GENE-Y
),2980,O
and,2980,O
PA,2980,B-GENE-N
activities,2980,O
were,2980,O
determined,2980,O
.,2980,O
Normal,2981,O
citrated,2981,O
plasma,2981,O
was,2981,O
supplemented,2981,O
with,2981,O
31,2981,O
to,2981,O
"1,000",2981,O
IU/mL,2981,O
u-PA,2981,O
",",2981,O
0.31,2981,O
to,2981,O
20,2981,O
microg/mL,2981,O
t-PA,2981,B-GENE-N
",",2981,O
125,2981,O
to,2981,O
"4,000",2981,O
IU/mL,2981,O
SK,2981,B-GENE-N
",",2981,O
12.5,2981,O
to,2981,O
400,2981,O
U/mL,2981,O
PSAC,2981,B-GENE-N
",",2981,O
125,2981,O
to,2981,O
"4,000",2981,O
U/mL,2981,O
RP,2981,O
",",2981,O
or,2981,O
0.31,2981,O
to,2981,O
10,2981,O
microg/mL,2981,O
TP,2981,O
.,2981,O
Ten,2982,O
IU/mL,2982,O
urokinase,2982,B-GENE-N
was,2982,O
also,2982,O
incubated,2982,O
with,2982,O
pooled,2982,O
plasma,2982,O
of,2982,O
stroke,2982,O
patients,2982,O
",",2982,O
that,2982,O
was,2982,O
previously,2982,O
oxidized,2982,O
with,2982,O
the,2982,O
singlet,2982,B-CHEMICAL
oxygen,2982,I-CHEMICAL
(,2982,O
1O2,2982,B-CHEMICAL
),2982,O
donor,2982,O
chloramine,2982,B-CHEMICAL
T,2982,I-CHEMICAL
(,2982,O
CT,2982,B-CHEMICAL
),2982,O
",",2982,O
to,2982,O
destroy,2982,O
plasmatic,2982,B-GENE-Y
PAI-1,2982,I-GENE-Y
and,2982,O
alpha2-antiplasmin,2982,O
.,2982,O
After,2983,O
0,2983,O
to,2983,O
80,2983,O
minutes,2983,O
(,2983,O
37,2983,O
degrees,2983,O
C,2983,O
),2983,O
",",2983,O
50-microL,2983,O
samples,2983,O
were,2983,O
withdrawn,2983,O
and,2983,O
added,2983,O
to,2983,O
100,2983,O
microL,2983,O
1.5,2983,O
M,2983,O
arginine,2983,B-CHEMICAL
",",2983,O
pH,2983,O
8.7,2983,O
",",2983,O
and,2983,O
oxidized,2983,O
with,2983,O
50,2983,O
microL,2983,O
of,2983,O
20,2983,O
mM,2983,O
CT.,2983,B-CHEMICAL
For,2983,O
determination,2983,O
of,2983,O
plasmin,2983,B-GENE-Y
activity,2983,O
",",2983,O
10,2983,O
microL,2983,O
thereof,2983,O
was,2983,O
incubated,2983,O
with,2983,O
150,2983,O
microL,2983,O
1.5,2983,O
M,2983,O
arginine,2983,B-CHEMICAL
",",2983,O
pH,2983,O
8.7,2983,O
",",2983,O
and,2983,O
100,2983,O
microL,2983,O
20,2983,O
mM,2983,O
CT,2983,B-CHEMICAL
preoxidized,2983,O
(,2983,O
15,2983,O
minutes,2983,O
37,2983,O
degrees,2983,O
C,2983,O
),2983,O
pooled,2983,O
normal,2983,O
citrate,2983,B-CHEMICAL
buffered,2983,O
EDTA-plasma,2983,B-CHEMICAL
for,2983,O
30,2983,O
minutes,2983,O
(,2983,O
37,2983,O
degrees,2983,O
C,2983,O
),2983,O
.,2983,O
For,2984,O
determination,2984,O
of,2984,O
[,2984,O
PA+Pli,2984,B-GENE-N
],2984,O
-activity,2984,O
",",2984,O
arginine,2984,B-CHEMICAL
was,2984,O
added,2984,O
after,2984,O
this,2984,O
incubation,2984,O
.,2984,O
25-microL,2985,O
6,2985,O
mM,2985,O
Val-Leu-Lys-pNA,2985,B-CHEMICAL
were,2985,O
added,2985,O
and,2985,O
deltaA/h,2985,O
at,2985,O
room,2985,O
temperature,2985,O
(,2985,O
RT,2985,O
),2985,O
was,2985,O
monitored,2985,O
",",2985,O
using,2985,O
a,2985,O
microtiterplate,2985,O
reader,2985,O
.,2985,O
[,2986,O
PA+Pli,2986,B-GENE-N
],2986,O
-Pli,2986,O
=,2986,O
PA,2986,B-GENE-N
.,2986,O
The,2987,O
PA,2987,B-GENE-N
concentration,2987,O
required,2987,O
to,2987,O
induce,2987,O
25,2987,O
%,2987,O
[,2987,O
ED25,2987,O
],2987,O
of,2987,O
the,2987,O
maximally,2987,O
inducible,2987,O
Pli-activity,2987,B-GENE-Y
in,2987,O
plasma,2987,O
(,2987,O
=,2987,O
1,2987,O
U/mL,2987,O
=,2987,O
45,2987,O
mg/L,2987,O
=,2987,O
0.53,2987,O
micromol/L,2987,O
active,2987,O
Pli,2987,B-GENE-Y
;,2987,O
deltaA,2987,O
=,2987,O
363,2987,O
+/-,2987,O
8,2987,O
mA/h,2987,O
RT,2987,O
),2987,O
after,2987,O
10,2987,O
minutes,2987,O
(,2987,O
37,2987,O
degrees,2987,O
C,2987,O
),2987,O
were,2987,O
320,2987,O
IU/mL,2987,O
u-PA,2987,B-GENE-Y
",",2987,O
8,2987,O
microg/mL,2987,O
t-PA,2987,B-GENE-Y
",",2987,O
140,2987,O
U/mL,2987,O
PSAC,2987,O
",",2987,O
"6,000",2987,O
IU/mL,2987,O
SK,2987,O
",",2987,O
720,2987,O
U/mL,2987,O
RP,2987,O
",",2987,O
and,2987,O
approximately,2987,O
150,2987,O
microg/mL,2987,O
TP,2987,O
.,2987,O
The,2988,O
approximate,2988,O
activity,2988,O
half-lives,2988,O
of,2988,O
the,2988,O
PA,2988,B-GENE-N
in,2988,O
plasma,2988,O
were,2988,O
30,2988,O
minutes,2988,O
for,2988,O
u-PA,2988,B-GENE-Y
",",2988,O
30,2988,O
minutes,2988,O
for,2988,O
t-PA,2988,B-GENE-Y
",",2988,O
greater,2988,O
than,2988,O
80,2988,O
minutes,2988,O
for,2988,O
SK,2988,B-GENE-N
",",2988,O
greater,2988,O
than,2988,O
80,2988,O
minutes,2988,O
for,2988,O
PSAC,2988,B-GENE-N
",",2988,O
50,2988,O
minutes,2988,O
for,2988,O
RP,2988,O
",",2988,O
and,2988,O
80,2988,O
minutes,2988,O
for,2988,O
TP,2988,O
.,2988,O
The,2989,O
present,2989,O
study,2989,O
shows,2989,O
--,2989,O
for,2989,O
the,2989,O
first,2989,O
time,2989,O
--,2989,O
a,2989,O
combined,2989,O
kinetic,2989,O
in,2989,O
vitro,2989,O
simulation,2989,O
of,2989,O
the,2989,O
plasmatic,2989,O
activity,2989,O
of,2989,O
six,2989,O
different,2989,O
PAs,2989,B-GENE-N
.,2989,O
At,2990,O
clinically,2990,O
used,2990,O
concentrations,2990,O
",",2990,O
RP,2990,O
induces,2990,O
the,2990,O
highest,2990,O
plasmatic,2990,B-GENE-Y
Pli,2990,I-GENE-Y
activity,2990,O
.,2990,O
Due,2991,O
to,2991,O
unselective,2991,O
generation,2991,O
of,2991,O
plasmin,2991,B-GENE-Y
in,2991,O
plasma,2991,O
",",2991,O
all,2991,O
PA,2991,B-GENE-N
are,2991,O
of,2991,O
some,2991,O
danger,2991,O
in,2991,O
inducing,2991,O
severe,2991,O
hemorrhagias,2991,O
.,2991,O
Clinical,2992,O
thrombolysis,2992,O
might,2992,O
be,2992,O
improved,2992,O
by,2992,O
usage,2992,O
of,2992,O
more,2992,O
physiologic,2992,O
activators,2992,O
of,2992,O
thrombolysis,2992,O
",",2992,O
such,2992,O
as,2992,O
activators,2992,O
of,2992,O
polymorphonuclear,2992,O
neutrophils,2992,O
.,2992,O
Novel,2993,O
assays,2993,O
for,2993,O
detection,2993,O
of,2993,O
urinary,2993,O
KIM-1,2993,B-GENE-Y
in,2993,O
mouse,2993,O
models,2993,O
of,2993,O
kidney,2993,O
injury,2993,O
.,2993,O
Kidney,2994,B-GENE-Y
injury,2994,I-GENE-Y
molecule-1,2994,I-GENE-Y
(,2994,O
KIM-1,2994,B-GENE-Y
),2994,O
has,2994,O
been,2994,O
qualified,2994,O
by,2994,O
the,2994,O
Food,2994,O
and,2994,O
Drug,2994,O
Administration,2994,O
and,2994,O
European,2994,O
Medicines,2994,O
Agency,2994,O
as,2994,O
a,2994,O
urinary,2994,O
biomarker,2994,O
to,2994,O
monitor,2994,O
preclinical,2994,O
nephrotoxicity,2994,O
in,2994,O
rats,2994,O
and,2994,O
on,2994,O
a,2994,O
case-by-case,2994,O
basis,2994,O
for,2994,O
the,2994,O
translation,2994,O
of,2994,O
potentially,2994,O
nephrotoxic,2994,O
drugs,2994,O
into,2994,O
first-in,2994,O
human,2994,O
studies,2994,O
.,2994,O
Although,2995,O
mouse,2995,O
models,2995,O
are,2995,O
widely,2995,O
employed,2995,O
in,2995,O
preclinical,2995,O
studies,2995,O
",",2995,O
few,2995,O
urinary,2995,O
biomarker,2995,O
studies,2995,O
have,2995,O
been,2995,O
performed,2995,O
in,2995,O
mice,2995,O
due,2995,O
to,2995,O
limited,2995,O
urine,2995,O
availability,2995,O
and,2995,O
lack,2995,O
of,2995,O
sensitive,2995,O
assays,2995,O
.,2995,O
Here,2996,O
",",2996,O
we,2996,O
report,2996,O
the,2996,O
development,2996,O
and,2996,O
validation,2996,O
of,2996,O
two,2996,O
different,2996,O
assays,2996,O
for,2996,O
quantitative,2996,O
assessment,2996,O
of,2996,O
mouse,2996,B-GENE-Y
urinary,2996,I-GENE-Y
KIM-1,2996,I-GENE-Y
(,2996,O
uKIM-1,2996,B-GENE-Y
),2996,O
and,2996,O
compare,2996,O
the,2996,O
sensitivity,2996,O
of,2996,O
KIM-1,2996,B-GENE-Y
relative,2996,O
to,2996,O
other,2996,O
standard,2996,O
markers,2996,O
in,2996,O
ischemia,2996,O
reperfusion,2996,O
and,2996,O
aristolochic,2996,B-CHEMICAL
acid,2996,I-CHEMICAL
(,2996,O
AA,2996,O
),2996,O
-induced,2996,O
kidney,2996,O
injury,2996,O
in,2996,O
mice,2996,O
.,2996,O
A,2997,O
sensitive,2997,O
",",2997,O
reproducible,2997,O
",",2997,O
and,2997,O
quantitative,2997,O
microbead-based,2997,O
KIM-1,2997,B-GENE-Y
ELISA,2997,O
was,2997,O
established,2997,O
",",2997,O
which,2997,O
requires,2997,O
only,2997,O
10,2997,O
μl,2997,O
urine,2997,O
for,2997,O
triplicate,2997,O
determination,2997,O
with,2997,O
an,2997,O
assay,2997,O
range,2997,O
of,2997,O
12.21,2997,O
pg/ml,2997,O
to,2997,O
50,2997,O
ng/ml,2997,O
.,2997,O
The,2998,O
second,2998,O
assay,2998,O
is,2998,O
a,2998,O
laminar,2998,O
flow,2998,O
dipstick,2998,O
assay,2998,O
",",2998,O
which,2998,O
has,2998,O
an,2998,O
assay,2998,O
range,2998,O
of,2998,O
195,2998,O
pg/ml,2998,O
to,2998,O
50,2998,O
ng/ml,2998,O
and,2998,O
provides,2998,O
quantitative,2998,O
assessment,2998,O
of,2998,O
KIM-1,2998,B-GENE-Y
in,2998,O
15,2998,O
min,2998,O
.,2998,O
uKIM-1,2999,B-GENE-Y
levels,2999,O
increased,2999,O
with,2999,O
increasing,2999,O
time,2999,O
of,2999,O
ischemia,2999,O
or,2999,O
time,2999,O
after,2999,O
AA,2999,O
administration,2999,O
.,2999,O
After,3000,O
only,3000,O
10-min,3000,O
ischemia,3000,O
followed,3000,O
by,3000,O
24-h,3000,O
reperfusion,3000,O
",",3000,O
uKIM-1,3000,B-GENE-Y
was,3000,O
significantly,3000,O
elevated,3000,O
by,3000,O
13-fold,3000,O
",",3000,O
whereas,3000,O
serum,3000,O
creatinine,3000,B-CHEMICAL
(,3000,O
sCr,3000,O
),3000,O
",",3000,O
blood,3000,O
urea,3000,B-CHEMICAL
nitrogen,3000,B-CHEMICAL
",",3000,O
N-acetyl-β-glucosaminidase,3000,B-GENE-Y
(,3000,O
NAG,3000,B-GENE-Y
),3000,O
",",3000,O
and,3000,O
proteinuria,3000,O
levels,3000,O
did,3000,O
not,3000,O
change,3000,O
.,3000,O
After,3001,O
AA,3001,O
administration,3001,O
",",3001,O
uKIM-1,3001,B-GENE-Y
levels,3001,O
were,3001,O
significantly,3001,O
upregulated,3001,O
by,3001,O
greater,3001,O
than,3001,O
threefold,3001,O
within,3001,O
12,3001,O
h,3001,O
",",3001,O
whereas,3001,O
sCr,3001,O
and,3001,O
NAG,3001,B-GENE-Y
levels,3001,O
were,3001,O
unchanged,3001,O
.,3001,O
Mouse,3002,B-GENE-Y
KIM-1,3002,I-GENE-Y
was,3002,O
stable,3002,O
for,3002,O
multiple,3002,O
freeze-thaw,3002,O
cycles,3002,O
",",3002,O
for,3002,O
up,3002,O
to,3002,O
5,3002,O
days,3002,O
at,3002,O
room,3002,O
temperature,3002,O
and,3002,O
up,3002,O
to,3002,O
at,3002,O
least,3002,O
an,3002,O
year,3002,O
when,3002,O
stored,3002,O
at,3002,O
-80°C,3002,O
.,3002,O
Impaired,3003,O
antibody,3003,O
synthesis,3003,O
after,3003,O
spinal,3003,O
cord,3003,O
injury,3003,O
is,3003,O
level,3003,O
dependent,3003,O
and,3003,O
is,3003,O
due,3003,O
to,3003,O
sympathetic,3003,O
nervous,3003,O
system,3003,O
dysregulation,3003,O
.,3003,O
Individuals,3004,O
with,3004,O
spinal,3004,O
cord,3004,O
injury,3004,O
(,3004,O
SCI,3004,O
),3004,O
are,3004,O
highly,3004,O
susceptible,3004,O
to,3004,O
infection,3004,O
.,3004,O
This,3005,O
post-traumatic,3005,O
immune,3005,O
suppression,3005,O
is,3005,O
thought,3005,O
to,3005,O
occur,3005,O
via,3005,O
alterations,3005,O
in,3005,O
sympathetic,3005,O
nervous,3005,O
system,3005,O
(,3005,O
SNS,3005,O
),3005,O
or,3005,O
hypothalamic-pituitary-adrenal,3005,O
(,3005,O
HPA,3005,O
),3005,O
axis,3005,O
function,3005,O
.,3005,O
Normally,3006,O
",",3006,O
the,3006,O
HPA,3006,O
axis,3006,O
and,3006,O
SNS,3006,O
help,3006,O
coordinate,3006,O
proper,3006,O
immune,3006,O
function,3006,O
.,3006,O
After,3007,O
SCI,3007,O
",",3007,O
the,3007,O
HPA,3007,O
axis,3007,O
becomes,3007,O
activated,3007,O
and,3007,O
descending,3007,O
input,3007,O
to,3007,O
sympathetic,3007,O
preganglionic,3007,O
neurons,3007,O
(,3007,O
SPNs,3007,O
),3007,O
is,3007,O
impaired,3007,O
.,3007,O
Because,3008,O
lymphoid,3008,O
organs,3008,O
are,3008,O
innervated,3008,O
by,3008,O
SPNs,3008,O
distributed,3008,O
throughout,3008,O
the,3008,O
thoracolumbar,3008,O
spinal,3008,O
cord,3008,O
",",3008,O
we,3008,O
predicted,3008,O
level-dependent,3008,O
immune,3008,O
suppression,3008,O
after,3008,O
SCI,3008,O
due,3008,O
to,3008,O
activation,3008,O
of,3008,O
the,3008,O
HPA,3008,O
axis,3008,O
and,3008,O
loss,3008,O
of,3008,O
descending,3008,O
input,3008,O
to,3008,O
SPNs,3008,O
.,3008,O
We,3009,O
tested,3009,O
this,3009,O
hypothesis,3009,O
by,3009,O
measuring,3009,O
indices,3009,O
of,3009,O
HPA,3009,O
(,3009,O
circulating,3009,O
corticosterone,3009,B-CHEMICAL
;,3009,O
CORT,3009,B-CHEMICAL
),3009,O
and,3009,O
SNS,3009,O
function,3009,O
(,3009,O
norepinephrine,3009,B-CHEMICAL
(,3009,O
NE,3009,B-CHEMICAL
),3009,O
in,3009,O
spleen,3009,O
),3009,O
as,3009,O
well,3009,O
as,3009,O
antigen-specific,3009,O
antibody,3009,O
synthesis,3009,O
against,3009,O
an,3009,O
exogenous,3009,O
non-self,3009,O
protein,3009,O
following,3009,O
high-,3009,O
or,3009,O
low-level,3009,O
SCI,3009,O
.,3009,O
Using,3010,O
a,3010,O
mid-thoracic,3010,O
(,3010,O
T9,3010,O
),3010,O
spinal,3010,O
contusion,3010,O
injury,3010,O
model,3010,O
",",3010,O
we,3010,O
found,3010,O
that,3010,O
CORT,3010,B-CHEMICAL
was,3010,O
elevated,3010,O
after,3010,O
SCI,3010,O
with,3010,O
aberrant,3010,O
patterns,3010,O
of,3010,O
diurnal,3010,O
CORT,3010,B-CHEMICAL
synthesis,3010,O
evident,3010,O
through,3010,O
at,3010,O
least,3010,O
the,3010,O
first,3010,O
24,3010,O
h,3010,O
post-injury,3010,O
.,3010,O
However,3011,O
",",3011,O
splenic,3011,O
NE,3011,B-CHEMICAL
and,3011,O
antibody,3011,O
synthesis,3011,O
were,3011,O
similar,3011,O
to,3011,O
uninjured,3011,O
controls,3011,O
.,3011,O
Injury,3012,O
severity,3012,O
did,3012,O
not,3012,O
change,3012,O
these,3012,O
parameters,3012,O
.,3012,O
Indeed,3013,O
",",3013,O
CORT,3013,B-CHEMICAL
",",3013,O
NE,3013,B-CHEMICAL
and,3013,O
antibody,3013,O
synthesis,3013,O
were,3013,O
similar,3013,O
after,3013,O
T9,3013,O
contusion,3013,O
or,3013,O
transection,3013,O
SCI,3013,O
.,3013,O
In,3014,O
contrast,3014,O
",",3014,O
high-level,3014,O
SCI,3014,O
(,3014,O
T3,3014,O
),3014,O
caused,3014,O
sustained,3014,O
increases,3014,O
in,3014,O
CORT,3014,B-CHEMICAL
and,3014,O
splenic,3014,O
NE,3014,B-CHEMICAL
along,3014,O
with,3014,O
impaired,3014,O
antibody,3014,O
synthesis,3014,O
and,3014,O
elevated,3014,O
splenocyte,3014,O
apoptosis,3014,O
.,3014,O
The,3015,O
immunosuppressive,3015,O
effects,3015,O
of,3015,O
T3,3015,O
SCI,3015,O
were,3015,O
caused,3015,O
by,3015,O
NE,3015,B-CHEMICAL
acting,3015,O
at,3015,O
beta2-adrenergic,3015,B-GENE-Y
receptors,3015,I-GENE-Y
(,3015,O
beta2AR,3015,B-GENE-Y
),3015,O
and,3015,O
could,3015,O
be,3015,O
reversed,3015,O
using,3015,O
beta2AR,3015,B-GENE-Y
blockers,3015,O
.,3015,O
Interestingly,3016,O
",",3016,O
impaired,3016,O
antibody,3016,O
after,3016,O
T3,3016,O
SCI,3016,O
could,3016,O
be,3016,O
mimicked,3016,O
after,3016,O
T9,3016,O
SCI,3016,O
with,3016,O
a,3016,O
beta2AR,3016,B-GENE-Y
agonist,3016,O
.,3016,O
These,3017,O
data,3017,O
illustrate,3017,O
the,3017,O
immunosuppressive,3017,O
effects,3017,O
of,3017,O
the,3017,O
SNS,3017,O
after,3017,O
high-level,3017,O
SCI,3017,O
and,3017,O
indicate,3017,O
that,3017,O
immune,3017,O
deficits,3017,O
may,3017,O
be,3017,O
overcome,3017,O
using,3017,O
beta-blockers,3017,O
.,3017,O
Zuclopenthixol,3018,B-CHEMICAL
facilitates,3018,O
memory,3018,O
retrieval,3018,O
in,3018,O
rats,3018,O
:,3018,O
possible,3018,O
involvement,3018,O
of,3018,O
noradrenergic,3018,O
and,3018,O
serotonergic,3018,O
mechanisms,3018,O
.,3018,O
Although,3019,O
disturbed,3019,O
memory,3019,O
function,3019,O
often,3019,O
coexists,3019,O
with,3019,O
psychosis,3019,O
",",3019,O
the,3019,O
cognitive,3019,O
effects,3019,O
of,3019,O
antipsychotic,3019,O
medications,3019,O
with,3019,O
diverse,3019,O
pharmacodynamic,3019,O
properties,3019,O
are,3019,O
rarely,3019,O
investigated,3019,O
.,3019,O
The,3020,O
neurocognitive,3020,O
profile,3020,O
of,3020,O
zuclopenthixol,3020,B-CHEMICAL
",",3020,O
a,3020,O
thioxanthene,3020,B-CHEMICAL
dopaminergic,3020,O
antagonist,3020,O
and,3020,O
a,3020,O
conventional,3020,O
neuroleptic,3020,O
agent,3020,O
",",3020,O
has,3020,O
yet,3020,O
to,3020,O
be,3020,O
investigated,3020,O
despite,3020,O
the,3020,O
effect,3020,O
of,3020,O
the,3020,O
drug,3020,O
on,3020,O
a,3020,O
variety,3020,O
of,3020,O
neurotransmitter,3020,O
systems,3020,O
involved,3020,O
in,3020,O
mediation,3020,O
of,3020,O
learning,3020,O
and,3020,O
memory,3020,O
processes,3020,O
.,3020,O
In,3021,O
this,3021,O
study,3021,O
",",3021,O
the,3021,O
effect,3021,O
of,3021,O
zuclopenthixol,3021,B-CHEMICAL
was,3021,O
tested,3021,O
on,3021,O
memory,3021,O
retrieval,3021,O
24,3021,O
h,3021,O
after,3021,O
training,3021,O
using,3021,O
an,3021,O
inhibitory,3021,O
avoidance,3021,O
task,3021,O
in,3021,O
rats,3021,O
.,3021,O
Acute,3022,O
administration,3022,O
of,3022,O
zuclopenthixol,3022,B-CHEMICAL
(,3022,O
0.7,3022,O
and,3022,O
1.4,3022,O
mg/kg,3022,O
i.p,3022,O
.,3022,O
),3022,O
before,3023,O
retrieval,3023,O
testing,3023,O
increased,3023,O
step-through,3023,O
latency,3023,O
during,3023,O
the,3023,O
test,3023,O
session,3023,O
.,3023,O
The,3024,O
same,3024,O
doses,3024,O
of,3024,O
zuclopenthixol,3024,B-CHEMICAL
did,3024,O
not,3024,O
affect,3024,O
the,3024,O
ambulatory,3024,O
activity,3024,O
of,3024,O
rats,3024,O
in,3024,O
the,3024,O
openfield,3024,O
test,3024,O
and,3024,O
therefore,3024,O
the,3024,O
facilitatory,3024,O
effect,3024,O
of,3024,O
the,3024,O
drug,3024,O
on,3024,O
memory,3024,O
function,3024,O
could,3024,O
not,3024,O
be,3024,O
confounded,3024,O
with,3024,O
any,3024,O
motoric,3024,O
properties,3024,O
.,3024,O
This,3025,O
study,3025,O
also,3025,O
investigated,3025,O
the,3025,O
effect,3025,O
of,3025,O
zuclopenthixol,3025,B-CHEMICAL
on,3025,O
cortical,3025,O
and,3025,O
hippocampal,3025,O
monoaminergic,3025,O
neurotransmitters,3025,O
',3025,O
levels,3025,O
together,3025,O
with,3025,O
acetylcholinesterase,3025,B-GENE-Y
enzyme,3025,O
(,3025,O
AChE,3025,B-GENE-Y
),3025,O
activity,3025,O
",",3025,O
both,3025,O
of,3025,O
which,3025,O
are,3025,O
known,3025,O
to,3025,O
be,3025,O
important,3025,O
in,3025,O
control,3025,O
of,3025,O
cognitive,3025,O
function,3025,O
.,3025,O
Administration,3026,O
of,3026,O
zuclopenthixol,3026,B-CHEMICAL
(,3026,O
0.7,3026,O
and,3026,O
1.4,3026,O
mg/kg,3026,O
i.p,3026,O
.,3026,O
),3026,O
neither,3027,O
affected,3027,O
dopamine,3027,B-CHEMICAL
(,3027,O
DA,3027,B-CHEMICAL
),3027,O
level,3027,O
nor,3027,O
AChE,3027,B-GENE-Y
activity,3027,O
in,3027,O
rat,3027,O
cortex,3027,O
and,3027,O
hippocampus,3027,O
.,3027,O
On,3028,O
the,3028,O
other,3028,O
hand,3028,O
",",3028,O
the,3028,O
lower,3028,O
dose,3028,O
of,3028,O
zuclopenthixol,3028,B-CHEMICAL
elevated,3028,O
cortical,3028,O
norepinephrine,3028,B-CHEMICAL
(,3028,O
NE,3028,B-CHEMICAL
),3028,O
level,3028,O
",",3028,O
while,3028,O
the,3028,O
higher,3028,O
dose,3028,O
elevated,3028,O
both,3028,O
cortical,3028,O
and,3028,O
hippocampal,3028,O
NE,3028,B-CHEMICAL
level,3028,O
together,3028,O
with,3028,O
hippocampal,3028,O
serotonin,3028,B-CHEMICAL
(,3028,O
5-HT,3028,B-CHEMICAL
),3028,O
level,3028,O
.,3028,O
These,3029,O
results,3029,O
may,3029,O
suggest,3029,O
the,3029,O
involvement,3029,O
of,3029,O
adrenergic,3029,O
and,3029,O
serotonergic,3029,O
mechanisms,3029,O
in,3029,O
the,3029,O
facilitatory,3029,O
effect,3029,O
of,3029,O
zuclopenthixol,3029,B-CHEMICAL
on,3029,O
retrieval,3029,O
memory,3029,O
.,3029,O
Zuclopenthixol,3030,B-CHEMICAL
may,3030,O
therefore,3030,O
be,3030,O
a,3030,O
better,3030,O
alternative,3030,O
than,3030,O
other,3030,O
commonly,3030,O
used,3030,O
antipsychotic,3030,O
medications,3030,O
reported,3030,O
to,3030,O
impair,3030,O
cognitive,3030,O
function,3030,O
of,3030,O
schizophrenic,3030,O
patients,3030,O
.,3030,O
Selective,3031,O
Bisubstrate,3031,O
Inhibitors,3031,O
with,3031,O
Sub-nanomolar,3031,O
Affinity,3031,O
for,3031,O
Protein,3031,B-GENE-N
Kinase,3031,I-GENE-N
Pim-1,3031,B-GENE-Y
.,3031,O
Potent,3032,O
and,3032,O
selective,3032,O
:,3032,O
The,3032,O
unique,3032,O
nature,3032,O
of,3032,O
the,3032,O
ATP,3032,B-CHEMICAL
binding,3032,O
pocket,3032,O
structure,3032,O
of,3032,O
Pim,3032,B-GENE-N
family,3032,O
protein,3032,B-GENE-N
kinases,3032,I-GENE-N
(,3032,O
PKs,3032,B-GENE-N
),3032,O
was,3032,O
used,3032,O
for,3032,O
the,3032,O
development,3032,O
of,3032,O
bisubstrate,3032,O
inhibitors,3032,O
and,3032,O
a,3032,O
fluorescent,3032,O
probe,3032,O
with,3032,O
sub-nanomolar,3032,O
affinity,3032,O
.,3032,O
Conjugates,3033,O
of,3033,O
arginine-rich,3033,B-CHEMICAL
peptides,3033,O
with,3033,O
two,3033,O
ATP,3033,B-CHEMICAL
mimetic,3033,O
scaffolds,3033,O
were,3033,O
synthesized,3033,O
and,3033,O
tested,3033,O
as,3033,O
inhibitors,3033,O
of,3033,O
Pim-1,3033,B-GENE-Y
.,3033,O
Against,3034,O
a,3034,O
panel,3034,O
of,3034,O
124,3034,O
protein,3034,B-GENE-N
kinases,3034,I-GENE-N
",",3034,O
a,3034,O
novel,3034,O
ARC-PIM,3034,O
conjugate,3034,O
selectively,3034,O
inhibited,3034,O
PKs,3034,B-GENE-N
of,3034,O
the,3034,O
Pim,3034,B-GENE-N
family,3034,O
.,3034,O
Nuclear,3035,B-GENE-N
receptor,3035,I-GENE-N
CAR,3035,B-GENE-Y
specifically,3035,O
activates,3035,O
the,3035,O
two-pore,3035,O
K+,3035,B-GENE-N
channel,3035,I-GENE-N
Kcnk1,3035,B-GENE-Y
gene,3035,O
in,3035,O
male,3035,O
mouse,3035,O
livers,3035,O
",",3035,O
which,3035,O
attenuates,3035,O
phenobarbital-induced,3035,B-CHEMICAL
hepatic,3035,O
hyperplasia,3035,O
.,3035,O
KCNK1,3036,B-GENE-Y
",",3036,O
a,3036,O
member,3036,O
of,3036,O
the,3036,O
family,3036,O
of,3036,O
two-pore,3036,O
K,3036,B-GENE-N
(,3036,I-GENE-N
+,3036,I-GENE-N
),3036,I-GENE-N
ion,3036,I-GENE-N
channels,3036,I-GENE-N
",",3036,O
is,3036,O
specifically,3036,O
induced,3036,O
in,3036,O
the,3036,O
livers,3036,O
of,3036,O
male,3036,O
mice,3036,O
after,3036,O
phenobarbital,3036,B-CHEMICAL
treatment,3036,O
.,3036,O
Here,3037,O
",",3037,O
we,3037,O
have,3037,O
determined,3037,O
the,3037,O
molecular,3037,O
mechanism,3037,O
of,3037,O
this,3037,O
male-specific,3037,O
activation,3037,O
of,3037,O
the,3037,O
Kcnk1,3037,B-GENE-Y
gene,3037,O
and,3037,O
characterized,3037,O
KCNK1,3037,B-GENE-Y
as,3037,O
a,3037,O
phenobarbital-inducible,3037,B-CHEMICAL
antihyperplasia,3037,O
factor,3037,O
.,3037,O
Upon,3038,O
activation,3038,O
by,3038,O
phenobarbital,3038,B-CHEMICAL
",",3038,O
nuclear,3038,B-GENE-N
receptor,3038,I-GENE-N
CAR,3038,B-GENE-Y
binds,3038,O
the,3038,O
97-bp,3038,O
response,3038,O
element,3038,O
(,3038,O
-2441/-2345,3038,O
),3038,O
within,3038,O
the,3038,O
Kcnk1,3038,B-GENE-N
promoter,3038,I-GENE-N
.,3038,O
This,3039,O
binding,3039,O
is,3039,O
observed,3039,O
in,3039,O
the,3039,O
livers,3039,O
of,3039,O
male,3039,O
mice,3039,O
",",3039,O
but,3039,O
not,3039,O
in,3039,O
the,3039,O
livers,3039,O
of,3039,O
female,3039,O
mice,3039,O
and,3039,O
requires,3039,O
the,3039,O
pituitary,3039,O
gland,3039,O
",",3039,O
because,3039,O
hypophysectomy,3039,O
abrogates,3039,O
it,3039,O
.,3039,O
Hyperplasia,3040,O
further,3040,O
progressed,3040,O
in,3040,O
the,3040,O
livers,3040,O
of,3040,O
Kcnk1,3040,B-GENE-Y
(,3040,O
-/-,3040,O
),3040,O
male,3040,O
mice,3040,O
compared,3040,O
with,3040,O
those,3040,O
of,3040,O
Kcnk1,3040,B-GENE-Y
(,3040,O
+/+,3040,O
),3040,O
males,3040,O
after,3040,O
phenobarbital,3040,B-CHEMICAL
treatment,3040,O
.,3040,O
Thus,3041,O
",",3041,O
KCNK1,3041,B-GENE-Y
suppresses,3041,O
phenobarbital-induced,3041,B-CHEMICAL
hyperplasia,3041,O
.,3041,O
These,3042,O
results,3042,O
indicate,3042,O
that,3042,O
phenobarbital,3042,B-CHEMICAL
treatment,3042,O
induces,3042,O
KCNK1,3042,B-GENE-Y
to,3042,O
elicit,3042,O
a,3042,O
male-specific,3042,O
and,3042,O
growth-suppressing,3042,O
signal,3042,O
.,3042,O
Thus,3043,O
",",3043,O
KCNK1,3043,B-GENE-Y
and,3043,O
Kcnk1,3043,B-GENE-Y
(,3043,O
-/-,3043,O
),3043,O
mice,3043,O
provide,3043,O
an,3043,O
experimental,3043,O
tool,3043,O
for,3043,O
further,3043,O
investigation,3043,O
into,3043,O
the,3043,O
molecular,3043,O
mechanism,3043,O
of,3043,O
CAR-mediated,3043,B-GENE-Y
promotion,3043,O
of,3043,O
the,3043,O
development,3043,O
of,3043,O
hepatocellular,3043,O
carcinoma,3043,O
in,3043,O
mice,3043,O
.,3043,O
Development,3044,O
of,3044,O
new,3044,O
cyclic,3044,O
plasmin,3044,B-GENE-Y
inhibitors,3044,O
with,3044,O
excellent,3044,O
potency,3044,O
and,3044,O
selectivity,3044,O
.,3044,O
The,3045,O
trypsin-like,3045,B-GENE-N
serine,3045,B-GENE-N
protease,3045,I-GENE-N
plasmin,3045,B-GENE-Y
is,3045,O
a,3045,O
target,3045,O
for,3045,O
the,3045,O
development,3045,O
of,3045,O
antifibrinolytic,3045,O
drugs,3045,O
for,3045,O
use,3045,O
in,3045,O
cardiac,3045,O
surgery,3045,O
with,3045,O
cardiopulmonary,3045,O
bypass,3045,O
or,3045,O
organ,3045,O
transplantations,3045,O
to,3045,O
reduce,3045,O
excessive,3045,O
blood,3045,O
loss,3045,O
.,3045,O
The,3046,O
optimization,3046,O
of,3046,O
our,3046,O
recently,3046,O
described,3046,O
substrate-analogue,3046,O
plasmin,3046,B-GENE-Y
inhibitors,3046,O
",",3046,O
which,3046,O
were,3046,O
cyclized,3046,O
between,3046,O
their,3046,O
P3,3046,O
and,3046,O
P2,3046,O
side,3046,O
chains,3046,O
",",3046,O
provided,3046,O
a,3046,O
new,3046,O
series,3046,O
with,3046,O
improved,3046,O
efficacy,3046,O
and,3046,O
excellent,3046,O
selectivity,3046,O
.,3046,O
The,3047,O
most,3047,O
potent,3047,O
inhibitor,3047,O
8,3047,O
binds,3047,O
to,3047,O
plasmin,3047,B-GENE-Y
with,3047,O
an,3047,O
inhibition,3047,O
constant,3047,O
of,3047,O
0.2,3047,O
nM,3047,O
",",3047,O
whereas,3047,O
K,3047,O
(,3047,O
i,3047,O
),3047,O
values,3047,O
>,3047,O
1,3047,O
μM,3047,O
were,3047,O
determined,3047,O
for,3047,O
nearly,3047,O
all,3047,O
other,3047,O
tested,3047,O
trypsin-like,3047,B-GENE-N
serine,3047,I-GENE-N
proteases,3047,I-GENE-N
",",3047,O
with,3047,O
the,3047,O
exception,3047,O
of,3047,O
trypsin,3047,B-GENE-N
",",3047,O
which,3047,O
is,3047,O
also,3047,O
inhibited,3047,O
in,3047,O
the,3047,O
nanomolar,3047,O
range,3047,O
.,3047,O
Docking,3048,O
studies,3048,O
revealed,3048,O
a,3048,O
potential,3048,O
binding,3048,O
mode,3048,O
in,3048,O
the,3048,O
widely,3048,O
open,3048,O
active,3048,O
site,3048,O
of,3048,O
plasmin,3048,B-GENE-Y
that,3048,O
explains,3048,O
the,3048,O
strong,3048,O
potency,3048,O
and,3048,O
selectivity,3048,O
profile,3048,O
of,3048,O
these,3048,O
inhibitors,3048,O
.,3048,O
The,3049,O
dialkylated,3049,O
piperazine-linker,3049,B-CHEMICAL
segment,3049,O
contributes,3049,O
to,3049,O
an,3049,O
excellent,3049,O
solubility,3049,O
of,3049,O
all,3049,O
analogues,3049,O
.,3049,O
Based,3050,O
on,3050,O
their,3050,O
overall,3050,O
profile,3050,O
the,3050,O
presented,3050,O
inhibitors,3050,O
are,3050,O
well,3050,O
suited,3050,O
for,3050,O
further,3050,O
development,3050,O
as,3050,O
injectable,3050,O
antifibrinolytic,3050,O
drugs,3050,O
.,3050,O
Different,3051,O
responses,3051,O
to,3051,O
dexamethasone,3051,B-CHEMICAL
and,3051,O
prednisolone,3051,B-CHEMICAL
in,3051,O
the,3051,O
same,3051,O
depressed,3051,O
patients,3051,O
.,3051,O
RATIONALE,3052,O
:,3052,O
Patients,3052,O
with,3052,O
major,3052,O
depression,3052,O
show,3052,O
hypothalamic-pituitary-adrenal,3052,O
(,3052,O
HPA,3052,O
),3052,O
axis,3052,O
hyperactivity,3052,O
",",3052,O
but,3052,O
the,3052,O
mechanisms,3052,O
underlying,3052,O
this,3052,O
abnormality,3052,O
are,3052,O
still,3052,O
unclear,3052,O
.,3052,O
OBJECTIVES,3053,O
:,3053,O
We,3053,O
have,3053,O
compared,3053,O
two,3053,O
synthetic,3053,O
glucorticoids,3053,O
",",3053,O
dexamethasone,3053,B-CHEMICAL
and,3053,O
prednisolone,3053,B-CHEMICAL
",",3053,O
in,3053,O
their,3053,O
ability,3053,O
to,3053,O
suppress,3053,O
the,3053,O
hypothalamic-pituitary-adrenal,3053,O
(,3053,O
HPA,3053,O
),3053,O
axis,3053,O
in,3053,O
depressed,3053,O
patients,3053,O
.,3053,O
Dexamethasone,3054,B-CHEMICAL
probes,3054,O
glucocorticoid,3054,B-GENE-Y
receptor,3054,I-GENE-Y
(,3054,O
GR,3054,B-GENE-Y
),3054,O
function,3054,O
",",3054,O
while,3054,O
prednisolone,3054,B-CHEMICAL
probes,3054,O
both,3054,O
GR,3054,B-GENE-Y
and,3054,O
mineralocorticoid,3054,B-GENE-Y
receptor,3054,I-GENE-Y
(,3054,O
MR,3054,B-GENE-Y
),3054,O
function,3054,O
.,3054,O
MATERIALS,3055,O
AND,3055,O
METHODS,3055,O
:,3055,O
We,3055,O
used,3055,O
a,3055,O
single-blind,3055,O
",",3055,O
repeated-measure,3055,O
design,3055,O
.,3055,O
We,3056,O
administered,3056,O
placebo,3056,O
",",3056,O
prednisolone,3056,B-CHEMICAL
(,3056,O
5,3056,O
mg,3056,O
),3056,O
or,3056,O
dexamethasone,3056,B-CHEMICAL
(,3056,O
0.5,3056,O
mg,3056,O
),3056,O
",",3056,O
at,3056,O
22:00,3056,O
",",3056,O
to,3056,O
18,3056,O
severe,3056,O
",",3056,O
treatment-resistant,3056,O
depressed,3056,O
inpatients,3056,O
(,3056,O
15,3056,O
of,3056,O
them,3056,O
with,3056,O
a,3056,O
history,3056,O
of,3056,O
childhood,3056,O
trauma,3056,O
),3056,O
and,3056,O
14,3056,O
healthy,3056,O
volunteers,3056,O
.,3056,O
On,3057,O
the,3057,O
following,3057,O
days,3057,O
",",3057,O
we,3057,O
collected,3057,O
salivary,3057,O
cortisol,3057,B-CHEMICAL
from,3057,O
9:00,3057,O
to,3057,O
22:00,3057,O
.,3057,O
RESULTS,3058,O
:,3058,O
Depressed,3058,O
patients,3058,O
had,3058,O
higher,3058,O
salivary,3058,O
cortisol,3058,B-CHEMICAL
levels,3058,O
compared,3058,O
with,3058,O
controls,3058,O
",",3058,O
at,3058,O
baseline,3058,O
and,3058,O
after,3058,O
both,3058,O
prednisolone,3058,B-CHEMICAL
and,3058,O
dexamethasone,3058,B-CHEMICAL
(,3058,O
p,3058,O
<,3058,O
0.001,3058,O
),3058,O
.,3058,O
Consistent,3059,O
with,3059,O
previous,3059,O
studies,3059,O
",",3059,O
depressed,3059,O
inpatients,3059,O
showed,3059,O
impaired,3059,O
suppression,3059,O
by,3059,O
dexamethasone,3059,B-CHEMICAL
:,3059,O
based,3059,O
on,3059,O
the,3059,O
analysis,3059,O
of,3059,O
the,3059,O
areas,3059,O
under,3059,O
the,3059,O
curve,3059,O
(,3059,O
AUCs,3059,O
),3059,O
",",3059,O
suppression,3059,O
by,3059,O
dexamethasone,3059,B-CHEMICAL
(,3059,O
0.5,3059,O
mg,3059,O
),3059,O
was,3059,O
-85,3059,O
%,3059,O
in,3059,O
controls,3059,O
vs,3059,O
-46,3059,O
%,3059,O
in,3059,O
depressed,3059,O
patients,3059,O
(,3059,O
p=0.018,3059,O
),3059,O
.,3059,O
However,3060,O
",",3060,O
the,3060,O
same,3060,O
depressed,3060,O
patients,3060,O
showed,3060,O
normal,3060,O
suppression,3060,O
by,3060,O
prednisolone,3060,B-CHEMICAL
(,3060,O
5,3060,O
mg,3060,O
),3060,O
:,3060,O
suppression,3060,O
was,3060,O
-41,3060,O
%,3060,O
in,3060,O
controls,3060,O
and,3060,O
-36,3060,O
%,3060,O
in,3060,O
depressed,3060,O
patients,3060,O
(,3060,O
p=0.6,3060,O
),3060,O
.,3060,O
CONCLUSIONS,3061,O
:,3061,O
We,3061,O
suggest,3061,O
that,3061,O
the,3061,O
additional,3061,O
effects,3061,O
of,3061,O
prednisolone,3061,B-CHEMICAL
on,3061,O
the,3061,O
MR,3061,B-GENE-Y
explain,3061,O
the,3061,O
different,3061,O
responses,3061,O
to,3061,O
these,3061,O
glucocorticoids,3061,O
in,3061,O
the,3061,O
same,3061,O
depressed,3061,O
patients,3061,O
.,3061,O
Adolescence,3062,O
methylphenidate,3062,B-CHEMICAL
treatment,3062,O
in,3062,O
a,3062,O
rodent,3062,O
model,3062,O
of,3062,O
attention,3062,O
deficit/hyperactivity,3062,O
disorder,3062,O
:,3062,O
Dopamine,3062,B-GENE-Y
transporter,3062,I-GENE-Y
function,3062,O
and,3062,O
cellular,3062,O
distribution,3062,O
in,3062,O
adulthood,3062,O
.,3062,O
Attention,3063,O
deficit/hyperactivity,3063,O
disorder,3063,O
(,3063,O
ADHD,3063,O
),3063,O
is,3063,O
attributed,3063,O
to,3063,O
dysfunction,3063,O
of,3063,O
the,3063,O
prefrontal,3063,O
cortex,3063,O
.,3063,O
Methylphenidate,3064,B-CHEMICAL
",",3064,O
an,3064,O
inhibitor,3064,O
of,3064,O
dopamine,3064,B-GENE-N
and,3064,I-GENE-N
norepinephrine,3064,I-GENE-N
transporters,3064,I-GENE-N
(,3064,O
DAT,3064,B-GENE-Y
and,3064,O
NET,3064,B-GENE-Y
",",3064,O
respectively,3064,O
),3064,O
",",3064,O
is,3064,O
a,3064,O
standard,3064,O
treatment,3064,O
for,3064,O
ADHD,3064,O
.,3064,O
The,3065,O
Spontaneously,3065,O
Hypertensive,3065,O
Rat,3065,O
(,3065,O
SHR,3065,O
),3065,O
is,3065,O
a,3065,O
well-established,3065,O
animal,3065,O
model,3065,O
of,3065,O
ADHD,3065,O
.,3065,O
Our,3066,O
previous,3066,O
results,3066,O
showed,3066,O
that,3066,O
methylphenidate,3066,B-CHEMICAL
treatment,3066,O
in,3066,O
adolescent,3066,O
SHR,3066,O
enhanced,3066,O
cocaine,3066,B-CHEMICAL
self-administration,3066,O
during,3066,O
adulthood,3066,O
",",3066,O
and,3066,O
alterations,3066,O
in,3066,O
DAT,3066,B-GENE-Y
function,3066,O
in,3066,O
prefrontal,3066,O
cortex,3066,O
play,3066,O
a,3066,O
role,3066,O
in,3066,O
this,3066,O
response,3066,O
.,3066,O
Importantly,3067,O
",",3067,O
prefrontal,3067,O
cortex,3067,O
subregions,3067,O
",",3067,O
orbitofrontal,3067,O
cortex,3067,O
(,3067,O
OFC,3067,O
),3067,O
and,3067,O
medial,3067,O
prefrontal,3067,O
cortex,3067,O
(,3067,O
mPFC,3067,O
),3067,O
",",3067,O
have,3067,O
been,3067,O
shown,3067,O
to,3067,O
have,3067,O
distinct,3067,O
roles,3067,O
in,3067,O
ADHD,3067,O
and,3067,O
cocaine,3067,B-CHEMICAL
self-administration,3067,O
.,3067,O
In,3068,O
the,3068,O
current,3068,O
study,3068,O
",",3068,O
SHR,3068,O
",",3068,O
Wistar-Kyoto,3068,O
(,3068,O
WKY,3068,O
),3068,O
and,3068,O
Wistar,3068,O
(,3068,O
WIS,3068,O
),3068,O
rats,3068,O
received,3068,O
a,3068,O
therapeutically,3068,O
relevant,3068,O
dose,3068,O
of,3068,O
methylphenidate,3068,B-CHEMICAL
(,3068,O
1.5mg/kg,3068,O
",",3068,O
p.o,3068,O
.,3068,O
),3068,O
or,3069,O
vehicle,3069,O
during,3069,O
adolescence,3069,O
and,3069,O
then,3069,O
OFC,3069,O
and,3069,O
mPFC,3069,O
DAT,3069,B-GENE-Y
function,3069,O
and,3069,O
cellular,3069,O
expression,3069,O
were,3069,O
assessed,3069,O
during,3069,O
adulthood,3069,O
.,3069,O
In,3070,O
both,3070,O
OFC,3070,O
and,3070,O
mPFC,3070,O
",",3070,O
no,3070,O
strain,3070,O
differences,3070,O
in,3070,O
Vmax,3070,O
or,3070,O
Km,3070,O
for,3070,O
dopamine,3070,B-CHEMICAL
uptake,3070,O
into,3070,O
synaptosomes,3070,O
were,3070,O
found,3070,O
between,3070,O
vehicle-treated,3070,O
SHR,3070,O
",",3070,O
WKY,3070,O
and,3070,O
WIS.,3070,O
Methylphenidate,3070,B-CHEMICAL
increased,3070,O
DAT,3070,B-GENE-Y
Vmax,3070,O
in,3070,O
SHR,3070,O
mPFC,3070,O
and,3070,O
decreased,3070,O
DAT,3070,B-GENE-Y
Vmax,3070,O
in,3070,O
WKY,3070,O
OFC,3070,O
.,3070,O
Also,3071,O
",",3071,O
methylphenidate,3071,B-CHEMICAL
decreased,3071,O
DAT,3071,B-GENE-Y
Km,3071,O
in,3071,O
WIS,3071,O
OFC,3071,O
.,3071,O
Further,3072,O
",",3072,O
methylphenidate,3072,B-CHEMICAL
did,3072,O
not,3072,O
alter,3072,O
DAT,3072,B-GENE-Y
cellular,3072,O
localization,3072,O
",",3072,O
indicating,3072,O
that,3072,O
methylphenidate,3072,B-CHEMICAL
treatment,3072,O
during,3072,O
adolescence,3072,O
regulated,3072,O
DAT,3072,B-GENE-Y
function,3072,O
in,3072,O
SHR,3072,O
mPFC,3072,O
in,3072,O
a,3072,O
trafficking-independent,3072,O
manner,3072,O
.,3072,O
Thus,3073,O
",",3073,O
the,3073,O
increase,3073,O
in,3073,O
mPFC,3073,O
DAT,3073,B-GENE-Y
function,3073,O
was,3073,O
an,3073,O
SHR-specific,3073,O
long,3073,O
term,3073,O
consequence,3073,O
of,3073,O
methylphenidate,3073,B-CHEMICAL
treatment,3073,O
during,3073,O
adolescence,3073,O
",",3073,O
which,3073,O
may,3073,O
be,3073,O
responsible,3073,O
for,3073,O
the,3073,O
treatment-induced,3073,O
alterations,3073,O
in,3073,O
behavior,3073,O
including,3073,O
the,3073,O
observed,3073,O
increases,3073,O
in,3073,O
cocaine,3073,B-CHEMICAL
self-administration,3073,O
.,3073,O
Dual,3074,O
inhibitor,3074,O
of,3074,O
PDE7,3074,B-GENE-N
and,3074,O
GSK-3-VP1.15,3074,B-GENE-N
acts,3074,O
as,3074,O
antipsychotic,3074,O
and,3074,O
cognitive,3074,O
enhancer,3074,O
in,3074,O
C57BL/6J,3074,O
mice,3074,O
.,3074,O
Cognitive,3075,O
deficit,3075,O
is,3075,O
a,3075,O
core,3075,O
of,3075,O
schizophrenia,3075,O
and,3075,O
it,3075,O
is,3075,O
not,3075,O
effectively,3075,O
treated,3075,O
by,3075,O
the,3075,O
available,3075,O
antipsychotic,3075,O
drugs,3075,O
",",3075,O
hence,3075,O
new,3075,O
and,3075,O
more,3075,O
effective,3075,O
therapy,3075,O
is,3075,O
needed,3075,O
.,3075,O
Schizophrenia,3076,O
is,3076,O
considered,3076,O
as,3076,O
a,3076,O
pathway,3076,O
disorder,3076,O
where,3076,O
Disrupted-In-Schizophrenia-1,3076,B-GENE-Y
(,3076,O
DISC1,3076,B-GENE-Y
),3076,O
is,3076,O
important,3076,O
molecular,3076,O
player,3076,O
that,3076,O
regulates,3076,O
multiple,3076,O
cellular,3076,O
cascades,3076,O
.,3076,O
We,3077,O
recently,3077,O
reported,3077,O
synergistic,3077,O
action,3077,O
between,3077,O
phosphodiesterase-4,3077,B-GENE-N
(,3077,O
PDE4,3077,B-GENE-N
),3077,O
and,3077,O
glycogen,3077,B-GENE-N
synthase,3077,I-GENE-N
kinase-3,3077,I-GENE-N
(,3077,O
GSK-3,3077,B-GENE-N
),3077,O
as,3077,O
DISC1,3077,B-GENE-Y
interacting,3077,O
proteins,3077,O
.,3077,O
In,3078,O
the,3078,O
current,3078,O
study,3078,O
we,3078,O
characterized,3078,O
behavioural,3078,O
effects,3078,O
of,3078,O
a,3078,O
newly,3078,O
developed,3078,O
compound,3078,O
",",3078,O
VP1.15,3078,O
that,3078,O
inhibits,3078,O
both,3078,O
PDE7,3078,B-GENE-N
and,3078,O
GSK-3,3078,B-GENE-N
with,3078,O
main,3078,O
focus,3078,O
on,3078,O
its,3078,O
antipsychotic,3078,O
and,3078,O
cognitive,3078,O
capacities,3078,O
.,3078,O
VP1.15,3079,O
reduced,3079,O
ambulation,3079,O
in,3079,O
C57BL/6J,3079,O
mice,3079,O
in,3079,O
a,3079,O
dose-dependent,3079,O
manner,3079,O
(,3079,O
7.5,3079,O
mg/kg,3079,O
and,3079,O
3,3079,O
mg/kg,3079,O
",",3079,O
respectively,3079,O
),3079,O
and,3079,O
",",3079,O
hence,3079,O
",",3079,O
lower,3079,O
dose,3079,O
was,3079,O
chosen,3079,O
for,3079,O
the,3079,O
further,3079,O
analysis,3079,O
.,3079,O
VP1.1.5,3080,O
facilitated,3080,O
pre-pulse,3080,O
inhibition,3080,O
(,3080,O
PPI,3080,O
),3080,O
",",3080,O
reversed,3080,O
amphetamine-,3080,B-CHEMICAL
but,3080,O
not,3080,O
MK-801-induced,3080,B-CHEMICAL
PPI,3080,O
deficit,3080,O
.,3080,O
The,3081,O
drug,3081,O
was,3081,O
able,3081,O
to,3081,O
ameliorate,3081,O
the,3081,O
disrupted,3081,O
latent,3081,O
inhibition,3081,O
(,3081,O
LI,3081,O
),3081,O
induced,3081,O
by,3081,O
the,3081,O
increased,3081,O
number,3081,O
of,3081,O
conditioning,3081,O
trials,3081,O
and,3081,O
reversed,3081,O
amphetamine-induced,3081,B-CHEMICAL
LI,3081,O
deficit,3081,O
",",3081,O
supporting,3081,O
further,3081,O
its,3081,O
antipsychotic,3081,O
effects,3081,O
.,3081,O
The,3082,O
drug,3082,O
also,3082,O
significantly,3082,O
improved,3082,O
episodic,3082,O
memory,3082,O
in,3082,O
the,3082,O
spatial,3082,O
object,3082,O
recognition,3082,O
test,3082,O
",",3082,O
facilitated,3082,O
working,3082,O
memory,3082,O
in,3082,O
Y-maze,3082,O
and,3082,O
enhanced,3082,O
cued,3082,O
fear,3082,O
memory,3082,O
",",3082,O
but,3082,O
had,3082,O
no,3082,O
effect,3082,O
on,3082,O
executive,3082,O
function,3082,O
in,3082,O
the,3082,O
Puzzle,3082,O
box,3082,O
and,3082,O
contextual,3082,O
fear,3082,O
conditioning,3082,O
.,3082,O
Taken,3083,O
together,3083,O
",",3083,O
VP1.15,3083,O
elicited,3083,O
antipsychotic,3083,O
effects,3083,O
and,3083,O
also,3083,O
facilitated,3083,O
cognitive,3083,O
domains,3083,O
in,3083,O
mice,3083,O
",",3083,O
suggesting,3083,O
that,3083,O
multitarget,3083,O
drugs,3083,O
",",3083,O
affecting,3083,O
molecular,3083,O
substrates,3083,O
from,3083,O
the,3083,O
same,3083,O
pathway,3083,O
",",3083,O
perhaps,3083,O
could,3083,O
be,3083,O
antipsychotics,3083,O
of,3083,O
new-generation,3083,O
that,3083,O
open,3083,O
a,3083,O
new,3083,O
possibilities,3083,O
in,3083,O
drug,3083,O
discoveries,3083,O
.,3083,O
This,3084,O
article,3084,O
is,3084,O
part,3084,O
of,3084,O
a,3084,O
Special,3084,O
Issue,3084,O
entitled,3084,O
'Cognitive,3084,O
Enhancers,3084,O
',3084,O
.,3084,O
Comparison,3085,O
of,3085,O
inhibitory,3085,O
effects,3085,O
of,3085,O
meloxicam,3085,B-CHEMICAL
and,3085,O
diclofenac,3085,B-CHEMICAL
on,3085,O
human,3085,O
thromboxane,3085,B-CHEMICAL
biosynthesis,3085,O
after,3085,O
single,3085,O
doses,3085,O
and,3085,O
at,3085,O
steady,3085,O
state,3085,O
.,3085,O
OBJECTIVE,3086,O
:,3086,O
To,3086,O
evaluate,3086,O
the,3086,O
extent,3086,O
of,3086,O
human,3086,B-GENE-Y
cyclooxygenase-1,3086,I-GENE-Y
(,3086,O
COX-1,3086,B-GENE-Y
),3086,O
inhibition,3086,O
by,3086,O
meloxicam,3086,B-CHEMICAL
",",3086,O
which,3086,O
has,3086,O
been,3086,O
reported,3086,O
to,3086,O
preferentially,3086,O
inhibit,3086,O
cyclooxygenase-2,3086,B-GENE-Y
(,3086,O
COX-2,3086,B-GENE-Y
),3086,O
.,3086,O
The,3087,O
effects,3087,O
of,3087,O
meloxicam,3087,B-CHEMICAL
were,3087,O
compared,3087,O
with,3087,O
those,3087,O
of,3087,O
diclofenac,3087,B-CHEMICAL
",",3087,O
a,3087,O
nonselective,3087,O
COX,3087,B-GENE-N
inhibitor,3087,O
.,3087,O
METHODS,3088,O
:,3088,O
COX-1,3088,B-GENE-Y
inhibition,3088,O
was,3088,O
determined,3088,O
by,3088,O
measuring,3088,O
thromboxane,3088,B-CHEMICAL
B2,3088,I-CHEMICAL
(,3088,O
TXB2,3088,B-CHEMICAL
),3088,O
-generation,3088,O
from,3088,O
clotting,3088,O
whole,3088,O
blood,3088,O
ex,3088,O
vivo,3088,O
after,3088,O
single,3088,O
oral,3088,O
doses,3088,O
of,3088,O
7.5,3088,O
and,3088,O
15,3088,O
mg,3088,O
meloxicam,3088,B-CHEMICAL
and,3088,O
75,3088,O
mg,3088,O
diclofenac,3088,B-CHEMICAL
and,3088,O
at,3088,O
steady,3088,O
state,3088,O
(,3088,O
15,3088,O
mg,3088,O
meloxicam,3088,B-CHEMICAL
daily,3088,O
and,3088,O
150,3088,O
mg,3088,O
diclofenac,3088,B-CHEMICAL
daily,3088,O
),3088,O
.,3088,O
The,3089,O
effect,3089,O
was,3089,O
expressed,3089,O
as,3089,O
percentage,3089,O
inhibition,3089,O
of,3089,O
serum,3089,O
TXB2,3089,B-CHEMICAL
generation,3089,O
and,3089,O
was,3089,O
directly,3089,O
related,3089,O
to,3089,O
the,3089,O
serum,3089,O
drug,3089,O
concentration,3089,O
with,3089,O
use,3089,O
of,3089,O
a,3089,O
standard,3089,O
sigmoidal,3089,O
E,3089,O
(,3089,O
max,3089,O
),3089,O
model,3089,O
.,3089,O
RESULTS,3090,O
:,3090,O
In,3090,O
terms,3090,O
of,3090,O
inhibition,3090,O
of,3090,O
TXB2,3090,B-CHEMICAL
generation,3090,O
",",3090,O
diclofenac,3090,B-CHEMICAL
was,3090,O
about,3090,O
1,3090,O
order,3090,O
of,3090,O
magnitude,3090,O
more,3090,O
potent,3090,O
than,3090,O
meloxicam,3090,B-CHEMICAL
",",3090,O
indicated,3090,O
by,3090,O
a,3090,O
diclofenac,3090,B-CHEMICAL
EC50,3090,O
(,3090,O
concentration,3090,O
of,3090,O
drug,3090,O
required,3090,O
to,3090,O
cause,3090,O
50,3090,O
%,3090,O
of,3090,O
maximum,3090,O
effect,3090,O
),3090,O
that,3090,O
was,3090,O
about,3090,O
10,3090,O
times,3090,O
lower,3090,O
than,3090,O
that,3090,O
of,3090,O
meloxicam,3090,B-CHEMICAL
(,3090,O
EC50,3090,O
diclofenac,3090,B-CHEMICAL
single,3090,O
doses,3090,O
:,3090,O
37.50+/-29.64,3090,O
;,3090,O
EC50,3090,O
meloxicam,3090,B-CHEMICAL
single,3090,O
doses,3090,O
:,3090,O
677.50+/-189.08,3090,O
),3090,O
.,3090,O
However,3091,O
",",3091,O
serum,3091,O
concentrations,3091,O
of,3091,O
meloxicam,3091,B-CHEMICAL
after,3091,O
administration,3091,O
of,3091,O
15,3091,O
mg,3091,O
were,3091,O
approximately,3091,O
10-fold,3091,O
higher,3091,O
than,3091,O
those,3091,O
of,3091,O
diclofenac,3091,B-CHEMICAL
.,3091,O
Therefore,3092,O
there,3092,O
was,3092,O
no,3092,O
statistically,3092,O
significant,3092,O
difference,3092,O
in,3092,O
the,3092,O
area,3092,O
under,3092,O
the,3092,O
effect,3092,O
time,3092,O
curve,3092,O
(,3092,O
P,3092,O
=,3092,O
.115,3092,O
),3092,O
and,3092,O
the,3092,O
mean,3092,O
effect,3092,O
(,3092,O
P,3092,O
=,3092,O
.424,3092,O
),3092,O
between,3092,O
meloxicam,3092,B-CHEMICAL
and,3092,O
diclofenac,3092,B-CHEMICAL
.,3092,O
The,3093,O
EC50,3093,O
of,3093,O
both,3093,O
drugs,3093,O
was,3093,O
significantly,3093,O
higher,3093,O
at,3093,O
steady,3093,O
state,3093,O
(,3093,O
diclofenac,3093,B-CHEMICAL
steady,3093,O
state,3093,O
:,3093,O
87.07+/-55.24,3093,O
ng/mL,3093,O
;,3093,O
meloxicam,3093,B-CHEMICAL
steady,3093,O
state,3093,O
:,3093,O
1850.12+/-829.93,3093,O
ng/mL,3093,O
),3093,O
than,3093,O
after,3093,O
a,3093,O
single,3093,O
dose,3093,O
(,3093,O
P,3093,O
<,3093,O
.001,3093,O
),3093,O
.,3093,O
CONCLUSION,3094,O
:,3094,O
These,3094,O
data,3094,O
show,3094,O
that,3094,O
meloxicam,3094,B-CHEMICAL
inhibits,3094,O
TXB2,3094,B-CHEMICAL
generation,3094,O
at,3094,O
clinically,3094,O
relevant,3094,O
doses,3094,O
",",3094,O
although,3094,O
less,3094,O
potently,3094,O
than,3094,O
diclofenac,3094,B-CHEMICAL
.,3094,O
Thus,3095,O
our,3095,O
data,3095,O
suggest,3095,O
that,3095,O
the,3095,O
COX-2,3095,B-GENE-Y
preference,3095,O
of,3095,O
meloxicam,3095,B-CHEMICAL
observed,3095,O
in,3095,O
vitro,3095,O
may,3095,O
not,3095,O
result,3095,O
in,3095,O
clinical,3095,O
advantages,3095,O
when,3095,O
the,3095,O
higher,3095,O
dose,3095,O
of,3095,O
15,3095,O
mg,3095,O
is,3095,O
needed,3095,O
.,3095,O
Because,3096,O
of,3096,O
the,3096,O
increase,3096,O
in,3096,O
EC50,3096,O
at,3096,O
steady,3096,O
state,3096,O
",",3096,O
COX-1,3096,B-GENE-Y
is,3096,O
relatively,3096,O
spared,3096,O
when,3096,O
the,3096,O
lower,3096,O
dose,3096,O
of,3096,O
7.5,3096,O
mg,3096,O
is,3096,O
administered,3096,O
.,3096,O
Interleukin,3097,B-GENE-Y
2,3097,I-GENE-Y
toxin,3097,O
:,3097,O
a,3097,O
step,3097,O
toward,3097,O
selective,3097,O
immunomodulation,3097,O
.,3097,O
We,3098,O
have,3098,O
used,3098,O
protein,3098,O
engineering,3098,O
and,3098,O
recombinant,3098,O
DNA,3098,O
methodologies,3098,O
to,3098,O
genetically,3098,O
replace,3098,O
the,3098,O
eukaryotic,3098,B-GENE-N
cell,3098,I-GENE-N
receptor,3098,I-GENE-N
binding,3098,I-GENE-N
domain,3098,I-GENE-N
of,3098,O
diphtheria,3098,O
toxin,3098,O
with,3098,O
interleukin,3098,B-GENE-Y
2,3098,I-GENE-Y
(,3098,O
IL-2,3098,B-GENE-Y
),3098,O
.,3098,O
The,3099,O
toxin-related,3099,O
T,3099,B-GENE-N
cell,3099,I-GENE-N
growth,3099,I-GENE-N
factor,3099,I-GENE-N
fusion,3099,O
gene,3099,O
has,3099,O
been,3099,O
cloned,3099,O
in,3099,O
Escherichia,3099,O
coli,3099,O
K12,3099,O
.,3099,O
Recombinant,3100,O
strains,3100,O
of,3100,O
E,3100,O
coli,3100,O
produce,3100,O
a,3100,O
"68,086",3100,O
K,3100,O
hybrid,3100,O
toxin,3100,O
",",3100,O
IL-2,3100,B-GENE-Y
toxin,3100,O
that,3100,O
retains,3100,O
immunologic,3100,O
properties,3100,O
intrinsic,3100,O
to,3100,O
both,3100,O
its,3100,O
diphtheria,3100,O
toxin,3100,O
and,3100,O
IL-2,3100,B-GENE-Y
components,3100,O
.,3100,O
IL-2,3101,B-GENE-N
toxin,3101,O
has,3101,O
been,3101,O
found,3101,O
to,3101,O
selectively,3101,O
inhibit,3101,O
protein,3101,O
synthesis,3101,O
in,3101,O
both,3101,O
human,3101,O
and,3101,O
murine,3101,O
T,3101,O
cell,3101,O
lines,3101,O
that,3101,O
bear,3101,O
high,3101,O
affinity,3101,O
IL-2,3101,B-GENE-N
receptors,3101,I-GENE-N
",",3101,O
whereas,3101,O
the,3101,O
hybrid,3101,O
toxin,3101,O
is,3101,O
not,3101,O
active,3101,O
against,3101,O
cells,3101,O
that,3101,O
do,3101,O
not,3101,O
bear,3101,O
this,3101,O
receptor,3101,O
.,3101,O
The,3102,O
cytotoxic,3102,O
action,3102,O
of,3102,O
IL-2,3102,B-GENE-Y
toxin,3102,O
is,3102,O
specifically,3102,O
blocked,3102,O
by,3102,O
free,3102,O
IL-2,3102,B-GENE-Y
and,3102,O
monoclonal,3102,O
antibodies,3102,O
that,3102,O
bind,3102,O
to,3102,O
the,3102,O
p55,3102,B-GENE-Y
(,3102,O
Tac,3102,B-GENE-N
antigen,3102,O
),3102,O
subunit,3102,O
of,3102,O
the,3102,O
high,3102,O
affinity,3102,O
IL-2,3102,B-GENE-N
receptor,3102,I-GENE-N
.,3102,O
In,3103,O
addition,3103,O
",",3103,O
IL-2,3103,B-GENE-Y
toxin,3103,O
",",3103,O
like,3103,O
diphtheria,3103,O
toxin,3103,O
itself,3103,O
",",3103,O
must,3103,O
pass,3103,O
through,3103,O
an,3103,O
acidic,3103,O
compartment,3103,O
in,3103,O
order,3103,O
to,3103,O
deliver,3103,O
its,3103,O
adenosine,3103,B-GENE-N
diphosphate,3103,I-GENE-N
ribosyl,3103,I-GENE-N
transferase,3103,I-GENE-N
activity,3103,O
to,3103,O
the,3103,O
cytosol,3103,O
of,3103,O
target,3103,O
T,3103,O
cells,3103,O
.,3103,O
In,3104,O
a,3104,O
murine,3104,O
delayed,3104,O
type,3104,O
hypersensitivity,3104,O
(,3104,O
DTH,3104,O
),3104,O
model,3104,O
system,3104,O
",",3104,O
we,3104,O
have,3104,O
shown,3104,O
that,3104,O
IL-2,3104,B-GENE-Y
toxin,3104,O
treatment,3104,O
induces,3104,O
a,3104,O
marked,3104,O
immunosuppression,3104,O
.,3104,O
3D,3105,O
Organotypic,3105,O
Cultures,3105,O
of,3105,O
Human,3105,O
HepaRG,3105,O
Cells,3105,O
:,3105,O
A,3105,O
Tool,3105,O
for,3105,O
In,3105,O
Vitro,3105,O
Toxicity,3105,O
Studies,3105,O
.,3105,O
Drug-induced,3106,O
human,3106,O
hepatotoxicity,3106,O
is,3106,O
difficult,3106,O
to,3106,O
predict,3106,O
using,3106,O
the,3106,O
current,3106,O
in,3106,O
vitro,3106,O
systems,3106,O
.,3106,O
In,3107,O
this,3107,O
study,3107,O
",",3107,O
long-term,3107,O
3D,3107,O
organotypic,3107,O
cultures,3107,O
of,3107,O
the,3107,O
human,3107,O
hepatoma,3107,O
HepaRG,3107,O
cell,3107,O
line,3107,O
were,3107,O
prepared,3107,O
using,3107,O
a,3107,O
high-throughput,3107,O
hanging,3107,O
drop,3107,O
method,3107,O
.,3107,O
The,3108,O
organotypic,3108,O
cultures,3108,O
were,3108,O
maintained,3108,O
for,3108,O
3,3108,O
weeks,3108,O
and,3108,O
assessed,3108,O
for,3108,O
(,3108,O
1,3108,O
),3108,O
liver,3108,O
specific,3108,O
functions,3108,O
",",3108,O
including,3108,O
phase,3108,O
I,3108,O
enzyme,3108,O
and,3108,O
transporter,3108,O
activities,3108,O
",",3108,O
(,3108,O
2,3108,O
),3108,O
expression,3108,O
of,3108,O
liver-specific,3108,O
proteins,3108,O
",",3108,O
and,3108,O
(,3108,O
3,3108,O
),3108,O
responses,3108,O
to,3108,O
three,3108,O
drugs,3108,O
(,3108,O
acetaminophen,3108,B-CHEMICAL
",",3108,O
troglitazone,3108,B-CHEMICAL
",",3108,O
and,3108,O
rosiglitazone,3108,B-CHEMICAL
),3108,O
.,3108,O
Our,3109,O
results,3109,O
show,3109,O
that,3109,O
the,3109,O
organotypic,3109,O
cultures,3109,O
maintain,3109,O
high,3109,O
liver-specific,3109,O
functionality,3109,O
during,3109,O
3,3109,O
weeks,3109,O
of,3109,O
culture,3109,O
.,3109,O
The,3110,O
immunohistochemistry,3110,O
analyses,3110,O
illustrate,3110,O
that,3110,O
the,3110,O
organotypic,3110,O
cultures,3110,O
express,3110,O
liver-specific,3110,O
markers,3110,O
such,3110,O
as,3110,O
albumin,3110,B-GENE-Y
",",3110,O
CYP3A4,3110,B-GENE-Y
",",3110,O
CYP2E1,3110,B-GENE-Y
",",3110,O
and,3110,O
MRP-2,3110,B-GENE-Y
throughout,3110,O
the,3110,O
cultivation,3110,O
period,3110,O
.,3110,O
Accordingly,3111,O
",",3111,O
the,3111,O
production,3111,O
rates,3111,O
of,3111,O
albumin,3111,B-GENE-Y
and,3111,O
glucose,3111,B-CHEMICAL
",",3111,O
as,3111,O
well,3111,O
as,3111,O
CYP2E1,3111,B-GENE-Y
activity,3111,O
",",3111,O
were,3111,O
significantly,3111,O
higher,3111,O
in,3111,O
the,3111,O
3D,3111,O
versus,3111,O
the,3111,O
2D,3111,O
cultures,3111,O
.,3111,O
Toxicity,3112,O
studies,3112,O
show,3112,O
that,3112,O
the,3112,O
organotypic,3112,O
cultures,3112,O
are,3112,O
more,3112,O
sensitive,3112,O
to,3112,O
acetaminophen-,3112,B-CHEMICAL
and,3112,O
rosiglitazone-induced,3112,B-CHEMICAL
toxicity,3112,O
but,3112,O
less,3112,O
sensitive,3112,O
to,3112,O
troglitazone-induced,3112,B-CHEMICAL
toxicity,3112,O
than,3112,O
the,3112,O
2D,3112,O
cultures,3112,O
.,3112,O
Furthermore,3113,O
",",3113,O
the,3113,O
EC50,3113,O
value,3113,O
(,3113,O
2.7mM,3113,O
),3113,O
for,3113,O
acetaminophen,3113,B-CHEMICAL
on,3113,O
the,3113,O
3D,3113,O
cultures,3113,O
was,3113,O
similar,3113,O
to,3113,O
in,3113,O
vivo,3113,O
toxicity,3113,O
.,3113,O
In,3114,O
summary,3114,O
",",3114,O
the,3114,O
results,3114,O
from,3114,O
our,3114,O
study,3114,O
suggest,3114,O
that,3114,O
the,3114,O
3D,3114,O
organotypic,3114,O
HepaRG,3114,O
culture,3114,O
is,3114,O
a,3114,O
promising,3114,O
in,3114,O
vitro,3114,O
tool,3114,O
for,3114,O
more,3114,O
accurate,3114,O
assessment,3114,O
of,3114,O
acute,3114,O
and,3114,O
also,3114,O
possibly,3114,O
for,3114,O
chronic,3114,O
drug-induced,3114,O
hepatotoxicity,3114,O
.,3114,O
Inhibition,3115,O
of,3115,O
angiogenesis,3115,O
and,3115,O
invasion,3115,O
by,3115,O
DMBT,3115,B-CHEMICAL
is,3115,O
mediated,3115,O
by,3115,O
downregulation,3115,O
of,3115,O
VEGF,3115,B-GENE-N
and,3115,O
MMP-9,3115,B-GENE-Y
through,3115,O
Akt,3115,B-GENE-N
pathway,3115,O
in,3115,O
MDA-MB-231,3115,O
breast,3115,O
cancer,3115,O
cells,3115,O
.,3115,O
Invasion,3116,O
",",3116,O
either,3116,O
directly,3116,O
or,3116,O
via,3116,O
metastasis,3116,O
formation,3116,O
",",3116,O
is,3116,O
the,3116,O
main,3116,O
cause,3116,O
of,3116,O
death,3116,O
in,3116,O
cancer,3116,O
patients,3116,O
",",3116,O
development,3116,O
of,3116,O
efficient,3116,O
anti-invasive,3116,O
agents,3116,O
is,3116,O
an,3116,O
important,3116,O
research,3116,O
challenge,3116,O
.,3116,O
In,3117,O
order,3117,O
to,3117,O
obtain,3117,O
more,3117,O
potent,3117,O
inhibitors,3117,O
",",3117,O
a,3117,O
series,3117,O
of,3117,O
brartemicin,3117,B-CHEMICAL
analogs,3117,O
were,3117,O
synthesized,3117,O
and,3117,O
evaluated,3117,O
for,3117,O
their,3117,O
inhibitory,3117,O
activity,3117,O
against,3117,O
invasion,3117,O
.,3117,O
Among,3118,O
the,3118,O
synthetic,3118,O
analogs,3118,O
tested,3118,O
",",3118,O
DMBT,3118,B-CHEMICAL
",",3118,O
"6,6'-bis",3118,B-CHEMICAL
(,3118,I-CHEMICAL
"2,3-dimethoxybenzoyl",3118,I-CHEMICAL
),3118,I-CHEMICAL
-a,3118,I-CHEMICAL
",",3118,I-CHEMICAL
a-d-trehalose,3118,I-CHEMICAL
",",3118,O
was,3118,O
found,3118,O
to,3118,O
be,3118,O
the,3118,O
most,3118,O
potent,3118,O
anti-invasive,3118,O
agent,3118,O
.,3118,O
But,3119,O
the,3119,O
effects,3119,O
of,3119,O
DMBT,3119,B-CHEMICAL
on,3119,O
breast,3119,O
cancer,3119,O
cells,3119,O
were,3119,O
not,3119,O
known,3119,O
.,3119,O
In,3120,O
this,3120,O
study,3120,O
",",3120,O
the,3120,O
effects,3120,O
of,3120,O
DMBT,3120,B-CHEMICAL
on,3120,O
invasion,3120,O
and,3120,O
metastasis,3120,O
in,3120,O
MDA-MB-231,3120,O
cells,3120,O
were,3120,O
investigated,3120,O
.,3120,O
MTT,3121,B-CHEMICAL
assay,3121,O
showed,3121,O
that,3121,O
no,3121,O
obvious,3121,O
inhibitory,3121,O
or,3121,O
cytotoxic,3121,O
effect,3121,O
of,3121,O
DMBT,3121,B-CHEMICAL
was,3121,O
found,3121,O
.,3121,O
DMBT,3122,B-CHEMICAL
could,3122,O
inhibit,3122,O
invasion,3122,O
",",3122,O
migration,3122,O
and,3122,O
tube,3122,O
formation,3122,O
of,3122,O
HUVECs,3122,O
.,3122,O
Gelatin,3123,O
zymography,3123,O
showed,3123,O
that,3123,O
DMBT,3123,B-CHEMICAL
inhibited,3123,O
secretion,3123,O
and,3123,O
activity,3123,O
of,3123,O
MMP-9,3123,B-GENE-Y
.,3123,O
Western,3124,O
blotting,3124,O
demonstrated,3124,O
that,3124,O
DMBT,3124,B-CHEMICAL
effectively,3124,O
suppressed,3124,O
the,3124,O
expression,3124,O
of,3124,O
VEGF,3124,B-GENE-N
",",3124,O
p-VEGFR-2,3124,B-GENE-Y
",",3124,O
p-EGFR,3124,B-GENE-Y
",",3124,O
and,3124,O
p-Akt,3124,B-GENE-N
.,3124,O
These,3125,O
results,3125,O
suggested,3125,O
that,3125,O
DMBT,3125,B-CHEMICAL
could,3125,O
inhibit,3125,O
invasion,3125,O
and,3125,O
angiogenesis,3125,O
by,3125,O
downregulation,3125,O
of,3125,O
VEGFand,3125,B-GENE-N
MMP-9,3125,B-GENE-Y
",",3125,O
resulting,3125,O
from,3125,O
the,3125,O
inhibition,3125,O
of,3125,O
Akt,3125,B-GENE-N
pathway,3125,O
.,3125,O
DMBT,3126,B-CHEMICAL
might,3126,O
be,3126,O
a,3126,O
promising,3126,O
lead,3126,O
molecule,3126,O
for,3126,O
the,3126,O
anti-metastasis,3126,O
and,3126,O
serve,3126,O
as,3126,O
a,3126,O
therapeutic,3126,O
agent,3126,O
to,3126,O
inhibit,3126,O
breast,3126,O
cancer,3126,O
cell,3126,O
invasion,3126,O
and,3126,O
metastasis,3126,O
.,3126,O
Quantitative,3127,O
determination,3127,O
of,3127,O
fatty,3127,B-CHEMICAL
acid,3127,I-CHEMICAL
chain,3127,O
composition,3127,O
in,3127,O
pork,3127,O
meat,3127,O
products,3127,O
by,3127,O
high,3127,O
resolution,3127,O
1H,3127,B-CHEMICAL
NMR,3127,O
spectroscopy,3127,O
.,3127,O
High,3128,O
resolution,3128,O
(,3128,B-CHEMICAL
1,3128,I-CHEMICAL
),3128,I-CHEMICAL
H,3128,I-CHEMICAL
NMR,3128,O
spectroscopy,3128,O
was,3128,O
proposed,3128,O
for,3128,O
the,3128,O
determination,3128,O
of,3128,O
the,3128,O
fatty,3128,B-CHEMICAL
acid,3128,I-CHEMICAL
chain,3128,O
profile,3128,O
of,3128,O
lipids,3128,O
in,3128,O
pork,3128,O
meat,3128,O
products,3128,O
during,3128,O
ripening,3128,O
.,3128,O
Two,3129,O
typical,3129,O
Mediterranean,3129,O
PDO,3129,O
salami,3129,O
produced,3129,O
in,3129,O
Calabria,3129,O
",",3129,O
a,3129,O
region,3129,O
in,3129,O
the,3129,O
Southern,3129,O
Italy,3129,O
",",3129,O
were,3129,O
chosen,3129,O
as,3129,O
a,3129,O
case,3129,O
of,3129,O
study,3129,O
.,3129,O
Quantitative,3130,O
NMR,3130,O
analysis,3130,O
provided,3130,O
the,3130,O
fatty,3130,B-CHEMICAL
acid,3130,I-CHEMICAL
chain,3130,O
profiles,3130,O
of,3130,O
total,3130,O
lipid,3130,O
extracts,3130,O
.,3130,O
The,3131,O
transesterification,3131,O
of,3131,O
total,3131,O
lipid,3131,O
extracts,3131,O
furnished,3131,O
FAME,3131,B-CHEMICAL
mixtures,3131,O
that,3131,O
enabled,3131,O
quantitation,3131,O
of,3131,O
fatty,3131,B-CHEMICAL
acid,3131,I-CHEMICAL
acyl,3131,I-CHEMICAL
chains,3131,O
in,3131,O
the,3131,O
acylglycerol,3131,B-CHEMICAL
and,3131,O
FFA,3131,O
portions,3131,O
.,3131,O
In,3132,O
all,3132,O
cases,3132,O
",",3132,O
oleyl,3132,B-CHEMICAL
chains,3132,O
were,3132,O
predominant,3132,O
",",3132,O
and,3132,O
high,3132,O
amounts,3132,O
of,3132,O
polyunsaturated,3132,B-CHEMICAL
fatty,3132,I-CHEMICAL
acid,3132,I-CHEMICAL
chains,3132,O
were,3132,O
observed,3132,O
.,3132,O
The,3133,O
proposed,3133,O
spectroscopic,3133,O
method,3133,O
allowed,3133,O
also,3133,O
the,3133,O
estimation,3133,O
of,3133,O
the,3133,O
most,3133,O
important,3133,O
nutritional,3133,O
parameters,3133,O
of,3133,O
dry,3133,O
fermented,3133,O
meat,3133,O
products,3133,O
.,3133,O
Identification,3134,O
of,3134,O
the,3134,O
regulatory,3134,O
region,3134,O
of,3134,O
the,3134,O
L-type,3134,B-GENE-Y
pyruvate,3134,I-GENE-Y
kinase,3134,I-GENE-Y
gene,3134,O
in,3134,O
mouse,3134,O
liver,3134,O
by,3134,O
hydrodynamics-based,3134,O
gene,3134,O
transfection,3134,O
.,3134,O
Expression,3135,O
of,3135,O
L-type,3135,B-GENE-Y
pyruvate,3135,I-GENE-Y
kinase,3135,I-GENE-Y
(,3135,O
L-PK,3135,B-GENE-Y
),3135,O
is,3135,O
upregulated,3135,O
in,3135,O
the,3135,O
liver,3135,O
by,3135,O
dietary,3135,O
carbohydrate,3135,B-CHEMICAL
.,3135,O
Previously,3136,O
",",3136,O
3,3136,O
carbohydrate/insulin,3136,B-GENE-N
response,3136,I-GENE-N
elements,3136,I-GENE-N
were,3136,O
identified,3136,O
in,3136,O
the,3136,O
5'-flanking,3136,O
region,3136,O
of,3136,O
the,3136,O
L-PK,3136,B-GENE-Y
gene,3136,O
up,3136,O
to,3136,O
bp,3136,O
-170,3136,O
.,3136,O
Studies,3137,O
of,3137,O
the,3137,O
5'-flanking,3137,O
region,3137,O
beyond,3137,O
bp,3137,O
-183,3137,O
in,3137,O
transgenic,3137,O
mice,3137,O
suggested,3137,O
that,3137,O
other,3137,O
regulatory,3137,O
elements,3137,O
may,3137,O
be,3137,O
present,3137,O
upstream,3137,O
of,3137,O
bp,3137,O
-183,3137,O
",",3137,O
but,3137,O
the,3137,O
positions,3137,O
of,3137,O
these,3137,O
elements,3137,O
were,3137,O
uncertain,3137,O
.,3137,O
In,3138,O
the,3138,O
present,3138,O
study,3138,O
",",3138,O
the,3138,O
existence,3138,O
of,3138,O
regulatory,3138,O
regions,3138,O
of,3138,O
the,3138,O
L-PK,3138,B-GENE-Y
gene,3138,O
responding,3138,O
to,3138,O
stimulation,3138,O
by,3138,O
feeding,3138,O
was,3138,O
examined,3138,O
using,3138,O
in,3138,O
vivo,3138,O
hydrodynamics-based,3138,O
gene,3138,O
transfection,3138,O
(,3138,O
HT,3138,O
),3138,O
in,3138,O
mouse,3138,O
liver,3138,O
.,3138,O
The,3139,O
firefly-luciferase,3139,O
(,3139,O
FL,3139,O
),3139,O
gene,3139,O
",",3139,O
fused,3139,O
with,3139,O
various,3139,O
lengths,3139,O
of,3139,O
the,3139,O
5'-flanking,3139,O
region,3139,O
of,3139,O
the,3139,O
L-PK,3139,B-GENE-Y
gene,3139,O
",",3139,O
was,3139,O
introduced,3139,O
into,3139,O
mouse,3139,O
liver,3139,O
by,3139,O
HT,3139,O
.,3139,O
The,3140,O
mice,3140,O
had,3140,O
free,3140,O
access,3140,O
to,3140,O
a,3140,O
high-carbohydrate,3140,O
diet,3140,O
.,3140,O
In,3141,O
liver,3141,O
homogenate,3141,O
",",3141,O
luciferase,3141,O
activity,3141,O
of,3141,O
pL-PK,3141,O
(,3141,O
-1467,3141,O
),3141,O
-FL,3141,O
(,3141,O
which,3141,O
included,3141,O
the,3141,O
5'-flanking,3141,O
region,3141,O
from,3141,O
bp,3141,O
-1467,3141,O
to,3141,O
+17,3141,O
),3141,O
",",3141,O
was,3141,O
markedly,3141,O
stimulated,3141,O
by,3141,O
feeding,3141,O
.,3141,O
5'-Deletion,3142,O
up,3142,O
to,3142,O
bp,3142,O
-1065,3142,O
caused,3142,O
only,3142,O
minor,3142,O
changes,3142,O
in,3142,O
luciferase,3142,O
activity,3142,O
",",3142,O
but,3142,O
further,3142,O
deletion,3142,O
up,3142,O
to,3142,O
bp,3142,O
-690,3142,O
and,3142,O
bp,3142,O
-203,3142,O
caused,3142,O
significant,3142,O
",",3142,O
gradual,3142,O
decreases,3142,O
in,3142,O
activity,3142,O
.,3142,O
Further,3143,O
analyses,3143,O
utilizing,3143,O
5'-deletion,3143,O
mutants,3143,O
indicated,3143,O
the,3143,O
existence,3143,O
of,3143,O
positive,3143,O
regulatory,3143,O
regions,3143,O
that,3143,O
respond,3143,O
to,3143,O
stimulation,3143,O
by,3143,O
feeding,3143,O
between,3143,O
bp,3143,O
-1065,3143,O
and,3143,O
-945,3143,O
",",3143,O
and,3143,O
between,3143,O
-300,3143,O
and,3143,O
-203,3143,O
on,3143,O
the,3143,O
L-PK,3143,B-GENE-Y
gene,3143,O
.,3143,O
These,3144,O
results,3144,O
suggest,3144,O
that,3144,O
unidentified,3144,O
cis-acting,3144,B-GENE-N
DNA,3144,I-GENE-N
elements,3144,I-GENE-N
exist,3144,O
in,3144,O
the,3144,O
upstream,3144,O
region,3144,O
of,3144,O
the,3144,O
L-PK,3144,B-GENE-Y
gene,3144,O
",",3144,O
and,3144,O
that,3144,O
HT,3144,O
is,3144,O
a,3144,O
useful,3144,O
approach,3144,O
for,3144,O
detecting,3144,O
regulatory,3144,O
regions,3144,O
of,3144,O
genes,3144,O
expressed,3144,O
in,3144,O
the,3144,O
liver,3144,O
.,3144,O
The,3145,O
Ras-GTPase,3145,B-GENE-N
activity,3145,O
of,3145,O
neurofibromin,3145,B-GENE-Y
restrains,3145,O
ERK-dependent,3145,B-GENE-N
FGFR,3145,B-GENE-N
signaling,3145,O
during,3145,O
endochondral,3145,O
bone,3145,O
formation,3145,O
.,3145,O
The,3146,O
severe,3146,O
defects,3146,O
in,3146,O
growth,3146,O
plate,3146,O
development,3146,O
caused,3146,O
by,3146,O
chondrocyte,3146,O
extracellular,3146,B-GENE-N
signal-regulated,3146,I-GENE-N
protein,3146,I-GENE-N
kinases,3146,I-GENE-N
1,3146,I-GENE-N
and,3146,I-GENE-N
2,3146,I-GENE-N
(,3146,O
ERK1/2,3146,B-GENE-N
),3146,O
gain,3146,O
or,3146,O
loss-of-function,3146,O
suggest,3146,O
that,3146,O
tight,3146,O
spatial,3146,O
and,3146,O
temporal,3146,O
regulation,3146,O
of,3146,O
mitogen-activated,3146,B-GENE-N
protein,3146,I-GENE-N
kinase,3146,I-GENE-N
signaling,3146,O
is,3146,O
necessary,3146,O
to,3146,O
achieve,3146,O
harmonious,3146,O
growth,3146,O
plate,3146,O
elongation,3146,O
and,3146,O
structure,3146,O
.,3146,O
We,3147,O
provide,3147,O
here,3147,O
evidence,3147,O
that,3147,O
neurofibromin,3147,B-GENE-Y
",",3147,O
via,3147,O
its,3147,O
Ras,3147,B-GENE-N
guanosine,3147,B-GENE-N
triphosphatase,3147,I-GENE-N
-activating,3147,O
activity,3147,O
",",3147,O
controls,3147,O
ERK1/2-dependent,3147,B-GENE-N
fibroblast,3147,B-GENE-N
growth,3147,I-GENE-N
factor,3147,I-GENE-N
receptor,3147,I-GENE-N
(,3147,O
FGFR,3147,B-GENE-N
),3147,O
signaling,3147,O
in,3147,O
chondrocytes,3147,O
.,3147,O
We,3148,O
show,3148,O
first,3148,O
that,3148,O
neurofibromin,3148,B-GENE-Y
is,3148,O
expressed,3148,O
in,3148,O
FGFR-positive,3148,B-GENE-N
prehypertrophic,3148,O
and,3148,O
hypertrophic,3148,O
chondrocytes,3148,O
during,3148,O
growth,3148,O
plate,3148,O
endochondral,3148,O
ossification,3148,O
.,3148,O
Using,3149,O
mice,3149,O
lacking,3149,O
neurofibromin,3149,B-GENE-Y
1,3149,I-GENE-Y
(,3149,O
Nf1,3149,B-GENE-Y
),3149,O
in,3149,O
type,3149,B-GENE-N
II,3149,I-GENE-N
collagen-expressing,3149,O
cells,3149,O
",",3149,O
(,3149,O
Nf1col2,3149,B-GENE-Y
(,3149,O
-/-,3149,O
),3149,O
mutant,3149,O
mice,3149,O
),3149,O
",",3149,O
we,3149,O
then,3149,O
show,3149,O
that,3149,O
lack,3149,O
of,3149,O
neurofibromin,3149,B-GENE-Y
in,3149,O
post-mitotic,3149,O
chondrocytes,3149,O
triggers,3149,O
a,3149,O
number,3149,O
of,3149,O
phenotypes,3149,O
reminiscent,3149,O
of,3149,O
the,3149,O
ones,3149,O
observed,3149,O
in,3149,O
mice,3149,O
characterized,3149,O
by,3149,O
FGFR,3149,B-GENE-N
gain-of-function,3149,O
mutations,3149,O
.,3149,O
Those,3150,O
include,3150,O
dwarfism,3150,O
",",3150,O
constitutive,3150,O
ERK1/2,3150,B-GENE-N
activation,3150,O
",",3150,O
strongly,3150,O
reduced,3150,O
Ihh,3150,B-GENE-Y
expression,3150,O
and,3150,O
decreased,3150,O
chondrocyte,3150,O
proliferation,3150,O
and,3150,O
maturation,3150,O
",",3150,O
increased,3150,O
chondrocytic,3150,O
expression,3150,O
of,3150,O
Rankl,3150,B-GENE-Y
",",3150,O
matrix,3150,B-GENE-Y
metalloproteinase,3150,I-GENE-Y
9,3150,I-GENE-Y
(,3150,O
Mmp9,3150,B-GENE-Y
),3150,O
and,3150,O
Mmp13,3150,B-GENE-Y
and,3150,O
enhanced,3150,O
growth,3150,O
plate,3150,O
osteoclastogenesis,3150,O
",",3150,O
as,3150,O
well,3150,O
as,3150,O
increased,3150,O
sensitivity,3150,O
to,3150,O
caspase-9,3150,B-GENE-Y
mediated,3150,O
apoptosis,3150,O
.,3150,O
Using,3151,O
wildtype,3151,O
(,3151,O
WT,3151,O
),3151,O
and,3151,O
Nf1,3151,B-GENE-Y
(,3151,O
-/-,3151,O
),3151,O
chondrocyte,3151,O
cultures,3151,O
in,3151,O
vitro,3151,O
",",3151,O
we,3151,O
show,3151,O
that,3151,O
FGF2,3151,B-GENE-Y
pulse-stimulation,3151,O
triggers,3151,O
rapid,3151,O
ERK1/2,3151,B-GENE-N
phosphorylation,3151,O
in,3151,O
both,3151,O
genotypes,3151,O
",",3151,O
but,3151,O
that,3151,O
return,3151,O
to,3151,O
the,3151,O
basal,3151,O
level,3151,O
is,3151,O
delayed,3151,O
in,3151,O
Nf1,3151,B-GENE-Y
(,3151,O
-/-,3151,O
),3151,O
chondrocytes,3151,O
.,3151,O
Importantly,3152,O
",",3152,O
in,3152,O
vivo,3152,O
ERK1/2,3152,B-GENE-N
inhibition,3152,O
by,3152,O
daily,3152,O
injection,3152,O
of,3152,O
a,3152,O
recombinant,3152,O
form,3152,O
of,3152,O
C-type,3152,B-GENE-Y
natriuretic,3152,I-GENE-Y
peptide,3152,I-GENE-Y
to,3152,O
post-natal,3152,O
pups,3152,O
for,3152,O
18,3152,O
days,3152,O
was,3152,O
able,3152,O
to,3152,O
correct,3152,O
the,3152,O
short,3152,O
stature,3152,O
of,3152,O
Nf1col2,3152,B-GENE-Y
(,3152,O
-/-,3152,O
),3152,O
mice,3152,O
.,3152,O
Together,3153,O
",",3153,O
these,3153,O
results,3153,O
underscore,3153,O
the,3153,O
requirement,3153,O
of,3153,O
neurofibromin,3153,O
and,3153,O
ERK1/2,3153,B-GENE-N
for,3153,O
normal,3153,O
endochondral,3153,O
bone,3153,O
formation,3153,O
and,3153,O
support,3153,O
the,3153,O
notion,3153,O
that,3153,O
neurofibromin,3153,O
",",3153,O
by,3153,O
restraining,3153,O
RAS-ERK1/2,3153,B-GENE-N
signaling,3153,O
",",3153,O
is,3153,O
a,3153,O
negative,3153,O
regulator,3153,O
of,3153,O
FGFR,3153,B-GENE-N
signaling,3153,O
in,3153,O
differentiating,3153,O
chondrocytes,3153,O
.,3153,O
Felbamate,3154,B-CHEMICAL
block,3154,O
of,3154,O
recombinant,3154,O
N-methyl-D-aspartate,3154,B-GENE-N
receptors,3154,I-GENE-N
:,3154,O
selectivity,3154,O
for,3154,O
the,3154,O
NR2B,3154,B-GENE-Y
subunit,3154,O
.,3154,O
The,3155,O
anticonvulsant,3155,O
felbamate,3155,B-CHEMICAL
blocks,3155,O
N-methyl-D-asparate,3155,B-GENE-N
(,3155,I-GENE-N
NMDA,3155,I-GENE-N
),3155,I-GENE-N
receptors,3155,I-GENE-N
but,3155,O
fails,3155,O
to,3155,O
exhibit,3155,O
the,3155,O
neurobehavioral,3155,O
toxicity,3155,O
characteristic,3155,O
of,3155,O
other,3155,O
NMDA,3155,B-GENE-N
receptor,3155,I-GENE-N
antagonists,3155,O
.,3155,O
To,3156,O
investigate,3156,O
the,3156,O
possibility,3156,O
that,3156,O
felbamate,3156,O
's,3156,O
favorable,3156,O
toxicity,3156,O
profile,3156,O
could,3156,O
be,3156,O
related,3156,O
to,3156,O
NMDA,3156,B-GENE-N
receptor,3156,I-GENE-N
subtype,3156,O
selectivity,3156,O
",",3156,O
we,3156,O
examined,3156,O
the,3156,O
specificity,3156,O
of,3156,O
felbamate,3156,B-CHEMICAL
block,3156,O
of,3156,O
recombinant,3156,O
NMDA,3156,B-GENE-N
receptors,3156,I-GENE-N
composed,3156,O
of,3156,O
the,3156,O
NR1a,3156,B-GENE-Y
subunit,3156,O
and,3156,O
various,3156,O
NR2,3156,B-GENE-N
subunits,3156,O
.,3156,O
Felbamate,3157,B-CHEMICAL
produced,3157,O
a,3157,O
rapid,3157,O
",",3157,O
concentration-dependent,3157,O
block,3157,O
of,3157,O
currents,3157,O
evoked,3157,O
by,3157,O
50,3157,O
microM,3157,O
NMDA,3157,B-CHEMICAL
and,3157,O
10,3157,O
microM,3157,O
glycine,3157,B-CHEMICAL
in,3157,O
human,3157,O
embryonic,3157,O
kidney,3157,O
293,3157,O
cells,3157,O
expressing,3157,O
the,3157,O
rat,3157,B-GENE-Y
NR1a,3157,I-GENE-Y
subunit,3157,O
",",3157,O
and,3157,O
either,3157,O
the,3157,O
NR2A,3157,B-GENE-Y
",",3157,O
NR2B,3157,B-GENE-Y
or,3157,O
NR2C,3157,B-GENE-Y
subunits,3157,O
;,3157,O
the,3157,O
IC50,3157,O
values,3157,O
for,3157,O
block,3157,O
were,3157,O
2.6,3157,O
",",3157,O
0.52,3157,O
and,3157,O
2.4,3157,O
mM,3157,O
",",3157,O
respectively,3157,O
(,3157,O
holding,3157,O
potential,3157,O
",",3157,O
-,3157,O
60,3157,O
mV,3157,O
),3157,O
.,3157,O
The,3158,O
Hill,3158,O
coefficient,3158,O
values,3158,O
were,3158,O
<,3158,O
1,3158,O
and,3158,O
",",3158,O
in,3158,O
kinetic,3158,O
analyses,3158,O
",",3158,O
onset,3158,O
and,3158,O
recovery,3158,O
from,3158,O
block,3158,O
were,3158,O
well,3158,O
fit,3158,O
by,3158,O
double,3158,O
exponential,3158,O
functions,3158,O
",",3158,O
indicating,3158,O
binding,3158,O
to,3158,O
more,3158,O
than,3158,O
one,3158,O
blocking,3158,O
site,3158,O
on,3158,O
the,3158,O
NMDA,3158,B-GENE-N
receptor,3158,I-GENE-N
channel,3158,O
complex,3158,O
.,3158,O
The,3159,O
higher,3159,O
affinity,3159,O
of,3159,O
felbamate,3159,B-CHEMICAL
block,3159,O
of,3159,O
NMDA,3159,B-GENE-N
receptors,3159,I-GENE-N
containing,3159,O
the,3159,O
NR2B,3159,B-GENE-Y
subunit,3159,O
could,3159,O
be,3159,O
accounted,3159,O
for,3159,O
by,3159,O
more,3159,O
rapid,3159,O
association,3159,O
and,3159,O
slower,3159,O
dissociation,3159,O
from,3159,O
these,3159,O
sites,3159,O
.,3159,O
We,3160,O
conclude,3160,O
that,3160,O
felbamate,3160,B-CHEMICAL
exhibits,3160,O
modest,3160,O
selectivity,3160,O
for,3160,O
NMDA,3160,B-GENE-N
receptors,3160,I-GENE-N
composed,3160,O
of,3160,O
NR1a/NR2B,3160,B-GENE-Y
subunits,3160,O
.,3160,O
This,3161,O
selectivity,3161,O
could,3161,O
",",3161,O
in,3161,O
part,3161,O
",",3161,O
account,3161,O
for,3161,O
the,3161,O
more,3161,O
favorable,3161,O
clinical,3161,O
profile,3161,O
of,3161,O
felbamate,3161,B-CHEMICAL
in,3161,O
comparison,3161,O
with,3161,O
NMDA,3161,B-GENE-N
receptor,3161,I-GENE-N
antagonists,3161,O
that,3161,O
do,3161,O
not,3161,O
show,3161,O
subunit,3161,O
selectivity,3161,O
.,3161,O
Adrenocortical,3162,O
reserves,3162,O
in,3162,O
hyperthyroidism,3162,O
.,3162,O
Explicit,3163,O
data,3163,O
regarding,3163,O
the,3163,O
changes,3163,O
in,3163,O
adrenocortical,3163,O
reserves,3163,O
during,3163,O
hyperthyroidism,3163,O
do,3163,O
not,3163,O
exist,3163,O
.,3163,O
We,3164,O
aimed,3164,O
to,3164,O
document,3164,O
the,3164,O
capability,3164,O
(,3164,O
response,3164,O
),3164,O
of,3164,O
adrenal,3164,O
gland,3164,O
to,3164,O
secrete,3164,O
cortisol,3164,B-CHEMICAL
and,3164,O
DHEA-S,3164,B-CHEMICAL
during,3164,O
hyperthyroidism,3164,O
compared,3164,O
to,3164,O
euthyroidism,3164,O
",",3164,O
and,3164,O
to,3164,O
describe,3164,O
factors,3164,O
associated,3164,O
with,3164,O
these,3164,O
responses,3164,O
.,3164,O
A,3165,O
standard-dose,3165,O
(,3165,O
0.25,3165,O
mg/i.v,3165,O
.,3165,O
),3165,O
ACTH,3166,B-GENE-Y
stimulation,3166,O
test,3166,O
was,3166,O
performed,3166,O
to,3166,O
the,3166,O
same,3166,O
patients,3166,O
before,3166,O
hyperthyroidism,3166,O
treatment,3166,O
",",3166,O
and,3166,O
after,3166,O
attainment,3166,O
of,3166,O
euthyroidism,3166,O
.,3166,O
Baseline,3167,O
cortisol,3167,B-CHEMICAL
(,3167,O
Cor0,3167,O
),3167,O
",",3167,O
DHEA-S,3167,B-CHEMICAL
(,3167,O
DHEA-S0,3167,B-CHEMICAL
),3167,O
",",3167,O
cortisol,3167,B-GENE-Y
binding,3167,I-GENE-Y
globulin,3167,I-GENE-Y
(,3167,O
CBG,3167,B-GENE-Y
),3167,O
",",3167,O
ACTH,3167,B-GENE-Y
",",3167,O
calculated,3167,O
free,3167,O
cortisol,3167,B-CHEMICAL
(,3167,O
by,3167,O
Coolen,3167,O
's,3167,O
equation,3167,O
=,3167,O
CFC,3167,O
),3167,O
",",3167,O
free,3167,O
cortisol,3167,B-CHEMICAL
index,3167,O
(,3167,O
FCI,3167,O
),3167,O
",",3167,O
60-min,3167,O
cortisol,3167,B-CHEMICAL
(,3167,O
Cor60,3167,O
),3167,O
",",3167,O
and,3167,O
DHEA-S,3167,B-CHEMICAL
(,3167,O
DHEA-S60,3167,B-CHEMICAL
),3167,O
",",3167,O
delta,3167,B-CHEMICAL
cortisol,3167,I-CHEMICAL
(,3167,O
ΔCor,3167,B-CHEMICAL
),3167,O
",",3167,O
delta,3167,B-CHEMICAL
DHEA-S,3167,O
(,3167,O
ΔDHEA-S,3167,B-CHEMICAL
),3167,O
responses,3167,O
were,3167,O
evaluated,3167,O
.,3167,O
Forty-one,3168,O
patients,3168,O
[,3168,O
22,3168,O
females,3168,O
",",3168,O
49.5,3168,O
±,3168,O
15.2,3168,O
years,3168,O
old,3168,O
",",3168,O
32,3168,O
Graves,3168,O
disease,3168,O
",",3168,O
nine,3168,O
toxic,3168,O
nodular,3168,O
goiter,3168,O
],3168,O
had,3168,O
similar,3168,O
Cor0,3168,O
",",3168,O
DHEA-S0,3168,B-CHEMICAL
",",3168,O
CFC,3168,O
",",3168,O
FCI,3168,O
",",3168,O
and,3168,O
DHEA-S60,3168,B-CHEMICAL
in,3168,O
hyperthyroid,3168,O
and,3168,O
euthyroid,3168,O
states,3168,O
.,3168,O
Cor60,3169,O
",",3169,O
ΔCor,3169,B-CHEMICAL
",",3169,O
and,3169,O
ΔDHEA-S,3169,B-CHEMICAL
were,3169,O
lower,3169,O
in,3169,O
hyperthyroidism,3169,O
.,3169,O
In,3170,O
four,3170,O
(,3170,O
10,3170,O
%,3170,O
),3170,O
patients,3170,O
the,3170,O
peak,3170,O
ACTH-stimulated,3170,B-GENE-Y
cortisol,3170,B-CHEMICAL
values,3170,O
were,3170,O
lower,3170,O
than,3170,O
18,3170,O
μg/dL,3170,O
.,3170,O
When,3171,O
the,3171,O
test,3171,O
repeated,3171,O
after,3171,O
attainment,3171,O
of,3171,O
euthyroidism,3171,O
",",3171,O
all,3171,O
of,3171,O
the,3171,O
patients,3171,O
had,3171,O
normal,3171,O
cortisol,3171,B-CHEMICAL
response,3171,O
.,3171,O
Regression,3172,O
analysis,3172,O
demonstrated,3172,O
an,3172,O
independent,3172,O
association,3172,O
of,3172,O
Cor60,3172,O
with,3172,O
free,3172,O
T3,3172,O
in,3172,O
hyperthyroidism,3172,O
.,3172,O
However,3173,O
",",3173,O
the,3173,O
predictors,3173,O
of,3173,O
CFC,3173,O
",",3173,O
FCI,3173,O
",",3173,O
and,3173,O
DHEA-S,3173,B-CHEMICAL
levels,3173,O
were,3173,O
serum,3173,O
creatinine,3173,B-CHEMICAL
levels,3173,O
in,3173,O
hyperthyroidism,3173,O
",",3173,O
and,3173,O
both,3173,O
creatinine,3173,B-CHEMICAL
and,3173,O
transaminase,3173,B-GENE-N
levels,3173,O
in,3173,O
euthyroidism,3173,O
.,3173,O
ACTH-stimulated,3174,B-GENE-Y
peak,3174,O
cortisol,3174,B-CHEMICAL
",",3174,O
delta,3174,B-CHEMICAL
cortisol,3174,I-CHEMICAL
",",3174,O
and,3174,O
delta,3174,B-CHEMICAL
DHEA-S,3174,O
levels,3174,O
are,3174,O
decreased,3174,O
during,3174,O
hyperthyroidism,3174,O
",",3174,O
probably,3174,O
due,3174,O
to,3174,O
increased,3174,O
turnover,3174,O
.,3174,O
Since,3175,O
about,3175,O
10,3175,O
%,3175,O
of,3175,O
the,3175,O
subjects,3175,O
with,3175,O
hyperthyroidism,3175,O
are,3175,O
at,3175,O
risk,3175,O
for,3175,O
adrenal,3175,O
insufficiency,3175,O
",",3175,O
clinicians,3175,O
dealing,3175,O
with,3175,O
Graves,3175,O
',3175,O
disease,3175,O
should,3175,O
be,3175,O
alert,3175,O
to,3175,O
the,3175,O
possibility,3175,O
of,3175,O
adrenal,3175,O
insufficiency,3175,O
during,3175,O
hyperthyroid,3175,O
stage,3175,O
.,3175,O
Mechanisms,3176,O
of,3176,O
agonist-induced,3176,O
down-regulation,3176,O
of,3176,O
the,3176,O
human,3176,B-GENE-Y
kappa-opioid,3176,I-GENE-Y
receptor,3176,I-GENE-Y
:,3176,O
internalization,3176,O
is,3176,O
required,3176,O
for,3176,O
down-regulation,3176,O
.,3176,O
Previously,3177,O
",",3177,O
we,3177,O
showed,3177,O
that,3177,O
the,3177,O
human,3177,B-GENE-Y
kappa-opioid,3177,I-GENE-Y
receptor,3177,I-GENE-Y
(,3177,O
hkor,3177,B-GENE-Y
),3177,O
stably,3177,O
expressed,3177,O
in,3177,O
Chinese,3177,O
hamster,3177,O
ovary,3177,O
(,3177,O
CHO,3177,O
),3177,O
cells,3177,O
underwent,3177,O
down-regulation,3177,O
after,3177,O
prolonged,3177,O
"U50,488H",3177,B-CHEMICAL
treatment,3177,O
.,3177,O
In,3178,O
the,3178,O
present,3178,O
study,3178,O
",",3178,O
we,3178,O
determined,3178,O
the,3178,O
mechanisms,3178,O
underlying,3178,O
this,3178,O
process,3178,O
.,3178,O
U50,3179,B-CHEMICAL
",",3179,I-CHEMICAL
488H,3179,I-CHEMICAL
caused,3179,O
a,3179,O
significant,3179,O
down-regulation,3179,O
of,3179,O
the,3179,O
hkor,3179,B-GENE-Y
",",3179,O
although,3179,O
etorphine,3179,B-CHEMICAL
did,3179,O
not,3179,O
.,3179,O
Neither,3180,O
"U50,488H",3180,B-CHEMICAL
nor,3180,O
etorphine,3180,B-CHEMICAL
caused,3180,O
down-regulation,3180,O
of,3180,O
the,3180,O
rat,3180,B-GENE-Y
kappa-opioid,3180,I-GENE-Y
receptor,3180,I-GENE-Y
.,3180,O
Thus,3181,O
",",3181,O
similar,3181,O
to,3181,O
internalization,3181,O
",",3181,O
there,3181,O
are,3181,O
agonist,3181,O
and,3181,O
species,3181,O
differences,3181,O
in,3181,O
down-regulation,3181,O
of,3181,O
kappa-opioid,3181,B-GENE-Y
receptors,3181,I-GENE-Y
.,3181,O
Expression,3182,O
of,3182,O
the,3182,O
dominant,3182,O
negative,3182,O
mutants,3182,O
arrestin-2,3182,B-GENE-Y
(,3182,O
319-418,3182,O
),3182,O
or,3182,O
dynamin,3182,B-GENE-Y
I-K44A,3182,O
significantly,3182,O
reduced,3182,O
"U50,488H-induced",3182,B-CHEMICAL
down-regulation,3182,O
of,3182,O
the,3182,O
hkor,3182,B-GENE-Y
.,3182,O
Coexpression,3183,O
of,3183,O
GRK2,3183,B-GENE-Y
or,3183,O
GRK2,3183,B-GENE-Y
and,3183,O
arrestin-2,3183,B-GENE-Y
permitted,3183,O
etorphine,3183,B-CHEMICAL
to,3183,O
induce,3183,O
down-regulation,3183,O
of,3183,O
the,3183,O
hkor,3183,B-GENE-Y
",",3183,O
although,3183,O
expression,3183,O
of,3183,O
arrestin-2,3183,B-GENE-Y
or,3183,O
dynamin,3183,B-GENE-Y
I,3183,I-GENE-Y
alone,3183,O
did,3183,O
not,3183,O
.,3183,O
Expression,3184,O
of,3184,O
the,3184,O
dominant,3184,O
negative,3184,O
mutants,3184,O
rab5A-N133I,3184,B-GENE-Y
or,3184,O
rab7-N125I,3184,B-GENE-N
blunted,3184,O
"U50,488H-induced",3184,B-CHEMICAL
down-regulation,3184,O
.,3184,O
Pretreatment,3185,O
with,3185,O
lysosomal,3185,O
enzyme,3185,O
inhibitors,3185,O
[,3185,B-CHEMICAL
(,3185,I-CHEMICAL
2S,3185,I-CHEMICAL
",",3185,I-CHEMICAL
3S,3185,I-CHEMICAL
),3185,I-CHEMICAL
trans-epoxysuccinyl-L-leucylamido-3-methylbutane,3185,I-CHEMICAL
ethyl,3185,I-CHEMICAL
ester,3185,I-CHEMICAL
or,3185,I-CHEMICAL
chloroquine,3185,I-CHEMICAL
],3185,I-CHEMICAL
or,3185,O
proteasome,3185,B-GENE-N
inhibitors,3185,O
(,3185,O
proteasome,3185,B-GENE-N
inhibitor,3185,O
I,3185,O
",",3185,O
MG-132,3185,B-CHEMICAL
",",3185,O
or,3185,O
lactacystin,3185,B-CHEMICAL
),3185,O
decreased,3185,O
the,3185,O
extent,3185,O
of,3185,O
"U50,488H-induced",3185,B-CHEMICAL
down-regulation,3185,O
.,3185,O
A,3186,O
combination,3186,O
of,3186,O
chloroquine,3186,B-CHEMICAL
and,3186,O
proteasome,3186,B-GENE-N
inhibitor,3186,O
I,3186,O
abolished,3186,O
"U50,488H-induced",3186,B-CHEMICAL
down-regulation,3186,O
.,3186,O
These,3187,O
results,3187,O
indicate,3187,O
that,3187,O
"U50,488H-induced",3187,B-CHEMICAL
down-regulation,3187,O
of,3187,O
the,3187,O
hkor,3187,B-GENE-Y
involves,3187,O
GRK-,3187,B-GENE-N
",",3187,O
arrestin-2-,3187,B-GENE-Y
",",3187,O
dynamin-,3187,B-GENE-N
",",3187,O
rab5-,3187,B-GENE-N
",",3187,O
and,3187,O
rab7-dependent,3187,B-GENE-N
mechanisms,3187,O
and,3187,O
receptors,3187,O
seem,3187,O
to,3187,O
be,3187,O
trafficked,3187,O
to,3187,O
lysosomes,3187,O
and,3187,O
proteasomes,3187,B-GENE-N
for,3187,O
degradation,3187,O
.,3187,O
Thus,3188,O
",",3188,O
"U50,488H-induced",3188,B-CHEMICAL
internalization,3188,O
and,3188,O
down-regulation,3188,O
of,3188,O
the,3188,O
hkor,3188,B-GENE-Y
share,3188,O
initial,3188,O
common,3188,O
mechanisms,3188,O
.,3188,O
To,3189,O
the,3189,O
best,3189,O
of,3189,O
our,3189,O
knowledge,3189,O
",",3189,O
these,3189,O
results,3189,O
represent,3189,O
the,3189,O
first,3189,O
report,3189,O
on,3189,O
the,3189,O
involvement,3189,O
of,3189,O
both,3189,O
rab5,3189,B-GENE-N
and,3189,O
rab7,3189,B-GENE-N
in,3189,O
agonist-induced,3189,O
down-regulation,3189,O
of,3189,O
a,3189,O
G,3189,B-GENE-N
protein-coupled,3189,I-GENE-N
receptor,3189,I-GENE-N
.,3189,O
In,3190,O
addition,3190,O
",",3190,O
this,3190,O
study,3190,O
is,3190,O
among,3190,O
the,3190,O
first,3190,O
to,3190,O
show,3190,O
the,3190,O
involvement,3190,O
of,3190,O
proteasomes,3190,B-GENE-N
in,3190,O
agonist-induced,3190,O
down-regulation,3190,O
of,3190,O
a,3190,O
G,3190,B-GENE-N
protein-coupled,3190,I-GENE-N
receptor,3190,I-GENE-N
.,3190,O
Dose-dependent,3191,O
release,3191,O
of,3191,O
endogenous,3191,O
tissue,3191,B-GENE-Y
factor,3191,I-GENE-Y
pathway,3191,O
inhibitor,3191,O
by,3191,O
different,3191,O
low,3191,O
molecular,3191,O
weight,3191,O
heparins,3191,O
.,3191,O
Tissue,3192,B-GENE-Y
factor,3192,I-GENE-Y
pathway,3192,O
inhibitor,3192,O
(,3192,O
TFPI,3192,O
),3192,O
is,3192,O
released,3192,O
to,3192,O
circulating,3192,O
blood,3192,O
after,3192,O
intravenous,3192,O
and,3192,O
subcutaneous,3192,O
injections,3192,O
of,3192,O
heparins,3192,O
",",3192,O
and,3192,O
may,3192,O
thus,3192,O
contribute,3192,O
to,3192,O
the,3192,O
antithrombotic,3192,O
effect,3192,O
of,3192,O
heparins,3192,O
.,3192,O
A,3193,O
previous,3193,O
study,3193,O
suggested,3193,O
different,3193,O
abilities,3193,O
of,3193,O
various,3193,O
low,3193,O
molecular,3193,O
weight,3193,O
heparins,3193,O
(,3193,O
LMWH,3193,O
),3193,O
to,3193,O
release,3193,O
endogenous,3193,O
TFPI,3193,O
",",3193,O
but,3193,O
the,3193,O
dose-response,3193,O
relationship,3193,O
was,3193,O
not,3193,O
determined,3193,O
.,3193,O
In,3194,O
the,3194,O
present,3194,O
study,3194,O
",",3194,O
the,3194,O
dose-response,3194,O
relationship,3194,O
for,3194,O
escalating,3194,O
doses,3194,O
of,3194,O
two,3194,O
LMWHs,3194,O
",",3194,O
dalteparin,3194,O
and,3194,O
enoxaparin,3194,O
",",3194,O
on,3194,O
the,3194,O
release,3194,O
of,3194,O
endogenous,3194,O
TFPI,3194,O
was,3194,O
investigated,3194,O
.,3194,O
Six,3195,O
healthy,3195,O
male,3195,O
participants,3195,O
were,3195,O
given,3195,O
50,3195,O
",",3195,O
100,3195,O
and,3195,O
200,3195,O
U/kg,3195,O
dalteparin,3195,O
and,3195,O
0.5,3195,O
",",3195,O
1.0,3195,O
and,3195,O
2.0,3195,O
mg/kg,3195,O
enoxaparin,3195,O
as,3195,O
a,3195,O
single,3195,O
subcutaneous,3195,O
injection,3195,O
.,3195,O
The,3196,O
study,3196,O
was,3196,O
a,3196,O
randomized,3196,O
",",3196,O
cross-over,3196,O
design,3196,O
with,3196,O
a,3196,O
1-week,3196,O
wash-out,3196,O
period,3196,O
between,3196,O
each,3196,O
injection,3196,O
.,3196,O
Peak,3197,O
free,3197,O
TFPI,3197,O
antigen,3197,O
and,3197,O
TFPI,3197,O
activity,3197,O
were,3197,O
detected,3197,O
after,3197,O
only,3197,O
1,3197,O
h,3197,O
",",3197,O
whereas,3197,O
anti-activated,3197,O
factor,3197,B-GENE-Y
X,3197,I-GENE-Y
(,3197,O
anti-FXa,3197,O
),3197,O
and,3197,O
anti-activated,3197,O
factor,3197,B-GENE-N
II,3197,I-GENE-N
(,3197,O
anti-FIIa,3197,O
),3197,O
activities,3197,O
were,3197,O
detected,3197,O
after,3197,O
2-6,3197,O
h.,3197,O
Putative,3197,O
therapeutic,3197,O
equivalent,3197,O
doses,3197,O
of,3197,O
dalteparin,3197,O
and,3197,O
enoxaparin,3197,O
gave,3197,O
similar,3197,O
release,3197,O
of,3197,O
endogenous,3197,O
TFPI,3197,O
",",3197,O
but,3197,O
dissimilar,3197,O
effects,3197,O
on,3197,O
anti-FXa,3197,O
and,3197,O
anti-FIIa,3197,O
activities,3197,O
.,3197,O
Life-threatening,3198,O
hypoglycemia,3198,O
associated,3198,O
with,3198,O
intentional,3198,O
insulin,3198,B-GENE-Y
ingestion,3198,O
.,3198,O
There,3199,O
are,3199,O
reports,3199,O
of,3199,O
insulin,3199,B-GENE-Y
overdose,3199,O
by,3199,O
injection,3199,O
",",3199,O
yet,3199,O
little,3199,O
is,3199,O
known,3199,O
regarding,3199,O
the,3199,O
potential,3199,O
harms,3199,O
of,3199,O
intentional,3199,O
oral,3199,O
ingestion,3199,O
of,3199,O
insulin,3199,B-GENE-Y
.,3199,O
In,3200,O
this,3200,O
report,3200,O
",",3200,O
we,3200,O
describe,3200,O
a,3200,O
case,3200,O
of,3200,O
massive,3200,O
insulin,3200,B-GENE-Y
ingestion,3200,O
and,3200,O
ensuing,3200,O
hypoglycemia,3200,O
.,3200,O
To,3201,O
our,3201,O
knowledge,3201,O
",",3201,O
there,3201,O
are,3201,O
no,3201,O
previously,3201,O
published,3201,O
cases,3201,O
of,3201,O
hypoglycemia,3201,O
caused,3201,O
by,3201,O
intentional,3201,O
insulin,3201,B-GENE-Y
ingestion,3201,O
.,3201,O
A,3202,O
51-year-old,3202,O
man,3202,O
intentionally,3202,O
ingested,3202,O
three,3202,O
10-ml,3202,O
vials,3202,O
(,3202,O
total,3202,O
of,3202,O
3000,3202,O
units,3202,O
),3202,O
of,3202,O
various,3202,O
insulins,3202,B-GENE-Y
:,3202,O
one,3202,O
vial,3202,O
each,3202,O
of,3202,O
insulin,3202,B-GENE-Y
aspart,3202,O
",",3202,O
lispro,3202,O
",",3202,O
and,3202,O
glargine,3202,O
.,3202,O
Four,3203,O
symptomatic,3203,O
hypoglycemic,3203,O
episodes,3203,O
",",3203,O
with,3203,O
blood,3203,O
glucose,3203,B-CHEMICAL
levels,3203,O
of,3203,O
48,3203,O
",",3203,O
25,3203,O
",",3203,O
34,3203,O
",",3203,O
and,3203,O
40,3203,O
mg/dl,3203,O
",",3203,O
occurred,3203,O
approximately,3203,O
1,3203,O
",",3203,O
3,3203,O
",",3203,O
4,3203,O
",",3203,O
and,3203,O
5,3203,O
hours,3203,O
",",3203,O
respectively,3203,O
",",3203,O
after,3203,O
ingestion,3203,O
.,3203,O
The,3204,O
hypoglycemia,3204,O
could,3204,O
not,3204,O
be,3204,O
explained,3204,O
other,3204,O
than,3204,O
the,3204,O
ingestion,3204,O
of,3204,O
the,3204,O
insulins,3204,B-GENE-Y
.,3204,O
The,3205,O
patient,3205,O
was,3205,O
admitted,3205,O
for,3205,O
observation,3205,O
",",3205,O
and,3205,O
euglycemia,3205,O
occurred,3205,O
within,3205,O
24,3205,O
hours,3205,O
without,3205,O
any,3205,O
additional,3205,O
hypoglycemic,3205,O
episodes,3205,O
.,3205,O
Hypoglycemia,3206,O
treatment,3206,O
is,3206,O
reviewed,3206,O
in,3206,O
this,3206,O
case,3206,O
report,3206,O
",",3206,O
and,3206,O
factors,3206,O
that,3206,O
may,3206,O
affect,3206,O
systemic,3206,O
response,3206,O
of,3206,O
orally,3206,O
ingested,3206,O
insulin,3206,B-GENE-Y
",",3206,O
including,3206,O
gastrointestinal,3206,O
absorption,3206,O
and,3206,O
insulin,3206,B-GENE-Y
sensitivity,3206,O
",",3206,O
are,3206,O
discussed,3206,O
.,3206,O
In,3207,O
addition,3207,O
",",3207,O
the,3207,O
findings,3207,O
of,3207,O
our,3207,O
case,3207,O
report,3207,O
may,3207,O
provide,3207,O
useful,3207,O
insight,3207,O
into,3207,O
the,3207,O
development,3207,O
of,3207,O
novel,3207,O
oral,3207,O
insulin,3207,B-GENE-Y
products,3207,O
that,3207,O
are,3207,O
currently,3207,O
in,3207,O
research,3207,O
.,3207,O
Despite,3208,O
poor,3208,O
bioavailability,3208,O
(,3208,O
1,3208,O
%,3208,O
),3208,O
when,3208,O
taken,3208,O
orally,3208,O
",",3208,O
insulin,3208,B-GENE-Y
may,3208,O
produce,3208,O
symptomatic,3208,O
hypoglycemia,3208,O
with,3208,O
a,3208,O
massive,3208,O
ingestion,3208,O
.,3208,O
Vigilant,3209,O
blood,3209,O
glucose,3209,B-CHEMICAL
monitoring,3209,O
",",3209,O
supportive,3209,O
care,3209,O
with,3209,O
glucose,3209,B-CHEMICAL
replacement,3209,O
therapy,3209,O
",",3209,O
and,3209,O
admission,3209,O
to,3209,O
the,3209,O
hospital,3209,O
for,3209,O
observation,3209,O
may,3209,O
be,3209,O
required,3209,O
.,3209,O
Effect,3210,O
of,3210,O
water,3210,O
extracts,3210,O
from,3210,O
edible,3210,O
myrtaceae,3210,O
plants,3210,O
on,3210,O
uptake,3210,O
of,3210,O
2-,3210,B-CHEMICAL
(,3210,I-CHEMICAL
n-,3210,I-CHEMICAL
(,3210,I-CHEMICAL
"7-nitrobenz-2-oxa-1,3-diazol-4-yl",3210,I-CHEMICAL
),3210,I-CHEMICAL
amino,3210,I-CHEMICAL
),3210,I-CHEMICAL
-2-deoxyglucose,3210,I-CHEMICAL
in,3210,O
TNF-α-treated,3210,B-GENE-Y
FL83B,3210,O
mouse,3210,O
hepatocytes,3210,O
.,3210,O
This,3211,O
study,3211,O
investigated,3211,O
the,3211,O
glucose,3211,B-CHEMICAL
uptake,3211,O
activity,3211,O
of,3211,O
the,3211,O
water,3211,O
extracts,3211,O
from,3211,O
the,3211,O
leaves,3211,O
and,3211,O
fruit,3211,O
of,3211,O
edible,3211,O
Myrtaceae,3211,O
plants,3211,O
",",3211,O
including,3211,O
guava,3211,O
(,3211,O
Psidium,3211,O
guajava,3211,O
Linn,3211,O
.,3211,O
),3212,O
",",3212,O
wax,3212,O
apples,3212,O
[,3212,O
Syzygium,3212,O
samarangense,3212,O
(,3212,O
Blume,3212,O
),3212,O
Merr,3212,O
.,3212,O
and,3213,O
L.M,3213,O
.,3213,O
Perry,3214,O
],3214,O
",",3214,O
Pu-Tau,3214,O
[,3214,O
Syzygium,3214,O
jambo,3214,O
(,3214,O
L.,3214,O
),3214,O
Alston,3214,O
],3214,O
",",3214,O
and,3214,O
Kan-Shi,3214,O
Pu-Tau,3214,O
(,3214,O
Syzygium,3214,O
cumini,3214,O
Linn,3214,O
.,3214,O
),3214,O
in,3215,O
FL83B,3215,O
mouse,3215,O
hepatocytes,3215,O
.,3215,O
The,3216,O
fluorescent,3216,O
dye,3216,O
2-,3216,I-CHEMICAL
(,3216,I-CHEMICAL
n-,3216,I-CHEMICAL
(,3216,I-CHEMICAL
"7-nitrobenz-2-oxa-1,3-diazol-4-yl",3216,I-CHEMICAL
),3216,I-CHEMICAL
amino,3216,I-CHEMICAL
),3216,I-CHEMICAL
-2-deoxyglucose,3216,O
was,3216,O
used,3216,O
to,3216,O
estimate,3216,O
the,3216,O
uptake,3216,O
ability,3216,O
of,3216,O
the,3216,O
cells,3216,O
.,3216,O
Glucose,3217,O
uptake,3217,O
test,3217,O
showed,3217,O
that,3217,O
pink,3217,O
wax,3217,O
apple,3217,O
fruit,3217,O
extract,3217,O
(,3217,O
PWFE,3217,O
),3217,O
exhibits,3217,O
the,3217,O
highest,3217,O
glucose,3217,O
uptake,3217,O
activity,3217,O
",",3217,O
at,3217,O
an,3217,O
increment,3217,O
of,3217,O
21,3217,O
%,3217,O
in,3217,O
the,3217,O
insulin-resistant,3217,O
FL83B,3217,O
mouse,3217,O
hepatocytes,3217,O
as,3217,O
compared,3217,O
with,3217,O
the,3217,O
TNF-α-treated,3217,O
control,3217,O
group,3217,O
.,3217,O
Vescalagin,3218,O
was,3218,O
isolated,3218,O
using,3218,O
column,3218,O
chromatography,3218,O
of,3218,O
PWFE,3218,O
.,3218,O
This,3219,O
compound,3219,O
",",3219,O
at,3219,O
the,3219,O
concentration,3219,O
of,3219,O
6.25,3219,O
µg/mL,3219,O
",",3219,O
exhibits,3219,O
the,3219,O
same,3219,O
glucose,3219,O
uptake,3219,O
improvement,3219,O
in,3219,O
insulin-resistant,3219,O
cells,3219,O
as,3219,O
PWFE,3219,O
at,3219,O
a,3219,O
100-µg/mL,3219,O
dose,3219,O
.,3219,O
We,3220,O
postulate,3220,O
that,3220,O
vescalagin,3220,O
is,3220,O
an,3220,O
active,3220,O
component,3220,O
in,3220,O
PWFE,3220,O
that,3220,O
may,3220,O
alleviate,3220,O
the,3220,O
insulin,3220,O
resistance,3220,O
in,3220,O
mouse,3220,O
hepatocytes,3220,O
.,3220,O
FXR-dependent,3221,B-GENE-Y
and,3221,O
-independent,3221,O
interaction,3221,O
of,3221,O
glucocorticoids,3221,O
with,3221,O
the,3221,O
regulatory,3221,O
pathways,3221,O
involved,3221,O
in,3221,O
the,3221,O
control,3221,O
of,3221,O
bile,3221,B-CHEMICAL
acid,3221,I-CHEMICAL
handling,3221,O
by,3221,O
the,3221,O
liver,3221,O
.,3221,O
Treatment,3222,O
with,3222,O
glucocorticoids,3222,O
(,3222,O
GCs,3222,O
),3222,O
may,3222,O
cause,3222,O
adverse,3222,O
effects,3222,O
",",3222,O
including,3222,O
cholestasis,3222,O
.,3222,O
The,3223,O
ability,3223,O
of,3223,O
dexamethasone,3223,B-CHEMICAL
",",3223,O
prednisolone,3223,B-CHEMICAL
and,3223,O
budesonide,3223,B-CHEMICAL
to,3223,O
affect,3223,O
the,3223,O
liver,3223,O
handling,3223,O
of,3223,O
bile,3223,B-CHEMICAL
acids,3223,I-CHEMICAL
(,3223,O
BAs,3223,O
),3223,O
has,3223,O
been,3223,O
investigated,3223,O
.,3223,O
In,3224,O
rats,3224,O
treated,3224,O
with,3224,O
GCs,3224,O
for,3224,O
4,3224,O
days,3224,O
",",3224,O
altered,3224,O
serum,3224,O
and,3224,O
bile,3224,O
BA,3224,O
levels,3224,O
",",3224,O
changed,3224,O
conjugation,3224,O
pattern,3224,O
",",3224,O
and,3224,O
delayed,3224,O
and,3224,O
decreased,3224,O
ability,3224,O
to,3224,O
conjugate/secrete,3224,O
exogenously,3224,O
administered,3224,O
deoxycholate,3224,B-CHEMICAL
",",3224,O
were,3224,O
found,3224,O
using,3224,O
HPLC-MS/MS,3224,O
.,3224,O
RT-QPCR,3225,O
analyses,3225,O
revealed,3225,O
that,3225,O
GC,3225,O
treatment,3225,O
also,3225,O
induced,3225,O
a,3225,O
down-regulation,3225,O
of,3225,O
liver,3225,B-GENE-N
nuclear,3225,I-GENE-N
receptors,3225,I-GENE-N
(,3225,O
Fxr,3225,B-GENE-Y
",",3225,O
Gr,3225,B-GENE-Y
and,3225,O
Shp,3225,B-GENE-Y
),3225,O
",",3225,O
transporters,3225,O
(,3225,O
Ntcp,3225,B-GENE-Y
",",3225,O
Mrp4,3225,B-GENE-Y
and,3225,O
Bcrp,3225,B-GENE-Y
),3225,O
and,3225,O
enzymes,3225,O
(,3225,O
Cyp7a1,3225,B-GENE-Y
and,3225,O
Baat,3225,B-GENE-Y
),3225,O
",",3225,O
whereas,3225,O
Bsep,3225,B-GENE-Y
",",3225,O
Mrp2,3225,B-GENE-Y
and,3225,O
Cyp27a1,3225,B-GENE-Y
were,3225,O
up-regulated,3225,O
.,3225,O
Human,3226,O
HepG2,3226,O
and,3226,O
Alexander,3226,O
cell,3226,O
lines,3226,O
were,3226,O
used,3226,O
as,3226,O
in,3226,O
vitro,3226,O
models,3226,O
of,3226,O
liver,3226,O
cells,3226,O
with,3226,O
and,3226,O
without,3226,O
constitutive,3226,O
FXR,3226,B-GENE-Y
expression,3226,O
",",3226,O
respectively,3226,O
.,3226,O
In,3227,O
HepG2,3227,O
cells,3227,O
",",3227,O
GCs,3227,O
induced,3227,O
a,3227,O
decreased,3227,O
expression,3227,O
of,3227,O
FXR,3227,B-GENE-Y
and,3227,O
SHP,3227,B-GENE-Y
",",3227,O
and,3227,O
inhibited,3227,O
the,3227,O
regulatory,3227,O
effect,3227,O
of,3227,O
GW4064,3227,B-CHEMICAL
on,3227,O
FXR-target,3227,B-GENE-Y
genes,3227,O
.,3227,O
In,3228,O
Alexander,3228,O
cells,3228,O
",",3228,O
only,3228,O
when,3228,O
they,3228,O
were,3228,O
transfected,3228,O
with,3228,O
FXR+RXR,3228,B-GENE-Y
",",3228,O
GW4064,3228,B-CHEMICAL
caused,3228,O
up-regulation,3228,O
of,3228,O
SHP,3228,B-GENE-Y
and,3228,O
OSTβ,3228,B-GENE-Y
",",3228,O
and,3228,O
a,3228,O
down-regulation,3228,O
of,3228,O
CYP27A1,3228,B-GENE-Y
.,3228,O
GCs,3229,O
had,3229,O
the,3229,O
opposite,3229,O
effect,3229,O
on,3229,O
these,3229,O
genes,3229,O
",",3229,O
both,3229,O
in,3229,O
the,3229,O
absence,3229,O
and,3229,O
in,3229,O
the,3229,O
presence,3229,O
of,3229,O
FXR,3229,B-GENE-Y
expression,3229,O
.,3229,O
Co-transfection,3230,O
of,3230,O
Alexander,3230,O
cells,3230,O
with,3230,O
IR-1-Luc,3230,O
and,3230,O
FXR+RXR,3230,B-GENE-Y
revealed,3230,O
that,3230,O
GCs,3230,O
did,3230,O
not,3230,O
inhibit,3230,O
but,3230,O
moderately,3230,O
enhanced,3230,O
FXR,3230,B-GENE-Y
activity,3230,O
.,3230,O
Moreover,3231,O
",",3231,O
GCs,3231,O
have,3231,O
a,3231,O
synergistic,3231,O
effect,3231,O
on,3231,O
GW4064-induced,3231,B-CHEMICAL
FXR,3231,B-GENE-Y
activation,3231,O
",",3231,O
whereas,3231,O
chenodeoxycholate,3231,B-CHEMICAL
and,3231,O
GW4064,3231,B-CHEMICAL
have,3231,O
an,3231,O
additive,3231,O
effect,3231,O
.,3231,O
In,3232,O
conclusion,3232,O
",",3232,O
GCs,3232,O
are,3232,O
able,3232,O
to,3232,O
directly,3232,O
or,3232,O
indirectly,3232,O
activate,3232,O
FXR,3232,B-GENE-Y
but,3232,O
they,3232,O
also,3232,O
antagonize,3232,O
",",3232,O
through,3232,O
FXR-independent,3232,B-GENE-Y
mechanisms,3232,O
",",3232,O
the,3232,O
expression,3232,O
of,3232,O
FXR,3232,B-GENE-Y
and,3232,O
FXR,3232,B-GENE-Y
target,3232,O
genes,3232,O
involved,3232,O
in,3232,O
the,3232,O
hepatic,3232,O
handling,3232,O
of,3232,O
BAs,3232,O
.,3232,O
Ethanol,3233,B-CHEMICAL
extract,3233,O
of,3233,O
Adiantum,3233,O
capillus-veneris,3233,O
L.,3233,O
suppresses,3233,O
the,3233,O
production,3233,O
of,3233,O
inflammatory,3233,O
mediators,3233,O
by,3233,O
inhibiting,3233,O
NF-κB,3233,B-GENE-N
activation,3233,O
.,3233,O
ETHNOPHARMACOLOGICAL,3234,O
RELEVANCE,3234,O
:,3234,O
Adiantum,3234,O
capillus-veneris,3234,O
L.,3234,O
is,3234,O
a,3234,O
wildly,3234,O
distributed,3234,O
plant,3234,O
species,3234,O
and,3234,O
has,3234,O
been,3234,O
extensively,3234,O
used,3234,O
in,3234,O
south,3234,O
of,3234,O
China,3234,O
as,3234,O
traditional,3234,O
folk,3234,O
medicine,3234,O
for,3234,O
the,3234,O
treatment,3234,O
of,3234,O
inflammatory,3234,O
diseases,3234,O
.,3234,O
AIM,3235,O
OF,3235,O
THE,3235,O
STUDY,3235,O
:,3235,O
To,3235,O
investigate,3235,O
the,3235,O
anti-inflammatory,3235,O
effect,3235,O
of,3235,O
ethanolic,3235,O
extracts,3235,O
of,3235,O
Adiantum,3235,O
capillus-veneris,3235,O
L.,3235,O
and,3235,O
the,3235,O
involvement,3235,O
of,3235,O
NF-κB,3235,B-GENE-N
signaling,3235,O
in,3235,O
the,3235,O
regulation,3235,O
of,3235,O
inflammation,3235,O
.,3235,O
MATERIALS,3236,O
AND,3236,O
METHODS,3236,O
:,3236,O
The,3236,O
plant,3236,O
ethanolic,3236,O
extracts,3236,O
were,3236,O
initially,3236,O
tested,3236,O
against,3236,O
lipopolysaccharide,3236,O
(,3236,O
LPS,3236,O
),3236,O
-induced,3236,O
prostaglandin,3236,B-CHEMICAL
E2,3236,I-CHEMICAL
(,3236,O
PGE2,3236,B-CHEMICAL
),3236,O
production,3236,O
in,3236,O
RAW264.7,3236,O
mouse,3236,O
macrophages,3236,O
",",3236,O
and,3236,O
interleukin,3236,B-GENE-Y
6,3236,I-GENE-Y
(,3236,O
IL-6,3236,B-GENE-Y
),3236,O
and,3236,O
tumor,3236,B-GENE-Y
necrosis,3236,I-GENE-Y
factor,3236,I-GENE-Y
(,3236,O
TNF,3236,B-GENE-Y
),3236,O
production,3236,O
in,3236,O
human,3236,O
U937,3236,O
monocytes,3236,O
.,3236,O
The,3237,O
effect,3237,O
of,3237,O
the,3237,O
plant,3237,O
extracts,3237,O
on,3237,O
the,3237,O
transcription,3237,O
factor,3237,O
nuclear,3237,B-GENE-N
factor,3237,I-GENE-N
kappa,3237,I-GENE-N
B,3237,I-GENE-N
(,3237,B-GENE-N
NF-κB,3237,I-GENE-N
),3237,O
pathway,3237,O
was,3237,O
evaluated,3237,O
in,3237,O
TNF-α,3237,B-GENE-Y
stimulated,3237,O
HepG2,3237,O
cells,3237,O
by,3237,O
luciferase,3237,O
gene,3237,O
reporter,3237,O
assay,3237,O
and,3237,O
Western,3237,O
blotting,3237,O
at,3237,O
the,3237,O
transcriptional,3237,O
and,3237,O
translational,3237,O
levels,3237,O
.,3237,O
Subsequently,3238,O
",",3238,O
the,3238,O
inhibition,3238,O
of,3238,O
NF-κB,3238,B-GENE-N
downstream,3238,O
gene,3238,O
expression,3238,O
(,3238,O
IL-8,3238,B-GENE-Y
and,3238,O
ICAM-1,3238,B-GENE-Y
),3238,O
by,3238,O
the,3238,O
plant,3238,O
extracts,3238,O
was,3238,O
assessed,3238,O
via,3238,O
quantitative,3238,O
real,3238,O
time,3238,O
polymerase,3238,O
chain,3238,O
reaction,3238,O
(,3238,O
qPCR,3238,O
),3238,O
.,3238,O
Lastly,3239,O
",",3239,O
the,3239,O
anti-inflammatory,3239,O
activities,3239,O
of,3239,O
the,3239,O
plant,3239,O
extracts,3239,O
in,3239,O
vivo,3239,O
were,3239,O
evaluated,3239,O
by,3239,O
testing,3239,O
spleen,3239,O
index,3239,O
and,3239,O
NF-κB,3239,B-GENE-N
related,3239,O
protein,3239,O
expression,3239,O
in,3239,O
LPS-stimulated,3239,O
CD1,3239,O
mice,3239,O
.,3239,O
RESULTS,3240,O
:,3240,O
The,3240,O
plant,3240,O
ethanolic,3240,O
extracts,3240,O
effectively,3240,O
suppressed,3240,O
PGE2,3240,B-CHEMICAL
",",3240,O
IL-6,3240,B-GENE-Y
and,3240,O
TNF,3240,B-GENE-Y
release,3240,O
with,3240,O
an,3240,O
IC50,3240,O
less,3240,O
than,3240,O
50μg/ml,3240,O
.,3240,O
Moreover,3241,O
",",3241,O
luciferase,3241,O
expression,3241,O
could,3241,O
be,3241,O
specifically,3241,O
blocked,3241,O
in,3241,O
HepG2,3241,O
cells,3241,O
",",3241,O
not,3241,O
in,3241,O
HEK293,3241,O
cells,3241,O
",",3241,O
showing,3241,O
that,3241,O
the,3241,O
plant,3241,O
extracts,3241,O
displayed,3241,O
a,3241,O
cell-specific,3241,O
pattern,3241,O
on,3241,O
NF-κB,3241,B-GENE-N
gene,3241,O
transcription,3241,O
.,3241,O
The,3242,O
assayed,3242,O
biological,3242,O
activity,3242,O
also,3242,O
depended,3242,O
on,3242,O
the,3242,O
order,3242,O
of,3242,O
adding,3242,O
TNF-α,3242,B-GENE-Y
and,3242,O
the,3242,O
plant,3242,O
extracts,3242,O
because,3242,O
the,3242,O
plant,3242,O
extracts,3242,O
could,3242,O
only,3242,O
block,3242,O
the,3242,O
NF-κB,3242,B-GENE-N
activation,3242,O
if,3242,O
added,3242,O
earlier,3242,O
but,3242,O
were,3242,O
unable,3242,O
to,3242,O
stop,3242,O
the,3242,O
signal,3242,O
when,3242,O
added,3242,O
after,3242,O
TNF-α,3242,B-GENE-Y
.,3242,O
However,3243,O
",",3243,O
the,3243,O
plant,3243,O
extracts,3243,O
did,3243,O
not,3243,O
exert,3243,O
any,3243,O
effect,3243,O
on,3243,O
ubiquitination,3243,O
which,3243,O
regulates,3243,O
several,3243,O
steps,3243,O
in,3243,O
the,3243,O
NF-κB,3243,B-GENE-N
pathway,3243,O
.,3243,O
Additionally,3244,O
",",3244,O
the,3244,O
plant,3244,O
extracts,3244,O
down-regulated,3244,O
phosphorylation,3244,O
of,3244,O
IKKα/β,3244,B-GENE-N
at,3244,O
S176/180,3244,O
",",3244,O
p38,3244,B-GENE-N
at,3244,O
T180/Y182,3244,O
and,3244,O
p65,3244,B-GENE-Y
at,3244,O
S536,3244,O
",",3244,O
but,3244,O
not,3244,O
p65,3244,B-GENE-Y
at,3244,O
S276,3244,O
.,3244,O
This,3245,O
was,3245,O
confirmed,3245,O
by,3245,O
their,3245,O
ability,3245,O
to,3245,O
selectively,3245,O
abrogate,3245,O
the,3245,O
induction,3245,O
of,3245,O
IL-8,3245,B-GENE-Y
transcription,3245,O
",",3245,O
whereas,3245,O
the,3245,O
ICAM-1,3245,B-GENE-Y
gene,3245,O
",",3245,O
which,3245,O
is,3245,O
not,3245,O
transcribed,3245,O
selectively,3245,O
by,3245,O
an,3245,O
NF-κB,3245,B-GENE-N
complex,3245,O
containing,3245,O
a,3245,O
form,3245,O
of,3245,O
p65,3245,B-GENE-Y
phosphorylated,3245,O
on,3245,O
Ser536,3245,B-CHEMICAL
",",3245,O
did,3245,O
not,3245,O
change,3245,O
.,3245,O
Finally,3246,O
",",3246,O
the,3246,O
plant,3246,O
extracts,3246,O
at,3246,O
200μg/mg,3246,O
could,3246,O
normalize,3246,O
the,3246,O
LPS-induced,3246,O
elevation,3246,O
of,3246,O
spleen,3246,O
index,3246,O
as,3246,O
well,3246,O
as,3246,O
NF-κB,3246,B-GENE-N
and,3246,O
p38,3246,B-GENE-N
activations,3246,O
in,3246,O
CD1,3246,O
mice,3246,O
.,3246,O
CONCLUSION,3247,O
:,3247,O
The,3247,O
present,3247,O
studies,3247,O
presents,3247,O
the,3247,O
potential,3247,O
utilization,3247,O
of,3247,O
this,3247,O
plant,3247,O
extracts,3247,O
",",3247,O
as,3247,O
a,3247,O
natural,3247,O
resources,3247,O
for,3247,O
the,3247,O
development,3247,O
of,3247,O
an,3247,O
anti-inflammatory,3247,O
medicine,3247,O
.,3247,O
Robust,3248,O
autoactivation,3248,O
",",3248,O
chymotrypsin,3248,B-GENE-Y
C,3248,I-GENE-Y
independence,3248,O
and,3248,O
diminished,3248,O
secretion,3248,O
define,3248,O
a,3248,O
subset,3248,O
of,3248,O
hereditary,3248,O
pancreatitis,3248,O
associated,3248,O
cationic,3248,B-GENE-Y
trypsinogen,3248,I-GENE-Y
mutants,3248,O
.,3248,O
Mutations,3249,O
in,3249,O
human,3249,B-GENE-Y
cationic,3249,I-GENE-Y
trypsinogen,3249,I-GENE-Y
cause,3249,O
hereditary,3249,O
pancreatitis,3249,O
by,3249,O
altering,3249,O
its,3249,O
proteolytic,3249,O
regulation,3249,O
of,3249,O
activation,3249,O
and,3249,O
degradation,3249,O
by,3249,O
chymotrypsin,3249,B-GENE-Y
C,3249,I-GENE-Y
(,3249,O
CTRC,3249,B-GENE-Y
),3249,O
.,3249,O
CTRC,3250,B-GENE-Y
stimulates,3250,O
trypsinogen,3250,O
autoactivation,3250,O
by,3250,O
processing,3250,O
the,3250,O
activation,3250,O
peptide,3250,O
to,3250,O
a,3250,O
shorter,3250,O
form,3250,O
but,3250,O
also,3250,O
promotes,3250,O
degradation,3250,O
by,3250,O
cleaving,3250,O
the,3250,O
calcium,3250,B-GENE-N
binding,3250,I-GENE-N
loop,3250,I-GENE-N
in,3250,O
trypsinogen,3250,O
.,3250,O
Mutations,3251,O
render,3251,O
trypsinogen,3251,O
resistant,3251,O
to,3251,O
CTRC-mediated,3251,B-GENE-Y
degradation,3251,O
and/or,3251,O
increase,3251,O
processing,3251,O
of,3251,O
the,3251,O
activation,3251,O
peptide,3251,O
by,3251,O
CTRC,3251,B-GENE-N
.,3251,O
Here,3252,O
we,3252,O
demonstrate,3252,O
that,3252,O
activation,3252,O
peptide,3252,O
mutations,3252,O
D19A,3252,B-GENE-N
",",3252,O
D22G,3252,B-GENE-N
",",3252,O
K23R,3252,B-GENE-N
and,3252,O
K23_I24insIDK,3252,B-GENE-N
robustly,3252,O
increased,3252,O
the,3252,O
rate,3252,O
of,3252,O
trypsinogen,3252,O
autoactivation,3252,O
",",3252,O
both,3252,O
in,3252,O
the,3252,O
presence,3252,O
and,3252,O
absence,3252,O
of,3252,O
CTRC,3252,B-GENE-Y
.,3252,O
Degradation,3253,O
of,3253,O
the,3253,O
mutants,3253,O
by,3253,O
CTRC,3253,B-GENE-Y
was,3253,O
unchanged,3253,O
and,3253,O
processing,3253,O
of,3253,O
the,3253,O
activation,3253,O
peptide,3253,O
was,3253,O
increased,3253,O
only,3253,O
in,3253,O
the,3253,O
D19A,3253,B-GENE-N
mutant,3253,O
by,3253,O
4-fold,3253,O
.,3253,O
Surprisingly,3254,O
",",3254,O
however,3254,O
",",3254,O
this,3254,O
increased,3254,O
processing,3254,O
had,3254,O
only,3254,O
a,3254,O
minimal,3254,O
effect,3254,O
on,3254,O
autoactivation,3254,O
.,3254,O
The,3255,O
tetra-aspartate,3255,B-GENE-N
motif,3255,I-GENE-N
in,3255,O
the,3255,O
trypsinogen,3255,O
activation,3255,O
peptide,3255,O
binds,3255,O
calcium,3255,B-CHEMICAL
(,3255,O
KD,3255,O
~1.6,3255,O
mM,3255,O
),3255,O
",",3255,O
which,3255,O
stimulates,3255,O
autoactivation,3255,O
.,3255,O
Unexpectedly,3256,O
",",3256,O
calcium,3256,B-CHEMICAL
binding,3256,O
was,3256,O
not,3256,O
compromised,3256,O
by,3256,O
any,3256,O
of,3256,O
the,3256,O
activation,3256,O
peptide,3256,O
mutations,3256,O
.,3256,O
Despite,3257,O
normal,3257,O
binding,3257,O
",",3257,O
autoactivation,3257,O
of,3257,O
mutants,3257,O
D22G,3257,B-GENE-N
and,3257,O
K23_I24insIDK,3257,B-GENE-N
was,3257,O
not,3257,O
stimulated,3257,O
by,3257,O
calcium,3257,B-CHEMICAL
.,3257,O
Finally,3258,O
",",3258,O
the,3258,O
activation,3258,O
peptide,3258,O
mutants,3258,O
exhibited,3258,O
reduced,3258,O
secretion,3258,O
from,3258,O
transfected,3258,O
cells,3258,O
",",3258,O
and,3258,O
secreted,3258,O
trypsinogen,3258,O
levels,3258,O
were,3258,O
inversely,3258,O
proportional,3258,O
with,3258,O
autoactivation,3258,O
rates,3258,O
.,3258,O
We,3259,O
conclude,3259,O
that,3259,O
D19A,3259,B-GENE-N
",",3259,O
D22G,3259,B-GENE-N
",",3259,O
K23R,3259,B-GENE-N
and,3259,O
K23_I24insIDK,3259,B-GENE-N
form,3259,O
a,3259,O
mechanistically,3259,O
distinct,3259,O
subset,3259,O
of,3259,O
hereditary,3259,O
pancreatitis,3259,O
associated,3259,O
mutations,3259,O
",",3259,O
which,3259,O
exert,3259,O
their,3259,O
effect,3259,O
primarily,3259,O
through,3259,O
direct,3259,O
stimulation,3259,O
of,3259,O
autoactivation,3259,O
",",3259,O
independently,3259,O
of,3259,O
CTRC,3259,B-GENE-Y
.,3259,O
The,3260,O
potentially,3260,O
severe,3260,O
clinical,3260,O
impact,3260,O
of,3260,O
the,3260,O
markedly,3260,O
increased,3260,O
autoactivation,3260,O
is,3260,O
offset,3260,O
by,3260,O
diminished,3260,O
secretion,3260,O
",",3260,O
resulting,3260,O
in,3260,O
a,3260,O
clinical,3260,O
phenotype,3260,O
indistinguishable,3260,O
from,3260,O
typical,3260,O
hereditary,3260,O
pancreatitis,3260,O
.,3260,O
This,3261,O
article,3261,O
is,3261,O
protected,3261,O
by,3261,O
copyright,3261,O
.,3261,O
All,3262,O
rights,3262,O
reserved,3262,O
.,3262,O
Small,3263,O
molecule,3263,O
mediated,3263,O
proliferation,3263,O
of,3263,O
primary,3263,O
retinal,3263,B-CHEMICAL
pigment,3263,O
epithelial,3263,O
cells,3263,O
.,3263,O
Retinal,3264,B-CHEMICAL
pigment,3264,O
epithelial,3264,O
(,3264,O
RPE,3264,O
),3264,O
cells,3264,O
form,3264,O
a,3264,O
monolayer,3264,O
adjacent,3264,O
to,3264,O
the,3264,O
retina,3264,O
and,3264,O
play,3264,O
a,3264,O
critical,3264,O
role,3264,O
in,3264,O
the,3264,O
visual,3264,O
light,3264,O
cycle,3264,O
.,3264,O
Degeneration,3265,O
of,3265,O
this,3265,O
layer,3265,O
results,3265,O
in,3265,O
vision,3265,O
loss,3265,O
",",3265,O
causing,3265,O
retinal,3265,O
disorders,3265,O
such,3265,O
as,3265,O
age-related,3265,O
macular,3265,O
degeneration,3265,O
.,3265,O
Cell,3266,O
transplant,3266,O
therapies,3266,O
exist,3266,O
to,3266,O
restore,3266,O
vision,3266,O
loss,3266,O
;,3266,O
however,3266,O
",",3266,O
risks,3266,O
associated,3266,O
with,3266,O
and,3266,O
an,3266,O
inadequate,3266,O
supply,3266,O
of,3266,O
donor,3266,O
cells,3266,O
have,3266,O
limited,3266,O
their,3266,O
therapeutic,3266,O
success,3266,O
.,3266,O
The,3267,O
identification,3267,O
of,3267,O
factors,3267,O
that,3267,O
proliferate,3267,O
RPE,3267,O
cells,3267,O
ex,3267,O
vivo,3267,O
could,3267,O
provide,3267,O
a,3267,O
renewable,3267,O
source,3267,O
of,3267,O
cells,3267,O
for,3267,O
the,3267,O
treatment,3267,O
of,3267,O
such,3267,O
disorders,3267,O
.,3267,O
We,3268,O
show,3268,O
that,3268,O
a,3268,O
small,3268,O
molecule,3268,O
(,3268,O
WS3,3268,O
),3268,O
can,3268,O
reversibly,3268,O
proliferate,3268,O
primary,3268,O
RPE,3268,O
cells,3268,O
isolated,3268,O
from,3268,O
fetal,3268,O
and,3268,O
adult,3268,O
human,3268,O
donors,3268,O
.,3268,O
Following,3269,O
withdrawal,3269,O
of,3269,O
WS3,3269,O
",",3269,O
RPE,3269,O
cells,3269,O
differentiate,3269,O
into,3269,O
a,3269,O
functional,3269,O
monolayer,3269,O
",",3269,O
as,3269,O
exhibited,3269,O
by,3269,O
their,3269,O
expression,3269,O
of,3269,O
mature,3269,O
RPE,3269,O
genes,3269,O
and,3269,O
phagocytosis,3269,O
of,3269,O
photoreceptor,3269,O
outer,3269,O
segments,3269,O
.,3269,O
Furthermore,3270,O
",",3270,O
chemically,3270,O
expanded,3270,O
RPE,3270,O
cells,3270,O
preserve,3270,O
vision,3270,O
when,3270,O
transplanted,3270,O
into,3270,O
dystrophic,3270,O
Royal,3270,O
College,3270,O
of,3270,O
Surgeons,3270,O
(,3270,O
RCS,3270,O
),3270,O
rats,3270,O
",",3270,O
a,3270,O
well-established,3270,O
model,3270,O
of,3270,O
retinal,3270,O
degeneration,3270,O
.,3270,O
Murine,3271,O
chromosomal,3271,O
location,3271,O
of,3271,O
the,3271,O
mu,3271,B-GENE-N
and,3271,I-GENE-N
kappa,3271,I-GENE-N
opioid,3271,I-GENE-N
receptor,3271,I-GENE-N
genes,3271,O
.,3271,O
Opioid,3272,B-GENE-N
receptors,3272,I-GENE-N
are,3272,O
the,3272,O
membrane,3272,O
proteins,3272,O
that,3272,O
mediate,3272,O
the,3272,O
pain-relieving,3272,O
effect,3272,O
of,3272,O
opioid,3272,O
drugs,3272,O
",",3272,O
such,3272,O
as,3272,O
morphine,3272,B-CHEMICAL
and,3272,O
fentanyl,3272,B-CHEMICAL
as,3272,O
well,3272,O
as,3272,O
endogenous,3272,B-GENE-N
opioid,3272,I-GENE-N
peptides,3272,I-GENE-N
enkephalins,3272,B-GENE-Y
and,3272,O
endorphins,3272,B-GENE-N
.,3272,O
Using,3273,O
cDNAs,3273,O
for,3273,O
the,3273,O
mu,3273,B-GENE-N
and,3273,I-GENE-N
the,3273,I-GENE-N
kappa,3273,I-GENE-N
opioid,3273,I-GENE-N
receptors,3273,I-GENE-N
",",3273,O
we,3273,O
mapped,3273,O
the,3273,O
chromosomal,3273,O
locations,3273,O
of,3273,O
their,3273,O
genes,3273,O
in,3273,O
mouse,3273,O
.,3273,O
Multilocus,3274,O
cross,3274,O
analysis,3274,O
located,3274,O
the,3274,O
mu,3274,B-GENE-Y
receptor,3274,I-GENE-Y
gene,3274,O
Oprm,3274,B-GENE-Y
on,3274,O
Chr,3274,O
10,3274,O
and,3274,O
the,3274,O
kappa,3274,B-GENE-Y
receptor,3274,I-GENE-Y
gene,3274,O
Oprk1,3274,B-GENE-Y
on,3274,O
Chr,3274,O
1,3274,O
.,3274,O
Both,3275,O
genes,3275,O
are,3275,O
near,3275,O
centromere,3275,O
",",3275,O
with,3275,O
no,3275,O
markers,3275,O
more,3275,O
centromeric,3275,O
.,3275,O
These,3276,O
data,3276,O
indicate,3276,O
that,3276,O
the,3276,O
two,3276,O
opioid,3276,B-GENE-N
receptors,3276,I-GENE-N
are,3276,O
different,3276,O
gene,3276,O
products,3276,O
",",3276,O
ruling,3276,O
out,3276,O
the,3276,O
possibility,3276,O
that,3276,O
they,3276,O
may,3276,O
be,3276,O
differential,3276,O
splicing,3276,O
products,3276,O
from,3276,O
the,3276,O
same,3276,O
gene,3276,O
.,3276,O
The,3277,O
exposure,3277,O
of,3277,O
highly,3277,O
toxic,3277,O
aconitine,3277,B-CHEMICAL
does,3277,O
not,3277,O
significantly,3277,O
impact,3277,O
the,3277,O
activity,3277,O
and,3277,O
expression,3277,O
of,3277,O
cytochrome,3277,B-GENE-N
P450,3277,I-GENE-N
3A,3277,I-GENE-N
in,3277,O
rats,3277,O
determined,3277,O
by,3277,O
a,3277,O
novel,3277,O
ultra,3277,O
performance,3277,O
liquid,3277,O
chromatography-tandem,3277,O
mass,3277,O
spectrometric,3277,O
method,3277,O
of,3277,O
a,3277,O
specific,3277,O
probe,3277,O
buspirone,3277,B-CHEMICAL
.,3277,O
Aconitum,3278,O
species,3278,O
are,3278,O
widely,3278,O
used,3278,O
to,3278,O
treat,3278,O
rheumatism,3278,O
",",3278,O
cardiovascular,3278,O
diseases,3278,O
",",3278,O
and,3278,O
tumors,3278,O
in,3278,O
China,3278,O
and,3278,O
other,3278,O
Asian,3278,O
countries,3278,O
.,3278,O
The,3279,O
herbs,3279,O
are,3279,O
always,3279,O
used,3279,O
with,3279,O
drugs,3279,O
such,3279,O
as,3279,O
paclitaxel,3279,B-CHEMICAL
.,3279,O
Aconitine,3280,B-CHEMICAL
(,3280,O
AC,3280,O
),3280,O
is,3280,O
one,3280,O
of,3280,O
the,3280,O
main,3280,O
bioactive/high-toxic,3280,O
alkaloids,3280,O
of,3280,O
Aconitum,3280,O
roots,3280,O
.,3280,O
AC,3281,O
is,3281,O
metabolized,3281,O
by,3281,O
cytochrome,3281,B-GENE-N
P450,3281,I-GENE-N
(,3281,I-GENE-N
CYP,3281,I-GENE-N
),3281,I-GENE-N
3A,3281,I-GENE-N
.,3281,O
However,3282,O
",",3282,O
whether,3282,O
AC,3282,O
inhibits/induces,3282,O
CYP3A,3282,B-GENE-N
",",3282,O
which,3282,O
causes,3282,O
drug-drug,3282,O
interaction,3282,O
(,3282,O
DDI,3282,O
),3282,O
is,3282,O
unclear,3282,O
.,3282,O
Our,3283,O
study,3283,O
aims,3283,O
to,3283,O
explore,3283,O
the,3283,O
potent,3283,O
effects,3283,O
of,3283,O
AC,3283,O
",",3283,O
as,3283,O
a,3283,O
marker,3283,O
component,3283,O
of,3283,O
Aconitum,3283,O
",",3283,O
on,3283,O
CYP3A,3283,B-GENE-N
using,3283,O
the,3283,O
probe,3283,O
buspirone,3283,B-CHEMICAL
in,3283,O
rats,3283,O
.,3283,O
The,3284,O
effects,3284,O
of,3284,O
oral,3284,O
AC,3284,O
on,3284,O
pharmacokinetics,3284,O
of,3284,O
buspirone,3284,B-CHEMICAL
were,3284,O
evaluated,3284,O
.,3284,O
CYP3A,3285,B-GENE-N
activity,3285,O
and,3285,O
protein,3285,O
levels,3285,O
in,3285,O
rat,3285,O
liver,3285,O
microsomes,3285,O
pretreated,3285,O
with,3285,O
oral,3285,O
AC,3285,O
were,3285,O
also,3285,O
measured,3285,O
using,3285,O
in,3285,O
vitro,3285,O
buspirone,3285,B-CHEMICAL
metabolism,3285,O
and,3285,O
Western,3285,O
blot,3285,O
.,3285,O
Buspirone,3286,B-CHEMICAL
and,3286,O
its,3286,O
major,3286,O
metabolites,3286,O
1-,3286,B-CHEMICAL
(,3286,I-CHEMICAL
2-pyrimidinyl,3286,I-CHEMICAL
),3286,I-CHEMICAL
piperazine,3286,I-CHEMICAL
and,3286,O
6'-hydroxybuspirone,3286,B-CHEMICAL
were,3286,O
determined,3286,O
using,3286,O
a,3286,O
newly,3286,O
validated,3286,O
UPLC-MS/MS,3286,O
method,3286,O
.,3286,O
Single,3287,O
dose,3287,O
and,3287,O
7-day,3287,O
AC,3287,O
administration,3287,O
at,3287,O
0.125mg/kg,3287,O
had,3287,O
no,3287,O
effect,3287,O
on,3287,O
CYP3A,3287,B-GENE-N
activity,3287,O
since,3287,O
no,3287,O
change,3287,O
in,3287,O
the,3287,O
formation,3287,O
of,3287,O
1-,3287,B-CHEMICAL
(,3287,I-CHEMICAL
2-pyrimidinyl,3287,I-CHEMICAL
),3287,I-CHEMICAL
piperazine,3287,I-CHEMICAL
and,3287,O
6'-hydroxybuspirone,3287,B-CHEMICAL
.,3287,O
CYP3A,3288,B-GENE-N
activity,3288,O
and,3288,O
protein,3288,O
levels,3288,O
in,3288,O
liver,3288,O
microsomes,3288,O
were,3288,O
also,3288,O
not,3288,O
affected,3288,O
by,3288,O
7-day,3288,O
AC,3288,O
pretreatment,3288,O
at,3288,O
0.125mg/kg,3288,O
.,3288,O
Therefore,3289,O
",",3289,O
AC,3289,O
neither,3289,O
inhibits,3289,O
nor,3289,O
induces,3289,O
CYP3A,3289,B-GENE-N
in,3289,O
rats,3289,O
",",3289,O
indicating,3289,O
AC,3289,O
does,3289,O
not,3289,O
cause,3289,O
CYP3A-related,3289,B-GENE-N
DDI,3289,O
in,3289,O
the,3289,O
liver,3289,O
.,3289,O
The,3290,O
yeast,3290,B-GENE-N
cap,3290,I-GENE-N
binding,3290,I-GENE-N
complex,3290,I-GENE-N
modulates,3290,O
transcription,3290,O
factor,3290,O
recruitment,3290,O
and,3290,O
establishes,3290,O
proper,3290,O
histone,3290,B-GENE-N
H3K36,3290,O
trimethylation,3290,O
during,3290,O
active,3290,O
transcription,3290,O
.,3290,O
Recent,3291,O
studies,3291,O
have,3291,O
revealed,3291,O
a,3291,O
close,3291,O
relationship,3291,O
between,3291,O
transcription,3291,O
",",3291,O
histone,3291,B-GENE-N
modification,3291,O
",",3291,O
and,3291,O
RNA,3291,O
processing,3291,O
.,3291,O
In,3292,O
fact,3292,O
",",3292,O
genome-wide,3292,O
analyses,3292,O
that,3292,O
correlate,3292,O
histone,3292,O
marks,3292,O
with,3292,O
RNA,3292,O
processing,3292,O
signals,3292,O
raise,3292,O
the,3292,O
possibility,3292,O
that,3292,O
specific,3292,O
RNA,3292,O
processing,3292,O
factors,3292,O
may,3292,O
modulate,3292,O
transcription,3292,O
and,3292,O
help,3292,O
to,3292,O
``,3292,O
write,3292,O
'',3292,O
chromatin,3292,O
marks,3292,O
.,3292,O
Here,3293,O
we,3293,O
show,3293,O
that,3293,O
the,3293,O
nuclear,3293,B-GENE-N
cap,3293,I-GENE-N
binding,3293,I-GENE-N
complex,3293,I-GENE-N
(,3293,O
CBC,3293,B-GENE-N
),3293,O
directs,3293,O
recruitment,3293,O
of,3293,O
transcription,3293,O
elongation,3293,O
factors,3293,O
and,3293,O
establishes,3293,O
proper,3293,O
histone,3293,B-GENE-N
marks,3293,O
during,3293,O
active,3293,O
transcription,3293,O
.,3293,O
A,3294,O
directed,3294,O
genetic,3294,O
screen,3294,O
revealed,3294,O
that,3294,O
deletion,3294,O
of,3294,O
either,3294,O
subunit,3294,O
of,3294,O
the,3294,O
CBC,3294,B-GENE-N
confers,3294,O
a,3294,O
synthetic,3294,O
growth,3294,O
defect,3294,O
when,3294,O
combined,3294,O
with,3294,O
deletion,3294,O
of,3294,O
genes,3294,O
encoding,3294,O
either,3294,O
Ctk2,3294,B-GENE-Y
or,3294,O
Bur2,3294,B-GENE-Y
",",3294,O
a,3294,O
component,3294,O
of,3294,O
the,3294,O
Saccharomyces,3294,O
cerevisiae,3294,O
ortholog,3294,O
of,3294,O
P-TEFb,3294,B-GENE-N
.,3294,O
The,3295,O
CBC,3295,B-GENE-N
physically,3295,O
associates,3295,O
with,3295,O
these,3295,O
complexes,3295,O
to,3295,O
recruit,3295,O
them,3295,O
during,3295,O
transcription,3295,O
and,3295,O
mediates,3295,O
phosphorylation,3295,O
at,3295,O
Ser-2,3295,B-CHEMICAL
of,3295,O
the,3295,O
C-terminal,3295,B-CHEMICAL
domain,3295,O
(,3295,O
CTD,3295,O
),3295,O
of,3295,O
RNA,3295,B-GENE-N
polymerase,3295,I-GENE-N
II,3295,I-GENE-N
.,3295,O
To,3296,O
understand,3296,O
how,3296,O
these,3296,O
interactions,3296,O
influence,3296,O
downstream,3296,O
events,3296,O
",",3296,O
histone,3296,B-GENE-N
H3K36me3,3296,O
was,3296,O
examined,3296,O
",",3296,O
and,3296,O
we,3296,O
demonstrate,3296,O
that,3296,O
CBCΔ,3296,B-GENE-N
affects,3296,O
proper,3296,O
Set2-dependent,3296,B-GENE-Y
H3K36me3,3296,B-GENE-N
.,3296,O
Consistent,3297,O
with,3297,O
this,3297,O
",",3297,O
the,3297,O
CBC,3297,B-GENE-N
and,3297,O
Set2,3297,B-GENE-Y
have,3297,O
similar,3297,O
effects,3297,O
on,3297,O
the,3297,O
ability,3297,O
to,3297,O
rapidly,3297,O
induce,3297,O
and,3297,O
sustain,3297,O
activated,3297,O
gene,3297,O
expression,3297,O
",",3297,O
and,3297,O
these,3297,O
effects,3297,O
are,3297,O
distinct,3297,O
from,3297,O
other,3297,O
histone,3297,B-GENE-N
methyltransferases,3297,O
.,3297,O
This,3298,O
work,3298,O
provides,3298,O
evidence,3298,O
for,3298,O
an,3298,O
emerging,3298,O
model,3298,O
that,3298,O
RNA,3298,O
processing,3298,O
factors,3298,O
can,3298,O
modulate,3298,O
the,3298,O
recruitment,3298,O
of,3298,O
transcription,3298,O
factors,3298,O
and,3298,O
influence,3298,O
histone,3298,B-GENE-N
modification,3298,O
during,3298,O
elongation,3298,O
.,3298,O
Kinetic,3299,O
and,3299,O
stereochemical,3299,O
studies,3299,O
on,3299,O
novel,3299,O
inactivators,3299,O
of,3299,O
C-terminal,3299,B-CHEMICAL
amidation,3299,O
.,3299,O
C-terminal,3300,B-CHEMICAL
amidation,3300,O
",",3300,O
a,3300,O
required,3300,O
post-translational,3300,O
modification,3300,O
for,3300,O
the,3300,O
bioactivation,3300,O
of,3300,O
many,3300,O
neuropeptides,3300,O
",",3300,O
entails,3300,O
sequential,3300,O
enzymic,3300,O
action,3300,O
by,3300,O
peptidylglycine,3300,B-GENE-Y
alpha-mono-oxygenase,3300,I-GENE-Y
(,3300,O
PAM,3300,B-GENE-Y
",",3300,O
EC,3300,B-GENE-Y
1.14.17.3,3300,I-GENE-Y
),3300,O
and,3300,O
peptidylamidoglycolate,3300,B-GENE-Y
lyase,3300,I-GENE-Y
(,3300,O
PGL,3300,B-GENE-Y
",",3300,O
EC,3300,B-GENE-Y
4.3.2.5,3300,I-GENE-Y
),3300,O
.,3300,O
Here,3301,O
we,3301,O
introduce,3301,O
novel,3301,O
compounds,3301,O
in,3301,O
which,3301,O
an,3301,O
olefinic,3301,O
functionality,3301,O
is,3301,O
incorporated,3301,O
into,3301,O
peptide,3301,O
analogues,3301,O
as,3301,O
the,3301,O
most,3301,O
potent,3301,O
turnover-dependent,3301,O
inactivators,3301,O
of,3301,O
PAM,3301,B-GENE-Y
.,3301,O
Kinetic,3302,O
parameters,3302,O
for,3302,O
PAM,3302,B-GENE-Y
inactivation,3302,O
by,3302,O
4-oxo-5-acetamido-6-phenyl-hex-2-enoic,3302,B-CHEMICAL
acid,3302,I-CHEMICAL
and,3302,I-CHEMICAL
4-oxo-5-acetamido-6-,3302,I-CHEMICAL
(,3302,I-CHEMICAL
2-thienyl,3302,I-CHEMICAL
),3302,I-CHEMICAL
-hex-2-enoic,3302,I-CHEMICAL
acid,3302,I-CHEMICAL
were,3302,O
obtained,3302,O
by,3302,O
using,3302,O
both,3302,O
the,3302,O
conventional,3302,O
dilution,3302,O
assay,3302,O
method,3302,O
and,3302,O
the,3302,O
more,3302,O
complex,3302,O
progress,3302,O
curve,3302,O
method,3302,O
.,3302,O
The,3303,O
results,3303,O
obtained,3303,O
from,3303,O
the,3303,O
progress,3303,O
curve,3303,O
method,3303,O
establish,3303,O
that,3303,O
these,3303,O
compounds,3303,O
exhibit,3303,O
the,3303,O
kinetic,3303,O
characteristics,3303,O
of,3303,O
pure,3303,O
competitive,3303,O
inactivators,3303,O
(,3303,O
i.e,3303,O
.,3303,O
no,3304,O
ESI,3304,O
complex,3304,O
forms,3304,O
during,3304,O
inactivation,3304,O
),3304,O
.,3304,O
On,3305,O
the,3305,O
basis,3305,O
of,3305,O
k,3305,O
(,3305,O
inact,3305,O
),3305,O
/K,3305,O
(,3305,O
i,3305,O
),3305,O
values,3305,O
",",3305,O
4-oxo-5-acetamido-6-,3305,B-CHEMICAL
(,3305,I-CHEMICAL
2-thienyl,3305,I-CHEMICAL
),3305,I-CHEMICAL
-hex-2-enoic,3305,I-CHEMICAL
acid,3305,I-CHEMICAL
is,3305,O
almost,3305,O
two,3305,O
orders,3305,O
of,3305,O
magnitude,3305,O
more,3305,O
potent,3305,O
than,3305,O
benzoylacrylate,3305,B-CHEMICAL
",",3305,O
a,3305,O
chemically,3305,O
analogous,3305,O
olefinic,3305,O
inactivator,3305,O
that,3305,O
lacks,3305,O
the,3305,O
peptide,3305,O
moiety,3305,O
.,3305,O
Stereochemical,3306,O
studies,3306,O
established,3306,O
that,3306,O
PAM,3306,B-GENE-Y
inactivation,3306,O
by,3306,O
4-oxo-5-acetamido-6-,3306,B-CHEMICAL
(,3306,I-CHEMICAL
2-thienyl,3306,I-CHEMICAL
),3306,I-CHEMICAL
-hex-2-enoic,3306,I-CHEMICAL
acid,3306,I-CHEMICAL
is,3306,O
stereospecific,3306,O
with,3306,O
respect,3306,O
to,3306,O
the,3306,O
moiety,3306,O
at,3306,O
the,3306,O
P,3306,O
(,3306,O
2,3306,O
),3306,O
position,3306,O
",",3306,O
which,3306,O
is,3306,O
consistent,3306,O
with,3306,O
previous,3306,O
results,3306,O
with,3306,O
substrates,3306,O
and,3306,O
reversible,3306,O
inhibitors,3306,O
.,3306,O
In,3307,O
contrast,3307,O
",",3307,O
2,3307,B-CHEMICAL
",",3307,I-CHEMICAL
4-dioxo-5-acetamido-6-phenylhexanoic,3307,I-CHEMICAL
acid,3307,I-CHEMICAL
",",3307,O
which,3307,O
is,3307,O
a,3307,O
competitive,3307,O
inhibitor,3307,O
with,3307,O
respect,3307,O
to,3307,O
ascorbate,3307,B-CHEMICAL
",",3307,O
exhibits,3307,O
a,3307,O
low,3307,O
degree,3307,O
of,3307,O
stereospecificity,3307,O
in,3307,O
binding,3307,O
to,3307,O
the,3307,O
ascorbate,3307,B-CHEMICAL
sites,3307,O
of,3307,O
both,3307,O
PAM,3307,B-GENE-Y
and,3307,O
dopamine-beta-hydroxylase,3307,B-GENE-Y
.,3307,O
Chalcogenopyrylium,3308,B-CHEMICAL
Dyes,3308,O
as,3308,O
Differential,3308,O
Modulators,3308,O
of,3308,O
Organic,3308,O
Anion,3308,O
Transport,3308,O
by,3308,O
MRP1,3308,B-GENE-Y
",",3308,O
MRP2,3308,B-GENE-Y
and,3308,O
MRP4,3308,B-GENE-Y
.,3308,O
Multidrug,3309,B-GENE-N
resistance,3309,I-GENE-N
proteins,3309,I-GENE-N
(,3309,O
MRPs,3309,B-GENE-N
),3309,O
mediate,3309,O
the,3309,O
ATP-dependent,3309,B-CHEMICAL
efflux,3309,O
of,3309,O
structurally,3309,O
diverse,3309,O
compounds,3309,O
",",3309,O
including,3309,O
anticancer,3309,O
drugs,3309,O
and,3309,O
physiological,3309,O
organic,3309,O
anions,3309,O
.,3309,O
Five,3310,O
classes,3310,O
of,3310,O
chalcogenopyrylium,3310,B-CHEMICAL
dyes,3310,O
(,3310,O
CGPs,3310,B-CHEMICAL
),3310,O
were,3310,O
examined,3310,O
for,3310,O
their,3310,O
ability,3310,O
to,3310,O
modulate,3310,O
transport,3310,O
of,3310,O
[,3310,B-CHEMICAL
(,3310,I-CHEMICAL
3,3310,I-CHEMICAL
),3310,I-CHEMICAL
H,3310,I-CHEMICAL
],3310,I-CHEMICAL
estradiol,3310,I-CHEMICAL
glucuronide,3310,I-CHEMICAL
(,3310,O
E217βG,3310,B-CHEMICAL
),3310,O
(,3310,O
a,3310,O
prototypical,3310,O
MRP,3310,B-GENE-N
substrate,3310,O
),3310,O
into,3310,O
MRP-enriched,3310,B-GENE-N
inside-out,3310,O
membrane,3310,O
vesicles,3310,O
.,3310,O
Additionally,3311,O
",",3311,O
some,3311,O
CGPs,3311,B-CHEMICAL
were,3311,O
tested,3311,O
in,3311,O
intact,3311,O
transfected,3311,O
cells,3311,O
using,3311,O
a,3311,O
calcein,3311,B-CHEMICAL
efflux,3311,O
assay,3311,O
.,3311,O
Sixteen,3312,O
of,3312,O
34,3312,O
CGPs,3312,B-CHEMICAL
inhibited,3312,O
MRP1-mediated,3312,B-GENE-Y
E217βG,3312,B-CHEMICAL
uptake,3312,O
by,3312,O
>,3312,O
50,3312,O
%,3312,O
(,3312,O
IC50,3312,O
's,3312,O
0.7-7.6,3312,O
μM,3312,O
),3312,O
.,3312,O
Of,3313,O
9,3313,O
CGPs,3313,B-CHEMICAL
with,3313,O
IC50,3313,O
's,3313,O
≤2,3313,O
μM,3313,O
",",3313,O
two,3313,O
belonged,3313,O
to,3313,O
Class,3313,O
I,3313,O
",",3313,O
two,3313,O
to,3313,O
Class,3313,O
III,3313,O
and,3313,O
five,3313,O
to,3313,O
Class,3313,O
V.,3313,O
When,3313,O
tested,3313,O
in,3313,O
the,3313,O
intact,3313,O
cells,3313,O
",",3313,O
only,3313,O
4,3313,O
of,3313,O
16,3313,O
CGPs,3313,B-CHEMICAL
(,3313,O
at,3313,O
10,3313,O
μM,3313,O
),3313,O
inhibited,3313,O
MRP1-mediated,3313,B-GENE-Y
calcein,3313,B-CHEMICAL
efflux,3313,O
by,3313,O
>,3313,O
50,3313,O
%,3313,O
(,3313,O
III-1,3313,O
",",3313,O
V-3,3313,O
",",3313,O
-4,3313,O
",",3313,O
-6,3313,O
),3313,O
while,3313,O
a,3313,O
fifth,3313,O
(,3313,O
I-5,3313,O
),3313,O
inhibited,3313,O
efflux,3313,O
by,3313,O
just,3313,O
23,3313,O
%,3313,O
.,3313,O
These,3314,O
five,3314,O
CGPs,3314,B-CHEMICAL
also,3314,O
inhibited,3314,O
[,3314,B-CHEMICAL
(,3314,I-CHEMICAL
3,3314,I-CHEMICAL
),3314,I-CHEMICAL
H,3314,I-CHEMICAL
],3314,I-CHEMICAL
E217βG,3314,I-CHEMICAL
uptake,3314,O
by,3314,O
MRP4,3314,B-GENE-Y
.,3314,O
In,3315,O
contrast,3315,O
",",3315,O
their,3315,O
effects,3315,O
on,3315,O
MRP2,3315,B-GENE-Y
varied,3315,O
with,3315,O
two,3315,O
(,3315,O
V-4,3315,O
",",3315,O
V-6,3315,O
),3315,O
inhibiting,3315,O
E217βG,3315,B-CHEMICAL
transport,3315,O
(,3315,O
IC50,3315,O
's,3315,O
2.0,3315,O
",",3315,O
9.2,3315,O
μM,3315,O
),3315,O
",",3315,O
two,3315,O
(,3315,O
V-3,3315,O
",",3315,O
III-1,3315,O
),3315,O
stimulating,3315,O
transport,3315,O
(,3315,O
>,3315,O
2-fold,3315,O
),3315,O
",",3315,O
while,3315,O
CGP,3315,B-CHEMICAL
I-5,3315,O
had,3315,O
no,3315,O
effect,3315,O
.,3315,O
Strikingly,3316,O
",",3316,O
although,3316,O
V-3,3316,O
and,3316,O
V-4,3316,O
had,3316,O
opposite,3316,O
effects,3316,O
on,3316,O
MRP2,3316,B-GENE-Y
activity,3316,O
",",3316,O
they,3316,O
are,3316,O
structurally,3316,O
identical,3316,O
except,3316,O
for,3316,O
their,3316,O
chalcogen,3316,B-CHEMICAL
atom,3316,O
(,3316,O
Se,3316,B-CHEMICAL
versus,3316,O
Te,3316,B-CHEMICAL
),3316,O
.,3316,O
This,3317,O
study,3317,O
is,3317,O
the,3317,O
first,3317,O
to,3317,O
identify,3317,O
Class,3317,O
V,3317,O
CGPs,3317,O
with,3317,O
their,3317,O
distinctive,3317,O
methine,3317,B-CHEMICAL
or,3317,O
trimethine,3317,B-CHEMICAL
linkage,3317,O
between,3317,O
two,3317,O
disubstituted,3317,O
pyrylium,3317,B-CHEMICAL
moieties,3317,O
as,3317,O
a,3317,O
particularly,3317,O
potent,3317,O
class,3317,O
of,3317,O
MRP,3317,B-GENE-N
modulators,3317,O
and,3317,O
also,3317,O
show,3317,O
that,3317,O
within,3317,O
this,3317,O
core,3317,O
structure,3317,O
",",3317,O
differences,3317,O
in,3317,O
the,3317,O
electronegativity,3317,O
associated,3317,O
with,3317,O
a,3317,O
chalcogen,3317,B-CHEMICAL
atom,3317,O
can,3317,O
be,3317,O
the,3317,O
sole,3317,O
determinant,3317,O
of,3317,O
whether,3317,O
a,3317,O
compound,3317,O
will,3317,O
stimulate,3317,O
or,3317,O
inhibit,3317,O
MRP2,3317,B-GENE-Y
.,3317,O
Zinc,3318,B-CHEMICAL
drives,3318,O
a,3318,O
tertiary,3318,O
fold,3318,O
in,3318,O
the,3318,O
prion,3318,B-GENE-N
protein,3318,I-GENE-N
with,3318,O
familial,3318,O
disease,3318,O
mutation,3318,O
sites,3318,O
at,3318,O
the,3318,O
interface,3318,O
.,3318,O
The,3319,O
cellular,3319,O
prion,3319,B-GENE-Y
protein,3319,I-GENE-Y
PrP,3319,I-GENE-Y
(,3319,I-GENE-Y
C,3319,I-GENE-Y
),3319,I-GENE-Y
consists,3319,O
of,3319,O
two,3319,O
domains,3319,O
--,3319,O
a,3319,O
flexible,3319,O
N-terminal,3319,B-CHEMICAL
domain,3319,O
",",3319,O
which,3319,O
participates,3319,O
in,3319,O
copper,3319,B-CHEMICAL
and,3319,O
zinc,3319,B-CHEMICAL
regulation,3319,O
",",3319,O
and,3319,O
a,3319,O
largely,3319,O
helical,3319,O
C-terminal,3319,B-CHEMICAL
domain,3319,O
that,3319,O
converts,3319,O
to,3319,O
β,3319,O
sheet,3319,O
in,3319,O
the,3319,O
course,3319,O
of,3319,O
prion,3319,O
disease,3319,O
.,3319,O
These,3320,O
two,3320,O
domains,3320,O
are,3320,O
thought,3320,O
to,3320,O
be,3320,O
fully,3320,O
independent,3320,O
and,3320,O
noninteracting,3320,O
.,3320,O
Compelling,3321,O
cellular,3321,O
and,3321,O
biophysical,3321,O
studies,3321,O
",",3321,O
however,3321,O
",",3321,O
suggest,3321,O
a,3321,O
higher,3321,O
order,3321,O
structure,3321,O
that,3321,O
is,3321,O
relevant,3321,O
to,3321,O
both,3321,O
PrP,3321,B-GENE-Y
(,3321,I-GENE-Y
C,3321,I-GENE-Y
),3321,I-GENE-Y
function,3321,O
and,3321,O
misfolding,3321,O
in,3321,O
disease,3321,O
.,3321,O
Here,3322,O
",",3322,O
we,3322,O
identify,3322,O
a,3322,O
Zn²⁺-driven,3322,B-CHEMICAL
N-terminal,3322,B-CHEMICAL
to,3322,O
C-terminal,3322,B-CHEMICAL
tertiary,3322,O
interaction,3322,O
in,3322,O
PrP,3322,B-GENE-Y
(,3322,I-GENE-Y
C,3322,I-GENE-Y
),3322,I-GENE-Y
.,3322,O
The,3323,O
C-terminal,3323,B-CHEMICAL
surface,3323,O
participating,3323,O
in,3323,O
this,3323,O
interaction,3323,O
carries,3323,O
the,3323,O
majority,3323,O
of,3323,O
the,3323,O
point,3323,O
mutations,3323,O
that,3323,O
confer,3323,O
familial,3323,O
prion,3323,O
disease,3323,O
.,3323,O
Investigation,3324,O
of,3324,O
mutant,3324,O
PrPs,3324,B-GENE-N
finds,3324,O
a,3324,O
systematic,3324,O
relationship,3324,O
between,3324,O
the,3324,O
type,3324,O
of,3324,O
mutation,3324,O
and,3324,O
the,3324,O
apparent,3324,O
strength,3324,O
of,3324,O
this,3324,O
domain,3324,O
structure,3324,O
.,3324,O
The,3325,O
structural,3325,O
features,3325,O
identified,3325,O
here,3325,O
suggest,3325,O
mechanisms,3325,O
by,3325,O
which,3325,O
physiologic,3325,O
metal,3325,O
ions,3325,O
trigger,3325,O
PrP,3325,B-GENE-Y
(,3325,I-GENE-Y
C,3325,I-GENE-Y
),3325,I-GENE-Y
trafficking,3325,O
and,3325,O
control,3325,O
prion,3325,O
disease,3325,O
.,3325,O
IFNα,3326,B-GENE-N
converts,3326,O
IL-22,3326,B-GENE-Y
into,3326,O
a,3326,O
cytokine,3326,B-GENE-N
efficiently,3326,O
activating,3326,O
STAT1,3326,B-GENE-Y
and,3326,O
its,3326,O
downstream,3326,O
targets,3326,O
.,3326,O
Besides,3327,O
their,3327,O
antiviral,3327,O
activity,3327,O
",",3327,O
type,3327,B-GENE-N
I,3327,I-GENE-N
Interferons,3327,I-GENE-N
(,3327,O
IFN,3327,B-GENE-N
),3327,O
display,3327,O
context-specific,3327,O
immunomodulation,3327,O
.,3327,O
In,3328,O
contrast,3328,O
to,3328,O
long-known,3328,O
IFNα/β,3328,B-GENE-N
",",3328,O
Interleukin,3328,B-GENE-Y
(,3328,I-GENE-Y
IL,3328,I-GENE-Y
),3328,I-GENE-Y
-22,3328,I-GENE-Y
is,3328,O
an,3328,O
anti-bacterial,3328,O
",",3328,O
largely,3328,O
tissue,3328,O
protective,3328,O
cytokine,3328,B-GENE-N
that,3328,O
recently,3328,O
gained,3328,O
attention,3328,O
.,3328,O
Herein,3329,O
",",3329,O
cellular,3329,O
IFNα/IL-22,3329,B-GENE-N
interactions,3329,O
are,3329,O
investigated,3329,O
.,3329,O
We,3330,O
report,3330,O
that,3330,O
pre-conditioning,3330,O
of,3330,O
epithelial,3330,O
cells,3330,O
with,3330,O
IFNα,3330,B-GENE-N
initiated,3330,O
dramatic,3330,O
changes,3330,O
in,3330,O
IL-22,3330,B-GENE-Y
signaling,3330,O
normally,3330,O
dominated,3330,O
by,3330,O
signal,3330,B-GENE-Y
transducer,3330,I-GENE-Y
and,3330,I-GENE-Y
activator,3330,I-GENE-Y
of,3330,I-GENE-Y
transcription,3330,I-GENE-Y
(,3330,I-GENE-Y
STAT,3330,I-GENE-Y
),3330,I-GENE-Y
-3,3330,I-GENE-Y
.,3330,O
Specifically,3331,O
",",3331,O
by,3331,O
using,3331,O
human,3331,O
DLD1,3331,O
colon,3331,O
epithelial/carcinoma,3331,O
cells,3331,O
we,3331,O
demonstrate,3331,O
that,3331,O
",",3331,O
upon,3331,O
IFNα,3331,B-GENE-N
",",3331,O
IL-22,3331,B-GENE-Y
converts,3331,O
into,3331,O
a,3331,O
cytokine,3331,B-GENE-N
robustly,3331,O
activating,3331,O
STAT1,3331,B-GENE-Y
and,3331,O
its,3331,O
downstream,3331,O
pro-inflammatory,3331,O
targets,3331,O
CXCL9,3331,B-GENE-Y
",",3331,O
CXCL10,3331,B-GENE-Y
",",3331,O
and,3331,O
inducible,3331,B-GENE-Y
nitric,3331,I-GENE-Y
oxide,3331,I-GENE-Y
synthase,3331,I-GENE-Y
(,3331,O
iNOS,3331,B-GENE-Y
),3331,O
.,3331,O
Accordingly,3332,O
",",3332,O
only,3332,O
after,3332,O
IFNα,3332,B-GENE-N
pre-incubation,3332,O
was,3332,O
IL-22-induced,3332,B-GENE-Y
STAT1,3332,B-GENE-Y
binding,3332,O
to,3332,O
the,3332,O
CXCL10,3332,B-GENE-N
promoter,3332,I-GENE-N
detectable,3332,O
.,3332,O
Using,3333,O
the,3333,O
viral,3333,O
mimic,3333,O
polyinosinic,3333,B-CHEMICAL
:,3333,I-CHEMICAL
polycytidylic,3333,I-CHEMICAL
acid,3333,I-CHEMICAL
and,3333,O
the,3333,O
IFNα/β,3333,B-GENE-N
antagonist,3333,O
B18R,3333,O
we,3333,O
furthermore,3333,O
demonstrate,3333,O
the,3333,O
capability,3333,O
of,3333,O
endogenous,3333,O
IFN,3333,B-GENE-N
to,3333,O
promote,3333,O
IL-22-induced,3333,B-GENE-Y
STAT1,3333,B-GENE-Y
activation,3333,O
and,3333,O
expression,3333,O
of,3333,O
CXCL10,3333,B-GENE-Y
.,3333,O
IL-22-induced,3334,B-GENE-Y
STAT1,3334,B-GENE-Y
activation,3334,O
subsequent,3334,O
to,3334,O
IFNα,3334,B-GENE-N
priming,3334,O
became,3334,O
likewise,3334,O
apparent,3334,O
in,3334,O
human,3334,O
Caco2,3334,O
colon,3334,O
epithelial/carcinoma,3334,O
cells,3334,O
",",3334,O
HepG2,3334,O
hepatoma,3334,O
cells,3334,O
",",3334,O
and,3334,O
primary,3334,O
keratinocytes,3334,O
.,3334,O
Current,3335,O
observations,3335,O
may,3335,O
relate,3335,O
to,3335,O
characteristics,3335,O
of,3335,O
IFNα/β,3335,B-GENE-N
in,3335,O
clinical,3335,O
therapy,3335,O
and,3335,O
expose,3335,O
margins,3335,O
of,3335,O
tissue,3335,O
protection,3335,O
by,3335,O
IL-22,3335,B-GENE-Y
application,3335,O
.,3335,O
Gemfibrozil,3336,B-CHEMICAL
",",3336,O
a,3336,O
lipid-lowering,3336,O
drug,3336,O
",",3336,O
inhibits,3336,O
the,3336,O
induction,3336,O
of,3336,O
nitric-oxide,3336,B-GENE-N
synthase,3336,I-GENE-N
in,3336,O
human,3336,O
astrocytes,3336,O
.,3336,O
Gemfibrozil,3337,B-CHEMICAL
",",3337,O
a,3337,O
lipid-lowering,3337,O
drug,3337,O
",",3337,O
inhibited,3337,O
cytokine-induced,3337,B-GENE-N
production,3337,O
of,3337,O
NO,3337,B-CHEMICAL
and,3337,O
the,3337,O
expression,3337,O
of,3337,O
inducible,3337,B-GENE-Y
nitric-oxide,3337,I-GENE-Y
synthase,3337,I-GENE-Y
(,3337,O
iNOS,3337,B-GENE-Y
),3337,O
in,3337,O
human,3337,O
U373MG,3337,O
astroglial,3337,O
cells,3337,O
and,3337,O
primary,3337,O
astrocytes,3337,O
.,3337,O
Similar,3338,O
to,3338,O
gemfibrozil,3338,B-CHEMICAL
",",3338,O
clofibrate,3338,B-CHEMICAL
",",3338,O
another,3338,O
fibrate,3338,B-CHEMICAL
drug,3338,O
",",3338,O
also,3338,O
inhibited,3338,O
the,3338,O
expression,3338,O
of,3338,O
iNOS,3338,B-GENE-Y
.,3338,O
Inhibition,3339,O
of,3339,O
human,3339,B-GENE-N
iNOS,3339,I-GENE-N
promoter-driven,3339,O
luciferase,3339,O
activity,3339,O
by,3339,O
gemfibrozil,3339,B-CHEMICAL
in,3339,O
cytokine-stimulated,3339,B-GENE-N
U373MG,3339,O
astroglial,3339,O
cells,3339,O
suggests,3339,O
that,3339,O
this,3339,O
compound,3339,O
inhibits,3339,O
the,3339,O
transcription,3339,O
of,3339,O
iNOS,3339,B-GENE-Y
.,3339,O
Since,3340,O
gemfibrozil,3340,B-CHEMICAL
is,3340,O
known,3340,O
to,3340,O
activate,3340,O
peroxisome,3340,B-GENE-Y
proliferator-activated,3340,I-GENE-Y
receptor-alpha,3340,I-GENE-Y
(,3340,O
PPAR-alpha,3340,B-GENE-Y
),3340,O
",",3340,O
we,3340,O
investigated,3340,O
the,3340,O
role,3340,O
of,3340,O
PPAR-alpha,3340,B-GENE-Y
in,3340,O
gemfibrozil-mediated,3340,B-CHEMICAL
inhibition,3340,O
of,3340,O
iNOS,3340,B-GENE-Y
.,3340,O
Gemfibrozil,3341,B-CHEMICAL
induced,3341,O
peroxisome,3341,B-GENE-N
proliferator-responsive,3341,I-GENE-N
element,3341,I-GENE-N
(,3341,O
PPRE,3341,B-GENE-N
),3341,O
-dependent,3341,O
luciferase,3341,O
activity,3341,O
",",3341,O
which,3341,O
was,3341,O
inhibited,3341,O
by,3341,O
the,3341,O
expression,3341,O
of,3341,O
DeltahPPAR-alpha,3341,B-GENE-Y
",",3341,O
the,3341,O
dominant-negative,3341,O
mutant,3341,O
of,3341,O
human,3341,B-GENE-Y
PPAR-alpha,3341,I-GENE-Y
.,3341,O
However,3342,O
",",3342,O
DeltahPPAR-alpha,3342,B-GENE-Y
was,3342,O
unable,3342,O
to,3342,O
abrogate,3342,O
gemfibrozil-mediated,3342,B-CHEMICAL
inhibition,3342,O
of,3342,O
iNOS,3342,B-GENE-Y
suggesting,3342,O
that,3342,O
gemfibrozil,3342,B-CHEMICAL
inhibits,3342,O
iNOS,3342,B-GENE-Y
independent,3342,O
of,3342,O
PPAR-alpha,3342,B-GENE-Y
.,3342,O
The,3343,O
human,3343,B-GENE-N
iNOS,3343,I-GENE-N
promoter,3343,I-GENE-N
contains,3343,O
consensus,3343,O
sequences,3343,O
for,3343,O
the,3343,O
binding,3343,O
of,3343,O
transcription,3343,O
factors,3343,O
",",3343,O
including,3343,O
interferon-gamma,3343,B-GENE-Y
(,3343,I-GENE-Y
IFN-gamma,3343,I-GENE-Y
),3343,I-GENE-Y
regulatory,3343,I-GENE-Y
factor-1,3343,I-GENE-Y
(,3343,O
IRF-1,3343,B-GENE-Y
),3343,O
binding,3343,O
to,3343,O
interferon-stimulated,3343,B-GENE-N
responsive,3343,I-GENE-N
element,3343,I-GENE-N
(,3343,O
ISRE,3343,B-GENE-N
),3343,O
",",3343,O
signal,3343,B-GENE-N
transducer,3343,I-GENE-N
and,3343,I-GENE-N
activator,3343,I-GENE-N
of,3343,I-GENE-N
transcription,3343,I-GENE-N
(,3343,O
STAT,3343,B-GENE-N
),3343,O
binding,3343,O
to,3343,O
gamma-activation,3343,O
site,3343,O
(,3343,O
GAS,3343,O
),3343,O
",",3343,O
nuclear,3343,B-GENE-N
factor-kappaB,3343,I-GENE-N
(,3343,O
NF-kappaB,3343,B-GENE-N
),3343,O
",",3343,O
activator,3343,B-GENE-Y
protein-1,3343,I-GENE-Y
(,3343,O
AP-1,3343,B-GENE-Y
),3343,O
",",3343,O
and,3343,O
CCAAT/enhancer-binding,3343,B-GENE-Y
protein,3343,I-GENE-Y
beta,3343,I-GENE-Y
(,3343,O
C/EBPbeta,3343,B-GENE-Y
),3343,O
;,3343,O
therefore,3343,O
",",3343,O
we,3343,O
investigated,3343,O
the,3343,O
effect,3343,O
of,3343,O
gemfibrozil,3343,B-CHEMICAL
on,3343,O
the,3343,O
activation,3343,O
of,3343,O
these,3343,O
transcription,3343,O
factors,3343,O
.,3343,O
The,3344,O
combination,3344,O
of,3344,O
interleukin,3344,B-GENE-Y
(,3344,I-GENE-Y
IL,3344,I-GENE-Y
),3344,I-GENE-Y
-1beta,3344,I-GENE-Y
and,3344,O
IFN-gamma,3344,B-GENE-Y
induced,3344,O
the,3344,O
activation,3344,O
of,3344,O
NF-kappaB,3344,B-GENE-N
",",3344,O
AP-1,3344,B-GENE-Y
",",3344,O
C/EBPbeta,3344,B-GENE-Y
",",3344,O
and,3344,O
GAS,3344,O
but,3344,O
not,3344,O
that,3344,O
of,3344,O
ISRE,3344,B-GENE-N
",",3344,O
suggesting,3344,O
that,3344,O
IRF-1,3344,B-GENE-Y
may,3344,O
not,3344,O
be,3344,O
involved,3344,O
in,3344,O
cytokine-induced,3344,B-GENE-N
expression,3344,O
of,3344,O
iNOS,3344,B-GENE-Y
in,3344,O
human,3344,O
astrocytes,3344,O
.,3344,O
Interestingly,3345,O
",",3345,O
gemfibrozil,3345,B-CHEMICAL
strongly,3345,O
inhibited,3345,O
the,3345,O
activation,3345,O
of,3345,O
NF-kappaB,3345,B-GENE-N
",",3345,O
AP-1,3345,B-GENE-Y
",",3345,O
and,3345,O
C/EBPbeta,3345,B-GENE-Y
but,3345,O
not,3345,O
that,3345,O
of,3345,O
GAS,3345,O
in,3345,O
cytokine-stimulated,3345,B-GENE-N
astroglial,3345,O
cells,3345,O
.,3345,O
These,3346,O
results,3346,O
suggest,3346,O
that,3346,O
gemfibrozil,3346,B-CHEMICAL
inhibits,3346,O
the,3346,O
induction,3346,O
of,3346,O
iNOS,3346,B-GENE-Y
probably,3346,O
by,3346,O
inhibiting,3346,O
the,3346,O
activation,3346,O
of,3346,O
NF-kappaB,3346,B-GENE-N
",",3346,O
AP-1,3346,B-GENE-Y
",",3346,O
and,3346,O
C/EBPbeta,3346,B-GENE-Y
and,3346,O
that,3346,O
gemfibrozil,3346,B-CHEMICAL
",",3346,O
a,3346,O
prescribed,3346,O
drug,3346,O
for,3346,O
humans,3346,O
",",3346,O
may,3346,O
further,3346,O
find,3346,O
its,3346,O
therapeutic,3346,O
use,3346,O
in,3346,O
neuroinflammatory,3346,O
diseases,3346,O
.,3346,O
Central,3347,O
sympatholysis,3347,O
as,3347,O
a,3347,O
novel,3347,O
countermeasure,3347,O
for,3347,O
cocaine-induced,3347,B-CHEMICAL
sympathetic,3347,O
activation,3347,O
and,3347,O
vasoconstriction,3347,O
in,3347,O
humans,3347,O
.,3347,O
OBJECTIVES,3348,O
:,3348,O
The,3348,O
aim,3348,O
of,3348,O
this,3348,O
study,3348,O
was,3348,O
to,3348,O
determine,3348,O
whether,3348,O
cocaine,3348,O
's,3348,O
sympathomimetic,3348,O
actions,3348,O
can,3348,O
be,3348,O
reversed,3348,O
by,3348,O
a,3348,O
potent,3348,O
centrally,3348,O
acting,3348,O
alpha2,3348,B-GENE-N
adrenergic,3348,I-GENE-N
receptor,3348,I-GENE-N
(,3348,O
AR,3348,B-GENE-N
),3348,O
agonist,3348,O
(,3348,O
dexmedetomidine,3348,B-CHEMICAL
),3348,O
.,3348,O
BACKGROUND,3349,O
:,3349,O
We,3349,O
recently,3349,O
showed,3349,O
that,3349,O
cocaine,3349,B-CHEMICAL
stimulates,3349,O
the,3349,O
human,3349,O
cardiovascular,3349,O
system,3349,O
primarily,3349,O
by,3349,O
acting,3349,O
in,3349,O
the,3349,O
brain,3349,O
to,3349,O
increase,3349,O
sympathetic,3349,O
nerve,3349,O
activity,3349,O
(,3349,O
SNA,3349,O
),3349,O
",",3349,O
the,3349,O
neural,3349,O
stimulus,3349,O
to,3349,O
norepinephrine,3349,B-CHEMICAL
release,3349,O
.,3349,O
Thus,3350,O
",",3350,O
SNA,3350,O
constitutes,3350,O
a,3350,O
putative,3350,O
new,3350,O
drug,3350,O
target,3350,O
to,3350,O
block,3350,O
cocaine,3350,O
's,3350,O
adverse,3350,O
cardiovascular,3350,O
effects,3350,O
at,3350,O
their,3350,O
origin,3350,O
.,3350,O
METHODS,3351,O
:,3351,O
In,3351,O
22,3351,O
healthy,3351,O
cocaine-naive,3351,B-CHEMICAL
humans,3351,O
",",3351,O
we,3351,O
measured,3351,O
skin,3351,O
SNA,3351,O
(,3351,O
microneurography,3351,O
),3351,O
and,3351,O
skin,3351,O
blood,3351,O
flow,3351,O
(,3351,O
laser,3351,O
Doppler,3351,O
velocimetry,3351,O
),3351,O
as,3351,O
well,3351,O
as,3351,O
heart,3351,O
rate,3351,O
and,3351,O
blood,3351,O
pressure,3351,O
before,3351,O
and,3351,O
after,3351,O
intranasal,3351,O
cocaine,3351,B-CHEMICAL
(,3351,O
2,3351,O
mg/kg,3351,O
),3351,O
alone,3351,O
and,3351,O
in,3351,O
combination,3351,O
with,3351,O
dexmedetomidine,3351,B-CHEMICAL
or,3351,O
saline,3351,O
.,3351,O
RESULTS,3352,O
:,3352,O
During,3352,O
intranasal,3352,O
cocaine,3352,B-CHEMICAL
alone,3352,O
",",3352,O
SNA,3352,O
increased,3352,O
by,3352,O
2-fold,3352,O
and,3352,O
skin,3352,O
vascular,3352,O
resistance,3352,O
increased,3352,O
from,3352,O
13.2,3352,O
+/-,3352,O
2.3,3352,O
to,3352,O
20.1,3352,O
+/-,3352,O
2.2,3352,O
resistance,3352,O
units,3352,O
while,3352,O
mean,3352,O
arterial,3352,O
pressure,3352,O
increased,3352,O
by,3352,O
14,3352,O
+/-,3352,O
3,3352,O
mm,3352,O
Hg,3352,O
and,3352,O
heart,3352,O
rate,3352,O
by,3352,O
18,3352,O
+/-,3352,O
3,3352,O
beats/min,3352,O
(,3352,O
p,3352,O
<,3352,O
0.01,3352,O
),3352,O
.,3352,O
Dexmedetomidine,3353,B-CHEMICAL
abolished,3353,O
these,3353,O
increases,3353,O
",",3353,O
whereas,3353,O
intravenous,3353,O
saline,3353,O
was,3353,O
without,3353,O
effect,3353,O
.,3353,O
Dexmedetomidine,3354,B-CHEMICAL
was,3354,O
effective,3354,O
in,3354,O
blocking,3354,O
these,3354,O
sympathomimetic,3354,O
actions,3354,O
of,3354,O
cocaine,3354,B-CHEMICAL
even,3354,O
in,3354,O
all,3354,O
7,3354,O
subjects,3354,O
who,3354,O
were,3354,O
homozygous,3354,O
for,3354,O
the,3354,O
Del322-325,3354,O
polymorphism,3354,O
in,3354,O
the,3354,O
alpha2C,3354,B-GENE-Y
AR,3354,I-GENE-Y
",",3354,O
a,3354,O
loss-of-function,3354,O
mutation,3354,O
that,3354,O
is,3354,O
highly,3354,O
enriched,3354,O
in,3354,O
blacks,3354,O
.,3354,O
CONCLUSIONS,3355,O
:,3355,O
The,3355,O
data,3355,O
advance,3355,O
the,3355,O
novel,3355,O
hypothesis,3355,O
that,3355,O
central,3355,O
sympatholysis,3355,O
with,3355,O
dexmedetomidine,3355,B-CHEMICAL
constitutes,3355,O
a,3355,O
highly,3355,O
effective,3355,O
countermeasure,3355,O
for,3355,O
cocaine,3355,O
's,3355,O
sympathomimetic,3355,O
actions,3355,O
on,3355,O
the,3355,O
human,3355,O
cardiovascular,3355,O
system,3355,O
",",3355,O
even,3355,O
in,3355,O
individuals,3355,O
carrying,3355,O
the,3355,O
alpha2CDel322-325,3355,B-GENE-Y
polymorphism,3355,O
.,3355,O
(,3356,O
Study,3356,O
to,3356,O
Improve,3356,O
Scientific,3356,O
Understanding,3356,O
of,3356,O
the,3356,O
Cardiovascular,3356,O
Actions,3356,O
of,3356,O
Cocaine,3356,B-CHEMICAL
;,3356,O
http,3356,O
:,3356,O
//clinicaltrials.gov/ct/show/NCT00338546,3356,O
?,3356,O
order=1,3356,O
;,3356,O
NCT00338546,3356,O
),3356,O
.,3356,O
The,3357,O
inhibitory,3357,O
effect,3357,O
of,3357,O
sodium,3357,B-CHEMICAL
nitroprusside,3357,I-CHEMICAL
on,3357,O
HIF-1,3357,B-GENE-N
activation,3357,O
is,3357,O
not,3357,O
dependent,3357,O
on,3357,O
nitric,3357,B-CHEMICAL
oxide-soluble,3357,O
guanylyl,3357,I-GENE-N
cyclase,3357,I-GENE-N
pathway,3357,O
.,3357,O
Adaptation,3358,O
to,3358,O
hypoxia,3358,O
and,3358,O
maintenance,3358,O
of,3358,O
O,3358,B-CHEMICAL
(,3358,I-CHEMICAL
2,3358,I-CHEMICAL
),3358,I-CHEMICAL
homeostasis,3358,O
involve,3358,O
a,3358,O
wide,3358,O
range,3358,O
of,3358,O
responses,3358,O
that,3358,O
occur,3358,O
at,3358,O
different,3358,O
organizational,3358,O
levels,3358,O
in,3358,O
the,3358,O
body,3358,O
.,3358,O
One,3359,O
of,3359,O
the,3359,O
most,3359,O
important,3359,O
transcription,3359,O
factors,3359,O
that,3359,O
activate,3359,O
the,3359,O
expression,3359,O
of,3359,O
O,3359,B-CHEMICAL
(,3359,I-CHEMICAL
2,3359,I-CHEMICAL
),3359,I-CHEMICAL
-regulated,3359,O
genes,3359,O
is,3359,O
hypoxia-inducible,3359,B-GENE-N
factor,3359,I-GENE-N
1,3359,I-GENE-N
(,3359,O
HIF-1,3359,B-GENE-N
),3359,O
.,3359,O
Nitric,3360,B-CHEMICAL
oxide,3360,I-CHEMICAL
(,3360,O
NO,3360,B-CHEMICAL
),3360,O
mediates,3360,O
a,3360,O
variety,3360,O
of,3360,O
biological,3360,O
effects,3360,O
including,3360,O
relaxation,3360,O
of,3360,O
blood,3360,O
vessels,3360,O
and,3360,O
cytotoxicity,3360,O
of,3360,O
activated,3360,O
macrophages,3360,O
.,3360,O
We,3361,O
investigated,3361,O
the,3361,O
effect,3361,O
of,3361,O
the,3361,O
clinically,3361,O
used,3361,O
nitrates,3361,O
nitroglycerin,3361,B-CHEMICAL
(,3361,O
NTG,3361,B-CHEMICAL
),3361,O
",",3361,O
isosorbide,3361,B-CHEMICAL
dinitrate,3361,I-CHEMICAL
(,3361,O
ISDN,3361,B-CHEMICAL
),3361,O
",",3361,O
and,3361,O
sodium,3361,B-CHEMICAL
nitroprusside,3361,I-CHEMICAL
(,3361,O
SNP,3361,B-CHEMICAL
),3361,O
on,3361,O
HIF-1-mediated,3361,B-GENE-N
transcriptional,3361,O
responses,3361,O
to,3361,O
hypoxia,3361,O
.,3361,O
We,3362,O
demonstrate,3362,O
that,3362,O
among,3362,O
the,3362,O
three,3362,O
nitrates,3362,O
",",3362,O
only,3362,O
SNP,3362,B-CHEMICAL
inhibits,3362,O
HIF-1,3362,B-GENE-N
activation,3362,O
in,3362,O
response,3362,O
to,3362,O
hypoxia,3362,O
.,3362,O
In,3363,O
contrast,3363,O
",",3363,O
NTG,3363,B-CHEMICAL
or,3363,O
ISDN,3363,B-CHEMICAL
does,3363,O
not,3363,O
affect,3363,O
HIF-1,3363,B-GENE-N
activity,3363,O
.,3363,O
SNP,3364,B-CHEMICAL
inhibits,3364,O
the,3364,O
accumulation,3364,O
of,3364,O
HIF-1alpha,3364,B-GENE-Y
",",3364,O
the,3364,O
regulatory,3364,O
subunit,3364,O
of,3364,O
HIF-1,3364,B-GENE-N
",",3364,O
and,3364,O
the,3364,O
transcriptional,3364,O
activation,3364,O
of,3364,O
HIF-1alpha,3364,B-GENE-Y
via,3364,O
a,3364,O
mechanism,3364,O
that,3364,O
is,3364,O
not,3364,O
dependent,3364,O
on,3364,O
either,3364,O
NO,3364,B-CHEMICAL
or,3364,O
soluble,3364,B-GENE-N
guanylate,3364,I-GENE-N
cyclase,3364,I-GENE-N
.,3364,O
Indomethacin,3365,B-CHEMICAL
activates,3365,O
carbonic,3365,B-GENE-N
anhydrase,3365,I-GENE-N
and,3365,O
antagonizes,3365,O
the,3365,O
effect,3365,O
of,3365,O
the,3365,O
specific,3365,O
carbonic,3365,B-GENE-N
anhydrase,3365,I-GENE-N
inhibitor,3365,O
acetazolamide,3365,B-CHEMICAL
",",3365,O
by,3365,O
a,3365,O
direct,3365,O
mechanism,3365,O
of,3365,O
action,3365,O
.,3365,O
OBJECTIVES,3366,O
:,3366,O
In,3366,O
this,3366,O
paper,3366,O
we,3366,O
investigated,3366,O
the,3366,O
effect,3366,O
of,3366,O
indomethacin,3366,B-CHEMICAL
",",3366,O
acetazolamide,3366,B-CHEMICAL
and,3366,O
their,3366,O
combination,3366,O
in,3366,O
vitro,3366,O
and,3366,O
in,3366,O
vivo,3366,O
on,3366,O
carbonic,3366,B-GENE-N
anhydrase,3366,I-GENE-N
(,3366,O
CA,3366,B-GENE-N
),3366,O
isozymes,3366,O
.,3366,O
METHOD,3367,O
:,3367,O
In,3367,O
vitro,3367,O
experiments,3367,O
followed,3367,O
the,3367,O
effect,3367,O
of,3367,O
the,3367,O
two,3367,O
substances,3367,O
at,3367,O
concentrations,3367,O
between,3367,O
10,3367,O
(,3367,O
-8,3367,O
),3367,O
-10,3367,O
(,3367,O
-4,3367,O
),3367,O
M,3367,O
on,3367,O
purified,3367,O
human,3367,B-GENE-N
red,3367,I-GENE-N
cell,3367,I-GENE-N
CA,3367,I-GENE-N
I,3367,I-GENE-N
and,3367,I-GENE-N
II,3367,I-GENE-N
as,3367,O
well,3367,O
as,3367,O
on,3367,O
human,3367,B-GENE-Y
gastric,3367,I-GENE-Y
mucosa,3367,I-GENE-Y
CA,3367,I-GENE-Y
IV,3367,I-GENE-Y
using,3367,O
dose-response,3367,O
relationships,3367,O
.,3367,O
Kinetic,3368,O
studies,3368,O
were,3368,O
also,3368,O
performed,3368,O
.,3368,O
The,3369,O
effects,3369,O
of,3369,O
single,3369,O
and,3369,O
combined,3369,O
administration,3369,O
of,3369,O
indomethacin,3369,B-CHEMICAL
and,3369,O
acetazolamide,3369,B-CHEMICAL
on,3369,O
red,3369,O
cell,3369,O
CA,3369,B-GENE-N
and,3369,O
on,3369,O
gastric,3369,O
acid,3369,O
secretion,3369,O
were,3369,O
studied,3369,O
in,3369,O
vivo,3369,O
.,3369,O
RESULTS,3370,O
:,3370,O
Indomethacin,3370,B-CHEMICAL
",",3370,O
in,3370,O
vitro,3370,O
and,3370,O
in,3370,O
vivo,3370,O
.,3370,O
induces,3371,O
an,3371,O
increase,3371,O
in,3371,O
erythorcyte,3371,O
CA,3371,B-GENE-Y
I,3371,I-GENE-Y
and,3371,O
CA,3371,B-GENE-Y
II,3371,I-GENE-Y
activity,3371,O
.,3371,O
Acetazolamide,3372,B-CHEMICAL
",",3372,O
a,3372,O
specific,3372,O
inhibitor,3372,O
of,3372,O
CA,3372,B-GENE-N
",",3372,O
reduces,3372,O
the,3372,O
activity,3372,O
of,3372,O
CA,3372,B-GENE-Y
I,3372,I-GENE-Y
and,3372,O
CA,3372,B-GENE-Y
II,3372,I-GENE-Y
from,3372,O
red,3372,O
cells,3372,O
.,3372,O
Indomethacin,3373,B-CHEMICAL
completely,3373,O
antagonizes,3373,O
CA,3373,B-GENE-N
activity,3373,O
",",3373,O
i.e,3373,O
.,3373,O
abolishes,3374,O
the,3374,O
inhibitory,3374,O
effect,3374,O
of,3374,O
acetazolamide,3374,B-CHEMICAL
on,3374,O
CA,3374,B-GENE-N
.,3374,O
In,3375,O
humans,3375,O
",",3375,O
an,3375,O
increase,3375,O
or,3375,O
decrease,3375,O
in,3375,O
erythrocyte,3375,O
CA,3375,B-GENE-Y
II,3375,I-GENE-Y
activity,3375,O
is,3375,O
correlated,3375,O
with,3375,O
an,3375,O
increase,3375,O
or,3375,O
decrease,3375,O
in,3375,O
gastric,3375,O
acid,3375,O
secretion,3375,O
.,3375,O
CONCLUSIONS,3376,O
:,3376,O
Our,3376,O
results,3376,O
show,3376,O
that,3376,O
indomethacin,3376,B-CHEMICAL
",",3376,O
a,3376,O
known,3376,O
cyclooxygenase,3376,B-GENE-N
(,3376,O
COX,3376,B-GENE-N
),3376,O
inhibitor,3376,O
",",3376,O
is,3376,O
also,3376,O
an,3376,O
activator,3376,O
of,3376,O
CA,3376,B-GENE-N
.,3376,O
Our,3377,O
data,3377,O
also,3377,O
prove,3377,O
that,3377,O
indomethacin,3377,B-CHEMICAL
is,3377,O
not,3377,O
only,3377,O
an,3377,O
activator,3377,O
of,3377,O
CA,3377,B-GENE-N
but,3377,O
also,3377,O
antagonizes,3377,O
the,3377,O
effect,3377,O
of,3377,O
acetazolamide,3377,B-CHEMICAL
",",3377,O
a,3377,O
specific,3377,O
inhibitor,3377,O
of,3377,O
this,3377,O
enzyme,3377,O
.,3377,O
In,3378,O
view,3378,O
of,3378,O
the,3378,O
role,3378,O
of,3378,O
CA,3378,B-GENE-N
in,3378,O
acid-base,3378,O
balance,3378,O
as,3378,O
well,3378,O
as,3378,O
the,3378,O
fact,3378,O
that,3378,O
an,3378,O
increase,3378,O
or,3378,O
decrease,3378,O
in,3378,O
its,3378,O
activity,3378,O
is,3378,O
accompanied,3378,O
by,3378,O
an,3378,O
increase,3378,O
or,3378,O
decrease,3378,O
in,3378,O
intra-,3378,O
and,3378,O
extracellular,3378,O
pH,3378,O
",",3378,O
our,3378,O
results,3378,O
suggest,3378,O
that,3378,O
:,3378,O
firstly,3378,O
",",3378,O
CA,3378,B-GENE-N
activation,3378,O
induced,3378,O
by,3378,O
indomethacin,3378,B-CHEMICAL
might,3378,O
cause,3378,O
changes,3378,O
in,3378,O
COX,3378,B-GENE-N
activity,3378,O
;,3378,O
secondly,3378,O
",",3378,O
PGs,3378,O
are,3378,O
synthetized,3378,O
as,3378,O
a,3378,O
consequence,3378,O
of,3378,O
the,3378,O
changes,3378,O
in,3378,O
COX,3378,B-GENE-N
activity,3378,O
",",3378,O
a,3378,O
hypothesis,3378,O
that,3378,O
requires,3378,O
further,3378,O
study,3378,O
.,3378,O
Recent,3379,O
developments,3379,O
in,3379,O
the,3379,O
synthesis,3379,O
of,3379,O
acetylcholinesterase,3379,B-GENE-Y
inhibitors,3379,O
.,3379,O
The,3380,O
acetylcholinesterase,3380,B-GENE-Y
(,3380,O
AChE,3380,B-GENE-Y
),3380,O
and,3380,O
butyrylcholinesterase,3380,B-GENE-Y
(,3380,O
BuChE,3380,B-GENE-Y
),3380,O
inhibitory,3380,O
activities,3380,O
of,3380,O
a,3380,O
series,3380,O
of,3380,O
pyrano,3380,B-CHEMICAL
[,3380,I-CHEMICAL
"2,3-b",3380,I-CHEMICAL
],3380,I-CHEMICAL
quinolines,3380,I-CHEMICAL
(,3380,O
2,3380,O
",",3380,O
3,3380,O
),3380,O
",",3380,O
[,3380,B-CHEMICAL
"1,8",3380,I-CHEMICAL
],3380,I-CHEMICAL
naphthyridines,3380,I-CHEMICAL
(,3380,O
5,3380,O
",",3380,O
6,3380,O
),3380,O
",",3380,O
"4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro",3380,B-CHEMICAL
[,3380,I-CHEMICAL
"2,3-b",3380,I-CHEMICAL
],3380,I-CHEMICAL
quinolines,3380,I-CHEMICAL
(,3380,O
11-13,3380,O
),3380,O
/,3380,O
"4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta",3380,B-CHEMICAL
[,3380,I-CHEMICAL
e,3380,I-CHEMICAL
],3380,I-CHEMICAL
furo,3380,I-CHEMICAL
[,3380,I-CHEMICAL
"2,3-b",3380,I-CHEMICAL
],3380,I-CHEMICAL
pyridine,3380,I-CHEMICAL
(,3380,O
14,3380,O
),3380,O
",",3380,O
"4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno",3380,B-CHEMICAL
[,3380,I-CHEMICAL
"2,3-b",3380,I-CHEMICAL
],3380,I-CHEMICAL
quinoline,3380,I-CHEMICAL
(,3380,O
15,3380,O
),3380,O
/,3380,O
"4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta",3380,B-CHEMICAL
[,3380,I-CHEMICAL
e,3380,I-CHEMICAL
],3380,I-CHEMICAL
thieno,3380,I-CHEMICAL
[,3380,I-CHEMICAL
"2,3-b",3380,I-CHEMICAL
],3380,I-CHEMICAL
pyridine,3380,I-CHEMICAL
(,3380,O
16,3380,O
),3380,O
are,3380,O
described,3380,O
.,3380,O
These,3381,O
compounds,3381,O
are,3381,O
tacrine,3381,B-CHEMICAL
analogues,3381,O
that,3381,O
have,3381,O
been,3381,O
prepared,3381,O
from,3381,O
readily,3381,O
available,3381,O
polyfunctionalized,3381,O
ethyl,3381,B-CHEMICAL
[,3381,I-CHEMICAL
6-amino-5-cyano-4H-pyran,3381,I-CHEMICAL
],3381,I-CHEMICAL
-3-carboxylates,3381,I-CHEMICAL
(,3381,O
9,3381,O
",",3381,O
10,3381,O
),3381,O
",",3381,O
ethyl,3381,B-CHEMICAL
[,3381,I-CHEMICAL
6-amino-5-cyanopyridine,3381,I-CHEMICAL
],3381,I-CHEMICAL
-3-carboxylates,3381,I-CHEMICAL
(,3381,O
7,3381,O
",",3381,O
8,3381,O
),3381,O
",",3381,O
"2-amino-3-cyano-4,5-diarylfurans",3381,B-CHEMICAL
(,3381,O
17-19,3381,O
),3381,O
and,3381,O
"2-amino-3-cyano-4,5-diphenylthiophene",3381,B-CHEMICAL
(,3381,O
20,3381,O
),3381,O
via,3381,O
Friedlander,3381,O
condensation,3381,O
with,3381,O
selected,3381,O
ketones,3381,B-CHEMICAL
.,3381,O
These,3382,O
compounds,3382,O
are,3382,O
competitive,3382,O
and,3382,O
",",3382,O
in,3382,O
a,3382,O
few,3382,O
cases,3382,O
",",3382,O
non-competitive,3382,O
inhibitors,3382,O
for,3382,O
AChE,3382,B-GENE-Y
",",3382,O
the,3382,O
most,3382,O
potent,3382,O
being,3382,O
compound,3382,O
(,3382,O
14,3382,O
),3382,O
",",3382,O
though,3382,O
three-fold,3382,O
less,3382,O
active,3382,O
than,3382,O
tacrine,3382,B-CHEMICAL
.,3382,O
The,3383,O
BuChE,3383,B-GENE-Y
inhibitory,3383,O
activity,3383,O
is,3383,O
only,3383,O
significant,3383,O
in,3383,O
compounds,3383,O
11,3383,O
and,3383,O
14,3383,O
",",3383,O
ten-fold,3383,O
less,3383,O
active,3383,O
than,3383,O
tacrine,3383,B-CHEMICAL
.,3383,O
Furthermore,3384,O
",",3384,O
the,3384,O
products,3384,O
12,3384,O
and,3384,O
13,3384,O
are,3384,O
selective,3384,O
and,3384,O
moderate,3384,O
AChE,3384,B-GENE-Y
inhibitors,3384,O
.,3384,O
Development,3385,O
and,3385,O
validation,3385,O
of,3385,O
NIR-chemometric,3385,O
methods,3385,O
for,3385,O
chemical,3385,O
and,3385,O
pharmaceutical,3385,O
characterization,3385,O
of,3385,O
meloxicam,3385,B-CHEMICAL
tablets,3385,O
.,3385,O
Abstract,3386,O
Context,3386,O
:,3386,O
Near-Infrared,3386,O
(,3386,O
NIR,3386,O
),3386,O
spectroscopy,3386,O
is,3386,O
an,3386,O
important,3386,O
component,3386,O
of,3386,O
a,3386,O
Process,3386,O
Analytical,3386,O
Technology,3386,O
(,3386,O
PAT,3386,O
),3386,O
toolbox,3386,O
and,3386,O
is,3386,O
a,3386,O
key,3386,O
technology,3386,O
for,3386,O
enabling,3386,O
the,3386,O
rapid,3386,O
analysis,3386,O
of,3386,O
pharmaceutical,3386,O
tablets,3386,O
.,3386,O
Objective,3387,O
:,3387,O
The,3387,O
aim,3387,O
of,3387,O
this,3387,O
research,3387,O
work,3387,O
was,3387,O
to,3387,O
develop,3387,O
and,3387,O
validate,3387,O
NIR-chemometric,3387,O
methods,3387,O
not,3387,O
only,3387,O
for,3387,O
the,3387,O
determination,3387,O
of,3387,O
active,3387,O
pharmaceutical,3387,O
ingredients,3387,O
content,3387,O
but,3387,O
also,3387,O
pharmaceutical,3387,O
properties,3387,O
(,3387,O
crushing,3387,O
strength,3387,O
",",3387,O
disintegration,3387,O
time,3387,O
),3387,O
of,3387,O
meloxicam,3387,B-CHEMICAL
tablets,3387,O
.,3387,O
Materials,3388,O
and,3388,O
methods,3388,O
:,3388,O
The,3388,O
development,3388,O
of,3388,O
the,3388,O
method,3388,O
for,3388,O
active,3388,O
content,3388,O
assay,3388,O
was,3388,O
performed,3388,O
on,3388,O
samples,3388,O
corresponding,3388,O
to,3388,O
80,3388,O
%,3388,O
",",3388,O
90,3388,O
%,3388,O
",",3388,O
100,3388,O
%,3388,O
",",3388,O
110,3388,O
%,3388,O
and,3388,O
120,3388,O
%,3388,O
of,3388,O
meloxicam,3388,B-CHEMICAL
content,3388,O
and,3388,O
the,3388,O
development,3388,O
of,3388,O
the,3388,O
methods,3388,O
for,3388,O
pharmaceutical,3388,O
characterization,3388,O
was,3388,O
performed,3388,O
on,3388,O
samples,3388,O
prepared,3388,O
at,3388,O
seven,3388,O
different,3388,O
compression,3388,O
forces,3388,O
(,3388,O
ranging,3388,O
from,3388,O
7,3388,O
to,3388,O
45,3388,O
kN,3388,O
),3388,O
using,3388,O
NIR,3388,O
transmission,3388,O
spectra,3388,O
of,3388,O
intact,3388,O
tablets,3388,O
and,3388,O
PLS,3388,O
as,3388,O
a,3388,O
regression,3388,O
method,3388,O
.,3388,O
Results,3389,O
:,3389,O
The,3389,O
results,3389,O
show,3389,O
that,3389,O
the,3389,O
developed,3389,O
methods,3389,O
have,3389,O
good,3389,O
trueness,3389,O
",",3389,O
precision,3389,O
and,3389,O
accuracy,3389,O
and,3389,O
are,3389,O
appropriate,3389,O
for,3389,O
direct,3389,O
active,3389,O
content,3389,O
assay,3389,O
in,3389,O
tablets,3389,O
(,3389,O
ranging,3389,O
from,3389,O
12,3389,O
to,3389,O
18,3389,O
mg/tablet,3389,O
),3389,O
and,3389,O
also,3389,O
for,3389,O
predicting,3389,O
crushing,3389,O
strength,3389,O
and,3389,O
disintegration,3389,O
time,3389,O
of,3389,O
intact,3389,O
meloxicam,3389,B-CHEMICAL
tablets,3389,O
.,3389,O
Discussion,3390,O
:,3390,O
The,3390,O
comparative,3390,O
data,3390,O
show,3390,O
that,3390,O
the,3390,O
proposed,3390,O
methods,3390,O
are,3390,O
in,3390,O
good,3390,O
agreement,3390,O
with,3390,O
the,3390,O
reference,3390,O
methods,3390,O
currently,3390,O
used,3390,O
for,3390,O
the,3390,O
characterization,3390,O
of,3390,O
meloxicam,3390,B-CHEMICAL
tablets,3390,O
(,3390,O
HPLC-UV,3390,O
methods,3390,O
for,3390,O
the,3390,O
assay,3390,O
and,3390,O
European,3390,O
Pharmacopeia,3390,O
methods,3390,O
for,3390,O
determining,3390,O
the,3390,O
crushing,3390,O
strength,3390,O
and,3390,O
disintegration,3390,O
time,3390,O
),3390,O
.,3390,O
Conclusion,3391,O
:,3391,O
The,3391,O
results,3391,O
show,3391,O
the,3391,O
possibility,3391,O
to,3391,O
predict,3391,O
both,3391,O
chemical,3391,O
properties,3391,O
(,3391,O
active,3391,O
content,3391,O
),3391,O
and,3391,O
physical/pharmaceutical,3391,O
properties,3391,O
(,3391,O
crushing,3391,O
strength,3391,O
and,3391,O
disintegration,3391,O
time,3391,O
),3391,O
directly,3391,O
",",3391,O
without,3391,O
any,3391,O
sample,3391,O
preparation,3391,O
",",3391,O
from,3391,O
the,3391,O
same,3391,O
NIR,3391,O
transmission,3391,O
spectrum,3391,O
of,3391,O
meloxicam,3391,B-CHEMICAL
tablets,3391,O
.,3391,O
Juglone,3392,B-CHEMICAL
",",3392,O
isolated,3392,O
from,3392,O
Juglans,3392,O
mandshurica,3392,O
Maxim,3392,O
",",3392,O
induces,3392,O
apoptosis,3392,O
via,3392,O
down-regulation,3392,O
of,3392,O
AR,3392,B-GENE-Y
expression,3392,O
in,3392,O
human,3392,O
prostate,3392,O
cancer,3392,O
LNCaP,3392,O
cells,3392,O
.,3392,O
Juglone,3393,B-CHEMICAL
is,3393,O
a,3393,O
natural,3393,O
compound,3393,O
which,3393,O
has,3393,O
been,3393,O
isolated,3393,O
from,3393,O
Juglans,3393,O
mandshurica,3393,O
Maxim,3393,O
.,3393,O
Recent,3394,O
studies,3394,O
have,3394,O
shown,3394,O
that,3394,O
juglone,3394,B-CHEMICAL
had,3394,O
various,3394,O
pharmacological,3394,O
effects,3394,O
such,3394,O
as,3394,O
anti-viral,3394,O
",",3394,O
anti-bacterial,3394,O
and,3394,O
anti-cancer,3394,O
.,3394,O
However,3395,O
",",3395,O
its,3395,O
anti-cancer,3395,O
activity,3395,O
on,3395,O
human,3395,O
prostate,3395,O
cancer,3395,O
LNCaP,3395,O
cell,3395,O
has,3395,O
not,3395,O
been,3395,O
examined,3395,O
.,3395,O
Thus,3396,O
",",3396,O
the,3396,O
current,3396,O
study,3396,O
was,3396,O
designed,3396,O
to,3396,O
elucidate,3396,O
the,3396,O
molecular,3396,O
mechanism,3396,O
of,3396,O
apoptosis,3396,O
induced,3396,O
by,3396,O
juglone,3396,B-CHEMICAL
in,3396,O
androgen-sensitive,3396,B-CHEMICAL
prostate,3396,O
cancer,3396,O
LNCaP,3396,O
cells,3396,O
.,3396,O
MTT,3397,B-CHEMICAL
assay,3397,O
was,3397,O
performed,3397,O
to,3397,O
examine,3397,O
the,3397,O
anti-proliferative,3397,O
effect,3397,O
of,3397,O
juglone,3397,B-CHEMICAL
.,3397,O
Occurrence,3398,O
of,3398,O
apoptosis,3398,O
was,3398,O
detected,3398,O
by,3398,O
Hoechst,3398,B-CHEMICAL
33342,3398,I-CHEMICAL
staining,3398,O
and,3398,O
flow,3398,O
cytometry,3398,O
in,3398,O
LNCaP,3398,O
cells,3398,O
treated,3398,O
with,3398,O
juglone,3398,B-CHEMICAL
for,3398,O
24h,3398,O
.,3398,O
The,3399,O
result,3399,O
shown,3399,O
that,3399,O
juglone,3399,B-CHEMICAL
inhibited,3399,O
the,3399,O
growth,3399,O
of,3399,O
LNCaP,3399,O
cells,3399,O
in,3399,O
a,3399,O
dose-dependent,3399,O
manner,3399,O
.,3399,O
Morphological,3400,O
changes,3400,O
of,3400,O
apoptotic,3400,O
body,3400,O
formation,3400,O
after,3400,O
juglone,3400,B-CHEMICAL
treatment,3400,O
were,3400,O
observed,3400,O
by,3400,O
Hoechst,3400,B-CHEMICAL
33342,3400,I-CHEMICAL
staining,3400,O
.,3400,O
This,3401,O
apoptotic,3401,O
induction,3401,O
was,3401,O
associated,3401,O
with,3401,O
loss,3401,O
of,3401,O
mitochondrial,3401,O
membrane,3401,O
potential,3401,O
",",3401,O
and,3401,O
caspase-3,3401,B-GENE-N
",",3401,I-GENE-N
-9,3401,I-GENE-N
activation,3401,O
.,3401,O
Moreover,3402,O
",",3402,O
we,3402,O
found,3402,O
that,3402,O
juglone,3402,B-CHEMICAL
significantly,3402,O
inhibited,3402,O
the,3402,O
expression,3402,O
levels,3402,O
of,3402,O
androgen,3402,B-GENE-Y
receptor,3402,I-GENE-Y
(,3402,O
AR,3402,B-GENE-Y
),3402,O
and,3402,O
prostate-specific,3402,B-GENE-Y
antigen,3402,I-GENE-Y
(,3402,O
PSA,3402,B-GENE-Y
),3402,O
in,3402,O
a,3402,O
dose-dependent,3402,O
manner,3402,O
",",3402,O
as,3402,O
well,3402,O
as,3402,O
abrogated,3402,O
up-regulation,3402,O
of,3402,O
AR,3402,B-GENE-Y
and,3402,O
PSA,3402,B-GENE-Y
genes,3402,O
with,3402,O
and/or,3402,O
without,3402,O
dihydrotestosterone,3402,B-CHEMICAL
(,3402,O
DHT,3402,B-CHEMICAL
),3402,O
.,3402,O
Take,3403,O
together,3403,O
",",3403,O
our,3403,O
results,3403,O
demonstrated,3403,O
that,3403,O
juglone,3403,B-CHEMICAL
might,3403,O
induce,3403,O
the,3403,O
apoptosis,3403,O
in,3403,O
LNCaP,3403,O
cell,3403,O
via,3403,O
down-regulation,3403,O
of,3403,O
AR,3403,B-GENE-Y
expression,3403,O
.,3403,O
Therefore,3404,O
",",3404,O
our,3404,O
results,3404,O
indicated,3404,O
that,3404,O
juglone,3404,B-CHEMICAL
may,3404,O
be,3404,O
a,3404,O
potential,3404,O
candidate,3404,O
of,3404,O
drug,3404,O
for,3404,O
androgen-sensitive,3404,B-CHEMICAL
prostate,3404,O
cancer,3404,O
.,3404,O
Anticancer,3405,O
activity,3405,O
of,3405,O
novel,3405,O
hybrid,3405,O
molecules,3405,O
containing,3405,O
5-benzylidene,3405,B-CHEMICAL
"thiazolidine-2,4-dione",3405,I-CHEMICAL
.,3405,O
Hybridization,3406,O
of,3406,O
two,3406,O
different,3406,O
bioactive,3406,O
molecules,3406,O
with,3406,O
different,3406,O
mechanism,3406,O
of,3406,O
action,3406,O
is,3406,O
one,3406,O
of,3406,O
the,3406,O
methods,3406,O
that,3406,O
are,3406,O
being,3406,O
adopted,3406,O
to,3406,O
treat,3406,O
cancer,3406,O
.,3406,O
Molecules,3407,O
bearing,3407,O
a,3407,O
"thiazolidine-2,4-dione",3407,B-CHEMICAL
scaffold,3407,O
have,3407,O
been,3407,O
recognized,3407,O
as,3407,O
antineoplastic,3407,O
agents,3407,O
with,3407,O
a,3407,O
broad,3407,O
spectrum,3407,O
of,3407,O
activity,3407,O
against,3407,O
many,3407,O
cancer,3407,O
cell,3407,O
lines,3407,O
.,3407,O
In,3408,O
this,3408,O
manuscript,3408,O
we,3408,O
have,3408,O
described,3408,O
the,3408,O
synthesis,3408,O
and,3408,O
biological,3408,O
evaluation,3408,O
of,3408,O
two,3408,O
series,3408,O
of,3408,O
N-3-substituted-5-arylidene,3408,B-CHEMICAL
"thiazolidine-2,4-diones",3408,I-CHEMICAL
",",3408,O
bearing,3408,O
the,3408,O
α-bromoacryloylamido,3408,B-CHEMICAL
moiety,3408,O
at,3408,O
the,3408,O
para-,3408,O
or,3408,O
meta-position,3408,O
on,3408,O
the,3408,O
phenyl,3408,B-CHEMICAL
of,3408,O
the,3408,O
arylidene,3408,B-CHEMICAL
portion,3408,O
.,3408,O
We,3409,O
have,3409,O
observed,3409,O
that,3409,O
selected,3409,O
compounds,3409,O
5a,3409,O
",",3409,O
5c,3409,O
and,3409,O
5g,3409,O
suppress,3409,O
proliferation,3409,O
of,3409,O
human,3409,O
myeloid,3409,O
leukaemia,3409,O
HL-60,3409,O
and,3409,O
U937,3409,O
cells,3409,O
by,3409,O
triggering,3409,O
morphological,3409,O
changes,3409,O
and,3409,O
internucleosomal,3409,O
DNA,3409,O
fragmentation,3409,O
",",3409,O
which,3409,O
are,3409,O
well-known,3409,O
features,3409,O
of,3409,O
apoptosis,3409,O
.,3409,O
Finally,3410,O
",",3410,O
our,3410,O
results,3410,O
indicated,3410,O
that,3410,O
the,3410,O
investigated,3410,O
compounds,3410,O
induced,3410,O
apoptotic,3410,O
cell,3410,O
death,3410,O
through,3410,O
a,3410,O
mechanism,3410,O
that,3410,O
involved,3410,O
activation,3410,O
of,3410,O
multiple,3410,O
caspases,3410,B-GENE-N
and,3410,O
was,3410,O
also,3410,O
associated,3410,O
with,3410,O
the,3410,O
release,3410,O
of,3410,O
cytochrome,3410,B-GENE-Y
c,3410,I-GENE-Y
from,3410,O
the,3410,O
mitochondria,3410,O
.,3410,O
Methylation,3411,O
damage,3411,O
to,3411,O
RNA,3411,O
induced,3411,O
in,3411,O
vivo,3411,O
in,3411,O
Escherichia,3411,O
coli,3411,O
is,3411,O
repaired,3411,O
by,3411,O
endogenous,3411,O
AlkB,3411,B-GENE-Y
as,3411,O
part,3411,O
of,3411,O
the,3411,O
adaptive,3411,O
response,3411,O
.,3411,O
Cytotoxic,3412,O
1-methyladenine,3412,B-CHEMICAL
(,3412,O
1-meA,3412,B-CHEMICAL
),3412,O
and,3412,O
3-methylcytosine,3412,B-CHEMICAL
(,3412,O
3-meC,3412,B-CHEMICAL
),3412,O
lesions,3412,O
induced,3412,O
in,3412,O
DNA,3412,O
and,3412,O
RNA,3412,O
in,3412,O
vitro,3412,O
and,3412,O
in,3412,O
pre-damaged,3412,O
DNA,3412,O
and,3412,O
RNA,3412,O
bacteriophages,3412,O
in,3412,O
vivo,3412,O
are,3412,O
repaired,3412,O
by,3412,O
the,3412,O
Escherichia,3412,B-GENE-Y
coli,3412,I-GENE-Y
(,3412,I-GENE-Y
E.,3412,I-GENE-Y
coli,3412,I-GENE-Y
),3412,I-GENE-Y
protein,3412,I-GENE-Y
AlkB,3412,I-GENE-Y
and,3412,O
a,3412,O
human,3412,B-GENE-Y
homolog,3412,I-GENE-Y
",",3412,I-GENE-Y
ALKBH3,3412,I-GENE-Y
.,3412,O
However,3413,O
",",3413,O
it,3413,O
is,3413,O
not,3413,O
known,3413,O
whether,3413,O
endogenous,3413,O
RNA,3413,O
is,3413,O
repaired,3413,O
in,3413,O
vivo,3413,O
by,3413,O
repair,3413,O
proteins,3413,O
present,3413,O
at,3413,O
physiological,3413,O
concentrations,3413,O
.,3413,O
The,3414,O
concept,3414,O
of,3414,O
RNA,3414,O
repair,3414,O
as,3414,O
a,3414,O
biologically,3414,O
relevant,3414,O
process,3414,O
has,3414,O
therefore,3414,O
remained,3414,O
elusive,3414,O
.,3414,O
Here,3415,O
",",3415,O
we,3415,O
demonstrate,3415,O
AlkB-mediated,3415,B-GENE-Y
repair,3415,O
of,3415,O
endogenous,3415,O
RNA,3415,O
in,3415,O
vivo,3415,O
by,3415,O
measuring,3415,O
differences,3415,O
in,3415,O
lesion-accumulation,3415,O
in,3415,O
two,3415,O
independent,3415,O
AlkB-proficient,3415,B-GENE-Y
and,3415,O
deficient,3415,O
E.,3415,O
coli,3415,O
strains,3415,O
during,3415,O
exposure,3415,O
to,3415,O
methyl,3415,B-CHEMICAL
methanesulfonate,3415,I-CHEMICAL
(,3415,O
MMS,3415,B-CHEMICAL
),3415,O
.,3415,O
Repair,3416,O
was,3416,O
observed,3416,O
both,3416,O
in,3416,O
AlkB-overproducing,3416,B-GENE-Y
strains,3416,O
and,3416,O
in,3416,O
the,3416,O
wild-type,3416,O
strains,3416,O
after,3416,O
AlkB,3416,B-GENE-Y
induction,3416,O
.,3416,O
RNA,3417,O
repair,3417,O
appeared,3417,O
to,3417,O
be,3417,O
highest,3417,O
in,3417,O
RNA,3417,O
species,3417,O
below,3417,O
200,3417,O
nucleotides,3417,B-CHEMICAL
in,3417,O
size,3417,O
",",3417,O
mainly,3417,O
comprising,3417,O
tRNAs,3417,O
.,3417,O
Strikingly,3418,O
",",3418,O
at,3418,O
least,3418,O
10-fold,3418,O
more,3418,O
lesions,3418,O
were,3418,O
repaired,3418,O
in,3418,O
RNA,3418,O
than,3418,O
in,3418,O
DNA,3418,O
.,3418,O
This,3419,O
may,3419,O
be,3419,O
a,3419,O
consequence,3419,O
of,3419,O
some,3419,O
30-fold,3419,O
higher,3419,O
levels,3419,O
of,3419,O
aberrant,3419,O
methylation,3419,O
in,3419,O
RNA,3419,O
than,3419,O
in,3419,O
DNA,3419,O
after,3419,O
exposure,3419,O
to,3419,O
MMS,3419,B-CHEMICAL
.,3419,O
A,3420,O
high,3420,O
primary,3420,O
kinetic,3420,O
isotope,3420,O
effect,3420,O
(,3420,O
>,3420,O
10,3420,O
),3420,O
was,3420,O
measured,3420,O
using,3420,O
a,3420,O
deuterated,3420,O
methylated,3420,O
RNA,3420,O
substrate,3420,O
",",3420,O
D3-1me,3420,O
(,3420,O
rA,3420,O
),3420,O
",",3420,O
demonstrating,3420,O
that,3420,O
it,3420,O
is,3420,O
the,3420,O
catalytic,3420,O
step,3420,O
",",3420,O
and,3420,O
not,3420,O
the,3420,O
search,3420,O
step,3420,O
that,3420,O
is,3420,O
rate-limiting,3420,O
.,3420,O
Our,3421,O
results,3421,O
demonstrate,3421,O
that,3421,O
RNA,3421,O
repair,3421,O
by,3421,O
AlkB,3421,B-GENE-Y
takes,3421,O
place,3421,O
in,3421,O
endogenous,3421,O
RNA,3421,O
as,3421,O
part,3421,O
of,3421,O
an,3421,O
adaptive,3421,O
response,3421,O
in,3421,O
wild-type,3421,O
E.,3421,O
coli,3421,O
cells,3421,O
.,3421,O
Association,3422,O
of,3422,O
serum,3422,B-GENE-Y
proprotein,3422,I-GENE-Y
convertase,3422,I-GENE-Y
subtilisin/kexin,3422,I-GENE-Y
type,3422,I-GENE-Y
9,3422,I-GENE-Y
with,3422,O
carotid,3422,O
intima,3422,O
media,3422,O
thickness,3422,O
in,3422,O
hypertensive,3422,O
subjects,3422,O
.,3422,O
OBJECTIVE,3423,O
:,3423,O
The,3423,O
clinical,3423,O
significance,3423,O
of,3423,O
the,3423,O
measurement,3423,O
of,3423,O
serum,3423,B-GENE-Y
PCSK9,3423,I-GENE-Y
(,3423,O
proprotein,3423,B-GENE-Y
subtilisin,3423,I-GENE-Y
kexin,3423,I-GENE-Y
type,3423,I-GENE-Y
9,3423,I-GENE-Y
),3423,O
is,3423,O
not,3423,O
well,3423,O
defined,3423,O
.,3423,O
This,3424,O
study,3424,O
investigated,3424,O
the,3424,O
association,3424,O
between,3424,O
serum,3424,B-GENE-Y
PCSK9,3424,I-GENE-Y
levels,3424,O
and,3424,O
atherosclerosis,3424,O
assessed,3424,O
by,3424,O
carotid,3424,O
intima,3424,O
media,3424,O
thickness,3424,O
(,3424,O
IMT,3424,O
),3424,O
in,3424,O
hypertensive,3424,O
patients,3424,O
.,3424,O
METHODS,3425,O
:,3425,O
A,3425,O
total,3425,O
of,3425,O
126,3425,O
hypertensive,3425,O
patients,3425,O
over,3425,O
the,3425,O
age,3425,O
of,3425,O
45,3425,O
were,3425,O
enrolled,3425,O
.,3425,O
The,3426,O
maximum,3426,O
carotid,3426,O
IMT,3426,O
(,3426,O
max-IMT,3426,O
),3426,O
and,3426,O
the,3426,O
mean,3426,O
carotid,3426,O
IMT,3426,O
(,3426,O
mean-IMT,3426,O
),3426,O
were,3426,O
measured,3426,O
at,3426,O
the,3426,O
time,3426,O
of,3426,O
enrollment,3426,O
.,3426,O
Clinical,3427,O
and,3427,O
laboratory,3427,O
parameters,3427,O
including,3427,O
serum,3427,B-GENE-Y
PCSK9,3427,I-GENE-Y
were,3427,O
analyzed,3427,O
.,3427,O
RESULTS,3428,O
:,3428,O
Patients,3428,O
were,3428,O
divided,3428,O
into,3428,O
tertiles,3428,O
based,3428,O
on,3428,O
serum,3428,B-GENE-Y
PCSK9,3428,I-GENE-Y
levels,3428,O
.,3428,O
After,3429,O
adjusting,3429,O
for,3429,O
age,3429,O
",",3429,O
sex,3429,O
",",3429,O
total,3429,O
cholesterol,3429,B-CHEMICAL
",",3429,O
HDL-cholesterol,3429,B-GENE-N
and,3429,O
triglyceride,3429,B-CHEMICAL
",",3429,O
max-IMT,3429,O
was,3429,O
significantly,3429,O
increased,3429,O
in,3429,O
the,3429,O
highest,3429,O
tertile,3429,O
of,3429,O
serum,3429,B-GENE-Y
PCSK9,3429,I-GENE-Y
(,3429,O
0.969±0.033,3429,O
vs,3429,O
0.959±0.033,3429,O
vs,3429,O
1.077±0.033mm,3429,O
",",3429,O
respectively,3429,O
;,3429,O
P=0.026,3429,O
),3429,O
.,3429,O
Mean-IMT,3430,O
showed,3430,O
a,3430,O
tendency,3430,O
to,3430,O
increase,3430,O
across,3430,O
the,3430,O
tertile,3430,O
groups,3430,O
(,3430,O
0.773±0.025,3430,O
vs,3430,O
0.790±0.026,3430,O
vs,3430,O
0.856±0.025mm,3430,O
",",3430,O
respectively,3430,O
;,3430,O
P=0.059,3430,O
),3430,O
.,3430,O
Multivariate,3431,O
regression,3431,O
analysis,3431,O
revealed,3431,O
that,3431,O
serum,3431,B-GENE-Y
PCSK9,3431,I-GENE-Y
was,3431,O
independently,3431,O
associated,3431,O
with,3431,O
carotid,3431,O
IMT,3431,O
(,3431,O
max-IMT,3431,O
:,3431,O
β=0.212,3431,O
",",3431,O
P=0.016,3431,O
;,3431,O
mean-IMT,3431,O
:,3431,O
β=0.184,3431,O
",",3431,O
P=0.04,3431,O
),3431,O
.,3431,O
CONCLUSION,3432,O
:,3432,O
The,3432,O
present,3432,O
study,3432,O
is,3432,O
the,3432,O
first,3432,O
to,3432,O
report,3432,O
the,3432,O
association,3432,O
between,3432,O
serum,3432,B-GENE-Y
PCSK9,3432,I-GENE-Y
levels,3432,O
and,3432,O
carotid,3432,O
IMT,3432,O
in,3432,O
hypertensive,3432,O
patients,3432,O
.,3432,O
These,3433,O
results,3433,O
suggest,3433,O
that,3433,O
serum,3433,B-GENE-Y
PCSK9,3433,I-GENE-Y
may,3433,O
have,3433,O
a,3433,O
certain,3433,O
role,3433,O
in,3433,O
early,3433,O
pathogenesis,3433,O
of,3433,O
atherosclerosis,3433,O
.,3433,O
Astemizole,3434,B-CHEMICAL
",",3434,O
a,3434,O
potent,3434,O
histamine,3434,B-GENE-Y
H1-receptor,3434,I-GENE-Y
antagonist,3434,O
:,3434,O
effect,3434,O
in,3434,O
allergic,3434,O
rhinoconjunctivitis,3434,O
",",3434,O
on,3434,O
antigen,3434,O
and,3434,O
histamine,3434,B-CHEMICAL
induced,3434,O
skin,3434,O
weal,3434,O
responses,3434,O
and,3434,O
relationship,3434,O
to,3434,O
serum,3434,O
levels,3434,O
.,3434,O
The,3435,O
efficacy,3435,O
of,3435,O
astemizole,3435,B-CHEMICAL
",",3435,O
a,3435,O
new,3435,O
",",3435,O
long,3435,O
acting,3435,O
",",3435,O
oral,3435,O
histamine,3435,B-GENE-Y
H1-receptor,3435,I-GENE-Y
antagonist,3435,O
was,3435,O
compared,3435,O
to,3435,O
placebo,3435,O
for,3435,O
the,3435,O
treatment,3435,O
of,3435,O
allergic,3435,O
rhinitis,3435,O
and,3435,O
conjunctivitis,3435,O
during,3435,O
the,3435,O
grass,3435,O
pollen,3435,O
season,3435,O
of,3435,O
1982,3435,O
.,3435,O
Sixty-three,3436,O
patients,3436,O
with,3436,O
a,3436,O
positive,3436,O
skin,3436,O
prick,3436,O
test,3436,O
to,3436,O
grass,3436,O
pollen,3436,O
and,3436,O
current,3436,O
symptoms,3436,O
participated,3436,O
in,3436,O
an,3436,O
8,3436,O
week,3436,O
",",3436,O
double-blind,3436,O
",",3436,O
randomized,3436,O
study,3436,O
.,3436,O
Astemizole,3437,B-CHEMICAL
",",3437,O
10,3437,O
mg,3437,O
",",3437,O
was,3437,O
significantly,3437,O
better,3437,O
than,3437,O
placebo,3437,O
in,3437,O
alleviating,3437,O
both,3437,O
nose,3437,O
(,3437,O
P,3437,O
less,3437,O
than,3437,O
0.05,3437,O
),3437,O
and,3437,O
eye,3437,O
(,3437,O
P,3437,O
less,3437,O
than,3437,O
0.01,3437,O
),3437,O
symptoms,3437,O
despite,3437,O
significantly,3437,O
greater,3437,O
use,3437,O
of,3437,O
the,3437,O
reserve,3437,O
medication,3437,O
",",3437,O
clemastine,3437,B-CHEMICAL
",",3437,O
by,3437,O
the,3437,O
placebo,3437,O
group,3437,O
(,3437,O
P,3437,O
less,3437,O
than,3437,O
0.003,3437,O
),3437,O
.,3437,O
There,3438,O
was,3438,O
a,3438,O
lag,3438,O
period,3438,O
of,3438,O
5,3438,O
days,3438,O
after,3438,O
initiation,3438,O
of,3438,O
therapy,3438,O
before,3438,O
treatment,3438,O
benefit,3438,O
became,3438,O
manifest,3438,O
.,3438,O
Subdivision,3439,O
of,3439,O
nasal,3439,O
symptoms,3439,O
indicated,3439,O
significant,3439,O
improvement,3439,O
compared,3439,O
to,3439,O
placebo,3439,O
over,3439,O
the,3439,O
8,3439,O
weeks,3439,O
for,3439,O
sneezing,3439,O
(,3439,O
P,3439,O
less,3439,O
than,3439,O
0.05,3439,O
),3439,O
and,3439,O
runny,3439,O
nose,3439,O
(,3439,O
P,3439,O
less,3439,O
than,3439,O
0.05,3439,O
),3439,O
but,3439,O
not,3439,O
blocked,3439,O
nose,3439,O
.,3439,O
The,3440,O
absence,3440,O
of,3440,O
effect,3440,O
on,3440,O
nasal,3440,O
blockage,3440,O
was,3440,O
confirmed,3440,O
by,3440,O
parallel,3440,O
measurement,3440,O
of,3440,O
nasal,3440,O
calibre,3440,O
by,3440,O
body,3440,O
plethysmography,3440,O
.,3440,O
The,3441,O
antihistaminic,3441,O
potency,3441,O
of,3441,O
astemizole,3441,B-CHEMICAL
was,3441,O
indicated,3441,O
by,3441,O
an,3441,O
80,3441,O
%,3441,O
inhibition,3441,O
of,3441,O
the,3441,O
histamine,3441,B-CHEMICAL
induced,3441,O
skin,3441,O
weal,3441,O
response,3441,O
after,3441,O
8,3441,O
weeks,3441,O
therapy,3441,O
.,3441,O
A,3442,O
positive,3442,O
correlation,3442,O
was,3442,O
found,3442,O
between,3442,O
serum,3442,O
drug,3442,O
levels,3442,O
and,3442,O
%,3442,O
inhibition,3442,O
of,3442,O
histamine,3442,B-CHEMICAL
skin,3442,O
weal,3442,O
(,3442,O
r,3442,O
=,3442,O
0.64,3442,O
",",3442,O
P,3442,O
less,3442,O
than,3442,O
0.001,3442,O
),3442,O
.,3442,O
Astemizole,3443,B-CHEMICAL
was,3443,O
free,3443,O
from,3443,O
adverse,3443,O
sedative,3443,O
or,3443,O
anticholinergic,3443,O
effects,3443,O
but,3443,O
did,3443,O
cause,3443,O
a,3443,O
mean,3443,O
increase,3443,O
in,3443,O
weight,3443,O
of,3443,O
1.3,3443,O
kg,3443,O
(,3443,O
P,3443,O
less,3443,O
than,3443,O
0.01,3443,O
),3443,O
after,3443,O
8,3443,O
weeks,3443,O
therapy,3443,O
",",3443,O
not,3443,O
found,3443,O
with,3443,O
placebo,3443,O
.,3443,O
Rivastigmine,3444,B-CHEMICAL
for,3444,O
Alzheimer,3444,O
's,3444,O
disease,3444,O
.,3444,O
BACKGROUND,3445,O
:,3445,O
Alzheimer,3445,O
's,3445,O
disease,3445,O
(,3445,O
AD,3445,O
),3445,O
is,3445,O
the,3445,O
commonest,3445,O
cause,3445,O
of,3445,O
dementia,3445,O
affecting,3445,O
older,3445,O
people,3445,O
.,3445,O
One,3446,O
of,3446,O
the,3446,O
therapeutic,3446,O
strategies,3446,O
aimed,3446,O
at,3446,O
ameliorating,3446,O
the,3446,O
clinical,3446,O
manifestations,3446,O
of,3446,O
Alzheimer,3446,O
's,3446,O
disease,3446,O
is,3446,O
to,3446,O
enhance,3446,O
cholinergic,3446,O
neurotransmission,3446,O
in,3446,O
relevant,3446,O
parts,3446,O
of,3446,O
the,3446,O
brain,3446,O
by,3446,O
the,3446,O
use,3446,O
of,3446,O
cholinesterase,3446,B-GENE-Y
inhibitors,3446,O
to,3446,O
delay,3446,O
the,3446,O
breakdown,3446,O
of,3446,O
acetylcholine,3446,B-CHEMICAL
released,3446,O
into,3446,O
synaptic,3446,O
clefts,3446,O
.,3446,O
Tacrine,3447,B-CHEMICAL
",",3447,O
the,3447,O
first,3447,O
of,3447,O
the,3447,O
cholinesterase,3447,B-GENE-Y
inhibitors,3447,O
to,3447,O
undergo,3447,O
extensive,3447,O
trials,3447,O
for,3447,O
this,3447,O
purpose,3447,O
",",3447,O
was,3447,O
associated,3447,O
with,3447,O
significant,3447,O
adverse,3447,O
effects,3447,O
including,3447,O
hepatotoxicity,3447,O
.,3447,O
Other,3448,O
cholinesterase,3448,B-GENE-Y
inhibitors,3448,O
",",3448,O
including,3448,O
rivastigmine,3448,B-CHEMICAL
",",3448,O
with,3448,O
superior,3448,O
properties,3448,O
in,3448,O
terms,3448,O
of,3448,O
specificity,3448,O
of,3448,O
action,3448,O
and,3448,O
low,3448,O
risk,3448,O
of,3448,O
adverse,3448,O
effects,3448,O
",",3448,O
have,3448,O
now,3448,O
been,3448,O
introduced,3448,O
.,3448,O
Rivastigmine,3449,B-CHEMICAL
has,3449,O
received,3449,O
approval,3449,O
for,3449,O
use,3449,O
in,3449,O
60,3449,O
countries,3449,O
including,3449,O
all,3449,O
member,3449,O
states,3449,O
of,3449,O
the,3449,O
European,3449,O
Union,3449,O
and,3449,O
the,3449,O
USA,3449,O
.,3449,O
OBJECTIVES,3450,O
:,3450,O
To,3450,O
determine,3450,O
the,3450,O
clinical,3450,O
efficacy,3450,O
and,3450,O
safety,3450,O
of,3450,O
rivastigmine,3450,B-CHEMICAL
for,3450,O
patients,3450,O
with,3450,O
dementia,3450,O
of,3450,O
Alzheimer,3450,O
's,3450,O
type,3450,O
.,3450,O
SEARCH,3451,O
STRATEGY,3451,O
:,3451,O
The,3451,O
Specialized,3451,O
Register,3451,O
of,3451,O
the,3451,O
Cochrane,3451,O
Dementia,3451,O
and,3451,O
Cognitive,3451,O
Improvement,3451,O
Group,3451,O
(,3451,O
CDCIG,3451,O
),3451,O
",",3451,O
The,3451,O
Cochrane,3451,O
Library,3451,O
",",3451,O
MEDLINE,3451,O
",",3451,O
EMBASE,3451,O
",",3451,O
PsycINFO,3451,O
",",3451,O
CINAHL,3451,O
and,3451,O
LILACS,3451,O
were,3451,O
searched,3451,O
on,3451,O
27,3451,O
March,3451,O
2008,3451,O
using,3451,O
the,3451,O
terms,3451,O
:,3451,O
Rivastigmine,3451,B-CHEMICAL
OR,3451,O
exelon,3451,B-CHEMICAL
OR,3451,O
ENA,3451,B-CHEMICAL
OR,3451,O
``,3451,O
SDZ,3451,B-CHEMICAL
ENA,3451,I-CHEMICAL
713,3451,I-CHEMICAL
'',3451,O
.,3451,O
The,3452,O
CDCIG,3452,O
Specialized,3452,O
Register,3452,O
contains,3452,O
records,3452,O
from,3452,O
all,3452,O
major,3452,O
health,3452,O
care,3452,O
databases,3452,O
(,3452,O
The,3452,O
Cochrane,3452,O
Library,3452,O
",",3452,O
MEDLINE,3452,O
",",3452,O
EMBASE,3452,O
",",3452,O
PsycINFO,3452,O
",",3452,O
CINAHL,3452,O
",",3452,O
LILACS,3452,O
),3452,O
as,3452,O
well,3452,O
as,3452,O
from,3452,O
many,3452,O
clinical,3452,O
trials,3452,O
registries,3452,O
and,3452,O
grey,3452,O
literature,3452,O
sources,3452,O
.,3452,O
SELECTION,3453,O
CRITERIA,3453,O
:,3453,O
All,3453,O
unconfounded,3453,O
",",3453,O
double-blind,3453,O
",",3453,O
randomized,3453,O
trials,3453,O
in,3453,O
which,3453,O
treatment,3453,O
with,3453,O
rivastigmine,3453,B-CHEMICAL
was,3453,O
administered,3453,O
to,3453,O
patients,3453,O
with,3453,O
dementia,3453,O
of,3453,O
the,3453,O
Alzheimer,3453,O
's,3453,O
type,3453,O
for,3453,O
more,3453,O
than,3453,O
two,3453,O
weeks,3453,O
and,3453,O
its,3453,O
effects,3453,O
compared,3453,O
with,3453,O
those,3453,O
of,3453,O
placebo,3453,O
in,3453,O
a,3453,O
parallel,3453,O
group,3453,O
of,3453,O
patients,3453,O
.,3453,O
DATA,3454,O
COLLECTION,3454,O
AND,3454,O
ANALYSIS,3454,O
:,3454,O
One,3454,O
reviewer,3454,O
(,3454,O
JSB,3454,O
),3454,O
applied,3454,O
study,3454,O
selection,3454,O
criteria,3454,O
",",3454,O
assessed,3454,O
the,3454,O
quality,3454,O
of,3454,O
studies,3454,O
and,3454,O
extracted,3454,O
data,3454,O
.,3454,O
MAIN,3455,O
RESULTS,3455,O
:,3455,O
Nine,3455,O
trials,3455,O
",",3455,O
involving,3455,O
4775,3455,O
participants,3455,O
",",3455,O
were,3455,O
included,3455,O
in,3455,O
the,3455,O
analyses,3455,O
.,3455,O
Use,3456,O
of,3456,O
rivastigmine,3456,B-CHEMICAL
in,3456,O
high,3456,O
doses,3456,O
was,3456,O
associated,3456,O
with,3456,O
statistically,3456,O
significant,3456,O
benefits,3456,O
on,3456,O
several,3456,O
measures,3456,O
.,3456,O
High-dose,3457,O
rivastigmine,3457,B-CHEMICAL
(,3457,O
6,3457,O
to,3457,O
12,3457,O
mg,3457,O
daily,3457,O
),3457,O
was,3457,O
associated,3457,O
with,3457,O
a,3457,O
two-point,3457,O
improvement,3457,O
in,3457,O
cognitive,3457,O
function,3457,O
on,3457,O
the,3457,O
ADAS-Cog,3457,O
score,3457,O
compared,3457,O
with,3457,O
placebo,3457,O
(,3457,O
weighted,3457,O
mean,3457,O
difference,3457,O
-1.99,3457,O
",",3457,O
95,3457,O
%,3457,O
confidence,3457,O
interval,3457,O
-2.49,3457,O
to,3457,O
-1.50,3457,O
",",3457,O
on,3457,O
an,3457,O
intention-to-treat,3457,O
basis,3457,O
),3457,O
and,3457,O
a,3457,O
2.2,3457,O
point,3457,O
improvement,3457,O
in,3457,O
activities,3457,O
of,3457,O
daily,3457,O
living,3457,O
assessed,3457,O
on,3457,O
the,3457,O
Progressive,3457,O
Deterioration,3457,O
Scale,3457,O
(,3457,O
weighted,3457,O
mean,3457,O
difference,3457,O
-2.15,3457,O
",",3457,O
95,3457,O
%,3457,O
confidence,3457,O
interval,3457,O
-3.16,3457,O
to,3457,O
-1.13,3457,O
",",3457,O
on,3457,O
an,3457,O
intention-to-treat,3457,O
basis,3457,O
),3457,O
at,3457,O
26,3457,O
weeks,3457,O
.,3457,O
At,3458,O
lower,3458,O
doses,3458,O
(,3458,O
4,3458,O
mg,3458,O
daily,3458,O
or,3458,O
lower,3458,O
),3458,O
differences,3458,O
were,3458,O
in,3458,O
the,3458,O
same,3458,O
direction,3458,O
but,3458,O
were,3458,O
statistically,3458,O
significant,3458,O
only,3458,O
for,3458,O
cognitive,3458,O
function,3458,O
.,3458,O
There,3459,O
were,3459,O
statistically,3459,O
significantly,3459,O
higher,3459,O
numbers,3459,O
of,3459,O
events,3459,O
of,3459,O
nausea,3459,O
",",3459,O
vomiting,3459,O
",",3459,O
diarrhoea,3459,O
",",3459,O
anorexia,3459,O
",",3459,O
headache,3459,O
",",3459,O
syncope,3459,O
",",3459,O
abdominal,3459,O
pain,3459,O
and,3459,O
dizziness,3459,O
among,3459,O
patients,3459,O
taking,3459,O
high-dose,3459,O
rivastigmine,3459,B-CHEMICAL
than,3459,O
among,3459,O
those,3459,O
taking,3459,O
placebo,3459,O
.,3459,O
There,3460,O
was,3460,O
some,3460,O
evidence,3460,O
that,3460,O
adverse,3460,O
events,3460,O
might,3460,O
be,3460,O
less,3460,O
common,3460,O
with,3460,O
more,3460,O
frequent,3460,O
",",3460,O
smaller,3460,O
doses,3460,O
of,3460,O
rivastigmine,3460,B-CHEMICAL
.,3460,O
The,3461,O
2008,3461,O
update,3461,O
includes,3461,O
a,3461,O
new,3461,O
study,3461,O
testing,3461,O
two,3461,O
types,3461,O
of,3461,O
rivastigmine,3461,B-CHEMICAL
transdermal,3461,O
patch,3461,O
",",3461,O
one,3461,O
delivering,3461,O
a,3461,O
higher,3461,O
dose,3461,O
than,3461,O
previously,3461,O
tested,3461,O
(,3461,O
17.4,3461,O
mg/day,3461,O
),3461,O
and,3461,O
a,3461,O
smaller,3461,O
patch,3461,O
delivering,3461,O
9.6,3461,O
mg/day,3461,O
.,3461,O
The,3462,O
efficacy,3462,O
of,3462,O
the,3462,O
smaller,3462,O
patch,3462,O
was,3462,O
not,3462,O
significantly,3462,O
different,3462,O
compared,3462,O
with,3462,O
the,3462,O
capsules,3462,O
of,3462,O
similar,3462,O
daily,3462,O
dose,3462,O
",",3462,O
but,3462,O
was,3462,O
associated,3462,O
with,3462,O
significantly,3462,O
fewer,3462,O
adverse,3462,O
events,3462,O
of,3462,O
nausea,3462,O
",",3462,O
vomiting,3462,O
",",3462,O
dizziness,3462,O
and,3462,O
asthenia,3462,O
.,3462,O
The,3463,O
efficacy,3463,O
of,3463,O
the,3463,O
larger,3463,O
patch,3463,O
was,3463,O
not,3463,O
significantly,3463,O
different,3463,O
compared,3463,O
with,3463,O
the,3463,O
smaller,3463,O
patch,3463,O
",",3463,O
but,3463,O
the,3463,O
smaller,3463,O
patch,3463,O
was,3463,O
associated,3463,O
with,3463,O
significantly,3463,O
fewer,3463,O
adverse,3463,O
events,3463,O
of,3463,O
nausea,3463,O
",",3463,O
vomiting,3463,O
",",3463,O
weight,3463,O
loss,3463,O
and,3463,O
dizziness,3463,O
.,3463,O
There,3464,O
appears,3464,O
to,3464,O
be,3464,O
advantages,3464,O
associated,3464,O
with,3464,O
the,3464,O
smaller,3464,O
patch,3464,O
compared,3464,O
with,3464,O
both,3464,O
the,3464,O
higher,3464,O
dose,3464,O
patch,3464,O
and,3464,O
the,3464,O
6-12,3464,O
mg/day,3464,O
capsules,3464,O
.,3464,O
AUTHORS,3465,O
',3465,O
CONCLUSIONS,3465,O
:,3465,O
Rivastigmine,3465,B-CHEMICAL
appears,3465,O
to,3465,O
be,3465,O
beneficial,3465,O
for,3465,O
people,3465,O
with,3465,O
mild,3465,O
to,3465,O
moderate,3465,O
Alzheimer,3465,O
's,3465,O
disease,3465,O
.,3465,O
In,3466,O
comparisons,3466,O
with,3466,O
placebo,3466,O
",",3466,O
improvements,3466,O
were,3466,O
seen,3466,O
in,3466,O
the,3466,O
rate,3466,O
of,3466,O
decline,3466,O
of,3466,O
cognitive,3466,O
function,3466,O
",",3466,O
activities,3466,O
of,3466,O
daily,3466,O
living,3466,O
",",3466,O
and,3466,O
severity,3466,O
of,3466,O
dementia,3466,O
with,3466,O
daily,3466,O
doses,3466,O
of,3466,O
6,3466,O
to,3466,O
12,3466,O
mg,3466,O
.,3466,O
Adverse,3467,O
events,3467,O
were,3467,O
consistent,3467,O
with,3467,O
the,3467,O
cholinergic,3467,O
actions,3467,O
of,3467,O
the,3467,O
drug,3467,O
.,3467,O
A,3468,O
transdermal,3468,O
patch,3468,O
has,3468,O
been,3468,O
tested,3468,O
in,3468,O
one,3468,O
trial,3468,O
",",3468,O
and,3468,O
there,3468,O
is,3468,O
evidence,3468,O
that,3468,O
the,3468,O
lower,3468,O
dose,3468,O
smaller,3468,O
patch,3468,O
is,3468,O
associated,3468,O
with,3468,O
fewer,3468,O
side,3468,O
effects,3468,O
than,3468,O
the,3468,O
capsules,3468,O
or,3468,O
the,3468,O
higher,3468,O
dose,3468,O
larger,3468,O
patch,3468,O
and,3468,O
has,3468,O
comparable,3468,O
efficacy,3468,O
to,3468,O
both,3468,O
.,3468,O
This,3469,O
review,3469,O
has,3469,O
not,3469,O
examined,3469,O
economic,3469,O
data,3469,O
.,3469,O
NHE3,3470,B-GENE-Y
inhibition,3470,O
activates,3470,O
duodenal,3470,O
bicarbonate,3470,O
secretion,3470,O
in,3470,O
the,3470,O
rat,3470,O
.,3470,O
We,3471,O
examined,3471,O
the,3471,O
effect,3471,O
of,3471,O
inhibition,3471,O
of,3471,O
Na+/H+,3471,B-GENE-N
exchange,3471,I-GENE-N
(,3471,O
NHE,3471,B-GENE-N
),3471,O
on,3471,O
duodenal,3471,O
bicarbonate,3471,O
secretion,3471,O
(,3471,O
DBS,3471,O
),3471,O
in,3471,O
rats,3471,O
to,3471,O
further,3471,O
understand,3471,O
DBS,3471,O
regulation,3471,O
.,3471,O
DBS,3472,O
was,3472,O
measured,3472,O
by,3472,O
using,3472,O
the,3472,O
pH-stat,3472,O
method,3472,O
and,3472,O
by,3472,O
using,3472,O
CO2-sensitive,3472,B-CHEMICAL
electrodes,3472,O
.,3472,O
5-,3473,B-CHEMICAL
(,3473,I-CHEMICAL
N,3473,I-CHEMICAL
",",3473,I-CHEMICAL
N-dimethyl,3473,I-CHEMICAL
),3473,I-CHEMICAL
-amiloride,3473,I-CHEMICAL
(,3473,O
50,3473,O
microM,3473,O
;,3473,O
DMA,3473,B-CHEMICAL
),3473,O
",",3473,O
a,3473,O
concentration,3473,O
that,3473,O
selectively,3473,O
inhibits,3473,O
the,3473,O
NHE,3473,B-GENE-N
isoforms,3473,O
NHE1,3473,B-GENE-Y
and,3473,O
NHE2,3473,B-GENE-Y
",",3473,O
but,3473,O
not,3473,O
NHE3,3473,B-GENE-Y
",",3473,O
did,3473,O
not,3473,O
affect,3473,O
DBS,3473,O
.,3473,O
Nevertheless,3474,O
",",3474,O
3,3474,O
mM,3474,O
DMA,3474,B-CHEMICAL
",",3474,O
a,3474,O
higher,3474,O
concentration,3474,O
that,3474,O
inhibits,3474,O
NHE1,3474,B-GENE-Y
",",3474,O
NHE2,3474,B-GENE-Y
",",3474,O
and,3474,O
NHE3,3474,B-GENE-Y
",",3474,O
significantly,3474,O
increased,3474,O
DBS,3474,O
.,3474,O
Moreover,3475,O
",",3475,O
S1611,3475,B-CHEMICAL
and,3475,O
S3226,3475,B-CHEMICAL
",",3475,O
both,3475,O
specific,3475,O
inhibitors,3475,O
of,3475,O
NHE3,3475,B-GENE-Y
only,3475,O
",",3475,O
or,3475,O
perfusion,3475,O
with,3475,O
Na+-free,3475,B-CHEMICAL
solutions,3475,O
",",3475,O
dose,3475,O
dependently,3475,O
increased,3475,O
DBS,3475,O
",",3475,O
as,3475,O
measured,3475,O
by,3475,O
pH-stat,3475,O
and,3475,O
CO2-sensitive,3475,B-CHEMICAL
electrode,3475,O
",",3475,O
without,3475,O
affecting,3475,O
intracellular,3475,O
pH,3475,O
.,3475,O
Coperfusion,3476,O
with,3476,O
0.1,3476,O
microM,3476,O
indomethacin,3476,B-CHEMICAL
",",3476,O
0.5,3476,O
mM,3476,O
DIDS,3476,O
",",3476,O
or,3476,O
1,3476,O
mM,3476,O
methazolamide,3476,B-CHEMICAL
did,3476,O
not,3476,O
affect,3476,O
S3226-induced,3476,B-CHEMICAL
DBS,3476,O
.,3476,O
Nevertheless,3477,O
",",3477,O
coperfusion,3477,O
with,3477,O
0.1,3477,O
and,3477,O
0.3,3477,O
mM,3477,O
5-nitro-2-,3477,B-CHEMICAL
(,3477,I-CHEMICAL
3-phenylpropylamino,3477,I-CHEMICAL
),3477,I-CHEMICAL
benzoic,3477,I-CHEMICAL
acid,3477,I-CHEMICAL
",",3477,O
which,3477,O
inhibits,3477,O
the,3477,O
cystic,3477,B-GENE-Y
fibrosis,3477,I-GENE-Y
transmembrane,3477,I-GENE-Y
conductor,3477,I-GENE-Y
regulator,3477,I-GENE-Y
(,3477,O
CFTR,3477,B-GENE-Y
),3477,O
",",3477,O
dose,3477,O
dependently,3477,O
inhibited,3477,O
S3226-induced,3477,B-CHEMICAL
DBS,3477,O
.,3477,O
In,3478,O
conclusion,3478,O
",",3478,O
only,3478,O
specific,3478,O
apical,3478,O
NHE3,3478,B-GENE-Y
inhibition,3478,O
increased,3478,O
DBS,3478,O
",",3478,O
whereas,3478,O
prostaglandin,3478,B-CHEMICAL
synthesis,3478,O
",",3478,O
Na+-HCO3-,3478,B-GENE-Y
cotransporter,3478,I-GENE-Y
activation,3478,O
",",3478,O
or,3478,O
intracellular,3478,O
HCO3-,3478,B-CHEMICAL
formation,3478,O
by,3478,O
carbonic,3478,B-GENE-N
anhydrase,3478,I-GENE-N
was,3478,O
not,3478,O
involved,3478,O
.,3478,O
Because,3479,O
NHE3,3479,B-GENE-Y
inhibition-increased,3479,O
DBS,3479,O
was,3479,O
inhibited,3479,O
by,3479,O
an,3479,O
anion,3479,B-GENE-N
channel,3479,I-GENE-N
inhibitor,3479,O
and,3479,O
because,3479,O
reciprocal,3479,O
CFTR,3479,B-GENE-Y
regulation,3479,O
has,3479,O
been,3479,O
previously,3479,O
shown,3479,O
between,3479,O
NHE3,3479,B-GENE-Y
and,3479,O
apical,3479,B-GENE-N
membrane,3479,I-GENE-N
anion,3479,I-GENE-N
transporters,3479,I-GENE-N
",",3479,O
we,3479,O
speculate,3479,O
that,3479,O
NHE3,3479,B-GENE-Y
inhibition,3479,O
increased,3479,O
DBS,3479,O
by,3479,O
altering,3479,O
anion,3479,O
transporter,3479,I-GENE-N
function,3479,O
.,3479,O
The,3480,O
Prevalence,3480,O
of,3480,O
Meeting,3480,O
A1C,3480,B-GENE-Y
",",3480,O
Blood,3480,O
Pressure,3480,O
",",3480,O
and,3480,O
LDL,3480,B-GENE-N
Goals,3480,O
Among,3480,O
People,3480,O
With,3480,O
Diabetes,3480,O
",",3480,O
1988-2010,3480,O
.,3480,O
OBJECTIVETo,3481,O
determine,3481,O
the,3481,O
prevalence,3481,O
of,3481,O
people,3481,O
with,3481,O
diabetes,3481,O
who,3481,O
meet,3481,O
hemoglobin,3481,B-GENE-Y
A,3481,I-GENE-Y
(,3481,I-GENE-Y
1c,3481,I-GENE-Y
),3481,I-GENE-Y
(,3481,O
A1C,3481,B-GENE-Y
),3481,O
",",3481,O
blood,3481,O
pressure,3481,O
(,3481,O
BP,3481,O
),3481,O
",",3481,O
and,3481,O
LDL,3481,B-GENE-N
cholesterol,3481,B-CHEMICAL
(,3481,O
ABC,3481,O
),3481,O
recommendations,3481,O
",",3481,O
and,3481,O
their,3481,O
current,3481,O
statin,3481,O
use,3481,O
",",3481,O
factors,3481,O
associated,3481,O
with,3481,O
goal,3481,O
achievement,3481,O
",",3481,O
and,3481,O
changes,3481,O
in,3481,O
the,3481,O
proportion,3481,O
achieving,3481,O
goals,3481,O
between,3481,O
1988,3481,O
and,3481,O
2010.RESEARCH,3481,O
AND,3481,O
DESIGN,3481,O
METHODSData,3481,O
were,3481,O
cross-sectional,3481,O
from,3481,O
the,3481,O
National,3481,O
Health,3481,O
and,3481,O
Nutrition,3481,O
Examination,3481,O
Surveys,3481,O
(,3481,O
NHANES,3481,O
),3481,O
from,3481,O
1988-1994,3481,O
",",3481,O
1999-2002,3481,O
",",3481,O
2003-2006,3481,O
",",3481,O
and,3481,O
2007-2010,3481,O
.,3481,O
Participants,3482,O
were,3482,O
"4,926",3482,O
adults,3482,O
aged,3482,O
≥20,3482,O
years,3482,O
who,3482,O
self-reported,3482,O
a,3482,O
previous,3482,O
diagnosis,3482,O
of,3482,O
diabetes,3482,O
and,3482,O
completed,3482,O
the,3482,O
household,3482,O
interview,3482,O
and,3482,O
physical,3482,O
examination,3482,O
(,3482,O
n,3482,O
=,3482,O
"1,558",3482,O
for,3482,O
valid,3482,O
LDL,3482,O
levels,3482,O
),3482,O
.,3482,O
Main,3483,O
outcome,3483,O
measures,3483,O
were,3483,O
A1C,3483,B-GENE-Y
",",3483,O
BP,3483,O
",",3483,O
and,3483,O
LDL,3483,B-GENE-N
cholesterol,3483,B-CHEMICAL
",",3483,O
in,3483,O
accordance,3483,O
with,3483,O
the,3483,O
American,3483,O
Diabetes,3483,O
Association,3483,O
recommendations,3483,O
",",3483,O
and,3483,O
current,3483,O
use,3483,O
of,3483,O
statins.RESULTSIn,3483,O
2007-2010,3483,O
",",3483,O
52.5,3483,O
%,3483,O
of,3483,O
people,3483,O
with,3483,O
diabetes,3483,O
achieved,3483,O
A1C,3483,B-GENE-Y
<,3483,O
7.0,3483,O
%,3483,O
(,3483,O
<,3483,O
53,3483,O
mmol/mol,3483,O
),3483,O
",",3483,O
51.1,3483,O
%,3483,O
achieved,3483,O
BP,3483,O
<,3483,O
130/80,3483,O
mmHg,3483,O
",",3483,O
56.2,3483,O
%,3483,O
achieved,3483,O
LDL,3483,B-GENE-N
<,3483,O
100,3483,O
mg/dL,3483,O
",",3483,O
and,3483,O
18.8,3483,O
%,3483,O
achieved,3483,O
all,3483,O
three,3483,O
ABCs,3483,O
.,3483,O
These,3484,O
levels,3484,O
of,3484,O
control,3484,O
were,3484,O
significant,3484,O
improvements,3484,O
from,3484,O
1988,3484,O
to,3484,O
1994,3484,O
(,3484,O
all,3484,O
P,3484,O
<,3484,O
0.05,3484,O
),3484,O
.,3484,O
Statin,3485,O
use,3485,O
significantly,3485,O
increased,3485,O
between,3485,O
1988-1994,3485,O
(,3485,O
4.2,3485,O
%,3485,O
),3485,O
and,3485,O
2007-2010,3485,O
(,3485,O
51.4,3485,O
%,3485,O
",",3485,O
P,3485,O
<,3485,O
0.01,3485,O
),3485,O
.,3485,O
Compared,3486,O
with,3486,O
non-Hispanic,3486,O
whites,3486,O
",",3486,O
Mexican,3486,O
Americans,3486,O
were,3486,O
less,3486,O
likely,3486,O
to,3486,O
meet,3486,O
A1C,3486,B-GENE-Y
and,3486,O
LDL,3486,B-GENE-N
goals,3486,O
(,3486,O
P,3486,O
<,3486,O
0.03,3486,O
),3486,O
",",3486,O
and,3486,O
non-Hispanic,3486,O
blacks,3486,O
were,3486,O
less,3486,O
likely,3486,O
to,3486,O
meet,3486,O
BP,3486,O
and,3486,O
LDL,3486,B-GENE-N
goals,3486,O
(,3486,O
P,3486,O
<,3486,O
0.02,3486,O
),3486,O
.,3486,O
Compared,3487,O
with,3487,O
non-Hispanic,3487,O
blacks,3487,O
",",3487,O
Mexican,3487,O
Americans,3487,O
were,3487,O
less,3487,O
likely,3487,O
to,3487,O
meet,3487,O
A1C,3487,B-GENE-Y
goals,3487,O
(,3487,O
P,3487,O
<,3487,O
0.01,3487,O
),3487,O
.,3487,O
Younger,3488,O
individuals,3488,O
were,3488,O
less,3488,O
likely,3488,O
to,3488,O
meet,3488,O
A1C,3488,B-GENE-Y
and,3488,O
LDL,3488,B-GENE-N
goals.CONCLUSIONSDespite,3488,O
significant,3488,O
improvement,3488,O
during,3488,O
the,3488,O
past,3488,O
decade,3488,O
",",3488,O
achieving,3488,O
the,3488,O
ABC,3488,O
goals,3488,O
remains,3488,O
suboptimal,3488,O
among,3488,O
adults,3488,O
with,3488,O
diabetes,3488,O
",",3488,O
particularly,3488,O
in,3488,O
some,3488,O
minority,3488,O
groups,3488,O
.,3488,O
Substantial,3489,O
opportunity,3489,O
exists,3489,O
to,3489,O
further,3489,O
improve,3489,O
diabetes,3489,O
control,3489,O
and,3489,O
",",3489,O
thus,3489,O
",",3489,O
to,3489,O
reduce,3489,O
diabetes-related,3489,O
morbidity,3489,O
and,3489,O
mortality,3489,O
.,3489,O
EphB1,3490,B-GENE-Y
null,3490,O
mice,3490,O
exhibit,3490,O
neuronal,3490,O
loss,3490,O
in,3490,O
substantia,3490,O
nigra,3490,O
pars,3490,O
reticulata,3490,O
and,3490,O
spontaneous,3490,O
locomotor,3490,O
hyperactivity,3490,O
.,3490,O
The,3491,O
molecular,3491,O
mechanisms,3491,O
that,3491,O
regulate,3491,O
basal,3491,O
ganglia,3491,O
development,3491,O
are,3491,O
largely,3491,O
unknown,3491,O
.,3491,O
Eph,3492,B-GENE-N
receptor,3492,I-GENE-N
tyrosine,3492,B-GENE-N
kinases,3492,I-GENE-N
are,3492,O
potential,3492,O
participants,3492,O
in,3492,O
this,3492,O
process,3492,O
as,3492,O
they,3492,O
regulate,3492,O
development,3492,O
of,3492,O
other,3492,O
CNS,3492,O
regions,3492,O
and,3492,O
are,3492,O
expressed,3492,O
in,3492,O
basal,3492,O
ganglia,3492,O
nuclei,3492,O
",",3492,O
such,3492,O
as,3492,O
the,3492,O
substantia,3492,O
nigra,3492,O
(,3492,O
SN,3492,O
),3492,O
and,3492,O
striatum,3492,O
.,3492,O
To,3493,O
address,3493,O
the,3493,O
role,3493,O
of,3493,O
Eph,3493,B-GENE-N
receptors,3493,I-GENE-N
in,3493,O
the,3493,O
development,3493,O
of,3493,O
these,3493,O
nuclei,3493,O
",",3493,O
we,3493,O
analysed,3493,O
anatomical,3493,O
changes,3493,O
in,3493,O
the,3493,O
SN,3493,O
and,3493,O
striatum,3493,O
of,3493,O
mice,3493,O
with,3493,O
null,3493,O
mutations,3493,O
for,3493,O
EphB1,3493,B-GENE-Y
.,3493,O
These,3494,O
mice,3494,O
express,3494,O
beta-galactosidase,3494,O
as,3494,O
a,3494,O
marker,3494,O
for,3494,O
cells,3494,O
normally,3494,O
expressing,3494,O
EphB1,3494,B-GENE-Y
.,3494,O
In,3495,O
situ,3495,O
hybridization,3495,O
data,3495,O
and,3495,O
a,3495,O
direct,3495,O
comparison,3495,O
of,3495,O
SN,3495,O
neurons,3495,O
expressing,3495,O
tyrosine,3495,B-GENE-Y
hydroxylase,3495,I-GENE-Y
(,3495,O
TH,3495,B-GENE-Y
),3495,O
and/or,3495,O
the,3495,O
beta-gal,3495,O
marker,3495,O
for,3495,O
EphB1,3495,B-GENE-Y
revealed,3495,O
that,3495,O
EphB1,3495,B-GENE-Y
is,3495,O
not,3495,O
expressed,3495,O
in,3495,O
TH+,3495,B-GENE-Y
neurons,3495,O
of,3495,O
pars,3495,O
compacta,3495,O
(,3495,O
SNc,3495,O
),3495,O
",",3495,O
but,3495,O
is,3495,O
restricted,3495,O
to,3495,O
neurons,3495,O
in,3495,O
pars,3495,O
reticulata,3495,O
(,3495,O
SNr,3495,O
),3495,O
.,3495,O
Consistent,3496,O
with,3496,O
this,3496,O
",",3496,O
we,3496,O
find,3496,O
that,3496,O
EphB1,3496,B-GENE-Y
null,3496,O
mice,3496,O
exhibit,3496,O
a,3496,O
significant,3496,O
decrease,3496,O
in,3496,O
the,3496,O
volume,3496,O
and,3496,O
number,3496,O
of,3496,O
neurons,3496,O
(,3496,O
40,3496,O
%,3496,O
decrease,3496,O
),3496,O
in,3496,O
SNr,3496,O
",",3496,O
whereas,3496,O
the,3496,O
volume,3496,O
and,3496,O
number,3496,O
of,3496,O
TH+,3496,B-GENE-Y
neurons,3496,O
in,3496,O
SNc,3496,O
is,3496,O
not,3496,O
significantly,3496,O
affected,3496,O
nor,3496,O
are,3496,O
there,3496,O
changes,3496,O
in,3496,O
the,3496,O
distribution,3496,O
of,3496,O
nigrostriatal,3496,O
dopamine,3496,B-CHEMICAL
neurons,3496,O
.,3496,O
Although,3497,O
EphB1,3497,B-GENE-Y
is,3497,O
expressed,3497,O
in,3497,O
the,3497,O
striatum,3497,O
",",3497,O
EphB1-/-,3497,B-GENE-Y
mice,3497,O
exhibit,3497,O
no,3497,O
significant,3497,O
changes,3497,O
in,3497,O
striatal,3497,O
volume,3497,O
and,3497,O
TH,3497,B-GENE-Y
fiber,3497,O
density,3497,O
",",3497,O
and,3497,O
have,3497,O
no,3497,O
obvious,3497,O
alterations,3497,O
in,3497,O
striatal,3497,O
patch/matrix,3497,O
organization,3497,O
.,3497,O
Behavioral,3498,O
evaluation,3498,O
of,3498,O
EphB1,3498,B-GENE-Y
null,3498,O
mice,3498,O
in,3498,O
an,3498,O
open-field,3498,O
environment,3498,O
revealed,3498,O
that,3498,O
these,3498,O
mice,3498,O
exhibited,3498,O
spontaneous,3498,O
locomotor,3498,O
hyperactivity,3498,O
.,3498,O
These,3499,O
results,3499,O
suggest,3499,O
that,3499,O
EphB1,3499,B-GENE-Y
is,3499,O
necessary,3499,O
for,3499,O
the,3499,O
proper,3499,O
formation,3499,O
of,3499,O
SNr,3499,O
",",3499,O
and,3499,O
that,3499,O
neuronal,3499,O
loss,3499,O
in,3499,O
SNr,3499,O
is,3499,O
associated,3499,O
with,3499,O
altered,3499,O
locomotor,3499,O
functions,3499,O
.,3499,O
pH-responsive,3500,O
composite,3500,O
microspheres,3500,O
based,3500,O
on,3500,O
magnetic,3500,O
mesoporous,3500,O
silica,3500,B-CHEMICAL
nanoparticle,3500,O
for,3500,O
drug,3500,O
delivery,3500,O
.,3500,O
pH-responsive,3501,O
composite,3501,O
microspheres,3501,O
",",3501,O
consisting,3501,O
of,3501,O
a,3501,O
core,3501,O
of,3501,O
Fe3O4,3501,B-CHEMICAL
nanoparticle,3501,O
",",3501,O
a,3501,O
sandwiched,3501,O
layer,3501,O
of,3501,O
mesoporous,3501,O
silica,3501,B-CHEMICAL
and,3501,O
a,3501,O
shell,3501,O
of,3501,O
crosslinked,3501,O
poly,3501,B-CHEMICAL
(,3501,I-CHEMICAL
methacrylic,3501,I-CHEMICAL
acid,3501,I-CHEMICAL
),3501,I-CHEMICAL
(,3501,O
PMAA,3501,B-CHEMICAL
),3501,O
",",3501,O
were,3501,O
successfully,3501,O
synthesized,3501,O
via,3501,O
distillation,3501,O
precipitation,3501,O
polymerization,3501,O
.,3501,O
The,3502,O
pKa,3502,O
of,3502,O
the,3502,O
composite,3502,O
microsphere,3502,O
increased,3502,O
with,3502,O
the,3502,O
increase,3502,O
in,3502,O
the,3502,O
crosslinking,3502,O
density,3502,O
.,3502,O
Doxorubicin,3503,B-CHEMICAL
hydrochloride,3503,I-CHEMICAL
(,3503,O
DOX,3503,B-CHEMICAL
),3503,O
was,3503,O
applied,3503,O
as,3503,O
a,3503,O
model,3503,O
drug,3503,O
",",3503,O
and,3503,O
the,3503,O
behavior,3503,O
of,3503,O
drug,3503,O
storage/release,3503,O
was,3503,O
investigated,3503,O
.,3503,O
The,3504,O
cumulative,3504,O
release,3504,O
of,3504,O
DOX-loaded,3504,B-CHEMICAL
composite,3504,O
microsphere,3504,O
in,3504,O
vitro,3504,O
showed,3504,O
that,3504,O
the,3504,O
drug,3504,O
release,3504,O
rate,3504,O
was,3504,O
much,3504,O
faster,3504,O
below,3504,O
its,3504,O
pKa,3504,O
than,3504,O
that,3504,O
of,3504,O
above,3504,O
its,3504,O
pKa,3504,O
.,3504,O
Because,3505,O
pH,3505,O
of,3505,O
most,3505,O
tumor,3505,O
tissues,3505,O
was,3505,O
lower,3505,O
than,3505,O
that,3505,O
of,3505,O
normal,3505,O
tissues,3505,O
",",3505,O
the,3505,O
pH-responsive,3505,O
composite,3505,O
microspheres,3505,O
are,3505,O
promising,3505,O
drug,3505,O
delivery,3505,O
system,3505,O
especially,3505,O
for,3505,O
cancer,3505,O
therapy,3505,O
.,3505,O
Novel,3506,O
therapeutic,3506,O
targets,3506,O
in,3506,O
non-small,3506,O
cell,3506,O
lung,3506,O
cancer,3506,O
.,3506,O
Oncogenic,3507,O
driver,3507,O
mutations,3507,O
frequently,3507,O
occur,3507,O
in,3507,O
lung,3507,O
cancer,3507,O
and,3507,O
play,3507,O
role,3507,O
in,3507,O
carcinogenesis,3507,O
.,3507,O
These,3508,O
mutations,3508,O
are,3508,O
usually,3508,O
associated,3508,O
with,3508,O
distinct,3508,O
clinical,3508,O
and,3508,O
histological,3508,O
features,3508,O
and,3508,O
are,3508,O
attractive,3508,O
targets,3508,O
for,3508,O
anticancer,3508,O
therapy,3508,O
.,3508,O
Recently,3509,O
",",3509,O
several,3509,O
molecularly,3509,O
distinct,3509,O
phenotypes,3509,O
of,3509,O
NSCLC,3509,O
based,3509,O
on,3509,O
specific,3509,O
and,3509,O
mutually,3509,O
exclusive,3509,O
genetic,3509,O
derangements,3509,O
have,3509,O
been,3509,O
described,3509,O
.,3509,O
Few,3510,O
targets,3510,O
like,3510,O
epidermal,3510,B-GENE-Y
growth,3510,I-GENE-Y
factor,3510,I-GENE-Y
receptor,3510,I-GENE-Y
(,3510,O
EGFR,3510,B-GENE-Y
),3510,O
mutations,3510,O
and,3510,O
anaplastic,3510,B-GENE-Y
lymphoma,3510,I-GENE-Y
kinase,3510,I-GENE-Y
(,3510,O
ALK,3510,B-GENE-Y
),3510,O
gene,3510,O
rearrangements,3510,O
have,3510,O
successfully,3510,O
been,3510,O
targeted,3510,O
with,3510,O
EGFR,3510,B-GENE-Y
tyrosine,3510,B-GENE-N
kinase,3510,I-GENE-N
inhibitors,3510,O
(,3510,O
TKIs,3510,O
),3510,O
and,3510,O
crizotinib,3510,B-CHEMICAL
",",3510,O
respectively,3510,O
.,3510,O
Many,3511,O
more,3511,O
inhibitors,3511,O
of,3511,O
specific,3511,O
driver,3511,O
mutations,3511,O
involving,3511,O
genes,3511,O
like,3511,O
ROS,3511,B-GENE-Y
",",3511,O
c-MET,3511,B-GENE-Y
",",3511,O
FGFR,3511,B-GENE-N
",",3511,O
mTOR,3511,B-GENE-Y
",",3511,O
IGFR,3511,B-GENE-Y
and,3511,O
RET,3511,B-GENE-Y
are,3511,O
currently,3511,O
under,3511,O
development,3511,O
.,3511,O
However,3512,O
",",3512,O
efforts,3512,O
to,3512,O
target,3512,O
some,3512,O
mutated,3512,O
genes,3512,O
like,3512,O
K-RAS,3512,B-GENE-Y
have,3512,O
been,3512,O
unsuccessful,3512,O
.,3512,O
Moreover,3513,O
",",3513,O
the,3513,O
emerging,3513,O
challenge,3513,O
of,3513,O
acquired,3513,O
resistance,3513,O
to,3513,O
initially,3513,O
effective,3513,O
therapy,3513,O
is,3513,O
becoming,3513,O
another,3513,O
major,3513,O
concern,3513,O
.,3513,O
In,3514,O
this,3514,O
review,3514,O
recent,3514,O
data,3514,O
on,3514,O
novel,3514,O
molecular,3514,O
targets,3514,O
and,3514,O
their,3514,O
future,3514,O
prospects,3514,O
are,3514,O
discussed,3514,O
.,3514,O
Mechanisms,3515,O
limiting,3515,O
distribution,3515,O
of,3515,O
the,3515,O
threonine-protein,3515,B-GENE-Y
kinase,3515,I-GENE-Y
B-RaF,3515,I-GENE-Y
(,3515,O
V600E,3515,B-GENE-N
),3515,O
inhibitor,3515,O
dabrafenib,3515,B-CHEMICAL
to,3515,O
the,3515,O
brain,3515,O
:,3515,O
implications,3515,O
for,3515,O
the,3515,O
treatment,3515,O
of,3515,O
melanoma,3515,O
brain,3515,O
metastases,3515,O
.,3515,O
Brain,3516,O
metastases,3516,O
are,3516,O
a,3516,O
common,3516,O
cause,3516,O
of,3516,O
death,3516,O
in,3516,O
stage,3516,O
IV,3516,O
metastatic,3516,O
melanoma,3516,O
.,3516,O
Dabrafenib,3517,O
is,3517,O
a,3517,O
BRAF,3517,B-GENE-Y
(,3517,O
gene,3517,O
encoding,3517,O
serine/threonine-protein,3517,B-GENE-Y
kinase,3517,I-GENE-Y
B-Raf,3517,I-GENE-Y
),3517,O
inhibitor,3517,O
that,3517,O
has,3517,O
been,3517,O
developed,3517,O
to,3517,O
selectively,3517,O
target,3517,O
the,3517,O
valine,3517,B-GENE-N
600,3517,I-GENE-N
to,3517,I-GENE-N
glutamic,3517,I-GENE-N
acid,3517,I-GENE-N
substitution,3517,O
(,3517,O
BRAF,3517,B-GENE-Y
(,3517,O
V600E,3517,B-GENE-N
),3517,O
),3517,O
",",3517,O
which,3517,O
is,3517,O
commonly,3517,O
found,3517,O
in,3517,O
metastatic,3517,O
melanoma,3517,O
.,3517,O
Clinical,3518,O
trials,3518,O
with,3518,O
dabrafenib,3518,B-CHEMICAL
have,3518,O
shown,3518,O
encouraging,3518,O
results,3518,O
;,3518,O
however,3518,O
",",3518,O
the,3518,O
central,3518,O
nervous,3518,O
system,3518,O
distribution,3518,O
of,3518,O
dabrafenib,3518,B-CHEMICAL
remains,3518,O
unknown,3518,O
.,3518,O
Thus,3519,O
",",3519,O
the,3519,O
objective,3519,O
of,3519,O
the,3519,O
current,3519,O
study,3519,O
was,3519,O
to,3519,O
evaluate,3519,O
the,3519,O
brain,3519,O
distribution,3519,O
of,3519,O
dabrafenib,3519,B-CHEMICAL
in,3519,O
mice,3519,O
",",3519,O
and,3519,O
to,3519,O
see,3519,O
whether,3519,O
active,3519,O
efflux,3519,O
by,3519,O
P-glycoprotein,3519,B-GENE-N
(,3519,O
P-gp,3519,B-GENE-N
),3519,O
and,3519,O
breast,3519,B-GENE-Y
cancer,3519,I-GENE-Y
resistance,3519,I-GENE-Y
protein,3519,I-GENE-Y
(,3519,O
BCRP,3519,B-GENE-Y
),3519,O
restricts,3519,O
its,3519,O
delivery,3519,O
across,3519,O
the,3519,O
blood-brain,3519,O
barrier,3519,O
(,3519,O
BBB,3519,O
),3519,O
.,3519,O
In,3520,O
vitro,3520,O
accumulation,3520,O
studies,3520,O
conducted,3520,O
in,3520,O
Madin-Darby,3520,O
canine,3520,O
kidney,3520,O
II,3520,O
cells,3520,O
indicate,3520,O
that,3520,O
dabrafenib,3520,B-CHEMICAL
is,3520,O
an,3520,O
avid,3520,O
substrate,3520,O
for,3520,O
both,3520,O
P-gp,3520,B-GENE-N
and,3520,O
BCRP,3520,B-GENE-Y
.,3520,O
Directional,3521,O
flux,3521,O
studies,3521,O
revealed,3521,O
greater,3521,O
transport,3521,O
in,3521,O
the,3521,O
basolateral,3521,O
to,3521,O
apical,3521,O
direction,3521,O
with,3521,O
corrected,3521,O
efflux,3521,O
ratios,3521,O
greater,3521,O
than,3521,O
2,3521,O
for,3521,O
both,3521,O
P-gp,3521,B-GENE-N
and,3521,O
Bcrp1,3521,B-GENE-Y
transfected,3521,O
cell,3521,O
lines,3521,O
.,3521,O
In,3522,O
vivo,3522,O
",",3522,O
the,3522,O
ratio,3522,O
of,3522,O
area,3522,O
under,3522,O
the,3522,O
concentration-time,3522,O
curve,3522,O
(,3522,O
AUC,3522,O
),3522,O
(,3522,O
brain,3522,O
),3522,O
to,3522,O
AUC,3522,O
(,3522,O
plasma,3522,O
),3522,O
(,3522,O
K,3522,O
(,3522,O
p,3522,O
),3522,O
),3522,O
of,3522,O
dabrafenib,3522,B-CHEMICAL
after,3522,O
an,3522,O
i.v,3522,O
.,3522,O
dose,3523,O
(,3523,O
2.5,3523,O
mg/kg,3523,O
),3523,O
was,3523,O
0.023,3523,O
",",3523,O
which,3523,O
increased,3523,O
by,3523,O
18-fold,3523,O
in,3523,O
Mdr1,3523,B-GENE-N
a/b,3523,I-GENE-N
(,3523,O
-/-,3523,O
),3523,O
Bcrp1,3523,B-GENE-Y
(,3523,O
-/-,3523,O
),3523,O
mice,3523,O
to,3523,O
0.42,3523,O
.,3523,O
Dabrafenib,3524,B-CHEMICAL
plasma,3524,O
exposure,3524,O
was,3524,O
∼2-fold,3524,O
greater,3524,O
in,3524,O
Mdr1,3524,B-GENE-N
a/b,3524,I-GENE-N
(,3524,O
-/-,3524,O
),3524,O
Bcrp1,3524,B-GENE-Y
(,3524,O
-/-,3524,O
),3524,O
mice,3524,O
as,3524,O
compared,3524,O
with,3524,O
wild-type,3524,O
with,3524,O
an,3524,O
oral,3524,O
dose,3524,O
(,3524,O
25,3524,O
mg/kg,3524,O
),3524,O
;,3524,O
however,3524,O
",",3524,O
the,3524,O
brain,3524,O
distribution,3524,O
was,3524,O
increased,3524,O
by,3524,O
~10-fold,3524,O
with,3524,O
a,3524,O
resulting,3524,O
K,3524,O
(,3524,O
p,3524,O
),3524,O
of,3524,O
0.25,3524,O
.,3524,O
Further,3525,O
",",3525,O
compared,3525,O
with,3525,O
vemurafenib,3525,B-CHEMICAL
",",3525,O
another,3525,O
BRAF,3525,B-GENE-Y
(,3525,O
V600E,3525,B-GENE-N
),3525,O
inhibitor,3525,O
",",3525,O
dabrafenib,3525,B-CHEMICAL
showed,3525,O
greater,3525,O
brain,3525,O
penetration,3525,O
with,3525,O
a,3525,O
similar,3525,O
dose,3525,O
.,3525,O
In,3526,O
conclusion,3526,O
",",3526,O
the,3526,O
dabrafenib,3526,B-CHEMICAL
brain,3526,O
distribution,3526,O
is,3526,O
limited,3526,O
in,3526,O
an,3526,O
intact,3526,O
BBB,3526,O
model,3526,O
",",3526,O
and,3526,O
the,3526,O
data,3526,O
presented,3526,O
herein,3526,O
may,3526,O
have,3526,O
clinical,3526,O
implications,3526,O
in,3526,O
the,3526,O
prevention,3526,O
and,3526,O
treatment,3526,O
of,3526,O
melanoma,3526,O
brain,3526,O
metastases,3526,O
.,3526,O
PXR,3527,B-GENE-Y
antagonists,3527,O
and,3527,O
implication,3527,O
in,3527,O
drug,3527,O
metabolism,3527,O
.,3527,O
Adopted,3528,O
orphan,3528,B-GENE-N
nuclear,3528,I-GENE-N
receptor,3528,I-GENE-N
(,3528,O
NR,3528,B-GENE-N
),3528,O
",",3528,O
pregnane,3528,B-GENE-Y
X,3528,I-GENE-Y
receptor,3528,I-GENE-Y
(,3528,O
PXR,3528,B-GENE-Y
),3528,O
",",3528,O
plays,3528,O
a,3528,O
central,3528,O
role,3528,O
in,3528,O
the,3528,O
regulation,3528,O
of,3528,O
xeno-,3528,O
and,3528,O
endobiotic,3528,O
metabolism,3528,O
.,3528,O
Since,3529,O
the,3529,O
discovery,3529,O
of,3529,O
the,3529,O
functional,3529,O
role,3529,O
of,3529,O
PXR,3529,B-GENE-Y
in,3529,O
1998,3529,O
",",3529,O
there,3529,O
is,3529,O
evolving,3529,O
evidence,3529,O
for,3529,O
the,3529,O
role,3529,O
of,3529,O
PXR,3529,B-GENE-Y
agonists,3529,O
in,3529,O
abrogating,3529,O
metabolic,3529,O
pathophysiology,3529,O
(,3529,O
e.g.,3529,O
",",3529,O
cholestasis,3529,O
",",3529,O
hypercholesterolemia,3529,O
",",3529,O
and,3529,O
inflammation,3529,O
),3529,O
.,3529,O
However,3530,O
",",3530,O
more,3530,O
recently,3530,O
",",3530,O
it,3530,O
is,3530,O
clear,3530,O
that,3530,O
PXR,3530,B-GENE-Y
is,3530,O
also,3530,O
an,3530,O
important,3530,O
mediator,3530,O
of,3530,O
adverse,3530,O
xeno-,3530,O
(,3530,O
e.g.,3530,O
",",3530,O
enhances,3530,O
acetaminophen,3530,B-CHEMICAL
toxicity,3530,O
),3530,O
and,3530,O
endobiotic,3530,O
(,3530,O
e.g.,3530,O
",",3530,O
hepatic,3530,O
steatosis,3530,O
),3530,O
metabolic,3530,O
phenotypes,3530,O
.,3530,O
Moreover,3531,O
",",3531,O
in,3531,O
cancer,3531,O
therapeutics,3531,O
",",3531,O
PXR,3531,B-GENE-Y
activation,3531,O
can,3531,O
induce,3531,O
drug,3531,O
resistance,3531,O
",",3531,O
and,3531,O
there,3531,O
is,3531,O
growing,3531,O
evidence,3531,O
for,3531,O
tissue-specific,3531,O
enhancement,3531,O
of,3531,O
the,3531,O
malignant,3531,O
phenotype,3531,O
.,3531,O
Thus,3532,O
",",3532,O
in,3532,O
these,3532,O
instances,3532,O
",",3532,O
there,3532,O
may,3532,O
be,3532,O
a,3532,O
role,3532,O
for,3532,O
PXR,3532,B-GENE-Y
antagonists,3532,O
.,3532,O
However,3533,O
",",3533,O
as,3533,O
opposed,3533,O
to,3533,O
the,3533,O
discovery,3533,O
efforts,3533,O
for,3533,O
PXR,3533,B-GENE-Y
agonists,3533,O
",",3533,O
there,3533,O
are,3533,O
only,3533,O
a,3533,O
few,3533,O
antagonists,3533,O
described,3533,O
.,3533,O
The,3534,O
mode,3534,O
of,3534,O
action,3534,O
of,3534,O
these,3534,O
antagonists,3534,O
(,3534,O
e.g.,3534,O
",",3534,O
sulforaphane,3534,B-CHEMICAL
),3534,O
remains,3534,O
less,3534,O
clear,3534,O
.,3534,O
Our,3535,O
laboratory,3535,O
efforts,3535,O
have,3535,O
focused,3535,O
on,3535,O
this,3535,O
question,3535,O
.,3535,O
Since,3536,O
the,3536,O
original,3536,O
discovery,3536,O
of,3536,O
azoles,3536,B-CHEMICAL
analogs,3536,O
as,3536,O
PXR,3536,B-GENE-Y
antagonists,3536,O
",",3536,O
we,3536,O
have,3536,O
preliminarily,3536,O
defined,3536,O
an,3536,O
important,3536,O
PXR,3536,B-GENE-Y
antagonist,3536,O
pharmacophore,3536,O
and,3536,O
developed,3536,O
less-toxic,3536,O
PXR,3536,B-GENE-Y
antagonists,3536,O
.,3536,O
In,3537,O
this,3537,O
review,3537,O
",",3537,O
we,3537,O
describe,3537,O
our,3537,O
published,3537,O
and,3537,O
unpublished,3537,O
findings,3537,O
on,3537,O
recent,3537,O
structure-function,3537,O
studies,3537,O
involving,3537,O
the,3537,O
azole,3537,B-CHEMICAL
chemical,3537,O
scaffold,3537,O
.,3537,O
Further,3538,O
work,3538,O
in,3538,O
the,3538,O
future,3538,O
is,3538,O
needed,3538,O
to,3538,O
fully,3538,O
define,3538,O
potent,3538,O
",",3538,O
more-selective,3538,O
PXR,3538,B-GENE-Y
antagonists,3538,O
that,3538,O
may,3538,O
be,3538,O
useful,3538,O
in,3538,O
clinical,3538,O
application,3538,O
.,3538,O
Biophysical,3539,O
properties,3539,O
",",3539,O
pharmacology,3539,O
",",3539,O
and,3539,O
modulation,3539,O
of,3539,O
human,3539,O
",",3539,O
neuronal,3539,O
L-type,3539,O
(,3539,O
alpha,3539,B-GENE-Y
(,3539,I-GENE-Y
1D,3539,I-GENE-Y
),3539,I-GENE-Y
",",3539,O
Ca,3539,B-GENE-Y
(,3539,I-GENE-Y
V,3539,I-GENE-Y
),3539,I-GENE-Y
1.3,3539,I-GENE-Y
),3539,O
voltage-dependent,3539,O
calcium,3539,B-CHEMICAL
currents,3539,O
.,3539,O
Voltage-dependent,3540,B-GENE-N
calcium,3540,I-GENE-N
channels,3540,I-GENE-N
(,3540,O
VDCCs,3540,O
),3540,O
are,3540,O
multimeric,3540,O
complexes,3540,O
composed,3540,O
of,3540,O
a,3540,O
pore-forming,3540,O
alpha,3540,O
(,3540,O
1,3540,O
),3540,O
subunit,3540,O
together,3540,O
with,3540,O
several,3540,O
accessory,3540,O
subunits,3540,O
",",3540,O
including,3540,O
alpha,3540,O
(,3540,O
2,3540,O
),3540,O
delta,3540,O
",",3540,O
beta,3540,O
",",3540,O
and,3540,O
",",3540,O
in,3540,O
some,3540,O
cases,3540,O
",",3540,O
gamma,3540,O
subunits,3540,O
.,3540,O
A,3541,O
family,3541,O
of,3541,O
VDCCs,3541,B-GENE-N
known,3541,O
as,3541,O
the,3541,O
L-type,3541,B-GENE-N
channels,3541,I-GENE-N
are,3541,O
formed,3541,O
specifically,3541,O
from,3541,O
alpha,3541,O
(,3541,O
1S,3541,O
),3541,O
(,3541,O
skeletal,3541,O
muscle,3541,O
),3541,O
",",3541,O
alpha,3541,O
(,3541,O
1C,3541,O
),3541,O
(,3541,O
in,3541,O
heart,3541,O
and,3541,O
brain,3541,O
),3541,O
",",3541,O
alpha,3541,O
(,3541,O
1D,3541,O
),3541,O
(,3541,O
mainly,3541,O
in,3541,O
brain,3541,O
",",3541,O
heart,3541,O
",",3541,O
and,3541,O
endocrine,3541,O
tissue,3541,O
),3541,O
",",3541,O
and,3541,O
alpha,3541,O
(,3541,O
1F,3541,O
),3541,O
(,3541,O
retina,3541,O
),3541,O
.,3541,O
Neuroendocrine,3542,O
L-type,3542,O
currents,3542,O
have,3542,O
a,3542,O
significant,3542,O
role,3542,O
in,3542,O
the,3542,O
control,3542,O
of,3542,O
neurosecretion,3542,O
and,3542,O
can,3542,O
be,3542,O
inhibited,3542,O
by,3542,O
GTP-binding,3542,B-GENE-N
(,3542,I-GENE-N
G-,3542,I-GENE-N
),3542,I-GENE-N
proteins,3542,I-GENE-N
.,3542,O
However,3543,O
",",3543,O
the,3543,O
subunit,3543,O
composition,3543,O
of,3543,O
the,3543,O
VDCCs,3543,B-GENE-N
underlying,3543,O
these,3543,O
G-protein-regulated,3543,B-GENE-N
neuroendocrine,3543,O
L-type,3543,O
currents,3543,O
is,3543,O
unknown,3543,O
.,3543,O
To,3544,O
investigate,3544,O
the,3544,O
biophysical,3544,O
and,3544,O
pharmacological,3544,O
properties,3544,O
and,3544,O
role,3544,O
of,3544,O
G-protein,3544,B-GENE-N
modulation,3544,O
of,3544,O
alpha,3544,B-GENE-Y
(,3544,I-GENE-Y
1D,3544,I-GENE-Y
),3544,I-GENE-Y
calcium,3544,I-GENE-Y
channels,3544,I-GENE-Y
",",3544,O
we,3544,O
have,3544,O
examined,3544,O
calcium,3544,B-GENE-N
channel,3544,I-GENE-N
currents,3544,O
formed,3544,O
by,3544,O
the,3544,O
human,3544,B-GENE-Y
neuronal,3544,I-GENE-Y
L-type,3544,I-GENE-Y
alpha,3544,I-GENE-Y
(,3544,I-GENE-Y
1D,3544,I-GENE-Y
),3544,I-GENE-Y
subunit,3544,O
",",3544,O
co-expressed,3544,O
with,3544,O
alpha,3544,O
(,3544,O
2,3544,O
),3544,O
delta-1,3544,O
and,3544,O
beta,3544,O
(,3544,O
3a,3544,O
),3544,O
",",3544,O
stably,3544,O
expressed,3544,O
in,3544,O
a,3544,O
human,3544,O
embryonic,3544,O
kidney,3544,O
(,3544,O
HEK,3544,O
),3544,O
293,3544,O
cell,3544,O
line,3544,O
",",3544,O
using,3544,O
whole,3544,O
cell,3544,O
and,3544,O
perforated,3544,O
patch-clamp,3544,O
techniques,3544,O
.,3544,O
The,3545,O
alpha,3545,O
(,3545,O
1D,3545,O
),3545,O
-expressing,3545,O
cell,3545,O
line,3545,O
exhibited,3545,O
L-type,3545,O
currents,3545,O
with,3545,O
typical,3545,O
characteristics,3545,O
.,3545,O
The,3546,O
currents,3546,O
were,3546,O
high-voltage,3546,O
activated,3546,O
(,3546,O
peak,3546,O
at,3546,O
+20,3546,O
mV,3546,O
in,3546,O
20,3546,O
mM,3546,O
Ba2+,3546,B-CHEMICAL
),3546,O
and,3546,O
showed,3546,O
little,3546,O
inactivation,3546,O
in,3546,O
external,3546,O
Ba2+,3546,B-CHEMICAL
",",3546,O
while,3546,O
displaying,3546,O
rapid,3546,O
inactivation,3546,O
kinetics,3546,O
in,3546,O
external,3546,O
Ca2+,3546,B-CHEMICAL
.,3546,O
The,3547,O
L-type,3547,O
currents,3547,O
were,3547,O
inhibited,3547,O
by,3547,O
the,3547,O
"1,4",3547,B-CHEMICAL
dihydropyridine,3547,I-CHEMICAL
(,3547,O
DHP,3547,B-CHEMICAL
),3547,O
antagonists,3547,O
nifedipine,3547,B-CHEMICAL
and,3547,O
nicardipine,3547,B-CHEMICAL
and,3547,O
were,3547,O
enhanced,3547,O
by,3547,O
the,3547,O
DHP,3547,B-CHEMICAL
agonist,3547,O
BayK,3547,B-CHEMICAL
S-,3547,I-CHEMICAL
(,3547,I-CHEMICAL
-,3547,I-CHEMICAL
),3547,I-CHEMICAL
8644,3547,I-CHEMICAL
.,3547,O
However,3548,O
",",3548,O
alpha,3548,B-GENE-Y
(,3548,I-GENE-Y
1D,3548,I-GENE-Y
),3548,I-GENE-Y
L-type,3548,O
currents,3548,O
were,3548,O
not,3548,O
modulated,3548,O
by,3548,O
activation,3548,O
of,3548,O
a,3548,O
number,3548,O
of,3548,O
G-protein,3548,B-GENE-N
pathways,3548,O
.,3548,O
Activation,3549,O
of,3549,O
endogenous,3549,O
somatostatin,3549,B-GENE-Y
receptor,3549,I-GENE-Y
subtype,3549,I-GENE-Y
2,3549,I-GENE-Y
(,3549,O
sst2,3549,B-GENE-Y
),3549,O
by,3549,O
somatostatin-14,3549,B-CHEMICAL
or,3549,O
activation,3549,O
of,3549,O
transiently,3549,O
transfected,3549,O
rat,3549,B-GENE-N
D2,3549,I-GENE-N
dopamine,3549,I-GENE-N
receptors,3549,I-GENE-N
(,3549,O
rD2,3549,B-GENE-N
(,3549,O
long,3549,O
),3549,O
),3549,O
by,3549,O
quinpirole,3549,B-CHEMICAL
had,3549,O
no,3549,O
effect,3549,O
.,3549,O
Direct,3550,O
activation,3550,O
of,3550,O
G-proteins,3550,O
by,3550,O
the,3550,O
nonhydrolyzable,3550,O
GTP,3550,B-CHEMICAL
analogue,3550,O
",",3550,O
guanosine,3550,B-CHEMICAL
5'-0-,3550,I-CHEMICAL
(,3550,I-CHEMICAL
3-thiotriphospate,3550,I-CHEMICAL
),3550,I-CHEMICAL
also,3550,O
had,3550,O
no,3550,O
effect,3550,O
on,3550,O
the,3550,O
alpha,3550,O
(,3550,O
1D,3550,O
),3550,O
currents,3550,O
.,3550,O
In,3551,O
contrast,3551,O
",",3551,O
in,3551,O
the,3551,O
same,3551,O
system,3551,O
",",3551,O
N-type,3551,B-CHEMICAL
currents,3551,O
",",3551,O
formed,3551,O
from,3551,O
transiently,3551,O
transfected,3551,O
alpha,3551,O
(,3551,O
1B,3551,O
),3551,O
/alpha,3551,O
(,3551,O
2,3551,O
),3551,O
delta-1/beta,3551,O
(,3551,O
3,3551,O
),3551,O
",",3551,O
showed,3551,O
strong,3551,O
G-protein-mediated,3551,B-GENE-N
inhibition,3551,O
.,3551,O
Furthermore,3552,O
",",3552,O
the,3552,O
I-II,3552,O
loop,3552,O
from,3552,O
the,3552,O
alpha,3552,O
(,3552,O
1D,3552,O
),3552,O
clone,3552,O
",",3552,O
expressed,3552,O
as,3552,O
a,3552,O
glutathione-S-transferase,3552,B-GENE-N
(,3552,O
GST,3552,B-GENE-N
),3552,O
fusion,3552,O
protein,3552,O
",",3552,O
did,3552,O
not,3552,O
bind,3552,O
Gbetagamma,3552,O
",",3552,O
unlike,3552,O
the,3552,O
alpha,3552,B-GENE-N
(,3552,I-GENE-N
1B,3552,I-GENE-N
),3552,I-GENE-N
I-II,3552,I-GENE-N
loop,3552,I-GENE-N
fusion,3552,O
protein,3552,O
.,3552,O
These,3553,O
data,3553,O
show,3553,O
that,3553,O
the,3553,O
biophysical,3553,O
and,3553,O
pharmacological,3553,O
properties,3553,O
of,3553,O
recombinant,3553,O
human,3553,O
alpha,3553,O
(,3553,O
1D,3553,O
),3553,O
L-type,3553,O
currents,3553,O
are,3553,O
similar,3553,O
to,3553,O
alpha,3553,O
(,3553,O
1C,3553,O
),3553,O
currents,3553,O
",",3553,O
and,3553,O
these,3553,O
currents,3553,O
are,3553,O
also,3553,O
resistant,3553,O
to,3553,O
modulation,3553,O
by,3553,O
G,3553,B-GENE-N
(,3553,I-GENE-N
i/o,3553,I-GENE-N
),3553,I-GENE-N
-linked,3553,O
G-protein-coupled,3553,B-GENE-N
receptors,3553,I-GENE-N
.,3553,O
Antofine-induced,3554,B-CHEMICAL
connexin43,3554,B-GENE-Y
gap,3554,O
junction,3554,O
disassembly,3554,O
in,3554,O
rat,3554,O
astrocytes,3554,O
involves,3554,O
protein,3554,B-GENE-Y
kinase,3554,I-GENE-Y
Cβ,3554,I-GENE-Y
.,3554,O
Antofine,3555,B-CHEMICAL
",",3555,O
a,3555,O
phenanthroindolizidine,3555,B-CHEMICAL
alkaloid,3555,I-CHEMICAL
derived,3555,O
from,3555,O
Cryptocaryachinensis,3555,O
and,3555,O
Ficusseptica,3555,O
in,3555,O
the,3555,O
Asclepiadaceae,3555,O
milkweed,3555,O
family,3555,O
",",3555,O
is,3555,O
cytotoxic,3555,O
for,3555,O
various,3555,O
cancer,3555,O
cell,3555,O
lines,3555,O
.,3555,O
In,3556,O
this,3556,O
study,3556,O
",",3556,O
we,3556,O
demonstrated,3556,O
that,3556,O
treatment,3556,O
of,3556,O
rat,3556,O
primary,3556,O
astrocytes,3556,O
with,3556,O
antofine,3556,B-CHEMICAL
induced,3556,O
dose-dependent,3556,O
inhibition,3556,O
of,3556,O
gap,3556,O
junction,3556,O
intercellular,3556,O
communication,3556,O
(,3556,O
GJIC,3556,O
),3556,O
",",3556,O
as,3556,O
assessed,3556,O
by,3556,O
scrape-loading,3556,O
6-carboxyfluorescein,3556,B-CHEMICAL
dye,3556,O
transfer,3556,O
.,3556,O
Levels,3557,O
of,3557,O
Cx43,3557,B-GENE-Y
protein,3557,O
were,3557,O
also,3557,O
decreased,3557,O
in,3557,O
a,3557,O
dose-,3557,O
and,3557,O
time-dependent,3557,O
manner,3557,O
following,3557,O
antofine,3557,B-CHEMICAL
treatment,3557,O
.,3557,O
Double-labeling,3558,O
immunofluorescence,3558,O
microscopy,3558,O
showed,3558,O
that,3558,O
antofine,3558,B-CHEMICAL
(,3558,O
10ng/ml,3558,O
),3558,O
induced,3558,O
endocytosis,3558,O
of,3558,O
surface,3558,O
gap,3558,O
junctions,3558,O
into,3558,O
the,3558,O
cytoplasm,3558,O
",",3558,O
where,3558,O
Cx43,3558,B-GENE-Y
was,3558,O
co-localized,3558,O
with,3558,O
the,3558,O
early,3558,O
endosome,3558,O
marker,3558,O
EEA1,3558,B-GENE-N
.,3558,O
Inhibition,3559,O
of,3559,O
lysosomes,3559,O
or,3559,O
proteasomes,3559,O
by,3559,O
co-treatment,3559,O
with,3559,O
antofine,3559,B-CHEMICAL
and,3559,O
their,3559,O
respective,3559,O
specific,3559,O
inhibitors,3559,O
",",3559,O
NH4Cl,3559,B-CHEMICAL
or,3559,O
MG132,3559,B-CHEMICAL
",",3559,O
partially,3559,O
inhibited,3559,O
the,3559,O
antofine-induced,3559,O
decrease,3559,O
in,3559,O
Cx43,3559,B-GENE-Y
protein,3559,O
levels,3559,O
",",3559,O
but,3559,O
did,3559,O
not,3559,O
inhibit,3559,O
the,3559,O
antofine-induced,3559,O
inhibition,3559,O
of,3559,O
GJIC,3559,O
.,3559,O
After,3560,O
30min,3560,O
of,3560,O
treatment,3560,O
",",3560,O
antofine,3560,O
induced,3560,O
a,3560,O
rapid,3560,O
increase,3560,O
in,3560,O
the,3560,O
intracellular,3560,O
Ca,3560,B-CHEMICAL
(,3560,I-CHEMICAL
2+,3560,I-CHEMICAL
),3560,I-CHEMICAL
concentration,3560,O
and,3560,O
activation,3560,O
of,3560,O
protein,3560,B-GENE-N
kinase,3560,I-GENE-N
C,3560,I-GENE-N
(,3560,I-GENE-N
PKC,3560,I-GENE-N
),3560,I-GENE-N
α/βII,3560,I-GENE-N
",",3560,O
which,3560,O
was,3560,O
maintained,3560,O
for,3560,O
at,3560,O
least,3560,O
6h,3560,O
.,3560,O
Co-treatment,3561,O
of,3561,O
astrocytes,3561,O
with,3561,O
antofine,3561,B-CHEMICAL
and,3561,O
the,3561,O
intracellular,3561,O
Ca,3561,B-CHEMICAL
(,3561,I-CHEMICAL
2+,3561,I-CHEMICAL
),3561,I-CHEMICAL
chelator,3561,O
BAPTA-AM,3561,B-CHEMICAL
prevented,3561,O
downregulation,3561,O
of,3561,O
Cx43,3561,B-GENE-Y
and,3561,O
inhibition,3561,O
of,3561,O
GJIC,3561,O
.,3561,O
Moreover,3562,O
",",3562,O
co-treatment,3562,O
with,3562,O
antofine,3562,B-CHEMICAL
and,3562,O
a,3562,O
specific,3562,O
PKCβ,3562,B-GENE-Y
inhibitor,3562,O
prevented,3562,O
endocytosis,3562,O
of,3562,O
gap,3562,O
junctions,3562,O
",",3562,O
downregulation,3562,O
of,3562,O
Cx43,3562,B-GENE-Y
",",3562,O
and,3562,O
inhibition,3562,O
of,3562,O
GJIC,3562,O
.,3562,O
Taken,3563,O
together,3563,O
",",3563,O
these,3563,O
findings,3563,O
indicate,3563,O
that,3563,O
antofine,3563,B-CHEMICAL
induces,3563,O
Cx43,3563,B-GENE-Y
gap,3563,O
junction,3563,O
disassembly,3563,O
by,3563,O
the,3563,O
PKCβ,3563,B-GENE-Y
signaling,3563,O
pathway,3563,O
.,3563,O
Inhibition,3564,O
of,3564,O
GJIC,3564,O
by,3564,O
antofine,3564,B-CHEMICAL
may,3564,O
undermine,3564,O
the,3564,O
neuroprotective,3564,O
effect,3564,O
of,3564,O
astrocytes,3564,O
in,3564,O
CNS,3564,O
.,3564,O
Torasemide,3565,B-CHEMICAL
inhibits,3565,O
angiotensin,3565,B-GENE-Y
II-induced,3565,O
vasoconstriction,3565,O
and,3565,O
intracellular,3565,O
calcium,3565,B-CHEMICAL
increase,3565,O
in,3565,O
the,3565,O
aorta,3565,O
of,3565,O
spontaneously,3565,O
hypertensive,3565,O
rats,3565,O
.,3565,O
Torasemide,3566,B-CHEMICAL
is,3566,O
a,3566,O
loop,3566,O
diuretic,3566,O
that,3566,O
is,3566,O
effective,3566,O
at,3566,O
low,3566,O
once-daily,3566,O
doses,3566,O
in,3566,O
the,3566,O
treatment,3566,O
of,3566,O
arterial,3566,O
hypertension,3566,O
.,3566,O
Because,3567,O
its,3567,O
antihypertensive,3567,O
mechanism,3567,O
of,3567,O
action,3567,O
may,3567,O
not,3567,O
be,3567,O
based,3567,O
entirely,3567,O
on,3567,O
the,3567,O
elimination,3567,O
of,3567,O
salt,3567,O
and,3567,O
water,3567,O
from,3567,O
the,3567,O
body,3567,O
",",3567,O
a,3567,O
vasodilator,3567,O
effect,3567,O
of,3567,O
this,3567,O
drug,3567,O
can,3567,O
be,3567,O
considered,3567,O
.,3567,O
In,3568,O
the,3568,O
present,3568,O
study,3568,O
",",3568,O
the,3568,O
ability,3568,O
of,3568,O
different,3568,O
concentrations,3568,O
of,3568,O
torasemide,3568,B-CHEMICAL
to,3568,O
modify,3568,O
angiotensin,3568,B-GENE-Y
II,3568,I-GENE-Y
(,3568,O
Ang,3568,B-GENE-Y
II,3568,I-GENE-Y
),3568,O
-induced,3568,O
vascular,3568,O
responses,3568,O
was,3568,O
examined,3568,O
",",3568,O
with,3568,O
the,3568,O
use,3568,O
of,3568,O
an,3568,O
organ,3568,O
bath,3568,O
system,3568,O
",",3568,O
in,3568,O
endothelium-denuded,3568,O
aortic,3568,O
rings,3568,O
from,3568,O
spontaneously,3568,O
hypertensive,3568,O
rats,3568,O
.,3568,O
Ang,3569,B-GENE-Y
II-induced,3569,O
increases,3569,O
of,3569,O
intracellular,3569,O
free,3569,O
calcium,3569,B-CHEMICAL
concentration,3569,O
(,3569,O
[,3569,O
Ca,3569,B-CHEMICAL
(,3569,I-CHEMICAL
2+,3569,I-CHEMICAL
),3569,I-CHEMICAL
],3569,O
(,3569,O
i,3569,O
),3569,O
),3569,O
were,3569,O
also,3569,O
examined,3569,O
by,3569,O
image,3569,O
analysis,3569,O
in,3569,O
cultured,3569,O
vascular,3569,O
smooth,3569,O
muscle,3569,O
cells,3569,O
(,3569,O
VSMCs,3569,O
),3569,O
from,3569,O
spontaneously,3569,O
hypertensive,3569,O
rats,3569,O
.,3569,O
A,3570,O
dose-response,3570,O
curve,3570,O
to,3570,O
Ang,3570,B-GENE-Y
II,3570,I-GENE-Y
was,3570,O
plotted,3570,O
for,3570,O
cumulative,3570,O
concentrations,3570,O
(,3570,O
from,3570,O
10,3570,O
(,3570,O
-9,3570,O
),3570,O
to,3570,O
10,3570,O
(,3570,O
-6,3570,O
),3570,O
mol/L,3570,O
),3570,O
in,3570,O
endothelium-denuded,3570,O
aortic,3570,O
rings,3570,O
(,3570,O
pD,3570,O
(,3570,O
2,3570,O
),3570,O
=7.5+/-0.3,3570,O
),3570,O
.,3570,O
Isometric,3571,O
contraction,3571,O
induced,3571,O
by,3571,O
a,3571,O
submaximal,3571,O
concentration,3571,O
of,3571,O
Ang,3571,B-GENE-Y
II,3571,I-GENE-Y
(,3571,O
10,3571,O
(,3571,O
-7,3571,O
),3571,O
mol/L,3571,O
),3571,O
was,3571,O
reduced,3571,O
in,3571,O
a,3571,O
dose-dependent,3571,O
way,3571,O
by,3571,O
torasemide,3571,B-CHEMICAL
(,3571,O
IC,3571,O
(,3571,O
50,3571,O
),3571,O
=0.5+/-0.04,3571,O
micromol/L,3571,O
),3571,O
.,3571,O
Incubation,3572,O
of,3572,O
VSMCs,3572,O
with,3572,O
different,3572,O
concentrations,3572,O
of,3572,O
Ang,3572,B-GENE-Y
II,3572,I-GENE-Y
(,3572,O
from,3572,O
10,3572,O
(,3572,O
-10,3572,O
),3572,O
to,3572,O
10,3572,O
(,3572,O
-6,3572,O
),3572,O
mol/L,3572,O
),3572,O
resulted,3572,O
in,3572,O
a,3572,O
dose-dependent,3572,O
rise,3572,O
of,3572,O
[,3572,O
Ca,3572,B-CHEMICAL
(,3572,I-CHEMICAL
2+,3572,I-CHEMICAL
),3572,I-CHEMICAL
],3572,O
(,3572,O
i,3572,O
),3572,O
(,3572,O
pD,3572,O
(,3572,O
2,3572,O
),3572,O
=7.5+/-0.3,3572,O
),3572,O
.,3572,O
The,3573,O
stimulatory,3573,O
effect,3573,O
of,3573,O
[,3573,O
Ca,3573,B-CHEMICAL
(,3573,I-CHEMICAL
2+,3573,I-CHEMICAL
),3573,I-CHEMICAL
],3573,O
(,3573,O
i,3573,O
),3573,O
induced,3573,O
by,3573,O
a,3573,O
submaximal,3573,O
concentration,3573,O
of,3573,O
Ang,3573,B-GENE-Y
II,3573,I-GENE-Y
(,3573,O
10,3573,O
(,3573,O
-7,3573,O
),3573,O
mol/L,3573,O
),3573,O
was,3573,O
blocked,3573,O
by,3573,O
torasemide,3573,B-CHEMICAL
(,3573,O
IC,3573,O
(,3573,O
50,3573,O
),3573,O
=0.5+/-0.3,3573,O
nmol/L,3573,O
),3573,O
.,3573,O
Our,3574,O
findings,3574,O
suggest,3574,O
that,3574,O
torasemide,3574,B-CHEMICAL
blocks,3574,O
the,3574,O
vasoconstrictor,3574,O
action,3574,O
of,3574,O
Ang,3574,B-GENE-Y
II,3574,I-GENE-Y
in,3574,O
vitro,3574,O
.,3574,O
This,3575,O
action,3575,O
can,3575,O
be,3575,O
related,3575,O
to,3575,O
the,3575,O
ability,3575,O
of,3575,O
torasemide,3575,B-CHEMICAL
to,3575,O
block,3575,O
the,3575,O
increase,3575,O
of,3575,O
[,3575,O
Ca,3575,B-CHEMICAL
(,3575,I-CHEMICAL
2+,3575,I-CHEMICAL
),3575,I-CHEMICAL
],3575,O
(,3575,O
i,3575,O
),3575,O
induced,3575,O
by,3575,O
Ang,3575,B-GENE-Y
II,3575,I-GENE-Y
in,3575,O
VSMCs,3575,O
.,3575,O
It,3576,O
is,3576,O
proposed,3576,O
that,3576,O
these,3576,O
actions,3576,O
might,3576,O
be,3576,O
involved,3576,O
in,3576,O
the,3576,O
antihypertensive,3576,O
effect,3576,O
of,3576,O
torasemide,3576,B-CHEMICAL
observed,3576,O
in,3576,O
vivo,3576,O
.,3576,O
Characterization,3577,O
of,3577,O
tyrosinase,3577,B-GENE-Y
inhibitors,3577,O
in,3577,O
the,3577,O
twigs,3577,O
of,3577,O
Cudrania,3577,O
tricuspidata,3577,O
and,3577,O
their,3577,O
structure-activity,3577,O
relationship,3577,O
study,3577,O
.,3577,O
The,3578,O
twigs,3578,O
of,3578,O
Cudrania,3578,O
tricuspidata,3578,O
were,3578,O
found,3578,O
to,3578,O
show,3578,O
strong,3578,O
tyrosinase,3578,B-GENE-Y
inhibitory,3578,O
activity,3578,O
",",3578,O
and,3578,O
further,3578,O
detailed,3578,O
component,3578,O
analysis,3578,O
resulted,3578,O
in,3578,O
the,3578,O
isolation,3578,O
of,3578,O
a,3578,O
new,3578,O
flavanol,3578,B-CHEMICAL
glucoside,3578,I-CHEMICAL
",",3578,O
(,3578,B-CHEMICAL
"2S,3S",3578,I-CHEMICAL
),3578,I-CHEMICAL
"-2,3-trans-dihydromorin-7-O-β-d-glucoside",3578,I-CHEMICAL
(,3578,O
1,3578,O
),3578,O
",",3578,O
plus,3578,O
twenty-seven,3578,O
known,3578,O
compounds,3578,O
(,3578,O
2-28,3578,O
),3578,O
.,3578,O
Their,3579,O
structures,3579,O
were,3579,O
elucidated,3579,O
on,3579,O
the,3579,O
basis,3579,O
of,3579,O
ESI-MS,3579,O
and,3579,O
NMR,3579,O
spectral,3579,O
data,3579,O
.,3579,O
Among,3580,O
the,3580,O
isolated,3580,O
compounds,3580,O
",",3580,O
trans-dihydromorin,3580,B-CHEMICAL
(,3580,O
8,3580,O
),3580,O
",",3580,O
oxyresveratrol,3580,B-CHEMICAL
(,3580,O
9,3580,O
),3580,O
",",3580,O
and,3580,O
steppogenin,3580,B-CHEMICAL
(,3580,O
12,3580,O
),3580,O
were,3580,O
found,3580,O
to,3580,O
exhibit,3580,O
significant,3580,O
tyrosinase,3580,B-GENE-Y
inhibition,3580,O
activities,3580,O
.,3580,O
Moreover,3581,O
",",3581,O
the,3581,O
structure-activity,3581,O
relationship,3581,O
of,3581,O
these,3581,O
isolated,3581,O
compounds,3581,O
was,3581,O
also,3581,O
discussed,3581,O
.,3581,O
Pyridoxal,3582,B-CHEMICAL
5'-phosphate,3582,I-CHEMICAL
may,3582,O
be,3582,O
curative,3582,O
in,3582,O
early-onset,3582,O
epileptic,3582,O
encephalopathy,3582,O
.,3582,O
Neonatal,3583,O
epileptic,3583,O
encephalopathy,3583,O
can,3583,O
be,3583,O
caused,3583,O
by,3583,O
inborn,3583,O
errors,3583,O
of,3583,O
metabolism,3583,O
.,3583,O
These,3584,O
conditions,3584,O
are,3584,O
often,3584,O
unresponsive,3584,O
to,3584,O
treatment,3584,O
with,3584,O
conventional,3584,O
antiepileptic,3584,O
drugs,3584,O
.,3584,O
Six,3585,O
children,3585,O
with,3585,O
pyridox,3585,B-GENE-Y
(,3585,I-GENE-Y
am,3585,I-GENE-Y
),3585,I-GENE-Y
ine-5'-phosphate,3585,I-GENE-Y
oxidase,3585,I-GENE-Y
(,3585,O
PNPO,3585,B-GENE-Y
),3585,O
deficiency,3585,O
presented,3585,O
with,3585,O
neonatal,3585,O
epileptic,3585,O
encephalopathy,3585,O
.,3585,O
Two,3586,O
were,3586,O
treated,3586,O
with,3586,O
pyridoxal,3586,B-CHEMICAL
5'-phosphate,3586,I-CHEMICAL
(,3586,O
PLP,3586,B-CHEMICAL
),3586,O
within,3586,O
the,3586,O
first,3586,O
month,3586,O
of,3586,O
life,3586,O
and,3586,O
showed,3586,O
normal,3586,O
development,3586,O
or,3586,O
moderate,3586,O
psychomotor,3586,O
retardation,3586,O
thereafter,3586,O
.,3586,O
Four,3587,O
children,3587,O
with,3587,O
late,3587,O
or,3587,O
no,3587,O
treatment,3587,O
died,3587,O
or,3587,O
showed,3587,O
severe,3587,O
mental,3587,O
handicap,3587,O
.,3587,O
All,3588,O
of,3588,O
the,3588,O
children,3588,O
showed,3588,O
atypical,3588,O
biochemical,3588,O
findings,3588,O
.,3588,O
Prompt,3589,O
treatment,3589,O
with,3589,O
PLP,3589,B-CHEMICAL
in,3589,O
all,3589,O
neonates,3589,O
and,3589,O
infants,3589,O
with,3589,O
epileptic,3589,O
encephalopathy,3589,O
should,3589,O
become,3589,O
mandatory,3589,O
",",3589,O
permitting,3589,O
normal,3589,O
development,3589,O
in,3589,O
at,3589,O
least,3589,O
some,3589,O
of,3589,O
those,3589,O
affected,3589,O
with,3589,O
PNPO,3589,B-GENE-Y
deficiency,3589,O
.,3589,O
The,3590,O
prostaglandin,3590,B-CHEMICAL
E,3590,I-CHEMICAL
series,3590,O
modulates,3590,O
high-voltage-activated,3590,B-GENE-N
calcium,3590,I-GENE-N
channels,3590,I-GENE-N
probably,3590,O
through,3590,O
the,3590,O
EP3,3590,B-GENE-Y
receptor,3590,I-GENE-Y
in,3590,O
rat,3590,O
paratracheal,3590,O
ganglia,3590,O
.,3590,O
The,3591,O
modulation,3591,O
of,3591,O
high-voltage-activated,3591,B-GENE-N
(,3591,I-GENE-N
HVA,3591,I-GENE-N
),3591,I-GENE-N
Ca2+,3591,I-GENE-N
channels,3591,I-GENE-N
by,3591,O
the,3591,O
prostaglandin,3591,B-CHEMICAL
E,3591,I-CHEMICAL
series,3591,O
(,3591,O
PGE1,3591,B-CHEMICAL
and,3591,O
PGE2,3591,B-CHEMICAL
),3591,O
was,3591,O
studied,3591,O
in,3591,O
the,3591,O
paratracheal,3591,O
ganglion,3591,O
cells,3591,O
.,3591,O
Prostaglandin,3592,B-CHEMICAL
E1,3592,I-CHEMICAL
",",3592,I-CHEMICAL
E2,3592,I-CHEMICAL
",",3592,I-CHEMICAL
STA2,3592,B-CHEMICAL
(,3592,O
a,3592,O
stable,3592,O
analogue,3592,O
of,3592,O
thromboxane,3592,B-CHEMICAL
A2,3592,I-CHEMICAL
),3592,O
",",3592,O
17-phenyl-trinor-PGE2,3592,B-CHEMICAL
(,3592,O
an,3592,O
EP1-selective,3592,B-GENE-Y
agonist,3592,O
),3592,O
and,3592,O
sulprostone,3592,B-CHEMICAL
(,3592,O
an,3592,O
EP3-selective,3592,B-GENE-Y
agonist,3592,O
),3592,O
inhibited,3592,O
the,3592,O
HVA,3592,O
Ca2+,3592,B-CHEMICAL
current,3592,O
(,3592,O
HVA,3592,O
ICa,3592,O
),3592,O
dose-dependently,3592,O
",",3592,O
and,3592,O
the,3592,O
rank,3592,O
order,3592,O
of,3592,O
potency,3592,O
to,3592,O
inhibit,3592,O
HVA,3592,B-GENE-N
Ca2+,3592,I-GENE-N
channels,3592,I-GENE-N
was,3592,O
sulprostone,3592,B-CHEMICAL
>,3592,O
PGE2,3592,B-CHEMICAL
",",3592,O
PGE1,3592,B-CHEMICAL
>,3592,O
STA2,3592,B-CHEMICAL
>,3592,O
>,3592,O
17-phenyl-trinor-PGE2,3592,B-CHEMICAL
.,3592,O
SC-51089,3593,B-CHEMICAL
(,3593,O
10,3593,O
(,3593,O
-5,3593,O
),3593,O
M,3593,O
),3593,O
",",3593,O
a,3593,O
selective,3593,O
EP1-receptor,3593,B-GENE-Y
antagonist,3593,O
",",3593,O
showed,3593,O
no,3593,O
effect,3593,O
on,3593,O
the,3593,O
PGE1-,3593,B-CHEMICAL
or,3593,O
PGE2-induced,3593,B-CHEMICAL
inhibition,3593,O
of,3593,O
the,3593,O
HVA,3593,O
ICa,3593,O
",",3593,O
thereby,3593,O
indicating,3593,O
that,3593,O
PGE1-,3593,B-CHEMICAL
and,3593,O
PGE2-induced,3593,B-CHEMICAL
inhibition,3593,O
of,3593,O
the,3593,O
HVA,3593,B-GENE-N
Ca2+,3593,I-GENE-N
channels,3593,I-GENE-N
is,3593,O
possibly,3593,O
mediated,3593,O
by,3593,O
the,3593,O
EP3,3593,B-GENE-Y
receptor,3593,I-GENE-Y
.,3593,O
The,3594,O
PGE1-sensitive,3594,B-CHEMICAL
component,3594,O
of,3594,O
the,3594,O
current,3594,O
was,3594,O
markedly,3594,O
reduced,3594,O
in,3594,O
the,3594,O
presence,3594,O
of,3594,O
omega-conotoxin-GVIA,3594,O
(,3594,O
3x10,3594,O
(,3594,O
-6,3594,O
),3594,O
M,3594,O
),3594,O
",",3594,O
but,3594,O
not,3594,O
with,3594,O
nifedipine,3594,B-CHEMICAL
(,3594,O
3x10,3594,O
(,3594,O
-6,3594,O
),3594,O
M,3594,O
),3594,O
.,3594,O
PGE1,3595,B-CHEMICAL
and,3595,O
PGE2,3595,B-CHEMICAL
also,3595,O
inhibited,3595,O
the,3595,O
remaining,3595,O
ICa,3595,O
in,3595,O
a,3595,O
saturating,3595,O
concentration,3595,O
of,3595,O
nifedipine,3595,B-CHEMICAL
",",3595,O
omega-conotoxin-GVIA,3595,O
and,3595,O
omega-conotoxin-MVIIC,3595,O
",",3595,O
suggesting,3595,O
that,3595,O
R-type,3595,B-GENE-N
Ca2+,3595,I-GENE-N
channels,3595,I-GENE-N
are,3595,O
involved,3595,O
.,3595,O
The,3596,O
inhibitory,3596,O
effect,3596,O
of,3596,O
PGE1,3596,B-CHEMICAL
or,3596,O
sulprostone,3596,B-CHEMICAL
was,3596,O
prevented,3596,O
by,3596,O
pretreatment,3596,O
with,3596,O
pertussis,3596,B-GENE-N
toxin,3596,I-GENE-N
[,3596,O
islet,3596,B-GENE-N
activating,3596,I-GENE-N
protein,3596,I-GENE-N
(,3596,O
IAP,3596,B-GENE-N
),3596,O
],3596,O
or,3596,O
phorbol-12-myristate-13-acetate,3596,B-CHEMICAL
(,3596,O
PMA,3596,B-CHEMICAL
),3596,O
",",3596,O
and,3596,O
the,3596,O
protein,3596,B-GENE-N
kinase,3596,I-GENE-N
C,3596,I-GENE-N
(,3596,O
PKC,3596,B-GENE-N
),3596,O
inhibitor,3596,O
chelerythrine,3596,B-CHEMICAL
blocked,3596,O
the,3596,O
action,3596,O
of,3596,O
PMA,3596,B-CHEMICAL
.,3596,O
It,3597,O
was,3597,O
concluded,3597,O
that,3597,O
PGE1,3597,B-CHEMICAL
selectively,3597,O
reduces,3597,O
both,3597,O
N-,3597,O
and,3597,O
R-type,3597,O
Ca2+,3597,B-CHEMICAL
currents,3597,O
by,3597,O
activating,3597,O
a,3597,O
G-protein,3597,B-GENE-N
probably,3597,O
through,3597,O
the,3597,O
EP3,3597,B-GENE-Y
receptor,3597,I-GENE-Y
in,3597,O
paratracheal,3597,O
ganglion,3597,O
cells,3597,O
.,3597,O
Inhibition,3598,O
of,3598,O
MCP-1,3598,B-GENE-Y
and,3598,O
MIP-2,3598,B-GENE-Y
transcription,3598,O
and,3598,O
translation,3598,O
by,3598,O
mimosine,3598,B-CHEMICAL
in,3598,O
muscle,3598,O
tissue,3598,O
infected,3598,O
with,3598,O
the,3598,O
parasite,3598,O
Trichinella,3598,O
spiralis,3598,O
.,3598,O
Mimosine,3599,B-CHEMICAL
is,3599,O
a,3599,O
non-toxic,3599,O
plant,3599,O
aminoacid,3599,B-CHEMICAL
which,3599,O
is,3599,O
an,3599,O
effective,3599,O
inhibitor,3599,O
of,3599,O
DNA,3599,O
replication,3599,O
by,3599,O
acting,3599,O
at,3599,O
the,3599,O
S-phase,3599,O
.,3599,O
In,3600,O
this,3600,O
study,3600,O
we,3600,O
infected,3600,O
mice,3600,O
with,3600,O
T.,3600,O
spiralis,3600,O
",",3600,O
a,3600,O
nematode,3600,O
parasite,3600,O
",",3600,O
and,3600,O
studied,3600,O
the,3600,O
inflammatory,3600,O
response,3600,O
through,3600,O
the,3600,O
determination,3600,O
of,3600,O
MIP-2,3600,B-GENE-Y
",",3600,O
a,3600,O
C-X-C,3600,B-GENE-N
chemokine,3600,I-GENE-N
and,3600,O
MCP-1,3600,B-GENE-Y
",",3600,O
a,3600,O
C-C,3600,B-GENE-N
chemokine,3600,I-GENE-N
in,3600,O
the,3600,O
inflamed,3600,O
area,3600,O
around,3600,O
the,3600,O
parasitic,3600,O
cyst,3600,O
.,3600,O
The,3601,O
animals,3601,O
were,3601,O
infected,3601,O
and,3601,O
their,3601,O
diaphragms,3601,O
were,3601,O
tested,3601,O
for,3601,O
inflammatory,3601,O
response,3601,O
.,3601,O
MCP-1,3602,B-GENE-Y
and,3602,O
MIP-2,3602,B-GENE-Y
was,3602,O
tested,3602,O
after,3602,O
1,3602,O
",",3602,O
10,3602,O
",",3602,O
20,3602,O
",",3602,O
30,3602,O
",",3602,O
and,3602,O
40,3602,O
days,3602,O
post,3602,O
inoculation,3602,O
",",3602,O
before,3602,O
and,3602,O
after,3602,O
mimosine,3602,B-CHEMICAL
treatment,3602,O
.,3602,O
The,3603,O
inflammatory,3603,O
index,3603,O
was,3603,O
calculated,3603,O
by,3603,O
counting,3603,O
the,3603,O
white,3603,O
blood,3603,O
cells,3603,O
around,3603,O
the,3603,O
nematode,3603,O
cysts,3603,O
",",3603,O
while,3603,O
expression,3603,O
of,3603,O
MIP-2,3603,B-GENE-Y
and,3603,O
MCP-1,3603,B-GENE-Y
was,3603,O
calculated,3603,O
by,3603,O
ELISA,3603,O
method,3603,O
and,3603,O
transcription,3603,O
by,3603,O
Northern,3603,O
blot,3603,O
and,3603,O
RT-PCR,3603,O
.,3603,O
Here,3604,O
we,3604,O
found,3604,O
that,3604,O
mimosine,3604,B-CHEMICAL
strongly,3604,O
inhibited,3604,O
the,3604,O
inflammatory,3604,O
index,3604,O
in,3604,O
the,3604,O
diaphragmatic,3604,O
tissue,3604,O
at,3604,O
10,3604,O
",",3604,O
20,3604,O
",",3604,O
30,3604,O
and,3604,O
40,3604,O
days,3604,O
post-treatment,3604,O
.,3604,O
In,3605,O
these,3605,O
experiments,3605,O
",",3605,O
mimosine,3605,B-CHEMICAL
had,3605,O
no,3605,O
effect,3605,O
on,3605,O
the,3605,O
number,3605,O
of,3605,O
cysts,3605,O
produced,3605,O
.,3605,O
In,3606,O
addition,3606,O
",",3606,O
we,3606,O
found,3606,O
that,3606,O
MCP-1,3606,B-GENE-Y
transcription,3606,O
and,3606,O
translation,3606,O
was,3606,O
completely,3606,O
inhibited,3606,O
by,3606,O
mimosine,3606,B-CHEMICAL
",",3606,O
while,3606,O
MIP-2,3606,B-GENE-Y
transcription,3606,O
and,3606,O
translation,3606,O
was,3606,O
partially,3606,O
inhibited,3606,O
at,3606,O
30,3606,O
and,3606,O
40,3606,O
days,3606,O
;,3606,O
yet,3606,O
it,3606,O
was,3606,O
totally,3606,O
inhibited,3606,O
after,3606,O
10,3606,O
and,3606,O
20,3606,O
days,3606,O
in,3606,O
encysted,3606,O
diaphragm,3606,O
tissue,3606,O
infected,3606,O
by,3606,O
T.,3606,O
spiralis,3606,O
.,3606,O
Our,3607,O
studies,3607,O
suggest,3607,O
that,3607,O
mimosine,3607,B-CHEMICAL
has,3607,O
an,3607,O
inhibitory,3607,O
effect,3607,O
through,3607,O
the,3607,O
inhibition,3607,O
of,3607,O
cytoplasmatic,3607,O
serine,3607,O
hydroxymethyltransferase,3607,O
altering,3607,O
the,3607,O
cell,3607,O
cycle,3607,O
of,3607,O
white,3607,O
blood,3607,O
cells,3607,O
.,3607,O
This,3608,O
study,3608,O
suggests,3608,O
for,3608,O
the,3608,O
first,3608,O
time,3608,O
the,3608,O
premise,3608,O
that,3608,O
mimosine,3608,B-CHEMICAL
acts,3608,O
as,3608,O
an,3608,O
anti-inflammatory,3608,O
compound,3608,O
.,3608,O
Balancing,3609,O
societal,3609,O
needs,3609,O
and,3609,O
regulatory,3609,O
certainty,3609,O
:,3609,O
the,3609,O
case,3609,O
study,3609,O
of,3609,O
peramivir,3609,B-CHEMICAL
in,3609,O
Japan,3609,O
.,3609,O
Regulators,3610,O
must,3610,O
balance,3610,O
societal,3610,O
and,3610,O
medical,3610,O
requirements,3610,O
against,3610,O
the,3610,O
need,3610,O
for,3610,O
certainty,3610,O
about,3610,O
benefit,3610,O
and,3610,O
risk,3610,O
for,3610,O
new,3610,O
medicines,3610,O
.,3610,O
This,3611,O
is,3611,O
described,3611,O
in,3611,O
a,3611,O
case,3611,O
study,3611,O
of,3611,O
the,3611,O
expedited,3611,O
review,3611,O
and,3611,O
approval,3611,O
of,3611,O
peramivir,3611,B-CHEMICAL
",",3611,O
a,3611,O
novel,3611,O
neuraminidase,3611,B-GENE-N
inhibitor,3611,O
",",3611,O
in,3611,O
Japan,3611,O
in,3611,O
the,3611,O
context,3611,O
of,3611,O
the,3611,O
emergence,3611,O
of,3611,O
new,3611,O
strain,3611,O
of,3611,O
influenza,3611,O
in,3611,O
2009,3611,O
.,3611,O
The,3612,O
case,3612,O
illustrates,3612,O
the,3612,O
importance,3612,O
of,3612,O
regulatory,3612,O
science,3612,O
and,3612,O
transparency,3612,O
in,3612,O
supporting,3612,O
such,3612,O
decision,3612,O
making,3612,O
.,3612,O
The,3613,O
influence,3613,O
of,3613,O
sex,3613,O
",",3613,O
ethnicity,3613,O
",",3613,O
and,3613,O
CYP2B6,3613,B-GENE-Y
genotype,3613,O
on,3613,O
bupropion,3613,B-CHEMICAL
metabolism,3613,O
as,3613,O
an,3613,O
index,3613,O
of,3613,O
hepatic,3613,O
CYP2B6,3613,B-GENE-Y
activity,3613,O
in,3613,O
humans,3613,O
.,3613,O
The,3614,O
effects,3614,O
of,3614,O
sex,3614,O
",",3614,O
ethnicity,3614,O
",",3614,O
and,3614,O
genetic,3614,O
polymorphism,3614,O
on,3614,O
hepatic,3614,O
CYP2B6,3614,B-GENE-Y
(,3614,O
cytochrome,3614,B-GENE-Y
P450,3614,I-GENE-Y
2B6,3614,I-GENE-Y
),3614,O
expression,3614,O
and,3614,O
activity,3614,O
were,3614,O
previously,3614,O
demonstrated,3614,O
in,3614,O
vitro,3614,O
.,3614,O
Race/ethnic,3615,O
differences,3615,O
in,3615,O
CYP2B6,3615,B-GENE-Y
genotype,3615,O
and,3615,O
phenotype,3615,O
were,3615,O
observed,3615,O
only,3615,O
in,3615,O
women,3615,O
.,3615,O
To,3616,O
identify,3616,O
important,3616,O
covariates,3616,O
associated,3616,O
with,3616,O
interindividual,3616,O
variation,3616,O
in,3616,O
CYP2B6,3616,B-GENE-Y
activity,3616,O
in,3616,O
vivo,3616,O
",",3616,O
we,3616,O
evaluated,3616,O
these,3616,O
effects,3616,O
in,3616,O
healthy,3616,O
volunteers,3616,O
using,3616,O
bupropion,3616,B-CHEMICAL
(,3616,O
Wellbutrin,3616,B-CHEMICAL
SR,3616,I-CHEMICAL
GlaxoSmithKline,3616,O
",",3616,O
Research,3616,O
Triangle,3616,O
Park,3616,O
",",3616,O
NC,3616,O
),3616,O
as,3616,O
a,3616,O
CYP2B6,3616,B-GENE-Y
probe,3616,O
substrate,3616,O
.,3616,O
A,3617,O
fixed,3617,O
150-mg,3617,O
oral,3617,O
sustained-release,3617,O
dose,3617,O
of,3617,O
bupropion,3617,B-CHEMICAL
was,3617,O
administered,3617,O
to,3617,O
100,3617,O
healthy,3617,O
volunteers,3617,O
comprising,3617,O
four,3617,O
sex/ethnicity,3617,O
cohorts,3617,O
(,3617,O
n,3617,O
=,3617,O
25,3617,O
each,3617,O
),3617,O
:,3617,O
Caucasian,3617,O
men,3617,O
and,3617,O
Caucasian,3617,O
",",3617,O
African,3617,O
American,3617,O
",",3617,O
and,3617,O
Hispanic,3617,O
women,3617,O
.,3617,O
Blood,3618,O
samples,3618,O
were,3618,O
obtained,3618,O
at,3618,O
0,3618,O
and,3618,O
6,3618,O
hours,3618,O
postdose,3618,O
for,3618,O
the,3618,O
measurement,3618,O
of,3618,O
serum,3618,O
bupropion,3618,B-CHEMICAL
(,3618,O
BU,3618,O
),3618,O
and,3618,O
hydroxybupropion,3618,B-CHEMICAL
(,3618,O
HB,3618,O
),3618,O
concentrations,3618,O
.,3618,O
Whole,3619,O
blood,3619,O
was,3619,O
obtained,3619,O
at,3619,O
baseline,3619,O
for,3619,O
CYP2B6,3619,B-GENE-Y
genotyping,3619,O
.,3619,O
To,3620,O
characterize,3620,O
the,3620,O
relationship,3620,O
between,3620,O
CYP2B6,3620,B-GENE-Y
activity,3620,O
and,3620,O
ethnicity,3620,O
",",3620,O
sex,3620,O
",",3620,O
and,3620,O
genotype,3620,O
when,3620,O
accounting,3620,O
for,3620,O
serum,3620,O
BU,3620,O
concentrations,3620,O
(,3620,O
dose-adjusted,3620,O
log,3620,O
(,3620,O
10,3620,O
),3620,O
-transformed,3620,O
),3620,O
",",3620,O
analysis,3620,O
of,3620,O
covariance,3620,O
model,3620,O
was,3620,O
fitted,3620,O
in,3620,O
which,3620,O
the,3620,O
dependent,3620,O
variable,3620,O
was,3620,O
CYP2B6,3620,B-GENE-Y
activity,3620,O
represented,3620,O
as,3620,O
the,3620,O
log,3620,O
(,3620,O
10,3620,O
),3620,O
-transformed,3620,O
",",3620,O
metabolic,3620,O
ratio,3620,O
of,3620,O
HB,3620,O
to,3620,O
BU,3620,O
concentrations,3620,O
.,3620,O
Several,3621,O
CYP2B6,3621,B-GENE-Y
polymorphisms,3621,O
were,3621,O
associated,3621,O
with,3621,O
CYP2B6,3621,B-GENE-Y
activity,3621,O
.,3621,O
Evidence,3622,O
of,3622,O
dependence,3622,O
of,3622,O
CYP2B6,3622,B-GENE-Y
activity,3622,O
on,3622,O
ethnicity,3622,O
or,3622,O
genotype-by-ethnicity,3622,O
interactions,3622,O
was,3622,O
not,3622,O
detected,3622,O
in,3622,O
women,3622,O
.,3622,O
These,3623,O
results,3623,O
suggest,3623,O
that,3623,O
CYP2B6,3623,B-GENE-Y
genotype,3623,O
is,3623,O
the,3623,O
most,3623,O
important,3623,O
patient,3623,O
variable,3623,O
for,3623,O
predicting,3623,O
the,3623,O
level,3623,O
of,3623,O
CYP2B6,3623,B-GENE-Y
activity,3623,O
in,3623,O
women,3623,O
",",3623,O
when,3623,O
measured,3623,O
by,3623,O
the,3623,O
metabolism,3623,O
of,3623,O
bupropion,3623,B-CHEMICAL
.,3623,O
The,3624,O
bupropion,3624,B-CHEMICAL
metabolic,3624,O
ratio,3624,O
appears,3624,O
to,3624,O
detect,3624,O
known,3624,O
differences,3624,O
in,3624,O
CYP2B6,3624,B-GENE-Y
activity,3624,O
associated,3624,O
with,3624,O
genetic,3624,O
polymorphism,3624,O
",",3624,O
across,3624,O
different,3624,O
ethnic,3624,O
groups,3624,O
.,3624,O
Prospective,3625,O
studies,3625,O
will,3625,O
be,3625,O
needed,3625,O
to,3625,O
validate,3625,O
the,3625,O
use,3625,O
of,3625,O
bupropion,3625,B-CHEMICAL
as,3625,O
a,3625,O
probe,3625,O
substrate,3625,O
for,3625,O
clinical,3625,O
use,3625,O
.,3625,O
Alpha-2,3626,B-GENE-N
adrenoceptor,3626,I-GENE-N
subtype,3626,O
causing,3626,O
nitric,3626,B-CHEMICAL
oxide-mediated,3626,O
vascular,3626,O
relaxation,3626,O
in,3626,O
rats,3626,O
.,3626,O
The,3627,O
alpha-2,3627,B-GENE-N
adrenoceptor,3627,I-GENE-N
subtype,3627,O
and,3627,O
its,3627,O
signal,3627,O
transduction,3627,O
pathway,3627,O
mediating,3627,O
vascular,3627,O
relaxation,3627,O
in,3627,O
rats,3627,O
were,3627,O
studied,3627,O
in,3627,O
vitro,3627,O
using,3627,O
rings,3627,O
of,3627,O
superior,3627,O
mesenteric,3627,O
arteries,3627,O
.,3627,O
Removal,3628,O
of,3628,O
endothelium,3628,O
or,3628,O
incubation,3628,O
with,3628,O
NG-nitro-L-arginine,3628,B-CHEMICAL
completely,3628,O
blocked,3628,O
relaxant,3628,O
responses,3628,O
to,3628,O
"UK14,304",3628,B-CHEMICAL
",",3628,O
suggesting,3628,O
endothelium-derived,3628,O
nitric,3628,B-CHEMICAL
oxide,3628,I-CHEMICAL
mediates,3628,O
relaxation,3628,O
.,3628,O
The,3629,O
order,3629,O
of,3629,O
potency,3629,O
for,3629,O
full,3629,O
(,3629,O
F,3629,O
),3629,O
or,3629,O
partial,3629,O
(,3629,O
P,3629,O
),3629,O
agonists,3629,O
causing,3629,O
relaxation,3629,O
was,3629,O
guanabenz,3629,B-CHEMICAL
(,3629,O
P,3629,O
),3629,O
>,3629,O
"UK14,304",3629,B-CHEMICAL
(,3629,O
F,3629,O
),3629,O
>,3629,O
clonidine,3629,B-CHEMICAL
(,3629,O
P,3629,O
),3629,O
>,3629,O
epinephrine,3629,B-CHEMICAL
(,3629,O
F,3629,O
),3629,O
>,3629,O
norepinephrine,3629,B-CHEMICAL
(,3629,O
F,3629,O
),3629,O
.,3629,O
Affinities,3630,O
(,3630,O
Ka,3630,O
),3630,O
of,3630,O
alpha-2,3630,B-GENE-N
adrenoceptor,3630,I-GENE-N
subtype-selective,3630,O
drugs,3630,O
for,3630,O
blocking,3630,O
relaxation,3630,O
were,3630,O
obtained,3630,O
in,3630,O
side-by-side,3630,O
experiments,3630,O
comparing,3630,O
rat,3630,O
mesenteric,3630,O
arteries,3630,O
with,3630,O
pig,3630,O
coronary,3630,O
arteries,3630,O
.,3630,O
Relaxation,3631,O
of,3631,O
pig,3631,O
coronary,3631,O
arteries,3631,O
is,3631,O
known,3631,O
to,3631,O
be,3631,O
mediated,3631,O
by,3631,O
the,3631,O
alpha-2A,3631,B-GENE-Y
adrenoceptor,3631,I-GENE-Y
subtype,3631,O
.,3631,O
Ka,3632,O
values,3632,O
in,3632,O
nM,3632,O
for,3632,O
rauwolscine,3632,B-CHEMICAL
(,3632,O
19,3632,O
),3632,O
",",3632,O
WB-4101,3632,B-CHEMICAL
(,3632,O
265,3632,O
),3632,O
",",3632,O
SKF-104078,3632,B-CHEMICAL
(,3632,O
197,3632,O
),3632,O
",",3632,O
spiroxatrine,3632,B-CHEMICAL
(,3632,O
128,3632,O
),3632,O
",",3632,O
and,3632,O
prazosin,3632,B-CHEMICAL
(,3632,O
1531,3632,O
),3632,O
for,3632,O
blocking,3632,O
relaxation,3632,O
in,3632,O
rat,3632,O
arteries,3632,O
were,3632,O
consistent,3632,O
with,3632,O
their,3632,O
affinities,3632,O
for,3632,O
binding,3632,O
at,3632,O
the,3632,O
alpha-2D,3632,B-GENE-Y
adrenoceptor,3632,I-GENE-Y
subtype,3632,O
.,3632,O
Ka,3633,O
values,3633,O
for,3633,O
rauwolscine,3633,B-CHEMICAL
and,3633,O
WB-4101,3633,B-CHEMICAL
",",3633,O
drugs,3633,O
distinguishing,3633,O
the,3633,O
alpha-2D,3633,O
from,3633,O
the,3633,O
alpha-2A,3633,B-GENE-Y
adrenoceptor,3633,I-GENE-Y
subtype,3633,O
",",3633,O
were,3633,O
significantly,3633,O
higher,3633,O
in,3633,O
blocking,3633,O
relaxation,3633,O
of,3633,O
rat,3633,O
arteries,3633,O
compared,3633,O
with,3633,O
pig,3633,O
arteries,3633,O
",",3633,O
suggesting,3633,O
the,3633,O
alpha-2D,3633,B-GENE-Y
adrenoceptor,3633,I-GENE-Y
subtype,3633,O
mediates,3633,O
NO-induced,3633,B-CHEMICAL
relaxation,3633,O
in,3633,O
rat,3633,O
arteries,3633,O
.,3633,O
We,3634,O
used,3634,O
forskolin,3634,B-CHEMICAL
to,3634,O
oppose,3634,O
alpha-2,3634,B-GENE-N
adrenoceptor-mediated,3634,O
inhibition,3634,O
of,3634,O
cAMP,3634,B-CHEMICAL
formation,3634,O
by,3634,O
directly,3634,O
stimulating,3634,O
cAMP,3634,B-CHEMICAL
formation,3634,O
in,3634,O
endothelium,3634,O
.,3634,O
Forskolin,3635,B-CHEMICAL
did,3635,O
not,3635,O
affect,3635,O
the,3635,O
relaxant,3635,O
response,3635,O
to,3635,O
"UK14,304",3635,B-CHEMICAL
",",3635,O
suggesting,3635,O
that,3635,O
cAMP,3635,B-CHEMICAL
is,3635,O
not,3635,O
involved,3635,O
in,3635,O
the,3635,O
coupling,3635,O
of,3635,O
alpha-2,3635,B-GENE-N
adrenoceptors,3635,I-GENE-N
to,3635,O
nitric,3635,B-CHEMICAL
oxide-induced,3635,O
vascular,3635,O
relaxation,3635,O
.,3635,O
Determination,3636,O
of,3636,O
paralytic,3636,O
shellfish,3636,O
poisoning,3636,O
toxins,3636,O
by,3636,O
HILIC-MS/MS,3636,O
coupled,3636,O
with,3636,O
dispersive,3636,O
solid,3636,O
phase,3636,O
extraction,3636,O
.,3636,O
This,3637,O
paper,3637,O
describes,3637,O
the,3637,O
use,3637,O
of,3637,O
QuEChERS,3637,O
(,3637,O
Quick,3637,O
",",3637,O
Easy,3637,O
",",3637,O
Cheap,3637,O
",",3637,O
Effective,3637,O
",",3637,O
Rugged,3637,O
and,3637,O
Safe,3637,O
),3637,O
for,3637,O
the,3637,O
extraction,3637,O
",",3637,O
cleanup,3637,O
and,3637,O
detection,3637,O
of,3637,O
10,3637,O
paralytic,3637,O
shellfish,3637,O
toxins,3637,O
(,3637,O
PSP,3637,O
),3637,O
in,3637,O
sea,3637,O
food,3637,O
by,3637,O
HILIC-MS/MS,3637,O
with,3637,O
positive,3637,O
ESI,3637,O
.,3637,O
Matrix,3638,O
matched,3638,O
calibration,3638,O
standards,3638,O
were,3638,O
used,3638,O
to,3638,O
compensate,3638,O
for,3638,O
matrix,3638,O
effects,3638,O
.,3638,O
The,3639,O
toxins,3639,O
were,3639,O
extracted,3639,O
with,3639,O
acetonitrile/water,3639,B-CHEMICAL
(,3639,O
90:10,3639,O
",",3639,O
v/v,3639,O
),3639,O
containing,3639,O
0.1,3639,O
%,3639,O
formic,3639,B-CHEMICAL
acid,3639,I-CHEMICAL
and,3639,O
cleaned,3639,O
by,3639,O
HLB,3639,O
and,3639,O
GCB,3639,B-CHEMICAL
sorbents,3639,O
.,3639,O
Qualitative,3640,O
and,3640,O
quantitative,3640,O
detection,3640,O
for,3640,O
the,3640,O
analytes,3640,O
were,3640,O
carried,3640,O
out,3640,O
under,3640,O
the,3640,O
multiple,3640,O
reaction,3640,O
monitoring,3640,O
(,3640,O
MRM,3640,O
),3640,O
in,3640,O
positive,3640,O
ionization,3640,O
mode,3640,O
after,3640,O
chromatography,3640,O
separation,3640,O
on,3640,O
a,3640,O
TSK-gel,3640,O
Amide-80®,3640,B-CHEMICAL
column,3640,O
(,3640,O
150,3640,O
mm×2.0,3640,O
mm×3,3640,O
μm,3640,O
),3640,O
.,3640,O
Studies,3641,O
at,3641,O
three,3641,O
fortification,3641,O
levels,3641,O
for,3641,O
the,3641,O
toxins,3641,O
in,3641,O
the,3641,O
range,3641,O
of,3641,O
8.1-225.5,3641,O
μg/kg,3641,O
gave,3641,O
mean,3641,O
recoveries,3641,O
from,3641,O
71.3,3641,O
%,3641,O
to,3641,O
104.6,3641,O
%,3641,O
with,3641,O
relative,3641,O
standard,3641,O
deviation,3641,O
(,3641,O
RSD,3641,O
),3641,O
≤,3641,O
15.8,3641,O
%,3641,O
.,3641,O
The,3642,O
limit,3642,O
of,3642,O
detection,3642,O
(,3642,O
LOD,3642,O
),3642,O
was,3642,O
below,3642,O
the,3642,O
recommended,3642,O
regulatory,3642,O
limit,3642,O
of,3642,O
170,3642,O
μgSTX,3642,O
(,3642,O
equ,3642,O
.,3642,O
),3643,O
/kg,3643,O
and,3643,O
the,3643,O
proposed,3643,O
method,3643,O
fully,3643,O
meets,3643,O
the,3643,O
needs,3643,O
of,3643,O
daily,3643,O
monitoring,3643,O
.,3643,O
Comparative,3644,O
gene,3644,O
expression,3644,O
profiling,3644,O
of,3644,O
in,3644,O
vitro,3644,O
differentiated,3644,O
megakaryocytes,3644,O
and,3644,O
erythroblasts,3644,O
identifies,3644,O
novel,3644,O
activatory,3644,O
and,3644,O
inhibitory,3644,O
platelet,3644,O
membrane,3644,O
proteins,3644,O
.,3644,O
To,3645,O
identify,3645,O
previously,3645,O
unknown,3645,O
platelet,3645,B-GENE-N
receptors,3645,I-GENE-N
we,3645,O
compared,3645,O
the,3645,O
transcriptomes,3645,O
of,3645,O
in,3645,O
vitro,3645,O
differentiated,3645,O
megakaryocytes,3645,O
(,3645,O
MKs,3645,O
),3645,O
and,3645,O
erythroblasts,3645,O
(,3645,O
EBs,3645,O
),3645,O
.,3645,O
RNA,3646,O
was,3646,O
obtained,3646,O
from,3646,O
purified,3646,O
",",3646,O
biologically,3646,O
paired,3646,O
MK,3646,O
and,3646,O
EB,3646,O
cultures,3646,O
and,3646,O
compared,3646,O
using,3646,O
cDNA,3646,O
microarrays,3646,O
.,3646,O
Bioinformatical,3647,O
analysis,3647,O
of,3647,O
MK-up-regulated,3647,O
genes,3647,O
identified,3647,O
151,3647,O
transcripts,3647,O
encoding,3647,O
transmembrane,3647,O
domain-containing,3647,O
proteins,3647,O
.,3647,O
Although,3648,O
many,3648,O
of,3648,O
these,3648,O
were,3648,O
known,3648,O
platelet,3648,O
genes,3648,O
",",3648,O
a,3648,O
number,3648,O
of,3648,O
previously,3648,O
unidentified,3648,O
or,3648,O
poorly,3648,O
characterized,3648,O
transcripts,3648,O
were,3648,O
also,3648,O
detected,3648,O
.,3648,O
Many,3649,O
of,3649,O
these,3649,O
transcripts,3649,O
",",3649,O
including,3649,O
G6b,3649,B-GENE-Y
",",3649,O
G6f,3649,B-GENE-Y
",",3649,O
LRRC32,3649,B-GENE-Y
",",3649,O
LAT2,3649,B-GENE-Y
",",3649,O
and,3649,O
the,3649,O
G,3649,B-GENE-N
protein-coupled,3649,I-GENE-N
receptor,3649,I-GENE-N
SUCNR1,3649,B-GENE-Y
",",3649,O
encode,3649,O
proteins,3649,O
with,3649,O
structural,3649,O
features,3649,O
or,3649,O
functions,3649,O
that,3649,O
suggest,3649,O
they,3649,O
may,3649,O
be,3649,O
involved,3649,O
in,3649,O
the,3649,O
modulation,3649,O
of,3649,O
platelet,3649,O
function,3649,O
.,3649,O
Immunoblotting,3650,O
on,3650,O
platelets,3650,O
confirmed,3650,O
the,3650,O
presence,3650,O
of,3650,O
the,3650,O
encoded,3650,O
proteins,3650,O
",",3650,O
and,3650,O
flow,3650,O
cytometric,3650,O
analysis,3650,O
confirmed,3650,O
the,3650,O
expression,3650,O
of,3650,O
G6b,3650,B-GENE-Y
",",3650,O
G6f,3650,B-GENE-Y
",",3650,O
and,3650,O
LRRC32,3650,B-GENE-Y
on,3650,O
the,3650,O
surface,3650,O
of,3650,O
platelets,3650,O
.,3650,O
Through,3651,O
comparative,3651,O
analysis,3651,O
of,3651,O
expression,3651,O
in,3651,O
platelets,3651,O
and,3651,O
other,3651,O
blood,3651,O
cells,3651,O
we,3651,O
demonstrated,3651,O
that,3651,O
G6b,3651,B-GENE-Y
",",3651,O
G6f,3651,B-GENE-Y
",",3651,O
and,3651,O
LRRC32,3651,B-GENE-Y
are,3651,O
restricted,3651,O
to,3651,O
the,3651,O
platelet,3651,O
lineage,3651,O
",",3651,O
whereas,3651,O
LAT2,3651,B-GENE-Y
and,3651,O
SUCNR1,3651,B-GENE-Y
were,3651,O
also,3651,O
detected,3651,O
in,3651,O
other,3651,O
blood,3651,O
cells,3651,O
.,3651,O
The,3652,O
identification,3652,O
of,3652,O
the,3652,O
succinate,3652,B-GENE-N
receptor,3652,I-GENE-N
SUCNR1,3652,B-GENE-Y
in,3652,O
platelets,3652,O
is,3652,O
of,3652,O
particular,3652,O
interest,3652,O
",",3652,O
because,3652,O
physiologically,3652,O
relevant,3652,O
concentrations,3652,O
of,3652,O
succinate,3652,B-CHEMICAL
were,3652,O
shown,3652,O
to,3652,O
potentiate,3652,O
the,3652,O
effect,3652,O
of,3652,O
low,3652,O
doses,3652,O
of,3652,O
a,3652,O
variety,3652,O
of,3652,O
platelet,3652,O
agonists,3652,O
.,3652,O
Neostigmine,3653,B-CHEMICAL
:,3653,O
safe,3653,O
and,3653,O
effective,3653,O
treatment,3653,O
for,3653,O
acute,3653,O
colonic,3653,O
pseudo-obstruction,3653,O
.,3653,O
BACKGROUND,3654,O
:,3654,O
Ogilvie,3654,O
's,3654,O
syndrome,3654,O
",",3654,O
or,3654,O
acute,3654,O
colonic,3654,O
pseudo-obstruction,3654,O
",",3654,O
is,3654,O
a,3654,O
common,3654,O
and,3654,O
relatively,3654,O
dangerous,3654,O
condition,3654,O
.,3654,O
If,3655,O
left,3655,O
untreated,3655,O
",",3655,O
it,3655,O
may,3655,O
cause,3655,O
ischemic,3655,O
necrosis,3655,O
and,3655,O
colonic,3655,O
perforation,3655,O
",",3655,O
with,3655,O
a,3655,O
mortality,3655,O
rate,3655,O
as,3655,O
high,3655,O
as,3655,O
50,3655,O
percent,3655,O
.,3655,O
Neostigmine,3656,B-CHEMICAL
enhances,3656,O
excitatory,3656,O
parasympathetic,3656,O
activity,3656,O
by,3656,O
competing,3656,O
with,3656,O
acetylcholine,3656,B-CHEMICAL
for,3656,O
attachment,3656,O
to,3656,O
acetylcholinesterase,3656,B-GENE-Y
at,3656,O
sites,3656,O
of,3656,O
cholinergic,3656,O
transmission,3656,O
and,3656,O
enhancing,3656,O
cholinergic,3656,O
action,3656,O
.,3656,O
We,3657,O
hypothesized,3657,O
that,3657,O
neostigmine,3657,B-CHEMICAL
would,3657,O
restore,3657,O
peristalsis,3657,O
in,3657,O
patients,3657,O
with,3657,O
acute,3657,O
colonic,3657,O
pseudo-obstruction,3657,O
.,3657,O
METHODS,3658,O
:,3658,O
Twenty-eight,3658,O
patients,3658,O
at,3658,O
Fletcher,3658,O
Allen,3658,O
Health,3658,O
Care,3658,O
and,3658,O
The,3658,O
Cleveland,3658,O
Clinic,3658,O
Foundation,3658,O
were,3658,O
treated,3658,O
for,3658,O
acute,3658,O
colonic,3658,O
pseudo-obstruction,3658,O
with,3658,O
neostigmine,3658,B-CHEMICAL
2.5,3658,O
mg,3658,O
IV,3658,O
over,3658,O
3,3658,O
minutes,3658,O
while,3658,O
being,3658,O
monitored,3658,O
with,3658,O
telemetry,3658,O
.,3658,O
Mechanical,3659,O
obstruction,3659,O
had,3659,O
been,3659,O
excluded,3659,O
.,3659,O
RESULTS,3660,O
:,3660,O
Complete,3660,O
clinical,3660,O
resolution,3660,O
of,3660,O
large,3660,O
bowel,3660,O
distention,3660,O
occurred,3660,O
in,3660,O
26,3660,O
of,3660,O
the,3660,O
28,3660,O
patients,3660,O
.,3660,O
Time,3661,O
to,3661,O
pass,3661,O
flatus,3661,O
varied,3661,O
from,3661,O
30,3661,O
seconds,3661,O
to,3661,O
10,3661,O
minutes,3661,O
after,3661,O
administration,3661,O
of,3661,O
neostigmine,3661,B-CHEMICAL
.,3661,O
No,3662,O
adverse,3662,O
effects,3662,O
or,3662,O
complications,3662,O
were,3662,O
noted,3662,O
.,3662,O
Of,3663,O
the,3663,O
two,3663,O
patients,3663,O
who,3663,O
did,3663,O
not,3663,O
resolve,3663,O
",",3663,O
one,3663,O
had,3663,O
a,3663,O
sigmoid,3663,O
cancer,3663,O
that,3663,O
required,3663,O
resection,3663,O
and,3663,O
one,3663,O
patient,3663,O
died,3663,O
from,3663,O
multiorgan,3663,O
failure,3663,O
.,3663,O
CONCLUSION,3664,O
:,3664,O
This,3664,O
study,3664,O
supports,3664,O
the,3664,O
theory,3664,O
that,3664,O
acute,3664,O
colonic,3664,O
pseudo-obstruction,3664,O
is,3664,O
the,3664,O
result,3664,O
of,3664,O
excessive,3664,O
parasympathetic,3664,O
suppression,3664,O
rather,3664,O
than,3664,O
sympathetic,3664,O
overactivity,3664,O
.,3664,O
We,3665,O
have,3665,O
shown,3665,O
that,3665,O
neostigmine,3665,B-CHEMICAL
is,3665,O
a,3665,O
safe,3665,O
and,3665,O
effective,3665,O
treatment,3665,O
for,3665,O
acute,3665,O
colonic,3665,O
pseudo-obstruction,3665,O
.,3665,O
Apoptosis,3666,O
initiation,3666,O
of,3666,O
β-ionone,3666,B-CHEMICAL
in,3666,O
SGC-7901,3666,O
gastric,3666,O
carcinoma,3666,O
cancer,3666,O
cells,3666,O
via,3666,O
a,3666,O
PI3K-AKT,3666,B-GENE-N
pathway,3666,O
.,3666,O
β-ionone,3667,B-CHEMICAL
has,3667,O
been,3667,O
shown,3667,O
to,3667,O
hold,3667,O
potent,3667,O
anti-proliferative,3667,O
and,3667,O
apoptosis,3667,O
induction,3667,O
properties,3667,O
in,3667,O
vitro,3667,O
and,3667,O
in,3667,O
vivo,3667,O
.,3667,O
To,3668,O
investigate,3668,O
the,3668,O
effects,3668,O
of,3668,O
β-ionone,3668,B-CHEMICAL
on,3668,O
apoptosis,3668,O
initiation,3668,O
and,3668,O
its,3668,O
possible,3668,O
mechanisms,3668,O
of,3668,O
action,3668,O
",",3668,O
we,3668,O
qualified,3668,O
cell,3668,O
apoptosis,3668,O
",",3668,O
proteins,3668,O
related,3668,O
to,3668,O
apoptosis,3668,O
and,3668,O
a,3668,O
phosphatidylinositol,3668,B-GENE-N
3-kinase,3668,I-GENE-N
(,3668,O
PI3K,3668,B-GENE-N
),3668,O
-AKT,3668,O
pathway,3668,O
in,3668,O
human,3668,O
gastric,3668,O
adenocarcinoma,3668,O
cancer,3668,O
SGC-7901,3668,O
cells,3668,O
.,3668,O
The,3669,O
results,3669,O
demonstrated,3669,O
that,3669,O
β-ionone-induced,3669,B-CHEMICAL
apoptosis,3669,O
in,3669,O
a,3669,O
dose-dependent,3669,O
manner,3669,O
in,3669,O
SGC-7901,3669,O
cells,3669,O
treated,3669,O
with,3669,O
β-ionone,3669,B-CHEMICAL
(,3669,O
25,3669,O
",",3669,O
50,3669,O
",",3669,O
100,3669,O
and,3669,O
200,3669,O
μmol/L,3669,O
),3669,O
for,3669,O
24,3669,O
h.,3669,O
β-ionone,3669,B-CHEMICAL
was,3669,O
also,3669,O
shown,3669,O
to,3669,O
induce,3669,O
the,3669,O
expression,3669,O
of,3669,O
cleaved-caspase-3,3669,O
and,3669,O
inhibit,3669,O
bcl-2,3669,B-GENE-Y
expression,3669,O
in,3669,O
SGC-7901,3669,O
cells,3669,O
in,3669,O
a,3669,O
dose-dependent,3669,O
manner,3669,O
.,3669,O
The,3670,O
significantly,3670,O
decreased,3670,O
levels,3670,O
of,3670,O
p-PI3K,3670,B-GENE-N
and,3670,O
p-AKT,3670,B-GENE-N
expression,3670,O
were,3670,O
observed,3670,O
in,3670,O
SGC-7901,3670,O
cells,3670,O
after,3670,O
β-ionone,3670,B-CHEMICAL
treatments,3670,O
in,3670,O
a,3670,O
time-,3670,O
and,3670,O
dose-dependent,3670,O
manner,3670,O
(,3670,O
P,3670,O
<,3670,O
0.01,3670,O
),3670,O
.,3670,O
Thus,3671,O
",",3671,O
the,3671,O
apoptosis,3671,O
induction,3671,O
in,3671,O
SGC-7901,3671,O
cells,3671,O
by,3671,O
β-ionone,3671,B-CHEMICAL
may,3671,O
be,3671,O
regulated,3671,O
through,3671,O
a,3671,O
PI3K-AKT,3671,B-GENE-N
pathway,3671,O
.,3671,O
These,3672,O
results,3672,O
demonstrate,3672,O
a,3672,O
potential,3672,O
mechanism,3672,O
by,3672,O
which,3672,O
β-ionone,3672,B-CHEMICAL
to,3672,O
induce,3672,O
apoptosis,3672,O
initiation,3672,O
in,3672,O
SGC-7901,3672,O
cells,3672,O
.,3672,O
Eprosartan,3673,B-CHEMICAL
for,3673,O
the,3673,O
treatment,3673,O
of,3673,O
hypertension,3673,O
.,3673,O
Antihypertensive,3674,O
agents,3674,O
are,3674,O
proven,3674,O
to,3674,O
reduce,3674,O
the,3674,O
cardiovascular,3674,O
risk,3674,O
of,3674,O
stroke,3674,O
",",3674,O
coronary,3674,O
heart,3674,O
disease,3674,O
and,3674,O
cardiac,3674,O
failure,3674,O
.,3674,O
The,3675,O
ideal,3675,O
antihypertensive,3675,O
agent,3675,O
should,3675,O
control,3675,O
all,3675,O
grades,3675,O
of,3675,O
hypertension,3675,O
and,3675,O
have,3675,O
a,3675,O
placebo-like,3675,O
side,3675,O
effect,3675,O
profile,3675,O
.,3675,O
Angiotensin,3676,B-GENE-N
II,3676,I-GENE-N
(,3676,I-GENE-N
AII,3676,I-GENE-N
),3676,I-GENE-N
receptor,3676,I-GENE-N
antagonists,3676,O
are,3676,O
a,3676,O
relatively,3676,O
new,3676,O
class,3676,O
of,3676,O
antihypertensive,3676,O
agent,3676,O
that,3676,O
block,3676,O
AII,3676,B-GENE-Y
Type,3676,I-GENE-Y
1,3676,I-GENE-Y
(,3676,I-GENE-Y
AT,3676,I-GENE-Y
(,3676,I-GENE-Y
1,3676,I-GENE-Y
),3676,I-GENE-Y
),3676,I-GENE-Y
receptors,3676,I-GENE-Y
",",3676,O
and,3676,O
reduce,3676,O
the,3676,O
pressor,3676,O
effects,3676,O
of,3676,O
AII,3676,B-GENE-Y
in,3676,O
the,3676,O
vasculature,3676,O
.,3676,O
By,3677,O
this,3677,O
mechanism,3677,O
",",3677,O
they,3677,O
induce,3677,O
similar,3677,O
pharmacological,3677,O
effects,3677,O
compared,3677,O
with,3677,O
angiotensin-converting,3677,B-GENE-Y
enzyme,3677,I-GENE-Y
(,3677,O
ACE,3677,B-GENE-Y
),3677,O
inhibitors,3677,O
",",3677,O
resulting,3677,O
in,3677,O
a,3677,O
lowering,3677,O
of,3677,O
blood,3677,O
pressure,3677,O
.,3677,O
However,3678,O
",",3678,O
AII,3678,B-GENE-N
receptor,3678,I-GENE-N
blockers,3678,O
differ,3678,O
from,3678,O
ACE,3678,B-GENE-Y
inhibitors,3678,O
with,3678,O
respect,3678,O
to,3678,O
side,3678,O
effects,3678,O
",",3678,O
and,3678,O
induce,3678,O
less,3678,O
cough,3678,O
",",3678,O
a,3678,O
side,3678,O
effect,3678,O
which,3678,O
may,3678,O
be,3678,O
related,3678,O
to,3678,O
bradykinin,3678,B-GENE-Y
or,3678,O
other,3678,O
mediators,3678,O
such,3678,O
as,3678,O
substance,3678,B-CHEMICAL
P.,3678,O
Within,3678,O
the,3678,O
class,3678,O
of,3678,O
AII,3678,B-GENE-Y
blockers,3678,O
",",3678,O
eprosartan,3678,B-CHEMICAL
differs,3678,O
from,3678,O
other,3678,O
currently,3678,O
available,3678,O
agents,3678,O
in,3678,O
terms,3678,O
of,3678,O
chemical,3678,O
structure,3678,O
",",3678,O
as,3678,O
it,3678,O
is,3678,O
a,3678,O
non-biphenyl,3678,O
",",3678,O
non-tetrazole,3678,O
",",3678,O
non-peptide,3678,O
antagonist,3678,O
with,3678,O
a,3678,O
dual,3678,O
pharmacological,3678,O
mode,3678,O
of,3678,O
action,3678,O
.,3678,O
Eprosartan,3679,B-CHEMICAL
acts,3679,O
at,3679,O
vascular,3679,O
AT,3679,B-GENE-Y
(,3679,I-GENE-Y
1,3679,I-GENE-Y
),3679,I-GENE-Y
receptors,3679,I-GENE-Y
(,3679,O
postsynaptically,3679,O
),3679,O
and,3679,O
at,3679,O
presynaptic,3679,O
AT,3679,B-GENE-Y
(,3679,I-GENE-Y
1,3679,I-GENE-Y
),3679,I-GENE-Y
receptors,3679,I-GENE-Y
",",3679,O
where,3679,O
it,3679,O
inhibits,3679,O
sympathetically,3679,O
stimulated,3679,O
noradrenaline,3679,B-CHEMICAL
release,3679,O
.,3679,O
Its,3680,O
lack,3680,O
of,3680,O
metabolism,3680,O
by,3680,O
cytochrome,3680,B-GENE-N
P450,3680,I-GENE-N
enzymes,3680,O
confers,3680,O
a,3680,O
low,3680,O
potential,3680,O
for,3680,O
metabolic,3680,O
drug,3680,O
interactions,3680,O
and,3680,O
may,3680,O
be,3680,O
of,3680,O
importance,3680,O
when,3680,O
treating,3680,O
elderly,3680,O
patients,3680,O
and,3680,O
those,3680,O
on,3680,O
multiple,3680,O
drugs,3680,O
.,3680,O
In,3681,O
clinical,3681,O
trials,3681,O
",",3681,O
eprosartan,3681,B-CHEMICAL
has,3681,O
been,3681,O
demonstrated,3681,O
to,3681,O
be,3681,O
at,3681,O
least,3681,O
as,3681,O
effective,3681,O
in,3681,O
reducing,3681,O
blood,3681,O
pressure,3681,O
as,3681,O
the,3681,O
ACE,3681,B-GENE-Y
inhibitor,3681,O
enalapril,3681,B-CHEMICAL
",",3681,O
and,3681,O
has,3681,O
significantly,3681,O
lower,3681,O
side,3681,O
effects,3681,O
.,3681,O
Eprosartan,3682,B-CHEMICAL
is,3682,O
safe,3682,O
",",3682,O
effective,3682,O
and,3682,O
well-tolerated,3682,O
in,3682,O
long-term,3682,O
treatment,3682,O
",",3682,O
either,3682,O
as,3682,O
a,3682,O
monotherapy,3682,O
or,3682,O
in,3682,O
combination,3682,O
with,3682,O
other,3682,O
antihypertensive,3682,O
drugs,3682,O
such,3682,O
as,3682,O
hydrochlorothiazide,3682,B-CHEMICAL
.,3682,O
Reductive,3683,O
detoxification,3683,O
of,3683,O
arylhydroxylamine,3683,B-CHEMICAL
carcinogens,3683,O
by,3683,O
human,3683,B-GENE-Y
NADH,3683,I-GENE-Y
cytochrome,3683,I-GENE-Y
b5,3683,I-GENE-Y
reductase,3683,I-GENE-Y
and,3683,O
cytochrome,3683,B-GENE-Y
b5,3683,I-GENE-Y
.,3683,O
Heterocyclic,3684,B-CHEMICAL
and,3684,I-CHEMICAL
aromatic,3684,I-CHEMICAL
amine,3684,I-CHEMICAL
carcinogens,3684,O
are,3684,O
thought,3684,O
to,3684,O
lead,3684,O
to,3684,O
tumor,3684,O
initiation,3684,O
via,3684,O
the,3684,O
formation,3684,O
of,3684,O
DNA,3684,O
adducts,3684,O
",",3684,O
and,3684,O
bioactivation,3684,O
to,3684,O
arylhydroxylamine,3684,B-CHEMICAL
metabolites,3684,O
is,3684,O
necessary,3684,O
for,3684,O
reactivity,3684,O
with,3684,O
DNA,3684,O
.,3684,O
Carcinogenic,3685,O
arylhydroxylamine,3685,B-CHEMICAL
metabolites,3685,O
are,3685,O
cleared,3685,O
by,3685,O
a,3685,O
microsomal,3685,O
",",3685,O
NADH-dependent,3685,B-CHEMICAL
",",3685,O
oxygen-insensitive,3685,B-CHEMICAL
reduction,3685,O
pathway,3685,O
in,3685,O
humans,3685,O
",",3685,O
which,3685,O
may,3685,O
be,3685,O
a,3685,O
source,3685,O
of,3685,O
interindividual,3685,O
variability,3685,O
in,3685,O
response,3685,O
to,3685,O
aromatic,3685,B-CHEMICAL
amine,3685,I-CHEMICAL
carcinogens,3685,O
.,3685,O
The,3686,O
purpose,3686,O
of,3686,O
this,3686,O
study,3686,O
was,3686,O
to,3686,O
characterize,3686,O
the,3686,O
identity,3686,O
of,3686,O
this,3686,O
reduction,3686,O
pathway,3686,O
in,3686,O
human,3686,O
liver,3686,O
.,3686,O
On,3687,O
the,3687,O
basis,3687,O
of,3687,O
our,3687,O
findings,3687,O
with,3687,O
structurally,3687,O
similar,3687,O
arylhydroxylamine,3687,B-CHEMICAL
metabolites,3687,O
of,3687,O
therapeutic,3687,O
drugs,3687,O
",",3687,O
we,3687,O
hypothesized,3687,O
that,3687,O
the,3687,O
reductive,3687,O
detoxification,3687,O
of,3687,O
arylhydroxylamine,3687,B-CHEMICAL
carcinogens,3687,O
was,3687,O
catalyzed,3687,O
by,3687,O
NADH,3687,B-GENE-Y
cytochrome,3687,I-GENE-Y
b5,3687,I-GENE-Y
reductase,3687,I-GENE-Y
(,3687,O
b5R,3687,B-GENE-Y
),3687,O
and,3687,O
cytochrome,3687,B-GENE-Y
b5,3687,I-GENE-Y
(,3687,O
cyt,3687,B-GENE-Y
b5,3687,I-GENE-Y
),3687,O
.,3687,O
We,3688,O
found,3688,O
that,3688,O
reduction,3688,O
of,3688,O
the,3688,O
carcinogenic,3688,O
hydroxylamines,3688,B-CHEMICAL
of,3688,O
the,3688,O
aromatic,3688,B-CHEMICAL
amine,3688,I-CHEMICAL
4-aminobiphenyl,3688,B-CHEMICAL
(,3688,O
4-ABP,3688,B-CHEMICAL
;,3688,O
found,3688,O
in,3688,O
cigarette,3688,O
smoke,3688,O
),3688,O
and,3688,O
the,3688,O
heterocyclic,3688,B-CHEMICAL
amine,3688,I-CHEMICAL
2-amino-1-methyl-6-phenylimidazo,3688,B-CHEMICAL
[,3688,I-CHEMICAL
"4,5-b",3688,I-CHEMICAL
],3688,I-CHEMICAL
pyridine,3688,I-CHEMICAL
(,3688,O
PhIP,3688,B-CHEMICAL
;,3688,O
found,3688,O
in,3688,O
grilled,3688,O
meats,3688,O
),3688,O
was,3688,O
indeed,3688,O
catalyzed,3688,O
by,3688,O
a,3688,O
purified,3688,O
system,3688,O
containing,3688,O
only,3688,O
human,3688,B-GENE-Y
b5R,3688,I-GENE-Y
and,3688,O
cyt,3688,B-GENE-Y
b5,3688,I-GENE-Y
.,3688,O
Specific,3689,O
activities,3689,O
were,3689,O
56-346-fold,3689,O
higher,3689,O
in,3689,O
the,3689,O
purified,3689,O
system,3689,O
as,3689,O
compared,3689,O
to,3689,O
human,3689,O
liver,3689,O
microsomes,3689,O
(,3689,O
HLM,3689,O
),3689,O
",",3689,O
with,3689,O
similar,3689,O
Michaelis-Menten,3689,O
constants,3689,O
(,3689,O
K,3689,O
(,3689,O
m,3689,O
),3689,O
values,3689,O
),3689,O
in,3689,O
both,3689,O
systems,3689,O
.,3689,O
The,3690,O
stoichiometry,3690,O
for,3690,O
b5R,3690,B-GENE-Y
and,3690,O
cyt,3690,B-GENE-Y
b5,3690,I-GENE-Y
that,3690,O
yielded,3690,O
the,3690,O
highest,3690,O
activity,3690,O
in,3690,O
the,3690,O
purified,3690,O
system,3690,O
was,3690,O
also,3690,O
similar,3690,O
to,3690,O
that,3690,O
found,3690,O
in,3690,O
native,3690,O
HLM,3690,O
(,3690,O
approximately,3690,O
1:8,3690,O
to,3690,O
1:10,3690,O
),3690,O
.,3690,O
Polyclonal,3691,O
antisera,3691,O
to,3691,O
either,3691,O
b5R,3691,B-GENE-Y
or,3691,O
cyt,3691,B-GENE-Y
b5,3691,I-GENE-Y
significantly,3691,O
inhibited,3691,O
N-hydroxy-4-aminobiphenyl,3691,B-CHEMICAL
(,3691,O
NHOH-4-ABP,3691,B-CHEMICAL
),3691,O
reduction,3691,O
by,3691,O
95,3691,O
and,3691,O
89,3691,O
%,3691,O
",",3691,O
respectively,3691,O
",",3691,O
and,3691,O
immunoreactive,3691,O
cyt,3691,O
b5,3691,O
protein,3691,O
content,3691,O
in,3691,O
individual,3691,O
HLM,3691,O
was,3691,O
significantly,3691,O
correlated,3691,O
with,3691,O
individual,3691,O
reduction,3691,O
of,3691,O
both,3691,O
NHOH-4-ABP,3691,B-CHEMICAL
and,3691,O
N-hydroxy-PhIP,3691,B-CHEMICAL
(,3691,O
NHOH-PhIP,3691,B-CHEMICAL
),3691,O
.,3691,O
Finally,3692,O
",",3692,O
titration,3692,O
of,3692,O
HLM,3692,O
into,3692,O
the,3692,O
purified,3692,O
b5R/cyt,3692,B-GENE-Y
b5,3692,I-GENE-Y
system,3692,O
did,3692,O
not,3692,O
enhance,3692,O
the,3692,O
efficiency,3692,O
of,3692,O
reduction,3692,O
activity,3692,O
.,3692,O
We,3693,O
conclude,3693,O
that,3693,O
b5R,3693,B-GENE-Y
and,3693,O
cyt,3693,B-GENE-Y
b5,3693,I-GENE-Y
are,3693,O
together,3693,O
solely,3693,O
capable,3693,O
of,3693,O
the,3693,O
reduction,3693,O
of,3693,O
arylhydroxylamine,3693,B-CHEMICAL
carcinogens,3693,O
",",3693,O
and,3693,O
we,3693,O
further,3693,O
hypothesize,3693,O
that,3693,O
this,3693,O
pathway,3693,O
may,3693,O
be,3693,O
a,3693,O
source,3693,O
of,3693,O
individual,3693,O
variability,3693,O
with,3693,O
respect,3693,O
to,3693,O
cancer,3693,O
susceptibility,3693,O
following,3693,O
4-ABP,3693,B-CHEMICAL
or,3693,O
PhIP,3693,B-CHEMICAL
exposure,3693,O
.,3693,O
Conformation,3694,O
Guides,3694,O
Molecular,3694,O
Efficacy,3694,O
in,3694,O
Docking,3694,O
Screens,3694,O
of,3694,O
Activated,3694,O
β-2,3694,B-GENE-Y
Adrenergic,3694,I-GENE-Y
G,3694,I-GENE-Y
Protein,3694,I-GENE-Y
Coupled,3694,I-GENE-Y
Receptor,3694,I-GENE-Y
.,3694,O
A,3695,O
prospective,3695,O
",",3695,O
large,3695,O
library,3695,O
virtual,3695,O
screen,3695,O
against,3695,O
an,3695,O
activated,3695,O
β2-adrenergic,3695,B-GENE-Y
receptor,3695,I-GENE-Y
(,3695,O
β2AR,3695,B-GENE-Y
),3695,O
structure,3695,O
returned,3695,O
potent,3695,O
agonists,3695,O
to,3695,O
the,3695,O
exclusion,3695,O
of,3695,O
inverse-agonists,3695,O
",",3695,O
providing,3695,O
the,3695,O
first,3695,O
complement,3695,O
to,3695,O
the,3695,O
previous,3695,O
virtual,3695,O
screening,3695,O
campaigns,3695,O
against,3695,O
inverse-agonist-bound,3695,O
G,3695,B-GENE-N
protein,3695,I-GENE-N
coupled,3695,I-GENE-N
receptor,3695,I-GENE-N
(,3695,O
GPCR,3695,B-GENE-N
),3695,O
structures,3695,O
",",3695,O
which,3695,O
predicted,3695,O
only,3695,O
inverse-agonists,3695,O
.,3695,O
In,3696,O
addition,3696,O
",",3696,O
two,3696,O
hits,3696,O
recapitulated,3696,O
the,3696,O
signaling,3696,O
profile,3696,O
of,3696,O
the,3696,O
co-crystal,3696,O
ligand,3696,O
with,3696,O
respect,3696,O
to,3696,O
the,3696,O
G,3696,B-GENE-N
protein,3696,I-GENE-N
and,3696,O
arrestin,3696,B-GENE-N
mediated,3696,O
signaling,3696,O
.,3696,O
This,3697,O
functional,3697,O
fidelity,3697,O
has,3697,O
important,3697,O
implications,3697,O
in,3697,O
drug,3697,O
design,3697,O
",",3697,O
as,3697,O
the,3697,O
ability,3697,O
to,3697,O
predict,3697,O
ligands,3697,O
with,3697,O
predefined,3697,O
signaling,3697,O
properties,3697,O
is,3697,O
highly,3697,O
desirable,3697,O
.,3697,O
However,3698,O
",",3698,O
the,3698,O
agonist-bound,3698,O
state,3698,O
provides,3698,O
an,3698,O
uncertain,3698,O
template,3698,O
for,3698,O
modeling,3698,O
the,3698,O
activated,3698,O
conformation,3698,O
of,3698,O
other,3698,O
GPCRs,3698,B-GENE-N
",",3698,O
as,3698,O
a,3698,O
dopamine,3698,B-GENE-N
D2,3698,I-GENE-N
receptor,3698,I-GENE-N
(,3698,O
DRD2,3698,B-GENE-Y
),3698,O
activated,3698,O
model,3698,O
templated,3698,O
on,3698,O
the,3698,O
activated,3698,O
β2AR,3698,B-GENE-Y
structure,3698,O
returned,3698,O
few,3698,O
hits,3698,O
of,3698,O
only,3698,O
marginal,3698,O
potency,3698,O
.,3698,O
Conformational,3699,O
transitions,3699,O
linked,3699,O
to,3699,O
active,3699,O
site,3699,O
ligation,3699,O
in,3699,O
human,3699,B-GENE-Y
thrombin,3699,I-GENE-Y
:,3699,O
effect,3699,O
on,3699,O
the,3699,O
interaction,3699,O
with,3699,O
fibrinogen,3699,B-GENE-N
and,3699,O
the,3699,O
cleavable,3699,B-GENE-N
platelet,3699,I-GENE-N
receptor,3699,I-GENE-N
.,3699,O
An,3700,O
experimental,3700,O
strategy,3700,O
based,3700,O
on,3700,O
solution,3700,O
viscosity,3700,O
perturbation,3700,O
allowed,3700,O
us,3700,O
to,3700,O
study,3700,O
the,3700,O
energetics,3700,O
of,3700,O
amide-substrates,3700,B-CHEMICAL
",",3700,O
p-aminobenzamidine,3700,B-CHEMICAL
(,3700,O
p-ABZ,3700,B-CHEMICAL
),3700,O
and,3700,O
proflavin,3700,B-CHEMICAL
binding,3700,O
to,3700,O
the,3700,O
catalytic,3700,O
site,3700,O
of,3700,O
two,3700,O
proteolyzed,3700,O
forms,3700,O
of,3700,O
alpha-thrombin,3700,B-GENE-Y
",",3700,O
i.e,3700,O
.,3700,O
zeta-,3701,B-GENE-N
and,3701,I-GENE-N
gamma,3701,I-GENE-N
T-thrombin,3701,I-GENE-N
.,3701,O
These,3702,O
thrombin,3702,B-GENE-Y
derivatives,3702,O
are,3702,O
cleaved,3702,O
at,3702,O
the,3702,O
Leu144-Gly150,3702,O
loop,3702,O
and,3702,O
at,3702,O
the,3702,O
fibrinogen,3702,B-GENE-N
recognition,3702,I-GENE-N
exosite,3702,I-GENE-N
(,3702,O
FRS,3702,B-GENE-N
),3702,O
",",3702,O
respectively,3702,O
.,3702,O
A,3703,O
phenomenological,3703,O
analysis,3703,O
of,3703,O
thermodynamic,3703,O
data,3703,O
showed,3703,O
that,3703,O
the,3703,O
amide,3703,B-CHEMICAL
substrates,3703,O
and,3703,O
p-ABZ,3703,B-CHEMICAL
interactions,3703,O
with,3703,O
zeta-thrombin,3703,B-GENE-Y
were,3703,O
respectively,3703,O
",",3703,O
associated,3703,O
with,3703,O
a,3703,O
chemical,3703,O
compensation,3703,O
(,3703,O
i.e,3703,O
.,3703,O
the,3704,O
linear,3704,O
relationship,3704,O
between,3704,O
entropy,3704,O
and,3704,O
enthalpy,3704,O
of,3704,O
binding,3704,O
),3704,O
and,3704,O
a,3704,O
hydrophobic,3704,O
phenomenon,3704,O
(,3704,O
i.e,3704,O
.,3704,O
a,3705,O
change,3705,O
in,3705,O
the,3705,O
standard,3705,O
heat,3705,O
capacity,3705,O
),3705,O
.,3705,O
The,3706,O
latter,3706,O
was,3706,O
slightly,3706,O
lower,3706,O
than,3706,O
that,3706,O
previously,3706,O
observed,3706,O
for,3706,O
a,3706,O
alpha-thrombin,3706,B-GENE-Y
(,3706,O
0.78,3706,O
+/-,3706,O
0.25,3706,O
versus,3706,O
1.01,3706,O
+/-,3706,O
0.17,3706,O
kcal/mol,3706,O
K,3706,O
),3706,O
.,3706,O
Both,3707,O
phenomenon,3707,O
were,3707,O
absent,3707,O
in,3707,O
gamma,3707,O
T-thrombin,3707,O
.,3707,O
The,3708,O
interaction,3708,O
of,3708,O
a,3708,O
alpha-,3708,B-GENE-N
",",3708,I-GENE-N
zeta-,3708,I-GENE-N
and,3708,I-GENE-N
gamma,3708,I-GENE-N
T-thrombin,3708,I-GENE-N
with,3708,O
macromolecular,3708,O
substrates,3708,O
that,3708,O
``,3708,O
bridge-bind,3708,O
'',3708,O
to,3708,O
both,3708,O
the,3708,O
catalytic,3708,O
site,3708,O
(,3708,O
CS,3708,O
),3708,O
and,3708,O
fibrinogen,3708,B-GENE-N
recognition,3708,I-GENE-N
exosite,3708,I-GENE-N
(,3708,O
FRS,3708,B-GENE-N
),3708,O
",",3708,O
such,3708,O
as,3708,O
fibrinogen,3708,B-GENE-N
and,3708,O
the,3708,O
cleavable,3708,B-GENE-N
platelet,3708,I-GENE-N
receptor,3708,I-GENE-N
(,3708,O
CPR,3708,B-GENE-N
),3708,O
",",3708,O
was,3708,O
also,3708,O
evaluated,3708,O
.,3708,O
These,3709,O
interactions,3709,O
were,3709,O
studied,3709,O
by,3709,O
following,3709,O
fibrinopeptide,3709,B-GENE-Y
A,3709,I-GENE-Y
(,3709,O
FpA,3709,B-GENE-Y
),3709,O
release,3709,O
and,3709,O
by,3709,O
measuring,3709,O
intraplatelet,3709,O
Ca2+,3709,B-CHEMICAL
changes,3709,O
induced,3709,O
by,3709,O
thrombin-CPR,3709,B-GENE-Y
interaction,3709,O
.,3709,O
It,3710,O
was,3710,O
found,3710,O
that,3710,O
the,3710,O
free,3710,O
energy,3710,O
of,3710,O
activation,3710,O
(,3710,O
RT,3710,O
ln,3710,O
Kcat/Km,3710,O
),3710,O
for,3710,O
both,3710,O
fibrinogen,3710,B-GENE-N
and,3710,O
CPR,3710,B-GENE-N
hydrolysis,3710,O
followed,3710,O
the,3710,O
same,3710,O
hierarchy,3710,O
",",3710,O
i.e,3710,O
.,3710,O
alpha,3711,O
>,3711,O
zeta,3711,O
>,3711,O
gamma,3711,O
.,3711,O
Moreover,3712,O
",",3712,O
the,3712,O
values,3712,O
of,3712,O
delta,3712,O
Cp,3712,O
for,3712,O
alpha-,3712,B-GENE-N
",",3712,I-GENE-N
zeta-,3712,I-GENE-N
and,3712,I-GENE-N
gamma,3712,I-GENE-N
T-thrombin,3712,I-GENE-N
interaction,3712,O
with,3712,O
p-ABZ,3712,B-CHEMICAL
were,3712,O
found,3712,O
to,3712,O
be,3712,O
linearly,3712,O
correlated,3712,O
to,3712,O
the,3712,O
free,3712,O
energy,3712,O
of,3712,O
activation,3712,O
for,3712,O
both,3712,O
fibrinogen,3712,B-GENE-N
and,3712,O
CPR,3712,B-GENE-N
cleavage,3712,O
.,3712,O
In,3713,O
conclusion,3713,O
",",3713,O
these,3713,O
data,3713,O
demonstrate,3713,O
that,3713,O
:,3713,O
(,3713,O
1,3713,O
),3713,O
the,3713,O
Leu144-Gly150,3713,O
loop,3713,O
and,3713,O
the,3713,O
FRS,3713,B-GENE-N
are,3713,O
both,3713,O
involved,3713,O
in,3713,O
the,3713,O
conformational,3713,O
transition,3713,O
linked,3713,O
to,3713,O
the,3713,O
binding,3713,O
of,3713,O
p-aminobenzamidine,3713,B-CHEMICAL
to,3713,O
the,3713,O
thrombin,3713,B-GENE-Y
active,3713,O
site,3713,O
;,3713,O
(,3713,O
2,3713,O
),3713,O
the,3713,O
extent,3713,O
of,3713,O
thrombin,3713,B-GENE-Y
's,3713,I-GENE-Y
capacity,3713,O
to,3713,O
undergo,3713,O
conformational,3713,O
transitions,3713,O
in,3713,O
alpha-,3713,O
",",3713,O
zeta-,3713,O
and,3713,O
gamma,3713,O
T,3713,O
forms,3713,O
is,3713,O
positively,3713,O
correlated,3713,O
to,3713,O
the,3713,O
free,3713,O
energy,3713,O
of,3713,O
activation,3713,O
for,3713,O
hydrolysis,3713,O
of,3713,O
macromolecular,3713,O
substrates,3713,O
interacting,3713,O
with,3713,O
both,3713,O
the,3713,O
catalytic,3713,O
domain,3713,O
and,3713,O
the,3713,O
FRS,3713,B-GENE-N
.,3713,O
Neuropsychological,3714,O
and,3714,O
conditioned,3714,O
blocking,3714,O
performance,3714,O
in,3714,O
patients,3714,O
with,3714,O
schizophrenia,3714,O
:,3714,O
assessment,3714,O
of,3714,O
the,3714,O
contribution,3714,O
of,3714,O
neuroleptic,3714,O
dose,3714,O
",",3714,O
serum,3714,O
levels,3714,O
and,3714,O
dopamine,3714,B-GENE-Y
D2-receptor,3714,I-GENE-Y
occupancy,3714,O
.,3714,O
Patients,3715,O
with,3715,O
schizophrenia,3715,O
show,3715,O
impairments,3715,O
of,3715,O
attention,3715,O
and,3715,O
neuropsychological,3715,O
performance,3715,O
",",3715,O
but,3715,O
the,3715,O
extent,3715,O
to,3715,O
which,3715,O
this,3715,O
is,3715,O
attributable,3715,O
to,3715,O
antipsychotic,3715,O
medication,3715,O
remains,3715,O
largely,3715,O
unexplored,3715,O
.,3715,O
We,3716,O
describe,3716,O
here,3716,O
the,3716,O
putative,3716,O
influence,3716,O
of,3716,O
the,3716,O
dose,3716,O
of,3716,O
antipsychotic,3716,O
medication,3716,O
(,3716,O
chlorpromazine,3716,B-CHEMICAL
equivalents,3716,O
",",3716,O
CPZ,3716,B-CHEMICAL
),3716,O
",",3716,O
the,3716,O
antipsychotic,3716,O
serum,3716,O
concentration,3716,O
of,3716,O
dopamine,3716,B-GENE-Y
(,3716,I-GENE-Y
DA,3716,I-GENE-Y
),3716,I-GENE-Y
D2-blocking,3716,O
activity,3716,O
and,3716,O
the,3716,O
approximated,3716,O
central,3716,O
dopamine,3716,B-CHEMICAL
D2-receptor,3716,B-GENE-Y
occupancy,3716,O
(,3716,O
DA,3716,B-CHEMICAL
D2-occupancy,3716,B-GENE-Y
),3716,O
",",3716,O
on,3716,O
conditioned,3716,O
blocking,3716,O
(,3716,O
CB,3716,O
),3716,O
measures,3716,O
of,3716,O
attention,3716,O
and,3716,O
performance,3716,O
on,3716,O
a,3716,O
neuropsychological,3716,O
battery,3716,O
",",3716,O
in,3716,O
108,3716,O
patients,3716,O
with,3716,O
schizophrenia,3716,O
(,3716,O
compared,3716,O
with,3716,O
62,3716,O
healthy,3716,O
controls,3716,O
),3716,O
.,3716,O
Antipsychotic,3717,O
serum,3717,O
concentration,3717,O
and,3717,O
D2-occupancy,3717,B-GENE-Y
were,3717,O
higher,3717,O
in,3717,O
patients,3717,O
with,3717,O
a,3717,O
paranoid,3717,O
versus,3717,O
non-paranoid,3717,O
diagnosis,3717,O
",",3717,O
and,3717,O
in,3717,O
female,3717,O
versus,3717,O
male,3717,O
patients,3717,O
(,3717,O
independent,3717,O
of,3717,O
symptom,3717,O
severity,3717,O
),3717,O
.,3717,O
Controlling,3718,O
for,3718,O
D2-occupancy,3718,B-GENE-Y
removed,3718,O
the,3718,O
difference,3718,O
between,3718,O
high,3718,O
CB,3718,O
in,3718,O
paranoid,3718,O
and,3718,O
impaired,3718,O
low,3718,O
CB,3718,O
in,3718,O
non-paranoid,3718,O
patients,3718,O
.,3718,O
Similar,3719,O
partial,3719,O
correlations,3719,O
for,3719,O
antipsychotic,3719,O
drug,3719,O
dose,3719,O
and,3719,O
serum,3719,O
levels,3719,O
of,3719,O
DA,3719,B-CHEMICAL
D2-blocking,3719,B-GENE-Y
activity,3719,O
with,3719,O
performance,3719,O
of,3719,O
the,3719,O
trail-making,3719,O
and,3719,O
picture,3719,O
completion,3719,O
tests,3719,O
(,3719,O
negative,3719,O
),3719,O
and,3719,O
the,3719,O
block-design,3719,O
task,3719,O
(,3719,O
positive,3719,O
),3719,O
showed,3719,O
the,3719,O
functional,3719,O
importance,3719,O
of,3719,O
DA-related,3719,B-CHEMICAL
activity,3719,O
.,3719,O
High,3720,O
estimates,3720,O
of,3720,O
central,3720,O
DA,3720,B-CHEMICAL
D2-occupancy,3720,B-GENE-Y
were,3720,O
related,3720,O
to,3720,O
impaired,3720,O
verbal,3720,O
fluency,3720,O
but,3720,O
were,3720,O
associated,3720,O
with,3720,O
improved,3720,O
recall,3720,O
of,3720,O
stories,3720,O
",",3720,O
especially,3720,O
in,3720,O
paranoid,3720,O
patients,3720,O
.,3720,O
This,3721,O
",",3721,O
the,3721,O
first,3721,O
study,3721,O
of,3721,O
its,3721,O
kind,3721,O
",",3721,O
tentatively,3721,O
imputes,3721,O
a,3721,O
role,3721,O
for,3721,O
DA,3721,B-CHEMICAL
D2-related,3721,B-GENE-Y
activity,3721,O
in,3721,O
left,3721,O
frontal,3721,O
(,3721,O
e.g,3721,O
.,3721,O
CB,3722,O
",",3722,O
verbal,3722,O
fluency,3722,O
),3722,O
and,3722,O
temporal,3722,O
lobe,3722,O
functions,3722,O
(,3722,O
verbal,3722,O
recall,3722,O
),3722,O
as,3722,O
well,3722,O
as,3722,O
in,3722,O
some,3722,O
non-verbal,3722,O
abilities,3722,O
mediated,3722,O
more,3722,O
in,3722,O
the,3722,O
right,3722,O
hemisphere,3722,O
in,3722,O
patients,3722,O
with,3722,O
schizophrenia,3722,O
.,3722,O
Clinical,3723,O
effects,3723,O
of,3723,O
pranlukast,3723,B-CHEMICAL
",",3723,O
an,3723,O
oral,3723,O
leukotriene,3723,B-GENE-N
receptor,3723,I-GENE-N
antagonist,3723,O
",",3723,O
in,3723,O
mild-to-moderate,3723,O
asthma,3723,O
:,3723,O
a,3723,O
4,3723,O
week,3723,O
randomized,3723,O
multicentre,3723,O
controlled,3723,O
trial,3723,O
.,3723,O
OBJECTIVE,3724,O
:,3724,O
Leukotriene,3724,B-CHEMICAL
antagonists,3724,O
are,3724,O
increasingly,3724,O
used,3724,O
in,3724,O
asthma,3724,O
management,3724,O
.,3724,O
Pranlukast,3725,B-CHEMICAL
is,3725,O
a,3725,O
new,3725,O
",",3725,O
orally,3725,O
active,3725,O
",",3725,O
selective,3725,O
inhibitor,3725,O
of,3725,O
CysLt1,3725,B-GENE-Y
leukotriene,3725,B-GENE-N
receptor,3725,I-GENE-N
.,3725,O
The,3726,O
present,3726,O
clinical,3726,O
trial,3726,O
was,3726,O
performed,3726,O
to,3726,O
study,3726,O
the,3726,O
effect,3726,O
and,3726,O
safety,3726,O
of,3726,O
pranlukast,3726,B-CHEMICAL
in,3726,O
mild-to-moderate,3726,O
asthma,3726,O
.,3726,O
METHODOLOGY,3727,O
:,3727,O
A,3727,O
randomized,3727,O
",",3727,O
double-blind,3727,O
",",3727,O
placebo-controlled,3727,O
",",3727,O
parallel,3727,O
group,3727,O
study,3727,O
was,3727,O
performed,3727,O
in,3727,O
eight,3727,O
medical,3727,O
centres,3727,O
in,3727,O
Korea,3727,O
.,3727,O
Mild-to-moderate,3728,O
asthma,3728,O
patients,3728,O
who,3728,O
had,3728,O
been,3728,O
treated,3728,O
with,3728,O
beta2-agonists,3728,O
and/or,3728,O
inhaled,3728,O
corticosteroids,3728,B-CHEMICAL
were,3728,O
studied,3728,O
.,3728,O
The,3729,O
patients,3729,O
',3729,O
symptoms,3729,O
were,3729,O
evaluated,3729,O
by,3729,O
asthma,3729,O
diary,3729,O
and,3729,O
twice-daily,3729,O
peak,3729,O
flow,3729,O
monitoring,3729,O
.,3729,O
RESULTS,3730,O
:,3730,O
Of,3730,O
the,3730,O
206,3730,O
patients,3730,O
enrolled,3730,O
",",3730,O
197,3730,O
were,3730,O
eligible,3730,O
for,3730,O
analysis,3730,O
.,3730,O
The,3731,O
pranlukast,3731,B-CHEMICAL
group,3731,O
(,3731,O
n,3731,O
=,3731,O
98,3731,O
),3731,O
showed,3731,O
statistically,3731,O
significant,3731,O
improvement,3731,O
in,3731,O
asthma,3731,O
symptoms,3731,O
",",3731,O
including,3731,O
asthma,3731,O
attack,3731,O
rate,3731,O
",",3731,O
daily,3731,O
living,3731,O
score,3731,O
",",3731,O
and,3731,O
morning,3731,O
and,3731,O
evening,3731,O
asthma,3731,O
scores,3731,O
.,3731,O
Pranlukast,3732,B-CHEMICAL
significantly,3732,O
reduced,3732,O
the,3732,O
consumption,3732,O
of,3732,O
beta2-agonist,3732,O
.,3732,O
Compared,3733,O
with,3733,O
the,3733,O
placebo,3733,O
group,3733,O
",",3733,O
forced,3733,O
vital,3733,O
capacity,3733,O
(,3733,O
FVC,3733,O
),3733,O
and,3733,O
forced,3733,O
expiratory,3733,O
volume,3733,O
in,3733,O
1,3733,O
s,3733,O
(,3733,O
FEV1,3733,O
),3733,O
were,3733,O
not,3733,O
significantly,3733,O
higher,3733,O
in,3733,O
the,3733,O
pranlukast,3733,B-CHEMICAL
group,3733,O
.,3733,O
Morning,3734,O
and,3734,O
evening,3734,O
peak,3734,O
expiratory,3734,O
flow,3734,O
(,3734,O
PEF,3734,O
),3734,O
were,3734,O
significantly,3734,O
increased,3734,O
after,3734,O
pranlukast,3734,B-CHEMICAL
treatment,3734,O
at,3734,O
weeks,3734,O
2,3734,O
and,3734,O
4,3734,O
(,3734,O
380.8,3734,O
+/-,3734,O
10.1,3734,O
L/min,3734,O
at,3734,O
baseline,3734,O
",",3734,O
394.5,3734,O
+/-,3734,O
10.1,3734,O
at,3734,O
week,3734,O
2,3734,O
",",3734,O
396.3,3734,O
+/-,3734,O
10.4,3734,O
at,3734,O
week,3734,O
4,3734,O
),3734,O
.,3734,O
There,3735,O
were,3735,O
no,3735,O
serious,3735,O
adverse,3735,O
reactions,3735,O
.,3735,O
CONCLUSION,3736,O
:,3736,O
Pranlukast,3736,B-CHEMICAL
",",3736,O
an,3736,O
oral,3736,O
leukotriene,3736,B-CHEMICAL
antagonist,3736,O
",",3736,O
was,3736,O
well,3736,O
tolerated,3736,O
and,3736,O
was,3736,O
effective,3736,O
for,3736,O
the,3736,O
management,3736,O
of,3736,O
mild-to-moderate,3736,O
asthma,3736,O
.,3736,O
Physicochemical,3737,O
parameters,3737,O
that,3737,O
influence,3737,O
carotenoids,3737,O
bioaccessibility,3737,O
from,3737,O
a,3737,O
tomato,3737,O
juice,3737,O
.,3737,O
In,3738,O
vitro,3738,O
digestion,3738,O
models,3738,O
have,3738,O
been,3738,O
developed,3738,O
to,3738,O
estimate,3738,O
carotenoid,3738,O
bioavailability,3738,O
but,3738,O
most,3738,O
do,3738,O
not,3738,O
consider,3738,O
that,3738,O
their,3738,O
diffusion,3738,O
from,3738,O
fruit,3738,O
matrix,3738,O
to,3738,O
the,3738,O
lipid,3738,O
phase,3738,O
of,3738,O
the,3738,O
bolus,3738,O
could,3738,O
be,3738,O
a,3738,O
limiting,3738,O
step,3738,O
.,3738,O
Therefore,3739,O
we,3739,O
designed,3739,O
a,3739,O
model,3739,O
in,3739,O
which,3739,O
tomato,3739,O
juice,3739,O
is,3739,O
mixed,3739,O
with,3739,O
oil,3739,O
or,3739,O
oil/water,3739,O
emulsions,3739,O
",",3739,O
and,3739,O
the,3739,O
carotenoids,3739,O
diffusing,3739,O
to,3739,O
oil,3739,O
are,3739,O
measured,3739,O
by,3739,O
spectrometry,3739,O
.,3739,O
Temperature,3740,O
",",3740,O
pH,3740,O
and,3740,O
tomato,3740,O
juice/peanut,3740,O
oil,3740,O
ratio,3740,O
were,3740,O
evaluated,3740,O
for,3740,O
their,3740,O
influence,3740,O
on,3740,O
carotenoid,3740,O
diffusion,3740,O
.,3740,O
When,3741,O
oil/tomato,3741,O
ratio,3741,O
was,3741,O
between,3741,O
0.11,3741,O
and,3741,O
1,3741,O
",",3741,O
extraction,3741,O
of,3741,O
lycopene,3741,B-CHEMICAL
was,3741,O
limited,3741,O
by,3741,O
the,3741,O
saturation,3741,O
of,3741,O
the,3741,O
oil,3741,O
phase,3741,O
.,3741,O
With,3742,O
a,3742,O
large,3742,O
excess,3742,O
of,3742,O
oil,3742,O
",",3742,O
diffusion,3742,O
was,3742,O
also,3742,O
limited,3742,O
",",3742,O
as,3742,O
only,3742,O
31,3742,O
±,3742,O
1,3742,O
%,3742,O
of,3742,O
lycopene,3742,B-CHEMICAL
could,3742,O
be,3742,O
extracted,3742,O
from,3742,O
the,3742,O
juice,3742,O
.,3742,O
Diffusion,3743,O
did,3743,O
not,3743,O
vary,3743,O
significantly,3743,O
with,3743,O
pH,3743,O
but,3743,O
doubled,3743,O
when,3743,O
temperature,3743,O
rose,3743,O
from,3743,O
10°C,3743,O
to,3743,O
37°C,3743,O
.,3743,O
When,3744,O
the,3744,O
juice,3744,O
was,3744,O
mixed,3744,O
in,3744,O
an,3744,O
emulsion,3744,O
stabilised,3744,O
with,3744,O
bovine,3744,B-GENE-Y
serum,3744,I-GENE-Y
albumin,3744,I-GENE-Y
or,3744,O
phospholipids,3744,O
the,3744,O
maximum,3744,O
extraction,3744,O
decreased,3744,O
to,3744,O
14.5,3744,O
±,3744,O
0.2,3744,O
%,3744,O
and,3744,O
18.5,3744,O
±,3744,O
1.5,3744,O
%,3744,O
respectively,3744,O
",",3744,O
indicating,3744,O
that,3744,O
in,3744,O
addition,3744,O
to,3744,O
the,3744,O
saturation,3744,O
of,3744,O
the,3744,O
oil,3744,O
phase,3744,O
at,3744,O
low,3744,O
oil/tomato,3744,O
ratio,3744,O
and,3744,O
in,3744,O
addition,3744,O
to,3744,O
intrinsic,3744,O
properties,3744,O
of,3744,O
the,3744,O
tomato,3744,O
juice,3744,O
in,3744,O
non-saturating,3744,O
conditions,3744,O
",",3744,O
lycopene,3744,B-CHEMICAL
diffusion,3744,O
was,3744,O
limited,3744,O
by,3744,O
the,3744,O
structure,3744,O
of,3744,O
the,3744,O
interface,3744,O
in,3744,O
emulsions,3744,O
.,3744,O
Acute,3745,O
and,3745,O
chronic,3745,O
interference,3745,O
with,3745,O
BDNF/TrkB-signaling,3745,B-GENE-Y
impair,3745,O
LTP,3745,O
selectively,3745,O
at,3745,O
mossy,3745,O
fiber,3745,O
synapses,3745,O
in,3745,O
the,3745,O
CA3,3745,O
region,3745,O
of,3745,O
mouse,3745,O
hippocampus,3745,O
.,3745,O
Brain-derived,3746,B-GENE-Y
neurotrophic,3746,I-GENE-Y
factor,3746,I-GENE-Y
(,3746,O
BDNF,3746,B-GENE-Y
),3746,O
signaling,3746,O
via,3746,O
TrkB,3746,B-GENE-Y
crucially,3746,O
regulates,3746,O
synaptic,3746,O
plasticity,3746,O
in,3746,O
the,3746,O
brain,3746,O
.,3746,O
Although,3747,O
BDNF,3747,B-GENE-Y
is,3747,O
abundant,3747,O
at,3747,O
hippocampal,3747,O
mossy,3747,O
fiber,3747,O
(,3747,O
MF,3747,O
),3747,O
synapses,3747,O
",",3747,O
which,3747,O
critically,3747,O
contribute,3747,O
to,3747,O
hippocampus,3747,O
dependent,3747,O
memory,3747,O
",",3747,O
its,3747,O
role,3747,O
in,3747,O
MF,3747,O
synaptic,3747,O
plasticity,3747,O
(,3747,O
long-term,3747,O
potentiation,3747,O
",",3747,O
LTP,3747,O
),3747,O
remained,3747,O
largely,3747,O
unclear,3747,O
.,3747,O
Using,3748,O
field,3748,O
potential,3748,O
recordings,3748,O
in,3748,O
CA3,3748,O
of,3748,O
adult,3748,O
heterozygous,3748,O
BDNF,3748,B-GENE-Y
knockout,3748,O
(,3748,O
ko,3748,O
",",3748,O
BDNF+/-,3748,B-GENE-Y
),3748,O
mice,3748,O
we,3748,O
observed,3748,O
impaired,3748,O
(,3748,O
∼50,3748,O
%,3748,O
),3748,O
NMDAR-independent,3748,B-GENE-N
MF-LTP,3748,O
.,3748,O
In,3749,O
contrast,3749,O
to,3749,O
MF,3749,O
synapses,3749,O
",",3749,O
LTP,3749,O
at,3749,O
neighboring,3749,O
associative/commissural,3749,O
(,3749,O
A/C,3749,O
),3749,O
fiber,3749,O
synapses,3749,O
remained,3749,O
unaffected,3749,O
.,3749,O
To,3750,O
exclude,3750,O
that,3750,O
impaired,3750,O
MF-LTP,3750,O
in,3750,O
BDNF+/-,3750,B-GENE-Y
mice,3750,O
was,3750,O
due,3750,O
to,3750,O
developmental,3750,O
changes,3750,O
in,3750,O
response,3750,O
to,3750,O
chronically,3750,O
reduced,3750,O
BDNF,3750,B-GENE-Y
levels,3750,O
",",3750,O
and,3750,O
to,3750,O
prove,3750,O
the,3750,O
importance,3750,O
of,3750,O
acute,3750,O
availability,3750,O
of,3750,O
BDNF,3750,B-GENE-Y
in,3750,O
MF-LTP,3750,O
",",3750,O
we,3750,O
also,3750,O
tested,3750,O
effects,3750,O
of,3750,O
acute,3750,O
interference,3750,O
with,3750,O
BDNF/TrkB,3750,B-GENE-Y
signaling,3750,O
.,3750,O
Inhibition,3751,O
of,3751,O
TrkB,3751,B-GENE-Y
tyrosine,3751,B-GENE-N
kinase,3751,I-GENE-N
signaling,3751,O
with,3751,O
k252a,3751,O
",",3751,O
or,3751,O
with,3751,O
the,3751,O
selective,3751,O
BDNF,3751,B-GENE-Y
scavenger,3751,O
TrkB-Fc,3751,B-GENE-Y
",",3751,O
both,3751,O
inhibited,3751,O
MF-LTP,3751,O
to,3751,O
the,3751,O
same,3751,O
extent,3751,O
as,3751,O
observed,3751,O
in,3751,O
BDNF+/-,3751,B-GENE-Y
mice,3751,O
.,3751,O
Basal,3752,O
synaptic,3752,O
transmission,3752,O
",",3752,O
short-term,3752,O
plasticity,3752,O
",",3752,O
and,3752,O
synaptic,3752,O
fatigue,3752,O
during,3752,O
LTP,3752,O
induction,3752,O
were,3752,O
not,3752,O
significantly,3752,O
altered,3752,O
by,3752,O
treatment,3752,O
with,3752,O
k252a,3752,O
or,3752,O
TrkB-Fc,3752,B-GENE-Y
",",3752,O
or,3752,O
by,3752,O
chronic,3752,O
BDNF,3752,B-GENE-Y
reduction,3752,O
in,3752,O
BDNF+/-,3752,B-GENE-Y
mice,3752,O
.,3752,O
Since,3753,O
the,3753,O
acute,3753,O
interference,3753,O
with,3753,O
BDNF-signaling,3753,B-GENE-Y
did,3753,O
not,3753,O
completely,3753,O
block,3753,O
MF-LTP,3753,O
",",3753,O
our,3753,O
results,3753,O
provide,3753,O
evidence,3753,O
that,3753,O
an,3753,O
additional,3753,O
mechanism,3753,O
besides,3753,O
BDNF,3753,B-GENE-Y
induced,3753,O
TrkB,3753,B-GENE-Y
signaling,3753,O
contributes,3753,O
to,3753,O
this,3753,O
type,3753,O
of,3753,O
LTP,3753,O
.,3753,O
Our,3754,O
results,3754,O
prove,3754,O
for,3754,O
the,3754,O
first,3754,O
time,3754,O
a,3754,O
mechanistic,3754,O
action,3754,O
of,3754,O
acute,3754,O
BDNF/TrkB,3754,B-GENE-Y
signaling,3754,O
in,3754,O
presynaptic,3754,O
expression,3754,O
of,3754,O
MF-LTP,3754,O
in,3754,O
adult,3754,O
hippocampus,3754,O
.,3754,O
Drug,3755,O
binding,3755,O
interactions,3755,O
in,3755,O
the,3755,O
inner,3755,O
cavity,3755,O
of,3755,O
HERG,3755,B-GENE-Y
channels,3755,O
:,3755,O
molecular,3755,O
insights,3755,O
from,3755,O
structure-activity,3755,O
relationships,3755,O
of,3755,O
clofilium,3755,B-CHEMICAL
and,3755,O
ibutilide,3755,B-CHEMICAL
analogs,3755,O
.,3755,O
Block,3756,O
of,3756,O
human,3756,B-GENE-Y
ether-a-go-go,3756,I-GENE-Y
related,3756,I-GENE-Y
gene,3756,I-GENE-Y
(,3756,I-GENE-Y
hERG,3756,I-GENE-Y
),3756,I-GENE-Y
K,3756,I-GENE-Y
(,3756,I-GENE-Y
+,3756,I-GENE-Y
),3756,I-GENE-Y
channels,3756,I-GENE-Y
by,3756,O
otherwise,3756,O
useful,3756,O
drugs,3756,O
is,3756,O
the,3756,O
most,3756,O
common,3756,O
cause,3756,O
of,3756,O
long,3756,O
QT,3756,O
syndrome,3756,O
",",3756,O
a,3756,O
disorder,3756,O
of,3756,O
cardiac,3756,O
repolarization,3756,O
that,3756,O
predisposes,3756,O
patients,3756,O
to,3756,O
potentially,3756,O
fatal,3756,O
arrhythmias,3756,O
.,3756,O
This,3757,O
undesirable,3757,O
long,3757,O
QT,3757,O
side,3757,O
effect,3757,O
has,3757,O
been,3757,O
a,3757,O
major,3757,O
reason,3757,O
for,3757,O
the,3757,O
withdrawal,3757,O
of,3757,O
medications,3757,O
from,3757,O
the,3757,O
pharmaceutical,3757,O
market,3757,O
.,3757,O
Understanding,3758,O
the,3758,O
molecular,3758,O
basis,3758,O
of,3758,O
hERG,3758,B-GENE-Y
block,3758,O
is,3758,O
therefore,3758,O
essential,3758,O
to,3758,O
facilitate,3758,O
the,3758,O
design,3758,O
of,3758,O
safe,3758,O
drugs,3758,O
.,3758,O
Binding,3759,O
sites,3759,O
for,3759,O
hERG,3759,B-GENE-Y
blockers,3759,O
have,3759,O
been,3759,O
mapped,3759,O
within,3759,O
the,3759,O
inner,3759,O
cavity,3759,O
of,3759,O
the,3759,O
channel,3759,O
and,3759,O
include,3759,O
aromatic,3759,O
residues,3759,O
in,3759,O
the,3759,O
S6,3759,O
helix,3759,O
(,3759,O
Tyr-652,3759,B-CHEMICAL
",",3759,O
Phe-656,3759,B-CHEMICAL
),3759,O
and,3759,O
residues,3759,O
in,3759,O
the,3759,O
pore,3759,O
helix,3759,O
(,3759,O
Thr-623,3759,B-CHEMICAL
",",3759,O
Ser-624,3759,B-CHEMICAL
",",3759,O
Val-625,3759,B-CHEMICAL
),3759,O
.,3759,O
We,3760,O
used,3760,O
mutagenesis,3760,O
of,3760,O
these,3760,O
residues,3760,O
",",3760,O
combined,3760,O
with,3760,O
an,3760,O
investigation,3760,O
of,3760,O
hERG,3760,B-GENE-Y
block,3760,O
by,3760,O
close,3760,O
analogs,3760,O
of,3760,O
clofilium,3760,B-CHEMICAL
and,3760,O
ibutilide,3760,B-CHEMICAL
",",3760,O
to,3760,O
assess,3760,O
how,3760,O
specific,3760,O
alterations,3760,O
in,3760,O
drug,3760,O
structure,3760,O
affected,3760,O
potency,3760,O
and,3760,O
binding,3760,O
interactions,3760,O
.,3760,O
Although,3761,O
changing,3761,O
the,3761,O
basic,3761,O
nitrogen,3761,B-CHEMICAL
from,3761,O
quaternary,3761,O
to,3761,O
tertiary,3761,O
accelerated,3761,O
the,3761,O
onset,3761,O
of,3761,O
block,3761,O
",",3761,O
the,3761,O
IC,3761,O
(,3761,O
50,3761,O
),3761,O
and,3761,O
kinetics,3761,O
for,3761,O
recovery,3761,O
from,3761,O
block,3761,O
were,3761,O
similar,3761,O
.,3761,O
In,3762,O
contrast,3762,O
",",3762,O
analogs,3762,O
with,3762,O
different,3762,O
para-substituents,3762,O
on,3762,O
the,3762,O
phenyl,3762,B-CHEMICAL
ring,3762,O
had,3762,O
significantly,3762,O
different,3762,O
potencies,3762,O
for,3762,O
wild-type,3762,O
hERG,3762,B-GENE-Y
block,3762,O
.,3762,O
The,3763,O
highest,3763,O
potency,3763,O
was,3763,O
achieved,3763,O
with,3763,O
polar,3763,O
or,3763,O
electronegative,3763,O
para-substituents,3763,O
",",3763,O
whereas,3763,O
neutral,3763,O
para-substituents,3763,O
had,3763,O
potencies,3763,O
more,3763,O
than,3763,O
100-fold,3763,O
lower,3763,O
.,3763,O
Results,3764,O
from,3764,O
mutagenesis,3764,O
and,3764,O
molecular,3764,O
modeling,3764,O
studies,3764,O
suggest,3764,O
that,3764,O
phenyl,3764,B-CHEMICAL
ring,3764,O
para-substituents,3764,O
influence,3764,O
drug,3764,O
interactions,3764,O
with,3764,O
Thr-623,3764,B-CHEMICAL
",",3764,O
Ser-624,3764,B-CHEMICAL
",",3764,O
and,3764,O
Tyr-652,3764,B-CHEMICAL
and,3764,O
strongly,3764,O
affect,3764,O
binding,3764,O
affinity,3764,O
.,3764,O
Together,3765,O
",",3765,O
these,3765,O
findings,3765,O
suggest,3765,O
that,3765,O
modifying,3765,O
the,3765,O
para-substituent,3765,O
could,3765,O
be,3765,O
a,3765,O
useful,3765,O
strategy,3765,O
for,3765,O
reducing,3765,O
hERG,3765,O
potency,3765,O
and,3765,O
increasing,3765,O
the,3765,O
safety,3765,O
margin,3765,O
of,3765,O
compounds,3765,O
in,3765,O
development,3765,O
.,3765,O
Iron,3766,B-CHEMICAL
overload,3766,O
inhibits,3766,O
osteoblast,3766,O
biological,3766,O
activity,3766,O
through,3766,O
oxidative,3766,O
stress,3766,O
.,3766,O
Iron,3767,B-CHEMICAL
overload,3767,O
has,3767,O
recently,3767,O
been,3767,O
connected,3767,O
with,3767,O
bone,3767,O
mineral,3767,O
density,3767,O
in,3767,O
osteoporosis,3767,O
.,3767,O
However,3768,O
",",3768,O
to,3768,O
date,3768,O
",",3768,O
the,3768,O
effect,3768,O
of,3768,O
iron,3768,B-CHEMICAL
overload,3768,O
on,3768,O
osteoblasts,3768,O
remains,3768,O
poorly,3768,O
understood,3768,O
.,3768,O
The,3769,O
purpose,3769,O
of,3769,O
this,3769,O
study,3769,O
is,3769,O
to,3769,O
examine,3769,O
osteoblast,3769,O
biological,3769,O
activity,3769,O
under,3769,O
iron,3769,B-CHEMICAL
overload,3769,O
.,3769,O
The,3770,O
osteoblast,3770,O
cells,3770,O
(,3770,O
hFOB1.19,3770,O
),3770,O
were,3770,O
cultured,3770,O
in,3770,O
a,3770,O
medium,3770,O
supplemented,3770,O
with,3770,O
different,3770,O
concentrations,3770,O
(,3770,O
50,3770,O
",",3770,O
100,3770,O
",",3770,O
and,3770,O
200,3770,O
μM,3770,O
),3770,O
of,3770,O
ferric,3770,B-CHEMICAL
ammonium,3770,I-CHEMICAL
citrate,3770,I-CHEMICAL
as,3770,O
a,3770,O
donor,3770,O
of,3770,O
ferric,3770,B-CHEMICAL
ion,3770,O
.,3770,O
Intracellular,3771,O
iron,3771,B-CHEMICAL
was,3771,O
measured,3771,O
with,3771,O
a,3771,O
confocal,3771,O
laser,3771,O
scanning,3771,O
microscope,3771,O
.,3771,O
Reactive,3772,O
oxygen,3772,B-CHEMICAL
species,3772,O
(,3772,O
ROS,3772,O
),3772,O
were,3772,O
detected,3772,O
by,3772,O
"2,7-dichlorofluorescin",3772,B-CHEMICAL
diacetate,3772,I-CHEMICAL
fluorophotometry,3772,O
.,3772,O
Osteoblast,3773,O
biological,3773,O
activities,3773,O
were,3773,O
evaluated,3773,O
by,3773,O
measuring,3773,O
the,3773,O
activity,3773,O
of,3773,O
alkaline,3773,B-GENE-N
phosphatase,3773,I-GENE-N
(,3773,O
ALP,3773,B-GENE-N
),3773,O
and,3773,O
mineralization,3773,O
function,3773,O
.,3773,O
Results,3774,O
indicated,3774,O
that,3774,O
iron,3774,B-CHEMICAL
overload,3774,O
could,3774,O
consequently,3774,O
increase,3774,O
intracellular,3774,O
iron,3774,B-CHEMICAL
concentration,3774,O
and,3774,O
intracellular,3774,O
ROS,3774,O
levels,3774,O
in,3774,O
a,3774,O
concentration-dependent,3774,O
manner,3774,O
.,3774,O
Additionally,3775,O
",",3775,O
ALP,3775,B-GENE-N
activity,3775,O
was,3775,O
suppressed,3775,O
",",3775,O
and,3775,O
a,3775,O
decline,3775,O
in,3775,O
the,3775,O
number,3775,O
of,3775,O
mineralized,3775,O
nodules,3775,O
was,3775,O
observed,3775,O
in,3775,O
in,3775,O
vitro,3775,O
cultured,3775,O
osteoblast,3775,O
cells,3775,O
.,3775,O
According,3776,O
to,3776,O
these,3776,O
results,3776,O
",",3776,O
it,3776,O
seems,3776,O
that,3776,O
iron,3776,B-CHEMICAL
overload,3776,O
probably,3776,O
inhibits,3776,O
osteoblast,3776,O
function,3776,O
through,3776,O
higher,3776,O
oxidative,3776,O
stress,3776,O
following,3776,O
increased,3776,O
intracellular,3776,O
iron,3776,B-CHEMICAL
concentrations,3776,O
.,3776,O
Adrenergic,3777,O
agonists,3777,O
suppress,3777,O
the,3777,O
proliferation,3777,O
of,3777,O
microglia,3777,O
through,3777,O
beta,3777,B-GENE-Y
2-adrenergic,3777,I-GENE-Y
receptor,3777,I-GENE-Y
.,3777,O
The,3778,O
effects,3778,O
of,3778,O
several,3778,O
cyclic,3778,B-CHEMICAL
adenosine,3778,I-CHEMICAL
monophosphate,3778,I-CHEMICAL
(,3778,O
cAMP,3778,B-CHEMICAL
),3778,O
-elevating,3778,O
agents,3778,O
on,3778,O
the,3778,O
proliferation,3778,O
of,3778,O
cultured,3778,O
rat,3778,O
microglia,3778,O
were,3778,O
investigated,3778,O
by,3778,O
immunocytochemical,3778,O
staining,3778,O
with,3778,O
an,3778,O
antibody,3778,O
against,3778,O
proliferating,3778,B-GENE-Y
cell,3778,I-GENE-Y
nuclear,3778,I-GENE-Y
antigen,3778,I-GENE-Y
(,3778,O
PCNA,3778,B-GENE-Y
),3778,O
.,3778,O
Epinephrine,3779,B-CHEMICAL
",",3779,O
isoproterenol,3779,B-CHEMICAL
",",3779,O
forskolin,3779,B-CHEMICAL
and,3779,O
8Br-cAMP,3779,B-CHEMICAL
suppressed,3779,O
the,3779,O
microglial,3779,O
proliferation,3779,O
.,3779,O
A,3780,O
beta2-selective,3780,O
agonist,3780,O
terbutaline,3780,B-CHEMICAL
but,3780,O
not,3780,O
a,3780,O
beta1-selective,3780,O
agonist,3780,O
dobutamine,3780,B-CHEMICAL
mimicked,3780,O
the,3780,O
effect,3780,O
of,3780,O
the,3780,O
above,3780,O
cAMP-elevating,3780,B-CHEMICAL
agents,3780,O
.,3780,O
Furthermore,3781,O
",",3781,O
a,3781,O
non-selective,3781,O
beta-receptor,3781,O
antagonist,3781,O
oxprenolol,3781,B-CHEMICAL
and,3781,O
a,3781,O
beta2-selective,3781,O
antagonist,3781,O
acebutalol,3781,B-CHEMICAL
",",3781,O
but,3781,O
not,3781,O
a,3781,O
beta1-selective,3781,O
antagonist,3781,O
butoxamine,3781,B-CHEMICAL
",",3781,O
counteracted,3781,O
the,3781,O
suppressive,3781,O
effects,3781,O
of,3781,O
the,3781,O
beta-agonists,3781,O
on,3781,O
microglial,3781,O
proliferation,3781,O
.,3781,O
These,3782,O
findings,3782,O
suggest,3782,O
that,3782,O
the,3782,O
beta-agonists,3782,O
suppress,3782,O
the,3782,O
proliferation,3782,O
of,3782,O
microglia,3782,O
by,3782,O
elevating,3782,O
intracellular,3782,O
cAMP,3782,B-CHEMICAL
level,3782,O
through,3782,O
an,3782,O
action,3782,O
on,3782,O
beta2-adrenergic,3782,B-GENE-Y
receptor,3782,I-GENE-Y
.,3782,O
Copper,3783,B-CHEMICAL
induced,3783,O
upregulation,3783,O
of,3783,O
apoptosis,3783,O
related,3783,O
genes,3783,O
in,3783,O
zebrafish,3783,O
(,3783,O
Danio,3783,O
rerio,3783,O
),3783,O
gill,3783,O
.,3783,O
Copper,3784,B-CHEMICAL
(,3784,O
Cu,3784,B-CHEMICAL
),3784,O
is,3784,O
an,3784,O
essential,3784,O
micronutrient,3784,O
that,3784,O
",",3784,O
when,3784,O
present,3784,O
in,3784,O
high,3784,O
concentrations,3784,O
",",3784,O
becomes,3784,O
toxic,3784,O
to,3784,O
aquatic,3784,O
organisms,3784,O
.,3784,O
It,3785,O
is,3785,O
known,3785,O
that,3785,O
Cu,3785,B-CHEMICAL
toxicity,3785,O
may,3785,O
induce,3785,O
apoptotic,3785,O
cell,3785,O
death,3785,O
.,3785,O
However,3786,O
",",3786,O
the,3786,O
precise,3786,O
mechanism,3786,O
and,3786,O
the,3786,O
pathways,3786,O
that,3786,O
are,3786,O
activated,3786,O
",",3786,O
in,3786,O
fish,3786,O
",",3786,O
are,3786,O
still,3786,O
unclear,3786,O
.,3786,O
Thus,3787,O
",",3787,O
this,3787,O
study,3787,O
aimed,3787,O
to,3787,O
assess,3787,O
which,3787,O
apoptotic,3787,O
pathways,3787,O
are,3787,O
triggered,3787,O
by,3787,O
Cu,3787,B-CHEMICAL
",",3787,O
in,3787,O
zebrafish,3787,O
(,3787,O
Danio,3787,O
rerio,3787,O
),3787,O
gill,3787,O
",",3787,O
the,3787,O
main,3787,O
target,3787,O
of,3787,O
waterborne,3787,O
pollutants,3787,O
.,3787,O
Fish,3788,O
where,3788,O
exposed,3788,O
to,3788,O
12.5,3788,O
and,3788,O
100,3788,O
μg/L,3788,O
of,3788,O
Cu,3788,B-CHEMICAL
during,3788,O
6,3788,O
",",3788,O
12,3788,O
",",3788,O
24,3788,O
and,3788,O
48,3788,O
h.,3788,O
Fish,3788,O
gills,3788,O
were,3788,O
collected,3788,O
to,3788,O
TUNEL,3788,O
assay,3788,O
and,3788,O
mRNA,3788,O
expression,3788,O
analysis,3788,O
of,3788,O
selected,3788,O
genes,3788,O
by,3788,O
real,3788,O
time,3788,O
PCR,3788,O
.,3788,O
An,3789,O
approach,3789,O
to,3789,O
different,3789,O
apoptosis,3789,O
pathways,3789,O
was,3789,O
done,3789,O
selecting,3789,O
p53,3789,B-GENE-Y
",",3789,O
caspase-8,3789,B-GENE-Y
",",3789,O
caspase-9,3789,B-GENE-Y
and,3789,O
apoptosis,3789,B-GENE-Y
inducing,3789,I-GENE-Y
factor,3789,I-GENE-Y
(,3789,O
AIF,3789,B-GENE-Y
),3789,O
genes,3789,O
.,3789,O
The,3790,O
higher,3790,O
incidence,3790,O
of,3790,O
TUNEL-positive,3790,O
cells,3790,O
",",3790,O
in,3790,O
gill,3790,O
epithelia,3790,O
of,3790,O
the,3790,O
exposed,3790,O
fish,3790,O
",",3790,O
proved,3790,O
that,3790,O
Cu,3790,B-CHEMICAL
induced,3790,O
apoptosis,3790,O
.,3790,O
The,3791,O
results,3791,O
suggest,3791,O
that,3791,O
different,3791,O
apoptosis,3791,O
pathways,3791,O
are,3791,O
triggered,3791,O
by,3791,O
Cu,3791,B-CHEMICAL
at,3791,O
different,3791,O
time,3791,O
points,3791,O
of,3791,O
the,3791,O
exposure,3791,O
period,3791,O
",",3791,O
as,3791,O
the,3791,O
increase,3791,O
in,3791,O
transcripts,3791,O
was,3791,O
sequential,3791,O
",",3791,O
instead,3791,O
of,3791,O
simultaneous,3791,O
.,3791,O
Apoptosis,3792,O
seems,3792,O
to,3792,O
be,3792,O
initiated,3792,O
via,3792,O
intrinsic,3792,O
pathway,3792,O
(,3792,O
caspase-9,3792,B-GENE-Y
),3792,O
",",3792,O
through,3792,O
p53,3792,B-GENE-Y
activation,3792,O
;,3792,O
then,3792,O
followed,3792,O
by,3792,O
the,3792,O
extrinsic,3792,O
pathway,3792,O
(,3792,O
caspase-8,3792,B-GENE-Y
),3792,O
and,3792,O
finally,3792,O
by,3792,O
the,3792,O
caspase-independent,3792,B-GENE-N
pathway,3792,O
(,3792,O
AIF,3792,B-GENE-Y
),3792,O
.,3792,O
A,3793,O
possible,3793,O
model,3793,O
for,3793,O
Cu-induce,3793,B-CHEMICAL
apoptosis,3793,O
pathways,3793,O
is,3793,O
proposed,3793,O
.,3793,O
Gene,3794,O
expression,3794,O
signature,3794,O
of,3794,O
parathion-transformed,3794,B-CHEMICAL
human,3794,O
breast,3794,O
epithelial,3794,O
cells,3794,O
.,3794,O
Environmental,3795,O
substances,3795,O
seem,3795,O
to,3795,O
be,3795,O
involved,3795,O
in,3795,O
the,3795,O
etiology,3795,O
of,3795,O
breast,3795,O
cancers,3795,O
.,3795,O
Many,3796,O
studies,3796,O
have,3796,O
found,3796,O
an,3796,O
association,3796,O
between,3796,O
human,3796,O
cancer,3796,O
and,3796,O
exposure,3796,O
to,3796,O
agricultural,3796,O
pesticides,3796,O
such,3796,O
as,3796,O
the,3796,O
organophosphorous,3796,B-CHEMICAL
pesticides,3796,O
.,3796,O
Parathion,3797,B-CHEMICAL
is,3797,O
a,3797,O
cholinesterase,3797,B-GENE-N
inhibitor,3797,O
that,3797,O
induces,3797,O
the,3797,O
hydrolysis,3797,O
of,3797,O
body,3797,O
choline,3797,B-CHEMICAL
esters,3797,I-CHEMICAL
",",3797,O
including,3797,O
acetylcholine,3797,B-CHEMICAL
at,3797,O
cholinergic,3797,O
synapses,3797,O
.,3797,O
The,3798,O
primary,3798,O
target,3798,O
of,3798,O
action,3798,O
in,3798,O
insects,3798,O
is,3798,O
the,3798,O
nervous,3798,O
system,3798,O
whereby,3798,O
pesticides,3798,O
inhibit,3798,O
the,3798,O
release,3798,O
of,3798,O
the,3798,O
enzyme,3798,O
acetylcholinesterase,3798,B-GENE-N
at,3798,O
the,3798,O
synaptic,3798,O
junction,3798,O
.,3798,O
Atropine,3799,O
is,3799,O
a,3799,O
parasympatholytic,3799,O
alkaloid,3799,O
used,3799,O
as,3799,O
an,3799,O
antidote,3799,O
to,3799,O
acetylcholinesterase,3799,B-GENE-N
inhibitors,3799,O
.,3799,O
The,3800,O
aim,3800,O
of,3800,O
this,3800,O
study,3800,O
was,3800,O
to,3800,O
determine,3800,O
the,3800,O
effect,3800,O
of,3800,O
parathion,3800,B-CHEMICAL
and,3800,O
atropine,3800,B-CHEMICAL
on,3800,O
cell,3800,O
transformation,3800,O
of,3800,O
human,3800,O
breast,3800,O
epithelial,3800,O
cells,3800,O
in,3800,O
vitro,3800,O
.,3800,O
These,3801,O
studies,3801,O
showed,3801,O
that,3801,O
parathion,3801,B-CHEMICAL
alone,3801,O
was,3801,O
able,3801,O
to,3801,O
induce,3801,O
malignant,3801,O
transformation,3801,O
of,3801,O
an,3801,O
immortalized,3801,O
human,3801,O
breast,3801,O
epithelial,3801,O
cell,3801,O
line,3801,O
",",3801,O
MCF-10F,3801,O
as,3801,O
indicated,3801,O
by,3801,O
increased,3801,O
cell,3801,O
proliferation,3801,O
",",3801,O
anchorage,3801,O
independency,3801,O
and,3801,O
invasive,3801,O
capabilities,3801,O
.,3801,O
There,3802,O
was,3802,O
also,3802,O
an,3802,O
increase,3802,O
in,3802,O
c-kit,3802,B-GENE-Y
",",3802,O
Trio,3802,B-GENE-Y
",",3802,O
Rho-A,3802,B-GENE-Y
",",3802,O
Rac-3,3802,B-GENE-Y
",",3802,O
EGFR,3802,B-GENE-Y
",",3802,O
Notch-4,3802,B-GENE-Y
",",3802,O
Dvl-2,3802,B-GENE-Y
",",3802,O
Ezrin,3802,B-GENE-Y
",",3802,O
beta,3802,B-GENE-Y
catenin,3802,I-GENE-Y
and,3802,O
mutant,3802,O
p53,3802,B-GENE-Y
protein,3802,O
expression,3802,O
in,3802,O
the,3802,O
parathion-treated,3802,B-CHEMICAL
cells,3802,O
.,3802,O
However,3803,O
",",3803,O
atropine,3803,B-CHEMICAL
significantly,3803,O
inhibited,3803,O
this,3803,O
increase,3803,O
.,3803,O
In,3804,O
a,3804,O
human,3804,O
cell,3804,O
cycle,3804,O
array,3804,O
of,3804,O
96,3804,O
genes,3804,O
",",3804,O
13,3804,O
of,3804,O
them,3804,O
were,3804,O
altered,3804,O
by,3804,O
parathion,3804,B-CHEMICAL
treatment,3804,O
.,3804,O
Among,3805,O
the,3805,O
genes,3805,O
affected,3805,O
were,3805,O
the,3805,O
cyclins,3805,B-GENE-N
",",3805,O
such,3805,O
as,3805,O
cyclin,3805,B-GENE-Y
D3,3805,I-GENE-Y
",",3805,O
the,3805,O
cyclin-dependent,3805,B-GENE-N
kinases,3805,I-GENE-N
(,3805,O
CDKs,3805,B-GENE-N
),3805,O
such,3805,O
as,3805,O
CDK41,3805,B-GENE-Y
and,3805,O
the,3805,O
minichromosome,3805,B-GENE-Y
maintenance,3805,I-GENE-Y
deficient,3805,I-GENE-Y
(,3805,I-GENE-Y
MCM,3805,I-GENE-Y
),3805,I-GENE-Y
MCM2,3805,I-GENE-Y
and,3805,O
MCM3,3805,B-GENE-Y
.,3805,O
It,3806,O
is,3806,O
suggested,3806,O
that,3806,O
parathion,3806,B-CHEMICAL
influences,3806,O
human,3806,O
breast,3806,O
epithelial,3806,O
cell,3806,O
transformation,3806,O
and,3806,O
is,3806,O
an,3806,O
initiator,3806,O
factor,3806,O
in,3806,O
the,3806,O
transformation,3806,O
process,3806,O
in,3806,O
breast,3806,O
cancer,3806,O
.,3806,O
Purification,3807,O
and,3807,O
multimeric,3807,O
structure,3807,O
of,3807,O
bovine,3807,O
N-acetylglucosamine-1-phosphodiester,3807,B-GENE-Y
alpha-N-acetylglucosaminidase,3807,I-GENE-Y
.,3807,O
N-Acetylglucosamine-1-phosphodiester,3808,B-GENE-Y
alpha-N-Acetylglucosaminidase,3808,I-GENE-Y
(,3808,O
EC,3808,B-GENE-Y
3.1.4.45,3808,I-GENE-Y
;,3808,O
phosphodiester,3808,B-GENE-Y
alpha-GlcNAcase,3808,I-GENE-Y
),3808,O
catalyzes,3808,O
the,3808,O
second,3808,O
step,3808,O
in,3808,O
the,3808,O
synthesis,3808,O
of,3808,O
the,3808,O
mannose,3808,B-CHEMICAL
6-phosphate,3808,I-CHEMICAL
determinant,3808,O
required,3808,O
for,3808,O
efficient,3808,O
intracellular,3808,O
targeting,3808,O
of,3808,O
newly,3808,O
synthesized,3808,O
lysosomal,3808,O
hydrolases,3808,O
to,3808,O
the,3808,O
lysosome,3808,O
.,3808,O
A,3809,O
partially,3809,O
purified,3809,O
preparation,3809,O
of,3809,O
phosphodiester,3809,B-GENE-Y
alpha-GlcNAcase,3809,I-GENE-Y
from,3809,O
bovine,3809,O
pancreas,3809,O
was,3809,O
used,3809,O
to,3809,O
generate,3809,O
a,3809,O
panel,3809,O
of,3809,O
murine,3809,O
monoclonal,3809,O
antibodies,3809,O
.,3809,O
The,3810,O
anti-phosphodiester,3810,O
alpha-GlcNAcase,3810,I-GENE-Y
monoclonal,3810,O
antibody,3810,O
UC1,3810,O
was,3810,O
coupled,3810,O
to,3810,O
a,3810,O
solid,3810,O
support,3810,O
and,3810,O
used,3810,O
to,3810,O
immunopurify,3810,O
the,3810,O
bovine,3810,O
liver,3810,O
enzyme,3810,O
"670,000-fold",3810,O
in,3810,O
two,3810,O
steps,3810,O
to,3810,O
apparent,3810,O
homogeneity,3810,O
with,3810,O
an,3810,O
overall,3810,O
yield,3810,O
of,3810,O
14,3810,O
%,3810,O
.,3810,O
The,3811,O
purified,3811,O
phosphodiester,3811,B-GENE-Y
alpha-GlcNAcase,3811,I-GENE-Y
has,3811,O
a,3811,O
specific,3811,O
activity,3811,O
of,3811,O
498,3811,O
micromol,3811,O
of,3811,O
[,3811,B-CHEMICAL
3H,3811,I-CHEMICAL
],3811,I-CHEMICAL
GlcNAc-alpha-phosphomannose-alpha-methyl,3811,I-CHEMICAL
cleaved,3811,O
per,3811,O
h,3811,O
per,3811,O
mg,3811,O
of,3811,O
protein,3811,O
using,3811,O
0.5,3811,O
mM,3811,O
[,3811,B-CHEMICAL
3H,3811,I-CHEMICAL
],3811,I-CHEMICAL
GlcNAc-alpha-phosphomannose-alpha-methyl,3811,I-CHEMICAL
as,3811,O
substrate,3811,O
.,3811,O
The,3812,O
subunit,3812,O
structure,3812,O
of,3812,O
the,3812,O
enzyme,3812,O
was,3812,O
determined,3812,O
using,3812,O
a,3812,O
combination,3812,O
of,3812,O
analytical,3812,O
gel,3812,O
filtration,3812,O
chromatography,3812,O
",",3812,O
SDS-polyacrylamide,3812,B-CHEMICAL
gel,3812,O
electrophoresis,3812,O
",",3812,O
and,3812,O
amino-terminal,3812,O
sequencing,3812,O
.,3812,O
The,3813,O
data,3813,O
indicate,3813,O
that,3813,O
bovine,3813,O
phosphodiester,3813,B-GENE-Y
alpha-GlcNAcase,3813,I-GENE-Y
is,3813,O
a,3813,O
"272,000-Da",3813,O
complex,3813,O
of,3813,O
four,3813,O
identical,3813,O
"68,000-Da",3813,O
glycoprotein,3813,O
subunits,3813,O
arranged,3813,O
as,3813,O
two,3813,O
disulfide-linked,3813,B-CHEMICAL
homodimers,3813,O
.,3813,O
A,3814,O
soluble,3814,O
form,3814,O
of,3814,O
the,3814,O
enzyme,3814,O
",",3814,O
isolated,3814,O
from,3814,O
fetal,3814,O
bovine,3814,O
serum,3814,O
",",3814,O
showed,3814,O
the,3814,O
same,3814,O
subunit,3814,O
structure,3814,O
.,3814,O
Both,3815,O
forms,3815,O
of,3815,O
the,3815,O
enzyme,3815,O
reacted,3815,O
with,3815,O
a,3815,O
rabbit,3815,O
antibody,3815,O
raised,3815,O
to,3815,O
the,3815,O
amino-terminal,3815,B-CHEMICAL
peptide,3815,O
of,3815,O
the,3815,O
liver,3815,O
enzyme,3815,O
",",3815,O
suggesting,3815,O
that,3815,O
phosphodiester,3815,B-GENE-Y
alpha-GlcNAcase,3815,I-GENE-Y
is,3815,O
a,3815,O
type,3815,B-GENE-N
I,3815,I-GENE-N
membrane-spanning,3815,I-GENE-N
glycoprotein,3815,I-GENE-N
with,3815,O
its,3815,O
amino,3815,B-CHEMICAL
terminus,3815,O
in,3815,O
the,3815,O
lumen,3815,O
of,3815,O
the,3815,O
Golgi,3815,O
apparatus,3815,O
.,3815,O
Impact,3816,O
of,3816,O
ketorolac,3816,B-CHEMICAL
administration,3816,O
around,3816,O
ovarian,3816,O
stimulation,3816,O
on,3816,O
in,3816,O
vivo,3816,O
and,3816,O
in,3816,O
vitro,3816,O
fertilization,3816,O
and,3816,O
subsequent,3816,O
embryo,3816,O
development,3816,O
.,3816,O
Abstract,3817,O
We,3817,O
performed,3817,O
this,3817,O
study,3817,O
to,3817,O
investigate,3817,O
the,3817,O
effect,3817,O
of,3817,O
ketorolac,3817,B-CHEMICAL
(,3817,O
a,3817,O
non-steroidal,3817,O
anti-inflammatory,3817,O
drug,3817,O
),3817,O
administration,3817,O
around,3817,O
ovarian,3817,O
stimulation,3817,O
on,3817,O
in,3817,O
vivo,3817,O
and,3817,O
in,3817,O
vitro,3817,O
fertilization,3817,O
process,3817,O
.,3817,O
Sixty-four,3818,O
female,3818,O
mice,3818,O
(,3818,O
ICR,3818,O
),3818,O
were,3818,O
injected,3818,O
with,3818,O
ketorolac,3818,B-CHEMICAL
(,3818,O
0,3818,O
",",3818,O
7.5,3818,O
",",3818,O
15,3818,O
and,3818,O
30,3818,O
µg/d,3818,O
),3818,O
for,3818,O
3,3818,O
d,3818,O
starting,3818,O
from,3818,O
the,3818,O
day,3818,O
of,3818,O
eCG,3818,B-GENE-N
treatment,3818,O
.,3818,O
In,3819,O
experiment,3819,O
1,3819,O
",",3819,O
41,3819,O
mice,3819,O
were,3819,O
triggered,3819,O
by,3819,O
hCG,3819,B-GENE-N
and,3819,O
then,3819,O
mated,3819,O
;,3819,O
two-cell,3819,O
embryos,3819,O
were,3819,O
obtained,3819,O
and,3819,O
in,3819,O
vitro,3819,O
development,3819,O
up,3819,O
to,3819,O
blastocyst,3819,O
was,3819,O
observed,3819,O
.,3819,O
In,3820,O
experiment,3820,O
2,3820,O
",",3820,O
23,3820,O
mice,3820,O
were,3820,O
triggered,3820,O
by,3820,O
hCG,3820,B-GENE-N
and,3820,O
mature,3820,O
oocytes,3820,O
were,3820,O
collected,3820,O
;,3820,O
in,3820,O
vitro,3820,O
fertilization,3820,O
rate,3820,O
and,3820,O
subsequent,3820,O
embryo,3820,O
development,3820,O
up,3820,O
to,3820,O
blastocyst,3820,O
was,3820,O
recorded,3820,O
.,3820,O
In,3821,O
experiment,3821,O
1,3821,O
",",3821,O
the,3821,O
blastocyst-forming,3821,O
rates,3821,O
per,3821,O
in,3821,O
vivo,3821,O
fertilized,3821,O
two-cell,3821,O
embryo,3821,O
showed,3821,O
an,3821,O
inverse,3821,O
relationship,3821,O
with,3821,O
a,3821,O
dosage,3821,O
of,3821,O
ketorolac,3821,B-CHEMICAL
(,3821,O
97.6,3821,O
%,3821,O
",",3821,O
64.2,3821,O
%,3821,O
",",3821,O
35.4,3821,O
%,3821,O
and,3821,O
25.9,3821,O
%,3821,O
),3821,O
.,3821,O
In,3822,O
experiment,3822,O
2,3822,O
",",3822,O
degenerated,3822,O
oocytes,3822,O
were,3822,O
frequently,3822,O
observed,3822,O
in,3822,O
a,3822,O
dose-dependent,3822,O
manner,3822,O
(,3822,O
4.3,3822,O
%,3822,O
",",3822,O
22.9,3822,O
%,3822,O
",",3822,O
22.4,3822,O
%,3822,O
and,3822,O
75.0,3822,O
%,3822,O
),3822,O
.,3822,O
Lower,3823,O
fertilization,3823,O
rates,3823,O
were,3823,O
noted,3823,O
in,3823,O
all,3823,O
the,3823,O
three,3823,O
ketorolac-treating,3823,B-CHEMICAL
groups,3823,O
;,3823,O
blastocyst-forming,3823,O
rate,3823,O
was,3823,O
significantly,3823,O
lower,3823,O
in,3823,O
30-µg-treating,3823,O
group,3823,O
when,3823,O
compared,3823,O
with,3823,O
the,3823,O
control,3823,O
group,3823,O
.,3823,O
Administration,3824,O
of,3824,O
ketorolac,3824,B-CHEMICAL
around,3824,O
ovarian,3824,O
stimulation,3824,O
significantly,3824,O
affects,3824,O
the,3824,O
development,3824,O
of,3824,O
in,3824,O
vivo,3824,O
fertilized,3824,O
embryo,3824,O
in,3824,O
a,3824,O
dose-dependent,3824,O
manner,3824,O
.,3824,O
High-dose,3825,O
ketorolac,3825,B-CHEMICAL
could,3825,O
result,3825,O
in,3825,O
a,3825,O
poor,3825,O
oocyte,3825,O
quality,3825,O
and,3825,O
decreased,3825,O
embryo,3825,O
developmental,3825,O
competence,3825,O
.,3825,O
Passive,3826,O
stiffness,3826,O
of,3826,O
airway,3826,O
smooth,3826,O
muscle,3826,O
:,3826,O
the,3826,O
next,3826,O
target,3826,O
for,3826,O
improving,3826,O
airway,3826,O
distensibility,3826,O
and,3826,O
treatment,3826,O
for,3826,O
asthma,3826,O
?,3826,O
Reduced,3827,O
airway,3827,O
distensibility,3827,O
due,3827,O
to,3827,O
increased,3827,O
airway,3827,O
stiffness,3827,O
is,3827,O
a,3827,O
characteristic,3827,O
of,3827,O
asthma,3827,O
.,3827,O
Airway,3828,O
stiffness,3828,O
is,3828,O
determined,3828,O
by,3828,O
the,3828,O
property,3828,O
and,3828,O
structural,3828,O
organization,3828,O
of,3828,O
the,3828,O
various,3828,O
elements,3828,O
of,3828,O
the,3828,O
airway,3828,O
wall,3828,O
",",3828,O
and,3828,O
is,3828,O
often,3828,O
divided,3828,O
into,3828,O
active,3828,O
and,3828,O
passive,3828,O
components,3828,O
.,3828,O
Active,3829,O
stiffness,3829,O
is,3829,O
thought,3829,O
to,3829,O
be,3829,O
associated,3829,O
with,3829,O
activation,3829,O
of,3829,O
muscle,3829,O
cells,3829,O
in,3829,O
the,3829,O
airway,3829,O
wall,3829,O
.,3829,O
This,3830,O
component,3830,O
of,3830,O
stiffness,3830,O
can,3830,O
be,3830,O
inhibited,3830,O
when,3830,O
active,3830,O
force,3830,O
produced,3830,O
by,3830,O
the,3830,O
muscle,3830,O
is,3830,O
abolished,3830,O
.,3830,O
Passive,3831,O
stiffness,3831,O
",",3831,O
on,3831,O
the,3831,O
other,3831,O
hand,3831,O
",",3831,O
is,3831,O
thought,3831,O
to,3831,O
stem,3831,O
from,3831,O
non-muscle,3831,O
component,3831,O
of,3831,O
the,3831,O
airway,3831,O
wall,3831,O
",",3831,O
especially,3831,O
the,3831,O
collagen/elastin,3831,B-GENE-N
fibrous,3831,O
network,3831,O
of,3831,O
the,3831,O
extracellular,3831,O
matrix,3831,O
within,3831,O
which,3831,O
the,3831,O
muscle,3831,O
cells,3831,O
are,3831,O
embedded,3831,O
.,3831,O
In,3832,O
this,3832,O
brief,3832,O
review,3832,O
",",3832,O
the,3832,O
notion,3832,O
that,3832,O
passive,3832,O
stiffness,3832,O
is,3832,O
exclusively,3832,O
extracellular,3832,O
in,3832,O
origin,3832,O
is,3832,O
challenged,3832,O
.,3832,O
Recent,3833,O
evidence,3833,O
suggests,3833,O
that,3833,O
a,3833,O
substantial,3833,O
portion,3833,O
of,3833,O
the,3833,O
passive,3833,O
stiffness,3833,O
of,3833,O
an,3833,O
in,3833,O
vitro,3833,O
preparation,3833,O
of,3833,O
tracheal,3833,O
smooth,3833,O
muscle,3833,O
is,3833,O
calcium,3833,B-CHEMICAL
sensitive,3833,O
and,3833,O
is,3833,O
regulated,3833,O
by,3833,O
Rho-kinase,3833,B-GENE-N
",",3833,O
although,3833,O
the,3833,O
underlying,3833,O
mechanism,3833,O
and,3833,O
the,3833,O
details,3833,O
of,3833,O
regulation,3833,O
for,3833,O
the,3833,O
development,3833,O
of,3833,O
this,3833,O
intracellular,3833,O
passive,3833,O
stiffness,3833,O
are,3833,O
still,3833,O
largely,3833,O
unknown,3833,O
.,3833,O
To,3834,O
reduce,3834,O
airway,3834,O
stiffness,3834,O
different,3834,O
lines,3834,O
of,3834,O
attack,3834,O
must,3834,O
be,3834,O
tailored,3834,O
to,3834,O
different,3834,O
components,3834,O
of,3834,O
the,3834,O
stiffness,3834,O
.,3834,O
The,3835,O
regulatable,3835,O
passive,3835,O
stiffness,3835,O
is,3835,O
distinct,3835,O
from,3835,O
the,3835,O
relatively,3835,O
permanent,3835,O
stiffness,3835,O
of,3835,O
the,3835,O
extracellular,3835,O
matrix,3835,O
and,3835,O
the,3835,O
stiffness,3835,O
associated,3835,O
with,3835,O
active,3835,O
muscle,3835,O
contraction,3835,O
.,3835,O
To,3836,O
improve,3836,O
airway,3836,O
distensibility,3836,O
during,3836,O
asthma,3836,O
exacerbation,3836,O
",",3836,O
a,3836,O
comprehensive,3836,O
approach,3836,O
to,3836,O
reduce,3836,O
overall,3836,O
airway,3836,O
stiffness,3836,O
should,3836,O
therefore,3836,O
include,3836,O
a,3836,O
strategy,3836,O
for,3836,O
targeting,3836,O
the,3836,O
regulatable,3836,O
passive,3836,O
stiffness,3836,O
.,3836,O
The,3837,O
vascular,3837,O
protective,3837,O
properties,3837,O
of,3837,O
kinsenoside,3837,B-CHEMICAL
isolated,3837,O
from,3837,O
Anoectochilus,3837,O
roxburghii,3837,O
under,3837,O
high,3837,O
glucose,3837,B-CHEMICAL
condition,3837,O
.,3837,O
Anoectochilus,3838,O
roxburghii,3838,O
is,3838,O
a,3838,O
traditional,3838,O
Chinese,3838,O
herb,3838,O
used,3838,O
for,3838,O
the,3838,O
treatment,3838,O
of,3838,O
diabetes,3838,O
and,3838,O
some,3838,O
other,3838,O
diseases,3838,O
.,3838,O
The,3839,O
vascular,3839,O
protective,3839,O
effect,3839,O
of,3839,O
its,3839,O
major,3839,O
active,3839,O
ingredient,3839,O
",",3839,O
kinsenoside,3839,B-CHEMICAL
",",3839,O
in,3839,O
high,3839,O
glucose,3839,B-CHEMICAL
conditions,3839,O
was,3839,O
investigated,3839,O
in,3839,O
in,3839,O
vivo,3839,O
and,3839,O
in,3839,O
vitro,3839,O
experiments,3839,O
.,3839,O
In,3840,O
in,3840,O
vivo,3840,O
tests,3840,O
",",3840,O
kinsenoside,3840,B-CHEMICAL
(,3840,O
50,3840,O
and,3840,O
100mg/kg,3840,O
),3840,O
efficiently,3840,O
lowered,3840,O
blood,3840,O
glucose,3840,B-CHEMICAL
and,3840,O
cholesterol,3840,B-CHEMICAL
levels,3840,O
and,3840,O
it,3840,O
enhanced,3840,O
the,3840,O
oxidation,3840,O
resistance,3840,O
of,3840,O
diabetic,3840,O
mice,3840,O
induced,3840,O
by,3840,O
streptozotocin,3840,B-CHEMICAL
.,3840,O
In,3841,O
the,3841,O
in,3841,O
vitro,3841,O
assay,3841,O
",",3841,O
kinsenoside,3841,B-CHEMICAL
(,3841,O
20,3841,O
and,3841,O
50μg/mL,3841,O
),3841,O
markedly,3841,O
inhibited,3841,O
changes,3841,O
in,3841,O
various,3841,O
biochemical,3841,O
substances,3841,O
(,3841,O
nitric,3841,B-CHEMICAL
oxide,3841,I-CHEMICAL
(,3841,O
NO,3841,B-CHEMICAL
),3841,O
",",3841,O
lactic,3841,B-GENE-N
dehydrogenase,3841,I-GENE-N
(,3841,O
LDH,3841,B-GENE-N
),3841,O
",",3841,O
superoxide,3841,B-GENE-N
dismutase,3841,I-GENE-N
(,3841,O
SOD,3841,B-GENE-N
),3841,O
",",3841,O
and,3841,O
catalase,3841,B-GENE-Y
(,3841,O
CAT,3841,B-GENE-Y
),3841,O
),3841,O
in,3841,O
human,3841,O
umbilical,3841,O
vein,3841,O
endothelial,3841,O
cells,3841,O
(,3841,O
HUVECs,3841,O
),3841,O
damaged,3841,O
by,3841,O
high,3841,O
glucose,3841,B-CHEMICAL
(,3841,O
35mM,3841,O
),3841,O
and,3841,O
restored,3841,O
vascular,3841,O
endothelial,3841,O
structure,3841,O
by,3841,O
balancing,3841,O
the,3841,O
matrix,3841,B-GENE-N
metalloproteinases-the,3841,O
tissue,3841,B-GENE-N
inhibitors,3841,I-GENE-N
of,3841,I-GENE-N
matrix,3841,I-GENE-N
metalloproteinases,3841,I-GENE-N
(,3841,O
MMP-TIMP,3841,B-GENE-N
),3841,O
system,3841,O
.,3841,O
The,3842,O
vascular,3842,O
protective,3842,O
effects,3842,O
of,3842,O
kinsenoside,3842,B-CHEMICAL
were,3842,O
speculated,3842,O
to,3842,O
be,3842,O
attributed,3842,O
to,3842,O
oxidative,3842,O
stress,3842,O
inhibition,3842,O
and,3842,O
the,3842,O
reduction,3842,O
of,3842,O
nuclear,3842,B-GENE-N
factor,3842,I-GENE-N
kappa,3842,I-GENE-N
B,3842,I-GENE-N
(,3842,O
NF-κB,3842,B-GENE-N
),3842,O
mRNA,3842,O
expression,3842,O
levels,3842,O
in,3842,O
high,3842,O
glucose,3842,B-CHEMICAL
conditions,3842,O
.,3842,O
Moreover,3843,O
",",3843,O
histological,3843,O
examination,3843,O
",",3843,O
including,3843,O
hematoxylin-eosin,3843,B-CHEMICAL
(,3843,O
H,3843,O
&,3843,O
E,3843,O
),3843,O
staining,3843,O
",",3843,O
masson,3843,O
trichrome,3843,O
(,3843,O
Masson,3843,O
),3843,O
staining,3843,O
",",3843,O
and,3843,O
periodic,3843,O
Schiff-methenamine,3843,O
(,3843,O
PASM,3843,O
),3843,O
staining,3843,O
",",3843,O
greatly,3843,O
supported,3843,O
the,3843,O
morphological,3843,O
and,3843,O
functional,3843,O
amelioration,3843,O
of,3843,O
diabetes-related,3843,O
changes,3843,O
in,3843,O
mice,3843,O
aortas,3843,O
after,3843,O
kinsenoside,3843,B-CHEMICAL
(,3843,O
20,3843,O
and,3843,O
50μg/mL,3843,O
),3843,O
treatment,3843,O
.,3843,O
These,3844,O
results,3844,O
indicated,3844,O
that,3844,O
kinsenoside,3844,B-CHEMICAL
might,3844,O
be,3844,O
a,3844,O
promising,3844,O
agent,3844,O
for,3844,O
the,3844,O
treatment,3844,O
of,3844,O
diabetic,3844,O
vascular,3844,O
disease,3844,O
.,3844,O
Prenatal,3845,O
exposure,3845,O
to,3845,O
bisphenol,3845,B-CHEMICAL
A,3845,I-CHEMICAL
impacts,3845,O
midbrain,3845,O
dopamine,3845,B-CHEMICAL
neurons,3845,O
and,3845,O
hippocampal,3845,O
spine,3845,O
synapses,3845,O
in,3845,O
non-human,3845,O
primates,3845,O
.,3845,O
Prevalent,3846,O
use,3846,O
of,3846,O
bisphenol-A,3846,B-CHEMICAL
(,3846,O
BPA,3846,B-CHEMICAL
),3846,O
in,3846,O
the,3846,O
manufacture,3846,O
of,3846,O
resins,3846,O
",",3846,O
plastics,3846,O
and,3846,O
paper,3846,O
products,3846,O
has,3846,O
led,3846,O
to,3846,O
frequent,3846,O
exposure,3846,O
of,3846,O
most,3846,O
people,3846,O
to,3846,O
this,3846,O
endocrine,3846,O
disruptor,3846,O
.,3846,O
Some,3847,O
rodent,3847,O
studies,3847,O
have,3847,O
suggested,3847,O
that,3847,O
BPA,3847,B-CHEMICAL
can,3847,O
exert,3847,O
detrimental,3847,O
effects,3847,O
on,3847,O
brain,3847,O
development,3847,O
.,3847,O
However,3848,O
as,3848,O
rodent,3848,O
models,3848,O
can,3848,O
not,3848,O
be,3848,O
relied,3848,O
on,3848,O
to,3848,O
predict,3848,O
consequences,3848,O
of,3848,O
human,3848,O
exposure,3848,O
to,3848,O
BPA,3848,B-CHEMICAL
during,3848,O
development,3848,O
",",3848,O
it,3848,O
is,3848,O
important,3848,O
to,3848,O
investigate,3848,O
the,3848,O
effects,3848,O
of,3848,O
BPA,3848,B-CHEMICAL
on,3848,O
non-human,3848,O
primate,3848,O
brain,3848,O
development,3848,O
.,3848,O
Previous,3849,O
research,3849,O
suggests,3849,O
that,3849,O
BPA,3849,B-CHEMICAL
preferentially,3849,O
targets,3849,O
dopamine,3849,B-CHEMICAL
neurons,3849,O
in,3849,O
ventral,3849,O
mesencephalon,3849,O
and,3849,O
glutamatergic,3849,O
neurons,3849,O
in,3849,O
hippocampus,3849,O
",",3849,O
so,3849,O
the,3849,O
present,3849,O
work,3849,O
examined,3849,O
the,3849,O
susceptibility,3849,O
of,3849,O
these,3849,O
systems,3849,O
to,3849,O
low,3849,O
dose,3849,O
BPA,3849,B-CHEMICAL
exposure,3849,O
at,3849,O
the,3849,O
fetal,3849,O
and,3849,O
juvenile,3849,O
stages,3849,O
of,3849,O
development,3849,O
in,3849,O
non-human,3849,O
primates,3849,O
.,3849,O
Exposure,3850,O
of,3850,O
pregnant,3850,O
rhesus,3850,O
monkeys,3850,O
to,3850,O
relatively,3850,O
low,3850,O
levels,3850,O
of,3850,O
BPA,3850,B-CHEMICAL
during,3850,O
the,3850,O
final,3850,O
2,3850,O
months,3850,O
of,3850,O
gestation,3850,O
",",3850,O
induced,3850,O
abnormalities,3850,O
in,3850,O
fetal,3850,O
ventral,3850,O
mesencephalon,3850,O
and,3850,O
hippocampus,3850,O
.,3850,O
Specifically,3851,O
",",3851,O
light,3851,O
microscopy,3851,O
revealed,3851,O
a,3851,O
decrease,3851,O
in,3851,O
tyrosine,3851,B-GENE-N
hydroxylase-expressing,3851,O
(,3851,O
dopamine,3851,B-CHEMICAL
),3851,O
neurons,3851,O
in,3851,O
the,3851,O
midbrain,3851,O
of,3851,O
BPA-exposed,3851,B-CHEMICAL
fetuses,3851,O
and,3851,O
electron,3851,O
microscopy,3851,O
identified,3851,O
a,3851,O
reduction,3851,O
in,3851,O
spine,3851,O
synapses,3851,O
in,3851,O
the,3851,O
CA1,3851,O
region,3851,O
of,3851,O
hippocampus,3851,O
.,3851,O
In,3852,O
contrast,3852,O
",",3852,O
administration,3852,O
of,3852,O
BPA,3852,B-CHEMICAL
to,3852,O
juvenile,3852,O
vervet,3852,O
monkeys,3852,O
(,3852,O
14-18,3852,O
months,3852,O
of,3852,O
age,3852,O
),3852,O
was,3852,O
without,3852,O
effect,3852,O
on,3852,O
these,3852,O
indices,3852,O
",",3852,O
or,3852,O
on,3852,O
dopamine,3852,B-CHEMICAL
and,3852,O
serotonin,3852,B-CHEMICAL
concentrations,3852,O
in,3852,O
striatum,3852,O
and,3852,O
prefrontal,3852,O
cortex,3852,O
",",3852,O
or,3852,O
on,3852,O
performance,3852,O
of,3852,O
a,3852,O
cognitive,3852,O
task,3852,O
that,3852,O
tests,3852,O
working,3852,O
memory,3852,O
capacity,3852,O
.,3852,O
These,3853,O
data,3853,O
indicate,3853,O
that,3853,O
BPA,3853,B-CHEMICAL
exerts,3853,O
an,3853,O
age-dependent,3853,O
detrimental,3853,O
impact,3853,O
on,3853,O
primate,3853,O
brain,3853,O
development,3853,O
",",3853,O
at,3853,O
blood,3853,O
levels,3853,O
within,3853,O
the,3853,O
range,3853,O
measured,3853,O
in,3853,O
humans,3853,O
having,3853,O
only,3853,O
environmental,3853,O
contact,3853,O
with,3853,O
BPA,3853,B-CHEMICAL
.,3853,O
Potentiation,3854,O
of,3854,O
sulfonylurea,3854,B-CHEMICAL
action,3854,O
by,3854,O
an,3854,O
EPAC-selective,3854,B-GENE-Y
cAMP,3854,B-CHEMICAL
analog,3854,O
in,3854,O
INS-1,3854,O
cells,3854,O
:,3854,O
comparison,3854,O
of,3854,O
tolbutamide,3854,B-CHEMICAL
and,3854,O
gliclazide,3854,B-CHEMICAL
and,3854,O
a,3854,O
potential,3854,O
role,3854,O
for,3854,O
EPAC,3854,B-GENE-Y
activation,3854,O
of,3854,O
a,3854,O
2-APB-sensitive,3854,O
Ca2+,3854,O
influx,3854,O
.,3854,O
Tolbutamide,3855,B-CHEMICAL
and,3855,O
gliclazide,3855,O
block,3855,O
the,3855,O
K,3855,B-GENE-N
(,3855,I-GENE-N
ATP,3855,I-GENE-N
),3855,I-GENE-N
channel,3855,I-GENE-N
K,3855,B-GENE-Y
(,3855,I-GENE-Y
ir,3855,I-GENE-Y
),3855,I-GENE-Y
6.2/Sur1,3855,O
",",3855,O
causing,3855,O
membrane,3855,O
depolarization,3855,O
and,3855,O
stimulating,3855,O
insulin,3855,B-GENE-Y
secretion,3855,O
in,3855,O
pancreatic,3855,O
beta,3855,O
cells,3855,O
.,3855,O
We,3856,O
examined,3856,O
the,3856,O
ability,3856,O
of,3856,O
the,3856,O
EPAC-selective,3856,B-GENE-Y
cAMP,3856,B-CHEMICAL
analog,3856,O
8-pCPT-2'-O-Me-cAMP-AM,3856,B-CHEMICAL
to,3856,O
potentiate,3856,O
the,3856,O
action,3856,O
of,3856,O
these,3856,O
drugs,3856,O
and,3856,O
the,3856,O
mechanism,3856,O
that,3856,O
might,3856,O
account,3856,O
for,3856,O
it,3856,O
.,3856,O
Insulin,3857,B-GENE-N
secretion,3857,O
stimulated,3857,O
by,3857,O
both,3857,O
200,3857,O
μM,3857,O
tolbutamide,3857,B-CHEMICAL
and,3857,O
20,3857,O
μM,3857,O
gliclazide,3857,B-CHEMICAL
",",3857,O
concentrations,3857,O
that,3857,O
had,3857,O
equivalent,3857,O
effects,3857,O
on,3857,O
membrane,3857,O
potential,3857,O
",",3857,O
was,3857,O
inhibited,3857,O
by,3857,O
thapsigargin,3857,B-CHEMICAL
(,3857,O
1,3857,O
μM,3857,O
),3857,O
or,3857,O
the,3857,O
L-type,3857,B-GENE-N
Ca,3857,I-GENE-N
(,3857,I-GENE-N
2+,3857,I-GENE-N
),3857,I-GENE-N
channel,3857,I-GENE-N
blocker,3857,O
nicardipine,3857,B-CHEMICAL
(,3857,O
2,3857,O
μM,3857,O
),3857,O
and,3857,O
was,3857,O
potentiated,3857,O
by,3857,O
8-pCPT-2'-O-Me-cAMP-AM,3857,B-CHEMICAL
at,3857,O
concentrations,3857,O
≥2,3857,O
μM,3857,O
in,3857,O
INS-1,3857,O
cells,3857,O
.,3857,O
Ca,3858,B-CHEMICAL
(,3858,I-CHEMICAL
2+,3858,I-CHEMICAL
),3858,I-CHEMICAL
transients,3858,O
stimulated,3858,O
by,3858,O
either,3858,O
tolbutamide,3858,B-CHEMICAL
or,3858,O
gliclazide,3858,B-CHEMICAL
were,3858,O
inhibited,3858,O
by,3858,O
thapsigargin,3858,B-CHEMICAL
or,3858,O
nicardipine,3858,B-CHEMICAL
and,3858,O
were,3858,O
significantly,3858,O
potentiated,3858,O
by,3858,O
8-pCPT-2'-O-Me-cAMP-AM,3858,O
at,3858,O
5,3858,O
μM,3858,O
but,3858,O
not,3858,O
1,3858,O
μM,3858,O
.,3858,O
Both,3859,O
tolbutamide,3859,B-CHEMICAL
and,3859,O
gliclazide,3859,B-CHEMICAL
stimulated,3859,O
phospholipase,3859,B-GENE-N
C,3859,I-GENE-N
activity,3859,O
;,3859,O
however,3859,O
",",3859,O
only,3859,O
gliclazide,3859,B-CHEMICAL
did,3859,O
so,3859,O
independently,3859,O
of,3859,O
its,3859,O
activity,3859,O
at,3859,O
K,3859,B-GENE-N
(,3859,I-GENE-N
ATP,3859,I-GENE-N
),3859,I-GENE-N
channels,3859,I-GENE-N
",",3859,O
and,3859,O
this,3859,O
activity,3859,O
was,3859,O
partially,3859,O
inhibited,3859,O
by,3859,O
pertussis,3859,B-GENE-N
toxin,3859,I-GENE-N
.,3859,O
8-pCPT-2'-O-Me-cAMP-AM,3860,B-CHEMICAL
alone,3860,O
(,3860,O
5,3860,O
μM,3860,O
),3860,O
did,3860,O
not,3860,O
stimulate,3860,O
insulin,3860,B-GENE-N
secretion,3860,O
",",3860,O
but,3860,O
did,3860,O
increase,3860,O
intracellular,3860,O
Ca,3860,B-CHEMICAL
(,3860,I-CHEMICAL
2+,3860,I-CHEMICAL
),3860,I-CHEMICAL
concentration,3860,O
significantly,3860,O
",",3860,O
and,3860,O
this,3860,O
activity,3860,O
was,3860,O
inhibited,3860,O
by,3860,O
25,3860,O
μM,3860,O
2-aminoethoxydiphenylborate,3860,B-CHEMICAL
(,3860,O
2-APB,3860,B-CHEMICAL
),3860,O
or,3860,O
the,3860,O
removal,3860,O
of,3860,O
extracellular,3860,O
Ca,3860,B-CHEMICAL
(,3860,I-CHEMICAL
2+,3860,I-CHEMICAL
),3860,I-CHEMICAL
.,3860,O
8-pCPT-2'-O-Me-cAMP-AM,3861,B-CHEMICAL
potentiation,3861,O
of,3861,O
insulin,3861,B-GENE-N
secretion,3861,O
stimulated,3861,O
by,3861,O
tolbutamide,3861,B-CHEMICAL
was,3861,O
markedly,3861,O
inhibited,3861,O
by,3861,O
2-APB,3861,B-CHEMICAL
(,3861,O
25,3861,O
μM,3861,O
),3861,O
and,3861,O
enhanced,3861,O
by,3861,O
the,3861,O
PKC,3861,B-GENE-N
inhibitor,3861,O
bisindolylmaleimide,3861,B-CHEMICAL
I,3861,I-CHEMICAL
(,3861,O
1,3861,O
μM,3861,O
),3861,O
.,3861,O
Our,3862,O
data,3862,O
demonstrate,3862,O
that,3862,O
the,3862,O
actions,3862,O
of,3862,O
both,3862,O
tolbutamide,3862,B-CHEMICAL
and,3862,O
gliclazide,3862,B-CHEMICAL
are,3862,O
strongly,3862,O
potentiated,3862,O
by,3862,O
8-pCPT-2'-O-Me-cAMP-AM,3862,B-CHEMICAL
",",3862,O
that,3862,O
gliclazide,3862,B-CHEMICAL
can,3862,O
stimulate,3862,O
phospholipase,3862,B-GENE-N
C,3862,I-GENE-N
activity,3862,O
via,3862,O
a,3862,O
partially,3862,O
pertussis,3862,B-GENE-N
toxin-sensitive,3862,O
mechanism,3862,O
",",3862,O
and,3862,O
that,3862,O
8-pCPT-2'-O-Me-cAMP-AM,3862,B-CHEMICAL
potentiation,3862,O
of,3862,O
tolbutamide,3862,O
action,3862,O
may,3862,O
involve,3862,O
activation,3862,O
of,3862,O
a,3862,O
2-APB-sensitive,3862,B-CHEMICAL
Ca,3862,B-CHEMICAL
(,3862,I-CHEMICAL
2+,3862,I-CHEMICAL
),3862,I-CHEMICAL
influx,3862,O
.,3862,O
Energy,3863,O
depletion,3863,O
of,3863,O
bovine,3863,O
mammary,3863,O
epithelial,3863,O
cells,3863,O
activates,3863,O
AMPK,3863,B-GENE-N
and,3863,O
suppresses,3863,O
protein,3863,O
synthesis,3863,O
through,3863,O
inhibition,3863,O
of,3863,O
mTORC1,3863,B-GENE-N
signaling,3863,O
.,3863,O
The,3864,O
molecular,3864,O
mechanisms,3864,O
by,3864,O
which,3864,O
cellular,3864,O
energy,3864,O
status,3864,O
regulates,3864,O
global,3864,O
protein,3864,O
synthesis,3864,O
in,3864,O
mammary,3864,O
epithelial,3864,O
cells,3864,O
have,3864,O
not,3864,O
been,3864,O
characterized,3864,O
.,3864,O
The,3865,O
objective,3865,O
of,3865,O
this,3865,O
study,3865,O
was,3865,O
to,3865,O
examine,3865,O
the,3865,O
effect,3865,O
of,3865,O
AMP-activated,3865,B-GENE-N
protein,3865,I-GENE-N
kinase,3865,I-GENE-N
(,3865,O
AMPK,3865,B-GENE-N
),3865,O
activation,3865,O
by,3865,O
2-deoxyglucose,3865,B-CHEMICAL
on,3865,O
protein,3865,O
synthesis,3865,O
and,3865,O
the,3865,O
mammalian,3865,B-GENE-N
target,3865,I-GENE-N
of,3865,I-GENE-N
rapamycin,3865,I-GENE-N
complex,3865,I-GENE-N
1,3865,I-GENE-N
(,3865,O
mTORC1,3865,B-GENE-N
),3865,O
signaling,3865,O
pathway,3865,O
in,3865,O
bovine,3865,O
mammary,3865,O
epithelial,3865,O
cells,3865,O
.,3865,O
Phosphorylation,3866,O
of,3866,O
AMPK,3866,B-GENE-N
at,3866,O
Thr172,3866,B-CHEMICAL
increased,3866,O
by,3866,O
1.4-fold,3866,O
within,3866,O
5,3866,O
min,3866,O
",",3866,O
and,3866,O
remained,3866,O
elevated,3866,O
throughout,3866,O
a,3866,O
30-min,3866,O
time,3866,O
course,3866,O
",",3866,O
in,3866,O
response,3866,O
to,3866,O
2-deoxyglucose,3866,B-CHEMICAL
.,3866,O
Global,3867,O
rates,3867,O
of,3867,O
protein,3867,O
synthesis,3867,O
declined,3867,O
by,3867,O
78,3867,O
%,3867,O
of,3867,O
control,3867,O
values,3867,O
.,3867,O
The,3868,O
decline,3868,O
in,3868,O
protein,3868,O
synthesis,3868,O
was,3868,O
associated,3868,O
with,3868,O
repression,3868,O
of,3868,O
mTORC1,3868,B-GENE-N
signaling,3868,O
",",3868,O
as,3868,O
indicated,3868,O
by,3868,O
reduced,3868,O
phosphorylation,3868,O
of,3868,O
ribosomal,3868,B-GENE-Y
protein,3868,I-GENE-Y
S6,3868,I-GENE-Y
kinase,3868,I-GENE-Y
1,3868,I-GENE-Y
and,3868,O
eIF4E,3868,B-GENE-Y
binding,3868,I-GENE-Y
protein-1,3868,I-GENE-Y
(,3868,O
4E-BP1,3868,B-GENE-Y
),3868,O
.,3868,O
Phosphorylation,3869,O
of,3869,O
ER-stress,3869,O
marker,3869,O
eIF2α,3869,B-GENE-Y
was,3869,O
also,3869,O
increased,3869,O
but,3869,O
only,3869,O
at,3869,O
30,3869,O
min,3869,O
of,3869,O
2-deoxyglucose,3869,B-CHEMICAL
exposure,3869,O
.,3869,O
2-Deoxyglucose,3870,B-CHEMICAL
increased,3870,O
phosphorylation,3870,O
of,3870,O
tuberous,3870,B-GENE-Y
sclerosis,3870,I-GENE-Y
complex,3870,I-GENE-Y
2,3870,I-GENE-Y
(,3870,O
TSC2,3870,B-GENE-Y
),3870,O
on,3870,O
AMPK,3870,B-GENE-N
consensus,3870,O
sites,3870,O
but,3870,O
did,3870,O
not,3870,O
change,3870,O
the,3870,O
amount,3870,O
of,3870,O
TSC1,3870,B-GENE-Y
bound,3870,O
to,3870,O
TSC2,3870,B-GENE-Y
.,3870,O
Activation,3871,O
of,3871,O
AMPK,3871,B-GENE-N
did,3871,O
not,3871,O
result,3871,O
in,3871,O
changes,3871,O
in,3871,O
the,3871,O
amount,3871,O
of,3871,O
raptor,3871,O
bound,3871,O
to,3871,O
mTOR,3871,B-GENE-Y
.,3871,O
The,3872,O
inhibitory,3872,O
effects,3872,O
of,3872,O
AMPK,3872,B-GENE-N
activation,3872,O
on,3872,O
mTORC1,3872,B-GENE-N
signaling,3872,O
were,3872,O
associated,3872,O
with,3872,O
a,3872,O
marked,3872,O
increase,3872,O
in,3872,O
Ser792,3872,B-CHEMICAL
phosphorylation,3872,O
on,3872,O
raptor,3872,O
.,3872,O
Collectively,3873,O
",",3873,O
the,3873,O
results,3873,O
suggest,3873,O
that,3873,O
activation,3873,O
of,3873,O
AMPK,3873,B-GENE-N
represses,3873,O
global,3873,O
protein,3873,O
synthesis,3873,O
in,3873,O
mammary,3873,O
epithelial,3873,O
cells,3873,O
through,3873,O
inhibition,3873,O
of,3873,O
mTORC1,3873,B-GENE-N
signaling,3873,O
.,3873,O
Conivaptan,3874,B-CHEMICAL
:,3874,O
a,3874,O
dual,3874,O
vasopressin,3874,B-GENE-N
receptor,3874,I-GENE-N
v1a/v2,3874,I-GENE-N
antagonist,3874,O
[,3874,O
corrected,3874,O
],3874,O
.,3874,O
Several,3875,O
fluid,3875,O
retentive,3875,O
states,3875,O
such,3875,O
as,3875,O
heart,3875,O
failure,3875,O
",",3875,O
cirrhosis,3875,O
of,3875,O
the,3875,O
liver,3875,O
",",3875,O
and,3875,O
syndrome,3875,O
of,3875,O
inappropriate,3875,O
antidiuretic,3875,O
hormone,3875,O
secretion,3875,O
are,3875,O
associated,3875,O
with,3875,O
inappropriate,3875,O
elevation,3875,O
in,3875,O
plasma,3875,O
levels,3875,O
of,3875,O
arginine,3875,B-GENE-Y
vasopressin,3875,I-GENE-Y
(,3875,O
AVP,3875,B-GENE-Y
),3875,O
",",3875,O
a,3875,O
neuropeptide,3875,O
that,3875,O
is,3875,O
secreted,3875,O
by,3875,O
the,3875,O
hypothalamus,3875,O
and,3875,O
plays,3875,O
a,3875,O
critical,3875,O
role,3875,O
in,3875,O
the,3875,O
regulation,3875,O
of,3875,O
serum,3875,O
osmolality,3875,O
and,3875,O
in,3875,O
circulatory,3875,O
homeostasis,3875,O
.,3875,O
The,3876,O
actions,3876,O
of,3876,O
AVP,3876,B-GENE-Y
are,3876,O
mediated,3876,O
by,3876,O
three,3876,O
receptor,3876,O
subtypes,3876,O
V1a,3876,O
",",3876,O
V2,3876,O
",",3876,O
and,3876,O
V1b,3876,O
.,3876,O
The,3877,O
V1a,3877,B-GENE-Y
receptor,3877,I-GENE-Y
regulates,3877,O
vasodilation,3877,O
and,3877,O
cellular,3877,O
hypertrophy,3877,O
while,3877,O
the,3877,O
V2,3877,B-GENE-Y
receptor,3877,I-GENE-Y
regulates,3877,O
free,3877,O
water,3877,O
excretion,3877,O
.,3877,O
The,3878,O
V1b,3878,B-GENE-Y
receptor,3878,I-GENE-Y
regulates,3878,O
adrenocorticotropin,3878,B-GENE-Y
hormone,3878,I-GENE-Y
release,3878,O
.,3878,O
Conivaptan,3879,B-CHEMICAL
is,3879,O
a,3879,O
nonpeptide,3879,O
dual,3879,O
V1a/V2,3879,B-GENE-N
AVP,3879,I-GENE-N
receptor,3879,I-GENE-N
antagonist,3879,O
.,3879,O
It,3880,O
binds,3880,O
with,3880,O
high,3880,O
affinity,3880,O
",",3880,O
competitively,3880,O
",",3880,O
and,3880,O
reversibly,3880,O
to,3880,O
the,3880,O
V1a/V2,3880,B-GENE-N
receptor,3880,I-GENE-N
subtypes,3880,O
;,3880,O
its,3880,O
antagonistic,3880,O
effect,3880,O
is,3880,O
concentration,3880,O
dependent,3880,O
.,3880,O
It,3881,O
inhibits,3881,O
CYP3A4,3881,B-GENE-Y
liver,3881,O
enzyme,3881,O
and,3881,O
elevates,3881,O
plasma,3881,O
levels,3881,O
of,3881,O
other,3881,O
drugs,3881,O
metabolized,3881,O
by,3881,O
this,3881,O
enzyme,3881,O
.,3881,O
It,3882,O
is,3882,O
approved,3882,O
only,3882,O
for,3882,O
short-term,3882,O
intravenous,3882,O
use,3882,O
.,3882,O
Infusion,3883,O
site,3883,O
reaction,3883,O
is,3883,O
the,3883,O
most,3883,O
common,3883,O
reason,3883,O
for,3883,O
discontinuation,3883,O
of,3883,O
the,3883,O
drug,3883,O
.,3883,O
In,3884,O
animals,3884,O
conivaptan,3884,O
increased,3884,O
urine,3884,O
volume,3884,O
and,3884,O
free,3884,O
water,3884,O
clearance,3884,O
.,3884,O
In,3885,O
heart,3885,O
failure,3885,O
models,3885,O
it,3885,O
improved,3885,O
hemodynamic,3885,O
parameters,3885,O
and,3885,O
free,3885,O
water,3885,O
excretion,3885,O
.,3885,O
Conivaptan,3886,B-CHEMICAL
has,3886,O
been,3886,O
shown,3886,O
to,3886,O
correct,3886,O
hyponatremia,3886,O
in,3886,O
euvolemic,3886,O
or,3886,O
hypervolemic,3886,O
patients,3886,O
.,3886,O
Its,3887,O
efficacy,3887,O
and,3887,O
safety,3887,O
for,3887,O
short-term,3887,O
use,3887,O
have,3887,O
led,3887,O
to,3887,O
the,3887,O
Food,3887,O
and,3887,O
Drug,3887,O
Administration,3887,O
(,3887,O
FDA,3887,O
),3887,O
approval,3887,O
of,3887,O
its,3887,O
intravenous,3887,O
form,3887,O
for,3887,O
the,3887,O
correction,3887,O
of,3887,O
hyponatremia,3887,O
in,3887,O
euvolemic,3887,O
and,3887,O
hypervolemic,3887,O
states,3887,O
.,3887,O
Despite,3888,O
its,3888,O
ability,3888,O
to,3888,O
block,3888,O
the,3888,O
action,3888,O
of,3888,O
AVP,3888,B-GENE-Y
on,3888,O
V1a,3888,B-GENE-Y
receptors,3888,I-GENE-Y
",",3888,O
no,3888,O
demonstrable,3888,O
benefit,3888,O
from,3888,O
this,3888,O
action,3888,O
was,3888,O
noted,3888,O
in,3888,O
patients,3888,O
with,3888,O
chronic,3888,O
compensated,3888,O
heart,3888,O
failure,3888,O
and,3888,O
it,3888,O
is,3888,O
not,3888,O
approved,3888,O
for,3888,O
this,3888,O
indication,3888,O
.,3888,O
Consideration,3889,O
should,3889,O
be,3889,O
given,3889,O
to,3889,O
further,3889,O
evaluation,3889,O
of,3889,O
its,3889,O
potential,3889,O
benefits,3889,O
in,3889,O
patients,3889,O
with,3889,O
acute,3889,O
decompensated,3889,O
heart,3889,O
failure,3889,O
.,3889,O
Histamine,3890,B-CHEMICAL
and,3890,O
asthma,3890,O
:,3890,O
an,3890,O
appraisal,3890,O
based,3890,O
on,3890,O
specific,3890,O
H1-receptor,3890,B-GENE-Y
antagonism,3890,O
.,3890,O
H1-receptor,3891,B-GENE-Y
antagonists,3891,O
have,3891,O
been,3891,O
utilized,3891,O
",",3891,O
following,3891,O
their,3891,O
initial,3891,O
chemical,3891,O
synthesis,3891,O
in,3891,O
1933,3891,O
",",3891,O
both,3891,O
in,3891,O
the,3891,O
treatment,3891,O
of,3891,O
conditions,3891,O
in,3891,O
which,3891,O
histamine,3891,B-CHEMICAL
is,3891,O
considered,3891,O
to,3891,O
be,3891,O
of,3891,O
pathogenic,3891,O
importance,3891,O
and,3891,O
conversely,3891,O
to,3891,O
help,3891,O
elucidate,3891,O
the,3891,O
role,3891,O
of,3891,O
histamine,3891,B-CHEMICAL
in,3891,O
disease,3891,O
",",3891,O
through,3891,O
an,3891,O
evaluation,3891,O
of,3891,O
their,3891,O
influence,3891,O
on,3891,O
disease,3891,O
expression,3891,O
.,3891,O
While,3892,O
there,3892,O
is,3892,O
considerable,3892,O
indirect,3892,O
evidence,3892,O
to,3892,O
implicate,3892,O
histamine,3892,B-CHEMICAL
in,3892,O
the,3892,O
pathogenesis,3892,O
of,3892,O
asthma,3892,O
",",3892,O
a,3892,O
critical,3892,O
evaluation,3892,O
of,3892,O
H1-receptor,3892,B-GENE-Y
antagonism,3892,O
in,3892,O
this,3892,O
condition,3892,O
has,3892,O
",",3892,O
until,3892,O
recently,3892,O
",",3892,O
proved,3892,O
difficult,3892,O
",",3892,O
as,3892,O
many,3892,O
of,3892,O
the,3892,O
early,3892,O
H1-receptor,3892,B-GENE-Y
antagonists,3892,O
possessed,3892,O
additional,3892,O
actions,3892,O
",",3892,O
such,3892,O
as,3892,O
anti-cholinergic,3892,O
",",3892,O
local,3892,O
anaesthetic,3892,O
",",3892,O
alpha-adrenoceptor,3892,B-GENE-N
antagonistic,3892,O
and,3892,O
anti-serotonin,3892,O
activity,3892,O
.,3892,O
In,3893,O
addition,3893,O
",",3893,O
H1-receptor,3893,B-GENE-Y
antagonists,3893,O
have,3893,O
been,3893,O
shown,3893,O
to,3893,O
have,3893,O
effects,3893,O
on,3893,O
mast,3893,O
cell,3893,O
function,3893,O
.,3893,O
In,3894,O
low,3894,O
concentrations,3894,O
in,3894,O
vitro,3894,O
",",3894,O
antihistamines,3894,O
have,3894,O
been,3894,O
found,3894,O
to,3894,O
inhibit,3894,O
immunologically,3894,O
stimulated,3894,O
mast,3894,O
cell,3894,O
mediator,3894,O
release,3894,O
",",3894,O
with,3894,O
the,3894,O
IC50,3894,O
in,3894,O
the,3894,O
nanomolar,3894,O
to,3894,O
micromolar,3894,O
range,3894,O
",",3894,O
while,3894,O
at,3894,O
higher,3894,O
concentrations,3894,O
they,3894,O
induce,3894,O
histamine,3894,B-CHEMICAL
release,3894,O
.,3894,O
The,3895,O
potency,3895,O
of,3895,O
these,3895,O
drugs,3895,O
in,3895,O
producing,3895,O
such,3895,O
effects,3895,O
is,3895,O
unrelated,3895,O
to,3895,O
their,3895,O
H1-receptor,3895,B-GENE-Y
blocking,3895,O
activity,3895,O
.,3895,O
Furthermore,3896,O
the,3896,O
sedative,3896,O
effects,3896,O
of,3896,O
these,3896,O
therapeutic,3896,O
agents,3896,O
limit,3896,O
the,3896,O
tolerable,3896,O
administrable,3896,O
dose,3896,O
and,3896,O
thus,3896,O
the,3896,O
degree,3896,O
of,3896,O
H1-receptor,3896,B-GENE-Y
blockade,3896,O
achievable,3896,O
within,3896,O
the,3896,O
airways,3896,O
.,3896,O
The,3897,O
recent,3897,O
development,3897,O
of,3897,O
H1-receptor,3897,B-GENE-Y
antagonists,3897,O
devoid,3897,O
of,3897,O
clinical,3897,O
sedative,3897,O
effects,3897,O
has,3897,O
enabled,3897,O
the,3897,O
administration,3897,O
of,3897,O
doses,3897,O
of,3897,O
H1-antihistamines,3897,B-GENE-Y
which,3897,O
achieve,3897,O
a,3897,O
greater,3897,O
degree,3897,O
of,3897,O
H1-receptor,3897,B-GENE-Y
blockade,3897,O
within,3897,O
the,3897,O
airways,3897,O
",",3897,O
thus,3897,O
permitting,3897,O
a,3897,O
better,3897,O
appraisal,3897,O
of,3897,O
the,3897,O
role,3897,O
of,3897,O
histamine,3897,B-CHEMICAL
in,3897,O
this,3897,O
condition,3897,O
.,3897,O
Furthermore,3898,O
",",3898,O
the,3898,O
receptor,3898,O
specificity,3898,O
of,3898,O
many,3898,O
of,3898,O
these,3898,O
agents,3898,O
has,3898,O
been,3898,O
focused,3898,O
such,3898,O
that,3898,O
terfenadine,3898,B-CHEMICAL
",",3898,O
astemizole,3898,B-CHEMICAL
",",3898,O
loratadine,3898,B-CHEMICAL
and,3898,O
cetirizine,3898,B-CHEMICAL
are,3898,O
devoid,3898,O
of,3898,O
anticholinergic,3898,O
activity,3898,O
and,3898,O
exhibit,3898,O
little,3898,O
alpha-antagonistic,3898,O
or,3898,O
anti-serotonin,3898,O
activity,3898,O
of,3898,O
clinical,3898,O
relevance,3898,O
.,3898,O
However,3899,O
",",3899,O
of,3899,O
these,3899,O
agents,3899,O
both,3899,O
loratadine,3899,B-CHEMICAL
and,3899,O
cetirizine,3899,B-CHEMICAL
possess,3899,O
additional,3899,O
actions,3899,O
likely,3899,O
to,3899,O
be,3899,O
of,3899,O
relevance,3899,O
to,3899,O
asthma,3899,O
.,3899,O
Pretreatment,3900,O
with,3900,O
loratadine,3900,B-CHEMICAL
has,3900,O
been,3900,O
shown,3900,O
to,3900,O
reduce,3900,O
the,3900,O
recovery,3900,O
of,3900,O
both,3900,O
histamine,3900,B-CHEMICAL
and,3900,O
prostaglandin,3900,B-CHEMICAL
D2,3900,I-CHEMICAL
(,3900,O
PGD2,3900,B-CHEMICAL
),3900,O
in,3900,O
nasal,3900,O
lavage,3900,O
fluid,3900,O
following,3900,O
nasal,3900,O
allergen,3900,O
challenge,3900,O
",",3900,O
a,3900,O
finding,3900,O
interpreted,3900,O
as,3900,O
indicative,3900,O
of,3900,O
in,3900,O
vivo,3900,O
mast,3900,O
cell,3900,O
stabilization,3900,O
",",3900,O
and,3900,O
cetirizine,3900,B-CHEMICAL
has,3900,O
been,3900,O
shown,3900,O
in,3900,O
vivo,3900,O
at,3900,O
therapeutic,3900,O
doses,3900,O
to,3900,O
inhibit,3900,O
allergen-induced,3900,O
eosinophil,3900,O
chemotaxis,3900,O
.,3900,O
Thus,3901,O
while,3901,O
both,3901,O
these,3901,O
agents,3901,O
offer,3901,O
the,3901,O
potential,3901,O
of,3901,O
an,3901,O
oral,3901,O
therapy,3901,O
for,3901,O
asthma,3901,O
based,3901,O
on,3901,O
an,3901,O
H1-receptor,3901,B-GENE-Y
antagonist,3901,O
",",3901,O
their,3901,O
additional,3901,O
actions,3901,O
do,3901,O
not,3901,O
make,3901,O
them,3901,O
ideally,3901,O
suited,3901,O
to,3901,O
the,3901,O
exploration,3901,O
of,3901,O
the,3901,O
role,3901,O
of,3901,O
histamine,3901,B-CHEMICAL
in,3901,O
asthma,3901,O
.,3901,O
(,3902,O
ABSTRACT,3902,O
TRUNCATED,3902,O
AT,3902,O
400,3902,O
WORDS,3902,O
),3902,O
Identification,3903,O
of,3903,O
novel,3903,O
FLT3,3903,B-GENE-Y
kinase,3903,B-GENE-N
inhibitors,3903,O
.,3903,O
FLT3,3904,B-GENE-Y
and,3904,O
PDGFR,3904,B-GENE-N
tyrosine,3904,B-GENE-N
kinases,3904,I-GENE-N
are,3904,O
important,3904,O
targets,3904,O
for,3904,O
therapy,3904,O
of,3904,O
different,3904,O
types,3904,O
of,3904,O
leukemia,3904,O
.,3904,O
Several,3905,O
FLT3/PDGFR,3905,B-GENE-Y
inhibitors,3905,O
are,3905,O
currently,3905,O
under,3905,O
clinical,3905,O
investigation,3905,O
for,3905,O
combination,3905,O
with,3905,O
standard,3905,O
therapy,3905,O
for,3905,O
treatment,3905,O
of,3905,O
acute,3905,O
myeloid,3905,O
leukemia,3905,O
(,3905,O
AML,3905,O
),3905,O
",",3905,O
however,3905,O
these,3905,O
agents,3905,O
only,3905,O
induce,3905,O
partial,3905,O
remission,3905,O
and,3905,O
development,3905,O
of,3905,O
resistance,3905,O
has,3905,O
been,3905,O
reported,3905,O
.,3905,O
In,3906,O
this,3906,O
work,3906,O
we,3906,O
describe,3906,O
the,3906,O
identification,3906,O
of,3906,O
potent,3906,O
and,3906,O
novel,3906,O
dual,3906,O
FLT3/PDGFR,3906,B-GENE-Y
inhibitors,3906,O
that,3906,O
resulted,3906,O
from,3906,O
our,3906,O
efforts,3906,O
to,3906,O
screen,3906,O
a,3906,O
library,3906,O
of,3906,O
"25,607",3906,O
small,3906,O
molecules,3906,O
against,3906,O
the,3906,O
FLT3,3906,B-GENE-Y
dependent,3906,O
cell,3906,O
line,3906,O
MOLM-13,3906,O
and,3906,O
the,3906,O
PDGFR,3906,B-GENE-N
dependent,3906,O
cell,3906,O
line,3906,O
EOL-1,3906,O
.,3906,O
This,3907,O
effort,3907,O
led,3907,O
to,3907,O
the,3907,O
identification,3907,O
of,3907,O
five,3907,O
compounds,3907,O
that,3907,O
were,3907,O
confirmed,3907,O
to,3907,O
be,3907,O
active,3907,O
on,3907,O
additional,3907,O
FLT3,3907,B-GENE-Y
dependent,3907,O
cell,3907,O
lines,3907,O
(,3907,O
cellular,3907,O
EC50,3907,O
values,3907,O
between,3907,O
35,3907,O
and,3907,O
700,3907,O
nM,3907,O
),3907,O
",",3907,O
while,3907,O
having,3907,O
no,3907,O
significant,3907,O
effect,3907,O
on,3907,O
24,3907,O
other,3907,O
tyrosine,3907,B-GENE-N
kinases,3907,I-GENE-N
.,3907,O
Enzyme-responsive,3908,O
surface,3908,O
erosion,3908,O
of,3908,O
poly,3908,B-CHEMICAL
(,3908,I-CHEMICAL
ethylene,3908,I-CHEMICAL
carbonate,3908,I-CHEMICAL
),3908,I-CHEMICAL
for,3908,O
controlled,3908,O
drug,3908,O
release,3908,O
.,3908,O
Cholesterol,3909,B-GENE-Y
esterase,3909,I-GENE-Y
(,3909,O
CE,3909,B-GENE-Y
),3909,O
induced,3909,O
surface,3909,O
erosion,3909,O
of,3909,O
poly,3909,B-CHEMICAL
(,3909,I-CHEMICAL
ethylene,3909,I-CHEMICAL
carbonate,3909,I-CHEMICAL
),3909,I-CHEMICAL
(,3909,O
PEC,3909,B-CHEMICAL
),3909,O
and,3909,O
drug,3909,O
release,3909,O
from,3909,O
PEC,3909,B-CHEMICAL
under,3909,O
mild,3909,O
physiological,3909,O
environment,3909,O
was,3909,O
investigated,3909,O
.,3909,O
The,3910,O
degradation,3910,O
process,3910,O
was,3910,O
monitored,3910,O
by,3910,O
changes,3910,O
of,3910,O
mass,3910,O
and,3910,O
molecular,3910,O
weight,3910,O
(,3910,O
MW,3910,O
),3910,O
and,3910,O
surface,3910,O
morphology,3910,O
of,3910,O
polymer,3910,O
films,3910,O
.,3910,O
During,3911,O
the,3911,O
whole,3911,O
period,3911,O
of,3911,O
degradation,3911,O
",",3911,O
MW,3911,O
of,3911,O
PEC,3911,B-CHEMICAL
was,3911,O
unchanged,3911,O
.,3911,O
Water,3912,O
uptake,3912,O
of,3912,O
the,3912,O
polymer,3912,O
was,3912,O
only,3912,O
2.8,3912,O
and,3912,O
0.2,3912,O
%,3912,O
for,3912,O
PEC,3912,B-CHEMICAL
with,3912,O
the,3912,O
MW,3912,O
of,3912,O
200,3912,O
kDa,3912,O
(,3912,O
PEC200,3912,B-CHEMICAL
),3912,O
and,3912,O
PEC,3912,B-CHEMICAL
with,3912,O
the,3912,O
MW,3912,O
of,3912,O
41,3912,O
kDa,3912,O
(,3912,O
PEC41,3912,B-CHEMICAL
),3912,O
",",3912,O
respectively,3912,O
.,3912,O
Degradation,3913,O
of,3913,O
less,3913,O
hydrophilic,3913,O
PEC41,3913,B-CHEMICAL
with,3913,O
higher,3913,O
density,3913,O
was,3913,O
slower,3913,O
than,3913,O
that,3913,O
of,3913,O
PEC200,3913,B-CHEMICAL
.,3913,O
By,3914,O
this,3914,O
mechanism,3914,O
",",3914,O
CE-responsive,3914,B-GENE-Y
drug,3914,O
in,3914,O
vitro,3914,O
release,3914,O
from,3914,O
PEC,3914,B-CHEMICAL
in,3914,O
situ,3914,O
forming,3914,O
depots,3914,O
(,3914,O
ISFD,3914,O
),3914,O
was,3914,O
conducted,3914,O
successfully,3914,O
.,3914,O
As,3915,O
expected,3915,O
",",3915,O
less,3915,O
bovine,3915,B-GENE-Y
serum,3915,I-GENE-Y
albumin,3915,I-GENE-Y
(,3915,O
BSA,3915,B-GENE-Y
),3915,O
was,3915,O
released,3915,O
from,3915,O
PEC41,3915,B-CHEMICAL
compared,3915,O
with,3915,O
that,3915,O
of,3915,O
PEC200,3915,B-CHEMICAL
in,3915,O
the,3915,O
same,3915,O
time,3915,O
period,3915,O
.,3915,O
In,3916,O
conclusion,3916,O
",",3916,O
this,3916,O
work,3916,O
enabled,3916,O
the,3916,O
in,3916,O
vitro,3916,O
drug,3916,O
release,3916,O
evaluation,3916,O
of,3916,O
existing,3916,O
PEC,3916,B-CHEMICAL
devices,3916,O
and,3916,O
implied,3916,O
a,3916,O
new,3916,O
candidate,3916,O
for,3916,O
the,3916,O
development,3916,O
of,3916,O
enzyme-responsive,3916,O
systems,3916,O
.,3916,O
Genome-wide,3917,O
integrated,3917,O
analyses,3917,O
of,3917,O
androgen,3917,B-GENE-Y
receptor,3917,I-GENE-Y
signaling,3917,O
in,3917,O
prostate,3917,O
cancer,3917,O
based,3917,O
on,3917,O
high-throughput,3917,O
technology,3917,O
.,3917,O
The,3918,O
androgen,3918,B-GENE-Y
receptor,3918,I-GENE-Y
(,3918,O
AR,3918,B-GENE-Y
),3918,O
is,3918,O
a,3918,O
steroid,3918,B-GENE-N
hormone,3918,I-GENE-N
receptor,3918,I-GENE-N
that,3918,O
functions,3918,O
as,3918,O
a,3918,O
ligand-dependent,3918,O
transcriptional,3918,O
factor,3918,O
",",3918,O
which,3918,O
plays,3918,O
a,3918,O
key,3918,O
role,3918,O
in,3918,O
the,3918,O
development,3918,O
and,3918,O
progression,3918,O
of,3918,O
prostate,3918,O
cancer,3918,O
.,3918,O
Recent,3919,O
advancement,3919,O
in,3919,O
high,3919,O
throughput,3919,O
technologies,3919,O
including,3919,O
microarrays,3919,O
and,3919,O
deep-sequencing,3919,O
provides,3919,O
unbiased,3919,O
genome-wide,3919,O
knowledge,3919,O
on,3919,O
the,3919,O
AR,3919,B-GENE-Y
signaling,3919,O
including,3919,O
datasets,3919,O
for,3919,O
androgen-regulated,3919,B-CHEMICAL
gene,3919,O
expression,3919,O
and,3919,O
genomic,3919,O
binding,3919,O
sites,3919,O
for,3919,O
AR,3919,B-GENE-Y
.,3919,O
In,3920,O
the,3920,O
present,3920,O
review,3920,O
",",3920,O
we,3920,O
will,3920,O
briefly,3920,O
summarize,3920,O
the,3920,O
main,3920,O
features,3920,O
of,3920,O
the,3920,O
AR,3920,B-GENE-Y
signaling,3920,O
as,3920,O
well,3920,O
as,3920,O
the,3920,O
individual,3920,O
AR,3920,B-GENE-Y
target,3920,O
genes,3920,O
identified,3920,O
by,3920,O
the,3920,O
integration,3920,O
of,3920,O
multiple,3920,O
datasets,3920,O
in,3920,O
prostate,3920,O
cancer,3920,O
.,3920,O
Cap,3921,O
analysis,3921,O
gene,3921,O
expression,3921,O
(,3921,O
CAGE,3921,O
),3921,O
is,3921,O
also,3921,O
featured,3921,O
as,3921,O
a,3921,O
unique,3921,O
transcriptome,3921,O
method,3921,O
",",3921,O
which,3921,O
particularly,3921,O
determines,3921,O
the,3921,O
androgen-dependent,3921,B-CHEMICAL
transcription,3921,O
start,3921,O
points,3921,O
in,3921,O
prostate,3921,O
cancer,3921,O
.,3921,O
Glucagon,3922,B-GENE-Y
receptor,3922,I-GENE-Y
antagonism,3922,O
improves,3922,O
islet,3922,O
function,3922,O
in,3922,O
mice,3922,O
with,3922,O
insulin,3922,B-GENE-N
resistance,3922,O
induced,3922,O
by,3922,O
a,3922,O
high-fat,3922,O
diet,3922,O
.,3922,O
AIMS/HYPOTHESIS,3923,O
:,3923,O
Increased,3923,O
glucagon,3923,B-GENE-Y
secretion,3923,O
predicts,3923,O
deterioration,3923,O
of,3923,O
glucose,3923,B-CHEMICAL
tolerance,3923,O
",",3923,O
and,3923,O
high,3923,O
glucagon,3923,B-GENE-Y
levels,3923,O
contribute,3923,O
to,3923,O
hyperglycaemia,3923,O
in,3923,O
type,3923,O
2,3923,O
diabetes,3923,O
.,3923,O
Inhibition,3924,O
of,3924,O
glucagon,3924,O
action,3924,O
may,3924,O
therefore,3924,O
be,3924,O
a,3924,O
potential,3924,O
novel,3924,O
target,3924,O
to,3924,O
reduce,3924,O
hyperglycaemia,3924,O
.,3924,O
Here,3925,O
",",3925,O
we,3925,O
investigated,3925,O
whether,3925,O
chronic,3925,O
treatment,3925,O
with,3925,O
a,3925,O
glucagon,3925,B-GENE-Y
receptor,3925,I-GENE-Y
antagonist,3925,O
(,3925,O
GRA,3925,O
),3925,O
improves,3925,O
islet,3925,O
dysfunction,3925,O
in,3925,O
female,3925,O
mice,3925,O
on,3925,O
a,3925,O
high-fat,3925,O
diet,3925,O
(,3925,O
HFD,3925,O
),3925,O
.,3925,O
MATERIALS,3926,O
AND,3926,O
METHODS,3926,O
:,3926,O
After,3926,O
8,3926,O
weeks,3926,O
of,3926,O
HFD,3926,O
",",3926,O
mice,3926,O
were,3926,O
treated,3926,O
with,3926,O
a,3926,O
small,3926,O
molecule,3926,O
GRA,3926,O
(,3926,O
300,3926,O
mg/kg,3926,O
",",3926,O
gavage,3926,O
once,3926,O
daily,3926,O
),3926,O
for,3926,O
up,3926,O
to,3926,O
30,3926,O
days,3926,O
.,3926,O
Insulin,3927,B-GENE-N
secretion,3927,O
was,3927,O
studied,3927,O
after,3927,O
oral,3927,O
and,3927,O
intravenous,3927,O
administration,3927,O
of,3927,O
glucose,3927,B-CHEMICAL
and,3927,O
glucagon,3927,B-GENE-Y
secretion,3927,O
after,3927,O
intravenous,3927,O
arginine,3927,B-CHEMICAL
.,3927,O
Islet,3928,O
morphology,3928,O
was,3928,O
examined,3928,O
and,3928,O
insulin,3928,B-GENE-N
secretion,3928,O
and,3928,O
glucose,3928,B-CHEMICAL
oxidation,3928,O
were,3928,O
measured,3928,O
in,3928,O
isolated,3928,O
islets,3928,O
.,3928,O
RESULTS,3929,O
:,3929,O
Fasting,3929,O
plasma,3929,O
glucose,3929,B-CHEMICAL
levels,3929,O
were,3929,O
reduced,3929,O
by,3929,O
GRA,3929,O
(,3929,O
6.0,3929,O
+/-,3929,O
0.2,3929,O
vs,3929,O
7.4,3929,O
+/-,3929,O
0.5,3929,O
mmol/l,3929,O
;,3929,O
p,3929,O
=,3929,O
0.017,3929,O
),3929,O
.,3929,O
The,3930,O
acute,3930,O
insulin,3930,B-GENE-N
response,3930,O
to,3930,O
intravenous,3930,O
glucose,3930,B-CHEMICAL
was,3930,O
augmented,3930,O
(,3930,O
"1,300",3930,O
+/-,3930,O
110,3930,O
vs,3930,O
790,3930,O
+/-,3930,O
64,3930,O
pmol/l,3930,O
;,3930,O
p,3930,O
<,3930,O
0.001,3930,O
),3930,O
.,3930,O
The,3931,O
early,3931,O
insulin,3931,B-GENE-N
response,3931,O
to,3931,O
oral,3931,O
glucose,3931,B-CHEMICAL
was,3931,O
reduced,3931,O
in,3931,O
mice,3931,O
on,3931,O
HFD,3931,O
+,3931,O
GRA,3931,O
(,3931,O
"1,890",3931,O
+/-,3931,O
160,3931,O
vs,3931,O
"3,040",3931,O
+/-,3931,O
420,3931,O
pmol/l,3931,O
;,3931,O
p,3931,O
=,3931,O
0.012,3931,O
),3931,O
",",3931,O
but,3931,O
glucose,3931,B-CHEMICAL
excursions,3931,O
were,3931,O
improved,3931,O
.,3931,O
Intravenous,3932,O
arginine,3932,B-CHEMICAL
significantly,3932,O
increased,3932,O
the,3932,O
acute,3932,O
glucagon,3932,B-GENE-Y
response,3932,O
(,3932,O
129,3932,O
+/-,3932,O
12,3932,O
vs,3932,O
36,3932,O
+/-,3932,O
6,3932,O
ng/l,3932,O
in,3932,O
controls,3932,O
;,3932,O
p,3932,O
<,3932,O
0.01,3932,O
),3932,O
",",3932,O
notably,3932,O
without,3932,O
affecting,3932,O
plasma,3932,O
glucose,3932,B-CHEMICAL
.,3932,O
GRA,3933,O
caused,3933,O
a,3933,O
modest,3933,O
increase,3933,O
in,3933,O
alpha,3933,O
cell,3933,O
mass,3933,O
",",3933,O
while,3933,O
beta,3933,O
cell,3933,O
mass,3933,O
was,3933,O
similar,3933,O
to,3933,O
that,3933,O
in,3933,O
mice,3933,O
on,3933,O
HFD,3933,O
+,3933,O
vehicle,3933,O
.,3933,O
Isolated,3934,O
islets,3934,O
displayed,3934,O
improved,3934,O
glucose-stimulated,3934,B-CHEMICAL
insulin,3934,B-GENE-N
secretion,3934,O
after,3934,O
GRA,3934,O
treatment,3934,O
(,3934,O
0.061,3934,O
+/-,3934,O
0.007,3934,O
vs,3934,O
0.030,3934,O
+/-,3934,O
0.004,3934,O
pmol,3934,O
islet,3934,O
(,3934,O
-1,3934,O
),3934,O
h,3934,O
(,3934,O
-1,3934,O
),3934,O
at,3934,O
16.7,3934,O
mmol/l,3934,O
glucose,3934,B-CHEMICAL
;,3934,O
p,3934,O
<,3934,O
0.001,3934,O
),3934,O
",",3934,O
without,3934,O
affecting,3934,O
islet,3934,O
glucose,3934,B-CHEMICAL
oxidation,3934,O
.,3934,O
CONCLUSIONS/INTERPRETATION,3935,O
:,3935,O
Chronic,3935,O
glucagon,3935,B-GENE-Y
receptor,3935,I-GENE-Y
antagonism,3935,O
in,3935,O
HFD-fed,3935,O
mice,3935,O
improves,3935,O
islet,3935,O
sensitivity,3935,O
to,3935,O
glucose,3935,B-CHEMICAL
and,3935,O
increases,3935,O
insulin,3935,B-GENE-N
secretion,3935,O
",",3935,O
suggesting,3935,O
improvement,3935,O
of,3935,O
key,3935,O
defects,3935,O
underlying,3935,O
impaired,3935,O
glucose,3935,B-CHEMICAL
tolerance,3935,O
and,3935,O
type,3935,O
2,3935,O
diabetes,3935,O
.,3935,O
Cis-silencing,3936,O
of,3936,O
PIP5K1B,3936,B-GENE-Y
evidenced,3936,O
in,3936,O
Friedreich,3936,O
's,3936,O
ataxia,3936,O
patient,3936,O
cells,3936,O
results,3936,O
in,3936,O
cytoskeleton,3936,O
anomalies,3936,O
.,3936,O
Friedreich,3937,O
's,3937,O
ataxia,3937,O
(,3937,O
FRDA,3937,O
),3937,O
is,3937,O
a,3937,O
progressive,3937,O
neurodegenerative,3937,O
disease,3937,O
characterized,3937,O
by,3937,O
ataxia,3937,O
",",3937,O
variously,3937,O
associating,3937,O
heart,3937,O
disease,3937,O
",",3937,O
diabetes,3937,O
mellitus,3937,O
and/or,3937,O
glucose,3937,B-CHEMICAL
intolerance,3937,O
.,3937,O
It,3938,O
results,3938,O
from,3938,O
intronic,3938,O
expansion,3938,O
of,3938,O
GAA,3938,B-GENE-N
triplet,3938,I-GENE-N
repeats,3938,I-GENE-N
at,3938,O
the,3938,O
FXN,3938,B-GENE-Y
locus,3938,O
.,3938,O
Homozygous,3939,O
expansions,3939,O
cause,3939,O
silencing,3939,O
of,3939,O
the,3939,O
FXN,3939,B-GENE-Y
gene,3939,O
and,3939,O
subsequent,3939,O
decreased,3939,O
expression,3939,O
of,3939,O
the,3939,O
encoded,3939,O
mitochondrial,3939,O
frataxin,3939,B-GENE-Y
.,3939,O
Detailed,3940,O
analyses,3940,O
in,3940,O
fibroblasts,3940,O
and,3940,O
neuronal,3940,O
tissues,3940,O
from,3940,O
FRDA,3940,O
patients,3940,O
have,3940,O
revealed,3940,O
profound,3940,O
cytoskeleton,3940,O
anomalies,3940,O
.,3940,O
So,3941,O
far,3941,O
",",3941,O
however,3941,O
",",3941,O
the,3941,O
molecular,3941,O
mechanism,3941,O
underlying,3941,O
these,3941,O
cytoskeleton,3941,O
defects,3941,O
remains,3941,O
unknown,3941,O
.,3941,O
We,3942,O
show,3942,O
here,3942,O
that,3942,O
gene,3942,O
silencing,3942,O
spreads,3942,O
in,3942,O
cis,3942,O
over,3942,O
the,3942,O
PIP5K1B,3942,B-GENE-Y
gene,3942,O
in,3942,O
cells,3942,O
from,3942,O
FRDA,3942,O
patients,3942,O
(,3942,O
circulating,3942,O
lymphocytes,3942,O
and,3942,O
primary,3942,O
fibroblasts,3942,O
),3942,O
",",3942,O
correlating,3942,O
with,3942,O
expanded,3942,O
GAA,3942,O
repeat,3942,O
size,3942,O
.,3942,O
PIP5K1B,3943,B-GENE-Y
encodes,3943,O
phosphatidylinositol,3943,B-GENE-Y
4-phosphate,3943,I-GENE-Y
5-kinase,3943,I-GENE-Y
β,3943,I-GENE-Y
type,3943,I-GENE-Y
I,3943,I-GENE-Y
(,3943,O
pip5k1β,3943,B-GENE-Y
),3943,O
",",3943,O
an,3943,O
enzyme,3943,O
functionally,3943,O
linked,3943,O
to,3943,O
actin,3943,B-GENE-N
cytoskeleton,3943,O
dynamics,3943,O
that,3943,O
phosphorylates,3943,O
phosphatidylinositol,3943,B-CHEMICAL
4-phosphate,3943,I-CHEMICAL
[,3943,O
PI,3943,B-CHEMICAL
(,3943,I-CHEMICAL
4,3943,I-CHEMICAL
),3943,I-CHEMICAL
P,3943,I-CHEMICAL
],3943,O
to,3943,O
generate,3943,O
"phosphatidylinositol-4,5-bisphosphate",3943,B-CHEMICAL
[,3943,O
PI,3943,B-CHEMICAL
(,3943,I-CHEMICAL
"4,5",3943,I-CHEMICAL
),3943,I-CHEMICAL
P2,3943,I-CHEMICAL
],3943,O
.,3943,O
Accordingly,3944,O
",",3944,O
loss,3944,O
of,3944,O
pip5k1β,3944,B-GENE-Y
function,3944,O
in,3944,O
FRDA,3944,O
cells,3944,O
was,3944,O
accompanied,3944,O
by,3944,O
decreased,3944,O
PI,3944,B-CHEMICAL
(,3944,I-CHEMICAL
"4,5",3944,I-CHEMICAL
),3944,I-CHEMICAL
P2,3944,I-CHEMICAL
levels,3944,O
and,3944,O
was,3944,O
shown,3944,O
instrumental,3944,O
for,3944,O
destabilization,3944,O
of,3944,O
the,3944,O
actin,3944,O
network,3944,O
and,3944,O
delayed,3944,O
cell,3944,O
spreading,3944,O
.,3944,O
Knockdown,3945,O
of,3945,O
PIP5K1B,3945,B-GENE-Y
in,3945,O
control,3945,O
fibroblasts,3945,O
using,3945,O
shRNA,3945,O
reproduced,3945,O
abnormal,3945,O
actin,3945,B-GENE-N
cytoskeleton,3945,O
remodeling,3945,O
",",3945,O
whereas,3945,O
over-expression,3945,O
of,3945,O
PIP5K1B,3945,B-GENE-Y
",",3945,O
but,3945,O
not,3945,O
FXN,3945,B-GENE-Y
",",3945,O
suppressed,3945,O
this,3945,O
phenotype,3945,O
in,3945,O
FRDA,3945,O
cells,3945,O
.,3945,O
In,3946,O
addition,3946,O
to,3946,O
provide,3946,O
new,3946,O
insights,3946,O
into,3946,O
the,3946,O
consequences,3946,O
of,3946,O
the,3946,O
FXN,3946,B-GENE-Y
gene,3946,O
expansion,3946,O
",",3946,O
these,3946,O
findings,3946,O
raise,3946,O
the,3946,O
question,3946,O
whether,3946,O
PIP5K1B,3946,B-GENE-Y
silencing,3946,O
may,3946,O
contribute,3946,O
to,3946,O
the,3946,O
variable,3946,O
manifestation,3946,O
of,3946,O
this,3946,O
complex,3946,O
disease,3946,O
.,3946,O
Involvement,3947,O
of,3947,O
regucalcin,3947,B-GENE-Y
in,3947,O
lipid,3947,O
metabolism,3947,O
and,3947,O
diabetes,3947,O
.,3947,O
Regucalcin,3948,B-GENE-Y
(,3948,O
RGN/SMP30,3948,B-GENE-Y
),3948,O
was,3948,O
originally,3948,O
discovered,3948,O
in,3948,O
1978,3948,O
as,3948,O
a,3948,O
unique,3948,O
calcium-binding,3948,B-CHEMICAL
protein,3948,O
that,3948,O
does,3948,O
not,3948,O
contain,3948,O
the,3948,O
EF-hand,3948,B-GENE-N
motif,3948,I-GENE-N
of,3948,O
calcium-binding,3948,B-GENE-N
domain,3948,I-GENE-N
.,3948,O
The,3949,O
regucalcin,3949,B-GENE-Y
gene,3949,O
(,3949,O
rgn,3949,B-GENE-Y
),3949,O
is,3949,O
localized,3949,O
on,3949,O
the,3949,O
X,3949,O
chromosome,3949,O
and,3949,O
is,3949,O
identified,3949,O
in,3949,O
over,3949,O
15,3949,O
species,3949,O
consisting,3949,O
the,3949,O
regucalcin,3949,B-GENE-Y
family,3949,O
.,3949,O
Regucalcin,3950,B-GENE-Y
has,3950,O
been,3950,O
shown,3950,O
to,3950,O
play,3950,O
a,3950,O
multifunctional,3950,O
role,3950,O
in,3950,O
cell,3950,O
regulation,3950,O
;,3950,O
maintaining,3950,O
of,3950,O
intracellular,3950,O
calcium,3950,B-CHEMICAL
homeostasis,3950,O
and,3950,O
suppressing,3950,O
of,3950,O
signal,3950,O
transduction,3950,O
",",3950,O
translational,3950,O
protein,3950,O
synthesis,3950,O
",",3950,O
nuclear,3950,O
deoxyribonucleic,3950,O
acid,3950,O
(,3950,O
DNA,3950,O
),3950,O
and,3950,O
ribonucleic,3950,O
acid,3950,O
(,3950,O
RNA,3950,O
),3950,O
synthesis,3950,O
",",3950,O
proliferation,3950,O
",",3950,O
and,3950,O
apoptosis,3950,O
in,3950,O
many,3950,O
cell,3950,O
types,3950,O
.,3950,O
Moreover,3951,O
",",3951,O
regucalcin,3951,B-GENE-Y
may,3951,O
play,3951,O
a,3951,O
pathophysiological,3951,O
role,3951,O
in,3951,O
metabolic,3951,O
disorder,3951,O
.,3951,O
The,3952,O
expression,3952,O
of,3952,O
regucalcin,3952,B-GENE-Y
is,3952,O
stimulated,3952,O
through,3952,O
the,3952,O
action,3952,O
of,3952,O
insulin,3952,B-GENE-Y
in,3952,O
liver,3952,O
cells,3952,O
in,3952,O
vitro,3952,O
and,3952,O
in,3952,O
vivo,3952,O
and,3952,O
it,3952,O
is,3952,O
decreased,3952,O
in,3952,O
the,3952,O
liver,3952,O
of,3952,O
rats,3952,O
with,3952,O
type,3952,O
I,3952,O
diabetes,3952,O
induced,3952,O
by,3952,O
streptozotocin,3952,B-CHEMICAL
administration,3952,O
in,3952,O
vivo,3952,O
.,3952,O
Overexpression,3953,O
of,3953,O
endogenous,3953,O
regucalcin,3953,B-GENE-Y
stimulates,3953,O
glucose,3953,B-CHEMICAL
utilization,3953,O
and,3953,O
lipid,3953,O
production,3953,O
in,3953,O
liver,3953,O
cells,3953,O
with,3953,O
glucose,3953,B-CHEMICAL
supplementation,3953,O
in,3953,O
vitro,3953,O
.,3953,O
Regucalcin,3954,B-GENE-Y
reveals,3954,O
insulin,3954,B-GENE-Y
resistance,3954,O
in,3954,O
liver,3954,O
cells,3954,O
.,3954,O
Deficiency,3955,O
of,3955,O
regucalcin,3955,B-GENE-Y
induces,3955,O
an,3955,O
impairment,3955,O
of,3955,O
glucose,3955,B-CHEMICAL
tolerance,3955,O
and,3955,O
lipid,3955,O
accumulation,3955,O
in,3955,O
the,3955,O
liver,3955,O
of,3955,O
mice,3955,O
in,3955,O
vivo,3955,O
.,3955,O
Overexpression,3956,O
of,3956,O
endogenous,3956,O
regucalcin,3956,B-GENE-Y
has,3956,O
been,3956,O
shown,3956,O
to,3956,O
decrease,3956,O
triglyceride,3956,B-CHEMICAL
",",3956,O
total,3956,O
cholesterol,3956,B-CHEMICAL
and,3956,O
glycogen,3956,O
contents,3956,O
in,3956,O
the,3956,O
liver,3956,O
of,3956,O
rats,3956,O
",",3956,O
inducing,3956,O
hyperlipidemia,3956,O
.,3956,O
Leptin,3957,B-GENE-Y
and,3957,O
adiponectin,3957,B-GENE-Y
mRNA,3957,O
expressions,3957,O
in,3957,O
the,3957,O
liver,3957,O
tissues,3957,O
are,3957,O
decreased,3957,O
in,3957,O
regucalcin,3957,B-GENE-Y
transgenic,3957,O
rats,3957,O
.,3957,O
Decrease,3958,O
in,3958,O
hepatic,3958,O
regucalcin,3958,B-GENE-Y
is,3958,O
associated,3958,O
with,3958,O
the,3958,O
development,3958,O
and,3958,O
progression,3958,O
of,3958,O
nonalcoholic,3958,O
fatty,3958,O
liver,3958,O
disease,3958,O
and,3958,O
fibrosis,3958,O
in,3958,O
human,3958,O
patients,3958,O
.,3958,O
Regucalcin,3959,O
may,3959,O
be,3959,O
a,3959,O
key,3959,O
molecule,3959,O
in,3959,O
lipid,3959,O
metabolic,3959,O
disorder,3959,O
and,3959,O
diabetes,3959,O
.,3959,O
AMP-activated,3960,B-GENE-N
protein,3960,I-GENE-N
kinase-dependent,3960,O
and,3960,O
-independent,3960,O
mechanisms,3960,O
underlying,3960,O
in,3960,O
vitro,3960,O
antiglioma,3960,O
action,3960,O
of,3960,O
compound,3960,O
C.,3960,O
We,3960,O
investigated,3960,O
the,3960,O
effect,3960,O
of,3960,O
compound,3960,O
C,3960,O
",",3960,O
a,3960,O
well-known,3960,O
inhibitor,3960,O
of,3960,O
the,3960,O
intracellular,3960,O
energy,3960,O
sensor,3960,O
AMP-activated,3960,B-GENE-N
protein,3960,I-GENE-N
kinase,3960,I-GENE-N
(,3960,O
AMPK,3960,B-GENE-N
),3960,O
",",3960,O
on,3960,O
proliferation,3960,O
and,3960,O
viability,3960,O
of,3960,O
human,3960,O
U251,3960,O
and,3960,O
rat,3960,O
C6,3960,O
glioma,3960,O
cell,3960,O
lines,3960,O
.,3960,O
Compound,3961,O
C,3961,O
caused,3961,O
G,3961,O
(,3961,O
2,3961,O
),3961,O
/M,3961,O
cell,3961,O
cycle,3961,O
block,3961,O
",",3961,O
accompanied,3961,O
by,3961,O
apoptotic,3961,O
glioma,3961,O
cell,3961,O
death,3961,O
characterized,3961,O
by,3961,O
caspase,3961,B-GENE-N
activation,3961,O
",",3961,O
phosphatidylserine,3961,B-CHEMICAL
exposure,3961,O
and,3961,O
DNA,3961,O
fragmentation,3961,O
.,3961,O
The,3962,O
mechanisms,3962,O
underlying,3962,O
the,3962,O
pro-apoptotic,3962,O
action,3962,O
of,3962,O
compound,3962,O
C,3962,O
involved,3962,O
induction,3962,O
of,3962,O
oxidative,3962,O
stress,3962,O
and,3962,O
downregulation,3962,O
of,3962,O
antiapoptotic,3962,O
molecule,3962,O
Bcl-2,3962,B-GENE-N
",",3962,O
while,3962,O
no,3962,O
alteration,3962,O
of,3962,O
pro-apoptotic,3962,O
Bax,3962,B-GENE-N
was,3962,O
observed,3962,O
.,3962,O
Compound,3963,O
C,3963,O
diminished,3963,O
AMPK,3963,B-GENE-N
phosphorylation,3963,O
and,3963,O
enzymatic,3963,O
activity,3963,O
",",3963,O
resulting,3963,O
in,3963,O
reduced,3963,O
phosphorylation,3963,O
of,3963,O
its,3963,O
target,3963,O
acetyl,3963,B-GENE-N
CoA,3963,I-GENE-N
carboxylase,3963,I-GENE-N
.,3963,O
AMPK,3964,B-GENE-N
activators,3964,O
metformin,3964,B-CHEMICAL
and,3964,O
AICAR,3964,B-CHEMICAL
partly,3964,O
prevented,3964,O
the,3964,O
cell,3964,O
cycle,3964,O
block,3964,O
",",3964,O
oxidative,3964,O
stress,3964,O
and,3964,O
apoptosis,3964,O
induced,3964,O
by,3964,O
compound,3964,O
C.,3964,O
The,3964,O
small,3964,O
interfering,3964,O
RNA,3964,O
(,3964,O
siRNA,3964,O
),3964,O
targeting,3964,O
of,3964,O
human,3964,B-GENE-Y
AMPK,3964,I-GENE-Y
mimicked,3964,O
compound,3964,O
C-induced,3964,O
G,3964,O
(,3964,O
2,3964,O
),3964,O
/M,3964,O
cell,3964,O
cycle,3964,O
arrest,3964,O
",",3964,O
but,3964,O
failed,3964,O
to,3964,O
induce,3964,O
oxidative,3964,O
stress,3964,O
and,3964,O
apoptosis,3964,O
in,3964,O
U251,3964,O
glioma,3964,O
cells,3964,O
.,3964,O
In,3965,O
conclusion,3965,O
",",3965,O
our,3965,O
data,3965,O
indicate,3965,O
that,3965,O
AMPK,3965,B-GENE-N
inhibition,3965,O
is,3965,O
required,3965,O
",",3965,O
but,3965,O
not,3965,O
sufficient,3965,O
for,3965,O
compound,3965,O
C-mediated,3965,O
apoptotic,3965,O
death,3965,O
of,3965,O
glioma,3965,O
cells,3965,O
.,3965,O
Evidence,3966,O
that,3966,O
the,3966,O
granulocyte,3966,B-GENE-Y
colony-stimulating,3966,I-GENE-Y
factor,3966,I-GENE-Y
(,3966,I-GENE-Y
G-CSF,3966,I-GENE-Y
),3966,I-GENE-Y
receptor,3966,I-GENE-Y
plays,3966,O
a,3966,O
role,3966,O
in,3966,O
the,3966,O
pharmacokinetics,3966,O
of,3966,O
G-CSF,3966,B-GENE-Y
and,3966,O
PegG-CSF,3966,O
using,3966,O
a,3966,O
G-CSF-R,3966,B-GENE-Y
KO,3966,O
model,3966,O
.,3966,O
The,3967,O
covalent,3967,O
attachment,3967,O
of,3967,O
polyethylene,3967,O
glycol,3967,O
to,3967,O
filgrastim,3967,O
results,3967,O
in,3967,O
a,3967,O
new,3967,O
molecule,3967,O
pegfilgrastim,3967,O
",",3967,O
which,3967,O
has,3967,O
a,3967,O
significantly,3967,O
longer,3967,O
half-life,3967,O
than,3967,O
filgrastim,3967,O
.,3967,O
It,3968,O
is,3968,O
likely,3968,O
that,3968,O
the,3968,O
clearance,3968,O
of,3968,O
both,3968,O
filgrastim,3968,O
and,3968,O
pegfilgrastim,3968,O
involves,3968,O
granulocyte,3968,B-GENE-Y
colony,3968,I-GENE-Y
simulating,3968,I-GENE-Y
factor,3968,I-GENE-Y
(,3968,I-GENE-Y
G-CSF,3968,I-GENE-Y
),3968,I-GENE-Y
receptor,3968,I-GENE-Y
binding,3968,O
",",3968,O
but,3968,O
the,3968,O
pharmacokinetics,3968,O
of,3968,O
these,3968,O
drugs,3968,O
have,3968,O
not,3968,O
been,3968,O
compared,3968,O
in,3968,O
mice,3968,O
with,3968,O
and,3968,O
without,3968,O
a,3968,O
functional,3968,O
G-CSF,3968,B-GENE-Y
receptor,3968,I-GENE-Y
.,3968,O
We,3969,O
sought,3969,O
to,3969,O
clarify,3969,O
the,3969,O
role,3969,O
of,3969,O
receptor-mediated,3969,O
clearance,3969,O
of,3969,O
filgrastim,3969,O
and,3969,O
pegfilgrastim,3969,O
using,3969,O
wild-type,3969,O
(,3969,O
WT,3969,O
),3969,O
mice,3969,O
or,3969,O
mice,3969,O
with,3969,O
a,3969,O
non-functional,3969,O
G-CSF-R,3969,B-GENE-Y
(,3969,O
knockout,3969,O
",",3969,O
KO,3969,O
),3969,O
.,3969,O
We,3970,O
administered,3970,O
single,3970,O
doses,3970,O
of,3970,O
filgrastim,3970,O
or,3970,O
pegfilgrastim,3970,O
(,3970,O
10,3970,O
or,3970,O
100,3970,O
microg,3970,O
kg,3970,O
(,3970,O
-1,3970,O
),3970,O
),3970,O
intravenously,3970,O
to,3970,O
WT,3970,O
and,3970,O
KO,3970,O
mice,3970,O
.,3970,O
Plasma,3971,O
levels,3971,O
of,3971,O
protein,3971,O
were,3971,O
measured,3971,O
by,3971,O
enzyme-linked,3971,O
immunosorbent,3971,O
assay,3971,O
(,3971,O
ELISA,3971,O
),3971,O
at,3971,O
preset,3971,O
time,3971,O
points,3971,O
",",3971,O
and,3971,O
AUC,3971,O
",",3971,O
MRT,3971,O
",",3971,O
CL,3971,O
",",3971,O
V,3971,O
(,3971,O
d,3971,O
),3971,O
",",3971,O
and,3971,O
T,3971,O
(,3971,O
1/2,3971,O
),3971,O
were,3971,O
calculated,3971,O
.,3971,O
When,3972,O
compared,3972,O
with,3972,O
WT,3972,O
mice,3972,O
",",3972,O
the,3972,O
G-CSF-R,3972,B-GENE-Y
KO,3972,O
mice,3972,O
had,3972,O
significantly,3972,O
greater,3972,O
AUC,3972,O
",",3972,O
longer,3972,O
MRT,3972,O
",",3972,O
longer,3972,O
T,3972,O
(,3972,O
1/2,3972,O
),3972,O
",",3972,O
and,3972,O
lower,3972,O
clearance,3972,O
.,3972,O
This,3973,O
was,3973,O
the,3973,O
case,3973,O
whether,3973,O
animals,3973,O
received,3973,O
10,3973,O
or,3973,O
100,3973,O
microg,3973,O
kg,3973,O
(,3973,O
-1,3973,O
),3973,O
and,3973,O
whether,3973,O
they,3973,O
received,3973,O
filgrastim,3973,O
or,3973,O
pegfilgrastim,3973,O
.,3973,O
The,3974,O
volume,3974,O
of,3974,O
protein,3974,O
distribution,3974,O
was,3974,O
identical,3974,O
among,3974,O
WT,3974,O
and,3974,O
KO,3974,O
mice,3974,O
.,3974,O
However,3975,O
",",3975,O
the,3975,O
V,3975,O
(,3975,O
d,3975,O
),3975,O
was,3975,O
larger,3975,O
after,3975,O
pegfilgrastim,3975,O
dosing,3975,O
than,3975,O
after,3975,O
filgrastim,3975,O
dosing,3975,O
.,3975,O
In,3976,O
both,3976,O
WT,3976,O
and,3976,O
KO,3976,O
mice,3976,O
",",3976,O
increasing,3976,O
the,3976,O
dose,3976,O
of,3976,O
figrastim,3976,O
or,3976,O
pegfilgrastim,3976,O
resulted,3976,O
in,3976,O
a,3976,O
proportional,3976,O
increase,3976,O
in,3976,O
the,3976,O
AUC,3976,O
.,3976,O
A,3977,O
functional,3977,O
G-CSF-R,3977,B-GENE-Y
is,3977,O
an,3977,O
important,3977,O
mechanism,3977,O
in,3977,O
the,3977,O
plasma,3977,O
clearance,3977,O
of,3977,O
both,3977,O
filgrastim,3977,O
and,3977,O
pegfilgrastim,3977,O
.,3977,O
Duloxetine,3978,B-CHEMICAL
hydrochloride,3978,I-CHEMICAL
:,3978,O
a,3978,O
new,3978,O
dual-acting,3978,O
medication,3978,O
for,3978,O
the,3978,O
treatment,3978,O
of,3978,O
major,3978,O
depressive,3978,O
disorder,3978,O
.,3978,O
BACKGROUND,3979,O
:,3979,O
Duloxetine,3979,B-CHEMICAL
hydrochloride,3979,I-CHEMICAL
has,3979,O
recently,3979,O
been,3979,O
approved,3979,O
by,3979,O
the,3979,O
US,3979,O
Food,3979,O
and,3979,O
Drug,3979,O
Administration,3979,O
for,3979,O
the,3979,O
treatment,3979,O
of,3979,O
major,3979,O
depressive,3979,O
disorder,3979,O
(,3979,O
MDD,3979,O
),3979,O
.,3979,O
Duloxetine,3980,B-CHEMICAL
is,3980,O
a,3980,O
potent,3980,O
inhibitor,3980,O
of,3980,O
serotonin,3980,B-CHEMICAL
and,3980,O
norepinephrine,3980,B-CHEMICAL
reuptake,3980,O
",",3980,O
with,3980,O
weak,3980,O
effects,3980,O
on,3980,O
dopamine,3980,B-CHEMICAL
reuptake,3980,O
.,3980,O
OBJECTIVE,3981,O
:,3981,O
This,3981,O
article,3981,O
reviews,3981,O
the,3981,O
literature,3981,O
on,3981,O
duloxetine,3981,B-CHEMICAL
with,3981,O
regard,3981,O
to,3981,O
its,3981,O
pharmacodynamics,3981,O
",",3981,O
pharmacokinetics,3981,O
",",3981,O
clinical,3981,O
efficacy,3981,O
",",3981,O
and,3981,O
tolerability,3981,O
.,3981,O
METHODS,3982,O
:,3982,O
A,3982,O
comprehensive,3982,O
search,3982,O
of,3982,O
MEDLINE,3982,O
was,3982,O
performed,3982,O
using,3982,O
the,3982,O
terms,3982,O
duloxetine,3982,B-CHEMICAL
",",3982,O
Cymbalta,3982,B-CHEMICAL
",",3982,O
and,3982,O
major,3982,O
depressive,3982,O
disorder,3982,O
",",3982,O
with,3982,O
no,3982,O
restriction,3982,O
on,3982,O
year,3982,O
.,3982,O
The,3983,O
Eli,3983,O
Lilly,3983,O
and,3983,O
Company,3983,O
clinical,3983,O
trial,3983,O
registry,3983,O
",",3983,O
and,3983,O
abstracts,3983,O
and,3983,O
posters,3983,O
from,3983,O
recent,3983,O
American,3983,O
Psychiatric,3983,O
Association,3983,O
meetings,3983,O
were,3983,O
also,3983,O
reviewed,3983,O
.,3983,O
RESULTS,3984,O
:,3984,O
Duloxetine,3984,B-CHEMICAL
exhibits,3984,O
linear,3984,O
",",3984,O
dose-dependent,3984,O
pharmacokinetics,3984,O
across,3984,O
the,3984,O
approved,3984,O
oral,3984,O
dosage,3984,O
range,3984,O
of,3984,O
40,3984,O
to,3984,O
60,3984,O
mg/d,3984,O
.,3984,O
No,3985,O
dose,3985,O
adjustment,3985,O
appears,3985,O
to,3985,O
be,3985,O
needed,3985,O
based,3985,O
on,3985,O
age,3985,O
.,3985,O
Duloxetine,3986,B-CHEMICAL
has,3986,O
shown,3986,O
efficacy,3986,O
in,3986,O
reducing,3986,O
depressive,3986,O
symptoms,3986,O
compared,3986,O
with,3986,O
placebo,3986,O
",",3986,O
and,3986,O
duloxetine,3986,O
recipients,3986,O
have,3986,O
shown,3986,O
significant,3986,O
improvements,3986,O
in,3986,O
global,3986,O
functioning,3986,O
compared,3986,O
with,3986,O
placebo,3986,O
(,3986,O
both,3986,O
",",3986,O
P,3986,O
<,3986,O
0.05,3986,O
),3986,O
.,3986,O
Response,3987,O
and,3987,O
remission,3987,O
rates,3987,O
have,3987,O
been,3987,O
comparable,3987,O
to,3987,O
or,3987,O
greater,3987,O
than,3987,O
those,3987,O
seen,3987,O
with,3987,O
fluoxetine,3987,B-CHEMICAL
or,3987,O
paroxetine,3987,B-CHEMICAL
.,3987,O
Duloxetine,3988,B-CHEMICAL
is,3988,O
generally,3988,O
well,3988,O
tolerated,3988,O
",",3988,O
with,3988,O
nausea,3988,O
",",3988,O
dry,3988,O
mouth,3988,O
",",3988,O
and,3988,O
fatigue,3988,O
being,3988,O
the,3988,O
most,3988,O
common,3988,O
treatment-emergent,3988,O
adverse,3988,O
effects,3988,O
.,3988,O
Cardiovascular,3989,O
adverse,3989,O
effects,3989,O
do,3989,O
not,3989,O
appear,3989,O
to,3989,O
result,3989,O
in,3989,O
sustained,3989,O
blood,3989,O
pressure,3989,O
elevations,3989,O
",",3989,O
QTc-interval,3989,O
prolongation,3989,O
",",3989,O
or,3989,O
other,3989,O
electrocardiographic,3989,O
changes,3989,O
.,3989,O
CONCLUSIONS,3990,O
:,3990,O
Based,3990,O
on,3990,O
the,3990,O
available,3990,O
evidence,3990,O
",",3990,O
duloxetine,3990,B-CHEMICAL
is,3990,O
a,3990,O
well-tolerated,3990,O
and,3990,O
effective,3990,O
treatment,3990,O
for,3990,O
MDD,3990,O
in,3990,O
adults,3990,O
.,3990,O
Randomized,3991,O
head-to-head,3991,O
comparisons,3991,O
against,3991,O
established,3991,O
antidepressants,3991,O
are,3991,O
needed,3991,O
to,3991,O
determine,3991,O
the,3991,O
relative,3991,O
safety,3991,O
and,3991,O
efficacy,3991,O
of,3991,O
duloxetine,3991,B-CHEMICAL
.,3991,O
In,3992,O
vivo,3992,O
effects,3992,O
of,3992,O
amtolmetin,3992,B-CHEMICAL
guacyl,3992,I-CHEMICAL
on,3992,O
lipid,3992,O
peroxidation,3992,O
and,3992,O
antioxidant,3992,O
defence,3992,O
systems,3992,O
.,3992,O
Comparison,3993,O
with,3993,O
non-selective,3993,O
and,3993,O
COX-2,3993,B-GENE-Y
selective,3993,O
NSAIDs,3993,O
.,3993,O
1,3994,O
.,3994,O
The,3995,O
in,3995,O
vivo,3995,O
effects,3995,O
of,3995,O
the,3995,O
non-steroid,3995,O
anti-inflammatory,3995,O
drug,3995,O
(,3995,O
NSAID,3995,O
),3995,O
amtolmetin,3995,B-CHEMICAL
guacyl,3995,I-CHEMICAL
",",3995,O
a,3995,O
pro-drug,3995,O
of,3995,O
the,3995,O
NSAID,3995,O
tolmetin,3995,B-CHEMICAL
",",3995,O
on,3995,O
lipid,3995,O
peroxidation,3995,O
",",3995,O
glutathione,3995,B-CHEMICAL
levels,3995,O
and,3995,O
activity,3995,O
of,3995,O
antioxidant,3995,O
enzymes,3995,O
(,3995,O
superoxide,3995,B-GENE-N
dismutase,3995,I-GENE-N
",",3995,O
catalase,3995,B-GENE-Y
",",3995,O
glutathione,3995,B-GENE-N
peroxidase,3995,I-GENE-N
and,3995,O
glutathione,3995,B-GENE-N
reductase,3995,I-GENE-N
),3995,O
in,3995,O
rat,3995,O
gastric,3995,O
mucosa,3995,O
",",3995,O
colon,3995,O
mucosa,3995,O
and,3995,O
liver,3995,O
",",3995,O
were,3995,O
compared,3995,O
with,3995,O
the,3995,O
effects,3995,O
of,3995,O
non-selective,3995,O
(,3995,O
indomethacin,3995,B-CHEMICAL
",",3995,O
diclofenac,3995,B-CHEMICAL
),3995,O
and,3995,O
COX-2,3995,B-GENE-Y
selective,3995,O
(,3995,O
celecoxib,3995,B-CHEMICAL
),3995,O
NSAIDs,3995,O
.,3995,O
2,3996,O
.,3996,O
Indomethacin,3997,B-CHEMICAL
treatment,3997,O
led,3997,O
to,3997,O
an,3997,O
increase,3997,O
in,3997,O
lipid,3997,O
peroxidation,3997,O
",",3997,O
glutathione,3997,B-GENE-N
peroxidase,3997,I-GENE-N
and,3997,O
glucose-6-phosphate,3997,B-GENE-Y
dehydrogenase,3997,I-GENE-Y
activities,3997,O
and,3997,O
to,3997,O
a,3997,O
decrease,3997,O
in,3997,O
catalase,3997,B-GENE-Y
activity,3997,O
and,3997,O
glutathione,3997,B-CHEMICAL
levels,3997,O
in,3997,O
gastric,3997,O
mucosa,3997,O
.,3997,O
In,3998,O
contrast,3998,O
",",3998,O
amtolmetin,3998,B-CHEMICAL
guacyl,3998,I-CHEMICAL
treatment,3998,O
was,3998,O
without,3998,O
effects,3998,O
in,3998,O
gastric,3998,O
and,3998,O
colon,3998,O
mucosa,3998,O
",",3998,O
or,3998,O
liver,3998,O
from,3998,O
control,3998,O
animals,3998,O
.,3998,O
Like,3999,O
amtolmetin,3999,B-CHEMICAL
guacyl,3999,I-CHEMICAL
",",3999,O
celecoxib,3999,B-CHEMICAL
had,3999,O
no,3999,O
effect,3999,O
on,3999,O
the,3999,O
lipid,3999,O
peroxidation,3999,O
",",3999,O
or,3999,O
on,3999,O
enzyme,3999,O
and,3999,O
non-enzyme,3999,O
antioxidant,3999,O
defence,3999,O
systems,3999,O
in,3999,O
gastric,3999,O
mucosa,3999,O
.,3999,O
3,4000,O
.,4000,O
It,4001,O
is,4001,O
suggested,4001,O
that,4001,O
the,4001,O
lack,4001,O
of,4001,O
pro-oxidant,4001,O
effects,4001,O
in,4001,O
vivo,4001,O
associated,4001,O
with,4001,O
amtolmetin,4001,B-CHEMICAL
guacyl,4001,I-CHEMICAL
treatment,4001,O
contribute,4001,O
improved,4001,O
gastric,4001,O
tolerability,4001,O
.,4001,O
Reversible,4002,O
inhibition,4002,O
of,4002,O
human,4002,B-GENE-N
carboxylesterases,4002,I-GENE-N
by,4002,O
acyl,4002,B-CHEMICAL
glucuronides,4002,I-CHEMICAL
.,4002,O
Carboxylesterases,4003,B-GENE-N
hydrolyze,4003,O
esters,4003,B-CHEMICAL
",",4003,O
amides,4003,B-CHEMICAL
",",4003,O
and,4003,O
thioesters,4003,B-CHEMICAL
to,4003,O
produce,4003,O
carboxylic,4003,B-CHEMICAL
acids,4003,I-CHEMICAL
and,4003,O
resulting,4003,O
alcohols,4003,B-CHEMICAL
",",4003,O
amines,4003,B-CHEMICAL
",",4003,O
and,4003,O
thiols,4003,B-CHEMICAL
",",4003,O
respectively,4003,O
.,4003,O
Uridine,4004,B-GENE-N
5'-diphosphate-,4004,I-GENE-N
glucuronosyltransferases,4004,I-GENE-N
are,4004,O
colocalized,4004,O
with,4004,O
carboxylesterases,4004,B-GENE-N
and,4004,O
have,4004,O
the,4004,O
potential,4004,O
to,4004,O
further,4004,O
metabolize,4004,O
carboxylic,4004,B-CHEMICAL
acids,4004,I-CHEMICAL
to,4004,O
acyl,4004,B-CHEMICAL
glucuronides,4004,I-CHEMICAL
",",4004,O
but,4004,O
it,4004,O
is,4004,O
currently,4004,O
unknown,4004,O
if,4004,O
acyl,4004,B-CHEMICAL
glucuronides,4004,I-CHEMICAL
",",4004,O
being,4004,O
esters,4004,B-CHEMICAL
",",4004,O
also,4004,O
interact,4004,O
with,4004,O
carboxylesterases,4004,B-GENE-N
.,4004,O
Objective,4005,O
:,4005,O
This,4005,O
study,4005,O
explores,4005,O
the,4005,O
ability,4005,O
of,4005,O
acyl,4005,B-CHEMICAL
glucuronides,4005,I-CHEMICAL
to,4005,O
act,4005,O
as,4005,O
substrates,4005,O
or,4005,O
inhibitors,4005,O
of,4005,O
human,4005,B-GENE-Y
carboxylesterases,4005,I-GENE-Y
1,4005,I-GENE-Y
(,4005,O
hCES1,4005,B-GENE-Y
),4005,O
and,4005,O
2,4005,O
(,4005,O
hCES2,4005,B-GENE-Y
),4005,O
.,4005,O
Methods,4006,O
:,4006,O
The,4006,O
stability,4006,O
of,4006,O
six,4006,O
acyl,4006,B-CHEMICAL
glucuronides,4006,I-CHEMICAL
in,4006,O
the,4006,O
presence,4006,O
of,4006,O
hCES1,4006,B-GENE-Y
",",4006,O
hCES2,4006,B-GENE-Y
",",4006,O
and,4006,O
buffer,4006,O
alone,4006,O
(,4006,O
100,4006,O
mM,4006,O
potassium,4006,B-CHEMICAL
phosphate,4006,I-CHEMICAL
",",4006,O
pH,4006,O
7.4,4006,O
",",4006,O
37°C,4006,O
),4006,O
were,4006,O
investigated,4006,O
.,4006,O
Reversible,4007,O
inhibition,4007,O
of,4007,O
4-nitrophenyl,4007,B-CHEMICAL
acetate,4007,I-CHEMICAL
hydrolysis,4007,O
by,4007,O
the,4007,O
acyl,4007,B-CHEMICAL
glucuronides,4007,I-CHEMICAL
was,4007,O
also,4007,O
studied,4007,O
.,4007,O
Diclofenac-β-d-glucuronide,4008,B-CHEMICAL
was,4008,O
used,4008,O
to,4008,O
explore,4008,O
potential,4008,O
time-dependent,4008,O
inactivation,4008,O
.,4008,O
Results,4009,O
:,4009,O
The,4009,O
chemical,4009,O
stability,4009,O
half-life,4009,O
values,4009,O
for,4009,O
CGP,4009,B-CHEMICAL
47292-β-d-glucuronide,4009,I-CHEMICAL
",",4009,O
diclofenac-β-d-glucuronide,4009,B-CHEMICAL
",",4009,O
(,4009,B-CHEMICAL
R,4009,I-CHEMICAL
),4009,I-CHEMICAL
-naproxen-β-d-glucuronide,4009,I-CHEMICAL
",",4009,O
(,4009,B-CHEMICAL
S,4009,I-CHEMICAL
),4009,I-CHEMICAL
-naproxen-β-d-glucuronide,4009,I-CHEMICAL
",",4009,O
ibuprofen-β-d-glucuronide,4009,B-CHEMICAL
(,4009,I-CHEMICAL
racemic,4009,I-CHEMICAL
),4009,I-CHEMICAL
",",4009,O
clopidogrel-β-d-glucuronide,4009,B-CHEMICAL
",",4009,O
and,4009,O
valproate-β-d-glucuronide,4009,B-CHEMICAL
were,4009,O
found,4009,O
to,4009,O
be,4009,O
0.252,4009,O
",",4009,O
0.537,4009,O
",",4009,O
0.996,4009,O
",",4009,O
1.77,4009,O
",",4009,O
3.67,4009,O
",",4009,O
5.02,4009,O
",",4009,O
and,4009,O
15.2,4009,O
hours,4009,O
",",4009,O
respectively,4009,O
.,4009,O
Diclofenac-β-d-glucuronide,4010,B-CHEMICAL
",",4010,O
clopidogrel-β-d-glucuronide,4010,B-CHEMICAL
",",4010,O
ibuprofen-β-d-glucuronide,4010,B-CHEMICAL
",",4010,O
(,4010,B-CHEMICAL
R,4010,I-CHEMICAL
),4010,I-CHEMICAL
-naproxen-β-d-glucuronide,4010,I-CHEMICAL
",",4010,O
and,4010,O
(,4010,B-CHEMICAL
S,4010,I-CHEMICAL
),4010,I-CHEMICAL
-naproxen-β-d-glucuronide,4010,I-CHEMICAL
selectively,4010,O
inhibited,4010,O
hCES1,4010,B-GENE-Y
",",4010,O
with,4010,O
Ki,4010,O
values,4010,O
of,4010,O
4.32,4010,O
±,4010,O
0.47,4010,O
",",4010,O
24.8,4010,O
±,4010,O
4.2,4010,O
",",4010,O
355,4010,O
±,4010,O
38,4010,O
",",4010,O
468,4010,O
±,4010,O
21,4010,O
",",4010,O
707,4010,O
±,4010,O
64,4010,O
µM,4010,O
",",4010,O
respectively,4010,O
",",4010,O
but,4010,O
did,4010,O
not,4010,O
significantly,4010,O
inhibit,4010,O
hCES2,4010,B-GENE-Y
.,4010,O
Valproate-β-d-glucuronide,4011,B-CHEMICAL
and,4011,O
CGP,4011,B-CHEMICAL
47292-β-d-glucuronide,4011,I-CHEMICAL
did,4011,O
not,4011,O
inhibit,4011,O
either,4011,O
hCES,4011,B-GENE-N
.,4011,O
Time-dependent,4012,O
inactivation,4012,O
of,4012,O
hCES1,4012,B-GENE-Y
by,4012,O
diclofenac-β-d-glucuronide,4012,B-CHEMICAL
was,4012,O
not,4012,O
observed,4012,O
.,4012,O
Lastly,4013,O
",",4013,O
both,4013,O
hCES1,4013,B-GENE-Y
and,4013,O
hCES2,4013,B-GENE-Y
were,4013,O
shown,4013,O
not,4013,O
to,4013,O
catalyze,4013,O
the,4013,O
hydrolysis,4013,O
of,4013,O
the,4013,O
acyl,4013,B-CHEMICAL
glucuronides,4013,I-CHEMICAL
studied,4013,O
.,4013,O
Conclusion,4014,O
:,4014,O
Drug-drug,4014,O
interaction,4014,O
studies,4014,O
may,4014,O
be,4014,O
warranted,4014,O
for,4014,O
drugs,4014,O
that,4014,O
metabolize,4014,O
to,4014,O
acyl,4014,B-CHEMICAL
glucuronides,4014,I-CHEMICAL
due,4014,O
to,4014,O
the,4014,O
potential,4014,O
inhibition,4014,O
of,4014,O
hCESs,4014,B-GENE-N
.,4014,O
NF-κB-associated,4015,B-GENE-N
mechanisms,4015,O
underlying,4015,O
the,4015,O
response,4015,O
of,4015,O
embryonic,4015,O
cells,4015,O
to,4015,O
Doxorubicin,4015,B-CHEMICAL
.,4015,O
The,4016,O
involvement,4016,O
of,4016,O
NF-κB,4016,B-GENE-N
in,4016,O
the,4016,O
regulation,4016,O
of,4016,O
teratogen-induced,4016,O
apoptosis,4016,O
has,4016,O
not,4016,O
been,4016,O
established,4016,O
yet,4016,O
.,4016,O
Therefore,4017,O
",",4017,O
we,4017,O
tried,4017,O
to,4017,O
assess,4017,O
the,4017,O
involvement,4017,O
of,4017,O
the,4017,O
p65,4017,B-GENE-Y
subunit,4017,O
of,4017,O
NF-κB,4017,B-GENE-N
in,4017,O
the,4017,O
embryonic,4017,O
response,4017,O
to,4017,O
the,4017,O
anti-cancer,4017,O
drug,4017,O
Doxorubicin,4017,B-CHEMICAL
(,4017,O
DOX,4017,B-CHEMICAL
),4017,O
.,4017,O
Thus,4018,O
",",4018,O
exposure,4018,O
of,4018,O
p65,4018,B-GENE-Y
knockout,4018,O
(,4018,O
p65,4018,B-GENE-Y
(,4018,O
-/-,4018,O
),4018,O
),4018,O
or,4018,O
wild,4018,O
type,4018,O
(,4018,O
WT,4018,O
),4018,O
mouse,4018,O
embryonic,4018,O
fibroblasts,4018,O
(,4018,O
MEFs,4018,O
),4018,O
to,4018,O
DOX,4018,B-CHEMICAL
resulted,4018,O
in,4018,O
a,4018,O
decrease,4018,O
in,4018,O
cell,4018,O
survival,4018,O
",",4018,O
culture,4018,O
density,4018,O
and,4018,O
cell,4018,O
proliferation,4018,O
",",4018,O
which,4018,O
was,4018,O
found,4018,O
to,4018,O
be,4018,O
more,4018,O
prominent,4018,O
in,4018,O
p65,4018,B-GENE-Y
(,4018,O
-/-,4018,O
),4018,O
MEFs,4018,O
.,4018,O
Those,4019,O
phenomena,4019,O
were,4019,O
accompanied,4019,O
by,4019,O
a,4019,O
DOX-induced,4019,B-CHEMICAL
increase,4019,O
in,4019,O
the,4019,O
proportion,4019,O
of,4019,O
apoptotic,4019,O
cells,4019,O
",",4019,O
which,4019,O
was,4019,O
demonstrated,4019,O
only,4019,O
in,4019,O
p65,4019,B-GENE-Y
(,4019,O
-/-,4019,O
),4019,O
cells,4019,O
and,4019,O
a,4019,O
G2/M,4019,O
arrest,4019,O
",",4019,O
which,4019,O
was,4019,O
found,4019,O
to,4019,O
be,4019,O
more,4019,O
prominent,4019,O
in,4019,O
WT,4019,O
cells,4019,O
.,4019,O
Furthermore,4020,O
",",4020,O
DOX-treated,4020,B-CHEMICAL
WT,4020,O
and,4020,O
p65,4020,B-GENE-Y
(,4020,O
-/-,4020,O
),4020,O
MEFs,4020,O
differed,4020,O
in,4020,O
their,4020,O
expression,4020,O
of,4020,O
various,4020,O
apoptosis-associated,4020,O
molecules,4020,O
",",4020,O
when,4020,O
the,4020,O
former,4020,O
demonstrated,4020,O
a,4020,O
decrease,4020,O
in,4020,O
the,4020,O
percentage,4020,O
of,4020,O
p65-positive,4020,B-GENE-Y
and,4020,O
a,4020,O
more,4020,O
prominent,4020,O
decrease,4020,O
in,4020,O
the,4020,O
percentage,4020,O
of,4020,O
p53-positive,4020,B-GENE-Y
cells,4020,O
",",4020,O
while,4020,O
a,4020,O
decreased,4020,O
percentage,4020,O
of,4020,O
IκBα-positive,4020,B-GENE-Y
and,4020,O
a,4020,O
more,4020,O
prominent,4020,O
decrease,4020,O
in,4020,O
the,4020,O
percentage,4020,O
of,4020,O
bcl-2-positive,4020,B-GENE-Y
cells,4020,O
was,4020,O
detected,4020,O
among,4020,O
the,4020,O
latter,4020,O
.,4020,O
The,4021,O
fact,4021,O
that,4021,O
the,4021,O
response,4021,O
of,4021,O
the,4021,O
cells,4021,O
to,4021,O
the,4021,O
teratogen,4021,O
was,4021,O
clearly,4021,O
p65-dependent,4021,B-GENE-Y
implicates,4021,O
this,4021,O
molecule,4021,O
to,4021,O
be,4021,O
involved,4021,O
in,4021,O
the,4021,O
response,4021,O
of,4021,O
the,4021,O
embryonic,4021,O
cells,4021,O
to,4021,O
DOX,4021,B-CHEMICAL
.,4021,O
Protective,4022,O
effect,4022,O
of,4022,O
crocin,4022,B-CHEMICAL
on,4022,O
diazinon,4022,B-CHEMICAL
induced,4022,O
cardiotoxicity,4022,O
in,4022,O
rats,4022,O
in,4022,O
subchronic,4022,O
exposure,4022,O
.,4022,O
This,4023,O
study,4023,O
was,4023,O
designed,4023,O
to,4023,O
evaluate,4023,O
the,4023,O
effectiveness,4023,O
of,4023,O
crocin,4023,B-CHEMICAL
",",4023,O
main,4023,O
component,4023,O
of,4023,O
Crocus,4023,O
sativus,4023,O
L.,4023,O
(,4023,O
Saffron,4023,O
),4023,O
against,4023,O
subchronic,4023,O
diazinon,4023,B-CHEMICAL
(,4023,O
DZN,4023,B-CHEMICAL
),4023,O
induced,4023,O
cardiotoxicity,4023,O
in,4023,O
rats,4023,O
.,4023,O
METHODS,4024,O
:,4024,O
Rats,4024,O
were,4024,O
divided,4024,O
into,4024,O
7,4024,O
groups,4024,O
;,4024,O
control,4024,O
(,4024,O
corn,4024,O
oil,4024,O
",",4024,O
gavage,4024,O
),4024,O
",",4024,O
DZN,4024,O
(,4024,O
15mg/kg/day,4024,O
",",4024,O
gavage,4024,O
",",4024,O
),4024,O
",",4024,O
crocin,4024,B-CHEMICAL
(,4024,O
12.5,4024,O
",",4024,O
25,4024,O
or,4024,O
50mg/kg/day,4024,O
",",4024,O
i.p,4024,O
),4024,O
plus,4024,O
DZN,4024,B-CHEMICAL
",",4024,O
vitamin,4024,B-CHEMICAL
E,4024,I-CHEMICAL
(,4024,O
200IU/kg,4024,O
",",4024,O
i.p,4024,O
",",4024,O
three,4024,O
times,4024,O
per,4024,O
week,4024,O
),4024,O
plus,4024,O
DZN,4024,B-CHEMICAL
and,4024,O
crocin,4024,B-CHEMICAL
(,4024,O
50mg/kg/day,4024,O
",",4024,O
i.p,4024,O
),4024,O
groups,4024,O
.,4024,O
Treatments,4025,O
were,4025,O
continued,4025,O
for,4025,O
4weeks,4025,O
.,4025,O
Creatine,4026,B-GENE-N
phosphokinase,4026,I-GENE-N
MB,4026,I-GENE-N
(,4026,O
CK-MB,4026,B-GENE-N
),4026,O
",",4026,O
malondealdehyde,4026,B-CHEMICAL
(,4026,O
MDA,4026,B-CHEMICAL
),4026,O
and,4026,O
glutathione,4026,B-CHEMICAL
(,4026,O
GSH,4026,B-CHEMICAL
),4026,O
levels,4026,O
were,4026,O
evaluated,4026,O
in,4026,O
heart,4026,O
tissue,4026,O
at,4026,O
the,4026,O
end,4026,O
of,4026,O
treatments,4026,O
.,4026,O
Levels,4027,O
of,4027,O
apoptotic,4027,O
proteins,4027,O
(,4027,O
Bax,4027,B-GENE-Y
",",4027,O
Bcl2,4027,B-GENE-Y
",",4027,O
caspase,4027,B-GENE-Y
3,4027,I-GENE-Y
),4027,O
and,4027,O
cytosolic,4027,B-GENE-Y
cytochrome,4027,I-GENE-Y
c,4027,I-GENE-Y
were,4027,O
analyzed,4027,O
by,4027,O
Western,4027,O
blotting,4027,O
.,4027,O
Transcript,4028,O
levels,4028,O
of,4028,O
Bax,4028,B-GENE-Y
and,4028,O
Bcl2,4028,B-GENE-Y
were,4028,O
also,4028,O
determined,4028,O
using,4028,O
qRT,4028,O
PCR,4028,O
.,4028,O
RESULTS,4029,O
:,4029,O
DZN,4029,B-CHEMICAL
induced,4029,O
histophatological,4029,O
damages,4029,O
and,4029,O
elevated,4029,O
the,4029,O
level,4029,O
of,4029,O
cardiac,4029,O
marker,4029,O
CK-MB,4029,B-GENE-N
.,4029,O
These,4030,O
effects,4030,O
were,4030,O
associated,4030,O
with,4030,O
increased,4030,O
MDA,4030,B-CHEMICAL
level,4030,O
",",4030,O
lower,4030,O
level,4030,O
of,4030,O
reduced,4030,O
GSH,4030,B-CHEMICAL
and,4030,O
induction,4030,O
of,4030,O
apoptosis,4030,O
through,4030,O
elevation,4030,O
of,4030,O
Bax/Bcl2,4030,B-GENE-Y
ratio,4030,O
(,4030,O
both,4030,O
protein,4030,O
and,4030,O
mRNA,4030,O
levels,4030,O
),4030,O
",",4030,O
cytochrome,4030,B-GENE-Y
c,4030,I-GENE-Y
release,4030,O
to,4030,O
the,4030,O
cytosol,4030,O
and,4030,O
activation,4030,O
caspase,4030,B-GENE-Y
3,4030,I-GENE-Y
in,4030,O
cardiac,4030,O
tissue,4030,O
.,4030,O
Crocin,4031,B-CHEMICAL
(,4031,O
25,4031,O
and,4031,O
50mg/kg,4031,O
),4031,O
or,4031,O
vitamin,4031,B-CHEMICAL
E,4031,I-CHEMICAL
improved,4031,O
histopathological,4031,O
damages,4031,O
",",4031,O
decreased,4031,O
MDA,4031,B-CHEMICAL
and,4031,O
CK-MB,4031,B-GENE-N
",",4031,O
increased,4031,O
GSH,4031,B-CHEMICAL
content,4031,O
and,4031,O
attenuated,4031,O
the,4031,O
increase,4031,O
of,4031,O
Bax/Bcl2,4031,B-GENE-Y
ratio,4031,O
",",4031,O
activation,4031,O
of,4031,O
caspase,4031,B-GENE-Y
3,4031,I-GENE-Y
and,4031,O
release,4031,O
of,4031,O
cytochrome,4031,B-GENE-Y
c,4031,I-GENE-Y
to,4031,O
the,4031,O
cytosol,4031,O
induced,4031,O
by,4031,O
DZN,4031,B-CHEMICAL
.,4031,O
In,4032,O
summary,4032,O
",",4032,O
DZN,4032,B-CHEMICAL
induced,4032,O
mitochondrial-mediated,4032,O
apoptosis,4032,O
in,4032,O
heart,4032,O
tissue,4032,O
of,4032,O
rat,4032,O
following,4032,O
subchronic,4032,O
exposure,4032,O
.,4032,O
Crocin,4033,B-CHEMICAL
",",4033,O
as,4033,O
an,4033,O
antioxidant,4033,O
",",4033,O
showed,4033,O
protective,4033,O
effects,4033,O
against,4033,O
DZN,4033,B-CHEMICAL
cardiotoxicity,4033,O
by,4033,O
reducing,4033,O
lipid,4033,O
peroxidation,4033,O
and,4033,O
alleviating,4033,O
apoptosis,4033,O
.,4033,O
Nutrients,4034,O
and,4034,O
bioactive,4034,O
compounds,4034,O
of,4034,O
Thai,4034,O
indigenous,4034,O
fruits,4034,O
.,4034,O
This,4035,O
study,4035,O
determined,4035,O
the,4035,O
nutritional,4035,O
potential,4035,O
of,4035,O
Thai,4035,O
indigenous,4035,O
fruits,4035,O
in,4035,O
terms,4035,O
of,4035,O
nutrients,4035,O
",",4035,O
bioactive,4035,O
compounds,4035,O
",",4035,O
and,4035,O
antioxidant,4035,O
activities,4035,O
.,4035,O
Three,4036,O
indigenous,4036,O
fruits,4036,O
were,4036,O
collected,4036,O
at,4036,O
two,4036,O
conservation,4036,O
areas,4036,O
in,4036,O
Kanchanaburi,4036,O
province,4036,O
",",4036,O
Thailand,4036,O
.,4036,O
The,4037,O
results,4037,O
showed,4037,O
that,4037,O
Phyllanthus,4037,O
emblica,4037,O
L.,4037,O
exhibited,4037,O
the,4037,O
highest,4037,O
levels,4037,O
of,4037,O
vitamin,4037,B-CHEMICAL
C,4037,I-CHEMICAL
(,4037,O
575±452mg/100g,4037,O
),4037,O
",",4037,O
total,4037,O
phenolics,4037,B-CHEMICAL
(,4037,O
TP,4037,O
),4037,O
(,4037,O
3703±1244mGAE/100g,4037,O
),4037,O
",",4037,O
and,4037,O
antioxidant,4037,O
activities,4037,O
",",4037,O
as,4037,O
measured,4037,O
by,4037,O
DPPH,4037,B-CHEMICAL
",",4037,O
FRAP,4037,O
and,4037,O
ORAC,4037,O
assays,4037,O
.,4037,O
Compared,4038,O
to,4038,O
the,4038,O
other,4038,O
two,4038,O
fruits,4038,O
",",4038,O
Antidesma,4038,O
velutinosum,4038,O
Blume,4038,O
contained,4038,O
higher,4038,O
levels,4038,O
of,4038,O
most,4038,O
nutrients,4038,O
and,4038,O
dietary,4038,O
fibre,4038,O
(,4038,O
15.6±5.9g/100g,4038,O
),4038,O
",",4038,O
as,4038,O
well,4038,O
as,4038,O
carotenoids,4038,O
(,4038,O
335±98μg/100g,4038,O
),4038,O
and,4038,O
phytosterols,4038,B-CHEMICAL
(,4038,O
22.1±3.9mg/100g,4038,O
),4038,O
.,4038,O
Spondias,4039,O
pinnata,4039,O
(,4039,O
L.f.,4039,O
),4039,O
Kurz,4039,O
was,4039,O
high,4039,O
in,4039,O
total,4039,O
phenolics,4039,B-CHEMICAL
(,4039,O
3178±887mGAE/100g,4039,O
),4039,O
and,4039,O
antioxidant,4039,O
activity,4039,O
.,4039,O
Moreover,4040,O
",",4040,O
high,4040,O
correlations,4040,O
were,4040,O
found,4040,O
between,4040,O
TP,4040,O
and,4040,O
antioxidant,4040,O
activities,4040,O
(,4040,O
r,4040,O
>,4040,O
0.9,4040,O
),4040,O
.,4040,O
These,4041,O
Thai,4041,O
indigenous,4041,O
fruits,4041,O
are,4041,O
potentially,4041,O
good,4041,O
sources,4041,O
of,4041,O
nutrients,4041,O
",",4041,O
bioactive,4041,O
compounds,4041,O
",",4041,O
and,4041,O
antioxidant,4041,O
activities,4041,O
.,4041,O
Conservation,4042,O
and,4042,O
utilisation,4042,O
should,4042,O
be,4042,O
promoted,4042,O
for,4042,O
food,4042,O
security,4042,O
and,4042,O
consumption,4042,O
as,4042,O
part,4042,O
of,4042,O
a,4042,O
healthy,4042,O
diet,4042,O
.,4042,O
A,4043,O
genetic,4043,O
program,4043,O
promotes,4043,O
C.,4043,O
elegans,4043,O
longevity,4043,O
at,4043,O
cold,4043,O
temperatures,4043,O
via,4043,O
a,4043,O
thermosensitive,4043,O
TRP,4043,B-GENE-N
channel,4043,I-GENE-N
.,4043,O
Both,4044,O
poikilotherms,4044,O
and,4044,O
homeotherms,4044,O
live,4044,O
longer,4044,O
at,4044,O
lower,4044,O
body,4044,O
temperatures,4044,O
",",4044,O
highlighting,4044,O
a,4044,O
general,4044,O
role,4044,O
of,4044,O
temperature,4044,O
reduction,4044,O
in,4044,O
lifespan,4044,O
extension,4044,O
.,4044,O
However,4045,O
",",4045,O
the,4045,O
underlying,4045,O
mechanisms,4045,O
remain,4045,O
unclear,4045,O
.,4045,O
One,4046,O
prominent,4046,O
model,4046,O
is,4046,O
that,4046,O
cold,4046,O
temperatures,4046,O
reduce,4046,O
the,4046,O
rate,4046,O
of,4046,O
chemical,4046,O
reactions,4046,O
",",4046,O
thereby,4046,O
slowing,4046,O
the,4046,O
rate,4046,O
of,4046,O
aging,4046,O
.,4046,O
This,4047,O
view,4047,O
suggests,4047,O
that,4047,O
cold-dependent,4047,O
lifespan,4047,O
extension,4047,O
is,4047,O
simply,4047,O
a,4047,O
passive,4047,O
thermodynamic,4047,O
process,4047,O
.,4047,O
Here,4048,O
",",4048,O
we,4048,O
challenge,4048,O
this,4048,O
view,4048,O
in,4048,O
C.,4048,O
elegans,4048,O
by,4048,O
showing,4048,O
that,4048,O
genetic,4048,O
programs,4048,O
actively,4048,O
promote,4048,O
longevity,4048,O
at,4048,O
cold,4048,O
temperatures,4048,O
.,4048,O
We,4049,O
find,4049,O
that,4049,O
TRPA-1,4049,B-GENE-Y
",",4049,O
a,4049,O
cold-sensitive,4049,O
TRP,4049,B-GENE-N
channel,4049,I-GENE-N
",",4049,O
detects,4049,O
temperature,4049,O
drop,4049,O
in,4049,O
the,4049,O
environment,4049,O
to,4049,O
extend,4049,O
lifespan,4049,O
.,4049,O
This,4050,O
effect,4050,O
requires,4050,O
cold-induced,4050,O
",",4050,O
TRPA-1-mediated,4050,B-GENE-Y
calcium,4050,B-CHEMICAL
influx,4050,O
and,4050,O
a,4050,O
calcium-sensitive,4050,B-CHEMICAL
PKC,4050,B-GENE-N
that,4050,O
signals,4050,O
to,4050,O
the,4050,O
transcription,4050,O
factor,4050,O
DAF-16/FOXO,4050,B-GENE-Y
.,4050,O
Human,4051,B-GENE-Y
TRPA1,4051,I-GENE-Y
can,4051,O
functionally,4051,O
substitute,4051,O
for,4051,O
worm,4051,B-GENE-N
TRPA-1,4051,I-GENE-N
in,4051,O
promoting,4051,O
longevity,4051,O
.,4051,O
Our,4052,O
results,4052,O
reveal,4052,O
a,4052,O
previously,4052,O
unrecognized,4052,O
function,4052,O
for,4052,O
TRP,4052,B-GENE-N
channels,4052,I-GENE-N
",",4052,O
link,4052,O
calcium,4052,B-CHEMICAL
signaling,4052,O
to,4052,O
longevity,4052,O
",",4052,O
and,4052,O
",",4052,O
importantly,4052,O
",",4052,O
demonstrate,4052,O
that,4052,O
genetic,4052,O
programs,4052,O
contribute,4052,O
to,4052,O
lifespan,4052,O
extension,4052,O
at,4052,O
cold,4052,O
temperatures,4052,O
.,4052,O
Effect,4053,O
of,4053,O
fenoterol-induced,4053,B-CHEMICAL
constitutive,4053,O
beta,4053,B-GENE-Y
(,4053,I-GENE-Y
2,4053,I-GENE-Y
),4053,I-GENE-Y
-adrenoceptor,4053,I-GENE-Y
activity,4053,O
on,4053,O
contractile,4053,O
receptor,4053,O
function,4053,O
in,4053,O
airway,4053,O
smooth,4053,O
muscle,4053,O
.,4053,O
In,4054,O
the,4054,O
present,4054,O
study,4054,O
",",4054,O
we,4054,O
investigated,4054,O
the,4054,O
effect,4054,O
of,4054,O
fenoterol-induced,4054,B-CHEMICAL
constitutive,4054,O
beta,4054,B-GENE-Y
(,4054,I-GENE-Y
2,4054,I-GENE-Y
),4054,I-GENE-Y
-adrenoceptor,4054,I-GENE-Y
activity,4054,O
on,4054,O
muscarinic,4054,B-GENE-N
receptor,4054,I-GENE-N
agonist-,4054,O
and,4054,O
histamine-induced,4054,B-CHEMICAL
bovine,4054,O
tracheal,4054,O
smooth,4054,O
muscle,4054,O
contractions,4054,O
.,4054,O
Bovine,4055,O
tracheal,4055,O
smooth,4055,O
muscle,4055,O
strips,4055,O
were,4055,O
incubated,4055,O
with,4055,O
10,4055,O
microM,4055,O
fenoterol,4055,B-CHEMICAL
or,4055,O
vehicle,4055,O
for,4055,O
various,4055,O
periods,4055,O
of,4055,O
time,4055,O
(,4055,O
5,4055,O
",",4055,O
30,4055,O
min,4055,O
",",4055,O
18,4055,O
h,4055,O
),4055,O
at,4055,O
37,4055,O
degrees,4055,O
C.,4055,O
After,4055,O
extensive,4055,O
washout,4055,O
(,4055,O
3,4055,O
h,4055,O
",",4055,O
37,4055,O
degrees,4055,O
C,4055,O
),4055,O
",",4055,O
isometric,4055,O
contractions,4055,O
were,4055,O
measured,4055,O
to,4055,O
the,4055,O
full,4055,O
muscarinic,4055,B-GENE-N
receptor,4055,I-GENE-N
agonist,4055,O
methacholine,4055,B-CHEMICAL
",",4055,O
the,4055,O
partial,4055,O
muscarinic,4055,B-GENE-N
receptor,4055,I-GENE-N
agonist,4055,O
4-,4055,B-CHEMICAL
(,4055,I-CHEMICAL
m-chlorophenyl-carbamoyloxy,4055,I-CHEMICAL
),4055,I-CHEMICAL
-2-butynyltrimethylammonium,4055,I-CHEMICAL
(,4055,O
McN-A-343,4055,B-CHEMICAL
),4055,O
and,4055,O
histamine,4055,B-CHEMICAL
.,4055,O
Fenoterol,4056,B-CHEMICAL
treatment,4056,O
significantly,4056,O
reduced,4056,O
the,4056,O
sensitivity,4056,O
(,4056,O
pEC,4056,O
(,4056,O
50,4056,O
),4056,O
),4056,O
to,4056,O
methacholine,4056,B-CHEMICAL
in,4056,O
a,4056,O
time-dependent,4056,O
manner,4056,O
",",4056,O
without,4056,O
affecting,4056,O
maximal,4056,O
contraction,4056,O
(,4056,O
E,4056,O
(,4056,O
max,4056,O
),4056,O
),4056,O
.,4056,O
Fenoterol,4057,B-CHEMICAL
treatment,4057,O
similarly,4057,O
reduced,4057,O
the,4057,O
pEC,4057,O
(,4057,O
50,4057,O
),4057,O
of,4057,O
McN-A-343,4057,B-CHEMICAL
and,4057,O
histamine,4057,B-CHEMICAL
;,4057,O
however,4057,O
",",4057,O
E,4057,O
(,4057,O
max,4057,O
),4057,O
values,4057,O
were,4057,O
also,4057,O
reduced,4057,O
",",4057,O
to,4057,O
approximately,4057,O
70,4057,O
%,4057,O
of,4057,O
control,4057,O
after,4057,O
18-h,4057,O
treatment,4057,O
.,4057,O
The,4058,O
inverse,4058,O
agonist,4058,O
timolol,4058,B-CHEMICAL
",",4058,O
having,4058,O
no,4058,O
effect,4058,O
on,4058,O
control,4058,O
preparations,4058,O
",",4058,O
consistently,4058,O
restored,4058,O
the,4058,O
reduced,4058,O
pEC,4058,O
(,4058,O
50,4058,O
),4058,O
and,4058,O
E,4058,O
(,4058,O
max,4058,O
),4058,O
values,4058,O
of,4058,O
the,4058,O
contractile,4058,O
agonists,4058,O
.,4058,O
Remarkably,4059,O
",",4059,O
in,4059,O
the,4059,O
presence,4059,O
of,4059,O
timolol,4059,O
the,4059,O
pEC,4059,O
(,4059,O
50,4059,O
),4059,O
values,4059,O
of,4059,O
McN-A-343,4059,B-CHEMICAL
and,4059,O
histamine,4059,B-CHEMICAL
in,4059,O
fenoterol-treated,4059,B-CHEMICAL
airways,4059,O
were,4059,O
significantly,4059,O
enhanced,4059,O
compared,4059,O
to,4059,O
controls,4059,O
.,4059,O
In,4060,O
conclusion,4060,O
",",4060,O
fenoterol-induced,4060,B-CHEMICAL
constitutive,4060,O
beta,4060,B-GENE-Y
(,4060,I-GENE-Y
2,4060,I-GENE-Y
),4060,I-GENE-Y
-adrenoceptor,4060,I-GENE-Y
activity,4060,O
reduces,4060,O
muscarinic,4060,B-GENE-N
receptor,4060,I-GENE-N
agonist-,4060,O
and,4060,O
histamine-induced,4060,B-CHEMICAL
contractions,4060,O
of,4060,O
bovine,4060,O
tracheal,4060,O
smooth,4060,O
muscle,4060,O
",",4060,O
which,4060,O
can,4060,O
be,4060,O
reversed,4060,O
by,4060,O
the,4060,O
inverse,4060,O
agonist,4060,O
timolol,4060,B-CHEMICAL
.,4060,O
Moreover,4061,O
",",4061,O
after,4061,O
beta,4061,B-GENE-Y
(,4061,I-GENE-Y
2,4061,I-GENE-Y
),4061,I-GENE-Y
-adrenoceptor,4061,I-GENE-Y
agonist,4061,O
treatment,4061,O
",",4061,O
inverse,4061,O
agonism,4061,O
by,4061,O
beta-adrenoceptor,4061,B-GENE-N
antagonists,4061,O
may,4061,O
cause,4061,O
enhanced,4061,O
airway,4061,O
reactivity,4061,O
to,4061,O
contractile,4061,O
mediators,4061,O
.,4061,O
Beta-glucogallin,4062,B-CHEMICAL
reduces,4062,O
the,4062,O
expression,4062,O
of,4062,O
lipopolysaccharide-induced,4062,O
inflammatory,4062,O
markers,4062,O
by,4062,O
inhibition,4062,O
of,4062,O
aldose,4062,B-GENE-Y
reductase,4062,I-GENE-Y
in,4062,O
murine,4062,O
macrophages,4062,O
and,4062,O
ocular,4062,O
tissues,4062,O
.,4062,O
Aldose,4063,B-GENE-Y
reductase,4063,I-GENE-Y
(,4063,O
AR,4063,B-GENE-Y
),4063,O
catalyzes,4063,O
the,4063,O
reduction,4063,O
of,4063,O
toxic,4063,O
lipid,4063,O
aldehydes,4063,B-CHEMICAL
to,4063,O
their,4063,O
alcohol,4063,B-CHEMICAL
products,4063,O
and,4063,O
mediates,4063,O
inflammatory,4063,O
signals,4063,O
triggered,4063,O
by,4063,O
lipopolysaccharide,4063,O
(,4063,O
LPS,4063,O
),4063,O
.,4063,O
Beta-glucogallin,4064,B-CHEMICAL
(,4064,O
BGG,4064,B-CHEMICAL
),4064,O
",",4064,O
a,4064,O
recently,4064,O
described,4064,O
AR,4064,B-GENE-Y
inhibitor,4064,O
",",4064,O
was,4064,O
purified,4064,O
from,4064,O
extracts,4064,O
of,4064,O
the,4064,O
Indian,4064,O
gooseberry,4064,O
(,4064,O
Emblica,4064,O
officinalis,4064,O
),4064,O
.,4064,O
In,4065,O
this,4065,O
study,4065,O
",",4065,O
we,4065,O
found,4065,O
that,4065,O
BGG,4065,B-CHEMICAL
showed,4065,O
low,4065,O
cytotoxicity,4065,O
in,4065,O
Raw264.7,4065,O
murine,4065,O
macrophages,4065,O
and,4065,O
effectively,4065,O
inhibited,4065,O
AR,4065,B-GENE-Y
activity,4065,O
as,4065,O
measured,4065,O
by,4065,O
a,4065,O
decrease,4065,O
in,4065,O
sorbitol,4065,B-CHEMICAL
accumulation,4065,O
.,4065,O
In,4066,O
addition,4066,O
",",4066,O
BGG-mediated,4066,B-CHEMICAL
inhibition,4066,O
of,4066,O
AR,4066,B-GENE-Y
prevented,4066,O
LPS-induced,4066,O
activation,4066,O
of,4066,O
JNK,4066,B-GENE-N
and,4066,O
p38,4066,B-GENE-N
and,4066,O
lowered,4066,O
ROS,4066,O
levels,4066,O
",",4066,O
which,4066,O
could,4066,O
inhibit,4066,O
LPS-induced,4066,O
apoptosis,4066,O
.,4066,O
Uveitis,4067,O
is,4067,O
a,4067,O
disease,4067,O
of,4067,O
the,4067,O
eye,4067,O
associated,4067,O
with,4067,O
chronic,4067,O
inflammation,4067,O
.,4067,O
In,4068,O
this,4068,O
study,4068,O
",",4068,O
we,4068,O
also,4068,O
demonstrated,4068,O
that,4068,O
treatment,4068,O
with,4068,O
BGG,4068,B-CHEMICAL
decreased,4068,O
the,4068,O
number,4068,O
of,4068,O
inflammatory,4068,O
cells,4068,O
that,4068,O
infiltrate,4068,O
the,4068,O
ocular,4068,O
media,4068,O
of,4068,O
mice,4068,O
with,4068,O
experimental,4068,O
uveitis,4068,O
.,4068,O
Accordingly,4069,O
",",4069,O
these,4069,O
results,4069,O
suggest,4069,O
BGG,4069,B-CHEMICAL
is,4069,O
a,4069,O
potential,4069,O
therapy,4069,O
for,4069,O
inflammatory,4069,O
diseases,4069,O
.,4069,O
Differential,4070,O
phosphoproteome,4070,O
of,4070,O
the,4070,O
striatum,4070,O
from,4070,O
pleiotrophin,4070,B-GENE-Y
knockout,4070,O
and,4070,O
midkine,4070,B-GENE-Y
knockout,4070,O
mice,4070,O
treated,4070,O
with,4070,O
amphetamine,4070,B-CHEMICAL
:,4070,O
Correlations,4070,O
with,4070,O
amphetamine-induced,4070,B-CHEMICAL
neurotoxicity,4070,O
.,4070,O
The,4071,O
neurotrophic,4071,O
factors,4071,O
pleiotrophin,4071,B-GENE-Y
(,4071,O
PTN,4071,B-GENE-Y
),4071,O
and,4071,O
midkine,4071,B-GENE-Y
(,4071,O
MK,4071,B-GENE-Y
),4071,O
have,4071,O
been,4071,O
shown,4071,O
to,4071,O
modulate,4071,O
amphetamine-induced,4071,B-CHEMICAL
neurotoxicity,4071,O
.,4071,O
Accordingly,4072,O
",",4072,O
PTN-/-,4072,B-GENE-Y
and,4072,O
MK-/-,4072,B-GENE-Y
mice,4072,O
show,4072,O
an,4072,O
increased,4072,O
vulnerability,4072,O
to,4072,O
amphetamine-induced,4072,B-CHEMICAL
neurotoxic,4072,O
effects,4072,O
.,4072,O
In,4073,O
an,4073,O
effort,4073,O
to,4073,O
uncover,4073,O
new,4073,O
pharmacological,4073,O
targets,4073,O
to,4073,O
prevent,4073,O
amphetamine,4073,B-CHEMICAL
neurotoxic,4073,O
effects,4073,O
",",4073,O
we,4073,O
have,4073,O
now,4073,O
used,4073,O
a,4073,O
proteomic,4073,O
approach,4073,O
to,4073,O
study,4073,O
protein,4073,O
phosphorylation,4073,O
",",4073,O
in,4073,O
which,4073,O
we,4073,O
combined,4073,O
phosphoprotein,4073,O
enrichment,4073,O
",",4073,O
by,4073,O
immobilized,4073,O
metal,4073,O
affinity,4073,O
chromatography,4073,O
(,4073,O
IMAC,4073,O
),4073,O
",",4073,O
with,4073,O
two-dimensional,4073,O
gel,4073,O
electrophoresis,4073,O
and,4073,O
mass,4073,O
spectrometry,4073,O
",",4073,O
in,4073,O
order,4073,O
to,4073,O
identify,4073,O
the,4073,O
phosphoproteins,4073,O
regulated,4073,O
in,4073,O
the,4073,O
striatum,4073,O
of,4073,O
PTN-/-,4073,B-GENE-Y
",",4073,O
MK-/-,4073,B-GENE-Y
and,4073,O
wild,4073,O
type,4073,O
(,4073,O
WT,4073,O
),4073,O
mice,4073,O
treated,4073,O
with,4073,O
amphetamine,4073,B-CHEMICAL
.,4073,O
We,4074,O
identified,4074,O
13,4074,O
differentially,4074,O
expressed,4074,O
phosphoproteins,4074,O
that,4074,O
are,4074,O
judged,4074,O
to,4074,O
be,4074,O
relevant,4074,O
in,4074,O
the,4074,O
neuroprotective,4074,O
roles,4074,O
of,4074,O
PTN,4074,B-GENE-Y
and,4074,O
MK,4074,B-GENE-Y
against,4074,O
amphetamine-induced,4074,B-CHEMICAL
neurotoxicity,4074,O
.,4074,O
It,4075,O
is,4075,O
very,4075,O
interesting,4075,O
to,4075,O
note,4075,O
that,4075,O
4,4075,O
of,4075,O
these,4075,O
phosphoproteins,4075,O
",",4075,O
annexin,4075,B-GENE-Y
A7,4075,I-GENE-Y
(,4075,O
ANXA7,4075,B-GENE-Y
),4075,O
",",4075,O
COP9,4075,B-GENE-Y
signalosome,4075,I-GENE-Y
subunit,4075,I-GENE-Y
5,4075,I-GENE-Y
(,4075,O
COPS5,4075,B-GENE-Y
),4075,O
",",4075,O
aldehyde,4075,B-GENE-Y
dehydrogenase,4075,I-GENE-Y
family,4075,I-GENE-Y
1,4075,I-GENE-Y
member,4075,I-GENE-Y
A1,4075,I-GENE-Y
(,4075,O
ALDH1A1,4075,B-GENE-Y
),4075,O
and,4075,O
creatine,4075,B-GENE-Y
kinase,4075,I-GENE-Y
U-type,4075,I-GENE-Y
(,4075,O
CKMT1,4075,B-GENE-Y
),4075,O
",",4075,O
are,4075,O
known,4075,O
to,4075,O
be,4075,O
involved,4075,O
in,4075,O
Parkinson,4075,O
's,4075,O
disease,4075,O
",",4075,O
a,4075,O
result,4075,O
of,4075,O
significant,4075,O
importance,4075,O
since,4075,O
PTN,4075,B-GENE-Y
and,4075,O
MK,4075,B-GENE-Y
have,4075,O
been,4075,O
also,4075,O
demonstrated,4075,O
to,4075,O
limit,4075,O
Parkinson,4075,O
's,4075,O
disease,4075,O
(,4075,O
PD,4075,O
),4075,O
progress,4075,O
and,4075,O
have,4075,O
been,4075,O
suggested,4075,O
to,4075,O
be,4075,O
among,4075,O
the,4075,O
important,4075,O
genetic,4075,O
factors,4075,O
possibly,4075,O
preventing,4075,O
the,4075,O
development,4075,O
of,4075,O
PD,4075,O
in,4075,O
methamphetamine,4075,B-CHEMICAL
abusers,4075,O
.,4075,O
The,4076,O
data,4076,O
identify,4076,O
phosphoproteins,4076,O
differentially,4076,O
regulated,4076,O
by,4076,O
amphetamine,4076,B-CHEMICAL
treatment,4076,O
and/or,4076,O
the,4076,O
presence,4076,O
of,4076,O
endogenous,4076,O
PTN/MK,4076,B-GENE-Y
which,4076,O
may,4076,O
be,4076,O
relevant,4076,O
mediators,4076,O
of,4076,O
PTN/MK,4076,B-GENE-Y
neuroprotective,4076,O
effects,4076,O
against,4076,O
amphetamine-induced,4076,B-CHEMICAL
neurotoxicity,4076,O
.,4076,O
The,4077,O
data,4077,O
support,4077,O
further,4077,O
studies,4077,O
to,4077,O
validate,4077,O
the,4077,O
phosphoproteins,4077,O
here,4077,O
identified,4077,O
as,4077,O
possible,4077,O
new,4077,O
pharmacological,4077,O
targets,4077,O
to,4077,O
prevent,4077,O
amphetamine,4077,B-CHEMICAL
neurotoxic,4077,O
effects,4077,O
.,4077,O
Universal,4078,O
rule,4078,O
on,4078,O
chirality-dependent,4078,O
bandgaps,4078,O
in,4078,O
graphene,4078,B-CHEMICAL
antidot,4078,O
lattices,4078,O
.,4078,O
Graphene,4079,B-CHEMICAL
with,4079,O
periodically,4079,O
patterned,4079,O
antidots,4079,O
has,4079,O
attracted,4079,O
intense,4079,O
research,4079,O
attention,4079,O
as,4079,O
it,4079,O
represents,4079,O
a,4079,O
facile,4079,O
route,4079,O
to,4079,O
open,4079,O
a,4079,O
bandgap,4079,O
for,4079,O
graphene,4079,B-CHEMICAL
electronics,4079,O
.,4079,O
However,4080,O
",",4080,O
not,4080,O
all,4080,O
graphene,4080,B-CHEMICAL
antidot,4080,O
lattices,4080,O
(,4080,O
GALs,4080,O
),4080,O
can,4080,O
open,4080,O
a,4080,O
bandgap,4080,O
and,4080,O
a,4080,O
guiding,4080,O
rule,4080,O
is,4080,O
missing,4080,O
.,4080,O
Here,4081,O
",",4081,O
through,4081,O
systematic,4081,O
first-principles,4081,O
calculations,4081,O
",",4081,O
it,4081,O
is,4081,O
found,4081,O
that,4081,O
bandgaps,4081,O
in,4081,O
triangular,4081,O
GALs,4081,O
are,4081,O
surprisingly,4081,O
well,4081,O
defined,4081,O
by,4081,O
a,4081,O
chirality,4081,O
vector,4081,O
R,4081,O
=,4081,O
n,4081,O
a1,4081,O
+,4081,O
ma2,4081,O
connecting,4081,O
two,4081,O
neighboring,4081,O
antidots,4081,O
",",4081,O
where,4081,O
a1,4081,O
and,4081,O
a2,4081,O
are,4081,O
the,4081,O
basis,4081,O
vectors,4081,O
of,4081,O
graphene,4081,B-CHEMICAL
.,4081,O
The,4082,O
bandgap,4082,O
opens,4082,O
in,4082,O
the,4082,O
GALs,4082,O
with,4082,O
(,4082,O
n-m,4082,O
),4082,O
mod3,4082,O
=,4082,O
0,4082,O
but,4082,O
remains,4082,O
closed,4082,O
in,4082,O
those,4082,O
with,4082,O
(,4082,O
n-m,4082,O
),4082,O
mod3,4082,O
=,4082,O
±1,4082,O
",",4082,O
reminiscent,4082,O
of,4082,O
the,4082,O
gap-chirality,4082,O
rule,4082,O
in,4082,O
carbon,4082,B-CHEMICAL
nanotubes,4082,O
.,4082,O
Remarkably,4083,O
",",4083,O
the,4083,O
gap,4083,O
value,4083,O
in,4083,O
GALs,4083,O
allows,4083,O
ample,4083,O
modulation,4083,O
by,4083,O
adjusting,4083,O
the,4083,O
length,4083,O
of,4083,O
chirality,4083,O
vectors,4083,O
",",4083,O
shape,4083,O
and,4083,O
size,4083,O
of,4083,O
the,4083,O
antidots,4083,O
.,4083,O
The,4084,O
gap-chirality,4084,O
relation,4084,O
in,4084,O
GALs,4084,O
stems,4084,O
from,4084,O
the,4084,O
chirality-dependent,4084,O
atomic,4084,O
structures,4084,O
of,4084,O
GALs,4084,O
as,4084,O
revealed,4084,O
by,4084,O
a,4084,O
super-atom,4084,O
model,4084,O
as,4084,O
well,4084,O
as,4084,O
Clar,4084,O
sextet,4084,O
analyses,4084,O
.,4084,O
This,4085,O
chirality-dependent,4085,O
bandgap,4085,O
is,4085,O
further,4085,O
shown,4085,O
to,4085,O
be,4085,O
a,4085,O
generic,4085,O
behavior,4085,O
in,4085,O
any,4085,O
parallelogram,4085,O
GAL,4085,O
and,4085,O
thus,4085,O
serves,4085,O
as,4085,O
an,4085,O
essential,4085,O
stepping,4085,O
stone,4085,O
for,4085,O
experimenters,4085,O
to,4085,O
realize,4085,O
graphene,4085,B-CHEMICAL
devices,4085,O
by,4085,O
antidot,4085,O
engineering,4085,O
.,4085,O
Exogenous,4086,O
C2-ceramide,4086,B-CHEMICAL
activates,4086,O
c-fos,4086,B-GENE-N
serum,4086,I-GENE-N
response,4086,I-GENE-N
element,4086,I-GENE-N
via,4086,O
Rac-dependent,4086,B-GENE-N
signalling,4086,O
pathway,4086,O
.,4086,O
Ceramide,4087,B-CHEMICAL
is,4087,O
an,4087,O
important,4087,O
regulatory,4087,O
molecule,4087,O
implicated,4087,O
in,4087,O
a,4087,O
variety,4087,O
of,4087,O
biological,4087,O
processes,4087,O
in,4087,O
response,4087,O
to,4087,O
stress,4087,O
and,4087,O
cytokines,4087,B-GENE-N
.,4087,O
To,4088,O
understand,4088,O
the,4088,O
signal,4088,O
transduction,4088,O
pathway,4088,O
of,4088,O
ceramide,4088,B-CHEMICAL
to,4088,O
the,4088,O
nucleus,4088,O
",",4088,O
in,4088,O
the,4088,O
present,4088,O
study,4088,O
",",4088,O
we,4088,O
examined,4088,O
whether,4088,O
C2-ceramide,4088,B-CHEMICAL
",",4088,O
a,4088,O
cell,4088,O
permeable,4088,O
ceramide,4088,B-CHEMICAL
",",4088,O
activates,4088,O
c-fos,4088,B-GENE-N
serum,4088,I-GENE-N
response,4088,I-GENE-N
element,4088,I-GENE-N
(,4088,O
SRE,4088,B-GENE-N
),4088,O
.,4088,O
Treatment,4089,O
of,4089,O
Rat-2,4089,O
fibroblast,4089,O
cells,4089,O
with,4089,O
C2-ceramide,4089,B-CHEMICAL
caused,4089,O
the,4089,O
stimulation,4089,O
of,4089,O
c-fos,4089,B-GENE-N
SRE-dependent,4089,O
reporter,4089,O
gene,4089,O
activity,4089,O
in,4089,O
a,4089,O
dose-,4089,O
and,4089,O
time-dependent,4089,O
manner,4089,O
by,4089,O
transient,4089,O
transfection,4089,O
analysis,4089,O
.,4089,O
Next,4090,O
",",4090,O
we,4090,O
examined,4090,O
the,4090,O
role,4090,O
of,4090,O
Rho,4090,B-GENE-N
family,4090,O
GTPases,4090,B-GENE-N
in,4090,O
the,4090,O
ceramide-induced,4090,B-CHEMICAL
signalling,4090,O
to,4090,O
SRE,4090,B-GENE-N
activation,4090,O
.,4090,O
By,4091,O
reporter,4091,O
gene,4091,O
analysis,4091,O
following,4091,O
transient,4091,O
transfections,4091,O
with,4091,O
various,4091,O
plasmids,4091,O
expressing,4091,O
a,4091,O
dominant,4091,O
negative,4091,O
mutant,4091,O
form,4091,O
of,4091,O
Cdc42,4091,B-GENE-Y
",",4091,O
Rac1,4091,B-GENE-Y
or,4091,O
RhoA,4091,B-GENE-Y
",",4091,O
C2-ceramide-induced,4091,B-CHEMICAL
SRE,4091,B-GENE-N
activation,4091,O
was,4091,O
shown,4091,O
to,4091,O
be,4091,O
selectively,4091,O
repressed,4091,O
by,4091,O
pEXV-RacN17,4091,O
encoding,4091,O
a,4091,O
dominant,4091,O
negative,4091,O
mutant,4091,O
of,4091,O
Rac1,4091,B-GENE-Y
",",4091,O
suggesting,4091,O
that,4091,O
Rac,4091,B-GENE-N
activity,4091,O
is,4091,O
essential,4091,O
for,4091,O
the,4091,O
signalling,4091,O
cascade,4091,O
of,4091,O
ceramide,4091,B-CHEMICAL
to,4091,O
the,4091,O
nucleus,4091,O
.,4091,O
In,4092,O
a,4092,O
further,4092,O
study,4092,O
to,4092,O
analyse,4092,O
the,4092,O
downstream,4092,O
mediator,4092,O
of,4092,O
Rac,4092,B-GENE-N
in,4092,O
the,4092,O
ceramide-signalling,4092,B-CHEMICAL
pathway,4092,O
",",4092,O
we,4092,O
observed,4092,O
that,4092,O
either,4092,O
pretreatment,4092,O
with,4092,O
mepacrine,4092,B-CHEMICAL
",",4092,O
a,4092,O
potent,4092,O
and,4092,O
specific,4092,O
inhibitor,4092,O
of,4092,O
phospholipase,4092,O
A2,4092,O
",",4092,O
or,4092,O
co-transfection,4092,O
with,4092,O
antisense,4092,O
cytosolic,4092,B-GENE-Y
phospholipase,4092,I-GENE-Y
A2,4092,I-GENE-Y
(,4092,O
cPLA2,4092,B-GENE-Y
),4092,O
oligonucleotide,4092,O
repressed,4092,O
the,4092,O
C2-ceramide-induced,4092,B-CHEMICAL
SRE,4092,B-GENE-N
activation,4092,O
selectively,4092,O
",",4092,O
implying,4092,O
a,4092,O
critical,4092,O
role,4092,O
of,4092,O
cPLA2,4092,B-GENE-Y
in,4092,O
C2-ceramide-induced,4092,B-CHEMICAL
signalling,4092,O
to,4092,O
nucleus,4092,O
.,4092,O
Consistent,4093,O
with,4093,O
these,4093,O
results,4093,O
",",4093,O
the,4093,O
translocation,4093,O
of,4093,O
cPLA2,4093,B-GENE-Y
protein,4093,O
as,4093,O
well,4093,O
as,4093,O
the,4093,O
release,4093,O
of,4093,O
arachidonic,4093,B-CHEMICAL
acid,4093,I-CHEMICAL
",",4093,O
a,4093,O
principal,4093,O
product,4093,O
of,4093,O
phospholipase,4093,B-GENE-Y
A2,4093,I-GENE-Y
",",4093,O
was,4093,O
rapidly,4093,O
induced,4093,O
by,4093,O
the,4093,O
addition,4093,O
of,4093,O
C2-ceramide,4093,B-CHEMICAL
in,4093,O
a,4093,O
Rac-dependent,4093,B-GENE-N
manner,4093,O
.,4093,O
Together,4094,O
",",4094,O
our,4094,O
findings,4094,O
suggest,4094,O
the,4094,O
critical,4094,O
role,4094,O
of,4094,O
'Rac,4094,O
and,4094,O
subsequent,4094,O
activation,4094,O
of,4094,O
phospholipase,4094,B-GENE-Y
A2,4094,I-GENE-Y
',4094,O
in,4094,O
ceramide-signalling,4094,B-CHEMICAL
to,4094,O
nucleus,4094,O
.,4094,O
Effect,4095,O
of,4095,O
ramelteon,4095,B-CHEMICAL
(,4095,O
TAK-375,4095,B-CHEMICAL
),4095,O
",",4095,O
a,4095,O
selective,4095,O
MT1/MT2,4095,B-GENE-N
receptor,4095,I-GENE-N
agonist,4095,O
",",4095,O
on,4095,O
motor,4095,O
performance,4095,O
in,4095,O
mice,4095,O
.,4095,O
Effect,4096,O
of,4096,O
(,4096,B-CHEMICAL
S,4096,I-CHEMICAL
),4096,I-CHEMICAL
-N-,4096,I-CHEMICAL
[,4096,I-CHEMICAL
2-,4096,I-CHEMICAL
(,4096,I-CHEMICAL
"1,6,7,8-tetrahydro-2H-indeno-",4096,I-CHEMICAL
[,4096,I-CHEMICAL
"5,4-b",4096,I-CHEMICAL
],4096,I-CHEMICAL
furan-8-yl,4096,I-CHEMICAL
),4096,I-CHEMICAL
ethyl,4096,I-CHEMICAL
],4096,I-CHEMICAL
propionamide,4096,I-CHEMICAL
(,4096,O
ramelteon,4096,B-CHEMICAL
",",4096,O
TAK-375,4096,B-CHEMICAL
),4096,O
",",4096,O
a,4096,O
selective,4096,O
MT1/MT2,4096,B-GENE-N
receptor,4096,I-GENE-N
agonist,4096,O
",",4096,O
on,4096,O
motor,4096,O
coordination,4096,O
was,4096,O
studied,4096,O
using,4096,O
rota-rod,4096,O
performance,4096,O
in,4096,O
mice,4096,O
.,4096,O
Ramelteon,4097,B-CHEMICAL
did,4097,O
not,4097,O
impair,4097,O
rota-rod,4097,O
performance,4097,O
at,4097,O
doses,4097,O
of,4097,O
3,4097,O
",",4097,O
10,4097,O
and,4097,O
30,4097,O
mg/kg,4097,O
",",4097,O
p.o,4097,O
.,4097,O
Melatonin,4098,B-CHEMICAL
and,4098,O
N-acetyl-5-hydroxytryptamine,4098,B-CHEMICAL
(,4098,O
N-acetyl-5-HT,4098,B-CHEMICAL
),4098,O
",",4098,O
a,4098,O
ligand,4098,O
of,4098,O
MT3,4098,B-GENE-N
biding,4098,O
site,4098,O
",",4098,O
also,4098,O
had,4098,O
no,4098,O
impairment,4098,O
on,4098,O
the,4098,O
performance,4098,O
",",4098,O
per,4098,O
se,4098,O
.,4098,O
However,4099,O
",",4099,O
in,4099,O
combination,4099,O
with,4099,O
a,4099,O
low,4099,O
dose,4099,O
of,4099,O
diazepam,4099,B-CHEMICAL
(,4099,O
3mg/kg,4099,O
",",4099,O
p.o,4099,O
.,4099,O
),4100,O
",",4100,O
treatment,4100,O
with,4100,O
melatonin,4100,O
and,4100,O
N-acetyl-5-HT,4100,O
exacerbated,4100,O
the,4100,O
impairment,4100,O
by,4100,O
diazepam,4100,O
.,4100,O
Ramelteon,4101,O
had,4101,O
no,4101,O
significant,4101,O
effect,4101,O
on,4101,O
the,4101,O
diazepam-induced,4101,O
impairment,4101,O
of,4101,O
motor,4101,O
coordination,4101,O
.,4101,O
The,4102,O
role,4102,O
of,4102,O
platelet/lymphocyte,4102,O
serotonin,4102,B-GENE-Y
transporter,4102,I-GENE-Y
in,4102,O
depression,4102,O
and,4102,O
beyond,4102,O
.,4102,O
A,4103,O
large,4103,O
amount,4103,O
of,4103,O
the,4103,O
data,4103,O
gathered,4103,O
in,4103,O
the,4103,O
last,4103,O
50,4103,O
years,4103,O
support,4103,O
the,4103,O
hypothesis,4103,O
that,4103,O
alterations,4103,O
of,4103,O
the,4103,O
serotonin,4103,B-CHEMICAL
(,4103,O
5-HT,4103,B-CHEMICAL
),4103,O
neurotransmission,4103,O
play,4103,O
a,4103,O
crucial,4103,O
role,4103,O
in,4103,O
the,4103,O
pathophysiology,4103,O
of,4103,O
not,4103,O
only,4103,O
major,4103,O
depression,4103,O
(,4103,O
MD,4103,O
),4103,O
",",4103,O
but,4103,O
also,4103,O
of,4103,O
different,4103,O
neuropsychiatric,4103,O
disorders,4103,O
.,4103,O
Research,4104,O
in,4104,O
this,4104,O
field,4104,O
has,4104,O
been,4104,O
substantially,4104,O
promoted,4104,O
by,4104,O
the,4104,O
evidence,4104,O
that,4104,O
the,4104,O
reuptake,4104,O
protein,4104,O
(,4104,O
SERT,4104,B-GENE-Y
),4104,O
",",4104,O
present,4104,O
in,4104,O
presynaptic,4104,O
neurons,4104,O
",",4104,O
is,4104,O
a,4104,O
key,4104,O
element,4104,O
in,4104,O
terminating,4104,O
the,4104,O
activity,4104,O
of,4104,O
the,4104,O
neurotransmitter,4104,O
in,4104,O
the,4104,O
synaptic,4104,O
cleft,4104,O
.,4104,O
For,4105,O
this,4105,O
reason,4105,O
",",4105,O
it,4105,O
was,4105,O
specifically,4105,O
targeted,4105,O
for,4105,O
the,4105,O
development,4105,O
of,4105,O
second-generation,4105,O
antidepressants,4105,O
",",4105,O
in,4105,O
particular,4105,O
of,4105,O
selective,4105,O
5-HT,4105,B-CHEMICAL
reuptake,4105,O
inhibitors,4105,O
(,4105,O
SSRIs,4105,O
),4105,O
",",4105,O
with,4105,O
the,4105,O
aim,4105,O
of,4105,O
increasing,4105,O
the,4105,O
intrasynaptic,4105,O
5-HT,4105,B-CHEMICAL
concentrations,4105,O
.,4105,O
Moreover,4106,O
",",4106,O
since,4106,O
a,4106,O
lot,4106,O
of,4106,O
studies,4106,O
showed,4106,O
that,4106,O
circulating,4106,O
platelets,4106,O
and,4106,O
",",4106,O
more,4106,O
recently,4106,O
",",4106,O
lymphocytes,4106,O
possess,4106,O
functional,4106,O
SERT,4106,B-GENE-Y
proteins,4106,O
",",4106,O
they,4106,O
have,4106,O
been,4106,O
widely,4106,O
used,4106,O
as,4106,O
peripheral,4106,O
mirrors,4106,O
of,4106,O
the,4106,O
same,4106,O
structures,4106,O
located,4106,O
in,4106,O
the,4106,O
central,4106,O
nervous,4106,O
system,4106,O
.,4106,O
The,4107,O
presence,4107,O
of,4107,O
functional,4107,O
SERT,4107,B-GENE-Y
in,4107,O
blood,4107,O
cells,4107,O
suggests,4107,O
strict,4107,O
relationships,4107,O
between,4107,O
the,4107,O
nervous,4107,O
and,4107,O
the,4107,O
immune,4107,O
system,4107,O
that,4107,O
need,4107,O
to,4107,O
be,4107,O
better,4107,O
clarified,4107,O
in,4107,O
MD,4107,O
",",4107,O
as,4107,O
well,4107,O
as,4107,O
the,4107,O
possibility,4107,O
of,4107,O
reciprocal,4107,O
modulation,4107,O
of,4107,O
the,4107,O
two,4107,O
systems,4107,O
by,4107,O
different,4107,O
drugs,4107,O
.,4107,O
This,4108,O
paper,4108,O
aims,4108,O
to,4108,O
review,4108,O
briefly,4108,O
the,4108,O
literature,4108,O
on,4108,O
the,4108,O
5-HT,4108,B-CHEMICAL
hypothesis,4108,O
of,4108,O
depression,4108,O
with,4108,O
a,4108,O
major,4108,O
focus,4108,O
on,4108,O
the,4108,O
possible,4108,O
role,4108,O
of,4108,O
SERT,4108,B-GENE-Y
in,4108,O
this,4108,O
disorder,4108,O
",",4108,O
while,4108,O
highlighting,4108,O
how,4108,O
recent,4108,O
data,4108,O
are,4108,O
more,4108,O
oriented,4108,O
on,4108,O
dimensional,4108,O
rather,4108,O
than,4108,O
nosological,4108,O
involvement,4108,O
of,4108,O
this,4108,O
structure,4108,O
in,4108,O
different,4108,O
conditions,4108,O
spanning,4108,O
from,4108,O
normality,4108,O
to,4108,O
pathology,4108,O
.,4108,O
Synthesis,4109,O
and,4109,O
cancer,4109,O
stem,4109,O
cell-based,4109,O
activity,4109,O
of,4109,O
substituted,4109,O
5-morpholino-7H-thieno,4109,B-CHEMICAL
[,4109,I-CHEMICAL
"3,2-b",4109,I-CHEMICAL
],4109,I-CHEMICAL
pyran-7-ones,4109,I-CHEMICAL
designed,4109,O
as,4109,O
next,4109,O
generation,4109,O
PI3K,4109,B-GENE-N
inhibitors,4109,O
.,4109,O
Dysregulation,4110,O
of,4110,O
the,4110,O
phosphatidylinositol-3-kinase,4110,B-GENE-N
(,4110,O
PI3K,4110,B-GENE-N
),4110,O
pathway,4110,O
in,4110,O
a,4110,O
wide,4110,O
range,4110,O
of,4110,O
tumors,4110,O
has,4110,O
made,4110,O
PI3K,4110,B-GENE-N
a,4110,O
consensus,4110,O
target,4110,O
to,4110,O
inhibit,4110,O
as,4110,O
illustrated,4110,O
by,4110,O
more,4110,O
than,4110,O
15,4110,O
inhibitors,4110,O
now,4110,O
in,4110,O
clinical,4110,O
trials,4110,O
.,4110,O
Our,4111,O
previous,4111,O
work,4111,O
",",4111,O
built,4111,O
on,4111,O
the,4111,O
early,4111,O
pioneering,4111,O
multikinase,4111,O
inhibitor,4111,O
LY294002,4111,B-CHEMICAL
",",4111,O
resulted,4111,O
in,4111,O
the,4111,O
only,4111,O
PI3K,4111,B-GENE-N
vascular-targeted,4111,O
PI3K,4111,B-GENE-N
inhibitor,4111,O
prodrug,4111,O
",",4111,O
SF1126,4111,B-CHEMICAL
",",4111,O
which,4111,O
has,4111,O
now,4111,O
completed,4111,O
Phase,4111,O
I,4111,O
clinical,4111,O
trials,4111,O
.,4111,O
This,4112,O
inhibitor,4112,O
has,4112,O
properties,4112,O
that,4112,O
impart,4112,O
more,4112,O
in,4112,O
vivo,4112,O
activity,4112,O
than,4112,O
should,4112,O
be,4112,O
warranted,4112,O
by,4112,O
its,4112,O
enzymatic,4112,O
potency,4112,O
",",4112,O
which,4112,O
in,4112,O
general,4112,O
is,4112,O
much,4112,O
lower,4112,O
than,4112,O
other,4112,O
clinical,4112,O
stage,4112,O
PI3K,4112,B-GENE-N
inhibitors,4112,O
.,4112,O
We,4113,O
embarked,4113,O
on,4113,O
the,4113,O
exploration,4113,O
of,4113,O
scaffolds,4113,O
that,4113,O
retained,4113,O
such,4113,O
properties,4113,O
while,4113,O
simultaneously,4113,O
exhibiting,4113,O
an,4113,O
increased,4113,O
potency,4113,O
toward,4113,O
PI3K,4113,B-GENE-N
.,4113,O
This,4114,O
work,4114,O
resulted,4114,O
in,4114,O
the,4114,O
discovery,4114,O
of,4114,O
the,4114,O
5-morpholino-7H-thieno,4114,B-CHEMICAL
[,4114,I-CHEMICAL
"3,2-b",4114,I-CHEMICAL
],4114,I-CHEMICAL
pyran-7-one,4114,I-CHEMICAL
system,4114,O
as,4114,O
the,4114,O
foundation,4114,O
of,4114,O
a,4114,O
new,4114,O
compound,4114,O
class,4114,O
of,4114,O
potential,4114,O
PI3K,4114,B-GENE-N
inhibitors,4114,O
having,4114,O
improved,4114,O
potency,4114,O
toward,4114,O
PI3K,4114,B-GENE-N
.,4114,O
The,4115,O
synthesis,4115,O
and,4115,O
cancer,4115,O
stem,4115,O
cell-based,4115,O
activity,4115,O
of,4115,O
these,4115,O
compounds,4115,O
are,4115,O
reported,4115,O
herein,4115,O
.,4115,O
Heterobivalent,4116,O
dual-target,4116,O
probe,4116,O
for,4116,O
targeting,4116,O
GRP,4116,B-GENE-Y
and,4116,O
Y1,4116,B-GENE-Y
receptors,4116,I-GENE-Y
on,4116,O
tumor,4116,O
cells,4116,O
.,4116,O
Receptor,4117,O
targeting,4117,O
ligands,4117,O
for,4117,O
imaging,4117,O
and/or,4117,O
therapy,4117,O
of,4117,O
cancer,4117,O
are,4117,O
limited,4117,O
by,4117,O
heterogeneity,4117,O
of,4117,O
receptor,4117,O
expression,4117,O
by,4117,O
tumor,4117,O
cells,4117,O
",",4117,O
both,4117,O
inter-patient,4117,O
and,4117,O
intra-patient,4117,O
.,4117,O
It,4118,O
is,4118,O
often,4118,O
more,4118,O
important,4118,O
for,4118,O
imaging,4118,O
agents,4118,O
to,4118,O
identify,4118,O
local,4118,O
and,4118,O
distant,4118,O
spread,4118,O
of,4118,O
disease,4118,O
than,4118,O
it,4118,O
is,4118,O
to,4118,O
identify,4118,O
a,4118,O
specific,4118,O
receptor,4118,O
presence,4118,O
.,4118,O
Two,4119,O
natural,4119,O
hormone,4119,O
peptide,4119,O
receptors,4119,O
",",4119,O
GRPR,4119,B-GENE-Y
and,4119,O
Y1,4119,B-GENE-Y
",",4119,O
are,4119,O
specifically,4119,O
interesting,4119,O
because,4119,O
expression,4119,O
of,4119,O
GRPR,4119,B-GENE-Y
",",4119,O
Y1,4119,B-GENE-Y
or,4119,O
both,4119,O
is,4119,O
up-regulated,4119,O
in,4119,O
most,4119,O
breast,4119,O
cancers,4119,O
.,4119,O
We,4120,O
describe,4120,O
here,4120,O
the,4120,O
design,4120,O
and,4120,O
development,4120,O
of,4120,O
a,4120,O
new,4120,O
heterobivalent,4120,O
peptide,4120,O
ligand,4120,O
",",4120,O
truncated,4120,B-GENE-N
bombesin,4120,I-GENE-N
(,4120,O
t-BBN,4120,B-GENE-N
),4120,O
/BVD15-DO3A,4120,O
",",4120,O
for,4120,O
dual-targeting,4120,O
of,4120,O
GRPR,4120,B-GENE-Y
and,4120,O
Y1,4120,B-GENE-Y
",",4120,O
and,4120,O
validation,4120,O
of,4120,O
its,4120,O
dual,4120,O
binding,4120,O
capability,4120,O
.,4120,O
Such,4121,O
a,4121,O
probe,4121,O
should,4121,O
be,4121,O
useful,4121,O
in,4121,O
imaging,4121,O
cells,4121,O
",",4121,O
tissues,4121,O
and,4121,O
tumors,4121,O
that,4121,O
are,4121,O
GRPR,4121,B-GENE-Y
and/or,4121,O
Y1,4121,B-GENE-Y
positive,4121,O
and,4121,O
should,4121,O
target,4121,O
radioisotopes,4121,O
",",4121,O
for,4121,O
example,4121,O
",",4121,O
(,4121,O
68,4121,O
),4121,O
Ga,4121,O
and/or,4121,O
(,4121,O
177,4121,O
),4121,O
Lu,4121,O
",",4121,O
to,4121,O
more,4121,O
tumors,4121,O
cells,4121,O
than,4121,O
single,4121,O
GRPR,4121,B-GENE-Y
or,4121,O
Y1,4121,B-GENE-Y
targeted,4121,O
probes,4121,O
.,4121,O
A,4122,O
GRP,4122,B-GENE-Y
targeting,4122,O
ligand,4122,O
",",4122,O
J-G-Abz4-QWAVGHLM-NH,4122,O
(,4122,O
2,4122,O
),4122,O
(,4122,O
J-G-Abz4-t-BBN,4122,O
),4122,O
",",4122,O
and,4122,O
an,4122,O
Y1,4122,B-GENE-Y
targeting,4122,O
ligand,4122,O
",",4122,O
INP-K,4122,O
[,4122,O
ε-J-,4122,O
(,4122,O
α-DO3A-ε-DGa,4122,O
),4122,O
-K,4122,O
],4122,O
-YRLRY-NH,4122,O
(,4122,O
2,4122,O
),4122,O
(,4122,O
[,4122,O
ε-J-,4122,O
(,4122,O
α-DO3A-ε-DGa,4122,O
),4122,O
-K,4122,O
],4122,O
-BVD-15,4122,O
),4122,O
",",4122,O
were,4122,O
synthesized,4122,O
and,4122,O
coupled,4122,O
to,4122,O
produce,4122,O
the,4122,O
heterobivalent,4122,O
ligand,4122,O
",",4122,O
t-BBN/BVD15-DO3A,4122,B-GENE-N
.,4122,O
Competitive,4123,O
displacement,4123,O
binding,4123,O
assays,4123,O
using,4123,O
t-BBN/BVD15-DO3A,4123,B-GENE-N
against,4123,O
(,4123,B-GENE-N
125,4123,I-GENE-N
),4123,I-GENE-N
I-Tyr,4123,I-GENE-N
(,4123,I-GENE-N
4,4123,I-GENE-N
),4123,I-GENE-N
-BBN,4123,I-GENE-N
yielded,4123,O
an,4123,O
IC,4123,O
(,4123,O
50,4123,O
),4123,O
value,4123,O
of,4123,O
18,4123,O
±,4123,O
0.7,4123,O
nM,4123,O
for,4123,O
GRPR,4123,B-GENE-Y
in,4123,O
T-47D,4123,O
cells,4123,O
",",4123,O
a,4123,O
human,4123,O
breast,4123,O
cancer,4123,O
cell,4123,O
line,4123,O
.,4123,O
A,4124,O
similar,4124,O
assay,4124,O
using,4124,O
t-BBN/BVD15-DO3A,4124,B-GENE-N
against,4124,O
porcine,4124,B-GENE-Y
(,4124,I-GENE-Y
125,4124,I-GENE-Y
),4124,I-GENE-Y
I-NPY,4124,I-GENE-Y
showed,4124,O
IC,4124,O
(,4124,O
50,4124,O
),4124,O
values,4124,O
of,4124,O
80,4124,O
±,4124,O
11,4124,O
nM,4124,O
for,4124,O
Y1,4124,B-GENE-Y
receptor,4124,I-GENE-Y
in,4124,O
MCF7,4124,O
cells,4124,O
",",4124,O
another,4124,O
human,4124,O
breast,4124,O
cancer,4124,O
cell,4124,O
line,4124,O
.,4124,O
In,4125,O
conclusion,4125,O
",",4125,O
it,4125,O
is,4125,O
possible,4125,O
to,4125,O
construct,4125,O
a,4125,O
single,4125,O
DO3A,4125,O
chelate,4125,O
containing,4125,O
probe,4125,O
that,4125,O
can,4125,O
target,4125,O
both,4125,O
GRPR,4125,B-GENE-Y
and,4125,O
Y1,4125,B-GENE-Y
on,4125,O
human,4125,O
tumor,4125,O
cells,4125,O
.,4125,O
Induction,4126,O
of,4126,O
the,4126,O
metabolic,4126,O
regulator,4126,O
Txnip,4126,B-GENE-Y
in,4126,O
fasting-induced,4126,O
and,4126,O
natural,4126,O
torpor,4126,O
.,4126,O
Torpor,4127,O
is,4127,O
a,4127,O
physiological,4127,O
state,4127,O
characterised,4127,O
by,4127,O
controlled,4127,O
lowering,4127,O
of,4127,O
metabolic,4127,O
rate,4127,O
and,4127,O
core,4127,O
body,4127,O
temperature,4127,O
",",4127,O
allowing,4127,O
substantial,4127,O
energy,4127,O
savings,4127,O
during,4127,O
periods,4127,O
of,4127,O
reduced,4127,O
food,4127,O
availability,4127,O
or,4127,O
harsh,4127,O
environmental,4127,O
conditions,4127,O
.,4127,O
The,4128,O
hypothalamus,4128,O
coordinates,4128,O
energy,4128,O
homeostasis,4128,O
and,4128,O
thermoregulation,4128,O
",",4128,O
and,4128,O
plays,4128,O
a,4128,O
key,4128,O
role,4128,O
in,4128,O
directing,4128,O
torpor,4128,O
.,4128,O
We,4129,O
recently,4129,O
showed,4129,O
that,4129,O
mice,4129,O
lacking,4129,O
the,4129,O
orphan,4129,B-GENE-N
G,4129,I-GENE-N
protein,4129,I-GENE-N
coupled,4129,I-GENE-N
receptor,4129,I-GENE-N
Gpr50,4129,B-GENE-Y
readily,4129,O
enter,4129,O
torpor,4129,O
in,4129,O
response,4129,O
to,4129,O
fasting,4129,O
",",4129,O
and,4129,O
have,4129,O
now,4129,O
used,4129,O
these,4129,O
mice,4129,O
to,4129,O
conduct,4129,O
a,4129,O
microarray,4129,O
analysis,4129,O
of,4129,O
hypothalamic,4129,O
gene,4129,O
expression,4129,O
changes,4129,O
related,4129,O
to,4129,O
the,4129,O
torpor,4129,O
state,4129,O
.,4129,O
This,4130,O
revealed,4130,O
a,4130,O
strong,4130,O
induction,4130,O
of,4130,O
thioredoxin,4130,B-GENE-Y
interacting,4130,I-GENE-Y
protein,4130,I-GENE-Y
(,4130,O
Txnip,4130,B-GENE-Y
),4130,O
in,4130,O
the,4130,O
hypothalamus,4130,O
of,4130,O
torpid,4130,O
mice,4130,O
",",4130,O
which,4130,O
was,4130,O
confirmed,4130,O
by,4130,O
quantitative,4130,O
RT-PCR,4130,O
and,4130,O
Western,4130,O
blot,4130,O
analyses,4130,O
.,4130,O
In,4131,O
situ,4131,O
hybridisation,4131,O
identified,4131,O
the,4131,O
ependyma,4131,O
lining,4131,O
the,4131,O
third,4131,O
ventricle,4131,O
as,4131,O
the,4131,O
principal,4131,O
site,4131,O
of,4131,O
torpor-related,4131,O
expression,4131,O
of,4131,O
Txnip,4131,B-GENE-Y
.,4131,O
To,4132,O
characterise,4132,O
further,4132,O
the,4132,O
relationship,4132,O
between,4132,O
Txnip,4132,B-GENE-Y
and,4132,O
torpor,4132,O
",",4132,O
we,4132,O
profiled,4132,O
Txnip,4132,B-GENE-Y
expression,4132,O
in,4132,O
mice,4132,O
during,4132,O
prolonged,4132,O
fasting,4132,O
",",4132,O
cold,4132,O
exposure,4132,O
",",4132,O
and,4132,O
2-deoxyglucose-induced,4132,B-CHEMICAL
hypometabolism,4132,O
",",4132,O
as,4132,O
well,4132,O
as,4132,O
in,4132,O
naturally,4132,O
occurring,4132,O
torpor,4132,O
bouts,4132,O
in,4132,O
the,4132,O
Siberian,4132,O
hamster,4132,O
.,4132,O
Strikingly,4133,O
",",4133,O
pronounced,4133,O
upregulation,4133,O
of,4133,O
Txnip,4133,B-GENE-Y
expression,4133,O
was,4133,O
only,4133,O
observed,4133,O
in,4133,O
WT,4133,O
mice,4133,O
when,4133,O
driven,4133,O
into,4133,O
torpor,4133,O
",",4133,O
and,4133,O
during,4133,O
torpor,4133,O
in,4133,O
the,4133,O
Siberian,4133,O
hamster,4133,O
.,4133,O
Increase,4134,O
of,4134,O
Txnip,4134,B-GENE-Y
was,4134,O
not,4134,O
limited,4134,O
to,4134,O
the,4134,O
hypothalamus,4134,O
",",4134,O
with,4134,O
exaggerated,4134,O
expression,4134,O
in,4134,O
white,4134,O
adipose,4134,O
tissue,4134,O
",",4134,O
brown,4134,O
adipose,4134,O
tissue,4134,O
",",4134,O
and,4134,O
liver,4134,O
also,4134,O
demonstrated,4134,O
in,4134,O
torpid,4134,O
mice,4134,O
.,4134,O
Given,4135,O
the,4135,O
recent,4135,O
identification,4135,O
of,4135,O
Txnip,4135,B-GENE-Y
as,4135,O
a,4135,O
molecular,4135,O
nutrient,4135,O
sensor,4135,O
important,4135,O
in,4135,O
the,4135,O
regulation,4135,O
of,4135,O
energy,4135,O
metabolism,4135,O
",",4135,O
our,4135,O
data,4135,O
suggest,4135,O
that,4135,O
elevated,4135,O
Txnip,4135,B-GENE-Y
expression,4135,O
is,4135,O
critical,4135,O
to,4135,O
regulating,4135,O
energy,4135,O
expenditure,4135,O
and,4135,O
fuel,4135,O
utilisation,4135,O
during,4135,O
the,4135,O
extreme,4135,O
hypometabolic,4135,O
state,4135,O
of,4135,O
torpor,4135,O
.,4135,O
Design,4136,O
",",4136,O
synthesis,4136,O
and,4136,O
antiproliferative,4136,O
properties,4136,O
of,4136,O
some,4136,O
new,4136,O
5-substituted-2-iminobenzimidazole,4136,B-CHEMICAL
derivatives,4136,O
.,4136,O
Some,4137,O
new,4137,O
"1,3,5-substituted-2,3-dihydro-2-imino-benzimidazoles",4137,B-CHEMICAL
were,4137,O
synthesized,4137,O
under,4137,O
solid-liquid,4137,O
phase,4137,O
transfer,4137,O
catalysis,4137,O
conditions,4137,O
using,4137,O
5-substituted-2-aminobenzimidazoles,4137,B-CHEMICAL
as,4137,O
precursors,4137,O
in,4137,O
order,4137,O
to,4137,O
assess,4137,O
their,4137,O
cytotoxicity,4137,O
respectively,4137,O
proliferative,4137,O
activity,4137,O
.,4137,O
The,4138,O
structures,4138,O
of,4138,O
the,4138,O
compounds,4138,O
were,4138,O
confirmed,4138,O
by,4138,O
IR,4138,O
",",4138,O
(,4138,B-CHEMICAL
1,4138,I-CHEMICAL
),4138,I-CHEMICAL
H,4138,I-CHEMICAL
NMR,4138,O
",",4138,O
(,4138,B-CHEMICAL
13,4138,I-CHEMICAL
),4138,I-CHEMICAL
C,4138,I-CHEMICAL
NMR,4138,O
and,4138,O
elemental,4138,O
analysis,4138,O
.,4138,O
Compounds,4139,O
9-10,4139,O
",",4139,O
12,4139,O
and,4139,O
16-17,4139,O
were,4139,O
evaluated,4139,O
for,4139,O
their,4139,O
cytotoxical,4139,O
effect,4139,O
on,4139,O
four,4139,O
cancer,4139,O
cell,4139,O
lines,4139,O
:,4139,O
HT-29,4139,O
",",4139,O
breast,4139,O
cancer,4139,O
cells,4139,O
MDA-MB-231,4139,O
",",4139,O
HeLa,4139,O
",",4139,O
HepG2,4139,O
and,4139,O
as,4139,O
well,4139,O
as,4139,O
human,4139,O
diploid,4139,O
cell,4139,O
line,4139,O
Lep-3,4139,O
.,4139,O
Significant,4140,O
cytotoxicity,4140,O
of,4140,O
hydrazone,4140,B-CHEMICAL
16,4140,O
against,4140,O
MDA-MB-231,4140,O
was,4140,O
established,4140,O
by,4140,O
biologically,4140,O
study,4140,O
",",4140,O
the,4140,O
IC50,4140,O
was,4140,O
6.2,4140,O
nM,4140,O
while,4140,O
the,4140,O
EC50,4140,O
value,4140,O
to,4140,O
Lep,4140,O
3,4140,O
is,4140,O
0.21,4140,O
nM,4140,O
.,4140,O
Relative,4141,O
high,4141,O
antiproliferative,4141,O
effects,4141,O
of,4141,O
the,4141,O
acetate,4141,B-CHEMICAL
12,4141,O
and,4141,O
compound,4141,O
16,4141,O
against,4141,O
HT-29,4141,O
were,4141,O
ascertained,4141,O
and,4141,O
the,4141,O
calculated,4141,O
IC50,4141,O
values,4141,O
were,4141,O
IC50,4141,O
-,4141,O
0.85,4141,O
nM,4141,O
and,4141,O
IC50,4141,O
-,4141,O
2.83,4141,O
nM,4141,O
respectively,4141,O
.,4141,O
Cytotoxic,4142,O
activity,4142,O
against,4142,O
HeLa,4142,O
and,4142,O
HepG2,4142,O
cells,4142,O
was,4142,O
demonstrated,4142,O
by,4142,O
hydrazone,4142,B-CHEMICAL
17,4142,O
",",4142,O
IC50,4142,O
was,4142,O
7.2,4142,O
nM,4142,O
and,4142,O
117,4142,O
nM,4142,O
respectively,4142,O
.,4142,O
All,4143,O
tested,4143,O
compounds,4143,O
revealed,4143,O
proliferative,4143,O
activities,4143,O
to,4143,O
human,4143,O
diploid,4143,O
cell,4143,O
line,4143,O
Lep-3,4143,O
.,4143,O
The,4144,O
EC50,4144,O
values,4144,O
were,4144,O
in,4144,O
the,4144,O
range,4144,O
from,4144,O
0.05,4144,O
to,4144,O
16.91,4144,O
nM,4144,O
.,4144,O
The,4145,O
obtained,4145,O
results,4145,O
prove,4145,O
the,4145,O
selective,4145,O
cytotoxicity,4145,O
of,4145,O
the,4145,O
tested,4145,O
compounds,4145,O
and,4145,O
are,4145,O
promising,4145,O
for,4145,O
further,4145,O
evaluation,4145,O
of,4145,O
the,4145,O
investigated,4145,O
compounds,4145,O
in,4145,O
vivo,4145,O
experiments,4145,O
using,4145,O
experimentally,4145,O
induced,4145,O
tumors,4145,O
in,4145,O
laboratory,4145,O
animals,4145,O
.,4145,O
Immunomodulatory,4146,O
properties,4146,O
of,4146,O
multi-walled,4146,O
carbon,4146,B-CHEMICAL
nanotubes,4146,O
in,4146,O
peripheral,4146,O
blood,4146,O
mononuclear,4146,O
cells,4146,O
from,4146,O
healthy,4146,O
subjects,4146,O
and,4146,O
allergic,4146,O
patients,4146,O
.,4146,O
In,4147,O
the,4147,O
present,4147,O
study,4147,O
",",4147,O
we,4147,O
investigated,4147,O
the,4147,O
immunomodulatory,4147,O
activity,4147,O
of,4147,O
multi-walled,4147,O
carbon,4147,B-CHEMICAL
nanotubes,4147,O
(,4147,O
MWCNTs,4147,O
),4147,O
in,4147,O
peripheral,4147,O
blood,4147,O
mononuclear,4147,O
cells,4147,O
(,4147,O
PBMCs,4147,O
),4147,O
from,4147,O
healthy,4147,O
donors,4147,O
and,4147,O
mite-allergic,4147,O
subjects,4147,O
.,4147,O
Freshly,4148,O
prepared,4148,O
PBMCs,4148,O
",",4148,O
stimulated,4148,O
or,4148,O
not,4148,O
with,4148,O
Toll-like,4148,B-GENE-N
receptor,4148,I-GENE-N
(,4148,I-GENE-N
TLR,4148,I-GENE-N
),4148,I-GENE-N
1-9,4148,I-GENE-N
agonists,4148,O
",",4148,O
a,4148,O
T,4148,B-GENE-N
cell,4148,I-GENE-N
mitogen,4148,I-GENE-N
(,4148,O
phytohemagglutinin,4148,B-GENE-N
A,4148,I-GENE-N
),4148,O
or,4148,O
mite,4148,O
allergen,4148,O
extract,4148,O
were,4148,O
cultured,4148,O
in,4148,O
the,4148,O
presence,4148,O
or,4148,O
absence,4148,O
of,4148,O
MWCNTs,4148,O
.,4148,O
Secretion,4149,O
of,4149,O
TNF-α,4149,B-GENE-Y
",",4149,O
IL-2,4149,B-GENE-Y
",",4149,O
IL-5,4149,B-GENE-Y
",",4149,O
IL-6,4149,B-GENE-Y
",",4149,O
IL-12/23p40,4149,B-GENE-N
or,4149,O
IFN-γ,4149,B-GENE-Y
was,4149,O
quantified,4149,O
in,4149,O
the,4149,O
culture,4149,O
supernatants,4149,O
by,4149,O
ELISA,4149,O
.,4149,O
Basal,4150,O
secretion,4150,O
of,4150,O
all,4150,O
the,4150,O
cytokines,4150,B-GENE-N
was,4150,O
not,4150,O
altered,4150,O
by,4150,O
MWCNTs,4150,O
in,4150,O
PBMCs,4150,O
from,4150,O
both,4150,O
healthy,4150,O
donors,4150,O
and,4150,O
allergic,4150,O
subjects,4150,O
.,4150,O
In,4151,O
PBMCs,4151,O
from,4151,O
healthy,4151,O
donors,4151,O
",",4151,O
TNF-α,4151,B-GENE-Y
",",4151,O
IL-6,4151,B-GENE-Y
and,4151,O
IL-12/23p40,4151,B-GENE-N
secretion,4151,O
in,4151,O
response,4151,O
to,4151,O
the,4151,O
TLR4,4151,B-GENE-Y
agonist,4151,O
",",4151,O
lipopolysaccharide,4151,O
was,4151,O
however,4151,O
increased,4151,O
in,4151,O
a,4151,O
dose-dependent,4151,O
manner,4151,O
by,4151,O
MWCNTs,4151,O
.,4151,O
Significant,4152,O
increases,4152,O
in,4152,O
the,4152,O
release,4152,O
of,4152,O
these,4152,O
cytokines,4152,B-GENE-N
were,4152,O
also,4152,O
observed,4152,O
in,4152,O
PBMCs,4152,O
stimulated,4152,O
with,4152,O
a,4152,O
TLR2,4152,B-GENE-Y
or,4152,O
TLR3,4152,B-GENE-Y
agonist,4152,O
.,4152,O
MWCNTs,4153,O
also,4153,O
increased,4153,O
the,4153,O
release,4153,O
of,4153,O
IL-2,4153,B-GENE-Y
and,4153,O
IFN-γ,4153,B-GENE-Y
by,4153,O
PBMCs,4153,O
stimulated,4153,O
with,4153,O
a,4153,O
T,4153,B-GENE-N
cell,4153,I-GENE-N
mitogen,4153,I-GENE-N
.,4153,O
In,4154,O
contrast,4154,O
",",4154,O
MWCNTs,4154,O
inhibited,4154,O
allergen-induced,4154,O
IL-5,4154,B-GENE-Y
secretion,4154,O
by,4154,O
PBMCs,4154,O
from,4154,O
mite-allergic,4154,O
subjects,4154,O
.,4154,O
As,4155,O
well,4155,O
",",4155,O
MWCNTs,4155,O
altered,4155,O
the,4155,O
capacity,4155,O
of,4155,O
PBMC-derived,4155,O
monocytes,4155,O
to,4155,O
differentiate,4155,O
into,4155,O
functional,4155,O
dendritic,4155,O
cells,4155,O
.,4155,O
All,4156,O
together,4156,O
",",4156,O
our,4156,O
data,4156,O
suggest,4156,O
that,4156,O
according,4156,O
to,4156,O
its,4156,O
immune,4156,O
cell,4156,O
target,4156,O
",",4156,O
MWCNTs,4156,O
may,4156,O
either,4156,O
promote,4156,O
or,4156,O
suppress,4156,O
immune,4156,O
responses,4156,O
in,4156,O
humans,4156,O
.,4156,O
Further,4157,O
investigations,4157,O
are,4157,O
necessary,4157,O
to,4157,O
fully,4157,O
understand,4157,O
the,4157,O
complexity,4157,O
behind,4157,O
interactions,4157,O
of,4157,O
engineered,4157,O
nanoparticles,4157,O
with,4157,O
the,4157,O
immune,4157,O
system,4157,O
.,4157,O
2-aminothiazoles,4158,B-CHEMICAL
with,4158,O
improved,4158,O
pharmacotherapeutic,4158,O
properties,4158,O
for,4158,O
treatment,4158,O
of,4158,O
prion,4158,O
disease,4158,O
.,4158,O
Recently,4159,O
",",4159,O
we,4159,O
described,4159,O
the,4159,O
aminothiazole,4159,B-CHEMICAL
lead,4159,O
(,4159,B-CHEMICAL
4-biphenyl-4-ylthiazol-2-yl,4159,I-CHEMICAL
),4159,I-CHEMICAL
-,4159,I-CHEMICAL
(,4159,I-CHEMICAL
6-methylpyridin-2-yl,4159,I-CHEMICAL
),4159,I-CHEMICAL
-amine,4159,I-CHEMICAL
(,4159,O
1,4159,O
),4159,O
",",4159,O
which,4159,O
exhibits,4159,O
many,4159,O
desirable,4159,O
properties,4159,O
",",4159,O
including,4159,O
excellent,4159,O
stability,4159,O
in,4159,O
liver,4159,O
microsomes,4159,O
",",4159,O
oral,4159,O
bioavailability,4159,O
of,4159,O
∼40,4159,O
%,4159,O
",",4159,O
and,4159,O
high,4159,O
exposure,4159,O
in,4159,O
the,4159,O
brains,4159,O
of,4159,O
mice,4159,O
.,4159,O
Despite,4160,O
its,4160,O
good,4160,O
pharmacokinetic,4160,O
properties,4160,O
",",4160,O
compound,4160,O
1,4160,O
exhibited,4160,O
only,4160,O
modest,4160,O
potency,4160,O
in,4160,O
mouse,4160,O
neuroblastoma,4160,O
cells,4160,O
overexpressing,4160,O
the,4160,O
disease-causing,4160,O
prion,4160,B-GENE-Y
protein,4160,I-GENE-Y
PrP,4160,I-GENE-Y
(,4160,I-GENE-Y
Sc,4160,I-GENE-Y
),4160,I-GENE-Y
.,4160,O
Accordingly,4161,O
",",4161,O
we,4161,O
sought,4161,O
to,4161,O
identify,4161,O
analogues,4161,O
of,4161,O
1,4161,O
with,4161,O
improved,4161,O
antiprion,4161,O
potency,4161,O
in,4161,O
ScN2a-cl3,4161,O
cells,4161,O
while,4161,O
retaining,4161,O
similar,4161,O
or,4161,O
superior,4161,O
properties,4161,O
.,4161,O
Herein,4162,O
we,4162,O
report,4162,O
the,4162,O
discovery,4162,O
of,4162,O
improved,4162,O
lead,4162,O
compounds,4162,O
such,4162,O
as,4162,O
(,4162,B-CHEMICAL
6-methylpyridin-2-yl,4162,I-CHEMICAL
),4162,I-CHEMICAL
-,4162,I-CHEMICAL
[,4162,I-CHEMICAL
4-,4162,I-CHEMICAL
(,4162,I-CHEMICAL
4-pyridin-3-yl-phenyl,4162,I-CHEMICAL
),4162,I-CHEMICAL
thiazol-2-yl,4162,I-CHEMICAL
],4162,I-CHEMICAL
amine,4162,I-CHEMICAL
and,4162,O
cyclopropanecarboxylic,4162,B-CHEMICAL
acid,4162,I-CHEMICAL
(,4162,I-CHEMICAL
4-biphenylthiazol-2-yl,4162,I-CHEMICAL
),4162,I-CHEMICAL
amide,4162,I-CHEMICAL
",",4162,O
which,4162,O
exhibit,4162,O
brain,4162,O
exposure/EC50,4162,O
ratios,4162,O
at,4162,O
least,4162,O
tenfold,4162,O
greater,4162,O
than,4162,O
that,4162,O
of,4162,O
compound,4162,O
1,4162,O
.,4162,O
Immunotherapy,4163,O
for,4163,O
De,4163,O
Novo,4163,O
renal,4163,O
transplantation,4163,O
:,4163,O
what,4163,O
's,4163,O
in,4163,O
the,4163,O
pipeline,4163,O
?,4163,O
Immunosuppressive,4164,O
drugs,4164,O
have,4164,O
been,4164,O
traditionally,4164,O
developed,4164,O
to,4164,O
prevent,4164,O
acute,4164,O
rejection,4164,O
and,4164,O
to,4164,O
improve,4164,O
short-term,4164,O
kidney,4164,O
transplant,4164,O
outcomes,4164,O
.,4164,O
There,4165,O
is,4165,O
still,4165,O
a,4165,O
medical,4165,O
need,4165,O
to,4165,O
improve,4165,O
outcomes,4165,O
among,4165,O
subgroups,4165,O
of,4165,O
patients,4165,O
at,4165,O
higher,4165,O
risk,4165,O
for,4165,O
graft,4165,O
loss,4165,O
and,4165,O
to,4165,O
reduce,4165,O
cardiovascular,4165,O
",",4165,O
infectious,4165,O
and,4165,O
malignancy-associated,4165,O
morbidity,4165,O
and,4165,O
mortality,4165,O
",",4165,O
and,4165,O
improve,4165,O
long-term,4165,O
adherence,4165,O
.,4165,O
Several,4166,O
new,4166,O
immunosuppressive,4166,O
agents,4166,O
and,4166,O
formulations,4166,O
are,4166,O
undergoing,4166,O
clinical,4166,O
investigation,4166,O
and,4166,O
are,4166,O
discussed,4166,O
in,4166,O
this,4166,O
review.A,4166,O
modified,4166,O
release,4166,O
tacrolimus,4166,B-CHEMICAL
formulation,4166,O
(,4166,O
MR4,4166,O
),4166,O
for,4166,O
once-daily,4166,O
administration,4166,O
is,4166,O
undergoing,4166,O
phase,4166,O
III,4166,O
trials,4166,O
.,4166,O
It,4167,O
has,4167,O
been,4167,O
developed,4167,O
to,4167,O
be,4167,O
administered,4167,O
de,4167,O
novo,4167,O
or,4167,O
for,4167,O
maintenance,4167,O
using,4167,O
the,4167,O
same,4167,O
therapeutic,4167,O
target,4167,O
tacrolimus,4167,B-CHEMICAL
trough,4167,O
concentrations,4167,O
as,4167,O
for,4167,O
the,4167,O
original,4167,O
formulation,4167,O
.,4167,O
Belatacept,4168,O
(,4168,O
LEA29Y,4168,O
),4168,O
",",4168,O
a,4168,O
second,4168,O
generation,4168,O
cytotoxic-T-lymphocyte-associated,4168,B-GENE-Y
antigen,4168,I-GENE-Y
immunoglobulin,4168,B-GENE-N
(,4168,O
CTLA4-Ig,4168,B-GENE-Y
),4168,O
",",4168,O
blocks,4168,O
the,4168,O
interaction,4168,O
between,4168,O
CD80/86,4168,B-GENE-N
and,4168,O
CD28,4168,B-GENE-Y
costimulatory,4168,O
pathways,4168,O
.,4168,O
In,4169,O
phase,4169,O
II,4169,O
trials,4169,O
",",4169,O
belatacept,4169,O
was,4169,O
as,4169,O
effective,4169,O
as,4169,O
ciclosporin,4169,B-CHEMICAL
(,4169,O
cyclosporine,4169,B-CHEMICAL
),4169,O
when,4169,O
administered,4169,O
in,4169,O
combination,4169,O
with,4169,O
basiliximab,4169,O
",",4169,O
mycophenolate,4169,B-CHEMICAL
mofetil,4169,I-CHEMICAL
(,4169,O
MMF,4169,B-CHEMICAL
),4169,O
and,4169,O
corticosteroids,4169,O
.,4169,O
Currently,4170,O
",",4170,O
belatacept,4170,O
is,4170,O
undergoing,4170,O
phase,4170,O
III,4170,O
trials,4170,O
including,4170,O
one,4170,O
study,4170,O
in,4170,O
recipients,4170,O
of,4170,O
organs,4170,O
from,4170,O
expanded,4170,O
criteria,4170,O
donors,4170,O
.,4170,O
Inhibitors,4171,O
of,4171,O
the,4171,O
Janus,4171,B-GENE-Y
protein,4171,I-GENE-Y
tyrosine,4171,I-GENE-Y
kinase,4171,I-GENE-Y
(,4171,I-GENE-Y
JAK,4171,I-GENE-Y
),4171,I-GENE-Y
-3,4171,I-GENE-Y
show,4171,O
some,4171,O
selectivity,4171,O
for,4171,O
cells,4171,O
of,4171,O
the,4171,O
lymphoid,4171,O
lineage,4171,O
and,4171,O
have,4171,O
been,4171,O
shown,4171,O
to,4171,O
be,4171,O
effective,4171,O
in,4171,O
late,4171,O
preclinical,4171,O
transplant,4171,O
models,4171,O
.,4171,O
The,4172,O
most,4172,O
frequent,4172,O
adverse,4172,O
effects,4172,O
have,4172,O
been,4172,O
related,4172,O
to,4172,O
nonspecific,4172,O
binding,4172,O
to,4172,O
JAK2,4172,B-GENE-Y
kinases,4172,B-GENE-N
.,4172,O
CP-690550,4173,B-CHEMICAL
",",4173,O
a,4173,O
JAK3,4173,B-GENE-Y
inhibitor,4173,O
is,4173,O
currently,4173,O
in,4173,O
phase,4173,O
II,4173,O
clinical,4173,O
trials.FK778,4173,O
",",4173,O
is,4173,O
a,4173,O
synthetic,4173,O
malononitrilamide,4173,B-CHEMICAL
that,4173,O
targets,4173,O
the,4173,O
critical,4173,O
enzyme,4173,O
of,4173,O
the,4173,O
de,4173,O
novo,4173,O
pyrimidine,4173,B-CHEMICAL
synthesis,4173,O
",",4173,O
dihydroorotic,4173,B-GENE-Y
acid,4173,I-GENE-Y
dehydrogenase,4173,I-GENE-Y
",",4173,O
and,4173,O
receptor-associated,4173,B-GENE-N
tyrosine,4173,I-GENE-N
kinases,4173,I-GENE-N
has,4173,O
completed,4173,O
phase,4173,O
II,4173,O
trials,4173,O
.,4173,O
FK778,4174,B-CHEMICAL
also,4174,O
shows,4174,O
antiviral,4174,O
activities,4174,O
that,4174,O
have,4174,O
been,4174,O
tested,4174,O
in,4174,O
patients,4174,O
with,4174,O
polyomavirus,4174,O
nephropathy,4174,O
.,4174,O
Fingolimod,4175,B-CHEMICAL
(,4175,O
FTY720,4175,B-CHEMICAL
),4175,O
",",4175,O
a,4175,O
synthetic,4175,O
sphingosine,4175,B-GENE-N
phosphate,4175,I-GENE-N
receptor,4175,I-GENE-N
modulator,4175,O
that,4175,O
reduces,4175,O
the,4175,O
recirculation,4175,O
of,4175,O
lymphocytes,4175,O
to,4175,O
blood,4175,O
and,4175,O
peripheral,4175,O
tissues,4175,O
including,4175,O
inflammatory,4175,O
lesions,4175,O
and,4175,O
graft,4175,O
sites,4175,O
is,4175,O
undergoing,4175,O
phase,4175,O
III,4175,O
trials,4175,O
.,4175,O
Although,4176,O
the,4176,O
efficacy,4176,O
of,4176,O
fingolimod,4176,B-CHEMICAL
is,4176,O
similar,4176,O
to,4176,O
MMF,4176,B-CHEMICAL
in,4176,O
patients,4176,O
receiving,4176,O
full,4176,O
doses,4176,O
of,4176,O
ciclosporin,4176,B-CHEMICAL
",",4176,O
safety,4176,O
issues,4176,O
such,4176,O
as,4176,O
a,4176,O
negative,4176,O
chronotropic,4176,O
effect,4176,O
",",4176,O
macular,4176,O
oedema,4176,O
",",4176,O
pulmonary,4176,O
adverse,4176,O
reactions,4176,O
and,4176,O
graft,4176,O
function,4176,O
resulted,4176,O
in,4176,O
premature,4176,O
discontinuation,4176,O
of,4176,O
the,4176,O
development,4176,O
programme,4176,O
for,4176,O
kidney,4176,O
transplantation,4176,O
.,4176,O
Because,4177,O
there,4177,O
was,4177,O
no,4177,O
clear,4177,O
clinical,4177,O
benefit,4177,O
over,4177,O
treatment,4177,O
options,4177,O
",",4177,O
the,4177,O
clinical,4177,O
development,4177,O
programme,4177,O
of,4177,O
FK778,4177,B-CHEMICAL
was,4177,O
discontinued.Finally,4177,O
",",4177,O
a,4177,O
new,4177,O
evolving,4177,O
strategy,4177,O
with,4177,O
powerful,4177,O
induction-induced,4177,O
prolonged,4177,O
T-cell,4177,O
depletion,4177,O
followed,4177,O
by,4177,O
low-dose,4177,O
immunosuppressive,4177,O
monotherapy,4177,O
is,4177,O
showing,4177,O
promising,4177,O
results,4177,O
.,4177,O
Effect,4178,O
of,4178,O
apocalmodulin,4178,B-GENE-Y
on,4178,O
recombinant,4178,O
human,4178,B-GENE-Y
brain,4178,I-GENE-Y
glutamic,4178,I-GENE-Y
acid,4178,I-GENE-Y
decarboxylase,4178,I-GENE-Y
.,4178,O
In,4179,O
this,4179,O
work,4179,O
",",4179,O
we,4179,O
report,4179,O
that,4179,O
the,4179,O
recombinant,4179,O
glutathione,4179,B-GENE-N
S-transferase,4179,I-GENE-N
(,4179,O
GST,4179,B-GENE-N
),4179,O
-human,4179,O
L-glutamic,4179,I-GENE-Y
acid,4179,I-GENE-Y
decarboxylase,4179,I-GENE-Y
(,4179,O
HGAD,4179,B-GENE-Y
),4179,O
isoforms,4179,O
",",4179,O
65-kDa,4179,B-GENE-Y
L-glutamic,4179,I-GENE-Y
acid,4179,I-GENE-Y
decarboxylase,4179,I-GENE-Y
(,4179,O
GAD,4179,B-GENE-Y
),4179,O
(,4179,O
GST-HGAD65,4179,B-GENE-N
),4179,O
fusion,4179,O
protein,4179,O
or,4179,O
free,4179,O
truncated,4179,O
HGAD65,4179,B-GENE-Y
",",4179,O
were,4179,O
activated,4179,O
by,4179,O
apocalmodulin,4179,B-GENE-Y
(,4179,O
ApoCaM,4179,B-GENE-Y
),4179,O
to,4179,O
an,4179,O
extent,4179,O
of,4179,O
60,4179,O
%,4179,O
.,4179,O
Both,4180,O
truncated,4180,O
forms,4180,O
of,4180,O
GAD67,4180,B-GENE-Y
(,4180,O
tGAD67,4180,B-GENE-Y
),4180,O
",",4180,O
HGAD67,4180,B-GENE-Y
(,4180,I-GENE-Y
Delta1-70,4180,I-GENE-Y
),4180,I-GENE-Y
and,4180,O
HGAD67,4180,B-GENE-Y
(,4180,I-GENE-Y
Delta1-90,4180,I-GENE-Y
),4180,I-GENE-Y
",",4180,O
were,4180,O
markedly,4180,O
activated,4180,O
by,4180,O
ApoCaM,4180,B-GENE-Y
to,4180,O
an,4180,O
extent,4180,O
of,4180,O
141,4180,O
and,4180,O
85,4180,O
%,4180,O
",",4180,O
respectively,4180,O
",",4180,O
while,4180,O
GST-HGAD67,4180,B-GENE-N
was,4180,O
not,4180,O
significantly,4180,O
affected,4180,O
.,4180,O
The,4181,O
activation,4181,O
appears,4181,O
to,4181,O
be,4181,O
due,4181,O
to,4181,O
an,4181,O
increase,4181,O
of,4181,O
GAD,4181,B-GENE-Y
affinity,4181,O
for,4181,O
its,4181,O
cofactor,4181,O
",",4181,O
pyridoxal,4181,B-CHEMICAL
phosphate,4181,I-CHEMICAL
(,4181,O
PLP,4181,B-CHEMICAL
),4181,O
.,4181,O
This,4182,O
conclusion,4182,O
is,4182,O
based,4182,O
on,4182,O
the,4182,O
following,4182,O
observations,4182,O
.,4182,O
Firstly,4183,O
",",4183,O
the,4183,O
V,4183,O
(,4183,O
max,4183,O
),4183,O
of,4183,O
GAD,4183,B-GENE-Y
was,4183,O
increased,4183,O
when,4183,O
ApoCaM,4183,B-GENE-Y
was,4183,O
present,4183,O
whereas,4183,O
the,4183,O
affinity,4183,O
for,4183,O
the,4183,O
substrate,4183,O
",",4183,O
glutamate,4183,B-CHEMICAL
",",4183,O
was,4183,O
not,4183,O
affected,4183,O
.,4183,O
Secondly,4184,O
",",4184,O
the,4184,O
affinity,4184,O
of,4184,O
GAD,4184,B-GENE-Y
for,4184,O
PLP,4184,B-CHEMICAL
was,4184,O
increased,4184,O
in,4184,O
the,4184,O
presence,4184,O
of,4184,O
ApoCaM,4184,B-GENE-Y
.,4184,O
Thirdly,4185,O
",",4185,O
results,4185,O
from,4185,O
calmodulin-agarose,4185,B-GENE-Y
affinity,4185,O
column,4185,O
chromatography,4185,O
studies,4185,O
indicated,4185,O
a,4185,O
direct,4185,O
interaction,4185,O
or,4185,O
binding,4185,O
between,4185,O
ApoCaM,4185,B-GENE-Y
and,4185,O
GAD,4185,B-GENE-Y
.,4185,O
Fourthly,4186,O
",",4186,O
ApoCaM,4186,B-GENE-Y
was,4186,O
found,4186,O
to,4186,O
be,4186,O
copurified,4186,O
with,4186,O
GAD65/GAD67,4186,B-GENE-Y
by,4186,O
anti-GAD65/67,4186,O
immunoaffinity,4186,O
column,4186,O
using,4186,O
rat,4186,O
brain,4186,O
extract,4186,O
.,4186,O
Hence,4187,O
",",4187,O
it,4187,O
is,4187,O
proposed,4187,O
that,4187,O
a,4187,O
conformational,4187,O
change,4187,O
is,4187,O
induced,4187,O
when,4187,O
ApoCaM,4187,B-GENE-Y
interacts,4187,O
with,4187,O
GAD65,4187,B-GENE-Y
or,4187,O
tGAD67,4187,B-GENE-Y
",",4187,O
resulting,4187,O
in,4187,O
an,4187,O
increase,4187,O
of,4187,O
GAD,4187,B-GENE-Y
affinity,4187,O
for,4187,O
PLP,4187,B-CHEMICAL
and,4187,O
the,4187,O
activation,4187,O
of,4187,O
GAD,4187,B-GENE-Y
.,4187,O
The,4188,O
physiological,4188,O
significance,4188,O
of,4188,O
the,4188,O
interaction,4188,O
between,4188,O
GAD,4188,B-GENE-Y
and,4188,O
ApoCaM,4188,B-GENE-Y
is,4188,O
discussed,4188,O
.,4188,O
Hydrogen,4189,B-CHEMICAL
sulfide,4189,I-CHEMICAL
acts,4189,O
as,4189,O
a,4189,O
mediator,4189,O
of,4189,O
inflammation,4189,O
in,4189,O
acute,4189,O
pancreatitis,4189,O
:,4189,O
in,4189,O
vitro,4189,O
studies,4189,O
using,4189,O
isolated,4189,O
mouse,4189,O
pancreatic,4189,O
acinar,4189,O
cells,4189,O
.,4189,O
Hydrogen,4190,B-CHEMICAL
sulphide,4190,I-CHEMICAL
(,4190,O
H,4190,B-CHEMICAL
(,4190,I-CHEMICAL
2,4190,I-CHEMICAL
),4190,I-CHEMICAL
S,4190,I-CHEMICAL
),4190,O
is,4190,O
synthesized,4190,O
from,4190,O
L-cysteine,4190,B-CHEMICAL
via,4190,O
the,4190,O
action,4190,O
of,4190,O
cystathionine-gamma-lyase,4190,B-GENE-Y
(,4190,O
CSE,4190,B-GENE-Y
),4190,O
and,4190,O
cystathionine-beta-synthase,4190,B-GENE-Y
(,4190,O
CBS,4190,B-GENE-Y
),4190,O
.,4190,O
We,4191,O
have,4191,O
earlier,4191,O
shown,4191,O
that,4191,O
H,4191,B-CHEMICAL
(,4191,I-CHEMICAL
2,4191,I-CHEMICAL
),4191,I-CHEMICAL
S,4191,I-CHEMICAL
acts,4191,O
as,4191,O
a,4191,O
mediator,4191,O
of,4191,O
inflammation,4191,O
.,4191,O
However,4192,O
the,4192,O
mechanism,4192,O
remains,4192,O
unclear,4192,O
.,4192,O
In,4193,O
this,4193,O
study,4193,O
",",4193,O
we,4193,O
investigated,4193,O
the,4193,O
presence,4193,O
of,4193,O
H,4193,B-CHEMICAL
(,4193,I-CHEMICAL
2,4193,I-CHEMICAL
),4193,I-CHEMICAL
S,4193,I-CHEMICAL
and,4193,O
the,4193,O
expression,4193,O
of,4193,O
H,4193,B-CHEMICAL
(,4193,I-CHEMICAL
2,4193,I-CHEMICAL
),4193,I-CHEMICAL
S,4193,I-CHEMICAL
synthesizing,4193,O
enzymes,4193,O
",",4193,O
CSE,4193,B-GENE-Y
and,4193,O
CBS,4193,B-GENE-Y
",",4193,O
in,4193,O
isolated,4193,O
mouse,4193,O
pancreatic,4193,O
acini,4193,O
.,4193,O
Pancreatic,4194,O
acinar,4194,O
cells,4194,O
from,4194,O
mice,4194,O
were,4194,O
incubated,4194,O
with,4194,O
or,4194,O
without,4194,O
caerulein,4194,B-CHEMICAL
(,4194,O
10,4194,O
(,4194,O
-7,4194,O
),4194,O
M,4194,O
for,4194,O
30,4194,O
and,4194,O
60,4194,O
min,4194,O
),4194,O
.,4194,O
Caerulein,4195,B-CHEMICAL
increased,4195,O
the,4195,O
levels,4195,O
of,4195,O
H,4195,B-CHEMICAL
(,4195,I-CHEMICAL
2,4195,I-CHEMICAL
),4195,I-CHEMICAL
S,4195,I-CHEMICAL
and,4195,O
CSE,4195,B-GENE-Y
mRNA,4195,O
expression,4195,O
while,4195,O
CBS,4195,B-GENE-Y
mRNA,4195,O
expression,4195,O
was,4195,O
decreased,4195,O
.,4195,O
In,4196,O
addition,4196,O
",",4196,O
cells,4196,O
pre-treated,4196,O
with,4196,O
DL-propargylglycine,4196,B-CHEMICAL
(,4196,O
PAG,4196,B-CHEMICAL
",",4196,O
3,4196,O
mM,4196,O
),4196,O
",",4196,O
a,4196,O
CSE,4196,B-GENE-Y
inhibitor,4196,O
",",4196,O
reduced,4196,O
the,4196,O
formation,4196,O
of,4196,O
H,4196,B-CHEMICAL
(,4196,I-CHEMICAL
2,4196,I-CHEMICAL
),4196,I-CHEMICAL
S,4196,I-CHEMICAL
in,4196,O
caerulein,4196,B-CHEMICAL
treated,4196,O
cells,4196,O
",",4196,O
suggesting,4196,O
that,4196,O
CSE,4196,B-GENE-Y
may,4196,O
be,4196,O
the,4196,O
main,4196,O
enzyme,4196,O
involved,4196,O
in,4196,O
H,4196,B-CHEMICAL
(,4196,I-CHEMICAL
2,4196,I-CHEMICAL
),4196,I-CHEMICAL
S,4196,I-CHEMICAL
formation,4196,O
in,4196,O
mouse,4196,O
acinar,4196,O
cells,4196,O
.,4196,O
Furthermore,4197,O
",",4197,O
substance,4197,B-GENE-Y
P,4197,I-GENE-Y
(,4197,O
SP,4197,B-GENE-Y
),4197,O
concentration,4197,O
in,4197,O
the,4197,O
acini,4197,O
and,4197,O
expression,4197,O
of,4197,O
SP,4197,B-GENE-Y
gene,4197,O
(,4197,O
preprotachykinin-A,4197,B-GENE-Y
",",4197,O
PPT-A,4197,B-GENE-Y
),4197,O
and,4197,O
neurokinin-1,4197,B-GENE-Y
receptor,4197,I-GENE-Y
(,4197,O
NK-1R,4197,B-GENE-Y
),4197,O
",",4197,O
the,4197,O
primary,4197,O
receptor,4197,O
for,4197,O
SP,4197,B-GENE-Y
",",4197,O
are,4197,O
increased,4197,O
in,4197,O
secretagogue,4197,O
caerulein-treated,4197,B-CHEMICAL
acinar,4197,O
cells,4197,O
.,4197,O
Inhibition,4198,O
of,4198,O
endogenous,4198,O
production,4198,O
of,4198,O
H,4198,B-CHEMICAL
(,4198,I-CHEMICAL
2,4198,I-CHEMICAL
),4198,I-CHEMICAL
S,4198,I-CHEMICAL
by,4198,O
PAG,4198,B-CHEMICAL
significantly,4198,O
suppressed,4198,O
SP,4198,B-GENE-Y
concentration,4198,O
",",4198,O
PPT-A,4198,B-GENE-Y
expression,4198,O
and,4198,O
NK1-R,4198,B-GENE-Y
expression,4198,O
in,4198,O
the,4198,O
acini,4198,O
.,4198,O
To,4199,O
determine,4199,O
whether,4199,O
H,4199,B-CHEMICAL
(,4199,I-CHEMICAL
2,4199,I-CHEMICAL
),4199,I-CHEMICAL
S,4199,I-CHEMICAL
itself,4199,O
provoked,4199,O
inflammation,4199,O
in,4199,O
acinar,4199,O
cells,4199,O
",",4199,O
the,4199,O
cells,4199,O
were,4199,O
treated,4199,O
with,4199,O
H,4199,B-CHEMICAL
(,4199,I-CHEMICAL
2,4199,I-CHEMICAL
),4199,I-CHEMICAL
S,4199,I-CHEMICAL
donor,4199,O
drug,4199,O
",",4199,O
sodium,4199,B-CHEMICAL
hydrosulphide,4199,I-CHEMICAL
(,4199,O
NaHS,4199,B-CHEMICAL
),4199,O
",",4199,O
(,4199,O
10,4199,O
",",4199,O
50,4199,O
and,4199,O
100,4199,O
muM,4199,O
),4199,O
",",4199,O
that,4199,O
resulted,4199,O
in,4199,O
a,4199,O
significant,4199,O
increase,4199,O
in,4199,O
SP,4199,B-GENE-Y
concentration,4199,O
and,4199,O
expression,4199,O
of,4199,O
PPT-A,4199,B-GENE-Y
and,4199,O
NK1-R,4199,B-GENE-Y
in,4199,O
acinar,4199,O
cells,4199,O
.,4199,O
These,4200,O
results,4200,O
suggest,4200,O
that,4200,O
the,4200,O
pro-inflammatory,4200,O
effect,4200,O
of,4200,O
H,4200,B-CHEMICAL
(,4200,I-CHEMICAL
2,4200,I-CHEMICAL
),4200,I-CHEMICAL
S,4200,I-CHEMICAL
may,4200,O
be,4200,O
mediated,4200,O
by,4200,O
SP-NK-1R,4200,B-GENE-Y
related,4200,O
pathway,4200,O
in,4200,O
mouse,4200,O
pancreatic,4200,O
acinar,4200,O
cells,4200,O
.,4200,O
Thermodynamic,4201,O
determination,4201,O
of,4201,O
the,4201,O
binding,4201,O
constants,4201,O
of,4201,O
angiotensin-converting,4201,B-GENE-Y
enzyme,4201,I-GENE-Y
inhibitors,4201,O
by,4201,O
a,4201,O
displacement,4201,O
method,4201,O
.,4201,O
Somatic,4202,O
angiotensin,4202,B-GENE-Y
I-converting,4202,I-GENE-Y
enzyme,4202,I-GENE-Y
(,4202,O
s-ACE,4202,O
),4202,O
plays,4202,O
a,4202,O
central,4202,O
role,4202,O
in,4202,O
blood,4202,O
pressure,4202,O
regulation,4202,O
and,4202,O
has,4202,O
been,4202,O
the,4202,O
target,4202,O
of,4202,O
most,4202,O
antihypertensive,4202,O
drugs,4202,O
.,4202,O
A,4203,O
displacement,4203,O
isothermal,4203,O
titration,4203,O
calorimetry,4203,O
method,4203,O
has,4203,O
been,4203,O
used,4203,O
to,4203,O
accurately,4203,O
determine,4203,O
the,4203,O
binding,4203,O
constant,4203,O
of,4203,O
three,4203,O
strong,4203,O
s-ACE,4203,O
inhibitors,4203,O
.,4203,O
Under,4204,O
the,4204,O
experimental,4204,O
conditions,4204,O
studied,4204,O
in,4204,O
this,4204,O
work,4204,O
",",4204,O
the,4204,O
relative,4204,O
potency,4204,O
of,4204,O
the,4204,O
inhibitors,4204,O
was,4204,O
determined,4204,O
to,4204,O
be,4204,O
enalaprilat,4204,B-CHEMICAL
>,4204,O
lisinopril,4204,B-CHEMICAL
>,4204,O
captopril,4204,B-CHEMICAL
.,4204,O
We,4205,O
analyze,4205,O
the,4205,O
thermodynamic,4205,O
behaviour,4205,O
of,4205,O
the,4205,O
binding,4205,O
process,4205,O
using,4205,O
the,4205,O
new,4205,O
structural,4205,O
information,4205,O
provided,4205,O
by,4205,O
the,4205,O
ACE,4205,B-GENE-Y
structures,4205,O
",",4205,O
as,4205,O
well,4205,O
as,4205,O
the,4205,O
conformational,4205,O
changes,4205,O
that,4205,O
occur,4205,O
upon,4205,O
binding,4205,O
.,4205,O
Antiaggressive,4206,O
activity,4206,O
of,4206,O
central,4206,O
oxytocin,4206,B-GENE-Y
in,4206,O
male,4206,O
rats,4206,O
.,4206,O
RATIONALE,4207,O
:,4207,O
A,4207,O
substantial,4207,O
body,4207,O
of,4207,O
research,4207,O
suggests,4207,O
that,4207,O
the,4207,O
neuropeptide,4207,O
oxytocin,4207,B-GENE-Y
promotes,4207,O
social,4207,O
affiliative,4207,O
behaviors,4207,O
in,4207,O
a,4207,O
wide,4207,O
range,4207,O
of,4207,O
animals,4207,O
including,4207,O
humans,4207,O
.,4207,O
However,4208,O
",",4208,O
its,4208,O
antiaggressive,4208,O
action,4208,O
has,4208,O
not,4208,O
been,4208,O
unequivocally,4208,O
demonstrated,4208,O
in,4208,O
male,4208,O
laboratory,4208,O
rodents,4208,O
.,4208,O
OBJECTIVE,4209,O
:,4209,O
Our,4209,O
primary,4209,O
goal,4209,O
was,4209,O
to,4209,O
examine,4209,O
the,4209,O
putative,4209,O
serenic,4209,O
effect,4209,O
of,4209,O
oxytocin,4209,B-GENE-Y
in,4209,O
a,4209,O
feral,4209,O
strain,4209,O
(,4209,O
wild,4209,O
type,4209,O
Groningen,4209,O
",",4209,O
WTG,4209,O
),4209,O
of,4209,O
rats,4209,O
that,4209,O
generally,4209,O
show,4209,O
a,4209,O
much,4209,O
broader,4209,O
variation,4209,O
and,4209,O
higher,4209,O
levels,4209,O
of,4209,O
intermale,4209,O
aggression,4209,O
than,4209,O
commonly,4209,O
used,4209,O
laboratory,4209,O
strains,4209,O
of,4209,O
rats,4209,O
.,4209,O
METHODS,4210,O
:,4210,O
Resident,4210,O
animals,4210,O
were,4210,O
intracerebroventricularly,4210,O
(,4210,O
icv,4210,O
),4210,O
administered,4210,O
with,4210,O
different,4210,O
doses,4210,O
of,4210,O
synthetic,4210,O
oxytocin,4210,B-GENE-Y
and,4210,O
oxytocin,4210,B-GENE-Y
receptor,4210,I-GENE-Y
antagonist,4210,O
",",4210,O
alone,4210,O
and,4210,O
in,4210,O
combination,4210,O
",",4210,O
in,4210,O
order,4210,O
to,4210,O
manipulate,4210,O
brain,4210,O
oxytocin,4210,B-GENE-Y
functioning,4210,O
and,4210,O
to,4210,O
assess,4210,O
their,4210,O
behavioral,4210,O
response,4210,O
to,4210,O
an,4210,O
intruder,4210,O
.,4210,O
RESULTS,4211,O
:,4211,O
Our,4211,O
data,4211,O
clearly,4211,O
demonstrate,4211,O
that,4211,O
acute,4211,O
icv,4211,O
administered,4211,O
oxytocin,4211,B-GENE-Y
produces,4211,O
dose-dependent,4211,O
and,4211,O
receptor-selective,4211,O
changes,4211,O
in,4211,O
social,4211,O
behavior,4211,O
",",4211,O
reducing,4211,O
aggression,4211,O
and,4211,O
potentiating,4211,O
social,4211,O
exploration,4211,O
.,4211,O
These,4212,O
antiaggressive,4212,O
effects,4212,O
are,4212,O
stronger,4212,O
in,4212,O
the,4212,O
more,4212,O
offensive,4212,O
rats,4212,O
.,4212,O
On,4213,O
the,4213,O
other,4213,O
hand,4213,O
",",4213,O
administration,4213,O
of,4213,O
an,4213,O
oxytocin,4213,B-GENE-Y
receptor,4213,I-GENE-Y
antagonist,4213,O
tends,4213,O
to,4213,O
increase,4213,O
(,4213,O
nonsignificantly,4213,O
),4213,O
aggression,4213,O
only,4213,O
in,4213,O
low-medium,4213,O
aggressive,4213,O
animals,4213,O
.,4213,O
CONCLUSIONS,4214,O
:,4214,O
These,4214,O
results,4214,O
suggest,4214,O
that,4214,O
transiently,4214,O
enhancing,4214,O
brain,4214,O
oxytocin,4214,B-GENE-Y
function,4214,O
has,4214,O
potent,4214,O
antiaggressive,4214,O
effects,4214,O
",",4214,O
whereas,4214,O
its,4214,O
attenuation,4214,O
tends,4214,O
to,4214,O
enhance,4214,O
aggressiveness,4214,O
.,4214,O
In,4215,O
addition,4215,O
",",4215,O
a,4215,O
possible,4215,O
inverse,4215,O
relationship,4215,O
between,4215,O
trait,4215,O
aggression,4215,O
and,4215,O
endogenous,4215,O
oxytocinergic,4215,O
signaling,4215,O
is,4215,O
revealed,4215,O
.,4215,O
Overall,4216,O
",",4216,O
this,4216,O
study,4216,O
emphasizes,4216,O
the,4216,O
importance,4216,O
of,4216,O
brain,4216,O
oxytocinergic,4216,O
signaling,4216,O
for,4216,O
regulating,4216,O
intermale,4216,O
offensive,4216,O
aggression,4216,O
.,4216,O
This,4217,O
study,4217,O
supports,4217,O
the,4217,O
suggestion,4217,O
that,4217,O
oxytocin,4217,B-GENE-Y
receptor,4217,I-GENE-Y
agonists,4217,O
could,4217,O
clinically,4217,O
be,4217,O
useful,4217,O
for,4217,O
curbing,4217,O
heightened,4217,O
aggression,4217,O
seen,4217,O
in,4217,O
a,4217,O
range,4217,O
of,4217,O
neuropsychiatric,4217,O
disorders,4217,O
like,4217,O
antisocial,4217,O
personality,4217,O
disorder,4217,O
",",4217,O
autism,4217,O
",",4217,O
and,4217,O
addiction,4217,O
.,4217,O
Possible,4218,O
Therapeutic,4218,O
Uses,4218,O
of,4218,O
Salvia,4218,O
triloba,4218,O
and,4218,O
Piper,4218,O
nigrum,4218,O
in,4218,O
Alzheimer,4218,O
's,4218,O
Disease-Induced,4218,O
Rats,4218,O
.,4218,O
Abstract,4219,O
This,4219,O
study,4219,O
aimed,4219,O
to,4219,O
investigate,4219,O
the,4219,O
role,4219,O
of,4219,O
Salvia,4219,O
triloba,4219,O
L.,4219,O
and,4219,O
Piper,4219,O
nigrum,4219,O
extracts,4219,O
in,4219,O
ameliorating,4219,O
neuroinflammatory,4219,O
insults,4219,O
characteristic,4219,O
of,4219,O
Alzheimer,4219,O
's,4219,O
disease,4219,O
(,4219,O
AD,4219,O
),4219,O
in,4219,O
an,4219,O
experimentally,4219,O
induced,4219,O
rat,4219,O
model,4219,O
.,4219,O
Adult,4220,O
male,4220,O
Sprague-Dawley,4220,O
rats,4220,O
were,4220,O
classified,4220,O
into,4220,O
Group,4220,O
1,4220,O
(,4220,O
n=10,4220,O
),4220,O
:,4220,O
normal,4220,O
healthy,4220,O
animals,4220,O
serving,4220,O
as,4220,O
the,4220,O
negative,4220,O
control,4220,O
group,4220,O
;,4220,O
Group,4220,O
2,4220,O
(,4220,O
n=60,4220,O
),4220,O
:,4220,O
the,4220,O
AD-induced,4220,O
group,4220,O
.,4220,O
After,4221,O
AD,4221,O
induction,4221,O
",",4221,O
animals,4221,O
in,4221,O
the,4221,O
AD-induced,4221,O
group,4221,O
were,4221,O
divided,4221,O
randomly,4221,O
and,4221,O
equally,4221,O
into,4221,O
6,4221,O
subgroups,4221,O
.,4221,O
The,4222,O
first,4222,O
subgroup,4222,O
served,4222,O
as,4222,O
AD,4222,O
control,4222,O
;,4222,O
the,4222,O
second,4222,O
one,4222,O
",",4222,O
which,4222,O
served,4222,O
as,4222,O
positive,4222,O
control,4222,O
",",4222,O
was,4222,O
treated,4222,O
orally,4222,O
with,4222,O
the,4222,O
conventional,4222,O
therapy,4222,O
for,4222,O
AD,4222,O
(,4222,O
rivastigmine,4222,B-CHEMICAL
),4222,O
at,4222,O
a,4222,O
dose,4222,O
of,4222,O
0.3,4222,O
mg/kg,4222,O
body,4222,O
weight,4222,O
(,4222,O
b.w,4222,O
.,4222,O
),4222,O
daily,4223,O
for,4223,O
3,4223,O
months,4223,O
.,4223,O
The,4224,O
third,4224,O
and,4224,O
fourth,4224,O
subgroups,4224,O
were,4224,O
",",4224,O
respectively,4224,O
",",4224,O
treated,4224,O
orally,4224,O
with,4224,O
the,4224,O
S.,4224,O
triloba,4224,O
extract,4224,O
at,4224,O
a,4224,O
dose,4224,O
of,4224,O
750,4224,O
and,4224,O
375,4224,O
mg/kg,4224,O
b.w,4224,O
.,4224,O
daily,4225,O
for,4225,O
3,4225,O
months,4225,O
.,4225,O
The,4226,O
fifth,4226,O
and,4226,O
sixth,4226,O
subgroups,4226,O
were,4226,O
",",4226,O
respectively,4226,O
",",4226,O
treated,4226,O
orally,4226,O
with,4226,O
the,4226,O
P.,4226,O
nigrum,4226,O
extract,4226,O
at,4226,O
a,4226,O
dose,4226,O
of,4226,O
187.5,4226,O
and,4226,O
93.75,4226,O
mg/kg,4226,O
b.w,4226,O
.,4226,O
daily,4227,O
for,4227,O
3,4227,O
months,4227,O
.,4227,O
Levels,4228,O
of,4228,O
brain,4228,O
acetylcholine,4228,B-CHEMICAL
(,4228,O
Ach,4228,O
),4228,O
",",4228,O
serum,4228,O
and,4228,O
brain,4228,O
acetylcholinesterase,4228,B-GENE-Y
(,4228,O
AchE,4228,B-GENE-Y
),4228,O
activity,4228,O
",",4228,O
C-reactive,4228,B-GENE-Y
protein,4228,I-GENE-Y
(,4228,O
CRP,4228,B-GENE-Y
),4228,O
",",4228,O
total,4228,O
nuclear,4228,B-GENE-N
factor,4228,I-GENE-N
kappa-B,4228,I-GENE-N
(,4228,O
NF-κB,4228,B-GENE-N
),4228,O
",",4228,O
and,4228,O
monocyte,4228,B-GENE-Y
chemoattractant,4228,I-GENE-Y
protein-1,4228,I-GENE-Y
(,4228,O
MCP-1,4228,B-GENE-Y
),4228,O
were,4228,O
estimated,4228,O
.,4228,O
The,4229,O
results,4229,O
showed,4229,O
that,4229,O
administration,4229,O
of,4229,O
AlCl3,4229,B-CHEMICAL
resulted,4229,O
in,4229,O
a,4229,O
significant,4229,O
elevation,4229,O
in,4229,O
the,4229,O
levels,4229,O
of,4229,O
AchE,4229,B-GENE-Y
activity,4229,O
",",4229,O
CRP,4229,B-GENE-Y
",",4229,O
NF-κB,4229,B-GENE-N
",",4229,O
and,4229,O
MCP-1,4229,B-GENE-Y
accompanied,4229,O
with,4229,O
a,4229,O
significant,4229,O
depletion,4229,O
in,4229,O
the,4229,O
Ach,4229,O
level,4229,O
.,4229,O
Treatment,4230,O
of,4230,O
AD,4230,O
rats,4230,O
with,4230,O
each,4230,O
of,4230,O
the,4230,O
selected,4230,O
medicinal,4230,O
plant,4230,O
extracts,4230,O
caused,4230,O
marked,4230,O
improvement,4230,O
in,4230,O
the,4230,O
measured,4230,O
biochemical,4230,O
parameters,4230,O
.,4230,O
In,4231,O
conclusion,4231,O
",",4231,O
S.,4231,O
triloba,4231,O
and,4231,O
P.,4231,O
nigrum,4231,O
methanolic,4231,O
extracts,4231,O
have,4231,O
potent,4231,O
anti-inflammatory,4231,O
effects,4231,O
against,4231,O
neuroinflammation,4231,O
characterizing,4231,O
AD,4231,O
.,4231,O
Glutathione,4232,B-CHEMICAL
conjugation,4232,O
attenuates,4232,O
biological,4232,O
activities,4232,O
of,4232,O
6-dehydroshogaol,4232,B-CHEMICAL
from,4232,O
ginger,4232,O
.,4232,O
6-Dehydroshogaol,4233,B-CHEMICAL
(,4233,O
6-DHSG,4233,B-CHEMICAL
),4233,O
is,4233,O
a,4233,O
bioactive,4233,O
α,4233,B-CHEMICAL
",",4233,I-CHEMICAL
β-unsaturated,4233,I-CHEMICAL
carbonyl,4233,I-CHEMICAL
compound,4233,O
isolated,4233,O
from,4233,O
fresh,4233,O
ginger,4233,O
with,4233,O
anti-inflammatory,4233,O
and,4233,O
phase,4233,O
II,4233,O
enzyme,4233,O
inducing,4233,O
activities,4233,O
.,4233,O
Here,4234,O
we,4234,O
describe,4234,O
the,4234,O
glutathione,4234,B-CHEMICAL
(,4234,O
GSH,4234,B-CHEMICAL
),4234,O
-dependent,4234,O
metabolism,4234,O
and,4234,O
the,4234,O
effect,4234,O
of,4234,O
this,4234,O
metabolic,4234,O
transformation,4234,O
on,4234,O
the,4234,O
biological,4234,O
activities,4234,O
of,4234,O
6-DHSG,4234,B-CHEMICAL
.,4234,O
Compared,4235,O
with,4235,O
other,4235,O
ginger,4235,O
compounds,4235,O
",",4235,O
such,4235,O
as,4235,O
6-gingerol,4235,B-CHEMICAL
and,4235,O
6-shogaol,4235,B-CHEMICAL
",",4235,O
6-DHSG,4235,B-CHEMICAL
showed,4235,O
the,4235,O
most,4235,O
potent,4235,O
anti-inflammatory,4235,O
effect,4235,O
in,4235,O
lipopolysaccharide,4235,O
(,4235,O
LPS,4235,O
),4235,O
-stimulated,4235,O
RAW,4235,O
264.7,4235,O
cells,4235,O
.,4235,O
The,4236,O
biological,4236,O
activities,4236,O
of,4236,O
6-DHSG,4236,B-CHEMICAL
were,4236,O
attenuated,4236,O
by,4236,O
sulfhydryl,4236,B-CHEMICAL
antioxidants,4236,O
such,4236,O
as,4236,O
glutathione,4236,B-CHEMICAL
(,4236,O
GSH,4236,B-CHEMICAL
),4236,O
or,4236,O
N-acetyl,4236,B-CHEMICAL
cysteine,4236,I-CHEMICAL
(,4236,O
NAC,4236,B-CHEMICAL
),4236,O
",",4236,O
but,4236,O
not,4236,O
ascorbic,4236,B-CHEMICAL
acid,4236,I-CHEMICAL
(,4236,O
ASC,4236,B-CHEMICAL
),4236,O
.,4236,O
6-DHSG,4237,B-CHEMICAL
was,4237,O
metabolised,4237,O
by,4237,O
GSH,4237,B-CHEMICAL
to,4237,O
form,4237,O
a,4237,O
GSH,4237,B-CHEMICAL
conjugate,4237,O
(,4237,O
GS-6-DHSG,4237,B-CHEMICAL
),4237,O
in,4237,O
RAW,4237,O
264.7,4237,O
cells,4237,O
",",4237,O
via,4237,O
a,4237,O
potential,4237,O
mechanism,4237,O
involving,4237,O
the,4237,O
catalytic,4237,O
activity,4237,O
of,4237,O
glutathione-S-transferase,4237,B-GENE-N
(,4237,O
GST,4237,B-GENE-N
),4237,O
.,4237,O
GS-6-DHSG,4238,B-CHEMICAL
showed,4238,O
reduced,4238,O
biological,4238,O
activities,4238,O
compared,4238,O
with,4238,O
6-DHSG,4238,B-CHEMICAL
in,4238,O
multiple,4238,O
biological,4238,O
assays,4238,O
.,4238,O
Together,4239,O
",",4239,O
these,4239,O
results,4239,O
indicate,4239,O
that,4239,O
GSH,4239,B-CHEMICAL
conjugation,4239,O
attenuates,4239,O
the,4239,O
biological,4239,O
activities,4239,O
of,4239,O
6-DHSG,4239,B-CHEMICAL
and,4239,O
other,4239,O
α,4239,B-CHEMICAL
",",4239,I-CHEMICAL
β-unsaturated,4239,I-CHEMICAL
carbonyl,4239,I-CHEMICAL
compounds,4239,O
.,4239,O
Hydrogen,4240,B-CHEMICAL
sulfide,4240,I-CHEMICAL
as,4240,O
an,4240,O
allosteric,4240,O
modulator,4240,O
of,4240,O
ATP-sensitive,4240,B-GENE-N
potassium,4240,I-GENE-N
channels,4240,I-GENE-N
in,4240,O
colonic,4240,O
inflammation,4240,O
.,4240,O
The,4241,O
ATP-sensitive,4241,B-GENE-N
potassium,4241,I-GENE-N
channel,4241,I-GENE-N
(,4241,O
K,4241,B-GENE-N
(,4241,I-GENE-N
ATP,4241,I-GENE-N
),4241,I-GENE-N
),4241,O
in,4241,O
mouse,4241,O
colonic,4241,O
smooth,4241,O
muscle,4241,O
cell,4241,O
is,4241,O
a,4241,O
complex,4241,O
containing,4241,O
a,4241,O
pore-forming,4241,O
subunit,4241,O
(,4241,O
Kir6.1,4241,B-GENE-Y
),4241,O
and,4241,O
a,4241,O
sulfonylurea,4241,B-GENE-N
receptor,4241,I-GENE-N
subunit,4241,O
(,4241,O
SUR2B,4241,B-GENE-Y
),4241,O
.,4241,O
These,4242,O
channels,4242,O
contribute,4242,O
to,4242,O
the,4242,O
cellular,4242,O
excitability,4242,O
of,4242,O
smooth,4242,O
muscle,4242,O
cells,4242,O
and,4242,O
hence,4242,O
regulate,4242,O
the,4242,O
motility,4242,O
patterns,4242,O
in,4242,O
the,4242,O
colon,4242,O
.,4242,O
Whole-cell,4243,O
voltage-clamp,4243,O
techniques,4243,O
were,4243,O
used,4243,O
to,4243,O
study,4243,O
the,4243,O
alterations,4243,O
in,4243,O
K,4243,B-GENE-N
(,4243,I-GENE-N
ATP,4243,I-GENE-N
),4243,I-GENE-N
channels,4243,I-GENE-N
in,4243,O
smooth,4243,O
muscle,4243,O
cells,4243,O
in,4243,O
experimental,4243,O
colitis,4243,O
.,4243,O
Colonic,4244,O
inflammation,4244,O
was,4244,O
induced,4244,O
in,4244,O
BALB/C,4244,O
mice,4244,O
after,4244,O
intracolonic,4244,O
administration,4244,O
of,4244,O
trinitrobenzene,4244,B-CHEMICAL
sulfonic,4244,I-CHEMICAL
acid,4244,I-CHEMICAL
.,4244,O
K,4245,B-CHEMICAL
(,4245,O
ATP,4245,B-CHEMICAL
),4245,O
currents,4245,O
were,4245,O
measured,4245,O
at,4245,O
a,4245,O
holding,4245,O
potential,4245,O
of,4245,O
-60,4245,O
mV,4245,O
in,4245,O
high,4245,O
K,4245,B-CHEMICAL
(,4245,I-CHEMICAL
+,4245,I-CHEMICAL
),4245,I-CHEMICAL
external,4245,O
solution,4245,O
.,4245,O
The,4246,O
concentration,4246,O
response,4246,O
to,4246,O
levcromakalim,4246,B-CHEMICAL
(,4246,O
LEVC,4246,B-CHEMICAL
),4246,O
",",4246,O
a,4246,O
K,4246,B-GENE-N
(,4246,I-GENE-N
ATP,4246,I-GENE-N
),4246,I-GENE-N
channel,4246,I-GENE-N
opener,4246,O
",",4246,O
was,4246,O
significantly,4246,O
shifted,4246,O
to,4246,O
the,4246,O
left,4246,O
in,4246,O
the,4246,O
inflamed,4246,O
smooth-muscle,4246,O
cells,4246,O
.,4246,O
Both,4247,O
the,4247,O
potency,4247,O
and,4247,O
maximal,4247,O
currents,4247,O
induced,4247,O
by,4247,O
LEVC,4247,B-CHEMICAL
were,4247,O
enhanced,4247,O
in,4247,O
inflammation,4247,O
.,4247,O
The,4248,O
EC,4248,O
(,4248,O
50,4248,O
),4248,O
values,4248,O
in,4248,O
control,4248,O
were,4248,O
6259,4248,O
nM,4248,O
(,4248,O
n,4248,O
=,4248,O
10,4248,O
),4248,O
and,4248,O
422,4248,O
nM,4248,O
(,4248,O
n,4248,O
=,4248,O
8,4248,O
),4248,O
in,4248,O
inflamed,4248,O
colon,4248,O
",",4248,O
and,4248,O
the,4248,O
maximal,4248,O
currents,4248,O
were,4248,O
9.9,4248,O
±,4248,O
0.71,4248,O
pA/pF,4248,O
(,4248,O
60,4248,O
μM,4248,O
),4248,O
in,4248,O
control,4248,O
and,4248,O
39.7,4248,O
±,4248,O
8.8,4248,O
pA/pF,4248,O
(,4248,O
3,4248,O
μM,4248,O
),4248,O
after,4248,O
inflammation,4248,O
.,4248,O
As,4249,O
was,4249,O
seen,4249,O
with,4249,O
LEVC,4249,B-CHEMICAL
",",4249,O
the,4249,O
potency,4249,O
and,4249,O
efficacy,4249,O
of,4249,O
sodium,4249,B-CHEMICAL
hydrogen,4249,I-CHEMICAL
sulfide,4249,I-CHEMICAL
(,4249,O
NaHS,4249,B-CHEMICAL
),4249,O
(,4249,O
10-1000,4249,O
μM,4249,O
),4249,O
on,4249,O
K,4249,B-CHEMICAL
(,4249,O
ATP,4249,B-CHEMICAL
),4249,O
currents,4249,O
were,4249,O
significantly,4249,O
greater,4249,O
in,4249,O
inflamed,4249,O
colon,4249,O
compared,4249,O
with,4249,O
controls,4249,O
.,4249,O
In,4250,O
control,4250,O
cells,4250,O
",",4250,O
pretreatment,4250,O
with,4250,O
100,4250,O
µM,4250,O
NaHS,4250,B-CHEMICAL
shifted,4250,O
the,4250,O
EC,4250,O
(,4250,O
50,4250,O
),4250,O
for,4250,O
LEV-induced,4250,O
currents,4250,O
from,4250,O
2838,4250,O
(,4250,O
n,4250,O
=,4250,O
6,4250,O
),4250,O
to,4250,O
154,4250,O
(,4250,O
n,4250,O
=,4250,O
8,4250,O
),4250,O
nM,4250,O
.,4250,O
Sulfhydration,4251,O
of,4251,O
sulfonylurea,4251,B-GENE-Y
receptor,4251,I-GENE-Y
2B,4251,I-GENE-Y
(,4251,O
SUR2B,4251,B-GENE-Y
),4251,O
was,4251,O
induced,4251,O
by,4251,O
NaHS,4251,B-CHEMICAL
and,4251,O
colonic,4251,O
inflammation,4251,O
.,4251,O
These,4252,O
data,4252,O
suggest,4252,O
that,4252,O
sulfhydration,4252,O
of,4252,O
SUR2B,4252,B-GENE-Y
induces,4252,O
allosteric,4252,O
modulation,4252,O
of,4252,O
K,4252,B-CHEMICAL
(,4252,O
ATP,4252,B-CHEMICAL
),4252,O
currents,4252,O
in,4252,O
colonic,4252,O
inflammation,4252,O
.,4252,O
[,4253,O
Short,4253,O
QT,4253,O
syndrome,4253,O
],4253,O
.,4253,O
Short,4254,O
QT,4254,O
syndrome,4254,O
is,4254,O
a,4254,O
new,4254,O
genetic,4254,O
disorder,4254,O
associated,4254,O
with,4254,O
familial,4254,O
atrial,4254,O
fibrillation,4254,O
and/or,4254,O
sudden,4254,O
death,4254,O
or,4254,O
syncope,4254,O
.,4254,O
To,4255,O
date,4255,O
",",4255,O
different,4255,O
mutations,4255,O
in,4255,O
genes,4255,O
encoding,4255,O
for,4255,O
cardiac,4255,B-GENE-N
ion,4255,I-GENE-N
channels,4255,I-GENE-N
(,4255,O
KCNH2,4255,B-GENE-Y
",",4255,O
KCNQ1,4255,B-GENE-Y
",",4255,O
and,4255,O
KCNJ2,4255,B-GENE-Y
),4255,O
have,4255,O
been,4255,O
identified,4255,O
to,4255,O
cause,4255,O
the,4255,O
short,4255,O
QT,4255,O
syndrome,4255,O
.,4255,O
The,4256,O
mutations,4256,O
lead,4256,O
to,4256,O
a,4256,O
gain,4256,O
of,4256,O
function,4256,O
of,4256,O
the,4256,O
affected,4256,O
current,4256,O
(,4256,O
IKr,4256,B-GENE-Y
",",4256,O
IKs,4256,B-GENE-Y
",",4256,O
and,4256,O
IK1,4256,B-GENE-Y
),4256,O
.,4256,O
The,4257,O
phenotype,4257,O
is,4257,O
characterized,4257,O
by,4257,O
a,4257,O
shortened,4257,O
QT,4257,O
interval,4257,O
<,4257,O
335,4257,O
ms,4257,O
after,4257,O
correction,4257,O
for,4257,O
heart,4257,O
rate,4257,O
at,4257,O
rates,4257,O
<,4257,O
80,4257,O
beats/min,4257,O
.,4257,O
Furthermore,4258,O
",",4258,O
the,4258,O
QT,4258,O
interval,4258,O
poorly,4258,O
adapts,4258,O
to,4258,O
heart,4258,O
rate,4258,O
.,4258,O
Patients,4259,O
exhibit,4259,O
shortened,4259,O
atrial,4259,O
and,4259,O
ventricular,4259,O
effective,4259,O
refractory,4259,O
periods,4259,O
and,4259,O
",",4259,O
in,4259,O
the,4259,O
majority,4259,O
",",4259,O
inducibility,4259,O
of,4259,O
ventricular,4259,O
fibrillation,4259,O
.,4259,O
Death,4260,O
occurs,4260,O
already,4260,O
in,4260,O
newborns,4260,O
.,4260,O
Therapy,4261,O
of,4261,O
choice,4261,O
seems,4261,O
to,4261,O
be,4261,O
the,4261,O
implantable,4261,O
cardioverter,4261,O
defibrillator,4261,O
because,4261,O
of,4261,O
the,4261,O
high,4261,O
incidence,4261,O
of,4261,O
sudden,4261,O
death,4261,O
.,4261,O
Pharmacological,4262,O
treatment,4262,O
has,4262,O
been,4262,O
studied,4262,O
and,4262,O
it,4262,O
could,4262,O
be,4262,O
demonstrated,4262,O
",",4262,O
that,4262,O
some,4262,O
mutant,4262,O
currents,4262,O
may,4262,O
be,4262,O
insufficiently,4262,O
suppressed,4262,O
by,4262,O
drugs,4262,O
targeted,4262,O
to,4262,O
block,4262,O
the,4262,O
specific,4262,O
current,4262,O
such,4262,O
as,4262,O
",",4262,O
e.g.,4262,O
",",4262,O
sotalol,4262,B-CHEMICAL
or,4262,O
ibutilide,4262,B-CHEMICAL
in,4262,O
patients,4262,O
with,4262,O
a,4262,O
mutation,4262,O
in,4262,O
the,4262,O
IKr-coding,4262,B-GENE-Y
gene,4262,O
KCNH2,4262,B-GENE-Y
(,4262,O
HERG,4262,B-GENE-Y
),4262,O
.,4262,O
Quinidine,4263,B-CHEMICAL
proved,4263,O
to,4263,O
be,4263,O
efficient,4263,O
in,4263,O
prolonging,4263,O
the,4263,O
QT,4263,O
interval,4263,O
and,4263,O
normalizing,4263,O
the,4263,O
effective,4263,O
refractory,4263,O
periods,4263,O
in,4263,O
some,4263,O
patients,4263,O
.,4263,O
The,4264,O
pure,4264,O
antiandrogen,4264,O
RU,4264,B-CHEMICAL
23908,4264,I-CHEMICAL
(,4264,O
Anandron,4264,B-CHEMICAL
),4264,O
",",4264,O
a,4264,O
candidate,4264,O
of,4264,O
choice,4264,O
for,4264,O
the,4264,O
combined,4264,O
antihormonal,4264,O
treatment,4264,O
of,4264,O
prostatic,4264,O
cancer,4264,O
:,4264,O
a,4264,O
review,4264,O
.,4264,O
The,4265,O
nonsteroidal,4265,O
antiandrogen,4265,O
RU,4265,B-CHEMICAL
23908,4265,I-CHEMICAL
(,4265,O
Anandron,4265,B-CHEMICAL
),4265,O
weakly,4265,O
interacts,4265,O
with,4265,O
the,4265,O
prostatic,4265,O
cytosolic,4265,O
androgen,4265,B-GENE-Y
receptor,4265,I-GENE-Y
and,4265,O
shows,4265,O
a,4265,O
fast,4265,O
dissociation,4265,O
rate,4265,O
.,4265,O
When,4266,O
administered,4266,O
to,4266,O
immature,4266,O
castrated,4266,O
rats,4266,O
up,4266,O
to,4266,O
the,4266,O
daily,4266,O
dose,4266,O
of,4266,O
100,4266,O
mg/kg,4266,O
",",4266,O
it,4266,O
is,4266,O
devoid,4266,O
of,4266,O
any,4266,O
androgenic,4266,O
activity,4266,O
but,4266,O
efficiently,4266,O
blocks,4266,O
the,4266,O
growth-promoting,4266,O
activity,4266,O
of,4266,O
androgens,4266,B-CHEMICAL
on,4266,O
ventral,4266,O
prostate,4266,O
and,4266,O
seminal,4266,O
vesicle,4266,O
weight,4266,O
",",4266,O
thus,4266,O
showing,4266,O
the,4266,O
characteristics,4266,O
of,4266,O
a,4266,O
pure,4266,O
antiandrogen,4266,O
.,4266,O
In,4267,O
intact,4267,O
animals,4267,O
",",4267,O
on,4267,O
the,4267,O
other,4267,O
hand,4267,O
",",4267,O
the,4267,O
antiandrogen,4267,O
administered,4267,O
alone,4267,O
exerts,4267,O
only,4267,O
a,4267,O
partial,4267,O
inhibition,4267,O
of,4267,O
prostate,4267,O
and,4267,O
seminal,4267,O
vesicle,4267,O
weight,4267,O
.,4267,O
This,4268,O
is,4268,O
due,4268,O
to,4268,O
the,4268,O
property,4268,O
of,4268,O
the,4268,O
pure,4268,O
antiandrogen,4268,O
to,4268,O
neutralize,4268,O
the,4268,O
inhibitory,4268,O
feedback,4268,O
effect,4268,O
of,4268,O
androgens,4268,B-CHEMICAL
at,4268,O
the,4268,O
pituitary,4268,O
level,4268,O
on,4268,O
the,4268,O
LH,4268,B-GENE-N
responsiveness,4268,O
to,4268,O
LHRH,4268,B-GENE-Y
",",4268,O
as,4268,O
illustrated,4268,O
in,4268,O
vitro,4268,O
in,4268,O
rat,4268,O
anterior,4268,O
pituitary,4268,O
cells,4268,O
in,4268,O
culture,4268,O
as,4268,O
well,4268,O
as,4268,O
in,4268,O
vivo,4268,O
in,4268,O
intact,4268,O
and,4268,O
castrated,4268,O
animals,4268,O
.,4268,O
In,4269,O
intact,4269,O
animals,4269,O
",",4269,O
neutralization,4269,O
of,4269,O
the,4269,O
inhibitory,4269,O
feedback,4269,O
action,4269,O
of,4269,O
endogenous,4269,O
androgens,4269,B-CHEMICAL
leads,4269,O
to,4269,O
an,4269,O
increased,4269,O
LH,4269,B-GENE-N
and,4269,O
testosterone,4269,B-CHEMICAL
secretion,4269,O
",",4269,O
which,4269,O
partly,4269,O
overcomes,4269,O
the,4269,O
direct,4269,O
action,4269,O
of,4269,O
the,4269,O
antiandrogen,4269,O
at,4269,O
the,4269,O
level,4269,O
of,4269,O
the,4269,O
prostate,4269,O
and,4269,O
seminal,4269,O
vesicles,4269,O
.,4269,O
In,4270,O
fact,4270,O
",",4270,O
the,4270,O
plasma,4270,O
testosterone,4270,B-CHEMICAL
concentration,4270,O
is,4270,O
more,4270,O
than,4270,O
doubled,4270,O
6,4270,O
hr,4270,O
after,4270,O
the,4270,O
administration,4270,O
of,4270,O
10,4270,O
mg,4270,O
of,4270,O
RU,4270,B-CHEMICAL
23908,4270,I-CHEMICAL
while,4270,O
plasma,4270,O
LH,4270,B-GENE-N
and,4270,O
testosterone,4270,B-CHEMICAL
levels,4270,O
are,4270,O
increased,4270,O
by,4270,O
7-,4270,O
and,4270,O
17-fold,4270,O
",",4270,O
respectively,4270,O
",",4270,O
after,4270,O
14,4270,O
days,4270,O
of,4270,O
similar,4270,O
daily,4270,O
treatment,4270,O
.,4270,O
Efficient,4271,O
neutralization,4271,O
of,4271,O
the,4271,O
androgenic,4271,O
action,4271,O
at,4271,O
the,4271,O
prostatic,4271,O
level,4271,O
in,4271,O
intact,4271,O
animals,4271,O
thus,4271,O
requires,4271,O
prevention,4271,O
of,4271,O
this,4271,O
escape,4271,O
phenomenon,4271,O
through,4271,O
inhibition,4271,O
of,4271,O
LH,4271,B-GENE-N
secretion,4271,O
.,4271,O
Although,4272,O
inhibition,4272,O
of,4272,O
LH,4272,B-GENE-N
release,4272,O
can,4272,O
be,4272,O
achieved,4272,O
by,4272,O
estrogen,4272,B-CHEMICAL
and,4272,O
progestins,4272,B-CHEMICAL
",",4272,O
an,4272,O
optimal,4272,O
inhibitory,4272,O
effect,4272,O
on,4272,O
the,4272,O
prostate,4272,O
is,4272,O
obtained,4272,O
by,4272,O
the,4272,O
combined,4272,O
administration,4272,O
of,4272,O
the,4272,O
antiandrogen,4272,O
with,4272,O
an,4272,O
LHRH,4272,B-GENE-Y
agonist,4272,O
that,4272,O
causes,4272,O
a,4272,O
specific,4272,O
blockage,4272,O
of,4272,O
testicular,4272,O
androgen,4272,B-CHEMICAL
biosynthesis,4272,O
as,4272,O
well,4272,O
as,4272,O
an,4272,O
inhibition,4272,O
of,4272,O
the,4272,O
LH,4272,B-GENE-N
responsiveness,4272,O
to,4272,O
LHRH,4272,B-GENE-Y
.,4272,O
Cytochrome,4273,B-GENE-N
P450-mediated,4273,O
herb-drug,4273,O
interaction,4273,O
potential,4273,O
of,4273,O
Galgeun-tang,4273,O
.,4273,O
We,4274,O
evaluated,4274,O
the,4274,O
herb-drug,4274,O
interaction,4274,O
potential,4274,O
of,4274,O
Galgeun-tang,4274,O
(,4274,O
GGT,4274,O
),4274,O
extracts,4274,O
",",4274,O
mediated,4274,O
by,4274,O
cytochrome,4274,B-GENE-N
P450,4274,I-GENE-N
(,4274,O
CYP,4274,B-GENE-N
),4274,O
inhibition/induction,4274,O
.,4274,O
Further,4275,O
",",4275,O
the,4275,O
effects,4275,O
of,4275,O
fermentation,4275,O
on,4275,O
the,4275,O
CYP-mediated,4275,B-GENE-N
herb-drug,4275,O
interaction,4275,O
potential,4275,O
of,4275,O
GGT,4275,O
extracts,4275,O
were,4275,O
determined,4275,O
.,4275,O
As,4276,O
measured,4276,O
by,4276,O
LC-ESI/MS/MS,4276,O
",",4276,O
GGT,4276,O
extracts,4276,O
(,4276,O
0-300μg/mL,4276,O
),4276,O
showed,4276,O
no,4276,O
inhibitory,4276,O
activity,4276,O
toward,4276,O
eight,4276,O
CYP,4276,B-GENE-N
isoforms,4276,O
(,4276,O
1A2,4276,B-GENE-N
",",4276,I-GENE-N
2A6,4276,I-GENE-N
",",4276,I-GENE-N
2B6,4276,I-GENE-N
",",4276,I-GENE-N
2C9,4276,I-GENE-N
",",4276,I-GENE-N
2C19,4276,I-GENE-N
",",4276,I-GENE-N
2D6,4276,I-GENE-N
",",4276,I-GENE-N
2E1,4276,I-GENE-N
",",4276,I-GENE-N
and,4276,I-GENE-N
3A4,4276,I-GENE-N
),4276,O
in,4276,O
pooled,4276,O
human,4276,O
liver,4276,O
microsomes,4276,O
",",4276,O
suggesting,4276,O
that,4276,O
GGT,4276,O
may,4276,O
have,4276,O
low,4276,O
potential,4276,O
for,4276,O
herb-drug,4276,O
interactions,4276,O
mediated,4276,O
by,4276,O
CYP,4276,B-GENE-N
inhibition,4276,O
.,4276,O
Hepatic,4277,O
CYP,4277,B-GENE-N
expression,4277,O
and,4277,O
activity,4277,O
in,4277,O
rats,4277,O
treated,4277,O
with,4277,O
GGT,4277,O
extracts,4277,O
twice,4277,O
per,4277,O
day,4277,O
for,4277,O
1week,4277,O
was,4277,O
examined,4277,O
.,4277,O
Among,4278,O
the,4278,O
tested,4278,O
CYP,4278,B-GENE-N
isoforms,4278,O
(,4278,O
1A1,4278,B-GENE-N
",",4278,I-GENE-N
1A2,4278,I-GENE-N
",",4278,I-GENE-N
1B1,4278,I-GENE-N
",",4278,I-GENE-N
2B1,4278,I-GENE-N
",",4278,I-GENE-N
2C11,4278,I-GENE-N
",",4278,I-GENE-N
2E1,4278,I-GENE-N
",",4278,I-GENE-N
3A1,4278,I-GENE-N
",",4278,I-GENE-N
3A2,4278,I-GENE-N
",",4278,I-GENE-N
and,4278,I-GENE-N
4A1,4278,I-GENE-N
),4278,O
",",4278,O
CYP1B1,4278,B-GENE-N
and,4278,I-GENE-N
4A1,4278,I-GENE-N
were,4278,O
increased,4278,O
by,4278,O
GGT,4278,O
extracts,4278,O
.,4278,O
Hepatic,4279,O
activities,4279,O
of,4279,O
7-ethoxyresorufin-O-deethylase,4279,B-GENE-Y
",",4279,O
7-pentoxyresorufin-O-depentylase,4279,B-GENE-Y
",",4279,O
and,4279,O
chlorzoxazone,4279,B-GENE-Y
6-hydroxylase,4279,I-GENE-Y
",",4279,O
but,4279,O
not,4279,O
midazolam,4279,B-GENE-N
hydroxylase,4279,I-GENE-N
were,4279,O
also,4279,O
elevated,4279,O
.,4279,O
These,4280,O
results,4280,O
raise,4280,O
the,4280,O
possibility,4280,O
that,4280,O
GGT,4280,O
extracts,4280,O
may,4280,O
increase,4280,O
the,4280,O
toxicity,4280,O
of,4280,O
environmental,4280,O
toxicants,4280,O
through,4280,O
the,4280,O
elevating,4280,O
CYP-dependent,4280,B-GENE-N
metabolic,4280,O
activation,4280,O
.,4280,O
Interestingly,4281,O
",",4281,O
the,4281,O
increases,4281,O
in,4281,O
CYP1B1,4281,B-GENE-Y
and,4281,O
CYP4A1,4281,B-GENE-Y
levels,4281,O
",",4281,O
and,4281,O
7-ethoxyresorufin-O-deethylase,4281,B-GENE-Y
",",4281,O
7-pentoxyresorufin-O-depentylase,4281,B-GENE-Y
",",4281,O
and,4281,O
chlorzoxazone,4281,B-GENE-Y
6-hydroxylase,4281,I-GENE-Y
activities,4281,O
were,4281,O
attenuated,4281,O
by,4281,O
fermentation,4281,O
of,4281,O
GGT,4281,O
extract,4281,O
using,4281,O
Lactobacillus,4281,O
plantarum,4281,O
KFRI,4281,O
402,4281,O
",",4281,O
but,4281,O
not,4281,O
144,4281,O
.,4281,O
Further,4282,O
studies,4282,O
are,4282,O
needed,4282,O
to,4282,O
identify,4282,O
the,4282,O
CYP,4282,B-GENE-N
regulatory,4282,O
component,4282,O
(,4282,O
s,4282,O
),4282,O
from,4282,O
GGT,4282,O
and,4282,O
determination,4282,O
its,4282,O
metabolism,4282,O
.,4282,O
Mechanisms,4283,O
of,4283,O
cefadroxil,4283,B-CHEMICAL
uptake,4283,O
in,4283,O
the,4283,O
choroid,4283,O
plexus,4283,O
:,4283,O
studies,4283,O
in,4283,O
wild-type,4283,O
and,4283,O
PEPT2,4283,B-GENE-Y
knockout,4283,O
mice,4283,O
.,4283,O
The,4284,O
choroid,4284,O
plexus,4284,O
uptake,4284,O
of,4284,O
[,4284,B-CHEMICAL
(,4284,I-CHEMICAL
3,4284,I-CHEMICAL
),4284,I-CHEMICAL
H,4284,I-CHEMICAL
],4284,I-CHEMICAL
cefadroxil,4284,I-CHEMICAL
was,4284,O
studied,4284,O
in,4284,O
peptide,4284,B-GENE-Y
transporter,4284,I-GENE-Y
2,4284,I-GENE-Y
(,4284,O
PEPT2,4284,B-GENE-Y
),4284,O
wild-type,4284,O
and,4284,O
null,4284,O
mice,4284,O
as,4284,O
a,4284,O
function,4284,O
of,4284,O
temperature,4284,O
",",4284,O
transport,4284,O
inhibitors,4284,O
",",4284,O
pH,4284,O
",",4284,O
and,4284,O
saturability,4284,O
.,4284,O
At,4285,O
normal,4285,O
pH,4285,O
(,4285,O
7.4,4285,O
),4285,O
and,4285,O
temperature,4285,O
(,4285,O
37,4285,O
degrees,4285,O
C,4285,O
),4285,O
",",4285,O
the,4285,O
uptake,4285,O
of,4285,O
1,4285,O
microM,4285,O
cefadroxil,4285,B-CHEMICAL
was,4285,O
reduced,4285,O
by,4285,O
83,4285,O
%,4285,O
in,4285,O
PEPT2,4285,B-GENE-Y
(,4285,O
-/-,4285,O
),4285,O
mice,4285,O
as,4285,O
compared,4285,O
with,4285,O
PEPT2,4285,B-GENE-Y
(,4285,O
+/+,4285,O
),4285,O
mice,4285,O
(,4285,O
p,4285,O
<,4285,O
0.001,4285,O
),4285,O
.,4285,O
A,4286,O
further,4286,O
reduction,4286,O
was,4286,O
achieved,4286,O
in,4286,O
null,4286,O
animals,4286,O
by,4286,O
reducing,4286,O
the,4286,O
temperature,4286,O
to,4286,O
4,4286,O
degrees,4286,O
C,4286,O
",",4286,O
or,4286,O
by,4286,O
adding,4286,O
saturating,4286,O
concentrations,4286,O
of,4286,O
unlabeled,4286,O
cefadroxil,4286,B-CHEMICAL
or,4286,O
p-aminohippurate,4286,B-CHEMICAL
(,4286,O
p,4286,O
<,4286,O
0.05,4286,O
),4286,O
.,4286,O
Glycylsarcosine,4287,B-CHEMICAL
coadministration,4287,O
could,4287,O
inhibit,4287,O
the,4287,O
uptake,4287,O
of,4287,O
cefadroxil,4287,B-CHEMICAL
in,4287,O
PEPT2,4287,B-GENE-Y
(,4287,O
+/+,4287,O
),4287,O
mice,4287,O
(,4287,O
p,4287,O
<,4287,O
0.01,4287,O
),4287,O
but,4287,O
not,4287,O
PEPT2,4287,B-GENE-Y
(,4287,O
-/-,4287,O
),4287,O
mice,4287,O
.,4287,O
Although,4288,O
a,4288,O
proton-stimulated,4288,O
uptake,4288,O
of,4288,O
cefadroxil,4288,B-CHEMICAL
was,4288,O
demonstrated,4288,O
in,4288,O
PEPT2,4288,B-GENE-Y
(,4288,O
+/+,4288,O
),4288,O
mice,4288,O
(,4288,O
pH,4288,O
6.5,4288,O
versus,4288,O
pH,4288,O
7.4,4288,O
;,4288,O
p,4288,O
<,4288,O
0.01,4288,O
),4288,O
",",4288,O
no,4288,O
pH,4288,O
dependence,4288,O
was,4288,O
observed,4288,O
in,4288,O
PEPT2,4288,B-GENE-Y
(,4288,O
-/-,4288,O
),4288,O
mice,4288,O
.,4288,O
Kinetic,4289,O
parameters,4289,O
for,4289,O
cefadroxil,4289,B-CHEMICAL
(,4289,O
without,4289,O
p-aminohippurate,4289,B-CHEMICAL
),4289,O
in,4289,O
wild-type,4289,O
mice,4289,O
were,4289,O
:,4289,O
V,4289,O
(,4289,O
max,4289,O
),4289,O
=,4289,O
5.4,4289,O
pmol/mg/min,4289,O
",",4289,O
K,4289,O
(,4289,O
m,4289,O
),4289,O
=,4289,O
34,4289,O
microM,4289,O
",",4289,O
and,4289,O
K,4289,O
(,4289,O
d,4289,O
),4289,O
=,4289,O
0.0069,4289,O
microl/mg/min,4289,O
;,4289,O
in,4289,O
the,4289,O
presence,4289,O
of,4289,O
p-aminohippurate,4289,B-CHEMICAL
",",4289,O
the,4289,O
parameters,4289,O
were,4289,O
:,4289,O
V,4289,O
(,4289,O
max,4289,O
),4289,O
=,4289,O
4.1,4289,O
pmol/mg/min,4289,O
",",4289,O
K,4289,O
(,4289,O
m,4289,O
),4289,O
=,4289,O
27,4289,O
microM,4289,O
",",4289,O
and,4289,O
K,4289,O
(,4289,O
d,4289,O
),4289,O
=,4289,O
0.0064,4289,O
microl/mg/min,4289,O
.,4289,O
In,4290,O
null,4290,O
animals,4290,O
",",4290,O
the,4290,O
kinetic,4290,O
parameters,4290,O
of,4290,O
cefadroxil,4290,B-CHEMICAL
(,4290,O
without,4290,O
p-aminohippurate,4290,B-CHEMICAL
),4290,O
were,4290,O
:,4290,O
V,4290,O
(,4290,O
max,4290,O
),4290,O
=,4290,O
2.7,4290,O
pmol/mg/min,4290,O
",",4290,O
K,4290,O
(,4290,O
m,4290,O
),4290,O
=,4290,O
110,4290,O
microM,4290,O
",",4290,O
and,4290,O
K,4290,O
(,4290,O
d,4290,O
),4290,O
=,4290,O
0.0084,4290,O
microl/mg/min,4290,O
;,4290,O
in,4290,O
the,4290,O
presence,4290,O
of,4290,O
p-aminohippurate,4290,B-CHEMICAL
",",4290,O
only,4290,O
a,4290,O
K,4290,O
(,4290,O
d,4290,O
),4290,O
=,4290,O
0.010,4290,O
microl/mg/min,4290,O
was,4290,O
observed,4290,O
.,4290,O
Based,4291,O
on,4291,O
kinetic,4291,O
and,4291,O
inhibitor,4291,O
analyses,4291,O
",",4291,O
it,4291,O
was,4291,O
determined,4291,O
that,4291,O
(,4291,O
under,4291,O
linear,4291,O
conditions,4291,O
),4291,O
",",4291,O
80,4291,O
to,4291,O
85,4291,O
%,4291,O
of,4291,O
cefadroxil,4291,O
's,4291,O
uptake,4291,O
in,4291,O
choroid,4291,O
plexus,4291,O
is,4291,O
mediated,4291,O
by,4291,O
PEPT2,4291,B-GENE-Y
",",4291,O
10,4291,O
to,4291,O
15,4291,O
%,4291,O
by,4291,O
organic,4291,B-GENE-Y
anion,4291,I-GENE-Y
transporter,4291,I-GENE-Y
(,4291,I-GENE-Y
s,4291,I-GENE-Y
),4291,I-GENE-Y
",",4291,O
and,4291,O
5,4291,O
%,4291,O
by,4291,O
nonspecific,4291,O
mechanisms,4291,O
.,4291,O
These,4292,O
findings,4292,O
demonstrate,4292,O
that,4292,O
PEPT2,4292,B-GENE-Y
is,4292,O
the,4292,O
primary,4292,O
transporter,4292,O
responsible,4292,O
for,4292,O
cefadroxil,4292,B-CHEMICAL
uptake,4292,O
in,4292,O
the,4292,O
choroid,4292,O
plexus,4292,O
.,4292,O
Moreover,4293,O
",",4293,O
the,4293,O
data,4293,O
suggest,4293,O
a,4293,O
role,4293,O
for,4293,O
PEPT2,4293,B-GENE-Y
in,4293,O
the,4293,O
clearance,4293,O
of,4293,O
peptidomimetics,4293,O
from,4293,O
cerebrospinal,4293,O
fluid,4293,O
.,4293,O
Comparative,4294,O
proteomics,4294,O
of,4294,O
ovarian,4294,O
epithelial,4294,O
tumors,4294,O
.,4294,O
We,4295,O
analyzed,4295,O
12,4295,O
ovarian,4295,O
epithelial,4295,O
tumors,4295,O
using,4295,O
2D,4295,O
PAGE-based,4295,O
comparative,4295,O
proteomics,4295,O
to,4295,O
construct,4295,O
intra-,4295,O
and,4295,O
inter-tumoral,4295,O
distance,4295,O
map,4295,O
trees,4295,O
and,4295,O
to,4295,O
discover,4295,O
surrogate,4295,O
biomarkers,4295,O
indicative,4295,O
of,4295,O
an,4295,O
ovarian,4295,O
tumor,4295,O
.,4295,O
The,4296,O
analysis,4296,O
was,4296,O
performed,4296,O
after,4296,O
laser,4296,O
microdissection,4296,O
of,4296,O
12,4296,O
fresh-frozen,4296,O
tissue,4296,O
samples,4296,O
",",4296,O
including,4296,O
4,4296,O
serous,4296,O
",",4296,O
5,4296,O
mucinous,4296,O
",",4296,O
and,4296,O
3,4296,O
endometrioid,4296,O
tumors,4296,O
",",4296,O
with,4296,O
correlation,4296,O
with,4296,O
their,4296,O
histopathological,4296,O
characteristics,4296,O
.,4296,O
Ovarian,4297,O
epithelial,4297,O
tumors,4297,O
and,4297,O
normal,4297,O
tissues,4297,O
showed,4297,O
an,4297,O
apparent,4297,O
separation,4297,O
on,4297,O
the,4297,O
distance,4297,O
map,4297,O
tree,4297,O
.,4297,O
Mucinous,4298,O
carcinomas,4298,O
were,4298,O
closest,4298,O
to,4298,O
the,4298,O
normal,4298,O
group,4298,O
",",4298,O
whereas,4298,O
serous,4298,O
carcinomas,4298,O
were,4298,O
located,4298,O
furthest,4298,O
from,4298,O
the,4298,O
normal,4298,O
group,4298,O
.,4298,O
All,4299,O
mucinous,4299,O
tumors,4299,O
with,4299,O
aggressive,4299,O
histology,4299,O
were,4299,O
separated,4299,O
from,4299,O
the,4299,O
low,4299,O
malignant,4299,O
potential,4299,O
(,4299,O
LMP,4299,O
),4299,O
group,4299,O
.,4299,O
The,4300,O
benign-looking,4300,O
cysts,4300,O
adjacent,4300,O
to,4300,O
the,4300,O
intraepithelial,4300,O
carcinoma,4300,O
(,4300,O
IEC,4300,O
),4300,O
showed,4300,O
an,4300,O
expression,4300,O
pattern,4300,O
identical,4300,O
to,4300,O
that,4300,O
of,4300,O
the,4300,O
IEC,4300,O
area,4300,O
.,4300,O
The,4301,O
extent,4301,O
of,4301,O
change,4301,O
on,4301,O
the,4301,O
lineages,4301,O
leading,4301,O
to,4301,O
the,4301,O
mucinous,4301,O
and,4301,O
serous,4301,O
carcinoma,4301,O
was,4301,O
1.98-fold,4301,O
different,4301,O
.,4301,O
The,4302,O
overall,4302,O
gene,4302,O
expression,4302,O
profiles,4302,O
of,4302,O
serous,4302,O
or,4302,O
endometrioid,4302,O
carcinomas,4302,O
appeared,4302,O
to,4302,O
be,4302,O
less,4302,O
affected,4302,O
by,4302,O
grade,4302,O
or,4302,O
stage,4302,O
than,4302,O
by,4302,O
histologic,4302,O
type,4302,O
.,4302,O
The,4303,O
potential,4303,O
candidate,4303,O
biomarkers,4303,O
screened,4303,O
in,4303,O
ovarian,4303,O
tumors,4303,O
and,4303,O
found,4303,O
to,4303,O
be,4303,O
significantly,4303,O
up-regulated,4303,O
in,4303,O
comparison,4303,O
to,4303,O
normal,4303,O
tissues,4303,O
were,4303,O
as,4303,O
follows,4303,O
:,4303,O
NM23,4303,B-GENE-Y
",",4303,O
annexin-1,4303,B-GENE-Y
",",4303,O
protein,4303,B-GENE-N
phosphatase-1,4303,I-GENE-N
",",4303,O
ferritin,4303,B-GENE-Y
light,4303,I-GENE-Y
chain,4303,I-GENE-Y
",",4303,O
proteasome,4303,B-GENE-Y
alpha-6,4303,I-GENE-Y
",",4303,O
and,4303,O
NAGK,4303,B-GENE-Y
(,4303,O
N-acetyl,4303,B-GENE-Y
glucosamine,4303,I-GENE-Y
kinase,4303,I-GENE-Y
),4303,O
.,4303,O
In,4304,O
conclusion,4304,O
",",4304,O
ovarian,4304,O
mucinous,4304,O
tumors,4304,O
are,4304,O
distinct,4304,O
from,4304,O
other,4304,O
ovarian,4304,O
epithelial,4304,O
tumors,4304,O
.,4304,O
LMP,4305,O
mucinous,4305,O
tumors,4305,O
showing,4305,O
histologically,4305,O
aggressive,4305,O
features,4305,O
belong,4305,O
to,4305,O
mucinous,4305,O
carcinoma,4305,O
on,4305,O
the,4305,O
proteomic,4305,O
basis,4305,O
.,4305,O
The,4306,O
effects,4306,O
of,4306,O
the,4306,O
adenosine,4306,B-GENE-Y
A3,4306,I-GENE-Y
receptor,4306,I-GENE-Y
agonist,4306,O
IB-MECA,4306,B-CHEMICAL
on,4306,O
sodium,4306,B-CHEMICAL
taurocholate-induced,4306,O
experimental,4306,O
acute,4306,O
pancreatitis,4306,O
.,4306,O
The,4307,O
role,4307,O
of,4307,O
adenosine,4307,B-GENE-Y
A3,4307,I-GENE-Y
receptors,4307,I-GENE-Y
and,4307,O
their,4307,O
distribution,4307,O
in,4307,O
the,4307,O
gastrointestinal,4307,O
tract,4307,O
have,4307,O
been,4307,O
widely,4307,O
investigated,4307,O
.,4307,O
Most,4308,O
of,4308,O
the,4308,O
reports,4308,O
discuss,4308,O
their,4308,O
role,4308,O
in,4308,O
intestinal,4308,O
inflammations,4308,O
.,4308,O
However,4309,O
",",4309,O
the,4309,O
role,4309,O
of,4309,O
adenosine,4309,B-GENE-Y
A3,4309,I-GENE-Y
receptor,4309,I-GENE-Y
agonist,4309,O
in,4309,O
pancreatitis,4309,O
has,4309,O
not,4309,O
been,4309,O
well,4309,O
established,4309,O
.,4309,O
The,4310,O
aim,4310,O
of,4310,O
this,4310,O
study,4310,O
is,4310,O
(,4310,O
Ed,4310,O
note,4310,O
:,4310,O
Purpose,4310,O
statements,4310,O
should,4310,O
be,4310,O
in,4310,O
present,4310,O
tense,4310,O
),4310,O
to,4310,O
evaluate,4310,O
the,4310,O
effects,4310,O
of,4310,O
the,4310,O
adenosine,4310,B-GENE-Y
A3,4310,I-GENE-Y
receptor,4310,I-GENE-Y
agonist,4310,O
on,4310,O
the,4310,O
course,4310,O
of,4310,O
sodium,4310,B-CHEMICAL
taurocholate-induced,4310,O
experimental,4310,O
acute,4310,O
pancreatitis,4310,O
(,4310,O
EAP,4310,O
),4310,O
.,4310,O
The,4311,O
experiments,4311,O
were,4311,O
performed,4311,O
on,4311,O
80,4311,O
male,4311,O
Wistar,4311,O
rats,4311,O
",",4311,O
58,4311,O
of,4311,O
which,4311,O
survived,4311,O
",",4311,O
subdivided,4311,O
into,4311,O
3,4311,O
groups,4311,O
:,4311,O
C-control,4311,O
rats,4311,O
",",4311,O
I-EAP,4311,O
group,4311,O
",",4311,O
and,4311,O
II-EAP,4311,O
group,4311,O
treated,4311,O
with,4311,O
the,4311,O
adenosine,4311,B-GENE-Y
A3,4311,I-GENE-Y
receptor,4311,I-GENE-Y
agonist,4311,O
IB-MECA,4311,B-CHEMICAL
(,4311,B-CHEMICAL
1-deoxy-1-6,4311,I-CHEMICAL
[,4311,I-CHEMICAL
[,4311,I-CHEMICAL
(,4311,I-CHEMICAL
3-iodophenyl,4311,I-CHEMICAL
),4311,I-CHEMICAL
methyl,4311,I-CHEMICAL
],4311,I-CHEMICAL
amino,4311,I-CHEMICAL
],4311,I-CHEMICAL
-9H-purin-9-yl,4311,I-CHEMICAL
),4311,I-CHEMICAL
-N-methyl-B-D-ribofuronamide,4311,I-CHEMICAL
at,4311,O
a,4311,O
dose,4311,O
of,4311,O
0.75,4311,O
mg/kg,4311,O
b.w,4311,O
.,4311,O
i.p,4312,O
.,4312,O
at,4313,O
48,4313,O
",",4313,O
24,4313,O
",",4313,O
12,4313,O
and,4313,O
1,4313,O
h,4313,O
before,4313,O
and,4313,O
1,4313,O
h,4313,O
after,4313,O
the,4313,O
injection,4313,O
of,4313,O
5,4313,O
%,4313,O
sodium,4313,B-CHEMICAL
taurocholate,4313,I-CHEMICAL
solution,4313,O
into,4313,O
the,4313,O
biliary-pancreatic,4313,O
duct,4313,O
.,4313,O
Serum,4314,O
for,4314,O
α-amylase,4314,B-GENE-N
and,4314,O
lipase,4314,B-GENE-N
determinations,4314,O
and,4314,O
tissue,4314,O
samples,4314,O
for,4314,O
morphological,4314,O
examinations,4314,O
were,4314,O
collected,4314,O
at,4314,O
2,4314,O
",",4314,O
6,4314,O
",",4314,O
and,4314,O
24,4314,O
h,4314,O
of,4314,O
the,4314,O
experiment,4314,O
.,4314,O
In,4315,O
the,4315,O
IB-MECA,4315,B-CHEMICAL
group,4315,O
",",4315,O
α-amylase,4315,B-GENE-N
activity,4315,O
was,4315,O
decreased,4315,O
with,4315,O
statistically,4315,O
high,4315,O
significance,4315,O
compared,4315,O
to,4315,O
group,4315,O
I,4315,O
.,4315,O
The,4316,O
activity,4316,O
of,4316,O
lipase,4316,B-GENE-N
was,4316,O
not,4316,O
significantly,4316,O
different,4316,O
among,4316,O
the,4316,O
experimental,4316,O
groups,4316,O
but,4316,O
higher,4316,O
than,4316,O
in,4316,O
the,4316,O
control,4316,O
group,4316,O
.,4316,O
The,4317,O
administration,4317,O
of,4317,O
IB-MECA,4317,B-CHEMICAL
attenuated,4317,O
the,4317,O
histological,4317,O
parameters,4317,O
of,4317,O
inflammation,4317,O
as,4317,O
compared,4317,O
to,4317,O
untreated,4317,O
animals,4317,O
.,4317,O
The,4318,O
use,4318,O
of,4318,O
A3,4318,B-GENE-Y
receptor,4318,I-GENE-Y
agonist,4318,O
IB-MECA,4318,B-CHEMICAL
attenuates,4318,O
EAP,4318,O
.,4318,O
Our,4319,O
findings,4319,O
suggest,4319,O
that,4319,O
stimulation,4319,O
of,4319,O
adenosine,4319,B-GENE-Y
A3,4319,I-GENE-Y
receptors,4319,I-GENE-Y
plays,4319,O
a,4319,O
positive,4319,O
role,4319,O
in,4319,O
the,4319,O
sodium,4319,B-CHEMICAL
taurocholate-induced,4319,O
EAP,4319,O
in,4319,O
rats,4319,O
.,4319,O
Pyrrolopyrazines,4320,B-CHEMICAL
as,4320,O
Selective,4320,O
Spleen,4320,B-GENE-Y
Tyrosine,4320,I-GENE-Y
Kinase,4320,I-GENE-Y
Inhibitors,4320,O
.,4320,O
We,4321,O
describe,4321,O
the,4321,O
discovery,4321,O
of,4321,O
several,4321,O
pyrrolopyrazines,4321,B-CHEMICAL
as,4321,O
potent,4321,O
and,4321,O
selective,4321,O
Syk,4321,B-GENE-Y
inhibitors,4321,O
and,4321,O
the,4321,O
efforts,4321,O
that,4321,O
eventually,4321,O
led,4321,O
to,4321,O
the,4321,O
desired,4321,O
improvements,4321,O
in,4321,O
physicochemical,4321,O
properties,4321,O
and,4321,O
human,4321,O
whole,4321,O
blood,4321,O
potencies,4321,O
.,4321,O
Ultimately,4322,O
",",4322,O
our,4322,O
mouse,4322,O
model,4322,O
revealed,4322,O
unexpected,4322,O
toxicity,4322,O
that,4322,O
precluded,4322,O
us,4322,O
from,4322,O
further,4322,O
advancing,4322,O
this,4322,O
series,4322,O
.,4322,O
Bioactive,4323,O
microconstituents,4323,O
and,4323,O
antioxidant,4323,O
properties,4323,O
of,4323,O
wild,4323,O
edible,4323,O
mushrooms,4323,O
from,4323,O
the,4323,O
island,4323,O
of,4323,O
Lesvos,4323,O
",",4323,O
Greece,4323,O
.,4323,O
Crude,4324,O
composition,4324,O
",",4324,O
fatty,4324,B-CHEMICAL
acids,4324,I-CHEMICAL
",",4324,O
sterols,4324,B-CHEMICAL
",",4324,O
total,4324,O
phenolic,4324,O
content,4324,O
(,4324,O
TPC,4324,O
),4324,O
",",4324,O
individual,4324,O
polyphenols,4324,B-CHEMICAL
and,4324,O
terpenic,4324,B-CHEMICAL
acids,4324,I-CHEMICAL
were,4324,O
determined,4324,O
in,4324,O
five,4324,O
wild,4324,O
edible,4324,O
mushrooms,4324,O
species,4324,O
(,4324,O
Lactarius,4324,O
deliciosus,4324,O
",",4324,O
Lactarius,4324,O
sanguifluus,4324,O
",",4324,O
Lactarius,4324,O
semisanguifluus,4324,O
",",4324,O
Russula,4324,O
delica,4324,O
",",4324,O
Suillus,4324,O
bellinii,4324,O
),4324,O
from,4324,O
Lesvos,4324,O
Island,4324,O
",",4324,O
Greece,4324,O
.,4324,O
In,4325,O
addition,4325,O
",",4325,O
the,4325,O
DPPH,4325,B-CHEMICAL
scavenging,4325,O
capacity,4325,O
",",4325,O
the,4325,O
ferric,4325,B-CHEMICAL
ion,4325,O
reducing,4325,O
power,4325,O
(,4325,O
FRAP,4325,O
),4325,O
and,4325,O
the,4325,O
ferrous,4325,B-CHEMICAL
ion,4325,O
chelating,4325,O
activity,4325,O
of,4325,O
mushroom,4325,O
methanolic,4325,O
extracts,4325,O
were,4325,O
assessed,4325,O
.,4325,O
Among,4326,O
sterols,4326,B-CHEMICAL
",",4326,O
ergosterol,4326,B-CHEMICAL
predominated,4326,O
at,4326,O
concentrations,4326,O
9.2-18.0mg/100g,4326,O
fw,4326,O
.,4326,O
Total,4327,O
phenolic,4327,O
content,4327,O
of,4327,O
mushroom,4327,O
extracts,4327,O
ranged,4327,O
from,4327,O
6.0,4327,O
to,4327,O
20.8mg,4327,O
GAE/100g,4327,O
fw,4327,O
.,4327,O
Up,4328,O
to,4328,O
19,4328,O
simple,4328,O
polyphenols,4328,B-CHEMICAL
were,4328,O
determined,4328,O
in,4328,O
mushrooms,4328,O
extracts,4328,O
",",4328,O
the,4328,O
more,4328,O
abundant,4328,O
being,4328,O
p-OH-benzoic,4328,B-CHEMICAL
acid,4328,I-CHEMICAL
",",4328,O
p-OH-phenylacetic,4328,B-CHEMICAL
acid,4328,I-CHEMICAL
",",4328,O
o-coumaric,4328,B-CHEMICAL
acid,4328,I-CHEMICAL
",",4328,O
ferulic,4328,B-CHEMICAL
acid,4328,I-CHEMICAL
and,4328,O
chrysin,4328,B-CHEMICAL
.,4328,O
In,4329,O
addition,4329,O
",",4329,O
the,4329,O
triterpenic,4329,B-CHEMICAL
acids,4329,I-CHEMICAL
oleanolic,4329,B-CHEMICAL
and,4329,O
ursolic,4329,B-CHEMICAL
were,4329,O
detected,4329,O
for,4329,O
the,4329,O
first,4329,O
time,4329,O
in,4329,O
mushrooms,4329,O
.,4329,O
All,4330,O
species,4330,O
exerted,4330,O
antioxidant,4330,O
activity,4330,O
and,4330,O
ferrous,4330,B-CHEMICAL
ion,4330,O
chelating,4330,O
capacity,4330,O
.,4330,O
Principal,4331,O
component,4331,O
analysis,4331,O
revealed,4331,O
good,4331,O
correlations,4331,O
between,4331,O
TPC,4331,O
",",4331,O
DPPH,4331,B-CHEMICAL
and,4331,O
FRAP,4331,O
but,4331,O
not,4331,O
with,4331,O
metal,4331,O
chelating,4331,O
activity,4331,O
.,4331,O
It,4332,O
seems,4332,O
that,4332,O
mushrooms,4332,O
polyphenols,4332,B-CHEMICAL
exert,4332,O
antiradical,4332,O
and,4332,O
reducing,4332,O
activities,4332,O
",",4332,O
but,4332,O
they,4332,O
are,4332,O
not,4332,O
strong,4332,O
metal,4332,O
chelators,4332,O
",",4332,O
the,4332,O
observed,4332,O
chelating,4332,O
ability,4332,O
being,4332,O
probably,4332,O
due,4332,O
to,4332,O
other,4332,O
classes,4332,O
of,4332,O
compounds,4332,O
.,4332,O
To,4333,O
our,4333,O
knowledge,4333,O
",",4333,O
this,4333,O
is,4333,O
the,4333,O
first,4333,O
report,4333,O
on,4333,O
the,4333,O
bioactive,4333,O
microconstituents,4333,O
and,4333,O
antioxidant,4333,O
activity,4333,O
of,4333,O
wild,4333,O
Greek,4333,O
edible,4333,O
mushrooms,4333,O
.,4333,O
Optimization,4334,O
of,4334,O
taxane,4334,B-CHEMICAL
binding,4334,O
to,4334,O
microtubules,4334,B-GENE-N
:,4334,O
binding,4334,O
affinity,4334,O
dissection,4334,O
and,4334,O
incremental,4334,O
construction,4334,O
of,4334,O
a,4334,O
high-affinity,4334,O
analog,4334,O
of,4334,O
paclitaxel,4334,B-CHEMICAL
.,4334,O
The,4335,O
microtubule,4335,B-GENE-N
binding,4335,O
affinities,4335,O
of,4335,O
a,4335,O
series,4335,O
of,4335,O
synthetic,4335,O
taxanes,4335,B-CHEMICAL
have,4335,O
been,4335,O
measured,4335,O
with,4335,O
the,4335,O
aims,4335,O
of,4335,O
dissecting,4335,O
individual,4335,O
group,4335,O
contributions,4335,O
and,4335,O
obtaining,4335,O
a,4335,O
rationale,4335,O
for,4335,O
the,4335,O
design,4335,O
of,4335,O
novel,4335,O
compounds,4335,O
with,4335,O
the,4335,O
ability,4335,O
to,4335,O
overcome,4335,O
drug,4335,O
resistance,4335,O
.,4335,O
As,4336,O
previously,4336,O
observed,4336,O
for,4336,O
epothilones,4336,B-CHEMICAL
",",4336,O
the,4336,O
positive,4336,O
and,4336,O
negative,4336,O
contributions,4336,O
of,4336,O
the,4336,O
different,4336,O
substituents,4336,O
to,4336,O
the,4336,O
binding,4336,O
free,4336,O
energies,4336,O
are,4336,O
cumulative,4336,O
.,4336,O
By,4337,O
combining,4337,O
the,4337,O
most,4337,O
favorable,4337,O
substitutions,4337,O
we,4337,O
increased,4337,O
the,4337,O
binding,4337,O
affinity,4337,O
of,4337,O
paclitaxel,4337,B-CHEMICAL
500-fold,4337,O
.,4337,O
Insight,4338,O
into,4338,O
the,4338,O
structural,4338,O
basis,4338,O
for,4338,O
this,4338,O
improvement,4338,O
was,4338,O
gained,4338,O
with,4338,O
molecular,4338,O
modeling,4338,O
and,4338,O
NMR,4338,O
data,4338,O
obtained,4338,O
for,4338,O
microtubule-bound,4338,B-GENE-N
docetaxel,4338,B-CHEMICAL
.,4338,O
Taxanes,4339,B-CHEMICAL
with,4339,O
affinities,4339,O
for,4339,O
microtubules,4339,B-GENE-N
well,4339,O
above,4339,O
their,4339,O
affinities,4339,O
for,4339,O
P-glycoprotein,4339,B-GENE-N
are,4339,O
shown,4339,O
not,4339,O
to,4339,O
be,4339,O
affected,4339,O
by,4339,O
multidrug,4339,O
resistance,4339,O
.,4339,O
This,4340,O
finding,4340,O
strongly,4340,O
indicates,4340,O
that,4340,O
optimization,4340,O
of,4340,O
the,4340,O
ligand-target,4340,O
interaction,4340,O
is,4340,O
a,4340,O
good,4340,O
strategy,4340,O
to,4340,O
overcome,4340,O
multidrug,4340,O
resistance,4340,O
mediated,4340,O
by,4340,O
efflux,4340,B-GENE-N
pumps,4340,I-GENE-N
.,4340,O
Effects,4341,O
of,4341,O
ozone,4341,B-CHEMICAL
and,4341,O
fine,4341,O
particulate,4341,O
matter,4341,O
(,4341,O
PM,4341,O
(,4341,O
2.5,4341,O
),4341,O
),4341,O
on,4341,O
rat,4341,O
system,4341,O
inflammation,4341,O
and,4341,O
cardiac,4341,O
function,4341,O
.,4341,O
In,4342,O
order,4342,O
to,4342,O
understand,4342,O
the,4342,O
toxic,4342,O
mechanisms,4342,O
of,4342,O
cardiovascular,4342,O
system,4342,O
injuries,4342,O
induced,4342,O
by,4342,O
ambient,4342,O
PM,4342,O
(,4342,O
2.5,4342,O
),4342,O
and/or,4342,O
ozone,4342,B-CHEMICAL
",",4342,O
a,4342,O
subacute,4342,O
toxicological,4342,O
animal,4342,O
experiment,4342,O
was,4342,O
designed,4342,O
with,4342,O
exposure,4342,O
twice,4342,O
a,4342,O
week,4342,O
for,4342,O
3,4342,O
continuous,4342,O
weeks,4342,O
.,4342,O
Wistar,4343,O
rats,4343,O
were,4343,O
randomly,4343,O
categorized,4343,O
into,4343,O
8,4343,O
groups,4343,O
(,4343,O
n=6,4343,O
),4343,O
:,4343,O
1,4343,O
control,4343,O
group,4343,O
",",4343,O
3,4343,O
groups,4343,O
exposed,4343,O
to,4343,O
fine,4343,O
particulate,4343,O
matters,4343,O
(,4343,O
PM,4343,O
(,4343,O
2.5,4343,O
),4343,O
),4343,O
alone,4343,O
at,4343,O
3,4343,O
doses,4343,O
(,4343,O
0.2,4343,O
",",4343,O
0.8,4343,O
",",4343,O
or,4343,O
3.2,4343,O
mg/rat,4343,O
),4343,O
",",4343,O
1,4343,O
group,4343,O
to,4343,O
ozone,4343,B-CHEMICAL
(,4343,O
0.81,4343,O
ppm,4343,O
),4343,O
alone,4343,O
and,4343,O
3,4343,O
groups,4343,O
to,4343,O
ozone,4343,B-CHEMICAL
plus,4343,O
PM,4343,O
(,4343,O
2.5,4343,O
),4343,O
at,4343,O
3,4343,O
doses,4343,O
(,4343,O
0.2,4343,O
",",4343,O
0.8,4343,O
",",4343,O
or,4343,O
3.2,4343,O
mg/rat,4343,O
),4343,O
.,4343,O
Heart,4344,O
rate,4344,O
(,4344,O
HR,4344,O
),4344,O
and,4344,O
electrocardiogram,4344,O
(,4344,O
ECG,4344,O
),4344,O
was,4344,O
monitored,4344,O
at,4344,O
approximately,4344,O
24-h,4344,O
both,4344,O
after,4344,O
the,4344,O
3rd,4344,O
exposure,4344,O
and,4344,O
the,4344,O
last,4344,O
(,4344,O
6th,4344,O
),4344,O
exposure,4344,O
",",4344,O
and,4344,O
systolic,4344,O
blood,4344,O
pressure,4344,O
(,4344,O
SBP,4344,O
),4344,O
was,4344,O
monitored,4344,O
at,4344,O
approximately,4344,O
24-h,4344,O
after,4344,O
the,4344,O
6th,4344,O
exposure,4344,O
.,4344,O
Biomarkers,4345,O
of,4345,O
systemic,4345,O
inflammation,4345,O
and,4345,O
injuries,4345,O
(,4345,O
CRP,4345,B-GENE-Y
",",4345,O
IL-6,4345,B-GENE-Y
",",4345,O
LDH,4345,B-GENE-N
",",4345,O
CK,4345,B-GENE-N
),4345,O
",",4345,O
heart,4345,O
oxidative,4345,O
stress,4345,O
(,4345,O
MDA,4345,B-CHEMICAL
",",4345,O
SOD,4345,B-GENE-N
),4345,O
and,4345,O
endothelial,4345,O
function,4345,O
(,4345,O
ET-1,4345,B-GENE-Y
",",4345,O
VEGF,4345,B-GENE-Y
),4345,O
were,4345,O
analyzed,4345,O
after,4345,O
the,4345,O
6th,4345,O
exposure,4345,O
.,4345,O
Additionally,4346,O
",",4346,O
myocardial,4346,O
ultrastructural,4346,O
alterations,4346,O
were,4346,O
observed,4346,O
under,4346,O
transmission,4346,O
electron,4346,O
microscopy,4346,O
(,4346,O
TEM,4346,O
),4346,O
for,4346,O
histopathological,4346,O
analyses,4346,O
.,4346,O
Results,4347,O
showed,4347,O
that,4347,O
PM,4347,O
(,4347,O
2.5,4347,O
),4347,O
alone,4347,O
exposure,4347,O
could,4347,O
trigger,4347,O
the,4347,O
significant,4347,O
increase,4347,O
of,4347,O
CRP,4347,B-GENE-Y
",",4347,O
MDA,4347,B-CHEMICAL
",",4347,O
CK,4347,B-GENE-N
",",4347,O
ET-1,4347,B-GENE-Y
and,4347,O
SBP,4347,O
and,4347,O
decrease,4347,O
of,4347,O
heart,4347,O
rate,4347,O
variability,4347,O
(,4347,O
HRV,4347,O
),4347,O
",",4347,O
a,4347,O
marker,4347,O
of,4347,O
cardiac,4347,O
autonomic,4347,O
nervous,4347,O
system,4347,O
(,4347,O
ANS,4347,O
),4347,O
function,4347,O
.,4347,O
Ozone,4348,B-CHEMICAL
alone,4348,O
exposure,4348,O
in,4348,O
rats,4348,O
did,4348,O
not,4348,O
show,4348,O
significant,4348,O
alterations,4348,O
in,4348,O
any,4348,O
indicators,4348,O
.,4348,O
Ozone,4349,B-CHEMICAL
plus,4349,O
PM,4349,O
(,4349,O
2.5,4349,O
),4349,O
exposure,4349,O
",",4349,O
however,4349,O
",",4349,O
induced,4349,O
CRP,4349,B-GENE-Y
",",4349,O
IL-6,4349,B-GENE-Y
",",4349,O
CK,4349,B-GENE-N
",",4349,O
LDH,4349,B-GENE-N
and,4349,O
MDA,4349,B-CHEMICAL
increase,4349,O
",",4349,O
SOD,4349,B-GENE-N
and,4349,O
HRV,4349,O
decrease,4349,O
significantly,4349,O
in,4349,O
a,4349,O
dose-response,4349,O
way,4349,O
.,4349,O
Meanwhile,4350,O
",",4350,O
abnormal,4350,O
ECG,4350,O
types,4350,O
were,4350,O
monitored,4350,O
in,4350,O
rats,4350,O
exposed,4350,O
to,4350,O
PM,4350,O
(,4350,O
2.5,4350,O
),4350,O
with,4350,O
and,4350,O
without,4350,O
ozone,4350,B-CHEMICAL
and,4350,O
obvious,4350,O
myocardial,4350,O
ultrastructural,4350,O
changes,4350,O
were,4350,O
observed,4350,O
by,4350,O
TEM,4350,O
.,4350,O
In,4351,O
conclusion,4351,O
",",4351,O
PM,4351,O
(,4351,O
2.5,4351,O
),4351,O
alone,4351,O
exposure,4351,O
could,4351,O
cause,4351,O
inflammation,4351,O
",",4351,O
endothelial,4351,O
function,4351,O
and,4351,O
ANS,4351,O
injuries,4351,O
",",4351,O
and,4351,O
ozone,4351,B-CHEMICAL
potentiated,4351,O
these,4351,O
effects,4351,O
induced,4351,O
by,4351,O
PM,4351,O
(,4351,O
2.5,4351,O
),4351,O
.,4351,O
Flavopiridol,4352,B-CHEMICAL
Hoechst,4352,O
AG,4352,O
.,4352,O
Hoechst,4353,O
is,4353,O
developing,4353,O
flavopiridol,4353,B-CHEMICAL
",",4353,O
a,4353,O
synthetic,4353,O
flavonoid,4353,B-CHEMICAL
based,4353,O
on,4353,O
an,4353,O
extract,4353,O
from,4353,O
an,4353,O
Indian,4353,O
plant,4353,O
",",4353,O
for,4353,O
the,4353,O
potential,4353,O
treatment,4353,O
of,4353,O
cancer,4353,O
.,4353,O
Flavopiridol,4354,B-CHEMICAL
",",4354,O
a,4354,O
cyclin-dependent,4354,B-GENE-N
kinase,4354,I-GENE-N
inhibitor,4354,O
",",4354,O
arrests,4354,O
cell,4354,O
division,4354,O
and,4354,O
causes,4354,O
apoptosis,4354,O
in,4354,O
non-small,4354,O
lung,4354,O
cancer,4354,O
cells,4354,O
[,4354,O
283660,4354,O
],4354,O
.,4354,O
A,4355,O
phase,4355,O
II,4355,O
trial,4355,O
",",4355,O
in,4355,O
collaboration,4355,O
with,4355,O
the,4355,O
National,4355,O
Cancer,4355,O
Institute,4355,O
",",4355,O
has,4355,O
commenced,4355,O
at,4355,O
the,4355,O
University,4355,O
of,4355,O
Chicago,4355,O
Medical,4355,O
Center,4355,O
",",4355,O
which,4355,O
involves,4355,O
patients,4355,O
with,4355,O
high,4355,O
or,4355,O
intermediate-grade,4355,O
lymphoma,4355,O
or,4355,O
multiple,4355,O
myeloma,4355,O
[,4355,O
272937,4355,O
],4355,O
",",4355,O
[,4355,O
277372,4355,O
],4355,O
.,4355,O
In,4356,O
ex,4356,O
vivo,4356,O
experiments,4356,O
with,4356,O
tumor,4356,O
cells,4356,O
from,4356,O
refractory,4356,O
chronic,4356,O
lymphoblastic,4356,O
leukemia,4356,O
",",4356,O
dose-dependent,4356,O
CDK2,4356,B-GENE-Y
inhibition,4356,O
associated,4356,O
with,4356,O
apoptotic,4356,O
changes,4356,O
was,4356,O
seen,4356,O
at,4356,O
concentrations,4356,O
greater,4356,O
than,4356,O
100,4356,O
nM,4356,O
of,4356,O
flavopiridol,4356,B-CHEMICAL
.,4356,O
In,4357,O
vitro,4357,O
pharmacokinetic,4357,O
studies,4357,O
have,4357,O
shown,4357,O
that,4357,O
flavopiridol,4357,B-CHEMICAL
undergoes,4357,O
hepatic,4357,O
biotransformation,4357,O
to,4357,O
its,4357,O
corresponding,4357,O
glucoronide,4357,B-CHEMICAL
by,4357,O
uridine,4357,B-CHEMICAL
diphosphate,4357,I-CHEMICAL
glucoronosyltransferases,4357,O
[,4357,O
283791,4357,O
],4357,O
.,4357,O
Flavopiridol,4358,B-CHEMICAL
inhibits,4358,O
CDK,4358,B-GENE-N
with,4358,O
an,4358,O
IC50,4358,O
value,4358,O
of,4358,O
0.4,4358,O
mM,4358,O
[,4358,O
285707,4358,O
],4358,O
.,4358,O
Preclinical,4359,O
toxicology,4359,O
studies,4359,O
in,4359,O
rats,4359,O
and,4359,O
dogs,4359,O
demonstrated,4359,O
dose-related,4359,O
leukopenia,4359,O
and,4359,O
drug-related,4359,O
lesions,4359,O
in,4359,O
the,4359,O
thymus,4359,O
",",4359,O
spleen,4359,O
and,4359,O
bone,4359,O
marrow,4359,O
.,4359,O
The,4360,O
gastrointestinal,4360,O
and,4360,O
bone,4360,O
marrow,4360,O
toxicity,4360,O
was,4360,O
dose-limiting,4360,O
[,4360,O
178579,4360,O
],4360,O
.,4360,O
Hoechst,4361,O
Marion,4361,O
Roussel,4361,O
expects,4361,O
to,4361,O
launch,4361,O
flavopiridol,4361,B-CHEMICAL
in,4361,O
the,4361,O
year,4361,O
2001,4361,O
",",4361,O
with,4361,O
potential,4361,O
sales,4361,O
in,4361,O
excess,4361,O
of,4361,O
DM,4361,O
750,4361,O
million,4361,O
[,4361,O
288651,4361,O
],4361,O
.,4361,O
Carbonic,4362,B-GENE-N
anhydrase,4362,I-GENE-N
inhibitors,4362,O
:,4362,O
aromatic,4362,B-CHEMICAL
and,4362,I-CHEMICAL
heterocyclic,4362,I-CHEMICAL
sulfonamides,4362,I-CHEMICAL
incorporating,4362,O
adamantyl,4362,B-CHEMICAL
moieties,4362,O
with,4362,O
strong,4362,O
anticonvulsant,4362,O
activity,4362,O
.,4362,O
A,4363,O
series,4363,O
of,4363,O
aromatic/heterocyclic,4363,B-CHEMICAL
sulfonamides,4363,I-CHEMICAL
incorporating,4363,O
adamantyl,4363,B-CHEMICAL
moieties,4363,O
were,4363,O
prepared,4363,O
by,4363,O
reaction,4363,O
of,4363,O
aromatic/heterocyclic,4363,B-CHEMICAL
aminosulfonamides,4363,I-CHEMICAL
with,4363,O
the,4363,O
acyl,4363,B-CHEMICAL
chlorides,4363,I-CHEMICAL
derived,4363,O
from,4363,O
adamantyl-1-carboxylic,4363,B-CHEMICAL
acid,4363,I-CHEMICAL
and,4363,O
1-adamantyl-acetic,4363,B-CHEMICAL
acid,4363,I-CHEMICAL
.,4363,O
Related,4364,O
derivatives,4364,O
were,4364,O
obtained,4364,O
from,4364,O
the,4364,O
above-mentioned,4364,O
aminosulfonamides,4364,B-CHEMICAL
with,4364,O
adamantyl,4364,B-CHEMICAL
isocyanate,4364,I-CHEMICAL
and,4364,O
adamantyl,4364,B-CHEMICAL
isothiocyanate,4364,I-CHEMICAL
",",4364,O
respectively,4364,O
.,4364,O
Some,4365,O
of,4365,O
these,4365,O
derivatives,4365,O
showed,4365,O
good,4365,O
inhibitory,4365,O
potency,4365,O
against,4365,O
two,4365,O
human,4365,B-GENE-N
CA,4365,I-GENE-N
isozymes,4365,O
involved,4365,O
in,4365,O
important,4365,O
physiological,4365,O
processes,4365,O
",",4365,O
CA,4365,B-GENE-Y
I,4365,I-GENE-Y
",",4365,O
and,4365,O
CA,4365,B-GENE-Y
II,4365,I-GENE-Y
",",4365,O
of,4365,O
the,4365,O
same,4365,O
order,4365,O
of,4365,O
magnitude,4365,O
as,4365,O
the,4365,O
clinically,4365,O
used,4365,O
drugs,4365,O
acetazolamide,4365,B-CHEMICAL
and,4365,O
methazolamide,4365,B-CHEMICAL
.,4365,O
The,4366,O
lipophilicity,4366,O
of,4366,O
the,4366,O
best,4366,O
CA,4366,B-GENE-N
inhibitors,4366,O
was,4366,O
determined,4366,O
and,4366,O
expressed,4366,O
as,4366,O
their,4366,O
experimental,4366,O
log,4366,O
k,4366,O
',4366,O
IAM,4366,O
and,4366,O
theoretical,4366,O
ClogP,4366,O
value,4366,O
.,4366,O
Their,4367,O
lipophilicity,4367,O
was,4367,O
propitious,4367,O
with,4367,O
the,4367,O
crossing,4367,O
of,4367,O
the,4367,O
blood-brain,4367,O
barrier,4367,O
(,4367,O
log,4367,O
k,4367,O
',4367,O
>,4367,O
IAM,4367,O
>,4367,O
1.35,4367,O
),4367,O
.,4367,O
The,4368,O
anticonvulsant,4368,O
activity,4368,O
of,4368,O
some,4368,O
of,4368,O
the,4368,O
best,4368,O
CA,4368,B-GENE-N
inhibitors,4368,O
reported,4368,O
here,4368,O
has,4368,O
been,4368,O
evaluated,4368,O
in,4368,O
a,4368,O
MES,4368,O
test,4368,O
in,4368,O
mice,4368,O
.,4368,O
After,4369,O
intraperitoneal,4369,O
injection,4369,O
(,4369,O
30,4369,O
mg,4369,O
kg,4369,O
(,4369,O
-1,4369,O
),4369,O
),4369,O
",",4369,O
compounds,4369,O
A8,4369,O
and,4369,O
A9,4369,O
exhibited,4369,O
a,4369,O
high,4369,O
protection,4369,O
against,4369,O
electrically,4369,O
induced,4369,O
convulsions,4369,O
(,4369,O
>,4369,O
90,4369,O
%,4369,O
),4369,O
.,4369,O
Their,4370,O
ED50,4370,O
was,4370,O
3.5,4370,O
and,4370,O
2.6,4370,O
mg,4370,O
kg,4370,O
(,4370,O
-1,4370,O
),4370,O
",",4370,O
respectively,4370,O
.,4370,O
Enzymatic,4371,O
characterization,4371,O
of,4371,O
a,4371,O
recombinant,4371,O
isoform,4371,O
hybrid,4371,O
of,4371,O
glutamic,4371,B-GENE-N
acid,4371,I-GENE-N
decarboxylase,4371,I-GENE-N
(,4371,O
rGAD67/65,4371,B-GENE-N
),4371,O
expressed,4371,O
in,4371,O
yeast,4371,O
.,4371,O
BACKGROUND,4372,O
AND,4372,O
AIMS,4372,O
:,4372,O
Glutamic,4372,B-GENE-N
acid,4372,I-GENE-N
decarboxylase,4372,I-GENE-N
(,4372,O
GAD,4372,B-GENE-N
",",4372,O
EC,4372,B-GENE-Y
4.1.1.15,4372,I-GENE-Y
),4372,O
catalyses,4372,O
the,4372,O
conversion,4372,O
of,4372,O
glutamate,4372,B-CHEMICAL
to,4372,O
gamma-aminobutyric,4372,B-CHEMICAL
acid,4372,I-CHEMICAL
(,4372,O
GABA,4372,B-CHEMICAL
),4372,O
.,4372,O
The,4373,O
65,4373,O
kDa,4373,O
isoform,4373,O
",",4373,O
GAD65,4373,B-GENE-Y
is,4373,O
a,4373,O
potent,4373,O
autoantigen,4373,O
in,4373,O
type,4373,O
1,4373,O
diabetes,4373,O
",",4373,O
whereas,4373,O
GAD67,4373,B-GENE-Y
is,4373,O
not,4373,O
.,4373,O
A,4374,O
hybrid,4374,O
cDNA,4374,O
was,4374,O
created,4374,O
by,4374,O
fusing,4374,O
a,4374,O
human,4374,O
cDNA,4374,O
for,4374,O
amino,4374,B-CHEMICAL
acids,4374,I-CHEMICAL
1-101,4374,O
of,4374,O
GAD67,4374,B-GENE-Y
to,4374,O
a,4374,O
human,4374,O
cDNA,4374,O
for,4374,O
amino,4374,B-CHEMICAL
acids,4374,I-CHEMICAL
96-585,4374,O
of,4374,O
GAD65,4374,B-GENE-Y
;,4374,O
the,4374,O
recombinant,4374,O
(,4374,O
r,4374,O
),4374,O
protein,4374,O
was,4374,O
expressed,4374,O
in,4374,O
yeast,4374,O
and,4374,O
was,4374,O
shown,4374,O
to,4374,O
have,4374,O
equivalent,4374,O
immunoreactivity,4374,O
to,4374,O
mammalian,4374,B-GENE-N
brain,4374,I-GENE-N
GAD,4374,I-GENE-N
with,4374,O
diabetes,4374,O
sera,4374,O
.,4374,O
We,4375,O
here,4375,O
report,4375,O
on,4375,O
enzymatic,4375,O
and,4375,O
molecular,4375,O
properties,4375,O
of,4375,O
rGAD67/65,4375,B-GENE-N
.,4375,O
METHODS,4376,O
:,4376,O
Studies,4376,O
were,4376,O
performed,4376,O
on,4376,O
enzymatic,4376,O
activity,4376,O
of,4376,O
rGAD67/65,4376,B-GENE-N
by,4376,O
production,4376,O
of,4376,O
3H-GABA,4376,B-CHEMICAL
from,4376,O
3H-glutamate,4376,B-CHEMICAL
",",4376,O
enzyme,4376,O
kinetics,4376,O
",",4376,O
binding,4376,O
to,4376,O
the,4376,O
enzyme,4376,O
cofactor,4376,O
pyridoxal,4376,B-CHEMICAL
phosphate,4376,I-CHEMICAL
(,4376,O
PLP,4376,B-CHEMICAL
),4376,O
",",4376,O
stability,4376,O
according,4376,O
to,4376,O
differences,4376,O
in,4376,O
pH,4376,O
",",4376,O
temperature,4376,O
and,4376,O
duration,4376,O
of,4376,O
storage,4376,O
",",4376,O
and,4376,O
antigenic,4376,O
reactivity,4376,O
with,4376,O
various,4376,O
GAD-specific,4376,B-GENE-N
antisera,4376,O
.,4376,O
RESULTS,4377,O
:,4377,O
The,4377,O
properties,4377,O
of,4377,O
rGAD67/65,4377,B-GENE-N
were,4377,O
compared,4377,O
with,4377,O
published,4377,O
data,4377,O
for,4377,O
mammalian,4377,B-GENE-N
brain,4377,I-GENE-N
GAD,4377,I-GENE-N
(,4377,O
brackets,4377,O
),4377,O
.,4377,O
These,4378,O
included,4378,O
a,4378,O
specific,4378,O
enzyme,4378,O
activity,4378,O
of,4378,O
22.7,4378,O
(,4378,O
16.7,4378,O
),4378,O
nKat,4378,O
",",4378,O
optimal,4378,O
pH,4378,O
for,4378,O
enzymatic,4378,O
activity,4378,O
7.4,4378,O
(,4378,O
6.8,4378,O
),4378,O
",",4378,O
K,4378,O
(,4378,O
m,4378,O
),4378,O
of,4378,O
1.3,4378,O
(,4378,O
1.3,4378,O
),4378,O
mM,4378,O
",",4378,O
efficient,4378,O
non-covalent,4378,O
binding,4378,O
to,4378,O
the,4378,O
cofactor,4378,O
PLP,4378,B-CHEMICAL
",",4378,O
and,4378,O
high,4378,O
autoantigenic,4378,O
potency,4378,O
.,4378,O
The,4379,O
stability,4379,O
of,4379,O
rGAD67/65,4379,B-GENE-N
was,4379,O
optimal,4379,O
over,4379,O
3,4379,O
months,4379,O
at,4379,O
-80,4379,O
degrees,4379,O
C,4379,O
",",4379,O
or,4379,O
in,4379,O
lyophilized,4379,O
form,4379,O
at,4379,O
-20,4379,O
degrees,4379,O
C.,4379,O
CONCLUSIONS,4379,O
:,4379,O
Hybrid,4379,O
rGAD67/65,4379,B-GENE-N
has,4379,O
enzymatic,4379,O
and,4379,O
other,4379,O
properties,4379,O
similar,4379,O
to,4379,O
those,4379,O
of,4379,O
the,4379,O
mixed,4379,O
isoforms,4379,O
of,4379,O
GAD,4379,B-GENE-N
in,4379,O
preparations,4379,O
from,4379,O
mammalian,4379,O
brain,4379,O
as,4379,O
described,4379,O
elsewhere,4379,O
",",4379,O
in,4379,O
addition,4379,O
to,4379,O
its,4379,O
previously,4379,O
described,4379,O
similar,4379,O
immunoreactivity,4379,O
.,4379,O
Bioactive,4380,O
phenolics,4380,B-CHEMICAL
from,4380,O
Seriphidium,4380,O
stenocephalum,4380,O
.,4380,O
Chromatographic,4381,O
separation,4381,O
of,4381,O
the,4381,O
ethyl,4381,B-CHEMICAL
acetate,4381,I-CHEMICAL
soluble,4381,O
part,4381,O
of,4381,O
the,4381,O
methanolic,4381,O
extract,4381,O
from,4381,O
Seriphidium,4381,O
stenocephalum,4381,O
yielded,4381,O
three,4381,O
new,4381,O
compounds,4381,O
:,4381,O
stenocepflavone,4381,B-CHEMICAL
(,4381,O
1,4381,O
),4381,O
",",4381,O
stenocepflavan,4381,B-CHEMICAL
(,4381,O
2,4381,O
),4381,O
",",4381,O
and,4381,O
stenocephol,4381,B-CHEMICAL
(,4381,O
3,4381,O
),4381,O
",",4381,O
together,4381,O
with,4381,O
cirsimaritin,4381,B-CHEMICAL
(,4381,O
4,4381,O
),4381,O
",",4381,O
"5,7,5'-trihydroxy-3',4',6-trimethoxyflavone",4381,B-CHEMICAL
(,4381,O
5,4381,O
),4381,O
",",4381,O
"5,6,7,5'-tetrahydroxy-4'-methoxyflavone",4381,B-CHEMICAL
(,4381,O
6,4381,O
),4381,O
",",4381,O
and,4381,O
axillaroside,4381,B-CHEMICAL
(,4381,O
7,4381,O
),4381,O
.,4381,O
All,4382,O
isolates,4382,O
were,4382,O
characterized,4382,O
with,4382,O
the,4382,O
help,4382,O
of,4382,O
spectroscopic,4382,O
data,4382,O
including,4382,O
1D,4382,O
",",4382,O
2D,4382,O
NMR,4382,O
",",4382,O
and,4382,O
high,4382,O
resolution,4382,O
mass,4382,O
spectrometry,4382,O
and/or,4382,O
in,4382,O
comparison,4382,O
with,4382,O
the,4382,O
related,4382,O
compounds,4382,O
in,4382,O
literature,4382,O
.,4382,O
All,4383,O
compounds,4383,O
were,4383,O
tested,4383,O
for,4383,O
in,4383,O
vitro,4383,O
enzyme,4383,O
inhibitory,4383,O
activities,4383,O
against,4383,O
acetylcholinesterase,4383,B-GENE-Y
",",4383,O
butyrylcholinesterase,4383,B-GENE-Y
",",4383,O
and,4383,O
lipoxygenase,4383,B-GENE-N
.,4383,O
Compounds,4384,O
1,4384,O
and,4384,O
4-7,4384,O
exhibited,4384,O
significant,4384,O
activity,4384,O
against,4384,O
all,4384,O
the,4384,O
tested,4384,O
enzymes,4384,O
",",4384,O
whereas,4384,O
compounds,4384,O
2,4384,O
and,4384,O
3,4384,O
were,4384,O
found,4384,O
inactive,4384,O
.,4384,O
Anti-inflammatory,4385,O
effect,4385,O
of,4385,O
essential,4385,O
oil,4385,O
and,4385,O
its,4385,O
constituents,4385,O
from,4385,O
fingered,4385,O
citron,4385,O
(,4385,O
Citrus,4385,O
medica,4385,O
L.,4385,O
var,4385,O
.,4385,O
sarcodactylis,4386,O
),4386,O
through,4386,O
blocking,4386,O
JNK,4386,B-GENE-N
",",4386,O
ERK,4386,B-GENE-N
and,4386,O
NF-κB,4386,B-GENE-N
signaling,4386,O
pathways,4386,O
in,4386,O
LPS-activated,4386,O
RAW,4386,O
264.7,4386,O
cells,4386,O
.,4386,O
We,4387,O
investigated,4387,O
the,4387,O
composition,4387,O
of,4387,O
essential,4387,O
oil,4387,O
from,4387,O
fingered,4387,O
citron,4387,O
(,4387,O
Citrus,4387,O
medica,4387,O
L.,4387,O
var,4387,O
.,4387,O
sarcodactylis,4388,O
),4388,O
(,4388,O
FCEO,4388,O
),4388,O
peels,4388,O
by,4388,O
GC-MS,4388,O
and,4388,O
its,4388,O
anti-inflammatory,4388,O
effects,4388,O
on,4388,O
lipopolysaccharide,4388,O
(,4388,O
LPS,4388,O
),4388,O
-,4388,O
stimulated,4388,O
mouse,4388,O
macrophage,4388,O
(,4388,O
RAW,4388,O
264.7,4388,O
),4388,O
cells,4388,O
.,4388,O
Fifteen,4389,O
compounds,4389,O
",",4389,O
representing,4389,O
98.97,4389,O
%,4389,O
of,4389,O
the,4389,O
essential,4389,O
oil,4389,O
",",4389,O
were,4389,O
tentatively,4389,O
identified,4389,O
;,4389,O
the,4389,O
main,4389,O
constituents,4389,O
were,4389,O
limonene,4389,B-CHEMICAL
(,4389,O
52.44,4389,O
%,4389,O
),4389,O
and,4389,O
γ-terpinene,4389,B-CHEMICAL
(,4389,O
28.41,4389,O
%,4389,O
),4389,O
.,4389,O
FCEO,4390,O
significantly,4390,O
inhibited,4390,O
nitric,4390,B-CHEMICAL
oxide,4390,I-CHEMICAL
(,4390,O
NO,4390,B-CHEMICAL
),4390,O
and,4390,O
prostaglandin,4390,B-CHEMICAL
E2,4390,I-CHEMICAL
(,4390,O
PGE2,4390,B-CHEMICAL
),4390,O
by,4390,O
suppressing,4390,O
the,4390,O
protein,4390,O
expression,4390,O
of,4390,O
inducible,4390,B-GENE-Y
nitric,4390,I-GENE-Y
oxide,4390,I-GENE-Y
synthase,4390,I-GENE-Y
(,4390,O
iNOS,4390,B-GENE-Y
),4390,O
and,4390,O
cyclooxygenase,4390,B-GENE-Y
(,4390,I-GENE-Y
COX,4390,I-GENE-Y
),4390,I-GENE-Y
-2,4390,I-GENE-Y
",",4390,O
respectively,4390,O
.,4390,O
Additionally,4391,O
",",4391,O
FCEO,4391,O
suppressed,4391,O
the,4391,O
production,4391,O
of,4391,O
tumor,4391,B-GENE-Y
necrosis,4391,I-GENE-Y
factor-α,4391,I-GENE-Y
(,4391,O
TNF-α,4391,B-GENE-Y
),4391,O
",",4391,O
interleukin,4391,B-GENE-Y
(,4391,I-GENE-Y
IL,4391,I-GENE-Y
),4391,I-GENE-Y
-1β,4391,I-GENE-Y
",",4391,O
and,4391,O
IL-6,4391,B-GENE-Y
.,4391,O
FCEO,4392,O
attenuated,4392,O
LPS-induced,4392,O
nuclear,4392,B-GENE-N
factor-κB,4392,I-GENE-N
(,4392,O
NF-κB,4392,B-GENE-N
),4392,O
activation,4392,O
via,4392,O
inhibition,4392,O
of,4392,O
inhibitor,4392,B-GENE-Y
κB-α,4392,I-GENE-Y
phosphorylation,4392,O
.,4392,O
Furthermore,4393,O
",",4393,O
FCEO,4393,O
blocked,4393,O
activation,4393,O
of,4393,O
c-Jun,4393,B-GENE-N
N-terminal,4393,I-GENE-N
kinase,4393,I-GENE-N
(,4393,O
JNK,4393,B-GENE-N
),4393,O
and,4393,O
extracellular,4393,B-GENE-N
signal-regulated,4393,I-GENE-N
kinase,4393,I-GENE-N
(,4393,O
ERK,4393,B-GENE-N
),4393,O
but,4393,O
not,4393,O
that,4393,O
of,4393,O
p38,4393,B-GENE-N
mitogen-activated,4393,I-GENE-N
protein,4393,I-GENE-N
kinase,4393,I-GENE-N
.,4393,O
These,4394,O
results,4394,O
indicate,4394,O
that,4394,O
FCEO,4394,O
inhibits,4394,O
LPS-stimulated,4394,O
inflammation,4394,O
by,4394,O
blocking,4394,O
the,4394,O
NF-κB,4394,B-GENE-N
",",4394,O
JNK,4394,B-GENE-N
",",4394,O
and,4394,O
ERK,4394,B-GENE-N
pathways,4394,O
in,4394,O
macrophages,4394,O
",",4394,O
and,4394,O
demonstrate,4394,O
that,4394,O
FCEO,4394,O
possesses,4394,O
anti-inflammatory,4394,O
properties,4394,O
.,4394,O
Modulation,4395,O
of,4395,O
TNF,4395,B-GENE-Y
and,4395,O
GM-CSF,4395,B-GENE-Y
release,4395,O
from,4395,O
dispersed,4395,O
human,4395,O
nasal,4395,O
polyp,4395,O
cells,4395,O
and,4395,O
human,4395,O
whole,4395,O
blood,4395,O
by,4395,O
inhibitors,4395,O
of,4395,O
different,4395,O
PDE,4395,B-GENE-N
isoenzymes,4395,O
and,4395,O
glucocorticoids,4395,O
.,4395,O
The,4396,O
aim,4396,O
of,4396,O
this,4396,O
study,4396,O
was,4396,O
to,4396,O
investigate,4396,O
the,4396,O
role,4396,O
of,4396,O
the,4396,O
inhibitors,4396,O
of,4396,O
different,4396,O
PDE,4396,B-GENE-N
isoenzymes,4396,O
(,4396,O
PDE,4396,B-GENE-N
1-5,4396,I-GENE-N
),4396,O
on,4396,O
the,4396,O
production,4396,O
of,4396,O
two,4396,O
pro-inflammatory,4396,O
cytokines,4396,B-GENE-N
-,4396,O
tumor,4396,B-GENE-Y
necrosis,4396,I-GENE-Y
factor,4396,I-GENE-Y
alpha,4396,I-GENE-Y
(,4396,O
TNF,4396,B-GENE-Y
),4396,O
and,4396,O
granulocyte-macrophage,4396,B-GENE-Y
colony-stimulating,4396,I-GENE-Y
factor,4396,I-GENE-Y
(,4396,O
GM-CSF,4396,B-GENE-Y
),4396,O
.,4396,O
Two,4397,O
in,4397,O
vitro,4397,O
models,4397,O
were,4397,O
used,4397,O
to,4397,O
compare,4397,O
the,4397,O
antiinflammatory,4397,O
properties,4397,O
of,4397,O
PDE,4397,B-GENE-N
inhibitors,4397,O
with,4397,O
that,4397,O
of,4397,O
glucocorticoids,4397,O
.,4397,O
The,4398,O
effect,4398,O
on,4398,O
TNF,4398,B-GENE-Y
release,4398,O
from,4398,O
diluted,4398,O
human,4398,O
blood,4398,O
following,4398,O
lipopolysaccharide,4398,O
(,4398,O
LPS,4398,O
from,4398,O
Salmonella,4398,O
abortus,4398,O
equi,4398,O
),4398,O
stimulation,4398,O
as,4398,O
well,4398,O
as,4398,O
the,4398,O
GM-CSF,4398,B-GENE-Y
and,4398,O
TNF,4398,B-GENE-Y
release,4398,O
from,4398,O
human,4398,O
nasal,4398,O
polyp,4398,O
cells,4398,O
following,4398,O
allergic,4398,O
stimulation,4398,O
were,4398,O
investigated,4398,O
.,4398,O
Both,4399,O
models,4399,O
proofed,4399,O
to,4399,O
be,4399,O
well,4399,O
suited,4399,O
for,4399,O
the,4399,O
characterisation,4399,O
of,4399,O
the,4399,O
antiinflammatory,4399,O
properties,4399,O
of,4399,O
new,4399,O
chemical,4399,O
entities,4399,O
.,4399,O
In,4400,O
diluted,4400,O
human,4400,O
blood,4400,O
and,4400,O
dispersed,4400,O
human,4400,O
nasal,4400,O
polyp,4400,O
cells,4400,O
the,4400,O
induced,4400,O
TNF,4400,B-GENE-Y
release,4400,O
was,4400,O
most,4400,O
potently,4400,O
suppressed,4400,O
by,4400,O
selective,4400,O
PDE4,4400,B-GENE-N
inhibitors,4400,O
.,4400,O
Amrinone,4401,B-CHEMICAL
and,4401,O
milrinone,4401,B-CHEMICAL
",",4401,O
selective,4401,O
PDE3,4401,B-GENE-N
inhibitors,4401,O
",",4401,O
suppressed,4401,O
TNF,4401,B-GENE-Y
secretion,4401,O
to,4401,O
a,4401,O
lesser,4401,O
extent,4401,O
.,4401,O
The,4402,O
effects,4402,O
of,4402,O
theophylline,4402,B-CHEMICAL
(,4402,O
unspecific,4402,O
PDE,4402,B-GENE-N
inhibitor,4402,O
),4402,O
",",4402,O
vinpocetine,4402,B-CHEMICAL
(,4402,O
PDE1,4402,B-GENE-N
inhibitor,4402,O
),4402,O
",",4402,O
EHNA,4402,O
(,4402,O
PDE2,4402,B-GENE-Y
inhibitor,4402,O
),4402,O
and,4402,O
the,4402,O
PDE5,4402,B-GENE-Y
inhibitors,4402,O
zaprinast,4402,B-CHEMICAL
and,4402,O
E,4402,B-CHEMICAL
4021,4402,I-CHEMICAL
were,4402,O
weak,4402,O
.,4402,O
In,4403,O
human,4403,O
blood,4403,O
",",4403,O
the,4403,O
tested,4403,O
glucocorticoids,4403,O
beclomethasone,4403,B-CHEMICAL
",",4403,O
dexamethasone,4403,B-CHEMICAL
and,4403,O
fluticasone,4403,B-CHEMICAL
inhibited,4403,O
the,4403,O
LPS,4403,O
induced,4403,O
TNF,4403,B-GENE-Y
release,4403,O
potently,4403,O
in,4403,O
a,4403,O
concentration,4403,O
dependent,4403,O
manner,4403,O
",",4403,O
whereas,4403,O
in,4403,O
dispersed,4403,O
human,4403,O
nasal,4403,O
polyp,4403,O
cells,4403,O
",",4403,O
the,4403,O
effect,4403,O
of,4403,O
the,4403,O
glucocorticoids,4403,O
on,4403,O
allergically,4403,O
induced,4403,O
TNF,4403,B-GENE-Y
release,4403,O
",",4403,O
with,4403,O
the,4403,O
exception,4403,O
of,4403,O
dexamethasone,4403,B-CHEMICAL
",",4403,O
was,4403,O
much,4403,O
less,4403,O
pronounced,4403,O
.,4403,O
Glucocorticoids,4404,O
were,4404,O
the,4404,O
most,4404,O
potent,4404,O
inhibitors,4404,O
of,4404,O
GM-CSF,4404,B-GENE-Y
release,4404,O
and,4404,O
the,4404,O
effect,4404,O
correlates,4404,O
well,4404,O
with,4404,O
the,4404,O
affinity,4404,O
to,4404,O
the,4404,O
glucocorticoid,4404,B-GENE-Y
receptor,4404,I-GENE-Y
.,4404,O
The,4405,O
selective,4405,O
PDE,4405,B-GENE-N
4,4405,I-GENE-N
inhibitors,4405,O
",",4405,O
and,4405,O
to,4405,O
a,4405,O
certain,4405,O
extent,4405,O
the,4405,O
PDE3,4405,B-GENE-N
inhibitors,4405,O
amrinone,4405,B-CHEMICAL
and,4405,O
milrinone,4405,B-CHEMICAL
",",4405,O
reduced,4405,O
the,4405,O
GM-CSF,4405,B-GENE-Y
release,4405,O
in,4405,O
a,4405,O
concentration,4405,O
dependent,4405,O
manner,4405,O
.,4405,O
In,4406,O
all,4406,O
investigations,4406,O
selective,4406,O
PDE4,4406,B-GENE-N
inhibitors,4406,O
reduced,4406,O
TNF,4406,B-GENE-Y
release,4406,O
to,4406,O
a,4406,O
much,4406,O
higher,4406,O
degree,4406,O
(,4406,O
4-10,4406,O
fold,4406,O
),4406,O
than,4406,O
GM-CSF,4406,B-GENE-Y
release,4406,O
.,4406,O
Activating,4407,O
glucocorticoid,4407,B-GENE-Y
receptor-ERK,4407,O
signaling,4407,O
pathway,4407,O
contributes,4407,O
to,4407,O
ginsenoside,4407,B-CHEMICAL
Rg1,4407,I-CHEMICAL
protection,4407,O
against,4407,O
β-amyloid,4407,B-GENE-Y
peptide-induced,4407,O
human,4407,O
endothelial,4407,O
cells,4407,O
apoptosis,4407,O
.,4407,O
The,4408,O
deposition,4408,O
of,4408,O
β-amyloid,4408,B-GENE-Y
(,4408,O
Aβ,4408,B-GENE-Y
),4408,O
in,4408,O
neurons,4408,O
and,4408,O
vascular,4408,O
cells,4408,O
of,4408,O
the,4408,O
brain,4408,O
has,4408,O
been,4408,O
characterized,4408,O
in,4408,O
Alzheimer,4408,O
's,4408,O
disease,4408,O
.,4408,O
Ginsenoside,4409,B-CHEMICAL
Rg1,4409,I-CHEMICAL
(,4409,O
Rg1,4409,B-CHEMICAL
),4409,O
is,4409,O
an,4409,O
active,4409,O
components,4409,O
in,4409,O
Panax,4409,O
ginseng,4409,O
",",4409,O
a,4409,O
famous,4409,O
traditional,4409,O
Chinese,4409,O
medicines,4409,O
recorded,4409,O
in,4409,O
Compendium,4409,O
of,4409,O
Materia,4409,O
Medica,4409,O
.,4409,O
Present,4410,O
study,4410,O
attempted,4410,O
to,4410,O
evaluate,4410,O
the,4410,O
potential,4410,O
mechanisms,4410,O
of,4410,O
Aβ-mediated,4410,B-GENE-Y
insult,4410,O
and,4410,O
the,4410,O
protective,4410,O
effects,4410,O
of,4410,O
Rg1,4410,B-CHEMICAL
on,4410,O
human,4410,O
endothelial,4410,O
cells,4410,O
.,4410,O
Rg1,4411,B-CHEMICAL
attenuated,4411,O
the,4411,O
Aβ25-35-associated,4411,B-GENE-Y
mitochondrial,4411,O
apoptotic,4411,O
events,4411,O
",",4411,O
accompanied,4411,O
by,4411,O
inhibiting,4411,O
HIF-1α,4411,B-GENE-Y
expression,4411,O
followed,4411,O
by,4411,O
intracellular,4411,O
reactive,4411,O
nitrogen,4411,B-CHEMICAL
species,4411,O
generation,4411,O
",",4411,O
and,4411,O
protein,4411,O
nitrotyrosination,4411,O
.,4411,O
These,4412,O
protective,4412,O
effects,4412,O
were,4412,O
abolished,4412,O
by,4412,O
glucocorticoid,4412,B-GENE-Y
receptor,4412,I-GENE-Y
(,4412,O
GR,4412,B-GENE-Y
),4412,O
antagonist,4412,O
RU486,4412,B-CHEMICAL
or,4412,O
p-ERK,4412,B-GENE-N
inhibitor,4412,O
U0126,4412,B-CHEMICAL
rather,4412,O
than,4412,O
estrogen,4412,B-GENE-Y
receptor,4412,I-GENE-Y
α,4412,I-GENE-Y
antagonist,4412,O
ICI,4412,B-CHEMICAL
"82,780",4412,I-CHEMICAL
.,4412,O
Taken,4413,O
together,4413,O
",",4413,O
our,4413,O
results,4413,O
suggested,4413,O
that,4413,O
Rg1,4413,B-CHEMICAL
protected,4413,O
against,4413,O
Aβ25-35-induced,4413,B-GENE-Y
apoptosis,4413,O
at,4413,O
least,4413,O
in,4413,O
part,4413,O
by,4413,O
two,4413,O
complementary,4413,O
GR-dependent,4413,B-GENE-Y
ERK,4413,B-GENE-N
phosphorylation,4413,O
pathways,4413,O
:,4413,O
(,4413,O
1,4413,O
),4413,O
down-regulating,4413,O
HIF-1α,4413,B-GENE-Y
initiated,4413,O
protein,4413,O
nitrotyrosination,4413,O
",",4413,O
and,4413,O
(,4413,O
2,4413,O
),4413,O
inhibiting,4413,O
mitochondrial,4413,O
apoptotic,4413,O
cascades,4413,O
.,4413,O
These,4414,O
data,4414,O
provided,4414,O
a,4414,O
novel,4414,O
insight,4414,O
to,4414,O
the,4414,O
mechanisms,4414,O
of,4414,O
Rg1protective,4414,B-CHEMICAL
effects,4414,O
on,4414,O
Aβ25-35-induced,4414,B-GENE-Y
endothelial,4414,O
cells,4414,O
apoptosis,4414,O
",",4414,O
suggesting,4414,O
that,4414,O
GR-ERK,4414,B-GENE-Y
signaling,4414,O
pathway,4414,O
might,4414,O
play,4414,O
an,4414,O
important,4414,O
role,4414,O
in,4414,O
it,4414,O
.,4414,O
Aberrant,4415,O
transcription,4415,O
of,4415,O
the,4415,O
LHCGR,4415,B-GENE-Y
gene,4415,O
caused,4415,O
by,4415,O
a,4415,O
mutation,4415,O
in,4415,O
exon,4415,O
6A,4415,O
leads,4415,O
to,4415,O
Leydig,4415,O
cell,4415,O
hypoplasia,4415,O
type,4415,O
II,4415,O
.,4415,O
The,4416,O
luteinizing,4416,B-GENE-Y
hormone/chorionic,4416,I-GENE-Y
gonadotropin,4416,I-GENE-Y
receptor,4416,I-GENE-Y
(,4416,O
LHCGR,4416,B-GENE-Y
),4416,O
is,4416,O
essential,4416,O
for,4416,O
normal,4416,O
male,4416,O
sex,4416,O
differentiation,4416,O
.,4416,O
Recently,4417,O
",",4417,O
the,4417,O
additional,4417,O
primate-specific,4417,O
exon,4417,O
6A,4417,O
of,4417,O
the,4417,O
LHCGR,4417,B-GENE-Y
was,4417,O
discovered,4417,O
and,4417,O
it,4417,O
was,4417,O
shown,4417,O
to,4417,O
act,4417,O
as,4417,O
regulatory,4417,O
element,4417,O
at,4417,O
the,4417,O
transcriptional,4417,O
level,4417,O
.,4417,O
Compound,4418,O
heterozygous,4418,O
mutations,4418,O
in,4418,O
exon,4418,O
6A,4418,O
(,4418,O
c.580,4418,B-GENE-N
A,4418,I-GENE-N
>,4418,I-GENE-N
G,4418,I-GENE-N
),4418,O
and,4418,O
exon,4418,O
11,4418,O
(,4418,O
c.1244T,4418,B-GENE-N
>,4418,I-GENE-N
C,4418,I-GENE-N
),4418,O
were,4418,O
identified,4418,O
in,4418,O
the,4418,O
LHCGR,4418,B-GENE-Y
of,4418,O
a,4418,O
male,4418,O
46,4418,O
",",4418,O
XY,4418,O
patient,4418,O
with,4418,O
genital,4418,O
malformation,4418,O
.,4418,O
Analysis,4419,O
revealed,4419,O
that,4419,O
mutation,4419,O
c.580A,4419,B-GENE-N
>,4419,I-GENE-N
G,4419,I-GENE-N
in,4419,O
exon,4419,O
6A,4419,O
affects,4419,O
the,4419,O
splicing,4419,O
pattern,4419,O
resulting,4419,O
in,4419,O
an,4419,O
increase,4419,O
of,4419,O
transcripts,4419,O
containing,4419,O
the,4419,O
internal,4419,O
variants,4419,O
of,4419,O
exon,4419,O
6A,4419,O
prone,4419,O
to,4419,O
nonsense-mediated,4419,O
decay,4419,O
.,4419,O
In,4420,O
contrast,4420,O
",",4420,O
mutation,4420,O
c.1244T,4420,B-GENE-N
>,4420,I-GENE-N
C,4420,I-GENE-N
results,4420,O
in,4420,O
an,4420,O
amino,4420,B-CHEMICAL
acid,4420,I-CHEMICAL
substitution,4420,O
(,4420,O
Ile415Thr,4420,B-GENE-N
),4420,O
",",4420,O
which,4420,O
abolishes,4420,O
signal,4420,O
transduction,4420,O
due,4420,O
to,4420,O
structural,4420,O
changes,4420,O
.,4420,O
When,4421,O
inherited,4421,O
in,4421,O
a,4421,O
compound,4421,O
heterozygous,4421,O
fashion,4421,O
these,4421,O
mutations,4421,O
result,4421,O
in,4421,O
Leydig,4421,O
cell,4421,O
hypoplasia,4421,O
(,4421,O
LCH,4421,O
),4421,O
type,4421,O
II,4421,O
.,4421,O
Thus,4422,O
this,4422,O
study,4422,O
provides,4422,O
proof,4422,O
that,4422,O
mutations,4422,O
causing,4422,O
aberrant,4422,O
transcription,4422,O
can,4422,O
impair,4422,O
receptor,4422,O
function,4422,O
and,4422,O
thereby,4422,O
be,4422,O
causative,4422,O
of,4422,O
LCH,4422,O
.,4422,O
Effectiveness,4423,O
of,4423,O
endopeptidase,4423,B-GENE-N
inhibition,4423,O
(,4423,O
candoxatril,4423,B-CHEMICAL
),4423,O
in,4423,O
congestive,4423,O
heart,4423,O
failure,4423,O
.,4423,O
Candoxatril,4424,B-CHEMICAL
is,4424,O
a,4424,O
novel,4424,O
",",4424,O
orally,4424,O
active,4424,O
inhibitor,4424,O
of,4424,O
neutral,4424,B-GENE-Y
endopeptidase,4424,I-GENE-Y
EC,4424,B-GENE-Y
3.4.24.11,4424,I-GENE-Y
",",4424,O
the,4424,O
enzyme,4424,O
that,4424,O
degrades,4424,O
atrial,4424,B-GENE-Y
natriuretic,4424,I-GENE-Y
peptide,4424,I-GENE-Y
(,4424,O
ANP,4424,B-GENE-Y
),4424,O
.,4424,O
The,4425,O
acute,4425,O
and,4425,O
chronic,4425,O
(,4425,O
10,4425,O
days,4425,O
treatment,4425,O
),4425,O
hemodynamic,4425,O
and,4425,O
hormonal,4425,O
effects,4425,O
of,4425,O
candoxatril,4425,B-CHEMICAL
(,4425,O
150,4425,O
mg,4425,O
twice,4425,O
daily,4425,O
),4425,O
in,4425,O
12,4425,O
patients,4425,O
with,4425,O
moderately,4425,O
severe,4425,O
congestive,4425,O
heart,4425,O
failure,4425,O
were,4425,O
investigated,4425,O
in,4425,O
a,4425,O
randomized,4425,O
",",4425,O
placebo-controlled,4425,O
",",4425,O
double-blind,4425,O
study,4425,O
.,4425,O
On,4426,O
study,4426,O
day,4426,O
1,4426,O
",",4426,O
candoxatril,4426,B-CHEMICAL
acutely,4426,O
increased,4426,O
plasma,4426,O
ANP,4426,B-GENE-Y
levels,4426,O
",",4426,O
suppressed,4426,O
aldosterone,4426,B-CHEMICAL
and,4426,O
decreased,4426,O
right,4426,O
atrial,4426,O
and,4426,O
pulmonary,4426,O
capillary,4426,O
wedge,4426,O
pressures,4426,O
.,4426,O
After,4427,O
10,4427,O
days,4427,O
of,4427,O
treatment,4427,O
",",4427,O
basal,4427,O
ANP,4427,B-GENE-Y
was,4427,O
increased,4427,O
and,4427,O
basal,4427,O
aldosterone,4427,B-CHEMICAL
was,4427,O
decreased,4427,O
.,4427,O
Body,4428,O
weight,4428,O
was,4428,O
reduced,4428,O
",",4428,O
most,4428,O
likely,4428,O
reflecting,4428,O
chronic,4428,O
natriuretic,4428,O
or,4428,O
diuretic,4428,O
effects,4428,O
",",4428,O
or,4428,O
both,4428,O
",",4428,O
and,4428,O
there,4428,O
was,4428,O
a,4428,O
trend,4428,O
toward,4428,O
increased,4428,O
cardiac,4428,O
index,4428,O
and,4428,O
reduced,4428,O
preload,4428,O
values,4428,O
.,4428,O
On,4429,O
study,4429,O
day,4429,O
10,4429,O
",",4429,O
the,4429,O
acute,4429,O
effects,4429,O
of,4429,O
candoxatril,4429,B-CHEMICAL
were,4429,O
similar,4429,O
to,4429,O
those,4429,O
on,4429,O
day,4429,O
1,4429,O
(,4429,O
i.e.,4429,O
",",4429,O
ANP,4429,B-GENE-Y
was,4429,O
further,4429,O
increased,4429,O
",",4429,O
aldosterone,4429,B-CHEMICAL
was,4429,O
suppressed,4429,O
",",4429,O
and,4429,O
right,4429,O
and,4429,O
left,4429,O
ventricular,4429,O
filling,4429,O
pressures,4429,O
were,4429,O
decreased,4429,O
),4429,O
.,4429,O
Thus,4430,O
",",4430,O
candoxatril,4430,B-CHEMICAL
may,4430,O
offer,4430,O
a,4430,O
new,4430,O
and,4430,O
effective,4430,O
therapeutic,4430,O
approach,4430,O
in,4430,O
the,4430,O
treatment,4430,O
of,4430,O
heart,4430,O
failure,4430,O
.,4430,O
Longer,4431,O
HSD11B2,4431,B-GENE-Y
CA-repeat,4431,B-GENE-N
in,4431,O
impaired,4431,O
glucose,4431,B-CHEMICAL
tolerance,4431,O
and,4431,O
type,4431,O
2,4431,O
diabetes,4431,O
.,4431,O
Type,4432,B-GENE-Y
2,4432,I-GENE-Y
11β-hydroxysteroid,4432,I-GENE-Y
dehydrogenase,4432,I-GENE-Y
encoded,4432,O
by,4432,O
the,4432,O
HSD11B2,4432,B-GENE-Y
gene,4432,O
converts,4432,O
cortisol,4432,B-CHEMICAL
to,4432,O
inactive,4432,O
cortisone,4432,B-CHEMICAL
",",4432,O
and,4432,O
alteration,4432,O
in,4432,O
this,4432,O
enzymatic,4432,O
activity,4432,O
might,4432,O
affect,4432,O
glucose,4432,B-CHEMICAL
homeostasis,4432,O
by,4432,O
affecting,4432,O
circulating,4432,O
levels,4432,O
or,4432,O
tissue,4432,O
availability,4432,O
of,4432,O
glucocorticoids,4432,O
.,4432,O
We,4433,O
investigated,4433,O
the,4433,O
association,4433,O
of,4433,O
HSD11B2,4433,B-GENE-Y
variant,4433,O
with,4433,O
glucose,4433,B-CHEMICAL
homeostasis,4433,O
.,4433,O
Subjects,4434,O
with,4434,O
normal,4434,O
glucose,4434,B-CHEMICAL
tolerance,4434,O
(,4434,O
n=585,4434,O
),4434,O
",",4434,O
impaired,4434,O
glucose,4434,B-CHEMICAL
tolerance,4434,O
(,4434,O
n=202,4434,O
),4434,O
and,4434,O
type,4434,O
2,4434,O
diabetes,4434,O
(,4434,O
n=355,4434,O
),4434,O
were,4434,O
genotyped,4434,O
for,4434,O
a,4434,O
highly,4434,O
polymorphic,4434,O
CA-repeat,4434,B-GENE-N
polymorphism,4434,O
in,4434,O
the,4434,O
first,4434,O
intron,4434,O
of,4434,O
HSD11B2,4434,B-GENE-Y
.,4434,O
Allele,4435,O
and,4435,O
genotype,4435,O
frequencies,4435,O
differed,4435,O
between,4435,O
normal,4435,O
and,4435,O
impaired,4435,O
glucose,4435,B-CHEMICAL
tolerance,4435,O
(,4435,O
P,4435,O
=,4435,O
0.0014,4435,O
and,4435,O
0.0407,4435,O
",",4435,O
respectively,4435,O
;,4435,O
4DF,4435,O
),4435,O
or,4435,O
type,4435,O
2,4435,O
diabetes,4435,O
(,4435,O
P,4435,O
=,4435,O
0.0053,4435,O
and,4435,O
0.0078,4435,O
),4435,O
",",4435,O
with,4435,O
significant,4435,O
linear,4435,O
trends,4435,O
between,4435,O
the,4435,O
repeat,4435,O
length,4435,O
and,4435,O
the,4435,O
phenotype,4435,O
fraction,4435,O
.,4435,O
In,4436,O
normal,4436,O
subjects,4436,O
",",4436,O
total,4436,O
CA-repeat,4436,B-GENE-N
length,4436,O
was,4436,O
negatively,4436,O
correlated,4436,O
with,4436,O
fasting,4436,O
insulin,4436,B-GENE-Y
and,4436,O
HOMA-β,4436,O
.,4436,O
Thus,4437,O
",",4437,O
subjects,4437,O
having,4437,O
more,4437,O
CA,4437,B-GENE-N
repeats,4437,I-GENE-N
are,4437,O
susceptible,4437,O
to,4437,O
developing,4437,O
abnormal,4437,O
glucose,4437,B-CHEMICAL
tolerance,4437,O
",",4437,O
whereas,4437,O
normal,4437,O
subjects,4437,O
carrying,4437,O
more,4437,O
CA,4437,B-GENE-N
repeats,4437,I-GENE-N
appeared,4437,O
to,4437,O
have,4437,O
frugal,4437,O
characteristics,4437,O
in,4437,O
insulin,4437,B-GENE-Y
secretion,4437,O
.,4437,O
Efficacy,4438,O
and,4438,O
safety,4438,O
of,4438,O
tamsulosin,4438,B-CHEMICAL
in,4438,O
the,4438,O
treatment,4438,O
of,4438,O
urological,4438,O
diseases,4438,O
.,4438,O
The,4439,O
alpha,4439,B-GENE-N
(,4439,I-GENE-N
1,4439,I-GENE-N
),4439,I-GENE-N
-adrenoceptor,4439,I-GENE-N
antagonist,4439,O
",",4439,O
tamsulosin,4439,B-CHEMICAL
",",4439,O
is,4439,O
selective,4439,O
for,4439,O
alpha,4439,B-GENE-N
(,4439,I-GENE-N
1A,4439,I-GENE-N
),4439,I-GENE-N
-,4439,I-GENE-N
and,4439,I-GENE-N
alpha,4439,I-GENE-N
(,4439,I-GENE-N
1D,4439,I-GENE-N
),4439,I-GENE-N
-,4439,I-GENE-N
over,4439,I-GENE-N
alpha,4439,I-GENE-N
(,4439,I-GENE-N
1B,4439,I-GENE-N
),4439,I-GENE-N
-adrenoceptors,4439,I-GENE-N
.,4439,O
Both,4440,O
placebo-controlled,4440,O
and,4440,O
comparative,4440,O
studies,4440,O
with,4440,O
other,4440,O
agents,4440,O
have,4440,O
demonstrated,4440,O
tamsulosin,4440,B-CHEMICAL
to,4440,O
be,4440,O
an,4440,O
effective,4440,O
treatment,4440,O
for,4440,O
patients,4440,O
with,4440,O
lower,4440,O
urinary,4440,O
symptoms,4440,O
suggestive,4440,O
of,4440,O
benign,4440,O
prostatic,4440,O
hyperplasia,4440,O
.,4440,O
Its,4441,O
effectiveness,4441,O
appears,4441,O
to,4441,O
be,4441,O
maintained,4441,O
over,4441,O
many,4441,O
years,4441,O
.,4441,O
Tamsulosin,4442,B-CHEMICAL
may,4442,O
also,4442,O
effectively,4442,O
reduce,4442,O
lower,4442,O
urinary,4442,O
tract,4442,O
symptoms,4442,O
in,4442,O
other,4442,O
urological,4442,O
diseases,4442,O
.,4442,O
A,4443,O
dose,4443,O
of,4443,O
tamsulosin,4443,B-CHEMICAL
0.4,4443,O
mg/day,4443,O
has,4443,O
a,4443,O
tolerability,4443,O
close,4443,O
to,4443,O
that,4443,O
of,4443,O
placebo,4443,O
and,4443,O
has,4443,O
little,4443,O
",",4443,O
if,4443,O
any,4443,O
",",4443,O
blood,4443,O
pressure,4443,O
lowering,4443,O
effects,4443,O
.,4443,O
Tolerability,4444,O
and,4444,O
lack,4444,O
of,4444,O
blood,4444,O
pressure,4444,O
lowering,4444,O
are,4444,O
maintained,4444,O
even,4444,O
in,4444,O
high-risk,4444,O
patients,4444,O
such,4444,O
as,4444,O
those,4444,O
with,4444,O
cardiovascular,4444,O
comorbidity,4444,O
and/or,4444,O
comedication,4444,O
.,4444,O
Apart,4445,O
from,4445,O
adrenoceptor,4445,B-GENE-N
subtype-selectivity,4445,O
",",4445,O
a,4445,O
smooth,4445,O
pharmacokinetic,4445,O
profile,4445,O
of,4445,O
its,4445,O
modified-release,4445,O
formulation,4445,O
and,4445,O
a,4445,O
selective,4445,O
accumulation,4445,O
in,4445,O
target,4445,O
tissues,4445,O
may,4445,O
contribute,4445,O
to,4445,O
an,4445,O
excellent,4445,O
efficacy,4445,O
:,4445,O
tolerability,4445,O
ratio,4445,O
.,4445,O
Pioglitazone,4446,B-CHEMICAL
protects,4446,O
against,4446,O
cisplatin,4446,B-CHEMICAL
induced,4446,O
nephrotoxicity,4446,O
in,4446,O
rats,4446,O
and,4446,O
potentiates,4446,O
its,4446,O
anticancer,4446,O
activity,4446,O
against,4446,O
human,4446,O
renal,4446,O
adenocarcinoma,4446,O
cell,4446,O
lines,4446,O
.,4446,O
Cisplatin-induced,4447,B-CHEMICAL
nephrotoxicity,4447,O
is,4447,O
a,4447,O
serious,4447,O
problem,4447,O
that,4447,O
limits,4447,O
its,4447,O
use,4447,O
in,4447,O
cancer,4447,O
treatment,4447,O
.,4447,O
The,4448,O
present,4448,O
study,4448,O
aimed,4448,O
to,4448,O
investigate,4448,O
the,4448,O
renal,4448,O
protective,4448,O
capacity,4448,O
of,4448,O
pioglitazone,4448,B-CHEMICAL
to,4448,O
reduce,4448,O
the,4448,O
cisplatin-,4448,B-CHEMICAL
induced,4448,O
nephrotoxicity,4448,O
.,4448,O
The,4449,O
underlying,4449,O
suggested,4449,O
mechanism,4449,O
(,4449,O
s,4449,O
),4449,O
and,4449,O
whether,4449,O
this,4449,O
nephroprotective,4449,O
effect,4449,O
(,4449,O
if,4449,O
any,4449,O
),4449,O
interferes,4449,O
with,4449,O
the,4449,O
cytotoxic,4449,O
effect,4449,O
of,4449,O
cisplatin,4449,B-CHEMICAL
on,4449,O
cancer,4449,O
cells,4449,O
were,4449,O
also,4449,O
investigated,4449,O
.,4449,O
Pioglitazone,4450,B-CHEMICAL
",",4450,O
Bisphenol,4450,B-CHEMICAL
A,4450,I-CHEMICAL
diglycidyl,4450,I-CHEMICAL
ether,4450,I-CHEMICAL
",",4450,O
BADGE,4450,B-CHEMICAL
",",4450,O
IP,4450,O
injected,4450,O
(,4450,O
Peroxisome,4450,B-GENE-Y
proliferator-,4450,I-GENE-Y
activated,4450,I-GENE-Y
receptor,4450,I-GENE-Y
gamma,4450,I-GENE-Y
(,4450,O
PPAR-γ,4450,B-GENE-Y
),4450,O
antagonist,4450,O
),4450,O
",",4450,O
or,4450,O
their,4450,O
combination,4450,O
were,4450,O
administered,4450,O
to,4450,O
rats,4450,O
one,4450,O
hour,4450,O
before,4450,O
cisplatin,4450,B-CHEMICAL
injection,4450,O
.,4450,O
Moreover,4451,O
",",4451,O
their,4451,O
effects,4451,O
on,4451,O
the,4451,O
cell,4451,O
viability,4451,O
of,4451,O
human,4451,O
renal,4451,O
adenocarcinoma,4451,O
cell,4451,O
models,4451,O
(,4451,O
ACHN,4451,O
),4451,O
were,4451,O
studied,4451,O
.,4451,O
The,4452,O
obtained,4452,O
results,4452,O
showed,4452,O
that,4452,O
pioglitazone,4452,B-CHEMICAL
improved,4452,O
the,4452,O
renal,4452,O
function,4452,O
",",4452,O
structural,4452,O
changes,4452,O
",",4452,O
renal,4452,O
malondialdehyde,4452,B-CHEMICAL
(,4452,O
MDA,4452,B-CHEMICAL
),4452,O
",",4452,O
tumor,4452,B-GENE-Y
necrosis,4452,I-GENE-Y
factor,4452,I-GENE-Y
alpha,4452,I-GENE-Y
(,4452,O
TNF-α,4452,B-GENE-Y
),4452,O
",",4452,O
nuclear,4452,B-GENE-N
factor,4452,I-GENE-N
kappa,4452,I-GENE-N
B,4452,I-GENE-N
(,4452,O
NF-κB,4452,B-GENE-N
),4452,O
genes,4452,O
expression,4452,O
in,4452,O
cisplatin,4452,B-CHEMICAL
injected,4452,O
rats,4452,O
.,4452,O
It,4453,O
increased,4453,O
both,4453,O
renal,4453,O
reduced,4453,O
glutathione,4453,B-CHEMICAL
(,4453,O
GSH,4453,B-CHEMICAL
),4453,O
content,4453,O
and,4453,O
PPAR-γ,4453,B-GENE-Y
gene,4453,O
expression,4453,O
.,4453,O
In,4454,O
contrast,4454,O
to,4454,O
the,4454,O
data,4454,O
obtained,4454,O
by,4454,O
prior,4454,O
administration,4454,O
of,4454,O
BADGE,4454,B-CHEMICAL
.,4454,O
Pioglitazone,4455,B-CHEMICAL
also,4455,O
potentiated,4455,O
the,4455,O
cytotoxic,4455,O
effect,4455,O
of,4455,O
cisplatin,4455,B-CHEMICAL
on,4455,O
human,4455,O
renal,4455,O
adenocarcinoma,4455,O
cells,4455,O
and,4455,O
this,4455,O
effect,4455,O
was,4455,O
abolished,4455,O
by,4455,O
BADGE,4455,B-CHEMICAL
co,4455,O
administration,4455,O
.,4455,O
In,4456,O
conclusion,4456,O
",",4456,O
these,4456,O
results,4456,O
suggested,4456,O
that,4456,O
pioglitazone,4456,B-CHEMICAL
protected,4456,O
against,4456,O
cisplatin-,4456,B-CHEMICAL
induced,4456,O
nephrotoxicity,4456,O
through,4456,O
its,4456,O
interaction,4456,O
with,4456,O
PPAR-γ,4456,B-GENE-Y
receptors,4456,O
and,4456,O
antioxidant,4456,O
effects,4456,O
.,4456,O
Furthermore,4457,O
",",4457,O
pioglitazone,4457,B-CHEMICAL
did,4457,O
not,4457,O
interfere,4457,O
but,4457,O
rather,4457,O
potentiated,4457,O
the,4457,O
cytotoxic,4457,O
effects,4457,O
of,4457,O
cisplatin,4457,B-CHEMICAL
on,4457,O
human,4457,O
renal,4457,O
adenocarcinoma,4457,O
cells,4457,O
.,4457,O
A,4458,O
structural,4458,O
and,4458,O
functional,4458,O
perspective,4458,O
into,4458,O
the,4458,O
mechanism,4458,O
of,4458,O
Ca2+-sensitizers,4458,B-CHEMICAL
that,4458,O
target,4458,O
the,4458,O
cardiac,4458,O
troponin,4458,B-GENE-N
complex,4458,I-GENE-N
.,4458,O
The,4459,O
Ca,4459,B-CHEMICAL
(,4459,I-CHEMICAL
2+,4459,I-CHEMICAL
),4459,I-CHEMICAL
dependent,4459,O
interaction,4459,O
between,4459,O
troponin,4459,B-GENE-N
I,4459,I-GENE-N
(,4459,O
cTnI,4459,B-GENE-N
),4459,O
and,4459,O
troponin,4459,B-GENE-N
C,4459,I-GENE-N
(,4459,O
cTnC,4459,B-GENE-N
),4459,O
triggers,4459,O
contraction,4459,O
in,4459,O
heart,4459,O
muscle,4459,O
.,4459,O
Heart,4460,O
failure,4460,O
is,4460,O
characterized,4460,O
by,4460,O
a,4460,O
decrease,4460,O
in,4460,O
cardiac,4460,O
output,4460,O
",",4460,O
and,4460,O
compounds,4460,O
that,4460,O
increase,4460,O
the,4460,O
sensitivity,4460,O
of,4460,O
cardiac,4460,O
muscle,4460,O
to,4460,O
Ca,4460,B-CHEMICAL
(,4460,I-CHEMICAL
2+,4460,I-CHEMICAL
),4460,I-CHEMICAL
have,4460,O
therapeutic,4460,O
potential,4460,O
.,4460,O
The,4461,O
Ca,4461,B-CHEMICAL
(,4461,I-CHEMICAL
2+,4461,I-CHEMICAL
),4461,I-CHEMICAL
-sensitizer,4461,O
",",4461,O
levosimendan,4461,B-CHEMICAL
",",4461,O
targets,4461,O
cTnC,4461,O
;,4461,O
however,4461,O
",",4461,O
detailed,4461,O
understanding,4461,O
of,4461,O
its,4461,O
mechanism,4461,O
has,4461,O
been,4461,O
obscured,4461,O
by,4461,O
its,4461,O
instability,4461,O
.,4461,O
In,4462,O
order,4462,O
to,4462,O
understand,4462,O
how,4462,O
this,4462,O
class,4462,O
of,4462,O
positive,4462,O
inotropes,4462,O
function,4462,O
",",4462,O
we,4462,O
investigated,4462,O
the,4462,O
mode,4462,O
of,4462,O
action,4462,O
of,4462,O
two,4462,O
fluorine,4462,B-CHEMICAL
containing,4462,O
novel,4462,O
analogs,4462,O
of,4462,O
levosimendan,4462,B-CHEMICAL
;,4462,O
"2',4'-difluoro",4462,B-CHEMICAL
(,4462,I-CHEMICAL
"1,1'-biphenyl",4462,I-CHEMICAL
),4462,I-CHEMICAL
-4-yloxy,4462,I-CHEMICAL
acetic,4462,I-CHEMICAL
acid,4462,I-CHEMICAL
(,4462,O
dfbp-o,4462,B-CHEMICAL
),4462,O
and,4462,O
"2',4'-difluoro",4462,B-CHEMICAL
(,4462,I-CHEMICAL
"1,1'-biphenyl",4462,I-CHEMICAL
),4462,I-CHEMICAL
-4-yl,4462,I-CHEMICAL
acetic,4462,I-CHEMICAL
acid,4462,I-CHEMICAL
(,4462,O
dfbp,4462,B-CHEMICAL
),4462,O
.,4462,O
The,4463,O
affinities,4463,O
of,4463,O
dfbp,4463,B-CHEMICAL
and,4463,O
dfbp-o,4463,B-CHEMICAL
for,4463,O
the,4463,O
regulatory,4463,O
domain,4463,O
of,4463,O
cTnC,4463,B-GENE-N
were,4463,O
measured,4463,O
in,4463,O
the,4463,O
absence,4463,O
and,4463,O
presence,4463,O
of,4463,O
cTnI,4463,O
by,4463,O
NMR,4463,O
spectroscopy,4463,O
",",4463,O
and,4463,O
dfbp-o,4463,B-CHEMICAL
was,4463,O
found,4463,O
to,4463,O
bind,4463,O
more,4463,O
strongly,4463,O
than,4463,O
dfbp,4463,B-CHEMICAL
.,4463,O
Dfbp-o,4464,B-CHEMICAL
also,4464,O
increased,4464,O
the,4464,O
affinity,4464,O
of,4464,O
cTnI,4464,B-GENE-N
for,4464,O
cTnC,4464,B-GENE-N
.,4464,O
Dfbp-o,4465,B-CHEMICAL
increased,4465,O
the,4465,O
Ca,4465,B-CHEMICAL
(,4465,I-CHEMICAL
2+,4465,I-CHEMICAL
),4465,I-CHEMICAL
-sensitivity,4465,O
of,4465,O
demembranated,4465,O
cardiac,4465,O
trabeculae,4465,O
in,4465,O
a,4465,O
manner,4465,O
similar,4465,O
to,4465,O
levosimendan,4465,B-CHEMICAL
.,4465,O
The,4466,O
high,4466,O
resolution,4466,O
NMR,4466,O
solution,4466,O
structure,4466,O
of,4466,O
the,4466,O
cTnC-cTnI-dfbp-o,4466,B-GENE-N
ternary,4466,O
complex,4466,O
showed,4466,O
that,4466,O
dfbp-o,4466,B-CHEMICAL
bound,4466,O
at,4466,O
the,4466,O
hydrophobic,4466,O
interface,4466,O
formed,4466,O
by,4466,O
cTnC,4466,B-GENE-N
and,4466,O
cTnI,4466,B-GENE-N
making,4466,O
critical,4466,O
interactions,4466,O
with,4466,O
residues,4466,O
such,4466,O
as,4466,O
Arg147,4466,O
of,4466,O
cTnI,4466,B-GENE-N
.,4466,O
In,4467,O
the,4467,O
absence,4467,O
of,4467,O
cTnI,4467,B-GENE-N
",",4467,O
docking,4467,O
localized,4467,O
dfbp-o,4467,B-CHEMICAL
to,4467,O
the,4467,O
same,4467,O
position,4467,O
in,4467,O
the,4467,O
hydrophobic,4467,O
groove,4467,O
of,4467,O
cTnC,4467,B-GENE-N
.,4467,O
The,4468,O
structural,4468,O
and,4468,O
functional,4468,O
data,4468,O
reveal,4468,O
that,4468,O
the,4468,O
levosimendan,4468,B-CHEMICAL
class,4468,O
of,4468,O
Ca,4468,B-CHEMICAL
(,4468,I-CHEMICAL
2+,4468,I-CHEMICAL
),4468,I-CHEMICAL
-sensitizers,4468,O
work,4468,O
by,4468,O
binding,4468,O
to,4468,O
the,4468,O
regulatory,4468,O
domain,4468,O
of,4468,O
cTnC,4468,B-GENE-N
and,4468,O
stabilizing,4468,O
the,4468,O
pivotal,4468,O
cTnC-cTnI,4468,B-GENE-N
regulatory,4468,O
unit,4468,O
via,4468,O
a,4468,O
network,4468,O
of,4468,O
hydrophobic,4468,O
and,4468,O
electrostatic,4468,O
interactions,4468,O
",",4468,O
in,4468,O
contrast,4468,O
to,4468,O
the,4468,O
destabilizing,4468,O
effects,4468,O
of,4468,O
antagonists,4468,O
such,4468,O
as,4468,O
W7,4468,O
at,4468,O
the,4468,O
same,4468,O
interface,4468,O
.,4468,O
Induction,4469,O
of,4469,O
cyp1a1,4469,B-GENE-Y
is,4469,O
a,4469,O
nonspecific,4469,O
biomarker,4469,O
of,4469,O
aryl,4469,B-GENE-Y
hydrocarbon,4469,I-GENE-Y
receptor,4469,I-GENE-Y
activation,4469,O
:,4469,O
results,4469,O
of,4469,O
large,4469,O
scale,4469,O
screening,4469,O
of,4469,O
pharmaceuticals,4469,O
and,4469,O
toxicants,4469,O
in,4469,O
vivo,4469,O
and,4469,O
in,4469,O
vitro,4469,O
.,4469,O
Expression,4470,O
of,4470,O
Cyp1a1,4470,B-GENE-Y
and,4470,O
its,4470,O
related,4470,O
enzyme,4470,O
activity,4470,O
have,4470,O
long,4470,O
been,4470,O
used,4470,O
as,4470,O
a,4470,O
biomarker,4470,O
for,4470,O
aryl,4470,B-GENE-Y
hydrocarbon,4470,I-GENE-Y
receptor,4470,I-GENE-Y
(,4470,O
AhR,4470,B-GENE-Y
),4470,O
activation,4470,O
and,4470,O
a,4470,O
warning,4470,O
of,4470,O
dioxin-like,4470,B-CHEMICAL
toxicity,4470,O
.,4470,O
As,4471,O
a,4471,O
result,4471,O
",",4471,O
induction,4471,O
of,4471,O
Cyp1a1,4471,B-GENE-Y
by,4471,O
pharmaceutical,4471,O
drug,4471,O
candidates,4471,O
or,4471,O
environmental,4471,O
contaminants,4471,O
raises,4471,O
significant,4471,O
concern,4471,O
in,4471,O
risk,4471,O
assessment,4471,O
.,4471,O
The,4472,O
current,4472,O
study,4472,O
evaluates,4472,O
the,4472,O
specificity,4472,O
of,4472,O
Cyp1a1,4472,B-GENE-Y
induction,4472,O
as,4472,O
a,4472,O
marker,4472,O
for,4472,O
AhR,4472,B-GENE-Y
affinity,4472,O
and,4472,O
activation,4472,O
and,4472,O
provides,4472,O
context,4472,O
to,4472,O
assess,4472,O
the,4472,O
relevancy,4472,O
of,4472,O
AhR,4472,B-GENE-Y
activation,4472,O
to,4472,O
risk,4472,O
assessment,4472,O
.,4472,O
In,4473,O
vivo,4473,O
experiments,4473,O
examined,4473,O
the,4473,O
expression,4473,O
of,4473,O
Cyp1a1,4473,B-GENE-Y
and,4473,O
other,4473,O
AhR-regulated,4473,B-GENE-Y
genes,4473,O
in,4473,O
liver,4473,O
",",4473,O
kidney,4473,O
",",4473,O
and,4473,O
heart,4473,O
in,4473,O
response,4473,O
to,4473,O
596,4473,O
compounds,4473,O
.,4473,O
From,4474,O
this,4474,O
data,4474,O
set,4474,O
",",4474,O
a,4474,O
subset,4474,O
of,4474,O
147,4474,O
compounds,4474,O
was,4474,O
then,4474,O
evaluated,4474,O
for,4474,O
their,4474,O
ability,4474,O
to,4474,O
activate,4474,O
or,4474,O
bind,4474,O
to,4474,O
the,4474,O
AhR,4474,B-GENE-Y
using,4474,O
a,4474,O
combination,4474,O
of,4474,O
gel,4474,O
shift,4474,O
",",4474,O
reporter,4474,O
gene,4474,O
",",4474,O
and,4474,O
competitive,4474,O
receptor,4474,O
binding,4474,O
assays,4474,O
.,4474,O
Whereas,4475,O
in,4475,O
vivo,4475,O
Cyp1a1,4475,B-GENE-Y
mRNA,4475,O
expression,4475,O
is,4475,O
a,4475,O
sensitive,4475,O
marker,4475,O
for,4475,O
AhR,4475,B-GENE-Y
activation,4475,O
",",4475,O
it,4475,O
lacks,4475,O
specificity,4475,O
",",4475,O
because,4475,O
81,4475,O
(,4475,O
59,4475,O
%,4475,O
),4475,O
of,4475,O
137,4475,O
compounds,4475,O
were,4475,O
found,4475,O
to,4475,O
significantly,4475,O
induce,4475,O
Cyp1a1,4475,B-GENE-Y
in,4475,O
vivo,4475,O
but,4475,O
were,4475,O
not,4475,O
verified,4475,O
to,4475,O
bind,4475,O
or,4475,O
activate,4475,O
the,4475,O
AhR,4475,B-GENE-Y
in,4475,O
vitro,4475,O
.,4475,O
Combining,4476,O
in,4476,O
vivo,4476,O
and,4476,O
in,4476,O
vitro,4476,O
findings,4476,O
",",4476,O
we,4476,O
identified,4476,O
nine,4476,O
AhR,4476,B-GENE-Y
agonists,4476,O
",",4476,O
six,4476,O
of,4476,O
which,4476,O
are,4476,O
marketed,4476,O
therapeutics,4476,O
and,4476,O
have,4476,O
been,4476,O
approved,4476,O
by,4476,O
the,4476,O
U.S.,4476,O
Food,4476,O
and,4476,O
Drug,4476,O
Administration,4476,O
",",4476,O
including,4476,O
leflunomide,4476,B-CHEMICAL
",",4476,O
flutamide,4476,B-CHEMICAL
",",4476,O
and,4476,O
nimodipine,4476,B-CHEMICAL
.,4476,O
These,4477,O
drugs,4477,O
do,4477,O
not,4477,O
produce,4477,O
dioxin-like,4477,B-CHEMICAL
toxicity,4477,O
in,4477,O
rats,4477,O
or,4477,O
in,4477,O
humans,4477,O
.,4477,O
These,4478,O
data,4478,O
demonstrate,4478,O
that,4478,O
induction,4478,O
of,4478,O
Cyp1a1,4478,B-GENE-Y
is,4478,O
a,4478,O
nonspecific,4478,O
biomarker,4478,O
of,4478,O
direct,4478,O
AhR,4478,B-GENE-Y
affinity,4478,O
and,4478,O
activation,4478,O
and,4478,O
lend,4478,O
further,4478,O
support,4478,O
to,4478,O
the,4478,O
hypothesis,4478,O
that,4478,O
Cyp1a1,4478,B-GENE-Y
induction,4478,O
and/or,4478,O
AhR,4478,B-GENE-Y
activation,4478,O
is,4478,O
not,4478,O
synonymous,4478,O
with,4478,O
dioxin-like,4478,B-CHEMICAL
toxicity,4478,O
.,4478,O
No,4479,O
mutations,4479,O
in,4479,O
the,4479,O
serotonin,4479,B-CHEMICAL
related,4479,O
TPH1,4479,B-GENE-Y
and,4479,O
HTR1B,4479,B-GENE-Y
genes,4479,O
in,4479,O
patients,4479,O
with,4479,O
monogenic,4479,O
sclerosing,4479,O
bone,4479,O
disorders,4479,O
.,4479,O
Since,4480,O
the,4480,O
identification,4480,O
of,4480,O
LRP5,4480,B-GENE-Y
as,4480,O
the,4480,O
causative,4480,O
gene,4480,O
for,4480,O
the,4480,O
osteoporosis,4480,O
pseudoglioma,4480,O
syndrome,4480,O
(,4480,O
OPPG,4480,O
),4480,O
as,4480,O
well,4480,O
as,4480,O
the,4480,O
high,4480,O
bone,4480,O
mass,4480,O
(,4480,O
HBM,4480,O
),4480,O
phenotype,4480,O
",",4480,O
LRP5,4480,B-GENE-Y
and,4480,O
the,4480,O
Wnt/β-catenin,4480,B-GENE-N
signaling,4480,O
have,4480,O
been,4480,O
extensively,4480,O
studied,4480,O
for,4480,O
their,4480,O
role,4480,O
in,4480,O
the,4480,O
differentiation,4480,O
and,4480,O
proliferation,4480,O
of,4480,O
osteoblasts,4480,O
",",4480,O
in,4480,O
the,4480,O
apoptosis,4480,O
of,4480,O
osteoblasts,4480,O
and,4480,O
osteocytes,4480,O
and,4480,O
in,4480,O
the,4480,O
response,4480,O
of,4480,O
bone,4480,O
to,4480,O
mechanical,4480,O
loading,4480,O
.,4480,O
However,4481,O
",",4481,O
more,4481,O
recently,4481,O
the,4481,O
direct,4481,O
effect,4481,O
of,4481,O
LRP5,4481,B-GENE-Y
on,4481,O
osteoblasts,4481,O
and,4481,O
bone,4481,O
formation,4481,O
has,4481,O
been,4481,O
questioned,4481,O
.,4481,O
Gene,4482,O
expression,4482,O
studies,4482,O
showed,4482,O
that,4482,O
mice,4482,O
lacking,4482,O
lrp5,4482,B-GENE-Y
have,4482,O
increased,4482,O
expression,4482,O
of,4482,O
tph1,4482,B-GENE-Y
",",4482,O
the,4482,O
rate,4482,O
limiting,4482,O
enzyme,4482,O
for,4482,O
the,4482,O
production,4482,O
of,4482,O
serotonin,4482,B-CHEMICAL
in,4482,O
the,4482,O
gut,4482,O
.,4482,O
Furthermore,4483,O
mice,4483,O
lacking,4483,O
either,4483,O
tph1,4483,B-GENE-Y
or,4483,O
htr1B,4483,B-GENE-Y
",",4483,O
the,4483,O
receptor,4483,O
for,4483,O
serotonin,4483,B-CHEMICAL
on,4483,O
the,4483,O
osteoblasts,4483,O
",",4483,O
were,4483,O
reported,4483,O
to,4483,O
have,4483,O
an,4483,O
increased,4483,O
bone,4483,O
mass,4483,O
due,4483,O
to,4483,O
increased,4483,O
bone,4483,O
formation,4483,O
.,4483,O
This,4484,O
led,4484,O
to,4484,O
the,4484,O
still,4484,O
controversial,4484,O
hypothesis,4484,O
that,4484,O
LRP5,4484,B-GENE-Y
influences,4484,O
bone,4484,O
formation,4484,O
indirectly,4484,O
by,4484,O
regulating,4484,O
the,4484,O
expression,4484,O
of,4484,O
thp1,4484,B-GENE-Y
and,4484,O
as,4484,O
a,4484,O
consequence,4484,O
influencing,4484,O
the,4484,O
production,4484,O
of,4484,O
serotonin,4484,B-CHEMICAL
in,4484,O
the,4484,O
gut,4484,O
.,4484,O
Based,4485,O
on,4485,O
these,4485,O
data,4485,O
we,4485,O
decided,4485,O
to,4485,O
evaluate,4485,O
the,4485,O
role,4485,O
of,4485,O
TPH1,4485,B-GENE-Y
and,4485,O
HTR1B,4485,B-GENE-Y
in,4485,O
the,4485,O
development,4485,O
of,4485,O
craniotubular,4485,O
hyperostoses,4485,O
",",4485,O
a,4485,O
group,4485,O
of,4485,O
monogenic,4485,O
sclerosing,4485,O
bone,4485,O
dysplasias,4485,O
.,4485,O
We,4486,O
screened,4486,O
the,4486,O
coding,4486,O
regions,4486,O
of,4486,O
both,4486,O
genes,4486,O
in,4486,O
53,4486,O
patients,4486,O
lacking,4486,O
a,4486,O
mutation,4486,O
in,4486,O
the,4486,O
known,4486,O
causative,4486,O
genes,4486,O
LRP5,4486,B-GENE-Y
",",4486,O
LRP4,4486,B-GENE-Y
and,4486,O
SOST,4486,B-GENE-Y
.,4486,O
We,4487,O
could,4487,O
not,4487,O
find,4487,O
disease-causing,4487,O
coding,4487,O
variants,4487,O
in,4487,O
neither,4487,O
of,4487,O
the,4487,O
tested,4487,O
genes,4487,O
and,4487,O
therefore,4487,O
",",4487,O
we,4487,O
can,4487,O
not,4487,O
provide,4487,O
support,4487,O
for,4487,O
an,4487,O
important,4487,O
function,4487,O
of,4487,O
TPH1,4487,B-GENE-Y
and,4487,O
HTR1B,4487,B-GENE-Y
in,4487,O
the,4487,O
pathogenesis,4487,O
of,4487,O
sclerosing,4487,O
bone,4487,O
dysplasias,4487,O
in,4487,O
our,4487,O
tested,4487,O
patient,4487,O
cohort,4487,O
.,4487,O
Grb10-mediated,4488,B-GENE-Y
Negative,4488,O
Regulation,4488,O
of,4488,O
IGF1R-Activated,4488,B-GENE-Y
Signalling,4488,O
Pathway,4488,O
Results,4488,O
in,4488,O
Cognitive,4488,O
Disorder,4488,O
in,4488,O
Diabetic,4488,O
Rats,4488,O
.,4488,O
Growth,4489,B-GENE-Y
factor,4489,I-GENE-Y
receptor-bound,4489,I-GENE-Y
protein,4489,I-GENE-Y
10,4489,I-GENE-Y
(,4489,O
Grb10,4489,B-GENE-Y
),4489,O
is,4489,O
a,4489,O
Src,4489,B-GENE-N
homology,4489,I-GENE-N
2,4489,I-GENE-N
(,4489,I-GENE-N
SH2,4489,I-GENE-N
),4489,I-GENE-N
domain-containing,4489,O
protein,4489,O
and,4489,O
one,4489,O
of,4489,O
the,4489,O
binding,4489,O
partners,4489,O
for,4489,O
several,4489,O
trans-membrane,4489,O
tyrosine-kinase,4489,B-GENE-N
receptors,4489,I-GENE-N
",",4489,O
including,4489,O
insulin,4489,B-GENE-Y
receptor,4489,I-GENE-Y
(,4489,O
IR,4489,B-GENE-Y
),4489,O
and,4489,O
insulin-like,4489,B-GENE-Y
growth,4489,I-GENE-Y
factor-1,4489,I-GENE-Y
receptor,4489,I-GENE-Y
(,4489,O
IGF1-R,4489,B-GENE-Y
),4489,O
.,4489,O
The,4490,O
hippocampus,4490,O
",",4490,O
which,4490,O
is,4490,O
critical,4490,O
for,4490,O
cognitive,4490,O
functions,4490,O
",",4490,O
is,4490,O
one,4490,O
of,4490,O
the,4490,O
main,4490,O
distribution,4490,O
areas,4490,O
of,4490,O
Grb10,4490,B-GENE-Y
in,4490,O
the,4490,O
central,4490,O
nervous,4490,O
system,4490,O
.,4490,O
In,4491,O
recent,4491,O
years,4491,O
",",4491,O
diabetic,4491,O
encephalopathy,4491,O
has,4491,O
been,4491,O
defined,4491,O
as,4491,O
a,4491,O
third,4491,O
type,4491,O
of,4491,O
diabetes,4491,O
and,4491,O
the,4491,O
IGF1-IR,4491,B-GENE-Y
pathway,4491,O
has,4491,O
been,4491,O
shown,4491,O
to,4491,O
be,4491,O
critical,4491,O
for,4491,O
the,4491,O
neuropathogenic,4491,O
process,4491,O
of,4491,O
cognitive,4491,O
disorder,4491,O
in,4491,O
diabetes,4491,O
.,4491,O
However,4492,O
",",4492,O
the,4492,O
role,4492,O
of,4492,O
endogenous,4492,O
Grb10,4492,B-GENE-Y
in,4492,O
regulating,4492,O
the,4492,O
IGF1-IR,4492,B-GENE-Y
pathway,4492,O
and,4492,O
neurobehavioral,4492,O
changes,4492,O
is,4492,O
not,4492,O
explicit,4492,O
.,4492,O
The,4493,O
objective,4493,O
of,4493,O
this,4493,O
study,4493,O
was,4493,O
to,4493,O
determine,4493,O
the,4493,O
in,4493,O
vivo,4493,O
function,4493,O
of,4493,O
endogenous,4493,O
Grb10,4493,B-GENE-Y
in,4493,O
diabetic,4493,O
encephalopathy,4493,O
and,4493,O
the,4493,O
underlying,4493,O
mechanisms,4493,O
.,4493,O
Using,4494,O
stereotaxic,4494,O
surgical,4494,O
techniques,4494,O
and,4494,O
lentiviral,4494,O
vectors,4494,O
expressing,4494,O
specific,4494,O
short,4494,O
hairpin,4494,O
RNA,4494,O
(,4494,O
shRNA,4494,O
),4494,O
",",4494,O
we,4494,O
could,4494,O
steadily,4494,O
knock,4494,O
down,4494,O
Grb10,4494,B-GENE-Y
expression,4494,O
in,4494,O
the,4494,O
hippocampus,4494,O
.,4494,O
More,4495,O
importantly,4495,O
",",4495,O
we,4495,O
demonstrated,4495,O
that,4495,O
hippocampus-specific,4495,O
modulation,4495,O
of,4495,O
Grb10,4495,B-GENE-Y
protein,4495,O
levels,4495,O
led,4495,O
to,4495,O
a,4495,O
prominent,4495,O
remission,4495,O
of,4495,O
cognitive,4495,O
disorder,4495,O
",",4495,O
including,4495,O
improvements,4495,O
in,4495,O
both,4495,O
ultrastructural,4495,O
pathology,4495,O
and,4495,O
abnormal,4495,O
neurobehavioural,4495,O
changes,4495,O
.,4495,O
Our,4496,O
findings,4496,O
indicate,4496,O
that,4496,O
endogenous,4496,O
overexpression,4496,O
of,4496,O
Grb10,4496,B-GENE-Y
functions,4496,O
as,4496,O
a,4496,O
suppressor,4496,O
of,4496,O
the,4496,O
IGF1-IR,4496,B-GENE-Y
pathway,4496,O
",",4496,O
which,4496,O
may,4496,O
represent,4496,O
an,4496,O
important,4496,O
mechanism,4496,O
that,4496,O
regulates,4496,O
cognitive,4496,O
disorder,4496,O
in,4496,O
diabetes,4496,O
.,4496,O
This,4497,O
article,4497,O
is,4497,O
protected,4497,O
by,4497,O
copyright,4497,O
.,4497,O
All,4498,O
rights,4498,O
reserved,4498,O
.,4498,O
Drug,4499,O
cocktail,4499,O
interaction,4499,O
study,4499,O
on,4499,O
the,4499,O
effect,4499,O
of,4499,O
the,4499,O
orally,4499,O
administered,4499,O
lavender,4499,O
oil,4499,O
preparation,4499,O
silexan,4499,O
on,4499,O
cytochrome,4499,B-GENE-N
p450,4499,I-GENE-N
enzymes,4499,O
in,4499,O
healthy,4499,O
volunteers,4499,O
.,4499,O
This,4500,O
cocktail,4500,O
study,4500,O
evaluated,4500,O
the,4500,O
interaction,4500,O
potential,4500,O
of,4500,O
the,4500,O
oral,4500,O
lavender,4500,O
oil,4500,O
preparation,4500,O
silexan,4500,O
with,4500,O
major,4500,O
P450,4500,B-GENE-N
(,4500,O
cytochrome,4500,B-GENE-N
P450,4500,I-GENE-N
),4500,O
enzymes,4500,O
.,4500,O
Subjects,4501,O
and,4501,O
Methods,4501,O
:,4501,O
Sixteen,4501,O
healthy,4501,O
male,4501,O
or,4501,O
female,4501,O
Caucasians,4501,O
completed,4501,O
this,4501,O
double-blind,4501,O
",",4501,O
randomized,4501,O
",",4501,O
2-fold,4501,O
crossover,4501,O
study,4501,O
.,4501,O
Silexan,4502,O
(,4502,O
160,4502,O
mg,4502,O
),4502,O
or,4502,O
placebo,4502,O
were,4502,O
administered,4502,O
once,4502,O
daily,4502,O
for,4502,O
11,4502,O
days,4502,O
.,4502,O
Additionally,4503,O
",",4503,O
on,4503,O
day,4503,O
11,4503,O
of,4503,O
both,4503,O
study,4503,O
periods,4503,O
",",4503,O
150,4503,O
mg,4503,O
caffeine,4503,B-CHEMICAL
(,4503,O
CYP1A2,4503,B-GENE-Y
),4503,O
",",4503,O
125,4503,O
mg,4503,O
tolbutamide,4503,B-CHEMICAL
(,4503,O
CYP2C9,4503,B-GENE-Y
),4503,O
",",4503,O
20,4503,O
mg,4503,O
omeprazole,4503,B-CHEMICAL
(,4503,O
CYP2C19,4503,B-GENE-Y
),4503,O
",",4503,O
30,4503,O
mg,4503,O
dextromethorphan-HBr,4503,B-CHEMICAL
(,4503,O
CYP2D6,4503,B-GENE-Y
),4503,O
",",4503,O
and,4503,O
2,4503,O
mg,4503,O
midazolam,4503,B-CHEMICAL
(,4503,O
CYP3A4,4503,B-GENE-Y
),4503,O
were,4503,O
administered,4503,O
orally,4503,O
.,4503,O
Formal,4504,O
interaction,4504,O
was,4504,O
excluded,4504,O
if,4504,O
the,4504,O
90,4504,O
%,4504,O
confidence,4504,O
interval,4504,O
(,4504,O
CI,4504,O
),4504,O
for,4504,O
the,4504,O
silexan,4504,O
over,4504,O
placebo,4504,O
ratios,4504,O
for,4504,O
phenotyping,4504,O
metrics,4504,O
(,4504,O
primary,4504,O
:,4504,O
AUC0-t,4504,O
),4504,O
was,4504,O
within,4504,O
a,4504,O
0.70-1.43,4504,O
range,4504,O
.,4504,O
Results,4505,O
:,4505,O
According,4505,O
to,4505,O
the,4505,O
AUC0-t,4505,O
comparisons,4505,O
",",4505,O
silexan,4505,O
had,4505,O
no,4505,O
relevant,4505,O
effect,4505,O
on,4505,O
CYP1A2,4505,B-GENE-N
",",4505,I-GENE-N
2C9,4505,I-GENE-N
",",4505,I-GENE-N
2D6,4505,I-GENE-N
",",4505,I-GENE-N
and,4505,I-GENE-N
3A4,4505,I-GENE-N
activity,4505,O
.,4505,O
Secondary,4506,O
phenotyping,4506,O
metrics,4506,O
confirmed,4506,O
this,4506,O
result,4506,O
.,4506,O
Mean,4507,O
ratios,4507,O
for,4507,O
all,4507,O
omeprazole-derived,4507,B-CHEMICAL
metrics,4507,O
were,4507,O
close,4507,O
to,4507,O
unity,4507,O
.,4507,O
The,4508,O
90,4508,O
%,4508,O
CI,4508,O
for,4508,O
the,4508,O
AUC0-t,4508,O
ratio,4508,O
of,4508,O
omeprazole,4508,B-CHEMICAL
but,4508,O
not,4508,O
for,4508,O
omeprazole/5-OH-omeprazole,4508,B-CHEMICAL
plasma,4508,O
ratio,4508,O
3,4508,O
hours,4508,O
post-dose,4508,O
or,4508,O
omeprazole/5-OH-omeprazole,4508,B-CHEMICAL
AUC0-t,4508,O
ratio,4508,O
(,4508,O
secondary,4508,O
CYP2C19,4508,B-GENE-Y
metrics,4508,O
),4508,O
was,4508,O
above,4508,O
the,4508,O
predefined,4508,O
threshold,4508,O
of,4508,O
1.43,4508,O
",",4508,O
probably,4508,O
caused,4508,O
by,4508,O
the,4508,O
inherent,4508,O
high,4508,O
variability,4508,O
of,4508,O
omeprazole,4508,B-CHEMICAL
pharmacokinetics,4508,O
.,4508,O
Silexan,4509,O
and,4509,O
the,4509,O
phenotyping,4509,O
drugs,4509,O
were,4509,O
well,4509,O
tolerated,4509,O
.,4509,O
Repeated,4510,O
silexan,4510,O
(,4510,O
160,4510,O
mg/day,4510,O
),4510,O
administration,4510,O
has,4510,O
no,4510,O
clinically,4510,O
relevant,4510,O
inhibitory,4510,O
or,4510,O
inducing,4510,O
effects,4510,O
on,4510,O
the,4510,O
CYP1A2,4510,B-GENE-N
",",4510,I-GENE-N
2C9,4510,I-GENE-N
",",4510,I-GENE-N
2C19,4510,I-GENE-N
",",4510,I-GENE-N
2D6,4510,I-GENE-N
",",4510,I-GENE-N
and,4510,I-GENE-N
3A4,4510,I-GENE-N
enzymes,4510,O
in,4510,O
vivo,4510,O
.,4510,O
Sulindac,4511,B-CHEMICAL
independently,4511,O
modulates,4511,O
extracellular,4511,B-GENE-N
signal-regulated,4511,I-GENE-N
kinase,4511,I-GENE-N
1/2,4511,I-GENE-N
and,4511,O
cyclic,4511,B-GENE-N
GMP-dependent,4511,I-GENE-N
protein,4511,I-GENE-N
kinase,4511,I-GENE-N
signaling,4511,O
pathways,4511,O
.,4511,O
Colorectal,4512,O
cancer,4512,O
is,4512,O
the,4512,O
second,4512,O
leading,4512,O
cause,4512,O
of,4512,O
cancer,4512,O
mortality,4512,O
in,4512,O
the,4512,O
United,4512,O
States,4512,O
.,4512,O
Substantial,4513,O
human,4513,O
and,4513,O
animal,4513,O
data,4513,O
support,4513,O
the,4513,O
ability,4513,O
of,4513,O
nonsteroidal,4513,O
anti-inflammatory,4513,O
drugs,4513,O
to,4513,O
cause,4513,O
regression,4513,O
of,4513,O
existing,4513,O
colon,4513,O
tumors,4513,O
and,4513,O
prevent,4513,O
new,4513,O
tumor,4513,O
formation,4513,O
.,4513,O
The,4514,O
mechanism,4514,O
by,4514,O
which,4514,O
the,4514,O
nonsteroidal,4514,O
anti-inflammatory,4514,O
drug,4514,O
sulindac,4514,B-CHEMICAL
prevents,4514,O
tumor,4514,O
growth,4514,O
is,4514,O
poorly,4514,O
understood,4514,O
and,4514,O
seems,4514,O
complex,4514,O
as,4514,O
sulindac,4514,B-CHEMICAL
can,4514,O
modulate,4514,O
several,4514,O
growth-related,4514,O
signaling,4514,O
pathways,4514,O
.,4514,O
Sulindac,4515,B-CHEMICAL
metabolites,4515,O
simultaneously,4515,O
(,4515,O
a,4515,O
),4515,O
increase,4515,O
cellular,4515,O
cyclic,4515,B-CHEMICAL
GMP,4515,I-CHEMICAL
and,4515,O
subsequently,4515,O
activate,4515,O
cyclic,4515,B-GENE-N
GMP-dependent,4515,I-GENE-N
protein,4515,I-GENE-N
kinase,4515,I-GENE-N
(,4515,O
PKG,4515,B-GENE-N
),4515,O
;,4515,O
(,4515,O
b,4515,O
),4515,O
activate,4515,O
c-jun,4515,B-GENE-N
NH2-terminal,4515,I-GENE-N
kinase,4515,I-GENE-N
(,4515,O
JNK,4515,B-GENE-N
),4515,O
;,4515,O
(,4515,O
c,4515,O
),4515,O
inhibit,4515,O
extracellular,4515,B-GENE-N
signal-regulated,4515,I-GENE-N
kinase,4515,I-GENE-N
1/2,4515,I-GENE-N
(,4515,O
ERK1/2,4515,B-GENE-N
),4515,O
;,4515,O
and,4515,O
(,4515,O
d,4515,O
),4515,O
decrease,4515,O
beta-catenin,4515,B-GENE-Y
protein,4515,O
expression,4515,O
at,4515,O
times,4515,O
and,4515,O
doses,4515,O
consistent,4515,O
with,4515,O
apoptosis,4515,O
.,4515,O
The,4516,O
purpose,4516,O
of,4516,O
this,4516,O
study,4516,O
was,4516,O
to,4516,O
determine,4516,O
if,4516,O
PKG,4516,B-GENE-N
",",4516,O
ERK1/2,4516,B-GENE-N
",",4516,O
JNK,4516,B-GENE-N
",",4516,O
and,4516,O
beta-catenin,4516,B-GENE-Y
are,4516,O
independent,4516,O
targets,4516,O
for,4516,O
sulindac,4516,B-CHEMICAL
in,4516,O
vitro,4516,O
.,4516,O
Pharmacologic,4517,O
activation,4517,O
of,4517,O
PKG,4517,B-GENE-N
with,4517,O
YC-1,4517,B-CHEMICAL
increases,4517,O
JNK,4517,B-GENE-N
phosphorylation,4517,O
and,4517,O
induces,4517,O
apoptosis,4517,O
in,4517,O
colon,4517,O
cancer,4517,O
cells,4517,O
without,4517,O
modulating,4517,O
ERK1/2,4517,B-GENE-N
phosphorylation,4517,O
or,4517,O
beta-catenin,4517,B-GENE-Y
protein,4517,O
expression,4517,O
.,4517,O
Inhibition,4518,O
of,4518,O
ERK1/2,4518,B-GENE-N
with,4518,O
U0126,4518,B-CHEMICAL
induces,4518,O
apoptosis,4518,O
but,4518,O
fails,4518,O
to,4518,O
activate,4518,O
JNK,4518,B-GENE-N
phosphorylation,4518,O
or,4518,O
down-regulate,4518,O
beta-catenin,4518,B-GENE-Y
protein,4518,O
expression,4518,O
.,4518,O
Cotreatment,4519,O
with,4519,O
U0126,4519,B-CHEMICAL
and,4519,O
YC-1,4519,B-CHEMICAL
synergistically,4519,O
increases,4519,O
apoptosis,4519,O
in,4519,O
colorectal,4519,O
cancer,4519,O
cells,4519,O
and,4519,O
recapitulates,4519,O
the,4519,O
effects,4519,O
of,4519,O
sulindac,4519,B-CHEMICAL
treatment,4519,O
on,4519,O
ERK1/2,4519,B-GENE-N
",",4519,O
JNK,4519,B-GENE-N
",",4519,O
and,4519,O
beta-catenin,4519,B-GENE-Y
.,4519,O
These,4520,O
results,4520,O
indicate,4520,O
that,4520,O
sulindac,4520,B-CHEMICAL
metabolites,4520,O
modulate,4520,O
ERK1/2,4520,B-GENE-N
and,4520,O
PKG,4520,B-GENE-N
pathways,4520,O
independently,4520,O
in,4520,O
colon,4520,O
cancer,4520,O
cells,4520,O
and,4520,O
suggest,4520,O
that,4520,O
the,4520,O
full,4520,O
apoptotic,4520,O
effect,4520,O
of,4520,O
sulindac,4520,B-CHEMICAL
is,4520,O
mediated,4520,O
by,4520,O
more,4520,O
than,4520,O
one,4520,O
pathway,4520,O
.,4520,O
Using,4521,O
similar,4521,O
combinatorial,4521,O
approaches,4521,O
in,4521,O
vivo,4521,O
may,4521,O
provide,4521,O
more,4521,O
effective,4521,O
",",4521,O
less,4521,O
toxic,4521,O
chemopreventive,4521,O
and,4521,O
chemotherapeutic,4521,O
strategies,4521,O
.,4521,O
Such,4522,O
therapies,4522,O
could,4522,O
dramatically,4522,O
reduce,4522,O
the,4522,O
incidence,4522,O
and,4522,O
death,4522,O
rate,4522,O
from,4522,O
colorectal,4522,O
cancer,4522,O
.,4522,O
Synthesis,4523,O
and,4523,O
antagonistic,4523,O
activity,4523,O
at,4523,O
muscarinic,4523,B-GENE-N
receptor,4523,I-GENE-N
subtypes,4523,O
of,4523,O
some,4523,O
2-carbonyl,4523,B-CHEMICAL
derivatives,4523,O
of,4523,O
diphenidol,4523,B-CHEMICAL
.,4523,O
A,4524,O
series,4524,O
of,4524,O
2-carbonyl,4524,B-CHEMICAL
analogues,4524,O
of,4524,O
the,4524,O
muscarinic,4524,O
antagonist,4524,O
diphenidol,4524,B-CHEMICAL
bearing,4524,O
1-substituents,4524,O
of,4524,O
different,4524,O
lipophilic,4524,O
",",4524,O
electronic,4524,O
",",4524,O
and,4524,O
steric,4524,O
properties,4524,O
was,4524,O
synthesized,4524,O
and,4524,O
their,4524,O
affinity,4524,O
for,4524,O
the,4524,O
M2,4524,B-GENE-N
and,4524,I-GENE-N
M3,4524,I-GENE-N
muscarinic,4524,I-GENE-N
receptor,4524,I-GENE-N
subtypes,4524,O
was,4524,O
evaluated,4524,O
by,4524,O
functional,4524,O
tests,4524,O
.,4524,O
Two,4525,O
derivatives,4525,O
(,4525,O
2g,4525,O
and,4525,O
2d,4525,O
),4525,O
showed,4525,O
an,4525,O
M2-selective,4525,B-GENE-Y
profile,4525,O
which,4525,O
was,4525,O
confirmed,4525,O
by,4525,O
functional,4525,O
tests,4525,O
on,4525,O
the,4525,O
M1,4525,B-GENE-N
and,4525,I-GENE-N
M4,4525,I-GENE-N
receptors,4525,I-GENE-N
.,4525,O
A,4526,O
possible,4526,O
relationship,4526,O
between,4526,O
M2,4526,B-GENE-Y
selectivity,4526,O
and,4526,O
lipophilicity,4526,O
of,4526,O
the,4526,O
1-substituent,4526,O
was,4526,O
suggested,4526,O
by,4526,O
structure-activity,4526,O
analysis,4526,O
.,4526,O
This,4527,O
work,4527,O
showed,4527,O
that,4527,O
appropriate,4527,O
structural,4527,O
modification,4527,O
of,4527,O
diphenidol,4527,B-CHEMICAL
can,4527,O
lead,4527,O
to,4527,O
M2-selective,4527,B-GENE-Y
muscarinic,4527,O
antagonists,4527,O
of,4527,O
possible,4527,O
interest,4527,O
in,4527,O
the,4527,O
field,4527,O
of,4527,O
Alzheimer,4527,O
's,4527,O
disease,4527,O
.,4527,O
Activation,4528,O
of,4528,O
an,4528,O
apoptotic,4528,O
signal,4528,O
transduction,4528,O
pathway,4528,O
involved,4528,O
in,4528,O
the,4528,O
upregulation,4528,O
of,4528,O
calpain,4528,B-GENE-N
and,4528,O
apoptosis-inducing,4528,B-GENE-Y
factor,4528,I-GENE-Y
in,4528,O
aldosterone-induced,4528,B-CHEMICAL
primary,4528,O
cultured,4528,O
cardiomyocytes,4528,O
.,4528,O
In,4529,O
this,4529,O
study,4529,O
",",4529,O
aldosterone,4529,B-CHEMICAL
(,4529,O
ALD,4529,B-CHEMICAL
),4529,O
-induced,4529,O
apoptosis,4529,O
of,4529,O
cardiomyocyte,4529,O
was,4529,O
evaluated,4529,O
based,4529,O
on,4529,O
the,4529,O
previous,4529,O
studies,4529,O
",",4529,O
and,4529,O
the,4529,O
roles,4529,O
of,4529,O
calpain,4529,B-GENE-N
signaling,4529,O
were,4529,O
clarified,4529,O
.,4529,O
Primary,4530,O
cultured,4530,O
rat,4530,O
cardiomyocytes,4530,O
were,4530,O
injured,4530,O
by,4530,O
ALD,4530,B-CHEMICAL
(,4530,O
0.01-10,4530,O
μM,4530,O
),4530,O
for,4530,O
varying,4530,O
time,4530,O
periods,4530,O
.,4530,O
Then,4531,O
",",4531,O
the,4531,O
effects,4531,O
of,4531,O
ethylene,4531,B-CHEMICAL
glycol,4531,I-CHEMICAL
tetraacetic,4531,I-CHEMICAL
acid,4531,I-CHEMICAL
(,4531,O
EGTA,4531,B-CHEMICAL
),4531,O
(,4531,O
0.5,4531,O
mM,4531,O
),4531,O
",",4531,O
calpeptin,4531,B-CHEMICAL
(,4531,O
2.5,4531,O
μM,4531,O
),4531,O
",",4531,O
and,4531,O
spironoclactone,4531,B-CHEMICAL
(,4531,O
10,4531,O
μM,4531,O
),4531,O
were,4531,O
evaluated,4531,O
on,4531,O
cardiomyocytes,4531,O
activated,4531,O
by,4531,O
ALD,4531,B-CHEMICAL
.,4531,O
Cardiomyocytes,4532,O
that,4532,O
were,4532,O
injured,4532,O
by,4532,O
ALD,4532,B-CHEMICAL
were,4532,O
assayed,4532,O
by,4532,O
the,4532,O
MTT,4532,B-CHEMICAL
and,4532,O
LDH,4532,B-GENE-N
leakage,4532,O
ratio,4532,O
.,4532,O
Apoptosis,4533,O
was,4533,O
evaluated,4533,O
by,4533,O
a,4533,O
TUNEL,4533,O
assay,4533,O
",",4533,O
annexin,4533,O
V/PI,4533,O
staining,4533,O
",",4533,O
and,4533,O
caspase-3,4533,B-GENE-Y
activity,4533,O
.,4533,O
The,4534,O
expression,4534,O
of,4534,O
cleavage,4534,O
of,4534,O
Bid,4534,B-GENE-Y
(,4534,O
tBid,4534,B-GENE-Y
),4534,O
",",4534,O
calpain,4534,B-GENE-N
and,4534,O
apoptosis-inducing,4534,B-GENE-Y
factor,4534,I-GENE-Y
(,4534,O
AIF,4534,B-GENE-Y
),4534,O
was,4534,O
evaluated,4534,O
by,4534,O
western,4534,O
blot,4534,O
analysis,4534,O
.,4534,O
ALD,4535,B-CHEMICAL
increased,4535,O
calpain,4535,B-GENE-N
expression,4535,O
and,4535,O
caspase-3,4535,B-GENE-Y
activity,4535,O
and,4535,O
promoted,4535,O
Bid,4535,O
cleavage,4535,O
.,4535,O
It,4536,O
also,4536,O
induced,4536,O
the,4536,O
release,4536,O
of,4536,O
AIF,4536,B-GENE-Y
from,4536,O
mitochondria,4536,O
into,4536,O
the,4536,O
cytosol,4536,O
.,4536,O
The,4537,O
upregulation,4537,O
of,4537,O
calpain,4537,B-GENE-N
",",4537,O
tBid,4537,B-GENE-Y
and,4537,O
caspase-3,4537,B-GENE-Y
activity,4537,O
were,4537,O
further,4537,O
inhibited,4537,O
by,4537,O
treatment,4537,O
with,4537,O
EGTA,4537,B-CHEMICAL
in,4537,O
the,4537,O
presence,4537,O
of,4537,O
ALD,4537,B-CHEMICAL
.,4537,O
Additionally,4538,O
",",4538,O
AIF,4538,B-GENE-Y
levels,4538,O
in,4538,O
the,4538,O
cytosol,4538,O
decreased,4538,O
due,4538,O
to,4538,O
EGTA,4538,B-CHEMICAL
but,4538,O
not,4538,O
due,4538,O
to,4538,O
calpeptin,4538,B-CHEMICAL
.,4538,O
This,4539,O
was,4539,O
also,4539,O
accompanied,4539,O
by,4539,O
a,4539,O
significant,4539,O
decrease,4539,O
in,4539,O
apoptosis,4539,O
.,4539,O
Furthermore,4540,O
",",4540,O
treatment,4540,O
with,4540,O
spironoclactone,4540,B-CHEMICAL
not,4540,O
only,4540,O
attenuated,4540,O
the,4540,O
pro-apoptotic,4540,O
effect,4540,O
of,4540,O
ALD,4540,B-CHEMICAL
but,4540,O
reversed,4540,O
the,4540,O
ALD-induced,4540,B-CHEMICAL
increase,4540,O
of,4540,O
calpain,4540,B-GENE-N
and,4540,O
AIF,4540,B-GENE-Y
levels,4540,O
.,4540,O
Loperamide,4541,B-CHEMICAL
",",4541,O
an,4541,O
opiate,4541,O
analog,4541,O
",",4541,O
differently,4541,O
modifies,4541,O
the,4541,O
adrenocorticotropin,4541,B-GENE-Y
responses,4541,O
to,4541,O
corticotropin-releasing,4541,B-GENE-Y
hormone,4541,I-GENE-Y
and,4541,O
lysine,4541,B-GENE-Y
vasopressin,4541,I-GENE-Y
in,4541,O
patients,4541,O
with,4541,O
Addison,4541,O
's,4541,O
disease,4541,O
.,4541,O
Loperamide,4542,B-CHEMICAL
is,4542,O
a,4542,O
peripheral,4542,O
opiate,4542,O
agonist,4542,O
able,4542,O
to,4542,O
inhibit,4542,O
ACTH,4542,B-GENE-Y
secretion,4542,O
.,4542,O
In,4543,O
this,4543,O
work,4543,O
",",4543,O
the,4543,O
interactions,4543,O
between,4543,O
loperamide,4543,B-CHEMICAL
and,4543,O
two,4543,O
ACTH,4543,B-GENE-Y
secretagogues,4543,O
",",4543,O
lysine,4543,B-GENE-Y
vasopressin,4543,I-GENE-Y
(,4543,O
LVP,4543,B-GENE-Y
),4543,O
and,4543,O
corticotropin-releasing,4543,B-GENE-Y
hormone,4543,I-GENE-Y
(,4543,O
CRH,4543,B-GENE-Y
),4543,O
",",4543,O
were,4543,O
investigated,4543,O
in,4543,O
patients,4543,O
with,4543,O
Addison,4543,O
's,4543,O
disease,4543,O
.,4543,O
After,4544,O
loperamide,4544,B-CHEMICAL
(,4544,O
16,4544,O
mg,4544,O
orally,4544,O
),4544,O
or,4544,O
placebo,4544,O
administration,4544,O
",",4544,O
5,4544,O
patients,4544,O
received,4544,O
LVP,4544,B-GENE-Y
(,4544,O
0.06,4544,O
IU/kg,4544,O
i.v,4544,O
.,4544,O
over,4545,O
1,4545,O
h,4545,O
),4545,O
and,4545,O
6,4545,O
patients,4545,O
received,4545,O
oCRH,4545,B-GENE-Y
(,4545,O
1,4545,O
micrograms/kg,4545,O
i.v,4545,O
.,4545,O
as,4546,O
bolus,4546,O
),4546,O
.,4546,O
In,4547,O
all,4547,O
patients,4547,O
loperamide,4547,B-CHEMICAL
induced,4547,O
a,4547,O
significant,4547,O
fall,4547,O
in,4547,O
plasma,4547,O
ACTH,4547,B-GENE-Y
levels,4547,O
.,4547,O
LVP,4548,B-GENE-Y
increased,4548,O
ACTH,4548,B-GENE-Y
levels,4548,O
after,4548,O
both,4548,O
loperamide,4548,B-CHEMICAL
(,4548,O
from,4548,O
48,4548,O
+/-,4548,O
17.3,4548,O
to,4548,O
a,4548,O
peak,4548,O
of,4548,O
95,4548,O
+/-,4548,O
21,4548,O
pmol/l,4548,O
),4548,O
and,4548,O
placebo,4548,O
(,4548,O
from,4548,O
231,4548,O
+/-,4548,O
59.5,4548,O
to,4548,O
365,4548,O
+/-,4548,O
86.6,4548,O
pmol/l,4548,O
),4548,O
:,4548,O
the,4548,O
interaction,4548,O
between,4548,O
treatments,4548,O
and,4548,O
time,4548,O
was,4548,O
not,4548,O
significant,4548,O
.,4548,O
CRH,4549,B-GENE-Y
caused,4549,O
a,4549,O
rise,4549,O
in,4549,O
plasma,4549,O
ACTH,4549,B-GENE-Y
after,4549,O
both,4549,O
loperamide,4549,B-CHEMICAL
(,4549,O
from,4549,O
30,4549,O
+/-,4549,O
16.6,4549,O
to,4549,O
a,4549,O
peak,4549,O
of,4549,O
108,4549,O
+/-,4549,O
31,4549,O
pmol/l,4549,O
),4549,O
and,4549,O
placebo,4549,O
(,4549,O
from,4549,O
98.5,4549,O
+/-,4549,O
47,4549,O
to,4549,O
211,4549,O
+/-,4549,O
61.7,4549,O
pmol/l,4549,O
),4549,O
:,4549,O
the,4549,O
interaction,4549,O
between,4549,O
treatments,4549,O
and,4549,O
time,4549,O
was,4549,O
significant,4549,O
",",4549,O
and,4549,O
the,4549,O
first,4549,O
phase,4549,O
of,4549,O
CRH-induced,4549,B-GENE-Y
ACTH,4549,B-GENE-Y
secretion,4549,O
was,4549,O
significantly,4549,O
lower,4549,O
after,4549,O
loperamide,4549,B-CHEMICAL
.,4549,O
These,4550,O
data,4550,O
demonstrate,4550,O
that,4550,O
loperamide,4550,B-CHEMICAL
differently,4550,O
modifies,4550,O
the,4550,O
stimulatory,4550,O
action,4550,O
of,4550,O
LVP,4550,B-GENE-Y
and,4550,O
CRH,4550,B-GENE-Y
on,4550,O
ACTH,4550,B-GENE-Y
secretion,4550,O
:,4550,O
namely,4550,O
",",4550,O
LVP,4550,B-GENE-Y
and,4550,O
loperamide,4550,B-CHEMICAL
act,4550,O
in,4550,O
an,4550,O
additive,4550,O
manner,4550,O
",",4550,O
while,4550,O
CRH,4550,B-GENE-Y
and,4550,O
loperamide,4550,B-CHEMICAL
interact,4550,O
in,4550,O
a,4550,O
non,4550,O
additive,4550,O
way,4550,O
.,4550,O
Although,4551,O
these,4551,O
findings,4551,O
might,4551,O
be,4551,O
explained,4551,O
by,4551,O
the,4551,O
involvement,4551,O
of,4551,O
different,4551,O
intracellular,4551,O
ACTH-secreting,4551,B-GENE-Y
mechanisms,4551,O
",",4551,O
an,4551,O
influence,4551,O
of,4551,O
loperamide,4551,B-CHEMICAL
on,4551,O
some,4551,O
suprapituitary,4551,O
factors,4551,O
modulating,4551,O
the,4551,O
ACTH,4551,B-GENE-Y
response,4551,O
is,4551,O
suggested,4551,O
.,4551,O
Comparisons,4552,O
of,4552,O
beta-adrenergic,4552,O
blocking,4552,O
properties,4552,O
of,4552,O
S-,4552,B-CHEMICAL
and,4552,I-CHEMICAL
R-timolol,4552,I-CHEMICAL
in,4552,O
humans,4552,O
.,4552,O
In,4553,O
animals,4553,O
",",4553,O
the,4553,O
R-enantiomer,4553,B-CHEMICAL
of,4553,I-CHEMICAL
timolol,4553,I-CHEMICAL
causes,4553,O
a,4553,O
significant,4553,O
reduction,4553,O
in,4553,O
intraocular,4553,O
pressure,4553,O
but,4553,O
had,4553,O
only,4553,O
1/80,4553,O
the,4553,O
activity,4553,O
of,4553,O
the,4553,O
S-enantiomer,4553,O
at,4553,O
extraocular,4553,B-GENE-N
receptors,4553,I-GENE-N
.,4553,O
The,4554,O
beta,4554,B-GENE-N
1-,4554,I-GENE-N
and,4554,I-GENE-N
beta,4554,I-GENE-N
2-adrenoceptor,4554,I-GENE-N
blocking,4554,O
properties,4554,O
of,4554,O
orally,4554,O
administered,4554,O
R-,4554,B-CHEMICAL
and,4554,I-CHEMICAL
S-timolol,4554,I-CHEMICAL
were,4554,O
compared,4554,O
in,4554,O
a,4554,O
double-blind,4554,O
placebo,4554,O
controlled,4554,O
trial,4554,O
in,4554,O
two,4554,O
groups,4554,O
of,4554,O
healthy,4554,O
men,4554,O
.,4554,O
Each,4555,O
subject,4555,O
in,4555,O
group,4555,O
A,4555,O
(,4555,O
n,4555,O
=,4555,O
6,4555,O
),4555,O
received,4555,O
placebo,4555,O
",",4555,O
1,4555,O
and,4555,O
3,4555,O
mg,4555,O
S-timolol,4555,B-CHEMICAL
and,4555,O
25,4555,O
and,4555,O
75,4555,O
mg,4555,O
R-timolol,4555,B-CHEMICAL
in,4555,O
random,4555,O
order,4555,O
",",4555,O
group,4555,O
B,4555,O
(,4555,O
n,4555,O
=,4555,O
5,4555,O
),4555,O
received,4555,O
placebo,4555,O
",",4555,O
0.5,4555,O
",",4555,O
and,4555,O
1,4555,O
mg,4555,O
S-timolol,4555,B-CHEMICAL
and,4555,O
3,4555,O
and,4555,O
10,4555,O
mg,4555,O
R-timolol,4555,B-CHEMICAL
.,4555,O
In,4556,O
both,4556,O
groups,4556,O
",",4556,O
R-,4556,B-CHEMICAL
and,4556,I-CHEMICAL
S-timolol,4556,I-CHEMICAL
comparably,4556,O
inhibited,4556,O
isoproterenol-induced,4556,B-CHEMICAL
increases,4556,O
in,4556,O
heart,4556,O
rate,4556,O
(,4556,O
P,4556,O
<,4556,O
.05,4556,O
),4556,O
",",4556,O
forearm,4556,O
blood,4556,O
flow,4556,O
(,4556,O
P,4556,O
<,4556,O
.05,4556,O
",",4556,O
except,4556,O
at,4556,O
3,4556,O
micrograms/minute,4556,O
of,4556,O
isoproterenol,4556,B-CHEMICAL
after,4556,O
the,4556,O
R-doses,4556,O
in,4556,O
group,4556,O
B,4556,O
),4556,O
",",4556,O
and,4556,O
finger,4556,O
tremor,4556,O
(,4556,O
P,4556,O
<,4556,O
.05,4556,O
),4556,O
in,4556,O
comparison,4556,O
with,4556,O
placebo,4556,O
.,4556,O
The,4557,O
findings,4557,O
for,4557,O
the,4557,O
R-enantiomer,4557,O
in,4557,O
this,4557,O
study,4557,O
were,4557,O
unexpected,4557,O
based,4557,O
on,4557,O
the,4557,O
animal,4557,O
studies,4557,O
and,4557,O
previous,4557,O
studies,4557,O
that,4557,O
demonstrated,4557,O
marked,4557,O
differences,4557,O
in,4557,O
beta,4557,O
blocking,4557,O
effects,4557,O
of,4557,O
other,4557,O
beta-blockers,4557,O
in,4557,O
which,4557,O
the,4557,O
R-enantiomers,4557,O
were,4557,O
less,4557,O
inhibitory,4557,O
.,4557,O
Rosmarinic,4558,B-CHEMICAL
acid,4558,I-CHEMICAL
ameliorates,4558,O
acute,4558,O
liver,4558,O
damage,4558,O
and,4558,O
fibrogenesis,4558,O
in,4558,O
carbon,4558,B-CHEMICAL
tetrachloride-intoxicated,4558,O
mice,4558,O
.,4558,O
The,4559,O
aim,4559,O
of,4559,O
this,4559,O
study,4559,O
was,4559,O
to,4559,O
investigate,4559,O
the,4559,O
therapeutic,4559,O
potential,4559,O
of,4559,O
rosmarinic,4559,B-CHEMICAL
acid,4559,I-CHEMICAL
(,4559,O
RA,4559,O
),4559,O
",",4559,O
a,4559,O
natural,4559,O
phenolic,4559,O
",",4559,O
in,4559,O
the,4559,O
treatment,4559,O
of,4559,O
acute,4559,O
liver,4559,O
toxicity,4559,O
.,4559,O
RA,4560,O
at,4560,O
10,4560,O
",",4560,O
25,4560,O
and,4560,O
50mg/kg,4560,O
was,4560,O
administered,4560,O
by,4560,O
gavage,4560,O
once,4560,O
daily,4560,O
for,4560,O
2,4560,O
consecutive,4560,O
days,4560,O
",",4560,O
6h,4560,O
after,4560,O
CCl,4560,B-CHEMICAL
(,4560,I-CHEMICAL
4,4560,I-CHEMICAL
),4560,I-CHEMICAL
intoxication,4560,O
.,4560,O
CCl,4561,B-CHEMICAL
(,4561,I-CHEMICAL
4,4561,I-CHEMICAL
),4561,I-CHEMICAL
intoxication,4561,O
caused,4561,O
hepatic,4561,O
necrosis,4561,O
and,4561,O
increased,4561,O
serum,4561,O
ALT,4561,B-GENE-N
activity,4561,O
.,4561,O
In,4562,O
the,4562,O
livers,4562,O
",",4562,O
oxidative/nitrosative,4562,O
stress,4562,O
was,4562,O
evidenced,4562,O
by,4562,O
increased,4562,O
3-nitrotyrosine,4562,B-CHEMICAL
(,4562,O
3-NT,4562,B-CHEMICAL
),4562,O
and,4562,O
thiobarbituric,4562,B-CHEMICAL
acid,4562,I-CHEMICAL
reactive,4562,O
substances,4562,O
(,4562,O
TBARS,4562,O
),4562,O
formation,4562,O
and,4562,O
a,4562,O
significant,4562,O
decrease,4562,O
in,4562,O
Cu/Zn,4562,B-GENE-Y
superoxide,4562,I-GENE-Y
dismutase,4562,I-GENE-Y
(,4562,O
SOD,4562,B-GENE-N
),4562,O
activity,4562,O
.,4562,O
CCl,4563,B-CHEMICAL
(,4563,I-CHEMICAL
4,4563,I-CHEMICAL
),4563,I-CHEMICAL
administration,4563,O
triggered,4563,O
inflammatory,4563,O
response,4563,O
in,4563,O
mice,4563,O
livers,4563,O
by,4563,O
activating,4563,O
nuclear,4563,B-GENE-N
factor-kappaB,4563,I-GENE-N
(,4563,O
NF-κB,4563,B-GENE-N
),4563,O
",",4563,O
which,4563,O
coincided,4563,O
with,4563,O
the,4563,O
induction,4563,O
of,4563,O
tumor,4563,B-GENE-Y
necrosis,4563,I-GENE-Y
factor-alpha,4563,I-GENE-Y
(,4563,O
TNF-α,4563,B-GENE-Y
),4563,O
and,4563,O
cyclooxygenase-2,4563,B-GENE-Y
(,4563,O
COX-2,4563,B-GENE-Y
),4563,O
.,4563,O
RA,4564,O
improved,4564,O
histological,4564,O
and,4564,O
serum,4564,O
markers,4564,O
of,4564,O
liver,4564,O
damage,4564,O
and,4564,O
significantly,4564,O
ameliorated,4564,O
oxidative/nitrosative,4564,O
stress,4564,O
and,4564,O
inflammatory,4564,O
response,4564,O
in,4564,O
liver,4564,O
tissue,4564,O
.,4564,O
Additionally,4565,O
",",4565,O
RA,4565,O
prevented,4565,O
transforming,4565,B-GENE-Y
growth,4565,I-GENE-Y
factor-beta1,4565,I-GENE-Y
(,4565,O
TGF-β1,4565,B-GENE-Y
),4565,O
and,4565,O
alpha-smooth,4565,B-GENE-Y
muscle,4565,I-GENE-Y
actin,4565,I-GENE-Y
(,4565,O
α-SMA,4565,B-GENE-Y
),4565,O
expression,4565,O
",",4565,O
suggesting,4565,O
suppression,4565,O
of,4565,O
profibrotic,4565,O
response,4565,O
.,4565,O
Furthermore,4566,O
",",4566,O
RA,4566,O
significantly,4566,O
inhibited,4566,O
the,4566,O
CCl,4566,B-CHEMICAL
(,4566,I-CHEMICAL
4,4566,I-CHEMICAL
),4566,I-CHEMICAL
-induced,4566,O
apoptosis,4566,O
",",4566,O
which,4566,O
was,4566,O
evident,4566,O
from,4566,O
decreased,4566,O
cleavage,4566,O
of,4566,O
caspase-3,4566,B-GENE-Y
.,4566,O
The,4567,O
hepatoprotective,4567,O
activity,4567,O
of,4567,O
RA,4567,O
coincided,4567,O
with,4567,O
enhanced,4567,O
NF-E2-related,4567,B-GENE-Y
factor,4567,I-GENE-Y
2,4567,I-GENE-Y
(,4567,O
Nrf2,4567,B-GENE-Y
),4567,O
and,4567,O
heme,4567,B-GENE-Y
oxygenase-1,4567,I-GENE-Y
(,4567,O
HO-1,4567,B-GENE-Y
),4567,O
expression,4567,O
.,4567,O
The,4568,O
results,4568,O
of,4568,O
this,4568,O
study,4568,O
indicates,4568,O
that,4568,O
RA,4568,O
possesses,4568,O
antioxidant,4568,O
",",4568,O
anti-inflammatory,4568,O
",",4568,O
antiapoptotic,4568,O
and,4568,O
antifibrotic,4568,O
activity,4568,O
against,4568,O
acute,4568,O
liver,4568,O
toxicity,4568,O
.,4568,O
Pre-clinical,4569,O
pharmacology,4569,O
of,4569,O
zolmitriptan,4569,B-CHEMICAL
(,4569,O
Zomig,4569,B-CHEMICAL
;,4569,O
formerly,4569,B-CHEMICAL
311C90,4569,B-CHEMICAL
),4569,O
",",4569,O
a,4569,O
centrally,4569,O
and,4569,O
peripherally,4569,O
acting,4569,O
5HT1B/1D,4569,B-GENE-N
agonist,4569,O
for,4569,O
migraine,4569,O
.,4569,O
Zolmitriptan,4570,B-CHEMICAL
(,4570,O
Zomig,4570,B-CHEMICAL
;,4570,O
formerly,4570,B-CHEMICAL
311C90,4570,B-CHEMICAL
),4570,O
is,4570,O
a,4570,O
novel,4570,O
5-hydroxytryptamine,4570,B-GENE-N
(,4570,I-GENE-N
5HT,4570,I-GENE-N
),4570,I-GENE-N
1B/1D,4570,I-GENE-N
receptor,4570,O
agonist,4570,O
with,4570,O
proven,4570,O
efficacy,4570,O
in,4570,O
the,4570,O
acute,4570,O
treatment,4570,O
of,4570,O
migraine,4570,O
with,4570,O
or,4570,O
without,4570,O
preceding,4570,O
aura,4570,O
.,4570,O
The,4571,O
drug,4571,O
differs,4571,O
from,4571,O
presently,4571,O
available,4571,O
members,4571,O
of,4571,O
this,4571,O
drug,4571,O
class,4571,O
in,4571,O
that,4571,O
it,4571,O
combines,4571,O
5HT1B/1D,4571,B-GENE-N
receptor,4571,O
partial,4571,O
agonist,4571,O
activity,4571,O
with,4571,O
robust,4571,O
oral,4571,O
pharmacokinetics,4571,O
and,4571,O
an,4571,O
ability,4571,O
to,4571,O
inhibit,4571,O
trigeminovascular,4571,O
activation,4571,O
centrally,4571,O
as,4571,O
well,4571,O
as,4571,O
peripherally,4571,O
in,4571,O
preclinical,4571,O
studies,4571,O
.,4571,O
Consistent,4572,O
with,4572,O
its,4572,O
selectivity,4572,O
for,4572,O
5HT1B/1D,4572,B-GENE-N
receptors,4572,O
",",4572,O
zolmitriptan,4572,B-CHEMICAL
produces,4572,O
constriction,4572,O
of,4572,O
various,4572,O
isolated,4572,O
blood,4572,O
vessels,4572,O
",",4572,O
most,4572,O
notably,4572,O
cranial,4572,O
arteries,4572,O
.,4572,O
In,4573,O
anaesthetized,4573,O
animals,4573,O
",",4573,O
these,4573,O
vascular,4573,O
effects,4573,O
manifest,4573,O
as,4573,O
a,4573,O
selective,4573,O
constriction,4573,O
of,4573,O
cranial,4573,O
arterio-venous,4573,O
anastomoses,4573,O
resulting,4573,O
in,4573,O
a,4573,O
redistribution,4573,O
of,4573,O
carotid,4573,O
arterial,4573,O
blood,4573,O
flow,4573,O
.,4573,O
This,4574,O
effect,4574,O
is,4574,O
produced,4574,O
without,4574,O
significant,4574,O
effects,4574,O
on,4574,O
heart,4574,O
rate,4574,O
",",4574,O
blood,4574,O
pressure,4574,O
or,4574,O
blood,4574,O
flow,4574,O
to,4574,O
the,4574,O
brain,4574,O
",",4574,O
heart,4574,O
or,4574,O
lungs,4574,O
.,4574,O
Zolmitriptan,4575,B-CHEMICAL
also,4575,O
inhibits,4575,O
trigeminal-evoked,4575,O
increases,4575,O
in,4575,O
cerebral,4575,O
blood,4575,O
flow,4575,O
in,4575,O
anaesthetized,4575,O
cats,4575,O
and,4575,O
blocks,4575,O
trigeminal-evoked,4575,O
plasma,4575,O
protein,4575,O
extravasation,4575,O
in,4575,O
the,4575,O
dura,4575,O
of,4575,O
guinea-pigs,4575,O
.,4575,O
These,4576,O
actions,4576,O
are,4576,O
consistent,4576,O
with,4576,O
a,4576,O
pre-junctional,4576,O
inhibition,4576,O
of,4576,O
neuropeptide,4576,O
release,4576,O
from,4576,O
perivascular,4576,O
afferents,4576,O
of,4576,O
the,4576,O
trigeminal,4576,O
nerve,4576,O
",",4576,O
as,4576,O
confirmed,4576,O
by,4576,O
independent,4576,O
studies,4576,O
showing,4576,O
that,4576,O
zolmitriptan,4576,B-CHEMICAL
blocks,4576,O
elevations,4576,O
of,4576,O
calcitonin-gene-related,4576,B-GENE-N
peptide,4576,I-GENE-N
in,4576,O
jugular,4576,O
venous,4576,O
blood,4576,O
during,4576,O
electrical,4576,O
stimulation,4576,O
of,4576,O
the,4576,O
trigeminal,4576,O
ganglion,4576,O
.,4576,O
In,4577,O
all,4577,O
of,4577,O
these,4577,O
effects,4577,O
",",4577,O
zolmitriptan,4577,B-CHEMICAL
is,4577,O
three,4577,O
to,4577,O
four,4577,O
times,4577,O
more,4577,O
potent,4577,O
than,4577,O
sumatriptan,4577,B-CHEMICAL
",",4577,O
but,4577,O
produces,4577,O
the,4577,O
same,4577,O
maximum,4577,O
response,4577,O
.,4577,O
Zolmitriptan,4578,B-CHEMICAL
crosses,4578,O
the,4578,O
intact,4578,O
blood-brain,4578,O
barrier,4578,O
to,4578,O
inhibit,4578,O
trigeminovascular,4578,O
activation,4578,O
in,4578,O
the,4578,O
brainstem,4578,O
.,4578,O
This,4579,O
was,4579,O
shown,4579,O
initially,4579,O
by,4579,O
the,4579,O
ability,4579,O
of,4579,O
the,4579,O
drug,4579,O
to,4579,O
block,4579,O
a,4579,O
brainstem,4579,O
reflex,4579,O
provoking,4579,O
vasoactive,4579,O
intestinal,4579,O
peptide,4579,O
release,4579,O
from,4579,O
the,4579,O
VIIth,4579,O
cranial,4579,O
(,4579,O
facial,4579,O
),4579,O
nerve,4579,O
during,4579,O
trigeminal,4579,O
stimulation,4579,O
.,4579,O
Subsequent,4580,O
ex,4580,O
vivo,4580,O
autoradiography,4580,O
confirmed,4580,O
that,4580,O
intravenously,4580,O
injected,4580,O
[,4580,B-CHEMICAL
3H,4580,I-CHEMICAL
],4580,I-CHEMICAL
zolmitriptan,4580,I-CHEMICAL
labels,4580,O
a,4580,O
discrete,4580,O
population,4580,O
of,4580,O
cells,4580,O
in,4580,O
the,4580,O
trigeminal,4580,O
nucleus,4580,O
caudalis,4580,O
(,4580,O
TNC,4580,O
),4580,O
and,4580,O
nucleus,4580,O
tractus,4580,O
solitarius,4580,O
.,4580,O
Direct,4581,O
evidence,4581,O
for,4581,O
a,4581,O
central,4581,O
neuromodulatory,4581,O
effect,4581,O
of,4581,O
zolmitriptan,4581,B-CHEMICAL
was,4581,O
provided,4581,O
by,4581,O
electrophysiological,4581,O
experiments,4581,O
which,4581,O
clearly,4581,O
demonstrated,4581,O
that,4581,O
the,4581,O
drug,4581,O
inhibits,4581,O
the,4581,O
excitability,4581,O
of,4581,O
cells,4581,O
in,4581,O
the,4581,O
TNC,4581,O
after,4581,O
systemic,4581,O
administration,4581,O
.,4581,O
This,4582,O
novel,4582,O
pre-clinical,4582,O
profile,4582,O
not,4582,O
only,4582,O
distinguishes,4582,O
zolmitriptan,4582,B-CHEMICAL
from,4582,O
sumatriptan,4582,B-CHEMICAL
",",4582,O
but,4582,O
raises,4582,O
intriguing,4582,O
questions,4582,O
about,4582,O
the,4582,O
clinical,4582,O
relevance,4582,O
of,4582,O
a,4582,O
dual,4582,O
action,4582,O
.,4582,O
Studies,4583,O
to,4583,O
date,4583,O
show,4583,O
that,4583,O
zolmitriptan,4583,B-CHEMICAL
indeed,4583,O
modulates,4583,O
cranial,4583,O
sensory,4583,O
processing,4583,O
in,4583,O
humans,4583,O
",",4583,O
yet,4583,O
central,4583,O
side-effects,4583,O
are,4583,O
no,4583,O
different,4583,O
from,4583,O
sumatriptan,4583,B-CHEMICAL
.,4583,O
This,4584,O
property,4584,O
may,4584,O
account,4584,O
for,4584,O
the,4584,O
remarkable,4584,O
consistency,4584,O
in,4584,O
clinical,4584,O
efficacy,4584,O
observed,4584,O
in,4584,O
clinical,4584,O
trials,4584,O
.,4584,O
Oligomeric,4585,O
procyanidins,4585,B-CHEMICAL
of,4585,O
lotus,4585,O
seedpod,4585,O
inhibits,4585,O
the,4585,O
formation,4585,O
of,4585,O
advanced,4585,O
glycation,4585,O
end-products,4585,O
by,4585,O
scavenging,4585,O
reactive,4585,O
carbonyls,4585,B-CHEMICAL
.,4585,O
It,4586,O
has,4586,O
been,4586,O
reported,4586,O
that,4586,O
oligomeric,4586,O
procyanidins,4586,B-CHEMICAL
of,4586,O
lotus,4586,O
seedpod,4586,O
(,4586,O
LSOPC,4586,O
),4586,O
is,4586,O
effective,4586,O
in,4586,O
the,4586,O
alleviation,4586,O
of,4586,O
Alzheimer,4586,O
's,4586,O
disease,4586,O
and,4586,O
diabetes,4586,O
through,4586,O
its,4586,O
antioxidant,4586,O
and,4586,O
insulin-potentiating,4586,B-GENE-Y
activities,4586,O
.,4586,O
This,4587,O
study,4587,O
investigated,4587,O
the,4587,O
anti-glycative,4587,O
activity,4587,O
of,4587,O
LSOPC,4587,O
in,4587,O
a,4587,O
bovine,4587,B-GENE-Y
serum,4587,I-GENE-Y
albumin,4587,I-GENE-Y
(,4587,O
BSA,4587,B-GENE-Y
),4587,O
-glucose,4587,O
model,4587,O
.,4587,O
The,4588,O
level,4588,O
of,4588,O
glycation,4588,O
and,4588,O
conformational,4588,O
alterations,4588,O
were,4588,O
assessed,4588,O
by,4588,O
specific,4588,O
fluorescence,4588,O
",",4588,O
Congo,4588,O
red,4588,O
binding,4588,O
assay,4588,O
and,4588,O
circular,4588,O
dichroism,4588,O
.,4588,O
The,4589,O
results,4589,O
show,4589,O
that,4589,O
LSOPC,4589,O
has,4589,O
a,4589,O
significant,4589,O
anti-glycative,4589,O
activity,4589,O
in,4589,O
vitro,4589,O
and,4589,O
it,4589,O
can,4589,O
also,4589,O
effectively,4589,O
protect,4589,O
the,4589,O
secondary,4589,O
structure,4589,O
of,4589,O
BSA,4589,B-GENE-Y
during,4589,O
glycation,4589,O
.,4589,O
LSOPC,4590,O
or,4590,O
catechin,4590,B-CHEMICAL
(,4590,O
a,4590,O
major,4590,O
constituent,4590,O
unit,4590,O
of,4590,O
LSOPC,4590,O
),4590,O
",",4590,O
were,4590,O
used,4590,O
to,4590,O
react,4590,O
with,4590,O
methylglyoxal,4590,B-CHEMICAL
.,4590,O
The,4591,O
structures,4591,O
of,4591,O
their,4591,O
carbonyl,4591,B-CHEMICAL
adducts,4591,O
were,4591,O
tentatively,4591,O
identified,4591,O
using,4591,O
HPLC-MS,4591,O
(,4591,O
2,4591,O
),4591,O
.,4591,O
Their,4592,O
capacity,4592,O
to,4592,O
scavenge,4592,O
methylglyoxal,4592,B-CHEMICAL
suggested,4592,O
carbonyl,4592,B-CHEMICAL
scavenging,4592,O
as,4592,O
a,4592,O
major,4592,O
mechanism,4592,O
of,4592,O
antiglycation,4592,O
.,4592,O
Therefore,4593,O
",",4593,O
LSOPC,4593,O
could,4593,O
be,4593,O
helpful,4593,O
to,4593,O
prevent,4593,O
AGEs-associated,4593,O
diseases,4593,O
",",4593,O
and,4593,O
with,4593,O
the,4593,O
potential,4593,O
to,4593,O
be,4593,O
used,4593,O
as,4593,O
functional,4593,O
food,4593,O
ingredients,4593,O
.,4593,O
Pegylated,4594,B-GENE-N
recombinant,4594,I-GENE-N
human,4594,I-GENE-N
arginase,4594,I-GENE-N
(,4594,O
"rhArg-peg5,000mw",4594,B-GENE-N
),4594,O
inhibits,4594,O
the,4594,O
in,4594,O
vitro,4594,O
and,4594,O
in,4594,O
vivo,4594,O
proliferation,4594,O
of,4594,O
human,4594,O
hepatocellular,4594,O
carcinoma,4594,O
through,4594,O
arginine,4594,B-CHEMICAL
depletion,4594,O
.,4594,O
Hepatocellular,4595,O
carcinoma,4595,O
(,4595,O
HCC,4595,O
),4595,O
is,4595,O
believed,4595,O
to,4595,O
be,4595,O
auxotrophic,4595,O
for,4595,O
arginine,4595,B-CHEMICAL
through,4595,O
the,4595,O
lack,4595,O
of,4595,O
expression,4595,O
of,4595,O
argininosuccinate,4595,B-GENE-Y
synthetase,4595,I-GENE-Y
(,4595,O
ASS,4595,B-GENE-Y
),4595,O
.,4595,O
The,4596,O
successful,4596,O
use,4596,O
of,4596,O
the,4596,O
arginine-depleting,4596,B-GENE-N
enzyme,4596,I-GENE-N
arginine,4596,B-GENE-N
deiminase,4596,I-GENE-N
(,4596,O
ADI,4596,B-GENE-N
),4596,O
to,4596,O
treat,4596,O
ASS-deficient,4596,B-GENE-Y
tumors,4596,O
has,4596,O
opened,4596,O
up,4596,O
new,4596,O
possibilities,4596,O
for,4596,O
effective,4596,O
cancer,4596,O
therapy,4596,O
.,4596,O
Nevertheless,4597,O
",",4597,O
many,4597,O
ASS-positive,4597,B-GENE-Y
HCC,4597,O
cell,4597,O
lines,4597,O
are,4597,O
found,4597,O
to,4597,O
be,4597,O
resistant,4597,O
to,4597,O
ADI,4597,B-GENE-N
treatment,4597,O
",",4597,O
although,4597,O
most,4597,O
require,4597,O
arginine,4597,B-CHEMICAL
for,4597,O
proliferation,4597,O
.,4597,O
Thus,4598,O
far,4598,O
",",4598,O
an,4598,O
arginine-depleting,4598,B-GENE-N
enzyme,4598,I-GENE-N
for,4598,O
killing,4598,O
ASS-positive,4598,B-GENE-Y
tumors,4598,O
has,4598,O
not,4598,O
been,4598,O
reported,4598,O
.,4598,O
Here,4599,O
",",4599,O
we,4599,O
provide,4599,O
direct,4599,O
evidence,4599,O
that,4599,O
recombinant,4599,O
human,4599,B-GENE-N
arginase,4599,I-GENE-N
(,4599,O
rhArg,4599,B-GENE-N
),4599,O
inhibits,4599,O
ASS-positive,4599,B-GENE-Y
HCCs,4599,O
.,4599,O
All,4600,O
the,4600,O
five,4600,O
human,4600,O
HCC,4600,O
cell,4600,O
lines,4600,O
we,4600,O
used,4600,O
were,4600,O
sensitive,4600,O
to,4600,O
rhArg,4600,B-GENE-N
but,4600,O
ADI,4600,B-GENE-N
had,4600,O
virtually,4600,O
no,4600,O
effect,4600,O
on,4600,O
these,4600,O
cells,4600,O
.,4600,O
They,4601,O
all,4601,O
expressed,4601,O
ASS,4601,B-GENE-Y
",",4601,O
but,4601,O
not,4601,O
ornithine,4601,B-GENE-Y
transcarbamylase,4601,I-GENE-Y
(,4601,O
OTC,4601,B-GENE-Y
),4601,O
",",4601,O
the,4601,O
enzyme,4601,O
that,4601,O
converts,4601,O
ornithine,4601,B-CHEMICAL
",",4601,O
the,4601,O
product,4601,O
of,4601,O
degradation,4601,O
of,4601,O
arginine,4601,B-CHEMICAL
with,4601,O
rhArg,4601,B-GENE-N
",",4601,O
to,4601,O
citrulline,4601,B-CHEMICAL
",",4601,O
which,4601,O
is,4601,O
converted,4601,O
back,4601,O
to,4601,O
arginine,4601,B-CHEMICAL
via,4601,O
ASS,4601,B-GENE-Y
.,4601,O
Transfection,4602,O
of,4602,O
HCC,4602,O
cells,4602,O
with,4602,O
OTC,4602,B-GENE-Y
resulted,4602,O
in,4602,O
resistance,4602,O
to,4602,O
rhArg,4602,B-GENE-N
.,4602,O
Thus,4603,O
",",4603,O
OTC,4603,B-GENE-Y
expression,4603,O
alone,4603,O
may,4603,O
be,4603,O
sufficient,4603,O
to,4603,O
induce,4603,O
rhArg,4603,B-GENE-N
resistance,4603,O
in,4603,O
ASS-positive,4603,B-GENE-Y
HCC,4603,O
cells,4603,O
.,4603,O
This,4604,O
surprising,4604,O
correlation,4604,O
between,4604,O
the,4604,O
lack,4604,O
of,4604,O
OTC,4604,B-GENE-Y
expression,4604,O
and,4604,O
sensitivity,4604,O
of,4604,O
ASS-positive,4604,B-GENE-Y
HCC,4604,O
cells,4604,O
shows,4604,O
that,4604,O
OTC-deficient,4604,B-GENE-Y
HCCs,4604,O
are,4604,O
sensitive,4604,O
to,4604,O
rhArg-mediated,4604,B-GENE-N
arginine,4604,B-CHEMICAL
depletion,4604,O
.,4604,O
Therefore,4605,O
",",4605,O
pretreatment,4605,O
tumor,4605,O
gene,4605,O
expression,4605,O
profiling,4605,O
of,4605,O
ASS,4605,B-GENE-Y
and,4605,O
OTC,4605,B-GENE-Y
could,4605,O
aid,4605,O
in,4605,O
predicting,4605,O
tumor,4605,O
response,4605,O
to,4605,O
arginine,4605,B-CHEMICAL
depletion,4605,O
with,4605,O
arginine-depleting,4605,B-GENE-N
enzymes,4605,I-GENE-N
.,4605,O
We,4606,O
have,4606,O
also,4606,O
shown,4606,O
that,4606,O
the,4606,O
rhArg,4606,B-GENE-N
native,4606,O
enzyme,4606,O
and,4606,O
the,4606,O
pegylated,4606,B-GENE-N
rhArg,4606,I-GENE-N
(,4606,O
rhArg-peg,4606,B-GENE-N
(,4606,O
"5,000mw",4606,O
),4606,O
),4606,O
gave,4606,O
similar,4606,O
anticancer,4606,O
efficacy,4606,O
in,4606,O
vitro,4606,O
.,4606,O
Furthermore,4607,O
",",4607,O
the,4607,O
growth,4607,O
of,4607,O
the,4607,O
OTC-deficient,4607,B-GENE-Y
Hep3B,4607,O
tumor,4607,O
cells,4607,O
(,4607,O
ASS-positive,4607,B-GENE-Y
and,4607,O
ADI-resistant,4607,B-GENE-N
),4607,O
in,4607,O
mice,4607,O
was,4607,O
inhibited,4607,O
by,4607,O
treatment,4607,O
with,4607,O
rhArg-peg,4607,B-GENE-N
(,4607,O
"5,000mw",4607,O
),4607,O
",",4607,O
which,4607,O
is,4607,O
active,4607,O
alone,4607,O
and,4607,O
is,4607,O
synergistic,4607,O
in,4607,O
combination,4607,O
with,4607,O
5-fluorouracil,4607,B-CHEMICAL
.,4607,O
Thus,4608,O
",",4608,O
our,4608,O
data,4608,O
suggest,4608,O
that,4608,O
rhArg-peg,4608,B-GENE-N
(,4608,O
"5,000mw",4608,O
),4608,O
is,4608,O
a,4608,O
novel,4608,O
agent,4608,O
for,4608,O
effective,4608,O
cancer,4608,O
therapy,4608,O
.,4608,O
Visualization,4609,O
and,4609,O
virtual,4609,O
screening,4609,O
of,4609,O
the,4609,O
chemical,4609,O
universe,4609,O
database,4609,O
GDB-17,4609,O
.,4609,O
The,4610,O
chemical,4610,O
universe,4610,O
database,4610,O
GDB-17,4610,O
contains,4610,O
166.4,4610,O
billion,4610,O
molecules,4610,O
of,4610,O
up,4610,O
to,4610,O
17,4610,O
atoms,4610,O
of,4610,O
C,4610,B-CHEMICAL
",",4610,O
N,4610,B-CHEMICAL
",",4610,O
O,4610,B-CHEMICAL
",",4610,O
S,4610,B-CHEMICAL
",",4610,O
and,4610,O
halogens,4610,B-CHEMICAL
obeying,4610,O
rules,4610,O
for,4610,O
chemical,4610,O
stability,4610,O
",",4610,O
synthetic,4610,O
feasibility,4610,O
",",4610,O
and,4610,O
medicinal,4610,O
chemistry,4610,O
.,4610,O
GDB-17,4611,O
was,4611,O
analyzed,4611,O
using,4611,O
42,4611,O
integer,4611,O
value,4611,O
descriptors,4611,O
of,4611,O
molecular,4611,O
structure,4611,O
which,4611,O
we,4611,O
term,4611,O
``,4611,O
Molecular,4611,O
Quantum,4611,O
Numbers,4611,O
'',4611,O
(,4611,O
MQN,4611,O
),4611,O
.,4611,O
Principal,4612,O
component,4612,O
analysis,4612,O
and,4612,O
representation,4612,O
of,4612,O
the,4612,O
(,4612,O
PC1,4612,O
",",4612,O
PC2,4612,O
),4612,O
-plane,4612,O
provided,4612,O
a,4612,O
graphical,4612,O
overview,4612,O
of,4612,O
the,4612,O
GDB-17,4612,O
chemical,4612,O
space,4612,O
.,4612,O
Rapid,4613,O
ligand-based,4613,O
virtual,4613,O
screening,4613,O
(,4613,O
LBVS,4613,O
),4613,O
of,4613,O
GDB-17,4613,O
using,4613,O
the,4613,O
city-block,4613,O
distance,4613,O
CBD,4613,O
(,4613,O
MQN,4613,O
),4613,O
as,4613,O
a,4613,O
similarity,4613,O
search,4613,O
measure,4613,O
was,4613,O
enabled,4613,O
by,4613,O
a,4613,O
hashed,4613,O
MQN-fingerprint,4613,O
.,4613,O
LBVS,4614,O
of,4614,O
the,4614,O
entire,4614,O
GDB-17,4614,O
and,4614,O
of,4614,O
selected,4614,O
subsets,4614,O
identified,4614,O
shape,4614,O
similar,4614,O
",",4614,O
scaffold,4614,O
hopping,4614,O
analogs,4614,O
(,4614,O
ROCS,4614,O
>,4614,O
1.6,4614,O
and,4614,O
T,4614,O
(,4614,O
SF,4614,O
),4614,O
<,4614,O
0.5,4614,O
),4614,O
of,4614,O
15,4614,O
drugs,4614,O
.,4614,O
Over,4615,O
97,4615,O
%,4615,O
of,4615,O
these,4615,O
analogs,4615,O
occurred,4615,O
within,4615,O
CBD,4615,O
(,4615,O
MQN,4615,O
),4615,O
≤,4615,O
12,4615,O
from,4615,O
each,4615,O
drug,4615,O
",",4615,O
a,4615,O
constraint,4615,O
which,4615,O
might,4615,O
help,4615,O
focus,4615,O
advanced,4615,O
virtual,4615,O
screening,4615,O
.,4615,O
An,4616,O
MQN-searchable,4616,O
50,4616,O
million,4616,O
subset,4616,O
of,4616,O
GDB-17,4616,O
is,4616,O
publicly,4616,O
available,4616,O
at,4616,O
www.gdb.unibe.ch,4616,O
.,4616,O
Both,4617,O
5-HT1B,4617,B-GENE-Y
and,4617,O
5-HT1F,4617,B-GENE-Y
receptors,4617,O
modulate,4617,O
c-fos,4617,B-GENE-Y
expression,4617,O
within,4617,O
rat,4617,O
trigeminal,4617,O
nucleus,4617,O
caudalis,4617,O
.,4617,O
A,4618,O
possible,4618,O
mechanism,4618,O
of,4618,O
action,4618,O
of,4618,O
antimigraine,4618,O
drugs,4618,O
such,4618,O
as,4618,O
sumatriptan,4618,B-CHEMICAL
is,4618,O
inhibition,4618,O
of,4618,O
the,4618,O
trigeminovascular,4618,O
pathway,4618,O
.,4618,O
Sumatriptan,4619,O
's,4619,O
effects,4619,O
might,4619,O
be,4619,O
mediated,4619,O
by,4619,O
5-HT1B,4619,B-GENE-Y
",",4619,O
5-HT1D,4619,B-GENE-Y
or,4619,O
5-HT1F,4619,B-GENE-Y
receptors,4619,O
.,4619,O
To,4620,O
establish,4620,O
the,4620,O
relative,4620,O
importance,4620,O
of,4620,O
these,4620,O
subtypes,4620,O
",",4620,O
we,4620,O
compared,4620,O
the,4620,O
effects,4620,O
of,4620,O
sumatriptan,4620,B-CHEMICAL
with,4620,O
those,4620,O
of,4620,O
a,4620,O
selective,4620,O
5-HT1F,4620,B-GENE-Y
receptor,4620,O
agonist,4620,O
(,4620,O
LY,4620,B-CHEMICAL
344864,4620,I-CHEMICAL
),4620,O
on,4620,O
c-fos,4620,B-GENE-Y
protein,4620,O
expression,4620,O
in,4620,O
the,4620,O
trigeminal,4620,O
nucleus,4620,O
caudalis,4620,O
.,4620,O
c-fos,4621,B-GENE-Y
expression,4621,O
was,4621,O
induced,4621,O
in,4621,O
urethane-anaesthetized,4621,B-CHEMICAL
rats,4621,O
by,4621,O
intracisternal,4621,O
capsaicin,4621,B-CHEMICAL
administration,4621,O
.,4621,O
Sumatriptan,4622,B-CHEMICAL
and,4622,O
LY,4622,B-CHEMICAL
344864,4622,I-CHEMICAL
decreased,4622,O
the,4622,O
number,4622,O
of,4622,O
capsaicin-induced,4622,B-CHEMICAL
c-fos-like,4622,B-GENE-Y
immunoreactive,4622,O
cells,4622,O
within,4622,O
trigeminal,4622,O
nucleus,4622,O
caudalis,4622,O
(,4622,O
ID50,4622,O
=,4622,O
0.04,4622,O
and,4622,O
0.6,4622,O
mg,4622,O
kg,4622,O
(,4622,O
-1,4622,O
),4622,O
),4622,O
.,4622,O
The,4623,O
effect,4623,O
of,4623,O
sumatriptan,4623,B-CHEMICAL
",",4623,O
but,4623,O
not,4623,O
of,4623,O
LY,4623,B-CHEMICAL
344864,4623,I-CHEMICAL
",",4623,O
was,4623,O
prevented,4623,O
by,4623,O
pretreatment,4623,O
with,4623,O
the,4623,O
antagonist,4623,O
SDZ,4623,B-CHEMICAL
21-009,4623,I-CHEMICAL
",",4623,O
which,4623,O
displays,4623,O
high,4623,O
affinity,4623,O
for,4623,O
rat,4623,B-GENE-Y
5-HT1B,4623,I-GENE-Y
receptors,4623,O
.,4623,O
LY,4624,B-CHEMICAL
344864,4624,I-CHEMICAL
appears,4624,O
to,4624,O
attenuate,4624,O
c-fos-like,4624,O
immunoreactivity,4624,O
via,4624,O
5-HT1F,4624,B-GENE-Y
receptors,4624,O
",",4624,O
while,4624,O
sumatriptan,4624,B-CHEMICAL
acts,4624,O
via,4624,O
5-HT1B,4624,B-GENE-Y
receptors,4624,O
.,4624,O
The,4625,O
fact,4625,O
that,4625,O
activation,4625,O
of,4625,O
5-HT1F,4625,B-GENE-Y
receptors,4625,O
is,4625,O
sufficient,4625,O
to,4625,O
modulate,4625,O
the,4625,O
activity,4625,O
of,4625,O
the,4625,O
trigeminal,4625,O
system,4625,O
suggests,4625,O
that,4625,O
this,4625,O
receptor,4625,O
may,4625,O
be,4625,O
a,4625,O
target,4625,O
for,4625,O
antimigraine,4625,O
drugs,4625,O
with,4625,O
improved,4625,O
safety,4625,O
profile,4625,O
.,4625,O
Disruption,4626,O
of,4626,O
the,4626,O
cereblon,4626,B-GENE-Y
gene,4626,O
enhances,4626,O
hepatic,4626,O
AMPK,4626,B-GENE-N
activity,4626,O
and,4626,O
prevents,4626,O
high,4626,O
fat,4626,O
diet-induced,4626,O
obesity,4626,O
and,4626,O
insulin,4626,B-GENE-N
resistance,4626,O
in,4626,O
mice,4626,O
.,4626,O
A,4627,O
nonsense,4627,O
mutation,4627,O
in,4627,O
cereblon,4627,B-GENE-Y
(,4627,O
CRBN,4627,B-GENE-Y
),4627,O
causes,4627,O
a,4627,O
mild,4627,O
type,4627,O
of,4627,O
mental,4627,O
retardation,4627,O
in,4627,O
humans,4627,O
.,4627,O
An,4628,O
earlier,4628,O
study,4628,O
showed,4628,O
that,4628,O
CRBN,4628,B-GENE-Y
negatively,4628,O
regulates,4628,O
the,4628,O
functional,4628,O
activity,4628,O
of,4628,O
AMP-activated,4628,B-GENE-N
protein,4628,I-GENE-N
kinase,4628,I-GENE-N
(,4628,O
AMPK,4628,B-GENE-N
),4628,O
in,4628,O
vitro,4628,O
by,4628,O
binding,4628,O
directly,4628,O
to,4628,O
the,4628,O
α1,4628,B-GENE-Y
subunit,4628,I-GENE-Y
of,4628,I-GENE-Y
the,4628,I-GENE-Y
AMPK,4628,I-GENE-Y
complex,4628,O
.,4628,O
However,4629,O
",",4629,O
the,4629,O
in,4629,O
vivo,4629,O
role,4629,O
of,4629,O
CRBN,4629,B-GENE-Y
was,4629,O
not,4629,O
studied,4629,O
.,4629,O
To,4630,O
elucidate,4630,O
the,4630,O
physiological,4630,O
functions,4630,O
of,4630,O
Crbn,4630,B-GENE-Y
",",4630,O
a,4630,O
mouse,4630,O
strain,4630,O
was,4630,O
generated,4630,O
in,4630,O
which,4630,O
the,4630,O
Crbn,4630,B-GENE-Y
gene,4630,O
was,4630,O
deleted,4630,O
throughout,4630,O
the,4630,O
whole,4630,O
body,4630,O
.,4630,O
In,4631,O
Crbn-deficient,4631,B-GENE-Y
mice,4631,O
fed,4631,O
a,4631,O
normal,4631,O
diet,4631,O
",",4631,O
AMPK,4631,B-GENE-N
in,4631,O
the,4631,O
liver,4631,O
showed,4631,O
hyper-phosphorylation,4631,O
",",4631,O
which,4631,O
indicated,4631,O
the,4631,O
constitutive,4631,O
activation,4631,O
of,4631,O
AMPK,4631,B-GENE-N
.,4631,O
Since,4632,O
Crbn-deficient,4632,B-GENE-Y
mice,4632,O
showed,4632,O
significantly,4632,O
less,4632,O
weight,4632,O
gain,4632,O
when,4632,O
fed,4632,O
a,4632,O
high,4632,O
fat,4632,O
diet,4632,O
and,4632,O
their,4632,O
insulin,4632,O
sensitivity,4632,O
was,4632,O
considerably,4632,O
improved,4632,O
",",4632,O
the,4632,O
functions,4632,O
of,4632,O
Crbn,4632,B-GENE-Y
in,4632,O
the,4632,O
liver,4632,O
were,4632,O
primarily,4632,O
investigated,4632,O
.,4632,O
These,4633,O
results,4633,O
provide,4633,O
the,4633,O
first,4633,O
in,4633,O
vivo,4633,O
evidence,4633,O
that,4633,O
Crbn,4633,B-GENE-Y
is,4633,O
a,4633,O
negative,4633,O
modulator,4633,O
of,4633,O
AMPK,4633,B-GENE-N
",",4633,O
which,4633,O
suggests,4633,O
that,4633,O
Crbn,4633,B-GENE-Y
may,4633,O
be,4633,O
a,4633,O
potential,4633,O
target,4633,O
for,4633,O
metabolic,4633,O
disorders,4633,O
of,4633,O
the,4633,O
liver,4633,O
.,4633,O
Involvement,4634,O
of,4634,O
EP1,4634,B-GENE-Y
and,4634,O
EP2,4634,B-GENE-Y
receptors,4634,I-GENE-Y
in,4634,O
the,4634,O
regulation,4634,O
of,4634,O
the,4634,O
Na,4634,B-GENE-N
",",4634,I-GENE-N
K-ATPase,4634,I-GENE-N
by,4634,O
prostaglandins,4634,B-CHEMICAL
in,4634,O
MDCK,4634,O
cells,4634,O
.,4634,O
Prostaglandins,4635,B-CHEMICAL
are,4635,O
key,4635,O
regulators,4635,O
of,4635,O
ion,4635,O
transport,4635,O
in,4635,O
the,4635,O
kidney,4635,O
.,4635,O
In,4636,O
MDCK,4636,O
cells,4636,O
",",4636,O
which,4636,O
model,4636,O
distal,4636,O
tubule,4636,O
cells,4636,O
",",4636,O
the,4636,O
transcription,4636,O
of,4636,O
the,4636,O
Na,4636,B-GENE-N
",",4636,I-GENE-N
K-ATPase,4636,I-GENE-N
beta1,4636,I-GENE-N
subunit,4636,O
is,4636,O
regulated,4636,O
by,4636,O
PGE1,4636,O
and,4636,O
PGE2,4636,O
.,4636,O
To,4637,O
identify,4637,O
the,4637,O
EP,4637,B-GENE-N
receptors,4637,I-GENE-N
that,4637,O
mediate,4637,O
transcriptional,4637,O
regulation,4637,O
",",4637,O
transient,4637,O
transfection,4637,O
studies,4637,O
are,4637,O
conducted,4637,O
using,4637,O
the,4637,O
human,4637,O
beta1promoter/luciferase,4637,O
construct,4637,O
",",4637,O
pHbeta1-1141,4637,O
Luc,4637,O
.,4637,O
The,4638,O
involvement,4638,O
of,4638,O
EP1,4638,B-GENE-Y
and,4638,O
EP2,4638,B-GENE-Y
receptors,4638,I-GENE-Y
is,4638,O
indicated,4638,O
by,4638,O
studies,4638,O
with,4638,O
the,4638,O
EP1,4638,B-GENE-Y
selective,4638,O
agonist,4638,O
17-phenyl,4638,B-CHEMICAL
trinor,4638,I-CHEMICAL
PGE2,4638,I-CHEMICAL
",",4638,O
and,4638,O
the,4638,O
EP2,4638,B-GENE-Y
selective,4638,O
agonist,4638,O
butaprost,4638,B-CHEMICAL
(,4638,O
which,4638,O
stimulate,4638,O
),4638,O
",",4638,O
as,4638,O
well,4638,O
as,4638,O
by,4638,O
studies,4638,O
with,4638,O
the,4638,O
antagonists,4638,O
SC-51089,4638,B-CHEMICAL
(,4638,O
EP1,4638,O
specific,4638,O
),4638,O
and,4638,O
AH,4638,B-CHEMICAL
6809,4638,I-CHEMICAL
(,4638,O
EP1,4638,B-GENE-Y
and,4638,O
EP2,4638,B-GENE-Y
specific,4638,O
),4638,O
.,4638,O
Consistent,4639,O
with,4639,O
the,4639,O
involvement,4639,O
of,4639,O
Gs,4639,B-GENE-N
coupled,4639,O
EP2,4639,B-GENE-Y
receptors,4639,I-GENE-Y
",",4639,O
is,4639,O
that,4639,O
the,4639,O
PGE1,4639,B-CHEMICAL
stimulation,4639,O
is,4639,O
inhibited,4639,O
by,4639,O
the,4639,O
PKAI,4639,B-GENE-N
expression,4639,O
vector,4639,O
(,4639,O
encoding,4639,O
the,4639,O
protein,4639,B-GENE-N
kinase,4639,I-GENE-N
A,4639,I-GENE-N
(,4639,I-GENE-N
PKA,4639,I-GENE-N
),4639,I-GENE-N
inhibitory,4639,I-GENE-N
protein,4639,I-GENE-N
),4639,O
",",4639,O
as,4639,O
well,4639,O
as,4639,O
by,4639,O
the,4639,O
myristolated,4639,B-GENE-N
PKA,4639,I-GENE-N
inhibitory,4639,I-GENE-N
peptide,4639,I-GENE-N
PKI,4639,O
.,4639,O
In,4640,O
addition,4640,O
to,4640,O
this,4640,O
evidence,4640,O
(,4640,O
for,4640,O
the,4640,O
involvement,4640,O
of,4640,O
EP2,4640,B-GENE-Y
receptors,4640,I-GENE-Y
),4640,O
",",4640,O
evidence,4640,O
for,4640,O
the,4640,O
involvement,4640,O
of,4640,O
EP1,4640,B-GENE-Y
receptors,4640,I-GENE-Y
in,4640,O
the,4640,O
PGE1,4640,B-CHEMICAL
mediated,4640,O
stimulation,4640,O
of,4640,O
Na,4640,B-GENE-N
",",4640,I-GENE-N
K-ATPase,4640,I-GENE-N
beta,4640,I-GENE-N
subunit,4640,O
gene,4640,O
transcription,4640,O
includes,4640,O
the,4640,O
stimulatory,4640,O
effect,4640,O
of,4640,O
17-phenyl,4640,B-CHEMICAL
trinor,4640,I-CHEMICAL
PGE2,4640,I-CHEMICAL
",",4640,O
as,4640,O
well,4640,O
as,4640,O
the,4640,O
inhibitory,4640,O
effects,4640,O
of,4640,O
SC-51089,4640,B-CHEMICAL
.,4640,O
Also,4641,O
consistent,4641,O
with,4641,O
the,4641,O
involvement,4641,O
of,4641,O
Gq,4641,B-GENE-N
coupled,4641,O
EP1,4641,B-GENE-Y
receptors,4641,I-GENE-Y
",",4641,O
the,4641,O
PGE1,4641,B-CHEMICAL
stimulation,4641,O
is,4641,O
inhibited,4641,O
by,4641,O
the,4641,O
PKCI,4641,B-GENE-N
vector,4641,O
(,4641,O
encoding,4641,O
the,4641,O
PKC,4641,B-GENE-N
inhibitory,4641,I-GENE-N
domain,4641,I-GENE-N
),4641,O
",",4641,O
the,4641,O
PKC,4641,B-GENE-N
inhibitor,4641,O
Go,4641,B-CHEMICAL
6976,4641,I-CHEMICAL
",",4641,O
thapsigargin,4641,B-CHEMICAL
",",4641,O
as,4641,O
well,4641,O
as,4641,O
the,4641,O
calmodulin,4641,B-GENE-N
antagonists,4641,O
W7,4641,B-CHEMICAL
and,4641,O
W13,4641,B-CHEMICAL
.,4641,O
VMAT2,4642,B-GENE-Y
:,4642,O
a,4642,O
dynamic,4642,O
regulator,4642,O
of,4642,O
brain,4642,O
monoaminergic,4642,O
neuronal,4642,O
function,4642,O
interacting,4642,O
with,4642,O
drugs,4642,O
of,4642,O
abuse,4642,O
.,4642,O
The,4643,O
monoaminergic,4643,O
neuron,4643,O
",",4643,O
in,4643,O
particular,4643,O
the,4643,O
dopaminergic,4643,O
neuron,4643,O
",",4643,O
is,4643,O
central,4643,O
to,4643,O
mediating,4643,O
the,4643,O
hedonic,4643,O
and,4643,O
addictive,4643,O
properties,4643,O
of,4643,O
drugs,4643,O
of,4643,O
abuse,4643,O
.,4643,O
The,4644,O
effects,4644,O
of,4644,O
amphetamine,4644,B-CHEMICAL
(,4644,O
AMPH,4644,B-CHEMICAL
),4644,O
and,4644,O
cocaine,4644,B-CHEMICAL
(,4644,O
COC,4644,B-CHEMICAL
),4644,O
",",4644,O
for,4644,O
example,4644,O
",",4644,O
depend,4644,O
on,4644,O
the,4644,O
ability,4644,O
to,4644,O
increase,4644,O
dopamine,4644,B-CHEMICAL
in,4644,O
the,4644,O
synapse,4644,O
",",4644,O
by,4644,O
effects,4644,O
on,4644,O
either,4644,O
the,4644,O
plasma,4644,O
membrane,4644,O
transporter,4644,O
DAT,4644,B-GENE-Y
or,4644,O
the,4644,O
vesicular,4644,O
transporter,4644,O
for,4644,O
monoamine,4644,B-CHEMICAL
storage,4644,O
",",4644,O
VMAT2,4644,B-GENE-Y
.,4644,O
The,4645,O
potential,4645,O
role,4645,O
of,4645,O
DAT,4645,B-GENE-Y
as,4645,O
a,4645,O
target,4645,O
for,4645,O
AMPH,4645,B-CHEMICAL
and,4645,O
COC,4645,B-CHEMICAL
has,4645,O
been,4645,O
reviewed,4645,O
extensively,4645,O
.,4645,O
Here,4646,O
",",4646,O
we,4646,O
present,4646,O
VMAT2,4646,B-GENE-Y
as,4646,O
a,4646,O
target,4646,O
that,4646,O
enables,4646,O
the,4646,O
rewarding,4646,O
and,4646,O
addictive,4646,O
actions,4646,O
of,4646,O
these,4646,O
drugs,4646,O
",",4646,O
based,4646,O
on,4646,O
imaging,4646,O
",",4646,O
neurochemical,4646,O
",",4646,O
biochemical,4646,O
",",4646,O
cell,4646,O
biological,4646,O
",",4646,O
genetic,4646,O
",",4646,O
and,4646,O
immunohistochemical,4646,O
evidence,4646,O
.,4646,O
The,4647,O
presence,4647,O
of,4647,O
VMAT2,4647,B-GENE-Y
in,4647,O
noradrenergic,4647,O
",",4647,O
serotoninergic,4647,O
",",4647,O
histaminergic,4647,O
",",4647,O
and,4647,O
potentially,4647,O
trace,4647,O
aminergic,4647,O
neurons,4647,O
invites,4647,O
consideration,4647,O
of,4647,O
a,4647,O
wider,4647,O
role,4647,O
for,4647,O
aminergic,4647,O
neurotransmission,4647,O
in,4647,O
AMPH,4647,B-CHEMICAL
and,4647,O
COC,4647,B-CHEMICAL
abuse,4647,O
and,4647,O
addiction,4647,O
.,4647,O
Spiro,4648,O
heterocycles,4648,O
as,4648,O
potential,4648,O
inhibitors,4648,O
of,4648,O
SIRT1,4648,B-GENE-Y
:,4648,O
Pd/C-mediated,4648,B-CHEMICAL
synthesis,4648,O
of,4648,O
novel,4648,O
N-indolylmethyl,4648,B-CHEMICAL
"spiroindoline-3,2'-quinazolines",4648,I-CHEMICAL
.,4648,O
Novel,4649,O
N-indolylmethyl,4649,B-CHEMICAL
substituted,4649,I-CHEMICAL
"spiroindoline-3,2'-quinazolines",4649,I-CHEMICAL
were,4649,O
designed,4649,O
as,4649,O
potential,4649,O
inhibitiors,4649,O
of,4649,O
SIRT1,4649,B-GENE-Y
.,4649,O
These,4650,O
compounds,4650,O
were,4650,O
synthesized,4650,O
in,4650,O
good,4650,O
yields,4650,O
by,4650,O
using,4650,O
Pd/C-Cu,4650,B-CHEMICAL
mediated,4650,O
coupling-cyclization,4650,O
strategy,4650,O
as,4650,O
a,4650,O
key,4650,O
step,4650,O
involving,4650,O
the,4650,O
reaction,4650,O
of,4650,O
1-,4650,B-CHEMICAL
(,4650,I-CHEMICAL
prop-2-ynyl,4650,I-CHEMICAL
),4650,I-CHEMICAL
-1,4650,I-CHEMICAL
',4650,I-CHEMICAL
H-spiro,4650,I-CHEMICAL
[,4650,I-CHEMICAL
"indoline-3,2'-quinazoline",4650,I-CHEMICAL
],4650,I-CHEMICAL
"-2,4",4650,I-CHEMICAL
',4650,I-CHEMICAL
(,4650,I-CHEMICAL
3,4650,I-CHEMICAL
',4650,I-CHEMICAL
H,4650,I-CHEMICAL
),4650,I-CHEMICAL
-dione,4650,I-CHEMICAL
with,4650,O
2-iodoanilides,4650,B-CHEMICAL
.,4650,O
Some,4651,O
of,4651,O
the,4651,O
compounds,4651,O
synthesized,4651,O
have,4651,O
shown,4651,O
encouraging,4651,O
inhibition,4651,O
of,4651,O
Sir,4651,B-GENE-Y
2,4651,I-GENE-Y
protein,4651,O
(,4651,O
a,4651,O
yeast,4651,O
homologue,4651,O
of,4651,O
mammalian,4651,B-GENE-N
SIRT1,4651,I-GENE-N
),4651,O
in,4651,O
vitro,4651,O
and,4651,O
three,4651,O
of,4651,O
them,4651,O
showed,4651,O
dose,4651,O
dependent,4651,O
inhibition,4651,O
of,4651,O
Sir,4651,B-GENE-Y
2,4651,I-GENE-Y
.,4651,O
The,4652,O
docking,4652,O
results,4652,O
suggested,4652,O
that,4652,O
the,4652,O
benzene,4652,B-CHEMICAL
ring,4652,O
of,4652,O
"1,2,3,4-tetrahydroquinazolin",4652,B-CHEMICAL
ring,4652,O
system,4652,O
of,4652,O
these,4652,O
molecules,4652,O
occupied,4652,O
the,4652,O
deep,4652,O
hydrophobic,4652,O
pocket,4652,O
of,4652,O
the,4652,O
protein,4652,O
and,4652,O
one,4652,O
of,4652,O
the,4652,O
NH,4652,B-CHEMICAL
along,4652,O
with,4652,O
the,4652,O
sulfonyl,4652,B-CHEMICAL
group,4652,O
participated,4652,O
in,4652,O
strong,4652,O
H-bonding,4652,B-CHEMICAL
interaction,4652,O
with,4652,O
the,4652,O
amino,4652,B-CHEMICAL
acid,4652,I-CHEMICAL
residues,4652,O
.,4652,O
Cyclopentenone,4653,B-CHEMICAL
prostaglandins,4653,I-CHEMICAL
suppress,4653,O
activation,4653,O
of,4653,O
microglia,4653,O
:,4653,O
down-regulation,4653,O
of,4653,O
inducible,4653,B-GENE-Y
nitric-oxide,4653,I-GENE-Y
synthase,4653,I-GENE-Y
by,4653,O
"15-deoxy-Delta12,14-prostaglandin",4653,B-CHEMICAL
J2,4653,I-CHEMICAL
.,4653,O
Mechanisms,4654,O
leading,4654,O
to,4654,O
down-regulation,4654,O
of,4654,O
activated,4654,O
microglia,4654,O
and,4654,O
astrocytes,4654,O
are,4654,O
poorly,4654,O
understood,4654,O
",",4654,O
in,4654,O
spite,4654,O
of,4654,O
the,4654,O
potentially,4654,O
detrimental,4654,O
role,4654,O
of,4654,O
activated,4654,O
glia,4654,O
in,4654,O
neurodegeneration,4654,O
.,4654,O
Prostaglandins,4655,B-CHEMICAL
",",4655,O
produced,4655,O
both,4655,O
by,4655,O
neurons,4655,O
and,4655,O
glia,4655,O
",",4655,O
may,4655,O
serve,4655,O
as,4655,O
mediators,4655,O
of,4655,O
glial,4655,O
and,4655,O
neuronal,4655,O
functions,4655,O
.,4655,O
We,4656,O
examined,4656,O
the,4656,O
influence,4656,O
of,4656,O
cyclopentenone,4656,B-CHEMICAL
prostaglandins,4656,I-CHEMICAL
and,4656,O
their,4656,O
precursors,4656,O
on,4656,O
activated,4656,O
glia,4656,O
.,4656,O
As,4657,O
models,4657,O
of,4657,O
glial,4657,O
activation,4657,O
",",4657,O
production,4657,O
of,4657,O
inducible,4657,B-GENE-Y
nitric-oxide,4657,I-GENE-Y
synthase,4657,I-GENE-Y
(,4657,O
iNOS,4657,B-GENE-Y
),4657,O
was,4657,O
studied,4657,O
in,4657,O
lipopolysaccharide-stimulated,4657,O
rat,4657,O
microglia,4657,O
",",4657,O
a,4657,O
murine,4657,O
microglial,4657,O
cell,4657,O
line,4657,O
BV-2,4657,O
",",4657,O
and,4657,O
IL-1beta-stimulated,4657,B-GENE-Y
rat,4657,O
astrocytes,4657,O
.,4657,O
Cyclopentenone,4658,B-CHEMICAL
prostaglandins,4658,I-CHEMICAL
were,4658,O
potent,4658,O
inhibitors,4658,O
of,4658,O
iNOS,4658,B-GENE-Y
induction,4658,O
and,4658,O
were,4658,O
more,4658,O
effective,4658,O
than,4658,O
their,4658,O
precursors,4658,O
",",4658,O
prostaglandins,4658,B-CHEMICAL
E2,4658,I-CHEMICAL
and,4658,I-CHEMICAL
D2,4658,I-CHEMICAL
.,4658,O
"15-Deoxy-Delta12,14-prostaglandin",4659,B-CHEMICAL
J2,4659,I-CHEMICAL
(,4659,O
15d-PGJ2,4659,B-CHEMICAL
),4659,O
was,4659,O
the,4659,O
most,4659,O
potent,4659,O
prostaglandin,4659,B-CHEMICAL
among,4659,O
those,4659,O
tested,4659,O
.,4659,O
In,4660,O
activated,4660,O
microglia,4660,O
",",4660,O
15d-PGJ2,4660,B-CHEMICAL
suppressed,4660,O
iNOS,4660,B-GENE-N
promoter,4660,I-GENE-N
activity,4660,O
",",4660,O
iNOS,4660,B-GENE-Y
mRNA,4660,O
",",4660,O
and,4660,O
protein,4660,O
levels,4660,O
.,4660,O
The,4661,O
action,4661,O
of,4661,O
15d-PGJ2,4661,B-CHEMICAL
does,4661,O
not,4661,O
appear,4661,O
to,4661,O
involve,4661,O
its,4661,O
nuclear,4661,O
receptor,4661,O
peroxisome,4661,B-GENE-Y
proliferator-activated,4661,I-GENE-Y
receptor,4661,I-GENE-Y
gamma,4661,I-GENE-Y
(,4661,O
PPARgamma,4661,B-GENE-Y
),4661,O
because,4661,O
troglitazone,4661,B-CHEMICAL
",",4661,O
a,4661,O
specific,4661,O
ligand,4661,O
of,4661,O
PPARgamma,4661,B-GENE-Y
",",4661,O
was,4661,O
unable,4661,O
to,4661,O
inhibit,4661,O
iNOS,4661,B-GENE-Y
induction,4661,O
",",4661,O
and,4661,O
neither,4661,O
troglitazone,4661,B-CHEMICAL
nor,4661,O
15d-PGJ2,4661,B-CHEMICAL
could,4661,O
stimulate,4661,O
the,4661,O
activity,4661,O
of,4661,O
a,4661,O
PPAR-dependent,4661,B-GENE-N
promoter,4661,O
in,4661,O
the,4661,O
absence,4661,O
of,4661,O
cotransfected,4661,O
PPARgamma,4661,B-GENE-Y
.,4661,O
15d-PGJ2,4662,B-CHEMICAL
did,4662,O
not,4662,O
block,4662,O
nuclear,4662,O
translocation,4662,O
or,4662,O
DNA-binding,4662,O
activity,4662,O
of,4662,O
the,4662,O
transcription,4662,O
factor,4662,O
NFkappaB,4662,B-GENE-N
",",4662,O
but,4662,O
it,4662,O
did,4662,O
inhibit,4662,O
the,4662,O
activity,4662,O
of,4662,O
an,4662,O
NFkappaB,4662,B-GENE-N
reporter,4662,O
construct,4662,O
",",4662,O
suggesting,4662,O
that,4662,O
the,4662,O
mechanism,4662,O
of,4662,O
suppression,4662,O
of,4662,O
microglial,4662,O
iNOS,4662,B-GENE-Y
by,4662,O
15d-PGJ2,4662,B-CHEMICAL
may,4662,O
involve,4662,O
interference,4662,O
with,4662,O
NFkappaB,4662,B-GENE-N
transcriptional,4662,O
activity,4662,O
in,4662,O
the,4662,O
nucleus,4662,O
.,4662,O
Thus,4663,O
",",4663,O
our,4663,O
data,4663,O
suggest,4663,O
the,4663,O
existence,4663,O
of,4663,O
a,4663,O
novel,4663,O
pathway,4663,O
mediated,4663,O
by,4663,O
cyclopentenone,4663,B-CHEMICAL
prostaglandins,4663,I-CHEMICAL
",",4663,O
which,4663,O
may,4663,O
represent,4663,O
part,4663,O
of,4663,O
a,4663,O
feedback,4663,O
mechanism,4663,O
leading,4663,O
to,4663,O
the,4663,O
cessation,4663,O
of,4663,O
inflammatory,4663,O
glial,4663,O
responses,4663,O
in,4663,O
the,4663,O
brain,4663,O
.,4663,O
Mechanism,4664,O
of,4664,O
the,4664,O
haemostatic,4664,O
effect,4664,O
of,4664,O
ethanolamine,4664,B-CHEMICAL
oleate,4664,I-CHEMICAL
in,4664,O
the,4664,O
injection,4664,O
sclerotherapy,4664,O
for,4664,O
oesophageal,4664,O
varices,4664,O
.,4664,O
Changes,4665,O
in,4665,O
coagulation,4665,O
and,4665,O
fibrinolysis,4665,O
were,4665,O
investigated,4665,O
in,4665,O
20,4665,O
patients,4665,O
with,4665,O
oesophageal,4665,O
varices,4665,O
",",4665,O
who,4665,O
underwent,4665,O
endoscopic,4665,O
injection,4665,O
sclerotherapy,4665,O
(,4665,O
EIS,4665,O
),4665,O
with,4665,O
5,4665,O
per,4665,O
cent,4665,O
ethanolamine,4665,B-CHEMICAL
oleate,4665,I-CHEMICAL
(,4665,O
EO,4665,B-CHEMICAL
),4665,O
",",4665,O
by,4665,O
means,4665,O
of,4665,O
serial,4665,O
determination,4665,O
of,4665,O
plasma,4665,O
fibrinopeptide,4665,B-GENE-Y
A,4665,I-GENE-Y
(,4665,O
FPA,4665,B-GENE-Y
),4665,O
and,4665,O
fibrinopeptide,4665,B-GENE-Y
B,4665,I-GENE-Y
beta,4665,I-GENE-Y
15-42,4665,I-GENE-Y
(,4665,O
B,4665,B-GENE-Y
beta,4665,I-GENE-Y
15-42,4665,I-GENE-Y
),4665,O
.,4665,O
One,4666,O
hour,4666,O
after,4666,O
the,4666,O
completion,4666,O
of,4666,O
EIS,4666,O
",",4666,O
the,4666,O
value,4666,O
of,4666,O
FPA,4666,B-GENE-Y
was,4666,O
significantly,4666,O
increased,4666,O
to,4666,O
38.1,4666,O
+/-,4666,O
11.1,4666,O
ng/ml,4666,O
(,4666,O
mean,4666,O
+/-,4666,O
s.e.m,4666,O
.,4666,O
),4666,O
from,4667,O
a,4667,O
pre-EIS,4667,O
value,4667,O
of,4667,O
7.1,4667,O
+/-,4667,O
1.4,4667,O
ng/ml,4667,O
(,4667,O
P,4667,O
less,4667,O
than,4667,O
0.01,4667,O
),4667,O
and,4667,O
it,4667,O
gradually,4667,O
returned,4667,O
to,4667,O
normal,4667,O
range,4667,O
by,4667,O
48,4667,O
h,4667,O
after,4667,O
EIS,4667,O
.,4667,O
A,4668,O
very,4668,O
similar,4668,O
change,4668,O
was,4668,O
observed,4668,O
in,4668,O
the,4668,O
value,4668,O
of,4668,O
B,4668,B-GENE-Y
beta,4668,I-GENE-Y
15-42,4668,I-GENE-Y
(,4668,O
P,4668,O
less,4668,O
than,4668,O
0.01,4668,O
),4668,O
.,4668,O
These,4669,O
observations,4669,O
indicated,4669,O
that,4669,O
EIS,4669,O
provokes,4669,O
transient,4669,O
activation,4669,O
of,4669,O
coagulation,4669,O
and,4669,O
fibrinolysis,4669,O
.,4669,O
In,4670,O
vitro,4670,O
studies,4670,O
",",4670,O
however,4670,O
",",4670,O
revealed,4670,O
that,4670,O
EO,4670,B-CHEMICAL
inhibits,4670,O
fibrin,4670,B-GENE-N
clot,4670,O
formation,4670,O
because,4670,O
of,4670,O
the,4670,O
Ca2+-chelating,4670,B-CHEMICAL
ability,4670,O
of,4670,O
its,4670,O
constituent,4670,O
ethanolamine,4670,B-CHEMICAL
",",4670,O
although,4670,O
oleate,4670,B-CHEMICAL
or,4670,O
benzyl,4670,B-CHEMICAL
alcohol,4670,I-CHEMICAL
exhibited,4670,O
procoagulant,4670,O
activity,4670,O
in,4670,O
FPA,4670,B-GENE-Y
formation,4670,O
in,4670,O
vitro,4670,O
.,4670,O
Nevertheless,4671,O
",",4671,O
an,4671,O
external,4671,O
application,4671,O
of,4671,O
EO,4671,B-CHEMICAL
or,4671,O
oleate,4671,B-CHEMICAL
over,4671,O
decapsulized,4671,O
kidney,4671,O
of,4671,O
rat,4671,O
resulted,4671,O
in,4671,O
a,4671,O
significant,4671,O
accumulation,4671,O
of,4671,O
125I-labelled,4671,B-CHEMICAL
fibrin,4671,B-GENE-N
(,4671,I-GENE-N
ogen,4671,I-GENE-N
),4671,I-GENE-N
.,4671,O
From,4672,O
these,4672,O
results,4672,O
it,4672,O
was,4672,O
suggested,4672,O
that,4672,O
intravascular,4672,O
injection,4672,O
of,4672,O
EO,4672,B-CHEMICAL
",",4672,O
which,4672,O
exerts,4672,O
an,4672,O
inhibitory,4672,O
effect,4672,O
on,4672,O
coagulation,4672,O
in,4672,O
vitro,4672,O
",",4672,O
activates,4672,O
the,4672,O
local,4672,O
coagulation,4672,O
system,4672,O
.,4672,O
The,4673,O
activation,4673,O
may,4673,O
be,4673,O
accelerated,4673,O
by,4673,O
an,4673,O
acute,4673,O
inflammatory,4673,O
process,4673,O
provoked,4673,O
by,4673,O
oleate,4673,B-CHEMICAL
",",4673,O
which,4673,O
is,4673,O
supported,4673,O
by,4673,O
such,4673,O
clinical,4673,O
manifestations,4673,O
as,4673,O
mild,4673,O
fever,4673,O
",",4673,O
retrosternal,4673,O
pain,4673,O
leukocytosis,4673,O
and,4673,O
an,4673,O
increase,4673,O
in,4673,O
plasma,4673,O
fibrinogen,4673,B-GENE-N
level,4673,O
which,4673,O
was,4673,O
observed,4673,O
in,4673,O
all,4673,O
during,4673,O
the,4673,O
period,4673,O
.,4673,O
Renal,4674,O
failure,4674,O
associated,4674,O
with,4674,O
the,4674,O
use,4674,O
of,4674,O
celecoxib,4674,B-CHEMICAL
and,4674,O
rofecoxib,4674,B-CHEMICAL
.,4674,O
OBJECTIVE,4675,O
:,4675,O
Celecoxib,4675,B-CHEMICAL
and,4675,O
rofecoxib,4675,B-CHEMICAL
are,4675,O
two,4675,O
relatively,4675,O
new,4675,O
nonsteroidal,4675,O
anti-inflammatory,4675,O
drugs,4675,O
(,4675,O
NSAIDs,4675,O
),4675,O
that,4675,O
selectively,4675,O
inhibit,4675,O
the,4675,O
cyclo-oxygenase-2,4675,B-GENE-Y
(,4675,O
COX-2,4675,B-GENE-Y
),4675,O
isoenzyme,4675,O
at,4675,O
therapeutic,4675,O
concentrations,4675,O
.,4675,O
The,4676,O
nephrotoxic,4676,O
potential,4676,O
of,4676,O
selective,4676,O
COX-2,4676,B-GENE-Y
inhibitors,4676,O
has,4676,O
not,4676,O
been,4676,O
clearly,4676,O
established,4676,O
.,4676,O
This,4677,O
study,4677,O
was,4677,O
conducted,4677,O
in,4677,O
order,4677,O
to,4677,O
understand,4677,O
the,4677,O
association,4677,O
between,4677,O
acute,4677,O
renal,4677,O
failure,4677,O
and,4677,O
the,4677,O
two,4677,O
COX-2,4677,B-GENE-Y
inhibitors,4677,O
celecoxib,4677,B-CHEMICAL
and,4677,O
rofecoxib,4677,B-CHEMICAL
.,4677,O
METHODS,4678,O
:,4678,O
A,4678,O
search,4678,O
was,4678,O
performed,4678,O
in,4678,O
the,4678,O
US,4678,O
Food,4678,O
and,4678,O
Drug,4678,O
Administration,4678,O
's,4678,O
(,4678,O
FDA,4678,O
),4678,O
Adverse,4678,O
Event,4678,O
Reporting,4678,O
System,4678,O
(,4678,O
AERS,4678,O
),4678,O
to,4678,O
identify,4678,O
cases,4678,O
of,4678,O
renal,4678,O
failure,4678,O
submitted,4678,O
to,4678,O
the,4678,O
FDA,4678,O
.,4678,O
A,4679,O
MEDLINE,4679,O
search,4679,O
of,4679,O
the,4679,O
English,4679,O
language,4679,O
literature,4679,O
was,4679,O
also,4679,O
performed,4679,O
to,4679,O
identify,4679,O
published,4679,O
cases,4679,O
of,4679,O
renal,4679,O
failure,4679,O
associated,4679,O
with,4679,O
celecoxib,4679,B-CHEMICAL
and,4679,O
rofecoxib,4679,B-CHEMICAL
.,4679,O
RESULTS,4680,O
:,4680,O
One,4680,O
hundred,4680,O
twenty-two,4680,O
and,4680,O
142,4680,O
domestic,4680,O
US,4680,O
cases,4680,O
of,4680,O
celecoxib,4680,B-CHEMICAL
and,4680,O
rofecoxib-associated,4680,B-CHEMICAL
renal,4680,O
failure,4680,O
",",4680,O
respectively,4680,O
",",4680,O
were,4680,O
identified,4680,O
in,4680,O
the,4680,O
AERS,4680,O
database,4680,O
.,4680,O
The,4681,O
literature,4681,O
search,4681,O
identified,4681,O
19,4681,O
cases,4681,O
of,4681,O
acute,4681,O
renal,4681,O
impairment,4681,O
in,4681,O
association,4681,O
with,4681,O
celecoxib,4681,B-CHEMICAL
and,4681,O
rofecoxib,4681,B-CHEMICAL
.,4681,O
In,4682,O
addition,4682,O
",",4682,O
drug,4682,O
regulatory,4682,O
authorities,4682,O
in,4682,O
the,4682,O
UK,4682,O
",",4682,O
Canada,4682,O
",",4682,O
and,4682,O
Australia,4682,O
have,4682,O
received,4682,O
about,4682,O
50,4682,O
reports,4682,O
of,4682,O
renal,4682,O
failure,4682,O
with,4682,O
celecoxib,4682,B-CHEMICAL
and,4682,O
rofecoxib,4682,B-CHEMICAL
.,4682,O
Descriptive,4683,O
statistics,4683,O
of,4683,O
the,4683,O
AERS,4683,O
cases,4683,O
have,4683,O
been,4683,O
summarised,4683,O
in,4683,O
this,4683,O
report,4683,O
.,4683,O
CONCLUSIONS,4684,O
:,4684,O
Data,4684,O
from,4684,O
AERS,4684,O
and,4684,O
published,4684,O
case,4684,O
reports,4684,O
suggest,4684,O
that,4684,O
use,4684,O
of,4684,O
both,4684,O
these,4684,O
drugs,4684,O
is,4684,O
associated,4684,O
with,4684,O
renal,4684,O
effects,4684,O
similar,4684,O
to,4684,O
that,4684,O
of,4684,O
conventional,4684,O
nonselective,4684,O
NSAIDs,4684,O
.,4684,O
Physicians,4685,O
should,4685,O
be,4685,O
aware,4685,O
that,4685,O
serious,4685,O
or,4685,O
life-threatening,4685,O
renal,4685,O
failure,4685,O
has,4685,O
been,4685,O
reported,4685,O
in,4685,O
patients,4685,O
with,4685,O
normal,4685,O
or,4685,O
impaired,4685,O
renal,4685,O
function,4685,O
after,4685,O
short-term,4685,O
therapy,4685,O
with,4685,O
celecoxib,4685,B-CHEMICAL
and,4685,O
rofecoxib,4685,B-CHEMICAL
.,4685,O
Patients,4686,O
at,4686,O
greatest,4686,O
risk,4686,O
for,4686,O
renal,4686,O
injury,4686,O
are,4686,O
those,4686,O
with,4686,O
pre-existing,4686,O
renal,4686,O
impairment,4686,O
",",4686,O
heart,4686,O
failure,4686,O
",",4686,O
liver,4686,O
dysfunction,4686,O
",",4686,O
those,4686,O
taking,4686,O
diuretics,4686,O
and/or,4686,O
ACE,4686,B-GENE-Y
inhibitors,4686,O
",",4686,O
and,4686,O
the,4686,O
elderly,4686,O
.,4686,O
Kidney,4687,O
function,4687,O
should,4687,O
be,4687,O
monitored,4687,O
closely,4687,O
for,4687,O
any,4687,O
signs,4687,O
of,4687,O
potential,4687,O
renal,4687,O
injuries,4687,O
soon,4687,O
after,4687,O
initiating,4687,O
treatment,4687,O
with,4687,O
these,4687,O
agents,4687,O
",",4687,O
especially,4687,O
in,4687,O
high-risk,4687,O
populations,4687,O
.,4687,O
In,4688,O
addition,4688,O
",",4688,O
healthcare,4688,O
practitioners,4688,O
should,4688,O
adequately,4688,O
warn,4688,O
patients,4688,O
of,4688,O
the,4688,O
signs,4688,O
and,4688,O
symptoms,4688,O
of,4688,O
serious,4688,O
renal,4688,O
toxicity,4688,O
",",4688,O
and,4688,O
of,4688,O
the,4688,O
need,4688,O
for,4688,O
them,4688,O
to,4688,O
see,4688,O
their,4688,O
physician,4688,O
promptly,4688,O
if,4688,O
they,4688,O
occur,4688,O
.,4688,O
Celecoxib,4689,B-CHEMICAL
and,4689,O
rofecoxib,4689,B-CHEMICAL
are,4689,O
not,4689,O
recommended,4689,O
for,4689,O
use,4689,O
in,4689,O
patients,4689,O
with,4689,O
advanced,4689,O
renal,4689,O
disease,4689,O
.,4689,O
Evaluation,4690,O
of,4690,O
the,4690,O
pharmacological,4690,O
selectivity,4690,O
profile,4690,O
of,4690,O
alpha,4690,B-GENE-N
1,4690,I-GENE-N
adrenoceptor,4690,I-GENE-N
antagonists,4690,O
at,4690,O
prostatic,4690,O
alpha,4690,B-GENE-N
1,4690,I-GENE-N
adrenoceptors,4690,I-GENE-N
:,4690,O
binding,4690,O
",",4690,O
functional,4690,O
and,4690,O
in,4690,O
vivo,4690,O
studies,4690,O
.,4690,O
1,4691,O
.,4691,O
The,4692,O
profile,4692,O
of,4692,O
a,4692,O
range,4692,O
of,4692,O
alpha,4692,B-GENE-N
1,4692,I-GENE-N
adrenoceptor,4692,I-GENE-N
antagonists,4692,O
was,4692,O
determined,4692,O
in,4692,O
vitro,4692,O
against,4692,O
cloned,4692,O
human,4692,B-GENE-N
alpha,4692,I-GENE-N
1A,4692,I-GENE-N
",",4692,I-GENE-N
alpha,4692,I-GENE-N
1B,4692,I-GENE-N
and,4692,I-GENE-N
alpha,4692,I-GENE-N
1D,4692,I-GENE-N
adrenoceptors,4692,I-GENE-N
and,4692,O
against,4692,O
noradrenaline-mediated,4692,B-CHEMICAL
contractions,4692,O
of,4692,O
rat,4692,O
aorta,4692,O
and,4692,O
human,4692,O
prostate,4692,O
.,4692,O
The,4693,O
in,4693,O
vivo,4693,O
profile,4693,O
of,4693,O
compounds,4693,O
was,4693,O
determined,4693,O
in,4693,O
an,4693,O
anaesthetized,4693,O
dog,4693,O
model,4693,O
which,4693,O
allowed,4693,O
the,4693,O
simultaneous,4693,O
assessment,4693,O
of,4693,O
antagonist,4693,O
potency,4693,O
against,4693,O
phenylephrine-mediated,4693,B-CHEMICAL
increases,4693,O
in,4693,O
blood,4693,O
pressure,4693,O
and,4693,O
prostatic,4693,O
pressure,4693,O
.,4693,O
2,4694,O
.,4694,O
The,4695,O
quinazoline,4695,B-CHEMICAL
antagonists,4695,O
",",4695,O
prazosin,4695,B-CHEMICAL
",",4695,O
doxazosin,4695,B-CHEMICAL
and,4695,O
alfuzosin,4695,B-CHEMICAL
displayed,4695,O
high,4695,O
affinity,4695,O
but,4695,O
were,4695,O
non,4695,O
selective,4695,O
for,4695,O
the,4695,O
three,4695,O
cloned,4695,O
human,4695,B-GENE-N
alpha,4695,I-GENE-N
1,4695,I-GENE-N
adrenoceptors,4695,I-GENE-N
.,4695,O
Indoramin,4696,B-CHEMICAL
and,4696,O
SNAP,4696,B-CHEMICAL
1069,4696,I-CHEMICAL
showed,4696,O
selectivity,4696,O
for,4696,O
alpha,4696,B-GENE-N
1A,4696,I-GENE-N
and,4696,I-GENE-N
alpha,4696,I-GENE-N
1B,4696,I-GENE-N
adrenoceptors,4696,I-GENE-N
relative,4696,O
to,4696,O
the,4696,O
alpha,4696,B-GENE-Y
1D,4696,I-GENE-Y
subtype,4696,I-GENE-Y
.,4696,O
Rec,4697,B-CHEMICAL
15/2739,4697,I-CHEMICAL
",",4697,O
WB,4697,B-CHEMICAL
4101,4697,I-CHEMICAL
",",4697,O
SL,4697,B-CHEMICAL
"89,0591",4697,I-CHEMICAL
",",4697,O
(,4697,B-CHEMICAL
+,4697,I-CHEMICAL
),4697,I-CHEMICAL
-,4697,I-CHEMICAL
and,4697,I-CHEMICAL
(,4697,I-CHEMICAL
-,4697,I-CHEMICAL
),4697,I-CHEMICAL
-,4697,I-CHEMICAL
tamsulosin,4697,I-CHEMICAL
showed,4697,O
selectivity,4697,O
for,4697,O
alpha,4697,B-GENE-N
1A,4697,I-GENE-N
and,4697,I-GENE-N
alpha,4697,I-GENE-N
1D,4697,I-GENE-N
adrenoceptors,4697,I-GENE-N
relative,4697,O
to,4697,O
the,4697,O
alpha,4697,B-GENE-Y
1B,4697,I-GENE-Y
subtype,4697,I-GENE-Y
.,4697,O
RS,4698,B-CHEMICAL
17053,4698,I-CHEMICAL
showed,4698,O
high,4698,O
affinity,4698,O
and,4698,O
selectivity,4698,O
for,4698,O
alpha,4698,B-GENE-Y
1A,4698,I-GENE-Y
adrenoceptors,4698,I-GENE-Y
(,4698,O
pKi,4698,O
8.6,4698,O
),4698,O
relative,4698,O
to,4698,O
alpha,4698,B-GENE-Y
1B,4698,I-GENE-Y
(,4698,O
pKi,4698,O
=,4698,O
7.3,4698,O
),4698,O
and,4698,O
alpha,4698,B-GENE-Y
1D,4698,I-GENE-Y
(,4698,O
pKi,4698,O
=,4698,O
7.1,4698,O
),4698,O
subtypes,4698,O
.,4698,O
3,4699,O
.,4699,O
(,4700,B-CHEMICAL
+,4700,I-CHEMICAL
),4700,I-CHEMICAL
-Tamsulosin,4700,I-CHEMICAL
",",4700,O
(,4700,B-CHEMICAL
-,4700,I-CHEMICAL
),4700,I-CHEMICAL
-tamsulosin,4700,I-CHEMICAL
",",4700,O
SL,4700,B-CHEMICAL
"89,0591",4700,I-CHEMICAL
",",4700,O
Rec,4700,B-CHEMICAL
15/2739,4700,I-CHEMICAL
",",4700,O
SNAP,4700,B-CHEMICAL
1069,4700,I-CHEMICAL
and,4700,O
RS,4700,B-CHEMICAL
17053,4700,I-CHEMICAL
appeared,4700,O
to,4700,O
act,4700,O
as,4700,O
competitive,4700,O
antagonists,4700,O
of,4700,O
noradrenaline-mediated,4700,B-CHEMICAL
contractions,4700,O
of,4700,O
rat,4700,O
aorta,4700,O
yielding,4700,O
pA2,4700,O
affinity,4700,O
estimates,4700,O
which,4700,O
were,4700,O
similar,4700,O
to,4700,O
binding,4700,O
affinities,4700,O
at,4700,O
cloned,4700,O
human,4700,B-GENE-Y
alpha,4700,I-GENE-Y
1D,4700,I-GENE-Y
adrenoceptors,4700,I-GENE-Y
.,4700,O
The,4701,O
following,4701,O
rank,4701,O
order,4701,O
was,4701,O
obtained,4701,O
:,4701,O
prazosin,4701,B-CHEMICAL
=,4701,O
(,4701,B-CHEMICAL
-,4701,I-CHEMICAL
),4701,I-CHEMICAL
-tamsulosin,4701,I-CHEMICAL
>,4701,O
doxazosin,4701,B-CHEMICAL
>,4701,O
SL,4701,B-CHEMICAL
"89,0591",4701,I-CHEMICAL
=,4701,O
(,4701,B-CHEMICAL
+,4701,I-CHEMICAL
),4701,I-CHEMICAL
-tamsulosin,4701,I-CHEMICAL
>,4701,O
Rec,4701,B-CHEMICAL
15/2739,4701,I-CHEMICAL
>,4701,O
RS,4701,B-CHEMICAL
17053,4701,I-CHEMICAL
=,4701,O
SNAP,4701,B-CHEMICAL
1069,4701,I-CHEMICAL
.,4701,O
4,4702,O
.,4702,O
(,4703,B-CHEMICAL
-,4703,I-CHEMICAL
),4703,I-CHEMICAL
-Tamsulosin,4703,I-CHEMICAL
was,4703,O
a,4703,O
very,4703,O
potent,4703,O
",",4703,O
insurmountable,4703,O
antagonist,4703,O
of,4703,O
noradrenaline-mediated,4703,B-CHEMICAL
contractions,4703,O
of,4703,O
human,4703,O
prostate,4703,O
",",4703,O
yielding,4703,O
an,4703,O
approximate,4703,O
pA2,4703,O
estimate,4703,O
of,4703,O
9.8,4703,O
at,4703,O
1,4703,O
nM,4703,O
.,4703,O
The,4704,O
corresponding,4704,O
(,4704,O
+,4704,O
),4704,O
-enantiomer,4704,O
was,4704,O
30,4704,O
fold,4704,O
weaker,4704,O
.,4704,O
SL,4705,O
"89,0591",4705,O
",",4705,O
SNAP,4705,O
1069,4705,O
and,4705,O
Rec,4705,O
15/2739,4705,O
yielded,4705,O
pA2,4705,O
estimates,4705,O
which,4705,O
compared,4705,O
well,4705,O
with,4705,O
their,4705,O
alpha,4705,B-GENE-Y
1A,4705,I-GENE-Y
binding,4705,O
affinities,4705,O
.,4705,O
The,4706,O
affinity,4706,O
estimate,4706,O
for,4706,O
prazosin,4706,B-CHEMICAL
on,4706,O
human,4706,O
prostate,4706,O
was,4706,O
lower,4706,O
than,4706,O
the,4706,O
corresponding,4706,O
binding,4706,O
affinity,4706,O
determined,4706,O
at,4706,O
alpha,4706,B-GENE-Y
1A,4706,I-GENE-Y
adrenoceptors,4706,I-GENE-Y
and,4706,O
RS,4706,B-CHEMICAL
17053,4706,I-CHEMICAL
was,4706,O
a,4706,O
very,4706,O
weak,4706,O
antagonist,4706,O
on,4706,O
human,4706,O
prostate,4706,O
(,4706,O
pA2,4706,O
=,4706,O
6.0,4706,O
),4706,O
relative,4706,O
to,4706,O
the,4706,O
high,4706,O
affinity,4706,O
(,4706,O
pKi,4706,O
=,4706,O
8.6,4706,O
),4706,O
determined,4706,O
at,4706,O
cloned,4706,O
human,4706,B-GENE-Y
alpha,4706,I-GENE-Y
1A,4706,I-GENE-Y
adrenoceptors,4706,I-GENE-Y
.,4706,O
5,4707,O
.,4707,O
In,4708,O
the,4708,O
anaesthetized,4708,O
dog,4708,O
",",4708,O
in,4708,O
vivo,4708,O
pseudo,4708,O
``,4708,O
pA2,4708,O
',4708,O
values,4708,O
showed,4708,O
that,4708,O
doxazosin,4708,B-CHEMICAL
",",4708,O
(,4708,B-CHEMICAL
+,4708,I-CHEMICAL
),4708,I-CHEMICAL
-,4708,I-CHEMICAL
and,4708,I-CHEMICAL
(,4708,I-CHEMICAL
-,4708,I-CHEMICAL
),4708,I-CHEMICAL
-tamsulosin,4708,I-CHEMICAL
inhibited,4708,O
phenylephrine-induced,4708,B-CHEMICAL
increases,4708,O
in,4708,O
prostatic,4708,O
and,4708,O
blood,4708,O
pressure,4708,O
with,4708,O
similar,4708,O
affinity,4708,O
",",4708,O
implying,4708,O
that,4708,O
these,4708,O
agents,4708,O
show,4708,O
little,4708,O
or,4708,O
no,4708,O
selectivity,4708,O
for,4708,O
prostatic,4708,O
responses,4708,O
in,4708,O
this,4708,O
model,4708,O
.,4708,O
SL,4709,O
"89,0591",4709,O
and,4709,O
SNAP,4709,O
1069,4709,O
were,4709,O
moderately,4709,O
selective,4709,O
(,4709,O
3,4709,O
and,4709,O
6,4709,O
fold,4709,O
respectively,4709,O
),4709,O
for,4709,O
prostatic,4709,O
pressure,4709,O
relative,4709,O
to,4709,O
blood,4709,O
pressure,4709,O
.,4709,O
Rec,4710,B-CHEMICAL
15/2739,4710,I-CHEMICAL
was,4710,O
a,4710,O
more,4710,O
potent,4710,O
antagonist,4710,O
of,4710,O
phenylephrine-mediated,4710,B-CHEMICAL
increases,4710,O
in,4710,O
prostatic,4710,O
pressure,4710,O
(,4710,O
``,4710,O
pA2,4710,O
',4710,O
=,4710,O
8.74,4710,O
),4710,O
compared,4710,O
to,4710,O
blood,4710,O
pressure,4710,O
(,4710,O
``,4710,O
pA2,4710,O
',4710,O
=,4710,O
7.51,4710,O
),4710,O
.,4710,O
6,4711,O
.,4711,O
Data,4712,O
in,4712,O
this,4712,O
study,4712,O
suggest,4712,O
that,4712,O
the,4712,O
alpha,4712,B-GENE-N
1,4712,I-GENE-N
adrenoceptor,4712,I-GENE-N
mediating,4712,O
noradrenaline-induced,4712,B-CHEMICAL
contractions,4712,O
of,4712,O
human,4712,O
prostate,4712,O
",",4712,O
whilst,4712,O
having,4712,O
some,4712,O
of,4712,O
the,4712,O
characteristics,4712,O
of,4712,O
an,4712,O
alpha,4712,B-GENE-Y
1A,4712,I-GENE-Y
adrenoceptor,4712,I-GENE-Y
",",4712,O
can,4712,O
not,4712,O
be,4712,O
satisfactorily,4712,O
aligned,4712,O
with,4712,O
cloned,4712,O
alpha,4712,B-GENE-N
1A,4712,I-GENE-N
",",4712,I-GENE-N
alpha,4712,I-GENE-N
1B,4712,I-GENE-N
or,4712,I-GENE-N
alpha,4712,I-GENE-N
1D,4712,I-GENE-N
adrenoceptors,4712,I-GENE-N
.,4712,O
In,4713,O
addition,4713,O
",",4713,O
studies,4713,O
in,4713,O
the,4713,O
anaesthetized,4713,O
dog,4713,O
have,4713,O
shown,4713,O
that,4713,O
agents,4713,O
having,4713,O
high,4713,O
affinity,4713,O
and,4713,O
selectivity,4713,O
for,4713,O
prostatic,4713,O
alpha,4713,B-GENE-N
1,4713,I-GENE-N
adrenoceptors,4713,I-GENE-N
",",4713,O
particularly,4713,O
over,4713,O
the,4713,O
alpha,4713,B-GENE-Y
1D,4713,I-GENE-Y
subtype,4713,I-GENE-Y
",",4713,O
appear,4713,O
to,4713,O
inhibit,4713,O
phenylephrine-induced,4713,B-CHEMICAL
increases,4713,O
in,4713,O
prostatic,4713,O
pressure,4713,O
selectively,4713,O
compared,4713,O
to,4713,O
blood,4713,O
pressure,4713,O
.,4713,O
In,4714,O
functional,4714,O
experiments,4714,O
",",4714,O
risperidone,4714,B-CHEMICAL
is,4714,O
selective,4714,O
",",4714,O
not,4714,O
for,4714,O
the,4714,O
B,4714,O
",",4714,O
but,4714,O
for,4714,O
the,4714,O
A,4714,O
subtype,4714,O
of,4714,O
alpha,4714,B-GENE-N
1-adrenoceptors,4714,I-GENE-N
.,4714,O
The,4715,O
potency,4715,O
of,4715,O
the,4715,O
antipsychotic,4715,O
drug,4715,O
",",4715,O
risperidone,4715,B-CHEMICAL
",",4715,O
to,4715,O
antagonize,4715,O
alpha,4715,B-GENE-Y
1A-adrenoceptor-mediated,4715,O
contraction,4715,O
in,4715,O
rat,4715,O
vas,4715,O
deferens,4715,O
and,4715,O
vasoconstriction,4715,O
in,4715,O
rat,4715,O
perfused,4715,O
kidney,4715,O
",",4715,O
and,4715,O
alpha,4715,B-GENE-Y
1B-adrenoceptor-mediated,4715,O
contractions,4715,O
in,4715,O
spleen,4715,O
from,4715,O
guinea-pig,4715,O
and,4715,O
mouse,4715,O
was,4715,O
evaluated,4715,O
and,4715,O
compared,4715,O
to,4715,O
that,4715,O
of,4715,O
alpha,4715,B-GENE-N
1-adrenoceptor,4715,I-GENE-N
subtype-discriminating,4715,O
antagonists,4715,O
.,4715,O
Prazosin,4716,B-CHEMICAL
was,4716,O
found,4716,O
to,4716,O
be,4716,O
unselective,4716,O
;,4716,O
2-,4716,B-CHEMICAL
(,4716,I-CHEMICAL
"2,6-dimethoxyphenoxyethyl",4716,I-CHEMICAL
),4716,I-CHEMICAL
"aminomethyl-1,4-benzodioxane",4716,I-CHEMICAL
(,4716,O
WB,4716,B-CHEMICAL
4101,4716,I-CHEMICAL
),4716,O
",",4716,O
5-methyl-urapidil,4716,B-CHEMICAL
",",4716,O
indoramin,4716,B-CHEMICAL
and,4716,O
(,4716,B-CHEMICAL
+,4716,I-CHEMICAL
),4716,I-CHEMICAL
-niguldipine,4716,I-CHEMICAL
were,4716,O
confirmed,4716,O
as,4716,O
selective,4716,O
for,4716,O
the,4716,O
alpha,4716,B-GENE-Y
1A-adrenoceptor,4716,I-GENE-Y
",",4716,O
whereas,4716,O
spiperone,4716,B-CHEMICAL
was,4716,O
weakly,4716,O
alpha,4716,O
1B-selective,4716,O
.,4716,O
Risperidone,4717,B-CHEMICAL
was,4717,O
equipotent,4717,O
to,4717,O
prazosin,4717,B-CHEMICAL
at,4717,O
alpha,4717,B-GENE-Y
1A-adrenoceptors,4717,I-GENE-Y
in,4717,O
rat,4717,O
vas,4717,O
deferens,4717,O
and,4717,O
kidney,4717,O
.,4717,O
However,4718,O
",",4718,O
at,4718,O
guinea-pig,4718,B-GENE-N
and,4718,I-GENE-N
mouse,4718,I-GENE-N
splenic,4718,I-GENE-N
alpha,4718,I-GENE-N
1B-adrenoceptors,4718,I-GENE-N
",",4718,O
the,4718,O
affinity,4718,O
values,4718,O
of,4718,O
risperidone,4718,B-CHEMICAL
were,4718,O
10-fold,4718,O
lower,4718,O
than,4718,O
those,4718,O
of,4718,O
prazosin,4718,B-CHEMICAL
.,4718,O
Thus,4719,O
",",4719,O
in,4719,O
functional,4719,O
experiments,4719,O
the,4719,O
presumed,4719,O
high,4719,O
selectivity,4719,O
of,4719,O
risperidone,4719,B-CHEMICAL
for,4719,O
the,4719,O
B,4719,O
subtype,4719,O
of,4719,O
alpha,4719,B-GENE-N
1-adrenoceptors,4719,I-GENE-N
could,4719,O
not,4719,O
be,4719,O
confirmed,4719,O
",",4719,O
the,4719,O
drug,4719,O
instead,4719,O
appears,4719,O
to,4719,O
be,4719,O
moderately,4719,O
selective,4719,O
(,4719,O
10-fold,4719,O
),4719,O
for,4719,O
the,4719,O
A,4719,O
subtype,4719,O
.,4719,O
New,4720,O
assignments,4720,O
for,4720,O
multitasking,4720,O
signal,4720,O
transduction,4720,O
inhibitors,4720,O
.,4720,O
An,4721,O
article,4721,O
presented,4721,O
in,4721,O
this,4721,O
issue,4721,O
of,4721,O
Molecular,4721,O
Pharmacology,4721,O
(,4721,O
p.,4721,O
1527,4721,O
),4721,O
provides,4721,O
an,4721,O
intriguing,4721,O
example,4721,O
of,4721,O
how,4721,O
tyrosine,4721,B-GENE-N
kinase,4721,I-GENE-N
inhibitors,4721,O
can,4721,O
be,4721,O
put,4721,O
to,4721,O
many,4721,O
uses,4721,O
.,4721,O
In,4722,O
this,4722,O
article,4722,O
",",4722,O
the,4722,O
action,4722,O
of,4722,O
dasatinib,4722,B-CHEMICAL
(,4722,O
BMS-354825,4722,B-CHEMICAL
),4722,O
is,4722,O
contrasted,4722,O
with,4722,O
that,4722,O
of,4722,O
imatinib,4722,B-CHEMICAL
",",4722,O
a,4722,O
kinase,4722,B-GENE-N
inhibitor,4722,O
that,4722,O
is,4722,O
currently,4722,O
being,4722,O
used,4722,O
to,4722,O
treat,4722,O
chronic,4722,O
myelogenous,4722,O
leukemia,4722,O
and,4722,O
other,4722,O
disorders,4722,O
.,4722,O
Both,4723,O
pharmacologic,4723,O
inhibitors,4723,O
target,4723,O
several,4723,O
tyrosine,4723,B-GENE-N
kinases,4723,I-GENE-N
",",4723,O
including,4723,O
Bcr-Abl,4723,B-GENE-Y
and,4723,O
the,4723,O
platelet-derived,4723,B-GENE-N
growth,4723,I-GENE-N
factor,4723,I-GENE-N
receptor,4723,I-GENE-N
(,4723,O
PDGFR,4723,B-GENE-N
),4723,O
.,4723,O
Up,4724,O
to,4724,O
this,4724,O
point,4724,O
",",4724,O
the,4724,O
PDGFR,4724,B-GENE-N
has,4724,O
not,4724,O
been,4724,O
a,4724,O
primary,4724,O
therapeutic,4724,O
target,4724,O
for,4724,O
this,4724,O
class,4724,O
of,4724,O
agents,4724,O
.,4724,O
The,4725,O
work,4725,O
of,4725,O
Chen,4725,O
and,4725,O
colleagues,4725,O
shows,4725,O
that,4725,O
dasatinib,4725,B-CHEMICAL
is,4725,O
a,4725,O
particularly,4725,O
potent,4725,O
inhibitor,4725,O
of,4725,O
PDGFR,4725,B-GENE-N
and,4725,O
that,4725,O
the,4725,O
compound,4725,O
also,4725,O
targets,4725,O
Src,4725,B-GENE-Y
kinase,4725,I-GENE-Y
.,4725,O
The,4726,O
authors,4726,O
suggest,4726,O
that,4726,O
this,4726,O
combination,4726,O
of,4726,O
activities,4726,O
could,4726,O
be,4726,O
useful,4726,O
in,4726,O
the,4726,O
treatment,4726,O
of,4726,O
vascular,4726,O
obstructive,4726,O
diseases,4726,O
.,4726,O
Although,4727,O
a,4727,O
lack,4727,O
of,4727,O
absolute,4727,O
specificity,4727,O
has,4727,O
typically,4727,O
been,4727,O
regarded,4727,O
as,4727,O
a,4727,O
pharmacologic,4727,O
drawback,4727,O
",",4727,O
this,4727,O
study,4727,O
exemplifies,4727,O
how,4727,O
drugs,4727,O
with,4727,O
multiple,4727,O
molecular,4727,O
targets,4727,O
can,4727,O
potentially,4727,O
provide,4727,O
a,4727,O
very,4727,O
beneficial,4727,O
spectrum,4727,O
of,4727,O
therapeutic,4727,O
activities,4727,O
in,4727,O
multiple,4727,O
disease,4727,O
states,4727,O
.,4727,O
Serotonin,4728,B-GENE-Y
transporter,4728,I-GENE-Y
function,4728,O
in,4728,O
vivo,4728,O
:,4728,O
assessment,4728,O
by,4728,O
chronoamperometry,4728,O
.,4728,O
Local,4729,O
application,4729,O
of,4729,O
selective,4729,O
serotonin,4729,B-CHEMICAL
reuptake,4729,O
inhibitors,4729,O
",",4729,O
fluvoxamine,4729,B-CHEMICAL
and,4729,O
citalopram,4729,B-CHEMICAL
",",4729,O
prolonged,4729,O
the,4729,O
clearance,4729,O
of,4729,O
exogenously,4729,O
administered,4729,O
serotonin,4729,B-CHEMICAL
(,4729,O
5-HT,4729,B-CHEMICAL
),4729,O
in,4729,O
both,4729,O
the,4729,O
dentate,4729,O
gyrus,4729,O
and,4729,O
CA3,4729,O
region,4729,O
of,4729,O
the,4729,O
dorsal,4729,O
hippocampus,4729,O
",",4729,O
as,4729,O
measured,4729,O
using,4729,O
in,4729,O
vivo,4729,O
chronoamperometry,4729,O
.,4729,O
These,4730,O
effects,4730,O
were,4730,O
abolished,4730,O
in,4730,O
rats,4730,O
pretreated,4730,O
with,4730,O
"5,7-dihydroxytryptamine",4730,B-CHEMICAL
.,4730,O
The,4731,O
NE,4731,B-CHEMICAL
uptake,4731,O
inhibitors,4731,O
",",4731,O
desipramine,4731,B-CHEMICAL
and,4731,O
protriptyline,4731,B-CHEMICAL
",",4731,O
did,4731,O
not,4731,O
alter,4731,O
the,4731,O
5-HT,4731,B-CHEMICAL
signal,4731,O
in,4731,O
the,4731,O
CA3,4731,O
region,4731,O
",",4731,O
but,4731,O
prolonged,4731,O
the,4731,O
clearance,4731,O
of,4731,O
5-HT,4731,B-CHEMICAL
in,4731,O
the,4731,O
dentate,4731,O
gyrus,4731,O
;,4731,O
this,4731,O
effect,4731,O
was,4731,O
absent,4731,O
in,4731,O
rats,4731,O
pretreated,4731,O
with,4731,O
6-hydroxydopamine,4731,B-CHEMICAL
.,4731,O
From,4732,O
these,4732,O
data,4732,O
",",4732,O
it,4732,O
is,4732,O
inferred,4732,O
that,4732,O
both,4732,O
the,4732,O
SERT,4732,B-GENE-Y
and,4732,O
NET,4732,B-GENE-Y
contribute,4732,O
to,4732,O
the,4732,O
active,4732,O
clearance,4732,O
of,4732,O
exogenously,4732,O
applied,4732,O
5-HT,4732,B-CHEMICAL
in,4732,O
the,4732,O
dentate,4732,O
gyrus,4732,O
.,4732,O
In,4733,O
another,4733,O
experiment,4733,O
",",4733,O
cyanopindolol,4733,B-CHEMICAL
",",4733,O
an,4733,O
antagonist,4733,O
of,4733,O
the,4733,O
serotonin,4733,B-GENE-N
terminal,4733,I-GENE-N
autoreceptor,4733,I-GENE-N
",",4733,O
also,4733,O
prolonged,4733,O
the,4733,O
clearance,4733,O
of,4733,O
5-HT,4733,B-CHEMICAL
from,4733,O
the,4733,O
CA3,4733,O
region,4733,O
.,4733,O
These,4734,O
and,4734,O
other,4734,O
data,4734,O
have,4734,O
generated,4734,O
a,4734,O
working,4734,O
hypothesis,4734,O
that,4734,O
activation,4734,O
of,4734,O
the,4734,O
terminal,4734,O
serotonin,4734,B-GENE-N
autoreceptor,4734,I-GENE-N
enhances,4734,O
the,4734,O
kinetics,4734,O
of,4734,O
5-HT,4734,B-CHEMICAL
uptake,4734,O
through,4734,O
an,4734,O
effect,4734,O
on,4734,O
the,4734,O
serotonin,4734,B-GENE-Y
transporter,4734,I-GENE-Y
.,4734,O
Effect,4735,O
of,4735,O
minaprine,4735,B-CHEMICAL
on,4735,O
cycloheximide-induced,4735,B-CHEMICAL
amnesia,4735,O
in,4735,O
mice,4735,O
.,4735,O
The,4736,O
effects,4736,O
of,4736,O
minaprine,4736,B-CHEMICAL
on,4736,O
cycloheximide-induced,4736,B-CHEMICAL
amnesia,4736,O
were,4736,O
investigated,4736,O
in,4736,O
a,4736,O
step-down,4736,O
passive,4736,O
avoidance,4736,O
task,4736,O
in,4736,O
mice,4736,O
.,4736,O
Minaprine,4737,B-CHEMICAL
significantly,4737,O
improved,4737,O
cycloheximide-induced,4737,B-CHEMICAL
amnesia,4737,O
.,4737,O
This,4738,O
effect,4738,O
was,4738,O
inhibited,4738,O
by,4738,O
scopolamine,4738,B-CHEMICAL
",",4738,O
but,4738,O
was,4738,O
potentiated,4738,O
by,4738,O
physostigmine,4738,B-CHEMICAL
.,4738,O
The,4739,O
anti-amnesic,4739,O
effect,4739,O
of,4739,O
minaprine,4739,B-CHEMICAL
on,4739,O
the,4739,O
cycloheximide-induced,4739,B-CHEMICAL
memory,4739,O
impairment,4739,O
was,4739,O
also,4739,O
antagonized,4739,O
by,4739,O
a,4739,O
serotonin,4739,B-CHEMICAL
(,4739,O
5-HT,4739,B-CHEMICAL
),4739,O
releaser,4739,O
",",4739,O
p-chloroamphetamine,4739,B-CHEMICAL
",",4739,O
and,4739,O
by,4739,O
a,4739,O
5-HT,4739,B-CHEMICAL
precursor,4739,O
",",4739,O
5-hydroxytryptophan,4739,B-CHEMICAL
",",4739,O
whereas,4739,O
a,4739,O
5-HT1A-selective,4739,B-GENE-Y
agonist,4739,O
",",4739,O
8-hydroxy-2-,4739,B-CHEMICAL
(,4739,I-CHEMICAL
di-n-propylamino,4739,I-CHEMICAL
),4739,I-CHEMICAL
tetralin,4739,I-CHEMICAL
",",4739,O
was,4739,O
inactive,4739,O
.,4739,O
The,4740,O
memory-improving,4740,O
effect,4740,O
of,4740,O
minaprine,4740,B-CHEMICAL
on,4740,O
cycloheximide-induced,4740,B-CHEMICAL
amnesia,4740,O
was,4740,O
potentiated,4740,O
by,4740,O
a,4740,O
selective,4740,O
5-HT2,4740,B-GENE-N
antagonist,4740,O
",",4740,O
ritanserin,4740,B-CHEMICAL
.,4740,O
These,4741,O
results,4741,O
suggest,4741,O
that,4741,O
the,4741,O
beneficial,4741,O
effect,4741,O
of,4741,O
minaprine,4741,B-CHEMICAL
on,4741,O
cycloheximide-induced,4741,B-CHEMICAL
amnesia,4741,O
may,4741,O
be,4741,O
related,4741,O
not,4741,O
only,4741,O
to,4741,O
cholinergic,4741,O
but,4741,O
also,4741,O
serotonergic,4741,O
neuronal,4741,O
systems,4741,O
(,4741,O
5-HT2,4741,B-GENE-N
receptors,4741,I-GENE-N
),4741,O
.,4741,O
Extracts,4742,O
of,4742,O
Scutellaria,4742,O
baicalensis,4742,O
reduced,4742,O
body,4742,O
weight,4742,O
and,4742,O
blood,4742,O
triglyceride,4742,B-CHEMICAL
in,4742,O
db/db,4742,O
Mice,4742,O
.,4742,O
Scutellaria,4743,O
baicalensis,4743,O
has,4743,O
been,4743,O
extensively,4743,O
employed,4743,O
for,4743,O
the,4743,O
clinical,4743,O
treatment,4743,O
of,4743,O
hyperlipidemia,4743,O
",",4743,O
atherosclerosis,4743,O
",",4743,O
hypertension,4743,O
",",4743,O
dysentery,4743,O
",",4743,O
inflammatory,4743,O
diseases,4743,O
",",4743,O
and,4743,O
the,4743,O
common,4743,O
cold,4743,O
.,4743,O
The,4744,O
present,4744,O
study,4744,O
was,4744,O
performed,4744,O
to,4744,O
investigate,4744,O
the,4744,O
anti-obesity,4744,O
and,4744,O
anti-dyslipidemia,4744,O
effect,4744,O
of,4744,O
Scutellaria,4744,O
baicalensis,4744,O
extracts,4744,O
(,4744,O
SBE,4744,O
),4744,O
in,4744,O
type,4744,O
2,4744,O
diabetic,4744,O
db/db,4744,O
mice,4744,O
.,4744,O
Male,4745,O
db/db,4745,O
mice,4745,O
were,4745,O
divided,4745,O
into,4745,O
three,4745,O
groups,4745,O
(,4745,O
n,4745,O
=,4745,O
5,4745,O
),4745,O
and,4745,O
orally,4745,O
administrated,4745,O
vehicle,4745,O
(,4745,O
control,4745,O
),4745,O
",",4745,O
SBE,4745,O
10,4745,O
",",4745,O
and,4745,O
100,4745,O
mg/kg,4745,O
body,4745,O
weight/day,4745,O
for,4745,O
4,4745,O
weeks,4745,O
everyday,4745,O
.,4745,O
Administration,4746,O
of,4746,O
SBE,4746,O
improves,4746,O
weight,4746,O
gain,4746,O
",",4746,O
hypertriglyceridemia,4746,O
",",4746,O
and,4746,O
hyperinsulinemia,4746,O
in,4746,O
db/db,4746,O
mice,4746,O
.,4746,O
In,4747,O
obese,4747,O
db/db,4747,O
mice,4747,O
",",4747,O
SBE,4747,O
treatment,4747,O
also,4747,O
reduced,4747,O
plasma,4747,O
alanine,4747,B-GENE-N
aminotransferase,4747,I-GENE-N
levels,4747,O
.,4747,O
In,4748,O
the,4748,O
livers,4748,O
of,4748,O
db/db,4748,O
mice,4748,O
",",4748,O
SBE,4748,O
promoted,4748,O
5,4748,B-GENE-N
',4748,I-GENE-N
AMP-activated,4748,I-GENE-N
protein,4748,I-GENE-N
kinase,4748,I-GENE-N
activity,4748,O
and,4748,O
restored,4748,O
metabolic,4748,O
process,4748,O
and,4748,O
insulin,4748,B-GENE-N
signaling,4748,O
pathways,4748,O
.,4748,O
Our,4749,O
data,4749,O
demonstrate,4749,O
that,4749,O
SBE,4749,O
exerts,4749,O
potent,4749,O
anti-obesity,4749,O
and,4749,O
anti-hypertriglyceride,4749,O
effects,4749,O
suggesting,4749,O
its,4749,O
useful,4749,O
potential,4749,O
function,4749,O
as,4749,O
adjuvant,4749,O
therapeutic,4749,O
agent,4749,O
for,4749,O
the,4749,O
treatment,4749,O
of,4749,O
weight,4749,O
gain,4749,O
and,4749,O
hypertriglyceridemia,4749,O
.,4749,O
Altered,4750,O
methionine,4750,B-CHEMICAL
metabolism,4750,O
in,4750,O
long,4750,O
living,4750,O
Ames,4750,O
dwarf,4750,O
mice,4750,O
.,4750,O
Ames,4751,O
dwarf,4751,O
mice,4751,O
(,4751,O
df/df,4751,O
),4751,O
are,4751,O
deficient,4751,O
in,4751,O
growth,4751,B-GENE-Y
hormone,4751,I-GENE-Y
",",4751,O
prolactin,4751,B-GENE-Y
",",4751,O
and,4751,O
thyroid-stimulating,4751,B-GENE-N
hormone,4751,I-GENE-N
and,4751,O
live,4751,O
significantly,4751,O
longer,4751,O
than,4751,O
their,4751,O
normal,4751,O
siblings,4751,O
.,4751,O
In,4752,O
the,4752,O
current,4752,O
study,4752,O
",",4752,O
we,4752,O
found,4752,O
that,4752,O
the,4752,O
hormone,4752,O
deficiencies,4752,O
affect,4752,O
methionine,4752,B-CHEMICAL
metabolism,4752,O
.,4752,O
We,4753,O
previously,4753,O
reported,4753,O
that,4753,O
the,4753,O
dwarf,4753,O
mice,4753,O
exhibit,4753,O
enzyme,4753,O
activities,4753,O
and,4753,O
levels,4753,O
that,4753,O
combat,4753,O
oxidative,4753,O
stress,4753,O
more,4753,O
efficiently,4753,O
than,4753,O
those,4753,O
of,4753,O
normal,4753,O
mice,4753,O
.,4753,O
Moreover,4754,O
",",4754,O
methionine,4754,B-CHEMICAL
or,4754,O
metabolites,4754,O
of,4754,O
methionine,4754,B-CHEMICAL
are,4754,O
involved,4754,O
in,4754,O
antioxidative,4754,O
processes,4754,O
.,4754,O
Thus,4755,O
",",4755,O
we,4755,O
performed,4755,O
an,4755,O
experiment,4755,O
that,4755,O
compared,4755,O
various,4755,O
parameters,4755,O
of,4755,O
methionine,4755,B-CHEMICAL
metabolism,4755,O
between,4755,O
18-month,4755,O
old,4755,O
male,4755,O
dwarf,4755,O
(,4755,O
N=6,4755,O
),4755,O
and,4755,O
wild,4755,O
type,4755,O
(,4755,O
N=5,4755,O
),4755,O
mice,4755,O
.,4755,O
The,4756,O
specific,4756,O
activity,4756,O
of,4756,O
liver,4756,B-GENE-N
methionine,4756,I-GENE-N
adenosyltransferase,4756,I-GENE-N
(,4756,O
MAT,4756,B-GENE-N
),4756,O
was,4756,O
significantly,4756,O
elevated,4756,O
(,4756,O
205,4756,O
%,4756,O
",",4756,O
p,4756,O
<,4756,O
0.0001,4756,O
),4756,O
in,4756,O
the,4756,O
dwarf,4756,O
mice,4756,O
",",4756,O
as,4756,O
were,4756,O
cystathionine,4756,B-GENE-N
synthase,4756,I-GENE-N
(,4756,O
50,4756,O
%,4756,O
",",4756,O
p,4756,O
<,4756,O
0.01,4756,O
),4756,O
",",4756,O
cystathionase,4756,B-GENE-Y
(,4756,O
83,4756,O
%,4756,O
",",4756,O
p,4756,O
<,4756,O
0.001,4756,O
),4756,O
",",4756,O
and,4756,O
glycine,4756,B-GENE-Y
N-methyltransferase,4756,I-GENE-Y
(,4756,O
GNMT,4756,B-GENE-Y
",",4756,O
91,4756,O
%,4756,O
",",4756,O
p,4756,O
<,4756,O
0.001,4756,O
),4756,O
activities,4756,O
.,4756,O
Even,4757,O
though,4757,O
the,4757,O
activities,4757,O
of,4757,O
MAT,4757,B-GENE-N
and,4757,O
GNMT,4757,B-GENE-Y
were,4757,O
elevated,4757,O
",",4757,O
the,4757,O
concentration,4757,O
of,4757,O
liver,4757,O
S-adenosylmethionine,4757,B-CHEMICAL
was,4757,O
decreased,4757,O
(,4757,O
24,4757,O
%,4757,O
",",4757,O
p,4757,O
<,4757,O
0.001,4757,O
),4757,O
and,4757,O
S-adenosylhomocysteine,4757,B-CHEMICAL
increased,4757,O
(,4757,O
113,4757,O
%,4757,O
",",4757,O
p,4757,O
<,4757,O
0.001,4757,O
),4757,O
in,4757,O
the,4757,O
dwarf,4757,O
mice,4757,O
.,4757,O
These,4758,O
data,4758,O
indicate,4758,O
that,4758,O
dwarf,4758,O
mice,4758,O
",",4758,O
compared,4758,O
to,4758,O
wild,4758,O
type,4758,O
mice,4758,O
",",4758,O
have,4758,O
a,4758,O
markedly,4758,O
different,4758,O
metabolism,4758,O
of,4758,O
methionine,4758,B-CHEMICAL
.,4758,O
Altered,4759,O
methionine,4759,B-CHEMICAL
metabolism,4759,O
may,4759,O
partially,4759,O
explain,4759,O
earlier,4759,O
reports,4759,O
indicating,4759,O
less,4759,O
oxidative,4759,O
damage,4759,O
to,4759,O
proteins,4759,O
in,4759,O
dwarf,4759,O
mice,4759,O
.,4759,O
Taken,4760,O
together,4760,O
",",4760,O
the,4760,O
data,4760,O
suggest,4760,O
that,4760,O
methionine,4760,B-CHEMICAL
metabolism,4760,O
may,4760,O
play,4760,O
a,4760,O
role,4760,O
in,4760,O
oxidative,4760,O
defense,4760,O
in,4760,O
the,4760,O
dwarf,4760,O
mouse,4760,O
and,4760,O
should,4760,O
be,4760,O
studied,4760,O
as,4760,O
a,4760,O
potential,4760,O
mechanism,4760,O
of,4760,O
extended,4760,O
lifespan,4760,O
.,4760,O
The,4761,O
potential,4761,O
of,4761,O
nicotinic,4761,O
enhancement,4761,O
of,4761,O
cognitive,4761,O
remediation,4761,O
training,4761,O
in,4761,O
schizophrenia,4761,O
.,4761,O
Cognitive,4762,O
deficits,4762,O
in,4762,O
schizophrenia,4762,O
are,4762,O
critically,4762,O
important,4762,O
predictors,4762,O
of,4762,O
long-term,4762,O
psychosocial,4762,O
outcome,4762,O
and,4762,O
are,4762,O
not,4762,O
significantly,4762,O
ameliorated,4762,O
by,4762,O
currently,4762,O
available,4762,O
medications,4762,O
.,4762,O
Cognitive,4763,O
remediation,4763,O
training,4763,O
has,4763,O
shown,4763,O
promise,4763,O
for,4763,O
alleviating,4763,O
cognitive,4763,O
symptoms,4763,O
of,4763,O
schizophrenia,4763,O
",",4763,O
but,4763,O
the,4763,O
clinical,4763,O
significance,4763,O
has,4763,O
often,4763,O
been,4763,O
limited,4763,O
by,4763,O
small,4763,O
effect,4763,O
sizes,4763,O
.,4763,O
Approaches,4764,O
that,4764,O
achieve,4764,O
larger,4764,O
improvement,4764,O
involve,4764,O
time,4764,O
requirements,4764,O
that,4764,O
can,4764,O
be,4764,O
cost-prohibitive,4764,O
within,4764,O
the,4764,O
current,4764,O
clinical,4764,O
care,4764,O
system,4764,O
.,4764,O
This,4765,O
mini-review,4765,O
evaluates,4765,O
the,4765,O
theoretical,4765,O
potential,4765,O
of,4765,O
a,4765,O
pharmacological,4765,O
enhancement,4765,O
strategy,4765,O
of,4765,O
cognitive,4765,O
remediation,4765,O
training,4765,O
with,4765,O
nicotinic,4765,B-GENE-N
acetylcholine,4765,I-GENE-N
receptor,4765,I-GENE-N
(,4765,O
nAChR,4765,B-GENE-N
),4765,O
agonists,4765,O
.,4765,O
nAChR,4766,B-GENE-N
agonists,4766,O
can,4766,O
facilitate,4766,O
sensory,4766,O
processing,4766,O
",",4766,O
alertness,4766,O
",",4766,O
attention,4766,O
",",4766,O
learning,4766,O
and,4766,O
memory,4766,O
.,4766,O
While,4767,O
these,4767,O
effects,4767,O
may,4767,O
be,4767,O
too,4767,O
subtle,4767,O
and,4767,O
short-lasting,4767,O
to,4767,O
be,4767,O
of,4767,O
clinical,4767,O
relevance,4767,O
as,4767,O
a,4767,O
primary,4767,O
treatment,4767,O
of,4767,O
cognitive,4767,O
deficits,4767,O
",",4767,O
they,4767,O
constitute,4767,O
an,4767,O
ideal,4767,O
effects,4767,O
profile,4767,O
for,4767,O
enhancing,4767,O
training,4767,O
benefits,4767,O
.,4767,O
Several,4768,O
mechanisms,4768,O
are,4768,O
described,4768,O
through,4768,O
which,4768,O
repeated,4768,O
coupling,4768,O
of,4768,O
cognitive,4768,O
training,4768,O
challenges,4768,O
with,4768,O
nAChR,4768,B-GENE-N
stimulation,4768,O
may,4768,O
enhance,4768,O
and,4768,O
accelerate,4768,O
cognitive,4768,O
remediation,4768,O
training,4768,O
effects,4768,O
",",4768,O
advancing,4768,O
such,4768,O
interventions,4768,O
into,4768,O
more,4768,O
effective,4768,O
and,4768,O
practicable,4768,O
treatments,4768,O
of,4768,O
some,4768,O
of,4768,O
the,4768,O
most,4768,O
debilitating,4768,O
symptoms,4768,O
of,4768,O
schizophrenia,4768,O
.,4768,O
This,4769,O
article,4769,O
is,4769,O
part,4769,O
of,4769,O
a,4769,O
Special,4769,O
Issue,4769,O
entitled,4769,O
'Cognitive,4769,O
Enhancers,4769,O
',4769,O
.,4769,O
Activation,4770,O
of,4770,O
alpha,4770,B-GENE-Y
2B-adrenoceptors,4770,I-GENE-Y
mediates,4770,O
the,4770,O
cardiovascular,4770,O
effects,4770,O
of,4770,O
etomidate,4770,B-CHEMICAL
.,4770,O
BACKGROUND,4771,O
:,4771,O
The,4771,O
intravenous,4771,O
anesthetic,4771,O
etomidate,4771,B-CHEMICAL
exhibits,4771,O
structural,4771,O
similarities,4771,O
to,4771,O
specific,4771,O
alpha2-adrenoceptor,4771,B-GENE-N
agonists,4771,O
of,4771,O
the,4771,O
type,4771,O
such,4771,O
as,4771,O
dexmedetomidine,4771,B-CHEMICAL
.,4771,O
The,4772,O
current,4772,O
study,4772,O
was,4772,O
performed,4772,O
to,4772,O
elucidate,4772,O
the,4772,O
possible,4772,O
interaction,4772,O
of,4772,O
etomidate,4772,B-CHEMICAL
with,4772,O
alpha2-adrenoceptors,4772,B-GENE-N
in,4772,O
mice,4772,O
lacking,4772,O
individual,4772,O
alpha2-adrenoceptor,4772,B-GENE-N
subtypes,4772,O
(,4772,O
alpha2-KO,4772,O
),4772,O
.,4772,O
METHODS,4773,O
:,4773,O
Sedative,4773,O
and,4773,O
cardiovascular,4773,O
responses,4773,O
to,4773,O
etomidate,4773,B-CHEMICAL
and,4773,O
the,4773,O
alpha2-agonist,4773,O
",",4773,O
dexmedetomidine,4773,B-CHEMICAL
",",4773,O
were,4773,O
determined,4773,O
in,4773,O
mice,4773,O
deficient,4773,O
in,4773,O
alpha2-receptor,4773,B-GENE-N
subtypes,4773,O
.,4773,O
Inhibition,4774,O
of,4774,O
binding,4774,O
of,4774,O
the,4774,O
alpha2-receptor,4774,B-GENE-N
antagonist,4774,O
[,4774,B-CHEMICAL
3H,4774,I-CHEMICAL
],4774,I-CHEMICAL
RX821002,4774,I-CHEMICAL
to,4774,O
recombinant,4774,O
alpha2-receptors,4774,B-GENE-N
by,4774,O
etomidate,4774,B-CHEMICAL
was,4774,O
tested,4774,O
in,4774,O
human,4774,O
embryonic,4774,O
kidney,4774,O
(,4774,O
HEK293,4774,O
),4774,O
cells,4774,O
in,4774,O
vitro,4774,O
.,4774,O
RESULTS,4775,O
:,4775,O
In,4775,O
vivo,4775,O
",",4775,O
loss,4775,O
and,4775,O
recovery,4775,O
of,4775,O
the,4775,O
righting,4775,O
reflex,4775,O
required,4775,O
similar,4775,O
times,4775,O
after,4775,O
intraperitoneal,4775,O
injection,4775,O
of,4775,O
etomidate,4775,B-CHEMICAL
in,4775,O
wild-type,4775,O
and,4775,O
in,4775,O
alpha2A-receptor-deficient,4775,B-GENE-Y
mice,4775,O
",",4775,O
indicating,4775,O
that,4775,O
the,4775,O
hypnotic,4775,O
effect,4775,O
of,4775,O
etomidate,4775,B-CHEMICAL
in,4775,O
mice,4775,O
does,4775,O
not,4775,O
require,4775,O
the,4775,O
alpha2A-receptor,4775,B-GENE-Y
subtype,4775,O
.,4775,O
Intravenous,4776,O
injection,4776,O
of,4776,O
etomidate,4776,B-CHEMICAL
resulted,4776,O
in,4776,O
a,4776,O
transient,4776,O
increase,4776,O
(,4776,O
duration,4776,O
2.4,4776,O
+/-,4776,O
0.2,4776,O
min,4776,O
),4776,O
in,4776,O
arterial,4776,O
blood,4776,O
pressure,4776,O
in,4776,O
wild-type,4776,O
mice,4776,O
(,4776,O
17,4776,O
+/-,4776,O
3,4776,O
mmHg,4776,O
),4776,O
.,4776,O
Etomidate,4777,B-CHEMICAL
did,4777,O
not,4777,O
affect,4777,O
blood,4777,O
pressure,4777,O
in,4777,O
alpha2B-KO,4777,O
or,4777,O
alpha2AB-KO,4777,O
mice,4777,O
.,4777,O
In,4778,O
membranes,4778,O
from,4778,O
HEK293,4778,O
cells,4778,O
transfected,4778,O
with,4778,O
alpha2-receptors,4778,B-GENE-N
",",4778,O
etomidate,4778,B-CHEMICAL
inhibited,4778,O
binding,4778,O
of,4778,O
the,4778,O
alpha2-antagonist,4778,O
",",4778,O
[,4778,B-CHEMICAL
3H,4778,I-CHEMICAL
],4778,I-CHEMICAL
RX821002,4778,I-CHEMICAL
",",4778,O
with,4778,O
higher,4778,O
potency,4778,O
from,4778,O
alpha2B-,4778,B-GENE-N
and,4778,I-GENE-N
alpha2C-receptors,4778,I-GENE-N
than,4778,O
from,4778,O
alpha2A-receptors,4778,B-GENE-Y
(,4778,O
Ki,4778,O
alpha2A,4778,O
208,4778,O
microm,4778,O
",",4778,O
alpha2B,4778,O
26,4778,O
microm,4778,O
",",4778,O
alpha2C,4778,O
56,4778,O
microm,4778,O
),4778,O
.,4778,O
In,4779,O
alpha2B-receptor-expressing,4779,B-GENE-Y
HEK293,4779,O
cells,4779,O
",",4779,O
etomidate,4779,B-CHEMICAL
rapidly,4779,O
increased,4779,O
phosphorylation,4779,O
of,4779,O
the,4779,O
extracellular,4779,B-GENE-N
signal-related,4779,I-GENE-N
kinases,4779,I-GENE-N
ERK1/2,4779,B-GENE-N
.,4779,O
CONCLUSIONS,4780,O
:,4780,O
These,4780,O
results,4780,O
indicate,4780,O
that,4780,O
etomidate,4780,B-CHEMICAL
acts,4780,O
as,4780,O
an,4780,O
agonist,4780,O
at,4780,O
alpha2-adrenoceptors,4780,B-GENE-N
",",4780,O
which,4780,O
appears,4780,O
in,4780,O
vivo,4780,O
primarily,4780,O
as,4780,O
an,4780,O
alpha2B-receptor-mediated,4780,B-GENE-Y
increase,4780,O
in,4780,O
blood,4780,O
pressure,4780,O
.,4780,O
This,4781,O
effect,4781,O
of,4781,O
etomidate,4781,B-CHEMICAL
may,4781,O
contribute,4781,O
to,4781,O
the,4781,O
cardiovascular,4781,O
stability,4781,O
of,4781,O
patients,4781,O
after,4781,O
induction,4781,O
of,4781,O
anesthesia,4781,O
with,4781,O
etomidate,4781,B-CHEMICAL
.,4781,O
Silica,4782,B-CHEMICAL
nanoparticles-induced,4782,O
cytotoxicity,4782,O
",",4782,O
oxidative,4782,O
stress,4782,O
and,4782,O
apoptosis,4782,O
in,4782,O
cultured,4782,O
A431,4782,O
and,4782,O
A549,4782,O
cells,4782,O
.,4782,O
In,4783,O
medicine,4783,O
",",4783,O
the,4783,O
use,4783,O
of,4783,O
silica,4783,B-CHEMICAL
nanoparticles,4783,O
(,4783,O
SiO,4783,B-CHEMICAL
(,4783,I-CHEMICAL
2,4783,I-CHEMICAL
),4783,I-CHEMICAL
NPs,4783,O
),4783,O
offers,4783,O
new,4783,O
perspectives,4783,O
in,4783,O
biosensor,4783,O
",",4783,O
drug,4783,O
delivery,4783,O
and,4783,O
cancer,4783,O
therapy,4783,O
.,4783,O
However,4784,O
",",4784,O
questions,4784,O
about,4784,O
potential,4784,O
toxic,4784,O
and,4784,O
deleterious,4784,O
effects,4784,O
of,4784,O
SiO,4784,B-CHEMICAL
(,4784,I-CHEMICAL
2,4784,I-CHEMICAL
),4784,I-CHEMICAL
NPs,4784,O
have,4784,O
also,4784,O
been,4784,O
raised,4784,O
.,4784,O
The,4785,O
aim,4785,O
of,4785,O
this,4785,O
study,4785,O
was,4785,O
to,4785,O
investigate,4785,O
the,4785,O
induction,4785,O
of,4785,O
cytotoxicity,4785,O
",",4785,O
oxidative,4785,O
stress,4785,O
and,4785,O
apoptosis,4785,O
by,4785,O
SiO,4785,B-CHEMICAL
(,4785,I-CHEMICAL
2,4785,I-CHEMICAL
),4785,I-CHEMICAL
NPs,4785,O
(,4785,O
size,4785,O
15,4785,O
nm,4785,O
),4785,O
in,4785,O
human,4785,O
skin,4785,O
epithelial,4785,O
(,4785,O
A431,4785,O
),4785,O
and,4785,O
human,4785,O
lung,4785,O
epithelial,4785,O
(,4785,O
A549,4785,O
),4785,O
cells,4785,O
.,4785,O
SiO,4786,B-CHEMICAL
(,4786,I-CHEMICAL
2,4786,I-CHEMICAL
),4786,I-CHEMICAL
NPs,4786,O
(,4786,O
concentration,4786,O
range,4786,O
25-200,4786,O
µg/ml,4786,O
),4786,O
induced,4786,O
dose-dependent,4786,O
cytotoxicity,4786,O
in,4786,O
both,4786,O
types,4786,O
of,4786,O
cells,4786,O
",",4786,O
which,4786,O
was,4786,O
demonstrated,4786,O
by,4786,O
cell,4786,O
viability,4786,O
(,4786,O
3-,4786,B-CHEMICAL
(,4786,I-CHEMICAL
"4,5-dimethylthiazol-2-yl",4786,I-CHEMICAL
),4786,I-CHEMICAL
"-2,5-diphenyltetrazoliumbromide",4786,I-CHEMICAL
),4786,O
and,4786,O
lactate,4786,B-GENE-N
dehydrogenase,4786,I-GENE-N
leakage,4786,O
assays,4786,O
.,4786,O
SiO,4787,B-CHEMICAL
(,4787,I-CHEMICAL
2,4787,I-CHEMICAL
),4787,I-CHEMICAL
NPs,4787,O
were,4787,O
also,4787,O
found,4787,O
to,4787,O
induce,4787,O
oxidative,4787,O
stress,4787,O
in,4787,O
a,4787,O
dose-dependent,4787,O
manner,4787,O
",",4787,O
indicated,4787,O
by,4787,O
depletion,4787,O
of,4787,O
glutathione,4787,B-CHEMICAL
and,4787,O
induction,4787,O
of,4787,O
reactive,4787,O
oxygen,4787,B-CHEMICAL
species,4787,O
(,4787,O
ROS,4787,O
),4787,O
generation,4787,O
and,4787,O
lipid,4787,O
peroxidation,4787,O
.,4787,O
Quantitative,4788,O
real-time,4788,O
polymerase,4788,O
chain,4788,O
reaction,4788,O
analysis,4788,O
showed,4788,O
that,4788,O
following,4788,O
the,4788,O
exposure,4788,O
of,4788,O
cells,4788,O
to,4788,O
SiO,4788,B-CHEMICAL
(,4788,I-CHEMICAL
2,4788,I-CHEMICAL
),4788,I-CHEMICAL
NPs,4788,O
",",4788,O
the,4788,O
messenger,4788,O
RNA,4788,O
level,4788,O
of,4788,O
apoptotic,4788,O
genes,4788,O
(,4788,O
caspase-3,4788,B-GENE-Y
and,4788,O
caspase-9,4788,B-GENE-Y
),4788,O
were,4788,O
upregulated,4788,O
in,4788,O
a,4788,O
dose-dependent,4788,O
manner,4788,O
.,4788,O
Moreover,4789,O
",",4789,O
activities,4789,O
of,4789,O
caspase-3,4789,B-GENE-Y
and,4789,O
caspase-9,4789,B-GENE-Y
enzymes,4789,O
were,4789,O
also,4789,O
significantly,4789,O
higher,4789,O
in,4789,O
both,4789,O
kinds,4789,O
of,4789,O
cells,4789,O
exposed,4789,O
to,4789,O
SiO,4789,B-CHEMICAL
(,4789,I-CHEMICAL
2,4789,I-CHEMICAL
),4789,I-CHEMICAL
NPs,4789,O
.,4789,O
This,4790,O
study,4790,O
suggested,4790,O
that,4790,O
SiO,4790,B-CHEMICAL
(,4790,I-CHEMICAL
2,4790,I-CHEMICAL
),4790,I-CHEMICAL
NPs,4790,O
induce,4790,O
cytotoxicity,4790,O
and,4790,O
apoptosis,4790,O
in,4790,O
A431,4790,O
and,4790,O
A549,4790,O
cells,4790,O
",",4790,O
which,4790,O
is,4790,O
likely,4790,O
to,4790,O
be,4790,O
mediated,4790,O
through,4790,O
ROS,4790,O
generation,4790,O
and,4790,O
oxidative,4790,O
stress,4790,O
.,4790,O
The,4791,O
CYP2B6,4791,B-GENE-Y
*,4791,I-GENE-Y
6,4791,I-GENE-Y
Allele,4791,O
Significantly,4791,O
Alters,4791,O
the,4791,O
N-demethylation,4791,O
of,4791,O
Ketamine,4791,B-CHEMICAL
Enantiomers,4791,O
In,4791,O
Vitro,4791,O
.,4791,O
Ketamine,4792,B-CHEMICAL
is,4792,O
primarily,4792,O
metabolized,4792,O
to,4792,O
norketamine,4792,B-CHEMICAL
by,4792,O
hepatic,4792,O
cytochrome,4792,B-GENE-Y
P450,4792,I-GENE-Y
(,4792,I-GENE-Y
CYP,4792,I-GENE-Y
),4792,I-GENE-Y
2B6,4792,I-GENE-Y
and,4792,O
CYP3A4-mediated,4792,B-GENE-Y
N-demethylation,4792,O
.,4792,O
However,4793,O
",",4793,O
the,4793,O
relative,4793,O
contribution,4793,O
from,4793,O
each,4793,O
enzyme,4793,O
remains,4793,O
controversial,4793,O
.,4793,O
The,4794,O
CYP2B6,4794,B-GENE-Y
*,4794,I-GENE-Y
6,4794,I-GENE-Y
allele,4794,O
is,4794,O
associated,4794,O
with,4794,O
reduced,4794,O
enzyme,4794,O
expression,4794,O
and,4794,O
activity,4794,O
that,4794,O
may,4794,O
lead,4794,O
to,4794,O
interindividual,4794,O
variability,4794,O
in,4794,O
ketamine,4794,B-CHEMICAL
metabolism,4794,O
.,4794,O
We,4795,O
examined,4795,O
the,4795,O
N-demethylation,4795,O
of,4795,O
individual,4795,O
ketamine,4795,B-CHEMICAL
enantiomers,4795,O
using,4795,O
human,4795,O
liver,4795,O
microsomes,4795,O
(,4795,O
HLMs,4795,O
),4795,O
genotyped,4795,O
for,4795,O
the,4795,O
CYP2B6,4795,B-GENE-Y
*,4795,I-GENE-Y
6,4795,I-GENE-Y
allele,4795,O
",",4795,O
insect,4795,O
cell,4795,O
expressed,4795,O
recombinant,4795,O
CYP2B6,4795,B-GENE-Y
and,4795,O
CYP3A4,4795,B-GENE-Y
enzymes,4795,O
and,4795,O
COS-1,4795,O
cell,4795,O
expressed,4795,O
recombinant,4795,O
CYP2B6.1,4795,B-GENE-Y
and,4795,O
CYP2B6.6,4795,B-GENE-Y
protein,4795,O
variant,4795,O
.,4795,O
Effects,4796,O
of,4796,O
CYP-selective,4796,B-GENE-N
inhibitors,4796,O
on,4796,O
norketamine,4796,B-CHEMICAL
formation,4796,O
were,4796,O
also,4796,O
determined,4796,O
in,4796,O
HLMs,4796,O
.,4796,O
The,4797,O
two-enzyme,4797,O
Michaelis-Menten,4797,O
model,4797,O
best,4797,O
fitted,4797,O
the,4797,O
HLM,4797,O
kinetic,4797,O
data,4797,O
.,4797,O
The,4798,O
Km,4798,O
value,4798,O
for,4798,O
the,4798,O
high,4798,O
affinity,4798,O
enzyme,4798,O
and,4798,O
the,4798,O
low,4798,O
affinity,4798,O
enzyme,4798,O
were,4798,O
similar,4798,O
to,4798,O
those,4798,O
for,4798,O
the,4798,O
expressed,4798,O
CYP2B6,4798,B-GENE-Y
and,4798,O
CYP3A4,4798,B-GENE-Y
",",4798,O
respectively,4798,O
.,4798,O
The,4799,O
intrinsic,4799,O
clearance,4799,O
for,4799,O
both,4799,O
ketamine,4799,B-CHEMICAL
enantiomers,4799,O
by,4799,O
the,4799,O
high,4799,O
affinity,4799,O
enzyme,4799,O
in,4799,O
HLMs,4799,O
with,4799,O
CYP2B6,4799,B-GENE-Y
*,4799,I-GENE-Y
1/,4799,O
*,4799,O
1,4799,O
genotype,4799,O
were,4799,O
at,4799,O
least,4799,O
2-fold,4799,O
and,4799,O
6-fold,4799,O
higher,4799,O
",",4799,O
respectively,4799,O
",",4799,O
than,4799,O
those,4799,O
for,4799,O
CYP2B6,4799,B-GENE-Y
*,4799,I-GENE-Y
1/,4799,O
*,4799,O
6,4799,O
genotype,4799,O
and,4799,O
CYP2B6,4799,B-GENE-Y
*,4799,I-GENE-Y
6/,4799,O
*,4799,O
6,4799,O
genotype,4799,O
.,4799,O
The,4800,O
Vmax,4800,O
and,4800,O
Km,4800,O
values,4800,O
for,4800,O
CYP2B6.1,4800,B-GENE-Y
were,4800,O
approximately,4800,O
160,4800,O
%,4800,O
and,4800,O
70,4800,O
%,4800,O
of,4800,O
those,4800,O
for,4800,O
CYP2B6.6,4800,B-GENE-Y
",",4800,O
respectively,4800,O
.,4800,O
ThioTEPA,4801,B-CHEMICAL
(,4801,O
CYP2B6,4801,B-GENE-Y
inhibitor,4801,O
",",4801,O
25,4801,O
μM,4801,O
),4801,O
and,4801,O
the,4801,O
monoclonal,4801,O
antibody,4801,O
against,4801,O
CYP2B6,4801,B-GENE-Y
but,4801,O
not,4801,O
troleandomycin,4801,B-CHEMICAL
(,4801,O
CYP3A4,4801,B-GENE-Y
inhibitor,4801,O
",",4801,O
25,4801,O
μM,4801,O
),4801,O
or,4801,O
the,4801,O
monoclonal,4801,O
antibody,4801,O
against,4801,O
CYP3A4,4801,B-GENE-Y
inhibited,4801,O
ketamine,4801,B-CHEMICAL
N-demethylation,4801,O
at,4801,O
clinically,4801,O
relevant,4801,O
concentrations,4801,O
.,4801,O
The,4802,O
degree,4802,O
of,4802,O
inhibition,4802,O
was,4802,O
significantly,4802,O
reduced,4802,O
in,4802,O
HLMs,4802,O
with,4802,O
the,4802,O
CYP2B6,4802,B-GENE-Y
*,4802,I-GENE-Y
6,4802,I-GENE-Y
allele,4802,O
(,4802,O
gene-dose,4802,O
P,4802,O
<,4802,O
0.05,4802,O
),4802,O
.,4802,O
These,4803,O
results,4803,O
indicate,4803,O
a,4803,O
major,4803,O
role,4803,O
of,4803,O
CYP2B6,4803,B-GENE-Y
in,4803,O
ketamine,4803,B-CHEMICAL
N-demethylation,4803,O
in,4803,O
vitro,4803,O
and,4803,O
a,4803,O
significant,4803,O
impact,4803,O
of,4803,O
the,4803,O
CYP2B6,4803,B-GENE-Y
*,4803,I-GENE-Y
6,4803,I-GENE-Y
allele,4803,O
on,4803,O
enzyme-ketamine,4803,O
binding,4803,O
and,4803,O
catalytic,4803,O
activity,4803,O
.,4803,O
A,4804,O
Role,4804,O
for,4804,O
Cargo,4804,B-GENE-N
in,4804,O
the,4804,O
Activation,4804,O
of,4804,O
ADP-Ribosylation,4804,B-GENE-N
Factors,4804,I-GENE-N
(,4804,O
Arf,4804,B-GENE-N
),4804,O
and,4804,O
Adaptor,4804,B-GENE-N
Recruitment,4804,O
.,4804,O
Membrane,4805,O
traffic,4805,O
requires,4805,O
the,4805,O
specific,4805,O
concentration,4805,O
of,4805,O
protein,4805,B-GENE-N
cargos,4805,I-GENE-N
and,4805,O
exclusion,4805,O
of,4805,O
other,4805,O
proteins,4805,O
into,4805,O
nascent,4805,O
carriers,4805,O
.,4805,O
Critical,4806,O
components,4806,O
of,4806,O
this,4806,O
selectivity,4806,O
are,4806,O
the,4806,O
protein,4806,B-GENE-N
adaptors,4806,I-GENE-N
that,4806,O
bind,4806,O
to,4806,O
short,4806,O
",",4806,O
linear,4806,O
motifs,4806,O
in,4806,O
the,4806,O
cytoplasmic,4806,O
tails,4806,O
of,4806,O
transmembrane,4806,O
protein,4806,B-GENE-N
cargos,4806,I-GENE-N
and,4806,O
sequester,4806,O
them,4806,O
into,4806,O
nascent,4806,O
carriers,4806,O
.,4806,O
The,4807,O
recruitment,4807,O
of,4807,O
the,4807,O
adaptors,4807,O
is,4807,O
mediated,4807,O
by,4807,O
activated,4807,O
Arf,4807,B-GENE-N
GTPases,4807,B-GENE-N
and,4807,O
the,4807,O
Arf-adaptor,4807,B-GENE-N
complexes,4807,O
mark,4807,O
sites,4807,O
of,4807,O
carrier,4807,O
formation,4807,O
.,4807,O
However,4808,O
",",4808,O
the,4808,O
nature,4808,O
of,4808,O
the,4808,O
signal,4808,O
(,4808,O
s,4808,O
),4808,O
that,4808,O
initiate,4808,O
carrier,4808,O
biogenesis,4808,O
remains,4808,O
unknown,4808,O
.,4808,O
We,4809,O
examined,4809,O
the,4809,O
specificity,4809,O
and,4809,O
initial,4809,O
sites,4809,O
of,4809,O
recruitment,4809,O
of,4809,O
Arf-dependent,4809,B-GENE-N
adaptors,4809,B-GENE-N
(,4809,O
AP-1,4809,B-GENE-N
and,4809,O
GGAs,4809,B-GENE-N
),4809,O
in,4809,O
response,4809,O
to,4809,O
the,4809,O
Golgi,4809,O
or,4809,O
endosomal,4809,O
localization,4809,O
of,4809,O
specific,4809,O
cargo,4809,B-GENE-N
proteins,4809,I-GENE-N
(,4809,O
furin,4809,B-GENE-Y
",",4809,O
mannose-6-phosphate,4809,B-GENE-Y
receptor,4809,I-GENE-Y
(,4809,O
M6PR,4809,B-GENE-Y
),4809,O
and,4809,O
M6PR,4809,B-GENE-Y
lacking,4809,O
a,4809,O
C-terminal,4809,B-CHEMICAL
domain,4809,O
M6PRΔC,4809,B-GENE-Y
),4809,O
.,4809,O
We,4810,O
find,4810,O
that,4810,O
cargo,4810,B-GENE-N
promotes,4810,O
the,4810,O
recruitment,4810,O
of,4810,O
specific,4810,O
adaptors,4810,B-GENE-N
",",4810,O
suggesting,4810,O
that,4810,O
it,4810,O
is,4810,O
part,4810,O
of,4810,O
an,4810,O
upstream,4810,O
signaling,4810,O
event,4810,O
.,4810,O
Cargos,4811,B-GENE-N
do,4811,O
not,4811,O
promote,4811,O
adaptor,4811,B-GENE-N
recruitment,4811,O
to,4811,O
all,4811,O
compartments,4811,O
in,4811,O
which,4811,O
they,4811,O
reside,4811,O
and,4811,O
thus,4811,O
additional,4811,O
factors,4811,O
regulate,4811,O
the,4811,O
cargo,4811,B-GENE-N
's,4811,I-GENE-N
ability,4811,O
to,4811,O
promote,4811,O
Arf,4811,B-GENE-N
activation,4811,O
and,4811,O
adaptor,4811,B-GENE-N
recruitment,4811,O
.,4811,O
We,4812,O
document,4812,O
that,4812,O
within,4812,O
a,4812,O
given,4812,O
compartment,4812,O
different,4812,O
cargos,4812,B-GENE-N
recruit,4812,O
different,4812,O
adaptors,4812,B-GENE-N
suggesting,4812,O
that,4812,O
there,4812,O
is,4812,O
little,4812,O
or,4812,O
no,4812,O
free,4812,O
",",4812,O
activated,4812,O
Arf,4812,B-GENE-N
at,4812,O
the,4812,O
membrane,4812,O
and,4812,O
that,4812,O
Arf,4812,B-GENE-N
activation,4812,O
is,4812,O
spatially,4812,O
and,4812,O
temporally,4812,O
coupled,4812,O
to,4812,O
the,4812,O
cargo,4812,B-GENE-N
and,4812,O
the,4812,O
adaptor,4812,B-GENE-N
.,4812,O
Using,4813,O
temperature,4813,O
block,4813,O
",",4813,O
Brefeldin,4813,B-CHEMICAL
A,4813,I-CHEMICAL
",",4813,O
and,4813,O
recovery,4813,O
from,4813,O
each,4813,O
",",4813,O
we,4813,O
found,4813,O
that,4813,O
the,4813,O
cytoplasmic,4813,O
tail,4813,O
of,4813,O
M6PR,4813,B-GENE-Y
causes,4813,O
the,4813,O
recruitment,4813,O
of,4813,O
AP-1,4813,B-GENE-N
and,4813,O
GGAs,4813,B-GENE-N
to,4813,O
recycling,4813,O
endosomes,4813,O
and,4813,O
not,4813,O
at,4813,O
the,4813,O
Golgi,4813,O
",",4813,O
as,4813,O
predicted,4813,O
by,4813,O
steady,4813,O
state,4813,O
staining,4813,O
profiles,4813,O
.,4813,O
These,4814,O
results,4814,O
are,4814,O
discussed,4814,O
with,4814,O
respect,4814,O
to,4814,O
the,4814,O
generation,4814,O
of,4814,O
novel,4814,O
models,4814,O
for,4814,O
cargo-dependent,4814,B-GENE-N
regulation,4814,O
of,4814,O
membrane,4814,O
traffic,4814,O
.,4814,O
Aromatase,4815,B-GENE-Y
inhibitors,4815,O
for,4815,O
male,4815,O
infertility,4815,O
.,4815,O
PURPOSE,4816,O
:,4816,O
Testosterone-to-estradiol,4816,B-CHEMICAL
ratio,4816,O
levels,4816,O
in,4816,O
infertile,4816,O
men,4816,O
improve,4816,O
during,4816,O
treatment,4816,O
with,4816,O
the,4816,O
aromatase,4816,B-GENE-Y
inhibitor,4816,O
",",4816,O
testolactone,4816,B-CHEMICAL
",",4816,O
and,4816,O
resulting,4816,O
changes,4816,O
in,4816,O
semen,4816,O
parameters,4816,O
.,4816,O
We,4817,O
evaluated,4817,O
the,4817,O
effect,4817,O
of,4817,O
anastrozole,4817,B-CHEMICAL
",",4817,O
a,4817,O
more,4817,O
selective,4817,O
aromatase,4817,B-GENE-Y
inhibitor,4817,O
",",4817,O
on,4817,O
the,4817,O
hormonal,4817,O
and,4817,O
semen,4817,O
profiles,4817,O
of,4817,O
infertile,4817,O
men,4817,O
with,4817,O
abnormal,4817,O
baseline,4817,O
testosterone-to-estradiol,4817,B-CHEMICAL
ratios,4817,O
.,4817,O
MATERIALS,4818,O
AND,4818,O
METHODS,4818,O
:,4818,O
A,4818,O
total,4818,O
of,4818,O
140,4818,O
subfertile,4818,O
men,4818,O
with,4818,O
abnormal,4818,O
testosterone-to-estradiol,4818,B-CHEMICAL
ratios,4818,O
were,4818,O
treated,4818,O
with,4818,O
100,4818,O
to,4818,O
200,4818,O
mg.,4818,O
testolactone,4818,B-CHEMICAL
daily,4818,O
or,4818,O
1,4818,O
mg.,4818,O
anastrozole,4818,B-CHEMICAL
daily,4818,O
.,4818,O
Changes,4819,O
in,4819,O
testosterone,4819,B-CHEMICAL
",",4819,O
estradiol,4819,B-CHEMICAL
",",4819,O
testosterone-to-estradiol,4819,B-CHEMICAL
ratios,4819,O
and,4819,O
semen,4819,O
parameters,4819,O
were,4819,O
evaluated,4819,O
during,4819,O
therapy,4819,O
.,4819,O
The,4820,O
effect,4820,O
of,4820,O
obesity,4820,O
",",4820,O
diagnosis,4820,O
of,4820,O
the,4820,O
Klinefelter,4820,O
syndrome,4820,O
",",4820,O
and,4820,O
presence,4820,O
of,4820,O
varicocele,4820,O
and/or,4820,O
history,4820,O
of,4820,O
varicocele,4820,O
repair,4820,O
on,4820,O
treatment,4820,O
results,4820,O
was,4820,O
studied,4820,O
.,4820,O
RESULTS,4821,O
:,4821,O
Men,4821,O
treated,4821,O
with,4821,O
testolactone,4821,B-CHEMICAL
had,4821,O
an,4821,O
increase,4821,O
in,4821,O
testosterone-to-estradiol,4821,B-CHEMICAL
ratios,4821,O
during,4821,O
therapy,4821,O
(,4821,O
mean,4821,O
plus,4821,O
or,4821,O
minus,4821,O
standard,4821,O
error,4821,O
of,4821,O
the,4821,O
mean,4821,O
5.3,4821,O
+/-,4821,O
0.2,4821,O
versus,4821,O
12.4,4821,O
+/-,4821,O
1.1,4821,O
",",4821,O
p,4821,O
<,4821,O
0.001,4821,O
),4821,O
.,4821,O
This,4822,O
change,4822,O
was,4822,O
confirmed,4822,O
in,4822,O
subgroups,4822,O
of,4822,O
men,4822,O
with,4822,O
the,4822,O
Klinefelter,4822,O
syndrome,4822,O
",",4822,O
a,4822,O
history,4822,O
of,4822,O
varicocele,4822,O
repair,4822,O
and,4822,O
those,4822,O
with,4822,O
varicocele,4822,O
.,4822,O
A,4823,O
total,4823,O
of,4823,O
12,4823,O
oligospermic,4823,O
men,4823,O
had,4823,O
semen,4823,O
analysis,4823,O
before,4823,O
and,4823,O
during,4823,O
testolactone,4823,B-CHEMICAL
treatment,4823,O
with,4823,O
an,4823,O
increase,4823,O
in,4823,O
sperm,4823,O
concentration,4823,O
(,4823,O
5.5,4823,O
versus,4823,O
11.2,4823,O
million,4823,O
sperm,4823,O
per,4823,O
ml.,4823,O
",",4823,O
p,4823,O
<,4823,O
0.01,4823,O
),4823,O
",",4823,O
motility,4823,O
(,4823,O
14.7,4823,O
%,4823,O
versus,4823,O
21.0,4823,O
%,4823,O
",",4823,O
p,4823,O
<,4823,O
0.05,4823,O
),4823,O
",",4823,O
morphology,4823,O
(,4823,O
6.5,4823,O
%,4823,O
versus,4823,O
12.8,4823,O
%,4823,O
",",4823,O
p,4823,O
=,4823,O
0.05,4823,O
),4823,O
",",4823,O
and,4823,O
motility,4823,O
index,4823,O
(,4823,O
606.3,4823,O
versus,4823,O
1685.2,4823,O
million,4823,O
motile,4823,O
sperm,4823,O
per,4823,O
ejaculate,4823,O
",",4823,O
respectively,4823,O
",",4823,O
p,4823,O
<,4823,O
0.05,4823,O
),4823,O
appreciated,4823,O
.,4823,O
During,4824,O
anastrozole,4824,B-CHEMICAL
treatment,4824,O
",",4824,O
similar,4824,O
changes,4824,O
in,4824,O
the,4824,O
testosterone-to-estradiol,4824,B-CHEMICAL
ratios,4824,O
were,4824,O
seen,4824,O
(,4824,O
7.2,4824,O
+/-,4824,O
0.3,4824,O
versus,4824,O
18.1,4824,O
+/-,4824,O
1.0,4824,O
",",4824,O
respectively,4824,O
",",4824,O
p,4824,O
<,4824,O
0.001,4824,O
),4824,O
.,4824,O
This,4825,O
improvement,4825,O
of,4825,O
hormonal,4825,O
parameters,4825,O
was,4825,O
noted,4825,O
for,4825,O
all,4825,O
subgroups,4825,O
except,4825,O
those,4825,O
patients,4825,O
with,4825,O
the,4825,O
Klinefelter,4825,O
syndrome,4825,O
.,4825,O
A,4826,O
total,4826,O
of,4826,O
25,4826,O
oligospermic,4826,O
men,4826,O
with,4826,O
semen,4826,O
analysis,4826,O
before,4826,O
and,4826,O
during,4826,O
anastrozole,4826,B-CHEMICAL
treatment,4826,O
had,4826,O
an,4826,O
increase,4826,O
in,4826,O
semen,4826,O
volume,4826,O
(,4826,O
2.9,4826,O
versus,4826,O
3.5,4826,O
ml.,4826,O
",",4826,O
p,4826,O
<,4826,O
0.05,4826,O
),4826,O
",",4826,O
sperm,4826,O
concentration,4826,O
(,4826,O
5.5,4826,O
versus,4826,O
15.6,4826,O
million,4826,O
sperm,4826,O
per,4826,O
ml.,4826,O
",",4826,O
p,4826,O
<,4826,O
0.001,4826,O
),4826,O
and,4826,O
motility,4826,O
index,4826,O
(,4826,O
832.8,4826,O
versus,4826,O
2930.8,4826,O
million,4826,O
motile,4826,O
sperm,4826,O
per,4826,O
ejaculate,4826,O
",",4826,O
respectively,4826,O
",",4826,O
p,4826,O
<,4826,O
0.005,4826,O
),4826,O
.,4826,O
These,4827,O
changes,4827,O
were,4827,O
similar,4827,O
to,4827,O
those,4827,O
observed,4827,O
in,4827,O
men,4827,O
treated,4827,O
with,4827,O
testolactone,4827,B-CHEMICAL
.,4827,O
No,4828,O
significant,4828,O
difference,4828,O
in,4828,O
serum,4828,O
testosterone,4828,B-CHEMICAL
levels,4828,O
during,4828,O
treatment,4828,O
with,4828,O
testolactone,4828,B-CHEMICAL
and,4828,O
anastrozole,4828,B-CHEMICAL
was,4828,O
observed,4828,O
.,4828,O
However,4829,O
",",4829,O
the,4829,O
anastrozole,4829,B-CHEMICAL
treatment,4829,O
group,4829,O
did,4829,O
have,4829,O
a,4829,O
statistically,4829,O
better,4829,O
improvement,4829,O
of,4829,O
serum,4829,O
estradiol,4829,B-CHEMICAL
concentration,4829,O
and,4829,O
testosterone-to-estradiol,4829,B-CHEMICAL
ratios,4829,O
(,4829,O
p,4829,O
<,4829,O
0.001,4829,O
),4829,O
.,4829,O
CONCLUSIONS,4830,O
:,4830,O
Men,4830,O
who,4830,O
are,4830,O
infertile,4830,O
with,4830,O
a,4830,O
low,4830,O
serum,4830,O
testosterone-to-estradiol,4830,B-CHEMICAL
ratio,4830,O
can,4830,O
be,4830,O
treated,4830,O
with,4830,O
an,4830,O
aromatase,4830,B-GENE-Y
inhibitor,4830,O
.,4830,O
With,4831,O
treatment,4831,O
",",4831,O
an,4831,O
increase,4831,O
in,4831,O
testosterone-to-estradiol,4831,B-CHEMICAL
ratio,4831,O
occurred,4831,O
in,4831,O
association,4831,O
with,4831,O
increased,4831,O
semen,4831,O
parameters,4831,O
.,4831,O
Anastrozole,4832,B-CHEMICAL
and,4832,O
testolactone,4832,B-CHEMICAL
have,4832,O
similar,4832,O
effects,4832,O
on,4832,O
hormonal,4832,O
profiles,4832,O
and,4832,O
semen,4832,O
analysis,4832,O
.,4832,O
Anastrazole,4833,B-CHEMICAL
appears,4833,O
to,4833,O
be,4833,O
at,4833,O
least,4833,O
as,4833,O
effective,4833,O
as,4833,O
testolactone,4833,B-CHEMICAL
for,4833,O
treating,4833,O
men,4833,O
with,4833,O
abnormal,4833,O
testosterone-to-estradiol,4833,B-CHEMICAL
ratios,4833,O
",",4833,O
except,4833,O
for,4833,O
the,4833,O
subset,4833,O
with,4833,O
the,4833,O
Klinefelter,4833,O
syndrome,4833,O
",",4833,O
who,4833,O
appeared,4833,O
to,4833,O
be,4833,O
more,4833,O
effectively,4833,O
treated,4833,O
with,4833,O
testolactone,4833,B-CHEMICAL
.,4833,O
Interactions,4834,O
between,4834,O
CYP2E1,4834,B-GENE-Y
and,4834,O
CYP2B4,4834,B-GENE-Y
:,4834,O
effects,4834,O
on,4834,O
affinity,4834,O
for,4834,O
NADPH-cytochrome,4834,B-GENE-Y
P450,4834,I-GENE-Y
reductase,4834,I-GENE-Y
and,4834,O
substrate,4834,O
metabolism,4834,O
.,4834,O
Studies,4835,O
in,4835,O
microsomal,4835,O
and,4835,O
reconstituted,4835,O
systems,4835,O
have,4835,O
shown,4835,O
that,4835,O
the,4835,O
presence,4835,O
of,4835,O
one,4835,O
cytochrome,4835,B-GENE-N
P450,4835,I-GENE-N
isoform,4835,O
can,4835,O
significantly,4835,O
influence,4835,O
the,4835,O
catalytic,4835,O
activity,4835,O
of,4835,O
another,4835,O
isoform,4835,O
.,4835,O
In,4836,O
this,4836,O
study,4836,O
",",4836,O
we,4836,O
assessed,4836,O
whether,4836,O
CYP2E1,4836,B-GENE-Y
could,4836,O
influence,4836,O
the,4836,O
catalytic,4836,O
activity,4836,O
of,4836,O
CYP2B4,4836,B-GENE-Y
under,4836,O
steady-state,4836,O
turnover,4836,O
conditions,4836,O
.,4836,O
The,4837,O
results,4837,O
show,4837,O
that,4837,O
CYP2E1,4837,B-GENE-Y
inhibits,4837,O
CYP2B4-mediated,4837,B-GENE-Y
metabolism,4837,O
of,4837,O
benzphetamine,4837,B-CHEMICAL
(,4837,O
BNZ,4837,B-CHEMICAL
),4837,O
with,4837,O
a,4837,O
K,4837,O
(,4837,O
i,4837,O
),4837,O
of,4837,O
0.04,4837,O
µM,4837,O
.,4837,O
However,4838,O
",",4838,O
CYP2B4,4838,B-GENE-Y
is,4838,O
not,4838,O
an,4838,O
inhibitor,4838,O
of,4838,O
CYP2E1-mediated,4838,B-GENE-Y
p-nitrophenol,4838,B-CHEMICAL
hydroxylation,4838,O
.,4838,O
When,4839,O
these,4839,O
inhibition,4839,O
studies,4839,O
were,4839,O
performed,4839,O
with,4839,O
the,4839,O
artificial,4839,O
oxidant,4839,O
tert-butyl,4839,B-CHEMICAL
hydroperoxide,4839,I-CHEMICAL
",",4839,O
CYP2E1,4839,B-GENE-Y
did,4839,O
not,4839,O
significantly,4839,O
inhibit,4839,O
CYP2B4,4839,B-GENE-Y
activity,4839,O
.,4839,O
Determinations,4840,O
of,4840,O
the,4840,O
apparent,4840,O
K,4840,O
(,4840,O
M,4840,O
),4840,O
and,4840,O
k,4840,O
(,4840,O
cat,4840,O
),4840,O
of,4840,O
CYP2B4,4840,B-GENE-Y
for,4840,O
CPR,4840,B-GENE-Y
in,4840,O
the,4840,O
presence,4840,O
of,4840,O
increasing,4840,O
concentrations,4840,O
of,4840,O
CYP2E1,4840,B-GENE-Y
revealed,4840,O
a,4840,O
mixed,4840,O
inhibition,4840,O
of,4840,O
CYP2B4,4840,B-GENE-Y
by,4840,O
CYP2E1,4840,B-GENE-Y
.,4840,O
At,4841,O
low,4841,O
concentrations,4841,O
of,4841,O
CYP2E1,4841,B-GENE-Y
",",4841,O
the,4841,O
apparent,4841,O
K,4841,O
(,4841,O
M,4841,O
),4841,O
of,4841,O
CYP2B4,4841,B-GENE-Y
for,4841,O
CPR,4841,B-GENE-Y
increased,4841,O
up,4841,O
to,4841,O
23-fold,4841,O
with,4841,O
virtually,4841,O
no,4841,O
change,4841,O
in,4841,O
the,4841,O
k,4841,O
(,4841,O
cat,4841,O
),4841,O
for,4841,O
the,4841,O
reaction,4841,O
",",4841,O
however,4841,O
",",4841,O
at,4841,O
higher,4841,O
concentrations,4841,O
of,4841,O
CYP2E1,4841,B-GENE-Y
",",4841,O
the,4841,O
apparent,4841,O
K,4841,O
(,4841,O
M,4841,O
),4841,O
of,4841,O
CYP2B4,4841,B-GENE-Y
for,4841,O
CPR,4841,B-GENE-Y
decreased,4841,O
to,4841,O
levels,4841,O
similar,4841,O
to,4841,O
those,4841,O
observed,4841,O
in,4841,O
the,4841,O
absence,4841,O
of,4841,O
CYP2E1,4841,B-GENE-Y
and,4841,O
the,4841,O
k,4841,O
(,4841,O
cat,4841,O
),4841,O
also,4841,O
decreased,4841,O
by,4841,O
11-fold,4841,O
.,4841,O
Additionally,4842,O
",",4842,O
CYP2E1,4842,B-GENE-Y
increased,4842,O
the,4842,O
apparent,4842,O
K,4842,O
(,4842,O
M,4842,O
),4842,O
of,4842,O
CYP2B4,4842,B-GENE-Y
for,4842,O
BNZ,4842,B-CHEMICAL
by,4842,O
8-fold,4842,O
and,4842,O
the,4842,O
apparent,4842,O
K,4842,O
(,4842,O
M,4842,O
),4842,O
did,4842,O
not,4842,O
decrease,4842,O
to,4842,O
its,4842,O
original,4842,O
value,4842,O
when,4842,O
saturating,4842,O
concentrations,4842,O
of,4842,O
CPR,4842,B-GENE-Y
were,4842,O
used,4842,O
.,4842,O
While,4843,O
the,4843,O
individual,4843,O
apparent,4843,O
K,4843,O
(,4843,O
M,4843,O
),4843,O
values,4843,O
of,4843,O
CYP2B4,4843,B-GENE-Y
and,4843,O
CYP2E1,4843,B-GENE-Y
for,4843,O
CPR,4843,B-GENE-Y
are,4843,O
similar,4843,O
",",4843,O
the,4843,O
apparent,4843,O
K,4843,O
(,4843,O
M,4843,O
),4843,O
of,4843,O
CYP2E1,4843,B-GENE-Y
for,4843,O
CPR,4843,B-GENE-Y
in,4843,O
the,4843,O
presence,4843,O
of,4843,O
CYP2B4,4843,B-GENE-N
decreased,4843,O
significantly,4843,O
",",4843,O
thus,4843,O
suggesting,4843,O
that,4843,O
CYP2B4,4843,B-GENE-Y
enhances,4843,O
the,4843,O
affinity,4843,O
of,4843,O
CYP2E1,4843,B-GENE-Y
for,4843,O
CPR,4843,B-GENE-Y
and,4843,O
this,4843,O
may,4843,O
allow,4843,O
CYP2E1,4843,B-GENE-Y
to,4843,O
out-compete,4843,O
CYP2B4,4843,B-GENE-Y
for,4843,O
CPR,4843,B-GENE-Y
.,4843,O
Prosocial,4844,O
effects,4844,O
of,4844,O
oxytocin,4844,B-GENE-Y
in,4844,O
two,4844,O
mouse,4844,O
models,4844,O
of,4844,O
autism,4844,O
spectrum,4844,O
disorders,4844,O
.,4844,O
Clinical,4845,O
evidence,4845,O
suggests,4845,O
that,4845,O
oxytocin,4845,B-GENE-Y
treatment,4845,O
improves,4845,O
social,4845,O
deficits,4845,O
and,4845,O
repetitive,4845,O
behavior,4845,O
in,4845,O
autism,4845,O
spectrum,4845,O
disorders,4845,O
(,4845,O
ASDs,4845,O
),4845,O
.,4845,O
However,4846,O
",",4846,O
the,4846,O
neuropeptide,4846,B-GENE-N
has,4846,O
a,4846,O
short,4846,O
plasma,4846,O
half-life,4846,O
and,4846,O
poor,4846,O
ability,4846,O
to,4846,O
penetrate,4846,O
the,4846,O
blood-brain,4846,O
barrier,4846,O
.,4846,O
In,4847,O
order,4847,O
to,4847,O
facilitate,4847,O
the,4847,O
development,4847,O
of,4847,O
more,4847,O
bioavailable,4847,O
oxytocinergic,4847,O
compounds,4847,O
as,4847,O
therapeutics,4847,O
to,4847,O
treat,4847,O
core,4847,O
ASD,4847,O
symptoms,4847,O
",",4847,O
small,4847,O
animal,4847,O
models,4847,O
must,4847,O
be,4847,O
validated,4847,O
for,4847,O
preclinical,4847,O
screens,4847,O
.,4847,O
This,4848,O
study,4848,O
examined,4848,O
the,4848,O
preclinical,4848,O
utility,4848,O
of,4848,O
two,4848,O
inbred,4848,O
mouse,4848,O
strains,4848,O
",",4848,O
BALB/cByJ,4848,O
and,4848,O
C58/J,4848,O
",",4848,O
that,4848,O
exhibit,4848,O
phenotypes,4848,O
relevant,4848,O
to,4848,O
core,4848,O
ASD,4848,O
symptoms,4848,O
.,4848,O
Mice,4849,O
from,4849,O
both,4849,O
strains,4849,O
were,4849,O
intraperitoneally,4849,O
administered,4849,O
oxytocin,4849,B-GENE-Y
",",4849,O
using,4849,O
either,4849,O
acute,4849,O
or,4849,O
sub-chronic,4849,O
regimens,4849,O
.,4849,O
Acute,4850,O
oxytocin,4850,B-GENE-Y
did,4850,O
not,4850,O
increase,4850,O
sociability,4850,O
in,4850,O
BALB/cByJ,4850,O
;,4850,O
however,4850,O
",",4850,O
sub-chronic,4850,O
oxytocin,4850,B-GENE-Y
had,4850,O
significant,4850,O
prosocial,4850,O
effects,4850,O
in,4850,O
both,4850,O
BALB/cByJ,4850,O
and,4850,O
C58/J,4850,O
.,4850,O
Increased,4851,O
sociability,4851,O
was,4851,O
observed,4851,O
24,4851,O
hours,4851,O
following,4851,O
the,4851,O
final,4851,O
oxytocin,4851,B-GENE-Y
dose,4851,O
in,4851,O
BALB/cByJ,4851,O
",",4851,O
while,4851,O
prosocial,4851,O
effects,4851,O
of,4851,O
oxytocin,4851,B-CHEMICAL
emerged,4851,O
1-2,4851,O
weeks,4851,O
post-treatment,4851,O
in,4851,O
C58/J,4851,O
.,4851,O
Furthermore,4852,O
",",4852,O
acute,4852,O
oxytocin,4852,B-GENE-Y
decreased,4852,O
motor,4852,O
stereotypy,4852,O
in,4852,O
C58/J,4852,O
and,4852,O
did,4852,O
not,4852,O
induce,4852,O
hypoactivity,4852,O
or,4852,O
anxiolytic-like,4852,O
effects,4852,O
in,4852,O
an,4852,O
open,4852,O
field,4852,O
test,4852,O
.,4852,O
This,4853,O
study,4853,O
demonstrates,4853,O
that,4853,O
oxytocin,4853,B-GENE-Y
administration,4853,O
can,4853,O
attenuate,4853,O
social,4853,O
deficits,4853,O
and,4853,O
repetitive,4853,O
behavior,4853,O
in,4853,O
mouse,4853,O
models,4853,O
of,4853,O
ASD,4853,O
",",4853,O
dependent,4853,O
on,4853,O
dose,4853,O
regimen,4853,O
and,4853,O
genotype,4853,O
.,4853,O
These,4854,O
findings,4854,O
provide,4854,O
validation,4854,O
of,4854,O
the,4854,O
BALB/cByJ,4854,O
and,4854,O
C58/J,4854,O
models,4854,O
as,4854,O
useful,4854,O
platforms,4854,O
for,4854,O
screening,4854,O
novel,4854,O
drugs,4854,O
for,4854,O
intervention,4854,O
in,4854,O
ASDs,4854,O
and,4854,O
for,4854,O
elucidating,4854,O
the,4854,O
mechanisms,4854,O
contributing,4854,O
to,4854,O
the,4854,O
prosocial,4854,O
effects,4854,O
of,4854,O
oxytocin,4854,B-GENE-Y
.,4854,O
Probing,4855,O
for,4855,O
a,4855,O
hydrophobic,4855,O
a,4855,O
binding,4855,O
register,4855,O
in,4855,O
prostate-specific,4855,B-GENE-Y
membrane,4855,I-GENE-Y
antigen,4855,I-GENE-Y
with,4855,O
phenylalkylphosphonamidates,4855,B-CHEMICAL
.,4855,O
To,4856,O
explore,4856,O
for,4856,O
the,4856,O
existence,4856,O
of,4856,O
an,4856,O
auxiliary,4856,O
hydrophobic,4856,O
binding,4856,O
register,4856,O
remote,4856,O
from,4856,O
the,4856,O
active,4856,O
site,4856,O
of,4856,O
PSMA,4856,B-GENE-Y
a,4856,O
series,4856,O
of,4856,O
phenylalkylphosphonamidate,4856,B-CHEMICAL
derivatives,4856,O
of,4856,O
glutamic,4856,B-CHEMICAL
acid,4856,I-CHEMICAL
were,4856,O
synthesized,4856,O
and,4856,O
evaluated,4856,O
for,4856,O
their,4856,O
inhibitory,4856,O
potencies,4856,O
against,4856,O
PSMA,4856,B-GENE-Y
.,4856,O
Both,4857,O
the,4857,O
phenyl-,4857,B-CHEMICAL
and,4857,I-CHEMICAL
benzylphosphonamidates,4857,I-CHEMICAL
(,4857,O
1a,4857,O
and,4857,O
1b,4857,O
),4857,O
exhibited,4857,O
only,4857,O
modest,4857,O
inhibitory,4857,O
potency,4857,O
against,4857,O
.,4857,O
The,4858,O
phenethyl,4858,B-CHEMICAL
analog,4858,O
1c,4858,O
was,4858,O
intermediate,4858,O
in,4858,O
inhibitory,4858,O
potency,4858,O
while,4858,O
inhibitors,4858,O
possessing,4858,O
a,4858,O
longer,4858,O
alkyl,4858,B-CHEMICAL
tether,4858,O
from,4858,O
the,4858,O
phenyl,4858,O
ring,4858,O
",",4858,O
resulted,4858,O
in,4858,O
markedly,4858,O
improved,4858,O
K,4858,O
(,4858,O
i,4858,O
),4858,O
values,4858,O
.,4858,O
The,4859,O
greatest,4859,O
inhibitory,4859,O
potency,4859,O
was,4859,O
obtained,4859,O
for,4859,O
the,4859,O
inhibitors,4859,O
in,4859,O
which,4859,O
the,4859,O
phenyl,4859,O
ring,4859,O
was,4859,O
extended,4859,O
furthest,4859,O
from,4859,O
the,4859,O
central,4859,O
phosphorus,4859,B-CHEMICAL
(,4859,O
1f,4859,O
",",4859,O
n=5,4859,O
and,4859,O
1g,4859,O
",",4859,O
n=6,4859,O
),4859,O
.,4859,O
The,4860,O
slightly,4860,O
serrated,4860,O
pattern,4860,O
that,4860,O
emerged,4860,O
as,4860,O
the,4860,O
alkyl,4860,B-CHEMICAL
tether,4860,O
increased,4860,O
from,4860,O
three,4860,O
to,4860,O
six,4860,O
methylene,4860,O
units,4860,O
suggests,4860,O
that,4860,O
inhibitory,4860,O
potency,4860,O
is,4860,O
not,4860,O
simply,4860,O
correlated,4860,O
to,4860,O
increased,4860,O
hydrophobicity,4860,O
imparted,4860,O
by,4860,O
the,4860,O
phenylalkyl,4860,B-CHEMICAL
chain,4860,O
",",4860,O
but,4860,O
rather,4860,O
that,4860,O
one,4860,O
or,4860,O
more,4860,O
hydrophobic,4860,O
binding,4860,O
registers,4860,O
may,4860,O
exist,4860,O
remote,4860,O
from,4860,O
the,4860,O
substrate,4860,O
recognition,4860,O
architecture,4860,O
in,4860,O
the,4860,O
active,4860,O
site,4860,O
of,4860,O
PSMA,4860,B-GENE-Y
.,4860,O
Deficits,4861,O
in,4861,O
male,4861,O
sexual,4861,O
behavior,4861,O
in,4861,O
adulthood,4861,O
after,4861,O
social,4861,O
instability,4861,O
stress,4861,O
in,4861,O
adolescence,4861,O
in,4861,O
rats,4861,O
.,4861,O
There,4862,O
is,4862,O
increasing,4862,O
evidence,4862,O
that,4862,O
exposure,4862,O
to,4862,O
stressors,4862,O
in,4862,O
adolescence,4862,O
has,4862,O
long-lasting,4862,O
effects,4862,O
on,4862,O
emotional,4862,O
and,4862,O
cognitive,4862,O
behavior,4862,O
",",4862,O
but,4862,O
little,4862,O
is,4862,O
known,4862,O
as,4862,O
to,4862,O
whether,4862,O
reproductive,4862,O
functions,4862,O
are,4862,O
affected,4862,O
.,4862,O
We,4863,O
investigated,4863,O
appetitive,4863,O
and,4863,O
consummatory,4863,O
aspects,4863,O
of,4863,O
sexual,4863,O
behavior,4863,O
in,4863,O
male,4863,O
rats,4863,O
that,4863,O
were,4863,O
exposed,4863,O
to,4863,O
chronic,4863,O
social,4863,O
instability,4863,O
stress,4863,O
(,4863,O
SS,4863,O
",",4863,O
n=24,4863,O
),4863,O
for,4863,O
16,4863,O
days,4863,O
in,4863,O
mid-adolescence,4863,O
compared,4863,O
to,4863,O
control,4863,O
rats,4863,O
(,4863,O
CTL,4863,O
",",4863,O
n=24,4863,O
),4863,O
.,4863,O
Over,4864,O
five,4864,O
sexual,4864,O
behavior,4864,O
test,4864,O
sessions,4864,O
with,4864,O
a,4864,O
receptive,4864,O
female,4864,O
",",4864,O
SS,4864,O
rats,4864,O
made,4864,O
fewer,4864,O
ejaculations,4864,O
(,4864,O
p=0.02,4864,O
),4864,O
and,4864,O
had,4864,O
longer,4864,O
latencies,4864,O
to,4864,O
ejaculation,4864,O
(,4864,O
p=0.03,4864,O
),4864,O
.,4864,O
When,4865,O
only,4865,O
data,4865,O
from,4865,O
rats,4865,O
that,4865,O
ejaculated,4865,O
in,4865,O
the,4865,O
fifth,4865,O
session,4865,O
were,4865,O
analyzed,4865,O
",",4865,O
SS,4865,O
rats,4865,O
(,4865,O
n=18,4865,O
),4865,O
had,4865,O
reduced,4865,O
copulatory,4865,O
efficiency,4865,O
(,4865,O
more,4865,O
mounts,4865,O
and,4865,O
intromissions,4865,O
before,4865,O
ejaculation,4865,O
),4865,O
compared,4865,O
to,4865,O
CTL,4865,O
rats,4865,O
(,4865,O
n=19,4865,O
),4865,O
(,4865,O
p=0.004,4865,O
),4865,O
",",4865,O
and,4865,O
CTL,4865,O
rats,4865,O
were,4865,O
twice,4865,O
as,4865,O
likely,4865,O
as,4865,O
SS,4865,O
rats,4865,O
to,4865,O
make,4865,O
more,4865,O
than,4865,O
one,4865,O
ejaculation,4865,O
in,4865,O
the,4865,O
fifth,4865,O
session,4865,O
(,4865,O
p=0.05,4865,O
),4865,O
.,4865,O
Further,4866,O
",",4866,O
more,4866,O
CTL,4866,O
(,4866,O
14/24,4866,O
),4866,O
than,4866,O
SS,4866,O
(,4866,O
5/25,4866,O
),4866,O
rats,4866,O
ejaculated,4866,O
in,4866,O
four,4866,O
or,4866,O
more,4866,O
sessions,4866,O
(,4866,O
p=0.05,4866,O
),4866,O
.,4866,O
SS,4867,O
rats,4867,O
had,4867,O
lower,4867,O
plasma,4867,O
testosterone,4867,B-CHEMICAL
concentrations,4867,O
than,4867,O
CTL,4867,O
rats,4867,O
(,4867,O
p=0.05,4867,O
),4867,O
",",4867,O
but,4867,O
did,4867,O
not,4867,O
differ,4867,O
in,4867,O
androgen,4867,B-GENE-Y
receptor,4867,I-GENE-Y
",",4867,O
estrogen,4867,B-GENE-Y
receptor,4867,I-GENE-Y
alpha,4867,I-GENE-Y
",",4867,O
or,4867,O
Fos,4867,B-GENE-Y
immunoreactive,4867,O
cell,4867,O
counts,4867,O
in,4867,O
the,4867,O
medial,4867,O
preoptic,4867,O
area,4867,O
.,4867,O
The,4868,O
groups,4868,O
did,4868,O
not,4868,O
differ,4868,O
in,4868,O
a,4868,O
partner,4868,O
preference,4868,O
test,4868,O
administered,4868,O
between,4868,O
the,4868,O
fourth,4868,O
and,4868,O
fifth,4868,O
sexual,4868,O
behavior,4868,O
session,4868,O
.,4868,O
The,4869,O
results,4869,O
suggest,4869,O
that,4869,O
developmental,4869,O
history,4869,O
contributes,4869,O
to,4869,O
individual,4869,O
differences,4869,O
in,4869,O
reproductive,4869,O
behavior,4869,O
",",4869,O
and,4869,O
that,4869,O
stress,4869,O
exposures,4869,O
in,4869,O
adolescence,4869,O
may,4869,O
be,4869,O
a,4869,O
factor,4869,O
in,4869,O
sexual,4869,O
sluggishness,4869,O
.,4869,O
Low-Dose,4870,O
Dexamethasone,4870,B-CHEMICAL
Treatment,4870,O
Promotes,4870,O
Pro-Survival,4870,O
Signalling,4870,O
Pathway,4870,O
In,4870,O
Adult,4870,O
Rat,4870,O
Prefrontal,4870,O
Cortex,4870,O
.,4870,O
Synthetic,4871,O
glucocorticoid,4871,O
dexamethasone,4871,B-CHEMICAL
(,4871,O
DEX,4871,B-CHEMICAL
),4871,O
",",4871,O
a,4871,O
highly,4871,O
potent,4871,O
anti-inflammatory,4871,O
and,4871,O
immunosuppressive,4871,O
agent,4871,O
",",4871,O
is,4871,O
widely,4871,O
used,4871,O
in,4871,O
treatments,4871,O
of,4871,O
brain,4871,O
cancer,4871,O
",",4871,O
inflammatory,4871,O
and,4871,O
autoimmune,4871,O
diseases,4871,O
.,4871,O
The,4872,O
objective,4872,O
of,4872,O
the,4872,O
current,4872,O
study,4872,O
was,4872,O
to,4872,O
determine,4872,O
whether,4872,O
a,4872,O
low-dose,4872,O
subchronic,4872,O
DEX,4872,B-CHEMICAL
treatment,4872,O
(,4872,O
100,4872,O
μg/kg,4872,O
for,4872,O
8,4872,O
consecutive,4872,O
days,4872,O
),4872,O
exerts,4872,O
long-term,4872,O
effects,4872,O
on,4872,O
apoptosis,4872,O
in,4872,O
the,4872,O
adult,4872,O
rat,4872,O
prefrontal,4872,O
cortex,4872,O
(,4872,O
PFC,4872,O
),4872,O
by,4872,O
examining,4872,O
the,4872,O
expression,4872,O
of,4872,O
cell,4872,O
death-promoting,4872,O
molecules,4872,O
(,4872,O
poly,4872,B-GENE-N
(,4872,I-GENE-N
ADP-ribose,4872,I-GENE-N
),4872,I-GENE-N
polymerase,4872,I-GENE-N
(,4872,O
PARP,4872,B-GENE-N
),4872,O
",",4872,O
p53,4872,B-GENE-Y
",",4872,O
procaspase,4872,B-GENE-Y
3,4872,I-GENE-Y
",",4872,O
cleaved,4872,O
caspase,4872,B-GENE-Y
3,4872,I-GENE-Y
",",4872,O
Bax,4872,B-GENE-Y
),4872,O
and,4872,O
cell-survival,4872,O
molecules,4872,O
(,4872,O
AKT,4872,B-GENE-N
",",4872,O
Bcl-2,4872,B-GENE-Y
),4872,O
.,4872,O
Our,4873,O
results,4873,O
revealed,4873,O
that,4873,O
body,4873,O
",",4873,O
thymus,4873,O
and,4873,O
adrenal,4873,O
weight,4873,O
as,4873,O
well,4873,O
corticosterone,4873,B-CHEMICAL
level,4873,O
in,4873,O
the,4873,O
serum,4873,O
and,4873,O
PFC,4873,O
were,4873,O
reduced,4873,O
a,4873,O
day,4873,O
following,4873,O
last,4873,O
DEX,4873,B-CHEMICAL
injection,4873,O
.,4873,O
In,4874,O
PFC,4874,O
",",4874,O
DEX,4874,B-CHEMICAL
caused,4874,O
activation,4874,O
of,4874,O
AKT,4874,B-GENE-N
",",4874,O
augmentation,4874,O
of,4874,O
pro-survival,4874,O
Bcl-2,4874,B-GENE-Y
protein,4874,O
and,4874,O
enhanced,4874,O
Bcl-2/Bax,4874,B-GENE-Y
protein,4874,O
ratio,4874,O
",",4874,O
as,4874,O
well,4874,O
Bcl-2,4874,B-GENE-Y
translocation,4874,O
to,4874,O
mitochondria,4874,O
.,4874,O
The,4875,O
unaltered,4875,O
profile,4875,O
in,4875,O
the,4875,O
protein,4875,O
expression,4875,O
of,4875,O
apoptotic,4875,O
molecules,4875,O
PARP,4875,B-GENE-N
",",4875,O
procaspase,4875,B-GENE-Y
3,4875,I-GENE-Y
and,4875,O
Bax,4875,B-GENE-Y
was,4875,O
detected,4875,O
",",4875,O
while,4875,O
the,4875,O
p53,4875,B-GENE-Y
protein,4875,O
was,4875,O
decreased,4875,O
.,4875,O
Results,4876,O
of,4876,O
RT-PCR,4876,O
analysis,4876,O
showed,4876,O
decrease,4876,O
of,4876,O
p53,4876,B-GENE-Y
mRNA,4876,O
level,4876,O
and,4876,O
no,4876,O
significant,4876,O
difference,4876,O
in,4876,O
Bcl-2,4876,B-GENE-Y
and,4876,O
Bax,4876,B-GENE-Y
mRNA,4876,O
expressions,4876,O
in,4876,O
DEX-treated,4876,B-CHEMICAL
rats,4876,O
.,4876,O
Finally,4877,O
",",4877,O
the,4877,O
DNA,4877,O
fragmentation,4877,O
assay,4877,O
and,4877,O
Fluoro-Jade,4877,O
staining,4877,O
demonstrated,4877,O
no,4877,O
considerable,4877,O
changes,4877,O
in,4877,O
the,4877,O
apoptosis,4877,O
in,4877,O
rat,4877,O
PFC,4877,O
.,4877,O
Our,4878,O
findings,4878,O
support,4878,O
the,4878,O
concept,4878,O
that,4878,O
a,4878,O
low-dose,4878,O
DEX,4878,B-CHEMICAL
creates,4878,O
the,4878,O
hypocorticoid,4878,O
state,4878,O
in,4878,O
the,4878,O
brain,4878,O
and,4878,O
indicate,4878,O
that,4878,O
subchronic,4878,O
DEX,4878,B-CHEMICAL
treatment,4878,O
activates,4878,O
pro-survival,4878,O
signalling,4878,O
pathway,4878,O
but,4878,O
does,4878,O
not,4878,O
change,4878,O
apoptotic,4878,O
markers,4878,O
in,4878,O
rat,4878,O
PFC,4878,O
.,4878,O
This,4879,O
mechanism,4879,O
might,4879,O
be,4879,O
relevant,4879,O
for,4879,O
DEX-induced,4879,B-CHEMICAL
apoptosis,4879,O
resistance,4879,O
observed,4879,O
during,4879,O
and,4879,O
after,4879,O
chemotherapy,4879,O
of,4879,O
patients,4879,O
with,4879,O
brain,4879,O
tumours,4879,O
.,4879,O
©,4880,O
2013,4880,O
British,4880,O
Society,4880,O
for,4880,O
Neuroendocrinology,4880,O
.,4880,O
Crystal,4881,O
structure,4881,O
of,4881,O
the,4881,O
IL-2,4881,B-GENE-Y
signaling,4881,O
complex,4881,O
:,4881,O
paradigm,4881,O
for,4881,O
a,4881,O
heterotrimeric,4881,O
cytokine,4881,B-GENE-N
receptor,4881,I-GENE-N
.,4881,O
IL-2,4882,B-GENE-Y
is,4882,O
a,4882,O
cytokine,4882,B-GENE-N
that,4882,O
functions,4882,O
as,4882,O
a,4882,O
growth,4882,O
factor,4882,O
and,4882,O
central,4882,O
regulator,4882,O
in,4882,O
the,4882,O
immune,4882,O
system,4882,O
and,4882,O
mediates,4882,O
its,4882,O
effects,4882,O
through,4882,O
ligand-induced,4882,O
hetero-trimerization,4882,O
of,4882,O
the,4882,O
receptor,4882,O
subunits,4882,O
IL-2R,4882,B-GENE-Y
alpha,4882,I-GENE-Y
",",4882,O
IL-2R,4882,B-GENE-N
beta,4882,I-GENE-N
",",4882,I-GENE-N
and,4882,I-GENE-N
gamma,4882,I-GENE-N
(,4882,I-GENE-N
c,4882,I-GENE-N
),4882,I-GENE-N
.,4882,O
Here,4883,O
",",4883,O
we,4883,O
describe,4883,O
the,4883,O
crystal,4883,O
structure,4883,O
of,4883,O
the,4883,O
trimeric,4883,O
assembly,4883,O
of,4883,O
the,4883,O
human,4883,B-GENE-N
IL-2,4883,I-GENE-N
receptor,4883,I-GENE-N
ectodomains,4883,O
in,4883,O
complex,4883,O
with,4883,O
IL-2,4883,B-GENE-Y
at,4883,O
3.0,4883,O
A,4883,O
resolution,4883,O
.,4883,O
The,4884,O
quaternary,4884,O
structure,4884,O
is,4884,O
consistent,4884,O
with,4884,O
a,4884,O
stepwise,4884,O
assembly,4884,O
from,4884,O
IL-2/IL-2R,4884,B-GENE-Y
alpha,4884,I-GENE-Y
to,4884,O
IL-2/IL-2R,4884,B-GENE-Y
alpha/IL-2R,4884,O
beta,4884,I-GENE-Y
to,4884,O
IL-2/IL-2R,4884,B-GENE-Y
alpha/IL-2R,4884,O
beta/gamma,4884,I-GENE-N
(,4884,I-GENE-N
c,4884,I-GENE-N
),4884,I-GENE-N
.,4884,O
The,4885,O
IL-2R,4885,B-GENE-Y
alpha,4885,I-GENE-Y
subunit,4885,O
forms,4885,O
the,4885,O
largest,4885,O
of,4885,O
the,4885,O
three,4885,O
IL-2/IL-2R,4885,B-GENE-Y
interfaces,4885,O
",",4885,O
which,4885,O
",",4885,O
together,4885,O
with,4885,O
the,4885,O
high,4885,O
abundance,4885,O
of,4885,O
charge-charge,4885,O
interactions,4885,O
",",4885,O
correlates,4885,O
well,4885,O
with,4885,O
the,4885,O
rapid,4885,O
association,4885,O
rate,4885,O
and,4885,O
high-affinity,4885,O
interaction,4885,O
of,4885,O
IL-2R,4885,B-GENE-Y
alpha,4885,I-GENE-Y
with,4885,O
IL-2,4885,B-GENE-Y
at,4885,O
the,4885,O
cell,4885,O
surface,4885,O
.,4885,O
Surprisingly,4886,O
",",4886,O
IL-2R,4886,B-GENE-Y
alpha,4886,I-GENE-Y
makes,4886,O
no,4886,O
contacts,4886,O
with,4886,O
IL-2R,4886,B-GENE-N
beta,4886,I-GENE-N
or,4886,I-GENE-N
gamma,4886,I-GENE-N
(,4886,I-GENE-N
c,4886,I-GENE-N
),4886,I-GENE-N
",",4886,O
and,4886,O
only,4886,O
minor,4886,O
changes,4886,O
are,4886,O
observed,4886,O
in,4886,O
the,4886,O
IL-2,4886,B-GENE-Y
structure,4886,O
in,4886,O
response,4886,O
to,4886,O
receptor,4886,O
binding,4886,O
.,4886,O
These,4887,O
findings,4887,O
support,4887,O
the,4887,O
principal,4887,O
role,4887,O
of,4887,O
IL-2R,4887,B-GENE-Y
alpha,4887,I-GENE-Y
to,4887,O
deliver,4887,O
IL-2,4887,B-GENE-Y
to,4887,O
the,4887,O
signaling,4887,O
complex,4887,O
and,4887,O
act,4887,O
as,4887,O
regulator,4887,O
of,4887,O
signal,4887,O
transduction,4887,O
.,4887,O
Cooperativity,4888,O
in,4888,O
assembly,4888,O
of,4888,O
the,4888,O
final,4888,O
quaternary,4888,O
complex,4888,O
is,4888,O
easily,4888,O
explained,4888,O
by,4888,O
the,4888,O
extraordinarily,4888,O
extensive,4888,O
set,4888,O
of,4888,O
interfaces,4888,O
found,4888,O
within,4888,O
the,4888,O
fully,4888,O
assembled,4888,O
IL-2,4888,B-GENE-Y
signaling,4888,O
complex,4888,O
",",4888,O
which,4888,O
nearly,4888,O
span,4888,O
the,4888,O
entire,4888,O
length,4888,O
of,4888,O
the,4888,O
IL-2R,4888,B-GENE-N
beta,4888,I-GENE-N
and,4888,I-GENE-N
gamma,4888,I-GENE-N
(,4888,I-GENE-N
c,4888,I-GENE-N
),4888,I-GENE-N
subunits,4888,O
.,4888,O
Helix,4889,O
A,4889,O
of,4889,O
IL-2,4889,B-GENE-Y
wedges,4889,O
tightly,4889,O
between,4889,O
IL-2R,4889,B-GENE-N
beta,4889,I-GENE-N
and,4889,I-GENE-N
gamma,4889,I-GENE-N
(,4889,I-GENE-N
c,4889,I-GENE-N
),4889,I-GENE-N
to,4889,O
form,4889,O
a,4889,O
three-way,4889,O
junction,4889,O
that,4889,O
coalesces,4889,O
into,4889,O
a,4889,O
composite,4889,O
binding,4889,O
site,4889,O
for,4889,O
the,4889,O
final,4889,O
gamma,4889,O
(,4889,O
c,4889,O
),4889,O
recruitment,4889,O
.,4889,O
The,4890,O
IL-2/gamma,4890,B-GENE-Y
(,4890,O
c,4890,O
),4890,O
interface,4890,O
itself,4890,O
exhibits,4890,O
the,4890,O
smallest,4890,O
buried,4890,O
surface,4890,O
and,4890,O
the,4890,O
fewest,4890,O
hydrogen,4890,B-CHEMICAL
bonds,4890,O
in,4890,O
the,4890,O
complex,4890,O
",",4890,O
which,4890,O
is,4890,O
consistent,4890,O
with,4890,O
its,4890,O
promiscuous,4890,O
use,4890,O
in,4890,O
other,4890,O
cytokine,4890,B-GENE-N
receptor,4890,I-GENE-N
complexes,4890,O
.,4890,O
Antitumor,4891,O
activity,4891,O
of,4891,O
sorafenib,4891,B-CHEMICAL
in,4891,O
FLT3-driven,4891,B-GENE-Y
leukemic,4891,O
cells,4891,O
.,4891,O
Activating,4892,O
internal,4892,O
tandem,4892,O
duplication,4892,O
(,4892,O
ITD,4892,O
),4892,O
insertions,4892,O
in,4892,O
the,4892,O
juxtamembrane,4892,B-GENE-N
domain,4892,I-GENE-N
of,4892,O
the,4892,O
FLT3,4892,B-GENE-Y
tyrosine,4892,B-GENE-N
kinase,4892,I-GENE-N
are,4892,O
found,4892,O
in,4892,O
about,4892,O
one,4892,O
fourth,4892,O
of,4892,O
patients,4892,O
with,4892,O
acute,4892,O
myeloid,4892,O
leukemia,4892,O
and,4892,O
have,4892,O
been,4892,O
shown,4892,O
to,4892,O
be,4892,O
an,4892,O
independent,4892,O
negative,4892,O
prognostic,4892,O
factor,4892,O
for,4892,O
survival,4892,O
.,4892,O
We,4893,O
show,4893,O
that,4893,O
sorafenib,4893,B-CHEMICAL
(,4893,O
BAY,4893,B-CHEMICAL
43-9006,4893,I-CHEMICAL
",",4893,O
Nexavar,4893,B-CHEMICAL
),4893,O
potently,4893,O
inhibits,4893,O
FLT3,4893,B-GENE-Y
enzymatic,4893,O
and,4893,O
signaling,4893,O
activities,4893,O
.,4893,O
In,4894,O
HEK293,4894,O
cells,4894,O
stably,4894,O
transfected,4894,O
with,4894,O
FLT3-WT,4894,B-GENE-Y
or,4894,O
FLT3-ITD,4894,B-GENE-Y
",",4894,O
sorafenib,4894,B-CHEMICAL
blocked,4894,O
basal,4894,O
and,4894,O
ligand,4894,O
dependent,4894,O
FLT3-mediated,4894,B-GENE-Y
tyrosine,4894,B-CHEMICAL
autophosphorylation,4894,O
as,4894,O
well,4894,O
as,4894,O
extracellular,4894,B-GENE-N
signal-regulated,4894,I-GENE-N
kinase1/2,4894,I-GENE-N
and,4894,O
Stat5,4894,B-GENE-Y
phosphorylation,4894,O
.,4894,O
In,4895,O
leukemia,4895,O
cell,4895,O
lines,4895,O
MV4-11,4895,O
and,4895,O
EOL-1,4895,O
",",4895,O
sorafenib,4895,B-CHEMICAL
treatment,4895,O
resulted,4895,O
in,4895,O
decreased,4895,O
cell,4895,O
proliferation,4895,O
and,4895,O
inhibition,4895,O
of,4895,O
FLT3,4895,B-GENE-Y
signaling,4895,O
.,4895,O
The,4896,O
growth,4896,O
of,4896,O
the,4896,O
FLT3-independent,4896,B-GENE-Y
RS4-11,4896,O
cell,4896,O
line,4896,O
was,4896,O
only,4896,O
weakly,4896,O
inhibited,4896,O
by,4896,O
sorafenib,4896,B-CHEMICAL
.,4896,O
Cell,4897,O
cycle,4897,O
arrest,4897,O
and,4897,O
induction,4897,O
of,4897,O
apoptosis,4897,O
were,4897,O
observed,4897,O
upon,4897,O
treatment,4897,O
with,4897,O
sorafenib,4897,B-CHEMICAL
in,4897,O
MV4-11,4897,O
and,4897,O
EOL-1,4897,O
cells,4897,O
.,4897,O
The,4898,O
antitumor,4898,O
efficacy,4898,O
of,4898,O
sorafenib,4898,B-CHEMICAL
was,4898,O
evaluated,4898,O
against,4898,O
the,4898,O
MV4-11,4898,O
leukemia,4898,O
grown,4898,O
subcutaneously,4898,O
in,4898,O
NCr,4898,O
nu/nu,4898,O
mice,4898,O
.,4898,O
Doses,4899,O
of,4899,O
3,4899,O
and,4899,O
10,4899,O
mg/kg,4899,O
administered,4899,O
orally,4899,O
for,4899,O
14,4899,O
days,4899,O
resulted,4899,O
in,4899,O
six,4899,O
and,4899,O
nine,4899,O
out,4899,O
of,4899,O
10,4899,O
animals,4899,O
with,4899,O
complete,4899,O
responses,4899,O
",",4899,O
respectively,4899,O
.,4899,O
The,4900,O
demonstration,4900,O
that,4900,O
sorafenib,4900,B-CHEMICAL
exhibits,4900,O
potent,4900,O
target,4900,O
inhibition,4900,O
and,4900,O
efficacy,4900,O
in,4900,O
FLT3-driven,4900,B-GENE-Y
models,4900,O
suggests,4900,O
that,4900,O
this,4900,O
compound,4900,O
may,4900,O
have,4900,O
a,4900,O
therapeutic,4900,O
benefit,4900,O
for,4900,O
patients,4900,O
with,4900,O
FLT3-driven,4900,B-GENE-Y
leukemias,4900,O
.,4900,O
Apoptosis,4901,O
induced,4901,O
neurotoxicity,4901,O
of,4901,O
Di-n-butyl-di-,4901,B-CHEMICAL
(,4901,I-CHEMICAL
4-chlorobenzohydroxamato,4901,I-CHEMICAL
),4901,I-CHEMICAL
Tin,4901,I-CHEMICAL
(,4901,I-CHEMICAL
IV,4901,I-CHEMICAL
),4901,I-CHEMICAL
via,4901,O
mitochondria-mediated,4901,O
pathway,4901,O
in,4901,O
PC12,4901,O
cells,4901,O
.,4901,O
The,4902,O
severe,4902,O
toxicity,4902,O
of,4902,O
antitumor,4902,O
organotin,4902,B-CHEMICAL
(,4902,I-CHEMICAL
IV,4902,I-CHEMICAL
),4902,I-CHEMICAL
compounds,4902,O
limits,4902,O
their,4902,O
application,4902,O
in,4902,O
clinic,4902,O
",",4902,O
however,4902,O
",",4902,O
the,4902,O
toxic,4902,O
mechanism,4902,O
is,4902,O
still,4902,O
unclear,4902,O
.,4902,O
Di-n-butyl-di-,4903,B-CHEMICAL
(,4903,I-CHEMICAL
4-chlorobenzohydroxamato,4903,I-CHEMICAL
),4903,I-CHEMICAL
Tin,4903,I-CHEMICAL
(,4903,I-CHEMICAL
IV,4903,I-CHEMICAL
),4903,I-CHEMICAL
(,4903,O
DBDCT,4903,B-CHEMICAL
),4903,O
",",4903,O
an,4903,O
antitumor,4903,O
agent,4903,O
with,4903,O
high,4903,O
activity,4903,O
and,4903,O
obvious,4903,O
neurotoxicity,4903,O
was,4903,O
chosen,4903,O
as,4903,O
a,4903,O
typical,4903,O
diorganotin,4903,B-CHEMICAL
(,4903,I-CHEMICAL
IV,4903,I-CHEMICAL
),4903,I-CHEMICAL
compound,4903,O
to,4903,O
investigate,4903,O
its,4903,O
neurotoxic,4903,O
mechanism,4903,O
using,4903,O
PC12,4903,O
cells,4903,O
and,4903,O
comprehensive,4903,O
methods,4903,O
.,4903,O
Treatment,4904,O
with,4904,O
DBDCT,4904,B-CHEMICAL
resulted,4904,O
in,4904,O
a,4904,O
dose-,4904,O
and,4904,O
time-dependent,4904,O
growth,4904,O
inhibition,4904,O
of,4904,O
PC12,4904,O
cells,4904,O
.,4904,O
The,4905,O
changes,4905,O
in,4905,O
cell,4905,O
morphology,4905,O
were,4905,O
observed,4905,O
using,4905,O
light,4905,O
microscopy,4905,O
",",4905,O
fluorescence,4905,O
microscopy,4905,O
and,4905,O
transmission,4905,O
electron,4905,O
microscopy,4905,O
.,4905,O
PC12,4906,O
cell,4906,O
apoptosis,4906,O
induced,4906,O
by,4906,O
DBDCT,4906,B-CHEMICAL
was,4906,O
confirmed,4906,O
by,4906,O
annexin,4906,O
V/propidium,4906,O
iodide,4906,I-CHEMICAL
staining,4906,O
",",4906,O
and,4906,O
characterized,4906,O
by,4906,O
cleavage,4906,O
of,4906,O
caspase-9,4906,B-GENE-Y
and,4906,O
caspase-3,4906,B-GENE-Y
proteins,4906,O
.,4906,O
DBDCT,4907,B-CHEMICAL
induced,4907,O
the,4907,O
release,4907,O
of,4907,O
cytochrome,4907,B-GENE-Y
c,4907,I-GENE-Y
from,4907,O
the,4907,O
mitochondria,4907,O
to,4907,O
the,4907,O
cytosol,4907,O
and,4907,O
the,4907,O
generation,4907,O
of,4907,O
reactive,4907,O
oxygen,4907,B-CHEMICAL
species,4907,O
.,4907,O
DBDCT,4908,B-CHEMICAL
up-regulated,4908,O
the,4908,O
expression,4908,O
of,4908,O
Bax,4908,B-GENE-Y
",",4908,O
down-regulated,4908,O
the,4908,O
expression,4908,O
of,4908,O
Bcl-2,4908,B-GENE-Y
",",4908,O
and,4908,O
significantly,4908,O
increased,4908,O
the,4908,O
ratio,4908,O
of,4908,O
Bax/Bcl-2,4908,B-GENE-Y
.,4908,O
DBDCT,4909,B-CHEMICAL
also,4909,O
caused,4909,O
the,4909,O
phosphorylation,4909,O
of,4909,O
JNK,4909,B-GENE-N
and,4909,O
p38,4909,B-GENE-N
(,4909,O
MAPK,4909,B-GENE-N
),4909,O
.,4909,O
In,4910,O
rats,4910,O
exposed,4910,O
to,4910,O
DBDCT,4910,B-CHEMICAL
",",4910,O
apoptosis,4910,O
was,4910,O
also,4910,O
observed,4910,O
in,4910,O
brain,4910,O
",",4910,O
as,4910,O
shown,4910,O
by,4910,O
the,4910,O
detection,4910,O
of,4910,O
cleaved,4910,O
caspase-9,4910,B-GENE-Y
and,4910,O
caspase-3,4910,B-GENE-Y
proteins,4910,O
and,4910,O
increased,4910,O
TUNEL,4910,O
positive,4910,O
staining,4910,O
.,4910,O
In,4911,O
conclusion,4911,O
",",4911,O
the,4911,O
results,4911,O
demonstrated,4911,O
that,4911,O
DBDCT,4911,B-CHEMICAL
caused,4911,O
the,4911,O
neurotoxicity,4911,O
by,4911,O
inducing,4911,O
apoptosis,4911,O
via,4911,O
mitochondria-mediated,4911,O
pathway,4911,O
.,4911,O
Structure-based,4912,O
design,4912,O
of,4912,O
aliskiren,4912,B-CHEMICAL
",",4912,O
a,4912,O
novel,4912,O
orally,4912,O
effective,4912,O
renin,4912,B-GENE-Y
inhibitor,4912,O
.,4912,O
Hypertension,4913,O
is,4913,O
a,4913,O
major,4913,O
risk,4913,O
factor,4913,O
for,4913,O
cardiovascular,4913,O
diseases,4913,O
such,4913,O
as,4913,O
stroke,4913,O
",",4913,O
myocardial,4913,O
infarction,4913,O
",",4913,O
and,4913,O
heart,4913,O
failure,4913,O
",",4913,O
the,4913,O
leading,4913,O
causes,4913,O
of,4913,O
death,4913,O
in,4913,O
the,4913,O
Western,4913,O
world,4913,O
.,4913,O
Inhibitors,4914,O
of,4914,O
the,4914,O
renin-angiotensin,4914,B-GENE-Y
system,4914,O
(,4914,O
RAS,4914,O
),4914,O
have,4914,O
proven,4914,O
to,4914,O
be,4914,O
successful,4914,O
treatments,4914,O
for,4914,O
hypertension,4914,O
.,4914,O
As,4915,O
renin,4915,B-GENE-Y
specifically,4915,O
catalyses,4915,O
the,4915,O
rate-limiting,4915,O
step,4915,O
of,4915,O
the,4915,O
RAS,4915,O
",",4915,O
it,4915,O
represents,4915,O
the,4915,O
optimal,4915,O
target,4915,O
for,4915,O
RAS,4915,O
inhibition,4915,O
.,4915,O
Several,4916,O
peptide-like,4916,O
renin,4916,B-GENE-Y
inhibitors,4916,O
have,4916,O
been,4916,O
synthesized,4916,O
previously,4916,O
",",4916,O
but,4916,O
poor,4916,O
pharmacokinetic,4916,O
properties,4916,O
meant,4916,O
that,4916,O
these,4916,O
compounds,4916,O
were,4916,O
not,4916,O
clinically,4916,O
useful,4916,O
.,4916,O
We,4917,O
employed,4917,O
a,4917,O
combination,4917,O
of,4917,O
molecular,4917,O
modelling,4917,O
and,4917,O
crystallographic,4917,O
structure,4917,O
analysis,4917,O
to,4917,O
design,4917,O
renin,4917,B-GENE-Y
inhibitors,4917,O
lacking,4917,O
the,4917,O
extended,4917,O
peptide-like,4917,O
backbone,4917,O
of,4917,O
earlier,4917,O
inhibitors,4917,O
",",4917,O
for,4917,O
improved,4917,O
pharmacokinetic,4917,O
properties,4917,O
.,4917,O
This,4918,O
led,4918,O
to,4918,O
the,4918,O
discovery,4918,O
of,4918,O
aliskiren,4918,B-CHEMICAL
",",4918,O
a,4918,O
highly,4918,O
potent,4918,O
and,4918,O
selective,4918,O
inhibitor,4918,O
of,4918,O
human,4918,B-GENE-Y
renin,4918,I-GENE-Y
in,4918,O
vitro,4918,O
",",4918,O
and,4918,O
in,4918,O
vivo,4918,O
;,4918,O
once-daily,4918,O
oral,4918,O
doses,4918,O
of,4918,O
aliskiren,4918,B-CHEMICAL
inhibit,4918,O
renin,4918,B-GENE-Y
and,4918,O
lower,4918,O
blood,4918,O
pressure,4918,O
in,4918,O
sodium-depleted,4918,B-CHEMICAL
marmosets,4918,O
and,4918,O
hypertensive,4918,O
human,4918,O
patients,4918,O
.,4918,O
Aliskiren,4919,B-CHEMICAL
represents,4919,O
the,4919,O
first,4919,O
in,4919,O
a,4919,O
novel,4919,O
class,4919,O
of,4919,O
renin,4919,B-GENE-Y
inhibitors,4919,O
with,4919,O
the,4919,O
potential,4919,O
for,4919,O
treatment,4919,O
of,4919,O
hypertension,4919,O
and,4919,O
related,4919,O
cardiovascular,4919,O
diseases,4919,O
.,4919,O
Functional,4920,O
divergence,4920,O
of,4920,O
a,4920,O
unique,4920,O
C-terminal,4920,B-CHEMICAL
domain,4920,O
of,4920,O
leucyl-tRNA,4920,B-GENE-N
synthetase,4920,I-GENE-N
to,4920,O
accommodate,4920,O
its,4920,O
splicing,4920,O
and,4920,O
aminoacylation,4920,O
roles,4920,O
.,4920,O
Leucyl-tRNA,4921,B-GENE-Y
synthetase,4921,I-GENE-Y
(,4921,O
LeuRS,4921,B-GENE-Y
),4921,O
performs,4921,O
dual,4921,O
essential,4921,O
roles,4921,O
in,4921,O
group,4921,O
I,4921,O
intron,4921,O
RNA,4921,O
splicing,4921,O
as,4921,O
well,4921,O
as,4921,O
protein,4921,O
synthesis,4921,O
within,4921,O
the,4921,O
yeast,4921,O
mitochondria,4921,O
.,4921,O
Deletions,4922,O
of,4922,O
the,4922,O
C,4922,B-CHEMICAL
terminus,4922,O
differentially,4922,O
impact,4922,O
the,4922,O
two,4922,O
functions,4922,O
of,4922,O
the,4922,O
enzyme,4922,O
in,4922,O
splicing,4922,O
and,4922,O
aminoacylation,4922,O
in,4922,O
vivo,4922,O
.,4922,O
Herein,4923,O
",",4923,O
we,4923,O
determined,4923,O
that,4923,O
a,4923,O
fiveamino,4923,B-CHEMICAL
acid,4923,I-CHEMICAL
C-terminal,4923,B-CHEMICAL
deletion,4923,O
of,4923,O
LeuRS,4923,B-GENE-Y
",",4923,O
which,4923,O
does,4923,O
not,4923,O
complement,4923,O
a,4923,O
null,4923,O
strain,4923,O
",",4923,O
can,4923,O
form,4923,O
a,4923,O
ternary,4923,O
complex,4923,O
with,4923,O
the,4923,O
bI4,4923,O
intron,4923,O
and,4923,O
its,4923,O
maturase,4923,O
splicing,4923,O
partner,4923,O
.,4923,O
However,4924,O
",",4924,O
the,4924,O
complex,4924,O
fails,4924,O
to,4924,O
stimulate,4924,O
splicing,4924,O
activity,4924,O
.,4924,O
The,4925,O
x-ray,4925,O
co-crystal,4925,O
structure,4925,O
of,4925,O
LeuRS,4925,B-GENE-Y
showed,4925,O
that,4925,O
a,4925,O
C-terminal,4925,B-CHEMICAL
extension,4925,O
of,4925,O
about,4925,O
60,4925,O
amino,4925,B-CHEMICAL
acids,4925,I-CHEMICAL
forms,4925,O
a,4925,O
discrete,4925,O
domain,4925,O
",",4925,O
which,4925,O
is,4925,O
unique,4925,O
among,4925,O
the,4925,O
LeuRSs,4925,B-GENE-Y
and,4925,O
interacts,4925,O
with,4925,O
the,4925,O
corner,4925,O
of,4925,O
the,4925,O
L-shaped,4925,O
tRNALeu,4925,O
.,4925,O
Interestingly,4926,O
",",4926,O
deletion,4926,O
of,4926,O
the,4926,O
entire,4926,O
yeast,4926,B-GENE-Y
mitochondrial,4926,I-GENE-Y
LeuRS,4926,I-GENE-Y
C-terminal,4926,B-CHEMICAL
domain,4926,O
enhanced,4926,O
its,4926,O
aminoacylation,4926,O
and,4926,O
amino,4926,B-CHEMICAL
acid,4926,I-CHEMICAL
editing,4926,O
activities,4926,O
.,4926,O
In,4927,O
striking,4927,O
contrast,4927,O
",",4927,O
deletion,4927,O
of,4927,O
the,4927,O
corresponding,4927,O
C-terminal,4927,B-CHEMICAL
domain,4927,O
of,4927,O
Escherichia,4927,B-GENE-Y
coli,4927,I-GENE-Y
LeuRS,4927,I-GENE-Y
abolished,4927,O
aminoacylation,4927,O
of,4927,O
tRNALeu,4927,O
and,4927,O
also,4927,O
amino,4927,B-CHEMICAL
acid,4927,I-CHEMICAL
editing,4927,O
of,4927,O
mischarged,4927,O
tRNA,4927,O
molecules,4927,O
.,4927,O
These,4928,O
results,4928,O
suggest,4928,O
that,4928,O
the,4928,O
role,4928,O
of,4928,O
the,4928,O
leucine-specific,4928,B-CHEMICAL
C-terminal,4928,B-CHEMICAL
domain,4928,O
in,4928,O
tRNA,4928,O
recognition,4928,O
for,4928,O
aminoacylation,4928,O
and,4928,O
amino,4928,B-CHEMICAL
acid,4928,I-CHEMICAL
editing,4928,O
has,4928,O
adapted,4928,O
differentially,4928,O
and,4928,O
with,4928,O
surprisingly,4928,O
opposite,4928,O
effects,4928,O
.,4928,O
We,4929,O
propose,4929,O
that,4929,O
the,4929,O
secondary,4929,O
role,4929,O
of,4929,O
yeast,4929,B-GENE-Y
mitochondrial,4929,I-GENE-Y
LeuRS,4929,I-GENE-Y
in,4929,O
RNA,4929,O
splicing,4929,O
has,4929,O
impacted,4929,O
the,4929,O
functional,4929,O
evolution,4929,O
of,4929,O
this,4929,O
critical,4929,O
C-terminal,4929,B-CHEMICAL
domain,4929,O
.,4929,O
Everolimus,4930,B-CHEMICAL
:,4930,O
the,4930,O
first,4930,O
approved,4930,O
product,4930,O
for,4930,O
patients,4930,O
with,4930,O
advanced,4930,O
renal,4930,O
cell,4930,O
cancer,4930,O
after,4930,O
sunitinib,4930,B-CHEMICAL
and/or,4930,O
sorafenib,4930,B-CHEMICAL
.,4930,O
Everolimus,4931,B-CHEMICAL
(,4931,O
RAD001,4931,B-CHEMICAL
",",4931,O
Afinitor,4931,B-CHEMICAL
(,4931,I-CHEMICAL
(,4931,I-CHEMICAL
R,4931,I-CHEMICAL
),4931,I-CHEMICAL
),4931,I-CHEMICAL
Novartis,4931,I-CHEMICAL
),4931,O
is,4931,O
the,4931,O
first,4931,O
oral,4931,O
inhibitor,4931,O
of,4931,O
mTOR,4931,B-GENE-Y
(,4931,O
mammalian,4931,B-GENE-Y
target,4931,I-GENE-Y
of,4931,I-GENE-Y
rapamycin,4931,I-GENE-Y
),4931,O
to,4931,O
reach,4931,O
the,4931,O
oncology,4931,O
clinic,4931,O
.,4931,O
Everolimus,4932,B-CHEMICAL
10,4932,O
mg,4932,O
daily,4932,O
achieves,4932,O
complete,4932,O
inhibition,4932,O
of,4932,O
its,4932,O
target,4932,O
at,4932,O
below,4932,O
the,4932,O
maximum,4932,O
tolerable,4932,O
dose,4932,O
for,4932,O
most,4932,O
patients,4932,O
.,4932,O
A,4933,O
phase,4933,O
III,4933,O
randomized,4933,O
placebo-controlled,4933,O
trial,4933,O
has,4933,O
examined,4933,O
the,4933,O
impact,4933,O
of,4933,O
everolimus,4933,B-CHEMICAL
in,4933,O
patients,4933,O
with,4933,O
clear,4933,O
cell,4933,O
renal,4933,O
cancers,4933,O
and,4933,O
progressive,4933,O
disease,4933,O
on,4933,O
or,4933,O
within,4933,O
6,4933,O
months,4933,O
of,4933,O
the,4933,O
VEGFR,4933,B-GENE-N
tyrosine,4933,B-GENE-N
kinase,4933,I-GENE-N
inhibitors,4933,O
sunitinib,4933,B-CHEMICAL
and/or,4933,O
sorafenib,4933,B-CHEMICAL
.,4933,O
The,4934,O
primary,4934,O
endpoint,4934,O
of,4934,O
progression-free,4934,O
survival,4934,O
was,4934,O
increased,4934,O
from,4934,O
median,4934,O
1.9,4934,O
to,4934,O
4.9,4934,O
months,4934,O
(,4934,O
hazard,4934,O
ratio,4934,O
0.33,4934,O
",",4934,O
P,4934,O
<,4934,O
0.001,4934,O
),4934,O
and,4934,O
25,4934,O
%,4934,O
were,4934,O
still,4934,O
progression-free,4934,O
after,4934,O
10,4934,O
months,4934,O
of,4934,O
everolimus,4934,B-CHEMICAL
therapy,4934,O
.,4934,O
There,4935,O
was,4935,O
a,4935,O
delay,4935,O
in,4935,O
time,4935,O
to,4935,O
decline,4935,O
of,4935,O
performance,4935,O
status,4935,O
and,4935,O
trends,4935,O
to,4935,O
improvement,4935,O
in,4935,O
quality,4935,O
of,4935,O
life,4935,O
",",4935,O
disease-related,4935,O
symptoms,4935,O
",",4935,O
and,4935,O
overall,4935,O
survival,4935,O
despite,4935,O
crossover,4935,O
of,4935,O
the,4935,O
majority,4935,O
of,4935,O
patients,4935,O
assigned,4935,O
to,4935,O
placebo,4935,O
.,4935,O
In,4936,O
2009,4936,O
",",4936,O
everolimus,4936,B-CHEMICAL
was,4936,O
approved,4936,O
in,4936,O
the,4936,O
US,4936,O
and,4936,O
Europe,4936,O
as,4936,O
the,4936,O
only,4936,O
validated,4936,O
option,4936,O
for,4936,O
this,4936,O
indication,4936,O
.,4936,O
Toxicities,4937,O
are,4937,O
usually,4937,O
mild,4937,O
to,4937,O
moderate,4937,O
and,4937,O
can,4937,O
be,4937,O
managed,4937,O
with,4937,O
dose,4937,O
reduction,4937,O
or,4937,O
interruption,4937,O
if,4937,O
necessary,4937,O
.,4937,O
Opportunistic,4938,O
infections,4938,O
and,4938,O
non-infectious,4938,O
pneumonitis,4938,O
are,4938,O
seen,4938,O
as,4938,O
a,4938,O
class,4938,O
effect,4938,O
.,4938,O
Management,4939,O
of,4939,O
common,4939,O
practical,4939,O
management,4939,O
issues,4939,O
are,4939,O
discussed,4939,O
.,4939,O
Clinical,4940,O
trials,4940,O
are,4940,O
in,4940,O
progress,4940,O
to,4940,O
examine,4940,O
additional,4940,O
roles,4940,O
for,4940,O
everolimus,4940,B-CHEMICAL
in,4940,O
renal,4940,O
cancer,4940,O
",",4940,O
alone,4940,O
and,4940,O
in,4940,O
combination,4940,O
with,4940,O
other,4940,O
agents,4940,O
.,4940,O
Anti-aging,4941,O
molecule,4941,O
",",4941,O
Sirt1,4941,B-GENE-Y
:,4941,O
a,4941,O
novel,4941,O
therapeutic,4941,O
target,4941,O
for,4941,O
diabetic,4941,O
nephropathy,4941,O
.,4941,O
Caloric,4942,O
restriction,4942,O
prolongs,4942,O
the,4942,O
lifespan,4942,O
of,4942,O
many,4942,O
species,4942,O
.,4942,O
Therefore,4943,O
",",4943,O
investigators,4943,O
have,4943,O
researched,4943,O
the,4943,O
usefulness,4943,O
of,4943,O
caloric,4943,O
restriction,4943,O
for,4943,O
healthy,4943,O
lifespan,4943,O
extension,4943,O
.,4943,O
Sirt1,4944,B-GENE-Y
",",4944,O
an,4944,O
NAD,4944,B-GENE-N
(,4944,I-GENE-N
+,4944,I-GENE-N
),4944,I-GENE-N
-dependent,4944,I-GENE-N
deacetylase,4944,I-GENE-N
",",4944,O
was,4944,O
identified,4944,O
as,4944,O
a,4944,O
molecule,4944,O
necessary,4944,O
for,4944,O
caloric,4944,O
restriction-related,4944,O
anti-aging,4944,O
strategies,4944,O
.,4944,O
Sirt1,4945,B-GENE-Y
functions,4945,O
as,4945,O
an,4945,O
intracellular,4945,O
energy,4945,O
sensor,4945,O
to,4945,O
detect,4945,O
the,4945,O
concentration,4945,O
of,4945,O
NAD,4945,B-CHEMICAL
(,4945,I-CHEMICAL
+,4945,I-CHEMICAL
),4945,I-CHEMICAL
",",4945,O
and,4945,O
controls,4945,O
in,4945,O
vivo,4945,O
metabolic,4945,O
changes,4945,O
under,4945,O
caloric,4945,O
restriction,4945,O
and,4945,O
starvation,4945,O
through,4945,O
its,4945,O
deacetylase,4945,B-GENE-N
activity,4945,O
to,4945,O
many,4945,O
targets,4945,O
including,4945,O
histones,4945,B-GENE-N
",",4945,O
nuclear,4945,O
transcriptional,4945,O
factors,4945,O
",",4945,O
and,4945,O
enzymes,4945,O
.,4945,O
During,4946,O
the,4946,O
past,4946,O
decade,4946,O
",",4946,O
investigators,4946,O
have,4946,O
reported,4946,O
the,4946,O
relationship,4946,O
between,4946,O
disturbance,4946,O
of,4946,O
Sirt1,4946,B-GENE-Y
activation,4946,O
and,4946,O
the,4946,O
onset,4946,O
of,4946,O
aging-,4946,O
and,4946,O
obesity-associated,4946,O
diseases,4946,O
such,4946,O
as,4946,O
diabetes,4946,O
",",4946,O
cardiovascular,4946,O
disease,4946,O
and,4946,O
neurodegenerative,4946,O
disorders,4946,O
.,4946,O
Consequently,4947,O
",",4947,O
a,4947,O
calorie,4947,O
restriction-mimetic,4947,O
action,4947,O
of,4947,O
Sirt1,4947,B-GENE-Y
is,4947,O
now,4947,O
expected,4947,O
as,4947,O
a,4947,O
new,4947,O
therapy,4947,O
for,4947,O
these,4947,O
diseases,4947,O
.,4947,O
In,4948,O
addition,4948,O
",",4948,O
recent,4948,O
studies,4948,O
have,4948,O
gradually,4948,O
clarified,4948,O
the,4948,O
role,4948,O
of,4948,O
Sirt1,4948,B-GENE-Y
in,4948,O
the,4948,O
onset,4948,O
of,4948,O
kidney,4948,O
disease,4948,O
.,4948,O
Its,4949,O
activation,4949,O
may,4949,O
also,4949,O
become,4949,O
a,4949,O
new,4949,O
target,4949,O
of,4949,O
treatment,4949,O
in,4949,O
the,4949,O
patients,4949,O
with,4949,O
chronic,4949,O
kidney,4949,O
disease,4949,O
including,4949,O
diabetic,4949,O
nephropathy,4949,O
.,4949,O
In,4950,O
this,4950,O
article,4950,O
",",4950,O
we,4950,O
would,4950,O
like,4950,O
to,4950,O
review,4950,O
the,4950,O
role,4950,O
of,4950,O
Sirt1,4950,B-GENE-Y
in,4950,O
the,4950,O
onset,4950,O
of,4950,O
kidney,4950,O
disease,4950,O
based,4950,O
on,4950,O
previous,4950,O
studies,4950,O
",",4950,O
and,4950,O
discuss,4950,O
its,4950,O
possibility,4950,O
as,4950,O
the,4950,O
target,4950,O
of,4950,O
treatment,4950,O
in,4950,O
diabetic,4950,O
nephropathy,4950,O
.,4950,O
Sucralfate,4951,B-CHEMICAL
:,4951,O
the,4951,O
Bangkok,4951,O
review,4951,O
.,4951,O
Sucralfate,4952,B-CHEMICAL
is,4952,O
a,4952,O
site-protective,4952,O
ulcer,4952,O
healing,4952,O
drug,4952,O
with,4952,O
a,4952,O
remarkable,4952,O
range,4952,O
of,4952,O
mechanisms,4952,O
of,4952,O
action,4952,O
.,4952,O
Recent,4953,O
studies,4953,O
highlight,4953,O
the,4953,O
capacity,4953,O
of,4953,O
sucralfate,4953,B-CHEMICAL
to,4953,O
bind,4953,O
basic,4953,B-GENE-Y
fibroblast,4953,I-GENE-Y
growth,4953,I-GENE-Y
factor,4953,I-GENE-Y
(,4953,O
bFGF,4953,B-GENE-Y
),4953,O
and,4953,O
deliver,4953,O
it,4953,O
in,4953,O
high,4953,O
concentration,4953,O
to,4953,O
the,4953,O
ulcer,4953,O
.,4953,O
Basic,4954,B-GENE-Y
fibroblast,4954,I-GENE-Y
growth,4954,I-GENE-Y
factor,4954,I-GENE-Y
stimulates,4954,O
the,4954,O
production,4954,O
of,4954,O
granulation,4954,O
tissue,4954,O
",",4954,O
angiogenesis,4954,O
and,4954,O
re-epithelization,4954,O
",",4954,O
thus,4954,O
improving,4954,O
the,4954,O
quality,4954,O
of,4954,O
ulcer,4954,O
healing,4954,O
.,4954,O
The,4955,O
effect,4955,O
of,4955,O
sucralfate,4955,B-CHEMICAL
in,4955,O
reducing,4955,O
parietal,4955,O
cell,4955,O
sensitivity,4955,O
may,4955,O
be,4955,O
another,4955,O
factor,4955,O
important,4955,O
in,4955,O
the,4955,O
lower,4955,O
relapse,4955,O
rate,4955,O
demonstrated,4955,O
after,4955,O
duodenal,4955,O
ulcer,4955,O
healing,4955,O
.,4955,O
Sucralfate,4956,B-CHEMICAL
has,4956,O
been,4956,O
demonstrated,4956,O
to,4956,O
be,4956,O
efficacious,4956,O
in,4956,O
healing,4956,O
both,4956,O
duodenal,4956,O
and,4956,O
gastric,4956,O
ulcers,4956,O
together,4956,O
with,4956,O
mild,4956,O
oesophagitis,4956,O
",",4956,O
and,4956,O
it,4956,O
is,4956,O
safe,4956,O
for,4956,O
both,4956,O
short-term,4956,O
use,4956,O
and,4956,O
maintenance,4956,O
.,4956,O
In,4957,O
stress,4957,O
ulcer,4957,O
prophylaxis,4957,O
it,4957,O
is,4957,O
as,4957,O
effective,4957,O
as,4957,O
acid,4957,O
suppression,4957,O
or,4957,O
neutralization,4957,O
and,4957,O
has,4957,O
the,4957,O
advantage,4957,O
of,4957,O
lesser,4957,O
rates,4957,O
of,4957,O
nosocomial,4957,O
pneumonia,4957,O
than,4957,O
are,4957,O
demonstrated,4957,O
with,4957,O
antacids,4957,O
or,4957,O
H2,4957,O
antagonists,4957,O
.,4957,O
The,4958,O
potential,4958,O
advantages,4958,O
of,4958,O
sucralfate,4958,B-CHEMICAL
lie,4958,O
in,4958,O
the,4958,O
better,4958,O
quality,4958,O
of,4958,O
ulcer,4958,O
healing,4958,O
associated,4958,O
with,4958,O
longer,4958,O
duration,4958,O
of,4958,O
remission,4958,O
.,4958,O
Synthesis,4959,O
and,4959,O
structure-activity,4959,O
relationship,4959,O
of,4959,O
pyripyropene,4959,B-CHEMICAL
A,4959,I-CHEMICAL
derivatives,4959,O
as,4959,O
potent,4959,O
and,4959,O
selective,4959,O
acyl-CoA,4959,B-GENE-Y
:,4959,I-GENE-Y
cholesterol,4959,I-GENE-Y
acyltransferase,4959,I-GENE-Y
2,4959,I-GENE-Y
(,4959,O
ACAT2,4959,B-GENE-Y
),4959,O
inhibitors,4959,O
:,4959,O
Part,4959,O
2,4959,O
.,4959,O
Synthesis,4960,O
and,4960,O
structure-activity,4960,O
relationships,4960,O
of,4960,O
7-O-p-cyanobenzoyl,4960,B-CHEMICAL
pyripyropene,4960,I-CHEMICAL
A,4960,I-CHEMICAL
derivatives,4960,O
with,4960,O
modification,4960,O
at,4960,O
C1,4960,O
and,4960,O
11,4960,O
are,4960,O
described,4960,O
.,4960,O
Regioselective,4961,O
mono-deprotection,4961,O
of,4961,O
di-tert-butylsilylene,4961,B-CHEMICAL
acetal,4961,I-CHEMICAL
was,4961,O
critical,4961,O
in,4961,O
their,4961,O
synthesis,4961,O
.,4961,O
Involvement,4962,O
of,4962,O
pertussis,4962,B-GENE-N
toxin-sensitive,4962,O
G-proteins,4962,B-GENE-N
in,4962,O
the,4962,O
hormonal,4962,O
inhibition,4962,O
of,4962,O
dihydropyridine-sensitive,4962,B-CHEMICAL
Ca2+,4962,B-CHEMICAL
currents,4962,O
in,4962,O
an,4962,O
insulin-secreting,4962,B-GENE-Y
cell,4962,O
line,4962,O
(,4962,O
RINm5F,4962,O
),4962,O
.,4962,O
Adrenaline,4963,B-CHEMICAL
inhibits,4963,O
insulin,4963,B-GENE-Y
secretion,4963,O
via,4963,O
pertussis,4963,O
toxin-sensitive,4963,O
mechanisms,4963,O
.,4963,O
Since,4964,O
voltage-dependent,4964,O
Ca2+,4964,B-CHEMICAL
currents,4964,O
play,4964,O
a,4964,O
key,4964,O
role,4964,O
in,4964,O
insulin,4964,B-GENE-Y
secretion,4964,O
",",4964,O
we,4964,O
examined,4964,O
whether,4964,O
adrenaline,4964,B-CHEMICAL
modulates,4964,O
voltage-dependent,4964,O
Ca2+,4964,B-CHEMICAL
currents,4964,O
of,4964,O
the,4964,O
rat,4964,O
insulinoma,4964,O
cell,4964,O
line,4964,O
",",4964,O
RINm5F,4964,O
.,4964,O
In,4965,O
the,4965,O
whole-cell,4965,O
configuration,4965,O
of,4965,O
the,4965,O
patch-clamp,4965,O
technique,4965,O
",",4965,O
dihydropyridine-,4965,B-CHEMICAL
but,4965,O
not,4965,O
omega-conotoxin-sensitive,4965,O
Ca2+,4965,B-CHEMICAL
currents,4965,O
were,4965,O
identified,4965,O
.,4965,O
Adrenaline,4966,B-CHEMICAL
via,4966,O
alpha,4966,B-GENE-N
2-adrenoceptors,4966,I-GENE-N
inhibited,4966,O
the,4966,O
Ca2+,4966,B-CHEMICAL
currents,4966,O
by,4966,O
about,4966,O
50,4966,O
%,4966,O
.,4966,O
Somatostatin,4967,B-GENE-Y
which,4967,O
also,4967,O
inhibits,4967,O
insulin,4967,B-GENE-Y
secretion,4967,O
was,4967,O
less,4967,O
efficient,4967,O
(,4967,O
inhibition,4967,O
by,4967,O
20,4967,O
%,4967,O
),4967,O
.,4967,O
The,4968,O
hormonal,4968,O
inhibition,4968,O
of,4968,O
Ca2+,4968,B-CHEMICAL
currents,4968,O
was,4968,O
not,4968,O
affected,4968,O
by,4968,O
intracellularly,4968,O
applied,4968,O
cAMP,4968,B-CHEMICAL
but,4968,O
blocked,4968,O
by,4968,O
the,4968,O
intracellularly,4968,O
applied,4968,O
GDP,4968,B-CHEMICAL
analog,4968,O
guanosine,4968,B-CHEMICAL
5'-O-,4968,I-CHEMICAL
(,4968,I-CHEMICAL
2-thiodiphosphate,4968,I-CHEMICAL
),4968,I-CHEMICAL
and,4968,O
by,4968,O
pretreatment,4968,O
of,4968,O
cells,4968,O
with,4968,O
pertussis,4968,B-GENE-N
toxin,4968,I-GENE-N
.,4968,O
In,4969,O
contrast,4969,O
to,4969,O
adrenaline,4969,B-CHEMICAL
and,4969,O
somatostatin,4969,B-GENE-Y
",",4969,O
galanin,4969,B-GENE-Y
",",4969,O
another,4969,O
inhibitor,4969,O
of,4969,O
insulin,4969,B-GENE-Y
secretion,4969,O
",",4969,O
reduced,4969,O
Ca2+,4969,B-CHEMICAL
currents,4969,O
by,4969,O
about,4969,O
40,4969,O
%,4969,O
in,4969,O
a,4969,O
pertussis,4969,B-GENE-N
toxin-insensitive,4969,O
manner,4969,O
.,4969,O
Immunoblot,4970,O
experiments,4970,O
performed,4970,O
with,4970,O
antibodies,4970,O
generated,4970,O
against,4970,O
synthetic,4970,O
peptides,4970,O
revealed,4970,O
that,4970,O
membranes,4970,O
of,4970,O
RINm5F,4970,O
cells,4970,O
possess,4970,O
four,4970,O
pertussis,4970,B-GENE-N
toxin-sensitive,4970,O
G-proteins,4970,B-GENE-N
including,4970,O
Gi1,4970,B-GENE-Y
",",4970,O
Gi2,4970,B-GENE-Y
",",4970,O
Go2,4970,B-GENE-Y
",",4970,O
and,4970,O
another,4970,O
Go,4970,B-GENE-N
subtype,4970,O
",",4970,O
most,4970,O
likely,4970,O
representing,4970,O
Go1,4970,B-GENE-Y
.,4970,O
In,4971,O
membranes,4971,O
of,4971,O
control,4971,O
but,4971,O
not,4971,O
of,4971,O
pertussis,4971,B-GENE-N
toxin-treated,4971,O
cells,4971,O
",",4971,O
adrenaline,4971,B-CHEMICAL
via,4971,O
alpha,4971,B-GENE-N
2-adrenoceptors,4971,I-GENE-N
stimulated,4971,O
incorporation,4971,O
of,4971,O
the,4971,O
photo-reactive,4971,O
GTP,4971,B-CHEMICAL
analog,4971,O
[,4971,B-CHEMICAL
alpha-32P,4971,I-CHEMICAL
],4971,I-CHEMICAL
GTP,4971,I-CHEMICAL
azidoanilide,4971,I-CHEMICAL
into,4971,O
pertussis,4971,O
toxin,4971,O
substrates,4971,O
comigrating,4971,O
with,4971,O
the,4971,O
alpha-subunits,4971,O
of,4971,O
Gi2,4971,B-GENE-Y
",",4971,O
Go2,4971,B-GENE-Y
",",4971,O
and,4971,O
the,4971,O
not,4971,O
further,4971,O
identified,4971,O
Go,4971,B-GENE-N
subtype,4971,O
.,4971,O
The,4972,O
present,4972,O
findings,4972,O
indicate,4972,O
that,4972,O
activated,4972,O
alpha,4972,B-GENE-N
2-adrenoceptors,4972,I-GENE-N
of,4972,O
RINm5F,4972,O
cells,4972,O
interact,4972,O
with,4972,O
multiple,4972,O
G-proteins,4972,B-GENE-N
",",4972,O
i.e,4972,O
.,4972,O
two,4973,O
forms,4973,O
of,4973,O
Go,4973,B-GENE-N
and,4973,O
with,4973,O
Gi2,4973,B-GENE-Y
.,4973,O
These,4974,O
G-proteins,4974,B-GENE-N
are,4974,O
likely,4974,O
to,4974,O
be,4974,O
involved,4974,O
in,4974,O
the,4974,O
adrenaline-induced,4974,B-CHEMICAL
inhibition,4974,O
of,4974,O
dihydropyridine-sensitive,4974,B-CHEMICAL
Ca2+,4974,B-CHEMICAL
currents,4974,O
and,4974,O
in,4974,O
other,4974,O
signal,4974,O
transduction,4974,O
pathways,4974,O
contributing,4974,O
to,4974,O
the,4974,O
adrenaline-induced,4974,B-CHEMICAL
inhibition,4974,O
of,4974,O
insulin,4974,B-GENE-Y
secretion,4974,O
.,4974,O
Synthesis,4975,O
and,4975,O
in,4975,O
Vitro,4975,O
Characterisation,4975,O
of,4975,O
Ifenprodil-Based,4975,B-CHEMICAL
Fluorescein,4975,B-CHEMICAL
Conjugates,4975,O
as,4975,O
GluN1/GluN2B,4975,B-GENE-Y
N-Methyl-D-aspartate,4975,B-GENE-N
Receptor,4975,I-GENE-N
Antagonists,4975,O
.,4975,O
GluN2B-containing,4976,B-GENE-Y
NMDA,4976,B-GENE-N
receptors,4976,I-GENE-N
are,4976,O
involved,4976,O
in,4976,O
many,4976,O
important,4976,O
physiological,4976,O
functions,4976,O
and,4976,O
play,4976,O
a,4976,O
pivotal,4976,O
role,4976,O
in,4976,O
mediating,4976,O
pain,4976,O
as,4976,O
well,4976,O
as,4976,O
in,4976,O
several,4976,O
neurodegenerative,4976,O
disorders,4976,O
.,4976,O
We,4977,O
aimed,4977,O
to,4977,O
develop,4977,O
fluorescent,4977,O
probes,4977,O
to,4977,O
target,4977,O
the,4977,O
GluN2B,4977,B-GENE-Y
subunit,4977,O
selectively,4977,O
in,4977,O
order,4977,O
to,4977,O
allow,4977,O
better,4977,O
understanding,4977,O
of,4977,O
the,4977,O
relationships,4977,O
between,4977,O
receptor,4977,O
localisation,4977,O
and,4977,O
physiological,4977,O
importance,4977,O
.,4977,O
Ifenprodil,4978,B-CHEMICAL
",",4978,O
known,4978,O
as,4978,O
the,4978,O
GluNR2B,4978,B-GENE-Y
antagonist,4978,O
of,4978,O
reference,4978,O
",",4978,O
was,4978,O
chosen,4978,O
as,4978,O
the,4978,O
template,4978,O
for,4978,O
the,4978,O
elaboration,4978,O
of,4978,O
probes,4978,O
.,4978,O
We,4979,O
had,4979,O
previously,4979,O
reported,4979,O
a,4979,O
fluorescein,4979,B-CHEMICAL
conjugate,4979,O
that,4979,O
was,4979,O
shown,4979,O
(,4979,O
by,4979,O
confocal,4979,O
microscopy,4979,O
imaging,4979,O
of,4979,O
DS-red-labelled,4979,O
cortical,4979,O
neurons,4979,O
),4979,O
to,4979,O
bind,4979,O
specifically,4979,O
to,4979,O
GluN2B,4979,B-GENE-Y
.,4979,O
To,4980,O
elaborate,4980,O
this,4980,O
probe,4980,O
",",4980,O
we,4980,O
explored,4980,O
the,4980,O
influence,4980,O
of,4980,O
both,4980,O
the,4980,O
nature,4980,O
and,4980,O
the,4980,O
attachment,4980,O
point,4980,O
of,4980,O
the,4980,O
spacer,4980,O
between,4980,O
the,4980,O
fluorophore,4980,O
and,4980,O
the,4980,O
parent,4980,O
compound,4980,O
",",4980,O
ifenprodil,4980,B-CHEMICAL
.,4980,O
We,4981,O
performed,4981,O
chemical,4981,O
modifications,4981,O
of,4981,O
ifenprodil,4981,B-CHEMICAL
at,4981,O
the,4981,O
benzylic,4981,B-CHEMICAL
position,4981,O
and,4981,O
on,4981,O
the,4981,O
phenol,4981,B-CHEMICAL
ring,4981,O
by,4981,O
introducing,4981,O
secondary,4981,B-CHEMICAL
amine,4981,I-CHEMICAL
or,4981,I-CHEMICAL
amide,4981,I-CHEMICAL
functions,4981,O
and,4981,O
evaluated,4981,O
alkyl,4981,O
chains,4981,O
from,4981,O
two,4981,O
to,4981,O
20,4981,O
bonds,4981,O
either,4981,O
including,4981,O
or,4981,O
not,4981,O
including,4981,O
secondary,4981,B-CHEMICAL
amide,4981,I-CHEMICAL
functions,4981,O
as,4981,O
spacers,4981,O
.,4981,O
The,4982,O
previously,4982,O
developed,4982,O
probe,4982,O
was,4982,O
found,4982,O
to,4982,O
display,4982,O
the,4982,O
greatest,4982,O
activity,4982,O
in,4982,O
the,4982,O
inhibition,4982,O
of,4982,O
NMDA-induced,4982,B-CHEMICAL
Ca,4982,B-CHEMICAL
(,4982,I-CHEMICAL
2+,4982,I-CHEMICAL
),4982,I-CHEMICAL
influx,4982,O
by,4982,O
calcium,4982,B-CHEMICAL
imaging,4982,O
experiments,4982,O
on,4982,O
HEK293,4982,O
cells,4982,O
transfected,4982,O
with,4982,O
the,4982,O
cDNA,4982,O
encoding,4982,O
for,4982,O
GluN1-1A,4982,B-GENE-Y
and,4982,O
GluN2B,4982,B-GENE-Y
.,4982,O
Further,4983,O
investigations,4983,O
revealed,4983,O
that,4983,O
this,4983,O
probe,4983,O
had,4983,O
a,4983,O
neuroprotective,4983,O
effect,4983,O
equivalent,4983,O
to,4983,O
that,4983,O
of,4983,O
ifenprodil,4983,B-CHEMICAL
in,4983,O
a,4983,O
standard,4983,O
test,4983,O
for,4983,O
neurotoxicity,4983,O
.,4983,O
Despite,4984,O
effects,4984,O
of,4984,O
lesser,4984,O
amplitude,4984,O
with,4984,O
these,4984,O
probes,4984,O
relative,4984,O
to,4984,O
ifenprodil,4984,B-CHEMICAL
",",4984,O
we,4984,O
demonstrated,4984,O
that,4984,O
they,4984,O
displaced,4984,O
[,4984,B-CHEMICAL
(,4984,I-CHEMICAL
3,4984,I-CHEMICAL
),4984,I-CHEMICAL
H,4984,I-CHEMICAL
],4984,I-CHEMICAL
ifenprodil,4984,I-CHEMICAL
in,4984,O
mouse,4984,O
brain,4984,O
slices,4984,O
in,4984,O
a,4984,O
similar,4984,O
manner,4984,O
.,4984,O
Conformational,4985,O
epitopes,4985,O
on,4985,O
the,4985,O
diabetes,4985,O
autoantigen,4985,O
GAD65,4985,B-GENE-Y
identified,4985,O
by,4985,O
peptide,4985,O
phage,4985,O
display,4985,O
and,4985,O
molecular,4985,O
modeling,4985,O
.,4985,O
The,4986,O
major,4986,B-GENE-N
diabetes,4986,I-GENE-N
autoantigen,4986,I-GENE-N
",",4986,O
glutamic,4986,B-GENE-N
acid,4986,I-GENE-N
decarboxylase,4986,I-GENE-N
(,4986,O
GAD65,4986,B-GENE-Y
),4986,O
",",4986,O
contains,4986,O
a,4986,O
region,4986,O
of,4986,O
sequence,4986,O
similarity,4986,O
",",4986,O
including,4986,O
six,4986,O
identical,4986,O
residues,4986,O
PEVKEK,4986,B-GENE-N
",",4986,O
to,4986,O
the,4986,O
P2C,4986,B-GENE-Y
protein,4986,I-GENE-Y
of,4986,O
coxsackie,4986,O
B,4986,O
virus,4986,O
",",4986,O
suggesting,4986,O
that,4986,O
cross-reactivity,4986,O
between,4986,O
coxsackie,4986,O
B,4986,O
virus,4986,O
and,4986,O
GAD65,4986,B-GENE-Y
can,4986,O
initiate,4986,O
autoimmune,4986,O
diabetes,4986,O
.,4986,O
We,4987,O
used,4987,O
the,4987,O
human,4987,O
islet,4987,O
cell,4987,O
mAbs,4987,O
MICA3,4987,O
and,4987,O
MICA4,4987,O
to,4987,O
identify,4987,O
the,4987,O
Ab,4987,O
epitopes,4987,O
of,4987,O
GAD65,4987,B-GENE-Y
by,4987,O
screening,4987,O
phage-displayed,4987,O
random,4987,O
peptide,4987,O
libraries,4987,O
.,4987,O
The,4988,O
identified,4988,O
peptide,4988,O
sequences,4988,O
could,4988,O
be,4988,O
mapped,4988,O
to,4988,O
a,4988,O
homology,4988,O
model,4988,O
of,4988,O
the,4988,O
pyridoxal,4988,B-GENE-N
phosphate,4988,I-GENE-N
(,4988,I-GENE-N
PLP,4988,I-GENE-N
),4988,I-GENE-N
binding,4988,I-GENE-N
domain,4988,I-GENE-N
of,4988,O
GAD65,4988,B-GENE-Y
.,4988,O
For,4989,O
MICA3,4989,O
",",4989,O
a,4989,O
surface,4989,O
loop,4989,O
containing,4989,O
the,4989,O
sequence,4989,O
PEVKEK,4989,B-GENE-N
and,4989,O
two,4989,O
adjacent,4989,O
exposed,4989,O
helixes,4989,O
were,4989,O
identified,4989,O
in,4989,O
the,4989,O
PLP,4989,B-GENE-N
binding,4989,I-GENE-N
domain,4989,I-GENE-N
as,4989,O
well,4989,O
as,4989,O
a,4989,O
region,4989,O
of,4989,O
the,4989,O
C,4989,B-CHEMICAL
terminus,4989,O
of,4989,O
GAD65,4989,B-GENE-Y
that,4989,O
has,4989,O
previously,4989,O
been,4989,O
identified,4989,O
as,4989,O
critical,4989,O
for,4989,O
MICA3,4989,O
binding,4989,O
.,4989,O
To,4990,O
confirm,4990,O
that,4990,O
the,4990,O
loop,4990,O
containing,4990,O
the,4990,O
PEVKEK,4990,B-GENE-N
sequence,4990,O
contributes,4990,O
to,4990,O
the,4990,O
MICA3,4990,O
epitope,4990,O
",",4990,O
this,4990,O
loop,4990,O
was,4990,O
deleted,4990,O
by,4990,O
mutagenesis,4990,O
.,4990,O
This,4991,O
reduced,4991,O
binding,4991,O
of,4991,O
MICA3,4991,O
by,4991,O
70,4991,O
%,4991,O
.,4991,O
Peptide,4992,O
sequences,4992,O
selected,4992,O
using,4992,O
MICA4,4992,O
were,4992,O
rich,4992,O
in,4992,O
basic,4992,O
or,4992,O
hydroxyl-containing,4992,B-CHEMICAL
amino,4992,B-CHEMICAL
acids,4992,I-CHEMICAL
",",4992,O
and,4992,O
the,4992,O
surface,4992,O
of,4992,O
the,4992,O
GAD65,4992,B-GENE-N
PLP-binding,4992,I-GENE-N
domain,4992,I-GENE-N
surrounding,4992,O
Lys358,4992,O
",",4992,O
which,4992,O
is,4992,O
known,4992,O
to,4992,O
be,4992,O
critical,4992,O
for,4992,O
MICA4,4992,O
binding,4992,O
",",4992,O
was,4992,O
likewise,4992,O
rich,4992,O
in,4992,O
these,4992,O
amino,4992,B-CHEMICAL
acids,4992,I-CHEMICAL
.,4992,O
Also,4993,O
",",4993,O
the,4993,O
two,4993,O
phage,4993,O
most,4993,O
reactive,4993,O
with,4993,O
MICA4,4993,O
encoded,4993,O
the,4993,O
motif,4993,O
VALxG,4993,B-GENE-N
",",4993,O
and,4993,O
the,4993,O
reverse,4993,O
of,4993,O
this,4993,O
sequence,4993,O
",",4993,O
LAV,4993,B-GENE-N
",",4993,O
was,4993,O
located,4993,O
in,4993,O
this,4993,O
same,4993,O
region,4993,O
.,4993,O
Thus,4994,O
",",4994,O
we,4994,O
have,4994,O
defined,4994,O
the,4994,O
MICA3,4994,O
and,4994,O
MICA4,4994,O
epitopes,4994,O
on,4994,O
GAD65,4994,B-GENE-Y
using,4994,O
the,4994,O
combination,4994,O
of,4994,O
phage,4994,O
display,4994,O
",",4994,O
molecular,4994,O
modeling,4994,O
",",4994,O
and,4994,O
mutagenesis,4994,O
and,4994,O
have,4994,O
provided,4994,O
compelling,4994,O
evidence,4994,O
for,4994,O
the,4994,O
involvement,4994,O
of,4994,O
the,4994,O
PEVKEK,4994,B-GENE-N
loop,4994,O
in,4994,O
the,4994,O
MICA3,4994,O
epitope,4994,O
.,4994,O
Molecular,4995,O
determinants,4995,O
for,4995,O
the,4995,O
selective,4995,O
inhibition,4995,O
of,4995,O
cyclooxygenase-2,4995,B-GENE-Y
by,4995,O
lumiracoxib,4995,B-CHEMICAL
.,4995,O
Lumiracoxib,4996,B-CHEMICAL
is,4996,O
the,4996,O
first,4996,O
example,4996,O
of,4996,O
a,4996,O
marketed,4996,O
COX-2,4996,B-GENE-Y
inhibitor,4996,O
of,4996,O
the,4996,O
arylacetic,4996,B-CHEMICAL
acid,4996,I-CHEMICAL
class,4996,O
",",4996,O
and,4996,O
it,4996,O
is,4996,O
reported,4996,O
to,4996,O
be,4996,O
the,4996,O
most,4996,O
selective,4996,O
COXIB,4996,O
in,4996,O
vivo,4996,O
.,4996,O
However,4997,O
",",4997,O
the,4997,O
molecular,4997,O
basis,4997,O
of,4997,O
its,4997,O
COX-2,4997,B-GENE-Y
inhibition,4997,O
has,4997,O
not,4997,O
been,4997,O
completely,4997,O
defined,4997,O
.,4997,O
Using,4998,O
standard,4998,O
assays,4998,O
",",4998,O
lumiracoxib,4998,B-CHEMICAL
was,4998,O
found,4998,O
to,4998,O
be,4998,O
a,4998,O
poor,4998,O
inhibitor,4998,O
of,4998,O
purified,4998,O
ovine,4998,B-GENE-Y
COX-1,4998,I-GENE-Y
and,4998,O
a,4998,O
relatively,4998,O
weak,4998,O
inhibitor,4998,O
of,4998,O
purified,4998,O
human,4998,B-GENE-Y
COX-2,4998,I-GENE-Y
.,4998,O
The,4999,O
extent,4999,O
of,4999,O
COX-2,4999,B-GENE-Y
inhibition,4999,O
plateaued,4999,O
at,4999,O
around,4999,O
50,4999,O
%,4999,O
and,4999,O
suggested,4999,O
that,4999,O
the,4999,O
inhibitor,4999,O
may,4999,O
be,4999,O
reversibly,4999,O
bound,4999,O
to,4999,O
the,4999,O
enzyme,4999,O
.,4999,O
Kinetic,5000,O
studies,5000,O
with,5000,O
lumiracoxib,5000,B-CHEMICAL
demonstrated,5000,O
that,5000,O
it,5000,O
was,5000,O
a,5000,O
time-dependent,5000,O
and,5000,O
slowly,5000,O
reversible,5000,O
inhibitor,5000,O
of,5000,O
human,5000,B-GENE-Y
COX-2,5000,I-GENE-Y
that,5000,O
exhibited,5000,O
at,5000,O
least,5000,O
two,5000,O
binding,5000,O
steps,5000,O
during,5000,O
inhibition,5000,O
.,5000,O
Derivatives,5001,O
of,5001,O
lumiracoxib,5001,B-CHEMICAL
were,5001,O
synthesized,5001,O
with,5001,O
or,5001,O
without,5001,O
the,5001,O
methyl,5001,B-CHEMICAL
group,5001,O
on,5001,O
the,5001,O
phenylacetic,5001,B-CHEMICAL
acid,5001,I-CHEMICAL
ring,5001,O
and,5001,O
with,5001,O
various,5001,O
substitutions,5001,O
on,5001,O
the,5001,O
lower,5001,O
aniline,5001,B-CHEMICAL
ring,5001,O
.,5001,O
Inhibition,5002,O
studies,5002,O
demonstrated,5002,O
that,5002,O
the,5002,O
methyl,5002,B-CHEMICAL
group,5002,O
on,5002,O
the,5002,O
phenylacetic,5002,B-CHEMICAL
acid,5002,I-CHEMICAL
ring,5002,O
is,5002,O
required,5002,O
for,5002,O
COX-2,5002,B-GENE-Y
selectivity,5002,O
.,5002,O
The,5003,O
chemical,5003,O
identity,5003,O
and,5003,O
position,5003,O
of,5003,O
the,5003,O
substituents,5003,O
on,5003,O
the,5003,O
lower,5003,O
aniline,5003,B-CHEMICAL
ring,5003,O
were,5003,O
important,5003,O
in,5003,O
determining,5003,O
the,5003,O
potency,5003,O
and,5003,O
extent,5003,O
of,5003,O
COX,5003,B-GENE-N
inhibition,5003,O
as,5003,O
well,5003,O
as,5003,O
COX-2,5003,B-GENE-Y
selectivity,5003,O
.,5003,O
Mutation,5004,O
of,5004,O
Ser-530,5004,B-GENE-N
to,5004,I-GENE-N
Ala,5004,I-GENE-N
or,5004,O
Val-349,5004,B-GENE-N
to,5004,I-GENE-N
Ala,5004,I-GENE-N
or,5004,I-GENE-N
Leu,5004,I-GENE-N
abolished,5004,O
the,5004,O
potent,5004,O
inhibition,5004,O
observed,5004,O
with,5004,O
wild-type,5004,O
human,5004,B-GENE-Y
COX-2,5004,I-GENE-Y
and,5004,O
key,5004,O
lumiracoxib,5004,B-CHEMICAL
analogs,5004,O
.,5004,O
Interestingly,5005,O
",",5005,O
a,5005,O
Val-349,5005,B-GENE-N
to,5005,I-GENE-N
Ile,5005,I-GENE-N
mutant,5005,O
was,5005,O
inhibited,5005,O
with,5005,O
equal,5005,O
potency,5005,O
to,5005,O
human,5005,B-GENE-Y
COX-2,5005,I-GENE-Y
with,5005,O
"2,6-dichloro-",5005,B-CHEMICAL
",",5005,O
"2,6-dimethyl-",5005,B-CHEMICAL
",",5005,O
or,5005,O
2-chloro-6-methyl-substituted,5005,B-CHEMICAL
inhibitors,5005,O
and,5005,O
",",5005,O
in,5005,O
the,5005,O
case,5005,O
of,5005,O
lumiracoxib,5005,B-CHEMICAL
",",5005,O
actually,5005,O
showed,5005,O
an,5005,O
increase,5005,O
in,5005,O
potency,5005,O
.,5005,O
Taken,5006,O
together,5006,O
with,5006,O
a,5006,O
recent,5006,O
crystal,5006,O
structure,5006,O
of,5006,O
a,5006,O
lumiracoxib-COX-2,5006,B-CHEMICAL
complex,5006,O
",",5006,O
the,5006,O
kinetic,5006,O
analyses,5006,O
presented,5006,O
herein,5006,O
of,5006,O
the,5006,O
inhibition,5006,O
of,5006,O
mutant,5006,O
COX-2s,5006,B-GENE-Y
by,5006,O
lumiracoxib,5006,B-CHEMICAL
allows,5006,O
the,5006,O
definition,5006,O
of,5006,O
the,5006,O
molecular,5006,O
basis,5006,O
of,5006,O
COX-2,5006,B-GENE-Y
inhibition,5006,O
.,5006,O
Cerebral,5007,O
D2,5007,B-GENE-N
and,5007,I-GENE-N
5-HT2,5007,I-GENE-N
receptor,5007,I-GENE-N
occupancy,5007,O
in,5007,O
Schizophrenic,5007,O
patients,5007,O
treated,5007,O
with,5007,O
olanzapine,5007,B-CHEMICAL
or,5007,O
clozapine,5007,B-CHEMICAL
.,5007,O
We,5008,O
report,5008,O
the,5008,O
results,5008,O
of,5008,O
a,5008,O
double-blind,5008,O
",",5008,O
randomized,5008,O
prospective,5008,O
trial,5008,O
on,5008,O
D2,5008,B-GENE-N
and,5008,I-GENE-N
5-HT2,5008,I-GENE-N
receptor,5008,I-GENE-N
occupancy,5008,O
and,5008,O
the,5008,O
clinical,5008,O
effects,5008,O
of,5008,O
olanzapine,5008,B-CHEMICAL
versus,5008,O
clozapine,5008,B-CHEMICAL
in,5008,O
a,5008,O
sample,5008,O
of,5008,O
neuroleptic-refractory,5008,O
schizophrenic,5008,O
patients,5008,O
.,5008,O
Receptor,5009,O
occupancy,5009,O
was,5009,O
evaluated,5009,O
in,5009,O
different,5009,O
cortical,5009,O
areas,5009,O
and,5009,O
in,5009,O
basal,5009,O
ganglia,5009,O
using,5009,O
[,5009,B-CHEMICAL
18F,5009,I-CHEMICAL
],5009,I-CHEMICAL
fluoro-ethyl-spiperone,5009,I-CHEMICAL
(,5009,O
[,5009,B-CHEMICAL
18F,5009,I-CHEMICAL
],5009,I-CHEMICAL
FESP,5009,I-CHEMICAL
),5009,O
and,5009,O
positron,5009,O
emission,5009,O
tomography,5009,O
(,5009,O
PET,5009,O
),5009,O
.,5009,O
A,5010,O
total,5010,O
of,5010,O
15,5010,O
neuroleptic-free,5010,O
patients,5010,O
completed,5010,O
the,5010,O
study,5010,O
undergoing,5010,O
a,5010,O
baseline,5010,O
and,5010,O
a,5010,O
post-treatment,5010,O
PET,5010,O
scan,5010,O
(,5010,O
olanzapine,5010,B-CHEMICAL
",",5010,O
nine,5010,O
patients,5010,O
",",5010,O
one,5010,O
female,5010,O
;,5010,O
clozapine,5010,B-CHEMICAL
",",5010,O
six,5010,O
patients,5010,O
",",5010,O
three,5010,O
female,5010,O
),5010,O
8,5010,O
weeks,5010,O
after,5010,O
starting,5010,O
treatment,5010,O
.,5010,O
PET,5011,O
data,5011,O
were,5011,O
analysed,5011,O
both,5011,O
by,5011,O
regions,5011,O
of,5011,O
interest,5011,O
and,5011,O
on,5011,O
a,5011,O
voxel-by-voxel,5011,O
basis,5011,O
using,5011,O
Statistical,5011,O
Parametric,5011,O
Mapping,5011,O
(,5011,O
SPM96,5011,O
),5011,O
.,5011,O
Olanzapine,5012,B-CHEMICAL
and,5012,O
clozapine,5012,B-CHEMICAL
induced,5012,O
a,5012,O
similar,5012,O
and,5012,O
significant,5012,O
inhibition,5012,O
of,5012,O
[,5012,B-CHEMICAL
18F,5012,I-CHEMICAL
],5012,I-CHEMICAL
FESP,5012,I-CHEMICAL
binding,5012,O
index,5012,O
in,5012,O
the,5012,O
cortex,5012,O
.,5012,O
In,5013,O
the,5013,O
basal,5013,O
ganglia,5013,O
",",5013,O
receptor,5013,O
occupancy,5013,O
was,5013,O
significantly,5013,O
higher,5013,O
with,5013,O
olanzapine,5013,B-CHEMICAL
than,5013,O
with,5013,O
clozapine,5013,B-CHEMICAL
(,5013,O
p=0.0018,5013,O
),5013,O
.,5013,O
By,5014,O
contrast,5014,O
",",5014,O
no,5014,O
differences,5014,O
in,5014,O
receptor,5014,O
occupancy,5014,O
were,5014,O
detected,5014,O
at,5014,O
the,5014,O
level,5014,O
of,5014,O
the,5014,O
pituitary,5014,O
gland,5014,O
.,5014,O
Clinical,5015,O
outcomes,5015,O
",",5015,O
in,5015,O
particular,5015,O
a,5015,O
full,5015,O
extra,5015,O
pyramidal,5015,O
tolerability,5015,O
",",5015,O
were,5015,O
similar,5015,O
.,5015,O
In,5016,O
this,5016,O
sample,5016,O
of,5016,O
neuroleptic-refractory,5016,O
schizophrenic,5016,O
patients,5016,O
",",5016,O
olanzapine,5016,B-CHEMICAL
and,5016,O
clozapine,5016,B-CHEMICAL
showed,5016,O
a,5016,O
different,5016,O
pattern,5016,O
of,5016,O
occupancy,5016,O
of,5016,O
D2-like,5016,B-GENE-Y
receptor,5016,I-GENE-Y
despite,5016,O
a,5016,O
common,5016,O
lack,5016,O
of,5016,O
extrapyramidal,5016,O
side-effects,5016,O
.,5016,O
Inhibitory,5017,O
effect,5017,O
of,5017,O
selective,5017,O
serotonin,5017,B-CHEMICAL
reuptake,5017,O
inhibitors,5017,O
on,5017,O
the,5017,O
vesicular,5017,B-GENE-Y
monoamine,5017,I-GENE-Y
transporter,5017,I-GENE-Y
2,5017,I-GENE-Y
.,5017,O
The,5018,O
neuronal,5018,B-GENE-Y
vesicular,5018,I-GENE-Y
monoamine,5018,I-GENE-Y
transporter,5018,I-GENE-Y
(,5018,O
VMAT2,5018,B-GENE-Y
),5018,O
is,5018,O
the,5018,O
target,5018,O
molecule,5018,O
of,5018,O
action,5018,O
of,5018,O
some,5018,O
psychostimulants,5018,O
",",5018,O
such,5018,O
as,5018,O
methamphetamine,5018,B-CHEMICAL
and,5018,O
"3,4-methylenedioxymethamphetamine",5018,B-CHEMICAL
(,5018,O
MDMA,5018,B-CHEMICAL
),5018,O
.,5018,O
The,5019,O
present,5019,O
study,5019,O
examined,5019,O
the,5019,O
effect,5019,O
of,5019,O
antidepressants,5019,O
",",5019,O
such,5019,O
as,5019,O
selective,5019,O
serotonin,5019,B-CHEMICAL
reuptake,5019,O
inhibitors,5019,O
(,5019,O
SSRIs,5019,O
),5019,O
",",5019,O
on,5019,O
VMAT2,5019,B-GENE-Y
activity,5019,O
by,5019,O
measuring,5019,O
adenosine,5019,B-CHEMICAL
triphosphate-dependent,5019,O
[,5019,B-CHEMICAL
(,5019,I-CHEMICAL
3,5019,I-CHEMICAL
),5019,I-CHEMICAL
H,5019,I-CHEMICAL
],5019,I-CHEMICAL
dopamine,5019,I-CHEMICAL
uptake,5019,O
into,5019,O
synaptic,5019,O
vesicles,5019,O
prepared,5019,O
from,5019,O
rat,5019,O
striatum,5019,O
.,5019,O
SSRIs,5020,O
",",5020,O
fluoxetine,5020,B-CHEMICAL
",",5020,O
paroxetine,5020,B-CHEMICAL
",",5020,O
and,5020,O
fluvoxamine,5020,B-CHEMICAL
",",5020,O
inhibited,5020,O
vesicular,5020,O
[,5020,B-CHEMICAL
(,5020,I-CHEMICAL
3,5020,I-CHEMICAL
),5020,I-CHEMICAL
H,5020,I-CHEMICAL
],5020,I-CHEMICAL
dopamine,5020,I-CHEMICAL
uptake,5020,O
in,5020,O
vitro,5020,O
.,5020,O
The,5021,O
rank,5021,O
order,5021,O
of,5021,O
potency,5021,O
was,5021,O
reserpine,5021,B-CHEMICAL
>,5021,O
>,5021,O
fluoxetine,5021,B-CHEMICAL
",",5021,O
paroxetine,5021,B-CHEMICAL
>,5021,O
fluvoxamine,5021,B-CHEMICAL
",",5021,O
methamphetamine,5021,B-CHEMICAL
>,5021,O
MDMA,5021,B-CHEMICAL
.,5021,O
Moreover,5022,O
",",5022,O
kinetic,5022,O
analysis,5022,O
revealed,5022,O
that,5022,O
inhibition,5022,O
by,5022,O
reserpine,5022,B-CHEMICAL
",",5022,O
a,5022,O
typical,5022,O
VMAT2,5022,B-GENE-Y
inhibitor,5022,O
",",5022,O
was,5022,O
uncompetitive,5022,O
",",5022,O
decreasing,5022,O
maximum,5022,O
velocity,5022,O
and,5022,O
affinity,5022,O
for,5022,O
dopamine,5022,B-CHEMICAL
.,5022,O
Inhibition,5023,O
by,5023,O
fluoxetine,5023,B-CHEMICAL
was,5023,O
noncompetitive,5023,O
",",5023,O
only,5023,O
decreasing,5023,O
maximum,5023,O
velocity,5023,O
for,5023,O
dopamine,5023,B-CHEMICAL
.,5023,O
These,5024,O
results,5024,O
suggest,5024,O
that,5024,O
fluoxetine,5024,B-CHEMICAL
inhibited,5024,O
the,5024,O
activity,5024,O
of,5024,O
VMAT2,5024,B-GENE-Y
by,5024,O
a,5024,O
mechanism,5024,O
different,5024,O
from,5024,O
that,5024,O
of,5024,O
reserpine,5024,B-CHEMICAL
and,5024,O
did,5024,O
not,5024,O
directly,5024,O
interact,5024,O
with,5024,O
the,5024,O
active,5024,O
site,5024,O
of,5024,O
VMAT2,5024,B-GENE-Y
.,5024,O
Anti-inflammatory,5025,O
effects,5025,O
of,5025,O
an,5025,O
aqueous,5025,O
extract,5025,O
of,5025,O
Welsh,5025,O
onion,5025,O
green,5025,O
leaves,5025,O
in,5025,O
mice,5025,O
.,5025,O
The,5026,O
anti-inflammatory,5026,O
effects,5026,O
of,5026,O
an,5026,O
aqueous,5026,O
extract,5026,O
of,5026,O
Welsh,5026,O
onion,5026,O
green,5026,O
leaves,5026,O
(,5026,O
WOE,5026,O
),5026,O
in,5026,O
mice,5026,O
was,5026,O
investigated,5026,O
.,5026,O
Administration,5027,O
of,5027,O
WOE,5027,O
",",5027,O
in,5027,O
the,5027,O
range,5027,O
of,5027,O
0.25-1g/kg,5027,O
",",5027,O
showed,5027,O
a,5027,O
concentration,5027,O
dependent,5027,O
inhibition,5027,O
on,5027,O
paw,5027,O
edema,5027,O
development,5027,O
after,5027,O
carrageenan,5027,O
treatment,5027,O
in,5027,O
mice,5027,O
.,5027,O
The,5028,O
anti-inflammatory,5028,O
effects,5028,O
of,5028,O
WOE,5028,O
were,5028,O
closely,5028,O
attributed,5028,O
to,5028,O
decreased,5028,O
levels,5028,O
of,5028,O
tissue,5028,O
NO,5028,B-CHEMICAL
and,5028,O
tumor,5028,B-GENE-Y
necrosis,5028,I-GENE-Y
factor-α,5028,I-GENE-Y
(,5028,O
TNF-α,5028,B-GENE-Y
),5028,O
.,5028,O
Further,5029,O
evidence,5029,O
for,5029,O
WOE,5029,O
's,5029,O
protection,5029,O
is,5029,O
shown,5029,O
in,5029,O
the,5029,O
reduction,5029,O
of,5029,O
lipid,5029,O
oxidation,5029,O
and,5029,O
the,5029,O
increase,5029,O
of,5029,O
antioxidant,5029,O
enzyme,5029,O
activities,5029,O
",",5029,O
including,5029,O
catalase,5029,B-GENE-Y
(,5029,O
CAT,5029,B-GENE-Y
),5029,O
",",5029,O
superoxide,5029,B-GENE-N
dismutase,5029,I-GENE-N
(,5029,O
SOD,5029,B-GENE-N
),5029,O
",",5029,O
and,5029,O
glutathione,5029,B-GENE-N
peroxidase,5029,I-GENE-N
(,5029,O
GPX,5029,B-GENE-N
),5029,O
in,5029,O
vivo,5029,O
.,5029,O
Further,5030,O
",",5030,O
WOE,5030,O
also,5030,O
decreased,5030,O
the,5030,O
number,5030,O
of,5030,O
acetic,5030,B-CHEMICAL
acid-induced,5030,O
writhing,5030,O
responses,5030,O
and,5030,O
formalin-induced,5030,B-CHEMICAL
pain,5030,O
in,5030,O
the,5030,O
late,5030,O
phase,5030,O
in,5030,O
mice,5030,O
.,5030,O
Overall,5031,O
",",5031,O
the,5031,O
results,5031,O
showed,5031,O
that,5031,O
WOE,5031,O
might,5031,O
serve,5031,O
as,5031,O
a,5031,O
natural,5031,O
source,5031,O
of,5031,O
anti-inflammatory,5031,O
compounds,5031,O
.,5031,O
Application,5032,O
of,5032,O
the,5032,O
bradford,5032,O
hill,5032,O
criteria,5032,O
to,5032,O
assess,5032,O
the,5032,O
causality,5032,O
of,5032,O
cisapride-induced,5032,B-CHEMICAL
arrhythmia,5032,O
:,5032,O
a,5032,O
model,5032,O
for,5032,O
assessing,5032,O
causal,5032,O
association,5032,O
in,5032,O
pharmacovigilance,5032,O
.,5032,O
INTRODUCTION,5033,O
:,5033,O
The,5033,O
Bradford,5033,O
Hill,5033,O
criteria,5033,O
are,5033,O
a,5033,O
widely,5033,O
used,5033,O
",",5033,O
useful,5033,O
tool,5033,O
for,5033,O
the,5033,O
assessment,5033,O
of,5033,O
biomedical,5033,O
causation,5033,O
.,5033,O
We,5034,O
have,5034,O
examined,5034,O
their,5034,O
application,5034,O
to,5034,O
pharmacovigilance,5034,O
using,5034,O
the,5034,O
example,5034,O
of,5034,O
cisapride-induced,5034,B-CHEMICAL
QTc,5034,O
interval,5034,O
prolongation/arrhythmia,5034,O
.,5034,O
METHODS,5035,O
:,5035,O
A,5035,O
literature,5035,O
search,5035,O
was,5035,O
conducted,5035,O
using,5035,O
MEDLINE,5035,O
",",5035,O
EMBASE,5035,O
",",5035,O
Reactions,5035,O
Weekly,5035,O
and,5035,O
regulatory,5035,O
websites,5035,O
to,5035,O
identify,5035,O
evidence,5035,O
for,5035,O
the,5035,O
association,5035,O
between,5035,O
cisapride,5035,B-CHEMICAL
and,5035,O
QTc,5035,O
interval,5035,O
prolongation/arrhythmia,5035,O
that,5035,O
had,5035,O
been,5035,O
published,5035,O
in,5035,O
the,5035,O
English,5035,O
language,5035,O
.,5035,O
Two,5036,O
hundred,5036,O
and,5036,O
five,5036,O
publications,5036,O
were,5036,O
identified,5036,O
as,5036,O
being,5036,O
potentially,5036,O
suitable,5036,O
for,5036,O
the,5036,O
study,5036,O
.,5036,O
After,5037,O
excluding,5037,O
irrelevant,5037,O
articles,5037,O
",",5037,O
studies,5037,O
on,5037,O
high-risk,5037,O
populations,5037,O
and,5037,O
review,5037,O
articles,5037,O
",",5037,O
70,5037,O
publications,5037,O
were,5037,O
assessed,5037,O
using,5037,O
the,5037,O
Bradford,5037,O
Hill,5037,O
criteria,5037,O
.,5037,O
These,5038,O
included,5038,O
24,5038,O
case,5038,O
reports,5038,O
",",5038,O
case,5038,O
series,5038,O
or,5038,O
spontaneous,5038,O
report,5038,O
summaries,5038,O
;,5038,O
eight,5038,O
epidemiological,5038,O
studies,5038,O
;,5038,O
22,5038,O
clinical,5038,O
studies,5038,O
;,5038,O
and,5038,O
16,5038,O
experimental,5038,O
(,5038,O
in,5038,O
vivo,5038,O
and,5038,O
in,5038,O
vitro,5038,O
),5038,O
publications,5038,O
.,5038,O
RESULTS,5039,O
:,5039,O
The,5039,O
most,5039,O
compelling,5039,O
evidence,5039,O
for,5039,O
an,5039,O
association,5039,O
between,5039,O
cisapride,5039,B-CHEMICAL
use,5039,O
and,5039,O
QTc,5039,O
interval,5039,O
prolongation/arrhythmia,5039,O
came,5039,O
from,5039,O
case/spontaneous,5039,O
reports,5039,O
and,5039,O
biological,5039,O
plausibility,5039,O
.,5039,O
Considering,5040,O
the,5040,O
rare,5040,O
incidence,5040,O
of,5040,O
serious,5040,O
cardiac,5040,O
events,5040,O
",",5040,O
these,5040,O
criteria,5040,O
formed,5040,O
the,5040,O
basis,5040,O
for,5040,O
the,5040,O
strength,5040,O
of,5040,O
the,5040,O
association,5040,O
.,5040,O
The,5041,O
number,5041,O
of,5041,O
reports,5041,O
from,5041,O
different,5041,O
populations,5041,O
showed,5041,O
consistency,5041,O
.,5041,O
Specificity,5042,O
was,5042,O
supported,5042,O
by,5042,O
clinical,5042,O
and,5042,O
cardiographic,5042,O
characterisation,5042,O
of,5042,O
the,5042,O
events,5042,O
.,5042,O
There,5043,O
were,5043,O
temporal,5043,O
relationships,5043,O
between,5043,O
the,5043,O
events,5043,O
and,5043,O
the,5043,O
initiation,5043,O
of,5043,O
cisapride,5043,B-CHEMICAL
treatment,5043,O
",",5043,O
increases,5043,O
in,5043,O
the,5043,O
dosage,5043,O
and,5043,O
the,5043,O
receipt,5043,O
of,5043,O
interacting,5043,O
medications,5043,O
.,5043,O
The,5044,O
relationships,5044,O
between,5044,O
the,5044,O
adverse,5044,O
events,5044,O
and,5044,O
the,5044,O
latter,5044,O
two,5044,O
factors,5044,O
exhibited,5044,O
biological,5044,O
gradients,5044,O
.,5044,O
Experimental,5045,O
evidence,5045,O
could,5045,O
be,5045,O
found,5045,O
from,5045,O
biological,5045,O
models,5045,O
",",5045,O
as,5045,O
well,5045,O
as,5045,O
reports,5045,O
of,5045,O
positive,5045,O
dechallenge,5045,O
and/or,5045,O
rechallenge,5045,O
found,5045,O
in,5045,O
individual,5045,O
patients,5045,O
.,5045,O
Cisapride,5046,B-CHEMICAL
was,5046,O
found,5046,O
to,5046,O
bind,5046,O
the,5046,O
human,5046,B-GENE-Y
ether-a-go-go-related,5046,I-GENE-Y
gene,5046,I-GENE-Y
(,5046,I-GENE-Y
HERG,5046,I-GENE-Y
),5046,I-GENE-Y
potassium,5046,I-GENE-Y
channel,5046,I-GENE-Y
",",5046,O
which,5046,O
provides,5046,O
a,5046,O
plausible,5046,O
mechanism,5046,O
for,5046,O
QTc,5046,O
interval,5046,O
prolongation/arrhythmia,5046,O
.,5046,O
Other,5047,O
QTc,5047,O
interval-prolonging/arrhythmic,5047,O
drugs,5047,O
that,5047,O
also,5047,O
bind,5047,O
to,5047,O
HERG,5047,B-GENE-Y
provided,5047,O
an,5047,O
analogy,5047,O
for,5047,O
cisapride,5047,B-CHEMICAL
causing,5047,O
QTc,5047,O
interval,5047,O
prolongation/arrhythmia,5047,O
via,5047,O
this,5047,O
mechanism,5047,O
.,5047,O
The,5048,O
evidence,5048,O
provided,5048,O
by,5048,O
clinical,5048,O
studies,5048,O
was,5048,O
inconsistent,5048,O
",",5048,O
and,5048,O
epidemiological,5048,O
studies,5048,O
failed,5048,O
to,5048,O
demonstrate,5048,O
an,5048,O
association,5048,O
.,5048,O
Nevertheless,5049,O
",",5049,O
this,5049,O
did,5049,O
not,5049,O
prevent,5049,O
the,5049,O
assessment,5049,O
of,5049,O
causation,5049,O
.,5049,O
DISCUSSION,5050,O
:,5050,O
This,5050,O
study,5050,O
showed,5050,O
how,5050,O
different,5050,O
types,5050,O
of,5050,O
evidence,5050,O
found,5050,O
in,5050,O
pharmacovigilance,5050,O
can,5050,O
be,5050,O
evaluated,5050,O
using,5050,O
the,5050,O
Bradford,5050,O
Hill,5050,O
criteria,5050,O
.,5050,O
Further,5051,O
work,5051,O
is,5051,O
required,5051,O
to,5051,O
examine,5051,O
how,5051,O
the,5051,O
criteria,5051,O
can,5051,O
be,5051,O
applied,5051,O
to,5051,O
different,5051,O
types,5051,O
of,5051,O
adverse,5051,O
events,5051,O
and,5051,O
how,5051,O
they,5051,O
may,5051,O
be,5051,O
applied,5051,O
to,5051,O
pharmacovigilance,5051,O
.,5051,O
Betaxolol,5052,B-CHEMICAL
",",5052,O
a,5052,O
beta,5052,B-GENE-Y
(,5052,I-GENE-Y
1,5052,I-GENE-Y
),5052,I-GENE-Y
-adrenoceptor,5052,I-GENE-Y
antagonist,5052,O
",",5052,O
reduces,5052,O
Na,5052,B-CHEMICAL
(,5052,I-CHEMICAL
+,5052,I-CHEMICAL
),5052,I-CHEMICAL
influx,5052,O
into,5052,O
cortical,5052,O
synaptosomes,5052,O
by,5052,O
direct,5052,O
interaction,5052,O
with,5052,O
Na,5052,B-GENE-N
(,5052,I-GENE-N
+,5052,I-GENE-N
),5052,I-GENE-N
channels,5052,I-GENE-N
:,5052,O
comparison,5052,O
with,5052,O
other,5052,O
beta-adrenoceptor,5052,B-GENE-N
antagonists,5052,O
.,5052,O
Betaxolol,5053,B-CHEMICAL
",",5053,O
a,5053,O
beta,5053,B-GENE-Y
(,5053,I-GENE-Y
1,5053,I-GENE-Y
),5053,I-GENE-Y
-adrenoceptor,5053,I-GENE-Y
antagonist,5053,O
used,5053,O
for,5053,O
the,5053,O
treatment,5053,O
of,5053,O
glaucoma,5053,O
",",5053,O
is,5053,O
known,5053,O
to,5053,O
be,5053,O
neuroprotective,5053,O
in,5053,O
paradigms,5053,O
of,5053,O
ischaemia/excitotoxicity,5053,O
.,5053,O
In,5054,O
this,5054,O
study,5054,O
",",5054,O
we,5054,O
examined,5054,O
whether,5054,O
betaxolol,5054,B-CHEMICAL
and,5054,O
other,5054,O
beta-adrenoceptor,5054,B-GENE-N
antagonists,5054,O
interact,5054,O
directly,5054,O
with,5054,O
neurotoxin,5054,O
binding,5054,O
to,5054,O
sites,5054,O
1,5054,O
and,5054,O
2,5054,O
of,5054,O
the,5054,O
voltage-sensitive,5054,B-GENE-N
sodium,5054,I-GENE-N
channel,5054,I-GENE-N
(,5054,O
Na,5054,B-GENE-N
(,5054,I-GENE-N
+,5054,I-GENE-N
),5054,I-GENE-N
channel,5054,I-GENE-N
),5054,O
in,5054,O
rat,5054,O
cerebrocortical,5054,O
synaptosomes,5054,O
.,5054,O
Betaxolol,5055,B-CHEMICAL
inhibited,5055,O
specific,5055,O
[,5055,B-CHEMICAL
(,5055,I-CHEMICAL
3,5055,I-CHEMICAL
),5055,I-CHEMICAL
H,5055,I-CHEMICAL
],5055,I-CHEMICAL
-batrachotoxinin-A,5055,I-CHEMICAL
20-alpha-benzoate,5055,I-CHEMICAL
(,5055,O
[,5055,B-CHEMICAL
(,5055,I-CHEMICAL
3,5055,I-CHEMICAL
),5055,I-CHEMICAL
H,5055,I-CHEMICAL
],5055,I-CHEMICAL
-BTX-B,5055,I-CHEMICAL
),5055,O
binding,5055,O
to,5055,O
neurotoxin,5055,B-GENE-N
site,5055,I-GENE-N
2,5055,I-GENE-N
in,5055,O
a,5055,O
concentration-dependent,5055,O
manner,5055,O
with,5055,O
an,5055,O
IC,5055,O
(,5055,O
50,5055,O
),5055,O
value,5055,O
of,5055,O
9.8,5055,O
microM,5055,O
.,5055,O
Comparison,5056,O
of,5056,O
all,5056,O
the,5056,O
beta-adrenoceptor,5056,B-GENE-N
antagonists,5056,O
tested,5056,O
revealed,5056,O
a,5056,O
potency,5056,O
order,5056,O
of,5056,O
propranolol,5056,B-CHEMICAL
>,5056,O
betaxolol,5056,B-CHEMICAL
approximately,5056,O
levobetaxolol,5056,B-CHEMICAL
>,5056,O
levobunolol,5056,B-CHEMICAL
approximately,5056,O
carteolol,5056,B-CHEMICAL
>,5056,O
/=timolol,5056,O
>,5056,O
atenolol,5056,B-CHEMICAL
.,5056,O
None,5057,O
of,5057,O
the,5057,O
drugs,5057,O
caused,5057,O
a,5057,O
significant,5057,O
inhibition,5057,O
of,5057,O
[,5057,B-CHEMICAL
(,5057,I-CHEMICAL
3,5057,I-CHEMICAL
),5057,I-CHEMICAL
H,5057,I-CHEMICAL
],5057,I-CHEMICAL
-saxitoxin,5057,I-CHEMICAL
binding,5057,O
to,5057,O
neurotoxin,5057,B-GENE-N
receptor,5057,I-GENE-N
site,5057,I-GENE-N
1,5057,I-GENE-N
",",5057,O
even,5057,O
at,5057,O
concentrations,5057,O
as,5057,O
high,5057,O
as,5057,O
250,5057,O
microM,5057,O
.,5057,O
Saturation,5058,O
experiments,5058,O
showed,5058,O
that,5058,O
betaxolol,5058,B-CHEMICAL
increased,5058,O
the,5058,O
K,5058,O
(,5058,O
D,5058,O
),5058,O
of,5058,O
[,5058,B-CHEMICAL
(,5058,I-CHEMICAL
3,5058,I-CHEMICAL
),5058,I-CHEMICAL
H,5058,I-CHEMICAL
],5058,I-CHEMICAL
-BTX-B,5058,I-CHEMICAL
binding,5058,O
but,5058,O
had,5058,O
no,5058,O
effect,5058,O
on,5058,O
the,5058,O
B,5058,O
(,5058,O
max,5058,O
),5058,O
.,5058,O
The,5059,O
association,5059,O
kinetics,5059,O
of,5059,O
[,5059,B-CHEMICAL
(,5059,I-CHEMICAL
3,5059,I-CHEMICAL
),5059,I-CHEMICAL
H,5059,I-CHEMICAL
],5059,I-CHEMICAL
-BTX-B,5059,I-CHEMICAL
were,5059,O
unaffected,5059,O
by,5059,O
betaxolol,5059,B-CHEMICAL
",",5059,O
but,5059,O
the,5059,O
drug,5059,O
significantly,5059,O
accelerated,5059,O
the,5059,O
dissociation,5059,O
rate,5059,O
of,5059,O
the,5059,O
radioligand,5059,O
.,5059,O
These,5060,O
findings,5060,O
argue,5060,O
for,5060,O
a,5060,O
competitive,5060,O
",",5060,O
indirect,5060,O
",",5060,O
allosteric,5060,O
mode,5060,O
of,5060,O
inhibition,5060,O
of,5060,O
[,5060,B-CHEMICAL
(,5060,I-CHEMICAL
3,5060,I-CHEMICAL
),5060,I-CHEMICAL
H,5060,I-CHEMICAL
],5060,I-CHEMICAL
-BTX-B,5060,I-CHEMICAL
binding,5060,O
by,5060,O
betaxolol,5060,B-CHEMICAL
.,5060,O
Betaxolol,5061,B-CHEMICAL
inhibited,5061,O
veratridine-stimulated,5061,B-CHEMICAL
Na,5061,B-CHEMICAL
(,5061,I-CHEMICAL
+,5061,I-CHEMICAL
),5061,I-CHEMICAL
influx,5061,O
in,5061,O
rat,5061,O
cortical,5061,O
synaptosomes,5061,O
with,5061,O
an,5061,O
IC,5061,O
(,5061,O
50,5061,O
),5061,O
value,5061,O
of,5061,O
28,5061,O
.,5061,O
3,5062,O
microM,5062,O
.,5062,O
Carteolol,5063,B-CHEMICAL
",",5063,O
levobunolol,5063,B-CHEMICAL
",",5063,O
timolol,5063,B-CHEMICAL
and,5063,O
atenolol,5063,B-CHEMICAL
were,5063,O
significantly,5063,O
less,5063,O
effective,5063,O
than,5063,O
betaxolol,5063,B-CHEMICAL
at,5063,O
reducing,5063,O
veratridine-evoked,5063,B-CHEMICAL
Na,5063,B-CHEMICAL
(,5063,I-CHEMICAL
+,5063,I-CHEMICAL
),5063,I-CHEMICAL
influx,5063,O
.,5063,O
The,5064,O
ability,5064,O
of,5064,O
betaxolol,5064,B-CHEMICAL
to,5064,O
interact,5064,O
with,5064,O
neurotoxin,5064,O
site,5064,O
2,5064,O
of,5064,O
the,5064,O
Na,5064,B-GENE-N
(,5064,I-GENE-N
+,5064,I-GENE-N
),5064,I-GENE-N
channel,5064,I-GENE-N
and,5064,O
inhibit,5064,O
Na,5064,B-CHEMICAL
(,5064,I-CHEMICAL
+,5064,I-CHEMICAL
),5064,I-CHEMICAL
influx,5064,O
may,5064,O
have,5064,O
a,5064,O
role,5064,O
in,5064,O
its,5064,O
neuroprotective,5064,O
action,5064,O
in,5064,O
paradigms,5064,O
of,5064,O
excitotoxicity/ischaemia,5064,O
and,5064,O
in,5064,O
its,5064,O
therapeutic,5064,O
effect,5064,O
in,5064,O
glaucoma,5064,O
.,5064,O
Synthesis,5065,O
of,5065,O
novel,5065,O
"1,3,4-trisubstituted",5065,B-CHEMICAL
pyrazoles,5065,I-CHEMICAL
as,5065,O
anti-inflammatory,5065,O
and,5065,O
analgesic,5065,O
agents,5065,O
.,5065,O
Some,5066,O
novel,5066,O
"1,3,4-trisubstituted",5066,B-CHEMICAL
pyrazoles,5066,I-CHEMICAL
were,5066,O
synthesized,5066,O
and,5066,O
screened,5066,O
for,5066,O
their,5066,O
anti-inflammatory,5066,O
and,5066,O
analgesic,5066,O
activities,5066,O
as,5066,O
well,5066,O
as,5066,O
their,5066,O
ulcerogenic,5066,O
liability,5066,O
.,5066,O
They,5067,O
showed,5067,O
anti-inflammatory,5067,O
and,5067,O
analgesic,5067,O
activities,5067,O
with,5067,O
better,5067,O
GIT,5067,O
tolerance,5067,O
than,5067,O
the,5067,O
standard,5067,O
drug,5067,O
phenylbutazone,5067,B-CHEMICAL
.,5067,O
In,5068,O
addition,5068,O
",",5068,O
IC50,5068,O
values,5068,O
for,5068,O
5e,5068,O
and,5068,O
8e,5068,O
were,5068,O
recorded,5068,O
.,5068,O
Compound,5069,O
5e,5069,O
was,5069,O
found,5069,O
to,5069,O
be,5069,O
the,5069,O
most,5069,O
active,5069,O
one,5069,O
as,5069,O
anti-inflammatory,5069,O
and,5069,O
analgesic,5069,O
agent,5069,O
.,5069,O
On,5070,O
the,5070,O
other,5070,O
hand,5070,O
",",5070,O
COX-1/COX-2,5070,B-GENE-Y
isozyme,5070,O
selectivity,5070,O
was,5070,O
also,5070,O
done,5070,O
which,5070,O
showed,5070,O
equal,5070,O
inhibition,5070,O
to,5070,O
both,5070,O
isoforms,5070,O
.,5070,O
Leukotriene,5071,B-CHEMICAL
D4,5071,I-CHEMICAL
induces,5071,O
cognitive,5071,O
impairment,5071,O
through,5071,O
enhancement,5071,O
of,5071,O
CysLT₁,5071,B-GENE-Y
R-mediated,5071,O
amyloid-β,5071,B-GENE-Y
generation,5071,O
in,5071,O
mice,5071,O
.,5071,O
Amyloid,5072,B-GENE-Y
plaques,5072,O
in,5072,O
the,5072,O
extracellular,5072,O
parenchyma,5072,O
mainly,5072,O
consist,5072,O
of,5072,O
amyloid-β,5072,B-GENE-Y
peptides,5072,I-GENE-Y
(,5072,O
Aβ,5072,B-GENE-Y
),5072,O
",",5072,O
one,5072,O
of,5072,O
the,5072,O
pathological,5072,O
hallmarks,5072,O
in,5072,O
Alzheimer,5072,O
's,5072,O
disease,5072,O
(,5072,O
AD,5072,O
),5072,O
.,5072,O
In,5073,O
the,5073,O
present,5073,O
study,5073,O
",",5073,O
we,5073,O
examined,5073,O
neuroinflammation,5073,O
",",5073,O
amyloidogenesis,5073,O
",",5073,O
and,5073,O
memory,5073,O
performance,5073,O
following,5073,O
intracerebral,5073,O
infusions,5073,O
of,5073,O
leukotriene,5073,B-CHEMICAL
D4,5073,I-CHEMICAL
(,5073,O
LTD4,5073,B-CHEMICAL
),5073,O
in,5073,O
mice,5073,O
.,5073,O
The,5074,O
results,5074,O
demonstrated,5074,O
that,5074,O
intracerebral,5074,O
infusions,5074,O
of,5074,O
LTD4,5074,B-CHEMICAL
(,5074,O
1,5074,O
ng/mouse,5074,O
),5074,O
produced,5074,O
memory,5074,O
impairment,5074,O
as,5074,O
determined,5074,O
by,5074,O
Morris,5074,O
water,5074,O
maze,5074,O
test,5074,O
and,5074,O
Y-maze,5074,O
test,5074,O
in,5074,O
mice,5074,O
",",5074,O
and,5074,O
caused,5074,O
the,5074,O
accumulation,5074,O
of,5074,O
Aβ1-40,5074,B-GENE-Y
and,5074,O
Aβ1-42,5074,B-GENE-Y
in,5074,O
the,5074,O
hippocampus,5074,O
and,5074,O
cortex,5074,O
through,5074,O
increased,5074,O
activity,5074,O
of,5074,O
β-,5074,O
and,5074,O
γ-secretases,5074,O
accompanied,5074,O
with,5074,O
increased,5074,O
expression,5074,O
of,5074,O
amyloid,5074,B-GENE-Y
precursor,5074,I-GENE-Y
protein,5074,I-GENE-Y
(,5074,O
APP,5074,B-GENE-Y
),5074,O
.,5074,O
LTD4,5075,B-CHEMICAL
also,5075,O
induced,5075,O
expression,5075,O
of,5075,O
cysteinyl,5075,B-GENE-Y
leukotriene,5075,I-GENE-Y
receptor,5075,I-GENE-Y
1,5075,I-GENE-Y
(,5075,O
CysLT,5075,B-GENE-Y
(,5075,I-GENE-Y
1,5075,I-GENE-Y
),5075,I-GENE-Y
R,5075,I-GENE-Y
),5075,O
and,5075,O
NF-κB,5075,B-GENE-N
p65,5075,B-GENE-Y
in,5075,O
the,5075,O
hippocampus,5075,O
and,5075,O
cortex,5075,O
.,5075,O
Pretreatment,5076,O
with,5076,O
pranlukast,5076,B-CHEMICAL
(,5076,O
1.5,5076,O
ng/mouse,5076,O
",",5076,O
intracerebroventricularly,5076,O
),5076,O
",",5076,O
a,5076,O
CysLT,5076,B-GENE-Y
(,5076,I-GENE-Y
1,5076,I-GENE-Y
),5076,I-GENE-Y
R,5076,I-GENE-Y
antagonist,5076,O
",",5076,O
blocked,5076,O
LTD4-induced,5076,B-CHEMICAL
amyloidogenesis,5076,O
",",5076,O
memory,5076,O
deficits,5076,O
.,5076,O
Pranlukast,5077,B-CHEMICAL
(,5077,O
0.6,5077,O
μM,5077,O
),5077,O
also,5077,O
prevented,5077,O
LTD4,5077,B-CHEMICAL
(,5077,O
20,5077,O
nM,5077,O
),5077,O
-induced,5077,O
amyloidogenesis,5077,O
in,5077,O
the,5077,O
cultured,5077,O
neurons,5077,O
in,5077,O
vitro,5077,O
.,5077,O
Moreover,5078,O
",",5078,O
LTD4-induced,5078,B-CHEMICAL
increases,5078,O
in,5078,O
CysLT,5078,B-GENE-Y
(,5078,I-GENE-Y
1,5078,I-GENE-Y
),5078,I-GENE-Y
R,5078,I-GENE-Y
and,5078,O
NF-κB,5078,B-GENE-N
p65,5078,B-GENE-Y
in,5078,O
the,5078,O
brain,5078,O
were,5078,O
also,5078,O
attenuated,5078,O
by,5078,O
pranlukast,5078,B-CHEMICAL
.,5078,O
These,5079,O
results,5079,O
suggest,5079,O
that,5079,O
LTD4,5079,B-CHEMICAL
increases,5079,O
Aβ,5079,B-GENE-Y
peptide,5079,I-GENE-Y
burden,5079,O
via,5079,O
activation,5079,O
of,5079,O
CysLT,5079,B-GENE-Y
(,5079,I-GENE-Y
1,5079,I-GENE-Y
),5079,I-GENE-Y
R,5079,I-GENE-Y
",",5079,O
which,5079,O
further,5079,O
affects,5079,O
APP,5079,B-GENE-Y
levels,5079,O
and,5079,O
activity,5079,O
of,5079,O
β-,5079,O
and,5079,O
γ-secretases,5079,O
via,5079,O
the,5079,O
NF-κB,5079,B-GENE-N
pathway,5079,O
.,5079,O
Our,5080,O
findings,5080,O
identify,5080,O
CysLT,5080,B-GENE-Y
(,5080,I-GENE-Y
1,5080,I-GENE-Y
),5080,I-GENE-Y
R,5080,I-GENE-Y
signaling,5080,O
as,5080,O
a,5080,O
novel,5080,O
proinflammatory,5080,O
and,5080,O
proamyloidogenic,5080,O
pathway,5080,O
",",5080,O
and,5080,O
suggest,5080,O
a,5080,O
rationale,5080,O
for,5080,O
development,5080,O
of,5080,O
therapeutics,5080,O
targeting,5080,O
the,5080,O
CysLT,5080,B-GENE-Y
(,5080,I-GENE-Y
1,5080,I-GENE-Y
),5080,I-GENE-Y
R,5080,I-GENE-Y
in,5080,O
neuroinflammatory,5080,O
diseases,5080,O
such,5080,O
as,5080,O
AD,5080,O
.,5080,O
Predicting,5081,O
cardiomyopathic,5081,O
phenotypes,5081,O
by,5081,O
altering,5081,O
Ca2+,5081,B-CHEMICAL
affinity,5081,O
of,5081,O
cardiac,5081,B-GENE-Y
troponin,5081,I-GENE-Y
C.,5081,O
Cardiac,5081,O
diseases,5081,O
associated,5081,O
with,5081,O
mutations,5081,O
in,5081,O
troponin,5081,B-GENE-N
subunits,5081,O
include,5081,O
hypertrophic,5081,O
cardiomyopathy,5081,O
(,5081,O
HCM,5081,O
),5081,O
",",5081,O
dilated,5081,O
cardiomyopathy,5081,O
(,5081,O
DCM,5081,O
),5081,O
",",5081,O
and,5081,O
restrictive,5081,O
cardiomyopathy,5081,O
(,5081,O
RCM,5081,O
),5081,O
.,5081,O
Altered,5082,O
calcium,5082,O
handling,5082,O
in,5082,O
these,5082,O
diseases,5082,O
is,5082,O
evidenced,5082,O
by,5082,O
changes,5082,O
in,5082,O
the,5082,O
Ca,5082,B-CHEMICAL
(,5082,I-CHEMICAL
2+,5082,I-CHEMICAL
),5082,I-CHEMICAL
sensitivity,5082,O
of,5082,O
contraction,5082,O
.,5082,O
Mutations,5083,O
in,5083,O
the,5083,O
Ca,5083,B-CHEMICAL
(,5083,I-CHEMICAL
2+,5083,I-CHEMICAL
),5083,I-CHEMICAL
sensor,5083,O
",",5083,O
troponin,5083,B-GENE-Y
C,5083,I-GENE-Y
(,5083,O
TnC,5083,B-GENE-Y
),5083,O
",",5083,O
were,5083,O
generated,5083,O
to,5083,O
increase/decrease,5083,O
the,5083,O
Ca,5083,B-CHEMICAL
(,5083,I-CHEMICAL
2+,5083,I-CHEMICAL
),5083,I-CHEMICAL
sensitivity,5083,O
of,5083,O
cardiac,5083,O
skinned,5083,O
fibers,5083,O
to,5083,O
create,5083,O
the,5083,O
characteristic,5083,O
effects,5083,O
of,5083,O
DCM,5083,O
",",5083,O
HCM,5083,O
",",5083,O
and,5083,O
RCM,5083,O
.,5083,O
We,5084,O
also,5084,O
used,5084,O
a,5084,O
reconstituted,5084,O
assay,5084,O
to,5084,O
determine,5084,O
the,5084,O
mutation,5084,O
effects,5084,O
on,5084,O
ATPase,5084,B-GENE-N
activation,5084,O
and,5084,O
inhibition,5084,O
.,5084,O
One,5085,O
mutant,5085,O
(,5085,O
A23Q,5085,B-GENE-N
),5085,O
was,5085,O
found,5085,O
with,5085,O
HCM-like,5085,O
properties,5085,O
(,5085,O
increased,5085,O
Ca,5085,B-CHEMICAL
(,5085,I-CHEMICAL
2+,5085,I-CHEMICAL
),5085,I-CHEMICAL
sensitivity,5085,O
of,5085,O
force,5085,O
and,5085,O
normal,5085,O
levels,5085,O
of,5085,O
ATPase,5085,B-GENE-N
inhibition,5085,O
),5085,O
.,5085,O
Three,5086,O
mutants,5086,O
(,5086,O
S37G,5086,B-GENE-N
",",5086,O
V44Q,5086,B-GENE-N
",",5086,O
and,5086,O
L48Q,5086,B-GENE-N
),5086,O
were,5086,O
identified,5086,O
with,5086,O
RCM-like,5086,O
properties,5086,O
(,5086,O
a,5086,O
large,5086,O
increase,5086,O
in,5086,O
Ca,5086,B-CHEMICAL
(,5086,I-CHEMICAL
2+,5086,I-CHEMICAL
),5086,I-CHEMICAL
sensitivity,5086,O
",",5086,O
partial,5086,O
loss,5086,O
of,5086,O
ATPase,5086,B-GENE-N
inhibition,5086,O
",",5086,O
and,5086,O
increased,5086,O
basal,5086,O
force,5086,O
),5086,O
.,5086,O
Two,5087,O
mutations,5087,O
were,5087,O
identified,5087,O
(,5087,O
E40A,5087,B-GENE-N
and,5087,O
I61Q,5087,B-GENE-N
),5087,O
with,5087,O
DCM,5087,O
properties,5087,O
(,5087,O
decreased,5087,O
Ca,5087,B-CHEMICAL
(,5087,I-CHEMICAL
2+,5087,I-CHEMICAL
),5087,I-CHEMICAL
sensitivity,5087,O
",",5087,O
maximal,5087,O
force,5087,O
recovery,5087,O
",",5087,O
and,5087,O
activation,5087,O
of,5087,O
the,5087,O
ATPase,5087,B-GENE-N
at,5087,O
high,5087,O
[,5087,O
Ca,5087,B-CHEMICAL
(,5087,I-CHEMICAL
2+,5087,I-CHEMICAL
),5087,I-CHEMICAL
],5087,O
),5087,O
.,5087,O
Steady-state,5088,O
fluorescence,5088,O
was,5088,O
utilized,5088,O
to,5088,O
assess,5088,O
Ca,5088,B-CHEMICAL
(,5088,I-CHEMICAL
2+,5088,I-CHEMICAL
),5088,I-CHEMICAL
affinity,5088,O
in,5088,O
isolated,5088,O
cardiac,5088,B-GENE-Y
(,5088,I-GENE-Y
c,5088,I-GENE-Y
),5088,I-GENE-Y
TnCs,5088,I-GENE-Y
containing,5088,O
F27W,5088,B-GENE-N
and,5088,O
did,5088,O
not,5088,O
necessarily,5088,O
mirror,5088,O
the,5088,O
fiber,5088,O
Ca,5088,B-CHEMICAL
(,5088,I-CHEMICAL
2+,5088,I-CHEMICAL
),5088,I-CHEMICAL
sensitivity,5088,O
.,5088,O
Circular,5089,O
dichroism,5089,O
of,5089,O
mutant,5089,O
cTnCs,5089,B-GENE-Y
revealed,5089,O
a,5089,O
trend,5089,O
where,5089,O
increased,5089,O
alpha-helical,5089,O
content,5089,O
correlated,5089,O
with,5089,O
increased,5089,O
Ca,5089,B-CHEMICAL
(,5089,I-CHEMICAL
2+,5089,I-CHEMICAL
),5089,I-CHEMICAL
sensitivity,5089,O
in,5089,O
skinned,5089,O
fibers,5089,O
and,5089,O
vice,5089,O
versa,5089,O
.,5089,O
The,5090,O
main,5090,O
findings,5090,O
from,5090,O
this,5090,O
study,5090,O
were,5090,O
as,5090,O
follows,5090,O
:,5090,O
1,5090,O
),5090,O
cTnC,5090,B-GENE-Y
mutants,5090,O
demonstrated,5090,O
distinct,5090,O
functional,5090,O
phenotypes,5090,O
reminiscent,5090,O
of,5090,O
bona,5090,O
fide,5090,O
HCM,5090,O
",",5090,O
RCM,5090,O
",",5090,O
and,5090,O
DCM,5090,O
mutations,5090,O
;,5090,O
2,5090,O
),5090,O
a,5090,O
region,5090,O
in,5090,O
cTnC,5090,B-GENE-Y
associated,5090,O
with,5090,O
increased,5090,O
Ca,5090,B-CHEMICAL
(,5090,I-CHEMICAL
2+,5090,I-CHEMICAL
),5090,I-CHEMICAL
sensitivity,5090,O
in,5090,O
skinned,5090,O
fibers,5090,O
was,5090,O
identified,5090,O
;,5090,O
and,5090,O
3,5090,O
),5090,O
the,5090,O
F27W,5090,B-GENE-N
reporter,5090,O
mutation,5090,O
affected,5090,O
Ca,5090,B-CHEMICAL
(,5090,I-CHEMICAL
2+,5090,I-CHEMICAL
),5090,I-CHEMICAL
sensitivity,5090,O
",",5090,O
maximal,5090,O
force,5090,O
",",5090,O
and,5090,O
ATPase,5090,B-GENE-N
activation,5090,O
of,5090,O
some,5090,O
mutants,5090,O
.,5090,O
DNA,5091,O
methylation,5091,O
and,5091,O
histone,5091,B-GENE-N
modification,5091,O
profiles,5091,O
of,5091,O
mouse,5091,B-GENE-N
organic,5091,I-GENE-N
anion,5091,I-GENE-N
transporting,5091,I-GENE-N
polypeptides,5091,I-GENE-N
.,5091,O
Organic,5092,B-GENE-N
anion,5092,I-GENE-N
transporting,5092,I-GENE-N
polypeptides,5092,I-GENE-N
(,5092,O
rodents,5092,O
",",5092,O
Oatps,5092,B-GENE-N
;,5092,O
human,5092,O
",",5092,O
OATPs,5092,B-GENE-N
),5092,O
are,5092,O
primarily,5092,O
involved,5092,O
in,5092,O
the,5092,O
transmembrane,5092,O
transportation,5092,O
of,5092,O
a,5092,O
wide,5092,O
range,5092,O
of,5092,O
endogenous,5092,O
and,5092,O
exogenous,5092,O
compounds,5092,O
.,5092,O
Multiple,5093,O
mouse,5093,B-GENE-Y
Oatp1,5093,I-GENE-Y
isoforms,5093,O
are,5093,O
closely,5093,O
located,5093,O
on,5093,O
chromosome,5093,O
6,5093,O
",",5093,O
where,5093,O
each,5093,O
isoform,5093,O
shows,5093,O
distinct,5093,O
tissue,5093,O
distribution,5093,O
;,5093,O
Oatp1b2,5093,B-GENE-Y
",",5093,O
Oatp1a6,5093,B-GENE-N
",",5093,O
and,5093,O
Oatp1c1,5093,B-GENE-Y
are,5093,O
expressed,5093,O
exclusively,5093,O
in,5093,O
the,5093,O
liver,5093,O
",",5093,O
kidney,5093,O
",",5093,O
and,5093,O
cerebrum,5093,O
",",5093,O
respectively,5093,O
;,5093,O
Oatp1a1,5093,B-GENE-Y
in,5093,O
the,5093,O
liver,5093,O
and,5093,O
kidney,5093,O
;,5093,O
and,5093,O
Oatp1a4,5093,B-GENE-Y
in,5093,O
the,5093,O
liver,5093,O
and,5093,O
cerebrum,5093,O
.,5093,O
We,5094,O
have,5094,O
identified,5094,O
tissue-dependent,5094,B-GENE-N
differentially,5094,I-GENE-N
methylated,5094,I-GENE-N
region,5094,I-GENE-N
(,5094,O
T-DMR,5094,B-GENE-N
),5094,O
around,5094,O
the,5094,O
transcriptional,5094,B-GENE-N
start,5094,I-GENE-N
site,5094,I-GENE-N
(,5094,O
TSS,5094,B-GENE-N
),5094,O
of,5094,O
Oatp1b2,5094,B-GENE-Y
",",5094,O
which,5094,O
correlates,5094,O
with,5094,O
its,5094,O
liver-specific,5094,O
expression,5094,O
.,5094,O
Bisulfite,5095,B-CHEMICAL
sequencing,5095,O
also,5095,O
demonstrated,5095,O
the,5095,O
presence,5095,O
of,5095,O
T-DMRs,5095,B-GENE-N
around,5095,O
the,5095,O
TSS,5095,B-GENE-N
in,5095,O
other,5095,O
Oatp1,5095,B-GENE-Y
genes,5095,O
:,5095,O
CpG,5095,O
dinucleotides,5095,O
at,5095,O
+149,5095,O
relative,5095,O
to,5095,O
the,5095,O
TSS,5095,B-GENE-N
for,5095,O
Oatp1c1,5095,B-GENE-Y
;,5095,O
-48,5095,O
",",5095,O
+101,5095,O
",",5095,O
and,5095,O
+356,5095,O
for,5095,O
Oatp1a4,5095,B-GENE-Y
;,5095,O
-572,5095,O
and,5095,O
-550,5095,O
for,5095,O
Oatp1a1,5095,B-GENE-Y
;,5095,O
and,5095,O
-122,5095,O
and,5095,O
+216,5095,O
for,5095,O
Oatp1a6,5095,B-GENE-N
were,5095,O
differentially,5095,O
methylated,5095,O
among,5095,O
the,5095,O
liver,5095,O
",",5095,O
kidney,5095,O
",",5095,O
and,5095,O
cerebrum,5095,O
.,5095,O
These,5096,O
methylation,5096,O
profiles,5096,O
were,5096,O
largely,5096,O
consistent,5096,O
with,5096,O
the,5096,O
tissue,5096,O
distribution,5096,O
of,5096,O
Oatp1,5096,B-GENE-Y
mRNAs,5096,O
.,5096,O
Chromatin,5097,O
immunoprecipitation,5097,O
assay,5097,O
revealed,5097,O
that,5097,O
the,5097,O
mRNA,5097,O
expression,5097,O
of,5097,O
Oatp1,5097,B-GENE-Y
genes,5097,O
was,5097,O
accompanied,5097,O
by,5097,O
acetylated,5097,O
histone,5097,B-GENE-N
H3,5097,I-GENE-N
.,5097,O
Human,5098,B-GENE-Y
OATP1B1,5098,I-GENE-Y
and,5098,O
OATP1B3,5098,B-GENE-Y
are,5098,O
located,5098,O
on,5098,O
chromosome,5098,O
12p12,5098,O
in,5098,O
the,5098,O
OATP1,5098,B-GENE-Y
cluster,5098,O
;,5098,O
both,5098,O
show,5098,O
predominant,5098,O
expression,5098,O
in,5098,O
the,5098,O
liver,5098,O
.,5098,O
These,5099,O
genes,5099,O
also,5099,O
contained,5099,O
T-DMRs,5099,B-GENE-N
that,5099,O
were,5099,O
hypomethylated,5099,O
in,5099,O
the,5099,O
liver,5099,O
",",5099,O
compared,5099,O
with,5099,O
kidney,5099,O
cortex,5099,O
:,5099,O
-511,5099,O
",",5099,O
-411,5099,O
",",5099,O
and,5099,O
+92,5099,O
relative,5099,O
to,5099,O
the,5099,O
TSS,5099,B-GENE-N
for,5099,O
OATP1B1,5099,B-GENE-Y
and,5099,O
-331,5099,O
",",5099,O
+70,5099,O
",",5099,O
and,5099,O
+73,5099,O
for,5099,O
OATP1B3,5099,B-GENE-Y
.,5099,O
These,5100,O
results,5100,O
suggest,5100,O
that,5100,O
the,5100,O
difference,5100,O
in,5100,O
epigenetic,5100,O
profiles,5100,O
comprising,5100,O
DNA,5100,O
methylation,5100,O
and,5100,O
histone,5100,B-GENE-N
acetylation,5100,O
determines,5100,O
the,5100,O
distinct,5100,O
tissue,5100,O
distribution,5100,O
of,5100,O
Oatp/OATP,5100,B-GENE-N
mRNAs,5100,O
.,5100,O
Escitalopram,5101,B-CHEMICAL
.,5101,O
Escitalopram,5102,B-CHEMICAL
oxalate,5102,I-CHEMICAL
(,5102,O
S-citalopram,5102,B-CHEMICAL
",",5102,O
Lexapro,5102,B-CHEMICAL
),5102,O
",",5102,O
a,5102,O
selective,5102,O
serotonin,5102,B-CHEMICAL
re-uptake,5102,O
inhibitor,5102,O
antidepressant,5102,O
which,5102,O
is,5102,O
the,5102,O
S-enantiomer,5102,B-CHEMICAL
of,5102,I-CHEMICAL
citalopram,5102,I-CHEMICAL
",",5102,O
is,5102,O
in,5102,O
clinical,5102,O
development,5102,O
worldwide,5102,O
for,5102,O
the,5102,O
treatment,5102,O
of,5102,O
depression,5102,O
and,5102,O
anxiety,5102,O
disorders,5102,O
.,5102,O
Preclinical,5103,O
studies,5103,O
demonstrate,5103,O
that,5103,O
the,5103,O
therapeutic,5103,O
activity,5103,O
of,5103,O
citalopram,5103,B-CHEMICAL
resides,5103,O
in,5103,O
the,5103,O
S-isomer,5103,O
and,5103,O
that,5103,O
escitalopram,5103,B-CHEMICAL
binds,5103,O
with,5103,O
high,5103,O
affinity,5103,O
to,5103,O
the,5103,O
human,5103,B-GENE-Y
serotonin,5103,I-GENE-Y
transporter,5103,I-GENE-Y
.,5103,O
Conversely,5104,O
",",5104,O
R-citalopram,5104,B-CHEMICAL
is,5104,O
approximately,5104,O
30-fold,5104,O
less,5104,O
potent,5104,O
than,5104,O
escitalopram,5104,B-CHEMICAL
at,5104,O
this,5104,O
transporter,5104,O
.,5104,O
Escitalopram,5105,B-CHEMICAL
has,5105,O
linear,5105,O
pharmacokinetics,5105,O
",",5105,O
so,5105,O
that,5105,O
plasma,5105,O
levels,5105,O
increase,5105,O
proportionately,5105,O
and,5105,O
predictably,5105,O
with,5105,O
increased,5105,O
doses,5105,O
and,5105,O
its,5105,O
half-life,5105,O
of,5105,O
27,5105,O
-,5105,O
32,5105,O
h,5105,O
is,5105,O
consistent,5105,O
with,5105,O
once-daily,5105,O
dosing,5105,O
.,5105,O
In,5106,O
addition,5106,O
",",5106,O
escitalopram,5106,B-CHEMICAL
has,5106,O
negligible,5106,O
effects,5106,O
on,5106,O
cytochrome,5106,B-GENE-N
P450,5106,I-GENE-N
drug-metabolising,5106,O
enzymes,5106,O
in,5106,O
vitro,5106,O
",",5106,O
suggesting,5106,O
a,5106,O
low,5106,O
potential,5106,O
for,5106,O
drug-drug,5106,O
interactions,5106,O
.,5106,O
The,5107,O
efficacy,5107,O
of,5107,O
escitalopram,5107,B-CHEMICAL
in,5107,O
patients,5107,O
with,5107,O
major,5107,O
depressive,5107,O
disorder,5107,O
has,5107,O
been,5107,O
demonstrated,5107,O
in,5107,O
multiple,5107,O
short-term,5107,O
",",5107,O
placebo-controlled,5107,O
clinical,5107,O
trials,5107,O
",",5107,O
three,5107,O
of,5107,O
which,5107,O
included,5107,O
citalopram,5107,B-CHEMICAL
as,5107,O
an,5107,O
active,5107,O
control,5107,O
",",5107,O
as,5107,O
well,5107,O
as,5107,O
in,5107,O
a,5107,O
36-week,5107,O
study,5107,O
evaluating,5107,O
efficacy,5107,O
in,5107,O
the,5107,O
prevention,5107,O
of,5107,O
depression,5107,O
relapse,5107,O
.,5107,O
In,5108,O
these,5108,O
studies,5108,O
",",5108,O
escitalopram,5108,B-CHEMICAL
was,5108,O
shown,5108,O
to,5108,O
have,5108,O
robust,5108,O
efficacy,5108,O
in,5108,O
the,5108,O
treatment,5108,O
of,5108,O
depression,5108,O
and,5108,O
associated,5108,O
symptoms,5108,O
of,5108,O
anxiety,5108,O
relative,5108,O
to,5108,O
placebo,5108,O
.,5108,O
Efficacy,5109,O
has,5109,O
also,5109,O
been,5109,O
shown,5109,O
in,5109,O
treating,5109,O
generalised,5109,O
anxiety,5109,O
disorder,5109,O
",",5109,O
panic,5109,O
disorder,5109,O
and,5109,O
social,5109,O
anxiety,5109,O
disorder,5109,O
.,5109,O
Results,5110,O
also,5110,O
suggest,5110,O
that,5110,O
",",5110,O
at,5110,O
comparable,5110,O
doses,5110,O
",",5110,O
escitalopram,5110,B-CHEMICAL
demonstrates,5110,O
clinically,5110,O
relevant,5110,O
and,5110,O
statistically,5110,O
significant,5110,O
superiority,5110,O
to,5110,O
placebo,5110,O
treatment,5110,O
earlier,5110,O
than,5110,O
citalopram,5110,B-CHEMICAL
.,5110,O
Analysis,5111,O
of,5111,O
the,5111,O
safety,5111,O
database,5111,O
shows,5111,O
a,5111,O
low,5111,O
rate,5111,O
of,5111,O
discontinuation,5111,O
due,5111,O
to,5111,O
adverse,5111,O
events,5111,O
",",5111,O
and,5111,O
there,5111,O
was,5111,O
no,5111,O
statistically,5111,O
significant,5111,O
difference,5111,O
between,5111,O
escitalopram,5111,B-CHEMICAL
10,5111,O
mg/day,5111,O
and,5111,O
placebo,5111,O
in,5111,O
the,5111,O
proportion,5111,O
of,5111,O
patients,5111,O
who,5111,O
discontinued,5111,O
treatment,5111,O
early,5111,O
because,5111,O
of,5111,O
adverse,5111,O
events,5111,O
.,5111,O
The,5112,O
most,5112,O
common,5112,O
adverse,5112,O
events,5112,O
associated,5112,O
with,5112,O
escitalopram,5112,B-CHEMICAL
which,5112,O
occurred,5112,O
at,5112,O
a,5112,O
rate,5112,O
greater,5112,O
than,5112,O
placebo,5112,O
include,5112,O
nausea,5112,O
",",5112,O
insomnia,5112,O
",",5112,O
ejaculation,5112,O
disorder,5112,O
",",5112,O
diarrhoea,5112,O
",",5112,O
dry,5112,O
mouth,5112,O
and,5112,O
somnolence,5112,O
.,5112,O
Only,5113,O
nausea,5113,O
occurred,5113,O
in,5113,O
>,5113,O
10,5113,O
%,5113,O
of,5113,O
escitalopram-treated,5113,B-CHEMICAL
patients,5113,O
.,5113,O
Statins,5114,B-CHEMICAL
increase,5114,O
p21,5114,B-GENE-Y
through,5114,O
inhibition,5114,O
of,5114,O
histone,5114,B-GENE-N
deacetylase,5114,I-GENE-N
activity,5114,O
and,5114,O
release,5114,O
of,5114,O
promoter-associated,5114,O
HDAC1/2,5114,B-GENE-N
.,5114,O
Statins,5115,B-CHEMICAL
are,5115,O
3-hydroxy-3-methylglutaryl-CoA,5115,B-GENE-Y
reductase,5115,I-GENE-Y
inhibitors,5115,O
broadly,5115,O
used,5115,O
for,5115,O
the,5115,O
control,5115,O
of,5115,O
hypercholesterolemia,5115,O
.,5115,O
Recently,5116,O
",",5116,O
they,5116,O
are,5116,O
reported,5116,O
to,5116,O
have,5116,O
beneficial,5116,O
effects,5116,O
on,5116,O
certain,5116,O
cancers,5116,O
.,5116,O
In,5117,O
this,5117,O
study,5117,O
",",5117,O
we,5117,O
show,5117,O
that,5117,O
statins,5117,O
inhibited,5117,O
the,5117,O
histone,5117,B-GENE-N
deacetylase,5117,I-GENE-N
(,5117,O
HDAC,5117,B-GENE-N
),5117,O
activity,5117,O
and,5117,O
increased,5117,O
the,5117,O
accumulation,5117,O
of,5117,O
acetylated,5117,B-GENE-N
histone-H3,5117,I-GENE-N
and,5117,O
the,5117,O
expression,5117,O
of,5117,O
p21,5117,B-GENE-Y
(,5117,O
WAF/CIP,5117,B-GENE-Y
),5117,O
in,5117,O
human,5117,O
cancer,5117,O
cells,5117,O
.,5117,O
Computational,5118,O
modeling,5118,O
showed,5118,O
the,5118,O
direct,5118,O
interaction,5118,O
of,5118,O
the,5118,O
carboxylic,5118,B-CHEMICAL
acid,5118,I-CHEMICAL
moiety,5118,O
of,5118,O
statins,5118,O
with,5118,O
the,5118,O
catalytic,5118,O
site,5118,O
of,5118,O
HDAC2,5118,B-GENE-Y
.,5118,O
In,5119,O
the,5119,O
subsequent,5119,O
enzymatic,5119,O
assay,5119,O
",",5119,O
it,5119,O
was,5119,O
shown,5119,O
that,5119,O
lovastatin,5119,B-CHEMICAL
inhibited,5119,O
HDAC2,5119,B-GENE-Y
activity,5119,O
competitively,5119,O
with,5119,O
a,5119,O
K,5119,O
(,5119,O
i,5119,O
),5119,O
value,5119,O
of,5119,O
31.6,5119,O
micromol/L,5119,O
.,5119,O
Sp1,5120,B-GENE-Y
but,5120,O
not,5120,O
p53,5120,B-GENE-Y
sites,5120,O
were,5120,O
found,5120,O
to,5120,O
be,5120,O
the,5120,O
statins-responsive,5120,B-GENE-N
element,5120,I-GENE-N
shown,5120,O
by,5120,O
p21,5120,B-GENE-Y
luciferase-promoter,5120,O
assays,5120,O
.,5120,O
DNA,5121,O
affinity,5121,O
protein,5121,O
binding,5121,O
assay,5121,O
and,5121,O
chromatin,5121,O
immunoprecipitation,5121,O
assay,5121,O
showed,5121,O
the,5121,O
dissociation,5121,O
of,5121,O
HDAC1/2,5121,B-GENE-N
and,5121,O
association,5121,O
of,5121,O
CBP,5121,B-GENE-Y
",",5121,O
leading,5121,O
to,5121,O
the,5121,O
histone-H3,5121,B-GENE-N
acetylation,5121,O
on,5121,O
the,5121,O
Sp1,5121,B-GENE-Y
sites,5121,O
of,5121,O
p21,5121,B-GENE-N
promoter,5121,I-GENE-N
.,5121,O
In,5122,O
vitro,5122,O
cell,5122,O
proliferation,5122,O
and,5122,O
in,5122,O
vivo,5122,O
tumor,5122,O
growth,5122,O
were,5122,O
both,5122,O
inhibited,5122,O
by,5122,O
statins,5122,O
.,5122,O
These,5123,O
results,5123,O
suggest,5123,O
a,5123,O
novel,5123,O
mechanism,5123,O
for,5123,O
statins,5123,O
through,5123,O
abrogation,5123,O
of,5123,O
the,5123,O
HDAC,5123,B-GENE-N
activity,5123,O
and,5123,O
promoter,5123,O
histone-H3,5123,B-GENE-N
acetylation,5123,O
to,5123,O
regulate,5123,O
p21,5123,B-GENE-Y
expression,5123,O
.,5123,O
Therefore,5124,O
",",5124,O
statins,5124,O
might,5124,O
serve,5124,O
as,5124,O
novel,5124,O
HDAC,5124,B-GENE-N
inhibitors,5124,O
for,5124,O
cancer,5124,O
therapy,5124,O
and,5124,O
chemoprevention,5124,O
.,5124,O
Imatinib,5125,B-CHEMICAL
mesylate,5125,I-CHEMICAL
(,5125,O
Gleevec,5125,B-CHEMICAL
),5125,O
enhances,5125,O
mature,5125,O
osteoclast,5125,O
apoptosis,5125,O
and,5125,O
suppresses,5125,O
osteoclast,5125,O
bone,5125,O
resorbing,5125,O
activity,5125,O
.,5125,O
Recent,5126,O
studies,5126,O
have,5126,O
reported,5126,O
that,5126,O
imatinib,5126,B-CHEMICAL
mesylate,5126,I-CHEMICAL
",",5126,O
a,5126,O
kinase,5126,B-GENE-N
inhibitor,5126,O
that,5126,O
targets,5126,O
the,5126,O
intracellular,5126,O
tyrosine,5126,B-GENE-N
kinase,5126,I-GENE-N
BCR-ABL,5126,B-GENE-Y
and,5126,O
the,5126,O
platelet,5126,B-GENE-N
derived,5126,I-GENE-N
growth,5126,I-GENE-N
factor,5126,I-GENE-N
(,5126,I-GENE-N
PDGF,5126,I-GENE-N
),5126,I-GENE-N
receptor,5126,I-GENE-N
",",5126,O
is,5126,O
an,5126,O
effective,5126,O
inhibitor,5126,O
of,5126,O
the,5126,O
macrophage,5126,B-GENE-Y
colony,5126,I-GENE-Y
stimulating,5126,I-GENE-Y
factor,5126,I-GENE-Y
(,5126,I-GENE-Y
M-CSF,5126,I-GENE-Y
),5126,I-GENE-Y
receptor,5126,I-GENE-Y
",",5126,O
c-FMS,5126,B-GENE-Y
.,5126,O
Given,5127,O
that,5127,O
M-CSF,5127,B-GENE-Y
signalling,5127,O
through,5127,O
c-FMS,5127,B-GENE-Y
plays,5127,O
an,5127,O
important,5127,O
role,5127,O
in,5127,O
osteoclast,5127,O
biology,5127,O
",",5127,O
we,5127,O
speculated,5127,O
that,5127,O
blocking,5127,O
such,5127,O
a,5127,O
pathway,5127,O
with,5127,O
imatinib,5127,B-CHEMICAL
may,5127,O
modulate,5127,O
osteoclast,5127,O
activity,5127,O
.,5127,O
Using,5128,O
a,5128,O
cell,5128,O
model,5128,O
of,5128,O
mature,5128,O
rabbit,5128,O
osteoclasts,5128,O
",",5128,O
we,5128,O
thus,5128,O
investigated,5128,O
the,5128,O
effect,5128,O
of,5128,O
imatinib,5128,B-CHEMICAL
on,5128,O
in,5128,O
vitro,5128,O
osteoclast,5128,O
apoptosis,5128,O
and,5128,O
bone,5128,O
resorbing,5128,O
activity,5128,O
.,5128,O
Our,5129,O
findings,5129,O
demonstrate,5129,O
that,5129,O
imatinib,5129,B-CHEMICAL
dose-dependently,5129,O
stimulates,5129,O
osteoclast,5129,O
apoptosis,5129,O
",",5129,O
a,5129,O
phenomenon,5129,O
which,5129,O
is,5129,O
blocked,5129,O
by,5129,O
the,5129,O
caspase,5129,B-GENE-Y
I,5129,I-GENE-Y
inhibitor,5129,O
Z-VAD-fmk,5129,O
.,5129,O
The,5130,O
ability,5130,O
of,5130,O
imatinib,5130,B-CHEMICAL
to,5130,O
enhance,5130,O
osteoclast,5130,O
cell,5130,O
death,5130,O
was,5130,O
accompanied,5130,O
by,5130,O
a,5130,O
dose-dependent,5130,O
inhibition,5130,O
of,5130,O
osteoclast,5130,O
bone,5130,O
resorbing,5130,O
activity,5130,O
.,5130,O
Imatinib,5131,B-CHEMICAL
was,5131,O
also,5131,O
found,5131,O
to,5131,O
inhibit,5131,O
M-CSF-induced,5131,B-GENE-Y
osteoclast,5131,O
survival,5131,O
as,5131,O
well,5131,O
as,5131,O
M-CSF-induced,5131,B-GENE-Y
osteoclast,5131,O
bone,5131,O
resorbing,5131,O
activity,5131,O
",",5131,O
but,5131,O
was,5131,O
without,5131,O
effect,5131,O
on,5131,O
interleukin,5131,B-GENE-Y
1alpha,5131,I-GENE-Y
(,5131,O
IL-1alpha,5131,B-GENE-Y
),5131,O
and,5131,O
receptor,5131,B-GENE-Y
activator,5131,I-GENE-Y
of,5131,I-GENE-Y
nuclear,5131,I-GENE-Y
factor,5131,I-GENE-Y
kappa,5131,I-GENE-Y
B,5131,I-GENE-Y
ligand,5131,I-GENE-Y
(,5131,O
RANKL,5131,B-GENE-Y
),5131,O
-induced,5131,O
inhibition,5131,O
of,5131,O
osteoclasts,5131,O
apoptosis,5131,O
",",5131,O
further,5131,O
supporting,5131,O
the,5131,O
hypothesis,5131,O
that,5131,O
imatinib,5131,B-CHEMICAL
may,5131,O
affect,5131,O
mature,5131,O
osteoclasts,5131,O
through,5131,O
the,5131,O
inhibition,5131,O
of,5131,O
c-FMS,5131,B-GENE-Y
.,5131,O
Taken,5132,O
together,5132,O
",",5132,O
these,5132,O
results,5132,O
suggest,5132,O
that,5132,O
imatinib,5132,B-CHEMICAL
could,5132,O
be,5132,O
of,5132,O
clinical,5132,O
value,5132,O
in,5132,O
treating,5132,O
diseases,5132,O
where,5132,O
bone,5132,O
destruction,5132,O
can,5132,O
occur,5132,O
due,5132,O
to,5132,O
excessive,5132,O
M-CSF,5132,B-GENE-Y
production,5132,O
such,5132,O
as,5132,O
osteoporosis,5132,O
",",5132,O
inflammatory-and,5132,O
tumor-induced,5132,O
osteolysis,5132,O
.,5132,O
Structural,5133,O
basis,5133,O
for,5133,O
LFA-1,5133,B-GENE-Y
inhibition,5133,O
upon,5133,O
lovastatin,5133,B-CHEMICAL
binding,5133,O
to,5133,O
the,5133,O
CD11a,5133,B-GENE-N
I-domain,5133,I-GENE-N
.,5133,O
The,5134,O
lymphocyte,5134,B-GENE-Y
function-associated,5134,I-GENE-Y
antigen,5134,I-GENE-Y
(,5134,O
LFA-1,5134,B-GENE-Y
),5134,O
belongs,5134,O
to,5134,O
the,5134,O
family,5134,O
of,5134,O
beta2-integrins,5134,B-GENE-Y
and,5134,O
plays,5134,O
an,5134,O
important,5134,O
role,5134,O
in,5134,O
T-cell,5134,O
activation,5134,O
and,5134,O
leukocyte,5134,O
migration,5134,O
to,5134,O
sites,5134,O
of,5134,O
inflammation,5134,O
.,5134,O
We,5135,O
report,5135,O
here,5135,O
that,5135,O
lovastatin,5135,B-CHEMICAL
",",5135,O
a,5135,O
drug,5135,O
clinically,5135,O
used,5135,O
for,5135,O
lowering,5135,O
cholesterol,5135,B-CHEMICAL
levels,5135,O
",",5135,O
inhibits,5135,O
the,5135,O
interaction,5135,O
of,5135,O
human,5135,B-GENE-Y
LFA-1,5135,I-GENE-Y
with,5135,O
its,5135,O
counter-receptor,5135,O
intercellular,5135,B-GENE-Y
adhesion,5135,I-GENE-Y
molecule-1,5135,I-GENE-Y
.,5135,O
Using,5136,O
nuclear,5136,O
magnetic,5136,O
resonance,5136,O
spectroscopy,5136,O
and,5136,O
X-ray,5136,O
crystallography,5136,O
we,5136,O
show,5136,O
that,5136,O
the,5136,O
inhibitor,5136,O
binds,5136,O
to,5136,O
a,5136,O
highly,5136,O
conserved,5136,O
domain,5136,O
of,5136,O
the,5136,O
LFA-1,5136,B-GENE-Y
alpha-chain,5136,I-GENE-Y
called,5136,O
the,5136,O
I-domain,5136,B-GENE-N
.,5136,O
The,5137,O
first,5137,O
three-dimensional,5137,O
structure,5137,O
of,5137,O
an,5137,O
integrin,5137,B-GENE-N
inhibitor,5137,O
bound,5137,O
to,5137,O
its,5137,O
receptor,5137,O
reveals,5137,O
atomic,5137,O
details,5137,O
for,5137,O
a,5137,O
hitherto,5137,O
unknown,5137,O
mode,5137,O
of,5137,O
LFA-1,5137,B-GENE-Y
inhibition,5137,O
.,5137,O
It,5138,O
also,5138,O
sheds,5138,O
light,5138,O
into,5138,O
possible,5138,O
mechanisms,5138,O
of,5138,O
LFA-1,5138,B-GENE-Y
mediated,5138,O
signalling,5138,O
and,5138,O
will,5138,O
support,5138,O
the,5138,O
design,5138,O
of,5138,O
novel,5138,O
anti-adhesive,5138,O
and,5138,O
immunosuppressive,5138,O
drugs,5138,O
.,5138,O
Inhibition,5139,O
of,5139,O
matrix,5139,B-GENE-N
metalloproteinases,5139,I-GENE-N
(,5139,O
MMPs,5139,B-GENE-N
),5139,O
as,5139,O
a,5139,O
potential,5139,O
strategy,5139,O
to,5139,O
ameliorate,5139,O
hypertension-induced,5139,O
cardiovascular,5139,O
alterations,5139,O
.,5139,O
A,5140,O
group,5140,O
of,5140,O
proteases,5140,O
",",5140,O
the,5140,O
matrix,5140,B-GENE-N
metalloproteinases,5140,I-GENE-N
(,5140,O
MMPs,5140,B-GENE-N
),5140,O
are,5140,O
well,5140,O
known,5140,O
for,5140,O
their,5140,O
capacity,5140,O
to,5140,O
degrade,5140,O
extracellular,5140,B-GENE-N
matrix,5140,I-GENE-N
(,5140,I-GENE-N
ECM,5140,I-GENE-N
),5140,I-GENE-N
proteins,5140,I-GENE-N
.,5140,O
Particularly,5141,O
MMP-2,5141,B-GENE-Y
and,5141,O
MMP-9,5141,B-GENE-Y
contribute,5141,O
to,5141,O
the,5141,O
degradation,5141,O
and,5141,O
reorganization,5141,O
of,5141,O
the,5141,O
ECM,5141,O
components,5141,O
and,5141,O
are,5141,O
involved,5141,O
in,5141,O
the,5141,O
pathophysiology,5141,O
of,5141,O
cardiovascular,5141,O
remodeling,5141,O
.,5141,O
Imbalanced,5142,O
MMP,5142,B-GENE-N
activity,5142,O
promotes,5142,O
vascular,5142,O
smooth,5142,O
muscle,5142,O
cells,5142,O
and,5142,O
migration,5142,O
and,5142,O
proliferation,5142,O
and,5142,O
endothelial,5142,O
dysfunction,5142,O
",",5142,O
thus,5142,O
resulting,5142,O
in,5142,O
increased,5142,O
cardiovascular,5142,O
stiffness,5142,O
and,5142,O
hypertrophy,5142,O
.,5142,O
Furthermore,5143,O
",",5143,O
MMP-2,5143,B-GENE-Y
cleaves,5143,O
non-ECM,5143,O
protein,5143,O
substrates,5143,O
including,5143,O
cellular,5143,O
receptors,5143,O
and,5143,O
intracellular,5143,O
proteins,5143,O
",",5143,O
thus,5143,O
causing,5143,O
cardiac,5143,O
and,5143,O
vascular,5143,O
dysfunction,5143,O
.,5143,O
It,5144,O
is,5144,O
now,5144,O
becoming,5144,O
clear,5144,O
that,5144,O
increased,5144,O
MMP,5144,B-GENE-N
activity,5144,O
promotes,5144,O
long-lasting,5144,O
cardiovascular,5144,O
structural,5144,O
and,5144,O
functional,5144,O
alterations,5144,O
in,5144,O
both,5144,O
experimental,5144,O
and,5144,O
clinical,5144,O
hypertension,5144,O
",",5144,O
and,5144,O
this,5144,O
alteration,5144,O
may,5144,O
contribute,5144,O
to,5144,O
sustained,5144,O
hypertension,5144,O
and,5144,O
its,5144,O
complications,5144,O
.,5144,O
Other,5145,O
pathogenic,5145,O
mechanisms,5145,O
including,5145,O
activation,5145,O
of,5145,O
the,5145,O
renin-angiotensin-aldosterone,5145,B-GENE-Y
system,5145,O
and,5145,O
oxidative,5145,O
stress,5145,O
activate,5145,O
and,5145,O
upregulate,5145,O
MMPs,5145,B-GENE-N
.,5145,O
Therefore,5146,O
",",5146,O
MMP,5146,B-GENE-N
inhibition,5146,O
may,5146,O
prevent,5146,O
the,5146,O
deleterious,5146,O
consequences,5146,O
of,5146,O
hypertension,5146,O
to,5146,O
the,5146,O
cardiovascular,5146,O
system,5146,O
.,5146,O
This,5147,O
review,5147,O
article,5147,O
will,5147,O
focus,5147,O
on,5147,O
growing,5147,O
evidence,5147,O
supporting,5147,O
the,5147,O
relevance,5147,O
of,5147,O
MMPs,5147,B-GENE-N
in,5147,O
hypertension,5147,O
and,5147,O
the,5147,O
effects,5147,O
of,5147,O
MMP,5147,B-GENE-N
inhibitors,5147,O
.,5147,O
Particularly,5148,O
",",5148,O
the,5148,O
effects,5148,O
of,5148,O
doxycycline,5148,B-CHEMICAL
used,5148,O
as,5148,O
a,5148,O
non,5148,O
selective,5148,O
MMP,5148,B-GENE-N
inhibitor,5148,O
in,5148,O
experimental,5148,O
and,5148,O
clinical,5148,O
studies,5148,O
will,5148,O
be,5148,O
discussed,5148,O
.,5148,O
Time-dependent,5149,O
changes,5149,O
in,5149,O
hepatic,5149,O
and,5149,O
intestinal,5149,O
induction,5149,O
of,5149,O
cytochrome,5149,B-GENE-N
P450,5149,I-GENE-N
3A,5149,I-GENE-N
after,5149,O
administration,5149,O
of,5149,O
dexamethasone,5149,B-CHEMICAL
to,5149,O
rats,5149,O
.,5149,O
Abstract,5150,O
1,5150,O
.,5150,O
We,5151,O
investigated,5151,O
the,5151,O
effects,5151,O
of,5151,O
the,5151,O
dose,5151,O
of,5151,O
and,5151,O
the,5151,O
number,5151,O
of,5151,O
times,5151,O
an,5151,O
inducer,5151,O
was,5151,O
administered,5151,O
and,5151,O
the,5151,O
duration,5151,O
of,5151,O
induction,5151,O
of,5151,O
hepatic,5151,O
and,5151,O
intestinal,5151,O
cytochrome,5151,B-GENE-N
P450,5151,I-GENE-N
3A,5151,I-GENE-N
(,5151,O
CYP3A,5151,B-GENE-N
),5151,O
in,5151,O
rats,5151,O
using,5151,O
dexamethasone,5151,B-CHEMICAL
21-phosphate,5151,I-CHEMICAL
(,5151,O
DEX-P,5151,B-CHEMICAL
),5151,O
and,5151,O
midazolam,5151,B-CHEMICAL
(,5151,O
MDZ,5151,B-CHEMICAL
),5151,O
as,5151,O
an,5151,O
inducer,5151,O
and,5151,O
a,5151,O
substrate,5151,O
to,5151,O
CYP3A,5151,B-GENE-N
",",5151,O
respectively,5151,O
.,5151,O
2,5152,O
.,5152,O
The,5153,O
number,5153,O
of,5153,O
times,5153,O
DEX-P,5153,B-CHEMICAL
was,5153,O
administered,5153,O
was,5153,O
not,5153,O
a,5153,O
significant,5153,O
factor,5153,O
in,5153,O
the,5153,O
induction,5153,O
of,5153,O
either,5153,O
hepatic,5153,O
or,5153,O
intestinal,5153,O
CYP3A,5153,B-GENE-N
;,5153,O
however,5153,O
",",5153,O
administration,5153,O
of,5153,O
DEX-P,5153,B-CHEMICAL
multiple,5153,O
times,5153,O
markedly,5153,O
decreased,5153,O
the,5153,O
bioavailability,5153,O
of,5153,O
DEX-P,5153,B-CHEMICAL
by,5153,O
self-induction,5153,O
of,5153,O
CYP3A,5153,B-GENE-N
.,5153,O
3,5154,O
.,5154,O
CYP3A,5155,B-GENE-N
induction,5155,O
in,5155,O
the,5155,O
liver,5155,O
increased,5155,O
depending,5155,O
on,5155,O
the,5155,O
dose,5155,O
of,5155,O
DEX-P,5155,B-CHEMICAL
",",5155,O
whereas,5155,O
that,5155,O
in,5155,O
intestine,5155,O
showed,5155,O
a,5155,O
mild,5155,O
increase,5155,O
",",5155,O
but,5155,O
the,5155,O
induction,5155,O
level,5155,O
was,5155,O
almost,5155,O
constant,5155,O
regardless,5155,O
of,5155,O
the,5155,O
dose,5155,O
of,5155,O
DEX-P.,5155,B-CHEMICAL
4,5155,O
.,5155,O
Administration,5156,O
of,5156,O
a,5156,O
single,5156,O
dose,5156,O
of,5156,O
DEX-P,5156,B-CHEMICAL
showed,5156,O
a,5156,O
temporal,5156,O
increase,5156,O
in,5156,O
CYP3A,5156,B-GENE-N
activity,5156,O
in,5156,O
both,5156,O
tissues,5156,O
and,5156,O
the,5156,O
induction,5156,O
ratios,5156,O
reached,5156,O
maximum,5156,O
values,5156,O
at,5156,O
12,5156,O
h,5156,O
after,5156,O
DEX-P,5156,B-CHEMICAL
administration,5156,O
.,5156,O
On,5157,O
the,5157,O
other,5157,O
hand,5157,O
",",5157,O
a,5157,O
mild,5157,O
increase,5157,O
of,5157,O
CYP3A,5157,B-GENE-N
activity,5157,O
",",5157,O
which,5157,O
lasted,5157,O
for,5157,O
at,5157,O
least,5157,O
48,5157,O
h,5157,O
",",5157,O
was,5157,O
observed,5157,O
in,5157,O
both,5157,O
tissues,5157,O
after,5157,O
administration,5157,O
of,5157,O
multiple,5157,O
doses,5157,O
.,5157,O
5,5158,O
.,5158,O
Some,5159,O
physiological,5159,O
compounds,5159,O
such,5159,O
as,5159,O
cytokines,5159,B-GENE-N
might,5159,O
be,5159,O
involved,5159,O
in,5159,O
decreasing,5159,O
the,5159,O
CYP3A,5159,B-GENE-N
activity,5159,O
to,5159,O
maintain,5159,O
homeostasis,5159,O
of,5159,O
the,5159,O
body,5159,O
.,5159,O
Autoradiographic,5160,O
study,5160,O
of,5160,O
serotonin,5160,B-GENE-Y
transporter,5160,I-GENE-Y
during,5160,O
memory,5160,O
formation,5160,O
.,5160,O
Serotonin,5161,B-GENE-Y
transporter,5161,I-GENE-Y
(,5161,O
SERT,5161,B-GENE-Y
),5161,O
has,5161,O
been,5161,O
associated,5161,O
with,5161,O
drugs,5161,O
of,5161,O
abuse,5161,O
like,5161,O
d-methamphetamine,5161,B-CHEMICAL
(,5161,O
METH,5161,B-CHEMICAL
),5161,O
.,5161,O
METH,5162,B-CHEMICAL
is,5162,O
well,5162,O
known,5162,O
to,5162,O
produce,5162,O
effects,5162,O
on,5162,O
the,5162,O
monoamine,5162,B-CHEMICAL
systems,5162,O
but,5162,O
it,5162,O
is,5162,O
unclear,5162,O
how,5162,O
METH,5162,B-CHEMICAL
affects,5162,O
SERT,5162,B-GENE-Y
and,5162,O
memory,5162,O
.,5162,O
Here,5163,O
the,5163,O
effects,5163,O
of,5163,O
METH,5163,B-CHEMICAL
and,5163,O
the,5163,O
serotonin,5163,B-CHEMICAL
reuptake,5163,O
inhibitor,5163,O
fluoxetine,5163,B-CHEMICAL
(,5163,O
FLX,5163,B-CHEMICAL
),5163,O
on,5163,O
autoshaping,5163,O
and,5163,O
novel,5163,O
object,5163,O
recognition,5163,O
(,5163,O
NOR,5163,O
),5163,O
were,5163,O
investigated,5163,O
.,5163,O
Notably,5164,O
",",5164,O
both,5164,O
memory,5164,O
tasks,5164,O
recruit,5164,O
different,5164,O
behavioral,5164,O
",",5164,O
neural,5164,O
and,5164,O
cognitive,5164,O
demand,5164,O
.,5164,O
In,5165,O
autoshaping,5165,O
task,5165,O
a,5165,O
dose-response,5165,O
curve,5165,O
for,5165,O
METH,5165,B-CHEMICAL
was,5165,O
determined,5165,O
.,5165,O
METH,5166,B-CHEMICAL
(,5166,O
1.0mg/kg,5166,O
),5166,O
impaired,5166,O
short-term,5166,O
memory,5166,O
(,5166,O
STM,5166,O
;,5166,O
lasting,5166,O
less,5166,O
of,5166,O
90min,5166,O
),5166,O
in,5166,O
NOR,5166,O
and,5166,O
impaired,5166,O
both,5166,O
STM,5166,O
and,5166,O
long-term,5166,O
memory,5166,O
(,5166,O
LTM,5166,O
;,5166,O
lasting,5166,O
24,5166,O
and,5166,O
48h,5166,O
),5166,O
in,5166,O
autoshaping,5166,O
",",5166,O
indicating,5166,O
that,5166,O
METH,5166,B-CHEMICAL
had,5166,O
long-lasting,5166,O
effects,5166,O
in,5166,O
the,5166,O
latter,5166,O
task,5166,O
.,5166,O
A,5167,O
comparative,5167,O
autoradiography,5167,O
study,5167,O
of,5167,O
the,5167,O
relationship,5167,O
between,5167,O
the,5167,O
binding,5167,O
pattern,5167,O
of,5167,O
SERT,5167,B-GENE-Y
in,5167,O
autoshaping,5167,O
new,5167,O
untrained,5167,O
vs.,5167,O
trained,5167,O
treated,5167,O
(,5167,O
METH,5167,B-CHEMICAL
",",5167,O
FLX,5167,B-CHEMICAL
",",5167,O
or,5167,O
both,5167,O
),5167,O
animals,5167,O
was,5167,O
made,5167,O
.,5167,O
Considering,5168,O
that,5168,O
hemispheric,5168,O
dominance,5168,O
is,5168,O
important,5168,O
for,5168,O
LTM,5168,O
",",5168,O
hence,5168,O
right,5168,O
vs.,5168,O
left,5168,O
hemisphere,5168,O
of,5168,O
the,5168,O
brain,5168,O
was,5168,O
compared,5168,O
.,5168,O
Results,5169,O
showed,5169,O
that,5169,O
trained,5169,O
animals,5169,O
decreased,5169,O
cortical,5169,O
SERT,5169,B-GENE-Y
binding,5169,O
relative,5169,O
to,5169,O
untrained,5169,O
ones,5169,O
.,5169,O
In,5170,O
untrained,5170,O
and,5170,O
trained,5170,O
treated,5170,O
animals,5170,O
with,5170,O
the,5170,O
amnesic,5170,O
dose,5170,O
(,5170,O
1.0mg/kg,5170,O
),5170,O
of,5170,O
METH,5170,B-CHEMICAL
SERT,5170,B-GENE-Y
binding,5170,O
in,5170,O
several,5170,O
areas,5170,O
including,5170,O
hippocampus,5170,O
and,5170,O
cortex,5170,O
decreased,5170,O
",",5170,O
more,5170,O
remarkably,5170,O
in,5170,O
the,5170,O
trained,5170,O
animals,5170,O
.,5170,O
In,5171,O
contrast,5171,O
",",5171,O
FLX,5171,O
improved,5171,O
memory,5171,O
",",5171,O
increased,5171,O
SERT,5171,B-GENE-Y
binding,5171,O
",",5171,O
prevented,5171,O
the,5171,O
METH,5171,B-CHEMICAL
amnesic,5171,O
effect,5171,O
and,5171,O
re-established,5171,O
the,5171,O
SERT,5171,B-GENE-Y
binding,5171,O
.,5171,O
In,5172,O
general,5172,O
",",5172,O
memory,5172,O
and,5172,O
amnesia,5172,O
seemed,5172,O
to,5172,O
make,5172,O
SERT,5172,B-GENE-Y
more,5172,O
vulnerable,5172,O
to,5172,O
drugs,5172,O
effects,5172,O
.,5172,O
Hypoxia,5173,O
and,5173,O
lactate,5173,B-CHEMICAL
production,5173,O
in,5173,O
trophoblast,5173,O
cells,5173,O
.,5173,O
The,5174,O
etiology,5174,O
of,5174,O
preeclampsia,5174,O
is,5174,O
unknown,5174,O
but,5174,O
is,5174,O
thought,5174,O
to,5174,O
be,5174,O
related,5174,O
to,5174,O
hypoxia,5174,O
in,5174,O
the,5174,O
placenta,5174,O
.,5174,O
We,5175,O
previously,5175,O
reported,5175,O
that,5175,O
the,5175,O
enzyme,5175,O
lactate,5175,B-GENE-N
dehydrogenase,5175,I-GENE-N
(,5175,O
LDH,5175,B-GENE-N
),5175,O
has,5175,O
increased,5175,O
activity,5175,O
and,5175,O
gene,5175,O
expression,5175,O
in,5175,O
placentas,5175,O
from,5175,O
preeclamptic,5175,O
pregnancies,5175,O
[,5175,O
Tsoi,5175,O
SCM,5175,O
",",5175,O
Zheng,5175,O
J,5175,O
",",5175,O
Xu,5175,O
F,5175,O
",",5175,O
Kay,5175,O
HH,5175,O
.,5175,O
Differential,5176,O
expression,5176,O
of,5176,O
lactate,5176,B-GENE-N
dehydrogenase,5176,I-GENE-N
isozymes,5176,O
(,5176,O
LDH,5176,B-GENE-N
),5176,O
in,5176,O
human,5176,O
placenta,5176,O
with,5176,O
high,5176,O
expression,5176,O
of,5176,O
LDH-A,5176,B-GENE-Y
(,5176,I-GENE-Y
4,5176,I-GENE-Y
),5176,I-GENE-Y
isozyme,5176,O
in,5176,O
the,5176,O
endothelial,5176,O
cells,5176,O
of,5176,O
pre-eclampsia,5176,O
villi,5176,O
.,5176,O
Placenta,5177,O
2001,5177,O
;,5177,O
22:317-22,5177,O
],5177,O
.,5177,O
LDH,5178,B-GENE-N
is,5178,O
responsible,5178,O
for,5178,O
pyruvate,5178,B-CHEMICAL
conversion,5178,O
to,5178,O
lactate,5178,B-CHEMICAL
through,5178,O
glycolysis,5178,O
.,5178,O
In,5179,O
this,5179,O
study,5179,O
",",5179,O
we,5179,O
further,5179,O
investigated,5179,O
the,5179,O
role,5179,O
of,5179,O
hypoxia,5179,O
in,5179,O
primary,5179,O
trophoblast,5179,O
cells,5179,O
and,5179,O
a,5179,O
cultured,5179,O
cell,5179,O
line,5179,O
",",5179,O
JEG3,5179,O
cells,5179,O
",",5179,O
to,5179,O
obtain,5179,O
a,5179,O
better,5179,O
understanding,5179,O
of,5179,O
how,5179,O
it,5179,O
affects,5179,O
the,5179,O
activities,5179,O
of,5179,O
lactate,5179,B-GENE-N
dehydrogenase,5179,I-GENE-N
",",5179,O
lactate,5179,B-CHEMICAL
production,5179,O
and,5179,O
regulatory,5179,O
genes,5179,O
",",5179,O
as,5179,O
a,5179,O
possible,5179,O
model,5179,O
for,5179,O
preeclampsia,5179,O
.,5179,O
Primary,5180,O
trophoblast,5180,O
cells,5180,O
and,5180,O
JEG3,5180,O
cells,5180,O
were,5180,O
cultured,5180,O
under,5180,O
1,5180,O
%,5180,O
oxygen,5180,B-CHEMICAL
.,5180,O
At,5181,O
6,5181,O
",",5181,O
12,5181,O
and,5181,O
24h,5181,O
",",5181,O
cells,5181,O
were,5181,O
analyzed,5181,O
for,5181,O
LDHA,5181,B-GENE-Y
and,5181,O
LDHB,5181,B-GENE-Y
isozyme,5181,O
activities,5181,O
",",5181,O
mRNA,5181,O
and,5181,O
protein,5181,O
expression,5181,O
compared,5181,O
to,5181,O
standard,5181,O
culture,5181,O
conditions,5181,O
.,5181,O
Lactate,5182,B-CHEMICAL
was,5182,O
measured,5182,O
from,5182,O
cell,5182,O
medium,5182,O
.,5182,O
The,5183,O
hypoxia,5183,B-GENE-N
inducible,5183,I-GENE-N
transcription,5183,I-GENE-N
factor,5183,I-GENE-N
(,5183,O
HIF-1alpha,5183,B-GENE-Y
),5183,O
protein,5183,O
expression,5183,O
was,5183,O
confirmed,5183,O
by,5183,O
western,5183,O
blot,5183,O
.,5183,O
Two,5184,O
lactate,5184,B-GENE-N
transporters,5184,I-GENE-N
(,5184,O
MCT1,5184,B-GENE-Y
and,5184,O
MCT4,5184,B-GENE-Y
),5184,O
mRNA,5184,O
and,5184,O
protein,5184,O
expression,5184,O
were,5184,O
also,5184,O
studied,5184,O
under,5184,O
hypoxia,5184,O
.,5184,O
Finally,5185,O
",",5185,O
lactate,5185,B-CHEMICAL
was,5185,O
measured,5185,O
in,5185,O
plasma,5185,O
obtained,5185,O
from,5185,O
patients,5185,O
with,5185,O
severe,5185,O
preeclampsia,5185,O
.,5185,O
Under,5186,O
hypoxic,5186,O
conditions,5186,O
",",5186,O
LDHA,5186,B-GENE-Y
mRNA,5186,O
is,5186,O
increased,5186,O
in,5186,O
primary,5186,O
trophoblast,5186,O
cells,5186,O
and,5186,O
JEG3,5186,O
cells,5186,O
.,5186,O
The,5187,O
HIF-1alpha,5187,B-GENE-Y
protein,5187,O
expression,5187,O
is,5187,O
higher,5187,O
in,5187,O
hypoxia-treated,5187,O
JEG3,5187,O
cells,5187,O
than,5187,O
control,5187,O
.,5187,O
LDHA,5188,B-GENE-Y
isozyme,5188,O
activity,5188,O
and,5188,O
its,5188,O
protein,5188,O
expression,5188,O
are,5188,O
increased,5188,O
most,5188,O
significantly,5188,O
at,5188,O
24h,5188,O
of,5188,O
culture,5188,O
under,5188,O
hypoxia,5188,O
.,5188,O
However,5189,O
",",5189,O
LDHB,5189,B-GENE-Y
protein,5189,O
is,5189,O
unchanged,5189,O
while,5189,O
its,5189,O
mRNA,5189,O
is,5189,O
decreased,5189,O
.,5189,O
Lactate,5190,B-CHEMICAL
secretion,5190,O
from,5190,O
JEG3,5190,O
cells,5190,O
under,5190,O
hypoxia,5190,O
is,5190,O
increased,5190,O
",",5190,O
as,5190,O
is,5190,O
the,5190,O
lactate,5190,B-CHEMICAL
levels,5190,O
in,5190,O
the,5190,O
plasma,5190,O
from,5190,O
preeclampsia,5190,O
patients,5190,O
.,5190,O
Of,5191,O
the,5191,O
two,5191,O
lactate,5191,B-CHEMICAL
transporters,5191,O
studied,5191,O
",",5191,O
MCT4,5191,B-GENE-Y
mRNA,5191,O
and,5191,O
protein,5191,O
level,5191,O
are,5191,O
increased,5191,O
under,5191,O
hypoxia,5191,O
.,5191,O
Our,5192,O
findings,5192,O
support,5192,O
the,5192,O
role,5192,O
of,5192,O
hypoxia,5192,O
in,5192,O
inducing,5192,O
HIF-1alpha,5192,B-GENE-Y
activity,5192,O
in,5192,O
trophoblasts,5192,O
and,5192,O
increasing,5192,O
LDH,5192,B-GENE-N
transcription,5192,O
as,5192,O
well,5192,O
as,5192,O
its,5192,O
activity,5192,O
.,5192,O
Higher,5193,O
levels,5193,O
of,5193,O
lactate,5193,B-CHEMICAL
are,5193,O
produced,5193,O
and,5193,O
secreted,5193,O
which,5193,O
may,5193,O
contribute,5193,O
to,5193,O
the,5193,O
higher,5193,O
lactate,5193,B-CHEMICAL
levels,5193,O
in,5193,O
plasma,5193,O
of,5193,O
preeclamptic,5193,O
patients,5193,O
.,5193,O
These,5194,O
mechanisms,5194,O
may,5194,O
be,5194,O
important,5194,O
in,5194,O
the,5194,O
pathophysiology,5194,O
of,5194,O
preeclampsia,5194,O
.,5194,O
Preclinical,5195,O
pharmacokinetics,5195,O
and,5195,O
in,5195,O
vitro,5195,O
metabolism,5195,O
of,5195,O
dasatinib,5195,B-CHEMICAL
(,5195,O
BMS-354825,5195,B-CHEMICAL
),5195,O
:,5195,O
a,5195,O
potent,5195,O
oral,5195,O
multi-targeted,5195,O
kinase,5195,B-GENE-N
inhibitor,5195,O
against,5195,O
SRC,5195,B-GENE-Y
and,5195,O
BCR-ABL,5195,B-GENE-Y
.,5195,O
PURPOSE,5196,O
:,5196,O
Dasatinib,5196,B-CHEMICAL
(,5196,O
BMS-354825,5196,B-CHEMICAL
),5196,O
",",5196,O
a,5196,O
potent,5196,O
oral,5196,O
multi-targeted,5196,O
kinase,5196,B-GENE-N
inhibitor,5196,O
against,5196,O
SRC,5196,B-GENE-Y
and,5196,O
BCR-ABL,5196,B-GENE-Y
",",5196,O
has,5196,O
recently,5196,O
been,5196,O
approved,5196,O
for,5196,O
the,5196,O
treatment,5196,O
of,5196,O
chronic,5196,O
myelogenous,5196,O
leukaemia,5196,O
(,5196,O
CML,5196,O
),5196,O
in,5196,O
imatinib-acquired,5196,B-CHEMICAL
resistance,5196,O
and,5196,O
intolerance,5196,O
.,5196,O
In,5197,O
vitro,5197,O
and,5197,O
in,5197,O
vivo,5197,O
studies,5197,O
were,5197,O
conducted,5197,O
to,5197,O
characterize,5197,O
the,5197,O
pharmacokinetics,5197,O
and,5197,O
metabolism,5197,O
of,5197,O
dasatinib,5197,B-CHEMICAL
in,5197,O
mouse,5197,O
",",5197,O
rat,5197,O
",",5197,O
dog,5197,O
",",5197,O
and,5197,O
monkey,5197,O
.,5197,O
Possible,5198,O
mechanisms,5198,O
contributing,5198,O
to,5198,O
the,5198,O
incomplete,5198,O
oral,5198,O
bioavailability,5198,O
of,5198,O
dasatinib,5198,B-CHEMICAL
in,5198,O
animals,5198,O
were,5198,O
investigated,5198,O
.,5198,O
METHODS,5199,O
:,5199,O
Metabolic,5199,O
stability,5199,O
of,5199,O
dasatinib,5199,B-CHEMICAL
was,5199,O
measured,5199,O
after,5199,O
incubation,5199,O
with,5199,O
liver,5199,O
microsomes,5199,O
(,5199,O
either,5199,O
NADPH-,5199,B-CHEMICAL
or,5199,O
UDPGA-fortified,5199,B-CHEMICAL
),5199,O
and,5199,O
isolated,5199,O
hepatocytes,5199,O
obtained,5199,O
from,5199,O
mouse,5199,O
",",5199,O
rat,5199,O
",",5199,O
dog,5199,O
",",5199,O
monkey,5199,O
",",5199,O
and,5199,O
human,5199,O
.,5199,O
In,5200,O
all,5200,O
cases,5200,O
",",5200,O
substrate,5200,O
depletion,5200,O
over,5200,O
time,5200,O
was,5200,O
measured,5200,O
",",5200,O
and,5200,O
appropriate,5200,O
scaling,5200,O
factors,5200,O
were,5200,O
used,5200,O
to,5200,O
predict,5200,O
in,5200,O
vivo,5200,O
clearance,5200,O
.,5200,O
Pharmacokinetics,5201,O
of,5201,O
dasatinib,5201,B-CHEMICAL
were,5201,O
determined,5201,O
in,5201,O
mice,5201,O
",",5201,O
rats,5201,O
",",5201,O
dogs,5201,O
",",5201,O
and,5201,O
monkeys,5201,O
after,5201,O
administration,5201,O
of,5201,O
single,5201,O
intravenous,5201,O
or,5201,O
oral,5201,O
doses,5201,O
.,5201,O
In,5202,O
addition,5202,O
",",5202,O
the,5202,O
routes,5202,O
of,5202,O
excretion,5202,O
were,5202,O
investigated,5202,O
after,5202,O
administration,5202,O
of,5202,O
dasatinib,5202,B-CHEMICAL
to,5202,O
bile,5202,O
duct,5202,O
cannulated,5202,O
(,5202,O
BDC,5202,O
),5202,O
rats,5202,O
.,5202,O
Absorption,5203,O
and,5203,O
first-pass,5203,O
metabolism,5203,O
were,5203,O
evaluated,5203,O
as,5203,O
possible,5203,O
reasons,5203,O
for,5203,O
the,5203,O
incomplete,5203,O
oral,5203,O
bioavailability,5203,O
using,5203,O
various,5203,O
in,5203,O
vitro,5203,O
and,5203,O
in,5203,O
vivo,5203,O
models,5203,O
like,5203,O
Caco-2,5203,O
cells,5203,O
",",5203,O
P-glycoprotein,5203,B-GENE-N
(,5203,O
P-gp,5203,B-GENE-N
),5203,O
knockout,5203,O
mice,5203,O
",",5203,O
and,5203,O
intra-portal,5203,O
dosing,5203,O
in,5203,O
rats,5203,O
.,5203,O
RESULTS,5204,O
:,5204,O
In,5204,O
vivo,5204,O
systemic,5204,O
plasma,5204,O
clearance,5204,O
values,5204,O
of,5204,O
dasatinib,5204,B-CHEMICAL
were,5204,O
62,5204,O
",",5204,O
26,5204,O
",",5204,O
25,5204,O
",",5204,O
and,5204,O
34,5204,O
ml/min/kg,5204,O
in,5204,O
mouse,5204,O
",",5204,O
rat,5204,O
",",5204,O
dog,5204,O
",",5204,O
and,5204,O
monkey,5204,O
",",5204,O
respectively,5204,O
.,5204,O
Scaling,5205,O
of,5205,O
in,5205,O
vitro,5205,O
hepatocyte,5205,O
and,5205,O
liver,5205,O
microsomal,5205,O
data,5205,O
gave,5205,O
reasonably,5205,O
good,5205,O
predictions,5205,O
of,5205,O
in,5205,O
vivo,5205,O
clearances,5205,O
across,5205,O
all,5205,O
species,5205,O
.,5205,O
Percent,5206,O
distribution,5206,O
in,5206,O
blood,5206,O
cells,5206,O
ranged,5206,O
from,5206,O
43,5206,O
%,5206,O
in,5206,O
mouse,5206,O
to,5206,O
57,5206,O
%,5206,O
in,5206,O
dog,5206,O
.,5206,O
Dasatinib,5207,B-CHEMICAL
showed,5207,O
high,5207,O
volumes,5207,O
of,5207,O
distribution,5207,O
(,5207,O
>,5207,O
3,5207,O
l/kg,5207,O
),5207,O
and,5207,O
high,5207,O
serum,5207,O
protein,5207,O
binding,5207,O
values,5207,O
(,5207,O
>,5207,O
90,5207,O
%,5207,O
),5207,O
in,5207,O
all,5207,O
four,5207,O
species,5207,O
tested,5207,O
.,5207,O
Oral,5208,O
bioavailability,5208,O
of,5208,O
dasatinib,5208,B-CHEMICAL
ranged,5208,O
from,5208,O
14,5208,O
%,5208,O
in,5208,O
the,5208,O
mouse,5208,O
to,5208,O
34,5208,O
%,5208,O
in,5208,O
the,5208,O
dog,5208,O
.,5208,O
In,5209,O
rats,5209,O
",",5209,O
bioavailability,5209,O
after,5209,O
an,5209,O
intraportal,5209,O
dose,5209,O
was,5209,O
comparable,5209,O
to,5209,O
that,5209,O
after,5209,O
intra-arterial,5209,O
administration,5209,O
.,5209,O
In,5210,O
BDC,5210,O
rats,5210,O
",",5210,O
less,5210,O
than,5210,O
15,5210,O
%,5210,O
of,5210,O
an,5210,O
intravenous,5210,O
dose,5210,O
was,5210,O
excreted,5210,O
unchanged,5210,O
in,5210,O
urine,5210,O
",",5210,O
bile,5210,O
",",5210,O
and,5210,O
the,5210,O
gastrointestinal,5210,O
tract,5210,O
",",5210,O
suggesting,5210,O
that,5210,O
dasatinib,5210,B-CHEMICAL
is,5210,O
cleared,5210,O
primarily,5210,O
via,5210,O
metabolism,5210,O
.,5210,O
Dasatinib,5211,B-CHEMICAL
has,5211,O
high,5211,O
intrinsic,5211,O
permeability,5211,O
in,5211,O
Caco-2,5211,O
cells,5211,O
",",5211,O
however,5211,O
",",5211,O
the,5211,O
efflux,5211,O
ratio,5211,O
was,5211,O
approximately,5211,O
two-fold,5211,O
indicating,5211,O
that,5211,O
it,5211,O
may,5211,O
be,5211,O
a,5211,O
substrate,5211,O
for,5211,O
an,5211,O
intestinal,5211,O
efflux,5211,O
transporter,5211,O
.,5211,O
However,5212,O
",",5212,O
in,5212,O
vivo,5212,O
studies,5212,O
in,5212,O
P-gp,5212,B-GENE-N
knockout,5212,O
mice,5212,O
versus,5212,O
wild-type,5212,O
mice,5212,O
showed,5212,O
no,5212,O
difference,5212,O
in,5212,O
the,5212,O
amount,5212,O
of,5212,O
dasatinib,5212,B-CHEMICAL
remaining,5212,O
unabsorbed,5212,O
in,5212,O
the,5212,O
gastrointestinal,5212,O
tract,5212,O
",",5212,O
suggesting,5212,O
that,5212,O
P-gp,5212,B-GENE-N
may,5212,O
not,5212,O
be,5212,O
responsible,5212,O
for,5212,O
the,5212,O
incomplete,5212,O
bioavailability,5212,O
.,5212,O
CONCLUSIONS,5213,O
:,5213,O
Dasatinib,5213,B-CHEMICAL
shows,5213,O
intermediate,5213,O
clearance,5213,O
in,5213,O
mouse,5213,O
",",5213,O
rat,5213,O
",",5213,O
dog,5213,O
",",5213,O
and,5213,O
monkey,5213,O
",",5213,O
and,5213,O
distributes,5213,O
extensively,5213,O
in,5213,O
those,5213,O
species,5213,O
.,5213,O
Oxidative,5214,O
metabolism,5214,O
appears,5214,O
to,5214,O
be,5214,O
the,5214,O
predominant,5214,O
clearance,5214,O
pathway,5214,O
.,5214,O
The,5215,O
incomplete,5215,O
oral,5215,O
bioavailability,5215,O
may,5215,O
be,5215,O
due,5215,O
to,5215,O
both,5215,O
incomplete,5215,O
absorption,5215,O
and,5215,O
high,5215,O
first-pass,5215,O
metabolism,5215,O
.,5215,O
However,5216,O
",",5216,O
the,5216,O
efflux,5216,B-GENE-N
transporter,5216,I-GENE-N
",",5216,O
P-glycoprotein,5216,B-GENE-N
does,5216,O
not,5216,O
appear,5216,O
to,5216,O
be,5216,O
limiting,5216,O
oral,5216,O
absorption,5216,O
.,5216,O
Genetic,5217,O
linkage,5217,O
of,5217,O
Fc,5217,B-GENE-Y
gamma,5217,I-GENE-Y
RIIa,5217,I-GENE-Y
and,5217,O
Fc,5217,B-GENE-Y
gamma,5217,I-GENE-Y
RIIIa,5217,I-GENE-Y
and,5217,O
implications,5217,O
for,5217,O
their,5217,O
use,5217,O
in,5217,O
predicting,5217,O
clinical,5217,O
responses,5217,O
to,5217,O
CD20-directed,5217,B-GENE-Y
monoclonal,5217,O
antibody,5217,O
therapy,5217,O
.,5217,O
BACKGROUND,5218,O
:,5218,O
Polymorphisms,5218,O
in,5218,O
FcgammaRIIa,5218,B-GENE-Y
and,5218,O
FcgammaRIIIa,5218,B-GENE-Y
receptors,5218,O
are,5218,O
associated,5218,O
with,5218,O
responses,5218,O
to,5218,O
the,5218,O
CD20-directed,5218,B-GENE-Y
immunoglobulin,5218,B-GENE-Y
G1,5218,I-GENE-Y
(,5218,O
IgG1,5218,B-GENE-Y
),5218,O
monoclonal,5218,O
antibody,5218,O
rituximab,5218,O
among,5218,O
patients,5218,O
with,5218,O
indolent,5218,O
lymphoma,5218,O
.,5218,O
At,5219,O
odds,5219,O
with,5219,O
the,5219,O
aforementioned,5219,O
clinical,5219,O
observations,5219,O
has,5219,O
been,5219,O
the,5219,O
finding,5219,O
that,5219,O
IgG1,5219,B-GENE-Y
binding,5219,O
is,5219,O
impacted,5219,O
by,5219,O
polymorphisms,5219,O
in,5219,O
FcgammaRIIIa,5219,B-GENE-Y
but,5219,O
not,5219,O
FcgammaRIIa,5219,B-GENE-Y
.,5219,O
One,5220,O
possibility,5220,O
for,5220,O
this,5220,O
discrepancy,5220,O
might,5220,O
involve,5220,O
linkage,5220,O
of,5220,O
polymorphisms,5220,O
between,5220,O
FcgammaRIIa,5220,B-GENE-Y
and,5220,O
FcgammaRIIIa,5220,B-GENE-Y
.,5220,O
MATERIALS,5221,O
AND,5221,O
METHODS,5221,O
:,5221,O
As,5221,O
such,5221,O
",",5221,O
we,5221,O
performed,5221,O
allelespecific,5221,O
polymerase,5221,O
chain,5221,O
reaction,5221,O
and,5221,O
directed,5221,O
sequencing,5221,O
of,5221,O
the,5221,O
genomic,5221,O
DNA,5221,O
coding,5221,O
region,5221,O
of,5221,O
FcgammaRIIA,5221,B-GENE-Y
and,5221,O
FcgammaRIIIA,5221,B-GENE-Y
for,5221,O
52,5221,O
healthy,5221,O
individuals,5221,O
.,5221,O
RESULTS,5222,O
:,5222,O
Two,5222,O
common,5222,O
polymorphisms,5222,O
were,5222,O
observed,5222,O
for,5222,O
FcgammaRIIA,5222,B-GENE-Y
(,5222,O
at,5222,O
positions,5222,O
27,5222,O
and,5222,O
131,5222,O
),5222,O
and,5222,O
FcgammaRIIIA,5222,B-GENE-Y
(,5222,O
at,5222,O
positions,5222,O
48,5222,O
and,5222,O
158,5222,O
),5222,O
.,5222,O
Importantly,5223,O
",",5223,O
we,5223,O
observed,5223,O
linkage,5223,O
among,5223,O
polymorphisms,5223,O
within,5223,O
and,5223,O
between,5223,O
FcgammaRIIa,5223,B-GENE-Y
and,5223,O
FcgammaRIIIa,5223,B-GENE-Y
",",5223,O
including,5223,O
the,5223,O
expression,5223,O
of,5223,O
histidine,5223,O
at,5223,O
FcgammaRIIa-131,5223,B-GENE-Y
and,5223,O
valine,5223,O
at,5223,O
FcgammaRIIIa,5223,B-GENE-Y
",",5223,O
both,5223,O
of,5223,O
which,5223,O
are,5223,O
associated,5223,O
with,5223,O
enhanced,5223,O
responses,5223,O
to,5223,O
rituximab,5223,O
.,5223,O
The,5224,O
results,5224,O
of,5224,O
these,5224,O
studies,5224,O
demonstrate,5224,O
that,5224,O
there,5224,O
is,5224,O
wide,5224,O
linkage,5224,O
within,5224,O
and,5224,O
between,5224,O
polymorphisms,5224,O
in,5224,O
FcgammaRIIa,5224,B-GENE-Y
and,5224,O
FcgammaRIIIa,5224,B-GENE-Y
and,5224,O
might,5224,O
provide,5224,O
an,5224,O
explanation,5224,O
for,5224,O
why,5224,O
polymorphisms,5224,O
at,5224,O
FcgammaRIIa,5224,B-GENE-Y
are,5224,O
associated,5224,O
with,5224,O
rituximab,5224,O
responses,5224,O
despite,5224,O
a,5224,O
lack,5224,O
of,5224,O
impact,5224,O
on,5224,O
IgG1,5224,B-GENE-Y
binding,5224,O
.,5224,O
CONCLUSION,5225,O
:,5225,O
Knowledge,5225,O
of,5225,O
such,5225,O
linkages,5225,O
could,5225,O
facilitate,5225,O
the,5225,O
development,5225,O
of,5225,O
diagnostic,5225,O
tests,5225,O
aimed,5225,O
at,5225,O
identifying,5225,O
patients,5225,O
who,5225,O
might,5225,O
be,5225,O
more,5225,O
suitable,5225,O
for,5225,O
treatment,5225,O
with,5225,O
rituximab,5225,O
and,5225,O
possibly,5225,O
other,5225,O
therapeutic,5225,O
antibodies,5225,O
.,5225,O
Characterization,5226,O
of,5226,O
an,5226,O
alpha,5226,B-GENE-Y
1D-adrenoceptor,5226,I-GENE-Y
mediating,5226,O
the,5226,O
contractile,5226,O
response,5226,O
of,5226,O
rat,5226,O
aorta,5226,O
to,5226,O
noradrenaline,5226,B-CHEMICAL
.,5226,O
1,5227,O
.,5227,O
The,5228,O
affinities,5228,O
of,5228,O
a,5228,O
number,5228,O
of,5228,O
alpha,5228,B-GENE-N
1-adrenoceptor,5228,I-GENE-N
antagonists,5228,O
were,5228,O
determined,5228,O
by,5228,O
displacement,5228,O
of,5228,O
[,5228,B-CHEMICAL
3H,5228,I-CHEMICAL
],5228,I-CHEMICAL
-prazosin,5228,I-CHEMICAL
binding,5228,O
from,5228,O
cloned,5228,O
human,5228,B-GENE-Y
alpha,5228,I-GENE-Y
1A-adrenoceptors,5228,I-GENE-Y
(,5228,O
previously,5228,O
designated,5228,O
cloned,5228,O
alpha,5228,O
1c,5228,O
subtype,5228,O
),5228,O
",",5228,O
alpha,5228,O
1B,5228,O
alpha,5228,O
1D,5228,O
and,5228,O
rat,5228,B-GENE-Y
alpha,5228,I-GENE-Y
1D-adrenoceptors,5228,I-GENE-Y
",",5228,O
stably,5228,O
expressed,5228,O
in,5228,O
rat-1,5228,O
fibroblasts,5228,O
.,5228,O
Functional,5229,O
affinity,5229,O
estimates,5229,O
for,5229,O
these,5229,O
compounds,5229,O
were,5229,O
also,5229,O
determined,5229,O
from,5229,O
noradrenaline-mediated,5229,B-CHEMICAL
contractions,5229,O
of,5229,O
rat,5229,O
aorta,5229,O
.,5229,O
2,5230,O
.,5230,O
BMY,5231,B-CHEMICAL
7378,5231,I-CHEMICAL
displayed,5231,O
high,5231,O
affinity,5231,O
for,5231,O
cloned,5231,O
human,5231,B-GENE-Y
alpha,5231,I-GENE-Y
1D-adrenoceptors,5231,I-GENE-Y
(,5231,O
pKi,5231,O
=,5231,O
8.2,5231,O
+/-,5231,O
0.10,5231,O
),5231,O
and,5231,O
was,5231,O
selective,5231,O
over,5231,O
alpha,5231,O
1A,5231,O
(,5231,O
pKi,5231,O
=,5231,O
6.2,5231,O
+/-,5231,O
0.10,5231,O
),5231,O
and,5231,O
alpha,5231,O
1B,5231,O
subtypes,5231,O
(,5231,O
6.7,5231,O
+/-,5231,O
0.11,5231,O
),5231,O
.,5231,O
WB,5232,O
4101,5232,O
",",5232,O
benoxathian,5232,B-CHEMICAL
and,5232,O
phentolamine,5232,B-CHEMICAL
displayed,5232,O
high,5232,O
affinity,5232,O
for,5232,O
alpha,5232,B-GENE-N
1A,5232,I-GENE-N
and,5232,I-GENE-N
alpha,5232,I-GENE-N
1D,5232,I-GENE-N
adrenoceptors,5232,I-GENE-N
compared,5232,O
to,5232,O
the,5232,O
alpha,5232,O
1B,5232,O
subtype,5232,O
.,5232,O
Spiperone,5233,B-CHEMICAL
displayed,5233,O
high,5233,O
affinity,5233,O
and,5233,O
selectivity,5233,O
for,5233,O
alpha,5233,B-GENE-Y
1B,5233,I-GENE-Y
adrenoceptors,5233,I-GENE-Y
(,5233,O
pKi,5233,O
8.8,5233,O
+/-,5233,O
0.16,5233,O
),5233,O
.,5233,O
5-Methyl-urapidil,5234,B-CHEMICAL
was,5234,O
selective,5234,O
for,5234,O
cloned,5234,O
alpha,5234,B-GENE-Y
1A,5234,I-GENE-Y
adrenoceptors,5234,I-GENE-Y
.,5234,O
3,5235,O
.,5235,O
Comparative,5236,O
binding,5236,O
affinities,5236,O
(,5236,O
pKi,5236,O
),5236,O
for,5236,O
compounds,5236,O
at,5236,O
cloned,5236,O
human,5236,B-GENE-N
and,5236,I-GENE-N
rat1D,5236,I-GENE-N
adrenoceptors,5236,I-GENE-N
were,5236,O
almost,5236,O
identical,5236,O
(,5236,O
r,5236,O
=,5236,O
0.99,5236,O
",",5236,O
slope,5236,O
=,5236,O
1.08,5236,O
),5236,O
.,5236,O
4,5237,O
.,5237,O
Prazosin,5238,B-CHEMICAL
",",5238,O
doxazosin,5238,B-CHEMICAL
and,5238,O
5-methyl-urapidil,5238,B-CHEMICAL
were,5238,O
potent,5238,O
",",5238,O
competitive,5238,O
antagonists,5238,O
of,5238,O
noradrenaline-mediated,5238,B-CHEMICAL
contractions,5238,O
of,5238,O
rat,5238,O
aorta,5238,O
(,5238,O
pA2,5238,O
values,5238,O
of,5238,O
9.8,5238,O
",",5238,O
8.8,5238,O
and,5238,O
7.8,5238,O
respectively,5238,O
),5238,O
.,5238,O
The,5239,O
selective,5239,O
alpha,5239,O
1D,5239,O
antagonist,5239,O
BMY,5239,B-CHEMICAL
7378,5239,I-CHEMICAL
was,5239,O
also,5239,O
a,5239,O
potent,5239,O
antagonist,5239,O
on,5239,O
rat,5239,O
aorta,5239,O
(,5239,O
pKB,5239,O
=,5239,O
8.3,5239,O
+/-,5239,O
0.1,5239,O
),5239,O
but,5239,O
the,5239,O
interaction,5239,O
of,5239,O
this,5239,O
compound,5239,O
was,5239,O
not,5239,O
consistent,5239,O
with,5239,O
competitive,5239,O
antagonism,5239,O
at,5239,O
a,5239,O
single,5239,O
population,5239,O
of,5239,O
receptors,5239,O
.,5239,O
5,5240,O
.,5240,O
Functional,5241,O
affinities,5241,O
for,5241,O
compounds,5241,O
determined,5241,O
against,5241,O
noradrenaline-mediated,5241,B-CHEMICAL
contractions,5241,O
of,5241,O
rat,5241,O
aorta,5241,O
correlated,5241,O
well,5241,O
with,5241,O
binding,5241,O
affinities,5241,O
at,5241,O
cloned,5241,O
alpha,5241,B-GENE-Y
1D-adrenoceptors,5241,I-GENE-Y
(,5241,O
r,5241,O
=,5241,O
0.96,5241,O
),5241,O
",",5241,O
but,5241,O
not,5241,O
with,5241,O
alpha,5241,O
1A,5241,O
(,5241,O
r,5241,O
=,5241,O
0.61,5241,O
),5241,O
or,5241,O
alpha,5241,O
1B,5241,O
(,5241,O
r,5241,O
=,5241,O
0.46,5241,O
),5241,O
subtypes,5241,O
.,5241,O
6,5242,O
.,5242,O
Noradrenaline-mediated,5243,B-CHEMICAL
contractions,5243,O
of,5243,O
rat,5243,O
aorta,5243,O
were,5243,O
sensitive,5243,O
to,5243,O
the,5243,O
alkylating,5243,O
effects,5243,O
of,5243,O
chlorethylclonidine,5243,B-CHEMICAL
(,5243,O
CEC,5243,B-CHEMICAL
),5243,O
.,5243,O
CEC,5244,O
(,5244,O
10,5244,O
microM,5244,O
),5244,O
caused,5244,O
a,5244,O
small,5244,O
rightward,5244,O
shift,5244,O
in,5244,O
the,5244,O
noradrenaline,5244,B-CHEMICAL
concentration-response,5244,O
curve,5244,O
.,5244,O
CEC,5245,B-CHEMICAL
at,5245,O
100,5245,O
microM,5245,O
caused,5245,O
a,5245,O
further,5245,O
shift,5245,O
and,5245,O
suppression,5245,O
of,5245,O
the,5245,O
maximum,5245,O
response,5245,O
to,5245,O
noradrenaline.7,5245,B-CHEMICAL
.,5245,O
The,5246,O
results,5246,O
of,5246,O
this,5246,O
study,5246,O
suggest,5246,O
that,5246,O
noradrenaline,5246,B-CHEMICAL
predominantly,5246,O
",",5246,O
but,5246,O
not,5246,O
exclusively,5246,O
",",5246,O
mediates,5246,O
contraction,5246,O
of,5246,O
rat,5246,O
aorta,5246,O
through,5246,O
the,5246,O
activation,5246,O
of,5246,O
an,5246,O
alphalD-adrenoceptor,5246,B-GENE-Y
.,5246,O
Display,5247,O
of,5247,O
amino,5247,B-CHEMICAL
groups,5247,O
on,5247,O
substrate,5247,O
surfaces,5247,O
by,5247,O
simple,5247,O
dip-coating,5247,O
of,5247,O
methacrylate-based,5247,B-CHEMICAL
polymers,5247,O
and,5247,O
its,5247,O
application,5247,O
to,5247,O
DNA,5247,O
immobilization,5247,O
.,5247,O
The,5248,O
implementation,5248,O
of,5248,O
a,5248,O
reactive,5248,O
functional,5248,O
group,5248,O
onto,5248,O
a,5248,O
material,5248,O
surface,5248,O
is,5248,O
of,5248,O
great,5248,O
importance,5248,O
.,5248,O
Reactive,5249,O
functional,5249,O
groups,5249,O
(,5249,O
e.g.,5249,O
",",5249,O
an,5249,O
amino,5249,B-CHEMICAL
group,5249,O
and,5249,O
a,5249,O
hydroxyl,5249,B-CHEMICAL
group,5249,O
),5249,O
are,5249,O
usually,5249,O
hydrophilic,5249,O
",",5249,O
which,5249,O
makes,5249,O
it,5249,O
difficult,5249,O
to,5249,O
display,5249,O
them,5249,O
on,5249,O
a,5249,O
dry,5249,O
polymer,5249,O
surface,5249,O
.,5249,O
We,5250,O
here,5250,O
propose,5250,O
a,5250,O
novel,5250,O
method,5250,O
for,5250,O
displaying,5250,O
amino,5250,B-CHEMICAL
groups,5250,O
on,5250,O
the,5250,O
surfaces,5250,O
of,5250,O
polymeric,5250,O
substrates,5250,O
through,5250,O
dip-coating,5250,O
of,5250,O
a,5250,O
methacrylate-based,5250,B-CHEMICAL
copolymer,5250,O
.,5250,O
We,5251,O
synthesized,5251,O
copolymers,5251,O
composed,5251,O
of,5251,O
methyl,5251,B-CHEMICAL
methacrylate,5251,I-CHEMICAL
and,5251,O
2-aminoethyl,5251,B-CHEMICAL
methacrylate,5251,I-CHEMICAL
with,5251,O
different,5251,O
protecting,5251,O
groups,5251,O
or,5251,O
ion-complexes,5251,O
on,5251,O
their,5251,O
amino,5251,B-CHEMICAL
groups,5251,O
",",5251,O
then,5251,O
dip-coated,5251,O
the,5251,O
copolymers,5251,O
onto,5251,O
a,5251,O
poly,5251,B-CHEMICAL
(,5251,I-CHEMICAL
methyl,5251,I-CHEMICAL
methacrylate,5251,I-CHEMICAL
),5251,I-CHEMICAL
(,5251,O
PMMA,5251,B-CHEMICAL
),5251,O
substrate,5251,O
.,5251,O
Evaluation,5252,O
using,5252,O
a,5252,O
cleavable,5252,O
fluorescent,5252,O
compound,5252,O
",",5252,O
which,5252,O
was,5252,O
synthesized,5252,O
in,5252,O
the,5252,O
present,5252,O
study,5252,O
to,5252,O
quantify,5252,O
a,5252,O
small,5252,O
amount,5252,O
(,5252,O
pmol/cm,5252,O
(,5252,O
2,5252,O
),5252,O
),5252,O
of,5252,O
amino,5252,B-CHEMICAL
groups,5252,O
on,5252,O
a,5252,O
solid,5252,O
surface,5252,O
",",5252,O
revealed,5252,O
that,5252,O
the,5252,O
protection,5252,O
of,5252,O
amino,5252,B-CHEMICAL
groups,5252,O
affected,5252,O
their,5252,O
surface,5252,O
segregation,5252,O
in,5252,O
the,5252,O
copolymer,5252,O
coating,5252,O
.,5252,O
p-Toluenesulfonate,5253,B-CHEMICAL
ion-complex,5253,O
and,5253,O
tert-butoxycarbonyl,5253,B-CHEMICAL
(,5253,O
Boc,5253,B-CHEMICAL
),5253,O
protection,5253,O
of,5253,O
amino,5253,B-CHEMICAL
groups,5253,O
were,5253,O
found,5253,O
to,5253,O
effectively,5253,O
display,5253,O
amino,5253,B-CHEMICAL
groups,5253,O
on,5253,O
the,5253,O
surface,5253,O
(,5253,O
more,5253,O
than,5253,O
70,5253,O
pmol/cm,5253,O
(,5253,O
2,5253,O
),5253,O
),5253,O
.,5253,O
The,5254,O
density,5254,O
of,5254,O
amino,5254,B-CHEMICAL
groups,5254,O
displayed,5254,O
on,5254,O
a,5254,O
surface,5254,O
can,5254,O
be,5254,O
easily,5254,O
controlled,5254,O
by,5254,O
mixing,5254,O
the,5254,O
copolymer,5254,O
and,5254,O
PMMA,5254,B-CHEMICAL
before,5254,O
dip-coating,5254,O
.,5254,O
Dip-coating,5255,O
of,5255,O
the,5255,O
copolymer,5255,O
with,5255,O
Boc,5255,B-CHEMICAL
protection,5255,O
on,5255,O
various,5255,O
polymeric,5255,O
substrates,5255,O
also,5255,O
successfully,5255,O
displayed,5255,O
amino,5255,B-CHEMICAL
groups,5255,O
on,5255,O
their,5255,O
surfaces,5255,O
.,5255,O
Finally,5256,O
",",5256,O
we,5256,O
demonstrated,5256,O
that,5256,O
the,5256,O
amino,5256,B-CHEMICAL
groups,5256,O
displayed,5256,O
can,5256,O
be,5256,O
utilized,5256,O
for,5256,O
the,5256,O
immobilization,5256,O
of,5256,O
a,5256,O
DNA,5256,O
oligonucleotide,5256,O
on,5256,O
a,5256,O
substrate,5256,O
surface,5256,O
.,5256,O
Neuroprotective,5257,O
role,5257,O
of,5257,O
ATP-sensitive,5257,B-GENE-N
potassium,5257,I-GENE-N
channels,5257,I-GENE-N
in,5257,O
cerebral,5257,O
ischemia,5257,O
.,5257,O
ATP-sensitive,5258,B-GENE-N
potassium,5258,I-GENE-N
(,5258,I-GENE-N
K,5258,I-GENE-N
(,5258,I-GENE-N
ATP,5258,I-GENE-N
),5258,I-GENE-N
),5258,I-GENE-N
channels,5258,I-GENE-N
are,5258,O
weak,5258,O
",",5258,O
inward,5258,O
rectifiers,5258,O
that,5258,O
couple,5258,O
metabolic,5258,O
status,5258,O
to,5258,O
cell,5258,O
membrane,5258,O
electrical,5258,O
activity,5258,O
",",5258,O
thus,5258,O
modulating,5258,O
many,5258,O
cellular,5258,O
functions,5258,O
.,5258,O
An,5259,O
increase,5259,O
in,5259,O
the,5259,O
ADP/ATP,5259,B-CHEMICAL
ratio,5259,O
opens,5259,O
K,5259,B-GENE-N
(,5259,I-GENE-N
ATP,5259,I-GENE-N
),5259,I-GENE-N
channels,5259,I-GENE-N
",",5259,O
leading,5259,O
to,5259,O
membrane,5259,O
hyperpolarization,5259,O
.,5259,O
K,5260,B-GENE-N
(,5260,I-GENE-N
ATP,5260,I-GENE-N
),5260,I-GENE-N
channels,5260,I-GENE-N
are,5260,O
ubiquitously,5260,O
expressed,5260,O
in,5260,O
neurons,5260,O
located,5260,O
in,5260,O
different,5260,O
regions,5260,O
of,5260,O
the,5260,O
brain,5260,O
",",5260,O
including,5260,O
the,5260,O
hippocampus,5260,O
and,5260,O
cortex,5260,O
.,5260,O
Brief,5261,O
hypoxia,5261,O
triggers,5261,O
membrane,5261,O
hyperpolarization,5261,O
in,5261,O
these,5261,O
central,5261,O
neurons,5261,O
.,5261,O
In,5262,O
vivo,5262,O
animal,5262,O
studies,5262,O
confirmed,5262,O
that,5262,O
knocking,5262,O
out,5262,O
the,5262,O
Kir6.2,5262,B-GENE-N
subunit,5262,O
of,5262,O
the,5262,O
K,5262,B-GENE-N
(,5262,I-GENE-N
ATP,5262,I-GENE-N
),5262,I-GENE-N
channels,5262,I-GENE-N
increases,5262,O
ischemic,5262,O
infarction,5262,O
",",5262,O
and,5262,O
overexpression,5262,O
of,5262,O
the,5262,O
Kir6.2,5262,B-GENE-N
subunit,5262,O
reduces,5262,O
neuronal,5262,O
injury,5262,O
from,5262,O
ischemic,5262,O
insults,5262,O
.,5262,O
These,5263,O
findings,5263,O
provide,5263,O
the,5263,O
basis,5263,O
for,5263,O
a,5263,O
practical,5263,O
strategy,5263,O
whereby,5263,O
activation,5263,O
of,5263,O
endogenous,5263,O
K,5263,B-GENE-N
(,5263,I-GENE-N
ATP,5263,I-GENE-N
),5263,I-GENE-N
channels,5263,I-GENE-N
reduces,5263,O
cellular,5263,O
damage,5263,O
resulting,5263,O
from,5263,O
cerebral,5263,O
ischemic,5263,O
stroke,5263,O
.,5263,O
K,5264,B-GENE-N
(,5264,I-GENE-N
ATP,5264,I-GENE-N
),5264,I-GENE-N
channel,5264,I-GENE-N
modulators,5264,O
may,5264,O
prove,5264,O
to,5264,O
be,5264,O
clinically,5264,O
useful,5264,O
as,5264,O
part,5264,O
of,5264,O
a,5264,O
combination,5264,O
therapy,5264,O
for,5264,O
stroke,5264,O
management,5264,O
in,5264,O
the,5264,O
future,5264,O
.,5264,O
Comparison,5265,O
of,5265,O
the,5265,O
effect,5265,O
of,5265,O
rofecoxib,5265,B-CHEMICAL
(,5265,O
a,5265,O
cyclooxygenase,5265,B-GENE-Y
2,5265,I-GENE-Y
inhibitor,5265,O
),5265,O
",",5265,O
ibuprofen,5265,B-CHEMICAL
",",5265,O
and,5265,O
placebo,5265,O
on,5265,O
the,5265,O
gastroduodenal,5265,O
mucosa,5265,O
of,5265,O
patients,5265,O
with,5265,O
osteoarthritis,5265,O
:,5265,O
a,5265,O
randomized,5265,O
",",5265,O
double-blind,5265,O
",",5265,O
placebo-controlled,5265,O
trial,5265,O
.,5265,O
The,5266,O
Rofecoxib,5266,B-CHEMICAL
Osteoarthritis,5266,O
Endoscopy,5266,O
Multinational,5266,O
Study,5266,O
Group,5266,O
.,5266,O
OBJECTIVE,5267,O
:,5267,O
This,5267,O
randomized,5267,O
",",5267,O
double-blind,5267,O
study,5267,O
tested,5267,O
the,5267,O
hypothesis,5267,O
that,5267,O
rofecoxib,5267,B-CHEMICAL
",",5267,O
a,5267,O
drug,5267,O
that,5267,O
specifically,5267,O
inhibits,5267,O
cyclooxygenase,5267,B-GENE-Y
2,5267,I-GENE-Y
",",5267,O
would,5267,O
cause,5267,O
fewer,5267,O
gastroduodenal,5267,O
ulcers,5267,O
than,5267,O
ibuprofen,5267,B-CHEMICAL
(,5267,O
in,5267,O
a,5267,O
multicenter,5267,O
trial,5267,O
),5267,O
",",5267,O
and,5267,O
its,5267,O
side,5267,O
effects,5267,O
would,5267,O
be,5267,O
equivalent,5267,O
to,5267,O
those,5267,O
of,5267,O
placebo,5267,O
(,5267,O
in,5267,O
a,5267,O
prespecified,5267,O
analysis,5267,O
combining,5267,O
the,5267,O
results,5267,O
with,5267,O
another,5267,O
trial,5267,O
of,5267,O
identical,5267,O
design,5267,O
),5267,O
.,5267,O
METHODS,5268,O
:,5268,O
Seven,5268,O
hundred,5268,O
seventy-five,5268,O
patients,5268,O
with,5268,O
osteoarthritis,5268,O
were,5268,O
randomized,5268,O
to,5268,O
receive,5268,O
rofecoxib,5268,B-CHEMICAL
at,5268,O
a,5268,O
dosage,5268,O
of,5268,O
25,5268,O
mg,5268,O
or,5268,O
50,5268,O
mg,5268,O
once,5268,O
daily,5268,O
",",5268,O
ibuprofen,5268,O
800,5268,O
mg,5268,O
3,5268,O
times,5268,O
daily,5268,O
",",5268,O
or,5268,O
placebo,5268,O
.,5268,O
Gastroduodenal,5269,O
ulceration,5269,O
was,5269,O
assessed,5269,O
by,5269,O
endoscopy,5269,O
at,5269,O
6,5269,O
",",5269,O
12,5269,O
",",5269,O
and,5269,O
(,5269,O
for,5269,O
active,5269,O
treatment,5269,O
),5269,O
24,5269,O
weeks,5269,O
.,5269,O
The,5270,O
primary,5270,O
and,5270,O
secondary,5270,O
end,5270,O
points,5270,O
were,5270,O
the,5270,O
incidence,5270,O
of,5270,O
gastroduodenal,5270,O
ulcers,5270,O
at,5270,O
12,5270,O
and,5270,O
24,5270,O
weeks,5270,O
",",5270,O
respectively,5270,O
.,5270,O
RESULTS,5271,O
:,5271,O
Ulcers,5271,O
were,5271,O
significantly,5271,O
less,5271,O
common,5271,O
(,5271,O
P,5271,O
<,5271,O
0.001,5271,O
),5271,O
following,5271,O
treatment,5271,O
with,5271,O
rofecoxib,5271,B-CHEMICAL
(,5271,O
25,5271,O
mg,5271,O
or,5271,O
50,5271,O
mg,5271,O
),5271,O
than,5271,O
with,5271,O
ibuprofen,5271,B-CHEMICAL
after,5271,O
12,5271,O
weeks,5271,O
(,5271,O
5.3,5271,O
%,5271,O
and,5271,O
8.8,5271,O
%,5271,O
versus,5271,O
29.2,5271,O
%,5271,O
",",5271,O
respectively,5271,O
),5271,O
or,5271,O
24,5271,O
weeks,5271,O
(,5271,O
9.9,5271,O
%,5271,O
and,5271,O
12.4,5271,O
%,5271,O
versus,5271,O
46.8,5271,O
%,5271,O
",",5271,O
respectively,5271,O
),5271,O
.,5271,O
In,5272,O
the,5272,O
combined,5272,O
analysis,5272,O
",",5272,O
the,5272,O
12-week,5272,O
ulcer,5272,O
incidence,5272,O
with,5272,O
25,5272,O
mg,5272,O
rofecoxib,5272,B-CHEMICAL
(,5272,O
4.7,5272,O
%,5272,O
),5272,O
and,5272,O
with,5272,O
placebo,5272,O
(,5272,O
7.3,5272,O
%,5272,O
),5272,O
satisfied,5272,O
prespecified,5272,O
criteria,5272,O
for,5272,O
equivalence,5272,O
.,5272,O
CONCLUSION,5273,O
:,5273,O
At,5273,O
2-4,5273,O
times,5273,O
the,5273,O
therapeutically,5273,O
effective,5273,O
dose,5273,O
",",5273,O
rofecoxib,5273,B-CHEMICAL
caused,5273,O
fewer,5273,O
endoscopically,5273,O
detected,5273,O
ulcers,5273,O
than,5273,O
did,5273,O
ibuprofen,5273,B-CHEMICAL
.,5273,O
Rofecoxib,5274,O
at,5274,O
a,5274,O
dose,5274,O
of,5274,O
25,5274,O
mg,5274,O
(,5274,O
the,5274,O
highest,5274,O
dose,5274,O
recommended,5274,O
for,5274,O
osteoarthritis,5274,O
),5274,O
satisfied,5274,O
prespecified,5274,O
criteria,5274,O
for,5274,O
equivalence,5274,O
to,5274,O
placebo,5274,O
.,5274,O
Profiling,5275,O
976,5275,O
ToxCast,5275,O
chemicals,5275,O
across,5275,O
331,5275,O
enzymatic,5275,O
and,5275,O
receptor,5275,O
signaling,5275,O
assays,5275,O
.,5275,O
Understanding,5276,O
potential,5276,O
health,5276,O
risks,5276,O
is,5276,O
a,5276,O
significant,5276,O
challenge,5276,O
due,5276,O
to,5276,O
large,5276,O
numbers,5276,O
of,5276,O
diverse,5276,O
chemicals,5276,O
with,5276,O
poorly,5276,O
characterized,5276,O
exposures,5276,O
and,5276,O
mechanisms,5276,O
of,5276,O
toxicities,5276,O
.,5276,O
The,5277,O
present,5277,O
study,5277,O
analyzes,5277,O
976,5277,O
chemicals,5277,O
(,5277,O
including,5277,O
failed,5277,O
pharmaceuticals,5277,O
",",5277,O
alternative,5277,O
plasticizers,5277,O
",",5277,O
food,5277,O
additives,5277,O
",",5277,O
and,5277,O
pesticides,5277,O
),5277,O
in,5277,O
Phase,5277,O
I,5277,O
and,5277,O
II,5277,O
of,5277,O
the,5277,O
U.S.,5277,O
EPA,5277,O
's,5277,O
ToxCast™,5277,O
project,5277,O
across,5277,O
331,5277,O
cell-free,5277,O
enzymatic,5277,O
and,5277,O
ligand-binding,5277,O
high-throughput,5277,O
screening,5277,O
(,5277,O
HTS,5277,O
),5277,O
assays,5277,O
.,5277,O
Half-maximal,5278,O
activity,5278,O
concentrations,5278,O
(,5278,O
AC50,5278,O
),5278,O
were,5278,O
identified,5278,O
for,5278,O
729,5278,O
chemicals,5278,O
in,5278,O
256,5278,O
assays,5278,O
(,5278,O
"7,135",5278,O
chemical-assay,5278,O
pairs,5278,O
),5278,O
.,5278,O
Some,5279,O
of,5279,O
the,5279,O
most,5279,O
commonly,5279,O
affected,5279,O
assays,5279,O
were,5279,O
CYPs,5279,B-GENE-N
(,5279,O
CYP2C9,5279,B-GENE-Y
",",5279,O
CYP2C19,5279,B-GENE-Y
),5279,O
",",5279,O
transporters,5279,O
(,5279,O
mitochondrial,5279,O
TSPO,5279,O
",",5279,O
norepinephrine,5279,B-CHEMICAL
",",5279,O
dopaminergic,5279,O
),5279,O
",",5279,O
and,5279,O
GPCRs,5279,B-GENE-N
(,5279,O
aminergic,5279,O
),5279,O
.,5279,O
Heavy,5280,O
metals,5280,O
",",5280,O
surfactants,5280,O
",",5280,O
and,5280,O
dithiocarbamate,5280,B-CHEMICAL
fungicides,5280,O
showed,5280,O
promiscuous,5280,O
",",5280,O
but,5280,O
distinctly,5280,O
different,5280,O
patterns,5280,O
of,5280,O
activity,5280,O
whereas,5280,O
many,5280,O
of,5280,O
the,5280,O
pharma,5280,O
compounds,5280,O
showed,5280,O
promiscuous,5280,O
activity,5280,O
across,5280,O
GPCRs,5280,B-GENE-N
.,5280,O
Literature,5281,O
analysis,5281,O
confirmed,5281,O
>,5281,O
50,5281,O
%,5281,O
of,5281,O
the,5281,O
activities,5281,O
for,5281,O
the,5281,O
most,5281,O
potent,5281,O
chemical-assay,5281,O
pairs,5281,O
(,5281,O
56,5281,O
),5281,O
",",5281,O
but,5281,O
also,5281,O
revealed,5281,O
10,5281,O
missed,5281,O
interactions,5281,O
.,5281,O
Twenty-two,5282,O
chemicals,5282,O
with,5282,O
known,5282,O
estrogenic,5282,O
activity,5282,O
were,5282,O
correctly,5282,O
identified,5282,O
for,5282,O
the,5282,O
majority,5282,O
(,5282,O
77,5282,O
%,5282,O
),5282,O
",",5282,O
missing,5282,O
only,5282,O
the,5282,O
weaker,5282,O
interactions,5282,O
.,5282,O
In,5283,O
many,5283,O
cases,5283,O
",",5283,O
novel,5283,O
findings,5283,O
for,5283,O
previously,5283,O
unreported,5283,O
chemical-target,5283,O
combinations,5283,O
clustered,5283,O
with,5283,O
known,5283,O
chemical-target,5283,O
interactions,5283,O
.,5283,O
Results,5284,O
from,5284,O
this,5284,O
large,5284,O
inventory,5284,O
of,5284,O
chemical-biological,5284,O
interactions,5284,O
can,5284,O
inform,5284,O
read-across,5284,O
methods,5284,O
as,5284,O
well,5284,O
as,5284,O
to,5284,O
link,5284,O
potential,5284,O
targets,5284,O
to,5284,O
molecular,5284,O
initiating,5284,O
events,5284,O
in,5284,O
adverse,5284,O
outcome,5284,O
pathways,5284,O
for,5284,O
diverse,5284,O
toxicities,5284,O
.,5284,O
This,5285,O
abstract,5285,O
does,5285,O
not,5285,O
necessarily,5285,O
reflect,5285,O
U.S.,5285,O
EPA,5285,O
policy,5285,O
.,5285,O
A,5286,O
combination,5286,O
of,5286,O
[,5286,B-CHEMICAL
+,5286,I-CHEMICAL
],5286,I-CHEMICAL
and,5286,I-CHEMICAL
[,5286,I-CHEMICAL
-,5286,I-CHEMICAL
],5286,I-CHEMICAL
-Huperzine,5286,I-CHEMICAL
A,5286,I-CHEMICAL
improves,5286,O
protection,5286,O
against,5286,O
soman,5286,O
toxicity,5286,O
compared,5286,O
to,5286,O
[,5286,B-CHEMICAL
+,5286,I-CHEMICAL
],5286,I-CHEMICAL
-Huperzine,5286,I-CHEMICAL
A,5286,I-CHEMICAL
in,5286,O
guinea,5286,O
pigs,5286,O
.,5286,O
The,5287,O
neuropathologic,5287,O
mechanisms,5287,O
after,5287,O
exposure,5287,O
to,5287,O
lethal,5287,O
doses,5287,O
of,5287,O
nerve,5287,O
agent,5287,O
are,5287,O
complex,5287,O
and,5287,O
involve,5287,O
multiple,5287,O
biochemical,5287,O
pathways,5287,O
.,5287,O
Effective,5288,O
treatment,5288,O
requires,5288,O
drugs,5288,O
that,5288,O
can,5288,O
simultaneously,5288,O
protect,5288,O
by,5288,O
reversible,5288,O
binding,5288,O
to,5288,O
the,5288,O
acetylcholinesterase,5288,B-GENE-Y
(,5288,O
AChE,5288,B-GENE-Y
),5288,O
and,5288,O
blocking,5288,O
cascades,5288,O
of,5288,O
seizure,5288,O
related,5288,O
brain,5288,O
damage,5288,O
",",5288,O
inflammation,5288,O
",",5288,O
neuronal,5288,O
degeneration,5288,O
as,5288,O
well,5288,O
as,5288,O
promoting,5288,O
induction,5288,O
of,5288,O
neuroregeneration,5288,O
.,5288,O
[,5289,B-CHEMICAL
-,5289,I-CHEMICAL
],5289,I-CHEMICAL
-Huperzine,5289,I-CHEMICAL
A,5289,I-CHEMICAL
(,5289,O
[,5289,B-CHEMICAL
-,5289,I-CHEMICAL
],5289,I-CHEMICAL
-Hup,5289,I-CHEMICAL
A,5289,I-CHEMICAL
),5289,O
",",5289,O
is,5289,O
a,5289,O
naturally,5289,O
occurring,5289,O
potent,5289,O
reversible,5289,O
AChE,5289,B-GENE-Y
inhibitor,5289,O
that,5289,O
penetrates,5289,O
the,5289,O
blood-brain,5289,O
barrier,5289,O
.,5289,O
It,5290,O
also,5290,O
has,5290,O
several,5290,O
neuroprotective,5290,O
effects,5290,O
including,5290,O
modification,5290,O
of,5290,O
beta-amyloid,5290,B-GENE-Y
peptide,5290,I-GENE-Y
",",5290,O
reduction,5290,O
of,5290,O
oxidative,5290,O
stress,5290,O
",",5290,O
anti-inflammatory,5290,O
",",5290,O
anti-apoptotic,5290,O
and,5290,O
induction,5290,O
and,5290,O
regulation,5290,O
of,5290,O
nerve,5290,B-GENE-Y
growth,5290,I-GENE-Y
factor,5290,I-GENE-Y
.,5290,O
Toxicities,5291,O
at,5291,O
higher,5291,O
doses,5291,O
restrict,5291,O
the,5291,O
neuroporotective,5291,O
ability,5291,O
of,5291,O
[,5291,B-CHEMICAL
-,5291,I-CHEMICAL
],5291,I-CHEMICAL
-Hup,5291,I-CHEMICAL
A,5291,I-CHEMICAL
for,5291,O
treatment,5291,O
.,5291,O
The,5292,O
synthetic,5292,O
stereoisomer,5292,O
",",5292,O
[,5292,B-CHEMICAL
+,5292,I-CHEMICAL
],5292,I-CHEMICAL
-Hup,5292,I-CHEMICAL
A,5292,I-CHEMICAL
",",5292,O
is,5292,O
less,5292,O
toxic,5292,O
due,5292,O
to,5292,O
poor,5292,O
AChE,5292,B-GENE-Y
inhibition,5292,O
and,5292,O
is,5292,O
suitable,5292,O
for,5292,O
both,5292,O
pre-/post-exposure,5292,O
treatments,5292,O
of,5292,O
nerve,5292,O
agent,5292,O
toxicity,5292,O
.,5292,O
[,5293,B-CHEMICAL
+,5293,I-CHEMICAL
],5293,I-CHEMICAL
-Hup,5293,I-CHEMICAL
A,5293,I-CHEMICAL
block,5293,O
the,5293,O
N-methyl-d-aspartate,5293,B-CHEMICAL
(,5293,O
NMDA,5293,B-CHEMICAL
),5293,O
-induced,5293,O
seizure,5293,O
in,5293,O
rats,5293,O
",",5293,O
reduce,5293,O
excitatory,5293,O
amino,5293,B-CHEMICAL
acid,5293,I-CHEMICAL
induced,5293,O
neurotoxicity,5293,O
and,5293,O
also,5293,O
prevent,5293,O
soman,5293,O
induced,5293,O
toxicity,5293,O
with,5293,O
minimum,5293,O
performance,5293,O
decrement,5293,O
.,5293,O
Unique,5294,O
combinations,5294,O
of,5294,O
two,5294,O
stereo-isomers,5294,O
of,5294,O
Hup,5294,B-CHEMICAL
A,5294,I-CHEMICAL
may,5294,O
provide,5294,O
an,5294,O
excellent,5294,O
pre/post-treatment,5294,O
drug,5294,O
for,5294,O
the,5294,O
nerve,5294,O
agent,5294,O
induced,5294,O
seizure/status,5294,O
epilepticus,5294,O
.,5294,O
We,5295,O
investigated,5295,O
a,5295,O
combination,5295,O
of,5295,O
[,5295,B-CHEMICAL
+,5295,I-CHEMICAL
],5295,I-CHEMICAL
-Hup,5295,I-CHEMICAL
A,5295,I-CHEMICAL
with,5295,O
a,5295,O
small,5295,O
dose,5295,O
of,5295,O
[,5295,B-CHEMICAL
-,5295,I-CHEMICAL
],5295,I-CHEMICAL
-Hup,5295,I-CHEMICAL
A,5295,I-CHEMICAL
(,5295,O
[,5295,B-CHEMICAL
+,5295,I-CHEMICAL
],5295,I-CHEMICAL
and,5295,I-CHEMICAL
[,5295,I-CHEMICAL
-,5295,I-CHEMICAL
],5295,I-CHEMICAL
-Hup,5295,I-CHEMICAL
A,5295,I-CHEMICAL
),5295,O
against,5295,O
soman,5295,B-CHEMICAL
toxicity,5295,O
.,5295,O
Our,5296,O
data,5296,O
showed,5296,O
that,5296,O
pretreatment,5296,O
with,5296,O
a,5296,O
combination,5296,O
[,5296,B-CHEMICAL
+,5296,I-CHEMICAL
],5296,I-CHEMICAL
and,5296,I-CHEMICAL
[,5296,I-CHEMICAL
-,5296,I-CHEMICAL
],5296,I-CHEMICAL
-Hup,5296,I-CHEMICAL
A,5296,I-CHEMICAL
significantly,5296,O
increased,5296,O
the,5296,O
survival,5296,O
rate,5296,O
and,5296,O
reduced,5296,O
behavioral,5296,O
abnormalities,5296,O
after,5296,O
exposure,5296,O
to,5296,O
1.2×LD50,5296,O
soman,5296,O
compared,5296,O
to,5296,O
[,5296,B-CHEMICAL
+,5296,I-CHEMICAL
],5296,I-CHEMICAL
-Hup,5296,I-CHEMICAL
A,5296,I-CHEMICAL
in,5296,O
guinea,5296,O
pigs,5296,O
.,5296,O
In,5297,O
addition,5297,O
",",5297,O
[,5297,B-CHEMICAL
+,5297,I-CHEMICAL
],5297,I-CHEMICAL
and,5297,I-CHEMICAL
[,5297,I-CHEMICAL
-,5297,I-CHEMICAL
],5297,I-CHEMICAL
-Hup,5297,I-CHEMICAL
A,5297,I-CHEMICAL
pretreatment,5297,O
inhibited,5297,O
the,5297,O
development,5297,O
of,5297,O
high,5297,O
power,5297,O
of,5297,O
EEG,5297,O
better,5297,O
than,5297,O
[,5297,B-CHEMICAL
+,5297,I-CHEMICAL
],5297,I-CHEMICAL
-Hup,5297,I-CHEMICAL
A,5297,I-CHEMICAL
pretreatment,5297,O
alone,5297,O
.,5297,O
These,5298,O
data,5298,O
suggest,5298,O
that,5298,O
a,5298,O
combination,5298,O
of,5298,O
[,5298,B-CHEMICAL
+,5298,I-CHEMICAL
],5298,I-CHEMICAL
and,5298,I-CHEMICAL
[,5298,I-CHEMICAL
-,5298,I-CHEMICAL
],5298,I-CHEMICAL
-Hup,5298,I-CHEMICAL
A,5298,I-CHEMICAL
offers,5298,O
better,5298,O
protection,5298,O
than,5298,O
[,5298,B-CHEMICAL
+,5298,I-CHEMICAL
],5298,I-CHEMICAL
-Hup,5298,I-CHEMICAL
A,5298,I-CHEMICAL
and,5298,O
serves,5298,O
as,5298,O
a,5298,O
potent,5298,O
medical,5298,O
countermeasure,5298,O
against,5298,O
lethal,5298,O
dose,5298,O
nerve,5298,O
agent,5298,O
toxicity,5298,O
in,5298,O
guinea,5298,O
pigs,5298,O
.,5298,O
Vinblastine-induced,5299,B-CHEMICAL
apoptosis,5299,O
of,5299,O
melanoma,5299,O
cells,5299,O
is,5299,O
mediated,5299,O
by,5299,O
Ras,5299,B-GENE-Y
homologous,5299,I-GENE-Y
A,5299,I-GENE-Y
protein,5299,I-GENE-Y
(,5299,O
Rho,5299,B-GENE-Y
A,5299,I-GENE-Y
),5299,O
via,5299,O
mitochondrial,5299,O
and,5299,O
non-mitochondrial-dependent,5299,O
mechanisms,5299,O
.,5299,O
Despite,5300,O
the,5300,O
availability,5300,O
of,5300,O
melanoma,5300,O
treatment,5300,O
at,5300,O
the,5300,O
primary,5300,O
site,5300,O
",",5300,O
the,5300,O
recurrence,5300,O
of,5300,O
local,5300,O
melanoma,5300,O
can,5300,O
metastasize,5300,O
to,5300,O
any,5300,O
distant,5300,O
organ,5300,O
.,5300,O
Currently,5301,O
",",5301,O
the,5301,O
available,5301,O
therapies,5301,O
for,5301,O
the,5301,O
treatment,5301,O
of,5301,O
metastatic,5301,O
melanoma,5301,O
are,5301,O
of,5301,O
limited,5301,O
benefit,5301,O
.,5301,O
Thus,5302,O
",",5302,O
the,5302,O
functional,5302,O
analysis,5302,O
of,5302,O
conventional,5302,O
therapies,5302,O
may,5302,O
help,5302,O
to,5302,O
improve,5302,O
their,5302,O
efficiency,5302,O
in,5302,O
the,5302,O
treatment,5302,O
of,5302,O
metastatic,5302,O
melanoma,5302,O
.,5302,O
In,5303,O
the,5303,O
present,5303,O
study,5303,O
",",5303,O
the,5303,O
exposure,5303,O
of,5303,O
melanoma,5303,O
cells,5303,O
to,5303,O
vinblastine,5303,B-CHEMICAL
was,5303,O
found,5303,O
to,5303,O
trigger,5303,O
apoptosis,5303,O
as,5303,O
evidenced,5303,O
by,5303,O
the,5303,O
loss,5303,O
of,5303,O
mitochondrial,5303,O
membrane,5303,O
potential,5303,O
",",5303,O
the,5303,O
release,5303,O
of,5303,O
both,5303,O
cytochrome,5303,B-GENE-Y
c,5303,I-GENE-Y
and,5303,O
apoptosis,5303,B-GENE-Y
inducing,5303,I-GENE-Y
factor,5303,I-GENE-Y
",",5303,O
activation,5303,O
of,5303,O
caspase-9,5303,B-GENE-N
and,5303,I-GENE-N
3,5303,I-GENE-N
",",5303,O
and,5303,O
cleavage,5303,O
of,5303,O
Poly,5303,B-GENE-N
(,5303,I-GENE-N
ADP-ribose,5303,I-GENE-N
),5303,I-GENE-N
-Polymerase,5303,I-GENE-N
.,5303,O
Also,5304,O
",",5304,O
vinblastine,5304,B-CHEMICAL
enhances,5304,O
the,5304,O
phosphorylation,5304,O
of,5304,O
Ras,5304,B-GENE-Y
homologous,5304,I-GENE-Y
protein,5304,I-GENE-Y
A,5304,I-GENE-Y
",",5304,O
the,5304,O
accumulation,5304,O
of,5304,O
reactive,5304,O
oxygen,5304,B-CHEMICAL
species,5304,O
",",5304,O
the,5304,O
release,5304,O
of,5304,O
intracellular,5304,O
Ca,5304,B-CHEMICAL
(,5304,I-CHEMICAL
2+,5304,I-CHEMICAL
),5304,I-CHEMICAL
",",5304,O
as,5304,O
well,5304,O
as,5304,O
the,5304,O
activation,5304,O
of,5304,O
apoptosis,5304,B-GENE-Y
signal-regulating,5304,I-GENE-Y
kinase,5304,I-GENE-Y
1,5304,I-GENE-Y
",",5304,O
c-jun-N-terminal,5304,B-GENE-N
kinase,5304,I-GENE-N
",",5304,O
p38,5304,B-GENE-N
",",5304,O
inhibitor,5304,B-GENE-Y
of,5304,I-GENE-Y
kappaBα,5304,I-GENE-Y
(,5304,O
IκBα,5304,B-GENE-Y
),5304,O
kinase,5304,B-GENE-N
",",5304,O
and,5304,O
inositol,5304,B-GENE-Y
requiring,5304,I-GENE-Y
enzyme,5304,I-GENE-Y
1α,5304,I-GENE-Y
.,5304,O
In,5305,O
addition,5305,O
",",5305,O
vinblastine,5305,B-CHEMICAL
induces,5305,O
the,5305,O
DNA-binding,5305,O
activities,5305,O
of,5305,O
the,5305,O
transcription,5305,O
factor,5305,O
NF-κB,5305,B-GENE-N
",",5305,O
HSF1,5305,B-GENE-Y
",",5305,O
AP-1,5305,B-GENE-Y
",",5305,O
and,5305,O
ATF-2,5305,B-GENE-Y
",",5305,O
together,5305,O
with,5305,O
the,5305,O
expression,5305,O
of,5305,O
HSP70,5305,B-GENE-N
and,5305,O
Bax,5305,B-GENE-Y
proteins,5305,O
.,5305,O
Moreover,5306,O
",",5306,O
inhibitory,5306,O
experiments,5306,O
addressed,5306,O
a,5306,O
central,5306,O
role,5306,O
for,5306,O
Rho,5306,B-GENE-Y
A,5306,I-GENE-Y
in,5306,O
the,5306,O
regulation,5306,O
of,5306,O
vinblastine-induced,5306,B-CHEMICAL
apoptosis,5306,O
of,5306,O
melanoma,5306,O
cells,5306,O
via,5306,O
mitochondrial,5306,O
and,5306,O
non-mitochondrial-dependent,5306,O
mechanisms,5306,O
.,5306,O
In,5307,O
conclusion,5307,O
",",5307,O
the,5307,O
present,5307,O
study,5307,O
addresses,5307,O
for,5307,O
the,5307,O
first,5307,O
time,5307,O
a,5307,O
central,5307,O
role,5307,O
for,5307,O
Rho,5307,B-GENE-Y
A,5307,I-GENE-Y
in,5307,O
the,5307,O
modulation,5307,O
of,5307,O
vinblastine-induced,5307,B-CHEMICAL
apoptosis,5307,O
of,5307,O
melanoma,5307,O
cells,5307,O
and,5307,O
thereby,5307,O
provides,5307,O
an,5307,O
insight,5307,O
into,5307,O
the,5307,O
molecular,5307,O
action,5307,O
of,5307,O
vinblastine,5307,B-CHEMICAL
in,5307,O
melanoma,5307,O
treatment,5307,O
.,5307,O
Cloning,5308,O
and,5308,O
characterization,5308,O
of,5308,O
a,5308,O
novel,5308,O
human,5308,B-GENE-N
phosphodiesterase,5308,I-GENE-N
that,5308,O
hydrolyzes,5308,O
both,5308,O
cAMP,5308,B-CHEMICAL
and,5308,O
cGMP,5308,B-CHEMICAL
(,5308,O
PDE10A,5308,B-GENE-Y
),5308,O
.,5308,O
cDNA,5309,O
encoding,5309,O
a,5309,O
novel,5309,O
phosphodiesterase,5309,B-GENE-N
(,5309,O
PDE,5309,B-GENE-N
),5309,O
was,5309,O
isolated,5309,O
from,5309,O
a,5309,O
human,5309,O
fetal,5309,O
lung,5309,O
cDNA,5309,O
library,5309,O
and,5309,O
designated,5309,O
PDE10A,5309,B-GENE-Y
.,5309,O
The,5310,O
deduced,5310,O
amino,5310,B-CHEMICAL
acid,5310,I-CHEMICAL
sequence,5310,O
contains,5310,O
779,5310,O
amino,5310,B-CHEMICAL
acids,5310,I-CHEMICAL
",",5310,O
including,5310,O
a,5310,O
putative,5310,O
cGMP,5310,B-GENE-N
binding,5310,I-GENE-N
sequence,5310,I-GENE-N
in,5310,O
the,5310,O
amino-terminal,5310,B-CHEMICAL
portion,5310,O
of,5310,O
the,5310,O
molecule,5310,O
and,5310,O
a,5310,O
catalytic,5310,O
domain,5310,O
that,5310,O
is,5310,O
16-47,5310,O
%,5310,O
identical,5310,O
in,5310,O
amino,5310,B-CHEMICAL
acid,5310,I-CHEMICAL
sequence,5310,O
to,5310,O
those,5310,O
of,5310,O
other,5310,O
PDE,5310,B-GENE-N
families,5310,O
.,5310,O
Recombinant,5311,O
PDE10A,5311,B-GENE-Y
transfected,5311,O
and,5311,O
expressed,5311,O
in,5311,O
COS-7,5311,O
cells,5311,O
hydrolyzed,5311,O
cAMP,5311,B-CHEMICAL
and,5311,O
cGMP,5311,B-CHEMICAL
with,5311,O
Km,5311,O
values,5311,O
of,5311,O
0.26,5311,O
and,5311,O
7.2,5311,O
microM,5311,O
",",5311,O
respectively,5311,O
",",5311,O
and,5311,O
Vmax,5311,O
with,5311,O
cGMP,5311,B-CHEMICAL
was,5311,O
almost,5311,O
twice,5311,O
that,5311,O
with,5311,O
cAMP,5311,B-CHEMICAL
.,5311,O
Of,5312,O
the,5312,O
PDE,5312,B-GENE-N
inhibitors,5312,O
tested,5312,O
",",5312,O
dipyridamole,5312,B-CHEMICAL
was,5312,O
most,5312,O
effective,5312,O
",",5312,O
with,5312,O
IC50,5312,O
values,5312,O
of,5312,O
1.2,5312,O
and,5312,O
0.45,5312,O
microM,5312,O
for,5312,O
inhibition,5312,O
of,5312,O
cAMP,5312,B-CHEMICAL
and,5312,O
cGMP,5312,B-CHEMICAL
hydrolysis,5312,O
",",5312,O
respectively,5312,O
.,5312,O
cGMP,5313,B-CHEMICAL
inhibited,5313,O
hydrolysis,5313,O
of,5313,O
cAMP,5313,B-CHEMICAL
",",5313,O
and,5313,O
cAMP,5313,B-CHEMICAL
inhibited,5313,O
cGMP,5313,B-CHEMICAL
hydrolysis,5313,O
with,5313,O
IC50,5313,O
values,5313,O
of,5313,O
14,5313,O
and,5313,O
0.39,5313,O
microM,5313,O
",",5313,O
respectively,5313,O
.,5313,O
Thus,5314,O
",",5314,O
PDE10A,5314,B-GENE-Y
exhibited,5314,O
properties,5314,O
of,5314,O
a,5314,O
cAMP,5314,B-GENE-N
PDE,5314,I-GENE-N
and,5314,O
a,5314,O
cAMP-inhibited,5314,B-GENE-N
cGMP,5314,I-GENE-N
PDE,5314,I-GENE-N
.,5314,O
PDE10A,5315,B-GENE-Y
transcripts,5315,O
were,5315,O
particularly,5315,O
abundant,5315,O
in,5315,O
the,5315,O
putamen,5315,O
and,5315,O
caudate,5315,O
nucleus,5315,O
regions,5315,O
of,5315,O
brain,5315,O
and,5315,O
in,5315,O
thyroid,5315,O
and,5315,O
testis,5315,O
",",5315,O
and,5315,O
in,5315,O
much,5315,O
lower,5315,O
amounts,5315,O
in,5315,O
other,5315,O
tissues,5315,O
.,5315,O
The,5316,O
PDE10A,5316,B-GENE-Y
gene,5316,O
was,5316,O
located,5316,O
on,5316,O
chromosome,5316,O
6q26,5316,O
by,5316,O
fluorescent,5316,O
in,5316,O
situ,5316,O
hybridization,5316,O
analysis,5316,O
.,5316,O
PDE10A,5317,B-GENE-Y
represents,5317,O
a,5317,O
new,5317,O
member,5317,O
of,5317,O
the,5317,O
PDE,5317,B-GENE-N
superfamily,5317,O
",",5317,O
exhibiting,5317,O
unique,5317,O
kinetic,5317,O
properties,5317,O
and,5317,O
inhibitor,5317,O
sensitivity,5317,O
.,5317,O
Effects,5318,O
of,5318,O
5-aza-2'-deoxycytidine,5318,B-CHEMICAL
on,5318,O
fetal,5318,B-GENE-N
hemoglobin,5318,I-GENE-N
levels,5318,O
",",5318,O
red,5318,O
cell,5318,O
adhesion,5318,O
",",5318,O
and,5318,O
hematopoietic,5318,O
differentiation,5318,O
in,5318,O
patients,5318,O
with,5318,O
sickle,5318,O
cell,5318,O
disease,5318,O
.,5318,O
Fetal,5319,B-GENE-N
hemoglobin,5319,I-GENE-N
(,5319,O
HbF,5319,B-GENE-N
),5319,O
decreases,5319,O
polymerization,5319,O
of,5319,O
sickle,5319,B-GENE-N
hemoglobin,5319,I-GENE-N
(,5319,O
HbS,5319,B-GENE-N
),5319,O
and,5319,O
improves,5319,O
outcomes,5319,O
in,5319,O
sickle,5319,O
cell,5319,O
disease,5319,O
(,5319,O
SSD,5319,O
),5319,O
.,5319,O
Therefore,5320,O
",",5320,O
a,5320,O
therapeutic,5320,O
goal,5320,O
in,5320,O
SSD,5320,O
is,5320,O
pharmacologic,5320,O
reactivation,5320,O
of,5320,O
HbF,5320,B-GENE-N
.,5320,O
Silencing,5321,O
of,5321,O
the,5321,O
gamma-globin,5321,B-GENE-N
(,5321,O
HbF,5321,B-GENE-N
),5321,O
gene,5321,O
is,5321,O
associated,5321,O
with,5321,O
DNA,5321,O
methylation,5321,O
.,5321,O
The,5322,O
cytosine,5322,B-CHEMICAL
analog,5322,O
5-aza-2'-deoxycytidine,5322,B-CHEMICAL
(,5322,O
decitabine,5322,B-CHEMICAL
),5322,O
hypomethylates,5322,O
DNA,5322,O
by,5322,O
inhibiting,5322,O
DNA,5322,B-GENE-N
methyltransferase,5322,I-GENE-N
.,5322,O
We,5323,O
examined,5323,O
if,5323,O
subcutaneous,5323,O
decitabine,5323,B-CHEMICAL
could,5323,O
increase,5323,O
HbF,5323,B-GENE-N
levels,5323,O
and,5323,O
improve,5323,O
SSD,5323,O
pathophysiology,5323,O
without,5323,O
cytotoxicity,5323,O
.,5323,O
Eight,5324,O
symptomatic,5324,O
SSD,5324,O
patients,5324,O
resistant,5324,O
or,5324,O
intolerant,5324,O
of,5324,O
standard,5324,O
treatment,5324,O
with,5324,O
hydroxyurea,5324,B-CHEMICAL
received,5324,O
decitabine,5324,B-CHEMICAL
0.2,5324,O
mg/kg,5324,O
subcutaneously,5324,O
1,5324,O
to,5324,O
3,5324,O
times,5324,O
per,5324,O
week,5324,O
in,5324,O
2,5324,O
cycles,5324,O
of,5324,O
6-week,5324,O
duration,5324,O
.,5324,O
Treatment,5325,O
decreased,5325,O
neutrophils,5325,O
and,5325,O
increased,5325,O
mean,5325,O
HbF,5325,B-GENE-N
(,5325,O
6.5,5325,O
%,5325,O
to,5325,O
20.4,5325,O
%,5325,O
",",5325,O
P,5325,O
<,5325,O
.0001,5325,O
),5325,O
and,5325,O
mean,5325,O
total,5325,O
hemoglobin,5325,B-GENE-N
(,5325,O
76,5325,O
to,5325,O
96,5325,O
g/L,5325,O
[,5325,O
7.6,5325,O
to,5325,O
9.6,5325,O
g/dL,5325,O
],5325,O
",",5325,O
P,5325,O
<,5325,O
.001,5325,O
),5325,O
.,5325,O
Features,5326,O
of,5326,O
vaso-occlusive,5326,O
crisis,5326,O
pathophysiology,5326,O
such,5326,O
as,5326,O
red,5326,O
cell,5326,O
adhesion,5326,O
",",5326,O
endothelial,5326,O
damage,5326,O
",",5326,O
and,5326,O
coagulation,5326,O
pathway,5326,O
activity,5326,O
significantly,5326,O
improved,5326,O
.,5326,O
gamma-Globin,5327,B-GENE-N
gene,5327,I-GENE-N
promoter,5327,I-GENE-N
methylation,5327,O
decreased,5327,O
",",5327,O
and,5327,O
platelets,5327,O
and,5327,O
the,5327,O
proportion,5327,O
of,5327,O
megakaryocytes,5327,O
and,5327,O
erythroid,5327,O
cells,5327,O
in,5327,O
the,5327,O
marrow,5327,O
increased,5327,O
without,5327,O
a,5327,O
decrease,5327,O
in,5327,O
marrow,5327,O
cellularity,5327,O
",",5327,O
consistent,5327,O
with,5327,O
a,5327,O
DNA,5327,O
hypomethylating,5327,O
",",5327,O
noncytotoxic,5327,O
mechanism,5327,O
of,5327,O
action,5327,O
.,5327,O
Weekly,5328,O
subcutaneous,5328,O
decitabine,5328,B-CHEMICAL
produces,5328,O
cumulative,5328,O
increases,5328,O
in,5328,O
HbF,5328,B-GENE-N
and,5328,O
total,5328,O
hemoglobin,5328,B-GENE-N
through,5328,O
a,5328,O
noncytotoxic,5328,O
mechanism,5328,O
of,5328,O
action,5328,O
.,5328,O
Chronic,5329,O
dosing,5329,O
and,5329,O
sustained,5329,O
increases,5329,O
in,5329,O
hemoglobin,5329,B-GENE-N
F,5329,I-GENE-N
and,5329,O
total,5329,O
hemoglobin,5329,B-GENE-N
levels,5329,O
may,5329,O
be,5329,O
possible,5329,O
.,5329,O
Further,5330,O
studies,5330,O
in,5330,O
SSD,5330,O
and,5330,O
thalassemia,5330,O
are,5330,O
indicated,5330,O
.,5330,O
Quinone,5331,B-CHEMICAL
compounds,5331,O
regulate,5331,O
the,5331,O
level,5331,O
of,5331,O
ROS,5331,O
production,5331,O
by,5331,O
the,5331,O
NADPH,5331,B-GENE-N
oxidase,5331,I-GENE-N
Nox4,5331,B-GENE-Y
.,5331,O
NADPH,5332,B-GENE-N
oxidase,5332,I-GENE-N
Nox4,5332,B-GENE-Y
is,5332,O
expressed,5332,O
in,5332,O
a,5332,O
wide,5332,O
range,5332,O
of,5332,O
tissues,5332,O
and,5332,O
plays,5332,O
a,5332,O
role,5332,O
in,5332,O
cellular,5332,O
signaling,5332,O
by,5332,O
providing,5332,O
reactive,5332,O
oxygen,5332,B-CHEMICAL
species,5332,O
(,5332,O
ROS,5332,O
),5332,O
as,5332,O
intracellular,5332,O
messengers,5332,O
.,5332,O
Nox4,5333,B-GENE-Y
oxidase,5333,B-GENE-N
activity,5333,O
is,5333,O
thought,5333,O
to,5333,O
be,5333,O
constitutive,5333,O
and,5333,O
regulated,5333,O
at,5333,O
the,5333,O
transcriptional,5333,O
level,5333,O
;,5333,O
however,5333,O
",",5333,O
we,5333,O
challenge,5333,O
this,5333,O
point,5333,O
of,5333,O
view,5333,O
and,5333,O
suggest,5333,O
that,5333,O
specific,5333,O
quinone,5333,B-CHEMICAL
derivatives,5333,O
could,5333,O
modulate,5333,O
this,5333,O
activity,5333,O
.,5333,O
In,5334,O
fact,5334,O
",",5334,O
we,5334,O
demonstrated,5334,O
a,5334,O
significant,5334,O
stimulation,5334,O
of,5334,O
Nox4,5334,B-GENE-Y
activity,5334,O
by,5334,O
4,5334,O
quinone,5334,B-CHEMICAL
derivatives,5334,O
(,5334,O
AA-861,5334,B-CHEMICAL
",",5334,O
tBuBHQ,5334,B-CHEMICAL
",",5334,O
tBuBQ,5334,B-CHEMICAL
",",5334,O
and,5334,O
duroquinone,5334,B-CHEMICAL
),5334,O
observed,5334,O
in,5334,O
3,5334,O
different,5334,O
cellular,5334,O
models,5334,O
",",5334,O
HEK293E,5334,O
",",5334,O
T-REx™,5334,O
",",5334,O
and,5334,O
chondrocyte,5334,O
cell,5334,O
lines,5334,O
.,5334,O
Our,5335,O
results,5335,O
indicate,5335,O
that,5335,O
the,5335,O
effect,5335,O
is,5335,O
specific,5335,O
toward,5335,O
Nox4,5335,B-GENE-Y
versus,5335,O
Nox2,5335,B-GENE-Y
.,5335,O
Furthermore,5336,O
",",5336,O
we,5336,O
showed,5336,O
that,5336,O
NAD,5336,B-GENE-Y
(,5336,I-GENE-Y
P,5336,I-GENE-Y
),5336,I-GENE-Y
H,5336,I-GENE-Y
:,5336,I-GENE-Y
quinone,5336,I-GENE-Y
oxidoreductase,5336,I-GENE-Y
(,5336,O
NQO1,5336,B-GENE-Y
),5336,O
may,5336,O
participate,5336,O
in,5336,O
this,5336,O
stimulation,5336,O
.,5336,O
Interestingly,5337,O
",",5337,O
Nox4,5337,B-GENE-Y
activity,5337,O
is,5337,O
also,5337,O
stimulated,5337,O
by,5337,O
reducing,5337,O
agents,5337,O
that,5337,O
possibly,5337,O
act,5337,O
by,5337,O
reducing,5337,O
the,5337,O
disulfide,5337,B-CHEMICAL
bridge,5337,O
(,5337,O
Cys226,5337,B-CHEMICAL
",",5337,O
Cys270,5337,B-CHEMICAL
),5337,O
located,5337,O
in,5337,O
the,5337,O
extracellular,5337,B-GENE-N
E-loop,5337,I-GENE-N
of,5337,O
Nox4,5337,B-GENE-Y
.,5337,O
Such,5338,O
model,5338,O
of,5338,O
Nox4,5338,B-GENE-Y
activity,5338,O
regulation,5338,O
could,5338,O
provide,5338,O
new,5338,O
insight,5338,O
into,5338,O
the,5338,O
understanding,5338,O
of,5338,O
the,5338,O
molecular,5338,O
mechanism,5338,O
of,5338,O
the,5338,O
electron,5338,O
transfer,5338,O
through,5338,O
the,5338,O
enzyme,5338,O
",",5338,O
i.e.,5338,O
",",5338,O
its,5338,O
potential,5338,O
redox,5338,O
regulation,5338,O
",",5338,O
and,5338,O
could,5338,O
also,5338,O
define,5338,O
new,5338,O
therapeutic,5338,O
targets,5338,O
in,5338,O
diseases,5338,O
in,5338,O
which,5338,O
quinones,5338,B-CHEMICAL
and,5338,O
Nox4,5338,B-GENE-Y
are,5338,O
implicated,5338,O
.,5338,O
Does,5339,O
aspirin,5339,B-CHEMICAL
acetylate,5339,O
multiple,5339,O
cellular,5339,O
proteins,5339,O
?,5339,O
(,5340,O
Review,5340,O
),5340,O
.,5340,O
Aspirin,5341,B-CHEMICAL
is,5341,O
a,5341,O
salicylate,5341,B-CHEMICAL
drug,5341,O
that,5341,O
is,5341,O
extensively,5341,O
used,5341,O
for,5341,O
its,5341,O
anti-inflammatory,5341,O
",",5341,O
antipyretic,5341,O
",",5341,O
analgesic,5341,O
and,5341,O
anti-thrombotic,5341,O
effects,5341,O
.,5341,O
More,5342,O
recently,5342,O
",",5342,O
it,5342,O
has,5342,O
been,5342,O
shown,5342,O
to,5342,O
decrease,5342,O
the,5342,O
incidence,5342,O
of,5342,O
cancers,5342,O
of,5342,O
epithelial,5342,O
origin,5342,O
.,5342,O
In,5343,O
most,5343,O
cases,5343,O
",",5343,O
aspirin,5343,B-CHEMICAL
is,5343,O
relatively,5343,O
safe,5343,O
.,5343,O
However,5344,O
",",5344,O
it,5344,O
does,5344,O
cause,5344,O
a,5344,O
host,5344,O
of,5344,O
adverse,5344,O
effects,5344,O
and,5344,O
toxicities,5344,O
",",5344,O
including,5344,O
gastrointestinal,5344,O
bleeding,5344,O
",",5344,O
ulcerations,5344,O
",",5344,O
nephrotoxicity,5344,O
and,5344,O
hypersensitivity,5344,O
reactions,5344,O
.,5344,O
Although,5345,O
the,5345,O
inhibition,5345,O
of,5345,O
cyclooxygenases,5345,B-GENE-N
by,5345,O
aspirin,5345,B-CHEMICAL
",",5345,O
which,5345,O
leads,5345,O
to,5345,O
its,5345,O
anti-inflammatory/analgesic,5345,O
properties,5345,O
",",5345,O
has,5345,O
been,5345,O
well,5345,O
studied,5345,O
",",5345,O
the,5345,O
mechanisms,5345,O
involved,5345,O
in,5345,O
its,5345,O
chemopreventive,5345,O
effects,5345,O
as,5345,O
well,5345,O
as,5345,O
some,5345,O
of,5345,O
its,5345,O
adverse,5345,O
effects,5345,O
are,5345,O
as,5345,O
yet,5345,O
ill-defined,5345,O
.,5345,O
Studies,5346,O
over,5346,O
the,5346,O
past,5346,O
decades,5346,O
suggest,5346,O
that,5346,O
",",5346,O
besides,5346,O
cyclooxygenases,5346,B-GENE-N
",",5346,O
aspirin,5346,B-CHEMICAL
acetylates,5346,O
other,5346,O
cellular,5346,O
proteins,5346,O
.,5346,O
These,5347,O
studies,5347,O
used,5347,O
radiolabeled,5347,O
3H,5347,B-CHEMICAL
or,5347,O
14C,5347,B-CHEMICAL
aspirin,5347,B-CHEMICAL
",",5347,O
the,5347,O
only,5347,O
approach,5347,O
used,5347,O
to,5347,O
date,5347,O
for,5347,O
the,5347,O
detection,5347,O
of,5347,O
proteins,5347,O
acetylated,5347,O
by,5347,O
aspirin,5347,B-CHEMICAL
.,5347,O
In,5348,O
a,5348,O
recent,5348,O
study,5348,O
using,5348,O
protein-specific,5348,O
anti-acetyl,5348,O
lysine,5348,B-CHEMICAL
antibodies,5348,O
and,5348,O
immunological,5348,O
methods,5348,O
",",5348,O
we,5348,O
demonstrated,5348,O
the,5348,O
ability,5348,O
of,5348,O
aspirin,5348,B-CHEMICAL
to,5348,O
acetylate,5348,O
the,5348,O
tumor,5348,B-GENE-Y
suppressor,5348,I-GENE-Y
protein,5348,I-GENE-Y
p53,5348,I-GENE-Y
.,5348,O
In,5349,O
this,5349,O
review,5349,O
",",5349,O
we,5349,O
present,5349,O
current,5349,O
research,5349,O
from,5349,O
the,5349,O
literature,5349,O
on,5349,O
the,5349,O
aspirin-induced,5349,B-CHEMICAL
acetylation,5349,O
of,5349,O
proteins,5349,O
.,5349,O
We,5350,O
also,5350,O
describe,5350,O
an,5350,O
immunological,5350,O
approach,5350,O
to,5350,O
detecting,5350,O
acetylated,5350,O
proteins,5350,O
in,5350,O
aspirin-treated,5350,B-CHEMICAL
cells,5350,O
",",5350,O
and,5350,O
demonstrate,5350,O
that,5350,O
multiple,5350,O
proteins,5350,O
are,5350,O
acetylated,5350,O
.,5350,O
Since,5351,O
post-translational,5351,O
modification,5351,O
of,5351,O
proteins,5351,O
",",5351,O
such,5351,O
as,5351,O
acetylation,5351,O
",",5351,O
may,5351,O
lead,5351,O
to,5351,O
the,5351,O
alteration,5351,O
of,5351,O
their,5351,O
function,5351,O
",",5351,O
it,5351,O
is,5351,O
possible,5351,O
that,5351,O
some,5351,O
of,5351,O
the,5351,O
hitherto,5351,O
unexplained,5351,O
beneficial,5351,O
or,5351,O
adverse,5351,O
effects,5351,O
of,5351,O
aspirin,5351,B-CHEMICAL
could,5351,O
occur,5351,O
as,5351,O
a,5351,O
result,5351,O
of,5351,O
these,5351,O
modifications,5351,O
.,5351,O
The,5352,O
identification,5352,O
of,5352,O
these,5352,O
novel,5352,O
acetylation,5352,O
targets,5352,O
of,5352,O
aspirin,5352,B-CHEMICAL
represents,5352,O
a,5352,O
new,5352,O
area,5352,O
for,5352,O
investigation,5352,O
.,5352,O
Topoisomerase,5353,B-GENE-Y
IIβ,5353,I-GENE-Y
deficiency,5353,O
enhances,5353,O
camptothecin-induced,5353,B-CHEMICAL
apoptosis,5353,O
.,5353,O
Camptothecin,5354,B-CHEMICAL
(,5354,O
CPT,5354,B-CHEMICAL
),5354,O
",",5354,O
a,5354,O
topoisomerase,5354,B-GENE-Y
(,5354,I-GENE-Y
Top,5354,I-GENE-Y
),5354,I-GENE-Y
I-targeting,5354,O
drug,5354,O
that,5354,O
stabilizes,5354,O
Top1-DNA,5354,B-GENE-Y
covalent,5354,O
adducts,5354,O
",",5354,O
can,5354,O
induce,5354,O
S-phase-specific,5354,O
cytotoxicity,5354,O
due,5354,O
to,5354,O
the,5354,O
arrest,5354,O
of,5354,O
progressing,5354,O
replication,5354,O
forks,5354,O
.,5354,O
However,5355,O
",",5355,O
CPT-induced,5355,B-CHEMICAL
non-S-phase,5355,O
cytotoxicity,5355,O
is,5355,O
less,5355,O
well,5355,O
characterized,5355,O
.,5355,O
In,5356,O
this,5356,O
study,5356,O
",",5356,O
we,5356,O
have,5356,O
identified,5356,O
topoisomerase,5356,B-GENE-Y
IIβ,5356,I-GENE-Y
(,5356,O
Top2β,5356,B-GENE-Y
),5356,O
as,5356,O
a,5356,O
specific,5356,O
determinant,5356,O
for,5356,O
CPT,5356,B-CHEMICAL
sensitivity,5356,O
",",5356,O
but,5356,O
not,5356,O
for,5356,O
many,5356,O
other,5356,O
cytotoxic,5356,O
agents,5356,O
",",5356,O
in,5356,O
non-S-phase,5356,O
cells,5356,O
.,5356,O
First,5357,O
",",5357,O
quiescent,5357,O
mouse,5357,O
embryonic,5357,O
fibroblasts,5357,O
(,5357,O
MEFs,5357,O
),5357,O
lacking,5357,O
Top2β,5357,B-GENE-Y
were,5357,O
shown,5357,O
to,5357,O
be,5357,O
hypersensitive,5357,O
to,5357,O
CPT,5357,B-CHEMICAL
with,5357,O
prominent,5357,O
induction,5357,O
of,5357,O
apoptosis,5357,O
.,5357,O
Second,5358,O
",",5358,O
ICRF-187,5358,B-CHEMICAL
",",5358,O
a,5358,O
Top2,5358,B-GENE-Y
catalytic,5358,O
inhibitor,5358,O
known,5358,O
to,5358,O
deplete,5358,O
Top2β,5358,B-GENE-Y
",",5358,O
specifically,5358,O
sensitized,5358,O
MEFs,5358,O
to,5358,O
CPT,5358,B-CHEMICAL
.,5358,O
To,5359,O
explore,5359,O
the,5359,O
molecular,5359,O
basis,5359,O
for,5359,O
CPT,5359,B-CHEMICAL
hypersensitivity,5359,O
in,5359,O
Top2β-deficient,5359,B-GENE-Y
cells,5359,O
",",5359,O
we,5359,O
found,5359,O
that,5359,O
upon,5359,O
CPT,5359,B-CHEMICAL
exposure,5359,O
",",5359,O
the,5359,O
RNA,5359,B-GENE-N
polymerase,5359,I-GENE-N
II,5359,I-GENE-N
large,5359,I-GENE-N
subunit,5359,I-GENE-N
(,5359,O
RNAP,5359,B-GENE-N
LS,5359,I-GENE-N
),5359,O
became,5359,O
progressively,5359,O
depleted,5359,O
",",5359,O
followed,5359,O
by,5359,O
recovery,5359,O
to,5359,O
nearly,5359,O
the,5359,O
original,5359,O
level,5359,O
in,5359,O
wild-type,5359,O
MEFs,5359,O
",",5359,O
whereas,5359,O
RNAP,5359,B-GENE-N
LS,5359,I-GENE-N
remained,5359,O
depleted,5359,O
without,5359,O
recovery,5359,O
in,5359,O
Top2β-deficient,5359,B-GENE-Y
cells,5359,O
.,5359,O
Concomitant,5360,O
with,5360,O
the,5360,O
reduction,5360,O
of,5360,O
the,5360,O
RNAP,5360,B-GENE-N
LS,5360,I-GENE-N
level,5360,O
",",5360,O
the,5360,O
p53,5360,B-GENE-Y
protein,5360,O
level,5360,O
was,5360,O
greatly,5360,O
induced,5360,O
.,5360,O
Interestingly,5361,O
",",5361,O
RNAP,5361,B-GENE-N
LS,5361,I-GENE-N
depletion,5361,O
has,5361,O
been,5361,O
well,5361,O
documented,5361,O
to,5361,O
lead,5361,O
to,5361,O
p53-dependent,5361,B-GENE-Y
apoptosis,5361,O
.,5361,O
Altogether,5362,O
",",5362,O
our,5362,O
findings,5362,O
support,5362,O
a,5362,O
model,5362,O
in,5362,O
which,5362,O
Top2β,5362,B-GENE-Y
deficiency,5362,O
promotes,5362,O
CPT-induced,5362,B-CHEMICAL
apoptosis,5362,O
in,5362,O
quiescent,5362,O
non-S-phase,5362,O
cells,5362,O
",",5362,O
possibly,5362,O
due,5362,O
to,5362,O
RNAP,5362,B-GENE-N
LS,5362,I-GENE-N
depletion,5362,O
and,5362,O
p53,5362,B-GENE-Y
accumulation,5362,O
.,5362,O
Effects,5363,O
of,5363,O
felodipine,5363,B-CHEMICAL
(,5363,O
a,5363,O
dihydropyridine,5363,B-CHEMICAL
calcium,5363,B-GENE-N
channel,5363,I-GENE-N
blocker,5363,O
),5363,O
and,5363,O
analogues,5363,O
on,5363,O
calmodulin-dependent,5363,B-GENE-N
enzymes,5363,I-GENE-N
.,5363,O
We,5364,O
have,5364,O
examined,5364,O
the,5364,O
effects,5364,O
on,5364,O
the,5364,O
activities,5364,O
of,5364,O
three,5364,O
calmodulin-dependent,5364,B-GENE-N
enzymes,5364,I-GENE-N
(,5364,O
cAMP,5364,B-GENE-N
phosphodiesterase,5364,I-GENE-N
",",5364,O
caldesmon,5364,B-GENE-N
kinase,5364,I-GENE-N
and,5364,O
myosin,5364,B-GENE-Y
light,5364,I-GENE-Y
chain,5364,I-GENE-Y
kinase,5364,I-GENE-Y
),5364,O
of,5364,O
the,5364,O
dihydropyridine,5364,B-CHEMICAL
Ca2+,5364,B-GENE-N
channel,5364,I-GENE-N
blocker,5364,O
felodipine,5364,B-CHEMICAL
and,5364,O
three,5364,O
analogues,5364,O
(,5364,O
p-chloro,5364,B-CHEMICAL
",",5364,O
oxidized,5364,O
and,5364,O
t-butyl,5364,B-CHEMICAL
),5364,O
exhibiting,5364,O
different,5364,O
pharmacological,5364,O
potencies,5364,O
.,5364,O
The,5365,O
cAMP,5365,B-GENE-N
phosphodiesterase,5365,I-GENE-N
was,5365,O
inhibited,5365,O
completely,5365,O
by,5365,O
felodipine,5365,B-CHEMICAL
and,5365,O
the,5365,O
p-chloro,5365,B-CHEMICAL
analogue,5365,O
with,5365,O
IC50,5365,O
values,5365,O
of,5365,O
3.7,5365,O
and,5365,O
1.5,5365,O
microM,5365,O
respectively,5365,O
.,5365,O
The,5366,O
oxidized,5366,O
and,5366,O
t-butyl,5366,B-CHEMICAL
analogues,5366,O
were,5366,O
relatively,5366,O
ineffective,5366,O
in,5366,O
inhibiting,5366,O
cAMP,5366,B-GENE-N
phosphodiesterase,5366,I-GENE-N
.,5366,O
Felodipine,5367,B-CHEMICAL
and,5367,O
the,5367,O
p-chloro,5367,B-CHEMICAL
analogue,5367,O
inhibited,5367,O
the,5367,O
basal,5367,O
(,5367,O
Ca2+/calmodulin-independent,5367,B-CHEMICAL
),5367,O
activity,5367,O
of,5367,O
cAMP,5367,B-GENE-N
phosphodiesterase,5367,I-GENE-N
as,5367,O
well,5367,O
as,5367,O
the,5367,O
calmodulin-stimulated,5367,B-GENE-Y
activity,5367,O
.,5367,O
Calmodulin,5368,B-GENE-Y
was,5368,O
relatively,5368,O
ineffective,5368,O
in,5368,O
preventing,5368,O
inhibition,5368,O
of,5368,O
cAMP,5368,B-GENE-N
phosphodiesterase,5368,I-GENE-N
by,5368,O
felodipine,5368,B-CHEMICAL
and,5368,O
the,5368,O
p-chloro,5368,B-CHEMICAL
analogue,5368,O
.,5368,O
These,5369,O
observations,5369,O
suggest,5369,O
that,5369,O
felodipine,5369,B-CHEMICAL
may,5369,O
act,5369,O
directly,5369,O
on,5369,O
the,5369,O
phosphodiesterase,5369,B-GENE-N
as,5369,O
well,5369,O
as,5369,O
through,5369,O
calmodulin,5369,B-GENE-Y
.,5369,O
Felodipine,5370,B-CHEMICAL
and,5370,O
the,5370,O
p-chloro,5370,B-CHEMICAL
analogue,5370,O
inhibited,5370,O
Ca2+/calmodulin-dependent,5370,B-CHEMICAL
caldesmon,5370,B-GENE-N
kinase,5370,I-GENE-N
with,5370,O
similar,5370,O
potencies,5370,O
(,5370,O
IC50,5370,O
=,5370,O
17.4,5370,O
microM,5370,O
),5370,O
",",5370,O
whereas,5370,O
the,5370,O
oxidized,5370,O
and,5370,O
t-butyl,5370,B-CHEMICAL
analogues,5370,O
caused,5370,O
no,5370,O
inhibition,5370,O
.,5370,O
Similarly,5371,O
",",5371,O
felodipine,5371,B-CHEMICAL
and,5371,O
the,5371,O
p-chloro,5371,B-CHEMICAL
analogue,5371,O
inhibited,5371,O
myosin,5371,B-GENE-Y
light,5371,I-GENE-Y
chain,5371,I-GENE-Y
kinase,5371,I-GENE-Y
activity,5371,O
whether,5371,O
the,5371,O
isolated,5371,O
20,5371,O
kD,5371,O
light,5371,O
chain,5371,O
(,5371,O
IC50,5371,O
=,5371,O
12.6,5371,O
microM,5371,O
),5371,O
or,5371,O
intact,5371,O
myosin,5371,B-GENE-N
(,5371,O
IC50,5371,O
=,5371,O
11.0,5371,O
microM,5371,O
),5371,O
was,5371,O
used,5371,O
as,5371,O
substrate,5371,O
.,5371,O
Inhibition,5372,O
in,5372,O
each,5372,O
case,5372,O
was,5372,O
prevented,5372,O
by,5372,O
excess,5372,O
calmodulin,5372,B-GENE-Y
.,5372,O
The,5373,O
oxidized,5373,O
and,5373,O
t-butyl,5373,B-CHEMICAL
derivatives,5373,O
caused,5373,O
little,5373,O
or,5373,O
no,5373,O
inhibition,5373,O
.,5373,O
Finally,5374,O
",",5374,O
the,5374,O
effects,5374,O
of,5374,O
felodipine,5374,B-CHEMICAL
and,5374,O
the,5374,O
three,5374,O
analogues,5374,O
on,5374,O
two,5374,O
processes,5374,O
which,5374,O
are,5374,O
dependent,5374,O
on,5374,O
myosin,5374,B-GENE-N
phosphorylation,5374,O
were,5374,O
examined,5374,O
",",5374,O
namely,5374,O
the,5374,O
actin-activated,5374,B-GENE-N
Mg2+-ATPase,5374,B-GENE-N
activity,5374,O
of,5374,O
myosin,5374,B-GENE-N
and,5374,O
the,5374,O
assembly,5374,O
of,5374,O
myosin,5374,B-GENE-N
filaments,5374,O
.,5374,O
Felodipine,5375,B-CHEMICAL
and,5375,O
the,5375,O
p-chloro,5375,B-CHEMICAL
analogue,5375,O
inhibited,5375,O
the,5375,O
actin-activated,5375,B-GENE-N
Mg2+-ATPase,5375,B-GENE-N
activity,5375,O
of,5375,O
smooth,5375,O
muscle,5375,O
myosin,5375,B-GENE-N
(,5375,O
IC50,5375,O
=,5375,O
25.1,5375,O
microM,5375,O
),5375,O
.,5375,O
The,5376,O
oxidized,5376,O
and,5376,O
t-butyl,5376,B-CHEMICAL
analogues,5376,O
exhibited,5376,O
no,5376,O
inhibition,5376,O
.,5376,O
Similarly,5377,O
",",5377,O
felodipine,5377,B-CHEMICAL
and,5377,O
the,5377,O
p-chloro,5377,B-CHEMICAL
analogue,5377,O
blocked,5377,O
myosin,5377,B-GENE-N
filament,5377,O
assembly,5377,O
induced,5377,O
by,5377,O
low,5377,O
concentrations,5377,O
of,5377,O
calmodulin,5377,B-GENE-Y
",",5377,O
whereas,5377,O
the,5377,O
oxidized,5377,O
and,5377,O
t-butyl,5377,B-CHEMICAL
analogues,5377,O
did,5377,O
not,5377,O
.,5377,O
Again,5378,O
",",5378,O
inhibition,5378,O
of,5378,O
the,5378,O
actin-activated,5378,B-GENE-N
myosin,5378,B-GENE-N
Mg2+-ATPase,5378,B-GENE-N
and,5378,O
myosin,5378,B-GENE-N
filament,5378,O
assembly,5378,O
by,5378,O
felodipine,5378,B-CHEMICAL
and,5378,O
the,5378,O
p-chloro,5378,B-CHEMICAL
analogue,5378,O
could,5378,O
be,5378,O
reversed,5378,O
by,5378,O
raising,5378,O
the,5378,O
calmodulin,5378,B-GENE-Y
concentration,5378,O
.,5378,O
These,5379,O
observations,5379,O
suggest,5379,O
that,5379,O
some,5379,O
of,5379,O
the,5379,O
pharmacological,5379,O
actions,5379,O
of,5379,O
felodipine,5379,B-CHEMICAL
on,5379,O
smooth,5379,O
muscle,5379,O
may,5379,O
involve,5379,O
inhibition,5379,O
of,5379,O
calmodulin-dependent,5379,B-GENE-N
enzymes,5379,I-GENE-N
which,5379,O
are,5379,O
functionally,5379,O
involved,5379,O
in,5379,O
the,5379,O
regulation,5379,O
of,5379,O
smooth,5379,O
muscle,5379,O
contraction,5379,O
.,5379,O
Aldosterone-induced,5380,B-CHEMICAL
ENaC,5380,B-GENE-N
and,5380,O
basal,5380,O
Na,5380,B-GENE-N
(,5380,I-GENE-N
+,5380,I-GENE-N
),5380,I-GENE-N
/K,5380,I-GENE-N
(,5380,I-GENE-N
+,5380,I-GENE-N
),5380,I-GENE-N
-ATPase,5380,I-GENE-N
trafficking,5380,O
via,5380,O
protein,5380,B-GENE-Y
kinase,5380,I-GENE-Y
D1-phosphatidylinositol,5380,O
4-kinaseIIIβ,5380,I-GENE-Y
trans,5380,O
Golgi,5380,O
signalling,5380,O
in,5380,O
M1,5380,O
cortical,5380,O
collecting,5380,O
duct,5380,O
cells,5380,O
.,5380,O
Aldosterone,5381,B-CHEMICAL
regulates,5381,O
Na,5381,B-CHEMICAL
(,5381,I-CHEMICAL
+,5381,I-CHEMICAL
),5381,I-CHEMICAL
transport,5381,O
in,5381,O
the,5381,O
distal,5381,O
nephron,5381,O
through,5381,O
multiple,5381,O
mechanisms,5381,O
that,5381,O
include,5381,O
the,5381,O
transcriptional,5381,O
control,5381,O
of,5381,O
epithelial,5381,O
sodium,5381,B-GENE-N
channel,5381,I-GENE-N
(,5381,O
ENaC,5381,B-GENE-N
),5381,O
and,5381,O
Na,5381,B-GENE-N
(,5381,I-GENE-N
+,5381,I-GENE-N
),5381,I-GENE-N
/K,5381,I-GENE-N
(,5381,I-GENE-N
+,5381,I-GENE-N
),5381,I-GENE-N
-ATPase,5381,I-GENE-N
subunits,5381,O
.,5381,O
Aldosterone,5382,B-CHEMICAL
also,5382,O
induces,5382,O
the,5382,O
rapid,5382,O
phosphorylation,5382,O
of,5382,O
Protein,5382,B-GENE-Y
Kinase,5382,I-GENE-Y
D1,5382,I-GENE-Y
(,5382,O
PKD1,5382,B-GENE-Y
),5382,O
.,5382,O
PKD,5383,B-GENE-Y
isoforms,5383,O
regulate,5383,O
protein,5383,O
trafficking,5383,O
",",5383,O
by,5383,O
the,5383,O
control,5383,O
of,5383,O
vesicle,5383,O
fission,5383,O
from,5383,O
the,5383,O
trans,5383,O
Golgi,5383,O
network,5383,O
(,5383,O
TGN,5383,O
),5383,O
through,5383,O
activation,5383,O
of,5383,O
phosphatidylinositol,5383,B-GENE-Y
4-kinaseIIIβ,5383,I-GENE-Y
(,5383,O
PI4KIIIβ,5383,B-GENE-Y
),5383,O
.,5383,O
We,5384,O
report,5384,O
rapid,5384,O
ENaCγ,5384,B-GENE-Y
translocation,5384,O
to,5384,O
the,5384,O
plasma,5384,O
membrane,5384,O
after,5384,O
30min,5384,O
aldosterone,5384,O
treatment,5384,O
in,5384,O
polarized,5384,O
M1,5384,O
cortical,5384,O
collecting,5384,O
duct,5384,O
cells,5384,O
",",5384,O
which,5384,O
was,5384,O
significantly,5384,O
impaired,5384,O
in,5384,O
PKD1,5384,B-GENE-Y
shRNA-mediated,5384,O
knockdown,5384,O
cells,5384,O
.,5384,O
In,5385,O
PKD1-deficient,5385,B-GENE-Y
cells,5385,O
",",5385,O
the,5385,O
ouabain-sensitive,5385,B-CHEMICAL
current,5385,O
was,5385,O
significantly,5385,O
reduced,5385,O
and,5385,O
Na,5385,B-GENE-N
(,5385,I-GENE-N
+,5385,I-GENE-N
),5385,I-GENE-N
/K,5385,I-GENE-N
(,5385,I-GENE-N
+,5385,I-GENE-N
),5385,I-GENE-N
-ATPase,5385,I-GENE-N
α,5385,I-GENE-N
and,5385,I-GENE-N
β,5385,I-GENE-N
subunits,5385,O
showed,5385,O
aberrant,5385,O
localization,5385,O
.,5385,O
PKD1,5386,B-GENE-Y
and,5386,O
PI4KIIIβ,5386,B-GENE-Y
localize,5386,O
to,5386,O
the,5386,O
TGN,5386,O
",",5386,O
and,5386,O
aldosterone,5386,B-CHEMICAL
induced,5386,O
an,5386,O
interaction,5386,O
between,5386,O
PKD1,5386,B-GENE-Y
and,5386,O
PI4KIIIβ,5386,B-GENE-Y
following,5386,O
aldosterone,5386,B-CHEMICAL
treatment,5386,O
.,5386,O
This,5387,O
study,5387,O
reveals,5387,O
a,5387,O
novel,5387,O
mechanism,5387,O
for,5387,O
rapid,5387,O
regulation,5387,O
of,5387,O
ENaC,5387,B-GENE-N
and,5387,O
the,5387,O
Na,5387,B-GENE-N
(,5387,I-GENE-N
+,5387,I-GENE-N
),5387,I-GENE-N
/K,5387,I-GENE-N
(,5387,I-GENE-N
+,5387,I-GENE-N
),5387,I-GENE-N
-ATPase,5387,I-GENE-N
",",5387,O
via,5387,O
directed,5387,O
trafficking,5387,O
through,5387,O
PKD1-PI4KIIIβ,5387,B-GENE-Y
signalling,5387,O
at,5387,O
the,5387,O
level,5387,O
of,5387,O
the,5387,O
TGN,5387,O
.,5387,O
The,5388,O
role,5388,O
of,5388,O
5-HT,5388,B-GENE-Y
(,5388,I-GENE-Y
1A,5388,I-GENE-Y
),5388,I-GENE-Y
and,5388,O
5-HT,5388,B-GENE-N
(,5388,I-GENE-N
1B/1D,5388,I-GENE-N
),5388,I-GENE-N
receptors,5388,I-GENE-N
on,5388,O
the,5388,O
modulation,5388,O
of,5388,O
acute,5388,O
fluoxetine-induced,5388,B-CHEMICAL
changes,5388,O
in,5388,O
extracellular,5388,O
5-HT,5388,B-CHEMICAL
:,5388,O
the,5388,O
mechanism,5388,O
of,5388,O
action,5388,O
of,5388,O
(,5388,B-CHEMICAL
+/-,5388,I-CHEMICAL
),5388,I-CHEMICAL
pindolol,5388,I-CHEMICAL
.,5388,O
Some,5389,O
clinical,5389,O
evidence,5389,O
has,5389,O
suggested,5389,O
that,5389,O
(,5389,B-CHEMICAL
+/-,5389,I-CHEMICAL
),5389,I-CHEMICAL
pindolol,5389,I-CHEMICAL
can,5389,O
be,5389,O
effective,5389,O
at,5389,O
producing,5389,O
a,5389,O
shortened,5389,O
time,5389,O
to,5389,O
onset,5389,O
of,5389,O
antidepressant,5389,O
activity,5389,O
when,5389,O
co-administered,5389,O
with,5389,O
a,5389,O
serotonin,5389,B-CHEMICAL
specific,5389,O
reuptake,5389,O
inhibitor,5389,O
(,5389,O
SSRI,5389,O
),5389,O
.,5389,O
This,5390,O
effect,5390,O
has,5390,O
been,5390,O
attributed,5390,O
to,5390,O
the,5390,O
antagonist,5390,O
effects,5390,O
of,5390,O
pindolol,5390,B-CHEMICAL
at,5390,O
the,5390,O
5-HT,5390,B-GENE-Y
(,5390,I-GENE-Y
1A,5390,I-GENE-Y
),5390,I-GENE-Y
receptor,5390,O
.,5390,O
In,5391,O
the,5391,O
present,5391,O
study,5391,O
",",5391,O
we,5391,O
compared,5391,O
the,5391,O
pharmacology,5391,O
of,5391,O
(,5391,B-CHEMICAL
+/-,5391,I-CHEMICAL
),5391,I-CHEMICAL
pindolol,5391,I-CHEMICAL
",",5391,O
WAY-100635,5391,B-CHEMICAL
(,5391,O
a,5391,O
5-HT,5391,B-GENE-Y
(,5391,I-GENE-Y
1A,5391,I-GENE-Y
),5391,I-GENE-Y
antagonist,5391,O
),5391,O
",",5391,O
GR127935,5391,B-CHEMICAL
(,5391,O
a,5391,O
5-HT,5391,B-GENE-N
(,5391,I-GENE-N
1B/1D,5391,I-GENE-N
),5391,I-GENE-N
antagonist,5391,O
),5391,O
",",5391,O
and,5391,O
isamoltane,5391,B-CHEMICAL
(,5391,O
a,5391,O
5-HT,5391,B-GENE-Y
(,5391,I-GENE-Y
1B,5391,I-GENE-Y
),5391,I-GENE-Y
antagonist,5391,O
),5391,O
",",5391,O
when,5391,O
given,5391,O
acutely,5391,O
in,5391,O
combination,5391,O
with,5391,O
fluoxetine,5391,B-CHEMICAL
",",5391,O
using,5391,O
in,5391,O
vivo,5391,O
microdialysis,5391,O
in,5391,O
the,5391,O
frontal,5391,O
cortex,5391,O
of,5391,O
the,5391,O
freely,5391,O
moving,5391,O
rat,5391,O
.,5391,O
We,5392,O
have,5392,O
determined,5392,O
that,5392,O
the,5392,O
acute,5392,O
fluoxetine-induced,5392,B-CHEMICAL
increases,5392,O
in,5392,O
extracellular,5392,O
5-HT,5392,B-CHEMICAL
can,5392,O
be,5392,O
augmented,5392,O
by,5392,O
(,5392,B-CHEMICAL
+/-,5392,I-CHEMICAL
),5392,I-CHEMICAL
pindolol,5392,I-CHEMICAL
",",5392,O
WAY100635,5392,B-CHEMICAL
",",5392,O
GR127935,5392,B-CHEMICAL
and,5392,O
isamoltane,5392,B-CHEMICAL
with,5392,O
maximum,5392,O
increases,5392,O
of,5392,O
216+/-32,5392,O
%,5392,O
",",5392,O
235+/-49,5392,O
%,5392,O
",",5392,O
240+/-18,5392,O
%,5392,O
and,5392,O
171+/-47,5392,O
%,5392,O
of,5392,O
preinjection,5392,O
control,5392,O
levels,5392,O
",",5392,O
respectively,5392,O
.,5392,O
Combination,5393,O
of,5393,O
both,5393,O
5-HT,5393,B-GENE-Y
(,5393,I-GENE-Y
1A,5393,I-GENE-Y
),5393,I-GENE-Y
and,5393,O
5-HT,5393,B-GENE-N
(,5393,I-GENE-N
1B/1D,5393,I-GENE-N
),5393,I-GENE-N
autoreceptor,5393,O
antagonists,5393,O
with,5393,O
fluoxetine,5393,B-CHEMICAL
produced,5393,O
additive,5393,O
increases,5393,O
in,5393,O
extracellular,5393,O
5-HT,5393,B-CHEMICAL
(,5393,O
i.e,5393,O
.,5393,O
WAY100635+GR127935+fluoxetine,5394,B-CHEMICAL
and,5394,O
WAY100635+isamoltane+fluoxetine,5394,B-CHEMICAL
produced,5394,O
a,5394,O
four-,5394,O
and,5394,O
five-fold,5394,O
potentiation,5394,O
",",5394,O
respectively,5394,O
),5394,O
",",5394,O
suggesting,5394,O
that,5394,O
this,5394,O
strategy,5394,O
may,5394,O
be,5394,O
useful,5394,O
in,5394,O
further,5394,O
augmenting,5394,O
the,5394,O
action,5394,O
of,5394,O
a,5394,O
SSRI,5394,O
in,5394,O
the,5394,O
treatment,5394,O
of,5394,O
depression,5394,O
.,5394,O
In,5395,O
addition,5395,O
",",5395,O
by,5395,O
comparing,5395,O
the,5395,O
combined,5395,O
administration,5395,O
of,5395,O
(,5395,B-CHEMICAL
+/-,5395,I-CHEMICAL
),5395,I-CHEMICAL
pindolol,5395,I-CHEMICAL
with,5395,O
either,5395,O
WAY100635,5395,B-CHEMICAL
",",5395,O
GR127935,5395,B-CHEMICAL
or,5395,O
isamoltane,5395,B-CHEMICAL
",",5395,O
we,5395,O
have,5395,O
determined,5395,O
that,5395,O
(,5395,B-CHEMICAL
+/-,5395,I-CHEMICAL
),5395,I-CHEMICAL
pindolol,5395,I-CHEMICAL
produces,5395,O
much,5395,O
of,5395,O
its,5395,O
acute,5395,O
potentiation,5395,O
of,5395,O
fluoxetine-induced,5395,B-CHEMICAL
increases,5395,O
in,5395,O
extracellular,5395,O
5-HT,5395,B-CHEMICAL
via,5395,O
its,5395,O
action,5395,O
at,5395,O
the,5395,O
5-HT,5395,B-GENE-N
(,5395,I-GENE-N
1B/D,5395,I-GENE-N
),5395,I-GENE-N
receptor,5395,I-GENE-N
in,5395,O
addition,5395,O
to,5395,O
any,5395,O
activity,5395,O
it,5395,O
has,5395,O
at,5395,O
the,5395,O
presynaptic,5395,O
5-HT,5395,B-GENE-Y
(,5395,I-GENE-Y
1A,5395,I-GENE-Y
),5395,I-GENE-Y
receptor,5395,O
.,5395,O
Design,5396,O
",",5396,O
synthesis,5396,O
and,5396,O
biological,5396,O
evaluation,5396,O
of,5396,O
novel,5396,O
hybrid,5396,O
compounds,5396,O
of,5396,O
imidazole,5396,B-CHEMICAL
scaffold-based,5396,O
2-benzylbenzofuran,5396,B-CHEMICAL
as,5396,O
potent,5396,O
anticancer,5396,O
agents,5396,O
.,5396,O
A,5397,O
series,5397,O
of,5397,O
novel,5397,O
hybrid,5397,O
compounds,5397,O
between,5397,O
2-benzylbenzofuran,5397,B-CHEMICAL
and,5397,O
imidazole,5397,B-CHEMICAL
has,5397,O
been,5397,O
prepared,5397,O
and,5397,O
evaluated,5397,O
in,5397,O
vitro,5397,O
against,5397,O
a,5397,O
panel,5397,O
of,5397,O
human,5397,O
tumor,5397,O
cell,5397,O
lines,5397,O
.,5397,O
The,5398,O
results,5398,O
suggest,5398,O
that,5398,O
the,5398,O
existence,5398,O
of,5398,O
benzimidazole,5398,B-CHEMICAL
ring,5398,O
and,5398,O
substitution,5398,O
of,5398,O
the,5398,O
imidazolyl-3-position,5398,B-CHEMICAL
with,5398,O
a,5398,O
naphthylacyl,5398,B-CHEMICAL
or,5398,O
4-methoxyphenacyl,5398,B-CHEMICAL
group,5398,O
were,5398,O
vital,5398,O
for,5398,O
modulating,5398,O
cytotoxic,5398,O
activity,5398,O
.,5398,O
In,5399,O
particular,5399,O
",",5399,O
hybrid,5399,O
compounds,5399,O
46,5399,O
and,5399,O
47,5399,O
were,5399,O
found,5399,O
to,5399,O
be,5399,O
the,5399,O
most,5399,O
potent,5399,O
derivatives,5399,O
against,5399,O
5,5399,O
strains,5399,O
human,5399,O
tumor,5399,O
cell,5399,O
lines,5399,O
and,5399,O
more,5399,O
active,5399,O
than,5399,O
cisplatin,5399,B-CHEMICAL
(,5399,O
DDP,5399,B-CHEMICAL
),5399,O
",",5399,O
and,5399,O
exhibited,5399,O
cytotoxic,5399,O
activities,5399,O
selectively,5399,O
against,5399,O
breast,5399,O
carcinoma,5399,O
(,5399,O
MCF-7,5399,O
),5399,O
and,5399,O
myeloid,5399,O
liver,5399,O
carcinoma,5399,O
(,5399,O
SMMC-7721,5399,O
),5399,O
",",5399,O
respectively,5399,O
.,5399,O
Involvement,5400,O
of,5400,O
serotonin,5400,B-CHEMICAL
5-HT3,5400,B-GENE-Y
receptors,5400,O
in,5400,O
the,5400,O
modulation,5400,O
of,5400,O
noradrenergic,5400,O
transmission,5400,O
by,5400,O
serotonin,5400,B-CHEMICAL
reuptake,5400,O
inhibitors,5400,O
:,5400,O
a,5400,O
microdialysis,5400,O
study,5400,O
in,5400,O
rat,5400,O
brain,5400,O
.,5400,O
RATIONALE,5401,O
:,5401,O
Selective,5401,O
serotonin,5401,B-CHEMICAL
reuptake,5401,O
inhibitors,5401,O
(,5401,O
SSRIs,5401,O
),5401,O
",",5401,O
in,5401,O
addition,5401,O
to,5401,O
being,5401,O
able,5401,O
to,5401,O
enhance,5401,O
serotonergic,5401,O
neurotransmission,5401,O
",",5401,O
are,5401,O
able,5401,O
to,5401,O
modulate,5401,O
other,5401,O
brain,5401,O
systems,5401,O
involved,5401,O
in,5401,O
depression,5401,O
.,5401,O
OBJECTIVES,5402,O
:,5402,O
This,5402,O
study,5402,O
evaluates,5402,O
the,5402,O
neurochemical,5402,O
effect,5402,O
of,5402,O
the,5402,O
SSRI,5402,O
citalopram,5402,O
on,5402,O
brain,5402,O
noradrenergic,5402,O
activity,5402,O
and,5402,O
the,5402,O
serotonin,5402,B-GENE-N
receptor,5402,I-GENE-N
involved,5402,O
in,5402,O
this,5402,O
effect,5402,O
.,5402,O
METHODS,5403,O
:,5403,O
Dual-probe,5403,O
microdialysis,5403,O
in,5403,O
the,5403,O
locus,5403,O
coeruleus,5403,O
(,5403,O
LC,5403,O
),5403,O
and,5403,O
prefrontal,5403,O
cortex,5403,O
(,5403,O
PFC,5403,O
),5403,O
was,5403,O
performed,5403,O
in,5403,O
freely,5403,O
awake,5403,O
rats,5403,O
.,5403,O
RESULTS,5404,O
:,5404,O
Systemic,5404,O
citalopram,5404,B-CHEMICAL
(,5404,O
10,5404,O
mg/kg,5404,O
",",5404,O
i.p,5404,O
.,5404,O
),5404,O
increased,5405,O
noradrenaline,5405,B-CHEMICAL
(,5405,O
NA,5405,O
),5405,O
in,5405,O
the,5405,O
LC,5405,O
(,5405,O
E,5405,O
max,5405,O
=,5405,O
141,5405,O
±,5405,O
13,5405,O
%,5405,O
),5405,O
and,5405,O
simultaneously,5405,O
decreased,5405,O
NA,5405,O
in,5405,O
the,5405,O
PFC,5405,O
(,5405,O
Emax,5405,O
=,5405,O
-46,5405,O
±,5405,O
7,5405,O
%,5405,O
),5405,O
.,5405,O
In,5406,O
the,5406,O
local,5406,O
presence,5406,O
into,5406,O
the,5406,O
LC,5406,O
of,5406,O
the,5406,O
α2-adrenoceptor,5406,B-GENE-N
antagonist,5406,O
RS79948,5406,B-CHEMICAL
(,5406,O
1,5406,O
μM,5406,O
),5406,O
",",5406,O
systemic,5406,O
citalopram,5406,B-CHEMICAL
increased,5406,O
NA,5406,O
in,5406,O
the,5406,O
LC,5406,O
(,5406,O
Emax,5406,O
=,5406,O
157,5406,O
±,5406,O
25,5406,O
%,5406,O
),5406,O
and,5406,O
PFC,5406,O
(,5406,O
Emax,5406,O
=,5406,O
175,5406,O
±,5406,O
24,5406,O
%,5406,O
),5406,O
.,5406,O
Local,5407,O
citalopram,5407,B-CHEMICAL
(,5407,O
0.1-100,5407,O
μM,5407,O
),5407,O
into,5407,O
the,5407,O
LC,5407,O
induced,5407,O
NA,5407,O
increase,5407,O
in,5407,O
the,5407,O
LC,5407,O
(,5407,O
Emax,5407,O
=,5407,O
210,5407,O
±,5407,O
25,5407,O
%,5407,O
),5407,O
and,5407,O
decrease,5407,O
in,5407,O
the,5407,O
PFC,5407,O
(,5407,O
Emax,5407,O
=,5407,O
-38,5407,O
±,5407,O
9,5407,O
%,5407,O
),5407,O
.,5407,O
Local,5408,O
LC,5408,O
citalopram,5408,B-CHEMICAL
effect,5408,O
was,5408,O
abolished,5408,O
by,5408,O
LC,5408,O
presence,5408,O
of,5408,O
the,5408,O
5-HT3,5408,B-GENE-Y
receptor,5408,O
antagonist,5408,O
MDL72222,5408,B-CHEMICAL
(,5408,O
1,5408,O
μM,5408,O
),5408,O
but,5408,O
not,5408,O
the,5408,O
5-HT1/2,5408,B-GENE-N
receptor,5408,O
antagonist,5408,O
methiothepin,5408,B-CHEMICAL
(,5408,O
1,5408,O
μM,5408,O
),5408,O
.,5408,O
Systemic,5409,O
citalopram,5409,B-CHEMICAL
in,5409,O
the,5409,O
LC,5409,O
presence,5409,O
of,5409,O
MDL72222,5409,B-CHEMICAL
did,5409,O
not,5409,O
modify,5409,O
NA,5409,O
in,5409,O
the,5409,O
LC,5409,O
but,5409,O
increased,5409,O
NA,5409,O
in,5409,O
the,5409,O
PFC,5409,O
(,5409,O
Emax,5409,O
=,5409,O
158,5409,O
±,5409,O
26,5409,O
%,5409,O
),5409,O
.,5409,O
Local,5410,O
citalopram,5410,B-CHEMICAL
into,5410,O
the,5410,O
PFC,5410,O
enhanced,5410,O
NA,5410,O
(,5410,O
Emax,5410,O
=,5410,O
376,5410,O
±,5410,O
18,5410,O
%,5410,O
),5410,O
in,5410,O
the,5410,O
area,5410,O
",",5410,O
which,5410,O
was,5410,O
prevented,5410,O
by,5410,O
MDL72222,5410,B-CHEMICAL
.,5410,O
CONCLUSIONS,5411,O
:,5411,O
The,5411,O
SSRI,5411,O
citalopram,5411,B-CHEMICAL
modulates,5411,O
central,5411,O
noradrenergic,5411,O
neurotransmission,5411,O
by,5411,O
activation,5411,O
",",5411,O
through,5411,O
endogenous,5411,O
serotonin,5411,B-CHEMICAL
",",5411,O
of,5411,O
5-HT3,5411,B-GENE-Y
receptors,5411,O
expressed,5411,O
in,5411,O
the,5411,O
somatodendritic,5411,O
(,5411,O
LC,5411,O
),5411,O
and,5411,O
terminal,5411,O
(,5411,O
PFC,5411,O
),5411,O
areas,5411,O
",",5411,O
which,5411,O
subsequently,5411,O
promote,5411,O
an,5411,O
enhancement,5411,O
of,5411,O
local,5411,O
NA,5411,O
.,5411,O
Therefore,5412,O
",",5412,O
5-HT3,5412,B-GENE-Y
receptors,5412,O
and,5412,O
somatodendritic,5412,O
α2-adrenoceptors,5412,B-GENE-N
in,5412,O
the,5412,O
LC,5412,O
play,5412,O
an,5412,O
important,5412,O
role,5412,O
in,5412,O
the,5412,O
global,5412,O
effect,5412,O
of,5412,O
SSRIs,5412,O
.,5412,O
Expressions,5413,O
and,5413,O
mechanical,5413,O
functions,5413,O
of,5413,O
alpha1-adrenoceptor,5413,B-GENE-N
subtypes,5413,O
in,5413,O
hamster,5413,O
ureter,5413,O
.,5413,O
We,5414,O
characterized,5414,O
the,5414,O
alpha,5414,B-GENE-N
(,5414,I-GENE-N
1,5414,I-GENE-N
),5414,I-GENE-N
-adrenoceptor,5414,I-GENE-N
subtypes,5414,O
in,5414,O
hamster,5414,O
ureters,5414,O
according,5414,O
to,5414,O
gene,5414,O
and,5414,O
protein,5414,O
expressions,5414,O
and,5414,O
contractile,5414,O
function,5414,O
.,5414,O
Real-time,5415,O
quantitative,5415,O
reverse-transcription,5415,O
polymerase,5415,O
chain,5415,O
reaction,5415,O
and,5415,O
immunohistochemical,5415,O
analysis,5415,O
were,5415,O
performed,5415,O
to,5415,O
determine,5415,O
mRNA,5415,O
levels,5415,O
and,5415,O
receptor,5415,O
protein,5415,O
expressions,5415,O
respectively,5415,O
",",5415,O
for,5415,O
alpha,5415,B-GENE-N
(,5415,I-GENE-N
1A,5415,I-GENE-N
),5415,I-GENE-N
-,5415,I-GENE-N
",",5415,I-GENE-N
alpha,5415,I-GENE-N
(,5415,I-GENE-N
1B,5415,I-GENE-N
),5415,I-GENE-N
-,5415,I-GENE-N
and,5415,I-GENE-N
alpha,5415,I-GENE-N
(,5415,I-GENE-N
1D,5415,I-GENE-N
),5415,I-GENE-N
-adrenoceptors,5415,I-GENE-N
in,5415,O
hamster,5415,O
ureteral,5415,O
smooth,5415,O
muscle,5415,O
.,5415,O
alpha,5416,B-GENE-N
(,5416,I-GENE-N
1,5416,I-GENE-N
),5416,I-GENE-N
-Adrenoceptor,5416,I-GENE-N
antagonists,5416,O
were,5416,O
tested,5416,O
against,5416,O
the,5416,O
phenylephrine,5416,B-CHEMICAL
(,5416,O
alpha,5416,B-GENE-N
(,5416,I-GENE-N
1,5416,I-GENE-N
),5416,I-GENE-N
-adrenoceptor,5416,I-GENE-N
agonist,5416,O
),5416,O
-induced,5416,O
contraction,5416,O
in,5416,O
isolated,5416,O
hamster,5416,O
ureteral,5416,O
preparations,5416,O
using,5416,O
a,5416,O
functional,5416,O
experimental,5416,O
approach,5416,O
.,5416,O
In,5417,O
the,5417,O
smooth,5417,O
muscle,5417,O
",",5417,O
relative,5417,O
mRNA,5417,O
expression,5417,O
levels,5417,O
for,5417,O
alpha,5417,B-GENE-N
(,5417,I-GENE-N
1a,5417,I-GENE-N
),5417,I-GENE-N
-,5417,I-GENE-N
",",5417,I-GENE-N
alpha,5417,I-GENE-N
(,5417,I-GENE-N
1b,5417,I-GENE-N
),5417,I-GENE-N
-,5417,I-GENE-N
and,5417,I-GENE-N
alpha,5417,I-GENE-N
(,5417,I-GENE-N
1d,5417,I-GENE-N
),5417,I-GENE-N
-adrenoceptors,5417,I-GENE-N
were,5417,O
10.7,5417,O
%,5417,O
",",5417,O
1.2,5417,O
%,5417,O
and,5417,O
88.1,5417,O
%,5417,O
",",5417,O
respectively,5417,O
",",5417,O
and,5417,O
protein,5417,O
expressions,5417,O
were,5417,O
identified,5417,O
for,5417,O
alpha,5417,B-GENE-N
(,5417,I-GENE-N
1A,5417,I-GENE-N
),5417,I-GENE-N
-,5417,I-GENE-N
and,5417,I-GENE-N
alpha,5417,I-GENE-N
(,5417,I-GENE-N
1D,5417,I-GENE-N
),5417,I-GENE-N
-adrenoceptors,5417,I-GENE-N
immunohistochemically,5417,O
.,5417,O
Noradrenaline,5418,B-CHEMICAL
and,5418,O
phenylephrine,5418,B-CHEMICAL
(,5418,O
alpha,5418,B-GENE-N
(,5418,I-GENE-N
1,5418,I-GENE-N
),5418,I-GENE-N
-adrenoceptor,5418,I-GENE-N
agonist,5418,O
),5418,O
each,5418,O
produced,5418,O
a,5418,O
concentration-dependent,5418,O
tonic,5418,O
contraction,5418,O
",",5418,O
their,5418,O
pD,5418,O
(,5418,O
2,5418,O
),5418,O
values,5418,O
being,5418,O
6.87+/-0.08,5418,O
and,5418,O
6.10+/-0.05,5418,O
",",5418,O
respectively,5418,O
.,5418,O
Prazosin,5419,B-CHEMICAL
(,5419,O
nonselective,5419,O
alpha,5419,B-GENE-N
(,5419,I-GENE-N
1,5419,I-GENE-N
),5419,I-GENE-N
-adrenoceptor,5419,I-GENE-N
antagonist,5419,O
),5419,O
",",5419,O
silodosin,5419,B-CHEMICAL
(,5419,O
selective,5419,O
alpha,5419,B-GENE-N
(,5419,I-GENE-N
1A,5419,I-GENE-N
),5419,I-GENE-N
-adrenoceptor,5419,I-GENE-N
antagonist,5419,O
),5419,O
and,5419,O
BMY-7378,5419,B-CHEMICAL
(,5419,O
8-,5419,B-CHEMICAL
[,5419,I-CHEMICAL
2-,5419,I-CHEMICAL
[,5419,I-CHEMICAL
4-,5419,I-CHEMICAL
(,5419,I-CHEMICAL
2-methoxyphenyl,5419,I-CHEMICAL
),5419,I-CHEMICAL
-1-piperazinyl,5419,I-CHEMICAL
],5419,I-CHEMICAL
ethyl,5419,I-CHEMICAL
],5419,I-CHEMICAL
-8-azaspiro,5419,I-CHEMICAL
[,5419,I-CHEMICAL
4.5,5419,I-CHEMICAL
],5419,I-CHEMICAL
"decane-7,9-dione",5419,I-CHEMICAL
dihydrochloride,5419,I-CHEMICAL
),5419,O
(,5419,O
selective,5419,O
alpha,5419,B-GENE-N
(,5419,I-GENE-N
1D,5419,I-GENE-N
),5419,I-GENE-N
-adrenoceptor,5419,I-GENE-N
antagonist,5419,O
),5419,O
competitively,5419,O
antagonized,5419,O
the,5419,O
phenylephrine-induced,5419,B-CHEMICAL
contraction,5419,O
(,5419,O
pA,5419,O
(,5419,O
2,5419,O
),5419,O
values,5419,O
",",5419,O
8.60+/-0.07,5419,O
",",5419,O
9.44+/-0.06,5419,O
and,5419,O
5.75+/-0.07,5419,O
",",5419,O
respectively,5419,O
),5419,O
.,5419,O
Chloroethylclonidine,5420,B-CHEMICAL
(,5420,O
3x10,5420,O
(,5420,O
-6,5420,O
),5420,O
mol/L,5420,O
or,5420,O
more,5420,O
),5420,O
produced,5420,O
a,5420,O
rightward,5420,O
shift,5420,O
in,5420,O
the,5420,O
concentration-response,5420,O
curve,5420,O
for,5420,O
phenylephrine,5420,B-CHEMICAL
.,5420,O
Thus,5421,O
",",5421,O
in,5421,O
hamster,5421,O
ureters,5421,O
",",5421,O
alpha,5421,B-GENE-N
(,5421,I-GENE-N
1A,5421,I-GENE-N
),5421,I-GENE-N
-,5421,I-GENE-N
and,5421,I-GENE-N
alpha,5421,I-GENE-N
(,5421,I-GENE-N
1D,5421,I-GENE-N
),5421,I-GENE-N
-adrenoceptors,5421,I-GENE-N
were,5421,O
more,5421,O
prevalent,5421,O
than,5421,O
the,5421,O
alpha,5421,B-GENE-Y
(,5421,I-GENE-Y
1B,5421,I-GENE-Y
),5421,I-GENE-Y
-adrenoceptor,5421,I-GENE-Y
",",5421,O
with,5421,O
contraction,5421,O
being,5421,O
mediated,5421,O
mainly,5421,O
via,5421,O
alpha,5421,B-GENE-N
(,5421,I-GENE-N
1A,5421,I-GENE-N
),5421,I-GENE-N
-adrenoceptors,5421,I-GENE-N
.,5421,O
If,5422,O
these,5422,O
findings,5422,O
hold,5422,O
true,5422,O
for,5422,O
humans,5422,O
",",5422,O
alpha,5422,B-GENE-N
(,5422,I-GENE-N
1A,5422,I-GENE-N
),5422,I-GENE-N
-adrenoceptor,5422,I-GENE-N
antagonists,5422,O
could,5422,O
become,5422,O
useful,5422,O
medication,5422,O
for,5422,O
stone,5422,O
passage,5422,O
in,5422,O
urolithiasis,5422,O
patients,5422,O
.,5422,O
Amylin,5423,B-GENE-Y
receptors,5423,O
:,5423,O
molecular,5423,O
composition,5423,O
and,5423,O
pharmacology,5423,O
.,5423,O
Several,5424,O
receptors,5424,O
which,5424,O
bind,5424,O
the,5424,O
hormone,5424,O
AMY,5424,B-GENE-Y
(,5424,O
amylin,5424,B-GENE-Y
),5424,O
with,5424,O
high,5424,O
affinity,5424,O
have,5424,O
now,5424,O
been,5424,O
identified,5424,O
.,5424,O
The,5425,O
minimum,5425,O
binding,5425,O
unit,5425,O
is,5425,O
composed,5425,O
of,5425,O
the,5425,O
CT,5425,B-GENE-Y
(,5425,I-GENE-Y
calcitonin,5425,I-GENE-Y
),5425,I-GENE-Y
receptor,5425,I-GENE-Y
at,5425,O
its,5425,O
core,5425,O
",",5425,O
plus,5425,O
a,5425,O
RAMP,5425,B-GENE-N
(,5425,O
receptor,5425,B-GENE-N
activity,5425,I-GENE-N
modifying,5425,I-GENE-N
protein,5425,I-GENE-N
),5425,O
.,5425,O
The,5426,O
receptors,5426,O
have,5426,O
been,5426,O
named,5426,O
AMY,5426,B-GENE-N
(,5426,I-GENE-N
1,5426,I-GENE-N
(,5426,I-GENE-N
a,5426,I-GENE-N
),5426,I-GENE-N
),5426,I-GENE-N
",",5426,O
AMY,5426,B-GENE-N
(,5426,I-GENE-N
2,5426,I-GENE-N
(,5426,I-GENE-N
a,5426,I-GENE-N
),5426,I-GENE-N
),5426,I-GENE-N
and,5426,O
AMY,5426,B-GENE-N
(,5426,I-GENE-N
3,5426,I-GENE-N
(,5426,I-GENE-N
a,5426,I-GENE-N
),5426,I-GENE-N
),5426,I-GENE-N
in,5426,O
accordance,5426,O
with,5426,O
the,5426,O
association,5426,O
of,5426,O
the,5426,O
CT,5426,B-GENE-Y
receptor,5426,I-GENE-Y
(,5426,B-GENE-Y
CT,5426,I-GENE-Y
(,5426,I-GENE-Y
(,5426,I-GENE-Y
a,5426,I-GENE-Y
),5426,I-GENE-Y
),5426,I-GENE-Y
),5426,I-GENE-Y
with,5426,O
RAMP1,5426,B-GENE-Y
",",5426,O
RAMP2,5426,B-GENE-Y
and,5426,O
RAMP3,5426,B-GENE-Y
respectively,5426,O
.,5426,O
The,5427,O
challenge,5427,O
is,5427,O
now,5427,O
to,5427,O
determine,5427,O
the,5427,O
localization,5427,O
and,5427,O
pharmacological,5427,O
nature,5427,O
of,5427,O
each,5427,O
of,5427,O
these,5427,O
receptors,5427,O
.,5427,O
Recent,5428,O
attempts,5428,O
to,5428,O
achieve,5428,O
these,5428,O
aims,5428,O
will,5428,O
be,5428,O
briefly,5428,O
discussed,5428,O
.,5428,O
Hospitalized,5429,O
osteoporotic,5429,O
vertebral,5429,O
fracture,5429,O
increases,5429,O
the,5429,O
risk,5429,O
of,5429,O
stroke,5429,O
:,5429,O
a,5429,O
population-based,5429,O
cohort,5429,O
study,5429,O
.,5429,O
The,5430,O
association,5430,O
between,5430,O
osteoporosis,5430,O
and,5430,O
cardiovascular,5430,O
diseases,5430,O
has,5430,O
been,5430,O
demonstrated,5430,O
.,5430,O
Higher,5431,O
cardiovascular,5431,O
risk,5431,O
has,5431,O
also,5431,O
been,5431,O
correlated,5431,O
with,5431,O
vertebral,5431,O
fractures,5431,O
.,5431,O
However,5432,O
",",5432,O
the,5432,O
association,5432,O
between,5432,O
osteoporotic,5432,O
vertebral,5432,O
fracture,5432,O
and,5432,O
the,5432,O
possibly,5432,O
higher,5432,O
risk,5432,O
of,5432,O
stroke,5432,O
remains,5432,O
uncertain,5432,O
.,5432,O
This,5433,O
study,5433,O
aimed,5433,O
to,5433,O
evaluate,5433,O
the,5433,O
incidence,5433,O
",",5433,O
risk,5433,O
",",5433,O
and,5433,O
type,5433,O
of,5433,O
stroke,5433,O
in,5433,O
patients,5433,O
with,5433,O
osteoporotic,5433,O
vertebral,5433,O
fracture,5433,O
.,5433,O
Patients,5434,O
with,5434,O
osteoporotic,5434,O
vertebral,5434,O
fracture,5434,O
were,5434,O
identified,5434,O
(,5434,O
n,5434,O
=,5434,O
380,5434,O
),5434,O
and,5434,O
10,5434,O
age-,5434,O
and,5434,O
sex-matched,5434,O
controls,5434,O
per,5434,O
case,5434,O
(,5434,O
comparison,5434,O
group,5434,O
",",5434,O
n,5434,O
=,5434,O
3795,5434,O
),5434,O
were,5434,O
chosen,5434,O
from,5434,O
a,5434,O
nationwide,5434,O
representative,5434,O
cohort,5434,O
of,5434,O
"999,997",5434,O
people,5434,O
from,5434,O
1998,5434,O
to,5434,O
2005,5434,O
.,5434,O
Both,5435,O
groups,5435,O
were,5435,O
followed-up,5435,O
for,5435,O
stroke,5435,O
events,5435,O
for,5435,O
3,5435,O
years,5435,O
",",5435,O
matched,5435,O
by,5435,O
propensity,5435,O
scores,5435,O
with,5435,O
adjustments,5435,O
for,5435,O
covariates,5435,O
such,5435,O
as,5435,O
comorbidities,5435,O
(,5435,O
ie,5435,O
",",5435,O
hypertension,5435,O
",",5435,O
diabetes,5435,O
",",5435,O
arrhythmia,5435,O
",",5435,O
or,5435,O
coronary,5435,O
heart,5435,O
diseases,5435,O
),5435,O
and,5435,O
exposure,5435,O
to,5435,O
medications,5435,O
(,5435,O
ie,5435,O
",",5435,O
aspirin,5435,B-CHEMICAL
",",5435,O
lipid,5435,O
lowering,5435,O
drug,5435,O
",",5435,O
or,5435,O
nitrates,5435,B-CHEMICAL
),5435,O
",",5435,O
and,5435,O
assessed,5435,O
by,5435,O
Kaplan-Meier,5435,O
and,5435,O
Cox,5435,O
regression,5435,O
analyses,5435,O
.,5435,O
The,5436,O
incidence,5436,O
rate,5436,O
of,5436,O
stroke,5436,O
in,5436,O
the,5436,O
osteoporotic,5436,O
vertebral,5436,O
fracture,5436,O
group,5436,O
(,5436,O
37.5,5436,O
per,5436,O
1000,5436,O
person-years,5436,O
;,5436,O
95,5436,O
%,5436,O
confidence,5436,O
interval,5436,O
[,5436,O
CI,5436,O
],5436,O
",",5436,O
27.5-51.2,5436,O
),5436,O
was,5436,O
significantly,5436,O
higher,5436,O
than,5436,O
in,5436,O
the,5436,O
comparison,5436,O
group,5436,O
(,5436,O
14.0,5436,O
per,5436,O
1000,5436,O
person-years,5436,O
;,5436,O
95,5436,O
%,5436,O
CI,5436,O
",",5436,O
12.0-16.4,5436,O
",",5436,O
p,5436,O
<,5436,O
0.001,5436,O
),5436,O
.,5436,O
Stroke,5437,O
was,5437,O
more,5437,O
likely,5437,O
to,5437,O
occur,5437,O
in,5437,O
the,5437,O
osteoporotic,5437,O
vertebral,5437,O
fracture,5437,O
patients,5437,O
than,5437,O
in,5437,O
the,5437,O
normal,5437,O
controls,5437,O
(,5437,O
crude,5437,O
hazard,5437,O
ratio,5437,O
[,5437,O
HR,5437,O
],5437,O
2.68,5437,O
",",5437,O
95,5437,O
%,5437,O
CI,5437,O
1.89-3.79,5437,O
",",5437,O
p,5437,O
<,5437,O
0.001,5437,O
;,5437,O
adjusted,5437,O
HR,5437,O
2.71,5437,O
",",5437,O
95,5437,O
%,5437,O
CI,5437,O
1.90-3.86,5437,O
",",5437,O
p,5437,O
<,5437,O
0.001,5437,O
),5437,O
.,5437,O
In,5438,O
conclusion,5438,O
",",5438,O
patients,5438,O
with,5438,O
osteoporotic,5438,O
vertebral,5438,O
fracture,5438,O
have,5438,O
a,5438,O
higher,5438,O
risk,5438,O
of,5438,O
stroke,5438,O
(,5438,O
ie,5438,O
",",5438,O
both,5438,O
ischemic,5438,O
and,5438,O
hemorrhagic,5438,O
),5438,O
and,5438,O
require,5438,O
stroke,5438,O
prevention,5438,O
strategies,5438,O
.,5438,O
Inhibition,5439,O
of,5439,O
recombinant,5439,O
L-type,5439,B-GENE-N
voltage-gated,5439,I-GENE-N
calcium,5439,I-GENE-N
channels,5439,I-GENE-N
by,5439,O
positive,5439,O
allosteric,5439,O
modulators,5439,O
of,5439,O
GABAA,5439,B-GENE-N
receptors,5439,I-GENE-N
.,5439,O
Benzodiazepines,5440,B-CHEMICAL
(,5440,O
BDZs,5440,B-CHEMICAL
),5440,O
depress,5440,O
neuronal,5440,O
excitability,5440,O
via,5440,O
positive,5440,O
allosteric,5440,O
modulation,5440,O
of,5440,O
inhibitory,5440,O
GABA,5440,B-GENE-N
(,5440,I-GENE-N
A,5440,I-GENE-N
),5440,I-GENE-N
receptors,5440,I-GENE-N
(,5440,O
GABA,5440,B-GENE-N
(,5440,I-GENE-N
A,5440,I-GENE-N
),5440,I-GENE-N
R,5440,I-GENE-N
),5440,O
.,5440,O
BDZs,5441,B-CHEMICAL
and,5441,O
other,5441,O
positive,5441,O
GABA,5441,B-GENE-N
(,5441,I-GENE-N
A,5441,I-GENE-N
),5441,I-GENE-N
R,5441,I-GENE-N
modulators,5441,O
",",5441,O
including,5441,O
barbiturates,5441,B-CHEMICAL
",",5441,O
ethanol,5441,B-CHEMICAL
",",5441,O
and,5441,O
neurosteroids,5441,B-CHEMICAL
",",5441,O
can,5441,O
also,5441,O
inhibit,5441,O
L-type,5441,B-GENE-N
voltage-gated,5441,I-GENE-N
calcium,5441,I-GENE-N
channels,5441,I-GENE-N
(,5441,O
L-VGCCs,5441,B-GENE-N
),5441,O
",",5441,O
which,5441,O
could,5441,O
contribute,5441,O
to,5441,O
reduced,5441,O
neuronal,5441,O
excitability,5441,O
.,5441,O
Because,5442,O
neuronal,5442,O
L-VGCC,5442,B-GENE-N
function,5442,O
is,5442,O
up-regulated,5442,O
after,5442,O
long-term,5442,O
GABA,5442,B-GENE-N
(,5442,I-GENE-N
A,5442,I-GENE-N
),5442,I-GENE-N
R,5442,I-GENE-N
modulator,5442,O
exposure,5442,O
",",5442,O
an,5442,O
interaction,5442,O
with,5442,O
L-VGCCs,5442,B-GENE-N
may,5442,O
also,5442,O
play,5442,O
a,5442,O
role,5442,O
in,5442,O
physical,5442,O
dependence,5442,O
.,5442,O
The,5443,O
current,5443,O
studies,5443,O
assessed,5443,O
the,5443,O
effects,5443,O
of,5443,O
BDZs,5443,B-CHEMICAL
(,5443,O
diazepam,5443,B-CHEMICAL
",",5443,O
flurazepam,5443,B-CHEMICAL
",",5443,O
and,5443,O
desalkylflurazepam,5443,B-CHEMICAL
),5443,O
",",5443,O
allopregnanolone,5443,B-CHEMICAL
",",5443,O
pentobarbital,5443,B-CHEMICAL
",",5443,O
and,5443,O
ethanol,5443,B-CHEMICAL
on,5443,O
whole-cell,5443,O
Ba,5443,B-CHEMICAL
(,5443,I-CHEMICAL
2+,5443,I-CHEMICAL
),5443,I-CHEMICAL
currents,5443,O
through,5443,O
recombinant,5443,O
neuronal,5443,O
Ca,5443,B-GENE-Y
(,5443,I-GENE-Y
v,5443,I-GENE-Y
),5443,I-GENE-Y
1.2,5443,I-GENE-Y
and,5443,O
Ca,5443,B-GENE-Y
(,5443,I-GENE-Y
v,5443,I-GENE-Y
),5443,I-GENE-Y
1.3,5443,I-GENE-Y
L-VGCCs,5443,B-GENE-N
expressed,5443,O
with,5443,O
beta,5443,O
(,5443,O
3,5443,O
),5443,O
and,5443,O
alpha,5443,O
(,5443,O
2,5443,O
),5443,O
delta-1,5443,O
in,5443,O
HEK293T,5443,O
cells,5443,O
.,5443,O
Allopregnanolone,5444,B-CHEMICAL
was,5444,O
the,5444,O
most,5444,O
potent,5444,O
inhibitor,5444,O
(,5444,O
IC,5444,O
(,5444,O
50,5444,O
),5444,O
",",5444,O
approximately,5444,O
10,5444,O
muM,5444,O
),5444,O
",",5444,O
followed,5444,O
by,5444,O
BDZs,5444,B-CHEMICAL
(,5444,O
IC,5444,O
(,5444,O
50,5444,O
),5444,O
",",5444,O
approximately,5444,O
50,5444,O
muM,5444,O
),5444,O
",",5444,O
pentobarbital,5444,B-CHEMICAL
(,5444,O
IC,5444,O
(,5444,O
50,5444,O
),5444,O
",",5444,O
0.3-1,5444,O
mM,5444,O
),5444,O
",",5444,O
and,5444,O
ethanol,5444,B-CHEMICAL
(,5444,O
IC,5444,O
(,5444,O
50,5444,O
),5444,O
",",5444,O
approximately,5444,O
300,5444,O
mM,5444,O
),5444,O
.,5444,O
Ca,5445,B-GENE-Y
(,5445,I-GENE-Y
v,5445,I-GENE-Y
),5445,I-GENE-Y
1.3,5445,I-GENE-Y
channels,5445,O
were,5445,O
less,5445,O
sensitive,5445,O
to,5445,O
pentobarbital,5445,B-CHEMICAL
inhibition,5445,O
than,5445,O
Ca,5445,B-GENE-Y
(,5445,I-GENE-Y
v,5445,I-GENE-Y
),5445,I-GENE-Y
1.2,5445,I-GENE-Y
channels,5445,O
",",5445,O
similar,5445,O
to,5445,O
dihydropyridine,5445,B-CHEMICAL
(,5445,O
DHP,5445,B-CHEMICAL
),5445,O
L-VGCC,5445,B-GENE-N
antagonists,5445,O
.,5445,O
All,5446,O
GABA,5446,B-GENE-N
(,5446,I-GENE-N
A,5446,I-GENE-N
),5446,I-GENE-N
R,5446,I-GENE-N
modulators,5446,O
induced,5446,O
a,5446,O
negative,5446,O
shift,5446,O
in,5446,O
the,5446,O
steady-state,5446,O
inactivation,5446,O
curve,5446,O
of,5446,O
Ca,5446,B-GENE-Y
(,5446,I-GENE-Y
v,5446,I-GENE-Y
),5446,I-GENE-Y
1.3,5446,I-GENE-Y
channels,5446,O
",",5446,O
but,5446,O
only,5446,O
BDZs,5446,B-CHEMICAL
and,5446,O
pentobarbital,5446,B-CHEMICAL
induced,5446,O
a,5446,O
negative,5446,O
shift,5446,O
in,5446,O
Ca,5446,B-GENE-Y
(,5446,I-GENE-Y
v,5446,I-GENE-Y
),5446,I-GENE-Y
1.2,5446,I-GENE-Y
channel,5446,O
inactivation,5446,O
.,5446,O
Mutation,5447,O
of,5447,O
the,5447,O
high-affinity,5447,B-GENE-N
DHP,5447,I-GENE-N
binding,5447,I-GENE-N
site,5447,I-GENE-N
(,5447,O
T1039Y,5447,B-GENE-N
and,5447,O
Q1043M,5447,B-GENE-N
),5447,O
in,5447,O
Ca,5447,B-GENE-Y
(,5447,I-GENE-Y
v,5447,I-GENE-Y
),5447,I-GENE-Y
1.2,5447,I-GENE-Y
channels,5447,O
reduced,5447,O
pentobarbital,5447,B-CHEMICAL
potency,5447,O
.,5447,O
Despite,5448,O
the,5448,O
structural,5448,O
similarity,5448,O
between,5448,O
benzothiazepines,5448,B-CHEMICAL
and,5448,O
BDZs,5448,B-CHEMICAL
",",5448,O
mutation,5448,O
of,5448,O
an,5448,O
amino,5448,B-CHEMICAL
acid,5448,I-CHEMICAL
important,5448,O
for,5448,O
diltiazem,5448,B-CHEMICAL
potency,5448,O
(,5448,O
I1150A,5448,B-GENE-N
),5448,O
did,5448,O
not,5448,O
affect,5448,O
diazepam,5448,B-CHEMICAL
potency,5448,O
.,5448,O
Although,5449,O
L-VGCC,5449,B-GENE-N
inhibition,5449,O
by,5449,O
BDZs,5449,B-CHEMICAL
occurred,5449,O
at,5449,O
concentrations,5449,O
that,5449,O
are,5449,O
possibly,5449,O
too,5449,O
high,5449,O
to,5449,O
be,5449,O
clinically,5449,O
relevant,5449,O
and,5449,O
is,5449,O
not,5449,O
likely,5449,O
to,5449,O
play,5449,O
a,5449,O
role,5449,O
in,5449,O
the,5449,O
up-regulation,5449,O
of,5449,O
L-VGCCs,5449,B-GENE-N
during,5449,O
long-term,5449,O
treatment,5449,O
",",5449,O
pentobarbital,5449,B-CHEMICAL
and,5449,O
ethanol,5449,O
inhibited,5449,O
L-VGCCs,5449,B-GENE-N
at,5449,O
clinically,5449,O
relevant,5449,O
concentrations,5449,O
.,5449,O
"5-Hydroxy-3,6,7,8,3",5450,B-CHEMICAL
',5450,I-CHEMICAL
4'-hexamethoxyflavone,5450,I-CHEMICAL
inhibits,5450,O
nitric,5450,B-CHEMICAL
oxide,5450,I-CHEMICAL
production,5450,O
in,5450,O
lipopolysaccharide-stimulated,5450,O
BV2,5450,O
microglia,5450,O
via,5450,O
NF-κB,5450,B-GENE-N
suppression,5450,O
and,5450,O
Nrf-2-dependent,5450,B-GENE-Y
heme,5450,B-GENE-Y
oxygenase-1,5450,I-GENE-Y
induction,5450,O
.,5450,O
In,5451,O
this,5451,O
study,5451,O
",",5451,O
we,5451,O
found,5451,O
that,5451,O
"5-hydroxy-3,6,7,8,3",5451,B-CHEMICAL
',5451,I-CHEMICAL
4'-hexamethoxyflavone,5451,I-CHEMICAL
(,5451,O
5HHMF,5451,B-CHEMICAL
),5451,O
from,5451,O
Hizikia,5451,O
fusiforme,5451,O
considerably,5451,O
inhibits,5451,O
lipopolysaccharide,5451,O
(,5451,O
LPS,5451,O
),5451,O
-stimulated,5451,O
NO,5451,B-CHEMICAL
production,5451,O
by,5451,O
suppressing,5451,O
the,5451,O
expression,5451,O
of,5451,O
inducible,5451,B-GENE-Y
NO,5451,I-GENE-Y
synthase,5451,I-GENE-Y
(,5451,O
iNOS,5451,B-GENE-Y
),5451,O
in,5451,O
BV2,5451,O
microglia,5451,O
.,5451,O
In,5452,O
addition,5452,O
",",5452,O
5HHMF,5452,B-CHEMICAL
blocked,5452,O
LPS-induced,5452,O
phosphorylation,5452,O
of,5452,O
IκB,5452,B-GENE-N
",",5452,O
resulting,5452,O
in,5452,O
suppression,5452,O
of,5452,O
the,5452,O
nuclear,5452,O
translocation,5452,O
of,5452,O
nuclear,5452,B-GENE-N
factor-κB,5452,I-GENE-N
(,5452,O
NF-κB,5452,B-GENE-N
),5452,O
subunits,5452,O
",",5452,O
namely,5452,O
p65,5452,B-GENE-Y
and,5452,O
p50,5452,B-GENE-Y
",",5452,O
which,5452,O
are,5452,O
important,5452,O
molecules,5452,O
involved,5452,O
in,5452,O
the,5452,O
regulation,5452,O
of,5452,O
iNOS,5452,B-GENE-Y
expression,5452,O
.,5452,O
Pyrrolidine,5453,B-CHEMICAL
dithiocarbamate,5453,I-CHEMICAL
(,5453,O
PDTC,5453,B-CHEMICAL
),5453,O
",",5453,O
a,5453,O
specific,5453,O
NF-κB,5453,B-GENE-N
inhibitor,5453,O
",",5453,O
along,5453,O
with,5453,O
20S,5453,B-GENE-N
proteasome,5453,I-GENE-N
inhibitor,5453,O
(,5453,O
PSI,5453,O
),5453,O
significantly,5453,O
inhibited,5453,O
LPS-induced,5453,O
iNOS,5453,B-GENE-Y
expression,5453,O
",",5453,O
which,5453,O
indirectly,5453,O
suggested,5453,O
that,5453,O
5HHMF,5453,B-CHEMICAL
downregulated,5453,O
iNOS,5453,B-GENE-Y
expression,5453,O
by,5453,O
suppressing,5453,O
NF-κB,5453,B-GENE-N
activity,5453,O
.,5453,O
Thus,5454,O
",",5454,O
we,5454,O
found,5454,O
that,5454,O
5HHMF,5454,B-CHEMICAL
enhances,5454,O
heme,5454,B-GENE-Y
oxygenase-1,5454,I-GENE-Y
(,5454,O
HO-1,5454,B-GENE-Y
),5454,O
expression,5454,O
via,5454,O
nuclear,5454,B-GENE-Y
factor-erythroid,5454,I-GENE-Y
2-related,5454,I-GENE-Y
factor,5454,I-GENE-Y
2,5454,I-GENE-Y
(,5454,O
Nrf2,5454,B-GENE-Y
),5454,O
activation,5454,O
.,5454,O
In,5455,O
addition,5455,O
",",5455,O
cobalt,5455,B-CHEMICAL
protoporphyrin,5455,I-CHEMICAL
(,5455,O
CoPP,5455,B-CHEMICAL
),5455,O
",",5455,O
a,5455,O
specific,5455,O
HO-1,5455,B-GENE-Y
inducer,5455,O
",",5455,O
predominantly,5455,O
suppressed,5455,O
LPS-induced,5455,O
NO,5455,B-CHEMICAL
production,5455,O
.,5455,O
In,5456,O
contrast,5456,O
",",5456,O
zinc,5456,B-CHEMICAL
protoporphyrin,5456,I-CHEMICAL
(,5456,O
ZnPP,5456,B-CHEMICAL
),5456,O
",",5456,O
a,5456,O
specific,5456,O
HO-1,5456,B-GENE-Y
inhibitor,5456,O
",",5456,O
showed,5456,O
a,5456,O
partial,5456,O
suppressive,5456,O
effect,5456,O
of,5456,O
5HHMF,5456,B-CHEMICAL
on,5456,O
LPS-induced,5456,O
NO,5456,B-CHEMICAL
production,5456,O
.,5456,O
Further,5457,O
",",5457,O
5HHMF,5457,B-CHEMICAL
increased,5457,O
specific,5457,O
DNA-binding,5457,O
activity,5457,O
of,5457,O
Nrf2,5457,B-GENE-Y
",",5457,O
and,5457,O
transient,5457,O
knockdown,5457,O
with,5457,O
Nrf2,5457,B-GENE-Y
siRNA,5457,O
subsequently,5457,O
reversed,5457,O
5HHMF-induced,5457,B-CHEMICAL
NO,5457,B-CHEMICAL
inhibition,5457,O
",",5457,O
which,5457,O
was,5457,O
followed,5457,O
by,5457,O
suppression,5457,O
of,5457,O
HO-1,5457,B-GENE-Y
activity,5457,O
.,5457,O
Taken,5458,O
together,5458,O
",",5458,O
our,5458,O
findings,5458,O
indicate,5458,O
that,5458,O
5HHMF,5458,B-CHEMICAL
suppresses,5458,O
NO,5458,B-CHEMICAL
production,5458,O
through,5458,O
modulation,5458,O
of,5458,O
iNOS,5458,B-GENE-Y
",",5458,O
consequently,5458,O
suppressing,5458,O
NF-κB,5458,B-GENE-N
activity,5458,O
and,5458,O
induction,5458,O
of,5458,O
Nrf2-dependent,5458,B-GENE-Y
HO-1,5458,B-GENE-Y
activity,5458,O
.,5458,O
Synthesis,5459,O
and,5459,O
antitumor,5459,O
activity,5459,O
of,5459,O
"1,3,4-oxadiazole",5459,B-CHEMICAL
possessing,5459,O
"1,4-benzodioxan",5459,B-CHEMICAL
moiety,5459,O
as,5459,O
a,5459,O
novel,5459,O
class,5459,O
of,5459,O
potent,5459,O
methionine,5459,B-GENE-Y
aminopeptidase,5459,I-GENE-Y
type,5459,I-GENE-Y
II,5459,I-GENE-Y
inhibitors,5459,O
.,5459,O
A,5460,O
series,5460,O
of,5460,O
"1,3,4-oxadiazole",5460,B-CHEMICAL
derivatives,5460,O
containing,5460,O
"1,4-benzodioxan",5460,B-CHEMICAL
moiety,5460,O
(,5460,O
7a-7q,5460,O
),5460,O
have,5460,O
been,5460,O
designed,5460,O
",",5460,O
synthesized,5460,O
and,5460,O
evaluated,5460,O
for,5460,O
their,5460,O
antitumor,5460,O
activity,5460,O
.,5460,O
Most,5461,O
of,5461,O
the,5461,O
synthesized,5461,O
compounds,5461,O
were,5461,O
proved,5461,O
to,5461,O
have,5461,O
potent,5461,O
antitumor,5461,O
activity,5461,O
and,5461,O
low,5461,O
toxicity,5461,O
.,5461,O
Among,5462,O
them,5462,O
",",5462,O
compound,5462,O
7a,5462,O
showed,5462,O
the,5462,O
most,5462,O
potent,5462,O
biological,5462,O
activity,5462,O
against,5462,O
Human,5462,O
Umbilical,5462,O
Vein,5462,O
Endothelial,5462,O
cells,5462,O
",",5462,O
which,5462,O
was,5462,O
comparable,5462,O
to,5462,O
the,5462,O
positive,5462,O
control,5462,O
.,5462,O
The,5463,O
results,5463,O
of,5463,O
apoptosis,5463,O
and,5463,O
flow,5463,O
cytometry,5463,O
(,5463,O
FCM,5463,O
),5463,O
demonstrated,5463,O
that,5463,O
compound,5463,O
7a,5463,O
induce,5463,O
cell,5463,O
apoptosis,5463,O
by,5463,O
the,5463,O
inhibition,5463,O
of,5463,O
MetAP2,5463,B-GENE-Y
pathway,5463,O
.,5463,O
Molecular,5464,O
docking,5464,O
was,5464,O
performed,5464,O
to,5464,O
position,5464,O
compound,5464,O
7a,5464,O
into,5464,O
MetAP2,5464,B-GENE-Y
binding,5464,O
site,5464,O
in,5464,O
order,5464,O
to,5464,O
explore,5464,O
the,5464,O
potential,5464,O
target,5464,O
.,5464,O
Discovery,5465,O
of,5465,O
novel,5465,O
cannabinoid,5465,B-GENE-N
receptor,5465,I-GENE-N
ligands,5465,O
by,5465,O
a,5465,O
virtual,5465,O
screening,5465,O
approach,5465,O
:,5465,O
further,5465,O
development,5465,O
of,5465,O
"2,4,6-trisubstituted",5465,B-CHEMICAL
"1,3,5-triazines",5465,I-CHEMICAL
as,5465,O
CB2,5465,B-GENE-Y
agonists,5465,O
.,5465,O
3D,5466,O
ligand-based,5466,O
virtual,5466,O
screening,5466,O
was,5466,O
employed,5466,O
to,5466,O
identify,5466,O
novel,5466,O
scaffolds,5466,O
for,5466,O
cannabinoid,5466,B-GENE-N
receptor,5466,I-GENE-N
ligand,5466,O
development,5466,O
.,5466,O
A,5467,O
total,5467,O
of,5467,O
112,5467,O
compounds,5467,O
with,5467,O
diverse,5467,O
structures,5467,O
were,5467,O
purchased,5467,O
from,5467,O
commercial,5467,O
vendors,5467,O
.,5467,O
12,5468,O
CB1,5468,B-GENE-Y
receptor,5468,O
antagonists/inverse,5468,O
agonists,5468,O
and,5468,O
10,5468,O
CB2,5468,B-GENE-Y
receptor,5468,O
agonists,5468,O
were,5468,O
identified,5468,O
in,5468,O
vitro,5468,O
.,5468,O
One,5469,O
of,5469,O
the,5469,O
CB2,5469,B-GENE-Y
agonists,5469,O
",",5469,O
N-cyclopentyl-4-ethoxy-6-,5469,B-CHEMICAL
(,5469,I-CHEMICAL
4-methylpiperidin-1-yl,5469,I-CHEMICAL
),5469,I-CHEMICAL
"-1,3,5-triazin-2-amine",5469,I-CHEMICAL
(,5469,O
19,5469,O
",",5469,O
-logEC,5469,O
(,5469,O
50,5469,O
),5469,O
=7.5,5469,O
",",5469,O
E,5469,O
(,5469,O
max,5469,O
),5469,O
=255,5469,O
%,5469,O
),5469,O
was,5469,O
selected,5469,O
for,5469,O
further,5469,O
development,5469,O
.,5469,O
As,5470,O
far,5470,O
as,5470,O
we,5470,O
are,5470,O
aware,5470,O
",",5470,O
the,5470,O
compound,5470,O
's,5470,O
"1,3,5-triazine",5470,B-CHEMICAL
scaffold,5470,O
represents,5470,O
a,5470,O
new,5470,O
core,5470,O
structure,5470,O
for,5470,O
CB2,5470,B-GENE-Y
agonists,5470,O
.,5470,O
A,5471,O
library,5471,O
of,5471,O
fifty-seven,5471,O
"2,4,6-trisubstituted-1,3,5-triazines",5471,B-CHEMICAL
was,5471,O
created,5471,O
to,5471,O
clarify,5471,O
the,5471,O
structure-activity,5471,O
relationship,5471,O
study,5471,O
of,5471,O
the,5471,O
analogs,5471,O
.,5471,O
Inborn,5472,O
errors,5472,O
in,5472,O
the,5472,O
metabolism,5472,O
of,5472,O
glutathione,5472,B-CHEMICAL
.,5472,O
Glutathione,5473,B-CHEMICAL
is,5473,O
a,5473,O
tripeptide,5473,B-CHEMICAL
composed,5473,O
of,5473,O
glutamate,5473,B-CHEMICAL
",",5473,O
cysteine,5473,B-CHEMICAL
and,5473,O
glycine,5473,B-CHEMICAL
.,5473,O
Glutathione,5474,B-CHEMICAL
is,5474,O
present,5474,O
in,5474,O
millimolar,5474,O
concentrations,5474,O
in,5474,O
most,5474,O
mammalian,5474,O
cells,5474,O
and,5474,O
it,5474,O
is,5474,O
involved,5474,O
in,5474,O
several,5474,O
fundamental,5474,O
biological,5474,O
functions,5474,O
",",5474,O
including,5474,O
free,5474,O
radical,5474,O
scavenging,5474,O
",",5474,O
detoxification,5474,O
of,5474,O
xenobiotics,5474,O
and,5474,O
carcinogens,5474,O
",",5474,O
redox,5474,O
reactions,5474,O
",",5474,O
biosynthesis,5474,O
of,5474,O
DNA,5474,O
",",5474,O
proteins,5474,O
and,5474,O
leukotrienes,5474,B-CHEMICAL
",",5474,O
as,5474,O
well,5474,O
as,5474,O
neurotransmission/neuromodulation,5474,O
.,5474,O
Glutathione,5475,B-CHEMICAL
is,5475,O
metabolised,5475,O
via,5475,O
the,5475,O
gamma-glutamyl,5475,B-CHEMICAL
cycle,5475,O
",",5475,O
which,5475,O
is,5475,O
catalyzed,5475,O
by,5475,O
six,5475,O
enzymes,5475,O
.,5475,O
In,5476,O
man,5476,O
",",5476,O
hereditary,5476,O
deficiencies,5476,O
have,5476,O
been,5476,O
found,5476,O
in,5476,O
five,5476,O
of,5476,O
the,5476,O
six,5476,O
enzymes,5476,O
.,5476,O
Glutathione,5477,B-GENE-Y
synthetase,5477,I-GENE-Y
deficiency,5477,O
is,5477,O
the,5477,O
most,5477,O
frequently,5477,O
recognized,5477,O
disorder,5477,O
and,5477,O
",",5477,O
in,5477,O
its,5477,O
severe,5477,O
form,5477,O
",",5477,O
it,5477,O
is,5477,O
associated,5477,O
with,5477,O
hemolytic,5477,O
anemia,5477,O
",",5477,O
metabolic,5477,O
acidosis,5477,O
",",5477,O
5-oxoprolinuria,5477,O
",",5477,O
central,5477,O
nervous,5477,O
system,5477,O
(,5477,O
CNS,5477,O
),5477,O
damage,5477,O
and,5477,O
recurrent,5477,O
bacterial,5477,O
infections,5477,O
.,5477,O
Gamma-glutamylcysteine,5478,B-GENE-Y
synthetase,5478,I-GENE-Y
deficiency,5478,O
is,5478,O
also,5478,O
associated,5478,O
with,5478,O
hemolytic,5478,O
anemia,5478,O
",",5478,O
and,5478,O
some,5478,O
patients,5478,O
with,5478,O
this,5478,O
disorder,5478,O
show,5478,O
defects,5478,O
of,5478,O
neuromuscular,5478,O
function,5478,O
and,5478,O
generalized,5478,O
aminoaciduria,5478,O
.,5478,O
Gamma-glutamyl,5479,B-GENE-Y
transpeptidase,5479,I-GENE-Y
deficiency,5479,O
has,5479,O
been,5479,O
found,5479,O
in,5479,O
patients,5479,O
with,5479,O
CNS,5479,O
involvement,5479,O
and,5479,O
glutathionuria,5479,O
.,5479,O
5-Oxoprolinase,5480,B-GENE-Y
deficiency,5480,O
is,5480,O
associated,5480,O
with,5480,O
5-oxoprolinuria,5480,O
but,5480,O
without,5480,O
a,5480,O
clear,5480,O
association,5480,O
with,5480,O
other,5480,O
symptoms,5480,O
.,5480,O
Dipeptidase,5481,B-GENE-N
deficiency,5481,O
has,5481,O
been,5481,O
described,5481,O
in,5481,O
one,5481,O
patient,5481,O
.,5481,O
All,5482,O
disorders,5482,O
are,5482,O
very,5482,O
rare,5482,O
and,5482,O
inherited,5482,O
in,5482,O
an,5482,O
autosomal,5482,O
recessive,5482,O
manner,5482,O
.,5482,O
Most,5483,O
of,5483,O
the,5483,O
mutations,5483,O
are,5483,O
leaky,5483,O
so,5483,O
that,5483,O
many,5483,O
patients,5483,O
have,5483,O
residual,5483,O
enzyme,5483,O
activity,5483,O
.,5483,O
Diagnosis,5484,O
is,5484,O
made,5484,O
by,5484,O
measuring,5484,O
the,5484,O
concentration,5484,O
of,5484,O
different,5484,O
metabolites,5484,O
in,5484,O
the,5484,O
gamma-glutamyl,5484,B-CHEMICAL
cycle,5484,O
",",5484,O
enzyme,5484,O
activity,5484,O
and,5484,O
in,5484,O
glutathione,5484,B-GENE-Y
synthetase,5484,I-GENE-Y
and,5484,O
gamma-glutamylcysteine,5484,B-GENE-Y
synthetase,5484,I-GENE-Y
deficiency,5484,O
",",5484,O
also,5484,O
by,5484,O
mutation,5484,O
analysis,5484,O
.,5484,O
Prenatal,5485,O
diagnosis,5485,O
has,5485,O
been,5485,O
preformed,5485,O
in,5485,O
glutathione,5485,B-CHEMICAL
synthetase,5485,O
deficiency,5485,O
.,5485,O
The,5486,O
prognosis,5486,O
is,5486,O
difficult,5486,O
to,5486,O
predict,5486,O
",",5486,O
as,5486,O
few,5486,O
patients,5486,O
are,5486,O
known,5486,O
",",5486,O
but,5486,O
seems,5486,O
to,5486,O
vary,5486,O
significantly,5486,O
between,5486,O
different,5486,O
patients,5486,O
.,5486,O
The,5487,O
aims,5487,O
of,5487,O
the,5487,O
treatment,5487,O
of,5487,O
glutathione,5487,B-CHEMICAL
synthesis,5487,O
defects,5487,O
are,5487,O
to,5487,O
avoid,5487,O
hemolytic,5487,O
crises,5487,O
and,5487,O
to,5487,O
increase,5487,O
the,5487,O
defense,5487,O
against,5487,O
reactive,5487,O
oxygen,5487,B-CHEMICAL
species,5487,O
.,5487,O
No,5488,O
treatment,5488,O
has,5488,O
been,5488,O
recommended,5488,O
for,5488,O
gamma-glutamyl,5488,B-GENE-Y
transpeptidase,5488,I-GENE-Y
",",5488,O
5-oxoprolinase,5488,B-GENE-Y
and,5488,O
dipeptidase,5488,B-GENE-N
deficiency,5488,O
.,5488,O
Properties,5489,O
of,5489,O
purified,5489,O
recombinant,5489,O
human,5489,B-GENE-N
polyamine,5489,I-GENE-N
oxidase,5489,I-GENE-N
",",5489,O
PAOh1/SMO,5489,B-GENE-Y
.,5489,O
The,5490,O
discovery,5490,O
of,5490,O
an,5490,O
inducible,5490,O
oxidase,5490,B-GENE-N
whose,5490,O
apparent,5490,O
substrate,5490,O
preference,5490,O
is,5490,O
spermine,5490,B-CHEMICAL
indicates,5490,O
that,5490,O
polyamine,5490,B-CHEMICAL
catabolism,5490,O
is,5490,O
more,5490,O
complex,5490,O
than,5490,O
that,5490,O
originally,5490,O
proposed,5490,O
.,5490,O
To,5491,O
facilitate,5491,O
the,5491,O
study,5491,O
of,5491,O
this,5491,O
enzyme,5491,O
",",5491,O
the,5491,O
purification,5491,O
and,5491,O
characterization,5491,O
of,5491,O
the,5491,O
recombinant,5491,O
human,5491,B-GENE-Y
PAOh1/SMO,5491,O
polyamine,5491,B-GENE-N
oxidase,5491,I-GENE-N
are,5491,O
reported,5491,O
.,5491,O
Purified,5492,O
PAOh1/SMO,5492,B-GENE-Y
oxidizes,5492,O
both,5492,O
spermine,5492,B-CHEMICAL
(,5492,O
K,5492,O
(,5492,O
m,5492,O
),5492,O
=1.6,5492,O
microM,5492,O
),5492,O
and,5492,O
N,5492,B-CHEMICAL
(,5492,I-CHEMICAL
1,5492,I-CHEMICAL
),5492,I-CHEMICAL
-acetylspermine,5492,I-CHEMICAL
(,5492,O
K,5492,O
(,5492,O
m,5492,O
),5492,O
=51,5492,O
microM,5492,O
),5492,O
",",5492,O
but,5492,O
does,5492,O
not,5492,O
oxidize,5492,O
spermidine,5492,B-CHEMICAL
.,5492,O
The,5493,O
purified,5493,O
human,5493,O
enzyme,5493,O
also,5493,O
does,5493,O
not,5493,O
oxidize,5493,O
eight,5493,O
representative,5493,O
antitumor,5493,O
polyamine,5493,B-CHEMICAL
analogues,5493,O
;,5493,O
however,5493,O
",",5493,O
specific,5493,O
oligamine,5493,O
analogues,5493,O
were,5493,O
found,5493,O
to,5493,O
be,5493,O
potent,5493,O
inhibitors,5493,O
of,5493,O
the,5493,O
oxidation,5493,O
of,5493,O
spermine,5493,B-CHEMICAL
by,5493,O
PAOh1/SMO,5493,B-GENE-Y
.,5493,O
The,5494,O
results,5494,O
of,5494,O
these,5494,O
studies,5494,O
are,5494,O
consistent,5494,O
with,5494,O
the,5494,O
hypothesis,5494,O
that,5494,O
PAOh1/SMO,5494,B-GENE-Y
represents,5494,O
a,5494,O
new,5494,O
addition,5494,O
to,5494,O
the,5494,O
polyamine,5494,B-CHEMICAL
metabolic,5494,O
pathway,5494,O
that,5494,O
may,5494,O
represent,5494,O
a,5494,O
new,5494,O
target,5494,O
for,5494,O
antineoplastic,5494,O
drug,5494,O
development,5494,O
.,5494,O
Effects,5495,O
of,5495,O
serine/threonine,5495,B-GENE-N
protein,5495,I-GENE-N
phosphatase,5495,I-GENE-N
inhibitors,5495,O
on,5495,O
morphine-induced,5495,B-CHEMICAL
antinociception,5495,O
in,5495,O
the,5495,O
tail,5495,O
flick,5495,O
test,5495,O
in,5495,O
mice,5495,O
.,5495,O
The,5496,O
aim,5496,O
of,5496,O
this,5496,O
study,5496,O
was,5496,O
to,5496,O
evaluate,5496,O
the,5496,O
effects,5496,O
of,5496,O
serine/threonine,5496,B-GENE-N
protein,5496,I-GENE-N
phosphatase,5496,I-GENE-N
(,5496,O
PP,5496,B-GENE-N
),5496,O
inhibitors,5496,O
on,5496,O
morphine-induced,5496,B-CHEMICAL
antinociception,5496,O
in,5496,O
the,5496,O
tail,5496,O
flick,5496,O
test,5496,O
in,5496,O
mice,5496,O
",",5496,O
and,5496,O
on,5496,O
[,5496,B-CHEMICAL
3H,5496,I-CHEMICAL
],5496,I-CHEMICAL
naloxone,5496,I-CHEMICAL
binding,5496,O
to,5496,O
the,5496,O
forebrain,5496,O
crude,5496,O
synaptosome,5496,O
fraction,5496,O
.,5496,O
Neither,5497,O
okadaic,5497,B-CHEMICAL
acid,5497,I-CHEMICAL
nor,5497,O
cantharidin,5497,B-CHEMICAL
(,5497,O
1-10000,5497,O
nM,5497,O
),5497,O
displaced,5497,O
[,5497,B-CHEMICAL
3H,5497,I-CHEMICAL
],5497,I-CHEMICAL
naloxone,5497,I-CHEMICAL
from,5497,O
its,5497,O
specific,5497,O
binding,5497,O
sites,5497,O
",",5497,O
which,5497,O
indicates,5497,O
that,5497,O
they,5497,O
do,5497,O
not,5497,O
interact,5497,O
at,5497,O
the,5497,O
opioid,5497,B-GENE-N
receptor,5497,I-GENE-N
level,5497,O
.,5497,O
The,5498,O
i.c.v,5498,O
.,5498,O
administration,5499,O
of,5499,O
very,5499,O
low,5499,O
doses,5499,O
of,5499,O
okadaic,5499,B-CHEMICAL
acid,5499,I-CHEMICAL
(,5499,O
0.001-1,5499,O
pg/mouse,5499,O
),5499,O
and,5499,O
cantharidin,5499,B-CHEMICAL
(,5499,O
0.001-1,5499,O
ng/mouse,5499,O
),5499,O
",",5499,O
which,5499,O
inhibit,5499,O
PP2A,5499,B-GENE-N
",",5499,O
produced,5499,O
a,5499,O
dose-dependent,5499,O
antagonism,5499,O
of,5499,O
the,5499,O
antinociception,5499,O
induced,5499,O
by,5499,O
morphine,5499,B-CHEMICAL
(,5499,O
s.c.,5499,O
),5499,O
.,5499,O
However,5500,O
",",5500,O
L-nor-okadaone,5500,B-CHEMICAL
(,5500,O
0.001,5500,O
pg/mouse-1,5500,O
ng/mouse,5500,O
",",5500,O
i.c.v,5500,O
.,5500,O
),5501,O
",",5501,O
an,5501,O
analogue,5501,O
of,5501,O
okadaic,5501,I-CHEMICAL
acid,5501,O
lacking,5501,O
activity,5501,O
against,5501,O
protein,5501,I-GENE-N
phosphatases,5501,O
",",5501,O
did,5501,O
not,5501,O
affect,5501,O
the,5501,O
antinociceptive,5501,O
effect,5501,O
of,5501,O
morphine,5501,O
.,5501,O
On,5502,O
the,5502,O
other,5502,O
hand,5502,O
",",5502,O
high,5502,O
doses,5502,O
of,5502,O
okadaic,5502,I-CHEMICAL
acid,5502,O
(,5502,O
10,5502,O
ng/mouse,5502,O
",",5502,O
i.c.v,5502,O
.,5502,O
),5502,O
and,5503,O
cantharidin,5503,O
(,5503,O
1,5503,O
microg/mouse,5503,O
",",5503,O
i.c.v,5503,O
.,5503,O
),5504,O
",",5504,O
which,5504,O
also,5504,O
block,5504,O
PP1,5504,O
",",5504,O
and,5504,O
calyculin-A,5504,O
(,5504,O
0.1,5504,O
fg/mouse-1,5504,O
ng/mouse,5504,O
",",5504,O
i.c.v,5504,O
.,5504,O
),5505,O
",",5505,O
which,5505,O
inhibits,5505,O
equally,5505,O
both,5505,O
PP1,5505,O
and,5505,O
PP2A,5505,O
",",5505,O
did,5505,O
not,5505,O
modify,5505,O
the,5505,O
morphine-induced,5505,O
antinociception,5505,O
.,5505,O
These,5506,O
results,5506,O
suggest,5506,O
that,5506,O
the,5506,O
activation,5506,O
of,5506,B-GENE-N
type,5506,I-GENE-N
2A,5506,I-GENE-N
serine/threonine,5506,I-GENE-N
protein,5506,I-GENE-N
phosphatases,5506,O
may,5506,O
play,5506,O
a,5506,O
role,5506,O
in,5506,O
the,5506,O
antinociceptive,5506,O
effect,5506,O
of,5506,B-CHEMICAL
morphine,5506,O
",",5506,O
and,5506,O
that,5506,O
PP1,5506,O
might,5506,O
counterbalace,5506,O
this,5506,O
activity,5506,O
.,5506,O
Carbonic,5507,B-GENE-N
anhydrase,5507,I-GENE-N
inhibitors,5507,O
.,5507,O
Inhibition,5508,O
of,5508,O
mammalian,5508,B-GENE-N
isoforms,5508,I-GENE-N
I-XIV,5508,I-GENE-N
with,5508,O
a,5508,O
series,5508,O
of,5508,O
natural,5508,O
product,5508,O
polyphenols,5508,B-CHEMICAL
and,5508,O
phenolic,5508,B-CHEMICAL
acids,5508,I-CHEMICAL
.,5508,O
A,5509,O
series,5509,O
of,5509,O
phenolic,5509,B-CHEMICAL
acids,5509,I-CHEMICAL
and,5509,O
phenol,5509,B-CHEMICAL
natural,5509,O
products,5509,O
",",5509,O
such,5509,O
as,5509,O
p-hydroxybenzoic,5509,B-CHEMICAL
acid,5509,I-CHEMICAL
",",5509,O
p-coumaric,5509,B-CHEMICAL
acid,5509,I-CHEMICAL
",",5509,O
caffeic,5509,B-CHEMICAL
acid,5509,I-CHEMICAL
",",5509,O
ferulic,5509,B-CHEMICAL
acid,5509,I-CHEMICAL
",",5509,O
gallic,5509,B-CHEMICAL
acid,5509,I-CHEMICAL
",",5509,O
syringic,5509,B-CHEMICAL
acid,5509,I-CHEMICAL
",",5509,O
quercetin,5509,B-CHEMICAL
",",5509,O
and,5509,O
ellagic,5509,B-CHEMICAL
acid,5509,I-CHEMICAL
",",5509,O
were,5509,O
investigated,5509,O
for,5509,O
their,5509,O
inhibitory,5509,O
effects,5509,O
against,5509,O
the,5509,O
metalloenzyme,5509,B-GENE-N
carbonic,5509,B-GENE-N
anhydrase,5509,I-GENE-N
(,5509,O
CA,5509,B-GENE-N
",",5509,O
EC,5509,B-GENE-Y
4.2.1.1,5509,I-GENE-Y
),5509,O
.,5509,O
All,5510,O
mammalian,5510,O
isozymes,5510,O
of,5510,O
human,5510,O
(,5510,O
h,5510,O
),5510,O
or,5510,O
murine,5510,O
(,5510,O
m,5510,O
),5510,O
origin,5510,O
hCA,5510,B-GENE-Y
I-hCA,5510,O
XII,5510,I-GENE-Y
",",5510,O
mCA,5510,B-GENE-Y
XIII,5510,I-GENE-Y
and,5510,O
hCA,5510,B-GENE-Y
XIV,5510,I-GENE-Y
were,5510,O
inhibited,5510,O
in,5510,O
the,5510,O
low,5510,O
micromolar,5510,O
or,5510,O
submicromolar,5510,O
range,5510,O
by,5510,O
these,5510,O
(,5510,O
poly,5510,O
),5510,O
phenols,5510,O
(,5510,O
K,5510,O
(,5510,O
I,5510,O
),5510,O
s,5510,O
in,5510,O
the,5510,O
range,5510,O
of,5510,O
0.87-7.79,5510,O
microM,5510,O
),5510,O
.,5510,O
p-Hydroxybenzoic,5511,B-CHEMICAL
acid,5511,I-CHEMICAL
was,5511,O
the,5511,O
best,5511,O
inhibitor,5511,O
of,5511,O
all,5511,O
isozymes,5511,O
(,5511,O
K,5511,O
(,5511,O
I,5511,O
),5511,O
s,5511,O
of,5511,O
0.87-35.4,5511,O
microM,5511,O
),5511,O
and,5511,O
the,5511,O
different,5511,O
isozymes,5511,O
showed,5511,O
very,5511,O
variable,5511,O
inhibition,5511,O
profiles,5511,O
with,5511,O
these,5511,O
derivatives,5511,O
.,5511,O
Phenols,5512,B-CHEMICAL
like,5512,O
the,5512,O
ones,5512,O
investigated,5512,O
here,5512,O
possess,5512,O
a,5512,O
CA,5512,B-GENE-N
inhibition,5512,O
mechanism,5512,O
distinct,5512,O
of,5512,O
that,5512,O
of,5512,O
the,5512,O
sulfonamides/sulfamates,5512,B-CHEMICAL
used,5512,O
clinically,5512,O
or,5512,O
the,5512,O
coumarins,5512,B-CHEMICAL
.,5512,O
Unlike,5513,O
the,5513,O
sulfonamides,5513,B-CHEMICAL
",",5513,O
which,5513,O
bind,5513,O
to,5513,O
the,5513,O
catalytic,5513,O
zinc,5513,B-CHEMICAL
ion,5513,O
",",5513,O
phenols,5513,B-CHEMICAL
are,5513,O
anchored,5513,O
at,5513,O
the,5513,O
Zn,5513,B-CHEMICAL
(,5513,I-CHEMICAL
II,5513,I-CHEMICAL
),5513,I-CHEMICAL
-coordinated,5513,O
water,5513,O
molecule,5513,O
and,5513,O
bind,5513,O
more,5513,O
externally,5513,O
within,5513,O
the,5513,O
active,5513,O
site,5513,O
cavity,5513,O
",",5513,O
making,5513,O
contacts,5513,O
with,5513,O
various,5513,O
amino,5513,B-CHEMICAL
acid,5513,I-CHEMICAL
residues,5513,O
.,5513,O
As,5514,O
this,5514,O
is,5514,O
the,5514,O
region,5514,O
with,5514,O
the,5514,O
highest,5514,O
variability,5514,O
between,5514,O
the,5514,O
many,5514,O
CA,5514,B-GENE-N
isozymes,5514,O
found,5514,O
in,5514,O
mammals,5514,O
",",5514,O
this,5514,O
class,5514,O
of,5514,O
compounds,5514,O
may,5514,O
lead,5514,O
to,5514,O
isoform-selective,5514,O
inhibitors,5514,O
targeting,5514,O
just,5514,O
one,5514,O
or,5514,O
few,5514,O
of,5514,O
the,5514,O
medicinally,5514,O
relevant,5514,O
CAs,5514,B-GENE-N
.,5514,O
Crystal,5515,O
structure,5515,O
of,5515,O
the,5515,O
pyridoxal-5'-phosphate-dependent,5515,B-CHEMICAL
serine,5515,B-GENE-Y
dehydratase,5515,I-GENE-Y
from,5515,O
human,5515,O
liver,5515,O
.,5515,O
L-serine,5516,B-GENE-Y
dehydratase,5516,I-GENE-Y
(,5516,O
SDH,5516,B-GENE-Y
),5516,O
",",5516,O
a,5516,O
member,5516,O
of,5516,O
the,5516,O
beta-family,5516,O
of,5516,O
pyridoxal,5516,B-CHEMICAL
phosphate-dependent,5516,O
(,5516,O
PLP,5516,O
),5516,O
enzymes,5516,O
",",5516,O
catalyzes,5516,O
the,5516,O
deamination,5516,O
of,5516,O
L-serine,5516,B-CHEMICAL
and,5516,O
L-threonine,5516,B-CHEMICAL
to,5516,O
yield,5516,O
pyruvate,5516,B-CHEMICAL
or,5516,O
2-oxobutyrate,5516,B-CHEMICAL
.,5516,O
The,5517,O
crystal,5517,O
structure,5517,O
of,5517,O
L-serine,5517,B-GENE-Y
dehydratase,5517,I-GENE-Y
from,5517,O
human,5517,O
liver,5517,O
(,5517,O
hSDH,5517,B-GENE-Y
),5517,O
has,5517,O
been,5517,O
solved,5517,O
at,5517,O
2.5,5517,O
A-resolution,5517,O
by,5517,O
molecular,5517,O
replacement,5517,O
.,5517,O
The,5518,O
structure,5518,O
is,5518,O
a,5518,O
homodimer,5518,O
and,5518,O
reveals,5518,O
a,5518,O
fold,5518,O
typical,5518,O
for,5518,O
beta-family,5518,O
PLP-dependent,5518,O
enzymes,5518,O
.,5518,O
Each,5519,O
monomer,5519,O
serves,5519,O
as,5519,O
an,5519,O
active,5519,O
unit,5519,O
and,5519,O
is,5519,O
subdivided,5519,O
into,5519,O
two,5519,O
distinct,5519,O
domains,5519,O
:,5519,O
a,5519,O
small,5519,O
domain,5519,O
and,5519,O
a,5519,O
PLP-binding,5519,B-GENE-N
domain,5519,I-GENE-N
that,5519,O
covalently,5519,O
anchors,5519,O
the,5519,O
cofactor,5519,O
.,5519,O
Both,5520,O
domains,5520,O
show,5520,O
the,5520,O
typical,5520,O
open,5520,O
alpha/beta,5520,O
architecture,5520,O
of,5520,O
PLP,5520,O
enzymes,5520,O
.,5520,O
Comparison,5521,O
with,5521,O
the,5521,O
rSDH-,5521,B-GENE-Y
(,5521,O
PLP-OMS,5521,O
),5521,O
holo-enzyme,5521,O
reveals,5521,O
a,5521,O
large,5521,O
structural,5521,O
difference,5521,O
in,5521,O
active,5521,O
sites,5521,O
caused,5521,O
by,5521,O
the,5521,O
artifical,5521,O
O-methylserine,5521,B-CHEMICAL
.,5521,O
Furthermore,5522,O
",",5522,O
the,5522,O
activity,5522,O
of,5522,O
hSDH-PLP,5522,B-GENE-Y
was,5522,O
assayed,5522,O
and,5522,O
it,5522,O
proved,5522,O
to,5522,O
show,5522,O
catalytic,5522,O
activity,5522,O
.,5522,O
That,5523,O
suggests,5523,O
that,5523,O
the,5523,O
structure,5523,O
of,5523,O
hSDH-PLP,5523,B-GENE-Y
is,5523,O
the,5523,O
first,5523,O
structure,5523,O
of,5523,O
the,5523,O
active,5523,O
natural,5523,O
holo-SDH,5523,O
.,5523,O
Synthesis,5524,O
and,5524,O
evaluation,5524,O
of,5524,O
carbamoylmethylene,5524,B-CHEMICAL
linked,5524,O
prodrugs,5524,O
of,5524,O
BMS-582949,5524,B-CHEMICAL
",",5524,O
a,5524,O
clinical,5524,O
p38α,5524,B-GENE-Y
inhibitor,5524,O
.,5524,O
A,5525,O
series,5525,O
of,5525,O
carbamoylmethylene,5525,B-CHEMICAL
linked,5525,O
prodrugs,5525,O
of,5525,O
1,5525,O
(,5525,O
BMS-582949,5525,B-CHEMICAL
),5525,O
",",5525,O
a,5525,O
clinical,5525,O
p38α,5525,B-GENE-Y
inhibitor,5525,O
",",5525,O
were,5525,O
synthesized,5525,O
and,5525,O
evaluated,5525,O
.,5525,O
Though,5526,O
the,5526,O
phosphoryloxymethylene,5526,B-CHEMICAL
carbamates,5526,I-CHEMICAL
(,5526,O
3,5526,O
",",5526,O
4,5526,O
",",5526,O
and,5526,O
5,5526,O
),5526,O
and,5526,O
α-aminoacyloxymethylene,5526,B-CHEMICAL
carbamates,5526,I-CHEMICAL
(,5526,O
22,5526,O
",",5526,O
23,5526,O
",",5526,O
and,5526,O
26,5526,O
),5526,O
were,5526,O
found,5526,O
unstable,5526,O
at,5526,O
neutral,5526,O
pH,5526,O
values,5526,O
",",5526,O
fumaric,5526,B-CHEMICAL
acid,5526,I-CHEMICAL
derived,5526,O
acyloxymethylene,5526,B-CHEMICAL
carbamates,5526,I-CHEMICAL
(,5526,O
2,5526,O
",",5526,O
28,5526,O
",",5526,O
and,5526,O
31,5526,O
),5526,O
were,5526,O
highly,5526,O
stable,5526,O
under,5526,O
both,5526,O
acidic,5526,O
and,5526,O
neutral,5526,O
conditions,5526,O
.,5526,O
Prodrugs,5527,O
2,5527,O
and,5527,O
31,5527,O
were,5527,O
also,5527,O
highly,5527,O
soluble,5527,O
at,5527,O
both,5527,O
acidic,5527,O
and,5527,O
neutral,5527,O
pH,5527,O
values,5527,O
.,5527,O
At,5528,O
a,5528,O
solution,5528,O
dose,5528,O
of,5528,O
14.2mpk,5528,O
(,5528,O
equivalent,5528,O
to,5528,O
10mpk,5528,O
of,5528,O
1,5528,O
),5528,O
",",5528,O
2,5528,O
gave,5528,O
essentially,5528,O
the,5528,O
same,5528,O
exposure,5528,O
of,5528,O
1,5528,O
compared,5528,O
to,5528,O
dosing,5528,O
10mpk,5528,O
of,5528,O
1,5528,O
itself,5528,O
.,5528,O
At,5529,O
a,5529,O
suspension,5529,O
dose,5529,O
of,5529,O
142mpk,5529,O
(,5529,O
equivalent,5529,O
to,5529,O
100mpk,5529,O
of,5529,O
1,5529,O
),5529,O
",",5529,O
2,5529,O
demonstrated,5529,O
that,5529,O
it,5529,O
could,5529,O
overcome,5529,O
the,5529,O
solubility,5529,O
issue,5529,O
associated,5529,O
with,5529,O
1,5529,O
and,5529,O
provide,5529,O
a,5529,O
much,5529,O
higher,5529,O
exposure,5529,O
of,5529,O
1,5529,O
.,5529,O
To,5530,O
our,5530,O
knowledge,5530,O
",",5530,O
the,5530,O
unique,5530,O
type,5530,O
of,5530,O
prodrugs,5530,O
like,5530,O
2,5530,O
",",5530,O
28,5530,O
",",5530,O
and,5530,O
31,5530,O
was,5530,O
not,5530,O
reported,5530,O
in,5530,O
the,5530,O
past,5530,O
and,5530,O
could,5530,O
represent,5530,O
a,5530,O
novel,5530,O
prodrug,5530,O
approach,5530,O
for,5530,O
secondary,5530,B-CHEMICAL
amides,5530,I-CHEMICAL
",",5530,O
a,5530,O
class,5530,O
of,5530,O
molecules,5530,O
frequently,5530,O
identified,5530,O
as,5530,O
drug,5530,O
candidates,5530,O
.,5530,O
Iron,5531,B-CHEMICAL
and,5531,O
diabetes,5531,O
risk,5531,O
.,5531,O
Iron,5532,B-CHEMICAL
overload,5532,O
is,5532,O
a,5532,O
risk,5532,O
factor,5532,O
for,5532,O
diabetes,5532,O
.,5532,O
The,5533,O
link,5533,O
between,5533,O
iron,5533,B-CHEMICAL
and,5533,O
diabetes,5533,O
was,5533,O
first,5533,O
recognized,5533,O
in,5533,O
pathologic,5533,O
conditions-hereditary,5533,O
hemochromatosis,5533,O
and,5533,O
thalassemia-but,5533,O
high,5533,O
levels,5533,O
of,5533,O
dietary,5533,O
iron,5533,B-CHEMICAL
also,5533,O
impart,5533,O
diabetes,5533,O
risk,5533,O
.,5533,O
Iron,5534,B-CHEMICAL
plays,5534,O
a,5534,O
direct,5534,O
and,5534,O
causal,5534,O
role,5534,O
in,5534,O
diabetes,5534,O
pathogenesis,5534,O
mediated,5534,O
both,5534,O
by,5534,O
β,5534,O
cell,5534,O
failure,5534,O
and,5534,O
insulin,5534,B-GENE-Y
resistance,5534,O
.,5534,O
Iron,5535,B-CHEMICAL
also,5535,O
regulates,5535,O
metabolism,5535,O
in,5535,O
most,5535,O
tissues,5535,O
involved,5535,O
in,5535,O
fuel,5535,O
homeostasis,5535,O
",",5535,O
with,5535,O
the,5535,O
adipocyte,5535,O
in,5535,O
particular,5535,O
serving,5535,O
an,5535,O
iron-sensing,5535,B-CHEMICAL
role,5535,O
.,5535,O
The,5536,O
underlying,5536,O
molecular,5536,O
mechanisms,5536,O
mediating,5536,O
these,5536,O
effects,5536,O
are,5536,O
numerous,5536,O
and,5536,O
incompletely,5536,O
understood,5536,O
but,5536,O
include,5536,O
oxidant,5536,O
stress,5536,O
and,5536,O
modulation,5536,O
of,5536,O
adipokines,5536,B-GENE-N
and,5536,O
intracellular,5536,O
signal,5536,O
transduction,5536,O
pathways,5536,O
.,5536,O
Changes,5537,O
of,5537,O
phosphorylation,5537,O
of,5537,O
cAMP,5537,B-GENE-N
response,5537,I-GENE-N
element,5537,I-GENE-N
binding,5537,I-GENE-N
protein,5537,I-GENE-N
in,5537,O
rat,5537,O
nucleus,5537,O
accumbens,5537,O
after,5537,O
chronic,5537,O
ethanol,5537,B-CHEMICAL
intake,5537,O
:,5537,O
naloxone,5537,B-CHEMICAL
reversal,5537,O
.,5537,O
AIM,5538,O
:,5538,O
To,5538,O
study,5538,O
the,5538,O
changes,5538,O
in,5538,O
the,5538,O
expression,5538,O
and,5538,O
phosphorylation,5538,O
of,5538,O
cAMP,5538,B-GENE-N
response,5538,I-GENE-N
element,5538,I-GENE-N
binding,5538,I-GENE-N
protein,5538,I-GENE-N
(,5538,O
CREB,5538,B-GENE-N
),5538,O
in,5538,O
the,5538,O
rat,5538,O
nucleus,5538,O
accumbens,5538,O
after,5538,O
chronic,5538,O
ethanol,5538,B-CHEMICAL
intake,5538,O
and,5538,O
its,5538,O
withdrawal,5538,O
.,5538,O
METHODS,5539,O
:,5539,O
Ethanol,5539,B-CHEMICAL
was,5539,O
given,5539,O
in,5539,O
drinking,5539,O
water,5539,O
at,5539,O
the,5539,O
concentration,5539,O
of,5539,O
6,5539,O
%,5539,O
(,5539,O
v/v,5539,O
),5539,O
",",5539,O
for,5539,O
one,5539,O
month,5539,O
.,5539,O
Changes,5540,O
in,5540,O
the,5540,O
levels,5540,O
of,5540,O
CREB,5540,B-GENE-N
and,5540,O
phospho-CREB,5540,B-GENE-N
(,5540,O
p-CREB,5540,B-GENE-N
),5540,O
protein,5540,O
in,5540,O
the,5540,O
nucleus,5540,O
accumbens,5540,O
were,5540,O
measured,5540,O
by,5540,O
immunohistochemistry,5540,O
methods,5540,O
.,5540,O
RESULTS,5541,O
:,5541,O
Ethanol,5541,B-CHEMICAL
given,5541,O
to,5541,O
rats,5541,O
in,5541,O
drinking,5541,O
water,5541,O
decreased,5541,O
the,5541,O
level,5541,O
of,5541,O
p-CREB,5541,B-GENE-N
protein,5541,O
in,5541,O
the,5541,O
nucleus,5541,O
accumbens,5541,O
(,5541,O
-75,5541,O
%,5541,O
),5541,O
at,5541,O
the,5541,O
time,5541,O
of,5541,O
exposure,5541,O
to,5541,O
ethanol,5541,B-CHEMICAL
.,5541,O
The,5542,O
decrement,5542,O
of,5542,O
p-CREB,5542,B-GENE-N
protein,5542,O
in,5542,O
the,5542,O
nucleus,5542,O
accumbens,5542,O
remained,5542,O
at,5542,O
24,5542,O
h,5542,O
(,5542,O
-35,5542,O
%,5542,O
),5542,O
and,5542,O
72,5542,O
h,5542,O
(,5542,O
-28,5542,O
%,5542,O
),5542,O
of,5542,O
ethanol,5542,B-CHEMICAL
withdrawal,5542,O
",",5542,O
which,5542,O
recovered,5542,O
toward,5542,O
control,5542,O
level,5542,O
after,5542,O
7,5542,O
d,5542,O
of,5542,O
ethanol,5542,B-CHEMICAL
withdrawal,5542,O
.,5542,O
However,5543,O
",",5543,O
chronic,5543,O
ethanol,5543,B-CHEMICAL
",",5543,O
as,5543,O
well,5543,O
as,5543,O
ethanol,5543,B-CHEMICAL
withdrawal,5543,O
failed,5543,O
to,5543,O
produce,5543,O
any,5543,O
significant,5543,O
alteration,5543,O
in,5543,O
the,5543,O
level,5543,O
of,5543,O
CREB,5543,B-GENE-N
protein,5543,O
in,5543,O
the,5543,O
nucleus,5543,O
accumbens,5543,O
.,5543,O
Naloxone,5544,B-CHEMICAL
(,5544,O
alone,5544,O
),5544,O
treatment,5544,O
of,5544,O
rats,5544,O
had,5544,O
no,5544,O
effect,5544,O
on,5544,O
the,5544,O
levels,5544,O
of,5544,O
CREB,5544,B-GENE-N
and,5544,O
p-CREB,5544,B-GENE-N
protein,5544,O
in,5544,O
the,5544,O
nucleus,5544,O
accumbens,5544,O
.,5544,O
However,5545,O
",",5545,O
when,5545,O
naloxone,5545,O
was,5545,O
administered,5545,O
concurrently,5545,O
with,5545,O
ethanol,5545,B-CHEMICAL
treatment,5545,O
",",5545,O
it,5545,O
antagonized,5545,O
the,5545,O
down-regulation,5545,O
of,5545,O
p-CREB,5545,B-GENE-N
protein,5545,O
in,5545,O
the,5545,O
nucleus,5545,O
accumbens,5545,O
(,5545,O
142,5545,O
%,5545,O
),5545,O
of,5545,O
rats,5545,O
exposed,5545,O
to,5545,O
ethanol,5545,B-CHEMICAL
.,5545,O
CONCLUSION,5546,O
:,5546,O
A,5546,O
long-term,5546,O
intake,5546,O
of,5546,O
ethanol,5546,B-CHEMICAL
solution,5546,O
down-regulates,5546,O
the,5546,O
phosphorylation,5546,O
of,5546,O
CREB,5546,B-GENE-N
in,5546,O
the,5546,O
nucleus,5546,O
accumbens,5546,O
",",5546,O
and,5546,O
those,5546,O
changes,5546,O
can,5546,O
be,5546,O
reversed,5546,O
by,5546,O
naloxone,5546,B-CHEMICAL
",",5546,O
which,5546,O
may,5546,O
be,5546,O
one,5546,O
kind,5546,O
of,5546,O
the,5546,O
molecular,5546,O
mechanisms,5546,O
associated,5546,O
with,5546,O
ethanol,5546,B-CHEMICAL
dependence,5546,O
.,5546,O
Impaired,5547,O
function,5547,O
of,5547,O
prejunctional,5547,O
adenosine,5547,B-GENE-Y
A1,5547,I-GENE-Y
receptors,5547,I-GENE-Y
expressed,5547,O
by,5547,O
perivascular,5547,O
sympathetic,5547,O
nerves,5547,O
in,5547,O
DOCA-salt,5547,B-CHEMICAL
hypertensive,5547,O
rats,5547,O
.,5547,O
Increased,5548,O
sympathetic,5548,O
nervous,5548,O
system,5548,O
activity,5548,O
contributes,5548,O
to,5548,O
deoxycorticosterone,5548,B-CHEMICAL
acetate,5548,I-CHEMICAL
(,5548,O
DOCA,5548,B-CHEMICAL
),5548,O
-salt,5548,O
hypertension,5548,O
in,5548,O
rats,5548,O
.,5548,O
ATP,5549,B-CHEMICAL
and,5549,O
norepinephrine,5549,B-CHEMICAL
(,5549,O
NE,5549,O
),5549,O
are,5549,O
coreleased,5549,O
from,5549,O
perivascular,5549,O
sympathetic,5549,O
nerves,5549,O
.,5549,O
NE,5550,O
acts,5550,O
at,5550,O
prejunctional,5550,O
α2-adrenergic,5550,B-GENE-N
receptors,5550,I-GENE-N
(,5550,O
α2ARs,5550,B-GENE-N
),5550,O
to,5550,O
inhibit,5550,O
NE,5550,O
release,5550,O
",",5550,O
and,5550,O
α2AR,5550,B-GENE-N
function,5550,O
is,5550,O
impaired,5550,O
in,5550,O
DOCA-salt,5550,B-CHEMICAL
rats,5550,O
.,5550,O
Adenosine,5551,B-CHEMICAL
",",5551,O
an,5551,O
enzymatic,5551,O
ATP,5551,B-CHEMICAL
degradation,5551,O
product,5551,O
",",5551,O
acts,5551,O
at,5551,O
prejunctional,5551,O
A1,5551,B-GENE-Y
adenosine,5551,I-GENE-Y
receptors,5551,I-GENE-Y
(,5551,O
A1Rs,5551,B-GENE-Y
),5551,O
to,5551,O
inhibit,5551,O
NE,5551,O
release,5551,O
.,5551,O
We,5552,O
tested,5552,O
the,5552,O
hypothesis,5552,O
that,5552,O
prejunctional,5552,O
A1R,5552,B-GENE-Y
function,5552,O
is,5552,O
impaired,5552,O
in,5552,O
sympathetic,5552,O
nerves,5552,O
supplying,5552,O
mesenteric,5552,O
arteries,5552,O
(,5552,O
MAs,5552,O
),5552,O
and,5552,O
veins,5552,O
(,5552,O
MVs,5552,O
),5552,O
of,5552,O
DOCA-salt,5552,B-CHEMICAL
rats,5552,O
.,5552,O
Electrically,5553,O
evoked,5553,O
NE,5553,O
release,5553,O
and,5553,O
constrictions,5553,O
of,5553,O
blood,5553,O
vessels,5553,O
were,5553,O
studied,5553,O
in,5553,O
vitro,5553,O
with,5553,O
use,5553,O
of,5553,O
amperometry,5553,O
to,5553,O
measure,5553,O
NE,5553,O
oxidation,5553,O
currents,5553,O
and,5553,O
video,5553,O
microscopy,5553,O
",",5553,O
respectively,5553,O
.,5553,O
Immunohistochemical,5554,O
methods,5554,O
were,5554,O
used,5554,O
to,5554,O
localize,5554,O
tyrosine,5554,B-GENE-Y
hydroxylase,5554,I-GENE-Y
(,5554,O
TH,5554,B-GENE-Y
),5554,O
and,5554,O
A1Rs,5554,B-GENE-Y
in,5554,O
perivascular,5554,O
sympathetic,5554,O
nerves,5554,O
.,5554,O
TH,5555,B-GENE-Y
and,5555,O
A1Rs,5555,B-GENE-Y
colocalized,5555,O
to,5555,O
perivascular,5555,O
sympathetic,5555,O
nerves,5555,O
.,5555,O
Adenosine,5556,B-CHEMICAL
and,5556,O
N,5556,B-CHEMICAL
(,5556,I-CHEMICAL
6,5556,I-CHEMICAL
),5556,I-CHEMICAL
-cyclopentyl-adenosine,5556,I-CHEMICAL
(,5556,O
CPA,5556,B-CHEMICAL
",",5556,O
A1R,5556,B-GENE-Y
agonist,5556,O
),5556,O
constricted,5556,O
MVs,5556,O
but,5556,O
not,5556,O
MAs,5556,O
.,5556,O
Adenosine,5557,B-CHEMICAL
and,5557,O
CPA,5557,B-CHEMICAL
(,5557,O
0.001-10,5557,O
µM,5557,O
),5557,O
inhibited,5557,O
neurogenic,5557,O
constrictions,5557,O
and,5557,O
NE,5557,O
release,5557,O
in,5557,O
MAs,5557,O
and,5557,O
MVs,5557,O
.,5557,O
DOCA-salt,5558,B-CHEMICAL
arteries,5558,O
were,5558,O
resistant,5558,O
to,5558,O
adenosine,5558,B-CHEMICAL
and,5558,O
CPA-mediated,5558,B-CHEMICAL
inhibition,5558,O
of,5558,O
NE,5558,O
release,5558,O
and,5558,O
constriction,5558,O
.,5558,O
The,5559,O
A2A,5559,B-GENE-Y
adenosine,5559,I-GENE-Y
receptor,5559,I-GENE-Y
agonist,5559,O
CGS21680,5559,B-CHEMICAL
(,5559,O
C23H29N7O6.HCl.xH2O,5559,B-CHEMICAL
),5559,O
(,5559,O
0.001-0.1,5559,O
μM,5559,O
),5559,O
did,5559,O
not,5559,O
alter,5559,O
NE,5559,O
oxidation,5559,O
currents,5559,O
.,5559,O
We,5560,O
conclude,5560,O
that,5560,O
there,5560,O
are,5560,O
prejunctional,5560,O
A1Rs,5560,B-GENE-Y
in,5560,O
arteries,5560,O
and,5560,O
both,5560,O
pre-,5560,O
and,5560,O
postjunctional,5560,O
A1Rs,5560,B-GENE-Y
in,5560,O
veins,5560,O
;,5560,O
thus,5560,O
",",5560,O
adenosine,5560,B-CHEMICAL
selectively,5560,O
constricts,5560,O
the,5560,O
veins,5560,O
.,5560,O
Prejunctional,5561,O
A1R,5561,B-GENE-Y
function,5561,O
is,5561,O
impaired,5561,O
in,5561,O
arteries,5561,O
",",5561,O
but,5561,O
not,5561,O
veins,5561,O
",",5561,O
from,5561,O
DOCA-salt,5561,B-CHEMICAL
rats,5561,O
.,5561,O
Sympathetic,5562,O
autoreceptor,5562,O
dysfunction,5562,O
is,5562,O
not,5562,O
specific,5562,O
to,5562,O
α2ARs,5562,B-GENE-N
",",5562,O
but,5562,O
there,5562,O
is,5562,O
a,5562,O
more,5562,O
general,5562,O
disruption,5562,O
of,5562,O
prejunctional,5562,O
mechanisms,5562,O
controlling,5562,O
sympathetic,5562,O
neurotransmitter,5562,O
release,5562,O
in,5562,O
DOCA-salt,5562,B-CHEMICAL
hypertension,5562,O
.,5562,O
Functional,5563,O
consequences,5563,O
of,5563,O
the,5563,O
arrhythmogenic,5563,O
G306R,5563,B-GENE-N
KvLQT1,5563,B-GENE-Y
K+,5563,B-GENE-N
channel,5563,I-GENE-N
mutant,5563,O
probed,5563,O
by,5563,O
viral,5563,O
gene,5563,O
transfer,5563,O
in,5563,O
cardiomyocytes,5563,O
.,5563,O
IKs,5564,O
",",5564,O
the,5564,O
slow,5564,O
component,5564,O
of,5564,O
the,5564,O
delayed,5564,O
rectifier,5564,O
potassium,5564,B-CHEMICAL
current,5564,O
",",5564,O
figures,5564,O
prominently,5564,O
in,5564,O
the,5564,O
repolarization,5564,O
of,5564,O
heart,5564,O
cells,5564,O
.,5564,O
The,5565,O
K+,5565,B-GENE-N
channel,5565,I-GENE-N
gene,5565,O
KvLQT1,5565,B-GENE-Y
is,5565,O
mutated,5565,O
in,5565,O
the,5565,O
heritable,5565,O
long,5565,O
QT,5565,O
(,5565,O
LQT,5565,O
),5565,O
syndrome,5565,O
.,5565,O
Heterologous,5566,O
coexpression,5566,O
of,5566,O
KvLQT1,5566,B-GENE-Y
and,5566,O
the,5566,O
accessory,5566,O
protein,5566,O
minK,5566,B-GENE-Y
yields,5566,O
an,5566,O
IKs-like,5566,O
current,5566,O
.,5566,O
Nevertheless,5567,O
",",5567,O
the,5567,O
links,5567,O
between,5567,O
KvLQT1,5567,B-GENE-Y
and,5567,O
cardiac,5567,O
IKs,5567,O
are,5567,O
largely,5567,O
inferential,5567,O
.,5567,O
Since,5568,O
the,5568,O
LQT,5568,O
syndrome,5568,O
mutant,5568,O
KvLQT1-G306R,5568,B-GENE-Y
suppresses,5568,O
channel,5568,O
activity,5568,O
when,5568,O
coexpressed,5568,O
with,5568,O
wild-type,5568,O
KvLQT1,5568,B-GENE-Y
in,5568,O
a,5568,O
heterologous,5568,O
system,5568,O
",",5568,O
overexpression,5568,O
of,5568,O
this,5568,O
mutant,5568,O
in,5568,O
cardiomyocytes,5568,O
should,5568,O
reduce,5568,O
or,5568,O
eliminate,5568,O
native,5568,O
IKs,5568,O
if,5568,O
KvLQT1,5568,B-GENE-Y
is,5568,O
indeed,5568,O
the,5568,O
major,5568,O
molecular,5568,O
component,5568,O
of,5568,O
this,5568,O
current,5568,O
.,5568,O
To,5569,O
test,5569,O
this,5569,O
idea,5569,O
",",5569,O
we,5569,O
created,5569,O
the,5569,O
adenovirus,5569,O
AdRMGI-KvLQT1-G306R,5569,O
",",5569,O
which,5569,O
overexpresses,5569,O
KvLQT1-G306R,5569,B-GENE-Y
channels,5569,O
.,5569,O
In,5570,O
>,5570,O
60,5570,O
%,5570,O
of,5570,O
neonatal,5570,O
mouse,5570,O
myocytes,5570,O
",",5570,O
a,5570,O
sizable,5570,O
IKs,5570,O
could,5570,O
be,5570,O
measured,5570,O
using,5570,O
perforated-patch,5570,O
recordings,5570,O
(,5570,O
8.0,5570,O
+/-,5570,O
1.6,5570,O
pA,5570,O
pF-1,5570,O
",",5570,O
n,5570,O
=,5570,O
13,5570,O
),5570,O
.,5570,O
IKs,5571,O
was,5571,O
increased,5571,O
by,5571,O
forskolin,5571,B-CHEMICAL
and,5571,O
blocked,5571,O
by,5571,O
clofilium,5571,B-CHEMICAL
or,5571,O
indapamide,5571,B-CHEMICAL
but,5571,O
not,5571,O
by,5571,O
E-4031,5571,B-CHEMICAL
.,5571,O
While,5572,O
cells,5572,O
infected,5572,O
with,5572,O
a,5572,O
reporter,5572,O
virus,5572,O
expressing,5572,O
only,5572,O
green,5572,O
fluorescent,5572,O
protein,5572,O
(,5572,O
GFP,5572,O
),5572,O
displayed,5572,O
IKs,5572,O
similar,5572,O
to,5572,O
that,5572,O
in,5572,O
uninfected,5572,O
cells,5572,O
",",5572,O
AdRMGI-KvLQT1-G306R-infected,5572,O
cells,5572,O
showed,5572,O
a,5572,O
significantly,5572,O
reduced,5572,O
IKs,5572,O
(,5572,O
2.4,5572,O
+/-,5572,O
1.1,5572,O
pA,5572,O
pF-1,5572,O
",",5572,O
n,5572,O
=,5572,O
10,5572,O
",",5572,O
P,5572,O
<,5572,O
0.01,5572,O
),5572,O
when,5572,O
measured,5572,O
60-72,5572,O
h,5572,O
after,5572,O
infection,5572,O
.,5572,O
Similar,5573,O
results,5573,O
were,5573,O
observed,5573,O
in,5573,O
adult,5573,O
guinea-pig,5573,O
myocytes,5573,O
(,5573,O
5.9,5573,O
+/-,5573,O
1.2,5573,O
pA,5573,O
pF-1,5573,O
",",5573,O
n,5573,O
=,5573,O
9,5573,O
",",5573,O
for,5573,O
control,5573,O
vs.,5573,O
0.1,5573,O
+/-,5573,O
0.1,5573,O
pA,5573,O
pF-1,5573,O
",",5573,O
n,5573,O
=,5573,O
5,5573,O
",",5573,O
for,5573,O
AdRMGI-KvLQT1-G306R-infected,5573,O
cells,5573,O
),5573,O
.,5573,O
We,5574,O
conclude,5574,O
that,5574,O
KvLQT1,5574,B-GENE-Y
is,5574,O
the,5574,O
major,5574,O
molecular,5574,O
component,5574,O
of,5574,O
IKs,5574,O
.,5574,O
Our,5575,O
results,5575,O
further,5575,O
establish,5575,O
a,5575,O
dominant-negative,5575,O
mechanism,5575,O
for,5575,O
the,5575,O
G306R,5575,B-GENE-N
LQT,5575,O
syndrome,5575,O
mutation,5575,O
.,5575,O
Pasireotide,5576,B-CHEMICAL
:,5576,O
A,5576,O
Review,5576,O
of,5576,O
Its,5576,O
Use,5576,O
in,5576,O
Cushing,5576,O
's,5576,O
Disease,5576,O
.,5576,O
Pasireotide,5577,B-CHEMICAL
(,5577,O
Signifor,5577,B-CHEMICAL
(,5577,O
®,5577,O
),5577,O
),5577,O
is,5577,O
a,5577,O
new,5577,O
subcutaneous,5577,O
somatostatin,5577,B-GENE-Y
analogue,5577,O
that,5577,O
acts,5577,O
via,5577,O
somatostatin,5577,B-GENE-N
receptors,5577,I-GENE-N
to,5577,O
inhibit,5577,O
the,5577,O
secretion,5577,O
of,5577,O
corticotropin,5577,B-GENE-Y
from,5577,O
the,5577,O
pituitary,5577,O
adenoma,5577,O
in,5577,O
patients,5577,O
with,5577,O
Cushing,5577,O
's,5577,O
disease,5577,O
.,5577,O
Pasireotide,5578,B-CHEMICAL
has,5578,O
a,5578,O
receptor,5578,O
binding,5578,O
profile,5578,O
that,5578,O
is,5578,O
distinct,5578,O
from,5578,O
that,5578,O
of,5578,O
other,5578,O
somatostatin,5578,B-GENE-Y
analogues,5578,O
",",5578,O
binding,5578,O
with,5578,O
high,5578,O
affinity,5578,O
to,5578,O
somatostatin,5578,B-GENE-Y
receptor,5578,I-GENE-Y
subtype,5578,I-GENE-Y
5,5578,I-GENE-Y
",",5578,O
which,5578,O
is,5578,O
strongly,5578,O
over,5578,O
expressed,5578,O
in,5578,O
corticotroph,5578,O
adenoma,5578,O
cells,5578,O
.,5578,O
Pasireotide,5579,B-CHEMICAL
is,5579,O
the,5579,O
first,5579,O
pituitary-directed,5579,O
agent,5579,O
to,5579,O
be,5579,O
approved,5579,O
for,5579,O
use,5579,O
in,5579,O
Cushing,5579,O
's,5579,O
disease,5579,O
.,5579,O
In,5580,O
a,5580,O
phase,5580,O
III,5580,O
clinical,5580,O
trial,5580,O
in,5580,O
patients,5580,O
with,5580,O
Cushing,5580,O
's,5580,O
disease,5580,O
",",5580,O
twice-daily,5580,O
pasireotide,5580,B-CHEMICAL
600,5580,O
or,5580,O
900,5580,O
μg,5580,O
for,5580,O
6,5580,O
months,5580,O
led,5580,O
to,5580,O
normalization,5580,O
of,5580,O
urinary,5580,O
free,5580,O
cortisol,5580,B-CHEMICAL
(,5580,O
UFC,5580,O
),5580,O
levels,5580,O
in,5580,O
up,5580,O
to,5580,O
a,5580,O
quarter,5580,O
of,5580,O
all,5580,O
patients,5580,O
(,5580,O
primary,5580,O
endpoint,5580,O
),5580,O
and,5580,O
significantly,5580,O
reduced,5580,O
mean,5580,O
UFC,5580,O
levels,5580,O
.,5580,O
The,5581,O
reduction,5581,O
in,5581,O
UFC,5581,O
levels,5581,O
is,5581,O
rapid,5581,O
(,5581,O
within,5581,O
one,5581,O
to,5581,O
two,5581,O
months,5581,O
),5581,O
and,5581,O
sustained,5581,O
(,5581,O
up,5581,O
to,5581,O
24,5581,O
months,5581,O
),5581,O
.,5581,O
Most,5582,O
patients,5582,O
who,5582,O
do,5582,O
not,5582,O
have,5582,O
an,5582,O
early,5582,O
response,5582,O
to,5582,O
pasireotide,5582,B-CHEMICAL
do,5582,O
not,5582,O
respond,5582,O
at,5582,O
a,5582,O
later,5582,O
time,5582,O
point,5582,O
.,5582,O
Decreases,5583,O
in,5583,O
UFC,5583,O
levels,5583,O
achieved,5583,O
during,5583,O
pasireotide,5583,B-CHEMICAL
treatment,5583,O
are,5583,O
accompanied,5583,O
by,5583,O
decreases,5583,O
in,5583,O
serum,5583,O
and,5583,O
salivary,5583,O
cortisol,5583,B-CHEMICAL
levels,5583,O
",",5583,O
as,5583,O
well,5583,O
as,5583,O
improvements,5583,O
in,5583,O
clinical,5583,O
signs,5583,O
and,5583,O
symptoms,5583,O
",",5583,O
including,5583,O
body,5583,O
weight,5583,O
",",5583,O
blood,5583,O
pressure,5583,O
and,5583,O
health-related,5583,O
quality-of-life,5583,O
.,5583,O
Pasireotide,5584,B-CHEMICAL
has,5584,O
a,5584,O
generally,5584,O
similar,5584,O
tolerability,5584,O
profile,5584,O
to,5584,O
that,5584,O
of,5584,O
other,5584,O
somatostatin,5584,B-GENE-Y
analogues,5584,O
",",5584,O
but,5584,O
is,5584,O
associated,5584,O
with,5584,O
a,5584,O
relatively,5584,O
high,5584,O
incidence,5584,O
of,5584,O
hyperglycaemia,5584,O
",",5584,O
requiring,5584,O
the,5584,O
addition,5584,O
or,5584,O
intensification,5584,O
of,5584,O
glucose-lowering,5584,B-CHEMICAL
medication,5584,O
in,5584,O
a,5584,O
substantial,5584,O
proportion,5584,O
of,5584,O
patients,5584,O
.,5584,O
Thus,5585,O
",",5585,O
pasireotide,5585,B-CHEMICAL
",",5585,O
together,5585,O
with,5585,O
on-going,5585,O
patient,5585,O
monitoring,5585,O
",",5585,O
provides,5585,O
a,5585,O
promising,5585,O
new,5585,O
option,5585,O
for,5585,O
the,5585,O
medical,5585,O
management,5585,O
of,5585,O
Cushing,5585,O
's,5585,O
disease,5585,O
.,5585,O
SB365,5586,B-CHEMICAL
",",5586,O
Pulsatilla,5586,B-CHEMICAL
saponin,5586,I-CHEMICAL
D,5586,I-CHEMICAL
suppresses,5586,O
the,5586,O
proliferation,5586,O
of,5586,O
human,5586,O
colon,5586,O
cancer,5586,O
cells,5586,O
and,5586,O
induces,5586,O
apoptosis,5586,O
by,5586,O
modulating,5586,O
the,5586,O
AKT/mTOR,5586,B-GENE-N
signalling,5586,O
pathway,5586,O
.,5586,O
Pulsatilla,5587,O
koreana,5587,O
has,5587,O
been,5587,O
used,5587,O
as,5587,O
a,5587,O
traditional,5587,O
medicine,5587,O
for,5587,O
the,5587,O
treatment,5587,O
of,5587,O
several,5587,O
diseases,5587,O
.,5587,O
The,5588,O
purpose,5588,O
of,5588,O
this,5588,O
study,5588,O
was,5588,O
to,5588,O
determine,5588,O
if,5588,O
SB365,5588,B-CHEMICAL
",",5588,O
Pulsatilla,5588,B-CHEMICAL
saponin,5588,I-CHEMICAL
D,5588,I-CHEMICAL
isolated,5588,O
from,5588,O
the,5588,O
root,5588,O
of,5588,O
P.,5588,O
koreana,5588,O
inhibits,5588,O
the,5588,O
progression,5588,O
of,5588,O
colon,5588,O
cancer,5588,O
.,5588,O
We,5589,O
found,5589,O
that,5589,O
SB365,5589,B-CHEMICAL
strongly,5589,O
suppressed,5589,O
the,5589,O
growth,5589,O
and,5589,O
proliferation,5589,O
of,5589,O
colon,5589,O
cancer,5589,O
cells,5589,O
and,5589,O
induced,5589,O
their,5589,O
apoptosis,5589,O
.,5589,O
Also,5590,O
",",5590,O
SB365,5590,B-CHEMICAL
showed,5590,O
anti-angiogenic,5590,O
activity,5590,O
by,5590,O
decreasing,5590,O
the,5590,O
expression,5590,O
of,5590,O
HIF-1α,5590,B-GENE-Y
and,5590,O
VEGF,5590,B-GENE-Y
.,5590,O
These,5591,O
results,5591,O
were,5591,O
confirmed,5591,O
by,5591,O
an,5591,O
in,5591,O
vivo,5591,O
study,5591,O
showing,5591,O
that,5591,O
SB365,5591,B-CHEMICAL
significantly,5591,O
inhibited,5591,O
tumor,5591,O
growth,5591,O
by,5591,O
the,5591,O
induction,5591,O
of,5591,O
apoptosis,5591,O
and,5591,O
inhibition,5591,O
of,5591,O
angiogenesis,5591,O
with,5591,O
stronger,5591,O
anticancer,5591,O
activity,5591,O
than,5591,O
5-FU,5591,B-CHEMICAL
.,5591,O
When,5592,O
further,5592,O
examined,5592,O
for,5592,O
its,5592,O
anticancer,5592,O
mechanism,5592,O
",",5592,O
SB365,5592,B-CHEMICAL
effectively,5592,O
suppressed,5592,O
the,5592,O
AKT/mTOR,5592,B-GENE-N
pathway,5592,O
both,5592,O
in,5592,O
vitro,5592,O
and,5592,O
in,5592,O
vivo,5592,O
.,5592,O
Taken,5593,O
together,5593,O
",",5593,O
our,5593,O
study,5593,O
demonstrated,5593,O
that,5593,O
SB365,5593,B-CHEMICAL
inhibits,5593,O
the,5593,O
AKT/mTOR,5593,B-GENE-N
pathway,5593,O
",",5593,O
leading,5593,O
to,5593,O
the,5593,O
suppression,5593,O
of,5593,O
tumor,5593,O
growth,5593,O
and,5593,O
angiogenesis,5593,O
together,5593,O
with,5593,O
induction,5593,O
of,5593,O
apoptosis,5593,O
.,5593,O
Therefore,5594,O
",",5594,O
SB365,5594,B-CHEMICAL
is,5594,O
a,5594,O
good,5594,O
candidate,5594,O
as,5594,O
a,5594,O
natural,5594,O
product,5594,O
for,5594,O
use,5594,O
in,5594,O
the,5594,O
treatment,5594,O
of,5594,O
colon,5594,O
cancer,5594,O
.,5594,O
Apolipoprotein,5595,B-GENE-Y
E3,5595,I-GENE-Y
(,5595,O
apoE3,5595,B-GENE-Y
),5595,O
safeguards,5595,O
pig,5595,O
proximal,5595,O
tubular,5595,O
LLC-PK1,5595,O
cells,5595,O
against,5595,O
reduction,5595,O
in,5595,O
SGLT1,5595,B-GENE-Y
activity,5595,O
induced,5595,O
by,5595,O
gentamicin,5595,B-CHEMICAL
C.,5595,O
Megalin,5595,O
",",5595,O
a,5595,O
family,5595,O
of,5595,O
endocytic,5595,B-GENE-N
receptors,5595,I-GENE-N
related,5595,O
to,5595,O
the,5595,O
low-density,5595,B-GENE-N
lipoprotein,5595,I-GENE-N
(,5595,I-GENE-N
LDL,5595,I-GENE-N
),5595,I-GENE-N
receptor,5595,I-GENE-N
",",5595,O
is,5595,O
a,5595,O
major,5595,O
pathway,5595,O
for,5595,O
proximal,5595,O
tubular,5595,O
aminoglycoside,5595,B-CHEMICAL
accumulation,5595,O
.,5595,O
We,5596,O
previously,5596,O
reported,5596,O
that,5596,O
aminoglycoside,5596,B-CHEMICAL
antibiotics,5596,O
reduce,5596,O
SGLT1-dependent,5596,B-GENE-Y
glucose,5596,B-CHEMICAL
transport,5596,O
in,5596,O
pig,5596,O
proximal,5596,O
tubular,5596,O
epithelial,5596,O
LLC-PK1,5596,O
cells,5596,O
in,5596,O
parallel,5596,O
with,5596,O
the,5596,O
order,5596,O
of,5596,O
their,5596,O
nephrotoxicity,5596,O
.,5596,O
In,5597,O
this,5597,O
study,5597,O
",",5597,O
using,5597,O
a,5597,O
model,5597,O
of,5597,O
gentamicin,5597,B-CHEMICAL
C,5597,I-CHEMICAL
(,5597,O
GMC,5597,B-CHEMICAL
),5597,O
-induced,5597,O
reduction,5597,O
in,5597,O
SGLT1,5597,B-GENE-Y
activity,5597,O
",",5597,O
we,5597,O
examined,5597,O
whether,5597,O
ligands,5597,O
for,5597,O
megalin,5597,O
protect,5597,O
LLC-PK1,5597,O
cells,5597,O
from,5597,O
the,5597,O
GMC-induced,5597,B-CHEMICAL
reduction,5597,O
in,5597,O
SGLT1,5597,B-GENE-Y
activity,5597,O
.,5597,O
We,5598,O
employed,5598,O
apolipoprotein,5598,B-GENE-Y
E3,5598,I-GENE-Y
(,5598,O
apoE3,5598,B-GENE-Y
),5598,O
and,5598,O
lactoferrin,5598,B-GENE-Y
as,5598,O
ligands,5598,O
for,5598,O
megalin,5598,O
.,5598,O
Then,5599,O
the,5599,O
cells,5599,O
were,5599,O
treated,5599,O
with,5599,O
various,5599,O
concentrations,5599,O
of,5599,O
apoE3,5599,B-GENE-Y
",",5599,O
lactoferrin,5599,B-GENE-Y
and,5599,O
bovine,5599,B-GENE-Y
serum,5599,I-GENE-Y
albumin,5599,I-GENE-Y
with,5599,O
or,5599,O
without,5599,O
100,5599,O
microg/ml,5599,O
of,5599,O
GMC,5599,B-CHEMICAL
",",5599,O
and,5599,O
the,5599,O
SGLT1-dependent,5599,B-GENE-Y
methyl,5599,B-CHEMICAL
alpha-D-glucopyranoside,5599,I-CHEMICAL
(,5599,O
AMG,5599,B-CHEMICAL
),5599,O
uptake,5599,O
and,5599,O
levels,5599,O
of,5599,O
SGLT1,5599,B-GENE-Y
expression,5599,O
were,5599,O
determined,5599,O
.,5599,O
As,5600,O
a,5600,O
result,5600,O
",",5600,O
we,5600,O
demonstrated,5600,O
that,5600,O
the,5600,O
apoE3,5600,B-GENE-Y
significantly,5600,O
protects,5600,O
these,5600,O
cells,5600,O
from,5600,O
GMC-induced,5600,B-CHEMICAL
reduction,5600,O
in,5600,O
AMG,5600,B-CHEMICAL
uptake,5600,O
",",5600,O
but,5600,O
neither,5600,O
lactoferrin,5600,B-GENE-Y
nor,5600,O
albumin,5600,B-GENE-Y
does,5600,O
.,5600,O
In,5601,O
accord,5601,O
with,5601,O
a,5601,O
rise,5601,O
in,5601,O
AMG,5601,B-CHEMICAL
uptake,5601,O
activity,5601,O
",",5601,O
the,5601,O
mRNA,5601,O
and,5601,O
protein,5601,O
levels,5601,O
of,5601,O
SGLT1,5601,B-GENE-Y
were,5601,O
apparently,5601,O
up-regulated,5601,O
in,5601,O
the,5601,O
presence,5601,O
of,5601,O
apoE3,5601,B-GENE-Y
.,5601,O
Furthermore,5602,O
",",5602,O
we,5602,O
found,5602,O
that,5602,O
the,5602,O
uptake,5602,O
of,5602,O
[,5602,B-CHEMICAL
3H,5602,I-CHEMICAL
],5602,I-CHEMICAL
gentamicin,5602,I-CHEMICAL
is,5602,O
decreased,5602,O
by,5602,O
apoE3,5602,B-GENE-Y
",",5602,O
and,5602,O
that,5602,O
apoE3,5602,B-GENE-Y
showed,5602,O
obvious,5602,O
protection,5602,O
against,5602,O
the,5602,O
GMC-dependent,5602,B-CHEMICAL
N-acetyl-beta-D-glucosamidase,5602,B-GENE-N
(,5602,O
NAG,5602,B-GENE-N
),5602,O
release,5602,O
from,5602,O
LLC-PK1,5602,O
cells,5602,O
.,5602,O
Thus,5603,O
",",5603,O
these,5603,O
results,5603,O
indicate,5603,O
that,5603,O
apoE3,5603,B-GENE-Y
could,5603,O
be,5603,O
a,5603,O
valuable,5603,O
tool,5603,O
for,5603,O
the,5603,O
prevention,5603,O
of,5603,O
aminoglycoside,5603,B-CHEMICAL
nephrotoxicity,5603,O
.,5603,O
Actions,5604,O
of,5604,O
nizatidine,5604,B-CHEMICAL
",",5604,O
a,5604,O
selective,5604,O
histamine,5604,B-GENE-N
H2-receptor,5604,I-GENE-N
antagonist,5604,O
",",5604,O
on,5604,O
gastric,5604,O
acid,5604,O
secretion,5604,O
in,5604,O
dogs,5604,O
",",5604,O
rats,5604,O
and,5604,O
frogs,5604,O
.,5604,O
Nizatidine,5605,B-CHEMICAL
(,5605,O
LY139037,5605,B-CHEMICAL
),5605,O
",",5605,O
a,5605,O
selective,5605,O
histamine,5605,B-GENE-N
H2-receptor,5605,I-GENE-N
antagonist,5605,O
",",5605,O
is,5605,O
a,5605,O
potent,5605,O
inhibitor,5605,O
of,5605,O
gastric,5605,O
acid,5605,O
secretion,5605,O
.,5605,O
It,5606,O
was,5606,O
17.8,5606,O
times,5606,O
as,5606,O
active,5606,O
as,5606,O
cimetidine,5606,B-CHEMICAL
on,5606,O
histamine,5606,B-CHEMICAL
(,5606,O
10,5606,O
(,5606,O
-5,5606,O
),5606,O
M,5606,O
),5606,O
-induced,5606,O
secretion,5606,O
from,5606,O
the,5606,O
isolated,5606,O
gastric,5606,O
mucosa,5606,O
of,5606,O
the,5606,O
bullfrog,5606,O
.,5606,O
Nizatidine,5607,B-CHEMICAL
was,5607,O
8.9,5607,O
times,5607,O
as,5607,O
active,5607,O
as,5607,O
cimetidine,5607,B-CHEMICAL
on,5607,O
basal,5607,O
acid,5607,O
secretion,5607,O
of,5607,O
the,5607,O
chronic,5607,O
gastric,5607,O
fistula,5607,O
rats,5607,O
after,5607,O
s.c.,5607,O
administration,5607,O
.,5607,O
Against,5608,O
acid,5608,O
secretion,5608,O
from,5608,O
the,5608,O
vagally,5608,O
innervated,5608,O
gastric,5608,O
fistula,5608,O
and,5608,O
Heidenhain,5608,O
pouch,5608,O
of,5608,O
dogs,5608,O
stimulated,5608,O
with,5608,O
submaximal,5608,O
doses,5608,O
of,5608,O
histamine,5608,B-CHEMICAL
",",5608,O
methacholine,5608,B-CHEMICAL
and,5608,O
gastrin,5608,B-GENE-Y
",",5608,O
nizatidine,5608,B-CHEMICAL
was,5608,O
",",5608,O
respectively,5608,O
",",5608,O
6.5,5608,O
",",5608,O
5,5608,O
and,5608,O
4.7,5608,O
times,5608,O
as,5608,O
active,5608,O
as,5608,O
cimetidine,5608,B-CHEMICAL
by,5608,O
i.v,5608,O
.,5608,O
administration,5609,O
.,5609,O
Nizatidine,5610,B-CHEMICAL
was,5610,O
very,5610,O
well,5610,O
absorbed,5610,O
from,5610,O
the,5610,O
gut,5610,O
and,5610,O
was,5610,O
5,5610,O
to,5610,O
10,5610,O
times,5610,O
as,5610,O
active,5610,O
as,5610,O
cimetidine,5610,B-CHEMICAL
on,5610,O
gastric,5610,O
acid,5610,O
secretion,5610,O
of,5610,O
dogs,5610,O
induced,5610,O
by,5610,O
submaximal,5610,O
and,5610,O
maximal,5610,O
doses,5610,O
of,5610,O
histamine,5610,B-CHEMICAL
when,5610,O
given,5610,O
p.o,5610,O
.,5610,O
Equal,5611,O
molar,5611,O
doses,5611,O
of,5611,O
nizatidine,5611,B-CHEMICAL
showed,5611,O
equal,5611,O
peak,5611,O
effects,5611,O
when,5611,O
given,5611,O
i.v.,5611,O
",",5611,O
s.c.,5611,O
or,5611,O
i.m,5611,O
.,5611,O
Pharmacological,5612,O
data,5612,O
indicate,5612,O
that,5612,O
nizatidine,5612,B-CHEMICAL
is,5612,O
safe,5612,O
and,5612,O
effective,5612,O
as,5612,O
an,5612,O
agent,5612,O
for,5612,O
the,5612,O
control,5612,O
of,5612,O
excessive,5612,O
gastric,5612,O
acid,5612,O
secretion,5612,O
.,5612,O
3D-QSAR-assisted,5613,O
drug,5613,O
design,5613,O
:,5613,O
identification,5613,O
of,5613,O
a,5613,O
potent,5613,O
quinazoline-based,5613,B-CHEMICAL
Aurora,5613,B-GENE-N
kinase,5613,I-GENE-N
inhibitor,5613,O
.,5613,O
We,5614,O
describe,5614,O
the,5614,O
3D-QSAR-assisted,5614,O
design,5614,O
of,5614,O
an,5614,O
Aurora,5614,B-GENE-Y
kinase,5614,I-GENE-Y
A,5614,I-GENE-Y
inhibitor,5614,O
with,5614,O
improved,5614,O
physicochemical,5614,O
properties,5614,O
",",5614,O
in,5614,O
vitro,5614,O
activity,5614,O
",",5614,O
and,5614,O
in,5614,O
vivo,5614,O
pharmacokinetic,5614,O
profiles,5614,O
over,5614,O
those,5614,O
of,5614,O
the,5614,O
initial,5614,O
lead,5614,O
.,5614,O
Three,5615,O
different,5615,O
3D-QSAR,5615,O
models,5615,O
were,5615,O
built,5615,O
and,5615,O
validated,5615,O
by,5615,O
using,5615,O
a,5615,O
set,5615,O
of,5615,O
66,5615,O
pyrazole,5615,B-CHEMICAL
(,5615,O
Model,5615,O
I,5615,O
),5615,O
and,5615,O
furanopyrimidine,5615,B-CHEMICAL
(,5615,O
Model,5615,O
II,5615,O
),5615,O
compounds,5615,O
with,5615,O
IC,5615,O
(,5615,O
50,5615,O
),5615,O
values,5615,O
toward,5615,O
Aurora,5615,B-GENE-Y
kinase,5615,I-GENE-Y
A,5615,I-GENE-Y
ranging,5615,O
from,5615,O
33,5615,O
nM,5615,O
to,5615,O
10.5,5615,O
μM,5615,O
.,5615,O
The,5616,O
best,5616,O
3D-QSAR,5616,O
model,5616,O
",",5616,O
Model,5616,O
III,5616,O
",",5616,O
constructed,5616,O
with,5616,O
24,5616,O
training,5616,O
set,5616,O
compounds,5616,O
from,5616,O
both,5616,O
series,5616,O
",",5616,O
showed,5616,O
robustness,5616,O
(,5616,O
r,5616,O
(,5616,O
2,5616,O
),5616,O
(,5616,O
CV,5616,O
),5616,O
=0.54,5616,O
and,5616,O
0.52,5616,O
for,5616,O
CoMFA,5616,O
and,5616,O
CoMSIA,5616,O
",",5616,O
respectively,5616,O
),5616,O
and,5616,O
superior,5616,O
predictive,5616,O
capacity,5616,O
for,5616,O
42,5616,O
test,5616,O
set,5616,O
compounds,5616,O
(,5616,O
R,5616,O
(,5616,O
2,5616,O
),5616,O
(,5616,O
pred,5616,O
),5616,O
=0.52,5616,O
and,5616,O
0.67,5616,O
",",5616,O
CoMFA,5616,O
and,5616,O
CoMSIA,5616,O
),5616,O
.,5616,O
Superimposition,5617,O
of,5617,O
CoMFA,5617,O
and,5617,O
CoMSIA,5617,O
Model,5617,O
III,5617,O
over,5617,O
the,5617,O
crystal,5617,O
structure,5617,O
of,5617,O
Aurora,5617,B-GENE-Y
kinase,5617,I-GENE-Y
A,5617,I-GENE-Y
suggests,5617,O
the,5617,O
potential,5617,O
to,5617,O
improve,5617,O
the,5617,O
activity,5617,O
of,5617,O
the,5617,O
ligands,5617,O
by,5617,O
decreasing,5617,O
the,5617,O
steric,5617,O
clash,5617,O
with,5617,O
Val147,5617,O
and,5617,O
Leu139,5617,O
and,5617,O
by,5617,O
increasing,5617,O
hydrophobic,5617,O
contact,5617,O
with,5617,O
Leu139,5617,O
and,5617,O
Gly216,5617,O
residues,5617,O
in,5617,O
the,5617,O
solvent-exposed,5617,O
region,5617,O
of,5617,O
the,5617,O
enzyme,5617,O
.,5617,O
Based,5618,O
on,5618,O
these,5618,O
suggestions,5618,O
",",5618,O
the,5618,O
rational,5618,O
redesign,5618,O
of,5618,O
furanopyrimidine,5618,B-CHEMICAL
24,5618,O
(,5618,O
clog,5618,O
P=7.41,5618,O
;,5618,O
Aurora,5618,B-GENE-Y
A,5618,I-GENE-Y
IC,5618,O
(,5618,O
50,5618,O
),5618,O
=43,5618,O
nM,5618,O
;,5618,O
HCT-116,5618,O
IC,5618,O
(,5618,O
50,5618,O
),5618,O
=400,5618,O
nM,5618,O
),5618,O
led,5618,O
to,5618,O
the,5618,O
identification,5618,O
of,5618,O
quinazoline,5618,B-CHEMICAL
67,5618,O
(,5618,O
clog,5618,O
P=5.28,5618,O
;,5618,O
Aurora,5618,B-GENE-Y
A,5618,I-GENE-Y
IC,5618,O
(,5618,O
50,5618,O
),5618,O
=25,5618,O
nM,5618,O
;,5618,O
HCT-116,5618,O
IC,5618,O
(,5618,O
50,5618,O
),5618,O
=23,5618,O
nM,5618,O
),5618,O
.,5618,O
Rat,5619,O
in,5619,O
vivo,5619,O
pharmacokinetic,5619,O
studies,5619,O
showed,5619,O
that,5619,O
67,5619,O
has,5619,O
better,5619,O
systemic,5619,O
exposure,5619,O
after,5619,O
i.v,5619,O
.,5619,O
administration,5620,O
than,5620,O
24,5620,O
",",5620,O
and,5620,O
holds,5620,O
potential,5620,O
for,5620,O
further,5620,O
development,5620,O
.,5620,O
NMDA,5621,B-GENE-N
Receptor,5621,I-GENE-N
Activation,5621,O
Down-Regulates,5621,O
Expression,5621,O
of,5621,O
δ,5621,B-GENE-Y
Subunit-Containing,5621,I-GENE-Y
GABA-A,5621,I-GENE-Y
Receptors,5621,I-GENE-Y
in,5621,O
Cultured,5621,O
Hippocampal,5621,O
Neurons,5621,O
.,5621,O
Neurosteroids,5622,O
are,5622,O
endogenous,5622,O
allosteric,5622,O
modulators,5622,O
of,5622,O
γ,5622,B-GENE-N
amino-butyric,5622,I-GENE-N
acid,5622,I-GENE-N
type,5622,I-GENE-N
A,5622,I-GENE-N
receptors,5622,I-GENE-N
(,5622,O
GABARs,5622,B-GENE-N
),5622,O
",",5622,O
and,5622,O
enhance,5622,O
GABAR-mediated,5622,B-GENE-N
inhibition,5622,O
.,5622,O
However,5623,O
",",5623,O
GABARs,5623,B-GENE-N
expressed,5623,O
on,5623,O
hippocampal,5623,O
dentate,5623,O
granule,5623,O
neurons,5623,O
of,5623,O
epileptic,5623,O
animals,5623,O
are,5623,O
modified,5623,O
such,5623,O
that,5623,O
their,5623,O
neurosteroid,5623,O
sensitivity,5623,O
is,5623,O
reduced,5623,O
and,5623,O
δ,5623,O
subunit,5623,O
expression,5623,O
is,5623,O
diminished,5623,O
.,5623,O
The,5624,O
molecular,5624,O
mechanisms,5624,O
triggering,5624,O
this,5624,O
GABAR,5624,B-GENE-N
plasticity,5624,O
were,5624,O
explored,5624,O
.,5624,O
In,5625,O
the,5625,O
cultured,5625,O
hippocampal,5625,O
neurons,5625,O
treatment,5625,O
with,5625,O
NMDA,5625,B-CHEMICAL
(,5625,O
10,5625,O
μM,5625,O
),5625,O
for,5625,O
48,5625,O
hrs,5625,O
reduced,5625,O
surface,5625,O
expression,5625,O
of,5625,O
δ,5625,O
and,5625,O
α4,5625,O
subunits,5625,O
",",5625,O
but,5625,O
did,5625,O
not,5625,O
increase,5625,O
expression,5625,O
of,5625,O
γ2,5625,O
subunits,5625,O
.,5625,O
The,5626,O
tonic,5626,O
current,5626,O
recorded,5626,O
from,5626,O
neurons,5626,O
in,5626,O
NMDA-treated,5626,B-CHEMICAL
cultures,5626,O
was,5626,O
reduced,5626,O
",",5626,O
and,5626,O
its,5626,O
neurosteroid,5626,O
modulation,5626,O
was,5626,O
also,5626,O
diminished,5626,O
.,5626,O
In,5627,O
contrast,5627,O
",",5627,O
synaptic,5627,O
inhibition,5627,O
and,5627,O
its,5627,O
modulation,5627,O
by,5627,O
neurosteroids,5627,O
were,5627,O
preserved,5627,O
in,5627,O
these,5627,O
neurons,5627,O
.,5627,O
The,5628,O
time,5628,O
course,5628,O
of,5628,O
NMDA,5628,B-CHEMICAL
effects,5628,O
on,5628,O
surface,5628,O
and,5628,O
total,5628,O
δ,5628,O
subunit,5628,O
expression,5628,O
were,5628,O
distinct,5628,O
;,5628,O
shorter,5628,O
(,5628,O
6,5628,O
hrs,5628,O
),5628,O
treatment,5628,O
decreased,5628,O
surface,5628,O
expression,5628,O
",",5628,O
whereas,5628,O
longer,5628,O
treatment,5628,O
reduced,5628,O
both,5628,O
surface,5628,O
and,5628,O
total,5628,O
expression,5628,O
.,5628,O
APV,5629,B-CHEMICAL
blocked,5629,O
NMDA,5629,B-CHEMICAL
effects,5629,O
on,5629,O
δ,5629,O
subunit,5629,O
expression,5629,O
.,5629,O
Chelation,5630,O
of,5630,O
calcium,5630,B-CHEMICAL
ions,5630,O
by,5630,O
BAPTA-AM,5630,B-CHEMICAL
or,5630,O
blockade,5630,O
of,5630,O
ERK1/2,5630,B-GENE-N
activation,5630,O
by,5630,O
UO126,5630,B-CHEMICAL
also,5630,O
prevented,5630,O
the,5630,O
NMDA,5630,B-CHEMICAL
effects,5630,O
.,5630,O
Thus,5631,O
prolonged,5631,O
activation,5631,O
of,5631,O
NMDA,5631,B-GENE-N
receptors,5631,I-GENE-N
in,5631,O
hippocampal,5631,O
neurons,5631,O
reduced,5631,O
GABAR,5631,B-GENE-Y
δ,5631,I-GENE-Y
subunit,5631,I-GENE-Y
expression,5631,O
through,5631,O
Ca2+,5631,B-CHEMICAL
entry,5631,O
and,5631,O
at,5631,O
least,5631,O
in,5631,O
part,5631,O
by,5631,O
ERK1/2,5631,B-GENE-N
activation,5631,O
.,5631,O
Conjugated,5632,O
linoleic,5632,B-CHEMICAL
acid,5632,I-CHEMICAL
and,5632,O
calcium,5632,B-CHEMICAL
co-supplementation,5632,O
improves,5632,O
bone,5632,O
health,5632,O
in,5632,O
ovariectomised,5632,O
mice,5632,O
.,5632,O
Osteoporosis,5633,O
is,5633,O
a,5633,O
significant,5633,O
health,5633,O
concern,5633,O
for,5633,O
the,5633,O
elderly,5633,O
;,5633,O
conjugated,5633,O
linoleic,5633,B-CHEMICAL
acid,5633,I-CHEMICAL
(,5633,O
CLA,5633,O
),5633,O
has,5633,O
been,5633,O
shown,5633,O
to,5633,O
improve,5633,O
overall,5633,O
bone,5633,O
mass,5633,O
when,5633,O
calcium,5633,B-CHEMICAL
is,5633,O
included,5633,O
as,5633,O
a,5633,O
co-supplement,5633,O
.,5633,O
However,5634,O
",",5634,O
potential,5634,O
effects,5634,O
of,5634,O
CLA,5634,O
and,5634,O
calcium,5634,B-CHEMICAL
on,5634,O
bone,5634,O
mass,5634,O
during,5634,O
a,5634,O
period,5634,O
of,5634,O
bone,5634,O
loss,5634,O
have,5634,O
not,5634,O
been,5634,O
reported,5634,O
.,5634,O
The,5635,O
purpose,5635,O
of,5635,O
this,5635,O
study,5635,O
was,5635,O
to,5635,O
determine,5635,O
how,5635,O
dietary,5635,O
calcium,5635,B-CHEMICAL
modulates,5635,O
the,5635,O
effects,5635,O
of,5635,O
conjugated,5635,O
linoleic,5635,B-CHEMICAL
acid,5635,I-CHEMICAL
(,5635,O
CLA,5635,O
),5635,O
in,5635,O
preventing,5635,O
bone,5635,O
loss,5635,O
",",5635,O
using,5635,O
an,5635,O
ovariectomised,5635,O
mouse,5635,O
model,5635,O
.,5635,O
CLA,5636,O
supplementation,5636,O
significantly,5636,O
prevented,5636,O
ovariectomy-associated,5636,O
weight,5636,O
and,5636,O
fat,5636,O
mass,5636,O
gain,5636,O
",",5636,O
compared,5636,O
to,5636,O
non-supplemented,5636,O
controls,5636,O
.,5636,O
CLA,5637,O
significantly,5637,O
increased,5637,O
bone,5637,O
markers,5637,O
without,5637,O
major,5637,O
changes,5637,O
in,5637,O
bone,5637,O
mineral,5637,O
composition,5637,O
in,5637,O
the,5637,O
femur,5637,O
compared,5637,O
to,5637,O
respective,5637,O
controls,5637,O
.,5637,O
CLA,5638,O
treatment,5638,O
increased,5638,O
serum,5638,O
parathyroid,5638,B-GENE-Y
hormone,5638,I-GENE-Y
(,5638,O
PTH,5638,B-GENE-Y
),5638,O
significantly,5638,O
(,5638,O
p=0.0172,5638,O
),5638,O
",",5638,O
while,5638,O
serum,5638,O
"1,25-dihydroxyvitamin",5638,B-CHEMICAL
D3,5638,I-CHEMICAL
concentration,5638,O
was,5638,O
not,5638,O
changed,5638,O
by,5638,O
CLA,5638,O
.,5638,O
Meanwhile,5639,O
",",5639,O
CLA,5639,O
significantly,5639,O
reduced,5639,O
femur,5639,O
tartrate,5639,B-GENE-Y
resistant,5639,I-GENE-Y
acid,5639,I-GENE-Y
phosphatase,5639,I-GENE-Y
(,5639,O
TRAP,5639,B-GENE-Y
),5639,O
activity,5639,O
",",5639,O
suggesting,5639,O
potential,5639,O
reduction,5639,O
of,5639,O
osteoclastogenesis,5639,O
.,5639,O
The,5640,O
data,5640,O
suggest,5640,O
that,5640,O
CLA,5640,O
",",5640,O
along,5640,O
with,5640,O
dietary,5640,O
calcium,5640,B-CHEMICAL
",",5640,O
has,5640,O
great,5640,O
potential,5640,O
to,5640,O
be,5640,O
used,5640,O
to,5640,O
prevent,5640,O
bone,5640,O
loss,5640,O
and,5640,O
weight,5640,O
gain,5640,O
associated,5640,O
with,5640,O
menopause,5640,O
.,5640,O
Testosterone,5641,B-CHEMICAL
deficiency,5641,O
induces,5641,O
markedly,5641,O
decreased,5641,O
serum,5641,O
triglycerides,5641,B-CHEMICAL
",",5641,O
increased,5641,O
small,5641,O
dense,5641,O
LDL,5641,B-GENE-N
",",5641,O
and,5641,O
hepatic,5641,O
steatosis,5641,O
mediated,5641,O
by,5641,O
dysregulation,5641,O
of,5641,O
lipid,5641,O
assembly,5641,O
and,5641,O
secretion,5641,O
in,5641,O
mice,5641,O
fed,5641,O
a,5641,O
high-fat,5641,O
diet,5641,O
.,5641,O
OBJECTIVE,5642,O
:,5642,O
Although,5642,O
low,5642,O
serum,5642,O
testosterone,5642,B-CHEMICAL
(,5642,O
T,5642,O
),5642,O
is,5642,O
associated,5642,O
with,5642,O
metabolic,5642,O
disorders,5642,O
",",5642,O
the,5642,O
mechanism,5642,O
of,5642,O
this,5642,O
association,5642,O
is,5642,O
unclear,5642,O
.,5642,O
The,5643,O
objective,5643,O
of,5643,O
the,5643,O
present,5643,O
study,5643,O
was,5643,O
to,5643,O
investigate,5643,O
the,5643,O
combined,5643,O
effects,5643,O
of,5643,O
T,5643,O
deficiency,5643,O
and,5643,O
a,5643,O
high-fat,5643,O
diet,5643,O
(,5643,O
HFD,5643,O
),5643,O
on,5643,O
hepatic,5643,O
lipid,5643,O
homeostasis,5643,O
in,5643,O
mice,5643,O
.,5643,O
MATERIALS/METHODS,5644,O
:,5644,O
Orchiectomized,5644,O
(,5644,O
ORX,5644,O
),5644,O
mice,5644,O
and,5644,O
sham-operated,5644,O
(,5644,O
SHAM,5644,O
),5644,O
mice,5644,O
were,5644,O
randomly,5644,O
divided,5644,O
into,5644,O
five,5644,O
groups,5644,O
:,5644,O
SHAM,5644,O
mice,5644,O
fed,5644,O
a,5644,O
standard,5644,O
diet,5644,O
(,5644,O
SD,5644,O
),5644,O
",",5644,O
SHAM,5644,O
mice,5644,O
fed,5644,O
HFD,5644,O
",",5644,O
ORX,5644,O
mice,5644,O
fed,5644,O
SD,5644,O
",",5644,O
ORX,5644,O
mice,5644,O
fed,5644,O
HFD,5644,O
",",5644,O
and,5644,O
ORX,5644,O
mice,5644,O
fed,5644,O
HFD,5644,O
with,5644,O
T,5644,O
supplementation,5644,O
.,5644,O
After,5645,O
4weeks,5645,O
of,5645,O
treatment,5645,O
",",5645,O
we,5645,O
investigated,5645,O
the,5645,O
synthesis,5645,O
and,5645,O
secretion,5645,O
of,5645,O
lipids,5645,O
in,5645,O
the,5645,O
liver,5645,O
and,5645,O
detailed,5645,O
serum,5645,O
lipoprotein,5645,O
profiles,5645,O
in,5645,O
each,5645,O
group,5645,O
.,5645,O
RESULTS,5646,O
:,5646,O
ORX,5646,O
mice,5646,O
fed,5646,O
HFD,5646,O
showed,5646,O
increased,5646,O
hepatic,5646,O
steatosis,5646,O
",",5646,O
markedly,5646,O
decreased,5646,O
serum,5646,O
triglyceride,5646,B-CHEMICAL
(,5646,O
TG,5646,O
),5646,O
and,5646,O
TG-VLDL,5646,O
content,5646,O
",",5646,O
and,5646,O
increased,5646,O
serum,5646,O
very,5646,O
small-LDL,5646,O
content,5646,O
.,5646,O
Gene,5647,O
expression,5647,O
analysis,5647,O
revealed,5647,O
that,5647,O
ORX,5647,O
mice,5647,O
fed,5647,O
HFD,5647,O
showed,5647,O
significantly,5647,O
decreased,5647,O
expression,5647,O
of,5647,O
microsomal,5647,B-GENE-Y
triglyceride,5647,I-GENE-Y
transfer,5647,I-GENE-Y
protein,5647,I-GENE-Y
",",5647,O
lipin-1,5647,B-GENE-Y
",",5647,O
peroxisome,5647,B-GENE-Y
proliferator-activated,5647,I-GENE-Y
receptor,5647,I-GENE-Y
(,5647,I-GENE-Y
PPAR,5647,I-GENE-Y
),5647,I-GENE-Y
-α,5647,I-GENE-Y
and,5647,O
PPAR-γ,5647,B-GENE-Y
coactivator,5647,I-GENE-Y
1-α,5647,I-GENE-Y
",",5647,O
and,5647,O
significantly,5647,O
increased,5647,O
sterol,5647,B-GENE-Y
regulatory,5647,I-GENE-Y
element-binding,5647,I-GENE-Y
protein-1,5647,I-GENE-Y
",",5647,O
diacylglycerol,5647,B-GENE-Y
acyltransferase-2,5647,I-GENE-Y
and,5647,O
fatty,5647,B-GENE-Y
acid,5647,I-GENE-Y
synthase,5647,I-GENE-Y
.,5647,O
Reduction,5648,O
of,5648,O
hepatic,5648,O
AMPK,5648,B-GENE-N
phosphorylation,5648,O
was,5648,O
observed,5648,O
in,5648,O
ORX,5648,O
mice,5648,O
fed,5648,O
HFD,5648,O
.,5648,O
These,5649,O
perturbations,5649,O
in,5649,O
ORX,5649,O
mice,5649,O
fed,5649,O
HFD,5649,O
were,5649,O
normalized,5649,O
to,5649,O
the,5649,O
levels,5649,O
of,5649,O
SHAM,5649,O
mice,5649,O
fed,5649,O
HFD,5649,O
by,5649,O
T,5649,O
supplementation,5649,O
.,5649,O
CONCLUSION,5650,O
:,5650,O
T,5650,O
deficiency,5650,O
is,5650,O
associated,5650,O
with,5650,O
failure,5650,O
of,5650,O
lipid,5650,O
homeostasis,5650,O
mediated,5650,O
by,5650,O
altered,5650,O
expression,5650,O
of,5650,O
genes,5650,O
involved,5650,O
in,5650,O
hepatic,5650,O
assembly,5650,O
and,5650,O
secretion,5650,O
of,5650,O
lipids,5650,O
.,5650,O
Two,5651,O
distinct,5651,O
mechanisms,5651,O
of,5651,O
Topoisomerase,5651,B-GENE-Y
1-dependent,5651,O
mutagenesis,5651,O
in,5651,O
yeast,5651,O
.,5651,O
Topoisomerase,5652,B-GENE-Y
1,5652,I-GENE-Y
(,5652,O
Top1,5652,B-GENE-Y
),5652,O
resolves,5652,O
transcription-associated,5652,O
supercoils,5652,O
by,5652,O
generating,5652,O
transient,5652,O
single-strand,5652,O
breaks,5652,O
in,5652,O
DNA,5652,O
.,5652,O
Top1,5653,B-GENE-Y
activity,5653,O
in,5653,O
yeast,5653,O
is,5653,O
a,5653,O
major,5653,O
source,5653,O
of,5653,O
transcription-associated,5653,O
mutagenesis,5653,O
",",5653,O
generating,5653,O
a,5653,O
distinctive,5653,O
mutation,5653,O
signature,5653,O
characterized,5653,O
by,5653,O
deletions,5653,O
in,5653,O
short,5653,O
",",5653,O
tandem,5653,O
repeats,5653,O
.,5653,O
A,5654,O
similar,5654,O
signature,5654,O
is,5654,O
associated,5654,O
with,5654,O
the,5654,O
persistence,5654,O
of,5654,O
ribonucleoside,5654,B-CHEMICAL
monophosphates,5654,I-CHEMICAL
(,5654,O
rNMPs,5654,B-CHEMICAL
),5654,O
in,5654,O
DNA,5654,O
",",5654,O
and,5654,O
it,5654,O
also,5654,O
depends,5654,O
on,5654,O
Top1,5654,B-GENE-Y
activity,5654,O
.,5654,O
There,5655,O
is,5655,O
only,5655,O
partial,5655,O
overlap,5655,O
",",5655,O
however,5655,O
",",5655,O
between,5655,O
Top1-dependent,5655,B-GENE-Y
deletion,5655,O
hotspots,5655,O
identified,5655,O
in,5655,O
highly,5655,O
transcribed,5655,O
DNA,5655,O
and,5655,O
those,5655,O
associated,5655,O
with,5655,O
rNMPs,5655,B-CHEMICAL
",",5655,O
suggesting,5655,O
the,5655,O
existence,5655,O
of,5655,O
both,5655,O
rNMP-dependent,5655,B-CHEMICAL
and,5655,O
rNMP-independent,5655,B-CHEMICAL
events,5655,O
.,5655,O
Here,5656,O
",",5656,O
we,5656,O
present,5656,O
genetic,5656,O
studies,5656,O
confirming,5656,O
that,5656,O
there,5656,O
are,5656,O
two,5656,O
distinct,5656,O
types,5656,O
of,5656,O
hotspots,5656,O
.,5656,O
Data,5657,O
suggest,5657,O
a,5657,O
novel,5657,O
model,5657,O
in,5657,O
which,5657,O
rNMP-dependent,5657,B-CHEMICAL
hotspots,5657,O
are,5657,O
generated,5657,O
by,5657,O
sequential,5657,O
Top1,5657,B-GENE-Y
reactions,5657,O
and,5657,O
are,5657,O
consistent,5657,O
with,5657,O
rNMP-independent,5657,B-CHEMICAL
hotspots,5657,O
reflecting,5657,O
processing,5657,O
of,5657,O
a,5657,O
trapped,5657,O
Top1,5657,B-GENE-Y
cleavage,5657,O
complex,5657,O
.,5657,O
Covalent,5658,O
modification,5658,O
of,5658,O
stathmin,5658,B-GENE-Y
by,5658,O
CCNU,5658,O
determined,5658,O
by,5658,O
FTMS,5658,O
analysis,5658,O
of,5658,O
modified,5658,O
proteins,5658,O
and,5658,O
tryptic,5658,O
peptides,5658,O
.,5658,O
Chemical,5659,O
modification,5659,O
of,5659,O
proteins,5659,O
is,5659,O
often,5659,O
carried,5659,O
out,5659,O
to,5659,O
generate,5659,O
protein-small,5659,O
molecule,5659,O
conjugates,5659,O
for,5659,O
various,5659,O
applications,5659,O
.,5659,O
The,5660,O
high,5660,O
resolution,5660,O
and,5660,O
mass,5660,O
accuracy,5660,O
of,5660,O
a,5660,O
Fourier,5660,O
transform,5660,O
mass,5660,O
spectrometer,5660,O
is,5660,O
particularly,5660,O
useful,5660,O
for,5660,O
assessing,5660,O
the,5660,O
extent,5660,O
or,5660,O
sites,5660,O
of,5660,O
covalent,5660,O
modifications,5660,O
.,5660,O
As,5661,O
protein-small,5661,O
molecule,5661,O
reactions,5661,O
often,5661,O
produce,5661,O
products,5661,O
with,5661,O
variable,5661,O
numbers,5661,O
of,5661,O
the,5661,O
compound,5661,O
incorporated,5661,O
at,5661,O
different,5661,O
sites,5661,O
",",5661,O
a,5661,O
direct,5661,O
mass,5661,O
analysis,5661,O
of,5661,O
the,5661,O
reaction,5661,O
products,5661,O
at,5661,O
times,5661,O
yields,5661,O
mass,5661,O
spectra,5661,O
hard,5661,O
to,5661,O
interpret,5661,O
.,5661,O
Chromatographic,5662,O
separation,5662,O
at,5662,O
protein,5662,O
level,5662,O
could,5662,O
reduce,5662,O
the,5662,O
complexity,5662,O
of,5662,O
a,5662,O
sample,5662,O
",",5662,O
thus,5662,O
allowing,5662,O
more,5662,O
accurate,5662,O
mass,5662,O
spectrometric,5662,O
analysis,5662,O
.,5662,O
In,5663,O
this,5663,O
report,5663,O
",",5663,O
we,5663,O
demonstrate,5663,O
the,5663,O
utility,5663,O
of,5663,O
reversed-phase,5663,O
protein,5663,O
chromatography,5663,O
and,5663,O
FT-ICR,5663,O
mass,5663,O
spectrometry,5663,O
in,5663,O
analyzing,5663,O
CCNU,5663,O
(,5663,O
lomustine,5663,B-CHEMICAL
",",5663,O
1-,5663,B-CHEMICAL
(,5663,I-CHEMICAL
2-chloroethyl,5663,I-CHEMICAL
),5663,I-CHEMICAL
-3-cyclohexyl-1-nitroso-urea,5663,I-CHEMICAL
",",5663,O
MW,5663,O
:,5663,O
233.7Da,5663,O
),5663,O
modification,5663,O
of,5663,O
stathmin,5663,B-GENE-Y
.,5663,O
With,5664,O
this,5664,O
combined,5664,O
approach,5664,O
",",5664,O
we,5664,O
determined,5664,O
the,5664,O
stoichiometry,5664,O
as,5664,O
well,5664,O
as,5664,O
sites,5664,O
of,5664,O
CCNU,5664,O
incorporation,5664,O
into,5664,O
the,5664,O
protein,5664,O
",",5664,O
demonstrating,5664,O
differential,5664,O
reactivity,5664,O
of,5664,O
several,5664,O
lysyl,5664,O
residues,5664,O
to,5664,O
CCNU,5664,O
alkylation,5664,O
.,5664,O
Amitriptyline,5665,B-CHEMICAL
is,5665,O
a,5665,O
TrkA,5665,B-GENE-Y
and,5665,O
TrkB,5665,B-GENE-Y
receptor,5665,O
agonist,5665,O
that,5665,O
promotes,5665,O
TrkA/TrkB,5665,B-GENE-Y
heterodimerization,5665,O
and,5665,O
has,5665,O
potent,5665,O
neurotrophic,5665,O
activity,5665,O
.,5665,O
Neurotrophins,5666,B-GENE-N
",",5666,O
the,5666,O
cognate,5666,O
ligands,5666,O
for,5666,O
the,5666,O
Trk,5666,B-GENE-N
receptors,5666,I-GENE-N
",",5666,O
are,5666,O
homodimers,5666,O
and,5666,O
induce,5666,O
Trk,5666,B-GENE-N
dimerization,5666,O
through,5666,O
a,5666,O
symmetric,5666,O
bivalent,5666,O
mechanism,5666,O
.,5666,O
We,5667,O
report,5667,O
here,5667,O
that,5667,O
amitriptyline,5667,B-CHEMICAL
",",5667,O
an,5667,O
antidepressant,5667,O
drug,5667,O
",",5667,O
directly,5667,O
binds,5667,O
TrkA,5667,B-GENE-Y
and,5667,O
TrkB,5667,B-GENE-Y
and,5667,O
triggers,5667,O
their,5667,O
dimerization,5667,O
and,5667,O
activation,5667,O
.,5667,O
Amitriptyline,5668,B-CHEMICAL
",",5668,O
but,5668,O
not,5668,O
any,5668,O
other,5668,O
tricyclic,5668,B-CHEMICAL
or,5668,O
selective,5668,O
serotonin,5668,B-CHEMICAL
reuptake,5668,O
inhibitor,5668,O
antidepressants,5668,O
",",5668,O
promotes,5668,O
TrkA,5668,B-GENE-Y
autophosphorylation,5668,O
in,5668,O
primary,5668,O
neurons,5668,O
and,5668,O
induces,5668,O
neurite,5668,O
outgrowth,5668,O
in,5668,O
PC12,5668,O
cells,5668,O
.,5668,O
Amitriptyline,5669,B-CHEMICAL
binds,5669,O
the,5669,O
extracellular,5669,O
domain,5669,O
of,5669,O
both,5669,O
TrkA,5669,B-GENE-Y
and,5669,O
TrkB,5669,B-GENE-Y
and,5669,O
promotes,5669,O
TrkA-TrkB,5669,B-GENE-Y
receptor,5669,O
heterodimerization,5669,O
.,5669,O
Truncation,5670,O
of,5670,O
amitriptyline,5670,B-CHEMICAL
binding,5670,O
motif,5670,O
on,5670,O
TrkA,5670,B-GENE-Y
abrogates,5670,O
the,5670,O
receptor,5670,O
dimerization,5670,O
by,5670,O
amitriptyline,5670,B-CHEMICAL
.,5670,O
Administration,5671,O
of,5671,O
amitriptyline,5671,B-CHEMICAL
to,5671,O
mice,5671,O
activates,5671,O
both,5671,O
receptors,5671,O
and,5671,O
significantly,5671,O
reduces,5671,O
kainic,5671,B-CHEMICAL
acid-triggered,5671,O
neuronal,5671,O
cell,5671,O
death,5671,O
.,5671,O
Inhibition,5672,O
of,5672,O
TrkA,5672,B-GENE-Y
",",5672,O
but,5672,O
not,5672,O
TrkB,5672,B-GENE-Y
",",5672,O
abolishes,5672,O
amitriptyline,5672,O
's,5672,O
neuroprotective,5672,O
effect,5672,O
without,5672,O
impairing,5672,O
its,5672,O
antidepressant,5672,O
activity,5672,O
.,5672,O
Thus,5673,O
",",5673,O
amitriptyline,5673,B-CHEMICAL
acts,5673,O
as,5673,O
a,5673,O
TrkA,5673,B-GENE-Y
and,5673,O
TrkB,5673,B-GENE-Y
agonist,5673,O
and,5673,O
possesses,5673,O
marked,5673,O
neurotrophic,5673,O
activity,5673,O
.,5673,O
Truncated,5674,O
ErbB2,5674,B-GENE-Y
receptor,5674,O
(,5674,O
p95ErbB2,5674,B-GENE-Y
),5674,O
is,5674,O
regulated,5674,O
by,5674,O
heregulin,5674,B-GENE-Y
through,5674,O
heterodimer,5674,O
formation,5674,O
with,5674,O
ErbB3,5674,B-GENE-Y
yet,5674,O
remains,5674,O
sensitive,5674,O
to,5674,O
the,5674,O
dual,5674,O
EGFR/ErbB2,5674,B-GENE-Y
kinase,5674,O
inhibitor,5674,O
GW572016,5674,B-CHEMICAL
.,5674,O
The,5675,O
expression,5675,O
of,5675,O
the,5675,O
NH2,5675,B-CHEMICAL
terminally,5675,O
truncated,5675,O
ErbB2,5675,B-GENE-Y
receptor,5675,O
(,5675,O
p95ErbB2,5675,B-GENE-Y
),5675,O
in,5675,O
breast,5675,O
cancer,5675,O
correlates,5675,O
with,5675,O
metastatic,5675,O
disease,5675,O
progression,5675,O
compared,5675,O
with,5675,O
the,5675,O
expression,5675,O
of,5675,O
full-length,5675,O
p185ErbB2,5675,B-GENE-Y
.,5675,O
We,5676,O
now,5676,O
show,5676,O
that,5676,O
heregulin,5676,B-GENE-Y
(,5676,O
HRG,5676,B-GENE-Y
),5676,O
",",5676,O
but,5676,O
not,5676,O
EGF,5676,B-GENE-Y
",",5676,O
stimulates,5676,O
p95ErbB2,5676,B-GENE-Y
phosphorylation,5676,O
in,5676,O
BT474,5676,O
breast,5676,O
cancer,5676,O
cells,5676,O
.,5676,O
Furthermore,5677,O
",",5677,O
phospho-p95ErbB2,5677,B-GENE-Y
forms,5677,O
heterodimers,5677,O
with,5677,O
ErbB3,5677,B-GENE-Y
",",5677,O
but,5677,O
not,5677,O
EGFR,5677,B-GENE-Y
",",5677,O
while,5677,O
p185ErbB2,5677,B-GENE-Y
heterodimerizes,5677,O
with,5677,O
both,5677,O
EGFR,5677,B-GENE-Y
and,5677,O
ErbB3,5677,B-GENE-Y
.,5677,O
The,5678,O
predilection,5678,O
of,5678,O
p95ErbB2,5678,B-GENE-Y
to,5678,O
heterodimerize,5678,O
with,5678,O
ErbB3,5678,B-GENE-Y
provides,5678,O
an,5678,O
explanation,5678,O
for,5678,O
its,5678,O
regulation,5678,O
by,5678,O
HRG,5678,B-GENE-Y
",",5678,O
an,5678,O
ErbB3,5678,B-GENE-Y
ligand,5678,O
.,5678,O
GW572016,5679,B-CHEMICAL
",",5679,O
a,5679,O
reversible,5679,O
small,5679,O
molecule,5679,O
inhibitor,5679,O
of,5679,O
EGFR,5679,B-GENE-Y
and,5679,O
ErbB2,5679,B-GENE-Y
tyrosine,5679,B-GENE-N
kinases,5679,I-GENE-N
",",5679,O
inhibits,5679,O
baseline,5679,O
p95ErbB2,5679,B-GENE-Y
phosphorylation,5679,O
in,5679,O
BT474,5679,O
cells,5679,O
and,5679,O
tumor,5679,O
xenografts,5679,O
.,5679,O
Inhibition,5680,O
of,5680,O
p95ErbB2,5680,B-GENE-Y
",",5680,O
p185ErbB2,5680,B-GENE-Y
",",5680,O
and,5680,O
EGFR,5680,B-GENE-Y
phosphorylation,5680,O
by,5680,O
GW572016,5680,B-CHEMICAL
resulted,5680,O
in,5680,O
the,5680,O
inhibition,5680,O
of,5680,O
downstream,5680,O
phospho-Erk1/2,5680,O
",",5680,O
phospho-AKT,5680,O
",",5680,O
and,5680,O
cyclin,5680,B-GENE-N
D,5680,I-GENE-N
steady-state,5680,O
protein,5680,O
levels,5680,O
.,5680,O
Increased,5681,O
phosphorylation,5681,O
of,5681,O
p95ErbB2,5681,B-GENE-Y
and,5681,O
AKT,5681,B-GENE-N
in,5681,O
response,5681,O
to,5681,O
HRG,5681,B-GENE-N
was,5681,O
abrogated,5681,O
to,5681,O
varying,5681,O
degrees,5681,O
by,5681,O
GW572016,5681,B-CHEMICAL
.,5681,O
In,5682,O
contrast,5682,O
",",5682,O
trastuzumab,5682,O
did,5682,O
not,5682,O
inhibit,5682,O
p95ErbB2,5682,B-GENE-Y
phosphorylation,5682,O
or,5682,O
the,5682,O
expression,5682,O
of,5682,O
downstream,5682,O
phospho-Erk1/2,5682,O
",",5682,O
phospho-AKT,5682,B-GENE-N
",",5682,O
or,5682,O
cyclin,5682,B-GENE-N
D.,5682,O
It,5682,O
is,5682,O
tempting,5682,O
to,5682,O
speculate,5682,O
that,5682,O
trastuzumab,5682,O
resistance,5682,O
may,5682,O
be,5682,O
mediated,5682,O
in,5682,O
part,5682,O
by,5682,O
the,5682,O
selection,5682,O
of,5682,O
p95ErbB2-expressing,5682,B-GENE-Y
breast,5682,O
cancer,5682,O
cells,5682,O
capable,5682,O
of,5682,O
exerting,5682,O
potent,5682,O
growth,5682,O
and,5682,O
prosurvival,5682,O
signals,5682,O
through,5682,O
p95ErbB2-ErbB3,5682,B-GENE-Y
heterodimers,5682,O
.,5682,O
Thus,5683,O
",",5683,O
p95ErbB2,5683,B-GENE-Y
represents,5683,O
a,5683,O
target,5683,O
for,5683,O
therapeutic,5683,O
intervention,5683,O
",",5683,O
and,5683,O
one,5683,O
that,5683,O
is,5683,O
sensitive,5683,O
to,5683,O
GW572016,5683,B-CHEMICAL
therapy,5683,O
.,5683,O
Nonsteroidal,5684,O
anti-inflammatory,5684,O
drugs,5684,O
induce,5684,O
colorectal,5684,O
cancer,5684,O
cell,5684,O
apoptosis,5684,O
by,5684,O
suppressing,5684,O
14-3-3epsilon,5684,B-GENE-Y
.,5684,O
To,5685,O
determine,5685,O
the,5685,O
role,5685,O
of,5685,O
14-3-3,5685,B-GENE-N
in,5685,O
colorectal,5685,O
cancer,5685,O
apoptosis,5685,O
induced,5685,O
by,5685,O
nonsteroidal,5685,O
anti-inflammatory,5685,O
drugs,5685,O
(,5685,O
NSAIDs,5685,O
),5685,O
",",5685,O
we,5685,O
evaluated,5685,O
the,5685,O
effects,5685,O
of,5685,O
sulindac,5685,B-CHEMICAL
on,5685,O
14-3-3epsilon,5685,B-GENE-Y
protein,5685,I-GENE-Y
expression,5685,O
in,5685,O
colorectal,5685,O
cancer,5685,O
cells,5685,O
.,5685,O
Sulindac,5686,B-CHEMICAL
sulfide,5686,I-CHEMICAL
inhibited,5686,O
14-3-3epsilon,5686,B-GENE-Y
proteins,5686,I-GENE-Y
in,5686,O
HT-29,5686,O
and,5686,O
DLD-1,5686,O
cells,5686,O
in,5686,O
a,5686,O
time-,5686,O
and,5686,O
concentration-dependent,5686,O
manner,5686,O
.,5686,O
Sulindac,5687,B-CHEMICAL
sulfone,5687,I-CHEMICAL
at,5687,O
600,5687,O
mumol/L,5687,O
inhibited,5687,O
14-3-3epsilon,5687,O
protein,5687,O
expression,5687,O
in,5687,O
HT-29,5687,O
.,5687,O
Indomethacin,5688,B-CHEMICAL
and,5688,O
SC-236,5688,B-CHEMICAL
",",5688,O
a,5688,O
selective,5688,O
cyclooxygenase-2,5688,B-GENE-Y
(,5688,O
COX-2,5688,B-GENE-Y
),5688,O
inhibitor,5688,O
",",5688,O
exerted,5688,O
a,5688,O
similar,5688,O
effect,5688,O
as,5688,O
sulindac,5688,B-CHEMICAL
.,5688,O
Sulindac,5689,B-CHEMICAL
suppressed,5689,O
14-3-3epsilon,5689,O
promoter,5689,O
activity,5689,O
.,5689,O
As,5690,O
14-3-3epsilon,5690,B-GENE-N
promoter,5690,I-GENE-N
activation,5690,O
is,5690,O
mediated,5690,O
by,5690,O
peroxisome,5690,B-GENE-Y
proliferator-activated,5690,I-GENE-Y
receptor,5690,I-GENE-Y
delta,5690,I-GENE-Y
(,5690,O
PPARdelta,5690,B-GENE-Y
),5690,O
",",5690,O
we,5690,O
determined,5690,O
the,5690,O
correlation,5690,O
between,5690,O
14-3-3epsilon,5690,B-GENE-Y
inhibition,5690,O
and,5690,O
PPARdelta,5690,B-GENE-Y
suppression,5690,O
by,5690,O
NSAIDs,5690,O
.,5690,O
Sulindac,5691,B-CHEMICAL
sulfide,5691,I-CHEMICAL
inhibited,5691,O
PPARdelta,5691,B-GENE-Y
protein,5691,O
expression,5691,O
and,5691,O
PPARdelta,5691,B-GENE-Y
transcriptional,5691,O
activity,5691,O
.,5691,O
Overexpression,5692,O
of,5692,O
PPARdelta,5692,B-GENE-Y
by,5692,O
adenoviral,5692,O
transfer,5692,O
rescued,5692,O
14-3-3epsilon,5692,B-GENE-Y
proteins,5692,O
from,5692,O
elimination,5692,O
by,5692,O
sulindac,5692,B-CHEMICAL
or,5692,O
indomethacin,5692,B-CHEMICAL
.,5692,O
NSAID-induced,5693,O
14-3-3epsilon,5693,B-GENE-Y
suppression,5693,O
was,5693,O
associated,5693,O
with,5693,O
reduced,5693,O
cytosolic,5693,B-GENE-Y
Bad,5693,I-GENE-Y
with,5693,O
elevation,5693,O
of,5693,O
mitochondrial,5693,B-GENE-Y
Bad,5693,I-GENE-Y
and,5693,O
increase,5693,O
in,5693,O
apoptosis,5693,O
which,5693,O
was,5693,O
rescued,5693,O
by,5693,O
Ad-PPARdelta,5693,O
transduction,5693,O
.,5693,O
Stable,5694,O
expression,5694,O
of,5694,O
14-3-3epsilon,5694,B-GENE-Y
in,5694,O
HT-29,5694,O
significantly,5694,O
protected,5694,O
cells,5694,O
from,5694,O
apoptosis,5694,O
.,5694,O
Our,5695,O
findings,5695,O
shed,5695,O
light,5695,O
on,5695,O
a,5695,O
novel,5695,O
mechanism,5695,O
by,5695,O
which,5695,O
NSAIDs,5695,O
induce,5695,O
colorectal,5695,O
cancer,5695,O
apoptosis,5695,O
via,5695,O
the,5695,O
PPARdelta/14-3-3epsilon,5695,B-GENE-Y
transcriptional,5695,O
pathway,5695,O
.,5695,O
These,5696,O
results,5696,O
suggest,5696,O
that,5696,O
14-3-3epsilon,5696,B-GENE-Y
is,5696,O
a,5696,O
target,5696,O
for,5696,O
the,5696,O
prevention,5696,O
and,5696,O
therapy,5696,O
of,5696,O
colorectal,5696,O
cancer,5696,O
.,5696,O
Cellular,5697,O
and,5697,O
pharmacogenetics,5697,O
foundation,5697,O
of,5697,O
synergistic,5697,O
interaction,5697,O
of,5697,O
pemetrexed,5697,B-CHEMICAL
and,5697,O
gemcitabine,5697,B-CHEMICAL
in,5697,O
human,5697,O
non-small-cell,5697,O
lung,5697,O
cancer,5697,O
cells,5697,O
.,5697,O
Gemcitabine,5698,B-CHEMICAL
and,5698,O
pemetrexed,5698,B-CHEMICAL
are,5698,O
effective,5698,O
agents,5698,O
in,5698,O
the,5698,O
treatment,5698,O
of,5698,O
non-small-cell,5698,O
lung,5698,O
cancer,5698,O
(,5698,O
NSCLC,5698,O
),5698,O
",",5698,O
and,5698,O
the,5698,O
present,5698,O
study,5698,O
investigates,5698,O
cellular,5698,O
and,5698,O
genetic,5698,O
aspects,5698,O
of,5698,O
their,5698,O
interaction,5698,O
against,5698,O
A549,5698,O
",",5698,O
Calu-1,5698,O
",",5698,O
and,5698,O
Calu-6,5698,O
cells,5698,O
.,5698,O
Cells,5699,O
were,5699,O
treated,5699,O
with,5699,O
pemetrexed,5699,B-CHEMICAL
and,5699,O
gemcitabine,5699,B-CHEMICAL
",",5699,O
and,5699,O
their,5699,O
interaction,5699,O
was,5699,O
assessed,5699,O
using,5699,O
the,5699,O
combination,5699,O
index,5699,O
.,5699,O
The,5700,O
role,5700,O
of,5700,O
drug,5700,O
metabolism,5700,O
in,5700,O
gemcitabine,5700,B-CHEMICAL
cytotoxicity,5700,O
was,5700,O
examined,5700,O
with,5700,O
inhibitors,5700,O
of,5700,O
deoxycytidine,5700,B-GENE-Y
kinase,5700,I-GENE-Y
(,5700,O
dCK,5700,B-GENE-Y
),5700,O
",",5700,O
5'-nucleotidase,5700,B-GENE-Y
",",5700,O
and,5700,O
cytidine,5700,B-GENE-Y
deaminase,5700,I-GENE-Y
",",5700,O
whereas,5700,O
the,5700,O
role,5700,O
of,5700,O
pemetrexed,5700,O
targets,5700,O
",",5700,O
thymidylate,5700,B-GENE-Y
synthase,5700,I-GENE-Y
(,5700,O
TS,5700,B-GENE-Y
),5700,O
",",5700,O
dihydrofolate,5700,B-GENE-Y
reductase,5700,I-GENE-Y
(,5700,O
DHFR,5700,B-GENE-Y
),5700,O
",",5700,O
and,5700,O
glycinamide,5700,B-GENE-Y
ribonucleotide,5700,I-GENE-Y
formyltransferase,5700,I-GENE-Y
(,5700,O
GARFT,5700,B-GENE-Y
),5700,O
in,5700,O
drug,5700,O
chemosensitivity,5700,O
was,5700,O
analyzed,5700,O
in,5700,O
cytotoxicity,5700,O
rescue,5700,O
studies,5700,O
.,5700,O
The,5701,O
effect,5701,O
of,5701,O
gemcitabine,5701,B-CHEMICAL
and,5701,O
pemetrexed,5701,O
on,5701,O
Akt,5701,B-GENE-N
phosphorylation,5701,O
was,5701,O
investigated,5701,O
with,5701,O
enzyme-linked,5701,O
immunosorbent,5701,O
assay,5701,O
",",5701,O
whereas,5701,O
quantitative,5701,O
polymerase,5701,O
chain,5701,O
reaction,5701,O
(,5701,O
PCR,5701,O
),5701,O
was,5701,O
used,5701,O
to,5701,O
study,5701,O
target,5701,O
gene-expression,5701,O
profiles,5701,O
and,5701,O
its,5701,O
modulation,5701,O
by,5701,O
each,5701,O
drug,5701,O
.,5701,O
Synergistic,5702,O
cytotoxicity,5702,O
was,5702,O
demonstrated,5702,O
",",5702,O
and,5702,O
pemetrexed,5702,B-CHEMICAL
significantly,5702,O
decreased,5702,O
the,5702,O
amount,5702,O
of,5702,O
phosphorylated,5702,B-GENE-N
Akt,5702,I-GENE-N
",",5702,O
enhanced,5702,O
apoptosis,5702,O
",",5702,O
and,5702,O
increased,5702,O
the,5702,O
expression,5702,O
of,5702,O
dCK,5702,B-GENE-Y
in,5702,O
A549,5702,O
and,5702,O
Calu-6,5702,O
cells,5702,O
",",5702,O
as,5702,O
well,5702,O
as,5702,O
the,5702,O
expression,5702,O
of,5702,O
the,5702,O
human,5702,B-GENE-Y
nucleoside,5702,I-GENE-Y
equilibrative,5702,I-GENE-Y
transporter,5702,I-GENE-Y
1,5702,I-GENE-Y
(,5702,O
hENT1,5702,B-GENE-Y
),5702,O
in,5702,O
all,5702,O
cell,5702,O
lines,5702,O
.,5702,O
PCR,5703,O
demonstrated,5703,O
a,5703,O
correlation,5703,O
between,5703,O
dCK,5703,B-GENE-Y
expression,5703,O
and,5703,O
gemcitabine,5703,B-CHEMICAL
sensitivity,5703,O
",",5703,O
whereas,5703,O
expression,5703,O
of,5703,O
TS,5703,B-GENE-Y
",",5703,O
DHFR,5703,B-GENE-Y
",",5703,O
and,5703,O
GARFT,5703,B-GENE-Y
was,5703,O
predictive,5703,O
of,5703,O
pemetrexed,5703,B-CHEMICAL
chemosensitivity,5703,O
.,5703,O
These,5704,O
data,5704,O
demonstrated,5704,O
that,5704,O
1,5704,O
),5704,O
gemcitabine,5704,B-CHEMICAL
and,5704,O
pemetrexed,5704,B-CHEMICAL
synergistically,5704,O
interact,5704,O
against,5704,O
NSCLC,5704,O
cells,5704,O
through,5704,O
the,5704,O
suppression,5704,O
of,5704,O
Akt,5704,B-GENE-N
phosphorylation,5704,O
and,5704,O
induction,5704,O
of,5704,O
apoptosis,5704,O
;,5704,O
2,5704,O
),5704,O
the,5704,O
gene,5704,O
expression,5704,O
profile,5704,O
of,5704,O
critical,5704,O
genes,5704,O
may,5704,O
predict,5704,O
for,5704,O
drug,5704,O
chemosensitivity,5704,O
;,5704,O
and,5704,O
3,5704,O
),5704,O
pemetrexed,5704,B-CHEMICAL
enhances,5704,O
dCK,5704,B-GENE-Y
and,5704,O
hENT1,5704,B-GENE-Y
expression,5704,O
",",5704,O
thus,5704,O
suggesting,5704,O
the,5704,O
role,5704,O
of,5704,O
gene-expression,5704,O
modulation,5704,O
for,5704,O
rational,5704,O
development,5704,O
of,5704,O
chemotherapy,5704,O
combinations,5704,O
.,5704,O
Tissue,5705,O
expression,5705,O
and,5705,O
translational,5705,O
control,5705,O
of,5705,O
rat,5705,B-GENE-Y
kynurenine,5705,I-GENE-Y
aminotransferase/glutamine,5705,O
transaminase,5705,I-GENE-Y
K,5705,I-GENE-Y
mRNAs,5705,O
.,5705,O
Kynurenic,5706,B-CHEMICAL
acid,5706,I-CHEMICAL
(,5706,O
KA,5706,B-CHEMICAL
),5706,O
is,5706,O
an,5706,O
endogenous,5706,O
glutamate,5706,B-GENE-N
receptor,5706,I-GENE-N
antagonist,5706,O
at,5706,O
the,5706,O
level,5706,O
of,5706,O
the,5706,O
different,5706,O
ionotropic,5706,B-GENE-N
glutamate,5706,I-GENE-N
receptors,5706,I-GENE-N
.,5706,O
One,5707,O
of,5707,O
the,5707,O
enzymes,5707,O
responsible,5707,O
for,5707,O
the,5707,O
production,5707,O
of,5707,O
KA,5707,B-CHEMICAL
",",5707,O
kynurenine,5707,B-GENE-Y
aminotransferase,5707,I-GENE-Y
I,5707,I-GENE-Y
(,5707,O
KATI,5707,B-GENE-Y
),5707,O
",",5707,O
also,5707,O
catalyses,5707,O
the,5707,O
reversible,5707,O
transamination,5707,O
of,5707,O
glutamine,5707,B-CHEMICAL
to,5707,O
oxoglutaramic,5707,B-CHEMICAL
acid,5707,I-CHEMICAL
(,5707,O
GTK,5707,B-GENE-Y
",",5707,O
EC,5707,B-GENE-Y
2.6.1.15,5707,I-GENE-Y
),5707,O
.,5707,O
The,5708,O
enzyme,5708,O
exists,5708,O
in,5708,O
a,5708,O
cytosolic,5708,O
and,5708,O
in,5708,O
a,5708,O
mitochondrial,5708,O
form,5708,O
because,5708,O
of,5708,O
the,5708,O
presence,5708,O
of,5708,O
two,5708,O
different,5708,O
KATI,5708,B-GENE-Y
mRNAs,5708,O
coding,5708,O
for,5708,O
a,5708,O
protein,5708,O
respectively,5708,O
with,5708,O
and,5708,O
without,5708,O
leader,5708,B-GENE-N
sequence,5708,I-GENE-N
targeting,5708,O
the,5708,O
protein,5708,O
into,5708,O
mitochondria,5708,O
.,5708,O
We,5709,O
have,5709,O
cloned,5709,O
from,5709,O
a,5709,O
phage,5709,O
library,5709,O
of,5709,O
rat,5709,O
kidney,5709,O
cDNA,5709,O
four,5709,O
new,5709,O
KATI,5709,B-GENE-Y
cDNAs,5709,O
containing,5709,O
different,5709,O
5,5709,B-GENE-N
',5709,I-GENE-N
untranslated,5709,I-GENE-N
regions,5709,I-GENE-N
(,5709,O
UTRs,5709,B-GENE-N
),5709,O
.,5709,O
One,5710,O
of,5710,O
the,5710,O
transcripts,5710,O
(,5710,O
+14KATI,5710,O
cDNA,5710,O
),5710,O
contains,5710,O
an,5710,O
alternative,5710,O
site,5710,O
of,5710,O
initiation,5710,O
of,5710,O
translation,5710,O
.,5710,O
The,5711,O
tissue,5711,O
distribution,5711,O
of,5711,O
the,5711,O
different,5711,O
transcripts,5711,O
was,5711,O
studied,5711,O
by,5711,O
RT-PCR,5711,O
.,5711,O
The,5712,O
study,5712,O
demonstrated,5712,O
that,5712,O
several,5712,O
KATI,5712,B-GENE-Y
mRNAs,5712,O
are,5712,O
constitutively,5712,O
expressed,5712,O
in,5712,O
ubiquitous,5712,O
manner,5712,O
",",5712,O
while,5712,O
+14KATI,5712,O
mRNA,5712,O
is,5712,O
present,5712,O
only,5712,O
in,5712,O
kidney,5712,O
.,5712,O
The,5713,O
translational,5713,O
efficiency,5713,O
of,5713,O
the,5713,O
different,5713,O
transcripts,5713,O
was,5713,O
studied,5713,O
in,5713,O
vitro,5713,O
and,5713,O
enzymatic,5713,O
activities,5713,O
were,5713,O
measured,5713,O
in,5713,O
transiently,5713,O
transfected,5713,O
Cos-1,5713,O
cells,5713,O
.,5713,O
Each,5714,O
KATI,5714,B-GENE-Y
mRNA,5714,O
exhibits,5714,O
a,5714,O
different,5714,O
in,5714,O
vitro,5714,O
translational,5714,O
efficiency,5714,O
",",5714,O
which,5714,O
corresponds,5714,O
to,5714,O
different,5714,O
levels,5714,O
of,5714,O
KAT,5714,B-GENE-Y
enzymatic,5714,O
activity,5714,O
in,5714,O
transfected,5714,O
cells,5714,O
.,5714,O
Both,5715,O
findings,5715,O
correlate,5715,O
with,5715,O
the,5715,O
predicted,5715,O
accessibility,5715,O
of,5715,O
the,5715,O
ribosomal,5715,O
binding,5715,O
sites,5715,O
of,5715,O
the,5715,O
different,5715,O
mRNAs,5715,O
.,5715,O
The,5716,O
structure,5716,O
of,5716,O
the,5716,O
rat,5716,B-GENE-Y
KATI/GTK,5716,O
gene,5716,O
was,5716,O
also,5716,O
studied,5716,O
.,5716,O
The,5717,O
expression,5717,O
of,5717,O
several,5717,O
KATI,5717,B-GENE-Y
mRNAs,5717,O
with,5717,O
different,5717,O
5'UTRs,5717,B-GENE-N
represents,5717,O
an,5717,O
interesting,5717,O
example,5717,O
of,5717,O
transcriptional/translational,5717,O
control,5717,O
on,5717,O
the,5717,O
expression,5717,O
of,5717,O
pyridoxal,5717,B-GENE-N
phosphate,5717,I-GENE-N
(,5717,I-GENE-N
PLP,5717,I-GENE-N
),5717,I-GENE-N
-dependent,5717,I-GENE-N
aminotransferases,5717,I-GENE-N
.,5717,O
Down-regulation,5718,O
of,5718,O
LRRK2,5718,B-GENE-Y
in,5718,O
control,5718,O
and,5718,O
DAT,5718,B-GENE-Y
transfected,5718,O
HEK,5718,O
cells,5718,O
increases,5718,O
manganese-induced,5718,B-CHEMICAL
oxidative,5718,O
stress,5718,O
and,5718,O
cell,5718,O
toxicity,5718,O
.,5718,O
The,5719,O
extra-pyramidal,5719,O
symptoms,5719,O
associated,5719,O
with,5719,O
manganism,5719,B-CHEMICAL
often,5719,O
overlap,5719,O
with,5719,O
that,5719,O
seen,5719,O
in,5719,O
Parkinsonism,5719,O
suggesting,5719,O
a,5719,O
common,5719,O
link,5719,O
between,5719,O
the,5719,O
two,5719,O
disorders,5719,O
.,5719,O
Since,5720,O
wide,5720,O
deviations,5720,O
are,5720,O
observed,5720,O
in,5720,O
susceptibility,5720,O
and,5720,O
characteristics,5720,O
of,5720,O
the,5720,O
symptoms,5720,O
observed,5720,O
in,5720,O
manganism,5720,B-CHEMICAL
",",5720,O
these,5720,O
differences,5720,O
may,5720,O
be,5720,O
due,5720,O
to,5720,O
underlying,5720,O
genetic,5720,O
variability,5720,O
.,5720,O
Genes,5721,O
linked,5721,O
to,5721,O
early,5721,O
onset,5721,O
of,5721,O
Parkinsonism,5721,O
which,5721,O
includes,5721,O
ATP13A2,5721,B-GENE-Y
and,5721,O
parkin,5721,B-GENE-Y
have,5721,O
already,5721,O
been,5721,O
suggested,5721,O
to,5721,O
promote,5721,O
development,5721,O
of,5721,O
Mn,5721,B-CHEMICAL
toxicity,5721,O
.,5721,O
Of,5722,O
the,5722,O
other,5722,O
Parkinson-linked,5722,O
genes,5722,O
",",5722,O
mutations,5722,O
in,5722,O
LRRK2,5722,B-GENE-Y
",",5722,O
an,5722,O
autosomal,5722,O
dominant,5722,O
gene,5722,O
",",5722,O
represent,5722,O
another,5722,O
likely,5722,O
candidate,5722,O
involved,5722,O
in,5722,O
the,5722,O
development,5722,O
of,5722,O
manganism,5722,B-CHEMICAL
.,5722,O
In,5723,O
this,5723,O
paper,5723,O
the,5723,O
effect,5723,O
of,5723,O
shRNA,5723,O
LRRK2,5723,B-GENE-Y
knock-down,5723,O
on,5723,O
Mn,5723,B-CHEMICAL
toxicity,5723,O
was,5723,O
examined,5723,O
in,5723,O
control,5723,O
and,5723,O
DAT,5723,B-GENE-Y
transfected,5723,O
HEK293,5723,O
cells,5723,O
.,5723,O
Results,5724,O
demonstrate,5724,O
that,5724,O
LRRK2,5724,B-GENE-Y
down-regulation,5724,O
potentiates,5724,O
Mn,5724,B-CHEMICAL
toxicity,5724,O
in,5724,O
both,5724,O
control,5724,O
and,5724,O
DAT-transfected,5724,B-GENE-Y
cell,5724,O
as,5724,O
well,5724,O
as,5724,O
potentiates,5724,O
DA,5724,O
toxicity,5724,O
.,5724,O
Combined,5725,O
treatment,5725,O
of,5725,O
Mn,5725,B-CHEMICAL
and,5725,O
DA,5725,O
further,5725,O
augments,5725,O
cell,5725,O
toxicity,5725,O
",",5725,O
ROS,5725,O
production,5725,O
and,5725,O
JNK,5725,B-GENE-N
phosphorylation,5725,O
in,5725,O
LRRK2,5725,B-GENE-Y
deficient,5725,O
cells,5725,O
compared,5725,O
to,5725,O
controls,5725,O
.,5725,O
Consistent,5726,O
with,5726,O
studies,5726,O
demonstrating,5726,O
that,5726,O
LRRK2,5726,B-GENE-N
plays,5726,O
a,5726,O
role,5726,O
in,5726,O
the,5726,O
phosphorylation,5726,O
of,5726,O
p38,5726,B-GENE-N
",",5726,O
our,5726,O
results,5726,O
similarly,5726,O
demonstrate,5726,O
a,5726,O
decrease,5726,O
in,5726,O
p38,5726,B-GENE-N
activation,5726,O
in,5726,O
LRRK2,5726,B-GENE-Y
knock-down,5726,O
cells,5726,O
.,5726,O
Our,5727,O
findings,5727,O
suggest,5727,O
that,5727,O
null,5727,O
mutations,5727,O
in,5727,O
LRRK2,5727,B-GENE-Y
which,5727,O
cause,5727,O
Parkinsonism,5727,O
potentiate,5727,O
Mn,5727,B-CHEMICAL
toxicity,5727,O
and,5727,O
increase,5727,O
susceptibility,5727,O
to,5727,O
develop,5727,O
manganism,5727,B-CHEMICAL
.,5727,O
Swim,5728,O
training,5728,O
of,5728,O
monosodium,5728,B-CHEMICAL
L-glutamate-obese,5728,O
mice,5728,O
improves,5728,O
the,5728,O
impaired,5728,O
insulin,5728,B-GENE-Y
receptor,5728,I-GENE-Y
tyrosine,5728,B-CHEMICAL
phosphorylation,5728,O
in,5728,O
pancreatic,5728,O
islets,5728,O
.,5728,O
The,5729,O
goal,5729,O
of,5729,O
the,5729,O
present,5729,O
study,5729,O
was,5729,O
to,5729,O
investigate,5729,O
changes,5729,O
on,5729,O
glucose,5729,B-CHEMICAL
homoeostasis,5729,O
and,5729,O
of,5729,O
the,5729,O
insulin,5729,B-GENE-Y
receptor,5729,I-GENE-Y
(,5729,O
IR,5729,B-GENE-Y
),5729,O
and,5729,O
insulin,5729,B-GENE-Y
receptor,5729,I-GENE-Y
substrate-1,5729,I-GENE-Y
(,5729,O
IRS-1,5729,B-GENE-Y
),5729,O
signalling,5729,O
in,5729,O
pancreatic,5729,O
islets,5729,O
from,5729,O
MSG-obese,5729,B-CHEMICAL
mice,5729,O
submitted,5729,O
to,5729,O
or,5729,O
not,5729,O
submitted,5729,O
to,5729,O
swim,5729,O
training,5729,O
.,5729,O
Swim,5730,O
training,5730,O
of,5730,O
90-day-old,5730,O
MSG,5730,B-CHEMICAL
mice,5730,O
was,5730,O
used,5730,O
to,5730,O
evaluate,5730,O
whether,5730,O
signalling,5730,O
pathways,5730,O
of,5730,O
the,5730,O
IR,5730,B-GENE-Y
and,5730,O
IRS-1,5730,B-GENE-Y
in,5730,O
islets,5730,O
are,5730,O
involved,5730,O
with,5730,O
the,5730,O
insulin,5730,B-GENE-N
resistance,5730,O
and,5730,O
glucose,5730,B-CHEMICAL
intolerance,5730,O
observed,5730,O
in,5730,O
this,5730,O
obese,5730,O
animal,5730,O
model,5730,O
.,5730,O
The,5731,O
results,5731,O
showed,5731,O
that,5731,O
IR,5731,B-GENE-Y
tyrosine,5731,B-CHEMICAL
phosphorylation,5731,O
(,5731,O
pIR,5731,B-GENE-Y
),5731,O
was,5731,O
reduced,5731,O
by,5731,O
42,5731,O
%,5731,O
in,5731,O
MSG-obese,5731,B-CHEMICAL
mice,5731,O
(,5731,O
MSG,5731,B-CHEMICAL
",",5731,O
6.7,5731,O
±,5731,O
0.2,5731,O
arbitrary,5731,O
units,5731,O
(,5731,O
a.u,5731,O
.,5731,O
),5732,O
;,5732,O
control,5732,O
",",5732,O
11.5,5732,O
±,5732,O
0.4,5732,O
a.u,5732,O
.,5732,O
),5733,O
;,5733,O
on,5733,O
the,5733,O
other,5733,O
hand,5733,O
",",5733,O
exercise,5733,O
training,5733,O
increased,5733,O
pIR,5733,O
by,5733,O
76,5733,O
%,5733,O
in,5733,O
MSG,5733,O
mice,5733,O
without,5733,O
affecting,5733,O
control,5733,O
mice,5733,O
(,5733,I-CHEMICAL
MSG,5733,O
",",5733,O
11.8,5733,O
±,5733,O
0.3,5733,O
;,5733,O
control,5733,O
",",5733,O
12.8,5733,O
±,5733,O
0.2,5733,O
a.u,5733,O
.,5733,O
),5733,O
.,5733,O
Although,5734,O
the,5734,O
treatment,5734,O
with,5734,O
MSG,5734,O
increased,5734,O
IRS-1,5734,O
tyrosine,5734,O
phosphorylation,5734,O
(,5734,I-GENE-Y
pIRS-1,5734,O
),5734,O
by,5734,O
96,5734,O
%,5734,O
(,5734,I-CHEMICAL
MSG,5734,O
",",5734,O
17.02,5734,O
±,5734,O
0.6,5734,O
;,5734,O
control,5734,O
",",5734,O
8.7,5734,O
±,5734,O
0.2,5734,O
a.u,5734,O
.,5734,O
),5735,O
",",5735,O
exercise,5735,O
training,5735,O
also,5735,O
increased,5735,O
it,5735,O
in,5735,O
both,5735,O
groups,5735,O
(,5735,O
control,5735,O
",",5735,O
13.6,5735,O
±,5735,O
0.1,5735,O
;,5735,I-CHEMICAL
MSG,5735,O
",",5735,O
22.2,5735,O
±,5735,O
1.1,5735,O
a.u,5735,O
.,5735,O
),5735,O
.,5735,O
Current,5736,O
research,5736,O
shows,5736,O
that,5736,O
the,5736,O
practice,5736,O
of,5736,O
swim,5736,O
training,5736,O
increases,5736,O
the,5736,O
tyrosine,5736,O
phosphorylation,5736,O
of,5736,B-GENE-Y
IRS-1,5736,O
which,5736,O
can,5736,O
modulate,5736,O
the,5736,O
effect,5736,O
caused,5736,O
by,5736,O
obesity,5736,O
in,5736,B-GENE-Y
insulin,5736,I-GENE-Y
receptors,5736,O
.,5736,O
Long-term,5737,O
use,5737,O
of,5737,O
sildenafil,5737,B-CHEMICAL
.,5737,O
The,5738,O
treatment,5738,O
of,5738,O
erectile,5738,O
dysfunction,5738,O
(,5738,O
ED,5738,O
),5738,O
has,5738,O
been,5738,O
revolutionised,5738,O
by,5738,O
new,5738,O
agents,5738,O
to,5738,O
inhibit,5738,O
the,5738,O
enzyme,5738,O
PDE5,5738,B-GENE-Y
.,5738,O
The,5739,O
scientific,5739,O
basis,5739,O
of,5739,O
this,5739,O
treatment,5739,O
of,5739,O
ED,5739,O
includes,5739,O
relaxation,5739,O
of,5739,O
the,5739,O
corpus,5739,O
cavernosum,5739,O
smooth,5739,O
muscle,5739,O
tissue,5739,O
by,5739,O
inhibition,5739,O
of,5739,O
PDE5,5739,B-GENE-Y
that,5739,O
breaks,5739,O
down,5739,O
cGMP,5739,B-CHEMICAL
",",5739,O
the,5739,O
key,5739,O
pathway,5739,O
for,5739,O
the,5739,O
production,5739,O
of,5739,O
erectile,5739,O
function,5739,O
in,5739,O
humans,5739,O
.,5739,O
Many,5740,O
clinical,5740,O
studies,5740,O
",",5740,O
both,5740,O
pre-,5740,O
and,5740,O
post-marketing,5740,O
",",5740,O
have,5740,O
demonstrated,5740,O
the,5740,O
clinical,5740,O
efficacy,5740,O
and,5740,O
safety,5740,O
of,5740,O
sildenafil,5740,B-CHEMICAL
(,5740,O
Viagra,5740,B-CHEMICAL
",",5740,O
Pfizer,5740,O
),5740,O
-,5740,O
the,5740,O
first,5740,O
approved,5740,O
selective,5740,O
PDE,5740,B-GENE-N
inhibitor,5740,O
for,5740,O
the,5740,O
treatment,5740,O
of,5740,O
ED,5740,O
.,5740,O
Sildenafil,5741,B-CHEMICAL
is,5741,O
inhibitory,5741,O
of,5741,O
PDE5,5741,B-GENE-Y
at,5741,O
a,5741,O
rate,5741,O
tenfold,5741,O
higher,5741,O
than,5741,O
for,5741,O
the,5741,O
next,5741,O
PDE,5741,B-GENE-N
(,5741,O
PDE6,5741,B-GENE-N
),5741,O
",",5741,O
which,5741,O
produces,5741,O
visual,5741,O
changes,5741,O
through,5741,O
the,5741,O
retinal,5741,O
rods,5741,O
.,5741,O
Its,5742,O
clinical,5742,O
effectiveness,5742,O
has,5742,O
been,5742,O
well,5742,O
documented,5742,O
in,5742,O
the,5742,O
majority,5742,O
of,5742,O
men,5742,O
with,5742,O
ED,5742,O
irrespective,5742,O
of,5742,O
aetiology,5742,O
.,5742,O
The,5743,O
aetiology,5743,O
of,5743,O
ED,5743,O
",",5743,O
also,5743,O
",",5743,O
does,5743,O
not,5743,O
appear,5743,O
to,5743,O
effect,5743,O
the,5743,O
function,5743,O
of,5743,O
sildenafil,5743,B-CHEMICAL
in,5743,O
relaxing,5743,O
corpus,5743,O
cavernosum,5743,O
smooth,5743,O
muscle,5743,O
tissue,5743,O
.,5743,O
Adverse,5744,O
events,5744,O
are,5744,O
usually,5744,O
associated,5744,O
with,5744,O
the,5744,O
vascular,5744,O
changes,5744,O
from,5744,O
PDE5,5744,B-GENE-Y
inhibition,5744,O
.,5744,O
These,5745,O
include,5745,O
headache,5745,O
and,5745,O
flushing,5745,O
.,5745,O
Each,5746,O
of,5746,O
these,5746,O
adverse,5746,O
events,5746,O
",",5746,O
however,5746,O
",",5746,O
declines,5746,O
with,5746,O
medication,5746,O
use,5746,O
.,5746,O
With,5747,O
the,5747,O
use,5747,O
of,5747,O
sildenafil,5747,B-CHEMICAL
",",5747,O
it,5747,O
has,5747,O
been,5747,O
clearly,5747,O
",",5747,O
clinically,5747,O
demonstrated,5747,O
that,5747,O
the,5747,O
selective,5747,O
inhibition,5747,O
of,5747,O
PDE5,5747,B-GENE-Y
is,5747,O
an,5747,O
appropriate,5747,O
",",5747,O
effective,5747,O
",",5747,O
safe,5747,O
method,5747,O
for,5747,O
the,5747,O
treatment,5747,O
of,5747,O
ED,5747,O
of,5747,O
all,5747,O
aetiologies,5747,O
and,5747,O
severities,5747,O
.,5747,O
Cytosolic,5748,B-GENE-Y
aspartate,5748,I-GENE-Y
aminotransferase,5748,I-GENE-Y
",",5748,O
a,5748,O
new,5748,O
partner,5748,O
in,5748,O
adipocyte,5748,O
glyceroneogenesis,5748,O
and,5748,O
an,5748,O
atypical,5748,O
target,5748,O
of,5748,O
thiazolidinedione,5748,B-CHEMICAL
.,5748,O
We,5749,O
show,5749,O
that,5749,O
cytosolic,5749,B-GENE-Y
aspartate,5749,I-GENE-Y
aminotransferase,5749,I-GENE-Y
(,5749,O
cAspAT,5749,B-GENE-Y
),5749,O
is,5749,O
involved,5749,O
in,5749,O
adipocyte,5749,O
glyceroneogenesis,5749,O
",",5749,O
a,5749,O
regulated,5749,O
pathway,5749,O
that,5749,O
controls,5749,O
fatty,5749,B-CHEMICAL
acid,5749,I-CHEMICAL
homeostasis,5749,O
by,5749,O
promoting,5749,O
glycerol,5749,B-CHEMICAL
3-phosphate,5749,I-CHEMICAL
formation,5749,O
for,5749,O
fatty,5749,B-CHEMICAL
acid,5749,I-CHEMICAL
re-esterification,5749,O
during,5749,O
fasting,5749,O
.,5749,O
cAspAT,5750,B-GENE-Y
activity,5750,O
",",5750,O
as,5750,O
well,5750,O
as,5750,O
the,5750,O
incorporation,5750,O
of,5750,O
[,5750,B-CHEMICAL
(,5750,I-CHEMICAL
14,5750,I-CHEMICAL
),5750,I-CHEMICAL
C,5750,I-CHEMICAL
],5750,I-CHEMICAL
aspartate,5750,I-CHEMICAL
into,5750,O
the,5750,O
neutral,5750,O
lipid,5750,O
fraction,5750,O
of,5750,O
3T3-F442A,5750,O
adipocytes,5750,O
was,5750,O
stimulated,5750,O
by,5750,O
the,5750,O
thiazolidinedione,5750,B-CHEMICAL
(,5750,O
TZD,5750,B-CHEMICAL
),5750,O
rosiglitazone,5750,B-CHEMICAL
.,5750,O
Conversely,5751,O
",",5751,O
the,5751,O
ratio,5751,O
of,5751,O
fatty,5751,B-CHEMICAL
acid,5751,I-CHEMICAL
to,5751,O
glycerol,5751,B-CHEMICAL
released,5751,O
into,5751,O
the,5751,O
medium,5751,O
decreased,5751,O
.,5751,O
Regulation,5752,O
of,5752,O
cAspAT,5752,B-GENE-Y
gene,5752,O
expression,5752,O
was,5752,O
specific,5752,O
to,5752,O
differentiated,5752,O
adipocytes,5752,O
and,5752,O
did,5752,O
not,5752,O
require,5752,O
any,5752,O
peroxisome,5752,B-GENE-Y
proliferator-activated,5752,I-GENE-Y
receptor,5752,I-GENE-Y
gamma,5752,I-GENE-Y
(,5752,O
PPARgamma,5752,B-GENE-Y
),5752,O
/retinoid,5752,O
X,5752,I-GENE-Y
receptor-alpha,5752,I-GENE-Y
direct,5752,O
binding,5752,O
.,5752,O
Nevertheless,5753,O
",",5753,O
PPARgamma,5753,B-GENE-Y
is,5753,O
indirectly,5753,O
necessary,5753,O
for,5753,O
both,5753,O
cAspAT,5753,B-GENE-Y
basal,5753,O
expression,5753,O
and,5753,O
TZD,5753,B-CHEMICAL
responsiveness,5753,O
because,5753,O
they,5753,O
are,5753,O
",",5753,O
respectively,5753,O
",",5753,O
diminished,5753,O
and,5753,O
abolished,5753,O
by,5753,O
ectopic,5753,O
overexpression,5753,O
of,5753,O
a,5753,O
dominant,5753,O
negative,5753,O
PPARgamma,5753,B-GENE-Y
.,5753,O
The,5754,O
cAspAT,5754,B-GENE-Y
TZD-responsive,5754,B-CHEMICAL
site,5754,O
was,5754,O
restricted,5754,O
to,5754,O
a,5754,O
single,5754,O
AGGACA,5754,B-CHEMICAL
hexanucleotide,5754,B-CHEMICAL
located,5754,O
at,5754,O
-381,5754,O
to,5754,O
-376,5754,O
bp,5754,O
whose,5754,O
mutation,5754,O
impaired,5754,O
the,5754,O
specific,5754,O
RORalpha,5754,B-GENE-Y
binding,5754,O
.,5754,O
RORalpha,5755,B-GENE-Y
ectopic,5755,O
expression,5755,O
activated,5755,O
the,5755,O
cAspAT,5755,B-GENE-Y
gene,5755,O
transcription,5755,O
in,5755,O
absence,5755,O
of,5755,O
rosiglitazone,5755,B-CHEMICAL
",",5755,O
and,5755,O
its,5755,O
protein,5755,O
amount,5755,O
in,5755,O
nuclear,5755,O
extracts,5755,O
is,5755,O
1.8-fold,5755,O
increased,5755,O
by,5755,O
rosiglitazone,5755,B-CHEMICAL
treatment,5755,O
of,5755,O
adipocytes,5755,O
.,5755,O
Finally,5756,O
",",5756,O
the,5756,O
amounts,5756,O
of,5756,O
RORalpha,5756,B-GENE-Y
and,5756,O
cAspAT,5756,B-GENE-Y
mRNAs,5756,O
were,5756,O
similarly,5756,O
increased,5756,O
by,5756,O
TZD,5756,B-CHEMICAL
treatment,5756,O
of,5756,O
human,5756,O
adipose,5756,O
tissue,5756,O
explants,5756,O
",",5756,O
confirming,5756,O
coordinated,5756,O
regulation,5756,O
.,5756,O
Our,5757,O
data,5757,O
identify,5757,O
cAspAT,5757,B-GENE-Y
as,5757,O
a,5757,O
new,5757,O
member,5757,O
of,5757,O
glyceroneogenesis,5757,O
",",5757,O
transcriptionally,5757,O
regulated,5757,O
by,5757,O
TZD,5757,B-CHEMICAL
via,5757,O
the,5757,O
control,5757,O
of,5757,O
RORalpha,5757,B-GENE-Y
expression,5757,O
by,5757,O
PPARgamma,5757,B-GENE-Y
in,5757,O
adipocytes,5757,O
.,5757,O
ABT-199,5758,B-CHEMICAL
",",5758,O
a,5758,O
potent,5758,O
and,5758,O
selective,5758,O
BCL-2,5758,B-GENE-Y
inhibitor,5758,O
",",5758,O
achieves,5758,O
antitumor,5758,O
activity,5758,O
while,5758,O
sparing,5758,O
platelets,5758,O
.,5758,O
Proteins,5759,O
in,5759,O
the,5759,O
B,5759,B-GENE-Y
cell,5759,I-GENE-Y
CLL/lymphoma,5759,I-GENE-Y
2,5759,I-GENE-Y
(,5759,O
BCL-2,5759,B-GENE-Y
),5759,O
family,5759,O
are,5759,O
key,5759,O
regulators,5759,O
of,5759,O
the,5759,O
apoptotic,5759,O
process,5759,O
.,5759,O
This,5760,O
family,5760,O
comprises,5760,O
proapoptotic,5760,O
and,5760,O
prosurvival,5760,O
proteins,5760,O
",",5760,O
and,5760,O
shifting,5760,O
the,5760,O
balance,5760,O
toward,5760,O
the,5760,O
latter,5760,O
is,5760,O
an,5760,O
established,5760,O
mechanism,5760,O
whereby,5760,O
cancer,5760,O
cells,5760,O
evade,5760,O
apoptosis,5760,O
.,5760,O
The,5761,O
therapeutic,5761,O
potential,5761,O
of,5761,O
directly,5761,O
inhibiting,5761,O
prosurvival,5761,O
proteins,5761,O
was,5761,O
unveiled,5761,O
with,5761,O
the,5761,O
development,5761,O
of,5761,O
navitoclax,5761,B-CHEMICAL
",",5761,O
a,5761,O
selective,5761,O
inhibitor,5761,O
of,5761,O
both,5761,O
BCL-2,5761,B-GENE-Y
and,5761,O
BCL-2-like,5761,B-GENE-Y
1,5761,I-GENE-Y
(,5761,O
BCL-X,5761,B-GENE-Y
(,5761,I-GENE-Y
L,5761,I-GENE-Y
),5761,I-GENE-Y
),5761,O
",",5761,O
which,5761,O
has,5761,O
shown,5761,O
clinical,5761,O
efficacy,5761,O
in,5761,O
some,5761,O
BCL-2-dependent,5761,B-GENE-Y
hematological,5761,O
cancers,5761,O
.,5761,O
However,5762,O
",",5762,O
concomitant,5762,O
on-target,5762,O
thrombocytopenia,5762,O
caused,5762,O
by,5762,O
BCL-X,5762,B-GENE-Y
(,5762,I-GENE-Y
L,5762,I-GENE-Y
),5762,I-GENE-Y
inhibition,5762,O
limits,5762,O
the,5762,O
efficacy,5762,O
achievable,5762,O
with,5762,O
this,5762,O
agent,5762,O
.,5762,O
Here,5763,O
we,5763,O
report,5763,O
the,5763,O
re-engineering,5763,O
of,5763,O
navitoclax,5763,B-CHEMICAL
to,5763,O
create,5763,O
a,5763,O
highly,5763,O
potent,5763,O
",",5763,O
orally,5763,O
bioavailable,5763,O
and,5763,O
BCL-2-selective,5763,B-GENE-Y
inhibitor,5763,O
",",5763,O
ABT-199,5763,B-CHEMICAL
.,5763,O
This,5764,O
compound,5764,O
inhibits,5764,O
the,5764,O
growth,5764,O
of,5764,O
BCL-2-dependent,5764,B-GENE-Y
tumors,5764,O
in,5764,O
vivo,5764,O
and,5764,O
spares,5764,O
human,5764,O
platelets,5764,O
.,5764,O
A,5765,O
single,5765,O
dose,5765,O
of,5765,O
ABT-199,5765,B-CHEMICAL
in,5765,O
three,5765,O
patients,5765,O
with,5765,O
refractory,5765,O
chronic,5765,O
lymphocytic,5765,O
leukemia,5765,O
resulted,5765,O
in,5765,O
tumor,5765,O
lysis,5765,O
within,5765,O
24,5765,O
h.,5765,O
These,5765,O
data,5765,O
indicate,5765,O
that,5765,O
selective,5765,O
pharmacological,5765,O
inhibition,5765,O
of,5765,O
BCL-2,5765,B-GENE-Y
shows,5765,O
promise,5765,O
for,5765,O
the,5765,O
treatment,5765,O
of,5765,O
BCL-2-dependent,5765,B-GENE-Y
hematological,5765,O
cancers,5765,O
.,5765,O
Smad3,5766,B-GENE-Y
mediates,5766,O
cigarette,5766,O
smoke,5766,O
extract,5766,O
(,5766,O
CSE,5766,O
),5766,O
induction,5766,O
of,5766,O
VEGF,5766,B-GENE-Y
release,5766,O
by,5766,O
human,5766,O
fetal,5766,O
lung,5766,O
fibroblasts,5766,O
.,5766,O
Cigarette,5767,O
smoke,5767,O
is,5767,O
the,5767,O
major,5767,O
cause,5767,O
of,5767,O
chronic,5767,O
obstructive,5767,O
pulmonary,5767,O
disease,5767,O
(,5767,O
COPD,5767,O
),5767,O
",",5767,O
yet,5767,O
pathogenic,5767,O
mechanisms,5767,O
are,5767,O
not,5767,O
fully,5767,O
understood,5767,O
.,5767,O
Vascular,5768,B-GENE-Y
endothelial,5768,I-GENE-Y
growth,5768,I-GENE-Y
factor,5768,I-GENE-Y
(,5768,O
VEGF,5768,B-GENE-Y
),5768,O
is,5768,O
one,5768,O
of,5768,O
the,5768,O
major,5768,O
regulators,5768,O
of,5768,O
endothelial,5768,O
cell,5768,O
survival,5768,O
and,5768,O
is,5768,O
believed,5768,O
to,5768,O
play,5768,O
a,5768,O
role,5768,O
in,5768,O
the,5768,O
pathogenesis,5768,O
of,5768,O
COPD,5768,O
.,5768,O
Fibroblasts,5769,O
are,5769,O
a,5769,O
significant,5769,O
source,5769,O
of,5769,O
VEGF,5769,B-GENE-Y
in,5769,O
the,5769,O
lungs,5769,O
;,5769,O
however,5769,O
the,5769,O
effect,5769,O
of,5769,O
cigarette,5769,O
smoke,5769,O
exposure,5769,O
on,5769,O
VEGF,5769,B-GENE-Y
release,5769,O
by,5769,O
fibroblasts,5769,O
is,5769,O
not,5769,O
fully,5769,O
understood,5769,O
.,5769,O
We,5770,O
hypothesized,5770,O
that,5770,O
cigarette,5770,O
smoke-induced,5770,O
disturbed,5770,O
VEGF,5770,B-GENE-Y
release,5770,O
by,5770,O
human,5770,O
lung,5770,O
fibroblasts,5770,O
is,5770,O
a,5770,O
potential,5770,O
pathogenic,5770,O
mechanism,5770,O
that,5770,O
could,5770,O
contribute,5770,O
to,5770,O
COPD,5770,O
.,5770,O
Cigarette,5771,O
smoke,5771,O
extract,5771,O
(,5771,O
CSE,5771,O
),5771,O
was,5771,O
prepared,5771,O
by,5771,O
modification,5771,O
of,5771,O
the,5771,O
methods,5771,O
of,5771,O
Carp,5771,O
and,5771,O
Janoff,5771,O
(,5771,O
American,5771,O
Review,5771,O
of,5771,O
Respiratory,5771,O
Disease,5771,O
",",5771,O
1978,5771,O
),5771,O
.,5771,O
Human,5772,O
fetal,5772,O
lung,5772,O
fibroblasts,5772,O
(,5772,O
HFL-1,5772,O
),5772,O
were,5772,O
exposed,5772,O
to,5772,O
different,5772,O
concentrations,5772,O
of,5772,O
CSE,5772,O
and,5772,O
for,5772,O
different,5772,O
durations,5772,O
.,5772,O
VEGF,5773,B-GENE-Y
release,5773,O
into,5773,O
the,5773,O
media,5773,O
was,5773,O
measured,5773,O
using,5773,O
ELISA,5773,O
.,5773,O
TGF-β1,5774,B-GENE-Y
receptor,5774,I-GENE-Y
(,5774,O
TβR1,5774,B-GENE-Y
),5774,O
/Smad3,5774,O
as,5774,O
a,5774,O
potential,5774,O
pathway,5774,O
for,5774,O
CSE,5774,O
modulated,5774,O
VEGF,5774,B-GENE-Y
release,5774,O
was,5774,O
also,5774,O
investigated,5774,O
using,5774,O
biochemical,5774,O
analyses,5774,O
and,5774,O
siRNA,5774,O
inhibition,5774,O
of,5774,O
Smad3,5774,B-GENE-Y
and,5774,O
siRNA,5774,O
and,5774,O
pharmacologic,5774,O
inhibition,5774,O
of,5774,O
TβR1,5774,B-GENE-Y
.,5774,O
CSE,5775,O
induced,5775,O
VEGF,5775,B-GENE-Y
release,5775,O
by,5775,O
HFL-1,5775,O
in,5775,O
concentration,5775,O
and,5775,O
time,5775,O
dependent,5775,O
manner,5775,O
.,5775,O
This,5776,O
was,5776,O
confirmed,5776,O
in,5776,O
two,5776,O
additional,5776,O
types,5776,O
of,5776,O
primary,5776,O
human,5776,O
fetal,5776,O
lung,5776,O
fibroblasts,5776,O
.,5776,O
CSE,5777,O
induced,5777,O
Smad3,5777,B-GENE-Y
phosphorylation,5777,O
and,5777,O
nuclear,5777,O
translocation,5777,O
in,5777,O
HFL-1,5777,O
cells,5777,O
.,5777,O
Silencing,5778,O
of,5778,O
Smad3,5778,B-GENE-Y
by,5778,O
siRNA,5778,O
not,5778,O
only,5778,O
eliminated,5778,O
the,5778,O
stimulatory,5778,O
effect,5778,O
of,5778,O
CSE,5778,O
on,5778,O
VEGF,5778,B-GENE-Y
release,5778,O
but,5778,O
also,5778,O
inhibited,5778,O
baseline,5778,O
VEGF,5778,B-GENE-Y
production,5778,O
.,5778,O
Suppression,5779,O
of,5779,O
TβR1,5779,B-GENE-Y
by,5779,O
the,5779,O
pharmacological,5779,O
inhibitor,5779,O
(,5779,O
SB431542,5779,B-CHEMICAL
),5779,O
markedly,5779,O
reduced,5779,O
VEGF,5779,B-GENE-Y
release,5779,O
by,5779,O
HFL-1,5779,O
in,5779,O
response,5779,O
to,5779,O
CSE,5779,O
and,5779,O
this,5779,O
effect,5779,O
was,5779,O
confirmed,5779,O
by,5779,O
TβR1,5779,B-GENE-Y
siRNA,5779,O
.,5779,O
In,5780,O
contrast,5780,O
",",5780,O
nicotine,5780,O
inhibited,5780,O
VEGF,5780,B-GENE-Y
release,5780,O
by,5780,O
HFL-1,5780,O
in,5780,O
a,5780,O
dose,5780,O
and,5780,O
time,5780,O
dependent,5780,O
manner,5780,O
.,5780,O
Our,5781,O
findings,5781,O
indicate,5781,O
that,5781,O
CSE,5781,O
stimulates,5781,O
Smad3-mediated,5781,B-GENE-Y
VEGF,5781,B-GENE-Y
release,5781,O
by,5781,O
lung,5781,O
fibroblasts,5781,O
.,5781,O
Nicotine,5782,B-CHEMICAL
does,5782,O
not,5782,O
account,5782,O
for,5782,O
the,5782,O
CSE,5782,O
stimulation,5782,O
of,5782,O
VEGF,5782,B-GENE-Y
in,5782,O
HFL-1,5782,O
.,5782,O
The,5783,O
ability,5783,O
of,5783,O
lung,5783,O
fibroblasts,5783,O
to,5783,O
produce,5783,O
VEGF,5783,B-GENE-Y
may,5783,O
play,5783,O
a,5783,O
role,5783,O
in,5783,O
pathogenesis,5783,O
of,5783,O
cigarette,5783,O
smoke,5783,O
induced,5783,O
lung,5783,O
disease,5783,O
.,5783,O
A,5784,O
novel,5784,O
metabotropic,5784,B-GENE-Y
glutamate,5784,I-GENE-Y
receptor,5784,I-GENE-Y
5,5784,I-GENE-Y
positive,5784,O
allosteric,5784,O
modulator,5784,O
acts,5784,O
at,5784,O
a,5784,O
unique,5784,O
site,5784,O
and,5784,O
confers,5784,O
stimulus,5784,O
bias,5784,O
to,5784,O
mGlu5,5784,B-GENE-Y
signaling,5784,O
.,5784,O
Metabotropic,5785,B-GENE-Y
glutamate,5785,I-GENE-Y
receptor,5785,I-GENE-Y
5,5785,I-GENE-Y
(,5785,O
mGlu5,5785,B-GENE-Y
),5785,O
is,5785,O
a,5785,O
target,5785,O
for,5785,O
the,5785,O
treatment,5785,O
of,5785,O
central,5785,O
nervous,5785,O
system,5785,O
(,5785,O
CNS,5785,O
),5785,O
disorders,5785,O
",",5785,O
such,5785,O
as,5785,O
schizophrenia,5785,O
and,5785,O
Alzheimer,5785,O
's,5785,O
disease,5785,O
.,5785,O
Furthermore,5786,O
",",5786,O
mGlu5,5786,B-GENE-Y
has,5786,O
been,5786,O
shown,5786,O
to,5786,O
play,5786,O
an,5786,O
important,5786,O
role,5786,O
in,5786,O
hippocampal,5786,O
synaptic,5786,O
plasticity,5786,O
",",5786,O
specifically,5786,O
in,5786,O
long-term,5786,O
depression,5786,O
(,5786,O
LTD,5786,O
),5786,O
and,5786,O
long-term,5786,O
potentiation,5786,O
(,5786,O
LTP,5786,O
),5786,O
",",5786,O
which,5786,O
is,5786,O
thought,5786,O
to,5786,O
be,5786,O
involved,5786,O
in,5786,O
cognition,5786,O
.,5786,O
Multiple,5787,O
mGlu5-positive,5787,B-GENE-Y
allosteric,5787,O
modulators,5787,O
(,5787,O
PAMs,5787,O
),5787,O
have,5787,O
been,5787,O
developed,5787,O
from,5787,O
a,5787,O
variety,5787,O
of,5787,O
different,5787,O
scaffolds,5787,O
.,5787,O
Previous,5788,O
work,5788,O
has,5788,O
extensively,5788,O
characterized,5788,O
a,5788,O
common,5788,O
allosteric,5788,O
site,5788,O
on,5788,O
mGlu5,5788,B-GENE-Y
",",5788,O
termed,5788,O
the,5788,O
MPEP,5788,B-CHEMICAL
(,5788,O
2-Methyl-6-,5788,B-CHEMICAL
(,5788,I-CHEMICAL
phenylethynyl,5788,I-CHEMICAL
),5788,I-CHEMICAL
pyridine,5788,I-CHEMICAL
),5788,O
binding,5788,O
site,5788,O
.,5788,O
However,5789,O
",",5789,O
one,5789,O
mGlu5,5789,B-GENE-Y
PAM,5789,O
",",5789,O
CPPHA,5789,B-CHEMICAL
(,5789,O
N-,5789,B-CHEMICAL
(,5789,I-CHEMICAL
4-chloro-2-,5789,I-CHEMICAL
[,5789,I-CHEMICAL
(,5789,I-CHEMICAL
"1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl",5789,I-CHEMICAL
),5789,I-CHEMICAL
methyl,5789,I-CHEMICAL
],5789,I-CHEMICAL
phenyl,5789,I-CHEMICAL
),5789,I-CHEMICAL
-2-hydroxybenzamide,5789,I-CHEMICAL
),5789,O
",",5789,O
interacts,5789,O
with,5789,O
a,5789,O
separate,5789,O
allosteric,5789,O
site,5789,O
on,5789,O
mGlu5,5789,B-GENE-Y
.,5789,O
Using,5790,O
cell-based,5790,O
assays,5790,O
and,5790,O
brain,5790,O
slice,5790,O
preparations,5790,O
",",5790,O
we,5790,O
characterized,5790,O
the,5790,O
interaction,5790,O
of,5790,O
a,5790,O
potent,5790,O
and,5790,O
efficacious,5790,O
mGlu5,5790,B-GENE-Y
PAM,5790,O
from,5790,O
the,5790,O
CPPHA,5790,B-CHEMICAL
series,5790,O
termed,5790,O
NCFP,5790,B-CHEMICAL
(,5790,O
N-,5790,B-CHEMICAL
(,5790,I-CHEMICAL
4-chloro-2-,5790,I-CHEMICAL
(,5790,I-CHEMICAL
(,5790,I-CHEMICAL
"4-fluoro-1,3-dioxoisoindolin-2-yl",5790,I-CHEMICAL
),5790,I-CHEMICAL
methyl,5790,I-CHEMICAL
),5790,I-CHEMICAL
phenyl,5790,I-CHEMICAL
),5790,I-CHEMICAL
picolinamide,5790,I-CHEMICAL
),5790,O
.,5790,O
NCFP,5791,B-CHEMICAL
binds,5791,O
to,5791,O
the,5791,O
CPPHA,5791,B-CHEMICAL
site,5791,O
on,5791,O
mGlu5,5791,B-GENE-Y
and,5791,O
potentiates,5791,O
mGlu5-mediated,5791,B-GENE-Y
responses,5791,O
in,5791,O
both,5791,O
recombinant,5791,O
and,5791,O
native,5791,O
systems,5791,O
.,5791,O
However,5792,O
",",5792,O
NCFP,5792,B-CHEMICAL
provides,5792,O
greater,5792,O
mGlu5,5792,B-GENE-Y
subtype,5792,O
selectivity,5792,O
than,5792,O
does,5792,O
CPPHA,5792,B-CHEMICAL
",",5792,O
making,5792,O
it,5792,O
more,5792,O
suitable,5792,O
for,5792,O
studies,5792,O
of,5792,O
effects,5792,O
on,5792,O
mGlu5,5792,B-GENE-Y
in,5792,O
CNS,5792,O
preparations,5792,O
.,5792,O
Of,5793,O
interest,5793,O
",",5793,O
NCFP,5793,B-CHEMICAL
does,5793,O
not,5793,O
potentiate,5793,O
responses,5793,O
involved,5793,O
in,5793,O
hippocampal,5793,O
synaptic,5793,O
plasticity,5793,O
(,5793,O
LTD/LTP,5793,O
),5793,O
",",5793,O
setting,5793,O
it,5793,O
apart,5793,O
from,5793,O
other,5793,O
previously,5793,O
characterized,5793,O
MPEP,5793,B-CHEMICAL
site,5793,O
PAMs,5793,O
.,5793,O
This,5794,O
suggests,5794,O
that,5794,O
although,5794,O
mGlu5,5794,B-GENE-Y
PAMs,5794,O
may,5794,O
have,5794,O
similar,5794,O
responses,5794,O
in,5794,O
some,5794,O
systems,5794,O
",",5794,O
they,5794,O
can,5794,O
induce,5794,O
differential,5794,O
effects,5794,O
on,5794,O
mGlu5-mediated,5794,B-GENE-Y
physiologic,5794,O
responses,5794,O
in,5794,O
the,5794,O
CNS,5794,O
.,5794,O
Such,5795,O
stimulus,5795,O
bias,5795,O
by,5795,O
mGlu5,5795,B-GENE-Y
PAMs,5795,O
may,5795,O
complicate,5795,O
drug,5795,O
discovery,5795,O
efforts,5795,O
but,5795,O
would,5795,O
also,5795,O
allow,5795,O
for,5795,O
specifically,5795,O
tailored,5795,O
therapies,5795,O
",",5795,O
if,5795,O
pharmacological,5795,O
biases,5795,O
can,5795,O
be,5795,O
attributed,5795,O
to,5795,O
different,5795,O
therapeutic,5795,O
outcomes,5795,O
.,5795,O
G,5796,B-GENE-N
protein-coupled,5796,I-GENE-N
receptors,5796,I-GENE-N
as,5796,O
direct,5796,O
targets,5796,O
of,5796,O
inhaled,5796,O
anesthetics,5796,O
.,5796,O
The,5797,O
molecular,5797,O
pharmacology,5797,O
of,5797,O
inhalational,5797,O
anesthetics,5797,O
remains,5797,O
poorly,5797,O
understood,5797,O
.,5797,O
Despite,5798,O
accumulating,5798,O
evidence,5798,O
suggesting,5798,O
that,5798,O
neuronal,5798,O
membrane,5798,O
proteins,5798,O
are,5798,O
potential,5798,O
targets,5798,O
of,5798,O
inhaled,5798,O
anesthetics,5798,O
",",5798,O
most,5798,O
currently,5798,O
favored,5798,O
membrane,5798,O
protein,5798,O
targets,5798,O
lack,5798,O
any,5798,O
direct,5798,O
evidence,5798,O
for,5798,O
anesthetic,5798,O
binding,5798,O
.,5798,O
We,5799,O
report,5799,O
herein,5799,O
the,5799,O
location,5799,O
of,5799,O
the,5799,O
binding,5799,O
site,5799,O
for,5799,O
the,5799,O
inhaled,5799,O
anesthetic,5799,O
halothane,5799,B-CHEMICAL
at,5799,O
the,5799,O
amino,5799,B-CHEMICAL
acid,5799,I-CHEMICAL
residue,5799,O
level,5799,O
of,5799,O
resolution,5799,O
in,5799,O
the,5799,O
ligand,5799,O
binding,5799,O
cavity,5799,O
in,5799,O
a,5799,O
prototypical,5799,O
G,5799,B-GENE-N
protein-coupled,5799,I-GENE-N
receptor,5799,I-GENE-N
",",5799,O
bovine,5799,B-GENE-Y
rhodopsin,5799,I-GENE-Y
.,5799,O
Tryptophan,5800,B-CHEMICAL
fluorescence,5800,O
quenching,5800,O
and,5800,O
direct,5800,O
photoaffinity,5800,O
labeling,5800,O
with,5800,O
[,5800,B-CHEMICAL
(,5800,I-CHEMICAL
14,5800,I-CHEMICAL
),5800,I-CHEMICAL
C,5800,I-CHEMICAL
],5800,I-CHEMICAL
halothane,5800,I-CHEMICAL
suggested,5800,O
an,5800,O
interhelical,5800,O
location,5800,O
of,5800,O
halothane,5800,B-CHEMICAL
with,5800,O
a,5800,O
stoichiometry,5800,O
of,5800,O
1,5800,O
(,5800,O
halothane/rhodopsin,5800,B-CHEMICAL
molar,5800,O
ratio,5800,O
),5800,O
.,5800,O
Radiosequence,5801,O
analysis,5801,O
of,5801,O
[,5801,B-CHEMICAL
(,5801,I-CHEMICAL
14,5801,I-CHEMICAL
),5801,I-CHEMICAL
C,5801,I-CHEMICAL
],5801,I-CHEMICAL
halothane-labeled,5801,O
rhodopsin,5801,B-GENE-Y
revealed,5801,O
that,5801,O
halothane,5801,B-CHEMICAL
contacts,5801,O
an,5801,O
amino,5801,B-CHEMICAL
acid,5801,I-CHEMICAL
residue,5801,O
(,5801,O
Trp265,5801,O
),5801,O
lining,5801,O
the,5801,O
ligand,5801,O
binding,5801,O
cavity,5801,O
in,5801,O
the,5801,O
transmembrane,5801,O
core,5801,O
of,5801,O
the,5801,O
receptor,5801,O
.,5801,O
The,5802,O
predicted,5802,O
functional,5802,O
consequence,5802,O
",",5802,O
competition,5802,O
between,5802,O
halothane,5802,B-CHEMICAL
and,5802,O
the,5802,O
ligand,5802,O
retinal,5802,O
",",5802,O
was,5802,O
shown,5802,O
here,5802,O
by,5802,O
spectroscopy,5802,O
and,5802,O
is,5802,O
known,5802,O
to,5802,O
exist,5802,O
in,5802,O
vivo,5802,O
.,5802,O
These,5803,O
data,5803,O
suggest,5803,O
that,5803,O
competition,5803,O
with,5803,O
endogenous,5803,O
ligands,5803,O
may,5803,O
be,5803,O
a,5803,O
general,5803,O
mechanism,5803,O
of,5803,O
the,5803,O
action,5803,O
of,5803,O
halothane,5803,B-CHEMICAL
at,5803,O
this,5803,O
large,5803,O
family,5803,O
of,5803,O
signaling,5803,O
proteins,5803,O
.,5803,O
Effects,5804,O
of,5804,O
venlafaxine,5804,B-CHEMICAL
on,5804,O
extracellular,5804,O
concentrations,5804,O
of,5804,O
5-HT,5804,B-CHEMICAL
and,5804,O
noradrenaline,5804,B-CHEMICAL
in,5804,O
the,5804,O
rat,5804,O
frontal,5804,O
cortex,5804,O
:,5804,O
augmentation,5804,O
via,5804,O
5-HT1A,5804,B-GENE-Y
receptor,5804,O
antagonism,5804,O
.,5804,O
Venlafaxine,5805,B-CHEMICAL
is,5805,O
a,5805,O
novel,5805,O
serotonin/noradrenaline,5805,B-CHEMICAL
reuptake,5805,O
inhibitor,5805,O
(,5805,O
SNRI,5805,O
),5805,O
which,5805,O
has,5805,O
been,5805,O
shown,5805,O
clinically,5805,O
to,5805,O
be,5805,O
an,5805,O
effective,5805,O
antidepressant,5805,O
(,5805,O
AD,5805,O
),5805,O
with,5805,O
a,5805,O
faster,5805,O
onset,5805,O
of,5805,O
action,5805,O
than,5805,O
serotonin,5805,B-CHEMICAL
specific,5805,O
reuptake,5805,O
inhibitors,5805,O
(,5805,O
SSRI,5805,O
),5805,O
.,5805,O
Preclinically,5806,O
",",5806,O
venlafaxine,5806,B-CHEMICAL
has,5806,O
been,5806,O
shown,5806,O
to,5806,O
potently,5806,O
inhibit,5806,O
dorsal,5806,O
raphe,5806,O
neuronal,5806,O
(,5806,O
DRN,5806,O
),5806,O
firing,5806,O
through,5806,O
a,5806,O
5-HT1A,5806,B-GENE-Y
mediated,5806,O
mechanism,5806,O
",",5806,O
in,5806,O
a,5806,O
similar,5806,O
manner,5806,O
to,5806,O
SSRIs,5806,O
.,5806,O
Here,5807,O
we,5807,O
demonstrate,5807,O
the,5807,O
acute,5807,O
neurochemical,5807,O
effects,5807,O
of,5807,O
venlafaxine,5807,B-CHEMICAL
on,5807,O
extracellular,5807,O
concentrations,5807,O
of,5807,O
5-HT,5807,B-CHEMICAL
and,5807,O
noradrenaline,5807,B-CHEMICAL
(,5807,O
NA,5807,B-CHEMICAL
),5807,O
from,5807,O
the,5807,O
rat,5807,O
frontal,5807,O
cortex,5807,O
using,5807,O
in,5807,O
vivo,5807,O
microdialysis,5807,O
.,5807,O
Administration,5808,O
of,5808,O
venlafaxine,5808,B-CHEMICAL
(,5808,O
3-50,5808,O
mg/kg,5808,O
s.c.,5808,O
),5808,O
resulted,5808,O
in,5808,O
a,5808,O
significant,5808,O
dose-dependent,5808,O
increase,5808,O
in,5808,O
extracellular,5808,O
NA,5808,B-CHEMICAL
",",5808,O
but,5808,O
produced,5808,O
no,5808,O
significant,5808,O
increase,5808,O
in,5808,O
5-HT,5808,B-CHEMICAL
concentrations,5808,O
.,5808,O
Combination,5809,O
treatment,5809,O
with,5809,O
the,5809,O
selective,5809,O
5-HT1A,5809,B-GENE-Y
antagonist,5809,O
WAY100635,5809,B-CHEMICAL
produced,5809,O
a,5809,O
dose-dependent,5809,O
augmentation,5809,O
of,5809,O
venlafaxine-induced,5809,B-CHEMICAL
(,5809,O
3-30,5809,O
mg/kg,5809,O
s.c,5809,O
),5809,O
extracellular,5809,O
5-HT,5809,B-CHEMICAL
concentrations,5809,O
",",5809,O
but,5809,O
had,5809,O
no,5809,O
further,5809,O
effect,5809,O
on,5809,O
NA,5809,B-CHEMICAL
above,5809,O
that,5809,O
produced,5809,O
by,5809,O
venlafaxine,5809,B-CHEMICAL
alone,5809,O
.,5809,O
WAY100635,5810,B-CHEMICAL
",",5810,O
at,5810,O
doses,5810,O
as,5810,O
low,5810,O
as,5810,O
0.03,5810,O
mg/kg,5810,O
s.c.,5810,O
",",5810,O
maintained,5810,O
this,5810,O
potentiation,5810,O
effect,5810,O
.,5810,O
The,5811,O
beta-adrenergic/5-HT1A,5811,O
receptor,5811,O
antagonist,5811,O
(,5811,B-CHEMICAL
+/-,5811,I-CHEMICAL
),5811,I-CHEMICAL
pindolol,5811,I-CHEMICAL
and,5811,O
the,5811,O
selective,5811,O
5-HT1B/D,5811,B-GENE-N
antagonist,5811,O
GR127935,5811,B-CHEMICAL
produced,5811,O
no,5811,O
significant,5811,O
augmentation,5811,O
of,5811,O
venlafaxine-induced,5811,B-CHEMICAL
changes,5811,O
in,5811,O
either,5811,O
5-HT,5811,B-CHEMICAL
or,5811,O
NA,5811,B-CHEMICAL
.,5811,O
Using,5812,O
the,5812,O
alpha1,5812,B-GENE-N
and,5812,I-GENE-N
alpha2-adrenoceptor,5812,I-GENE-N
antagonists,5812,O
",",5812,O
prazosin,5812,B-CHEMICAL
and,5812,O
idazoxane,5812,B-CHEMICAL
",",5812,O
we,5812,O
also,5812,O
demonstrate,5812,O
the,5812,O
role,5812,O
of,5812,O
the,5812,O
alpha-adrenoceptors,5812,B-GENE-N
in,5812,O
the,5812,O
augmentation,5812,O
of,5812,O
venlafaxine-induced,5812,B-CHEMICAL
changes,5812,O
.,5812,O
The,5813,O
possible,5813,O
mechanisms,5813,O
underlying,5813,O
venlafaxines,5813,B-CHEMICAL
improved,5813,O
clinical,5813,O
AD,5813,O
action,5813,O
and,5813,O
the,5813,O
potential,5813,O
for,5813,O
further,5813,O
enhancement,5813,O
of,5813,O
this,5813,O
SNRIs,5813,O
clinical,5813,O
effects,5813,O
are,5813,O
discussed,5813,O
.,5813,O
GluR5,5814,B-GENE-Y
kainate,5814,B-GENE-N
receptors,5814,I-GENE-N
",",5814,O
seizures,5814,O
",",5814,O
and,5814,O
the,5814,O
amygdala,5814,O
.,5814,O
The,5815,O
amygdala,5815,O
is,5815,O
a,5815,O
critical,5815,O
brain,5815,O
region,5815,O
for,5815,O
limbic,5815,O
seizure,5815,O
activity,5815,O
",",5815,O
but,5815,O
the,5815,O
mechanisms,5815,O
underlying,5815,O
its,5815,O
epileptic,5815,O
susceptibility,5815,O
are,5815,O
obscure,5815,O
.,5815,O
Several,5816,O
lines,5816,O
of,5816,O
evidence,5816,O
implicate,5816,O
GluR5,5816,B-GENE-Y
(,5816,O
GLU,5816,B-GENE-Y
(,5816,I-GENE-Y
K5,5816,I-GENE-Y
),5816,I-GENE-Y
),5816,O
kainate,5816,B-GENE-N
receptors,5816,I-GENE-N
",",5816,O
a,5816,O
type,5816,O
of,5816,O
ionotropic,5816,B-GENE-N
glutamate,5816,I-GENE-N
receptor,5816,I-GENE-N
",",5816,O
in,5816,O
the,5816,O
amygdala,5816,O
's,5816,O
vulnerability,5816,O
to,5816,O
seizures,5816,O
and,5816,O
epileptogenesis,5816,O
.,5816,O
GluR5,5817,B-GENE-Y
mRNA,5817,O
is,5817,O
abundant,5817,O
in,5817,O
temporal,5817,O
lobe,5817,O
structures,5817,O
including,5817,O
the,5817,O
amygdala,5817,O
.,5817,O
Brain,5818,O
slice,5818,O
recordings,5818,O
indicate,5818,O
that,5818,O
GluR5,5818,B-GENE-Y
kainate,5818,B-GENE-N
receptors,5818,I-GENE-N
mediate,5818,O
a,5818,O
portion,5818,O
of,5818,O
the,5818,O
synaptic,5818,O
excitation,5818,O
of,5818,O
neurons,5818,O
in,5818,O
the,5818,O
rat,5818,O
basolateral,5818,O
amygdala,5818,O
.,5818,O
Whole-cell,5819,O
voltage-clamp,5819,O
studies,5819,O
demonstrate,5819,O
that,5819,O
GluR5,5819,B-GENE-Y
kainate,5819,B-GENE-N
receptor-mediated,5819,O
synaptic,5819,O
currents,5819,O
are,5819,O
inwardly,5819,O
rectifying,5819,O
and,5819,O
are,5819,O
likely,5819,O
to,5819,O
be,5819,O
calcium,5819,B-CHEMICAL
permeable,5819,O
.,5819,O
Prolonged,5820,O
activation,5820,O
of,5820,O
basolateral,5820,O
amygdala,5820,O
GluR5,5820,B-GENE-Y
kainate,5820,B-GENE-N
receptors,5820,I-GENE-N
results,5820,O
in,5820,O
enduring,5820,O
synaptic,5820,O
facilitation,5820,O
through,5820,O
a,5820,O
calcium-dependent,5820,B-CHEMICAL
process,5820,O
.,5820,O
The,5821,O
selective,5821,O
GluR5,5821,B-GENE-Y
kainate,5821,B-GENE-N
receptor,5821,I-GENE-N
agonist,5821,O
ATPA,5821,O
induces,5821,O
spontaneous,5821,O
epileptiform,5821,O
bursting,5821,O
that,5821,O
is,5821,O
sensitive,5821,O
to,5821,O
the,5821,O
GluR5,5821,B-GENE-Y
kainate,5821,B-GENE-N
receptor,5821,I-GENE-N
antagonist,5821,O
LY293558,5821,B-CHEMICAL
.,5821,O
Intra-amygdala,5822,O
infusion,5822,O
of,5822,O
ATPA,5822,O
in,5822,O
the,5822,O
rat,5822,O
induces,5822,O
limbic,5822,O
status,5822,O
epilepticus,5822,O
;,5822,O
in,5822,O
some,5822,O
animals,5822,O
",",5822,O
recurrent,5822,O
spontaneous,5822,O
seizures,5822,O
occur,5822,O
for,5822,O
months,5822,O
after,5822,O
the,5822,O
ATPA,5822,O
treatment,5822,O
.,5822,O
Together,5823,O
",",5823,O
these,5823,O
observations,5823,O
indicate,5823,O
that,5823,O
GluR5,5823,B-GENE-Y
kainate,5823,B-GENE-N
receptors,5823,I-GENE-N
have,5823,O
a,5823,O
unique,5823,O
role,5823,O
in,5823,O
triggering,5823,O
epileptiform,5823,O
activity,5823,O
in,5823,O
the,5823,O
amygdala,5823,O
and,5823,O
could,5823,O
participate,5823,O
in,5823,O
long-term,5823,O
plasticity,5823,O
mechanisms,5823,O
that,5823,O
underlie,5823,O
some,5823,O
forms,5823,O
of,5823,O
epileptogenesis,5823,O
.,5823,O
Accordingly,5824,O
",",5824,O
GluR5,5824,B-GENE-Y
kainate,5824,B-GENE-N
receptors,5824,I-GENE-N
represent,5824,O
a,5824,O
potential,5824,O
target,5824,O
for,5824,O
antiepileptic,5824,O
and,5824,O
antiepileptogenic,5824,O
drug,5824,O
treatments,5824,O
.,5824,O
Most,5825,O
antiepileptic,5825,O
drugs,5825,O
do,5825,O
not,5825,O
act,5825,O
through,5825,O
effects,5825,O
on,5825,O
glutamate,5825,B-GENE-N
receptors,5825,I-GENE-N
.,5825,O
However,5826,O
",",5826,O
topiramate,5826,B-CHEMICAL
at,5826,O
low,5826,O
concentrations,5826,O
causes,5826,O
slow,5826,O
inhibition,5826,O
of,5826,O
GluR5,5826,B-GENE-Y
kainate,5826,B-GENE-N
receptor-mediated,5826,O
synaptic,5826,O
currents,5826,O
in,5826,O
the,5826,O
basolateral,5826,O
amygdala,5826,O
",",5826,O
indicating,5826,O
that,5826,O
it,5826,O
may,5826,O
protect,5826,O
against,5826,O
seizures,5826,O
",",5826,O
at,5826,O
least,5826,O
in,5826,O
part,5826,O
",",5826,O
through,5826,O
suppression,5826,O
of,5826,O
GluR5,5826,B-GENE-Y
kainate,5826,B-GENE-N
receptor,5826,I-GENE-N
responses,5826,O
.,5826,O
Multidrug,5827,B-GENE-N
resistance-associated,5827,I-GENE-N
proteins,5827,I-GENE-N
are,5827,O
involved,5827,O
in,5827,O
the,5827,O
transport,5827,O
of,5827,O
the,5827,O
glutathione,5827,B-CHEMICAL
conjugates,5827,O
of,5827,O
the,5827,O
ultimate,5827,O
carcinogen,5827,O
of,5827,O
benzo,5827,B-CHEMICAL
[,5827,I-CHEMICAL
a,5827,I-CHEMICAL
],5827,I-CHEMICAL
pyrene,5827,I-CHEMICAL
in,5827,O
human,5827,O
Caco-2,5827,O
cells,5827,O
.,5827,O
A,5828,O
wide,5828,O
variety,5828,O
of,5828,O
contaminants,5828,O
are,5828,O
ingested,5828,O
through,5828,O
food,5828,O
",",5828,O
among,5828,O
them,5828,O
the,5828,O
pro-carcinogenic,5828,O
polycyclic,5828,O
aromatic,5828,O
hydrocarbon,5828,O
benzo,5828,B-CHEMICAL
[,5828,I-CHEMICAL
a,5828,I-CHEMICAL
],5828,I-CHEMICAL
pyrene,5828,I-CHEMICAL
(,5828,O
BP,5828,O
),5828,O
that,5828,O
is,5828,O
resorbed,5828,O
and,5828,O
partially,5828,O
metabolized,5828,O
in,5828,O
the,5828,O
enterocytes,5828,O
of,5828,O
the,5828,O
small,5828,O
intestine,5828,O
.,5828,O
Previous,5829,O
in,5829,O
vitro,5829,O
studies,5829,O
have,5829,O
revealed,5829,O
that,5829,O
BP,5829,B-CHEMICAL
phenols,5829,I-CHEMICAL
are,5829,O
excreted,5829,O
as,5829,O
Phase,5829,O
II,5829,O
metabolites,5829,O
including,5829,O
glucuronides,5829,O
and,5829,O
sulfates,5829,B-CHEMICAL
.,5829,O
This,5830,O
export,5830,O
is,5830,O
mediated,5830,O
by,5830,O
the,5830,O
breast,5830,B-GENE-Y
cancer,5830,I-GENE-Y
resistance,5830,I-GENE-Y
protein,5830,I-GENE-Y
(,5830,O
ABCG2,5830,B-GENE-Y
),5830,O
.,5830,O
The,5831,O
ultimate,5831,O
carcinogenic,5831,O
Phase,5831,O
I,5831,O
BP,5831,O
metabolite,5831,O
"anti-BP-7,8-dihydrodiol-9,10-epoxide",5831,O
(,5831,O
BPDE,5831,B-CHEMICAL
),5831,O
can,5831,O
be,5831,O
detoxified,5831,O
by,5831,O
glutathione,5831,B-CHEMICAL
conjugate,5831,O
formation,5831,O
catalyzed,5831,O
by,5831,O
glutathione,5831,B-GENE-N
S-transferases,5831,I-GENE-N
.,5831,O
In,5832,O
the,5832,O
present,5832,O
study,5832,O
",",5832,O
differentiated,5832,O
human,5832,O
intestinal,5832,O
Caco-2,5832,O
cells,5832,O
were,5832,O
used,5832,O
as,5832,O
a,5832,O
model,5832,O
for,5832,O
the,5832,O
human,5832,O
small,5832,O
intestine,5832,O
to,5832,O
investigate,5832,O
the,5832,O
detoxification,5832,O
of,5832,O
BPDE,5832,B-CHEMICAL
and,5832,O
excretion,5832,O
of,5832,O
stereoisomeric,5832,O
glutathione,5832,B-CHEMICAL
conjugates,5832,O
in,5832,O
the,5832,O
presence,5832,O
of,5832,O
an,5832,O
inhibitor,5832,O
of,5832,O
the,5832,O
glutathione-cleaving,5832,B-GENE-N
enzyme,5832,I-GENE-N
γ-glutamyl,5832,B-GENE-N
transpeptidase,5832,I-GENE-N
at,5832,O
the,5832,O
cell,5832,O
surface,5832,O
.,5832,O
The,5833,O
results,5833,O
indicate,5833,O
that,5833,O
the,5833,O
glutathione,5833,B-CHEMICAL
conjugates,5833,O
of,5833,O
BPDE,5833,B-CHEMICAL
are,5833,O
formed,5833,O
and,5833,O
excreted,5833,O
mainly,5833,O
to,5833,O
the,5833,O
apical,5833,O
and,5833,O
to,5833,O
a,5833,O
minor,5833,O
extent,5833,O
to,5833,O
the,5833,O
basolateral,5833,O
side,5833,O
of,5833,O
polarized,5833,O
Caco-2,5833,O
monolayers,5833,O
.,5833,O
Inhibition,5834,O
studies,5834,O
revealed,5834,O
that,5834,O
the,5834,O
multidrug,5834,B-GENE-N
resistance-associated,5834,I-GENE-N
proteins,5834,I-GENE-N
(,5834,O
ABCCs,5834,B-GENE-N
),5834,O
are,5834,O
involved,5834,O
in,5834,O
the,5834,O
transport,5834,O
of,5834,O
BPDE,5834,B-CHEMICAL
glutathione,5834,I-CHEMICAL
conjugates,5834,O
.,5834,O
Stable,5835,O
ABCC1,5835,B-GENE-Y
",",5835,O
ABCC2,5835,B-GENE-Y
and,5835,O
ABCC3,5835,B-GENE-Y
knockdown,5835,O
cell,5835,O
lines,5835,O
were,5835,O
generated,5835,O
",",5835,O
thus,5835,O
making,5835,O
it,5835,O
possible,5835,O
to,5835,O
demonstrate,5835,O
that,5835,O
ABCC1,5835,B-GENE-Y
mediates,5835,O
the,5835,O
basolateral,5835,O
and,5835,O
ABCC2,5835,B-GENE-Y
the,5835,O
apical,5835,O
excretion,5835,O
of,5835,O
BPDE,5835,B-CHEMICAL
glutathione,5835,I-CHEMICAL
conjugates,5835,O
.,5835,O
In,5836,O
conclusion,5836,O
",",5836,O
the,5836,O
ultimate,5836,O
carcinogen,5836,O
BPDE,5836,B-CHEMICAL
is,5836,O
detoxified,5836,O
via,5836,O
glutathione,5836,B-CHEMICAL
conjugation,5836,O
and,5836,O
subsequently,5836,O
excreted,5836,O
by,5836,O
Caco-2,5836,O
cells,5836,O
in,5836,O
both,5836,O
apical,5836,O
and,5836,O
basolateral,5836,O
directions,5836,O
.,5836,O
This,5837,O
finding,5837,O
is,5837,O
equivalent,5837,O
to,5837,O
a,5837,O
transport,5837,O
into,5837,O
feces,5837,O
as,5837,O
well,5837,O
as,5837,O
blood,5837,O
system,5837,O
in,5837,O
the,5837,O
in,5837,O
vivo,5837,O
situation,5837,O
.,5837,O
Evaluation,5838,O
of,5838,O
biological,5838,O
activities,5838,O
of,5838,O
a,5838,O
groundnut,5838,O
(,5838,O
Apios,5838,O
americana,5838,O
Medik,5838,O
),5838,O
extract,5838,O
containing,5838,O
a,5838,O
novel,5838,O
isoflavone,5838,B-CHEMICAL
.,5838,O
Groundnut,5839,O
(,5839,O
Apios,5839,O
americana,5839,O
Medik,5839,O
),5839,O
contains,5839,O
a,5839,O
novel,5839,O
isoflavone,5839,B-CHEMICAL
",",5839,O
genistein-7-O-gentiobioside,5839,B-CHEMICAL
.,5839,O
In,5840,O
the,5840,O
present,5840,O
study,5840,O
",",5840,O
we,5840,O
examined,5840,O
the,5840,O
biological,5840,O
activities,5840,O
of,5840,O
an,5840,O
alcohol,5840,B-CHEMICAL
extract,5840,O
of,5840,O
groundnut,5840,O
containing,5840,O
genistein-7-O-gentiobioside,5840,B-CHEMICAL
as,5840,O
the,5840,O
main,5840,O
component,5840,O
.,5840,O
Although,5841,O
the,5841,O
groundnut,5841,O
extract,5841,O
by,5841,O
itself,5841,O
did,5841,O
not,5841,O
show,5841,O
antioxidative,5841,O
activity,5841,O
",",5841,O
it,5841,O
drove,5841,O
the,5841,O
antioxidative,5841,O
system,5841,O
in,5841,O
cells,5841,O
.,5841,O
Pretreatment,5842,O
of,5842,O
human,5842,O
breast,5842,O
carcinoma,5842,O
MCF-7,5842,O
cells,5842,O
for,5842,O
24,5842,O
h,5842,O
with,5842,O
the,5842,O
groundnut,5842,O
extract,5842,O
and,5842,O
soybean,5842,O
isoflavone,5842,B-CHEMICAL
increased,5842,O
gene,5842,O
expression,5842,O
of,5842,O
heme,5842,B-GENE-Y
oxygenase-1,5842,I-GENE-Y
(,5842,O
HO-1,5842,B-GENE-Y
),5842,O
",",5842,O
a,5842,O
major,5842,O
antioxidative,5842,O
stress,5842,O
enzyme,5842,O
.,5842,O
These,5843,O
groundnut,5843,O
extract-treated,5843,O
cells,5843,O
showed,5843,O
antioxidative,5843,O
activity,5843,O
against,5843,O
free,5843,O
radicals,5843,O
derived,5843,O
from,5843,O
a,5843,O
radical,5843,O
initiator,5843,O
.,5843,O
Pretreatment,5844,O
of,5844,O
cells,5844,O
with,5844,O
100,5844,O
μg/mL,5844,O
groundnut,5844,O
extract,5844,O
prevented,5844,O
the,5844,O
depletion,5844,O
of,5844,O
glutathione,5844,B-CHEMICAL
by,5844,O
the,5844,O
radical,5844,O
initiator,5844,O
;,5844,O
however,5844,O
",",5844,O
treatment,5844,O
with,5844,O
100,5844,O
μg/mL,5844,O
of,5844,O
soybean,5844,O
isoflavone,5844,B-CHEMICAL
injured,5844,O
the,5844,O
cell,5844,O
membrane,5844,O
",",5844,O
indicating,5844,O
that,5844,O
glutathione,5844,B-CHEMICAL
might,5844,O
be,5844,O
released,5844,O
to,5844,O
the,5844,O
extracellular,5844,O
environment,5844,O
.,5844,O
These,5845,O
results,5845,O
suggest,5845,O
that,5845,O
the,5845,O
groundnut,5845,O
extract,5845,O
had,5845,O
isoflavone-like,5845,B-CHEMICAL
activity,5845,O
.,5845,O
Like,5846,O
soybean,5846,O
",",5846,O
groundnuts,5846,O
are,5846,O
a,5846,O
good,5846,O
source,5846,O
of,5846,O
isoflavones,5846,B-CHEMICAL
.,5846,O
Comparison,5847,O
of,5847,O
cyclooxygenase,5847,B-GENE-N
inhibitory,5847,O
activity,5847,O
and,5847,O
ocular,5847,O
anti-inflammatory,5847,O
effects,5847,O
of,5847,O
ketorolac,5847,B-CHEMICAL
tromethamine,5847,I-CHEMICAL
and,5847,O
bromfenac,5847,B-CHEMICAL
sodium,5847,I-CHEMICAL
.,5847,O
OBJECTIVE,5848,O
:,5848,O
To,5848,O
compare,5848,O
the,5848,O
cyclooxygenase,5848,B-GENE-N
(,5848,O
COX,5848,B-GENE-N
),5848,O
activity,5848,O
and,5848,O
anti-inflammatory,5848,O
effects,5848,O
of,5848,O
the,5848,O
nonsteroidal,5848,O
anti-inflammatory,5848,O
drugs,5848,O
(,5848,O
NSAIDs,5848,O
),5848,O
ketorolac,5848,B-CHEMICAL
tromethamine,5848,I-CHEMICAL
(,5848,O
ketorolac,5848,B-CHEMICAL
),5848,O
and,5848,O
bromfenac,5848,B-CHEMICAL
sodium,5848,I-CHEMICAL
(,5848,O
bromfenac,5848,B-CHEMICAL
),5848,O
.,5848,O
METHODS,5849,O
:,5849,O
Cyclooxygenase,5849,B-GENE-N
activity,5849,O
and,5849,O
selectivity,5849,O
was,5849,O
determined,5849,O
in,5849,O
vitro,5849,O
by,5849,O
measuring,5849,O
prostaglandin,5849,B-CHEMICAL
E,5849,I-CHEMICAL
(,5849,I-CHEMICAL
2,5849,I-CHEMICAL
),5849,I-CHEMICAL
(,5849,O
PGE,5849,B-CHEMICAL
(,5849,I-CHEMICAL
2,5849,I-CHEMICAL
),5849,I-CHEMICAL
),5849,O
production,5849,O
following,5849,O
incubation,5849,O
of,5849,O
varying,5849,O
concentrations,5849,O
of,5849,O
NSAID,5849,O
with,5849,O
human,5849,B-GENE-Y
recombinant,5849,I-GENE-Y
COX-1,5849,I-GENE-Y
or,5849,O
COX-2,5849,B-GENE-Y
and,5849,O
arachidonic,5849,B-CHEMICAL
acid,5849,I-CHEMICAL
.,5849,O
Anti-inflammatory,5850,O
effects,5850,O
were,5850,O
evaluated,5850,O
in,5850,O
a,5850,O
rabbit,5850,O
model,5850,O
in,5850,O
which,5850,O
an,5850,O
ocular,5850,O
inflammatory,5850,O
response,5850,O
was,5850,O
induced,5850,O
by,5850,O
intravenous,5850,O
injection,5850,O
of,5850,O
10,5850,O
microg/kg,5850,O
lipopolysaccharide,5850,O
(,5850,O
LPS,5850,O
),5850,O
.,5850,O
In,5851,O
study,5851,O
animals,5851,O
",",5851,O
one,5851,O
eye,5851,O
was,5851,O
treated,5851,O
with,5851,O
50,5851,O
microL,5851,O
(,5851,B-CHEMICAL
+/-,5851,I-CHEMICAL
),5851,I-CHEMICAL
ketorolac,5851,I-CHEMICAL
0.4,5851,O
%,5851,O
(,5851,O
Acular,5851,B-CHEMICAL
LS,5851,I-CHEMICAL
),5851,O
or,5851,O
bromfenac,5851,B-CHEMICAL
0.09,5851,O
%,5851,O
(,5851,O
Xibrom,5851,B-CHEMICAL
),5851,O
and,5851,O
the,5851,O
other,5851,O
eye,5851,O
with,5851,O
50,5851,O
microL,5851,O
buffered,5851,O
saline,5851,O
.,5851,O
In,5852,O
control,5852,O
animals,5852,O
",",5852,O
both,5852,O
eyes,5852,O
were,5852,O
treated,5852,O
with,5852,O
vehicle,5852,O
.,5852,O
All,5853,O
animals,5853,O
were,5853,O
treated,5853,O
twice,5853,O
:,5853,O
2,5853,O
hours,5853,O
and,5853,O
1,5853,O
hour,5853,O
before,5853,O
LPS,5853,O
.,5853,O
MAIN,5854,O
OUTCOME,5854,O
MEASURES,5854,O
:,5854,O
PGE,5854,B-CHEMICAL
(,5854,I-CHEMICAL
2,5854,I-CHEMICAL
),5854,I-CHEMICAL
production,5854,O
in,5854,O
vitro,5854,O
",",5854,O
measured,5854,O
by,5854,O
enzyme,5854,O
immunoassay,5854,O
;,5854,O
fluorescein,5854,B-CHEMICAL
isothiocyanate,5854,I-CHEMICAL
(,5854,O
FITC,5854,B-CHEMICAL
),5854,O
-dextran,5854,O
leakage,5854,O
into,5854,O
the,5854,O
anterior,5854,O
chamber,5854,O
",",5854,O
measured,5854,O
by,5854,O
fluorophotometry,5854,O
;,5854,O
aqueous,5854,O
PGE,5854,B-CHEMICAL
(,5854,I-CHEMICAL
2,5854,I-CHEMICAL
),5854,I-CHEMICAL
levels,5854,O
in,5854,O
vivo,5854,O
",",5854,O
measured,5854,O
by,5854,O
ELISA,5854,O
immunoassay,5854,O
.,5854,O
RESULTS,5855,O
:,5855,O
Ketorolac,5855,B-CHEMICAL
was,5855,O
six,5855,O
times,5855,O
more,5855,O
active,5855,O
against,5855,O
COX-1,5855,B-GENE-Y
(,5855,O
IC,5855,O
(,5855,O
50,5855,O
),5855,O
=,5855,O
0.02,5855,O
microM,5855,O
),5855,O
than,5855,O
COX-2,5855,B-GENE-Y
(,5855,O
IC,5855,O
(,5855,O
50,5855,O
),5855,O
=,5855,O
0.12,5855,O
microM,5855,O
),5855,O
while,5855,O
bromfenac,5855,B-CHEMICAL
was,5855,O
approximately,5855,O
32,5855,O
times,5855,O
more,5855,O
active,5855,O
against,5855,O
COX-2,5855,B-GENE-Y
(,5855,O
IC,5855,O
(,5855,O
50,5855,O
),5855,O
=,5855,O
0.0066,5855,O
microM,5855,O
),5855,O
than,5855,O
COX-1,5855,B-GENE-Y
(,5855,O
IC,5855,O
(,5855,O
50,5855,O
),5855,O
=,5855,O
0.210,5855,O
microM,5855,O
),5855,O
.,5855,O
In,5856,O
the,5856,O
animal,5856,O
model,5856,O
",",5856,O
both,5856,O
drugs,5856,O
resulted,5856,O
in,5856,O
nearly,5856,O
complete,5856,O
inhibition,5856,O
of,5856,O
FITC-dextran,5856,B-CHEMICAL
leakage,5856,O
and,5856,O
PGE,5856,B-CHEMICAL
(,5856,I-CHEMICAL
2,5856,I-CHEMICAL
),5856,I-CHEMICAL
production,5856,O
in,5856,O
the,5856,O
anterior,5856,O
chamber,5856,O
of,5856,O
treated,5856,O
eyes,5856,O
.,5856,O
There,5857,O
was,5857,O
also,5857,O
a,5857,O
79,5857,O
%,5857,O
inhibition,5857,O
(,5857,O
p,5857,O
<,5857,O
0.001,5857,O
),5857,O
of,5857,O
FITC-dextran,5857,B-CHEMICAL
leakage,5857,O
in,5857,O
the,5857,O
contralateral,5857,O
eyes,5857,O
of,5857,O
bromfenac-treated,5857,B-CHEMICAL
rabbits,5857,O
",",5857,O
and,5857,O
a,5857,O
22.5,5857,O
%,5857,O
inhibition,5857,O
(,5857,O
not,5857,O
statistically,5857,O
significant,5857,O
),5857,O
in,5857,O
the,5857,O
contralateral,5857,O
eyes,5857,O
of,5857,O
ketorolac-treated,5857,B-CHEMICAL
rabbits,5857,O
.,5857,O
CONCLUSIONS,5858,O
:,5858,O
Ketorolac,5858,B-CHEMICAL
is,5858,O
relatively,5858,O
COX-1,5858,B-GENE-Y
selective,5858,O
while,5858,O
bromfenac,5858,B-CHEMICAL
is,5858,O
potently,5858,O
selective,5858,O
for,5858,O
COX-2,5858,B-GENE-Y
over,5858,O
COX-1,5858,B-GENE-Y
.,5858,O
In,5859,O
the,5859,O
animal,5859,O
model,5859,O
",",5859,O
both,5859,O
ketorolac,5859,B-CHEMICAL
0.4,5859,O
%,5859,O
and,5859,O
bromfenac,5859,B-CHEMICAL
0.09,5859,O
%,5859,O
demonstrated,5859,O
maximal,5859,O
anti-inflammatory,5859,O
activity,5859,O
in,5859,O
treated,5859,O
eyes,5859,O
.,5859,O
Only,5860,O
bromfenac,5860,B-CHEMICAL
0.09,5860,O
%,5860,O
had,5860,O
a,5860,O
significant,5860,O
effect,5860,O
on,5860,O
the,5860,O
contralateral,5860,O
eye,5860,O
",",5860,O
suggesting,5860,O
possible,5860,O
systemic,5860,O
absorption,5860,O
of,5860,O
this,5860,O
drug,5860,O
.,5860,O
Tumor-growth-promoting,5861,O
cyclooxygenase-2,5861,B-GENE-Y
prostaglandin,5861,B-CHEMICAL
E2,5861,I-CHEMICAL
pathway,5861,O
provides,5861,O
medulloblastoma,5861,O
therapeutic,5861,O
targets,5861,O
.,5861,O
Prostaglandin,5862,B-CHEMICAL
E,5862,I-CHEMICAL
(,5862,I-CHEMICAL
2,5862,I-CHEMICAL
),5862,I-CHEMICAL
(,5862,O
PGE,5862,B-CHEMICAL
(,5862,I-CHEMICAL
2,5862,I-CHEMICAL
),5862,I-CHEMICAL
),5862,O
has,5862,O
been,5862,O
shown,5862,O
to,5862,O
play,5862,O
important,5862,O
roles,5862,O
in,5862,O
several,5862,O
aspects,5862,O
of,5862,O
tumor,5862,O
development,5862,O
and,5862,O
progression,5862,O
.,5862,O
PGE,5863,B-CHEMICAL
(,5863,I-CHEMICAL
2,5863,I-CHEMICAL
),5863,I-CHEMICAL
is,5863,O
synthesized,5863,O
from,5863,O
arachidonic,5863,B-CHEMICAL
acid,5863,I-CHEMICAL
by,5863,O
cyclooxygenases,5863,B-GENE-N
(,5863,O
COX,5863,B-GENE-N
),5863,O
and,5863,O
prostaglandin,5863,B-GENE-N
E,5863,I-GENE-N
synthases,5863,I-GENE-N
(,5863,O
PGES,5863,B-GENE-N
),5863,O
and,5863,O
mediates,5863,O
its,5863,O
biological,5863,O
activity,5863,O
through,5863,O
binding,5863,O
to,5863,O
the,5863,O
four,5863,O
prostanoid,5863,B-GENE-Y
receptors,5863,I-GENE-Y
EP,5863,I-GENE-Y
(,5863,I-GENE-Y
1,5863,I-GENE-Y
),5863,I-GENE-Y
through,5863,O
EP,5863,B-GENE-Y
(,5863,I-GENE-Y
4,5863,I-GENE-Y
),5863,I-GENE-Y
.,5863,O
In,5864,O
this,5864,O
study,5864,O
",",5864,O
we,5864,O
show,5864,O
for,5864,O
the,5864,O
first,5864,O
time,5864,O
that,5864,O
medulloblastoma,5864,O
(,5864,O
MB,5864,O
),5864,O
",",5864,O
the,5864,O
most,5864,O
common,5864,O
malignant,5864,O
childhood,5864,O
brain,5864,O
tumor,5864,O
",",5864,O
expresses,5864,O
high,5864,O
levels,5864,O
of,5864,O
COX-2,5864,B-GENE-Y
",",5864,O
microsomal,5864,B-GENE-Y
prostaglandin,5864,I-GENE-Y
E,5864,I-GENE-Y
synthase-1,5864,I-GENE-Y
",",5864,O
and,5864,O
EP,5864,B-GENE-Y
(,5864,I-GENE-Y
1,5864,I-GENE-Y
),5864,I-GENE-Y
through,5864,O
EP,5864,B-GENE-Y
(,5864,I-GENE-Y
4,5864,I-GENE-Y
),5864,I-GENE-Y
and,5864,O
secretes,5864,O
PGE,5864,B-CHEMICAL
(,5864,I-CHEMICAL
2,5864,I-CHEMICAL
),5864,I-CHEMICAL
.,5864,O
PGE,5865,B-CHEMICAL
(,5865,I-CHEMICAL
2,5865,I-CHEMICAL
),5865,I-CHEMICAL
and,5865,O
the,5865,O
EP,5865,B-GENE-Y
(,5865,I-GENE-Y
2,5865,I-GENE-Y
),5865,I-GENE-Y
receptor,5865,I-GENE-Y
agonist,5865,O
butaprost,5865,O
stimulated,5865,O
MB,5865,O
cell,5865,O
proliferation,5865,O
.,5865,O
Treatment,5866,O
of,5866,O
MB,5866,O
cells,5866,O
with,5866,O
COX,5866,B-GENE-N
inhibitors,5866,O
suppressed,5866,O
PGE,5866,B-CHEMICAL
(,5866,I-CHEMICAL
2,5866,I-CHEMICAL
),5866,I-CHEMICAL
production,5866,O
and,5866,O
induced,5866,O
caspase-dependent,5866,B-GENE-N
apoptosis,5866,O
.,5866,O
Similarly,5867,O
",",5867,O
specific,5867,O
COX-2,5867,B-GENE-Y
silencing,5867,O
by,5867,O
small,5867,O
interfering,5867,O
RNA,5867,O
inhibited,5867,O
MB,5867,O
cell,5867,O
growth,5867,O
.,5867,O
EP,5868,B-GENE-Y
(,5868,I-GENE-Y
1,5868,I-GENE-Y
),5868,I-GENE-Y
and,5868,O
EP,5868,B-GENE-Y
(,5868,I-GENE-Y
3,5868,I-GENE-Y
),5868,I-GENE-Y
receptor,5868,I-GENE-Y
antagonists,5868,O
ONO-8713,5868,B-CHEMICAL
and,5868,O
ONO-AE3-240,5868,B-CHEMICAL
",",5868,O
but,5868,O
not,5868,O
the,5868,O
EP,5868,B-GENE-Y
(,5868,I-GENE-Y
4,5868,I-GENE-Y
),5868,I-GENE-Y
antagonists,5868,O
ONO-AE3-208,5868,B-CHEMICAL
and,5868,O
AH,5868,B-CHEMICAL
23848,5868,I-CHEMICAL
",",5868,O
inhibited,5868,O
tumor,5868,O
cell,5868,O
proliferation,5868,O
",",5868,O
indicating,5868,O
the,5868,O
significance,5868,O
of,5868,O
EP,5868,B-GENE-Y
(,5868,I-GENE-Y
1,5868,I-GENE-Y
),5868,I-GENE-Y
and,5868,O
EP,5868,B-GENE-Y
(,5868,I-GENE-Y
3,5868,I-GENE-Y
),5868,I-GENE-Y
but,5868,O
not,5868,O
EP,5868,B-GENE-Y
(,5868,I-GENE-Y
4,5868,I-GENE-Y
),5868,I-GENE-Y
for,5868,O
MB,5868,O
growth,5868,O
.,5868,O
Administration,5869,O
of,5869,O
COX,5869,B-GENE-N
inhibitors,5869,O
at,5869,O
clinically,5869,O
achievable,5869,O
nontoxic,5869,O
concentrations,5869,O
significantly,5869,O
inhibited,5869,O
growth,5869,O
of,5869,O
established,5869,O
human,5869,O
MB,5869,O
xenografts,5869,O
.,5869,O
Apoptosis,5870,O
was,5870,O
increased,5870,O
",",5870,O
proliferation,5870,O
was,5870,O
reduced,5870,O
",",5870,O
and,5870,O
angiogenesis,5870,O
was,5870,O
inhibited,5870,O
in,5870,O
MBs,5870,O
treated,5870,O
with,5870,O
COX,5870,B-GENE-N
inhibitors,5870,O
.,5870,O
This,5871,O
study,5871,O
suggests,5871,O
that,5871,O
PGE,5871,B-CHEMICAL
(,5871,I-CHEMICAL
2,5871,I-CHEMICAL
),5871,I-CHEMICAL
is,5871,O
important,5871,O
for,5871,O
MB,5871,O
growth,5871,O
and,5871,O
that,5871,O
therapies,5871,O
targeting,5871,O
the,5871,O
prostanoid,5871,O
metabolic,5871,O
pathway,5871,O
are,5871,O
potentially,5871,O
beneficial,5871,O
and,5871,O
should,5871,O
be,5871,O
tested,5871,O
in,5871,O
clinical,5871,O
settings,5871,O
for,5871,O
treatment,5871,O
of,5871,O
children,5871,O
with,5871,O
MB,5871,O
.,5871,O
Fluticasone,5872,B-CHEMICAL
propionate,5872,I-CHEMICAL
:,5872,O
safety,5872,O
profile,5872,O
.,5872,O
Fluticasone,5873,B-CHEMICAL
propionate,5873,I-CHEMICAL
is,5873,O
a,5873,O
potent,5873,O
fluorinated,5873,O
corticosteroid,5873,O
used,5873,O
for,5873,O
the,5873,O
topical,5873,O
therapy,5873,O
of,5873,O
dermatoses,5873,O
and,5873,O
as,5873,O
inhalation,5873,O
therapy,5873,O
for,5873,O
bronchial,5873,O
asthma,5873,O
and,5873,O
allergic,5873,O
rhinitis,5873,O
.,5873,O
This,5874,O
agent,5874,O
has,5874,O
a,5874,O
good,5874,O
safety,5874,O
profile,5874,O
with,5874,O
a,5874,O
low,5874,O
propensity,5874,O
for,5874,O
systemic,5874,O
side,5874,O
effects,5874,O
",",5874,O
such,5874,O
as,5874,O
suppression,5874,O
of,5874,O
the,5874,O
hypothalamic-pituitary-adrenal,5874,O
(,5874,O
HPA,5874,O
),5874,O
axis,5874,O
",",5874,O
and,5874,O
a,5874,O
low,5874,O
incidence,5874,O
of,5874,O
local,5874,O
side,5874,O
effects,5874,O
such,5874,O
as,5874,O
pruritus,5874,O
",",5874,O
burning,5874,O
",",5874,O
or,5874,O
skin,5874,O
atrophy,5874,O
.,5874,O
The,5875,O
pharmacologic,5875,O
properties,5875,O
of,5875,O
fluticasone,5875,B-CHEMICAL
propionate-including,5875,O
high,5875,O
lipophilicity,5875,O
",",5875,O
high,5875,O
selectivity,5875,O
and,5875,O
affinity,5875,O
for,5875,O
the,5875,O
glucocorticoid,5875,B-GENE-Y
receptor,5875,I-GENE-Y
",",5875,O
low,5875,O
systemic,5875,O
absorption,5875,O
",",5875,O
and,5875,O
rapid,5875,O
metabolism,5875,O
and,5875,O
clearance-combine,5875,O
to,5875,O
give,5875,O
fluticasone,5875,B-CHEMICAL
propionate,5875,I-CHEMICAL
a,5875,O
high,5875,O
therapeutic,5875,O
index,5875,O
.,5875,O
Bioreducible,5876,O
polymers,5876,O
as,5876,O
a,5876,O
determining,5876,O
factor,5876,O
for,5876,O
polyplex,5876,B-CHEMICAL
decomplexation,5876,O
rate,5876,O
and,5876,O
transfection,5876,O
.,5876,O
Polyplex,5877,B-CHEMICAL
formation,5877,O
(,5877,O
complexation,5877,O
),5877,O
and,5877,O
gene,5877,O
release,5877,O
from,5877,O
the,5877,O
polyplexes,5877,B-CHEMICAL
(,5877,O
decomplexation,5877,O
),5877,O
are,5877,O
major,5877,O
events,5877,O
in,5877,O
polymeric,5877,O
gene,5877,O
delivery,5877,O
;,5877,O
however,5877,O
",",5877,O
the,5877,O
effect,5877,O
of,5877,O
the,5877,O
decomplexation,5877,O
rate,5877,O
on,5877,O
transfection,5877,O
has,5877,O
been,5877,O
rarely,5877,O
investigated,5877,O
.,5877,O
This,5878,O
study,5878,O
employed,5878,O
mixed,5878,O
polymers,5878,O
of,5878,O
poly,5878,B-CHEMICAL
(,5878,I-CHEMICAL
(,5878,I-CHEMICAL
L,5878,I-CHEMICAL
),5878,I-CHEMICAL
-lysine,5878,I-CHEMICAL
),5878,I-CHEMICAL
(,5878,O
PLL,5878,B-CHEMICAL
:,5878,O
MW,5878,O
~7.4,5878,O
kDa,5878,O
),5878,O
and,5878,O
reducible,5878,O
PLL,5878,B-CHEMICAL
(,5878,O
RPLL,5878,O
),5878,O
(,5878,O
MW,5878,O
~6.7,5878,O
kDa,5878,O
),5878,O
to,5878,O
design,5878,O
decomplexation,5878,O
rate-controllable,5878,O
PLL,5878,B-CHEMICAL
(,5878,O
100-x,5878,O
),5878,O
RPLL,5878,O
(,5878,O
x,5878,O
),5878,O
/pDNA,5878,O
complexes,5878,O
(,5878,O
PRL,5878,O
(,5878,O
x,5878,O
),5878,O
polyplexes,5878,B-CHEMICAL
),5878,O
.,5878,O
The,5879,O
transfection,5879,O
efficiency,5879,O
of,5879,O
a,5879,O
model,5879,O
gene,5879,O
(,5879,O
luciferase,5879,O
),5879,O
in,5879,O
MCF7,5879,O
and,5879,O
HEK293,5879,O
cell,5879,O
lines,5879,O
increased,5879,O
with,5879,O
increasing,5879,O
x,5879,O
(,5879,O
RPLL,5879,O
content,5879,O
),5879,O
in,5879,O
the,5879,O
PRL,5879,O
(,5879,O
x,5879,O
),5879,O
polyplexes,5879,B-CHEMICAL
until,5879,O
peaking,5879,O
at,5879,O
x,5879,O
=,5879,O
2.5,5879,O
and,5879,O
10,5879,O
",",5879,O
respectively,5879,O
",",5879,O
after,5879,O
which,5879,O
point,5879,O
transfection,5879,O
efficiency,5879,O
declined,5879,O
rapidly,5879,O
.,5879,O
In,5880,O
MCF7,5880,O
cells,5880,O
",",5880,O
PRL,5880,O
(,5880,O
2.5,5880,O
),5880,O
polyplex,5880,B-CHEMICAL
produced,5880,O
3,5880,O
or,5880,O
223,5880,O
times,5880,O
higher,5880,O
gene,5880,O
expression,5880,O
than,5880,O
PLL,5880,B-CHEMICAL
or,5880,O
RPLL,5880,O
polyplexes,5880,B-CHEMICAL
",",5880,O
respectively,5880,O
.,5880,O
Similarly,5881,O
",",5881,O
the,5881,O
transfection,5881,O
efficiency,5881,O
of,5881,O
PRL,5881,O
(,5881,O
10,5881,O
),5881,O
polyplex-transfected,5881,B-CHEMICAL
HEK293,5881,O
cells,5881,O
was,5881,O
3.8,5881,O
or,5881,O
67,5881,O
times,5881,O
higher,5881,O
than,5881,O
that,5881,O
of,5881,O
PLL,5881,B-CHEMICAL
or,5881,O
RPLL,5881,O
polyplexes,5881,B-CHEMICAL
",",5881,O
respectively,5881,O
.,5881,O
The,5882,O
transfection,5882,O
results,5882,O
were,5882,O
not,5882,O
apparently,5882,O
related,5882,O
to,5882,O
the,5882,O
particle,5882,O
size,5882,O
",",5882,O
surface,5882,O
charge,5882,O
",",5882,O
complexation/compactness,5882,O
",",5882,O
cellular,5882,O
uptake,5882,O
",",5882,O
or,5882,O
cytotoxicity,5882,O
of,5882,O
the,5882,O
tested,5882,O
polyplexes,5882,B-CHEMICAL
.,5882,O
However,5883,O
",",5883,O
the,5883,O
decomplexation,5883,O
rate,5883,O
varied,5883,O
by,5883,O
RPLL,5883,O
content,5883,O
in,5883,O
the,5883,O
polyplexes,5883,B-CHEMICAL
",",5883,O
which,5883,O
in,5883,O
turn,5883,O
influenced,5883,O
the,5883,O
gene,5883,O
transfection,5883,O
.,5883,O
The,5884,O
nuclear,5884,O
localization,5884,O
of,5884,O
pDNA,5884,O
delivered,5884,O
by,5884,O
PRL,5884,O
(,5884,O
x,5884,O
),5884,O
polyplexes,5884,B-CHEMICAL
showed,5884,O
a,5884,O
similar,5884,O
trend,5884,O
to,5884,O
their,5884,O
transfection,5884,O
efficiencies,5884,O
.,5884,O
This,5885,O
study,5885,O
suggests,5885,O
that,5885,O
an,5885,O
optimum,5885,O
decomplexation,5885,O
rate,5885,O
may,5885,O
result,5885,O
in,5885,O
high,5885,O
nuclear,5885,O
localization,5885,O
of,5885,O
pDNA,5885,O
and,5885,O
transfection,5885,O
.,5885,O
Understanding,5886,O
in,5886,O
decomplexation,5886,O
and,5886,O
intracellular,5886,O
localization,5886,O
of,5886,O
pDNA,5886,O
may,5886,O
help,5886,O
develop,5886,O
more,5886,O
effective,5886,O
polyplexes,5886,B-CHEMICAL
.,5886,O
Phosphodiesterase,5887,B-GENE-N
4,5887,I-GENE-N
inhibitors,5887,O
delay,5887,O
human,5887,O
eosinophil,5887,O
and,5887,O
neutrophil,5887,O
apoptosis,5887,O
in,5887,O
the,5887,O
absence,5887,O
and,5887,O
presence,5887,O
of,5887,O
salbutamol,5887,B-CHEMICAL
.,5887,O
In,5888,O
asthma,5888,O
and,5888,O
chronic,5888,O
obstructive,5888,O
pulmonary,5888,O
disease,5888,O
(,5888,O
COPD,5888,O
),5888,O
",",5888,O
the,5888,O
number,5888,O
of,5888,O
eosinophils,5888,O
and,5888,O
neutrophils,5888,O
in,5888,O
the,5888,O
lung,5888,O
is,5888,O
increased,5888,O
.,5888,O
One,5889,O
described,5889,O
mechanism,5889,O
leading,5889,O
to,5889,O
the,5889,O
impaired,5889,O
clearance,5889,O
of,5889,O
these,5889,O
cells,5889,O
from,5889,O
the,5889,O
lung,5889,O
is,5889,O
the,5889,O
delay,5889,O
in,5889,O
their,5889,O
programmed,5889,O
cell,5889,O
death,5889,O
(,5889,O
apoptosis,5889,O
),5889,O
.,5889,O
Selective,5890,O
inhibitors,5890,O
of,5890,O
phosphodiesterases,5890,B-GENE-N
(,5890,O
PDEs,5890,B-GENE-N
),5890,O
are,5890,O
under,5890,O
development,5890,O
for,5890,O
the,5890,O
treatment,5890,O
of,5890,O
lung,5890,O
diseases,5890,O
because,5890,O
of,5890,O
their,5890,O
anti-inflammatory,5890,O
and,5890,O
bronchodilator,5890,O
activity,5890,O
.,5890,O
The,5891,O
aim,5891,O
of,5891,O
the,5891,O
present,5891,O
study,5891,O
was,5891,O
to,5891,O
establish,5891,O
whether,5891,O
inhibitors,5891,O
of,5891,O
PDE3,5891,B-GENE-N
",",5891,O
PDE4,5891,B-GENE-N
and,5891,O
PDE5,5891,B-GENE-Y
modulate,5891,O
human,5891,O
eosinophil,5891,O
or,5891,O
neutrophil,5891,O
apoptosis,5891,O
or,5891,O
beta,5891,B-GENE-Y
2-adrenoceptor,5891,I-GENE-Y
agonist-,5891,O
or,5891,O
cytokine-afforded,5891,B-GENE-N
survival,5891,O
.,5891,O
We,5892,O
also,5892,O
evaluated,5892,O
whether,5892,O
a,5892,O
PDE4,5892,B-GENE-N
inhibitor,5892,O
could,5892,O
modulate,5892,O
the,5892,O
effect,5892,O
of,5892,O
a,5892,O
corticosteroid,5892,B-CHEMICAL
on,5892,O
eosinophil,5892,O
and,5892,O
neutrophil,5892,O
apoptosis,5892,O
.,5892,O
Apoptosis,5893,O
was,5893,O
measured,5893,O
by,5893,O
using,5893,O
the,5893,O
relative,5893,O
DNA,5893,O
fragmentation,5893,O
assay,5893,O
and,5893,O
Annexin-V,5893,O
binding,5893,O
.,5893,O
Inhibitors,5894,O
of,5894,O
PDE4,5894,B-GENE-N
(,5894,O
rolipram,5894,B-CHEMICAL
;,5894,O
0.1-10,5894,O
microM,5894,O
),5894,O
and,5894,O
PDE3,5894,B-GENE-N
(,5894,O
cilostazol,5894,B-CHEMICAL
;,5894,O
0.1-10,5894,O
microM,5894,O
),5894,O
delayed,5894,O
spontaneous,5894,O
eosinophil,5894,O
apoptosis,5894,O
maximally,5894,O
by,5894,O
25,5894,O
%,5894,O
and,5894,O
15,5894,O
%,5894,O
",",5894,O
respectively,5894,O
.,5894,O
A,5895,O
combination,5895,O
of,5895,O
a,5895,O
PDE4,5895,B-GENE-N
or,5895,O
PDE3,5895,B-GENE-N
inhibitor,5895,O
(,5895,O
10,5895,O
microM,5895,O
),5895,O
with,5895,O
salbutamol,5895,B-CHEMICAL
(,5895,O
100,5895,O
nM,5895,O
),5895,O
further,5895,O
delayed,5895,O
eosinophil,5895,O
apoptosis,5895,O
maximally,5895,O
by,5895,O
42-49,5895,O
%,5895,O
.,5895,O
In,5896,O
neutrophils,5896,O
",",5896,O
rolipram,5896,B-CHEMICAL
(,5896,O
10,5896,O
microM,5896,O
),5896,O
also,5896,O
decreased,5896,O
apoptosis,5896,O
with,5896,O
a,5896,O
maximal,5896,O
inhibition,5896,O
of,5896,O
13,5896,O
%,5896,O
.,5896,O
The,5897,O
combination,5897,O
of,5897,O
rolipram,5897,B-CHEMICAL
(,5897,O
10,5897,O
microM,5897,O
),5897,O
and,5897,O
salbutamol,5897,B-CHEMICAL
(,5897,O
100,5897,O
nM,5897,O
),5897,O
produced,5897,O
a,5897,O
27,5897,O
%,5897,O
inhibition,5897,O
of,5897,O
neutrophil,5897,O
apoptosis,5897,O
.,5897,O
Inhibitor,5898,O
of,5898,O
cGMP-specific,5898,B-GENE-Y
PDE5,5898,I-GENE-Y
(,5898,O
zaprinast,5898,B-CHEMICAL
;,5898,O
0.1-10,5898,O
microM,5898,O
),5898,O
did,5898,O
not,5898,O
affect,5898,O
eosinophil,5898,O
apoptosis,5898,O
and,5898,O
only,5898,O
slightly,5898,O
increased,5898,O
spontaneous,5898,O
neutrophil,5898,O
apoptosis,5898,O
.,5898,O
The,5899,O
effect,5899,O
of,5899,O
budesonide,5899,B-CHEMICAL
on,5899,O
apoptosis,5899,O
was,5899,O
not,5899,O
significantly,5899,O
modulated,5899,O
by,5899,O
a,5899,O
PDE4,5899,B-GENE-N
inhibitor,5899,O
in,5899,O
eosinophils,5899,O
or,5899,O
neutrophils,5899,O
.,5899,O
The,5900,O
present,5900,O
results,5900,O
show,5900,O
that,5900,O
selective,5900,O
inhibitors,5900,O
of,5900,O
cAMP-hydrolyzing,5900,B-GENE-N
PDEs,5900,I-GENE-N
(,5900,O
PDE3,5900,B-GENE-N
and,5900,O
PDE4,5900,B-GENE-N
),5900,O
delay,5900,O
eosinophil,5900,O
apoptosis,5900,O
and,5900,O
",",5900,O
thus,5900,O
",",5900,O
increase,5900,O
their,5900,O
survival,5900,O
in,5900,O
vitro,5900,O
.,5900,O
Furthermore,5901,O
",",5901,O
beta,5901,B-GENE-Y
2-adrenoceptor,5901,I-GENE-Y
agonists,5901,O
enhance,5901,O
the,5901,O
anti-apoptotic,5901,O
effects,5901,O
of,5901,O
PDE3,5901,B-GENE-N
and,5901,O
PDE4,5901,B-GENE-N
inhibitors,5901,O
",",5901,O
suggesting,5901,O
that,5901,O
such,5901,O
drug,5901,O
combinations,5901,O
may,5901,O
prolong,5901,O
eosinophil,5901,O
and,5901,O
neutrophil,5901,O
longevity,5901,O
in,5901,O
the,5901,O
lung,5901,O
.,5901,O
Significance,5902,O
of,5902,O
the,5902,O
transient,5902,B-GENE-Y
receptor,5902,I-GENE-Y
potential,5902,I-GENE-Y
canonical,5902,I-GENE-Y
2,5902,I-GENE-Y
(,5902,O
TRPC2,5902,B-GENE-Y
),5902,O
channel,5902,O
in,5902,O
the,5902,O
regulation,5902,O
of,5902,O
rat,5902,O
thyroid,5902,O
FRTL-5,5902,O
cell,5902,O
proliferation,5902,O
",",5902,O
migration,5902,O
",",5902,O
adhesion,5902,O
and,5902,O
invasion,5902,O
.,5902,O
Mammalian,5903,B-GENE-N
transient,5903,I-GENE-N
receptor,5903,I-GENE-N
potential,5903,I-GENE-N
(,5903,I-GENE-N
TRP,5903,I-GENE-N
),5903,I-GENE-N
channels,5903,I-GENE-N
are,5903,O
involved,5903,O
in,5903,O
many,5903,O
physiologically,5903,O
important,5903,O
processes,5903,O
.,5903,O
Here,5904,O
",",5904,O
we,5904,O
have,5904,O
studied,5904,O
the,5904,O
significance,5904,O
of,5904,O
the,5904,O
TRPC2,5904,B-GENE-Y
channel,5904,O
in,5904,O
the,5904,O
regulation,5904,O
of,5904,O
rat,5904,O
thyroid,5904,O
FRTL-5,5904,O
cell,5904,O
proliferation,5904,O
",",5904,O
migration,5904,O
",",5904,O
adhesion,5904,O
and,5904,O
invasion,5904,O
",",5904,O
using,5904,O
stable,5904,O
TRPC2,5904,B-GENE-Y
(,5904,O
shTRPC2,5904,O
),5904,O
knock-down,5904,O
cells,5904,O
.,5904,O
In,5905,O
the,5905,O
shTRPC2,5905,O
cells,5905,O
",",5905,O
proliferation,5905,O
was,5905,O
decreased,5905,O
due,5905,O
to,5905,O
a,5905,O
prolonged,5905,O
G1/S,5905,O
cell,5905,O
cycle,5905,O
phase,5905,O
.,5905,O
The,5906,O
tumor,5906,B-GENE-Y
suppressor,5906,I-GENE-Y
p53,5906,I-GENE-Y
and,5906,O
the,5906,O
cyclin-dependant,5906,B-GENE-Y
kinase,5906,I-GENE-Y
inhibitors,5906,I-GENE-Y
p27,5906,I-GENE-Y
and,5906,O
p21,5906,B-GENE-Y
were,5906,O
upregulated,5906,O
.,5906,O
Cell,5907,O
invasion,5907,O
",",5907,O
adhesion,5907,O
and,5907,O
migration,5907,O
were,5907,O
also,5907,O
attenuated,5907,O
in,5907,O
shTRPC2,5907,O
cells,5907,O
",",5907,O
probably,5907,O
due,5907,O
to,5907,O
decreased,5907,O
activity,5907,O
of,5907,O
both,5907,O
Rac,5907,B-GENE-N
and,5907,O
calpain,5907,B-GENE-N
",",5907,O
and,5907,O
a,5907,O
decreased,5907,O
secretion,5907,O
and,5907,O
activity,5907,O
of,5907,O
matrix,5907,B-GENE-Y
metalloproteinase,5907,I-GENE-Y
2,5907,I-GENE-Y
.,5907,O
The,5908,O
attenuated,5908,O
proliferation,5908,O
",",5908,O
migration,5908,O
",",5908,O
invasion,5908,O
and,5908,O
ATP-evoked,5908,B-CHEMICAL
calcium,5908,B-CHEMICAL
entry,5908,O
was,5908,O
mimicked,5908,O
by,5908,O
overexpressing,5908,O
a,5908,O
non-conducting,5908,O
",",5908,O
truncated,5908,O
TRPC2,5908,B-GENE-Y
(,5908,O
TRPC2-DN,5908,B-GENE-Y
),5908,O
in,5908,O
wild,5908,O
type,5908,O
cells,5908,O
",",5908,O
and,5908,O
was,5908,O
reversed,5908,O
by,5908,O
overexpression,5908,O
of,5908,O
TRPC2-GFP,5908,B-GENE-Y
in,5908,O
shTRPC2,5908,O
cells,5908,O
.,5908,O
In,5909,O
conclusion,5909,O
",",5909,O
TRPC2,5909,B-GENE-Y
is,5909,O
an,5909,O
important,5909,O
regulator,5909,O
of,5909,O
rat,5909,O
thyroid,5909,O
cell,5909,O
function,5909,O
.,5909,O
Lutein,5910,O
and,5910,O
eicosapentaenoic,5910,B-CHEMICAL
acid,5910,I-CHEMICAL
interact,5910,O
to,5910,O
modify,5910,O
iNOS,5910,B-GENE-Y
mRNA,5910,O
levels,5910,O
through,5910,O
the,5910,O
PPARgamma/RXR,5910,B-GENE-Y
pathway,5910,O
in,5910,O
chickens,5910,O
and,5910,O
HD11,5910,O
cell,5910,O
lines,5910,O
.,5910,O
Two,5911,O
experiments,5911,O
were,5911,O
conducted,5911,O
to,5911,O
investigate,5911,O
the,5911,O
effect,5911,O
of,5911,O
lutein,5911,O
and,5911,O
fat,5911,O
or,5911,O
eicosapentaenoic,5911,B-CHEMICAL
acid,5911,I-CHEMICAL
(,5911,O
EPA,5911,B-CHEMICAL
),5911,O
interaction,5911,O
on,5911,O
inducible,5911,B-GENE-Y
nitric,5911,I-GENE-Y
oxide,5911,I-GENE-Y
synthase,5911,I-GENE-Y
(,5911,O
iNOS,5911,B-GENE-Y
),5911,O
",",5911,O
PPARs,5911,B-GENE-N
alpha,5911,I-GENE-N
",",5911,I-GENE-N
beta,5911,I-GENE-N
",",5911,I-GENE-N
and,5911,I-GENE-N
gamma,5911,I-GENE-N
",",5911,O
and,5911,O
retinoic,5911,B-GENE-N
acid,5911,I-GENE-N
X,5911,I-GENE-N
receptor,5911,I-GENE-N
(,5911,I-GENE-N
RXR,5911,I-GENE-N
),5911,I-GENE-N
alpha,5911,I-GENE-N
and,5911,I-GENE-N
gamma,5911,I-GENE-N
mRNA,5911,O
levels,5911,O
.,5911,O
In,5912,O
Expt,5912,O
.,5912,O
1,5913,O
",",5913,O
macrophages,5913,O
were,5913,O
collected,5913,O
from,5913,O
broiler,5913,O
chicks,5913,O
fed,5913,O
3,5913,O
or,5913,O
6,5913,O
%,5913,O
dietary,5913,O
fat,5913,O
(,5913,O
g/100,5913,O
g,5913,O
),5913,O
with,5913,O
0,5913,O
",",5913,O
25,5913,O
",",5913,O
and,5913,O
50,5913,O
mg,5913,O
lutein/kg,5913,O
feed,5913,O
for,5913,O
23,5913,O
d.,5913,O
In,5913,O
Expt,5913,O
.,5913,O
2,5914,O
",",5914,O
using,5914,O
a,5914,O
3,5914,O
x,5914,O
3,5914,O
factorial,5914,O
",",5914,O
eicosapentaenoic,5914,B-CHEMICAL
acid,5914,I-CHEMICAL
(,5914,O
EPA,5914,B-CHEMICAL
),5914,O
at,5914,O
0,5914,O
",",5914,O
15,5914,O
and,5914,O
50,5914,O
micromol/L,5914,O
and,5914,O
lutein,5914,O
at,5914,O
0,5914,O
",",5914,O
10,5914,O
and,5914,O
100,5914,O
micromol/L,5914,O
were,5914,O
applied,5914,O
to,5914,O
HD11,5914,O
cell,5914,O
culture,5914,O
for,5914,O
24,5914,O
h.,5914,O
In,5914,O
both,5914,O
experiments,5914,O
",",5914,O
cells,5914,O
were,5914,O
stimulated,5914,O
with,5914,O
lipopolysaccharide,5914,O
before,5914,O
RNA,5914,O
isolation,5914,O
.,5914,O
Lutein,5915,O
interacted,5915,O
with,5915,O
fat,5915,O
in,5915,O
Expt,5915,O
.,5915,O
1,5916,O
and,5916,O
with,5916,O
EPA,5916,O
in,5916,O
Expt,5916,O
.,5916,O
2,5917,O
to,5917,O
affect,5917,O
mRNA,5917,O
levels,5917,O
of,5917,O
iNOS,5917,B-GENE-Y
",",5917,O
PPARgamma,5917,B-GENE-Y
",",5917,O
and,5917,O
RXRalpha,5917,B-GENE-Y
in,5917,O
chicken,5917,O
macrophages,5917,O
and,5917,O
HD11,5917,O
cells,5917,O
",",5917,O
respectively,5917,O
(,5917,O
P,5917,O
<,5917,O
0.05,5917,O
),5917,O
.,5917,O
At,5918,O
3,5918,O
%,5918,O
dietary,5918,O
fat,5918,O
or,5918,O
up,5918,O
to,5918,O
15,5918,O
micromol/L,5918,O
EPA,5918,O
in,5918,O
the,5918,O
medium,5918,O
",",5918,O
increasing,5918,O
lutein,5918,O
increased,5918,O
the,5918,O
iNOS,5918,B-GENE-Y
mRNA,5918,O
.,5918,O
However,5919,O
",",5919,O
at,5919,O
6,5919,O
%,5919,O
dietary,5919,O
fat,5919,O
or,5919,O
50,5919,O
micromol/L,5919,O
EPA,5919,O
",",5919,O
lutein,5919,O
did,5919,O
not,5919,O
cause,5919,O
a,5919,O
rise,5919,O
in,5919,O
iNOS,5919,B-GENE-Y
mRNA,5919,O
.,5919,O
Increasing,5920,O
lutein,5920,O
in,5920,O
the,5920,O
medium,5920,O
from,5920,O
0,5920,O
to,5920,O
100,5920,O
micromol/L,5920,O
decreased,5920,O
iNOS,5920,B-GENE-Y
mRNA,5920,O
.,5920,O
Increasing,5921,O
lutein,5921,O
with,5921,O
high,5921,O
fat,5921,O
(,5921,O
6,5921,O
%,5921,O
),5921,O
or,5921,O
EPA,5921,O
(,5921,O
15,5921,O
micromol/L,5921,O
EPA,5921,O
),5921,O
increased,5921,O
PPARgamma,5921,B-GENE-Y
and,5921,O
RXRalpha,5921,B-GENE-Y
mRNA,5921,O
levels,5921,O
.,5921,O
Lutein,5922,O
increased,5922,O
PPARalpha,5922,B-GENE-Y
mRNA,5922,O
levels,5922,O
in,5922,O
both,5922,O
macrophages,5922,O
(,5922,O
P,5922,O
<,5922,O
0.01,5922,O
),5922,O
and,5922,O
HD11,5922,O
(,5922,O
P,5922,O
=,5922,O
0.01,5922,O
),5922,O
cells,5922,O
and,5922,O
RXRgamma,5922,B-GENE-Y
(,5922,O
P,5922,O
<,5922,O
0.01,5922,O
),5922,O
mRNA,5922,O
levels,5922,O
in,5922,O
macrophages,5922,O
.,5922,O
GW9662,5923,B-CHEMICAL
",",5923,O
a,5923,O
PPARgamma,5923,B-GENE-Y
antagonist,5923,O
",",5923,O
prevented,5923,O
(,5923,O
P,5923,O
<,5923,O
0.01,5923,O
),5923,O
the,5923,O
lutein-induced,5923,O
iNOS,5923,B-GENE-Y
mRNA,5923,O
downregulation,5923,O
in,5923,O
HD11,5923,O
cells,5923,O
.,5923,O
LG101208,5924,O
",",5924,O
a,5924,O
RXR,5924,B-GENE-N
antagonist,5924,O
",",5924,O
prevented,5924,O
(,5924,O
P,5924,O
<,5924,O
0.01,5924,O
),5924,O
iNOS,5924,B-GENE-Y
upregulation,5924,O
induced,5924,O
by,5924,O
10,5924,O
micromol/L,5924,O
lutein,5924,O
and,5924,O
iNOS,5924,B-GENE-Y
mRNA,5924,O
downregulation,5924,O
induced,5924,O
by,5924,O
100,5924,O
micromol/L,5924,O
lutein,5924,O
.,5924,O
We,5925,O
conclude,5925,O
that,5925,O
lutein,5925,O
and,5925,O
EPA,5925,B-CHEMICAL
interact,5925,O
through,5925,O
the,5925,O
PPARgamma,5925,B-GENE-Y
and,5925,O
RXR,5925,B-GENE-N
pathways,5925,O
to,5925,O
modulate,5925,O
iNOS,5925,B-GENE-Y
mRNA,5925,O
.,5925,O
Occupancy,5926,O
of,5926,O
dopamine,5926,B-CHEMICAL
D,5926,B-GENE-Y
(,5926,I-GENE-Y
1,5926,I-GENE-Y
),5926,I-GENE-Y
",",5926,O
D,5926,B-GENE-Y
(,5926,I-GENE-Y
2,5926,I-GENE-Y
),5926,I-GENE-Y
and,5926,O
serotonin,5926,B-GENE-Y
(,5926,I-GENE-Y
2A,5926,I-GENE-Y
),5926,I-GENE-Y
receptors,5926,I-GENE-Y
in,5926,O
schizophrenic,5926,O
patients,5926,O
treated,5926,O
with,5926,O
flupentixol,5926,B-CHEMICAL
in,5926,O
comparison,5926,O
with,5926,O
risperidone,5926,B-CHEMICAL
and,5926,O
haloperidol,5926,B-CHEMICAL
.,5926,O
RATIONALE,5927,O
:,5927,O
Flupentixol,5927,B-CHEMICAL
(,5927,O
FLX,5927,B-CHEMICAL
),5927,O
has,5927,O
been,5927,O
used,5927,O
as,5927,O
a,5927,O
neuroleptic,5927,O
for,5927,O
nearly,5927,O
4,5927,O
decades,5927,O
.,5927,O
In,5928,O
vitro,5928,O
data,5928,O
show,5928,O
comparable,5928,O
affinity,5928,O
to,5928,O
dopamine,5928,B-GENE-Y
D,5928,I-GENE-Y
(,5928,I-GENE-Y
2,5928,I-GENE-Y
),5928,I-GENE-Y
",",5928,O
D,5928,B-GENE-Y
(,5928,I-GENE-Y
1,5928,I-GENE-Y
),5928,I-GENE-Y
and,5928,O
5-HT,5928,B-GENE-Y
(,5928,I-GENE-Y
2A,5928,I-GENE-Y
),5928,I-GENE-Y
receptors,5928,I-GENE-Y
and,5928,O
recently,5928,O
",",5928,O
FLX,5928,B-CHEMICAL
showed,5928,O
to,5928,O
be,5928,O
not,5928,O
inferior,5928,O
to,5928,O
risperidone,5928,B-CHEMICAL
in,5928,O
schizophrenic,5928,O
patients,5928,O
with,5928,O
predominant,5928,O
negative,5928,O
symptomatology,5928,O
",",5928,O
which,5928,O
was,5928,O
implicated,5928,O
with,5928,O
flupentixol,5928,O
's,5928,O
interaction,5928,O
with,5928,O
5-HT,5928,B-GENE-Y
(,5928,I-GENE-Y
2A,5928,I-GENE-Y
),5928,I-GENE-Y
and/or,5928,O
D,5928,B-GENE-Y
(,5928,I-GENE-Y
1,5928,I-GENE-Y
),5928,I-GENE-Y
receptors,5928,I-GENE-Y
.,5928,O
OBJECTIVES,5929,O
:,5929,O
To,5929,O
assess,5929,O
in,5929,O
vivo,5929,O
receptor,5929,O
occupancy,5929,O
(,5929,O
RO,5929,O
),5929,O
in,5929,O
patients,5929,O
clinically,5929,O
treated,5929,O
with,5929,O
FLX,5929,O
(,5929,O
n,5929,O
=,5929,O
13,5929,O
",",5929,O
5.7,5929,O
+/-,5929,O
1.4,5929,O
mg/day,5929,O
),5929,O
in,5929,O
comparison,5929,O
with,5929,O
risperidone,5929,B-CHEMICAL
(,5929,O
RIS,5929,O
",",5929,O
n,5929,O
=,5929,O
11,5929,O
",",5929,O
3.6,5929,O
+/-,5929,O
1.3,5929,O
mg/day,5929,O
),5929,O
and,5929,O
haloperidol,5929,B-CHEMICAL
(,5929,O
HAL,5929,O
",",5929,O
n,5929,O
=,5929,O
11,5929,O
",",5929,O
8.5,5929,O
+/-,5929,O
5.5,5929,O
mg/day,5929,O
),5929,O
.,5929,O
MATERIALS,5930,O
AND,5930,O
METHODS,5930,O
:,5930,O
Each,5930,O
patient,5930,O
underwent,5930,O
two,5930,O
PET,5930,O
scans,5930,O
with,5930,O
3-N-,5930,B-CHEMICAL
[,5930,I-CHEMICAL
(,5930,I-CHEMICAL
11,5930,I-CHEMICAL
),5930,I-CHEMICAL
C,5930,I-CHEMICAL
],5930,I-CHEMICAL
methylspiperone,5930,I-CHEMICAL
(,5930,O
target,5930,O
:,5930,O
frontal,5930,O
5-HT,5930,B-GENE-Y
(,5930,I-GENE-Y
2A,5930,I-GENE-Y
),5930,I-GENE-Y
),5930,O
",",5930,O
[,5930,B-CHEMICAL
(,5930,I-CHEMICAL
11,5930,I-CHEMICAL
),5930,I-CHEMICAL
C,5930,I-CHEMICAL
],5930,I-CHEMICAL
SCH23390,5930,I-CHEMICAL
(,5930,O
striatal,5930,O
D,5930,B-GENE-Y
(,5930,I-GENE-Y
1,5930,I-GENE-Y
),5930,I-GENE-Y
),5930,O
or,5930,O
[,5930,B-CHEMICAL
(,5930,I-CHEMICAL
11,5930,I-CHEMICAL
),5930,I-CHEMICAL
C,5930,I-CHEMICAL
],5930,I-CHEMICAL
raclopride,5930,I-CHEMICAL
(,5930,O
striatal,5930,O
D,5930,B-GENE-Y
(,5930,I-GENE-Y
2,5930,I-GENE-Y
),5930,I-GENE-Y
),5930,O
.,5930,O
RO,5931,O
was,5931,O
calculated,5931,O
as,5931,O
the,5931,O
percentage,5931,O
reduction,5931,O
of,5931,O
specific,5931,O
binding,5931,O
in,5931,O
comparison,5931,O
with,5931,O
healthy,5931,O
controls,5931,O
.,5931,O
RESULTS,5932,O
:,5932,O
D,5932,B-GENE-Y
(,5932,I-GENE-Y
2,5932,I-GENE-Y
),5932,I-GENE-Y
-RO,5932,O
under,5932,O
FLX,5932,O
was,5932,O
between,5932,O
50,5932,O
%,5932,O
and,5932,O
70,5932,O
%,5932,O
",",5932,O
indicating,5932,O
an,5932,O
ED,5932,O
(,5932,O
50,5932,O
),5932,O
of,5932,O
about,5932,O
0.7,5932,O
ng/ml,5932,O
serum,5932,O
.,5932,O
5-HT,5933,B-GENE-Y
(,5933,I-GENE-Y
2A,5933,I-GENE-Y
),5933,I-GENE-Y
and,5933,O
D,5933,B-GENE-Y
(,5933,I-GENE-Y
1,5933,I-GENE-Y
),5933,I-GENE-Y
-RO,5933,O
was,5933,O
20,5933,O
+/-,5933,O
10,5933,O
%,5933,O
and,5933,O
20,5933,O
+/-,5933,O
5,5933,O
%,5933,O
(,5933,O
mean,5933,O
",",5933,O
SEM,5933,O
),5933,O
.,5933,O
Under,5934,O
HAL,5934,O
",",5934,O
D,5934,B-GENE-Y
(,5934,I-GENE-Y
1,5934,I-GENE-Y
),5934,I-GENE-Y
-RO,5934,O
was,5934,O
14,5934,O
+/-,5934,O
6,5934,O
%,5934,O
and,5934,O
under,5934,O
RIS,5934,O
not,5934,O
significantly,5934,O
different,5934,O
from,5934,O
zero,5934,O
.,5934,O
CONCLUSIONS,5935,O
:,5935,O
We,5935,O
were,5935,O
able,5935,O
to,5935,O
demonstrate,5935,O
a,5935,O
moderate,5935,O
5-HT,5935,B-GENE-Y
(,5935,I-GENE-Y
2A,5935,I-GENE-Y
),5935,I-GENE-Y
and,5935,O
D,5935,B-GENE-Y
(,5935,I-GENE-Y
1,5935,I-GENE-Y
),5935,I-GENE-Y
occupancy,5935,O
under,5935,O
clinically,5935,O
relevant,5935,O
doses,5935,O
of,5935,O
flupentixol,5935,B-CHEMICAL
",",5935,O
albeit,5935,O
lower,5935,O
than,5935,O
expected,5935,O
from,5935,O
in,5935,O
vitro,5935,O
data,5935,O
and,5935,O
clearly,5935,O
below,5935,O
saturation,5935,O
.,5935,O
Therefore,5936,O
",",5936,O
if,5936,O
flupentixol,5936,O
's,5936,O
efficacy,5936,O
on,5936,O
negative,5936,O
symptoms,5936,O
is,5936,O
based,5936,O
on,5936,O
its,5936,O
interaction,5936,O
with,5936,O
5-HT,5936,B-GENE-Y
(,5936,I-GENE-Y
2A,5936,I-GENE-Y
),5936,I-GENE-Y
and/or,5936,O
D,5936,B-GENE-Y
(,5936,I-GENE-Y
1,5936,I-GENE-Y
),5936,I-GENE-Y
receptors,5936,I-GENE-Y
",",5936,O
it,5936,O
should,5936,O
be,5936,O
highly,5936,O
dependent,5936,O
on,5936,O
serum,5936,O
concentration,5936,O
and,5936,O
thus,5936,O
on,5936,O
dosage,5936,O
and,5936,O
metabolism,5936,O
.,5936,O
However,5937,O
",",5937,O
these,5937,O
data,5937,O
suggest,5937,O
that,5937,O
mechanisms,5937,O
other,5937,O
than,5937,O
D,5937,B-GENE-Y
(,5937,I-GENE-Y
1,5937,I-GENE-Y
),5937,I-GENE-Y
or,5937,O
5-HT,5937,B-GENE-Y
(,5937,I-GENE-Y
2A,5937,I-GENE-Y
),5937,I-GENE-Y
antagonism,5937,O
may,5937,O
contribute,5937,O
to,5937,O
flupentixol,5937,O
's,5937,O
efficacy,5937,O
on,5937,O
negative,5937,O
symptoms,5937,O
.,5937,O
Stereospecific,5938,O
inhibition,5938,O
of,5938,O
monoamine,5938,B-GENE-N
uptake,5938,I-GENE-N
transporters,5938,I-GENE-N
by,5938,O
meta-hydroxyephedrine,5938,B-CHEMICAL
isomers,5938,O
.,5938,O
Meta-hydroxyephedrine,5939,B-CHEMICAL
(,5939,O
HED,5939,B-CHEMICAL
),5939,O
comprises,5939,O
four,5939,O
stereoisomers,5939,O
consisting,5939,O
of,5939,O
two,5939,O
enantiomeric,5939,O
pairs,5939,O
related,5939,O
to,5939,O
ephedrine,5939,B-CHEMICAL
and,5939,O
pseudoephedrine,5939,B-CHEMICAL
.,5939,O
HED,5940,B-CHEMICAL
is,5940,O
transported,5940,O
into,5940,O
adrenergic,5940,O
neurons,5940,O
and,5940,O
radiolabeled,5940,O
HED,5940,B-CHEMICAL
has,5940,O
been,5940,O
employed,5940,O
in,5940,O
positron,5940,O
emission,5940,O
tomography,5940,O
(,5940,O
PET,5940,O
),5940,O
to,5940,O
image,5940,O
adrenergic,5940,O
neurons,5940,O
in,5940,O
vivo,5940,O
.,5940,O
To,5941,O
extend,5941,O
structure-activity,5941,O
analyses,5941,O
of,5941,O
binding,5941,O
sites,5941,O
within,5941,O
monoamine,5941,B-GENE-N
transporters,5941,I-GENE-N
and,5941,O
to,5941,O
determine,5941,O
which,5941,O
stereoisomer,5941,O
displayed,5941,O
the,5941,O
best,5941,O
selectivity,5941,O
for,5941,O
PET,5941,O
imaging,5941,O
applications,5941,O
",",5941,O
we,5941,O
tested,5941,O
the,5941,O
HED,5941,B-CHEMICAL
compounds,5941,O
for,5941,O
their,5941,O
abilities,5941,O
to,5941,O
inhibit,5941,O
[,5941,O
(,5941,B-CHEMICAL
3,5941,I-CHEMICAL
),5941,I-CHEMICAL
H,5941,I-CHEMICAL
],5941,O
neurotransmitter,5941,O
uptake,5941,O
into,5941,O
platelets,5941,O
",",5941,O
transfected,5941,O
cells,5941,O
",",5941,O
and,5941,O
chromaffin,5941,O
vesicles,5941,O
.,5941,O
We,5942,O
hypothesized,5942,O
that,5942,O
the,5942,O
HED,5942,B-CHEMICAL
compounds,5942,O
would,5942,O
be,5942,O
most,5942,O
potent,5942,O
at,5942,O
the,5942,O
norepinephrine,5942,B-GENE-Y
transporter,5942,I-GENE-Y
(,5942,O
NET,5942,B-GENE-Y
),5942,O
compared,5942,O
to,5942,O
the,5942,O
serotonin,5942,B-GENE-N
or,5942,I-GENE-N
dopamine,5942,I-GENE-N
transporters,5942,I-GENE-N
and,5942,O
that,5942,O
the,5942,O
1R,5942,O
diastereomers,5942,O
would,5942,O
be,5942,O
more,5942,O
effective,5942,O
than,5942,O
1S,5942,O
diastereomers,5942,O
.,5942,O
Supporting,5943,O
the,5943,O
hypotheses,5943,O
",",5943,O
all,5943,O
stereoisomers,5943,O
were,5943,O
most,5943,O
potent,5943,O
at,5943,O
the,5943,O
NET,5943,B-GENE-Y
and,5943,O
the,5943,O
"1R,2S",5943,O
stereoisomer,5943,O
was,5943,O
the,5943,O
most,5943,O
potent,5943,O
inhibitor,5943,O
overall,5943,O
.,5943,O
However,5944,O
",",5944,O
the,5944,O
"1S,2R",5944,O
isomer,5944,O
may,5944,O
be,5944,O
preferred,5944,O
for,5944,O
PET,5944,O
applications,5944,O
because,5944,O
of,5944,O
better,5944,O
selectivity,5944,O
among,5944,O
the,5944,O
transporters,5944,O
and,5944,O
reduced,5944,O
neuronal,5944,O
recycling,5944,O
.,5944,O
TCDD,5945,B-CHEMICAL
inhibition,5945,O
of,5945,O
canonical,5945,O
wnt,5945,B-GENE-N
signaling,5945,O
disrupts,5945,O
prostatic,5945,O
bud,5945,O
formation,5945,O
in,5945,O
mouse,5945,O
urogenital,5945,O
sinus,5945,O
.,5945,O
In,5946,O
mice,5946,O
",",5946,O
in,5946,O
utero,5946,O
exposure,5946,O
to,5946,O
"2,3,7,8-tetrachlorodibenzo-p-",5946,B-CHEMICAL
dioxin,5946,I-CHEMICAL
(,5946,O
TCDD,5946,B-CHEMICAL
),5946,O
reduces,5946,O
the,5946,O
number,5946,O
of,5946,O
dorsolateral,5946,O
prostatic,5946,O
buds,5946,O
resulting,5946,O
in,5946,O
a,5946,O
smaller,5946,O
dorsolateral,5946,O
prostate,5946,O
and,5946,O
prevents,5946,O
formation,5946,O
of,5946,O
ventral,5946,O
buds,5946,O
culminating,5946,O
in,5946,O
ventral,5946,O
prostate,5946,O
agenesis,5946,O
.,5946,O
The,5947,O
genes,5947,O
and,5947,O
signaling,5947,O
pathways,5947,O
affected,5947,O
by,5947,O
TCDD,5947,B-CHEMICAL
that,5947,O
are,5947,O
responsible,5947,O
for,5947,O
disrupting,5947,O
prostate,5947,O
development,5947,O
are,5947,O
largely,5947,O
unknown,5947,O
.,5947,O
Here,5948,O
we,5948,O
show,5948,O
that,5948,O
treatment,5948,O
of,5948,O
urogenital,5948,O
sinus,5948,O
(,5948,O
UGS,5948,O
),5948,O
organ,5948,O
cultures,5948,O
with,5948,O
known,5948,O
inhibitors,5948,O
of,5948,O
canonical,5948,O
Wnt,5948,B-GENE-N
signaling,5948,O
also,5948,O
inhibits,5948,O
prostatic,5948,O
bud,5948,O
formation,5948,O
.,5948,O
In,5949,O
support,5949,O
of,5949,O
the,5949,O
hypothesis,5949,O
that,5949,O
TCDD,5949,B-CHEMICAL
decreases,5949,O
canonical,5949,O
Wnt,5949,B-GENE-N
signaling,5949,O
",",5949,O
we,5949,O
identify,5949,O
inhibitory,5949,O
effects,5949,O
of,5949,O
TCDD,5949,B-CHEMICAL
on,5949,O
multiple,5949,O
components,5949,O
of,5949,O
the,5949,O
canonical,5949,O
Wnt,5949,B-GENE-N
signaling,5949,O
pathway,5949,O
in,5949,O
the,5949,O
UGS,5949,O
that,5949,O
temporally,5949,O
coincide,5949,O
with,5949,O
the,5949,O
inhibitory,5949,O
effect,5949,O
of,5949,O
TCDD,5949,B-CHEMICAL
on,5949,O
prostatic,5949,O
bud,5949,O
formation,5949,O
:,5949,O
(,5949,O
1,5949,O
),5949,O
expression,5949,O
of,5949,O
R-spondins,5949,B-GENE-N
(,5949,O
Rspo2,5949,B-GENE-Y
and,5949,O
Rspo3,5949,B-GENE-Y
),5949,O
that,5949,O
promote,5949,O
canonical,5949,O
Wnt,5949,B-GENE-N
signaling,5949,O
is,5949,O
reduced,5949,O
;,5949,O
(,5949,O
2,5949,O
),5949,O
expression,5949,O
of,5949,O
Lef1,5949,B-GENE-Y
",",5949,O
Tcf1,5949,B-GENE-Y
",",5949,O
and,5949,O
Wif1,5949,B-GENE-Y
",",5949,O
established,5949,O
canonical,5949,O
Wnt,5949,B-GENE-N
target,5949,O
genes,5949,O
",",5949,O
is,5949,O
decreased,5949,O
;,5949,O
(,5949,O
3,5949,O
),5949,O
expression,5949,O
of,5949,O
Lgr5,5949,B-GENE-Y
",",5949,O
a,5949,O
RSPO,5949,B-GENE-Y
receptor,5949,I-GENE-Y
that,5949,O
activates,5949,O
canonical,5949,O
Wnt,5949,B-GENE-N
signaling,5949,O
",",5949,O
is,5949,O
reduced,5949,O
;,5949,O
and,5949,O
(,5949,O
4,5949,O
),5949,O
expression,5949,O
of,5949,O
Dickkopfs,5949,B-GENE-N
(,5949,O
Dkks,5949,B-GENE-N
),5949,O
",",5949,O
inhibitors,5949,O
of,5949,O
canonical,5949,O
Wnt,5949,B-GENE-N
signaling,5949,O
",",5949,O
is,5949,O
not,5949,O
increased,5949,O
by,5949,O
TCDD,5949,B-CHEMICAL
.,5949,O
Thus,5950,O
",",5950,O
the,5950,O
TCDD-induced,5950,B-CHEMICAL
reduction,5950,O
in,5950,O
canonical,5950,O
Wnt,5950,B-GENE-N
signaling,5950,O
is,5950,O
associated,5950,O
with,5950,O
a,5950,O
decrease,5950,O
in,5950,O
activators,5950,O
(,5950,O
Rspo2,5950,B-GENE-Y
and,5950,O
Rspo3,5950,B-GENE-Y
),5950,O
rather,5950,O
than,5950,O
an,5950,O
increase,5950,O
in,5950,O
inhibitors,5950,O
(,5950,O
Dkk1,5950,B-GENE-Y
and,5950,O
Dkk2,5950,B-GENE-Y
),5950,O
of,5950,O
the,5950,O
pathway,5950,O
.,5950,O
This,5951,O
study,5951,O
focuses,5951,O
on,5951,O
determining,5951,O
whether,5951,O
treatment,5951,O
of,5951,O
TCDD-exposed,5951,B-CHEMICAL
UGS,5951,O
organ,5951,O
cultures,5951,O
with,5951,O
RSPO2,5951,B-GENE-Y
and/or,5951,O
RSPO3,5951,B-GENE-Y
is,5951,O
capable,5951,O
of,5951,O
rescuing,5951,O
the,5951,O
inhibitory,5951,O
effects,5951,O
of,5951,O
TCDD,5951,B-CHEMICAL
on,5951,O
canonical,5951,O
Wnt,5951,B-GENE-N
signaling,5951,O
and,5951,O
prostatic,5951,O
bud,5951,O
formation,5951,O
.,5951,O
We,5952,O
discovered,5952,O
that,5952,O
each,5952,O
RSPO,5952,B-GENE-N
alone,5952,O
or,5952,O
in,5952,O
combination,5952,O
partially,5952,O
rescues,5952,O
TCDD,5952,B-CHEMICAL
inhibition,5952,O
of,5952,O
both,5952,O
canonical,5952,O
Wnt,5952,B-GENE-N
signaling,5952,O
and,5952,O
prostatic,5952,O
bud,5952,O
formation,5952,O
.,5952,O
CYP2J2,5953,B-GENE-Y
overexpression,5953,O
increases,5953,O
EETs,5953,B-CHEMICAL
and,5953,O
protects,5953,O
against,5953,O
angiotensin,5953,B-GENE-Y
II-induced,5953,O
abdominal,5953,O
aortic,5953,O
aneurysm,5953,O
in,5953,O
mice,5953,O
.,5953,O
Cytochrome,5954,B-GENE-Y
P450,5954,I-GENE-Y
epoxygenase,5954,I-GENE-Y
2J2,5954,I-GENE-Y
(,5954,O
CYP2J2,5954,B-GENE-Y
),5954,O
metabolizes,5954,O
arachidonic,5954,B-CHEMICAL
acids,5954,I-CHEMICAL
to,5954,O
form,5954,O
epoxyeicosatrienoic,5954,B-CHEMICAL
acids,5954,I-CHEMICAL
(,5954,O
EETs,5954,B-CHEMICAL
),5954,O
",",5954,O
which,5954,O
possess,5954,O
various,5954,O
beneficial,5954,O
effects,5954,O
on,5954,O
the,5954,O
cardiovascular,5954,O
system,5954,O
.,5954,O
However,5955,O
",",5955,O
whether,5955,O
increasing,5955,O
EETs,5955,B-CHEMICAL
production,5955,O
by,5955,O
CYP2J2,5955,B-GENE-Y
overexpression,5955,O
in,5955,O
vivo,5955,O
could,5955,O
prevent,5955,O
abdominal,5955,O
aortic,5955,O
aneurysm,5955,O
(,5955,O
AAA,5955,O
),5955,O
remains,5955,O
unknown,5955,O
.,5955,O
Here,5956,O
we,5956,O
investigated,5956,O
the,5956,O
effects,5956,O
of,5956,O
recombinant,5956,O
adeno-associated,5956,O
virus,5956,O
(,5956,O
rAAV,5956,O
),5956,O
-mediated,5956,O
CYP2J2,5956,B-GENE-Y
overexpression,5956,O
on,5956,O
angiotensin,5956,B-GENE-Y
(,5956,I-GENE-Y
Ang,5956,I-GENE-Y
),5956,I-GENE-Y
II-induced,5956,O
AAA,5956,O
in,5956,O
apoE-deficient,5956,O
mice,5956,O
.,5956,O
rAAV-CYP2J2,5957,O
delivery,5957,O
led,5957,O
to,5957,O
an,5957,O
abundant,5957,O
aortic,5957,O
CYP2J2,5957,B-GENE-Y
expression,5957,O
and,5957,O
increased,5957,O
EETs,5957,B-CHEMICAL
generation,5957,O
.,5957,O
It,5958,O
was,5958,O
shown,5958,O
that,5958,O
CYP2J2,5958,B-GENE-Y
overexpression,5958,O
attenuated,5958,O
matrix,5958,B-GENE-N
metalloproteinase,5958,I-GENE-N
expression,5958,O
and,5958,O
activity,5958,O
",",5958,O
elastin,5958,B-GENE-Y
degradation,5958,O
",",5958,O
and,5958,O
AAA,5958,O
formation,5958,O
",",5958,O
which,5958,O
was,5958,O
associated,5958,O
with,5958,O
reduced,5958,O
aortic,5958,O
inflammation,5958,O
and,5958,O
macrophage,5958,O
infiltration,5958,O
.,5958,O
In,5959,O
cultured,5959,O
vascular,5959,O
smooth,5959,O
muscle,5959,O
cells,5959,O
(,5959,O
VSMCs,5959,O
),5959,O
",",5959,O
rAAV-mediated,5959,O
CYP2J2,5959,B-GENE-Y
overexpression,5959,O
and,5959,O
EETs,5959,B-CHEMICAL
markedly,5959,O
suppressed,5959,O
Ang,5959,B-GENE-Y
II-induced,5959,O
inflammatory,5959,O
cytokine,5959,B-GENE-N
expression,5959,O
.,5959,O
Moreover,5960,O
",",5960,O
overexpressed,5960,O
CYP2J2,5960,B-GENE-Y
and,5960,O
EETs,5960,B-CHEMICAL
inhibited,5960,O
Ang,5960,B-GENE-Y
II-induced,5960,O
macrophage,5960,O
migration,5960,O
in,5960,O
a,5960,O
VSMC-macrophage,5960,O
coculture,5960,O
system,5960,O
.,5960,O
We,5961,O
further,5961,O
indicated,5961,O
that,5961,O
these,5961,O
protective,5961,O
effects,5961,O
were,5961,O
mediated,5961,O
by,5961,O
peroxisome,5961,B-GENE-Y
proliferator-activated,5961,I-GENE-Y
receptor,5961,I-GENE-Y
(,5961,I-GENE-Y
PPAR,5961,I-GENE-Y
),5961,I-GENE-Y
γ,5961,I-GENE-Y
activation,5961,O
.,5961,O
Taken,5962,O
together,5962,O
",",5962,O
these,5962,O
results,5962,O
provide,5962,O
evidence,5962,O
that,5962,O
rAAV-mediated,5962,O
CYP2J2,5962,B-GENE-Y
overexpression,5962,O
prevents,5962,O
AAA,5962,O
development,5962,O
which,5962,O
is,5962,O
likely,5962,O
via,5962,O
PPARγ,5962,B-GENE-Y
activation,5962,O
and,5962,O
anti-inflammatory,5962,O
action,5962,O
",",5962,O
suggesting,5962,O
that,5962,O
increasing,5962,O
EETs,5962,B-CHEMICAL
levels,5962,O
could,5962,O
be,5962,O
considered,5962,O
as,5962,O
a,5962,O
potential,5962,O
strategy,5962,O
to,5962,O
prevent,5962,O
and,5962,O
treat,5962,O
AAA,5962,O
.,5962,O
Differential,5963,O
effects,5963,O
of,5963,O
organic,5963,O
and,5963,O
inorganic,5963,O
selenium,5963,B-CHEMICAL
compounds,5963,O
on,5963,O
adenosine,5963,B-GENE-Y
deaminase,5963,I-GENE-Y
activity,5963,O
and,5963,O
scavenger,5963,O
capacity,5963,O
in,5963,O
cerebral,5963,O
cortex,5963,O
slices,5963,O
of,5963,O
young,5963,O
rats,5963,O
.,5963,O
Selenium,5964,B-CHEMICAL
(,5964,O
Se,5964,B-CHEMICAL
),5964,O
has,5964,O
anti-inflammatory,5964,O
and,5964,O
antioxidant,5964,O
properties,5964,O
and,5964,O
is,5964,O
necessary,5964,O
for,5964,O
the,5964,O
development,5964,O
and,5964,O
normal,5964,O
function,5964,O
of,5964,O
the,5964,O
central,5964,O
nervous,5964,O
system,5964,O
.,5964,O
This,5965,O
study,5965,O
was,5965,O
aimed,5965,O
to,5965,O
compare,5965,O
the,5965,O
in,5965,O
vitro,5965,O
effects,5965,O
of,5965,O
3-methyl-1-phenyl-2-,5965,B-CHEMICAL
(,5965,I-CHEMICAL
phenylseleno,5965,I-CHEMICAL
),5965,I-CHEMICAL
oct-2-en-1-one,5965,I-CHEMICAL
(,5965,O
C21H2HOSe,5965,B-CHEMICAL
;,5965,O
organoselenium,5965,B-CHEMICAL
),5965,O
and,5965,O
sodium,5965,B-CHEMICAL
selenate,5965,I-CHEMICAL
(,5965,O
inorganic,5965,O
Se,5965,B-CHEMICAL
),5965,O
on,5965,O
adenosine,5965,B-GENE-Y
deaminase,5965,I-GENE-Y
(,5965,O
ADA,5965,B-GENE-Y
),5965,O
activity,5965,O
",",5965,O
cell,5965,O
viability,5965,O
",",5965,O
lipid,5965,O
peroxidation,5965,O
",",5965,O
scavenger,5965,O
of,5965,O
nitric,5965,B-CHEMICAL
oxide,5965,I-CHEMICAL
(,5965,O
NO,5965,B-CHEMICAL
),5965,O
and,5965,O
nonprotein,5965,O
thiols,5965,B-CHEMICAL
(,5965,O
NP-SH,5965,O
),5965,O
content,5965,O
in,5965,O
the,5965,O
cerebral,5965,O
cortex,5965,O
slices,5965,O
of,5965,O
the,5965,O
young,5965,O
rats,5965,O
.,5965,O
A,5966,O
decrease,5966,O
in,5966,O
ADA,5966,B-GENE-Y
activity,5966,O
was,5966,O
observed,5966,O
when,5966,O
the,5966,O
slices,5966,O
were,5966,O
exposed,5966,O
to,5966,O
organoselenium,5966,B-CHEMICAL
at,5966,O
the,5966,O
concentrations,5966,O
of,5966,O
1,5966,O
",",5966,O
10,5966,O
and,5966,O
30,5966,O
µM,5966,O
.,5966,O
The,5967,O
same,5967,O
compound,5967,O
showed,5967,O
higher,5967,O
scavenger,5967,O
capacity,5967,O
of,5967,O
NO,5967,B-CHEMICAL
than,5967,O
the,5967,O
inorganic,5967,O
compound,5967,O
.,5967,O
Inorganic,5968,O
Se,5968,B-CHEMICAL
was,5968,O
able,5968,O
to,5968,O
protect,5968,O
against,5968,O
sodium,5968,B-CHEMICAL
nitroprusside-induced,5968,O
oxidative,5968,O
damage,5968,O
and,5968,O
increased,5968,O
the,5968,O
NP-SH,5968,O
content,5968,O
.,5968,O
Both,5969,O
the,5969,O
compounds,5969,O
displayed,5969,O
distinctive,5969,O
antioxidant,5969,O
capacities,5969,O
and,5969,O
were,5969,O
not,5969,O
cytotoxic,5969,O
for,5969,O
the,5969,O
cerebral,5969,O
cortex,5969,O
slices,5969,O
in,5969,O
the,5969,O
conditions,5969,O
tested,5969,O
.,5969,O
These,5970,O
findings,5970,O
are,5970,O
likely,5970,O
to,5970,O
be,5970,O
related,5970,O
to,5970,O
immunomodulatory,5970,O
and,5970,O
antioxidant,5970,O
properties,5970,O
of,5970,O
this,5970,O
compound,5970,O
.,5970,O
Antigenotoxic,5971,O
potencies,5971,O
of,5971,O
a,5971,O
lichen,5971,O
species,5971,O
",",5971,O
Evernia,5971,O
prunastri,5971,O
.,5971,O
In,5972,O
this,5972,O
article,5972,O
",",5972,O
the,5972,O
genotoxic,5972,O
and,5972,O
antigenotoxic,5972,O
effects,5972,O
of,5972,O
methanol,5972,B-CHEMICAL
extract,5972,O
of,5972,O
Evernia,5972,O
prunastri,5972,O
(,5972,O
Huds,5972,O
.,5972,O
),5972,O
Willd,5973,O
.,5973,O
(,5974,O
MEP,5974,O
),5974,O
were,5974,O
studied,5974,O
using,5974,O
WP2,5974,O
",",5974,O
Ames,5974,O
(,5974,O
TA1535,5974,O
and,5974,O
TA1537,5974,O
),5974,O
and,5974,O
sister,5974,O
chromatid,5974,O
exchange,5974,O
(,5974,O
SCE,5974,O
),5974,O
test,5974,O
systems,5974,O
.,5974,O
The,5975,O
results,5975,O
obtained,5975,O
from,5975,O
bacterial,5975,O
test,5975,O
systems,5975,O
demonstrated,5975,O
that,5975,O
MEP,5975,O
has,5975,O
strong,5975,O
antimutagenic,5975,O
potencies,5975,O
on,5975,O
TA1537,5975,O
and,5975,O
WP2,5975,O
strains,5975,O
.,5975,O
The,5976,O
highest,5976,O
inhibition,5976,O
rates,5976,O
for,5976,O
MEP,5976,O
on,5976,O
TA1537,5976,O
and,5976,O
WP2,5976,O
strains,5976,O
were,5976,O
37.70,5976,O
%,5976,O
and,5976,O
69.70,5976,O
%,5976,O
",",5976,O
respectively,5976,O
.,5976,O
According,5977,O
to,5977,O
the,5977,O
SCE,5977,O
test,5977,O
system,5977,O
",",5977,O
MEP,5977,O
reduced,5977,O
the,5977,O
genotoxic,5977,O
effects,5977,O
of,5977,O
aflatoxin,5977,B-CHEMICAL
.,5977,O
In,5978,O
order,5978,O
to,5978,O
clarify,5978,O
the,5978,O
mechanism,5978,O
underlying,5978,O
the,5978,O
antigenotoxic,5978,O
effects,5978,O
of,5978,O
MEP,5978,O
",",5978,O
the,5978,O
antioxidants,5978,O
were,5978,O
determined,5978,O
.,5978,O
Cotreatments,5979,O
of,5979,O
5,5979,O
",",5979,O
10,5979,O
and,5979,O
20,5979,O
µg/mL,5979,O
concentrations,5979,O
of,5979,O
MEP,5979,O
with,5979,O
aflatoxin,5979,B-CHEMICAL
B,5979,I-CHEMICAL
(,5979,I-CHEMICAL
1,5979,I-CHEMICAL
),5979,I-CHEMICAL
decreased,5979,O
the,5979,O
frequencies,5979,O
of,5979,O
SCE,5979,O
and,5979,O
the,5979,O
malondialdehyde,5979,B-CHEMICAL
level,5979,O
and,5979,O
increased,5979,O
amount,5979,O
of,5979,O
superoxide,5979,B-GENE-N
dismutase,5979,I-GENE-N
",",5979,O
glutathione,5979,B-CHEMICAL
and,5979,O
glutathione,5979,B-GENE-N
peroxidase,5979,I-GENE-N
which,5979,O
were,5979,O
decreased,5979,O
by,5979,O
aflatoxin,5979,B-CHEMICAL
.,5979,O
The,5980,O
data,5980,O
obtained,5980,O
from,5980,O
this,5980,O
work,5980,O
have,5980,O
clearly,5980,O
shown,5980,O
that,5980,O
MEP,5980,O
has,5980,O
significant,5980,O
antigenotoxic,5980,O
effects,5980,O
which,5980,O
are,5980,O
thought,5980,O
to,5980,O
be,5980,O
partly,5980,O
due,5980,O
to,5980,O
the,5980,O
antioxidant,5980,O
activities,5980,O
and,5980,O
antioxidant,5980,O
inducing,5980,O
capability,5980,O
of,5980,O
MEP,5980,O
.,5980,O
This,5981,O
is,5981,O
the,5981,O
first,5981,O
report,5981,O
indicating,5981,O
the,5981,O
antigenotoxic,5981,O
activities,5981,O
of,5981,O
MEP,5981,O
against,5981,O
several,5981,O
mutagen,5981,O
agents,5981,O
such,5981,O
as,5981,O
N-methyl-N'-nitro-N-nitrosoguanidine,5981,B-CHEMICAL
",",5981,O
acridin,5981,B-CHEMICAL
and,5981,O
aflatoxin,5981,B-CHEMICAL
.,5981,O
Cross-talk,5982,O
between,5982,O
constitutive,5982,B-GENE-Y
androstane,5982,I-GENE-Y
receptor,5982,I-GENE-Y
and,5982,O
hypoxia-inducible,5982,B-GENE-N
factor,5982,I-GENE-N
in,5982,O
the,5982,O
regulation,5982,O
of,5982,O
gene,5982,O
expression,5982,O
.,5982,O
Hypoxia,5983,B-GENE-N
inducible,5983,I-GENE-N
factor,5983,I-GENE-N
(,5983,O
HIF,5983,B-GENE-N
),5983,O
and,5983,O
5'-AMP-activated,5983,B-GENE-N
protein,5983,I-GENE-N
kinase,5983,I-GENE-N
are,5983,O
often,5983,O
activated,5983,O
under,5983,O
similar,5983,O
physiological,5983,O
conditions,5983,O
.,5983,O
Constitutive,5984,B-GENE-Y
androstane,5984,I-GENE-Y
receptor,5984,I-GENE-Y
(,5984,O
CAR,5984,B-GENE-Y
),5984,O
translocates,5984,O
into,5984,O
the,5984,O
nucleus,5984,O
in,5984,O
accordance,5984,O
with,5984,O
5'-AMP-activated,5984,B-GENE-N
protein,5984,I-GENE-N
kinase,5984,I-GENE-N
and,5984,O
thus,5984,O
confers,5984,O
transactivation,5984,O
.,5984,O
The,5985,O
aim,5985,O
of,5985,O
the,5985,O
present,5985,O
study,5985,O
was,5985,O
to,5985,O
investigate,5985,O
a,5985,O
possible,5985,O
link,5985,O
between,5985,O
CAR,5985,B-GENE-Y
and,5985,O
HIFα,5985,B-GENE-Y
.,5985,O
Phenobarbital,5986,B-CHEMICAL
(,5986,O
PB,5986,O
),5986,O
",",5986,O
a,5986,O
typical,5986,O
CAR,5986,B-GENE-Y
activator,5986,O
",",5986,O
increased,5986,O
the,5986,O
gene,5986,O
expression,5986,O
of,5986,O
HIF-target,5986,B-GENE-N
genes,5986,O
in,5986,O
the,5986,O
livers,5986,O
of,5986,O
mice,5986,O
",",5986,O
including,5986,O
erythropoietin,5986,B-GENE-Y
",",5986,O
heme,5986,B-GENE-Y
oxygenase-1,5986,I-GENE-Y
and,5986,O
vascular,5986,B-GENE-Y
endothelial,5986,I-GENE-Y
growth,5986,I-GENE-Y
factor-a,5986,I-GENE-Y
.,5986,O
PB,5987,O
induced,5987,O
an,5987,O
accumulation,5987,O
of,5987,O
nuclear,5987,O
HIF-1α,5987,B-GENE-Y
and,5987,O
an,5987,O
increase,5987,O
in,5987,O
the,5987,O
HIF-responsive,5987,B-GENE-N
element-mediated,5987,O
transactivation,5987,O
in,5987,O
HepG2,5987,O
cells,5987,O
.,5987,O
Cobalt,5988,B-CHEMICAL
chloride,5988,I-CHEMICAL
",",5988,O
a,5988,O
typical,5988,O
HIF,5988,B-GENE-N
activator,5988,O
",",5988,O
induced,5988,O
the,5988,O
gene,5988,O
expression,5988,O
of,5988,O
CAR-target,5988,B-GENE-Y
genes,5988,O
",",5988,O
including,5988,O
cyp2b9,5988,B-GENE-Y
and,5988,O
cyp2b10,5988,B-GENE-Y
",",5988,O
an,5988,O
accumulation,5988,O
of,5988,O
nuclear,5988,O
CAR,5988,B-GENE-Y
and,5988,O
an,5988,O
increase,5988,O
in,5988,O
the,5988,O
PB-responsive,5988,B-GENE-N
enhancer,5988,I-GENE-N
module-mediated,5988,O
transactivation,5988,O
in,5988,O
the,5988,O
mouse,5988,O
liver,5988,O
.,5988,O
Immunoprecipitation-immunoblot,5989,O
and,5989,O
chromatin,5989,O
immunoprecipitation,5989,O
analyses,5989,O
suggest,5989,O
that,5989,O
CAR,5989,B-GENE-Y
binds,5989,O
to,5989,O
the,5989,O
PB-responsive,5989,B-GENE-N
enhancer,5989,I-GENE-N
module,5989,I-GENE-N
with,5989,O
HIF-1α,5989,B-GENE-Y
in,5989,O
the,5989,O
liver,5989,O
of,5989,O
untreated,5989,O
mice,5989,O
and,5989,O
that,5989,O
the,5989,O
complex,5989,O
dissociates,5989,O
upon,5989,O
PB,5989,O
treatment,5989,O
.,5989,O
Taken,5990,O
together,5990,O
these,5990,O
results,5990,O
suggest,5990,O
that,5990,O
CAR,5990,B-GENE-Y
and,5990,O
HIF-α,5990,B-GENE-Y
interact,5990,O
and,5990,O
reciprocally,5990,O
modulate,5990,O
the,5990,O
functions,5990,O
of,5990,O
each,5990,O
other,5990,O
.,5990,O
Methionine,5991,B-GENE-Y
adenosyltransferase,5991,I-GENE-Y
II,5991,I-GENE-Y
beta,5991,I-GENE-Y
subunit,5991,O
gene,5991,O
expression,5991,O
provides,5991,O
a,5991,O
proliferative,5991,O
advantage,5991,O
in,5991,O
human,5991,O
hepatoma,5991,O
.,5991,O
BACKGROUND,5992,O
&,5992,O
AIMS,5992,O
:,5992,O
Of,5992,O
the,5992,O
2,5992,O
genes,5992,O
(,5992,O
MAT1A,5992,B-GENE-Y
",",5992,O
MAT2A,5992,B-GENE-Y
),5992,O
encoding,5992,O
methionine,5992,B-GENE-N
adenosyltransferase,5992,I-GENE-N
",",5992,O
the,5992,O
enzyme,5992,O
that,5992,O
synthesizes,5992,O
S-adenosylmethionine,5992,B-CHEMICAL
",",5992,O
MAT1A,5992,B-GENE-Y
",",5992,O
is,5992,O
expressed,5992,O
in,5992,O
liver,5992,O
",",5992,O
whereas,5992,O
MAT2A,5992,B-GENE-Y
is,5992,O
expressed,5992,O
in,5992,O
extrahepatic,5992,O
tissues,5992,O
.,5992,O
In,5993,O
liver,5993,O
",",5993,O
MAT2A,5993,B-GENE-Y
expression,5993,O
associates,5993,O
with,5993,O
growth,5993,O
",",5993,O
dedifferentiation,5993,O
",",5993,O
and,5993,O
cancer,5993,O
.,5993,O
Here,5994,O
",",5994,O
we,5994,O
identified,5994,O
the,5994,O
beta,5994,O
subunit,5994,O
as,5994,O
a,5994,O
regulator,5994,O
of,5994,O
proliferation,5994,O
in,5994,O
human,5994,O
hepatoma,5994,O
cell,5994,O
lines,5994,O
.,5994,O
The,5995,O
beta,5995,O
subunit,5995,O
has,5995,O
been,5995,O
cloned,5995,O
and,5995,O
shown,5995,O
to,5995,O
lower,5995,O
the,5995,O
K,5995,O
(,5995,O
m,5995,O
),5995,O
of,5995,O
methionine,5995,B-GENE-Y
adenosyltransferase,5995,I-GENE-Y
II,5995,I-GENE-Y
alpha2,5995,I-GENE-Y
(,5995,O
the,5995,O
MAT2A,5995,B-GENE-Y
product,5995,O
),5995,O
for,5995,O
methionine,5995,B-CHEMICAL
and,5995,O
to,5995,O
render,5995,O
the,5995,O
enzyme,5995,O
more,5995,O
susceptible,5995,O
to,5995,O
S-adenosylmethionine,5995,B-CHEMICAL
inhibition,5995,O
.,5995,O
METHODS,5996,O
:,5996,O
Methionine,5996,B-GENE-N
adenosyltransferase,5996,I-GENE-N
II,5996,I-GENE-N
alpha2,5996,I-GENE-N
and,5996,I-GENE-N
beta,5996,I-GENE-N
subunit,5996,O
expression,5996,O
was,5996,O
analyzed,5996,O
in,5996,O
human,5996,O
and,5996,O
rat,5996,O
liver,5996,O
and,5996,O
hepatoma,5996,O
cell,5996,O
lines,5996,O
and,5996,O
their,5996,O
interaction,5996,O
studied,5996,O
in,5996,O
HuH7,5996,O
cells,5996,O
.,5996,O
beta,5997,O
Subunit,5997,O
expression,5997,O
was,5997,O
up-,5997,O
and,5997,O
down-regulated,5997,O
in,5997,O
human,5997,O
hepatoma,5997,O
cell,5997,O
lines,5997,O
and,5997,O
the,5997,O
effect,5997,O
on,5997,O
DNA,5997,O
synthesis,5997,O
determined,5997,O
.,5997,O
RESULTS,5998,O
:,5998,O
We,5998,O
found,5998,O
that,5998,O
beta,5998,O
subunit,5998,O
is,5998,O
expressed,5998,O
in,5998,O
rat,5998,O
extrahepatic,5998,O
tissues,5998,O
but,5998,O
not,5998,O
in,5998,O
normal,5998,O
liver,5998,O
.,5998,O
In,5999,O
human,5999,O
liver,5999,O
",",5999,O
beta,5999,O
subunit,5999,O
expression,5999,O
associates,5999,O
with,5999,O
cirrhosis,5999,O
and,5999,O
hepatoma,5999,O
.,5999,O
beta,6000,O
Subunit,6000,O
is,6000,O
expressed,6000,O
in,6000,O
most,6000,O
(,6000,O
HepG2,6000,O
",",6000,O
PLC,6000,O
",",6000,O
and,6000,O
Hep3B,6000,O
),6000,O
but,6000,O
not,6000,O
all,6000,O
(,6000,O
HuH7,6000,O
),6000,O
hepatoma,6000,O
cell,6000,O
lines,6000,O
.,6000,O
Transfection,6001,O
of,6001,O
beta,6001,O
subunit,6001,O
reduced,6001,O
S-adenosylmethionine,6001,B-CHEMICAL
content,6001,O
and,6001,O
stimulated,6001,O
DNA,6001,O
synthesis,6001,O
in,6001,O
HuH7,6001,O
cells,6001,O
",",6001,O
whereas,6001,O
down-regulation,6001,O
of,6001,O
beta,6001,O
subunit,6001,O
expression,6001,O
diminished,6001,O
DNA,6001,O
synthesis,6001,O
in,6001,O
HepG2,6001,O
.,6001,O
The,6002,O
interaction,6002,O
between,6002,O
methionine,6002,B-GENE-N
adenosyltransferase,6002,I-GENE-N
II,6002,I-GENE-N
alpha2,6002,I-GENE-N
and,6002,I-GENE-N
beta,6002,I-GENE-N
subunit,6002,O
was,6002,O
demonstrated,6002,O
in,6002,O
HuH7,6002,O
cells,6002,O
.,6002,O
CONCLUSIONS,6003,O
:,6003,O
Our,6003,O
findings,6003,O
indicate,6003,O
that,6003,O
beta,6003,O
subunit,6003,O
associates,6003,O
with,6003,O
cirrhosis,6003,O
and,6003,O
cancer,6003,O
providing,6003,O
a,6003,O
proliferative,6003,O
advantage,6003,O
in,6003,O
hepatoma,6003,O
cells,6003,O
through,6003,O
its,6003,O
interaction,6003,O
with,6003,O
methionine,6003,B-GENE-Y
adenosyltransferase,6003,I-GENE-Y
II,6003,I-GENE-Y
alpha2,6003,I-GENE-Y
and,6003,O
down-regulation,6003,O
of,6003,O
S-adenosylmethionine,6003,B-CHEMICAL
levels,6003,O
.,6003,O
Temporal,6004,O
profile,6004,O
of,6004,O
brain,6004,O
and,6004,O
pituitary,6004,O
GnRHs,6004,B-GENE-N
",",6004,O
GnRH-R,6004,B-GENE-Y
and,6004,O
gonadotropin,6004,B-GENE-N
mRNA,6004,O
expression,6004,O
and,6004,O
content,6004,O
during,6004,O
early,6004,O
development,6004,O
in,6004,O
European,6004,O
sea,6004,O
bass,6004,O
(,6004,O
Dicentrarchus,6004,O
labrax,6004,O
L.,6004,O
),6004,O
.,6004,O
A,6005,O
likely,6005,O
endocrine,6005,O
control,6005,O
mechanism,6005,O
for,6005,O
sexual,6005,O
differentiation,6005,O
in,6005,O
size-graded,6005,O
populations,6005,O
of,6005,O
European,6005,O
sea,6005,O
bass,6005,O
(,6005,O
Dicentrarchus,6005,O
labrax,6005,O
),6005,O
is,6005,O
proposed,6005,O
by,6005,O
evaluating,6005,O
the,6005,O
brain,6005,O
expression,6005,O
and,6005,O
pituitary,6005,O
content,6005,O
of,6005,O
two,6005,O
forms,6005,O
of,6005,O
gonadotropin-releasing,6005,B-GENE-N
hormone,6005,I-GENE-N
(,6005,O
GnRH,6005,B-GENE-N
),6005,O
",",6005,O
namely,6005,O
sea,6005,O
bream,6005,O
(,6005,O
sbGnRH,6005,B-GENE-N
),6005,O
and,6005,O
salmon,6005,O
(,6005,O
sGnRH,6005,B-GENE-N
),6005,O
",",6005,O
the,6005,O
pituitary,6005,O
expression,6005,O
of,6005,O
one,6005,O
subtype,6005,O
of,6005,O
GnRH,6005,B-GENE-Y
receptor,6005,I-GENE-Y
(,6005,O
dlGnRH-R-2A,6005,B-GENE-N
),6005,O
and,6005,O
the,6005,O
three,6005,O
gonadotropin,6005,B-GENE-N
(,6005,O
GtH,6005,B-GENE-N
),6005,O
subunits,6005,O
",",6005,O
namely,6005,O
glycoprotein,6005,B-GENE-N
alpha,6005,I-GENE-N
(,6005,O
GPalpha,6005,B-GENE-N
),6005,O
",",6005,O
follicle-stimulating,6005,B-GENE-N
hormone,6005,I-GENE-N
beta,6005,I-GENE-N
(,6005,O
FSHbeta,6005,B-GENE-N
),6005,O
and,6005,O
luteinizing,6005,B-GENE-N
hormone,6005,I-GENE-N
beta,6005,I-GENE-N
(,6005,O
LHbeta,6005,B-GENE-N
),6005,O
",",6005,O
as,6005,O
well,6005,O
as,6005,O
the,6005,O
pituitary,6005,O
and,6005,O
plasma,6005,O
LH,6005,B-GENE-N
levels,6005,O
between,6005,O
50,6005,O
and,6005,O
300,6005,O
days,6005,O
post-hatching,6005,O
(,6005,O
dph,6005,O
),6005,O
.,6005,O
Four,6006,O
gradings,6006,O
were,6006,O
conducted,6006,O
between,6006,O
2,6006,O
and,6006,O
8,6006,O
months,6006,O
after,6006,O
hatching,6006,O
",",6006,O
resulting,6006,O
in,6006,O
a,6006,O
population,6006,O
of,6006,O
large,6006,O
and,6006,O
small,6006,O
individuals,6006,O
",",6006,O
having,6006,O
96.5,6006,O
%,6006,O
females,6006,O
(,6006,O
female-dominant,6006,O
population,6006,O
),6006,O
and,6006,O
69.2,6006,O
%,6006,O
males,6006,O
(,6006,O
male-dominant,6006,O
population,6006,O
),6006,O
",",6006,O
respectively,6006,O
",",6006,O
after,6006,O
the,6006,O
last,6006,O
grading,6006,O
.,6006,O
The,6007,O
onset,6007,O
of,6007,O
gonadal,6007,O
differentiation,6007,O
was,6007,O
different,6007,O
in,6007,O
the,6007,O
two,6007,O
sexes,6007,O
",",6007,O
and,6007,O
coincided,6007,O
with,6007,O
a,6007,O
peak,6007,O
of,6007,O
expression,6007,O
of,6007,O
sbGnRH,6007,B-GENE-N
or,6007,O
sGnRH,6007,B-GENE-N
.,6007,O
Furthermore,6008,O
",",6008,O
the,6008,O
expression,6008,O
of,6008,O
these,6008,O
GnRHs,6008,B-GENE-N
was,6008,O
correlated,6008,O
with,6008,O
the,6008,O
expression,6008,O
of,6008,O
dlGnRH-R-2A,6008,B-GENE-N
.,6008,O
Sex-related,6009,O
differences,6009,O
in,6009,O
the,6009,O
brain,6009,O
and,6009,O
pituitary,6009,O
content,6009,O
of,6009,O
sbGnRH,6009,B-GENE-N
were,6009,O
also,6009,O
found,6009,O
at,6009,O
the,6009,O
time,6009,O
of,6009,O
sexual,6009,O
differentiation,6009,O
.,6009,O
Moreover,6010,O
",",6010,O
the,6010,O
observed,6010,O
sexual,6010,O
dimorphism,6010,O
at,6010,O
the,6010,O
transcriptional,6010,O
or,6010,O
synthesis,6010,O
level,6010,O
of,6010,O
these,6010,O
GnRH,6010,B-GENE-N
forms,6010,O
suggests,6010,O
that,6010,O
a,6010,O
different,6010,O
neuro-hormonal,6010,O
regulation,6010,O
is,6010,O
operating,6010,O
according,6010,O
to,6010,O
sex,6010,O
.,6010,O
At,6011,O
the,6011,O
onset,6011,O
of,6011,O
sex,6011,O
differentiation,6011,O
",",6011,O
FSHbeta,6011,B-GENE-N
transcriptional,6011,O
activity,6011,O
reached,6011,O
maximal,6011,O
values,6011,O
",",6011,O
which,6011,O
were,6011,O
maintained,6011,O
until,6011,O
the,6011,O
completion,6011,O
of,6011,O
the,6011,O
process,6011,O
.,6011,O
The,6012,O
present,6012,O
study,6012,O
suggests,6012,O
a,6012,O
role,6012,O
for,6012,O
sbGnRH,6012,B-GENE-N
",",6012,O
sGnRH,6012,B-GENE-N
and,6012,O
the,6012,O
dlGnRH-R-2A,6012,B-GENE-N
during,6012,O
gonadal,6012,O
differentiation,6012,O
",",6012,O
possibly,6012,O
through,6012,O
enhancement,6012,O
of,6012,O
FSHbeta,6012,B-GENE-N
gene,6012,O
expression,6012,O
.,6012,O
In,6013,O
males,6013,O
",",6013,O
a,6013,O
different,6013,O
endocrine,6013,O
regulation,6013,O
seems,6013,O
to,6013,O
exist,6013,O
also,6013,O
during,6013,O
spermiogenesis,6013,O
and,6013,O
spermiation,6013,O
",",6013,O
when,6013,O
gene,6013,O
transcription,6013,O
",",6013,O
peptide,6013,O
synthesis,6013,O
and,6013,O
release,6013,O
of,6013,O
LH,6013,B-GENE-N
are,6013,O
of,6013,O
greater,6013,O
importance,6013,O
.,6013,O
Linking,6014,O
GABA,6014,B-GENE-N
(,6014,I-GENE-N
A,6014,I-GENE-N
),6014,I-GENE-N
receptor,6014,I-GENE-N
subunits,6014,O
to,6014,O
alcohol-induced,6014,B-CHEMICAL
conditioned,6014,O
taste,6014,O
aversion,6014,O
and,6014,O
recovery,6014,O
from,6014,O
acute,6014,O
alcohol,6014,B-CHEMICAL
intoxication,6014,O
.,6014,O
GABA,6015,B-GENE-N
type,6015,I-GENE-N
A,6015,I-GENE-N
receptors,6015,I-GENE-N
(,6015,O
GABA,6015,B-GENE-N
(,6015,I-GENE-N
A,6015,I-GENE-N
),6015,I-GENE-N
-R,6015,I-GENE-N
),6015,O
are,6015,O
important,6015,O
for,6015,O
ethanol,6015,B-CHEMICAL
actions,6015,O
and,6015,O
it,6015,O
is,6015,O
of,6015,O
interest,6015,O
to,6015,O
link,6015,O
individual,6015,O
subunits,6015,O
with,6015,O
specific,6015,O
ethanol,6015,B-CHEMICAL
behaviors,6015,O
.,6015,O
We,6016,O
studied,6016,O
null,6016,O
mutant,6016,O
mice,6016,O
for,6016,O
six,6016,O
different,6016,O
GABA,6016,B-GENE-N
(,6016,I-GENE-N
A,6016,I-GENE-N
),6016,I-GENE-N
-R,6016,I-GENE-N
subunits,6016,I-GENE-N
(,6016,I-GENE-N
α1,6016,I-GENE-N
",",6016,I-GENE-N
α2,6016,I-GENE-N
",",6016,I-GENE-N
α3,6016,I-GENE-N
",",6016,I-GENE-N
α4,6016,I-GENE-N
",",6016,I-GENE-N
α5,6016,I-GENE-N
and,6016,I-GENE-N
δ,6016,I-GENE-N
),6016,O
.,6016,O
Only,6017,O
mice,6017,O
lacking,6017,O
the,6017,O
α2,6017,O
subunit,6017,O
showed,6017,O
reduction,6017,O
of,6017,O
conditioned,6017,O
taste,6017,O
aversion,6017,O
(,6017,O
CTA,6017,O
),6017,O
to,6017,O
ethanol,6017,B-CHEMICAL
.,6017,O
These,6018,O
results,6018,O
are,6018,O
in,6018,O
agreement,6018,O
with,6018,O
data,6018,O
from,6018,O
knock-in,6018,O
mice,6018,O
with,6018,O
mutation,6018,O
of,6018,O
the,6018,O
ethanol-sensitive,6018,B-CHEMICAL
site,6018,O
in,6018,O
the,6018,O
α2-subunit,6018,O
(,6018,O
Blednov,6018,O
et,6018,O
al.,6018,O
",",6018,O
2011,6018,O
),6018,O
.,6018,O
All,6019,O
together,6019,O
",",6019,O
they,6019,O
indicate,6019,O
that,6019,O
aversive,6019,O
property,6019,O
of,6019,O
ethanol,6019,B-CHEMICAL
is,6019,O
dependent,6019,O
on,6019,O
ethanol,6019,B-CHEMICAL
action,6019,O
on,6019,O
α2-containing,6019,B-GENE-Y
GABA,6019,I-GENE-Y
(,6019,I-GENE-Y
A,6019,I-GENE-Y
),6019,I-GENE-Y
-R.,6019,O
Deletion,6019,O
of,6019,O
the,6019,O
α2-subunit,6019,O
led,6019,O
to,6019,O
faster,6019,O
recovery,6019,O
whereas,6019,O
absence,6019,O
of,6019,O
the,6019,O
α3-subunit,6019,O
slowed,6019,O
recovery,6019,O
from,6019,O
ethanol-induced,6019,B-CHEMICAL
incoordination,6019,O
(,6019,O
rotarod,6019,O
),6019,O
.,6019,O
Deletion,6020,O
of,6020,O
the,6020,O
other,6020,O
four,6020,O
subunits,6020,O
did,6020,O
not,6020,O
affect,6020,O
this,6020,O
behavior,6020,O
.,6020,O
Similar,6021,O
changes,6021,O
in,6021,O
this,6021,O
behavior,6021,O
for,6021,O
the,6021,O
α2,6021,O
and,6021,O
α3,6021,O
null,6021,O
mutants,6021,O
were,6021,O
found,6021,O
for,6021,O
flurazepam,6021,B-CHEMICAL
motor,6021,O
incoordination,6021,O
.,6021,O
However,6022,O
",",6022,O
no,6022,O
differences,6022,O
in,6022,O
recovery,6022,O
were,6022,O
found,6022,O
in,6022,O
motor-incoordinating,6022,O
effects,6022,O
of,6022,O
an,6022,O
α1-selective,6022,O
modulator,6022,O
(,6022,O
zolpidem,6022,B-CHEMICAL
),6022,O
or,6022,O
an,6022,O
α4-selective,6022,O
agonist,6022,O
(,6022,O
gaboxadol,6022,B-CHEMICAL
),6022,O
.,6022,O
Therefore,6023,O
",",6023,O
recovery,6023,O
of,6023,O
rotarod,6023,O
incoordination,6023,O
is,6023,O
under,6023,O
control,6023,O
of,6023,O
two,6023,O
GABA,6023,B-GENE-N
(,6023,I-GENE-N
A,6023,I-GENE-N
),6023,I-GENE-N
-R,6023,I-GENE-N
subunits,6023,I-GENE-N
:,6023,I-GENE-N
α2,6023,I-GENE-N
and,6023,I-GENE-N
α3,6023,I-GENE-N
.,6023,O
For,6024,O
motor,6024,O
activity,6024,O
",",6024,O
α3,6024,O
null,6024,O
mice,6024,O
demonstrated,6024,O
higher,6024,O
activation,6024,O
by,6024,O
ethanol,6024,B-CHEMICAL
(,6024,O
1,6024,O
g/kg,6024,O
),6024,O
whereas,6024,O
both,6024,O
α2,6024,O
(,6024,O
-/-,6024,O
),6024,O
and,6024,O
α3,6024,O
(,6024,O
-/Y,6024,O
),6024,O
knockout,6024,O
mice,6024,O
were,6024,O
less,6024,O
sensitive,6024,O
to,6024,O
ethanol-induced,6024,B-CHEMICAL
reduction,6024,O
of,6024,O
motor,6024,O
activity,6024,O
(,6024,O
1.5,6024,O
g/kg,6024,O
),6024,O
.,6024,O
These,6025,O
studies,6025,O
demonstrate,6025,O
that,6025,O
the,6025,O
effects,6025,O
of,6025,O
ethanol,6025,B-CHEMICAL
at,6025,O
GABAergic,6025,O
synapses,6025,O
containing,6025,O
α2,6025,O
subunit,6025,O
are,6025,O
important,6025,O
for,6025,O
specific,6025,O
behavioral,6025,O
effects,6025,O
of,6025,O
ethanol,6025,B-CHEMICAL
which,6025,O
may,6025,O
be,6025,O
relevant,6025,O
to,6025,O
the,6025,O
genetic,6025,O
linkage,6025,O
of,6025,O
the,6025,O
α2,6025,O
subunit,6025,O
with,6025,O
human,6025,O
alcoholism,6025,O
.,6025,O
Pancreatic,6026,O
β-Cell,6026,O
Dysfunction,6026,O
and,6026,O
Risk,6026,O
of,6026,O
New-Onset,6026,O
Diabetes,6026,O
After,6026,O
Kidney,6026,O
Transplantation,6026,O
.,6026,O
OBJECTIVEChronic,6027,O
exposure,6027,O
to,6027,O
calcineurin,6027,B-GENE-N
inhibitors,6027,O
and,6027,O
corticosteroids,6027,O
poses,6027,O
renal,6027,O
transplant,6027,O
recipients,6027,O
(,6027,O
RTR,6027,O
),6027,O
at,6027,O
high,6027,O
risk,6027,O
for,6027,O
development,6027,O
of,6027,O
new-onset,6027,O
diabetes,6027,O
after,6027,O
transplantation,6027,O
(,6027,O
NODAT,6027,O
),6027,O
.,6027,O
Pancreatic,6028,O
β-cell,6028,O
dysfunction,6028,O
may,6028,O
be,6028,O
crucial,6028,O
to,6028,O
the,6028,O
pathophysiology,6028,O
of,6028,O
NODAT,6028,O
and,6028,O
specific,6028,O
markers,6028,O
for,6028,O
β-cell,6028,O
dysfunction,6028,O
may,6028,O
have,6028,O
additive,6028,O
value,6028,O
for,6028,O
predicting,6028,O
NODAT,6028,O
in,6028,O
this,6028,O
population,6028,O
.,6028,O
Therefore,6029,O
",",6029,O
we,6029,O
prospectively,6029,O
investigated,6029,O
whether,6029,O
proinsulin,6029,B-GENE-Y
",",6029,O
as,6029,O
a,6029,O
marker,6029,O
of,6029,O
pancreatic,6029,O
β-cell,6029,O
dysfunction,6029,O
",",6029,O
is,6029,O
associated,6029,O
with,6029,O
future,6029,O
development,6029,O
of,6029,O
NODAT,6029,O
and,6029,O
improves,6029,O
prediction,6029,O
of,6029,O
it.RESEARCH,6029,O
DESIGN,6029,O
AND,6029,O
METHODSAll,6029,O
RTR,6029,O
between,6029,O
2001,6029,O
and,6029,O
2003,6029,O
with,6029,O
a,6029,O
functioning,6029,O
graft,6029,O
for,6029,O
≥1,6029,O
year,6029,O
were,6029,O
considered,6029,O
eligible,6029,O
for,6029,O
inclusion,6029,O
",",6029,O
except,6029,O
for,6029,O
subjects,6029,O
with,6029,O
diabetes,6029,O
at,6029,O
baseline,6029,O
who,6029,O
were,6029,O
excluded,6029,O
.,6029,O
We,6030,O
recorded,6030,O
incidence,6030,O
of,6030,O
NODAT,6030,O
until,6030,O
April,6030,O
2012.RESULTSA,6030,O
total,6030,O
of,6030,O
487,6030,O
RTR,6030,O
(,6030,O
age,6030,O
50,6030,O
±,6030,O
12,6030,O
years,6030,O
",",6030,O
55,6030,O
%,6030,O
men,6030,O
),6030,O
participated,6030,O
at,6030,O
a,6030,O
median,6030,O
time,6030,O
of,6030,O
6.0,6030,O
(,6030,O
interquartile,6030,O
range,6030,O
[,6030,O
IQR,6030,O
],6030,O
",",6030,O
2.6-11.5,6030,O
),6030,O
years,6030,O
after,6030,O
transplantation,6030,O
.,6030,O
Median,6031,O
fasting,6031,O
proinsulin,6031,B-GENE-Y
levels,6031,O
were,6031,O
16.6,6031,O
(,6031,O
IQR,6031,O
",",6031,O
11.0-24.2,6031,O
),6031,O
pmol/L,6031,O
.,6031,O
During,6032,O
median,6032,O
follow-up,6032,O
for,6032,O
10.1,6032,O
(,6032,O
IQR,6032,O
",",6032,O
9.1-10.4,6032,O
),6032,O
years,6032,O
",",6032,O
42,6032,O
(,6032,O
35,6032,O
%,6032,O
),6032,O
RTR,6032,O
had,6032,O
development,6032,O
of,6032,O
NODAT,6032,O
in,6032,O
the,6032,O
highest,6032,O
quartile,6032,O
of,6032,O
the,6032,O
distribution,6032,O
of,6032,O
proinsulin,6032,B-GENE-Y
versus,6032,O
34,6032,O
(,6032,O
9,6032,O
%,6032,O
),6032,O
in,6032,O
the,6032,O
lowest,6032,O
three,6032,O
quartiles,6032,O
(,6032,O
P,6032,O
<,6032,O
0.001,6032,O
),6032,O
.,6032,O
In,6033,O
Cox,6033,O
regression,6033,O
analyses,6033,O
",",6033,O
proinsulin,6033,B-GENE-Y
(,6033,O
hazard,6033,O
ratio,6033,O
",",6033,O
2.29,6033,O
;,6033,O
95,6033,O
%,6033,O
confidence,6033,O
interval,6033,O
",",6033,O
1.85-2.83,6033,O
;,6033,O
P,6033,O
<,6033,O
0.001,6033,O
),6033,O
was,6033,O
strongly,6033,O
associated,6033,O
with,6033,O
NODAT,6033,O
development,6033,O
.,6033,O
This,6034,O
was,6034,O
independent,6034,O
of,6034,O
age,6034,O
",",6034,O
sex,6034,O
",",6034,O
calcineurine,6034,B-GENE-N
inhibitors,6034,O
",",6034,O
prednisolone,6034,B-CHEMICAL
use,6034,O
",",6034,O
components,6034,O
of,6034,O
the,6034,O
metabolic,6034,O
syndrome,6034,O
",",6034,O
or,6034,O
homeostasis,6034,O
model,6034,O
assessment.CONCLUSIONSIn,6034,O
conclusion,6034,O
",",6034,O
fasting,6034,O
proinsulin,6034,B-GENE-Y
is,6034,O
strongly,6034,O
associated,6034,O
with,6034,O
NODAT,6034,O
development,6034,O
in,6034,O
RTR,6034,O
.,6034,O
Our,6035,O
results,6035,O
highlight,6035,O
the,6035,O
role,6035,O
of,6035,O
β-cell,6035,O
dysfunction,6035,O
in,6035,O
the,6035,O
pathophysiology,6035,O
of,6035,O
NODAT,6035,O
and,6035,O
indicate,6035,O
the,6035,O
potential,6035,O
value,6035,O
of,6035,O
proinsulin,6035,B-GENE-Y
for,6035,O
identification,6035,O
of,6035,O
RTR,6035,O
at,6035,O
increased,6035,O
risk,6035,O
for,6035,O
NODAT,6035,O
.,6035,O
Resveratrol,6036,B-CHEMICAL
attenuates,6036,O
hepatotoxicity,6036,O
of,6036,O
rats,6036,O
exposed,6036,O
to,6036,O
arsenic,6036,B-CHEMICAL
trioxide,6036,I-CHEMICAL
.,6036,O
Arsenic,6037,B-CHEMICAL
trioxide,6037,I-CHEMICAL
(,6037,O
As,6037,B-CHEMICAL
(,6037,I-CHEMICAL
2,6037,I-CHEMICAL
),6037,I-CHEMICAL
O,6037,I-CHEMICAL
(,6037,I-CHEMICAL
3,6037,I-CHEMICAL
),6037,I-CHEMICAL
),6037,O
is,6037,O
an,6037,O
environmental,6037,O
pollutant,6037,O
and,6037,O
potent,6037,O
toxicant,6037,O
to,6037,O
humans,6037,O
.,6037,O
However,6038,O
",",6038,O
it,6038,O
also,6038,O
shows,6038,O
substantial,6038,O
anti-cancer,6038,O
activity,6038,O
in,6038,O
individuals,6038,O
with,6038,O
acute,6038,O
promyelocytic,6038,O
leukemia,6038,O
(,6038,O
APL,6038,O
),6038,O
.,6038,O
Unfortunately,6039,O
",",6039,O
As,6039,B-CHEMICAL
(,6039,I-CHEMICAL
2,6039,I-CHEMICAL
),6039,I-CHEMICAL
O,6039,I-CHEMICAL
(,6039,I-CHEMICAL
3,6039,I-CHEMICAL
),6039,I-CHEMICAL
-treated,6039,O
leukemia,6039,O
patients,6039,O
suffer,6039,O
hepatotoxicity,6039,O
.,6039,O
Resveratrol,6040,B-CHEMICAL
has,6040,O
been,6040,O
demonstrated,6040,O
to,6040,O
have,6040,O
efficient,6040,O
antioxidant,6040,O
and,6040,O
antineoplastic,6040,O
activities,6040,O
.,6040,O
The,6041,O
study,6041,O
that,6041,O
how,6041,O
As,6041,B-CHEMICAL
(,6041,I-CHEMICAL
2,6041,I-CHEMICAL
),6041,I-CHEMICAL
O,6041,I-CHEMICAL
(,6041,I-CHEMICAL
3,6041,I-CHEMICAL
),6041,I-CHEMICAL
in,6041,O
combination,6041,O
with,6041,O
resveratrol,6041,B-CHEMICAL
affects,6041,O
hepatotoxicity,6041,O
and,6041,O
arsenic,6041,B-CHEMICAL
accumulation,6041,O
in,6041,O
the,6041,O
liver,6041,O
is,6041,O
lacking,6041,O
",",6041,O
and,6041,O
the,6041,O
present,6041,O
study,6041,O
tackles,6041,O
this,6041,O
question,6041,O
.,6041,O
Wistar,6042,O
rats,6042,O
were,6042,O
injected,6042,O
with,6042,O
3mg/kg,6042,O
As,6042,B-CHEMICAL
(,6042,I-CHEMICAL
2,6042,I-CHEMICAL
),6042,I-CHEMICAL
O,6042,I-CHEMICAL
(,6042,I-CHEMICAL
3,6042,I-CHEMICAL
),6042,I-CHEMICAL
on,6042,O
alternate,6042,O
days,6042,O
;,6042,O
resveratrol,6042,B-CHEMICAL
(,6042,O
8mg/kg,6042,O
),6042,O
was,6042,O
administered,6042,O
1h,6042,O
before,6042,O
As,6042,B-CHEMICAL
(,6042,I-CHEMICAL
2,6042,I-CHEMICAL
),6042,I-CHEMICAL
O,6042,I-CHEMICAL
(,6042,I-CHEMICAL
3,6042,I-CHEMICAL
),6042,I-CHEMICAL
.,6042,O
Rats,6043,O
were,6043,O
killed,6043,O
on,6043,O
the,6043,O
8th,6043,O
day,6043,O
to,6043,O
determine,6043,O
histological,6043,O
liver,6043,O
damage,6043,O
",",6043,O
the,6043,O
antioxidant,6043,O
enzymes,6043,O
in,6043,O
serum,6043,O
",",6043,O
the,6043,O
ratio,6043,O
of,6043,O
reduced,6043,B-CHEMICAL
glutathione,6043,I-CHEMICAL
(,6043,O
GSH,6043,B-CHEMICAL
),6043,O
to,6043,O
oxidized,6043,B-CHEMICAL
glutathione,6043,I-CHEMICAL
(,6043,O
GSSG,6043,B-CHEMICAL
),6043,O
",",6043,O
and,6043,O
arsenic,6043,B-CHEMICAL
accumulation,6043,O
in,6043,O
the,6043,O
liver,6043,O
.,6043,O
In,6044,O
the,6044,O
resveratrol+As,6044,B-CHEMICAL
(,6044,I-CHEMICAL
2,6044,I-CHEMICAL
),6044,I-CHEMICAL
O,6044,I-CHEMICAL
(,6044,I-CHEMICAL
3,6044,I-CHEMICAL
),6044,I-CHEMICAL
group,6044,O
",",6044,O
activities,6044,O
of,6044,O
superoxide,6044,B-GENE-N
dismutase,6044,I-GENE-N
",",6044,O
catalase,6044,B-GENE-Y
in,6044,O
serum,6044,O
and,6044,O
GSH/GSSG,6044,B-CHEMICAL
were,6044,O
significantly,6044,O
increased,6044,O
",",6044,O
histopathological,6044,O
effects,6044,O
were,6044,O
reduced,6044,O
",",6044,O
and,6044,O
arsenic,6044,B-CHEMICAL
accumulation,6044,O
markedly,6044,O
decreased,6044,O
in,6044,O
the,6044,O
liver,6044,O
",",6044,O
compared,6044,O
with,6044,O
the,6044,O
As,6044,B-CHEMICAL
(,6044,I-CHEMICAL
2,6044,I-CHEMICAL
),6044,I-CHEMICAL
O,6044,I-CHEMICAL
(,6044,I-CHEMICAL
3,6044,I-CHEMICAL
),6044,I-CHEMICAL
-treated,6044,O
group,6044,O
.,6044,O
Thus,6045,O
",",6045,O
resveratrol,6045,B-CHEMICAL
attenuated,6045,O
As,6045,B-CHEMICAL
(,6045,I-CHEMICAL
2,6045,I-CHEMICAL
),6045,I-CHEMICAL
O,6045,I-CHEMICAL
(,6045,I-CHEMICAL
3,6045,I-CHEMICAL
),6045,I-CHEMICAL
-induced,6045,O
hepatotoxicity,6045,O
by,6045,O
decreasing,6045,O
oxidative,6045,O
stress,6045,O
and,6045,O
arsenic,6045,B-CHEMICAL
accumulation,6045,O
in,6045,O
the,6045,O
liver,6045,O
.,6045,O
These,6046,O
data,6046,O
suggest,6046,O
that,6046,O
use,6046,O
of,6046,O
resveratrol,6046,B-CHEMICAL
as,6046,O
post-remission,6046,O
therapy,6046,O
of,6046,O
APL,6046,O
and,6046,O
adjunctive,6046,O
therapy,6046,O
in,6046,O
patients,6046,O
with,6046,O
chronic,6046,O
exposure,6046,O
to,6046,O
arsenic,6046,B-CHEMICAL
may,6046,O
decrease,6046,O
arsenic,6046,B-CHEMICAL
hepatotoxicity,6046,O
.,6046,O
Influence,6047,O
of,6047,O
stimulant-induced,6047,O
hyperactivity,6047,O
on,6047,O
social,6047,O
approach,6047,O
in,6047,O
the,6047,O
BTBR,6047,O
mouse,6047,O
model,6047,O
of,6047,O
autism,6047,O
.,6047,O
Translational,6048,O
research,6048,O
is,6048,O
needed,6048,O
to,6048,O
discover,6048,O
pharmacological,6048,O
targets,6048,O
and,6048,O
treatments,6048,O
for,6048,O
the,6048,O
diagnostic,6048,O
behavioral,6048,O
domains,6048,O
of,6048,O
autism,6048,O
spectrum,6048,O
disorders,6048,O
.,6048,O
Animal,6049,O
models,6049,O
with,6049,O
phenotypic,6049,O
relevance,6049,O
to,6049,O
diagnostic,6049,O
criteria,6049,O
offer,6049,O
clear,6049,O
experimental,6049,O
strategies,6049,O
to,6049,O
test,6049,O
the,6049,O
efficacy,6049,O
and,6049,O
safety,6049,O
of,6049,O
novel,6049,O
treatments,6049,O
.,6049,O
Antagonists,6050,O
of,6050,O
mGluR5,6050,B-GENE-Y
receptors,6050,O
are,6050,O
in,6050,O
clinical,6050,O
trials,6050,O
for,6050,O
Fragile,6050,O
X,6050,O
syndrome,6050,O
and,6050,O
under,6050,O
investigation,6050,O
for,6050,O
the,6050,O
treatment,6050,O
of,6050,O
autism,6050,O
spectrum,6050,O
disorders,6050,O
.,6050,O
However,6051,O
",",6051,O
in,6051,O
preclinical,6051,O
studies,6051,O
of,6051,O
mGluR5,6051,B-GENE-Y
compounds,6051,O
tested,6051,O
in,6051,O
our,6051,O
laboratory,6051,O
and,6051,O
others,6051,O
",",6051,O
increased,6051,O
locomotion,6051,O
following,6051,O
mGluR5,6051,B-GENE-Y
modulation,6051,O
has,6051,O
been,6051,O
observed,6051,O
.,6051,O
Understanding,6052,O
the,6052,O
influence,6052,O
of,6052,O
general,6052,O
activity,6052,O
on,6052,O
sociability,6052,O
and,6052,O
repetitive,6052,O
behaviors,6052,O
will,6052,O
increase,6052,O
the,6052,O
accuracy,6052,O
of,6052,O
interpretations,6052,O
of,6052,O
positive,6052,O
outcomes,6052,O
measured,6052,O
from,6052,O
pharmacological,6052,O
treatment,6052,O
that,6052,O
produces,6052,O
locomotor,6052,O
activating,6052,O
or,6052,O
sedating,6052,O
effects,6052,O
.,6052,O
In,6053,O
the,6053,O
present,6053,O
studies,6053,O
",",6053,O
dose-response,6053,O
curves,6053,O
for,6053,O
d-amphetamine,6053,B-CHEMICAL
(,6053,O
AMPH,6053,B-CHEMICAL
),6053,O
-induced,6053,O
hyperlocomotion,6053,O
were,6053,O
similar,6053,O
in,6053,O
standard,6053,O
B6,6053,O
mice,6053,O
and,6053,O
in,6053,O
the,6053,O
BTBR,6053,O
mouse,6053,O
model,6053,O
of,6053,O
autism,6053,O
.,6053,O
AMPH,6054,B-CHEMICAL
produced,6054,O
significant,6054,O
",",6054,O
robust,6054,O
reductions,6054,O
in,6054,O
the,6054,O
high,6054,O
level,6054,O
of,6054,O
repetitive,6054,O
self-grooming,6054,O
that,6054,O
characterizes,6054,O
BTBR,6054,O
",",6054,O
and,6054,O
also,6054,O
reduced,6054,O
the,6054,O
low,6054,O
baseline,6054,O
grooming,6054,O
in,6054,O
B6,6054,O
",",6054,O
indicating,6054,O
that,6054,O
AMPH-induced,6054,B-CHEMICAL
hyperlocomotion,6054,O
competes,6054,O
with,6054,O
time,6054,O
spent,6054,O
engaged,6054,O
in,6054,O
self-grooming,6054,O
.,6054,O
We,6055,O
then,6055,O
tested,6055,O
AMPH,6055,B-CHEMICAL
in,6055,O
B6,6055,O
and,6055,O
BTBR,6055,O
on,6055,O
the,6055,O
3-chambered,6055,O
social,6055,O
approach,6055,O
task,6055,O
.,6055,O
One,6056,O
component,6056,O
of,6056,O
sociability,6056,O
",",6056,O
the,6056,O
time,6056,O
spent,6056,O
in,6056,O
the,6056,O
chamber,6056,O
with,6056,O
the,6056,O
novel,6056,O
mouse,6056,O
",",6056,O
in,6056,O
B6,6056,O
mice,6056,O
was,6056,O
reduced,6056,O
",",6056,O
while,6056,O
the,6056,O
sniffing,6056,O
time,6056,O
component,6056,O
of,6056,O
sociability,6056,O
in,6056,O
BTBR,6056,O
mice,6056,O
was,6056,O
enhanced,6056,O
.,6056,O
This,6057,O
finding,6057,O
replicated,6057,O
across,6057,O
multiple,6057,O
cohorts,6057,O
treated,6057,O
with,6057,O
AMPH,6057,B-CHEMICAL
and,6057,O
saline,6057,O
vehicle,6057,O
.,6057,O
In-depth,6058,O
analysis,6058,O
revealed,6058,O
that,6058,O
AMPH,6058,B-CHEMICAL
increased,6058,O
the,6058,O
number,6058,O
and,6058,O
decreased,6058,O
the,6058,O
duration,6058,O
of,6058,O
sniffing,6058,O
bouts,6058,O
in,6058,O
BTBR,6058,O
",",6058,O
suggesting,6058,O
BTBR,6058,O
treated,6058,O
with,6058,O
AMPH,6058,B-CHEMICAL
mostly,6058,O
engaged,6058,O
in,6058,O
brief,6058,O
sniffs,6058,O
rather,6058,O
than,6058,O
true,6058,O
social,6058,O
interactions,6058,O
with,6058,O
the,6058,O
novel,6058,O
mouse,6058,O
during,6058,O
the,6058,O
social,6058,O
approach,6058,O
task,6058,O
.,6058,O
Our,6059,O
data,6059,O
suggest,6059,O
that,6059,O
compounds,6059,O
with,6059,O
stimulant,6059,O
properties,6059,O
may,6059,O
have,6059,O
some,6059,O
direct,6059,O
benefits,6059,O
on,6059,O
reducing,6059,O
repetitive,6059,O
behaviors,6059,O
in,6059,O
autism,6059,O
spectrum,6059,O
disorders,6059,O
",",6059,O
particularly,6059,O
in,6059,O
the,6059,O
subset,6059,O
of,6059,O
autistic,6059,O
individuals,6059,O
with,6059,O
hyperactivity,6059,O
.,6059,O
This,6060,O
article,6060,O
is,6060,O
part,6060,O
of,6060,O
the,6060,O
Special,6060,O
Issue,6060,O
entitled,6060,O
'Neurodevelopmental,6060,O
Disorders,6060,O
',6060,O
.,6060,O
Decreased,6061,O
serum,6061,O
concentrations,6061,O
of,6061,O
25-hydroxycholecalciferol,6061,B-CHEMICAL
are,6061,O
associated,6061,O
with,6061,O
increased,6061,O
risk,6061,O
of,6061,O
progression,6061,O
to,6061,O
impaired,6061,O
fasting,6061,O
glucose,6061,B-CHEMICAL
and,6061,O
diabetes,6061,O
.,6061,O
OBJECTIVE,6062,O
To,6062,O
study,6062,O
the,6062,O
association,6062,O
between,6062,O
vitamin,6062,B-CHEMICAL
D,6062,I-CHEMICAL
status,6062,O
and,6062,O
the,6062,O
risk,6062,O
of,6062,O
incident,6062,O
impaired,6062,O
fasting,6062,O
glucose,6062,B-CHEMICAL
(,6062,O
IFG,6062,O
),6062,O
and,6062,O
diabetes,6062,O
in,6062,O
a,6062,O
population-based,6062,O
cohort,6062,O
of,6062,O
diabetes-free,6062,O
subjects,6062,O
.,6062,O
RESEARCH,6063,O
DESIGN,6063,O
AND,6063,O
METHODS,6063,O
In,6063,O
a,6063,O
historical,6063,O
prospective,6063,O
cohort,6063,O
study,6063,O
of,6063,O
subjects,6063,O
from,6063,O
the,6063,O
Clalit,6063,O
Health,6063,O
Services,6063,O
database,6063,O
",",6063,O
which,6063,O
includes,6063,O
information,6063,O
on,6063,O
nearly,6063,O
4,6063,O
million,6063,O
people,6063,O
",",6063,O
diabetes-free,6063,O
subjects,6063,O
aged,6063,O
40-70,6063,O
years,6063,O
with,6063,O
serum,6063,O
25-hydroxycholecalciferol,6063,B-CHEMICAL
(,6063,O
25-OHD,6063,B-CHEMICAL
),6063,O
measurements,6063,O
available,6063,O
were,6063,O
followed,6063,O
for,6063,O
2,6063,O
years,6063,O
to,6063,O
assess,6063,O
the,6063,O
development,6063,O
of,6063,O
IFG,6063,O
and,6063,O
diabetes,6063,O
in,6063,O
five,6063,O
25-OHD,6063,B-CHEMICAL
subgroups,6063,O
:,6063,O
≥25,6063,O
",",6063,O
25.1-37.5,6063,O
",",6063,O
37.6-50,6063,O
",",6063,O
50.1-75,6063,O
",",6063,O
and,6063,O
>,6063,O
75,6063,O
nmol/L,6063,O
.,6063,O
RESULTS,6064,O
The,6064,O
baseline,6064,O
cohort,6064,O
included,6064,O
"117,960",6064,O
adults,6064,O
:,6064,O
"83,526",6064,O
normoglycemic,6064,O
subjects,6064,O
and,6064,O
"34,434",6064,O
subjects,6064,O
with,6064,O
IFG,6064,O
.,6064,O
During,6065,O
follow-up,6065,O
",",6065,O
"8,629",6065,O
subjects,6065,O
(,6065,O
10.3,6065,O
%,6065,O
of,6065,O
the,6065,O
normoglycemic,6065,O
group,6065,O
),6065,O
developed,6065,O
IFG,6065,O
",",6065,O
and,6065,O
"2,162",6065,O
subjects,6065,O
(,6065,O
1.8,6065,O
%,6065,O
of,6065,O
the,6065,O
total,6065,O
cohort,6065,O
),6065,O
progressed,6065,O
to,6065,O
diabetes,6065,O
.,6065,O
A,6066,O
multivariable,6066,O
model,6066,O
adjusted,6066,O
for,6066,O
age,6066,O
",",6066,O
sex,6066,O
",",6066,O
population,6066,O
group,6066,O
",",6066,O
immigrant,6066,O
status,6066,O
",",6066,O
BMI,6066,O
",",6066,O
season,6066,O
of,6066,O
vitamin,6066,B-CHEMICAL
D,6066,I-CHEMICAL
measurement,6066,O
",",6066,O
LDL,6066,B-GENE-N
and,6066,O
HDL,6066,B-GENE-N
cholesterol,6066,B-CHEMICAL
",",6066,O
triglycerides,6066,B-CHEMICAL
",",6066,O
estimated,6066,O
glomerular,6066,O
filtration,6066,O
rate,6066,O
",",6066,O
history,6066,O
of,6066,O
hypertension,6066,O
or,6066,O
cardiovascular,6066,O
disease,6066,O
",",6066,O
Charlson,6066,O
comorbidity,6066,O
index,6066,O
",",6066,O
smoking,6066,O
",",6066,O
and,6066,O
socioeconomic,6066,O
status,6066,O
revealed,6066,O
an,6066,O
inverse,6066,O
association,6066,O
between,6066,O
25-OHD,6066,B-CHEMICAL
and,6066,O
the,6066,O
risk,6066,O
of,6066,O
progression,6066,O
to,6066,O
IFG,6066,O
and,6066,O
diabetes,6066,O
.,6066,O
The,6067,O
odds,6067,O
of,6067,O
transitioning,6067,O
from,6067,O
normoglycemia,6067,O
to,6067,O
IFG,6067,O
",",6067,O
from,6067,O
normoglycemia,6067,O
to,6067,O
diabetes,6067,O
",",6067,O
and,6067,O
from,6067,O
IFG,6067,O
to,6067,O
diabetes,6067,O
in,6067,O
subjects,6067,O
with,6067,O
a,6067,O
25-OHD,6067,B-CHEMICAL
level,6067,O
≤25,6067,O
nmol/L,6067,O
were,6067,O
greater,6067,O
than,6067,O
those,6067,O
of,6067,O
subjects,6067,O
with,6067,O
a,6067,O
25-OHD,6067,B-CHEMICAL
level,6067,O
>,6067,O
75,6067,O
nmol/L,6067,O
[,6067,O
odds,6067,O
ratio,6067,O
1.13,6067,O
(,6067,O
95,6067,O
%,6067,O
CI,6067,O
1.03-1.24,6067,O
),6067,O
",",6067,O
1.77,6067,O
(,6067,O
1.11-2.83,6067,O
),6067,O
",",6067,O
and,6067,O
1.43,6067,O
(,6067,O
1.16-1.76,6067,O
),6067,O
",",6067,O
respectively,6067,O
],6067,O
.,6067,O
CONCLUSIONS,6068,O
Vitamin,6068,B-CHEMICAL
D,6068,I-CHEMICAL
deficiency,6068,O
appears,6068,O
to,6068,O
be,6068,O
an,6068,O
independent,6068,O
risk,6068,O
factor,6068,O
for,6068,O
the,6068,O
development,6068,O
of,6068,O
IFG,6068,O
and,6068,O
diabetes,6068,O
.,6068,O
Structural,6069,O
features,6069,O
of,6069,O
the,6069,O
central,6069,O
cannabinoid,6069,B-CHEMICAL
CB1,6069,B-GENE-Y
receptor,6069,O
involved,6069,O
in,6069,O
the,6069,O
binding,6069,O
of,6069,O
the,6069,O
specific,6069,O
CB1,6069,B-GENE-Y
antagonist,6069,O
SR,6069,B-CHEMICAL
141716A,6069,I-CHEMICAL
.,6069,O
The,6070,O
antagonist,6070,O
SR,6070,B-CHEMICAL
141716A,6070,I-CHEMICAL
has,6070,O
a,6070,O
high,6070,O
specificity,6070,O
for,6070,O
the,6070,O
central,6070,O
CB1,6070,B-GENE-Y
cannabinoid,6070,B-GENE-N
receptor,6070,I-GENE-N
and,6070,O
negligeable,6070,O
affinity,6070,O
for,6070,O
the,6070,O
peripheral,6070,O
CB2,6070,B-GENE-Y
receptor,6070,O
",",6070,O
making,6070,O
it,6070,O
an,6070,O
excellent,6070,O
tool,6070,O
for,6070,O
probing,6070,O
receptor,6070,O
structure-activity,6070,O
relationships,6070,O
.,6070,O
From,6071,O
binding,6071,O
experiments,6071,O
with,6071,O
mutated,6071,O
CB1,6071,B-GENE-Y
and,6071,O
with,6071,O
chimeric,6071,O
CB1/CB2,6071,B-GENE-Y
receptors,6071,O
we,6071,O
have,6071,O
begun,6071,O
to,6071,O
identify,6071,O
the,6071,O
domains,6071,O
of,6071,O
CB1,6071,B-GENE-Y
implicated,6071,O
in,6071,O
the,6071,O
recognition,6071,O
of,6071,O
SR,6071,B-CHEMICAL
141716A,6071,I-CHEMICAL
.,6071,O
Receptors,6072,O
were,6072,O
transiently,6072,O
expressed,6072,O
in,6072,O
COS-3,6072,O
cells,6072,O
",",6072,O
and,6072,O
their,6072,O
binding,6072,O
characteristics,6072,O
were,6072,O
studied,6072,O
with,6072,O
SR,6072,B-CHEMICAL
141716A,6072,I-CHEMICAL
and,6072,O
with,6072,O
CP,6072,B-CHEMICAL
"55,940",6072,I-CHEMICAL
",",6072,O
an,6072,O
agonist,6072,O
recognized,6072,O
equally,6072,O
well,6072,O
by,6072,O
the,6072,O
two,6072,O
receptors,6072,O
.,6072,O
The,6073,O
region,6073,O
delineated,6073,O
by,6073,O
the,6073,O
fourth,6073,O
and,6073,O
fifth,6073,O
transmembrane,6073,O
helices,6073,O
of,6073,O
CB1,6073,B-GENE-Y
proved,6073,O
to,6073,O
be,6073,O
crucial,6073,O
for,6073,O
high,6073,O
affinity,6073,O
binding,6073,O
of,6073,O
SR,6073,B-CHEMICAL
141716A,6073,I-CHEMICAL
.,6073,O
The,6074,O
CB1,6074,B-GENE-Y
and,6074,O
CB2,6074,B-GENE-Y
second,6074,O
extracellular,6074,O
loops,6074,O
",",6074,O
e2,6074,O
",",6074,O
were,6074,O
exchanged,6074,O
",",6074,O
modifications,6074,O
that,6074,O
had,6074,O
no,6074,O
effect,6074,O
on,6074,O
SR,6074,B-CHEMICAL
141716A,6074,I-CHEMICAL
binding,6074,O
in,6074,O
the,6074,O
CB1,6074,B-GENE-Y
variant,6074,O
but,6074,O
that,6074,O
eliminated,6074,O
CP,6074,B-CHEMICAL
"55,940",6074,I-CHEMICAL
binding,6074,O
in,6074,O
both,6074,O
mutants,6074,O
.,6074,O
The,6075,O
replacement,6075,O
of,6075,O
the,6075,O
conserved,6075,O
cysteine,6075,B-CHEMICAL
residues,6075,O
in,6075,O
e2,6075,O
of,6075,O
CB2,6075,B-GENE-Y
by,6075,O
serine,6075,B-CHEMICAL
also,6075,O
eliminated,6075,O
CP,6075,B-CHEMICAL
"55,940",6075,I-CHEMICAL
binding,6075,O
",",6075,O
but,6075,O
replacement,6075,O
of,6075,O
those,6075,O
in,6075,O
CB1,6075,B-GENE-Y
resulted,6075,O
in,6075,O
the,6075,O
sequestration,6075,O
of,6075,O
the,6075,O
mutated,6075,O
receptors,6075,O
in,6075,O
the,6075,O
cell,6075,O
cytoplasm,6075,O
.,6075,O
The,6076,O
e2,6076,B-GENE-N
domain,6076,I-GENE-N
thus,6076,O
plays,6076,O
some,6076,O
role,6076,O
in,6076,O
CP,6076,B-CHEMICAL
"55,940",6076,I-CHEMICAL
binding,6076,O
but,6076,O
none,6076,O
in,6076,O
SR,6076,B-CHEMICAL
141716A,6076,I-CHEMICAL
recognition,6076,O
",",6076,O
binding,6076,O
of,6076,O
the,6076,O
latter,6076,O
clearly,6076,O
implicating,6076,O
residues,6076,O
in,6076,O
the,6076,O
adjoining,6076,O
transmembrane,6076,O
helices,6076,O
.,6076,O
Drosophila,6077,B-GENE-N
GABA-gated,6077,I-GENE-N
chloride,6077,I-GENE-N
channel,6077,I-GENE-N
:,6077,O
modified,6077,O
[,6077,B-CHEMICAL
3H,6077,I-CHEMICAL
],6077,I-CHEMICAL
EBOB,6077,I-CHEMICAL
binding,6077,O
site,6077,O
associated,6077,O
with,6077,O
Ala,6077,B-CHEMICAL
--,6077,O
>,6077,O
Ser,6077,B-CHEMICAL
or,6077,O
Gly,6077,B-CHEMICAL
mutants,6077,O
of,6077,O
Rdl,6077,B-GENE-Y
subunit,6077,O
.,6077,O
The,6078,O
non-competitive,6078,O
blocker,6078,O
site,6078,O
of,6078,O
the,6078,O
GABA-gated,6078,B-GENE-N
chloride,6078,I-GENE-N
ion,6078,I-GENE-N
channel,6078,I-GENE-N
in,6078,O
normal,6078,O
susceptible,6078,O
strains,6078,O
of,6078,O
Drosophila,6078,O
melanogaster,6078,O
and,6078,O
simulans,6078,O
binds,6078,O
4-n-,6078,B-CHEMICAL
[,6078,I-CHEMICAL
3H,6078,I-CHEMICAL
],6078,I-CHEMICAL
propyl-4'-ethynylbicycloorthobenzoate,6078,I-CHEMICAL
(,6078,O
[,6078,B-CHEMICAL
3H,6078,I-CHEMICAL
],6078,I-CHEMICAL
EBOB,6078,I-CHEMICAL
),6078,O
at,6078,O
specific,6078,O
sites,6078,O
with,6078,O
KdS,6078,O
of,6078,O
1.6-1.9,6078,O
nM,6078,O
and,6078,O
BmaxS,6078,O
of,6078,O
171-181,6078,O
fmol/mg,6078,O
protein,6078,O
.,6078,O
This,6079,O
specific,6079,O
binding,6079,O
of,6079,O
[,6079,B-CHEMICAL
3H,6079,I-CHEMICAL
],6079,I-CHEMICAL
EBOB,6079,I-CHEMICAL
is,6079,O
strongly,6079,O
inhibited,6079,O
by,6079,O
:,6079,O
a,6079,O
large,6079,O
number,6079,O
and,6079,O
variety,6079,O
of,6079,O
insecticidal,6079,O
channel,6079,O
blockers,6079,O
at,6079,O
20,6079,O
nM,6079,O
(,6079,O
lindane,6079,B-CHEMICAL
",",6079,O
alpha-endosulfan,6079,B-CHEMICAL
",",6079,O
dieldrin,6079,B-CHEMICAL
",",6079,O
12-ketoendrin,6079,B-CHEMICAL
",",6079,O
fipronil,6079,B-CHEMICAL
",",6079,O
and,6079,O
a,6079,O
representative,6079,O
bicycloorthobenzoate,6079,B-CHEMICAL
and,6079,O
dithiane,6079,B-CHEMICAL
),6079,O
or,6079,O
200,6079,O
nM,6079,O
(,6079,O
picrotoxinin,6079,B-CHEMICAL
),6079,O
;,6079,O
the,6079,O
insecticidal,6079,O
channel,6079,O
activators,6079,O
avermectin,6079,B-CHEMICAL
and,6079,O
moxidectin,6079,B-CHEMICAL
at,6079,O
20,6079,O
nM,6079,O
;,6079,O
muscimol,6079,B-CHEMICAL
at,6079,O
30,6079,O
microM,6079,O
and,6079,O
GABA,6079,B-CHEMICAL
at,6079,O
300,6079,O
microM,6079,O
.,6079,O
Cyclodiene,6080,B-CHEMICAL
resistance,6080,O
in,6080,O
D.,6080,O
melanogaster,6080,O
has,6080,O
been,6080,O
attributed,6080,O
to,6080,O
a,6080,O
mutation,6080,O
resulting,6080,O
in,6080,O
an,6080,O
Ala302,6080,B-GENE-N
--,6080,I-GENE-N
>,6080,I-GENE-N
Ser,6080,I-GENE-N
replacement,6080,O
in,6080,O
the,6080,O
Rdl,6080,B-GENE-Y
GABA,6080,I-GENE-Y
receptor,6080,I-GENE-Y
subunit,6080,O
and,6080,O
in,6080,O
D.,6080,O
simulans,6080,O
to,6080,O
an,6080,O
homologous,6080,O
Ala,6080,B-CHEMICAL
--,6080,O
>,6080,O
Ser,6080,B-CHEMICAL
or,6080,O
Gly,6080,B-CHEMICAL
replacement,6080,O
.,6080,O
These,6081,O
mutations,6081,O
are,6081,O
shown,6081,O
here,6081,O
to,6081,O
greatly,6081,O
reduce,6081,O
[,6081,B-CHEMICAL
3H,6081,I-CHEMICAL
],6081,I-CHEMICAL
EBOB,6081,I-CHEMICAL
binding,6081,O
",",6081,O
i.e,6081,O
.,6081,O
lower,6082,O
affinity,6082,O
and,6082,O
apparent,6082,O
number,6082,O
of,6082,O
binding,6082,O
sites,6082,O
.,6082,O
The,6083,O
Ala,6083,B-CHEMICAL
--,6083,O
>,6083,O
Ser,6083,B-CHEMICAL
replacement,6083,O
with,6083,O
both,6083,O
melanogaster,6083,O
and,6083,O
simulans,6083,O
almost,6083,O
always,6083,O
reduces,6083,O
the,6083,O
potency,6083,O
in,6083,O
inhibiting,6083,O
[,6083,B-CHEMICAL
3H,6083,I-CHEMICAL
],6083,I-CHEMICAL
EBOB,6083,I-CHEMICAL
binding,6083,O
of,6083,O
each,6083,O
of,6083,O
eight,6083,O
channel,6083,O
blockers,6083,O
and,6083,O
of,6083,O
muscimol,6083,B-CHEMICAL
and,6083,O
GABA,6083,B-CHEMICAL
.,6083,O
The,6084,O
Ala,6084,B-CHEMICAL
--,6084,O
>,6084,O
Gly,6084,B-CHEMICAL
replacement,6084,O
in,6084,O
D.,6084,O
simulans,6084,O
is,6084,O
generally,6084,O
less,6084,O
effective,6084,O
than,6084,O
the,6084,O
Ala,6084,B-CHEMICAL
--,6084,O
>,6084,O
Ser,6084,B-CHEMICAL
modification,6084,O
in,6084,O
reducing,6084,O
sensitivity,6084,O
to,6084,O
the,6084,O
channel,6084,O
blockers,6084,O
and,6084,O
to,6084,O
muscimol,6084,B-CHEMICAL
and,6084,O
GABA,6084,B-CHEMICAL
.,6084,O
The,6085,O
channel,6085,O
activators,6085,O
avermectin,6085,B-CHEMICAL
and,6085,O
moxidectin,6085,B-CHEMICAL
usually,6085,O
retain,6085,O
their,6085,O
inhibitory,6085,O
potency,6085,O
in,6085,O
the,6085,O
Rdl,6085,B-GENE-Y
subunit,6085,O
mutants,6085,O
.,6085,O
Thus,6086,O
",",6086,O
it,6086,O
appears,6086,O
that,6086,O
replacement,6086,O
of,6086,O
Ala,6086,B-CHEMICAL
by,6086,O
Ser,6086,B-CHEMICAL
generally,6086,O
modifies,6086,O
the,6086,O
non-competitive,6086,O
blocker,6086,O
site,6086,O
and,6086,O
its,6086,O
coupling,6086,O
to,6086,O
the,6086,O
GABA-recognition,6086,B-CHEMICAL
site,6086,O
with,6086,O
less,6086,O
effect,6086,O
on,6086,O
the,6086,O
channel,6086,O
activator,6086,O
site,6086,O
.,6086,O
In,6087,O
contrast,6087,O
",",6087,O
the,6087,O
Ala,6087,B-CHEMICAL
--,6087,O
>,6087,O
Gly,6087,B-CHEMICAL
replacement,6087,O
has,6087,O
less,6087,O
impact,6087,O
in,6087,O
protecting,6087,O
the,6087,O
chloride,6087,B-GENE-N
channel,6087,I-GENE-N
from,6087,O
the,6087,O
action,6087,O
of,6087,O
insecticidal,6087,O
blockers,6087,O
.,6087,O
Each,6088,O
of,6088,O
the,6088,O
resistant,6088,O
strains,6088,O
has,6088,O
the,6088,O
same,6088,O
level,6088,O
of,6088,O
resistance,6088,O
to,6088,O
the,6088,O
lethal,6088,O
action,6088,O
of,6088,O
the,6088,O
five,6088,O
channel,6088,O
blockers,6088,O
examined,6088,O
but,6088,O
none,6088,O
to,6088,O
avermectins,6088,B-CHEMICAL
and,6088,O
muscimol,6088,B-CHEMICAL
.,6088,O
In,6089,O
vitro,6089,O
antiprogestational/antiglucocorticoid,6089,O
activity,6089,O
and,6089,O
progestin,6089,B-GENE-N
and,6089,O
glucocorticoid,6089,B-GENE-Y
receptor,6089,I-GENE-Y
binding,6089,O
of,6089,O
the,6089,O
putative,6089,O
metabolites,6089,O
and,6089,O
synthetic,6089,O
derivatives,6089,O
of,6089,O
CDB-2914,6089,B-CHEMICAL
",",6089,O
CDB-4124,6089,B-CHEMICAL
",",6089,O
and,6089,O
mifepristone,6089,B-CHEMICAL
.,6089,O
In,6090,O
determining,6090,O
the,6090,O
biological,6090,O
profiles,6090,O
of,6090,O
various,6090,O
antiprogestins,6090,O
",",6090,O
it,6090,O
is,6090,O
important,6090,O
to,6090,O
assess,6090,O
the,6090,O
hormonal,6090,O
and,6090,O
antihormonal,6090,O
activity,6090,O
",",6090,O
selectivity,6090,O
",",6090,O
and,6090,O
potency,6090,O
of,6090,O
their,6090,O
proximal,6090,O
metabolites,6090,O
.,6090,O
The,6091,O
early,6091,O
metabolism,6091,O
of,6091,O
mifepristone,6091,B-CHEMICAL
is,6091,O
characterized,6091,O
by,6091,O
rapid,6091,O
demethylation,6091,O
and,6091,O
hydroxylation,6091,O
.,6091,O
Similar,6092,O
initial,6092,O
metabolic,6092,O
pathways,6092,O
have,6092,O
been,6092,O
proposed,6092,O
for,6092,O
CDB-2914,6092,B-CHEMICAL
(,6092,O
CDB,6092,O
:,6092,O
Contraceptive,6092,O
Development,6092,O
Branch,6092,O
of,6092,O
NICHD,6092,O
),6092,O
and,6092,O
CDB-4124,6092,B-CHEMICAL
",",6092,O
and,6092,O
their,6092,O
putative,6092,O
metabolites,6092,O
have,6092,O
been,6092,O
synthesized,6092,O
.,6092,O
We,6093,O
have,6093,O
examined,6093,O
the,6093,O
functional,6093,O
activities,6093,O
and,6093,O
potencies,6093,O
",",6093,O
in,6093,O
various,6093,O
cell-based,6093,O
assays,6093,O
",",6093,O
and,6093,O
relative,6093,O
binding,6093,O
affinities,6093,O
(,6093,O
RBAs,6093,O
),6093,O
for,6093,O
progesterone,6093,B-GENE-N
receptors,6093,I-GENE-N
(,6093,O
PR,6093,B-GENE-N
),6093,O
and,6093,O
glucocorticoid,6093,B-GENE-Y
receptors,6093,I-GENE-Y
(,6093,O
GR,6093,B-GENE-Y
),6093,O
of,6093,O
the,6093,O
putative,6093,O
mono-,6093,O
and,6093,O
didemethylated,6093,O
metabolites,6093,O
of,6093,O
CDB-2914,6093,B-CHEMICAL
",",6093,O
CDB-4124,6093,B-CHEMICAL
",",6093,O
and,6093,O
mifepristone,6093,B-CHEMICAL
and,6093,O
of,6093,O
the,6093,O
17alpha-hydroxy,6093,B-CHEMICAL
and,6093,O
aromatic,6093,O
A-ring,6093,O
derivatives,6093,O
of,6093,O
CDB-2914,6093,B-CHEMICAL
and,6093,O
CDB-4124,6093,B-CHEMICAL
.,6093,O
The,6094,O
binding,6094,O
affinities,6094,O
of,6094,O
the,6094,O
monodemethylated,6094,O
metabolites,6094,O
for,6094,O
rabbit,6094,B-GENE-Y
uterine,6094,I-GENE-Y
PR,6094,I-GENE-Y
and,6094,O
human,6094,B-GENE-Y
PR-A,6094,I-GENE-Y
and,6094,O
PR-B,6094,B-GENE-Y
were,6094,O
similar,6094,O
to,6094,O
those,6094,O
of,6094,O
the,6094,O
parent,6094,O
compounds,6094,O
.,6094,O
Monodemethylated,6095,O
mifepristone,6095,B-CHEMICAL
bound,6095,O
to,6095,O
rabbit,6095,B-GENE-Y
thymic,6095,I-GENE-Y
GR,6095,I-GENE-Y
with,6095,O
higher,6095,O
affinity,6095,O
than,6095,O
monodemethylated,6095,O
CDB-2914,6095,B-CHEMICAL
or,6095,O
CDB-4124,6095,B-CHEMICAL
.,6095,O
T47D-CO,6096,O
cells,6096,O
were,6096,O
used,6096,O
to,6096,O
assess,6096,O
inhibition,6096,O
of,6096,O
R5020-stimulated,6096,O
endogenous,6096,O
alkaline,6096,B-GENE-N
phosphatase,6096,I-GENE-N
activity,6096,O
and,6096,O
transactivation,6096,O
of,6096,O
the,6096,O
PRE,6096,B-GENE-N
(,6096,I-GENE-N
2,6096,I-GENE-N
),6096,I-GENE-N
-thymidine,6096,O
kinase,6096,I-GENE-N
(,6096,O
tk,6096,B-GENE-N
),6096,O
-luciferase,6096,O
(,6096,O
LUC,6096,O
),6096,O
reporter,6096,O
plasmid,6096,O
in,6096,O
transient,6096,O
transfections,6096,O
.,6096,O
The,6097,O
antiprogestational,6097,O
potency,6097,O
was,6097,O
as,6097,O
follows,6097,O
:,6097,O
mifepristone/CDB-2914/CDB-4124/monodemethylated,6097,B-CHEMICAL
metabolites,6097,O
(,6097,O
IC,6097,O
(,6097,O
50,6097,O
),6097,O
's,6097,O
approximately,6097,O
10,6097,O
(,6097,O
-9,6097,O
),6097,O
M,6097,O
),6097,O
>,6097,O
aromatic,6097,O
A-ring,6097,O
derivatives,6097,O
(,6097,O
IC,6097,O
(,6097,O
50,6097,O
),6097,O
's,6097,O
approximately,6097,O
10,6097,O
(,6097,O
-8,6097,O
),6097,O
M,6097,O
),6097,O
>,6097,O
didemethylated/17alpha-hydroxy,6097,O
derivatives,6097,O
(,6097,O
IC,6097,O
(,6097,O
50,6097,O
),6097,O
's,6097,O
approximately,6097,O
10,6097,O
(,6097,O
-7,6097,O
),6097,O
M,6097,O
),6097,O
.,6097,O
Antiglucocorticoid,6098,O
activity,6098,O
was,6098,O
determined,6098,O
by,6098,O
inhibition,6098,O
of,6098,O
dexamethasone-stimulated,6098,B-CHEMICAL
transcriptional,6098,O
activity,6098,O
in,6098,O
HepG2,6098,O
cells,6098,O
.,6098,O
The,6099,O
mono-,6099,O
and,6099,O
didemethylated,6099,O
metabolites,6099,O
of,6099,O
CDB-2914,6099,B-CHEMICAL
and,6099,O
CDB-4124,6099,B-CHEMICAL
had,6099,O
less,6099,O
antiglucocorticoid,6099,O
activity,6099,O
(,6099,O
IC,6099,O
(,6099,O
50,6099,O
),6099,O
's,6099,O
approximately,6099,O
10,6099,O
(,6099,O
-6,6099,O
),6099,O
M,6099,O
),6099,O
than,6099,O
monodemethylated,6099,O
mifepristone,6099,B-CHEMICAL
(,6099,O
IC,6099,O
(,6099,O
50,6099,O
),6099,O
approximately,6099,O
10,6099,O
(,6099,O
-8,6099,O
),6099,O
M,6099,O
),6099,O
or,6099,O
the,6099,O
other,6099,O
test,6099,O
compounds,6099,O
.,6099,O
At,6100,O
10,6100,O
(,6100,O
-6,6100,O
),6100,O
M,6100,O
in,6100,O
transcription,6100,O
assays,6100,O
",",6100,O
none,6100,O
of,6100,O
these,6100,O
compounds,6100,O
showed,6100,O
progestin,6100,B-GENE-Y
agonist,6100,O
activity,6100,O
",",6100,O
whereas,6100,O
mifepristone,6100,B-CHEMICAL
and,6100,O
its,6100,O
monodemethylated,6100,O
metabolite,6100,O
manifested,6100,O
slight,6100,O
glucocorticoid,6100,B-GENE-Y
agonist,6100,O
activity,6100,O
.,6100,O
The,6101,O
reduced,6101,O
antiglucocorticoid,6101,O
activity,6101,O
of,6101,O
monodemethylated,6101,O
CDB-2914,6101,B-CHEMICAL
and,6101,O
CDB-4124,6101,B-CHEMICAL
was,6101,O
confirmed,6101,O
in,6101,O
vivo,6101,O
by,6101,O
the,6101,O
thymus,6101,O
involution,6101,O
assay,6101,O
in,6101,O
adrenalectomized,6101,O
male,6101,O
rats,6101,O
.,6101,O
The,6102,O
aromatic,6102,O
A-ring,6102,O
derivatives-stimulated,6102,O
transcription,6102,O
of,6102,O
an,6102,O
estrogen-responsive,6102,B-CHEMICAL
reporter,6102,O
plasmid,6102,O
in,6102,O
MCF-7,6102,O
and,6102,O
T47D-CO,6102,O
human,6102,O
breast,6102,O
cancer,6102,O
cells,6102,O
but,6102,O
were,6102,O
much,6102,O
less,6102,O
potent,6102,O
than,6102,O
estradiol,6102,B-CHEMICAL
.,6102,O
Taken,6103,O
together,6103,O
",",6103,O
these,6103,O
data,6103,O
suggest,6103,O
that,6103,O
the,6103,O
proximal,6103,O
metabolites,6103,O
of,6103,O
mifepristone,6103,B-CHEMICAL
",",6103,O
CDB-2914,6103,B-CHEMICAL
",",6103,O
and,6103,O
CDB-4124,6103,B-CHEMICAL
contribute,6103,O
significantly,6103,O
to,6103,O
the,6103,O
antiprogestational,6103,O
activity,6103,O
of,6103,O
the,6103,O
parent,6103,O
compounds,6103,O
in,6103,O
vivo,6103,O
.,6103,O
Furthermore,6104,O
",",6104,O
the,6104,O
reduced,6104,O
antiglucocorticoid,6104,O
activity,6104,O
of,6104,O
CDB-2914,6104,B-CHEMICAL
and,6104,O
CDB-4124,6104,B-CHEMICAL
compared,6104,O
to,6104,O
mifepristone,6104,B-CHEMICAL
in,6104,O
vivo,6104,O
may,6104,O
be,6104,O
due,6104,O
in,6104,O
part,6104,O
to,6104,O
decreased,6104,O
activity,6104,O
of,6104,O
their,6104,O
putative,6104,O
proximal,6104,O
metabolites,6104,O
.,6104,O
Different,6105,O
mechanisms,6105,O
of,6105,O
acquired,6105,O
resistance,6105,O
to,6105,O
fluorinated,6105,B-CHEMICAL
pyrimidines,6105,I-CHEMICAL
in,6105,O
human,6105,O
colorectal,6105,O
cancer,6105,O
cells,6105,O
.,6105,O
5-Fluorouracil,6106,B-CHEMICAL
(,6106,O
5-FU,6106,B-CHEMICAL
),6106,O
",",6106,O
5-fluoro-2'-deoxyuridine,6106,B-CHEMICAL
(,6106,O
FdUrd,6106,B-CHEMICAL
),6106,O
and,6106,O
5-trifluorothymidine,6106,B-CHEMICAL
(,6106,O
F3,6106,B-CHEMICAL
(,6106,I-CHEMICAL
d,6106,I-CHEMICAL
),6106,I-CHEMICAL
Thd,6106,I-CHEMICAL
),6106,O
are,6106,O
antimetabolites,6106,O
which,6106,O
are,6106,O
metabolized,6106,O
to,6106,O
their,6106,O
corresponding,6106,O
active,6106,O
forms,6106,O
which,6106,O
inhibit,6106,O
DNA,6106,O
synthesis,6106,O
via,6106,O
inhibition,6106,O
of,6106,O
thymidylate,6106,B-GENE-Y
synthase,6106,I-GENE-Y
(,6106,O
TS,6106,B-GENE-Y
),6106,O
.,6106,O
To,6107,O
investigate,6107,O
ways,6107,O
of,6107,O
overcoming,6107,O
5-FU-resistance,6107,B-CHEMICAL
",",6107,O
we,6107,O
established,6107,O
acquired-resistant,6107,O
colorectal,6107,O
cancer,6107,O
cell,6107,O
lines,6107,O
against,6107,O
these,6107,O
three,6107,O
drugs,6107,O
by,6107,O
continuous,6107,O
and,6107,O
step-wise,6107,O
escalation,6107,O
of,6107,O
drugs,6107,O
",",6107,O
and,6107,O
analyzed,6107,O
the,6107,O
cytotoxicity,6107,O
and,6107,O
the,6107,O
mechanism,6107,O
of,6107,O
resistance,6107,O
to,6107,O
the,6107,O
drugs,6107,O
.,6107,O
When,6108,O
cells,6108,O
were,6108,O
incubated,6108,O
with,6108,O
the,6108,O
3,6108,O
drugs,6108,O
for,6108,O
72,6108,O
h,6108,O
",",6108,O
the,6108,O
resistance,6108,O
ratio,6108,O
to,6108,O
parental,6108,O
DLD-1,6108,O
human,6108,O
colorectal,6108,O
tumor,6108,O
cells,6108,O
was,6108,O
65.2,6108,O
for,6108,O
DLD-1/5-FU,6108,O
",",6108,O
9.7,6108,O
for,6108,O
DLD-1/FdUrd,6108,O
and,6108,O
448.6,6108,O
for,6108,O
DLD-1/F3,6108,O
(,6108,I-CHEMICAL
d,6108,I-CHEMICAL
),6108,I-CHEMICAL
Thd,6108,I-CHEMICAL
cells,6108,O
.,6108,O
DLD-1/5-FU,6109,O
cells,6109,O
did,6109,O
not,6109,O
show,6109,O
any,6109,O
cross-resistance,6109,O
against,6109,O
FdUrd,6109,B-CHEMICAL
and,6109,O
F,6109,B-CHEMICAL
(,6109,I-CHEMICAL
3,6109,I-CHEMICAL
),6109,I-CHEMICAL
dThd,6109,I-CHEMICAL
.,6109,O
However,6110,O
",",6110,O
DLD-1/FdUrd,6110,O
cells,6110,O
showed,6110,O
3-,6110,O
and,6110,O
9-fold,6110,O
increased,6110,O
resistance,6110,O
to,6110,O
5-FU,6110,B-CHEMICAL
and,6110,O
F3,6110,B-CHEMICAL
(,6110,I-CHEMICAL
d,6110,I-CHEMICAL
),6110,I-CHEMICAL
Thd,6110,I-CHEMICAL
",",6110,O
respectively,6110,O
",",6110,O
and,6110,O
DLD-1/F3,6110,O
(,6110,I-CHEMICAL
d,6110,I-CHEMICAL
),6110,I-CHEMICAL
Thd,6110,I-CHEMICAL
cells,6110,O
also,6110,O
showed,6110,O
about,6110,O
90-fold,6110,O
resistance,6110,O
to,6110,O
FdUrd,6110,B-CHEMICAL
.,6110,O
Analysis,6111,O
of,6111,O
enzyme,6111,O
activities,6111,O
and,6111,O
gene,6111,O
expression,6111,O
associated,6111,O
with,6111,O
pyrimidine,6111,B-CHEMICAL
metabolism,6111,O
indicated,6111,O
that,6111,O
a,6111,O
significant,6111,O
decrease,6111,O
in,6111,O
orotate,6111,B-GENE-Y
phosphoribosyltransferase,6111,I-GENE-Y
activity,6111,O
in,6111,O
DLD-1/5-FU,6111,O
cells,6111,O
",",6111,O
a,6111,O
7-fold,6111,O
increase,6111,O
of,6111,O
TS,6111,B-GENE-Y
mRNA,6111,O
in,6111,O
DLD-1/FdUrd,6111,O
cells,6111,O
",",6111,O
and,6111,O
a,6111,O
37-fold,6111,O
decrease,6111,O
in,6111,O
thymidine,6111,B-GENE-Y
kinase,6111,I-GENE-Y
activity,6111,O
of,6111,O
DLD-1/F3,6111,O
(,6111,I-CHEMICAL
d,6111,I-CHEMICAL
),6111,I-CHEMICAL
Thd,6111,I-CHEMICAL
cells,6111,O
were,6111,O
the,6111,O
major,6111,O
mechanisms,6111,O
of,6111,O
drug,6111,O
resistance,6111,O
.,6111,O
These,6112,O
findings,6112,O
were,6112,O
closely,6112,O
associated,6112,O
with,6112,O
the,6112,O
cytotoxicity,6112,O
of,6112,O
5-FU,6112,B-CHEMICAL
",",6112,O
FdUrd,6112,B-CHEMICAL
and,6112,O
F3,6112,B-CHEMICAL
(,6112,I-CHEMICAL
d,6112,I-CHEMICAL
),6112,I-CHEMICAL
Thd,6112,I-CHEMICAL
against,6112,O
the,6112,O
established,6112,O
5-FU-,6112,B-CHEMICAL
",",6112,O
FdUrd-,6112,B-CHEMICAL
or,6112,O
F3,6112,B-CHEMICAL
(,6112,I-CHEMICAL
d,6112,I-CHEMICAL
),6112,I-CHEMICAL
Thd-resistant,6112,O
cells,6112,O
.,6112,O
When,6113,O
DLD-1/FdUrd,6113,O
cells,6113,O
expressing,6113,O
increased,6113,O
TS,6113,B-GENE-Y
mRNA,6113,O
were,6113,O
treated,6113,O
with,6113,O
FdUrd,6113,B-CHEMICAL
and,6113,O
F3,6113,B-CHEMICAL
(,6113,I-CHEMICAL
d,6113,I-CHEMICAL
),6113,I-CHEMICAL
Thd,6113,I-CHEMICAL
for,6113,O
only,6113,O
4,6113,O
h,6113,O
",",6113,O
the,6113,O
resistance,6113,O
ratios,6113,O
of,6113,O
DLD-1/FdUrd,6113,O
cells,6113,O
to,6113,O
parental,6113,O
DLD-1,6113,O
cells,6113,O
were,6113,O
markedly,6113,O
different,6113,O
for,6113,O
FdUrd,6113,B-CHEMICAL
and,6113,O
F3,6113,B-CHEMICAL
(,6113,I-CHEMICAL
d,6113,I-CHEMICAL
),6113,I-CHEMICAL
Thd,6113,I-CHEMICAL
",",6113,O
suggesting,6113,O
that,6113,O
the,6113,O
cytotoxicity,6113,O
with,6113,O
short-time,6113,O
exposure,6113,O
to,6113,O
F3,6113,B-CHEMICAL
(,6113,I-CHEMICAL
d,6113,I-CHEMICAL
),6113,I-CHEMICAL
Thd,6113,I-CHEMICAL
is,6113,O
due,6113,O
to,6113,O
a,6113,O
mechanism,6113,O
other,6113,O
than,6113,O
TS,6113,B-GENE-Y
inhibition,6113,O
",",6113,O
although,6113,O
the,6113,O
cytotoxicity,6113,O
of,6113,O
F3,6113,B-CHEMICAL
(,6113,I-CHEMICAL
d,6113,I-CHEMICAL
),6113,I-CHEMICAL
Thd,6113,I-CHEMICAL
in,6113,O
the,6113,O
short-time,6113,O
is,6113,O
low,6113,O
compared,6113,O
to,6113,O
that,6113,O
of,6113,O
long-time,6113,O
exposure,6113,O
.,6113,O
In,6114,O
conclusion,6114,O
",",6114,O
F3,6114,B-CHEMICAL
(,6114,I-CHEMICAL
d,6114,I-CHEMICAL
),6114,I-CHEMICAL
Thd,6114,I-CHEMICAL
",",6114,O
an,6114,O
antimetabolite,6114,O
that,6114,O
inhibits,6114,O
TS,6114,B-GENE-Y
activity,6114,O
",",6114,O
may,6114,O
be,6114,O
effective,6114,O
against,6114,O
5-FU,6114,B-CHEMICAL
and/or,6114,O
FdUrd-resistance,6114,B-CHEMICAL
in,6114,O
colorectal,6114,O
cancer,6114,O
cells,6114,O
caused,6114,O
by,6114,O
amplification,6114,O
of,6114,O
TS,6114,B-GENE-N
and/or,6114,O
deletion,6114,O
of,6114,O
orotate,6114,B-GENE-Y
phosphoribosyltransferase,6114,I-GENE-Y
.,6114,O
Failure,6115,O
of,6115,O
ritodrine,6115,B-CHEMICAL
to,6115,O
prevent,6115,O
preterm,6115,O
labor,6115,O
in,6115,O
the,6115,O
sheep,6115,O
.,6115,O
OBJECTIVES,6116,O
:,6116,O
The,6116,O
purpose,6116,O
of,6116,O
this,6116,O
study,6116,O
was,6116,O
to,6116,O
determine,6116,O
whether,6116,O
continuous,6116,O
infusion,6116,O
of,6116,O
ritodrine,6116,B-CHEMICAL
could,6116,O
prevent,6116,O
preterm,6116,O
delivery,6116,O
in,6116,O
sheep,6116,O
.,6116,O
STUDY,6117,O
DESIGN,6117,O
:,6117,O
Sheep,6117,O
in,6117,O
preterm,6117,O
labor,6117,O
induced,6117,O
by,6117,O
RU,6117,B-CHEMICAL
486,6117,I-CHEMICAL
(,6117,O
mifepristone,6117,B-CHEMICAL
),6117,O
received,6117,O
infusions,6117,O
of,6117,O
either,6117,O
ritodrine,6117,B-CHEMICAL
(,6117,O
n,6117,O
=,6117,O
5,6117,O
),6117,O
or,6117,O
saline,6117,O
solution,6117,O
(,6117,O
n,6117,O
=,6117,O
5,6117,O
),6117,O
",",6117,O
and,6117,O
the,6117,O
progress,6117,O
of,6117,O
labor,6117,O
was,6117,O
monitored,6117,O
.,6117,O
beta,6118,B-GENE-Y
2-Adrenergic,6118,I-GENE-Y
receptor,6118,I-GENE-Y
density,6118,O
and,6118,O
function,6118,O
(,6118,O
agonist-induced,6118,O
cyclic,6118,B-CHEMICAL
adenosine,6118,I-CHEMICAL
monophosphate,6118,I-CHEMICAL
production,6118,O
),6118,O
was,6118,O
measured,6118,O
in,6118,O
myometrial,6118,O
samples,6118,O
from,6118,O
both,6118,O
groups,6118,O
.,6118,O
RESULTS,6119,O
:,6119,O
Ritodrine,6119,B-CHEMICAL
initially,6119,O
inhibited,6119,O
labor,6119,O
contractions,6119,O
.,6119,O
This,6120,O
inhibition,6120,O
was,6120,O
only,6120,O
maintained,6120,O
for,6120,O
16,6120,O
hours,6120,O
",",6120,O
after,6120,O
which,6120,O
both,6120,O
the,6120,O
amplitude,6120,O
and,6120,O
frequency,6120,O
of,6120,O
electromyographic,6120,O
bursts,6120,O
and,6120,O
contractions,6120,O
returned,6120,O
.,6120,O
The,6121,O
failure,6121,O
of,6121,O
the,6121,O
myometrium,6121,O
to,6121,O
respond,6121,O
to,6121,O
ritodrine,6121,B-CHEMICAL
(,6121,O
desensitization,6121,O
),6121,O
was,6121,O
associated,6121,O
with,6121,O
significant,6121,O
reductions,6121,O
in,6121,O
agonist-induced,6121,O
cyclic,6121,B-CHEMICAL
adenosine,6121,I-CHEMICAL
monophosphate,6121,I-CHEMICAL
production,6121,O
and,6121,O
beta,6121,B-GENE-Y
2-adrenergic,6121,I-GENE-Y
receptor,6121,I-GENE-Y
concentration,6121,O
in,6121,O
myometrial,6121,O
tissue,6121,O
collected,6121,O
from,6121,O
these,6121,O
animals,6121,O
compared,6121,O
with,6121,O
the,6121,O
saline,6121,O
solution-treated,6121,O
controls,6121,O
.,6121,O
CONCLUSIONS,6122,O
:,6122,O
Continuous,6122,O
infusion,6122,O
of,6122,O
ritodrine,6122,B-CHEMICAL
to,6122,O
sheep,6122,O
in,6122,O
preterm,6122,O
labor,6122,O
produces,6122,O
only,6122,O
a,6122,O
transient,6122,O
inhibition,6122,O
of,6122,O
contractions,6122,O
.,6122,O
This,6123,O
desensitization,6123,O
is,6123,O
caused,6123,O
by,6123,O
a,6123,O
down-regulation,6123,O
of,6123,O
myometrial,6123,O
beta,6123,B-GENE-Y
2-adrenergic,6123,I-GENE-Y
receptors,6123,I-GENE-Y
.,6123,O
Smoothened,6124,B-GENE-Y
is,6124,O
a,6124,O
fully,6124,O
competent,6124,O
activator,6124,O
of,6124,O
the,6124,O
heterotrimeric,6124,O
G,6124,B-GENE-N
protein,6124,I-GENE-N
G,6124,B-GENE-N
(,6124,I-GENE-N
i,6124,I-GENE-N
),6124,I-GENE-N
.,6124,O
Smoothened,6125,B-GENE-Y
(,6125,O
Smo,6125,B-GENE-Y
),6125,O
is,6125,O
a,6125,O
7-transmembrane,6125,O
protein,6125,O
essential,6125,O
to,6125,O
the,6125,O
activation,6125,O
of,6125,O
Gli,6125,B-GENE-Y
transcription,6125,O
factors,6125,O
(,6125,O
Gli,6125,B-GENE-Y
),6125,O
by,6125,O
hedgehog,6125,O
morphogens,6125,O
.,6125,O
The,6126,O
structure,6126,O
of,6126,O
Smo,6126,B-GENE-Y
implies,6126,O
interactions,6126,O
with,6126,O
heterotrimeric,6126,O
G,6126,B-GENE-N
proteins,6126,I-GENE-N
",",6126,O
but,6126,O
the,6126,O
degree,6126,O
to,6126,O
which,6126,O
G,6126,B-GENE-N
proteins,6126,I-GENE-N
participate,6126,O
in,6126,O
the,6126,O
actions,6126,O
of,6126,O
hedgehogs,6126,O
remains,6126,O
controversial,6126,O
.,6126,O
We,6127,O
posit,6127,O
that,6127,O
the,6127,O
G,6127,B-GENE-N
(,6127,I-GENE-N
i,6127,I-GENE-N
),6127,I-GENE-N
family,6127,O
of,6127,O
G,6127,B-GENE-N
proteins,6127,I-GENE-N
provides,6127,O
to,6127,O
hedgehogs,6127,O
the,6127,O
ability,6127,O
to,6127,O
expand,6127,O
well,6127,O
beyond,6127,O
the,6127,O
bounds,6127,O
of,6127,O
Gli,6127,B-GENE-Y
.,6127,O
In,6128,O
this,6128,O
regard,6128,O
",",6128,O
we,6128,O
evaluate,6128,O
here,6128,O
the,6128,O
efficacy,6128,O
of,6128,O
Smo,6128,B-GENE-Y
as,6128,O
it,6128,O
relates,6128,O
to,6128,O
the,6128,O
activation,6128,O
of,6128,O
G,6128,B-GENE-N
(,6128,I-GENE-N
i,6128,I-GENE-N
),6128,I-GENE-N
",",6128,O
by,6128,O
comparing,6128,O
Smo,6128,B-GENE-Y
with,6128,O
the,6128,O
5-hydroxytryptamine,6128,B-GENE-Y
(,6128,I-GENE-Y
1A,6128,I-GENE-Y
),6128,I-GENE-Y
(,6128,O
5-HT,6128,B-GENE-Y
(,6128,I-GENE-Y
1A,6128,I-GENE-Y
),6128,I-GENE-Y
),6128,O
receptor,6128,O
",",6128,O
a,6128,O
quintessential,6128,O
G,6128,B-GENE-N
(,6128,I-GENE-N
i,6128,I-GENE-N
),6128,I-GENE-N
-coupled,6128,I-GENE-N
receptor,6128,I-GENE-N
.,6128,O
We,6129,O
find,6129,O
that,6129,O
with,6129,O
use,6129,O
of,6129,O
[,6129,B-CHEMICAL
(,6129,I-CHEMICAL
35,6129,I-CHEMICAL
),6129,I-CHEMICAL
S,6129,I-CHEMICAL
],6129,I-CHEMICAL
guanosine,6129,I-CHEMICAL
5'-,6129,I-CHEMICAL
(,6129,I-CHEMICAL
3-O-thio,6129,I-CHEMICAL
),6129,I-CHEMICAL
triphosphate,6129,I-CHEMICAL
",",6129,O
first,6129,O
",",6129,O
with,6129,O
forms,6129,O
of,6129,O
G,6129,B-GENE-N
(,6129,I-GENE-N
i,6129,I-GENE-N
),6129,I-GENE-N
endogenous,6129,O
to,6129,O
human,6129,O
embryonic,6129,O
kidney,6129,O
(,6129,O
HEK,6129,O
),6129,O
-293,6129,O
cells,6129,O
made,6129,O
to,6129,O
express,6129,O
epitope-tagged,6129,O
receptors,6129,O
and,6129,O
",",6129,O
second,6129,O
",",6129,O
with,6129,O
individual,6129,O
forms,6129,O
of,6129,O
Gα,6129,B-GENE-N
(,6129,I-GENE-N
i,6129,I-GENE-N
),6129,I-GENE-N
fused,6129,O
to,6129,O
the,6129,O
C,6129,O
terminus,6129,O
of,6129,O
each,6129,O
receptor,6129,O
",",6129,O
Smo,6129,B-GENE-Y
is,6129,O
equivalent,6129,O
to,6129,O
the,6129,O
5-HT,6129,B-GENE-Y
(,6129,I-GENE-Y
1A,6129,I-GENE-Y
),6129,I-GENE-Y
receptor,6129,O
in,6129,O
the,6129,O
assay,6129,O
as,6129,O
it,6129,O
relates,6129,O
to,6129,O
capacity,6129,O
to,6129,O
activate,6129,O
G,6129,B-GENE-N
(,6129,I-GENE-N
i,6129,I-GENE-N
),6129,I-GENE-N
.,6129,O
This,6130,O
finding,6130,O
is,6130,O
true,6130,O
regardless,6130,O
of,6130,O
subtype,6130,O
of,6130,O
G,6130,B-GENE-N
(,6130,I-GENE-N
i,6130,I-GENE-N
),6130,I-GENE-N
(,6130,O
e.g.,6130,O
",",6130,O
G,6130,B-GENE-Y
(,6130,I-GENE-Y
i2,6130,I-GENE-Y
),6130,I-GENE-Y
",",6130,O
G,6130,B-GENE-Y
(,6130,I-GENE-Y
o,6130,I-GENE-Y
),6130,I-GENE-Y
",",6130,O
and,6130,O
G,6130,B-GENE-Y
(,6130,I-GENE-Y
z,6130,I-GENE-Y
),6130,I-GENE-Y
),6130,O
tested,6130,O
.,6130,O
We,6131,O
also,6131,O
find,6131,O
that,6131,O
Smo,6131,B-GENE-Y
endogenous,6131,O
to,6131,O
HEK-293,6131,O
cells,6131,O
",",6131,O
ostensibly,6131,O
through,6131,O
inhibition,6131,O
of,6131,O
adenylyl,6131,B-GENE-N
cyclase,6131,I-GENE-N
",",6131,O
decreases,6131,O
intracellular,6131,O
levels,6131,O
of,6131,O
cAMP,6131,B-CHEMICAL
.,6131,O
The,6132,O
results,6132,O
indicate,6132,O
that,6132,O
Smo,6132,B-GENE-Y
is,6132,O
a,6132,O
receptor,6132,O
that,6132,O
can,6132,O
engage,6132,O
not,6132,O
only,6132,O
Gli,6132,B-GENE-Y
but,6132,O
also,6132,O
other,6132,O
more,6132,O
immediate,6132,O
effectors,6132,O
.,6132,O
Antiarrhythmic,6133,O
effects,6133,O
of,6133,O
(,6133,B-CHEMICAL
-,6133,I-CHEMICAL
),6133,I-CHEMICAL
-epicatechin-3-gallate,6133,I-CHEMICAL
",",6133,O
a,6133,O
novel,6133,O
sodium,6133,B-GENE-N
channel,6133,I-GENE-N
agonist,6133,O
in,6133,O
cultured,6133,O
neonatal,6133,O
rat,6133,O
ventricular,6133,O
myocytes,6133,O
.,6133,O
(,6134,B-CHEMICAL
-,6134,I-CHEMICAL
),6134,I-CHEMICAL
-Epicatechin-3-gallate,6134,I-CHEMICAL
(,6134,O
ECG,6134,B-CHEMICAL
),6134,O
",",6134,O
a,6134,O
polyphenol,6134,B-CHEMICAL
extracted,6134,O
from,6134,O
green,6134,O
tea,6134,O
",",6134,O
has,6134,O
been,6134,O
proposed,6134,O
as,6134,O
an,6134,O
effective,6134,O
compound,6134,O
for,6134,O
improving,6134,O
cardiac,6134,O
contractility,6134,O
.,6134,O
However,6135,O
",",6135,O
the,6135,O
therapeutic,6135,O
potential,6135,O
of,6135,O
ECG,6135,B-CHEMICAL
on,6135,O
the,6135,O
treatment,6135,O
of,6135,O
arrhythmia,6135,O
remains,6135,O
unknown,6135,O
.,6135,O
We,6136,O
investigated,6136,O
the,6136,O
direct,6136,O
actions,6136,O
of,6136,O
ECG,6136,B-CHEMICAL
on,6136,O
the,6136,O
modulation,6136,O
of,6136,O
ion,6136,O
currents,6136,O
and,6136,O
cardiac,6136,O
cell,6136,O
excitability,6136,O
in,6136,O
the,6136,O
primary,6136,O
culture,6136,O
of,6136,O
neonatal,6136,O
rat,6136,O
ventricular,6136,O
myocyte,6136,O
(,6136,O
NRVM,6136,O
),6136,O
",",6136,O
which,6136,O
is,6136,O
considered,6136,O
a,6136,O
hypertrophic,6136,O
model,6136,O
for,6136,O
analysis,6136,O
of,6136,O
myocardial,6136,O
arrhythmias,6136,O
.,6136,O
By,6137,O
using,6137,O
the,6137,O
whole-cell,6137,O
patch-clamp,6137,O
configurations,6137,O
",",6137,O
we,6137,O
found,6137,O
ECG,6137,B-CHEMICAL
enhanced,6137,O
the,6137,O
slowly,6137,O
inactivating,6137,O
component,6137,O
of,6137,O
voltage-gated,6137,O
Na,6137,B-CHEMICAL
(,6137,I-CHEMICAL
+,6137,I-CHEMICAL
),6137,I-CHEMICAL
currents,6137,O
(,6137,O
I,6137,O
(,6137,O
Na,6137,B-CHEMICAL
),6137,O
),6137,O
in,6137,O
a,6137,O
concentration-dependent,6137,O
manner,6137,O
(,6137,O
0.1-100,6137,O
μM,6137,O
),6137,O
with,6137,O
an,6137,O
EC,6137,O
(,6137,O
50,6137,O
),6137,O
value,6137,O
of,6137,O
3.8,6137,O
μM,6137,O
.,6137,O
ECG,6138,B-CHEMICAL
not,6138,O
only,6138,O
shifted,6138,O
the,6138,O
current-voltage,6138,O
relationship,6138,O
of,6138,O
peak,6138,O
I,6138,O
(,6138,O
Na,6138,B-CHEMICAL
),6138,O
to,6138,O
the,6138,O
hyperpolarizing,6138,O
direction,6138,O
but,6138,O
also,6138,O
accelerated,6138,O
I,6138,O
(,6138,O
Na,6138,B-CHEMICAL
),6138,O
recovery,6138,O
kinetics,6138,O
.,6138,O
Working,6139,O
at,6139,O
a,6139,O
concentration,6139,O
level,6139,O
of,6139,O
I,6139,O
(,6139,O
Na,6139,B-CHEMICAL
),6139,O
enhancement,6139,O
",",6139,O
ECG,6139,B-CHEMICAL
has,6139,O
no,6139,O
notable,6139,O
effect,6139,O
on,6139,O
voltage-gated,6139,O
K,6139,B-CHEMICAL
(,6139,I-CHEMICAL
+,6139,I-CHEMICAL
),6139,I-CHEMICAL
currents,6139,O
and,6139,O
L-type,6139,O
Ca,6139,B-CHEMICAL
(,6139,I-CHEMICAL
2+,6139,I-CHEMICAL
),6139,I-CHEMICAL
currents,6139,O
.,6139,O
With,6140,O
culture,6140,O
time,6140,O
increment,6140,O
",",6140,O
the,6140,O
firing,6140,O
rate,6140,O
of,6140,O
spontaneous,6140,O
action,6140,O
potential,6140,O
(,6140,O
sAP,6140,O
),6140,O
in,6140,O
NRVMs,6140,O
was,6140,O
gradually,6140,O
decreased,6140,O
until,6140,O
spontaneous,6140,O
early,6140,O
after-depolarization,6140,O
(,6140,O
EAD,6140,O
),6140,O
was,6140,O
observed,6140,O
after,6140,O
about,6140,O
one,6140,O
week,6140,O
culture,6140,O
.,6140,O
ECG,6141,B-CHEMICAL
increased,6141,O
the,6141,O
firing,6141,O
rate,6141,O
of,6141,O
normal,6141,O
sAP,6141,O
about,6141,O
two-fold,6141,O
without,6141,O
waveform,6141,O
alteration,6141,O
.,6141,O
Interestingly,6142,O
",",6142,O
the,6142,O
bradycardia-dependent,6142,O
EAD,6142,O
could,6142,O
be,6142,O
significantly,6142,O
restored,6142,O
by,6142,O
ECG,6142,B-CHEMICAL
in,6142,O
fast,6142,O
firing,6142,O
rate,6142,O
to,6142,O
normal,6142,O
sAP,6142,O
waveform,6142,O
.,6142,O
The,6143,O
expression,6143,O
of,6143,O
dominant,6143,O
cardiac,6143,O
sodium,6143,B-GENE-N
channel,6143,I-GENE-N
subunit,6143,O
",",6143,O
Nav1.5,6143,B-GENE-Y
",",6143,O
was,6143,O
consistently,6143,O
detected,6143,O
throughout,6143,O
the,6143,O
culture,6143,O
periods,6143,O
.,6143,O
Our,6144,O
results,6144,O
reveal,6144,O
how,6144,O
ECG,6144,B-CHEMICAL
",",6144,O
the,6144,O
novel,6144,O
I,6144,O
(,6144,O
Na,6144,B-CHEMICAL
),6144,O
agonist,6144,O
",",6144,O
may,6144,O
act,6144,O
as,6144,O
a,6144,O
promising,6144,O
candidate,6144,O
in,6144,O
clinical,6144,O
applications,6144,O
on,6144,O
cardiac,6144,O
arrhythmias,6144,O
.,6144,O
Liver,6145,O
choline,6145,B-GENE-Y
dehydrogenase,6145,I-GENE-Y
and,6145,O
kidney,6145,O
betaine-homocysteine,6145,B-GENE-N
methyltransferase,6145,I-GENE-N
expression,6145,O
are,6145,O
not,6145,O
affected,6145,O
by,6145,O
methionine,6145,B-CHEMICAL
or,6145,O
choline,6145,B-CHEMICAL
intake,6145,O
in,6145,O
growing,6145,O
rats,6145,O
.,6145,O
Choline,6146,B-GENE-Y
dehydrogenase,6146,I-GENE-Y
(,6146,O
CHDH,6146,B-GENE-Y
),6146,O
and,6146,O
betaine-homocysteine,6146,B-GENE-N
methyltransferase,6146,I-GENE-N
(,6146,O
BHMT,6146,B-GENE-N
),6146,O
are,6146,O
2,6146,O
enzymes,6146,O
involved,6146,O
in,6146,O
choline,6146,B-CHEMICAL
oxidation,6146,O
.,6146,O
BHMT,6147,B-GENE-N
is,6147,O
expressed,6147,O
at,6147,O
high,6147,O
levels,6147,O
in,6147,O
rat,6147,O
liver,6147,O
and,6147,O
its,6147,O
expression,6147,O
is,6147,O
regulated,6147,O
by,6147,O
dietary,6147,O
Met,6147,B-CHEMICAL
and,6147,O
choline,6147,B-CHEMICAL
.,6147,O
BHMT,6148,B-GENE-N
is,6148,O
also,6148,O
found,6148,O
in,6148,O
rat,6148,O
kidney,6148,O
",",6148,O
albeit,6148,O
in,6148,O
substantially,6148,O
lower,6148,O
amounts,6148,O
",",6148,O
but,6148,O
it,6148,O
is,6148,O
not,6148,O
known,6148,O
whether,6148,O
kidney,6148,O
BHMT,6148,B-GENE-N
expression,6148,O
is,6148,O
regulated,6148,O
by,6148,O
dietary,6148,O
Met,6148,B-CHEMICAL
or,6148,O
choline,6148,B-CHEMICAL
.,6148,O
Similarly,6149,O
",",6149,O
CHDH,6149,B-GENE-Y
activity,6149,O
is,6149,O
highest,6149,O
in,6149,O
the,6149,O
liver,6149,O
and,6149,O
kidney,6149,O
",",6149,O
but,6149,O
the,6149,O
regulation,6149,O
of,6149,O
its,6149,O
expression,6149,O
by,6149,O
diet,6149,O
has,6149,O
not,6149,O
been,6149,O
thoroughly,6149,O
investigated,6149,O
.,6149,O
Sprague,6150,O
Dawley,6150,O
rats,6150,O
(,6150,O
approximately,6150,O
50,6150,O
g,6150,O
),6150,O
were,6150,O
fed,6150,O
",",6150,O
for,6150,O
9,6150,O
d,6150,O
in,6150,O
2,6150,O
x,6150,O
3,6150,O
factorial,6150,O
design,6150,O
(,6150,O
n,6150,O
=,6150,O
8,6150,O
),6150,O
",",6150,O
an,6150,O
l-amino,6150,B-CHEMICAL
acid-defined,6150,O
diet,6150,O
varying,6150,O
in,6150,O
l-Met,6150,B-CHEMICAL
(,6150,O
0.125,6150,O
",",6150,O
0.3,6150,O
",",6150,O
or,6150,O
0.8,6150,O
%,6150,O
),6150,O
and,6150,O
choline,6150,B-CHEMICAL
(,6150,O
0,6150,O
or,6150,O
25,6150,O
mmol/kg,6150,O
diet,6150,O
),6150,O
.,6150,O
Liver,6151,O
and,6151,O
kidney,6151,O
BHMT,6151,B-GENE-N
and,6151,O
CHDH,6151,B-GENE-Y
were,6151,O
assessed,6151,O
using,6151,O
enzymatic,6151,O
",",6151,O
Western,6151,O
blot,6151,O
",",6151,O
and,6151,O
real-time,6151,O
PCR,6151,O
analyses,6151,O
.,6151,O
Liver,6152,O
samples,6152,O
were,6152,O
also,6152,O
fixed,6152,O
for,6152,O
histological,6152,O
analysis,6152,O
.,6152,O
Liver,6153,O
BHMT,6153,B-GENE-N
activity,6153,O
was,6153,O
1.3-fold,6153,O
higher,6153,O
in,6153,O
rats,6153,O
fed,6153,O
the,6153,O
Met,6153,B-CHEMICAL
deficient,6153,O
diet,6153,O
containing,6153,O
choline,6153,B-CHEMICAL
",",6153,O
which,6153,O
was,6153,O
reflected,6153,O
in,6153,O
corresponding,6153,O
increases,6153,O
in,6153,O
mRNA,6153,O
content,6153,O
and,6153,O
immunodetectable,6153,O
protein,6153,O
.,6153,O
Independent,6154,O
of,6154,O
dietary,6154,O
choline,6154,B-CHEMICAL
",",6154,O
supplemental,6154,O
Met,6154,B-CHEMICAL
increased,6154,O
hepatic,6154,O
BHMT,6154,B-GENE-N
activity,6154,O
approximately,6154,O
30,6154,O
%,6154,O
.,6154,O
Kidney,6155,O
BHMT,6155,B-GENE-N
and,6155,O
liver,6155,O
CHDH,6155,B-GENE-Y
expression,6155,O
were,6155,O
refractory,6155,O
to,6155,O
these,6155,O
diets,6155,O
.,6155,O
Some,6156,O
degree,6156,O
of,6156,O
fatty,6156,O
liver,6156,O
developed,6156,O
in,6156,O
all,6156,O
rats,6156,O
fed,6156,O
a,6156,O
choline-devoid,6156,B-CHEMICAL
diet,6156,O
",",6156,O
indicating,6156,O
that,6156,O
supplemental,6156,O
Met,6156,B-CHEMICAL
can,6156,O
not,6156,O
completely,6156,O
compensate,6156,O
for,6156,O
the,6156,O
lack,6156,O
of,6156,O
dietary,6156,O
choline,6156,B-CHEMICAL
in,6156,O
growing,6156,O
rats,6156,O
.,6156,O
Identification,6157,O
of,6157,O
a,6157,O
new,6157,O
interaction,6157,O
mode,6157,O
between,6157,O
the,6157,O
Src,6157,B-GENE-N
homology,6157,I-GENE-N
2,6157,I-GENE-N
(,6157,I-GENE-N
SH2,6157,I-GENE-N
),6157,I-GENE-N
domain,6157,I-GENE-N
of,6157,O
C-terminal,6157,B-GENE-Y
Src,6157,I-GENE-Y
kinase,6157,I-GENE-Y
(,6157,O
Csk,6157,B-GENE-Y
),6157,O
and,6157,O
Csk-binding,6157,B-GENE-Y
protein,6157,I-GENE-Y
(,6157,O
Cbp,6157,B-GENE-Y
),6157,O
/phosphoprotein,6157,O
associated,6157,I-GENE-Y
with,6157,I-GENE-Y
glycosphingolipid,6157,I-GENE-Y
microdomains,6157,I-GENE-Y
(,6157,O
PAG,6157,B-GENE-Y
),6157,O
.,6157,O
Proteins,6158,O
with,6158,O
Src,6158,B-GENE-N
homology,6158,I-GENE-N
2,6158,I-GENE-N
(,6158,I-GENE-N
SH2,6158,I-GENE-N
),6158,I-GENE-N
domains,6158,I-GENE-N
play,6158,O
major,6158,O
roles,6158,O
in,6158,O
tyrosine,6158,B-GENE-N
kinase,6158,I-GENE-N
signaling,6158,O
.,6158,O
Structures,6159,O
of,6159,O
many,6159,O
SH2,6159,B-GENE-N
domains,6159,I-GENE-N
have,6159,O
been,6159,O
studied,6159,O
",",6159,O
and,6159,O
the,6159,O
regions,6159,O
involved,6159,O
in,6159,O
their,6159,O
interactions,6159,O
with,6159,O
ligands,6159,O
have,6159,O
been,6159,O
elucidated,6159,O
.,6159,O
However,6160,O
",",6160,O
these,6160,O
analyses,6160,O
have,6160,O
been,6160,O
performed,6160,O
using,6160,O
short,6160,O
peptides,6160,O
comprising,6160,O
phosphotyrosine,6160,B-CHEMICAL
followed,6160,O
by,6160,O
a,6160,O
few,6160,O
amino,6160,B-CHEMICAL
acids,6160,I-CHEMICAL
",",6160,O
which,6160,O
are,6160,O
described,6160,O
as,6160,O
the,6160,O
canonical,6160,O
recognition,6160,O
sites,6160,O
.,6160,O
Here,6161,O
we,6161,O
report,6161,O
the,6161,O
solution,6161,O
structure,6161,O
of,6161,O
the,6161,O
SH2,6161,B-GENE-N
domain,6161,I-GENE-N
of,6161,O
C-terminal,6161,B-GENE-Y
Src,6161,I-GENE-Y
kinase,6161,I-GENE-Y
(,6161,O
Csk,6161,B-GENE-Y
),6161,O
in,6161,O
complex,6161,O
with,6161,O
a,6161,O
longer,6161,O
phosphopeptide,6161,O
from,6161,O
Csk-binding,6161,B-GENE-Y
protein,6161,I-GENE-Y
(,6161,O
Cbp,6161,B-GENE-Y
),6161,O
.,6161,O
This,6162,O
structure,6162,O
",",6162,O
together,6162,O
with,6162,O
biochemical,6162,O
experiments,6162,O
",",6162,O
revealed,6162,O
the,6162,O
existence,6162,O
of,6162,O
a,6162,O
novel,6162,O
binding,6162,O
region,6162,O
in,6162,O
addition,6162,O
to,6162,O
the,6162,O
canonical,6162,O
phosphotyrosine-314,6162,B-CHEMICAL
binding,6162,O
site,6162,O
of,6162,O
Cbp,6162,B-GENE-Y
.,6162,O
Mutational,6163,O
analysis,6163,O
of,6163,O
this,6163,O
second,6163,O
region,6163,O
in,6163,O
cells,6163,O
showed,6163,O
that,6163,O
both,6163,O
canonical,6163,O
and,6163,O
novel,6163,O
binding,6163,O
sites,6163,O
are,6163,O
required,6163,O
for,6163,O
tumor,6163,O
suppression,6163,O
through,6163,O
the,6163,O
Cbp-Csk,6163,B-GENE-Y
interaction,6163,O
.,6163,O
Furthermore,6164,O
",",6164,O
the,6164,O
data,6164,O
indicate,6164,O
an,6164,O
allosteric,6164,O
connection,6164,O
between,6164,O
Cbp,6164,B-GENE-Y
binding,6164,O
and,6164,O
Csk,6164,B-GENE-Y
activation,6164,O
that,6164,O
arises,6164,O
from,6164,O
residues,6164,O
in,6164,O
the,6164,O
βB/βC,6164,O
loop,6164,O
of,6164,O
the,6164,O
SH2,6164,B-GENE-N
domain,6164,I-GENE-N
.,6164,O
Protective,6165,O
effects,6165,O
of,6165,O
protein,6165,O
transduction,6165,O
domain-metallothionein,6165,O
fusion,6165,O
proteins,6165,O
against,6165,O
hypoxia-,6165,O
and,6165,O
oxidative,6165,O
stress-induced,6165,O
apoptosis,6165,O
in,6165,O
an,6165,O
ischemia/reperfusion,6165,O
rat,6165,O
model,6165,O
.,6165,O
Ischemic,6166,O
heart,6166,O
diseases,6166,O
caused,6166,O
by,6166,O
insufficient,6166,O
oxygen,6166,B-CHEMICAL
supply,6166,O
to,6166,O
the,6166,O
cardiac,6166,O
muscle,6166,O
require,6166,O
pharmaceutical,6166,O
agents,6166,O
for,6166,O
the,6166,O
prevention,6166,O
of,6166,O
the,6166,O
progress,6166,O
and,6166,O
recurrence,6166,O
.,6166,O
Metallothionein,6167,B-GENE-N
(,6167,O
MT,6167,B-GENE-N
),6167,O
has,6167,O
a,6167,O
potential,6167,O
as,6167,O
a,6167,O
protein,6167,O
therapeutic,6167,O
for,6167,O
the,6167,O
treatment,6167,O
of,6167,O
this,6167,O
disease,6167,O
due,6167,O
to,6167,O
its,6167,O
anti-oxidative,6167,O
effects,6167,O
under,6167,O
stressful,6167,O
conditions,6167,O
.,6167,O
In,6168,O
spite,6168,O
of,6168,O
its,6168,O
therapeutic,6168,O
potential,6168,O
",",6168,O
efficient,6168,O
delivery,6168,O
systems,6168,O
need,6168,O
to,6168,O
be,6168,O
developed,6168,O
to,6168,O
overcome,6168,O
limitations,6168,O
such,6168,O
as,6168,O
low,6168,O
transduction,6168,O
efficiency,6168,O
",",6168,O
instability,6168,O
and,6168,O
short,6168,O
half-life,6168,O
in,6168,O
the,6168,O
body,6168,O
.,6168,O
To,6169,O
enhance,6169,O
intra-cellular,6169,O
transduction,6169,O
efficiency,6169,O
",",6169,O
Tat,6169,O
sequence,6169,O
as,6169,O
a,6169,O
protein,6169,O
transduction,6169,O
domain,6169,O
(,6169,O
PTD,6169,O
),6169,O
was,6169,O
fused,6169,O
with,6169,O
MT,6169,B-GENE-N
in,6169,O
a,6169,O
recombinant,6169,O
method,6169,O
.,6169,O
Anti-apoptotic,6170,O
and,6170,O
anti-oxidative,6170,O
effects,6170,O
of,6170,O
Tat-MT,6170,O
fusion,6170,O
protein,6170,O
were,6170,O
evaluated,6170,O
under,6170,O
hyperglycemia,6170,O
and,6170,O
hypoxia,6170,O
stress,6170,O
conditions,6170,O
in,6170,O
cultured,6170,O
H9c2,6170,O
cells,6170,O
.,6170,O
Recovery,6171,O
of,6171,O
cardiac,6171,O
functions,6171,O
by,6171,O
anti-apoptotic,6171,O
and,6171,O
anti-fibrotic,6171,O
effects,6171,O
of,6171,O
Tat-MT,6171,O
was,6171,O
confirmed,6171,O
in,6171,O
an,6171,O
ischemia/reperfusion,6171,O
(,6171,O
I/R,6171,O
),6171,O
rat,6171,O
myocardial,6171,O
infarction,6171,O
model,6171,O
.,6171,O
Tat-MT,6172,O
fusion,6172,O
protein,6172,O
effectively,6172,O
protected,6172,O
H9c2,6172,O
cells,6172,O
under,6172,O
stressful,6172,O
conditions,6172,O
by,6172,O
reducing,6172,O
intracellular,6172,O
ROS,6172,O
production,6172,O
and,6172,O
inhibiting,6172,O
caspase-3,6172,O
activation,6172,O
.,6172,O
Tat-MT,6173,O
fusion,6173,O
protein,6173,O
inhibited,6173,O
apoptosis,6173,O
",",6173,O
reduced,6173,O
fibrosis,6173,O
area,6173,O
and,6173,O
enhanced,6173,O
cardiac,6173,O
functions,6173,O
in,6173,O
I/R,6173,O
.,6173,O
Tat-MT,6174,O
fusion,6174,O
protein,6174,O
could,6174,O
be,6174,O
a,6174,O
promising,6174,O
therapeutic,6174,O
for,6174,O
the,6174,O
treatment,6174,O
of,6174,O
ischemic,6174,O
heart,6174,O
diseases,6174,O
.,6174,O
Lifelong,6175,O
exposure,6175,O
to,6175,O
bisphenol,6175,B-CHEMICAL
a,6175,I-CHEMICAL
alters,6175,O
cardiac,6175,O
structure/function,6175,O
",",6175,O
protein,6175,O
expression,6175,O
",",6175,O
and,6175,O
DNA,6175,O
methylation,6175,O
in,6175,O
adult,6175,O
mice,6175,O
.,6175,O
Bisphenol,6176,B-CHEMICAL
A,6176,I-CHEMICAL
(,6176,O
BPA,6176,B-CHEMICAL
),6176,O
is,6176,O
an,6176,O
estrogenizing,6176,O
endocrine,6176,O
disruptor,6176,O
compound,6176,O
of,6176,O
concern,6176,O
.,6176,O
Our,6177,O
objective,6177,O
was,6177,O
to,6177,O
test,6177,O
whether,6177,O
lifelong,6177,O
BPA,6177,B-CHEMICAL
would,6177,O
impact,6177,O
cardiac,6177,O
structure/function,6177,O
",",6177,O
calcium,6177,B-CHEMICAL
homeostasis,6177,O
protein,6177,O
expression,6177,O
",",6177,O
and,6177,O
the,6177,O
DNA,6177,O
methylation,6177,O
of,6177,O
cardiac,6177,O
genes,6177,O
.,6177,O
We,6178,O
delivered,6178,O
0.5,6178,O
and,6178,O
5.0,6178,O
µg/kg/day,6178,O
BPA,6178,B-CHEMICAL
lifelong,6178,O
from,6178,O
gestation,6178,O
day,6178,O
11,6178,O
or,6178,O
200,6178,O
µg/kg/day,6178,O
from,6178,O
gestation,6178,O
day,6178,O
11,6178,O
to,6178,O
postnatal,6178,O
day,6178,O
21,6178,O
via,6178,O
the,6178,O
drinking,6178,O
water,6178,O
to,6178,O
C57bl/6n,6178,O
mice,6178,O
.,6178,O
BPA,6179,B-CHEMICAL
5.0,6179,O
males,6179,O
and,6179,O
females,6179,O
had,6179,O
increased,6179,O
body,6179,O
weight,6179,O
",",6179,O
body,6179,O
mass,6179,O
index,6179,O
",",6179,O
body,6179,O
surface,6179,O
area,6179,O
",",6179,O
and,6179,O
adiposity,6179,O
.,6179,O
Echocardiography,6180,O
identified,6180,O
concentric,6180,O
remodeling,6180,O
in,6180,O
all,6180,O
BPA-treated,6180,B-CHEMICAL
males,6180,O
.,6180,O
Systolic,6181,O
and,6181,O
diastolic,6181,O
cardiac,6181,O
functions,6181,O
were,6181,O
essentially,6181,O
similar,6181,O
",",6181,O
but,6181,O
lifelong,6181,O
BPA,6181,B-CHEMICAL
enhanced,6181,O
male,6181,O
and,6181,O
reduced,6181,O
female,6181,O
sex-specific,6181,O
differences,6181,O
in,6181,O
velocity,6181,O
of,6181,O
circumferential,6181,O
shortening,6181,O
and,6181,O
ascending,6181,O
aorta,6181,O
velocity,6181,O
time,6181,O
integral,6181,O
.,6181,O
Diastolic,6182,O
blood,6182,O
pressure,6182,O
was,6182,O
increased,6182,O
in,6182,O
all,6182,O
BPA,6182,B-CHEMICAL
females,6182,O
.,6182,O
The,6183,O
calcium,6183,B-CHEMICAL
homeostasis,6183,O
proteins,6183,O
sarcoendoplasmic,6183,B-GENE-Y
reticulum,6183,I-GENE-Y
ATPase,6183,I-GENE-Y
2a,6183,I-GENE-Y
(,6183,O
SERCA2a,6183,B-GENE-Y
),6183,O
",",6183,O
sodium,6183,B-GENE-Y
calcium,6183,I-GENE-Y
exchanger-1,6183,I-GENE-Y
",",6183,O
phospholamban,6183,B-GENE-Y
(,6183,O
PLB,6183,B-GENE-Y
),6183,O
",",6183,O
phospho-PLB,6183,B-GENE-Y
",",6183,O
and,6183,O
calsequestrin,6183,B-GENE-Y
2,6183,I-GENE-Y
are,6183,O
important,6183,O
for,6183,O
contraction,6183,O
and,6183,O
relaxation,6183,O
.,6183,O
Changes,6184,O
in,6184,O
their,6184,O
expression,6184,O
suggest,6184,O
increased,6184,O
calcium,6184,B-CHEMICAL
mobility,6184,O
in,6184,O
males,6184,O
and,6184,O
reduced,6184,O
calcium,6184,B-CHEMICAL
mobility,6184,O
in,6184,O
females,6184,O
supporting,6184,O
the,6184,O
cardiac,6184,O
function,6184,O
changes,6184,O
.,6184,O
DNA,6185,B-GENE-Y
methyltransferase,6185,I-GENE-Y
3a,6185,I-GENE-Y
expression,6185,O
was,6185,O
increased,6185,O
in,6185,O
all,6185,O
BPA,6185,B-CHEMICAL
males,6185,O
and,6185,O
BPA,6185,B-CHEMICAL
0.5,6185,O
females,6185,O
and,6185,O
reduced,6185,O
in,6185,O
BPA,6185,B-CHEMICAL
200,6185,O
females,6185,O
.,6185,O
Global,6186,O
DNA,6186,O
methylation,6186,O
was,6186,O
increased,6186,O
in,6186,O
BPA,6186,B-CHEMICAL
0.5,6186,O
males,6186,O
and,6186,O
reduced,6186,O
in,6186,O
BPA,6186,B-CHEMICAL
0.5,6186,O
females,6186,O
.,6186,O
BPA,6187,B-CHEMICAL
induced,6187,O
sex-specific,6187,O
altered,6187,O
DNA,6187,O
methylation,6187,O
in,6187,O
specific,6187,O
CpG,6187,B-CHEMICAL
pairs,6187,O
in,6187,O
the,6187,O
calsequestrin,6187,B-GENE-Y
2,6187,I-GENE-Y
CpG,6187,O
island,6187,O
.,6187,O
These,6188,O
results,6188,O
suggest,6188,O
that,6188,O
continual,6188,O
exposure,6188,O
to,6188,O
BPA,6188,B-CHEMICAL
impacts,6188,O
cardiac,6188,O
structure/function,6188,O
",",6188,O
protein,6188,O
expression,6188,O
",",6188,O
and,6188,O
epigenetic,6188,O
DNA,6188,O
methylation,6188,O
marks,6188,O
in,6188,O
males,6188,O
and,6188,O
females,6188,O
.,6188,O
Wogonoside,6189,B-CHEMICAL
induces,6189,O
autophagy,6189,O
in,6189,O
MDA-MB-231,6189,O
cells,6189,O
by,6189,O
regulating,6189,O
MAPK-mTOR,6189,B-GENE-N
pathway,6189,O
.,6189,O
Previous,6190,O
studies,6190,O
have,6190,O
demonstrated,6190,O
that,6190,O
wogonoside,6190,B-CHEMICAL
",",6190,O
a,6190,O
bioactive,6190,O
flavonoid,6190,B-CHEMICAL
extracted,6190,O
from,6190,O
the,6190,O
root,6190,O
of,6190,O
Scutellaria,6190,O
baicalensis,6190,O
Gerogi,6190,O
",",6190,O
has,6190,O
anti-inflammatory,6190,O
and,6190,O
anti-angiogenic,6190,O
activities,6190,O
.,6190,O
In,6191,O
this,6191,O
study,6191,O
",",6191,O
we,6191,O
evaluated,6191,O
wogonoside-induced,6191,B-CHEMICAL
autophagy,6191,O
on,6191,O
human,6191,O
breast,6191,O
MDA-MB-231,6191,O
cells,6191,O
.,6191,O
We,6192,O
report,6192,O
that,6192,O
wogonoside,6192,B-CHEMICAL
triggered,6192,O
the,6192,O
formation,6192,O
of,6192,O
microtubule-associated,6192,B-GENE-N
protein-light,6192,I-GENE-N
chain,6192,I-GENE-N
3,6192,I-GENE-N
(,6192,O
MAP-LC3,6192,B-GENE-N
),6192,O
positive,6192,O
autophagosomes,6192,O
and,6192,O
the,6192,O
accumulation,6192,O
of,6192,O
acidic,6192,O
vesicular,6192,O
and,6192,O
autolysosomes,6192,O
in,6192,O
MDA-MB-231,6192,O
cells,6192,O
.,6192,O
In,6193,O
addition,6193,O
",",6193,O
cells,6193,O
treated,6193,O
by,6193,O
wogonoside,6193,B-CHEMICAL
developed,6193,O
autophagosome-like,6193,O
characteristics,6193,O
",",6193,O
including,6193,O
single,6193,O
and,6193,O
double,6193,O
membrane,6193,O
vacuoles,6193,O
containing,6193,O
intact,6193,O
and,6193,O
degraded,6193,O
cellular,6193,O
debris,6193,O
.,6193,O
The,6194,O
results,6194,O
showed,6194,O
that,6194,O
wogonoside,6194,B-CHEMICAL
promotes,6194,O
the,6194,O
expression,6194,O
of,6194,O
LC3-II,6194,B-GENE-Y
and,6194,O
Beclin-1,6194,B-GENE-Y
.,6194,O
Furthermore,6195,O
",",6195,O
wogonoside,6195,B-CHEMICAL
inhibited,6195,O
cell,6195,O
growth,6195,O
of,6195,O
MDA-MB-231,6195,O
cells,6195,O
in,6195,O
a,6195,O
concentration-,6195,O
and,6195,O
time-dependent,6195,O
manner,6195,O
",",6195,O
which,6195,O
was,6195,O
associated,6195,O
with,6195,O
wogonoside-induced,6195,B-CHEMICAL
autophagy,6195,O
.,6195,O
Wogonoside,6196,B-CHEMICAL
also,6196,O
suppressed,6196,O
the,6196,O
activation,6196,O
of,6196,O
mammalian,6196,B-GENE-Y
target,6196,I-GENE-Y
of,6196,I-GENE-Y
rapamycin,6196,I-GENE-Y
(,6196,O
mTOR,6196,B-GENE-Y
),6196,O
and,6196,O
p70-S6,6196,B-GENE-N
kinase,6196,I-GENE-N
(,6196,O
p70S6K,6196,B-GENE-N
),6196,I-GENE-N
by,6196,O
regulating,6196,O
the,6196,O
expression,6196,O
of,6196,O
the,6196,O
extracellular,6196,B-GENE-N
signal-regulated,6196,I-GENE-N
kinase,6196,I-GENE-N
(,6196,O
ERK1/2,6196,B-GENE-N
),6196,O
and,6196,O
p38,6196,B-GENE-N
involved,6196,O
mitogen-activated,6196,B-GENE-N
protein,6196,I-GENE-N
kinase,6196,I-GENE-N
(,6196,O
MAPK,6196,B-GENE-N
),6196,O
signaling,6196,O
pathway,6196,O
.,6196,O
Taken,6197,O
together,6197,O
",",6197,O
these,6197,O
results,6197,O
suggest,6197,O
that,6197,O
wogonoside,6197,B-CHEMICAL
partially,6197,O
inhibits,6197,O
MDA-MB-231,6197,O
cell,6197,O
growth,6197,O
by,6197,O
inducing,6197,O
autophagy,6197,O
through,6197,O
the,6197,O
MAPK-mTOR,6197,B-GENE-N
pathway,6197,O
and,6197,O
may,6197,O
be,6197,O
a,6197,O
promising,6197,O
anti-tumor,6197,O
agent,6197,O
.,6197,O
A,6198,O
mutation,6198,O
in,6198,O
the,6198,O
FAM36A,6198,B-GENE-Y
gene,6198,O
",",6198,O
the,6198,O
human,6198,O
ortholog,6198,O
of,6198,O
COX20,6198,B-GENE-N
",",6198,O
impairs,6198,O
cytochrome,6198,B-GENE-N
c,6198,I-GENE-N
oxidase,6198,I-GENE-N
assembly,6198,O
and,6198,O
is,6198,O
associated,6198,O
with,6198,O
ataxia,6198,O
and,6198,O
muscle,6198,O
hypotonia,6198,O
.,6198,O
The,6199,O
mitochondrial,6199,B-GENE-N
respiratory,6199,I-GENE-N
chain,6199,I-GENE-N
complex,6199,I-GENE-N
IV,6199,I-GENE-N
(,6199,O
cytochrome,6199,B-GENE-N
c,6199,I-GENE-N
oxidase,6199,I-GENE-N
),6199,O
is,6199,O
a,6199,O
multi-subunit,6199,O
enzyme,6199,O
that,6199,O
transfers,6199,O
electrons,6199,O
from,6199,O
cytochrome,6199,B-GENE-Y
c,6199,I-GENE-Y
to,6199,O
molecular,6199,O
oxygen,6199,B-CHEMICAL
",",6199,O
yielding,6199,O
water,6199,O
.,6199,O
Its,6200,O
biogenesis,6200,O
requires,6200,O
concerted,6200,O
expression,6200,O
of,6200,O
mitochondria-,6200,O
and,6200,O
nuclear-encoded,6200,O
subunits,6200,O
and,6200,O
assembly,6200,O
factors,6200,O
.,6200,O
In,6201,O
this,6201,O
report,6201,O
",",6201,O
we,6201,O
describe,6201,O
a,6201,O
homozygous,6201,O
missense,6201,O
mutation,6201,O
in,6201,O
FAM36A,6201,B-GENE-Y
from,6201,O
a,6201,O
patient,6201,O
who,6201,O
displays,6201,O
ataxia,6201,O
and,6201,O
muscle,6201,O
hypotonia,6201,O
.,6201,O
The,6202,O
FAM36A,6202,B-GENE-Y
gene,6202,O
is,6202,O
a,6202,O
remote,6202,O
",",6202,O
putative,6202,O
ortholog,6202,O
of,6202,O
the,6202,O
fungal,6202,B-GENE-N
complex,6202,I-GENE-N
IV,6202,I-GENE-N
assembly,6202,I-GENE-N
factor,6202,I-GENE-N
COX20,6202,B-GENE-N
.,6202,O
Messenger,6203,O
RNA,6203,O
(,6203,O
mRNA,6203,O
),6203,O
and,6203,O
protein,6203,O
co-expression,6203,O
analyses,6203,O
support,6203,O
the,6203,O
involvement,6203,O
of,6203,O
FAM36A,6203,B-GENE-Y
in,6203,O
complex,6203,B-GENE-N
IV,6203,I-GENE-N
function,6203,O
in,6203,O
mammals,6203,O
.,6203,O
The,6204,O
c.154A,6204,B-GENE-N
>,6204,I-GENE-N
C,6204,I-GENE-N
mutation,6204,O
in,6204,O
the,6204,O
FAM36A,6204,B-GENE-Y
gene,6204,O
",",6204,O
a,6204,O
mutation,6204,O
that,6204,O
is,6204,O
absent,6204,O
in,6204,O
sequenced,6204,O
exomes,6204,O
",",6204,O
leads,6204,O
to,6204,O
a,6204,O
reduced,6204,O
activity,6204,O
and,6204,O
lower,6204,O
levels,6204,O
of,6204,O
complex,6204,B-GENE-N
IV,6204,I-GENE-N
and,6204,O
its,6204,O
protein,6204,O
subunits,6204,O
.,6204,O
The,6205,O
FAM36A,6205,B-GENE-Y
protein,6205,O
is,6205,O
nearly,6205,O
absent,6205,O
in,6205,O
patient,6205,O
's,6205,O
fibroblasts,6205,O
.,6205,O
Cells,6206,O
affected,6206,O
by,6206,O
the,6206,O
mutation,6206,O
accumulate,6206,O
subassemblies,6206,O
of,6206,O
complex,6206,B-GENE-N
IV,6206,I-GENE-N
that,6206,O
contain,6206,O
COX1,6206,B-GENE-Y
but,6206,O
are,6206,O
almost,6206,O
devoid,6206,O
of,6206,O
COX2,6206,B-GENE-Y
protein,6206,O
.,6206,O
We,6207,O
observe,6207,O
co-purification,6207,O
of,6207,O
FAM36A,6207,B-GENE-Y
and,6207,O
COX2,6207,B-GENE-Y
proteins,6207,O
",",6207,O
supporting,6207,O
that,6207,O
the,6207,O
FAM36A,6207,B-GENE-Y
defect,6207,O
hampers,6207,O
the,6207,O
early,6207,O
step,6207,O
of,6207,O
complex,6207,B-GENE-N
IV,6207,I-GENE-N
assembly,6207,O
at,6207,O
the,6207,O
incorporation,6207,O
of,6207,O
the,6207,O
COX2,6207,B-GENE-Y
subunit,6207,O
.,6207,O
Lentiviral,6208,O
complementation,6208,O
of,6208,O
patient,6208,O
's,6208,O
fibroblasts,6208,O
with,6208,O
wild-type,6208,O
FAM36A,6208,B-GENE-Y
increases,6208,O
the,6208,O
complex,6208,B-GENE-N
IV,6208,I-GENE-N
activity,6208,O
as,6208,O
well,6208,O
as,6208,O
the,6208,O
amount,6208,O
of,6208,O
holocomplex,6208,B-GENE-N
IV,6208,I-GENE-N
and,6208,O
of,6208,O
individual,6208,O
subunits,6208,O
.,6208,O
These,6209,O
results,6209,O
establish,6209,O
the,6209,O
function,6209,O
of,6209,O
the,6209,O
human,6209,B-GENE-Y
gene,6209,I-GENE-Y
FAM36A/COX20,6209,O
in,6209,O
complex,6209,B-GENE-N
IV,6209,I-GENE-N
assembly,6209,O
and,6209,O
support,6209,O
a,6209,O
causal,6209,O
role,6209,O
of,6209,O
the,6209,O
gene,6209,O
in,6209,O
complex,6209,B-GENE-N
IV,6209,I-GENE-N
deficiency,6209,O
.,6209,O
Deduced,6210,O
amino,6210,B-CHEMICAL
acid,6210,I-CHEMICAL
sequence,6210,O
from,6210,O
the,6210,O
bovine,6210,B-GENE-Y
oxytocin-neurophysin,6210,I-GENE-Y
I,6210,I-GENE-Y
precursor,6210,I-GENE-Y
cDNA,6210,O
.,6210,O
The,6211,O
nonapeptide,6211,O
hormone,6211,O
oxytocin-like,6211,B-GENE-Y
arginine-vasopressin,6211,B-GENE-Y
(,6211,O
AVP,6211,B-GENE-Y
),6211,O
is,6211,O
synthesized,6211,O
as,6211,O
part,6211,O
of,6211,O
a,6211,O
larger,6211,O
precursor,6211,O
polypeptide,6211,O
.,6211,O
The,6212,O
precursor,6212,O
also,6212,O
includes,6212,O
the,6212,O
neurophysin,6212,B-GENE-N
molecule,6212,O
with,6212,O
which,6212,O
the,6212,O
hormone,6212,O
is,6212,O
associated,6212,O
in,6212,O
the,6212,O
neurosecretory,6212,O
granules,6212,O
of,6212,O
the,6212,O
hypothalamo-pituitary,6212,O
tract,6212,O
.,6212,O
A,6213,O
protein,6213,O
of,6213,O
molecular,6213,O
weight,6213,O
(,6213,O
Mr,6213,O
),6213,O
approximately,6213,O
"20,000",6213,O
has,6213,O
been,6213,O
isolated,6213,O
from,6213,O
supraoptic,6213,O
nuclei,6213,O
of,6213,O
rat,6213,O
hypothalami,6213,O
which,6213,O
",",6213,O
after,6213,O
tryptic,6213,O
cleavage,6213,O
",",6213,O
released,6213,O
a,6213,O
neurophysin-like,6213,B-GENE-N
molecule,6213,O
of,6213,O
Mr,6213,O
approximately,6213,O
"10,000",6213,O
and,6213,O
an,6213,O
oligopeptide,6213,O
related,6213,O
to,6213,O
oxytocin,6213,B-GENE-Y
.,6213,O
This,6214,O
result,6214,O
was,6214,O
complemented,6214,O
by,6214,O
in,6214,O
vitro,6214,O
translation,6214,O
of,6214,O
bovine,6214,O
hypothalamic,6214,O
mRNA,6214,O
.,6214,O
Among,6215,O
the,6215,O
primary,6215,O
translation,6215,O
products,6215,O
a,6215,O
single,6215,O
polypeptide,6215,O
of,6215,O
Mr,6215,O
approximately,6215,O
"16,500",6215,O
was,6215,O
shown,6215,O
to,6215,O
contain,6215,O
antigenic,6215,O
determinants,6215,O
recognized,6215,O
by,6215,O
specific,6215,O
antisera,6215,O
against,6215,O
bovine,6215,B-GENE-Y
neurophysin,6215,I-GENE-Y
I,6215,I-GENE-Y
and,6215,O
oxytocin,6215,B-GENE-Y
.,6215,O
Here,6216,O
we,6216,O
report,6216,O
the,6216,O
amino,6216,B-CHEMICAL
acid,6216,I-CHEMICAL
sequence,6216,O
of,6216,O
the,6216,O
bovine,6216,B-GENE-Y
oxytocin-neurophysin,6216,I-GENE-Y
I,6216,I-GENE-Y
(,6216,I-GENE-Y
OT-NpI,6216,I-GENE-Y
),6216,I-GENE-Y
precursor,6216,I-GENE-Y
which,6216,O
was,6216,O
derived,6216,O
from,6216,O
sequence,6216,O
analysis,6216,O
of,6216,O
the,6216,O
cloned,6216,O
cDNA,6216,O
.,6216,O
As,6217,O
is,6217,O
the,6217,O
case,6217,O
for,6217,O
the,6217,O
bovine,6217,B-GENE-Y
arginine-vasopressin-neurophysin,6217,I-GENE-Y
II,6217,I-GENE-Y
(,6217,I-GENE-Y
AVP-NpII,6217,I-GENE-Y
),6217,I-GENE-Y
precursor,6217,I-GENE-Y
",",6217,O
the,6217,O
signal,6217,O
sequence,6217,O
of,6217,O
the,6217,O
OT-NpI,6217,B-GENE-Y
precursor,6217,O
is,6217,O
immediately,6217,O
followed,6217,O
by,6217,O
the,6217,O
nonapeptide,6217,O
hormone,6217,O
which,6217,O
is,6217,O
connected,6217,O
to,6217,O
neurophysin,6217,B-GENE-Y
I,6217,I-GENE-Y
by,6217,O
a,6217,O
Gly-Lys-Arg,6217,B-GENE-N
sequence,6217,O
.,6217,O
A,6218,O
striking,6218,O
feature,6218,O
of,6218,O
the,6218,O
nucleic,6218,O
acid,6218,O
sequence,6218,O
is,6218,O
the,6218,O
197-nucleotide,6218,O
long,6218,O
perfect,6218,O
homology,6218,O
with,6218,O
the,6218,O
AVP-NpII,6218,B-GENE-Y
precursor,6218,I-GENE-Y
mRNA,6218,O
sequence,6218,O
encoding,6218,O
the,6218,O
conserved,6218,O
middle,6218,O
part,6218,O
of,6218,O
neurophysins,6218,B-GENE-N
I,6218,I-GENE-N
and,6218,I-GENE-N
II,6218,I-GENE-N
.,6218,O
Pelargonidin,6219,B-CHEMICAL
activates,6219,O
the,6219,O
AhR,6219,B-GENE-Y
and,6219,O
induces,6219,O
CYP1A1,6219,B-GENE-Y
in,6219,O
primary,6219,O
human,6219,O
hepatocytes,6219,O
and,6219,O
human,6219,O
cancer,6219,O
cell,6219,O
lines,6219,O
HepG2,6219,O
and,6219,O
LS174T,6219,O
.,6219,O
We,6220,O
examined,6220,O
the,6220,O
effects,6220,O
of,6220,O
anthocyanidins,6220,B-CHEMICAL
(,6220,O
cyanidin,6220,B-CHEMICAL
",",6220,O
delphinidin,6220,B-CHEMICAL
",",6220,O
malvidin,6220,B-CHEMICAL
",",6220,O
peonidin,6220,B-CHEMICAL
",",6220,O
petunidin,6220,B-CHEMICAL
",",6220,O
pelargonidin,6220,B-CHEMICAL
),6220,O
on,6220,O
the,6220,O
aryl,6220,B-GENE-Y
hydrocarbon,6220,I-GENE-Y
receptor,6220,I-GENE-Y
(,6220,O
AhR,6220,B-GENE-Y
),6220,O
-CYP1A1,6220,O
signaling,6220,O
pathway,6220,O
in,6220,O
human,6220,O
hepatocytes,6220,O
",",6220,O
hepatic,6220,O
HepG2,6220,O
and,6220,O
intestinal,6220,O
LS174T,6220,O
cancer,6220,O
cells,6220,O
.,6220,O
AhR-dependent,6221,B-GENE-Y
reporter,6221,O
gene,6221,O
expression,6221,O
in,6221,O
transfected,6221,O
HepG2,6221,O
cells,6221,O
was,6221,O
increased,6221,O
by,6221,O
pelargonidin,6221,B-CHEMICAL
in,6221,O
a,6221,O
concentration-dependent,6221,O
manner,6221,O
at,6221,O
24h,6221,O
.,6221,O
Similarly,6222,O
",",6222,O
pelargonidin,6222,B-CHEMICAL
induced,6222,O
the,6222,O
expression,6222,O
of,6222,O
CYP1A1,6222,B-GENE-Y
mRNA,6222,O
up,6222,O
to,6222,O
5-fold,6222,O
in,6222,O
HepG2,6222,O
and,6222,O
LS174T,6222,O
cells,6222,O
relative,6222,O
to,6222,O
the,6222,O
induction,6222,O
by,6222,O
5,6222,O
nM,6222,O
"2,3,7,8-tetrachlorodibenzodioxin",6222,B-CHEMICAL
(,6222,O
TCDD,6222,B-CHEMICAL
),6222,O
",",6222,O
the,6222,O
most,6222,O
potent,6222,O
activator,6222,O
of,6222,O
AhR,6222,B-GENE-Y
.,6222,O
CYP1A1,6223,B-GENE-Y
and,6223,O
CYP1A2,6223,B-GENE-Y
mRNAs,6223,O
were,6223,O
also,6223,O
increased,6223,O
by,6223,O
pelargonidin,6223,B-CHEMICAL
in,6223,O
three,6223,O
primary,6223,O
human,6223,O
hepatocytes,6223,O
cultures,6223,O
(,6223,O
approximately,6223,O
5,6223,O
%,6223,O
of,6223,O
TCDD,6223,B-CHEMICAL
potency,6223,O
),6223,O
and,6223,O
the,6223,O
increase,6223,O
in,6223,O
CYP1A1,6223,B-GENE-Y
protein,6223,O
in,6223,O
HepG2,6223,O
and,6223,O
LS174T,6223,O
cells,6223,O
was,6223,O
comparable,6223,O
to,6223,O
the,6223,O
increase,6223,O
in,6223,O
catalytic,6223,O
activity,6223,O
of,6223,O
CYP1A1,6223,B-GENE-Y
enzyme,6223,O
.,6223,O
Ligand,6224,O
binding,6224,O
analysis,6224,O
demonstrated,6224,O
that,6224,O
pelargonidin,6224,B-CHEMICAL
was,6224,O
a,6224,O
weak,6224,O
ligand,6224,O
of,6224,O
AhR,6224,B-GENE-Y
.,6224,O
Enzyme,6225,O
kinetic,6225,O
analyses,6225,O
using,6225,O
human,6225,O
liver,6225,O
microsomes,6225,O
revealed,6225,O
inhibition,6225,O
of,6225,O
CYP1A1,6225,B-GENE-Y
activity,6225,O
by,6225,O
delphinidin,6225,B-CHEMICAL
(,6225,O
IC50,6225,O
78,6225,O
μM,6225,O
),6225,O
and,6225,O
pelargonidin,6225,B-CHEMICAL
(,6225,O
IC50,6225,O
33,6225,O
μM,6225,O
),6225,O
.,6225,O
Overall,6226,O
",",6226,O
although,6226,O
most,6226,O
anthocyanidins,6226,B-CHEMICAL
had,6226,O
no,6226,O
effects,6226,O
on,6226,O
AhR-CYP1A1,6226,B-GENE-Y
signaling,6226,O
",",6226,O
pelargonidin,6226,B-CHEMICAL
can,6226,O
bind,6226,O
to,6226,O
and,6226,O
activate,6226,O
the,6226,O
AhR,6226,B-GENE-Y
and,6226,O
AhR-dependent,6226,B-GENE-Y
gene,6226,O
expression,6226,O
",",6226,O
and,6226,O
pelargonidin,6226,B-CHEMICAL
and,6226,O
delphinidin,6226,B-CHEMICAL
inhibit,6226,O
the,6226,O
CYP1A1,6226,B-GENE-Y
catalytic,6226,O
activity,6226,O
.,6226,O
Cloning,6227,O
and,6227,O
expression,6227,O
of,6227,O
a,6227,O
novel,6227,O
serotonin,6227,B-GENE-N
receptor,6227,I-GENE-N
with,6227,O
high,6227,O
affinity,6227,O
for,6227,O
tricyclic,6227,B-CHEMICAL
psychotropic,6227,O
drugs,6227,O
.,6227,O
We,6228,O
have,6228,O
used,6228,O
the,6228,O
polymerase,6228,O
chain,6228,O
reaction,6228,O
technique,6228,O
to,6228,O
selectively,6228,O
amplify,6228,O
a,6228,O
guanine,6228,B-GENE-N
nucleotide-binding,6228,I-GENE-N
protein-coupled,6228,I-GENE-N
receptor,6228,I-GENE-N
cDNA,6228,O
sequence,6228,O
from,6228,O
rat,6228,O
striatal,6228,O
mRNA,6228,O
that,6228,O
exhibits,6228,O
high,6228,O
homology,6228,O
to,6228,O
previously,6228,O
cloned,6228,O
serotonin,6228,B-GENE-N
receptors,6228,I-GENE-N
.,6228,O
Sequencing,6229,O
of,6229,O
a,6229,O
full,6229,O
length,6229,O
clone,6229,O
isolated,6229,O
from,6229,O
a,6229,O
rat,6229,O
striatal,6229,O
cDNA,6229,O
library,6229,O
revealed,6229,O
an,6229,O
open,6229,O
reading,6229,O
frame,6229,O
of,6229,O
1311,6229,O
base,6229,O
pairs,6229,O
",",6229,O
encoding,6229,O
a,6229,O
437-residue,6229,O
protein,6229,O
with,6229,O
seven,6229,O
hydrophobic,6229,O
regions,6229,O
.,6229,O
Within,6230,O
these,6230,O
hydrophobic,6230,O
regions,6230,O
",",6230,O
this,6230,O
receptor,6230,O
was,6230,O
found,6230,O
to,6230,O
be,6230,O
41-36,6230,O
%,6230,O
identical,6230,O
to,6230,O
the,6230,O
following,6230,O
serotonin,6230,B-GENE-N
[,6230,I-GENE-N
5-hydroxytryptamine,6230,I-GENE-N
(,6230,I-GENE-N
5-HT,6230,I-GENE-N
),6230,I-GENE-N
],6230,I-GENE-N
receptors,6230,I-GENE-N
:,6230,O
5-HT2,6230,B-GENE-Y
>,6230,O
5-HT1D,6230,B-GENE-Y
>,6230,O
5-HT1C,6230,B-GENE-Y
>,6230,O
5-HT1B,6230,B-GENE-Y
>,6230,O
5-HT1A,6230,B-GENE-Y
>,6230,O
5-HT1E,6230,B-GENE-Y
.,6230,O
Northern,6231,O
blots,6231,O
revealed,6231,O
a,6231,O
approximately,6231,O
4.2-kilobase,6231,O
transcript,6231,O
localized,6231,O
in,6231,O
various,6231,O
brain,6231,O
regions,6231,O
",",6231,O
with,6231,O
the,6231,O
following,6231,O
rank,6231,O
order,6231,O
of,6231,O
abundance,6231,O
:,6231,O
striatum,6231,O
>,6231,O
>,6231,O
olfactory,6231,O
tubercle,6231,O
>,6231,O
cerebral,6231,O
cortex,6231,O
>,6231,O
hippocampus,6231,O
.,6231,O
Expression,6232,O
of,6232,O
this,6232,O
clone,6232,O
in,6232,O
COS-7,6232,O
cells,6232,O
resulted,6232,O
in,6232,O
the,6232,O
appearance,6232,O
of,6232,O
high,6232,O
affinity,6232,O
",",6232,O
saturable,6232,O
binding,6232,O
of,6232,O
(,6232,B-CHEMICAL
+,6232,I-CHEMICAL
),6232,I-CHEMICAL
-,6232,I-CHEMICAL
[,6232,I-CHEMICAL
2-125I,6232,I-CHEMICAL
],6232,I-CHEMICAL
iodolysergic,6232,I-CHEMICAL
acid,6232,I-CHEMICAL
diethylamide,6232,I-CHEMICAL
(,6232,O
[,6232,B-CHEMICAL
125I,6232,I-CHEMICAL
],6232,I-CHEMICAL
LSD,6232,I-CHEMICAL
),6232,O
with,6232,O
a,6232,O
Kd,6232,O
of,6232,O
1.26,6232,O
nM,6232,O
.,6232,O
Among,6233,O
endogenous,6233,O
biogenic,6233,O
amines,6233,O
",",6233,O
only,6233,O
5-HT,6233,B-CHEMICAL
completely,6233,O
inhibited,6233,O
[,6233,B-CHEMICAL
125I,6233,I-CHEMICAL
],6233,I-CHEMICAL
LSD,6233,I-CHEMICAL
binding,6233,O
(,6233,O
Ki,6233,O
=,6233,O
150,6233,O
nM,6233,O
),6233,O
.,6233,O
The,6234,O
inhibition,6234,O
of,6234,O
[,6234,B-CHEMICAL
125I,6234,I-CHEMICAL
],6234,I-CHEMICAL
LSD,6234,I-CHEMICAL
binding,6234,O
by,6234,O
other,6234,O
serotonergic,6234,O
agonists,6234,O
and,6234,O
antagonists,6234,O
revealed,6234,O
a,6234,O
pharmacological,6234,O
profile,6234,O
that,6234,O
does,6234,O
not,6234,O
correlate,6234,O
with,6234,O
that,6234,O
of,6234,O
any,6234,O
previously,6234,O
described,6234,O
serotonin,6234,B-GENE-N
receptor,6234,I-GENE-N
subtype,6234,O
.,6234,O
In,6235,O
addition,6235,O
",",6235,O
this,6235,O
receptor,6235,O
exhibits,6235,O
high,6235,O
affinity,6235,O
for,6235,O
a,6235,O
number,6235,O
of,6235,O
tricyclic,6235,B-CHEMICAL
antipsychotic,6235,O
and,6235,O
antidepressant,6235,O
drugs,6235,O
",",6235,O
including,6235,O
clozapine,6235,B-CHEMICAL
",",6235,O
amoxipine,6235,B-CHEMICAL
",",6235,O
and,6235,O
amitriptyline,6235,B-CHEMICAL
.,6235,O
In,6236,O
HEK-293,6236,O
cells,6236,O
stably,6236,O
transfected,6236,O
with,6236,O
this,6236,O
receptor,6236,O
",",6236,O
serotonin,6236,B-CHEMICAL
elicits,6236,O
a,6236,O
potent,6236,O
stimulation,6236,O
of,6236,O
adenylyl,6236,B-GENE-N
cyclase,6236,I-GENE-N
activity,6236,O
",",6236,O
which,6236,O
is,6236,O
blocked,6236,O
by,6236,O
antipsychotic,6236,O
and,6236,O
antidepressant,6236,O
drugs,6236,O
.,6236,O
The,6237,O
distinct,6237,O
structural,6237,O
and,6237,O
pharmacological,6237,O
properties,6237,O
of,6237,O
this,6237,O
receptor,6237,O
site,6237,O
indicate,6237,O
that,6237,O
it,6237,O
represents,6237,O
a,6237,O
completely,6237,O
novel,6237,O
subtype,6237,O
of,6237,O
serotonin,6237,B-GENE-N
receptor,6237,I-GENE-N
.,6237,O
Based,6238,O
on,6238,O
its,6238,O
affinity,6238,O
for,6238,O
tricyclic,6238,B-CHEMICAL
psychotropic,6238,O
drugs,6238,O
and,6238,O
its,6238,O
localization,6238,O
to,6238,O
limbic,6238,O
and,6238,O
cortical,6238,O
regions,6238,O
of,6238,O
the,6238,O
brain,6238,O
",",6238,O
it,6238,O
is,6238,O
likely,6238,O
that,6238,O
this,6238,O
receptor,6238,O
may,6238,O
play,6238,O
a,6238,O
role,6238,O
in,6238,O
several,6238,O
neuropsychiatric,6238,O
disorders,6238,O
that,6238,O
involve,6238,O
serotonergic,6238,O
systems,6238,O
.,6238,O
The,6239,O
use,6239,O
of,6239,O
insulin,6239,B-GENE-Y
analogues,6239,O
in,6239,O
pregnancy,6239,O
.,6239,O
Excellent,6240,O
glycaemic,6240,O
control,6240,O
is,6240,O
essential,6240,O
in,6240,O
pregnancy,6240,O
to,6240,O
optimise,6240,O
maternal,6240,O
and,6240,O
foetal,6240,O
outcomes,6240,O
.,6240,O
The,6241,O
aim,6241,O
of,6241,O
this,6241,O
review,6241,O
is,6241,O
to,6241,O
assess,6241,O
the,6241,O
efficacy,6241,O
and,6241,O
safety,6241,O
of,6241,O
insulin,6241,B-GENE-Y
analogues,6241,O
in,6241,O
pregnancy,6241,O
.,6241,O
Insulin,6242,B-GENE-Y
lispro,6242,O
and,6242,O
insulin,6242,B-GENE-Y
aspart,6242,O
are,6242,O
safe,6242,O
in,6242,O
pregnancy,6242,O
and,6242,O
may,6242,O
improve,6242,O
post-prandial,6242,O
glycaemic,6242,O
control,6242,O
in,6242,O
women,6242,O
with,6242,O
type,6242,O
1,6242,O
diabetes,6242,O
.,6242,O
However,6243,O
",",6243,O
a,6243,O
lack,6243,O
of,6243,O
data,6243,O
indicating,6243,O
improved,6243,O
foetal,6243,O
outcomes,6243,O
would,6243,O
suggest,6243,O
that,6243,O
there,6243,O
is,6243,O
no,6243,O
imperative,6243,O
to,6243,O
switch,6243,O
to,6243,O
a,6243,O
short-acting,6243,O
analogue,6243,O
where,6243,O
the,6243,O
woman,6243,O
's,6243,O
diabetes,6243,O
is,6243,O
well,6243,O
controlled,6243,O
with,6243,O
human,6243,B-GENE-Y
insulin,6243,I-GENE-Y
.,6243,O
There,6244,O
are,6244,O
no,6244,O
reports,6244,O
of,6244,O
the,6244,O
use,6244,O
of,6244,O
insulin,6244,B-GENE-Y
glulisine,6244,O
in,6244,O
pregnancy,6244,O
and,6244,O
so,6244,O
its,6244,O
use,6244,O
can,6244,O
not,6244,O
be,6244,O
recommended,6244,O
.,6244,O
Most,6245,O
studies,6245,O
of,6245,O
insulin,6245,B-GENE-Y
glargine,6245,O
in,6245,O
pregnancy,6245,O
are,6245,O
small,6245,O
",",6245,O
retrospective,6245,O
and,6245,O
include,6245,O
women,6245,O
with,6245,O
pre-existing,6245,O
diabetes,6245,O
and,6245,O
gestational,6245,O
diabetes,6245,O
.,6245,O
There,6246,O
appear,6246,O
to,6246,O
be,6246,O
no,6246,O
major,6246,O
safety,6246,O
concerns,6246,O
and,6246,O
so,6246,O
it,6246,O
seems,6246,O
reasonable,6246,O
to,6246,O
continue,6246,O
insulin,6246,B-GENE-Y
glargine,6246,O
if,6246,O
required,6246,O
to,6246,O
achieve,6246,O
excellent,6246,O
glycaemic,6246,O
control,6246,O
.,6246,O
A,6247,O
head-to-head,6247,O
comparison,6247,O
between,6247,O
insulin,6247,B-GENE-Y
detemir,6247,O
and,6247,O
NPH,6247,O
insulin,6247,B-GENE-Y
in,6247,O
women,6247,O
with,6247,O
type,6247,O
1,6247,O
diabetes,6247,O
showed,6247,O
that,6247,O
while,6247,O
foetal,6247,O
outcomes,6247,O
did,6247,O
not,6247,O
differ,6247,O
",",6247,O
fasting,6247,O
plasma,6247,O
glucose,6247,B-CHEMICAL
improved,6247,O
with,6247,O
insulin,6247,B-GENE-Y
detemir,6247,O
without,6247,O
an,6247,O
increased,6247,O
incidence,6247,O
of,6247,O
hypoglycaemia,6247,O
.,6247,O
The,6248,O
greater,6248,O
evidence,6248,O
base,6248,O
supports,6248,O
the,6248,O
use,6248,O
of,6248,O
insulin,6248,B-GENE-Y
detemir,6248,O
as,6248,O
the,6248,O
first,6248,O
line,6248,O
long-acting,6248,O
analogue,6248,O
in,6248,O
pregnancy,6248,O
but,6248,O
the,6248,O
lack,6248,O
of,6248,O
definitive,6248,O
foetal,6248,O
benefits,6248,O
means,6248,O
that,6248,O
there,6248,O
is,6248,O
no,6248,O
strong,6248,O
need,6248,O
to,6248,O
switch,6248,O
a,6248,O
woman,6248,O
who,6248,O
is,6248,O
well,6248,O
controlled,6248,O
on,6248,O
NPH,6248,O
insulin,6248,B-GENE-Y
.,6248,O
There,6249,O
seems,6249,O
little,6249,O
justification,6249,O
in,6249,O
using,6249,O
long,6249,O
acting,6249,O
insulin,6249,B-GENE-Y
analogues,6249,O
in,6249,O
women,6249,O
with,6249,O
gestational,6249,O
diabetes,6249,O
or,6249,O
type,6249,O
2,6249,O
diabetes,6249,O
where,6249,O
the,6249,O
risk,6249,O
of,6249,O
hypoglycaemia,6249,O
is,6249,O
low,6249,O
.,6249,O
alpha-Linolenic,6250,B-CHEMICAL
acid,6250,I-CHEMICAL
",",6250,O
Delta6-desaturase,6250,B-GENE-Y
gene,6250,O
polymorphism,6250,O
",",6250,O
and,6250,O
the,6250,O
risk,6250,O
of,6250,O
nonfatal,6250,O
myocardial,6250,O
infarction,6250,O
.,6250,O
BACKGROUND,6251,O
:,6251,O
Delta,6251,B-GENE-Y
(,6251,I-GENE-Y
6,6251,I-GENE-Y
),6251,I-GENE-Y
-Desaturase,6251,I-GENE-Y
(,6251,O
FADS2,6251,B-GENE-Y
),6251,O
is,6251,O
the,6251,O
rate-limiting,6251,O
step,6251,O
in,6251,O
the,6251,O
polyunsaturated,6251,B-CHEMICAL
fatty,6251,I-CHEMICAL
acid,6251,I-CHEMICAL
(,6251,O
PUFA,6251,B-CHEMICAL
),6251,O
biosynthetic,6251,O
pathway,6251,O
.,6251,O
OBJECTIVE,6252,O
:,6252,O
The,6252,O
aim,6252,O
was,6252,O
to,6252,O
test,6252,O
whether,6252,O
the,6252,O
common,6252,O
deletion,6252,O
[,6252,O
T/-,6252,O
],6252,O
in,6252,O
the,6252,O
promoter,6252,O
of,6252,O
FADS2,6252,B-GENE-Y
affects,6252,O
the,6252,O
PUFA,6252,B-CHEMICAL
biosynthetic,6252,O
pathway,6252,O
and,6252,O
consequently,6252,O
modifies,6252,O
the,6252,O
effect,6252,O
of,6252,O
alpha-linolenic,6252,B-CHEMICAL
acid,6252,I-CHEMICAL
(,6252,O
ALA,6252,B-CHEMICAL
),6252,O
on,6252,O
myocardial,6252,O
infarction,6252,O
(,6252,O
MI,6252,O
),6252,O
.,6252,O
DESIGN,6253,O
:,6253,O
Case,6253,O
subjects,6253,O
(,6253,O
n,6253,O
=1694,6253,O
),6253,O
with,6253,O
a,6253,O
first,6253,O
nonfatal,6253,O
acute,6253,O
MI,6253,O
were,6253,O
matched,6253,O
by,6253,O
age,6253,O
",",6253,O
sex,6253,O
",",6253,O
and,6253,O
area,6253,O
of,6253,O
residence,6253,O
to,6253,O
1694,6253,O
population-based,6253,O
control,6253,O
subjects,6253,O
in,6253,O
Costa,6253,O
Rica,6253,O
.,6253,O
PUFAs,6254,B-CHEMICAL
were,6254,O
quantified,6254,O
by,6254,O
gas-liquid,6254,O
chromatography,6254,O
from,6254,O
plasma,6254,O
and,6254,O
adipose,6254,O
tissue,6254,O
samples,6254,O
.,6254,O
Least-squares,6255,O
means,6255,O
from,6255,O
generalized,6255,O
linear,6255,O
models,6255,O
and,6255,O
odds,6255,O
ratios,6255,O
(,6255,O
ORs,6255,O
),6255,O
and,6255,O
95,6255,O
%,6255,O
CIs,6255,O
from,6255,O
multiple,6255,O
conditional,6255,O
logistic,6255,O
regression,6255,O
models,6255,O
were,6255,O
estimated,6255,O
.,6255,O
RESULTS,6256,O
:,6256,O
The,6256,O
prevalence,6256,O
of,6256,O
the,6256,O
variant,6256,O
T/-,6256,O
allele,6256,O
was,6256,O
48,6256,O
%,6256,O
.,6256,O
Eicosapentaenoic,6257,B-CHEMICAL
acid,6257,I-CHEMICAL
",",6257,O
gamma-linolenic,6257,B-CHEMICAL
acid,6257,I-CHEMICAL
",",6257,O
and,6257,O
arachidonic,6257,B-CHEMICAL
acid,6257,I-CHEMICAL
decreased,6257,O
in,6257,O
adipose,6257,O
tissue,6257,O
and,6257,O
plasma,6257,O
with,6257,O
increasing,6257,O
number,6257,O
of,6257,O
copies,6257,O
of,6257,O
the,6257,O
variant,6257,O
allele,6257,O
with,6257,O
a,6257,O
monotonic,6257,O
trend,6257,O
(,6257,O
P,6257,O
<,6257,O
0.05,6257,O
for,6257,O
all,6257,O
),6257,O
.,6257,O
Fasting,6258,O
plasma,6258,O
triacylglycerols,6258,B-CHEMICAL
by,6258,O
genotype,6258,O
were,6258,O
2.08,6258,O
mmol/L,6258,O
for,6258,O
TT,6258,O
",",6258,O
2.16,6258,O
mmol/L,6258,O
for,6258,O
T-,6258,O
",",6258,O
and,6258,O
2.26,6258,O
mmol/L,6258,O
for,6258,O
-,6258,O
-,6258,O
[,6258,O
ie,6258,O
",",6258,O
homozygous,6258,O
for,6258,O
the,6258,O
variant,6258,O
(,6258,O
deletion,6258,O
),6258,O
allele,6258,O
],6258,O
(,6258,O
P,6258,O
=,6258,O
0.03,6258,O
),6258,O
.,6258,O
The,6259,O
FADS2,6259,B-GENE-Y
deletion,6259,O
was,6259,O
not,6259,O
associated,6259,O
with,6259,O
MI,6259,O
and,6259,O
did,6259,O
not,6259,O
significantly,6259,O
modify,6259,O
the,6259,O
association,6259,O
between,6259,O
adipose,6259,O
tissue,6259,O
ALA,6259,B-CHEMICAL
and,6259,O
the,6259,O
risk,6259,O
of,6259,O
MI,6259,O
.,6259,O
CONCLUSIONS,6260,O
:,6260,O
The,6260,O
FADS2,6260,B-GENE-Y
deletion,6260,O
may,6260,O
prevent,6260,O
the,6260,O
conversion,6260,O
of,6260,O
ALA,6260,B-CHEMICAL
into,6260,O
very-long-chain,6260,B-CHEMICAL
PUFAs,6260,I-CHEMICAL
.,6260,O
However,6261,O
",",6261,O
this,6261,O
metabolic,6261,O
effect,6261,O
is,6261,O
not,6261,O
translated,6261,O
into,6261,O
an,6261,O
attenuated,6261,O
risk,6261,O
between,6261,O
ALA,6261,B-CHEMICAL
and,6261,O
MI,6261,O
among,6261,O
carriers,6261,O
of,6261,O
the,6261,O
variant,6261,O
.,6261,O
It,6262,O
is,6262,O
possible,6262,O
that,6262,O
",",6262,O
at,6262,O
current,6262,O
intakes,6262,O
of,6262,O
ALA,6262,B-CHEMICAL
",",6262,O
any,6262,O
potential,6262,O
defect,6262,O
in,6262,O
the,6262,O
transcription,6262,O
of,6262,O
the,6262,O
gene,6262,O
is,6262,O
masked,6262,O
by,6262,O
the,6262,O
availability,6262,O
of,6262,O
substrate,6262,O
.,6262,O
Further,6263,O
research,6263,O
in,6263,O
populations,6263,O
deficient,6263,O
in,6263,O
ALA,6263,B-CHEMICAL
intake,6263,O
is,6263,O
warranted,6263,O
.,6263,O
Altered,6264,O
vasoreactivity,6264,O
to,6264,O
angiotensin,6264,B-GENE-Y
II,6264,I-GENE-Y
in,6264,O
experimental,6264,O
diabetic,6264,O
neuropathy,6264,O
:,6264,O
role,6264,O
of,6264,O
nitric,6264,B-CHEMICAL
oxide,6264,I-CHEMICAL
.,6264,O
We,6265,O
evaluated,6265,O
the,6265,O
effects,6265,O
of,6265,O
angiotensin,6265,B-GENE-Y
II,6265,I-GENE-Y
and,6265,O
an,6265,O
angiotensin-converting,6265,B-GENE-Y
enzyme,6265,I-GENE-Y
inhibitor,6265,O
(,6265,O
cilazapril,6265,B-CHEMICAL
),6265,O
on,6265,O
nerve,6265,O
blood,6265,O
flow,6265,O
(,6265,O
NBF,6265,O
),6265,O
and,6265,O
electrophysiology,6265,O
in,6265,O
control,6265,O
and,6265,O
diabetic,6265,O
rats,6265,O
.,6265,O
When,6266,O
applied,6266,O
locally,6266,O
to,6266,O
the,6266,O
sciatic,6266,O
nerve,6266,O
",",6266,O
the,6266,O
dose-response,6266,O
curve,6266,O
of,6266,O
angiotensin,6266,B-GENE-Y
II,6266,I-GENE-Y
was,6266,O
more,6266,O
potent,6266,O
in,6266,O
experimental,6266,O
diabetic,6266,O
neuropathy,6266,O
(,6266,O
EDN,6266,O
),6266,O
than,6266,O
control,6266,O
rats,6266,O
.,6266,O
No,6267,O
difference,6267,O
existed,6267,O
in,6267,O
plasma,6267,O
angiotensin,6267,B-GENE-Y
II,6267,I-GENE-Y
levels,6267,O
between,6267,O
EDN,6267,O
and,6267,O
controls,6267,O
.,6267,O
The,6268,O
rats,6268,O
were,6268,O
given,6268,O
typical,6268,O
rat,6268,O
pellets,6268,O
or,6268,O
pellets,6268,O
treated,6268,O
with,6268,O
10,6268,O
mg/kg,6268,O
per,6268,O
day,6268,O
cilazapril,6268,B-CHEMICAL
for,6268,O
4,6268,O
weeks,6268,O
.,6268,O
Diabetes,6269,O
caused,6269,O
a,6269,O
significant,6269,O
reduction,6269,O
in,6269,O
NBF,6269,O
",",6269,O
nerve,6269,O
conduction,6269,O
velocity,6269,O
",",6269,O
and,6269,O
compound,6269,O
muscle,6269,O
action,6269,O
potential,6269,O
(,6269,O
CMAP,6269,O
),6269,O
amplitudes,6269,O
.,6269,O
NBF,6270,O
was,6270,O
significantly,6270,O
increased,6270,O
in,6270,O
diabetic,6270,O
rats,6270,O
supplemented,6270,O
with,6270,O
cilazapril,6270,B-CHEMICAL
diet,6270,O
",",6270,O
and,6270,O
nerve,6270,O
conduction,6270,O
velocity,6270,O
and,6270,O
amplitudes,6270,O
of,6270,O
the,6270,O
CMAP,6270,O
were,6270,O
also,6270,O
improved,6270,O
after,6270,O
4,6270,O
weeks,6270,O
on,6270,O
this,6270,O
diet,6270,O
.,6270,O
Direct,6271,O
application,6271,O
10,6271,O
(,6271,O
-3,6271,O
),6271,O
mol/L,6271,O
cilazapril,6271,B-CHEMICAL
on,6271,O
sciatic,6271,O
nerve,6271,O
did,6271,O
not,6271,O
increase,6271,O
NBF,6271,O
in,6271,O
normal,6271,O
and,6271,O
EDN,6271,O
rats,6271,O
.,6271,O
We,6272,O
topically,6272,O
applied,6272,O
the,6272,O
nitric,6272,B-GENE-N
oxide,6272,I-GENE-N
synthase,6272,I-GENE-N
(,6272,O
NOS,6272,B-GENE-N
),6272,O
inhibitor,6272,O
",",6272,O
NG-nitro-L-arginine,6272,B-CHEMICAL
",",6272,O
on,6272,O
sciatic,6272,O
nerve,6272,O
and,6272,O
observed,6272,O
reduced,6272,O
inhibition,6272,O
of,6272,O
NBF,6272,O
in,6272,O
EDN,6272,O
",",6272,O
which,6272,O
was,6272,O
correctable,6272,O
with,6272,O
a,6272,O
cilazapril,6272,B-CHEMICAL
diet,6272,O
.,6272,O
These,6273,O
results,6273,O
suggest,6273,O
that,6273,O
diabetic,6273,O
neuropathy,6273,O
may,6273,O
have,6273,O
an,6273,O
increasing,6273,O
vasopressor,6273,O
action,6273,O
with,6273,O
angiotensin,6273,B-GENE-Y
II,6273,I-GENE-Y
and,6273,O
this,6273,O
is,6273,O
likely,6273,O
to,6273,O
be,6273,O
the,6273,O
mechanism,6273,O
of,6273,O
NOS,6273,B-GENE-N
inhibition,6273,O
.,6273,O
Angiotensin,6274,B-GENE-Y
II-converting,6274,I-GENE-Y
enzyme,6274,I-GENE-Y
inhibitors,6274,O
may,6274,O
have,6274,O
potential,6274,O
in,6274,O
the,6274,O
treatment,6274,O
of,6274,O
diabetic,6274,O
neuropathy,6274,O
.,6274,O
Effect,6275,O
of,6275,O
the,6275,O
R,6275,B-CHEMICAL
(,6275,I-CHEMICAL
-,6275,I-CHEMICAL
),6275,I-CHEMICAL
and,6275,I-CHEMICAL
S,6275,I-CHEMICAL
(,6275,I-CHEMICAL
+,6275,I-CHEMICAL
),6275,I-CHEMICAL
isomers,6275,I-CHEMICAL
of,6275,I-CHEMICAL
MDA,6275,I-CHEMICAL
and,6275,O
MDMA,6275,B-CHEMICAL
on,6275,O
phosphatidyl,6275,B-CHEMICAL
inositol,6275,I-CHEMICAL
turnover,6275,O
in,6275,O
cultured,6275,O
cells,6275,O
expressing,6275,O
5-HT2A,6275,B-GENE-Y
or,6275,O
5-HT2C,6275,B-GENE-Y
receptors,6275,O
.,6275,O
The,6276,O
effect,6276,O
of,6276,O
the,6276,O
R,6276,B-CHEMICAL
(,6276,I-CHEMICAL
-,6276,I-CHEMICAL
),6276,I-CHEMICAL
and,6276,I-CHEMICAL
S,6276,I-CHEMICAL
(,6276,I-CHEMICAL
+,6276,I-CHEMICAL
),6276,I-CHEMICAL
isomers,6276,I-CHEMICAL
of,6276,I-CHEMICAL
"3,4-methylenedioxyamphetamine",6276,I-CHEMICAL
(,6276,O
MDA,6276,B-CHEMICAL
),6276,O
and,6276,O
its,6276,O
N-methyl,6276,B-CHEMICAL
analog,6276,I-CHEMICAL
"3,4-methylenedioxymethamphetamine",6276,I-CHEMICAL
(,6276,O
MDMA,6276,B-CHEMICAL
),6276,O
on,6276,O
[,6276,B-CHEMICAL
3H,6276,I-CHEMICAL
],6276,I-CHEMICAL
inositol,6276,I-CHEMICAL
monophosphate,6276,I-CHEMICAL
accumulation,6276,O
was,6276,O
studied,6276,O
in,6276,O
cells,6276,O
expressing,6276,O
either,6276,O
5-HT2A,6276,B-GENE-Y
or,6276,O
5-HT2C,6276,B-GENE-Y
receptors,6276,O
.,6276,O
The,6277,O
isomers,6277,O
of,6277,O
MDA,6277,B-CHEMICAL
produced,6277,O
a,6277,O
concentration,6277,O
dependent,6277,O
increase,6277,O
in,6277,O
phosphatidyl,6277,B-CHEMICAL
inositol,6277,I-CHEMICAL
(,6277,O
PI,6277,B-CHEMICAL
),6277,O
hydrolysis,6277,O
at,6277,O
the,6277,O
5-HT2A,6277,B-GENE-Y
receptors,6277,O
",",6277,O
with,6277,O
the,6277,O
R,6277,B-CHEMICAL
(,6277,I-CHEMICAL
-,6277,I-CHEMICAL
),6277,I-CHEMICAL
isomer,6277,I-CHEMICAL
of,6277,I-CHEMICAL
MDA,6277,I-CHEMICAL
being,6277,O
more,6277,O
potent,6277,O
than,6277,O
the,6277,O
S,6277,O
(,6277,O
+,6277,O
),6277,O
at,6277,O
the,6277,O
5-HT2A,6277,B-GENE-Y
receptor,6277,O
.,6277,O
The,6278,O
R,6278,B-CHEMICAL
(,6278,I-CHEMICAL
-,6278,I-CHEMICAL
),6278,I-CHEMICAL
and,6278,I-CHEMICAL
S,6278,I-CHEMICAL
(,6278,I-CHEMICAL
+,6278,I-CHEMICAL
),6278,I-CHEMICAL
isomers,6278,I-CHEMICAL
of,6278,I-CHEMICAL
MDMA,6278,I-CHEMICAL
were,6278,O
significantly,6278,O
less,6278,O
efficacious,6278,O
at,6278,O
the,6278,O
5-HT2A,6278,B-GENE-Y
receptor,6278,O
as,6278,O
compared,6278,O
to,6278,O
MDA,6278,B-CHEMICAL
;,6278,O
S,6278,B-CHEMICAL
(,6278,I-CHEMICAL
+,6278,I-CHEMICAL
),6278,I-CHEMICAL
MDMA,6278,I-CHEMICAL
had,6278,O
no,6278,O
effect,6278,O
.,6278,O
At,6279,O
the,6279,O
5-HT2C,6279,B-GENE-Y
receptor,6279,O
",",6279,O
both,6279,O
R,6279,B-CHEMICAL
(,6279,I-CHEMICAL
-,6279,I-CHEMICAL
),6279,I-CHEMICAL
and,6279,I-CHEMICAL
S,6279,I-CHEMICAL
(,6279,I-CHEMICAL
+,6279,I-CHEMICAL
),6279,I-CHEMICAL
MDA,6279,I-CHEMICAL
were,6279,O
equipotent,6279,O
at,6279,O
stimulating,6279,O
PI,6279,B-CHEMICAL
hydrolysis,6279,O
",",6279,O
with,6279,O
the,6279,O
S,6279,B-CHEMICAL
(,6279,I-CHEMICAL
+,6279,I-CHEMICAL
),6279,I-CHEMICAL
isomer,6279,I-CHEMICAL
of,6279,I-CHEMICAL
MDMA,6279,I-CHEMICAL
being,6279,O
more,6279,O
efficacious,6279,O
at,6279,O
the,6279,O
5-HT2C,6279,B-GENE-Y
receptor,6279,O
compared,6279,O
with,6279,O
the,6279,O
R,6279,O
(,6279,O
-,6279,O
),6279,O
isomer,6279,O
.,6279,O
In,6280,O
all,6280,O
cases,6280,O
at,6280,O
both,6280,O
the,6280,O
5-HT2A,6280,B-GENE-Y
and,6280,O
5-HT2C,6280,B-GENE-Y
receptors,6280,O
",",6280,O
the,6280,O
affinities,6280,O
of,6280,O
the,6280,O
isomers,6280,O
of,6280,O
MDMA,6280,B-CHEMICAL
and,6280,O
MDA,6280,B-CHEMICAL
were,6280,O
at,6280,O
least,6280,O
2-3,6280,O
orders,6280,O
of,6280,O
magnitude,6280,O
less,6280,O
than,6280,O
5-HT,6280,B-CHEMICAL
.,6280,O
Despite,6281,O
the,6281,O
weak,6281,O
effect,6281,O
of,6281,O
these,6281,O
compounds,6281,O
at,6281,O
the,6281,O
5-HT2A,6281,B-GENE-Y
and,6281,O
5-HT2C,6281,B-GENE-Y
receptors,6281,O
",",6281,O
these,6281,O
substituted,6281,O
amphetamines,6281,B-CHEMICAL
do,6281,O
possess,6281,O
intrinsic,6281,O
activity,6281,O
which,6281,O
may,6281,O
contribute,6281,O
to,6281,O
their,6281,O
neurotoxic,6281,O
effects,6281,O
when,6281,O
administered,6281,O
at,6281,O
high,6281,O
doses,6281,O
.,6281,O
Hepatocytes,6282,O
display,6282,O
a,6282,O
compensatory,6282,O
survival,6282,O
response,6282,O
against,6282,O
cadmium,6282,B-CHEMICAL
toxicity,6282,O
by,6282,O
a,6282,O
mechanism,6282,O
mediated,6282,O
by,6282,O
EGFR,6282,B-GENE-Y
and,6282,O
Src,6282,B-GENE-Y
.,6282,O
Although,6283,O
the,6283,O
liver,6283,O
is,6283,O
a,6283,O
cadmium-target,6283,B-CHEMICAL
organ,6283,O
",",6283,O
hepatocyte,6283,O
response,6283,O
involved,6283,O
in,6283,O
its,6283,O
toxicity,6283,O
is,6283,O
not,6283,O
yet,6283,O
elucidated,6283,O
.,6283,O
A,6284,O
link,6284,O
between,6284,O
this,6284,O
heavy,6284,O
metal,6284,O
treatment,6284,O
and,6284,O
Stat3,6284,B-GENE-Y
signaling,6284,O
pathways,6284,O
was,6284,O
examined,6284,O
in,6284,O
primary,6284,O
mouse,6284,O
hepatocytes,6284,O
.,6284,O
We,6285,O
provided,6285,O
evidence,6285,O
of,6285,O
a,6285,O
novel,6285,O
link,6285,O
among,6285,O
NADPH,6285,B-GENE-N
oxidase,6285,I-GENE-N
and,6285,O
Stat3,6285,B-GENE-Y
signaling,6285,O
",",6285,O
mediated,6285,O
by,6285,O
Src,6285,B-GENE-Y
",",6285,O
EGFR,6285,B-GENE-Y
",",6285,O
and,6285,O
Erk1/2,6285,B-GENE-N
.,6285,O
Cadmium,6286,B-CHEMICAL
activates,6286,O
NADPH,6286,B-GENE-N
oxidase,6286,I-GENE-N
.,6286,O
ROS,6287,O
produced,6287,O
by,6287,O
this,6287,O
oxidase,6287,B-GENE-N
activates,6287,O
Src,6287,B-GENE-Y
",",6287,O
enable,6287,O
that,6287,O
in,6287,O
turn,6287,O
",",6287,O
transactivates,6287,O
EGFR,6287,B-GENE-Y
that,6287,O
activates,6287,O
Stat3,6287,B-GENE-Y
in,6287,O
tyrosine,6287,B-CHEMICAL
",",6287,O
allowing,6287,O
its,6287,O
dimerization,6287,O
.,6287,O
Also,6288,O
",",6288,O
ROS,6288,O
from,6288,O
NADPH,6288,B-GENE-N
oxidase,6288,I-GENE-N
favors,6288,O
ERK1/2,6288,B-GENE-N
activation,6288,O
that,6288,O
phosphorylates,6288,O
Stat3,6288,B-GENE-Y
in,6288,O
serine,6288,B-CHEMICAL
",",6288,O
resulting,6288,O
in,6288,O
a,6288,O
compensatory,6288,O
or,6288,O
adaptive,6288,O
survival,6288,O
response,6288,O
such,6288,O
as,6288,O
production,6288,O
of,6288,O
metallothionein-II,6288,B-GENE-Y
in,6288,O
short,6288,O
Cd,6288,B-CHEMICAL
exposure,6288,O
times,6288,O
.,6288,O
However,6289,O
",",6289,O
after,6289,O
12h,6289,O
CdCl2,6289,B-CHEMICAL
treatment,6289,O
",",6289,O
cell,6289,O
viability,6289,O
diminished,6289,O
in,6289,O
50,6289,O
%,6289,O
",",6289,O
accompanied,6289,O
by,6289,O
a,6289,O
drastic,6289,O
decrease,6289,O
of,6289,O
metallothionein-II,6289,B-GENE-Y
production,6289,O
",",6289,O
and,6289,O
an,6289,O
increase,6289,O
in,6289,O
p53,6289,B-GENE-Y
activation,6289,O
and,6289,O
the,6289,O
pro-apoptotic,6289,O
protein,6289,O
Bax,6289,B-GENE-Y
.,6289,O
[,6290,O
Screening,6290,O
of,6290,O
short,6290,O
peptides,6290,O
binding,6290,O
to,6290,O
cell,6290,O
surface,6290,O
interleukin-2,6290,B-GENE-Y
receptor,6290,I-GENE-Y
alpha,6290,I-GENE-Y
chain,6290,I-GENE-Y
],6290,O
.,6290,O
OBJECTIVE,6291,O
:,6291,O
To,6291,O
screen,6291,O
and,6291,O
characterize,6291,O
the,6291,O
short,6291,O
peptides,6291,O
which,6291,O
bind,6291,O
specifically,6291,O
to,6291,O
interleukin-2,6291,B-GENE-Y
(,6291,I-GENE-Y
IL-2,6291,I-GENE-Y
),6291,I-GENE-Y
receptor,6291,I-GENE-Y
alpha,6291,I-GENE-Y
chain,6291,I-GENE-Y
(,6291,O
IL-2Ralpha,6291,B-GENE-Y
),6291,O
for,6291,O
acquisition,6291,O
of,6291,O
small,6291,O
antagonists,6291,O
for,6291,O
blocking,6291,O
the,6291,O
binding,6291,O
of,6291,O
IL-2,6291,B-GENE-Y
with,6291,O
IL-2Ralpha,6291,B-GENE-Y
.,6291,O
METHODS,6292,O
:,6292,O
12-mer,6292,O
phage,6292,O
displayed,6292,O
peptide,6292,O
library,6292,O
was,6292,O
screened,6292,O
with,6292,O
the,6292,O
target,6292,O
cells,6292,O
of,6292,O
MT-2,6292,O
cells,6292,O
which,6292,O
expressed,6292,O
IL-2Ralpha,6292,B-GENE-Y
at,6292,O
high,6292,O
levels,6292,O
.,6292,O
The,6293,O
binding,6293,O
phage,6293,O
clones,6293,O
were,6293,O
eluted,6293,O
by,6293,O
anti-IL-2Ralpha,6293,O
monoclonal,6293,O
antibody,6293,O
.,6293,O
After,6294,O
3,6294,O
rounds,6294,O
of,6294,O
screening,6294,O
",",6294,O
the,6294,O
positive,6294,O
phage,6294,O
clones,6294,O
were,6294,O
identified,6294,O
by,6294,O
enzyme-linked,6294,O
immunosorbent,6294,O
assay,6294,O
(,6294,O
ELISA,6294,O
),6294,O
and,6294,O
immunohistochemistry,6294,O
",",6294,O
and,6294,O
the,6294,O
amino,6294,B-CHEMICAL
acid,6294,I-CHEMICAL
sequences,6294,O
of,6294,O
the,6294,O
positive,6294,O
clones,6294,O
were,6294,O
deduced,6294,O
from,6294,O
the,6294,O
DNA,6294,O
sequences,6294,O
.,6294,O
RESULTS,6295,O
:,6295,O
Seven,6295,O
positive,6295,O
clones,6295,O
were,6295,O
screened,6295,O
out,6295,O
of,6295,O
the,6295,O
17,6295,O
phage,6295,O
clones,6295,O
bound,6295,O
to,6295,O
MT-2,6295,O
cells,6295,O
.,6295,O
The,6296,O
positive,6296,O
clone,6296,O
M15,6296,O
could,6296,O
bind,6296,O
specifically,6296,O
to,6296,O
MT-2,6296,O
cell,6296,O
and,6296,O
PHA-activated,6296,O
peripheral,6296,O
blood,6296,O
monouclear,6296,O
cells,6296,O
.,6296,O
Amino,6297,B-CHEMICAL
acid,6297,I-CHEMICAL
sequence,6297,O
analysis,6297,O
identified,6297,O
6,6297,O
sequences,6297,O
",",6297,O
all,6297,O
of,6297,O
which,6297,O
contained,6297,O
hydrophilic,6297,O
residues,6297,O
",",6297,O
and,6297,O
5,6297,O
of,6297,O
these,6297,O
6,6297,O
sequences,6297,O
included,6297,O
Tyr,6297,B-CHEMICAL
",",6297,O
Phe,6297,B-CHEMICAL
and,6297,O
Leu,6297,B-CHEMICAL
conservative,6297,O
residues,6297,O
.,6297,O
CONCLUSION,6298,O
:,6298,O
The,6298,O
peptide,6298,O
sequences,6298,O
containing,6298,O
Tyr,6298,B-CHEMICAL
",",6298,O
Phe,6298,B-CHEMICAL
conservative,6298,O
residues,6298,O
identified,6298,O
in,6298,O
this,6298,O
study,6298,O
can,6298,O
bind,6298,O
to,6298,O
cell,6298,O
surface,6298,O
IL-2Ralpha,6298,B-GENE-Y
.,6298,O
Peyer,6299,O
's,6299,O
patch-mediated,6299,O
intestinal,6299,O
immune,6299,O
system,6299,O
modulating,6299,O
activity,6299,O
of,6299,O
pectic-type,6299,O
polysaccharide,6299,O
from,6299,O
peel,6299,O
of,6299,O
Citrus,6299,O
unshiu,6299,O
.,6299,O
An,6300,O
intestinal,6300,O
immune,6300,O
system,6300,O
modulating,6300,O
polysaccharide,6300,O
(,6300,O
CUI-3IIb-3-2,6300,O
",",6300,O
18kDa,6300,O
),6300,O
was,6300,O
purified,6300,O
from,6300,O
Citrus,6300,O
unshiu,6300,O
peel,6300,O
.,6300,O
CUI-3IIb-3-2,6301,O
mainly,6301,O
comprised,6301,O
GalA,6301,B-CHEMICAL
",",6301,O
GlcA,6301,B-CHEMICAL
",",6301,O
Ara,6301,B-CHEMICAL
",",6301,O
Gal,6301,B-CHEMICAL
and,6301,O
Rha,6301,B-CHEMICAL
",",6301,O
and,6301,O
it,6301,O
consisted,6301,O
of,6301,O
4-linked,6301,O
GalA,6301,B-CHEMICAL
",",6301,O
terminal,6301,O
Araf,6301,B-CHEMICAL
",",6301,O
4-,6301,O
or,6301,O
"5-linked/3,4-",6301,O
or,6301,O
"3,5-branched",6301,O
Ara,6301,B-CHEMICAL
",",6301,O
terminal,6301,O
Gal,6301,B-CHEMICAL
",",6301,O
and,6301,O
"2-linked/2,4-branched",6301,O
Rha,6301,B-CHEMICAL
.,6301,O
After,6302,O
CUI-3IIb-3-2,6302,O
digestion,6302,O
by,6302,O
endo-α-d-,6302,O
(,6302,O
1→4,6302,O
),6302,O
-polygalacturonase,6302,O
",",6302,O
its,6302,O
hydrolysate,6302,O
was,6302,O
fractionated,6302,O
into,6302,O
PG-1,6302,O
and,6302,O
PG-2,6302,O
.,6302,O
Methylation,6303,O
analyses,6303,O
of,6303,O
PG-1,6303,O
and,6303,O
PG-2,6303,O
using,6303,O
base-catalysed,6303,O
β-elimination,6303,O
suggested,6303,O
that,6303,O
CUI-3IIb-3-2,6303,O
be,6303,O
assumed,6303,O
as,6303,O
pectic-type,6303,O
polysaccharide,6303,O
.,6303,O
Since,6304,O
the,6304,O
activities,6304,O
of,6304,O
PG-1,6304,O
and,6304,O
PG-2,6304,O
were,6304,O
potently,6304,O
decreased,6304,O
",",6304,O
the,6304,O
whole,6304,O
polysaccharide,6304,O
structure,6304,O
of,6304,O
CUI-3IIb-3-2,6304,O
would,6304,O
be,6304,O
essential,6304,O
to,6304,O
maintain,6304,O
the,6304,O
activity,6304,O
.,6304,O
Meanwhile,6305,O
",",6305,O
when,6305,O
CUI-3IIb,6305,O
was,6305,O
orally,6305,O
administered,6305,O
in,6305,O
mice,6305,O
",",6305,O
bone,6305,O
marrow,6305,O
cell,6305,O
proliferation,6305,O
and,6305,O
GM-CSF/IL-6,6305,O
production,6305,O
from,6305,O
Peyer,6305,O
's,6305,O
patch,6305,O
cell,6305,O
were,6305,O
significantly,6305,O
higher,6305,O
(,6305,O
1.76-,6305,O
and,6305,O
2.03/2.51-fold,6305,O
",",6305,O
respectively,6305,O
),6305,O
than,6305,O
a,6305,O
saline,6305,O
.,6305,O
Therefore,6306,O
",",6306,O
a,6306,O
pectic-type,6306,O
polysaccharide,6306,O
from,6306,O
citrus,6306,O
peel,6306,O
could,6306,O
stimulate,6306,O
Peyer,6306,O
's,6306,O
patches,6306,O
and,6306,O
produce,6306,O
hematopoietic,6306,O
growth,6306,O
factors,6306,O
resulted,6306,O
in,6306,O
bone,6306,O
marrow,6306,O
cell,6306,O
proliferation,6306,O
.,6306,O
An,6307,O
Indian,6307,O
butyrylcholinesterase,6307,B-GENE-Y
variant,6307,O
L307P,6307,B-GENE-N
is,6307,O
not,6307,O
structurally,6307,O
stable,6307,O
:,6307,O
A,6307,O
molecular,6307,O
dynamics,6307,O
simulation,6307,O
study,6307,O
.,6307,O
The,6308,O
human,6308,B-GENE-Y
butyrylcholinesterase,6308,I-GENE-Y
(,6308,O
BChE,6308,B-GENE-Y
),6308,O
activity,6308,O
is,6308,O
less,6308,O
than,6308,O
1,6308,O
%,6308,O
in,6308,O
the,6308,O
serum,6308,O
of,6308,O
silent,6308,O
variant,6308,O
individuals,6308,O
of,6308,O
Vysya,6308,O
community,6308,O
in,6308,O
India,6308,O
.,6308,O
They,6309,O
are,6309,O
homozygous,6309,O
for,6309,O
a,6309,O
point,6309,O
mutation,6309,O
at,6309,O
codon,6309,O
307,6309,O
(,6309,O
CTT→CCT,6309,B-GENE-N
),6309,O
resulting,6309,O
in,6309,O
the,6309,O
substitution,6309,O
of,6309,O
leucine,6309,B-GENE-N
307,6309,I-GENE-N
by,6309,I-GENE-N
proline,6309,I-GENE-N
.,6309,O
The,6310,O
reason,6310,O
for,6310,O
the,6310,O
disappearance,6310,O
of,6310,O
the,6310,O
protein,6310,O
in,6310,O
the,6310,O
serum,6310,O
has,6310,O
not,6310,O
been,6310,O
explicated,6310,O
till,6310,O
date,6310,O
.,6310,O
Based,6311,O
on,6311,O
this,6311,O
background,6311,O
",",6311,O
we,6311,O
performed,6311,O
molecular,6311,O
dynamics,6311,O
simulation,6311,O
to,6311,O
probe,6311,O
the,6311,O
structural,6311,O
stability,6311,O
of,6311,O
Indian,6311,O
variant,6311,O
(,6311,O
L307P,6311,B-GENE-N
),6311,O
in,6311,O
comparison,6311,O
with,6311,O
wild,6311,O
and,6311,O
other,6311,O
BChE,6311,B-GENE-Y
variants,6311,O
(,6311,O
D70G,6311,B-GENE-N
",",6311,O
E497V,6311,B-GENE-N
",",6311,O
V142M,6311,B-GENE-N
),6311,O
having,6311,O
differential,6311,O
esterase,6311,B-GENE-N
activity,6311,O
.,6311,O
The,6312,O
simulation,6312,O
of,6312,O
all,6312,O
the,6312,O
mutants,6312,O
except,6312,O
D70G,6312,B-GENE-N
showed,6312,O
a,6312,O
much,6312,O
larger,6312,O
Cα,6312,O
root,6312,O
mean,6312,O
square,6312,O
deviation,6312,O
from,6312,O
the,6312,O
wild,6312,O
BChE,6312,B-GENE-Y
crystal,6312,O
structure,6312,O
",",6312,O
showing,6312,O
the,6312,O
overall,6312,O
conformational,6312,O
disturbance,6312,O
.,6312,O
Further,6313,O
analysis,6313,O
revealed,6313,O
that,6313,O
secondary,6313,O
structure,6313,O
of,6313,O
the,6313,O
mutant,6313,O
proteins,6313,O
was,6313,O
not,6313,O
stable,6313,O
.,6313,O
The,6314,O
orientation,6314,O
of,6314,O
the,6314,O
catalytic,6314,O
triad,6314,O
is,6314,O
also,6314,O
distorted,6314,O
in,6314,O
all,6314,O
the,6314,O
mutants,6314,O
.,6314,O
The,6315,O
distance,6315,O
between,6315,O
δ,6315,O
nitrogen,6315,B-CHEMICAL
of,6315,O
His438,6315,B-CHEMICAL
to,6315,O
ε,6315,O
oxygen,6315,B-CHEMICAL
of,6315,O
Glu325,6315,B-CHEMICAL
and,6315,O
ε,6315,O
nitrogen,6315,B-CHEMICAL
of,6315,O
His438,6315,B-CHEMICAL
to,6315,O
γ,6315,O
oxygen,6315,B-CHEMICAL
of,6315,O
Ser198,6315,B-CHEMICAL
were,6315,O
highly,6315,O
altered,6315,O
in,6315,O
L307P,6315,B-GENE-N
mutant,6315,O
than,6315,O
the,6315,O
wild,6315,O
and,6315,O
other,6315,O
three,6315,O
variants,6315,O
throughout,6315,O
the,6315,O
simulation,6315,O
.,6315,O
Such,6316,O
disparity,6316,O
of,6316,O
distances,6316,O
between,6316,O
the,6316,O
catalytic,6316,O
residues,6316,O
may,6316,O
be,6316,O
due,6316,O
to,6316,O
the,6316,O
change,6316,O
in,6316,O
the,6316,O
protein,6316,O
conformation,6316,O
attributing,6316,O
to,6316,O
their,6316,O
differential,6316,O
catalytic,6316,O
activity,6316,O
.,6316,O
Our,6317,O
studies,6317,O
thus,6317,O
prove,6317,O
that,6317,O
the,6317,O
Indian,6317,O
BChE,6317,B-GENE-Y
L307P,6317,B-GENE-N
mutant,6317,O
with,6317,O
negligible,6317,O
activity,6317,O
is,6317,O
possibly,6317,O
due,6317,O
to,6317,O
its,6317,O
structural,6317,O
instability,6317,O
when,6317,O
compared,6317,O
to,6317,O
other,6317,O
BChE,6317,B-GENE-Y
variants,6317,O
.,6317,O
The,6318,O
inhibitory,6318,O
effect,6318,O
of,6318,O
ginseng,6318,B-CHEMICAL
saponins,6318,I-CHEMICAL
on,6318,O
the,6318,O
stress-induced,6318,O
plasma,6318,O
interleukin-6,6318,B-GENE-Y
level,6318,O
in,6318,O
mice,6318,O
.,6318,O
The,6319,O
effect,6319,O
of,6319,O
ginseng,6319,B-CHEMICAL
saponins,6319,I-CHEMICAL
on,6319,O
plasma,6319,O
interleukin-6,6319,B-GENE-Y
(,6319,O
IL-6,6319,B-GENE-Y
),6319,O
in,6319,O
non-stressed,6319,O
and,6319,O
immobilization-stressed,6319,O
mice,6319,O
were,6319,O
investigated,6319,O
.,6319,O
Ginseng,6320,O
total,6320,O
saponins,6320,B-CHEMICAL
",",6320,O
ginsenosides,6320,B-CHEMICAL
Rb2,6320,I-CHEMICAL
",",6320,I-CHEMICAL
Rg1,6320,I-CHEMICAL
and,6320,I-CHEMICAL
Rd,6320,I-CHEMICAL
administered,6320,O
intraperitoneally,6320,O
attenuated,6320,O
the,6320,O
immobilization,6320,O
stress-induced,6320,O
increase,6320,O
in,6320,O
plasma,6320,O
IL-6,6320,B-GENE-Y
level,6320,O
.,6320,O
But,6321,O
",",6321,O
intracerebroventricular,6321,O
injection,6321,O
of,6321,O
each,6321,O
ginsenoside,6321,B-CHEMICAL
did,6321,O
not,6321,O
affect,6321,O
plasma,6321,O
IL-6,6321,B-GENE-Y
level,6321,O
induced,6321,O
by,6321,O
immobilization,6321,O
stress,6321,O
.,6321,O
Ginsenosides,6322,B-CHEMICAL
Rb2,6322,I-CHEMICAL
",",6322,I-CHEMICAL
Rd,6322,I-CHEMICAL
and,6322,I-CHEMICAL
Rg1,6322,I-CHEMICAL
significantly,6322,O
decreased,6322,O
norepinephrine,6322,B-CHEMICAL
and/or,6322,O
epinephrine-induced,6322,B-CHEMICAL
increase,6322,O
of,6322,O
IL-6,6322,B-GENE-Y
level,6322,O
in,6322,O
macrophage,6322,O
cell,6322,O
line,6322,O
(,6322,O
RAW,6322,O
264.7,6322,O
),6322,O
.,6322,O
Thus,6323,O
",",6323,O
it,6323,O
can,6323,O
be,6323,O
suggested,6323,O
that,6323,O
the,6323,O
inhibitory,6323,O
action,6323,O
of,6323,O
ginseng,6323,B-CHEMICAL
saponins,6323,I-CHEMICAL
against,6323,O
the,6323,O
immobilization,6323,O
stress-induced,6323,O
increase,6323,O
of,6323,O
plasma,6323,O
IL-6,6323,B-GENE-Y
level,6323,O
would,6323,O
be,6323,O
in,6323,O
periphery,6323,O
;,6323,O
at,6323,O
least,6323,O
in,6323,O
part,6323,O
",",6323,O
mediated,6323,O
by,6323,O
blocking,6323,O
norepinephrine-,6323,B-CHEMICAL
and/or,6323,O
epinephrine-induced,6323,B-CHEMICAL
increase,6323,O
of,6323,O
IL-6,6323,B-GENE-Y
level,6323,O
in,6323,O
macrophage,6323,O
rather,6323,O
than,6323,O
in,6323,O
the,6323,O
brain,6323,O
.,6323,O
Ginseng,6324,B-CHEMICAL
saponins,6324,I-CHEMICAL
might,6324,O
be,6324,O
proposed,6324,O
as,6324,O
a,6324,O
possible,6324,O
candidate,6324,O
in,6324,O
the,6324,O
research,6324,O
or,6324,O
therapeutic,6324,O
modulation,6324,O
of,6324,O
stress-related,6324,O
disorders,6324,O
.,6324,O
Sitagliptin,6325,B-CHEMICAL
.,6325,O
Sitagliptin,6326,B-CHEMICAL
",",6326,O
an,6326,O
oral,6326,O
dipeptidyl,6326,B-GENE-Y
peptidase-4,6326,I-GENE-Y
(,6326,O
DPP-4,6326,B-GENE-Y
),6326,O
inhibitor,6326,O
",",6326,O
improves,6326,O
glycaemic,6326,O
control,6326,O
by,6326,O
inhibiting,6326,O
DPP-4,6326,B-GENE-Y
inactivation,6326,O
of,6326,O
the,6326,O
incretin,6326,B-GENE-N
hormones,6326,I-GENE-N
glucagon-like,6326,B-GENE-Y
peptide-1,6326,I-GENE-Y
and,6326,O
glucose-dependent,6326,B-GENE-Y
insulinotropic,6326,I-GENE-Y
polypeptide,6326,I-GENE-Y
.,6326,O
This,6327,O
increases,6327,O
active,6327,O
incretin,6327,B-GENE-N
and,6327,O
insulin,6327,B-GENE-Y
levels,6327,O
",",6327,O
and,6327,O
decreases,6327,O
glucagon,6327,B-GENE-Y
levels,6327,O
and,6327,O
post-glucose-load,6327,O
glucose,6327,B-CHEMICAL
excursion,6327,O
.,6327,O
In,6328,O
large,6328,O
",",6328,O
well,6328,O
designed,6328,O
phase,6328,O
III,6328,O
trials,6328,O
in,6328,O
patients,6328,O
with,6328,O
type,6328,O
2,6328,O
diabetes,6328,O
mellitus,6328,O
",",6328,O
sitagliptin,6328,B-CHEMICAL
100,6328,O
or,6328,O
200mg,6328,O
once,6328,O
daily,6328,O
alone,6328,O
or,6328,O
in,6328,O
combination,6328,O
with,6328,O
other,6328,O
antihyperglycaemics,6328,O
was,6328,O
associated,6328,O
with,6328,O
significant,6328,O
improvements,6328,O
relative,6328,O
to,6328,O
placebo,6328,O
in,6328,O
overall,6328,O
glycaemic,6328,O
control,6328,O
and,6328,O
indices,6328,O
for,6328,O
insulin,6328,B-GENE-Y
response,6328,O
and,6328,O
beta-cell,6328,O
function,6328,O
.,6328,O
Improvements,6329,O
from,6329,O
baseline,6329,O
in,6329,O
mean,6329,O
glycosylated,6329,B-GENE-Y
haemoglobin,6329,I-GENE-Y
(,6329,O
HbA,6329,B-GENE-Y
(,6329,I-GENE-Y
1c,6329,I-GENE-Y
),6329,I-GENE-Y
),6329,O
were,6329,O
significantly,6329,O
greater,6329,O
with,6329,O
sitagliptin,6329,B-CHEMICAL
monotherapy,6329,O
than,6329,O
with,6329,O
placebo,6329,O
in,6329,O
patients,6329,O
with,6329,O
type,6329,O
2,6329,O
diabetes,6329,O
.,6329,O
As,6330,O
add-on,6330,O
therapy,6330,O
in,6330,O
patients,6330,O
with,6330,O
suboptimal,6330,O
glycaemic,6330,O
control,6330,O
despite,6330,O
oral,6330,O
antihyperglycaemic,6330,O
treatment,6330,O
",",6330,O
sitagliptin,6330,B-CHEMICAL
improved,6330,O
HbA,6330,B-GENE-Y
(,6330,I-GENE-Y
1c,6330,I-GENE-Y
),6330,I-GENE-Y
to,6330,O
a,6330,O
significantly,6330,O
greater,6330,O
extent,6330,O
than,6330,O
placebo,6330,O
when,6330,O
added,6330,O
to,6330,O
metformin,6330,B-CHEMICAL
or,6330,O
pioglitazone,6330,B-CHEMICAL
and,6330,O
was,6330,O
noninferior,6330,O
to,6330,O
glipizide,6330,B-CHEMICAL
when,6330,O
added,6330,O
to,6330,O
metformin,6330,B-CHEMICAL
.,6330,O
Sitagliptin,6331,B-CHEMICAL
was,6331,O
well,6331,O
tolerated,6331,O
when,6331,O
administered,6331,O
alone,6331,O
or,6331,O
in,6331,O
combination,6331,O
with,6331,O
other,6331,O
antihyperglycaemics,6331,O
",",6331,O
with,6331,O
an,6331,O
adverse,6331,O
event,6331,O
profile,6331,O
similar,6331,O
to,6331,O
that,6331,O
shown,6331,O
with,6331,O
placebo,6331,O
.,6331,O
The,6332,O
incidence,6332,O
of,6332,O
hypoglycaemia,6332,O
with,6332,O
sitagliptin,6332,B-CHEMICAL
was,6332,O
similar,6332,O
to,6332,O
that,6332,O
with,6332,O
placebo,6332,O
and,6332,O
",",6332,O
in,6332,O
combination,6332,O
with,6332,O
metformin,6332,B-CHEMICAL
",",6332,O
lower,6332,O
than,6332,O
that,6332,O
with,6332,O
glipizide,6332,B-CHEMICAL
.,6332,O
Sitagliptin,6333,B-CHEMICAL
had,6333,O
a,6333,O
generally,6333,O
neutral,6333,O
effect,6333,O
on,6333,O
bodyweight,6333,O
.,6333,O
Streptococcus,6334,B-GENE-Y
pneumoniae,6334,I-GENE-Y
ClpP,6334,I-GENE-Y
protease,6334,B-GENE-N
induces,6334,O
apoptosis,6334,O
via,6334,O
caspase-independent,6334,B-GENE-N
pathway,6334,O
in,6334,O
human,6334,O
neuroblastoma,6334,O
cells,6334,O
:,6334,O
cytoplasmic,6334,O
relocalization,6334,O
of,6334,O
p53,6334,B-GENE-Y
.,6334,O
Streptococcus,6335,O
pneumoniae,6335,O
causes,6335,O
the,6335,O
most,6335,O
severe,6335,O
form,6335,O
of,6335,O
the,6335,O
bacterial,6335,O
meningitis,6335,O
which,6335,O
is,6335,O
the,6335,O
major,6335,O
cause,6335,O
of,6335,O
bacterial,6335,O
meningitis,6335,O
.,6335,O
Virulence,6336,O
factors,6336,O
produced,6336,O
by,6336,O
S.,6336,O
pneumoniae,6336,O
have,6336,O
been,6336,O
known,6336,O
to,6336,O
contribute,6336,O
significantly,6336,O
to,6336,O
the,6336,O
disease,6336,O
process,6336,O
.,6336,O
ClpP,6337,B-GENE-Y
protease,6337,B-GENE-N
(,6337,O
ClpP,6337,B-GENE-Y
),6337,O
which,6337,O
is,6337,O
essential,6337,O
for,6337,O
virulence,6337,O
and,6337,O
survival,6337,O
under,6337,O
stress,6337,O
conditions,6337,O
in,6337,O
S.,6337,O
pneumonia,6337,O
was,6337,O
examined,6337,O
for,6337,O
the,6337,O
ability,6337,O
to,6337,O
induce,6337,O
apoptosis,6337,O
and,6337,O
the,6337,O
mechanism,6337,O
of,6337,O
the,6337,O
induction,6337,O
of,6337,O
apoptosis,6337,O
in,6337,O
human,6337,O
neuron-like,6337,O
cells,6337,O
",",6337,O
SK-N-SH,6337,O
neuroblastoma,6337,O
cells,6337,O
.,6337,O
ClpP,6338,B-GENE-Y
inhibited,6338,O
cell,6338,O
growth,6338,O
and,6338,O
induced,6338,O
apoptosis,6338,O
in,6338,O
SK-N-SH,6338,O
cells,6338,O
.,6338,O
Treatment,6339,O
with,6339,O
ClpP,6339,B-GENE-Y
resulted,6339,O
in,6339,O
hypodiploid,6339,O
DNA,6339,O
contents,6339,O
",",6339,O
increased,6339,O
Bax/,6339,B-GENE-Y
Bcl-2,6339,B-GENE-Y
ratio,6339,O
and,6339,O
induction,6339,O
of,6339,O
reactive,6339,O
oxygen,6339,B-CHEMICAL
species,6339,O
(,6339,O
ROS,6339,O
),6339,O
production,6339,O
.,6339,O
The,6340,O
release,6340,O
of,6340,O
cytochrome,6340,B-GENE-Y
c,6340,I-GENE-Y
from,6340,O
mitochondria,6340,O
into,6340,O
the,6340,O
cytosol,6340,O
",",6340,O
which,6340,O
is,6340,O
an,6340,O
initiator,6340,O
of,6340,O
the,6340,O
activation,6340,O
of,6340,O
caspase,6340,B-GENE-N
cascades,6340,O
",",6340,O
was,6340,O
not,6340,O
observed,6340,O
in,6340,O
ClpP-treated,6340,B-GENE-Y
cells,6340,O
.,6340,O
In,6341,O
addition,6341,O
",",6341,O
pretreatment,6341,O
with,6341,O
Z-Val-Ala-Asp-fluoromethylketone,6341,B-CHEMICAL
(,6341,O
Z-VAD-fmk,6341,B-CHEMICAL
),6341,O
",",6341,O
a,6341,O
broad,6341,O
spectrum,6341,O
of,6341,O
caspase,6341,B-GENE-N
inhibitor,6341,O
",",6341,O
could,6341,O
not,6341,O
rescue,6341,O
apoptotic,6341,O
cells,6341,O
from,6341,O
ClpP,6341,B-GENE-Y
toxicity,6341,O
.,6341,O
Coincidently,6342,O
",",6342,O
caspase-3,6342,B-GENE-N
and,6342,I-GENE-N
-8,6342,I-GENE-N
activation,6342,O
and,6342,O
cleavage,6342,O
of,6342,O
PARP,6342,B-GENE-N
were,6342,O
not,6342,O
detected,6342,O
.,6342,O
Moreover,6343,O
",",6343,O
caspase,6343,B-GENE-N
independent,6343,O
apoptosis-inducing,6343,B-GENE-Y
factor,6343,I-GENE-Y
(,6343,O
AIF,6343,B-GENE-Y
),6343,O
was,6343,O
released,6343,O
from,6343,O
mitochondria,6343,O
and,6343,O
translocated,6343,O
to,6343,O
the,6343,O
nucleus,6343,O
in,6343,O
response,6343,O
to,6343,O
ClpP,6343,B-GENE-Y
.,6343,O
We,6344,O
also,6344,O
found,6344,O
that,6344,O
ClpP,6344,B-GENE-Y
treatment,6344,O
resulted,6344,O
in,6344,O
the,6344,O
increase,6344,O
of,6344,O
p53,6344,B-GENE-Y
activity,6344,O
and,6344,O
cytoplasmic,6344,O
p53,6344,B-GENE-Y
levels,6344,O
were,6344,O
increased,6344,O
by,6344,O
ClpP,6344,B-GENE-Y
",",6344,O
suggesting,6344,O
that,6344,O
functional,6344,O
activation,6344,O
of,6344,O
p53,6344,B-GENE-Y
is,6344,O
intact,6344,O
despite,6344,O
increased,6344,O
cytoplasmic,6344,O
accumulation,6344,O
.,6344,O
Taken,6345,O
together,6345,O
",",6345,O
these,6345,O
data,6345,O
suggest,6345,O
that,6345,O
ClpP,6345,B-GENE-Y
contributes,6345,O
to,6345,O
neuronal,6345,O
damage,6345,O
in,6345,O
meningitis,6345,O
and,6345,O
provide,6345,O
further,6345,O
insight,6345,O
into,6345,O
the,6345,O
mechanisms,6345,O
underlying,6345,O
action,6345,O
of,6345,O
pneumococcal,6345,O
virulence,6345,O
factors,6345,O
during,6345,O
bacterial,6345,O
pathogenesis,6345,O
.,6345,O
New,6346,O
aspects,6346,O
in,6346,O
the,6346,O
management,6346,O
of,6346,O
obesity,6346,O
:,6346,O
operation,6346,O
and,6346,O
the,6346,O
impact,6346,O
of,6346,O
lipase,6346,B-GENE-N
inhibitors,6346,O
.,6346,O
Obesity,6347,O
is,6347,O
an,6347,O
increasing,6347,O
health,6347,O
problem,6347,O
in,6347,O
most,6347,O
developed,6347,O
countries,6347,O
and,6347,O
its,6347,O
prevalence,6347,O
is,6347,O
also,6347,O
increasing,6347,O
in,6347,O
developing,6347,O
countries,6347,O
.,6347,O
There,6348,O
has,6348,O
been,6348,O
no,6348,O
great,6348,O
success,6348,O
with,6348,O
dietary,6348,O
means,6348,O
and,6348,O
life,6348,O
style,6348,O
modification,6348,O
for,6348,O
permanent,6348,O
weight,6348,O
loss,6348,O
.,6348,O
Various,6349,O
surgical,6349,O
treatment,6349,O
methods,6349,O
for,6349,O
obesity,6349,O
are,6349,O
now,6349,O
available,6349,O
.,6349,O
They,6350,O
are,6350,O
aimed,6350,O
at,6350,O
limiting,6350,O
oral,6350,O
energy,6350,O
intake,6350,O
with,6350,O
or,6350,O
without,6350,O
causing,6350,O
dumping,6350,O
or,6350,O
inducing,6350,O
selective,6350,O
maldigestion,6350,O
and,6350,O
malabsorption,6350,O
.,6350,O
Based,6351,O
on,6351,O
current,6351,O
literature,6351,O
",",6351,O
up,6351,O
to,6351,O
75,6351,O
%,6351,O
of,6351,O
excess,6351,O
weight,6351,O
is,6351,O
lost,6351,O
by,6351,O
surgical,6351,O
treatment,6351,O
with,6351,O
concomitant,6351,O
disappearance,6351,O
of,6351,O
hyperlipidaemias,6351,O
",",6351,O
type,6351,O
2,6351,O
diabetes,6351,O
",",6351,O
hypertension,6351,O
or,6351,O
sleep,6351,O
apnoea,6351,O
.,6351,O
The,6352,O
main,6352,O
indication,6352,O
for,6352,O
operative,6352,O
treatment,6352,O
is,6352,O
morbid,6352,O
obesity,6352,O
(,6352,O
body,6352,O
mass,6352,O
index,6352,O
greater,6352,O
than,6352,O
40,6352,O
kg/m2,6352,O
),6352,O
or,6352,O
severe,6352,O
obesity,6352,O
(,6352,O
body,6352,O
mass,6352,O
index,6352,O
>,6352,O
35,6352,O
kg/m2,6352,O
),6352,O
with,6352,O
comorbidities,6352,O
of,6352,O
obesity,6352,O
.,6352,O
Orlistat,6353,B-CHEMICAL
is,6353,O
a,6353,O
new,6353,O
inhibitor,6353,O
of,6353,O
pancreatic,6353,B-GENE-Y
lipase,6353,I-GENE-Y
enzyme,6353,O
.,6353,O
At,6354,O
doses,6354,O
of,6354,O
120,6354,O
mg,6354,O
three,6354,O
times,6354,O
per,6354,O
day,6354,O
with,6354,O
meals,6354,O
it,6354,O
results,6354,O
in,6354,O
a,6354,O
30,6354,O
%,6354,O
reduction,6354,O
in,6354,O
dietary,6354,O
fat,6354,O
absorption,6354,O
",",6354,O
which,6354,O
equals,6354,O
approximately,6354,O
200,6354,O
kcal,6354,O
daily,6354,O
energy,6354,O
deficit,6354,O
.,6354,O
In,6355,O
the,6355,O
long,6355,O
term,6355,O
",",6355,O
orlistat,6355,B-CHEMICAL
has,6355,O
been,6355,O
shown,6355,O
to,6355,O
be,6355,O
more,6355,O
effective,6355,O
than,6355,O
placebo,6355,O
in,6355,O
reducing,6355,O
body,6355,O
weight,6355,O
and,6355,O
serum,6355,O
total,6355,O
and,6355,O
low-density,6355,B-GENE-N
lipoprotein,6355,I-GENE-N
cholesterol,6355,B-CHEMICAL
levels,6355,O
.,6355,O
Orlistat,6356,B-CHEMICAL
has,6356,O
a,6356,O
lowering,6356,O
effect,6356,O
on,6356,O
serum,6356,O
cholesterol,6356,B-CHEMICAL
independent,6356,O
of,6356,O
weight,6356,O
loss,6356,O
.,6356,O
Along,6357,O
with,6357,O
weight,6357,O
loss,6357,O
",",6357,O
orlistat,6357,B-CHEMICAL
also,6357,O
favourably,6357,O
affects,6357,O
blood,6357,O
pressure,6357,O
and,6357,O
glucose,6357,B-CHEMICAL
and,6357,O
insulin,6357,B-GENE-Y
levels,6357,O
in,6357,O
obese,6357,O
individuals,6357,O
and,6357,O
in,6357,O
obese,6357,O
type,6357,O
2,6357,O
diabetic,6357,O
patients,6357,O
.,6357,O
The,6358,O
characteristics,6358,O
of,6358,O
genistin-induced,6358,B-CHEMICAL
inhibitory,6358,O
effects,6358,O
on,6358,O
intestinal,6358,O
motility,6358,O
.,6358,O
Genistin,6359,B-CHEMICAL
belongs,6359,O
to,6359,O
isoflavones,6359,B-CHEMICAL
.,6359,O
Based,6360,O
on,6360,O
the,6360,O
facts,6360,O
that,6360,O
genistin,6360,B-CHEMICAL
exerts,6360,O
inhibitory,6360,O
effects,6360,O
on,6360,O
the,6360,O
contractility,6360,O
of,6360,O
vascular,6360,O
smooth,6360,O
muscle,6360,O
",",6360,O
the,6360,O
present,6360,O
study,6360,O
was,6360,O
designed,6360,O
to,6360,O
characterize,6360,O
the,6360,O
effects,6360,O
of,6360,O
genistin,6360,B-CHEMICAL
on,6360,O
intestinal,6360,O
contractility,6360,O
and,6360,O
evaluate,6360,O
its,6360,O
potential,6360,O
clinical,6360,O
implication,6360,O
.,6360,O
Ex,6361,O
vivo,6361,O
[,6361,O
isolated,6361,O
jejunal,6361,O
segment,6361,O
(,6361,O
IJS,6361,O
),6361,O
of,6361,O
rat,6361,O
],6361,O
",",6361,O
in,6361,O
vitro,6361,O
",",6361,O
and,6361,O
in,6361,O
vivo,6361,O
assays,6361,O
were,6361,O
used,6361,O
in,6361,O
the,6361,O
study,6361,O
.,6361,O
The,6362,O
results,6362,O
indicated,6362,O
that,6362,O
genistin,6362,B-CHEMICAL
(,6362,O
5-80,6362,O
μmol/L,6362,O
),6362,O
inhibited,6362,O
the,6362,O
contraction,6362,O
of,6362,O
IJS,6362,O
in,6362,O
a,6362,O
dose-dependent,6362,O
manner,6362,O
and,6362,O
inhibited,6362,O
the,6362,O
increased-contractility,6362,O
of,6362,O
IJS,6362,O
induced,6362,O
by,6362,O
acetylcholine,6362,B-CHEMICAL
(,6362,O
ACh,6362,B-CHEMICAL
),6362,O
",",6362,O
histamine,6362,B-CHEMICAL
",",6362,O
high,6362,O
Ca,6362,B-CHEMICAL
(,6362,I-CHEMICAL
2+,6362,I-CHEMICAL
),6362,I-CHEMICAL
",",6362,O
and,6362,O
erythromycin,6362,B-CHEMICAL
",",6362,O
respectively,6362,O
.,6362,O
The,6363,O
inhibitory,6363,O
effects,6363,O
of,6363,O
genistin,6363,B-CHEMICAL
were,6363,O
correlated,6363,O
with,6363,O
the,6363,O
stimulation,6363,O
of,6363,O
alpha,6363,B-GENE-N
adrenergic,6363,I-GENE-N
and,6363,I-GENE-N
beta,6363,I-GENE-N
adrenergic,6363,I-GENE-N
receptors,6363,I-GENE-N
since,6363,O
these,6363,O
inhibitory,6363,O
effects,6363,O
were,6363,O
significantly,6363,O
blocked,6363,O
in,6363,O
the,6363,O
presence,6363,O
of,6363,O
phentolamine,6363,B-CHEMICAL
and,6363,O
propranolol,6363,B-CHEMICAL
respectively,6363,O
.,6363,O
No,6364,O
further,6364,O
inhibitory,6364,O
effects,6364,O
of,6364,O
genistin,6364,B-CHEMICAL
were,6364,O
observed,6364,O
in,6364,O
the,6364,O
presence,6364,O
of,6364,O
verapamil,6364,B-CHEMICAL
or,6364,O
in,6364,O
Ca,6364,B-CHEMICAL
(,6364,I-CHEMICAL
2+,6364,I-CHEMICAL
),6364,I-CHEMICAL
-free,6364,O
condition,6364,O
",",6364,O
indicating,6364,O
genistin-induced,6364,B-CHEMICAL
inhibitory,6364,O
effects,6364,O
are,6364,O
Ca,6364,B-CHEMICAL
(,6364,I-CHEMICAL
2+,6364,I-CHEMICAL
),6364,I-CHEMICAL
-dependent,6364,O
.,6364,O
Genistin,6365,B-CHEMICAL
decreased,6365,O
myosin,6365,B-GENE-Y
light,6365,I-GENE-Y
chain,6365,I-GENE-Y
kinase,6365,I-GENE-Y
(,6365,O
MLCK,6365,B-GENE-Y
),6365,O
protein,6365,O
contents,6365,O
and,6365,O
MLCK,6365,B-GENE-Y
mRNA,6365,O
expression,6365,O
in,6365,O
IJS,6365,O
",",6365,O
and,6365,O
inhibited,6365,O
both,6365,O
phosphorylation,6365,O
and,6365,O
Mg,6365,B-CHEMICAL
(,6365,I-CHEMICAL
2+,6365,I-CHEMICAL
),6365,I-CHEMICAL
-ATPase,6365,O
activity,6365,O
of,6365,O
purified,6365,O
myosin,6365,O
",",6365,O
implicating,6365,O
that,6365,O
the,6365,O
decrease,6365,O
of,6365,O
MLCK,6365,B-GENE-Y
contents,6365,O
and,6365,O
inhibition,6365,O
of,6365,O
MLCK,6365,B-GENE-Y
activity,6365,O
are,6365,O
involved,6365,O
in,6365,O
the,6365,O
genistin-induced,6365,B-CHEMICAL
inhibitory,6365,O
effects,6365,O
.,6365,O
The,6366,O
study,6366,O
suggests,6366,O
the,6366,O
potential,6366,O
clinical,6366,O
implications,6366,O
of,6366,O
genistin,6366,B-CHEMICAL
in,6366,O
relieving,6366,O
intestinal,6366,O
hypercontractility,6366,O
.,6366,O
Contribution,6367,O
of,6367,O
single-minded,6367,B-GENE-Y
2,6367,I-GENE-Y
to,6367,O
hyperglycaemia-induced,6367,O
neurotoxicity,6367,O
.,6367,O
Diabetes,6368,O
mellitus,6368,O
is,6368,O
associated,6368,O
to,6368,O
central,6368,O
nervous,6368,O
system,6368,O
damage,6368,O
",",6368,O
which,6368,O
results,6368,O
in,6368,O
impairment,6368,O
of,6368,O
brain,6368,O
functions,6368,O
and,6368,O
cognitive,6368,O
deficits,6368,O
and,6368,O
decline,6368,O
in,6368,O
memory,6368,O
.,6368,O
However,6369,O
",",6369,O
the,6369,O
mechanisms,6369,O
mediating,6369,O
the,6369,O
actions,6369,O
of,6369,O
glucose,6369,B-CHEMICAL
on,6369,O
the,6369,O
neurons,6369,O
remained,6369,O
elusive,6369,O
.,6369,O
Single-minded,6370,B-GENE-Y
2,6370,I-GENE-Y
(,6370,O
Sim2,6370,B-GENE-Y
),6370,O
",",6370,O
a,6370,O
basic,6370,B-GENE-N
helix-loop-helix,6370,I-GENE-N
(,6370,O
bHLH,6370,B-GENE-N
),6370,O
-PAS,6370,O
transcriptional,6370,O
repressor,6370,O
",",6370,O
is,6370,O
thought,6370,O
to,6370,O
be,6370,O
involved,6370,O
in,6370,O
some,6370,O
symptoms,6370,O
of,6370,O
Down,6370,O
syndrome,6370,O
.,6370,O
We,6371,O
hypothesized,6371,O
that,6371,O
Sim2,6371,B-GENE-Y
mediated,6371,O
hyperglycaemia-induced,6371,O
neuronal,6371,O
injury,6371,O
and,6371,O
impairment,6371,O
of,6371,O
learning,6371,O
and,6371,O
memory,6371,O
.,6371,O
It,6372,O
was,6372,O
found,6372,O
that,6372,O
expression,6372,O
of,6372,O
Sim2,6372,B-GENE-Y
protein,6372,O
in,6372,O
cortical,6372,O
neurons,6372,O
was,6372,O
increased,6372,O
in,6372,O
streptozotocin-induced,6372,B-CHEMICAL
diabetes,6372,O
mellitus,6372,O
rat,6372,O
model,6372,O
.,6372,O
Drebrin,6373,B-GENE-Y
",",6373,O
down-regulated,6373,O
by,6373,O
Sim2,6373,B-GENE-Y
",",6373,O
was,6373,O
subsequently,6373,O
decreased,6373,O
as,6373,O
detected,6373,O
by,6373,O
confocal,6373,O
laser,6373,O
scanning,6373,O
microscopy,6373,O
and,6373,O
Western,6373,O
blot,6373,O
analysis,6373,O
.,6373,O
The,6374,O
expression,6374,O
pattern,6374,O
of,6374,O
Sim2,6374,B-GENE-Y
and,6374,O
Drebrin,6374,B-GENE-Y
correspond,6374,O
to,6374,O
50mmol/L,6374,O
glucose,6374,B-CHEMICAL
(,6374,O
hyperglycaemia,6374,O
),6374,O
was,6374,O
also,6374,O
found,6374,O
in,6374,O
primary,6374,O
cultured,6374,O
neurons,6374,O
.,6374,O
Curcumin,6375,B-CHEMICAL
",",6375,O
one,6375,O
neuroprotective,6375,O
agent,6375,O
",",6375,O
inhibited,6375,O
hyperglycaemia-induced,6375,O
neurotoxicity,6375,O
.,6375,O
Moreover,6376,O
",",6376,O
curcumin,6376,B-CHEMICAL
alleviated,6376,O
Sim2,6376,B-GENE-Y
expression,6376,O
",",6376,O
and,6376,O
reversely,6376,O
raised,6376,O
Drebrin,6376,B-GENE-Y
expression,6376,O
in,6376,O
neurons,6376,O
treated,6376,O
with,6376,O
hyperglycaemia,6376,O
.,6376,O
Finally,6377,O
",",6377,O
we,6377,O
found,6377,O
that,6377,O
silencing,6377,O
Sim2,6377,B-GENE-Y
expression,6377,O
decreased,6377,O
hyperglycaemia-induced,6377,O
neuronal,6377,O
injury,6377,O
.,6377,O
In,6378,O
conclusion,6378,O
",",6378,O
Sim2,6378,B-GENE-Y
may,6378,O
mediate,6378,O
neurotoxicity,6378,O
during,6378,O
hyperglycaemia,6378,O
and,6378,O
thereby,6378,O
play,6378,O
a,6378,O
critical,6378,O
role,6378,O
in,6378,O
the,6378,O
development,6378,O
of,6378,O
hyperglycaemia-induced,6378,O
cognitive,6378,O
deficits,6378,O
.,6378,O
Global,6379,O
analysis,6379,O
of,6379,O
Drosophila,6379,B-GENE-N
Cys2-His2,6379,I-GENE-N
zinc,6379,I-GENE-N
finger,6379,I-GENE-N
proteins,6379,I-GENE-N
reveals,6379,O
a,6379,O
multitude,6379,O
of,6379,O
novel,6379,O
recognition,6379,O
motifs,6379,O
and,6379,O
binding,6379,O
determinants,6379,O
.,6379,O
Cys2-His2,6380,B-GENE-N
zinc,6380,I-GENE-N
finger,6380,I-GENE-N
proteins,6380,I-GENE-N
(,6380,O
ZFPs,6380,B-GENE-N
),6380,O
are,6380,O
the,6380,O
largest,6380,O
group,6380,O
of,6380,O
transcription,6380,O
factors,6380,O
in,6380,O
higher,6380,O
metazoans,6380,O
.,6380,O
A,6381,O
complete,6381,O
characterization,6381,O
of,6381,O
these,6381,O
ZFPs,6381,B-GENE-N
and,6381,O
their,6381,O
associated,6381,O
target,6381,O
sequences,6381,O
is,6381,O
pivotal,6381,O
to,6381,O
fully,6381,O
annotate,6381,O
transcriptional,6381,O
regulatory,6381,O
networks,6381,O
in,6381,O
metazoan,6381,O
genomes,6381,O
.,6381,O
As,6382,O
a,6382,O
first,6382,O
step,6382,O
in,6382,O
this,6382,O
process,6382,O
",",6382,O
we,6382,O
have,6382,O
characterized,6382,O
the,6382,O
DNA-binding,6382,O
specificities,6382,O
of,6382,O
129,6382,O
zinc,6382,B-GENE-N
finger,6382,I-GENE-N
sets,6382,O
from,6382,O
Drosophila,6382,O
using,6382,O
a,6382,O
bacterial,6382,O
one-hybrid,6382,O
system,6382,O
.,6382,O
This,6383,O
data,6383,O
set,6383,O
contains,6383,O
the,6383,O
DNA-binding,6383,O
specificities,6383,O
for,6383,O
at,6383,O
least,6383,O
one,6383,O
encoded,6383,O
ZFP,6383,B-GENE-N
from,6383,O
70,6383,O
unique,6383,O
genes,6383,O
and,6383,O
23,6383,O
alternate,6383,O
splice,6383,O
isoforms,6383,O
representing,6383,O
the,6383,O
largest,6383,O
set,6383,O
of,6383,O
characterized,6383,O
ZFPs,6383,B-GENE-N
from,6383,O
any,6383,O
organism,6383,O
described,6383,O
to,6383,O
date,6383,O
.,6383,O
These,6384,O
recognition,6384,O
motifs,6384,O
can,6384,O
be,6384,O
used,6384,O
to,6384,O
predict,6384,O
genomic,6384,O
binding,6384,O
sites,6384,O
for,6384,O
these,6384,O
factors,6384,O
within,6384,O
the,6384,O
fruit,6384,O
fly,6384,O
genome,6384,O
.,6384,O
Subsets,6385,O
of,6385,O
fingers,6385,O
from,6385,O
these,6385,O
ZFPs,6385,B-GENE-N
were,6385,O
characterized,6385,O
to,6385,O
define,6385,O
their,6385,O
orientation,6385,O
and,6385,O
register,6385,O
on,6385,O
their,6385,O
recognition,6385,O
sequences,6385,O
",",6385,O
thereby,6385,O
allowing,6385,O
us,6385,O
to,6385,O
define,6385,O
the,6385,O
recognition,6385,O
diversity,6385,O
within,6385,O
this,6385,O
finger,6385,O
set,6385,O
.,6385,O
We,6386,O
find,6386,O
that,6386,O
the,6386,O
characterized,6386,O
fingers,6386,O
can,6386,O
specify,6386,O
47,6386,O
of,6386,O
the,6386,O
64,6386,O
possible,6386,O
DNA,6386,O
triplets,6386,O
.,6386,O
To,6387,O
confirm,6387,O
the,6387,O
utility,6387,O
of,6387,O
our,6387,O
finger,6387,O
recognition,6387,O
models,6387,O
",",6387,O
we,6387,O
employed,6387,O
subsets,6387,O
of,6387,O
Drosophila,6387,O
fingers,6387,O
in,6387,O
combination,6387,O
with,6387,O
an,6387,O
existing,6387,O
archive,6387,O
of,6387,O
artificial,6387,O
zinc,6387,B-GENE-N
finger,6387,I-GENE-N
modules,6387,O
to,6387,O
create,6387,O
ZFPs,6387,B-GENE-N
with,6387,O
novel,6387,O
DNA-binding,6387,O
specificity,6387,O
.,6387,O
These,6388,O
hybrids,6388,O
of,6388,O
natural,6388,O
and,6388,O
artificial,6388,O
fingers,6388,O
can,6388,O
be,6388,O
used,6388,O
to,6388,O
create,6388,O
functional,6388,O
zinc,6388,B-GENE-N
finger,6388,I-GENE-N
nucleases,6388,I-GENE-N
for,6388,O
editing,6388,O
vertebrate,6388,O
genomes,6388,O
.,6388,O
Polymorphisms,6389,O
in,6389,O
dopamine,6389,B-GENE-Y
transporter,6389,I-GENE-Y
(,6389,O
SLC6A3,6389,B-GENE-Y
),6389,O
are,6389,O
associated,6389,O
with,6389,O
stimulant,6389,O
effects,6389,O
of,6389,O
D-amphetamine,6389,B-CHEMICAL
:,6389,O
an,6389,O
exploratory,6389,O
pharmacogenetic,6389,O
study,6389,O
using,6389,O
healthy,6389,O
volunteers,6389,O
.,6389,O
Individuals,6390,O
vary,6390,O
in,6390,O
their,6390,O
subjective,6390,O
responses,6390,O
to,6390,O
stimulant,6390,O
drugs,6390,O
",",6390,O
and,6390,O
these,6390,O
differences,6390,O
are,6390,O
believed,6390,O
to,6390,O
be,6390,O
partially,6390,O
genetic,6390,O
in,6390,O
origin,6390,O
.,6390,O
We,6391,O
evaluated,6391,O
associations,6391,O
between,6391,O
mood,6391,O
",",6391,O
cognitive,6391,O
and,6391,O
cardiovascular,6391,O
responses,6391,O
to,6391,O
d-amphetamine,6391,B-CHEMICAL
and,6391,O
four,6391,O
polymorphisms,6391,O
in,6391,O
the,6391,O
dopamine,6391,B-GENE-Y
transporter,6391,I-GENE-Y
(,6391,O
SLC6A3,6391,B-GENE-Y
),6391,O
:,6391,O
rs460000,6391,O
",",6391,O
rs3756450,6391,O
",",6391,O
rs37022,6391,O
and,6391,O
rs6869645,6391,O
.,6391,O
Healthy,6392,O
Caucasian,6392,O
male,6392,O
and,6392,O
female,6392,O
volunteers,6392,O
(,6392,O
N,6392,O
=,6392,O
152,6392,O
),6392,O
participated,6392,O
in,6392,O
a,6392,O
double-blind,6392,O
",",6392,O
crossover,6392,O
design,6392,O
study,6392,O
in,6392,O
which,6392,O
they,6392,O
received,6392,O
placebo,6392,O
",",6392,O
10,6392,O
and,6392,O
20,6392,O
mg,6392,O
of,6392,O
d-amphetamine,6392,B-CHEMICAL
.,6392,O
We,6393,O
measured,6393,O
self-reported,6393,O
rating,6393,O
of,6393,O
mood,6393,O
",",6393,O
performance,6393,O
on,6393,O
the,6393,O
Digit,6393,O
Symbol,6393,O
Substitution,6393,O
Task,6393,O
",",6393,O
blood,6393,O
pressure,6393,O
and,6393,O
heart,6393,O
rate,6393,O
.,6393,O
Individuals,6394,O
with,6394,O
the,6394,O
C/C,6394,O
genotype,6394,O
at,6394,O
rs460000,6394,O
(,6394,O
N,6394,O
=,6394,O
83,6394,O
),6394,O
reported,6394,O
approximately,6394,O
twofold,6394,O
higher,6394,O
ratings,6394,O
of,6394,O
stimulation,6394,O
and,6394,O
euphoria,6394,O
relative,6394,O
to,6394,O
the,6394,O
A/A+A/C,6394,O
(,6394,O
N,6394,O
=,6394,O
69,6394,O
),6394,O
genotype,6394,O
group,6394,O
",",6394,O
at,6394,O
both,6394,O
the,6394,O
10,6394,O
and,6394,O
20,6394,O
mg,6394,O
doses,6394,O
.,6394,O
No,6395,O
other,6395,O
responses,6395,O
or,6395,O
SNPs,6395,O
showed,6395,O
significant,6395,O
effects,6395,O
.,6395,O
rs460000,6396,O
is,6396,O
in,6396,O
perfect,6396,O
LD,6396,O
with,6396,O
rs463379,6396,O
(,6396,O
CEU,6396,O
:,6396,O
D,6396,O
',6396,O
=,6396,O
1,6396,O
;,6396,O
r,6396,O
(,6396,O
2,6396,O
),6396,O
=,6396,O
1,6396,O
),6396,O
",",6396,O
which,6396,O
was,6396,O
not,6396,O
studied,6396,O
here,6396,O
",",6396,O
but,6396,O
has,6396,O
been,6396,O
associated,6396,O
with,6396,O
etiology,6396,O
of,6396,O
Attention,6396,O
Deficit,6396,O
Hyperactivity,6396,O
Disorder,6396,O
(,6396,O
ADHD,6396,O
),6396,O
.,6396,O
These,6397,O
findings,6397,O
suggest,6397,O
a,6397,O
pleiotropic,6397,O
effect,6397,O
of,6397,O
this,6397,O
polymorphic,6397,O
locus,6397,O
on,6397,O
both,6397,O
ADHD,6397,O
and,6397,O
sensitivity,6397,O
to,6397,O
the,6397,O
subjective,6397,O
effects,6397,O
of,6397,O
amphetamine,6397,B-CHEMICAL
.,6397,O
The,6398,O
structure,6398,O
and,6398,O
properties,6398,O
of,6398,O
septin,6398,B-GENE-Y
3,6398,I-GENE-Y
:,6398,O
a,6398,O
possible,6398,O
missing,6398,O
link,6398,O
in,6398,O
septin,6398,B-GENE-N
filament,6398,O
formation,6398,O
.,6398,O
The,6399,O
human,6399,O
genome,6399,O
codes,6399,O
for,6399,O
13,6399,O
members,6399,O
of,6399,O
a,6399,O
family,6399,O
of,6399,O
filament-forming,6399,O
GTP-binding,6399,B-GENE-N
proteins,6399,I-GENE-N
known,6399,O
as,6399,O
septins,6399,B-GENE-N
.,6399,O
These,6400,O
have,6400,O
been,6400,O
divided,6400,O
into,6400,O
four,6400,O
different,6400,O
subgroups,6400,O
on,6400,O
the,6400,O
basis,6400,O
of,6400,O
sequence,6400,O
similarity,6400,O
.,6400,O
The,6401,O
differences,6401,O
between,6401,O
the,6401,O
subgroups,6401,O
are,6401,O
believed,6401,O
to,6401,O
control,6401,O
their,6401,O
correct,6401,O
assembly,6401,O
into,6401,O
heterofilaments,6401,O
which,6401,O
have,6401,O
specific,6401,O
roles,6401,O
in,6401,O
membrane,6401,O
remodelling,6401,O
events,6401,O
.,6401,O
Many,6402,O
different,6402,O
combinations,6402,O
of,6402,O
the,6402,O
13,6402,O
proteins,6402,O
are,6402,O
theoretically,6402,O
possible,6402,O
and,6402,O
it,6402,O
is,6402,O
therefore,6402,O
important,6402,O
to,6402,O
understand,6402,O
the,6402,O
structural,6402,O
basis,6402,O
of,6402,O
specific,6402,O
filament,6402,O
assembly,6402,O
.,6402,O
However,6403,O
",",6403,O
three-dimensional,6403,O
structures,6403,O
are,6403,O
currently,6403,O
available,6403,O
for,6403,O
only,6403,O
three,6403,O
of,6403,O
the,6403,O
four,6403,O
subgroups,6403,O
.,6403,O
In,6404,O
the,6404,O
present,6404,O
study,6404,O
we,6404,O
describe,6404,O
the,6404,O
crystal,6404,O
structure,6404,O
of,6404,O
a,6404,O
construct,6404,O
of,6404,O
human,6404,B-GENE-Y
SEPT3,6404,I-GENE-Y
which,6404,O
belongs,6404,O
to,6404,O
the,6404,O
outstanding,6404,O
subgroup,6404,O
.,6404,O
This,6405,O
construct,6405,O
(,6405,O
SEPT3-GC,6405,B-GENE-Y
),6405,O
",",6405,O
which,6405,O
includes,6405,O
the,6405,O
GTP-binding,6405,B-GENE-N
and,6405,I-GENE-N
C-terminal,6405,I-GENE-N
domains,6405,I-GENE-N
",",6405,O
purifies,6405,O
as,6405,O
a,6405,O
nucleotide-free,6405,B-CHEMICAL
monomer,6405,O
",",6405,O
allowing,6405,O
for,6405,O
its,6405,O
characterization,6405,O
in,6405,O
terms,6405,O
of,6405,O
GTP-binding,6405,B-CHEMICAL
and,6405,O
hydrolysis,6405,O
.,6405,O
In,6406,O
the,6406,O
crystal,6406,O
structure,6406,O
",",6406,O
SEPT3-GC,6406,B-GENE-Y
forms,6406,O
foreshortened,6406,O
filaments,6406,O
which,6406,O
employ,6406,O
the,6406,O
same,6406,O
NC,6406,O
and,6406,O
G,6406,O
interfaces,6406,O
observed,6406,O
in,6406,O
the,6406,O
heterotrimeric,6406,O
complex,6406,O
of,6406,O
human,6406,B-GENE-N
septins,6406,I-GENE-N
2,6406,I-GENE-N
",",6406,I-GENE-N
6,6406,I-GENE-N
and,6406,I-GENE-N
7,6406,I-GENE-N
",",6406,O
reinforcing,6406,O
the,6406,O
notion,6406,O
of,6406,O
'promiscuous,6406,O
',6406,O
interactions,6406,O
described,6406,O
previously,6406,O
.,6406,O
In,6407,O
the,6407,O
present,6407,O
study,6407,O
we,6407,O
describe,6407,O
these,6407,O
two,6407,O
interfaces,6407,O
and,6407,O
relate,6407,O
the,6407,O
structure,6407,O
to,6407,O
its,6407,O
tendency,6407,O
to,6407,O
form,6407,O
monomers,6407,O
and,6407,O
its,6407,O
efficiency,6407,O
in,6407,O
the,6407,O
hydrolysis,6407,O
of,6407,O
GTP,6407,B-CHEMICAL
.,6407,O
The,6408,O
relevance,6408,O
of,6408,O
these,6408,O
results,6408,O
is,6408,O
emphasized,6408,O
by,6408,O
the,6408,O
fact,6408,O
that,6408,O
septins,6408,O
from,6408,O
the,6408,O
SEPT3,6408,B-GENE-Y
subgroup,6408,O
may,6408,O
be,6408,O
important,6408,O
determinants,6408,O
of,6408,O
polymerization,6408,O
by,6408,O
occupying,6408,O
the,6408,O
terminal,6408,O
position,6408,O
in,6408,O
octameric,6408,O
units,6408,O
which,6408,O
themselves,6408,O
form,6408,O
the,6408,O
building,6408,O
blocks,6408,O
of,6408,O
at,6408,O
least,6408,O
some,6408,O
heterofilaments,6408,O
.,6408,O
The,6409,O
effect,6409,O
of,6409,O
inorganic,6409,O
arsenic,6409,B-CHEMICAL
on,6409,O
endothelium-dependent,6409,O
relaxation,6409,O
:,6409,O
Role,6409,O
of,6409,O
NADPH,6409,B-GENE-N
oxidase,6409,I-GENE-N
and,6409,O
hydrogen,6409,B-CHEMICAL
peroxide,6409,I-CHEMICAL
.,6409,O
Chronic,6410,O
arsenic,6410,B-CHEMICAL
ingestion,6410,O
predisposes,6410,O
to,6410,O
vascular,6410,O
disease,6410,O
",",6410,O
but,6410,O
underlying,6410,O
mechanisms,6410,O
are,6410,O
poorly,6410,O
understood,6410,O
.,6410,O
In,6411,O
the,6411,O
present,6411,O
study,6411,O
we,6411,O
have,6411,O
analyzed,6411,O
the,6411,O
effects,6411,O
of,6411,O
short-term,6411,O
arsenite,6411,B-CHEMICAL
exposure,6411,O
on,6411,O
vascular,6411,O
function,6411,O
and,6411,O
endothelium-dependent,6411,O
relaxation,6411,O
.,6411,O
Endothelium-dependent,6412,O
relaxations,6412,O
",",6412,O
nitric,6412,B-CHEMICAL
oxide,6412,I-CHEMICAL
(,6412,O
NO,6412,B-CHEMICAL
),6412,O
and,6412,O
endothelium,6412,O
derived,6412,O
hyperpolarizing,6412,O
factor,6412,O
(,6412,O
EDHF,6412,O
),6412,O
-type,6412,O
",",6412,O
were,6412,O
studied,6412,O
in,6412,O
rabbit,6412,O
iliac,6412,O
artery,6412,O
and,6412,O
aortic,6412,O
rings,6412,O
using,6412,O
the,6412,O
G,6412,B-GENE-N
protein-coupled,6412,I-GENE-N
receptor,6412,I-GENE-N
agonist,6412,O
acetylcholine,6412,B-CHEMICAL
(,6412,O
ACh,6412,B-CHEMICAL
),6412,O
and,6412,O
by,6412,O
cyclopiazonic,6412,B-CHEMICAL
acid,6412,I-CHEMICAL
(,6412,O
CPA,6412,B-CHEMICAL
),6412,O
",",6412,O
which,6412,O
promotes,6412,O
store-operated,6412,O
Ca,6412,B-CHEMICAL
(,6412,I-CHEMICAL
2+,6412,I-CHEMICAL
),6412,I-CHEMICAL
entry,6412,O
by,6412,O
inhibiting,6412,O
the,6412,O
endothelial,6412,O
SERCA,6412,B-GENE-N
pump,6412,O
.,6412,O
Production,6413,O
of,6413,O
reactive,6413,O
oxygen,6413,B-CHEMICAL
species,6413,O
(,6413,O
ROS,6413,O
),6413,O
in,6413,O
the,6413,O
endothelium,6413,O
of,6413,O
rabbit,6413,O
aortic,6413,O
valve,6413,O
leaflets,6413,O
and,6413,O
endothelium-denuded,6413,O
RIA,6413,O
and,6413,O
aortic,6413,O
rings,6413,O
was,6413,O
assessed,6413,O
by,6413,O
imaging,6413,O
of,6413,O
dihydroethidium,6413,B-CHEMICAL
.,6413,O
In,6414,O
the,6414,O
iliac,6414,O
artery,6414,O
",",6414,O
exposure,6414,O
to,6414,O
100μM,6414,O
arsenite,6414,B-CHEMICAL
for,6414,O
30min,6414,O
potentiated,6414,O
EDHF-type,6414,O
relaxations,6414,O
evoked,6414,O
by,6414,O
both,6414,O
CPA,6414,B-CHEMICAL
and,6414,O
ACh,6414,B-CHEMICAL
.,6414,O
Potentiation,6415,O
was,6415,O
prevented,6415,O
by,6415,O
catalase,6415,B-GENE-Y
",",6415,O
the,6415,O
catalase/superoxide,6415,B-GENE-Y
dismutase,6415,I-GENE-N
mimetic,6415,O
manganese,6415,B-CHEMICAL
porphyrin,6415,I-CHEMICAL
and,6415,O
the,6415,O
NADPH,6415,B-GENE-N
oxidase,6415,I-GENE-N
inhibitor,6415,O
apocynin,6415,B-CHEMICAL
.,6415,O
By,6416,O
contrast,6416,O
in,6416,O
aortic,6416,O
rings,6416,O
",",6416,O
that,6416,O
exhibited,6416,O
negligible,6416,O
EDHF-type,6416,O
responses,6416,O
",",6416,O
endothelium-dependent,6416,O
NO-mediated,6416,B-CHEMICAL
relaxations,6416,O
evoked,6416,O
by,6416,O
CPA,6416,B-CHEMICAL
and,6416,O
ACh,6416,B-CHEMICAL
were,6416,O
unaffected,6416,O
by,6416,O
arsenite,6416,B-CHEMICAL
.,6416,O
Arsenite,6417,B-CHEMICAL
induced,6417,O
apocynin-sensitive,6417,B-CHEMICAL
increases,6417,O
in,6417,O
ROS,6417,O
production,6417,O
in,6417,O
the,6417,O
aortic,6417,O
valve,6417,O
endothelium,6417,O
",",6417,O
but,6417,O
not,6417,O
in,6417,O
the,6417,O
media,6417,O
and,6417,O
adventitia,6417,O
of,6417,O
the,6417,O
iliac,6417,O
artery,6417,O
and,6417,O
aorta,6417,O
.,6417,O
Our,6418,O
results,6418,O
suggest,6418,O
that,6418,O
arsenite,6418,B-CHEMICAL
can,6418,O
potentiate,6418,O
EDHF-type,6418,O
relaxations,6418,O
via,6418,O
a,6418,O
mechanism,6418,O
that,6418,O
is,6418,O
dependent,6418,O
on,6418,O
hydrogen,6418,B-CHEMICAL
peroxide,6418,I-CHEMICAL
",",6418,O
thus,6418,O
demonstrating,6418,O
that,6418,O
dismutation,6418,O
of,6418,O
the,6418,O
superoxide,6418,B-CHEMICAL
anion,6418,O
generated,6418,O
by,6418,O
NADPH,6418,B-GENE-N
oxidase,6418,I-GENE-N
can,6418,O
potentially,6418,O
offset,6418,O
loss,6418,O
of,6418,O
NO,6418,B-CHEMICAL
bioavailability,6418,O
under,6418,O
conditions,6418,O
of,6418,O
reduced,6418,O
eNOS,6418,B-GENE-Y
activity,6418,O
.,6418,O
By,6419,O
contrast,6419,O
",",6419,O
selective,6419,O
increases,6419,O
in,6419,O
endothelial,6419,O
ROS,6419,O
production,6419,O
following,6419,O
exposure,6419,O
to,6419,O
arsenite,6419,B-CHEMICAL
failed,6419,O
to,6419,O
modify,6419,O
relaxations,6419,O
mediated,6419,O
by,6419,O
endogenous,6419,O
NO,6419,B-CHEMICAL
.,6419,O
Anthocyanin,6420,B-CHEMICAL
",",6420,O
antioxidant,6420,O
activity,6420,O
and,6420,O
stress-induced,6420,O
gene,6420,O
expression,6420,O
in,6420,O
high,6420,O
CO2-treated,6420,B-CHEMICAL
table,6420,O
grapes,6420,O
stored,6420,O
at,6420,O
low,6420,O
temperature,6420,O
.,6420,O
A,6421,O
pretreatment,6421,O
with,6421,O
20kPa,6421,O
CO2+20,6421,B-CHEMICAL
kPa,6421,O
O2+60,6421,O
kPa,6421,O
N2,6421,B-CHEMICAL
for,6421,O
3,6421,O
days,6421,O
proved,6421,O
effective,6421,O
in,6421,O
maintaining,6421,O
the,6421,O
fruit,6421,O
quality,6421,O
and,6421,O
controlling,6421,O
decay,6421,O
in,6421,O
table,6421,O
grapes,6421,O
(,6421,O
Vitis,6421,O
vinifera,6421,O
cv,6421,O
.,6421,O
Cardinal,6422,O
),6422,O
stored,6422,O
at,6422,O
0,6422,O
degrees,6422,O
C.,6422,O
In,6422,O
the,6422,O
present,6422,O
work,6422,O
",",6422,O
we,6422,O
analyzed,6422,O
whether,6422,O
total,6422,O
anthocyanin,6422,B-CHEMICAL
content,6422,O
",",6422,O
the,6422,O
molecular,6422,O
mechanism,6422,O
implicated,6422,O
in,6422,O
their,6422,O
biosynthesis,6422,O
and,6422,O
antioxidant,6422,O
activity,6422,O
is,6422,O
related,6422,O
to,6422,O
the,6422,O
beneficial,6422,O
effect,6422,O
of,6422,O
this,6422,O
gaseous,6422,O
treatment,6422,O
.,6422,O
We,6423,O
isolated,6423,O
partial,6423,O
cDNAs,6423,O
that,6423,O
codified,6423,O
for,6423,O
enzymes,6423,O
implicated,6423,O
in,6423,O
the,6423,O
anthocyanin,6423,B-CHEMICAL
biosynthesis,6423,O
such,6423,O
as,6423,O
l-phenylalanine,6423,B-GENE-Y
ammonia-lyase,6423,I-GENE-Y
(,6423,O
PAL,6423,B-GENE-Y
),6423,O
and,6423,O
chalcone,6423,B-GENE-Y
synthase,6423,I-GENE-Y
(,6423,O
CHS,6423,B-GENE-Y
),6423,O
",",6423,O
and,6423,O
an,6423,O
antioxidant,6423,O
enzyme,6423,O
such,6423,O
as,6423,O
ascorbate,6423,B-GENE-Y
peroxidase,6423,I-GENE-Y
(,6423,O
APX,6423,B-GENE-Y
),6423,O
.,6423,O
Low,6424,O
temperatures,6424,O
induced,6424,O
an,6424,O
accumulation,6424,O
of,6424,O
total,6424,O
anthocyanin,6424,B-CHEMICAL
content,6424,O
in,6424,O
the,6424,O
skin,6424,O
of,6424,O
both,6424,O
treated,6424,O
and,6424,O
non-treated,6424,O
grapes,6424,O
",",6424,O
although,6424,O
levels,6424,O
were,6424,O
lower,6424,O
in,6424,O
CO2-treated,6424,B-CHEMICAL
fruit,6424,O
.,6424,O
By,6425,O
contrast,6425,O
",",6425,O
antioxidant,6425,O
activity,6425,O
decreased,6425,O
during,6425,O
storage,6425,O
at,6425,O
0,6425,O
degrees,6425,O
C,6425,O
in,6425,O
non-treated,6425,O
grapes,6425,O
but,6425,O
did,6425,O
not,6425,O
change,6425,O
in,6425,O
CO2-treated,6425,B-CHEMICAL
grapes,6425,O
.,6425,O
The,6426,O
up-regulation,6426,O
of,6426,O
anthocyanin,6426,B-CHEMICAL
biosynthesis,6426,O
gene,6426,O
expression,6426,O
and,6426,O
VcAPX,6426,B-GENE-Y
mRNA,6426,O
observed,6426,O
in,6426,O
non-treated,6426,O
grape,6426,O
is,6426,O
not,6426,O
enhanced,6426,O
in,6426,O
CO2-treated,6426,B-CHEMICAL
grapes,6426,O
",",6426,O
which,6426,O
presented,6426,O
low,6426,O
total,6426,O
decay,6426,O
.,6426,O
These,6427,O
results,6427,O
point,6427,O
out,6427,O
the,6427,O
ability,6427,O
of,6427,O
CO2-treated,6427,B-CHEMICAL
grapes,6427,O
to,6427,O
prevent,6427,O
the,6427,O
generation,6427,O
of,6427,O
reactive,6427,O
oxygen,6427,B-CHEMICAL
species,6427,O
rather,6427,O
than,6427,O
their,6427,O
inactivation,6427,O
by,6427,O
means,6427,O
of,6427,O
induction,6427,O
of,6427,O
studied,6427,O
defense,6427,O
systems,6427,O
.,6427,O
MUC1-C,6428,B-GENE-Y
oncoprotein,6428,O
as,6428,O
a,6428,O
target,6428,O
in,6428,O
breast,6428,O
cancer,6428,O
:,6428,O
activation,6428,O
of,6428,O
signaling,6428,O
pathways,6428,O
and,6428,O
therapeutic,6428,O
approaches,6428,O
.,6428,O
Mucin,6429,B-GENE-Y
1,6429,I-GENE-Y
(,6429,O
MUC1,6429,B-GENE-Y
),6429,O
is,6429,O
a,6429,O
heterodimeric,6429,O
protein,6429,O
formed,6429,O
by,6429,O
two,6429,O
subunits,6429,O
that,6429,O
is,6429,O
aberrantly,6429,O
overexpressed,6429,O
in,6429,O
human,6429,O
breast,6429,O
cancer,6429,O
and,6429,O
other,6429,O
cancers,6429,O
.,6429,O
Historically,6430,O
",",6430,O
much,6430,O
of,6430,O
the,6430,O
early,6430,O
work,6430,O
on,6430,O
MUC1,6430,B-GENE-Y
focused,6430,O
on,6430,O
the,6430,O
shed,6430,O
mucin,6430,B-GENE-N
subunit,6430,O
.,6430,O
However,6431,O
",",6431,O
more,6431,O
recent,6431,O
studies,6431,O
have,6431,O
been,6431,O
directed,6431,O
at,6431,O
the,6431,O
transmembrane,6431,O
MUC1-C-terminal,6431,B-GENE-Y
subunit,6431,I-GENE-Y
(,6431,O
MUC1-C,6431,B-GENE-Y
),6431,O
that,6431,O
functions,6431,O
as,6431,O
an,6431,O
oncoprotein,6431,O
.,6431,O
MUC1-C,6432,B-GENE-Y
interacts,6432,O
with,6432,O
EGFR,6432,B-GENE-Y
(,6432,O
epidermal,6432,B-GENE-Y
growth,6432,I-GENE-Y
factor,6432,I-GENE-Y
receptor,6432,I-GENE-Y
),6432,O
",",6432,O
ErbB2,6432,B-GENE-Y
and,6432,O
other,6432,O
receptor,6432,B-GENE-N
tyrosine,6432,I-GENE-N
kinases,6432,I-GENE-N
at,6432,O
the,6432,O
cell,6432,O
membrane,6432,O
and,6432,O
contributes,6432,O
to,6432,O
activation,6432,O
of,6432,O
the,6432,O
PI3KAKT,6432,B-GENE-N
and,6432,O
mitogen-activated,6432,B-GENE-N
protein,6432,I-GENE-N
kinase,6432,I-GENE-N
kinase,6432,I-GENE-N
(,6432,O
MEK,6432,B-GENE-N
),6432,O
extracellular,6432,O
signal-regulated,6432,I-GENE-N
kinase,6432,I-GENE-N
(,6432,O
ERK,6432,B-GENE-N
),6432,O
pathways,6432,O
.,6432,O
MUC1-C,6433,B-GENE-Y
also,6433,O
localizes,6433,O
to,6433,O
the,6433,O
nucleus,6433,O
where,6433,O
it,6433,O
activates,6433,O
the,6433,O
Wnt/β-catenin,6433,B-GENE-N
",",6433,O
signal,6433,B-GENE-N
transducer,6433,I-GENE-N
and,6433,I-GENE-N
activator,6433,I-GENE-N
of,6433,I-GENE-N
transcription,6433,I-GENE-N
(,6433,O
STAT,6433,B-GENE-N
),6433,O
and,6433,O
NF,6433,B-GENE-N
(,6433,B-GENE-N
nuclear,6433,I-GENE-N
factor,6433,I-GENE-N
),6433,I-GENE-N
-κB,6433,I-GENE-N
RelA,6433,B-GENE-Y
pathways,6433,O
.,6433,O
These,6434,O
findings,6434,O
and,6434,O
the,6434,O
demonstration,6434,O
that,6434,O
MUC1-C,6434,B-GENE-Y
is,6434,O
a,6434,O
druggable,6434,O
target,6434,O
have,6434,O
provided,6434,O
the,6434,O
experimental,6434,O
basis,6434,O
for,6434,O
designing,6434,O
agents,6434,O
that,6434,O
block,6434,O
MUC1-C,6434,B-GENE-Y
function,6434,O
.,6434,O
Notably,6435,O
",",6435,O
inhibitors,6435,O
of,6435,O
the,6435,O
MUC1-C,6435,B-GENE-Y
subunit,6435,O
have,6435,O
been,6435,O
developed,6435,O
that,6435,O
directly,6435,O
block,6435,O
its,6435,O
oncogenic,6435,O
function,6435,O
and,6435,O
induce,6435,O
death,6435,O
of,6435,O
breast,6435,O
cancer,6435,O
cells,6435,O
in,6435,O
vitro,6435,O
and,6435,O
in,6435,O
xenograft,6435,O
models,6435,O
.,6435,O
On,6436,O
the,6436,O
basis,6436,O
of,6436,O
these,6436,O
findings,6436,O
",",6436,O
a,6436,O
first-in-class,6436,O
MUC1-C,6436,B-GENE-Y
inhibitor,6436,O
has,6436,O
entered,6436,O
phase,6436,O
I,6436,O
evaluation,6436,O
as,6436,O
a,6436,O
potential,6436,O
agent,6436,O
for,6436,O
the,6436,O
treatment,6436,O
of,6436,O
patients,6436,O
with,6436,O
breast,6436,O
cancers,6436,O
who,6436,O
express,6436,O
this,6436,O
oncoprotein,6436,O
.,6436,O
Synthesis,6437,O
",",6437,O
crystal,6437,O
structure,6437,O
and,6437,O
antidiabetic,6437,O
activity,6437,O
of,6437,O
substituted,6437,O
(,6437,B-CHEMICAL
E,6437,I-CHEMICAL
),6437,I-CHEMICAL
-3-,6437,I-CHEMICAL
(,6437,I-CHEMICAL
Benzo,6437,I-CHEMICAL
[,6437,I-CHEMICAL
d,6437,I-CHEMICAL
],6437,I-CHEMICAL
thiazol-2-ylamino,6437,I-CHEMICAL
),6437,I-CHEMICAL
phenylprop-2-en-1-one,6437,I-CHEMICAL
.,6437,O
A,6438,O
novel,6438,O
series,6438,O
of,6438,O
substituted,6438,O
(,6438,B-CHEMICAL
E,6438,I-CHEMICAL
),6438,I-CHEMICAL
-3-,6438,I-CHEMICAL
(,6438,I-CHEMICAL
Benzo,6438,I-CHEMICAL
[,6438,I-CHEMICAL
d,6438,I-CHEMICAL
],6438,I-CHEMICAL
thiazol-2-ylamino,6438,I-CHEMICAL
),6438,I-CHEMICAL
phenylprop-2-en-1-onewere,6438,O
synthesized,6438,O
starting,6438,O
from,6438,O
2-aminobenzothiazole,6438,B-CHEMICAL
and,6438,O
"1-aryl-3,3-bis-",6438,B-CHEMICAL
(,6438,I-CHEMICAL
methylsulfanyl,6438,I-CHEMICAL
),6438,I-CHEMICAL
-2-propen-1-onesin,6438,O
the,6438,O
presence,6438,O
of,6438,O
a,6438,O
catalytic,6438,O
amount,6438,O
of,6438,O
sodium,6438,B-CHEMICAL
hydride,6438,I-CHEMICAL
in,6438,O
THF,6438,B-CHEMICAL
.,6438,O
The,6439,O
synthesised,6439,O
compounds,6439,O
',6439,O
structures,6439,O
were,6439,O
confirmed,6439,O
by,6439,O
IR,6439,O
",",6439,O
Mass,6439,O
spectrometry,6439,O
",",6439,O
(,6439,B-CHEMICAL
1,6439,I-CHEMICAL
),6439,I-CHEMICAL
H,6439,I-CHEMICAL
NMR,6439,O
",",6439,O
(,6439,B-CHEMICAL
13,6439,I-CHEMICAL
),6439,I-CHEMICAL
C,6439,I-CHEMICAL
NMR,6439,O
and,6439,O
HRMS,6439,O
spectral,6439,O
data,6439,O
.,6439,O
These,6440,O
compounds,6440,O
were,6440,O
evaluated,6440,O
for,6440,O
their,6440,O
antidiabetic,6440,O
activity,6440,O
",",6440,O
and,6440,O
most,6440,O
of,6440,O
the,6440,O
derivatives,6440,O
of,6440,O
(,6440,B-CHEMICAL
E,6440,I-CHEMICAL
),6440,I-CHEMICAL
-3-,6440,I-CHEMICAL
(,6440,I-CHEMICAL
Benzo,6440,I-CHEMICAL
[,6440,I-CHEMICAL
d,6440,I-CHEMICAL
],6440,I-CHEMICAL
thiazol-2-ylamino,6440,I-CHEMICAL
),6440,I-CHEMICAL
phenylprop-2-en-1-one,6440,I-CHEMICAL
displayed,6440,O
significant,6440,O
antidiabetic,6440,O
activity,6440,O
.,6440,O
Acetaminophen,6441,B-CHEMICAL
(,6441,O
paracetamol,6441,B-CHEMICAL
),6441,O
is,6441,O
a,6441,O
selective,6441,O
cyclooxygenase-2,6441,B-GENE-Y
inhibitor,6441,O
in,6441,O
man,6441,O
.,6441,O
For,6442,O
more,6442,O
than,6442,O
three,6442,O
decades,6442,O
",",6442,O
acetaminophen,6442,B-CHEMICAL
(,6442,O
INN,6442,B-CHEMICAL
",",6442,O
paracetamol,6442,B-CHEMICAL
),6442,O
has,6442,O
been,6442,O
claimed,6442,O
to,6442,O
be,6442,O
devoid,6442,O
of,6442,O
significant,6442,O
inhibition,6442,O
of,6442,O
peripheral,6442,O
prostanoids,6442,B-CHEMICAL
.,6442,O
Meanwhile,6443,O
",",6443,O
attempts,6443,O
to,6443,O
explain,6443,O
its,6443,O
action,6443,O
by,6443,O
inhibition,6443,O
of,6443,O
a,6443,O
central,6443,O
cyclooxygenase,6443,B-GENE-N
(,6443,I-GENE-N
COX,6443,I-GENE-N
),6443,I-GENE-N
-3,6443,I-GENE-N
have,6443,O
been,6443,O
rejected,6443,O
.,6443,O
The,6444,O
fact,6444,O
that,6444,O
acetaminophen,6444,B-CHEMICAL
acts,6444,O
functionally,6444,O
as,6444,O
a,6444,O
selective,6444,O
COX-2,6444,B-GENE-Y
inhibitor,6444,O
led,6444,O
us,6444,O
to,6444,O
investigate,6444,O
the,6444,O
hypothesis,6444,O
of,6444,O
whether,6444,O
it,6444,O
works,6444,O
via,6444,O
preferential,6444,O
COX-2,6444,B-GENE-Y
blockade,6444,O
.,6444,O
Ex,6445,O
vivo,6445,O
COX,6445,B-GENE-N
inhibition,6445,O
and,6445,O
pharmacokinetics,6445,O
of,6445,O
acetaminophen,6445,B-CHEMICAL
were,6445,O
assessed,6445,O
in,6445,O
5,6445,O
volunteers,6445,O
receiving,6445,O
single,6445,O
1000,6445,O
mg,6445,O
doses,6445,O
orally,6445,O
.,6445,O
Coagulation-induced,6446,O
thromboxane,6446,B-CHEMICAL
B,6446,I-CHEMICAL
(,6446,I-CHEMICAL
2,6446,I-CHEMICAL
),6446,I-CHEMICAL
and,6446,O
lipopolysaccharide-induced,6446,O
prostaglandin,6446,B-CHEMICAL
E,6446,I-CHEMICAL
(,6446,I-CHEMICAL
2,6446,I-CHEMICAL
),6446,I-CHEMICAL
were,6446,O
measured,6446,O
ex,6446,O
vivo,6446,O
and,6446,O
in,6446,O
vitro,6446,O
in,6446,O
human,6446,O
whole,6446,O
blood,6446,O
as,6446,O
indices,6446,O
of,6446,O
COX-1,6446,B-GENE-Y
and,6446,O
COX-2,6446,B-GENE-Y
activity,6446,O
.,6446,O
In,6447,O
vitro,6447,O
",",6447,O
acetaminophen,6447,B-CHEMICAL
elicited,6447,O
a,6447,O
4.4-fold,6447,O
selectivity,6447,O
toward,6447,O
COX-2,6447,B-GENE-Y
inhibition,6447,O
(,6447,O
IC,6447,O
(,6447,O
50,6447,O
),6447,O
=113.7,6447,O
micromol/L,6447,O
for,6447,O
COX-1,6447,B-GENE-Y
;,6447,O
IC,6447,O
(,6447,O
50,6447,O
),6447,O
=25.8,6447,O
micromol/L,6447,O
for,6447,O
COX-2,6447,B-GENE-Y
),6447,O
.,6447,O
Following,6448,O
oral,6448,O
administration,6448,O
of,6448,O
the,6448,O
drug,6448,O
",",6448,O
maximal,6448,O
ex,6448,O
vivo,6448,O
inhibitions,6448,O
were,6448,O
56,6448,O
%,6448,O
(,6448,O
COX-1,6448,B-GENE-Y
),6448,O
and,6448,O
83,6448,O
%,6448,O
(,6448,O
COX-2,6448,B-GENE-Y
),6448,O
.,6448,O
Acetaminophen,6449,B-CHEMICAL
plasma,6449,O
concentrations,6449,O
remained,6449,O
above,6449,O
the,6449,O
in,6449,O
vitro,6449,O
IC,6449,O
(,6449,O
50,6449,O
),6449,O
for,6449,O
COX-2,6449,B-GENE-Y
for,6449,O
at,6449,O
least,6449,O
5,6449,O
h,6449,O
postadministration,6449,O
.,6449,O
Ex,6450,O
vivo,6450,O
IC,6450,O
(,6450,O
50,6450,O
),6450,O
values,6450,O
(,6450,O
COX-1,6450,B-GENE-Y
:,6450,O
105.2,6450,O
micromol/L,6450,O
;,6450,O
COX-2,6450,B-GENE-Y
:,6450,O
26.3,6450,O
micromol/L,6450,O
),6450,O
of,6450,O
acetaminophen,6450,B-CHEMICAL
compared,6450,O
favorably,6450,O
with,6450,O
its,6450,O
in,6450,O
vitro,6450,O
IC,6450,O
(,6450,O
50,6450,O
),6450,O
values,6450,O
.,6450,O
In,6451,O
contrast,6451,O
to,6451,O
previous,6451,O
concepts,6451,O
",",6451,O
acetaminophen,6451,B-CHEMICAL
inhibited,6451,O
COX-2,6451,B-GENE-Y
by,6451,O
more,6451,O
than,6451,O
80,6451,O
%,6451,O
",",6451,O
i.e.,6451,O
",",6451,O
to,6451,O
a,6451,O
degree,6451,O
comparable,6451,O
to,6451,O
nonsteroidal,6451,O
antiinflammatory,6451,O
drugs,6451,O
(,6451,O
NSAIDs,6451,O
),6451,O
and,6451,O
selective,6451,O
COX-2,6451,B-GENE-Y
inhibitors,6451,O
.,6451,O
However,6452,O
",",6452,O
a,6452,O
>,6452,O
95,6452,O
%,6452,O
COX-1,6452,B-GENE-Y
blockade,6452,O
relevant,6452,O
for,6452,O
suppression,6452,O
of,6452,O
platelet,6452,O
function,6452,O
was,6452,O
not,6452,O
achieved,6452,O
.,6452,O
Our,6453,O
data,6453,O
may,6453,O
explain,6453,O
acetaminophen,6453,O
's,6453,O
analgesic,6453,O
and,6453,O
antiinflammatory,6453,O
action,6453,O
as,6453,O
well,6453,O
as,6453,O
its,6453,O
superior,6453,O
overall,6453,O
gastrointestinal,6453,O
safety,6453,O
profile,6453,O
compared,6453,O
with,6453,O
NSAIDs,6453,O
.,6453,O
In,6454,O
view,6454,O
of,6454,O
its,6454,O
substantial,6454,O
COX-2,6454,B-GENE-Y
inhibition,6454,O
",",6454,O
recently,6454,O
defined,6454,O
cardiovascular,6454,O
warnings,6454,O
for,6454,O
use,6454,O
of,6454,O
COX-2,6454,B-GENE-Y
inhibitors,6454,O
should,6454,O
also,6454,O
be,6454,O
considered,6454,O
for,6454,O
acetaminophen,6454,B-CHEMICAL
.,6454,O
Effect,6455,O
of,6455,O
galantamine,6455,B-CHEMICAL
on,6455,O
acetylcholinesterase,6455,B-GENE-Y
and,6455,O
butyrylcholinesterase,6455,B-GENE-Y
activities,6455,O
in,6455,O
the,6455,O
presence,6455,O
of,6455,O
L-carnitine,6455,B-CHEMICAL
in,6455,O
rat,6455,O
selected,6455,O
brain,6455,O
and,6455,O
peripheral,6455,O
tissues,6455,O
.,6455,O
OBJECTIVES,6456,O
:,6456,O
The,6456,O
alkaloid,6456,O
galantamine,6456,B-CHEMICAL
(,6456,O
GAL,6456,B-CHEMICAL
),6456,O
",",6456,O
which,6456,O
exhibits,6456,O
a,6456,O
combined,6456,O
anticholinesterase,6456,B-GENE-Y
and,6456,O
direct,6456,O
parasympathomimetic,6456,O
mechanism,6456,O
of,6456,O
action,6456,O
",",6456,O
is,6456,O
employed,6456,O
in,6456,O
conjunction,6456,O
with,6456,O
therapeutic,6456,O
interventions,6456,O
in,6456,O
the,6456,O
stimulation,6456,O
of,6456,O
central,6456,O
cholinergic,6456,O
transfer,6456,O
in,6456,O
cognitive,6456,O
diseases,6456,O
.,6456,O
We,6457,O
attempted,6457,O
to,6457,O
achieve,6457,O
pharmacologically-induced,6457,O
enhancement,6457,O
of,6457,O
the,6457,O
parasympathomimetic,6457,O
activity,6457,O
of,6457,O
GAL,6457,B-CHEMICAL
in,6457,O
the,6457,O
key,6457,O
areas,6457,O
of,6457,O
rat,6457,O
brain,6457,O
",",6457,O
using,6457,O
an,6457,O
interactive,6457,O
combination,6457,O
of,6457,O
the,6457,O
alkaloid,6457,O
with,6457,O
the,6457,O
transmembrane,6457,O
enhancer,6457,O
L-carnitine,6457,B-CHEMICAL
(,6457,O
CAR,6457,B-CHEMICAL
),6457,O
.,6457,O
METHODS,6458,O
:,6458,O
We,6458,O
investigated,6458,O
activities,6458,O
of,6458,O
acetylcholinesterase,6458,B-GENE-Y
(,6458,O
AChE,6458,B-GENE-Y
),6458,O
in,6458,O
brain,6458,O
areas,6458,O
(,6458,O
frontal,6458,O
cortex,6458,O
",",6458,O
basal,6458,O
ganglia,6458,O
",",6458,O
septum,6458,O
and,6458,O
hippocampus,6458,O
),6458,O
and,6458,O
the,6458,O
hypophysis,6458,O
",",6458,O
and,6458,O
that,6458,O
of,6458,O
butyrylcholinesterase,6458,B-GENE-Y
(,6458,O
BuChE,6458,B-GENE-Y
),6458,O
in,6458,O
plasma,6458,O
and,6458,O
liver,6458,O
.,6458,O
RESULTS,6459,O
:,6459,O
Following,6459,O
administration,6459,O
of,6459,O
the,6459,O
highest,6459,O
of,6459,O
the,6459,O
GAL,6459,B-CHEMICAL
doses,6459,O
used,6459,O
(,6459,O
2.5,6459,O
;,6459,O
5,6459,O
;,6459,O
10,6459,O
mg/kg,6459,O
i.m,6459,O
.,6459,O
),6460,O
",",6460,O
AChE,6460,O
activity,6460,O
decreased,6460,O
mainly,6460,O
in,6460,O
the,6460,O
frontal,6460,O
cortex,6460,O
",",6460,O
hippocampus,6460,O
and,6460,O
hypophysis,6460,O
.,6460,O
In,6461,O
the,6461,O
interaction,6461,O
of,6461,O
GAL,6461,O
and,6461,O
CAR,6461,O
",",6461,O
AChE,6461,O
inhibition,6461,O
was,6461,O
stronger,6461,O
but,6461,O
without,6461,O
any,6461,O
statistical,6461,O
significance,6461,O
.,6461,O
The,6462,O
peripheral,6462,O
inhibition,6462,O
of,6462,O
BuChE,6462,O
was,6462,O
found,6462,O
to,6462,O
be,6462,O
dose-dependent,6462,O
.,6462,O
Premedication,6463,O
by,6463,O
CAR,6463,O
led,6463,O
to,6463,O
a,6463,O
slight,6463,O
change,6463,O
in,6463,O
the,6463,O
values,6463,O
of,6463,O
the,6463,O
activities,6463,O
monitored,6463,O
.,6463,O
CONCLUSIONS,6464,O
:,6464,O
CAR,6464,O
in,6464,O
terms,6464,O
of,6464,O
positive,6464,O
modulation,6464,O
of,6464,O
GAL,6464,O
targeting,6464,O
to,6464,O
the,6464,O
central,6464,O
nervous,6464,O
system,6464,O
had,6464,O
no,6464,O
statistically,6464,O
significant,6464,O
effect,6464,O
.,6464,O
Inhibition,6465,O
of,6465,O
neurite,6465,O
outgrowth,6465,O
and,6465,O
alteration,6465,O
of,6465,O
cytoskeletal,6465,O
gene,6465,O
expression,6465,O
by,6465,O
sodium,6465,B-CHEMICAL
arsenite,6465,I-CHEMICAL
.,6465,O
Arsenic,6466,B-CHEMICAL
compounds,6466,O
that,6466,O
are,6466,O
often,6466,O
found,6466,O
in,6466,O
drinking,6466,O
water,6466,O
increase,6466,O
the,6466,O
risk,6466,O
of,6466,O
developmental,6466,O
brain,6466,O
disorders,6466,O
.,6466,O
In,6467,O
this,6467,O
study,6467,O
",",6467,O
we,6467,O
performed,6467,O
live,6467,O
imaging,6467,O
analyses,6467,O
of,6467,O
Neuro-2a,6467,O
cells,6467,O
expressing,6467,O
SCAT3,6467,O
",",6467,O
a,6467,O
caspase-3,6467,B-GENE-Y
cleavage,6467,O
peptide,6467,O
sequence,6467,O
linking,6467,O
two,6467,O
fluorescent,6467,O
proteins,6467,O
;,6467,O
enhanced,6467,O
cyan,6467,O
fluorescence,6467,O
protein,6467,O
(,6467,O
ECFP,6467,O
),6467,O
and,6467,O
Venus,6467,O
",",6467,O
to,6467,O
determine,6467,O
whether,6467,O
sodium,6467,B-CHEMICAL
arsenite,6467,I-CHEMICAL
(,6467,O
NaAsO,6467,B-CHEMICAL
(,6467,I-CHEMICAL
2,6467,I-CHEMICAL
),6467,I-CHEMICAL
;,6467,O
0,6467,O
",",6467,O
1,6467,O
",",6467,O
5,6467,O
",",6467,O
or,6467,O
10,6467,O
μM,6467,O
),6467,O
affects,6467,O
both,6467,O
neurite,6467,O
outgrowth,6467,O
and/or,6467,O
induces,6467,O
apoptosis,6467,O
with,6467,O
the,6467,O
same,6467,O
doses,6467,O
and,6467,O
in,6467,O
the,6467,O
same,6467,O
cell,6467,O
cultures,6467,O
.,6467,O
We,6468,O
observed,6468,O
that,6468,O
the,6468,O
area,6468,O
ratio,6468,O
of,6468,O
neurite,6468,O
to,6468,O
cell,6468,O
body,6468,O
in,6468,O
SCAT3-expressing,6468,O
cells,6468,O
was,6468,O
significantly,6468,O
reduced,6468,O
by,6468,O
5,6468,O
and,6468,O
10,6468,O
μM,6468,O
NaAsO,6468,B-CHEMICAL
(,6468,I-CHEMICAL
2,6468,I-CHEMICAL
),6468,I-CHEMICAL
",",6468,O
but,6468,O
not,6468,O
by,6468,O
1,6468,O
μM,6468,O
",",6468,O
although,6468,O
the,6468,O
emission,6468,O
ratio,6468,O
of,6468,O
ECFP,6468,O
to,6468,O
Venus,6468,O
",",6468,O
an,6468,O
endpoint,6468,O
of,6468,O
caspase-3,6468,B-GENE-Y
activity,6468,O
",",6468,O
was,6468,O
not,6468,O
changed,6468,O
.,6468,O
However,6469,O
",",6469,O
cytological,6469,O
assay,6469,O
using,6469,O
apoptotic,6469,O
and,6469,O
necrotic,6469,O
markers,6469,O
resulted,6469,O
in,6469,O
that,6469,O
apoptosis,6469,O
",",6469,O
but,6469,O
not,6469,O
necrosis,6469,O
",",6469,O
was,6469,O
significantly,6469,O
induced,6469,O
in,6469,O
Neuro-2a,6469,O
cells,6469,O
when,6469,O
NaAsO,6469,B-CHEMICAL
(,6469,I-CHEMICAL
2,6469,I-CHEMICAL
),6469,I-CHEMICAL
exposure,6469,O
continued,6469,O
after,6469,O
the,6469,O
significant,6469,O
effects,6469,O
of,6469,O
NaAsO,6469,B-CHEMICAL
(,6469,I-CHEMICAL
2,6469,I-CHEMICAL
),6469,I-CHEMICAL
on,6469,O
neurite,6469,O
outgrowth,6469,O
were,6469,O
found,6469,O
by,6469,O
live,6469,O
imaging,6469,O
.,6469,O
These,6470,O
results,6470,O
suggested,6470,O
that,6470,O
neurite,6470,O
outgrowth,6470,O
was,6470,O
suppressed,6470,O
by,6470,O
NaAsO,6470,B-CHEMICAL
(,6470,I-CHEMICAL
2,6470,I-CHEMICAL
),6470,I-CHEMICAL
prior,6470,O
to,6470,O
NaAsO,6470,B-CHEMICAL
(,6470,I-CHEMICAL
2,6470,I-CHEMICAL
),6470,I-CHEMICAL
-induced,6470,O
apoptosis,6470,O
.,6470,O
Next,6471,O
",",6471,O
we,6471,O
examined,6471,O
the,6471,O
effects,6471,O
of,6471,O
NaAsO,6471,B-CHEMICAL
(,6471,I-CHEMICAL
2,6471,I-CHEMICAL
),6471,I-CHEMICAL
on,6471,O
cytoskeletal,6471,O
gene,6471,O
expression,6471,O
in,6471,O
Neuro-2a,6471,O
cells,6471,O
.,6471,O
NaAsO,6472,B-CHEMICAL
(,6472,I-CHEMICAL
2,6472,I-CHEMICAL
),6472,I-CHEMICAL
increased,6472,O
the,6472,O
mRNA,6472,O
levels,6472,O
of,6472,O
the,6472,O
light,6472,B-GENE-N
and,6472,I-GENE-N
medium,6472,I-GENE-N
subunits,6472,I-GENE-N
of,6472,I-GENE-N
neurofilament,6472,I-GENE-N
and,6472,O
decreased,6472,O
the,6472,O
mRNA,6472,O
levels,6472,O
of,6472,O
tau,6472,B-GENE-Y
and,6472,O
tubulin,6472,B-GENE-N
in,6472,O
a,6472,O
dose-dependent,6472,O
manner,6472,O
;,6472,O
no,6472,O
significant,6472,O
effect,6472,O
was,6472,O
found,6472,O
in,6472,O
the,6472,O
mRNA,6472,O
levels,6472,O
of,6472,O
the,6472,O
heavy,6472,B-GENE-Y
subunit,6472,I-GENE-Y
of,6472,I-GENE-Y
neurofilament,6472,I-GENE-Y
",",6472,O
microtubule-associated,6472,B-GENE-Y
protein,6472,I-GENE-Y
2,6472,I-GENE-Y
",",6472,O
or,6472,O
actin,6472,B-GENE-N
.,6472,O
The,6473,O
changes,6473,O
in,6473,O
cytoskeletal,6473,O
gene,6473,O
expression,6473,O
are,6473,O
likely,6473,O
responsible,6473,O
for,6473,O
the,6473,O
inhibitory,6473,O
effects,6473,O
of,6473,O
NaAsO,6473,B-CHEMICAL
(,6473,I-CHEMICAL
2,6473,I-CHEMICAL
),6473,I-CHEMICAL
on,6473,O
neurite,6473,O
outgrowth,6473,O
.,6473,O
A,6474,O
naloxone-steroid,6474,B-CHEMICAL
hybrid,6474,I-CHEMICAL
azine,6474,I-CHEMICAL
with,6474,O
selective,6474,O
and,6474,O
long-acting,6474,O
opioid,6474,O
antagonism,6474,O
at,6474,O
delta,6474,B-GENE-Y
receptors,6474,I-GENE-Y
in,6474,O
vitro,6474,O
.,6474,O
The,6475,O
interaction,6475,O
of,6475,O
naloxone,6475,B-CHEMICAL
estrone,6475,I-CHEMICAL
azine,6475,I-CHEMICAL
(,6475,O
N-EH,6475,B-CHEMICAL
),6475,O
with,6475,O
various,6475,O
opioid,6475,B-GENE-N
receptor,6475,I-GENE-N
types,6475,O
was,6475,O
studied,6475,O
in,6475,O
vitro,6475,O
.,6475,O
Its,6476,O
potency,6476,O
as,6476,O
an,6476,O
antagonist,6476,O
of,6476,O
opioid,6476,O
effects,6476,O
was,6476,O
compared,6476,O
to,6476,O
that,6476,O
of,6476,O
naloxone,6476,B-CHEMICAL
on,6476,O
the,6476,O
electrically,6476,O
evoked,6476,O
contractions,6476,O
of,6476,O
mouse,6476,O
vas,6476,O
deferens,6476,O
(,6476,O
Mvd,6476,O
),6476,O
and,6476,O
guinea,6476,O
pig,6476,O
ileum,6476,O
myenteric,6476,O
plexus,6476,O
longitudinal,6476,O
muscle,6476,O
(,6476,O
Gpi,6476,O
),6476,O
preparations,6476,O
.,6476,O
N-EH,6477,B-CHEMICAL
was,6477,O
found,6477,O
to,6477,O
be,6477,O
9-fold,6477,O
more,6477,O
potent,6477,O
than,6477,O
naloxone,6477,B-CHEMICAL
in,6477,O
antagonizing,6477,O
the,6477,O
effects,6477,O
of,6477,O
D-Ala2-Leu5-enkephalin,6477,B-CHEMICAL
in,6477,O
the,6477,O
Mvd,6477,O
and,6477,O
22-fold,6477,O
less,6477,O
potent,6477,O
in,6477,O
antagonizing,6477,O
normorphine,6477,B-CHEMICAL
in,6477,O
the,6477,O
Gpi,6477,O
.,6477,O
In,6478,O
the,6478,O
Mvd,6478,O
",",6478,O
the,6478,O
recovery,6478,O
half-time,6478,O
for,6478,O
N-EH,6478,B-CHEMICAL
was,6478,O
longer,6478,O
than,6478,O
1000,6478,O
min,6478,O
.,6478,O
Neither,6479,O
compound,6479,O
showed,6479,O
agonism,6479,O
.,6479,O
The,6480,O
two,6480,O
compounds,6480,O
were,6480,O
also,6480,O
compared,6480,O
for,6480,O
their,6480,O
capacity,6480,O
to,6480,O
displace,6480,O
the,6480,O
binding,6480,O
of,6480,O
3H-D-Ala2-Leu5-enkephalin,6480,B-CHEMICAL
",",6480,O
3H-dihydromorphine,6480,B-CHEMICAL
",",6480,O
and,6480,O
3H-ethylketocyclazocine,6480,B-CHEMICAL
to,6480,O
rat,6480,O
brain,6480,O
membranes,6480,O
under,6480,O
conditions,6480,O
where,6480,O
delta,6480,O
",",6480,O
mu,6480,O
",",6480,O
and,6480,O
kappa,6480,O
sites,6480,O
were,6480,O
labeled,6480,O
.,6480,O
The,6481,O
relative,6481,O
affinities,6481,O
were,6481,O
0.70,6481,O
",",6481,O
0.16,6481,O
",",6481,O
and,6481,O
0.14,6481,O
for,6481,O
N-EH,6481,B-CHEMICAL
and,6481,O
0.05,6481,O
",",6481,O
0.87,6481,O
",",6481,O
and,6481,O
0.08,6481,O
for,6481,O
naloxone,6481,B-CHEMICAL
",",6481,O
respectively,6481,O
.,6481,O
Thus,6482,O
",",6482,O
compared,6482,O
to,6482,O
naloxone,6482,B-CHEMICAL
",",6482,O
which,6482,O
is,6482,O
mu,6482,O
selective,6482,O
",",6482,O
N-EH,6482,B-CHEMICAL
is,6482,O
a,6482,O
delta-selective,6482,O
antagonist,6482,O
.,6482,O
Inhibition,6483,O
of,6483,O
dipeptidyl,6483,B-GENE-Y
peptidase-IV,6483,I-GENE-Y
(,6483,O
DPP-IV,6483,B-GENE-Y
),6483,O
by,6483,O
atorvastatin,6483,B-CHEMICAL
.,6483,O
Dipeptidyl,6484,B-GENE-Y
peptidase-IV,6484,I-GENE-Y
(,6484,O
DPP-IV,6484,B-GENE-Y
),6484,O
is,6484,O
an,6484,O
enzyme,6484,O
responsible,6484,O
for,6484,O
the,6484,O
inactivation,6484,O
of,6484,O
the,6484,O
glucoregulatory,6484,O
incretin,6484,B-GENE-N
hormones,6484,I-GENE-N
glucagon-like,6484,B-GENE-Y
peptide-1,6484,I-GENE-Y
(,6484,O
GLP-1,6484,B-GENE-Y
),6484,O
and,6484,O
glucose-dependent,6484,B-GENE-Y
insulinotropic,6484,I-GENE-Y
polypeptide,6484,I-GENE-Y
(,6484,O
GIP,6484,B-GENE-Y
),6484,O
.,6484,O
In,6485,O
this,6485,O
report,6485,O
",",6485,O
we,6485,O
show,6485,O
that,6485,O
the,6485,O
hypolipidemic,6485,O
agent,6485,O
atorvastatin,6485,B-CHEMICAL
is,6485,O
a,6485,O
competitive,6485,O
inhibitor,6485,O
of,6485,O
porcine,6485,B-GENE-Y
DPP-IV,6485,I-GENE-Y
in,6485,O
vitro,6485,O
",",6485,O
with,6485,O
K,6485,O
(,6485,O
i,6485,O
),6485,O
=57.8+/-2.3,6485,O
microM,6485,O
.,6485,O
These,6486,O
results,6486,O
may,6486,O
have,6486,O
implications,6486,O
in,6486,O
the,6486,O
development,6486,O
of,6486,O
novel,6486,O
DPP-IV,6486,B-GENE-Y
inhibitors,6486,O
based,6486,O
on,6486,O
the,6486,O
use,6486,O
of,6486,O
atorvastatin,6486,B-CHEMICAL
as,6486,O
a,6486,O
lead,6486,O
compound,6486,O
for,6486,O
the,6486,O
treatment,6486,O
of,6486,O
type,6486,O
2,6486,O
diabetes,6486,O
.,6486,O
Neoechinulin,6487,B-CHEMICAL
A,6487,I-CHEMICAL
suppresses,6487,O
amyloid-β,6487,B-GENE-Y
oligomer-induced,6487,O
microglia,6487,O
activation,6487,O
and,6487,O
thereby,6487,O
protects,6487,O
PC-12,6487,O
cells,6487,O
from,6487,O
inflammation-mediated,6487,O
toxicity,6487,O
.,6487,O
A,6488,O
pathological,6488,O
hallmark,6488,O
of,6488,O
Alzheimer,6488,O
's,6488,O
disease,6488,O
(,6488,O
AD,6488,O
),6488,O
",",6488,O
aggregation,6488,O
and,6488,O
deposition,6488,O
of,6488,O
amyloid-β,6488,B-GENE-Y
peptides,6488,I-GENE-Y
",",6488,O
has,6488,O
been,6488,O
recognized,6488,O
as,6488,O
a,6488,O
potent,6488,O
activator,6488,O
of,6488,O
microglia-mediated,6488,O
neuroinflammation,6488,O
and,6488,O
neuronal,6488,O
dysfunction,6488,O
.,6488,O
Therefore,6489,O
",",6489,O
downregulation,6489,O
of,6489,O
microglial,6489,O
activation,6489,O
has,6489,O
a,6489,O
significant,6489,O
therapeutic,6489,O
demand,6489,O
.,6489,O
In,6490,O
this,6490,O
study,6490,O
",",6490,O
focus,6490,O
was,6490,O
given,6490,O
to,6490,O
evaluate,6490,O
the,6490,O
ability,6490,O
of,6490,O
neoechinulin,6490,B-CHEMICAL
A,6490,I-CHEMICAL
",",6490,O
an,6490,O
indole,6490,B-CHEMICAL
alkaloid,6490,O
isolated,6490,O
from,6490,O
marine-derived,6490,O
Microsporum,6490,O
sp.,6490,O
",",6490,O
to,6490,O
attenuate,6490,O
microglial,6490,O
activation,6490,O
by,6490,O
oligomeric,6490,O
amyloid-β,6490,B-GENE-Y
1-42,6490,I-GENE-Y
(,6490,O
Aβ42,6490,B-GENE-Y
),6490,O
.,6490,O
Neoechinulin,6491,B-CHEMICAL
A,6491,I-CHEMICAL
treatment,6491,O
significantly,6491,O
inhibited,6491,O
the,6491,O
generation,6491,O
of,6491,O
reactive,6491,O
oxygen,6491,B-CHEMICAL
and,6491,O
nitrogen,6491,B-CHEMICAL
species,6491,O
in,6491,O
Aβ42-activated,6491,B-GENE-Y
BV-2,6491,O
microglia,6491,O
cells,6491,O
.,6491,O
In,6492,O
addition,6492,O
",",6492,O
we,6492,O
found,6492,O
that,6492,O
neoechinulin,6492,B-CHEMICAL
A,6492,I-CHEMICAL
significantly,6492,O
suppressed,6492,O
the,6492,O
production,6492,O
of,6492,O
neurotoxic,6492,O
inflammatory,6492,O
mediator,6492,O
tumour,6492,B-GENE-Y
necrosis,6492,I-GENE-Y
factor-α,6492,I-GENE-Y
(,6492,O
TNF-α,6492,B-GENE-Y
),6492,O
",",6492,O
interleukin-1β,6492,B-GENE-Y
(,6492,O
IL-1β,6492,B-GENE-Y
),6492,O
",",6492,O
interleukin-6,6492,B-GENE-Y
(,6492,O
IL-6,6492,B-GENE-Y
),6492,O
",",6492,O
and,6492,O
prostaglandin,6492,B-CHEMICAL
E2,6492,I-CHEMICAL
(,6492,O
PGE2,6492,B-CHEMICAL
),6492,O
in,6492,O
activated,6492,O
BV-2,6492,O
cells,6492,O
.,6492,O
Moreover,6493,O
",",6493,O
the,6493,O
treatment,6493,O
downregulated,6493,O
the,6493,O
protein,6493,O
and,6493,O
gene,6493,O
expressions,6493,O
of,6493,O
inducible,6493,B-GENE-Y
nitric,6493,I-GENE-Y
oxide,6493,I-GENE-Y
synthase,6493,I-GENE-Y
(,6493,O
iNOS,6493,B-GENE-Y
),6493,O
",",6493,O
cyclooxygenase-2,6493,B-GENE-Y
(,6493,O
COX-2,6493,B-GENE-Y
),6493,O
",",6493,O
TNF-α,6493,B-GENE-Y
",",6493,O
IL-1β,6493,B-GENE-Y
and,6493,O
IL-6,6493,B-GENE-Y
.,6493,O
Further,6494,O
",",6494,O
activated,6494,O
microglia-mediated,6494,O
apoptosis,6494,O
of,6494,O
PC-12,6494,O
pheochromocytoma,6494,O
cells,6494,O
was,6494,O
significantly,6494,O
repressed,6494,O
by,6494,O
neoechinulin,6494,B-CHEMICAL
A,6494,I-CHEMICAL
.,6494,O
The,6495,O
molecular,6495,O
mechanism,6495,O
studies,6495,O
suggested,6495,O
that,6495,O
neoechinulin,6495,B-CHEMICAL
A,6495,I-CHEMICAL
may,6495,O
block,6495,O
the,6495,O
phosphorylation,6495,O
of,6495,O
mitogen-activated,6495,B-GENE-N
protein,6495,I-GENE-N
kinase,6495,I-GENE-N
(,6495,O
MAPK,6495,B-GENE-N
),6495,O
molecule,6495,O
p38,6495,B-GENE-N
",",6495,O
apoptosis,6495,B-GENE-Y
signal-regulating,6495,I-GENE-Y
kinase,6495,I-GENE-Y
1,6495,I-GENE-Y
(,6495,O
ASK-1,6495,B-GENE-Y
),6495,O
and,6495,O
nuclear,6495,O
translocation,6495,O
of,6495,O
nuclear,6495,B-GENE-N
factor-κB,6495,I-GENE-N
(,6495,O
NF-κB,6495,B-GENE-N
),6495,O
p65,6495,B-GENE-Y
and,6495,O
p50,6495,B-GENE-Y
subunits,6495,O
.,6495,O
Regulation,6496,O
of,6496,O
these,6496,O
signalling,6496,O
pathways,6496,O
have,6496,O
most,6496,O
probably,6496,O
contributed,6496,O
to,6496,O
the,6496,O
anti-inflammatory,6496,O
activity,6496,O
of,6496,O
neoechinulin,6496,B-CHEMICAL
A,6496,I-CHEMICAL
.,6496,O
Collectively,6497,O
",",6497,O
these,6497,O
results,6497,O
suggest,6497,O
that,6497,O
with,6497,O
further,6497,O
studies,6497,O
neoechinulin,6497,B-CHEMICAL
A,6497,I-CHEMICAL
have,6497,O
a,6497,O
potential,6497,O
to,6497,O
be,6497,O
developed,6497,O
as,6497,O
a,6497,O
modulator,6497,O
of,6497,O
neuroinflammatory,6497,O
process,6497,O
in,6497,O
AD,6497,O
.,6497,O
WNT6,6498,B-GENE-Y
is,6498,O
a,6498,O
novel,6498,O
target,6498,O
gene,6498,O
of,6498,O
caveolin-1,6498,B-GENE-Y
promoting,6498,O
chemoresistance,6498,O
to,6498,O
epirubicin,6498,B-CHEMICAL
in,6498,O
human,6498,O
gastric,6498,O
cancer,6498,O
cells,6498,O
.,6498,O
Resistance,6499,O
to,6499,O
chemotherapy,6499,O
is,6499,O
a,6499,O
major,6499,O
obstacle,6499,O
for,6499,O
curative,6499,O
treatment,6499,O
of,6499,O
human,6499,O
gastric,6499,O
cancer,6499,O
(,6499,O
GC,6499,O
),6499,O
.,6499,O
However,6500,O
",",6500,O
the,6500,O
underlying,6500,O
molecular,6500,O
mechanisms,6500,O
are,6500,O
largely,6500,O
unknown,6500,O
.,6500,O
Wingless-type,6501,B-GENE-N
MMTV,6501,I-GENE-N
integration,6501,I-GENE-N
site,6501,I-GENE-N
family,6501,I-GENE-N
members,6501,I-GENE-N
(,6501,O
WNTs,6501,B-GENE-N
),6501,O
are,6501,O
secreted,6501,O
glycoproteins,6501,O
involved,6501,O
in,6501,O
embryogenesis,6501,O
and,6501,O
",",6501,O
on,6501,O
inappropriate,6501,O
expression,6501,O
in,6501,O
the,6501,O
adult,6501,O
",",6501,O
in,6501,O
cancer,6501,O
.,6501,O
Here,6502,O
",",6502,O
we,6502,O
show,6502,O
expression,6502,O
of,6502,O
WNT6,6502,B-GENE-Y
in,6502,O
GC,6502,O
patient,6502,O
specimens,6502,O
",",6502,O
human,6502,O
GC,6502,O
cell,6502,O
lines,6502,O
and,6502,O
in,6502,O
a,6502,O
mouse,6502,O
model,6502,O
of,6502,O
GC,6502,O
.,6502,O
In,6503,O
human,6503,O
GC,6503,O
cells,6503,O
",",6503,O
WNT6,6503,B-GENE-Y
expression,6503,O
was,6503,O
enhanced,6503,O
by,6503,O
caveolin-1,6503,B-GENE-Y
(,6503,O
Cav1,6503,B-GENE-Y
),6503,O
",",6503,O
a,6503,O
scaffold,6503,O
protein,6503,O
of,6503,O
plasma,6503,O
membrane,6503,O
caveolae,6503,O
.,6503,O
WNT6,6504,B-GENE-Y
knock-down,6504,O
and,6504,O
overexpression,6504,O
experiments,6504,O
demonstrated,6504,O
that,6504,O
WNT6,6504,B-GENE-Y
increased,6504,O
the,6504,O
resistance,6504,O
to,6504,O
apoptotic,6504,O
cell,6504,O
death,6504,O
induced,6504,O
by,6504,O
the,6504,O
anthracycline,6504,B-CHEMICAL
chemotherapeutics,6504,O
epirubicin,6504,B-CHEMICAL
(,6504,O
Epi,6504,B-CHEMICAL
),6504,O
and,6504,O
doxorubicin,6504,B-CHEMICAL
(,6504,O
Dox,6504,B-CHEMICAL
),6504,O
.,6504,O
Epi,6505,B-CHEMICAL
increased,6505,O
the,6505,O
activity,6505,O
of,6505,O
the,6505,O
human,6505,B-GENE-N
WNT6,6505,I-GENE-N
promoter,6505,I-GENE-N
through,6505,O
Cav1-dependent,6505,B-GENE-Y
binding,6505,O
of,6505,O
β-catenin,6505,B-GENE-Y
to,6505,O
the,6505,O
proximal,6505,O
WNT6,6505,B-GENE-N
promoter,6505,I-GENE-N
.,6505,O
Epi,6506,B-CHEMICAL
increased,6506,O
both,6506,O
WNT6/Wnt6,6506,B-GENE-Y
and,6506,O
Cav1,6506,B-GENE-Y
expression,6506,O
in,6506,O
human,6506,O
GC,6506,O
cells,6506,O
and,6506,O
within,6506,O
the,6506,O
tumor,6506,O
area,6506,O
of,6506,O
a,6506,O
murine,6506,O
model,6506,O
of,6506,O
GC,6506,O
(,6506,O
CEA424-SV40,6506,O
TAg,6506,O
),6506,O
.,6506,O
In,6507,O
GC,6507,O
patients,6507,O
",",6507,O
WNT6,6507,B-GENE-Y
expression,6507,O
was,6507,O
positively,6507,O
associated,6507,O
with,6507,O
the,6507,O
tumor,6507,O
stage,6507,O
and,6507,O
the,6507,O
nodal,6507,O
status,6507,O
",",6507,O
and,6507,O
inversely,6507,O
correlated,6507,O
with,6507,O
the,6507,O
response,6507,O
to,6507,O
ECF,6507,O
(,6507,O
Epi,6507,B-CHEMICAL
",",6507,O
cisplatin,6507,B-CHEMICAL
",",6507,O
5-fluorouracil,6507,B-CHEMICAL
),6507,O
chemotherapy,6507,O
.,6507,O
These,6508,O
results,6508,O
showed,6508,O
that,6508,O
WNT6,6508,B-GENE-Y
and,6508,O
Cav1,6508,B-GENE-Y
are,6508,O
upregulated,6508,O
by,6508,O
chemotherapeutics,6508,O
and,6508,O
enhance,6508,O
the,6508,O
resistance,6508,O
of,6508,O
GC,6508,O
cells,6508,O
to,6508,O
anthracycline,6508,B-CHEMICAL
drugs,6508,O
.,6508,O
Understanding,6509,O
the,6509,O
molecular,6509,O
mechanisms,6509,O
driving,6509,O
WNT6/Cav1-induced,6509,B-GENE-Y
drug,6509,O
resistance,6509,O
will,6509,O
provide,6509,O
benefits,6509,O
in,6509,O
developing,6509,O
new,6509,O
therapies,6509,O
for,6509,O
GC,6509,O
.,6509,O
"2,3,7,8-Tetrachlorodibenzo-p-dioxin-induced",6510,B-CHEMICAL
inflammatory,6510,O
activation,6510,O
is,6510,O
mediated,6510,O
by,6510,O
intracellular,6510,O
free,6510,O
calcium,6510,B-CHEMICAL
in,6510,O
microglial,6510,O
cells,6510,O
.,6510,O
"2,3,7,8-Tetrachlorodibenzo-p-dioxin",6511,B-CHEMICAL
(,6511,O
TCDD,6511,B-CHEMICAL
),6511,O
has,6511,O
been,6511,O
known,6511,O
to,6511,O
induce,6511,O
inflammatory,6511,O
signaling,6511,O
in,6511,O
a,6511,O
number,6511,O
of,6511,O
cell,6511,O
types,6511,O
and,6511,O
tissues,6511,O
.,6511,O
However,6512,O
",",6512,O
the,6512,O
adverse,6512,O
effects,6512,O
of,6512,O
TCDD,6512,B-CHEMICAL
on,6512,O
the,6512,O
central,6512,O
nervous,6512,O
system,6512,O
(,6512,O
CNS,6512,O
),6512,O
have,6512,O
not,6512,O
been,6512,O
entirely,6512,O
elucidated,6512,O
.,6512,O
In,6513,O
this,6513,O
study,6513,O
",",6513,O
using,6513,O
reverse,6513,O
transcriptase,6513,O
PCR,6513,O
(,6513,O
RT-PCR,6513,O
),6513,O
and,6513,O
ELISA,6513,O
",",6513,O
we,6513,O
showed,6513,O
that,6513,O
TCDD,6513,B-CHEMICAL
up-regulated,6513,O
the,6513,O
expression,6513,O
and,6513,O
secretion,6513,O
of,6513,O
tumor,6513,B-GENE-Y
necrosis,6513,I-GENE-Y
factor-alpha,6513,I-GENE-Y
(,6513,O
TNF-α,6513,B-GENE-Y
),6513,O
in,6513,O
a,6513,O
time-dependent,6513,O
manner,6513,O
in,6513,O
cultured,6513,O
HAPI,6513,O
microglial,6513,O
cells,6513,O
.,6513,O
TCDD,6514,B-CHEMICAL
also,6514,O
caused,6514,O
a,6514,O
fast,6514,O
(,6514,O
within,6514,O
30min,6514,O
as,6514,O
judged,6514,O
by,6514,O
the,6514,O
increase,6514,O
in,6514,O
its,6514,O
mRNA,6514,O
level,6514,O
),6514,O
activation,6514,O
of,6514,O
cytosolic,6514,B-GENE-Y
phospholipase,6514,I-GENE-Y
A2,6514,I-GENE-Y
(,6514,O
cPLA2,6514,B-GENE-Y
),6514,O
.,6514,O
This,6515,O
initial,6515,O
action,6515,O
was,6515,O
accompanied,6515,O
by,6515,O
up-regulation,6515,O
of,6515,O
cyclooxygenase-2,6515,B-GENE-Y
(,6515,O
COX-2,6515,B-GENE-Y
),6515,O
",",6515,O
an,6515,O
important,6515,O
inflammation,6515,O
marker,6515,O
within,6515,O
1h,6515,O
after,6515,O
TCDD,6515,B-CHEMICAL
treatment,6515,O
.,6515,O
These,6516,O
pro-inflammatory,6516,O
responses,6516,O
were,6516,O
inhibited,6516,O
by,6516,O
two,6516,O
types,6516,O
of,6516,O
Ca,6516,B-CHEMICAL
(,6516,I-CHEMICAL
2+,6516,I-CHEMICAL
),6516,I-CHEMICAL
blockers,6516,O
",",6516,O
bis-,6516,B-CHEMICAL
(,6516,I-CHEMICAL
o-aminophenoxy,6516,I-CHEMICAL
),6516,I-CHEMICAL
ethane-N,6516,I-CHEMICAL
",",6516,I-CHEMICAL
N,6516,I-CHEMICAL
",",6516,I-CHEMICAL
N,6516,I-CHEMICAL
',6516,I-CHEMICAL
",",6516,I-CHEMICAL
N'-tetra-acetic,6516,I-CHEMICAL
acid,6516,I-CHEMICAL
acetoxymethyl,6516,I-CHEMICAL
ester,6516,I-CHEMICAL
(,6516,O
BAPTA-AM,6516,B-CHEMICAL
),6516,O
and,6516,O
nifedipine,6516,B-CHEMICAL
",",6516,O
thus,6516,O
",",6516,O
indicating,6516,O
that,6516,O
the,6516,O
effects,6516,O
are,6516,O
triggered,6516,O
by,6516,O
initial,6516,O
increase,6516,O
in,6516,O
the,6516,O
intracellular,6516,O
concentration,6516,O
of,6516,O
free,6516,O
Ca,6516,B-CHEMICAL
(,6516,I-CHEMICAL
2+,6516,I-CHEMICAL
),6516,I-CHEMICAL
(,6516,O
[,6516,O
Ca,6516,B-CHEMICAL
(,6516,I-CHEMICAL
2+,6516,I-CHEMICAL
),6516,I-CHEMICAL
],6516,O
i,6516,O
),6516,O
.,6516,O
Further,6517,O
",",6517,O
TCDD,6517,B-CHEMICAL
exposure,6517,O
could,6517,O
induce,6517,O
phosphorylation-,6517,O
and,6517,O
ubiquitination-dependent,6517,O
degradation,6517,O
of,6517,O
IкBα,6517,B-GENE-Y
",",6517,O
and,6517,O
the,6517,O
translocation,6517,O
of,6517,O
NF-κB,6517,B-GENE-Y
p65,6517,I-GENE-Y
from,6517,O
the,6517,O
cytosol,6517,O
to,6517,O
the,6517,O
nucleus,6517,O
in,6517,O
this,6517,O
microglial,6517,O
cell,6517,O
line,6517,O
.,6517,O
Thus,6518,O
",",6518,O
the,6518,O
NF-κB,6518,B-GENE-N
signaling,6518,O
pathway,6518,O
can,6518,O
be,6518,O
activated,6518,O
after,6518,O
TCDD,6518,B-CHEMICAL
treatment,6518,O
.,6518,O
However,6519,O
",",6519,O
Ca,6519,B-CHEMICAL
(,6519,I-CHEMICAL
2+,6519,I-CHEMICAL
),6519,I-CHEMICAL
blockers,6519,O
also,6519,O
obviously,6519,O
attenuated,6519,O
NF-κB,6519,B-GENE-N
activation,6519,O
and,6519,O
transnuclear,6519,O
transport,6519,O
induced,6519,O
by,6519,O
TCDD,6519,B-CHEMICAL
.,6519,O
In,6520,O
concert,6520,O
with,6520,O
these,6520,O
results,6520,O
",",6520,O
we,6520,O
highlighted,6520,O
that,6520,O
the,6520,O
secretion,6520,O
of,6520,O
pro-inflammatory,6520,O
cytokine,6520,B-GENE-N
and,6520,O
NF-κB,6520,B-GENE-N
activation,6520,O
induced,6520,O
by,6520,O
TCDD,6520,B-CHEMICAL
can,6520,O
be,6520,O
mediated,6520,O
by,6520,O
elevation,6520,O
of,6520,O
[,6520,O
Ca,6520,B-CHEMICAL
(,6520,I-CHEMICAL
2+,6520,I-CHEMICAL
),6520,I-CHEMICAL
],6520,O
i,6520,O
in,6520,O
HAPI,6520,O
microglial,6520,O
cells,6520,O
.,6520,O
Introduction,6521,O
:,6521,O
The,6521,O
pharmacological,6521,O
profile,6521,O
of,6521,O
eprosartan,6521,B-CHEMICAL
--,6521,O
implications,6521,O
for,6521,O
cerebrovascular,6521,O
and,6521,O
cardiovascular,6521,O
risk,6521,O
reduction,6521,O
.,6521,O
Moderate,6522,O
elevations,6522,O
in,6522,O
blood,6522,O
pressure,6522,O
translate,6522,O
to,6522,O
significant,6522,O
increases,6522,O
in,6522,O
cardiovascular,6522,O
and,6522,O
cerebro,6522,O
vascular,6522,O
risk,6522,O
.,6522,O
Beneficially,6523,O
",",6523,O
this,6523,O
relationship,6523,O
allows,6523,O
small,6523,O
decreases,6523,O
in,6523,O
blood,6523,O
pressure,6523,O
to,6523,O
be,6523,O
associated,6523,O
with,6523,O
risk,6523,O
reduction,6523,O
.,6523,O
Both,6524,O
the,6524,O
renin-angiotensin,6524,B-GENE-Y
system,6524,O
and,6524,O
the,6524,O
sympathetic,6524,O
nervous,6524,O
system,6524,O
are,6524,O
involved,6524,O
in,6524,O
hypertension,6524,O
",",6524,O
hence,6524,O
targeting,6524,O
these,6524,O
systems,6524,O
is,6524,O
likely,6524,O
to,6524,O
be,6524,O
of,6524,O
benefit,6524,O
in,6524,O
the,6524,O
treatment,6524,O
of,6524,O
hypertension,6524,O
.,6524,O
Angiotensin,6525,B-GENE-Y
II,6525,I-GENE-Y
type,6525,I-GENE-Y
1,6525,I-GENE-Y
receptor,6525,I-GENE-Y
blockers,6525,O
(,6525,O
ARBs,6525,O
),6525,O
are,6525,O
used,6525,O
for,6525,O
controlling,6525,O
blood,6525,O
pressure,6525,O
and,6525,O
treating,6525,O
heart,6525,O
failure,6525,O
in,6525,O
a,6525,O
broad,6525,O
range,6525,O
of,6525,O
patients,6525,O
",",6525,O
including,6525,O
those,6525,O
with,6525,O
diabetes,6525,O
and,6525,O
the,6525,O
elderly,6525,O
.,6525,O
Not,6526,O
only,6526,O
have,6526,O
ARBs,6526,O
shown,6526,O
good,6526,O
efficacy,6526,O
and,6526,O
tolerability,6526,O
",",6526,O
they,6526,O
also,6526,O
appear,6526,O
to,6526,O
have,6526,O
a,6526,O
protective,6526,O
effect,6526,O
that,6526,O
goes,6526,O
beyond,6526,O
that,6526,O
expected,6526,O
from,6526,O
the,6526,O
reduction,6526,O
of,6526,O
blood,6526,O
pressure,6526,O
.,6526,O
The,6527,O
ARB,6527,O
eprosartan,6527,B-CHEMICAL
is,6527,O
a,6527,O
nonbiphenyl,6527,O
nontetrazole,6527,O
angiotensin,6527,B-GENE-Y
II,6527,I-GENE-Y
type,6527,I-GENE-Y
1,6527,I-GENE-Y
receptor,6527,I-GENE-Y
(,6527,O
AT1,6527,B-GENE-Y
),6527,O
antagonist,6527,O
",",6527,O
which,6527,O
acts,6527,O
to,6527,O
decrease,6527,O
total,6527,O
peripheral,6527,O
resistance,6527,O
.,6527,O
Eprosartan,6528,B-CHEMICAL
acts,6528,O
at,6528,O
vascular,6528,O
AT1,6528,B-GENE-Y
receptors,6528,I-GENE-Y
(,6528,O
postsynaptically,6528,O
),6528,O
and,6528,O
at,6528,O
presynaptic,6528,O
AT1,6528,B-GENE-Y
receptors,6528,I-GENE-Y
",",6528,O
where,6528,O
it,6528,O
inhibits,6528,O
noradrenaline,6528,B-CHEMICAL
release,6528,O
.,6528,O
In,6529,O
clinical,6529,O
studies,6529,O
",",6529,O
eprosartan,6529,B-CHEMICAL
has,6529,O
been,6529,O
shown,6529,O
to,6529,O
significantly,6529,O
reduce,6529,O
cardiovascular,6529,O
and,6529,O
cerebrovascular,6529,O
events,6529,O
",",6529,O
whilst,6529,O
avoiding,6529,O
the,6529,O
persistent,6529,O
cough,6529,O
that,6529,O
commonly,6529,O
occurs,6529,O
with,6529,O
the,6529,O
use,6529,O
of,6529,O
angiotensin-converting,6529,B-GENE-Y
enzyme,6529,I-GENE-Y
inhibitors,6529,O
.,6529,O
Eprosartan,6530,B-CHEMICAL
can,6530,O
also,6530,O
be,6530,O
differentiated,6530,O
from,6530,O
other,6530,O
ARBs,6530,O
due,6530,O
to,6530,O
its,6530,O
noradrenergic,6530,O
effects,6530,O
",",6530,O
which,6530,O
other,6530,O
ARBs,6530,O
used,6530,O
at,6530,O
therapeutic,6530,O
doses,6530,O
do,6530,O
not,6530,O
possess,6530,O
.,6530,O
Eprosartan,6531,B-CHEMICAL
",",6531,O
therefore,6531,O
",",6531,O
represents,6531,O
a,6531,O
useful,6531,O
therapeutic,6531,O
option,6531,O
in,6531,O
the,6531,O
management,6531,O
of,6531,O
patients,6531,O
with,6531,O
hypertension,6531,O
",",6531,O
including,6531,O
those,6531,O
with,6531,O
a,6531,O
history,6531,O
of,6531,O
stroke,6531,O
or,6531,O
with,6531,O
co-morbid,6531,O
type,6531,O
2,6531,O
diabetes,6531,O
mellitus,6531,O
.,6531,O
Analysis,6532,O
of,6532,O
alpha,6532,B-GENE-N
1L-adrenoceptor,6532,I-GENE-N
pharmacology,6532,O
in,6532,O
rat,6532,O
small,6532,O
mesenteric,6532,O
artery,6532,O
.,6532,O
1,6533,O
.,6533,O
To,6534,O
illuminate,6534,O
the,6534,O
controversy,6534,O
on,6534,O
alpha,6534,B-GENE-Y
1A-,6534,O
or,6534,O
alpha,6534,B-GENE-N
1L-adrenoceptor,6534,I-GENE-N
involvement,6534,O
in,6534,O
noradrenaline-mediated,6534,B-CHEMICAL
contractions,6534,O
of,6534,O
rat,6534,O
small,6534,O
mesenteric,6534,O
artery,6534,O
(,6534,O
SMA,6534,O
),6534,O
",",6534,O
we,6534,O
have,6534,O
studied,6534,O
the,6534,O
effects,6534,O
of,6534,O
subtype-selective,6534,O
alpha,6534,B-GENE-N
1-adrenoceptor,6534,I-GENE-N
agonists,6534,O
and,6534,O
antagonists,6534,O
under,6534,O
different,6534,O
experimental,6534,O
conditions,6534,O
.,6534,O
2,6535,O
.,6535,O
The,6536,O
agonist,6536,O
potency,6536,O
order,6536,O
in,6536,O
rat,6536,O
SMA,6536,O
was,6536,O
:,6536,O
A61603,6536,B-CHEMICAL
>,6536,O
>,6536,O
SKF89748-A,6536,B-CHEMICAL
>,6536,O
cirazoline,6536,B-CHEMICAL
>,6536,O
noradrenaline,6536,B-CHEMICAL
>,6536,O
ST-587,6536,B-CHEMICAL
>,6536,O
methoxamine,6536,B-CHEMICAL
.,6536,O
Prazosin,6537,B-CHEMICAL
antagonized,6537,O
all,6537,O
agonists,6537,O
with,6537,O
a,6537,O
low,6537,O
potency,6537,O
(,6537,O
pA2,6537,O
:,6537,O
8.29-8.80,6537,O
),6537,O
indicating,6537,O
the,6537,O
involvement,6537,O
of,6537,O
alpha,6537,B-GENE-N
1L-rather,6537,O
than,6537,O
alpha,6537,B-GENE-Y
1A-adrenoceptors,6537,I-GENE-Y
.,6537,O
3,6538,O
.,6538,O
The,6539,O
putative,6539,O
alpha,6539,B-GENE-N
1L-adrenoceptor,6539,I-GENE-N
antagonist,6539,O
JTH-601,6539,B-CHEMICAL
",",6539,O
but,6539,O
not,6539,O
the,6539,O
alpha,6539,B-GENE-Y
1B-adrenoceptor,6539,I-GENE-Y
antagonist,6539,O
chloroethylclonidine,6539,B-CHEMICAL
(,6539,O
10,6539,O
microM,6539,O
),6539,O
antagonized,6539,O
noradrenaline-induced,6539,B-CHEMICAL
contractions,6539,O
of,6539,O
SMA,6539,O
.,6539,O
The,6540,O
potency,6540,O
of,6540,O
the,6540,O
selective,6540,O
alpha,6540,B-GENE-Y
1D-adrenoceptor,6540,I-GENE-Y
antagonist,6540,O
BMY,6540,B-CHEMICAL
7378,6540,I-CHEMICAL
against,6540,O
noradrenaline,6540,B-CHEMICAL
(,6540,O
pA2,6540,O
=,6540,O
6.16,6540,O
+/-,6540,O
0.13,6540,O
),6540,O
and,6540,O
of,6540,O
the,6540,O
selective,6540,O
alpha,6540,B-GENE-Y
1A-adrenoceptor,6540,I-GENE-Y
antagonist,6540,O
RS-17053,6540,B-CHEMICAL
against,6540,O
noradrenaline,6540,B-CHEMICAL
(,6540,O
pKB,6540,O
=,6540,O
8.35,6540,O
+/-,6540,O
0.10,6540,O
),6540,O
and,6540,O
against,6540,O
the,6540,O
selective,6540,O
alpha,6540,B-GENE-Y
1A-adrenoceptor,6540,I-GENE-Y
agonist,6540,O
A-61603,6540,B-CHEMICAL
(,6540,O
pKB,6540,O
=,6540,O
8.40,6540,O
+/-,6540,O
0.09,6540,O
),6540,O
were,6540,O
too,6540,O
low,6540,O
to,6540,O
account,6540,O
for,6540,O
alpha,6540,B-GENE-Y
1D-,6540,O
and,6540,O
alpha,6540,B-GENE-Y
1A-adrenoceptor,6540,I-GENE-Y
involvement,6540,O
.,6540,O
4,6541,O
.,6541,O
The,6542,O
potency,6542,O
of,6542,O
RS-17053,6542,B-CHEMICAL
(,6542,O
pKB/pA2,6542,O
's,6542,O
=,6542,O
7.72-8.46,6542,O
),6542,O
was,6542,O
not,6542,O
affected,6542,O
by,6542,O
lowering,6542,O
temperature,6542,O
",",6542,O
changing,6542,O
experimental,6542,O
protocol,6542,O
or,6542,O
inducing,6542,O
myogenic,6542,O
tone,6542,O
via,6542,O
KCl,6542,B-CHEMICAL
or,6542,O
U46619,6542,B-CHEMICAL
.,6542,O
5,6543,O
.,6543,O
Selective,6544,O
protection,6544,O
of,6544,O
a,6544,O
putative,6544,O
alpha,6544,B-GENE-Y
1A-adrenoceptor,6544,I-GENE-Y
population,6544,O
against,6544,O
the,6544,O
irreversible,6544,O
action,6544,O
of,6544,O
phenoxybenzamine,6544,B-CHEMICAL
also,6544,O
failed,6544,O
to,6544,O
increase,6544,O
the,6544,O
potency,6544,O
of,6544,O
RS-17053,6544,B-CHEMICAL
(,6544,O
pA2,6544,O
=,6544,O
8.25,6544,O
+/-,6544,O
0.06,6544,O
against,6544,O
A61603,6544,O
),6544,O
.,6544,O
6,6545,O
.,6545,O
Combined,6546,O
concentration-ratio,6546,O
analysis,6546,O
demonstrated,6546,O
that,6546,O
tamsulosin,6546,B-CHEMICAL
",",6546,O
which,6546,O
does,6546,O
not,6546,O
discriminate,6546,O
between,6546,O
alpha,6546,B-GENE-Y
1A-,6546,O
and,6546,O
alpha,6546,B-GENE-N
1L-adrenoceptors,6546,I-GENE-N
",",6546,O
and,6546,O
RS-17053,6546,B-CHEMICAL
competed,6546,O
for,6546,O
binding,6546,O
at,6546,O
the,6546,O
same,6546,O
site,6546,O
in,6546,O
the,6546,O
SMA,6546,O
.,6546,O
7,6547,O
.,6547,O
In,6548,O
summary,6548,O
",",6548,O
data,6548,O
obtained,6548,O
in,6548,O
our,6548,O
experiments,6548,O
in,6548,O
rat,6548,O
SMA,6548,O
indicate,6548,O
that,6548,O
the,6548,O
alpha,6548,B-GENE-N
1-adrenoceptor,6548,I-GENE-N
mediating,6548,O
noradrenaline-induced,6548,B-CHEMICAL
contraction,6548,O
displays,6548,O
a,6548,O
distinct,6548,O
alpha,6548,B-GENE-N
1L-adrenoceptor,6548,I-GENE-N
pharmacology,6548,O
.,6548,O
This,6549,O
study,6549,O
does,6549,O
not,6549,O
provide,6549,O
evidence,6549,O
for,6549,O
the,6549,O
hypothesis,6549,O
that,6549,O
alpha,6549,B-GENE-N
1L-adrenoceptors,6549,I-GENE-N
represent,6549,O
an,6549,O
affinity,6549,O
state,6549,O
of,6549,O
the,6549,O
alpha,6549,B-GENE-Y
1A-adrenoceptor,6549,I-GENE-Y
in,6549,O
functional,6549,O
assays,6549,O
.,6549,O
Furthermore,6550,O
",",6550,O
there,6550,O
is,6550,O
no,6550,O
co-existing,6550,O
alpha,6550,B-GENE-Y
1A-adrenoceptor,6550,I-GENE-Y
in,6550,O
the,6550,O
SMA,6550,O
.,6550,O
Discriminative,6551,O
stimulus,6551,O
effects,6551,O
of,6551,O
esteratic,6551,O
local,6551,O
anesthetics,6551,O
in,6551,O
squirrel,6551,O
monkeys,6551,O
.,6551,O
A,6552,O
number,6552,O
of,6552,O
esteratic,6552,O
local,6552,O
anesthetics,6552,O
serve,6552,O
as,6552,O
positive,6552,O
reinforcers,6552,O
and,6552,O
produce,6552,O
cocaine-like,6552,B-CHEMICAL
discriminative,6552,O
stimulus,6552,O
effects,6552,O
in,6552,O
animals,6552,O
.,6552,O
It,6553,O
has,6553,O
been,6553,O
suggested,6553,O
that,6553,O
the,6553,O
affinity,6553,O
of,6553,O
these,6553,O
compounds,6553,O
for,6553,O
a,6553,O
site,6553,O
on,6553,O
the,6553,O
dopamine,6553,B-GENE-Y
transporter,6553,I-GENE-Y
",",6553,O
and,6553,O
not,6553,O
their,6553,O
local,6553,O
anesthetic,6553,O
actions,6553,O
",",6553,O
is,6553,O
responsible,6553,O
for,6553,O
these,6553,O
abuse-related,6553,O
behavioral,6553,O
effects,6553,O
.,6553,O
In,6554,O
the,6554,O
present,6554,O
study,6554,O
",",6554,O
three,6554,O
local,6554,O
anesthetics,6554,O
previously,6554,O
shown,6554,O
to,6554,O
be,6554,O
self-administered,6554,O
in,6554,O
animals,6554,O
were,6554,O
examined,6554,O
in,6554,O
squirrel,6554,O
monkeys,6554,O
trained,6554,O
to,6554,O
discriminate,6554,O
cocaine,6554,B-CHEMICAL
(,6554,O
0.3,6554,O
mg/kg,6554,O
),6554,O
from,6554,O
saline,6554,O
in,6554,O
a,6554,O
two-lever,6554,O
",",6554,O
food-reinforced,6554,O
procedure,6554,O
.,6554,O
Dimethocaine,6555,B-CHEMICAL
(,6555,O
0.1-3.0,6555,O
mg/kg,6555,O
),6555,O
fully,6555,O
and,6555,O
dose-dependently,6555,O
substituted,6555,O
for,6555,O
cocaine,6555,B-CHEMICAL
.,6555,O
Doses,6556,O
of,6556,O
dimethocaine,6556,B-CHEMICAL
(,6556,O
1.7,6556,O
mg/kg,6556,O
),6556,O
and,6556,O
cocaine,6556,B-CHEMICAL
(,6556,O
0.3,6556,O
mg/kg,6556,O
),6556,O
which,6556,O
produced,6556,O
full,6556,O
(,6556,O
>,6556,O
80,6556,O
%,6556,O
),6556,O
substitution,6556,O
for,6556,O
cocaine,6556,B-CHEMICAL
were,6556,O
administered,6556,O
in,6556,O
combination,6556,O
with,6556,O
the,6556,O
dopamine,6556,B-GENE-Y
D1,6556,I-GENE-Y
receptor,6556,I-GENE-Y
antagonist,6556,O
SCH,6556,B-CHEMICAL
39166,6556,I-CHEMICAL
(,6556,O
(,6556,B-CHEMICAL
-,6556,I-CHEMICAL
),6556,I-CHEMICAL
"-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H",6556,I-CHEMICAL
-benzo,6556,I-CHEMICAL
[,6556,I-CHEMICAL
d,6556,I-CHEMICAL
],6556,I-CHEMICAL
naphtho-,6556,I-CHEMICAL
(,6556,I-CHEMICAL
"2,1-b",6556,I-CHEMICAL
),6556,I-CHEMICAL
azepine,6556,I-CHEMICAL
),6556,O
and,6556,O
the,6556,O
dopamine,6556,B-GENE-Y
D2,6556,I-GENE-Y
receptor,6556,I-GENE-Y
antagonist,6556,O
raclopride,6556,B-CHEMICAL
(,6556,O
both,6556,O
at,6556,O
0.003-0.03,6556,O
mg/kg,6556,O
),6556,O
.,6556,O
SCH,6557,B-CHEMICAL
39166,6557,I-CHEMICAL
fully,6557,O
blocked,6557,O
the,6557,O
cocaine-like,6557,B-CHEMICAL
discriminative,6557,O
stimulus,6557,O
effects,6557,O
of,6557,O
dimethocaine,6557,B-CHEMICAL
and,6557,O
cocaine,6557,B-CHEMICAL
",",6557,O
but,6557,O
raclopride,6557,B-CHEMICAL
produced,6557,O
only,6557,O
partial,6557,O
antagonism,6557,O
of,6557,O
cocaine-lever,6557,B-CHEMICAL
selection,6557,O
.,6557,O
In,6558,O
addition,6558,O
",",6558,O
there,6558,O
was,6558,O
some,6558,O
evidence,6558,O
that,6558,O
raclopride,6558,B-CHEMICAL
blocked,6558,O
cocaine-lever,6558,B-CHEMICAL
responding,6558,O
produced,6558,O
by,6558,O
a,6558,O
lower,6558,O
dose,6558,O
of,6558,O
dimethocaine,6558,B-CHEMICAL
.,6558,O
In,6559,O
substitution,6559,O
studies,6559,O
",",6559,O
neither,6559,O
procaine,6559,B-CHEMICAL
(,6559,O
1-10,6559,O
mg/kg,6559,O
),6559,O
nor,6559,O
chloroprocaine,6559,B-CHEMICAL
(,6559,O
1-30,6559,O
mg/kg,6559,O
),6559,O
produced,6559,O
cocaine-like,6559,B-CHEMICAL
effects,6559,O
.,6559,O
These,6560,O
results,6560,O
support,6560,O
a,6560,O
role,6560,O
for,6560,O
dopamine,6560,B-CHEMICAL
in,6560,O
the,6560,O
behavioral,6560,O
effects,6560,O
of,6560,O
some,6560,O
local,6560,O
anesthetics,6560,O
.,6560,O
Plasma,6561,O
N-terminal,6561,B-GENE-Y
pro-brain,6561,I-GENE-Y
natriuretic,6561,I-GENE-Y
peptide,6561,I-GENE-Y
and,6561,O
adrenomedullin,6561,B-GENE-Y
:,6561,O
prognostic,6561,O
utility,6561,O
and,6561,O
prediction,6561,O
of,6561,O
benefit,6561,O
from,6561,O
carvedilol,6561,B-CHEMICAL
in,6561,O
chronic,6561,O
ischemic,6561,O
left,6561,O
ventricular,6561,O
dysfunction,6561,O
.,6561,O
Australia-New,6562,O
Zealand,6562,O
Heart,6562,O
Failure,6562,O
Group,6562,O
.,6562,O
OBJECTIVES,6563,O
:,6563,O
We,6563,O
sought,6563,O
to,6563,O
assess,6563,O
plasma,6563,O
concentrations,6563,O
of,6563,O
the,6563,O
amino,6563,B-GENE-Y
(,6563,I-GENE-Y
N,6563,I-GENE-Y
),6563,I-GENE-Y
-terminal,6563,I-GENE-Y
portion,6563,I-GENE-Y
of,6563,I-GENE-Y
pro-brain,6563,I-GENE-Y
natriuretic,6563,I-GENE-Y
peptide,6563,I-GENE-Y
(,6563,O
N-BNP,6563,B-GENE-Y
),6563,O
and,6563,O
adrenomedullin,6563,B-GENE-Y
for,6563,O
prediction,6563,O
of,6563,O
adverse,6563,O
outcomes,6563,O
and,6563,O
responses,6563,O
to,6563,O
treatment,6563,O
in,6563,O
297,6563,O
patients,6563,O
with,6563,O
ischemic,6563,O
left,6563,O
ventricular,6563,O
(,6563,O
LV,6563,O
),6563,O
dysfunction,6563,O
who,6563,O
were,6563,O
randomly,6563,O
assigned,6563,O
to,6563,O
receive,6563,O
carvedilol,6563,B-CHEMICAL
or,6563,O
placebo,6563,O
.,6563,O
BACKGROUND,6564,O
:,6564,O
Although,6564,O
neurohormonal,6564,O
status,6564,O
has,6564,O
known,6564,O
prognostic,6564,O
significance,6564,O
in,6564,O
heart,6564,O
failure,6564,O
",",6564,O
the,6564,O
predictive,6564,O
power,6564,O
of,6564,O
either,6564,O
N-BNP,6564,B-GENE-Y
or,6564,O
adrenomedullin,6564,B-GENE-Y
in,6564,O
chronic,6564,O
ischemic,6564,O
LV,6564,O
dysfunction,6564,O
has,6564,O
not,6564,O
been,6564,O
previously,6564,O
reported,6564,O
.,6564,O
METHODS,6565,O
:,6565,O
Plasma,6565,O
N-BNP,6565,B-GENE-Y
and,6565,O
adrenomedullin,6565,B-GENE-Y
were,6565,O
measured,6565,O
in,6565,O
297,6565,O
patients,6565,O
with,6565,O
chronic,6565,O
ischemic,6565,O
(,6565,O
LV,6565,O
),6565,O
dysfunction,6565,O
before,6565,O
randomization,6565,O
to,6565,O
carvedilol,6565,B-CHEMICAL
or,6565,O
placebo,6565,O
",",6565,O
added,6565,O
to,6565,O
established,6565,O
treatment,6565,O
with,6565,O
a,6565,O
converting,6565,O
enzyme,6565,O
inhibitor,6565,O
and,6565,O
loop,6565,O
diuretic,6565,O
(,6565,O
with,6565,O
or,6565,O
without,6565,O
digoxin,6565,O
),6565,O
.,6565,O
The,6566,O
patients,6566,O
',6566,O
clinical,6566,O
outcomes,6566,O
",",6566,O
induding,6566,O
mortality,6566,O
and,6566,O
heart,6566,O
failure,6566,O
events,6566,O
",",6566,O
were,6566,O
recorded,6566,O
for,6566,O
18,6566,O
months,6566,O
.,6566,O
RESULTS,6567,O
:,6567,O
Above-median,6567,O
N-BNP,6567,B-GENE-Y
and,6567,O
adrenomedullin,6567,B-GENE-Y
levels,6567,O
conferred,6567,O
increased,6567,O
risks,6567,O
(,6567,O
all,6567,O
p,6567,O
<,6567,O
0.001,6567,O
),6567,O
of,6567,O
mortality,6567,O
(,6567,O
risk,6567,O
ratios,6567,O
[,6567,O
95,6567,O
%,6567,O
confidence,6567,O
intervals,6567,O
],6567,O
:,6567,O
4.67,6567,O
[,6567,O
2-10.9,6567,O
],6567,O
and,6567,O
3.92,6567,O
[,6567,O
1.76-8.7,6567,O
],6567,O
",",6567,O
respectively,6567,O
),6567,O
and,6567,O
hospital,6567,O
admission,6567,O
with,6567,O
heart,6567,O
failure,6567,O
(,6567,O
4.7,6567,O
[,6567,O
2.2-10.3,6567,O
],6567,O
and,6567,O
2.4,6567,O
[,6567,O
1.3-4.5,6567,O
],6567,O
",",6567,O
respectively,6567,O
),6567,O
.,6567,O
Both,6568,O
of,6568,O
these,6568,O
predicted,6568,O
death,6568,O
or,6568,O
heart,6568,O
failure,6568,O
independent,6568,O
of,6568,O
age,6568,O
",",6568,O
New,6568,O
York,6568,O
Heart,6568,O
Association,6568,O
functional,6568,O
class,6568,O
",",6568,O
LV,6568,O
ejection,6568,O
fraction,6568,O
",",6568,O
previous,6568,O
myocardial,6568,O
infarction,6568,O
or,6568,O
previous,6568,O
admission,6568,O
with,6568,O
heart,6568,O
failure,6568,O
.,6568,O
Carvedilol,6569,B-CHEMICAL
reduced,6569,O
the,6569,O
risk,6569,O
of,6569,O
death,6569,O
or,6569,O
heart,6569,O
failure,6569,O
in,6569,O
patients,6569,O
with,6569,O
above-median,6569,O
levels,6569,O
of,6569,O
N-BNP,6569,B-GENE-Y
or,6569,O
adrenomedullin,6569,B-GENE-Y
",",6569,O
or,6569,O
both,6569,O
",",6569,O
to,6569,O
rates,6569,O
not,6569,O
significantly,6569,O
different,6569,O
from,6569,O
those,6569,O
observed,6569,O
in,6569,O
patients,6569,O
with,6569,O
levels,6569,O
below,6569,O
the,6569,O
median,6569,O
value,6569,O
.,6569,O
CONCLUSIONS,6570,O
:,6570,O
In,6570,O
patients,6570,O
with,6570,O
established,6570,O
ischemic,6570,O
LV,6570,O
dysfunction,6570,O
",",6570,O
plasma,6570,O
N-BNP,6570,B-GENE-Y
and,6570,O
adrenomedullin,6570,B-GENE-Y
are,6570,O
independent,6570,O
predictors,6570,O
of,6570,O
mortality,6570,O
and,6570,O
heart,6570,O
failure,6570,O
.,6570,O
Carvedilol,6571,B-CHEMICAL
reduced,6571,O
mortality,6571,O
and,6571,O
heart,6571,O
failure,6571,O
in,6571,O
patients,6571,O
with,6571,O
higher,6571,O
pre-treatment,6571,O
plasma,6571,O
N-BNP,6571,B-GENE-Y
and,6571,O
adrenomedullin,6571,B-GENE-Y
.,6571,O
Synergistic,6572,O
anti-cancer,6572,O
effects,6572,O
of,6572,O
resveratrol,6572,B-CHEMICAL
and,6572,O
chemotherapeutic,6572,O
agent,6572,O
clofarabine,6572,B-CHEMICAL
against,6572,O
human,6572,O
malignant,6572,O
mesothelioma,6572,O
MSTO-211H,6572,O
cells,6572,O
.,6572,O
Dietary,6573,O
phytochemicals,6573,O
as,6573,O
adjuvants,6573,O
have,6573,O
been,6573,O
suggested,6573,O
to,6573,O
play,6573,O
important,6573,O
roles,6573,O
in,6573,O
enhancing,6573,O
chemotherapeutic,6573,O
potential,6573,O
owing,6573,O
to,6573,O
multitargeted,6573,O
chemopreventive,6573,O
properties,6573,O
and,6573,O
lack,6573,O
of,6573,O
substantial,6573,O
toxicity,6573,O
.,6573,O
Here,6574,O
",",6574,O
we,6574,O
investigated,6574,O
the,6574,O
efficacy,6574,O
of,6574,O
the,6574,O
combined,6574,O
treatment,6574,O
of,6574,O
various,6574,O
phytochemicals,6574,O
with,6574,O
the,6574,O
anticancer,6574,O
drug,6574,O
clofarabine,6574,B-CHEMICAL
in,6574,O
malignant,6574,O
mesothelioma,6574,O
MSTO-211H,6574,O
cells,6574,O
and,6574,O
normal,6574,O
mesothelial,6574,O
MeT-5A,6574,O
cells,6574,O
.,6574,O
The,6575,O
combined,6575,O
treatment,6575,O
of,6575,O
resveratrol,6575,B-CHEMICAL
and,6575,O
clofarabine,6575,B-CHEMICAL
produced,6575,O
a,6575,O
synergistic,6575,O
antiproliferative,6575,O
effect,6575,O
in,6575,O
MSTO-211H,6575,O
cells,6575,O
",",6575,O
but,6575,O
not,6575,O
in,6575,O
MeT-5A,6575,O
cells,6575,O
.,6575,O
In,6576,O
MSTO-211H,6576,O
cells,6576,O
",",6576,O
the,6576,O
nuclear,6576,O
accumulation,6576,O
of,6576,O
Sp1,6576,B-GENE-Y
and,6576,O
the,6576,O
levels,6576,O
of,6576,O
p-Akt,6576,B-GENE-N
",",6576,O
Sp1,6576,B-GENE-Y
",",6576,O
c-Met,6576,B-GENE-Y
",",6576,O
cyclin,6576,B-GENE-Y
D1,6576,I-GENE-Y
",",6576,O
and,6576,O
p21,6576,B-GENE-Y
were,6576,O
effectively,6576,O
decreased,6576,O
by,6576,O
the,6576,O
combined,6576,O
treatment,6576,O
of,6576,O
them,6576,O
.,6576,O
In,6577,O
combination,6577,O
with,6577,O
clofarabine,6577,B-CHEMICAL
",",6577,O
the,6577,O
ability,6577,O
of,6577,O
resveratrol,6577,B-CHEMICAL
to,6577,O
reduce,6577,O
the,6577,O
contents,6577,O
of,6577,O
Sp1,6577,B-GENE-Y
and,6577,O
its,6577,O
target,6577,O
gene,6577,O
products,6577,O
was,6577,O
also,6577,O
evident,6577,O
in,6577,O
a,6577,O
time-,6577,O
and,6577,O
dose-dependent,6577,O
experiment,6577,O
.,6577,O
The,6578,O
inhibition,6578,O
of,6578,O
phosphoinositide,6578,B-GENE-N
3-kinase,6578,I-GENE-N
using,6578,O
Ly294002,6578,B-CHEMICAL
augmented,6578,O
a,6578,O
decrease,6578,O
in,6578,O
the,6578,O
p21,6578,B-GENE-Y
level,6578,O
induced,6578,O
by,6578,O
their,6578,O
combination,6578,O
",",6578,O
but,6578,O
it,6578,O
showed,6578,O
no,6578,O
significant,6578,O
effects,6578,O
on,6578,O
expression,6578,O
of,6578,O
Sp1,6578,B-GENE-Y
and,6578,O
cyclin,6578,B-GENE-Y
D1,6578,I-GENE-Y
.,6578,O
Taken,6579,O
together,6579,O
",",6579,O
the,6579,O
data,6579,O
provide,6579,O
evidence,6579,O
that,6579,O
the,6579,O
synergistic,6579,O
antiproliferative,6579,O
effect,6579,O
of,6579,O
resveratrol,6579,B-CHEMICAL
and,6579,O
clofarabine,6579,B-CHEMICAL
is,6579,O
linked,6579,O
to,6579,O
the,6579,O
inhibition,6579,O
of,6579,O
Akt,6579,B-GENE-N
and,6579,O
Sp1,6579,B-GENE-Y
activities,6579,O
",",6579,O
and,6579,O
suggest,6579,O
that,6579,O
this,6579,O
combination,6579,O
may,6579,O
have,6579,O
therapeutic,6579,O
value,6579,O
in,6579,O
treatment,6579,O
of,6579,O
malignant,6579,O
mesothelioma,6579,O
.,6579,O
Phillyrin,6580,B-CHEMICAL
attenuates,6580,O
high,6580,O
glucose-induced,6580,B-CHEMICAL
lipid,6580,O
accumulation,6580,O
in,6580,O
human,6580,O
HepG2,6580,O
hepatocytes,6580,O
through,6580,O
the,6580,O
activation,6580,O
of,6580,O
LKB1/AMP-activated,6580,B-GENE-Y
protein,6580,I-GENE-N
kinase-dependent,6580,O
signalling,6580,O
.,6580,O
Phillyrin,6581,B-CHEMICAL
",",6581,O
an,6581,O
active,6581,O
constituent,6581,O
found,6581,O
in,6581,O
many,6581,O
medicinal,6581,O
plants,6581,O
and,6581,O
certain,6581,O
functional,6581,O
foods,6581,O
",",6581,O
has,6581,O
anti-obesity,6581,O
activity,6581,O
in,6581,O
vivo,6581,O
.,6581,O
The,6582,O
aim,6582,O
of,6582,O
our,6582,O
study,6582,O
was,6582,O
to,6582,O
provide,6582,O
new,6582,O
data,6582,O
on,6582,O
the,6582,O
molecular,6582,O
mechanism,6582,O
(,6582,O
s,6582,O
),6582,O
underlying,6582,O
the,6582,O
role,6582,O
of,6582,O
phillyrin,6582,B-CHEMICAL
in,6582,O
the,6582,O
prevention,6582,O
of,6582,O
high,6582,O
glucose-induced,6582,B-CHEMICAL
lipid,6582,O
accumulation,6582,O
in,6582,O
human,6582,O
HepG2,6582,O
hepatocytes,6582,O
.,6582,O
We,6583,O
found,6583,O
that,6583,O
phillyrin,6583,B-CHEMICAL
suppressed,6583,O
high,6583,O
glucose-induced,6583,B-CHEMICAL
lipid,6583,O
accumulation,6583,O
in,6583,O
HepG2,6583,O
cells,6583,O
.,6583,O
Phillyrin,6584,B-CHEMICAL
strongly,6584,O
inhibited,6584,O
high,6584,O
glucose-induced,6584,B-CHEMICAL
fatty,6584,B-GENE-Y
acid,6584,I-GENE-Y
synthase,6584,I-GENE-Y
(,6584,O
FAS,6584,B-GENE-Y
),6584,O
expression,6584,O
by,6584,O
modulating,6584,O
sterol,6584,B-GENE-Y
regulatory,6584,I-GENE-Y
element-binding,6584,I-GENE-Y
protein-1c,6584,I-GENE-Y
(,6584,O
SREBP-1c,6584,B-GENE-Y
),6584,O
activation,6584,O
.,6584,O
Moreover,6585,O
",",6585,O
use,6585,O
of,6585,O
the,6585,O
pharmacological,6585,O
AMP-activated,6585,B-GENE-N
protein,6585,I-GENE-N
kinase,6585,I-GENE-N
(,6585,O
AMPK,6585,B-GENE-N
),6585,O
inhibitor,6585,O
compound,6585,B-CHEMICAL
C,6585,I-CHEMICAL
revealed,6585,O
that,6585,O
AMPK,6585,B-GENE-N
is,6585,O
essential,6585,O
for,6585,O
suppressing,6585,O
SREBP-1c,6585,B-GENE-Y
expression,6585,O
in,6585,O
phillyrin-treated,6585,B-CHEMICAL
cells,6585,O
.,6585,O
Finally,6586,O
",",6586,O
we,6586,O
found,6586,O
that,6586,O
liver,6586,B-GENE-Y
kinase,6586,I-GENE-Y
B1,6586,I-GENE-Y
(,6586,O
LKB1,6586,B-GENE-Y
),6586,O
phosphorylation,6586,O
is,6586,O
required,6586,O
for,6586,O
the,6586,O
phillyrin-enhanced,6586,B-CHEMICAL
activation,6586,O
of,6586,O
AMPK,6586,B-GENE-N
in,6586,O
HepG2,6586,O
hepatocytes,6586,O
.,6586,O
These,6587,O
results,6587,O
indicate,6587,O
that,6587,O
phillyrin,6587,B-CHEMICAL
prevents,6587,O
lipid,6587,O
accumulation,6587,O
in,6587,O
HepG2,6587,O
cells,6587,O
by,6587,O
blocking,6587,O
the,6587,O
expression,6587,O
of,6587,O
SREBP-1c,6587,B-GENE-Y
and,6587,O
FAS,6587,B-GENE-Y
through,6587,O
LKB1/AMPK,6587,B-GENE-Y
activation,6587,O
",",6587,O
suggesting,6587,O
that,6587,O
phillyrin,6587,B-CHEMICAL
is,6587,O
a,6587,O
novel,6587,O
AMPK,6587,B-GENE-N
activator,6587,O
with,6587,O
a,6587,O
role,6587,O
in,6587,O
the,6587,O
prevention,6587,O
and,6587,O
treatment,6587,O
of,6587,O
obesity,6587,O
.,6587,O
Structural,6588,O
",",6588,O
kinetic,6588,O
",",6588,O
and,6588,O
thermodynamic,6588,O
analysis,6588,O
of,6588,O
the,6588,O
binding,6588,O
of,6588,O
the,6588,O
40,6588,O
kDa,6588,O
PEG-interferon-alpha2a,6588,B-CHEMICAL
and,6588,O
its,6588,O
individual,6588,O
positional,6588,O
isomers,6588,O
to,6588,O
the,6588,O
extracellular,6588,O
domain,6588,O
of,6588,O
the,6588,O
receptor,6588,O
IFNAR2,6588,B-GENE-Y
.,6588,O
Type-I,6589,B-GENE-N
Interferons,6589,I-GENE-N
exert,6589,O
antiviral,6589,O
and,6589,O
antiproliferative,6589,O
activities,6589,O
through,6589,O
the,6589,O
binding,6589,O
to,6589,O
a,6589,O
common,6589,O
cell,6589,O
surface,6589,O
receptor,6589,O
comprising,6589,O
two,6589,O
subunits,6589,O
",",6589,O
IFNAR1,6589,B-GENE-Y
and,6589,O
IFNAR2,6589,B-GENE-Y
.,6589,O
Human,6590,B-GENE-Y
recombinant,6590,I-GENE-Y
Interferon-alpha,6590,I-GENE-Y
(,6590,I-GENE-Y
2a,6590,I-GENE-Y
),6590,I-GENE-Y
(,6590,O
IFNalpha,6590,B-GENE-Y
(,6590,I-GENE-Y
2a,6590,I-GENE-Y
),6590,I-GENE-Y
),6590,O
is,6590,O
a,6590,O
potent,6590,O
drug,6590,O
(,6590,O
Roferon-A,6590,O
),6590,O
used,6590,O
to,6590,O
treat,6590,O
various,6590,O
cancers,6590,O
and,6590,O
viral,6590,O
diseases,6590,O
including,6590,O
Hepatitis,6590,O
B/C,6590,O
infections,6590,O
.,6590,O
To,6591,O
significantly,6591,O
improve,6591,O
the,6591,O
pharmacological,6591,O
properties,6591,O
of,6591,O
the,6591,O
drug,6591,O
",",6591,O
a,6591,O
pegylated,6591,O
form,6591,O
of,6591,O
IFNalpha,6591,B-GENE-Y
(,6591,I-GENE-Y
2a,6591,I-GENE-Y
),6591,I-GENE-Y
was,6591,O
developed,6591,O
(,6591,O
PEGASYS,6591,O
),6591,O
.,6591,O
This,6592,O
40,6592,O
kDa,6592,O
PEG-conjugated,6592,B-CHEMICAL
IFNalpha,6592,B-GENE-Y
(,6592,I-GENE-Y
2a,6592,I-GENE-Y
),6592,I-GENE-Y
(,6592,O
(,6592,O
40,6592,O
),6592,O
PEG-IFNalpha,6592,O
(,6592,I-GENE-Y
2a,6592,I-GENE-Y
),6592,I-GENE-Y
),6592,O
is,6592,O
obtained,6592,O
by,6592,O
the,6592,O
covalent,6592,O
binding,6592,O
of,6592,O
one,6592,O
40,6592,O
kDa,6592,O
branched,6592,O
PEG-polymer,6592,O
to,6592,O
a,6592,O
lysine,6592,B-CHEMICAL
side-chain,6592,O
of,6592,O
IFNalpha,6592,B-GENE-Y
(,6592,I-GENE-Y
2a,6592,I-GENE-Y
),6592,I-GENE-Y
.,6592,O
Here,6593,O
",",6593,O
we,6593,O
report,6593,O
the,6593,O
detailed,6593,O
structural,6593,O
",",6593,O
kinetic,6593,O
",",6593,O
and,6593,O
thermodynamic,6593,O
analysis,6593,O
of,6593,O
the,6593,O
binding,6593,O
to,6593,O
the,6593,O
extracellular,6593,O
domain,6593,O
of,6593,O
the,6593,O
receptor,6593,O
IFNAR2,6593,B-GENE-Y
of,6593,O
(,6593,O
40,6593,O
),6593,O
PEG-IFNalpha,6593,O
(,6593,I-GENE-Y
2a,6593,I-GENE-Y
),6593,I-GENE-Y
and,6593,O
its,6593,O
isolated,6593,O
positional,6593,O
isomers,6593,O
modified,6593,O
at,6593,O
K31,6593,O
",",6593,O
K134,6593,O
",",6593,O
K131,6593,O
",",6593,O
K121,6593,O
",",6593,O
K164,6593,O
",",6593,O
and,6593,O
K70,6593,O
",",6593,O
respectively,6593,O
",",6593,O
in,6593,O
comparison,6593,O
with,6593,O
unmodified,6593,O
IFNalpha,6593,B-GENE-Y
(,6593,I-GENE-Y
2a,6593,I-GENE-Y
),6593,I-GENE-Y
.,6593,O
Our,6594,O
binding,6594,O
studies,6594,O
",",6594,O
using,6594,O
the,6594,O
surface,6594,O
plasmon,6594,O
resonance,6594,O
technique,6594,O
",",6594,O
show,6594,O
that,6594,O
the,6594,O
pegylation,6594,O
does,6594,O
not,6594,O
abolish,6594,O
the,6594,O
binding,6594,O
to,6594,O
the,6594,O
receptor,6594,O
",",6594,O
but,6594,O
significantly,6594,O
reduces,6594,O
the,6594,O
affinity,6594,O
mainly,6594,O
due,6594,O
to,6594,O
a,6594,O
change,6594,O
of,6594,O
the,6594,O
association,6594,O
rate,6594,O
.,6594,O
The,6595,O
results,6595,O
are,6595,O
supported,6595,O
by,6595,O
modeling,6595,O
and,6595,O
simulation,6595,O
of,6595,O
the,6595,O
binding,6595,O
",",6595,O
using,6595,O
Self-Avoiding-Walk,6595,O
calculations,6595,O
for,6595,O
the,6595,O
polymer,6595,O
conformations,6595,O
.,6595,O
A,6596,O
correlation,6596,O
between,6596,O
the,6596,O
structural,6596,O
parameters,6596,O
and,6596,O
the,6596,O
kinetic,6596,O
and,6596,O
thermodynamic,6596,O
parameters,6596,O
of,6596,O
the,6596,O
binding,6596,O
of,6596,O
the,6596,O
positional,6596,O
isomers,6596,O
could,6596,O
be,6596,O
established,6596,O
.,6596,O
For,6597,O
the,6597,O
Isomer-K31,6597,O
and,6597,O
-K164,6597,O
",",6597,O
the,6597,O
PEG-polymer,6597,O
attachment,6597,O
point,6597,O
is,6597,O
located,6597,O
in,6597,O
proximity,6597,O
to,6597,O
the,6597,O
binding,6597,O
interface,6597,O
",",6597,O
and,6597,O
the,6597,O
isomers,6597,O
display,6597,O
affinity,6597,O
in,6597,O
the,6597,O
range,6597,O
150-520,6597,O
nM,6597,O
in,6597,O
an,6597,O
enthalpy-driven,6597,O
binding,6597,O
process,6597,O
.,6597,O
In,6598,O
contrast,6598,O
for,6598,O
the,6598,O
Isomer-K134,6598,O
",",6598,O
-K131,6598,O
",",6598,O
-K121,6598,O
",",6598,O
and,6598,O
-K70,6598,O
",",6598,O
the,6598,O
PEG-polymer,6598,B-CHEMICAL
is,6598,O
attached,6598,O
remotely,6598,O
from,6598,O
the,6598,O
binding,6598,O
interface,6598,O
",",6598,O
and,6598,O
the,6598,O
isomers,6598,O
exhibit,6598,O
a,6598,O
higher,6598,O
affinity,6598,O
(,6598,O
32-76,6598,O
nM,6598,O
),6598,O
in,6598,O
an,6598,O
entropy-driven,6598,O
binding,6598,O
process,6598,O
.,6598,O
This,6599,O
study,6599,O
constitutes,6599,O
an,6599,O
essential,6599,O
collection,6599,O
of,6599,O
knowledge,6599,O
on,6599,O
which,6599,O
the,6599,O
interaction,6599,O
of,6599,O
(,6599,O
40,6599,O
),6599,O
PEG-IFNalpha,6599,O
(,6599,I-GENE-Y
2a,6599,I-GENE-Y
),6599,I-GENE-Y
and,6599,O
its,6599,O
positional,6599,O
isomers,6599,O
with,6599,O
its,6599,O
cellular,6599,O
receptors,6599,O
can,6599,O
be,6599,O
better,6599,O
understood,6599,O
.,6599,O
Noncanonical,6600,O
control,6600,O
of,6600,O
C.,6600,O
elegans,6600,O
germline,6600,O
apoptosis,6600,O
by,6600,O
the,6600,O
insulin/IGF-1,6600,B-GENE-N
and,6600,O
Ras/MAPK,6600,B-GENE-N
signaling,6600,O
pathways,6600,O
.,6600,O
The,6601,O
insulin/IGF-1,6601,B-GENE-N
pathway,6601,O
controls,6601,O
a,6601,O
number,6601,O
of,6601,O
physiological,6601,O
processes,6601,O
in,6601,O
the,6601,O
nematode,6601,O
worm,6601,O
Caenorhabditis,6601,O
elegans,6601,O
",",6601,O
including,6601,O
development,6601,O
",",6601,O
aging,6601,O
and,6601,O
stress,6601,O
response,6601,O
.,6601,O
We,6602,O
previously,6602,O
found,6602,O
that,6602,O
the,6602,O
Akt/PKB,6602,B-GENE-Y
ortholog,6602,O
AKT-1,6602,B-GENE-Y
dampens,6602,O
the,6602,O
apoptotic,6602,O
response,6602,O
to,6602,O
genotoxic,6602,O
stress,6602,O
in,6602,O
the,6602,O
germline,6602,O
by,6602,O
negatively,6602,O
regulating,6602,O
the,6602,O
p53-like,6602,B-GENE-Y
transcription,6602,I-GENE-Y
factor,6602,I-GENE-Y
CEP-1,6602,B-GENE-Y
.,6602,O
Here,6603,O
",",6603,O
we,6603,O
report,6603,O
unexpected,6603,O
rearrangements,6603,O
to,6603,O
the,6603,O
insulin/IGF-1,6603,B-GENE-N
pathway,6603,O
",",6603,O
whereby,6603,O
the,6603,O
insulin-like,6603,B-GENE-Y
receptor,6603,I-GENE-Y
DAF-2,6603,B-GENE-Y
and,6603,O
3-phosphoinositide-dependent,6603,B-GENE-Y
protein,6603,I-GENE-Y
kinase,6603,I-GENE-Y
PDK-1,6603,I-GENE-Y
oppose,6603,O
AKT-1,6603,B-GENE-Y
to,6603,O
promote,6603,O
DNA,6603,O
damage-induced,6603,O
apoptosis,6603,O
.,6603,O
While,6604,O
DNA,6604,O
damage,6604,O
does,6604,O
not,6604,O
affect,6604,O
phosphorylation,6604,O
at,6604,O
the,6604,O
PDK-1,6604,B-GENE-Y
site,6604,O
Thr350/Thr308,6604,B-GENE-N
of,6604,O
AKT-1,6604,B-GENE-Y
",",6604,O
it,6604,O
increased,6604,O
phosphorylation,6604,O
at,6604,O
Ser517/Ser473,6604,B-GENE-N
.,6604,O
Although,6605,O
ablation,6605,O
of,6605,O
daf-2,6605,B-GENE-Y
or,6605,O
pdk-1,6605,B-GENE-Y
completely,6605,O
suppressed,6605,O
akt-1-dependent,6605,B-GENE-Y
apoptosis,6605,O
",",6605,O
the,6605,O
transcriptional,6605,O
activation,6605,O
of,6605,O
CEP-1,6605,B-GENE-Y
was,6605,O
unaffected,6605,O
",",6605,O
suggesting,6605,O
that,6605,O
daf-2,6605,B-GENE-Y
and,6605,O
pdk-1,6605,B-GENE-Y
act,6605,O
independently,6605,O
or,6605,O
downstream,6605,O
of,6605,O
cep-1,6605,B-GENE-Y
and,6605,O
akt-1,6605,B-GENE-Y
.,6605,O
Ablation,6606,O
of,6606,O
the,6606,O
akt-1,6606,B-GENE-Y
paralog,6606,O
akt-2,6606,B-GENE-Y
or,6606,O
the,6606,O
downstream,6606,O
target,6606,O
of,6606,O
the,6606,O
insulin/IGF-1,6606,B-GENE-N
pathway,6606,O
daf-16,6606,B-GENE-Y
(,6606,O
a,6606,O
FOXO,6606,B-GENE-Y
transcription,6606,O
factor,6606,O
),6606,O
restored,6606,O
sensitivity,6606,O
to,6606,O
damage-induced,6606,O
apoptosis,6606,O
in,6606,O
daf-2,6606,B-GENE-Y
and,6606,O
pdk-1,6606,B-GENE-Y
mutants,6606,O
.,6606,O
In,6607,O
addition,6607,O
",",6607,O
daf-2,6607,B-GENE-Y
and,6607,O
pdk-1,6607,B-GENE-Y
mutants,6607,O
have,6607,O
reduced,6607,O
levels,6607,O
of,6607,O
phospho-MPK-1/ERK,6607,B-GENE-Y
in,6607,O
their,6607,O
germ,6607,O
cells,6607,O
",",6607,O
indicating,6607,O
that,6607,O
the,6607,O
insulin/IGF-1,6607,B-GENE-N
pathway,6607,O
promotes,6607,O
Ras,6607,B-GENE-N
signaling,6607,O
in,6607,O
the,6607,O
germline,6607,O
.,6607,O
Ablation,6608,O
of,6608,O
the,6608,O
Ras,6608,B-GENE-N
effector,6608,O
gla-3,6608,B-GENE-Y
",",6608,O
a,6608,O
negative,6608,O
regulator,6608,O
of,6608,O
mpk-1,6608,B-GENE-Y
",",6608,O
restored,6608,O
sensitivity,6608,O
to,6608,O
apoptosis,6608,O
in,6608,O
daf-2,6608,B-GENE-Y
mutants,6608,O
",",6608,O
suggesting,6608,O
that,6608,O
gla-3,6608,B-GENE-Y
acts,6608,O
downstream,6608,O
of,6608,O
daf-2,6608,B-GENE-Y
.,6608,O
In,6609,O
addition,6609,O
",",6609,O
the,6609,O
hypersensitivity,6609,O
of,6609,O
let-60/Ras,6609,B-GENE-Y
gain-of-function,6609,O
mutants,6609,O
to,6609,O
damage-induced,6609,O
apoptosis,6609,O
was,6609,O
suppressed,6609,O
to,6609,O
wild-type,6609,O
levels,6609,O
by,6609,O
ablation,6609,O
of,6609,O
daf-2,6609,B-GENE-Y
.,6609,O
Thus,6610,O
",",6610,O
insulin/IGF-1,6610,B-GENE-N
signaling,6610,O
selectively,6610,O
engages,6610,O
AKT-2/DAF-16,6610,B-GENE-Y
to,6610,O
promote,6610,O
DNA,6610,O
damage-induced,6610,O
germ,6610,O
cell,6610,O
apoptosis,6610,O
downstream,6610,O
of,6610,O
CEP-1,6610,B-GENE-Y
through,6610,O
the,6610,O
Ras,6610,B-GENE-N
pathway,6610,O
.,6610,O
Carbonic,6611,B-GENE-N
anhydrase,6611,I-GENE-N
inhibitors,6611,O
.,6611,O
Benzenesulfonamides,6612,B-CHEMICAL
incorporating,6612,O
cyanoacrylamide,6612,B-CHEMICAL
moieties,6612,O
strongly,6612,O
inhibit,6612,O
Saccharomyces,6612,B-GENE-Y
cerevisiae,6612,I-GENE-Y
β-carbonic,6612,I-GENE-Y
anhydrase,6612,I-GENE-Y
.,6612,O
A,6613,O
series,6613,O
of,6613,O
benzenesulfonamides,6613,B-CHEMICAL
incorporating,6613,O
cyanoacrylamide,6613,B-CHEMICAL
moieties,6613,O
(,6613,O
tyrphostine,6613,B-CHEMICAL
analogs,6613,O
),6613,O
were,6613,O
assayed,6613,O
as,6613,O
inhibitors,6613,O
of,6613,O
the,6613,O
β-carbonic,6613,B-GENE-Y
anhydrase,6613,I-GENE-Y
(,6613,O
CA,6613,B-GENE-N
",",6613,O
EC,6613,B-GENE-Y
4.2.1.1,6613,I-GENE-Y
),6613,O
from,6613,O
Saccharomyces,6613,O
cerevisiae,6613,O
",",6613,O
ScCA,6613,B-GENE-Y
.,6613,O
Some,6614,O
of,6614,O
these,6614,O
compounds,6614,O
were,6614,O
low,6614,O
nanomolar,6614,O
or,6614,O
subnanomolar,6614,O
ScCA,6614,B-GENE-Y
inhibitors,6614,O
and,6614,O
showed,6614,O
selectivity,6614,O
ratios,6614,O
in,6614,O
the,6614,O
range,6614,O
of,6614,O
4.91-69.86,6614,O
for,6614,O
inhibiting,6614,O
the,6614,O
yeast,6614,O
enzyme,6614,O
over,6614,O
the,6614,O
offtarget,6614,O
human,6614,O
(,6614,O
h,6614,O
),6614,O
isoforms,6614,O
hCA,6614,B-GENE-Y
I,6614,I-GENE-Y
and,6614,O
of,6614,O
6.46-13.52,6614,O
for,6614,O
inhibiting,6614,O
ScCA,6614,B-GENE-Y
over,6614,O
hCA,6614,B-GENE-Y
II,6614,I-GENE-Y
.,6614,O
The,6615,O
model,6615,O
organism,6615,O
S.,6615,O
cerevisiae,6615,O
and,6615,O
this,6615,O
particular,6615,O
enzyme,6615,O
may,6615,O
be,6615,O
useful,6615,O
for,6615,O
detecting,6615,O
antifungals,6615,O
with,6615,O
a,6615,O
novel,6615,O
mechanism,6615,O
of,6615,O
action,6615,O
compared,6615,O
to,6615,O
the,6615,O
classical,6615,O
azole,6615,B-CHEMICAL
drugs,6615,O
to,6615,O
which,6615,O
significant,6615,O
drug,6615,O
resistance,6615,O
emerged,6615,O
.,6615,O
Indeed,6616,O
",",6616,O
some,6616,O
of,6616,O
these,6616,O
sulfonamides,6616,B-CHEMICAL
inhibited,6616,O
the,6616,O
growth,6616,O
of,6616,O
the,6616,O
yeast,6616,O
with,6616,O
CC50-s,6616,O
in,6616,O
the,6616,O
range,6616,O
of,6616,O
0.73-6.54μM,6616,O
.,6616,O
Artemisinic,6617,B-CHEMICAL
acid,6617,I-CHEMICAL
inhibits,6617,O
melanogenesis,6617,O
through,6617,O
downregulation,6617,O
of,6617,O
C/EBP,6617,B-GENE-Y
α-dependent,6617,O
expression,6617,O
of,6617,O
HMG-CoA,6617,B-GENE-Y
reductase,6617,I-GENE-Y
gene,6617,O
.,6617,O
Cholesterol,6618,B-CHEMICAL
is,6618,O
associated,6618,O
with,6618,O
the,6618,O
regulation,6618,O
of,6618,O
melanogenesis,6618,O
which,6618,O
is,6618,O
the,6618,O
major,6618,O
physiological,6618,O
defense,6618,O
against,6618,O
solar,6618,O
irradiation,6618,O
.,6618,O
The,6619,O
present,6619,O
study,6619,O
was,6619,O
designed,6619,O
to,6619,O
determine,6619,O
the,6619,O
effects,6619,O
of,6619,O
artemisinic,6619,B-CHEMICAL
acid,6619,I-CHEMICAL
on,6619,O
melanogenesis,6619,O
and,6619,O
its,6619,O
mechanisms,6619,O
of,6619,O
action,6619,O
in,6619,O
human,6619,O
epidermal,6619,O
melanocytes,6619,O
.,6619,O
In,6620,O
this,6620,O
study,6620,O
",",6620,O
we,6620,O
found,6620,O
that,6620,O
artemisinic,6620,B-CHEMICAL
acid,6620,I-CHEMICAL
inhibited,6620,O
melanin,6620,O
content,6620,O
.,6620,O
The,6621,O
mRNA,6621,O
levels,6621,O
of,6621,O
microphthalmia-associated,6621,B-GENE-Y
transcription,6621,I-GENE-Y
factor,6621,I-GENE-Y
(,6621,O
MITF,6621,B-GENE-Y
),6621,O
and,6621,O
its,6621,O
downstream,6621,O
genes,6621,O
tyrosinase,6621,B-GENE-Y
",",6621,O
tyrosinase-related,6621,B-GENE-Y
protein,6621,I-GENE-Y
(,6621,I-GENE-Y
TRP,6621,I-GENE-Y
),6621,I-GENE-Y
-1,6621,I-GENE-Y
",",6621,O
and,6621,O
TRP-2,6621,B-GENE-Y
were,6621,O
reduced,6621,O
by,6621,O
artemisinic,6621,B-CHEMICAL
acid,6621,I-CHEMICAL
treatment,6621,O
.,6621,O
Additionally,6622,O
",",6622,O
the,6622,O
mRNA,6622,O
levels,6622,O
of,6622,O
melanogenesis-related,6622,O
genes,6622,O
(,6622,O
c-KIT,6622,B-GENE-Y
",",6622,O
stem,6622,B-GENE-Y
cell,6622,I-GENE-Y
factor,6622,I-GENE-Y
(,6622,O
SCF,6622,B-GENE-Y
),6622,O
",",6622,O
and,6622,O
macrophage,6622,B-GENE-Y
migration,6622,I-GENE-Y
inhibitory,6622,I-GENE-Y
factor,6622,I-GENE-Y
(,6622,O
MIF,6622,B-GENE-Y
),6622,O
),6622,O
were,6622,O
down-regulated,6622,O
by,6622,O
artemisinic,6622,B-CHEMICAL
acid,6622,I-CHEMICAL
.,6622,O
Furthermore,6623,O
",",6623,O
cAMP,6623,B-CHEMICAL
production,6623,O
and,6623,O
protein,6623,B-GENE-N
kinase,6623,I-GENE-N
A,6623,I-GENE-N
(,6623,O
PKA,6623,B-GENE-N
),6623,O
activity,6623,O
were,6623,O
suppressed,6623,O
by,6623,O
artemisinic,6623,B-CHEMICAL
acid,6623,I-CHEMICAL
.,6623,O
Moreover,6624,O
",",6624,O
attempts,6624,O
to,6624,O
elucidate,6624,O
a,6624,O
possible,6624,O
mechanism,6624,O
underlying,6624,O
the,6624,O
artemisinic,6624,B-CHEMICAL
acid-mediated,6624,O
effects,6624,O
revealed,6624,O
that,6624,O
artemisinic,6624,B-CHEMICAL
acid,6624,I-CHEMICAL
regulated,6624,O
melanogenesis,6624,O
by,6624,O
inhibiting,6624,O
cholesterol,6624,B-CHEMICAL
synthesis,6624,O
through,6624,O
downregulation,6624,O
of,6624,O
the,6624,O
hydroxymethylglutaryl,6624,B-GENE-Y
CoA,6624,I-GENE-Y
(,6624,I-GENE-Y
HMG,6624,I-GENE-Y
CoA,6624,I-GENE-Y
),6624,I-GENE-Y
reductase,6624,I-GENE-Y
gene,6624,O
",",6624,O
which,6624,O
was,6624,O
mediated,6624,O
through,6624,O
reduced,6624,O
expression,6624,O
of,6624,O
the,6624,O
CCAAT/enhancer-binding,6624,B-GENE-Y
protein,6624,I-GENE-Y
(,6624,I-GENE-Y
C/EBP,6624,I-GENE-Y
),6624,I-GENE-Y
α,6624,I-GENE-Y
gene,6624,O
.,6624,O
Taken,6625,O
together,6625,O
",",6625,O
these,6625,O
findings,6625,O
indicate,6625,O
that,6625,O
the,6625,O
inhibition,6625,O
of,6625,O
melanogenesis,6625,O
by,6625,O
artemisinic,6625,B-CHEMICAL
acid,6625,I-CHEMICAL
occurs,6625,O
through,6625,O
reduced,6625,O
expression,6625,O
of,6625,O
the,6625,O
HMG,6625,B-GENE-Y
CoA,6625,I-GENE-Y
reductase,6625,I-GENE-Y
gene,6625,O
",",6625,O
which,6625,O
is,6625,O
mediated,6625,O
by,6625,O
C/EBP,6625,B-GENE-Y
α,6625,I-GENE-Y
inhibition,6625,O
and,6625,O
suggest,6625,O
that,6625,O
artemisinic,6625,B-CHEMICAL
acid,6625,I-CHEMICAL
may,6625,O
be,6625,O
useful,6625,O
as,6625,O
a,6625,O
hyperpigmentation,6625,O
inhibitor,6625,O
.,6625,O
Norethisterone,6626,B-CHEMICAL
metabolites,6626,O
modulate,6626,O
the,6626,O
uteroglobin,6626,B-GENE-Y
and,6626,O
progesterone,6626,B-GENE-Y
receptor,6626,I-GENE-Y
gene,6626,O
expression,6626,O
in,6626,O
prepubertal,6626,O
rabbits,6626,O
.,6626,O
Norethisterone,6627,B-CHEMICAL
(,6627,O
NET,6627,B-CHEMICAL
),6627,O
is,6627,O
a,6627,O
synthetic,6627,O
progestin,6627,B-CHEMICAL
",",6627,O
used,6627,O
as,6627,O
a,6627,O
contraceptive,6627,O
agent,6627,O
",",6627,O
that,6627,O
is,6627,O
biotransformed,6627,O
at,6627,O
target,6627,O
tissues,6627,O
into,6627,O
5,6627,B-CHEMICAL
alpha-NET,6627,I-CHEMICAL
and,6627,O
3,6627,B-CHEMICAL
"beta,5",6627,I-CHEMICAL
alpha-NET,6627,I-CHEMICAL
",",6627,O
which,6627,O
possess,6627,O
different,6627,O
pharmacological,6627,O
properties,6627,O
.,6627,O
The,6628,O
effects,6628,O
of,6628,O
these,6628,O
metabolites,6628,O
on,6628,O
the,6628,O
expression,6628,O
of,6628,O
uteroglobin,6628,B-GENE-Y
(,6628,O
UG,6628,B-GENE-Y
),6628,O
and,6628,O
progesterone,6628,B-GENE-N
receptor,6628,I-GENE-N
(,6628,O
PR,6628,B-GENE-N
),6628,O
genes,6628,O
",",6628,O
both,6628,O
regulated,6628,O
by,6628,O
progesterone,6628,B-CHEMICAL
(,6628,I-CHEMICAL
P4,6628,I-CHEMICAL
),6628,I-CHEMICAL
",",6628,O
were,6628,O
evaluated,6628,O
in,6628,O
the,6628,O
uterus,6628,O
of,6628,O
prepubertal,6628,O
female,6628,O
rabbits,6628,O
that,6628,O
were,6628,O
simultaneously,6628,O
treated,6628,O
with,6628,O
P4,6628,O
(,6628,O
1.0,6628,O
mg,6628,O
),6628,O
for,6628,O
5,6628,O
consecutive,6628,O
days,6628,O
.,6628,O
As,6629,O
determined,6629,O
by,6629,O
Western,6629,O
and,6629,O
Northern,6629,O
blot,6629,O
analyses,6629,O
",",6629,O
5,6629,B-CHEMICAL
alpha-NET,6629,I-CHEMICAL
inhibited,6629,O
the,6629,O
P4-induced,6629,O
UG,6629,B-GENE-Y
gene,6629,O
expression,6629,O
in,6629,O
a,6629,O
dose-dependent,6629,O
manner,6629,O
.,6629,O
A,6630,O
similar,6630,O
inhibition,6630,O
was,6630,O
observed,6630,O
with,6630,O
the,6630,O
administration,6630,O
of,6630,O
RU-486,6630,B-CHEMICAL
.,6630,O
The,6631,O
estrogenic,6631,O
agent,6631,O
3,6631,B-CHEMICAL
"beta,5",6631,I-CHEMICAL
alpha-NET,6631,I-CHEMICAL
and,6631,O
estradiol,6631,B-CHEMICAL
at,6631,O
a,6631,O
dose,6631,O
of,6631,O
1.0,6631,O
mg,6631,O
also,6631,O
inhibited,6631,O
the,6631,O
UG,6631,B-GENE-Y
gene,6631,O
expression,6631,O
induced,6631,O
by,6631,O
P4,6631,O
.,6631,O
Both,6632,O
5,6632,B-CHEMICAL
alpha-NET,6632,I-CHEMICAL
and,6632,O
3,6632,B-CHEMICAL
"beta,5",6632,I-CHEMICAL
alpha-NET,6632,I-CHEMICAL
blocked,6632,O
the,6632,O
PR,6632,B-GENE-Y
down-regulation,6632,O
induced,6632,O
by,6632,O
P4,6632,O
as,6632,O
assessed,6632,O
by,6632,O
Western,6632,O
and,6632,O
Northern,6632,O
blot,6632,O
methods,6632,O
.,6632,O
The,6633,O
inhibition,6633,O
of,6633,O
UG,6633,B-GENE-Y
synthesis,6633,O
and,6633,O
PR,6633,B-GENE-Y
down-regulation,6633,O
by,6633,O
5,6633,B-CHEMICAL
alpha-NET,6633,I-CHEMICAL
and,6633,O
3,6633,B-CHEMICAL
"beta,5",6633,I-CHEMICAL
alpha-NET,6633,I-CHEMICAL
indicates,6633,O
that,6633,O
these,6633,O
NET,6633,B-CHEMICAL
metabolites,6633,O
possess,6633,O
antiprogestational,6633,O
properties,6633,O
.,6633,O
Dioscin-induced,6634,B-CHEMICAL
autophagy,6634,O
mitigates,6634,O
cell,6634,O
apoptosis,6634,O
through,6634,O
modulation,6634,O
of,6634,O
PI3K/Akt,6634,B-GENE-N
and,6634,O
ERK,6634,B-GENE-N
and,6634,O
JNK,6634,B-GENE-N
signaling,6634,O
pathways,6634,O
in,6634,O
human,6634,O
lung,6634,O
cancer,6634,O
cell,6634,O
lines,6634,O
.,6634,O
Our,6635,O
previous,6635,O
study,6635,O
has,6635,O
revealed,6635,O
that,6635,O
dioscin,6635,B-CHEMICAL
",",6635,O
a,6635,O
compound,6635,O
with,6635,O
anti-inflammatory,6635,O
",",6635,O
lipid-lowering,6635,O
",",6635,O
anticancer,6635,O
and,6635,O
hepatoprotective,6635,O
effects,6635,O
",",6635,O
may,6635,O
induce,6635,O
autophagy,6635,O
in,6635,O
hepatoma,6635,O
cells,6635,O
.,6635,O
Autophagy,6636,O
is,6636,O
a,6636,O
lysosomal,6636,O
degradation,6636,O
pathway,6636,O
that,6636,O
is,6636,O
essential,6636,O
for,6636,O
cell,6636,O
survival,6636,O
and,6636,O
tissue,6636,O
homeostasis,6636,O
.,6636,O
In,6637,O
this,6637,O
study,6637,O
",",6637,O
the,6637,O
role,6637,O
of,6637,O
autophagy,6637,O
and,6637,O
related,6637,O
signaling,6637,O
pathways,6637,O
during,6637,O
dioscin-induced,6637,B-CHEMICAL
apoptosis,6637,O
in,6637,O
human,6637,O
lung,6637,O
cancer,6637,O
cells,6637,O
was,6637,O
investigated,6637,O
.,6637,O
Results,6638,O
from,6638,O
4'-6-diamidino-2-phenylindole,6638,B-CHEMICAL
and,6638,O
annexin-V/PI,6638,O
double-staining,6638,O
assay,6638,O
showed,6638,O
that,6638,O
caspase-3-,6638,B-GENE-Y
and,6638,O
caspase-8-dependent,6638,B-GENE-Y
",",6638,O
and,6638,O
dose-dependent,6638,O
apoptoses,6638,O
were,6638,O
detected,6638,O
after,6638,O
a,6638,O
24-h,6638,O
dioscin,6638,B-CHEMICAL
treatment,6638,O
.,6638,O
Meanwhile,6639,O
",",6639,O
autophagy,6639,O
was,6639,O
detected,6639,O
as,6639,O
early,6639,O
as,6639,O
12,6639,O
h,6639,O
after,6639,O
an,6639,O
exposure,6639,O
to,6639,O
low-dose,6639,O
dioscin,6639,B-CHEMICAL
",",6639,O
as,6639,O
indicated,6639,O
by,6639,O
an,6639,O
up-regulated,6639,O
expression,6639,O
of,6639,O
LC3-II,6639,B-GENE-Y
and,6639,O
beclin-1,6639,B-GENE-Y
proteins,6639,O
.,6639,O
Blockade,6640,O
of,6640,O
autophagy,6640,O
with,6640,O
bafilomycin,6640,B-CHEMICAL
A1,6640,I-CHEMICAL
or,6640,O
3-methyladenine,6640,B-CHEMICAL
sensitized,6640,O
the,6640,O
A549,6640,O
and,6640,O
H1299,6640,O
cells,6640,O
to,6640,O
apoptosis,6640,O
.,6640,O
Treatment,6641,O
of,6641,O
A549,6641,O
and,6641,O
H1299,6641,O
cells,6641,O
with,6641,O
dioscin,6641,B-CHEMICAL
caused,6641,O
a,6641,O
dose-dependent,6641,O
increase,6641,O
in,6641,O
ERK1/2,6641,B-GENE-N
and,6641,O
JNK1/2,6641,B-GENE-N
activity,6641,O
",",6641,O
accompanied,6641,O
with,6641,O
a,6641,O
decreased,6641,O
PI3K,6641,B-GENE-N
expression,6641,O
and,6641,O
decreased,6641,O
phosphorylation,6641,O
of,6641,O
Akt,6641,B-GENE-N
and,6641,O
mTOR,6641,B-GENE-N
.,6641,O
Taken,6642,O
together,6642,O
",",6642,O
this,6642,O
study,6642,O
demonstrated,6642,O
for,6642,O
the,6642,O
first,6642,O
time,6642,O
that,6642,O
autophagy,6642,O
occurred,6642,O
earlier,6642,O
than,6642,O
apoptosis,6642,O
during,6642,O
dioscin-induced,6642,B-CHEMICAL
human,6642,O
lung,6642,O
cancer,6642,O
cell,6642,O
line,6642,O
apoptosis,6642,O
.,6642,O
Dioscin-induced,6643,B-CHEMICAL
autophagy,6643,O
via,6643,O
ERK1/2,6643,B-GENE-N
and,6643,O
JNK1/2,6643,B-GENE-N
pathways,6643,O
may,6643,O
provide,6643,O
a,6643,O
protective,6643,O
mechanism,6643,O
for,6643,O
cell,6643,O
survival,6643,O
against,6643,O
dioscin-induced,6643,B-CHEMICAL
apoptosis,6643,O
to,6643,O
act,6643,O
as,6643,O
a,6643,O
cytoprotective,6643,O
reaction,6643,O
.,6643,O
2-Hydroxy-3-methylanthraquinone,6644,B-CHEMICAL
from,6644,O
Hedyotis,6644,O
diffusa,6644,O
Willd,6644,O
induces,6644,O
apoptosis,6644,O
in,6644,O
human,6644,O
leukemic,6644,O
U937,6644,O
cells,6644,O
through,6644,O
modulation,6644,O
of,6644,O
MAPK,6644,B-GENE-N
pathways,6644,O
.,6644,O
The,6645,O
herb,6645,O
of,6645,O
Hedyotis,6645,O
diffusa,6645,O
Willd,6645,O
(,6645,O
H.,6645,O
diffusa,6645,O
Willd,6645,O
),6645,O
",",6645,O
an,6645,O
annual,6645,O
herb,6645,O
distributed,6645,O
in,6645,O
northeastern,6645,O
Asia,6645,O
",",6645,O
has,6645,O
been,6645,O
known,6645,O
as,6645,O
a,6645,O
traditional,6645,O
oriental,6645,O
medicine,6645,O
for,6645,O
the,6645,O
treatment,6645,O
of,6645,O
cancer,6645,O
.,6645,O
Recently,6646,O
",",6646,O
Chinese,6646,O
researchers,6646,O
have,6646,O
discovered,6646,O
that,6646,O
two,6646,O
anthraquinones,6646,B-CHEMICAL
isolated,6646,O
from,6646,O
a,6646,O
water,6646,O
extract,6646,O
of,6646,O
H.,6646,O
diffusa,6646,O
Willd,6646,O
showed,6646,O
apoptosis-inducing,6646,O
effects,6646,O
against,6646,O
cancer,6646,O
cells,6646,O
.,6646,O
However,6647,O
",",6647,O
the,6647,O
cellular,6647,O
and,6647,O
molecular,6647,O
mechanisms,6647,O
responsible,6647,O
for,6647,O
this,6647,O
phenomenon,6647,O
are,6647,O
poorly,6647,O
understood,6647,O
.,6647,O
The,6648,O
current,6648,O
study,6648,O
determines,6648,O
the,6648,O
role,6648,O
of,6648,O
mitogen-activated,6648,B-GENE-N
protein,6648,I-GENE-N
kinases,6648,I-GENE-N
(,6648,O
MAPK,6648,B-GENE-N
),6648,O
in,6648,O
human,6648,O
leukemic,6648,O
U937,6648,O
cells,6648,O
apoptosis,6648,O
induced,6648,O
by,6648,O
2-hydroxy-3-methylanthraquinone,6648,B-CHEMICAL
from,6648,O
H.,6648,O
diffusa,6648,O
.,6648,O
Our,6649,O
results,6649,O
showed,6649,O
that,6649,O
2-hydroxy-3-methylanthraquinone,6649,B-CHEMICAL
decreased,6649,O
phosphorylation-ERK1/2,6649,O
(,6649,O
p-ERK1/2,6649,B-GENE-N
),6649,O
",",6649,O
and,6649,O
increased,6649,O
p-p38MAPK,6649,B-GENE-N
",",6649,O
but,6649,O
did,6649,O
not,6649,O
affect,6649,O
expressions,6649,O
of,6649,O
p-JNK1/2,6649,B-GENE-N
in,6649,O
U937,6649,O
cells,6649,O
.,6649,O
Moreover,6650,O
",",6650,O
treatment,6650,O
of,6650,O
U937,6650,O
cells,6650,O
with,6650,O
2-hydroxy-3-methylanthraquinone,6650,B-CHEMICAL
resulted,6650,O
in,6650,O
activation,6650,O
of,6650,O
caspase-3,6650,B-GENE-Y
.,6650,O
Furthermore,6651,O
",",6651,O
PD98059,6651,B-CHEMICAL
(,6651,O
ERK1/2,6651,B-GENE-N
inhibitor,6651,O
),6651,O
significantly,6651,O
enhanced,6651,O
2-hydroxy-3-methylanthraquinone-induced,6651,B-CHEMICAL
apoptosis,6651,O
in,6651,O
U937,6651,O
cells,6651,O
",",6651,O
whereas,6651,O
caspase-3,6651,B-GENE-Y
inhibitor,6651,O
or,6651,O
SB203580,6651,B-CHEMICAL
(,6651,O
p-p38MAPK,6651,B-GENE-N
inhibitor,6651,O
),6651,O
",",6651,O
decreased,6651,O
apoptosis,6651,O
in,6651,O
U937,6651,O
cells,6651,O
.,6651,O
Taken,6652,O
together,6652,O
",",6652,O
our,6652,O
study,6652,O
for,6652,O
the,6652,O
first,6652,O
time,6652,O
suggests,6652,O
that,6652,O
2-hydroxy-3-methylanthraquinone,6652,B-CHEMICAL
is,6652,O
able,6652,O
to,6652,O
enhance,6652,O
apoptosis,6652,O
of,6652,O
U937,6652,O
cells,6652,O
",",6652,O
at,6652,O
least,6652,O
in,6652,O
part,6652,O
",",6652,O
through,6652,O
activation,6652,O
of,6652,O
p-p38MAPK,6652,B-GENE-N
and,6652,O
downregulation,6652,O
of,6652,O
p-ERK1/2,6652,B-GENE-N
.,6652,O
Moreover,6653,O
",",6653,O
the,6653,O
triggering,6653,O
of,6653,O
caspase-3,6653,B-GENE-Y
activation,6653,O
mediated,6653,O
apoptotic,6653,O
induction,6653,O
.,6653,O
Hormonal,6654,O
therapy,6654,O
of,6654,O
prostate,6654,O
cancer,6654,O
.,6654,O
Of,6655,O
all,6655,O
cancers,6655,O
",",6655,O
prostate,6655,O
cancer,6655,O
is,6655,O
the,6655,O
most,6655,O
sensitive,6655,O
to,6655,O
hormones,6655,O
:,6655,O
it,6655,O
is,6655,O
thus,6655,O
very,6655,O
important,6655,O
to,6655,O
take,6655,O
advantage,6655,O
of,6655,O
this,6655,O
unique,6655,O
property,6655,O
and,6655,O
to,6655,O
always,6655,O
use,6655,O
optimal,6655,O
androgen,6655,B-CHEMICAL
blockade,6655,O
when,6655,O
hormone,6655,O
therapy,6655,O
is,6655,O
the,6655,O
appropriate,6655,O
treatment,6655,O
.,6655,O
A,6656,O
fundamental,6656,O
observation,6656,O
is,6656,O
that,6656,O
the,6656,O
serum,6656,O
testosterone,6656,B-CHEMICAL
concentration,6656,O
only,6656,O
reflects,6656,O
the,6656,O
amount,6656,O
of,6656,O
testosterone,6656,B-CHEMICAL
of,6656,O
testicular,6656,O
origin,6656,O
which,6656,O
is,6656,O
released,6656,O
in,6656,O
the,6656,O
blood,6656,O
from,6656,O
which,6656,O
it,6656,O
reaches,6656,O
all,6656,O
tissues,6656,O
.,6656,O
Recent,6657,O
data,6657,O
show,6657,O
",",6657,O
however,6657,O
",",6657,O
that,6657,O
an,6657,O
approximately,6657,O
equal,6657,O
amount,6657,O
of,6657,O
testosterone,6657,B-CHEMICAL
is,6657,O
made,6657,O
from,6657,O
dehydroepiandrosterone,6657,B-CHEMICAL
(,6657,O
DHEA,6657,B-CHEMICAL
),6657,O
directly,6657,O
in,6657,O
the,6657,O
peripheral,6657,O
tissues,6657,O
",",6657,O
including,6657,O
the,6657,O
prostate,6657,O
",",6657,O
and,6657,O
does,6657,O
not,6657,O
appear,6657,O
in,6657,O
the,6657,O
blood,6657,O
.,6657,O
Consequently,6658,O
",",6658,O
after,6658,O
castration,6658,O
",",6658,O
the,6658,O
95-97,6658,O
%,6658,O
fall,6658,O
in,6658,O
serum,6658,O
testosterone,6658,B-CHEMICAL
does,6658,O
not,6658,O
reflect,6658,O
the,6658,O
40-50,6658,O
%,6658,O
testosterone,6658,B-CHEMICAL
(,6658,O
testo,6658,B-CHEMICAL
),6658,O
and,6658,O
dihydrotestosterone,6658,B-CHEMICAL
(,6658,O
DHT,6658,B-CHEMICAL
),6658,O
made,6658,O
locally,6658,O
in,6658,O
the,6658,O
prostate,6658,O
from,6658,O
DHEA,6658,B-CHEMICAL
of,6658,O
adrenal,6658,O
origin,6658,O
.,6658,O
In,6659,O
fact,6659,O
",",6659,O
while,6659,O
elimination,6659,O
of,6659,O
testicular,6659,O
androgens,6659,B-CHEMICAL
by,6659,O
castration,6659,O
alone,6659,O
has,6659,O
never,6659,O
been,6659,O
shown,6659,O
to,6659,O
prolong,6659,O
life,6659,O
in,6659,O
metastatic,6659,O
prostate,6659,O
cancer,6659,O
",",6659,O
combination,6659,O
of,6659,O
castration,6659,O
(,6659,O
surgical,6659,O
or,6659,O
medical,6659,O
with,6659,O
a,6659,O
gonadotropin-releasing,6659,B-GENE-Y
hormone,6659,I-GENE-Y
(,6659,O
GnRH,6659,B-GENE-Y
),6659,O
agonist,6659,O
),6659,O
with,6659,O
a,6659,O
pure,6659,O
anti-androgen,6659,O
has,6659,O
been,6659,O
the,6659,O
first,6659,O
treatment,6659,O
shown,6659,O
to,6659,O
prolong,6659,O
life,6659,O
.,6659,O
Most,6660,O
importantly,6660,O
",",6660,O
when,6660,O
applied,6660,O
at,6660,O
the,6660,O
localized,6660,O
stage,6660,O
",",6660,O
the,6660,O
same,6660,O
combined,6660,O
androgen,6660,B-CHEMICAL
blockade,6660,O
(,6660,O
CAB,6660,O
),6660,O
can,6660,O
provide,6660,O
long-term,6660,O
control,6660,O
or,6660,O
cure,6660,O
of,6660,O
the,6660,O
disease,6660,O
in,6660,O
more,6660,O
than,6660,O
90,6660,O
%,6660,O
of,6660,O
cases,6660,O
.,6660,O
Obviously,6661,O
",",6661,O
since,6661,O
prostate,6661,O
cancer,6661,O
usually,6661,O
grows,6661,O
and,6661,O
metastasizes,6661,O
without,6661,O
signs,6661,O
or,6661,O
symptoms,6661,O
",",6661,O
screening,6661,O
with,6661,O
prostate-specific,6661,B-GENE-Y
antigen,6661,I-GENE-Y
(,6661,O
PSA,6661,B-GENE-Y
),6661,O
is,6661,O
absolutely,6661,O
needed,6661,O
to,6661,O
diagnose,6661,O
prostate,6661,O
cancer,6661,O
at,6661,O
an,6661,O
'early,6661,O
',6661,O
stage,6661,O
before,6661,O
metastasis,6661,O
occurs,6661,O
and,6661,O
the,6661,O
cancer,6661,O
becomes,6661,O
non-curable,6661,O
.,6661,O
While,6662,O
the,6662,O
role,6662,O
of,6662,O
androgens,6662,B-CHEMICAL
was,6662,O
believed,6662,O
to,6662,O
have,6662,O
become,6662,O
non-significant,6662,O
in,6662,O
cancer,6662,O
progressing,6662,O
under,6662,O
any,6662,O
form,6662,O
of,6662,O
androgen,6662,B-CHEMICAL
blockade,6662,O
",",6662,O
recent,6662,O
data,6662,O
have,6662,O
shown,6662,O
increased,6662,O
expression,6662,O
of,6662,O
the,6662,O
androgen,6662,B-GENE-Y
receptor,6662,I-GENE-Y
(,6662,O
AR,6662,B-GENE-Y
),6662,O
in,6662,O
treatment-resistant,6662,O
disease,6662,O
with,6662,O
a,6662,O
benefit,6662,O
of,6662,O
further,6662,O
androgen,6662,B-CHEMICAL
blockade,6662,O
.,6662,O
Since,6663,O
the,6663,O
available,6663,O
anti-androgens,6663,O
have,6663,O
low,6663,O
affinity,6663,O
for,6663,O
AR,6663,B-GENE-Y
and,6663,O
can,6663,O
not,6663,O
block,6663,O
androgen,6663,B-CHEMICAL
action,6663,O
completely,6663,O
",",6663,O
especially,6663,O
in,6663,O
the,6663,O
presence,6663,O
of,6663,O
increased,6663,O
AR,6663,B-GENE-Y
levels,6663,O
",",6663,O
it,6663,O
becomes,6663,O
important,6663,O
to,6663,O
discover,6663,O
more,6663,O
potent,6663,O
and,6663,O
purely,6663,O
antagonistic,6663,O
blockers,6663,O
of,6663,O
AR,6663,B-GENE-Y
.,6663,O
The,6664,O
data,6664,O
obtained,6664,O
with,6664,O
compounds,6664,O
under,6664,O
development,6664,O
are,6664,O
promising,6664,O
.,6664,O
While,6665,O
waiting,6665,O
for,6665,O
this,6665,O
(,6665,O
these,6665,O
),6665,O
new,6665,O
anti-androgen,6665,O
(,6665,I-CHEMICAL
s,6665,I-CHEMICAL
),6665,I-CHEMICAL
",",6665,O
combined,6665,O
treatment,6665,O
with,6665,O
castration,6665,O
and,6665,O
a,6665,O
pure,6665,O
anti-androgen,6665,O
(,6665,O
bicalutamide,6665,B-CHEMICAL
",",6665,O
flutamide,6665,B-CHEMICAL
or,6665,O
nilutamide,6665,B-CHEMICAL
),6665,O
is,6665,O
the,6665,O
only,6665,O
available,6665,O
and,6665,O
the,6665,O
best,6665,O
scientifically,6665,O
based,6665,O
means,6665,O
of,6665,O
treating,6665,O
prostate,6665,O
cancer,6665,O
by,6665,O
hormone,6665,O
therapy,6665,O
at,6665,O
any,6665,O
stage,6665,O
of,6665,O
the,6665,O
disease,6665,O
with,6665,O
the,6665,O
optimal,6665,O
chance,6665,O
of,6665,O
success,6665,O
and,6665,O
even,6665,O
cure,6665,O
in,6665,O
localized,6665,O
disease,6665,O
.,6665,O
Spectrum,6666,O
of,6666,O
mutations,6666,O
in,6666,O
mut,6666,B-GENE-Y
methylmalonic,6666,O
acidemia,6666,O
and,6666,O
identification,6666,O
of,6666,O
a,6666,O
common,6666,O
Hispanic,6666,O
mutation,6666,O
and,6666,O
haplotype,6666,O
.,6666,O
Cobalamin,6667,B-CHEMICAL
nonresponsive,6667,O
methylmalonic,6667,O
acidemia,6667,O
(,6667,O
MMA,6667,O
",",6667,O
mut,6667,O
complementation,6667,O
class,6667,O
),6667,O
results,6667,O
from,6667,O
mutations,6667,O
in,6667,O
the,6667,O
nuclear,6667,O
gene,6667,O
MUT,6667,B-GENE-Y
",",6667,O
which,6667,O
codes,6667,O
for,6667,O
the,6667,O
mitochondrial,6667,O
enzyme,6667,O
methylmalonyl,6667,B-GENE-Y
CoA,6667,I-GENE-Y
mutase,6667,I-GENE-Y
(,6667,O
MCM,6667,B-GENE-Y
),6667,O
.,6667,O
To,6668,O
better,6668,O
elucidate,6668,O
the,6668,O
spectrum,6668,O
of,6668,O
mutations,6668,O
that,6668,O
cause,6668,O
MMA,6668,O
",",6668,O
the,6668,O
MUT,6668,B-GENE-Y
gene,6668,O
was,6668,O
sequenced,6668,O
in,6668,O
160,6668,O
patients,6668,O
with,6668,O
mut,6668,B-GENE-Y
MMA,6668,O
.,6668,O
Sequence,6669,O
analysis,6669,O
identified,6669,O
mutations,6669,O
in,6669,O
96,6669,O
%,6669,O
of,6669,O
disease,6669,O
alleles,6669,O
.,6669,O
Mutations,6670,O
were,6670,O
found,6670,O
in,6670,O
all,6670,O
coding,6670,O
exons,6670,O
",",6670,O
but,6670,O
predominantly,6670,O
in,6670,O
exons,6670,O
2,6670,O
",",6670,O
3,6670,O
",",6670,O
6,6670,O
",",6670,O
and,6670,O
11,6670,O
.,6670,O
A,6671,O
total,6671,O
of,6671,O
116,6671,O
different,6671,O
mutations,6671,O
",",6671,O
68,6671,O
of,6671,O
which,6671,O
were,6671,O
novel,6671,O
",",6671,O
were,6671,O
identified,6671,O
.,6671,O
Of,6672,O
the,6672,O
116,6672,O
different,6672,O
mutations,6672,O
",",6672,O
53,6672,O
%,6672,O
were,6672,O
missense,6672,O
mutations,6672,O
",",6672,O
22,6672,O
%,6672,O
were,6672,O
deletions,6672,O
",",6672,O
duplications,6672,O
or,6672,O
insertions,6672,O
",",6672,O
16,6672,O
%,6672,O
were,6672,O
nonsense,6672,O
mutations,6672,O
",",6672,O
and,6672,O
9,6672,O
%,6672,O
were,6672,O
splice-site,6672,O
mutations,6672,O
.,6672,O
Sixty-one,6673,O
of,6673,O
the,6673,O
mutations,6673,O
have,6673,O
only,6673,O
been,6673,O
identified,6673,O
in,6673,O
one,6673,O
family,6673,O
.,6673,O
A,6674,O
novel,6674,O
mutation,6674,O
in,6674,O
exon,6674,O
2,6674,O
",",6674,O
c.322C,6674,O
>,6674,I-GENE-N
T,6674,I-GENE-N
(,6674,O
p.R108C,6674,O
),6674,O
",",6674,O
was,6674,O
identified,6674,O
in,6674,O
16,6674,O
of,6674,O
27,6674,O
Hispanic,6674,O
patients,6674,O
.,6674,O
SNP,6675,O
genotyping,6675,O
data,6675,O
demonstrated,6675,O
that,6675,O
Hispanic,6675,O
patients,6675,O
with,6675,O
this,6675,O
mutation,6675,O
share,6675,O
a,6675,O
common,6675,O
haplotype,6675,O
.,6675,O
Three,6676,O
other,6676,O
mutations,6676,O
were,6676,O
seen,6676,O
exclusively,6676,O
in,6676,O
Hispanic,6676,O
patients,6676,O
:,6676,O
c.280G,6676,O
>,6676,I-GENE-N
A,6676,I-GENE-N
(,6676,O
p.G94R,6676,O
),6676,O
",",6676,O
c.1022dupA,6676,O
",",6676,O
and,6676,O
c.970G,6676,O
>,6676,I-GENE-N
A,6676,I-GENE-N
(,6676,O
p.A324T,6676,O
),6676,O
.,6676,O
Seven,6677,O
mutations,6677,O
were,6677,O
seen,6677,O
almost,6677,O
exclusively,6677,O
in,6677,O
black,6677,O
patients,6677,O
",",6677,O
including,6677,O
the,6677,O
previously,6677,O
reported,6677,O
c.2150G,6677,O
>,6677,I-GENE-N
T,6677,I-GENE-N
(,6677,O
p.G717V,6677,O
),6677,O
mutation,6677,O
",",6677,O
which,6677,O
was,6677,O
identified,6677,O
in,6677,O
12,6677,O
of,6677,O
29,6677,O
black,6677,O
patients,6677,O
.,6677,O
Two,6678,O
mutations,6678,O
were,6678,O
seen,6678,O
only,6678,O
in,6678,O
Asian,6678,O
patients,6678,O
.,6678,O
Some,6679,O
frequently,6679,O
identified,6679,O
mutations,6679,O
were,6679,O
not,6679,O
population-specific,6679,O
and,6679,O
were,6679,O
identified,6679,O
in,6679,O
patients,6679,O
of,6679,O
various,6679,O
ethnic,6679,O
backgrounds,6679,O
.,6679,O
Some,6680,O
of,6680,O
these,6680,O
mutations,6680,O
were,6680,O
found,6680,O
in,6680,O
mutation,6680,O
clusters,6680,O
in,6680,O
exons,6680,O
2,6680,O
",",6680,O
3,6680,O
",",6680,O
6,6680,O
",",6680,O
and,6680,O
11,6680,O
",",6680,O
suggesting,6680,O
a,6680,O
recurrent,6680,O
mutation,6680,O
.,6680,O
Common,6681,O
resistance,6681,O
mechanisms,6681,O
to,6681,O
deoxynucleoside,6681,O
analogues,6681,O
in,6681,O
variants,6681,O
of,6681,O
the,6681,O
human,6681,O
erythroleukaemic,6681,O
line,6681,O
K562,6681,O
.,6681,O
Resistant,6682,O
variants,6682,O
of,6682,O
the,6682,O
human,6682,O
leukaemic,6682,O
line,6682,O
K562,6682,O
were,6682,O
developed,6682,O
using,6682,O
selection,6682,O
with,6682,O
the,6682,O
deoxynucleoside,6682,O
analogues,6682,O
cytosine,6682,B-CHEMICAL
arabinoside,6682,I-CHEMICAL
",",6682,O
2-chlorodeoxyadenosine,6682,B-CHEMICAL
",",6682,O
fludarabine,6682,B-CHEMICAL
and,6682,O
gemcitabine,6682,B-CHEMICAL
.,6682,O
The,6683,O
resistant,6683,O
lines,6683,O
displayed,6683,O
a,6683,O
high,6683,O
degree,6683,O
of,6683,O
cross,6683,O
resistance,6683,O
to,6683,O
all,6683,O
deoxynucleoside,6683,O
analogues,6683,O
",",6683,O
with,6683,O
little,6683,O
or,6683,O
no,6683,O
cross,6683,O
resistance,6683,O
to,6683,O
other,6683,O
agents,6683,O
.,6683,O
There,6684,O
was,6684,O
a,6684,O
profound,6684,O
accumulation,6684,O
defect,6684,O
of,6684,O
all,6684,O
nucleoside,6684,O
analogues,6684,O
in,6684,O
the,6684,O
resistant,6684,O
variants,6684,O
but,6684,O
no,6684,O
significant,6684,O
defect,6684,O
in,6684,O
nucleoside,6684,O
transport,6684,O
in,6684,O
any,6684,O
of,6684,O
the,6684,O
variants,6684,O
.,6684,O
5,6685,B-GENE-Y
',6685,I-GENE-Y
nucleotidase,6685,I-GENE-Y
activity,6685,O
was,6685,O
strongly,6685,O
increased,6685,O
and,6685,O
deoxycytidine,6685,B-GENE-Y
kinase,6685,I-GENE-Y
activity,6685,O
was,6685,O
moderately,6685,O
reduced,6685,O
in,6685,O
all,6685,O
of,6685,O
the,6685,O
resistant,6685,O
variants,6685,O
",",6685,O
resulting,6685,O
in,6685,O
reduced,6685,O
accumulation,6685,O
of,6685,O
triphosphate,6685,B-CHEMICAL
analogues,6685,O
.,6685,O
In,6686,O
addition,6686,O
a,6686,O
deletion,6686,O
in,6686,O
one,6686,O
of,6686,O
the,6686,O
alleles,6686,O
of,6686,O
the,6686,O
deoxycytidine,6686,B-GENE-Y
kinase,6686,I-GENE-Y
was,6686,O
detected,6686,O
in,6686,O
the,6686,O
fludarabine-resistant,6686,B-CHEMICAL
line,6686,O
.,6686,O
Ribonucleotide,6687,B-GENE-N
reductase,6687,I-GENE-N
activity,6687,O
was,6687,O
found,6687,O
to,6687,O
be,6687,O
strongly,6687,O
increased,6687,O
in,6687,O
the,6687,O
gemcitabine-selected,6687,B-CHEMICAL
line,6687,O
and,6687,O
purine,6687,B-GENE-Y
nucleoside,6687,I-GENE-Y
phosphorylase,6687,I-GENE-Y
was,6687,O
increased,6687,O
in,6687,O
the,6687,O
2-chlorodeoxyadenosine-selected,6687,B-CHEMICAL
line,6687,O
.,6687,O
Free,6688,O
nucleotide,6688,B-CHEMICAL
pools,6688,O
were,6688,O
increased,6688,O
in,6688,O
the,6688,O
2-chlorodeoxyadenosine-selected,6688,B-CHEMICAL
line,6688,O
.,6688,O
There,6689,O
was,6689,O
no,6689,O
expression,6689,O
of,6689,O
the,6689,O
mdr1,6689,B-GENE-Y
gene,6689,O
by,6689,O
the,6689,O
resistant,6689,O
lines,6689,O
.,6689,O
Karyotypic,6690,O
analysis,6690,O
and,6690,O
FISH,6690,O
experiments,6690,O
using,6690,O
a,6690,O
6q21,6690,O
specific,6690,O
probe,6690,O
showed,6690,O
alterations,6690,O
in,6690,O
the,6690,O
6,6690,O
(,6690,O
q16-q22,6690,O
),6690,O
region,6690,O
which,6690,O
contains,6690,O
the,6690,O
5'-nucleotidase,6690,B-GENE-Y
gene,6690,O
.,6690,O
Early,6691,O
events,6691,O
in,6691,O
the,6691,O
activation,6691,O
and,6691,O
degradation,6691,O
of,6691,O
deoxynucleoside,6691,O
analogues,6691,O
appear,6691,O
to,6691,O
constitute,6691,O
common,6691,O
mechanisms,6691,O
of,6691,O
resistance,6691,O
to,6691,O
these,6691,O
compounds,6691,O
.,6691,O
A,6692,O
new,6692,O
series,6692,O
of,6692,O
N2-substituted-5-,6692,B-CHEMICAL
(,6692,I-CHEMICAL
p-toluenesulfonylamino,6692,I-CHEMICAL
),6692,I-CHEMICAL
phthalimide,6692,I-CHEMICAL
analogues,6692,O
as,6692,O
α-glucosidase,6692,B-GENE-N
inhibitors,6692,O
.,6692,O
Several,6693,O
members,6693,O
of,6693,O
a,6693,O
new,6693,O
family,6693,O
of,6693,O
non-sugar-type,6693,O
α-glycosidase,6693,B-GENE-N
inhibitors,6693,O
",",6693,O
bearing,6693,O
a,6693,O
5-,6693,B-CHEMICAL
(,6693,I-CHEMICAL
p-toluenesulfonylamino,6693,I-CHEMICAL
),6693,I-CHEMICAL
phthalimide,6693,I-CHEMICAL
moiety,6693,O
and,6693,O
various,6693,O
substituent,6693,O
at,6693,O
the,6693,O
N2,6693,O
position,6693,O
",",6693,O
were,6693,O
synthesized,6693,O
and,6693,O
their,6693,O
activities,6693,O
were,6693,O
investigated,6693,O
.,6693,O
The,6694,O
newly,6694,O
synthesized,6694,O
compounds,6694,O
displayed,6694,O
different,6694,O
inhibition,6694,O
profile,6694,O
towards,6694,O
yeast,6694,B-GENE-Y
α-glycosidase,6694,I-GENE-Y
and,6694,O
rat,6694,B-GENE-N
intestinal,6694,I-GENE-N
α-glycosidase,6694,I-GENE-N
.,6694,O
Almost,6695,O
all,6695,O
the,6695,O
compounds,6695,O
had,6695,O
strong,6695,O
inhibitory,6695,O
activities,6695,O
against,6695,O
yeast,6695,B-GENE-Y
α-glycosidase,6695,I-GENE-Y
.,6695,O
Regarding,6696,O
rat,6696,B-GENE-N
intestinal,6696,I-GENE-N
α-glycosidase,6696,I-GENE-N
",",6696,O
only,6696,O
analogs,6696,O
with,6696,O
N2-aromatic,6696,O
substituents,6696,O
displayed,6696,O
varying,6696,O
degrees,6696,O
of,6696,O
inhibitory,6696,O
activities,6696,O
on,6696,O
rat,6696,B-GENE-N
intestinal,6696,I-GENE-N
maltase,6696,I-GENE-N
and,6696,O
lactase,6696,B-GENE-N
and,6696,O
nearly,6696,O
all,6696,O
compounds,6696,O
showed,6696,O
no,6696,O
inhibition,6696,O
against,6696,O
rat,6696,B-GENE-N
intestinal,6696,I-GENE-N
α-amylase,6696,I-GENE-N
.,6696,O
Structure-activity,6697,O
relationship,6697,O
studies,6697,O
indicated,6697,O
that,6697,O
5-,6697,B-CHEMICAL
(,6697,I-CHEMICAL
p-toluenesulfonylamino,6697,I-CHEMICAL
),6697,I-CHEMICAL
phthalimide,6697,I-CHEMICAL
moiety,6697,O
is,6697,O
a,6697,O
favorable,6697,O
scaffold,6697,O
to,6697,O
exert,6697,O
the,6697,O
α-glucosidase,6697,B-GENE-N
inhibitory,6697,O
activity,6697,O
and,6697,O
substituents,6697,O
at,6697,O
the,6697,O
N2,6697,O
position,6697,O
have,6697,O
considerable,6697,O
influence,6697,O
on,6697,O
the,6697,O
efficacy,6697,O
of,6697,O
the,6697,O
inhibition,6697,O
activities,6697,O
.,6697,O
The,6698,O
R740S,6698,B-GENE-N
mutation,6698,O
in,6698,O
the,6698,O
V-ATPase,6698,B-GENE-N
a3,6698,I-GENE-N
subunit,6698,O
increases,6698,O
lysosomal,6698,O
pH,6698,O
",",6698,O
impairs,6698,O
NFATc1,6698,B-GENE-Y
translocation,6698,O
",",6698,O
and,6698,O
decreases,6698,O
in,6698,O
vitro,6698,O
osteoclastogenesis,6698,O
.,6698,O
Vacuolar,6699,B-GENE-N
H,6699,I-GENE-N
(,6699,I-GENE-N
+,6699,I-GENE-N
),6699,I-GENE-N
-ATPase,6699,I-GENE-N
(,6699,O
V-ATPase,6699,B-GENE-N
),6699,O
",",6699,O
a,6699,O
multisubunit,6699,O
enzyme,6699,O
located,6699,O
at,6699,O
the,6699,O
ruffled,6699,O
border,6699,O
and,6699,O
in,6699,O
lysosomes,6699,O
of,6699,O
osteoclasts,6699,O
",",6699,O
is,6699,O
necessary,6699,O
for,6699,O
bone,6699,O
resorption,6699,O
.,6699,O
We,6700,O
previously,6700,O
showed,6700,O
that,6700,O
heterozygous,6700,O
mice,6700,O
with,6700,O
an,6700,O
R740S,6700,B-GENE-N
mutation,6700,O
in,6700,O
the,6700,O
a3,6700,O
subunit,6700,O
of,6700,O
V-ATPase,6700,B-GENE-N
(,6700,O
+/R740S,6700,O
),6700,O
have,6700,O
mild,6700,O
osteopetrosis,6700,O
resulting,6700,O
from,6700,O
an,6700,O
∼90,6700,O
%,6700,O
reduction,6700,O
in,6700,O
proton,6700,O
translocation,6700,O
across,6700,O
osteoclast,6700,O
membranes,6700,O
.,6700,O
Here,6701,O
we,6701,O
show,6701,O
that,6701,O
lysosomal,6701,O
pH,6701,O
is,6701,O
also,6701,O
higher,6701,O
in,6701,O
+/R740S,6701,O
compared,6701,O
with,6701,O
wild-type,6701,O
(,6701,O
+/+,6701,O
),6701,O
osteoclasts,6701,O
.,6701,O
Both,6702,O
osteoclast,6702,O
number,6702,O
and,6702,O
size,6702,O
were,6702,O
decreased,6702,O
in,6702,O
cultures,6702,O
of,6702,O
+/R740S,6702,O
compared,6702,O
with,6702,O
+/+,6702,O
bone,6702,O
marrow,6702,O
cells,6702,O
",",6702,O
with,6702,O
concomitant,6702,O
decreased,6702,O
expression,6702,O
of,6702,O
key,6702,O
osteoclast,6702,O
markers,6702,O
(,6702,O
TRAP,6702,B-GENE-N
",",6702,O
cathepsin,6702,B-GENE-N
K,6702,I-GENE-N
",",6702,O
OSCAR,6702,B-GENE-N
",",6702,O
DC-STAMP,6702,B-GENE-N
",",6702,O
and,6702,O
NFATc1,6702,B-GENE-N
),6702,O
",",6702,O
suggesting,6702,O
that,6702,O
low,6702,O
lysosomal,6702,O
pH,6702,O
plays,6702,O
an,6702,O
important,6702,O
role,6702,O
in,6702,O
osteoclastogenesis,6702,O
.,6702,O
To,6703,O
elucidate,6703,O
the,6703,O
molecular,6703,O
mechanism,6703,O
of,6703,O
this,6703,O
inhibition,6703,O
",",6703,O
NFATc1,6703,B-GENE-N
activation,6703,O
was,6703,O
assessed,6703,O
.,6703,O
NFATc1,6704,B-GENE-N
nuclear,6704,O
translocation,6704,O
was,6704,O
significantly,6704,O
reduced,6704,O
in,6704,O
+/R740S,6704,O
compared,6704,O
with,6704,O
+/+,6704,O
cells,6704,O
;,6704,O
however,6704,O
",",6704,O
this,6704,O
was,6704,O
not,6704,O
because,6704,O
of,6704,O
impaired,6704,O
enzymatic,6704,O
activity,6704,O
of,6704,O
calcineurin,6704,O
",",6704,O
the,6704,O
phosphatase,6704,O
responsible,6704,O
for,6704,O
NFATc1,6704,B-GENE-N
dephosphorylation,6704,O
.,6704,O
Protein,6705,O
and,6705,O
RNA,6705,O
expression,6705,O
levels,6705,O
of,6705,O
regulator,6705,O
of,6705,O
calcineurin,6705,B-GENE-N
1,6705,I-GENE-N
(,6705,O
RCAN1,6705,B-GENE-N
),6705,O
",",6705,O
an,6705,O
endogenous,6705,O
inhibitor,6705,O
of,6705,O
NFATc1,6705,B-GENE-N
activation,6705,O
and,6705,O
a,6705,O
protein,6705,O
degraded,6705,O
in,6705,O
lysosomes,6705,O
",",6705,O
were,6705,O
not,6705,O
significantly,6705,O
different,6705,O
between,6705,O
+/R740S,6705,O
and,6705,O
+/+,6705,O
osteoclasts,6705,O
",",6705,O
but,6705,O
the,6705,O
RCAN1/NFATc1,6705,B-GENE-N
ratio,6705,O
was,6705,O
significantly,6705,O
higher,6705,O
in,6705,O
+/R740S,6705,O
versus,6705,O
+/+,6705,O
cells,6705,O
.,6705,O
The,6706,O
lysosomal,6706,O
inhibitor,6706,O
chloroquine,6706,B-CHEMICAL
significantly,6706,O
increased,6706,O
RCAN1,6706,B-GENE-N
accumulation,6706,O
in,6706,O
+/+,6706,O
cells,6706,O
",",6706,O
consistent,6706,O
with,6706,O
the,6706,O
hypothesis,6706,O
that,6706,O
higher,6706,O
lysosomal,6706,O
pH,6706,O
impairs,6706,O
RCAN1,6706,B-GENE-N
degradation,6706,O
",",6706,O
leading,6706,O
to,6706,O
a,6706,O
higher,6706,O
RCAN1/NFATc1,6706,B-GENE-N
ratio,6706,O
and,6706,O
consequently,6706,O
NFATc1,6706,B-GENE-N
inhibition,6706,O
.,6706,O
Our,6707,O
data,6707,O
indicate,6707,O
that,6707,O
increased,6707,O
lysosomal,6707,O
pH,6707,O
in,6707,O
osteoclasts,6707,O
leads,6707,O
to,6707,O
decreased,6707,O
NFATc1,6707,B-GENE-N
signaling,6707,O
and,6707,O
nuclear,6707,O
translocation,6707,O
",",6707,O
resulting,6707,O
in,6707,O
a,6707,O
cell,6707,O
autonomous,6707,O
impairment,6707,O
of,6707,O
osteoclastogenesis,6707,O
in,6707,O
vitro,6707,O
.,6707,O
p38,6708,B-GENE-N
Mitogen,6708,B-GENE-N
Activated,6708,I-GENE-N
Protein,6708,I-GENE-N
Kinase,6708,I-GENE-N
Regulates,6708,O
the,6708,O
Nuclear,6708,B-GENE-N
Receptor,6708,I-GENE-N
CAR,6708,B-GENE-Y
to,6708,O
Activate,6708,O
the,6708,O
CYP2B6,6708,B-GENE-Y
Gene,6708,O
.,6708,O
The,6709,O
constitutive,6709,B-GENE-Y
active/androstane,6709,I-GENE-Y
receptor,6709,I-GENE-Y
(,6709,O
CAR,6709,B-GENE-Y
),6709,O
regulates,6709,O
hepatic,6709,O
drug,6709,O
metabolism,6709,O
by,6709,O
activating,6709,O
genes,6709,O
such,6709,O
as,6709,O
cytochrome,6709,B-GENE-N
P450,6709,I-GENE-N
(,6709,O
CYP,6709,B-GENE-N
),6709,O
and,6709,O
certain,6709,O
transferases,6709,B-GENE-N
.,6709,O
p38,6710,B-GENE-N
mitogen,6710,B-GENE-N
activated,6710,I-GENE-N
protein,6710,I-GENE-N
kinase,6710,I-GENE-N
(,6710,O
MAPK,6710,B-GENE-N
),6710,O
is,6710,O
highly,6710,O
activated,6710,O
in,6710,O
human,6710,O
primary,6710,O
hepatocytes,6710,O
but,6710,O
barely,6710,O
in,6710,O
human,6710,O
hepatoma,6710,O
cell-lines,6710,O
including,6710,O
HepG2,6710,O
cells,6710,O
.,6710,O
Liganded-CAR,6711,O
induced,6711,O
CYP2B6,6711,B-GENE-Y
mRNA,6711,O
in,6711,O
human,6711,O
primary,6711,O
hepatocytes,6711,O
far,6711,O
more,6711,O
effectively,6711,O
than,6711,O
in,6711,O
HepG2,6711,O
cells,6711,O
ectopically,6711,O
expressing,6711,O
CAR,6711,B-GENE-Y
.,6711,O
Here,6712,O
",",6712,O
we,6712,O
have,6712,O
now,6712,O
found,6712,O
that,6712,O
activation,6712,O
of,6712,O
p38,6712,B-GENE-N
MAPK,6712,B-GENE-N
by,6712,O
anisomycin,6712,B-CHEMICAL
potentiated,6712,O
induction,6712,O
of,6712,O
CYP2B6,6712,B-GENE-Y
mRNA,6712,O
by,6712,O
CAR,6712,B-GENE-Y
ligand,6712,O
in,6712,O
HepG2,6712,O
cells,6712,O
to,6712,O
levels,6712,O
observed,6712,O
in,6712,O
ligand-treated,6712,O
human,6712,O
primary,6712,O
hepatocytes,6712,O
.,6712,O
siRNA,6713,O
knockdown,6713,O
of,6713,O
p38,6713,B-GENE-N
MAPK,6713,B-GENE-N
abrogated,6713,O
the,6713,O
ability,6713,O
of,6713,O
anisomycin,6713,B-CHEMICAL
to,6713,O
synergistically,6713,O
induce,6713,O
CYP2B6,6713,B-GENE-Y
mRNA,6713,O
.,6713,O
In,6714,O
addition,6714,O
to,6714,O
CYP2B6,6714,B-GENE-Y
",",6714,O
anisomycin,6714,B-CHEMICAL
co-treatment,6714,O
potentiated,6714,O
an,6714,O
increase,6714,O
in,6714,O
CYP2A7,6714,B-GENE-Y
and,6714,O
CYP2C9,6714,B-GENE-Y
mRNAs,6714,O
but,6714,O
not,6714,O
CYP3A4,6714,B-GENE-Y
or,6714,O
UDP-glucuronosyltransferase,6714,B-GENE-Y
1A1,6714,I-GENE-Y
mRNAs,6714,O
.,6714,O
Thus,6715,O
",",6715,O
activated,6715,O
p38,6715,B-GENE-N
MAPK,6715,B-GENE-N
is,6715,O
required,6715,O
for,6715,O
liganded-CAR,6715,O
to,6715,O
selectively,6715,O
activate,6715,O
a,6715,O
set,6715,O
of,6715,O
genes,6715,O
that,6715,O
encode,6715,O
drug,6715,O
metabolizing,6715,O
enzymes,6715,O
.,6715,O
Our,6716,O
present,6716,O
results,6716,O
suggest,6716,O
that,6716,O
CAR-mediated,6716,B-GENE-Y
induction,6716,O
of,6716,O
these,6716,O
enzymes,6716,O
can,6716,O
not,6716,O
be,6716,O
understood,6716,O
by,6716,O
ligand,6716,O
binding,6716,O
alone,6716,O
because,6716,O
the,6716,O
specificity,6716,O
and,6716,O
magnitude,6716,O
of,6716,O
induction,6716,O
are,6716,O
co-determined,6716,O
by,6716,O
a,6716,O
given,6716,O
cell,6716,O
signaling,6716,O
such,6716,O
as,6716,O
p38,6716,B-GENE-N
MAPK,6716,B-GENE-N
;,6716,O
both,6716,O
physiological,6716,O
and,6716,O
pathophysiological,6716,O
states,6716,O
of,6716,O
cell,6716,O
signaling,6716,O
may,6716,O
have,6716,O
a,6716,O
strong,6716,O
impact,6716,O
in,6716,O
hepatic,6716,O
drug,6716,O
metabolizing,6716,O
capability,6716,O
during,6716,O
therapeutic,6716,O
treatments,6716,O
.,6716,O
Parnaparin,6717,O
",",6717,O
a,6717,O
low-molecular-weight,6717,O
heparin,6717,O
",",6717,O
prevents,6717,O
P-selectin-dependent,6717,B-GENE-Y
formation,6717,O
of,6717,O
platelet-leukocyte,6717,O
aggregates,6717,O
in,6717,O
human,6717,O
whole,6717,O
blood,6717,O
.,6717,O
Parnaparin,6718,O
",",6718,O
a,6718,O
low-molecular-weight,6718,O
heparin,6718,O
(,6718,O
LMWH,6718,O
),6718,O
",",6718,O
prevents,6718,O
platelet,6718,O
activation,6718,O
and,6718,O
interaction,6718,O
with,6718,O
polymorphonuclear,6718,O
leukocyte,6718,O
(,6718,O
PMN,6718,O
),6718,O
in,6718,O
a,6718,O
washed,6718,O
cell,6718,O
system,6718,O
.,6718,O
The,6719,O
in-vitro,6719,O
effect,6719,O
of,6719,O
parnaparin,6719,O
was,6719,O
studied,6719,O
here,6719,O
on,6719,O
platelet-PMN,6719,O
aggregates,6719,O
formed,6719,O
with,6719,O
more,6719,O
physiologic,6719,O
approaches,6719,O
in,6719,O
whole,6719,O
blood,6719,O
",",6719,O
in,6719,O
parallel,6719,O
with,6719,O
unfractionated,6719,O
heparin,6719,O
and,6719,O
enoxaparin,6719,O
",",6719,O
another,6719,O
LMWH,6719,O
.,6719,O
Citrated,6720,O
blood,6720,O
from,6720,O
healthy,6720,O
subjects,6720,O
was,6720,O
stimulated,6720,O
:,6720,O
i,6720,O
),6720,O
from,6720,O
passage,6720,O
through,6720,O
the,6720,O
``,6720,O
Platelet,6720,O
Function,6720,O
Analyzer,6720,O
'',6720,O
(,6720,O
PFA-100,6720,O
),6720,O
",",6720,O
a,6720,O
device,6720,O
that,6720,O
exposes,6720,O
blood,6720,O
to,6720,O
standardized,6720,O
high,6720,O
shear,6720,O
flow,6720,O
through,6720,O
collagen/ADP,6720,B-GENE-N
cartridges,6720,O
;,6720,O
ii,6720,O
),6720,O
by,6720,O
collagen,6720,O
and,6720,O
ADP,6720,B-CHEMICAL
(,6720,O
2,6720,O
and,6720,O
50,6720,O
mug/ml,6720,O
",",6720,O
respectively,6720,O
),6720,O
added,6720,O
in,6720,O
combination,6720,O
under,6720,O
stirring,6720,O
in,6720,O
an,6720,O
aggregometer,6720,O
cuvette,6720,O
;,6720,O
iii,6720,O
),6720,O
with,6720,O
recombinant,6720,O
Tissue,6720,B-GENE-Y
Factor,6720,I-GENE-Y
",",6720,O
to,6720,O
generate,6720,O
thrombin,6720,B-GENE-Y
concentrations,6720,O
able,6720,O
to,6720,O
activate,6720,O
platelets,6720,O
without,6720,O
inducing,6720,O
blood,6720,O
clotting,6720,O
",",6720,O
or,6720,O
iv,6720,O
),6720,O
the,6720,O
Thrombin,6720,O
Receptor,6720,O
Activating,6720,O
Peptide-6,6720,O
(,6720,O
TRAP-6,6720,O
),6720,O
.,6720,O
Platelet,6721,B-GENE-Y
P-selectin,6721,I-GENE-Y
and,6721,O
platelet-PMN,6721,O
aggregates,6721,O
were,6721,O
measured,6721,O
by,6721,O
flow,6721,O
cytometry,6721,O
upon,6721,O
stimulation,6721,O
of,6721,O
blood,6721,O
.,6721,O
Fibrinogen,6722,B-GENE-N
binding,6722,O
to,6722,O
platelets,6722,O
and,6722,O
markers,6722,O
of,6722,O
PMN,6722,O
activation,6722,O
were,6722,O
also,6722,O
detected,6722,O
.,6722,O
Platelet,6723,B-GENE-Y
P-selectin,6723,I-GENE-Y
expression,6723,O
and,6723,O
platelet-PMN,6723,O
aggregate,6723,O
formation,6723,O
were,6723,O
induced,6723,O
in,6723,O
all,6723,O
four,6723,O
activation,6723,O
conditions,6723,O
tested,6723,O
.,6723,O
Parnaparin,6724,O
prevented,6724,O
in,6724,O
a,6724,O
concentration-dependent,6724,O
manner,6724,O
(,6724,O
0.3-0.8,6724,O
IUaXa/ml,6724,O
),6724,O
the,6724,O
expression,6724,O
of,6724,O
P-selectin,6724,B-GENE-Y
and,6724,O
the,6724,O
formation,6724,O
of,6724,O
mixed,6724,O
aggregates,6724,O
",",6724,O
while,6724,O
the,6724,O
two,6724,O
reference,6724,O
heparin,6724,O
preparations,6724,O
had,6724,O
a,6724,O
much,6724,O
weaker,6724,O
effect,6724,O
.,6724,O
Platelet,6725,B-GENE-N
fibrinogen,6725,I-GENE-N
binding,6725,O
and,6725,O
PMN,6725,O
activation,6725,O
markers,6725,O
(,6725,O
fibrinogen,6725,B-GENE-N
binding,6725,O
",",6725,O
CD11b,6725,B-GENE-Y
and,6725,O
CD40,6725,B-GENE-Y
),6725,O
were,6725,O
also,6725,O
prevented,6725,O
by,6725,O
parnaparin,6725,O
.,6725,O
These,6726,O
data,6726,O
extend,6726,O
in,6726,O
more,6726,O
physiological,6726,O
systems,6726,O
of,6726,O
platelet,6726,O
activation,6726,O
",",6726,O
the,6726,O
anti-inflammatory,6726,O
profile,6726,O
of,6726,O
parnaparin,6726,O
",",6726,O
previously,6726,O
reported,6726,O
in,6726,O
washed,6726,O
cells,6726,O
.,6726,O
The,6727,O
greater,6727,O
effect,6727,O
of,6727,O
parnaparin,6727,O
",",6727,O
as,6727,O
compared,6727,O
to,6727,O
the,6727,O
reference,6727,O
heparins,6727,O
",",6727,O
could,6727,O
be,6727,O
due,6727,O
to,6727,O
chemico-physical,6727,O
differences,6727,O
possibly,6727,O
unrelated,6727,O
to,6727,O
their,6727,O
anticoagulant,6727,O
effect,6727,O
.,6727,O
Diverse,6728,O
effects,6728,O
of,6728,O
macromolecular,6728,O
crowding,6728,O
on,6728,O
the,6728,O
sequential,6728,O
glycan-processing,6728,O
pathway,6728,O
involved,6728,O
in,6728,O
glycoprotein,6728,O
quality,6728,O
control,6728,O
.,6728,O
Compared,6729,O
with,6729,O
in,6729,O
vitro,6729,O
conditions,6729,O
",",6729,O
the,6729,O
intracellular,6729,O
environment,6729,O
is,6729,O
highly,6729,O
crowded,6729,O
with,6729,O
biomolecules,6729,O
;,6729,O
this,6729,O
has,6729,O
numerous,6729,O
effects,6729,O
on,6729,O
protein,6729,O
functions,6729,O
",",6729,O
including,6729,O
enzymatic,6729,O
activity,6729,O
.,6729,O
We,6730,O
examined,6730,O
the,6730,O
effects,6730,O
of,6730,O
macromolecular,6730,O
crowding,6730,O
on,6730,O
glycan,6730,O
processing,6730,O
of,6730,O
N-glycoprotein,6730,B-CHEMICAL
in,6730,O
the,6730,O
endoplasmic,6730,O
reticulum,6730,O
as,6730,O
a,6730,O
model,6730,O
sequential,6730,O
metabolic,6730,O
pathway,6730,O
.,6730,O
Experiments,6731,O
with,6731,O
synthetic,6731,O
substrates,6731,O
of,6731,O
physiological,6731,O
glycan,6731,O
structure,6731,O
clearly,6731,O
showed,6731,O
that,6731,O
the,6731,O
first,6731,O
half,6731,O
of,6731,O
the,6731,O
pathway,6731,O
(,6731,O
glucose,6731,B-CHEMICAL
trimming,6731,O
),6731,O
was,6731,O
accelerated,6731,O
",",6731,O
whereas,6731,O
the,6731,O
second,6731,O
(,6731,O
mannose,6731,B-CHEMICAL
trimming,6731,O
),6731,O
was,6731,O
decelerated,6731,O
under,6731,O
molecular,6731,O
crowding,6731,O
conditions,6731,O
.,6731,O
Furthermore,6732,O
",",6732,O
calreticulin,6732,B-GENE-Y
",",6732,O
a,6732,O
lectin-like,6732,B-GENE-N
molecular,6732,O
chaperone,6732,O
",",6732,O
bound,6732,O
more,6732,O
strongly,6732,O
to,6732,O
a,6732,O
glycan-processing,6732,O
intermediate,6732,O
under,6732,O
these,6732,O
conditions,6732,O
.,6732,O
This,6733,O
study,6733,O
demonstrates,6733,O
the,6733,O
diverse,6733,O
effects,6733,O
of,6733,O
molecular,6733,O
crowding,6733,O
on,6733,O
sequential,6733,O
enzymatic,6733,O
processing,6733,O
",",6733,O
and,6733,O
the,6733,O
importance,6733,O
of,6733,O
the,6733,O
effects,6733,O
of,6733,O
macromolecular,6733,O
crowding,6733,O
on,6733,O
in,6733,O
vitro,6733,O
assays,6733,O
for,6733,O
understanding,6733,O
sequential,6733,O
metabolic,6733,O
pathways,6733,O
.,6733,O
X-ray,6734,O
structure,6734,O
analysis,6734,O
of,6734,O
a,6734,O
solid,6734,O
solution,6734,O
of,6734,O
milbemycins,6734,B-CHEMICAL
A3,6734,I-CHEMICAL
and,6734,I-CHEMICAL
A4,6734,I-CHEMICAL
.,6734,O
Milbemycins,6735,B-CHEMICAL
A3,6735,I-CHEMICAL
and,6735,I-CHEMICAL
A4,6735,I-CHEMICAL
are,6735,O
pharmaceutically,6735,O
and,6735,O
agriculturally,6735,O
useful,6735,O
macrolides,6735,O
isolated,6735,O
from,6735,O
Streptomyces,6735,O
species,6735,O
.,6735,O
The,6736,O
molecular,6736,O
structures,6736,O
of,6736,O
the,6736,O
title,6736,O
compounds,6736,O
were,6736,O
unambiguously,6736,O
established,6736,O
by,6736,O
a,6736,O
single,6736,O
crystal,6736,O
X-ray,6736,O
analysis,6736,O
of,6736,O
the,6736,O
solid,6736,O
solution,6736,O
of,6736,O
both,6736,O
compounds,6736,O
.,6736,O
The,6737,O
crystals,6737,O
present,6737,O
trigonal,6737,O
system,6737,O
",",6737,O
space,6737,O
group,6737,O
P32,6737,O
with,6737,O
Z,6737,O
=,6737,O
3,6737,O
",",6737,O
unit,6737,O
cell,6737,O
dimensions,6737,O
:,6737,O
a,6737,O
=,6737,O
12.2211,6737,O
(,6737,O
4,6737,O
),6737,O
",",6737,O
c,6737,O
=,6737,O
17.5372,6737,O
(,6737,O
7,6737,O
),6737,O
Å,6737,O
;,6737,O
V,6737,O
=,6737,O
2268.4,6737,O
(,6737,O
1,6737,O
),6737,O
Å,6737,O
(,6737,O
3,6737,O
),6737,O
",",6737,O
μ,6737,O
=,6737,O
0.082,6737,O
mm,6737,O
(,6737,O
-,6737,O
1,6737,O
),6737,O
;,6737,O
d,6737,O
=,6737,O
1.183,6737,O
g,6737,O
cm,6737,O
(,6737,O
-,6737,O
3,6737,O
),6737,O
.,6737,O
An,6738,O
interesting,6738,O
system,6738,O
of,6738,O
intramolecular,6738,O
hydrogen,6738,B-CHEMICAL
bonds,6738,O
and,6738,O
weak,6738,O
intermolecular,6738,O
CH…O,6738,B-CHEMICAL
type,6738,O
hydrogen,6738,B-CHEMICAL
bond,6738,O
was,6738,O
observed,6738,O
in,6738,O
the,6738,O
solid,6738,O
state,6738,O
.,6738,O
In,6739,O
vitro,6739,O
exploration,6739,O
of,6739,O
potential,6739,O
mechanisms,6739,O
of,6739,O
toxicity,6739,O
of,6739,O
the,6739,O
human,6739,O
hepatotoxic,6739,O
drug,6739,O
fenclozic,6739,B-CHEMICAL
acid,6739,I-CHEMICAL
.,6739,O
The,6740,O
carboxylic,6740,B-CHEMICAL
acid,6740,I-CHEMICAL
NSAID,6740,O
fenclozic,6740,B-CHEMICAL
acid,6740,I-CHEMICAL
exhibited,6740,O
an,6740,O
excellent,6740,O
preclinical,6740,O
safety,6740,O
profile,6740,O
and,6740,O
promising,6740,O
clinical,6740,O
efficacy,6740,O
",",6740,O
yet,6740,O
was,6740,O
withdrawn,6740,O
from,6740,O
clinical,6740,O
development,6740,O
in,6740,O
1971,6740,O
due,6740,O
to,6740,O
hepatotoxicity,6740,O
observed,6740,O
in,6740,O
clinical,6740,O
trials,6740,O
.,6740,O
A,6741,O
variety,6741,O
of,6741,O
modern,6741,O
in,6741,O
vitro,6741,O
approaches,6741,O
have,6741,O
been,6741,O
used,6741,O
to,6741,O
explore,6741,O
potential,6741,O
underlying,6741,O
mechanisms,6741,O
.,6741,O
Covalent,6742,O
binding,6742,O
studies,6742,O
were,6742,O
undertaken,6742,O
with,6742,O
[,6742,B-CHEMICAL
(,6742,I-CHEMICAL
14,6742,I-CHEMICAL
),6742,I-CHEMICAL
C,6742,I-CHEMICAL
],6742,I-CHEMICAL
-fenclozic,6742,I-CHEMICAL
acid,6742,I-CHEMICAL
to,6742,O
investigate,6742,O
the,6742,O
possible,6742,O
role,6742,O
of,6742,O
reactive,6742,O
metabolites,6742,O
.,6742,O
Time-dependent,6743,O
covalent,6743,O
binding,6743,O
to,6743,O
protein,6743,O
was,6743,O
observed,6743,O
in,6743,O
NADPH-supplemented,6743,B-CHEMICAL
liver,6743,O
microsomes,6743,O
",",6743,O
although,6743,O
no,6743,O
metabolites,6743,O
were,6743,O
detected,6743,O
in,6743,O
these,6743,O
incubations,6743,O
or,6743,O
in,6743,O
reactive,6743,O
metabolite,6743,O
trapping,6743,O
experiments,6743,O
.,6743,O
In,6744,O
human,6744,O
hepatocytes,6744,O
",",6744,O
covalent,6744,O
binding,6744,O
was,6744,O
observed,6744,O
at,6744,O
lower,6744,O
levels,6744,O
than,6744,O
in,6744,O
microsomes,6744,O
and,6744,O
a,6744,O
minor,6744,O
uncharacterizable,6744,O
metabolite,6744,O
was,6744,O
also,6744,O
observed,6744,O
.,6744,O
In,6745,O
addition,6745,O
",",6745,O
covalent,6745,O
binding,6745,O
was,6745,O
observed,6745,O
in,6745,O
incubations,6745,O
undertaken,6745,O
with,6745,O
dog,6745,O
and,6745,O
rat,6745,O
hepatocytes,6745,O
",",6745,O
where,6745,O
a,6745,O
taurine,6745,B-CHEMICAL
conjugate,6745,O
of,6745,O
the,6745,O
drug,6745,O
was,6745,O
detected,6745,O
.,6745,O
Although,6746,O
an,6746,O
acyl,6746,B-CHEMICAL
glucuronide,6746,I-CHEMICAL
metabolite,6746,O
was,6746,O
detected,6746,O
when,6746,O
liver,6746,O
microsomes,6746,O
from,6746,O
human,6746,O
",",6746,O
rat,6746,O
and,6746,O
dog,6746,O
were,6746,O
supplemented,6746,O
with,6746,O
UDPGA,6746,B-CHEMICAL
",",6746,O
there,6746,O
was,6746,O
no,6746,O
detectable,6746,O
UDPGA-dependent,6746,B-CHEMICAL
covalent,6746,O
binding,6746,O
.,6746,O
No,6747,O
effects,6747,O
were,6747,O
observed,6747,O
when,6747,O
fenclozic,6747,B-CHEMICAL
acid,6747,I-CHEMICAL
was,6747,O
assessed,6747,O
for,6747,O
P450-dependent,6747,B-GENE-N
and,6747,O
P450-independent,6747,B-GENE-N
cytotoxicity,6747,O
to,6747,O
THLE,6747,O
cell,6747,O
lines,6747,O
",",6747,O
time-dependent,6747,O
inhibition,6747,O
of,6747,O
five,6747,O
major,6747,O
human,6747,B-GENE-N
cytochrome,6747,I-GENE-N
P450,6747,I-GENE-N
enzymes,6747,O
",",6747,O
inhibition,6747,O
of,6747,O
the,6747,O
biliary,6747,O
efflux,6747,B-GENE-N
transporters,6747,I-GENE-N
BSEP,6747,B-GENE-Y
and,6747,O
MRP2,6747,B-GENE-Y
or,6747,O
mitochondrial,6747,O
toxicity,6747,O
to,6747,O
THLE,6747,O
or,6747,O
HepG2,6747,O
cells,6747,O
.,6747,O
These,6748,O
data,6748,O
suggest,6748,O
that,6748,O
Phase,6748,O
1,6748,O
bioactivation,6748,O
plays,6748,O
a,6748,O
role,6748,O
in,6748,O
the,6748,O
hepatotoxicity,6748,O
of,6748,O
fenclozic,6748,B-CHEMICAL
acid,6748,I-CHEMICAL
and,6748,O
highlight,6748,O
the,6748,O
unique,6748,O
insight,6748,O
into,6748,O
mechanisms,6748,O
of,6748,O
human,6748,O
drug,6748,O
toxicity,6748,O
that,6748,O
can,6748,O
be,6748,O
provided,6748,O
by,6748,O
investigations,6748,O
of,6748,O
biotransformation,6748,O
and,6748,O
covalent,6748,O
binding,6748,O
to,6748,O
proteins,6748,O
.,6748,O
Mechanism,6749,O
of,6749,O
organophosphates,6749,B-CHEMICAL
(,6749,O
nerve,6749,O
gases,6749,O
and,6749,O
pesticides,6749,O
),6749,O
and,6749,O
antidotes,6749,O
:,6749,O
electron,6749,O
transfer,6749,O
and,6749,O
oxidative,6749,O
stress,6749,O
.,6749,O
Evidence,6750,O
indicates,6750,O
that,6750,O
nerve,6750,O
gas,6750,O
toxins,6750,O
operate,6750,O
in,6750,O
ways,6750,O
in,6750,O
addition,6750,O
to,6750,O
inhibition,6750,O
of,6750,O
acetylcholine,6750,B-GENE-Y
esterase,6750,I-GENE-Y
.,6750,O
Alternative,6751,O
bioactivities,6751,O
are,6751,O
discussed,6751,O
with,6751,O
focus,6751,O
on,6751,O
electron,6751,O
transfer,6751,O
.,6751,O
The,6752,O
main,6752,O
class,6752,O
",",6752,O
including,6752,O
pralidoxime,6752,B-CHEMICAL
(,6752,O
2-PAM,6752,B-CHEMICAL
),6752,O
",",6752,O
incorporates,6752,O
conjugated,6752,O
iminium,6752,B-CHEMICAL
and,6752,O
oxime,6752,B-CHEMICAL
moieties,6752,O
that,6752,O
are,6752,O
electron,6752,O
affinic,6752,O
.,6752,O
Various,6753,O
physiological,6753,O
properties,6753,O
of,6753,O
iminium,6753,B-CHEMICAL
and,6753,O
oxime,6753,B-CHEMICAL
species,6753,O
are,6753,O
reviewed,6753,O
.,6753,O
The,6754,O
organophosphates,6754,B-CHEMICAL
encompass,6754,O
both,6754,O
nerve,6754,O
gases,6754,O
and,6754,O
insecticides,6754,O
",",6754,O
possessing,6754,O
similar,6754,O
properties,6754,O
",",6754,O
but,6754,O
different,6754,O
activities,6754,O
.,6754,O
Toxic,6755,O
manifestations,6755,O
are,6755,O
apparently,6755,O
due,6755,O
",",6755,O
in,6755,O
part,6755,O
",",6755,O
to,6755,O
oxidative,6755,O
stress,6755,O
.,6755,O
Alkylation,6756,O
of,6756,O
DNA,6756,O
takes,6756,O
place,6756,O
which,6756,O
may,6756,O
lead,6756,O
to,6756,O
generation,6756,O
of,6756,O
reactive,6756,O
oxygen,6756,B-CHEMICAL
species,6756,O
.,6756,O
Structure-activity,6757,O
relationships,6757,O
are,6757,O
examined,6757,O
",",6757,O
including,6757,O
reduction,6757,O
potentials,6757,O
and,6757,O
the,6757,O
captodative,6757,O
effect,6757,O
.,6757,O
Auranofin,6758,B-CHEMICAL
",",6758,O
as,6758,O
an,6758,O
anti-rheumatic,6758,O
gold,6758,O
compound,6758,O
",",6758,O
suppresses,6758,O
LPS-induced,6758,O
homodimerization,6758,O
of,6758,O
TLR4,6758,B-GENE-Y
.,6758,O
Toll-like,6759,B-GENE-N
receptors,6759,I-GENE-N
(,6759,I-GENE-N
TLRs,6759,I-GENE-N
),6759,I-GENE-N
",",6759,O
which,6759,O
are,6759,O
activated,6759,O
by,6759,O
invading,6759,O
microorganisms,6759,O
or,6759,O
endogenous,6759,O
molecules,6759,O
",",6759,O
evoke,6759,O
immune,6759,O
and,6759,O
inflammatory,6759,O
responses,6759,O
.,6759,O
TLR,6760,B-GENE-N
activation,6760,O
is,6760,O
closely,6760,O
linked,6760,O
to,6760,O
the,6760,O
development,6760,O
of,6760,O
many,6760,O
chronic,6760,O
inflammatory,6760,O
diseases,6760,O
including,6760,O
rheumatoid,6760,O
arthritis,6760,O
.,6760,O
Auranofin,6761,B-CHEMICAL
",",6761,O
an,6761,O
Au,6761,B-CHEMICAL
(,6761,I-CHEMICAL
I,6761,I-CHEMICAL
),6761,I-CHEMICAL
compound,6761,O
",",6761,O
is,6761,O
a,6761,O
well-known,6761,O
and,6761,O
long-used,6761,O
anti-rheumatic,6761,O
drug,6761,O
.,6761,O
However,6762,O
",",6762,O
the,6762,O
mechanism,6762,O
as,6762,O
to,6762,O
how,6762,O
auranofin,6762,B-CHEMICAL
relieves,6762,O
the,6762,O
symptom,6762,O
of,6762,O
rheumatoid,6762,O
arthritis,6762,O
has,6762,O
not,6762,O
been,6762,O
fully,6762,O
clarified,6762,O
.,6762,O
Our,6763,O
results,6763,O
demonstrated,6763,O
that,6763,O
auranofin,6763,B-CHEMICAL
suppressed,6763,O
TLR4-mediated,6763,B-GENE-Y
activation,6763,O
of,6763,O
transcription,6763,O
factors,6763,O
",",6763,O
NF-kappaB,6763,B-GENE-N
and,6763,O
IRF3,6763,B-GENE-Y
",",6763,O
and,6763,O
expression,6763,O
of,6763,O
COX-2,6763,B-GENE-Y
",",6763,O
a,6763,O
pro-inflammatory,6763,O
enzyme,6763,O
.,6763,O
This,6764,O
suppression,6764,O
was,6764,O
well,6764,O
correlated,6764,O
with,6764,O
the,6764,O
inhibitory,6764,O
effect,6764,O
of,6764,O
auranofin,6764,B-CHEMICAL
on,6764,O
the,6764,O
homodimerization,6764,O
of,6764,O
TLR4,6764,B-GENE-Y
induced,6764,O
by,6764,O
an,6764,O
agonist,6764,O
.,6764,O
Furthermore,6765,O
",",6765,O
auranofin,6765,B-CHEMICAL
inhibited,6765,O
NF-kappaB,6765,B-GENE-N
activation,6765,O
induced,6765,O
by,6765,O
MyD88-dependent,6765,B-GENE-Y
downstream,6765,O
signaling,6765,O
components,6765,O
of,6765,O
TLR4,6765,B-GENE-Y
",",6765,O
MyD88,6765,B-GENE-Y
",",6765,O
IKKbeta,6765,B-GENE-Y
",",6765,O
and,6765,O
p65,6765,B-GENE-Y
.,6765,O
IRF3,6766,B-GENE-Y
activation,6766,O
induced,6766,O
by,6766,O
MyD88-independent,6766,B-GENE-Y
signaling,6766,O
components,6766,O
",",6766,O
TRIF,6766,B-GENE-Y
and,6766,O
TBK1,6766,B-GENE-Y
",",6766,O
was,6766,O
also,6766,O
downregulated,6766,O
by,6766,O
auranofin,6766,B-CHEMICAL
.,6766,O
Our,6767,O
results,6767,O
first,6767,O
demonstrate,6767,O
that,6767,O
auranofin,6767,B-CHEMICAL
suppresses,6767,O
the,6767,O
multiple,6767,O
steps,6767,O
in,6767,O
TLR4,6767,B-GENE-Y
signaling,6767,O
",",6767,O
especially,6767,O
the,6767,O
homodimerization,6767,O
of,6767,O
TLR4,6767,B-GENE-Y
.,6767,O
The,6768,O
results,6768,O
suggest,6768,O
that,6768,O
the,6768,O
suppression,6768,O
of,6768,O
TLR4,6768,B-GENE-Y
activity,6768,O
by,6768,O
auranofin,6768,B-CHEMICAL
may,6768,O
be,6768,O
the,6768,O
molecular,6768,O
mechanism,6768,O
through,6768,O
which,6768,O
auranofin,6768,B-CHEMICAL
exerts,6768,O
anti-rheumatic,6768,O
activity,6768,O
.,6768,O
Differential,6769,O
binding,6769,O
of,6769,O
fibroblast,6769,B-GENE-N
growth,6769,I-GENE-N
factor-2,6769,I-GENE-N
and,6769,I-GENE-N
-7,6769,I-GENE-N
to,6769,O
basement,6769,O
membrane,6769,O
heparan,6769,O
sulfate,6769,B-CHEMICAL
:,6769,O
comparison,6769,O
of,6769,O
normal,6769,O
and,6769,O
abnormal,6769,O
human,6769,O
tissues,6769,O
.,6769,O
Fibroblast,6770,B-GENE-N
growth,6770,I-GENE-N
factors,6770,I-GENE-N
(,6770,O
FGFs,6770,B-GENE-N
),6770,O
play,6770,O
multiple,6770,O
roles,6770,O
during,6770,O
development,6770,O
and,6770,O
in,6770,O
adult,6770,O
tissues,6770,O
as,6770,O
paracrine,6770,O
regulators,6770,O
of,6770,O
growth,6770,O
and,6770,O
differentiation,6770,O
.,6770,O
FGFs,6771,B-GENE-N
signal,6771,O
through,6771,O
transmembrane,6771,B-GENE-N
receptor,6771,I-GENE-N
tyrosine,6771,I-GENE-N
kinases,6771,I-GENE-N
",",6771,O
but,6771,O
heparan,6771,O
sulfate,6771,B-CHEMICAL
is,6771,O
also,6771,O
required,6771,O
for,6771,O
signaling,6771,O
by,6771,O
members,6771,O
of,6771,O
the,6771,O
FGF,6771,B-GENE-N
family,6771,O
.,6771,O
In,6772,O
addition,6772,O
",",6772,O
heparan,6772,O
sulfate,6772,O
may,6772,O
be,6772,O
involved,6772,O
in,6772,O
determining,6772,O
tissue,6772,O
distribution,6772,O
of,6772,O
FGFs,6772,B-GENE-N
.,6772,O
Using,6773,O
biotinylated,6773,O
FGF-2,6773,B-GENE-Y
and,6773,O
FGF-7,6773,B-GENE-Y
(,6773,O
KGF,6773,B-GENE-Y
),6773,O
as,6773,O
probes,6773,O
",",6773,O
we,6773,O
have,6773,O
identified,6773,O
specific,6773,O
interactions,6773,O
between,6773,O
FGFs,6773,B-GENE-N
and,6773,O
heparan,6773,O
sulfates,6773,B-CHEMICAL
in,6773,O
human,6773,O
tissues,6773,O
.,6773,O
Both,6774,O
FGF,6774,B-GENE-N
species,6774,O
bind,6774,O
to,6774,O
tissue,6774,O
mast,6774,O
cells,6774,O
and,6774,O
to,6774,O
epithelial,6774,O
cell,6774,O
membranes,6774,O
.,6774,O
Binding,6775,O
to,6775,O
basement,6775,O
membrane,6775,O
heparan,6775,O
sulfate,6775,B-CHEMICAL
is,6775,O
tissue,6775,O
source,6775,O
dependent,6775,O
and,6775,O
specific,6775,O
.,6775,O
Although,6776,O
FGF-2,6776,B-GENE-Y
strongly,6776,O
binds,6776,O
to,6776,O
basement,6776,O
membrane,6776,O
heparan,6776,O
sulfate,6776,B-CHEMICAL
in,6776,O
skin,6776,O
and,6776,O
most,6776,O
other,6776,O
tissue,6776,O
sites,6776,O
examined,6776,O
",",6776,O
FGF-7,6776,B-GENE-Y
fails,6776,O
to,6776,O
bind,6776,O
to,6776,O
basement,6776,O
membrane,6776,O
heparan,6776,O
sulfate,6776,B-CHEMICAL
in,6776,O
most,6776,O
locations,6776,O
.,6776,O
However,6777,O
",",6777,O
in,6777,O
subendothelial,6777,O
matrix,6777,O
in,6777,O
blood,6777,O
vessels,6777,O
and,6777,O
in,6777,O
the,6777,O
basement,6777,O
membrane,6777,O
of,6777,O
a,6777,O
papillary,6777,O
renal,6777,O
cell,6777,O
carcinoma,6777,O
",",6777,O
strong,6777,O
FGF-7,6777,B-GENE-Y
binding,6777,O
is,6777,O
seen,6777,O
.,6777,O
In,6778,O
summary,6778,O
",",6778,O
distinct,6778,O
and,6778,O
specific,6778,O
affinities,6778,O
of,6778,O
heparan,6778,O
sulfates,6778,B-CHEMICAL
for,6778,O
different,6778,O
FGFs,6778,B-GENE-N
were,6778,O
identified,6778,O
that,6778,O
may,6778,O
affect,6778,O
growth,6778,O
factor,6778,O
activation,6778,O
and,6778,O
local,6778,O
distribution,6778,O
.,6778,O
Heparan,6779,O
sulfate,6779,B-CHEMICAL
may,6779,O
have,6779,O
a,6779,O
gatekeeper,6779,O
function,6779,O
to,6779,O
either,6779,O
restrict,6779,O
or,6779,O
permit,6779,O
diffusion,6779,O
of,6779,O
heparin-binding,6779,O
growth,6779,O
factors,6779,O
across,6779,O
the,6779,O
basement,6779,O
membrane,6779,O
.,6779,O
Vandetanib,6780,B-CHEMICAL
:,6780,O
opening,6780,O
a,6780,O
new,6780,O
treatment,6780,O
practice,6780,O
in,6780,O
advanced,6780,O
medullary,6780,O
thyroid,6780,O
carcinoma,6780,O
.,6780,O
Medullary,6781,O
thyroid,6781,O
cancer,6781,O
(,6781,O
MTC,6781,O
),6781,O
is,6781,O
frequently,6781,O
diagnosed,6781,O
in,6781,O
a,6781,O
locally,6781,O
advanced,6781,O
or,6781,O
metastatic,6781,O
stage,6781,O
",",6781,O
and,6781,O
10-year,6781,O
survival,6781,O
rates,6781,O
in,6781,O
these,6781,O
cases,6781,O
are,6781,O
below,6781,O
20,6781,O
%,6781,O
.,6781,O
Cytotoxic,6782,O
chemotherapy,6782,O
has,6782,O
no,6782,O
significant,6782,O
impact,6782,O
on,6782,O
overall,6782,O
or,6782,O
progression-free,6782,O
survival,6782,O
.,6782,O
Vandetanib,6783,B-CHEMICAL
(,6783,O
Caprelsa,6783,B-CHEMICAL
(,6783,O
®,6783,O
),6783,O
",",6783,O
AstraZeneca,6783,O
),6783,O
is,6783,O
a,6783,O
once-daily,6783,O
oral,6783,O
tyrosine,6783,B-GENE-N
kinase,6783,I-GENE-N
inhibitor,6783,O
that,6783,O
selectively,6783,O
inhibits,6783,O
signalling,6783,O
mediated,6783,O
by,6783,O
growth-factor,6783,B-GENE-N
receptor,6783,I-GENE-N
tyrosine,6783,I-GENE-N
kinase,6783,I-GENE-N
RET,6783,B-GENE-Y
(,6783,O
constitutively,6783,O
activated,6783,O
in,6783,O
roughly,6783,O
60,6783,O
%,6783,O
of,6783,O
all,6783,O
MTCs,6783,O
),6783,O
",",6783,O
vascular,6783,B-GENE-N
endothelial,6783,I-GENE-N
growth-factor,6783,I-GENE-N
receptors,6783,I-GENE-N
2,6783,I-GENE-N
and,6783,I-GENE-N
3,6783,I-GENE-N
",",6783,O
and,6783,O
epidermal,6783,B-GENE-Y
growth-factor,6783,I-GENE-Y
receptors,6783,I-GENE-Y
.,6783,O
It,6784,O
is,6784,O
the,6784,O
first,6784,O
systemic,6784,O
drug,6784,O
with,6784,O
demonstrated,6784,O
anti-tumor,6784,O
benefits,6784,O
in,6784,O
advanced,6784,O
MTC,6784,O
",",6784,O
and,6784,O
it,6784,O
has,6784,O
recently,6784,O
been,6784,O
approved,6784,O
for,6784,O
locally,6784,O
advanced,6784,O
or,6784,O
metastatic,6784,O
MTC,6784,O
by,6784,O
the,6784,O
United,6784,O
States,6784,O
Food,6784,O
and,6784,O
Drug,6784,O
Administration,6784,O
(,6784,O
April,6784,O
2011,6784,O
),6784,O
and,6784,O
the,6784,O
European,6784,O
Medicines,6784,O
Agency,6784,O
(,6784,O
February,6784,O
2012,6784,O
),6784,O
.,6784,O
This,6785,O
review,6785,O
",",6785,O
starting,6785,O
from,6785,O
the,6785,O
phases,6785,O
II,6785,O
and,6785,O
III,6785,O
efficacy,6785,O
and,6785,O
safety,6785,O
data,6785,O
that,6785,O
led,6785,O
to,6785,O
these,6785,O
approvals,6785,O
",",6785,O
explores,6785,O
important,6785,O
issues,6785,O
related,6785,O
to,6785,O
dosing,6785,O
",",6785,O
patient,6785,O
selection,6785,O
",",6785,O
and,6785,O
strategies,6785,O
for,6785,O
managing,6785,O
the,6785,O
substantial,6785,O
risk,6785,O
of,6785,O
toxicity,6785,O
associated,6785,O
with,6785,O
the,6785,O
drug,6785,O
(,6785,O
including,6785,O
life-threatening,6785,O
cardiac,6785,O
events,6785,O
that,6785,O
are,6785,O
the,6785,O
subject,6785,O
of,6785,O
a,6785,O
black-box,6785,O
warning,6785,O
in,6785,O
the,6785,O
United,6785,O
States,6785,O
),6785,O
.,6785,O
All,6786,O
these,6786,O
issues,6786,O
still,6786,O
remain,6786,O
to,6786,O
be,6786,O
defined,6786,O
.,6786,O
Vandetanib,6787,B-CHEMICAL
is,6787,O
becoming,6787,O
a,6787,O
standard,6787,O
of,6787,O
care,6787,O
for,6787,O
symptomatic,6787,O
",",6787,O
progressive,6787,O
",",6787,O
metastatic,6787,O
MTCs,6787,O
",",6787,O
to,6787,O
be,6787,O
used,6787,O
selectively,6787,O
in,6787,O
those,6787,O
patients,6787,O
who,6787,O
are,6787,O
likely,6787,O
to,6787,O
benefit,6787,O
from,6787,O
it,6787,O
.,6787,O
Potent,6788,O
fibrinolysis,6788,O
inhibitor,6788,O
discovered,6788,O
by,6788,O
shape,6788,O
and,6788,O
electrostatic,6788,O
complementarity,6788,O
to,6788,O
the,6788,O
drug,6788,O
tranexamic,6788,B-CHEMICAL
Acid,6788,I-CHEMICAL
.,6788,O
Protein-protein,6789,O
interfaces,6789,O
provide,6789,O
an,6789,O
important,6789,O
class,6789,O
of,6789,O
drug,6789,O
targets,6789,O
currently,6789,O
receiving,6789,O
increased,6789,O
attention,6789,O
.,6789,O
The,6790,O
typical,6790,O
design,6790,O
strategy,6790,O
to,6790,O
inhibit,6790,O
protein-protein,6790,O
interactions,6790,O
usually,6790,O
involves,6790,O
large,6790,O
molecules,6790,O
such,6790,O
as,6790,O
peptides,6790,O
and,6790,O
macrocycles,6790,O
.,6790,O
One,6791,O
exception,6791,O
is,6791,O
tranexamic,6791,B-CHEMICAL
acid,6791,I-CHEMICAL
(,6791,O
TXA,6791,B-CHEMICAL
),6791,O
",",6791,O
which,6791,O
",",6791,O
as,6791,O
a,6791,O
lysine,6791,B-CHEMICAL
mimetic,6791,O
",",6791,O
inhibits,6791,O
binding,6791,O
of,6791,O
plasminogen,6791,B-GENE-Y
to,6791,O
fibrin,6791,B-GENE-N
.,6791,O
However,6792,O
",",6792,O
the,6792,O
daily,6792,O
dose,6792,O
of,6792,O
TXA,6792,B-CHEMICAL
is,6792,O
high,6792,O
due,6792,O
to,6792,O
its,6792,O
modest,6792,O
potency,6792,O
and,6792,O
pharmacokinetic,6792,O
properties,6792,O
.,6792,O
In,6793,O
this,6793,O
study,6793,O
",",6793,O
we,6793,O
report,6793,O
a,6793,O
computational,6793,O
approach,6793,O
",",6793,O
where,6793,O
the,6793,O
focus,6793,O
was,6793,O
on,6793,O
finding,6793,O
electrostatic,6793,O
potential,6793,O
similarities,6793,O
to,6793,O
TXA,6793,B-CHEMICAL
.,6793,O
Coupling,6794,O
this,6794,O
computational,6794,O
technique,6794,O
with,6794,O
a,6794,O
high-quality,6794,O
low-throughput,6794,O
screen,6794,O
identified,6794,O
5-,6794,B-CHEMICAL
(,6794,I-CHEMICAL
4-piperidyl,6794,I-CHEMICAL
),6794,I-CHEMICAL
-3-isoxazolol,6794,I-CHEMICAL
(,6794,O
4-PIOL,6794,B-CHEMICAL
),6794,O
as,6794,O
a,6794,O
potent,6794,O
plasminogen,6794,B-GENE-Y
binding,6794,O
inhibitor,6794,O
with,6794,O
the,6794,O
potential,6794,O
for,6794,O
the,6794,O
treatment,6794,O
of,6794,O
various,6794,O
bleeding,6794,O
disorders,6794,O
.,6794,O
Remarkably,6795,O
",",6795,O
4-PIOL,6795,B-CHEMICAL
was,6795,O
found,6795,O
to,6795,O
be,6795,O
more,6795,O
than,6795,O
four,6795,O
times,6795,O
as,6795,O
potent,6795,O
as,6795,O
the,6795,O
drug,6795,O
TXA,6795,B-CHEMICAL
.,6795,O
Gene,6796,O
deletion,6796,O
reveals,6796,O
roles,6796,O
for,6796,O
annexin,6796,B-GENE-Y
A1,6796,I-GENE-Y
in,6796,O
the,6796,O
regulation,6796,O
of,6796,O
lipolysis,6796,O
and,6796,O
IL-6,6796,B-GENE-Y
release,6796,O
in,6796,O
epididymal,6796,O
adipose,6796,O
tissue,6796,O
.,6796,O
In,6797,O
this,6797,O
study,6797,O
",",6797,O
epididymal,6797,O
adipose,6797,O
tissue,6797,O
from,6797,O
male,6797,O
annexin,6797,B-GENE-Y
1,6797,I-GENE-Y
(,6797,O
ANXA1,6797,B-GENE-Y
),6797,O
-null,6797,O
and,6797,O
wild-type,6797,O
control,6797,O
mice,6797,O
were,6797,O
used,6797,O
to,6797,O
explore,6797,O
the,6797,O
potential,6797,O
role,6797,O
of,6797,O
ANXA1,6797,B-GENE-Y
in,6797,O
adipocyte,6797,O
biology,6797,O
.,6797,O
ANXA1,6798,B-GENE-Y
was,6798,O
detected,6798,O
by,6798,O
Western,6798,O
blot,6798,O
analysis,6798,O
in,6798,O
wild-type,6798,O
tissue,6798,O
and,6798,O
localized,6798,O
predominantly,6798,O
to,6798,O
the,6798,O
stromal-vascular,6798,O
compartment,6798,O
.,6798,O
Epididymal,6799,O
fat,6799,O
pad,6799,O
mass,6799,O
was,6799,O
reduced,6799,O
by,6799,O
ANXA1,6799,B-GENE-Y
gene,6799,O
deletion,6799,O
",",6799,O
but,6799,O
adipocyte,6799,O
size,6799,O
was,6799,O
unchanged,6799,O
",",6799,O
suggesting,6799,O
that,6799,O
ANXA1,6799,B-GENE-Y
is,6799,O
required,6799,O
for,6799,O
the,6799,O
maintenance,6799,O
of,6799,O
adipocyte,6799,O
and/or,6799,O
preadipocyte,6799,O
cell,6799,O
number,6799,O
.,6799,O
Epididymal,6800,O
tissue,6800,O
from,6800,O
wild-type,6800,O
mice,6800,O
responded,6800,O
in,6800,O
vitro,6800,O
to,6800,O
noradrenaline,6800,B-CHEMICAL
and,6800,O
isoprenaline,6800,B-CHEMICAL
with,6800,O
increased,6800,O
glycerol,6800,B-CHEMICAL
release,6800,O
",",6800,O
reduced,6800,O
IL-6,6800,B-GENE-Y
release,6800,O
",",6800,O
and,6800,O
increased,6800,O
cAMP,6800,B-CHEMICAL
accumulation,6800,O
.,6800,O
Qualitatively,6801,O
similar,6801,O
but,6801,O
significantly,6801,O
attenuated,6801,O
responses,6801,O
to,6801,O
the,6801,O
catecholamines,6801,B-CHEMICAL
were,6801,O
observed,6801,O
in,6801,O
tissue,6801,O
from,6801,O
ANXA1-null,6801,B-GENE-Y
mice,6801,O
",",6801,O
an,6801,O
effect,6801,O
that,6801,O
was,6801,O
not,6801,O
associated,6801,O
with,6801,O
changes,6801,O
in,6801,O
beta-adrenoceptor,6801,B-GENE-N
mRNA,6801,O
expression,6801,O
.,6801,O
Lipopolysaccharide,6802,O
(,6802,O
LPS,6802,O
),6802,O
also,6802,O
stimulated,6802,O
lipolysis,6802,O
in,6802,O
vitro,6802,O
",",6802,O
but,6802,O
its,6802,O
effects,6802,O
were,6802,O
muted,6802,O
by,6802,O
ANXA1,6802,B-GENE-Y
gene,6802,O
deletion,6802,O
.,6802,O
By,6803,O
contrast,6803,O
",",6803,O
LPS,6803,O
failed,6803,O
to,6803,O
influence,6803,O
IL-6,6803,B-GENE-Y
release,6803,O
from,6803,O
wild-type,6803,O
tissue,6803,O
but,6803,O
stimulated,6803,O
the,6803,O
release,6803,O
of,6803,O
the,6803,O
cytokine,6803,B-GENE-N
from,6803,O
tissue,6803,O
from,6803,O
ANXA1-null,6803,B-GENE-Y
mice,6803,O
.,6803,O
ANXA1,6804,B-GENE-Y
gene,6804,O
deletion,6804,O
did,6804,O
not,6804,O
affect,6804,O
glucocorticoid,6804,B-GENE-Y
receptor,6804,I-GENE-Y
expression,6804,O
or,6804,O
the,6804,O
ability,6804,O
of,6804,O
dexamethasone,6804,B-CHEMICAL
to,6804,O
suppress,6804,O
catecholamine-induced,6804,B-CHEMICAL
lipolysis,6804,O
.,6804,O
It,6805,O
did,6805,O
",",6805,O
however,6805,O
",",6805,O
augment,6805,O
IL-6,6805,B-GENE-Y
expression,6805,O
and,6805,O
modify,6805,O
the,6805,O
inhibitory,6805,O
effects,6805,O
of,6805,O
glucocorticoids,6805,O
on,6805,O
IL-6,6805,B-GENE-Y
release,6805,O
.,6805,O
Collectively,6806,O
",",6806,O
these,6806,O
studies,6806,O
suggest,6806,O
that,6806,O
ANXA1,6806,B-GENE-Y
supports,6806,O
aspects,6806,O
of,6806,O
adipose,6806,O
tissue,6806,O
mass,6806,O
and,6806,O
alters,6806,O
the,6806,O
sensitivity,6806,O
of,6806,O
epididymal,6806,O
adipose,6806,O
tissue,6806,O
to,6806,O
catecholamines,6806,B-CHEMICAL
",",6806,O
glucocorticoids,6806,O
",",6806,O
and,6806,O
LPS,6806,O
",",6806,O
thereby,6806,O
modulating,6806,O
lipolysis,6806,O
and,6806,O
IL-6,6806,B-GENE-Y
release,6806,O
.,6806,O
Phospholipase,6807,B-GENE-Y
A2,6807,I-GENE-Y
inhibitors,6807,O
p-bromophenacyl,6807,B-CHEMICAL
bromide,6807,I-CHEMICAL
and,6807,O
arachidonyl,6807,B-CHEMICAL
trifluoromethyl,6807,I-CHEMICAL
ketone,6807,I-CHEMICAL
suppressed,6807,O
interleukin-2,6807,B-GENE-Y
(,6807,O
IL-2,6807,B-GENE-Y
),6807,O
expression,6807,O
in,6807,O
murine,6807,O
primary,6807,O
splenocytes,6807,O
.,6807,O
Phospholipase,6808,B-GENE-Y
A2,6808,I-GENE-Y
(,6808,O
PLA2,6808,B-GENE-Y
),6808,O
has,6808,O
been,6808,O
postulated,6808,O
to,6808,O
play,6808,O
a,6808,O
role,6808,O
in,6808,O
the,6808,O
regulation,6808,O
of,6808,O
cytokine,6808,B-GENE-N
expression,6808,O
.,6808,O
Therefore,6809,O
",",6809,O
the,6809,O
objective,6809,O
of,6809,O
the,6809,O
present,6809,O
study,6809,O
was,6809,O
to,6809,O
investigate,6809,O
the,6809,O
effects,6809,O
of,6809,O
PLA2,6809,B-GENE-Y
inhibitors,6809,O
p-bromophenacyl,6809,B-CHEMICAL
bromide,6809,I-CHEMICAL
(,6809,O
BPB,6809,B-CHEMICAL
),6809,O
and,6809,O
arachidonyl,6809,B-CHEMICAL
trifluoromethyl,6809,I-CHEMICAL
ketone,6809,I-CHEMICAL
(,6809,O
AACOCF3,6809,B-CHEMICAL
),6809,O
on,6809,O
interleukin-2,6809,B-GENE-Y
(,6809,O
IL-2,6809,B-GENE-Y
),6809,O
expression,6809,O
in,6809,O
murine,6809,O
primary,6809,O
splenocytes,6809,O
.,6809,O
Pretreatment,6810,O
of,6810,O
the,6810,O
splenocytes,6810,O
with,6810,O
both,6810,O
BPB,6810,B-CHEMICAL
and,6810,O
AACOCF3,6810,B-CHEMICAL
suppressed,6810,O
phorbol,6810,B-CHEMICAL
12-myristate,6810,I-CHEMICAL
13-acetate,6810,I-CHEMICAL
plus,6810,O
ionomycin-induced,6810,O
IL-2,6810,B-GENE-Y
secretion,6810,O
in,6810,O
a,6810,O
concentration-dependent,6810,O
manner,6810,O
.,6810,O
Inhibition,6811,O
>,6811,O
90,6811,O
%,6811,O
of,6811,O
IL-2,6811,B-GENE-Y
secretion,6811,O
was,6811,O
observed,6811,O
at,6811,O
1,6811,O
microM,6811,O
BPB,6811,B-CHEMICAL
and,6811,O
10,6811,O
microM,6811,O
AACOCF3,6811,B-CHEMICAL
compared,6811,O
to,6811,O
the,6811,O
respective,6811,O
vehicle,6811,O
control,6811,O
.,6811,O
Likewise,6812,O
",",6812,O
IL-2,6812,B-GENE-Y
steady-state,6812,O
mRNA,6812,O
expression,6812,O
was,6812,O
inhibited,6812,O
by,6812,O
both,6812,O
PLA2,6812,B-GENE-Y
inhibitors,6812,O
in,6812,O
a,6812,O
concentration-dependent,6812,O
fashion,6812,O
with,6812,O
>,6812,O
90,6812,O
%,6812,O
inhibition,6812,O
at,6812,O
1,6812,O
microM,6812,O
BPB,6812,B-CHEMICAL
and,6812,O
20,6812,O
microM,6812,O
AACOCF3,6812,B-CHEMICAL
.,6812,O
Taken,6813,O
together,6813,O
",",6813,O
these,6813,O
data,6813,O
demonstrated,6813,O
that,6813,O
PLA2,6813,B-GENE-Y
inhibitors,6813,O
BPB,6813,B-CHEMICAL
and,6813,O
AACOCF3,6813,B-CHEMICAL
are,6813,O
robust,6813,O
inhibitors,6813,O
of,6813,O
IL-2,6813,B-GENE-Y
expression,6813,O
at,6813,O
both,6813,O
the,6813,O
mRNA,6813,O
and,6813,O
protein,6813,O
levels,6813,O
in,6813,O
murine,6813,O
splenocytes,6813,O
.,6813,O
Moreover,6814,O
",",6814,O
these,6814,O
findings,6814,O
suggest,6814,O
that,6814,O
drugs,6814,O
and,6814,O
chemicals,6814,O
which,6814,O
inhibit,6814,O
PLA2,6814,B-GENE-Y
may,6814,O
have,6814,O
marked,6814,O
effects,6814,O
on,6814,O
T-cell,6814,O
function,6814,O
.,6814,O
Polymorphisms,6815,O
in,6815,O
OCTN1,6815,B-GENE-Y
and,6815,O
OCTN2,6815,B-GENE-Y
transporters,6815,O
genes,6815,O
are,6815,O
associated,6815,O
with,6815,O
prolonged,6815,O
time,6815,O
to,6815,O
progression,6815,O
in,6815,O
unresectable,6815,O
gastrointestinal,6815,O
stromal,6815,O
tumours,6815,O
treated,6815,O
with,6815,O
imatinib,6815,B-CHEMICAL
therapy,6815,O
.,6815,O
The,6816,O
two,6816,O
basic,6816,O
mainstays,6816,O
of,6816,O
gastrointestinal,6816,O
stromal,6816,O
tumours,6816,O
(,6816,O
GIST,6816,O
),6816,O
treatment,6816,O
are,6816,O
surgery,6816,O
and,6816,O
imatinib,6816,B-CHEMICAL
",",6816,O
a,6816,O
selective,6816,O
tyrosine,6816,B-GENE-N
kinase,6816,I-GENE-N
inhibitor,6816,O
that,6816,O
allows,6816,O
achieving,6816,O
a,6816,O
stable,6816,O
or,6816,O
responding,6816,O
disease,6816,O
in,6816,O
about,6816,O
80,6816,O
%,6816,O
of,6816,O
patients,6816,O
with,6816,O
unresectable/metastatic,6816,O
GIST,6816,O
.,6816,O
Response,6817,O
to,6817,O
imatinib,6817,B-CHEMICAL
mainly,6817,O
depends,6817,O
from,6817,O
KIT,6817,B-GENE-Y
and,6817,O
PDGFRα,6817,B-GENE-Y
mutational,6817,O
status,6817,O
.,6817,O
Nevertheless,6818,O
",",6818,O
some,6818,O
patients,6818,O
with,6818,O
a,6818,O
potentially,6818,O
responsive,6818,O
genotype,6818,O
do,6818,O
not,6818,O
respond,6818,O
",",6818,O
and,6818,O
others,6818,O
develop,6818,O
a,6818,O
pattern,6818,O
of,6818,O
resistance,6818,O
to,6818,O
imatinib,6818,B-CHEMICAL
which,6818,O
is,6818,O
not,6818,O
associated,6818,O
with,6818,O
secondary,6818,O
mutations,6818,O
.,6818,O
This,6819,O
emphasizes,6819,O
the,6819,O
presence,6819,O
of,6819,O
mechanisms,6819,O
of,6819,O
resistance,6819,O
other,6819,O
than,6819,O
the,6819,O
receptor-related,6819,O
genotype,6819,O
",",6819,O
and,6819,O
the,6819,O
need,6819,O
of,6819,O
biological,6819,O
predictors,6819,O
to,6819,O
select,6819,O
the,6819,O
optimal,6819,O
therapeutic,6819,O
strategy,6819,O
",",6819,O
particularly,6819,O
now,6819,O
that,6819,O
other,6819,O
potent,6819,O
inhibitors,6819,O
are,6819,O
available,6819,O
.,6819,O
We,6820,O
investigated,6820,O
a,6820,O
panel,6820,O
of,6820,O
31,6820,O
polymorphisms,6820,O
in,6820,O
11,6820,O
genes,6820,O
",",6820,O
potentially,6820,O
associated,6820,O
with,6820,O
the,6820,O
pharmacogenetics,6820,O
of,6820,O
imatinib,6820,B-CHEMICAL
",",6820,O
in,6820,O
a,6820,O
group,6820,O
of,6820,O
54,6820,O
unresectable/metastatic,6820,O
GISTs,6820,O
treated,6820,O
with,6820,O
imatinib,6820,B-CHEMICAL
400mg,6820,O
daily,6820,O
as,6820,O
first,6820,O
line,6820,O
therapy,6820,O
.,6820,O
Included,6821,O
in,6821,O
this,6821,O
analysis,6821,O
were,6821,O
polymorphisms,6821,O
in,6821,O
the,6821,O
transporters,6821,O
',6821,O
family,6821,O
SLC22,6821,B-GENE-N
",",6821,O
SLCO,6821,B-GENE-N
",",6821,O
ABC,6821,B-GENE-N
",",6821,O
and,6821,O
in,6821,O
the,6821,O
metabolizing,6821,O
genes,6821,O
CYP-3A4,6821,B-GENE-N
and,6821,I-GENE-N
-3A5,6821,I-GENE-N
.,6821,O
Time,6822,O
to,6822,O
progression,6822,O
was,6822,O
significantly,6822,O
improved,6822,O
in,6822,O
presence,6822,O
of,6822,O
the,6822,O
C,6822,O
allele,6822,O
in,6822,O
SLC22A4,6822,B-GENE-Y
(,6822,O
OCTN1,6822,B-GENE-Y
rs1050152,6822,O
),6822,O
",",6822,O
and,6822,O
the,6822,O
two,6822,O
minor,6822,O
alleles,6822,O
(,6822,O
G,6822,O
),6822,O
in,6822,O
SLC22A5,6822,B-GENE-Y
(,6822,O
OCTN2,6822,B-GENE-Y
rs2631367,6822,O
and,6822,O
rs2631372,6822,O
),6822,O
.,6822,O
Importantly,6823,O
",",6823,O
multivariate,6823,O
analysis,6823,O
",",6823,O
adjusting,6823,O
for,6823,O
age,6823,O
",",6823,O
gender,6823,O
",",6823,O
KIT/PDGFRα,6823,B-GENE-Y
mutational,6823,O
status,6823,O
",",6823,O
and,6823,O
tumour,6823,O
size,6823,O
",",6823,O
revealed,6823,O
that,6823,O
all,6823,O
the,6823,O
three,6823,O
genotypes,6823,O
maintained,6823,O
independent,6823,O
predictive,6823,O
significance,6823,O
.,6823,O
In,6824,O
conclusion,6824,O
",",6824,O
in,6824,O
this,6824,O
study,6824,O
we,6824,O
showed,6824,O
that,6824,O
SLC22A4,6824,B-GENE-Y
and,6824,O
SLC22A5,6824,B-GENE-Y
genotypes,6824,O
may,6824,O
be,6824,O
an,6824,O
important,6824,O
predictor,6824,O
of,6824,O
time,6824,O
to,6824,O
progression,6824,O
in,6824,O
GIST,6824,O
patients,6824,O
receiving,6824,O
imatinib,6824,B-CHEMICAL
therapy,6824,O
.,6824,O
Further,6825,O
investigations,6825,O
are,6825,O
required,6825,O
in,6825,O
an,6825,O
attempt,6825,O
to,6825,O
further,6825,O
personalize,6825,O
GIST,6825,O
therapy,6825,O
.,6825,O
Acute,6826,O
Macrovascular,6826,O
Dysfunction,6826,O
in,6826,O
Patients,6826,O
With,6826,O
Type,6826,O
2,6826,O
Diabetes,6826,O
Induced,6826,O
by,6826,O
Ingestion,6826,O
of,6826,O
Advanced,6826,O
Glycated,6826,B-GENE-N
β-Lactoglobulins,6826,I-GENE-N
.,6826,O
OBJECTIVE,6827,O
Recent,6827,O
evidence,6827,O
indicates,6827,O
that,6827,O
heat-enhanced,6827,O
food,6827,O
advanced,6827,O
glycation,6827,O
end,6827,O
products,6827,O
(,6827,O
AGEs,6827,O
),6827,O
adversely,6827,O
affect,6827,O
vascular,6827,O
function,6827,O
.,6827,O
The,6828,O
aim,6828,O
of,6828,O
this,6828,O
study,6828,O
was,6828,O
to,6828,O
examine,6828,O
the,6828,O
acute,6828,O
effects,6828,O
of,6828,O
an,6828,O
oral,6828,O
load,6828,O
of,6828,O
heat-treated,6828,O
",",6828,O
AGE-modified,6828,O
β-lactoglobulins,6828,B-GENE-N
(,6828,O
AGE-BLG,6828,O
),6828,O
compared,6828,O
with,6828,O
heat-treated,6828,O
",",6828,O
nonglycated,6828,B-GENE-N
BLG,6828,I-GENE-N
(,6828,O
C-BLG,6828,B-GENE-N
),6828,O
on,6828,O
vascular,6828,O
function,6828,O
in,6828,O
patients,6828,O
with,6828,O
type,6828,O
2,6828,O
diabetes,6828,O
mellitus,6828,O
(,6828,O
T2DM,6828,O
),6828,O
.,6828,O
RESEARCH,6829,O
DESIGN,6829,O
AND,6829,O
METHODS,6829,O
In,6829,O
a,6829,O
double-blind,6829,O
",",6829,O
controlled,6829,O
",",6829,O
randomized,6829,O
",",6829,O
crossover,6829,O
study,6829,O
",",6829,O
19,6829,O
patients,6829,O
with,6829,O
T2DM,6829,O
received,6829,O
",",6829,O
on,6829,O
two,6829,O
different,6829,O
occasions,6829,O
",",6829,O
beverages,6829,O
containing,6829,O
either,6829,O
AGE-BLG,6829,O
or,6829,O
C-BLG,6829,B-GENE-N
.,6829,O
We,6830,O
measured,6830,O
macrovascular,6830,O
[,6830,O
brachial,6830,O
ultrasound,6830,O
of,6830,O
flow-mediated,6830,O
dilatation,6830,O
(,6830,O
FMD,6830,O
),6830,O
],6830,O
and,6830,O
microvascular,6830,O
(,6830,O
laser-Doppler,6830,O
measurements,6830,O
of,6830,O
reactive,6830,O
hyperemia,6830,O
in,6830,O
the,6830,O
hand,6830,O
),6830,O
functions,6830,O
at,6830,O
baseline,6830,O
(,6830,O
T0,6830,O
),6830,O
",",6830,O
90,6830,O
(,6830,O
T90,6830,O
),6830,O
",",6830,O
and,6830,O
180,6830,O
(,6830,O
T180,6830,O
),6830,O
min,6830,O
.,6830,O
RESULTS,6831,O
Following,6831,O
the,6831,O
AGE-BLG,6831,O
",",6831,O
FMD,6831,O
decreased,6831,O
at,6831,O
T90,6831,O
by,6831,O
80,6831,O
%,6831,O
from,6831,O
baseline,6831,O
and,6831,O
remained,6831,O
decreased,6831,O
by,6831,O
42,6831,O
%,6831,O
at,6831,O
T180,6831,O
(,6831,O
P,6831,O
<,6831,O
0.05,6831,O
vs.,6831,O
baseline,6831,O
",",6831,O
P,6831,O
<,6831,O
0.05,6831,O
vs.,6831,O
C-BLG,6831,B-GENE-N
at,6831,O
T90,6831,O
),6831,O
.,6831,O
By,6832,O
comparison,6832,O
",",6832,O
following,6832,O
C-BLG,6832,B-GENE-N
",",6832,O
FMD,6832,O
decreased,6832,O
by,6832,O
27,6832,O
%,6832,O
at,6832,O
T90,6832,O
and,6832,O
51,6832,O
%,6832,O
at,6832,O
T180,6832,O
(,6832,O
P,6832,O
<,6832,O
0.05,6832,O
vs.,6832,O
baseline,6832,O
at,6832,O
T180,6832,O
),6832,O
.,6832,O
A,6833,O
significant,6833,O
decrease,6833,O
in,6833,O
nitrite,6833,B-CHEMICAL
(,6833,O
T180,6833,O
),6833,O
and,6833,O
nitrate,6833,B-CHEMICAL
(,6833,O
T90,6833,O
and,6833,O
T180,6833,O
),6833,O
",",6833,O
as,6833,O
well,6833,O
as,6833,O
a,6833,O
significant,6833,O
increase,6833,O
in,6833,O
N,6833,B-CHEMICAL
(,6833,I-CHEMICAL
ε,6833,I-CHEMICAL
),6833,I-CHEMICAL
-carboxymethyllisine,6833,I-CHEMICAL
",",6833,O
accompanied,6833,O
intake,6833,O
of,6833,O
AGE-BLG,6833,O
.,6833,O
There,6834,O
was,6834,O
no,6834,O
change,6834,O
in,6834,O
microvascular,6834,O
function,6834,O
caused,6834,O
by,6834,O
either,6834,O
beverage,6834,O
.,6834,O
CONCLUSIONS,6835,O
In,6835,O
patients,6835,O
with,6835,O
T2DM,6835,O
",",6835,O
acute,6835,O
oral,6835,O
administration,6835,O
of,6835,O
a,6835,O
single,6835,O
AGE-modified,6835,O
protein,6835,O
class,6835,O
significantly,6835,O
though,6835,O
transiently,6835,O
impaired,6835,O
macrovascular,6835,O
function,6835,O
in,6835,O
concert,6835,O
with,6835,O
decreased,6835,O
nitric,6835,B-CHEMICAL
oxide,6835,I-CHEMICAL
bioavailability,6835,O
.,6835,O
These,6836,O
AGE-related,6836,O
changes,6836,O
were,6836,O
independent,6836,O
of,6836,O
heat,6836,O
treatment,6836,O
.,6836,O
In,6837,O
situ,6837,O
forming,6837,O
reduction-sensitive,6837,O
degradable,6837,O
nanogels,6837,O
for,6837,O
facile,6837,O
loading,6837,O
and,6837,O
triggered,6837,O
intracellular,6837,O
release,6837,O
of,6837,O
proteins,6837,O
.,6837,O
In,6838,O
situ,6838,O
forming,6838,O
reduction-sensitive,6838,O
degradable,6838,O
nanogels,6838,O
were,6838,O
designed,6838,O
and,6838,O
developed,6838,O
based,6838,O
on,6838,O
poly,6838,B-CHEMICAL
(,6838,I-CHEMICAL
ethylene,6838,I-CHEMICAL
glycol,6838,I-CHEMICAL
),6838,I-CHEMICAL
-b-poly,6838,I-CHEMICAL
(,6838,I-CHEMICAL
2-,6838,I-CHEMICAL
(,6838,I-CHEMICAL
hydroxyethyl,6838,I-CHEMICAL
),6838,I-CHEMICAL
methacrylate-co-acryloyl,6838,I-CHEMICAL
carbonate,6838,I-CHEMICAL
),6838,I-CHEMICAL
(,6838,O
PEG-P,6838,B-CHEMICAL
(,6838,I-CHEMICAL
HEMA-co-AC,6838,I-CHEMICAL
),6838,I-CHEMICAL
),6838,O
block,6838,O
copolymers,6838,O
for,6838,O
efficient,6838,O
loading,6838,O
as,6838,O
well,6838,O
as,6838,O
triggered,6838,O
intracellular,6838,O
release,6838,O
of,6838,O
proteins,6838,O
.,6838,O
PEG-P,6839,B-CHEMICAL
(,6839,I-CHEMICAL
HEMA-co-AC,6839,I-CHEMICAL
),6839,I-CHEMICAL
copolymers,6839,O
were,6839,O
prepared,6839,O
with,6839,O
controlled,6839,O
Mn,6839,O
of,6839,O
9.1,6839,O
",",6839,O
9.5,6839,O
",",6839,O
and,6839,O
9.9,6839,O
kg/mol,6839,O
and,6839,O
varying,6839,O
numbers,6839,O
of,6839,O
AC,6839,O
units,6839,O
per,6839,O
molecule,6839,O
of,6839,O
7,6839,O
",",6839,O
9,6839,O
and,6839,O
11,6839,O
",",6839,O
respectively,6839,O
(,6839,O
denoted,6839,O
as,6839,O
copolymer,6839,O
1,6839,O
",",6839,O
2,6839,O
",",6839,O
and,6839,O
3,6839,O
),6839,O
by,6839,O
reversible,6839,O
addition-fragmentation,6839,O
chain,6839,O
transfer,6839,O
copolymerization,6839,O
.,6839,O
These,6840,O
copolymers,6840,O
were,6840,O
freely,6840,O
soluble,6840,O
in,6840,O
phosphate,6840,B-CHEMICAL
buffer,6840,O
but,6840,O
formed,6840,O
disulfide-cross-linked,6840,B-CHEMICAL
nanogels,6840,O
with,6840,O
defined,6840,O
sizes,6840,O
ranging,6840,O
from,6840,O
72.5,6840,O
to,6840,O
124.1,6840,O
nm,6840,O
in,6840,O
the,6840,O
presence,6840,O
of,6840,O
cystamine,6840,B-CHEMICAL
via,6840,O
ring-opening,6840,O
reaction,6840,O
with,6840,O
cyclic,6840,B-CHEMICAL
carbonate,6840,I-CHEMICAL
groups,6840,O
.,6840,O
The,6841,O
sizes,6841,O
of,6841,O
nanogels,6841,O
decreased,6841,O
with,6841,O
increasing,6841,O
AC,6841,O
units,6841,O
as,6841,O
a,6841,O
result,6841,O
of,6841,O
increased,6841,O
cross-linking,6841,O
density,6841,O
.,6841,O
Dynamic,6842,O
light,6842,O
scattering,6842,O
studies,6842,O
showed,6842,O
that,6842,O
these,6842,O
nanogels,6842,O
though,6842,O
stable,6842,O
at,6842,O
physiological,6842,O
conditions,6842,O
were,6842,O
rapidly,6842,O
dissociated,6842,O
in,6842,O
response,6842,O
to,6842,O
10,6842,O
mM,6842,O
dithiothreitol,6842,B-CHEMICAL
(,6842,O
DTT,6842,B-CHEMICAL
),6842,O
.,6842,O
Interestingly,6843,O
",",6843,O
FITC-labeled,6843,B-CHEMICAL
cytochrome,6843,B-GENE-Y
C,6843,I-GENE-Y
(,6843,O
FITC-CC,6843,B-CHEMICAL
),6843,O
could,6843,O
be,6843,O
readily,6843,O
loaded,6843,O
into,6843,O
nanogels,6843,O
with,6843,O
remarkable,6843,O
loading,6843,O
efficiencies,6843,O
(,6843,O
up,6843,O
to,6843,O
98.2,6843,O
%,6843,O
),6843,O
and,6843,O
loading,6843,O
contents,6843,O
(,6843,O
up,6843,O
to,6843,O
48.2,6843,O
wt.,6843,O
%,6843,O
),6843,O
.,6843,O
The,6844,O
in,6844,O
vitro,6844,O
release,6844,O
studies,6844,O
showed,6844,O
that,6844,O
release,6844,O
of,6844,O
FITC-CC,6844,B-CHEMICAL
was,6844,O
minimal,6844,O
under,6844,O
physiological,6844,O
conditions,6844,O
but,6844,O
significantly,6844,O
enhanced,6844,O
under,6844,O
reductive,6844,O
conditions,6844,O
in,6844,O
the,6844,O
presence,6844,O
of,6844,O
10,6844,O
mM,6844,O
DTT,6844,B-CHEMICAL
with,6844,O
about,6844,O
96.8,6844,O
%,6844,O
of,6844,O
FITC-CC,6844,B-CHEMICAL
released,6844,O
in,6844,O
22,6844,O
h,6844,O
from,6844,O
nanogel,6844,O
1,6844,O
.,6844,O
In,6845,O
contrast,6845,O
",",6845,O
protein,6845,O
release,6845,O
from,6845,O
"1,4-butanediamine",6845,B-CHEMICAL
cross-linked,6845,O
nanogels,6845,O
(,6845,O
reduction-insensitive,6845,O
control,6845,O
),6845,O
remained,6845,O
low,6845,O
under,6845,O
otherwise,6845,O
the,6845,O
same,6845,O
conditions,6845,O
.,6845,O
MTT,6846,B-CHEMICAL
assays,6846,O
showed,6846,O
that,6846,O
these,6846,O
nanogels,6846,O
were,6846,O
nontoxic,6846,O
to,6846,O
HeLa,6846,O
cells,6846,O
up,6846,O
to,6846,O
a,6846,O
tested,6846,O
concentration,6846,O
of,6846,O
2,6846,O
mg/mL,6846,O
.,6846,O
Confocal,6847,O
microscopy,6847,O
results,6847,O
showed,6847,O
that,6847,O
nanogel,6847,O
1,6847,O
delivered,6847,O
and,6847,O
released,6847,O
FITC-CC,6847,B-CHEMICAL
into,6847,O
the,6847,O
perinuclei,6847,O
region,6847,O
of,6847,O
HeLa,6847,O
cells,6847,O
following,6847,O
8,6847,O
h,6847,O
incubation,6847,O
.,6847,O
CC-loaded,6848,B-GENE-Y
reductively,6848,O
degradable,6848,O
nanogels,6848,O
demonstrated,6848,O
apparently,6848,O
better,6848,O
apoptotic,6848,O
activity,6848,O
than,6848,O
free,6848,O
CC,6848,B-GENE-Y
as,6848,O
well,6848,O
as,6848,O
reduction-insensitive,6848,O
controls,6848,O
.,6848,O
These,6849,O
in,6849,O
situ,6849,O
forming,6849,O
",",6849,O
surfactant,6849,O
and,6849,O
oil-free,6849,O
",",6849,O
and,6849,O
reduction-sensitive,6849,O
degradable,6849,O
nanogels,6849,O
are,6849,O
highly,6849,O
promising,6849,O
for,6849,O
targeted,6849,O
protein,6849,O
therapy,6849,O
.,6849,O
Brugada,6850,O
syndrome,6850,O
.,6850,O
A,6851,O
novel,6851,O
clinical,6851,O
entity,6851,O
characterized,6851,O
by,6851,O
ST,6851,O
segment,6851,O
elevation,6851,O
in,6851,O
right,6851,O
precordial,6851,O
leads,6851,O
(,6851,O
V1,6851,O
to,6851,O
V3,6851,O
),6851,O
",",6851,O
incomplete,6851,O
or,6851,O
complete,6851,O
right,6851,O
bundle,6851,O
branch,6851,O
block,6851,O
",",6851,O
and,6851,O
susceptibility,6851,O
to,6851,O
ventricular,6851,O
tachyarrhythmia,6851,O
and,6851,O
sudden,6851,O
cardiac,6851,O
death,6851,O
has,6851,O
been,6851,O
described,6851,O
by,6851,O
Brugada,6851,O
et,6851,O
al,6851,O
.,6851,O
in,6852,O
1992,6852,O
.,6852,O
This,6853,O
disease,6853,O
is,6853,O
now,6853,O
frequently,6853,O
called,6853,O
``,6853,O
Brugada,6853,O
syndrome,6853,O
'',6853,O
(,6853,O
BrS,6853,O
),6853,O
.,6853,O
The,6854,O
prevalence,6854,O
of,6854,O
BrS,6854,O
in,6854,O
the,6854,O
general,6854,O
population,6854,O
is,6854,O
unknown,6854,O
.,6854,O
The,6855,O
suggested,6855,O
prevalence,6855,O
ranges,6855,O
from,6855,O
"5/1,000",6855,O
(,6855,O
Caucasians,6855,O
),6855,O
to,6855,O
"14/1,000",6855,O
(,6855,O
Japanese,6855,O
),6855,O
.,6855,O
Syncope,6856,O
",",6856,O
typically,6856,O
occurring,6856,O
at,6856,O
rest,6856,O
or,6856,O
during,6856,O
sleep,6856,O
(,6856,O
in,6856,O
individuals,6856,O
in,6856,O
their,6856,O
third,6856,O
or,6856,O
fourth,6856,O
decades,6856,O
of,6856,O
life,6856,O
),6856,O
is,6856,O
a,6856,O
common,6856,O
presentation,6856,O
of,6856,O
BrS,6856,O
.,6856,O
In,6857,O
some,6857,O
cases,6857,O
",",6857,O
tachycardia,6857,O
does,6857,O
not,6857,O
terminate,6857,O
spontaneously,6857,O
and,6857,O
it,6857,O
may,6857,O
degenerate,6857,O
into,6857,O
ventricular,6857,O
fibrillation,6857,O
and,6857,O
lead,6857,O
to,6857,O
sudden,6857,O
death,6857,O
.,6857,O
Both,6858,O
sporadic,6858,O
and,6858,O
familial,6858,O
cases,6858,O
have,6858,O
been,6858,O
reported,6858,O
and,6858,O
pedigree,6858,O
analysis,6858,O
suggests,6858,O
an,6858,O
autosomal,6858,O
dominant,6858,O
pattern,6858,O
of,6858,O
inheritance,6858,O
.,6858,O
In,6859,O
approximately,6859,O
20,6859,O
%,6859,O
of,6859,O
the,6859,O
cases,6859,O
BrS,6859,O
is,6859,O
caused,6859,O
by,6859,O
mutations,6859,O
in,6859,O
the,6859,O
SCN5A,6859,B-GENE-Y
gene,6859,O
on,6859,O
chromosome,6859,O
3p21-23,6859,O
",",6859,O
encoding,6859,O
the,6859,O
cardiac,6859,O
sodium,6859,B-GENE-N
channel,6859,I-GENE-N
",",6859,O
a,6859,O
protein,6859,O
involved,6859,O
in,6859,O
the,6859,O
control,6859,O
of,6859,O
myocardial,6859,O
excitability,6859,O
.,6859,O
Since,6860,O
the,6860,O
use,6860,O
of,6860,O
the,6860,O
implantable,6860,O
cardioverter,6860,O
defibrillator,6860,O
(,6860,O
ICD,6860,O
),6860,O
is,6860,O
the,6860,O
only,6860,O
therapeutic,6860,O
option,6860,O
of,6860,O
proven,6860,O
efficacy,6860,O
for,6860,O
primary,6860,O
and,6860,O
secondary,6860,O
prophylaxis,6860,O
of,6860,O
cardiac,6860,O
arrest,6860,O
",",6860,O
the,6860,O
identification,6860,O
of,6860,O
high-risk,6860,O
subjects,6860,O
is,6860,O
one,6860,O
of,6860,O
the,6860,O
major,6860,O
goals,6860,O
in,6860,O
the,6860,O
clinical,6860,O
decision-making,6860,O
process,6860,O
.,6860,O
Quinidine,6861,B-CHEMICAL
may,6861,O
be,6861,O
regarded,6861,O
as,6861,O
an,6861,O
adjunctive,6861,O
therapy,6861,O
for,6861,O
patients,6861,O
at,6861,O
higher,6861,O
risk,6861,O
and,6861,O
may,6861,O
reduce,6861,O
the,6861,O
number,6861,O
of,6861,O
cases,6861,O
of,6861,O
ICD,6861,O
shock,6861,O
in,6861,O
patients,6861,O
with,6861,O
multiple,6861,O
recurrences,6861,O
.,6861,O
Thiazolidinediones,6862,B-CHEMICAL
(,6862,O
TZDs,6862,B-CHEMICAL
),6862,O
affect,6862,O
osteoblast,6862,O
viability,6862,O
and,6862,O
biomarkers,6862,O
independently,6862,O
of,6862,O
the,6862,O
TZD,6862,B-CHEMICAL
effects,6862,O
on,6862,O
aromatase,6862,B-GENE-Y
.,6862,O
Thiazolidinediones,6863,B-CHEMICAL
(,6863,O
TZDs,6863,B-CHEMICAL
),6863,O
are,6863,O
insulin,6863,B-GENE-Y
sensitizers,6863,O
used,6863,O
for,6863,O
treatment,6863,O
of,6863,O
diabetes,6863,O
.,6863,O
We,6864,O
have,6864,O
previously,6864,O
reported,6864,O
that,6864,O
TZDs,6864,B-CHEMICAL
reduce,6864,O
estrogen,6864,B-CHEMICAL
synthesis,6864,O
by,6864,O
inhibiting,6864,O
aromatase,6864,B-GENE-Y
activity,6864,O
in,6864,O
human,6864,O
granulosa,6864,O
cells,6864,O
(,6864,O
HGC,6864,O
),6864,O
.,6864,O
Multiple,6865,O
clinical,6865,O
trials,6865,O
demonstrated,6865,O
that,6865,O
TZDs,6865,B-CHEMICAL
increase,6865,O
the,6865,O
risk,6865,O
of,6865,O
fractures,6865,O
in,6865,O
postmenopausal,6865,O
women,6865,O
with,6865,O
type,6865,O
2,6865,O
diabetes,6865,O
.,6865,O
We,6866,O
studied,6866,O
mouse,6866,O
osteoblasts,6866,O
alone,6866,O
or,6866,O
in,6866,O
a,6866,O
co-culture,6866,O
with,6866,O
HGC,6866,O
to,6866,O
determine,6866,O
whether,6866,O
TZD,6866,B-CHEMICAL
inhibition,6866,O
of,6866,O
aromatase,6866,B-GENE-Y
plays,6866,O
a,6866,O
role,6866,O
in,6866,O
their,6866,O
effects,6866,O
on,6866,O
bone,6866,O
metabolism,6866,O
.,6866,O
Mouse,6867,O
osteoblasts,6867,O
were,6867,O
cultured,6867,O
with,6867,O
and,6867,O
without,6867,O
HGC,6867,O
",",6867,O
and,6867,O
incubated,6867,O
in,6867,O
a,6867,O
medium,6867,O
with,6867,O
or,6867,O
without,6867,O
testosterone,6867,B-CHEMICAL
",",6867,O
pioglitazone,6867,B-CHEMICAL
or,6867,O
rosiglitazone,6867,B-CHEMICAL
.,6867,O
Cell,6868,O
growth,6868,O
",",6868,O
oleic,6868,O
acid,6868,O
uptake,6868,O
",",6868,O
alkaline,6868,B-GENE-N
phosphatase,6868,I-GENE-N
activity,6868,O
",",6868,O
and,6868,O
osteocalcin,6868,B-GENE-Y
production,6868,O
were,6868,O
measured,6868,O
.,6868,O
TZDs,6869,B-CHEMICAL
inhibited,6869,O
estradiol,6869,B-CHEMICAL
production,6869,O
by,6869,O
up,6869,O
to,6869,O
84,6869,O
%,6869,O
in,6869,O
HGC/mouse,6869,O
osteoblast,6869,O
co-cultures,6869,O
.,6869,O
TZDs,6870,B-CHEMICAL
induced,6870,O
mouse,6870,O
osteoblast,6870,O
death,6870,O
and,6870,O
increased,6870,O
oleic,6870,B-CHEMICAL
acid,6870,I-CHEMICAL
uptake,6870,O
.,6870,O
TZDs,6871,B-CHEMICAL
also,6871,O
inhibited,6871,O
alkaline,6871,B-GENE-N
phosphatase,6871,I-GENE-N
activity,6871,O
(,6871,O
58-75,6871,O
%,6871,O
",",6871,O
p,6871,O
<,6871,O
0.046,6871,O
),6871,O
and,6871,O
osteocalcin,6871,B-GENE-Y
production,6871,O
(,6871,O
52-75,6871,O
%,6871,O
",",6871,O
p,6871,O
<,6871,O
0.031,6871,O
),6871,O
.,6871,O
For,6872,O
all,6872,O
the,6872,O
parameters,6872,O
",",6872,O
there,6872,O
were,6872,O
no,6872,O
significant,6872,O
differences,6872,O
between,6872,O
the,6872,O
osteoblast,6872,O
cultures,6872,O
alone,6872,O
and,6872,O
the,6872,O
HCG/osteoblast,6872,O
co-cultures,6872,O
.,6872,O
TZD,6873,B-CHEMICAL
effects,6873,O
on,6873,O
osteoblast,6873,O
viability,6873,O
",",6873,O
oleic,6873,O
acid,6873,O
uptake,6873,O
",",6873,O
alkaline,6873,B-GENE-N
phosphatase,6873,I-GENE-N
and,6873,O
osteocalcin,6873,B-GENE-Y
production,6873,O
are,6873,O
independent,6873,O
of,6873,O
their,6873,O
effects,6873,O
on,6873,O
aromatase,6873,B-GENE-Y
.,6873,O
P2Y12,6874,B-GENE-Y
",",6874,O
a,6874,O
new,6874,O
platelet,6874,O
ADP,6874,B-GENE-N
receptor,6874,I-GENE-N
",",6874,O
target,6874,O
of,6874,O
clopidogrel,6874,B-CHEMICAL
.,6874,O
Clopidogrel,6875,B-CHEMICAL
is,6875,O
a,6875,O
potent,6875,O
antithrombotic,6875,O
drug,6875,O
that,6875,O
inhibits,6875,O
ADP-induced,6875,B-CHEMICAL
platelet,6875,O
aggregation,6875,O
.,6875,O
The,6876,O
results,6876,O
of,6876,O
large,6876,O
clinical,6876,O
trials,6876,O
have,6876,O
demonstrated,6876,O
an,6876,O
overall,6876,O
benefit,6876,O
of,6876,O
clopidogrel,6876,B-CHEMICAL
over,6876,O
aspirin,6876,B-CHEMICAL
in,6876,O
the,6876,O
prevention,6876,O
of,6876,O
vascular,6876,O
ischemic,6876,O
events,6876,O
(,6876,O
myocardial,6876,O
infarction,6876,O
",",6876,O
stroke,6876,O
",",6876,O
vascular,6876,O
death,6876,O
),6876,O
in,6876,O
patients,6876,O
with,6876,O
a,6876,O
history,6876,O
of,6876,O
symptomatic,6876,O
atherosclerotic,6876,O
disease,6876,O
.,6876,O
The,6877,O
antiaggregating,6877,O
effect,6877,O
of,6877,O
clopidogrel,6877,B-CHEMICAL
is,6877,O
attributed,6877,O
to,6877,O
an,6877,O
irreversible,6877,O
inhibition,6877,O
of,6877,O
ADP,6877,B-CHEMICAL
binding,6877,O
to,6877,O
a,6877,O
purinergic,6877,B-GENE-N
receptor,6877,I-GENE-N
present,6877,O
at,6877,O
the,6877,O
platelet,6877,O
surface,6877,O
.,6877,O
Clopidogrel,6878,B-CHEMICAL
is,6878,O
not,6878,O
active,6878,O
in,6878,O
vitro,6878,O
and,6878,O
can,6878,O
be,6878,O
considered,6878,O
a,6878,O
precursor,6878,O
of,6878,O
an,6878,O
active,6878,O
metabolite,6878,O
formed,6878,O
in,6878,O
the,6878,O
liver,6878,O
.,6878,O
The,6879,O
chemical,6879,O
structure,6879,O
of,6879,O
this,6879,O
active,6879,O
metabolite,6879,O
and,6879,O
its,6879,O
biological,6879,O
activity,6879,O
have,6879,O
been,6879,O
described,6879,O
recently,6879,O
.,6879,O
Several,6880,O
purinergic,6880,B-GENE-N
receptors,6880,I-GENE-N
have,6880,O
been,6880,O
described,6880,O
on,6880,O
platelets,6880,O
;,6880,O
P2X,6880,B-GENE-Y
(,6880,I-GENE-Y
1,6880,I-GENE-Y
),6880,I-GENE-Y
",",6880,O
a,6880,O
calcium,6880,B-GENE-N
channel,6880,I-GENE-N
",",6880,O
and,6880,O
P2Y1,6880,B-GENE-Y
a,6880,O
Gq-coupled,6880,B-GENE-N
seven-transmembrane,6880,I-GENE-N
domain,6880,I-GENE-N
receptor,6880,I-GENE-N
",",6880,O
have,6880,O
been,6880,O
found,6880,O
not,6880,O
to,6880,O
be,6880,O
antagonized,6880,O
by,6880,O
clopidogrel,6880,B-CHEMICAL
.,6880,O
Another,6881,O
Gi,6881,B-GENE-N
(,6881,I-GENE-N
2,6881,I-GENE-N
),6881,I-GENE-N
-coupled,6881,I-GENE-N
receptor,6881,I-GENE-N
(,6881,O
named,6881,O
P2Y12,6881,B-GENE-Y
),6881,O
has,6881,O
been,6881,O
recently,6881,O
cloned,6881,O
and,6881,O
stably,6881,O
expressed,6881,O
in,6881,O
CHO,6881,O
cells,6881,O
.,6881,O
These,6882,O
cells,6882,O
displayed,6882,O
a,6882,O
strong,6882,O
affinity,6882,O
for,6882,O
(,6882,B-CHEMICAL
33,6882,I-CHEMICAL
),6882,I-CHEMICAL
P-2MeS-ADP,6882,I-CHEMICAL
",",6882,O
a,6882,O
stable,6882,O
analogue,6882,O
of,6882,O
ADP,6882,B-CHEMICAL
",",6882,O
the,6882,O
binding,6882,O
characteristics,6882,O
of,6882,O
which,6882,O
corresponded,6882,O
in,6882,O
all,6882,O
points,6882,O
to,6882,O
those,6882,O
observed,6882,O
on,6882,O
platelets,6882,O
.,6882,O
The,6883,O
binding,6883,O
of,6883,O
(,6883,B-CHEMICAL
33,6883,I-CHEMICAL
),6883,I-CHEMICAL
P-2MeS-ADP,6883,I-CHEMICAL
to,6883,O
these,6883,O
cells,6883,O
was,6883,O
strongly,6883,O
inhibited,6883,O
by,6883,O
the,6883,O
active,6883,O
metabolite,6883,O
of,6883,O
clopidogrel,6883,B-CHEMICAL
with,6883,O
a,6883,O
potency,6883,O
that,6883,O
was,6883,O
consistent,6883,O
with,6883,O
that,6883,O
observed,6883,O
for,6883,O
this,6883,O
compound,6883,O
on,6883,O
platelets,6883,O
.,6883,O
In,6884,O
these,6884,O
transfected,6884,O
CHO,6884,O
cells,6884,O
",",6884,O
as,6884,O
in,6884,O
platelets,6884,O
",",6884,O
ADP,6884,B-CHEMICAL
and,6884,O
2MeS-ADP,6884,B-CHEMICAL
induced,6884,O
adenylyl,6884,B-CHEMICAL
cyclase,6884,O
downregulation,6884,O
",",6884,O
an,6884,O
effect,6884,O
that,6884,O
was,6884,O
inhibited,6884,O
by,6884,O
the,6884,O
active,6884,O
metabolite,6884,O
of,6884,O
clopidogrel,6884,B-CHEMICAL
.,6884,O
These,6885,O
results,6885,O
demonstrate,6885,O
that,6885,O
this,6885,O
receptor,6885,O
corresponds,6885,O
to,6885,O
the,6885,O
previously,6885,O
called,6885,O
``,6885,O
P2t,6885,B-GENE-Y
'',6885,O
platelet,6885,B-GENE-N
receptor,6885,I-GENE-N
and,6885,O
show,6885,O
that,6885,O
the,6885,O
active,6885,O
metabolite,6885,O
of,6885,O
clopidogrel,6885,B-CHEMICAL
binds,6885,O
in,6885,O
a,6885,O
covalent,6885,O
manner,6885,O
to,6885,O
this,6885,O
receptor,6885,O
",",6885,O
thus,6885,O
explaining,6885,O
how,6885,O
it,6885,O
blocks,6885,O
the,6885,O
aggregating,6885,O
effect,6885,O
of,6885,O
ADP,6885,B-CHEMICAL
on,6885,O
platelets,6885,O
.,6885,O
Redesign,6886,O
of,6886,O
carnitine,6886,B-GENE-Y
acetyltransferase,6886,I-GENE-Y
specificity,6886,O
by,6886,O
protein,6886,O
engineering,6886,O
.,6886,O
In,6887,O
eukaryotes,6887,O
",",6887,O
L-carnitine,6887,B-CHEMICAL
is,6887,O
involved,6887,O
in,6887,O
energy,6887,O
metabolism,6887,O
by,6887,O
facilitating,6887,O
beta-oxidation,6887,O
of,6887,O
fatty,6887,B-CHEMICAL
acids,6887,I-CHEMICAL
.,6887,O
Carnitine,6888,B-GENE-Y
acetyltransferases,6888,I-GENE-Y
(,6888,O
CrAT,6888,B-GENE-Y
),6888,O
catalyze,6888,O
the,6888,O
reversible,6888,O
conversion,6888,O
of,6888,O
acetyl-CoA,6888,B-CHEMICAL
and,6888,O
carnitine,6888,B-CHEMICAL
to,6888,O
acetylcarnitine,6888,B-CHEMICAL
and,6888,O
free,6888,O
CoA,6888,O
.,6888,O
To,6889,O
redesign,6889,O
the,6889,O
specificity,6889,O
of,6889,O
rat,6889,B-GENE-Y
CrAT,6889,I-GENE-Y
toward,6889,O
its,6889,O
substrates,6889,O
",",6889,O
we,6889,O
mutated,6889,O
Met564,6889,O
.,6889,O
The,6890,O
M564G,6890,B-GENE-N
mutated,6890,O
CrAT,6890,B-GENE-Y
showed,6890,O
higher,6890,O
activity,6890,O
toward,6890,O
longer,6890,O
chain,6890,O
acyl-CoAs,6890,B-CHEMICAL
:,6890,O
activity,6890,O
toward,6890,O
myristoyl-CoA,6890,B-CHEMICAL
was,6890,O
1250-fold,6890,O
higher,6890,O
than,6890,O
that,6890,O
of,6890,O
the,6890,O
wild-type,6890,O
CrAT,6890,B-GENE-Y
",",6890,O
and,6890,O
lower,6890,O
activity,6890,O
toward,6890,O
its,6890,O
natural,6890,O
substrate,6890,O
",",6890,O
acetyl-CoA,6890,B-CHEMICAL
.,6890,O
Kinetic,6891,O
constants,6891,O
of,6891,O
the,6891,O
mutant,6891,O
CrAT,6891,B-GENE-Y
showed,6891,O
modification,6891,O
in,6891,O
favor,6891,O
of,6891,O
longer,6891,O
acyl-CoAs,6891,B-CHEMICAL
as,6891,O
substrates,6891,O
.,6891,O
In,6892,O
the,6892,O
reverse,6892,O
case,6892,O
",",6892,O
mutation,6892,O
of,6892,O
the,6892,O
orthologous,6892,O
glycine,6892,B-GENE-N
(,6892,I-GENE-N
Gly553,6892,I-GENE-N
),6892,I-GENE-N
to,6892,I-GENE-N
methionine,6892,I-GENE-N
in,6892,O
carnitine,6892,B-GENE-Y
octanoyltransferase,6892,I-GENE-Y
(,6892,O
COT,6892,B-GENE-Y
),6892,O
decreased,6892,O
activity,6892,O
toward,6892,O
its,6892,O
natural,6892,O
substrates,6892,O
",",6892,O
medium-,6892,O
and,6892,O
long-chain,6892,O
acyl-CoAs,6892,B-CHEMICAL
",",6892,O
and,6892,O
increased,6892,O
activity,6892,O
toward,6892,O
short-chain,6892,O
acyl-CoAs,6892,B-CHEMICAL
.,6892,O
Another,6893,O
CrAT,6893,B-GENE-Y
mutant,6893,O
",",6893,O
M564A,6893,B-GENE-N
",",6893,O
was,6893,O
prepared,6893,O
and,6893,O
tested,6893,O
in,6893,O
the,6893,O
same,6893,O
way,6893,O
",",6893,O
with,6893,O
similar,6893,O
results,6893,O
.,6893,O
We,6894,O
conclude,6894,O
that,6894,O
Met564,6894,O
blocks,6894,O
the,6894,O
entry,6894,O
of,6894,O
medium-,6894,O
and,6894,O
long-chain,6894,O
acyl-CoAs,6894,B-CHEMICAL
to,6894,O
the,6894,O
catalytic,6894,O
site,6894,O
of,6894,O
CrAT,6894,B-GENE-Y
.,6894,O
Three-dimensional,6895,O
models,6895,O
of,6895,O
wild-type,6895,O
and,6895,O
mutated,6895,O
CrAT,6895,B-GENE-Y
and,6895,O
COT,6895,B-GENE-Y
support,6895,O
this,6895,O
hypothesis,6895,O
.,6895,O
We,6896,O
show,6896,O
for,6896,O
the,6896,O
first,6896,O
time,6896,O
that,6896,O
a,6896,O
single,6896,O
amino,6896,B-CHEMICAL
acid,6896,I-CHEMICAL
is,6896,O
able,6896,O
to,6896,O
determine,6896,O
the,6896,O
substrate,6896,O
specificity,6896,O
of,6896,O
CrAT,6896,B-GENE-Y
and,6896,O
COT,6896,B-GENE-Y
.,6896,O
Cooperative,6897,O
homotropic,6897,O
interaction,6897,O
of,6897,O
L-noradrenaline,6897,B-CHEMICAL
with,6897,O
the,6897,O
catalytic,6897,O
site,6897,O
of,6897,O
phenylalanine,6897,B-GENE-Y
4-monooxygenase,6897,I-GENE-Y
.,6897,O
Catecholamines,6898,B-CHEMICAL
(,6898,O
adrenaline,6898,B-CHEMICAL
",",6898,O
noradrenaline,6898,B-CHEMICAL
and,6898,O
dopamine,6898,B-CHEMICAL
),6898,O
are,6898,O
potent,6898,O
inhibitors,6898,O
of,6898,O
phenylalanine,6898,B-GENE-Y
4-monooxygenase,6898,I-GENE-Y
(,6898,O
phenylalanine,6898,B-GENE-Y
hydroxylase,6898,I-GENE-Y
",",6898,O
EC,6898,B-GENE-Y
1.14.16.1,6898,I-GENE-Y
),6898,O
.,6898,O
The,6899,O
amines,6899,O
bind,6899,O
to,6899,O
the,6899,O
enzyme,6899,O
by,6899,O
a,6899,O
direct,6899,O
coordination,6899,O
to,6899,O
the,6899,O
high-spin,6899,O
(,6899,O
S,6899,O
=,6899,O
5/2,6899,O
),6899,O
Fe,6899,O
(,6899,O
III,6899,O
),6899,O
at,6899,O
the,6899,O
active,6899,O
site,6899,O
(,6899,O
charge,6899,O
transfer,6899,O
interaction,6899,O
),6899,O
",",6899,O
as,6899,O
seen,6899,O
by,6899,O
resonance,6899,O
Raman,6899,O
and,6899,O
EPR,6899,O
spectroscopy,6899,O
.,6899,O
Experimental,6900,O
evidence,6900,O
is,6900,O
presented,6900,O
that,6900,O
a,6900,O
group,6900,O
with,6900,O
an,6900,O
apparent,6900,O
pKa,6900,O
value,6900,O
of,6900,O
about,6900,O
5.1,6900,O
(,6900,O
20,6900,O
degrees,6900,O
C,6900,O
),6900,O
is,6900,O
involved,6900,O
in,6900,O
the,6900,O
interaction,6900,O
between,6900,O
the,6900,O
catecholamine,6900,B-CHEMICAL
and,6900,O
the,6900,O
enzyme,6900,O
.,6900,O
The,6901,O
high-affinity,6901,O
binding,6901,O
of,6901,O
L-noradrenaline,6901,B-CHEMICAL
to,6901,O
phenylalanine,6901,B-GENE-Y
hydroxylase,6901,I-GENE-Y
",",6901,O
as,6901,O
studied,6901,O
by,6901,O
equilibrium,6901,O
microdialysis,6901,O
(,6901,O
anaerobically,6901,O
),6901,O
and,6901,O
ultrafiltration,6901,O
(,6901,O
aerobically,6901,O
),6901,O
",",6901,O
shows,6901,O
positive,6901,O
cooperativity,6901,O
(,6901,O
h,6901,O
=,6901,O
1.9,6901,O
),6901,O
;,6901,O
at,6901,O
pH,6901,O
7.2,6901,O
and,6901,O
20,6901,O
degrees,6901,O
C,6901,O
the,6901,O
rat,6901,O
enzyme,6901,O
binds,6901,O
about,6901,O
0.5,6901,O
mol,6901,O
L-noradrenaline/mol,6901,B-CHEMICAL
subunit,6901,O
with,6901,O
a,6901,O
half-maximal,6901,O
binding,6901,O
(,6901,O
S50,6901,O
),6901,O
at,6901,O
0.25,6901,O
microM,6901,O
L-noradrenaline,6901,B-CHEMICAL
.,6901,O
No,6902,O
binding,6902,O
to,6902,O
the,6902,O
ferrous,6902,O
form,6902,O
of,6902,O
the,6902,O
enzyme,6902,O
was,6902,O
observed,6902,O
.,6902,O
The,6903,O
affinity,6903,O
decreases,6903,O
with,6903,O
decreasing,6903,O
pH,6903,O
",",6903,O
by,6903,O
phosphorylation,6903,O
and,6903,O
by,6903,O
preincubation,6903,O
of,6903,O
the,6903,O
enzyme,6903,O
with,6903,O
the,6903,O
substrate,6903,O
L-phenylalanine,6903,B-CHEMICAL
",",6903,O
while,6903,O
it,6903,O
increases,6903,O
after,6903,O
alkylation,6903,O
of,6903,O
the,6903,O
enzyme,6903,O
with,6903,O
the,6903,O
activator,6903,O
N-ethylmaleimide,6903,B-CHEMICAL
.,6903,O
Preincubation,6904,O
of,6904,O
the,6904,O
enzyme,6904,O
with,6904,O
L-phenylalanine,6904,B-CHEMICAL
also,6904,O
leads,6904,O
to,6904,O
a,6904,O
complete,6904,O
loss,6904,O
of,6904,O
the,6904,O
cooperativity,6904,O
of,6904,O
L-noradrenaline,6904,B-CHEMICAL
binding,6904,O
(,6904,O
h,6904,O
=,6904,O
1.0,6904,O
),6904,O
.,6904,O
The,6905,O
many,6905,O
similarities,6905,O
in,6905,O
binding,6905,O
properties,6905,O
of,6905,O
the,6905,O
inhibitor,6905,O
L-noradrenaline,6905,B-CHEMICAL
and,6905,O
the,6905,O
activator/substrate,6905,O
L-phenylalanine,6905,B-CHEMICAL
makes,6905,O
it,6905,O
likely,6905,O
that,6905,O
the,6905,O
cooperative,6905,O
interactions,6905,O
of,6905,O
these,6905,O
effectors,6905,O
are,6905,O
due,6905,O
to,6905,O
their,6905,O
binding,6905,O
to,6905,O
the,6905,O
same,6905,O
site,6905,O
.,6905,O
The,6906,O
high-affinity,6906,O
of,6906,O
catecholamines,6906,B-CHEMICAL
to,6906,O
phenylalanine,6906,B-GENE-Y
hydroxylase,6906,I-GENE-Y
is,6906,O
a,6906,O
valuable,6906,O
probe,6906,O
to,6906,O
study,6906,O
the,6906,O
active,6906,O
site,6906,O
of,6906,O
this,6906,O
enzyme,6906,O
and,6906,O
is,6906,O
also,6906,O
relevant,6906,O
for,6906,O
the,6906,O
homologous,6906,O
enzyme,6906,O
tyrosine,6906,B-GENE-Y
hydroxylase,6906,I-GENE-Y
",",6906,O
which,6906,O
is,6906,O
purified,6906,O
as,6906,O
a,6906,O
stable,6906,O
catecholamine-Fe,6906,B-CHEMICAL
(,6906,I-CHEMICAL
III,6906,I-CHEMICAL
),6906,I-CHEMICAL
complex,6906,O
.,6906,O
The,6907,O
design,6907,O
and,6907,O
realization,6907,O
of,6907,O
a,6907,O
large-area,6907,O
flexible,6907,O
nanofiber-based,6907,O
mat,6907,O
for,6907,O
pollutant,6907,O
degradation,6907,O
:,6907,O
an,6907,O
application,6907,O
in,6907,O
photocatalysis,6907,O
.,6907,O
This,6908,O
work,6908,O
demonstrates,6908,O
a,6908,O
novel,6908,O
multifunctional,6908,O
nanofibrous,6908,O
mat,6908,O
for,6908,O
photocatalytic,6908,O
applications,6908,O
based,6908,O
on,6908,O
TiO2,6908,B-CHEMICAL
nanocables,6908,O
functionalized,6908,O
by,6908,O
Ag,6908,B-CHEMICAL
nanoparticles,6908,O
and,6908,O
coated,6908,O
with,6908,O
a,6908,O
thin,6908,O
(,6908,O
∼2,6908,O
nm,6908,O
),6908,O
graphitic,6908,B-CHEMICAL
shell,6908,O
.,6908,O
In,6909,O
this,6909,O
mat,6909,O
",",6909,O
which,6909,O
was,6909,O
realized,6909,O
by,6909,O
an,6909,O
electrospinning,6909,O
technique,6909,O
",",6909,O
each,6909,O
component,6909,O
serves,6909,O
a,6909,O
unique,6909,O
function,6909,O
:,6909,O
the,6909,O
carbon,6909,B-CHEMICAL
coating,6909,O
acts,6909,O
as,6909,O
both,6909,O
an,6909,O
adsorption,6909,O
material,6909,O
for,6909,O
capturing,6909,O
pollutants,6909,O
and,6909,O
as,6909,O
a,6909,O
charge-transfer,6909,O
material,6909,O
",",6909,O
the,6909,O
Ag,6909,B-CHEMICAL
nanoparticles,6909,O
act,6909,O
as,6909,O
a,6909,O
visible-light,6909,O
sensitizing,6909,O
agent,6909,O
and,6909,O
also,6909,O
as,6909,O
a,6909,O
charge-transfer,6909,O
material,6909,O
",",6909,O
finally,6909,O
the,6909,O
TiO2,6909,B-CHEMICAL
nanocable,6909,O
mat,6909,O
acts,6909,O
as,6909,O
a,6909,O
UV,6909,O
sensitive,6909,O
photocatalytic,6909,O
matrix,6909,O
and,6909,O
as,6909,O
the,6909,O
flexible,6909,O
substrate,6909,O
for,6909,O
the,6909,O
other,6909,O
functional,6909,O
components,6909,O
.,6909,O
This,6910,O
multicomponent,6910,O
nanocable,6910,O
mat,6910,O
exhibits,6910,O
excellent,6910,O
photocatalytic,6910,O
activity,6910,O
under,6910,O
simulated,6910,O
solar,6910,O
irradiation,6910,O
for,6910,O
the,6910,O
degradation,6910,O
of,6910,O
model,6910,O
pollutants,6910,O
including,6910,O
RhB,6910,B-CHEMICAL
and,6910,O
phenol,6910,B-CHEMICAL
.,6910,O
The,6911,O
significant,6911,O
photocatalytic,6911,O
properties,6911,O
are,6911,O
attributed,6911,O
to,6911,O
the,6911,O
synergetic,6911,O
effect,6911,O
of,6911,O
the,6911,O
three,6911,O
functional,6911,O
components,6911,O
and,6911,O
the,6911,O
unique,6911,O
charge,6911,O
transport,6911,O
``,6911,O
freeway,6911,O
'',6911,O
property,6911,O
of,6911,O
the,6911,O
nanofibrous,6911,O
mat,6911,O
.,6911,O
In,6912,O
addition,6912,O
",",6912,O
the,6912,O
porous,6912,O
carbon,6912,B-CHEMICAL
coating,6912,O
infiltrated,6912,O
into,6912,O
the,6912,O
nanocable,6912,O
matrix,6912,O
endows,6912,O
the,6912,O
mat,6912,O
with,6912,O
excellent,6912,O
flexibility,6912,O
and,6912,O
enables,6912,O
robust,6912,O
",",6912,O
large-area,6912,O
(,6912,O
10,6912,O
×,6912,O
10,6912,O
cm,6912,O
),6912,O
fabrication,6912,O
",",6912,O
representing,6912,O
a,6912,O
significant,6912,O
advantage,6912,O
over,6912,O
previous,6912,O
brittle,6912,O
ceramic,6912,O
nanofibrous,6912,O
mat,6912,O
photocatalyst,6912,O
substrates,6912,O
.,6912,O
This,6913,O
study,6913,O
provides,6913,O
new,6913,O
insight,6913,O
into,6913,O
the,6913,O
design,6913,O
and,6913,O
preparation,6913,O
of,6913,O
an,6913,O
advanced,6913,O
",",6913,O
yet,6913,O
commercially,6913,O
practical,6913,O
and,6913,O
scaleable,6913,O
photocatalytic,6913,O
composite,6913,O
membrane,6913,O
material,6913,O
.,6913,O
The,6914,O
as-prepared,6914,O
photocatalytic,6914,O
mat,6914,O
might,6914,O
also,6914,O
be,6914,O
of,6914,O
interest,6914,O
in,6914,O
solar,6914,O
cell,6914,O
",",6914,O
catalysis,6914,O
",",6914,O
separation,6914,O
technology,6914,O
",",6914,O
biomedical,6914,O
engineering,6914,O
",",6914,O
and,6914,O
nanotechnology,6914,O
.,6914,O
The,6915,O
effects,6915,O
of,6915,O
kisspeptin,6915,B-GENE-N
in,6915,O
human,6915,O
reproductive,6915,O
function,6915,O
-,6915,O
therapeutic,6915,O
implications,6915,O
.,6915,O
Kisspeptin,6916,B-GENE-N
is,6916,O
a,6916,O
54-amino,6916,O
acid,6916,I-CHEMICAL
peptide,6916,O
which,6916,O
is,6916,O
encoded,6916,O
by,6916,O
the,6916,O
KiSS-1,6916,B-GENE-Y
gene,6916,O
and,6916,O
activates,6916,O
the,6916,O
G,6916,B-GENE-N
protein-coupled,6916,I-GENE-N
receptor,6916,I-GENE-N
GPR54,6916,B-GENE-Y
.,6916,O
Evidence,6917,O
suggests,6917,O
that,6917,O
this,6917,O
system,6917,O
is,6917,O
a,6917,O
key,6917,O
regulator,6917,O
of,6917,O
mammalian,6917,O
and,6917,O
human,6917,O
reproduction,6917,O
.,6917,O
Animal,6918,O
studies,6918,O
have,6918,O
shown,6918,O
that,6918,O
GPR54-deficient,6918,B-GENE-Y
mice,6918,O
have,6918,O
abnormal,6918,O
sexual,6918,O
development,6918,O
.,6918,O
Central,6919,O
and,6919,O
peripheral,6919,O
administration,6919,O
of,6919,O
kisspeptin,6919,B-GENE-N
stimulates,6919,O
the,6919,O
hypothalamic-pituitary-gonadal,6919,O
(,6919,O
HPG,6919,O
),6919,O
axis,6919,O
whilst,6919,O
pre-administration,6919,O
of,6919,O
a,6919,O
gonadotrophin,6919,B-GENE-Y
releasing,6919,I-GENE-Y
hormone,6919,I-GENE-Y
(,6919,O
GnRH,6919,B-GENE-Y
),6919,O
antagonist,6919,O
abolishes,6919,O
this,6919,O
effect,6919,O
.,6919,O
In,6920,O
humans,6920,O
",",6920,O
inactivating,6920,O
GPR54,6920,B-GENE-Y
mutations,6920,O
cause,6920,O
normosmic,6920,O
hypogonadotrophic,6920,O
hypogonadism,6920,O
whilst,6920,O
activation,6920,O
of,6920,O
GPR54,6920,B-GENE-Y
signalling,6920,O
is,6920,O
associated,6920,O
with,6920,O
premature,6920,O
puberty,6920,O
.,6920,O
In,6921,O
healthy,6921,O
human,6921,O
volunteers,6921,O
",",6921,O
the,6921,O
acute,6921,O
intravenous,6921,O
administration,6921,O
of,6921,O
kisspeptin,6921,O
potently,6921,O
increases,6921,O
plasma,6921,O
luteinising,6921,B-GENE-N
hormone,6921,I-GENE-N
(,6921,O
LH,6921,B-GENE-N
),6921,O
levels,6921,O
and,6921,O
significantly,6921,O
increases,6921,O
plasma,6921,O
follicle,6921,B-GENE-N
stimulating,6921,I-GENE-N
hormone,6921,I-GENE-N
(,6921,O
FSH,6921,B-GENE-N
),6921,O
and,6921,O
testosterone,6921,B-CHEMICAL
without,6921,O
side,6921,O
effects,6921,O
in,6921,O
both,6921,O
males,6921,O
and,6921,O
in,6921,O
females,6921,O
particularly,6921,O
in,6921,O
the,6921,O
preovulatatory,6921,O
phase,6921,O
of,6921,O
the,6921,O
menstrual,6921,O
cycle,6921,O
.,6921,O
In,6922,O
infertility,6922,O
due,6922,O
to,6922,O
hypothalamic,6922,O
amenorrhoea,6922,O
acute,6922,O
administration,6922,O
of,6922,O
kisspeptin,6922,B-GENE-N
results,6922,O
in,6922,O
stimulation,6922,O
of,6922,O
reproductive,6922,O
hormones,6922,O
.,6922,O
The,6923,O
kisspeptin/GPR54,6923,B-GENE-N
system,6923,O
therefore,6923,O
appears,6923,O
to,6923,O
play,6923,O
an,6923,O
important,6923,O
role,6923,O
in,6923,O
the,6923,O
regulation,6923,O
of,6923,O
reproduction,6923,O
in,6923,O
humans,6923,O
.,6923,O
Hence,6924,O
kisspeptin,6924,B-GENE-N
has,6924,O
potential,6924,O
as,6924,O
a,6924,O
novel,6924,O
tool,6924,O
for,6924,O
the,6924,O
manipulation,6924,O
of,6924,O
the,6924,O
HPG,6924,O
axis,6924,O
and,6924,O
treatment,6924,O
of,6924,O
infertility,6924,O
in,6924,O
humans,6924,O
.,6924,O
This,6925,O
review,6925,O
discusses,6925,O
the,6925,O
evidence,6925,O
highlighting,6925,O
kisspeptin,6925,B-GENE-N
's,6925,I-GENE-N
key,6925,O
role,6925,O
in,6925,O
human,6925,O
reproduction,6925,O
.,6925,O
Species-specific,6926,O
differences,6926,O
in,6926,O
the,6926,O
glucocorticoid,6926,B-GENE-Y
receptor,6926,I-GENE-Y
transactivation,6926,O
function,6926,O
upon,6926,O
binding,6926,O
with,6926,O
betamethasone-esters,6926,B-CHEMICAL
.,6926,O
Glucocorticoids,6927,O
(,6927,O
GCs,6927,O
),6927,O
are,6927,O
the,6927,O
most,6927,O
effective,6927,O
drugs,6927,O
for,6927,O
anti-inflammatory,6927,O
diseases,6927,O
.,6927,O
A,6928,O
number,6928,O
of,6928,O
adverse,6928,O
side,6928,O
effects,6928,O
",",6928,O
however,6928,O
",",6928,O
limit,6928,O
chronic,6928,O
treatment,6928,O
with,6928,O
GCs,6928,O
.,6928,O
To,6929,O
improve,6929,O
their,6929,O
therapeutic,6929,O
usefulness,6929,O
",",6929,O
attempts,6929,O
have,6929,O
been,6929,O
made,6929,O
to,6929,O
dissociate,6929,O
the,6929,O
two,6929,O
main,6929,O
actions,6929,O
of,6929,O
the,6929,O
glucocorticoid,6929,B-GENE-Y
receptor,6929,I-GENE-Y
(,6929,O
GR,6929,B-GENE-Y
),6929,O
",",6929,O
transactivation,6929,O
and,6929,O
transrepression,6929,O
",",6929,O
which,6929,O
are,6929,O
believed,6929,O
to,6929,O
be,6929,O
responsible,6929,O
for,6929,O
the,6929,O
side,6929,O
effects,6929,O
and,6929,O
anti-inflammatory,6929,O
effects,6929,O
",",6929,O
respectively,6929,O
.,6929,O
We,6930,O
report,6930,O
here,6930,O
species-specific,6930,O
differences,6930,O
in,6930,O
the,6930,O
transactivation,6930,O
response,6930,O
mediated,6930,O
by,6930,O
GR,6930,B-GENE-Y
.,6930,O
Dexamethasone,6931,B-CHEMICAL
(,6931,O
DEX,6931,B-CHEMICAL
),6931,O
",",6931,O
betamethasone,6931,B-CHEMICAL
(,6931,O
BM,6931,B-CHEMICAL
),6931,O
",",6931,O
and,6931,O
their,6931,O
esterified-derivatives,6931,O
had,6931,O
full,6931,O
transrepression,6931,O
agonistic,6931,O
activity,6931,O
in,6931,O
a,6931,O
reporter,6931,O
assay,6931,O
using,6931,O
CV-1,6931,O
cells,6931,O
transfected,6931,O
with,6931,O
either,6931,O
human,6931,B-GENE-N
or,6931,I-GENE-N
rat,6931,I-GENE-N
GR,6931,I-GENE-N
.,6931,O
These,6932,O
GCs,6932,O
also,6932,O
had,6932,O
full,6932,O
transactivation,6932,O
agonistic,6932,O
activity,6932,O
in,6932,O
CV-1,6932,O
cells,6932,O
transfected,6932,O
with,6932,O
human,6932,B-GENE-Y
GR,6932,I-GENE-Y
.,6932,O
The,6933,O
esterified-BM,6933,O
",",6933,O
however,6933,O
",",6933,O
had,6933,O
only,6933,O
partial,6933,O
transactivation,6933,O
agonistic,6933,O
activity,6933,O
in,6933,O
cells,6933,O
transfected,6933,O
with,6933,O
rat,6933,B-GENE-Y
GR,6933,I-GENE-Y
",",6933,O
whereas,6933,O
BM,6933,B-CHEMICAL
and,6933,O
esterified-DEX,6933,O
had,6933,O
full,6933,O
transactivation,6933,O
agonistic,6933,O
activity,6933,O
.,6933,O
Moreover,6934,O
",",6934,O
in,6934,O
rat,6934,O
hepatoma,6934,O
H4-II-E,6934,O
cells,6934,O
",",6934,O
the,6934,O
esterified-BM,6934,O
failed,6934,O
to,6934,O
induce,6934,O
tyrosine,6934,B-GENE-Y
aminotransferase,6934,I-GENE-Y
",",6934,O
which,6934,O
is,6934,O
regulated,6934,O
by,6934,O
GR-mediated,6934,B-GENE-Y
transactivation,6934,O
activity,6934,O
.,6934,O
There,6935,O
were,6935,O
no,6935,O
significant,6935,O
differences,6935,O
between,6935,O
the,6935,O
binding,6935,O
affinity,6935,O
of,6935,O
these,6935,O
GCs,6935,O
to,6935,O
human,6935,B-GENE-N
and,6935,I-GENE-N
rat,6935,I-GENE-N
GR,6935,I-GENE-N
.,6935,O
Consistent,6936,O
with,6936,O
the,6936,O
weak,6936,O
transactivation,6936,O
activity,6936,O
of,6936,O
esterified-BM,6936,O
mediated,6936,O
by,6936,O
rat,6936,B-GENE-Y
GR,6936,I-GENE-Y
",",6936,O
there,6936,O
were,6936,O
few,6936,O
side,6936,O
effects,6936,O
",",6936,O
evaluated,6936,O
by,6936,O
thymus,6936,O
involution,6936,O
and,6936,O
body,6936,O
weight,6936,O
loss,6936,O
",",6936,O
in,6936,O
an,6936,O
antigen-induced,6936,O
asthmatic,6936,O
model,6936,O
in,6936,O
rats,6936,O
.,6936,O
These,6937,O
results,6937,O
suggest,6937,O
that,6937,O
the,6937,O
potency,6937,O
of,6937,O
esterified-BM,6937,O
to,6937,O
induce,6937,O
transactivation,6937,O
activity,6937,O
is,6937,O
different,6937,O
between,6937,O
species,6937,O
and,6937,O
that,6937,O
this,6937,O
difference,6937,O
is,6937,O
not,6937,O
due,6937,O
to,6937,O
differences,6937,O
in,6937,O
receptor,6937,O
binding,6937,O
.,6937,O
Amsacrine,6938,B-CHEMICAL
and,6938,O
etoposide,6938,B-CHEMICAL
hypersensitivity,6938,O
of,6938,O
yeast,6938,O
cells,6938,O
overexpressing,6938,O
DNA,6938,B-GENE-Y
topoisomerase,6938,I-GENE-Y
II,6938,I-GENE-Y
.,6938,O
Increasing,6939,O
the,6939,O
cellular,6939,O
concentration,6939,O
of,6939,O
DNA,6939,B-GENE-Y
topoisomerase,6939,I-GENE-Y
II,6939,I-GENE-Y
in,6939,O
yeast,6939,O
by,6939,O
expressing,6939,O
constitutively,6939,O
a,6939,O
plasmid-borne,6939,O
TOP2,6939,B-GENE-Y
gene,6939,O
encoding,6939,O
the,6939,O
enzyme,6939,O
greatly,6939,O
increases,6939,O
the,6939,O
sensitivity,6939,O
of,6939,O
the,6939,O
cells,6939,O
to,6939,O
amsacrine,6939,B-CHEMICAL
and,6939,O
etoposide,6939,B-CHEMICAL
(,6939,O
VP-16,6939,B-CHEMICAL
),6939,O
.,6939,O
This,6940,O
increased,6940,O
drug,6940,O
sensitivity,6940,O
at,6940,O
a,6940,O
higher,6940,O
intracellular,6940,O
DNA,6940,B-GENE-Y
topoisomerase,6940,I-GENE-Y
II,6940,I-GENE-Y
level,6940,O
is,6940,O
observed,6940,O
in,6940,O
both,6940,O
RAD52+,6940,B-GENE-Y
repair-proficient,6940,O
strains,6940,O
and,6940,O
rad52,6940,B-GENE-Y
mutants,6940,O
that,6940,O
are,6940,O
defective,6940,O
in,6940,O
the,6940,O
repair,6940,O
of,6940,O
double-stranded,6940,O
breaks,6940,O
.,6940,O
These,6941,O
results,6941,O
provide,6941,O
strong,6941,O
support,6941,O
of,6941,O
the,6941,O
hypothesis,6941,O
that,6941,O
the,6941,O
cellular,6941,O
target,6941,O
of,6941,O
these,6941,O
drugs,6941,O
is,6941,O
DNA,6941,B-GENE-Y
topoisomerase,6941,I-GENE-Y
II,6941,I-GENE-Y
",",6941,O
and,6941,O
that,6941,O
these,6941,O
drugs,6941,O
kill,6941,O
cells,6941,O
by,6941,O
converting,6941,O
DNA,6941,B-GENE-Y
topoisomerase,6941,I-GENE-Y
II,6941,I-GENE-Y
into,6941,O
a,6941,O
DNA,6941,O
damaging,6941,O
agent,6941,O
.,6941,O
Characterization,6942,O
of,6942,O
insulin-like,6942,B-GENE-N
growth,6942,I-GENE-N
factor-binding,6942,I-GENE-N
protein-related,6942,I-GENE-N
proteins,6942,I-GENE-N
(,6942,I-GENE-N
IGFBP-rPs,6942,I-GENE-N
),6942,I-GENE-N
1,6942,I-GENE-N
",",6942,I-GENE-N
2,6942,I-GENE-N
",",6942,I-GENE-N
and,6942,I-GENE-N
3,6942,I-GENE-N
in,6942,O
human,6942,O
prostate,6942,O
epithelial,6942,O
cells,6942,O
:,6942,O
potential,6942,O
roles,6942,O
for,6942,O
IGFBP-rP1,6942,B-GENE-N
and,6942,I-GENE-N
2,6942,I-GENE-N
in,6942,O
senescence,6942,O
of,6942,O
the,6942,O
prostatic,6942,O
epithelium,6942,O
.,6942,O
Insulin-like,6943,B-GENE-N
growth,6943,I-GENE-N
factor,6943,I-GENE-N
(,6943,I-GENE-N
IGF,6943,I-GENE-N
),6943,I-GENE-N
-binding,6943,I-GENE-N
protein,6943,I-GENE-N
(,6943,I-GENE-N
IGFBP,6943,I-GENE-N
),6943,I-GENE-N
-related,6943,I-GENE-N
proteins,6943,I-GENE-N
(,6943,O
IGFBP-rPs,6943,B-GENE-N
),6943,O
are,6943,O
newly,6943,O
described,6943,O
cysteine-rich,6943,B-CHEMICAL
proteins,6943,O
that,6943,O
share,6943,O
significant,6943,O
aminoterminal,6943,O
structural,6943,O
similarity,6943,O
with,6943,O
the,6943,O
conventional,6943,O
IGFBPs,6943,B-GENE-N
and,6943,O
are,6943,O
involved,6943,O
in,6943,O
a,6943,O
diversity,6943,O
of,6943,O
biological,6943,O
functions,6943,O
",",6943,O
including,6943,O
growth,6943,O
regulation,6943,O
.,6943,O
IGFBP-rP1,6944,B-GENE-Y
(,6944,O
MAC25/Angiomodulin/prostacyclin-stimulating,6944,B-GENE-Y
factor,6944,I-GENE-Y
),6944,O
is,6944,O
a,6944,O
potential,6944,O
tumor-suppressor,6944,O
gene,6944,O
that,6944,O
is,6944,O
differentially,6944,O
expressed,6944,O
in,6944,O
meningiomas,6944,O
",",6944,O
mammary,6944,O
and,6944,O
prostatic,6944,O
cancers,6944,O
",",6944,O
compared,6944,O
with,6944,O
their,6944,O
malignant,6944,O
counterparts,6944,O
.,6944,O
We,6945,O
have,6945,O
previously,6945,O
shown,6945,O
that,6945,O
IGFBP-rP1,6945,B-GENE-Y
is,6945,O
preferentially,6945,O
produced,6945,O
by,6945,O
primary,6945,O
cultures,6945,O
of,6945,O
human,6945,O
prostate,6945,O
epithelial,6945,O
cells,6945,O
(,6945,O
HPECs,6945,O
),6945,O
and,6945,O
by,6945,O
poorly,6945,O
tumorigenic,6945,O
P69SV40T,6945,O
cells,6945,O
",",6945,O
compared,6945,O
with,6945,O
the,6945,O
cancerous,6945,O
prostatic,6945,O
LNCaP,6945,O
",",6945,O
DU145,6945,O
",",6945,O
PC-3,6945,O
",",6945,O
and,6945,O
M12,6945,O
cells,6945,O
.,6945,O
We,6946,O
now,6946,O
show,6946,O
that,6946,O
IGFBP-rP1,6946,B-GENE-Y
increases,6946,O
during,6946,O
senescence,6946,O
of,6946,O
HPEC,6946,O
.,6946,O
IGFBP-rP2,6947,B-GENE-Y
(,6947,O
also,6947,O
known,6947,O
as,6947,O
connective,6947,B-GENE-Y
tissue,6947,I-GENE-Y
growth,6947,I-GENE-Y
factor,6947,I-GENE-Y
),6947,O
",",6947,O
a,6947,O
downstream,6947,O
effector,6947,O
of,6947,O
transforming,6947,B-GENE-N
growth,6947,I-GENE-N
factor,6947,I-GENE-N
(,6947,I-GENE-N
TGF,6947,I-GENE-N
),6947,I-GENE-N
-beta,6947,I-GENE-N
and,6947,O
modulator,6947,O
of,6947,O
growth,6947,O
for,6947,O
both,6947,O
fibroblasts,6947,O
and,6947,O
endothelial,6947,O
cells,6947,O
",",6947,O
was,6947,O
detected,6947,O
in,6947,O
most,6947,O
of,6947,O
the,6947,O
normal,6947,O
and,6947,O
malignant,6947,O
prostatic,6947,O
epithelial,6947,O
cells,6947,O
tested,6947,O
",",6947,O
with,6947,O
a,6947,O
marked,6947,O
up-regulation,6947,O
of,6947,O
IGFBP-rP2,6947,B-GENE-Y
during,6947,O
senescence,6947,O
of,6947,O
HPEC,6947,O
.,6947,O
Moreover,6948,O
",",6948,O
IGFBP-rP2,6948,B-GENE-Y
noticeably,6948,O
increased,6948,O
in,6948,O
response,6948,O
to,6948,O
TGF-beta1,6948,B-GENE-Y
and,6948,O
all-trans,6948,B-CHEMICAL
retinoic,6948,I-CHEMICAL
acid,6948,I-CHEMICAL
(,6948,O
atRA,6948,B-CHEMICAL
),6948,O
in,6948,O
HPEC,6948,O
and,6948,O
PC-3,6948,O
cells,6948,O
",",6948,O
and,6948,O
it,6948,O
decreased,6948,O
in,6948,O
response,6948,O
to,6948,O
IGF-I,6948,B-GENE-Y
in,6948,O
HPEC,6948,O
.,6948,O
IGFBP-rP3,6949,B-GENE-Y
[,6949,O
nephroblastoma,6949,B-GENE-Y
overexpressed,6949,I-GENE-Y
(,6949,O
NOV,6949,B-GENE-Y
),6949,O
],6949,O
",",6949,O
the,6949,O
protein,6949,O
product,6949,O
of,6949,O
the,6949,O
NOV,6949,B-GENE-Y
protooncogene,6949,O
",",6949,O
was,6949,O
not,6949,O
detected,6949,O
in,6949,O
HPEC,6949,O
but,6949,O
was,6949,O
expressed,6949,O
in,6949,O
the,6949,O
tumorigenic,6949,O
DU145,6949,O
and,6949,O
PC-3,6949,O
cells,6949,O
.,6949,O
It,6950,O
was,6950,O
also,6950,O
synthesized,6950,O
by,6950,O
the,6950,O
SV40-T,6950,O
antigen-transformed,6950,O
P69,6950,O
and,6950,O
malignant,6950,O
M12,6950,O
cells,6950,O
",",6950,O
where,6950,O
it,6950,O
was,6950,O
down-regulated,6950,O
by,6950,O
atRA,6950,B-CHEMICAL
.,6950,O
These,6951,O
observations,6951,O
suggest,6951,O
biological,6951,O
roles,6951,O
of,6951,O
IGFBP-rPs,6951,B-GENE-N
in,6951,O
the,6951,O
human,6951,O
prostate,6951,O
.,6951,O
IGFBP-rP1,6952,B-GENE-Y
and,6952,O
IGFBP-rP2,6952,B-GENE-Y
are,6952,O
likely,6952,O
to,6952,O
negatively,6952,O
regulate,6952,O
growth,6952,O
",",6952,O
because,6952,O
they,6952,O
seem,6952,O
to,6952,O
increase,6952,O
during,6952,O
senescence,6952,O
of,6952,O
the,6952,O
prostate,6952,O
epithelium,6952,O
and,6952,O
in,6952,O
response,6952,O
to,6952,O
growth,6952,O
inhibitors,6952,O
(,6952,O
TGF-beta1,6952,B-GENE-Y
and,6952,O
atRA,6952,O
),6952,O
.,6952,O
Although,6953,O
the,6953,O
data,6953,O
collected,6953,O
on,6953,O
IGFBP-rP3,6953,B-GENE-Y
in,6953,O
prostate,6953,O
are,6953,O
modest,6953,O
",",6953,O
its,6953,O
role,6953,O
as,6953,O
a,6953,O
growth,6953,O
stimulator,6953,O
and/or,6953,O
protooncogene,6953,O
is,6953,O
supported,6953,O
by,6953,O
its,6953,O
preferential,6953,O
expression,6953,O
in,6953,O
cancerous,6953,O
cells,6953,O
and,6953,O
its,6953,O
down-regulation,6953,O
by,6953,O
atRA,6953,B-CHEMICAL
.,6953,O
[,6954,O
Disorders,6954,O
with,6954,O
eosinophilia,6954,O
",",6954,O
treatment,6954,O
of,6954,O
hypereosinophilic,6954,O
syndrome,6954,O
],6954,O
.,6954,O
Eosinophilia,6955,O
may,6955,O
be,6955,O
associated,6955,O
with,6955,O
reactive,6955,O
conditions,6955,O
and,6955,O
with,6955,O
clonal,6955,O
disorders,6955,O
of,6955,O
the,6955,O
hematopoietic,6955,O
cells,6955,O
.,6955,O
The,6956,O
hypereosinophilic,6956,O
syndrome,6956,O
takes,6956,O
an,6956,O
intermedier,6956,O
place,6956,O
in,6956,O
this,6956,O
group,6956,O
.,6956,O
In,6957,O
this,6957,O
disease,6957,O
a,6957,O
sustained,6957,O
eosinophilia,6957,O
with,6957,O
end,6957,O
organ,6957,O
damage,6957,O
can,6957,O
occur,6957,O
.,6957,O
The,6958,O
author,6958,O
summarized,6958,O
the,6958,O
diagnostic,6958,O
procedures,6958,O
and,6958,O
differential,6958,O
diagnosis,6958,O
in,6958,O
the,6958,O
group,6958,O
of,6958,O
these,6958,O
diseases,6958,O
focusing,6958,O
on,6958,O
characteristics,6958,O
and,6958,O
treatment,6958,O
of,6958,O
hypereosinophilic,6958,O
syndrome,6958,O
.,6958,O
The,6959,O
treatment,6959,O
has,6959,O
been,6959,O
varied,6959,O
and,6959,O
included,6959,O
steroids,6959,B-CHEMICAL
",",6959,O
hydroxyurea,6959,B-CHEMICAL
",",6959,O
interferon-alpha,6959,B-GENE-N
",",6959,O
and,6959,O
in,6959,O
some,6959,O
cases,6959,O
chemotherapy,6959,O
.,6959,O
On,6960,O
the,6960,O
basis,6960,O
of,6960,O
FIP1L1-PDGFRa,6960,B-GENE-Y
fusion,6960,O
gene,6960,O
hypereosinophilic,6960,O
syndrome,6960,O
would,6960,O
be,6960,O
classified,6960,O
as,6960,O
a,6960,O
clonal,6960,O
disease,6960,O
and,6960,O
in,6960,O
the,6960,O
FIP1L1-PDGFRa,6960,B-GENE-Y
positive,6960,O
cases,6960,O
the,6960,O
tyrosine,6960,B-GENE-N
kinase,6960,I-GENE-N
inhibitor,6960,O
imatinib,6960,B-CHEMICAL
mesylate,6960,I-CHEMICAL
(,6960,O
Glivec,6960,O
),6960,O
would,6960,O
be,6960,O
effective,6960,O
.,6960,O
Transport,6961,O
by,6961,O
OATP1B1,6961,B-GENE-Y
and,6961,O
OATP1B3,6961,B-GENE-Y
enhances,6961,O
the,6961,O
cytotoxicity,6961,O
of,6961,O
epigallocatechin,6961,B-CHEMICAL
3-O-gallate,6961,I-CHEMICAL
and,6961,O
several,6961,O
quercetin,6961,B-CHEMICAL
derivatives,6961,O
.,6961,O
Organic,6962,B-GENE-N
anion,6962,I-GENE-N
transporting,6962,I-GENE-N
polypeptides,6962,I-GENE-N
(,6962,I-GENE-N
OATPs,6962,I-GENE-N
),6962,I-GENE-N
1B1,6962,I-GENE-N
and,6962,I-GENE-N
1B3,6962,I-GENE-N
are,6962,O
transporters,6962,O
that,6962,O
are,6962,O
expressed,6962,O
selectively,6962,O
in,6962,O
human,6962,O
hepatocytes,6962,O
under,6962,O
normal,6962,O
conditions,6962,O
.,6962,O
OATP1B3,6963,B-GENE-Y
is,6963,O
also,6963,O
expressed,6963,O
in,6963,O
certain,6963,O
cancers,6963,O
.,6963,O
Flavonoids,6964,B-CHEMICAL
such,6964,O
as,6964,O
green,6964,O
tea,6964,O
catechins,6964,B-CHEMICAL
and,6964,O
quercetin,6964,B-CHEMICAL
glycosides,6964,I-CHEMICAL
have,6964,O
been,6964,O
shown,6964,O
to,6964,O
modulate,6964,O
the,6964,O
function,6964,O
of,6964,O
some,6964,O
OATPs,6964,B-GENE-N
.,6964,O
In,6965,O
the,6965,O
present,6965,O
study,6965,O
",",6965,O
the,6965,O
extent,6965,O
to,6965,O
which,6965,O
six,6965,O
substituted,6965,O
quercetin,6965,B-CHEMICAL
derivatives,6965,O
(,6965,O
1-6,6965,O
),6965,O
affected,6965,O
the,6965,O
function,6965,O
of,6965,O
OATP1B1,6965,B-GENE-Y
and,6965,O
OATP1B3,6965,B-GENE-Y
was,6965,O
investigated,6965,O
.,6965,O
Uptake,6966,O
of,6966,O
the,6966,O
radiolabeled,6966,O
model,6966,O
substrates,6966,O
estradiol,6966,B-CHEMICAL
17β-glucuronide,6966,I-CHEMICAL
",",6966,O
estrone,6966,B-CHEMICAL
3-sulfate,6966,I-CHEMICAL
",",6966,O
and,6966,O
dehydroepiandrosterone,6966,B-CHEMICAL
sulfate,6966,I-CHEMICAL
(,6966,O
DHEAS,6966,B-CHEMICAL
),6966,O
was,6966,O
determined,6966,O
in,6966,O
the,6966,O
absence,6966,O
and,6966,O
presence,6966,O
of,6966,O
compounds,6966,O
1-6,6966,O
using,6966,O
Chinese,6966,O
hamster,6966,O
ovary,6966,O
(,6966,O
CHO,6966,O
),6966,O
cells,6966,O
stably,6966,O
expressing,6966,O
either,6966,O
OATP1B1,6966,B-GENE-Y
or,6966,O
OATP1B3,6966,B-GENE-Y
.,6966,O
Several,6967,O
of,6967,O
compounds,6967,O
1-6,6967,O
inhibited,6967,O
OATP-mediated,6967,B-GENE-N
uptake,6967,O
of,6967,O
all,6967,O
three,6967,O
model,6967,O
substrates,6967,O
",",6967,O
suggesting,6967,O
that,6967,O
they,6967,O
could,6967,O
also,6967,O
be,6967,O
potential,6967,O
substrates,6967,O
.,6967,O
Compound,6968,O
6,6968,O
stimulated,6968,O
OATP1B3-mediated,6968,B-GENE-Y
estradiol,6968,B-CHEMICAL
17β-glucuronide,6968,I-CHEMICAL
uptake,6968,O
by,6968,O
increasing,6968,O
the,6968,O
apparent,6968,O
affinity,6968,O
of,6968,O
OATP1B3,6968,B-GENE-Y
for,6968,O
its,6968,O
substrate,6968,O
.,6968,O
Cytotoxicity,6969,O
assays,6969,O
demonstrated,6969,O
that,6969,O
epigallocatechin,6969,B-CHEMICAL
3-O-gallate,6969,I-CHEMICAL
(,6969,O
EGCG,6969,B-CHEMICAL
),6969,O
and,6969,O
most,6969,O
of,6969,O
compounds,6969,O
1-6,6969,O
killed,6969,O
preferentially,6969,O
OATP-expressing,6969,B-GENE-N
CHO,6969,O
cells,6969,O
.,6969,O
EGCG,6970,B-CHEMICAL
",",6970,O
1,6970,O
",",6970,O
and,6970,O
3,6970,O
were,6970,O
the,6970,O
most,6970,O
potent,6970,O
cytotoxic,6970,O
compounds,6970,O
",",6970,O
with,6970,O
EGCG,6970,B-CHEMICAL
and,6970,O
3,6970,O
selectively,6970,O
killing,6970,O
OATP1B3-expressing,6970,B-GENE-Y
cells,6970,O
.,6970,O
Given,6971,O
that,6971,O
OATP1B3,6971,B-GENE-Y
is,6971,O
expressed,6971,O
in,6971,O
several,6971,O
cancers,6971,O
",",6971,O
EGCG,6971,B-CHEMICAL
and,6971,O
some,6971,O
of,6971,O
the,6971,O
quercetin,6971,B-CHEMICAL
derivatives,6971,O
studied,6971,O
might,6971,O
be,6971,O
promising,6971,O
lead,6971,O
compounds,6971,O
for,6971,O
the,6971,O
development,6971,O
of,6971,O
novel,6971,O
anticancer,6971,O
drugs,6971,O
.,6971,O
Silencing,6972,O
"α1,3-fucosyltransferases",6972,B-GENE-N
in,6972,O
human,6972,O
leukocytes,6972,O
reveals,6972,O
a,6972,O
role,6972,O
for,6972,O
FUT9,6972,B-GENE-Y
enzyme,6972,O
during,6972,O
E-selectin-mediated,6972,B-GENE-Y
cell,6972,O
adhesion,6972,O
.,6972,O
Leukocyte,6973,O
adhesion,6973,O
during,6973,O
inflammation,6973,O
is,6973,O
initiated,6973,O
by,6973,O
the,6973,O
binding,6973,O
of,6973,O
sialofucosylated,6973,O
carbohydrates,6973,B-CHEMICAL
expressed,6973,O
on,6973,O
leukocytes,6973,O
to,6973,O
endothelial,6973,O
E/P-selectin,6973,B-GENE-N
.,6973,O
Although,6974,O
the,6974,O
glycosyltransferases,6974,B-GENE-N
(,6974,O
glycoTs,6974,B-GENE-N
),6974,O
constructing,6974,O
selectin-ligands,6974,B-GENE-N
have,6974,O
largely,6974,O
been,6974,O
identified,6974,O
using,6974,O
knock-out,6974,O
mice,6974,O
",",6974,O
important,6974,O
differences,6974,O
may,6974,O
exist,6974,O
between,6974,O
humans,6974,O
and,6974,O
mice,6974,O
.,6974,O
To,6975,O
address,6975,O
this,6975,O
",",6975,O
we,6975,O
developed,6975,O
a,6975,O
systematic,6975,O
lentivirus-based,6975,O
shRNA,6975,O
delivery,6975,O
workflow,6975,O
to,6975,O
create,6975,O
human,6975,O
leukocytic,6975,O
HL-60,6975,O
cell,6975,O
lines,6975,O
that,6975,O
lack,6975,O
up,6975,O
to,6975,O
three,6975,O
glycoTs,6975,B-GENE-N
.,6975,O
Using,6976,O
this,6976,O
",",6976,O
the,6976,O
contributions,6976,O
of,6976,O
all,6976,O
three,6976,O
myeloid,6976,O
"α1,3-fucosyltransferases",6976,B-GENE-N
(,6976,O
FUT4,6976,B-GENE-Y
",",6976,O
FUT7,6976,B-GENE-Y
",",6976,O
and,6976,O
FUT9,6976,B-GENE-Y
),6976,O
to,6976,O
selectin-ligand,6976,B-GENE-N
biosynthesis,6976,O
were,6976,O
evaluated,6976,O
.,6976,O
The,6977,O
cell,6977,O
adhesion,6977,O
properties,6977,O
of,6977,O
these,6977,O
modified,6977,O
cells,6977,O
to,6977,O
L-,6977,B-GENE-N
",",6977,I-GENE-N
E-,6977,I-GENE-N
",",6977,I-GENE-N
and,6977,I-GENE-N
P-selectin,6977,I-GENE-N
under,6977,O
hydrodynamic,6977,O
shear,6977,O
were,6977,O
compared,6977,O
with,6977,O
bone,6977,O
marrow-derived,6977,O
neutrophils,6977,O
from,6977,O
Fut4,6977,B-GENE-Y
(,6977,O
-/-,6977,O
),6977,O
Fut7,6977,B-GENE-Y
(,6977,O
-/-,6977,O
),6977,O
dual,6977,O
knock-out,6977,O
mice,6977,O
.,6977,O
Results,6978,O
demonstrate,6978,O
that,6978,O
predominantly,6978,O
FUT7,6978,B-GENE-Y
",",6978,O
and,6978,O
to,6978,O
a,6978,O
lesser,6978,O
extent,6978,O
FUT4,6978,B-GENE-Y
",",6978,O
forms,6978,O
the,6978,O
selectin-ligand,6978,B-GENE-N
at,6978,O
the,6978,O
N,6978,B-CHEMICAL
terminus,6978,O
of,6978,O
leukocyte,6978,O
P-selectin,6978,B-GENE-N
glycoprotein,6978,I-GENE-N
ligand-1,6978,I-GENE-N
(,6978,O
PSGL-1,6978,B-GENE-N
),6978,O
in,6978,O
humans,6978,O
and,6978,O
mice,6978,O
.,6978,O
Here,6979,O
",",6979,O
85,6979,O
%,6979,O
reduction,6979,O
in,6979,O
leukocyte,6979,O
interaction,6979,O
was,6979,O
observed,6979,O
in,6979,O
human,6979,B-GENE-N
FUT4,6979,I-GENE-N
(,6979,I-GENE-N
-,6979,I-GENE-N
),6979,I-GENE-N
7,6979,I-GENE-N
(,6979,O
-,6979,O
),6979,O
dual,6979,O
knockdowns,6979,O
on,6979,O
P/L-selectin,6979,B-GENE-N
substrates,6979,O
.,6979,O
Unlike,6980,O
Fut4,6980,B-GENE-Y
(,6980,O
-/-,6980,O
),6980,O
Fut7,6980,B-GENE-Y
(,6980,O
-/-,6980,O
),6980,O
mouse,6980,O
neutrophils,6980,O
",",6980,O
however,6980,O
",",6980,O
human,6980,O
knockdowns,6980,O
lacking,6980,O
FUT4,6980,B-GENE-Y
and,6980,O
FUT7,6980,B-GENE-Y
only,6980,O
exhibited,6980,O
partial,6980,O
reduction,6980,O
in,6980,O
rolling,6980,O
interaction,6980,O
on,6980,O
E-selectin,6980,B-GENE-Y
.,6980,O
In,6981,O
this,6981,O
case,6981,O
",",6981,O
the,6981,O
third,6981,O
"α1,3-fucosyltransferase",6981,B-GENE-N
FUT9,6981,B-GENE-Y
played,6981,O
an,6981,O
important,6981,O
role,6981,O
because,6981,O
leukocyte,6981,O
adhesion,6981,O
was,6981,O
reduced,6981,O
by,6981,O
50-60,6981,O
%,6981,O
in,6981,O
FUT9-HL-60,6981,B-GENE-Y
",",6981,O
70-80,6981,O
%,6981,O
in,6981,O
dual,6981,O
knockdown,6981,O
FUT7,6981,B-GENE-N
(,6981,I-GENE-N
-,6981,I-GENE-N
),6981,I-GENE-N
9,6981,I-GENE-N
(,6981,O
-,6981,O
),6981,O
cells,6981,O
",",6981,O
and,6981,O
∼85,6981,O
%,6981,O
in,6981,O
FUT4,6981,B-GENE-N
(,6981,I-GENE-N
-,6981,I-GENE-N
),6981,I-GENE-N
7,6981,I-GENE-N
(,6981,I-GENE-N
-,6981,I-GENE-N
),6981,I-GENE-N
9,6981,I-GENE-N
(,6981,O
-,6981,O
),6981,O
triple,6981,O
knockdowns,6981,O
.,6981,O
Gene,6982,O
silencing,6982,O
results,6982,O
are,6982,O
in,6982,O
agreement,6982,O
with,6982,O
gain-of-function,6982,O
experiments,6982,O
where,6982,O
all,6982,O
three,6982,O
fucosyltransferases,6982,B-GENE-N
conferred,6982,O
E-selectin-mediated,6982,B-GENE-Y
rolling,6982,O
in,6982,O
HEK293T,6982,O
cells,6982,O
.,6982,O
This,6983,O
study,6983,O
advances,6983,O
new,6983,O
tools,6983,O
to,6983,O
study,6983,O
human,6983,B-GENE-N
glycoT,6983,I-GENE-N
function,6983,O
.,6983,O
It,6984,O
suggests,6984,O
a,6984,O
species-specific,6984,O
role,6984,O
for,6984,O
FUT9,6984,B-GENE-Y
during,6984,O
the,6984,O
biosynthesis,6984,O
of,6984,O
human,6984,B-GENE-Y
E-selectin,6984,I-GENE-Y
ligands,6984,O
.,6984,O
Optimization,6985,O
of,6985,O
frozen,6985,O
sour,6985,O
cherries,6985,O
vacuum,6985,O
drying,6985,O
process,6985,O
.,6985,O
The,6986,O
objective,6986,O
of,6986,O
this,6986,O
research,6986,O
was,6986,O
to,6986,O
optimize,6986,O
the,6986,O
vacuum-drying,6986,O
of,6986,O
frozen,6986,O
sour,6986,O
cherries,6986,O
in,6986,O
order,6986,O
to,6986,O
preserve,6986,O
health-beneficial,6986,O
phytochemicals,6986,O
",",6986,O
as,6986,O
well,6986,O
as,6986,O
textural,6986,O
characteristics,6986,O
.,6986,O
Investigated,6987,O
range,6987,O
of,6987,O
temperature,6987,O
was,6987,O
46-74°C,6987,O
and,6987,O
",",6987,O
of,6987,O
pressure,6987,O
",",6987,O
17-583mbar,6987,O
",",6987,O
in,6987,O
a,6987,O
new,6987,O
design,6987,O
of,6987,O
vacuum-dryer,6987,O
equipment,6987,O
.,6987,O
The,6988,O
total,6988,O
solids,6988,O
",",6988,O
a,6988,O
(,6988,O
w,6988,O
),6988,O
value,6988,O
",",6988,O
total,6988,O
phenolics,6988,B-CHEMICAL
",",6988,O
vitamin,6988,B-CHEMICAL
C,6988,I-CHEMICAL
",",6988,O
antioxidant,6988,O
activity,6988,O
",",6988,O
anthocyanin,6988,B-CHEMICAL
content,6988,O
",",6988,O
total,6988,O
colour,6988,O
change,6988,O
and,6988,O
firmness,6988,O
were,6988,O
used,6988,O
as,6988,O
quality,6988,O
indicators,6988,O
of,6988,O
dried,6988,O
sour,6988,O
cherry,6988,O
.,6988,O
Within,6989,O
the,6989,O
experimental,6989,O
range,6989,O
of,6989,O
studied,6989,O
variables,6989,O
",",6989,O
the,6989,O
optimum,6989,O
conditions,6989,O
of,6989,O
54.03°C,6989,O
and,6989,O
148.16mbar,6989,O
were,6989,O
established,6989,O
for,6989,O
vacuum,6989,O
drying,6989,O
of,6989,O
sour,6989,O
cherry,6989,O
.,6989,O
Separate,6990,O
validation,6990,O
experiments,6990,O
were,6990,O
conducted,6990,O
",",6990,O
under,6990,O
optimum,6990,O
conditions,6990,O
",",6990,O
to,6990,O
verify,6990,O
predictions,6990,O
and,6990,O
adequacy,6990,O
of,6990,O
the,6990,O
second-order,6990,O
polynomial,6990,O
models,6990,O
.,6990,O
Under,6991,O
these,6991,O
optimal,6991,O
conditions,6991,O
",",6991,O
the,6991,O
predicted,6991,O
amount,6991,O
of,6991,O
total,6991,O
phenolics,6991,B-CHEMICAL
was,6991,O
744mg,6991,O
CAE/100,6991,O
dw,6991,O
",",6991,O
vitamin,6991,B-CHEMICAL
C,6991,I-CHEMICAL
1.44mg/100g,6991,O
per,6991,O
dry,6991,O
weight,6991,O
(,6991,O
g,6991,O
dw,6991,O
),6991,O
",",6991,O
anthocyanin,6991,B-CHEMICAL
content,6991,O
125mg/100g,6991,O
dw,6991,O
",",6991,O
IC,6991,O
(,6991,O
50,6991,O
),6991,O
3.23mg/ml,6991,O
",",6991,O
total,6991,O
solids,6991,O
70.72,6991,O
%,6991,O
",",6991,O
a,6991,O
(,6991,O
w,6991,O
),6991,O
value,6991,O
0.646,6991,O
",",6991,O
total,6991,O
colour,6991,O
change,6991,O
52.61,6991,O
and,6991,O
firmness,6991,O
3395.4g,6991,O
.,6991,O
The,6992,O
investigated,6992,O
parameters,6992,O
had,6992,O
a,6992,O
significant,6992,O
effect,6992,O
on,6992,O
the,6992,O
quality,6992,O
of,6992,O
the,6992,O
dried,6992,O
sour,6992,O
cherries,6992,O
.,6992,O
Dopamine,6993,B-GENE-Y
D2-receptor,6993,I-GENE-Y
imaging,6993,O
with,6993,O
123I-iodobenzamide,6993,B-CHEMICAL
SPECT,6993,O
in,6993,O
migraine,6993,O
patients,6993,O
abusing,6993,O
ergotamine,6993,B-CHEMICAL
:,6993,O
does,6993,O
ergotamine,6993,B-CHEMICAL
cross,6993,O
the,6993,O
blood,6993,O
brain,6993,O
barrier,6993,O
?,6993,O
Two,6994,O
migraine,6994,O
patients,6994,O
were,6994,O
studied,6994,O
by,6994,O
in,6994,O
vivo,6994,O
SPECT,6994,O
using,6994,O
the,6994,O
dopamine,6994,B-GENE-Y
D2-receptor,6994,I-GENE-Y
specific,6994,O
radioligand,6994,O
123I-3-iodo-6-methoxybenzamide,6994,B-CHEMICAL
(,6994,O
123I-IBZM,6994,B-CHEMICAL
),6994,O
during,6994,O
ergotamine,6994,B-CHEMICAL
abuse,6994,O
and,6994,O
after,6994,O
withdrawal,6994,O
.,6994,O
Results,6995,O
were,6995,O
compared,6995,O
with,6995,O
15,6995,O
healthy,6995,O
controls,6995,O
.,6995,O
Striatum/cerebellum,6996,O
and,6996,O
striatum/occipital,6996,O
cortex,6996,O
ratios,6996,O
of,6996,O
count,6996,O
rate,6996,O
density,6996,O
were,6996,O
calculated,6996,O
as,6996,O
a,6996,O
semiquantitative,6996,O
measurement,6996,O
for,6996,O
striatal,6996,O
dopamine,6996,B-GENE-Y
D2-receptor,6996,I-GENE-Y
binding,6996,O
potential,6996,O
.,6996,O
No,6997,O
differences,6997,O
were,6997,O
found,6997,O
in,6997,O
striatal,6997,O
uptake,6997,O
of,6997,O
123I-IBZM,6997,B-CHEMICAL
between,6997,O
healthy,6997,O
controls,6997,O
and,6997,O
the,6997,O
patients,6997,O
when,6997,O
on,6997,O
or,6997,O
off,6997,O
ergotamine,6997,B-CHEMICAL
.,6997,O
Preliminary,6998,O
evidence,6998,O
suggests,6998,O
that,6998,O
ergotamine,6998,B-CHEMICAL
may,6998,O
not,6998,O
occupy,6998,O
striatal,6998,O
dopamine,6998,B-GENE-Y
D2-receptors,6998,I-GENE-Y
to,6998,O
a,6998,O
large,6998,O
extent,6998,O
and,6998,O
thus,6998,O
may,6998,O
not,6998,O
cross,6998,O
the,6998,O
blood,6998,O
brain,6998,O
barrier,6998,O
in,6998,O
large,6998,O
quantities,6998,O
.,6998,O
Reboxetine,6999,B-CHEMICAL
versus,6999,O
fluvoxamine,6999,B-CHEMICAL
in,6999,O
the,6999,O
treatment,6999,O
of,6999,O
motor,6999,O
vehicle,6999,O
accident-related,6999,O
posttraumatic,6999,O
stress,6999,O
disorder,6999,O
:,6999,O
a,6999,O
double-blind,6999,O
",",6999,O
fixed-dosage,6999,O
",",6999,O
controlled,6999,O
trial,6999,O
.,6999,O
BACKGROUND,7000,O
:,7000,O
Motor,7000,O
vehicle,7000,O
accidents,7000,O
(,7000,O
MVAs,7000,O
),7000,O
are,7000,O
a,7000,O
leading,7000,O
cause,7000,O
of,7000,O
posttraumatic,7000,O
stress,7000,O
disorder,7000,O
(,7000,O
PTSD,7000,O
),7000,O
in,7000,O
the,7000,O
general,7000,O
population,7000,O
.,7000,O
Alterations,7001,O
in,7001,O
norepinephrine,7001,B-CHEMICAL
and,7001,O
serotonin,7001,B-CHEMICAL
systems,7001,O
have,7001,O
been,7001,O
proposed,7001,O
as,7001,O
mechanisms,7001,O
involved,7001,O
in,7001,O
the,7001,O
pathophysiology,7001,O
of,7001,O
the,7001,O
condition,7001,O
",",7001,O
with,7001,O
treatment,7001,O
directed,7001,O
at,7001,O
these,7001,O
neurotransmitter,7001,O
systems,7001,O
.,7001,O
Reboxetine,7002,B-CHEMICAL
",",7002,O
a,7002,O
selective,7002,O
norepinephrine,7002,B-CHEMICAL
reuptake,7002,O
inhibitor,7002,O
",",7002,O
exhibits,7002,O
high,7002,O
affinity,7002,O
and,7002,O
selectivity,7002,O
for,7002,O
the,7002,O
human,7002,B-GENE-Y
norepinephrine,7002,I-GENE-Y
transporter,7002,I-GENE-Y
.,7002,O
Inasmuch,7003,O
as,7003,O
PTSD,7003,O
may,7003,O
be,7003,O
associated,7003,O
with,7003,O
dysregulation,7003,O
of,7003,O
noradrenergic,7003,O
activity,7003,O
",",7003,O
the,7003,O
present,7003,O
double-blind,7003,O
randomized,7003,O
clinical,7003,O
trial,7003,O
intended,7003,O
to,7003,O
evaluate,7003,O
reboxetine,7003,O
's,7003,O
efficacy,7003,O
in,7003,O
the,7003,O
management,7003,O
of,7003,O
MVA-related,7003,O
PTSD,7003,O
and,7003,O
to,7003,O
compare,7003,O
its,7003,O
efficacy,7003,O
with,7003,O
a,7003,O
medication,7003,O
commonly,7003,O
used,7003,O
in,7003,O
PTSD,7003,O
",",7003,O
the,7003,O
selective,7003,O
serotonin,7003,B-CHEMICAL
reuptake,7003,O
inhibitor,7003,O
fluvoxamine,7003,B-CHEMICAL
.,7003,O
METHODS,7004,O
:,7004,O
Forty,7004,O
patients,7004,O
with,7004,O
MVA-related,7004,O
PTSD,7004,O
attending,7004,O
a,7004,O
local,7004,O
community,7004,O
mental,7004,O
health,7004,O
outpatient,7004,O
clinic,7004,O
were,7004,O
randomized,7004,O
to,7004,O
receive,7004,O
a,7004,O
fixed,7004,O
dose,7004,O
of,7004,O
either,7004,O
reboxetine,7004,B-CHEMICAL
(,7004,O
8,7004,O
mg/d,7004,O
),7004,O
or,7004,O
fluvoxamine,7004,B-CHEMICAL
(,7004,O
150,7004,O
mg/d,7004,O
),7004,O
in,7004,O
a,7004,O
double-blind,7004,O
fashion,7004,O
for,7004,O
a,7004,O
period,7004,O
of,7004,O
8,7004,O
weeks,7004,O
.,7004,O
RESULTS,7005,O
:,7005,O
At,7005,O
baseline,7005,O
and,7005,O
at,7005,O
study,7005,O
end,7005,O
point,7005,O
",",7005,O
the,7005,O
2,7005,O
subgroups,7005,O
demonstrated,7005,O
no,7005,O
statistical,7005,O
differences,7005,O
in,7005,O
scores,7005,O
on,7005,O
PTSD,7005,O
",",7005,O
depression,7005,O
",",7005,O
and,7005,O
anxiety,7005,O
rating,7005,O
scales,7005,O
.,7005,O
Both,7006,O
medications,7006,O
led,7006,O
to,7006,O
significant,7006,O
improvements,7006,O
in,7006,O
all,7006,O
clinical,7006,O
scales,7006,O
measured,7006,O
.,7006,O
Nine,7007,O
patients,7007,O
receiving,7007,O
reboxetine,7007,B-CHEMICAL
and,7007,O
3,7007,O
receiving,7007,O
fluvoxamine,7007,B-CHEMICAL
withdrew,7007,O
from,7007,O
the,7007,O
study,7007,O
because,7007,O
of,7007,O
side,7007,O
effects,7007,O
.,7007,O
CONCLUSIONS,7008,O
:,7008,O
Study,7008,O
observations,7008,O
indicate,7008,O
comparable,7008,O
efficacy,7008,O
of,7008,O
reboxetine,7008,B-CHEMICAL
and,7008,O
fluvoxamine,7008,B-CHEMICAL
in,7008,O
the,7008,O
management,7008,O
of,7008,O
MVA-related,7008,O
PTSD,7008,O
despite,7008,O
reboxetine,7008,O
's,7008,O
selective,7008,O
noradrenergic,7008,O
activity,7008,O
.,7008,O
Reboxetine,7009,B-CHEMICAL
appears,7009,O
to,7009,O
be,7009,O
at,7009,O
least,7009,O
as,7009,O
effective,7009,O
as,7009,O
fluvoxamine,7009,B-CHEMICAL
and,7009,O
may,7009,O
offer,7009,O
an,7009,O
alternative,7009,O
management,7009,O
option,7009,O
in,7009,O
this,7009,O
often,7009,O
difficult-to-treat,7009,O
and,7009,O
disabling,7009,O
condition,7009,O
.,7009,O
A,7010,O
lower,7010,O
and,7010,O
flexible,7010,O
reboxetine,7010,B-CHEMICAL
dosing,7010,O
schedule,7010,O
will,7010,O
be,7010,O
recommended,7010,O
for,7010,O
future,7010,O
research,7010,O
to,7010,O
improve,7010,O
its,7010,O
tolerability,7010,O
in,7010,O
PTSD,7010,O
patients,7010,O
.,7010,O
Current,7011,O
understanding,7011,O
of,7011,O
TRPM7,7011,B-GENE-Y
pharmacology,7011,O
and,7011,O
drug,7011,O
development,7011,O
for,7011,O
stroke,7011,O
.,7011,O
The,7012,O
initial,7012,O
excitement,7012,O
and,7012,O
countless,7012,O
efforts,7012,O
to,7012,O
find,7012,O
a,7012,O
pharmacological,7012,O
agent,7012,O
that,7012,O
disrupts,7012,O
the,7012,O
excitotoxic,7012,O
pathway,7012,O
of,7012,O
ischemic,7012,O
neuronal,7012,O
death,7012,O
have,7012,O
only,7012,O
led,7012,O
to,7012,O
disappointing,7012,O
clinical,7012,O
trials,7012,O
.,7012,O
Currently,7013,O
",",7013,O
a,7013,O
thrombolytic,7013,O
agent,7013,O
called,7013,O
recombinant,7013,B-GENE-Y
tissue,7013,I-GENE-Y
plasminogen,7013,I-GENE-Y
activator,7013,I-GENE-Y
(,7013,O
rt-PA,7013,B-GENE-Y
),7013,O
is,7013,O
the,7013,O
only,7013,O
pharmacological,7013,O
treatment,7013,O
available,7013,O
for,7013,O
patients,7013,O
with,7013,O
acute,7013,O
ischemic,7013,O
stroke,7013,O
in,7013,O
most,7013,O
countries,7013,O
.,7013,O
Even,7014,O
though,7014,O
its,7014,O
efficacy,7014,O
has,7014,O
been,7014,O
confirmed,7014,O
repeatedly,7014,O
",",7014,O
rt-PA,7014,B-GENE-Y
is,7014,O
considerably,7014,O
underused,7014,O
due,7014,O
to,7014,O
reasons,7014,O
including,7014,O
a,7014,O
short,7014,O
therapeutic,7014,O
window,7014,O
and,7014,O
repeated,7014,O
complications,7014,O
associated,7014,O
with,7014,O
its,7014,O
use,7014,O
.,7014,O
A,7015,O
search,7015,O
for,7015,O
alternative,7015,O
mechanisms,7015,O
that,7015,O
may,7015,O
operate,7015,O
dependently,7015,O
or,7015,O
independently,7015,O
with,7015,O
the,7015,O
well-established,7015,O
excitotoxic,7015,O
mechanism,7015,O
has,7015,O
led,7015,O
researchers,7015,O
to,7015,O
the,7015,O
discovery,7015,O
of,7015,O
newly,7015,O
described,7015,O
non-glutamate,7015,O
mechanisms,7015,O
.,7015,O
Among,7016,O
the,7016,O
latter,7016,O
",",7016,O
transient,7016,B-GENE-Y
receptor,7016,I-GENE-Y
potential,7016,I-GENE-Y
melastatin,7016,I-GENE-Y
7,7016,I-GENE-Y
(,7016,O
TRPM7,7016,B-GENE-Y
),7016,O
is,7016,O
one,7016,O
of,7016,O
the,7016,O
important,7016,O
nonglutamate,7016,O
mechanisms,7016,O
in,7016,O
stroke,7016,O
",",7016,O
which,7016,O
has,7016,O
been,7016,O
evaluated,7016,O
in,7016,O
both,7016,O
in-vitro,7016,O
and,7016,O
in-vivo,7016,O
.,7016,O
In,7017,O
this,7017,O
review,7017,O
",",7017,O
we,7017,O
will,7017,O
discuss,7017,O
the,7017,O
current,7017,O
state,7017,O
of,7017,O
pharmacological,7017,O
treatments,7017,O
of,7017,O
ischemic,7017,O
stroke,7017,O
and,7017,O
provide,7017,O
evidence,7017,O
that,7017,O
TRPM7,7017,B-GENE-Y
is,7017,O
a,7017,O
promising,7017,O
therapeutic,7017,O
target,7017,O
of,7017,O
stroke,7017,O
.,7017,O
Analgesic,7018,O
and,7018,O
anti-inflammatory,7018,O
activities,7018,O
of,7018,O
aqueous,7018,O
extract,7018,O
from,7018,O
Glycine,7018,B-CHEMICAL
tomentella,7018,O
root,7018,O
in,7018,O
mice,7018,O
.,7018,O
In,7019,O
the,7019,O
present,7019,O
study,7019,O
",",7019,O
we,7019,O
have,7019,O
investigated,7019,O
the,7019,O
analgesic,7019,O
effect,7019,O
of,7019,O
the,7019,O
aqueous,7019,O
extract,7019,O
of,7019,O
the,7019,O
root,7019,O
of,7019,O
Glycine,7019,B-CHEMICAL
tomentella,7019,O
(,7019,O
AGT,7019,O
),7019,O
using,7019,O
models,7019,O
of,7019,O
acetic,7019,B-CHEMICAL
acid-induced,7019,O
writhing,7019,O
response,7019,O
and,7019,O
formalin,7019,B-CHEMICAL
test,7019,O
",",7019,O
the,7019,O
anti-inflammatory,7019,O
effect,7019,O
of,7019,O
AGT,7019,O
using,7019,O
model,7019,O
of,7019,O
lambda-carrageenan-induced,7019,O
paw,7019,O
edema,7019,O
.,7019,O
In,7020,O
order,7020,O
to,7020,O
investigate,7020,O
the,7020,O
anti-inflammatory,7020,O
mechanism,7020,O
of,7020,O
AGT,7020,O
",",7020,O
we,7020,O
have,7020,O
detected,7020,O
the,7020,O
activities,7020,O
of,7020,O
glutathione,7020,B-GENE-N
peroxidase,7020,I-GENE-N
(,7020,O
GPx,7020,B-GENE-N
),7020,O
and,7020,O
glutathione,7020,B-GENE-Y
reductase,7020,I-GENE-Y
(,7020,O
GRx,7020,B-GENE-Y
),7020,O
in,7020,O
the,7020,O
liver,7020,O
and,7020,O
the,7020,O
levels,7020,O
of,7020,O
malondialdehyde,7020,B-CHEMICAL
(,7020,O
MDA,7020,B-CHEMICAL
),7020,O
and,7020,O
NO,7020,B-CHEMICAL
in,7020,O
the,7020,O
edema,7020,O
paw,7020,O
.,7020,O
In,7021,O
the,7021,O
analgesic,7021,O
test,7021,O
",",7021,O
AGT,7021,O
(,7021,O
0.5,7021,O
and,7021,O
1.0,7021,O
g/kg,7021,O
),7021,O
decreased,7021,O
the,7021,O
acetic,7021,B-CHEMICAL
acid-induced,7021,O
writhing,7021,O
response,7021,O
and,7021,O
the,7021,O
licking,7021,O
time,7021,O
on,7021,O
the,7021,O
late,7021,O
phase,7021,O
in,7021,O
the,7021,O
formalin,7021,B-CHEMICAL
test,7021,O
.,7021,O
In,7022,O
the,7022,O
anti-inflammatory,7022,O
test,7022,O
",",7022,O
AGT,7022,O
(,7022,O
0.5,7022,O
and,7022,O
1.0,7022,O
g/kg,7022,O
),7022,O
decreased,7022,O
the,7022,O
paw,7022,O
edema,7022,O
at,7022,O
the,7022,O
third,7022,O
",",7022,O
fourth,7022,O
",",7022,O
fifth,7022,O
and,7022,O
sixth,7022,O
hour,7022,O
after,7022,O
lambda-carrageenan,7022,O
administration,7022,O
",",7022,O
and,7022,O
increased,7022,O
the,7022,O
activities,7022,O
of,7022,O
SOD,7022,B-GENE-N
",",7022,O
GPx,7022,B-GENE-N
and,7022,O
GRx,7022,B-GENE-Y
in,7022,O
the,7022,O
liver,7022,O
tissue,7022,O
and,7022,O
decreased,7022,O
the,7022,O
MDA,7022,B-CHEMICAL
level,7022,O
in,7022,O
the,7022,O
edema,7022,O
paw,7022,O
at,7022,O
the,7022,O
third,7022,O
hour,7022,O
after,7022,O
lambda-carrageenan,7022,O
injection,7022,O
.,7022,O
However,7023,O
",",7023,O
AGT,7023,O
could,7023,O
not,7023,O
affect,7023,O
the,7023,O
NO,7023,B-CHEMICAL
level,7023,O
which,7023,O
induced,7023,O
by,7023,O
lambda-carrageenan,7023,O
.,7023,O
These,7024,O
results,7024,O
suggested,7024,O
that,7024,O
AGT,7024,O
possessed,7024,O
analgesic,7024,O
and,7024,O
anti-inflammatory,7024,O
effects,7024,O
.,7024,O
The,7025,O
anti-inflammatory,7025,O
mechanism,7025,O
of,7025,O
AGT,7025,O
might,7025,O
be,7025,O
related,7025,O
to,7025,O
the,7025,O
decrease,7025,O
in,7025,O
the,7025,O
level,7025,O
of,7025,O
MDA,7025,B-CHEMICAL
in,7025,O
the,7025,O
edema,7025,O
paw,7025,O
via,7025,O
increasing,7025,O
the,7025,O
activities,7025,O
of,7025,O
SOD,7025,B-GENE-N
",",7025,O
GPx,7025,B-GENE-N
and,7025,O
GRx,7025,B-GENE-Y
in,7025,O
the,7025,O
liver,7025,O
.,7025,O
Enhancing,7026,O
Raman,7026,O
Scattering,7026,O
without,7026,O
Plasmons,7026,O
:,7026,O
Unprecedented,7026,O
Sensitivity,7026,O
Achieved,7026,O
by,7026,O
TiO2,7026,B-CHEMICAL
Shell-Based,7026,O
Resonators,7026,O
.,7026,O
A,7027,O
remarkable,7027,O
enhancement,7027,O
of,7027,O
Raman,7027,O
scattering,7027,O
is,7027,O
achieved,7027,O
by,7027,O
TiO2,7027,B-CHEMICAL
shell-based,7027,O
spherical,7027,O
resonators,7027,O
in,7027,O
the,7027,O
absence,7027,O
of,7027,O
plasmonic,7027,O
enhancers,7027,O
.,7027,O
This,7028,O
effect,7028,O
is,7028,O
ascribed,7028,O
to,7028,O
the,7028,O
synergistic,7028,O
combination,7028,O
of,7028,O
high,7028,O
refractive,7028,O
index,7028,O
of,7028,O
the,7028,O
shell,7028,O
layer,7028,O
",",7028,O
multiple,7028,O
light,7028,O
scattering,7028,O
through,7028,O
the,7028,O
spheres,7028,O
",",7028,O
and,7028,O
related,7028,O
geometrical,7028,O
factors,7028,O
and,7028,O
can,7028,O
be,7028,O
exploited,7028,O
to,7028,O
fabricate,7028,O
a,7028,O
new,7028,O
generation,7028,O
of,7028,O
self-diagnostic,7028,O
",",7028,O
recyclable,7028,O
SERS-active,7028,O
substrates,7028,O
.,7028,O
Degradation,7029,O
of,7029,O
MAC13243,7029,B-CHEMICAL
and,7029,O
studies,7029,O
of,7029,O
the,7029,O
interaction,7029,O
of,7029,O
resulting,7029,O
thiourea,7029,B-CHEMICAL
compounds,7029,O
with,7029,O
the,7029,O
lipoprotein,7029,B-GENE-N
targeting,7029,O
chaperone,7029,B-GENE-N
LolA,7029,B-GENE-N
.,7029,O
The,7030,O
discovery,7030,O
of,7030,O
novel,7030,O
small,7030,O
molecules,7030,O
that,7030,O
function,7030,O
as,7030,O
antibacterial,7030,O
agents,7030,O
or,7030,O
cellular,7030,O
probes,7030,O
of,7030,O
biology,7030,O
is,7030,O
hindered,7030,O
by,7030,O
our,7030,O
limited,7030,O
understanding,7030,O
of,7030,O
bacterial,7030,O
physiology,7030,O
and,7030,O
our,7030,O
ability,7030,O
to,7030,O
assign,7030,O
mechanism,7030,O
of,7030,O
action,7030,O
.,7030,O
We,7031,O
previously,7031,O
employed,7031,O
a,7031,O
chemical,7031,O
genomic,7031,O
strategy,7031,O
to,7031,O
identify,7031,O
a,7031,O
novel,7031,O
small,7031,O
molecule,7031,O
",",7031,O
MAC13243,7031,B-CHEMICAL
",",7031,O
as,7031,O
a,7031,O
likely,7031,O
inhibitor,7031,O
of,7031,O
the,7031,O
bacterial,7031,B-GENE-N
lipoprotein,7031,I-GENE-N
targeting,7031,O
chaperone,7031,B-GENE-N
",",7031,O
LolA,7031,B-GENE-N
.,7031,O
Here,7032,O
",",7032,O
we,7032,O
report,7032,O
on,7032,O
the,7032,O
degradation,7032,O
of,7032,O
MAC13243,7032,B-CHEMICAL
into,7032,O
the,7032,O
active,7032,O
species,7032,O
",",7032,O
S-,7032,B-CHEMICAL
(,7032,I-CHEMICAL
4-chlorobenzyl,7032,I-CHEMICAL
),7032,I-CHEMICAL
isothiourea,7032,I-CHEMICAL
.,7032,O
Analogs,7033,O
of,7033,O
this,7033,O
compound,7033,O
(,7033,O
e.g.,7033,O
",",7033,O
A22,7033,O
),7033,O
have,7033,O
previously,7033,O
been,7033,O
characterized,7033,O
as,7033,O
inhibitors,7033,O
of,7033,O
the,7033,O
bacterial,7033,B-GENE-N
actin-like,7033,I-GENE-N
protein,7033,I-GENE-N
",",7033,O
MreB,7033,B-GENE-N
.,7033,O
Herein,7034,O
",",7034,O
we,7034,O
demonstrate,7034,O
that,7034,O
the,7034,O
antibacterial,7034,O
activity,7034,O
of,7034,O
MAC13243,7034,B-CHEMICAL
and,7034,O
the,7034,O
thiourea,7034,B-CHEMICAL
compounds,7034,O
are,7034,O
similar,7034,O
;,7034,O
these,7034,O
activities,7034,O
are,7034,O
suppressed,7034,O
or,7034,O
sensitized,7034,O
in,7034,O
response,7034,O
to,7034,O
increases,7034,O
or,7034,O
decreases,7034,O
of,7034,O
LolA,7034,B-GENE-N
copy,7034,O
number,7034,O
",",7034,O
respectively,7034,O
.,7034,O
We,7035,O
provide,7035,O
STD,7035,O
NMR,7035,O
data,7035,O
which,7035,O
confirms,7035,O
a,7035,O
physical,7035,O
interaction,7035,O
between,7035,O
LolA,7035,B-GENE-N
and,7035,O
the,7035,O
thiourea,7035,B-CHEMICAL
degradation,7035,O
product,7035,O
of,7035,O
MAC13243,7035,B-CHEMICAL
",",7035,O
with,7035,O
a,7035,O
Kd,7035,O
of,7035,O
~150,7035,O
μM,7035,O
.,7035,O
Taken,7036,O
together,7036,O
",",7036,O
we,7036,O
conclude,7036,O
that,7036,O
the,7036,O
thiourea,7036,B-CHEMICAL
series,7036,O
of,7036,O
compounds,7036,O
share,7036,O
a,7036,O
similar,7036,O
cellular,7036,O
mechanism,7036,O
that,7036,O
includes,7036,O
interaction,7036,O
with,7036,O
LolA,7036,B-GENE-N
in,7036,O
addition,7036,O
to,7036,O
the,7036,O
well-characterized,7036,O
target,7036,O
MreB,7036,B-GENE-N
.,7036,O
Alpha1-adrenergic,7037,B-GENE-N
receptors,7037,I-GENE-N
and,7037,O
their,7037,O
inhibitors,7037,O
in,7037,O
lower,7037,O
urinary,7037,O
tract,7037,O
symptoms,7037,O
and,7037,O
benign,7037,O
prostatic,7037,O
hyperplasia,7037,O
.,7037,O
PURPOSE,7038,O
:,7038,O
We,7038,O
provide,7038,O
a,7038,O
comprehensive,7038,O
overview,7038,O
of,7038,O
the,7038,O
role,7038,O
of,7038,O
alpha1-adrenergic,7038,B-GENE-N
receptors,7038,O
(,7038,O
alpha1ARs,7038,B-GENE-N
),7038,O
as,7038,O
critical,7038,O
mediators,7038,O
of,7038,O
lower,7038,O
urinary,7038,O
tract,7038,O
symptoms,7038,O
(,7038,O
LUTS,7038,O
),7038,O
and,7038,O
pathophysiology,7038,O
in,7038,O
benign,7038,O
prostatic,7038,O
hyperplasia,7038,O
(,7038,O
BPH,7038,O
),7038,O
",",7038,O
and,7038,O
we,7038,O
review,7038,O
the,7038,O
pharmacological,7038,O
antagonists,7038,O
of,7038,O
alpha1ARs,7038,B-GENE-N
.,7038,O
MATERIALS,7039,O
AND,7039,O
METHODS,7039,O
:,7039,O
A,7039,O
review,7039,O
was,7039,O
performed,7039,O
of,7039,O
pertinent,7039,O
studies,7039,O
in,7039,O
the,7039,O
literature,7039,O
relating,7039,O
to,7039,O
the,7039,O
pathophysiology,7039,O
of,7039,O
LUTS,7039,O
and,7039,O
BPH,7039,O
",",7039,O
focusing,7039,O
on,7039,O
the,7039,O
role,7039,O
of,7039,O
alpha1ARs,7039,B-GENE-N
",",7039,O
and,7039,O
of,7039,O
clinical,7039,O
trial,7039,O
and,7039,O
practice,7039,O
data,7039,O
evaluating,7039,O
the,7039,O
different,7039,O
agents,7039,O
that,7039,O
inhibit,7039,O
these,7039,O
receptors,7039,O
.,7039,O
RESULTS,7040,O
:,7040,O
Further,7040,O
characterization,7040,O
of,7040,O
the,7040,O
alpha1AR,7040,B-GENE-N
gene,7040,O
family,7040,O
indicates,7040,O
that,7040,O
3,7040,O
receptor,7040,O
subtypes,7040,O
exist,7040,O
in,7040,O
humans,7040,O
.,7040,O
Their,7041,O
different,7041,O
distribution,7041,O
between,7041,O
urinary,7041,O
tract,7041,O
and,7041,O
cardiovascular,7041,O
tissues,7041,O
has,7041,O
provided,7041,O
a,7041,O
strategy,7041,O
for,7041,O
the,7041,O
development,7041,O
of,7041,O
improved,7041,O
therapeutic,7041,O
agents,7041,O
.,7041,O
Since,7042,O
excessive,7042,O
activity,7042,O
of,7042,O
the,7042,O
alpha1aAR,7042,B-GENE-Y
and,7042,O
alpha1dAR,7042,B-GENE-Y
subtypes,7042,O
appears,7042,O
to,7042,O
be,7042,O
a,7042,O
common,7042,O
feature,7042,O
in,7042,O
symptomatic,7042,O
BPH,7042,O
and,7042,O
alpha1aARs,7042,B-GENE-Y
are,7042,O
enriched,7042,O
in,7042,O
prostatic,7042,O
tissue,7042,O
",",7042,O
drugs,7042,O
that,7042,O
demonstrate,7042,O
high,7042,O
alpha1aAR,7042,B-GENE-Y
selectivity,7042,O
have,7042,O
attracted,7042,O
attention,7042,O
.,7042,O
Tamsulosin,7043,B-CHEMICAL
",",7043,O
which,7043,O
has,7043,O
high,7043,O
affinity,7043,O
for,7043,O
alpha1aAR,7043,B-GENE-Y
and,7043,O
alpha1dAR,7043,B-GENE-Y
subtypes,7043,O
but,7043,O
not,7043,O
for,7043,O
alpha1bAR,7043,B-GENE-Y
",",7043,O
shows,7043,O
efficacy,7043,O
similar,7043,O
to,7043,O
the,7043,O
nonsubtype,7043,O
selective,7043,O
agents,7043,O
terazosin,7043,B-CHEMICAL
and,7043,O
doxazosin,7043,B-CHEMICAL
.,7043,O
It,7044,O
is,7044,O
associated,7044,O
with,7044,O
fewer,7044,O
cardiovascular,7044,O
side,7044,O
effects,7044,O
",",7044,O
although,7044,O
it,7044,O
has,7044,O
some,7044,O
ejaculatory,7044,O
side,7044,O
effects,7044,O
.,7044,O
The,7045,O
nonsubtype,7045,O
selective,7045,O
agent,7045,O
alfuzosin,7045,B-CHEMICAL
also,7045,O
demonstrates,7045,O
efficacy,7045,O
and,7045,O
offers,7045,O
an,7045,O
enhanced,7045,O
side,7045,O
effect,7045,O
profile,7045,O
",",7045,O
particularly,7045,O
minimizing,7045,O
hypotension,7045,O
.,7045,O
Other,7046,O
agents,7046,O
with,7046,O
super,7046,O
selective,7046,O
specificity,7046,O
for,7046,O
the,7046,O
alpha1aAR,7046,B-GENE-Y
subtype,7046,O
are,7046,O
under,7046,O
investigation,7046,O
.,7046,O
CONCLUSIONS,7047,O
:,7047,O
Further,7047,O
advances,7047,O
in,7047,O
the,7047,O
treatment,7047,O
of,7047,O
LUTS,7047,O
associated,7047,O
with,7047,O
BPH,7047,O
may,7047,O
depend,7047,O
not,7047,O
only,7047,O
on,7047,O
receptor,7047,O
subtype,7047,O
selectivity,7047,O
",",7047,O
but,7047,O
also,7047,O
on,7047,O
other,7047,O
pharmacokinetic,7047,O
and,7047,O
pharmacodynamic,7047,O
factors,7047,O
.,7047,O
Effect,7048,O
of,7048,O
low,7048,O
dose,7048,O
Bisphenol,7048,B-CHEMICAL
A,7048,I-CHEMICAL
on,7048,O
the,7048,O
early,7048,O
differentiation,7048,O
of,7048,O
human,7048,O
embryonic,7048,O
stem,7048,O
cells,7048,O
into,7048,O
mammary,7048,O
epithelial,7048,O
cells,7048,O
.,7048,O
It,7049,O
has,7049,O
been,7049,O
previously,7049,O
reported,7049,O
that,7049,O
Bisphenol,7049,B-CHEMICAL
A,7049,I-CHEMICAL
(,7049,O
BPA,7049,B-CHEMICAL
),7049,O
can,7049,O
disturb,7049,O
the,7049,O
development,7049,O
of,7049,O
mammary,7049,O
structure,7049,O
and,7049,O
increase,7049,O
the,7049,O
risk,7049,O
of,7049,O
breast,7049,O
cancer,7049,O
in,7049,O
experimental,7049,O
animals,7049,O
.,7049,O
In,7050,O
this,7050,O
study,7050,O
",",7050,O
an,7050,O
in,7050,O
vitro,7050,O
model,7050,O
of,7050,O
human,7050,O
embryonic,7050,O
stem,7050,O
cell,7050,O
(,7050,O
hESC,7050,O
),7050,O
differentiation,7050,O
into,7050,O
mammary,7050,O
epithelial,7050,O
cells,7050,O
was,7050,O
applied,7050,O
to,7050,O
investigate,7050,O
the,7050,O
effect,7050,O
of,7050,O
low,7050,O
dose,7050,O
BPA,7050,B-CHEMICAL
on,7050,O
the,7050,O
early,7050,O
stages,7050,O
of,7050,O
mammogenesis,7050,O
.,7050,O
A,7051,O
newly,7051,O
established,7051,O
hESC,7051,O
line,7051,O
was,7051,O
directionally,7051,O
differentiated,7051,O
into,7051,O
mammary,7051,O
epithelial,7051,O
cells,7051,O
by,7051,O
a,7051,O
well-established,7051,O
three-dimensional,7051,O
(,7051,O
3D,7051,O
),7051,O
culture,7051,O
system,7051,O
.,7051,O
The,7052,O
differentiated,7052,O
mammary,7052,O
epithelial,7052,O
cells,7052,O
were,7052,O
characterized,7052,O
by,7052,O
immunofluorescence,7052,O
and,7052,O
western,7052,O
blotting,7052,O
assay,7052,O
",",7052,O
and,7052,O
were,7052,O
called,7052,O
induced,7052,O
differentiated,7052,O
mammary,7052,O
epithelial,7052,O
cells,7052,O
(,7052,O
iDMECs,7052,O
),7052,O
based,7052,O
on,7052,O
these,7052,O
data,7052,O
.,7052,O
The,7053,O
hESCs,7053,O
were,7053,O
treated,7053,O
with,7053,O
low,7053,O
doses,7053,O
of,7053,O
BPA,7053,B-CHEMICAL
range,7053,O
10,7053,O
(,7053,O
-9,7053,O
),7053,O
-10,7053,O
(,7053,O
-6,7053,O
),7053,O
M,7053,O
during,7053,O
the,7053,O
differentiation,7053,O
process,7053,O
",",7053,O
with,7053,O
DMSO,7053,B-CHEMICAL
as,7053,O
the,7053,O
solvent,7053,O
control,7053,O
and,7053,O
17-β-estrodiol,7053,B-CHEMICAL
(,7053,O
E2,7053,O
),7053,O
as,7053,O
the,7053,O
estrogen-positive,7053,O
control,7053,O
.,7053,O
Our,7054,O
results,7054,O
showed,7054,O
that,7054,O
low,7054,O
dose,7054,O
BPA,7054,B-CHEMICAL
and,7054,O
E2,7054,O
could,7054,O
influence,7054,O
the,7054,O
mammosphere,7054,O
area,7054,O
of,7054,O
iDMECs,7054,O
and,7054,O
upregulate,7054,O
the,7054,O
expression,7054,O
level,7054,O
of,7054,O
Oct4,7054,B-GENE-Y
and,7054,O
Nanog,7054,B-GENE-Y
proteins,7054,O
",",7054,O
while,7054,O
only,7054,O
BPA,7054,B-CHEMICAL
could,7054,O
downregulate,7054,O
the,7054,O
expression,7054,O
of,7054,O
E-cadherin,7054,B-GENE-Y
protein,7054,O
.,7054,O
Taken,7055,O
together,7055,O
",",7055,O
this,7055,O
study,7055,O
provides,7055,O
some,7055,O
insights,7055,O
into,7055,O
the,7055,O
effects,7055,O
of,7055,O
low,7055,O
dose,7055,O
BPA,7055,B-CHEMICAL
on,7055,O
the,7055,O
early,7055,O
differentiation,7055,O
stage,7055,O
of,7055,O
mammary,7055,O
epithelial,7055,O
cells,7055,O
and,7055,O
suggests,7055,O
an,7055,O
easier,7055,O
canceration,7055,O
status,7055,O
of,7055,O
iDMECs,7055,O
under,7055,O
the,7055,O
effect,7055,O
of,7055,O
low,7055,O
dose,7055,O
BPA,7055,B-CHEMICAL
during,7055,O
its,7055,O
early,7055,O
differentiation,7055,O
stage,7055,O
.,7055,O
Absence,7056,O
of,7056,O
correlation,7056,O
between,7056,O
oxysterol,7056,B-CHEMICAL
accumulation,7056,O
in,7056,O
lipid,7056,B-GENE-N
raft,7056,I-GENE-N
microdomains,7056,I-GENE-N
",",7056,O
calcium,7056,B-CHEMICAL
increase,7056,O
",",7056,O
and,7056,O
apoptosis,7056,O
induction,7056,O
on,7056,O
158N,7056,O
murine,7056,O
oligodendrocytes,7056,O
.,7056,O
There,7057,O
is,7057,O
some,7057,O
evidence,7057,O
that,7057,O
oxidized,7057,O
derivatives,7057,O
of,7057,O
cholesterol,7057,B-CHEMICAL
",",7057,O
7-ketocholesterol,7057,B-CHEMICAL
(,7057,O
7KC,7057,B-CHEMICAL
),7057,O
and,7057,O
7β-hydroxycholesterol,7057,B-CHEMICAL
(,7057,O
7βOHC,7057,B-CHEMICAL
),7057,O
",",7057,O
are,7057,O
increased,7057,O
in,7057,O
the,7057,O
plasma,7057,O
of,7057,O
patients,7057,O
with,7057,O
neurodegenerative,7057,O
diseases,7057,O
associated,7057,O
with,7057,O
demyelinization,7057,O
of,7057,O
the,7057,O
central,7057,O
nervous,7057,O
system,7057,O
(,7057,O
CNS,7057,O
),7057,O
.,7057,O
It,7058,O
was,7058,O
therefore,7058,O
of,7058,O
interest,7058,O
to,7058,O
investigate,7058,O
the,7058,O
effects,7058,O
of,7058,O
these,7058,O
oxysterols,7058,B-CHEMICAL
on,7058,O
oligodendrocytes,7058,O
",",7058,O
the,7058,O
myelin-forming,7058,O
cells,7058,O
in,7058,O
the,7058,O
CNS,7058,O
.,7058,O
To,7059,O
this,7059,O
end,7059,O
",",7059,O
158N,7059,O
murine,7059,O
oligodendrocytes,7059,O
were,7059,O
treated,7059,O
with,7059,O
7KC,7059,B-CHEMICAL
or,7059,O
7βOHC,7059,B-CHEMICAL
inducing,7059,O
an,7059,O
apoptotic,7059,O
mode,7059,O
of,7059,O
cell,7059,O
death,7059,O
characterized,7059,O
by,7059,O
condensation/fragmentation,7059,O
of,7059,O
the,7059,O
nuclei,7059,O
",",7059,O
dephosphorylation,7059,O
of,7059,O
Akt,7059,B-GENE-Y
and,7059,O
GSK3,7059,B-GENE-N
",",7059,O
mitochondrial,7059,O
depolarization,7059,O
involving,7059,O
Mcl-1,7059,B-GENE-Y
",",7059,O
and,7059,O
caspase-3,7059,B-GENE-Y
activation,7059,O
.,7059,O
In,7060,O
contrast,7060,O
",",7060,O
under,7060,O
treatment,7060,O
with,7060,O
27-hydroxycholesterol,7060,B-CHEMICAL
(,7060,O
27OHC,7060,O
),7060,O
",",7060,O
no,7060,O
cell,7060,O
death,7060,O
was,7060,O
observed,7060,O
.,7060,O
When,7061,O
the,7061,O
cells,7061,O
were,7061,O
stained,7061,O
with,7061,O
Fura-2,7061,B-CHEMICAL
",",7061,O
no,7061,O
significant,7061,O
Ca,7061,B-CHEMICAL
(,7061,I-CHEMICAL
2+,7061,I-CHEMICAL
),7061,I-CHEMICAL
rise,7061,O
was,7061,O
found,7061,O
with,7061,O
the,7061,O
different,7061,O
oxysterols,7061,B-CHEMICAL
",",7061,O
whereas,7061,O
strong,7061,O
signals,7061,O
were,7061,O
detected,7061,O
with,7061,O
ionomycin,7061,B-CHEMICAL
used,7061,O
as,7061,O
positive,7061,O
control,7061,O
.,7061,O
At,7062,O
concentrations,7062,O
which,7062,O
induced,7062,O
apoptosis,7062,O
",",7062,O
7KC,7062,B-CHEMICAL
but,7062,O
not,7062,O
7βOHC,7062,B-CHEMICAL
accumulated,7062,O
in,7062,O
lipid,7062,O
rafts,7062,O
.,7062,O
Although,7063,O
not,7063,O
cytotoxic,7063,O
",",7063,O
27OHC,7063,B-CHEMICAL
was,7063,O
mainly,7063,O
detected,7063,O
in,7063,O
lipid,7063,O
rafts,7063,O
.,7063,O
It,7064,O
is,7064,O
noteworthy,7064,O
that,7064,O
α-tocopherol,7064,B-CHEMICAL
(,7064,O
but,7064,O
not,7064,O
ellagic,7064,B-CHEMICAL
acid,7064,I-CHEMICAL
and,7064,O
resveratrol,7064,B-CHEMICAL
),7064,O
was,7064,O
able,7064,O
to,7064,O
counteract,7064,O
7KC-,7064,B-CHEMICAL
and,7064,O
7βOHC-induced,7064,B-CHEMICAL
apoptosis,7064,O
and,7064,O
to,7064,O
decrease,7064,O
the,7064,O
accumulation,7064,O
of,7064,O
7KC,7064,B-CHEMICAL
and,7064,O
27OHC,7064,B-CHEMICAL
in,7064,O
lipid,7064,O
rafts,7064,O
.,7064,O
Thus,7065,O
",",7065,O
in,7065,O
158N,7065,O
cells,7065,O
",",7065,O
the,7065,O
ability,7065,O
of,7065,O
oxysterols,7065,B-CHEMICAL
to,7065,O
trigger,7065,O
a,7065,O
mode,7065,O
of,7065,O
cell,7065,O
death,7065,O
by,7065,O
apoptosis,7065,O
involving,7065,O
GSK-3,7065,B-GENE-N
and,7065,O
caspase-3,7065,B-GENE-Y
activation,7065,O
is,7065,O
independent,7065,O
of,7065,O
the,7065,O
increase,7065,O
in,7065,O
the,7065,O
Ca,7065,B-CHEMICAL
(,7065,I-CHEMICAL
2+,7065,I-CHEMICAL
),7065,I-CHEMICAL
level,7065,O
and,7065,O
of,7065,O
their,7065,O
accumulation,7065,O
in,7065,O
lipid,7065,O
raft,7065,O
microdomains,7065,O
.,7065,O
Can,7066,O
peripheral,7066,O
blood,7066,O
γδ,7066,O
T,7066,O
cells,7066,O
predict,7066,O
osteonecrosis,7066,O
of,7066,O
the,7066,O
jaw,7066,O
?,7066,O
An,7067,O
immunological,7067,O
perspective,7067,O
on,7067,O
the,7067,O
adverse,7067,O
drug,7067,O
effects,7067,O
of,7067,O
aminobisphosphonate,7067,B-CHEMICAL
therapy,7067,O
.,7067,O
Nitrogen-bisphosphonates,7068,B-CHEMICAL
(,7068,O
n-BP,7068,B-CHEMICAL
),7068,O
",",7068,O
often,7068,O
referred,7068,O
to,7068,O
as,7068,O
aminobisphosphonates,7068,B-CHEMICAL
",",7068,O
are,7068,O
the,7068,O
most,7068,O
commonly,7068,O
prescribed,7068,O
drugs,7068,O
for,7068,O
the,7068,O
treatment,7068,O
of,7068,O
disorders,7068,O
of,7068,O
bone,7068,O
fragility,7068,O
.,7068,O
However,7069,O
",",7069,O
long-term,7069,O
continuous,7069,O
treatment,7069,O
predisposes,7069,O
certain,7069,O
individuals,7069,O
to,7069,O
serious,7069,O
rare,7069,O
side,7069,O
effects,7069,O
",",7069,O
such,7069,O
as,7069,O
bisphosphonate-associated,7069,B-CHEMICAL
osteonecrosis,7069,O
of,7069,O
the,7069,O
jaw,7069,O
(,7069,O
BAONJ,7069,O
),7069,O
.,7069,O
n-BP,7070,B-CHEMICAL
use,7070,O
is,7070,O
known,7070,O
to,7070,O
unintentionally,7070,O
activate,7070,O
a,7070,O
subset,7070,O
of,7070,O
innate,7070,O
T,7070,O
cells,7070,O
called,7070,O
Vγ9Vδ2,7070,O
T,7070,O
cells,7070,O
",",7070,O
but,7070,O
the,7070,O
consequence,7070,O
of,7070,O
this,7070,O
chronic,7070,O
immune,7070,O
stimulation,7070,O
has,7070,O
remained,7070,O
unexplored,7070,O
.,7070,O
The,7071,O
primary,7071,O
objectives,7071,O
of,7071,O
this,7071,O
study,7071,O
were,7071,O
to,7071,O
1,7071,O
),7071,O
determine,7071,O
the,7071,O
fate,7071,O
of,7071,O
Vγ9Vδ2,7071,O
T,7071,O
cells,7071,O
in,7071,O
osteoporotic,7071,O
patients,7071,O
on,7071,O
n-BP,7071,B-CHEMICAL
therapy,7071,O
as,7071,O
a,7071,O
function,7071,O
of,7071,O
time,7071,O
and,7071,O
type,7071,O
of,7071,O
therapy,7071,O
;,7071,O
2,7071,O
),7071,O
evaluate,7071,O
the,7071,O
proportion,7071,O
of,7071,O
Vγ9Vδ2,7071,O
T,7071,O
cells,7071,O
in,7071,O
patients,7071,O
who,7071,O
had,7071,O
recently,7071,O
experienced,7071,O
n-BP-associated,7071,B-CHEMICAL
ONJ,7071,O
.,7071,O
We,7072,O
found,7072,O
there,7072,O
is,7072,O
a,7072,O
notable,7072,O
loss,7072,O
of,7072,O
Vγ9Vδ2,7072,O
T,7072,O
cells,7072,O
over,7072,O
time,7072,O
in,7072,O
osteoporotic,7072,O
patients,7072,O
on,7072,O
n-BP,7072,B-CHEMICAL
therapy,7072,O
",",7072,O
particularly,7072,O
those,7072,O
on,7072,O
intravenous,7072,O
(,7072,O
iv,7072,O
),7072,O
therapy,7072,O
(,7072,O
Spearman,7072,O
r,7072,O
=,7072,O
-0.55,7072,O
",",7072,O
p,7072,O
<,7072,O
0.0001,7072,O
iv,7072,O
;,7072,O
r,7072,O
=,7072,O
-0.3,7072,O
",",7072,O
p,7072,O
<,7072,O
0.03,7072,O
oral,7072,O
),7072,O
(,7072,O
n,7072,O
=,7072,O
68,7072,O
),7072,O
;,7072,O
no,7072,O
difference,7072,O
was,7072,O
observed,7072,O
in,7072,O
total,7072,O
T,7072,O
cells,7072,O
",",7072,O
monocytes,7072,O
",",7072,O
or,7072,O
granulocytes,7072,O
.,7072,O
Importantly,7073,O
",",7073,O
the,7073,O
observed,7073,O
negative,7073,O
effect,7073,O
on,7073,O
Vγ9Vδ2,7073,O
T,7073,O
cells,7073,O
coincides,7073,O
with,7073,O
the,7073,O
reported,7073,O
route,7073,O
of,7073,O
administration,7073,O
and,7073,O
timing,7073,O
of,7073,O
the,7073,O
rare,7073,O
occurrence,7073,O
of,7073,O
BAONJ,7073,O
.,7073,O
Patients,7074,O
(,7074,O
n,7074,O
=,7074,O
6,7074,O
),7074,O
who,7074,O
had,7074,O
experienced,7074,O
BAONJ,7074,O
were,7074,O
all,7074,O
found,7074,O
to,7074,O
be,7074,O
significantly,7074,O
deficient,7074,O
in,7074,O
Vγ9Vδ2,7074,O
T,7074,O
cells,7074,O
(,7074,O
median,7074,O
=,7074,O
0.07,7074,O
%,7074,O
),7074,O
in,7074,O
comparison,7074,O
to,7074,O
age-,7074,O
and,7074,O
sex-matched,7074,O
treatment-naïve,7074,O
controls,7074,O
(,7074,O
N,7074,O
=,7074,O
11,7074,O
;,7074,O
median,7074,O
=,7074,O
2.40,7074,O
%,7074,O
),7074,O
",",7074,O
U,7074,O
=,7074,O
0,7074,O
",",7074,O
p,7074,O
=,7074,O
0.001,7074,O
;,7074,O
this,7074,O
was,7074,O
the,7074,O
only,7074,O
consistent,7074,O
difference,7074,O
in,7074,O
the,7074,O
leukocytes,7074,O
assessed,7074,O
.,7074,O
All,7075,O
BAONJ,7075,O
cases,7075,O
had,7075,O
an,7075,O
underlying,7075,O
condition,7075,O
that,7075,O
further,7075,O
contributed,7075,O
to,7075,O
impaired,7075,O
immunity,7075,O
.,7075,O
We,7076,O
propose,7076,O
Vγ9Vδ2,7076,O
T,7076,O
cells,7076,O
show,7076,O
a,7076,O
strong,7076,O
potential,7076,O
to,7076,O
serve,7076,O
as,7076,O
harbingers,7076,O
of,7076,O
possible,7076,O
adverse,7076,O
immune,7076,O
effects,7076,O
of,7076,O
n-BP,7076,B-CHEMICAL
therapy,7076,O
",",7076,O
particularly,7076,O
in,7076,O
those,7076,O
patients,7076,O
already,7076,O
having,7076,O
a,7076,O
compromised,7076,O
immune,7076,O
system,7076,O
as,7076,O
they,7076,O
may,7076,O
be,7076,O
most,7076,O
vulnerable,7076,O
to,7076,O
the,7076,O
development,7076,O
of,7076,O
conditions,7076,O
such,7076,O
as,7076,O
BAONJ,7076,O
.,7076,O
A,7077,O
PET,7077,O
study,7077,O
of,7077,O
dopamine,7077,B-GENE-N
D2,7077,I-GENE-N
and,7077,I-GENE-N
serotonin,7077,I-GENE-N
5-HT2,7077,I-GENE-N
receptor,7077,I-GENE-N
occupancy,7077,O
in,7077,O
patients,7077,O
with,7077,O
schizophrenia,7077,O
treated,7077,O
with,7077,O
therapeutic,7077,O
doses,7077,O
of,7077,O
ziprasidone,7077,B-CHEMICAL
.,7077,O
OBJECTIVE,7078,O
:,7078,O
Ziprasidone,7078,B-CHEMICAL
is,7078,O
an,7078,O
atypical,7078,O
antipsychotic,7078,O
drug,7078,O
that,7078,O
shows,7078,O
a,7078,O
higher,7078,O
affinity,7078,O
for,7078,O
serotonin,7078,B-CHEMICAL
5-HT,7078,B-GENE-Y
(,7078,I-GENE-Y
2,7078,I-GENE-Y
),7078,I-GENE-Y
receptors,7078,I-GENE-Y
compared,7078,O
with,7078,O
dopamine,7078,B-GENE-Y
D,7078,I-GENE-Y
(,7078,I-GENE-Y
2,7078,I-GENE-Y
),7078,I-GENE-Y
receptors,7078,I-GENE-Y
in,7078,O
vitro,7078,O
.,7078,O
The,7079,O
affinity,7079,O
of,7079,O
ziprasidone,7079,B-CHEMICAL
for,7079,O
these,7079,O
receptors,7079,O
in,7079,O
vivo,7079,O
in,7079,O
patients,7079,O
was,7079,O
examined,7079,O
in,7079,O
a,7079,O
positron,7079,O
emission,7079,O
tomography,7079,O
(,7079,O
PET,7079,O
),7079,O
study,7079,O
.,7079,O
METHOD,7080,O
:,7080,O
The,7080,O
authors,7080,O
conducted,7080,O
a,7080,O
PET,7080,O
study,7080,O
to,7080,O
evaluate,7080,O
D,7080,B-GENE-Y
(,7080,I-GENE-Y
2,7080,I-GENE-Y
),7080,I-GENE-Y
occupancy,7080,O
(,7080,O
using,7080,O
[,7080,B-CHEMICAL
(,7080,I-CHEMICAL
11,7080,I-CHEMICAL
),7080,I-CHEMICAL
C,7080,I-CHEMICAL
],7080,I-CHEMICAL
raclopride,7080,I-CHEMICAL
),7080,O
and,7080,O
5-HT,7080,B-GENE-Y
(,7080,I-GENE-Y
2,7080,I-GENE-Y
),7080,I-GENE-Y
occupancy,7080,O
(,7080,O
using,7080,O
[,7080,B-CHEMICAL
(,7080,I-CHEMICAL
18,7080,I-CHEMICAL
),7080,I-CHEMICAL
F,7080,I-CHEMICAL
],7080,I-CHEMICAL
setoperone,7080,I-CHEMICAL
),7080,O
in,7080,O
brain,7080,O
regions,7080,O
of,7080,O
interest,7080,O
in,7080,O
16,7080,O
patients,7080,O
with,7080,O
schizophrenia,7080,O
or,7080,O
schizoaffective,7080,O
disorder,7080,O
randomly,7080,O
assigned,7080,O
to,7080,O
receive,7080,O
40,7080,O
",",7080,O
80,7080,O
",",7080,O
120,7080,O
",",7080,O
or,7080,O
160,7080,O
mg/day,7080,O
of,7080,O
ziprasidone,7080,B-CHEMICAL
",",7080,O
which,7080,O
reflected,7080,O
the,7080,O
recommended,7080,O
dose,7080,O
range,7080,O
.,7080,O
PET,7081,O
scanning,7081,O
was,7081,O
done,7081,O
after,7081,O
3,7081,O
weeks,7081,O
of,7081,O
administration,7081,O
and,7081,O
at,7081,O
trough,7081,O
plasma,7081,O
levels,7081,O
",",7081,O
i.e.,7081,O
",",7081,O
12-16,7081,O
hours,7081,O
after,7081,O
the,7081,O
last,7081,O
dose,7081,O
.,7081,O
RESULTS,7082,O
:,7082,O
The,7082,O
mean,7082,O
5-HT,7082,B-GENE-Y
(,7082,I-GENE-Y
2,7082,I-GENE-Y
),7082,I-GENE-Y
receptor,7082,O
occupancy,7082,O
was,7082,O
significantly,7082,O
higher,7082,O
than,7082,O
the,7082,O
mean,7082,O
D,7082,B-GENE-Y
(,7082,I-GENE-Y
2,7082,I-GENE-Y
),7082,I-GENE-Y
receptor,7082,I-GENE-Y
occupancy,7082,O
(,7082,O
mean=76,7082,O
%,7082,O
",",7082,O
SD=15,7082,O
%,7082,O
",",7082,O
and,7082,O
mean=56,7082,O
%,7082,O
",",7082,O
SD=18,7082,O
%,7082,O
",",7082,O
respectively,7082,O
),7082,O
.,7082,O
The,7083,O
estimated,7083,O
plasma,7083,O
ziprasidone,7083,B-CHEMICAL
concentration,7083,O
associated,7083,O
with,7083,O
50,7083,O
%,7083,O
maximal,7083,O
5-HT,7083,B-GENE-Y
(,7083,I-GENE-Y
2,7083,I-GENE-Y
),7083,I-GENE-Y
receptor,7083,O
occupancy,7083,O
was,7083,O
almost,7083,O
four,7083,O
times,7083,O
lower,7083,O
than,7083,O
that,7083,O
for,7083,O
D,7083,B-GENE-Y
(,7083,I-GENE-Y
2,7083,I-GENE-Y
),7083,I-GENE-Y
receptor,7083,I-GENE-Y
occupancy,7083,O
.,7083,O
CONCLUSIONS,7084,O
:,7084,O
These,7084,O
data,7084,O
affirm,7084,O
that,7084,O
ziprasidone,7084,B-CHEMICAL
is,7084,O
similar,7084,O
to,7084,O
other,7084,O
novel,7084,O
antipsychotics,7084,O
in,7084,O
having,7084,O
greater,7084,O
5-HT,7084,B-GENE-Y
(,7084,I-GENE-Y
2,7084,I-GENE-Y
),7084,I-GENE-Y
than,7084,O
D,7084,B-GENE-N
(,7084,I-GENE-N
2,7084,I-GENE-N
),7084,I-GENE-N
receptor,7084,I-GENE-N
occupancy,7084,O
at,7084,O
therapeutic,7084,O
doses,7084,O
and,7084,O
suggest,7084,O
that,7084,O
the,7084,O
optimal,7084,O
effective,7084,O
dose,7084,O
of,7084,O
ziprasidone,7084,B-CHEMICAL
is,7084,O
closer,7084,O
to,7084,O
120,7084,O
mg/day,7084,O
than,7084,O
to,7084,O
the,7084,O
lower,7084,O
doses,7084,O
suggested,7084,O
by,7084,O
previous,7084,O
PET,7084,O
studies,7084,O
.,7084,O
The,7085,O
relatively,7085,O
high,7085,O
D,7085,B-GENE-Y
(,7085,I-GENE-Y
2,7085,I-GENE-Y
),7085,I-GENE-Y
receptor,7085,I-GENE-Y
occupancy,7085,O
",",7085,O
even,7085,O
at,7085,O
trough,7085,O
plasma,7085,O
levels,7085,O
",",7085,O
suggests,7085,O
that,7085,O
ziprasidone,7085,B-CHEMICAL
is,7085,O
more,7085,O
similar,7085,O
to,7085,O
risperidone,7085,B-CHEMICAL
and,7085,O
olanzapine,7085,O
in,7085,O
receptor,7085,O
occupancy,7085,O
profile,7085,O
than,7085,O
to,7085,O
clozapine,7085,B-CHEMICAL
and,7085,O
quetiapine,7085,B-CHEMICAL
.,7085,O
Since,7086,O
ziprasidone,7086,B-CHEMICAL
plasma,7086,O
levels,7086,O
show,7086,O
significant,7086,O
(,7086,O
more,7086,O
than,7086,O
twofold,7086,O
),7086,O
variation,7086,O
within,7086,O
a,7086,O
single,7086,O
dose,7086,O
cycle,7086,O
",",7086,O
studies,7086,O
that,7086,O
are,7086,O
aimed,7086,O
at,7086,O
peak,7086,O
plasma,7086,O
levels,7086,O
(,7086,O
6,7086,O
hours,7086,O
after,7086,O
the,7086,O
last,7086,O
dose,7086,O
),7086,O
and,7086,O
that,7086,O
examine,7086,O
extrastriatal,7086,O
regions,7086,O
are,7086,O
required,7086,O
to,7086,O
fully,7086,O
characterize,7086,O
the,7086,O
in,7086,O
vivo,7086,O
occupancy,7086,O
profile,7086,O
of,7086,O
ziprasidone,7086,B-CHEMICAL
.,7086,O
Sulindac,7087,B-CHEMICAL
sulfide,7087,I-CHEMICAL
inhibits,7087,O
epidermal,7087,B-GENE-Y
growth,7087,I-GENE-Y
factor-induced,7087,O
phosphorylation,7087,O
of,7087,O
extracellular-regulated,7087,B-GENE-N
kinase,7087,I-GENE-N
1/2,7087,I-GENE-N
and,7087,O
Bad,7087,B-GENE-Y
in,7087,O
human,7087,O
colon,7087,O
cancer,7087,O
cells,7087,O
.,7087,O
Colorectal,7088,O
cancer,7088,O
is,7088,O
the,7088,O
second,7088,O
leading,7088,O
cause,7088,O
of,7088,O
cancer,7088,O
death,7088,O
in,7088,O
the,7088,O
United,7088,O
States,7088,O
.,7088,O
Nonsteroidal,7089,O
anti-inflammatory,7089,O
drugs,7089,O
including,7089,O
sulindac,7089,B-CHEMICAL
are,7089,O
promising,7089,O
chemopreventive,7089,O
agents,7089,O
for,7089,O
colorectal,7089,O
cancer,7089,O
.,7089,O
Sulindac,7090,B-CHEMICAL
and,7090,O
selective,7090,O
cyclooxygenase,7090,B-GENE-Y
(,7090,I-GENE-Y
COX,7090,I-GENE-Y
),7090,I-GENE-Y
-2,7090,I-GENE-Y
inhibitors,7090,O
cause,7090,O
regression,7090,O
of,7090,O
colonic,7090,O
polyps,7090,O
in,7090,O
familial,7090,O
polyposis,7090,O
patients,7090,O
.,7090,O
Sulindac,7091,B-CHEMICAL
induces,7091,O
apoptotic,7091,O
cell,7091,O
death,7091,O
in,7091,O
cancer,7091,O
cells,7091,O
in,7091,O
vitro,7091,O
and,7091,O
in,7091,O
vivo,7091,O
.,7091,O
In,7092,O
tumor,7092,O
cells,7092,O
",",7092,O
activation,7092,O
of,7092,O
extracellular-regulated,7092,B-GENE-N
kinase,7092,I-GENE-N
(,7092,I-GENE-N
ERK,7092,I-GENE-N
),7092,I-GENE-N
1/2,7092,I-GENE-N
results,7092,O
in,7092,O
phosphorylation,7092,O
of,7092,O
several,7092,O
ERK1/2,7092,B-GENE-N
effectors,7092,O
",",7092,O
including,7092,O
the,7092,O
proapoptotic,7092,O
protein,7092,O
Bad,7092,B-GENE-Y
.,7092,O
Phosphorylation,7093,O
of,7093,O
Ser112,7093,B-CHEMICAL
by,7093,O
ERK1/2,7093,B-GENE-N
inactivates,7093,O
Bad,7093,B-GENE-Y
and,7093,O
protects,7093,O
the,7093,O
tumor,7093,O
cell,7093,O
from,7093,O
apoptosis,7093,O
.,7093,O
Sulindac,7094,B-CHEMICAL
metabolites,7094,O
and,7094,O
other,7094,O
nonsteroidal,7094,O
anti-inflammatory,7094,O
drugs,7094,O
selectively,7094,O
inhibit,7094,O
ERK1/2,7094,B-GENE-N
phosphorylation,7094,O
in,7094,O
human,7094,O
colon,7094,O
cancer,7094,O
cells,7094,O
.,7094,O
In,7095,O
this,7095,O
study,7095,O
we,7095,O
show,7095,O
that,7095,O
epidermal,7095,B-GENE-Y
growth,7095,I-GENE-Y
factor,7095,I-GENE-Y
(,7095,O
EGF,7095,B-GENE-Y
),7095,O
strongly,7095,O
induces,7095,O
phosphorylation,7095,O
of,7095,O
ERK1/2,7095,B-GENE-N
and,7095,O
Bad,7095,B-GENE-Y
in,7095,O
HT29,7095,O
colon,7095,O
cancer,7095,O
cells,7095,O
.,7095,O
EGF-stimulated,7096,B-GENE-Y
phosphorylation,7096,O
of,7096,O
ERK,7096,B-GENE-N
and,7096,O
Bad,7096,B-GENE-Y
is,7096,O
blocked,7096,O
by,7096,O
pretreatment,7096,O
with,7096,O
U0126,7096,B-CHEMICAL
",",7096,O
a,7096,O
selective,7096,O
MAP,7096,B-GENE-N
kinase,7096,I-GENE-N
kinase,7096,I-GENE-N
(,7096,I-GENE-N
MKK,7096,I-GENE-N
),7096,I-GENE-N
1/2,7096,I-GENE-N
inhibitor,7096,O
.,7096,O
Similarly,7097,O
",",7097,O
pretreatment,7097,O
with,7097,O
sulindac,7097,B-CHEMICAL
sulfide,7097,I-CHEMICAL
blocks,7097,O
the,7097,O
ability,7097,O
of,7097,O
EGF,7097,B-GENE-Y
to,7097,O
induce,7097,O
ERK1/2,7097,B-GENE-N
and,7097,O
Bad,7097,B-GENE-Y
phosphorylation,7097,O
",",7097,O
but,7097,O
also,7097,O
down-regulates,7097,O
total,7097,O
Bad,7097,B-GENE-Y
but,7097,O
not,7097,O
ERK1/2,7097,B-GENE-N
protein,7097,O
levels,7097,O
.,7097,O
The,7098,O
ability,7098,O
of,7098,O
sulindac,7098,B-CHEMICAL
to,7098,O
block,7098,O
ERK1/2,7098,B-GENE-N
signaling,7098,O
by,7098,O
the,7098,O
EGF,7098,B-GENE-Y
receptor,7098,I-GENE-Y
may,7098,O
account,7098,O
for,7098,O
at,7098,O
least,7098,O
part,7098,O
of,7098,O
its,7098,O
potent,7098,O
growth-inhibitory,7098,O
effects,7098,O
against,7098,O
cancer,7098,O
cells,7098,O
.,7098,O
Fibrillar,7099,O
Morphology,7099,O
of,7099,O
Derivatives,7099,O
of,7099,O
Poly,7099,B-CHEMICAL
(,7099,I-CHEMICAL
3-alkylthiophene,7099,I-CHEMICAL
),7099,I-CHEMICAL
s,7099,I-CHEMICAL
by,7099,O
Solvent,7099,O
Vapor,7099,O
Annealing,7099,O
:,7099,O
Effects,7099,O
of,7099,O
Conformational,7099,O
Transition,7099,O
and,7099,O
Conjugate,7099,O
Length,7099,O
.,7099,O
A,7100,O
fibrillar,7100,O
morphology,7100,O
was,7100,O
obtained,7100,O
",",7100,O
compared,7100,O
to,7100,O
the,7100,O
featherless,7100,O
pristine,7100,O
films,7100,O
",",7100,O
via,7100,O
solvent,7100,O
annealing,7100,O
the,7100,O
films,7100,O
of,7100,O
a,7100,O
series,7100,O
of,7100,O
derivatives,7100,O
of,7100,O
poly,7100,B-CHEMICAL
(,7100,I-CHEMICAL
3-alkylthiophene,7100,I-CHEMICAL
),7100,I-CHEMICAL
s,7100,I-CHEMICAL
(,7100,O
P3ATs,7100,B-CHEMICAL
),7100,O
:,7100,O
poly,7100,B-CHEMICAL
(,7100,I-CHEMICAL
3-dodecylthiophene,7100,I-CHEMICAL
),7100,I-CHEMICAL
(,7100,O
P3DDT,7100,B-CHEMICAL
),7100,O
",",7100,O
poly,7100,B-CHEMICAL
(,7100,I-CHEMICAL
"3,3‴-didodecyl-quaterthiophene",7100,I-CHEMICAL
),7100,I-CHEMICAL
(,7100,O
PQT12,7100,B-CHEMICAL
),7100,O
",",7100,O
and,7100,O
poly,7100,B-CHEMICAL
(,7100,I-CHEMICAL
"2,5-bis",7100,I-CHEMICAL
(,7100,I-CHEMICAL
3-dodecylthiophen-2-yl,7100,I-CHEMICAL
),7100,I-CHEMICAL
thieno,7100,I-CHEMICAL
[,7100,I-CHEMICAL
"3,2-b",7100,I-CHEMICAL
],7100,I-CHEMICAL
thiophene,7100,I-CHEMICAL
),7100,I-CHEMICAL
(,7100,O
pBTTT12,7100,B-CHEMICAL
),7100,O
.,7100,O
Among,7101,O
the,7101,O
solvents,7101,O
used,7101,O
",",7101,O
including,7101,O
dichloromethane,7101,B-CHEMICAL
",",7101,O
chloroform,7101,B-CHEMICAL
",",7101,O
tetrahydrofuran,7101,B-CHEMICAL
",",7101,O
and,7101,O
carbon,7101,B-CHEMICAL
disulfide,7101,I-CHEMICAL
(,7101,O
CS2,7101,B-CHEMICAL
),7101,O
",",7101,O
CS2,7101,B-CHEMICAL
was,7101,O
the,7101,O
best,7101,O
to,7101,O
induce,7101,O
fibril,7101,O
formation,7101,O
because,7101,O
its,7101,O
solubility,7101,O
parameter,7101,O
is,7101,O
closest,7101,O
to,7101,O
those,7101,O
of,7101,O
the,7101,O
P3AT,7101,B-CHEMICAL
derivatives,7101,O
.,7101,O
It,7102,O
was,7102,O
found,7102,O
that,7102,O
higher,7102,O
critical,7102,O
CS2,7102,B-CHEMICAL
vapor,7102,O
pressures,7102,O
were,7102,O
needed,7102,O
to,7102,O
form,7102,O
crystal,7102,O
nuclei,7102,O
with,7102,O
increasing,7102,O
conjugation,7102,O
length,7102,O
and,7102,O
molecular,7102,O
weight,7102,O
of,7102,O
the,7102,O
P3AT,7102,B-CHEMICAL
derivatives,7102,O
;,7102,O
i.e.,7102,O
",",7102,O
the,7102,O
critical,7102,O
vapor,7102,O
pressures,7102,O
for,7102,O
P3DDT,7102,B-CHEMICAL
13.9k,7102,O
and,7102,O
PQT12,7102,B-CHEMICAL
15.5k,7102,O
were,7102,O
59.0,7102,O
%,7102,O
and,7102,O
80.7,7102,O
%,7102,O
",",7102,O
respectively,7102,O
",",7102,O
and,7102,O
there,7102,O
were,7102,O
no,7102,O
nuclei,7102,O
of,7102,O
fibrils,7102,O
for,7102,O
pBTTT12,7102,B-CHEMICAL
15.6k,7102,O
with,7102,O
the,7102,O
highest,7102,O
conjugation,7102,O
length,7102,O
",",7102,O
even,7102,O
at,7102,O
a,7102,O
CS2,7102,B-CHEMICAL
vapor,7102,O
pressure,7102,O
of,7102,O
98.3,7102,O
%,7102,O
.,7102,O
Meanwhile,7103,O
",",7103,O
at,7103,O
the,7103,O
highest,7103,O
vapor,7103,O
pressure,7103,O
",",7103,O
the,7103,O
fibril,7103,O
density,7103,O
decreased,7103,O
with,7103,O
increasing,7103,O
conjugation,7103,O
length,7103,O
and,7103,O
molecular,7103,O
weight,7103,O
of,7103,O
the,7103,O
P3AT,7103,B-CHEMICAL
derivatives,7103,O
.,7103,O
This,7104,O
is,7104,O
attributed,7104,O
to,7104,O
the,7104,O
rod-like,7104,O
conformation,7104,O
prevailing,7104,O
for,7104,O
polymers,7104,O
with,7104,O
larger,7104,O
conjugation,7104,O
length,7104,O
and,7104,O
higher,7104,O
molecular,7104,O
weight,7104,O
during,7104,O
solvent,7104,O
annealing,7104,O
",",7104,O
making,7104,O
the,7104,O
conformational,7104,O
transition,7104,O
toward,7104,O
coils,7104,O
more,7104,O
difficult,7104,O
and,7104,O
hindering,7104,O
diffusion,7104,O
of,7104,O
molecules,7104,O
.,7104,O
The,7105,O
results,7105,O
presented,7105,O
here,7105,O
are,7105,O
expected,7105,O
to,7105,O
be,7105,O
helpful,7105,O
for,7105,O
the,7105,O
design,7105,O
and,7105,O
processing,7105,O
of,7105,O
conjugated,7105,O
semiconductor,7105,O
polymers,7105,O
.,7105,O
Histamine,7106,B-GENE-Y
H4,7106,I-GENE-Y
receptor,7106,I-GENE-Y
antagonism,7106,O
diminishes,7106,O
existing,7106,O
airway,7106,O
inflammation,7106,O
and,7106,O
dysfunction,7106,O
via,7106,O
modulation,7106,O
of,7106,O
Th2,7106,B-GENE-N
cytokines,7106,I-GENE-N
.,7106,O
BACKGROUND,7107,O
:,7107,O
Airway,7107,O
remodeling,7107,O
and,7107,O
dysfunction,7107,O
are,7107,O
characteristic,7107,O
features,7107,O
of,7107,O
asthma,7107,O
thought,7107,O
to,7107,O
be,7107,O
caused,7107,O
by,7107,O
aberrant,7107,O
production,7107,O
of,7107,O
Th2,7107,B-GENE-N
cytokines,7107,I-GENE-N
.,7107,O
Histamine,7108,B-GENE-Y
H4,7108,I-GENE-Y
receptor,7108,I-GENE-Y
(,7108,O
H4R,7108,B-GENE-Y
),7108,O
perturbation,7108,O
has,7108,O
previously,7108,O
been,7108,O
shown,7108,O
to,7108,O
modify,7108,O
acute,7108,O
inflammation,7108,O
and,7108,O
Th2,7108,B-GENE-N
cytokine,7108,I-GENE-N
production,7108,O
in,7108,O
a,7108,O
murine,7108,O
model,7108,O
of,7108,O
asthma,7108,O
.,7108,O
We,7109,O
examined,7109,O
the,7109,O
ability,7109,O
of,7109,O
H4R,7109,B-GENE-Y
antagonists,7109,O
to,7109,O
therapeutically,7109,O
modify,7109,O
the,7109,O
effects,7109,O
of,7109,O
Th2,7109,B-GENE-N
cytokine,7109,I-GENE-N
production,7109,O
such,7109,O
as,7109,O
goblet,7109,O
cell,7109,O
hyperplasia,7109,O
(,7109,O
GCH,7109,O
),7109,O
",",7109,O
and,7109,O
collagen,7109,B-GENE-N
deposition,7109,O
in,7109,O
a,7109,O
sub-chronic,7109,O
model,7109,O
of,7109,O
asthma,7109,O
.,7109,O
In,7110,O
addition,7110,O
",",7110,O
effects,7110,O
on,7110,O
Th2,7110,O
mediated,7110,O
lung,7110,O
dysfunction,7110,O
were,7110,O
also,7110,O
determined,7110,O
.,7110,O
METHODS,7111,O
:,7111,O
Mice,7111,O
were,7111,O
sensitized,7111,O
to,7111,O
ovalbumin,7111,B-GENE-Y
(,7111,O
OVA,7111,B-GENE-Y
),7111,O
followed,7111,O
by,7111,O
repeated,7111,O
airway,7111,O
challenge,7111,O
with,7111,O
OVA,7111,B-GENE-Y
.,7111,O
After,7112,O
inflammation,7112,O
was,7112,O
established,7112,O
mice,7112,O
were,7112,O
dosed,7112,O
with,7112,O
the,7112,O
H4R,7112,B-GENE-Y
antagonist,7112,O
",",7112,O
JNJ,7112,B-CHEMICAL
7777120,7112,I-CHEMICAL
",",7112,O
or,7112,O
anti-IL-13,7112,O
antibody,7112,O
for,7112,O
comparison,7112,O
.,7112,O
Airway,7113,O
hyperreactivity,7113,O
(,7113,O
AHR,7113,O
),7113,O
was,7113,O
measured,7113,O
",",7113,O
lungs,7113,O
lavaged,7113,O
and,7113,O
tissues,7113,O
collected,7113,O
for,7113,O
analysis,7113,O
.,7113,O
RESULTS,7114,O
:,7114,O
Therapeutic,7114,O
H4R,7114,B-GENE-Y
antagonism,7114,O
inhibited,7114,O
T,7114,O
cell,7114,O
infiltration,7114,O
in,7114,O
to,7114,O
the,7114,O
lung,7114,O
and,7114,O
decreased,7114,O
Th2,7114,B-GENE-N
cytokines,7114,I-GENE-N
IL-13,7114,B-GENE-Y
and,7114,O
IL-5,7114,B-GENE-Y
.,7114,O
IL-13,7115,B-GENE-Y
dependent,7115,O
remodeling,7115,O
parameters,7115,O
such,7115,O
as,7115,O
GCH,7115,O
and,7115,O
lung,7115,O
collagen,7115,B-GENE-N
were,7115,O
reduced,7115,O
.,7115,O
Intervention,7116,O
with,7116,O
H4R,7116,B-GENE-Y
antagonist,7116,O
also,7116,O
improved,7116,O
measures,7116,O
of,7116,O
central,7116,O
and,7116,O
peripheral,7116,O
airway,7116,O
dysfunction,7116,O
.,7116,O
CONCLUSIONS,7117,O
:,7117,O
These,7117,O
data,7117,O
demonstrate,7117,O
that,7117,O
therapeutic,7117,O
H4R,7117,B-GENE-Y
antagonism,7117,O
can,7117,O
significantly,7117,O
ameliorate,7117,O
allergen,7117,O
induced,7117,O
",",7117,O
Th2,7117,B-GENE-N
cytokine,7117,I-GENE-N
driven,7117,O
pathologies,7117,O
such,7117,O
as,7117,O
lung,7117,O
remodeling,7117,O
and,7117,O
airway,7117,O
dysfunction,7117,O
.,7117,O
The,7118,O
ability,7118,O
of,7118,O
H4R,7118,B-GENE-Y
antagonists,7118,O
to,7118,O
affect,7118,O
these,7118,O
key,7118,O
manifestations,7118,O
of,7118,O
asthma,7118,O
suggests,7118,O
their,7118,O
potential,7118,O
as,7118,O
novel,7118,O
human,7118,O
therapeutics,7118,O
.,7118,O
Research,7119,O
on,7119,O
the,7119,O
preparation,7119,O
of,7119,O
antioxidant,7119,O
peptides,7119,O
derived,7119,O
from,7119,O
egg,7119,O
white,7119,O
with,7119,O
assisting,7119,O
of,7119,O
high-intensity,7119,O
pulsed,7119,O
electric,7119,O
field,7119,O
.,7119,O
Egg,7120,O
white,7120,O
protein,7120,O
powder,7120,O
",",7120,O
one,7120,O
of,7120,O
the,7120,O
main,7120,O
egg,7120,O
products,7120,O
",",7120,O
was,7120,O
hydrolysed,7120,O
by,7120,O
Alcalase,7120,B-GENE-Y
",",7120,O
Trypsin,7120,B-GENE-N
",",7120,O
and,7120,O
Pepsin,7120,B-GENE-N
respectively,7120,O
to,7120,O
prepare,7120,O
antioxidant,7120,O
peptides,7120,O
.,7120,O
All,7121,O
hydrolysates,7121,O
were,7121,O
assayed,7121,O
by,7121,O
determination,7121,O
of,7121,O
reducing,7121,O
power,7121,O
(,7121,O
RP,7121,O
),7121,O
ability,7121,O
.,7121,O
Three,7122,O
kinds,7122,O
of,7122,O
hydrolysates,7122,O
were,7122,O
prepared,7122,O
under,7122,O
optimal,7122,O
enzymatic,7122,O
parameters,7122,O
that,7122,O
were,7122,O
obtained,7122,O
from,7122,O
the,7122,O
preliminary,7122,O
one-factor-at-a-time,7122,O
(,7122,O
OFAT,7122,O
),7122,O
and,7122,O
response,7122,O
surface,7122,O
methodology,7122,O
(,7122,O
RSM,7122,O
),7122,O
experiments,7122,O
.,7122,O
The,7123,O
results,7123,O
showed,7123,O
that,7123,O
the,7123,O
Alcalase,7123,B-GENE-Y
hydrolysates,7123,O
exerted,7123,O
the,7123,O
best,7123,O
RP,7123,O
ability,7123,O
.,7123,O
Thereafter,7124,O
",",7124,O
the,7124,O
Alcalase,7124,B-GENE-Y
hydrolysates,7124,O
were,7124,O
sequentially,7124,O
fractionated,7124,O
by,7124,O
ultra,7124,O
filtration,7124,O
membranes,7124,O
in,7124,O
cut-off,7124,O
molecular,7124,O
weight,7124,O
(,7124,O
MW,7124,O
),7124,O
of,7124,O
30,7124,O
",",7124,O
10,7124,O
",",7124,O
and,7124,O
1kDa,7124,O
",",7124,O
and,7124,O
tested,7124,O
their,7124,O
antioxidant,7124,O
activities,7124,O
in,7124,O
terms,7124,O
of,7124,O
RP,7124,O
ability,7124,O
",",7124,O
DPPH,7124,B-CHEMICAL
radical,7124,O
scavenging,7124,O
ability,7124,O
",",7124,O
ABTS,7124,B-CHEMICAL
radical,7124,O
scavenging,7124,O
ability,7124,O
",",7124,O
and,7124,O
FRAP,7124,O
assay,7124,O
.,7124,O
Effects,7125,O
of,7125,O
high,7125,O
intensity,7125,O
pulsed,7125,O
electric,7125,O
field,7125,O
treatment,7125,O
were,7125,O
further,7125,O
investigated,7125,O
on,7125,O
antioxidant,7125,O
peptides,7125,O
to,7125,O
improve,7125,O
their,7125,O
activities,7125,O
.,7125,O
The,7126,O
results,7126,O
showed,7126,O
that,7126,O
Alcalase,7126,B-GENE-Y
hydrolysates,7126,O
possessed,7126,O
the,7126,O
strongest,7126,O
antioxidant,7126,O
ability,7126,O
compared,7126,O
with,7126,O
the,7126,O
other,7126,O
two,7126,O
hydrolysates,7126,O
",",7126,O
particularly,7126,O
for,7126,O
the,7126,O
Fraction-3,7126,O
with,7126,O
MW,7126,O
<,7126,O
1kDa,7126,O
.,7126,O
After,7127,O
PEF,7127,O
treatment,7127,O
",",7127,O
this,7127,O
fraction,7127,O
showed,7127,O
a,7127,O
significant,7127,O
improvement,7127,O
of,7127,O
RP,7127,O
ability,7127,O
within,7127,O
5h,7127,O
(,7127,O
P,7127,O
<,7127,O
0.05,7127,O
),7127,O
.,7127,O
Development,7128,O
and,7128,O
validation,7128,O
of,7128,O
a,7128,O
non-radioactive,7128,O
DNA,7128,B-GENE-N
polymerase,7128,I-GENE-N
assay,7128,O
for,7128,O
studying,7128,O
cytomegalovirus,7128,O
resistance,7128,O
to,7128,O
foscarnet,7128,B-CHEMICAL
.,7128,O
Phenotypic,7129,O
characterisation,7129,O
of,7129,O
the,7129,O
human,7129,B-GENE-Y
cytomegalovirus,7129,I-GENE-Y
(,7129,I-GENE-Y
HCMV,7129,I-GENE-Y
),7129,I-GENE-Y
pUL54,7129,I-GENE-Y
DNA,7129,B-GENE-N
polymerase,7129,I-GENE-N
is,7129,O
a,7129,O
useful,7129,O
tool,7129,O
for,7129,O
testing,7129,O
for,7129,O
mutations,7129,O
in,7129,O
the,7129,O
UL54,7129,B-GENE-Y
gene,7129,O
thought,7129,O
to,7129,O
render,7129,O
HCMV,7129,O
resistant,7129,O
to,7129,O
foscarnet,7129,B-CHEMICAL
.,7129,O
In,7130,O
this,7130,O
study,7130,O
",",7130,O
an,7130,O
in-house,7130,O
non-isotopic,7130,O
method,7130,O
for,7130,O
assessing,7130,O
polymerase,7130,O
enzymatic,7130,O
activity,7130,O
in,7130,O
the,7130,O
presence,7130,O
and,7130,O
absence,7130,O
of,7130,O
foscarnet,7130,B-CHEMICAL
was,7130,O
developed,7130,O
and,7130,O
its,7130,O
utility,7130,O
for,7130,O
HCMV,7130,B-GENE-N
polymerase,7130,I-GENE-N
phenotyping,7130,O
evaluated,7130,O
.,7130,O
Polymerase,7131,B-GENE-N
activity,7131,O
was,7131,O
assessed,7131,O
by,7131,O
monitoring,7131,O
the,7131,O
incorporation,7131,O
of,7131,O
digoxigenin-labelled,7131,B-CHEMICAL
nucleotides,7131,O
into,7131,O
the,7131,O
growing,7131,O
DNA,7131,O
chain,7131,O
and,7131,O
foscarnet,7131,B-CHEMICAL
concentrations,7131,O
inhibiting,7131,O
enzymatic,7131,O
activity,7131,O
by,7131,O
50,7131,O
%,7131,O
were,7131,O
determined,7131,O
.,7131,O
HCMV,7132,B-GENE-N
DNA,7132,I-GENE-N
polymerases,7132,I-GENE-N
were,7132,O
synthesised,7132,O
in,7132,O
vitro,7132,O
by,7132,O
expression,7132,O
of,7132,O
UL54,7132,B-GENE-Y
under,7132,O
the,7132,O
control,7132,O
of,7132,O
the,7132,O
T7,7132,B-GENE-N
promoter,7132,I-GENE-N
.,7132,O
Mutations,7133,O
of,7133,O
interest,7133,O
were,7133,O
introduced,7133,O
into,7133,O
the,7133,O
wild-type,7133,O
UL54,7133,B-GENE-Y
gene,7133,O
by,7133,O
site-directed,7133,O
mutagenesis,7133,O
.,7133,O
Mutated,7134,O
polymerases,7134,B-GENE-N
and,7134,O
polymerases,7134,B-GENE-N
from,7134,O
HCMV,7134,O
reference,7134,O
strains,7134,O
were,7134,O
studied,7134,O
.,7134,O
The,7135,O
activity,7135,O
of,7135,O
polymerases,7135,B-GENE-N
containing,7135,O
mutations,7135,O
known,7135,O
to,7135,O
confer,7135,O
resistance,7135,O
to,7135,O
foscarnet,7135,B-CHEMICAL
(,7135,O
V715M,7135,B-GENE-N
",",7135,O
T700A,7135,B-GENE-N
and,7135,O
N495K,7135,B-GENE-N
),7135,O
was,7135,O
inhibited,7135,O
by,7135,O
concentrations,7135,O
of,7135,O
foscarnet,7135,B-CHEMICAL
eight,7135,O
to,7135,O
14,7135,O
times,7135,O
higher,7135,O
than,7135,O
those,7135,O
required,7135,O
to,7135,O
inhibit,7135,O
wild-type,7135,O
polymerases,7135,B-GENE-N
.,7135,O
Our,7136,O
in-house,7136,O
non-radioactive,7136,O
phenotypic,7136,O
assay,7136,O
was,7136,O
sensitive,7136,O
and,7136,O
reproducible,7136,O
.,7136,O
It,7137,O
is,7137,O
also,7137,O
easy,7137,O
to,7137,O
perform,7137,O
and,7137,O
could,7137,O
provide,7137,O
a,7137,O
convenient,7137,O
method,7137,O
for,7137,O
characterising,7137,O
mutations,7137,O
conferring,7137,O
resistance,7137,O
to,7137,O
foscarnet,7137,B-CHEMICAL
in,7137,O
HCMV,7137,O
.,7137,O
In,7138,O
vitro,7138,O
study,7138,O
of,7138,O
intestinal,7138,O
transport,7138,O
of,7138,O
fluoride,7138,B-CHEMICAL
using,7138,O
the,7138,O
Caco-2,7138,O
cell,7138,O
line,7138,O
.,7138,O
Water,7139,O
and,7139,O
food,7139,O
are,7139,O
the,7139,O
main,7139,O
sources,7139,O
of,7139,O
fluoride,7139,B-CHEMICAL
exposure,7139,O
and,7139,O
therefore,7139,O
it,7139,O
is,7139,O
necessary,7139,O
to,7139,O
study,7139,O
intestinal,7139,O
absorption,7139,O
in,7139,O
order,7139,O
to,7139,O
make,7139,O
a,7139,O
correct,7139,O
evaluation,7139,O
of,7139,O
the,7139,O
risk/benefit,7139,O
associated,7139,O
with,7139,O
exposure,7139,O
to,7139,O
fluoride,7139,B-CHEMICAL
.,7139,O
The,7140,O
present,7140,O
study,7140,O
characterizes,7140,O
intestinal,7140,O
transport,7140,O
of,7140,O
fluoride,7140,B-CHEMICAL
",",7140,O
using,7140,O
the,7140,O
Caco-2,7140,O
cell,7140,O
line,7140,O
as,7140,O
a,7140,O
model,7140,O
of,7140,O
the,7140,O
intestinal,7140,O
epithelium,7140,O
",",7140,O
and,7140,O
evaluates,7140,O
the,7140,O
coefficients,7140,O
of,7140,O
apparent,7140,O
permeability,7140,O
and,7140,O
intracellular,7140,O
accumulation,7140,O
in,7140,O
various,7140,O
conditions,7140,O
(,7140,O
pH,7140,O
",",7140,O
temperature,7140,O
",",7140,O
opening,7140,O
of,7140,O
cell,7140,O
junctions,7140,O
",",7140,O
presence,7140,O
of,7140,O
anions,7140,O
),7140,O
.,7140,O
The,7141,O
results,7141,O
indicate,7141,O
that,7141,O
fluoride,7141,B-CHEMICAL
is,7141,O
an,7141,O
element,7141,O
with,7141,O
moderate,7141,O
absorption,7141,O
(,7141,O
<,7141,O
70,7141,O
%,7141,O
),7141,O
in,7141,O
both,7141,O
directions,7141,O
(,7141,O
absorptive,7141,O
and,7141,O
secretory,7141,O
),7141,O
.,7141,O
Both,7142,O
in,7142,O
absorption,7142,O
(,7142,O
apical-basolateral,7142,O
),7142,O
and,7142,O
in,7142,O
secretion,7142,O
(,7142,O
basolateral-apical,7142,O
),7142,O
there,7142,O
is,7142,O
transport,7142,O
by,7142,O
the,7142,O
paracellular,7142,O
pathway,7142,O
",",7142,O
which,7142,O
may,7142,O
be,7142,O
considered,7142,O
predominant,7142,O
.,7142,O
Absorption,7143,O
and,7143,O
secretion,7143,O
of,7143,O
fluoride,7143,B-CHEMICAL
increase,7143,O
at,7143,O
acid,7143,O
pH,7143,O
levels,7143,O
",",7143,O
possibly,7143,O
because,7143,O
of,7143,O
its,7143,O
non-ionized,7143,O
state,7143,O
at,7143,O
these,7143,O
pHs,7143,O
and/or,7143,O
because,7143,O
of,7143,O
participation,7143,O
of,7143,O
a,7143,O
F,7143,B-GENE-N
(,7143,I-GENE-N
-,7143,I-GENE-N
),7143,I-GENE-N
/H,7143,I-GENE-N
(,7143,I-GENE-N
+,7143,I-GENE-N
),7143,I-GENE-N
cotransporter,7143,I-GENE-N
or,7143,O
a,7143,O
F,7143,B-GENE-N
(,7143,I-GENE-N
-,7143,I-GENE-N
),7143,I-GENE-N
/OH,7143,I-GENE-N
(,7143,I-GENE-N
-,7143,I-GENE-N
),7143,I-GENE-N
antiporter,7143,I-GENE-N
.,7143,O
The,7144,O
results,7144,O
also,7144,O
suggest,7144,O
transcellular,7144,O
participation,7144,O
of,7144,O
mechanisms,7144,O
involved,7144,O
in,7144,O
transport,7144,O
of,7144,O
Cl,7144,B-CHEMICAL
(,7144,I-CHEMICAL
-,7144,I-CHEMICAL
),7144,I-CHEMICAL
and,7144,O
of,7144,O
an,7144,O
active,7144,O
transport,7144,O
in,7144,O
the,7144,O
secretory,7144,O
direction,7144,O
.,7144,O
The,7145,O
present,7145,O
study,7145,O
extend,7145,O
the,7145,O
knowledge,7145,O
on,7145,O
the,7145,O
cellular,7145,O
transport,7145,O
of,7145,O
fluoride,7145,B-CHEMICAL
and,7145,O
provide,7145,O
the,7145,O
basis,7145,O
for,7145,O
future,7145,O
studies,7145,O
aimed,7145,O
at,7145,O
identifying,7145,O
potential,7145,O
transporters,7145,O
involved,7145,O
in,7145,O
human,7145,O
fluoride,7145,B-CHEMICAL
absorption,7145,O
.,7145,O
Structure,7146,O
activity,7146,O
relationship,7146,O
studies,7146,O
of,7146,O
tricyclic,7146,B-CHEMICAL
bispyran,7146,I-CHEMICAL
sulfone,7146,I-CHEMICAL
γ-secretase,7146,B-GENE-N
inhibitors,7146,O
.,7146,O
An,7147,O
investigation,7147,O
is,7147,O
detailed,7147,O
of,7147,O
the,7147,O
structure,7147,O
activity,7147,O
relationships,7147,O
(,7147,O
SAR,7147,O
),7147,O
of,7147,O
two,7147,O
sulfone,7147,B-CHEMICAL
side,7147,O
chains,7147,O
of,7147,O
compound,7147,O
(,7147,O
-,7147,O
),7147,O
-1a,7147,O
(,7147,O
SCH,7147,B-CHEMICAL
900229,7147,I-CHEMICAL
),7147,O
",",7147,O
a,7147,O
potent,7147,O
",",7147,O
PS1-selective,7147,B-GENE-Y
γ-secretase,7147,B-GENE-N
inhibitor,7147,O
and,7147,O
clinical,7147,O
candidate,7147,O
for,7147,O
the,7147,O
treatment,7147,O
of,7147,O
Alzheimer,7147,O
's,7147,O
disease,7147,O
.,7147,O
Specifically,7148,O
",",7148,O
4-CF,7148,B-CHEMICAL
(,7148,I-CHEMICAL
3,7148,I-CHEMICAL
),7148,I-CHEMICAL
and,7148,O
4-Br,7148,B-CHEMICAL
substituted,7148,O
arylsulfone,7148,B-CHEMICAL
analogs,7148,O
",",7148,O
(,7148,O
-,7148,O
),7148,O
-1b,7148,O
and,7148,O
(,7148,O
-,7148,O
),7148,O
-1c,7148,O
",",7148,O
are,7148,O
equipotent,7148,O
to,7148,O
compound,7148,O
(,7148,O
-,7148,O
),7148,O
-1a,7148,O
.,7148,O
On,7149,O
the,7149,O
right,7149,O
hand,7149,O
side,7149,O
chain,7149,O
",",7149,O
linker,7149,O
size,7149,O
and,7149,O
terminal,7149,O
substituents,7149,O
of,7149,O
the,7149,O
pendant,7149,O
sulfone,7149,B-CHEMICAL
group,7149,O
are,7149,O
also,7149,O
investigated,7149,O
.,7149,O
Formation,7150,O
of,7150,O
Mallory,7150,O
body-like,7150,O
inclusions,7150,O
and,7150,O
cell,7150,O
death,7150,O
induced,7150,O
by,7150,O
deregulated,7150,O
expression,7150,O
of,7150,O
keratin,7150,B-GENE-Y
18,7150,I-GENE-Y
.,7150,O
Mallory,7151,O
bodies,7151,O
(,7151,O
MBs,7151,O
),7151,O
are,7151,O
cytoplasmic,7151,O
inclusions,7151,O
that,7151,O
contain,7151,O
keratin,7151,B-GENE-Y
8,7151,I-GENE-Y
(,7151,O
K8,7151,B-GENE-Y
),7151,O
and,7151,O
K18,7151,B-GENE-Y
and,7151,O
are,7151,O
present,7151,O
in,7151,O
hepatocytes,7151,O
of,7151,O
individuals,7151,O
with,7151,O
alcoholic,7151,B-CHEMICAL
liver,7151,O
disease,7151,O
",",7151,O
nonalcoholic,7151,B-CHEMICAL
steatohepatitis,7151,O
",",7151,O
or,7151,O
benign,7151,O
or,7151,O
malignant,7151,O
hepatocellular,7151,O
neoplasia,7151,O
.,7151,O
Mice,7152,O
fed,7152,O
long,7152,O
term,7152,O
with,7152,O
griseofulvin,7152,B-CHEMICAL
are,7152,O
an,7152,O
animal,7152,O
model,7152,O
of,7152,O
MB,7152,O
formation,7152,O
.,7152,O
However,7153,O
",",7153,O
the,7153,O
lack,7153,O
of,7153,O
a,7153,O
cellular,7153,O
model,7153,O
has,7153,O
impeded,7153,O
understanding,7153,O
of,7153,O
the,7153,O
molecular,7153,O
mechanism,7153,O
of,7153,O
this,7153,O
process,7153,O
.,7153,O
Culture,7154,O
of,7154,O
HepG2,7154,O
cells,7154,O
with,7154,O
griseofulvin,7154,B-CHEMICAL
has,7154,O
now,7154,O
been,7154,O
shown,7154,O
to,7154,O
induce,7154,O
both,7154,O
the,7154,O
formation,7154,O
of,7154,O
intracellular,7154,O
aggregates,7154,O
containing,7154,O
K18,7154,B-GENE-Y
as,7154,O
well,7154,O
as,7154,O
an,7154,O
increase,7154,O
in,7154,O
the,7154,O
abundance,7154,O
of,7154,O
K18,7154,B-GENE-Y
mRNA,7154,O
.,7154,O
Overexpression,7155,O
of,7155,O
K18,7155,B-GENE-Y
in,7155,O
HepG2,7155,O
",",7155,O
HeLa,7155,O
",",7155,O
or,7155,O
COS-7,7155,O
cells,7155,O
also,7155,O
induced,7155,O
the,7155,O
formation,7155,O
of,7155,O
intracellular,7155,O
aggregates,7155,O
that,7155,O
stained,7155,O
with,7155,O
antibodies,7155,O
to,7155,O
ubiquitin,7155,B-GENE-N
and,7155,O
with,7155,O
rhodamine,7155,B-CHEMICAL
B,7155,I-CHEMICAL
(,7155,O
characteristics,7155,O
of,7155,O
MBs,7155,O
formed,7155,O
in,7155,O
vivo,7155,O
),7155,O
",",7155,O
eventually,7155,O
leading,7155,O
to,7155,O
cell,7155,O
death,7155,O
.,7155,O
The,7156,O
MB-like,7156,O
aggregates,7156,O
were,7156,O
deposited,7156,O
around,7156,O
centrosomes,7156,O
and,7156,O
disrupted,7156,O
the,7156,O
microtubular,7156,O
array,7156,O
.,7156,O
Coexpression,7157,O
of,7157,O
K8,7157,B-GENE-Y
with,7157,O
K18,7157,B-GENE-Y
restored,7157,O
the,7157,O
normal,7157,O
fibrous,7157,O
pattern,7157,O
of,7157,O
keratin,7157,B-GENE-N
distribution,7157,O
and,7157,O
reduced,7157,O
the,7157,O
toxicity,7157,O
of,7157,O
K18,7157,B-GENE-Y
.,7157,O
In,7158,O
contrast,7158,O
",",7158,O
an,7158,O
NH,7158,B-CHEMICAL
(,7158,I-CHEMICAL
2,7158,I-CHEMICAL
),7158,I-CHEMICAL
-terminal,7158,O
deletion,7158,O
mutant,7158,O
of,7158,O
K8,7158,B-GENE-Y
promoted,7158,O
the,7158,O
formation,7158,O
of,7158,O
intracellular,7158,O
aggregates,7158,O
even,7158,O
in,7158,O
the,7158,O
absence,7158,O
of,7158,O
K18,7158,B-GENE-Y
overexpression,7158,O
.,7158,O
Deregulated,7159,O
expression,7159,O
of,7159,O
K18,7159,B-GENE-Y
",",7159,O
or,7159,O
an,7159,O
imbalance,7159,O
between,7159,O
K8,7159,B-GENE-Y
and,7159,O
K18,7159,B-GENE-Y
",",7159,O
may,7159,O
thus,7159,O
be,7159,O
an,7159,O
important,7159,O
determinant,7159,O
of,7159,O
MB,7159,O
formation,7159,O
",",7159,O
which,7159,O
compromises,7159,O
the,7159,O
function,7159,O
of,7159,O
centrosomes,7159,O
and,7159,O
the,7159,O
microtubule,7159,O
network,7159,O
and,7159,O
leads,7159,O
to,7159,O
cell,7159,O
death,7159,O
.,7159,O
Anti-Ulcerative,7160,O
Colitis,7160,O
Activity,7160,O
of,7160,O
Compounds,7160,O
from,7160,O
Euphorbia,7160,O
granuleta,7160,O
Forssk,7160,O
.,7160,O
The,7161,O
aim,7161,O
of,7161,O
the,7161,O
present,7161,O
study,7161,O
was,7161,O
to,7161,O
evaluate,7161,O
the,7161,O
anti-ulcerative,7161,O
colitis,7161,O
(,7161,O
UC,7161,O
),7161,O
activity,7161,O
of,7161,O
the,7161,O
total,7161,O
alcohol,7161,B-CHEMICAL
extracts,7161,O
of,7161,O
Euphorbia,7161,O
granuleta,7161,O
Forssk,7161,O
.,7161,O
(,7162,O
Euphorpiaceae,7162,O
),7162,O
",",7162,O
isolate,7162,O
and,7162,O
identify,7162,O
the,7162,O
active,7162,O
compounds,7162,O
that,7162,O
could,7162,O
be,7162,O
responsible,7162,O
for,7162,O
the,7162,O
activity,7162,O
",",7162,O
in,7162,O
addition,7162,O
to,7162,O
determination,7162,O
of,7162,O
the,7162,O
possible,7162,O
mechanism,7162,O
of,7162,O
action,7162,O
.,7162,O
Six,7163,O
compounds,7163,O
were,7163,O
isolated,7163,O
and,7163,O
identified,7163,O
from,7163,O
this,7163,O
plant,7163,O
:,7163,O
three,7163,O
phenolic,7163,B-CHEMICAL
compounds,7163,O
(,7163,O
kampferol,7163,B-CHEMICAL
",",7163,O
kampferol-3-glucoside,7163,B-CHEMICAL
and,7163,O
kampferol-3-galactoside,7163,B-CHEMICAL
),7163,O
in,7163,O
addition,7163,O
to,7163,O
three,7163,O
steroidal,7163,O
compounds,7163,O
(,7163,O
1-ethoxypentacosane,7163,B-CHEMICAL
",",7163,O
heptacosan-1-ol,7163,B-CHEMICAL
and,7163,O
β-sitosterol,7163,B-CHEMICAL
),7163,O
.,7163,O
Three,7164,O
compounds,7164,O
(,7164,O
heptacosan-1-ol,7164,B-CHEMICAL
",",7164,O
β-sitosterol,7164,B-CHEMICAL
and,7164,O
kampferol-3-galactoside,7164,B-CHEMICAL
),7164,O
were,7164,O
found,7164,O
to,7164,O
be,7164,O
responsible,7164,O
for,7164,O
the,7164,O
anti-UC,7164,O
activity,7164,O
of,7164,O
E.,7164,O
granuleta,7164,O
extract,7164,O
.,7164,O
The,7165,O
anti-UC,7165,O
activity,7165,O
of,7165,O
these,7165,O
compounds,7165,O
may,7165,O
be,7165,O
explained,7165,O
by,7165,O
reducing,7165,O
the,7165,O
pro-inflammatory,7165,O
cytokine,7165,B-GENE-N
tumor,7165,B-GENE-Y
necrosis,7165,I-GENE-Y
factor-alpha,7165,I-GENE-Y
(,7165,O
TNF-α,7165,B-GENE-Y
),7165,O
",",7165,O
in,7165,O
addition,7165,O
to,7165,O
reduction,7165,O
of,7165,O
colonic,7165,O
malondialdehyde,7165,B-CHEMICAL
(,7165,O
MDA,7165,B-CHEMICAL
),7165,O
contents,7165,O
.,7165,O
No,7166,O
side,7166,O
effects,7166,O
were,7166,O
reported,7166,O
on,7166,O
liver,7166,O
and,7166,O
kidney,7166,O
functions,7166,O
.,7166,O
The,7167,O
active,7167,O
compounds,7167,O
reduced,7167,O
both,7167,O
serum,7167,O
TNF-α,7167,B-GENE-Y
and,7167,O
mucosal,7167,O
MDA,7167,B-CHEMICAL
levels,7167,O
.,7167,O
Copyright,7168,O
©,7168,O
2013,7168,O
John,7168,O
Wiley,7168,O
&,7168,O
Sons,7168,O
",",7168,O
Ltd,7168,O
.,7168,O
MDMA-,7169,B-CHEMICAL
and,7169,O
p-chlorophenylalanine-induced,7169,B-CHEMICAL
reduction,7169,O
in,7169,O
5-HT,7169,B-CHEMICAL
concentrations,7169,O
:,7169,O
effects,7169,O
on,7169,O
serotonin,7169,B-GENE-Y
transporter,7169,I-GENE-Y
densities,7169,O
.,7169,O
Low,7170,O
levels,7170,O
of,7170,O
serotonin,7170,B-CHEMICAL
may,7170,O
reduce,7170,O
the,7170,O
density,7170,O
of,7170,O
the,7170,O
serotonin,7170,B-GENE-Y
transporter,7170,I-GENE-Y
(,7170,O
SERT,7170,B-GENE-Y
),7170,O
by,7170,O
either,7170,O
increasing,7170,O
trafficking,7170,O
or,7170,O
reducing,7170,O
synthesis,7170,O
;,7170,O
a,7170,O
``,7170,O
neuroadaptive,7170,O
response,7170,O
'',7170,O
.,7170,O
To,7171,O
determine,7171,O
whether,7171,O
"3,4-methylenedioxymethamphetamine",7171,B-CHEMICAL
(,7171,O
MDMA,7171,B-CHEMICAL
),7171,O
-induced,7171,O
reductions,7171,O
in,7171,O
SERT,7171,B-GENE-Y
density,7171,O
could,7171,O
be,7171,O
related,7171,O
to,7171,O
such,7171,O
a,7171,O
mechanism,7171,O
",",7171,O
p-chlorophenylalanine,7171,B-CHEMICAL
or,7171,O
MDMA,7171,B-CHEMICAL
was,7171,O
administered,7171,O
to,7171,O
rats,7171,O
",",7171,O
and,7171,O
brain,7171,O
serotonin,7171,B-CHEMICAL
and,7171,O
SERT,7171,B-GENE-Y
density,7171,O
were,7171,O
measured,7171,O
.,7171,O
As,7172,O
expected,7172,O
",",7172,O
both,7172,O
treatments,7172,O
led,7172,O
to,7172,O
serotonin,7172,B-CHEMICAL
depletion,7172,O
1,7172,O
",",7172,O
7,7172,O
and,7172,O
14,7172,O
days,7172,O
later,7172,O
.,7172,O
However,7173,O
",",7173,O
only,7173,O
MDMA,7173,B-CHEMICAL
reduced,7173,O
SERT,7173,B-GENE-Y
density,7173,O
.,7173,O
This,7174,O
observation,7174,O
suggests,7174,O
that,7174,O
MDMA-induced,7174,B-CHEMICAL
reductions,7174,O
in,7174,O
SERT,7174,B-GENE-Y
density,7174,O
do,7174,O
not,7174,O
represent,7174,O
neuroadaptive,7174,O
responses,7174,O
to,7174,O
decreased,7174,O
levels,7174,O
of,7174,O
brain,7174,O
serotonin,7174,B-CHEMICAL
",",7174,O
but,7174,O
may,7174,O
occur,7174,O
in,7174,O
response,7174,O
to,7174,O
some,7174,O
other,7174,O
stimulus,7174,O
or,7174,O
to,7174,O
the,7174,O
neurotoxic,7174,O
effects,7174,O
of,7174,O
MDMA,7174,B-CHEMICAL
.,7174,O
Curcumin,7175,B-CHEMICAL
improves,7175,O
TNBS-induced,7175,O
colitis,7175,O
in,7175,O
rats,7175,O
by,7175,O
inhibiting,7175,O
IL-27,7175,B-GENE-Y
expression,7175,O
via,7175,O
the,7175,O
TLR4/NF-κB,7175,B-GENE-Y
signaling,7175,O
pathway,7175,O
.,7175,O
Curcumin,7176,B-CHEMICAL
is,7176,O
a,7176,O
widely,7176,O
used,7176,O
spice,7176,O
with,7176,O
anti-inflammatory,7176,O
and,7176,O
anticancer,7176,O
properties,7176,O
.,7176,O
It,7177,O
has,7177,O
been,7177,O
reported,7177,O
to,7177,O
have,7177,O
beneficial,7177,O
effects,7177,O
in,7177,O
experimental,7177,O
colitis,7177,O
.,7177,O
This,7178,O
study,7178,O
explored,7178,O
whether,7178,O
curcumin,7178,B-CHEMICAL
improves,7178,O
colonic,7178,O
inflammation,7178,O
in,7178,O
a,7178,O
rat,7178,O
colitis,7178,O
model,7178,O
through,7178,O
inhibition,7178,O
of,7178,O
the,7178,O
TLR4/NF-κB,7178,B-GENE-Y
signaling,7178,O
pathway,7178,O
and,7178,O
IL-27,7178,B-GENE-Y
expression,7178,O
.,7178,O
After,7179,O
induction,7179,O
of,7179,O
colitis,7179,O
with,7179,O
"2,4,6-trinitrobenzene",7179,B-CHEMICAL
sulfonic,7179,I-CHEMICAL
acid,7179,I-CHEMICAL
",",7179,O
rats,7179,O
were,7179,O
intragastrically,7179,O
administered,7179,O
with,7179,O
curcumin,7179,B-CHEMICAL
or,7179,O
sulfasalazine,7179,B-CHEMICAL
daily,7179,O
for,7179,O
one,7179,O
week,7179,O
.,7179,O
Rat,7180,O
intestinal,7180,O
mucosa,7180,O
was,7180,O
collected,7180,O
for,7180,O
evaluation,7180,O
of,7180,O
the,7180,O
disease,7180,O
activity,7180,O
index,7180,O
",",7180,O
colonic,7180,O
mucosa,7180,O
damage,7180,O
index,7180,O
",",7180,O
and,7180,O
histological,7180,O
score,7180,O
.,7180,O
Myeloperoxidase,7181,B-GENE-Y
activity,7181,O
was,7181,O
detected,7181,O
by,7181,O
immunohistochemistry,7181,O
",",7181,O
and,7181,O
mRNA,7181,O
and,7181,O
protein,7181,O
expression,7181,O
levels,7181,O
of,7181,O
TLR4,7181,B-GENE-Y
",",7181,O
NF-κB,7181,B-GENE-N
",",7181,O
and,7181,O
IL-27,7181,B-GENE-Y
in,7181,O
colonic,7181,O
mucosa,7181,O
were,7181,O
detected,7181,O
by,7181,O
RT-PCR,7181,O
and,7181,O
Western,7181,O
blot,7181,O
.,7181,O
Compared,7182,O
with,7182,O
the,7182,O
untreated,7182,O
colitis,7182,O
group,7182,O
",",7182,O
the,7182,O
curcumin-treated,7182,B-CHEMICAL
group,7182,O
showed,7182,O
significant,7182,O
decreases,7182,O
in,7182,O
the,7182,O
disease,7182,O
activity,7182,O
index,7182,O
",",7182,O
colonic,7182,O
mucosa,7182,O
damage,7182,O
index,7182,O
",",7182,O
histological,7182,O
score,7182,O
",",7182,O
myeloperoxidase,7182,B-GENE-Y
activity,7182,O
",",7182,O
and,7182,O
expressions,7182,O
of,7182,O
NF-κB,7182,B-GENE-N
mRNA,7182,O
",",7182,O
IL-27,7182,B-GENE-Y
mRNA,7182,O
",",7182,O
TLR4,7182,B-GENE-Y
protein,7182,O
",",7182,O
NF-κB,7182,B-GENE-N
p65,7182,B-GENE-Y
protein,7182,O
",",7182,O
and,7182,O
IL-27,7182,B-GENE-Y
p28,7182,B-GENE-Y
protein,7182,O
(,7182,O
p,7182,O
<,7182,O
0.05,7182,O
),7182,O
.,7182,O
TLR4,7183,B-GENE-Y
mRNA,7183,O
expression,7183,O
did,7183,O
not,7183,O
differ,7183,O
between,7183,O
groups,7183,O
.,7183,O
Disease,7184,O
activity,7184,O
index,7184,O
decreased,7184,O
more,7184,O
rapidly,7184,O
in,7184,O
the,7184,O
curcumin-treated,7184,B-CHEMICAL
group,7184,O
than,7184,O
in,7184,O
the,7184,O
sulfasalazine-treated,7184,B-CHEMICAL
group,7184,O
(,7184,O
p,7184,O
<,7184,O
0.05,7184,O
),7184,O
.,7184,O
There,7185,O
was,7185,O
no,7185,O
significant,7185,O
difference,7185,O
in,7185,O
TLR4,7185,B-GENE-Y
",",7185,O
NF-κB,7185,B-GENE-N
",",7185,O
and,7185,O
IL-27,7185,B-GENE-Y
mRNA,7185,O
and,7185,O
proteins,7185,O
between,7185,O
curcumin-treated,7185,B-CHEMICAL
and,7185,O
sulfasalazine-treated,7185,B-CHEMICAL
groups,7185,O
.,7185,O
Curcumin,7186,B-CHEMICAL
shows,7186,O
significant,7186,O
therapeutic,7186,O
effects,7186,O
on,7186,O
"2,4,6-trinitrobenzene",7186,B-CHEMICAL
sulfonic,7186,I-CHEMICAL
acid-induced,7186,O
colitis,7186,O
that,7186,O
are,7186,O
comparable,7186,O
to,7186,O
sulfasalazine,7186,B-CHEMICAL
.,7186,O
The,7187,O
anti-inflammatory,7187,O
actions,7187,O
of,7187,O
curcumin,7187,B-CHEMICAL
on,7187,O
colitis,7187,O
may,7187,O
involve,7187,O
inhibition,7187,O
of,7187,O
the,7187,O
TLR4/NF-κB,7187,B-GENE-Y
signaling,7187,O
pathway,7187,O
and,7187,O
of,7187,O
IL-27,7187,B-GENE-Y
expression,7187,O
.,7187,O
Bovine,7188,B-GENE-N
and,7188,I-GENE-N
ovine,7188,I-GENE-N
gonadotropin-releasing,7188,I-GENE-N
hormone,7188,I-GENE-N
(,7188,I-GENE-N
GnRH,7188,I-GENE-N
),7188,I-GENE-N
-II,7188,I-GENE-N
ligand,7188,O
precursors,7188,O
and,7188,O
type,7188,B-GENE-N
II,7188,I-GENE-N
GnRH,7188,I-GENE-N
receptor,7188,I-GENE-N
genes,7188,O
are,7188,O
functionally,7188,O
inactivated,7188,O
.,7188,O
The,7189,O
decapeptide,7189,O
sequence,7189,O
of,7189,O
GnRH-II,7189,B-GENE-N
is,7189,O
conserved,7189,O
in,7189,O
all,7189,O
jawed,7189,O
vertebrate,7189,O
species,7189,O
studied,7189,O
to,7189,O
date,7189,O
.,7189,O
New,7190,O
data,7190,O
for,7190,O
cattle,7190,O
(,7190,O
Bos,7190,O
taurus,7190,O
),7190,O
indicates,7190,O
a,7190,O
gene,7190,O
encoding,7190,O
GnRH-II,7190,B-GENE-Y
decapeptide,7190,O
possessing,7190,O
arginine,7190,B-CHEMICAL
(,7190,O
codon,7190,O
:,7190,O
CGG,7190,B-CHEMICAL
),7190,O
rather,7190,O
than,7190,O
tryptophan,7190,B-CHEMICAL
(,7190,O
TGG,7190,B-CHEMICAL
),7190,O
at,7190,O
position,7190,O
three,7190,O
in,7190,O
the,7190,O
mature,7190,O
peptide,7190,O
.,7190,O
This,7191,O
substitution,7191,O
is,7191,O
unique,7191,O
.,7191,O
We,7192,O
confirmed,7192,O
the,7192,O
DNA,7192,O
sequence,7192,O
after,7192,O
cloning,7192,O
part,7192,O
of,7192,O
the,7192,O
bovine,7192,B-GENE-Y
prepro-GnRH-II,7192,I-GENE-Y
gene,7192,O
.,7192,O
Bovine,7193,B-GENE-Y
GnRH-II,7193,I-GENE-Y
peptide,7193,O
was,7193,O
synthesized,7193,O
and,7193,O
pharmacologically,7193,O
characterized,7193,O
.,7193,O
It,7194,O
did,7194,O
not,7194,O
bind,7194,O
to,7194,O
mammalian,7194,O
GnRH,7194,B-GENE-N
receptors,7194,I-GENE-N
expressed,7194,O
in,7194,O
different,7194,O
types,7194,O
of,7194,O
cell,7194,O
nor,7194,O
did,7194,O
it,7194,O
exhibit,7194,O
agonist,7194,O
or,7194,O
antagonist,7194,O
properties,7194,O
on,7194,O
types,7194,B-GENE-N
I,7194,I-GENE-N
or,7194,I-GENE-N
II,7194,I-GENE-N
GnRH,7194,I-GENE-N
receptors,7194,I-GENE-N
expressed,7194,O
in,7194,O
COS-7,7194,O
cells,7194,O
.,7194,O
Bovine,7195,O
primers,7195,O
facilitated,7195,O
cloning,7195,O
of,7195,O
ovine,7195,B-GENE-Y
GnRH-II,7195,I-GENE-Y
DNA,7195,O
.,7195,O
A,7196,O
premature,7196,O
stop,7196,O
codon,7196,O
(,7196,O
TGA,7196,O
),7196,O
replaces,7196,O
the,7196,O
expected,7196,O
tryptophan,7196,B-CHEMICAL
codon,7196,O
at,7196,O
position,7196,O
seven,7196,O
of,7196,O
GnRH-II,7196,B-GENE-Y
in,7196,O
sheep,7196,O
DNA,7196,O
.,7196,O
Thus,7197,O
",",7197,O
both,7197,O
species,7197,O
possess,7197,O
prepro-GnRH-II,7197,B-GENE-N
genes,7197,O
encoding,7197,O
inactive,7197,O
peptides,7197,O
",",7197,O
as,7197,O
previously,7197,O
described,7197,O
for,7197,O
chimpanzee,7197,B-GENE-Y
GnRH-II,7197,I-GENE-Y
.,7197,O
The,7198,O
updated,7198,O
bovine,7198,B-GENE-Y
type,7198,I-GENE-Y
II,7198,I-GENE-Y
GnRH,7198,I-GENE-Y
receptor,7198,I-GENE-Y
gene,7198,O
sequence,7198,O
revealed,7198,O
inactivation,7198,O
by,7198,O
frame,7198,O
shifts,7198,O
",",7198,O
premature,7198,O
stop,7198,O
codons,7198,O
",",7198,O
and,7198,O
nucleotide,7198,B-CHEMICAL
changes,7198,O
specifying,7198,O
nonconservative,7198,O
replacement,7198,O
of,7198,O
amino,7198,B-CHEMICAL
acid,7198,I-CHEMICAL
residues,7198,O
",",7198,O
similar,7198,O
to,7198,O
inactivation,7198,O
of,7198,O
sheep,7198,B-GENE-Y
type,7198,I-GENE-Y
II,7198,I-GENE-Y
GnRH,7198,I-GENE-Y
receptor,7198,I-GENE-Y
.,7198,O
Spliced,7199,O
RNA,7199,O
transcripts,7199,O
from,7199,O
the,7199,O
disrupted,7199,O
receptor,7199,O
gene,7199,O
were,7199,O
not,7199,O
detected,7199,O
in,7199,O
bovine,7199,O
pituitary,7199,O
.,7199,O
In,7200,O
contrast,7200,O
",",7200,O
bovine,7200,B-GENE-Y
prepro-GnRH-I,7200,I-GENE-Y
and,7200,O
type,7200,B-GENE-Y
I,7200,I-GENE-Y
GnRH,7200,I-GENE-Y
receptor,7200,I-GENE-Y
genes,7200,O
are,7200,O
intact,7200,O
",",7200,O
encoding,7200,O
well-conserved,7200,O
protein,7200,O
sequences,7200,O
.,7200,O
These,7201,O
findings,7201,O
",",7201,O
and,7201,O
previous,7201,O
descriptions,7201,O
of,7201,O
inactivation,7201,O
of,7201,O
the,7201,O
human,7201,B-GENE-Y
type,7201,I-GENE-Y
II,7201,I-GENE-Y
GnRH,7201,I-GENE-Y
receptor,7201,I-GENE-Y
and,7201,O
deletions,7201,O
of,7201,O
prepro-GnRH-II,7201,B-GENE-N
and,7201,O
type,7201,B-GENE-N
II,7201,I-GENE-N
GnRH,7201,I-GENE-N
receptor,7201,I-GENE-N
in,7201,O
laboratory,7201,O
rodents,7201,O
",",7201,O
suggest,7201,O
the,7201,O
GnRH-II,7201,B-GENE-N
system,7201,O
has,7201,O
been,7201,O
replaced,7201,O
by,7201,O
the,7201,O
GnRH-I,7201,B-GENE-N
system,7201,O
or,7201,O
is,7201,O
redundant,7201,O
in,7201,O
certain,7201,O
mammals,7201,O
.,7201,O
Biosynthetic,7202,O
regulation,7202,O
and,7202,O
intracellular,7202,O
transport,7202,O
of,7202,O
phosphatidylserine,7202,B-CHEMICAL
in,7202,O
mammalian,7202,O
cells,7202,O
.,7202,O
In,7203,O
mammalian,7203,O
cells,7203,O
",",7203,O
phosphatidylserine,7203,B-CHEMICAL
(,7203,O
PtdSer,7203,B-CHEMICAL
),7203,O
is,7203,O
synthesized,7203,O
through,7203,O
the,7203,O
action,7203,O
of,7203,O
the,7203,O
endoplasmic,7203,O
reticulum,7203,O
enzymes,7203,O
",",7203,O
PtdSer,7203,B-GENE-N
synthase,7203,I-GENE-N
1,7203,I-GENE-N
and,7203,I-GENE-N
2,7203,I-GENE-N
",",7203,O
and,7203,O
the,7203,O
decarboxylation,7203,O
of,7203,O
PtdSer,7203,O
accounts,7203,O
for,7203,O
the,7203,O
majority,7203,O
of,7203,O
phosphatidylethanolamine,7203,B-CHEMICAL
(,7203,O
PtdEtn,7203,B-CHEMICAL
),7203,O
synthesis,7203,O
.,7203,O
PtdSer,7204,B-CHEMICAL
decarboxylation,7204,O
for,7204,O
PtdEtn,7204,B-CHEMICAL
formation,7204,O
occurs,7204,O
in,7204,O
the,7204,O
mitochondria,7204,O
.,7204,O
In,7205,O
addition,7205,O
",",7205,O
the,7205,O
transport,7205,O
of,7205,O
PtdSer,7205,B-CHEMICAL
from,7205,O
the,7205,O
endoplasmic,7205,O
reticulum,7205,O
to,7205,O
the,7205,O
mitochondria,7205,O
is,7205,O
probably,7205,O
a,7205,O
rate,7205,O
limiting,7205,O
step,7205,O
for,7205,O
PtdEtn,7205,B-CHEMICAL
synthesis,7205,O
through,7205,O
the,7205,O
decarboxylation,7205,O
pathway,7205,O
.,7205,O
Therefore,7206,O
",",7206,O
the,7206,O
regulation,7206,O
of,7206,O
PtdSer,7206,B-CHEMICAL
synthesis,7206,O
and,7206,O
its,7206,O
intracellular,7206,O
transport,7206,O
appear,7206,O
to,7206,O
be,7206,O
essential,7206,O
events,7206,O
for,7206,O
the,7206,O
maintenance,7206,O
of,7206,O
normal,7206,O
cellular,7206,O
PtdSer,7206,B-CHEMICAL
and,7206,O
PtdEtn,7206,B-CHEMICAL
levels,7206,O
.,7206,O
Here,7207,O
we,7207,O
describe,7207,O
the,7207,O
current,7207,O
understanding,7207,O
of,7207,O
the,7207,O
regulation,7207,O
of,7207,O
PtdSer,7207,B-CHEMICAL
biosynthesis,7207,O
and,7207,O
the,7207,O
transport,7207,O
of,7207,O
PtdSer,7207,B-CHEMICAL
from,7207,O
the,7207,O
ER,7207,O
to,7207,O
the,7207,O
mitochondria,7207,O
in,7207,O
mammalian,7207,O
cells,7207,O
.,7207,O
Use,7208,O
of,7208,O
nitisinone,7208,B-CHEMICAL
in,7208,O
patients,7208,O
with,7208,O
alkaptonuria,7208,O
.,7208,O
Alkaptonuria,7209,O
",",7209,O
a,7209,O
rare,7209,O
autosomal,7209,O
recessive,7209,O
disorder,7209,O
caused,7209,O
by,7209,O
mutations,7209,O
in,7209,O
the,7209,O
HGD,7209,B-GENE-Y
gene,7209,O
and,7209,O
deficiency,7209,O
of,7209,O
homogentisate,7209,B-GENE-Y
"1,2",7209,I-GENE-Y
dioxygenase,7209,I-GENE-Y
",",7209,O
is,7209,O
characterized,7209,O
by,7209,O
ochronosis,7209,O
",",7209,O
arthritis,7209,O
",",7209,O
and,7209,O
daily,7209,O
excretion,7209,O
of,7209,O
gram,7209,O
quantities,7209,O
of,7209,O
homogentisic,7209,B-CHEMICAL
acid,7209,I-CHEMICAL
(,7209,O
HGA,7209,B-CHEMICAL
),7209,O
.,7209,O
Nitisinone,7210,O
",",7210,O
an,7210,O
inhibitor,7210,O
of,7210,O
the,7210,O
enzyme,7210,O
4-hydroxyphenylpyruvate,7210,B-GENE-Y
dioxygenase,7210,I-GENE-Y
",",7210,O
can,7210,O
drastically,7210,O
reduce,7210,O
urinary,7210,O
excretion,7210,O
of,7210,O
HGA,7210,B-CHEMICAL
in,7210,O
individuals,7210,O
with,7210,O
alkaptonuria,7210,O
.,7210,O
We,7211,O
investigated,7211,O
the,7211,O
safety,7211,O
and,7211,O
the,7211,O
HGA-depleting,7211,B-CHEMICAL
efficacy,7211,O
of,7211,O
nitisinone,7211,B-CHEMICAL
in,7211,O
an,7211,O
open-label,7211,O
",",7211,O
single-center,7211,O
study,7211,O
of,7211,O
9,7211,O
alkaptonuria,7211,O
patients,7211,O
(,7211,O
5,7211,O
women,7211,O
",",7211,O
4,7211,O
men,7211,O
;,7211,O
35-69,7211,O
years,7211,O
of,7211,O
age,7211,O
),7211,O
over,7211,O
the,7211,O
course,7211,O
of,7211,O
3,7211,O
to,7211,O
4,7211,O
months,7211,O
.,7211,O
Each,7212,O
patient,7212,O
received,7212,O
nitisinone,7212,B-CHEMICAL
in,7212,O
incremental,7212,O
doses,7212,O
",",7212,O
0.35,7212,O
mg,7212,O
bid,7212,O
followed,7212,O
by,7212,O
1.05,7212,O
mg,7212,O
bid,7212,O
",",7212,O
and,7212,O
remained,7212,O
on,7212,O
this,7212,O
dosage,7212,O
and,7212,O
a,7212,O
regular,7212,O
diet,7212,O
for,7212,O
3,7212,O
months,7212,O
.,7212,O
Nitisinone,7213,B-CHEMICAL
reduced,7213,O
urinary,7213,O
HGA,7213,B-CHEMICAL
levels,7213,O
from,7213,O
an,7213,O
average,7213,O
of,7213,O
4.0,7213,O
+/-,7213,O
1.8,7213,O
(,7213,O
SD,7213,O
),7213,O
g/day,7213,O
to,7213,O
0.2,7213,O
+/-,7213,O
0.2,7213,O
g/day,7213,O
(,7213,O
P,7213,O
<,7213,O
.001,7213,O
),7213,O
.,7213,O
The,7214,O
average,7214,O
plasma,7214,O
tyrosine,7214,B-CHEMICAL
concentration,7214,O
",",7214,O
initially,7214,O
68,7214,O
+/-,7214,O
18,7214,O
mmicro,7214,O
mol/L,7214,O
",",7214,O
rose,7214,O
to,7214,O
760,7214,O
+/-,7214,O
181,7214,O
micro,7214,O
mol/L,7214,O
(,7214,O
P,7214,O
<,7214,O
.001,7214,O
),7214,O
.,7214,O
During,7215,O
the,7215,O
final,7215,O
week,7215,O
of,7215,O
the,7215,O
study,7215,O
",",7215,O
5,7215,O
patients,7215,O
adhered,7215,O
to,7215,O
a,7215,O
protein-restricted,7215,O
diet,7215,O
(,7215,O
40,7215,O
g/day,7215,O
),7215,O
",",7215,O
and,7215,O
their,7215,O
mean,7215,O
plasma,7215,O
tyrosine,7215,B-CHEMICAL
level,7215,O
fell,7215,O
from,7215,O
755,7215,O
+/-,7215,O
167,7215,O
to,7215,O
603,7215,O
+/-,7215,O
114,7215,O
mu,7215,O
mol/L,7215,O
.,7215,O
Six,7216,O
of,7216,O
the,7216,O
7,7216,O
patients,7216,O
who,7216,O
received,7216,O
nitisinone,7216,B-CHEMICAL
for,7216,O
more,7216,O
than,7216,O
1,7216,O
week,7216,O
reported,7216,O
decreased,7216,O
pain,7216,O
in,7216,O
their,7216,O
affected,7216,O
joints,7216,O
.,7216,O
Weekly,7217,O
ophthalmologic,7217,O
examinations,7217,O
showed,7217,O
no,7217,O
signs,7217,O
of,7217,O
corneal,7217,O
toxicity,7217,O
.,7217,O
Adverse,7218,O
events,7218,O
included,7218,O
the,7218,O
passing,7218,O
of,7218,O
kidney,7218,O
stones,7218,O
",",7218,O
the,7218,O
recognition,7218,O
of,7218,O
symptoms,7218,O
related,7218,O
to,7218,O
aortic,7218,O
stenosis,7218,O
",",7218,O
and,7218,O
elevation,7218,O
of,7218,O
liver,7218,O
transaminase,7218,B-GENE-N
levels,7218,O
.,7218,O
We,7219,O
conclude,7219,O
that,7219,O
low-dose,7219,O
nitisinone,7219,B-CHEMICAL
effectively,7219,O
reduced,7219,O
urinary,7219,O
HGA,7219,B-CHEMICAL
levels,7219,O
in,7219,O
patients,7219,O
with,7219,O
alkaptonuria,7219,O
.,7219,O
Future,7220,O
long-term,7220,O
clinical,7220,O
trials,7220,O
are,7220,O
planned,7220,O
to,7220,O
determine,7220,O
the,7220,O
benefits,7220,O
of,7220,O
nitisinone,7220,B-CHEMICAL
in,7220,O
preventing,7220,O
joint,7220,O
deterioration,7220,O
and,7220,O
providing,7220,O
pain,7220,O
relief,7220,O
",",7220,O
and,7220,O
its,7220,O
long-term,7220,O
side,7220,O
effects,7220,O
.,7220,O
Functional,7221,O
and,7221,O
molecular,7221,O
characterization,7221,O
of,7221,O
multiple,7221,O
K-Cl,7221,B-GENE-N
cotransporter,7221,I-GENE-N
isoforms,7221,O
in,7221,O
corneal,7221,O
epithelial,7221,O
cells,7221,O
.,7221,O
The,7222,O
dependence,7222,O
of,7222,O
regulatory,7222,O
volume,7222,O
decrease,7222,O
(,7222,O
RVD,7222,O
),7222,O
activity,7222,O
on,7222,O
potassium-chloride,7222,B-GENE-N
cotransporter,7222,I-GENE-N
(,7222,O
KCC,7222,B-GENE-N
),7222,O
isoform,7222,O
expression,7222,O
was,7222,O
characterized,7222,O
in,7222,O
corneal,7222,O
epithelial,7222,O
cells,7222,O
(,7222,O
CEC,7222,O
),7222,O
.,7222,O
During,7223,O
exposure,7223,O
to,7223,O
a,7223,O
50,7223,O
%,7223,O
hypotonic,7223,O
challenge,7223,O
",",7223,O
the,7223,O
RVD,7223,O
response,7223,O
was,7223,O
larger,7223,O
in,7223,O
SV40-immortalized,7223,O
human,7223,O
CEC,7223,O
(,7223,O
HCEC,7223,O
),7223,O
than,7223,O
in,7223,O
SV40-immortalized,7223,O
rabbit,7223,O
CEC,7223,O
(,7223,O
RCEC,7223,O
),7223,O
.,7223,O
A,7224,O
KCC,7224,B-GENE-N
inhibitor-,7224,O
[,7224,B-CHEMICAL
(,7224,I-CHEMICAL
dihydroindenyl,7224,I-CHEMICAL
),7224,I-CHEMICAL
oxy,7224,I-CHEMICAL
],7224,I-CHEMICAL
alkanoic,7224,I-CHEMICAL
acid,7224,I-CHEMICAL
(,7224,O
DIOA,7224,B-CHEMICAL
),7224,O
-blocked,7224,O
RVD,7224,O
more,7224,O
in,7224,O
HCEC,7224,O
than,7224,O
RCEC,7224,O
.,7224,O
Under,7225,O
isotonic,7225,O
conditions,7225,O
",",7225,O
N-ethylmaleimide,7225,B-CHEMICAL
(,7225,O
NEM,7225,B-CHEMICAL
),7225,O
produced,7225,O
KCC,7225,B-GENE-N
activation,7225,O
and,7225,O
transient,7225,O
cell,7225,O
shrinkage,7225,O
.,7225,O
Both,7226,O
of,7226,O
these,7226,O
changes,7226,O
were,7226,O
greater,7226,O
in,7226,O
HCEC,7226,O
than,7226,O
in,7226,O
RCEC,7226,O
.,7226,O
Immunoblot,7227,O
analysis,7227,O
of,7227,O
HCEC,7227,O
",",7227,O
RCEC,7227,O
",",7227,O
primary,7227,O
human,7227,O
CEC,7227,O
(,7227,O
pHCEC,7227,O
),7227,O
",",7227,O
and,7227,O
primary,7227,O
bovine,7227,O
CEC,7227,O
(,7227,O
BCEC,7227,O
),7227,O
plasma,7227,O
membrane,7227,O
enriched,7227,O
fractions,7227,O
revealed,7227,O
KCC1,7227,B-GENE-N
",",7227,O
KCC3,7227,B-GENE-N
",",7227,O
and,7227,O
KCC4,7227,B-GENE-N
isoform,7227,O
expression,7227,O
",",7227,O
whereas,7227,O
KCC2,7227,B-GENE-N
was,7227,O
undetectable,7227,O
.,7227,O
During,7228,O
a,7228,O
hypotonic,7228,O
challenge,7228,O
",",7228,O
KCC1,7228,B-GENE-N
membrane,7228,O
content,7228,O
increased,7228,O
more,7228,O
rapidly,7228,O
in,7228,O
HCEC,7228,O
than,7228,O
in,7228,O
RCEC,7228,O
.,7228,O
Such,7229,O
a,7229,O
challenge,7229,O
induced,7229,O
a,7229,O
larger,7229,O
increase,7229,O
and,7229,O
more,7229,O
transient,7229,O
p44/42MAPK,7229,B-GENE-N
activation,7229,O
in,7229,O
HCEC,7229,O
than,7229,O
RCEC,7229,O
.,7229,O
On,7230,O
the,7230,O
other,7230,O
hand,7230,O
",",7230,O
HCEC,7230,O
and,7230,O
RCEC,7230,O
p38MAPK,7230,B-GENE-N
phosphorylation,7230,O
reached,7230,O
peak,7230,O
activations,7230,O
at,7230,O
2.5,7230,O
and,7230,O
15,7230,O
min,7230,O
",",7230,O
respectively,7230,O
.,7230,O
Only,7231,O
in,7231,O
HCEC,7231,O
",",7231,O
pharmacological,7231,O
manipulation,7231,O
of,7231,O
KCC,7231,B-GENE-N
activity,7231,O
modified,7231,O
the,7231,O
hypotonicity-induced,7231,O
activation,7231,O
of,7231,O
p44/42MAPK,7231,B-GENE-N
",",7231,O
whereas,7231,O
p38MAPK,7231,B-GENE-N
phosphorylation,7231,O
was,7231,O
insensitive,7231,O
to,7231,O
such,7231,O
procedures,7231,O
in,7231,O
both,7231,O
cell,7231,O
lines,7231,O
.,7231,O
Larger,7232,O
increases,7232,O
in,7232,O
HCEC,7232,O
KCC1,7232,B-GENE-Y
membrane,7232,O
protein,7232,O
content,7232,O
correlated,7232,O
with,7232,O
their,7232,O
ability,7232,O
to,7232,O
undergo,7232,O
faster,7232,O
and,7232,O
more,7232,O
complete,7232,O
RVD,7232,O
.,7232,O
Furthermore,7233,O
",",7233,O
pharmacological,7233,O
activation,7233,O
of,7233,O
KCC,7233,B-GENE-N
increased,7233,O
p44/42MAPK,7233,B-GENE-N
phosphorylation,7233,O
in,7233,O
HCEC,7233,O
but,7233,O
not,7233,O
in,7233,O
RCEC,7233,O
",",7233,O
presumably,7233,O
a,7233,O
reflection,7233,O
of,7233,O
low,7233,O
KCC1,7233,B-GENE-Y
membrane,7233,O
expression,7233,O
in,7233,O
RCEC,7233,O
.,7233,O
These,7234,O
findings,7234,O
suggest,7234,O
that,7234,O
KCC1,7234,B-GENE-N
plays,7234,O
a,7234,O
role,7234,O
in,7234,O
(,7234,O
i,7234,O
),7234,O
maintaining,7234,O
isotonic,7234,O
steady-state,7234,O
cell,7234,O
volume,7234,O
homeostasis,7234,O
",",7234,O
(,7234,O
ii,7234,O
),7234,O
recovery,7234,O
of,7234,O
isotonic,7234,O
cell,7234,O
volume,7234,O
after,7234,O
a,7234,O
hypotonic,7234,O
challenge,7234,O
through,7234,O
RVD,7234,O
",",7234,O
and,7234,O
(,7234,O
iii,7234,O
),7234,O
regulating,7234,O
hypotonicity-induced,7234,O
activation,7234,O
of,7234,O
the,7234,O
p44/42MAPK,7234,B-GENE-N
signaling,7234,O
pathway,7234,O
required,7234,O
for,7234,O
cell,7234,O
proliferation,7234,O
.,7234,O
Changes,7235,O
in,7235,O
morphometry,7235,O
and,7235,O
association,7235,O
between,7235,O
whole-body,7235,O
fatty,7235,B-CHEMICAL
acids,7235,I-CHEMICAL
and,7235,O
steroid,7235,B-CHEMICAL
hormone,7235,O
profiles,7235,O
in,7235,O
relation,7235,O
to,7235,O
bioaccumulation,7235,O
patterns,7235,O
in,7235,O
salmon,7235,O
larvae,7235,O
exposed,7235,O
to,7235,O
perfluorooctane,7235,B-CHEMICAL
sulfonic,7235,I-CHEMICAL
or,7235,I-CHEMICAL
perfluorooctane,7235,I-CHEMICAL
carboxylic,7235,I-CHEMICAL
acids,7235,I-CHEMICAL
.,7235,O
In,7236,O
the,7236,O
present,7236,O
study,7236,O
",",7236,O
we,7236,O
have,7236,O
used,7236,O
salmon,7236,O
embryos,7236,O
whose,7236,O
continuous,7236,O
exposure,7236,O
to,7236,O
waterborne,7236,O
PFOA,7236,B-CHEMICAL
or,7236,O
PFOS,7236,B-CHEMICAL
at,7236,O
100,7236,O
μg/L,7236,O
started,7236,O
as,7236,O
freshly,7236,O
fertilized,7236,O
eggs,7236,O
",",7236,O
and,7236,O
lasted,7236,O
for,7236,O
a,7236,O
total,7236,O
of,7236,O
52,7236,O
days,7236,O
.,7236,O
PFOS,7237,B-CHEMICAL
and,7237,O
PFOA,7237,B-CHEMICAL
were,7237,O
dissolved,7237,O
in,7237,O
methanol,7237,B-CHEMICAL
(,7237,O
carrier,7237,O
vehicle,7237,O
),7237,O
whose,7237,O
concentration,7237,O
never,7237,O
exceeded,7237,O
0.01,7237,O
%,7237,O
of,7237,O
total,7237,O
tank,7237,O
volume,7237,O
.,7237,O
Samples,7238,O
were,7238,O
collected,7238,O
at,7238,O
day,7238,O
21,7238,O
",",7238,O
28,7238,O
",",7238,O
35,7238,O
",",7238,O
52,7238,O
",",7238,O
49,7238,O
and,7238,O
56,7238,O
after,7238,O
the,7238,O
start,7238,O
of,7238,O
the,7238,O
exposure,7238,O
.,7238,O
Note,7239,O
that,7239,O
days,7239,O
49,7239,O
and,7239,O
56,7239,O
represent,7239,O
end,7239,O
of,7239,O
exposure,7239,O
and,7239,O
1,7239,O
week,7239,O
after,7239,O
a,7239,O
recovery,7239,O
period,7239,O
",",7239,O
respectively,7239,O
.,7239,O
Tissue,7240,O
bioaccumulations,7240,O
were,7240,O
determined,7240,O
by,7240,O
HPLC/MS/MS,7240,O
",",7240,O
steroid,7240,B-CHEMICAL
hormones,7240,O
",",7240,O
fatty,7240,B-CHEMICAL
acids,7240,I-CHEMICAL
(,7240,O
FAs,7240,B-CHEMICAL
),7240,O
and,7240,O
lipids,7240,O
were,7240,O
determined,7240,O
by,7240,O
GC-MS,7240,O
",",7240,O
while,7240,O
mRNA,7240,O
expression,7240,O
levels,7240,O
of,7240,O
genes,7240,O
were,7240,O
determined,7240,O
by,7240,O
qPCR,7240,O
in,7240,O
whole,7240,O
body,7240,O
homogenate,7240,O
.,7240,O
We,7241,O
observed,7241,O
that,7241,O
PFOS,7241,B-CHEMICAL
and,7241,O
PFOA,7241,B-CHEMICAL
showed,7241,O
a,7241,O
steady,7241,O
increase,7241,O
in,7241,O
whole,7241,O
body,7241,O
burden,7241,O
during,7241,O
the,7241,O
exposure,7241,O
period,7241,O
",",7241,O
with,7241,O
a,7241,O
slight,7241,O
decrease,7241,O
after,7241,O
the,7241,O
recovery,7241,O
period,7241,O
.,7241,O
Calculated,7242,O
somatic,7242,O
indexes,7242,O
showed,7242,O
that,7242,O
PFOA,7242,B-CHEMICAL
produced,7242,O
increases,7242,O
in,7242,O
heart-,7242,O
",",7242,O
thymus-,7242,O
",",7242,O
liver-,7242,O
and,7242,O
kidney,7242,O
somatic,7242,O
indexes,7242,O
(,7242,O
HSI,7242,O
",",7242,O
TSI,7242,O
",",7242,O
LSI,7242,O
and,7242,O
KSI,7242,O
),7242,O
.,7242,O
PFOA,7243,B-CHEMICAL
and,7243,O
PFOS,7243,B-CHEMICAL
exposure,7243,O
produced,7243,O
significant,7243,O
decreases,7243,O
in,7243,O
whole,7243,O
body,7243,O
dehydroepiandrosterone,7243,B-CHEMICAL
(,7243,O
DHEA,7243,B-CHEMICAL
),7243,O
",",7243,O
estrone,7243,O
and,7243,O
testosterone,7243,B-CHEMICAL
at,7243,O
sampling,7243,O
day,7243,O
21,7243,O
and,7243,O
a,7243,O
strong,7243,O
increase,7243,O
of,7243,O
cortisol,7243,B-CHEMICAL
and,7243,O
cholesterol,7243,B-CHEMICAL
at,7243,O
the,7243,O
end,7243,O
of,7243,O
recovery,7243,O
period,7243,O
(,7243,O
day,7243,O
56,7243,O
),7243,O
.,7243,O
PFOA,7244,B-CHEMICAL
and,7244,O
PFOS,7244,B-CHEMICAL
effects,7244,O
differed,7244,O
with,7244,O
DHEA,7244,B-CHEMICAL
and,7244,O
estrone,7244,B-CHEMICAL
.,7244,O
While,7245,O
PFOS,7245,B-CHEMICAL
decreased,7245,O
DHEA,7245,B-CHEMICAL
levels,7245,O
",",7245,O
PFOA,7245,B-CHEMICAL
produced,7245,O
an,7245,O
increase,7245,O
at,7245,O
day,7245,O
49,7245,O
",",7245,O
and,7245,O
while,7245,O
PFOS,7245,B-CHEMICAL
decreased,7245,O
estrone,7245,B-CHEMICAL
",",7245,O
PFOA,7245,B-CHEMICAL
produced,7245,O
a,7245,O
slight,7245,O
increase,7245,O
at,7245,O
day,7245,O
56,7245,O
.,7245,O
We,7246,O
observed,7246,O
changes,7246,O
in,7246,O
FA,7246,O
composition,7246,O
that,7246,O
predominantly,7246,O
involved,7246,O
increases,7246,O
in,7246,O
FA,7246,B-CHEMICAL
methyl,7246,I-CHEMICAL
esters,7246,I-CHEMICAL
(,7246,O
FAMEs,7246,B-CHEMICAL
),7246,O
",",7246,O
mono-,7246,B-CHEMICAL
and,7246,I-CHEMICAL
poly-unsaturated,7246,I-CHEMICAL
FA,7246,I-CHEMICAL
(,7246,O
MUFA,7246,B-CHEMICAL
and,7246,O
PUFA,7246,B-CHEMICAL
),7246,O
and,7246,O
a,7246,O
decrease,7246,O
in,7246,O
n-3/n-6,7246,O
PUFA,7246,B-CHEMICAL
ratio,7246,O
by,7246,O
both,7246,O
PFOA,7246,B-CHEMICAL
and,7246,O
PFOS,7246,B-CHEMICAL
.,7246,O
Particularly,7247,O
",",7247,O
an,7247,O
increase,7247,O
in,7247,O
-,7247,O
pentadecenoic,7247,B-CHEMICAL
MUFA,7247,I-CHEMICAL
(,7247,O
15:1,7247,O
),7247,O
",",7247,O
two,7247,O
n-3,7247,O
PUFAs,7247,B-CHEMICAL
α-linolenic,7247,B-CHEMICAL
acid,7247,I-CHEMICAL
[,7247,O
ALA,7247,B-CHEMICAL
:,7247,O
18:3,7247,O
n3,7247,O
],7247,O
and,7247,O
eicosapentaenoic,7247,B-CHEMICAL
acid,7247,I-CHEMICAL
[,7247,O
EPA,7247,B-CHEMICAL
:,7247,O
20:5,7247,O
n-3,7247,O
],7247,O
and,7247,O
n-6,7247,O
PUFA,7247,B-CHEMICAL
:,7247,O
arachidonic,7247,B-CHEMICAL
acid,7247,I-CHEMICAL
[,7247,O
ARA,7247,B-CHEMICAL
:,7247,O
20:4,7247,O
n6,7247,O
],7247,O
",",7247,O
docosapentaenoic,7247,B-CHEMICAL
acid,7247,I-CHEMICAL
(,7247,O
DPA,7247,B-CHEMICAL
),7247,O
by,7247,O
PFOA,7247,B-CHEMICAL
and,7247,O
PFOS,7247,B-CHEMICAL
were,7247,O
observed,7247,O
.,7247,O
These,7248,O
effects,7248,O
were,7248,O
associated,7248,O
with,7248,O
changes,7248,O
in,7248,O
mRNA,7248,O
expression,7248,O
of,7248,O
FA,7248,B-GENE-N
elongase,7248,I-GENE-N
(,7248,O
FAE,7248,B-GENE-N
),7248,O
",",7248,O
Δ5-desaturase,7248,B-GENE-Y
(,7248,O
FAD5,7248,B-GENE-Y
),7248,O
and,7248,O
Δ6-desaturase,7248,B-GENE-Y
(,7248,O
FAD6,7248,B-GENE-Y
),7248,O
genes,7248,O
.,7248,O
In,7249,O
summary,7249,O
",",7249,O
the,7249,O
changes,7249,O
in,7249,O
hormonal,7249,O
and,7249,O
FA,7249,O
profiles,7249,O
may,7249,O
represent,7249,O
cellular,7249,O
and/or,7249,O
physiological,7249,O
adaptation,7249,O
to,7249,O
continuous,7249,O
PFOS,7249,B-CHEMICAL
and,7249,O
PFOA,7249,B-CHEMICAL
exposure,7249,O
by,7249,O
increasing,7249,O
membrane,7249,O
fluidity,7249,O
",",7249,O
and/or,7249,O
overt,7249,O
developmental,7249,O
effects,7249,O
.,7249,O
The,7250,O
present,7250,O
findings,7250,O
provide,7250,O
some,7250,O
potential,7250,O
insights,7250,O
and,7250,O
basis,7250,O
for,7250,O
a,7250,O
better,7250,O
understanding,7250,O
on,7250,O
the,7250,O
possible,7250,O
mechanisms,7250,O
of,7250,O
PFCs,7250,O
toxicity,7250,O
in,7250,O
fish,7250,O
.,7250,O
Drugs,7251,O
in,7251,O
Development,7251,O
for,7251,O
Relapsing,7251,O
Multiple,7251,O
Sclerosis,7251,O
.,7251,O
Drug,7252,O
development,7252,O
for,7252,O
multiple,7252,O
sclerosis,7252,O
(,7252,O
MS,7252,O
),7252,O
",",7252,O
as,7252,O
with,7252,O
any,7252,O
other,7252,O
neurological,7252,O
disease,7252,O
",",7252,O
faces,7252,O
numerous,7252,O
challenges,7252,O
",",7252,O
with,7252,O
many,7252,O
drugs,7252,O
failing,7252,O
at,7252,O
various,7252,O
stages,7252,O
of,7252,O
development,7252,O
.,7252,O
The,7253,O
disease-modifying,7253,O
therapies,7253,O
(,7253,O
DMTs,7253,O
),7253,O
first,7253,O
introduced,7253,O
for,7253,O
MS,7253,O
are,7253,O
only,7253,O
moderately,7253,O
effective,7253,O
",",7253,O
but,7253,O
given,7253,O
the,7253,O
lack,7253,O
of,7253,O
competition,7253,O
",",7253,O
they,7253,O
have,7253,O
been,7253,O
widely,7253,O
accepted,7253,O
in,7253,O
clinical,7253,O
practice,7253,O
.,7253,O
Although,7254,O
safety,7254,O
and,7254,O
efficacy,7254,O
continue,7254,O
to,7254,O
be,7254,O
the,7254,O
two,7254,O
main,7254,O
metrics,7254,O
by,7254,O
which,7254,O
drugs,7254,O
will,7254,O
be,7254,O
judged,7254,O
",",7254,O
the,7254,O
newer,7254,O
agents,7254,O
in,7254,O
the,7254,O
market,7254,O
also,7254,O
face,7254,O
challenges,7254,O
of,7254,O
a,7254,O
more,7254,O
comparative,7254,O
nature-are,7254,O
they,7254,O
more,7254,O
efficacious,7254,O
than,7254,O
the,7254,O
currently,7254,O
available,7254,O
drugs,7254,O
on,7254,O
the,7254,O
market,7254,O
?,7254,O
Are,7255,O
they,7255,O
safer,7255,O
or,7255,O
better,7255,O
tolerated,7255,O
?,7255,O
Do,7256,O
they,7256,O
offer,7256,O
any,7256,O
practical,7256,O
advantages,7256,O
over,7256,O
current,7256,O
treatments,7256,O
?,7256,O
Fingolimod,7257,B-CHEMICAL
represented,7257,O
a,7257,O
milestone,7257,O
following,7257,O
its,7257,O
approval,7257,O
as,7257,O
an,7257,O
oral,7257,O
drug,7257,O
for,7257,O
MS,7257,O
in,7257,O
2010,7257,O
",",7257,O
offering,7257,O
patients,7257,O
a,7257,O
far,7257,O
more,7257,O
convenient,7257,O
administration,7257,O
route,7257,O
.,7257,O
However,7258,O
",",7258,O
association,7258,O
with,7258,O
cardiovascular,7258,O
complications,7258,O
has,7258,O
led,7258,O
to,7258,O
a,7258,O
more,7258,O
cautious,7258,O
approach,7258,O
in,7258,O
its,7258,O
initial,7258,O
prescribing,7258,O
",",7258,O
now,7258,O
requiring,7258,O
cardiac,7258,O
monitoring,7258,O
for,7258,O
the,7258,O
first,7258,O
6,7258,O
h,7258,O
as,7258,O
well,7258,O
as,7258,O
subsequent,7258,O
monitoring,7258,O
of,7258,O
blood,7258,O
pressure,7258,O
and,7258,O
for,7258,O
macular,7258,O
oedema,7258,O
.,7258,O
Natalizumab,7259,O
",",7259,O
amongst,7259,O
licensed,7259,O
drugs,7259,O
",",7259,O
represents,7259,O
the,7259,O
current,7259,O
benchmark,7259,O
for,7259,O
efficacy,7259,O
.,7259,O
The,7260,O
risk,7260,O
of,7260,O
progressive,7260,O
multifocal,7260,O
leukoencephalopathy,7260,O
during,7260,O
natalizumab,7260,O
treatment,7260,O
is,7260,O
now,7260,O
more,7260,O
quantifiable,7260,O
.,7260,O
Other,7261,O
monoclonal,7261,O
antibodies,7261,O
are,7261,O
in,7261,O
various,7261,O
phases,7261,O
of,7261,O
development,7261,O
.,7261,O
Marketing,7262,O
authorisation,7262,O
for,7262,O
alemtuzumab,7262,O
has,7262,O
been,7262,O
filed,7262,O
",",7262,O
and,7262,O
whilst,7262,O
trial,7262,O
data,7262,O
suggest,7262,O
that,7262,O
its,7262,O
efficacy,7262,O
outperforms,7262,O
both,7262,O
licensed,7262,O
drugs,7262,O
and,7262,O
others,7262,O
in,7262,O
development,7262,O
",",7262,O
there,7262,O
is,7262,O
a,7262,O
significant,7262,O
risk,7262,O
of,7262,O
secondary,7262,O
autoimmunity,7262,O
.,7262,O
Its,7263,O
once-yearly,7263,O
administration,7263,O
",",7263,O
however,7263,O
",",7263,O
seems,7263,O
particularly,7263,O
advantageous,7263,O
.,7263,O
Rituximab,7264,O
is,7264,O
unlikely,7264,O
to,7264,O
be,7264,O
developed,7264,O
further,7264,O
as,7264,O
its,7264,O
license,7264,O
will,7264,O
expire,7264,O
",",7264,O
but,7264,O
ocrelizumab,7264,O
",",7264,O
another,7264,O
monoclonal,7264,O
antibody,7264,O
directly,7264,O
targeting,7264,O
B,7264,O
cells,7264,O
",",7264,O
is,7264,O
currently,7264,O
in,7264,O
phase,7264,O
2,7264,O
development,7264,O
and,7264,O
looks,7264,O
promising,7264,O
.,7264,O
Daclizumab,7265,O
is,7265,O
also,7265,O
moderately,7265,O
efficacious,7265,O
but,7265,O
may,7265,O
struggle,7265,O
to,7265,O
establish,7265,O
itself,7265,O
given,7265,O
its,7265,O
monthly,7265,O
subcutaneous,7265,O
dosing,7265,O
.,7265,O
There,7266,O
are,7266,O
new,7266,O
oral,7266,O
drugs,7266,O
in,7266,O
development,7266,O
",",7266,O
and,7266,O
it,7266,O
is,7266,O
likely,7266,O
that,7266,O
BG-12,7266,B-CHEMICAL
will,7266,O
be,7266,O
licensed,7266,O
this,7266,O
year,7266,O
.,7266,O
This,7267,O
has,7267,O
been,7267,O
licensed,7267,O
for,7267,O
psoriasis,7267,O
so,7267,O
there,7267,O
are,7267,O
good,7267,O
safety,7267,O
data,7267,O
in,7267,O
humans,7267,O
that,7267,O
may,7267,O
also,7267,O
hold,7267,O
true,7267,O
in,7267,O
MS,7267,O
;,7267,O
however,7267,O
",",7267,O
its,7267,O
three,7267,O
times,7267,O
daily,7267,O
dosage,7267,O
will,7267,O
probably,7267,O
impact,7267,O
on,7267,O
patient,7267,O
compliance,7267,O
.,7267,O
Laquinimod,7268,B-CHEMICAL
has,7268,O
lower,7268,O
efficacy,7268,O
than,7268,O
BG-12,7268,B-CHEMICAL
but,7268,O
appears,7268,O
safe,7268,O
and,7268,O
could,7268,O
find,7268,O
a,7268,O
place,7268,O
as,7268,O
a,7268,O
first-line,7268,O
agent,7268,O
.,7268,O
Teriflunomide,7269,B-CHEMICAL
has,7269,O
just,7269,O
been,7269,O
licensed,7269,O
by,7269,O
the,7269,O
US,7269,O
FDA,7269,O
and,7269,O
may,7269,O
challenge,7269,O
the,7269,O
current,7269,O
injectable,7269,O
first-line,7269,O
therapies,7269,O
as,7269,O
it,7269,O
has,7269,O
a,7269,O
similar,7269,O
efficacy,7269,O
but,7269,O
the,7269,O
advantage,7269,O
of,7269,O
being,7269,O
taken,7269,O
orally,7269,O
.,7269,O
However,7270,O
",",7270,O
risk,7270,O
of,7270,O
teratogenicity,7270,O
may,7270,O
caution,7270,O
against,7270,O
its,7270,O
use,7270,O
in,7270,O
some,7270,O
women,7270,O
of,7270,O
child-bearing,7270,O
potential,7270,O
.,7270,O
This,7271,O
review,7271,O
will,7271,O
examine,7271,O
drugs,7271,O
that,7271,O
have,7271,O
been,7271,O
recently,7271,O
approved,7271,O
as,7271,O
well,7271,O
as,7271,O
those,7271,O
that,7271,O
are,7271,O
in,7271,O
late,7271,O
phase,7271,O
2,7271,O
or,7271,O
3,7271,O
development,7271,O
as,7271,O
treatment,7271,O
for,7271,O
relapsing,7271,O
MS,7271,O
",",7271,O
highlighting,7271,O
their,7271,O
mechanism,7271,O
of,7271,O
action,7271,O
as,7271,O
well,7271,O
as,7271,O
the,7271,O
clinical,7271,O
trial,7271,O
and,7271,O
safety,7271,O
data,7271,O
before,7271,O
discussing,7271,O
their,7271,O
potential,7271,O
for,7271,O
success,7271,O
in,7271,O
an,7271,O
increasingly,7271,O
florid,7271,O
and,7271,O
complex,7271,O
DMT,7271,O
armamentarium,7271,O
.,7271,O
Toxicity,7272,O
of,7272,O
the,7272,O
flame-retardant,7272,O
BDE-49,7272,B-CHEMICAL
on,7272,O
brain,7272,O
mitochondria,7272,O
and,7272,O
neuronal,7272,O
progenitor,7272,O
striatal,7272,O
cells,7272,O
enhanced,7272,O
by,7272,O
a,7272,O
PTEN-deficient,7272,B-GENE-Y
background,7272,O
.,7272,O
Polybrominated,7273,B-CHEMICAL
diphenyl,7273,I-CHEMICAL
ethers,7273,I-CHEMICAL
(,7273,O
PBDEs,7273,B-CHEMICAL
),7273,O
represent,7273,O
an,7273,O
important,7273,O
group,7273,O
of,7273,O
flame,7273,O
retardants,7273,O
extensively,7273,O
used,7273,O
",",7273,O
tonnage,7273,O
of,7273,O
which,7273,O
in,7273,O
the,7273,O
environment,7273,O
has,7273,O
been,7273,O
steadily,7273,O
increasing,7273,O
over,7273,O
the,7273,O
past,7273,O
25,7273,O
years,7273,O
.,7273,O
PBDEs,7274,B-CHEMICAL
or,7274,O
metabolites,7274,O
can,7274,O
induce,7274,O
neurotoxicity,7274,O
and,7274,O
mitochondrial,7274,O
dysfunction,7274,O
(,7274,O
MD,7274,O
),7274,O
through,7274,O
a,7274,O
variety,7274,O
of,7274,O
mechanisms,7274,O
.,7274,O
Recently,7275,O
",",7275,O
PBDEs,7275,B-CHEMICAL
with,7275,O
<,7275,O
5,7275,O
Br,7275,B-CHEMICAL
substitutions,7275,O
(,7275,O
i.e.,7275,O
",",7275,O
"2,2',4,4'-tetrabromodiphenyl",7275,B-CHEMICAL
ether,7275,I-CHEMICAL
[,7275,O
BDE-47,7275,B-CHEMICAL
],7275,O
and,7275,O
"2,2',4,5'-tetrabromodiphenyl",7275,B-CHEMICAL
ether,7275,I-CHEMICAL
[,7275,O
BDE-49,7275,B-CHEMICAL
],7275,O
),7275,O
have,7275,O
gained,7275,O
interest,7275,O
because,7275,O
of,7275,O
their,7275,O
high,7275,O
bioaccumulation,7275,O
.,7275,O
In,7276,O
particular,7276,O
",",7276,O
congeners,7276,O
such,7276,O
as,7276,O
BDE-49,7276,B-CHEMICAL
arise,7276,O
as,7276,O
one,7276,O
of,7276,O
the,7276,O
most,7276,O
biologically,7276,O
active,7276,O
",",7276,O
with,7276,O
concentrations,7276,O
typically,7276,O
lower,7276,O
than,7276,O
those,7276,O
observed,7276,O
for,7276,O
BDE-47,7276,B-CHEMICAL
in,7276,O
biological,7276,O
tissues,7276,O
;,7276,O
however,7276,O
",",7276,O
its,7276,O
potential,7276,O
to,7276,O
cause,7276,O
MD,7276,O
at,7276,O
biologically,7276,O
relevant,7276,O
concentrations,7276,O
is,7276,O
unknown,7276,O
.,7276,O
To,7277,O
this,7277,O
end,7277,O
",",7277,O
the,7277,O
effect,7277,O
of,7277,O
BDE-49,7277,B-CHEMICAL
was,7277,O
studied,7277,O
in,7277,O
brain,7277,O
mitochondria,7277,O
and,7277,O
neuronal,7277,O
progenitor,7277,O
striatal,7277,O
cells,7277,O
(,7277,O
NPC,7277,O
),7277,O
.,7277,O
BDE-49,7278,B-CHEMICAL
uncoupled,7278,O
mitochondria,7278,O
at,7278,O
concentrations,7278,O
<,7278,O
0.1,7278,O
nM,7278,O
",",7278,O
whereas,7278,O
at,7278,O
>,7278,O
1,7278,O
nM,7278,O
",",7278,O
it,7278,O
inhibited,7278,O
the,7278,O
electron,7278,O
transport,7278,O
at,7278,O
Complex,7278,O
V,7278,O
(,7278,O
mixed,7278,O
type,7278,O
inhibition,7278,O
;,7278,O
IC,7278,O
(,7278,O
50,7278,O
),7278,O
=,7278,O
6,7278,O
nM,7278,O
),7278,O
and,7278,O
Complex,7278,O
IV,7278,O
(,7278,O
noncompetitive,7278,O
inhibition,7278,O
;,7278,O
IC,7278,O
(,7278,O
50,7278,O
),7278,O
=,7278,O
40,7278,O
nM,7278,O
),7278,O
.,7278,O
These,7279,O
concentrations,7279,O
are,7279,O
easily,7279,O
achieved,7279,O
in,7279,O
plasma,7279,O
concentrations,7279,O
considering,7279,O
that,7279,O
BDE-49,7279,B-CHEMICAL
(,7279,O
this,7279,O
study,7279,O
",",7279,O
400-fold,7279,O
),7279,O
and,7279,O
other,7279,O
PBDEs,7279,B-CHEMICAL
accumulate,7279,O
1-3,7279,O
orders,7279,O
of,7279,O
magnitude,7279,O
in,7279,O
the,7279,O
cells,7279,O
",",7279,O
particularly,7279,O
in,7279,O
mitochondria,7279,O
and,7279,O
microsomes,7279,O
.,7279,O
Similar,7280,O
effects,7280,O
were,7280,O
observed,7280,O
in,7280,O
NPC,7280,O
and,7280,O
exacerbated,7280,O
with,7280,O
PTEN,7280,B-GENE-Y
(,7280,O
negative,7280,O
modulator,7280,O
of,7280,O
the,7280,O
PI3K/Akt,7280,B-GENE-N
pathway,7280,O
),7280,O
deficiency,7280,O
",",7280,O
background,7280,O
associated,7280,O
with,7280,O
autism-like,7280,O
behavior,7280,O
",",7280,O
schizophrenia,7280,O
",",7280,O
and,7280,O
epilepsy,7280,O
.,7280,O
PBDE-mediated,7281,B-CHEMICAL
MD,7281,O
per,7281,O
se,7281,O
or,7281,O
enhanced,7281,O
by,7281,O
a,7281,O
background,7281,O
that,7281,O
confers,7281,O
susceptibility,7281,O
to,7281,O
this,7281,O
exposure,7281,O
may,7281,O
have,7281,O
profound,7281,O
implications,7281,O
in,7281,O
the,7281,O
energy,7281,O
balance,7281,O
of,7281,O
brain,7281,O
.,7281,O
Pharmacological,7282,O
properties,7282,O
of,7282,O
lorglumide,7282,B-CHEMICAL
as,7282,O
a,7282,O
member,7282,O
of,7282,O
a,7282,O
new,7282,O
class,7282,O
of,7282,O
cholecystokinin,7282,B-GENE-Y
antagonists,7282,O
.,7282,O
Derivatives,7283,O
of,7283,O
5-,7283,B-CHEMICAL
(,7283,I-CHEMICAL
dipentylamino,7283,I-CHEMICAL
),7283,I-CHEMICAL
-5-oxo-pentanoic,7283,I-CHEMICAL
acid,7283,I-CHEMICAL
are,7283,O
a,7283,O
new,7283,O
class,7283,O
of,7283,O
non-peptide,7283,O
cholecystokinin,7283,B-GENE-Y
(,7283,O
CCK,7283,B-GENE-Y
),7283,O
antagonists,7283,O
.,7283,O
The,7284,O
most,7284,O
potent,7284,O
compound,7284,O
",",7284,O
D,7284,B-CHEMICAL
",",7284,I-CHEMICAL
L-4-,7284,I-CHEMICAL
(,7284,I-CHEMICAL
"3,4-dichlorobenzoylamino",7284,I-CHEMICAL
),7284,I-CHEMICAL
-5-,7284,I-CHEMICAL
(,7284,I-CHEMICAL
dipentylamino,7284,I-CHEMICAL
),7284,I-CHEMICAL
-5-oxo-pen,7284,I-CHEMICAL
tanoic,7284,I-CHEMICAL
acid,7284,I-CHEMICAL
(,7284,O
lorglumide,7284,B-CHEMICAL
",",7284,O
CR,7284,B-CHEMICAL
1409,7284,I-CHEMICAL
),7284,O
",",7284,O
has,7284,O
a,7284,O
great,7284,O
affinity,7284,O
for,7284,O
the,7284,O
pancreatic,7284,O
CCK,7284,B-GENE-N
receptors,7284,I-GENE-N
and,7284,O
is,7284,O
a,7284,O
competitive,7284,O
",",7284,O
specific,7284,O
and,7284,O
potent,7284,O
CCK,7284,B-GENE-Y
antagonist,7284,O
on,7284,O
the,7284,O
smooth,7284,O
muscles,7284,O
of,7284,O
the,7284,O
gall,7284,O
bladder,7284,O
and,7284,O
ileum,7284,O
of,7284,O
the,7284,O
guinea,7284,O
pig,7284,O
and,7284,O
on,7284,O
the,7284,O
CCK-induced,7284,B-GENE-Y
amylase,7284,B-GENE-N
secretion,7284,O
of,7284,O
isolated,7284,O
pancreatic,7284,O
acini,7284,O
.,7284,O
In,7285,O
vivo,7285,O
lorglumide,7285,B-CHEMICAL
antagonizes,7285,O
the,7285,O
contraction,7285,O
of,7285,O
the,7285,O
gall,7285,O
bladder,7285,O
of,7285,O
the,7285,O
guinea,7285,O
pig,7285,O
and,7285,O
of,7285,O
the,7285,O
dog,7285,O
provoked,7285,O
by,7285,O
i.v,7285,O
.,7285,O
CCK-8,7286,B-GENE-N
or,7286,O
ceruletide,7286,B-CHEMICAL
(,7286,O
caerulein,7286,B-CHEMICAL
),7286,O
.,7286,O
It,7287,O
antagonizes,7287,O
the,7287,O
satiety,7287,O
effect,7287,O
of,7287,O
CCK-8,7287,B-GENE-Y
in,7287,O
the,7287,O
rat,7287,O
and,7287,O
is,7287,O
protective,7287,O
against,7287,O
ceruletide-,7287,B-CHEMICAL
",",7287,O
taurocholate-,7287,B-CHEMICAL
and,7287,O
diet-induced,7287,O
pancreatitis,7287,O
.,7287,O
Lorglumide,7288,B-CHEMICAL
is,7288,O
therefore,7288,O
a,7288,O
useful,7288,O
pharmacological,7288,O
tool,7288,O
to,7288,O
study,7288,O
the,7288,O
functions,7288,O
of,7288,O
CCK,7288,B-GENE-Y
.,7288,O
For,7289,O
its,7289,O
pharmacological,7289,O
properties,7289,O
",",7289,O
its,7289,O
relatively,7289,O
low,7289,O
toxicity,7289,O
and,7289,O
because,7289,O
it,7289,O
is,7289,O
active,7289,O
also,7289,O
after,7289,O
oral,7289,O
administration,7289,O
",",7289,O
lorglumide,7289,B-CHEMICAL
is,7289,O
a,7289,O
candidate,7289,O
for,7289,O
diagnostic,7289,O
or,7289,O
therapeutic,7289,O
use,7289,O
in,7289,O
man,7289,O
when,7289,O
an,7289,O
involvement,7289,O
of,7289,O
CCK,7289,B-GENE-Y
is,7289,O
suspected,7289,O
.,7289,O
Synthesis,7290,O
and,7290,O
Structure-Activity,7290,O
Relationship,7290,O
Studies,7290,O
of,7290,O
Derivatives,7290,O
of,7290,O
the,7290,O
Dual,7290,O
Aromatase-Sulfatase,7290,B-GENE-Y
Inhibitor,7290,O
4-,7290,B-CHEMICAL
{,7290,I-CHEMICAL
[,7290,I-CHEMICAL
(,7290,I-CHEMICAL
4-Cyanophenyl,7290,I-CHEMICAL
),7290,I-CHEMICAL
(,7290,I-CHEMICAL
"4H-1,2,4-triazol-4-yl",7290,I-CHEMICAL
),7290,I-CHEMICAL
amino,7290,I-CHEMICAL
],7290,I-CHEMICAL
methyl,7290,I-CHEMICAL
},7290,I-CHEMICAL
phenyl,7290,I-CHEMICAL
sulfamate,7290,I-CHEMICAL
.,7290,O
4-,7291,B-CHEMICAL
{,7291,I-CHEMICAL
[,7291,I-CHEMICAL
(,7291,I-CHEMICAL
4-Cyanophenyl,7291,I-CHEMICAL
),7291,I-CHEMICAL
(,7291,I-CHEMICAL
"4H-1,2,4-triazol-4-yl",7291,I-CHEMICAL
),7291,I-CHEMICAL
amino,7291,I-CHEMICAL
],7291,I-CHEMICAL
methyl,7291,I-CHEMICAL
},7291,I-CHEMICAL
phenyl,7291,I-CHEMICAL
sulfamate,7291,I-CHEMICAL
and,7291,O
its,7291,O
ortho-halogenated,7291,O
(,7291,O
F,7291,B-CHEMICAL
",",7291,O
Cl,7291,B-CHEMICAL
",",7291,O
Br,7291,B-CHEMICAL
),7291,O
derivatives,7291,O
are,7291,O
first-generation,7291,O
dual,7291,O
aromatase,7291,B-GENE-Y
and,7291,O
sulfatase,7291,B-GENE-Y
inhibitors,7291,O
(,7291,O
DASIs,7291,O
),7291,O
.,7291,O
Structure-activity,7292,O
relationship,7292,O
studies,7292,O
were,7292,O
performed,7292,O
on,7292,O
these,7292,O
compounds,7292,O
",",7292,O
and,7292,O
various,7292,O
modifications,7292,O
were,7292,O
made,7292,O
to,7292,O
their,7292,O
structures,7292,O
involving,7292,O
relocation,7292,O
of,7292,O
the,7292,O
halogen,7292,B-CHEMICAL
atom,7292,O
",",7292,O
introduction,7292,O
of,7292,O
more,7292,O
halogen,7292,B-CHEMICAL
atoms,7292,O
",",7292,O
replacement,7292,O
of,7292,O
the,7292,O
halogen,7292,B-CHEMICAL
with,7292,O
another,7292,O
group,7292,O
",",7292,O
replacement,7292,O
of,7292,O
the,7292,O
methylene,7292,B-CHEMICAL
linker,7292,O
with,7292,O
a,7292,O
difluoromethylene,7292,B-CHEMICAL
linker,7292,O
",",7292,O
replacement,7292,O
of,7292,O
the,7292,O
para-cyanophenyl,7292,B-CHEMICAL
ring,7292,O
with,7292,O
other,7292,O
ring,7292,O
structures,7292,O
",",7292,O
and,7292,O
replacement,7292,O
of,7292,O
the,7292,O
triazolyl,7292,B-CHEMICAL
group,7292,O
with,7292,O
an,7292,O
imidazolyl,7292,B-CHEMICAL
group,7292,O
.,7292,O
The,7293,O
most,7293,O
potent,7293,O
in,7293,O
vitro,7293,O
DASI,7293,O
discovered,7293,O
is,7293,O
an,7293,O
imidazole,7293,B-CHEMICAL
derivative,7293,O
with,7293,O
IC50,7293,O
values,7293,O
against,7293,O
aromatase,7293,B-GENE-Y
and,7293,O
steroid,7293,B-GENE-Y
sulfatase,7293,I-GENE-Y
in,7293,O
a,7293,O
JEG-3,7293,O
cell,7293,O
preparation,7293,O
of,7293,O
0.2,7293,O
and,7293,O
2.5,7293,O
nM,7293,O
",",7293,O
respectively,7293,O
.,7293,O
The,7294,O
parent,7294,O
phenol,7294,B-CHEMICAL
of,7294,O
this,7294,O
compound,7294,O
inhibits,7294,O
aromatase,7294,B-GENE-Y
with,7294,O
an,7294,O
IC50,7294,O
value,7294,O
of,7294,O
0.028,7294,O
nM,7294,O
in,7294,O
the,7294,O
same,7294,O
assay,7294,O
.,7294,O
The,7295,O
circadian,7295,O
clock,7295,O
circuitry,7295,O
and,7295,O
the,7295,O
AHR,7295,B-GENE-Y
signaling,7295,O
pathway,7295,O
in,7295,O
physiology,7295,O
and,7295,O
pathology,7295,O
.,7295,O
Life,7296,O
forms,7296,O
populating,7296,O
the,7296,O
Earth,7296,O
must,7296,O
face,7296,O
environmental,7296,O
challenges,7296,O
to,7296,O
assure,7296,O
individual,7296,O
and,7296,O
species,7296,O
survival,7296,O
.,7296,O
The,7297,O
strategies,7297,O
predisposed,7297,O
to,7297,O
maintain,7297,O
organismal,7297,O
homeostasis,7297,O
and,7297,O
grant,7297,O
selective,7297,O
advantage,7297,O
rely,7297,O
on,7297,O
anticipatory,7297,O
phenomena,7297,O
facing,7297,O
periodic,7297,O
modifications,7297,O
",",7297,O
and,7297,O
compensatory,7297,O
phenomena,7297,O
facing,7297,O
unpredictable,7297,O
changes,7297,O
.,7297,O
Biological,7298,O
processes,7298,O
bringing,7298,O
about,7298,O
these,7298,O
responses,7298,O
are,7298,O
respectively,7298,O
driven,7298,O
by,7298,O
the,7298,O
circadian,7298,O
timing,7298,O
system,7298,O
",",7298,O
a,7298,O
complex,7298,O
of,7298,O
biological,7298,O
oscillators,7298,O
entrained,7298,O
to,7298,O
the,7298,O
environmental,7298,O
light/dark,7298,O
cycle,7298,O
",",7298,O
and,7298,O
by,7298,O
regulatory,7298,O
and,7298,O
metabolic,7298,O
networks,7298,O
that,7298,O
precisely,7298,O
direct,7298,O
the,7298,O
body,7298,O
's,7298,O
adjustments,7298,O
to,7298,O
variations,7298,O
of,7298,O
external,7298,O
conditions,7298,O
and,7298,O
internal,7298,O
milieu,7298,O
.,7298,O
A,7299,O
critical,7299,O
role,7299,O
in,7299,O
organismal,7299,O
homeostatic,7299,O
functions,7299,O
is,7299,O
played,7299,O
by,7299,O
the,7299,O
aryl,7299,B-GENE-Y
hydrocarbon,7299,I-GENE-Y
receptor,7299,I-GENE-Y
(,7299,O
AHR,7299,B-GENE-Y
),7299,O
complex,7299,O
",",7299,O
which,7299,O
senses,7299,O
environmental,7299,O
and,7299,O
endogenous,7299,O
compounds,7299,O
",",7299,O
influences,7299,O
metabolic,7299,O
responses,7299,O
controlling,7299,O
phase,7299,O
I/II,7299,O
gene,7299,O
expression,7299,O
",",7299,O
and,7299,O
modulates,7299,O
vital,7299,O
phenomena,7299,O
such,7299,O
as,7299,O
development,7299,O
",",7299,O
inflammation,7299,O
and,7299,O
adaptive,7299,O
immunity,7299,O
.,7299,O
A,7300,O
physiological,7300,O
cross-talk,7300,O
between,7300,O
circadian,7300,O
and,7300,O
AHR,7300,B-GENE-Y
signaling,7300,O
pathways,7300,O
has,7300,O
been,7300,O
evidenced,7300,O
.,7300,O
The,7301,O
alteration,7301,O
of,7301,O
AHR,7301,B-GENE-Y
signaling,7301,O
pathway,7301,O
deriving,7301,O
from,7301,O
genetic,7301,O
damage,7301,O
with,7301,O
polymorphisms,7301,O
or,7301,O
mutations,7301,O
",",7301,O
or,7301,O
produced,7301,O
by,7301,O
exogenous,7301,O
or,7301,O
endogenous,7301,O
AHR,7301,B-GENE-Y
activation,7301,O
",",7301,O
and,7301,O
chronodisruption,7301,O
caused,7301,O
by,7301,O
mismatch,7301,O
between,7301,O
the,7301,O
body,7301,O
's,7301,O
internal,7301,O
clock,7301,O
and,7301,O
geophysical,7301,O
time/social,7301,O
schedules,7301,O
",",7301,O
are,7301,O
capable,7301,O
of,7301,O
triggering,7301,O
pathological,7301,O
mechanisms,7301,O
involved,7301,O
in,7301,O
metabolic,7301,O
",",7301,O
immune-related,7301,O
and,7301,O
neoplastic,7301,O
diseases,7301,O
.,7301,O
On,7302,O
the,7302,O
other,7302,O
hand,7302,O
",",7302,O
the,7302,O
molecular,7302,O
components,7302,O
of,7302,O
the,7302,O
circadian,7302,O
clock,7302,O
circuitry,7302,O
and,7302,O
AHR,7302,B-GENE-Y
signaling,7302,O
pathway,7302,O
may,7302,O
represent,7302,O
useful,7302,O
tools,7302,O
for,7302,O
preventive,7302,O
interventions,7302,O
and,7302,O
valuable,7302,O
targets,7302,O
of,7302,O
therapeutic,7302,O
approaches,7302,O
.,7302,O
Protective,7303,O
effect,7303,O
of,7303,O
cinnamon,7303,O
polyphenols,7303,B-CHEMICAL
against,7303,O
STZ-diabetic,7303,B-CHEMICAL
mice,7303,O
fed,7303,O
high-sugar,7303,O
",",7303,O
high-fat,7303,O
diet,7303,O
and,7303,O
its,7303,O
underlying,7303,O
mechanism,7303,O
.,7303,O
This,7304,O
study,7304,O
was,7304,O
designed,7304,O
to,7304,O
investigate,7304,O
the,7304,O
potential,7304,O
effects,7304,O
of,7304,O
14days,7304,O
',7304,O
intragastrically,7304,O
given,7304,O
of,7304,O
cinnamon,7304,O
polyphenols,7304,B-CHEMICAL
(,7304,O
CPS,7304,O
),7304,O
in,7304,O
treating,7304,O
diabetic,7304,O
mice,7304,O
induced,7304,O
by,7304,O
intraperitoneal,7304,O
injection,7304,O
of,7304,O
streptozotocin,7304,B-CHEMICAL
(,7304,O
150mgkg,7304,O
(,7304,O
-1,7304,O
),7304,O
),7304,O
and,7304,O
fed,7304,O
high-sugar,7304,O
",",7304,O
high-fat,7304,O
diet,7304,O
.,7304,O
The,7305,O
diabetic,7305,O
mice,7305,O
model,7305,O
was,7305,O
successfully,7305,O
established,7305,O
through,7305,O
determining,7305,O
on,7305,O
fasting,7305,O
blood-glucose,7305,O
(,7305,O
FBG,7305,O
),7305,O
test,7305,O
.,7305,O
As,7306,O
revealed,7306,O
by,7306,O
glucose,7306,B-GENE-N
oxidase,7306,I-GENE-N
(,7306,O
GOD,7306,O
),7306,O
and,7306,O
radioimmunoassay,7306,O
(,7306,O
RIA,7306,O
),7306,O
",",7306,O
both,7306,O
dimethyldiguanide,7306,B-CHEMICAL
(,7306,O
DC,7306,O
",",7306,O
0.6gkg,7306,O
(,7306,O
-1,7306,O
),7306,O
d,7306,O
(,7306,O
-1,7306,O
),7306,O
),7306,O
and,7306,O
CPS,7306,O
(,7306,O
0.3,7306,O
",",7306,O
0.6,7306,O
",",7306,O
1.2gkg,7306,O
(,7306,O
-1,7306,O
),7306,O
d,7306,O
(,7306,O
-1,7306,O
),7306,O
),7306,O
treatments,7306,O
significantly,7306,O
resulted,7306,O
in,7306,O
down-regulation,7306,O
of,7306,O
blood,7306,O
glucose,7306,B-CHEMICAL
and,7306,O
insulin,7306,B-GENE-N
levels,7306,O
in,7306,O
serum,7306,O
",",7306,O
while,7306,O
the,7306,O
levels,7306,O
of,7306,O
oxidative,7306,O
stress,7306,O
markers,7306,O
were,7306,O
markedly,7306,O
lowered,7306,O
through,7306,O
ELISA,7306,O
assay,7306,O
.,7306,O
Meanwhile,7307,O
",",7307,O
the,7307,O
pathological,7307,O
damage,7307,O
in,7307,O
islet,7307,O
with,7307,O
pancreatic,7307,O
beta,7307,O
cells,7307,O
was,7307,O
ameliorated,7307,O
by,7307,O
treatment,7307,O
of,7307,O
CPS,7307,O
at,7307,O
different,7307,O
doses,7307,O
",",7307,O
as,7307,O
shown,7307,O
in,7307,O
HE,7307,O
stain,7307,O
.,7307,O
At,7308,O
the,7308,O
same,7308,O
time,7308,O
",",7308,O
the,7308,O
treatments,7308,O
also,7308,O
caused,7308,O
notable,7308,O
reduction,7308,O
of,7308,O
iNOS,7308,B-GENE-Y
",",7308,O
NF-κB,7308,B-GENE-N
expressions,7308,O
showing,7308,O
in,7308,O
Western,7308,O
blot,7308,O
analysis,7308,O
.,7308,O
These,7309,O
findings,7309,O
demonstrate,7309,O
that,7309,O
cinnamon,7309,O
polyphenols,7309,B-CHEMICAL
can,7309,O
exert,7309,O
the,7309,O
hypoglycemic,7309,O
and,7309,O
hypolipidemic,7309,O
effects,7309,O
through,7309,O
the,7309,O
mechanisms,7309,O
that,7309,O
may,7309,O
be,7309,O
associated,7309,O
with,7309,O
repairing,7309,O
pancreatic,7309,O
beta,7309,O
cells,7309,O
in,7309,O
diabetic,7309,O
mice,7309,O
and,7309,O
improving,7309,O
its,7309,O
anti-oxidative,7309,O
capacity,7309,O
",",7309,O
as,7309,O
well,7309,O
as,7309,O
attenuating,7309,O
cytotoxicity,7309,O
via,7309,O
inhibition,7309,O
of,7309,O
iNOS,7309,B-GENE-Y
",",7309,O
NF-κB,7309,B-GENE-N
activation,7309,O
.,7309,O
Nonadrenergic,7310,O
imidazoline,7310,B-CHEMICAL
binding,7310,O
sites,7310,O
on,7310,O
human,7310,O
platelets,7310,O
.,7310,O
Human,7311,O
platelets,7311,O
are,7311,O
shown,7311,O
to,7311,O
possess,7311,O
at,7311,O
least,7311,O
two,7311,O
high-affinity,7311,O
",",7311,O
imidazol,7311,B-CHEMICAL
(,7311,I-CHEMICAL
in,7311,I-CHEMICAL
),7311,I-CHEMICAL
e-preferring,7311,O
binding,7311,O
sites,7311,O
that,7311,O
are,7311,O
pharmacologically,7311,O
distinct,7311,O
from,7311,O
alpha-2,7311,B-GENE-N
adrenoceptors,7311,I-GENE-N
.,7311,O
These,7312,O
nonadrenergic,7312,O
sites,7312,O
were,7312,O
radiolabeled,7312,O
even,7312,O
in,7312,O
the,7312,O
presence,7312,O
of,7312,O
a,7312,O
10,7312,O
microM,7312,O
norepinephrine,7312,B-CHEMICAL
mask,7312,O
of,7312,O
alpha-2,7312,B-GENE-N
adrenoceptors,7312,I-GENE-N
.,7312,O
Heterogeneity,7313,O
at,7313,O
the,7313,O
nonadrenergic,7313,O
sites,7313,O
was,7313,O
demonstrated,7313,O
by,7313,O
comparing,7313,O
[,7313,B-CHEMICAL
3H,7313,I-CHEMICAL
],7313,I-CHEMICAL
idazoxan,7313,I-CHEMICAL
(,7313,O
IDX,7313,B-CHEMICAL
),7313,O
binding,7313,O
vs.,7313,O
[,7313,B-CHEMICAL
125I,7313,I-CHEMICAL
],7313,I-CHEMICAL
p-iodoclonidine,7313,I-CHEMICAL
(,7313,O
PIC,7313,B-CHEMICAL
),7313,O
binding,7313,O
.,7313,O
Nonadrenergic,7314,O
[,7314,B-CHEMICAL
125I,7314,I-CHEMICAL
],7314,I-CHEMICAL
PIC-labeled,7314,O
sites,7314,O
were,7314,O
enriched,7314,O
in,7314,O
platelet,7314,O
plasma,7314,O
membranes,7314,O
",",7314,O
whereas,7314,O
the,7314,O
nonadrenergic,7314,O
sites,7314,O
labeled,7314,O
by,7314,O
[,7314,B-CHEMICAL
3H,7314,I-CHEMICAL
],7314,I-CHEMICAL
IDX,7314,I-CHEMICAL
were,7314,O
codistributed,7314,O
between,7314,O
plasma,7314,O
and,7314,O
internal,7314,O
membranes,7314,O
(,7314,O
nonadrenergic,7314,O
[,7314,B-CHEMICAL
125I,7314,I-CHEMICAL
],7314,I-CHEMICAL
PIC-labeled,7314,O
sites,7314,O
had,7314,O
Bmax,7314,O
=,7314,O
62,7314,O
fmol/mg,7314,O
in,7314,O
plasma,7314,O
membranes,7314,O
and,7314,O
20,7314,O
fmol/mg,7314,O
in,7314,O
internal,7314,O
membranes,7314,O
vs.,7314,O
the,7314,O
[,7314,B-CHEMICAL
3H,7314,I-CHEMICAL
],7314,I-CHEMICAL
IDX-labeled,7314,O
sites,7314,O
had,7314,O
Bmax,7314,O
=,7314,O
141,7314,O
fmol/mg,7314,O
in,7314,O
plasma,7314,O
membranes,7314,O
and,7314,O
192,7314,O
fmol/mg,7314,O
in,7314,O
internal,7314,O
membranes,7314,O
),7314,O
.,7314,O
Furthermore,7315,O
",",7315,O
competition,7315,O
binding,7315,O
studies,7315,O
in,7315,O
the,7315,O
presence,7315,O
of,7315,O
a,7315,O
10,7315,O
microM,7315,O
norepinephrine,7315,B-CHEMICAL
mask,7315,O
revealed,7315,O
major,7315,O
(,7315,O
approximately,7315,O
75,7315,O
%,7315,O
),7315,O
and,7315,O
minor,7315,O
(,7315,O
approximately,7315,O
25,7315,O
%,7315,O
),7315,O
binding,7315,O
components,7315,O
on,7315,O
plasma,7315,O
membranes,7315,O
for,7315,O
[,7315,B-CHEMICAL
125I,7315,I-CHEMICAL
],7315,I-CHEMICAL
PIC,7315,I-CHEMICAL
.,7315,O
Affinities,7316,O
for,7316,O
the,7316,O
major,7316,O
nonadrenergic,7316,O
[,7316,B-CHEMICAL
125I,7316,I-CHEMICAL
],7316,I-CHEMICAL
PIC,7316,I-CHEMICAL
binding,7316,O
site,7316,O
were,7316,O
highly,7316,O
comparable,7316,O
to,7316,O
human,7316,B-GENE-Y
subtype-I1,7316,I-GENE-Y
imidazol,7316,I-GENE-Y
(,7316,I-GENE-Y
in,7316,I-GENE-Y
),7316,I-GENE-Y
e,7316,I-GENE-Y
receptor,7316,I-GENE-Y
sites,7316,O
in,7316,O
the,7316,O
brain,7316,O
stem,7316,O
(,7316,O
rank,7316,O
order,7316,O
:,7316,O
moxonidine,7316,B-CHEMICAL
>,7316,O
clonidine,7316,B-CHEMICAL
>,7316,O
cirazoline,7316,B-CHEMICAL
>,7316,O
IDX,7316,B-CHEMICAL
>,7316,O
amiloride,7316,B-CHEMICAL
),7316,O
.,7316,O
However,7317,O
",",7317,O
the,7317,O
minor,7317,O
component,7317,O
of,7317,O
[,7317,B-CHEMICAL
125I,7317,I-CHEMICAL
],7317,I-CHEMICAL
PIC,7317,I-CHEMICAL
binding,7317,O
was,7317,O
similar,7317,O
to,7317,O
a,7317,O
site,7317,O
reported,7317,O
in,7317,O
kidney,7317,O
",",7317,O
having,7317,O
low,7317,O
affinities,7317,O
for,7317,O
all,7317,O
compounds,7317,O
tested,7317,O
",",7317,O
except,7317,O
guanabenz,7317,B-CHEMICAL
.,7317,O
Finally,7318,O
",",7318,O
a,7318,O
third,7318,O
nonadrenergic,7318,O
internal,7318,O
membrane,7318,O
site,7318,O
",",7318,O
labeled,7318,O
by,7318,O
[,7318,B-CHEMICAL
3H,7318,I-CHEMICAL
],7318,I-CHEMICAL
IDX,7318,I-CHEMICAL
",",7318,O
was,7318,O
consistent,7318,O
with,7318,O
a,7318,O
subtype-I2,7318,B-GENE-N
imidazol,7318,I-GENE-N
(,7318,I-GENE-N
in,7318,I-GENE-N
),7318,I-GENE-N
e,7318,I-GENE-N
receptor,7318,I-GENE-N
site,7318,O
(,7318,O
rank,7318,O
order,7318,O
:,7318,O
cirazoline,7318,B-CHEMICAL
>,7318,O
IDX,7318,O
>,7318,O
>,7318,O
amiloride,7318,B-CHEMICAL
>,7318,O
moxonidine,7318,B-CHEMICAL
>,7318,O
clonidine,7318,B-CHEMICAL
),7318,O
.,7318,O
Thus,7319,O
",",7319,O
based,7319,O
on,7319,O
differential,7319,O
subcellular,7319,O
distributions,7319,O
and,7319,O
affinity,7319,O
constants,7319,O
",",7319,O
human,7319,O
platelets,7319,O
appear,7319,O
to,7319,O
possess,7319,O
imidazoline,7319,B-GENE-N
receptors,7319,I-GENE-N
(,7319,O
subtype-I1,7319,B-GENE-Y
imidazol,7319,I-GENE-Y
(,7319,I-GENE-Y
in,7319,I-GENE-Y
),7319,I-GENE-Y
e,7319,I-GENE-Y
receptor,7319,I-GENE-Y
and,7319,O
subtype-I2,7319,B-GENE-N
imidazol,7319,I-GENE-N
(,7319,I-GENE-N
in,7319,I-GENE-N
),7319,I-GENE-N
e,7319,I-GENE-N
receptor,7319,I-GENE-N
),7319,O
",",7319,O
plus,7319,O
a,7319,O
novel,7319,O
guanabenz-sensitive,7319,B-CHEMICAL
site,7319,O
",",7319,O
as,7319,O
well,7319,O
as,7319,O
an,7319,O
alpha-2A,7319,B-GENE-Y
adrenoceptor,7319,I-GENE-Y
.,7319,O
These,7320,O
nonadrenoceptor,7320,O
binding,7320,O
sites,7320,O
may,7320,O
explain,7320,O
certain,7320,O
novel,7320,O
platelet,7320,O
aggregatory,7320,O
properties,7320,O
previously,7320,O
ascribed,7320,O
to,7320,O
clonidine,7320,B-CHEMICAL
and,7320,O
endogenous,7320,O
clonidine-displacing,7320,B-CHEMICAL
substance,7320,O
(,7320,O
s,7320,O
),7320,O
",",7320,O
and,7320,O
may,7320,O
serve,7320,O
as,7320,O
markers,7320,O
of,7320,O
imidazoline,7320,B-GENE-N
receptors,7320,I-GENE-N
in,7320,O
humans,7320,O
.,7320,O
Age,7321,O
dependent,7321,O
differences,7321,O
in,7321,O
the,7321,O
regulation,7321,O
of,7321,O
hippocampal,7321,O
steroid,7321,B-CHEMICAL
hormones,7321,O
and,7321,O
receptor,7321,O
genes,7321,O
:,7321,O
relations,7321,O
to,7321,O
motivation,7321,O
and,7321,O
cognition,7321,O
in,7321,O
male,7321,O
rats,7321,O
.,7321,O
Estrogen,7322,B-CHEMICAL
and,7322,O
estrogenic,7322,O
functions,7322,O
are,7322,O
age-dependently,7322,O
involved,7322,O
in,7322,O
the,7322,O
modulation,7322,O
of,7322,O
learning,7322,O
",",7322,O
memory,7322,O
and,7322,O
mood,7322,O
in,7322,O
female,7322,O
humans,7322,O
and,7322,O
animals,7322,O
.,7322,O
However,7323,O
",",7323,O
the,7323,O
investigation,7323,O
of,7323,O
estrogenic,7323,O
effects,7323,O
in,7323,O
males,7323,O
has,7323,O
been,7323,O
largely,7323,O
neglected,7323,O
.,7323,O
Therefore,7324,O
",",7324,O
we,7324,O
investigated,7324,O
the,7324,O
hippocampal,7324,O
gene,7324,O
expression,7324,O
of,7324,O
estrogen,7324,B-GENE-N
receptors,7324,I-GENE-N
α,7324,I-GENE-N
and,7324,I-GENE-N
β,7324,I-GENE-N
(,7324,O
ERα,7324,B-GENE-N
",",7324,I-GENE-N
β,7324,I-GENE-N
),7324,O
in,7324,O
8-week-old,7324,O
",",7324,O
12-week-old,7324,O
and,7324,O
24-week-old,7324,O
male,7324,O
rats,7324,O
.,7324,O
To,7325,O
control,7325,O
for,7325,O
possible,7325,O
interactions,7325,O
between,7325,O
the,7325,O
expression,7325,O
of,7325,O
the,7325,O
estrogen,7325,B-GENE-Y
receptor,7325,I-GENE-Y
genes,7325,O
and,7325,O
other,7325,O
learning-related,7325,O
steroid,7325,B-GENE-N
receptors,7325,I-GENE-N
",",7325,O
androgen,7325,B-GENE-Y
receptors,7325,I-GENE-Y
(,7325,O
AR,7325,B-GENE-Y
),7325,O
",",7325,O
corticosterone-binding,7325,B-CHEMICAL
glucocorticoid,7325,B-GENE-Y
receptors,7325,I-GENE-Y
(,7325,O
GR,7325,B-GENE-Y
),7325,O
and,7325,O
mineralocorticoid,7325,B-GENE-Y
receptors,7325,I-GENE-Y
(,7325,O
MR,7325,B-GENE-Y
),7325,O
were,7325,O
also,7325,O
measured,7325,O
.,7325,O
Furthermore,7326,O
",",7326,O
the,7326,O
concentrations,7326,O
of,7326,O
the,7326,O
ligands,7326,O
17β-estradiol,7326,B-CHEMICAL
",",7326,O
testosterone,7326,B-CHEMICAL
and,7326,O
corticosterone,7326,B-CHEMICAL
were,7326,O
measured,7326,O
.,7326,O
The,7327,O
spatial,7327,O
training,7327,O
was,7327,O
conducted,7327,O
in,7327,O
a,7327,O
hole-board,7327,O
.,7327,O
The,7328,O
8-week-old,7328,O
rats,7328,O
exhibited,7328,O
higher,7328,O
levels,7328,O
of,7328,O
general,7328,O
activity,7328,O
and,7328,O
exploration,7328,O
during,7328,O
the,7328,O
training,7328,O
and,7328,O
performed,7328,O
best,7328,O
with,7328,O
respect,7328,O
to,7328,O
spatial,7328,O
learning,7328,O
and,7328,O
memory,7328,O
",",7328,O
whereas,7328,O
no,7328,O
difference,7328,O
was,7328,O
found,7328,O
between,7328,O
the,7328,O
12-week-old,7328,O
and,7328,O
24-week-old,7328,O
rats,7328,O
.,7328,O
The,7329,O
trained,7329,O
8-week-old,7329,O
rats,7329,O
exhibited,7329,O
increased,7329,O
gene,7329,O
expression,7329,O
of,7329,O
ERα,7329,B-GENE-Y
compared,7329,O
with,7329,O
the,7329,O
untrained,7329,O
rats,7329,O
in,7329,O
this,7329,O
age,7329,O
group,7329,O
as,7329,O
well,7329,O
as,7329,O
the,7329,O
trained,7329,O
12-week-old,7329,O
and,7329,O
24-week-old,7329,O
rats,7329,O
.,7329,O
The,7330,O
concentrations,7330,O
of,7330,O
estradiol,7330,B-CHEMICAL
and,7330,O
testosterone,7330,B-CHEMICAL
",",7330,O
however,7330,O
",",7330,O
were,7330,O
generally,7330,O
higher,7330,O
in,7330,O
the,7330,O
24-week-old,7330,O
rats,7330,O
than,7330,O
in,7330,O
the,7330,O
8-week-old,7330,O
and,7330,O
12-week-old,7330,O
rats,7330,O
.,7330,O
The,7331,O
ERα,7331,B-GENE-Y
mRNA,7331,O
concentrations,7331,O
correlated,7331,O
positively,7331,O
with,7331,O
behavior,7331,O
that,7331,O
indicate,7331,O
general,7331,O
learning,7331,O
motivation,7331,O
.,7331,O
These,7332,O
results,7332,O
suggest,7332,O
a,7332,O
specific,7332,O
role,7332,O
of,7332,O
ERα,7332,B-GENE-Y
in,7332,O
the,7332,O
age-related,7332,O
differences,7332,O
in,7332,O
motivation,7332,O
and,7332,O
subsequent,7332,O
success,7332,O
in,7332,O
the,7332,O
task,7332,O
.,7332,O
Thus,7333,O
",",7333,O
estrogen,7333,B-CHEMICAL
and,7333,O
estrogenic,7333,O
functions,7333,O
may,7333,O
play,7333,O
a,7333,O
more,7333,O
prominent,7333,O
role,7333,O
in,7333,O
young,7333,O
male,7333,O
behavior,7333,O
and,7333,O
development,7333,O
than,7333,O
has,7333,O
been,7333,O
previously,7333,O
assumed,7333,O
.,7333,O
Effects,7334,O
of,7334,O
ORF,7334,B-CHEMICAL
17583,7334,I-CHEMICAL
",",7334,O
other,7334,O
histamine,7334,B-GENE-N
H2-receptor,7334,I-GENE-N
antagonists,7334,O
and,7334,O
omeprazole,7334,B-CHEMICAL
on,7334,O
gastric,7334,O
acid,7334,O
secretory,7334,O
states,7334,O
in,7334,O
rats,7334,O
and,7334,O
dogs,7334,O
.,7334,O
ORF,7335,B-CHEMICAL
17583,7335,I-CHEMICAL
",",7335,O
a,7335,O
histamine,7335,B-GENE-N
H2-receptor,7335,I-GENE-N
antagonist,7335,O
",",7335,O
inhibited,7335,O
gastric,7335,O
acid,7335,O
secretion,7335,O
in,7335,O
pylorus-ligated,7335,O
rats,7335,O
(,7335,O
ED50,7335,O
=,7335,O
4.9,7335,O
mg/kg,7335,O
intraduodenal,7335,O
;,7335,O
3.4,7335,O
mg/kg,7335,O
p.o,7335,O
.,7335,O
;,7336,O
and,7336,O
0.21,7336,O
mg/kg,7336,O
i.p,7336,O
.,7336,O
),7336,O
and,7337,O
in,7337,O
total,7337,O
gastric,7337,O
fistula,7337,O
or,7337,O
Heidenhain,7337,O
pouch,7337,O
dogs,7337,O
stimulated,7337,O
by,7337,O
betazole,7337,O
(,7337,O
ED50,7337,O
=,7337,O
0.12,7337,O
mg/kg,7337,O
p.o,7337,O
.,7337,O
and,7338,O
0.08,7338,O
mg/kg,7338,O
i.v,7338,O
.,7338,O
),7339,O
",",7339,B-CHEMICAL
histamine,7339,O
",",7339,B-CHEMICAL
tetragastrin,7339,O
",",7339,B-CHEMICAL
bethanechol,7339,O
",",7339,B-CHEMICAL
2-deoxy-D-glucose,7339,O
or,7339,O
a,7339,O
meal,7339,O
(,7339,O
ED50,7339,O
values,7339,O
ranged,7339,O
from,7339,O
0.11-0.26,7339,O
mg/kg,7339,O
p.o,7339,O
.,7339,O
),7339,O
.,7339,O
The,7340,O
nonspecific,7340,O
inhibition,7340,O
of,7340,O
gastric,7340,O
acid,7340,O
by,7340,O
ORF,7340,I-CHEMICAL
17583,7340,O
supports,7340,O
the,7340,O
existence,7340,O
of,7340,O
interdependence,7340,O
between,7340,O
histamine,7340,I-GENE-N
and,7340,I-GENE-N
the,7340,I-GENE-N
gastrin,7340,I-GENE-N
and,7340,I-GENE-N
cholinergic,7340,I-GENE-N
receptors,7340,O
on,7340,O
the,7340,O
parietal,7340,O
cell,7340,O
surface,7340,O
.,7340,O
Antisecretory,7341,O
potency,7341,O
of,7341,O
ORF,7341,I-CHEMICAL
17583,7341,O
after,7341,O
intraduodenal,7341,O
administration,7341,O
in,7341,O
pylorus-ligated,7341,O
rats,7341,O
was,7341,O
6.4,7341,O
times,7341,O
greater,7341,O
than,7341,O
cimetidine,7341,O
",",7341,O
1.8,7341,O
times,7341,O
greater,7341,O
than,7341,O
ranitidine,7341,O
",",7341,O
equal,7341,O
to,7341,O
that,7341,O
of,7341,O
omeprazole,7341,O
and,7341,O
8,7341,O
times,7341,O
less,7341,O
than,7341,O
that,7341,O
of,7341,O
famotidine,7341,O
.,7341,O
Oral,7342,O
antisecretory,7342,O
potency,7342,O
of,7342,O
ORF,7342,I-CHEMICAL
17583,7342,O
in,7342,O
gastric,7342,O
fistula,7342,O
dogs,7342,O
was,7342,O
31,7342,O
times,7342,O
greater,7342,O
than,7342,O
cimetidine,7342,O
",",7342,O
3.7,7342,O
times,7342,O
greater,7342,O
than,7342,O
ranitidine,7342,O
and,7342,O
equal,7342,O
to,7342,O
that,7342,O
of,7342,O
omeprazole,7342,O
and,7342,O
famotidine,7342,O
.,7342,O
Studies,7343,O
using,7343,O
equieffective,7343,O
antisecretory,7343,O
doses,7343,O
of,7343,O
ORF,7343,I-CHEMICAL
17583,7343,O
and,7343,O
ranitidine,7343,O
in,7343,O
dogs,7343,O
suggested,7343,O
that,7343,O
ORF,7343,I-CHEMICAL
17583,7343,O
has,7343,O
a,7343,O
short,7343,O
duration,7343,O
of,7343,O
antisecretory,7343,O
activity,7343,O
similar,7343,O
to,7343,O
that,7343,O
of,7343,O
ranitidine,7343,O
.,7343,O
Platelet-derived,7344,O
microparticles,7344,O
in,7344,O
overweight/obese,7344,O
women,7344,O
with,7344,O
the,7344,O
polycystic,7344,O
ovary,7344,O
syndrome,7344,O
.,7344,O
A,7345,O
substantial,7345,O
proportion,7345,O
of,7345,O
women,7345,O
with,7345,O
the,7345,O
polycystic,7345,O
ovary,7345,O
syndrome,7345,O
(,7345,O
PCOS,7345,O
),7345,O
are,7345,O
obese,7345,O
and,7345,O
obesity,7345,O
is,7345,O
considered,7345,O
as,7345,O
a,7345,O
prothrombotic,7345,O
state,7345,O
.,7345,O
Platelet-derived,7346,O
microparticles,7346,O
(,7346,O
PMPs,7346,O
),7346,O
might,7346,O
be,7346,O
implicated,7346,O
in,7346,O
the,7346,O
activation,7346,O
of,7346,O
the,7346,O
coagulation,7346,O
cascade,7346,O
.,7346,O
We,7347,O
aimed,7347,O
to,7347,O
assess,7347,O
plasma,7347,O
PMPs,7347,O
in,7347,O
overweight/obese,7347,O
women,7347,O
with,7347,O
PCOS,7347,O
.,7347,O
We,7348,O
measured,7348,O
plasma,7348,O
PMPs,7348,O
and,7348,O
determined,7348,O
anthropometric,7348,O
",",7348,O
metabolic,7348,O
",",7348,O
hormonal,7348,O
and,7348,O
ultrasonographic,7348,O
features,7348,O
of,7348,O
PCOS,7348,O
in,7348,O
67,7348,O
overweight/obese,7348,O
women,7348,O
with,7348,O
PCOS,7348,O
(,7348,O
with,7348,O
body,7348,O
mass,7348,O
index,7348,O
[,7348,O
BMI,7348,O
],7348,O
>,7348,O
25.0,7348,O
kg/m,7348,O
(,7348,O
2,7348,O
),7348,O
),7348,O
and,7348,O
in,7348,O
21,7348,O
BMI-matched,7348,O
healthy,7348,O
women,7348,O
.,7348,O
Circulating,7349,O
androgens,7349,B-CHEMICAL
and,7349,O
markers,7349,O
of,7349,O
insulin,7349,B-GENE-Y
resistance,7349,O
(,7349,O
IR,7349,O
),7349,O
were,7349,O
higher,7349,O
in,7349,O
women,7349,O
with,7349,O
PCOS,7349,O
than,7349,O
in,7349,O
controls,7349,O
.,7349,O
Plasma,7350,O
PMPs,7350,O
were,7350,O
also,7350,O
higher,7350,O
in,7350,O
women,7350,O
with,7350,O
PCOS,7350,O
than,7350,O
in,7350,O
controls,7350,O
(,7350,O
p,7350,O
=,7350,O
0.046,7350,O
),7350,O
.,7350,O
In,7351,O
women,7351,O
with,7351,O
PCOS,7351,O
",",7351,O
plasma,7351,O
PMPs,7351,O
correlated,7351,O
with,7351,O
the,7351,O
mean,7351,O
number,7351,O
of,7351,O
follicles,7351,O
in,7351,O
the,7351,O
ovaries,7351,O
(,7351,O
r,7351,O
=,7351,O
0.343,7351,O
;,7351,O
p,7351,O
=,7351,O
0.006,7351,O
),7351,O
.,7351,O
In,7352,O
controls,7352,O
",",7352,O
plasma,7352,O
PMPs,7352,O
did,7352,O
not,7352,O
correlate,7352,O
with,7352,O
any,7352,O
of,7352,O
the,7352,O
studied,7352,O
parameters,7352,O
.,7352,O
In,7353,O
conclusion,7353,O
",",7353,O
plasma,7353,O
PMPs,7353,O
are,7353,O
elevated,7353,O
in,7353,O
overweight/obese,7353,O
women,7353,O
with,7353,O
PCOS,7353,O
compared,7353,O
with,7353,O
BMI-matched,7353,O
controls,7353,O
.,7353,O
The,7354,O
cause,7354,O
of,7354,O
this,7354,O
increase,7354,O
is,7354,O
unclear,7354,O
but,7354,O
both,7354,O
IR,7354,O
and,7354,O
hyperandrogenemia,7354,O
might,7354,O
be,7354,O
implicated,7354,O
.,7354,O
More,7355,O
studies,7355,O
are,7355,O
required,7355,O
to,7355,O
elucidate,7355,O
the,7355,O
pathogenesis,7355,O
of,7355,O
the,7355,O
elevation,7355,O
of,7355,O
PMPs,7355,O
in,7355,O
PCOS,7355,O
and,7355,O
to,7355,O
assess,7355,O
its,7355,O
implications,7355,O
on,7355,O
the,7355,O
cardiovascular,7355,O
risk,7355,O
of,7355,O
these,7355,O
patients,7355,O
.,7355,O
Underexpression,7356,O
of,7356,O
the,7356,O
Na+-dependent,7356,B-GENE-N
neutral,7356,I-GENE-N
amino,7356,I-GENE-N
acid,7356,I-GENE-N
transporter,7356,I-GENE-N
ASCT2,7356,B-GENE-Y
in,7356,O
the,7356,O
spontaneously,7356,O
hypertensive,7356,O
rat,7356,O
kidney,7356,O
.,7356,O
This,7357,O
study,7357,O
examined,7357,O
the,7357,O
inward,7357,O
transport,7357,O
of,7357,O
l-,7357,B-CHEMICAL
[,7357,I-CHEMICAL
(,7357,I-CHEMICAL
14,7357,I-CHEMICAL
),7357,I-CHEMICAL
C,7357,I-CHEMICAL
],7357,I-CHEMICAL
alanine,7357,I-CHEMICAL
",",7357,O
an,7357,O
ASCT2,7357,B-GENE-Y
preferential,7357,O
substrate,7357,O
",",7357,O
in,7357,O
monolayers,7357,O
of,7357,O
immortalized,7357,O
renal,7357,O
proximal,7357,O
tubular,7357,O
epithelial,7357,O
(,7357,O
PTE,7357,O
),7357,O
cells,7357,O
from,7357,O
Wistar-Kyoto,7357,O
(,7357,O
WKY,7357,O
),7357,O
and,7357,O
spontaneously,7357,O
hypertensive,7357,O
(,7357,O
SHR,7357,O
),7357,O
rats,7357,O
.,7357,O
The,7358,O
expression,7358,O
of,7358,O
ASCT2,7358,B-GENE-Y
in,7358,O
WKY,7358,O
and,7358,O
SHR,7358,O
PTE,7358,O
cells,7358,O
and,7358,O
kidney,7358,O
cortices,7358,O
from,7358,O
WKY,7358,O
and,7358,O
SHR,7358,O
was,7358,O
also,7358,O
evaluated,7358,O
.,7358,O
l-,7359,B-CHEMICAL
[,7359,I-CHEMICAL
(,7359,I-CHEMICAL
14,7359,I-CHEMICAL
),7359,I-CHEMICAL
C,7359,I-CHEMICAL
],7359,I-CHEMICAL
alanine,7359,I-CHEMICAL
uptake,7359,O
was,7359,O
highly,7359,O
dependent,7359,O
on,7359,O
extracellular,7359,O
Na,7359,B-CHEMICAL
(,7359,I-CHEMICAL
+,7359,I-CHEMICAL
),7359,I-CHEMICAL
.,7359,O
Replacement,7360,O
of,7360,O
NaCl,7360,B-CHEMICAL
by,7360,O
LiCl,7360,B-CHEMICAL
or,7360,O
choline,7360,B-CHEMICAL
chloride,7360,I-CHEMICAL
abolished,7360,O
transport,7360,O
activity,7360,O
in,7360,O
SHR,7360,O
and,7360,O
WKY,7360,O
PTE,7360,O
cells,7360,O
.,7360,O
In,7361,O
the,7361,O
presence,7361,O
of,7361,O
the,7361,O
system,7361,O
L,7361,O
inhibitor,7361,O
BCH,7361,O
",",7361,O
Na,7361,B-CHEMICAL
(,7361,I-CHEMICAL
+,7361,I-CHEMICAL
),7361,I-CHEMICAL
-dependent,7361,O
l-alanine,7361,B-CHEMICAL
uptake,7361,O
in,7361,O
WKY,7361,O
and,7361,O
SHR,7361,O
PTE,7361,O
cells,7361,O
was,7361,O
inhibited,7361,O
by,7361,O
alanine,7361,B-CHEMICAL
",",7361,O
serine,7361,B-CHEMICAL
",",7361,O
and,7361,O
cysteine,7361,B-CHEMICAL
",",7361,O
which,7361,O
is,7361,O
consistent,7361,O
with,7361,O
amino,7361,B-CHEMICAL
acid,7361,I-CHEMICAL
transport,7361,O
through,7361,O
ASCT2,7361,B-GENE-Y
.,7361,O
The,7362,O
saturable,7362,O
component,7362,O
of,7362,O
Na,7362,B-CHEMICAL
(,7362,I-CHEMICAL
+,7362,I-CHEMICAL
),7362,I-CHEMICAL
-dependent,7362,O
l-alanine,7362,B-CHEMICAL
transport,7362,O
under,7362,O
V,7362,O
(,7362,O
max,7362,O
),7362,O
conditions,7362,O
in,7362,O
SHR,7362,O
PTE,7362,O
cells,7362,O
was,7362,O
one-half,7362,O
of,7362,O
that,7362,O
in,7362,O
WKY,7362,O
PTE,7362,O
cells,7362,O
",",7362,O
with,7362,O
similar,7362,O
K,7362,O
(,7362,O
m,7362,O
),7362,O
values,7362,O
.,7362,O
Differences,7363,O
in,7363,O
magnitude,7363,O
of,7363,O
Na,7363,B-CHEMICAL
(,7363,I-CHEMICAL
+,7363,I-CHEMICAL
),7363,I-CHEMICAL
-dependent,7363,O
l-alanine,7363,B-CHEMICAL
uptake,7363,O
through,7363,O
ASCT2,7363,B-GENE-Y
between,7363,O
WKY,7363,O
and,7363,O
SHR,7363,O
PTE,7363,O
cells,7363,O
correlated,7363,O
positively,7363,O
with,7363,O
differences,7363,O
in,7363,O
ASCT2,7363,B-GENE-Y
protein,7363,O
expression,7363,O
",",7363,O
this,7363,O
being,7363,O
more,7363,O
abundant,7363,O
in,7363,O
WKY,7363,O
PTE,7363,O
cells,7363,O
.,7363,O
Abundance,7364,O
of,7364,O
ASCT2,7364,B-GENE-Y
transcript,7364,O
and,7364,O
protein,7364,O
in,7364,O
kidney,7364,O
cortices,7364,O
of,7364,O
SHR,7364,O
rats,7364,O
was,7364,O
also,7364,O
lower,7364,O
than,7364,O
that,7364,O
in,7364,O
normotensive,7364,O
WKY,7364,O
rats,7364,O
.,7364,O
In,7365,O
conclusion,7365,O
",",7365,O
immortalized,7365,O
SHR,7365,O
and,7365,O
WKY,7365,O
PTE,7365,O
cells,7365,O
take,7365,O
up,7365,O
l-alanine,7365,B-CHEMICAL
mainly,7365,O
through,7365,O
a,7365,O
high-affinity,7365,O
Na,7365,B-GENE-N
(,7365,I-GENE-N
+,7365,I-GENE-N
),7365,I-GENE-N
-dependent,7365,I-GENE-N
amino,7365,I-GENE-N
acid,7365,I-GENE-N
transporter,7365,I-GENE-N
",",7365,O
with,7365,O
functional,7365,O
features,7365,O
of,7365,O
ASCT2,7365,B-GENE-Y
transport,7365,O
.,7365,O
The,7366,O
activity,7366,O
and,7366,O
expression,7366,O
of,7366,O
the,7366,O
ASCT2,7366,B-GENE-Y
transporter,7366,O
were,7366,O
considerably,7366,O
lower,7366,O
in,7366,O
the,7366,O
SHR,7366,O
cells,7366,O
.,7366,O
The,7367,O
antipsychotic,7367,O
drugs,7367,O
sertindole,7367,B-CHEMICAL
and,7367,O
pimozide,7367,B-CHEMICAL
block,7367,O
erg3,7367,B-GENE-Y
",",7367,O
a,7367,O
human,7367,B-GENE-N
brain,7367,I-GENE-N
K,7367,I-GENE-N
(,7367,I-GENE-N
+,7367,I-GENE-N
),7367,I-GENE-N
channel,7367,I-GENE-N
.,7367,O
The,7368,O
antipsychotic,7368,O
drugs,7368,O
sertindole,7368,B-CHEMICAL
and,7368,O
pimozide,7368,B-CHEMICAL
are,7368,O
known,7368,O
to,7368,O
prolong,7368,O
the,7368,O
QT,7368,O
interval,7368,O
on,7368,O
the,7368,O
electrocardiogram,7368,O
via,7368,O
a,7368,O
high,7368,O
affinity,7368,O
block,7368,O
of,7368,O
the,7368,O
cardiac,7368,B-GENE-N
K,7368,I-GENE-N
(,7368,I-GENE-N
+,7368,I-GENE-N
),7368,I-GENE-N
channel,7368,I-GENE-N
known,7368,O
as,7368,O
HERG,7368,B-GENE-Y
(,7368,O
human,7368,B-GENE-Y
ether-a-go-go-related,7368,I-GENE-Y
gene,7368,I-GENE-Y
;,7368,O
erg1,7368,B-GENE-Y
),7368,O
.,7368,O
We,7369,O
wished,7369,O
to,7369,O
test,7369,O
whether,7369,O
these,7369,O
drugs,7369,O
also,7369,O
displayed,7369,O
high,7369,O
affinity,7369,O
for,7369,O
the,7369,O
related,7369,O
neuronal,7369,B-GENE-N
K,7369,I-GENE-N
(,7369,I-GENE-N
+,7369,I-GENE-N
),7369,I-GENE-N
channel,7369,I-GENE-N
erg3,7369,B-GENE-Y
.,7369,O
The,7370,O
cDNA,7370,O
encoding,7370,O
erg3,7370,B-GENE-Y
channel,7370,O
was,7370,O
cloned,7370,O
from,7370,O
a,7370,O
human,7370,O
brain,7370,O
library,7370,O
.,7370,O
Northern,7371,O
analysis,7371,O
confirmed,7371,O
that,7371,O
the,7371,O
channel,7371,O
was,7371,O
localized,7371,O
to,7371,O
brain,7371,O
relative,7371,O
to,7371,O
other,7371,O
tissues,7371,O
including,7371,O
heart,7371,O
",",7371,O
liver,7371,O
and,7371,O
lung,7371,O
.,7371,O
Within,7372,O
the,7372,O
brain,7372,O
",",7372,O
erg3,7372,B-GENE-Y
was,7372,O
expressed,7372,O
in,7372,O
higher,7372,O
amounts,7372,O
in,7372,O
the,7372,O
frontal,7372,O
lobe,7372,O
and,7372,O
cerebellum,7372,O
relative,7372,O
to,7372,O
the,7372,O
temporal,7372,O
",",7372,O
parietal,7372,O
and,7372,O
occipital,7372,O
lobes,7372,O
.,7372,O
Transient,7373,O
expression,7373,O
of,7373,O
erg3,7373,B-GENE-Y
in,7373,O
Chinese,7373,O
hamster,7373,O
ovary,7373,O
cells,7373,O
produced,7373,O
outwardly,7373,O
directed,7373,O
K,7373,B-CHEMICAL
(,7373,I-CHEMICAL
+,7373,I-CHEMICAL
),7373,I-CHEMICAL
currents,7373,O
that,7373,O
activated,7373,O
at,7373,O
approximately,7373,O
-50,7373,O
mV,7373,O
and,7373,O
produced,7373,O
a,7373,O
large,7373,O
transient,7373,O
component,7373,O
at,7373,O
positive,7373,O
membrane,7373,O
potentials,7373,O
.,7373,O
Inward,7374,O
tail,7374,O
currents,7374,O
measured,7374,O
at,7374,O
-100,7374,O
mV,7374,O
were,7374,O
blocked,7374,O
in,7374,O
a,7374,O
dose-dependent,7374,O
fashion,7374,O
by,7374,O
sertindole,7374,B-CHEMICAL
resulting,7374,O
in,7374,O
an,7374,O
IC,7374,O
(,7374,O
50,7374,O
),7374,O
value,7374,O
of,7374,O
43,7374,O
nM,7374,O
.,7374,O
Significant,7375,O
inhibition,7375,O
was,7375,O
observed,7375,O
at,7375,O
concentrations,7375,O
as,7375,O
low,7375,O
as,7375,O
3,7375,O
nM,7375,O
.,7375,O
Block,7376,O
of,7376,O
erg3,7376,B-GENE-Y
by,7376,O
sertindole,7376,B-CHEMICAL
also,7376,O
displayed,7376,O
a,7376,O
positive,7376,O
voltage-dependence,7376,O
.,7376,O
Pimozide,7377,B-CHEMICAL
blocked,7377,O
erg3,7377,B-GENE-Y
channel,7377,O
currents,7377,O
with,7377,O
an,7377,O
IC,7377,O
(,7377,O
50,7377,O
),7377,O
of,7377,O
103,7377,O
nM,7377,O
and,7377,O
significant,7377,O
inhibition,7377,O
was,7377,O
noted,7377,O
at,7377,O
concentrations,7377,O
of,7377,O
10,7377,O
nM,7377,O
and,7377,O
higher,7377,O
.,7377,O
We,7378,O
conclude,7378,O
that,7378,O
erg3,7378,B-GENE-Y
can,7378,O
be,7378,O
blocked,7378,O
by,7378,O
certain,7378,O
antipsychotic,7378,O
drugs,7378,O
like,7378,O
sertindole,7378,B-CHEMICAL
and,7378,O
pimozide,7378,B-CHEMICAL
.,7378,O
Inhibition,7379,O
of,7379,O
erg3,7379,B-GENE-Y
or,7379,O
related,7379,O
K,7379,B-GENE-N
(,7379,I-GENE-N
+,7379,I-GENE-N
),7379,I-GENE-N
channels,7379,I-GENE-N
in,7379,O
the,7379,O
brain,7379,O
may,7379,O
contribute,7379,O
to,7379,O
the,7379,O
efficacy/side,7379,O
effect,7379,O
profiles,7379,O
of,7379,O
some,7379,O
antipsychotic,7379,O
drugs,7379,O
.,7379,O
Different,7380,O
neuroleptics,7380,O
show,7380,O
common,7380,O
dose,7380,O
and,7380,O
time,7380,O
dependent,7380,O
effects,7380,O
in,7380,O
quantitative,7380,O
field,7380,O
potential,7380,O
analysis,7380,O
in,7380,O
freely,7380,O
moving,7380,O
rats,7380,O
.,7380,O
Under,7381,O
the,7381,O
assumption,7381,O
that,7381,O
field,7381,O
potentials,7381,O
recorded,7381,O
from,7381,O
particular,7381,O
brain,7381,O
areas,7381,O
reflect,7381,O
the,7381,O
net,7381,O
balance,7381,O
of,7381,O
neurotransmitter,7381,O
activities,7381,O
",",7381,O
the,7381,O
dose-,7381,O
and,7381,O
time-dependent,7381,O
responses,7381,O
induced,7381,O
by,7381,O
intraperitoneal,7381,O
application,7381,O
of,7381,O
different,7381,O
neuroleptic,7381,O
drugs,7381,O
are,7381,O
quantified,7381,O
by,7381,O
spectral,7381,O
analysis,7381,O
of,7381,O
the,7381,O
electroencephalogram,7381,O
recorded,7381,O
from,7381,O
frontal,7381,O
cortex,7381,O
",",7381,O
hippocampus,7381,O
",",7381,O
striatum,7381,O
and,7381,O
reticular,7381,O
formation,7381,O
.,7381,O
The,7382,O
actions,7382,O
of,7382,O
haloperidol,7382,B-CHEMICAL
",",7382,O
chlorpromazine,7382,B-CHEMICAL
",",7382,O
clozapine,7382,B-CHEMICAL
",",7382,O
prothipendyl,7382,B-CHEMICAL
and,7382,O
thioridazine,7382,B-CHEMICAL
in,7382,O
general,7382,O
were,7382,O
characterized,7382,O
by,7382,O
increases,7382,O
of,7382,O
the,7382,O
spectral,7382,O
power,7382,O
in,7382,O
the,7382,O
alpha,7382,O
1,7382,O
and,7382,O
beta,7382,O
range,7382,O
",",7382,O
at,7382,O
higher,7382,O
dosages,7382,O
also,7382,O
in,7382,O
the,7382,O
theta,7382,O
range,7382,O
.,7382,O
This,7383,O
observed,7383,O
pattern,7383,O
of,7383,O
changes,7383,O
is,7383,O
in,7383,O
line,7383,O
with,7383,O
the,7383,O
neuroleptic,7383,O
induced,7383,O
spectral,7383,O
changes,7383,O
reported,7383,O
in,7383,O
the,7383,O
literature,7383,O
for,7383,O
other,7383,O
animals,7383,O
and,7383,O
man,7383,O
.,7383,O
In,7384,O
the,7384,O
light,7384,O
of,7384,O
the,7384,O
already,7384,O
known,7384,O
effects,7384,O
of,7384,O
other,7384,O
psychoactive,7384,O
drugs,7384,O
on,7384,O
the,7384,O
frequency,7384,O
content,7384,O
of,7384,O
field,7384,O
potentials,7384,O
in,7384,O
the,7384,O
rat,7384,O
",",7384,O
it,7384,O
should,7384,O
now,7384,O
be,7384,O
possible,7384,O
to,7384,O
classify,7384,O
different,7384,O
drugs,7384,O
in,7384,O
terms,7384,O
of,7384,O
their,7384,O
clinical,7384,O
indication,7384,O
.,7384,O
With,7385,O
respect,7385,O
to,7385,O
the,7385,O
type,7385,O
of,7385,O
neurotransmitter,7385,O
control,7385,O
underlying,7385,O
the,7385,O
changes,7385,O
produced,7385,O
by,7385,O
various,7385,O
neuroleptics,7385,O
",",7385,O
it,7385,O
is,7385,O
quite,7385,O
obvious,7385,O
from,7385,O
the,7385,O
comparisons,7385,O
with,7385,O
the,7385,O
respective,7385,O
drug,7385,O
effects,7385,O
that,7385,O
dopamine-D1-receptor,7385,B-GENE-Y
controlled,7385,O
transmission,7385,O
is,7385,O
not,7385,O
responsible,7385,O
for,7385,O
this,7385,O
action,7385,O
.,7385,O
On,7386,O
the,7386,O
basis,7386,O
of,7386,O
earlier,7386,O
findings,7386,O
a,7386,O
possible,7386,O
interaction,7386,O
between,7386,O
dopamine-D2,7386,B-GENE-Y
receptor,7386,I-GENE-Y
or,7386,O
glutamatergic,7386,O
transmitter,7386,O
control,7386,O
is,7386,O
discussed,7386,O
.,7386,O
Single-walled,7387,O
carbon,7387,B-CHEMICAL
nanotube,7387,O
surface,7387,O
control,7387,O
of,7387,O
complement,7387,O
recognition,7387,O
and,7387,O
activation,7387,O
.,7387,O
Carbon,7388,B-CHEMICAL
nanotubes,7388,O
(,7388,O
CNTs,7388,O
),7388,O
are,7388,O
receiving,7388,O
considerable,7388,O
attention,7388,O
in,7388,O
site-specific,7388,O
drug,7388,O
and,7388,O
nucleic,7388,O
acid,7388,O
delivery,7388,O
",",7388,O
photodynamic,7388,O
therapy,7388,O
",",7388,O
and,7388,O
photoacoustic,7388,O
molecular,7388,O
imaging,7388,O
.,7388,O
Despite,7389,O
these,7389,O
advances,7389,O
",",7389,O
nanotubes,7389,O
may,7389,O
activate,7389,O
the,7389,O
complement,7389,O
system,7389,O
(,7389,O
an,7389,O
integral,7389,O
part,7389,O
of,7389,O
innate,7389,O
immunity,7389,O
),7389,O
",",7389,O
which,7389,O
can,7389,O
induce,7389,O
clinically,7389,O
significant,7389,O
anaphylaxis,7389,O
.,7389,O
We,7390,O
demonstrate,7390,O
that,7390,O
single-walled,7390,O
CNTs,7390,O
coated,7390,O
with,7390,O
human,7390,B-GENE-Y
serum,7390,I-GENE-Y
albumin,7390,I-GENE-Y
activate,7390,O
the,7390,O
complement,7390,O
system,7390,O
through,7390,O
C1q-mediated,7390,O
classical,7390,O
and,7390,O
the,7390,O
alternative,7390,O
pathways,7390,O
.,7390,O
Surface,7391,O
coating,7391,O
with,7391,O
methoxypoly,7391,B-CHEMICAL
(,7391,I-CHEMICAL
ethylene,7391,I-CHEMICAL
glycol,7391,I-CHEMICAL
),7391,I-CHEMICAL
-based,7391,O
amphiphiles,7391,O
",",7391,O
which,7391,O
confers,7391,O
solubility,7391,O
and,7391,O
prolongs,7391,O
circulation,7391,O
profiles,7391,O
of,7391,O
CNTs,7391,O
",",7391,O
activates,7391,O
the,7391,O
complement,7391,O
system,7391,O
differently,7391,O
",",7391,O
depending,7391,O
on,7391,O
the,7391,O
amphiphile,7391,O
structure,7391,O
.,7391,O
CNTs,7392,O
with,7392,O
linear,7392,O
poly,7392,B-CHEMICAL
(,7392,I-CHEMICAL
ethylene,7392,I-CHEMICAL
glycol,7392,I-CHEMICAL
),7392,I-CHEMICAL
amphiphiles,7392,O
trigger,7392,O
the,7392,O
lectin,7392,B-GENE-N
pathway,7392,O
of,7392,O
the,7392,O
complement,7392,O
through,7392,O
both,7392,O
L-ficolin,7392,O
and,7392,O
mannan-binding,7392,O
lectin,7392,B-GENE-N
recognition,7392,O
.,7392,O
The,7393,O
lectin,7393,B-GENE-N
pathway,7393,O
activation,7393,O
",",7393,O
however,7393,O
",",7393,O
did,7393,O
not,7393,O
trigger,7393,O
the,7393,O
amplification,7393,O
loop,7393,O
of,7393,O
the,7393,O
alternative,7393,O
pathway,7393,O
.,7393,O
An,7394,O
amphiphile,7394,O
with,7394,O
branched,7394,O
poly,7394,B-CHEMICAL
(,7394,I-CHEMICAL
ethylene,7394,I-CHEMICAL
glycol,7394,I-CHEMICAL
),7394,I-CHEMICAL
architecture,7394,O
also,7394,O
activated,7394,O
the,7394,O
lectin,7394,B-GENE-N
pathway,7394,O
but,7394,O
only,7394,O
through,7394,O
L-ficolin,7394,O
recognition,7394,O
.,7394,O
Importantly,7395,O
",",7395,O
this,7395,O
mode,7395,O
of,7395,O
activation,7395,O
neither,7395,O
generated,7395,O
anaphylatoxins,7395,O
nor,7395,O
induced,7395,O
triggering,7395,O
of,7395,O
the,7395,O
effector,7395,O
arm,7395,O
of,7395,O
the,7395,O
complement,7395,O
system,7395,O
.,7395,O
These,7396,O
observations,7396,O
provide,7396,O
a,7396,O
major,7396,O
step,7396,O
toward,7396,O
nanomaterial,7396,O
surface,7396,O
modification,7396,O
with,7396,O
polymers,7396,O
that,7396,O
have,7396,O
the,7396,O
properties,7396,O
to,7396,O
significantly,7396,O
improve,7396,O
innate,7396,O
immunocompatibility,7396,O
by,7396,O
limiting,7396,O
the,7396,O
formation,7396,O
of,7396,O
complement,7396,O
C3,7396,B-GENE-N
and,7396,I-GENE-N
C5,7396,I-GENE-N
convertases,7396,I-GENE-N
.,7396,O
Conformational,7397,O
variations,7397,O
of,7397,O
both,7397,O
phosphodiesterase-5,7397,B-GENE-Y
and,7397,O
inhibitors,7397,O
provide,7397,O
the,7397,O
structural,7397,O
basis,7397,O
for,7397,O
the,7397,O
physiological,7397,O
effects,7397,O
of,7397,O
vardenafil,7397,B-CHEMICAL
and,7397,O
sildenafil,7397,B-CHEMICAL
.,7397,O
Vardenafil,7398,B-CHEMICAL
has,7398,O
higher,7398,O
affinity,7398,O
to,7398,O
phosphodiesterase-5,7398,B-GENE-Y
(,7398,O
PDE5,7398,B-GENE-Y
),7398,O
than,7398,O
sildenafil,7398,B-CHEMICAL
and,7398,O
lower,7398,O
administered,7398,O
dosage,7398,O
for,7398,O
the,7398,O
treatment,7398,O
of,7398,O
erectile,7398,O
dysfunction,7398,O
.,7398,O
However,7399,O
",",7399,O
the,7399,O
molecular,7399,O
basis,7399,O
for,7399,O
these,7399,O
differences,7399,O
is,7399,O
puzzling,7399,O
because,7399,O
two,7399,O
drugs,7399,O
have,7399,O
similar,7399,O
chemical,7399,O
structures,7399,O
.,7399,O
Reported,7400,O
here,7400,O
is,7400,O
a,7400,O
crystal,7400,O
structure,7400,O
of,7400,O
the,7400,O
fully,7400,O
active,7400,O
and,7400,O
nonmutated,7400,O
PDE5A1,7400,B-GENE-N
catalytic,7400,I-GENE-N
domain,7400,I-GENE-N
in,7400,O
complex,7400,O
with,7400,O
vardenafil,7400,B-CHEMICAL
.,7400,O
The,7401,O
structure,7401,O
shows,7401,O
that,7401,O
the,7401,O
conformation,7401,O
of,7401,O
the,7401,O
H-loop,7401,O
in,7401,O
the,7401,O
PDE5A1-vardenafil,7401,B-GENE-Y
complex,7401,O
is,7401,O
different,7401,O
from,7401,O
those,7401,O
of,7401,O
any,7401,O
known,7401,O
structures,7401,O
of,7401,O
the,7401,O
unliganded,7401,O
PDE5,7401,B-GENE-Y
and,7401,O
its,7401,O
complexes,7401,O
with,7401,O
the,7401,O
inhibitors,7401,O
.,7401,O
In,7402,O
addition,7402,O
",",7402,O
the,7402,O
molecular,7402,O
configuration,7402,O
of,7402,O
vardenafil,7402,B-CHEMICAL
differs,7402,O
from,7402,O
that,7402,O
of,7402,O
sildenafil,7402,B-CHEMICAL
when,7402,O
bound,7402,O
to,7402,O
PDE5,7402,B-GENE-Y
.,7402,O
It,7403,O
is,7403,O
noteworthy,7403,O
that,7403,O
the,7403,O
binding,7403,O
of,7403,O
vardenafil,7403,B-CHEMICAL
causes,7403,O
loss,7403,O
of,7403,O
the,7403,O
divalent,7403,O
metal,7403,O
ions,7403,O
that,7403,O
have,7403,O
been,7403,O
observed,7403,O
in,7403,O
all,7403,O
the,7403,O
previously,7403,O
published,7403,O
PDE,7403,B-GENE-N
structures,7403,O
.,7403,O
The,7404,O
conformational,7404,O
variation,7404,O
of,7404,O
both,7404,O
PDE5,7404,B-GENE-Y
and,7404,O
the,7404,O
inhibitors,7404,O
provides,7404,O
structural,7404,O
insight,7404,O
into,7404,O
the,7404,O
different,7404,O
potencies,7404,O
of,7404,O
the,7404,O
drugs,7404,O
.,7404,O
Cucurbitacin,7405,B-CHEMICAL
I,7405,I-CHEMICAL
inhibits,7405,O
rac1,7405,B-GENE-Y
activation,7405,O
in,7405,O
breast,7405,O
cancer,7405,O
cells,7405,O
by,7405,O
a,7405,O
reactive,7405,O
oxygen,7405,B-CHEMICAL
species-mediated,7405,O
mechanism,7405,O
and,7405,O
independently,7405,O
of,7405,O
janus,7405,B-GENE-Y
tyrosine,7405,I-GENE-Y
kinase,7405,I-GENE-Y
2,7405,I-GENE-Y
and,7405,O
p-rex1,7405,B-GENE-Y
.,7405,O
The,7406,O
small,7406,O
GTPase,7406,B-GENE-N
Rac1,7406,B-GENE-Y
has,7406,O
been,7406,O
widely,7406,O
implicated,7406,O
in,7406,O
mammary,7406,O
tumorigenesis,7406,O
and,7406,O
metastasis,7406,O
.,7406,O
Previous,7407,O
studies,7407,O
established,7407,O
that,7407,O
stimulation,7407,O
of,7407,O
ErbB,7407,B-GENE-Y
receptors,7407,O
in,7407,O
breast,7407,O
cancer,7407,O
cells,7407,O
activates,7407,O
Rac1,7407,B-GENE-Y
and,7407,O
enhances,7407,O
motility,7407,O
via,7407,O
the,7407,O
Rac-guanine,7407,B-GENE-N
nucleotide,7407,I-GENE-N
exchange,7407,I-GENE-N
factor,7407,I-GENE-N
P-Rex1,7407,B-GENE-Y
.,7407,O
As,7408,O
the,7408,O
Janus,7408,B-GENE-Y
tyrosine,7408,I-GENE-Y
kinase,7408,I-GENE-Y
2,7408,I-GENE-Y
(,7408,O
Jak2,7408,B-GENE-Y
),7408,O
/signal,7408,O
transducer,7408,I-GENE-Y
and,7408,I-GENE-Y
activator,7408,I-GENE-Y
of,7408,I-GENE-Y
transcription,7408,I-GENE-Y
3,7408,I-GENE-Y
(,7408,O
Stat3,7408,B-GENE-Y
),7408,O
pathway,7408,O
has,7408,O
been,7408,O
shown,7408,O
to,7408,O
be,7408,O
functionally,7408,O
associated,7408,O
with,7408,O
ErbB,7408,B-GENE-Y
receptors,7408,O
",",7408,O
we,7408,O
asked,7408,O
if,7408,O
this,7408,O
pathway,7408,O
could,7408,O
mediate,7408,O
P-Rex1/Rac1,7408,B-GENE-Y
activation,7408,O
in,7408,O
response,7408,O
to,7408,O
ErbB,7408,B-GENE-Y
ligands,7408,O
.,7408,O
Here,7409,O
we,7409,O
found,7409,O
that,7409,O
the,7409,O
anticancer,7409,O
agent,7409,O
cucurbitacin,7409,B-CHEMICAL
I,7409,I-CHEMICAL
",",7409,O
a,7409,O
Jak2,7409,B-GENE-N
inhibitor,7409,O
",",7409,O
reduced,7409,O
the,7409,O
activation,7409,O
of,7409,O
Rac1,7409,B-GENE-Y
and,7409,O
motility,7409,O
in,7409,O
response,7409,O
to,7409,O
the,7409,O
ErbB3,7409,B-GENE-Y
ligand,7409,O
heregulin,7409,B-GENE-Y
in,7409,O
breast,7409,O
cancer,7409,O
cells,7409,O
.,7409,O
However,7410,O
",",7410,O
Rac1,7410,B-GENE-Y
activation,7410,O
was,7410,O
not,7410,O
affected,7410,O
by,7410,O
Jak2,7410,B-GENE-Y
or,7410,O
Stat3,7410,B-GENE-Y
RNA,7410,O
interference,7410,O
",",7410,O
suggesting,7410,O
that,7410,O
the,7410,O
effect,7410,O
of,7410,O
cucurbitacin,7410,B-CHEMICAL
I,7410,I-CHEMICAL
occurs,7410,O
through,7410,O
a,7410,O
Jak2-independent,7410,B-GENE-N
mechanism,7410,O
.,7410,O
Cucurbitacin,7411,B-CHEMICAL
I,7411,I-CHEMICAL
also,7411,O
failed,7411,O
to,7411,O
affect,7411,O
the,7411,O
activation,7411,O
of,7411,O
P-Rex1,7411,B-GENE-Y
by,7411,O
heregulin,7411,B-GENE-Y
.,7411,O
Subsequent,7412,O
analysis,7412,O
revealed,7412,O
that,7412,O
cucurbitacin,7412,B-CHEMICAL
I,7412,I-CHEMICAL
strongly,7412,O
activates,7412,O
RhoA,7412,B-GENE-N
and,7412,O
the,7412,O
Rho,7412,B-GENE-N
effector,7412,O
Rho,7412,B-GENE-N
kinase,7412,I-GENE-N
(,7412,O
ROCK,7412,B-GENE-N
),7412,O
in,7412,O
breast,7412,O
cancer,7412,O
cells,7412,O
and,7412,O
induces,7412,O
the,7412,O
formation,7412,O
of,7412,O
stress,7412,O
fibers,7412,O
.,7412,O
Interestingly,7413,O
",",7413,O
disruption,7413,O
of,7413,O
the,7413,O
RhoA-ROCK,7413,B-GENE-N
pathway,7413,O
prevented,7413,O
the,7413,O
inhibitory,7413,O
effect,7413,O
of,7413,O
cucurbitacin,7413,B-CHEMICAL
I,7413,I-CHEMICAL
on,7413,O
Rac1,7413,B-GENE-Y
activation,7413,O
by,7413,O
heregulin,7413,B-GENE-Y
.,7413,O
Lastly,7414,O
",",7414,O
we,7414,O
found,7414,O
that,7414,O
RhoA,7414,B-GENE-N
activation,7414,O
by,7414,O
cucurbitacin,7414,B-CHEMICAL
I,7414,I-CHEMICAL
is,7414,O
mediated,7414,O
by,7414,O
reactive,7414,O
oxygen,7414,B-CHEMICAL
species,7414,O
(,7414,O
ROS,7414,O
),7414,O
.,7414,O
The,7415,O
ROS,7415,O
scavenger,7415,O
N-acetyl,7415,B-CHEMICAL
l-cysteine,7415,I-CHEMICAL
and,7415,O
the,7415,O
mitochondrial,7415,O
antioxidant,7415,O
Mito-TEMPO,7415,O
rescued,7415,O
the,7415,O
inhibitory,7415,O
effect,7415,O
of,7415,O
cucurbitacin,7415,B-CHEMICAL
I,7415,I-CHEMICAL
on,7415,O
Rac1,7415,B-GENE-Y
activation,7415,O
.,7415,O
In,7416,O
conclusion,7416,O
",",7416,O
these,7416,O
results,7416,O
indicate,7416,O
that,7416,O
ErbB-driven,7416,B-GENE-Y
Rac1,7416,B-GENE-Y
activation,7416,O
in,7416,O
breast,7416,O
cancer,7416,O
cells,7416,O
proceeds,7416,O
independently,7416,O
of,7416,O
the,7416,O
Jak2,7416,B-GENE-N
pathway,7416,O
.,7416,O
Moreover,7417,O
",",7417,O
they,7417,O
established,7417,O
that,7417,O
the,7417,O
inhibitory,7417,O
effect,7417,O
of,7417,O
cucurbitacin,7417,B-CHEMICAL
I,7417,I-CHEMICAL
on,7417,O
Rac1,7417,B-GENE-Y
activity,7417,O
involves,7417,O
the,7417,O
alteration,7417,O
of,7417,O
the,7417,O
balance,7417,O
between,7417,O
Rho,7417,B-GENE-N
and,7417,O
Rac,7417,B-GENE-N
.,7417,O
Common,7418,O
and,7418,O
specific,7418,O
determinants,7418,O
for,7418,O
fibroblast,7418,B-GENE-N
growth,7418,I-GENE-N
factors,7418,I-GENE-N
in,7418,O
the,7418,O
ectodomain,7418,O
of,7418,O
the,7418,O
receptor,7418,B-GENE-N
kinase,7418,I-GENE-N
complex,7418,O
.,7418,O
The,7419,O
assembly,7419,O
and,7419,O
activation,7419,O
of,7419,O
oligomeric,7419,O
complexes,7419,O
of,7419,O
FGF,7419,B-GENE-N
",",7419,O
the,7419,O
transmembrane,7419,B-GENE-N
receptor,7419,I-GENE-N
kinase,7419,I-GENE-N
(,7419,O
FGFR,7419,B-GENE-N
),7419,O
",",7419,O
and,7419,O
heparan,7419,O
sulfate,7419,B-CHEMICAL
transmit,7419,O
intracellular,7419,O
signals,7419,O
regulating,7419,O
growth,7419,O
and,7419,O
function,7419,O
of,7419,O
cells,7419,O
.,7419,O
An,7420,O
understanding,7420,O
of,7420,O
the,7420,O
structural,7420,O
relationships,7420,O
between,7420,O
the,7420,O
three,7420,O
subunits,7420,O
and,7420,O
their,7420,O
redundancy,7420,O
and,7420,O
specificity,7420,O
is,7420,O
essential,7420,O
for,7420,O
understanding,7420,O
the,7420,O
ubiquitous,7420,O
FGF,7420,B-GENE-N
signaling,7420,O
system,7420,O
in,7420,O
health,7420,O
and,7420,O
disease,7420,O
.,7420,O
Previously,7421,O
",",7421,O
we,7421,O
reported,7421,O
that,7421,O
a,7421,O
primary,7421,O
heparin,7421,O
or,7421,O
heparan,7421,O
sulfate,7421,B-CHEMICAL
binding,7421,O
site,7421,O
resides,7421,O
in,7421,O
a,7421,O
distinct,7421,O
sequence,7421,O
in,7421,O
immunoglobulin,7421,B-GENE-N
(,7421,I-GENE-N
Ig,7421,I-GENE-N
),7421,I-GENE-N
-like,7421,I-GENE-N
module,7421,I-GENE-N
II,7421,I-GENE-N
of,7421,O
the,7421,O
three,7421,O
modules,7421,O
of,7421,O
FGFR,7421,B-GENE-N
.,7421,O
Here,7422,O
we,7422,O
report,7422,O
that,7422,O
in,7422,O
the,7422,O
absence,7422,O
of,7422,O
flanking,7422,O
sequences,7422,O
",",7422,O
isolated,7422,O
Ig,7422,B-GENE-N
module,7422,I-GENE-N
II,7422,I-GENE-N
of,7422,O
FGFR1,7422,B-GENE-Y
supports,7422,O
the,7422,O
binding,7422,O
of,7422,O
FGF-1,7422,B-GENE-Y
",",7422,O
FGF-2,7422,B-GENE-Y
",",7422,O
and,7422,O
FGF-7,7422,B-GENE-Y
in,7422,O
respective,7422,O
order,7422,O
of,7422,O
affinity,7422,O
.,7422,O
None,7423,O
of,7423,O
the,7423,O
three,7423,O
FGFs,7423,B-GENE-N
detectably,7423,O
bind,7423,O
Ig,7423,B-GENE-N
module,7423,I-GENE-N
I,7423,I-GENE-N
or,7423,I-GENE-N
the,7423,I-GENE-N
IIIb,7423,I-GENE-N
and,7423,I-GENE-N
IIIc,7423,I-GENE-N
splice,7423,O
variants,7423,O
of,7423,O
Ig,7423,B-GENE-N
module,7423,I-GENE-N
III,7423,I-GENE-N
in,7423,O
the,7423,O
absence,7423,O
of,7423,O
flanking,7423,O
sequences,7423,O
.,7423,O
Ig,7424,B-GENE-N
module,7424,I-GENE-N
I,7424,I-GENE-N
and,7424,O
the,7424,O
C-terminus,7424,B-CHEMICAL
of,7424,O
Ig,7424,B-GENE-N
module,7424,I-GENE-N
III,7424,I-GENE-N
are,7424,O
dispensable,7424,O
for,7424,O
high-affinity,7424,O
binding,7424,O
of,7424,O
FGF-1,7424,B-GENE-Y
",",7424,O
FGF-2,7424,B-GENE-Y
",",7424,O
and,7424,O
FGF-7,7424,B-GENE-Y
.,7424,O
Alterations,7425,O
in,7425,O
highly,7425,O
conserved,7425,O
Ig,7425,B-GENE-N
module,7425,I-GENE-N
II,7425,I-GENE-N
in,7425,O
the,7425,O
heparin,7425,O
binding,7425,O
domain,7425,O
and,7425,O
substitution,7425,O
of,7425,O
individual,7425,O
sequence,7425,O
domains,7425,O
spanning,7425,O
the,7425,O
entire,7425,O
sequence,7425,O
of,7425,O
Ig,7425,B-GENE-N
module,7425,I-GENE-N
II,7425,I-GENE-N
with,7425,O
those,7425,O
from,7425,O
Ig,7425,B-GENE-N
module,7425,I-GENE-N
I,7425,I-GENE-N
obliterated,7425,O
FGF,7425,B-GENE-N
binding,7425,O
.,7425,O
Addition,7426,O
of,7426,O
a,7426,O
specific,7426,O
number,7426,O
of,7426,O
FGFR,7426,B-GENE-N
sequences,7426,O
to,7426,O
the,7426,O
C-terminus,7426,B-CHEMICAL
of,7426,O
Ig,7426,B-GENE-N
module,7426,I-GENE-N
II,7426,I-GENE-N
resulted,7426,O
in,7426,O
a,7426,O
gain,7426,O
in,7426,O
affinity,7426,O
for,7426,O
FGF-7,7426,B-GENE-Y
.,7426,O
Several,7427,O
site-specific,7427,O
alterations,7427,O
in,7427,O
the,7427,O
C-terminus,7427,B-CHEMICAL
of,7427,O
full-length,7427,O
FGFR1IIIc,7427,B-GENE-N
",",7427,O
an,7427,O
isoform,7427,O
that,7427,O
otherwise,7427,O
absolutely,7427,O
rejects,7427,O
FGF-7,7427,B-GENE-Y
",",7427,O
resulted,7427,O
in,7427,O
gain,7427,O
of,7427,O
FGF-7,7427,B-GENE-Y
binding,7427,O
.,7427,O
These,7428,O
results,7428,O
suggest,7428,O
that,7428,O
a,7428,O
complex,7428,O
of,7428,O
Ig,7428,B-GENE-N
module,7428,I-GENE-N
II,7428,I-GENE-N
and,7428,O
heparan,7428,O
sulfate,7428,B-CHEMICAL
is,7428,O
the,7428,O
base,7428,O
common,7428,O
active,7428,O
core,7428,O
of,7428,O
the,7428,O
FGFR,7428,B-GENE-N
ectodomain,7428,I-GENE-N
and,7428,O
that,7428,O
flanking,7428,O
structural,7428,O
domains,7428,O
modify,7428,O
FGF,7428,B-GENE-N
affinity,7428,O
and,7428,O
determine,7428,O
specificity,7428,O
.,7428,O
Brain,7429,O
but,7429,O
not,7429,O
spinal,7429,O
NR2B,7429,B-GENE-Y
receptor,7429,O
is,7429,O
responsible,7429,O
for,7429,O
the,7429,O
anti-allodynic,7429,O
effect,7429,O
of,7429,O
an,7429,O
NR2B,7429,B-GENE-Y
subunit-selective,7429,O
antagonist,7429,O
"CP-101,606",7429,B-CHEMICAL
in,7429,O
a,7429,O
rat,7429,O
chronic,7429,O
constriction,7429,O
injury,7429,O
model,7429,O
.,7429,O
In,7430,O
order,7430,O
to,7430,O
examine,7430,O
the,7430,O
site,7430,O
of,7430,O
action,7430,O
of,7430,O
an,7430,O
NR2B,7430,B-GENE-Y
subtype-selective,7430,O
NMDA,7430,B-GENE-N
antagonist,7430,O
"CP-101,606",7430,B-CHEMICAL
",",7430,O
we,7430,O
investigated,7430,O
its,7430,O
analgesic,7430,O
effect,7430,O
in,7430,O
a,7430,O
rat,7430,O
model,7430,O
of,7430,O
neuropathic,7430,O
pain,7430,O
at,7430,O
various,7430,O
routes,7430,O
of,7430,O
administration,7430,O
.,7430,O
Mechanical,7431,O
allodynia,7431,O
was,7431,O
induced,7431,O
by,7431,O
chronic,7431,O
constriction,7431,O
injury,7431,O
(,7431,O
CCI,7431,O
),7431,O
of,7431,O
the,7431,O
sciatic,7431,O
nerve,7431,O
in,7431,O
male,7431,O
Sprague-Dawley,7431,O
rats,7431,O
.,7431,O
Subcutaneous,7432,O
treatment,7432,O
of,7432,O
the,7432,O
animals,7432,O
with,7432,O
"CP-101,606",7432,B-CHEMICAL
at,7432,O
10,7432,O
mg/kg,7432,O
significantly,7432,O
inhibited,7432,O
CCI-induced,7432,O
mechanical,7432,O
allodynia,7432,O
.,7432,O
Intracerebroventricular,7433,O
injection,7433,O
of,7433,O
"CP-101,606",7433,B-CHEMICAL
at,7433,O
10,7433,O
",",7433,O
30,7433,O
and,7433,O
100,7433,O
nmol,7433,O
also,7433,O
inhibited,7433,O
the,7433,O
mechanical,7433,O
allodynia,7433,O
in,7433,O
a,7433,O
dose-dependent,7433,O
manner,7433,O
",",7433,O
the,7433,O
statistically,7433,O
significant,7433,O
effect,7433,O
being,7433,O
achieved,7433,O
at,7433,O
the,7433,O
highest,7433,O
dose,7433,O
tested,7433,O
(,7433,O
100,7433,O
nmol,7433,O
),7433,O
without,7433,O
producing,7433,O
any,7433,O
behavioral,7433,O
abnormalities,7433,O
.,7433,O
However,7434,O
",",7434,O
intrathecal,7434,O
injection,7434,O
of,7434,O
"CP-101,606",7434,B-CHEMICAL
at,7434,O
a,7434,O
dose,7434,O
of,7434,O
300,7434,O
nmol,7434,O
failed,7434,O
to,7434,O
inhibit,7434,O
CCI-induced,7434,O
allodynia,7434,O
.,7434,O
A,7435,O
receptor,7435,O
binding,7435,O
assay,7435,O
using,7435,O
rat,7435,O
forebrain,7435,O
and,7435,O
spinal,7435,O
cord,7435,O
membrane,7435,O
preparations,7435,O
demonstrated,7435,O
that,7435,O
[,7435,B-CHEMICAL
3H,7435,I-CHEMICAL
],7435,I-CHEMICAL
"CP-101,606",7435,I-CHEMICAL
bound,7435,O
to,7435,O
the,7435,O
brain,7435,O
NR2B,7435,B-GENE-Y
receptor,7435,O
with,7435,O
a,7435,O
greater,7435,O
extent,7435,O
compared,7435,O
to,7435,O
the,7435,O
spinal,7435,O
cord,7435,O
one,7435,O
.,7435,O
These,7436,O
findings,7436,O
suggest,7436,O
that,7436,O
the,7436,O
anti-allodynia,7436,O
effect,7436,O
of,7436,O
"CP-101,606",7436,B-CHEMICAL
is,7436,O
ascribable,7436,O
to,7436,O
blockade,7436,O
of,7436,O
NR2B,7436,B-GENE-Y
receptors,7436,O
at,7436,O
the,7436,O
brain,7436,O
",",7436,O
but,7436,O
not,7436,O
at,7436,O
the,7436,O
spinal,7436,O
cord,7436,O
.,7436,O
In,7437,O
contrast,7437,O
",",7437,O
intrathecal,7437,O
injection,7437,O
of,7437,O
a,7437,O
non-selective,7437,O
NMDA,7437,B-GENE-N
antagonist,7437,O
",",7437,O
memantine,7437,B-CHEMICAL
",",7437,O
significantly,7437,O
inhibited,7437,O
CCI-induced,7437,O
mechanical,7437,O
allodynia,7437,O
at,7437,O
a,7437,O
dose,7437,O
of,7437,O
300,7437,O
nmol,7437,O
",",7437,O
indicating,7437,O
the,7437,O
difference,7437,O
in,7437,O
the,7437,O
site,7437,O
of,7437,O
action,7437,O
between,7437,O
the,7437,O
non-selective,7437,O
NMDA,7437,B-GENE-N
antagonist,7437,O
and,7437,O
the,7437,O
NR2B-specific,7437,B-GENE-Y
NMDA,7437,B-GENE-N
antagonist,7437,O
.,7437,O
Mutations,7438,O
within,7438,O
the,7438,O
human,7438,B-GENE-Y
GLYT2,7438,I-GENE-Y
(,7438,O
SLC6A5,7438,B-GENE-Y
),7438,O
gene,7438,O
associated,7438,O
with,7438,O
hyperekplexia,7438,O
.,7438,O
Hereditary,7439,O
hyperekplexia,7439,O
is,7439,O
a,7439,O
neuromotor,7439,O
disorder,7439,O
characterized,7439,O
by,7439,O
exaggerated,7439,O
startle,7439,O
reflexes,7439,O
and,7439,O
muscle,7439,O
stiffness,7439,O
in,7439,O
the,7439,O
neonate,7439,O
.,7439,O
The,7440,O
disease,7440,O
has,7440,O
been,7440,O
associated,7440,O
with,7440,O
mutations,7440,O
in,7440,O
the,7440,O
glycine,7440,B-GENE-N
receptor,7440,I-GENE-N
subunit,7440,O
genes,7440,O
GLRA1,7440,B-GENE-Y
and,7440,O
GLRB,7440,B-GENE-Y
.,7440,O
Here,7441,O
",",7441,O
we,7441,O
describe,7441,O
mutations,7441,O
within,7441,O
the,7441,O
neuronal,7441,O
glycine,7441,B-GENE-Y
transporter,7441,I-GENE-Y
2,7441,I-GENE-Y
gene,7441,O
(,7441,O
GLYT2,7441,B-GENE-Y
",",7441,O
or,7441,O
SLC6A5,7441,B-GENE-Y
",",7441,O
),7441,O
of,7441,O
hyperekplexia,7441,O
patients,7441,O
",",7441,O
whose,7441,O
symptoms,7441,O
can,7441,O
not,7441,O
be,7441,O
attributed,7441,O
to,7441,O
glycine,7441,B-GENE-N
receptor,7441,I-GENE-N
mutations,7441,O
.,7441,O
One,7442,O
of,7442,O
the,7442,O
GLYT2,7442,B-GENE-Y
mutations,7442,O
identified,7442,O
causes,7442,O
truncation,7442,O
of,7442,O
the,7442,O
transporter,7442,B-GENE-N
protein,7442,I-GENE-N
and,7442,O
a,7442,O
complete,7442,O
loss,7442,O
of,7442,O
transport,7442,O
function,7442,O
.,7442,O
Our,7443,O
results,7443,O
are,7443,O
consistent,7443,O
with,7443,O
GLYT2,7443,B-GENE-Y
being,7443,O
a,7443,O
disease,7443,O
gene,7443,O
in,7443,O
human,7443,O
hyperekplexia,7443,O
.,7443,O
Pharmacological,7444,O
properties,7444,O
of,7444,O
the,7444,O
anti-Parkinson,7444,O
drug,7444,O
rasagiline,7444,B-CHEMICAL
;,7444,O
modification,7444,O
of,7444,O
endogenous,7444,O
brain,7444,O
amines,7444,B-CHEMICAL
",",7444,O
reserpine,7444,B-CHEMICAL
reversal,7444,O
",",7444,O
serotonergic,7444,O
and,7444,O
dopaminergic,7444,O
behaviours,7444,O
.,7444,O
Rasagiline,7445,B-CHEMICAL
[,7445,O
N-propargyl-1R,7445,B-CHEMICAL
(,7445,I-CHEMICAL
+,7445,I-CHEMICAL
),7445,I-CHEMICAL
-aminoindan,7445,I-CHEMICAL
;,7445,O
TVP1012,7445,B-CHEMICAL
],7445,O
is,7445,O
a,7445,O
potent,7445,O
irreversible,7445,O
monoamine,7445,B-GENE-N
oxidase,7445,I-GENE-N
(,7445,O
MAO,7445,B-GENE-N
),7445,O
inhibitor,7445,O
with,7445,O
selectivity,7445,O
for,7445,O
type,7445,O
B,7445,O
of,7445,O
the,7445,O
enzyme,7445,O
",",7445,O
which,7445,O
is,7445,O
being,7445,O
developed,7445,O
for,7445,O
treatment,7445,O
of,7445,O
Parkinson,7445,O
's,7445,O
disease,7445,O
.,7445,O
In,7446,O
this,7446,O
study,7446,O
we,7446,O
examined,7446,O
effects,7446,O
of,7446,O
rasagiline,7446,B-CHEMICAL
on,7446,O
CNS,7446,O
monoamine,7446,B-CHEMICAL
levels,7446,O
",",7446,O
modification,7446,O
of,7446,O
behavioural,7446,O
response,7446,O
to,7446,O
L-tryptophan,7446,B-CHEMICAL
",",7446,O
fluoxetine,7446,B-CHEMICAL
and,7446,O
L-DOPA,7446,B-CHEMICAL
",",7446,O
and,7446,O
reversal,7446,O
of,7446,O
reserpine,7446,B-CHEMICAL
syndrome,7446,O
.,7446,O
Reserpine-induced,7447,B-CHEMICAL
ptosis,7447,O
was,7447,O
reversed,7447,O
by,7447,O
rasagiline,7447,B-CHEMICAL
at,7447,O
doses,7447,O
above,7447,O
2,7447,O
mg,7447,O
x,7447,O
kg,7447,O
(,7447,O
-1,7447,O
),7447,O
i.p.,7447,O
",",7447,O
which,7447,O
inhibit,7447,O
MAO-A,7447,B-GENE-Y
as,7447,O
well,7447,O
as,7447,O
MAO-B,7447,B-GENE-Y
",",7447,O
but,7447,O
not,7447,O
at,7447,O
MAO-B-selective,7447,B-GENE-Y
doses,7447,O
.,7447,O
However,7448,O
",",7448,O
combination,7448,O
of,7448,O
rasagiline,7448,B-CHEMICAL
(,7448,O
10,7448,O
mg,7448,O
x,7448,O
kg,7448,O
(,7448,O
-1,7448,O
),7448,O
i.p,7448,O
.,7448,O
),7448,O
with,7449,O
L-DOPA,7449,B-CHEMICAL
or,7449,O
L-tryptophan,7449,B-CHEMICAL
(,7449,O
50,7449,O
mg,7449,O
x,7449,O
kg,7449,O
(,7449,O
-1,7449,O
),7449,O
i.p,7449,O
.,7449,O
),7450,O
",",7450,O
or,7450,O
rasagiline,7450,O
(,7450,O
10,7450,O
mg,7450,O
x,7450,O
kg,7450,O
(,7450,O
-1,7450,O
),7450,O
p.o,7450,O
.,7450,O
),7450,O
with,7451,O
fluoxetine,7451,O
(,7451,O
10,7451,O
mg,7451,O
x,7451,O
kg,7451,O
(,7451,O
-1,7451,O
),7451,O
p.o,7451,O
.,7451,O
),7452,O
",",7452,O
did,7452,O
not,7452,O
induce,7452,O
the,7452,O
behavioural,7452,O
hyperactivity,7452,O
syndrome,7452,O
which,7452,O
is,7452,O
seen,7452,O
following,7452,O
inhibition,7452,O
of,7452,O
both,7452,O
MAO-A,7452,O
and,7452,O
MAO-B,7452,O
by,7452,O
tranylcypromine,7452,O
together,7452,O
with,7452,O
the,7452,O
monoamine,7452,O
precursors,7452,O
.,7452,O
Following,7453,O
oral,7453,O
administration,7453,O
",",7453,O
levels,7453,O
of,7453,O
noradrenaline,7453,O
(,7453,I-CHEMICAL
NA,7453,O
),7453,O
",",7453,B-CHEMICAL
5-hydroxytryptamine,7453,O
(,7453,I-CHEMICAL
5-HT,7453,O
),7453,O
and,7453,O
dopamine,7453,O
(,7453,I-CHEMICAL
DA,7453,O
),7453,O
were,7453,O
unaffected,7453,O
in,7453,O
hippocampus,7453,O
and,7453,O
striatum,7453,O
after,7453,O
single,7453,O
doses,7453,O
of,7453,O
rasagiline,7453,O
up,7453,O
to,7453,O
2,7453,O
mg,7453,O
x,7453,O
kg,7453,O
(,7453,O
-1,7453,O
),7453,O
.,7453,O
Following,7454,O
chronic,7454,O
oral,7454,O
administration,7454,O
(,7454,O
21,7454,O
days,7454,O
",",7454,O
one,7454,O
dose,7454,O
daily,7454,O
),7454,O
",",7454,O
levels,7454,O
of,7454,O
NA,7454,O
",",7454,B-CHEMICAL
5-HT,7454,O
and,7454,O
DA,7454,O
in,7454,O
hippocampus,7454,O
and,7454,O
striatum,7454,O
were,7454,O
unaffected,7454,O
by,7454,O
rasagiline,7454,O
at,7454,O
doses,7454,O
up,7454,O
to,7454,O
1,7454,O
mg,7454,O
x,7454,O
kg,7454,O
(,7454,O
-1,7454,O
),7454,O
.,7454,O
Rasagiline,7455,O
does,7455,O
not,7455,O
modify,7455,O
CNS,7455,O
monoamine,7455,O
tissue,7455,O
levels,7455,O
or,7455,O
monoamine-induced,7455,O
behavioural,7455,O
syndromes,7455,O
at,7455,O
doses,7455,O
which,7455,O
selectively,7455,O
inhibit,7455,O
MAO-B,7455,O
but,7455,O
not,7455,O
MAO-A,7455,O
.,7455,O
Characterization,7456,O
of,7456,O
the,7456,O
omega,7456,B-GENE-N
class,7456,I-GENE-N
of,7456,I-GENE-N
glutathione,7456,I-GENE-N
transferases,7456,I-GENE-N
.,7456,O
The,7457,O
Omega,7457,B-GENE-N
class,7457,I-GENE-N
of,7457,I-GENE-N
cytosolic,7457,I-GENE-N
glutathione,7457,I-GENE-N
transferases,7457,I-GENE-N
was,7457,O
initially,7457,O
recognized,7457,O
by,7457,O
bioinformatic,7457,O
analysis,7457,O
of,7457,O
human,7457,O
sequence,7457,O
databases,7457,O
",",7457,O
and,7457,O
orthologous,7457,O
sequences,7457,O
were,7457,O
subsequently,7457,O
discovered,7457,O
in,7457,O
mouse,7457,O
",",7457,O
rat,7457,O
",",7457,O
pig,7457,O
",",7457,O
Caenorhabditis,7457,O
elegans,7457,O
",",7457,O
Schistosoma,7457,O
mansoni,7457,O
",",7457,O
and,7457,O
Drosophila,7457,O
melanogaster,7457,O
.,7457,O
In,7458,O
humans,7458,O
and,7458,O
mice,7458,O
",",7458,O
two,7458,O
GSTO,7458,B-GENE-N
genes,7458,O
have,7458,O
been,7458,O
recognized,7458,O
and,7458,O
their,7458,O
genetic,7458,O
structures,7458,O
and,7458,O
expression,7458,O
patterns,7458,O
identified,7458,O
.,7458,O
In,7459,O
both,7459,O
species,7459,O
",",7459,O
GSTO1,7459,B-GENE-Y
mRNA,7459,O
is,7459,O
expressed,7459,O
in,7459,O
liver,7459,O
and,7459,O
heart,7459,O
as,7459,O
well,7459,O
as,7459,O
a,7459,O
range,7459,O
of,7459,O
other,7459,O
tissues,7459,O
.,7459,O
GSTO2,7460,B-GENE-Y
is,7460,O
expressed,7460,O
predominantly,7460,O
in,7460,O
the,7460,O
testis,7460,O
",",7460,O
although,7460,O
moderate,7460,O
levels,7460,O
of,7460,O
expression,7460,O
are,7460,O
seen,7460,O
in,7460,O
other,7460,O
tissues,7460,O
.,7460,O
Extensive,7461,O
immunohistochemistry,7461,O
of,7461,O
rat,7461,O
and,7461,O
human,7461,O
tissue,7461,O
sections,7461,O
has,7461,O
demonstrated,7461,O
cellular,7461,O
and,7461,O
subcellular,7461,O
specificity,7461,O
in,7461,O
the,7461,O
expression,7461,O
of,7461,O
GSTO1-1,7461,B-GENE-Y
.,7461,O
The,7462,O
crystal,7462,O
structure,7462,O
of,7462,O
recombinant,7462,O
human,7462,B-GENE-Y
GSTO1-1,7462,I-GENE-Y
has,7462,O
been,7462,O
determined,7462,O
",",7462,O
and,7462,O
it,7462,O
adopts,7462,O
the,7462,O
canonical,7462,O
GST,7462,B-GENE-N
fold,7462,I-GENE-N
.,7462,O
A,7463,O
cysteine,7463,B-CHEMICAL
residue,7463,O
in,7463,O
place,7463,O
of,7463,O
the,7463,O
catalytic,7463,O
tyrosine,7463,B-CHEMICAL
or,7463,O
serine,7463,B-CHEMICAL
residues,7463,O
found,7463,O
in,7463,O
other,7463,O
GSTs,7463,B-GENE-N
was,7463,O
shown,7463,O
to,7463,O
form,7463,O
a,7463,O
mixed,7463,O
disulfide,7463,B-CHEMICAL
with,7463,O
glutathione,7463,B-CHEMICAL
.,7463,O
Omega,7464,B-GENE-N
class,7464,I-GENE-N
GSTs,7464,I-GENE-N
have,7464,O
dehydroascorbate,7464,B-GENE-N
reductase,7464,I-GENE-N
and,7464,O
thioltransferase,7464,B-GENE-N
activities,7464,O
and,7464,O
also,7464,O
catalyze,7464,O
the,7464,O
reduction,7464,O
of,7464,O
monomethylarsonate,7464,B-CHEMICAL
",",7464,O
an,7464,O
intermediate,7464,O
in,7464,O
the,7464,O
pathway,7464,O
of,7464,O
arsenic,7464,B-CHEMICAL
biotransformation,7464,O
.,7464,O
Other,7465,O
diverse,7465,O
actions,7465,O
of,7465,O
human,7465,B-GENE-Y
GSTO1-1,7465,I-GENE-Y
include,7465,O
modulation,7465,O
of,7465,O
ryanodine,7465,B-GENE-N
receptors,7465,I-GENE-N
and,7465,O
interaction,7465,O
with,7465,O
cytokine,7465,B-GENE-N
release,7465,O
inhibitory,7465,O
drugs,7465,O
.,7465,O
In,7466,O
addition,7466,O
",",7466,O
GSTO1,7466,B-GENE-Y
has,7466,O
been,7466,O
linked,7466,O
to,7466,O
the,7466,O
age,7466,O
at,7466,O
onset,7466,O
of,7466,O
both,7466,O
Alzheimer,7466,O
's,7466,O
and,7466,O
Parkinson,7466,O
's,7466,O
diseases,7466,O
.,7466,O
Several,7467,O
polymorphisms,7467,O
have,7467,O
been,7467,O
identified,7467,O
in,7467,O
the,7467,O
coding,7467,O
regions,7467,O
of,7467,O
the,7467,O
human,7467,B-GENE-Y
GSTO1,7467,I-GENE-Y
and,7467,O
GSTO2,7467,B-GENE-Y
genes,7467,O
.,7467,O
Our,7468,O
laboratory,7468,O
has,7468,O
expressed,7468,O
recombinant,7468,O
human,7468,B-GENE-Y
GSTO1-1,7468,I-GENE-Y
and,7468,O
GSTO2-2,7468,B-GENE-Y
proteins,7468,O
",",7468,O
as,7468,O
well,7468,O
as,7468,O
a,7468,O
number,7468,O
of,7468,O
polymorphic,7468,O
variants,7468,O
.,7468,O
The,7469,O
expression,7469,O
and,7469,O
purification,7469,O
of,7469,O
these,7469,O
proteins,7469,O
and,7469,O
determination,7469,O
of,7469,O
their,7469,O
enzymatic,7469,O
activity,7469,O
is,7469,O
described,7469,O
.,7469,O
Tmem64,7470,B-GENE-Y
modulates,7470,O
calcium,7470,B-CHEMICAL
signaling,7470,O
during,7470,O
RANKL-mediated,7470,B-GENE-Y
osteoclast,7470,O
differentiation,7470,O
.,7470,O
Osteoclast,7471,O
maturation,7471,O
and,7471,O
function,7471,O
primarily,7471,O
depend,7471,O
on,7471,O
receptor,7471,B-GENE-Y
activator,7471,I-GENE-Y
of,7471,I-GENE-Y
NF-κB,7471,I-GENE-Y
ligand,7471,I-GENE-Y
(,7471,O
RANKL,7471,B-GENE-Y
),7471,O
-mediated,7471,O
induction,7471,O
of,7471,O
nuclear,7471,B-GENE-Y
factor,7471,I-GENE-Y
of,7471,I-GENE-Y
activated,7471,I-GENE-Y
T,7471,I-GENE-Y
cells,7471,I-GENE-Y
c1,7471,I-GENE-Y
(,7471,O
NFATc1,7471,B-GENE-Y
),7471,O
",",7471,O
which,7471,O
is,7471,O
further,7471,O
activated,7471,O
via,7471,O
increased,7471,O
intracellular,7471,O
calcium,7471,B-CHEMICAL
(,7471,O
[,7471,O
Ca,7471,B-CHEMICAL
(,7471,I-CHEMICAL
2+,7471,I-CHEMICAL
),7471,I-CHEMICAL
],7471,O
(,7471,O
i,7471,O
),7471,O
),7471,O
oscillation,7471,O
.,7471,O
However,7472,O
",",7472,O
the,7472,O
coordination,7472,O
mechanism,7472,O
that,7472,O
mediates,7472,O
Ca,7472,B-CHEMICAL
(,7472,I-CHEMICAL
2+,7472,I-CHEMICAL
),7472,I-CHEMICAL
oscillation,7472,O
during,7472,O
osteoclastogenesis,7472,O
remains,7472,O
ill,7472,O
defined,7472,O
.,7472,O
Here,7473,O
",",7473,O
we,7473,O
identified,7473,O
transmembrane,7473,B-GENE-Y
protein,7473,I-GENE-Y
64,7473,I-GENE-Y
(,7473,O
Tmem64,7473,B-GENE-Y
),7473,O
as,7473,O
a,7473,O
regulator,7473,O
of,7473,O
Ca,7473,B-CHEMICAL
(,7473,I-CHEMICAL
2+,7473,I-CHEMICAL
),7473,I-CHEMICAL
oscillation,7473,O
during,7473,O
osteoclastogenesis,7473,O
.,7473,O
We,7474,O
found,7474,O
that,7474,O
Tmem64-deficient,7474,B-GENE-Y
mice,7474,O
exhibit,7474,O
increased,7474,O
bone,7474,O
mass,7474,O
due,7474,O
in,7474,O
part,7474,O
to,7474,O
impaired,7474,O
osteoclast,7474,O
formation,7474,O
.,7474,O
Using,7475,O
in,7475,O
vitro,7475,O
osteoclast,7475,O
culture,7475,O
systems,7475,O
",",7475,O
we,7475,O
show,7475,O
here,7475,O
that,7475,O
Tmem64,7475,O
interacts,7475,O
with,7475,O
sarcoplasmic,7475,O
endoplasmic,7475,O
reticulum,7475,O
Ca,7475,B-CHEMICAL
(,7475,I-CHEMICAL
2+,7475,I-CHEMICAL
),7475,I-CHEMICAL
ATPase,7475,O
2,7475,O
(,7475,O
SERCA2,7475,O
),7475,O
and,7475,O
modulates,7475,O
its,7475,O
activity,7475,O
.,7475,O
Consequently,7476,O
",",7476,O
Tmem64,7476,B-GENE-Y
deficiency,7476,O
significantly,7476,O
diminishes,7476,O
RANKL-induced,7476,B-GENE-Y
[,7476,O
Ca,7476,B-CHEMICAL
(,7476,I-CHEMICAL
2+,7476,I-CHEMICAL
),7476,I-CHEMICAL
],7476,O
(,7476,O
i,7476,O
),7476,O
oscillation,7476,O
",",7476,O
which,7476,O
results,7476,O
in,7476,O
reduced,7476,O
Ca,7476,B-GENE-Y
(,7476,I-GENE-Y
2+,7476,I-GENE-Y
),7476,I-GENE-Y
/calmodulin-dependent,7476,I-GENE-Y
protein,7476,I-GENE-Y
kinases,7476,I-GENE-Y
(,7476,I-GENE-Y
CaMK,7476,I-GENE-Y
),7476,I-GENE-Y
IV,7476,I-GENE-Y
and,7476,O
mitochondrial,7476,O
ROS,7476,O
",",7476,O
both,7476,O
of,7476,O
which,7476,O
contribute,7476,O
to,7476,O
achieving,7476,O
the,7476,O
CREB,7476,B-GENE-N
activity,7476,O
necessary,7476,O
for,7476,O
osteoclast,7476,O
formation,7476,O
.,7476,O
These,7477,O
data,7477,O
demonstrate,7477,O
that,7477,O
Tmem64,7477,B-GENE-Y
is,7477,O
a,7477,O
positive,7477,O
modulator,7477,O
of,7477,O
osteoclast,7477,O
differentiation,7477,O
via,7477,O
SERCA2-dependent,7477,B-GENE-Y
Ca,7477,B-CHEMICAL
(,7477,I-CHEMICAL
2+,7477,I-CHEMICAL
),7477,I-CHEMICAL
signaling,7477,O
.,7477,O
Bimodal,7478,O
occurrence,7478,O
of,7478,O
aspartoacylase,7478,B-GENE-Y
in,7478,O
myelin,7478,O
and,7478,O
cytosol,7478,O
of,7478,O
brain,7478,O
.,7478,O
The,7479,O
growing,7479,O
use,7479,O
of,7479,O
N-acetylaspartate,7479,B-CHEMICAL
as,7479,O
an,7479,O
indicator,7479,O
of,7479,O
neuronal,7479,O
viability,7479,O
has,7479,O
fostered,7479,O
interest,7479,O
in,7479,O
the,7479,O
biological,7479,O
function,7479,O
(,7479,O
s,7479,O
),7479,O
of,7479,O
this,7479,O
unusual,7479,O
amino,7479,B-CHEMICAL
acid,7479,I-CHEMICAL
derivative,7479,O
.,7479,O
In,7480,O
considering,7480,O
the,7480,O
various,7480,O
physiological,7480,O
roles,7480,O
that,7480,O
have,7480,O
been,7480,O
proposed,7480,O
for,7480,O
this,7480,O
relatively,7480,O
abundant,7480,O
molecule,7480,O
one,7480,O
is,7480,O
obliged,7480,O
to,7480,O
take,7480,O
into,7480,O
account,7480,O
its,7480,O
unusual,7480,O
metabolic,7480,O
compartmentalization,7480,O
",",7480,O
according,7480,O
to,7480,O
which,7480,O
synthesis,7480,O
and,7480,O
storage,7480,O
occur,7480,O
in,7480,O
the,7480,O
neuron,7480,O
and,7480,O
hydrolytic,7480,O
cleavage,7480,O
in,7480,O
the,7480,O
oligodendrocyte,7480,O
.,7480,O
The,7481,O
latter,7481,O
reaction,7481,O
",",7481,O
catalyzed,7481,O
by,7481,O
aspartoacylase,7481,B-GENE-Y
(,7481,O
ASPA,7481,B-GENE-Y
),7481,O
",",7481,O
produces,7481,O
acetyl,7481,B-CHEMICAL
groups,7481,O
plus,7481,O
aspartate,7481,B-CHEMICAL
and,7481,O
has,7481,O
been,7481,O
proposed,7481,O
to,7481,O
occur,7481,O
in,7481,O
both,7481,O
soluble,7481,O
and,7481,O
membranous,7481,O
subfractions,7481,O
of,7481,O
white,7481,O
matter,7481,O
.,7481,O
Our,7482,O
study,7482,O
supports,7482,O
such,7482,O
bimodal,7482,O
occurrence,7482,O
and,7482,O
we,7482,O
now,7482,O
present,7482,O
immunoblot,7482,O
",",7482,O
proteomic,7482,O
",",7482,O
and,7482,O
biochemical,7482,O
evidence,7482,O
that,7482,O
the,7482,O
membrane-bound,7482,O
form,7482,O
of,7482,O
ASPA,7482,B-GENE-Y
is,7482,O
intrinsic,7482,O
to,7482,O
purified,7482,O
myelin,7482,O
membranes,7482,O
.,7482,O
This,7483,O
was,7483,O
supported,7483,O
by,7483,O
a,7483,O
novel,7483,O
TLC-based,7483,O
method,7483,O
for,7483,O
the,7483,O
assay,7483,O
of,7483,O
ASPA,7483,B-GENE-Y
.,7483,O
That,7484,O
observation,7484,O
",",7484,O
together,7484,O
with,7484,O
previous,7484,O
demonstrations,7484,O
of,7484,O
numerous,7484,O
lipid-synthesizing,7484,O
enzymes,7484,O
in,7484,O
myelin,7484,O
",",7484,O
suggests,7484,O
utilization,7484,O
of,7484,O
acetyl,7484,B-CHEMICAL
groups,7484,O
liberated,7484,O
by,7484,O
myelin-localized,7484,O
ASPA,7484,B-GENE-Y
for,7484,O
lipid,7484,O
synthesis,7484,O
within,7484,O
the,7484,O
myelin,7484,O
sheath,7484,O
.,7484,O
Such,7485,O
synthesis,7485,O
might,7485,O
be,7485,O
selective,7485,O
and,7485,O
could,7485,O
explain,7485,O
the,7485,O
deficit,7485,O
of,7485,O
myelin,7485,O
lipids,7485,O
in,7485,O
animals,7485,O
lacking,7485,O
ASPA,7485,B-GENE-N
.,7485,O
Chemoprevention,7486,O
for,7486,O
high-risk,7486,O
women,7486,O
:,7486,O
tamoxifen,7486,B-CHEMICAL
and,7486,O
beyond,7486,O
.,7486,O
The,7487,O
demonstration,7487,O
by,7487,O
the,7487,O
National,7487,O
Surgical,7487,O
Adjuvant,7487,O
Breast,7487,O
Project,7487,O
(,7487,O
NSABP,7487,O
),7487,O
that,7487,O
5,7487,O
years,7487,O
of,7487,O
tamoxifen,7487,B-CHEMICAL
therapy,7487,O
is,7487,O
associated,7487,O
with,7487,O
an,7487,O
approximate,7487,O
50,7487,O
%,7487,O
reduction,7487,O
in,7487,O
breast,7487,O
cancer,7487,O
incidence,7487,O
in,7487,O
high-risk,7487,O
women,7487,O
was,7487,O
a,7487,O
milestone,7487,O
in,7487,O
breast,7487,O
cancer,7487,O
prevention,7487,O
.,7487,O
Because,7488,O
tamoxifen,7488,B-CHEMICAL
is,7488,O
associated,7488,O
with,7488,O
increased,7488,O
risk,7488,O
of,7488,O
side-effects,7488,O
such,7488,O
as,7488,O
hot,7488,O
flashes,7488,O
",",7488,O
menstrual,7488,O
abnormalities,7488,O
",",7488,O
uterine,7488,O
cancer,7488,O
",",7488,O
and,7488,O
thromboembolic,7488,O
phenomena,7488,O
",",7488,O
its,7488,O
use,7488,O
will,7488,O
not,7488,O
be,7488,O
advisable,7488,O
or,7488,O
acceptable,7488,O
for,7488,O
all,7488,O
high-risk,7488,O
women,7488,O
.,7488,O
Women,7489,O
over,7489,O
50,7489,O
years,7489,O
of,7489,O
age,7489,O
appear,7489,O
to,7489,O
be,7489,O
at,7489,O
highest,7489,O
risk,7489,O
for,7489,O
serious,7489,O
adverse,7489,O
events,7489,O
",",7489,O
such,7489,O
as,7489,O
uterine,7489,O
cancer,7489,O
and,7489,O
thromboembolic,7489,O
phenomena,7489,O
.,7489,O
Individuals,7490,O
in,7490,O
whom,7490,O
tamoxifen-associated,7490,B-CHEMICAL
breast,7490,O
cancer,7490,O
risk,7490,O
reduction,7490,O
appears,7490,O
to,7490,O
outweigh,7490,O
risk,7490,O
of,7490,O
serious,7490,O
side-effects,7490,O
include,7490,O
women,7490,O
with,7490,O
prior,7490,O
in,7490,O
situ,7490,O
or,7490,O
estrogen,7490,B-GENE-Y
receptor,7490,I-GENE-Y
(,7490,O
ER,7490,B-GENE-Y
),7490,O
-positive,7490,O
invasive,7490,O
cancer,7490,O
",",7490,O
atypical,7490,O
hyperplasia,7490,O
",",7490,O
and/or,7490,O
women,7490,O
ages,7490,O
35-49,7490,O
with,7490,O
a,7490,O
calculated,7490,O
Gail,7490,O
5-year,7490,O
risk,7490,O
of,7490,O
>,7490,O
or,7490,O
=1.7,7490,O
%,7490,O
",",7490,O
hysterectomized,7490,O
women,7490,O
aged,7490,O
50,7490,O
and,7490,O
older,7490,O
with,7490,O
a,7490,O
5-year,7490,O
Gail,7490,O
risk,7490,O
of,7490,O
>,7490,O
or,7490,O
=2.5,7490,O
%,7490,O
",",7490,O
and,7490,O
nonhysterectomized,7490,O
women,7490,O
aged,7490,O
50,7490,O
and,7490,O
older,7490,O
with,7490,O
a,7490,O
5-year,7490,O
Gail,7490,O
risk,7490,O
of,7490,O
>,7490,O
5.0,7490,O
%,7490,O
.,7490,O
It,7491,O
is,7491,O
not,7491,O
yet,7491,O
clear,7491,O
whether,7491,O
tamoxifen,7491,B-CHEMICAL
can,7491,O
reduce,7491,O
breast,7491,O
cancer,7491,O
incidence,7491,O
in,7491,O
women,7491,O
with,7491,O
BRCA1,7491,B-GENE-Y
and,7491,O
BRCA2,7491,B-GENE-Y
mutations,7491,O
",",7491,O
although,7491,O
preliminary,7491,O
evidence,7491,O
favors,7491,O
benefit,7491,O
for,7491,O
at,7491,O
least,7491,O
those,7491,O
with,7491,O
a,7491,O
BRCA2,7491,B-GENE-Y
mutation,7491,O
.,7491,O
Raloxifene,7492,B-CHEMICAL
is,7492,O
a,7492,O
selective,7492,O
ER,7492,B-GENE-Y
modulator,7492,O
with,7492,O
less,7492,O
uterine,7492,O
estrogen,7492,B-CHEMICAL
agonist,7492,O
activity,7492,O
than,7492,O
tamoxifen,7492,B-CHEMICAL
",",7492,O
and,7492,O
it,7492,O
is,7492,O
hoped,7492,O
that,7492,O
it,7492,O
will,7492,O
result,7492,O
in,7492,O
fewer,7492,O
uterine,7492,O
cancers,7492,O
but,7492,O
will,7492,O
be,7492,O
equally,7492,O
efficacious,7492,O
in,7492,O
reducing,7492,O
the,7492,O
risk,7492,O
of,7492,O
breast,7492,O
cancer,7492,O
.,7492,O
The,7493,O
NSABP,7493,O
is,7493,O
currently,7493,O
conducting,7493,O
a,7493,O
randomized,7493,O
study,7493,O
of,7493,O
tamoxifen,7493,B-CHEMICAL
versus,7493,O
raloxifene,7493,B-CHEMICAL
in,7493,O
high-risk,7493,O
postmenopausal,7493,O
women,7493,O
.,7493,O
Approximately,7494,O
one,7494,O
third,7494,O
of,7494,O
invasive,7494,O
cancers,7494,O
are,7494,O
ER,7494,B-GENE-Y
negative,7494,O
.,7494,O
Tamoxifen,7495,B-CHEMICAL
does,7495,O
not,7495,O
reduce,7495,O
the,7495,O
incidence,7495,O
of,7495,O
ER-negative,7495,B-GENE-Y
cancers,7495,O
",",7495,O
nor,7495,O
does,7495,O
it,7495,O
appear,7495,O
to,7495,O
be,7495,O
effective,7495,O
in,7495,O
preventing,7495,O
the,7495,O
appearance,7495,O
of,7495,O
one,7495,O
third,7495,O
of,7495,O
ER-positive,7495,B-GENE-Y
cancers,7495,O
.,7495,O
Priorities,7496,O
in,7496,O
prevention,7496,O
research,7496,O
are,7496,O
to,7496,O
develop,7496,O
(,7496,O
a,7496,O
),7496,O
biomarkers,7496,O
to,7496,O
refine,7496,O
short-term,7496,O
risk,7496,O
assessments,7496,O
based,7496,O
on,7496,O
epidemiologic,7496,O
models,7496,O
",",7496,O
(,7496,O
b,7496,O
),7496,O
biomarkers,7496,O
predictive,7496,O
of,7496,O
response,7496,O
to,7496,O
specific,7496,O
classes,7496,O
of,7496,O
preventive,7496,O
agents,7496,O
",",7496,O
(,7496,O
c,7496,O
),7496,O
drugs,7496,O
with,7496,O
fewer,7496,O
side-effects,7496,O
and/or,7496,O
effective,7496,O
in,7496,O
ER-negative,7496,B-GENE-Y
or,7496,O
ER-positive,7496,B-GENE-Y
tamoxifen-resistant,7496,B-CHEMICAL
precancerous,7496,O
disease,7496,O
",",7496,O
and,7496,O
(,7496,O
d,7496,O
),7496,O
efficient,7496,O
clinical,7496,O
trial,7496,O
models,7496,O
to,7496,O
assess,7496,O
new,7496,O
agent,7496,O
efficacy,7496,O
.,7496,O
Breast,7497,O
intraepithelial,7497,O
neoplasia,7497,O
(,7497,O
IEN,7497,O
),7497,O
may,7497,O
be,7497,O
sampled,7497,O
by,7497,O
minimally,7497,O
invasive,7497,O
techniques,7497,O
and,7497,O
is,7497,O
an,7497,O
attractive,7497,O
short-term,7497,O
risk,7497,O
biomarker,7497,O
.,7497,O
Molecular,7498,O
abnormalities,7498,O
observed,7498,O
in,7498,O
IEN,7498,O
may,7498,O
be,7498,O
used,7498,O
to,7498,O
select,7498,O
potential,7498,O
agents,7498,O
for,7498,O
testing/therapy,7498,O
",",7498,O
and,7498,O
modulation,7498,O
of,7498,O
these,7498,O
abnormalities,7498,O
may,7498,O
be,7498,O
used,7498,O
in,7498,O
phase,7498,O
I,7498,O
trials,7498,O
to,7498,O
select,7498,O
appropriate,7498,O
doses,7498,O
and,7498,O
in,7498,O
phase,7498,O
II,7498,O
trials,7498,O
to,7498,O
assess,7498,O
response,7498,O
.,7498,O
Breast,7499,O
density,7499,O
volume,7499,O
and,7499,O
certain,7499,O
serum,7499,O
markers,7499,O
such,7499,O
as,7499,O
insulin-like,7499,B-GENE-Y
growth,7499,I-GENE-Y
factor-1,7499,I-GENE-Y
are,7499,O
also,7499,O
being,7499,O
studied,7499,O
as,7499,O
potential,7499,O
risk,7499,O
and,7499,O
response,7499,O
biomarkers,7499,O
.,7499,O
Reversal,7500,O
or,7500,O
prevention,7500,O
of,7500,O
advanced,7500,O
IEN,7500,O
as,7500,O
well,7500,O
as,7500,O
modulation,7500,O
of,7500,O
other,7500,O
risk,7500,O
biomarkers,7500,O
in,7500,O
randomized,7500,O
phase,7500,O
II,7500,O
and,7500,O
phase,7500,O
III,7500,O
trials,7500,O
is,7500,O
being,7500,O
evaluated,7500,O
as,7500,O
a,7500,O
means,7500,O
of,7500,O
more,7500,O
efficiently,7500,O
evaluating,7500,O
prevention,7500,O
drugs,7500,O
in,7500,O
the,7500,O
future,7500,O
.,7500,O
A,7501,O
number,7501,O
of,7501,O
agents,7501,O
are,7501,O
being,7501,O
developed,7501,O
that,7501,O
target,7501,O
molecular,7501,O
abnormalities,7501,O
in,7501,O
IEN,7501,O
",",7501,O
have,7501,O
fewer,7501,O
or,7501,O
different,7501,O
side,7501,O
effects,7501,O
than,7501,O
tamoxifen,7501,B-CHEMICAL
",",7501,O
and,7501,O
may,7501,O
be,7501,O
effective,7501,O
in,7501,O
ER-negative,7501,B-GENE-Y
or,7501,O
tamoxifen-resistant,7501,B-CHEMICAL
disease,7501,O
.,7501,O
Inhibition,7502,O
by,7502,O
troglitazone,7502,B-CHEMICAL
of,7502,O
the,7502,O
antigen-induced,7502,O
production,7502,O
of,7502,O
leukotrienes,7502,B-CHEMICAL
in,7502,O
immunoglobulin,7502,B-GENE-N
E-sensitized,7502,O
RBL-2H3,7502,O
cells,7502,O
.,7502,O
1,7503,O
.,7503,O
The,7504,O
effect,7504,O
of,7504,O
troglitazone,7504,B-CHEMICAL
",",7504,O
an,7504,O
anti-diabetic,7504,O
drug,7504,O
with,7504,O
insulin-sensitizing,7504,B-GENE-N
action,7504,O
",",7504,O
on,7504,O
antigen-induced,7504,O
production,7504,O
of,7504,O
leukotriene,7504,B-CHEMICAL
(,7504,I-CHEMICAL
LT,7504,I-CHEMICAL
),7504,I-CHEMICAL
B,7504,I-CHEMICAL
(,7504,I-CHEMICAL
4,7504,I-CHEMICAL
),7504,I-CHEMICAL
",",7504,I-CHEMICAL
C,7504,I-CHEMICAL
(,7504,I-CHEMICAL
4,7504,I-CHEMICAL
),7504,I-CHEMICAL
and,7504,I-CHEMICAL
E,7504,I-CHEMICAL
(,7504,I-CHEMICAL
4,7504,I-CHEMICAL
),7504,I-CHEMICAL
and,7504,O
prostaglandin,7504,B-CHEMICAL
D,7504,I-CHEMICAL
(,7504,I-CHEMICAL
2,7504,I-CHEMICAL
),7504,I-CHEMICAL
(,7504,O
PGD,7504,B-CHEMICAL
(,7504,I-CHEMICAL
2,7504,I-CHEMICAL
),7504,I-CHEMICAL
),7504,O
was,7504,O
examined,7504,O
in,7504,O
dinitrophenol,7504,B-CHEMICAL
(,7504,O
DNP,7504,B-CHEMICAL
),7504,O
-specific,7504,O
immunoglobulin,7504,B-GENE-N
E,7504,I-GENE-N
(,7504,O
IgE,7504,B-GENE-N
),7504,O
-sensitized,7504,O
RBL-2H3,7504,O
mast,7504,O
cells,7504,O
following,7504,O
stimulation,7504,O
by,7504,O
the,7504,O
antigen,7504,O
",",7504,O
DNP-conjugated,7504,B-CHEMICAL
human,7504,B-GENE-Y
serum,7504,I-GENE-Y
albumin,7504,I-GENE-Y
.,7504,O
Levels,7505,O
of,7505,O
LTB,7505,B-CHEMICAL
(,7505,I-CHEMICAL
4,7505,I-CHEMICAL
),7505,I-CHEMICAL
",",7505,O
C,7505,O
(,7505,O
4,7505,O
),7505,O
and,7505,O
E,7505,O
(,7505,O
4,7505,O
),7505,O
and,7505,O
PGD,7505,B-CHEMICAL
(,7505,I-CHEMICAL
2,7505,I-CHEMICAL
),7505,I-CHEMICAL
in,7505,O
the,7505,O
conditioned,7505,O
medium,7505,O
were,7505,O
enzyme-immunoassayed,7505,O
.,7505,O
2,7506,O
.,7506,O
Troglitazone,7507,B-CHEMICAL
inhibited,7507,O
the,7507,O
antigen-induced,7507,O
production,7507,O
of,7507,O
LTB,7507,B-CHEMICAL
(,7507,I-CHEMICAL
4,7507,I-CHEMICAL
),7507,I-CHEMICAL
",",7507,O
C,7507,O
(,7507,O
4,7507,O
),7507,O
and,7507,O
E,7507,O
(,7507,O
4,7507,O
),7507,O
and,7507,O
the,7507,O
potency,7507,O
of,7507,O
the,7507,O
inhibition,7507,O
was,7507,O
comparable,7507,O
to,7507,O
that,7507,O
of,7507,O
zileuton,7507,B-CHEMICAL
",",7507,O
a,7507,O
specific,7507,O
inhibitor,7507,O
of,7507,O
5-lipoxygenase,7507,B-GENE-Y
(,7507,O
5-LOX,7507,B-GENE-Y
),7507,O
and,7507,O
a,7507,O
clinically,7507,O
used,7507,O
anti-asthmatic,7507,O
drug,7507,O
.,7507,O
Neither,7508,O
troglitazone,7508,B-CHEMICAL
nor,7508,O
zileuton,7508,B-CHEMICAL
affected,7508,O
antigen-induced,7508,O
production,7508,O
of,7508,O
PGD,7508,B-CHEMICAL
(,7508,I-CHEMICAL
2,7508,I-CHEMICAL
),7508,I-CHEMICAL
",",7508,O
arachidonic,7508,B-CHEMICAL
acid,7508,I-CHEMICAL
release,7508,O
from,7508,O
membrane,7508,O
phospholipids,7508,O
and,7508,O
degranulation,7508,O
.,7508,O
3,7509,O
.,7509,O
Troglitazone,7510,B-CHEMICAL
inhibited,7510,O
LTB,7510,B-CHEMICAL
(,7510,I-CHEMICAL
4,7510,I-CHEMICAL
),7510,I-CHEMICAL
production,7510,O
by,7510,O
the,7510,O
supernatant,7510,O
fraction,7510,O
of,7510,O
RBL-2H3,7510,O
cell,7510,O
lysate,7510,O
with,7510,O
similar,7510,O
potency,7510,O
to,7510,O
zileuton,7510,B-CHEMICAL
",",7510,O
suggesting,7510,O
that,7510,O
troglitazone,7510,B-CHEMICAL
inhibits,7510,O
LT,7510,O
production,7510,O
by,7510,O
direct,7510,O
inhibition,7510,O
of,7510,O
5-LOX,7510,B-GENE-Y
activity,7510,O
.,7510,O
4,7511,O
.,7511,O
Furthermore,7512,O
",",7512,O
it,7512,O
was,7512,O
shown,7512,O
that,7512,O
troglitazone,7512,B-CHEMICAL
as,7512,O
well,7512,O
as,7512,O
zileuton,7512,B-CHEMICAL
inhibited,7512,O
LTB,7512,B-CHEMICAL
(,7512,I-CHEMICAL
4,7512,I-CHEMICAL
),7512,I-CHEMICAL
production,7512,O
in,7512,O
A23187-stimulated,7512,B-CHEMICAL
rat,7512,O
peritoneal,7512,O
neutrophils,7512,O
.,7512,O
5,7513,O
.,7513,O
These,7514,O
findings,7514,O
suggest,7514,O
that,7514,O
troglitazone,7514,B-CHEMICAL
inhibits,7514,O
antigen-induced,7514,O
LT,7514,O
production,7514,O
in,7514,O
the,7514,O
IgE-sensitized,7514,B-GENE-N
RBL-2H3,7514,O
cells,7514,O
and,7514,O
A23187-stimulated,7514,B-CHEMICAL
rat,7514,O
peritoneal,7514,O
neutrophils,7514,O
by,7514,O
direct,7514,O
inhibition,7514,O
of,7514,O
5-LOX,7514,B-GENE-Y
activity,7514,O
.,7514,O
[,7515,O
Protein,7515,O
profile,7515,O
and,7515,O
vitamin,7515,B-CHEMICAL
A,7515,I-CHEMICAL
in,7515,O
children,7515,O
of,7515,O
school,7515,O
age,7515,O
in,7515,O
Ivory,7515,O
Coast,7515,O
],7515,O
.,7515,O
The,7516,O
purpose,7516,O
of,7516,O
this,7516,O
transverse,7516,O
prospective,7516,O
study,7516,O
was,7516,O
to,7516,O
determine,7516,O
blood,7516,O
nutritional,7516,O
",",7516,O
immunity,7516,O
and,7516,O
inflammatory,7516,O
proteins,7516,O
change,7516,O
in,7516,O
vitamin,7516,B-CHEMICAL
A,7516,I-CHEMICAL
deficiency,7516,O
in,7516,O
children,7516,O
of,7516,O
school-age,7516,O
(,7516,O
262,7516,O
children,7516,O
",",7516,O
aged,7516,O
7,7516,O
to,7516,O
15,7516,O
years,7516,O
),7516,O
.,7516,O
Blood,7517,O
vitamin,7517,B-CHEMICAL
A,7517,I-CHEMICAL
has,7517,O
been,7517,O
determined,7517,O
by,7517,O
HPLC,7517,O
with,7517,O
UV,7517,O
detection,7517,O
.,7517,O
Proteins,7518,O
have,7518,O
been,7518,O
measured,7518,O
by,7518,O
radial,7518,O
immunodiffusion,7518,O
according,7518,O
to,7518,O
Mancini,7518,O
.,7518,O
Results,7519,O
showed,7519,O
that,7519,O
96,7519,O
children,7519,O
(,7519,O
36.6,7519,O
%,7519,O
),7519,O
presented,7519,O
a,7519,O
vitamin,7519,B-CHEMICAL
A,7519,I-CHEMICAL
deficiency,7519,O
(,7519,O
vitamin,7519,B-CHEMICAL
A,7519,I-CHEMICAL
<,7519,O
200,7519,O
microg/L,7519,O
with,7519,O
a,7519,O
retinol,7519,B-GENE-N
binding,7519,I-GENE-N
protein/transthyretin,7519,O
molar,7519,O
ratio,7519,O
=,7519,O
0.29,7519,O
+/-,7519,O
0.06,7519,O
),7519,O
while,7519,O
166,7519,O
(,7519,O
63.3,7519,O
%,7519,O
),7519,O
children,7519,O
presented,7519,O
normal,7519,O
blood,7519,O
concentrations,7519,O
of,7519,O
vitamin,7519,B-CHEMICAL
A,7519,I-CHEMICAL
(,7519,O
vitamin,7519,B-CHEMICAL
A,7519,I-CHEMICAL
>,7519,O
or,7519,O
=,7519,O
200,7519,O
microg/L,7519,O
with,7519,O
a,7519,O
Retinol,7519,B-GENE-N
Binding,7519,I-GENE-N
Protein/Transthyretin,7519,O
molar,7519,O
ratio,7519,O
=,7519,O
0.40,7519,O
+/-,7519,O
0.08,7519,O
),7519,O
.,7519,O
This,7520,O
study,7520,O
showed,7520,O
that,7520,O
the,7520,O
retinol,7520,B-GENE-N
binding,7520,I-GENE-N
protein,7520,I-GENE-N
and,7520,O
the,7520,O
immunoglobulin,7520,B-GENE-N
A,7520,I-GENE-N
are,7520,O
lower,7520,O
in,7520,O
children,7520,O
with,7520,O
vitamin,7520,B-CHEMICAL
A,7520,I-CHEMICAL
deficiency,7520,O
.,7520,O
On,7521,O
the,7521,O
other,7521,O
hand,7521,O
",",7521,O
an,7521,O
isolated,7521,O
increase,7521,O
of,7521,O
alpha-1,7521,B-GENE-Y
glycoprotein,7521,I-GENE-Y
acid,7521,I-GENE-Y
has,7521,O
been,7521,O
observed,7521,O
in,7521,O
boys,7521,O
with,7521,O
vitamin,7521,B-CHEMICAL
A,7521,I-CHEMICAL
deficiency,7521,O
.,7521,O
The,7522,O
vitamin,7522,B-CHEMICAL
A,7522,I-CHEMICAL
deficiency,7522,O
observed,7522,O
in,7522,O
this,7522,O
survey,7522,O
is,7522,O
due,7522,O
to,7522,O
a,7522,O
micronutrients,7522,O
deficiency,7522,O
in,7522,O
the,7522,O
diet,7522,O
which,7522,O
is,7522,O
essentially,7522,O
based,7522,O
on,7522,O
glucides,7522,O
.,7522,O
The,7523,O
positive,7523,O
correlation,7523,O
between,7523,O
vitamin,7523,B-CHEMICAL
A,7523,I-CHEMICAL
and,7523,O
immunoglobulin,7523,B-GENE-N
A,7523,I-GENE-N
concentrations,7523,O
might,7523,O
be,7523,O
the,7523,O
result,7523,O
of,7523,O
the,7523,O
vitamin,7523,B-CHEMICAL
A,7523,I-CHEMICAL
inductive,7523,O
effect,7523,O
during,7523,O
immunoglobulins,7523,B-GENE-N
A,7523,I-GENE-N
synthesis,7523,O
.,7523,O
The,7524,O
isolated,7524,O
increasing,7524,O
of,7524,O
alpha-1,7524,B-GENE-Y
glycoprotein,7524,I-GENE-Y
acid,7524,I-GENE-Y
in,7524,O
boys,7524,O
with,7524,O
vitamin,7524,B-CHEMICAL
A,7524,I-CHEMICAL
deficiency,7524,O
has,7524,O
been,7524,O
assigned,7524,O
to,7524,O
the,7524,O
ecosensitiveness,7524,O
of,7524,O
the,7524,O
unfavourable,7524,O
environment,7524,O
.,7524,O
We,7525,O
therefore,7525,O
concluded,7525,O
that,7525,O
",",7525,O
in,7525,O
Ivorian,7525,O
primary-school-aged,7525,O
children,7525,O
with,7525,O
vitamin,7525,B-CHEMICAL
A,7525,I-CHEMICAL
deficiency,7525,O
",",7525,O
nutritional,7525,O
",",7525,O
immunity,7525,O
and,7525,O
inflammatory,7525,O
proteins,7525,O
which,7525,O
are,7525,O
modified,7525,O
are,7525,O
respectively,7525,O
retinol,7525,B-GENE-N
binding,7525,I-GENE-N
protein,7525,I-GENE-N
",",7525,O
immunoglobulin,7525,B-GENE-N
A,7525,I-GENE-N
and,7525,O
alpha-1,7525,B-GENE-Y
glycoprotein,7525,I-GENE-Y
acid,7525,I-GENE-Y
.,7525,O
Verapamil,7526,B-CHEMICAL
prevents,7526,O
torsade,7526,O
de,7526,O
pointes,7526,O
by,7526,O
reduction,7526,O
of,7526,O
transmural,7526,O
dispersion,7526,O
of,7526,O
repolarization,7526,O
and,7526,O
suppression,7526,O
of,7526,O
early,7526,O
afterdepolarizations,7526,O
in,7526,O
an,7526,O
intact,7526,O
heart,7526,O
model,7526,O
of,7526,O
LQT3,7526,O
.,7526,O
BACKGROUND,7527,O
:,7527,O
In,7527,O
long,7527,O
QT,7527,O
syndrome,7527,O
(,7527,O
LQTS,7527,O
),7527,O
",",7527,O
prolongation,7527,O
of,7527,O
the,7527,O
QT-interval,7527,O
is,7527,O
associated,7527,O
with,7527,O
sudden,7527,O
cardiac,7527,O
death,7527,O
resulting,7527,O
from,7527,O
potentially,7527,O
life-threatening,7527,O
polymorphic,7527,O
tachycardia,7527,O
of,7527,O
the,7527,O
torsade,7527,O
de,7527,O
pointes,7527,O
(,7527,O
TdP,7527,O
),7527,O
type,7527,O
.,7527,O
Experimental,7528,O
as,7528,O
well,7528,O
as,7528,O
clinical,7528,O
reports,7528,O
support,7528,O
the,7528,O
hypothesis,7528,O
that,7528,O
calcium,7528,B-GENE-N
channel,7528,I-GENE-N
blockers,7528,O
such,7528,O
as,7528,O
verapamil,7528,B-CHEMICAL
may,7528,O
be,7528,O
an,7528,O
appropriate,7528,O
therapeutic,7528,O
approach,7528,O
in,7528,O
LQTS,7528,O
.,7528,O
We,7529,O
investigated,7529,O
the,7529,O
electrophysiologic,7529,O
mechanism,7529,O
by,7529,O
which,7529,O
verapamil,7529,O
suppresses,7529,O
TdP,7529,O
",",7529,O
in,7529,O
a,7529,O
recently,7529,O
developed,7529,O
intact,7529,O
heart,7529,O
model,7529,O
of,7529,O
LQT3,7529,O
.,7529,O
METHODS,7530,O
AND,7530,O
RESULTS,7530,O
:,7530,O
In,7530,O
8,7530,O
Langendorff-perfused,7530,O
rabbit,7530,O
hearts,7530,O
",",7530,O
veratridine,7530,B-CHEMICAL
(,7530,O
0.1,7530,O
microM,7530,O
),7530,O
",",7530,O
an,7530,O
inhibitor,7530,O
of,7530,O
sodium,7530,B-GENE-N
channel,7530,I-GENE-N
inactivation,7530,O
",",7530,O
led,7530,O
to,7530,O
a,7530,O
marked,7530,O
increase,7530,O
in,7530,O
QT-interval,7530,O
and,7530,O
simultaneously,7530,O
recorded,7530,O
monophasic,7530,O
ventricular,7530,O
action,7530,O
potentials,7530,O
(,7530,O
MAPs,7530,O
),7530,O
(,7530,O
p,7530,O
<,7530,O
0.05,7530,O
),7530,O
thereby,7530,O
mimicking,7530,O
LQT3,7530,O
.,7530,O
In,7531,O
bradycardic,7531,O
(,7531,O
AV-blocked,7531,O
),7531,O
hearts,7531,O
",",7531,O
simultaneous,7531,O
recording,7531,O
of,7531,O
up,7531,O
to,7531,O
eight,7531,O
epi-,7531,O
and,7531,O
endocardial,7531,O
MAPs,7531,O
demonstrated,7531,O
a,7531,O
significant,7531,O
increase,7531,O
in,7531,O
total,7531,O
dispersion,7531,O
of,7531,O
repolarization,7531,O
(,7531,O
56,7531,O
%,7531,O
",",7531,O
p,7531,O
<,7531,O
0.05,7531,O
),7531,O
and,7531,O
reverse,7531,O
frequency-dependence,7531,O
.,7531,O
After,7532,O
lowering,7532,O
potassium,7532,B-CHEMICAL
concentration,7532,O
",",7532,O
veratridine,7532,B-CHEMICAL
reproducibly,7532,O
led,7532,O
to,7532,O
early,7532,O
afterdepolarizations,7532,O
(,7532,O
EADs,7532,O
),7532,O
and,7532,O
TdP,7532,O
in,7532,O
6,7532,O
of,7532,O
8,7532,O
(,7532,O
75,7532,O
%,7532,O
),7532,O
hearts,7532,O
.,7532,O
Additional,7533,O
infusion,7533,O
of,7533,O
verapamil,7533,B-CHEMICAL
(,7533,O
0.75,7533,O
microM,7533,O
),7533,O
suppressed,7533,O
EADs,7533,O
and,7533,O
consecutively,7533,O
TdP,7533,O
in,7533,O
all,7533,O
hearts,7533,O
.,7533,O
Verapamil,7534,B-CHEMICAL
significantly,7534,O
shortened,7534,O
endocardial,7534,O
but,7534,O
not,7534,O
epicardial,7534,O
MAPs,7534,O
which,7534,O
resulted,7534,O
in,7534,O
significant,7534,O
reduction,7534,O
of,7534,O
ventricular,7534,O
transmural,7534,O
dispersion,7534,O
of,7534,O
repolarization,7534,O
.,7534,O
CONCLUSIONS,7535,O
:,7535,O
Verapamil,7535,B-CHEMICAL
is,7535,O
highly,7535,O
effective,7535,O
in,7535,O
preventing,7535,O
TdP,7535,O
via,7535,O
shortening,7535,O
of,7535,O
endocardial,7535,O
MAPs,7535,O
",",7535,O
reduction,7535,O
of,7535,O
left,7535,O
ventricular,7535,O
transmural,7535,O
dispersion,7535,O
of,7535,O
repolarization,7535,O
and,7535,O
suppression,7535,O
of,7535,O
EADs,7535,O
in,7535,O
an,7535,O
intact,7535,O
heart,7535,O
model,7535,O
of,7535,O
LQT3,7535,O
.,7535,O
These,7536,O
data,7536,O
suggest,7536,O
a,7536,O
possible,7536,O
therapeutic,7536,O
role,7536,O
of,7536,O
verapamil,7536,B-CHEMICAL
in,7536,O
the,7536,O
treatment,7536,O
of,7536,O
LQT3,7536,O
patients,7536,O
.,7536,O
Specificity,7537,O
of,7537,O
zebrafish,7537,B-GENE-Y
retinol,7537,I-GENE-Y
saturase,7537,I-GENE-Y
:,7537,O
formation,7537,O
of,7537,O
"all-trans-13,14-dihydroretinol",7537,B-CHEMICAL
and,7537,O
"all-trans-7,8-",7537,B-CHEMICAL
dihydroretinol,7537,I-CHEMICAL
.,7537,O
Metabolism,7538,O
of,7538,O
vitamin,7538,B-CHEMICAL
A,7538,I-CHEMICAL
",",7538,O
all-trans-retinol,7538,B-CHEMICAL
",",7538,O
leads,7538,O
to,7538,O
the,7538,O
formation,7538,O
of,7538,O
11-cis-retinaldehyde,7538,B-CHEMICAL
",",7538,O
the,7538,O
visual,7538,O
chromophore,7538,O
",",7538,O
and,7538,O
all-trans-retinoic,7538,B-CHEMICAL
acid,7538,I-CHEMICAL
",",7538,O
which,7538,O
is,7538,O
involved,7538,O
in,7538,O
the,7538,O
regulation,7538,O
of,7538,O
gene,7538,O
expression,7538,O
through,7538,O
the,7538,O
retinoic,7538,B-GENE-N
acid,7538,I-GENE-N
receptor,7538,I-GENE-N
.,7538,O
Enzymes,7539,O
and,7539,O
binding,7539,O
proteins,7539,O
involved,7539,O
in,7539,O
retinoid,7539,B-CHEMICAL
metabolism,7539,O
are,7539,O
highly,7539,O
conserved,7539,O
across,7539,O
species,7539,O
.,7539,O
We,7540,O
previously,7540,O
described,7540,O
a,7540,O
novel,7540,O
mammalian,7540,O
enzyme,7540,O
that,7540,O
saturates,7540,O
the,7540,O
13-14,7540,O
double,7540,O
bond,7540,O
of,7540,O
all-trans-retinol,7540,B-CHEMICAL
to,7540,O
produce,7540,O
"all-trans-13,14-dihydroretinol",7540,B-CHEMICAL
",",7540,O
which,7540,O
then,7540,O
follows,7540,O
the,7540,O
same,7540,O
metabolic,7540,O
fate,7540,O
as,7540,O
that,7540,O
of,7540,O
all-trans-retinol,7540,B-CHEMICAL
.,7540,O
Specifically,7541,O
",",7541,O
"all-trans-13,14-dihydroretinol",7541,B-CHEMICAL
is,7541,O
transiently,7541,O
oxidized,7541,O
to,7541,O
"all-trans-13,14-dihydroretinoic",7541,B-CHEMICAL
acid,7541,I-CHEMICAL
before,7541,O
being,7541,O
oxidized,7541,O
further,7541,O
by,7541,O
Cyp26,7541,B-GENE-Y
enzymes,7541,O
.,7541,O
Here,7542,O
",",7542,O
we,7542,O
report,7542,O
the,7542,O
identification,7542,O
of,7542,O
two,7542,O
putative,7542,O
RetSat,7542,B-GENE-Y
homologues,7542,O
in,7542,O
zebrafish,7542,O
",",7542,O
one,7542,O
of,7542,O
which,7542,O
",",7542,O
zebrafish,7542,B-GENE-Y
RetSat,7542,I-GENE-Y
A,7542,I-GENE-Y
(,7542,O
zRetSat,7542,B-GENE-Y
A,7542,I-GENE-Y
),7542,O
",",7542,O
also,7542,O
had,7542,O
retinol,7542,B-GENE-Y
saturase,7542,I-GENE-Y
activity,7542,O
",",7542,O
whereas,7542,O
zebrafish,7542,B-GENE-Y
RetSat,7542,I-GENE-Y
B,7542,I-GENE-Y
(,7542,O
zRetSat,7542,B-GENE-Y
B,7542,I-GENE-Y
),7542,O
was,7542,O
inactive,7542,O
under,7542,O
similar,7542,O
conditions,7542,O
.,7542,O
Unlike,7543,O
mouse,7543,B-GENE-Y
RetSat,7543,I-GENE-Y
(,7543,O
mRetSat,7543,B-GENE-Y
),7543,O
",",7543,O
zRetSat,7543,B-GENE-Y
A,7543,I-GENE-Y
had,7543,O
an,7543,O
altered,7543,O
bond,7543,O
specificity,7543,O
saturating,7543,O
either,7543,O
the,7543,O
13-14,7543,O
or,7543,O
7-8,7543,O
double,7543,O
bonds,7543,O
of,7543,O
all-trans-retinol,7543,B-CHEMICAL
to,7543,O
produce,7543,O
either,7543,O
"all-trans-13,14-dihydroretinol",7543,B-CHEMICAL
or,7543,O
"all-trans-7,8-dihydroretinol",7543,B-CHEMICAL
",",7543,O
respectively,7543,O
.,7543,O
zRetSat,7544,B-GENE-Y
A,7544,I-GENE-Y
also,7544,O
saturated,7544,O
the,7544,O
13-14,7544,O
or,7544,O
7-8,7544,O
double,7544,O
bonds,7544,O
of,7544,O
"all-trans-3,4-didehydroretinol",7544,B-CHEMICAL
(,7544,O
vitamin,7544,B-CHEMICAL
A2,7544,I-CHEMICAL
),7544,O
",",7544,O
a,7544,O
second,7544,O
endogenous,7544,O
form,7544,O
of,7544,O
vitamin,7544,B-CHEMICAL
A,7544,I-CHEMICAL
in,7544,O
zebrafish,7544,O
.,7544,O
The,7545,O
dual,7545,O
enzymatic,7545,O
activity,7545,O
of,7545,O
zRetSat,7545,B-GENE-Y
A,7545,I-GENE-Y
displays,7545,O
a,7545,O
newly,7545,O
acquired,7545,O
specificity,7545,O
for,7545,O
the,7545,O
13-14,7545,O
double,7545,O
bond,7545,O
retained,7545,O
in,7545,O
higher,7545,O
vertebrates,7545,O
and,7545,O
also,7545,O
the,7545,O
evolutionarily,7545,O
preserved,7545,O
activity,7545,O
of,7545,O
bacterial,7545,B-GENE-N
phytoene,7545,I-GENE-N
desaturases,7545,I-GENE-N
and,7545,O
plant,7545,B-GENE-N
carotenoid,7545,I-GENE-N
isomerases,7545,I-GENE-N
.,7545,O
Expression,7546,O
of,7546,O
zRetSat,7546,B-GENE-Y
A,7546,I-GENE-Y
was,7546,O
restricted,7546,O
to,7546,O
the,7546,O
liver,7546,O
and,7546,O
intestine,7546,O
of,7546,O
hatchlings,7546,O
and,7546,O
adult,7546,O
zebrafish,7546,O
",",7546,O
whereas,7546,O
zRetSat,7546,B-GENE-Y
B,7546,I-GENE-Y
was,7546,O
expressed,7546,O
in,7546,O
the,7546,O
same,7546,O
tissues,7546,O
but,7546,O
at,7546,O
earlier,7546,O
developmental,7546,O
stages,7546,O
.,7546,O
Exogenous,7547,O
all-trans-retinol,7547,B-CHEMICAL
",",7547,O
"all-trans-13,14-dihydroretinol",7547,B-CHEMICAL
",",7547,O
or,7547,O
"all-trans-7,8-dihydroretinol",7547,B-CHEMICAL
led,7547,O
to,7547,O
the,7547,O
strong,7547,O
induction,7547,O
of,7547,O
the,7547,O
expression,7547,O
of,7547,O
the,7547,O
retinoic,7547,B-CHEMICAL
acid-metabolizing,7547,O
enzyme,7547,O
",",7547,O
Cyp26A1,7547,B-GENE-Y
",",7547,O
arguing,7547,O
for,7547,O
an,7547,O
active,7547,O
signaling,7547,O
function,7547,O
of,7547,O
dihydroretinoid,7547,B-CHEMICAL
metabolites,7547,O
in,7547,O
zebrafish,7547,O
.,7547,O
These,7548,O
findings,7548,O
point,7548,O
to,7548,O
a,7548,O
conserved,7548,O
function,7548,O
but,7548,O
altered,7548,O
specificity,7548,O
of,7548,O
RetSat,7548,B-GENE-Y
in,7548,O
vertebrates,7548,O
",",7548,O
leading,7548,O
to,7548,O
the,7548,O
generation,7548,O
of,7548,O
various,7548,O
dihydroretinoid,7548,B-CHEMICAL
compounds,7548,O
",",7548,O
some,7548,O
of,7548,O
which,7548,O
could,7548,O
have,7548,O
signaling,7548,O
functions,7548,O
.,7548,O
Estimation,7549,O
of,7549,O
warfarin,7549,B-CHEMICAL
maintenance,7549,O
dose,7549,O
based,7549,O
on,7549,O
VKORC1,7549,B-GENE-Y
(,7549,O
-1639,7549,B-GENE-N
G,7549,I-GENE-N
>,7549,I-GENE-N
A,7549,I-GENE-N
),7549,O
and,7549,O
CYP2C9,7549,B-GENE-Y
genotypes,7549,O
.,7549,O
BACKGROUND,7550,O
:,7550,O
CYP2C9,7550,B-GENE-Y
polymorphisms,7550,O
are,7550,O
associated,7550,O
with,7550,O
decreased,7550,O
S-warfarin,7550,B-CHEMICAL
clearance,7550,O
and,7550,O
lower,7550,O
maintenance,7550,O
dosage,7550,O
.,7550,O
Decreased,7551,O
expression,7551,O
of,7551,O
VKORC1,7551,B-GENE-Y
resulting,7551,O
from,7551,O
the,7551,O
-1639G,7551,B-GENE-N
>,7551,I-GENE-N
A,7551,I-GENE-N
substitution,7551,O
has,7551,O
also,7551,O
been,7551,O
implicated,7551,O
in,7551,O
lower,7551,O
warfarin,7551,B-CHEMICAL
dose,7551,O
requirements,7551,O
.,7551,O
We,7552,O
investigated,7552,O
the,7552,O
additional,7552,O
contribution,7552,O
of,7552,O
this,7552,O
polymorphism,7552,O
to,7552,O
the,7552,O
variance,7552,O
in,7552,O
warfarin,7552,B-CHEMICAL
dose,7552,O
.,7552,O
METHODS,7553,O
:,7553,O
Sixty-five,7553,O
patients,7553,O
with,7553,O
stable,7553,O
anticoagulation,7553,O
were,7553,O
genotyped,7553,O
for,7553,O
CYP2C9,7553,B-GENE-Y
and,7553,O
VKORC1,7553,B-GENE-Y
with,7553,O
Tag-It,7553,O
allele-specific,7553,O
primer,7553,O
extension,7553,O
technology,7553,O
.,7553,O
Plasma,7554,O
S-warfarin,7554,B-CHEMICAL
concentrations,7554,O
and,7554,O
warfarin,7554,B-CHEMICAL
maintenance,7554,O
dose,7554,O
were,7554,O
compared,7554,O
among,7554,O
patients,7554,O
on,7554,O
the,7554,O
basis,7554,O
of,7554,O
the,7554,O
VKORC1,7554,B-GENE-Y
-1639G,7554,B-GENE-N
>,7554,I-GENE-N
A,7554,I-GENE-N
genotype,7554,O
.,7554,O
RESULTS,7555,O
:,7555,O
Eighty,7555,O
percent,7555,O
of,7555,O
CYP2C9,7555,B-GENE-Y
*,7555,O
1/,7555,O
*,7555,O
1,7555,O
patients,7555,O
stabilized,7555,O
on,7555,O
<,7555,O
4.0,7555,O
mg/day,7555,O
warfarin,7555,B-CHEMICAL
had,7555,O
at,7555,O
least,7555,O
1,7555,O
VKORC1,7555,B-GENE-Y
-1639A,7555,O
allele,7555,O
.,7555,O
Mean,7556,O
warfarin,7556,B-CHEMICAL
doses,7556,O
(,7556,O
SD,7556,O
),7556,O
were,7556,O
6.7,7556,O
(,7556,O
3.3,7556,O
),7556,O
",",7556,O
4.3,7556,O
(,7556,O
2.2,7556,O
),7556,O
",",7556,O
and,7556,O
2.7,7556,O
(,7556,O
1.2,7556,O
),7556,O
mg/day,7556,O
for,7556,O
patients,7556,O
with,7556,O
the,7556,O
VKORC1,7556,B-GENE-Y
-1639GG,7556,O
",",7556,O
GA,7556,O
",",7556,O
and,7556,O
AA,7556,O
genotypes,7556,O
",",7556,O
respectively,7556,O
.,7556,O
Steady-state,7557,O
plasma,7557,O
concentrations,7557,O
of,7557,O
S-warfarin,7557,B-CHEMICAL
were,7557,O
lowest,7557,O
in,7557,O
patients,7557,O
with,7557,O
the,7557,O
VKORC1,7557,B-GENE-Y
-1639AA,7557,O
genotype,7557,O
and,7557,O
demonstrated,7557,O
a,7557,O
positive,7557,O
association,7557,O
with,7557,O
the,7557,O
VKORC1,7557,B-GENE-Y
-1639G,7557,O
allele,7557,O
copy,7557,O
number,7557,O
(,7557,O
trend,7557,O
P,7557,O
=,7557,O
0.012,7557,O
),7557,O
.,7557,O
A,7558,O
model,7558,O
including,7558,O
VKORC1,7558,B-GENE-Y
and,7558,O
CYP2C9,7558,B-GENE-Y
genotypes,7558,O
",",7558,O
age,7558,O
",",7558,O
sex,7558,O
",",7558,O
and,7558,O
body,7558,O
weight,7558,O
accounted,7558,O
for,7558,O
61,7558,O
%,7558,O
of,7558,O
the,7558,O
variance,7558,O
in,7558,O
warfarin,7558,B-CHEMICAL
daily,7558,O
maintenance,7558,O
dose,7558,O
.,7558,O
CONCLUSIONS,7559,O
:,7559,O
The,7559,O
VKORC1,7559,B-GENE-Y
-1639A,7559,O
allele,7559,O
accounts,7559,O
for,7559,O
low,7559,O
dosage,7559,O
requirements,7559,O
of,7559,O
most,7559,O
patients,7559,O
without,7559,O
a,7559,O
CYP2C9,7559,B-GENE-Y
variant,7559,O
.,7559,O
Higher,7560,O
plasma,7560,O
S-warfarin,7560,B-CHEMICAL
concentrations,7560,O
corresponding,7560,O
to,7560,O
increased,7560,O
warfarin,7560,B-CHEMICAL
maintenance,7560,O
dosages,7560,O
support,7560,O
a,7560,O
hypothesis,7560,O
for,7560,O
increased,7560,O
expression,7560,O
of,7560,O
the,7560,O
VKORC1,7560,B-GENE-Y
-1639G,7560,O
allele,7560,O
.,7560,O
VKORC1,7561,B-GENE-Y
and,7561,O
CYP2C9,7561,B-GENE-Y
genotypes,7561,O
",",7561,O
age,7561,O
",",7561,O
sex,7561,O
",",7561,O
and,7561,O
body,7561,O
weight,7561,O
account,7561,O
for,7561,O
the,7561,O
majority,7561,O
of,7561,O
variance,7561,O
in,7561,O
warfarin,7561,B-CHEMICAL
dose,7561,O
among,7561,O
our,7561,O
study,7561,O
population,7561,O
.,7561,O
The,7562,O
role,7562,O
of,7562,O
rasagiline,7562,B-CHEMICAL
in,7562,O
the,7562,O
treatment,7562,O
of,7562,O
Parkinson,7562,O
's,7562,O
disease,7562,O
.,7562,O
Parkinson,7563,O
's,7563,O
disease,7563,O
(,7563,O
PD,7563,O
),7563,O
is,7563,O
the,7563,O
second,7563,O
most,7563,O
common,7563,O
neurodegenerative,7563,O
disorder,7563,O
",",7563,O
affecting,7563,O
1,7563,O
%,7563,O
to,7563,O
2,7563,O
%,7563,O
of,7563,O
people,7563,O
older,7563,O
than,7563,O
60,7563,O
years,7563,O
.,7563,O
Treatment,7564,O
of,7564,O
PD,7564,O
consists,7564,O
of,7564,O
symptomatic,7564,O
therapies,7564,O
while,7564,O
neuroprotective,7564,O
strategies,7564,O
have,7564,O
remained,7564,O
elusive,7564,O
.,7564,O
Rasagiline,7565,B-CHEMICAL
is,7565,O
a,7565,O
novel,7565,O
",",7565,O
potent,7565,O
",",7565,O
and,7565,O
irreversible,7565,O
monoamine,7565,B-GENE-Y
oxidase,7565,I-GENE-Y
type,7565,I-GENE-Y
B,7565,I-GENE-Y
(,7565,O
MAO-B,7565,B-GENE-Y
),7565,O
inhibitor,7565,O
which,7565,O
has,7565,O
been,7565,O
approved,7565,O
for,7565,O
treatment,7565,O
of,7565,O
PD,7565,O
.,7565,O
Rasagiline,7566,B-CHEMICAL
inhibits,7566,O
MAO-B,7566,B-GENE-Y
more,7566,O
potently,7566,O
than,7566,O
selegiline,7566,O
and,7566,O
has,7566,O
the,7566,O
advantage,7566,O
of,7566,O
once-daily,7566,O
dosing,7566,O
.,7566,O
In,7567,O
several,7567,O
large,7567,O
",",7567,O
randomized,7567,O
",",7567,O
placebo-controlled,7567,O
trials,7567,O
",",7567,O
rasagiline,7567,B-CHEMICAL
has,7567,O
demonstrated,7567,O
efficacy,7567,O
as,7567,O
monotherapy,7567,O
in,7567,O
early,7567,O
PD,7567,O
and,7567,O
as,7567,O
adjunctive,7567,O
therapy,7567,O
in,7567,O
advanced,7567,O
PD,7567,O
.,7567,O
In,7568,O
addition,7568,O
",",7568,O
rasagiline,7568,B-CHEMICAL
has,7568,O
been,7568,O
shown,7568,O
to,7568,O
have,7568,O
neuroprotective,7568,O
effects,7568,O
in,7568,O
in,7568,O
vitro,7568,O
and,7568,O
in,7568,O
vivo,7568,O
studies,7568,O
.,7568,O
The,7569,O
recently,7569,O
completed,7569,O
delayed-start,7569,O
ADAGIO,7569,O
(,7569,O
Attenuation,7569,O
of,7569,O
Disease,7569,O
Progression,7569,O
with,7569,O
Azilect,7569,O
Given,7569,O
Once-daily,7569,O
),7569,O
trial,7569,O
suggests,7569,O
a,7569,O
potential,7569,O
disease-modifying,7569,O
effect,7569,O
for,7569,O
rasagiline,7569,B-CHEMICAL
1,7569,O
mg/day,7569,O
",",7569,O
though,7569,O
the,7569,O
clinical,7569,O
import,7569,O
of,7569,O
this,7569,O
finding,7569,O
has,7569,O
yet,7569,O
to,7569,O
be,7569,O
established,7569,O
.,7569,O
Lithium,7570,B-CHEMICAL
modulates,7570,O
desensitization,7570,O
of,7570,O
the,7570,O
glutamate,7570,B-GENE-N
receptor,7570,I-GENE-N
subtype,7570,O
gluR3,7570,B-GENE-Y
in,7570,O
Xenopus,7570,O
oocytes,7570,O
.,7570,O
Analysis,7571,O
of,7571,O
splice,7571,O
variants,7571,O
and,7571,O
site-directed,7571,O
mutants,7571,O
of,7571,O
the,7571,O
AMPA,7571,B-GENE-N
receptor,7571,I-GENE-N
GluR3,7571,B-GENE-Y
expressed,7571,O
in,7571,O
Xenopus,7571,O
oocytes,7571,O
has,7571,O
shown,7571,O
that,7571,O
lithium,7571,B-CHEMICAL
produces,7571,O
a,7571,O
large,7571,O
potentiation,7571,O
of,7571,O
the,7571,O
GluR3,7571,B-GENE-Y
flop,7571,I-GENE-Y
splice,7571,O
variant,7571,O
and,7571,O
suggested,7571,O
that,7571,O
lithium,7571,B-CHEMICAL
might,7571,O
inhibit,7571,O
rapid,7571,O
desensitization,7571,O
",",7571,O
which,7571,O
is,7571,O
characteristic,7571,O
of,7571,O
this,7571,O
receptor,7571,O
(,7571,O
Karkanias,7571,O
",",7571,O
N.,7571,O
and,7571,O
Papke,7571,O
",",7571,O
R.,7571,O
",",7571,O
Subtype-specific,7571,O
effects,7571,O
of,7571,O
lithium,7571,B-CHEMICAL
on,7571,O
glutamate,7571,B-GENE-N
receptor,7571,I-GENE-N
function,7571,O
.,7571,O
J,7572,O
.,7572,O
Neurophysiol.,7573,O
",",7573,O
81,7573,O
(,7573,O
1999,7573,O
),7573,O
1506-1512,7573,O
),7573,O
.,7573,O
We,7574,O
now,7574,O
show,7574,O
that,7574,O
mutation,7574,O
of,7574,O
the,7574,O
769R/,7574,O
G,7574,O
desensitization,7574,O
site,7574,O
(,7574,O
Lomeli,7574,O
",",7574,O
H.M.J.,7574,O
",",7574,O
Melcher,7574,O
",",7574,O
T.,7574,O
",",7574,O
Hoger,7574,O
",",7574,O
T.,7574,O
",",7574,O
Geiger,7574,O
",",7574,O
J.R.,7574,O
",",7574,O
Kuner,7574,O
",",7574,O
T.,7574,O
",",7574,O
Monyer,7574,O
",",7574,O
H.,7574,O
",",7574,O
Higuchi,7574,O
",",7574,O
M.B.A.,7574,O
and,7574,O
Seeburg,7574,O
",",7574,O
P.H,7574,O
",",7574,O
Control,7574,O
of,7574,O
kinetic,7574,O
properties,7574,O
of,7574,O
AMPA,7574,B-GENE-N
receptor,7574,I-GENE-N
channels,7574,O
by,7574,O
nuclear,7574,O
RNA,7574,O
editing,7574,O
.,7574,O
Science,7575,O
",",7575,O
9,7575,O
(,7575,O
266,7575,O
),7575,O
(,7575,O
1994,7575,O
),7575,O
1709-1713,7575,O
),7575,O
greatly,7575,O
attenuates,7575,O
the,7575,O
lithium-induced,7575,B-CHEMICAL
potentiation,7575,O
of,7575,O
GluR3,7575,B-GENE-Y
.,7575,O
Additionally,7576,O
",",7576,O
experiments,7576,O
with,7576,O
the,7576,O
non-desensitizing,7576,O
site-directed,7576,O
mutant,7576,O
GluR3,7576,B-GENE-Y
(,7576,O
L507Y,7576,B-GENE-N
),7576,O
(,7576,O
Stern-Bach,7576,O
",",7576,O
Y.,7576,O
",",7576,O
Russo,7576,O
",",7576,O
S.,7576,O
",",7576,O
Neuman,7576,O
",",7576,O
M.,7576,O
and,7576,O
Rosenmund,7576,O
",",7576,O
C.,7576,O
",",7576,O
A,7576,O
point,7576,O
mutation,7576,O
in,7576,O
the,7576,O
glutamate,7576,B-CHEMICAL
binding,7576,O
site,7576,O
blocks,7576,O
desensitization,7576,O
of,7576,O
AMPA,7576,B-GENE-N
receptors,7576,I-GENE-N
.,7576,O
Neuron,7577,O
",",7577,O
21,7577,O
(,7577,O
1998,7577,O
),7577,O
907-918,7577,O
),7577,O
further,7577,O
confirms,7577,O
that,7577,O
lithium,7577,B-CHEMICAL
enhances,7577,O
GluR3,7577,B-GENE-Y
responses,7577,O
by,7577,O
reducing,7577,O
desensitization,7577,O
",",7577,O
since,7577,O
lithium,7577,O
's,7577,O
effects,7577,O
are,7577,O
reversed,7577,O
in,7577,O
this,7577,O
mutant,7577,O
.,7577,O
Lithium,7578,O
's,7578,O
effects,7578,O
on,7578,O
GluR3,7578,B-GENE-Y
desensitization,7578,O
are,7578,O
distinct,7578,O
from,7578,O
the,7578,O
effects,7578,O
of,7578,O
aniracetam,7578,B-CHEMICAL
on,7578,O
desensitization,7578,O
.,7578,O
Specifically,7579,O
",",7579,O
aniracetam,7579,B-CHEMICAL
",",7579,O
which,7579,O
potentiates,7579,O
wild-type,7579,O
AMPA,7579,B-GENE-N
receptors,7579,I-GENE-N
",",7579,O
is,7579,O
ineffective,7579,O
on,7579,O
the,7579,O
non-desensitizing,7579,O
GluR3,7579,B-GENE-Y
(,7579,O
L507Y,7579,B-GENE-N
),7579,O
mutant,7579,O
",",7579,O
but,7579,O
has,7579,O
synergistic,7579,O
effects,7579,O
with,7579,O
lithium,7579,B-CHEMICAL
on,7579,O
wild-type,7579,O
receptors,7579,O
.,7579,O
Oral,7580,O
administration,7580,O
of,7580,O
tetrahydrobiopterin,7580,B-CHEMICAL
prevents,7580,O
endothelial,7580,O
dysfunction,7580,O
and,7580,O
vascular,7580,O
oxidative,7580,O
stress,7580,O
in,7580,O
the,7580,O
aortas,7580,O
of,7580,O
insulin-resistant,7580,B-GENE-N
rats,7580,O
.,7580,O
We,7581,O
have,7581,O
reported,7581,O
that,7581,O
a,7581,O
deficiency,7581,O
of,7581,O
tetrahydrobiopterin,7581,B-CHEMICAL
(,7581,O
BH,7581,B-CHEMICAL
(,7581,I-CHEMICAL
4,7581,I-CHEMICAL
),7581,I-CHEMICAL
),7581,O
",",7581,O
an,7581,O
active,7581,O
cofactor,7581,O
of,7581,O
endothelial,7581,B-GENE-Y
NO,7581,I-GENE-Y
synthase,7581,I-GENE-Y
(,7581,O
eNOS,7581,B-GENE-Y
),7581,O
",",7581,O
contributes,7581,O
to,7581,O
the,7581,O
endothelial,7581,O
dysfunction,7581,O
through,7581,O
reduced,7581,O
eNOS,7581,B-GENE-Y
activity,7581,O
and,7581,O
increased,7581,O
superoxide,7581,B-CHEMICAL
anion,7581,I-CHEMICAL
(,7581,O
O,7581,B-CHEMICAL
(,7581,I-CHEMICAL
2,7581,I-CHEMICAL
),7581,I-CHEMICAL
(,7581,I-CHEMICAL
-,7581,I-CHEMICAL
),7581,I-CHEMICAL
),7581,O
generation,7581,O
in,7581,O
the,7581,O
insulin-resistant,7581,B-GENE-N
state,7581,O
.,7581,O
To,7582,O
further,7582,O
confirm,7582,O
this,7582,O
hypothesis,7582,O
",",7582,O
we,7582,O
investigated,7582,O
the,7582,O
effects,7582,O
of,7582,O
dietary,7582,O
treatment,7582,O
with,7582,O
BH,7582,B-CHEMICAL
(,7582,I-CHEMICAL
4,7582,I-CHEMICAL
),7582,I-CHEMICAL
on,7582,O
endothelium-dependent,7582,O
arterial,7582,O
relaxation,7582,O
and,7582,O
vascular,7582,O
oxidative,7582,O
stress,7582,O
in,7582,O
the,7582,O
aortas,7582,O
of,7582,O
insulin-resistant,7582,B-GENE-N
rats,7582,O
.,7582,O
Oral,7583,O
supplementation,7583,O
of,7583,O
BH,7583,B-CHEMICAL
(,7583,I-CHEMICAL
4,7583,I-CHEMICAL
),7583,I-CHEMICAL
(,7583,O
10,7583,O
mg.,7583,O
kg,7583,O
(,7583,O
-1,7583,O
),7583,O
.,7583,O
d,7584,O
(,7584,O
-1,7584,O
),7584,O
),7584,O
for,7584,O
8,7584,O
weeks,7584,O
significantly,7584,O
increased,7584,O
the,7584,O
BH,7584,B-CHEMICAL
(,7584,I-CHEMICAL
4,7584,I-CHEMICAL
),7584,I-CHEMICAL
content,7584,O
in,7584,O
cardiovascular,7584,O
tissues,7584,O
of,7584,O
rats,7584,O
fed,7584,O
high,7584,O
levels,7584,O
of,7584,O
fructose,7584,B-CHEMICAL
(,7584,O
fructose-fed,7584,B-CHEMICAL
rats,7584,O
),7584,O
.,7584,O
Impairment,7585,O
of,7585,O
endothelium-dependent,7585,O
arterial,7585,O
relaxation,7585,O
in,7585,O
the,7585,O
aortic,7585,O
strips,7585,O
of,7585,O
the,7585,O
fructose-fed,7585,B-CHEMICAL
rats,7585,O
was,7585,O
reversed,7585,O
with,7585,O
BH,7585,B-CHEMICAL
(,7585,I-CHEMICAL
4,7585,I-CHEMICAL
),7585,I-CHEMICAL
treatment,7585,O
.,7585,O
The,7586,O
BH,7586,B-CHEMICAL
(,7586,I-CHEMICAL
4,7586,I-CHEMICAL
),7586,I-CHEMICAL
treatment,7586,O
was,7586,O
associated,7586,O
with,7586,O
a,7586,O
2-fold,7586,O
increase,7586,O
in,7586,O
eNOS,7586,B-GENE-Y
activity,7586,O
as,7586,O
well,7586,O
as,7586,O
a,7586,O
70,7586,O
%,7586,O
reduction,7586,O
in,7586,O
endothelial,7586,O
O,7586,B-CHEMICAL
(,7586,I-CHEMICAL
2,7586,I-CHEMICAL
),7586,I-CHEMICAL
(,7586,I-CHEMICAL
-,7586,I-CHEMICAL
),7586,I-CHEMICAL
production,7586,O
compared,7586,O
with,7586,O
those,7586,O
in,7586,O
fructose-fed,7586,B-CHEMICAL
rats,7586,O
.,7586,O
The,7587,O
BH,7587,B-CHEMICAL
(,7587,I-CHEMICAL
4,7587,I-CHEMICAL
),7587,I-CHEMICAL
treatment,7587,O
also,7587,O
partially,7587,O
improved,7587,O
the,7587,O
insulin,7587,B-GENE-N
sensitivity,7587,O
and,7587,O
blood,7587,O
pressure,7587,O
",",7587,O
as,7587,O
well,7587,O
as,7587,O
the,7587,O
serum,7587,O
triglyceride,7587,B-CHEMICAL
concentration,7587,O
",",7587,O
in,7587,O
the,7587,O
fructose-fed,7587,B-CHEMICAL
rats,7587,O
.,7587,O
Moreover,7588,O
",",7588,O
BH,7588,B-CHEMICAL
(,7588,I-CHEMICAL
4,7588,I-CHEMICAL
),7588,I-CHEMICAL
treatment,7588,O
of,7588,O
the,7588,O
fructose-fed,7588,B-CHEMICAL
rats,7588,O
markedly,7588,O
reduced,7588,O
the,7588,O
lipid,7588,O
peroxide,7588,B-CHEMICAL
content,7588,O
of,7588,O
both,7588,O
aortic,7588,O
and,7588,O
cardiac,7588,O
tissues,7588,O
and,7588,O
inhibited,7588,O
the,7588,O
activation,7588,O
of,7588,O
2,7588,O
redox-sensitive,7588,O
transcription,7588,O
factors,7588,O
",",7588,O
nuclear,7588,B-GENE-N
factor-kappaB,7588,I-GENE-N
and,7588,O
activating,7588,B-GENE-Y
protein-1,7588,I-GENE-Y
",",7588,O
which,7588,O
were,7588,O
increased,7588,O
in,7588,O
fructose-fed,7588,B-CHEMICAL
rats,7588,O
.,7588,O
The,7589,O
BH,7589,B-CHEMICAL
(,7589,I-CHEMICAL
4,7589,I-CHEMICAL
),7589,I-CHEMICAL
treatment,7589,O
of,7589,O
control,7589,O
rats,7589,O
did,7589,O
not,7589,O
have,7589,O
any,7589,O
significant,7589,O
effects,7589,O
on,7589,O
these,7589,O
parameters,7589,O
.,7589,O
These,7590,O
results,7590,O
indicate,7590,O
that,7590,O
BH,7590,B-CHEMICAL
(,7590,I-CHEMICAL
4,7590,I-CHEMICAL
),7590,I-CHEMICAL
augmentation,7590,O
is,7590,O
essential,7590,O
for,7590,O
the,7590,O
restoration,7590,O
of,7590,O
eNOS,7590,B-GENE-Y
function,7590,O
and,7590,O
the,7590,O
reduction,7590,O
of,7590,O
vascular,7590,O
oxidative,7590,O
stress,7590,O
in,7590,O
insulin-resistant,7590,B-GENE-N
rats,7590,O
.,7590,O
A,7591,O
Re-evaluation,7591,O
of,7591,O
the,7591,O
Role,7591,O
of,7591,O
hCTR1,7591,B-GENE-Y
",",7591,O
the,7591,O
Human,7591,B-GENE-N
High,7591,I-GENE-N
Affinity,7591,I-GENE-N
Cu,7591,I-GENE-N
Transporter,7591,I-GENE-N
in,7591,O
Pt-Drug,7591,B-CHEMICAL
Entry,7591,O
into,7591,O
Human,7591,O
Cells,7591,O
.,7591,O
Cisplatin,7592,B-CHEMICAL
(,7592,O
cDDP,7592,B-CHEMICAL
),7592,O
is,7592,O
an,7592,O
anti-cancer,7592,O
drug,7592,O
used,7592,O
in,7592,O
a,7592,O
number,7592,O
of,7592,O
malignancies,7592,O
including,7592,O
testicular,7592,O
",",7592,O
ovarian,7592,O
",",7592,O
cervical,7592,O
",",7592,O
bladder,7592,O
",",7592,O
lung,7592,O
",",7592,O
head,7592,O
",",7592,O
and,7592,O
neck,7592,O
cancers,7592,O
.,7592,O
Its,7593,O
use,7593,O
is,7593,O
limited,7593,O
by,7593,O
the,7593,O
development,7593,O
of,7593,O
resistance,7593,O
",",7593,O
often,7593,O
rationalized,7593,O
via,7593,O
effects,7593,O
on,7593,O
cellular,7593,O
uptake,7593,O
.,7593,O
It,7594,O
has,7594,O
been,7594,O
claimed,7594,O
that,7594,O
hCTR1,7594,B-GENE-Y
",",7594,O
the,7594,O
human,7594,B-GENE-N
high,7594,I-GENE-N
affinity,7594,I-GENE-N
copper,7594,I-GENE-N
transporter,7594,I-GENE-N
",",7594,O
is,7594,O
the,7594,O
major,7594,O
entry,7594,O
pathway,7594,O
for,7594,O
cDDP,7594,B-CHEMICAL
and,7594,O
related,7594,O
drugs,7594,O
via,7594,O
a,7594,O
mechanism,7594,O
that,7594,O
mimics,7594,O
copper,7594,O
.,7594,O
This,7595,O
is,7595,O
an,7595,O
unexpected,7595,O
property,7595,O
of,7595,O
hCTR1,7595,B-GENE-Y
",",7595,O
a,7595,O
highly,7595,O
selective,7595,O
copper,7595,B-GENE-N
(,7595,I-GENE-N
I,7595,I-GENE-N
),7595,I-GENE-N
transporter,7595,I-GENE-N
.,7595,O
We,7596,O
compared,7596,O
the,7596,O
uptake,7596,O
rates,7596,O
of,7596,O
copper,7596,O
with,7596,O
cDDP,7596,O
(,7596,O
and,7596,O
several,7596,O
analogs,7596,O
),7596,O
into,7596,O
HEK293,7596,O
cells,7596,O
over-expressing,7596,O
wild-type,7596,O
or,7596,O
mutant,7596,O
hCTR1,7596,B-GENE-Y
",",7596,O
mouse,7596,O
embryonic,7596,O
fibroblasts,7596,O
(,7596,O
mefs,7596,O
),7596,O
that,7596,O
do,7596,O
or,7596,O
do,7596,O
not,7596,O
express,7596,O
CTR1,7596,B-GENE-Y
",",7596,O
and,7596,O
human,7596,O
ovarian,7596,O
tumor,7596,O
cells,7596,O
",",7596,O
sensitive,7596,O
or,7596,O
resistant,7596,O
to,7596,O
cDDP,7596,B-CHEMICAL
.,7596,O
We,7597,O
have,7597,O
also,7597,O
compared,7597,O
the,7597,O
effects,7597,O
of,7597,O
extracellular,7597,O
copper,7597,B-CHEMICAL
",",7597,O
which,7597,O
causes,7597,O
regulatory,7597,O
endocytosis,7597,O
of,7597,O
hCTR1,7597,B-GENE-Y
",",7597,O
to,7597,O
those,7597,O
of,7597,O
cDDP,7597,B-CHEMICAL
.,7597,O
We,7598,O
confirm,7598,O
the,7598,O
correlation,7598,O
between,7598,O
higher,7598,O
hCTR1,7598,B-GENE-Y
levels,7598,O
and,7598,O
higher,7598,O
Pt-drug,7598,B-CHEMICAL
uptake,7598,O
in,7598,O
tumor,7598,O
cells,7598,O
sensitive,7598,O
to,7598,O
the,7598,O
drug,7598,O
.,7598,O
However,7599,O
",",7599,O
we,7599,O
show,7599,O
that,7599,O
hCTR1,7599,B-GENE-Y
is,7599,O
not,7599,O
the,7599,O
major,7599,O
entry,7599,O
route,7599,O
of,7599,O
platinum-drugs,7599,B-CHEMICAL
and,7599,O
that,7599,O
the,7599,O
copper,7599,B-CHEMICAL
transporter,7599,O
is,7599,O
not,7599,O
internalized,7599,O
in,7599,O
response,7599,O
to,7599,O
extracellular,7599,O
drug,7599,O
.,7599,O
Our,7600,O
data,7600,O
suggest,7600,O
the,7600,O
major,7600,O
entry,7600,O
pathway,7600,O
for,7600,O
platinum-drugs,7600,B-CHEMICAL
is,7600,O
not,7600,O
saturable,7600,O
at,7600,O
relevant,7600,O
concentrations,7600,O
and,7600,O
not,7600,O
protein-mediated,7600,O
.,7600,O
Clinical,7601,O
trials,7601,O
have,7601,O
been,7601,O
initiated,7601,O
that,7601,O
depend,7601,O
upon,7601,O
regulating,7601,O
membrane,7601,O
levels,7601,O
of,7601,O
hCTR1,7601,B-GENE-Y
.,7601,O
If,7602,O
reduced,7602,O
drug,7602,O
uptake,7602,O
is,7602,O
a,7602,O
major,7602,O
factor,7602,O
in,7602,O
resistance,7602,O
",",7602,O
hCTR1,7602,B-GENE-Y
is,7602,O
unlikely,7602,O
to,7602,O
be,7602,O
a,7602,O
productive,7602,O
target,7602,O
in,7602,O
attempts,7602,O
to,7602,O
enhance,7602,O
efficacy,7602,O
",",7602,O
although,7602,O
the,7602,O
proteins,7602,O
involved,7602,O
in,7602,O
copper,7602,B-CHEMICAL
homeostasis,7602,O
may,7602,O
play,7602,O
a,7602,O
role,7602,O
.,7602,O
Acute,7603,O
effects,7603,O
of,7603,O
brexpiprazole,7603,B-CHEMICAL
on,7603,O
serotonin,7603,B-CHEMICAL
",",7603,O
dopamine,7603,B-CHEMICAL
",",7603,O
and,7603,O
norepinephrine,7603,B-CHEMICAL
systems,7603,O
:,7603,O
an,7603,O
in,7603,O
vivo,7603,O
electrophysiologic,7603,O
characterization,7603,O
.,7603,O
Brexpiprazole,7604,B-CHEMICAL
",",7604,O
a,7604,O
compound,7604,O
sharing,7604,O
structural,7604,O
molecular,7604,O
characteristics,7604,O
with,7604,O
aripiprazole,7604,B-CHEMICAL
",",7604,O
is,7604,O
currently,7604,O
under,7604,O
investigation,7604,O
for,7604,O
the,7604,O
treatment,7604,O
of,7604,O
schizophrenia,7604,O
and,7604,O
depression,7604,O
.,7604,O
Using,7605,O
electrophysiologic,7605,O
techniques,7605,O
",",7605,O
the,7605,O
present,7605,O
study,7605,O
assessed,7605,O
the,7605,O
in,7605,O
vivo,7605,O
action,7605,O
of,7605,O
brexpiprazole,7605,B-CHEMICAL
on,7605,O
serotonin,7605,B-GENE-N
(,7605,I-GENE-N
5-HT,7605,I-GENE-N
),7605,I-GENE-N
receptor,7605,I-GENE-N
subtypes,7605,O
5-HT1A,7605,B-GENE-Y
",",7605,O
5-HT1B,7605,B-GENE-Y
",",7605,O
and,7605,O
5-HT2A,7605,B-GENE-Y
;,7605,O
dopamine,7605,B-GENE-Y
(,7605,I-GENE-Y
DA,7605,I-GENE-Y
),7605,I-GENE-Y
D2,7605,I-GENE-Y
autoreceptors,7605,I-GENE-Y
",",7605,O
and,7605,O
alpha1-,7605,B-GENE-N
and,7605,I-GENE-N
alpha2-adrenergic,7605,I-GENE-N
receptors,7605,I-GENE-N
.,7605,O
In,7606,O
addition,7606,O
",",7606,O
the,7606,O
effects,7606,O
on,7606,O
5-HT1A,7606,B-GENE-Y
autoreceptors,7606,O
in,7606,O
the,7606,O
dorsal,7606,O
raphe,7606,O
nucleus,7606,O
(,7606,O
DRN,7606,O
),7606,O
and,7606,O
D2,7606,B-GENE-Y
autoreceptors,7606,I-GENE-Y
in,7606,O
the,7606,O
ventral,7606,O
tegmental,7606,O
area,7606,O
(,7606,O
VTA,7606,O
),7606,O
were,7606,O
compared,7606,O
with,7606,O
those,7606,O
of,7606,O
aripiprazole,7606,B-CHEMICAL
",",7606,O
an,7606,O
agent,7606,O
in,7606,O
wide,7606,O
clinical,7606,O
use,7606,O
.,7606,O
In,7607,O
the,7607,O
DRN,7607,O
",",7607,O
brexpiprazole,7607,B-CHEMICAL
completely,7607,O
inhibited,7607,O
the,7607,O
firing,7607,O
of,7607,O
5-HT,7607,B-CHEMICAL
neurons,7607,O
via,7607,O
5-HT1A,7607,B-GENE-Y
agonism,7607,O
and,7607,O
was,7607,O
more,7607,O
potent,7607,O
than,7607,O
aripiprazole,7607,B-CHEMICAL
(,7607,O
ED50,7607,O
=,7607,O
230,7607,O
and,7607,O
700,7607,O
mug/kg,7607,O
",",7607,O
respectively,7607,O
),7607,O
.,7607,O
In,7608,O
the,7608,O
locus,7608,O
coeruleus,7608,O
",",7608,O
brexpiprazole,7608,B-CHEMICAL
reversed,7608,O
the,7608,O
inhibitory,7608,O
effect,7608,O
of,7608,O
the,7608,O
preferential,7608,O
5-HT2A,7608,B-GENE-Y
receptor,7608,O
agonist,7608,O
DOI,7608,B-CHEMICAL
(,7608,O
"2,5-dimethoxy-4-iodoamphetamine",7608,B-CHEMICAL
),7608,O
on,7608,O
norepinephrine,7608,B-CHEMICAL
neuronal,7608,O
firing,7608,O
(,7608,O
ED50,7608,O
=,7608,O
110,7608,O
mug/kg,7608,O
),7608,O
",",7608,O
demonstrating,7608,O
5-HT2A,7608,B-GENE-Y
antagonistic,7608,O
action,7608,O
.,7608,O
Brexpiprazole,7609,B-CHEMICAL
reversed,7609,O
the,7609,O
inhibitory,7609,O
effect,7609,O
of,7609,O
the,7609,O
DA,7609,B-CHEMICAL
agonist,7609,O
apomorphine,7609,B-CHEMICAL
on,7609,O
VTA,7609,O
DA,7609,O
neurons,7609,O
(,7609,O
ED50,7609,O
=,7609,O
61,7609,O
mug/kg,7609,O
),7609,O
",",7609,O
whereas,7609,O
it,7609,O
was,7609,O
ineffective,7609,O
when,7609,O
administered,7609,O
alone,7609,O
",",7609,O
indicating,7609,O
partial,7609,O
agonistic,7609,O
action,7609,O
on,7609,O
D2,7609,B-GENE-Y
receptors,7609,I-GENE-Y
.,7609,O
Compared,7610,O
with,7610,O
aripiprazole,7610,B-CHEMICAL
",",7610,O
which,7610,O
significantly,7610,O
inhibited,7610,O
the,7610,O
firing,7610,O
activity,7610,O
of,7610,O
VTA,7610,O
DA,7610,B-CHEMICAL
neurons,7610,O
",",7610,O
brexpiprazole,7610,B-CHEMICAL
displayed,7610,O
less,7610,O
efficacy,7610,O
at,7610,O
D2,7610,B-GENE-Y
receptors,7610,I-GENE-Y
.,7610,O
In,7611,O
the,7611,O
hippocampus,7611,O
",",7611,O
brexpiprazole,7611,B-CHEMICAL
acted,7611,O
as,7611,O
a,7611,O
full,7611,O
agonist,7611,O
at,7611,O
5-HT1A,7611,B-GENE-Y
receptors,7611,O
on,7611,O
pyramidal,7611,O
neurons,7611,O
.,7611,O
Furthermore,7612,O
",",7612,O
it,7612,O
increased,7612,O
5-HT,7612,B-CHEMICAL
release,7612,O
by,7612,O
terminal,7612,O
alpha2-adrenergic,7612,B-GENE-N
heteroceptor,7612,I-GENE-N
but,7612,O
not,7612,O
5-HT1B,7612,B-GENE-Y
autoreceptor,7612,O
antagonism,7612,O
.,7612,O
In,7613,O
the,7613,O
lateral,7613,O
geniculate,7613,O
nucleus,7613,O
",",7613,O
brexpiprazole,7613,B-CHEMICAL
displayed,7613,O
alpha1B-adrenoceptor,7613,B-GENE-Y
antagonistic,7613,O
action,7613,O
.,7613,O
Taken,7614,O
together,7614,O
",",7614,O
these,7614,O
results,7614,O
provide,7614,O
insight,7614,O
into,7614,O
the,7614,O
in,7614,O
vivo,7614,O
action,7614,O
of,7614,O
brexpiprazole,7614,B-CHEMICAL
on,7614,O
monoamine,7614,B-CHEMICAL
targets,7614,O
relevant,7614,O
in,7614,O
the,7614,O
treatment,7614,O
of,7614,O
depression,7614,O
and,7614,O
schizophrenia,7614,O
.,7614,O
Anti-asthmatic,7615,O
Effects,7615,O
of,7615,O
Baicalin,7615,B-CHEMICAL
in,7615,O
a,7615,O
Mouse,7615,O
Model,7615,O
of,7615,O
Allergic,7615,O
Asthma,7615,O
.,7615,O
The,7616,O
aim,7616,O
of,7616,O
the,7616,O
study,7616,O
was,7616,O
to,7616,O
investigate,7616,O
the,7616,O
anti-asthmatic,7616,O
effects,7616,O
of,7616,O
baicalin,7616,B-CHEMICAL
(,7616,O
BA,7616,O
),7616,O
and,7616,O
the,7616,O
possible,7616,O
mechanisms,7616,O
.,7616,O
Asthma,7617,O
model,7617,O
was,7617,O
established,7617,O
by,7617,O
ovalbumin,7617,B-GENE-Y
(,7617,O
OVA,7617,B-GENE-Y
),7617,O
intraperitoneal,7617,O
injection,7617,O
.,7617,O
A,7618,O
total,7618,O
of,7618,O
60,7618,O
mice,7618,O
were,7618,O
randomly,7618,O
assigned,7618,O
to,7618,O
six,7618,O
experimental,7618,O
groups,7618,O
:,7618,O
control,7618,O
",",7618,O
model,7618,O
",",7618,O
dexamethasone,7618,B-CHEMICAL
(,7618,O
2,7618,O
mg/kg,7618,O
),7618,O
",",7618,O
and,7618,O
BA,7618,O
(,7618,O
10,7618,O
mg/kg,7618,O
",",7618,O
20,7618,O
mg/kg,7618,O
",",7618,O
40,7618,O
mg/kg,7618,O
),7618,O
.,7618,O
Airway,7619,O
resistance,7619,O
(,7619,O
RI,7619,O
),7619,O
and,7619,O
lung,7619,O
compliance,7619,O
(,7619,O
Cdyn,7619,O
),7619,O
were,7619,O
measured,7619,O
",",7619,O
histological,7619,O
studies,7619,O
were,7619,O
evaluated,7619,O
by,7619,O
the,7619,O
hematoxylin,7619,B-CHEMICAL
and,7619,O
eosin,7619,B-CHEMICAL
staining,7619,O
",",7619,O
Th1/Th2,7619,O
",",7619,O
OVA-specific,7619,B-GENE-Y
serum,7619,O
",",7619,O
and,7619,O
BALF,7619,O
IgE,7619,B-GENE-N
levels,7619,O
and,7619,O
Th17,7619,O
cytokines,7619,B-GENE-N
were,7619,O
evaluated,7619,O
by,7619,O
enzyme-linked,7619,O
immunosorbent,7619,O
assay,7619,O
",",7619,O
and,7619,O
Th17,7619,O
cells,7619,O
was,7619,O
evaluated,7619,O
by,7619,O
flow,7619,O
cytometry,7619,O
(,7619,O
FCM,7619,O
),7619,O
.,7619,O
Our,7620,O
study,7620,O
demonstrated,7620,O
that,7620,O
BA,7620,O
inhibited,7620,O
OVA-induced,7620,B-GENE-Y
increases,7620,O
in,7620,O
RI,7620,O
and,7620,O
eosinophil,7620,O
count,7620,O
;,7620,O
interleukin,7620,O
(,7620,B-GENE-Y
IL,7620,I-GENE-Y
),7620,I-GENE-Y
-4,7620,I-GENE-Y
",",7620,O
IL-17A,7620,B-GENE-Y
levels,7620,O
",",7620,O
and,7620,O
Cdyn,7620,O
were,7620,O
recovered,7620,O
and,7620,O
increased,7620,O
IFN-γ,7620,B-GENE-Y
level,7620,O
in,7620,O
bronchoalveolar,7620,O
lavage,7620,O
fluid,7620,O
.,7620,O
Histological,7621,O
studies,7621,O
demonstrated,7621,O
that,7621,O
BA,7621,O
substantially,7621,O
inhibited,7621,O
OVA-induced,7621,B-GENE-Y
eosinophilia,7621,O
in,7621,O
lung,7621,O
tissue,7621,O
and,7621,O
airway,7621,O
tissue,7621,O
.,7621,O
FCM,7622,O
studies,7622,O
demonstrated,7622,O
that,7622,O
BA,7622,O
substantially,7622,O
inhibited,7622,O
Th17,7622,O
cells,7622,O
.,7622,O
These,7623,O
findings,7623,O
suggest,7623,O
that,7623,O
BA,7623,O
may,7623,O
effectively,7623,O
ameliorate,7623,O
the,7623,O
progression,7623,O
of,7623,O
asthma,7623,O
and,7623,O
could,7623,O
be,7623,O
used,7623,O
as,7623,O
a,7623,O
therapy,7623,O
for,7623,O
patients,7623,O
with,7623,O
allergic,7623,O
asthma,7623,O
.,7623,O
Copyright,7624,O
©,7624,O
2013,7624,O
John,7624,O
Wiley,7624,O
&,7624,O
Sons,7624,O
",",7624,O
Ltd,7624,O
.,7624,O
Effects,7625,O
of,7625,O
fenofibrate,7625,B-CHEMICAL
",",7625,O
a,7625,O
PPAR-α,7625,B-GENE-Y
ligand,7625,O
",",7625,O
on,7625,O
the,7625,O
haemodynamics,7625,O
of,7625,O
glycerol-induced,7625,B-CHEMICAL
renal,7625,O
failure,7625,O
in,7625,O
rats,7625,O
.,7625,O
The,7626,O
modulating,7626,O
effect,7626,O
of,7626,O
peroxisome,7626,B-GENE-Y
proliferator-activated,7626,I-GENE-Y
receptor,7626,I-GENE-Y
α,7626,I-GENE-Y
ligand,7626,O
on,7626,O
haemodynamic,7626,O
effects,7626,O
of,7626,O
phenylepherine,7626,B-CHEMICAL
(,7626,O
PE,7626,O
),7626,O
",",7626,O
angiotensin,7626,B-GENE-Y
II,7626,I-GENE-Y
(,7626,O
AII,7626,B-GENE-Y
),7626,O
",",7626,O
endothelin,7626,B-GENE-Y
1,7626,I-GENE-Y
(,7626,O
ET1,7626,B-GENE-Y
),7626,O
",",7626,O
acetylcholine,7626,B-CHEMICAL
(,7626,O
Ach,7626,B-CHEMICAL
),7626,O
",",7626,O
sodium,7626,B-CHEMICAL
nitroprusside,7626,I-CHEMICAL
(,7626,O
SNP,7626,B-CHEMICAL
),7626,O
and,7626,O
isoproterenol,7626,B-CHEMICAL
(,7626,O
ISO,7626,B-CHEMICAL
),7626,O
were,7626,O
evaluated,7626,O
in,7626,O
glycerol-induced,7626,B-CHEMICAL
acute,7626,O
kidney,7626,O
injury,7626,O
in,7626,O
rats,7626,O
.,7626,O
The,7627,O
effect,7627,O
of,7627,O
PE,7627,O
on,7627,O
fenofibrate-treated,7627,B-CHEMICAL
animals,7627,O
was,7627,O
a,7627,O
dose-dependent,7627,O
increase,7627,O
in,7627,O
mean,7627,O
arterial,7627,O
blood,7627,O
pressure,7627,O
(,7627,O
MAP,7627,O
),7627,O
.,7627,O
For,7628,O
AII,7628,B-GENE-Y
and,7628,O
ET1,7628,B-GENE-Y
",",7628,O
MAP,7628,O
was,7628,O
also,7628,O
increased,7628,O
for,7628,O
the,7628,O
fenofibrate,7628,B-CHEMICAL
group,7628,O
but,7628,O
not,7628,O
in,7628,O
a,7628,O
dose-dependent,7628,O
fashion,7628,O
.,7628,O
On,7629,O
the,7629,O
medullary,7629,O
blood,7629,O
flow,7629,O
(,7629,O
MBF,7629,O
),7629,O
",",7629,O
while,7629,O
the,7629,O
lower,7629,O
doses,7629,O
of,7629,O
PE,7629,O
and,7629,O
AII,7629,B-GENE-Y
increased,7629,O
the,7629,O
perfusion,7629,O
unit,7629,O
on,7629,O
the,7629,O
fenofibrate-treated,7629,B-CHEMICAL
group,7629,O
",",7629,O
the,7629,O
higher,7629,O
doses,7629,O
decreased,7629,O
the,7629,O
perfusion,7629,O
unit,7629,O
.,7629,O
The,7630,O
ET1,7630,B-GENE-Y
increased,7630,O
the,7630,O
perfusion,7630,O
unit,7630,O
on,7630,O
this,7630,O
group,7630,O
but,7630,O
not,7630,O
in,7630,O
dose-dependent,7630,O
fashion,7630,O
.,7630,O
The,7631,O
effects,7631,O
of,7631,O
PE,7631,O
and,7631,O
AII,7631,B-GENE-Y
on,7631,O
the,7631,O
cortical,7631,O
blood,7631,O
flow,7631,O
(,7631,O
CBF,7631,O
),7631,O
of,7631,O
fenofibrate-treated,7631,B-CHEMICAL
group,7631,O
is,7631,O
similar,7631,O
to,7631,O
that,7631,O
of,7631,O
MBF,7631,O
for,7631,O
the,7631,O
same,7631,O
group,7631,O
but,7631,O
not,7631,O
for,7631,O
ET1,7631,B-GENE-Y
.,7631,O
The,7632,O
effect,7632,O
of,7632,O
Ach,7632,B-CHEMICAL
",",7632,O
SNP,7632,B-CHEMICAL
and,7632,O
ISO,7632,B-CHEMICAL
in,7632,O
all,7632,O
the,7632,O
groups,7632,O
was,7632,O
the,7632,O
decrease,7632,O
in,7632,O
MAP,7632,O
.,7632,O
ISO,7633,B-CHEMICAL
caused,7633,O
dose-dependent,7633,O
increase,7633,O
in,7633,O
MBF,7633,O
of,7633,O
fenofibrate-treated,7633,B-CHEMICAL
group,7633,O
.,7633,O
The,7634,O
effect,7634,O
of,7634,O
Ach,7634,B-CHEMICAL
",",7634,O
SNP,7634,B-CHEMICAL
and,7634,O
ISO,7634,B-CHEMICAL
on,7634,O
the,7634,O
CBF,7634,O
perfusion,7634,O
unit,7634,O
was,7634,O
that,7634,O
of,7634,O
the,7634,O
increase,7634,O
for,7634,O
the,7634,O
fenofibrate-treated,7634,B-CHEMICAL
group,7634,O
.,7634,O
The,7635,O
study,7635,O
showed,7635,O
that,7635,O
fenofibrate,7635,B-CHEMICAL
did,7635,O
not,7635,O
attenuate,7635,O
increased,7635,O
blood,7635,O
pressure,7635,O
induced,7635,O
by,7635,O
PE,7635,O
",",7635,O
AII,7635,B-GENE-Y
and,7635,O
ET1,7635,B-GENE-Y
but,7635,O
caused,7635,O
enhanced,7635,O
vasodilation,7635,O
by,7635,O
Ach,7635,B-CHEMICAL
",",7635,O
SNP,7635,B-CHEMICAL
and,7635,O
ISO,7635,B-CHEMICAL
.,7635,O
Nanobody-albumin,7636,O
nanoparticles,7636,O
(,7636,O
NANAPs,7636,O
),7636,O
for,7636,O
the,7636,O
delivery,7636,O
of,7636,O
a,7636,O
multikinase,7636,B-GENE-N
inhibitor,7636,O
17864,7636,B-CHEMICAL
to,7636,O
EGFR,7636,B-GENE-Y
overexpressing,7636,O
tumor,7636,O
cells,7636,O
.,7636,O
A,7637,O
novel,7637,O
",",7637,O
EGFR-targeted,7637,B-GENE-Y
nanomedicine,7637,O
has,7637,O
been,7637,O
developed,7637,O
in,7637,O
the,7637,O
current,7637,O
study,7637,O
.,7637,O
Glutaraldehyde,7638,B-CHEMICAL
crosslinked,7638,O
albumin,7638,B-GENE-Y
nanoparticles,7638,O
with,7638,O
a,7638,O
size,7638,O
of,7638,O
approximately,7638,O
100nm,7638,O
were,7638,O
loaded,7638,O
with,7638,O
the,7638,O
multikinase,7638,B-GENE-N
inhibitor,7638,O
17864-L,7638,B-CHEMICAL
(,7638,O
x,7638,O
),7638,O
-a,7638,O
platinum-bound,7638,B-CHEMICAL
sunitinib,7638,B-CHEMICAL
analogue-which,7638,O
couples,7638,O
the,7638,O
drug,7638,O
to,7638,O
methionine,7638,B-CHEMICAL
residues,7638,O
of,7638,O
albumin,7638,B-GENE-Y
and,7638,O
is,7638,O
released,7638,O
in,7638,O
a,7638,O
reductive,7638,O
environment,7638,O
.,7638,O
Albumin,7639,B-GENE-Y
nanoparticles,7639,O
were,7639,O
surface-coated,7639,O
with,7639,O
bifunctional,7639,O
polyethylene,7639,B-CHEMICAL
glycol,7639,I-CHEMICAL
3500,7639,O
(,7639,O
PEG,7639,B-CHEMICAL
),7639,O
and,7639,O
a,7639,O
nanobody-the,7639,O
single,7639,O
variable,7639,O
domain,7639,O
of,7639,O
an,7639,O
antibody-,7639,O
(,7639,O
Ega1,7639,O
),7639,O
against,7639,O
the,7639,O
epidermal,7639,B-GENE-Y
growth,7639,I-GENE-Y
factor,7639,I-GENE-Y
receptor,7639,I-GENE-Y
(,7639,O
EGFR,7639,B-GENE-Y
),7639,O
.,7639,O
EGa1-PEG,7640,O
functionalized,7640,O
nanoparticles,7640,O
showed,7640,O
a,7640,O
40-fold,7640,O
higher,7640,O
binding,7640,O
to,7640,O
EGFR-positive,7640,B-GENE-Y
14C,7640,B-CHEMICAL
squamous,7640,O
head,7640,O
and,7640,O
neck,7640,O
cancer,7640,O
cells,7640,O
in,7640,O
comparison,7640,O
to,7640,O
PEGylated,7640,O
nanoparticles,7640,O
.,7640,O
17864-L,7641,B-CHEMICAL
(,7641,O
x,7641,O
),7641,O
loaded,7641,O
EGa1-PEG,7641,O
nanoparticles,7641,O
were,7641,O
internalized,7641,O
by,7641,O
clathrin-mediated,7641,B-GENE-N
endocytosis,7641,O
and,7641,O
ultimately,7641,O
digested,7641,O
in,7641,O
lysosomes,7641,O
.,7641,O
The,7642,O
intracellular,7642,O
routing,7642,O
of,7642,O
EGa1,7642,O
targeted,7642,O
nanoparticles,7642,O
leads,7642,O
to,7642,O
a,7642,O
successful,7642,O
release,7642,O
of,7642,O
the,7642,O
kinase,7642,B-GENE-N
inhibitor,7642,O
in,7642,O
the,7642,O
cell,7642,O
and,7642,O
inhibition,7642,O
of,7642,O
proliferation,7642,O
whereas,7642,O
the,7642,O
non-targeted,7642,O
formulations,7642,O
had,7642,O
no,7642,O
antiproliferative,7642,O
effects,7642,O
on,7642,O
14C,7642,B-CHEMICAL
cells,7642,O
.,7642,O
The,7643,O
drug,7643,O
loaded,7643,O
targeted,7643,O
nanoparticles,7643,O
were,7643,O
as,7643,O
effective,7643,O
as,7643,O
the,7643,O
free,7643,O
drug,7643,O
in,7643,O
vitro,7643,O
.,7643,O
These,7644,O
results,7644,O
demonstrate,7644,O
that,7644,O
multikinase,7644,B-GENE-N
inhibitor,7644,O
loaded,7644,O
nanoparticles,7644,O
are,7644,O
interesting,7644,O
nanomedicines,7644,O
for,7644,O
the,7644,O
treatment,7644,O
of,7644,O
EGFR-positive,7644,B-GENE-Y
cancers,7644,O
.,7644,O
Chromosomal,7645,O
localization,7645,O
",",7645,O
gene,7645,O
structure,7645,O
",",7645,O
and,7645,O
expression,7645,O
pattern,7645,O
of,7645,O
DDAH1,7645,B-GENE-Y
:,7645,O
comparison,7645,O
with,7645,O
DDAH2,7645,B-GENE-Y
and,7645,O
implications,7645,O
for,7645,O
evolutionary,7645,O
origins,7645,O
.,7645,O
Endogenously,7646,O
produced,7646,O
asymmetrically,7646,O
methylated,7646,O
arginine,7646,B-CHEMICAL
residues,7646,O
are,7646,O
competitive,7646,O
inhibitors,7646,O
of,7646,O
all,7646,O
three,7646,O
isoforms,7646,O
of,7646,O
nitric,7646,B-GENE-N
oxide,7646,I-GENE-N
synthase,7646,I-GENE-N
(,7646,O
NOS,7646,B-GENE-N
),7646,O
.,7646,O
The,7647,O
enzyme,7647,O
dimethylarginine,7647,B-GENE-N
dimethylaminohydrolase,7647,I-GENE-N
(,7647,O
DDAH,7647,B-GENE-N
),7647,O
specifically,7647,O
hydrolyzes,7647,O
these,7647,O
asymmetrically,7647,O
methylated,7647,O
arginine,7647,B-CHEMICAL
residues,7647,O
to,7647,O
citrulline,7647,O
and,7647,O
methylamines,7647,O
.,7647,O
Previously,7648,O
we,7648,O
have,7648,O
proposed,7648,O
that,7648,O
regulation,7648,O
of,7648,O
asymmetric,7648,O
methylarginine,7648,B-CHEMICAL
concentration,7648,O
by,7648,O
DDAH,7648,B-GENE-N
may,7648,O
provide,7648,O
a,7648,O
novel,7648,O
mechanism,7648,O
for,7648,O
the,7648,O
regulation,7648,O
of,7648,O
NOS,7648,B-GENE-N
activity,7648,O
in,7648,O
vivo,7648,O
.,7648,O
Recently,7649,O
we,7649,O
reported,7649,O
the,7649,O
cloning,7649,O
of,7649,O
human,7649,B-GENE-N
DDAH,7649,I-GENE-N
and,7649,O
identified,7649,O
a,7649,O
novel,7649,O
human,7649,B-GENE-N
DDAH,7649,I-GENE-N
isoform,7649,O
(,7649,O
DDAH,7649,B-GENE-Y
I,7649,I-GENE-Y
and,7649,O
DDAH,7649,B-GENE-Y
II,7649,I-GENE-Y
",",7649,O
respectively,7649,O
),7649,O
.,7649,O
Here,7650,O
we,7650,O
report,7650,O
that,7650,O
the,7650,O
DDAH1,7650,B-GENE-Y
gene,7650,O
maps,7650,O
to,7650,O
chromosome,7650,O
1p22,7650,O
and,7650,O
confirm,7650,O
that,7650,O
DDAH2,7650,B-GENE-Y
maps,7650,O
to,7650,O
the,7650,O
MHC,7650,O
III,7650,O
region,7650,O
of,7650,O
chromosome,7650,O
6p21.3,7650,O
.,7650,O
Extensive,7651,O
analysis,7651,O
of,7651,O
the,7651,O
distribution,7651,O
of,7651,O
DDAH1,7651,B-GENE-Y
and,7651,O
DDAH2,7651,B-GENE-Y
mRNA,7651,O
in,7651,O
50,7651,O
human,7651,O
tissues,7651,O
indicates,7651,O
differential,7651,O
expression,7651,O
of,7651,O
DDAH,7651,B-GENE-N
isoforms,7651,O
in,7651,O
brain,7651,O
regions,7651,O
",",7651,O
in,7651,O
immune,7651,O
cells,7651,O
",",7651,O
and,7651,O
during,7651,O
development,7651,O
.,7651,O
DDAH2,7652,B-GENE-Y
expression,7652,O
predominates,7652,O
in,7652,O
highly,7652,O
vascularized,7652,O
tissues,7652,O
that,7652,O
express,7652,O
the,7652,O
endothelial,7652,B-GENE-Y
NOS,7652,I-GENE-Y
isoform,7652,O
and,7652,O
in,7652,O
immune,7652,O
tissues,7652,O
that,7652,O
can,7652,O
express,7652,O
iNOS,7652,B-GENE-Y
.,7652,O
Whereas,7653,O
DDAH2,7653,B-GENE-Y
is,7653,O
expressed,7653,O
at,7653,O
relatively,7653,O
high,7653,O
levels,7653,O
in,7653,O
all,7653,O
fetal,7653,O
tissues,7653,O
examined,7653,O
",",7653,O
DDAH1,7653,B-GENE-Y
expression,7653,O
varies,7653,O
little,7653,O
between,7653,O
fetal,7653,O
and,7653,O
adult,7653,O
tissues,7653,O
.,7653,O
The,7654,O
chromosomal,7654,O
localization,7654,O
of,7654,O
the,7654,O
DDAHs,7654,B-GENE-N
is,7654,O
consistent,7654,O
with,7654,O
gene,7654,O
duplication,7654,O
",",7654,O
and,7654,O
consistent,7654,O
with,7654,O
this,7654,O
",",7654,O
comparison,7654,O
of,7654,O
the,7654,O
gene,7654,O
structures,7654,O
indicates,7654,O
that,7654,O
the,7654,O
intron/exon,7654,O
organization,7654,O
is,7654,O
highly,7654,O
conserved,7654,O
.,7654,O
Phylogenetic,7655,O
analysis,7655,O
of,7655,O
DDAH,7655,B-GENE-N
sequences,7655,O
from,7655,O
diverse,7655,O
species,7655,O
suggests,7655,O
that,7655,O
DDAH,7655,B-GENE-N
gene,7655,O
duplication,7655,O
occurred,7655,O
prior,7655,O
to,7655,O
the,7655,O
emergence,7655,O
of,7655,O
bony,7655,O
fish,7655,O
some,7655,O
400,7655,O
million,7655,O
years,7655,O
ago,7655,O
.,7655,O
Overall,7656,O
the,7656,O
data,7656,O
suggest,7656,O
that,7656,O
DDAH2,7656,B-GENE-Y
may,7656,O
be,7656,O
the,7656,O
more,7656,O
ancient,7656,O
of,7656,O
the,7656,O
two,7656,O
genes,7656,O
.,7656,O
Structure-based,7657,O
design,7657,O
of,7657,O
novel,7657,O
dihydroisoquinoline,7657,B-CHEMICAL
BACE-1,7657,B-GENE-Y
inhibitors,7657,O
that,7657,O
do,7657,O
not,7657,O
engage,7657,O
the,7657,O
catalytic,7657,O
aspartates,7657,B-CHEMICAL
.,7657,O
The,7658,O
structure-activity,7658,O
relationship,7658,O
of,7658,O
a,7658,O
series,7658,O
of,7658,O
dihydroisoquinoline,7658,B-CHEMICAL
BACE-1,7658,B-GENE-Y
inhibitors,7658,O
is,7658,O
described,7658,O
.,7658,O
Application,7659,O
of,7659,O
structure-based,7659,O
design,7659,O
to,7659,O
screening,7659,O
hit,7659,O
1,7659,O
yielded,7659,O
sub-micromolar,7659,O
inhibitors,7659,O
.,7659,O
Replacement,7660,O
of,7660,O
the,7660,O
carboxylic,7660,B-CHEMICAL
acid,7660,I-CHEMICAL
of,7660,O
1,7660,O
was,7660,O
guided,7660,O
by,7660,O
X-ray,7660,O
crystallography,7660,O
",",7660,O
which,7660,O
allowed,7660,O
the,7660,O
replacement,7660,O
of,7660,O
a,7660,O
key,7660,O
water-mediated,7660,O
hydrogen,7660,B-CHEMICAL
bond,7660,O
.,7660,O
This,7661,O
work,7661,O
culminated,7661,O
in,7661,O
compounds,7661,O
such,7661,O
as,7661,O
31,7661,O
",",7661,O
which,7661,O
possess,7661,O
good,7661,O
BACE-1,7661,B-GENE-Y
potency,7661,O
",",7661,O
excellent,7661,O
permeability,7661,O
and,7661,O
a,7661,O
low,7661,O
P-gp,7661,B-GENE-N
efflux,7661,O
ratio,7661,O
.,7661,O
Antidepressant,7662,O
use,7662,O
and,7662,O
glycemic,7662,O
control,7662,O
.,7662,O
RATIONALE,7663,O
:,7663,O
Past,7663,O
research,7663,O
on,7663,O
the,7663,O
association,7663,O
of,7663,O
antidepressant,7663,O
medication,7663,O
use,7663,O
with,7663,O
glycemic,7663,O
control,7663,O
abnormalities,7663,O
has,7663,O
produced,7663,O
mixed,7663,O
results,7663,O
.,7663,O
OBJECTIVE,7664,O
:,7664,O
To,7664,O
examine,7664,O
the,7664,O
association,7664,O
of,7664,O
antidepressant,7664,O
use,7664,O
with,7664,O
glycemic,7664,O
control,7664,O
abnormalities,7664,O
and,7664,O
screen-positive,7664,O
diabetes,7664,O
in,7664,O
a,7664,O
representative,7664,O
population,7664,O
sample,7664,O
of,7664,O
US,7664,O
adults,7664,O
without,7664,O
a,7664,O
diagnosis,7664,O
of,7664,O
diabetes,7664,O
.,7664,O
METHODS,7665,O
:,7665,O
Using,7665,O
data,7665,O
from,7665,O
adult,7665,O
participants,7665,O
of,7665,O
the,7665,O
National,7665,O
Health,7665,O
and,7665,O
Nutrition,7665,O
Examination,7665,O
Survey,7665,O
(,7665,O
NHANES,7665,O
",",7665,O
2005-2010,7665,O
),7665,O
",",7665,O
the,7665,O
association,7665,O
of,7665,O
antidepressant,7665,O
use,7665,O
with,7665,O
continuous,7665,O
measures,7665,O
of,7665,O
HbA1c,7665,B-GENE-Y
",",7665,O
fasting,7665,O
blood,7665,O
sugar,7665,B-CHEMICAL
",",7665,O
2-h,7665,O
oral,7665,O
glucose,7665,B-CHEMICAL
tolerance,7665,O
test,7665,O
",",7665,O
insulin,7665,B-GENE-Y
sensitivity,7665,O
and,7665,O
screen-positive,7665,O
diabetes,7665,O
according,7665,O
to,7665,O
HbA1c,7665,B-GENE-Y
",",7665,O
fasting,7665,O
blood,7665,O
sugar,7665,O
and,7665,O
2-h,7665,O
oral,7665,O
glucose,7665,B-CHEMICAL
tolerance,7665,O
test,7665,O
were,7665,O
assessed,7665,O
.,7665,O
RESULTS,7666,O
:,7666,O
Antidepressant,7666,O
use,7666,O
was,7666,O
not,7666,O
associated,7666,O
with,7666,O
increased,7666,O
levels,7666,O
of,7666,O
HbA1c,7666,B-GENE-Y
",",7666,O
fasting,7666,O
blood,7666,O
sugar,7666,B-CHEMICAL
",",7666,O
2-h,7666,O
oral,7666,O
glucose,7666,B-CHEMICAL
tolerance,7666,O
test,7666,O
",",7666,O
reduced,7666,O
insulin,7666,B-GENE-Y
sensitivity,7666,O
or,7666,O
increased,7666,O
prevalence,7666,O
of,7666,O
screen-positive,7666,O
diabetes,7666,O
.,7666,O
Results,7667,O
were,7667,O
mostly,7667,O
consistent,7667,O
across,7667,O
sociodemographic,7667,O
groups,7667,O
and,7667,O
across,7667,O
different,7667,O
lengths,7667,O
of,7667,O
exposure,7667,O
",",7667,O
different,7667,O
classes,7667,O
of,7667,O
antidepressants,7667,O
and,7667,O
levels,7667,O
of,7667,O
body,7667,O
mass,7667,O
index,7667,O
.,7667,O
CONCLUSIONS,7668,O
:,7668,O
In,7668,O
this,7668,O
representative,7668,O
population,7668,O
sample,7668,O
",",7668,O
antidepressant,7668,O
use,7668,O
was,7668,O
not,7668,O
associated,7668,O
with,7668,O
an,7668,O
increased,7668,O
risk,7668,O
of,7668,O
abnormalities,7668,O
in,7668,O
glycemic,7668,O
control,7668,O
or,7668,O
undetected,7668,O
diabetes,7668,O
.,7668,O
Positive,7669,O
findings,7669,O
from,7669,O
past,7669,O
research,7669,O
may,7669,O
be,7669,O
attributable,7669,O
to,7669,O
detection,7669,O
bias,7669,O
",",7669,O
in,7669,O
that,7669,O
individuals,7669,O
prescribed,7669,O
antidepressants,7669,O
may,7669,O
be,7669,O
more,7669,O
likely,7669,O
to,7669,O
be,7669,O
tested,7669,O
and,7669,O
diagnosed,7669,O
with,7669,O
diabetes,7669,O
.,7669,O
Tissue-type,7670,B-GENE-Y
plasminogen,7670,I-GENE-Y
activator,7670,I-GENE-Y
acts,7670,O
as,7670,O
a,7670,O
cytokine,7670,B-GENE-N
that,7670,O
triggers,7670,O
intracellular,7670,O
signal,7670,O
transduction,7670,O
and,7670,O
induces,7670,O
matrix,7670,B-GENE-Y
metalloproteinase-9,7670,I-GENE-Y
gene,7670,O
expression,7670,O
.,7670,O
Tissue-type,7671,B-GENE-Y
plasminogen,7671,I-GENE-Y
activator,7671,I-GENE-Y
(,7671,O
tPA,7671,B-GENE-Y
),7671,O
",",7671,O
a,7671,O
serine,7671,B-GENE-N
protease,7671,I-GENE-N
well,7671,O
known,7671,O
for,7671,O
generating,7671,O
plasmin,7671,B-GENE-Y
",",7671,O
has,7671,O
been,7671,O
demonstrated,7671,O
to,7671,O
induce,7671,O
matrix,7671,B-GENE-Y
metalloproteinase-9,7671,I-GENE-Y
(,7671,O
MMP-9,7671,B-GENE-Y
),7671,O
gene,7671,O
expression,7671,O
and,7671,O
protein,7671,O
secretion,7671,O
in,7671,O
renal,7671,O
interstitial,7671,O
fibroblasts,7671,O
.,7671,O
However,7672,O
",",7672,O
exactly,7672,O
how,7672,O
tPA,7672,B-GENE-Y
transduces,7672,O
its,7672,O
signal,7672,O
into,7672,O
the,7672,O
nucleus,7672,O
to,7672,O
control,7672,O
gene,7672,O
expression,7672,O
is,7672,O
unknown,7672,O
.,7672,O
This,7673,O
study,7673,O
investigated,7673,O
the,7673,O
mechanism,7673,O
by,7673,O
which,7673,O
tPA,7673,B-GENE-Y
induces,7673,O
MMP-9,7673,B-GENE-Y
gene,7673,O
expression,7673,O
.,7673,O
Both,7674,O
wild-type,7674,O
and,7674,O
non-enzymatic,7674,O
mutant,7674,O
tPA,7674,B-GENE-Y
were,7674,O
found,7674,O
to,7674,O
induce,7674,O
MMP-9,7674,B-GENE-Y
expression,7674,O
in,7674,O
rat,7674,O
kidney,7674,O
interstitial,7674,O
fibroblasts,7674,O
(,7674,O
NRK-49F,7674,O
),7674,O
",",7674,O
indicating,7674,O
that,7674,O
the,7674,O
actions,7674,O
of,7674,O
tPA,7674,B-GENE-Y
are,7674,O
independent,7674,O
of,7674,O
its,7674,O
proteolytic,7674,O
activity,7674,O
.,7674,O
tPA,7675,B-GENE-Y
bound,7675,O
to,7675,O
the,7675,O
low,7675,B-GENE-Y
density,7675,I-GENE-Y
lipoprotein,7675,I-GENE-Y
receptor-related,7675,I-GENE-Y
protein-1,7675,I-GENE-Y
(,7675,O
LRP-1,7675,B-GENE-Y
),7675,O
in,7675,O
NRK-49F,7675,O
cells,7675,O
",",7675,O
and,7675,O
this,7675,O
binding,7675,O
was,7675,O
competitively,7675,O
abrogated,7675,O
by,7675,O
the,7675,O
LRP-1,7675,B-GENE-Y
antagonist,7675,O
",",7675,O
the,7675,O
receptor-associated,7675,O
protein,7675,O
.,7675,O
In,7676,O
mouse,7676,O
embryonic,7676,O
fibroblasts,7676,O
(,7676,O
PEA-13,7676,O
),7676,O
lacking,7676,O
LRP-1,7676,B-GENE-Y
",",7676,O
tPA,7676,B-GENE-Y
failed,7676,O
to,7676,O
induce,7676,O
MMP-9,7676,B-GENE-Y
expression,7676,O
.,7676,O
Furthermore,7677,O
",",7677,O
tPA,7677,B-GENE-Y
induced,7677,O
rapid,7677,O
tyrosine,7677,B-CHEMICAL
phosphorylation,7677,O
on,7677,O
the,7677,O
beta,7677,O
subunit,7677,O
of,7677,O
LRP-1,7677,B-GENE-Y
",",7677,O
which,7677,O
was,7677,O
followed,7677,O
by,7677,O
the,7677,O
activation,7677,O
of,7677,O
Mek1,7677,B-GENE-Y
and,7677,O
its,7677,O
downstream,7677,O
Erk-1,7677,B-GENE-N
and,7677,I-GENE-N
-2,7677,I-GENE-N
.,7677,O
Blockade,7678,O
of,7678,O
Erk-1/2,7678,B-GENE-N
activation,7678,O
by,7678,O
the,7678,O
Mek1,7678,B-GENE-Y
inhibitor,7678,O
abolished,7678,O
MMP-9,7678,B-GENE-Y
induction,7678,O
by,7678,O
tPA,7678,B-GENE-Y
in,7678,O
NRK-49F,7678,O
cells,7678,O
.,7678,O
Conversely,7679,O
",",7679,O
overexpression,7679,O
of,7679,O
constitutively,7679,B-GENE-Y
activated,7679,I-GENE-Y
Mek1,7679,I-GENE-Y
induced,7679,O
Erk-1/2,7679,B-GENE-N
phosphorylation,7679,O
and,7679,O
MMP-9,7679,B-GENE-Y
expression,7679,O
.,7679,O
In,7680,O
mouse,7680,O
obstructed,7680,O
kidney,7680,O
",",7680,O
tPA,7680,B-GENE-Y
",",7680,O
LRP-1,7680,B-GENE-Y
",",7680,O
and,7680,O
MMP-9,7680,B-GENE-Y
were,7680,O
concomitantly,7680,O
induced,7680,O
in,7680,O
the,7680,O
renal,7680,O
interstitium,7680,O
.,7680,O
Collectively,7681,O
",",7681,O
these,7681,O
results,7681,O
suggest,7681,O
that,7681,O
besides,7681,O
its,7681,O
classical,7681,O
proteolytic,7681,O
activity,7681,O
",",7681,O
tPA,7681,B-GENE-Y
acts,7681,O
as,7681,O
a,7681,O
cytokine,7681,B-GENE-N
that,7681,O
binds,7681,O
to,7681,O
the,7681,O
cell,7681,O
membrane,7681,O
receptor,7681,O
LRP-1,7681,B-GENE-Y
",",7681,O
induces,7681,O
its,7681,O
tyrosine,7681,B-CHEMICAL
phosphorylation,7681,O
",",7681,O
and,7681,O
triggers,7681,O
intracellular,7681,O
signal,7681,O
transduction,7681,O
",",7681,O
thereby,7681,O
inducing,7681,O
specific,7681,O
gene,7681,O
expression,7681,O
in,7681,O
renal,7681,O
interstitial,7681,O
fibroblasts,7681,O
.,7681,O
Cyclopenta,7682,B-CHEMICAL
[,7682,I-CHEMICAL
c,7682,I-CHEMICAL
],7682,I-CHEMICAL
phenanthrenes,7682,I-CHEMICAL
-,7682,O
Chemistry,7682,O
and,7682,O
biological,7682,O
activity,7682,O
.,7682,O
Despite,7683,O
cyclopenta-fused,7683,B-CHEMICAL
polycyclic,7683,I-CHEMICAL
aromatic,7683,I-CHEMICAL
hydrocarbons,7683,I-CHEMICAL
(,7683,O
CP-PAHs,7683,B-CHEMICAL
),7683,O
having,7683,O
been,7683,O
detected,7683,O
in,7683,O
the,7683,O
environment,7683,O
",",7683,O
the,7683,O
ability,7683,O
of,7683,O
these,7683,O
compounds,7683,O
to,7683,O
induce,7683,O
cellular,7683,O
and,7683,O
tissue,7683,O
responses,7683,O
remains,7683,O
poorly,7683,O
characterized,7683,O
.,7683,O
In,7684,O
this,7684,O
review,7684,O
",",7684,O
we,7684,O
look,7684,O
at,7684,O
the,7684,O
chemistry,7684,O
and,7684,O
biological,7684,O
activity,7684,O
of,7684,O
the,7684,O
cyclopenta,7684,B-CHEMICAL
[,7684,I-CHEMICAL
c,7684,I-CHEMICAL
],7684,I-CHEMICAL
phenanthrenes,7684,I-CHEMICAL
(,7684,O
CP,7684,B-CHEMICAL
[,7684,I-CHEMICAL
c,7684,I-CHEMICAL
],7684,I-CHEMICAL
Ph,7684,I-CHEMICAL
),7684,O
as,7684,O
potential,7684,O
chemicals,7684,O
of,7684,O
concern,7684,O
in,7684,O
the,7684,O
process,7684,O
of,7684,O
risk,7684,O
assessment,7684,O
.,7684,O
The,7685,O
first,7685,O
part,7685,O
of,7685,O
the,7685,O
review,7685,O
deals,7685,O
with,7685,O
the,7685,O
environmental,7685,O
occurrence,7685,O
and,7685,O
chemistry,7685,O
of,7685,O
CP-PAHs,7685,B-CHEMICAL
",",7685,O
focusing,7685,O
on,7685,O
available,7685,O
methods,7685,O
of,7685,O
CP,7685,B-CHEMICAL
[,7685,I-CHEMICAL
c,7685,I-CHEMICAL
],7685,I-CHEMICAL
Ph,7685,I-CHEMICAL
chemical,7685,O
synthesis,7685,O
.,7685,O
The,7686,O
most,7686,O
interesting,7686,O
structural,7686,O
feature,7686,O
of,7686,O
the,7686,O
CP,7686,B-CHEMICAL
[,7686,I-CHEMICAL
c,7686,I-CHEMICAL
],7686,I-CHEMICAL
Ph,7686,I-CHEMICAL
is,7686,O
the,7686,O
presence,7686,O
of,7686,O
a,7686,O
pseudo,7686,O
fjord-region,7686,O
constructed,7686,O
by,7686,O
the,7686,O
cyclopentane,7686,B-CHEMICAL
ring,7686,O
.,7686,O
This,7687,O
compound,7687,O
can,7687,O
be,7687,O
treated,7687,O
either,7687,O
as,7687,O
a,7687,O
structurally,7687,O
similar,7687,O
one,7687,O
to,7687,O
B,7687,B-CHEMICAL
[,7687,I-CHEMICAL
c,7687,I-CHEMICAL
],7687,I-CHEMICAL
Ph,7687,I-CHEMICAL
",",7687,O
or,7687,O
as,7687,O
a,7687,O
phenanthrene,7687,B-CHEMICAL
skeleton,7687,O
with,7687,O
an,7687,O
electrodonating,7687,O
alkyl,7687,B-CHEMICAL
substituent,7687,O
in,7687,O
the,7687,O
bay-region,7687,O
of,7687,O
the,7687,O
molecule,7687,O
.,7687,O
The,7688,O
second,7688,O
thread,7688,O
",",7688,O
providing,7688,O
available,7688,O
data,7688,O
on,7688,O
the,7688,O
adverse,7688,O
effects,7688,O
of,7688,O
CP,7688,B-CHEMICAL
[,7688,I-CHEMICAL
c,7688,I-CHEMICAL
],7688,I-CHEMICAL
Ph,7688,I-CHEMICAL
compounds,7688,O
on,7688,O
cells,7688,O
and,7688,O
tissues,7688,O
of,7688,O
living,7688,O
organisms,7688,O
",",7688,O
mainly,7688,O
fish,7688,O
",",7688,O
improves,7688,O
our,7688,O
understanding,7688,O
of,7688,O
these,7688,O
possible,7688,O
environmental,7688,O
hazards,7688,O
.,7688,O
The,7689,O
data,7689,O
show,7689,O
that,7689,O
CP,7689,B-CHEMICAL
[,7689,I-CHEMICAL
c,7689,I-CHEMICAL
],7689,I-CHEMICAL
Ph,7689,I-CHEMICAL
is,7689,O
less,7689,O
potent,7689,O
at,7689,O
inducing,7689,O
CYP1A,7689,B-GENE-N
gene,7689,O
expression,7689,O
in,7689,O
rainbow,7689,O
trout,7689,O
than,7689,O
benzo,7689,B-CHEMICAL
[,7689,I-CHEMICAL
a,7689,I-CHEMICAL
],7689,I-CHEMICAL
pyrene,7689,I-CHEMICAL
(,7689,O
B,7689,B-CHEMICAL
[,7689,I-CHEMICAL
a,7689,I-CHEMICAL
],7689,I-CHEMICAL
P,7689,I-CHEMICAL
),7689,O
",",7689,O
a,7689,O
well-known,7689,O
Ah-receptor,7689,O
agonist,7689,O
.,7689,O
Interestingly,7690,O
",",7690,O
the,7690,O
CP,7690,B-CHEMICAL
[,7690,I-CHEMICAL
c,7690,I-CHEMICAL
],7690,I-CHEMICAL
Ph,7690,I-CHEMICAL
dependent,7690,O
up-regulation,7690,O
of,7690,O
CYP1A,7690,B-GENE-N
mRNA,7690,O
is,7690,O
positively,7690,O
correlated,7690,O
with,7690,O
the,7690,O
incidences,7690,O
of,7690,O
clastogenic,7690,O
changes,7690,O
in,7690,O
rainbow,7690,O
trout,7690,O
erythrocytes,7690,O
.,7690,O
CP,7691,B-CHEMICAL
[,7691,I-CHEMICAL
c,7691,I-CHEMICAL
],7691,I-CHEMICAL
Ph,7691,I-CHEMICAL
has,7691,O
",",7691,O
comparably,7691,O
to,7691,O
B,7691,B-CHEMICAL
[,7691,I-CHEMICAL
a,7691,I-CHEMICAL
],7691,I-CHEMICAL
P,7691,I-CHEMICAL
",",7691,O
a,7691,O
potential,7691,O
to,7691,O
repress,7691,O
expression,7691,O
of,7691,O
tumor,7691,B-GENE-Y
suppressor,7691,I-GENE-Y
p53,7691,I-GENE-Y
",",7691,O
in,7691,O
the,7691,O
head,7691,O
kidney,7691,O
of,7691,O
rainbow,7691,O
trout,7691,O
.,7691,O
Furthermore,7692,O
",",7692,O
estrogen,7692,B-CHEMICAL
responsive,7692,O
genes,7692,O
in,7692,O
fish,7692,O
liver,7692,O
",",7692,O
ERα,7692,B-GENE-Y
and,7692,O
VTG,7692,B-GENE-Y
",",7692,O
are,7692,O
not,7692,O
induced,7692,O
by,7692,O
CP,7692,B-CHEMICAL
[,7692,I-CHEMICAL
c,7692,I-CHEMICAL
],7692,I-CHEMICAL
Ph,7692,I-CHEMICAL
",",7692,O
suggesting,7692,O
that,7692,O
the,7692,O
compound,7692,O
has,7692,O
no,7692,O
endocrine,7692,O
disrupting,7692,O
potential,7692,O
.,7692,O
However,7693,O
",",7693,O
some,7693,O
CP,7693,B-CHEMICAL
[,7693,I-CHEMICAL
c,7693,I-CHEMICAL
],7693,I-CHEMICAL
Phs,7693,I-CHEMICAL
show,7693,O
mutagenic,7693,O
activity,7693,O
when,7693,O
investigated,7693,O
in,7693,O
the,7693,O
Ames,7693,O
test,7693,O
",",7693,O
and,7693,O
exhibit,7693,O
genotoxic,7693,O
properties,7693,O
in,7693,O
in,7693,O
vitro,7693,O
micronucleus,7693,O
assay,7693,O
.,7693,O
The,7694,O
above,7694,O
characteristics,7694,O
suggest,7694,O
that,7694,O
CP-PAHs,7694,B-CHEMICAL
are,7694,O
chemicals,7694,O
of,7694,O
concern,7694,O
for,7694,O
which,7694,O
potential,7694,O
pathways,7694,O
of,7694,O
exposure,7694,O
should,7694,O
be,7694,O
further,7694,O
identified,7694,O
.,7694,O
Zymogen,7695,O
factor,7695,B-GENE-Y
IX,7695,I-GENE-Y
potentiates,7695,O
factor,7695,B-GENE-Y
IXa-catalyzed,7695,O
factor,7695,B-GENE-Y
X,7695,I-GENE-Y
activation,7695,O
.,7695,O
Intrinsic,7696,O
factor,7696,B-GENE-Y
X,7696,I-GENE-Y
activation,7696,O
is,7696,O
accelerated,7696,O
>,7696,O
10,7696,O
(,7696,O
7,7696,O
),7696,O
-fold,7696,O
by,7696,O
assembly,7696,O
of,7696,O
the,7696,O
entire,7696,O
complex,7696,O
on,7696,O
the,7696,O
activated,7696,O
platelet,7696,O
surface,7696,O
.,7696,O
We,7697,O
have,7697,O
now,7697,O
observed,7697,O
that,7697,O
increasing,7697,O
the,7697,O
concentration,7697,O
of,7697,O
zymogen,7697,O
factor,7697,B-GENE-Y
IX,7697,I-GENE-Y
to,7697,O
physiologic,7697,O
levels,7697,O
(,7697,O
approximately,7697,O
100,7697,O
nM,7697,O
),7697,O
potentiates,7697,O
factor,7697,B-GENE-Y
IXa-catalyzed,7697,O
activation,7697,O
of,7697,O
factor,7697,B-GENE-Y
X,7697,I-GENE-Y
on,7697,O
both,7697,O
activated,7697,O
platelets,7697,O
and,7697,O
on,7697,O
negatively,7697,O
charged,7697,O
phospholipid,7697,O
vesicles,7697,O
.,7697,O
In,7698,O
the,7698,O
presence,7698,O
and,7698,O
absence,7698,O
of,7698,O
factor,7698,B-GENE-Y
VIIIa,7698,I-GENE-Y
",",7698,O
factor,7698,B-GENE-Y
IX,7698,I-GENE-Y
(,7698,O
100,7698,O
nM,7698,O
),7698,O
lowered,7698,O
the,7698,O
K,7698,O
(,7698,O
d,7698,O
",",7698,O
appFIXa,7698,O
),7698,O
approximately,7698,O
4-fold,7698,O
on,7698,O
platelets,7698,O
and,7698,O
2-10-fold,7698,O
on,7698,O
lipid,7698,O
vesicles,7698,O
.,7698,O
Treatment,7699,O
of,7699,O
two,7699,O
factor,7699,B-GENE-Y
IX,7699,I-GENE-Y
preparations,7699,O
with,7699,O
active-site,7699,O
inhibitors,7699,O
did,7699,O
not,7699,O
affect,7699,O
these,7699,O
observations,7699,O
.,7699,O
Autoradiographs,7700,O
of,7700,O
PAGE-separated,7700,O
reactions,7700,O
containing,7700,O
either,7700,O
(,7700,B-CHEMICAL
125,7700,I-CHEMICAL
),7700,I-CHEMICAL
I-labeled,7700,O
factor,7700,B-GENE-Y
IX,7700,I-GENE-Y
or,7700,O
(,7700,B-CHEMICAL
125,7700,I-CHEMICAL
),7700,I-CHEMICAL
I-labeled,7700,O
factor,7700,B-GENE-Y
X,7700,I-GENE-Y
showed,7700,O
that,7700,O
the,7700,O
increased,7700,O
factor,7700,B-GENE-Y
X,7700,I-GENE-Y
activation,7700,O
was,7700,O
not,7700,O
due,7700,O
to,7700,O
factor,7700,B-GENE-Y
Xa-mediated,7700,O
feedback,7700,O
activation,7700,O
of,7700,O
factor,7700,B-GENE-Y
IX,7700,I-GENE-Y
and,7700,O
that,7700,O
there,7700,O
was,7700,O
increased,7700,O
cleavage,7700,O
of,7700,O
factor,7700,B-GENE-Y
X,7700,I-GENE-Y
heavy,7700,I-GENE-Y
chain,7700,I-GENE-Y
in,7700,O
the,7700,O
presence,7700,O
of,7700,O
factor,7700,B-GENE-Y
IX,7700,I-GENE-Y
in,7700,O
comparison,7700,O
with,7700,O
control,7700,O
reactions,7700,O
but,7700,O
only,7700,O
in,7700,O
the,7700,O
presence,7700,O
of,7700,O
both,7700,O
the,7700,O
enzyme,7700,O
and,7700,O
the,7700,O
surface,7700,O
.,7700,O
Since,7701,O
plasma,7701,O
concentrations,7701,O
of,7701,O
prothrombin,7701,B-GENE-Y
",",7701,O
factor,7701,B-GENE-Y
VII,7701,I-GENE-Y
",",7701,O
protein,7701,B-GENE-Y
C,7701,I-GENE-Y
",",7701,O
or,7701,O
protein,7701,B-GENE-Y
S,7701,I-GENE-Y
did,7701,O
not,7701,O
by,7701,O
themselves,7701,O
potentiate,7701,O
factor,7701,B-GENE-N
Xa,7701,I-GENE-N
generation,7701,O
and,7701,O
did,7701,O
not,7701,O
interfere,7701,O
with,7701,O
the,7701,O
potentiation,7701,O
of,7701,O
the,7701,O
reaction,7701,O
of,7701,O
factor,7701,B-GENE-Y
IX,7701,I-GENE-Y
",",7701,O
the,7701,O
effect,7701,O
is,7701,O
specific,7701,O
for,7701,O
factor,7701,B-GENE-Y
IX,7701,I-GENE-Y
and,7701,O
is,7701,O
not,7701,O
attributable,7701,O
to,7701,O
the,7701,O
Gla,7701,B-GENE-N
domain,7701,I-GENE-N
of,7701,O
all,7701,O
vitamin,7701,B-CHEMICAL
K-dependent,7701,O
proteins,7701,O
.,7701,O
These,7702,O
observations,7702,O
indicate,7702,O
that,7702,O
under,7702,O
physiologic,7702,O
conditions,7702,O
",",7702,O
plasma,7702,O
levels,7702,O
of,7702,O
the,7702,O
zymogen,7702,O
factor,7702,B-GENE-Y
IX,7702,I-GENE-Y
specifically,7702,O
increase,7702,O
the,7702,O
affinity,7702,O
of,7702,O
factor,7702,B-GENE-Y
IXa,7702,I-GENE-Y
for,7702,O
the,7702,O
intrinsic,7702,O
factor,7702,B-GENE-Y
X,7702,I-GENE-Y
activation,7702,O
complex,7702,O
.,7702,O
Biosynthesis,7703,O
",",7703,O
assembly,7703,O
and,7703,O
secretion,7703,O
of,7703,O
coagulation,7703,B-GENE-Y
factor,7703,I-GENE-Y
VIII,7703,I-GENE-Y
.,7703,O
Factor,7704,B-GENE-Y
VIII,7704,I-GENE-Y
is,7704,O
a,7704,O
large,7704,O
complex,7704,O
glycoprotein,7704,O
that,7704,O
is,7704,O
deficient,7704,O
in,7704,O
hemophilia,7704,O
A,7704,O
.,7704,O
It,7705,O
has,7705,O
a,7705,O
domain,7705,O
organization,7705,O
consisting,7705,O
of,7705,O
A1-A2-B-A3-C1-C2,7705,B-GENE-N
where,7705,O
the,7705,O
B,7705,B-GENE-N
domain,7705,I-GENE-N
is,7705,O
a,7705,O
heavily,7705,O
glycosylated,7705,O
region,7705,O
that,7705,O
is,7705,O
dispensable,7705,O
for,7705,O
procoagulant,7705,O
activity,7705,O
.,7705,O
Factor,7706,B-GENE-Y
VIII,7706,I-GENE-Y
expression,7706,O
is,7706,O
10-to,7706,O
20-fold,7706,O
lower,7706,O
than,7706,O
the,7706,O
homologous,7706,O
coagulation,7706,B-GENE-Y
factor,7706,I-GENE-Y
V.,7706,O
Factor,7706,B-GENE-Y
VIII,7706,I-GENE-Y
expression,7706,O
is,7706,O
limited,7706,O
due,7706,O
to,7706,O
a,7706,O
low,7706,O
level,7706,O
of,7706,O
steady-state,7706,O
messenger,7706,O
RNA,7706,O
in,7706,O
the,7706,O
cytoplasm,7706,O
and,7706,O
inefficient,7706,O
transport,7706,O
of,7706,O
the,7706,O
primary,7706,O
translation,7706,O
product,7706,O
from,7706,O
the,7706,O
endoplasmic,7706,O
reticulum,7706,O
to,7706,O
the,7706,O
Golgi,7706,O
apparatus,7706,O
.,7706,O
Within,7707,O
the,7707,O
secretory,7707,O
pathway,7707,O
",",7707,O
factor,7707,B-GENE-Y
VIII,7707,I-GENE-Y
is,7707,O
processed,7707,O
to,7707,O
a,7707,O
heterodimer,7707,O
of,7707,O
the,7707,O
heavy,7707,O
chain,7707,O
(,7707,O
domains,7707,B-GENE-N
A1-A2-B,7707,I-GENE-N
),7707,O
in,7707,O
a,7707,O
metal,7707,O
ion,7707,O
association,7707,O
with,7707,O
the,7707,O
light,7707,O
chain,7707,O
(,7707,O
domains,7707,B-GENE-N
A3-C1-C2,7707,I-GENE-N
),7707,O
.,7707,O
Upon,7708,O
secretion,7708,O
from,7708,O
the,7708,O
cell,7708,O
",",7708,O
von,7708,B-GENE-Y
Willebrand,7708,I-GENE-Y
factor,7708,I-GENE-Y
binds,7708,O
the,7708,O
light,7708,B-GENE-Y
chain,7708,I-GENE-Y
of,7708,I-GENE-Y
factor,7708,I-GENE-Y
VIII,7708,I-GENE-Y
and,7708,O
stabilizes,7708,O
the,7708,O
factor,7708,O
",",7708,O
preventing,7708,O
degradation,7708,O
.,7708,O
Protein,7709,O
folding,7709,O
within,7709,O
the,7709,O
mammalian,7709,O
secretory,7709,O
pathway,7709,O
is,7709,O
facilitated,7709,O
by,7709,O
molecular,7709,B-GENE-N
chaperones,7709,I-GENE-N
.,7709,O
Within,7710,O
the,7710,O
endoplasmic,7710,O
reticulum,7710,O
",",7710,O
factor,7710,B-GENE-Y
VIII,7710,I-GENE-Y
exhibits,7710,O
stable,7710,O
interaction,7710,O
with,7710,O
protein,7710,O
chaperones,7710,O
identified,7710,O
as,7710,O
the,7710,O
immunoglobulin-binding,7710,B-GENE-Y
protein,7710,I-GENE-Y
(,7710,O
BiP,7710,B-GENE-Y
),7710,O
",",7710,O
calnexin,7710,B-GENE-Y
and,7710,O
calreticulin,7710,B-GENE-Y
.,7710,O
BiP,7711,B-GENE-Y
is,7711,O
a,7711,O
peptide-dependent,7711,O
ATPase,7711,B-GENE-N
that,7711,O
interacts,7711,O
with,7711,O
exposed,7711,O
hydrophobic,7711,O
surfaces,7711,O
on,7711,O
unfolded,7711,O
proteins,7711,O
or,7711,O
unassembled,7711,O
protein,7711,O
subunits,7711,O
.,7711,O
A,7712,O
potential,7712,O
BiP,7712,B-GENE-N
binding,7712,I-GENE-N
site,7712,I-GENE-N
within,7712,O
factor,7712,B-GENE-Y
VIII,7712,I-GENE-Y
has,7712,O
been,7712,O
identified,7712,O
.,7712,O
Mutation,7713,O
of,7713,O
a,7713,O
single,7713,O
amino,7713,B-CHEMICAL
acid,7713,I-CHEMICAL
residue,7713,O
in,7713,O
the,7713,O
potential,7713,O
BiP,7713,B-GENE-N
binding,7713,I-GENE-N
site,7713,I-GENE-N
increased,7713,O
the,7713,O
secretion,7713,O
efficiency,7713,O
of,7713,O
factor,7713,B-GENE-Y
VIII,7713,I-GENE-Y
by,7713,O
threefold,7713,O
.,7713,O
Interestingly,7714,O
",",7714,O
the,7714,O
proposed,7714,O
BiP,7714,B-GENE-N
binding,7714,I-GENE-N
site,7714,I-GENE-N
is,7714,O
adjacent,7714,O
to,7714,O
a,7714,O
type-1,7714,B-GENE-N
copper,7714,I-GENE-N
binding,7714,I-GENE-N
site,7714,I-GENE-N
within,7714,O
the,7714,O
A1,7714,B-GENE-N
domain,7714,I-GENE-N
that,7714,O
is,7714,O
required,7714,O
for,7714,O
interaction,7714,O
between,7714,O
the,7714,O
factor,7714,B-GENE-N
VIII,7714,I-GENE-N
A1,7714,I-GENE-N
domain,7714,I-GENE-N
and,7714,O
the,7714,O
A3,7714,B-GENE-N
domain,7714,I-GENE-N
.,7714,O
We,7715,O
propose,7715,O
that,7715,O
Cu,7715,B-CHEMICAL
(,7715,I-CHEMICAL
I,7715,I-CHEMICAL
),7715,I-CHEMICAL
binds,7715,O
the,7715,O
type-1,7715,B-GENE-N
copper,7715,I-GENE-N
ion-binding,7715,I-GENE-N
site,7715,I-GENE-N
in,7715,O
the,7715,O
A1,7715,B-GENE-N
domain,7715,I-GENE-N
and,7715,O
provides,7715,O
the,7715,O
essential,7715,O
requirement,7715,O
for,7715,O
a,7715,O
stable,7715,O
interaction,7715,O
between,7715,O
the,7715,O
heavy,7715,O
and,7715,O
light,7715,O
chains,7715,O
.,7715,O
Calnexin,7716,B-GENE-Y
and,7716,O
calreticulin,7716,B-GENE-Y
are,7716,O
transmembrane,7716,O
and,7716,O
lumenal,7716,O
proteins,7716,O
",",7716,O
respectively,7716,O
",",7716,O
localized,7716,O
to,7716,O
the,7716,O
endoplasmic,7716,O
reticulum,7716,O
",",7716,O
which,7716,O
associate,7716,O
transiently,7716,O
with,7716,O
many,7716,O
soluble,7716,O
and,7716,O
membrane,7716,O
glycoproteins,7716,O
during,7716,O
folding,7716,O
and,7716,O
subunit,7716,O
assembly,7716,O
.,7716,O
The,7717,O
calnexin,7717,B-GENE-Y
and,7717,O
calreticulin,7717,B-GENE-Y
interaction,7717,O
with,7717,O
factor,7717,B-GENE-Y
VIII,7717,I-GENE-Y
occurs,7717,O
primarily,7717,O
through,7717,O
amino-terminal,7717,B-CHEMICAL
linked,7717,O
oligosaccharides,7717,O
within,7717,O
the,7717,O
heavily,7717,O
glycosylated,7717,O
factor,7717,B-GENE-N
VIII,7717,I-GENE-N
B,7717,I-GENE-N
domain,7717,I-GENE-N
and,7717,O
this,7717,O
interaction,7717,O
appears,7717,O
to,7717,O
be,7717,O
required,7717,O
for,7717,O
factor,7717,B-GENE-Y
VIII,7717,I-GENE-Y
secretion,7717,O
.,7717,O
The,7718,O
findings,7718,O
suggest,7718,O
that,7718,O
factor,7718,B-GENE-Y
VIII,7718,I-GENE-Y
cycles,7718,O
through,7718,O
interactions,7718,O
with,7718,O
BiP,7718,B-GENE-Y
",",7718,O
calnexin,7718,B-GENE-Y
and,7718,O
calreticulin,7718,B-GENE-Y
.,7718,O
Although,7719,O
the,7719,O
interaction,7719,O
with,7719,O
BiP,7719,B-GENE-Y
does,7719,O
not,7719,O
appear,7719,O
to,7719,O
be,7719,O
required,7719,O
for,7719,O
factor,7719,B-GENE-Y
VIII,7719,I-GENE-Y
secretion,7719,O
",",7719,O
data,7719,O
suggest,7719,O
that,7719,O
the,7719,O
calnexin,7719,B-GENE-Y
and/or,7719,O
calreticulin,7719,B-GENE-Y
interaction,7719,O
is,7719,O
required,7719,O
for,7719,O
secretion,7719,O
.,7719,O
The,7720,O
observations,7720,O
suggest,7720,O
a,7720,O
unique,7720,O
requirement,7720,O
for,7720,O
carbohydrate,7720,B-CHEMICAL
processing,7720,O
and,7720,O
calnexin/calreticulin,7720,B-GENE-Y
interaction,7720,O
that,7720,O
may,7720,O
limit,7720,O
the,7720,O
productive,7720,O
secretion,7720,O
of,7720,O
factor,7720,B-GENE-Y
VIII,7720,I-GENE-Y
and,7720,O
have,7720,O
implications,7720,O
for,7720,O
approaches,7720,O
towards,7720,O
somatic,7720,O
cell,7720,O
gene,7720,O
therapy,7720,O
for,7720,O
hemophilia,7720,O
A,7720,O
.,7720,O
Identification,7721,O
of,7721,O
benzofuran,7721,B-CHEMICAL
central,7721,O
cores,7721,O
for,7721,O
the,7721,O
inhibition,7721,O
of,7721,O
leukotriene,7721,B-GENE-Y
A,7721,I-GENE-Y
(,7721,I-GENE-Y
4,7721,I-GENE-Y
),7721,I-GENE-Y
hydrolase,7721,I-GENE-Y
.,7721,O
Leukotrienes,7722,B-CHEMICAL
(,7722,O
LT,7722,O
's,7722,O
),7722,O
are,7722,O
known,7722,O
to,7722,O
play,7722,O
a,7722,O
physiological,7722,O
role,7722,O
in,7722,O
inflammatory,7722,O
immune,7722,O
response,7722,O
.,7722,O
Leukotriene,7723,B-GENE-Y
A,7723,I-GENE-Y
(,7723,I-GENE-Y
4,7723,I-GENE-Y
),7723,I-GENE-Y
hydrolase,7723,I-GENE-Y
(,7723,O
LTA,7723,B-GENE-Y
(,7723,I-GENE-Y
4,7723,I-GENE-Y
),7723,I-GENE-Y
H,7723,I-GENE-Y
),7723,O
is,7723,O
a,7723,O
cystolic,7723,O
enzyme,7723,O
that,7723,O
stereospecifically,7723,O
catalyzes,7723,O
the,7723,O
transformation,7723,O
of,7723,O
LTA,7723,B-CHEMICAL
(,7723,I-CHEMICAL
4,7723,I-CHEMICAL
),7723,I-CHEMICAL
to,7723,O
LTB,7723,B-CHEMICAL
(,7723,I-CHEMICAL
4,7723,I-CHEMICAL
),7723,I-CHEMICAL
.,7723,O
LTB,7724,B-CHEMICAL
(,7724,I-CHEMICAL
4,7724,I-CHEMICAL
),7724,I-CHEMICAL
is,7724,O
a,7724,O
known,7724,O
pro-inflammatory,7724,O
mediator,7724,O
.,7724,O
This,7725,O
paper,7725,O
describes,7725,O
the,7725,O
identification,7725,O
and,7725,O
synthesis,7725,O
of,7725,O
substituted,7725,O
benzofurans,7725,B-CHEMICAL
as,7725,O
LTH,7725,B-GENE-Y
(,7725,I-GENE-Y
4,7725,I-GENE-Y
),7725,I-GENE-Y
H,7725,I-GENE-Y
inhibitors,7725,O
.,7725,O
The,7726,O
benzofuran,7726,B-CHEMICAL
series,7726,O
demonstrated,7726,O
reduced,7726,O
mouse,7726,O
and,7726,O
human,7726,O
whole,7726,O
blood,7726,O
LTB,7726,B-CHEMICAL
(,7726,I-CHEMICAL
4,7726,I-CHEMICAL
),7726,I-CHEMICAL
levels,7726,O
in,7726,O
vitro,7726,O
and,7726,O
led,7726,O
to,7726,O
the,7726,O
identification,7726,O
one,7726,O
analog,7726,O
for,7726,O
advanced,7726,O
profiling,7726,O
.,7726,O
Benzofuran,7727,B-CHEMICAL
28,7727,O
showed,7727,O
dose,7727,O
responsive,7727,O
target,7727,O
engagement,7727,O
and,7727,O
provides,7727,O
a,7727,O
useful,7727,O
tool,7727,O
to,7727,O
explore,7727,O
a,7727,O
LTA,7727,B-GENE-Y
(,7727,I-GENE-Y
4,7727,I-GENE-Y
),7727,I-GENE-Y
H,7727,I-GENE-Y
inhibitor,7727,O
for,7727,O
the,7727,O
treatment,7727,O
of,7727,O
inflammatory,7727,O
diseases,7727,O
",",7727,O
such,7727,O
as,7727,O
asthma,7727,O
and,7727,O
inflammatory,7727,O
bowel,7727,O
disease,7727,O
(,7727,O
IBD,7727,O
),7727,O
.,7727,O
Minocycline,7728,B-CHEMICAL
markedly,7728,O
protects,7728,O
the,7728,O
neonatal,7728,O
brain,7728,O
against,7728,O
hypoxic-ischemic,7728,O
injury,7728,O
.,7728,O
Hypoxic-ischemic,7729,O
brain,7729,O
injury,7729,O
in,7729,O
the,7729,O
perinatal,7729,O
period,7729,O
is,7729,O
a,7729,O
major,7729,O
cause,7729,O
of,7729,O
morbidity,7729,O
and,7729,O
mortality,7729,O
.,7729,O
Presently,7730,O
",",7730,O
there,7730,O
are,7730,O
no,7730,O
proven,7730,O
effective,7730,O
therapies,7730,O
with,7730,O
which,7730,O
to,7730,O
safeguard,7730,O
the,7730,O
human,7730,O
neonatal,7730,O
brain,7730,O
against,7730,O
this,7730,O
type,7730,O
of,7730,O
injury,7730,O
.,7730,O
Minocycline,7731,B-CHEMICAL
",",7731,O
a,7731,O
semisynthetic,7731,O
tetracycline,7731,B-CHEMICAL
",",7731,O
has,7731,O
been,7731,O
shown,7731,O
to,7731,O
be,7731,O
neuroprotective,7731,O
in,7731,O
certain,7731,O
adult,7731,O
ischemic,7731,O
injury/stroke,7731,O
and,7731,O
neurodegenerative,7731,O
disease,7731,O
models,7731,O
.,7731,O
However,7732,O
",",7732,O
minocycline,7732,O
's,7732,O
neuroprotective,7732,O
effects,7732,O
have,7732,O
not,7732,O
been,7732,O
assessed,7732,O
after,7732,O
insults,7732,O
to,7732,O
the,7732,O
neonatal,7732,O
brain,7732,O
.,7732,O
We,7733,O
now,7733,O
report,7733,O
that,7733,O
minocycline,7733,B-CHEMICAL
administered,7733,O
either,7733,O
immediately,7733,O
before,7733,O
or,7733,O
immediately,7733,O
after,7733,O
a,7733,O
hypoxic-ischemic,7733,O
insult,7733,O
substantially,7733,O
blocks,7733,O
tissue,7733,O
damage,7733,O
in,7733,O
a,7733,O
rodent,7733,O
model,7733,O
of,7733,O
neonatal,7733,O
hypoxic-ischemic,7733,O
brain,7733,O
injury,7733,O
.,7733,O
Minocycline,7734,B-CHEMICAL
treatment,7734,O
prevents,7734,O
the,7734,O
formation,7734,O
of,7734,O
activated,7734,O
caspase-3,7734,B-GENE-Y
",",7734,O
a,7734,O
known,7734,O
effector,7734,O
of,7734,O
apoptosis,7734,O
",",7734,O
as,7734,O
well,7734,O
as,7734,O
the,7734,O
appearance,7734,O
of,7734,O
a,7734,O
calpain,7734,B-GENE-N
cleaved,7734,O
substrate,7734,O
",",7734,O
a,7734,O
marker,7734,O
of,7734,O
excitotoxic/necrotic,7734,O
cell,7734,O
death,7734,O
.,7734,O
To,7735,O
our,7735,O
knowledge,7735,O
",",7735,O
this,7735,O
is,7735,O
the,7735,O
first,7735,O
report,7735,O
of,7735,O
a,7735,O
systemic,7735,O
treatment,7735,O
that,7735,O
can,7735,O
be,7735,O
administered,7735,O
after,7735,O
a,7735,O
hypoxic-ischemic,7735,O
insult,7735,O
",",7735,O
which,7735,O
provides,7735,O
robust,7735,O
",",7735,O
nearly,7735,O
complete,7735,O
neuroprotection,7735,O
to,7735,O
the,7735,O
developing,7735,O
brain,7735,O
.,7735,O
Our,7736,O
data,7736,O
suggest,7736,O
that,7736,O
minocycline,7736,B-CHEMICAL
or,7736,O
a,7736,O
related,7736,O
neuroprotective,7736,O
tetracycline,7736,B-CHEMICAL
may,7736,O
be,7736,O
a,7736,O
candidate,7736,O
to,7736,O
consider,7736,O
in,7736,O
human,7736,O
clinical,7736,O
trials,7736,O
to,7736,O
protect,7736,O
the,7736,O
developing,7736,O
brain,7736,O
against,7736,O
hypoxic-ischemic-induced,7736,O
damage,7736,O
.,7736,O
In,7737,O
vivo,7737,O
comparison,7737,O
of,7737,O
the,7737,O
reinforcing,7737,O
and,7737,O
dopamine,7737,B-GENE-Y
transporter,7737,I-GENE-Y
effects,7737,O
of,7737,O
local,7737,O
anesthetics,7737,O
in,7737,O
rhesus,7737,O
monkeys,7737,O
.,7737,O
Dopaminergic,7738,O
mechanisms,7738,O
are,7738,O
thought,7738,O
to,7738,O
play,7738,O
a,7738,O
central,7738,O
role,7738,O
in,7738,O
the,7738,O
reinforcing,7738,O
effects,7738,O
of,7738,O
cocaine,7738,B-CHEMICAL
.,7738,O
Similar,7739,O
to,7739,O
cocaine,7739,B-CHEMICAL
",",7739,O
other,7739,O
local,7739,O
anesthetics,7739,O
bind,7739,O
to,7739,O
the,7739,O
dopamine,7739,B-GENE-N
transporter,7739,I-GENE-N
(,7739,O
DAT,7739,B-GENE-N
),7739,O
and,7739,O
inhibit,7739,O
DA,7739,B-CHEMICAL
uptake,7739,O
in,7739,O
rodent,7739,O
and,7739,O
monkey,7739,O
brain,7739,O
.,7739,O
Additionally,7740,O
",",7740,O
local,7740,O
anesthetics,7740,O
are,7740,O
self-administered,7740,O
in,7740,O
rhesus,7740,O
monkeys,7740,O
",",7740,O
indicative,7740,O
of,7740,O
abuse,7740,O
liability,7740,O
.,7740,O
The,7741,O
present,7741,O
study,7741,O
examined,7741,O
the,7741,O
reinforcing,7741,O
and,7741,O
DAT,7741,B-GENE-Y
effects,7741,O
of,7741,O
the,7741,O
local,7741,O
anesthetics,7741,O
dimethocaine,7741,B-CHEMICAL
",",7741,O
procaine,7741,B-CHEMICAL
and,7741,O
cocaine,7741,B-CHEMICAL
using,7741,O
in,7741,O
vivo,7741,O
techniques,7741,O
.,7741,O
Monkeys,7742,O
were,7742,O
trained,7742,O
to,7742,O
respond,7742,O
under,7742,O
a,7742,O
second-order,7742,O
schedule,7742,O
for,7742,O
i.v,7742,O
.,7742,O
cocaine,7743,B-CHEMICAL
administration,7743,O
(,7743,O
0.10,7743,O
or,7743,O
0.30,7743,O
mg/kg/infusion,7743,O
),7743,O
.,7743,O
When,7744,O
responding,7744,O
was,7744,O
stable,7744,O
",",7744,O
dimethocaine,7744,B-CHEMICAL
(,7744,O
0.030-1.7,7744,O
mg/kg/,7744,O
infusion,7744,O
),7744,O
or,7744,O
procaine,7744,B-CHEMICAL
(,7744,O
0.10-10,7744,O
mg/kg/,7744,O
infusion,7744,O
),7744,O
was,7744,O
substituted,7744,O
for,7744,O
the,7744,O
cocaine,7744,B-CHEMICAL
training,7744,O
dose,7744,O
.,7744,O
Dimethocaine,7745,B-CHEMICAL
administration,7745,O
produced,7745,O
higher,7745,O
response,7745,O
rates,7745,O
compared,7745,O
with,7745,O
that,7745,O
of,7745,O
procaine,7745,B-CHEMICAL
",",7745,O
and,7745,O
was,7745,O
a,7745,O
more,7745,O
potent,7745,O
reinforcer,7745,O
.,7745,O
Drug,7746,O
effects,7746,O
on,7746,O
behavior,7746,O
were,7746,O
related,7746,O
to,7746,O
DAT,7746,B-GENE-Y
occupancy,7746,O
in,7746,O
monkey,7746,O
striatum,7746,O
during,7746,O
neuroimaging,7746,O
with,7746,O
positron,7746,O
emission,7746,O
tomography,7746,O
(,7746,O
PET,7746,O
),7746,O
.,7746,O
DAT,7747,B-GENE-Y
occupancy,7747,O
was,7747,O
determined,7747,O
by,7747,O
displacement,7747,O
of,7747,O
8-,7747,B-CHEMICAL
(,7747,I-CHEMICAL
2-,7747,I-CHEMICAL
[,7747,I-CHEMICAL
(,7747,I-CHEMICAL
18,7747,I-CHEMICAL
),7747,I-CHEMICAL
F,7747,I-CHEMICAL
],7747,I-CHEMICAL
fluroethyl,7747,I-CHEMICAL
),7747,I-CHEMICAL
2beta-carbomethoxy-3beta-,7747,I-CHEMICAL
(,7747,I-CHEMICAL
4-chlorophenyl,7747,I-CHEMICAL
),7747,I-CHEMICAL
nortropane,7747,I-CHEMICAL
(,7747,O
FECNT,7747,B-CHEMICAL
),7747,O
.,7747,O
DAT,7748,B-GENE-Y
occupancy,7748,O
was,7748,O
between,7748,O
66,7748,O
and,7748,O
82,7748,O
%,7748,O
and,7748,O
<,7748,O
10-41,7748,O
%,7748,O
for,7748,O
doses,7748,O
of,7748,O
dimethocaine,7748,B-CHEMICAL
and,7748,O
procaine,7748,B-CHEMICAL
that,7748,O
maintained,7748,O
maximum,7748,O
response,7748,O
rates,7748,O
",",7748,O
respectively,7748,O
.,7748,O
Finally,7749,O
",",7749,O
in,7749,O
vivo,7749,O
microdialysis,7749,O
in,7749,O
awake,7749,O
subjects,7749,O
determined,7749,O
drug-induced,7749,O
changes,7749,O
in,7749,O
extracellular,7749,O
DA,7749,B-CHEMICAL
in,7749,O
the,7749,O
caudate,7749,O
nucleus,7749,O
.,7749,O
There,7750,O
was,7750,O
close,7750,O
correspondence,7750,O
between,7750,O
peak,7750,O
increases,7750,O
in,7750,O
DA,7750,B-CHEMICAL
and,7750,O
DAT,7750,B-GENE-Y
occupancy,7750,O
.,7750,O
Overall,7751,O
",",7751,O
reinforcing,7751,O
effects,7751,O
were,7751,O
consistent,7751,O
with,7751,O
DAT,7751,B-GENE-Y
effects,7751,O
determined,7751,O
with,7751,O
in,7751,O
vivo,7751,O
techniques,7751,O
.,7751,O
The,7752,O
results,7752,O
further,7752,O
support,7752,O
a,7752,O
role,7752,O
for,7752,O
the,7752,O
DAT,7752,B-GENE-Y
in,7752,O
the,7752,O
abuse,7752,O
liability,7752,O
of,7752,O
local,7752,O
anesthetics,7752,O
.,7752,O
Bone,7753,O
growth,7753,O
retardation,7753,O
in,7753,O
mouse,7753,O
embryos,7753,O
expressing,7753,O
human,7753,B-GENE-Y
collagenase,7753,I-GENE-Y
1,7753,I-GENE-Y
.,7753,O
Cellular,7754,O
growth,7754,O
and,7754,O
differentiation,7754,O
are,7754,O
readouts,7754,O
of,7754,O
multiple,7754,O
signaling,7754,O
pathways,7754,O
from,7754,O
the,7754,O
intercellular,7754,O
and/or,7754,O
extracellular,7754,O
milieu,7754,O
.,7754,O
The,7755,O
extracellular,7755,O
matrix,7755,O
through,7755,O
the,7755,O
activation,7755,O
of,7755,O
cellular,7755,O
receptors,7755,O
transmits,7755,O
these,7755,O
signals,7755,O
.,7755,O
Therefore,7756,O
",",7756,O
extracellular,7756,O
matrix,7756,O
proteolysis,7756,O
could,7756,O
affect,7756,O
cell,7756,O
fate,7756,O
in,7756,O
a,7756,O
variety,7756,O
of,7756,O
biological,7756,O
events,7756,O
.,7756,O
However,7757,O
",",7757,O
the,7757,O
biological,7757,O
consequence,7757,O
of,7757,O
inadequate,7757,O
extracellular,7757,O
matrix,7757,O
degradation,7757,O
in,7757,O
vivo,7757,O
is,7757,O
not,7757,O
clear,7757,O
.,7757,O
We,7758,O
developed,7758,O
a,7758,O
mouse,7758,O
model,7758,O
expressing,7758,O
human,7758,B-GENE-Y
collagenase,7758,I-GENE-Y
(,7758,O
matrix,7758,B-GENE-Y
metalloproteinase-1,7758,I-GENE-Y
",",7758,O
MMP-1,7758,B-GENE-Y
),7758,O
under,7758,O
the,7758,O
control,7758,O
of,7758,O
Col2a1,7758,B-GENE-N
promoter,7758,I-GENE-N
.,7758,O
The,7759,O
mice,7759,O
showed,7759,O
significant,7759,O
growth,7759,O
retardation,7759,O
during,7759,O
embryogenesis,7759,O
and,7759,O
a,7759,O
loss,7759,O
of,7759,O
the,7759,O
demarcation,7759,O
of,7759,O
zonal,7759,O
structure,7759,O
and,7759,O
columnar,7759,O
array,7759,O
of,7759,O
the,7759,O
cartilage,7759,O
.,7759,O
Immunological,7760,O
examination,7760,O
revealed,7760,O
increased,7760,O
degradation,7760,O
of,7760,O
type,7760,B-GENE-N
II,7760,I-GENE-N
collagen,7760,I-GENE-N
and,7760,O
upregulation,7760,O
of,7760,O
fibronectin,7760,B-GENE-Y
and,7760,O
alpha,7760,B-GENE-Y
(,7760,I-GENE-Y
5,7760,I-GENE-Y
),7760,I-GENE-Y
-integrin,7760,I-GENE-Y
subunit,7760,O
in,7760,O
the,7760,O
transgenic,7760,O
cartilage,7760,O
.,7760,O
The,7761,O
resting,7761,O
zone,7761,O
and,7761,O
proliferating,7761,O
zone,7761,O
of,7761,O
the,7761,O
growth,7761,O
plate,7761,O
cartilage,7761,O
exhibited,7761,O
a,7761,O
simultaneous,7761,O
increase,7761,O
in,7761,O
bromodeoxyuridine,7761,B-CHEMICAL
(,7761,O
BrdU,7761,B-CHEMICAL
),7761,O
-incorporated,7761,O
proliferating,7761,O
cells,7761,O
and,7761,O
terminal,7761,O
deoxynucleotidyl,7761,O
transferase-mediated,7761,O
X-dUTP,7761,O
nick-end,7761,O
labeling-positive,7761,O
apoptotic,7761,O
cells,7761,O
",",7761,O
respectively,7761,O
.,7761,O
Chondrocyte,7762,O
differentiation,7762,O
was,7762,O
not,7762,O
disturbed,7762,O
in,7762,O
the,7762,O
transgenic,7762,O
mice,7762,O
as,7762,O
evidenced,7762,O
by,7762,O
normal,7762,O
expression,7762,O
of,7762,O
the,7762,O
Ihh,7762,O
and,7762,O
type,7762,B-GENE-N
X,7762,I-GENE-N
collagen,7762,I-GENE-N
expression,7762,O
.,7762,O
These,7763,O
data,7763,O
demonstrate,7763,O
that,7763,O
type,7763,B-GENE-N
II,7763,I-GENE-N
collagen,7763,I-GENE-N
proteolysis,7763,O
is,7763,O
an,7763,O
important,7763,O
determinant,7763,O
for,7763,O
the,7763,O
skeletal,7763,O
outgrowth,7763,O
through,7763,O
modulation,7763,O
of,7763,O
chondrocyte,7763,O
survival,7763,O
and,7763,O
cartilagenous,7763,O
growth,7763,O
.,7763,O
Neurochemical,7764,O
effects,7764,O
of,7764,O
the,7764,O
monoamine,7764,B-GENE-N
oxidase,7764,I-GENE-N
inhibitor,7764,O
phenelzine,7764,B-CHEMICAL
on,7764,O
brain,7764,O
GABA,7764,B-CHEMICAL
and,7764,O
alanine,7764,B-CHEMICAL
:,7764,O
A,7764,O
comparison,7764,O
with,7764,O
vigabatrin,7764,B-CHEMICAL
.,7764,O
PURPOSE,7765,O
:,7765,O
To,7765,O
compare,7765,O
phenelzine,7765,B-CHEMICAL
(,7765,O
PLZ,7765,B-CHEMICAL
),7765,O
",",7765,O
an,7765,O
antidepressant,7765,O
drug,7765,O
with,7765,O
anxiolytic,7765,O
properties,7765,O
which,7765,O
inhibits,7765,O
monoamine,7765,B-GENE-N
oxidase,7765,I-GENE-N
(,7765,O
MAO,7765,B-GENE-N
),7765,O
but,7765,O
also,7765,O
elevates,7765,O
rat,7765,O
brain,7765,O
levels,7765,O
of,7765,O
the,7765,O
amino,7765,B-CHEMICAL
acids,7765,I-CHEMICAL
?,7765,O
-aminobutyric,7765,O
acid,7765,I-CHEMICAL
(,7765,O
GABA,7765,B-CHEMICAL
),7765,O
and,7765,O
alanine,7765,B-CHEMICAL
(,7765,O
ALA,7765,B-CHEMICAL
),7765,O
",",7765,O
with,7765,O
vigabatrin,7765,B-CHEMICAL
(,7765,O
VIG,7765,B-CHEMICAL
),7765,O
",",7765,O
an,7765,O
anticonvulsant,7765,O
which,7765,O
elevates,7765,O
brain,7765,O
GABA,7765,B-CHEMICAL
by,7765,O
inhibition,7765,O
of,7765,O
GABA,7765,B-GENE-Y
transaminase,7765,I-GENE-Y
(,7765,O
GABA-T,7765,B-GENE-Y
),7765,O
",",7765,O
with,7765,O
regard,7765,O
to,7765,O
their,7765,O
actions,7765,O
on,7765,O
brain,7765,O
levels,7765,O
of,7765,O
GABA,7765,B-CHEMICAL
and,7765,O
ALA,7765,B-CHEMICAL
and,7765,O
on,7765,O
activities,7765,O
of,7765,O
MAO,7765,B-GENE-N
",",7765,O
GABA-T,7765,B-GENE-Y
and,7765,O
ALA,7765,B-GENE-N
transaminase,7765,I-GENE-N
(,7765,O
ALA-T,7765,B-GENE-N
),7765,O
.,7765,O
METHODS,7766,O
:,7766,O
Male,7766,O
rats,7766,O
were,7766,O
administered,7766,O
PLZ,7766,B-CHEMICAL
(,7766,O
10,7766,O
mg/kg,7766,O
),7766,O
or,7766,O
VIG,7766,B-CHEMICAL
(,7766,O
"1,000",7766,O
mg/kg,7766,O
),7766,O
i.p.,7766,O
",",7766,O
and,7766,O
the,7766,O
rats,7766,O
were,7766,O
euthanized,7766,O
4,7766,O
hours,7766,O
later,7766,O
and,7766,O
the,7766,O
brains,7766,O
removed,7766,O
for,7766,O
analysis,7766,O
of,7766,O
levels,7766,O
of,7766,O
GABA,7766,B-CHEMICAL
and,7766,O
ALA,7766,B-CHEMICAL
(,7766,O
by,7766,O
electron,7766,O
capture,7766,O
gas,7766,O
chromatography,7766,O
after,7766,O
derivatization,7766,O
),7766,O
and,7766,O
activities,7766,O
of,7766,O
MAO,7766,B-GENE-N
",",7766,O
GABA-T,7766,B-GENE-Y
and,7766,O
ALA-T,7766,B-GENE-N
(,7766,O
radiochemical,7766,O
assays,7766,O
),7766,O
.,7766,O
RESULTS,7767,O
:,7767,O
Both,7767,O
PLZ,7767,B-CHEMICAL
and,7767,O
VIG,7767,B-CHEMICAL
inhibited,7767,O
GABA-T,7767,B-GENE-Y
and,7767,O
elevated,7767,O
GABA,7767,B-CHEMICAL
levels,7767,O
.,7767,O
Only,7768,O
PLZ,7768,B-CHEMICAL
inhibited,7768,O
MAO,7768,B-GENE-N
and,7768,O
ALA-T,7768,B-GENE-N
and,7768,O
elevated,7768,O
ALA,7768,B-CHEMICAL
levels,7768,O
.,7768,O
The,7769,O
effects,7769,O
of,7769,O
PLZ,7769,B-CHEMICAL
on,7769,O
both,7769,O
amino,7769,B-CHEMICAL
acids,7769,I-CHEMICAL
and,7769,O
their,7769,O
transaminases,7769,B-GENE-N
were,7769,O
blocked,7769,O
by,7769,O
pre-treatment,7769,O
with,7769,O
the,7769,O
MAO,7769,B-GENE-N
inhibitor,7769,O
tranylcypromine,7769,B-CHEMICAL
.,7769,O
This,7770,O
pretreament,7770,O
had,7770,O
no,7770,O
effect,7770,O
on,7770,O
the,7770,O
inhibition,7770,O
of,7770,O
GABA-T,7770,B-GENE-Y
or,7770,O
the,7770,O
elevation,7770,O
of,7770,O
brain,7770,O
GABA,7770,B-CHEMICAL
levels,7770,O
produced,7770,O
by,7770,O
VIG,7770,B-CHEMICAL
.,7770,O
CONCLUSIONS,7771,O
:,7771,O
At,7771,O
the,7771,O
doses,7771,O
studied,7771,O
",",7771,O
PLZ,7771,B-CHEMICAL
was,7771,O
as,7771,O
effective,7771,O
as,7771,O
VIG,7771,B-CHEMICAL
at,7771,O
elevating,7771,O
brain,7771,O
GABA,7771,B-CHEMICAL
levels,7771,O
",",7771,O
but,7771,O
",",7771,O
unlike,7771,O
VIG,7771,B-CHEMICAL
",",7771,O
also,7771,O
inhibited,7771,O
MAO,7771,B-GENE-N
and,7771,O
ALA-T,7771,B-GENE-N
(,7771,O
and,7771,O
increased,7771,O
brain,7771,O
ALA,7771,B-CHEMICAL
levels,7771,O
),7771,O
.,7771,O
Pretreatment,7772,O
of,7772,O
rats,7772,O
with,7772,O
the,7772,O
MAO,7772,B-GENE-N
inhibitor,7772,O
tranylcypromine,7772,B-CHEMICAL
prevented,7772,O
the,7772,O
increase,7772,O
in,7772,O
brain,7772,O
GABA,7772,B-CHEMICAL
and,7772,O
ALA,7772,B-CHEMICAL
levels,7772,O
with,7772,O
PLZ,7772,B-CHEMICAL
",",7772,O
but,7772,O
did,7772,O
not,7772,O
block,7772,O
the,7772,O
effect,7772,O
of,7772,O
VIG,7772,B-CHEMICAL
on,7772,O
GABA,7772,B-CHEMICAL
.,7772,O
These,7773,O
observations,7773,O
with,7773,O
tranylcypromine,7773,B-CHEMICAL
and,7773,O
PLZ,7773,B-CHEMICAL
support,7773,O
the,7773,O
hypothesis,7773,O
that,7773,O
an,7773,O
active,7773,O
metabolite,7773,O
of,7773,O
PLZ,7773,B-CHEMICAL
produced,7773,O
by,7773,O
the,7773,O
actions,7773,O
of,7773,O
MAO,7773,B-GENE-N
on,7773,O
this,7773,O
drug,7773,O
plays,7773,O
a,7773,O
major,7773,O
role,7773,O
in,7773,O
its,7773,O
GABA-,7773,B-CHEMICAL
and,7773,O
ALA-elevating,7773,B-CHEMICAL
actions,7773,O
.,7773,O
Clinical,7774,O
pharmacology,7774,O
of,7774,O
enalkiren,7774,B-CHEMICAL
",",7774,O
a,7774,O
novel,7774,O
",",7774,O
dipeptide,7774,B-CHEMICAL
renin,7774,B-GENE-Y
inhibitor,7774,O
.,7774,O
Enalkiren,7775,B-CHEMICAL
(,7775,O
A-64662,7775,B-CHEMICAL
),7775,O
",",7775,O
a,7775,O
potent,7775,O
",",7775,O
dipeptide,7775,B-CHEMICAL
renin,7775,B-GENE-Y
inhibitor,7775,O
",",7775,O
mimics,7775,O
the,7775,O
transition,7775,O
state,7775,O
of,7775,O
the,7775,O
human,7775,B-GENE-Y
renin,7775,I-GENE-Y
substrate,7775,O
",",7775,O
angiotensinogen,7775,B-GENE-Y
.,7775,O
Enalkiren,7776,B-CHEMICAL
has,7776,O
been,7776,O
shown,7776,O
to,7776,O
produce,7776,O
dose-related,7776,O
suppression,7776,O
of,7776,O
plasma,7776,O
renin,7776,B-GENE-Y
activity,7776,O
(,7776,O
PRA,7776,O
),7776,O
and,7776,O
angiotensin,7776,B-GENE-Y
II,7776,I-GENE-Y
when,7776,O
administered,7776,O
intravenously,7776,O
.,7776,O
Doses,7777,O
of,7777,O
enalkiren,7777,B-CHEMICAL
of,7777,O
less,7777,O
than,7777,O
0.1,7777,O
mg/kg,7777,O
induced,7777,O
little,7777,O
hemodynamic,7777,O
response,7777,O
in,7777,O
normotensive,7777,O
and,7777,O
hypertensive,7777,O
volunteers,7777,O
despite,7777,O
marked,7777,O
suppression,7777,O
of,7777,O
PRA,7777,O
.,7777,O
However,7778,O
",",7778,O
at,7778,O
doses,7778,O
of,7778,O
0.3,7778,O
and,7778,O
1.2,7778,O
mg/kg,7778,O
",",7778,O
enalkiren,7778,B-CHEMICAL
produced,7778,O
significant,7778,O
",",7778,O
dose-related,7778,O
decreases,7778,O
in,7778,O
systolic,7778,O
and,7778,O
diastolic,7778,O
blood,7778,O
pressure,7778,O
(,7778,O
BP,7778,O
),7778,O
in,7778,O
hypertensive,7778,O
patients,7778,O
",",7778,O
and,7778,O
the,7778,O
BP,7778,O
response,7778,O
was,7778,O
enhanced,7778,O
by,7778,O
pretreatment,7778,O
with,7778,O
hydrochlorothiazide,7778,B-CHEMICAL
.,7778,O
The,7779,O
effects,7779,O
of,7779,O
enalkiren,7779,B-CHEMICAL
on,7779,O
PRA,7779,O
and,7779,O
BP,7779,O
are,7779,O
prolonged,7779,O
despite,7779,O
its,7779,O
relatively,7779,O
short,7779,O
elimination,7779,O
phase,7779,O
plasma,7779,O
half-life,7779,O
(,7779,O
1.6,7779,O
h,7779,O
),7779,O
.,7779,O
Persistent,7780,O
pharmacologic,7780,O
activity,7780,O
without,7780,O
evidence,7780,O
of,7780,O
tachyphylaxis,7780,O
was,7780,O
demonstrated,7780,O
during,7780,O
1,7780,O
week,7780,O
of,7780,O
treatment,7780,O
in,7780,O
hypertensive,7780,O
patients,7780,O
.,7780,O
The,7781,O
observed,7781,O
dissociation,7781,O
between,7781,O
suppression,7781,O
of,7781,O
PRA,7781,O
and,7781,O
BP,7781,O
response,7781,O
and,7781,O
the,7781,O
recruitment,7781,O
of,7781,O
dose-related,7781,O
BP,7781,O
decrements,7781,O
",",7781,O
despite,7781,O
complete,7781,O
suppression,7781,O
of,7781,O
PRA,7781,O
",",7781,O
are,7781,O
unexplained,7781,O
phenomena,7781,O
.,7781,O
The,7782,O
results,7782,O
of,7782,O
clinical,7782,O
trials,7782,O
with,7782,O
enalkiren,7782,B-CHEMICAL
are,7782,O
encouraging,7782,O
",",7782,O
and,7782,O
suggest,7782,O
that,7782,O
renin,7782,B-GENE-Y
inhibitors,7782,O
may,7782,O
be,7782,O
safe,7782,O
",",7782,O
useful,7782,O
therapeutic,7782,O
agents,7782,O
in,7782,O
the,7782,O
management,7782,O
of,7782,O
hypertension,7782,O
.,7782,O
Methylenedioxymethamphetamine,7783,B-CHEMICAL
decreases,7783,O
plasmalemmal,7783,O
and,7783,O
vesicular,7783,O
dopamine,7783,B-CHEMICAL
transport,7783,O
:,7783,O
mechanisms,7783,O
and,7783,O
implications,7783,O
for,7783,O
neurotoxicity,7783,O
.,7783,O
Administration,7784,O
of,7784,O
a,7784,O
high-dose,7784,O
regimen,7784,O
of,7784,O
methamphetamine,7784,B-CHEMICAL
(,7784,O
METH,7784,B-CHEMICAL
),7784,O
rapidly,7784,O
and,7784,O
profoundly,7784,O
decreases,7784,O
plasmalemmal,7784,O
and,7784,O
vesicular,7784,O
dopamine,7784,B-CHEMICAL
(,7784,O
DA,7784,B-CHEMICAL
),7784,O
transport,7784,O
in,7784,O
the,7784,O
striatum,7784,O
",",7784,O
as,7784,O
assessed,7784,O
in,7784,O
synaptosomes,7784,O
and,7784,O
purified,7784,O
vesicles,7784,O
",",7784,O
respectively,7784,O
.,7784,O
To,7785,O
determine,7785,O
whether,7785,O
these,7785,O
responses,7785,O
were,7785,O
common,7785,O
to,7785,O
other,7785,O
amphetamines,7785,B-CHEMICAL
of,7785,O
abuse,7785,O
",",7785,O
effects,7785,O
of,7785,O
methylenedioxymethamphetamine,7785,B-CHEMICAL
(,7785,O
MDMA,7785,B-CHEMICAL
),7785,O
on,7785,O
the,7785,O
plasmalemmal,7785,O
DA,7785,B-GENE-Y
transporter,7785,I-GENE-Y
(,7785,O
DAT,7785,B-GENE-Y
),7785,O
and,7785,O
vesicular,7785,B-GENE-Y
monoamine,7785,I-GENE-Y
transporter-2,7785,I-GENE-Y
(,7785,O
VMAT-2,7785,B-GENE-Y
),7785,O
were,7785,O
assessed,7785,O
.,7785,O
Similar,7786,O
to,7786,O
effects,7786,O
of,7786,O
METH,7786,B-CHEMICAL
reported,7786,O
previously,7786,O
",",7786,O
multiple,7786,O
high-dose,7786,O
MDMA,7786,B-CHEMICAL
administrations,7786,O
rapidly,7786,O
(,7786,O
within,7786,O
1,7786,O
h,7786,O
),7786,O
decreased,7786,O
plasmalemmal,7786,O
DA,7786,B-CHEMICAL
uptake,7786,O
",",7786,O
as,7786,O
assessed,7786,O
ex,7786,O
vivo,7786,O
in,7786,O
synaptosomes,7786,O
prepared,7786,O
from,7786,O
treated,7786,O
rats,7786,O
.,7786,O
Unlike,7787,O
effects,7787,O
of,7787,O
multiple,7787,O
METH,7787,B-CHEMICAL
injections,7787,O
",",7787,O
this,7787,O
deficit,7787,O
was,7787,O
reversed,7787,O
completely,7787,O
24,7787,O
h,7787,O
after,7787,O
drug,7787,O
treatment,7787,O
.,7787,O
Also,7788,O
in,7788,O
contrast,7788,O
to,7788,O
effects,7788,O
of,7788,O
multiple,7788,O
METH,7788,B-CHEMICAL
injections,7788,O
",",7788,O
1,7788,O
),7788,O
MDMA,7788,B-CHEMICAL
caused,7788,O
little,7788,O
or,7788,O
no,7788,O
decrease,7788,O
in,7788,O
binding,7788,O
of,7788,O
the,7788,O
DAT,7788,B-GENE-Y
ligand,7788,O
WIN35428,7788,B-CHEMICAL
",",7788,O
and,7788,O
2,7788,O
),7788,O
neither,7788,O
prevention,7788,O
of,7788,O
hyperthermia,7788,O
nor,7788,O
prior,7788,O
depletion,7788,O
of,7788,O
DA,7788,B-CHEMICAL
prevented,7788,O
the,7788,O
MDMA-induced,7788,B-CHEMICAL
reduction,7788,O
in,7788,O
plasmalemmal,7788,O
DA,7788,B-CHEMICAL
transport,7788,O
.,7788,O
However,7789,O
",",7789,O
a,7789,O
role,7789,O
for,7789,O
phosphorylation,7789,O
was,7789,O
suggested,7789,O
because,7789,O
pretreatment,7789,O
with,7789,O
protein,7789,B-GENE-Y
kinase,7789,I-GENE-Y
C,7789,I-GENE-Y
inhibitors,7789,O
attenuated,7789,O
the,7789,O
deficit,7789,O
caused,7789,O
by,7789,O
MDMA,7789,B-CHEMICAL
in,7789,O
an,7789,O
in,7789,O
vitro,7789,O
model,7789,O
system,7789,O
.,7789,O
In,7790,O
addition,7790,O
to,7790,O
affecting,7790,O
DAT,7790,B-GENE-Y
function,7790,O
",",7790,O
MDMA,7790,B-CHEMICAL
rapidly,7790,O
decreased,7790,O
vesicular,7790,O
DA,7790,B-CHEMICAL
transport,7790,O
as,7790,O
assessed,7790,O
in,7790,O
striatal,7790,O
vesicles,7790,O
prepared,7790,O
from,7790,O
treated,7790,O
rats,7790,O
.,7790,O
Unlike,7791,O
effects,7791,O
of,7791,O
multiple,7791,O
METH,7791,B-CHEMICAL
injections,7791,O
reported,7791,O
previously,7791,O
",",7791,O
this,7791,O
decrease,7791,O
partially,7791,O
recovered,7791,O
by,7791,O
24,7791,O
h,7791,O
after,7791,O
drug,7791,O
treatment,7791,O
.,7791,O
Taken,7792,O
together,7792,O
",",7792,O
these,7792,O
results,7792,O
reveal,7792,O
several,7792,O
differences,7792,O
between,7792,O
effects,7792,O
of,7792,O
MDMA,7792,B-CHEMICAL
and,7792,O
previously,7792,O
reported,7792,O
METH,7792,B-CHEMICAL
on,7792,O
DAT,7792,B-GENE-Y
and,7792,O
VMAT-2,7792,B-GENE-Y
;,7792,O
differences,7792,O
that,7792,O
may,7792,O
underlie,7792,O
the,7792,O
dissimilar,7792,O
neurotoxic,7792,O
profile,7792,O
of,7792,O
these,7792,O
agents,7792,O
.,7792,O
Concentration-dependent,7793,O
inhibitory,7793,O
effects,7793,O
of,7793,O
baicalin,7793,B-CHEMICAL
on,7793,O
the,7793,O
metabolism,7793,O
of,7793,O
dextromethorphan,7793,B-CHEMICAL
",",7793,O
a,7793,O
dual,7793,O
probe,7793,O
of,7793,O
CYP2D,7793,B-GENE-N
and,7793,O
CYP3A,7793,B-GENE-N
",",7793,O
in,7793,O
rats,7793,O
.,7793,O
Baicalin,7794,B-CHEMICAL
has,7794,O
been,7794,O
shown,7794,O
to,7794,O
possess,7794,O
many,7794,O
pharmacological,7794,O
effects,7794,O
",",7794,O
including,7794,O
antiviral,7794,O
",",7794,O
antioxidant,7794,O
",",7794,O
anti-cancer,7794,O
and,7794,O
anti-inflammatory,7794,O
properties,7794,O
.,7794,O
In,7795,O
the,7795,O
current,7795,O
study,7795,O
",",7795,O
we,7795,O
reveal,7795,O
the,7795,O
inhibitory,7795,O
effects,7795,O
of,7795,O
baicalin,7795,B-CHEMICAL
on,7795,O
the,7795,O
metabolism,7795,O
of,7795,O
dextromethorphan,7795,B-CHEMICAL
(,7795,O
DXM,7795,B-CHEMICAL
),7795,O
",",7795,O
a,7795,O
dual,7795,O
probe,7795,O
substrate,7795,O
of,7795,O
CYP2D,7795,B-GENE-N
and,7795,O
CYP3A,7795,B-GENE-N
",",7795,O
in,7795,O
rats,7795,O
.,7795,O
Lineweaver-Burk,7796,O
plots,7796,O
demonstrated,7796,O
that,7796,O
baicalin,7796,B-CHEMICAL
inhibited,7796,O
the,7796,O
activities,7796,O
of,7796,O
CYP2D,7796,B-GENE-N
and,7796,O
CYP3A,7796,B-GENE-N
in,7796,O
a,7796,O
non-competitive,7796,O
manner,7796,O
in,7796,O
rat,7796,O
liver,7796,O
microsomes,7796,O
(,7796,O
RLMs,7796,O
),7796,O
.,7796,O
Concomitant,7797,O
administration,7797,O
of,7797,O
baicalin,7797,B-CHEMICAL
(,7797,O
0.90g/kg,7797,O
",",7797,O
i.v,7797,O
.,7797,O
),7797,O
and,7798,O
DXM,7798,B-CHEMICAL
(,7798,O
10mg/kg,7798,O
",",7798,O
i.v,7798,O
.,7798,O
),7798,O
increased,7799,O
the,7799,O
maximum,7799,O
drug,7799,O
concentration,7799,O
(,7799,O
Cmax,7799,O
),7799,O
(,7799,O
37,7799,O
%,7799,O
),7799,O
and,7799,O
the,7799,O
area,7799,O
under,7799,O
concentration-time,7799,O
curve,7799,O
(,7799,O
AUC,7799,O
),7799,O
(,7799,O
42,7799,O
%,7799,O
),7799,O
and,7799,O
decreased,7799,O
the,7799,O
clearance,7799,O
(,7799,O
CL,7799,O
),7799,O
(,7799,O
27,7799,O
%,7799,O
),7799,O
of,7799,O
DXM,7799,B-CHEMICAL
in,7799,O
a,7799,O
randomised,7799,O
",",7799,O
crossover,7799,O
study,7799,O
in,7799,O
rats,7799,O
(,7799,O
P,7799,O
<,7799,O
0.01,7799,O
),7799,O
.,7799,O
The,7800,O
change,7800,O
in,7800,O
the,7800,O
AUC,7800,O
of,7800,O
DXM,7800,B-CHEMICAL
was,7800,O
significantly,7800,O
correlated,7800,O
with,7800,O
the,7800,O
Cmax,7800,O
and,7800,O
AUC,7800,O
of,7800,O
baicalin,7800,B-CHEMICAL
(,7800,O
P,7800,O
<,7800,O
0.05,7800,O
),7800,O
.,7800,O
The,7801,O
inhibitory,7801,O
effects,7801,O
of,7801,O
multiple,7801,O
doses,7801,O
of,7801,O
baicalin,7801,B-CHEMICAL
(,7801,O
0.90g/kg,7801,O
",",7801,O
i.v.,7801,O
",",7801,O
12days,7801,O
),7801,O
on,7801,O
the,7801,O
metabolism,7801,O
of,7801,O
DXM,7801,B-CHEMICAL
were,7801,O
similar,7801,O
to,7801,O
those,7801,O
observed,7801,O
following,7801,O
a,7801,O
single,7801,O
dose,7801,O
in,7801,O
rats,7801,O
.,7801,O
The,7802,O
activity,7802,O
of,7802,O
CYP3A,7802,B-GENE-N
in,7802,O
excised,7802,O
liver,7802,O
samples,7802,O
from,7802,O
rats,7802,O
following,7802,O
multiple,7802,O
baicalin,7802,B-CHEMICAL
treatment,7802,O
was,7802,O
significantly,7802,O
decreased,7802,O
compared,7802,O
to,7802,O
that,7802,O
of,7802,O
the,7802,O
control,7802,O
group,7802,O
(,7802,O
P,7802,O
<,7802,O
0.05,7802,O
),7802,O
",",7802,O
whereas,7802,O
multiple,7802,O
doses,7802,O
of,7802,O
baicalin,7802,B-CHEMICAL
had,7802,O
no,7802,O
obvious,7802,O
effect,7802,O
on,7802,O
the,7802,O
activity,7802,O
of,7802,O
CYP2D,7802,B-GENE-N
.,7802,O
Taken,7803,O
together,7803,O
",",7803,O
these,7803,O
data,7803,O
demonstrate,7803,O
that,7803,O
baicalin,7803,B-CHEMICAL
inhibits,7803,O
the,7803,O
metabolism,7803,O
of,7803,O
DXM,7803,B-CHEMICAL
in,7803,O
a,7803,O
concentration-dependent,7803,O
manner,7803,O
in,7803,O
rats,7803,O
",",7803,O
possibly,7803,O
through,7803,O
inhibiting,7803,O
hepatic,7803,O
CYP2D,7803,B-GENE-N
and,7803,O
CYP3A,7803,B-GENE-N
activities,7803,O
.,7803,O
Identification,7804,O
of,7804,O
a,7804,O
novel,7804,O
benzimidazole,7804,B-CHEMICAL
derivative,7804,O
as,7804,O
a,7804,O
highly,7804,O
potent,7804,O
NPY,7804,B-GENE-Y
Y5,7804,I-GENE-Y
receptor,7804,I-GENE-Y
antagonist,7804,O
with,7804,O
an,7804,O
anti-obesity,7804,O
profile,7804,O
.,7804,O
Optimization,7805,O
of,7805,O
HTS,7805,O
hit,7805,O
1,7805,O
for,7805,O
NPY,7805,B-GENE-Y
Y5,7805,I-GENE-Y
receptor,7805,I-GENE-Y
binding,7805,O
affinity,7805,O
",",7805,O
CYP450,7805,B-GENE-N
inhibition,7805,O
",",7805,O
solubility,7805,O
and,7805,O
metabolic,7805,O
stability,7805,O
led,7805,O
to,7805,O
the,7805,O
identification,7805,O
of,7805,O
some,7805,O
orally,7805,O
available,7805,O
oxygen-linker,7805,B-CHEMICAL
derivatives,7805,O
for,7805,O
in,7805,O
vivo,7805,O
study,7805,O
.,7805,O
Among,7806,O
them,7806,O
",",7806,O
derivative,7806,O
4i,7806,O
inhibited,7806,O
food,7806,O
intake,7806,O
induced,7806,O
by,7806,O
the,7806,O
NPY,7806,B-GENE-Y
Y5,7806,I-GENE-Y
selective,7806,O
agonist,7806,O
",",7806,O
and,7806,O
chronic,7806,O
oral,7806,O
administration,7806,O
of,7806,O
4i,7806,O
in,7806,O
DIO,7806,O
mice,7806,O
caused,7806,O
a,7806,O
dose-dependent,7806,O
reduction,7806,O
of,7806,O
body,7806,O
weight,7806,O
gain,7806,O
.,7806,O
Esmolol,7807,B-CHEMICAL
reduces,7807,O
autonomic,7807,O
hypersensitivity,7807,O
and,7807,O
length,7807,O
of,7807,O
seizures,7807,O
induced,7807,O
by,7807,O
electroconvulsive,7807,O
therapy,7807,O
.,7807,O
We,7808,O
evaluated,7808,O
the,7808,O
clinical,7808,O
effectiveness,7808,O
of,7808,O
esmolol,7808,B-CHEMICAL
",",7808,O
an,7808,O
ultra-short-acting,7808,O
beta,7808,B-GENE-Y
1-adrenergic,7808,I-GENE-Y
receptor,7808,I-GENE-Y
blocking,7808,O
drug,7808,O
",",7808,O
to,7808,O
control,7808,O
the,7808,O
sinus,7808,O
tachycardia,7808,O
and,7808,O
increase,7808,O
in,7808,O
arterial,7808,O
blood,7808,O
pressures,7808,O
induced,7808,O
by,7808,O
electroconvulsive,7808,O
therapy,7808,O
(,7808,O
ECT,7808,O
),7808,O
.,7808,O
Each,7809,O
of,7809,O
20,7809,O
patients,7809,O
",",7809,O
ASA,7809,O
physical,7809,O
status,7809,O
I-III,7809,O
",",7809,O
participated,7809,O
in,7809,O
a,7809,O
double-blind,7809,O
",",7809,O
randomized,7809,O
study,7809,O
",",7809,O
involving,7809,O
four,7809,O
match-pair,7809,O
trials,7809,O
(,7809,O
placebo,7809,O
versus,7809,O
esmolol,7809,B-CHEMICAL
),7809,O
during,7809,O
ECT,7809,O
.,7809,O
Each,7810,O
patient,7810,O
acted,7810,O
as,7810,O
his,7810,O
or,7810,O
her,7810,O
own,7810,O
control,7810,O
(,7810,O
total,7810,O
number,7810,O
of,7810,O
ECT,7810,O
procedures,7810,O
",",7810,O
160,7810,O
),7810,O
.,7810,O
We,7811,O
administered,7811,O
a,7811,O
4-min,7811,O
infusion,7811,O
of,7811,O
either,7811,O
placebo,7811,O
or,7811,O
esmolol,7811,B-CHEMICAL
at,7811,O
the,7811,O
rate,7811,O
of,7811,O
500,7811,O
micrograms.kg-1.min-1,7811,O
.,7811,O
We,7812,O
then,7812,O
induced,7812,O
anesthesia,7812,O
with,7812,O
methohexital,7812,B-CHEMICAL
and,7812,O
succinylcholine,7812,B-CHEMICAL
.,7812,O
After,7813,O
administration,7813,O
of,7813,O
electrical,7813,O
stimulation,7813,O
for,7813,O
ECT,7813,O
",",7813,O
the,7813,O
rate,7813,O
of,7813,O
infusion,7813,O
decreased,7813,O
to,7813,O
300,7813,O
micrograms.kg-1.min-1,7813,O
for,7813,O
three,7813,O
additional,7813,O
minutes,7813,O
and,7813,O
was,7813,O
then,7813,O
discontinued,7813,O
.,7813,O
Statistically,7814,O
significant,7814,O
reductions,7814,O
in,7814,O
mean,7814,O
heart,7814,O
rate,7814,O
from,7814,O
minute,7814,O
2,7814,O
until,7814,O
minute,7814,O
15,7814,O
and,7814,O
in,7814,O
maximum,7814,O
heart,7814,O
rate,7814,O
(,7814,O
the,7814,O
mean,7814,O
of,7814,O
each,7814,O
patient,7814,O
's,7814,O
maximum,7814,O
heart,7814,O
rate,7814,O
after,7814,O
seizure,7814,O
changed,7814,O
from,7814,O
152,7814,O
+/-,7814,O
23,7814,O
to,7814,O
115,7814,O
+/-,7814,O
24,7814,O
beats/min,7814,O
),7814,O
occurred,7814,O
in,7814,O
patients,7814,O
given,7814,O
esmolol,7814,B-CHEMICAL
.,7814,O
During,7815,O
and,7815,O
immediately,7815,O
after,7815,O
infusion,7815,O
",",7815,O
arterial,7815,O
blood,7815,O
pressure,7815,O
also,7815,O
decreased,7815,O
.,7815,O
Finally,7816,O
",",7816,O
the,7816,O
length,7816,O
of,7816,O
seizures,7816,O
decreased,7816,O
",",7816,O
as,7816,O
manifested,7816,O
clinically,7816,O
from,7816,O
48,7816,O
+/-,7816,O
18,7816,O
to,7816,O
39,7816,O
+/-,7816,O
14,7816,O
s,7816,O
and,7816,O
on,7816,O
electroencephalogram,7816,O
from,7816,O
86,7816,O
+/-,7816,O
41,7816,O
to,7816,O
67,7816,O
+/-,7816,O
28,7816,O
s.,7816,O
We,7816,O
conclude,7816,O
that,7816,O
esmolol,7816,B-CHEMICAL
effectively,7816,O
controls,7816,O
the,7816,O
hyperdynamic,7816,O
response,7816,O
to,7816,O
ECT,7816,O
and,7816,O
reduces,7816,O
the,7816,O
length,7816,O
of,7816,O
seizures,7816,O
.,7816,O
The,7817,O
significance,7817,O
of,7817,O
the,7817,O
latter,7817,O
to,7817,O
the,7817,O
overall,7817,O
effectiveness,7817,O
of,7817,O
ECT,7817,O
is,7817,O
not,7817,O
known,7817,O
.,7817,O
A,7818,O
genetically,7818,O
encoded,7818,O
and,7818,O
gate,7818,O
for,7818,O
cell-targeted,7818,O
metabolic,7818,O
labeling,7818,O
of,7818,O
proteins,7818,O
.,7818,O
We,7819,O
describe,7819,O
a,7819,O
genetic,7819,O
AND,7819,O
gate,7819,O
for,7819,O
cell-targeted,7819,O
metabolic,7819,O
labeling,7819,O
and,7819,O
proteomic,7819,O
analysis,7819,O
in,7819,O
complex,7819,O
cellular,7819,O
systems,7819,O
.,7819,O
The,7820,O
centerpiece,7820,O
of,7820,O
the,7820,O
AND,7820,O
gate,7820,O
is,7820,O
a,7820,O
bisected,7820,O
methionyl-tRNA,7820,B-GENE-Y
synthetase,7820,I-GENE-Y
(,7820,O
MetRS,7820,B-GENE-Y
),7820,O
that,7820,O
charges,7820,O
the,7820,O
Met,7820,B-CHEMICAL
surrogate,7820,O
azidonorleucine,7820,B-CHEMICAL
(,7820,O
Anl,7820,B-CHEMICAL
),7820,O
to,7820,O
tRNA,7820,O
(,7820,O
Met,7820,B-CHEMICAL
),7820,O
.,7820,O
Cellular,7821,O
protein,7821,O
labeling,7821,O
occurs,7821,O
only,7821,O
upon,7821,O
activation,7821,O
of,7821,O
two,7821,O
different,7821,O
promoters,7821,O
that,7821,O
drive,7821,O
expression,7821,O
of,7821,O
the,7821,O
N-,7821,B-CHEMICAL
and,7821,O
C-terminal,7821,B-CHEMICAL
fragments,7821,O
of,7821,O
the,7821,O
bisected,7821,O
MetRS,7821,B-GENE-Y
.,7821,O
Anl-labeled,7822,B-CHEMICAL
proteins,7822,O
can,7822,O
be,7822,O
tagged,7822,O
with,7822,O
fluorescent,7822,O
dyes,7822,O
or,7822,O
affinity,7822,O
reagents,7822,O
via,7822,O
either,7822,O
copper-catalyzed,7822,B-CHEMICAL
or,7822,O
strain-promoted,7822,O
azide-alkyne,7822,O
cycloaddition,7822,O
.,7822,O
Protein,7823,O
labeling,7823,O
is,7823,O
apparent,7823,O
within,7823,O
5,7823,O
min,7823,O
after,7823,O
addition,7823,O
of,7823,O
Anl,7823,B-CHEMICAL
to,7823,O
bacterial,7823,O
cells,7823,O
in,7823,O
which,7823,O
the,7823,O
AND,7823,O
gate,7823,O
has,7823,O
been,7823,O
activated,7823,O
.,7823,O
This,7824,O
method,7824,O
allows,7824,O
spatial,7824,O
and,7824,O
temporal,7824,O
control,7824,O
of,7824,O
proteomic,7824,O
labeling,7824,O
and,7824,O
identification,7824,O
of,7824,O
proteins,7824,O
made,7824,O
in,7824,O
specific,7824,O
cellular,7824,O
subpopulations,7824,O
.,7824,O
The,7825,O
approach,7825,O
is,7825,O
demonstrated,7825,O
by,7825,O
selective,7825,O
labeling,7825,O
of,7825,O
proteins,7825,O
in,7825,O
bacterial,7825,O
cells,7825,O
immobilized,7825,O
in,7825,O
the,7825,O
center,7825,O
of,7825,O
a,7825,O
laminar-flow,7825,O
microfluidic,7825,O
channel,7825,O
",",7825,O
where,7825,O
they,7825,O
are,7825,O
exposed,7825,O
to,7825,O
overlapping,7825,O
",",7825,O
opposed,7825,O
gradients,7825,O
of,7825,O
inducers,7825,O
of,7825,O
the,7825,O
N-,7825,B-CHEMICAL
and,7825,O
C-terminal,7825,B-CHEMICAL
MetRS,7825,B-GENE-Y
fragments,7825,O
.,7825,O
The,7826,O
observed,7826,O
labeling,7826,O
profile,7826,O
is,7826,O
predicted,7826,O
accurately,7826,O
from,7826,O
the,7826,O
strengths,7826,O
of,7826,O
the,7826,O
individual,7826,O
input,7826,O
signals,7826,O
.,7826,O
Relative,7827,O
myotoxic,7827,O
and,7827,O
haemodynamic,7827,O
effects,7827,O
of,7827,O
the,7827,O
beta-agonists,7827,O
fenoterol,7827,B-CHEMICAL
and,7827,O
clenbuterol,7827,B-CHEMICAL
measured,7827,O
in,7827,O
conscious,7827,O
unrestrained,7827,O
rats,7827,O
.,7827,O
The,7828,O
beta,7828,B-GENE-Y
(,7828,I-GENE-Y
2,7828,I-GENE-Y
),7828,I-GENE-Y
-adrenoceptor,7828,I-GENE-Y
(,7828,O
beta,7828,B-GENE-Y
(,7828,I-GENE-Y
2,7828,I-GENE-Y
),7828,I-GENE-Y
-AR,7828,I-GENE-Y
),7828,O
agonists,7828,O
clenbuterol,7828,B-CHEMICAL
and,7828,O
fenoterol,7828,B-CHEMICAL
have,7828,O
similar,7828,O
beneficial,7828,O
effects,7828,O
in,7828,O
animal,7828,O
models,7828,O
of,7828,O
heart,7828,O
failure,7828,O
.,7828,O
However,7829,O
",",7829,O
large,7829,O
doses,7829,O
of,7829,O
clenbuterol,7829,B-CHEMICAL
can,7829,O
induce,7829,O
cardiomyocyte,7829,O
death,7829,O
",",7829,O
and,7829,O
it,7829,O
is,7829,O
not,7829,O
known,7829,O
which,7829,O
of,7829,O
these,7829,O
agents,7829,O
has,7829,O
the,7829,O
most,7829,O
favourable,7829,O
therapeutic,7829,O
profile,7829,O
.,7829,O
We,7830,O
have,7830,O
investigated,7830,O
the,7830,O
cardiotoxicity,7830,O
of,7830,O
clenbuterol,7830,B-CHEMICAL
and,7830,O
fenoterol,7830,B-CHEMICAL
alongside,7830,O
that,7830,O
of,7830,O
isoprenaline,7830,B-CHEMICAL
",",7830,O
and,7830,O
compared,7830,O
their,7830,O
haemodynamic,7830,O
effects,7830,O
.,7830,O
Wistar,7831,O
rats,7831,O
(,7831,O
n,7831,O
=,7831,O
6,7831,O
per,7831,O
group,7831,O
),7831,O
were,7831,O
subcutaneously,7831,O
injected,7831,O
with,7831,O
each,7831,O
beta-agonist,7831,O
(,7831,O
0.003-3,7831,O
mmol,7831,O
kg,7831,O
(,7831,O
-1,7831,O
),7831,O
),7831,O
or,7831,O
saline,7831,O
",",7831,O
and,7831,O
cardiomyocyte,7831,O
apoptosis,7831,O
was,7831,O
detected,7831,O
by,7831,O
caspase,7831,B-GENE-Y
3,7831,I-GENE-Y
immunohistochemistry,7831,O
.,7831,O
In,7832,O
a,7832,O
separate,7832,O
experiment,7832,O
",",7832,O
rats,7832,O
(,7832,O
n,7832,O
=,7832,O
4,7832,O
),7832,O
were,7832,O
given,7832,O
equivalent,7832,O
doses,7832,O
to,7832,O
those,7832,O
used,7832,O
in,7832,O
the,7832,O
myotoxicity,7832,O
studies,7832,O
",",7832,O
in,7832,O
a,7832,O
randomized,7832,O
cross-over,7832,O
design,7832,O
",",7832,O
and,7832,O
their,7832,O
blood,7832,O
pressure,7832,O
recorded,7832,O
via,7832,O
radiotelemetry,7832,O
.,7832,O
Injection,7833,O
of,7833,O
0.3,7833,O
mmol,7833,O
kg,7833,O
(,7833,O
-1,7833,O
),7833,O
fenoterol,7833,B-CHEMICAL
or,7833,O
isoprenaline,7833,B-CHEMICAL
",",7833,O
but,7833,O
not,7833,O
clenbuterol,7833,B-CHEMICAL
",",7833,O
induced,7833,O
significant,7833,O
cardiomyocyte,7833,O
apoptosis,7833,O
(,7833,O
0.4,7833,O
+/-,7833,O
0.05,7833,O
%,7833,O
;,7833,O
P,7833,O
<,7833,O
0.05,7833,O
),7833,O
.,7833,O
At,7834,O
3,7834,O
mmol,7834,O
kg,7834,O
(,7834,O
-1,7834,O
),7834,O
",",7834,O
all,7834,O
agonists,7834,O
induced,7834,O
apoptosis,7834,O
(,7834,O
fenoterol,7834,B-CHEMICAL
",",7834,O
1.1,7834,O
+/-,7834,O
0.1,7834,O
%,7834,O
;,7834,O
isoprenaline,7834,B-CHEMICAL
",",7834,O
0.9,7834,O
+/-,7834,O
0.8,7834,O
%,7834,O
;,7834,O
and,7834,O
clenbuterol,7834,B-CHEMICAL
",",7834,O
0.4,7834,O
+/-,7834,O
0.07,7834,O
%,7834,O
;,7834,O
P,7834,O
<,7834,O
0.05,7834,O
),7834,O
.,7834,O
beta,7835,B-GENE-Y
(,7835,I-GENE-Y
1,7835,I-GENE-Y
),7835,I-GENE-Y
-Adrenoceptor,7835,I-GENE-Y
antagonism,7835,O
(,7835,O
10,7835,O
mg,7835,O
kg,7835,O
(,7835,O
-1,7835,O
),7835,O
bisoprolol,7835,B-CHEMICAL
),7835,O
prevented,7835,O
92,7835,O
%,7835,O
(,7835,O
P,7835,O
<,7835,O
0.05,7835,O
),7835,O
of,7835,O
apoptosis,7835,O
induced,7835,O
by,7835,O
all,7835,O
three,7835,O
agonists,7835,O
",",7835,O
but,7835,O
clenbuterol-induced,7835,B-CHEMICAL
apoptosis,7835,O
could,7835,O
also,7835,O
be,7835,O
prevented,7835,O
by,7835,O
96,7835,O
%,7835,O
(,7835,O
P,7835,O
<,7835,O
0.05,7835,O
),7835,O
by,7835,O
beta,7835,B-GENE-Y
(,7835,I-GENE-Y
2,7835,I-GENE-Y
),7835,I-GENE-Y
-AR,7835,I-GENE-Y
antagonism,7835,O
(,7835,O
10,7835,O
mg,7835,O
kg,7835,O
(,7835,O
-1,7835,O
),7835,O
ICI,7835,O
118,7835,O
551,7835,O
),7835,O
.,7835,O
Clenbuterol,7836,B-CHEMICAL
decreased,7836,O
diastolic,7836,O
(,7836,O
1.3-,7836,O
to,7836,O
1.6-fold,7836,O
;,7836,O
P,7836,O
<,7836,O
0.05,7836,O
),7836,O
and,7836,O
systolic,7836,O
blood,7836,O
pressure,7836,O
(,7836,O
1.3-fold,7836,O
;,7836,O
P,7836,O
<,7836,O
0.05,7836,O
),7836,O
",",7836,O
and,7836,O
doses,7836,O
>,7836,O
0.3,7836,O
mmol,7836,O
kg,7836,O
(,7836,O
-1,7836,O
),7836,O
increased,7836,O
heart,7836,O
rate,7836,O
(,7836,O
1.4-fold,7836,O
;,7836,O
P,7836,O
<,7836,O
0.05,7836,O
),7836,O
.,7836,O
Fenoterol,7837,B-CHEMICAL
increased,7837,O
heart,7837,O
rate,7837,O
(,7837,O
1.2-,7837,O
to,7837,O
1.4-fold,7837,O
;,7837,O
P,7837,O
<,7837,O
0.05,7837,O
),7837,O
",",7837,O
and,7837,O
doses,7837,O
>,7837,O
0.3,7837,O
mmol,7837,O
kg,7837,O
(,7837,O
-1,7837,O
),7837,O
decreased,7837,O
diastolic,7837,O
blood,7837,O
pressure,7837,O
(,7837,O
1.3-fold,7837,O
;,7837,O
P,7837,O
<,7837,O
0.05,7837,O
),7837,O
.,7837,O
In,7838,O
conclusion,7838,O
",",7838,O
the,7838,O
cardiotoxicity,7838,O
of,7838,O
fenoterol,7838,B-CHEMICAL
was,7838,O
similar,7838,O
to,7838,O
isoprenaline,7838,B-CHEMICAL
and,7838,O
greater,7838,O
than,7838,O
clenbuterol,7838,B-CHEMICAL
",",7838,O
and,7838,O
fenoterol,7838,B-CHEMICAL
had,7838,O
less,7838,O
desirable,7838,O
haemodynamic,7838,O
effects,7838,O
.,7838,O
Characterization,7839,O
of,7839,O
four,7839,O
new,7839,O
mouse,7839,B-GENE-N
cytochrome,7839,I-GENE-N
P450,7839,I-GENE-N
enzymes,7839,O
of,7839,O
the,7839,O
CYP2J,7839,B-GENE-N
subfamily,7839,O
.,7839,O
The,7840,O
cytochrome,7840,B-GENE-N
P450,7840,I-GENE-N
superfamily,7840,O
encompasses,7840,O
a,7840,O
diverse,7840,O
group,7840,O
of,7840,O
enzymes,7840,O
that,7840,O
catalyze,7840,O
the,7840,O
oxidation,7840,O
of,7840,O
various,7840,O
substrates,7840,O
.,7840,O
The,7841,O
mouse,7841,O
CYP2J,7841,B-GENE-N
subfamily,7841,O
includes,7841,O
members,7841,O
that,7841,O
have,7841,O
wide,7841,O
tissue,7841,O
distribution,7841,O
and,7841,O
are,7841,O
active,7841,O
in,7841,O
the,7841,O
metabolism,7841,O
of,7841,O
arachidonic,7841,B-CHEMICAL
acid,7841,I-CHEMICAL
(,7841,O
AA,7841,O
),7841,O
",",7841,O
linoleic,7841,B-CHEMICAL
acid,7841,I-CHEMICAL
(,7841,O
LA,7841,O
),7841,O
",",7841,O
and,7841,O
other,7841,O
lipids,7841,O
and,7841,O
xenobiotics,7841,O
.,7841,O
The,7842,O
mouse,7842,B-GENE-N
Cyp2j,7842,I-GENE-N
locus,7842,O
contains,7842,O
seven,7842,O
genes,7842,O
and,7842,O
three,7842,O
pseudogenes,7842,O
located,7842,O
in,7842,O
a,7842,O
contiguous,7842,O
0.62,7842,O
megabase,7842,O
cluster,7842,O
on,7842,O
chromosome,7842,O
4,7842,O
.,7842,O
We,7843,O
describe,7843,O
four,7843,O
new,7843,O
mouse,7843,B-GENE-N
CYP2J,7843,I-GENE-N
isoforms,7843,O
(,7843,O
designated,7843,O
CYP2J8,7843,B-GENE-Y
",",7843,O
CYP2J11,7843,B-GENE-Y
",",7843,O
CYP2J12,7843,B-GENE-Y
",",7843,O
and,7843,O
CYP2J13,7843,B-GENE-Y
),7843,O
.,7843,O
The,7844,O
four,7844,O
cDNAs,7844,O
contain,7844,O
open,7844,O
reading,7844,O
frames,7844,O
that,7844,O
encode,7844,O
polypeptides,7844,O
with,7844,O
62-84,7844,O
%,7844,O
identity,7844,O
with,7844,O
the,7844,O
three,7844,O
previously,7844,O
identified,7844,O
mouse,7844,B-GENE-N
CYP2Js,7844,I-GENE-N
.,7844,O
All,7845,O
four,7845,O
new,7845,O
CYP2J,7845,B-GENE-N
proteins,7845,O
were,7845,O
expressed,7845,O
in,7845,O
Sf21,7845,O
insect,7845,O
cells,7845,O
.,7845,O
Each,7846,O
recombinant,7846,O
protein,7846,O
metabolized,7846,O
AA,7846,O
and,7846,O
LA,7846,O
to,7846,O
epoxides,7846,B-CHEMICAL
and,7846,O
hydroxy,7846,B-CHEMICAL
derivatives,7846,O
.,7846,O
Specific,7847,O
antibodies,7847,O
",",7847,O
mRNA,7847,O
probes,7847,O
",",7847,O
and,7847,O
polymerase,7847,O
chain,7847,O
reaction,7847,O
primer,7847,O
sets,7847,O
were,7847,O
developed,7847,O
for,7847,O
each,7847,O
mouse,7847,O
CYP2J,7847,B-GENE-N
to,7847,O
examine,7847,O
their,7847,O
tissue,7847,O
distribution,7847,O
.,7847,O
CYP2J8,7848,B-GENE-Y
transcripts,7848,O
were,7848,O
found,7848,O
in,7848,O
the,7848,O
kidney,7848,O
",",7848,O
liver,7848,O
",",7848,O
and,7848,O
brain,7848,O
",",7848,O
and,7848,O
protein,7848,O
expression,7848,O
was,7848,O
confirmed,7848,O
in,7848,O
the,7848,O
kidney,7848,O
and,7848,O
brain,7848,O
(,7848,O
neuropil,7848,O
),7848,O
.,7848,O
CYP2J11,7849,B-GENE-Y
transcripts,7849,O
were,7849,O
most,7849,O
abundant,7849,O
in,7849,O
the,7849,O
kidney,7849,O
and,7849,O
heart,7849,O
",",7849,O
with,7849,O
protein,7849,O
detected,7849,O
primarily,7849,O
in,7849,O
the,7849,O
kidney,7849,O
(,7849,O
proximal,7849,O
convoluted,7849,O
tubules,7849,O
),7849,O
",",7849,O
liver,7849,O
",",7849,O
and,7849,O
heart,7849,O
(,7849,O
cardiomyocytes,7849,O
),7849,O
.,7849,O
CYP2J12,7850,B-GENE-Y
transcripts,7850,O
were,7850,O
prominently,7850,O
present,7850,O
in,7850,O
the,7850,O
brain,7850,O
",",7850,O
and,7850,O
CYP2J13,7850,B-GENE-Y
transcripts,7850,O
were,7850,O
detected,7850,O
in,7850,O
multiple,7850,O
tissues,7850,O
",",7850,O
with,7850,O
the,7850,O
highest,7850,O
expression,7850,O
in,7850,O
the,7850,O
kidney,7850,O
.,7850,O
CYP2J12,7851,B-GENE-Y
and,7851,O
CYP2J13,7851,B-GENE-Y
protein,7851,O
expression,7851,O
could,7851,O
not,7851,O
be,7851,O
determined,7851,O
because,7851,O
the,7851,O
antibodies,7851,O
developed,7851,O
were,7851,O
not,7851,O
immunospecific,7851,O
.,7851,O
We,7852,O
conclude,7852,O
that,7852,O
the,7852,O
four,7852,O
new,7852,O
CYP2J,7852,B-GENE-N
isoforms,7852,O
might,7852,O
be,7852,O
involved,7852,O
in,7852,O
the,7852,O
metabolism,7852,O
of,7852,O
AA,7852,O
and,7852,O
LA,7852,O
to,7852,O
bioactive,7852,O
lipids,7852,O
in,7852,O
mouse,7852,O
hepatic,7852,O
and,7852,O
extrahepatic,7852,O
tissues,7852,O
.,7852,O
The,7853,O
effect,7853,O
of,7853,O
manganese,7853,B-CHEMICAL
on,7853,O
dopamine,7853,B-CHEMICAL
toxicity,7853,O
and,7853,O
dopamine,7853,B-GENE-Y
transporter,7853,I-GENE-Y
(,7853,O
DAT,7853,B-GENE-Y
),7853,O
in,7853,O
control,7853,O
and,7853,O
DAT,7853,B-GENE-Y
transfected,7853,O
HEK,7853,O
cells,7853,O
.,7853,O
Chronic,7854,O
exposure,7854,O
to,7854,O
Mn,7854,B-CHEMICAL
results,7854,O
in,7854,O
the,7854,O
development,7854,O
of,7854,O
a,7854,O
neurological,7854,O
disorder,7854,O
known,7854,O
as,7854,O
manganism,7854,O
characterized,7854,O
by,7854,O
neurological,7854,O
deficits,7854,O
resembling,7854,O
that,7854,O
seen,7854,O
in,7854,O
Parkinsonism,7854,O
.,7854,O
Although,7855,O
dopaminergic,7855,O
neurons,7855,O
within,7855,O
the,7855,O
nigrostriatal,7855,O
pathway,7855,O
appear,7855,O
intact,7855,O
",",7855,O
Mn-induced,7855,B-CHEMICAL
irregularities,7855,O
in,7855,O
DA,7855,O
transmission,7855,O
have,7855,O
been,7855,O
observed,7855,O
including,7855,O
decreased,7855,O
amphetamine-induced,7855,B-CHEMICAL
DA,7855,O
release,7855,O
and,7855,O
loss,7855,O
of,7855,O
the,7855,O
dopamine,7855,B-GENE-Y
transporter,7855,I-GENE-Y
(,7855,O
DAT,7855,B-GENE-Y
),7855,O
.,7855,O
Results,7856,O
of,7856,O
studies,7856,O
to,7856,O
evaluate,7856,O
the,7856,O
effect,7856,O
of,7856,O
Mn,7856,B-CHEMICAL
and,7856,O
DA,7856,O
on,7856,O
cell,7856,O
viability,7856,O
in,7856,O
control,7856,O
and,7856,O
DAT-transfected,7856,B-GENE-Y
HEK,7856,O
cells,7856,O
reveal,7856,O
that,7856,O
Mn,7856,B-CHEMICAL
is,7856,O
equally,7856,O
toxic,7856,O
to,7856,O
both,7856,O
cell,7856,O
lines,7856,O
whereas,7856,O
DA,7856,O
was,7856,O
only,7856,O
toxic,7856,O
to,7856,O
cells,7856,O
containing,7856,O
DAT,7856,B-GENE-Y
.,7856,O
DA,7857,O
toxicity,7857,O
was,7857,O
saturable,7857,O
suggesting,7857,O
that,7857,O
transport,7857,O
may,7857,O
be,7857,O
rate,7857,O
limiting,7857,O
.,7857,O
When,7858,O
Mn,7858,B-CHEMICAL
and,7858,O
DA,7858,O
were,7858,O
added,7858,O
simultaneously,7858,O
to,7858,O
the,7858,O
media,7858,O
",",7858,O
cell,7858,O
toxicity,7858,O
was,7858,O
similar,7858,O
to,7858,O
that,7858,O
produced,7858,O
by,7858,O
Mn,7858,B-CHEMICAL
alone,7858,O
suggesting,7858,O
that,7858,O
Mn,7858,B-CHEMICAL
may,7858,O
suppress,7858,O
DA,7858,O
uptake,7858,O
in,7858,O
the,7858,O
DAT,7858,B-GENE-Y
containing,7858,O
cells,7858,O
.,7858,O
Preincubation,7859,O
of,7859,O
DA,7859,O
prior,7859,O
to,7859,O
the,7859,O
addition,7859,O
of,7859,O
Mn,7859,B-CHEMICAL
resulted,7859,O
in,7859,O
cell,7859,O
death,7859,O
which,7859,O
was,7859,O
essentially,7859,O
additive,7859,O
with,7859,O
that,7859,O
produced,7859,O
independently,7859,O
by,7859,O
the,7859,O
two,7859,O
agents,7859,O
.,7859,O
Mn,7860,B-CHEMICAL
was,7860,O
also,7860,O
shown,7860,O
to,7860,O
decrease,7860,O
DA,7860,O
uptake,7860,O
and,7860,O
amphetamine-induced,7860,B-CHEMICAL
DA,7860,O
efflux,7860,O
in,7860,O
DAT,7860,B-GENE-Y
containing,7860,O
cells,7860,O
.,7860,O
Time-lapsed,7861,O
confocal,7861,O
microscopy,7861,O
indicates,7861,O
that,7861,O
Mn,7861,B-CHEMICAL
can,7861,O
promote,7861,O
trafficking,7861,O
of,7861,O
cell,7861,O
surface,7861,O
DAT,7861,B-GENE-Y
into,7861,O
intracellular,7861,O
compartments,7861,O
which,7861,O
may,7861,O
account,7861,O
for,7861,O
the,7861,O
decrease,7861,O
in,7861,O
DA,7861,O
uptake,7861,O
and,7861,O
DA,7861,O
efflux,7861,O
in,7861,O
these,7861,O
cells,7861,O
.,7861,O
Mn-induced,7862,B-CHEMICAL
internalization,7862,O
of,7862,O
DAT,7862,B-GENE-Y
may,7862,O
provide,7862,O
an,7862,O
explanation,7862,O
for,7862,O
disruption,7862,O
in,7862,O
DA,7862,O
transmission,7862,O
previously,7862,O
reported,7862,O
in,7862,O
the,7862,O
striatum,7862,O
.,7862,O
Structural,7863,O
model,7863,O
of,7863,O
carnitine,7863,B-GENE-Y
palmitoyltransferase,7863,I-GENE-Y
I,7863,I-GENE-Y
based,7863,O
on,7863,O
the,7863,O
carnitine,7863,B-GENE-Y
acetyltransferase,7863,I-GENE-Y
crystal,7863,O
.,7863,O
CPT,7864,B-GENE-Y
I,7864,I-GENE-Y
(,7864,O
carnitine,7864,B-GENE-Y
palmitoyltransferase,7864,I-GENE-Y
I,7864,I-GENE-Y
),7864,O
catalyses,7864,O
the,7864,O
conversion,7864,O
of,7864,O
palmitoyl-CoA,7864,B-CHEMICAL
into,7864,O
palmitoylcarnitine,7864,B-CHEMICAL
in,7864,O
the,7864,O
presence,7864,O
of,7864,O
L-carnitine,7864,B-CHEMICAL
",",7864,O
facilitating,7864,O
the,7864,O
entry,7864,O
of,7864,O
fatty,7864,B-CHEMICAL
acids,7864,I-CHEMICAL
into,7864,O
mitochondria,7864,O
.,7864,O
We,7865,O
propose,7865,O
a,7865,O
3-D,7865,O
(,7865,O
three-dimensional,7865,O
),7865,O
structural,7865,O
model,7865,O
for,7865,O
L-CPT,7865,B-GENE-Y
I,7865,I-GENE-Y
(,7865,O
liver,7865,B-GENE-Y
CPT,7865,I-GENE-Y
I,7865,I-GENE-Y
),7865,O
",",7865,O
based,7865,O
on,7865,O
the,7865,O
similarity,7865,O
of,7865,O
this,7865,O
enzyme,7865,O
to,7865,O
the,7865,O
recently,7865,O
crystallized,7865,O
mouse,7865,B-GENE-Y
carnitine,7865,I-GENE-Y
acetyltransferase,7865,I-GENE-Y
.,7865,O
The,7866,O
model,7866,O
includes,7866,O
607,7866,O
of,7866,O
the,7866,O
773,7866,O
amino,7866,B-CHEMICAL
acids,7866,I-CHEMICAL
of,7866,O
L-CPT,7866,B-GENE-Y
I,7866,I-GENE-Y
",",7866,O
and,7866,O
the,7866,O
positions,7866,O
of,7866,O
carnitine,7866,B-CHEMICAL
",",7866,O
CoA,7866,B-CHEMICAL
and,7866,O
the,7866,O
palmitoyl,7866,B-CHEMICAL
group,7866,O
were,7866,O
assigned,7866,O
by,7866,O
superposition,7866,O
and,7866,O
docking,7866,O
analysis,7866,O
.,7866,O
Functional,7867,O
analysis,7867,O
of,7867,O
this,7867,O
3-D,7867,O
model,7867,O
included,7867,O
the,7867,O
mutagenesis,7867,O
of,7867,O
several,7867,O
amino,7867,B-CHEMICAL
acids,7867,I-CHEMICAL
in,7867,O
order,7867,O
to,7867,O
identify,7867,O
putative,7867,O
catalytic,7867,O
residues,7867,O
.,7867,O
Mutants,7868,O
D477A,7868,B-GENE-N
",",7868,O
D567A,7868,B-GENE-N
and,7868,O
E590D,7868,B-GENE-N
showed,7868,O
reduced,7868,O
L-CPT,7868,B-GENE-Y
I,7868,I-GENE-Y
activity,7868,O
.,7868,O
In,7869,O
addition,7869,O
",",7869,O
individual,7869,O
mutation,7869,O
of,7869,O
amino,7869,B-CHEMICAL
acids,7869,I-CHEMICAL
forming,7869,O
the,7869,O
conserved,7869,O
Ser685-Thr686-Ser687,7869,O
motif,7869,O
abolished,7869,O
enzyme,7869,O
activity,7869,O
in,7869,O
mutants,7869,O
T686A,7869,B-GENE-N
and,7869,O
S687A,7869,B-GENE-N
and,7869,O
altered,7869,O
K,7869,O
(,7869,O
m,7869,O
),7869,O
and,7869,O
the,7869,O
catalytic,7869,O
efficiency,7869,O
for,7869,O
carnitine,7869,B-CHEMICAL
in,7869,O
mutant,7869,O
S685A,7869,B-GENE-N
.,7869,O
We,7870,O
conclude,7870,O
that,7870,O
the,7870,O
catalytic,7870,O
residues,7870,O
are,7870,O
His473,7870,O
and,7870,O
Asp477,7870,O
",",7870,O
while,7870,O
Ser687,7870,O
probably,7870,O
stabilizes,7870,O
the,7870,O
transition,7870,O
state,7870,O
.,7870,O
Several,7871,O
conserved,7871,O
lysines,7871,O
",",7871,O
i.e,7871,O
.,7871,O
Lys455,7872,O
",",7872,O
Lys505,7872,O
",",7872,O
Lys560,7872,O
and,7872,O
Lys561,7872,O
",",7872,O
were,7872,O
also,7872,O
mutated,7872,O
.,7872,O
Only,7873,O
mutants,7873,O
K455A,7873,B-GENE-N
and,7873,O
K560A,7873,B-GENE-N
showed,7873,O
decreases,7873,O
in,7873,O
activity,7873,O
of,7873,O
50,7873,O
%,7873,O
.,7873,O
The,7874,O
model,7874,O
rationalizes,7874,O
the,7874,O
finding,7874,O
of,7874,O
nine,7874,O
natural,7874,O
mutations,7874,O
in,7874,O
patients,7874,O
with,7874,O
hereditary,7874,O
L-CPT,7874,B-GENE-Y
I,7874,I-GENE-Y
deficiencies,7874,O
.,7874,O
Oxysterols,7875,B-CHEMICAL
in,7875,O
cancer,7875,O
cell,7875,O
proliferation,7875,O
and,7875,O
death,7875,O
.,7875,O
Oxysterols,7876,B-CHEMICAL
have,7876,O
been,7876,O
shown,7876,O
to,7876,O
interfere,7876,O
with,7876,O
proliferation,7876,O
and,7876,O
cause,7876,O
the,7876,O
death,7876,O
of,7876,O
many,7876,O
cancer,7876,O
cell,7876,O
types,7876,O
",",7876,O
such,7876,O
as,7876,O
leukaemia,7876,O
",",7876,O
glioblastoma,7876,O
",",7876,O
colon,7876,O
",",7876,O
breast,7876,O
and,7876,O
prostate,7876,O
cancer,7876,O
cells,7876,O
",",7876,O
while,7876,O
they,7876,O
have,7876,O
little,7876,O
or,7876,O
no,7876,O
effect,7876,O
on,7876,O
senescent,7876,O
cells,7876,O
.,7876,O
The,7877,O
mechanisms,7877,O
by,7877,O
which,7877,O
oxysterols,7877,B-CHEMICAL
may,7877,O
influence,7877,O
proliferation,7877,O
are,7877,O
manifold,7877,O
:,7877,O
they,7877,O
control,7877,O
the,7877,O
transcription,7877,O
and,7877,O
the,7877,O
turnover,7877,O
of,7877,O
the,7877,O
key,7877,O
enzyme,7877,O
in,7877,O
cholesterol,7877,B-CHEMICAL
synthesis,7877,O
",",7877,O
3-hydroxy-3-methylglutaryl,7877,B-GENE-Y
CoA,7877,I-GENE-Y
reductase,7877,I-GENE-Y
",",7877,O
by,7877,O
binding,7877,O
to,7877,O
Insig-1,7877,B-GENE-Y
",",7877,O
Insig-2,7877,B-GENE-Y
and,7877,O
liver,7877,B-GENE-N
X,7877,I-GENE-N
receptors,7877,I-GENE-N
.,7877,O
Oxysterols,7878,B-CHEMICAL
are,7878,O
thought,7878,O
to,7878,O
be,7878,O
generated,7878,O
in,7878,O
proportion,7878,O
to,7878,O
the,7878,O
rate,7878,O
of,7878,O
cholesterol,7878,B-CHEMICAL
synthesis,7878,O
.,7878,O
Although,7879,O
there,7879,O
is,7879,O
no,7879,O
consensus,7879,O
about,7879,O
the,7879,O
mechanism,7879,O
by,7879,O
which,7879,O
these,7879,O
oxysterols,7879,B-CHEMICAL
are,7879,O
generated,7879,O
in,7879,O
vivo,7879,O
",",7879,O
it,7879,O
clearly,7879,O
has,7879,O
to,7879,O
be,7879,O
ubiquitous,7879,O
.,7879,O
The,7880,O
25-,7880,B-GENE-N
and,7880,I-GENE-N
the,7880,I-GENE-N
27-cholesterol,7880,I-GENE-N
hydroxylases,7880,I-GENE-N
",",7880,O
present,7880,O
in,7880,O
almost,7880,O
all,7880,O
tissues,7880,O
",",7880,O
are,7880,O
possible,7880,O
candidates,7880,O
.,7880,O
Cholesterol,7881,B-CHEMICAL
uptake,7881,O
from,7881,O
lipoproteins,7881,B-GENE-N
",",7881,O
intracellular,7881,O
vesicle,7881,O
transport,7881,O
and,7881,O
lipid,7881,O
transfer,7881,O
are,7881,O
also,7881,O
modified,7881,O
by,7881,O
oxysterols,7881,B-CHEMICAL
.,7881,O
Oxysterols,7882,B-CHEMICAL
interfere,7882,O
with,7882,O
ERK,7882,B-GENE-N
",",7882,O
hedgehog,7882,B-GENE-N
and,7882,O
wnt,7882,B-GENE-N
pathways,7882,O
of,7882,O
proliferation,7882,O
and,7882,O
differentiation,7882,O
.,7882,O
When,7883,O
administered,7883,O
in,7883,O
vitro,7883,O
to,7883,O
cancer,7883,O
cell,7883,O
lines,7883,O
",",7883,O
oxysterols,7883,B-CHEMICAL
invariably,7883,O
both,7883,O
slow,7883,O
down,7883,O
proliferation,7883,O
and,7883,O
provoke,7883,O
cell,7883,O
death,7883,O
.,7883,O
Perhaps,7884,O
is,7884,O
it,7884,O
sufficient,7884,O
to,7884,O
stop,7884,O
proliferation,7884,O
of,7884,O
a,7884,O
cancer,7884,O
to,7884,O
provoke,7884,O
its,7884,O
eradication,7884,O
.,7884,O
Therefore,7885,O
",",7885,O
the,7885,O
two,7885,O
facets,7885,O
of,7885,O
oxysterol,7885,B-CHEMICAL
action,7885,O
that,7885,O
seem,7885,O
important,7885,O
for,7885,O
cancer,7885,O
treatment,7885,O
",",7885,O
cytostaticity,7885,O
and,7885,O
cytotoxicity,7885,O
",",7885,O
will,7885,O
be,7885,O
discussed,7885,O
.,7885,O
In,7886,O
vivo,7886,O
HIF-mediated,7886,B-GENE-N
reductive,7886,O
carboxylation,7886,O
is,7886,O
regulated,7886,O
by,7886,O
citrate,7886,B-CHEMICAL
levels,7886,O
and,7886,O
sensitizes,7886,O
VHL-deficient,7886,B-GENE-Y
cells,7886,O
to,7886,O
glutamine,7886,B-CHEMICAL
deprivation,7886,O
.,7886,O
Hypoxic,7887,O
and,7887,O
VHL-deficient,7887,B-GENE-Y
cells,7887,O
use,7887,O
glutamine,7887,B-CHEMICAL
to,7887,O
generate,7887,O
citrate,7887,B-CHEMICAL
and,7887,O
lipids,7887,O
through,7887,O
reductive,7887,O
carboxylation,7887,O
(,7887,O
RC,7887,O
),7887,O
of,7887,O
α-ketoglutarate,7887,B-CHEMICAL
.,7887,O
To,7888,O
gain,7888,O
insights,7888,O
into,7888,O
the,7888,O
role,7888,O
of,7888,O
HIF,7888,B-GENE-N
and,7888,O
the,7888,O
molecular,7888,O
mechanisms,7888,O
underlying,7888,O
RC,7888,O
",",7888,O
we,7888,O
took,7888,O
advantage,7888,O
of,7888,O
a,7888,O
panel,7888,O
of,7888,O
disease-associated,7888,O
VHL,7888,B-GENE-Y
mutants,7888,O
and,7888,O
showed,7888,O
that,7888,O
HIF,7888,B-GENE-N
expression,7888,O
is,7888,O
necessary,7888,O
and,7888,O
sufficient,7888,O
for,7888,O
the,7888,O
induction,7888,O
of,7888,O
RC,7888,O
in,7888,O
human,7888,O
renal,7888,O
cell,7888,O
carcinoma,7888,O
(,7888,O
RCC,7888,O
),7888,O
cells,7888,O
.,7888,O
HIF,7889,B-GENE-N
expression,7889,O
drastically,7889,O
reduced,7889,O
intracellular,7889,O
citrate,7889,B-CHEMICAL
levels,7889,O
.,7889,O
Feeding,7890,O
VHL-deficient,7890,B-GENE-Y
RCC,7890,O
cells,7890,O
with,7890,O
acetate,7890,B-CHEMICAL
or,7890,O
citrate,7890,B-CHEMICAL
or,7890,O
knocking,7890,O
down,7890,O
PDK-1,7890,B-GENE-Y
and,7890,O
ACLY,7890,B-GENE-Y
restored,7890,O
citrate,7890,B-CHEMICAL
levels,7890,O
and,7890,O
suppressed,7890,O
RC,7890,O
.,7890,O
These,7891,O
data,7891,O
suggest,7891,O
that,7891,O
HIF-induced,7891,B-GENE-N
low,7891,O
intracellular,7891,O
citrate,7891,B-CHEMICAL
levels,7891,O
promote,7891,O
the,7891,O
reductive,7891,O
flux,7891,O
by,7891,O
mass,7891,O
action,7891,O
to,7891,O
maintain,7891,O
lipogenesis,7891,O
.,7891,O
Using,7892,O
[,7892,B-CHEMICAL
(,7892,I-CHEMICAL
1-13,7892,I-CHEMICAL
),7892,I-CHEMICAL
C,7892,I-CHEMICAL
],7892,I-CHEMICAL
glutamine,7892,I-CHEMICAL
",",7892,O
we,7892,O
demonstrated,7892,O
in,7892,O
vivo,7892,O
RC,7892,O
activity,7892,O
in,7892,O
VHL-deficient,7892,B-GENE-Y
tumors,7892,O
growing,7892,O
as,7892,O
xenografts,7892,O
in,7892,O
mice,7892,O
.,7892,O
Lastly,7893,O
",",7893,O
HIF,7893,B-GENE-N
rendered,7893,O
VHL-deficient,7893,B-GENE-Y
cells,7893,O
sensitive,7893,O
to,7893,O
glutamine,7893,B-CHEMICAL
deprivation,7893,O
in,7893,O
vitro,7893,O
",",7893,O
and,7893,O
systemic,7893,O
administration,7893,O
of,7893,O
glutaminase,7893,B-GENE-N
inhibitors,7893,O
suppressed,7893,O
the,7893,O
growth,7893,O
of,7893,O
RCC,7893,O
cells,7893,O
as,7893,O
mice,7893,O
xenografts,7893,O
.,7893,O
Bioactive,7894,O
flavaglines,7894,B-CHEMICAL
and,7894,O
other,7894,O
constituents,7894,O
isolated,7894,O
from,7894,O
Aglaia,7894,O
perviridis,7894,O
.,7894,O
Eight,7895,O
new,7895,O
compounds,7895,O
",",7895,O
including,7895,O
two,7895,O
cyclopenta,7895,B-CHEMICAL
[,7895,I-CHEMICAL
b,7895,I-CHEMICAL
],7895,I-CHEMICAL
benzopyran,7895,I-CHEMICAL
derivatives,7895,O
(,7895,O
1,7895,O
",",7895,O
2,7895,O
),7895,O
",",7895,O
two,7895,O
cyclopenta,7895,B-CHEMICAL
[,7895,I-CHEMICAL
b,7895,I-CHEMICAL
],7895,I-CHEMICAL
benzofuran,7895,I-CHEMICAL
derivatives,7895,O
(,7895,O
3,7895,O
",",7895,O
4,7895,O
),7895,O
",",7895,O
three,7895,O
cycloartane,7895,B-CHEMICAL
triterpenoids,7895,I-CHEMICAL
(,7895,O
5-7,7895,O
),7895,O
",",7895,O
and,7895,O
an,7895,O
apocarotenoid,7895,O
(,7895,O
8,7895,O
),7895,O
",",7895,O
together,7895,O
with,7895,O
16,7895,O
known,7895,O
compounds,7895,O
",",7895,O
were,7895,O
isolated,7895,O
from,7895,O
the,7895,O
chloroform-soluble,7895,B-CHEMICAL
partitions,7895,O
of,7895,O
separate,7895,O
methanol,7895,B-CHEMICAL
extracts,7895,O
of,7895,O
a,7895,O
combination,7895,O
of,7895,O
the,7895,O
fruits,7895,O
",",7895,O
leaves,7895,O
",",7895,O
and,7895,O
twigs,7895,O
and,7895,O
of,7895,O
the,7895,O
roots,7895,O
of,7895,O
Aglaia,7895,O
perviridis,7895,O
collected,7895,O
in,7895,O
Vietnam,7895,O
.,7895,O
Isolation,7896,O
work,7896,O
was,7896,O
monitored,7896,O
using,7896,O
human,7896,O
colon,7896,O
cancer,7896,O
cells,7896,O
(,7896,O
HT-29,7896,O
),7896,O
and,7896,O
facilitated,7896,O
with,7896,O
an,7896,O
LC/MS,7896,O
dereplication,7896,O
procedure,7896,O
.,7896,O
The,7897,O
structures,7897,O
of,7897,O
the,7897,O
new,7897,O
compounds,7897,O
(,7897,O
1-8,7897,O
),7897,O
were,7897,O
determined,7897,O
on,7897,O
the,7897,O
basis,7897,O
of,7897,O
spectroscopic,7897,O
data,7897,O
interpretation,7897,O
.,7897,O
The,7898,O
Mosher,7898,O
ester,7898,O
method,7898,O
was,7898,O
employed,7898,O
to,7898,O
determine,7898,O
the,7898,O
absolute,7898,O
configurations,7898,O
of,7898,O
5-7,7898,O
",",7898,O
and,7898,O
the,7898,O
absolute,7898,O
configuration,7898,O
of,7898,O
the,7898,O
"9,10-diol",7898,O
unit,7898,O
of,7898,O
compound,7898,O
8,7898,O
was,7898,O
established,7898,O
by,7898,O
a,7898,O
dimolybdenum,7898,B-CHEMICAL
tetraacetate,7898,I-CHEMICAL
[,7898,O
Mo2,7898,B-CHEMICAL
(,7898,I-CHEMICAL
AcO,7898,I-CHEMICAL
),7898,I-CHEMICAL
4,7898,I-CHEMICAL
],7898,O
induced,7898,O
circular,7898,O
dichroism,7898,O
procedure,7898,O
.,7898,O
Seven,7899,O
known,7899,O
rocaglate,7899,B-CHEMICAL
derivatives,7899,O
(,7899,O
9-15,7899,O
),7899,O
exhibited,7899,O
significant,7899,O
cytotoxicity,7899,O
against,7899,O
the,7899,O
HT-29,7899,O
cell,7899,O
line,7899,O
",",7899,O
with,7899,O
rocaglaol,7899,B-CHEMICAL
(,7899,O
9,7899,O
),7899,O
being,7899,O
the,7899,O
most,7899,O
potent,7899,O
(,7899,O
ED50,7899,O
0.0007,7899,O
μM,7899,O
),7899,O
.,7899,O
The,7900,O
new,7900,O
compounds,7900,O
2-4,7900,O
were,7900,O
also,7900,O
active,7900,O
against,7900,O
this,7900,O
cell,7900,O
line,7900,O
",",7900,O
with,7900,O
ED50,7900,O
values,7900,O
ranging,7900,O
from,7900,O
0.46,7900,O
to,7900,O
4.7,7900,O
μM,7900,O
.,7900,O
The,7901,O
cytotoxic,7901,O
compounds,7901,O
were,7901,O
evaluated,7901,O
against,7901,O
a,7901,O
normal,7901,O
colon,7901,O
cell,7901,O
line,7901,O
",",7901,O
CCD-112CoN,7901,O
.,7901,O
In,7902,O
addition,7902,O
",",7902,O
the,7902,O
new,7902,O
compound,7902,O
perviridicin,7902,B-CHEMICAL
B,7902,I-CHEMICAL
(,7902,O
2,7902,O
),7902,O
",",7902,O
three,7902,O
known,7902,O
rocaglate,7902,B-CHEMICAL
derivatives,7902,O
(,7902,O
9,7902,O
",",7902,O
11,7902,O
",",7902,O
12,7902,O
),7902,O
",",7902,O
and,7902,O
a,7902,O
known,7902,O
sesquiterpene,7902,B-CHEMICAL
",",7902,O
2-oxaisodauc-5-en-12-al,7902,B-CHEMICAL
(,7902,O
17,7902,O
),7902,O
",",7902,O
showed,7902,O
significant,7902,O
NF-κB,7902,B-GENE-N
(,7902,O
p65,7902,B-GENE-Y
),7902,O
inhibitory,7902,O
activity,7902,O
in,7902,O
an,7902,O
ELISA,7902,O
assay,7902,O
.,7902,O
Synthesis,7903,O
and,7903,O
biological,7903,O
evaluation,7903,O
of,7903,O
novel,7903,O
aliphatic,7903,B-CHEMICAL
amido-quaternary,7903,I-CHEMICAL
ammonium,7903,I-CHEMICAL
salts,7903,I-CHEMICAL
for,7903,O
anticancer,7903,O
chemotherapy,7903,O
:,7903,O
Part,7903,O
II,7903,O
.,7903,O
A,7904,O
series,7904,O
of,7904,O
novel,7904,O
aliphatic,7904,B-CHEMICAL
amido-quaternary,7904,I-CHEMICAL
ammonium,7904,I-CHEMICAL
salts,7904,I-CHEMICAL
were,7904,O
synthesized,7904,O
and,7904,O
evaluated,7904,O
for,7904,O
their,7904,O
anticancer,7904,O
effects,7904,O
involving,7904,O
induction,7904,O
of,7904,O
RhoB,7904,B-GENE-Y
.,7904,O
Most,7905,O
of,7905,O
these,7905,O
compounds,7905,O
",",7905,O
featuring,7905,O
open-ring,7905,O
forms,7905,O
of,7905,O
aliphatic,7905,B-CHEMICAL
amido-quaternary,7905,I-CHEMICAL
ammonium,7905,I-CHEMICAL
salts,7905,I-CHEMICAL
",",7905,O
exhibited,7905,O
potent,7905,O
anti-proliferative,7905,O
activities,7905,O
in,7905,O
human,7905,O
cancer,7905,O
cell,7905,O
lines,7905,O
",",7905,O
including,7905,O
PC-3,7905,O
",",7905,O
NUGC-3,7905,O
",",7905,O
MDA-MB-231,7905,O
",",7905,O
ACHN,7905,O
",",7905,O
HCT-15,7905,O
",",7905,O
and,7905,O
NCI-H23,7905,O
.,7905,O
In,7906,O
further,7906,O
evaluation,7906,O
",",7906,O
the,7906,O
representative,7906,O
compound,7906,O
N,7906,B-CHEMICAL
",",7906,I-CHEMICAL
N-diethyl-N-,7906,I-CHEMICAL
(,7906,I-CHEMICAL
2-,7906,I-CHEMICAL
(,7906,I-CHEMICAL
N-methyltetradecanamido,7906,I-CHEMICAL
),7906,I-CHEMICAL
ethyl,7906,I-CHEMICAL
),7906,I-CHEMICAL
prop-2-en-1-aminium,7906,I-CHEMICAL
bromide,7906,I-CHEMICAL
(,7906,O
3b,7906,O
),7906,O
exhibited,7906,O
potent,7906,O
pro-apoptotic,7906,O
activity,7906,O
",",7906,O
through,7906,O
RhoB,7906,B-GENE-Y
activation,7906,O
",",7906,O
in,7906,O
HeLa,7906,O
cells,7906,O
.,7906,O
RNA,7907,O
interference-triggered,7907,O
reversal,7907,O
of,7907,O
ABCC2-dependent,7907,B-GENE-Y
cisplatin,7907,B-CHEMICAL
resistance,7907,O
in,7907,O
human,7907,O
cancer,7907,O
cells,7907,O
.,7907,O
The,7908,O
adenosine,7908,B-GENE-N
triphosphate,7908,I-GENE-N
binding,7908,I-GENE-N
cassette,7908,I-GENE-N
(,7908,I-GENE-N
ABC,7908,I-GENE-N
),7908,I-GENE-N
-transporter,7908,I-GENE-N
ABCC2,7908,B-GENE-Y
(,7908,O
MRP2/cMOAT,7908,B-GENE-Y
),7908,O
can,7908,O
mediate,7908,O
resistance,7908,O
against,7908,O
the,7908,O
commonly,7908,O
used,7908,O
anticancer,7908,O
drugs,7908,O
cisplatin,7908,B-CHEMICAL
and,7908,O
paclitaxel,7908,B-CHEMICAL
.,7908,O
To,7909,O
overcome,7909,O
the,7909,O
ABCC2-depending,7909,B-GENE-Y
drug,7909,O
resistance,7909,O
",",7909,O
two,7909,O
specific,7909,O
anti-ABCC2,7909,O
small,7909,O
interfering,7909,O
RNAs,7909,O
(,7909,O
siRNAs,7909,O
),7909,O
were,7909,O
designed,7909,O
for,7909,O
transient,7909,O
triggering,7909,O
of,7909,O
the,7909,O
gene-silencing,7909,O
RNA,7909,O
interference,7909,O
(,7909,O
RNAi,7909,O
),7909,O
pathway,7909,O
in,7909,O
the,7909,O
cisplatin-resistant,7909,B-CHEMICAL
human,7909,O
ovarian,7909,O
carcinoma,7909,O
cell,7909,O
line,7909,O
A2780RCIS,7909,O
.,7909,O
Since,7910,O
both,7910,O
siRNAs,7910,O
showed,7910,O
biological,7910,O
activity,7910,O
",",7910,O
for,7910,O
stable,7910,O
inhibition,7910,O
of,7910,O
ABCC2,7910,B-GENE-Y
a,7910,O
corresponding,7910,O
short,7910,O
hairpin,7910,O
RNA,7910,O
(,7910,O
shRNA,7910,O
),7910,O
-encoding,7910,O
expression,7910,O
vector,7910,O
was,7910,O
designed,7910,O
.,7910,O
By,7911,O
treatment,7911,O
of,7911,O
A2780RCIS,7911,O
cells,7911,O
with,7911,O
this,7911,O
construct,7911,O
",",7911,O
the,7911,O
expressions,7911,O
of,7911,O
the,7911,O
targeted,7911,O
ABCC2,7911,B-GENE-Y
encoding,7911,O
mRNA,7911,O
and,7911,O
transport,7911,O
protein,7911,O
were,7911,O
inhibited,7911,O
.,7911,O
These,7912,O
effects,7912,O
were,7912,O
accompanied,7912,O
by,7912,O
reversal,7912,O
of,7912,O
resistance,7912,O
against,7912,O
cisplatin,7912,B-CHEMICAL
and,7912,O
paclitaxel,7912,B-CHEMICAL
.,7912,O
Thus,7913,O
",",7913,O
the,7913,O
data,7913,O
demonstrate,7913,O
the,7913,O
utility,7913,O
of,7913,O
the,7913,O
analyzed,7913,O
RNAs,7913,O
as,7913,O
powerful,7913,O
laboratory,7913,O
tools,7913,O
and,7913,O
indicate,7913,O
that,7913,O
siRNA-,7913,O
and,7913,O
shRNA-mediated,7913,O
RNAi-based,7913,O
gene,7913,O
therapeutic,7913,O
approaches,7913,O
may,7913,O
be,7913,O
applicable,7913,O
in,7913,O
preventing,7913,O
and,7913,O
reversing,7913,O
ABCC2-depending,7913,B-GENE-Y
drug,7913,O
resistance,7913,O
.,7913,O
Epinastine,7914,B-CHEMICAL
(,7914,O
WAL,7914,B-CHEMICAL
801CL,7914,I-CHEMICAL
),7914,O
modulates,7914,O
the,7914,O
noncholinergic,7914,O
contraction,7914,O
in,7914,O
guinea-pig,7914,O
airways,7914,O
in,7914,O
vitro,7914,O
by,7914,O
a,7914,O
prejunctional,7914,O
5-HT1-like,7914,B-GENE-N
receptor,7914,I-GENE-N
.,7914,O
Electrical,7915,O
field,7915,O
stimulation,7915,O
(,7915,O
EFS,7915,O
),7915,O
of,7915,O
guinea-pig,7915,O
airways,7915,O
",",7915,O
in,7915,O
vitro,7915,O
",",7915,O
evokes,7915,O
an,7915,O
excitatory,7915,O
nonadrenergic,7915,O
noncholinergic,7915,O
(,7915,O
eNANC,7915,O
),7915,O
contraction,7915,O
mediated,7915,O
by,7915,O
release,7915,O
of,7915,O
tachykinins,7915,O
from,7915,O
sensory,7915,O
nerve,7915,O
endings,7915,O
.,7915,O
Epinastine,7916,B-CHEMICAL
(,7916,O
WAL,7916,B-CHEMICAL
801CL,7916,I-CHEMICAL
),7916,O
is,7916,O
an,7916,O
antihistaminic,7916,O
drug,7916,O
with,7916,O
binding,7916,O
affinity,7916,O
at,7916,O
certain,7916,O
other,7916,O
receptors,7916,O
",",7916,O
including,7916,O
alpha-adrenergic,7916,B-GENE-N
receptors,7916,I-GENE-N
and,7916,O
various,7916,O
serotonin,7916,B-GENE-N
(,7916,I-GENE-N
5-HT,7916,I-GENE-N
),7916,I-GENE-N
receptor,7916,I-GENE-N
subtypes,7916,O
.,7916,O
It,7917,O
is,7917,O
used,7917,O
in,7917,O
asthma,7917,O
treatment,7917,O
;,7917,O
however,7917,O
",",7917,O
its,7917,O
mechanism,7917,O
of,7917,O
action,7917,O
remains,7917,O
to,7917,O
be,7917,O
fully,7917,O
defined,7917,O
.,7917,O
We,7918,O
have,7918,O
investigated,7918,O
whether,7918,O
epinastine,7918,B-CHEMICAL
could,7918,O
modulate,7918,O
the,7918,O
eNANC,7918,O
contraction,7918,O
in,7918,O
guinea-pig,7918,O
airways,7918,O
in,7918,O
vitro,7918,O
",",7918,O
and,7918,O
have,7918,O
tried,7918,O
to,7918,O
elucidate,7918,O
its,7918,O
receptor,7918,O
mechanism,7918,O
.,7918,O
Epinastine,7919,B-CHEMICAL
(,7919,O
0.1-100,7919,O
microM,7919,O
),7919,O
produced,7919,O
a,7919,O
concentration-dependent,7919,O
inhibition,7919,O
of,7919,O
the,7919,O
noncholinergic,7919,O
contraction,7919,O
",",7919,O
with,7919,O
a,7919,O
maximum,7919,O
inhibition,7919,O
of,7919,O
91,7919,O
+/-,7919,O
7,7919,O
%,7919,O
at,7919,O
100,7919,O
microM,7919,O
.,7919,O
Pretreatment,7920,O
of,7920,O
the,7920,O
tissues,7920,O
with,7920,O
combined,7920,O
5-HT1/5-HT2,7920,B-GENE-N
antagonists,7920,O
",",7920,O
methysergide,7920,B-CHEMICAL
(,7920,O
1,7920,O
microM,7920,O
),7920,O
or,7920,O
methiothepin,7920,B-CHEMICAL
(,7920,O
0.1,7920,O
microM,7920,O
),7920,O
",",7920,O
significantly,7920,O
attenuated,7920,O
the,7920,O
inhibitory,7920,O
effect,7920,O
of,7920,O
epinastine,7920,B-CHEMICAL
on,7920,O
the,7920,O
noncholinergic,7920,O
contraction,7920,O
.,7920,O
Pretreatment,7921,O
with,7921,O
tropisetron,7921,B-CHEMICAL
(,7921,O
1,7921,O
microM,7921,O
),7921,O
",",7921,O
a,7921,O
5-HT3,7921,B-GENE-N
antagonist,7921,O
",",7921,O
ketanserin,7921,B-CHEMICAL
(,7921,O
10,7921,O
microM,7921,O
),7921,O
",",7921,O
a,7921,O
5-HT2,7921,B-GENE-N
antagonist,7921,O
",",7921,O
thioperamide,7921,B-CHEMICAL
(,7921,O
10,7921,O
microM,7921,O
),7921,O
",",7921,O
a,7921,O
histamine,7921,B-GENE-Y
H3,7921,I-GENE-Y
antagonist,7921,O
",",7921,O
or,7921,O
phentolamine,7921,B-CHEMICAL
(,7921,O
10,7921,O
microM,7921,O
),7921,O
",",7921,O
an,7921,O
alpha-adrenergic,7921,O
antagonist,7921,O
",",7921,O
however,7921,O
",",7921,O
had,7921,O
no,7921,O
effect,7921,O
.,7921,O
Chlorpheniramine,7922,B-CHEMICAL
(,7922,O
10,7922,O
microM,7922,O
),7922,O
",",7922,O
another,7922,O
histamine,7922,B-GENE-Y
H1,7922,I-GENE-Y
receptor,7922,I-GENE-Y
antagonist,7922,O
without,7922,O
significant,7922,O
5-HT,7922,B-GENE-N
receptor,7922,I-GENE-N
binding,7922,O
affinity,7922,O
",",7922,O
did,7922,O
not,7922,O
produce,7922,O
any,7922,O
inhibition,7922,O
of,7922,O
the,7922,O
eNANC,7922,O
contraction,7922,O
.,7922,O
Epinastine,7923,B-CHEMICAL
(,7923,O
100,7923,O
microM,7923,O
),7923,O
did,7923,O
not,7923,O
displace,7923,O
the,7923,O
dose-response,7923,O
curve,7923,O
to,7923,O
exogenously,7923,O
applied,7923,O
substance,7923,B-GENE-Y
P,7923,I-GENE-Y
(,7923,O
0.01-10,7923,O
microM,7923,O
),7923,O
.,7923,O
These,7924,O
results,7924,O
suggest,7924,O
that,7924,O
epinastine,7924,B-CHEMICAL
",",7924,O
although,7924,O
identified,7924,O
as,7924,O
a,7924,O
5-HT,7924,B-CHEMICAL
antagonist,7924,O
",",7924,O
acts,7924,O
as,7924,O
a,7924,O
5-HT1,7924,B-GENE-N
agonist,7924,O
and,7924,O
that,7924,O
it,7924,O
inhibits,7924,O
the,7924,O
noncholinergic,7924,O
contraction,7924,O
in,7924,O
guinea-pig,7924,O
airways,7924,O
through,7924,O
stimulation,7924,O
of,7924,O
a,7924,O
prejunctional,7924,O
5-HT1-like,7924,B-GENE-N
receptor,7924,I-GENE-N
",",7924,O
located,7924,O
to,7924,O
sensory,7924,O
nerves,7924,O
.,7924,O
Vitamin,7925,B-CHEMICAL
C,7925,I-CHEMICAL
forestalls,7925,O
cigarette,7925,O
smoke,7925,O
induced,7925,O
NF-κB,7925,B-GENE-N
activation,7925,O
in,7925,O
alveolar,7925,O
epithelial,7925,O
cells,7925,O
.,7925,O
Cigarette,7926,O
smoking,7926,O
causes,7926,O
cellular,7926,O
oxidative,7926,O
stress,7926,O
resulting,7926,O
in,7926,O
inflammatory,7926,O
diseases,7926,O
of,7926,O
lung,7926,O
wherein,7926,O
transcription,7926,O
factor,7926,O
NF-κB,7926,B-GENE-N
plays,7926,O
an,7926,O
important,7926,O
role,7926,O
.,7926,O
It,7927,O
is,7927,O
possible,7927,O
that,7927,O
vitamin,7927,B-CHEMICAL
C,7927,I-CHEMICAL
",",7927,O
an,7927,O
antioxidant,7927,O
",",7927,O
may,7927,O
prevent,7927,O
cigarette,7927,O
smoke,7927,O
(,7927,O
CS,7927,O
),7927,O
-induced,7927,O
NF-κB,7927,B-GENE-N
activation,7927,O
that,7927,O
involves,7927,O
degradation,7927,O
of,7927,O
I-κBε,7927,B-GENE-Y
and,7927,O
nuclear,7927,O
translocation,7927,O
of,7927,O
c-Rel/p50,7927,B-GENE-Y
in,7927,O
alveolar,7927,O
epithelial,7927,O
cells,7927,O
.,7927,O
Therefore,7928,O
",",7928,O
to,7928,O
examine,7928,O
the,7928,O
hypothesis,7928,O
",",7928,O
we,7928,O
verified,7928,O
the,7928,O
effect,7928,O
of,7928,O
vitamin,7928,B-CHEMICAL
C,7928,I-CHEMICAL
on,7928,O
CS-induced,7928,O
expression,7928,O
of,7928,O
NF-κB,7928,B-GENE-N
driven,7928,O
luciferase,7928,O
reporter,7928,O
and,7928,O
NF-κB,7928,B-GENE-N
binding,7928,O
at,7928,O
its,7928,O
target,7928,O
DNA,7928,O
by,7928,O
EMSA,7928,O
in,7928,O
alveolar,7928,O
epithelial,7928,O
A549,7928,O
cells,7928,O
.,7928,O
We,7929,O
also,7929,O
examined,7929,O
the,7929,O
level,7929,O
of,7929,O
I-κBε,7929,B-GENE-Y
and,7929,O
sub-cellular,7929,O
distribution,7929,O
of,7929,O
c-Rel,7929,B-GENE-Y
by,7929,O
western,7929,O
blotting,7929,O
and,7929,O
immunofluorescence,7929,O
respectively,7929,O
in,7929,O
CSE-treated,7929,O
A549,7929,O
cells,7929,O
with,7929,O
or,7929,O
without,7929,O
vitamin,7929,B-CHEMICAL
C,7929,I-CHEMICAL
pretreatment,7929,O
.,7929,O
We,7930,O
observed,7930,O
a,7930,O
significant,7930,O
reduction,7930,O
in,7930,O
CSE,7930,O
induced,7930,O
luciferase,7930,O
expression,7930,O
",",7930,O
NF-κB,7930,B-GENE-N
DNA,7930,O
binding,7930,O
",",7930,O
I-κBε,7930,B-GENE-Y
degradation,7930,O
and,7930,O
c-Rel,7930,B-GENE-Y
nuclear,7930,O
translocation,7930,O
in,7930,O
cells,7930,O
pretreated,7930,O
with,7930,O
vitamin,7930,B-CHEMICAL
C.,7930,O
To,7930,O
further,7930,O
validate,7930,O
the,7930,O
result,7930,O
",",7930,O
we,7930,O
examined,7930,O
sub-cellular,7930,O
distribution,7930,O
of,7930,O
c-Rel,7930,B-GENE-Y
in,7930,O
lungs,7930,O
of,7930,O
CS-exposed,7930,O
guinea,7930,O
pigs,7930,O
treated,7930,O
or,7930,O
untreated,7930,O
with,7930,O
vitamin,7930,B-CHEMICAL
C.,7930,O
Result,7930,O
showed,7930,O
that,7930,O
vitamin,7930,B-CHEMICAL
C,7930,I-CHEMICAL
treatment,7930,O
resulted,7930,O
in,7930,O
markedly,7930,O
reduced,7930,O
c-Rel,7930,B-GENE-Y
nuclear,7930,O
translocation,7930,O
.,7930,O
All,7931,O
these,7931,O
results,7931,O
demonstrate,7931,O
that,7931,O
vitamin,7931,B-CHEMICAL
C,7931,I-CHEMICAL
prevents,7931,O
CS,7931,O
(,7931,O
E,7931,O
),7931,O
-induced,7931,O
NF-κB,7931,B-GENE-N
activation,7931,O
and,7931,O
thus,7931,O
it,7931,O
could,7931,O
be,7931,O
used,7931,O
for,7931,O
the,7931,O
prevention,7931,O
of,7931,O
CS-induced,7931,O
inflammatory,7931,O
diseases,7931,O
.,7931,O
Catalpol,7932,B-CHEMICAL
suppresses,7932,O
advanced,7932,O
glycation,7932,O
end-products-induced,7932,O
inflammatory,7932,O
responses,7932,O
through,7932,O
inhibition,7932,O
of,7932,O
reactive,7932,O
oxygen,7932,B-CHEMICAL
species,7932,O
in,7932,O
human,7932,O
monocytic,7932,O
THP-1,7932,O
cells,7932,O
.,7932,O
Advanced,7933,O
glycation,7933,O
end-products,7933,O
(,7933,O
AGEs,7933,O
),7933,O
play,7933,O
a,7933,O
pivotal,7933,O
role,7933,O
in,7933,O
the,7933,O
development,7933,O
of,7933,O
diabetic,7933,O
complications,7933,O
by,7933,O
inducing,7933,O
inflammation,7933,O
.,7933,O
We,7934,O
previously,7934,O
reported,7934,O
that,7934,O
the,7934,O
fresh,7934,O
roots,7934,O
of,7934,O
Rehmannia,7934,O
glutinosa,7934,O
Libosch.,7934,O
",",7934,O
which,7934,O
have,7934,O
been,7934,O
used,7934,O
for,7934,O
the,7934,O
treatment,7934,O
of,7934,O
diabetes,7934,O
in,7934,O
traditional,7934,O
Korean,7934,O
medicine,7934,O
",",7934,O
also,7934,O
have,7934,O
the,7934,O
potential,7934,O
to,7934,O
suppress,7934,O
AGE-mediated,7934,O
inflammatory,7934,O
response,7934,O
in,7934,O
THP-1,7934,O
cells,7934,O
.,7934,O
In,7935,O
the,7935,O
present,7935,O
study,7935,O
",",7935,O
we,7935,O
isolated,7935,O
catalpol,7935,B-CHEMICAL
from,7935,O
R.,7935,O
glutinosa,7935,O
",",7935,O
and,7935,O
examined,7935,O
whether,7935,O
it,7935,O
has,7935,O
anti-inflammatory,7935,O
effects,7935,O
on,7935,O
AGE-stimulated,7935,O
THP-1,7935,O
cells,7935,O
.,7935,O
Catalpol,7936,B-CHEMICAL
reduced,7936,O
the,7936,O
expression,7936,O
of,7936,O
pro-inflammatory,7936,O
mediates,7936,O
",",7936,O
such,7936,O
as,7936,O
monocyte,7936,B-GENE-Y
chemotactic,7936,I-GENE-Y
protein-1,7936,I-GENE-Y
(,7936,O
MCP-1,7936,B-GENE-Y
),7936,O
",",7936,O
tumor,7936,B-GENE-Y
necrosis,7936,I-GENE-Y
factor-α,7936,I-GENE-Y
(,7936,O
TNF-α,7936,B-GENE-Y
),7936,O
",",7936,O
inducible,7936,B-GENE-Y
NO,7936,I-GENE-Y
synthase,7936,I-GENE-Y
(,7936,O
iNOS,7936,B-GENE-Y
),7936,O
",",7936,O
and,7936,O
receptor,7936,B-GENE-Y
for,7936,I-GENE-Y
AGE,7936,I-GENE-Y
(,7936,O
RAGE,7936,B-GENE-Y
),7936,O
.,7936,O
Promoter,7937,O
and,7937,O
electromobility,7937,O
shift,7937,O
assays,7937,O
showed,7937,O
that,7937,O
transcriptional,7937,O
activation,7937,O
of,7937,O
NF-κB,7937,B-GENE-N
was,7937,O
significantly,7937,O
reduced,7937,O
by,7937,O
catalpol,7937,B-CHEMICAL
treatment,7937,O
",",7937,O
while,7937,O
AP-1,7937,B-GENE-Y
was,7937,O
not,7937,O
.,7937,O
Catalpol,7938,B-CHEMICAL
also,7938,O
suppressed,7938,O
AGE-induced,7938,O
phosphorylation,7938,O
of,7938,O
mitogen,7938,B-GENE-N
activated,7938,I-GENE-N
protein,7938,I-GENE-N
(,7938,I-GENE-N
MAP,7938,I-GENE-N
),7938,I-GENE-N
kinases,7938,I-GENE-N
",",7938,O
degradation,7938,O
of,7938,O
IκBα,7938,B-GENE-Y
and,7938,O
the,7938,O
nuclear,7938,O
localization,7938,O
of,7938,O
NF-κB,7938,B-GENE-N
.,7938,O
Moreover,7939,O
",",7939,O
the,7939,O
production,7939,O
of,7939,O
intracellular,7939,O
reactive,7939,O
oxygen,7939,B-CHEMICAL
species,7939,O
(,7939,O
ROS,7939,O
),7939,O
elicited,7939,O
by,7939,O
AGE,7939,O
was,7939,O
also,7939,O
suppressed,7939,O
by,7939,O
catalpol,7939,B-CHEMICAL
treatment,7939,O
",",7939,O
through,7939,O
dual,7939,O
action,7939,O
of,7939,O
reducing,7939,O
ROS,7939,O
itself,7939,O
and,7939,O
inhibiting,7939,O
NADPH,7939,B-GENE-N
oxidase,7939,I-GENE-N
activity,7939,O
.,7939,O
Our,7940,O
findings,7940,O
indicate,7940,O
that,7940,O
catalpol,7940,B-CHEMICAL
suppresses,7940,O
AGE-mediated,7940,O
inflammation,7940,O
by,7940,O
inhibiting,7940,O
ROS,7940,O
production,7940,O
and,7940,O
NF-κB,7940,B-GENE-N
activity,7940,O
.,7940,O
We,7941,O
suggest,7941,O
that,7941,O
catalpol,7941,B-CHEMICAL
",",7941,O
a,7941,O
major,7941,O
constituent,7941,O
of,7941,O
the,7941,O
fresh,7941,O
roots,7941,O
of,7941,O
R.,7941,O
glutinosa,7941,O
",",7941,O
contributes,7941,O
to,7941,O
the,7941,O
prevention,7941,O
of,7941,O
AGE-mediated,7941,O
diabetic,7941,O
complications,7941,O
.,7941,O
Moxifloxacin,7942,B-CHEMICAL
enhances,7942,O
etoposide-induced,7942,B-CHEMICAL
cytotoxic,7942,O
",",7942,O
apoptotic,7942,O
and,7942,O
anti-topoisomerase,7942,O
II,7942,I-GENE-Y
effects,7942,O
in,7942,O
a,7942,O
human,7942,O
colon,7942,O
carcinoma,7942,O
cell,7942,O
line,7942,O
.,7942,O
Etoposide,7943,B-CHEMICAL
(,7943,O
VP-16,7943,B-CHEMICAL
),7943,O
is,7943,O
a,7943,O
topoisomerase-II,7943,B-GENE-Y
(,7943,O
topo,7943,B-GENE-Y
II,7943,I-GENE-Y
),7943,O
inhibitor,7943,O
chemotherapeutic,7943,O
agent,7943,O
.,7943,O
Studies,7944,O
have,7944,O
shown,7944,O
that,7944,O
a,7944,O
combination,7944,O
of,7944,O
VP-16,7944,B-CHEMICAL
with,7944,O
other,7944,O
drugs,7944,O
demonstrates,7944,O
better,7944,O
clinical,7944,O
responses,7944,O
.,7944,O
The,7945,O
aim,7945,O
of,7945,O
this,7945,O
study,7945,O
was,7945,O
to,7945,O
investigate,7945,O
the,7945,O
effects,7945,O
of,7945,O
moxifloxacin,7945,B-CHEMICAL
(,7945,O
MXF,7945,B-CHEMICAL
),7945,O
and,7945,O
VP-16,7945,B-CHEMICAL
on,7945,O
cellular,7945,O
topo,7945,B-GENE-Y
II,7945,I-GENE-Y
activity,7945,O
in,7945,O
drug-treated,7945,O
cells,7945,O
and,7945,O
evaluate,7945,O
the,7945,O
influence,7945,O
of,7945,O
MXF,7945,B-CHEMICAL
on,7945,O
the,7945,O
mode,7945,O
of,7945,O
action,7945,O
of,7945,O
VP-16,7945,B-CHEMICAL
",",7945,O
on,7945,O
proliferation,7945,O
and,7945,O
apoptosis,7945,O
of,7945,O
HT-29,7945,O
cells,7945,O
.,7945,O
Decatenation,7946,O
assay,7946,O
",",7946,O
band,7946,O
depletion,7946,O
and,7946,O
Western,7946,O
blot,7946,O
analysis,7946,O
",",7946,O
cytotoxic,7946,O
assay,7946,O
(,7946,O
MTT,7946,B-CHEMICAL
),7946,O
",",7946,O
flow,7946,O
cytometric,7946,O
studies,7946,O
(,7946,O
cell,7946,O
cycle,7946,O
and,7946,O
survivin,7946,O
expression,7946,O
),7946,O
",",7946,O
apoptosis,7946,O
(,7946,O
DAPI-sulforhodamine,7946,B-CHEMICAL
staining,7946,O
and,7946,O
caspase,7946,B-GENE-Y
3,7946,I-GENE-Y
activity,7946,O
),7946,O
and,7946,O
IL-8,7946,B-GENE-Y
and,7946,O
VEGF,7946,B-GENE-Y
secretion,7946,O
were,7946,O
determined,7946,O
.,7946,O
MXF,7947,B-CHEMICAL
or,7947,O
VP-16,7947,B-CHEMICAL
slightly,7947,O
affected,7947,O
cellular,7947,O
topo,7947,B-GENE-Y
II,7947,I-GENE-Y
activity,7947,O
in,7947,O
nuclear,7947,O
extracts,7947,O
derived,7947,O
from,7947,O
drug-treated,7947,O
cells,7947,O
while,7947,O
the,7947,O
combination,7947,O
enhanced,7947,O
inhibitory,7947,O
activity,7947,O
and,7947,O
the,7947,O
reduction,7947,O
in,7947,O
band,7947,O
depletion,7947,O
of,7947,O
topo,7947,B-GENE-Y
II,7947,I-GENE-Y
.,7947,O
VP-16,7948,B-CHEMICAL
induced,7948,O
cell,7948,O
cycle,7948,O
arrest,7948,O
at,7948,O
G2/M,7948,O
and,7948,O
the,7948,O
appearance,7948,O
of,7948,O
the,7948,O
subG1,7948,O
peak,7948,O
which,7948,O
was,7948,O
increased,7948,O
by,7948,O
the,7948,O
addition,7948,O
of,7948,O
MXF,7948,B-CHEMICAL
.,7948,O
Apoptosis,7949,O
studies,7949,O
(,7949,O
DAPI,7949,B-CHEMICAL
staining,7949,O
and,7949,O
caspase,7949,B-GENE-Y
3,7949,I-GENE-Y
activity,7949,O
),7949,O
showed,7949,O
a,7949,O
marked,7949,O
increase,7949,O
in,7949,O
the,7949,O
presence,7949,O
of,7949,O
MXF,7949,B-CHEMICAL
and,7949,O
VP-16,7949,B-CHEMICAL
compared,7949,O
to,7949,O
VP-16,7949,B-CHEMICAL
alone,7949,O
.,7949,O
VP-16,7950,B-CHEMICAL
induced,7950,O
the,7950,O
release,7950,O
of,7950,O
IL-8,7950,B-GENE-Y
",",7950,O
and,7950,O
addition,7950,O
of,7950,O
MXF,7950,B-CHEMICAL
reduced,7950,O
enhanced,7950,O
release,7950,O
and,7950,O
the,7950,O
spontaneous,7950,O
release,7950,O
of,7950,O
VEGF,7950,B-GENE-Y
from,7950,O
the,7950,O
cells,7950,O
.,7950,O
In,7951,O
conclusion,7951,O
",",7951,O
the,7951,O
results,7951,O
suggest,7951,O
that,7951,O
the,7951,O
enhancement,7951,O
in,7951,O
the,7951,O
reduction,7951,O
of,7951,O
topo,7951,B-GENE-Y
II,7951,I-GENE-Y
activity,7951,O
by,7951,O
the,7951,O
combined,7951,O
MXF/VP-16,7951,B-CHEMICAL
treatments,7951,O
was,7951,O
probably,7951,O
due,7951,O
to,7951,O
the,7951,O
increase,7951,O
in,7951,O
the,7951,O
level,7951,O
of,7951,O
the,7951,O
DNA-enzyme,7951,O
cleavable,7951,O
complexes,7951,O
formed,7951,O
by,7951,O
both,7951,O
drugs,7951,O
.,7951,O
The,7952,O
unique,7952,O
combination,7952,O
of,7952,O
MXF/VP-16,7952,B-CHEMICAL
may,7952,O
have,7952,O
clinical,7952,O
benefits,7952,O
and,7952,O
a,7952,O
cytotoxic,7952,O
drug,7952,O
'sparing,7952,O
effect,7952,O
',7952,O
and,7952,O
should,7952,O
be,7952,O
further,7952,O
studied,7952,O
in,7952,O
vivo,7952,O
.,7952,O
Thymidine,7953,B-GENE-N
kinase,7953,I-GENE-N
and,7953,O
thymidine,7953,B-GENE-Y
phosphorylase,7953,I-GENE-Y
level,7953,O
as,7953,O
the,7953,O
main,7953,O
predictive,7953,O
parameter,7953,O
for,7953,O
sensitivity,7953,O
to,7953,O
TAS-102,7953,B-CHEMICAL
in,7953,O
a,7953,O
mouse,7953,O
model,7953,O
.,7953,O
TAS-102,7954,B-CHEMICAL
is,7954,O
a,7954,O
new,7954,O
oral,7954,O
anti-cancer,7954,O
drug,7954,O
preparation,7954,O
",",7954,O
composed,7954,O
of,7954,O
a,7954,O
1:0.5,7954,O
mixture,7954,O
(,7954,O
on,7954,O
a,7954,O
molar,7954,O
basis,7954,O
),7954,O
of,7954,O
alpha,7954,B-CHEMICAL
",",7954,I-CHEMICAL
alpha,7954,I-CHEMICAL
",",7954,I-CHEMICAL
alpha-trifluorothymidine,7954,I-CHEMICAL
(,7954,O
FTD,7954,B-CHEMICAL
),7954,O
and,7954,O
5-chloro-6-,7954,B-CHEMICAL
[,7954,I-CHEMICAL
1-,7954,I-CHEMICAL
(,7954,I-CHEMICAL
2-iminopyrrolidinyl,7954,I-CHEMICAL
),7954,I-CHEMICAL
methyl,7954,I-CHEMICAL
],7954,I-CHEMICAL
"-2,4",7954,I-CHEMICAL
(,7954,I-CHEMICAL
"1H,3H",7954,I-CHEMICAL
),7954,I-CHEMICAL
-pyrimidinedione,7954,I-CHEMICAL
hydrochloride,7954,I-CHEMICAL
(,7954,O
TPI,7954,B-CHEMICAL
),7954,O
.,7954,O
TAS-102,7955,B-CHEMICAL
currently,7955,O
undergoing,7955,O
clinical,7955,O
trials,7955,O
",",7955,O
has,7955,O
been,7955,O
demonstrated,7955,O
to,7955,O
have,7955,O
at,7955,O
least,7955,O
two,7955,O
mechanisms,7955,O
",",7955,O
inhibition,7955,O
of,7955,O
TS,7955,B-GENE-Y
and,7955,O
incorporation,7955,O
into,7955,O
DNA,7955,O
.,7955,O
We,7956,O
hypothesized,7956,O
that,7956,O
the,7956,O
thymidine,7956,B-CHEMICAL
metabolism,7956,O
enzyme,7956,O
may,7956,O
be,7956,O
a,7956,O
crucial,7956,O
factor,7956,O
that,7956,O
affects,7956,O
the,7956,O
antitumor,7956,O
activity,7956,O
of,7956,O
TAS-102,7956,B-CHEMICAL
.,7956,O
In,7957,O
the,7957,O
present,7957,O
study,7957,O
",",7957,O
we,7957,O
measured,7957,O
the,7957,O
enzyme,7957,O
activity,7957,O
of,7957,O
thymidine,7957,B-GENE-N
kinase,7957,I-GENE-N
(,7957,O
TK,7957,B-GENE-N
),7957,O
",",7957,O
thymidine,7957,B-GENE-Y
phosphorylase,7957,I-GENE-Y
(,7957,O
TP,7957,B-GENE-Y
),7957,O
and,7957,O
thymidilate,7957,B-GENE-Y
synthase,7957,I-GENE-Y
(,7957,O
TS,7957,B-GENE-Y
),7957,O
in,7957,O
human,7957,O
cancer,7957,O
xenografts,7957,O
to,7957,O
investigate,7957,O
the,7957,O
contribution,7957,O
of,7957,O
these,7957,O
enzymes,7957,O
to,7957,O
the,7957,O
sensitivity,7957,O
of,7957,O
TAS-102,7957,B-CHEMICAL
.,7957,O
Antitumor,7958,O
activity,7958,O
of,7958,O
TAS-102,7958,B-CHEMICAL
appears,7958,O
to,7958,O
be,7958,O
associated,7958,O
with,7958,O
TK,7958,B-GENE-N
",",7958,O
tumor,7958,O
growth,7958,O
and,7958,O
TS,7958,B-GENE-Y
.,7958,O
However,7959,O
",",7959,O
the,7959,O
most,7959,O
related,7959,O
factors,7959,O
in,7959,O
this,7959,O
study,7959,O
were,7959,O
the,7959,O
TK,7959,B-GENE-N
and,7959,O
TP,7959,B-GENE-Y
ratio,7959,O
.,7959,O
There,7960,O
was,7960,O
a,7960,O
significant,7960,O
correlation,7960,O
(,7960,O
p=0.04,7960,O
),7960,O
between,7960,O
tumor,7960,O
growth,7960,O
inhibition,7960,O
and,7960,O
this,7960,O
ratio,7960,O
.,7960,O
These,7961,O
results,7961,O
suggested,7961,O
that,7961,O
the,7961,O
activation,7961,O
and,7961,O
degradation,7961,O
pattern,7961,O
of,7961,O
FTD,7961,B-CHEMICAL
plays,7961,O
an,7961,O
important,7961,O
role,7961,O
in,7961,O
the,7961,O
efficacy,7961,O
of,7961,O
TAS-102,7961,B-CHEMICAL
and,7961,O
that,7961,O
it,7961,O
is,7961,O
possible,7961,O
to,7961,O
use,7961,O
the,7961,O
TK/TP,7961,B-GENE-N
ratio,7961,O
to,7961,O
predict,7961,O
response,7961,O
to,7961,O
TAS-102,7961,B-CHEMICAL
therapy,7961,O
.,7961,O
We,7962,O
also,7962,O
studied,7962,O
the,7962,O
influence,7962,O
of,7962,O
TPI,7962,B-CHEMICAL
on,7962,O
the,7962,O
capacity,7962,O
of,7962,O
exogenous,7962,O
dThd,7962,O
to,7962,O
reverse,7962,O
FTD-dependent,7962,B-CHEMICAL
growth,7962,O
inhibition,7962,O
.,7962,O
Thymidine,7963,B-CHEMICAL
(,7963,O
dThd,7963,O
),7963,O
levels,7963,O
rescued,7963,O
the,7963,O
effect,7963,O
of,7963,O
FTD,7963,B-CHEMICAL
in,7963,O
vitro,7963,O
and,7963,O
significantly,7963,O
increased,7963,O
in,7963,O
serum,7963,O
after,7963,O
administration,7963,O
of,7963,O
TAS-102,7963,B-CHEMICAL
or,7963,O
TPI,7963,B-CHEMICAL
alone,7963,O
but,7963,O
not,7963,O
FTD,7963,B-CHEMICAL
alone,7963,O
.,7963,O
This,7964,O
may,7964,O
suggest,7964,O
the,7964,O
possibility,7964,O
of,7964,O
a,7964,O
decrease,7964,O
in,7964,O
antitumor,7964,O
effect,7964,O
.,7964,O
However,7965,O
",",7965,O
our,7965,O
study,7965,O
indicated,7965,O
that,7965,O
the,7965,O
therapeutic,7965,O
index,7965,O
was,7965,O
clearly,7965,O
increased,7965,O
by,7965,O
FTD,7965,B-CHEMICAL
combined,7965,O
with,7965,O
TPI,7965,B-CHEMICAL
",",7965,O
compared,7965,O
with,7965,O
FTD,7965,B-CHEMICAL
alone,7965,O
",",7965,O
suggesting,7965,O
FTD-induced,7965,B-CHEMICAL
toxicity,7965,O
to,7965,O
sensitive,7965,O
host,7965,O
tissue,7965,O
can,7965,O
be,7965,O
selectively,7965,O
reversed,7965,O
with,7965,O
dThd,7965,O
.,7965,O
In,7966,O
conclusion,7966,O
",",7966,O
TK,7966,B-GENE-N
and,7966,O
TPI,7966,B-CHEMICAL
effects,7966,O
on,7966,O
TP,7966,B-GENE-Y
play,7966,O
important,7966,O
roles,7966,O
in,7966,O
the,7966,O
cytotoxic,7966,O
action,7966,O
of,7966,O
TAS-102,7966,B-CHEMICAL
",",7966,O
and,7966,O
it,7966,O
is,7966,O
possible,7966,O
to,7966,O
use,7966,O
the,7966,O
TK/TP,7966,B-GENE-N
ratio,7966,O
to,7966,O
predict,7966,O
more,7966,O
precisely,7966,O
individual,7966,O
resistance,7966,O
or,7966,O
sensitivity,7966,O
.,7966,O
Furanodiene,7967,B-CHEMICAL
Presents,7967,O
Synergistic,7967,O
Anti-proliferative,7967,O
Activity,7967,O
With,7967,O
Paclitaxel,7967,B-CHEMICAL
Via,7967,O
Altering,7967,O
Cell,7967,O
Cycle,7967,O
and,7967,O
Integrin,7967,B-GENE-N
Signaling,7967,O
in,7967,O
95-D,7967,O
Lung,7967,O
Cancer,7967,O
Cells,7967,O
.,7967,O
Furanodiene,7968,B-CHEMICAL
(,7968,O
FUR,7968,B-CHEMICAL
),7968,O
is,7968,O
a,7968,O
natural,7968,O
terpenoid,7968,B-CHEMICAL
isolated,7968,O
from,7968,O
Rhizoma,7968,O
Curcumae,7968,O
",",7968,O
a,7968,O
well-known,7968,O
Chinese,7968,O
medicinal,7968,O
herb,7968,O
that,7968,O
presents,7968,O
anti-proliferative,7968,O
activities,7968,O
in,7968,O
several,7968,O
cancer,7968,O
cell,7968,O
lines,7968,O
.,7968,O
Recently,7969,O
",",7969,O
we,7969,O
found,7969,O
that,7969,O
the,7969,O
combined,7969,O
treatment,7969,O
of,7969,O
FUR,7969,B-CHEMICAL
with,7969,O
paclitaxel,7969,B-CHEMICAL
(,7969,O
TAX,7969,B-CHEMICAL
),7969,O
showed,7969,O
synergetic,7969,O
anti-proliferative,7969,O
activities,7969,O
in,7969,O
95-D,7969,O
lung,7969,O
cancer,7969,O
cells,7969,O
.,7969,O
Herein,7970,O
",",7970,O
we,7970,O
showed,7970,O
that,7970,O
FUR,7970,B-CHEMICAL
reduced,7970,O
the,7970,O
cell,7970,O
numbers,7970,O
distributed,7970,O
in,7970,O
mitosis,7970,O
phase,7970,O
induced,7970,O
by,7970,O
TAX,7970,B-CHEMICAL
while,7970,O
increased,7970,O
those,7970,O
in,7970,O
G1,7970,O
phase,7970,O
.,7970,O
The,7971,O
protein,7971,O
levels,7971,O
of,7971,O
cyclin,7971,B-GENE-Y
D1,7971,I-GENE-Y
",",7971,O
cyclin,7971,B-GENE-Y
B1,7971,I-GENE-Y
",",7971,O
CDK6,7971,B-GENE-Y
and,7971,O
c-Myc,7971,B-GENE-Y
were,7971,O
all,7971,O
down-regulated,7971,O
in,7971,O
the,7971,O
group,7971,O
of,7971,O
combined,7971,O
treatment,7971,O
.,7971,O
The,7972,O
dramatically,7972,O
down-regulated,7972,O
expression,7972,O
of,7972,O
integrin,7972,B-GENE-Y
β4,7972,I-GENE-Y
",",7972,O
focal,7972,B-GENE-Y
adhesion,7972,I-GENE-Y
kinase,7972,I-GENE-Y
and,7972,O
paxillin,7972,B-GENE-Y
might,7972,O
partially,7972,O
contribute,7972,O
to,7972,O
the,7972,O
synergic,7972,O
effect,7972,O
.,7972,O
Though,7973,O
FUR,7973,B-CHEMICAL
alone,7973,O
obviously,7973,O
induced,7973,O
endoplasmic,7973,O
reticulum,7973,O
stress,7973,O
",",7973,O
this,7973,O
signaling,7973,O
pathway,7973,O
may,7973,O
not,7973,O
contribute,7973,O
to,7973,O
the,7973,O
synergetic,7973,O
anti-proliferative,7973,O
effect,7973,O
as,7973,O
the,7973,O
protein,7973,O
expression,7973,O
of,7973,O
CHOP,7973,B-GENE-Y
and,7973,O
BIP,7973,B-GENE-Y
was,7973,O
similar,7973,O
in,7973,O
FUR,7973,B-CHEMICAL
alone,7973,O
and,7973,O
combined,7973,O
treatment,7973,O
group,7973,O
.,7973,O
Copyright,7974,O
©,7974,O
2013,7974,O
John,7974,O
Wiley,7974,O
&,7974,O
Sons,7974,O
",",7974,O
Ltd,7974,O
.,7974,O
The,7975,O
mechanisms,7975,O
responsible,7975,O
for,7975,O
garlic,7975,O
-,7975,O
drug,7975,O
interactions,7975,O
and,7975,O
their,7975,O
in,7975,O
vivo,7975,O
relevance,7975,O
.,7975,O
Garlic,7976,O
phytochemicals,7976,O
and,7976,O
garlic,7976,O
supplements,7976,O
influence,7976,O
the,7976,O
pharmacokinetic,7976,O
and,7976,O
pharmacodynamic,7976,O
behavior,7976,O
of,7976,O
concomitantly,7976,O
ingested,7976,O
drugs,7976,O
.,7976,O
In,7977,O
this,7977,O
paper,7977,O
we,7977,O
have,7977,O
summarized,7977,O
the,7977,O
mechanisms,7977,O
responsible,7977,O
for,7977,O
first-pass,7977,O
intestinal,7977,O
pharmacokinetic,7977,O
interactions,7977,O
by,7977,O
investigating,7977,O
the,7977,O
intestinal,7977,O
permeability,7977,O
of,7977,O
some,7977,O
cardiovascular,7977,O
",",7977,O
antiviral,7977,O
drugs,7977,O
",",7977,O
their,7977,O
transport,7977,O
with,7977,O
hepatic,7977,O
transporters,7977,O
and,7977,O
CYP3A4,7977,B-GENE-Y
metabolism,7977,O
.,7977,O
Transporter-enzyme,7978,O
interplay,7978,O
was,7978,O
studied,7978,O
with,7978,O
several,7978,O
in,7978,O
vitro,7978,O
models,7978,O
of,7978,O
varying,7978,O
complexity,7978,O
:,7978,O
rat,7978,O
small,7978,O
intestine,7978,O
and,7978,O
Caco-2,7978,O
cell,7978,O
monolayers,7978,O
were,7978,O
used,7978,O
in,7978,O
studies,7978,O
of,7978,O
intestinal,7978,O
processes,7978,O
",",7978,O
and,7978,O
hepatic,7978,O
pharmacokinetics,7978,O
was,7978,O
monitored,7978,O
in,7978,O
HepG2,7978,O
cells,7978,O
",",7978,O
isolated,7978,O
rat,7978,O
hepatocytes,7978,O
and,7978,O
rat,7978,O
liver,7978,O
slices,7978,O
.,7978,O
Garlic,7979,O
phytochemicals,7979,O
from,7979,O
aged,7979,O
garlic,7979,O
extract,7979,O
modified,7979,O
the,7979,O
activities,7979,O
of,7979,O
secretory,7979,O
and,7979,O
absorptive,7979,O
transporters,7979,O
in,7979,O
both,7979,O
intestine,7979,O
and,7979,O
liver,7979,O
and,7979,O
competitively,7979,O
inhibited,7979,O
CYP3A4,7979,B-GENE-Y
enzyme,7979,O
.,7979,O
The,7980,O
increased,7980,O
activities,7980,O
of,7980,O
the,7980,O
most,7980,O
important,7980,O
intestinal,7980,O
efflux,7980,O
(,7980,O
P-glycoprotein,7980,B-GENE-N
-,7980,O
Pgp,7980,B-GENE-N
",",7980,O
Multidrug,7980,B-GENE-Y
Resistance,7980,I-GENE-Y
Associated,7980,I-GENE-Y
Protein,7980,I-GENE-Y
2,7980,I-GENE-Y
-,7980,O
MRP-2,7980,B-GENE-Y
",",7980,O
Breast,7980,B-GENE-Y
Cancer,7980,I-GENE-Y
Resistance,7980,I-GENE-Y
Protein,7980,I-GENE-Y
-,7980,O
BCRP,7980,B-GENE-Y
),7980,O
and,7980,O
uptake,7980,O
(,7980,O
MonoCarboxylate,7980,B-GENE-Y
Transporter,7980,I-GENE-Y
1,7980,I-GENE-Y
-,7980,O
MCT1,7980,B-GENE-Y
",",7980,O
Organic,7980,B-GENE-N
Anion,7980,I-GENE-N
Transporting,7980,I-GENE-N
Polypeptide,7980,I-GENE-N
-,7980,O
OATP,7980,B-GENE-N
",",7980,O
Peptide,7980,B-GENE-Y
transporter,7980,I-GENE-Y
1,7980,I-GENE-Y
-,7980,O
PepT1,7980,B-GENE-Y
),7980,O
transporters,7980,O
were,7980,O
caused,7980,O
by,7980,O
changes,7980,O
in,7980,O
electrophysiological,7980,O
membrane,7980,O
properties,7980,O
and,7980,O
by,7980,O
allosteric,7980,O
modifications,7980,O
.,7980,O
Because,7981,O
clinical,7981,O
studies,7981,O
investigating,7981,O
interactions,7981,O
between,7981,O
garlic,7981,O
and,7981,O
human,7981,B-GENE-N
immunodeficiency,7981,I-GENE-N
virus,7981,I-GENE-N
protease,7981,I-GENE-N
inhibitors,7981,O
saquinavir,7981,B-CHEMICAL
and,7981,O
ritonavir,7981,B-CHEMICAL
have,7981,O
already,7981,O
been,7981,O
performed,7981,O
",",7981,O
we,7981,O
used,7981,O
these,7981,O
in,7981,O
vivo,7981,O
data,7981,O
to,7981,O
evaluate,7981,O
the,7981,O
in,7981,O
vitro,7981,O
results,7981,O
and,7981,O
the,7981,O
reliability,7981,O
of,7981,O
the,7981,O
models,7981,O
employed,7981,O
as,7981,O
screening,7981,O
tools,7981,O
for,7981,O
forecasting,7981,O
the,7981,O
potential,7981,O
of,7981,O
first-pass,7981,O
intestinal,7981,O
metabolism,7981,O
changes,7981,O
.,7981,O
We,7982,O
also,7982,O
assessed,7982,O
the,7982,O
probability,7982,O
of,7982,O
pharmacokinetic,7982,O
interactions,7982,O
with,7982,O
garlic,7982,O
of,7982,O
the,7982,O
novel,7982,O
drug,7982,O
darunavir,7982,B-CHEMICAL
and,7982,O
other,7982,O
cardiovascular,7982,O
drugs,7982,O
.,7982,O
Finally,7983,O
",",7983,O
selected,7983,O
garlic,7983,O
phytochemicals,7983,O
were,7983,O
tested,7983,O
for,7983,O
their,7983,O
ability,7983,O
to,7983,O
influence,7983,O
P-glycoprotein,7983,B-GENE-N
and,7983,O
CYP3A4,7983,B-GENE-Y
activities,7983,O
.,7983,O
The,7984,O
effects,7984,O
of,7984,O
labetalol,7984,B-CHEMICAL
and,7984,O
dilevalol,7984,B-CHEMICAL
on,7984,O
isolated,7984,O
cardiovascular,7984,O
preparations,7984,O
of,7984,O
the,7984,O
guinea-pig,7984,O
and,7984,O
rat,7984,O
.,7984,O
Differing,7985,O
effects,7985,O
of,7985,O
labetalol,7985,B-CHEMICAL
and,7985,O
dilevalol,7985,B-CHEMICAL
on,7985,O
cardiovascular,7985,O
preparations,7985,O
have,7985,O
been,7985,O
reported,7985,O
.,7985,O
I,7986,O
have,7986,O
studied,7986,O
the,7986,O
effects,7986,O
of,7986,O
labetalol,7986,B-CHEMICAL
and,7986,O
dilevalol,7986,B-CHEMICAL
on,7986,O
the,7986,O
contractile,7986,O
responses,7986,O
of,7986,O
the,7986,O
rat,7986,O
and,7986,O
guinea-pig,7986,O
left,7986,O
atria,7986,O
and,7986,O
rat,7986,O
portal,7986,O
vein,7986,O
.,7986,O
On,7987,O
the,7987,O
guinea-pig,7987,O
left,7987,O
atria,7987,O
low,7987,O
concentrations,7987,O
of,7987,O
labetalol,7987,B-CHEMICAL
(,7987,O
>,7987,O
or,7987,O
=,7987,O
10,7987,O
(,7987,O
-8,7987,O
),7987,O
M,7987,O
),7987,O
and,7987,O
of,7987,O
dilevalol,7987,B-CHEMICAL
(,7987,O
>,7987,O
or,7987,O
=,7987,O
10,7987,O
(,7987,O
-7,7987,O
),7987,O
M,7987,O
),7987,O
inhibited,7987,O
to,7987,O
a,7987,O
small,7987,O
extent,7987,O
the,7987,O
responses,7987,O
to,7987,O
electrical,7987,O
cardiac,7987,O
stimulation,7987,O
",",7987,O
which,7987,O
is,7987,O
indicative,7987,O
of,7987,O
membrane,7987,O
stabilizing,7987,O
activity,7987,O
.,7987,O
Labetalol,7988,B-CHEMICAL
(,7988,O
>,7988,O
or,7988,O
=,7988,O
3,7988,O
x,7988,O
10,7988,O
(,7988,O
-8,7988,O
),7988,O
M,7988,O
),7988,O
and,7988,O
dilevalol,7988,B-CHEMICAL
(,7988,O
>,7988,O
or,7988,O
=,7988,O
10,7988,O
(,7988,O
-8,7988,O
),7988,O
M,7988,O
),7988,O
caused,7988,O
surmountable,7988,O
antagonism,7988,O
of,7988,O
the,7988,O
isoprenaline,7988,B-CHEMICAL
responses,7988,O
of,7988,O
the,7988,O
atria,7988,O
and,7988,O
the,7988,O
pA2,7988,O
values,7988,O
were,7988,O
8.60,7988,O
and,7988,O
8.98,7988,O
at,7988,O
the,7988,O
beta,7988,B-GENE-N
1-adrenoceptors,7988,I-GENE-N
of,7988,O
the,7988,O
rat,7988,O
left,7988,O
atria,7988,O
and,7988,O
7.90,7988,O
and,7988,O
8.31,7988,O
",",7988,O
respectively,7988,O
",",7988,O
on,7988,O
the,7988,O
guinea-pig,7988,O
left,7988,O
atria,7988,O
which,7988,O
has,7988,O
functional,7988,O
beta,7988,B-GENE-N
1-,7988,I-GENE-N
and,7988,I-GENE-N
beta,7988,I-GENE-N
2-adrenoceptors,7988,I-GENE-N
.,7988,O
Labetalol,7989,B-CHEMICAL
and,7989,O
dilevalol,7989,B-CHEMICAL
(,7989,O
both,7989,O
at,7989,O
>,7989,O
or,7989,O
=,7989,O
10,7989,O
(,7989,O
-7,7989,O
),7989,O
M,7989,O
),7989,O
attenuated,7989,O
the,7989,O
spontaneous,7989,O
contractile,7989,O
activity,7989,O
of,7989,O
the,7989,O
rat,7989,O
portal,7989,O
vein,7989,O
and,7989,O
the,7989,O
attenuation,7989,O
to,7989,O
labetalol,7989,B-CHEMICAL
at,7989,O
10,7989,O
(,7989,O
-6,7989,O
),7989,O
M,7989,O
was,7989,O
abolished,7989,O
by,7989,O
ICI,7989,B-CHEMICAL
"118,551",7989,I-CHEMICAL
which,7989,O
illustrates,7989,O
that,7989,O
the,7989,O
labetalol-induced,7989,B-CHEMICAL
attenuation,7989,O
is,7989,O
beta,7989,B-GENE-Y
2-adrenoceptor,7989,I-GENE-Y
mediated,7989,O
.,7989,O
The,7990,O
isoprenaline,7990,B-CHEMICAL
attenuation,7990,O
responses,7990,O
of,7990,O
the,7990,O
portal,7990,O
vein,7990,O
were,7990,O
inhibited,7990,O
by,7990,O
labetalol,7990,B-CHEMICAL
and,7990,O
dilevalol,7990,B-CHEMICAL
(,7990,O
both,7990,O
at,7990,O
>,7990,O
or,7990,O
=,7990,O
10,7990,O
(,7990,O
-7,7990,O
),7990,O
M,7990,O
),7990,O
and,7990,O
the,7990,O
pA2,7990,O
value,7990,O
for,7990,O
the,7990,O
labetalol,7990,B-CHEMICAL
at,7990,O
beta,7990,B-GENE-N
2-adrenoceptors,7990,I-GENE-N
was,7990,O
7.59,7990,O
.,7990,O
It,7991,O
is,7991,O
concluded,7991,O
that,7991,O
labetalol,7991,B-CHEMICAL
and,7991,O
dilevalol,7991,B-CHEMICAL
are,7991,O
beta,7991,B-GENE-N
1-adrenoceptor,7991,I-GENE-N
selective,7991,O
antagonists,7991,O
.,7991,O
[,7992,O
Effect,7992,O
of,7992,O
mifepristone,7992,B-CHEMICAL
on,7992,O
the,7992,O
expression,7992,O
of,7992,O
progesterone,7992,B-GENE-Y
receptor,7992,I-GENE-Y
messenger,7992,O
RNA,7992,O
and,7992,O
protein,7992,O
in,7992,O
uterine,7992,O
leiomyomata,7992,O
],7992,O
.,7992,O
OBJECTIVE,7993,O
:,7993,O
To,7993,O
determine,7993,O
the,7993,O
expression,7993,O
of,7993,O
progesterone,7993,B-GENE-Y
receptor,7993,I-GENE-Y
(,7993,O
PR,7993,B-GENE-Y
),7993,O
mRNA,7993,O
and,7993,O
PR,7993,B-GENE-Y
protein,7993,I-GENE-Y
levels,7993,O
in,7993,O
the,7993,O
myometrium,7993,O
and,7993,O
leiomyomata,7993,O
from,7993,O
untreated,7993,O
and,7993,O
mifepristone,7993,B-CHEMICAL
pretreated,7993,O
women,7993,O
with,7993,O
leiomyoma,7993,O
and,7993,O
to,7993,O
examine,7993,O
the,7993,O
mechanism,7993,O
of,7993,O
mifepristone,7993,B-CHEMICAL
treatment,7993,O
on,7993,O
uterine,7993,O
leiomyomata,7993,O
.,7993,O
METHODS,7994,O
:,7994,O
Expression,7994,O
of,7994,O
PR,7994,B-GENE-N
mRNA,7994,I-GENE-N
and,7994,O
PR,7994,B-GENE-Y
protein,7994,I-GENE-Y
were,7994,O
determined,7994,O
by,7994,O
Northern,7994,O
blot,7994,O
and,7994,O
HAP,7994,O
of,7994,O
single-dose,7994,O
saturated,7994,O
analysis,7994,O
in,7994,O
myometrium,7994,O
and,7994,O
leiomyomata,7994,O
(,7994,O
center,7994,O
and,7994,O
marginal,7994,O
area,7994,O
),7994,O
from,7994,O
27,7994,O
untreated,7994,O
and,7994,O
6,7994,O
mifepristone,7994,B-CHEMICAL
pretreated,7994,O
women,7994,O
with,7994,O
leiomyomata,7994,O
.,7994,O
RESULTS,7995,O
:,7995,O
PR,7995,B-GENE-N
mRNA,7995,I-GENE-N
abundance,7995,O
and,7995,O
PR,7995,B-GENE-Y
protein,7995,I-GENE-Y
levels,7995,O
in,7995,O
both,7995,O
myomatous,7995,O
center,7995,O
and,7995,O
marginal,7995,O
area,7995,O
were,7995,O
significantly,7995,O
greater,7995,O
than,7995,O
those,7995,O
in,7995,O
corporal,7995,O
myometrium,7995,O
(,7995,O
P,7995,O
<,7995,O
0.01,7995,O
),7995,O
in,7995,O
both,7995,O
follicular,7995,O
and,7995,O
luteal,7995,O
phases,7995,O
",",7995,O
but,7995,O
similar,7995,O
between,7995,O
myomatous,7995,O
center,7995,O
and,7995,O
marginal,7995,O
area,7995,O
(,7995,O
P,7995,O
>,7995,O
0.05,7995,O
),7995,O
.,7995,O
6,7996,O
cases,7996,O
pretreated,7996,O
with,7996,O
mifepristone,7996,B-CHEMICAL
25,7996,O
mg/day,7996,O
for,7996,O
3,7996,O
months,7996,O
were,7996,O
operated,7996,O
",",7996,O
all,7996,O
but,7996,O
one,7996,O
patient,7996,O
displayed,7996,O
a,7996,O
decrease,7996,O
in,7996,O
leiomyomata,7996,O
volume,7996,O
.,7996,O
PR,7997,B-GENE-N
mRNA,7997,I-GENE-N
abundance,7997,O
in,7997,O
both,7997,O
myometruim,7997,O
and,7997,O
leiomyomata,7997,O
(,7997,O
center,7997,O
and,7997,O
marginal,7997,O
area,7997,O
),7997,O
was,7997,O
significantly,7997,O
decreased,7997,O
in,7997,O
4,7997,O
patients,7997,O
continuing,7997,O
mifepristone,7997,B-CHEMICAL
treatment,7997,O
before,7997,O
the,7997,O
operation,7997,O
but,7997,O
not,7997,O
in,7997,O
the,7997,O
other,7997,O
2,7997,O
patients,7997,O
stopping,7997,O
RU486,7997,B-CHEMICAL
1,7997,O
month,7997,O
before,7997,O
operation,7997,O
.,7997,O
PR,7998,B-GENE-Y
protein,7998,I-GENE-Y
levels,7998,O
in,7998,O
these,7998,O
tissues,7998,O
showed,7998,O
significant,7998,O
decrease,7998,O
in,7998,O
all,7998,O
6,7998,O
cases,7998,O
.,7998,O
CONCLUSION,7999,O
:,7999,O
There,7999,O
are,7999,O
overexpression,7999,O
of,7999,O
PRmRNA,7999,B-GENE-N
and,7999,O
PR,7999,B-GENE-Y
protein,7999,I-GENE-Y
in,7999,O
leiomyomata,7999,O
.,7999,O
One,8000,O
of,8000,O
the,8000,O
mechanism,8000,O
of,8000,O
mifepristone,8000,B-CHEMICAL
action,8000,O
on,8000,O
decreasing,8000,O
leiomyomata,8000,O
volume,8000,O
may,8000,O
be,8000,O
related,8000,O
to,8000,O
suppression,8000,O
on,8000,O
expression,8000,O
of,8000,O
PR,8000,B-GENE-Y
gene,8000,I-GENE-Y
.,8000,O
It,8001,O
seems,8001,O
that,8001,O
suppression,8001,O
on,8001,O
transcription,8001,O
of,8001,O
PR,8001,B-GENE-Y
gene,8001,I-GENE-Y
is,8001,O
reversible,8001,O
",",8001,O
but,8001,O
on,8001,O
translation,8001,O
of,8001,O
PR,8001,B-GENE-Y
gene,8001,I-GENE-Y
may,8001,O
maintain,8001,O
in,8001,O
a,8001,O
relatively,8001,O
longer,8001,O
period,8001,O
.,8001,O
Accumulation,8002,O
of,8002,O
cystathionine,8002,B-CHEMICAL
",",8002,O
cystathionine,8002,B-CHEMICAL
ketimine,8002,I-CHEMICAL
",",8002,O
and,8002,O
"perhydro-1,4-thiazepine-3,5-dicarboxylic",8002,B-CHEMICAL
acid,8002,I-CHEMICAL
in,8002,O
whole,8002,O
brain,8002,O
and,8002,O
various,8002,O
regions,8002,O
of,8002,O
the,8002,O
brain,8002,O
of,8002,O
D,8002,B-CHEMICAL
",",8002,I-CHEMICAL
L-propargylglycine-treated,8002,O
rats,8002,O
.,8002,O
Experimental,8003,O
cystathioninuria,8003,O
was,8003,O
induced,8003,O
in,8003,O
rats,8003,O
by,8003,O
administration,8003,O
of,8003,O
the,8003,O
cystathionine,8003,B-GENE-Y
gamma-lyase,8003,I-GENE-Y
inhibitor,8003,O
",",8003,O
D,8003,B-CHEMICAL
",",8003,I-CHEMICAL
L-propargylglycine,8003,I-CHEMICAL
.,8003,O
The,8004,O
cystathionine,8004,B-CHEMICAL
metabolites,8004,O
",",8004,O
cystathionine,8004,B-CHEMICAL
ketimine,8004,I-CHEMICAL
(,8004,O
CK,8004,B-CHEMICAL
),8004,O
and,8004,O
"perhydro-1,4-thiazepine-3,5-dicarboxylic",8004,B-CHEMICAL
acid,8004,I-CHEMICAL
(,8004,O
PHTZDC,8004,B-CHEMICAL
),8004,O
",",8004,O
were,8004,O
identified,8004,O
in,8004,O
whole,8004,O
brain,8004,O
and,8004,O
various,8004,O
regions,8004,O
of,8004,O
the,8004,O
brain,8004,O
in,8004,O
D,8004,B-CHEMICAL
",",8004,I-CHEMICAL
L-propargylglycine-treated,8004,O
rats,8004,O
.,8004,O
The,8005,O
concentration,8005,O
of,8005,O
CK,8005,B-CHEMICAL
and,8005,O
PHTZDC,8005,B-CHEMICAL
in,8005,O
whole,8005,O
brain,8005,O
and,8005,O
various,8005,O
regions,8005,O
of,8005,O
the,8005,O
brain,8005,O
increased,8005,O
gradually,8005,O
after,8005,O
administration,8005,O
of,8005,O
D,8005,B-CHEMICAL
",",8005,I-CHEMICAL
L-propargylglycine,8005,I-CHEMICAL
",",8005,O
and,8005,O
reached,8005,O
the,8005,O
highest,8005,O
value,8005,O
at,8005,O
about,8005,O
20,8005,O
hours,8005,O
.,8005,O
CK,8006,B-CHEMICAL
and,8006,O
PHTZDC,8006,B-CHEMICAL
accumulated,8006,O
in,8006,O
whole,8006,O
brain,8006,O
and,8006,O
various,8006,O
regions,8006,O
of,8006,O
the,8006,O
brain,8006,O
in,8006,O
proportion,8006,O
to,8006,O
the,8006,O
amount,8006,O
of,8006,O
accumulated,8006,O
cystathionine,8006,O
after,8006,O
D,8006,B-CHEMICAL
",",8006,I-CHEMICAL
L-propargylglycine,8006,I-CHEMICAL
administration,8006,O
.,8006,O
The,8007,O
concentration,8007,O
of,8007,O
these,8007,O
compounds,8007,O
in,8007,O
the,8007,O
cerebellum,8007,O
was,8007,O
higher,8007,O
versus,8007,O
the,8007,O
other,8007,O
regions,8007,O
of,8007,O
the,8007,O
rat,8007,O
brain,8007,O
.,8007,O
Changes,8008,O
in,8008,O
A1C,8008,B-GENE-Y
Levels,8008,O
Are,8008,O
Significantly,8008,O
Associated,8008,O
With,8008,O
Changes,8008,O
in,8008,O
Levels,8008,O
of,8008,O
the,8008,O
Cardiovascular,8008,O
Risk,8008,O
Biomarker,8008,O
hs-CRP,8008,B-GENE-Y
:,8008,O
Results,8008,O
from,8008,O
SteP,8008,O
Study,8008,O
.,8008,O
OBJECTIVEThe,8009,O
effect,8009,O
of,8009,O
therapeutic,8009,O
strategies,8009,O
on,8009,O
cardiovascular,8009,O
(,8009,O
CV,8009,O
),8009,O
disease,8009,O
can,8009,O
be,8009,O
evaluated,8009,O
by,8009,O
monitoring,8009,O
changes,8009,O
in,8009,O
CV,8009,O
risk,8009,O
biomarkers,8009,O
.,8009,O
This,8010,O
study,8010,O
investigated,8010,O
the,8010,O
effect,8010,O
of,8010,O
a,8010,O
structured,8010,O
self-monitoring,8010,O
of,8010,O
blood,8010,O
glucose,8010,B-CHEMICAL
(,8010,O
SMBG,8010,O
),8010,O
protocol,8010,O
and,8010,O
the,8010,O
resulting,8010,O
improvements,8010,O
in,8010,O
glycemic,8010,O
control,8010,O
on,8010,O
changes,8010,O
in,8010,O
high-sensitivity,8010,O
C-reactive,8010,B-GENE-Y
protein,8010,I-GENE-Y
(,8010,O
hs-CRP,8010,B-GENE-Y
),8010,O
in,8010,O
insulin-naïve,8010,B-GENE-Y
patients,8010,O
with,8010,O
type,8010,O
2,8010,O
diabetes.RESEARCH,8010,O
DESIGN,8010,O
AND,8010,O
METHODSThe,8010,O
Structured,8010,O
Testing,8010,O
Program,8010,O
(,8010,O
STeP,8010,O
),8010,O
study,8010,O
was,8010,O
a,8010,O
prospective,8010,O
",",8010,O
cluster-randomized,8010,O
",",8010,O
multicenter,8010,O
trial,8010,O
in,8010,O
which,8010,O
483,8010,O
poorly,8010,O
controlled,8010,O
",",8010,O
insulin-naïve,8010,B-GENE-Y
patients,8010,O
with,8010,O
type,8010,O
2,8010,O
diabetes,8010,O
were,8010,O
randomized,8010,O
to,8010,O
active,8010,O
control,8010,O
(,8010,O
ACG,8010,O
),8010,O
or,8010,O
structured,8010,O
testing,8010,O
(,8010,O
STG,8010,O
),8010,O
that,8010,O
included,8010,O
quarterly,8010,O
structured,8010,O
SMBG,8010,O
.,8010,O
Changes,8011,O
in,8011,O
A1C,8011,B-GENE-Y
",",8011,O
hs-CRP,8011,B-GENE-Y
",",8011,O
and,8011,O
glycemic,8011,O
variability,8011,O
(,8011,O
STG,8011,O
subjects,8011,O
only,8011,O
),8011,O
were,8011,O
measured,8011,O
at,8011,O
baseline,8011,O
and,8011,O
quarterly.RESULTSReductions,8011,O
in,8011,O
geometric,8011,O
mean,8011,O
hs-CRP,8011,B-GENE-Y
values,8011,O
were,8011,O
significantly,8011,O
greater,8011,O
in,8011,O
the,8011,O
STG,8011,O
group,8011,O
at,8011,O
months,8011,O
3,8011,O
(,8011,O
P,8011,O
=,8011,O
0.005,8011,O
),8011,O
",",8011,O
6,8011,O
(,8011,O
P,8011,O
=,8011,O
0.0003,8011,O
),8011,O
",",8011,O
and,8011,O
12,8011,O
(,8011,O
P,8011,O
=,8011,O
0.04,8011,O
),8011,O
than,8011,O
in,8011,O
the,8011,O
ACG,8011,O
group,8011,O
.,8011,O
STG,8012,O
patients,8012,O
at,8012,O
high,8012,O
CV,8012,O
risk,8012,O
(,8012,O
>,8012,O
3,8012,O
mg/L,8012,O
),8012,O
showed,8012,O
significantly,8012,O
greater,8012,O
reductions,8012,O
in,8012,O
hs-CRP,8012,B-GENE-Y
levels,8012,O
than,8012,O
ACG,8012,O
patients,8012,O
at,8012,O
high,8012,O
CV,8012,O
risk,8012,O
:,8012,O
-3.64,8012,O
mg/dL,8012,O
(,8012,O
95,8012,O
%,8012,O
CI,8012,O
-4.21,8012,O
to,8012,O
-3.06,8012,O
),8012,O
versus,8012,O
-2.18,8012,O
mg/dL,8012,O
(,8012,O
-2.93,8012,O
to,8012,O
-1.43,8012,O
),8012,O
",",8012,O
respectively,8012,O
(,8012,O
P,8012,O
=,8012,O
0.002,8012,O
),8012,O
.,8012,O
There,8013,O
was,8013,O
a,8013,O
strong,8013,O
correlation,8013,O
between,8013,O
reductions,8013,O
in,8013,O
hs-CRP,8013,B-GENE-Y
and,8013,O
A1C,8013,B-GENE-Y
in,8013,O
both,8013,O
groups,8013,O
:,8013,O
standardized,8013,O
coefficient,8013,O
(,8013,O
β,8013,O
),8013,O
was,8013,O
0.25,8013,O
for,8013,O
the,8013,O
entire,8013,O
cohort,8013,O
(,8013,O
P,8013,O
<,8013,O
0.0001,8013,O
),8013,O
",",8013,O
0.31,8013,O
for,8013,O
STG,8013,O
(,8013,O
P,8013,O
<,8013,O
0.0001,8013,O
),8013,O
",",8013,O
and,8013,O
0.16,8013,O
for,8013,O
ACG,8013,O
(,8013,O
P,8013,O
=,8013,O
0.02,8013,O
),8013,O
.CONCLUSIONSReductions,8013,O
in,8013,O
hs-CRP,8013,B-GENE-Y
level,8013,O
are,8013,O
associated,8013,O
with,8013,O
reductions,8013,O
in,8013,O
A1C,8013,B-GENE-Y
but,8013,O
not,8013,O
reductions,8013,O
in,8013,O
lipids,8013,O
or,8013,O
glycemic,8013,O
variability,8013,O
.,8013,O
Comprehensive,8014,O
structured,8014,O
SMBG-based,8014,O
interventions,8014,O
that,8014,O
lower,8014,O
A1C,8014,B-GENE-Y
may,8014,O
translate,8014,O
into,8014,O
improvements,8014,O
in,8014,O
CV,8014,O
risk,8014,O
",",8014,O
as,8014,O
evidenced,8014,O
by,8014,O
levels,8014,O
of,8014,O
the,8014,O
biomarker,8014,O
hs-CRP,8014,B-GENE-Y
.,8014,O
Adenosine,8015,B-GENE-N
receptor,8015,I-GENE-N
antagonists,8015,O
intensify,8015,O
the,8015,O
benzodiazepine,8015,B-CHEMICAL
withdrawal,8015,O
signs,8015,O
in,8015,O
mice,8015,O
.,8015,O
The,8016,O
aim,8016,O
of,8016,O
the,8016,O
present,8016,O
experiment,8016,O
was,8016,O
to,8016,O
assess,8016,O
the,8016,O
involvement,8016,O
of,8016,O
adenosine,8016,B-GENE-N
receptor,8016,I-GENE-N
antagonists,8016,O
in,8016,O
benzodiazepine,8016,B-CHEMICAL
(,8016,O
BDZ,8016,B-CHEMICAL
),8016,O
withdrawal,8016,O
signs,8016,O
",",8016,O
observed,8016,O
as,8016,O
the,8016,O
seizure,8016,O
susceptibility,8016,O
in,8016,O
mice,8016,O
.,8016,O
The,8017,O
discontinuation,8017,O
of,8017,O
chronic,8017,O
treatment,8017,O
with,8017,O
temazepam,8017,B-CHEMICAL
or,8017,O
diazepam,8017,B-CHEMICAL
decreased,8017,O
seizure,8017,O
threshold,8017,O
(,8017,O
one,8017,O
of,8017,O
BDZ,8017,B-CHEMICAL
withdrawal,8017,O
signs,8017,O
),8017,O
.,8017,O
The,8018,O
concomitant,8018,O
application,8018,O
of,8018,O
subconvulsive,8018,O
dose,8018,O
of,8018,O
pentetrazole,8018,B-CHEMICAL
(,8018,O
55.0,8018,O
mg/kg,8018,O
),8018,O
with,8018,O
low,8018,O
dose,8018,O
of,8018,O
flumazenil,8018,B-CHEMICAL
(,8018,O
5.0,8018,O
mg/kg,8018,O
),8018,O
-,8018,O
a,8018,O
BDZ,8018,B-GENE-N
receptor,8018,I-GENE-N
antagonist,8018,O
",",8018,O
immediately,8018,O
induced,8018,O
BDZ,8018,B-CHEMICAL
withdrawal,8018,O
signs,8018,O
in,8018,O
these,8018,O
animals,8018,O
.,8018,O
The,8019,O
non-selective,8019,O
adenosine,8019,B-GENE-N
receptor,8019,I-GENE-N
antagonist,8019,O
(,8019,O
caffeine,8019,B-CHEMICAL
),8019,O
",",8019,O
and,8019,O
the,8019,O
selective,8019,O
adenosine,8019,B-GENE-Y
A1,8019,I-GENE-Y
receptor,8019,I-GENE-Y
antagonist,8019,O
(,8019,O
DPCPX,8019,B-CHEMICAL
),8019,O
",",8019,O
injected,8019,O
15,8019,O
min,8019,O
before,8019,O
the,8019,O
application,8019,O
of,8019,O
pentetrazole,8019,B-CHEMICAL
and,8019,O
flumazenil,8019,B-CHEMICAL
",",8019,O
were,8019,O
able,8019,O
to,8019,O
intensify,8019,O
BDZ,8019,B-CHEMICAL
withdrawal,8019,O
signs,8019,O
in,8019,O
mice,8019,O
.,8019,O
The,8020,O
most,8020,O
apparent,8020,O
effects,8020,O
were,8020,O
observed,8020,O
after,8020,O
administration,8020,O
of,8020,O
DPCPX,8020,B-CHEMICAL
",",8020,O
indicating,8020,O
that,8020,O
the,8020,O
adenosine,8020,B-GENE-Y
A1,8020,I-GENE-Y
receptor,8020,I-GENE-Y
may,8020,O
play,8020,O
a,8020,O
more,8020,O
important,8020,O
role,8020,O
in,8020,O
these,8020,O
effects,8020,O
.,8020,O
The,8021,O
obtained,8021,O
data,8021,O
demonstrate,8021,O
that,8021,O
the,8021,O
adenosinergic,8021,O
system,8021,O
is,8021,O
involved,8021,O
in,8021,O
BDZ,8021,B-CHEMICAL
withdrawal,8021,O
signs,8021,O
in,8021,O
mice,8021,O
",",8021,O
and,8021,O
adenosine,8021,B-GENE-Y
A1,8021,I-GENE-Y
receptor,8021,I-GENE-Y
plays,8021,O
an,8021,O
important,8021,O
role,8021,O
in,8021,O
this,8021,O
process,8021,O
.,8021,O
Cross-inhibition,8022,O
of,8022,O
SR-BI-,8022,B-GENE-Y
and,8022,O
ABCA1-mediated,8022,B-GENE-Y
cholesterol,8022,B-CHEMICAL
transport,8022,O
by,8022,O
the,8022,O
small,8022,O
molecules,8022,O
BLT-4,8022,O
and,8022,O
glyburide,8022,B-CHEMICAL
.,8022,O
Scavenger,8023,B-GENE-Y
receptor,8023,I-GENE-Y
class,8023,I-GENE-Y
B,8023,I-GENE-Y
type,8023,I-GENE-Y
I,8023,I-GENE-Y
(,8023,O
SR-BI,8023,B-GENE-Y
),8023,O
and,8023,O
ABCA1,8023,B-GENE-N
are,8023,O
structurally,8023,O
dissimilar,8023,O
cell,8023,O
surface,8023,O
proteins,8023,O
that,8023,O
play,8023,O
key,8023,O
roles,8023,O
in,8023,O
HDL,8023,B-GENE-N
metabolism,8023,O
.,8023,O
SR-BI,8024,B-GENE-Y
is,8024,O
a,8024,O
receptor,8024,O
that,8024,O
binds,8024,O
HDL,8024,B-GENE-N
with,8024,O
high,8024,O
affinity,8024,O
and,8024,O
mediates,8024,O
both,8024,O
the,8024,O
selective,8024,O
lipid,8024,O
uptake,8024,O
of,8024,O
cholesteryl,8024,B-CHEMICAL
esters,8024,I-CHEMICAL
from,8024,O
lipid-rich,8024,O
HDL,8024,B-GENE-N
to,8024,O
cells,8024,O
and,8024,O
the,8024,O
efflux,8024,O
of,8024,O
unesterified,8024,O
cholesterol,8024,B-CHEMICAL
from,8024,O
cells,8024,O
to,8024,O
HDL,8024,B-GENE-N
.,8024,O
ABCA1,8025,B-GENE-Y
mediates,8025,O
the,8025,O
efflux,8025,O
of,8025,O
unesterified,8025,O
cholesterol,8025,B-CHEMICAL
and,8025,O
phospholipids,8025,O
from,8025,O
cells,8025,O
to,8025,O
lipid-poor,8025,O
apolipoprotein,8025,B-GENE-Y
A-I,8025,I-GENE-Y
(,8025,O
apoA-I,8025,B-GENE-Y
),8025,O
.,8025,O
The,8026,O
activities,8026,O
of,8026,O
ABCA1,8026,B-GENE-Y
and,8026,O
other,8026,O
ATP,8026,B-GENE-N
binding,8026,I-GENE-N
cassette,8026,I-GENE-N
superfamily,8026,I-GENE-N
members,8026,O
are,8026,O
inhibited,8026,O
by,8026,O
the,8026,O
drug,8026,O
glyburide,8026,B-CHEMICAL
",",8026,O
and,8026,O
SR-BI-mediated,8026,B-GENE-Y
lipid,8026,O
transport,8026,O
is,8026,O
blocked,8026,O
by,8026,O
small,8026,O
molecule,8026,O
inhibitors,8026,O
called,8026,O
BLTs,8026,O
.,8026,O
Here,8027,O
",",8027,O
we,8027,O
show,8027,O
that,8027,O
one,8027,O
BLT,8027,B-CHEMICAL
",",8027,O
[,8027,O
1-,8027,B-CHEMICAL
(,8027,I-CHEMICAL
2-methoxy-phenyl,8027,I-CHEMICAL
),8027,I-CHEMICAL
-3-naphthalen-2-yl-urea,8027,I-CHEMICAL
],8027,O
(,8027,O
BLT-4,8027,B-CHEMICAL
),8027,O
",",8027,O
blocked,8027,O
ABCA1-mediated,8027,B-GENE-Y
cholesterol,8027,B-CHEMICAL
efflux,8027,O
to,8027,O
lipid-poor,8027,O
apoA-I,8027,B-GENE-Y
at,8027,O
a,8027,O
potency,8027,O
similar,8027,O
to,8027,O
that,8027,O
for,8027,O
its,8027,O
inhibition,8027,O
of,8027,O
SR-BI,8027,B-GENE-Y
(,8027,O
IC,8027,O
(,8027,O
50,8027,O
),8027,O
approximately,8027,O
55-60,8027,O
microM,8027,O
),8027,O
.,8027,O
Reciprocally,8028,O
",",8028,O
glyburide,8028,B-CHEMICAL
blocked,8028,O
SR-BI-mediated,8028,B-GENE-Y
selective,8028,O
lipid,8028,O
uptake,8028,O
and,8028,O
efflux,8028,O
at,8028,O
a,8028,O
potency,8028,O
similar,8028,O
to,8028,O
that,8028,O
for,8028,O
its,8028,O
inhibition,8028,O
of,8028,O
ABCA1,8028,B-GENE-Y
(,8028,O
IC,8028,O
(,8028,O
50,8028,O
),8028,O
approximately,8028,O
275-300,8028,O
microM,8028,O
),8028,O
.,8028,O
As,8029,O
is,8029,O
the,8029,O
case,8029,O
with,8029,O
BLTs,8029,O
",",8029,O
glyburide,8029,B-CHEMICAL
increased,8029,O
the,8029,O
apparent,8029,O
affinity,8029,O
of,8029,O
HDL,8029,B-GENE-N
binding,8029,O
to,8029,O
SR-BI,8029,B-GENE-Y
.,8029,O
The,8030,O
reciprocal,8030,O
inhibition,8030,O
of,8030,O
SR-BI,8030,B-GENE-Y
and,8030,O
ABCA1,8030,B-GENE-Y
by,8030,O
BLT-4,8030,O
and,8030,O
glyburide,8030,B-CHEMICAL
raises,8030,O
the,8030,O
possibility,8030,O
that,8030,O
these,8030,O
proteins,8030,O
may,8030,O
share,8030,O
similar,8030,O
or,8030,O
common,8030,O
steps,8030,O
in,8030,O
their,8030,O
mechanisms,8030,O
of,8030,O
lipid,8030,O
transport,8030,O
.,8030,O
Protective,8031,O
effect,8031,O
of,8031,O
butylated,8031,B-CHEMICAL
hydroxytoluene,8031,I-CHEMICAL
on,8031,O
ferric,8031,B-CHEMICAL
nitrilotriacetate,8031,I-CHEMICAL
induced,8031,O
hepatotoxicity,8031,O
and,8031,O
oxidative,8031,O
stress,8031,O
in,8031,O
mice,8031,O
.,8031,O
The,8032,O
present,8032,O
study,8032,O
was,8032,O
undertaken,8032,O
to,8032,O
evaluate,8032,O
the,8032,O
possible,8032,O
ameliorating,8032,O
effect,8032,O
of,8032,O
butylated,8032,B-CHEMICAL
hydroxyl,8032,I-CHEMICAL
toluene,8032,I-CHEMICAL
(,8032,O
BHT,8032,B-CHEMICAL
),8032,O
",",8032,O
associated,8032,O
with,8032,O
ferric,8032,B-CHEMICAL
nitrilotriacetate,8032,I-CHEMICAL
(,8032,O
Fe-NTA,8032,B-CHEMICAL
),8032,O
-induced,8032,O
oxidative,8032,O
stress,8032,O
and,8032,O
liver,8032,O
injury,8032,O
in,8032,O
mice,8032,O
.,8032,O
The,8033,O
treatment,8033,O
of,8033,O
mice,8033,O
with,8033,O
Fe-NTA,8033,B-CHEMICAL
alone,8033,O
enhances,8033,O
ornithine,8033,B-GENE-Y
decarboxylase,8033,I-GENE-Y
activity,8033,O
to,8033,O
4.6,8033,O
folds,8033,O
",",8033,O
protein,8033,O
carbonyl,8033,B-CHEMICAL
formation,8033,O
increased,8033,O
up,8033,O
to,8033,O
2.9,8033,O
folds,8033,O
and,8033,O
DNA,8033,O
synthesis,8033,O
expressed,8033,O
in,8033,O
terms,8033,O
of,8033,O
[,8033,B-CHEMICAL
(,8033,I-CHEMICAL
3,8033,I-CHEMICAL
),8033,I-CHEMICAL
H,8033,I-CHEMICAL
],8033,I-CHEMICAL
thymidine,8033,I-CHEMICAL
incorporation,8033,O
increased,8033,O
to,8033,O
3.2,8033,O
folds,8033,O
",",8033,O
and,8033,O
antioxidants,8033,O
and,8033,O
antioxidant,8033,O
enzymes,8033,O
decreased,8033,O
to,8033,O
1.8-2.5,8033,O
folds,8033,O
",",8033,O
compared,8033,O
with,8033,O
the,8033,O
corresponding,8033,O
saline-treated,8033,O
controls,8033,O
.,8033,O
These,8034,O
changes,8034,O
were,8034,O
reversed,8034,O
significantly,8034,O
(,8034,O
p,8034,O
<,8034,O
0.001,8034,O
),8034,O
in,8034,O
animals,8034,O
receiving,8034,O
a,8034,O
pretreatment,8034,O
of,8034,O
BHT,8034,B-CHEMICAL
.,8034,O
Our,8035,O
data,8035,O
show,8035,O
that,8035,O
BHT,8035,B-CHEMICAL
can,8035,O
reciprocate,8035,O
the,8035,O
toxic,8035,O
effects,8035,O
of,8035,O
Fe-NTA,8035,B-CHEMICAL
and,8035,O
can,8035,O
serve,8035,O
as,8035,O
a,8035,O
potent,8035,O
chemopreventive,8035,O
agent,8035,O
.,8035,O
AKRs,8036,B-GENE-N
expression,8036,O
in,8036,O
peripheral,8036,O
blood,8036,O
lymphocytes,8036,O
from,8036,O
smokers,8036,O
:,8036,O
The,8036,O
role,8036,O
of,8036,O
body,8036,O
mass,8036,O
index,8036,O
.,8036,O
Aldo-keto,8037,B-GENE-N
reductases,8037,I-GENE-N
(,8037,O
AKRs,8037,B-GENE-N
),8037,O
metabolize,8037,O
a,8037,O
wide,8037,O
range,8037,O
of,8037,O
substrates,8037,O
",",8037,O
including,8037,O
polycyclic,8037,B-CHEMICAL
aromatic,8037,I-CHEMICAL
hydrocarbons,8037,I-CHEMICAL
(,8037,O
PAHs,8037,B-CHEMICAL
),8037,O
",",8037,O
generating,8037,O
metabolites,8037,O
(,8037,O
o-quinones,8037,B-CHEMICAL
),8037,O
and,8037,O
reactive,8037,O
oxygen,8037,B-CHEMICAL
species,8037,O
(,8037,O
ROS,8037,O
),8037,O
",",8037,O
which,8037,O
are,8037,O
capable,8037,O
of,8037,O
initiating,8037,O
and,8037,O
promoting,8037,O
carcinogenesis,8037,O
.,8037,O
Exposure,8038,O
to,8038,O
PAHs,8038,B-CHEMICAL
",",8038,O
their,8038,O
metabolites,8038,O
",",8038,O
and,8038,O
ROS,8038,O
further,8038,O
increase,8038,O
AKRs,8038,B-GENE-N
isoform,8038,O
expression,8038,O
that,8038,O
may,8038,O
amplify,8038,O
oxidative,8038,O
damage,8038,O
.,8038,O
Human,8039,B-GENE-N
AKR,8039,I-GENE-N
enzymes,8039,O
are,8039,O
highly,8039,O
polymorphic,8039,O
",",8039,O
and,8039,O
allelic,8039,O
variants,8039,O
may,8039,O
contribute,8039,O
to,8039,O
different,8039,O
AKRs,8039,B-GENE-N
expression,8039,O
in,8039,O
individuals,8039,O
.,8039,O
Despite,8040,O
the,8040,O
importance,8040,O
of,8040,O
AKRs,8040,B-GENE-N
in,8040,O
PAHs,8040,B-CHEMICAL
metabolism,8040,O
",",8040,O
there,8040,O
are,8040,O
no,8040,O
studies,8040,O
that,8040,O
evaluate,8040,O
",",8040,O
in,8040,O
general,8040,O
human,8040,O
populations,8040,O
",",8040,O
the,8040,O
effect,8040,O
of,8040,O
PAHs,8040,B-CHEMICAL
on,8040,O
AKRs,8040,B-GENE-N
expression,8040,O
in,8040,O
peripheral,8040,O
blood,8040,O
lymphocytes,8040,O
(,8040,O
PBLs,8040,O
),8040,O
.,8040,O
The,8041,O
aim,8041,O
of,8041,O
this,8041,O
study,8041,O
was,8041,O
to,8041,O
determine,8041,O
the,8041,O
effect,8041,O
of,8041,O
tobacco,8041,O
smoke,8041,O
exposure,8041,O
",",8041,O
and,8041,O
AKR1A1,8041,B-GENE-Y
*,8041,I-GENE-Y
2,8041,I-GENE-Y
and,8041,O
AKR1C3,8041,B-GENE-Y
*,8041,I-GENE-Y
2,8041,I-GENE-Y
polymorphisms,8041,O
",",8041,O
on,8041,O
AKR1A1,8041,B-GENE-Y
and,8041,O
AKR1C1-AKR1C3,8041,B-GENE-Y
messenger,8041,O
RNA,8041,O
(,8041,O
mRNA,8041,O
),8041,O
levels,8041,O
in,8041,O
PBLs,8041,O
from,8041,O
smokers,8041,O
.,8041,O
In,8042,O
the,8042,O
smoker,8042,O
group,8042,O
",",8042,O
there,8042,O
is,8042,O
a,8042,O
statistically,8042,O
significant,8042,O
positive,8042,O
association,8042,O
between,8042,O
AKR1A1,8042,B-GENE-Y
",",8042,O
AKR1C1,8042,B-GENE-Y
",",8042,O
and,8042,O
AKR1C3,8042,B-GENE-Y
mRNA,8042,O
induction,8042,O
and,8042,O
urine,8042,O
cotinine,8042,B-CHEMICAL
levels,8042,O
in,8042,O
individuals,8042,O
with,8042,O
a,8042,O
body,8042,O
mass,8042,O
index,8042,O
(,8042,O
BMI,8042,O
),8042,O
less,8042,O
than,8042,O
25,8042,O
.,8042,O
However,8043,O
",",8043,O
AKR1A1,8043,B-GENE-Y
*,8043,I-GENE-Y
2,8043,I-GENE-Y
and,8043,O
AKR1C3,8043,B-GENE-Y
*,8043,I-GENE-Y
2,8043,I-GENE-Y
alleles,8043,O
did,8043,O
not,8043,O
influence,8043,O
AKR1A1,8043,B-GENE-Y
and,8043,O
AKR1C1-AKR1C3,8043,B-GENE-Y
mRNA,8043,O
levels,8043,O
.,8043,O
These,8044,O
results,8044,O
suggest,8044,O
that,8044,O
AKRs,8044,B-GENE-N
induction,8044,O
by,8044,O
PAHs,8044,B-CHEMICAL
in,8044,O
smokers,8044,O
',8044,O
PBLs,8044,O
is,8044,O
associated,8044,O
with,8044,O
BMI,8044,O
;,8044,O
therefore,8044,O
",",8044,O
the,8044,O
role,8044,O
of,8044,O
adipose,8044,O
tissue,8044,O
accumulation,8044,O
in,8044,O
PAHs,8044,B-CHEMICAL
',8044,O
effects,8044,O
needs,8044,O
further,8044,O
investigation,8044,O
.,8044,O
Administration,8045,O
of,8045,O
the,8045,O
optimized,8045,O
β-Lapachone-poloxamer-cyclodextrin,8045,B-CHEMICAL
ternary,8045,O
system,8045,O
induces,8045,O
apoptosis,8045,O
",",8045,O
DNA,8045,O
damage,8045,O
and,8045,O
reduces,8045,O
tumor,8045,O
growth,8045,O
in,8045,O
a,8045,O
human,8045,O
breast,8045,O
adenocarcinoma,8045,O
xenograft,8045,O
mouse,8045,O
model,8045,O
.,8045,O
β-Lapachone,8046,B-CHEMICAL
(,8046,O
β-Lap,8046,B-CHEMICAL
),8046,O
is,8046,O
a,8046,O
"1,2-orthonaphthoquinone",8046,B-CHEMICAL
that,8046,O
selectively,8046,O
induces,8046,O
cell,8046,O
death,8046,O
in,8046,O
human,8046,O
cancer,8046,O
cells,8046,O
through,8046,O
NAD,8046,B-GENE-Y
(,8046,I-GENE-Y
P,8046,I-GENE-Y
),8046,I-GENE-Y
H,8046,I-GENE-Y
:,8046,I-GENE-Y
quinone,8046,I-GENE-Y
oxidoreductase-1,8046,I-GENE-Y
(,8046,O
NQO1,8046,B-GENE-Y
),8046,O
.,8046,O
NQO1,8047,B-GENE-Y
is,8047,O
overexpressed,8047,O
in,8047,O
a,8047,O
variety,8047,O
of,8047,O
tumors,8047,O
",",8047,O
as,8047,O
compared,8047,O
to,8047,O
normal,8047,O
adjacent,8047,O
tissue,8047,O
.,8047,O
However,8048,O
",",8048,O
the,8048,O
low,8048,O
solubility,8048,O
and,8048,O
non-specific,8048,O
distribution,8048,O
of,8048,O
β-Lap,8048,B-CHEMICAL
limit,8048,O
its,8048,O
suitability,8048,O
for,8048,O
clinical,8048,O
assays,8048,O
.,8048,O
We,8049,O
formulated,8049,O
β-Lap,8049,B-CHEMICAL
in,8049,O
an,8049,O
optimal,8049,O
random,8049,O
methylated-β-cyclodextrin/poloxamer,8049,B-CHEMICAL
407,8049,I-CHEMICAL
mixture,8049,O
(,8049,O
i.e.,8049,O
",",8049,O
β-Lap,8049,B-CHEMICAL
ternary,8049,O
system,8049,O
),8049,O
and,8049,O
",",8049,O
using,8049,O
human,8049,O
breast,8049,O
adenocarcinoma,8049,O
MCF-7,8049,O
cells,8049,O
and,8049,O
immunodeficient,8049,O
mice,8049,O
",",8049,O
performed,8049,O
in,8049,O
vitro,8049,O
and,8049,O
in,8049,O
vivo,8049,O
evaluation,8049,O
of,8049,O
its,8049,O
anti-tumor,8049,O
effects,8049,O
on,8049,O
proliferation,8049,O
",",8049,O
cell,8049,O
cycle,8049,O
",",8049,O
apoptosis,8049,O
",",8049,O
DNA,8049,O
damage,8049,O
",",8049,O
and,8049,O
tumor,8049,O
growth,8049,O
.,8049,O
This,8050,O
ternary,8050,O
system,8050,O
is,8050,O
fluid,8050,O
at,8050,O
room,8050,O
temperature,8050,O
",",8050,O
gels,8050,O
over,8050,O
29°C,8050,O
",",8050,O
and,8050,O
provides,8050,O
a,8050,O
significant,8050,O
amount,8050,O
of,8050,O
drug,8050,O
",",8050,O
thus,8050,O
facilitating,8050,O
intratumoral,8050,O
delivery,8050,O
",",8050,O
in,8050,O
situ,8050,O
gelation,8050,O
",",8050,O
and,8050,O
the,8050,O
formation,8050,O
of,8050,O
a,8050,O
depot,8050,O
for,8050,O
time-release,8050,O
.,8050,O
Administration,8051,O
of,8051,O
β-Lap,8051,B-CHEMICAL
ternary,8051,O
system,8051,O
to,8051,O
MCF-7,8051,O
cells,8051,O
induces,8051,O
an,8051,O
increase,8051,O
in,8051,O
apoptosis,8051,O
and,8051,O
DNA,8051,O
damage,8051,O
",",8051,O
while,8051,O
producing,8051,O
no,8051,O
changes,8051,O
in,8051,O
cell,8051,O
cycle,8051,O
.,8051,O
Moreover,8052,O
",",8052,O
in,8052,O
a,8052,O
mouse,8052,O
xenograft,8052,O
tumor,8052,O
model,8052,O
",",8052,O
intratumoral,8052,O
injection,8052,O
of,8052,O
the,8052,O
system,8052,O
significantly,8052,O
reduces,8052,O
tumor,8052,O
volume,8052,O
",",8052,O
while,8052,O
increasing,8052,O
apoptosis,8052,O
and,8052,O
DNA,8052,O
damage,8052,O
without,8052,O
visible,8052,O
toxicity,8052,O
to,8052,O
liver,8052,O
or,8052,O
kidney,8052,O
.,8052,O
These,8053,O
anti-tumoral,8053,O
effects,8053,O
and,8053,O
lack,8053,O
of,8053,O
visible,8053,O
toxicity,8053,O
make,8053,O
this,8053,O
system,8053,O
a,8053,O
promising,8053,O
new,8053,O
therapeutic,8053,O
agent,8053,O
for,8053,O
breast,8053,O
cancer,8053,O
treatment,8053,O
.,8053,O
Lanthanum,8054,B-CHEMICAL
(,8054,I-CHEMICAL
III,8054,I-CHEMICAL
),8054,I-CHEMICAL
regulates,8054,O
the,8054,O
nitrogen,8054,B-CHEMICAL
assimilation,8054,O
in,8054,O
soybean,8054,O
seedlings,8054,O
under,8054,O
ultraviolet-B,8054,O
radiation,8054,O
.,8054,O
Ultraviolet-B,8055,O
(,8055,O
UV-B,8055,O
",",8055,O
280-320,8055,O
nm,8055,O
),8055,O
radiation,8055,O
has,8055,O
seriously,8055,O
affected,8055,O
the,8055,O
growth,8055,O
of,8055,O
plants,8055,O
.,8055,O
Finding,8056,O
the,8056,O
technology/method,8056,O
to,8056,O
alleviate,8056,O
the,8056,O
damage,8056,O
of,8056,O
UV-B,8056,O
radiation,8056,O
has,8056,O
become,8056,O
a,8056,O
frontal,8056,O
topic,8056,O
in,8056,O
the,8056,O
field,8056,O
of,8056,O
environmental,8056,O
science,8056,O
.,8056,O
The,8057,O
pretreatment,8057,O
with,8057,O
rare,8057,O
earth,8057,O
elements,8057,O
(,8057,O
REEs,8057,O
),8057,O
is,8057,O
an,8057,O
effective,8057,O
method,8057,O
",",8057,O
but,8057,O
the,8057,O
regulation,8057,O
mechanism,8057,O
of,8057,O
REEs,8057,O
is,8057,O
unknown,8057,O
.,8057,O
Here,8058,O
",",8058,O
the,8058,O
regulation,8058,O
effects,8058,O
of,8058,O
lanthanum,8058,B-CHEMICAL
(,8058,O
La,8058,B-CHEMICAL
(,8058,I-CHEMICAL
III,8058,I-CHEMICAL
),8058,I-CHEMICAL
),8058,O
on,8058,O
nitrogen,8058,B-CHEMICAL
assimilation,8058,O
in,8058,O
soybean,8058,O
seedlings,8058,O
(,8058,O
Glycine,8058,O
max,8058,O
L.,8058,O
),8058,O
under,8058,O
ultraviolet-B,8058,O
radiation,8058,O
were,8058,O
investigated,8058,O
to,8058,O
elucidate,8058,O
the,8058,O
regulation,8058,O
mechanism,8058,O
of,8058,O
REEs,8058,O
on,8058,O
plants,8058,O
under,8058,O
UV-B,8058,O
radiation,8058,O
.,8058,O
UV-B,8059,O
radiation,8059,O
led,8059,O
to,8059,O
the,8059,O
inhibition,8059,O
in,8059,O
the,8059,O
activities,8059,O
of,8059,O
the,8059,O
key,8059,O
enzymes,8059,O
(,8059,O
nitrate,8059,B-GENE-N
reductase,8059,I-GENE-N
",",8059,O
glutamine,8059,B-GENE-N
synthetase,8059,I-GENE-N
",",8059,O
glutamate,8059,B-GENE-N
synthase,8059,I-GENE-N
),8059,O
in,8059,O
the,8059,O
nitrogen,8059,B-CHEMICAL
assimilation,8059,O
",",8059,O
the,8059,O
decrease,8059,O
in,8059,O
the,8059,O
contents,8059,O
of,8059,O
nitrate,8059,B-CHEMICAL
and,8059,O
soluble,8059,O
proteins,8059,O
",",8059,O
as,8059,O
well,8059,O
as,8059,O
the,8059,O
increase,8059,O
in,8059,O
the,8059,O
content,8059,O
of,8059,O
amino,8059,B-CHEMICAL
acid,8059,I-CHEMICAL
in,8059,O
soybean,8059,O
seedlings,8059,O
.,8059,O
The,8060,O
change,8060,O
degree,8060,O
of,8060,O
UV-B,8060,O
radiation,8060,O
at,8060,O
the,8060,O
high,8060,O
level,8060,O
(,8060,O
0.45,8060,O
W,8060,O
m,8060,O
(,8060,O
-2,8060,O
),8060,O
),8060,O
was,8060,O
higher,8060,O
than,8060,O
that,8060,O
of,8060,O
UV-B,8060,O
radiation,8060,O
at,8060,O
the,8060,O
low,8060,O
level,8060,O
(,8060,O
0.15,8060,O
W,8060,O
m,8060,O
(,8060,O
-2,8060,O
),8060,O
),8060,O
.,8060,O
The,8061,O
pretreatment,8061,O
with,8061,O
20,8061,O
mg,8061,O
L,8061,O
(,8061,O
-1,8061,O
),8061,O
La,8061,B-CHEMICAL
(,8061,I-CHEMICAL
III,8061,I-CHEMICAL
),8061,I-CHEMICAL
could,8061,O
alleviate,8061,O
the,8061,O
effects,8061,O
of,8061,O
UV-B,8061,O
radiation,8061,O
on,8061,O
the,8061,O
activities,8061,O
of,8061,O
nitrate,8061,B-GENE-N
reductase,8061,I-GENE-N
",",8061,O
glutamine,8061,B-GENE-N
synthetase,8061,I-GENE-N
",",8061,O
glutamate,8061,B-GENE-N
synthase,8061,I-GENE-N
",",8061,O
and,8061,O
glutamate,8061,B-GENE-N
dehydrogenase,8061,I-GENE-N
",",8061,O
promoting,8061,O
amino,8061,B-CHEMICAL
acid,8061,I-CHEMICAL
conversion,8061,O
and,8061,O
protein,8061,O
synthesis,8061,O
in,8061,O
soybean,8061,O
seedlings,8061,O
.,8061,O
The,8062,O
regulation,8062,O
effect,8062,O
of,8062,O
La,8062,B-CHEMICAL
(,8062,I-CHEMICAL
III,8062,I-CHEMICAL
),8062,I-CHEMICAL
under,8062,O
UV-B,8062,O
radiation,8062,O
at,8062,O
the,8062,O
low,8062,O
level,8062,O
was,8062,O
better,8062,O
than,8062,O
that,8062,O
of,8062,O
UV-B,8062,O
radiation,8062,O
at,8062,O
the,8062,O
high,8062,O
level,8062,O
.,8062,O
The,8063,O
results,8063,O
indicated,8063,O
that,8063,O
the,8063,O
pretreatment,8063,O
with,8063,O
20,8063,O
mg,8063,O
L,8063,O
(,8063,O
-1,8063,O
),8063,O
La,8063,B-CHEMICAL
(,8063,I-CHEMICAL
III,8063,I-CHEMICAL
),8063,I-CHEMICAL
could,8063,O
alleviate,8063,O
the,8063,O
inhibition,8063,O
of,8063,O
UV-B,8063,O
radiation,8063,O
on,8063,O
nitrogen,8063,B-CHEMICAL
assimilation,8063,O
in,8063,O
soybean,8063,O
seedlings,8063,O
.,8063,O
Significant,8064,O
receptor,8064,O
affinities,8064,O
of,8064,O
metabolites,8064,O
and,8064,O
a,8064,O
degradation,8064,O
product,8064,O
of,8064,O
mometasone,8064,B-CHEMICAL
furoate,8064,I-CHEMICAL
.,8064,O
Mometasone,8065,B-CHEMICAL
furoate,8065,I-CHEMICAL
(,8065,O
MF,8065,B-CHEMICAL
),8065,O
is,8065,O
a,8065,O
highly,8065,O
potent,8065,O
glucocorticoid,8065,O
used,8065,O
topically,8065,O
to,8065,O
treat,8065,O
inflammation,8065,O
in,8065,O
the,8065,O
lung,8065,O
",",8065,O
nose,8065,O
and,8065,O
on,8065,O
the,8065,O
skin,8065,O
.,8065,O
However,8066,O
",",8066,O
so,8066,O
far,8066,O
no,8066,O
information,8066,O
has,8066,O
been,8066,O
published,8066,O
on,8066,O
the,8066,O
human,8066,B-GENE-Y
glucocorticoid,8066,I-GENE-Y
receptor,8066,I-GENE-Y
activity,8066,O
of,8066,O
the,8066,O
metabolites,8066,O
or,8066,O
degradation,8066,O
products,8066,O
of,8066,O
MF,8066,B-CHEMICAL
.,8066,O
We,8067,O
have,8067,O
now,8067,O
determined,8067,O
the,8067,O
relative,8067,O
receptor,8067,O
binding,8067,O
affinities,8067,O
of,8067,O
the,8067,O
known,8067,O
metabolite,8067,O
6beta-OH,8067,B-CHEMICAL
MF,8067,I-CHEMICAL
and,8067,O
the,8067,O
degradation,8067,O
product,8067,O
"9,11-epoxy",8067,B-CHEMICAL
MF,8067,I-CHEMICAL
to,8067,O
understand,8067,O
their,8067,O
possible,8067,O
contribution,8067,O
to,8067,O
undesirable,8067,O
systemic,8067,O
side,8067,O
effects,8067,O
.,8067,O
In,8068,O
competition,8068,O
experiments,8068,O
with,8068,O
human,8068,B-GENE-Y
lung,8068,I-GENE-Y
glucocorticoid,8068,I-GENE-Y
receptors,8068,I-GENE-Y
we,8068,O
have,8068,O
determined,8068,O
the,8068,O
relative,8068,O
receptor,8068,O
affinities,8068,O
(,8068,O
RRA,8068,O
),8068,O
of,8068,O
these,8068,O
substances,8068,O
with,8068,O
reference,8068,O
to,8068,O
dexamethasone,8068,B-CHEMICAL
(,8068,O
RRA,8068,O
=,8068,O
100,8068,O
),8068,O
.,8068,O
We,8069,O
have,8069,O
discovered,8069,O
that,8069,O
6beta-OH,8069,B-CHEMICAL
MF,8069,I-CHEMICAL
and,8069,O
"9,11-epoxy",8069,B-CHEMICAL
MF,8069,I-CHEMICAL
display,8069,O
RRAs,8069,O
of,8069,O
206,8069,O
+/-,8069,O
15,8069,O
and,8069,O
220,8069,O
+/-,8069,O
22,8069,O
",",8069,O
respectively,8069,O
.,8069,O
This,8070,O
level,8070,O
of,8070,O
activity,8070,O
is,8070,O
similar,8070,O
to,8070,O
that,8070,O
of,8070,O
the,8070,O
clinically,8070,O
used,8070,O
inhaled,8070,O
corticosteroid,8070,B-CHEMICAL
flunisolide,8070,B-CHEMICAL
(,8070,O
RRA,8070,O
180,8070,O
+/-,8070,O
11,8070,O
),8070,O
.,8070,O
Furthermore,8071,O
we,8071,O
observed,8071,O
that,8071,O
"9,11-epoxy",8071,B-CHEMICAL
MF,8071,I-CHEMICAL
is,8071,O
a,8071,O
chemically,8071,O
reactive,8071,O
metabolite,8071,O
.,8071,O
In,8072,O
recovery,8072,O
experiments,8072,O
with,8072,O
human,8072,O
plasma,8072,O
and,8072,O
lung,8072,O
tissue,8072,O
we,8072,O
found,8072,O
a,8072,O
time,8072,O
dependent,8072,O
decrease,8072,O
in,8072,O
extractability,8072,O
of,8072,O
the,8072,O
compound,8072,O
.,8072,O
Hence,8073,O
",",8073,O
we,8073,O
provide,8073,O
data,8073,O
that,8073,O
might,8073,O
contribute,8073,O
to,8073,O
the,8073,O
understanding,8073,O
of,8073,O
the,8073,O
pharmacokinetics,8073,O
as,8073,O
well,8073,O
as,8073,O
the,8073,O
clinical,8073,O
effects,8073,O
of,8073,O
MF,8073,B-CHEMICAL
.,8073,O
Inhibition,8074,O
of,8074,O
monoamine,8074,B-GENE-N
oxidase,8074,I-GENE-N
by,8074,O
phthalide,8074,B-CHEMICAL
analogues,8074,O
.,8074,O
Based,8075,O
on,8075,O
recent,8075,O
reports,8075,O
that,8075,O
the,8075,O
small,8075,O
molecules,8075,O
",",8075,O
isatin,8075,B-CHEMICAL
and,8075,O
phthalimide,8075,B-CHEMICAL
",",8075,O
are,8075,O
suitable,8075,O
scaffolds,8075,O
for,8075,O
the,8075,O
design,8075,O
of,8075,O
high,8075,O
potency,8075,O
monoamine,8075,B-GENE-N
oxidase,8075,I-GENE-N
(,8075,O
MAO,8075,B-GENE-N
),8075,O
inhibitors,8075,O
",",8075,O
the,8075,O
present,8075,O
study,8075,O
examines,8075,O
the,8075,O
MAO,8075,B-GENE-N
inhibitory,8075,O
properties,8075,O
of,8075,O
a,8075,O
series,8075,O
of,8075,O
phthalide,8075,B-CHEMICAL
[,8075,O
2-benzofuran-1,8075,B-CHEMICAL
(,8075,I-CHEMICAL
3H,8075,I-CHEMICAL
),8075,I-CHEMICAL
-one,8075,I-CHEMICAL
],8075,O
analogues,8075,O
.,8075,O
Phthalide,8076,B-CHEMICAL
is,8076,O
structurally,8076,O
related,8076,O
to,8076,O
isatin,8076,B-CHEMICAL
and,8076,O
phthalimide,8076,B-CHEMICAL
and,8076,O
it,8076,O
is,8076,O
demonstrated,8076,O
here,8076,O
that,8076,O
substitution,8076,O
at,8076,O
C6,8076,O
of,8076,O
the,8076,O
phthalide,8076,B-CHEMICAL
moiety,8076,O
yields,8076,O
compounds,8076,O
endowed,8076,O
with,8076,O
high,8076,O
binding,8076,O
affinities,8076,O
to,8076,O
both,8076,O
human,8076,B-GENE-N
MAO,8076,I-GENE-N
isoforms,8076,O
.,8076,O
Among,8077,O
the,8077,O
nineteen,8077,O
homologues,8077,O
evaluated,8077,O
",",8077,O
the,8077,O
lowest,8077,O
IC,8077,O
(,8077,O
50,8077,O
),8077,O
values,8077,O
recorded,8077,O
for,8077,O
the,8077,O
inhibition,8077,O
of,8077,O
MAO-A,8077,B-GENE-N
and,8077,I-GENE-N
-B,8077,I-GENE-N
were,8077,O
0.096,8077,O
and,8077,O
0.0014,8077,O
μM,8077,O
",",8077,O
respectively,8077,O
.,8077,O
In,8078,O
most,8078,O
instances,8078,O
",",8078,O
C6-substituted,8078,O
phthalides,8078,B-CHEMICAL
exhibit,8078,O
MAO-B,8078,B-GENE-Y
specific,8078,O
inhibition,8078,O
.,8078,O
Among,8079,O
a,8079,O
series,8079,O
of,8079,O
6-benzyloxyphthalides,8079,B-CHEMICAL
bearing,8079,O
substituents,8079,O
on,8079,O
the,8079,O
para,8079,O
position,8079,O
of,8079,O
the,8079,O
phenyl,8079,B-CHEMICAL
ring,8079,O
the,8079,O
general,8079,O
order,8079,O
of,8079,O
potency,8079,O
was,8079,O
CF,8079,B-CHEMICAL
(,8079,I-CHEMICAL
3,8079,I-CHEMICAL
),8079,I-CHEMICAL
>,8079,O
I,8079,B-CHEMICAL
>,8079,O
Br,8079,B-CHEMICAL
>,8079,O
Cl,8079,B-CHEMICAL
>,8079,O
F,8079,B-CHEMICAL
>,8079,O
CH,8079,B-CHEMICAL
(,8079,I-CHEMICAL
3,8079,I-CHEMICAL
),8079,I-CHEMICAL
>,8079,O
H.,8079,B-CHEMICAL
The,8079,O
results,8079,O
also,8079,O
show,8079,O
that,8079,O
the,8079,O
binding,8079,O
modes,8079,O
of,8079,O
representative,8079,O
phthalides,8079,B-CHEMICAL
are,8079,O
reversible,8079,O
and,8079,O
competitive,8079,O
at,8079,O
both,8079,O
MAO,8079,B-GENE-N
isoforms,8079,O
.,8079,O
Based,8080,O
on,8080,O
these,8080,O
data,8080,O
",",8080,O
C6-substituted,8080,B-CHEMICAL
phthalides,8080,B-CHEMICAL
may,8080,O
serve,8080,O
as,8080,O
leads,8080,O
for,8080,O
the,8080,O
development,8080,O
of,8080,O
therapies,8080,O
for,8080,O
neurodegenerative,8080,O
disorders,8080,O
such,8080,O
as,8080,O
Parkinson,8080,O
's,8080,O
disease,8080,O
.,8080,O
Long,8081,O
range,8081,O
effect,8081,O
of,8081,O
mutations,8081,O
on,8081,O
specific,8081,O
conformational,8081,O
changes,8081,O
in,8081,O
the,8081,O
extracellular,8081,O
loop,8081,O
2,8081,O
of,8081,O
angiotensin,8081,B-GENE-Y
II,8081,I-GENE-Y
type,8081,I-GENE-Y
1,8081,I-GENE-Y
receptor,8081,I-GENE-Y
.,8081,O
The,8082,O
topology,8082,O
of,8082,O
the,8082,O
second,8082,O
extracellular,8082,O
loop,8082,O
(,8082,O
ECL2,8082,O
),8082,O
and,8082,O
its,8082,O
interaction,8082,O
with,8082,O
ligands,8082,O
is,8082,O
unique,8082,O
in,8082,O
each,8082,O
G,8082,B-GENE-N
protein-coupled,8082,I-GENE-N
receptor,8082,I-GENE-N
.,8082,O
When,8083,O
the,8083,O
orthosteric,8083,O
ligand,8083,O
pocket,8083,O
located,8083,O
in,8083,O
the,8083,O
transmembrane,8083,O
(,8083,O
TM,8083,O
),8083,O
domain,8083,O
is,8083,O
occupied,8083,O
",",8083,O
ligand-specific,8083,O
conformational,8083,O
changes,8083,O
occur,8083,O
in,8083,O
the,8083,O
ECL2,8083,O
.,8083,O
In,8084,O
more,8084,O
than,8084,O
90,8084,O
%,8084,O
of,8084,O
G,8084,B-GENE-N
protein-coupled,8084,I-GENE-N
receptors,8084,I-GENE-N
",",8084,O
ECL2,8084,O
is,8084,O
tethered,8084,O
to,8084,O
the,8084,O
third,8084,O
TM,8084,O
helix,8084,O
via,8084,O
a,8084,O
disulfide,8084,O
bond,8084,O
.,8084,O
Therefore,8085,O
",",8085,O
understanding,8085,O
the,8085,O
extent,8085,O
to,8085,O
which,8085,O
the,8085,O
TM,8085,O
domain,8085,O
and,8085,O
ECL2,8085,O
conformations,8085,O
are,8085,O
coupled,8085,O
is,8085,O
useful,8085,O
.,8085,O
To,8086,O
investigate,8086,O
this,8086,O
",",8086,O
we,8086,O
examined,8086,O
conformational,8086,O
changes,8086,O
in,8086,O
ECL2,8086,O
of,8086,O
the,8086,O
angiotensin,8086,B-GENE-Y
II,8086,I-GENE-Y
type,8086,I-GENE-Y
1,8086,I-GENE-Y
receptor,8086,I-GENE-Y
(,8086,O
AT1R,8086,B-GENE-Y
),8086,O
by,8086,O
introducing,8086,O
mutations,8086,O
in,8086,O
distant,8086,O
sites,8086,O
that,8086,O
alter,8086,O
the,8086,O
activation,8086,O
state,8086,O
equilibrium,8086,O
of,8086,O
the,8086,O
AT1R,8086,B-GENE-Y
.,8086,O
Differential,8087,O
accessibility,8087,O
of,8087,O
reporter,8087,O
cysteines,8087,B-CHEMICAL
introduced,8087,O
at,8087,O
four,8087,O
conformation-sensitive,8087,O
sites,8087,O
in,8087,O
ECL2,8087,O
of,8087,O
these,8087,O
mutants,8087,O
was,8087,O
measured,8087,O
.,8087,O
Binding,8088,O
of,8088,O
the,8088,O
agonist,8088,O
angiotensin,8088,B-GENE-Y
II,8088,I-GENE-Y
(,8088,O
AngII,8088,B-GENE-Y
),8088,O
and,8088,O
inverse,8088,O
agonist,8088,O
losartan,8088,B-CHEMICAL
in,8088,O
wild-type,8088,O
AT1R,8088,B-GENE-Y
changed,8088,O
the,8088,O
accessibility,8088,O
of,8088,O
reporter,8088,O
cysteines,8088,B-CHEMICAL
",",8088,O
and,8088,O
the,8088,O
pattern,8088,O
was,8088,O
consistent,8088,O
with,8088,O
ligand-specific,8088,O
``,8088,O
lid,8088,O
'',8088,O
conformations,8088,O
of,8088,O
ECL2,8088,O
.,8088,O
Without,8089,O
agonist,8089,O
stimulation,8089,O
",",8089,O
the,8089,O
ECL2,8089,O
in,8089,O
the,8089,O
gain,8089,O
of,8089,O
function,8089,O
mutant,8089,O
N111G,8089,B-GENE-N
assumed,8089,O
a,8089,O
lid,8089,O
conformation,8089,O
similar,8089,O
to,8089,O
AngII-bound,8089,B-GENE-Y
wild-type,8089,O
AT1R,8089,B-GENE-Y
.,8089,O
In,8090,O
the,8090,O
presence,8090,O
of,8090,O
inverse,8090,O
agonists,8090,O
",",8090,O
the,8090,O
conformation,8090,O
of,8090,O
ECL2,8090,O
in,8090,O
the,8090,O
N111G,8090,B-GENE-N
mutant,8090,O
was,8090,O
similar,8090,O
to,8090,O
the,8090,O
inactive,8090,O
state,8090,O
of,8090,O
wild-type,8090,O
AT1R,8090,B-GENE-Y
.,8090,O
In,8091,O
contrast,8091,O
",",8091,O
AngII,8091,B-GENE-Y
did,8091,O
not,8091,O
induce,8091,O
a,8091,O
lid,8091,O
conformation,8091,O
in,8091,O
ECL2,8091,O
in,8091,O
the,8091,O
loss,8091,O
of,8091,O
function,8091,O
D281A,8091,B-GENE-N
mutant,8091,O
",",8091,O
which,8091,O
is,8091,O
consistent,8091,O
with,8091,O
the,8091,O
reduced,8091,O
AngII,8091,B-GENE-Y
binding,8091,O
affinity,8091,O
in,8091,O
this,8091,O
mutant,8091,O
.,8091,O
However,8092,O
",",8092,O
a,8092,O
lid,8092,O
conformation,8092,O
was,8092,O
induced,8092,O
by,8092,O
[,8092,O
Sar,8092,B-CHEMICAL
(,8092,O
1,8092,O
),8092,O
",",8092,O
Gln,8092,B-CHEMICAL
(,8092,O
2,8092,O
),8092,O
",",8092,O
Ile,8092,B-CHEMICAL
(,8092,O
8,8092,O
),8092,O
],8092,O
AngII,8092,B-GENE-Y
",",8092,O
a,8092,O
specific,8092,O
analog,8092,O
that,8092,O
binds,8092,O
to,8092,O
the,8092,O
D281A,8092,B-GENE-N
mutant,8092,O
with,8092,O
better,8092,O
affinity,8092,O
than,8092,O
AngII,8092,B-GENE-Y
.,8092,O
These,8093,O
results,8093,O
provide,8093,O
evidence,8093,O
for,8093,O
the,8093,O
emerging,8093,O
paradigm,8093,O
of,8093,O
domain,8093,O
coupling,8093,O
facilitated,8093,O
by,8093,O
long,8093,O
range,8093,O
interactions,8093,O
at,8093,O
distant,8093,O
sites,8093,O
on,8093,O
the,8093,O
same,8093,O
receptor,8093,O
.,8093,O
Immunohistochemical,8094,O
characterization,8094,O
of,8094,O
pyrimidine,8094,B-CHEMICAL
synthetic,8094,O
enzymes,8094,O
",",8094,O
thymidine,8094,B-GENE-Y
kinase-1,8094,I-GENE-Y
and,8094,O
thymidylate,8094,B-GENE-Y
synthase,8094,I-GENE-Y
",",8094,O
in,8094,O
various,8094,O
types,8094,O
of,8094,O
cancer,8094,O
.,8094,O
Thymidine,8095,B-GENE-Y
kinase-1,8095,I-GENE-Y
(,8095,O
TK-1,8095,B-GENE-Y
),8095,I-GENE-Y
and,8095,O
thymidylate,8095,B-GENE-Y
synthase,8095,I-GENE-Y
(,8095,O
TS,8095,B-GENE-Y
),8095,O
are,8095,O
key,8095,O
enzymes,8095,O
for,8095,O
salvage,8095,O
and,8095,O
de,8095,O
novo,8095,O
pyrimidine,8095,B-CHEMICAL
synthesis,8095,O
",",8095,O
respectively,8095,O
.,8095,O
Numerous,8096,O
studies,8096,O
have,8096,O
suggested,8096,O
that,8096,O
increased,8096,O
TS,8096,B-GENE-Y
levels,8096,O
are,8096,O
associated,8096,O
closely,8096,O
with,8096,O
resistance,8096,O
to,8096,O
fluoropyrimidine-based,8096,B-CHEMICAL
chemotherapy,8096,O
.,8096,O
TAS-102,8097,B-CHEMICAL
is,8097,O
a,8097,O
novel,8097,O
drug,8097,O
containing,8097,O
trifluorothymidine,8097,B-CHEMICAL
",",8097,O
which,8097,O
is,8097,O
phosphorylated,8097,O
by,8097,O
TK-1,8097,B-GENE-Y
to,8097,O
its,8097,O
active,8097,O
monophosphated,8097,O
form,8097,O
",",8097,O
that,8097,O
in,8097,O
turn,8097,O
can,8097,O
inhibit,8097,O
TS,8097,B-GENE-Y
.,8097,O
TAS-102,8098,B-CHEMICAL
has,8098,O
been,8098,O
shown,8098,O
to,8098,O
exhibit,8098,O
antitumor,8098,O
activity,8098,O
in,8098,O
fluoropyrimidine-resistant,8098,B-CHEMICAL
human,8098,O
cancer,8098,O
cells,8098,O
.,8098,O
TAS-102,8099,B-CHEMICAL
is,8099,O
currently,8099,O
undergoing,8099,O
clinical,8099,O
trials,8099,O
for,8099,O
use,8099,O
in,8099,O
gastrointestinal,8099,O
cancers,8099,O
.,8099,O
In,8100,O
the,8100,O
present,8100,O
study,8100,O
",",8100,O
we,8100,O
used,8100,O
immunohistochemistry,8100,O
to,8100,O
investigate,8100,O
the,8100,O
expression,8100,O
of,8100,O
TK-1,8100,B-GENE-Y
and,8100,O
TS,8100,B-GENE-Y
in,8100,O
various,8100,O
types,8100,O
of,8100,O
cancer,8100,O
.,8100,O
TK-1,8101,B-GENE-Y
and,8101,O
TS,8101,B-GENE-Y
expression,8101,O
was,8101,O
markedly,8101,O
different,8101,O
between,8101,O
cancer,8101,O
types,8101,O
.,8101,O
High,8102,O
TK-1,8102,B-GENE-Y
expression,8102,O
was,8102,O
detected,8102,O
prominently,8102,O
in,8102,O
gastrointestinal,8102,O
adenocarcinomas,8102,O
and,8102,O
esophageal,8102,O
and,8102,O
uterine,8102,O
squamous,8102,O
cell,8102,O
carcinomas,8102,O
.,8102,O
Gastrointestinal,8103,O
adenocarcinomas,8103,O
and,8103,O
squamous,8103,O
cell,8103,O
uterine,8103,O
carcinomas,8103,O
were,8103,O
often,8103,O
accompanied,8103,O
by,8103,O
high,8103,O
TS,8103,B-GENE-Y
expression,8103,O
",",8103,O
indicating,8103,O
activation,8103,O
of,8103,O
pyrimidine,8103,B-CHEMICAL
synthesis,8103,O
through,8103,O
both,8103,O
the,8103,O
salvage,8103,O
and,8103,O
de,8103,O
novo,8103,O
pathways,8103,O
.,8103,O
These,8104,O
results,8104,O
led,8104,O
us,8104,O
to,8104,O
consider,8104,O
that,8104,O
TAS-102,8104,B-CHEMICAL
may,8104,O
also,8104,O
be,8104,O
effective,8104,O
for,8104,O
esophageal,8104,O
and,8104,O
uterine,8104,O
squamous,8104,O
cell,8104,O
carcinomas,8104,O
",",8104,O
as,8104,O
well,8104,O
as,8104,O
for,8104,O
gastrointestinal,8104,O
adenocarcinomas,8104,O
",",8104,O
even,8104,O
in,8104,O
fluoropyrimidine-resistant,8104,B-CHEMICAL
cases,8104,O
with,8104,O
high,8104,O
TS,8104,B-GENE-Y
expression,8104,O
.,8104,O
In,8105,O
contrast,8105,O
",",8105,O
thyroid,8105,O
papillary,8105,O
carcinomas,8105,O
",",8105,O
lung,8105,O
adenocarcinomas,8105,O
",",8105,O
hepatocellular,8105,O
carcinomas,8105,O
",",8105,O
pancreatic,8105,O
ductal,8105,O
carcinomas,8105,O
",",8105,O
and,8105,O
renal,8105,O
cell,8105,O
carcinomas,8105,O
",",8105,O
which,8105,O
exhibit,8105,O
low,8105,O
TK-1,8105,B-GENE-Y
expression,8105,O
",",8105,O
may,8105,O
be,8105,O
resistant,8105,O
to,8105,O
TAS-102,8105,B-CHEMICAL
.,8105,O
In,8106,O
non-small,8106,O
cell,8106,O
lung,8106,O
cancers,8106,O
",",8106,O
high,8106,O
TK-1,8106,B-GENE-Y
expression,8106,O
was,8106,O
demonstrated,8106,O
in,8106,O
squamous,8106,O
cell,8106,O
carcinomas,8106,O
",",8106,O
but,8106,O
not,8106,O
in,8106,O
adenocarcinomas,8106,O
.,8106,O
This,8107,O
result,8107,O
suggests,8107,O
that,8107,O
TAS-102,8107,B-CHEMICAL
efficacy,8107,O
and,8107,O
the,8107,O
pyrimidine,8107,B-CHEMICAL
synthetic,8107,O
pathway,8107,O
may,8107,O
differ,8107,O
depending,8107,O
on,8107,O
histological,8107,O
type,8107,O
.,8107,O
Our,8108,O
results,8108,O
indicate,8108,O
that,8108,O
administration,8108,O
of,8108,O
TAS-102,8108,B-CHEMICAL
could,8108,O
be,8108,O
selected,8108,O
on,8108,O
the,8108,O
basis,8108,O
of,8108,O
the,8108,O
immunohistochemical,8108,O
evaluation,8108,O
of,8108,O
TK-1,8108,B-GENE-Y
and,8108,O
TS,8108,B-GENE-Y
.,8108,O
Increased,8109,O
muscarinic,8109,B-GENE-N
receptor,8109,I-GENE-N
activity,8109,O
of,8109,O
airway,8109,O
smooth,8109,O
muscle,8109,O
isolated,8109,O
from,8109,O
a,8109,O
mouse,8109,O
model,8109,O
of,8109,O
allergic,8109,O
asthma,8109,O
.,8109,O
The,8110,O
mechanisms,8110,O
leading,8110,O
to,8110,O
airway,8110,O
hyper-responsiveness,8110,O
(,8110,O
AHR,8110,O
),8110,O
in,8110,O
asthma,8110,O
are,8110,O
still,8110,O
not,8110,O
fully,8110,O
understood,8110,O
.,8110,O
AHR,8111,O
could,8111,O
be,8111,O
produced,8111,O
by,8111,O
hypersensitivity,8111,O
of,8111,O
the,8111,O
airway,8111,O
smooth,8111,O
muscle,8111,O
or,8111,O
hyperreactivity,8111,O
of,8111,O
the,8111,O
airways,8111,O
.,8111,O
This,8112,O
study,8112,O
was,8112,O
conducted,8112,O
to,8112,O
ascertain,8112,O
whether,8112,O
AHR,8112,O
in,8112,O
a,8112,O
murine,8112,O
model,8112,O
of,8112,O
asthma,8112,O
is,8112,O
produced,8112,O
by,8112,O
changes,8112,O
at,8112,O
the,8112,O
level,8112,O
of,8112,O
the,8112,O
airway,8112,O
smooth,8112,O
muscle,8112,O
.,8112,O
Airway,8113,O
smooth,8113,O
muscle,8113,O
responses,8113,O
were,8113,O
characterised,8113,O
in,8113,O
vitro,8113,O
in,8113,O
isolated,8113,O
trachea,8113,O
spirals,8113,O
from,8113,O
naive,8113,O
mice,8113,O
and,8113,O
from,8113,O
an,8113,O
acute,8113,O
ovalbumin,8113,B-GENE-Y
(,8113,O
OVA,8113,B-GENE-Y
),8113,O
challenge,8113,O
model,8113,O
of,8113,O
allergic,8113,O
asthma,8113,O
.,8113,O
AHR,8114,O
was,8114,O
investigated,8114,O
in,8114,O
vivo,8114,O
in,8114,O
conscious,8114,O
",",8114,O
freely,8114,O
moving,8114,O
mice,8114,O
.,8114,O
Inflammatory,8115,O
cell,8115,O
influx,8115,O
into,8115,O
the,8115,O
lungs,8115,O
and,8115,O
antibody,8115,O
responses,8115,O
to,8115,O
the,8115,O
antigen,8115,O
were,8115,O
also,8115,O
measured,8115,O
.,8115,O
In,8116,O
vitro,8116,O
study,8116,O
of,8116,O
tracheal,8116,O
airway,8116,O
smooth,8116,O
muscle,8116,O
from,8116,O
naive,8116,O
mice,8116,O
demonstrated,8116,O
concentration-related,8116,O
contractions,8116,O
to,8116,O
methacholine,8116,B-CHEMICAL
and,8116,O
5-HT,8116,B-CHEMICAL
",",8116,O
but,8116,O
no,8116,O
responses,8116,O
to,8116,O
histamine,8116,B-CHEMICAL
or,8116,O
adenosine,8116,B-CHEMICAL
or,8116,O
its,8116,O
stable,8116,O
analogue,8116,O
",",8116,O
5'-N-ethyl-carboxamidoadenosine,8116,B-CHEMICAL
.,8116,O
The,8117,O
contractions,8117,O
to,8117,O
5-HT,8117,B-CHEMICAL
were,8117,O
inhibited,8117,O
by,8117,O
ketanserin,8117,B-CHEMICAL
and,8117,O
alosetron,8117,B-CHEMICAL
indicating,8117,O
involvement,8117,O
of,8117,O
5-HT,8117,B-GENE-Y
(,8117,I-GENE-Y
2A,8117,I-GENE-Y
),8117,I-GENE-Y
and,8117,O
5-HT,8117,B-GENE-Y
(,8117,I-GENE-Y
3,8117,I-GENE-Y
),8117,I-GENE-Y
receptors,8117,O
",",8117,O
respectively,8117,O
.,8117,O
In,8118,O
an,8118,O
acute,8118,O
model,8118,O
of,8118,O
allergic,8118,O
asthma,8118,O
",",8118,O
OVA-treated,8118,B-GENE-Y
mice,8118,O
were,8118,O
shown,8118,O
to,8118,O
be,8118,O
atopic,8118,O
by,8118,O
inflammatory,8118,O
cell,8118,O
influx,8118,O
to,8118,O
the,8118,O
lungs,8118,O
after,8118,O
OVA,8118,B-GENE-Y
challenge,8118,O
",",8118,O
increases,8118,O
in,8118,O
total,8118,O
IgE,8118,B-GENE-N
and,8118,O
OVA-specific,8118,B-GENE-Y
IgG,8118,B-GENE-N
levels,8118,O
and,8118,O
contractions,8118,O
to,8118,O
OVA,8118,B-GENE-Y
in,8118,O
isolated,8118,O
trachea,8118,O
.,8118,O
In,8119,O
the,8119,O
asthmatic,8119,O
model,8119,O
",",8119,O
AHR,8119,O
to,8119,O
methacholine,8119,B-CHEMICAL
was,8119,O
demonstrated,8119,O
in,8119,O
conscious,8119,O
",",8119,O
freely,8119,O
moving,8119,O
mice,8119,O
in,8119,O
vivo,8119,O
and,8119,O
in,8119,O
isolated,8119,O
trachea,8119,O
in,8119,O
vitro,8119,O
24,8119,O
and,8119,O
72h,8119,O
after,8119,O
OVA,8119,B-GENE-Y
challenge,8119,O
.,8119,O
No,8120,O
AHR,8120,O
in,8120,O
vitro,8120,O
was,8120,O
seen,8120,O
for,8120,O
5-HT,8120,B-CHEMICAL
",",8120,O
histamine,8120,B-CHEMICAL
or,8120,O
adenosine,8120,B-CHEMICAL
.,8120,O
These,8121,O
results,8121,O
suggest,8121,O
that,8121,O
",",8121,O
in,8121,O
our,8121,O
mouse,8121,O
model,8121,O
of,8121,O
asthma,8121,O
",",8121,O
changes,8121,O
occur,8121,O
at,8121,O
the,8121,O
level,8121,O
of,8121,O
the,8121,O
muscarinic,8121,B-GENE-N
receptor,8121,I-GENE-N
transduction,8121,O
pathway,8121,O
of,8121,O
coupling,8121,O
to,8121,O
airway,8121,O
smooth,8121,O
muscle,8121,O
contraction,8121,O
.,8121,O
These,8122,O
changes,8122,O
are,8122,O
maintained,8122,O
when,8122,O
tissues,8122,O
are,8122,O
removed,8122,O
from,8122,O
the,8122,O
inflammatory,8122,O
environment,8122,O
and,8122,O
for,8122,O
at,8122,O
least,8122,O
3,8122,O
days,8122,O
.,8122,O
Design,8123,O
",",8123,O
synthesis,8123,O
",",8123,O
characterization,8123,O
and,8123,O
anti-inflammatory,8123,O
evaluation,8123,O
of,8123,O
novel,8123,O
pyrazole,8123,B-CHEMICAL
amalgamated,8123,O
flavones,8123,B-CHEMICAL
.,8123,O
A,8124,O
series,8124,O
of,8124,O
novel,8124,O
pyrazole,8124,B-CHEMICAL
amalgamated,8124,O
flavones,8124,B-CHEMICAL
has,8124,O
been,8124,O
designed,8124,O
and,8124,O
synthesized,8124,O
from,8124,O
1-methyl-5-,8124,B-CHEMICAL
(,8124,I-CHEMICAL
"2,4,6-trimethoxy-phenyl",8124,I-CHEMICAL
),8124,I-CHEMICAL
-1H-pyrazole,8124,I-CHEMICAL
6,8124,O
.,8124,O
The,8125,O
structures,8125,O
of,8125,O
regioisomers,8125,O
6,8125,O
and,8125,O
7,8125,O
were,8125,O
resolved,8125,O
by,8125,O
2D,8125,O
(,8125,B-CHEMICAL
1,8125,I-CHEMICAL
),8125,I-CHEMICAL
H-,8125,O
(,8125,B-CHEMICAL
1,8125,I-CHEMICAL
),8125,I-CHEMICAL
H,8125,I-CHEMICAL
COSY,8125,O
",",8125,O
(,8125,B-CHEMICAL
1,8125,I-CHEMICAL
),8125,I-CHEMICAL
H-,8125,O
(,8125,B-CHEMICAL
13,8125,I-CHEMICAL
),8125,I-CHEMICAL
C,8125,I-CHEMICAL
HSQC,8125,O
and,8125,O
(,8125,B-CHEMICAL
1,8125,I-CHEMICAL
),8125,I-CHEMICAL
H-,8125,O
(,8125,B-CHEMICAL
13,8125,I-CHEMICAL
),8125,I-CHEMICAL
C,8125,I-CHEMICAL
HMBC,8125,O
experiments,8125,O
.,8125,O
The,8126,O
newly,8126,O
synthesized,8126,O
compounds,8126,O
were,8126,O
tested,8126,O
for,8126,O
their,8126,O
in,8126,O
vitro,8126,O
COX,8126,B-GENE-N
inhibition,8126,O
and,8126,O
in,8126,O
vivo,8126,O
carrageenan,8126,O
induced,8126,O
hind,8126,O
paw,8126,O
edema,8126,O
in,8126,O
rats,8126,O
and,8126,O
acetic,8126,B-CHEMICAL
acid,8126,I-CHEMICAL
induced,8126,O
vascular,8126,O
permeability,8126,O
in,8126,O
mice,8126,O
.,8126,O
Although,8127,O
the,8127,O
compounds,8127,O
have,8127,O
inhibitory,8127,O
profile,8127,O
against,8127,O
both,8127,O
COX-1,8127,B-GENE-Y
and,8127,O
COX-2,8127,B-GENE-Y
",",8127,O
some,8127,O
of,8127,O
the,8127,O
compounds,8127,O
are,8127,O
found,8127,O
to,8127,O
be,8127,O
selective,8127,O
against,8127,O
COX-2,8127,B-GENE-Y
",",8127,O
supported,8127,O
by,8127,O
inhibition,8127,O
of,8127,O
paw,8127,O
edema,8127,O
and,8127,O
vascular,8127,O
permeability,8127,O
.,8127,O
Docking,8128,O
studies,8128,O
were,8128,O
also,8128,O
carried,8128,O
out,8128,O
to,8128,O
determine,8128,O
the,8128,O
structural,8128,O
features,8128,O
which,8128,O
sway,8128,O
the,8128,O
anti-inflammatory,8128,O
activity,8128,O
of,8128,O
the,8128,O
tested,8128,O
compounds,8128,O
.,8128,O
The,8129,O
keto,8129,B-CHEMICAL
and,8129,O
phenolic,8129,B-CHEMICAL
-OH,8129,O
are,8129,O
major,8129,O
factors,8129,O
that,8129,O
are,8129,O
prominently,8129,O
involved,8129,O
in,8129,O
interaction,8129,O
with,8129,O
COX-2,8129,B-GENE-Y
active,8129,O
site,8129,O
.,8129,O
Superparamagnetic,8130,O
Hollow,8130,O
Hybrid,8130,O
Nanogels,8130,O
as,8130,O
a,8130,O
Potential,8130,O
Guidable,8130,O
Vehicle,8130,O
System,8130,O
of,8130,O
Stimuli-Mediated,8130,O
MR,8130,O
Imaging,8130,O
and,8130,O
Multiple,8130,O
Cancer,8130,O
Therapeutics,8130,O
.,8130,O
Hollow,8131,O
hybrid,8131,O
nanogels,8131,O
were,8131,O
prepared,8131,O
first,8131,O
by,8131,O
co-assembly,8131,O
of,8131,O
the,8131,O
citric,8131,B-CHEMICAL
acid-coated,8131,O
superparamagnetic,8131,O
iron,8131,B-CHEMICAL
oxide,8131,I-CHEMICAL
nanoparticles,8131,O
(,8131,O
SPIONs,8131,O
),8131,O
(,8131,O
44,8131,O
wt,8131,O
%,8131,O
),8131,O
with,8131,O
the,8131,O
graft,8131,O
copolymer,8131,O
(,8131,O
56,8131,O
wt,8131,O
%,8131,O
),8131,O
comprising,8131,O
acrylic,8131,B-CHEMICAL
acid,8131,I-CHEMICAL
and,8131,O
2-methacryloylethyl,8131,B-CHEMICAL
acrylate,8131,I-CHEMICAL
units,8131,O
as,8131,O
the,8131,O
backbone,8131,O
and,8131,O
poly,8131,B-CHEMICAL
(,8131,I-CHEMICAL
ethylene,8131,I-CHEMICAL
glycol,8131,I-CHEMICAL
),8131,I-CHEMICAL
and,8131,O
poly,8131,B-CHEMICAL
(,8131,I-CHEMICAL
N-isopropylacrylamide,8131,I-CHEMICAL
),8131,I-CHEMICAL
as,8131,O
the,8131,O
grafts,8131,O
in,8131,O
aqueous,8131,O
phase,8131,O
of,8131,O
pH,8131,O
3.0,8131,O
into,8131,O
the,8131,O
hybrid,8131,O
vesicle,8131,O
structure,8131,O
",",8131,O
followed,8131,O
by,8131,O
in,8131,O
situ,8131,O
covalent,8131,O
stabilization,8131,O
via,8131,O
the,8131,O
photo-initiated,8131,O
polymerization,8131,O
of,8131,O
MEA,8131,B-CHEMICAL
residues,8131,O
within,8131,O
vesicles,8131,O
.,8131,O
The,8132,O
resultant,8132,O
hollow,8132,O
nanogels,8132,O
",",8132,O
though,8132,O
slightly,8132,O
swollen,8132,O
",",8132,O
satisfactorily,8132,O
retain,8132,O
the,8132,O
structural,8132,O
integrity,8132,O
while,8132,O
the,8132,O
medium,8132,O
pH,8132,O
being,8132,O
adjusted,8132,O
to,8132,O
7.4,8132,O
.,8132,O
Confining,8133,O
SPION,8133,O
clusters,8133,O
to,8133,O
such,8133,O
a,8133,O
high,8133,O
level,8133,O
(,8133,O
44,8133,O
wt,8133,O
%,8133,O
),8133,O
within,8133,O
the,8133,O
pH-responsive,8133,O
thin,8133,O
gel,8133,O
layer,8133,O
remarkably,8133,O
enhances,8133,O
the,8133,O
transverse,8133,O
relaxivity,8133,O
(,8133,O
r2,8133,O
),8133,O
and,8133,O
renders,8133,O
the,8133,O
MR,8133,O
imaging,8133,O
highly,8133,O
pH-tunable,8133,O
.,8133,O
For,8134,O
example,8134,O
",",8134,O
with,8134,O
the,8134,O
pH,8134,O
being,8134,O
adjusted,8134,O
from,8134,O
4.0,8134,O
to,8134,O
7.4,8134,O
",",8134,O
the,8134,O
r2,8134,O
value,8134,O
can,8134,O
be,8134,O
dramatically,8134,O
increased,8134,O
from,8134,O
138.5,8134,O
to,8134,O
265.5,8134,O
mM-1,8134,O
s-1,8134,O
.,8134,O
The,8135,O
DOX-loaded,8135,O
hybrid,8135,O
nanogels,8135,O
also,8135,O
exhibit,8135,O
accelerated,8135,O
drug,8135,O
release,8135,O
in,8135,O
response,8135,O
to,8135,O
both,8135,O
pH,8135,O
reduction,8135,O
and,8135,O
temperature,8135,O
increase,8135,O
due,8135,O
to,8135,O
the,8135,O
substantial,8135,O
disruption,8135,O
of,8135,O
the,8135,O
interactions,8135,O
between,8135,O
drug,8135,O
molecules,8135,O
and,8135,O
copolymer,8135,O
components,8135,O
.,8135,O
With,8136,O
magnetic,8136,O
transport,8136,O
guidance,8136,O
toward,8136,O
the,8136,O
target,8136,O
and,8136,O
subsequent,8136,O
exposure,8136,O
to,8136,O
alternating,8136,O
magnetic,8136,O
field,8136,O
",",8136,O
this,8136,O
DOX-loaded,8136,O
nanogel,8136,O
system,8136,O
possessing,8136,O
combined,8136,O
capabilities,8136,O
of,8136,O
hyperthermia,8136,O
and,8136,O
stimuli-triggered,8136,O
drug,8136,O
release,8136,O
showed,8136,O
superior,8136,O
in,8136,O
vitro,8136,O
cytotoxicity,8136,O
against,8136,O
HeLa,8136,O
cells,8136,O
as,8136,O
compared,8136,O
to,8136,O
the,8136,O
case,8136,O
with,8136,O
only,8136,O
free,8136,O
drug,8136,O
or,8136,O
hyperthermia,8136,O
alone,8136,O
.,8136,O
This,8137,O
work,8137,O
demonstrates,8137,O
that,8137,O
the,8137,O
hollow,8137,O
inorganic/organic,8137,O
hybrid,8137,O
nanogels,8137,O
show,8137,O
great,8137,O
potential,8137,O
to,8137,O
serve,8137,O
as,8137,O
a,8137,O
multimodal,8137,O
theranostic,8137,O
vehicle,8137,O
functionalized,8137,O
with,8137,O
such,8137,O
desirable,8137,O
features,8137,O
as,8137,O
guidable,8137,O
delivery,8137,O
of,8137,O
stimuli-mediated,8137,O
diagnostic,8137,O
imaging,8137,O
and,8137,O
hyperthermia/chemotherapies,8137,O
.,8137,O
Progesterone,8138,B-GENE-Y
receptor,8138,I-GENE-Y
induces,8138,O
bcl-x,8138,B-GENE-Y
expression,8138,O
through,8138,O
intragenic,8138,B-GENE-N
binding,8138,I-GENE-N
sites,8138,I-GENE-N
favoring,8138,O
RNA,8138,B-GENE-N
polymerase,8138,I-GENE-N
II,8138,I-GENE-N
elongation,8138,O
.,8138,O
Steroid,8139,B-GENE-N
receptors,8139,I-GENE-N
were,8139,O
classically,8139,O
described,8139,O
for,8139,O
regulating,8139,O
transcription,8139,O
by,8139,O
binding,8139,O
to,8139,O
target,8139,O
gene,8139,O
promoters,8139,O
.,8139,O
However,8140,O
",",8140,O
genome-wide,8140,O
studies,8140,O
reveal,8140,O
that,8140,O
steroid,8140,B-GENE-N
receptors-binding,8140,I-GENE-N
sites,8140,I-GENE-N
are,8140,O
mainly,8140,O
located,8140,O
at,8140,O
intragenic,8140,O
regions,8140,O
.,8140,O
To,8141,O
determine,8141,O
the,8141,O
role,8141,O
of,8141,O
these,8141,O
sites,8141,O
",",8141,O
we,8141,O
examined,8141,O
the,8141,O
effect,8141,O
of,8141,O
progestins,8141,O
on,8141,O
the,8141,O
transcription,8141,O
of,8141,O
the,8141,O
bcl-x,8141,B-GENE-Y
gene,8141,O
",",8141,O
where,8141,O
only,8141,O
intragenic,8141,B-GENE-N
progesterone,8141,I-GENE-N
receptor-binding,8141,I-GENE-N
sites,8141,I-GENE-N
(,8141,O
PRbs,8141,B-GENE-N
),8141,O
were,8141,O
identified,8141,O
.,8141,O
We,8142,O
found,8142,O
that,8142,O
in,8142,O
response,8142,O
to,8142,O
hormone,8142,O
treatment,8142,O
",",8142,O
the,8142,O
PR,8142,B-GENE-Y
is,8142,O
recruited,8142,O
to,8142,O
these,8142,O
sites,8142,O
along,8142,O
with,8142,O
two,8142,O
histone,8142,B-GENE-N
acetyltransferases,8142,I-GENE-N
CREB-binding,8142,B-GENE-Y
protein,8142,I-GENE-Y
(,8142,O
CBP,8142,B-GENE-Y
),8142,O
and,8142,O
GCN5,8142,B-GENE-Y
",",8142,O
leading,8142,O
to,8142,O
an,8142,O
increase,8142,O
in,8142,O
histone,8142,B-GENE-N
H3,8142,I-GENE-N
and,8142,O
H4,8142,B-GENE-N
acetylation,8142,O
and,8142,O
to,8142,O
the,8142,O
binding,8142,O
of,8142,O
the,8142,O
SWI/SNF,8142,B-GENE-N
complex,8142,I-GENE-N
.,8142,O
Concomitant,8143,O
",",8143,O
a,8143,O
more,8143,O
relaxed,8143,O
chromatin,8143,O
was,8143,O
detected,8143,O
along,8143,O
bcl-x,8143,B-GENE-Y
gene,8143,O
mainly,8143,O
in,8143,O
the,8143,O
regions,8143,O
surrounding,8143,O
the,8143,O
intragenic,8143,O
PRbs,8143,B-GENE-N
.,8143,O
PR,8144,B-GENE-Y
also,8144,O
mediated,8144,O
the,8144,O
recruitment,8144,O
of,8144,O
the,8144,O
positive,8144,B-GENE-N
elongation,8144,I-GENE-N
factor,8144,I-GENE-N
pTEFb,8144,B-GENE-N
",",8144,O
favoring,8144,O
RNA,8144,B-GENE-N
polymerase,8144,I-GENE-N
II,8144,I-GENE-N
(,8144,O
Pol,8144,B-GENE-N
II,8144,I-GENE-N
),8144,O
elongation,8144,O
activity,8144,O
.,8144,O
Together,8145,O
these,8145,O
events,8145,O
promoted,8145,O
the,8145,O
re-distribution,8145,O
of,8145,O
the,8145,O
active,8145,O
Pol,8145,B-GENE-N
II,8145,I-GENE-N
toward,8145,O
the,8145,O
3'-end,8145,O
of,8145,O
the,8145,O
gene,8145,O
and,8145,O
a,8145,O
decrease,8145,O
in,8145,O
the,8145,O
ratio,8145,O
between,8145,O
proximal,8145,O
and,8145,O
distal,8145,O
transcription,8145,O
.,8145,O
These,8146,O
results,8146,O
suggest,8146,O
a,8146,O
novel,8146,O
mechanism,8146,O
by,8146,O
which,8146,O
PR,8146,B-GENE-Y
regulates,8146,O
gene,8146,O
expression,8146,O
by,8146,O
facilitating,8146,O
the,8146,O
proper,8146,O
passage,8146,O
of,8146,O
the,8146,O
polymerase,8146,B-GENE-N
along,8146,O
hormone-dependent,8146,O
genes,8146,O
.,8146,O
Lipoxygenase,8147,B-GENE-N
and,8147,O
urease,8147,B-GENE-N
inhibition,8147,O
of,8147,O
the,8147,O
aerial,8147,O
parts,8147,O
of,8147,O
the,8147,O
Polygonatum,8147,O
verticillatum,8147,O
.,8147,O
Over,8148,O
expression,8148,O
of,8148,O
lipoxygenase,8148,B-GENE-N
(,8148,O
LOX,8148,B-GENE-N
),8148,O
and,8148,O
urease,8148,B-GENE-N
has,8148,O
already,8148,O
contributed,8148,O
to,8148,O
the,8148,O
pathology,8148,O
of,8148,O
different,8148,O
human,8148,O
disease,8148,O
.,8148,O
Targeting,8149,O
the,8149,O
inhibition,8149,O
of,8149,O
these,8149,O
enzymes,8149,O
has,8149,O
proved,8149,O
great,8149,O
clinical,8149,O
utility,8149,O
.,8149,O
The,8150,O
aim,8150,O
of,8150,O
the,8150,O
present,8150,O
study,8150,O
was,8150,O
to,8150,O
scrutinised,8150,O
the,8150,O
inhibitory,8150,O
profile,8150,O
of,8150,O
the,8150,O
aerial,8150,O
parts,8150,O
of,8150,O
the,8150,O
Polygonatum,8150,O
verticillatum,8150,O
enzyme,8150,O
against,8150,O
LOX,8150,B-GENE-N
",",8150,O
urease,8150,B-GENE-N
",",8150,O
acetylcholinesterase,8150,B-GENE-Y
(,8150,O
AChE,8150,B-GENE-Y
),8150,O
and,8150,O
butyrylcholinesterase,8150,B-GENE-Y
(,8150,O
BChE,8150,B-GENE-Y
),8150,O
using,8150,O
standard,8150,O
experimental,8150,O
protocols,8150,O
.,8150,O
When,8151,O
checked,8151,O
against,8151,O
lipoxygenase,8151,B-GENE-N
",",8151,O
the,8151,O
extracts,8151,O
revealed,8151,O
significant,8151,O
attenuation,8151,O
.,8151,O
Of,8152,O
the,8152,O
tested,8152,O
extracts,8152,O
",",8152,O
the,8152,O
ethyl,8152,B-CHEMICAL
acetate,8152,I-CHEMICAL
fraction,8152,O
was,8152,O
the,8152,O
most,8152,O
potent,8152,O
(,8152,O
half-maximal,8152,O
inhibitory,8152,O
concentration,8152,O
(,8152,O
IC50,8152,O
),8152,O
:,8152,O
97,8152,O
µg/mL,8152,O
),8152,O
followed,8152,O
by,8152,O
aqueous,8152,O
fraction,8152,O
IC50,8152,O
:,8152,O
109,8152,O
µg/mL,8152,O
),8152,O
.,8152,O
Regarding,8153,O
urease,8153,B-GENE-N
inhibition,8153,O
",",8153,O
n-butanol,8153,B-CHEMICAL
was,8153,O
the,8153,O
most,8153,O
potent,8153,O
fraction,8153,O
(,8153,O
IC50,8153,O
:,8153,O
97,8153,O
µg/mL,8153,O
),8153,O
.,8153,O
However,8154,O
",",8154,O
the,8154,O
extracts,8154,O
did,8154,O
not,8154,O
show,8154,O
significant,8154,O
inhibition,8154,O
on,8154,O
AChE,8154,B-GENE-Y
and,8154,O
BChE,8154,B-GENE-Y
.,8154,O
In,8155,O
the,8155,O
preliminary,8155,O
phytochemical,8155,O
tests,8155,O
",",8155,O
the,8155,O
aerial,8155,O
parts,8155,O
of,8155,O
the,8155,O
plant,8155,O
showed,8155,O
the,8155,O
presence,8155,O
of,8155,O
saponins,8155,B-CHEMICAL
",",8155,O
alkaloids,8155,O
",",8155,O
flavonoids,8155,B-CHEMICAL
",",8155,O
phenols,8155,B-CHEMICAL
",",8155,O
tannins,8155,B-CHEMICAL
and,8155,O
terpenoids,8155,B-CHEMICAL
.,8155,O
The,8156,O
current,8156,O
findings,8156,O
could,8156,O
be,8156,O
attributed,8156,O
to,8156,O
these,8156,O
groups,8156,O
of,8156,O
compounds,8156,O
.,8156,O
A,8157,O
physiologically,8157,O
based,8157,O
pharmacokinetic,8157,O
model,8157,O
for,8157,O
the,8157,O
oxime,8157,B-CHEMICAL
TMB-4,8157,B-CHEMICAL
:,8157,O
simulation,8157,O
of,8157,O
rodent,8157,O
and,8157,O
human,8157,O
data,8157,O
.,8157,O
Multiple,8158,O
oximes,8158,B-CHEMICAL
have,8158,O
been,8158,O
synthesized,8158,O
and,8158,O
evaluated,8158,O
for,8158,O
use,8158,O
as,8158,O
countermeasures,8158,O
against,8158,O
chemical,8158,O
warfare,8158,O
nerve,8158,O
agents,8158,O
.,8158,O
The,8159,O
current,8159,O
U.S.,8159,O
military,8159,O
and,8159,O
civilian,8159,O
oxime,8159,B-CHEMICAL
countermeasure,8159,O
",",8159,O
2-,8159,B-CHEMICAL
[,8159,I-CHEMICAL
(,8159,I-CHEMICAL
hydroxyimino,8159,I-CHEMICAL
),8159,I-CHEMICAL
methyl,8159,I-CHEMICAL
],8159,I-CHEMICAL
-1-methylpyridin-1-ium,8159,I-CHEMICAL
chloride,8159,I-CHEMICAL
(,8159,O
2-PAM,8159,B-CHEMICAL
),8159,O
",",8159,O
is,8159,O
under,8159,O
consideration,8159,O
for,8159,O
replacement,8159,O
with,8159,O
a,8159,O
more,8159,O
effective,8159,O
acetylcholinesterase,8159,B-GENE-Y
reactivator,8159,O
",",8159,O
"1,1'-methylenebis",8159,B-CHEMICAL
{,8159,I-CHEMICAL
4-hydroxyiminomethyl,8159,I-CHEMICAL
},8159,I-CHEMICAL
pyridinium,8159,I-CHEMICAL
dimethanesulfonate,8159,I-CHEMICAL
(,8159,O
MMB-4,8159,B-CHEMICAL
),8159,O
.,8159,O
Kinetic,8160,O
data,8160,O
in,8160,O
the,8160,O
scientific,8160,O
literature,8160,O
for,8160,O
MMB-4,8160,B-CHEMICAL
are,8160,O
limited,8160,O
;,8160,O
therefore,8160,O
",",8160,O
a,8160,O
physiologically,8160,O
based,8160,O
pharmacokinetic,8160,O
(,8160,O
PBPK,8160,O
),8160,O
model,8160,O
was,8160,O
developed,8160,O
for,8160,O
a,8160,O
structurally,8160,O
related,8160,O
oxime,8160,B-CHEMICAL
",",8160,O
"1,1'-trimethylenebis",8160,B-CHEMICAL
{,8160,I-CHEMICAL
4-hydroximinomethyl,8160,I-CHEMICAL
},8160,I-CHEMICAL
pyridinium,8160,I-CHEMICAL
dibromide,8160,I-CHEMICAL
.,8160,O
Based,8161,O
on,8161,O
a,8161,O
previous,8161,O
model,8161,O
structure,8161,O
for,8161,O
the,8161,O
organophosphate,8161,B-CHEMICAL
diisopropylfluorophosphate,8161,B-CHEMICAL
",",8161,O
the,8161,O
model,8161,O
includes,8161,O
key,8161,O
sites,8161,O
of,8161,O
acetylcholinesterase,8161,B-GENE-Y
inhibition,8161,O
(,8161,O
brain,8161,O
and,8161,O
diaphragm,8161,O
),8161,O
",",8161,O
as,8161,O
well,8161,O
as,8161,O
fat,8161,O
",",8161,O
kidney,8161,O
",",8161,O
liver,8161,O
",",8161,O
rapidly,8161,O
perfused,8161,O
tissues,8161,O
and,8161,O
slowly,8161,O
perfused,8161,O
tissues,8161,O
.,8161,O
All,8162,O
tissue,8162,O
compartments,8162,O
are,8162,O
diffusion,8162,O
limited,8162,O
.,8162,O
Model,8163,O
parameters,8163,O
were,8163,O
collected,8163,O
from,8163,O
the,8163,O
literature,8163,O
",",8163,O
predicted,8163,O
using,8163,O
quantitative,8163,O
structure-property,8163,O
relationships,8163,O
or,8163,O
",",8163,O
when,8163,O
necessary,8163,O
",",8163,O
fit,8163,O
to,8163,O
available,8163,O
pharmacokinetic,8163,O
data,8163,O
from,8163,O
the,8163,O
literature,8163,O
.,8163,O
The,8164,O
model,8164,O
was,8164,O
parameterized,8164,O
using,8164,O
rat,8164,O
plasma,8164,O
",",8164,O
tissue,8164,O
and,8164,O
urine,8164,O
time,8164,O
course,8164,O
data,8164,O
from,8164,O
intramuscular,8164,O
administration,8164,O
",",8164,O
as,8164,O
well,8164,O
as,8164,O
human,8164,O
blood,8164,O
and,8164,O
urine,8164,O
data,8164,O
from,8164,O
intravenous,8164,O
and,8164,O
intramuscular,8164,O
administration,8164,O
;,8164,O
sensitivity,8164,O
analyses,8164,O
were,8164,O
performed,8164,O
.,8164,O
The,8165,O
PBPK,8165,O
model,8165,O
successfully,8165,O
simulates,8165,O
rat,8165,O
and,8165,O
human,8165,O
data,8165,O
sets,8165,O
and,8165,O
has,8165,O
been,8165,O
evaluated,8165,O
by,8165,O
predicting,8165,O
intravenous,8165,O
mouse,8165,O
and,8165,O
intramuscular,8165,O
human,8165,O
data,8165,O
not,8165,O
used,8165,O
in,8165,O
the,8165,O
development,8165,O
of,8165,O
the,8165,O
model,8165,O
.,8165,O
Monte,8166,O
Carlo,8166,O
analyses,8166,O
were,8166,O
performed,8166,O
to,8166,O
quantify,8166,O
human,8166,O
population,8166,O
kinetic,8166,O
variability,8166,O
in,8166,O
the,8166,O
human,8166,O
evaluation,8166,O
data,8166,O
set,8166,O
.,8166,O
The,8167,O
model,8167,O
identifies,8167,O
potential,8167,O
pharmacokinetic,8167,O
differences,8167,O
between,8167,O
rodents,8167,O
and,8167,O
humans,8167,O
",",8167,O
indicated,8167,O
by,8167,O
differences,8167,O
in,8167,O
model,8167,O
parameters,8167,O
between,8167,O
species,8167,O
.,8167,O
The,8168,O
PBPK,8168,O
model,8168,O
can,8168,O
be,8168,O
used,8168,O
to,8168,O
optimize,8168,O
the,8168,O
dosing,8168,O
regimen,8168,O
to,8168,O
improve,8168,O
oxime,8168,B-CHEMICAL
therapeutic,8168,O
efficacy,8168,O
in,8168,O
a,8168,O
human,8168,O
population,8168,O
.,8168,O
Creb1-Mecp2-,8169,B-GENE-Y
(,8169,B-CHEMICAL
m,8169,I-CHEMICAL
),8169,I-CHEMICAL
CpG,8169,I-CHEMICAL
complex,8169,O
transactivates,8169,O
postnatal,8169,O
murine,8169,O
neuronal,8169,O
glucose,8169,B-GENE-Y
transporter,8169,I-GENE-Y
isoform,8169,I-GENE-Y
3,8169,I-GENE-Y
expression,8169,O
.,8169,O
The,8170,O
murine,8170,O
neuronal,8170,O
facilitative,8170,O
glucose,8170,B-GENE-Y
transporter,8170,I-GENE-Y
isoform,8170,I-GENE-Y
3,8170,I-GENE-Y
(,8170,O
Glut3,8170,B-GENE-Y
),8170,O
is,8170,O
developmentally,8170,O
regulated,8170,O
",",8170,O
peaking,8170,O
in,8170,O
expression,8170,O
at,8170,O
postnatal,8170,O
day,8170,O
(,8170,O
PN,8170,O
),8170,O
14,8170,O
.,8170,O
In,8171,O
the,8171,O
present,8171,O
study,8171,O
",",8171,O
we,8171,O
characterized,8171,O
a,8171,O
canonical,8171,O
CpG,8171,B-CHEMICAL
island,8171,O
spanning,8171,O
the,8171,O
5'-flanking,8171,O
region,8171,O
of,8171,O
the,8171,O
glut3,8171,B-GENE-Y
gene,8171,O
.,8171,O
Methylation-specific,8172,O
PCR,8172,O
and,8172,O
bisulfite,8172,B-CHEMICAL
sequencing,8172,O
identified,8172,O
methylation,8172,O
of,8172,O
this,8172,O
CpG,8172,B-CHEMICAL
(,8172,O
(,8172,B-CHEMICAL
m,8172,I-CHEMICAL
),8172,I-CHEMICAL
CpG,8172,I-CHEMICAL
),8172,O
island,8172,O
of,8172,O
the,8172,O
glut3,8172,B-GENE-Y
gene,8172,O
",",8172,O
frequency,8172,O
of,8172,O
methylation,8172,O
increasing,8172,O
2.5-fold,8172,O
with,8172,O
a,8172,O
1.6-fold,8172,O
increase,8172,O
in,8172,O
DNA,8172,B-GENE-Y
methyl,8172,I-GENE-Y
transferase,8172,I-GENE-Y
3a,8172,I-GENE-Y
concentrations,8172,O
noted,8172,O
with,8172,O
advancing,8172,O
postnatal,8172,O
age,8172,O
(,8172,O
PN14,8172,O
vs,8172,O
PN3,8172,O
),8172,O
.,8172,O
5'-flanking,8173,O
region,8173,O
of,8173,O
glut3-luciferase,8173,B-GENE-Y
reporter,8173,O
transient,8173,O
transfection,8173,O
in,8173,O
HT22,8173,O
hippocampal,8173,O
neurons,8173,O
demonstrated,8173,O
that,8173,O
(,8173,B-CHEMICAL
m,8173,I-CHEMICAL
),8173,I-CHEMICAL
CpGs,8173,I-CHEMICAL
inhibit,8173,O
glut3,8173,B-GENE-Y
transcription,8173,O
.,8173,O
Contrary,8174,O
to,8174,O
this,8174,O
biological,8174,O
function,8174,O
",",8174,O
glut3,8174,B-GENE-Y
expression,8174,O
rises,8174,O
synchronously,8174,O
with,8174,O
(,8174,B-CHEMICAL
m,8174,I-CHEMICAL
),8174,I-CHEMICAL
CpGs,8174,I-CHEMICAL
in,8174,O
PN14,8174,O
vs,8174,O
PN3,8174,O
neurons,8174,O
.,8174,O
Chromatin,8175,O
immunoprecipitation,8175,O
(,8175,O
IP,8175,O
),8175,O
revealed,8175,O
that,8175,O
methyl-CpG,8175,B-GENE-Y
binding,8175,I-GENE-Y
protein,8175,I-GENE-Y
2,8175,I-GENE-Y
(,8175,O
Mecp2,8175,B-GENE-Y
),8175,O
bound,8175,O
the,8175,O
glut3-,8175,B-GENE-Y
(,8175,B-CHEMICAL
m,8175,I-CHEMICAL
),8175,I-CHEMICAL
CpGs,8175,I-CHEMICAL
.,8175,O
Depending,8176,O
on,8176,O
association,8176,O
with,8176,O
specific,8176,O
coregulators,8176,O
",",8176,O
Mecp2,8176,B-GENE-Y
",",8176,O
a,8176,O
dual,8176,O
regulator,8176,O
of,8176,O
gene,8176,O
transcription,8176,O
",",8176,O
may,8176,O
repress,8176,O
or,8176,O
activate,8176,O
a,8176,O
downstream,8176,O
gene,8176,O
.,8176,O
Sequential,8177,O
chromatin,8177,O
IP,8177,O
uncovered,8177,O
the,8177,O
glut3-,8177,B-GENE-Y
(,8177,B-CHEMICAL
m,8177,I-CHEMICAL
),8177,I-CHEMICAL
CpGs,8177,I-CHEMICAL
to,8177,O
bind,8177,O
Mecp2,8177,B-GENE-Y
exponentially,8177,O
upon,8177,O
recruitment,8177,O
of,8177,O
Creb1,8177,B-GENE-Y
rather,8177,O
than,8177,O
histone,8177,B-GENE-Y
deacetylase,8177,I-GENE-Y
1,8177,I-GENE-Y
.,8177,O
Co-IP,8178,O
and,8178,O
coimmunolocalization,8178,O
confirmed,8178,O
that,8178,O
Creb1,8178,B-GENE-Y
associated,8178,O
with,8178,O
Mecp2,8178,B-GENE-Y
and,8178,O
cotransfection,8178,O
with,8178,O
glut3-,8178,B-GENE-Y
(,8178,B-CHEMICAL
m,8178,I-CHEMICAL
),8178,I-CHEMICAL
CpG,8178,I-CHEMICAL
in,8178,O
HT22,8178,O
cells,8178,O
enhanced,8178,O
glut3,8178,B-GENE-Y
transcription,8178,O
.,8178,O
Separate,8179,O
5-aza-2'-deoxycytidine,8179,B-CHEMICAL
pretreatment,8179,O
or,8179,O
in,8179,O
combination,8179,O
with,8179,O
trichostatin,8179,B-CHEMICAL
A,8179,I-CHEMICAL
reduced,8179,O
(,8179,B-CHEMICAL
m,8179,I-CHEMICAL
),8179,I-CHEMICAL
CpG,8179,I-CHEMICAL
and,8179,O
specific,8179,O
small,8179,O
interference,8179,O
RNAs,8179,O
targeting,8179,O
Mecp2,8179,B-GENE-Y
and,8179,O
Creb1,8179,B-GENE-Y
separately,8179,O
or,8179,O
together,8179,O
depleting,8179,O
Mecp2,8179,B-GENE-Y
and/or,8179,O
Creb1,8179,B-GENE-Y
binding,8179,O
of,8179,O
glut3-,8179,B-GENE-Y
(,8179,B-CHEMICAL
m,8179,I-CHEMICAL
),8179,I-CHEMICAL
CpGs,8179,I-CHEMICAL
reduced,8179,O
glut3,8179,B-GENE-Y
expression,8179,O
in,8179,O
HT22,8179,O
cells,8179,O
.,8179,O
We,8180,O
conclude,8180,O
that,8180,O
Glut3,8180,B-GENE-Y
is,8180,O
a,8180,O
methylation-sensitive,8180,O
neuronal,8180,O
gene,8180,O
that,8180,O
recruits,8180,O
Mecp2,8180,B-GENE-Y
.,8180,O
Recruitment,8181,O
of,8181,O
Creb1-Mecp2,8181,B-GENE-Y
by,8181,O
glut3-,8181,B-GENE-Y
(,8181,B-CHEMICAL
m,8181,I-CHEMICAL
),8181,I-CHEMICAL
CpG,8181,I-CHEMICAL
contributes,8181,O
towards,8181,O
transactivation,8181,O
",",8181,O
formulating,8181,O
an,8181,O
escape,8181,O
from,8181,O
(,8181,B-CHEMICAL
m,8181,I-CHEMICAL
),8181,I-CHEMICAL
CpG-induced,8181,O
gene,8181,O
suppression,8181,O
",",8181,O
and,8181,O
thereby,8181,O
promoting,8181,O
developmental,8181,O
neuronal,8181,O
glut3,8181,B-GENE-Y
gene,8181,O
transcription,8181,O
and,8181,O
expression,8181,O
.,8181,O
Structure,8182,O
of,8182,O
human,8182,B-GENE-Y
microsomal,8182,I-GENE-Y
cytochrome,8182,I-GENE-Y
P450,8182,I-GENE-Y
2C8,8182,I-GENE-Y
.,8182,O
Evidence,8183,O
for,8183,O
a,8183,O
peripheral,8183,B-GENE-N
fatty,8183,I-GENE-N
acid,8183,I-GENE-N
binding,8183,I-GENE-N
site,8183,I-GENE-N
.,8183,O
A,8184,O
2.7-Angstrom,8184,O
molecular,8184,O
structure,8184,O
of,8184,O
human,8184,B-GENE-Y
microsomal,8184,I-GENE-Y
cytochrome,8184,I-GENE-Y
P450,8184,I-GENE-Y
2C8,8184,I-GENE-Y
(,8184,O
CYP2C8,8184,B-GENE-Y
),8184,O
was,8184,O
determined,8184,O
by,8184,O
x-ray,8184,O
crystallography,8184,O
.,8184,O
The,8185,O
membrane,8185,O
protein,8185,O
was,8185,O
modified,8185,O
for,8185,O
crystallization,8185,O
by,8185,O
replacement,8185,O
of,8185,O
the,8185,O
hydrophobic,8185,O
N-terminal,8185,O
transmembrane,8185,O
domain,8185,O
with,8185,O
a,8185,O
short,8185,O
hydrophilic,8185,O
sequence,8185,O
before,8185,O
residue,8185,O
28,8185,O
.,8185,O
The,8186,O
structure,8186,O
of,8186,O
the,8186,O
native,8186,O
sequence,8186,O
is,8186,O
complete,8186,O
from,8186,O
residue,8186,O
28,8186,O
to,8186,O
the,8186,O
beginning,8186,O
of,8186,O
a,8186,O
C-terminal,8186,B-CHEMICAL
histidine,8186,B-CHEMICAL
tag,8186,O
used,8186,O
for,8186,O
purification,8186,O
.,8186,O
CYP2C8,8187,B-GENE-Y
is,8187,O
one,8187,O
of,8187,O
the,8187,O
principal,8187,O
hepatic,8187,O
drug-metabolizing,8187,O
enzymes,8187,O
that,8187,O
oxidizes,8187,O
therapeutic,8187,O
drugs,8187,O
such,8187,O
as,8187,O
taxol,8187,O
and,8187,O
cerivastatin,8187,O
and,8187,O
endobiotics,8187,O
such,8187,O
as,8187,O
retinoic,8187,O
acid,8187,O
and,8187,O
arachidonic,8187,O
acid,8187,O
.,8187,O
Consistent,8188,O
with,8188,O
the,8188,O
relatively,8188,O
large,8188,O
size,8188,O
of,8188,O
its,8188,O
preferred,8188,O
substrates,8188,O
",",8188,O
the,8188,O
active,8188,O
site,8188,O
volume,8188,O
is,8188,O
twice,8188,O
that,8188,O
observed,8188,O
for,8188,O
the,8188,O
structure,8188,O
of,8188,O
CYP2C5,8188,B-GENE-Y
.,8188,O
The,8189,O
extended,8189,O
active,8189,O
site,8189,O
cavity,8189,O
is,8189,O
bounded,8189,O
by,8189,O
the,8189,O
beta1,8189,B-GENE-N
sheet,8189,I-GENE-N
and,8189,O
helix,8189,B-GENE-N
F,8189,I-GENE-N
',8189,I-GENE-N
that,8189,O
have,8189,O
not,8189,O
previously,8189,O
been,8189,O
implicated,8189,O
in,8189,O
substrate,8189,O
recognition,8189,O
by,8189,O
mammalian,8189,B-GENE-N
P450s,8189,I-GENE-N
.,8189,O
CYP2C8,8190,B-GENE-Y
crystallized,8190,O
as,8190,O
a,8190,O
symmetric,8190,O
dimer,8190,O
formed,8190,O
by,8190,O
the,8190,O
interaction,8190,O
of,8190,O
helices,8190,O
F,8190,I-GENE-N
",",8190,I-GENE-N
F,8190,I-GENE-N
',8190,I-GENE-N
",",8190,I-GENE-N
G,8190,I-GENE-N
',8190,I-GENE-N
",",8190,I-GENE-N
and,8190,I-GENE-N
G.,8190,O
Two,8190,O
molecules,8190,O
of,8190,O
palmitic,8190,B-CHEMICAL
acid,8190,I-CHEMICAL
are,8190,O
bound,8190,O
in,8190,O
the,8190,O
dimer,8190,O
interface,8190,O
.,8190,O
The,8191,O
dimer,8191,O
is,8191,O
observed,8191,O
in,8191,O
solution,8191,O
",",8191,O
and,8191,O
mass,8191,O
spectrometry,8191,O
confirmed,8191,O
the,8191,O
association,8191,O
of,8191,O
palmitic,8191,B-CHEMICAL
acid,8191,I-CHEMICAL
with,8191,O
the,8191,O
enzyme,8191,O
.,8191,O
This,8192,O
novel,8192,O
finding,8192,O
identifies,8192,O
a,8192,O
peripheral,8192,O
binding,8192,O
site,8192,O
in,8192,O
P450s,8192,B-GENE-N
that,8192,O
may,8192,O
contribute,8192,O
to,8192,O
drug-drug,8192,O
interactions,8192,O
in,8192,O
P450,8192,B-GENE-N
metabolism,8192,O
.,8192,O
Resistance,8193,O
to,8193,O
conventional,8193,O
insecticides,8193,O
in,8193,O
Pakistani,8193,O
populations,8193,O
of,8193,O
Musca,8193,O
domestica,8193,O
L.,8193,O
(,8193,O
Diptera,8193,O
:,8193,O
Muscidae,8193,O
),8193,O
:,8193,O
a,8193,O
potential,8193,O
ectoparasite,8193,O
of,8193,O
dairy,8193,O
animals,8193,O
.,8193,O
The,8194,O
house,8194,O
fly,8194,O
",",8194,O
Musca,8194,O
domestica,8194,O
L.,8194,O
",",8194,O
is,8194,O
an,8194,O
important,8194,O
hygienic,8194,O
pest,8194,O
of,8194,O
humans,8194,O
and,8194,O
dairy,8194,O
animals,8194,O
with,8194,O
the,8194,O
potential,8194,O
to,8194,O
develop,8194,O
resistance,8194,O
to,8194,O
most,8194,O
chemical,8194,O
classes,8194,O
of,8194,O
insecticides,8194,O
.,8194,O
Six,8195,O
adult,8195,O
house,8195,O
fly,8195,O
strains,8195,O
from,8195,O
dairy,8195,O
farms,8195,O
in,8195,O
Punjab,8195,O
",",8195,O
Pakistan,8195,O
were,8195,O
evaluated,8195,O
for,8195,O
resistance,8195,O
to,8195,O
selected,8195,O
insecticides,8195,O
from,8195,O
organochlorine,8195,B-CHEMICAL
",",8195,O
organophosphate,8195,B-CHEMICAL
",",8195,O
carbamate,8195,B-CHEMICAL
and,8195,O
pyrethroid,8195,B-CHEMICAL
classes,8195,O
.,8195,O
For,8196,O
a,8196,O
chlorocyclodiene,8196,B-CHEMICAL
and,8196,O
two,8196,O
organophosphates,8196,B-CHEMICAL
tested,8196,O
",",8196,O
the,8196,O
resistance,8196,O
ratios,8196,O
(,8196,O
RR,8196,O
),8196,O
at,8196,O
LC50,8196,O
were,8196,O
in,8196,O
the,8196,O
range,8196,O
of,8196,O
5.60-22.02,8196,O
fold,8196,O
for,8196,O
endosulfan,8196,B-CHEMICAL
",",8196,O
7.66-23.24,8196,O
fold,8196,O
for,8196,O
profenofos,8196,O
and,8196,O
2.47-7.44,8196,O
fold,8196,O
for,8196,O
chlorpyrifos,8196,B-CHEMICAL
.,8196,O
For,8197,O
two,8197,O
pyrethroids,8197,B-CHEMICAL
and,8197,O
one,8197,O
carbamate,8197,B-CHEMICAL
",",8197,O
the,8197,O
RR,8197,O
values,8197,O
at,8197,O
LC50,8197,O
were,8197,O
30.22-70.02,8197,O
for,8197,O
cypermethrin,8197,B-CHEMICAL
",",8197,O
5.73-18.31,8197,O
for,8197,O
deltamethrin,8197,B-CHEMICAL
",",8197,O
and,8197,O
4.39-15.50,8197,O
for,8197,O
methomyl,8197,B-CHEMICAL
.,8197,O
This,8198,O
is,8198,O
the,8198,O
first,8198,O
report,8198,O
of,8198,O
resistance,8198,O
to,8198,O
different,8198,O
classes,8198,O
of,8198,O
insecticides,8198,O
in,8198,O
Pakistani,8198,O
dairy,8198,O
populations,8198,O
of,8198,O
house,8198,O
flies,8198,O
.,8198,O
Regular,8199,O
insecticide,8199,O
resistance,8199,O
monitoring,8199,O
programs,8199,O
on,8199,O
dairy,8199,O
farms,8199,O
are,8199,O
needed,8199,O
to,8199,O
prevent,8199,O
field,8199,O
control,8199,O
failures,8199,O
.,8199,O
Moreover,8200,O
",",8200,O
integrated,8200,O
approaches,8200,O
including,8200,O
the,8200,O
judicious,8200,O
use,8200,O
of,8200,O
insecticides,8200,O
are,8200,O
needed,8200,O
to,8200,O
delay,8200,O
the,8200,O
development,8200,O
of,8200,O
insecticide,8200,O
resistance,8200,O
in,8200,O
house,8200,O
flies,8200,O
.,8200,O
Effect,8201,O
of,8201,O
antidepressant,8201,O
drugs,8201,O
in,8201,O
mice,8201,O
lacking,8201,O
the,8201,O
norepinephrine,8201,B-GENE-Y
transporter,8201,I-GENE-Y
.,8201,O
One,8202,O
of,8202,O
the,8202,O
main,8202,O
theories,8202,O
concerning,8202,O
the,8202,O
mechanism,8202,O
of,8202,O
action,8202,O
of,8202,O
antidepressant,8202,O
drugs,8202,O
(,8202,O
ADs,8202,O
),8202,O
is,8202,O
based,8202,O
on,8202,O
the,8202,O
notion,8202,O
that,8202,O
the,8202,O
neurochemical,8202,O
background,8202,O
of,8202,O
depression,8202,O
involves,8202,O
an,8202,O
impairment,8202,O
of,8202,O
central,8202,O
noradrenergic,8202,O
transmission,8202,O
with,8202,O
a,8202,O
concomitant,8202,O
decrease,8202,O
of,8202,O
the,8202,O
norepinephrine,8202,B-CHEMICAL
(,8202,O
NE,8202,B-CHEMICAL
),8202,O
in,8202,O
the,8202,O
synaptic,8202,O
gap,8202,O
.,8202,O
Many,8203,O
ADs,8203,O
increase,8203,O
synaptic,8203,O
NE,8203,B-CHEMICAL
availability,8203,O
by,8203,O
inhibition,8203,O
of,8203,O
the,8203,O
reuptake,8203,O
of,8203,O
NE,8203,B-CHEMICAL
.,8203,O
Using,8204,O
mice,8204,O
lacking,8204,O
NE,8204,B-GENE-Y
transporter,8204,I-GENE-Y
(,8204,O
NET-/-,8204,B-GENE-Y
),8204,O
we,8204,O
examined,8204,O
their,8204,O
baseline,8204,O
phenotype,8204,O
as,8204,O
well,8204,O
as,8204,O
the,8204,O
response,8204,O
in,8204,O
the,8204,O
forced,8204,O
swim,8204,O
test,8204,O
(,8204,O
FST,8204,O
),8204,O
and,8204,O
in,8204,O
the,8204,O
tail,8204,O
suspension,8204,O
test,8204,O
(,8204,O
TST,8204,O
),8204,O
upon,8204,O
treatment,8204,O
with,8204,O
ADs,8204,O
that,8204,O
display,8204,O
different,8204,O
pharmacological,8204,O
profiles,8204,O
.,8204,O
In,8205,O
both,8205,O
tests,8205,O
",",8205,O
the,8205,O
NET-/-,8205,B-GENE-Y
mice,8205,O
behaved,8205,O
like,8205,O
wild-type,8205,O
(,8205,O
WT,8205,O
),8205,O
mice,8205,O
acutely,8205,O
treated,8205,O
with,8205,O
ADs,8205,O
.,8205,O
Autoradiographic,8206,O
studies,8206,O
showed,8206,O
decreased,8206,O
binding,8206,O
of,8206,O
the,8206,O
beta-adrenergic,8206,O
ligand,8206,O
[,8206,B-CHEMICAL
3H,8206,I-CHEMICAL
],8206,I-CHEMICAL
CGP12177,8206,I-CHEMICAL
in,8206,O
the,8206,O
cerebral,8206,O
cortex,8206,O
of,8206,O
NET-/-,8206,B-GENE-Y
mice,8206,O
",",8206,O
indicating,8206,O
the,8206,O
changes,8206,O
at,8206,O
the,8206,O
level,8206,O
of,8206,O
beta-adrenergic,8206,B-GENE-N
receptors,8206,I-GENE-N
similar,8206,O
to,8206,O
those,8206,O
obtained,8206,O
with,8206,O
ADs,8206,O
treatment,8206,O
.,8206,O
The,8207,O
binding,8207,O
of,8207,O
[,8207,B-CHEMICAL
3H,8207,I-CHEMICAL
],8207,I-CHEMICAL
prazosin,8207,I-CHEMICAL
to,8207,O
alpha1-adrenergic,8207,B-GENE-N
receptors,8207,I-GENE-N
in,8207,O
the,8207,O
cerebral,8207,O
cortex,8207,O
of,8207,O
NET-/-,8207,B-GENE-Y
mice,8207,O
was,8207,O
also,8207,O
decreased,8207,O
",",8207,O
most,8207,O
probably,8207,O
as,8207,O
an,8207,O
adaptive,8207,O
response,8207,O
to,8207,O
the,8207,O
sustained,8207,O
elevation,8207,O
of,8207,O
extracellular,8207,O
NE,8207,B-CHEMICAL
levels,8207,O
observed,8207,O
in,8207,O
these,8207,O
mice,8207,O
.,8207,O
A,8208,O
pronounced,8208,O
NET,8208,B-GENE-Y
knockout-induced,8208,O
shortening,8208,O
of,8208,O
the,8208,O
immobility,8208,O
time,8208,O
in,8208,O
the,8208,O
TST,8208,O
(,8208,O
by,8208,O
ca,8208,O
50,8208,O
%,8208,O
),8208,O
compared,8208,O
to,8208,O
WT,8208,O
mice,8208,O
was,8208,O
not,8208,O
reduced,8208,O
any,8208,O
further,8208,O
by,8208,O
NET-inhibiting,8208,B-GENE-Y
ADs,8208,O
such,8208,O
as,8208,O
reboxetine,8208,B-CHEMICAL
",",8208,O
desipramine,8208,B-CHEMICAL
",",8208,O
and,8208,O
imipramine,8208,B-CHEMICAL
.,8208,O
Citalopram,8209,B-CHEMICAL
",",8209,O
which,8209,O
is,8209,O
devoid,8209,O
of,8209,O
affinity,8209,O
for,8209,O
the,8209,O
NET,8209,B-GENE-Y
",",8209,O
exerted,8209,O
a,8209,O
significant,8209,O
reduction,8209,O
of,8209,O
immobility,8209,O
time,8209,O
in,8209,O
the,8209,O
NET-/-,8209,B-GENE-Y
mice,8209,O
.,8209,O
In,8210,O
the,8210,O
FST,8210,O
",",8210,O
reboxetine,8210,B-CHEMICAL
",",8210,O
desipramine,8210,B-CHEMICAL
",",8210,O
imipramine,8210,B-CHEMICAL
",",8210,O
and,8210,O
citalopram,8210,B-CHEMICAL
administered,8210,O
acutely,8210,O
did,8210,O
not,8210,O
reduce,8210,O
any,8210,O
further,8210,O
the,8210,O
immobility,8210,O
time,8210,O
shortened,8210,O
by,8210,O
NET,8210,B-GENE-Y
knockout,8210,O
itself,8210,O
(,8210,O
ca,8210,O
25,8210,O
%,8210,O
),8210,O
;,8210,O
however,8210,O
",",8210,O
antidepressant-like,8210,O
action,8210,O
of,8210,O
repeatedly,8210,O
(,8210,O
7,8210,O
days,8210,O
),8210,O
administered,8210,O
desipramine,8210,B-CHEMICAL
was,8210,O
observed,8210,O
in,8210,O
NET-/-,8210,B-GENE-Y
mice,8210,O
",",8210,O
indicating,8210,O
that,8210,O
the,8210,O
chronic,8210,O
presence,8210,O
of,8210,O
this,8210,O
drug,8210,O
may,8210,O
also,8210,O
affect,8210,O
other,8210,O
neurochemical,8210,O
targets,8210,O
involved,8210,O
in,8210,O
the,8210,O
behavioral,8210,O
reactions,8210,O
monitored,8210,O
by,8210,O
this,8210,O
test,8210,O
.,8210,O
From,8211,O
the,8211,O
present,8211,O
study,8211,O
",",8211,O
it,8211,O
may,8211,O
be,8211,O
concluded,8211,O
that,8211,O
mice,8211,O
lacking,8211,O
the,8211,O
NET,8211,B-GENE-Y
may,8211,O
represent,8211,O
a,8211,O
good,8211,O
model,8211,O
of,8211,O
some,8211,O
aspects,8211,O
of,8211,O
depression-resistant,8211,O
behavior,8211,O
",",8211,O
paralleled,8211,O
with,8211,O
alterations,8211,O
in,8211,O
the,8211,O
expression,8211,O
of,8211,O
adrenergic,8211,B-GENE-N
receptors,8211,I-GENE-N
",",8211,O
which,8211,O
result,8211,O
as,8211,O
an,8211,O
adaptation,8211,O
to,8211,O
elevated,8211,O
levels,8211,O
of,8211,O
extracellular,8211,O
NE,8211,B-CHEMICAL
.,8211,O
In,8212,O
vitro,8212,O
inhibitory,8212,O
effects,8212,O
of,8212,O
non-steroidal,8212,O
anti-inflammatory,8212,O
drugs,8212,O
on,8212,O
4-methylumbelliferone,8212,B-CHEMICAL
glucuronidation,8212,O
in,8212,O
recombinant,8212,O
human,8212,B-GENE-Y
UDP-glucuronosyltransferase,8212,I-GENE-Y
1A9,8212,I-GENE-Y
--,8212,O
potent,8212,O
inhibition,8212,O
by,8212,O
niflumic,8212,B-CHEMICAL
acid,8212,I-CHEMICAL
.,8212,O
The,8213,O
inhibitory,8213,O
potencies,8213,O
of,8213,O
non-steroidal,8213,O
anti-inflammatory,8213,O
drugs,8213,O
(,8213,O
NSAIDs,8213,O
),8213,O
on,8213,O
UDP-glucuronosyltransferase,8213,B-GENE-Y
(,8213,I-GENE-Y
UGT,8213,I-GENE-Y
),8213,I-GENE-Y
1A9,8213,I-GENE-Y
activity,8213,O
were,8213,O
investigated,8213,O
in,8213,O
recombinant,8213,O
human,8213,B-GENE-Y
UGT1A9,8213,I-GENE-Y
using,8213,O
4-methylumbelliferone,8213,B-CHEMICAL
(,8213,O
4-MU,8213,B-CHEMICAL
),8213,O
as,8213,O
a,8213,O
substrate,8213,O
for,8213,O
glucuronidation,8213,O
.,8213,O
4-MU,8214,B-CHEMICAL
glucuronidation,8214,O
(,8214,O
4-MUG,8214,O
),8214,O
showed,8214,O
Michaelis-Menten,8214,O
kinetics,8214,O
with,8214,O
a,8214,O
Km,8214,O
value,8214,O
of,8214,O
6.7,8214,O
microM,8214,O
.,8214,O
The,8215,O
inhibitory,8215,O
effects,8215,O
of,8215,O
the,8215,O
following,8215,O
seven,8215,O
NSAIDs,8215,O
were,8215,O
investigated,8215,O
:,8215,O
acetaminophen,8215,B-CHEMICAL
",",8215,O
diclofenac,8215,B-CHEMICAL
",",8215,O
diflunisal,8215,B-CHEMICAL
",",8215,O
indomethacin,8215,B-CHEMICAL
",",8215,O
ketoprofen,8215,B-CHEMICAL
",",8215,O
naproxen,8215,B-CHEMICAL
and,8215,O
niflumic,8215,B-CHEMICAL
acid,8215,I-CHEMICAL
.,8215,O
Niflumic,8216,B-CHEMICAL
acid,8216,I-CHEMICAL
had,8216,O
the,8216,O
most,8216,O
potent,8216,O
inhibitory,8216,O
effect,8216,O
on,8216,O
4-MUG,8216,O
with,8216,O
an,8216,O
IC50,8216,O
value,8216,O
of,8216,O
0.0341,8216,O
microM,8216,O
.,8216,O
The,8217,O
IC50,8217,O
values,8217,O
of,8217,O
diflunisal,8217,B-CHEMICAL
",",8217,O
diclofenac,8217,B-CHEMICAL
and,8217,O
indomethacin,8217,B-CHEMICAL
were,8217,O
1.31,8217,O
",",8217,O
24.2,8217,O
",",8217,O
and,8217,O
34.1,8217,O
microM,8217,O
",",8217,O
respectively,8217,O
",",8217,O
while,8217,O
acetaminophen,8217,B-CHEMICAL
",",8217,O
ketoprofen,8217,B-CHEMICAL
and,8217,O
naproxen,8217,B-CHEMICAL
showed,8217,O
less,8217,O
potent,8217,O
inhibition,8217,O
.,8217,O
Niflumic,8218,B-CHEMICAL
acid,8218,I-CHEMICAL
",",8218,O
diflunisal,8218,B-CHEMICAL
",",8218,O
diclofenac,8218,B-CHEMICAL
and,8218,O
indomethacin,8218,B-CHEMICAL
inhibited,8218,O
4-MUG,8218,O
competitively,8218,O
with,8218,O
Ki,8218,O
values,8218,O
of,8218,O
0.0275,8218,O
",",8218,O
0.710,8218,O
",",8218,O
53.3,8218,O
and,8218,O
69.9,8218,O
microM,8218,O
",",8218,O
respectively,8218,O
",",8218,O
being,8218,O
similar,8218,O
to,8218,O
each,8218,O
IC50,8218,O
value,8218,O
.,8218,O
In,8219,O
conclusion,8219,O
",",8219,O
of,8219,O
the,8219,O
seven,8219,O
NSAIDs,8219,O
investigated,8219,O
",",8219,O
niflumic,8219,B-CHEMICAL
acid,8219,I-CHEMICAL
was,8219,O
the,8219,O
most,8219,O
potent,8219,O
inhibitor,8219,O
of,8219,O
recombinant,8219,O
UGT1A9,8219,B-GENE-Y
via,8219,O
4-MUG,8219,O
in,8219,O
a,8219,O
competitive,8219,O
manner,8219,O
.,8219,O
Affinities,8220,O
of,8220,O
venlafaxine,8220,B-CHEMICAL
and,8220,O
various,8220,O
reuptake,8220,O
inhibitors,8220,O
for,8220,O
the,8220,O
serotonin,8220,B-GENE-N
and,8220,I-GENE-N
norepinephrine,8220,I-GENE-N
transporters,8220,I-GENE-N
.,8220,O
In,8221,O
vitro,8221,O
radioligand,8221,O
binding,8221,O
studies,8221,O
were,8221,O
carried,8221,O
out,8221,O
in,8221,O
rat,8221,O
brain,8221,O
membranes,8221,O
to,8221,O
assess,8221,O
the,8221,O
affinity,8221,O
of,8221,O
various,8221,O
reuptake,8221,O
inhibitors,8221,O
for,8221,O
the,8221,O
serotonin,8221,B-GENE-N
(,8221,I-GENE-N
5-hydroxytryptamine,8221,I-GENE-N
",",8221,I-GENE-N
5-HT,8221,I-GENE-N
),8221,I-GENE-N
and,8221,I-GENE-N
the,8221,I-GENE-N
norepinephrine,8221,I-GENE-N
transporters,8221,I-GENE-N
using,8221,O
the,8221,O
selective,8221,O
ligands,8221,O
[,8221,B-CHEMICAL
3H,8221,I-CHEMICAL
],8221,I-CHEMICAL
cyanoimipramine,8221,I-CHEMICAL
and,8221,O
[,8221,B-CHEMICAL
3H,8221,I-CHEMICAL
],8221,I-CHEMICAL
nisoxetine,8221,I-CHEMICAL
",",8221,O
respectively,8221,O
.,8221,O
The,8222,O
selective,8222,O
5-HT,8222,B-CHEMICAL
reuptake,8222,O
inhibitors,8222,O
paroxetine,8222,B-CHEMICAL
",",8222,O
indalpine,8222,B-CHEMICAL
and,8222,O
fluvoxamine,8222,B-CHEMICAL
displayed,8222,O
a,8222,O
high,8222,O
affinity,8222,O
for,8222,O
the,8222,O
5-HT,8222,B-GENE-Y
transporter,8222,I-GENE-Y
",",8222,O
whereas,8222,O
the,8222,O
norepinephrine,8222,B-CHEMICAL
reuptake,8222,O
inhibitor,8222,O
desipramine,8222,B-CHEMICAL
had,8222,O
a,8222,O
high,8222,O
affinity,8222,O
for,8222,O
the,8222,O
norepinephrine,8222,B-GENE-Y
transporter,8222,I-GENE-Y
.,8222,O
Duloxetine,8223,B-CHEMICAL
",",8223,O
a,8223,O
dual,8223,O
5-HT,8223,B-CHEMICAL
and,8223,O
norepinephrine,8223,B-CHEMICAL
reuptake,8223,O
inhibitor,8223,O
",",8223,O
displayed,8223,O
a,8223,O
high,8223,O
affinity,8223,O
for,8223,O
both,8223,O
the,8223,O
5-HT,8223,B-GENE-N
and,8223,I-GENE-N
the,8223,I-GENE-N
norepinephrine,8223,I-GENE-N
transporters,8223,I-GENE-N
.,8223,O
Interestingly,8224,O
",",8224,O
venlafaxine,8224,B-CHEMICAL
",",8224,O
a,8224,O
dual,8224,O
5-HT,8224,B-CHEMICAL
and,8224,O
norepinephrine,8224,B-CHEMICAL
reuptake,8224,O
inhibitor,8224,O
",",8224,O
displayed,8224,O
only,8224,O
a,8224,O
moderate,8224,O
affinity,8224,O
for,8224,O
the,8224,O
5-HT,8224,B-GENE-Y
transporter,8224,I-GENE-Y
(,8224,O
Ki,8224,O
=,8224,O
74,8224,O
nM,8224,O
),8224,O
and,8224,O
a,8224,O
very,8224,O
low,8224,O
affinity,8224,O
for,8224,O
the,8224,O
norepinephrine,8224,B-GENE-Y
transporter,8224,I-GENE-Y
(,8224,O
Ki,8224,O
=,8224,O
1.26,8224,O
microM,8224,O
),8224,O
.,8224,O
The,8225,O
relatively,8225,O
low,8225,O
affinities,8225,O
of,8225,O
venlafaxine,8225,B-CHEMICAL
contrast,8225,O
with,8225,O
its,8225,O
potent,8225,O
in,8225,O
vivo,8225,O
5-HT,8225,B-CHEMICAL
and,8225,O
norepinephrine,8225,B-CHEMICAL
reuptake,8225,O
blocking,8225,O
properties,8225,O
.,8225,O
These,8226,O
results,8226,O
raise,8226,O
the,8226,O
possibility,8226,O
that,8226,O
the,8226,O
in,8226,O
vivo,8226,O
effects,8226,O
on,8226,O
the,8226,O
5-HT,8226,B-CHEMICAL
and,8226,O
norepinephrine,8226,B-CHEMICAL
reuptake,8226,O
observed,8226,O
with,8226,O
venlafaxine,8226,B-CHEMICAL
may,8226,O
not,8226,O
be,8226,O
mediated,8226,O
solely,8226,O
by,8226,O
its,8226,O
binding,8226,O
to,8226,O
the,8226,O
[,8226,B-CHEMICAL
3H,8226,I-CHEMICAL
],8226,I-CHEMICAL
cyanoimipramine,8226,I-CHEMICAL
and,8226,O
[,8226,B-CHEMICAL
3H,8226,I-CHEMICAL
],8226,I-CHEMICAL
nisoxetine,8226,I-CHEMICAL
binding,8226,O
sites,8226,O
.,8226,O
Xanthurenic,8227,O
aciduria,8227,O
due,8227,O
to,8227,O
a,8227,O
mutation,8227,O
in,8227,O
KYNU,8227,B-GENE-Y
encoding,8227,O
kynureninase,8227,B-GENE-Y
.,8227,O
Massive,8228,O
urinary,8228,O
excretion,8228,O
of,8228,O
xanthurenic,8228,B-CHEMICAL
acid,8228,I-CHEMICAL
",",8228,O
3-hydroxykynurenine,8228,B-CHEMICAL
and,8228,O
kynurenine,8228,B-CHEMICAL
",",8228,O
known,8228,O
as,8228,O
xanthurenic,8228,O
aciduria,8228,O
or,8228,O
hydroxykynureninuria,8228,O
",",8228,O
in,8228,O
a,8228,O
young,8228,O
Somali,8228,O
boy,8228,O
suggested,8228,O
kynureninase,8228,B-GENE-Y
deficiency,8228,O
.,8228,O
Mutation,8229,O
analysis,8229,O
of,8229,O
KYNU,8229,B-GENE-Y
encoding,8229,O
kynureninase,8229,B-GENE-Y
of,8229,O
the,8229,O
index,8229,O
case,8229,O
revealed,8229,O
homozygosity,8229,O
for,8229,O
a,8229,O
c.593,8229,O
A,8229,B-GENE-N
>,8229,I-GENE-N
G,8229,I-GENE-N
substitution,8229,O
leading,8229,O
to,8229,O
a,8229,O
threonine-to-alanine,8229,B-GENE-N
(,8229,O
T198A,8229,B-GENE-N
),8229,O
shift,8229,O
.,8229,O
A,8230,O
younger,8230,O
brother,8230,O
was,8230,O
found,8230,O
to,8230,O
have,8230,O
a,8230,O
similar,8230,O
excretion,8230,O
pattern,8230,O
and,8230,O
the,8230,O
same,8230,O
genotype,8230,O
.,8230,O
At,8231,O
present,8231,O
",",8231,O
neither,8231,O
of,8231,O
the,8231,O
two,8231,O
boys,8231,O
has,8231,O
symptoms,8231,O
of,8231,O
niacin,8231,O
deficiency,8231,O
.,8231,O
This,8232,O
is,8232,O
the,8232,O
first,8232,O
report,8232,O
linking,8232,O
xanthurenic,8232,O
aciduria,8232,O
to,8232,O
a,8232,O
mutation,8232,O
in,8232,O
the,8232,O
gene,8232,O
encoding,8232,O
kynureninase,8232,B-GENE-Y
.,8232,O
Co-C,8233,B-CHEMICAL
bond,8233,O
activation,8233,O
in,8233,O
methylmalonyl-CoA,8233,B-GENE-Y
mutase,8233,I-GENE-Y
by,8233,O
stabilization,8233,O
of,8233,O
the,8233,O
post-homolysis,8233,O
product,8233,O
Co2+,8233,B-CHEMICAL
cobalamin,8233,B-CHEMICAL
.,8233,O
Despite,8234,O
decades,8234,O
of,8234,O
research,8234,O
",",8234,O
the,8234,O
mechanism,8234,O
by,8234,O
which,8234,O
coenzyme,8234,B-CHEMICAL
B12,8234,I-CHEMICAL
(,8234,O
adenosylcobalamin,8234,B-CHEMICAL
",",8234,O
AdoCbl,8234,B-CHEMICAL
),8234,O
-dependent,8234,O
enzymes,8234,O
promote,8234,O
homolytic,8234,O
cleavage,8234,O
of,8234,O
the,8234,O
cofactor,8234,O
's,8234,O
Co-C,8234,B-CHEMICAL
bond,8234,O
to,8234,O
initiate,8234,O
catalysis,8234,O
has,8234,O
continued,8234,O
to,8234,O
elude,8234,O
researchers,8234,O
.,8234,O
In,8235,O
this,8235,O
work,8235,O
",",8235,O
we,8235,O
utilized,8235,O
magnetic,8235,O
circular,8235,O
dichroism,8235,O
spectroscopy,8235,O
to,8235,O
explore,8235,O
how,8235,O
the,8235,O
electronic,8235,O
structure,8235,O
of,8235,O
the,8235,O
reduced,8235,O
B12,8235,O
cofactor,8235,O
(,8235,O
i.e.,8235,O
",",8235,O
the,8235,O
post-homolysis,8235,O
product,8235,O
Co2+,8235,B-CHEMICAL
Cbl,8235,I-CHEMICAL
),8235,O
is,8235,O
modulated,8235,O
by,8235,O
the,8235,O
enzyme,8235,O
methylmalonyl-CoA,8235,B-GENE-Y
mutase,8235,I-GENE-Y
.,8235,O
Our,8236,O
data,8236,O
reveal,8236,O
a,8236,O
fairly,8236,O
uniform,8236,O
stabilization,8236,O
of,8236,O
the,8236,O
Co,8236,O
3d,8236,O
orbitals,8236,O
relative,8236,O
to,8236,O
the,8236,O
corrin,8236,O
pi/pi,8236,O
*,8236,O
-based,8236,O
molecular,8236,O
orbitals,8236,O
when,8236,O
Co2+,8236,B-CHEMICAL
Cbl,8236,I-CHEMICAL
is,8236,O
bound,8236,O
to,8236,O
the,8236,O
enzyme,8236,O
active,8236,O
site,8236,O
",",8236,O
particularly,8236,O
in,8236,O
the,8236,O
presence,8236,O
of,8236,O
substrate,8236,O
.,8236,O
Contrastingly,8237,O
",",8237,O
our,8237,O
previous,8237,O
studies,8237,O
(,8237,O
Brooks,8237,O
",",8237,O
A.,8237,O
J.,8237,O
;,8237,O
Vlasie,8237,O
",",8237,O
M.,8237,O
;,8237,O
Banerjee,8237,O
",",8237,O
R.,8237,O
;,8237,O
Brunold,8237,O
",",8237,O
T.,8237,O
C.,8237,O
J,8237,O
.,8237,O
Am,8238,O
.,8238,O
Chem,8239,O
.,8239,O
Soc,8240,O
.,8240,O
2004,8241,O
",",8241,O
126,8241,O
",",8241,O
8167-8180,8241,O
.,8241,O
),8241,O
showed,8242,O
that,8242,O
when,8242,O
AdoCbl,8242,B-CHEMICAL
is,8242,O
bound,8242,O
to,8242,O
the,8242,O
MMCM,8242,B-GENE-Y
active,8242,O
site,8242,O
",",8242,O
no,8242,O
enzymatic,8242,O
perturbation,8242,O
of,8242,O
the,8242,O
Co3+,8242,B-CHEMICAL
Cbl,8242,I-CHEMICAL
electronic,8242,O
structure,8242,O
occurs,8242,O
",",8242,O
even,8242,O
in,8242,O
the,8242,O
presence,8242,O
of,8242,O
substrate,8242,O
(,8242,O
analogues,8242,O
),8242,O
.,8242,O
Collectively,8243,O
",",8243,O
these,8243,O
observations,8243,O
provide,8243,O
direct,8243,O
evidence,8243,O
that,8243,O
enzymatic,8243,O
Co-C,8243,B-CHEMICAL
bond,8243,O
activation,8243,O
involves,8243,O
stabilization,8243,O
of,8243,O
the,8243,O
post-homolysis,8243,O
product,8243,O
",",8243,O
Co2+,8243,B-CHEMICAL
Cbl,8243,I-CHEMICAL
",",8243,O
rather,8243,O
than,8243,O
destabilization,8243,O
of,8243,O
the,8243,O
Co3+,8243,B-CHEMICAL
Cbl,8243,I-CHEMICAL
``,8243,O
ground,8243,O
'',8243,O
state,8243,O
.,8243,O
Neurotoxicity,8244,O
of,8244,O
``,8244,O
ecstasy,8244,B-CHEMICAL
'',8244,O
and,8244,O
its,8244,O
metabolites,8244,O
in,8244,O
human,8244,O
dopaminergic,8244,O
differentiated,8244,O
SH-SY5Y,8244,O
cells,8244,O
.,8244,O
Ecstasy,8245,O
(,8245,O
"3,4-methylenedioxymethamphetamine",8245,O
or,8245,O
MDMA,8245,O
),8245,I-CHEMICAL
is,8245,O
a,8245,O
widely,8245,O
abused,8245,O
recreational,8245,O
drug,8245,O
",",8245,O
reported,8245,O
to,8245,O
produce,8245,O
neurotoxic,8245,O
effects,8245,O
",",8245,O
both,8245,O
in,8245,O
laboratory,8245,O
animals,8245,O
and,8245,O
in,8245,O
humans,8245,O
.,8245,O
MDMA,8246,O
metabolites,8246,O
can,8246,O
be,8246,O
major,8246,O
contributors,8246,O
for,8246,O
MDMA,8246,O
neurotoxicity,8246,O
.,8246,O
This,8247,O
work,8247,O
studied,8247,O
the,8247,O
neurotoxicity,8247,O
of,8247,O
MDMA,8247,O
and,8247,O
its,8247,O
catechol,8247,O
metabolites,8247,O
",",8247,O
α-methyldopamine,8247,O
(,8247,I-CHEMICAL
α-MeDA,8247,O
),8247,I-CHEMICAL
and,8247,O
N-methyl-α-methyldopamine,8247,O
(,8247,I-CHEMICAL
N-Me-α-MeDA,8247,O
),8247,I-CHEMICAL
in,8247,O
human,8247,O
dopaminergic,8247,O
SH-SY5Y,8247,O
cells,8247,O
differentiated,8247,O
with,8247,O
retinoic,8247,O
acid,8247,I-CHEMICAL
and,8247,O
12-O-tetradecanoyl-phorbol-13-acetate,8247,O
.,8247,O
Differentiation,8248,O
led,8248,O
to,8248,O
SH-SY5Y,8248,O
neurons,8248,O
with,8248,O
higher,8248,O
ability,8248,O
to,8248,O
accumulate,8248,O
dopamine,8248,O
and,8248,O
higher,8248,O
resistance,8248,O
towards,8248,O
dopamine,8248,O
neurotoxicity,8248,O
.,8248,O
MDMA,8249,O
catechol,8249,O
metabolites,8249,O
were,8249,O
neurotoxic,8249,O
to,8249,O
SH-SY5Y,8249,O
neurons,8249,O
",",8249,O
leading,8249,O
to,8249,O
caspase,8249,O
3-independent,8249,O
cell,8249,O
death,8249,O
in,8249,O
a,8249,O
concentration-,8249,O
and,8249,O
time-dependent,8249,O
manner,8249,O
.,8249,O
MDMA,8250,O
did,8250,O
not,8250,O
show,8250,O
a,8250,O
concentration-,8250,O
and,8250,O
time-dependent,8250,O
death,8250,O
.,8250,O
Pre-treatment,8251,O
with,8251,O
the,8251,O
antioxidant,8251,O
and,8251,O
glutathione,8251,O
precursor,8251,O
",",8251,O
N-acetylcysteine,8251,O
(,8251,I-CHEMICAL
NAC,8251,O
),8251,I-CHEMICAL
",",8251,I-CHEMICAL
resulted,8251,O
in,8251,O
strong,8251,O
protection,8251,O
against,8251,O
the,8251,O
MDMA,8251,O
metabolites,8251,O
',8251,O
neurotoxicity,8251,O
.,8251,O
Neither,8252,O
the,8252,O
superoxide,8252,O
radical,8252,O
scavenger,8252,O
",",8252,O
tiron,8252,O
",",8252,O
nor,8252,O
the,8252,O
inhibitor,8252,O
of,8252,O
the,8252,O
dopamine,8252,O
(,8252,I-GENE-Y
DA,8252,I-GENE-Y
),8252,I-GENE-Y
transporter,8252,I-GENE-Y
",",8252,I-GENE-Y
GBR,8252,O
12909,8252,I-CHEMICAL
",",8252,I-CHEMICAL
prevented,8252,O
the,8252,O
metabolites,8252,O
',8252,O
toxicity,8252,O
.,8252,O
Cells,8253,O
exposed,8253,O
to,8253,O
α-MeDA,8253,O
showed,8253,O
an,8253,O
increase,8253,O
in,8253,O
intracellular,8253,O
glutathione,8253,O
(,8253,I-CHEMICAL
GSH,8253,O
),8253,I-CHEMICAL
levels,8253,O
",",8253,O
which,8253,O
",",8253,O
at,8253,O
the,8253,O
48,8253,O
h,8253,O
time-point,8253,O
",",8253,O
was,8253,O
not,8253,O
dependent,8253,O
in,8253,O
the,8253,O
activity,8253,O
increase,8253,O
of,8253,O
γ-glutamylcysteine,8253,O
synthetase,8253,I-GENE-Y
(,8253,I-GENE-Y
γ-GCS,8253,O
),8253,I-GENE-Y
",",8253,I-GENE-Y
revealing,8253,O
a,8253,O
possible,8253,O
transient,8253,O
effect,8253,O
.,8253,O
Importantly,8254,O
",",8254,O
pre-treatment,8254,O
with,8254,O
buthionine,8254,O
sulfoximine,8254,I-CHEMICAL
(,8254,I-CHEMICAL
BSO,8254,O
),8254,I-CHEMICAL
",",8254,I-CHEMICAL
an,8254,O
inhibitor,8254,O
of,8254,O
γ-GCS,8254,O
",",8254,I-GENE-Y
prevented,8254,O
α-MeDA,8254,O
induced,8254,O
increase,8254,O
in,8254,O
GSH,8254,O
levels,8254,O
",",8254,O
but,8254,O
did,8254,O
not,8254,O
augment,8254,O
this,8254,O
metabolite,8254,O
cytotoxicity,8254,O
.,8254,O
Even,8255,O
so,8255,O
",",8255,O
BSO,8255,O
pre-treatment,8255,O
abolished,8255,O
NAC,8255,O
protective,8255,O
effects,8255,O
against,8255,O
α-MeDA,8255,O
neurotoxicity,8255,O
",",8255,O
which,8255,O
were,8255,O
",",8255,O
at,8255,O
least,8255,O
partially,8255,O
",",8255,O
due,8255,O
to,8255,O
GSH,8255,O
de,8255,O
novo,8255,O
synthesis,8255,O
.,8255,O
Inversely,8256,O
",",8256,O
pre-treatment,8256,O
of,8256,O
cells,8256,O
with,8256,O
BSO,8256,O
augmented,8256,O
N-Me-α-MeDA-induced,8256,O
neurotoxicity,8256,O
",",8256,O
but,8256,O
only,8256,O
slightly,8256,O
affected,8256,O
NAC,8256,O
neuroprotection,8256,O
.,8256,O
In,8257,O
conclusion,8257,O
",",8257,O
MDMA,8257,O
catechol,8257,O
metabolites,8257,O
promote,8257,O
differential,8257,O
toxic,8257,O
effects,8257,O
to,8257,O
differentiated,8257,O
dopaminergic,8257,O
human,8257,O
SH-SY5Y,8257,O
cells,8257,O
.,8257,O
A,8258,O
New,8258,O
Proposed,8258,O
Rodent,8258,O
Model,8258,O
of,8258,O
Chemically,8258,O
Induced,8258,O
Prostate,8258,O
Carcinogenesis,8258,O
:,8258,O
Distinct,8258,O
Time-Course,8258,O
Prostate,8258,O
Cancer,8258,O
Progression,8258,O
in,8258,O
the,8258,O
Dorsolateral,8258,O
and,8258,O
Ventral,8258,O
Lobes,8258,O
.,8258,O
BACKGROUND,8259,O
:,8259,O
Characterization,8259,O
of,8259,O
novel,8259,O
rodent,8259,O
models,8259,O
for,8259,O
prostate,8259,O
cancer,8259,O
studies,8259,O
requires,8259,O
evaluation,8259,O
of,8259,O
either,8259,O
spontaneous,8259,O
and,8259,O
carcinogen-induced,8259,O
tumors,8259,O
as,8259,O
well,8259,O
as,8259,O
tumor,8259,O
incidence,8259,O
in,8259,O
different,8259,O
prostatic,8259,O
lobes,8259,O
.,8259,O
We,8260,O
propose,8260,O
a,8260,O
new,8260,O
short-term,8260,O
rodent,8260,O
model,8260,O
of,8260,O
chemically,8260,O
induced,8260,O
prostate,8260,O
carcinogenesis,8260,O
in,8260,O
which,8260,O
prostate,8260,O
cancer,8260,O
progression,8260,O
occurs,8260,O
differentially,8260,O
in,8260,O
the,8260,O
dorsolateral,8260,O
and,8260,O
ventral,8260,O
lobes,8260,O
.,8260,O
METHODS,8261,O
:,8261,O
Adult,8261,O
gerbils,8261,O
were,8261,O
treated,8261,O
with,8261,O
MNU,8261,B-CHEMICAL
alone,8261,O
or,8261,O
associated,8261,O
with,8261,O
testosterone,8261,B-CHEMICAL
for,8261,O
3,8261,O
or,8261,O
6,8261,O
months,8261,O
of,8261,O
treatment,8261,O
.,8261,O
Tumor,8262,O
incidence,8262,O
",",8262,O
latency,8262,O
",",8262,O
localization,8262,O
",",8262,O
and,8262,O
immunohistochemistry,8262,O
(,8262,O
AR,8262,B-GENE-N
",",8262,O
PCNA,8262,B-GENE-N
",",8262,O
smooth,8262,B-GENE-N
muscle,8262,I-GENE-N
α-actin,8262,I-GENE-N
",",8262,O
p63,8262,B-GENE-N
",",8262,O
MGMT,8262,B-GENE-N
",",8262,O
and,8262,O
E-cadherin,8262,B-GENE-Y
),8262,O
were,8262,O
studied,8262,O
in,8262,O
both,8262,O
lobes,8262,O
.,8262,O
RESULTS,8263,O
:,8263,O
Comparisons,8263,O
between,8263,O
both,8263,O
lobes,8263,O
revealed,8263,O
that,8263,O
lesions,8263,O
developed,8263,O
first,8263,O
in,8263,O
the,8263,O
DL,8263,O
while,8263,O
the,8263,O
VL,8263,O
presented,8263,O
longer,8263,O
tumor,8263,O
latency,8263,O
.,8263,O
However,8264,O
",",8264,O
after,8264,O
6,8264,O
months,8264,O
",",8264,O
there,8264,O
was,8264,O
a,8264,O
dramatic,8264,O
increase,8264,O
in,8264,O
tumor,8264,O
multiplicity,8264,O
in,8264,O
the,8264,O
VL,8264,O
",",8264,O
mainly,8264,O
in,8264,O
MNU-treated,8264,B-CHEMICAL
groups,8264,O
.,8264,O
Lesions,8265,O
clearly,8265,O
progressed,8265,O
from,8265,O
a,8265,O
premalignant,8265,O
to,8265,O
a,8265,O
malignant,8265,O
phenotype,8265,O
over,8265,O
time,8265,O
and,8265,O
tumor,8265,O
latency,8265,O
was,8265,O
decreased,8265,O
by,8265,O
MNU,8265,B-CHEMICAL
+,8265,O
testosterone,8265,B-CHEMICAL
administration,8265,O
.,8265,O
Three-dimensional,8266,O
reconstruction,8266,O
of,8266,O
the,8266,O
prostatic,8266,O
complex,8266,O
showed,8266,O
that,8266,O
the,8266,O
DL,8266,O
developed,8266,O
tumors,8266,O
exclusively,8266,O
in,8266,O
the,8266,O
periurethral,8266,O
area,8266,O
and,8266,O
showed,8266,O
intense,8266,O
AR,8266,B-GENE-N
",",8266,O
PCNA,8266,B-GENE-N
",",8266,O
and,8266,O
MGMT,8266,B-GENE-N
immunostaining,8266,O
.,8266,O
Moreover,8267,O
",",8267,O
VL,8267,O
lesions,8267,O
emerged,8267,O
throughout,8267,O
the,8267,O
entire,8267,O
lobe,8267,O
.,8267,O
MNU-induced,8268,B-CHEMICAL
lesions,8268,O
presented,8268,O
markers,8268,O
indicative,8268,O
of,8268,O
an,8268,O
aggressive,8268,O
phenotype,8268,O
:,8268,O
lack,8268,O
of,8268,O
basal,8268,O
cells,8268,O
",",8268,O
rupture,8268,O
of,8268,O
the,8268,O
smooth,8268,O
muscle,8268,O
cell,8268,O
layer,8268,O
",",8268,O
loss,8268,O
of,8268,O
E-cadherin,8268,B-GENE-Y
",",8268,O
and,8268,O
high,8268,O
MGMT,8268,B-GENE-N
staining,8268,O
.,8268,O
CONCLUSIONS,8269,O
:,8269,O
There,8269,O
are,8269,O
distinct,8269,O
pathways,8269,O
involved,8269,O
in,8269,O
tumor,8269,O
progression,8269,O
in,8269,O
gerbil,8269,O
prostate,8269,O
lobes,8269,O
.,8269,O
This,8270,O
animal,8270,O
provides,8270,O
a,8270,O
good,8270,O
model,8270,O
for,8270,O
prostate,8270,O
cancer,8270,O
since,8270,O
it,8270,O
allows,8270,O
the,8270,O
investigation,8270,O
of,8270,O
advanced,8270,O
steps,8270,O
of,8270,O
carcinogenesis,8270,O
with,8270,O
shorter,8270,O
latency,8270,O
periods,8270,O
in,8270,O
both,8270,O
lobes,8270,O
.,8270,O
Prostate,8271,O
©,8271,O
2013,8271,O
Wiley,8271,O
Periodicals,8271,O
",",8271,O
Inc,8271,O
.,8271,O
Green,8272,O
tea,8272,O
extract,8272,O
alleviates,8272,O
arsenic-induced,8272,B-CHEMICAL
biochemical,8272,O
toxicity,8272,O
and,8272,O
lipid,8272,O
peroxidation,8272,O
in,8272,O
rats,8272,O
.,8272,O
The,8273,O
present,8273,O
work,8273,O
was,8273,O
undertaken,8273,O
to,8273,O
evaluate,8273,O
the,8273,O
protective,8273,O
effect,8273,O
of,8273,O
an,8273,O
aqueous,8273,O
extract,8273,O
of,8273,O
green,8273,O
tea,8273,O
(,8273,O
GT,8273,O
",",8273,O
Camellia,8273,O
sinensis,8273,O
),8273,O
leaves,8273,O
against,8273,O
arsenic,8273,B-CHEMICAL
(,8273,O
NaAsO2,8273,B-CHEMICAL
),8273,O
-induced,8273,O
biochemical,8273,O
toxicity,8273,O
and,8273,O
lipid,8273,O
peroxidation,8273,O
production,8273,O
in,8273,O
experimental,8273,O
rats,8273,O
.,8273,O
The,8274,O
treatment,8274,O
with,8274,O
arsenic,8274,B-CHEMICAL
exhibited,8274,O
a,8274,O
significant,8274,O
increase,8274,O
in,8274,O
some,8274,O
serum,8274,O
hepatic,8274,O
and,8274,O
renal,8274,O
biochemical,8274,O
parameters,8274,O
(,8274,O
alanine,8274,B-GENE-N
aminotransferase,8274,I-GENE-N
",",8274,O
aspartate,8274,B-GENE-N
aminotransferase,8274,I-GENE-N
",",8274,O
alkaline,8274,B-GENE-N
phosphatase,8274,I-GENE-N
",",8274,O
total,8274,O
protein,8274,O
",",8274,O
albumin,8274,B-GENE-Y
",",8274,O
bilirubin,8274,B-CHEMICAL
",",8274,O
cholesterol,8274,B-CHEMICAL
",",8274,O
urea,8274,B-CHEMICAL
and,8274,O
creatinine,8274,B-CHEMICAL
),8274,O
.,8274,O
But,8275,O
the,8275,O
co-administration,8275,O
of,8275,O
GT,8275,O
has,8275,O
increased,8275,O
the,8275,O
level,8275,O
of,8275,O
plasmatic,8275,O
concentration,8275,O
of,8275,O
biochemical,8275,O
parameters,8275,O
.,8275,O
Exposure,8276,O
of,8276,O
rats,8276,O
to,8276,O
arsenic,8276,B-CHEMICAL
caused,8276,O
also,8276,O
a,8276,O
significant,8276,O
increase,8276,O
in,8276,O
liver,8276,O
",",8276,O
kidney,8276,O
and,8276,O
testicular,8276,O
thiobarbituric,8276,B-CHEMICAL
acid,8276,I-CHEMICAL
reactive,8276,O
substances,8276,O
compared,8276,O
to,8276,O
control,8276,O
.,8276,O
However,8277,O
",",8277,O
the,8277,O
co-administration,8277,O
of,8277,O
GT,8277,O
was,8277,O
effective,8277,O
in,8277,O
reducing,8277,O
its,8277,O
level,8277,O
.,8277,O
To,8278,O
conclude,8278,O
",",8278,O
our,8278,O
data,8278,O
suggest,8278,O
that,8278,O
arsenic,8278,B-CHEMICAL
exposure,8278,O
enhanced,8278,O
an,8278,O
oxidative,8278,O
stress,8278,O
by,8278,O
disturbing,8278,O
the,8278,O
tissue,8278,O
antioxidant,8278,O
defense,8278,O
system,8278,O
",",8278,O
but,8278,O
the,8278,O
GT,8278,O
co-administration,8278,O
alleviates,8278,O
the,8278,O
toxicity,8278,O
induced,8278,O
by,8278,O
arsenic,8278,B-CHEMICAL
exposure,8278,O
.,8278,O
Synthesis,8279,O
",",8279,O
receptor,8279,O
binding,8279,O
and,8279,O
functional,8279,O
studies,8279,O
of,8279,O
mesoridazine,8279,B-CHEMICAL
stereoisomers,8279,O
.,8279,O
The,8280,O
four,8280,O
stereoisomers,8280,O
of,8280,O
mesoridazine,8280,B-CHEMICAL
were,8280,O
synthesized,8280,O
and,8280,O
evaluated,8280,O
in,8280,O
D2,8280,B-GENE-Y
",",8280,O
5-HT1A,8280,B-GENE-Y
",",8280,O
5-HT2A,8280,B-GENE-Y
",",8280,O
5-HT2C,8280,B-GENE-Y
",",8280,O
D1,8280,B-GENE-Y
",",8280,O
and,8280,O
D3,8280,B-GENE-Y
receptor,8280,I-GENE-Y
binding,8280,O
and,8280,O
functional,8280,O
assays,8280,O
.,8280,O
Two,8281,O
isomers,8281,O
demonstrated,8281,O
potent,8281,O
D2,8281,O
receptor,8281,O
binding,8281,O
(,8281,O
Ki,8281,O
<,8281,O
3,8281,O
nM,8281,O
),8281,O
and,8281,O
functional,8281,O
antagonism,8281,O
(,8281,O
IC50,8281,O
<,8281,O
or,8281,O
=,8281,O
10,8281,O
nM,8281,O
),8281,O
activities,8281,O
.,8281,O
These,8282,O
two,8282,O
isomers,8282,O
also,8282,O
showed,8282,O
moderate,8282,O
affinity,8282,O
for,8282,O
the,8282,O
5-HT2A,8282,B-GENE-Y
and,8282,O
D3,8282,B-GENE-Y
receptors,8282,I-GENE-Y
.,8282,O
A,8283,O
third,8283,O
isomer,8283,O
was,8283,O
devoid,8283,O
of,8283,O
significant,8283,O
D2,8283,B-GENE-Y
receptor,8283,I-GENE-Y
binding,8283,O
",",8283,O
but,8283,O
did,8283,O
have,8283,O
moderate,8283,O
affinity,8283,O
for,8283,O
the,8283,O
5-HT2A,8283,B-GENE-Y
and,8283,O
D3,8283,B-GENE-Y
receptors,8283,I-GENE-Y
.,8283,O
The,8284,O
fourth,8284,O
isomer,8284,O
demonstrated,8284,O
poor,8284,O
affinity,8284,O
for,8284,O
all,8284,O
the,8284,O
receptors,8284,O
tested,8284,O
.,8284,O
Most,8285,O
significantly,8285,O
",",8285,O
the,8285,O
stereochemistry,8285,O
of,8285,O
the,8285,O
sulfoxide,8285,B-CHEMICAL
moiety,8285,O
played,8285,O
a,8285,O
dominant,8285,O
role,8285,O
in,8285,O
the,8285,O
observed,8285,O
structure-activity,8285,O
relationship,8285,O
(,8285,O
SAR,8285,O
),8285,O
.,8285,O
Sex,8286,O
differences,8286,O
in,8286,O
the,8286,O
antidepressant-like,8286,O
effects,8286,O
of,8286,O
ketamine,8286,B-CHEMICAL
.,8286,O
Current,8287,O
medications,8287,O
for,8287,O
major,8287,O
depression,8287,O
suffer,8287,O
from,8287,O
numerous,8287,O
limitations,8287,O
.,8287,O
Once,8288,O
the,8288,O
right,8288,O
drug,8288,O
for,8288,O
treatment,8288,O
has,8288,O
been,8288,O
determined,8288,O
",",8288,O
it,8288,O
still,8288,O
takes,8288,O
several,8288,O
weeks,8288,O
for,8288,O
it,8288,O
to,8288,O
take,8288,O
effect,8288,O
and,8288,O
improve,8288,O
mood,8288,O
.,8288,O
This,8289,O
time,8289,O
lag,8289,O
is,8289,O
a,8289,O
serious,8289,O
concern,8289,O
for,8289,O
the,8289,O
healthcare,8289,O
community,8289,O
when,8289,O
dealing,8289,O
with,8289,O
patients,8289,O
with,8289,O
suicidal,8289,O
thoughts,8289,O
.,8289,O
However,8290,O
",",8290,O
recent,8290,O
clinical,8290,O
studies,8290,O
have,8290,O
shown,8290,O
that,8290,O
a,8290,O
single,8290,O
low-dose,8290,O
injection,8290,O
of,8290,O
ketamine,8290,B-CHEMICAL
",",8290,O
an,8290,O
N-methyl,8290,B-GENE-N
d-aspartate,8290,I-GENE-N
receptor,8290,I-GENE-N
(,8290,O
NMDAR,8290,B-GENE-N
),8290,O
antagonist,8290,O
",",8290,O
has,8290,O
rapid,8290,O
antidepressant,8290,O
effects,8290,O
that,8290,O
are,8290,O
observed,8290,O
within,8290,O
hours,8290,O
and,8290,O
are,8290,O
long,8290,O
lasting,8290,O
.,8290,O
Although,8291,O
major,8291,O
depression,8291,O
affects,8291,O
twice,8291,O
as,8291,O
many,8291,O
women,8291,O
as,8291,O
men,8291,O
",",8291,O
all,8291,O
studies,8291,O
examining,8291,O
the,8291,O
rapid,8291,O
antidepressant,8291,O
effects,8291,O
of,8291,O
ketamine,8291,B-CHEMICAL
have,8291,O
focused,8291,O
on,8291,O
male,8291,O
subjects,8291,O
.,8291,O
Thus,8292,O
",",8292,O
we,8292,O
have,8292,O
investigated,8292,O
the,8292,O
behavioral,8292,O
and,8292,O
molecular,8292,O
effects,8292,O
of,8292,O
ketamine,8292,B-CHEMICAL
in,8292,O
both,8292,O
male,8292,O
and,8292,O
female,8292,O
rats,8292,O
and,8292,O
demonstrated,8292,O
greater,8292,O
sensitivity,8292,O
in,8292,O
female,8292,O
rats,8292,O
at,8292,O
a,8292,O
low,8292,O
dose,8292,O
of,8292,O
ketamine,8292,B-CHEMICAL
",",8292,O
a,8292,O
dose,8292,O
does,8292,O
not,8292,O
have,8292,O
antidepressant-like,8292,O
effects,8292,O
in,8292,O
male,8292,O
rats,8292,O
.,8292,O
The,8293,O
antidepressant-like,8293,O
effects,8293,O
of,8293,O
this,8293,O
low,8293,O
dose,8293,O
of,8293,O
ketamine,8293,B-CHEMICAL
were,8293,O
completely,8293,O
abolished,8293,O
when,8293,O
female,8293,O
rats,8293,O
were,8293,O
ovariectomized,8293,O
(,8293,O
OVX,8293,O
),8293,O
",",8293,O
and,8293,O
restored,8293,O
when,8293,O
physiological,8293,O
levels,8293,O
of,8293,O
estrogen,8293,B-CHEMICAL
and,8293,O
progesterone,8293,B-CHEMICAL
were,8293,O
supplemented,8293,O
",",8293,O
suggesting,8293,O
a,8293,O
critical,8293,O
role,8293,O
for,8293,O
gonadal,8293,O
hormones,8293,O
in,8293,O
enhancing,8293,O
the,8293,O
antidepressant-like,8293,O
effects,8293,O
of,8293,O
ketamine,8293,B-CHEMICAL
in,8293,O
female,8293,O
rats,8293,O
.,8293,O
In,8294,O
preclinical,8294,O
studies,8294,O
",",8294,O
the,8294,O
mammalian,8294,B-GENE-Y
target,8294,I-GENE-Y
of,8294,I-GENE-Y
rapamycin,8294,I-GENE-Y
(,8294,O
mTOR,8294,B-GENE-Y
),8294,O
in,8294,O
the,8294,O
medial,8294,O
prefrontal,8294,O
cortex,8294,O
and,8294,O
the,8294,O
eukaryotic,8294,B-GENE-N
elongation,8294,I-GENE-N
factor,8294,I-GENE-N
(,8294,O
eEF2,8294,B-GENE-Y
),8294,O
in,8294,O
the,8294,O
hippocampus,8294,O
have,8294,O
been,8294,O
proposed,8294,O
as,8294,O
critical,8294,O
mediators,8294,O
of,8294,O
ketamine,8294,B-CHEMICAL
's,8294,O
rapid,8294,O
antidepressant,8294,O
actions,8294,O
.,8294,O
In,8295,O
our,8295,O
hands,8295,O
",",8295,O
the,8295,O
increased,8295,O
sensitivity,8295,O
of,8295,O
female,8295,O
rats,8295,O
to,8295,O
a,8295,O
low,8295,O
dose,8295,O
of,8295,O
ketamine,8295,B-CHEMICAL
was,8295,O
not,8295,O
mediated,8295,O
through,8295,O
phosphorylation,8295,O
of,8295,O
mTOR,8295,B-GENE-Y
or,8295,O
eEF2,8295,B-GENE-Y
.,8295,O
Effects,8296,O
of,8296,O
17α-ethynylestradiol-induced,8296,B-CHEMICAL
cholestasis,8296,O
on,8296,O
the,8296,O
pharmacokinetics,8296,O
of,8296,O
doxorubicin,8296,B-CHEMICAL
in,8296,O
rats,8296,O
:,8296,O
reduced,8296,O
biliary,8296,O
excretion,8296,O
and,8296,O
hepatic,8296,O
metabolism,8296,O
of,8296,O
doxorubicin,8296,B-CHEMICAL
.,8296,O
Abstract,8297,O
1,8297,O
.,8297,O
Since,8298,O
the,8298,O
prevalent,8298,O
hormonal,8298,O
combination,8298,O
therapy,8298,O
with,8298,O
estrogen,8298,B-CHEMICAL
analogues,8298,O
in,8298,O
cancer,8298,O
patients,8298,O
has,8298,O
frequency,8298,O
and,8298,O
possibility,8298,O
to,8298,O
induce,8298,O
the,8298,O
cholestasis,8298,O
",",8298,O
the,8298,O
frequent,8298,O
combination,8298,O
therapy,8298,O
with,8298,O
17α-ethynylestradiol,8298,B-CHEMICAL
(,8298,O
EE,8298,O
",",8298,O
an,8298,O
oral,8298,O
contraceptive,8298,O
),8298,O
and,8298,O
doxorubicin,8298,B-CHEMICAL
(,8298,O
an,8298,O
anticancer,8298,O
drug,8298,O
),8298,O
might,8298,O
be,8298,O
monitored,8298,O
in,8298,O
aspect,8298,O
of,8298,O
efficacy,8298,O
and,8298,O
safety,8298,O
.,8298,O
Doxorubicin,8299,B-CHEMICAL
is,8299,O
mainly,8299,O
excreted,8299,O
into,8299,O
the,8299,O
bile,8299,O
via,8299,O
P-glycoprotein,8299,B-GENE-N
(,8299,O
P-gp,8299,B-GENE-N
),8299,O
and,8299,O
multidrug,8299,B-GENE-Y
resistance-associated,8299,I-GENE-Y
protein,8299,I-GENE-Y
2,8299,I-GENE-Y
(,8299,O
Mrp2,8299,B-GENE-Y
),8299,O
in,8299,O
hepatobiliary,8299,O
route,8299,O
and,8299,O
metabolized,8299,O
via,8299,O
cytochrome,8299,B-GENE-N
P450,8299,I-GENE-N
(,8299,I-GENE-N
CYP,8299,I-GENE-N
),8299,I-GENE-N
3A,8299,I-GENE-N
subfamily,8299,O
.,8299,O
Also,8300,O
the,8300,O
hepatic,8300,O
Mrp2,8300,B-GENE-Y
(,8300,O
not,8300,O
P-gp,8300,B-GENE-N
),8300,O
and,8300,O
CYP3A,8300,B-GENE-N
subfamily,8300,O
levels,8300,O
were,8300,O
reduced,8300,O
in,8300,O
EE-induced,8300,O
cholestatic,8300,O
(,8300,O
EEC,8300,O
),8300,O
rats,8300,O
.,8300,O
Thus,8301,O
",",8301,O
we,8301,O
herein,8301,O
report,8301,O
the,8301,O
pharmacokinetic,8301,O
changes,8301,O
of,8301,O
doxorubicin,8301,B-CHEMICAL
with,8301,O
respect,8301,O
to,8301,O
the,8301,O
changes,8301,O
in,8301,O
its,8301,O
biliary,8301,O
excretion,8301,O
and,8301,O
hepatic,8301,O
metabolism,8301,O
in,8301,O
EEC,8301,O
rats,8301,O
.,8301,O
2,8302,O
.,8302,O
The,8303,O
pharmacokinetic,8303,O
study,8303,O
of,8303,O
doxorubicin,8303,B-CHEMICAL
after,8303,O
intravenous,8303,O
administration,8303,O
of,8303,O
its,8303,O
hydrochloride,8303,B-CHEMICAL
was,8303,O
conducted,8303,O
along,8303,O
with,8303,O
the,8303,O
investigation,8303,O
of,8303,O
bile,8303,O
flow,8303,O
rate,8303,O
and,8303,O
hepatobiliary,8303,O
excretion,8303,O
of,8303,O
doxorubicin,8303,B-CHEMICAL
in,8303,O
control,8303,O
and,8303,O
EEC,8303,O
rats,8303,O
.,8303,O
3,8304,O
.,8304,O
The,8305,O
significantly,8305,O
greater,8305,O
AUC,8305,O
(,8305,O
58.7,8305,O
%,8305,O
increase,8305,O
),8305,O
of,8305,O
doxorubicin,8305,B-CHEMICAL
in,8305,O
EEC,8305,O
rats,8305,O
was,8305,O
due,8305,O
to,8305,O
the,8305,O
slower,8305,O
CL,8305,O
(,8305,O
32.9,8305,O
%,8305,O
decrease,8305,O
),8305,O
.,8305,O
The,8306,O
slower,8306,O
CL,8306,O
was,8306,O
due,8306,O
to,8306,O
the,8306,O
reduction,8306,O
of,8306,O
hepatic,8306,O
biliary,8306,O
excretion,8306,O
(,8306,O
67.0,8306,O
%,8306,O
decrease,8306,O
),8306,O
and,8306,O
hepatic,8306,O
CYP3A,8306,B-GENE-N
subfamily-mediated,8306,O
metabolism,8306,O
(,8306,O
21.9,8306,O
%,8306,O
decrease,8306,O
),8306,O
of,8306,O
doxorubicin,8306,B-CHEMICAL
.,8306,O
These,8307,O
results,8307,O
might,8307,O
have,8307,O
broader,8307,O
implications,8307,O
to,8307,O
understand,8307,O
the,8307,O
altered,8307,O
pharmacokinetics,8307,O
and/or,8307,O
pharmacologic,8307,O
effects,8307,O
of,8307,O
doxorubicin,8307,B-CHEMICAL
via,8307,O
biliary,8307,O
excretion,8307,O
and,8307,O
hepatic,8307,O
metabolism,8307,O
in,8307,O
experimental,8307,O
and,8307,O
clinical,8307,O
estrogen-induced,8307,B-CHEMICAL
cholestasis,8307,O
.,8307,O
Corticotropin-releasing,8308,B-GENE-Y
hormone,8308,I-GENE-Y
reduces,8308,O
pressure,8308,O
pain,8308,O
sensitivity,8308,O
in,8308,O
humans,8308,O
without,8308,O
involvement,8308,O
of,8308,O
beta-endorphin,8308,B-GENE-Y
(,8308,I-GENE-Y
1-31,8308,I-GENE-Y
),8308,I-GENE-Y
",",8308,O
but,8308,O
does,8308,O
not,8308,O
reduce,8308,O
heat,8308,O
pain,8308,O
sensitivity,8308,O
.,8308,O
In,8309,O
the,8309,O
present,8309,O
study,8309,O
the,8309,O
effects,8309,O
of,8309,O
intravenously,8309,O
administered,8309,O
corticotropin-releasing,8309,B-GENE-Y
hormone,8309,I-GENE-Y
(,8309,O
CRH,8309,B-GENE-Y
),8309,O
on,8309,O
the,8309,O
release,8309,O
of,8309,O
proopiomelanocortin,8309,B-GENE-Y
(,8309,O
POMC,8309,B-GENE-Y
),8309,O
derivatives,8309,O
such,8309,O
as,8309,O
adrenocorticotropic,8309,B-GENE-Y
hormone,8309,I-GENE-Y
(,8309,O
ACTH,8309,B-GENE-Y
),8309,O
",",8309,O
beta-lipotropin,8309,B-GENE-Y
(,8309,O
beta-LPH,8309,B-GENE-Y
),8309,O
and,8309,O
beta-endorphin,8309,B-GENE-Y
(,8309,O
beta-END,8309,B-GENE-Y
),8309,O
as,8309,O
well,8309,O
as,8309,O
direct,8309,O
effects,8309,O
of,8309,O
CRH,8309,B-GENE-Y
on,8309,O
pain,8309,O
sensitivity,8309,O
were,8309,O
examined,8309,O
.,8309,O
In,8310,O
16,8310,O
healthy,8310,O
volunteers,8310,O
we,8310,O
studied,8310,O
the,8310,O
effects,8310,O
of,8310,O
100,8310,O
microg,8310,O
intravenously,8310,O
administered,8310,O
CRH,8310,B-GENE-Y
in,8310,O
absence,8310,O
or,8310,O
presence,8310,O
of,8310,O
12,8310,O
mg,8310,O
naloxone,8310,B-CHEMICAL
on,8310,O
heat,8310,O
or,8310,O
pressure,8310,O
pain,8310,O
sensitivity,8310,O
",",8310,O
using,8310,O
a,8310,O
double-blind,8310,O
",",8310,O
cross-over,8310,O
and,8310,O
placebo-controlled,8310,O
design,8310,O
.,8310,O
To,8311,O
evaluate,8311,O
analgesic,8311,O
effects,8311,O
of,8311,O
CRH,8311,B-GENE-Y
via,8311,O
release,8311,O
of,8311,O
POMC,8311,B-GENE-Y
derivatives,8311,O
",",8311,O
we,8311,O
determined,8311,O
plasma,8311,O
concentrations,8311,O
of,8311,O
beta-END-immunoreactive,8311,B-GENE-Y
material,8311,O
(,8311,O
IRM,8311,O
),8311,O
",",8311,O
authentic,8311,O
beta-END,8311,B-GENE-Y
(,8311,O
beta-END,8311,B-GENE-Y
(,8311,I-GENE-Y
1-31,8311,I-GENE-Y
),8311,I-GENE-Y
),8311,O
and,8311,O
beta-LPH,8311,B-GENE-Y
IRM,8311,O
",",8311,O
in,8311,O
parallel,8311,O
with,8311,O
heat,8311,O
and,8311,O
pressure,8311,O
pain,8311,O
tolerance,8311,O
thresholds,8311,O
before,8311,O
and,8311,O
15,8311,O
and,8311,O
30,8311,O
min,8311,O
after,8311,O
treatment,8311,O
with,8311,O
CRH,8311,B-GENE-Y
(,8311,O
or,8311,O
placebo,8311,O
),8311,O
",",8311,O
and,8311,O
5,8311,O
min,8311,O
after,8311,O
naloxone,8311,B-CHEMICAL
(,8311,O
or,8311,O
placebo,8311,O
),8311,O
administration,8311,O
which,8311,O
was,8311,O
administered,8311,O
40,8311,O
min,8311,O
after,8311,O
CRH,8311,B-GENE-Y
(,8311,O
or,8311,O
placebo,8311,O
),8311,O
injection,8311,O
.,8311,O
CRH,8312,B-GENE-Y
increased,8312,O
levels,8312,O
of,8312,O
beta-END,8312,B-GENE-Y
IRM,8312,O
",",8312,O
beta-END,8312,B-GENE-Y
(,8312,I-GENE-Y
1-31,8312,I-GENE-Y
),8312,I-GENE-Y
and,8312,O
beta-LPH,8312,B-GENE-Y
IRM,8312,O
.,8312,O
As,8313,O
compared,8313,O
to,8313,O
beta-END,8313,B-GENE-Y
IRM,8313,O
levels,8313,O
measured,8313,O
by,8313,O
a,8313,O
commercial,8313,O
RIA,8313,O
kit,8313,O
",",8313,O
the,8313,O
beta-END,8313,B-GENE-Y
(,8313,I-GENE-Y
1-31,8313,I-GENE-Y
),8313,I-GENE-Y
levels,8313,O
determined,8313,O
by,8313,O
a,8313,O
highly,8313,O
specific,8313,O
two-site,8313,O
RIA,8313,O
",",8313,O
proved,8313,O
to,8313,O
be,8313,O
remarkably,8313,O
small,8313,O
.,8313,O
Furthermore,8314,O
",",8314,O
CRH,8314,B-GENE-Y
did,8314,O
not,8314,O
induce,8314,O
increases,8314,O
of,8314,O
heat,8314,O
pain,8314,O
tolerance,8314,O
thresholds,8314,O
",",8314,O
but,8314,O
of,8314,O
pressure,8314,O
pain,8314,O
tolerance,8314,O
thresholds,8314,O
",",8314,O
which,8314,O
",",8314,O
however,8314,O
",",8314,O
were,8314,O
not,8314,O
reversible,8314,O
by,8314,O
naloxone,8314,B-CHEMICAL
.,8314,O
Neither,8315,O
beta-END,8315,B-GENE-Y
nor,8315,O
beta-LPH,8315,B-GENE-Y
IRM,8315,O
nor,8315,O
beta-END,8315,B-GENE-Y
(,8315,I-GENE-Y
1-31,8315,I-GENE-Y
),8315,I-GENE-Y
levels,8315,O
correlated,8315,O
with,8315,O
heat,8315,O
or,8315,O
pressure,8315,O
pain,8315,O
tolerance,8315,O
thresholds,8315,O
.,8315,O
We,8316,O
conclude,8316,O
that,8316,O
CRH,8316,B-GENE-N
does,8316,O
not,8316,O
modulate,8316,O
heat,8316,O
",",8316,O
but,8316,O
pressure,8316,O
pain,8316,O
;,8316,O
POMC,8316,B-GENE-Y
derivatives,8316,O
like,8316,O
beta-END,8316,B-GENE-Y
IRM,8316,O
",",8316,O
beta-END,8316,B-GENE-Y
(,8316,I-GENE-Y
1-31,8316,I-GENE-Y
),8316,I-GENE-Y
or,8316,O
beta-LPH,8316,B-GENE-Y
do,8316,O
not,8316,O
mediate,8316,O
this,8316,O
effect,8316,O
.,8316,O
Activation,8317,O
of,8317,O
AMP-activated,8317,B-GENE-N
Protein,8317,I-GENE-N
Kinase,8317,I-GENE-N
and,8317,O
Phosphorylation,8317,O
of,8317,O
Glycogen,8317,B-GENE-Y
Synthase,8317,I-GENE-Y
Kinase3,8317,I-GENE-Y
β,8317,I-GENE-Y
Mediate,8317,O
Ursolic,8317,B-CHEMICAL
Acid,8317,I-CHEMICAL
Induced,8317,O
Apoptosis,8317,O
in,8317,O
HepG2,8317,O
Liver,8317,O
Cancer,8317,O
Cells,8317,O
.,8317,O
Despite,8318,O
the,8318,O
antitumour,8318,O
effect,8318,O
of,8318,O
ursolic,8318,B-CHEMICAL
acid,8318,I-CHEMICAL
observed,8318,O
in,8318,O
several,8318,O
cancers,8318,O
",",8318,O
the,8318,O
underlying,8318,O
mechanism,8318,O
remains,8318,O
unclear,8318,O
.,8318,O
Thus,8319,O
",",8319,O
in,8319,O
the,8319,O
present,8319,O
study,8319,O
",",8319,O
the,8319,O
roles,8319,O
of,8319,O
AMP-activated,8319,B-GENE-N
protein,8319,I-GENE-N
kinase,8319,I-GENE-N
(,8319,O
AMPK,8319,B-GENE-N
),8319,O
and,8319,O
glycogen,8319,B-GENE-Y
synthase,8319,I-GENE-Y
kinase,8319,I-GENE-Y
3,8319,I-GENE-Y
beta,8319,I-GENE-Y
(,8319,O
GSK3β,8319,B-GENE-Y
),8319,O
were,8319,O
examined,8319,O
in,8319,O
ursolic,8319,O
acid,8319,O
induced,8319,O
apoptosis,8319,O
in,8319,O
HepG2,8319,O
hepatocellular,8319,O
carcinoma,8319,O
cells,8319,O
.,8319,O
Ursolic,8320,B-CHEMICAL
acid,8320,I-CHEMICAL
significantly,8320,O
exerted,8320,O
cytotoxicity,8320,O
",",8320,O
increased,8320,O
the,8320,O
sub-G1,8320,O
population,8320,O
and,8320,O
the,8320,O
number,8320,O
of,8320,O
ethidium,8320,B-CHEMICAL
homodimer,8320,O
and,8320,O
terminal,8320,O
deoxynucleotidyl,8320,O
transferase,8320,O
(,8320,O
TdT,8320,O
),8320,O
mediated,8320,O
dUTP,8320,B-CHEMICAL
nick,8320,O
end,8320,O
labeling,8320,O
positive,8320,O
cells,8320,O
in,8320,O
HepG2,8320,O
cells,8320,O
.,8320,O
Also,8321,O
",",8321,O
ursolic,8321,O
acid,8321,O
enhanced,8321,O
the,8321,O
cleavages,8321,O
of,8321,O
poly-ADP-ribose,8321,B-GENE-N
polymerase,8321,I-GENE-N
(,8321,O
PARP,8321,B-GENE-N
),8321,O
and,8321,O
caspase3,8321,B-GENE-Y
",",8321,O
attenuated,8321,O
the,8321,O
expression,8321,O
of,8321,O
astrocyte,8321,B-GENE-Y
elevated,8321,I-GENE-Y
gene,8321,I-GENE-Y
(,8321,O
AEG1,8321,B-GENE-Y
),8321,O
and,8321,O
survivin,8321,B-GENE-Y
in,8321,O
HepG2,8321,O
cells,8321,O
.,8321,O
Interestingly,8322,O
",",8322,O
ursolic,8322,B-CHEMICAL
acid,8322,I-CHEMICAL
increased,8322,O
the,8322,O
phosphorylation,8322,O
of,8322,O
AMPK,8322,B-GENE-N
and,8322,O
coenzyme,8322,B-GENE-N
A,8322,I-GENE-N
carboxylase,8322,I-GENE-N
and,8322,O
also,8322,O
enhanced,8322,O
phosphorylation,8322,O
of,8322,O
GSK3β,8322,B-GENE-Y
at,8322,O
inactive,8322,O
form,8322,O
serine,8322,B-CHEMICAL
9,8322,O
",",8322,O
whereas,8322,O
ursolic,8322,B-CHEMICAL
acid,8322,I-CHEMICAL
attenuated,8322,O
the,8322,O
phosphorylation,8322,O
of,8322,O
AKT,8322,B-GENE-N
and,8322,O
mTOR,8322,B-GENE-Y
in,8322,O
HepG2,8322,O
cells,8322,O
.,8322,O
Conversely,8323,O
",",8323,O
AMPK,8323,B-GENE-N
inhibitor,8323,O
compound,8323,B-CHEMICAL
C,8323,I-CHEMICAL
or,8323,O
GSK3β,8323,B-GENE-Y
inhibitor,8323,O
SB216763,8323,B-CHEMICAL
blocked,8323,O
the,8323,O
cleavages,8323,O
of,8323,O
PARP,8323,B-GENE-N
and,8323,O
caspase,8323,B-GENE-Y
3,8323,I-GENE-Y
induced,8323,O
by,8323,O
ursolic,8323,B-CHEMICAL
acid,8323,I-CHEMICAL
in,8323,O
HepG2,8323,O
cells,8323,O
.,8323,O
Furthermore,8324,O
",",8324,O
proteosomal,8324,O
inhibitor,8324,O
MG132,8324,B-CHEMICAL
suppressed,8324,O
AMPK,8324,B-GENE-N
activation,8324,O
",",8324,O
GSK3β,8324,B-GENE-Y
phosphorylation,8324,O
",",8324,O
cleaved,8324,O
PARP,8324,B-GENE-N
and,8324,O
deceased,8324,O
AEG-1,8324,B-GENE-Y
induced,8324,O
by,8324,O
ursolic,8324,B-CHEMICAL
acid,8324,I-CHEMICAL
in,8324,O
HepG2,8324,O
cells,8324,O
.,8324,O
Overall,8325,O
",",8325,O
our,8325,O
findings,8325,O
suggest,8325,O
that,8325,O
ursolic,8325,B-CHEMICAL
acid,8325,I-CHEMICAL
induced,8325,O
apoptosis,8325,O
in,8325,O
HepG2,8325,O
cells,8325,O
via,8325,O
AMPK,8325,B-GENE-N
activation,8325,O
and,8325,O
GSK3β,8325,B-GENE-Y
phosphorylation,8325,O
as,8325,O
a,8325,O
potent,8325,O
chemopreventive,8325,O
agent,8325,O
.,8325,O
Copyright,8326,O
©,8326,O
2013,8326,O
John,8326,O
Wiley,8326,O
&,8326,O
Sons,8326,O
",",8326,O
Ltd,8326,O
.,8326,O
Adverse,8327,O
outcome,8327,O
pathways,8327,O
during,8327,O
zebrafish,8327,O
embryogenesis,8327,O
:,8327,O
a,8327,O
case,8327,O
study,8327,O
with,8327,O
paraoxon,8327,B-CHEMICAL
.,8327,O
Using,8328,O
paraoxon,8328,B-CHEMICAL
as,8328,O
a,8328,O
reference,8328,O
acetylcholinesterase,8328,B-GENE-Y
(,8328,O
AChE,8328,B-GENE-Y
),8328,O
inhibitor,8328,O
",",8328,O
the,8328,O
objective,8328,O
of,8328,O
this,8328,O
study,8328,O
was,8328,O
to,8328,O
develop,8328,O
an,8328,O
adverse,8328,O
outcome,8328,O
pathway,8328,O
(,8328,O
AOP,8328,O
),8328,O
that,8328,O
provided,8328,O
quantitative,8328,O
linkages,8328,O
across,8328,O
levels,8328,O
of,8328,O
biological,8328,O
organization,8328,O
during,8328,O
zebrafish,8328,O
embryogenesis,8328,O
.,8328,O
Within,8329,O
normal,8329,O
zebrafish,8329,O
embryos,8329,O
",",8329,O
we,8329,O
first,8329,O
demonstrated,8329,O
that,8329,O
ache,8329,B-GENE-Y
transcripts,8329,O
and,8329,O
AChE,8329,B-GENE-Y
activity,8329,O
increased,8329,O
in,8329,O
a,8329,O
stage-dependent,8329,O
manner,8329,O
following,8329,O
segmentation,8329,O
.,8329,O
We,8330,O
then,8330,O
showed,8330,O
that,8330,O
static,8330,O
exposure,8330,O
of,8330,O
embryos,8330,O
to,8330,O
paraoxon,8330,B-CHEMICAL
(,8330,O
31.2-500,8330,O
nM,8330,O
),8330,O
from,8330,O
5,8330,O
to,8330,O
96,8330,O
hpf,8330,O
resulted,8330,O
in,8330,O
significant,8330,O
stage-,8330,O
and,8330,O
concentration-dependent,8330,O
AChE,8330,B-GENE-Y
inhibition,8330,O
",",8330,O
albeit,8330,O
these,8330,O
effects,8330,O
were,8330,O
fully,8330,O
reversible,8330,O
within,8330,O
48,8330,O
h,8330,O
following,8330,O
transfer,8330,O
to,8330,O
clean,8330,O
water,8330,O
.,8330,O
However,8331,O
",",8331,O
even,8331,O
in,8331,O
the,8331,O
presence,8331,O
of,8331,O
significant,8331,O
AChE,8331,B-GENE-Y
inhibition,8331,O
",",8331,O
exposure,8331,O
to,8331,O
non-teratogenic,8331,O
paraoxon,8331,B-CHEMICAL
concentrations,8331,O
(,8331,O
≤250,8331,O
nM,8331,O
),8331,O
did,8331,O
not,8331,O
adversely,8331,O
impact,8331,O
secondary,8331,O
motoneuron,8331,O
development,8331,O
at,8331,O
96,8331,O
hpf,8331,O
.,8331,O
Therefore,8332,O
",",8332,O
we,8332,O
investigated,8332,O
the,8332,O
potential,8332,O
effects,8332,O
of,8332,O
paraoxon,8332,B-CHEMICAL
exposure,8332,O
on,8332,O
spontaneous,8332,O
tail,8332,O
contractions,8332,O
at,8332,O
26,8332,O
hpf,8332,O
-,8332,O
an,8332,O
early,8332,O
locomotor,8332,O
behavior,8332,O
that,8332,O
results,8332,O
from,8332,O
innervation,8332,O
of,8332,O
primary,8332,O
(,8332,O
not,8332,O
secondary,8332,O
),8332,O
motoneuron,8332,O
axons,8332,O
to,8332,O
target,8332,O
axial,8332,O
muscles,8332,O
.,8332,O
Based,8333,O
on,8333,O
these,8333,O
studies,8333,O
",",8333,O
the,8333,O
frequency,8333,O
of,8333,O
spontaneous,8333,O
tail,8333,O
contractions,8333,O
at,8333,O
26,8333,O
hpf,8333,O
-,8333,O
a,8333,O
developmental,8333,O
stage,8333,O
with,8333,O
minimal,8333,O
AChE,8333,B-GENE-Y
expression,8333,O
and,8333,O
activity,8333,O
-,8333,O
was,8333,O
significantly,8333,O
higher,8333,O
following,8333,O
exposure,8333,O
to,8333,O
paraoxon,8333,B-CHEMICAL
concentrations,8333,O
as,8333,O
low,8333,O
as,8333,O
31.2,8333,O
nM,8333,O
.,8333,O
Overall,8334,O
",",8334,O
our,8334,O
data,8334,O
suggest,8334,O
that,8334,O
(,8334,O
1,8334,O
),8334,O
normal,8334,O
AChE,8334,B-GENE-Y
activity,8334,O
is,8334,O
not,8334,O
required,8334,O
for,8334,O
secondary,8334,O
motoneuron,8334,O
development,8334,O
and,8334,O
(,8334,O
2,8334,O
),8334,O
spontaneous,8334,O
tail,8334,O
contractions,8334,O
at,8334,O
26,8334,O
hpf,8334,O
are,8334,O
sensitive,8334,O
to,8334,O
paraoxon,8334,B-CHEMICAL
exposure,8334,O
",",8334,O
an,8334,O
effect,8334,O
that,8334,O
may,8334,O
be,8334,O
independent,8334,O
of,8334,O
AChE,8334,B-GENE-Y
inhibition,8334,O
.,8334,O
Using,8335,O
a,8335,O
well-studied,8335,O
reference,8335,O
chemical,8335,O
",",8335,O
this,8335,O
study,8335,O
highlights,8335,O
the,8335,O
potential,8335,O
challenges,8335,O
in,8335,O
developing,8335,O
quantitative,8335,O
AOPs,8335,O
to,8335,O
support,8335,O
chemical,8335,O
screening,8335,O
and,8335,O
prioritization,8335,O
strategies,8335,O
.,8335,O
Depletion,8336,O
of,8336,O
molecular,8336,O
chaperones,8336,O
from,8336,O
the,8336,O
endoplasmic,8336,O
reticulum,8336,O
and,8336,O
fragmentation,8336,O
of,8336,O
the,8336,O
Golgi,8336,O
apparatus,8336,O
associated,8336,O
with,8336,O
pathogenesis,8336,O
in,8336,O
Pelizaeus-Merzbacher,8336,O
disease,8336,O
.,8336,O
Missense,8337,O
mutations,8337,O
in,8337,O
the,8337,O
proteolipid,8337,B-GENE-Y
protein,8337,I-GENE-Y
1,8337,I-GENE-Y
(,8337,O
PLP1,8337,B-GENE-Y
),8337,O
gene,8337,O
cause,8337,O
a,8337,O
wide,8337,O
spectrum,8337,O
of,8337,O
hypomyelinating,8337,O
disorders,8337,O
",",8337,O
from,8337,O
mild,8337,O
spastic,8337,O
paraplegia,8337,O
type,8337,O
2,8337,O
to,8337,O
severe,8337,O
Pelizaeus-Merzbacher,8337,O
disease,8337,O
(,8337,O
PMD,8337,O
),8337,O
.,8337,O
Mutant,8338,O
PLP1,8338,B-GENE-Y
accumulates,8338,O
in,8338,O
the,8338,O
endoplasmic,8338,O
reticulum,8338,O
(,8338,O
ER,8338,O
),8338,O
and,8338,O
induces,8338,O
ER,8338,O
stress,8338,O
.,8338,O
However,8339,O
",",8339,O
the,8339,O
link,8339,O
between,8339,O
the,8339,O
clinical,8339,O
severity,8339,O
of,8339,O
PMD,8339,O
and,8339,O
the,8339,O
cellular,8339,O
response,8339,O
induced,8339,O
by,8339,O
mutant,8339,O
PLP1,8339,B-GENE-Y
remains,8339,O
largely,8339,O
unknown,8339,O
.,8339,O
Accumulation,8340,O
of,8340,O
misfolded,8340,O
proteins,8340,O
in,8340,O
the,8340,O
ER,8340,O
generally,8340,O
leads,8340,O
to,8340,O
up-regulation,8340,O
of,8340,O
ER,8340,O
chaperones,8340,O
to,8340,O
alleviate,8340,O
ER,8340,O
stress,8340,O
.,8340,O
Here,8341,O
",",8341,O
we,8341,O
found,8341,O
that,8341,O
expression,8341,O
of,8341,O
the,8341,O
PLP1-A243V,8341,B-GENE-Y
mutant,8341,O
",",8341,O
which,8341,O
causes,8341,O
severe,8341,O
disease,8341,O
",",8341,O
depletes,8341,O
some,8341,O
ER,8341,O
chaperones,8341,O
with,8341,O
a,8341,O
KDEL,8341,B-GENE-N
(,8341,O
Lys-Asp-Glu-Leu,8341,B-GENE-N
),8341,O
motif,8341,O
",",8341,O
in,8341,O
HeLa,8341,O
cells,8341,O
",",8341,O
MO3.13,8341,O
oligodendrocytic,8341,O
cells,8341,O
",",8341,O
and,8341,O
primary,8341,O
oligodendrocytes,8341,O
.,8341,O
The,8342,O
same,8342,O
PLP1,8342,B-GENE-Y
mutant,8342,O
also,8342,O
induces,8342,O
fragmentation,8342,O
of,8342,O
the,8342,O
Golgi,8342,O
apparatus,8342,O
(,8342,O
GA,8342,O
),8342,O
.,8342,O
These,8343,O
organelle,8343,O
changes,8343,O
are,8343,O
less,8343,O
prominent,8343,O
in,8343,O
cells,8343,O
with,8343,O
milder,8343,O
disease-associated,8343,O
PLP1,8343,B-GENE-Y
mutants,8343,O
.,8343,O
Similar,8344,O
changes,8344,O
are,8344,O
also,8344,O
observed,8344,O
in,8344,O
cells,8344,O
expressing,8344,O
another,8344,O
disease-causing,8344,O
gene,8344,O
that,8344,O
triggers,8344,O
ER,8344,O
stress,8344,O
",",8344,O
as,8344,O
well,8344,O
as,8344,O
in,8344,O
cells,8344,O
treated,8344,O
with,8344,O
brefeldin,8344,B-CHEMICAL
A,8344,I-CHEMICAL
",",8344,O
which,8344,O
induces,8344,O
ER,8344,O
stress,8344,O
and,8344,O
GA,8344,O
fragmentation,8344,O
by,8344,O
inhibiting,8344,O
GA,8344,O
to,8344,O
ER,8344,O
trafficking,8344,O
.,8344,O
We,8345,O
also,8345,O
found,8345,O
that,8345,O
mutant,8345,O
PLP1,8345,B-GENE-Y
disturbs,8345,O
localization,8345,O
of,8345,O
the,8345,O
KDEL,8345,B-GENE-N
receptor,8345,O
",",8345,O
which,8345,O
transports,8345,O
the,8345,O
chaperones,8345,O
with,8345,O
the,8345,O
KDEL,8345,B-GENE-N
motif,8345,I-GENE-N
from,8345,O
the,8345,O
GA,8345,O
to,8345,O
the,8345,O
ER,8345,O
.,8345,O
These,8346,O
data,8346,O
show,8346,O
that,8346,O
PLP1,8346,B-GENE-Y
mutants,8346,O
inhibit,8346,O
GA,8346,O
to,8346,O
ER,8346,O
trafficking,8346,O
",",8346,O
which,8346,O
reduces,8346,O
the,8346,O
supply,8346,O
of,8346,O
ER,8346,O
chaperones,8346,O
and,8346,O
induces,8346,O
GA,8346,O
fragmentation,8346,O
.,8346,O
We,8347,O
propose,8347,O
that,8347,O
depletion,8347,O
of,8347,O
ER,8347,O
chaperones,8347,O
and,8347,O
GA,8347,O
fragmentation,8347,O
induced,8347,O
by,8347,O
mutant,8347,O
misfolded,8347,O
proteins,8347,O
contribute,8347,O
to,8347,O
the,8347,O
pathogenesis,8347,O
of,8347,O
inherited,8347,O
ER,8347,O
stress-related,8347,O
diseases,8347,O
and,8347,O
affect,8347,O
the,8347,O
disease,8347,O
severity,8347,O
.,8347,O
Endogenous,8348,O
opioid,8348,O
systems,8348,O
and,8348,O
alcohol,8348,B-CHEMICAL
addiction,8348,O
.,8348,O
Alcohol,8349,B-CHEMICAL
exerts,8349,O
numerous,8349,O
pharmacological,8349,O
effects,8349,O
through,8349,O
its,8349,O
interaction,8349,O
with,8349,O
various,8349,O
neurotransmitters,8349,O
and,8349,O
neuromodulators,8349,O
.,8349,O
Among,8350,O
the,8350,O
latter,8350,O
",",8350,O
the,8350,O
endogenous,8350,O
opioids,8350,O
play,8350,O
a,8350,O
key,8350,O
role,8350,O
in,8350,O
the,8350,O
rewarding,8350,O
(,8350,O
addictive,8350,O
),8350,O
properties,8350,O
of,8350,O
ethanol,8350,B-CHEMICAL
.,8350,O
Three,8351,O
types,8351,O
of,8351,O
opioid,8351,B-GENE-N
receptors,8351,I-GENE-N
(,8351,I-GENE-N
mu,8351,I-GENE-N
",",8351,I-GENE-N
delta,8351,I-GENE-N
and,8351,I-GENE-N
kappa,8351,I-GENE-N
),8351,I-GENE-N
represent,8351,O
the,8351,O
respective,8351,O
targets,8351,O
of,8351,O
the,8351,O
major,8351,O
opioid,8351,B-GENE-N
peptides,8351,I-GENE-N
(,8351,O
beta-endorphin,8351,B-GENE-Y
",",8351,O
enkephalins,8351,B-GENE-N
and,8351,O
dynorphins,8351,B-GENE-Y
",",8351,O
respectively,8351,O
),8351,O
.,8351,O
The,8352,O
rewarding,8352,O
(,8352,O
reinforcing,8352,O
),8352,O
properties,8352,O
of,8352,O
mu-,8352,B-GENE-N
and,8352,I-GENE-N
delta-receptor,8352,I-GENE-N
ligands,8352,O
are,8352,O
brought,8352,O
by,8352,O
activation,8352,O
of,8352,O
the,8352,O
mesolimbic,8352,O
dopamine,8352,O
system,8352,O
which,8352,O
ascends,8352,O
from,8352,O
the,8352,O
ventral,8352,O
tegmentum,8352,O
of,8352,O
the,8352,O
midbrain,8352,O
(,8352,O
VTA,8352,O
),8352,O
to,8352,O
rostral,8352,O
structures,8352,O
;,8352,O
of,8352,O
these,8352,O
",",8352,O
the,8352,O
nucleus,8352,O
accumbens,8352,O
(,8352,O
NAC,8352,O
),8352,O
is,8352,O
of,8352,O
particular,8352,O
importance,8352,O
in,8352,O
drug,8352,O
addiction,8352,O
.,8352,O
In,8353,O
contrast,8353,O
",",8353,O
dysphoria,8353,O
results,8353,O
from,8353,O
activation,8353,O
of,8353,O
kappa-receptors,8353,B-GENE-N
.,8353,O
The,8354,O
neurochemical,8354,O
manifestations,8354,O
of,8354,O
these,8354,O
opposing,8354,O
effects,8354,O
are,8354,O
",",8354,O
respectively,8354,O
",",8354,O
increases,8354,O
and,8354,O
decreases,8354,O
in,8354,O
dopamine,8354,B-CHEMICAL
release,8354,O
in,8354,O
the,8354,O
NAC,8354,O
.,8354,O
Several,8355,O
lines,8355,O
of,8355,O
evidence,8355,O
indicate,8355,O
that,8355,O
alcohol,8355,B-CHEMICAL
interferes,8355,O
with,8355,O
endogenous,8355,O
opioid,8355,O
mechanisms,8355,O
which,8355,O
are,8355,O
closely,8355,O
linked,8355,O
with,8355,O
dopamine,8355,B-CHEMICAL
transmission,8355,O
in,8355,O
the,8355,O
mesolimbic,8355,O
pathway,8355,O
.,8355,O
The,8356,O
view,8356,O
that,8356,O
condensation,8356,O
products,8356,O
of,8356,O
dopamine,8356,B-CHEMICAL
and,8356,O
alcohol-derived,8356,B-CHEMICAL
aldehyde,8356,B-CHEMICAL
(,8356,O
tetrahydroisoquinolines,8356,B-CHEMICAL
),8356,O
play,8356,O
a,8356,O
role,8356,O
remains,8356,O
controversial,8356,O
.,8356,O
There,8357,O
is,8357,O
",",8357,O
however,8357,O
",",8357,O
much,8357,O
information,8357,O
on,8357,O
the,8357,O
direct,8357,O
(,8357,O
acute,8357,O
and,8357,O
chronic,8357,O
),8357,O
effects,8357,O
of,8357,O
alcohol,8357,B-CHEMICAL
on,8357,O
the,8357,O
binding,8357,O
properties,8357,O
of,8357,O
opioid,8357,B-GENE-N
receptors,8357,I-GENE-N
",",8357,O
as,8357,O
well,8357,O
as,8357,O
modulation,8357,O
of,8357,O
opioid,8357,B-GENE-N
peptide,8357,I-GENE-N
synthesis,8357,O
and,8357,O
secretion,8357,O
(,8357,O
e.g,8357,O
.,8357,O
a,8358,O
suggested,8358,O
increase,8358,O
in,8358,O
beta-endorphin,8358,B-GENE-Y
release,8358,O
),8358,O
.,8358,O
In,8359,O
view,8359,O
of,8359,O
the,8359,O
reinforcing,8359,O
properties,8359,O
of,8359,O
alcohol,8359,B-CHEMICAL
",",8359,O
it,8359,O
is,8359,O
relevant,8359,O
to,8359,O
consider,8359,O
behavioural,8359,O
studies,8359,O
involving,8359,O
alcohol,8359,B-CHEMICAL
self-administration,8359,O
in,8359,O
rodents,8359,O
and,8359,O
primates,8359,O
.,8359,O
Low,8360,O
doses,8360,O
of,8360,O
morphine,8360,O
have,8360,O
been,8360,O
found,8360,O
to,8360,O
increase,8360,O
",",8360,O
and,8360,O
higher,8360,O
doses,8360,O
of,8360,O
the,8360,O
opiate,8360,O
to,8360,O
decrease,8360,O
",",8360,O
alcohol,8360,B-CHEMICAL
consumption,8360,O
.,8360,O
Conversely,8361,O
",",8361,O
opioid,8361,O
antagonists,8361,O
such,8361,O
as,8361,O
naloxone,8361,B-CHEMICAL
and,8361,O
naltrexone,8361,B-CHEMICAL
(,8361,O
which,8361,O
bind,8361,O
to,8361,O
non-selectively,8361,O
opioid,8361,B-GENE-N
receptors,8361,I-GENE-N
),8361,O
have,8361,O
been,8361,O
shown,8361,O
to,8361,O
decrease,8361,O
alcohol,8361,B-CHEMICAL
consumption,8361,O
under,8361,O
various,8361,O
experimental,8361,O
conditions,8361,O
.,8361,O
Similar,8362,O
results,8362,O
have,8362,O
been,8362,O
reported,8362,O
when,8362,O
selective,8362,O
mu-,8362,B-GENE-N
or,8362,I-GENE-N
delta-receptor,8362,I-GENE-N
antagonists,8362,O
are,8362,O
administered,8362,O
.,8362,O
Results,8363,O
obtained,8363,O
in,8363,O
genetic,8363,O
models,8363,O
of,8363,O
high,8363,O
preference,8363,O
for,8363,O
alcohol,8363,B-CHEMICAL
also,8363,O
support,8363,O
the,8363,O
view,8363,O
that,8363,O
alcohol,8363,O
intake,8363,O
depends,8363,O
on,8363,O
the,8363,O
activity,8363,O
of,8363,O
the,8363,O
endogenous,8363,O
opioid,8363,O
reward,8363,O
system,8363,O
and,8363,O
that,8363,O
alcohol,8363,B-CHEMICAL
consumption,8363,O
may,8363,O
serve,8363,O
to,8363,O
compensate,8363,O
for,8363,O
inherent,8363,O
deficits,8363,O
in,8363,O
this,8363,O
system,8363,O
.,8363,O
One,8364,O
hypothetical,8364,O
model,8364,O
proposes,8364,O
that,8364,O
reward,8364,O
results,8364,O
from,8364,O
activation,8364,O
of,8364,O
mu-opioid,8364,B-GENE-Y
receptors,8364,I-GENE-Y
in,8364,O
the,8364,O
VTA,8364,O
and/or,8364,O
delta-receptor,8364,B-GENE-Y
in,8364,O
the,8364,O
NAC,8364,O
;,8364,O
both,8364,O
these,8364,O
nuclei,8364,O
are,8364,O
targets,8364,O
of,8364,O
endogenous,8364,O
beta-endorphin,8364,B-GENE-Y
.,8364,O
It,8365,O
is,8365,O
suggested,8365,O
that,8365,O
alcohol,8365,B-CHEMICAL
interferes,8365,O
with,8365,O
this,8365,O
reward,8365,O
pathway,8365,O
either,8365,O
directly,8365,O
or,8365,O
indirectly,8365,O
.,8365,O
The,8366,O
available,8366,O
experimental,8366,O
data,8366,O
accord,8366,O
well,8366,O
with,8366,O
those,8366,O
obtained,8366,O
from,8366,O
clinical,8366,O
studies,8366,O
which,8366,O
opioid,8366,O
antagonists,8366,O
have,8366,O
been,8366,O
used,8366,O
to,8366,O
prevent,8366,O
relapse,8366,O
in,8366,O
alcoholics,8366,O
.,8366,O
Conceptual,8367,O
considerations,8367,O
concerning,8367,O
communalities,8367,O
between,8367,O
various,8367,O
forms,8367,O
of,8367,O
addictions,8367,O
are,8367,O
also,8367,O
discussed,8367,O
in,8367,O
this,8367,O
review,8367,O
.,8367,O
Dynamics,8368,O
of,8368,O
NO,8368,B-CHEMICAL
rebinding,8368,O
to,8368,O
the,8368,O
heme,8368,B-GENE-N
domain,8368,I-GENE-N
of,8368,I-GENE-N
NO,8368,I-GENE-N
synthase-like,8368,I-GENE-N
proteins,8368,I-GENE-N
from,8368,O
bacterial,8368,O
pathogens,8368,O
.,8368,O
Some,8369,O
Gram-positive,8369,O
bacterial,8369,O
pathogens,8369,O
harbor,8369,O
a,8369,O
gene,8369,O
that,8369,O
encodes,8369,O
a,8369,O
protein,8369,O
(,8369,O
HNS,8369,B-GENE-N
",",8369,O
Heme,8369,B-GENE-N
domain,8369,I-GENE-N
of,8369,I-GENE-N
NO,8369,I-GENE-N
Synthase-like,8369,I-GENE-N
proteins,8369,I-GENE-N
),8369,O
with,8369,O
striking,8369,O
sequence,8369,O
identity,8369,O
to,8369,O
the,8369,O
oxygenase,8369,B-GENE-N
domain,8369,I-GENE-N
of,8369,O
mammalian,8369,B-GENE-N
NO,8369,I-GENE-N
synthases,8369,I-GENE-N
(,8369,O
NOS,8369,B-GENE-N
),8369,O
.,8369,O
However,8370,O
",",8370,O
they,8370,O
lack,8370,O
the,8370,O
N-terminal,8370,B-GENE-N
and,8370,I-GENE-N
the,8370,I-GENE-N
Zn-cysteine,8370,I-GENE-N
motif,8370,I-GENE-N
participating,8370,O
to,8370,O
the,8370,O
stability,8370,O
of,8370,O
an,8370,O
active,8370,O
dimer,8370,O
in,8370,O
the,8370,O
mammalian,8370,O
isoforms,8370,O
.,8370,O
The,8371,O
unique,8371,O
properties,8371,O
of,8371,O
HNS,8371,B-GENE-N
make,8371,O
it,8371,O
an,8371,O
excellent,8371,O
model,8371,O
system,8371,O
for,8371,O
probing,8371,O
how,8371,O
the,8371,O
heme,8371,O
environment,8371,O
tunes,8371,O
NO,8371,B-CHEMICAL
dynamics,8371,O
and,8371,O
for,8371,O
comparing,8371,O
it,8371,O
to,8371,O
the,8371,O
endothelial,8371,B-GENE-N
NO,8371,I-GENE-N
synthase,8371,I-GENE-N
heme,8371,I-GENE-N
domain,8371,I-GENE-N
(,8371,O
eNOS,8371,B-GENE-N
(,8371,I-GENE-N
HD,8371,I-GENE-N
),8371,I-GENE-N
),8371,O
using,8371,O
ultrafast,8371,O
transient,8371,O
spectroscopy,8371,O
.,8371,O
NO,8372,B-CHEMICAL
rebinding,8372,O
in,8372,O
HNS,8372,B-GENE-N
from,8372,O
Staphylococcus,8372,O
aureus,8372,O
(,8372,O
SA-HNS,8372,B-GENE-N
),8372,O
is,8372,O
faster,8372,O
than,8372,O
that,8372,O
measured,8372,O
for,8372,O
either,8372,O
Bacillus,8372,O
anthracis,8372,O
(,8372,O
BA-HNS,8372,B-GENE-N
),8372,O
or,8372,O
for,8372,O
eNOS,8372,B-GENE-N
(,8372,I-GENE-N
HD,8372,I-GENE-N
),8372,I-GENE-N
in,8372,O
both,8372,O
oxidized,8372,O
and,8372,O
reduced,8372,O
forms,8372,O
in,8372,O
the,8372,O
presence,8372,O
of,8372,O
arginine,8372,B-CHEMICAL
.,8372,O
To,8373,O
test,8373,O
whether,8373,O
these,8373,O
distinct,8373,O
rates,8373,O
arise,8373,O
from,8373,O
different,8373,O
energy,8373,O
barriers,8373,O
for,8373,O
NO,8373,B-CHEMICAL
recombination,8373,O
",",8373,O
we,8373,O
measured,8373,O
rebinding,8373,O
kinetics,8373,O
at,8373,O
several,8373,O
temperatures,8373,O
.,8373,O
Our,8374,O
data,8374,O
are,8374,O
consistent,8374,O
with,8374,O
different,8374,O
barriers,8374,O
for,8374,O
NO,8374,B-CHEMICAL
recombination,8374,O
in,8374,O
SA-HNS,8374,B-GENE-N
and,8374,O
BA-HNS,8374,B-GENE-N
and,8374,O
the,8374,O
presence,8374,O
of,8374,O
a,8374,O
second,8374,O
NO-binding,8374,B-CHEMICAL
site,8374,O
.,8374,O
The,8375,O
hypothesis,8375,O
that,8375,O
an,8375,O
additional,8375,O
NO-binding,8375,B-CHEMICAL
cavity,8375,O
is,8375,O
present,8375,O
in,8375,O
BA-HNS,8375,B-GENE-N
is,8375,O
also,8375,O
consistent,8375,O
with,8375,O
the,8375,O
effect,8375,O
of,8375,O
the,8375,O
NO,8375,B-CHEMICAL
concentration,8375,O
on,8375,O
its,8375,O
rebinding,8375,O
.,8375,O
The,8376,O
lack,8376,O
of,8376,O
the,8376,O
effect,8376,O
of,8376,O
NO,8376,B-CHEMICAL
concentration,8376,O
on,8376,O
the,8376,O
geminate,8376,O
rebinding,8376,O
in,8376,O
SA-HNS,8376,B-GENE-N
could,8376,O
be,8376,O
due,8376,O
to,8376,O
an,8376,O
isolated,8376,O
second,8376,O
site,8376,O
.,8376,O
We,8377,O
confirm,8377,O
the,8377,O
existence,8377,O
of,8377,O
a,8377,O
second,8377,O
NO,8377,B-CHEMICAL
site,8377,O
in,8377,O
the,8377,O
oxygenase,8377,B-GENE-N
domain,8377,I-GENE-N
of,8377,O
the,8377,O
reduced,8377,B-GENE-Y
eNOS,8377,I-GENE-Y
as,8377,O
previously,8377,O
hypothesized,8377,O
[,8377,O
A.,8377,O
Slama-Schwok,8377,O
",",8377,O
M.,8377,O
Negrerie,8377,O
",",8377,O
V.,8377,O
Berka,8377,O
",",8377,O
J.C.,8377,O
Lambry,8377,O
",",8377,O
A.L,8377,O
.,8377,O
Tsai,8378,O
",",8378,O
M.H,8378,O
.,8378,O
Vos,8379,O
",",8379,O
J.L,8379,O
.,8379,O
Martin,8380,O
",",8380,O
Nitric,8380,B-CHEMICAL
oxide,8380,I-CHEMICAL
(,8380,O
NO,8380,B-CHEMICAL
),8380,O
traffic,8380,O
in,8380,O
endothelial,8380,B-GENE-Y
NO,8380,I-GENE-Y
synthase,8380,I-GENE-Y
.,8380,O
Evidence,8381,O
for,8381,O
a,8381,O
new,8381,O
NO,8381,B-CHEMICAL
binding,8381,O
site,8381,O
dependent,8381,O
on,8381,O
tetrahydrobiopterin,8381,B-CHEMICAL
?,8381,O
J.,8382,O
Biol,8382,O
.,8382,O
Chem,8383,O
.,8383,O
277,8384,O
(,8384,O
2002,8384,O
),8384,O
7581-7586,8384,O
],8384,O
.,8384,O
This,8385,O
site,8385,O
requires,8385,O
the,8385,O
presence,8385,O
of,8385,O
arginine,8385,B-CHEMICAL
and,8385,O
BH,8385,B-CHEMICAL
(,8385,I-CHEMICAL
4,8385,I-CHEMICAL
),8385,I-CHEMICAL
;,8385,O
and,8385,O
we,8385,O
propose,8385,O
that,8385,O
NO,8385,B-CHEMICAL
dynamic,8385,O
and,8385,O
escape,8385,O
from,8385,O
eNOS,8385,B-GENE-Y
is,8385,O
regulated,8385,O
by,8385,O
the,8385,O
active,8385,O
site,8385,O
H-bonding,8385,B-CHEMICAL
network,8385,O
connecting,8385,O
between,8385,O
the,8385,O
heme,8385,O
",",8385,O
the,8385,O
substrate,8385,O
",",8385,O
and,8385,O
cofactor,8385,O
.,8385,O
Nonthrombolytic,8386,O
intervention,8386,O
in,8386,O
acute,8386,O
myocardial,8386,O
infarction,8386,O
.,8386,O
Alternative,8387,O
interventions,8387,O
are,8387,O
available,8387,O
for,8387,O
patients,8387,O
in,8387,O
whom,8387,O
thrombolytic,8387,O
therapy,8387,O
is,8387,O
inappropriate,8387,O
after,8387,O
an,8387,O
acute,8387,O
myocardial,8387,O
infarction,8387,O
.,8387,O
Administration,8388,O
of,8388,O
a,8388,O
beta,8388,O
blocker,8388,O
within,8388,O
the,8388,O
first,8388,O
24,8388,O
hours,8388,O
of,8388,O
the,8388,O
patient,8388,O
's,8388,O
admission,8388,O
to,8388,O
the,8388,O
coronary,8388,O
care,8388,O
unit,8388,O
can,8388,O
reduce,8388,O
overall,8388,O
morbidity,8388,O
and,8388,O
mortality,8388,O
within,8388,O
the,8388,O
first,8388,O
7,8388,O
days,8388,O
by,8388,O
about,8388,O
15,8388,O
%,8388,O
.,8388,O
Maintenance,8389,O
therapy,8389,O
with,8389,O
an,8389,O
oral,8389,O
beta,8389,O
blocker,8389,O
can,8389,O
reduce,8389,O
mortality,8389,O
within,8389,O
the,8389,O
succeeding,8389,O
3,8389,O
years,8389,O
by,8389,O
about,8389,O
25,8389,O
%,8389,O
.,8389,O
Esmolol,8390,B-CHEMICAL
",",8390,O
a,8390,O
unique,8390,O
cardioselective,8390,O
beta,8390,B-GENE-Y
1-adrenergic,8390,I-GENE-Y
receptor,8390,I-GENE-Y
blocker,8390,O
with,8390,O
a,8390,O
half-life,8390,O
of,8390,O
9,8390,O
minutes,8390,O
",",8390,O
can,8390,O
enable,8390,O
some,8390,O
patients,8390,O
with,8390,O
relative,8390,O
contraindications,8390,O
to,8390,O
beta,8390,O
blockers,8390,O
to,8390,O
nevertheless,8390,O
benefit,8390,O
from,8390,O
early,8390,O
beta-blocking,8390,O
therapy,8390,O
.,8390,O
It,8391,O
also,8391,O
is,8391,O
useful,8391,O
in,8391,O
screening,8391,O
patients,8391,O
for,8391,O
subsequent,8391,O
therapy,8391,O
with,8391,O
beta,8391,O
blockers,8391,O
.,8391,O
Those,8392,O
who,8392,O
tolerate,8392,O
the,8392,O
esmolol,8392,B-CHEMICAL
infusion,8392,O
can,8392,O
be,8392,O
given,8392,O
a,8392,O
long-acting,8392,O
beta,8392,O
blocker,8392,O
.,8392,O
For,8393,O
patients,8393,O
who,8393,O
exhibit,8393,O
intolerance,8393,O
to,8393,O
esmolol,8393,B-CHEMICAL
",",8393,O
the,8393,O
infusion,8393,O
can,8393,O
be,8393,O
terminated,8393,O
with,8393,O
rapid,8393,O
return,8393,O
to,8393,O
baseline,8393,O
hemodynamics,8393,O
.,8393,O
Snake,8394,B-GENE-N
venom,8394,I-GENE-N
metalloproteinases,8394,I-GENE-N
.,8394,O
Recent,8395,O
proteomic,8395,O
analyses,8395,O
of,8395,O
snake,8395,O
venoms,8395,O
show,8395,O
that,8395,O
metalloproteinases,8395,B-GENE-N
represent,8395,O
major,8395,O
components,8395,O
in,8395,O
most,8395,O
of,8395,O
the,8395,O
Crotalid,8395,O
and,8395,O
Viperid,8395,O
venoms,8395,O
.,8395,O
In,8396,O
this,8396,O
chapter,8396,O
we,8396,O
discuss,8396,O
the,8396,O
multiple,8396,O
activities,8396,O
of,8396,O
the,8396,O
SVMPs,8396,B-GENE-N
.,8396,O
In,8397,O
addition,8397,O
to,8397,O
hemorrhagic,8397,O
activity,8397,O
",",8397,O
members,8397,O
of,8397,O
the,8397,O
SVMP,8397,B-GENE-N
family,8397,O
also,8397,O
have,8397,O
fibrin,8397,O
(,8397,O
ogen,8397,O
),8397,O
olytic,8397,O
activity,8397,O
",",8397,O
act,8397,O
as,8397,O
prothrombin,8397,B-GENE-Y
activators,8397,O
",",8397,O
activate,8397,O
blood,8397,O
coagulation,8397,B-GENE-Y
factor,8397,I-GENE-Y
X,8397,I-GENE-Y
",",8397,O
possess,8397,O
apoptotic,8397,O
activity,8397,O
",",8397,O
inhibit,8397,O
platelet,8397,O
aggregation,8397,O
",",8397,O
are,8397,O
pro-inflammatory,8397,O
and,8397,O
inactivate,8397,O
blood,8397,O
serine,8397,B-GENE-N
proteinase,8397,I-GENE-N
inhibitors,8397,O
.,8397,O
Clearly,8398,O
the,8398,O
SVMPs,8398,B-GENE-N
have,8398,O
multiple,8398,O
functions,8398,O
in,8398,O
addition,8398,O
to,8398,O
their,8398,O
well-known,8398,O
hemorrhagic,8398,O
activity,8398,O
.,8398,O
The,8399,O
realization,8399,O
that,8399,O
there,8399,O
are,8399,O
structural,8399,O
variations,8399,O
in,8399,O
the,8399,O
SVMPs,8399,B-GENE-N
and,8399,O
the,8399,O
early,8399,O
studies,8399,O
that,8399,O
led,8399,O
to,8399,O
their,8399,O
classification,8399,O
represents,8399,O
an,8399,O
important,8399,O
event,8399,O
in,8399,O
our,8399,O
understanding,8399,O
of,8399,O
the,8399,O
structural,8399,O
forms,8399,O
of,8399,O
the,8399,O
SVMPs,8399,B-GENE-N
.,8399,O
The,8400,O
SVMPs,8400,B-GENE-N
were,8400,O
subdivided,8400,O
into,8400,O
the,8400,O
P-I,8400,O
",",8400,O
P-II,8400,O
and,8400,O
P-III,8400,O
protein,8400,O
classes,8400,O
.,8400,O
The,8401,O
noticeable,8401,O
characteristic,8401,O
that,8401,O
distinguished,8401,O
the,8401,O
different,8401,O
classes,8401,O
was,8401,O
their,8401,O
size,8401,O
(,8401,O
molecular,8401,O
weight,8401,O
),8401,O
differences,8401,O
and,8401,O
domain,8401,O
structure,8401,O
:,8401,O
Class,8401,O
I,8401,O
(,8401,O
P-I,8401,O
),8401,O
",",8401,O
the,8401,O
small,8401,O
SVMPs,8401,B-GENE-N
",",8401,O
have,8401,O
molecular,8401,O
masses,8401,O
of,8401,O
20-30,8401,O
kDa,8401,O
",",8401,O
contain,8401,O
only,8401,O
a,8401,O
pro,8401,B-GENE-N
domain,8401,I-GENE-N
and,8401,O
the,8401,O
proteinase,8401,B-GENE-N
domain,8401,I-GENE-N
;,8401,O
Class,8401,O
II,8401,O
(,8401,O
P-II,8401,O
),8401,O
",",8401,O
the,8401,O
medium,8401,O
size,8401,O
SVMPs,8401,B-GENE-N
",",8401,O
molecular,8401,O
masses,8401,O
of,8401,O
30-60,8401,O
kDa,8401,O
",",8401,O
contain,8401,O
the,8401,O
pro,8401,B-GENE-N
domain,8401,I-GENE-N
",",8401,O
proteinase,8401,B-GENE-N
domain,8401,I-GENE-N
and,8401,O
disintegrin,8401,B-GENE-N
domain,8401,I-GENE-N
;,8401,O
Class,8401,O
III,8401,O
(,8401,O
P-III,8401,O
),8401,O
",",8401,O
the,8401,O
large,8401,O
SVMPs,8401,B-GENE-N
",",8401,O
have,8401,O
molecular,8401,O
masses,8401,O
of,8401,O
60-100,8401,O
kDa,8401,O
",",8401,O
contain,8401,O
pro,8401,B-GENE-N
",",8401,O
proteinase,8401,B-GENE-N
",",8401,O
disintegrin-like,8401,B-GENE-N
and,8401,O
cysteine-rich,8401,B-GENE-N
domain,8401,I-GENE-N
structure,8401,O
.,8401,O
Another,8402,O
significant,8402,O
advance,8402,O
in,8402,O
the,8402,O
SVMP,8402,B-GENE-N
field,8402,O
was,8402,O
the,8402,O
characterization,8402,O
of,8402,O
the,8402,O
crystal,8402,O
structure,8402,O
of,8402,O
the,8402,O
first,8402,O
P-I,8402,B-GENE-N
class,8402,I-GENE-N
SVMP,8402,I-GENE-N
.,8402,O
The,8403,O
structures,8403,O
of,8403,O
other,8403,O
P-I,8403,B-GENE-N
SVMPs,8403,I-GENE-N
soon,8403,O
followed,8403,O
and,8403,O
the,8403,O
structures,8403,O
of,8403,O
P-III,8403,B-GENE-N
SVMPs,8403,I-GENE-N
have,8403,O
also,8403,O
been,8403,O
determined,8403,O
.,8403,O
The,8404,O
active,8404,O
site,8404,O
of,8404,O
the,8404,O
metalloproteinase,8404,B-GENE-N
domain,8404,I-GENE-N
has,8404,O
a,8404,O
consensus,8404,O
HEXXHXXGXXHD,8404,B-GENE-N
sequence,8404,O
and,8404,O
a,8404,O
Met-turn,8404,B-CHEMICAL
.,8404,O
The,8405,O
``,8405,O
Met-turn,8405,B-CHEMICAL
'',8405,O
structure,8405,O
contains,8405,O
a,8405,O
conserved,8405,O
Met,8405,B-CHEMICAL
residue,8405,O
that,8405,O
forms,8405,O
a,8405,O
hydrophobic,8405,O
basement,8405,O
for,8405,O
the,8405,O
three,8405,O
zinc-binding,8405,B-CHEMICAL
histidines,8405,B-CHEMICAL
in,8405,O
the,8405,O
consensus,8405,O
sequence,8405,O
.,8405,O
Catalytic,8406,O
properties,8406,O
of,8406,O
mouse,8406,B-GENE-Y
carbonic,8406,I-GENE-Y
anhydrase,8406,I-GENE-Y
V.,8406,O
A,8406,O
cDNA,8406,O
encoding,8406,O
the,8406,O
mouse,8406,B-GENE-Y
carbonic,8406,I-GENE-Y
anhydrase,8406,I-GENE-Y
V,8406,I-GENE-Y
gene,8406,O
was,8406,O
isolated,8406,O
by,8406,O
reverse,8406,O
transcription,8406,O
and,8406,O
polymerase,8406,O
chain,8406,O
reaction,8406,O
from,8406,O
BALB/c,8406,O
mouse,8406,O
liver,8406,O
mRNA,8406,O
.,8406,O
Vectors,8407,O
containing,8407,O
the,8407,O
full,8407,O
coding,8407,O
sequence,8407,O
as,8407,O
well,8407,O
as,8407,O
two,8407,O
different,8407,O
NH2-terminal,8407,B-CHEMICAL
truncated,8407,O
genes,8407,O
expressed,8407,O
enzymatically,8407,O
active,8407,O
protein,8407,O
in,8407,O
Escherichia,8407,O
coli,8407,O
.,8407,O
The,8408,B-GENE-Y
carbonic,8408,I-GENE-Y
anhydrase,8408,I-GENE-Y
V,8408,I-GENE-Y
produced,8408,O
by,8408,O
a,8408,O
vector,8408,O
containing,8408,O
the,8408,O
full,8408,O
coding,8408,O
sequence,8408,O
",",8408,O
which,8408,O
includes,8408,O
a,8408,O
possible,8408,O
NH2-terminal,8408,B-CHEMICAL
mitochondrial,8408,O
targeting,8408,O
signal,8408,O
",",8408,O
was,8408,O
proteolytically,8408,O
processed,8408,O
by,8408,O
E.,8408,O
coli,8408,O
and,8408,O
contained,8408,O
several,8408,O
amino-terminal,8408,B-CHEMICAL
ends,8408,O
.,8408,O
The,8409,O
two,8409,O
NH2-terminal,8409,B-CHEMICAL
truncated,8409,O
vectors,8409,O
deleted,8409,O
",",8409,O
respectively,8409,O
",",8409,O
1,8409,O
),8409,O
the,8409,O
29-amino,8409,O
acid,8409,I-CHEMICAL
putative,8409,O
targeting,8409,O
sequence,8409,O
and,8409,O
2,8409,O
),8409,O
51,8409,O
amino,8409,B-CHEMICAL
acids,8409,I-CHEMICAL
",",8409,O
yielding,8409,O
a,8409,O
protein,8409,O
equivalent,8409,O
to,8409,O
a,8409,O
carbonic,8409,B-GENE-Y
anhydrase,8409,I-GENE-Y
(,8409,I-GENE-Y
CA,8409,I-GENE-Y
),8409,I-GENE-Y
V,8409,I-GENE-Y
isolated,8409,O
from,8409,O
mouse,8409,O
liver,8409,O
mitochondria,8409,O
;,8409,O
and,8409,O
both,8409,O
vectors,8409,O
produced,8409,O
homogeneous,8409,O
protein,8409,O
fractions,8409,O
.,8409,O
These,8410,O
latter,8410,O
two,8410,O
forms,8410,O
of,8410,O
CA,8410,B-GENE-Y
V,8410,I-GENE-Y
had,8410,O
identical,8410,O
steady-state,8410,O
constants,8410,O
for,8410,O
the,8410,O
hydration,8410,O
of,8410,O
CO2,8410,B-CHEMICAL
",",8410,O
with,8410,O
maximal,8410,O
values,8410,O
of,8410,O
kcat/Km,8410,O
at,8410,O
3,8410,O
x,8410,O
10,8410,O
(,8410,O
7,8410,O
),8410,O
M-1,8410,O
s-1,8410,O
and,8410,O
kcat,8410,O
at,8410,O
3,8410,O
x,8410,O
10,8410,O
(,8410,O
5,8410,O
),8410,O
s-1,8410,O
with,8410,O
an,8410,O
apparent,8410,O
pKa,8410,O
for,8410,O
catalysis,8410,O
of,8410,O
7.4,8410,O
determined,8410,O
from,8410,O
kcat/Km,8410,O
.,8410,O
In,8411,O
catalytic,8411,O
properties,8411,O
",",8411,O
mouse,8411,B-GENE-Y
CA,8411,I-GENE-Y
V,8411,I-GENE-Y
is,8411,O
closest,8411,O
to,8411,O
CA,8411,B-GENE-Y
I,8411,I-GENE-Y
;,8411,O
however,8411,O
",",8411,O
in,8411,O
inhibition,8411,O
by,8411,O
acetazolamide,8411,B-CHEMICAL
",",8411,O
ethoxzolamide,8411,B-CHEMICAL
",",8411,O
and,8411,O
cyanate,8411,B-CHEMICAL
",",8411,O
CA,8411,B-GENE-Y
V,8411,I-GENE-Y
is,8411,O
very,8411,O
similar,8411,O
to,8411,O
CA,8411,B-GENE-Y
II,8411,I-GENE-Y
.,8411,O
Mouse,8412,B-GENE-Y
CA,8412,I-GENE-Y
V,8412,I-GENE-Y
has,8412,O
a,8412,O
tyrosine,8412,O
at,8412,O
position,8412,O
64,8412,O
",",8412,O
where,8412,O
the,8412,O
highly,8412,O
active,8412,O
isozyme,8412,O
II,8412,O
has,8412,O
histidine,8412,B-CHEMICAL
serving,8412,O
as,8412,O
a,8412,O
proton,8412,O
shuttle,8412,O
in,8412,O
the,8412,O
catalytic,8412,O
pathway,8412,O
.,8412,O
Investigation,8413,O
of,8413,O
a,8413,O
site-specific,8413,O
mutant,8413,O
of,8413,O
CA,8413,B-GENE-Y
V,8413,I-GENE-Y
containing,8413,O
the,8413,O
replacement,8413,O
Tyr64,8413,B-GENE-N
--,8413,I-GENE-N
>,8413,I-GENE-N
His,8413,I-GENE-N
showed,8413,O
that,8413,O
the,8413,O
unique,8413,O
kinetic,8413,O
properties,8413,O
of,8413,O
CA,8413,B-GENE-Y
V,8413,I-GENE-Y
are,8413,O
not,8413,O
due,8413,O
to,8413,O
the,8413,O
presence,8413,O
of,8413,O
tyrosine,8413,B-CHEMICAL
at,8413,O
position,8413,O
64,8413,O
.,8413,O
Kinetic,8414,O
characterization,8414,O
of,8414,O
adenylosuccinate,8414,B-GENE-Y
synthetase,8414,I-GENE-Y
from,8414,O
the,8414,O
thermophilic,8414,O
archaea,8414,O
Methanocaldococcus,8414,O
jannaschii,8414,O
.,8414,O
Adenylosuccinate,8415,B-GENE-Y
synthetase,8415,I-GENE-Y
(,8415,O
AdSS,8415,B-GENE-Y
),8415,O
catalyzes,8415,O
the,8415,O
Mg2+,8415,B-CHEMICAL
dependent,8415,O
condensation,8415,O
of,8415,O
a,8415,O
molecule,8415,O
of,8415,O
IMP,8415,O
with,8415,O
aspartate,8415,B-CHEMICAL
to,8415,O
form,8415,O
adenylosuccinate,8415,B-CHEMICAL
",",8415,O
in,8415,O
a,8415,O
reaction,8415,O
driven,8415,O
by,8415,O
the,8415,O
hydrolysis,8415,O
of,8415,O
GTP,8415,B-CHEMICAL
to,8415,O
GDP,8415,B-CHEMICAL
.,8415,O
AdSS,8416,B-GENE-Y
from,8416,O
the,8416,O
thermophilic,8416,O
archaea,8416,O
",",8416,O
Methanocaldococcus,8416,O
jannaschii,8416,O
(,8416,O
MjAdSS,8416,B-GENE-Y
),8416,O
is,8416,O
345,8416,O
amino,8416,B-CHEMICAL
acids,8416,I-CHEMICAL
long,8416,O
against,8416,O
an,8416,O
average,8416,O
length,8416,O
of,8416,O
430-457,8416,O
amino,8416,B-CHEMICAL
acids,8416,I-CHEMICAL
for,8416,O
most,8416,O
mesophilic,8416,O
AdSS,8416,B-GENE-Y
.,8416,O
This,8417,O
short,8417,O
AdSS,8417,B-GENE-Y
has,8417,O
two,8417,O
large,8417,O
deletions,8417,O
that,8417,O
map,8417,O
to,8417,O
the,8417,O
middle,8417,O
and,8417,O
C-terminus,8417,B-CHEMICAL
of,8417,O
the,8417,O
protein,8417,O
.,8417,O
This,8418,O
article,8418,O
discusses,8418,O
the,8418,O
detailed,8418,O
kinetic,8418,O
characterization,8418,O
of,8418,O
MjAdSS,8418,B-GENE-Y
.,8418,O
Initial,8419,O
velocity,8419,O
and,8419,O
product,8419,O
inhibition,8419,O
studies,8419,O
",",8419,O
carried,8419,O
out,8419,O
at,8419,O
70,8419,O
degrees,8419,O
C,8419,O
",",8419,O
suggest,8419,O
a,8419,O
rapid,8419,O
equilibrium,8419,O
random,8419,O
AB,8419,O
steady-state,8419,O
ordered,8419,O
C,8419,O
kinetic,8419,O
mechanism,8419,O
for,8419,O
the,8419,O
MjAdSS,8419,B-GENE-Y
catalyzed,8419,O
reaction,8419,O
.,8419,O
AdSS,8420,B-GENE-Y
are,8420,O
known,8420,O
to,8420,O
exhibit,8420,O
monomer-dimer,8420,O
equilibrium,8420,O
with,8420,O
the,8420,O
dimer,8420,O
being,8420,O
implicated,8420,O
in,8420,O
catalysis,8420,O
.,8420,O
In,8421,O
contrast,8421,O
",",8421,O
our,8421,O
studies,8421,O
show,8421,O
that,8421,O
MjAdSS,8421,B-GENE-Y
is,8421,O
an,8421,O
equilibrium,8421,O
mixture,8421,O
of,8421,O
dimers,8421,O
and,8421,O
tetramers,8421,O
with,8421,O
the,8421,O
tetramer,8421,O
being,8421,O
the,8421,O
catalytically,8421,O
active,8421,O
form,8421,O
.,8421,O
The,8422,O
tetramer,8422,O
dissociates,8422,O
into,8422,O
dimers,8422,O
with,8422,O
a,8422,O
minor,8422,O
increase,8422,O
in,8422,O
ionic,8422,O
strength,8422,O
of,8422,O
the,8422,O
buffer,8422,O
",",8422,O
while,8422,O
the,8422,O
dimer,8422,O
is,8422,O
extremely,8422,O
stable,8422,O
and,8422,O
does,8422,O
not,8422,O
dissociate,8422,O
even,8422,O
at,8422,O
1.2,8422,O
M,8422,O
NaCl,8422,B-CHEMICAL
.,8422,O
Phosphate,8423,B-CHEMICAL
",",8423,O
a,8423,O
product,8423,O
of,8423,O
the,8423,O
reaction,8423,O
",",8423,O
was,8423,O
found,8423,O
to,8423,O
be,8423,O
a,8423,O
potent,8423,O
inhibitor,8423,O
of,8423,O
MjAdSS,8423,B-GENE-Y
showing,8423,O
biphasic,8423,O
inhibition,8423,O
of,8423,O
enzyme,8423,O
activity,8423,O
.,8423,O
The,8424,O
inhibition,8424,O
was,8424,O
competitive,8424,O
with,8424,O
IMP,8424,O
and,8424,O
noncompetitive,8424,O
with,8424,O
GTP,8424,B-CHEMICAL
.,8424,O
MjAdSS,8425,B-GENE-Y
",",8425,O
like,8425,O
the,8425,O
mouse,8425,B-GENE-N
acidic,8425,I-GENE-N
isozyme,8425,I-GENE-N
",",8425,O
exhibits,8425,O
substrate,8425,O
inhibition,8425,O
",",8425,O
with,8425,O
IMP,8425,O
inhibiting,8425,O
enzyme,8425,O
activity,8425,O
at,8425,O
subsaturating,8425,O
GTP,8425,B-CHEMICAL
concentrations,8425,O
.,8425,O
Regulation,8426,O
of,8426,O
enzyme,8426,O
activity,8426,O
by,8426,O
the,8426,O
glycolytic,8426,O
intermediate,8426,O
",",8426,O
fructose,8426,B-CHEMICAL
"1,6",8426,B-CHEMICAL
bisphosphate,8426,I-CHEMICAL
",",8426,O
was,8426,O
also,8426,O
observed,8426,O
with,8426,O
the,8426,O
inhibition,8426,O
being,8426,O
competitive,8426,O
with,8426,O
IMP,8426,O
and,8426,O
noncompetitive,8426,O
against,8426,O
GTP,8426,B-CHEMICAL
.,8426,O
Inhibition,8427,O
of,8427,O
NF-kappa,8427,B-GENE-N
B,8427,I-GENE-N
by,8427,O
sodium,8427,O
salicylate,8427,O
and,8427,O
aspirin,8427,O
.,8427,O
The,8428,O
transcription,8428,O
factor,8428,O
nuclear,8428,B-GENE-N
factor-kappa,8428,I-GENE-N
B,8428,I-GENE-N
(,8428,O
NF-kappa,8428,B-GENE-N
B,8428,I-GENE-N
),8428,O
is,8428,O
critical,8428,O
for,8428,O
the,8428,O
inducible,8428,O
expression,8428,O
of,8428,O
multiple,8428,O
cellular,8428,O
and,8428,O
viral,8428,O
genes,8428,O
involved,8428,O
in,8428,O
inflammation,8428,O
and,8428,O
infection,8428,O
including,8428,O
interleukin-1,8428,B-GENE-N
(,8428,O
IL-1,8428,B-GENE-N
),8428,O
",",8428,O
IL-6,8428,B-GENE-Y
",",8428,O
and,8428,O
adhesion,8428,O
molecules,8428,O
.,8428,O
The,8429,O
anti-inflammatory,8429,O
drugs,8429,O
sodium,8429,B-CHEMICAL
salicylate,8429,I-CHEMICAL
and,8429,O
aspirin,8429,B-CHEMICAL
inhibited,8429,O
the,8429,O
activation,8429,O
of,8429,O
NF-kappa,8429,B-GENE-N
B,8429,I-GENE-N
",",8429,O
which,8429,O
further,8429,O
explains,8429,O
the,8429,O
mechanism,8429,O
of,8429,O
action,8429,O
of,8429,O
these,8429,O
drugs,8429,O
.,8429,O
This,8430,O
inhibition,8430,O
prevented,8430,O
the,8430,O
degradation,8430,O
of,8430,O
the,8430,O
NF-kappa,8430,B-GENE-N
B,8430,I-GENE-N
inhibitor,8430,O
",",8430,O
I,8430,B-GENE-N
kappa,8430,I-GENE-N
B,8430,I-GENE-N
",",8430,O
and,8430,O
therefore,8430,O
NF-kappa,8430,B-GENE-N
B,8430,I-GENE-N
was,8430,O
retained,8430,O
in,8430,O
the,8430,O
cytosol,8430,O
.,8430,O
Sodium,8431,B-CHEMICAL
salicylate,8431,I-CHEMICAL
and,8431,O
aspirin,8431,B-CHEMICAL
also,8431,O
inhibited,8431,O
NF-kappa,8431,B-GENE-N
B-dependent,8431,O
transcription,8431,O
from,8431,O
the,8431,O
Ig,8431,B-GENE-Y
kappa,8431,I-GENE-Y
enhancer,8431,O
and,8431,O
the,8431,O
human,8431,O
immunodeficiency,8431,O
virus,8431,O
(,8431,O
HIV,8431,O
),8431,O
long,8431,O
terminal,8431,O
repeat,8431,O
(,8431,O
LTR,8431,O
),8431,O
in,8431,O
transfected,8431,O
T,8431,O
cells,8431,O
.,8431,O
Galanin,8432,B-GENE-Y
attenuates,8432,O
cyclic,8432,B-GENE-N
AMP,8432,I-GENE-N
regulatory,8432,I-GENE-N
element-binding,8432,I-GENE-N
protein,8432,I-GENE-N
(,8432,O
CREB,8432,B-GENE-N
),8432,O
phosphorylation,8432,O
induced,8432,O
by,8432,O
chronic,8432,O
morphine,8432,B-CHEMICAL
and,8432,O
naloxone,8432,B-CHEMICAL
challenge,8432,O
in,8432,O
Cath.a,8432,O
cells,8432,O
and,8432,O
primary,8432,O
striatal,8432,O
cultures,8432,O
.,8432,O
Repeated,8433,O
morphine,8433,B-CHEMICAL
administration,8433,O
leads,8433,O
to,8433,O
molecular,8433,O
alterations,8433,O
of,8433,O
the,8433,O
neural,8433,O
circuitry,8433,O
in,8433,O
the,8433,O
locus,8433,O
coeruleus,8433,O
and,8433,O
nucleus,8433,O
accumbens,8433,O
.,8433,O
These,8434,O
changes,8434,O
include,8434,O
increased,8434,O
activity,8434,O
of,8434,O
several,8434,O
components,8434,O
of,8434,O
the,8434,O
cAMP,8434,B-CHEMICAL
signaling,8434,O
pathway,8434,O
that,8434,O
are,8434,O
thought,8434,O
to,8434,O
be,8434,O
associated,8434,O
with,8434,O
psychological,8434,O
and,8434,O
somatic,8434,O
signs,8434,O
of,8434,O
opiate,8434,O
withdrawal,8434,O
.,8434,O
The,8435,O
neuropeptide,8435,O
galanin,8435,B-GENE-Y
has,8435,O
been,8435,O
shown,8435,O
to,8435,O
attenuate,8435,O
cAMP,8435,B-CHEMICAL
signaling,8435,O
in,8435,O
multiple,8435,O
cell,8435,O
types,8435,O
.,8435,O
The,8436,O
current,8436,O
study,8436,O
demonstrates,8436,O
that,8436,O
acute,8436,O
galanin,8436,B-GENE-Y
treatment,8436,O
blocks,8436,O
the,8436,O
consequences,8436,O
of,8436,O
increased,8436,O
cAMP,8436,B-CHEMICAL
signaling,8436,O
following,8436,O
chronic,8436,O
opiate,8436,O
administration,8436,O
and,8436,O
withdrawal,8436,O
in,8436,O
Cath.a,8436,O
cells,8436,O
and,8436,O
primary,8436,O
cultures,8436,O
of,8436,O
striatal,8436,O
neurons,8436,O
as,8436,O
measured,8436,O
by,8436,O
phosphorylation,8436,O
of,8436,O
the,8436,O
transcription,8436,O
factor,8436,O
cAMP,8436,B-GENE-N
regulatory,8436,I-GENE-N
element-binding,8436,I-GENE-N
protein,8436,I-GENE-N
(,8436,O
CREB,8436,B-GENE-N
),8436,O
.,8436,O
In,8437,O
addition,8437,O
",",8437,O
galanin-mediated,8437,B-GENE-Y
attenuation,8437,O
of,8437,O
CREB,8437,B-GENE-N
phosphorylation,8437,O
is,8437,O
independent,8437,O
of,8437,O
galanin-induced,8437,B-GENE-Y
extracellular,8437,B-GENE-N
signal-regulated,8437,I-GENE-N
kinase,8437,I-GENE-N
(,8437,I-GENE-N
ERK,8437,I-GENE-N
),8437,I-GENE-N
1/2,8437,I-GENE-N
phosphorylation,8437,O
in,8437,O
Cath.a,8437,O
cells,8437,O
.,8437,O
These,8438,O
data,8438,O
suggest,8438,O
that,8438,O
galanin,8438,B-GENE-N
receptors,8438,I-GENE-N
may,8438,O
serve,8438,O
as,8438,O
an,8438,O
additional,8438,O
potential,8438,O
therapeutic,8438,O
target,8438,O
for,8438,O
the,8438,O
treatment,8438,O
of,8438,O
opiate,8438,O
withdrawal,8438,O
.,8438,O
Na+/Ca2+,8439,B-CHEMICAL
exchange,8439,O
inhibitors,8439,O
:,8439,O
a,8439,O
new,8439,O
class,8439,O
of,8439,O
calcium,8439,B-CHEMICAL
regulators,8439,O
.,8439,O
The,8440,O
Na,8440,B-GENE-N
(,8440,I-GENE-N
+,8440,I-GENE-N
),8440,I-GENE-N
/Ca,8440,I-GENE-N
(,8440,I-GENE-N
2+,8440,I-GENE-N
),8440,I-GENE-N
exchanger,8440,I-GENE-N
(,8440,O
NCX,8440,B-GENE-N
),8440,O
is,8440,O
a,8440,O
bidirectional,8440,O
transporter,8440,O
that,8440,O
normally,8440,O
extrudes,8440,O
Ca,8440,B-CHEMICAL
(,8440,I-CHEMICAL
2+,8440,I-CHEMICAL
),8440,I-CHEMICAL
from,8440,O
the,8440,O
cell,8440,O
(,8440,O
forward,8440,O
mode,8440,O
),8440,O
",",8440,O
but,8440,O
also,8440,O
brings,8440,O
Ca,8440,B-CHEMICAL
(,8440,I-CHEMICAL
2+,8440,I-CHEMICAL
),8440,I-CHEMICAL
into,8440,O
the,8440,O
cell,8440,O
(,8440,O
reverse,8440,O
mode,8440,O
),8440,O
under,8440,O
special,8440,O
conditions,8440,O
such,8440,O
as,8440,O
intracellular,8440,O
Na,8440,B-CHEMICAL
(,8440,I-CHEMICAL
+,8440,I-CHEMICAL
),8440,I-CHEMICAL
(,8440,O
Na,8440,B-CHEMICAL
(,8440,I-CHEMICAL
+,8440,I-CHEMICAL
),8440,I-CHEMICAL
(,8440,O
i,8440,O
),8440,O
),8440,O
accumulation,8440,O
or,8440,O
membrane,8440,O
depolarization,8440,O
.,8440,O
There,8441,O
are,8441,O
three,8441,O
mammalian,8441,B-GENE-N
NCX,8441,I-GENE-N
isoforms,8441,O
:,8441,O
NCX1,8441,B-GENE-Y
is,8441,O
widely,8441,O
expressed,8441,O
in,8441,O
the,8441,O
heart,8441,O
",",8441,O
kidney,8441,O
",",8441,O
brain,8441,O
",",8441,O
blood,8441,O
vessels,8441,O
",",8441,O
and,8441,O
so,8441,O
on,8441,O
;,8441,O
whereas,8441,O
the,8441,O
expression,8441,O
of,8441,O
NCX2,8441,B-GENE-Y
and,8441,O
NCX3,8441,B-GENE-Y
is,8441,O
limited,8441,O
mainly,8441,O
to,8441,O
the,8441,O
brain,8441,O
and,8441,O
skeletal,8441,O
muscle,8441,O
.,8441,O
The,8442,O
pharmacology,8442,O
of,8442,O
NCX,8442,B-GENE-N
inhibitors,8442,O
has,8442,O
been,8442,O
studied,8442,O
extensively,8442,O
since,8442,O
the,8442,O
development,8442,O
of,8442,O
KB-R7943,8442,B-CHEMICAL
",",8442,O
a,8442,O
prototype,8442,O
benzyloxyphenyl,8442,B-CHEMICAL
NCX,8442,B-GENE-N
inhibitor,8442,O
",",8442,O
in,8442,O
1996,8442,O
.,8442,O
Currently,8443,O
",",8443,O
experiments,8443,O
are,8443,O
actively,8443,O
progressing,8443,O
with,8443,O
more,8443,O
selective,8443,O
inhibitors,8443,O
:,8443,O
SEA0400,8443,B-CHEMICAL
",",8443,O
SN-6,8443,B-CHEMICAL
",",8443,O
and,8443,O
YM-244769,8443,B-CHEMICAL
.,8443,O
Intriguingly,8444,O
",",8444,O
the,8444,O
inhibitory,8444,O
potency,8444,O
of,8444,O
benzyloxyphenyl,8444,B-CHEMICAL
NCX,8444,B-GENE-N
inhibitors,8444,O
is,8444,O
directly,8444,O
coupled,8444,O
to,8444,O
the,8444,O
rate,8444,O
of,8444,O
Na,8444,B-CHEMICAL
(,8444,I-CHEMICAL
+,8444,I-CHEMICAL
),8444,I-CHEMICAL
(,8444,O
i,8444,O
),8444,O
-dependent,8444,O
inactivation,8444,O
.,8444,O
Therefore,8445,O
",",8445,O
the,8445,O
benzyloxyphenyl,8445,B-CHEMICAL
inhibitors,8445,O
are,8445,O
apparently,8445,O
dormant,8445,O
during,8445,O
the,8445,O
forward,8445,O
mode,8445,O
under,8445,O
normal,8445,O
conditions,8445,O
(,8445,O
low,8445,O
Na,8445,B-CHEMICAL
(,8445,I-CHEMICAL
+,8445,I-CHEMICAL
),8445,I-CHEMICAL
(,8445,O
i,8445,O
),8445,O
),8445,O
",",8445,O
but,8445,O
become,8445,O
effective,8445,O
during,8445,O
the,8445,O
reverse,8445,O
mode,8445,O
under,8445,O
pathological,8445,O
conditions,8445,O
(,8445,O
high,8445,O
Na,8445,B-CHEMICAL
(,8445,I-CHEMICAL
+,8445,I-CHEMICAL
),8445,I-CHEMICAL
(,8445,O
i,8445,O
),8445,O
),8445,O
.,8445,O
This,8446,O
should,8446,O
be,8446,O
an,8446,O
ideal,8446,O
profile,8446,O
for,8446,O
calcium,8446,B-CHEMICAL
regulators,8446,O
against,8446,O
Na,8446,B-CHEMICAL
(,8446,I-CHEMICAL
+,8446,I-CHEMICAL
),8446,I-CHEMICAL
(,8446,O
i,8446,O
),8446,O
-related,8446,O
diseases,8446,O
",",8446,O
such,8446,O
as,8446,O
ischemia/reperfusion,8446,O
injuries,8446,O
",",8446,O
salt-dependent,8446,O
hypertension,8446,O
",",8446,O
and,8446,O
digitalis,8446,O
arrhythmia,8446,O
.,8446,O
Existing,8447,O
ion,8447,B-GENE-N
channel,8447,I-GENE-N
blockers,8447,O
",",8447,O
such,8447,O
as,8447,O
amiodarone,8447,B-CHEMICAL
",",8447,O
dronedarone,8447,B-CHEMICAL
",",8447,O
bepridil,8447,B-CHEMICAL
",",8447,O
aprindine,8447,B-CHEMICAL
",",8447,O
and,8447,O
cibenzoline,8447,B-CHEMICAL
",",8447,O
have,8447,O
been,8447,O
found,8447,O
to,8447,O
have,8447,O
an,8447,O
NCX,8447,B-GENE-N
inhibitory,8447,O
action,8447,O
.,8447,O
It,8448,O
is,8448,O
possible,8448,O
that,8448,O
this,8448,O
property,8448,O
is,8448,O
partly,8448,O
responsible,8448,O
for,8448,O
their,8448,O
antiarrhythmic,8448,O
and,8448,O
cardioprotective,8448,O
effects,8448,O
.,8448,O
This,8449,O
article,8449,O
presents,8449,O
the,8449,O
characteristics,8449,O
of,8449,O
selective,8449,O
and,8449,O
non-selective,8449,O
NCX,8449,B-GENE-N
inhibitors,8449,O
and,8449,O
their,8449,O
therapeutic,8449,O
potential,8449,O
as,8449,O
a,8449,O
new,8449,O
calcium,8449,B-CHEMICAL
regulator,8449,O
.,8449,O
Efficacy,8450,O
and,8450,O
safety,8450,O
of,8450,O
the,8450,O
dipeptidyl,8450,B-GENE-Y
peptidase-4,8450,I-GENE-Y
inhibitor,8450,O
",",8450,O
sitagliptin,8450,B-CHEMICAL
",",8450,O
in,8450,O
patients,8450,O
with,8450,O
type,8450,O
2,8450,O
diabetes,8450,O
mellitus,8450,O
inadequately,8450,O
controlled,8450,O
on,8450,O
glimepiride,8450,B-CHEMICAL
alone,8450,O
or,8450,O
on,8450,O
glimepiride,8450,B-CHEMICAL
and,8450,O
metformin,8450,B-CHEMICAL
.,8450,O
AIM,8451,O
:,8451,O
To,8451,O
assess,8451,O
the,8451,O
efficacy,8451,O
and,8451,O
safety,8451,O
of,8451,O
a,8451,O
24-week,8451,O
treatment,8451,O
with,8451,O
sitagliptin,8451,B-CHEMICAL
",",8451,O
a,8451,O
highly,8451,O
selective,8451,O
once-daily,8451,O
oral,8451,O
dipeptidyl,8451,B-GENE-Y
peptidase-4,8451,I-GENE-Y
(,8451,O
DPP-4,8451,B-GENE-Y
),8451,O
inhibitor,8451,O
",",8451,O
in,8451,O
patients,8451,O
with,8451,O
type,8451,O
2,8451,O
diabetes,8451,O
who,8451,O
had,8451,O
inadequate,8451,O
glycaemic,8451,O
control,8451,O
[,8451,O
glycosylated,8451,B-GENE-Y
haemoglobin,8451,I-GENE-Y
(,8451,O
HbA,8451,B-GENE-Y
(,8451,I-GENE-Y
1c,8451,I-GENE-Y
),8451,I-GENE-Y
),8451,O
>,8451,O
or=7.5,8451,O
%,8451,O
and,8451,O
<,8451,O
or=10.5,8451,O
%,8451,O
],8451,O
while,8451,O
on,8451,O
glimepiride,8451,O
alone,8451,O
or,8451,O
in,8451,O
combination,8451,O
with,8451,O
metformin,8451,O
.,8451,O
METHODS,8452,O
:,8452,O
After,8452,O
a,8452,O
screening,8452,O
",",8452,O
diet/exercise,8452,O
run-in,8452,O
and,8452,O
drug,8452,O
wash-off,8452,O
period,8452,O
",",8452,O
a,8452,O
glimepiride,8452,O
+/-,8452,O
metformin,8452,O
dose,8452,O
titration/stabilization,8452,O
period,8452,O
and,8452,O
a,8452,O
2-week,8452,O
",",8452,O
single-blind,8452,O
placebo,8452,O
run-in,8452,O
",",8452,O
441,8452,O
patients,8452,O
(,8452,O
of,8452,O
ages,8452,O
18-75,8452,O
years,8452,O
),8452,O
were,8452,O
randomized,8452,O
to,8452,O
receive,8452,O
the,8452,O
addition,8452,O
of,8452,O
sitagliptin,8452,O
100,8452,O
mg,8452,O
once,8452,O
daily,8452,O
or,8452,O
placebo,8452,O
in,8452,O
a,8452,O
1,8452,O
:,8452,O
1,8452,O
ratio,8452,O
for,8452,O
24,8452,O
weeks,8452,O
.,8452,O
Of,8453,O
these,8453,O
patients,8453,O
",",8453,O
212,8453,O
were,8453,O
on,8453,O
glimepiride,8453,O
(,8453,O
>,8453,O
or=4,8453,O
mg/day,8453,O
),8453,O
monotherapy,8453,O
and,8453,O
229,8453,O
were,8453,O
on,8453,O
glimepiride,8453,O
(,8453,O
>,8453,O
or=4,8453,O
mg/day,8453,O
),8453,O
plus,8453,O
metformin,8453,O
(,8453,O
>,8453,O
"or=1,500",8453,O
mg/day,8453,O
),8453,O
combination,8453,O
therapy,8453,O
.,8453,O
Patients,8454,O
exceeding,8454,O
pre-specified,8454,O
glycaemic,8454,O
thresholds,8454,O
during,8454,O
the,8454,O
double-blind,8454,O
treatment,8454,O
period,8454,O
were,8454,O
provided,8454,O
open-label,8454,O
rescue,8454,O
therapy,8454,O
(,8454,O
pioglitazone,8454,O
),8454,O
until,8454,O
study,8454,O
end,8454,O
.,8454,O
The,8455,O
primary,8455,O
efficacy,8455,O
analysis,8455,O
evaluated,8455,O
the,8455,O
change,8455,O
in,8455,O
HbA,8455,O
(,8455,O
1c,8455,O
),8455,O
from,8455,O
baseline,8455,O
to,8455,O
Week,8455,O
24,8455,O
.,8455,O
Secondary,8456,O
efficacy,8456,O
endpoints,8456,O
included,8456,O
fasting,8456,O
plasma,8456,O
glucose,8456,O
(,8456,O
FPG,8456,O
),8456,O
",",8456,O
2-h,8456,O
post-meal,8456,O
glucose,8456,O
and,8456,O
lipid,8456,O
measurements,8456,O
.,8456,O
RESULTS,8457,O
:,8457,O
Mean,8457,O
baseline,8457,O
HbA,8457,O
(,8457,O
1c,8457,O
),8457,O
was,8457,O
8.34,8457,O
%,8457,O
in,8457,O
the,8457,O
sitagliptin,8457,O
and,8457,O
placebo,8457,O
groups,8457,O
.,8457,O
After,8458,O
24,8458,O
weeks,8458,O
",",8458,O
sitagliptin,8458,O
reduced,8458,O
HbA,8458,O
(,8458,O
1c,8458,O
),8458,O
by,8458,O
0.74,8458,O
%,8458,O
(,8458,O
p,8458,O
<,8458,O
0.001,8458,O
),8458,O
relative,8458,O
to,8458,O
placebo,8458,O
.,8458,O
In,8459,O
the,8459,O
subset,8459,O
of,8459,O
patients,8459,O
on,8459,O
glimepiride,8459,O
plus,8459,O
metformin,8459,O
",",8459,O
sitagliptin,8459,O
reduced,8459,O
HbA,8459,O
(,8459,O
1c,8459,O
),8459,O
by,8459,O
0.89,8459,O
%,8459,O
relative,8459,O
to,8459,O
placebo,8459,O
",",8459,O
compared,8459,O
with,8459,O
a,8459,O
reduction,8459,O
of,8459,O
0.57,8459,O
%,8459,O
in,8459,O
the,8459,O
subset,8459,O
of,8459,O
patients,8459,O
on,8459,O
glimepiride,8459,O
alone,8459,O
.,8459,O
The,8460,O
addition,8460,O
of,8460,O
sitagliptin,8460,O
reduced,8460,O
FPG,8460,O
by,8460,O
20.1,8460,O
mg/dl,8460,O
(,8460,O
p,8460,O
<,8460,O
0.001,8460,O
),8460,O
and,8460,O
increased,8460,O
homeostasis,8460,O
model,8460,O
assessment-beta,8460,O
",",8460,O
a,8460,O
marker,8460,O
of,8460,O
beta-cell,8460,O
function,8460,O
",",8460,O
by,8460,O
12,8460,O
%,8460,O
(,8460,O
p,8460,O
<,8460,O
0.05,8460,O
),8460,O
relative,8460,O
to,8460,O
placebo,8460,O
.,8460,O
In,8461,O
patients,8461,O
who,8461,O
underwent,8461,O
a,8461,O
meal,8461,O
tolerance,8461,O
test,8461,O
(,8461,O
n,8461,O
=,8461,O
134,8461,O
),8461,O
",",8461,O
sitagliptin,8461,O
decreased,8461,O
2-h,8461,O
post-prandial,8461,O
glucose,8461,O
(,8461,O
PPG,8461,O
),8461,O
by,8461,O
36.1,8461,O
mg/dl,8461,O
(,8461,O
p,8461,O
<,8461,O
0.001,8461,O
),8461,O
relative,8461,O
to,8461,O
placebo,8461,O
.,8461,O
The,8462,O
addition,8462,O
of,8462,O
sitagliptin,8462,O
was,8462,O
generally,8462,O
well,8462,O
tolerated,8462,O
",",8462,O
although,8462,O
there,8462,O
was,8462,O
a,8462,O
higher,8462,O
incidence,8462,O
of,8462,O
overall,8462,O
(,8462,O
60,8462,O
vs.,8462,O
47,8462,O
%,8462,O
),8462,O
and,8462,O
drug-related,8462,O
adverse,8462,O
experiences,8462,O
(,8462,O
AEs,8462,O
),8462,O
(,8462,O
15,8462,O
vs.,8462,O
7,8462,O
%,8462,O
),8462,O
in,8462,O
the,8462,O
sitagliptin,8462,O
group,8462,O
than,8462,O
in,8462,O
the,8462,O
placebo,8462,O
group,8462,O
.,8462,O
This,8463,O
was,8463,O
largely,8463,O
because,8463,O
of,8463,O
a,8463,O
higher,8463,O
incidence,8463,O
of,8463,O
hypoglycaemia,8463,O
AEs,8463,O
(,8463,O
12,8463,O
vs.,8463,O
2,8463,O
%,8463,O
",",8463,O
respectively,8463,O
),8463,O
in,8463,O
the,8463,O
sitagliptin,8463,O
group,8463,O
compared,8463,O
with,8463,O
the,8463,O
placebo,8463,O
group,8463,O
.,8463,O
Body,8464,O
weight,8464,O
modestly,8464,O
increased,8464,O
with,8464,O
sitagliptin,8464,O
relative,8464,O
to,8464,O
placebo,8464,O
(,8464,O
+0.8,8464,O
vs.,8464,O
-0.4,8464,O
kg,8464,O
;,8464,O
p,8464,O
<,8464,O
0.001,8464,O
),8464,O
.,8464,O
CONCLUSIONS,8465,O
:,8465,O
Sitagliptin,8465,O
100,8465,O
mg,8465,O
once,8465,O
daily,8465,O
significantly,8465,O
improved,8465,O
glycaemic,8465,O
control,8465,O
and,8465,O
beta-cell,8465,O
function,8465,O
in,8465,O
patients,8465,O
with,8465,O
type,8465,O
2,8465,O
diabetes,8465,O
who,8465,O
had,8465,O
inadequate,8465,O
glycaemic,8465,O
control,8465,O
with,8465,O
glimepiride,8465,O
or,8465,O
glimepiride,8465,O
plus,8465,O
metformin,8465,O
therapy,8465,O
.,8465,O
The,8466,O
addition,8466,O
of,8466,O
sitagliptin,8466,O
was,8466,O
generally,8466,O
well,8466,O
tolerated,8466,O
",",8466,O
with,8466,O
a,8466,O
modest,8466,O
increase,8466,O
in,8466,O
hypoglycaemia,8466,O
and,8466,O
body,8466,O
weight,8466,O
",",8466,O
consistent,8466,O
with,8466,O
glimepiride,8466,O
therapy,8466,O
and,8466,O
the,8466,O
observed,8466,O
degree,8466,O
of,8466,O
glycaemic,8466,O
improvement,8466,O
.,8466,O
Compound,8467,O
and,8467,O
compositions,8467,O
as,8467,O
TGR5,8467,B-GENE-Y
agonists,8467,O
:,8467,O
WO2012082947,8467,O
.,8467,O
The,8468,O
patent,8468,O
application,8468,O
WO2012082947,8468,O
claims,8468,O
novel,8468,O
compounds,8468,O
as,8468,O
agonists,8468,O
of,8468,O
a,8468,O
plasma,8468,B-GENE-Y
membrane-bound,8468,I-GENE-Y
bile,8468,I-GENE-Y
acid,8468,I-GENE-Y
receptor,8468,I-GENE-Y
TGR5,8468,B-GENE-Y
.,8468,O
By,8469,O
activating,8469,O
TGR5,8469,B-GENE-Y
",",8469,O
the,8469,O
agonists,8469,O
improve,8469,O
glycemic,8469,O
control,8469,O
and,8469,O
enhance,8469,O
energy,8469,O
expenditure,8469,O
.,8469,O
The,8470,O
basic,8470,O
generic,8470,O
claim,8470,O
of,8470,O
the,8470,O
patent,8470,O
covers,8470,O
pyrazole,8470,B-CHEMICAL
derivatives,8470,O
",",8470,O
different,8470,O
permutations,8470,O
on,8470,O
the,8470,O
core,8470,O
pyrazole,8470,B-CHEMICAL
ring,8470,O
are,8470,O
covered,8470,O
in,8470,O
the,8470,O
subsidiary,8470,O
claims,8470,O
.,8470,O
The,8471,O
claimed,8471,O
compounds,8471,O
are,8471,O
human,8471,B-GENE-Y
TGR5,8471,I-GENE-Y
agonists,8471,O
having,8471,O
potency,8471,O
in,8471,O
the,8471,O
nM,8471,O
range,8471,O
.,8471,O
Hydroxysafflor,8472,B-CHEMICAL
yellow,8472,I-CHEMICAL
a,8472,I-CHEMICAL
inhibits,8472,O
lipopolysaccharide-induced,8472,O
inflammatory,8472,O
signal,8472,O
transduction,8472,O
in,8472,O
human,8472,O
alveolar,8472,O
epithelial,8472,O
A549,8472,O
cells,8472,O
.,8472,O
Hydroxysafflor,8473,B-CHEMICAL
yellow,8473,I-CHEMICAL
A,8473,I-CHEMICAL
(,8473,O
HSYA,8473,B-CHEMICAL
),8473,O
is,8473,O
an,8473,O
active,8473,O
ingredient,8473,O
obtained,8473,O
from,8473,O
the,8473,O
flower,8473,O
of,8473,O
Carthamus,8473,O
tinctorius,8473,O
L.,8473,O
The,8473,O
present,8473,O
study,8473,O
investigated,8473,O
the,8473,O
effects,8473,O
of,8473,O
HSYA,8473,B-CHEMICAL
on,8473,O
lipopolysaccharide,8473,O
(,8473,O
LPS,8473,O
),8473,O
-induced,8473,O
inflammatory,8473,O
signal,8473,O
transduction,8473,O
in,8473,O
human,8473,O
alveolar,8473,O
epithelial,8473,O
A549,8473,O
cells,8473,O
.,8473,O
A549,8474,O
cells,8474,O
stimulated,8474,O
with,8474,O
LPS,8474,O
were,8474,O
incubated,8474,O
with,8474,O
three,8474,O
doses,8474,O
of,8474,O
HSYA,8474,B-CHEMICAL
(,8474,O
1,8474,O
",",8474,O
4,8474,O
and,8474,O
16μmol/L,8474,O
),8474,O
.,8474,O
HSYA,8475,B-CHEMICAL
suppressed,8475,O
the,8475,O
expression,8475,O
of,8475,O
TLR-4,8475,B-GENE-Y
",",8475,O
Myd88,8475,B-GENE-Y
",",8475,O
ICAM-1,8475,B-GENE-Y
",",8475,O
TNFα,8475,B-GENE-Y
",",8475,O
IL-1β,8475,B-GENE-Y
and,8475,O
IL-6,8475,B-GENE-Y
at,8475,O
the,8475,O
mRNA,8475,O
and,8475,O
protein,8475,O
level,8475,O
",",8475,O
and,8475,O
inhibited,8475,O
the,8475,O
adhesion,8475,O
of,8475,O
leukocytes,8475,O
to,8475,O
A549,8475,O
cells,8475,O
.,8475,O
HSYA,8476,B-CHEMICAL
treatment,8476,O
also,8476,O
decreased,8476,O
NF-κB,8476,B-GENE-N
p65,8476,B-GENE-Y
nuclear,8476,O
translocation,8476,O
and,8476,O
inhibited,8476,O
the,8476,O
phosphorylation,8476,O
of,8476,O
p38,8476,B-GENE-N
mitogen-activated,8476,B-GENE-N
protein,8476,I-GENE-N
kinase,8476,I-GENE-N
(,8476,O
p38,8476,B-GENE-N
MAPK,8476,B-GENE-N
),8476,O
.,8476,O
These,8477,O
findings,8477,O
suggest,8477,O
that,8477,O
HSYA,8477,B-CHEMICAL
effectively,8477,O
inhibits,8477,O
LPS-induced,8477,O
inflammatory,8477,O
signal,8477,O
transduction,8477,O
in,8477,O
A549,8477,O
cells,8477,O
.,8477,O
Synthesis,8478,O
and,8478,O
biological,8478,O
evaluation,8478,O
of,8478,O
phosphorylated,8478,B-CHEMICAL
flavonoids,8478,I-CHEMICAL
as,8478,O
potent,8478,O
and,8478,O
selective,8478,O
inhibitors,8478,O
of,8478,O
cholesterol,8478,B-GENE-Y
esterase,8478,I-GENE-Y
.,8478,O
A,8479,O
series,8479,O
of,8479,O
phosphorylated,8479,B-CHEMICAL
flavonoids,8479,I-CHEMICAL
were,8479,O
synthesized,8479,O
and,8479,O
investigated,8479,O
in,8479,O
vitro,8479,O
as,8479,O
inhibitors,8479,O
of,8479,O
pancreatic,8479,O
cholesterol,8479,B-GENE-Y
esterase,8479,I-GENE-Y
(,8479,O
CEase,8479,B-GENE-Y
),8479,O
and,8479,O
acetylcholinesterase,8479,B-GENE-Y
(,8479,O
AChE,8479,B-GENE-Y
),8479,O
.,8479,O
The,8480,O
results,8480,O
showed,8480,O
that,8480,O
most,8480,O
of,8480,O
the,8480,O
synthesized,8480,O
compounds,8480,O
exhibited,8480,O
nanomolar,8480,O
potency,8480,O
against,8480,O
CEase,8480,B-GENE-Y
",",8480,O
much,8480,O
better,8480,O
than,8480,O
the,8480,O
parent,8480,O
flavonoids,8480,B-CHEMICAL
.,8480,O
Furthermore,8481,O
",",8481,O
these,8481,O
phosphorylated,8481,B-CHEMICAL
flavonoids,8481,I-CHEMICAL
demonstrated,8481,O
good,8481,O
to,8481,O
high,8481,O
selectivity,8481,O
for,8481,O
CEase,8481,B-GENE-Y
over,8481,O
AChE,8481,B-GENE-Y
",",8481,O
which,8481,O
only,8481,O
showed,8481,O
micromolar,8481,O
potency,8481,O
inhibition,8481,O
of,8481,O
AChE,8481,B-GENE-Y
.,8481,O
The,8482,O
most,8482,O
selective,8482,O
and,8482,O
potent,8482,O
inhibitor,8482,O
of,8482,O
CEase,8482,B-GENE-Y
(,8482,O
3e,8482,O
),8482,O
had,8482,O
IC50,8482,O
value,8482,O
of,8482,O
0.72,8482,O
nM,8482,O
and,8482,O
11800-fold,8482,O
selectivity,8482,O
for,8482,O
CEase,8482,B-GENE-Y
over,8482,O
AChE,8482,B-GENE-Y
.,8482,O
The,8483,O
structure-activity,8483,O
relationships,8483,O
revealed,8483,O
that,8483,O
the,8483,O
free,8483,O
hydroxyl,8483,B-CHEMICAL
group,8483,O
at,8483,O
position,8483,O
5,8483,O
and,8483,O
phosphate,8483,B-CHEMICAL
group,8483,O
at,8483,O
position,8483,O
7,8483,O
of,8483,O
the,8483,O
phosphorylated,8483,B-CHEMICAL
flavonoids,8483,I-CHEMICAL
are,8483,O
favorable,8483,O
to,8483,O
the,8483,O
inhibition,8483,O
of,8483,O
CEase,8483,B-GENE-Y
.,8483,O
The,8484,O
inhibition,8484,O
mechanism,8484,O
and,8484,O
kinetic,8484,O
characterization,8484,O
studies,8484,O
indicated,8484,O
that,8484,O
they,8484,O
are,8484,O
irreversible,8484,O
competitive,8484,O
inhibitors,8484,O
of,8484,O
CEase,8484,B-GENE-Y
.,8484,O
5-Amino-2-hydroxybenzoic,8485,B-CHEMICAL
acid,8485,I-CHEMICAL
4-,8485,B-CHEMICAL
(,8485,I-CHEMICAL
5-thioxo-5H-,8485,I-CHEMICAL
[,8485,I-CHEMICAL
"1,2",8485,I-CHEMICAL
],8485,I-CHEMICAL
dithiol-3yl,8485,I-CHEMICAL
),8485,I-CHEMICAL
-phenyl,8485,I-CHEMICAL
ester,8485,I-CHEMICAL
(,8485,O
ATB-429,8485,B-CHEMICAL
),8485,O
",",8485,O
a,8485,O
hydrogen,8485,B-CHEMICAL
sulfide-releasing,8485,O
derivative,8485,O
of,8485,O
mesalamine,8485,B-CHEMICAL
",",8485,O
exerts,8485,O
antinociceptive,8485,O
effects,8485,O
in,8485,O
a,8485,O
model,8485,O
of,8485,O
postinflammatory,8485,O
hypersensitivity,8485,O
.,8485,O
H,8486,B-CHEMICAL
(,8486,I-CHEMICAL
2,8486,I-CHEMICAL
),8486,I-CHEMICAL
S,8486,I-CHEMICAL
functions,8486,O
as,8486,O
a,8486,O
neuromodulator,8486,O
and,8486,O
exerts,8486,O
anti-inflammatory,8486,O
activities,8486,O
.,8486,O
Recent,8487,O
data,8487,O
indicate,8487,O
that,8487,O
irritable,8487,O
bowel,8487,O
syndrome,8487,O
(,8487,O
IBS,8487,O
),8487,O
is,8487,O
linked,8487,O
to,8487,O
inflammation,8487,O
of,8487,O
the,8487,O
gastrointestinal,8487,O
tract,8487,O
.,8487,O
In,8488,O
this,8488,O
study,8488,O
",",8488,O
we,8488,O
have,8488,O
investigated,8488,O
the,8488,O
role,8488,O
of,8488,O
a,8488,O
novel,8488,O
H,8488,B-CHEMICAL
(,8488,I-CHEMICAL
2,8488,I-CHEMICAL
),8488,I-CHEMICAL
S-releasing,8488,O
derivative,8488,O
of,8488,O
mesalamine,8488,B-CHEMICAL
(,8488,O
5-amino-2-hydroxybenzoic,8488,B-CHEMICAL
acid,8488,I-CHEMICAL
4-,8488,I-CHEMICAL
(,8488,I-CHEMICAL
5-thioxo-5H-,8488,I-CHEMICAL
[,8488,I-CHEMICAL
"1,2",8488,I-CHEMICAL
],8488,I-CHEMICAL
dithiol-3yl,8488,I-CHEMICAL
),8488,I-CHEMICAL
-phenyl,8488,I-CHEMICAL
ester,8488,I-CHEMICAL
",",8488,O
ATB-429,8488,B-CHEMICAL
),8488,O
in,8488,O
modulating,8488,O
nociception,8488,O
to,8488,O
colorectal,8488,O
distension,8488,O
(,8488,O
CRD,8488,O
),8488,O
",",8488,O
a,8488,O
model,8488,O
that,8488,O
mimics,8488,O
some,8488,O
features,8488,O
of,8488,O
IBS,8488,O
",",8488,O
in,8488,O
healthy,8488,O
and,8488,O
postcolitic,8488,O
rats,8488,O
.,8488,O
Four,8489,O
graded,8489,O
(,8489,O
0.4-1.6,8489,O
ml,8489,O
of,8489,O
water,8489,O
),8489,O
CRDs,8489,O
were,8489,O
produced,8489,O
in,8489,O
conscious,8489,O
rats,8489,O
",",8489,O
and,8489,O
colorectal,8489,O
sensitivity,8489,O
and,8489,O
pain,8489,O
were,8489,O
assessed,8489,O
by,8489,O
measuring,8489,O
the,8489,O
abdominal,8489,O
withdrawal,8489,O
response,8489,O
and,8489,O
spinal,8489,O
c-Fos,8489,B-GENE-Y
expression,8489,O
.,8489,O
In,8490,O
healthy,8490,O
rats,8490,O
",",8490,O
ATB-429,8490,B-CHEMICAL
dose,8490,O
dependently,8490,O
(,8490,O
25,8490,O
",",8490,O
50,8490,O
",",8490,O
or,8490,O
100,8490,O
mg/kg,8490,O
),8490,O
attenuated,8490,O
CRD-induced,8490,O
hypersensitivity,8490,O
and,8490,O
significantly,8490,O
inhibited,8490,O
CRD-induced,8490,O
overexpression,8490,O
of,8490,O
spinal,8490,O
c-FOS,8490,B-GENE-Y
mRNA,8490,O
",",8490,O
whereas,8490,O
mesalamine,8490,B-CHEMICAL
had,8490,O
no,8490,O
effect,8490,O
.,8490,O
ATB-429-induced,8491,B-CHEMICAL
antinociception,8491,O
was,8491,O
reversed,8491,O
by,8491,O
glibenclamide,8491,B-CHEMICAL
",",8491,O
a,8491,O
ATP-sensitive,8491,B-GENE-N
K,8491,I-GENE-N
(,8491,I-GENE-N
+,8491,I-GENE-N
),8491,I-GENE-N
(,8491,I-GENE-N
K,8491,I-GENE-N
(,8491,I-GENE-N
ATP,8491,I-GENE-N
),8491,I-GENE-N
),8491,I-GENE-N
channel,8491,I-GENE-N
inhibitor,8491,O
.,8491,O
The,8492,O
antinociceptive,8492,O
effect,8492,O
of,8492,O
ATB-429,8492,B-CHEMICAL
was,8492,O
maintained,8492,O
in,8492,O
a,8492,O
rodent,8492,O
model,8492,O
of,8492,O
postinflammatory,8492,O
hypersensitivity,8492,O
(,8492,O
4,8492,O
weeks,8492,O
after,8492,O
colitis,8492,O
induction,8492,O
),8492,O
.,8492,O
At,8493,O
a,8493,O
dose,8493,O
of,8493,O
100,8493,O
mg/kg,8493,O
",",8493,O
ATB-429,8493,B-CHEMICAL
reversed,8493,O
the,8493,O
allodynic,8493,O
response,8493,O
caused,8493,O
by,8493,O
CRD,8493,O
in,8493,O
postcolitic,8493,O
rats,8493,O
.,8493,O
Colonic,8494,O
cyclooxygenase-2,8494,B-GENE-Y
and,8494,O
interkeukin-1beta,8494,B-GENE-Y
mRNA,8494,O
and,8494,O
spinal,8494,O
c-FOS,8494,B-GENE-Y
mRNA,8494,O
expression,8494,O
were,8494,O
significantly,8494,O
down-regulated,8494,O
by,8494,O
ATB-429,8494,B-CHEMICAL
",",8494,O
but,8494,O
not,8494,O
by,8494,O
mesalamine,8494,B-CHEMICAL
.,8494,O
ATB-429,8495,B-CHEMICAL
",",8495,O
but,8495,O
not,8495,O
mesalamine,8495,B-CHEMICAL
",",8495,O
increased,8495,O
blood,8495,O
concentrations,8495,O
of,8495,O
H,8495,B-CHEMICAL
(,8495,I-CHEMICAL
2,8495,I-CHEMICAL
),8495,I-CHEMICAL
S,8495,I-CHEMICAL
in,8495,O
both,8495,O
healthy,8495,O
and,8495,O
postcolitic,8495,O
rats,8495,O
.,8495,O
Taken,8496,O
together,8496,O
",",8496,O
these,8496,O
data,8496,O
suggest,8496,O
that,8496,O
ATB-429,8496,B-CHEMICAL
inhibits,8496,O
hypersensitivity,8496,O
induced,8496,O
by,8496,O
CRD,8496,O
in,8496,O
both,8496,O
healthy,8496,O
and,8496,O
postcolitic,8496,O
",",8496,O
allodynic,8496,O
rats,8496,O
by,8496,O
a,8496,O
K,8496,B-GENE-N
(,8496,I-GENE-N
ATP,8496,I-GENE-N
),8496,I-GENE-N
channel-mediated,8496,O
mechanism,8496,O
.,8496,O
This,8497,O
study,8497,O
provides,8497,O
evidence,8497,O
that,8497,O
H,8497,B-CHEMICAL
(,8497,I-CHEMICAL
2,8497,I-CHEMICAL
),8497,I-CHEMICAL
S-releasing,8497,O
drugs,8497,O
might,8497,O
have,8497,O
beneficial,8497,O
effects,8497,O
in,8497,O
the,8497,O
treatment,8497,O
of,8497,O
painful,8497,O
intestinal,8497,O
disorders,8497,O
.,8497,O
Block,8498,O
of,8498,O
human,8498,B-GENE-Y
NaV1.5,8498,I-GENE-Y
sodium,8498,B-GENE-N
channels,8498,I-GENE-N
by,8498,O
novel,8498,O
alpha-hydroxyphenylamide,8498,B-CHEMICAL
analogues,8498,O
of,8498,O
phenytoin,8498,B-CHEMICAL
.,8498,O
Voltage-gated,8499,B-GENE-N
sodium,8499,I-GENE-N
(,8499,I-GENE-N
Na,8499,I-GENE-N
),8499,I-GENE-N
channels,8499,I-GENE-N
are,8499,O
a,8499,O
critical,8499,O
component,8499,O
of,8499,O
electrically,8499,O
excitable,8499,O
cells,8499,O
.,8499,O
Phenytoin,8500,B-CHEMICAL
(,8500,O
diphenylhydantoin,8500,B-CHEMICAL
",",8500,O
DPH,8500,B-CHEMICAL
),8500,O
is,8500,O
an,8500,O
established,8500,O
sodium,8500,B-GENE-N
channel,8500,I-GENE-N
blocker,8500,O
and,8500,O
is,8500,O
a,8500,O
useful,8500,O
anticonvulsant,8500,O
and,8500,O
class,8500,O
1b,8500,O
antiarrhythmic,8500,O
",",8500,O
and,8500,O
has,8500,O
been,8500,O
effectively,8500,O
used,8500,O
in,8500,O
the,8500,O
treatment,8500,O
of,8500,O
neuropathic,8500,O
pain,8500,O
.,8500,O
In,8501,O
this,8501,O
study,8501,O
",",8501,O
we,8501,O
have,8501,O
synthesized,8501,O
novel,8501,O
alpha-hydroxyphenylamide,8501,B-CHEMICAL
analogues,8501,O
of,8501,O
diphenylhydantoin,8501,B-CHEMICAL
and,8501,O
examined,8501,O
their,8501,O
ability,8501,O
to,8501,O
inhibit,8501,O
human,8501,B-GENE-Y
Na,8501,I-GENE-Y
(,8501,I-GENE-Y
V,8501,I-GENE-Y
),8501,I-GENE-Y
1.5,8501,I-GENE-Y
sodium,8501,B-GENE-N
channels,8501,I-GENE-N
expressed,8501,O
in,8501,O
Chinese,8501,O
Hamster,8501,O
Ovary,8501,O
(,8501,O
CHO-K1,8501,O
),8501,O
cells,8501,O
.,8501,O
Phenyl,8502,B-CHEMICAL
ring,8502,O
substitutions,8502,O
were,8502,O
examined,8502,O
including,8502,O
para-methyl,8502,B-CHEMICAL
",",8502,O
para-fluoro,8502,B-CHEMICAL
",",8502,O
para-chloro,8502,B-CHEMICAL
",",8502,O
ortho-chloro,8502,B-CHEMICAL
and,8502,O
meta-chloro,8502,B-CHEMICAL
.,8502,O
We,8503,O
have,8503,O
found,8503,O
that,8503,O
phenyl,8503,B-CHEMICAL
ring,8503,O
substitutions,8503,O
with,8503,O
electron,8503,O
withdrawing,8503,O
properties,8503,O
resulted,8503,O
in,8503,O
compounds,8503,O
with,8503,O
greater,8503,O
activity,8503,O
.,8503,O
In,8504,O
comparison,8504,O
to,8504,O
diphenylhydantoin,8504,B-CHEMICAL
",",8504,O
the,8504,O
novel,8504,O
chloro-substituted,8504,B-CHEMICAL
alpha-hydroxyphenylamide,8504,B-CHEMICAL
compounds,8504,O
produced,8504,O
as,8504,O
much,8504,O
as,8504,O
a,8504,O
20-fold,8504,O
greater,8504,O
tonic,8504,O
and,8504,O
frequency-dependent,8504,O
blockade,8504,O
of,8504,O
Na,8504,B-GENE-Y
(,8504,I-GENE-Y
V,8504,I-GENE-Y
),8504,I-GENE-Y
1.5,8504,I-GENE-Y
channels,8504,O
with,8504,O
an,8504,O
IC,8504,O
(,8504,O
50,8504,O
),8504,O
value,8504,O
of,8504,O
14.5,8504,O
microM,8504,O
.,8504,O
In,8505,O
addition,8505,O
",",8505,O
the,8505,O
chloro-substitutions,8505,B-CHEMICAL
have,8505,O
position,8505,O
specific,8505,O
state,8505,O
dependent,8505,O
blocking,8505,O
properties,8505,O
.,8505,O
The,8506,O
ortho-,8506,B-CHEMICAL
",",8506,I-CHEMICAL
meta-,8506,I-CHEMICAL
and,8506,I-CHEMICAL
para-chloro,8506,I-CHEMICAL
substitutions,8506,O
have,8506,O
an,8506,O
8-,8506,O
",",8506,O
13-,8506,O
and,8506,O
3-fold,8506,O
increased,8506,O
affinity,8506,O
for,8506,O
the,8506,O
inactivated,8506,O
state,8506,O
",",8506,O
respectively,8506,O
.,8506,O
Molecular,8507,O
modeling,8507,O
suggests,8507,O
that,8507,O
these,8507,O
differences,8507,O
in,8507,O
affinity,8507,O
are,8507,O
due,8507,O
to,8507,O
a,8507,O
direct,8507,O
interaction,8507,O
with,8507,O
the,8507,O
receptor,8507,O
.,8507,O
Comparing,8508,O
models,8508,O
of,8508,O
diphenylhydantoin,8508,B-CHEMICAL
to,8508,O
the,8508,O
novel,8508,O
alpha-hydroxyphenlyamide,8508,B-CHEMICAL
compound,8508,O
suggests,8508,O
that,8508,O
the,8508,O
increased,8508,O
activity,8508,O
may,8508,O
be,8508,O
due,8508,O
to,8508,O
an,8508,O
optimized,8508,O
phenyl,8508,B-CHEMICAL
ring,8508,O
position,8508,O
and,8508,O
increased,8508,O
molecular,8508,O
volume,8508,O
.,8508,O
This,8509,O
information,8509,O
may,8509,O
be,8509,O
useful,8509,O
in,8509,O
the,8509,O
development,8509,O
of,8509,O
more,8509,O
potent,8509,O
sodium,8509,B-GENE-N
channel,8509,I-GENE-N
blockers,8509,O
.,8509,O
Effects,8510,O
of,8510,O
a,8510,O
serotonin,8510,B-GENE-Y
5-HT,8510,I-GENE-Y
(,8510,I-GENE-Y
4,8510,I-GENE-Y
),8510,I-GENE-Y
receptor,8510,I-GENE-Y
antagonist,8510,O
SB-207266,8510,B-CHEMICAL
on,8510,O
gastrointestinal,8510,O
motor,8510,O
and,8510,O
sensory,8510,O
function,8510,O
in,8510,O
humans,8510,O
.,8510,O
BACKGROUND,8511,O
:,8511,O
Serotonin,8511,B-GENE-Y
5-HT,8511,I-GENE-Y
(,8511,I-GENE-Y
4,8511,I-GENE-Y
),8511,I-GENE-Y
receptors,8511,I-GENE-Y
are,8511,O
located,8511,O
on,8511,O
enteric,8511,O
cholinergic,8511,O
neurones,8511,O
and,8511,O
may,8511,O
regulate,8511,O
peristalsis,8511,O
.,8511,O
5-HT,8512,B-GENE-Y
(,8512,I-GENE-Y
4,8512,I-GENE-Y
),8512,I-GENE-Y
receptors,8512,O
on,8512,O
primary,8512,O
afferent,8512,O
neurones,8512,O
have,8512,O
been,8512,O
postulated,8512,O
to,8512,O
modulate,8512,O
visceral,8512,O
sensation,8512,O
.,8512,O
While,8513,O
5-HT,8513,B-GENE-Y
(,8513,I-GENE-Y
4,8513,I-GENE-Y
),8513,I-GENE-Y
agonists,8513,O
are,8513,O
used,8513,O
as,8513,O
prokinetic,8513,O
agents,8513,O
",",8513,O
the,8513,O
physiological,8513,O
role,8513,O
of,8513,O
5-HT,8513,B-GENE-Y
(,8513,I-GENE-Y
4,8513,I-GENE-Y
),8513,I-GENE-Y
receptors,8513,O
in,8513,O
the,8513,O
human,8513,O
gut,8513,O
is,8513,O
unknown,8513,O
.,8513,O
AIMS,8514,O
:,8514,O
Our,8514,O
aim,8514,O
was,8514,O
to,8514,O
characterise,8514,O
the,8514,O
role,8514,O
of,8514,O
5-HT,8514,B-GENE-Y
(,8514,I-GENE-Y
4,8514,I-GENE-Y
),8514,I-GENE-Y
receptors,8514,O
in,8514,O
regulating,8514,O
gastrointestinal,8514,O
motor,8514,O
and,8514,O
sensory,8514,O
function,8514,O
in,8514,O
healthy,8514,O
subjects,8514,O
under,8514,O
baseline,8514,O
and,8514,O
stimulated,8514,O
conditions,8514,O
with,8514,O
a,8514,O
5-HT,8514,B-GENE-Y
(,8514,I-GENE-Y
4,8514,I-GENE-Y
),8514,I-GENE-Y
receptor,8514,O
antagonist,8514,O
.,8514,O
METHODS,8515,O
:,8515,O
Part,8515,O
A,8515,O
compared,8515,O
the,8515,O
effects,8515,O
of,8515,O
placebo,8515,O
to,8515,O
four,8515,O
doses,8515,O
of,8515,O
a,8515,O
5-HT,8515,B-GENE-Y
(,8515,I-GENE-Y
4,8515,I-GENE-Y
),8515,I-GENE-Y
receptor,8515,O
antagonist,8515,O
(,8515,O
SB-207266,8515,B-CHEMICAL
),8515,O
on,8515,O
the,8515,O
cisapride,8515,B-CHEMICAL
mediated,8515,O
increase,8515,O
in,8515,O
plasma,8515,O
aldosterone,8515,B-CHEMICAL
(,8515,O
a,8515,O
5-HT,8515,B-GENE-Y
(,8515,I-GENE-Y
4,8515,I-GENE-Y
),8515,I-GENE-Y
mediated,8515,O
response,8515,O
),8515,O
and,8515,O
orocaecal,8515,O
transit,8515,O
in,8515,O
18,8515,O
subjects,8515,O
.,8515,O
In,8516,O
part,8516,O
B,8516,O
",",8516,O
52,8516,O
healthy,8516,O
subjects,8516,O
received,8516,O
placebo,8516,O
",",8516,O
or,8516,O
0.05,8516,O
",",8516,O
0.5,8516,O
",",8516,O
or,8516,O
5,8516,O
mg,8516,O
of,8516,O
SB-207266,8516,B-CHEMICAL
for,8516,O
10-12,8516,O
days,8516,O
;,8516,O
gastric,8516,O
",",8516,O
small,8516,O
bowel,8516,O
",",8516,O
and,8516,O
colonic,8516,O
transit,8516,O
were,8516,O
measured,8516,O
by,8516,O
scintigraphy,8516,O
on,8516,O
days,8516,O
7-9,8516,O
",",8516,O
and,8516,O
fasting,8516,O
and,8516,O
postprandial,8516,O
colonic,8516,O
motor,8516,O
function,8516,O
",",8516,O
compliance,8516,O
",",8516,O
and,8516,O
sensation,8516,O
during,8516,O
distensions,8516,O
were,8516,O
assessed,8516,O
on,8516,O
day,8516,O
12,8516,O
.,8516,O
RESULTS,8517,O
:,8517,O
Part,8517,O
A,8517,O
:,8517,O
0.5,8517,O
",",8517,O
5,8517,O
",",8517,O
and,8517,O
20,8517,O
mg,8517,O
doses,8517,O
of,8517,O
SB-207266,8517,B-CHEMICAL
had,8517,O
significant,8517,O
and,8517,O
quantitatively,8517,O
similar,8517,O
effects,8517,O
",",8517,O
antagonising,8517,O
the,8517,O
cisapride,8517,O
mediated,8517,O
increase,8517,O
in,8517,O
plasma,8517,O
aldosterone,8517,B-CHEMICAL
and,8517,O
acceleration,8517,O
of,8517,O
orocaecal,8517,O
transit,8517,O
.,8517,O
Part,8518,O
B,8518,O
:,8518,O
SB-207266,8518,B-CHEMICAL
tended,8518,O
to,8518,O
delay,8518,O
colonic,8518,O
transit,8518,O
(,8518,O
geometric,8518,O
centre,8518,O
of,8518,O
isotope,8518,O
at,8518,O
24,8518,O
(,8518,O
p=0.06,8518,O
),8518,O
and,8518,O
48,8518,O
hours,8518,O
(,8518,O
p=0.08,8518,O
),8518,O
),8518,O
",",8518,O
but,8518,O
did,8518,O
not,8518,O
have,8518,O
dose,8518,O
related,8518,O
effects,8518,O
on,8518,O
transit,8518,O
",",8518,O
fasting,8518,O
or,8518,O
postprandial,8518,O
colonic,8518,O
motor,8518,O
activity,8518,O
",",8518,O
compliance,8518,O
",",8518,O
or,8518,O
sensation,8518,O
.,8518,O
CONCLUSION,8519,O
:,8519,O
5-HT,8519,B-GENE-Y
(,8519,I-GENE-Y
4,8519,I-GENE-Y
),8519,I-GENE-Y
receptors,8519,O
are,8519,O
involved,8519,O
in,8519,O
the,8519,O
regulation,8519,O
of,8519,O
cisapride,8519,B-CHEMICAL
stimulated,8519,O
orocaecal,8519,O
transit,8519,O
;,8519,O
SB,8519,B-CHEMICAL
207266,8519,I-CHEMICAL
tends,8519,O
to,8519,O
modulate,8519,O
colonic,8519,O
transit,8519,O
but,8519,O
not,8519,O
sensory,8519,O
functions,8519,O
or,8519,O
compliance,8519,O
in,8519,O
healthy,8519,O
human,8519,O
subjects,8519,O
.,8519,O
Structures,8520,O
of,8520,O
wild-type,8520,O
and,8520,O
mutant,8520,O
human,8520,B-GENE-Y
spermidine/spermine,8520,I-GENE-Y
N1-acetyltransferase,8520,I-GENE-Y
",",8520,O
a,8520,O
potential,8520,O
therapeutic,8520,O
drug,8520,O
target,8520,O
.,8520,O
Spermidine/spermine,8521,B-GENE-Y
N1-acetyltransferase,8521,I-GENE-Y
(,8521,O
SSAT,8521,B-GENE-Y
),8521,O
is,8521,O
a,8521,O
key,8521,O
enzyme,8521,O
in,8521,O
the,8521,O
control,8521,O
of,8521,O
polyamine,8521,B-CHEMICAL
levels,8521,O
in,8521,O
human,8521,O
cells,8521,O
",",8521,O
as,8521,O
acetylation,8521,O
of,8521,O
spermidine,8521,B-CHEMICAL
and,8521,O
spermine,8521,B-CHEMICAL
triggers,8521,O
export,8521,O
or,8521,O
degradation,8521,O
.,8521,O
Increased,8522,O
intracellular,8522,O
polyamine,8522,B-CHEMICAL
levels,8522,O
accompany,8522,O
several,8522,O
types,8522,O
of,8522,O
cancers,8522,O
as,8522,O
well,8522,O
as,8522,O
other,8522,O
human,8522,O
diseases,8522,O
",",8522,O
and,8522,O
compounds,8522,O
that,8522,O
affect,8522,O
the,8522,O
expression,8522,O
",",8522,O
activity,8522,O
",",8522,O
or,8522,O
stability,8522,O
of,8522,O
SSAT,8522,B-GENE-Y
are,8522,O
being,8522,O
explored,8522,O
as,8522,O
potential,8522,O
therapeutic,8522,O
drugs,8522,O
.,8522,O
We,8523,O
have,8523,O
expressed,8523,O
human,8523,B-GENE-Y
SSAT,8523,I-GENE-Y
from,8523,O
the,8523,O
cloned,8523,O
cDNA,8523,O
in,8523,O
Escherichia,8523,O
coli,8523,O
and,8523,O
have,8523,O
determined,8523,O
high-resolution,8523,O
structures,8523,O
of,8523,O
wild-type,8523,O
and,8523,O
mutant,8523,O
SSAT,8523,B-GENE-Y
",",8523,O
as,8523,O
the,8523,O
free,8523,O
dimer,8523,O
and,8523,O
in,8523,O
binary,8523,O
and,8523,O
ternary,8523,O
complexes,8523,O
with,8523,O
CoA,8523,B-CHEMICAL
",",8523,O
acetyl-CoA,8523,B-CHEMICAL
(,8523,O
AcCoA,8523,B-CHEMICAL
),8523,O
",",8523,O
spermine,8523,B-CHEMICAL
",",8523,O
and,8523,O
the,8523,O
inhibitor,8523,O
N1,8523,B-CHEMICAL
",",8523,I-CHEMICAL
N11bis-,8523,I-CHEMICAL
(,8523,I-CHEMICAL
ethyl,8523,I-CHEMICAL
),8523,I-CHEMICAL
-norspermine,8523,I-CHEMICAL
(,8523,O
BE-3-3-3,8523,O
),8523,O
.,8523,O
These,8524,O
structures,8524,O
show,8524,O
details,8524,O
of,8524,O
binding,8524,O
sites,8524,O
for,8524,O
cofactor,8524,O
",",8524,O
substrates,8524,O
",",8524,O
and,8524,O
inhibitor,8524,O
and,8524,O
provide,8524,O
a,8524,O
framework,8524,O
to,8524,O
understand,8524,O
enzymatic,8524,O
activity,8524,O
",",8524,O
mutations,8524,O
",",8524,O
and,8524,O
the,8524,O
action,8524,O
of,8524,O
potential,8524,O
drugs,8524,O
.,8524,O
Two,8525,O
dimer,8525,O
conformations,8525,O
were,8525,O
observed,8525,O
:,8525,O
a,8525,O
symmetric,8525,O
form,8525,O
with,8525,O
two,8525,O
open,8525,O
surface,8525,O
channels,8525,O
capable,8525,O
of,8525,O
binding,8525,O
substrate,8525,O
or,8525,O
cofactor,8525,O
",",8525,O
and,8525,O
an,8525,O
asymmetric,8525,O
form,8525,O
in,8525,O
which,8525,O
only,8525,O
one,8525,O
of,8525,O
the,8525,O
surface,8525,O
channels,8525,O
appears,8525,O
capable,8525,O
of,8525,O
binding,8525,O
and,8525,O
acetylating,8525,O
polyamines,8525,B-CHEMICAL
.,8525,O
SSAT,8526,B-GENE-Y
was,8526,O
found,8526,O
to,8526,O
self-acetylate,8526,O
lysine-26,8526,B-CHEMICAL
in,8526,O
the,8526,O
presence,8526,O
of,8526,O
AcCoA,8526,B-CHEMICAL
and,8526,O
absence,8526,O
of,8526,O
substrate,8526,O
",",8526,O
a,8526,O
reaction,8526,O
apparently,8526,O
catalzyed,8526,O
by,8526,O
AcCoA,8526,B-CHEMICAL
bound,8526,O
in,8526,O
the,8526,O
second,8526,O
channel,8526,O
of,8526,O
the,8526,O
asymmetric,8526,O
dimer,8526,O
.,8526,O
These,8527,O
unexpected,8527,O
and,8527,O
intriguing,8527,O
complexities,8527,O
seem,8527,O
likely,8527,O
to,8527,O
have,8527,O
some,8527,O
as,8527,O
yet,8527,O
undefined,8527,O
role,8527,O
in,8527,O
regulating,8527,O
SSAT,8527,B-GENE-Y
activity,8527,O
or,8527,O
stability,8527,O
as,8527,O
a,8527,O
part,8527,O
of,8527,O
polyamine,8527,B-CHEMICAL
homeostasis,8527,O
.,8527,O
Sequence,8528,O
signatures,8528,O
group,8528,O
SSAT,8528,B-GENE-Y
with,8528,O
proteins,8528,O
that,8528,O
appear,8528,O
to,8528,O
have,8528,O
thialysine,8528,B-GENE-Y
Nepsilon-acetyltransferase,8528,I-GENE-Y
activity,8528,O
.,8528,O
Suppression,8529,O
of,8529,O
nuclear,8529,B-GENE-Y
factor,8529,I-GENE-Y
erythroid,8529,I-GENE-Y
2-related,8529,I-GENE-Y
factor,8529,I-GENE-Y
2,8529,I-GENE-Y
via,8529,O
extracellular,8529,B-GENE-N
signal-regulated,8529,I-GENE-N
kinase,8529,I-GENE-N
contributes,8529,O
to,8529,O
bleomycin-induced,8529,B-CHEMICAL
oxidative,8529,O
stress,8529,O
and,8529,O
fibrogenesis,8529,O
.,8529,O
Pulmonary,8530,O
fibrosis,8530,O
is,8530,O
a,8530,O
serious,8530,O
and,8530,O
irreversible,8530,O
lung,8530,O
injury,8530,O
with,8530,O
obscure,8530,O
etiologic,8530,O
mechanisms,8530,O
and,8530,O
no,8530,O
effective,8530,O
treatment,8530,O
to,8530,O
date,8530,O
.,8530,O
This,8531,O
study,8531,O
explored,8531,O
a,8531,O
crucial,8531,O
link,8531,O
between,8531,O
oxidative,8531,O
stress,8531,O
and,8531,O
pulmonary,8531,O
fibrogenesis,8531,O
",",8531,O
focusing,8531,O
on,8531,O
nuclear,8531,B-GENE-Y
factor,8531,I-GENE-Y
erythroid,8531,I-GENE-Y
2-related,8531,I-GENE-Y
factor,8531,I-GENE-Y
2,8531,I-GENE-Y
(,8531,O
Nrf2,8531,B-GENE-Y
),8531,O
",",8531,O
a,8531,O
core,8531,O
transcription,8531,O
factor,8531,O
in,8531,O
antioxidative,8531,O
regulation,8531,O
systems,8531,O
.,8531,O
Treatment,8532,O
of,8532,O
C57,8532,O
BL/6,8532,O
mice,8532,O
with,8532,O
bleomycin,8532,B-CHEMICAL
increased,8532,O
fibroblast,8532,O
viability,8532,O
and,8532,O
collagen,8532,B-GENE-N
production,8532,O
and,8532,O
significantly,8532,O
downregulated,8532,O
Nrf2,8532,B-GENE-N
.,8532,O
In,8533,O
addition,8533,O
",",8533,O
prominent,8533,O
oxidative,8533,O
stress,8533,O
was,8533,O
indicated,8533,O
by,8533,O
changes,8533,O
in,8533,O
superoxide,8533,B-GENE-N
dismutase,8533,I-GENE-N
",",8533,O
catalase,8533,B-GENE-N
activity,8533,O
",",8533,O
and,8533,O
glutathione,8533,B-CHEMICAL
and,8533,O
thiobarbituric,8533,B-CHEMICAL
acid-reactive,8533,O
substance,8533,O
levels,8533,O
.,8533,O
In,8534,O
a,8534,O
cell-based,8534,O
model,8534,O
",",8534,O
bleomycin,8534,B-CHEMICAL
suppressed,8534,O
Nrf2,8534,B-GENE-Y
activation,8534,O
via,8534,O
extracellular,8534,B-GENE-N
signal-related,8534,I-GENE-N
kinase,8534,I-GENE-N
phosphorylation,8534,O
",",8534,O
enhancing,8534,O
intracellular,8534,O
reactive,8534,O
oxygen,8534,B-CHEMICAL
species,8534,O
in,8534,O
lung,8534,O
fibroblasts,8534,O
and,8534,O
stimulating,8534,O
abnormal,8534,O
cell,8534,O
proliferation,8534,O
and,8534,O
collagen,8534,O
secretion,8534,O
.,8534,O
To,8535,O
confirm,8535,O
this,8535,O
novel,8535,O
mechanism,8535,O
of,8535,O
bleomycin-induced,8535,B-CHEMICAL
fibrogenesis,8535,O
",",8535,O
we,8535,O
attempted,8535,O
to,8535,O
upregulate,8535,O
Nrf2,8535,B-GENE-Y
and,8535,O
related,8535,O
antioxidant,8535,O
proteins,8535,O
in,8535,O
bleomycin-treated,8535,O
fibroblasts,8535,O
using,8535,O
a,8535,O
putative,8535,O
Nrf2,8535,B-GENE-Y
activator,8535,O
",",8535,O
caffeic,8535,B-CHEMICAL
acid,8535,I-CHEMICAL
phenethyl,8535,I-CHEMICAL
ester,8535,I-CHEMICAL
",",8535,O
and,8535,O
the,8535,O
results,8535,O
showed,8535,O
that,8535,O
bleomycin-induced,8535,B-CHEMICAL
fibroblast,8535,O
proliferation,8535,O
and,8535,O
collagen,8535,B-GENE-N
content,8535,O
were,8535,O
attenuated,8535,O
through,8535,O
improved,8535,O
redox,8535,O
balance,8535,O
.,8535,O
Collectively,8536,O
",",8536,O
these,8536,O
results,8536,O
disclose,8536,O
a,8536,O
potential,8536,O
regulatory,8536,O
mechanism,8536,O
in,8536,O
pulmonary,8536,O
fibrosis,8536,O
that,8536,O
will,8536,O
aid,8536,O
the,8536,O
development,8536,O
of,8536,O
new,8536,O
therapies,8536,O
.,8536,O
Pharmacokinetic,8537,O
and,8537,O
pharmacodynamic,8537,O
modeling,8537,O
of,8537,O
hedgehog,8537,B-GENE-N
inhibitor,8537,O
TAK-441,8537,B-CHEMICAL
for,8537,O
the,8537,O
inhibition,8537,O
of,8537,O
Gli1,8537,B-GENE-Y
messenger,8537,O
RNA,8537,O
expression,8537,O
and,8537,O
antitumor,8537,O
efficacy,8537,O
in,8537,O
xenografted,8537,O
tumor,8537,O
model,8537,O
mice,8537,O
.,8537,O
6-Ethyl-N-,8538,B-CHEMICAL
[,8538,I-CHEMICAL
1-,8538,I-CHEMICAL
(,8538,I-CHEMICAL
hydroxyacetyl,8538,I-CHEMICAL
),8538,I-CHEMICAL
piperidin-4-yl,8538,I-CHEMICAL
],8538,I-CHEMICAL
-1-methyl-4-oxo-5-,8538,I-CHEMICAL
(,8538,I-CHEMICAL
2-oxo-2-phenylethyl,8538,I-CHEMICAL
),8538,I-CHEMICAL
-3-,8538,I-CHEMICAL
(,8538,I-CHEMICAL
"2,2,2-trifluoroethoxy",8538,I-CHEMICAL
),8538,I-CHEMICAL
"-4,5-dihydro-1H-pyrrolo",8538,I-CHEMICAL
[,8538,I-CHEMICAL
"3,2-c",8538,I-CHEMICAL
],8538,I-CHEMICAL
pyridine-2-carboxamide,8538,I-CHEMICAL
(,8538,O
TAK-441,8538,B-CHEMICAL
),8538,O
is,8538,O
a,8538,O
potent,8538,O
",",8538,O
selective,8538,O
hedgehog,8538,B-GENE-N
signaling,8538,O
pathway,8538,O
inhibitor,8538,O
that,8538,O
binds,8538,O
to,8538,O
Smo,8538,B-GENE-Y
and,8538,O
is,8538,O
being,8538,O
developed,8538,O
for,8538,O
the,8538,O
treatment,8538,O
of,8538,O
cancer,8538,O
.,8538,O
The,8539,O
objectives,8539,O
of,8539,O
these,8539,O
studies,8539,O
were,8539,O
to,8539,O
explore,8539,O
the,8539,O
possibility,8539,O
of,8539,O
establishing,8539,O
of,8539,O
a,8539,O
link,8539,O
between,8539,O
the,8539,O
pharmacokinetics,8539,O
of,8539,O
TAK-441,8539,B-CHEMICAL
and,8539,O
the,8539,O
responses,8539,O
of,8539,O
Gli1,8539,B-GENE-Y
mRNA,8539,O
in,8539,O
tumor-associated,8539,O
stromal,8539,O
or,8539,O
skin,8539,O
cells,8539,O
and,8539,O
the,8539,O
antitumor,8539,O
effect,8539,O
of,8539,O
hedgehog,8539,B-GENE-N
inhibition,8539,O
.,8539,O
To,8540,O
this,8540,O
end,8540,O
",",8540,O
we,8540,O
built,8540,O
pharmacokinetic,8540,O
and,8540,O
pharmacodynamic,8540,O
models,8540,O
that,8540,O
describe,8540,O
the,8540,O
relationship,8540,O
of,8540,O
the,8540,O
concentrations,8540,O
of,8540,O
TAK-441,8540,B-CHEMICAL
plasma,8540,O
to,8540,O
the,8540,O
responses,8540,O
of,8540,O
Gli1,8540,B-GENE-Y
mRNA,8540,O
in,8540,O
the,8540,O
tumor,8540,O
(,8540,O
target,8540,O
),8540,O
and,8540,O
skin,8540,O
(,8540,O
surrogate,8540,O
),8540,O
and,8540,O
to,8540,O
tumor,8540,O
growth,8540,O
inhibition,8540,O
in,8540,O
mice,8540,O
bearing,8540,O
xenografts,8540,O
of,8540,O
human,8540,O
pancreatic,8540,O
tumors,8540,O
(,8540,O
PAN-04,8540,O
),8540,O
.,8540,O
The,8541,O
responses,8541,O
of,8541,O
Gli1,8541,B-GENE-Y
mRNA,8541,O
and,8541,O
tumor,8541,O
growth,8541,O
were,8541,O
described,8541,O
by,8541,O
an,8541,O
indirect,8541,O
response,8541,O
model,8541,O
and,8541,O
an,8541,O
exponential,8541,O
tumor,8541,O
growth,8541,O
model,8541,O
",",8541,O
respectively,8541,O
.,8541,O
The,8542,O
IC50,8542,O
values,8542,O
for,8542,O
Gli1,8542,B-GENE-Y
mRNA,8542,O
inhibition,8542,O
in,8542,O
the,8542,O
tumor,8542,O
and,8542,O
skin,8542,O
by,8542,O
TAK-441,8542,B-CHEMICAL
were,8542,O
estimated,8542,O
to,8542,O
be,8542,O
0.0457,8542,O
and,8542,O
0.113,8542,O
μg/ml,8542,O
",",8542,O
respectively,8542,O
.,8542,O
The,8543,O
IC90,8543,O
value,8543,O
for,8543,O
tumor,8543,O
growth,8543,O
inhibition,8543,O
was,8543,O
estimated,8543,O
to,8543,O
be,8543,O
0.68,8543,O
μg/ml,8543,O
.,8543,O
These,8544,O
results,8544,O
suggest,8544,O
that,8544,O
a,8544,O
>,8544,O
83,8544,O
%,8544,O
inhibition,8544,O
of,8544,O
Gli1,8544,B-GENE-Y
mRNA,8544,O
expression,8544,O
in,8544,O
the,8544,O
skin,8544,O
or,8544,O
a,8544,O
>,8544,O
94,8544,O
%,8544,O
inhibition,8544,O
of,8544,O
Gli1,8544,B-GENE-Y
mRNA,8544,O
expression,8544,O
in,8544,O
the,8544,O
tumor,8544,O
would,8544,O
be,8544,O
required,8544,O
to,8544,O
sufficiently,8544,O
inhibit,8544,O
(,8544,O
>,8544,O
90,8544,O
%,8544,O
),8544,O
hedgehog-related,8544,B-GENE-N
tumor,8544,O
growth,8544,O
in,8544,O
the,8544,O
xenografted,8544,O
model,8544,O
mice,8544,O
.,8544,O
We,8545,O
conclude,8545,O
that,8545,O
Gli1,8545,B-GENE-Y
mRNA,8545,O
expression,8545,O
in,8545,O
the,8545,O
tumor,8545,O
and,8545,O
skin,8545,O
could,8545,O
be,8545,O
a,8545,O
useful,8545,O
biomarker,8545,O
for,8545,O
predicting,8545,O
the,8545,O
antitumor,8545,O
effect,8545,O
of,8545,O
hedgehog,8545,B-GENE-N
inhibitors,8545,O
.,8545,O
Synergistic,8546,O
effects,8546,O
of,8546,O
new,8546,O
chemopreventive,8546,O
agents,8546,O
and,8546,O
conventional,8546,O
cytotoxic,8546,O
agents,8546,O
against,8546,O
human,8546,O
lung,8546,O
cancer,8546,O
cell,8546,O
lines,8546,O
.,8546,O
Non-small,8547,O
cell,8547,O
lung,8547,O
cancer,8547,O
(,8547,O
NSCLC,8547,O
),8547,O
cells,8547,O
have,8547,O
constitutively,8547,O
high,8547,O
expression,8547,O
of,8547,O
cytosolic,8547,B-GENE-Y
phospholipase,8547,I-GENE-Y
A2,8547,I-GENE-Y
(,8547,O
cPLA2,8547,B-GENE-Y
),8547,O
and,8547,O
cyclooxygenase,8547,B-GENE-Y
(,8547,I-GENE-Y
COX,8547,I-GENE-Y
),8547,I-GENE-Y
2,8547,I-GENE-Y
.,8547,O
These,8548,O
NSCLC,8548,O
cells,8548,O
also,8548,O
have,8548,O
increased,8548,O
prostaglandin,8548,B-CHEMICAL
expression,8548,O
(,8548,O
PGE2,8548,B-CHEMICAL
),8548,O
.,8548,O
Many,8549,O
lung,8549,O
cancers,8549,O
also,8549,O
express,8549,O
12-lipoxygenase,8549,B-GENE-Y
RNA,8549,O
and,8549,O
12-lipoxygenase,8549,B-GENE-Y
protein,8549,O
and,8549,O
biosynthesize,8549,O
12,8549,B-CHEMICAL
(,8549,I-CHEMICAL
S,8549,I-CHEMICAL
),8549,I-CHEMICAL
-hydroxyeicosatetraenoic,8549,I-CHEMICAL
acid,8549,I-CHEMICAL
",",8549,O
which,8549,O
correlates,8549,O
with,8549,O
their,8549,O
metastatic,8549,O
potential,8549,O
.,8549,O
Several,8550,O
studies,8550,O
have,8550,O
demonstrated,8550,O
that,8550,O
COX-1,8550,B-GENE-Y
and,8550,O
COX-2,8550,B-GENE-Y
inhibitors,8550,O
could,8550,O
inhibit,8550,O
the,8550,O
in,8550,O
vitro,8550,O
growth,8550,O
of,8550,O
human,8550,O
lung,8550,O
cancer,8550,O
cell,8550,O
lines,8550,O
.,8550,O
In,8551,O
this,8551,O
report,8551,O
",",8551,O
we,8551,O
evaluated,8551,O
the,8551,O
growth-inhibitory,8551,O
effects,8551,O
of,8551,O
sulindac,8551,B-CHEMICAL
sulfide,8551,I-CHEMICAL
",",8551,O
a,8551,O
COX-1,8551,B-GENE-Y
and,8551,O
COX-2,8551,B-GENE-Y
inhibitor,8551,O
;,8551,O
exisulind,8551,B-CHEMICAL
(,8551,O
sulindac,8551,B-CHEMICAL
sulfone,8551,I-CHEMICAL
),8551,O
",",8551,O
a,8551,O
novel,8551,O
proapoptotic,8551,O
agent,8551,O
that,8551,O
does,8551,O
not,8551,O
inhibit,8551,O
COX,8551,B-GENE-N
enzymes,8551,O
;,8551,O
and,8551,O
nordihydroguaiaretic,8551,B-CHEMICAL
acid,8551,I-CHEMICAL
(,8551,O
NDGA,8551,B-CHEMICAL
),8551,O
",",8551,O
a,8551,O
lipoxygenase,8551,B-GENE-N
inhibitor,8551,O
on,8551,O
human,8551,O
lung,8551,O
cancer,8551,O
cell,8551,O
lines,8551,O
.,8551,O
We,8552,O
compared,8552,O
these,8552,O
effects,8552,O
with,8552,O
those,8552,O
of,8552,O
13-cis-retinoic,8552,B-CHEMICAL
acid,8552,I-CHEMICAL
",",8552,O
a,8552,O
chemoprevention,8552,O
agent,8552,O
",",8552,O
and,8552,O
with,8552,O
the,8552,O
cytotoxic,8552,O
chemotherapeutic,8552,O
agents,8552,O
paclitaxel,8552,B-CHEMICAL
and,8552,O
cisplatin,8552,B-CHEMICAL
",",8552,O
alone,8552,O
or,8552,O
in,8552,O
combination,8552,O
.,8552,O
Our,8553,O
goal,8553,O
was,8553,O
to,8553,O
develop,8553,O
new,8553,O
chemoprevention,8553,O
and,8553,O
treatment,8553,O
strategies,8553,O
.,8553,O
Each,8554,O
of,8554,O
the,8554,O
six,8554,O
agents,8554,O
tested,8554,O
inhibited,8554,O
the,8554,O
in,8554,O
vitro,8554,O
growth,8554,O
of,8554,O
three,8554,O
NSCLC,8554,O
and,8554,O
three,8554,O
SCLC,8554,O
cell,8554,O
lines,8554,O
at,8554,O
the,8554,O
highest,8554,O
concentration,8554,O
.,8554,O
Paclitaxel,8555,B-CHEMICAL
was,8555,O
the,8555,O
most,8555,O
potent,8555,O
agent,8555,O
(,8555,O
IC50,8555,O
=,8555,O
0.003-0.150,8555,O
microM,8555,O
),8555,O
;,8555,O
sulindac,8555,B-CHEMICAL
sulfide,8555,I-CHEMICAL
",",8555,O
NDGA,8555,B-CHEMICAL
",",8555,O
and,8555,O
13-cis-retinoic,8555,B-CHEMICAL
acid,8555,I-CHEMICAL
had,8555,O
intermediate,8555,O
potency,8555,O
(,8555,O
IC50,8555,O
=,8555,O
4-80,8555,O
microM,8555,O
),8555,O
",",8555,O
and,8555,O
cisplatin,8555,B-CHEMICAL
and,8555,O
exisulind,8555,B-CHEMICAL
were,8555,O
the,8555,O
least,8555,O
potent,8555,O
(,8555,O
IC50,8555,O
=,8555,O
150-500,8555,O
microM,8555,O
),8555,O
.,8555,O
Combination,8556,O
studies,8556,O
showed,8556,O
synergistic,8556,O
interactions,8556,O
for,8556,O
sulindac,8556,B-CHEMICAL
sulfide,8556,I-CHEMICAL
",",8556,O
exisulind,8556,B-CHEMICAL
",",8556,O
and,8556,O
NDGA,8556,B-CHEMICAL
with,8556,O
paclitaxel,8556,B-CHEMICAL
",",8556,O
cisplatin,8556,B-CHEMICAL
",",8556,O
and,8556,O
13-cis-retinoic,8556,B-CHEMICAL
acid,8556,I-CHEMICAL
",",8556,O
regardless,8556,O
of,8556,O
drug-resistance,8556,O
phenotype,8556,O
.,8556,O
At,8557,O
high,8557,O
concentrations,8557,O
",",8557,O
the,8557,O
combination,8557,O
of,8557,O
13-cis-retinoic,8557,B-CHEMICAL
acid,8557,I-CHEMICAL
and,8557,O
each,8557,O
of,8557,O
the,8557,O
five,8557,O
other,8557,O
drugs,8557,O
resulted,8557,O
in,8557,O
a,8557,O
strong,8557,O
synergistic,8557,O
effect,8557,O
.,8557,O
These,8558,O
studies,8558,O
provide,8558,O
a,8558,O
rationale,8558,O
for,8558,O
chemoprevention,8558,O
(,8558,O
exisulind,8558,B-CHEMICAL
+/-,8558,O
retinoic,8558,B-CHEMICAL
acid,8558,I-CHEMICAL
+/-,8558,O
NDGA,8558,B-CHEMICAL
),8558,O
and,8558,O
therapeutic,8558,O
(,8558,O
exisulind,8558,B-CHEMICAL
+/-,8558,O
paclitaxel,8558,B-CHEMICAL
+/-,8558,O
cisplatin,8558,B-CHEMICAL
),8558,O
studies,8558,O
in,8558,O
patients,8558,O
at,8558,O
risk,8558,O
for,8558,O
",",8558,O
or,8558,O
with,8558,O
",",8558,O
lung,8558,O
cancer,8558,O
.,8558,O
Phenothiazines,8559,B-CHEMICAL
inhibit,8559,O
S100A4,8559,B-GENE-Y
function,8559,O
by,8559,O
inducing,8559,O
protein,8559,O
oligomerization,8559,O
.,8559,O
S100A4,8560,B-GENE-Y
",",8560,O
a,8560,O
member,8560,O
of,8560,O
the,8560,O
S100,8560,B-GENE-N
family,8560,O
of,8560,O
Ca,8560,B-CHEMICAL
(,8560,I-CHEMICAL
2+,8560,I-CHEMICAL
),8560,I-CHEMICAL
-binding,8560,O
proteins,8560,O
",",8560,O
regulates,8560,O
carcinoma,8560,O
cell,8560,O
motility,8560,O
via,8560,O
interactions,8560,O
with,8560,O
myosin-IIA,8560,B-GENE-Y
.,8560,O
Numerous,8561,O
studies,8561,O
indicate,8561,O
that,8561,O
S100A4,8561,B-GENE-Y
is,8561,O
not,8561,O
simply,8561,O
a,8561,O
marker,8561,O
for,8561,O
metastatic,8561,O
disease,8561,O
",",8561,O
but,8561,O
rather,8561,O
has,8561,O
a,8561,O
direct,8561,O
role,8561,O
in,8561,O
metastatic,8561,O
progression,8561,O
.,8561,O
These,8562,O
observations,8562,O
suggest,8562,O
that,8562,O
S100A4,8562,B-GENE-Y
is,8562,O
an,8562,O
excellent,8562,O
target,8562,O
for,8562,O
therapeutic,8562,O
intervention,8562,O
.,8562,O
Using,8563,O
a,8563,O
unique,8563,O
biosensor-based,8563,O
assay,8563,O
",",8563,O
trifluoperazine,8563,B-CHEMICAL
(,8563,O
TFP,8563,B-CHEMICAL
),8563,O
was,8563,O
identified,8563,O
as,8563,O
an,8563,O
inhibitor,8563,O
that,8563,O
disrupts,8563,O
the,8563,O
S100A4/myosin-IIA,8563,B-GENE-Y
interaction,8563,O
.,8563,O
To,8564,O
examine,8564,O
the,8564,O
interaction,8564,O
of,8564,O
S100A4,8564,B-GENE-Y
with,8564,O
TFP,8564,B-CHEMICAL
",",8564,O
we,8564,O
determined,8564,O
the,8564,O
2.3,8564,O
A,8564,O
crystal,8564,O
structure,8564,O
of,8564,O
human,8564,O
Ca,8564,B-CHEMICAL
(,8564,I-CHEMICAL
2+,8564,I-CHEMICAL
),8564,I-CHEMICAL
-S100A4,8564,O
bound,8564,O
to,8564,O
TFP,8564,B-CHEMICAL
.,8564,O
Two,8565,O
TFP,8565,B-CHEMICAL
molecules,8565,O
bind,8565,O
within,8565,O
the,8565,O
hydrophobic,8565,O
target,8565,O
binding,8565,O
pocket,8565,O
of,8565,O
Ca,8565,B-CHEMICAL
(,8565,I-CHEMICAL
2+,8565,I-CHEMICAL
),8565,I-CHEMICAL
-S100A4,8565,O
with,8565,O
no,8565,O
significant,8565,O
conformational,8565,O
changes,8565,O
observed,8565,O
in,8565,O
the,8565,O
protein,8565,O
upon,8565,O
complex,8565,O
formation,8565,O
.,8565,O
NMR,8566,O
chemical,8566,O
shift,8566,O
perturbations,8566,O
are,8566,O
consistent,8566,O
with,8566,O
the,8566,O
crystal,8566,O
structure,8566,O
and,8566,O
demonstrate,8566,O
that,8566,O
TFP,8566,B-CHEMICAL
binds,8566,O
to,8566,O
the,8566,O
target,8566,O
binding,8566,O
cleft,8566,O
of,8566,O
S100A4,8566,B-GENE-Y
in,8566,O
solution,8566,O
.,8566,O
Remarkably,8567,O
",",8567,O
TFP,8567,B-CHEMICAL
binding,8567,O
results,8567,O
in,8567,O
the,8567,O
assembly,8567,O
of,8567,O
five,8567,O
Ca,8567,B-CHEMICAL
(,8567,I-CHEMICAL
2+,8567,I-CHEMICAL
),8567,I-CHEMICAL
-S100A4/TFP,8567,O
dimers,8567,O
into,8567,O
a,8567,O
tightly,8567,O
packed,8567,O
pentameric,8567,O
ring,8567,O
.,8567,O
Within,8568,O
each,8568,O
pentamer,8568,O
most,8568,O
of,8568,O
the,8568,O
contacts,8568,O
between,8568,O
S100A4,8568,B-GENE-Y
dimers,8568,O
occurs,8568,O
through,8568,O
the,8568,O
TFP,8568,B-CHEMICAL
moieties,8568,O
.,8568,O
The,8569,O
Ca,8569,B-CHEMICAL
(,8569,I-CHEMICAL
2+,8569,I-CHEMICAL
),8569,I-CHEMICAL
-S100A4/prochlorperazine,8569,O
(,8569,O
PCP,8569,B-CHEMICAL
),8569,O
complex,8569,O
exhibits,8569,O
a,8569,O
similar,8569,O
pentameric,8569,O
assembly,8569,O
.,8569,O
Equilibrium,8570,O
sedimentation,8570,O
and,8570,O
cross-linking,8570,O
studies,8570,O
demonstrate,8570,O
the,8570,O
cooperative,8570,O
formation,8570,O
of,8570,O
a,8570,O
similarly,8570,O
sized,8570,O
S100A4/TFP,8570,B-GENE-Y
oligomer,8570,O
in,8570,O
solution,8570,O
.,8570,O
Assays,8571,O
examining,8571,O
the,8571,O
ability,8571,O
of,8571,O
TFP,8571,B-CHEMICAL
to,8571,O
block,8571,O
S100A4-mediated,8571,B-GENE-Y
disassembly,8571,O
of,8571,O
myosin-IIA,8571,B-GENE-Y
filaments,8571,O
demonstrate,8571,O
that,8571,O
significant,8571,O
inhibition,8571,O
of,8571,O
S100A4,8571,B-GENE-Y
function,8571,O
occurs,8571,O
only,8571,O
at,8571,O
TFP,8571,B-CHEMICAL
concentrations,8571,O
that,8571,O
promote,8571,O
S100A4,8571,B-GENE-Y
oligomerization,8571,O
.,8571,O
Together,8572,O
these,8572,O
studies,8572,O
support,8572,O
a,8572,O
unique,8572,O
mode,8572,O
of,8572,O
inhibition,8572,O
in,8572,O
which,8572,O
phenothiazines,8572,B-CHEMICAL
disrupt,8572,O
the,8572,O
S100A4/myosin-IIA,8572,B-GENE-Y
interaction,8572,O
by,8572,O
sequestering,8572,O
S100A4,8572,B-GENE-Y
via,8572,O
small,8572,O
molecule-induced,8572,O
oligomerization,8572,O
.,8572,O
Substrates,8573,O
of,8573,O
IAP,8573,B-GENE-N
ubiquitin,8573,B-GENE-N
ligases,8573,I-GENE-N
identified,8573,O
with,8573,O
a,8573,O
designed,8573,O
orthogonal,8573,O
E3,8573,B-GENE-N
ligase,8573,I-GENE-N
",",8573,O
the,8573,O
NEDDylator,8573,O
.,8573,O
Inhibitors,8574,B-GENE-N
of,8574,I-GENE-N
Apoptosis,8574,I-GENE-N
Protein,8574,I-GENE-N
(,8574,O
IAPs,8574,B-GENE-N
),8574,O
are,8574,O
guardian,8574,O
ubiquitin,8574,B-GENE-N
ligases,8574,I-GENE-N
that,8574,O
keep,8574,O
classic,8574,O
proapoptotic,8574,O
proteins,8574,O
in,8574,O
check,8574,O
.,8574,O
Systematic,8575,O
identification,8575,O
of,8575,O
additional,8575,O
IAP,8575,O
substrates,8575,O
is,8575,O
challenged,8575,O
by,8575,O
the,8575,O
heterogeneity,8575,O
and,8575,O
sheer,8575,O
number,8575,O
of,8575,O
ubiquitinated,8575,O
proteins,8575,O
(,8575,O
>,8575,O
"5,000",8575,O
),8575,O
.,8575,O
Here,8576,O
we,8576,O
report,8576,O
a,8576,O
powerful,8576,O
catalytic,8576,O
tagging,8576,O
tool,8576,O
",",8576,O
the,8576,O
NEDDylator,8576,O
",",8576,O
which,8576,O
fuses,8576,O
a,8576,O
NEDD8,8576,B-GENE-Y
E2-conjugating,8576,B-GENE-N
enzyme,8576,I-GENE-N
",",8576,O
Ubc12,8576,B-GENE-Y
",",8576,O
to,8576,O
the,8576,O
ubiquitin,8576,B-GENE-N
ligase,8576,I-GENE-N
",",8576,O
XIAP,8576,B-GENE-Y
or,8576,O
cIAP1,8576,B-GENE-Y
.,8576,O
This,8577,O
permits,8577,O
transfer,8577,O
of,8577,O
the,8577,O
rare,8577,O
ubiquitin,8577,B-GENE-N
homolog,8577,O
NEDD8,8577,B-GENE-Y
to,8577,O
the,8577,O
ubiquitin,8577,B-GENE-N
E3,8577,I-GENE-N
substrates,8577,O
",",8577,O
allowing,8577,O
them,8577,O
to,8577,O
be,8577,O
efficiently,8577,O
purified,8577,O
for,8577,O
LC-MS/MS,8577,O
identification,8577,O
.,8577,O
We,8578,O
have,8578,O
identified,8578,O
>,8578,O
50,8578,O
potential,8578,O
IAP,8578,B-GENE-N
substrates,8578,O
of,8578,O
both,8578,O
cytosolic,8578,O
and,8578,O
mitochondrial,8578,O
origin,8578,O
that,8578,O
bear,8578,O
hallmark,8578,O
N-terminal,8578,B-CHEMICAL
IAP,8578,B-GENE-N
binding,8578,O
motifs,8578,O
.,8578,O
These,8579,O
substrates,8579,O
include,8579,O
the,8579,O
recently,8579,O
discovered,8579,O
protein,8579,B-GENE-N
phosphatase,8579,I-GENE-N
PGAM5,8579,B-GENE-Y
",",8579,O
which,8579,O
we,8579,O
show,8579,O
is,8579,O
proteolytically,8579,O
processed,8579,O
",",8579,O
accumulates,8579,O
in,8579,O
cytosol,8579,O
during,8579,O
apoptosis,8579,O
",",8579,O
and,8579,O
sensitizes,8579,O
cells,8579,O
to,8579,O
death,8579,O
.,8579,O
These,8580,O
studies,8580,O
reveal,8580,O
mechanisms,8580,O
and,8580,O
antagonistic,8580,O
partners,8580,O
for,8580,O
specific,8580,O
IAPs,8580,B-GENE-N
",",8580,O
and,8580,O
provide,8580,O
a,8580,O
powerful,8580,O
technology,8580,O
for,8580,O
labeling,8580,O
binding,8580,O
partners,8580,O
in,8580,O
transient,8580,O
protein-protein,8580,O
complexes,8580,O
.,8580,O
Cloning,8581,O
and,8581,O
expression,8581,O
of,8581,O
the,8581,O
liver,8581,O
and,8581,O
muscle,8581,O
isoforms,8581,O
of,8581,O
ovine,8581,B-GENE-Y
carnitine,8581,I-GENE-Y
palmitoyltransferase,8581,I-GENE-Y
1,8581,I-GENE-Y
:,8581,O
residues,8581,O
within,8581,O
the,8581,O
N-terminus,8581,B-CHEMICAL
of,8581,O
the,8581,O
muscle,8581,O
isoform,8581,O
influence,8581,O
the,8581,O
kinetic,8581,O
properties,8581,O
of,8581,O
the,8581,O
enzyme,8581,O
.,8581,O
The,8582,O
nucleotide,8582,B-CHEMICAL
sequence,8582,O
data,8582,O
reported,8582,O
will,8582,O
appear,8582,O
in,8582,O
DDBJ,8582,O
",",8582,O
EMBL,8582,O
",",8582,O
GenBank,8582,O
(,8582,O
R,8582,O
),8582,O
and,8582,O
GSDB,8582,O
Nucleotide,8582,B-CHEMICAL
Sequence,8582,O
Databases,8582,O
;,8582,O
the,8582,O
sequences,8582,O
of,8582,O
ovine,8582,B-GENE-Y
CPT1A,8582,I-GENE-Y
and,8582,O
CPT1B,8582,B-GENE-Y
cDNAs,8582,O
have,8582,O
the,8582,O
accession,8582,O
numbers,8582,O
Y18387,8582,B-GENE-Y
and,8582,O
AJ272435,8582,B-GENE-Y
respectively,8582,O
and,8582,O
the,8582,O
partial,8582,O
adipose,8582,O
tissue,8582,O
and,8582,O
liver,8582,O
CPT1A,8582,B-GENE-Y
clones,8582,O
have,8582,O
the,8582,O
accession,8582,O
numbers,8582,O
Y18830,8582,B-GENE-Y
and,8582,O
Y18829,8582,B-GENE-Y
respectively,8582,O
.,8582,O
Fatty,8583,B-CHEMICAL
acid,8583,I-CHEMICAL
and,8583,O
ketone,8583,B-CHEMICAL
body,8583,O
metabolism,8583,O
differ,8583,O
considerably,8583,O
between,8583,O
monogastric,8583,O
and,8583,O
ruminant,8583,O
species,8583,O
.,8583,O
The,8584,O
regulation,8584,O
of,8584,O
the,8584,O
key,8584,O
enzymes,8584,O
involved,8584,O
may,8584,O
differ,8584,O
accordingly,8584,O
.,8584,O
Carnitine,8585,B-GENE-Y
palmitoyltransferase,8585,I-GENE-Y
1,8585,I-GENE-Y
(,8585,O
CPT,8585,B-GENE-Y
1,8585,I-GENE-Y
),8585,O
is,8585,O
the,8585,O
key,8585,O
locus,8585,O
for,8585,O
the,8585,O
control,8585,O
of,8585,O
long-chain,8585,O
fatty,8585,B-CHEMICAL
acid,8585,I-CHEMICAL
beta-oxidation,8585,O
and,8585,O
liver,8585,O
ketogenesis,8585,O
.,8585,O
Previously,8586,O
we,8586,O
showed,8586,O
that,8586,O
CPT,8586,B-GENE-N
1,8586,I-GENE-N
kinetics,8586,O
in,8586,O
sheep,8586,O
and,8586,O
rat,8586,O
liver,8586,O
mitochondria,8586,O
differ,8586,O
.,8586,O
We,8587,O
cloned,8587,O
cDNAs,8587,O
for,8587,O
both,8587,O
isoforms,8587,O
[,8587,O
liver-,8587,O
(,8587,O
L-,8587,O
),8587,O
and,8587,O
muscle-,8587,O
(,8587,O
M-,8587,O
),8587,O
],8587,O
of,8587,O
ovine,8587,B-GENE-Y
CPT,8587,I-GENE-Y
1,8587,I-GENE-Y
in,8587,O
order,8587,O
to,8587,O
elucidate,8587,O
the,8587,O
structural,8587,O
features,8587,O
of,8587,O
these,8587,O
proteins,8587,O
and,8587,O
their,8587,O
genes,8587,O
(,8587,O
CPT1A,8587,B-GENE-Y
and,8587,O
CPT1B,8587,B-GENE-Y
),8587,O
.,8587,O
Their,8588,O
deduced,8588,O
amino,8588,B-CHEMICAL
acid,8588,I-CHEMICAL
sequences,8588,O
show,8588,O
a,8588,O
high,8588,O
degree,8588,O
of,8588,O
conservation,8588,O
compared,8588,O
with,8588,O
orthologues,8588,O
from,8588,O
other,8588,O
mammalian,8588,O
species,8588,O
",",8588,O
with,8588,O
the,8588,O
notable,8588,O
exception,8588,O
of,8588,O
the,8588,O
N-terminus,8588,B-CHEMICAL
of,8588,O
ovine,8588,B-GENE-Y
M-CPT,8588,I-GENE-Y
1,8588,I-GENE-Y
.,8588,O
These,8589,O
differences,8589,O
were,8589,O
also,8589,O
present,8589,O
in,8589,O
bovine,8589,B-GENE-Y
M-CPT,8589,I-GENE-Y
1,8589,I-GENE-Y
",",8589,O
whose,8589,O
N-terminal,8589,B-CHEMICAL
sequence,8589,O
we,8589,O
determined,8589,O
.,8589,O
In,8590,O
addition,8590,O
",",8590,O
the,8590,O
5'-end,8590,O
of,8590,O
the,8590,O
sheep,8590,B-GENE-Y
CPT1B,8590,I-GENE-Y
cDNA,8590,O
suggested,8590,O
a,8590,O
different,8590,O
promoter,8590,O
architecture,8590,O
when,8590,O
compared,8590,O
with,8590,O
previously,8590,O
characterized,8590,O
CPT1B,8590,B-GENE-Y
genes,8590,O
.,8590,O
Northern,8591,O
blotting,8591,O
revealed,8591,O
differences,8591,O
in,8591,O
tissue,8591,O
distribution,8591,O
for,8591,O
both,8591,O
CPT1A,8591,B-GENE-Y
and,8591,O
CPT1B,8591,B-GENE-Y
transcripts,8591,O
compared,8591,O
with,8591,O
other,8591,O
species,8591,O
.,8591,O
In,8592,O
particular,8592,O
",",8592,O
ovine,8592,B-GENE-Y
CPT1B,8592,I-GENE-Y
mRNA,8592,O
was,8592,O
less,8592,O
tissue,8592,O
restricted,8592,O
",",8592,O
and,8592,O
the,8592,O
predominant,8592,O
transcript,8592,O
in,8592,O
the,8592,O
pancreas,8592,O
was,8592,O
CPT1B,8592,B-GENE-Y
.,8592,O
Expression,8593,O
in,8593,O
yeast,8593,O
allowed,8593,O
kinetic,8593,O
characterization,8593,O
of,8593,O
the,8593,O
two,8593,O
native,8593,O
enzymes,8593,O
",",8593,O
and,8593,O
of,8593,O
a,8593,O
chimaera,8593,O
in,8593,O
which,8593,O
the,8593,O
distinctive,8593,O
N-terminal,8593,B-CHEMICAL
segment,8593,O
of,8593,O
ovine,8593,B-GENE-Y
M-CPT,8593,I-GENE-Y
1,8593,I-GENE-Y
was,8593,O
replaced,8593,O
with,8593,O
that,8593,O
from,8593,O
rat,8593,B-GENE-Y
M-CPT,8593,I-GENE-Y
1,8593,I-GENE-Y
.,8593,O
The,8594,O
ovine,8594,O
N-terminal,8594,B-CHEMICAL
segment,8594,O
influences,8594,O
the,8594,O
kinetics,8594,O
of,8594,O
the,8594,O
enzyme,8594,O
for,8594,O
both,8594,O
its,8594,O
substrates,8594,O
",",8594,O
such,8594,O
that,8594,O
the,8594,O
K,8594,O
(,8594,O
m,8594,O
),8594,O
for,8594,O
palmitoyl-CoA,8594,B-CHEMICAL
is,8594,O
decreased,8594,O
and,8594,O
that,8594,O
for,8594,O
carnitine,8594,B-CHEMICAL
is,8594,O
increased,8594,O
for,8594,O
the,8594,O
chimaera,8594,O
",",8594,O
relative,8594,O
to,8594,O
the,8594,O
parental,8594,O
ovine,8594,B-GENE-Y
M-CPT,8594,I-GENE-Y
1,8594,I-GENE-Y
.,8594,O
Cardiac,8595,O
effects,8595,O
of,8595,O
the,8595,O
beta,8595,B-GENE-Y
3-adrenoceptor,8595,I-GENE-Y
agonist,8595,O
BRL35135,8595,B-CHEMICAL
in,8595,O
man,8595,O
.,8595,O
The,8596,O
aim,8596,O
of,8596,O
the,8596,O
present,8596,O
study,8596,O
was,8596,O
to,8596,O
evaluate,8596,O
the,8596,O
cardiac,8596,O
effects,8596,O
of,8596,O
the,8596,O
beta,8596,B-GENE-Y
3-adrenoceptor,8596,I-GENE-Y
agonist,8596,O
BRL35135,8596,B-CHEMICAL
",",8596,O
and,8596,O
determine,8596,O
whether,8596,O
beta,8596,B-GENE-Y
3-receptors,8596,I-GENE-Y
are,8596,O
involved,8596,O
in,8596,O
mediating,8596,O
chronotropic,8596,O
or,8596,O
inotropic,8596,O
responses,8596,O
in,8596,O
man,8596,O
.,8596,O
Eight,8597,O
normal,8597,O
males,8597,O
received,8597,O
single,8597,O
oral,8597,O
doses,8597,O
of,8597,O
BRL35135,8597,B-CHEMICAL
8,8597,O
mg,8597,O
(,8597,O
BRL,8597,B-CHEMICAL
),8597,O
or,8597,O
the,8597,O
selective,8597,O
beta,8597,B-GENE-Y
2-adrenoceptor,8597,I-GENE-Y
agonist,8597,O
salbutamol,8597,B-CHEMICAL
8,8597,O
mg,8597,O
(,8597,O
SAL,8597,B-CHEMICAL
),8597,O
",",8597,O
after,8597,O
pretreatment,8597,O
with,8597,O
either,8597,O
placebo,8597,O
(,8597,O
PL,8597,O
),8597,O
",",8597,O
bisoprolol,8597,B-CHEMICAL
5,8597,O
mg,8597,O
(,8597,O
B5,8597,O
),8597,O
as,8597,O
a,8597,O
selective,8597,O
beta,8597,B-GENE-Y
1-adrenoceptor,8597,I-GENE-Y
antagonist,8597,O
",",8597,O
or,8597,O
nadolol,8597,B-CHEMICAL
20,8597,O
mg,8597,O
(,8597,O
N20,8597,O
),8597,O
to,8597,O
block,8597,O
beta,8597,B-GENE-N
1-,8597,I-GENE-N
and,8597,I-GENE-N
beta,8597,I-GENE-N
2-,8597,I-GENE-N
but,8597,I-GENE-N
not,8597,I-GENE-N
beta,8597,I-GENE-N
3-receptors,8597,I-GENE-N
.,8597,O
Both,8598,O
BRL,8598,B-CHEMICAL
and,8598,O
SAL,8598,B-CHEMICAL
produced,8598,O
a,8598,O
significant,8598,O
increase,8598,O
in,8598,O
postural,8598,O
finger,8598,O
tremor,8598,O
in,8598,O
keeping,8598,O
with,8598,O
beta,8598,B-GENE-Y
2-adrenoceptor,8598,I-GENE-Y
stimulation,8598,O
",",8598,O
and,8598,O
this,8598,O
response,8598,O
was,8598,O
totally,8598,O
abolished,8598,O
by,8598,O
pretreatment,8598,O
with,8598,O
N20,8598,O
.,8598,O
Significant,8599,O
increases,8599,O
in,8599,O
systolic,8599,O
blood,8599,O
pressure,8599,O
and,8599,O
Doppler,8599,O
stroke,8599,O
distance,8599,O
occurred,8599,O
with,8599,O
BRL,8599,B-CHEMICAL
and,8599,O
SAL,8599,B-CHEMICAL
which,8599,O
were,8599,O
unaffected,8599,O
by,8599,O
pretreatment,8599,O
with,8599,O
B5,8599,O
and,8599,O
completely,8599,O
blocked,8599,O
by,8599,O
N20,8599,O
",",8599,O
in,8599,O
keeping,8599,O
with,8599,O
beta,8599,B-GENE-Y
2-mediated,8599,O
effects,8599,O
.,8599,O
BRL,8600,B-CHEMICAL
and,8600,O
SAL,8600,B-CHEMICAL
produced,8600,O
significant,8600,O
chronotropic,8600,O
and,8600,O
minute,8600,O
distance,8600,O
responses,8600,O
which,8600,O
were,8600,O
unaffected,8600,O
by,8600,O
beta,8600,B-GENE-Y
1-adrenoceptor,8600,I-GENE-Y
blockade,8600,O
.,8600,O
However,8601,O
",",8601,O
whereas,8601,O
N20,8601,O
blocked,8601,O
these,8601,O
responses,8601,O
to,8601,O
SAL,8601,B-CHEMICAL
",",8601,O
a,8601,O
small,8601,O
but,8601,O
significant,8601,O
response,8601,O
occurred,8601,O
with,8601,O
BRL,8601,B-CHEMICAL
in,8601,O
comparison,8601,O
with,8601,O
placebo,8601,O
despite,8601,O
complete,8601,O
blockade,8601,O
of,8601,O
co-existing,8601,O
beta,8601,B-GENE-Y
2-mediated,8601,O
effects,8601,O
.,8601,O
Compared,8602,O
with,8602,O
PL,8602,O
",",8602,O
the,8602,O
mean,8602,O
responses,8602,O
to,8602,O
N20/BRL,8602,O
",",8602,O
and,8602,O
the,8602,O
95,8602,O
%,8602,O
confidence,8602,O
interval,8602,O
for,8602,O
the,8602,O
differences,8602,O
between,8602,O
the,8602,O
means,8602,O
were,8602,O
7.4,8602,O
beats,8602,O
min-1,8602,O
[,8602,O
3.2,8602,O
to,8602,O
11.6,8602,O
],8602,O
(,8602,O
P,8602,O
=,8602,O
0.002,8602,O
),8602,O
for,8602,O
heart,8602,O
rate,8602,O
",",8602,O
and,8602,O
208.8,8602,O
cm,8602,O
[,8602,O
38.3,8602,O
to,8602,O
379.3,8602,O
],8602,O
(,8602,O
P,8602,O
=,8602,O
0.02,8602,O
),8602,O
for,8602,O
minute,8602,O
distance,8602,O
responses,8602,O
.,8602,O
(,8603,O
ABSTRACT,8603,O
TRUNCATED,8603,O
AT,8603,O
250,8603,O
WORDS,8603,O
),8603,O
Aryl,8604,B-GENE-Y
hydrocarbon,8604,I-GENE-Y
receptor-mediated,8604,O
disruption,8604,O
of,8604,O
contact,8604,O
inhibition,8604,O
is,8604,O
associated,8604,O
with,8604,O
connexin43,8604,B-GENE-Y
downregulation,8604,O
and,8604,O
inhibition,8604,O
of,8604,O
gap,8604,O
junctional,8604,O
intercellular,8604,O
communication,8604,O
.,8604,O
The,8605,O
aryl,8605,B-GENE-Y
hydrocarbon,8605,I-GENE-Y
receptor,8605,I-GENE-Y
(,8605,O
AhR,8605,B-GENE-Y
),8605,O
contributes,8605,O
to,8605,O
the,8605,O
control,8605,O
of,8605,O
cell-to-cell,8605,O
communication,8605,O
",",8605,O
cell,8605,O
adhesion,8605,O
",",8605,O
migration,8605,O
or,8605,O
proliferation,8605,O
.,8605,O
In,8606,O
the,8606,O
present,8606,O
study,8606,O
",",8606,O
we,8606,O
investigated,8606,O
the,8606,O
regulation,8606,O
of,8606,O
connexin43,8606,B-GENE-Y
(,8606,O
Cx43,8606,B-GENE-Y
),8606,O
and,8606,O
Cx43-mediated,8606,B-GENE-Y
gap,8606,O
junctional,8606,O
intercellular,8606,O
communication,8606,O
(,8606,O
GJIC,8606,O
),8606,O
during,8606,O
the,8606,O
AhR-dependent,8606,B-GENE-Y
disruption,8606,O
of,8606,O
contact,8606,O
inhibition,8606,O
in,8606,O
non-tumorigenic,8606,O
liver,8606,O
epithelial,8606,O
cells,8606,O
.,8606,O
The,8607,O
contact,8607,O
inhibition,8607,O
of,8607,O
cell,8607,O
proliferation,8607,O
is,8607,O
a,8607,O
process,8607,O
restricting,8607,O
the,8607,O
cell,8607,O
division,8607,O
of,8607,O
confluent,8607,O
non-transformed,8607,O
cells,8607,O
",",8607,O
which,8607,O
is,8607,O
frequently,8607,O
abolished,8607,O
in,8607,O
cancer,8607,O
cells,8607,O
;,8607,O
however,8607,O
",",8607,O
the,8607,O
mechanisms,8607,O
contributing,8607,O
to,8607,O
its,8607,O
disruption,8607,O
are,8607,O
still,8607,O
only,8607,O
partially,8607,O
understood,8607,O
.,8607,O
Disruption,8608,O
of,8608,O
contact,8608,O
inhibition,8608,O
",",8608,O
which,8608,O
was,8608,O
induced,8608,O
by,8608,O
toxic,8608,O
AhR,8608,B-GENE-Y
ligands,8608,O
"2,3,7,8-tetrachlorodibenzo-p-dioxin",8608,B-CHEMICAL
(,8608,O
TCDD,8608,B-CHEMICAL
),8608,O
or,8608,O
polycyclic,8608,B-CHEMICAL
aromatic,8608,I-CHEMICAL
hydrocarbons,8608,I-CHEMICAL
in,8608,O
epithelial,8608,O
WB-F344,8608,O
cells,8608,O
",",8608,O
reduced,8608,O
Cx43,8608,B-GENE-Y
protein,8608,O
levels,8608,O
",",8608,O
possibly,8608,O
via,8608,O
enhanced,8608,O
proteasomal,8608,O
degradation,8608,O
",",8608,O
significantly,8608,O
decreased,8608,O
the,8608,O
amount,8608,O
of,8608,O
gap,8608,O
junction,8608,O
plaques,8608,O
and,8608,O
downregulated,8608,O
GJIC,8608,O
",",8608,O
in,8608,O
an,8608,O
AhR-dependent,8608,B-GENE-Y
manner,8608,O
.,8608,O
Although,8609,O
both,8609,O
intracellular,8609,O
and,8609,O
membrane,8609,O
Cx43,8609,B-GENE-Y
pools,8609,O
were,8609,O
markedly,8609,O
reduced,8609,O
in,8609,O
cells,8609,O
released,8609,O
from,8609,O
contact,8609,O
inhibition,8609,O
by,8609,O
TCDD,8609,B-CHEMICAL
",",8609,O
siRNA-mediated,8609,O
Cx43,8609,B-GENE-Y
knock-down,8609,O
was,8609,O
not,8609,O
sufficient,8609,O
to,8609,O
stimulate,8609,O
proliferation,8609,O
in,8609,O
contact-inhibited,8609,O
cells,8609,O
.,8609,O
Our,8610,O
data,8610,O
suggest,8610,O
that,8610,O
downregulation,8610,O
of,8610,O
Cx43/GJIC,8610,B-GENE-Y
in,8610,O
non-transformed,8610,O
epithelial,8610,O
cells,8610,O
is,8610,O
an,8610,O
inherent,8610,O
part,8610,O
of,8610,O
disruption,8610,O
of,8610,O
contact,8610,O
inhibition,8610,O
",",8610,O
which,8610,O
occurs,8610,O
at,8610,O
the,8610,O
post-transcriptional,8610,O
level,8610,O
.,8610,O
This,8611,O
process,8611,O
runs,8611,O
in,8611,O
parallel,8611,O
with,8611,O
alterations,8611,O
of,8611,O
other,8611,O
forms,8611,O
of,8611,O
cell-to-cell,8611,O
communication,8611,O
",",8611,O
thus,8611,O
suggesting,8611,O
that,8611,O
toxic,8611,O
AhR,8611,B-GENE-Y
agonists,8611,O
may,8611,O
simultaneously,8611,O
abrogate,8611,O
contact,8611,O
inhibition,8611,O
and,8611,O
reduce,8611,O
GJIC,8611,O
",",8611,O
two,8611,O
essential,8611,O
mechanisms,8611,O
linked,8611,O
to,8611,O
deregulation,8611,O
of,8611,O
cell-to-cell,8611,O
communication,8611,O
during,8611,O
tumor,8611,O
promotion,8611,O
and,8611,O
progression,8611,O
.,8611,O
Heteromtoxin,8612,B-GENE-Y
(,8612,O
HmTx,8612,B-GENE-Y
),8612,O
",",8612,O
a,8612,O
novel,8612,O
heterodimeric,8612,O
phospholipase,8612,B-GENE-N
A,8612,I-GENE-N
(,8612,I-GENE-N
2,8612,I-GENE-N
),8612,I-GENE-N
from,8612,O
Heterometrus,8612,O
laoticus,8612,O
scorpion,8612,O
venom,8612,O
.,8612,O
Heteromtoxin,8613,B-GENE-Y
(,8613,O
HmTx,8613,B-GENE-Y
),8613,O
is,8613,O
a,8613,O
group,8613,B-GENE-N
III,8613,I-GENE-N
phospholipase,8613,I-GENE-N
A,8613,I-GENE-N
(,8613,I-GENE-N
2,8613,I-GENE-N
),8613,I-GENE-N
produced,8613,O
in,8613,O
Heterometrus,8613,O
laoticus,8613,O
",",8613,O
in,8613,O
Thailand,8613,O
.,8613,O
In,8614,O
this,8614,O
study,8614,O
",",8614,O
HmTx,8614,B-GENE-Y
was,8614,O
purified,8614,O
from,8614,O
venom,8614,O
by,8614,O
separation,8614,O
chromatography,8614,O
",",8614,O
and,8614,O
the,8614,O
PLA,8614,B-GENE-N
(,8614,I-GENE-N
2,8614,I-GENE-N
),8614,I-GENE-N
activity,8614,O
of,8614,O
the,8614,O
fractions,8614,O
was,8614,O
determined,8614,O
by,8614,O
lecithin,8614,O
agar,8614,O
assay,8614,O
.,8614,O
The,8615,O
enzyme,8615,O
is,8615,O
an,8615,O
acidic,8615,O
protein,8615,O
with,8615,O
a,8615,O
pI,8615,O
of,8615,O
5.6,8615,O
and,8615,O
an,8615,O
apparent,8615,O
molecular,8615,O
weight,8615,O
of,8615,O
14018.4,8615,O
Da,8615,O
.,8615,O
The,8616,O
nucleotide,8616,B-CHEMICAL
sequence,8616,O
of,8616,O
HmTx,8616,B-GENE-Y
contains,8616,O
649,8616,O
bp,8616,O
",",8616,O
and,8616,O
the,8616,O
mature,8616,O
protein,8616,O
is,8616,O
predicted,8616,O
to,8616,O
have,8616,O
131,8616,O
amino,8616,B-CHEMICAL
acid,8616,I-CHEMICAL
residues-104,8616,O
of,8616,O
which,8616,O
make,8616,O
up,8616,O
the,8616,O
large,8616,O
subunit,8616,O
",",8616,O
and,8616,O
27,8616,O
of,8616,O
which,8616,O
make,8616,O
up,8616,O
the,8616,O
small,8616,O
subunit,8616,O
.,8616,O
The,8617,O
subunit,8617,O
structure,8617,O
of,8617,O
HmTx,8617,B-GENE-Y
is,8617,O
highly,8617,O
similar,8617,O
to,8617,O
that,8617,O
of,8617,O
the,8617,O
other,8617,O
toxin,8617,O
",",8617,O
Pandinus,8617,O
imperator,8617,O
imperatoxin,8617,O
I,8617,O
(,8617,O
IpTx,8617,O
(,8617,O
i,8617,O
),8617,O
),8617,O
and,8617,O
to,8617,O
Mesobuthus,8617,B-GENE-N
tamulus,8617,I-GENE-N
phospholipase,8617,I-GENE-N
A,8617,I-GENE-N
(,8617,I-GENE-N
2,8617,I-GENE-N
),8617,I-GENE-N
(,8617,O
MtPLA,8617,B-GENE-N
(,8617,I-GENE-N
2,8617,I-GENE-N
),8617,I-GENE-N
),8617,O
.,8617,O
The,8618,O
3D-structure,8618,O
of,8618,O
HmTx,8618,B-GENE-Y
consists,8618,O
of,8618,O
three,8618,O
conserved,8618,O
alpha-helices,8618,O
:,8618,O
h1,8618,O
(,8618,O
Lys24-His34,8618,B-CHEMICAL
),8618,O
",",8618,O
h2,8618,O
(,8618,O
Cys59-Asp71,8618,B-CHEMICAL
),8618,O
",",8618,O
and,8618,O
h3,8618,O
(,8618,O
Ala80-Phe89,8618,B-CHEMICAL
),8618,O
.,8618,O
The,8619,O
beta-sheet,8619,O
consisted,8619,O
of,8619,O
a,8619,O
single,8619,O
stranded,8619,O
anti-parallel,8619,O
beta-sheet,8619,O
(,8619,O
b1.1,8619,O
at,8619,O
Glu43-Lys45,8619,B-CHEMICAL
and,8619,O
b1.2,8619,O
at,8619,O
Lys48-Asn50,8619,B-CHEMICAL
),8619,O
that,8619,O
was,8619,O
highly,8619,O
similar,8619,O
to,8619,O
the,8619,O
conserved,8619,O
sequences,8619,O
(,8619,O
-CGXG-,8619,O
",",8619,O
-CCXXHDXC-,8619,O
and,8619,O
CXCEXXXXXC-,8619,O
),8619,O
of,8619,O
Apis,8619,O
mellifera,8619,O
(,8619,O
bee,8619,O
),8619,O
phospholipases,8619,B-GENE-N
.,8619,O
Comparative,8620,O
phosphoproteomic,8620,O
analysis,8620,O
of,8620,O
checkpoint,8620,O
recovery,8620,O
identifies,8620,O
new,8620,O
regulators,8620,O
of,8620,O
the,8620,O
DNA,8620,O
damage,8620,O
response,8620,O
.,8620,O
How,8621,O
cells,8621,O
recover,8621,O
from,8621,O
a,8621,O
DNA,8621,O
damage-induced,8621,O
arrest,8621,O
is,8621,O
currently,8621,O
poorly,8621,O
understood,8621,O
.,8621,O
We,8622,O
performed,8622,O
large-scale,8622,O
quantitative,8622,O
phosphoproteomics,8622,O
to,8622,O
identify,8622,O
changes,8622,O
in,8622,O
protein,8622,O
phosphorylation,8622,O
that,8622,O
occurred,8622,O
during,8622,O
recovery,8622,O
from,8622,O
arrest,8622,O
in,8622,O
the,8622,O
G2,8622,O
phase,8622,O
of,8622,O
the,8622,O
cell,8622,O
cycle,8622,O
caused,8622,O
by,8622,O
DNA,8622,O
damage,8622,O
.,8622,O
We,8623,O
identified,8623,O
154,8623,O
proteins,8623,O
that,8623,O
were,8623,O
differentially,8623,O
phosphorylated,8623,O
",",8623,O
and,8623,O
systematic,8623,O
depletion,8623,O
of,8623,O
each,8623,O
of,8623,O
these,8623,O
differentially,8623,O
phosphorylated,8623,O
proteins,8623,O
by,8623,O
small,8623,O
interfering,8623,O
RNA,8623,O
(,8623,O
siRNA,8623,O
),8623,O
identified,8623,O
at,8623,O
least,8623,O
10,8623,O
potential,8623,O
regulators,8623,O
of,8623,O
recovery,8623,O
.,8623,O
Astrin,8624,B-GENE-Y
",",8624,O
a,8624,O
protein,8624,O
associated,8624,O
with,8624,O
the,8624,O
mitotic,8624,O
spindle,8624,O
",",8624,O
was,8624,O
among,8624,O
the,8624,O
potential,8624,O
regulators,8624,O
of,8624,O
recovery,8624,O
.,8624,O
We,8625,O
found,8625,O
that,8625,O
astrin,8625,B-GENE-Y
controlled,8625,O
the,8625,O
abundance,8625,O
of,8625,O
the,8625,O
cell,8625,O
cycle,8625,O
regulator,8625,O
p53,8625,B-GENE-Y
during,8625,O
DNA,8625,O
damage-induced,8625,O
arrest,8625,O
.,8625,O
Cells,8626,O
in,8626,O
which,8626,O
astrin,8626,B-GENE-Y
was,8626,O
depleted,8626,O
had,8626,O
decreased,8626,O
murine,8626,B-GENE-Y
double,8626,I-GENE-Y
minute,8626,I-GENE-Y
2,8626,I-GENE-Y
(,8626,O
MDM2,8626,B-GENE-Y
),8626,O
abundance,8626,O
and,8626,O
increased,8626,O
p53,8626,B-GENE-Y
at,8626,O
the,8626,O
later,8626,O
stages,8626,O
of,8626,O
the,8626,O
DNA,8626,O
damage,8626,O
response,8626,O
.,8626,O
Astrin,8627,B-GENE-Y
was,8627,O
required,8627,O
for,8627,O
continued,8627,O
expression,8627,O
of,8627,O
genes,8627,O
encoding,8627,O
proteins,8627,O
that,8627,O
promote,8627,O
cell,8627,O
cycle,8627,O
progression,8627,O
in,8627,O
arrested,8627,O
cells,8627,O
.,8627,O
Thus,8628,O
",",8628,O
by,8628,O
controlling,8628,O
p53,8628,B-GENE-Y
abundance,8628,O
in,8628,O
cells,8628,O
recovering,8628,O
from,8628,O
DNA,8628,O
damage,8628,O
",",8628,O
astrin,8628,B-GENE-Y
maintains,8628,O
the,8628,O
cells,8628,O
in,8628,O
a,8628,O
state,8628,O
competent,8628,O
to,8628,O
resume,8628,O
the,8628,O
cell,8628,O
cycle,8628,O
.,8628,O
Molecular,8629,O
mechanism,8629,O
of,8629,O
terbinafine,8629,B-CHEMICAL
resistance,8629,O
in,8629,O
Saccharomyces,8629,O
cerevisiae,8629,O
.,8629,O
Ten,8630,O
mutants,8630,O
of,8630,O
the,8630,O
yeast,8630,O
Saccharomyces,8630,O
cerevisiae,8630,O
resistant,8630,O
to,8630,O
the,8630,O
antimycotic,8630,O
terbinafine,8630,B-CHEMICAL
were,8630,O
isolated,8630,O
after,8630,O
chemical,8630,O
or,8630,O
UV,8630,O
mutagenesis,8630,O
.,8630,O
Molecular,8631,O
analysis,8631,O
of,8631,O
these,8631,O
mutants,8631,O
revealed,8631,O
single,8631,O
base,8631,O
pair,8631,O
exchanges,8631,O
in,8631,O
the,8631,O
ERG1,8631,B-GENE-Y
gene,8631,O
coding,8631,O
for,8631,O
squalene,8631,B-GENE-Y
epoxidase,8631,I-GENE-Y
",",8631,O
the,8631,O
target,8631,O
of,8631,O
terbinafine,8631,B-CHEMICAL
.,8631,O
The,8632,O
mutants,8632,O
did,8632,O
not,8632,O
show,8632,O
cross-resistance,8632,O
to,8632,O
any,8632,O
of,8632,O
the,8632,O
substrates,8632,O
of,8632,O
various,8632,O
pleiotropic,8632,O
drug,8632,O
resistance,8632,O
efflux,8632,O
pumps,8632,O
tested,8632,O
.,8632,O
The,8633,O
ERG1,8633,B-GENE-Y
mRNA,8633,O
levels,8633,O
in,8633,O
the,8633,O
mutants,8633,O
did,8633,O
not,8633,O
differ,8633,O
from,8633,O
those,8633,O
in,8633,O
the,8633,O
wild-type,8633,O
parent,8633,O
strains,8633,O
.,8633,O
Terbinafine,8634,B-CHEMICAL
resistance,8634,O
was,8634,O
transmitted,8634,O
with,8634,O
the,8634,O
mutated,8634,O
alleles,8634,O
in,8634,O
gene,8634,O
replacement,8634,O
experiments,8634,O
",",8634,O
proving,8634,O
that,8634,O
single,8634,O
amino,8634,B-CHEMICAL
acid,8634,I-CHEMICAL
substitutions,8634,O
in,8634,O
the,8634,O
Erg1,8634,B-GENE-Y
protein,8634,O
were,8634,O
sufficient,8634,O
to,8634,O
confer,8634,O
the,8634,O
resistance,8634,O
phenotype,8634,O
.,8634,O
The,8635,O
amino,8635,B-CHEMICAL
acid,8635,I-CHEMICAL
changes,8635,O
caused,8635,O
by,8635,O
the,8635,O
point,8635,O
mutations,8635,O
were,8635,O
clustered,8635,O
in,8635,O
two,8635,O
regions,8635,O
of,8635,O
the,8635,O
Erg1,8635,B-GENE-Y
protein,8635,O
.,8635,O
Seven,8636,O
mutants,8636,O
carried,8636,O
the,8636,O
amino,8636,B-CHEMICAL
acid,8636,I-CHEMICAL
substitutions,8636,O
F402L,8636,B-GENE-N
(,8636,O
one,8636,O
mutant,8636,O
),8636,O
",",8636,O
F420L,8636,B-GENE-N
(,8636,O
one,8636,O
mutant,8636,O
),8636,O
",",8636,O
and,8636,O
P430S,8636,B-GENE-N
(,8636,O
five,8636,O
mutants,8636,O
),8636,O
in,8636,O
the,8636,O
C-terminal,8636,B-CHEMICAL
part,8636,O
of,8636,O
the,8636,O
protein,8636,O
;,8636,O
and,8636,O
three,8636,O
mutants,8636,O
carried,8636,O
an,8636,O
L251F,8636,B-GENE-N
exchange,8636,O
in,8636,O
the,8636,O
central,8636,O
part,8636,O
of,8636,O
the,8636,O
protein,8636,O
.,8636,O
Interestingly,8637,O
",",8637,O
all,8637,O
exchanges,8637,O
identified,8637,O
involved,8637,O
amino,8637,B-CHEMICAL
acids,8637,I-CHEMICAL
which,8637,O
are,8637,O
conserved,8637,O
in,8637,O
the,8637,O
squalene,8637,B-GENE-N
epoxidases,8637,I-GENE-N
of,8637,O
yeasts,8637,O
and,8637,O
mammals,8637,O
.,8637,O
Two,8638,O
mutations,8638,O
that,8638,O
were,8638,O
generated,8638,O
by,8638,O
PCR,8638,O
mutagenesis,8638,O
of,8638,O
the,8638,O
ERG1,8638,B-GENE-Y
gene,8638,O
and,8638,O
that,8638,O
conferred,8638,O
terbinafine,8638,B-CHEMICAL
resistance,8638,O
mapped,8638,O
in,8638,O
the,8638,O
same,8638,O
regions,8638,O
of,8638,O
the,8638,O
Erg1,8638,B-GENE-Y
protein,8638,O
",",8638,O
with,8638,O
one,8638,O
resulting,8638,O
in,8638,O
an,8638,O
L251F,8638,B-GENE-N
exchange,8638,O
and,8638,O
the,8638,O
other,8638,O
resulting,8638,O
in,8638,O
an,8638,O
F433S,8638,B-GENE-N
exchange,8638,O
.,8638,O
The,8639,O
results,8639,O
strongly,8639,O
indicate,8639,O
that,8639,O
these,8639,O
regions,8639,O
are,8639,O
responsible,8639,O
for,8639,O
the,8639,O
interaction,8639,O
of,8639,O
yeast,8639,B-GENE-Y
squalene,8639,I-GENE-Y
epoxidase,8639,I-GENE-Y
with,8639,O
terbinafine,8639,B-CHEMICAL
.,8639,O
Ornithine,8640,B-CHEMICAL
metabolism,8640,O
in,8640,O
male,8640,O
and,8640,O
female,8640,O
rat,8640,O
kidney,8640,O
:,8640,O
mitochondrial,8640,O
expression,8640,O
of,8640,O
ornithine,8640,B-GENE-Y
aminotransferase,8640,I-GENE-Y
and,8640,O
arginase,8640,B-GENE-Y
II,8640,I-GENE-Y
.,8640,O
In,8641,O
the,8641,O
kidney,8641,O
",",8641,O
L-ornithine,8641,B-CHEMICAL
is,8641,O
reabsorbed,8641,O
along,8641,O
the,8641,O
proximal,8641,O
convoluted,8641,O
tubule,8641,O
(,8641,O
PCT,8641,O
),8641,O
",",8641,O
transported,8641,O
by,8641,O
basolateral,8641,O
carriers,8641,O
",",8641,O
and,8641,O
produced,8641,O
by,8641,O
arginase,8641,B-GENE-Y
II,8641,I-GENE-Y
(,8641,O
AII,8641,B-GENE-Y
),8641,O
.,8641,O
Here,8642,O
",",8642,O
the,8642,O
renal,8642,O
metabolic,8642,O
fate,8642,O
of,8642,O
L-ornithine,8642,B-CHEMICAL
was,8642,O
analyzed,8642,O
in,8642,O
male,8642,O
and,8642,O
female,8642,O
rats,8642,O
.,8642,O
Kidneys,8643,O
and,8643,O
renal,8643,O
zones,8643,O
were,8643,O
dissected,8643,O
and,8643,O
used,8643,O
for,8643,O
Western,8643,O
blot,8643,O
analysis,8643,O
",",8643,O
immunofluorescence,8643,O
",",8643,O
and,8643,O
electron,8643,O
microscopic,8643,O
studies,8643,O
.,8643,O
Ornithine,8644,B-GENE-Y
aminotransferase,8644,I-GENE-Y
(,8644,O
OAT,8644,B-GENE-Y
),8644,O
and,8644,O
AII,8644,B-GENE-Y
were,8644,O
localized,8644,O
using,8644,O
specific,8644,O
antibodies,8644,O
.,8644,O
Ornithine,8645,B-CHEMICAL
oxidation,8645,O
was,8645,O
determined,8645,O
by,8645,O
incubating,8645,O
microdissected,8645,O
tubules,8645,O
with,8645,O
L-,8645,B-CHEMICAL
[,8645,I-CHEMICAL
1-14C,8645,I-CHEMICAL
],8645,I-CHEMICAL
or,8645,O
L-,8645,B-CHEMICAL
[,8645,I-CHEMICAL
U-14C,8645,I-CHEMICAL
],8645,I-CHEMICAL
ornithine,8645,I-CHEMICAL
in,8645,O
the,8645,O
presence,8645,O
or,8645,O
absence,8645,O
of,8645,O
energy-providing,8645,O
substrates,8645,O
.,8645,O
Ornithine,8646,B-GENE-Y
decarboxylase,8646,I-GENE-Y
(,8646,O
ODC,8646,B-GENE-Y
),8646,O
mRNAs,8646,O
were,8646,O
localized,8646,O
by,8646,O
in,8646,O
situ,8646,O
hybridization,8646,O
.,8646,O
The,8647,O
48-kDa,8647,O
OAT,8647,B-GENE-Y
protein,8647,O
was,8647,O
detected,8647,O
in,8647,O
male,8647,O
and,8647,O
female,8647,O
kidneys,8647,O
",",8647,O
but,8647,O
its,8647,O
level,8647,O
was,8647,O
fourfold,8647,O
higher,8647,O
in,8647,O
the,8647,O
latter,8647,O
.,8647,O
OAT,8648,B-GENE-Y
relative,8648,O
distribution,8648,O
increased,8648,O
from,8648,O
the,8648,O
superficial,8648,O
cortex,8648,O
toward,8648,O
the,8648,O
outer,8648,O
medulla,8648,O
to,8648,O
reach,8648,O
its,8648,O
highest,8648,O
level,8648,O
.,8648,O
Almost,8649,O
all,8649,O
OAT,8649,B-GENE-Y
protein,8649,O
was,8649,O
localized,8649,O
in,8649,O
cortical,8649,O
and,8649,O
medullary,8649,O
proximal,8649,O
straight,8649,O
tubules,8649,O
(,8649,O
CPST,8649,O
and,8649,O
OSPST,8649,O
",",8649,O
respectively,8649,O
),8649,O
.,8649,O
In,8650,O
proximal,8650,O
straight,8650,O
tubule,8650,O
(,8650,O
PST,8650,O
),8650,O
",",8650,O
AII,8650,B-GENE-Y
protein,8650,O
distribution,8650,O
overlapped,8650,O
that,8650,O
of,8650,O
OAT,8650,B-GENE-Y
.,8650,O
No,8651,O
gender,8651,O
difference,8651,O
in,8651,O
AII,8651,B-GENE-Y
protein,8651,O
level,8651,O
was,8651,O
found,8651,O
.,8651,O
OAT,8652,B-GENE-Y
and,8652,O
AII,8652,B-GENE-Y
were,8652,O
colocalized,8652,O
within,8652,O
PST,8652,O
mitochondria,8652,O
.,8652,O
L-,8653,B-CHEMICAL
[,8653,I-CHEMICAL
1-14C,8653,I-CHEMICAL
],8653,I-CHEMICAL
ornithine,8653,I-CHEMICAL
decarboxylation,8653,O
occurred,8653,O
in,8653,O
all,8653,O
tubules,8653,O
",",8653,O
but,8653,O
predominantly,8653,O
in,8653,O
proximal,8653,O
tubules,8653,O
.,8653,O
L-,8654,B-CHEMICAL
[,8654,I-CHEMICAL
1-14C,8654,I-CHEMICAL
],8654,I-CHEMICAL
ornithine,8654,I-CHEMICAL
decarboxylation,8654,O
was,8654,O
enhanced,8654,O
when,8654,O
L-,8654,B-CHEMICAL
[,8654,I-CHEMICAL
1-14C,8654,I-CHEMICAL
],8654,I-CHEMICAL
ornithine,8654,I-CHEMICAL
was,8654,O
given,8654,O
to,8654,O
tubules,8654,O
as,8654,O
the,8654,O
sole,8654,O
substrate,8654,O
.,8654,O
The,8655,O
use,8655,O
of,8655,O
L-,8655,B-CHEMICAL
[,8655,I-CHEMICAL
U-14C,8655,I-CHEMICAL
],8655,I-CHEMICAL
ornithine,8655,I-CHEMICAL
demonstrated,8655,O
the,8655,O
complete,8655,O
oxidation,8655,O
of,8655,O
ornithine,8655,B-CHEMICAL
.,8655,O
In,8656,O
conclusion,8656,O
",",8656,O
the,8656,O
OAT,8656,B-GENE-Y
gene,8656,O
was,8656,O
expressed,8656,O
more,8656,O
in,8656,O
female,8656,O
rat,8656,O
proximal,8656,O
tubules,8656,O
than,8656,O
in,8656,O
male,8656,O
.,8656,O
Because,8657,O
OAT,8657,B-GENE-Y
and,8657,O
AII,8657,B-GENE-Y
proteins,8657,O
overlapped,8657,O
in,8657,O
PST,8657,O
mitochondria,8657,O
",",8657,O
L-arginine-derived,8657,B-CHEMICAL
ornithine,8657,B-CHEMICAL
may,8657,O
be,8657,O
preferentially,8657,O
converted,8657,O
to,8657,O
L-glutamate,8657,B-CHEMICAL
",",8657,O
as,8657,O
proven,8657,O
by,8657,O
ornithine,8657,B-CHEMICAL
oxidation,8657,O
.,8657,O
However,8658,O
",",8658,O
the,8658,O
coexpression,8658,O
of,8658,O
ODC,8658,B-GENE-Y
",",8658,O
glutamate,8658,B-GENE-N
decarboxylase,8658,I-GENE-N
",",8658,O
and,8658,O
glutamine,8658,B-GENE-Y
synthetase,8658,I-GENE-Y
in,8658,O
PST,8658,O
suggests,8658,O
that,8658,O
L-ornithine,8658,B-CHEMICAL
can,8658,O
also,8658,O
be,8658,O
metabolized,8658,O
to,8658,O
putrescine,8658,B-CHEMICAL
",",8658,O
GABA,8658,B-CHEMICAL
",",8658,O
and,8658,O
L-glutamine,8658,B-CHEMICAL
.,8658,O
The,8659,O
fate,8659,O
of,8659,O
L-ornithine,8659,B-CHEMICAL
may,8659,O
depend,8659,O
on,8659,O
the,8659,O
cellular,8659,O
context,8659,O
.,8659,O
Dexamethasone,8660,B-CHEMICAL
suppresses,8660,O
histamine,8660,B-CHEMICAL
synthesis,8660,O
by,8660,O
repressing,8660,O
both,8660,O
transcription,8660,O
and,8660,O
activity,8660,O
of,8660,O
HDC,8660,B-GENE-Y
in,8660,O
allergic,8660,O
rats,8660,O
.,8660,O
BACKGROUND,8661,O
:,8661,O
Histamine,8661,B-CHEMICAL
synthesized,8661,O
by,8661,O
histidine,8661,B-GENE-Y
decarboxylase,8661,I-GENE-Y
(,8661,O
HDC,8661,B-GENE-Y
),8661,O
from,8661,O
L-histidine,8661,B-CHEMICAL
is,8661,O
a,8661,O
major,8661,O
chemical,8661,O
mediator,8661,O
in,8661,O
the,8661,O
development,8661,O
of,8661,O
nasal,8661,O
allergy,8661,O
which,8661,O
is,8661,O
characterized,8661,O
by,8661,O
nasal,8661,O
hypersensitivity,8661,O
.,8661,O
However,8662,O
the,8662,O
regulatory,8662,O
mechanism,8662,O
of,8662,O
histamine,8662,B-CHEMICAL
synthesis,8662,O
by,8662,O
HDC,8662,B-GENE-Y
remains,8662,O
to,8662,O
be,8662,O
elucidated,8662,O
.,8662,O
The,8663,O
objectives,8663,O
of,8663,O
the,8663,O
present,8663,O
study,8663,O
were,8663,O
to,8663,O
examine,8663,O
the,8663,O
changes,8663,O
of,8663,O
histamine,8663,B-CHEMICAL
content,8663,O
",",8663,O
HDC,8663,B-GENE-Y
activity,8663,O
and,8663,O
HDC,8663,B-GENE-Y
mRNA,8663,O
expression,8663,O
in,8663,O
the,8663,O
nasal,8663,O
mucosa,8663,O
of,8663,O
allergy,8663,O
model,8663,O
rats,8663,O
sensitized,8663,O
by,8663,O
the,8663,O
exposure,8663,O
to,8663,O
toluene,8663,B-CHEMICAL
diisocyanate,8663,I-CHEMICAL
(,8663,O
TDI,8663,B-CHEMICAL
),8663,O
and,8663,O
to,8663,O
investigate,8663,O
the,8663,O
effect,8663,O
of,8663,O
dexamethasone,8663,B-CHEMICAL
on,8663,O
the,8663,O
above,8663,O
mentioned,8663,O
allergic,8663,O
parameters,8663,O
.,8663,O
METHODS,8664,O
:,8664,O
Rats,8664,O
were,8664,O
sensitized,8664,O
and,8664,O
provocated,8664,O
by,8664,O
TDI,8664,B-CHEMICAL
and,8664,O
the,8664,O
nasal,8664,O
allergy-like,8664,O
behaviors,8664,O
were,8664,O
scored,8664,O
during,8664,O
a,8664,O
10,8664,O
minute,8664,O
period,8664,O
after,8664,O
provocation,8664,O
.,8664,O
Histamine,8665,B-CHEMICAL
content,8665,O
and,8665,O
HDC,8665,B-GENE-Y
activity,8665,O
in,8665,O
the,8665,O
nasal,8665,O
mucosa,8665,O
were,8665,O
determined,8665,O
using,8665,O
fluorometric,8665,O
high,8665,O
performance,8665,O
liquid,8665,O
chromatography,8665,O
.,8665,O
The,8666,O
expression,8666,O
of,8666,O
HDC,8666,B-GENE-N
mRNA,8666,O
in,8666,O
nasal,8666,O
mucosa,8666,O
was,8666,O
determined,8666,O
using,8666,O
real-time,8666,O
quantitative,8666,O
reverse,8666,O
transcriptase-polymerase,8666,O
chain,8666,O
reaction,8666,O
(,8666,O
RT-PCR,8666,O
),8666,O
.,8666,O
RESULTS,8667,O
:,8667,O
In,8667,O
TDI-sensitized,8667,B-CHEMICAL
rats,8667,O
",",8667,O
nasal,8667,O
allergy-like,8667,O
behaviors,8667,O
such,8667,O
as,8667,O
sneezing,8667,O
and,8667,O
watery,8667,O
rhinorrhea,8667,O
were,8667,O
induced,8667,O
.,8667,O
Histamine,8668,B-CHEMICAL
content,8668,O
",",8668,O
HDC,8668,B-GENE-Y
activity,8668,O
and,8668,O
HDC,8668,B-GENE-Y
mRNA,8668,O
expression,8668,O
in,8668,O
nasal,8668,O
mucosa,8668,O
were,8668,O
also,8668,O
significantly,8668,O
increased,8668,O
after,8668,O
TDI,8668,B-CHEMICAL
provocation,8668,O
.,8668,O
Pretreatment,8669,O
with,8669,O
dexamethasone,8669,B-CHEMICAL
significantly,8669,O
suppressed,8669,O
nasal,8669,O
allergy-like,8669,O
behaviors,8669,O
",",8669,O
up-regulation,8669,O
of,8669,O
histamine,8669,B-CHEMICAL
content,8669,O
",",8669,O
HDC,8669,B-GENE-Y
activity,8669,O
and,8669,O
HDC,8669,B-GENE-Y
mRNA,8669,O
induced,8669,O
by,8669,O
TDI,8669,B-CHEMICAL
in,8669,O
TDI-sensitized,8669,B-CHEMICAL
rats,8669,O
.,8669,O
CONCLUSIONS,8670,O
:,8670,O
These,8670,O
findings,8670,O
indicate,8670,O
that,8670,O
increased,8670,O
synthesis,8670,O
of,8670,O
histamine,8670,B-CHEMICAL
through,8670,O
up-regulation,8670,O
of,8670,O
HDC,8670,B-GENE-Y
gene,8670,O
expression,8670,O
and,8670,O
HDC,8670,B-GENE-Y
activity,8670,O
in,8670,O
nasal,8670,O
mucosa,8670,O
plays,8670,O
an,8670,O
important,8670,O
role,8670,O
in,8670,O
the,8670,O
development,8670,O
of,8670,O
nasal,8670,O
hypersensitivity,8670,O
.,8670,O
Repression,8671,O
of,8671,O
HDC,8671,B-GENE-Y
gene,8671,O
expression,8671,O
and,8671,O
HDC,8671,B-GENE-Y
activity,8671,O
by,8671,O
dexamethasone,8671,B-CHEMICAL
may,8671,O
underlie,8671,O
its,8671,O
therapeutic,8671,O
effect,8671,O
in,8671,O
the,8671,O
treatment,8671,O
of,8671,O
allergy,8671,O
.,8671,O
The,8672,O
Effects,8672,O
of,8672,O
Carbohydrate,8672,B-CHEMICAL
",",8672,O
Unsaturated,8672,O
Fat,8672,O
",",8672,O
and,8672,O
Protein,8672,O
Intake,8672,O
on,8672,O
Measures,8672,O
of,8672,O
Insulin,8672,B-GENE-Y
Sensitivity,8672,O
:,8672,O
Results,8672,O
from,8672,O
the,8672,O
OmniHeart,8672,O
Trial,8672,O
.,8672,O
OBJECTIVE,8673,O
Impaired,8673,O
insulin,8673,B-GENE-Y
sensitivity,8673,O
increases,8673,O
the,8673,O
risk,8673,O
of,8673,O
cardiovascular,8673,O
disease,8673,O
.,8673,O
Although,8674,O
calorie,8674,O
restriction,8674,O
and,8674,O
weight,8674,O
loss,8674,O
increase,8674,O
insulin,8674,B-GENE-Y
sensitivity,8674,O
",",8674,O
the,8674,O
effects,8674,O
of,8674,O
modifying,8674,O
macronutrient,8674,O
composition,8674,O
on,8674,O
insulin,8674,B-GENE-Y
sensitivity,8674,O
are,8674,O
uncertain,8674,O
.,8674,O
The,8675,O
purpose,8675,O
of,8675,O
this,8675,O
study,8675,O
is,8675,O
to,8675,O
determine,8675,O
the,8675,O
effects,8675,O
on,8675,O
insulin,8675,B-GENE-Y
sensitivity,8675,O
of,8675,O
a,8675,O
carbohydrate-rich,8675,B-CHEMICAL
diet,8675,O
(,8675,O
CARB,8675,B-CHEMICAL
;,8675,O
similar,8675,O
to,8675,O
the,8675,O
Dietary,8675,O
Approaches,8675,O
to,8675,O
Stop,8675,O
Hypertension,8675,O
[,8675,O
DASH,8675,O
],8675,O
diet,8675,O
),8675,O
",",8675,O
a,8675,O
protein-rich,8675,O
diet,8675,O
(,8675,O
PROT,8675,O
;,8675,O
protein,8675,O
predominantly,8675,O
from,8675,O
plant,8675,O
sources,8675,O
),8675,O
",",8675,O
and,8675,O
an,8675,O
unsaturated,8675,O
fat-rich,8675,O
diet,8675,O
(,8675,O
UNSAT,8675,O
;,8675,O
predominantly,8675,O
monounsaturated,8675,O
),8675,O
.,8675,O
RESEARCH,8676,O
DESIGN,8676,O
AND,8676,O
METHODS,8676,O
This,8676,O
study,8676,O
was,8676,O
a,8676,O
randomized,8676,O
",",8676,O
controlled,8676,O
",",8676,O
three-period,8676,O
",",8676,O
crossover,8676,O
feeding,8676,O
study,8676,O
.,8676,O
The,8677,O
study,8677,O
participants,8677,O
were,8677,O
164,8677,O
individuals,8677,O
with,8677,O
prehypertension,8677,O
or,8677,O
stage,8677,O
1,8677,O
hypertension,8677,O
without,8677,O
diabetes,8677,O
.,8677,O
Diets,8678,O
were,8678,O
administered,8678,O
for,8678,O
6,8678,O
weeks,8678,O
each,8678,O
",",8678,O
with,8678,O
a,8678,O
washout,8678,O
period,8678,O
between,8678,O
diets,8678,O
of,8678,O
2-4,8678,O
weeks,8678,O
.,8678,O
Weight,8679,O
was,8679,O
held,8679,O
constant,8679,O
throughout,8679,O
the,8679,O
study,8679,O
.,8679,O
For,8680,O
our,8680,O
primary,8680,O
outcome,8680,O
",",8680,O
we,8680,O
calculated,8680,O
the,8680,O
quantitative,8680,O
insulin,8680,B-GENE-Y
sensitivity,8680,O
check,8680,O
index,8680,O
(,8680,O
QUICKI,8680,O
),8680,O
using,8680,O
the,8680,O
end-of-period,8680,O
fasting,8680,O
serum,8680,O
glucose,8680,B-CHEMICAL
and,8680,O
insulin,8680,B-GENE-Y
.,8680,O
QUICKI,8681,O
is,8681,O
a,8681,O
validated,8681,O
measure,8681,O
of,8681,O
insulin,8681,B-GENE-Y
sensitivity,8681,O
.,8681,O
The,8682,O
primary,8682,O
analyses,8682,O
used,8682,O
generalized,8682,O
estimating,8682,O
equations,8682,O
.,8682,O
RESULTS,8683,O
At,8683,O
baseline,8683,O
",",8683,O
mean,8683,O
(,8683,O
SD,8683,O
),8683,O
BMI,8683,O
was,8683,O
30.2,8683,O
(,8683,O
6.1,8683,O
),8683,O
kg/m,8683,O
(,8683,O
2,8683,O
),8683,O
",",8683,O
and,8683,O
mean,8683,O
(,8683,O
SD,8683,O
),8683,O
QUICKI,8683,O
was,8683,O
0.35,8683,O
(,8683,O
0.04,8683,O
),8683,O
.,8683,O
The,8684,O
UNSAT,8684,O
diet,8684,O
increased,8684,O
QUICKI,8684,O
by,8684,O
0.005,8684,O
",",8684,O
more,8684,O
than,8684,O
the,8684,O
CARB,8684,B-CHEMICAL
diet,8684,O
(,8684,O
P,8684,O
=,8684,O
0.04,8684,O
),8684,O
.,8684,O
PROT,8685,O
had,8685,O
no,8685,O
significant,8685,O
effect,8685,O
compared,8685,O
with,8685,O
CARB,8685,B-CHEMICAL
.,8685,O
CONCLUSIONS,8686,O
A,8686,O
diet,8686,O
that,8686,O
partially,8686,O
replaces,8686,O
carbohydrate,8686,B-CHEMICAL
with,8686,O
unsaturated,8686,O
fat,8686,O
may,8686,O
improve,8686,O
insulin,8686,B-GENE-Y
sensitivity,8686,O
in,8686,O
a,8686,O
population,8686,O
at,8686,O
risk,8686,O
for,8686,O
cardiovascular,8686,O
disease,8686,O
.,8686,O
Given,8687,O
the,8687,O
well-recognized,8687,O
challenges,8687,O
of,8687,O
sustaining,8687,O
weight,8687,O
loss,8687,O
",",8687,O
our,8687,O
results,8687,O
suggest,8687,O
an,8687,O
alternative,8687,O
approach,8687,O
for,8687,O
improving,8687,O
insulin,8687,B-GENE-Y
sensitivity,8687,O
.,8687,O
Antiobesity,8688,O
action,8688,O
of,8688,O
peripheral,8688,O
exenatide,8688,O
(,8688,O
exendin-4,8688,O
),8688,O
in,8688,O
rodents,8688,O
:,8688,O
effects,8688,O
on,8688,O
food,8688,O
intake,8688,O
",",8688,O
body,8688,O
weight,8688,O
",",8688,O
metabolic,8688,O
status,8688,O
and,8688,O
side-effect,8688,O
measures,8688,O
.,8688,O
BACKGROUND,8689,O
:,8689,O
Exenatide,8689,O
(,8689,O
exendin-4,8689,O
),8689,O
is,8689,O
an,8689,O
incretin,8689,B-GENE-Y
mimetic,8689,O
currently,8689,O
marketed,8689,O
as,8689,O
an,8689,O
antidiabetic,8689,O
agent,8689,O
for,8689,O
patients,8689,O
with,8689,O
type,8689,O
2,8689,O
diabetes,8689,O
.,8689,O
In,8690,O
preclinical,8690,O
models,8690,O
",",8690,O
a,8690,O
reduction,8690,O
in,8690,O
body,8690,O
weight,8690,O
has,8690,O
also,8690,O
been,8690,O
shown,8690,O
in,8690,O
low-fat-fed,8690,O
",",8690,O
leptin,8690,B-GENE-N
receptor-deficient,8690,O
rodents,8690,O
.,8690,O
OBJECTIVE,8691,O
:,8691,O
To,8691,O
more,8691,O
closely,8691,O
model,8691,O
the,8691,O
polygenic,8691,O
and,8691,O
environmental,8691,O
state,8691,O
of,8691,O
human,8691,O
obesity,8691,O
",",8691,O
we,8691,O
characterized,8691,O
the,8691,O
effect,8691,O
of,8691,O
exenatide,8691,O
on,8691,O
food,8691,O
intake,8691,O
and,8691,O
body,8691,O
weight,8691,O
in,8691,O
high-fat-fed,8691,O
",",8691,O
normal,8691,O
(,8691,O
those,8691,O
with,8691,O
an,8691,O
intact,8691,O
leptin,8691,B-GENE-N
signaling,8691,O
system,8691,O
),8691,O
rodents,8691,O
.,8691,O
As,8692,O
glucagon-like,8692,B-GENE-N
peptide-1,8692,I-GENE-N
receptor,8692,I-GENE-N
agonism,8692,O
has,8692,O
been,8692,O
found,8692,O
to,8692,O
elicit,8692,O
behaviors,8692,O
associated,8692,O
with,8692,O
visceral,8692,O
illness,8692,O
in,8692,O
rodents,8692,O
",",8692,O
we,8692,O
also,8692,O
examined,8692,O
the,8692,O
effect,8692,O
of,8692,O
peripheral,8692,O
exenatide,8692,O
on,8692,O
kaolin,8692,B-CHEMICAL
consumption,8692,O
and,8692,O
locomotor,8692,O
activity,8692,O
.,8692,O
METHODS,8693,O
AND,8693,O
RESULTS,8693,O
:,8693,O
High-fat-fed,8693,O
C57BL/6,8693,O
mice,8693,O
and,8693,O
Sprague-Dawley,8693,O
rats,8693,O
were,8693,O
treated,8693,O
with,8693,O
exenatide,8693,O
(,8693,O
3,8693,O
",",8693,O
10,8693,O
and,8693,O
30,8693,O
microg/kg/day,8693,O
),8693,O
for,8693,O
4,8693,O
weeks,8693,O
via,8693,O
subcutaneously,8693,O
implanted,8693,O
osmotic,8693,O
pumps,8693,O
.,8693,O
Food,8694,O
intake,8694,O
and,8694,O
body,8694,O
weight,8694,O
were,8694,O
assessed,8694,O
weekly,8694,O
.,8694,O
At,8695,O
4,8695,O
weeks,8695,O
",",8695,O
body,8695,O
composition,8695,O
and,8695,O
plasma,8695,O
metabolic,8695,O
profiles,8695,O
were,8695,O
measured,8695,O
.,8695,O
Kaolin,8696,B-CHEMICAL
consumption,8696,O
and,8696,O
locomotor,8696,O
activity,8696,O
were,8696,O
measured,8696,O
in,8696,O
fasted,8696,O
Sprague-Dawley,8696,O
rats,8696,O
following,8696,O
a,8696,O
single,8696,O
intraperitoneal,8696,O
injection,8696,O
of,8696,O
exenatide,8696,O
(,8696,O
0.1-10,8696,O
microg/kg,8696,O
),8696,O
.,8696,O
Exenatide,8697,O
treatment,8697,O
in,8697,O
mice,8697,O
and,8697,O
rats,8697,O
dose-dependently,8697,O
decreased,8697,O
food,8697,O
intake,8697,O
and,8697,O
body,8697,O
weight,8697,O
;,8697,O
significant,8697,O
reductions,8697,O
in,8697,O
body,8697,O
weight,8697,O
gain,8697,O
were,8697,O
observed,8697,O
throughout,8697,O
treatment,8697,O
at,8697,O
10,8697,O
and,8697,O
30,8697,O
microg/kg/day,8697,O
(,8697,O
P,8697,O
<,8697,O
0.05,8697,O
),8697,O
.,8697,O
Decreased,8698,O
body,8698,O
weight,8698,O
gain,8698,O
was,8698,O
associated,8698,O
with,8698,O
a,8698,O
significant,8698,O
decrease,8698,O
in,8698,O
fat,8698,O
mass,8698,O
(,8698,O
P,8698,O
<,8698,O
0.05,8698,O
),8698,O
with,8698,O
sparing,8698,O
of,8698,O
lean,8698,O
tissue,8698,O
.,8698,O
Plasma,8699,O
cholesterol,8699,B-CHEMICAL
",",8699,O
triglycerides,8699,B-CHEMICAL
and,8699,O
insulin,8699,B-GENE-N
were,8699,O
also,8699,O
significantly,8699,O
reduced,8699,O
(,8699,O
P,8699,O
<,8699,O
0.05,8699,O
),8699,O
.,8699,O
Exenatide,8700,O
at,8700,O
10,8700,O
microg/kg,8700,O
significantly,8700,O
reduced,8700,O
food,8700,O
intake,8700,O
(,8700,O
P,8700,O
<,8700,O
0.05,8700,O
),8700,O
but,8700,O
failed,8700,O
to,8700,O
induce,8700,O
kaolin,8700,B-CHEMICAL
intake,8700,O
.,8700,O
In,8701,O
general,8701,O
",",8701,O
locomotor,8701,O
activity,8701,O
was,8701,O
reduced,8701,O
at,8701,O
doses,8701,O
of,8701,O
exenatide,8701,O
that,8701,O
decreased,8701,O
food,8701,O
intake,8701,O
",",8701,O
although,8701,O
a,8701,O
slightly,8701,O
higher,8701,O
dose,8701,O
was,8701,O
required,8701,O
to,8701,O
produce,8701,O
significant,8701,O
changes,8701,O
in,8701,O
activity,8701,O
.,8701,O
CONCLUSION,8702,O
:,8702,O
Systemic,8702,O
exenatide,8702,O
reduces,8702,O
body,8702,O
weight,8702,O
gain,8702,O
in,8702,O
normal,8702,O
",",8702,O
high-fat-fed,8702,O
rodents,8702,O
",",8702,O
a,8702,O
model,8702,O
that,8702,O
parallels,8702,O
human,8702,O
genetic,8702,O
variation,8702,O
and,8702,O
food,8702,O
consumption,8702,O
patterns,8702,O
",",8702,O
and,8702,O
may,8702,O
play,8702,O
a,8702,O
role,8702,O
in,8702,O
metabolic,8702,O
pathways,8702,O
mediating,8702,O
food,8702,O
intake,8702,O
.,8702,O
Different,8703,O
effects,8703,O
of,8703,O
clopidogrel,8703,B-CHEMICAL
and,8703,O
clarithromycin,8703,B-CHEMICAL
on,8703,O
the,8703,O
enantioselective,8703,O
pharmacokinetics,8703,O
of,8703,O
sibutramine,8703,B-CHEMICAL
and,8703,O
its,8703,O
active,8703,O
metabolites,8703,O
in,8703,O
healthy,8703,O
subjects,8703,O
.,8703,O
In,8704,O
this,8704,O
study,8704,O
",",8704,O
we,8704,O
assessed,8704,O
the,8704,O
effects,8704,O
of,8704,O
clopidogrel,8704,B-CHEMICAL
and,8704,O
clarithromycin,8704,B-CHEMICAL
",",8704,O
known,8704,O
CYP2B6,8704,B-GENE-Y
and,8704,O
CYP3A,8704,B-GENE-N
inhibitors,8704,O
",",8704,O
respectively,8704,O
",",8704,O
on,8704,O
the,8704,O
enantioselective,8704,O
disposition,8704,O
of,8704,O
racemic,8704,B-CHEMICAL
sibutramine,8704,I-CHEMICAL
in,8704,O
conjunction,8704,O
with,8704,O
CYP2B6,8704,B-GENE-Y
polymorphisms,8704,O
in,8704,O
humans,8704,O
.,8704,O
Sibutramine,8705,B-CHEMICAL
showed,8705,O
enantioselective,8705,O
plasma,8705,O
profiles,8705,O
with,8705,O
consistently,8705,O
higher,8705,O
concentrations,8705,O
of,8705,O
R-enantiomers,8705,O
.,8705,O
Clopidogrel,8706,B-CHEMICAL
and,8706,O
clarithromycin,8706,B-CHEMICAL
significantly,8706,O
increased,8706,O
the,8706,O
sibutramine,8706,B-CHEMICAL
plasma,8706,O
concentration,8706,O
",",8706,O
but,8706,O
their,8706,O
effects,8706,O
differed,8706,O
between,8706,O
enantiomers,8706,O
;,8706,O
a,8706,O
2.2-fold,8706,O
versus,8706,O
4.1-fold,8706,O
increase,8706,O
in,8706,O
the,8706,O
AUC,8706,O
in,8706,O
S-enantiomer,8706,O
and,8706,O
1.8-fold,8706,O
versus,8706,O
2.0-fold,8706,O
for,8706,O
the,8706,O
R-enantiomer,8706,O
",",8706,O
respectively,8706,O
.,8706,O
The,8707,O
AUCs,8707,O
of,8707,O
S-,8707,O
and,8707,O
R-desmethyl,8707,O
metabolites,8707,O
changed,8707,O
significantly,8707,O
during,8707,O
the,8707,O
clopidogrel,8707,B-CHEMICAL
phase,8707,O
(,8707,O
P,8707,O
<,8707,O
.001,8707,O
and,8707,O
P,8707,O
<,8707,O
.001,8707,O
",",8707,O
respectively,8707,O
),8707,O
but,8707,O
not,8707,O
during,8707,O
the,8707,O
clarithromycin,8707,B-CHEMICAL
phase,8707,O
(,8707,O
P,8707,O
=,8707,O
.099,8707,O
and,8707,O
P,8707,O
=,8707,O
.090,8707,O
",",8707,O
respectively,8707,O
),8707,O
.,8707,O
Exposure,8708,O
to,8708,O
sibutramine,8708,B-CHEMICAL
was,8708,O
higher,8708,O
in,8708,O
subjects,8708,O
with,8708,O
the,8708,O
CYP2B6,8708,B-GENE-Y
*,8708,O
6/,8708,O
*,8708,O
6,8708,O
genotype,8708,O
",",8708,O
but,8708,O
no,8708,O
statistical,8708,O
difference,8708,O
was,8708,O
observed,8708,O
among,8708,O
the,8708,O
CYP2B6,8708,B-GENE-Y
genotypes,8708,O
.,8708,O
These,8709,O
results,8709,O
suggest,8709,O
that,8709,O
the,8709,O
enantioselective,8709,O
disposition,8709,O
of,8709,O
sibutramine,8709,B-CHEMICAL
and,8709,O
its,8709,O
active,8709,O
metabolites,8709,O
are,8709,O
influenced,8709,O
by,8709,O
the,8709,O
altered,8709,O
genetic,8709,O
and,8709,O
environmental,8709,O
factors,8709,O
of,8709,O
CYP2B6,8709,B-GENE-Y
and,8709,O
CYP3A,8709,B-GENE-N
activity,8709,O
in,8709,O
vivo,8709,O
.,8709,O
New,8710,O
selective,8710,O
inhibitors,8710,O
of,8710,O
MMP-13,8710,B-GENE-Y
for,8710,O
inflammatory,8710,O
diseases,8710,O
:,8710,O
a,8710,O
patent,8710,O
evaluation,8710,O
(,8710,O
W02012151158,8710,O
),8710,O
.,8710,O
A,8711,O
series,8711,O
of,8711,O
compounds,8711,O
incorporating,8711,O
an,8711,O
aromatic,8711,O
scaffold,8711,O
based,8711,O
on,8711,O
isoxazolines,8711,B-CHEMICAL
were,8711,O
prepared,8711,O
in,8711,O
the,8711,O
patent,8711,O
application,8711,O
(,8711,O
WO2012151158,8711,O
),8711,O
.,8711,O
The,8712,O
new,8712,O
compounds,8712,O
from,8712,O
the,8712,O
patent,8712,O
are,8712,O
defined,8712,O
to,8712,O
be,8712,O
biologically,8712,O
active,8712,O
metabolites,8712,O
",",8712,O
prodrugs,8712,O
",",8712,O
isomers,8712,O
",",8712,O
stereoisomers,8712,O
",",8712,O
solvates,8712,O
",",8712,O
hydrates,8712,O
and,8712,O
pharmaceutically,8712,O
acceptable,8712,O
salts,8712,O
",",8712,O
they,8712,O
are,8712,O
claimed,8712,O
to,8712,O
be,8712,O
useful,8712,O
for,8712,O
treating,8712,O
immunological,8712,O
conditions,8712,O
because,8712,O
of,8712,O
their,8712,O
inhibitory,8712,O
activities,8712,O
on,8712,O
matrix,8712,B-GENE-N
metalloproteinase,8712,I-GENE-N
(,8712,O
MMP-13,8712,B-GENE-Y
),8712,O
",",8712,O
although,8712,O
no,8712,O
specific,8712,O
MMP-13,8712,B-GENE-Y
inhibition,8712,O
data,8712,O
or,8712,O
other,8712,O
rationale,8712,O
to,8712,O
explain,8712,O
their,8712,O
biological,8712,O
effects,8712,O
is,8712,O
provided,8712,O
.,8712,O
The,8713,O
compounds,8713,O
have,8713,O
a,8713,O
broad,8713,O
potential,8713,O
utility,8713,O
with,8713,O
osteoarthritis,8713,O
",",8713,O
rheumatoid,8713,O
arthritis,8713,O
",",8713,O
juvenile,8713,O
arthritis,8713,O
",",8713,O
psoriatic,8713,O
arthritis,8713,O
",",8713,O
degenerative,8713,O
joint,8713,O
disease,8713,O
or,8713,O
systemic,8713,O
lupus,8713,O
erythematosus,8713,O
among,8713,O
the,8713,O
likely,8713,O
preferred,8713,O
indications,8713,O
.,8713,O
LIVER,8714,B-GENE-N
X,8714,I-GENE-N
RECEPTORS,8714,I-GENE-N
",",8714,O
NERVOUS,8714,O
SYSTEM,8714,O
AND,8714,O
LIPID,8714,O
METABOLISM,8714,O
.,8714,O
Lipids,8715,O
in,8715,O
the,8715,O
nervous,8715,O
system,8715,O
are,8715,O
represented,8715,O
by,8715,O
cholesterol,8715,B-CHEMICAL
and,8715,O
phospholipids,8715,O
as,8715,O
constituents,8715,O
of,8715,O
cell,8715,O
membranes,8715,O
and,8715,O
",",8715,O
in,8715,O
particular,8715,O
",",8715,O
of,8715,O
myelin,8715,O
.,8715,O
Therefore,8716,O
",",8716,O
lipids,8716,O
are,8716,O
finely,8716,O
regulated,8716,O
to,8716,O
guarantee,8716,O
physiological,8716,O
functions,8716,O
.,8716,O
In,8717,O
the,8717,O
central,8717,O
nervous,8717,O
system,8717,O
",",8717,O
cholesterol,8717,B-CHEMICAL
is,8717,O
locally,8717,O
synthesized,8717,O
due,8717,O
to,8717,O
the,8717,O
presence,8717,O
of,8717,O
the,8717,O
blood,8717,O
brain,8717,O
barrier,8717,O
.,8717,O
In,8718,O
the,8718,O
peripheral,8718,O
nervous,8718,O
system,8718,O
cholesterol,8718,B-CHEMICAL
is,8718,O
either,8718,O
uptaken,8718,O
by,8718,O
lipoproteins,8718,O
and/or,8718,O
produced,8718,O
by,8718,O
de,8718,O
novo,8718,O
biosynthesis,8718,O
.,8718,O
Defects,8719,O
in,8719,O
lipid,8719,O
homeostasis,8719,O
in,8719,O
these,8719,O
tissues,8719,O
lead,8719,O
to,8719,O
structural,8719,O
and,8719,O
functional,8719,O
changes,8719,O
that,8719,O
often,8719,O
result,8719,O
in,8719,O
different,8719,O
pathological,8719,O
conditions,8719,O
depending,8719,O
on,8719,O
the,8719,O
affected,8719,O
pathways,8719,O
(,8719,O
i.e,8719,O
.,8719,O
cholesterol,8720,B-CHEMICAL
biosynthesis,8720,O
",",8720,O
cholesterol,8720,B-CHEMICAL
efflux,8720,O
",",8720,O
fatty,8720,B-CHEMICAL
acid,8720,I-CHEMICAL
biosynthesis,8720,O
etc,8720,O
.,8720,O
),8720,O
.,8720,O
Alterations,8721,O
in,8721,O
cholesterol,8721,B-CHEMICAL
metabolism,8721,O
in,8721,O
the,8721,O
central,8721,O
nervous,8721,O
system,8721,O
are,8721,O
linked,8721,O
to,8721,O
several,8721,O
disorders,8721,O
such,8721,O
as,8721,O
Alzheimer,8721,O
's,8721,O
disease,8721,O
",",8721,O
Huntington,8721,O
disease,8721,O
",",8721,O
Parkinson,8721,O
disease,8721,O
",",8721,O
Multiple,8721,O
Sclerosis,8721,O
",",8721,O
Smith-Lemli-Opitz,8721,O
syndrome,8721,O
",",8721,O
Niemann-Pick,8721,O
type,8721,O
C,8721,O
disease,8721,O
",",8721,O
and,8721,O
glioblastoma,8721,O
.,8721,O
In,8722,O
the,8722,O
peripheral,8722,O
nervous,8722,O
system,8722,O
changes,8722,O
in,8722,O
lipid,8722,O
metabolism,8722,O
are,8722,O
associated,8722,O
with,8722,O
the,8722,O
development,8722,O
of,8722,O
peripheral,8722,O
neuropathy,8722,O
that,8722,O
may,8722,O
be,8722,O
caused,8722,O
by,8722,O
metabolic,8722,O
disorders,8722,O
",",8722,O
injuries,8722,O
",",8722,O
therapeutics,8722,O
and,8722,O
autoimmune,8722,O
diseases,8722,O
.,8722,O
Transcription,8723,O
factors,8723,O
",",8723,O
such,8723,O
as,8723,O
the,8723,O
Liver,8723,B-GENE-N
X,8723,I-GENE-N
receptors,8723,I-GENE-N
(,8723,O
LXRs,8723,B-GENE-N
),8723,O
",",8723,O
regulate,8723,O
both,8723,O
cholesterol,8723,B-CHEMICAL
and,8723,O
fatty,8723,B-CHEMICAL
acid,8723,I-CHEMICAL
metabolism,8723,O
in,8723,O
several,8723,O
tissues,8723,O
including,8723,O
the,8723,O
nervous,8723,O
system,8723,O
.,8723,O
In,8724,O
the,8724,O
last,8724,O
few,8724,O
years,8724,O
several,8724,O
studies,8724,O
elucidated,8724,O
the,8724,O
biology,8724,O
of,8724,O
LXRs,8724,B-GENE-N
in,8724,O
nervous,8724,O
system,8724,O
due,8724,O
to,8724,O
the,8724,O
availability,8724,O
of,8724,O
knock-out,8724,O
mice,8724,O
and,8724,O
the,8724,O
development,8724,O
of,8724,O
synthetic,8724,O
ligands,8724,O
.,8724,O
Here,8725,O
",",8725,O
we,8725,O
review,8725,O
a,8725,O
survey,8725,O
of,8725,O
the,8725,O
literature,8725,O
focused,8725,O
on,8725,O
central,8725,O
and,8725,O
peripheral,8725,O
nervous,8725,O
system,8725,O
and,8725,O
in,8725,O
physiological,8725,O
and,8725,O
pathological,8725,O
settings,8725,O
with,8725,O
particular,8725,O
attention,8725,O
on,8725,O
the,8725,O
roles,8725,O
played,8725,O
by,8725,O
LXRs,8725,B-GENE-N
in,8725,O
both,8725,O
districts,8725,O
.,8725,O
Cysteinyl,8726,B-CHEMICAL
leukotriene-dependent,8726,O
interleukin-5,8726,B-GENE-Y
production,8726,O
leading,8726,O
to,8726,O
eosinophilia,8726,O
during,8726,O
late,8726,O
asthmatic,8726,O
response,8726,O
in,8726,O
guinea-pigs,8726,O
.,8726,O
BACKGROUND,8727,O
:,8727,O
Allergic,8727,O
airway,8727,O
eosinophilia,8727,O
is,8727,O
suppressed,8727,O
by,8727,O
cysteinyl,8727,B-GENE-Y
leukotriene,8727,I-GENE-Y
(,8727,I-GENE-Y
CysLT,8727,I-GENE-Y
),8727,I-GENE-Y
receptor,8727,I-GENE-Y
(,8727,O
CysLT1,8727,B-GENE-Y
receptor,8727,O
),8727,O
antagonists,8727,O
in,8727,O
several,8727,O
species,8727,O
including,8727,O
humans,8727,O
and,8727,O
guinea-pigs,8727,O
",",8727,O
suggesting,8727,O
that,8727,O
CysLTs,8727,B-CHEMICAL
are,8727,O
directly,8727,O
or,8727,O
indirectly,8727,O
involved,8727,O
in,8727,O
induction,8727,O
of,8727,O
the,8727,O
response,8727,O
.,8727,O
OBJECTIVE,8728,O
:,8728,O
We,8728,O
examined,8728,O
the,8728,O
effect,8728,O
of,8728,O
CysLT,8728,B-CHEMICAL
antagonists,8728,O
(,8728,O
pranlukast,8728,B-CHEMICAL
and,8728,O
MCI-826,8728,B-CHEMICAL
),8728,O
on,8728,O
antigen,8728,O
inhalation-induced,8728,O
eosinophilia,8728,O
in,8728,O
peripheral,8728,O
blood,8728,O
and,8728,O
lung,8728,O
",",8728,O
and,8728,O
on,8728,O
IL-5,8728,B-GENE-Y
activity,8728,O
in,8728,O
serum,8728,O
during,8728,O
late,8728,O
increase,8728,O
of,8728,O
airway,8728,O
resistance,8728,O
(,8728,O
late,8728,O
asthmatic,8728,O
response,8728,O
",",8728,O
LAR,8728,O
),8728,O
in,8728,O
sensitized,8728,O
guinea-pigs,8728,O
.,8728,O
METHODS,8729,O
:,8729,O
Guinea-pigs,8729,O
inhaled,8729,O
ovalbumin,8729,B-GENE-Y
(,8729,O
OVA,8729,B-GENE-Y
),8729,O
+,8729,O
Al,8729,B-CHEMICAL
(,8729,I-CHEMICAL
OH,8729,I-CHEMICAL
),8729,I-CHEMICAL
3,8729,I-CHEMICAL
and,8729,O
OVA,8729,B-GENE-Y
mists,8729,O
alternately,8729,O
for,8729,O
sensitization,8729,O
and,8729,O
challenge,8729,O
",",8729,O
respectively,8729,O
",",8729,O
once,8729,O
every,8729,O
2,8729,O
weeks,8729,O
.,8729,O
At,8730,O
the,8730,O
fifth,8730,O
challenge,8730,O
",",8730,O
the,8730,O
effects,8730,O
of,8730,O
CysLT,8730,B-CHEMICAL
antagonists,8730,O
and,8730,O
an,8730,O
anti-IL-5,8730,O
antibody,8730,O
(,8730,O
TRFK-5,8730,O
),8730,O
on,8730,O
the,8730,O
occurrence,8730,O
of,8730,O
LAR,8730,O
",",8730,O
and,8730,O
blood,8730,O
and,8730,O
lung,8730,O
eosinophilia,8730,O
",",8730,O
which,8730,O
appeared,8730,O
at,8730,O
5,8730,O
h,8730,O
after,8730,O
challenge,8730,O
",",8730,O
were,8730,O
examined,8730,O
.,8730,O
The,8731,O
time-course,8731,O
of,8731,O
IL-5,8731,B-GENE-Y
activity,8731,O
in,8731,O
the,8731,O
serum,8731,O
after,8731,O
the,8731,O
challenge,8731,O
was,8731,O
evaluated,8731,O
by,8731,O
measuring,8731,O
in,8731,O
vitro,8731,O
'eosinophil,8731,O
survival,8731,O
prolongation,8731,O
activity,8731,O
',8731,O
.,8731,O
The,8732,O
influence,8732,O
of,8732,O
CysLT,8732,B-CHEMICAL
antagonists,8732,O
on,8732,O
IL-5,8732,B-GENE-Y
activity,8732,O
was,8732,O
assessed,8732,O
.,8732,O
RESULTS,8733,O
:,8733,O
CysLT,8733,B-CHEMICAL
antagonists,8733,O
and,8733,O
TRFK-5,8733,O
completely,8733,O
abolished,8733,O
blood,8733,O
and,8733,O
lung,8733,O
eosinophilia,8733,O
.,8733,O
LAR,8734,O
was,8734,O
suppressed,8734,O
by,8734,O
both,8734,O
MCI-826,8734,B-CHEMICAL
and,8734,O
TRFK-5,8734,O
by,8734,O
40-50,8734,O
%,8734,O
.,8734,O
Sera,8735,O
obtained,8735,O
from,8735,O
sensitized,8735,O
",",8735,O
challenged,8735,O
animals,8735,O
3,8735,O
h,8735,O
and,8735,O
4,8735,O
h,8735,O
after,8735,O
challenge,8735,O
induced,8735,O
an,8735,O
obvious,8735,O
prolongation,8735,O
of,8735,O
eosinophil,8735,O
survival,8735,O
.,8735,O
The,8736,O
activity,8736,O
of,8736,O
the,8736,O
sera,8736,O
was,8736,O
completely,8736,O
neutralized,8736,O
by,8736,O
prior,8736,O
exposure,8736,O
to,8736,O
TRFK-5,8736,O
",",8736,O
suggesting,8736,O
that,8736,O
it,8736,O
reflected,8736,O
IL-5,8736,B-GENE-Y
activity,8736,O
.,8736,O
Increased,8737,O
IL-5,8737,B-GENE-Y
activity,8737,O
in,8737,O
the,8737,O
serum,8737,O
was,8737,O
inhibited,8737,O
by,8737,O
both,8737,O
pranlukast,8737,B-CHEMICAL
and,8737,O
MCI-826,8737,B-CHEMICAL
by,8737,O
over,8737,O
90,8737,O
%,8737,O
.,8737,O
CONCLUSIONS,8738,O
:,8738,O
CysLTs,8738,B-CHEMICAL
produced,8738,O
after,8738,O
antigen,8738,O
provocation,8738,O
sequentially,8738,O
induced,8738,O
IL-5,8738,B-GENE-Y
production,8738,O
from,8738,O
some,8738,O
immune,8738,O
component,8738,O
cells,8738,O
via,8738,O
CysLT1,8738,B-GENE-Y
receptor,8738,O
activation,8738,O
.,8738,O
Thus,8739,O
",",8739,O
it,8739,O
is,8739,O
likely,8739,O
that,8739,O
CysLTs,8739,B-CHEMICAL
indirectly,8739,O
cause,8739,O
antigen-induced,8739,O
eosinophilia,8739,O
through,8739,O
IL-5,8739,B-GENE-Y
production,8739,O
.,8739,O
Theoretical,8740,O
study,8740,O
of,8740,O
the,8740,O
decomposition,8740,O
of,8740,O
ethyl,8740,B-CHEMICAL
and,8740,I-CHEMICAL
ethyl,8740,I-CHEMICAL
3-phenyl,8740,I-CHEMICAL
glycidate,8740,I-CHEMICAL
.,8740,O
The,8741,O
mechanism,8741,O
of,8741,O
the,8741,O
decomposition,8741,O
of,8741,O
ethyl,8741,B-CHEMICAL
and,8741,I-CHEMICAL
ethyl,8741,I-CHEMICAL
3-phenyl,8741,I-CHEMICAL
glycidate,8741,I-CHEMICAL
in,8741,O
gas,8741,O
phase,8741,O
was,8741,O
studied,8741,O
by,8741,O
density,8741,O
functional,8741,O
theory,8741,O
(,8741,O
DFT,8741,O
),8741,O
and,8741,O
MP2,8741,O
methods,8741,O
.,8741,O
A,8742,O
proposed,8742,O
mechanism,8742,O
for,8742,O
the,8742,O
reaction,8742,O
indicates,8742,O
that,8742,O
the,8742,O
ethyl,8742,B-CHEMICAL
side,8742,O
of,8742,O
the,8742,O
ester,8742,O
is,8742,O
eliminated,8742,O
as,8742,O
ethylene,8742,B-CHEMICAL
through,8742,O
a,8742,O
concerted,8742,O
six-membered,8742,O
cyclic,8742,O
transition,8742,O
state,8742,O
",",8742,O
and,8742,O
the,8742,O
unstable,8742,O
intermediate,8742,O
glycidic,8742,B-CHEMICAL
acid,8742,I-CHEMICAL
decarboxylates,8742,O
rapidly,8742,O
to,8742,O
give,8742,O
the,8742,O
corresponding,8742,O
aldehyde,8742,B-CHEMICAL
.,8742,O
Two,8743,O
possible,8743,O
pathways,8743,O
for,8743,O
glycidic,8743,B-CHEMICAL
acid,8743,I-CHEMICAL
decarboxylation,8743,O
were,8743,O
studied,8743,O
:,8743,O
one,8743,O
via,8743,O
a,8743,O
five-membered,8743,O
cyclic,8743,O
transition,8743,O
state,8743,O
",",8743,O
and,8743,O
the,8743,O
other,8743,O
via,8743,O
a,8743,O
four-membered,8743,O
cyclic,8743,O
transition,8743,O
state,8743,O
.,8743,O
The,8744,O
results,8744,O
of,8744,O
the,8744,O
calculations,8744,O
indicate,8744,O
that,8744,O
the,8744,O
decarboxylation,8744,O
reaction,8744,O
occurs,8744,O
via,8744,O
a,8744,O
mechanism,8744,O
with,8744,O
five-membered,8744,O
cyclic,8744,O
transition,8744,O
state,8744,O
.,8744,O
Meclofenamic,8745,B-CHEMICAL
acid,8745,I-CHEMICAL
and,8745,O
diclofenac,8745,B-CHEMICAL
",",8745,O
novel,8745,O
templates,8745,O
of,8745,O
KCNQ2/Q3,8745,B-GENE-N
potassium,8745,B-GENE-N
channel,8745,I-GENE-N
openers,8745,O
",",8745,O
depress,8745,O
cortical,8745,O
neuron,8745,O
activity,8745,O
and,8745,O
exhibit,8745,O
anticonvulsant,8745,O
properties,8745,O
.,8745,O
The,8746,O
voltage-dependent,8746,O
M-type,8746,O
potassium,8746,B-CHEMICAL
current,8746,O
(,8746,O
M-current,8746,O
),8746,O
plays,8746,O
a,8746,O
major,8746,O
role,8746,O
in,8746,O
controlling,8746,O
brain,8746,O
excitability,8746,O
by,8746,O
stabilizing,8746,O
the,8746,O
membrane,8746,O
potential,8746,O
and,8746,O
acting,8746,O
as,8746,O
a,8746,O
brake,8746,O
for,8746,O
neuronal,8746,O
firing,8746,O
.,8746,O
The,8747,O
KCNQ2/Q3,8747,B-GENE-N
heteromeric,8747,O
channel,8747,O
complex,8747,O
was,8747,O
identified,8747,O
as,8747,O
the,8747,O
molecular,8747,O
correlate,8747,O
of,8747,O
the,8747,O
M-current,8747,O
.,8747,O
Furthermore,8748,O
",",8748,O
the,8748,O
KCNQ2,8748,B-GENE-Y
and,8748,O
KCNQ3,8748,B-GENE-Y
channel,8748,I-GENE-Y
alpha,8748,I-GENE-Y
subunits,8748,I-GENE-Y
are,8748,O
mutated,8748,O
in,8748,O
families,8748,O
with,8748,O
benign,8748,O
familial,8748,O
neonatal,8748,O
convulsions,8748,O
",",8748,O
a,8748,O
neonatal,8748,O
form,8748,O
of,8748,O
epilepsy,8748,O
.,8748,O
Enhancement,8749,O
of,8749,O
KCNQ2/Q3,8749,B-GENE-N
potassium,8749,B-CHEMICAL
currents,8749,O
may,8749,O
provide,8749,O
an,8749,O
important,8749,O
target,8749,O
for,8749,O
antiepileptic,8749,O
drug,8749,O
development,8749,O
.,8749,O
Here,8750,O
",",8750,O
we,8750,O
show,8750,O
that,8750,O
meclofenamic,8750,B-CHEMICAL
acid,8750,I-CHEMICAL
(,8750,O
meclofenamate,8750,B-CHEMICAL
),8750,O
and,8750,O
diclofenac,8750,B-CHEMICAL
",",8750,O
two,8750,O
related,8750,O
molecules,8750,O
previously,8750,O
used,8750,O
as,8750,O
anti-inflammatory,8750,O
drugs,8750,O
",",8750,O
act,8750,O
as,8750,O
novel,8750,O
KCNQ2/Q3,8750,B-GENE-N
channel,8750,O
openers,8750,O
.,8750,O
Extracellular,8751,O
application,8751,O
of,8751,O
meclofenamate,8751,B-CHEMICAL
(,8751,O
EC,8751,O
(,8751,O
50,8751,O
),8751,O
=,8751,O
25,8751,O
microM,8751,O
),8751,O
and,8751,O
diclofenac,8751,B-CHEMICAL
(,8751,O
EC,8751,O
(,8751,O
50,8751,O
),8751,O
=,8751,O
2.6,8751,O
microM,8751,O
),8751,O
resulted,8751,O
in,8751,O
the,8751,O
activation,8751,O
of,8751,O
KCNQ2/Q3,8751,B-GENE-N
K,8751,O
(,8751,O
+,8751,O
),8751,O
currents,8751,O
",",8751,O
heterologously,8751,O
expressed,8751,O
in,8751,O
Chinese,8751,O
hamster,8751,O
ovary,8751,O
cells,8751,O
.,8751,O
Both,8752,O
openers,8752,O
activated,8752,O
KCNQ2/Q3,8752,B-GENE-N
channels,8752,O
by,8752,O
causing,8752,O
a,8752,O
hyperpolarizing,8752,O
shift,8752,O
of,8752,O
the,8752,O
voltage,8752,O
activation,8752,O
curve,8752,O
(,8752,O
-23,8752,O
and,8752,O
-15,8752,O
mV,8752,O
",",8752,O
respectively,8752,O
),8752,O
and,8752,O
by,8752,O
markedly,8752,O
slowing,8752,O
the,8752,O
deactivation,8752,O
kinetics,8752,O
.,8752,O
The,8753,O
effects,8753,O
of,8753,O
the,8753,O
drugs,8753,O
were,8753,O
stronger,8753,O
on,8753,O
KCNQ2,8753,B-GENE-Y
than,8753,O
on,8753,O
KCNQ3,8753,B-GENE-Y
channel,8753,I-GENE-Y
alpha,8753,I-GENE-Y
subunits,8753,I-GENE-Y
.,8753,O
In,8754,O
contrast,8754,O
",",8754,O
they,8754,O
did,8754,O
not,8754,O
enhance,8754,O
KCNQ1,8754,B-GENE-Y
K,8754,O
(,8754,O
+,8754,O
),8754,O
currents,8754,O
.,8754,O
Both,8755,O
openers,8755,O
increased,8755,O
KCNQ2/Q3,8755,B-GENE-N
current,8755,O
amplitude,8755,O
at,8755,O
physiologically,8755,O
relevant,8755,O
potentials,8755,O
and,8755,O
led,8755,O
to,8755,O
hyperpolarization,8755,O
of,8755,O
the,8755,O
resting,8755,O
membrane,8755,O
potential,8755,O
.,8755,O
In,8756,O
cultured,8756,O
cortical,8756,O
neurons,8756,O
",",8756,O
meclofenamate,8756,B-CHEMICAL
and,8756,O
diclofenac,8756,B-CHEMICAL
enhanced,8756,O
the,8756,O
M-current,8756,O
and,8756,O
reduced,8756,O
evoked,8756,O
and,8756,O
spontaneous,8756,O
action,8756,O
potentials,8756,O
",",8756,O
whereas,8756,O
in,8756,O
vivo,8756,O
diclofenac,8756,B-CHEMICAL
exhibited,8756,O
an,8756,O
anticonvulsant,8756,O
activity,8756,O
(,8756,O
ED,8756,O
(,8756,O
50,8756,O
),8756,O
=,8756,O
43,8756,O
mg/kg,8756,O
),8756,O
.,8756,O
These,8757,O
compounds,8757,O
potentially,8757,O
constitute,8757,O
novel,8757,O
drug,8757,O
templates,8757,O
for,8757,O
the,8757,O
treatment,8757,O
of,8757,O
neuronal,8757,O
hyperexcitability,8757,O
including,8757,O
epilepsy,8757,O
",",8757,O
migraine,8757,O
",",8757,O
or,8757,O
neuropathic,8757,O
pain,8757,O
.,8757,O
Atomoxetine,8758,B-CHEMICAL
increases,8758,O
extracellular,8758,O
levels,8758,O
of,8758,O
norepinephrine,8758,B-CHEMICAL
and,8758,O
dopamine,8758,B-CHEMICAL
in,8758,O
prefrontal,8758,O
cortex,8758,O
of,8758,O
rat,8758,O
:,8758,O
a,8758,O
potential,8758,O
mechanism,8758,O
for,8758,O
efficacy,8758,O
in,8758,O
attention,8758,O
deficit/hyperactivity,8758,O
disorder,8758,O
.,8758,O
The,8759,O
selective,8759,O
norepinephrine,8759,B-GENE-Y
(,8759,I-GENE-Y
NE,8759,I-GENE-Y
),8759,I-GENE-Y
transporter,8759,I-GENE-Y
inhibitor,8759,O
atomoxetine,8759,B-CHEMICAL
(,8759,O
formerly,8759,O
called,8759,O
tomoxetine,8759,B-CHEMICAL
or,8759,O
LY139603,8759,B-CHEMICAL
),8759,O
has,8759,O
been,8759,O
shown,8759,O
to,8759,O
alleviate,8759,O
symptoms,8759,O
in,8759,O
Attention,8759,O
Deficit/Hyperactivity,8759,O
Disorder,8759,O
(,8759,O
ADHD,8759,O
),8759,O
.,8759,O
We,8760,O
investigated,8760,O
the,8760,O
mechanism,8760,O
of,8760,O
action,8760,O
of,8760,O
atomoxetine,8760,B-CHEMICAL
in,8760,O
ADHD,8760,O
by,8760,O
evaluating,8760,O
the,8760,O
interaction,8760,O
of,8760,O
atomoxetine,8760,B-CHEMICAL
with,8760,O
monoamine,8760,B-GENE-N
transporters,8760,I-GENE-N
",",8760,O
the,8760,O
effects,8760,O
on,8760,O
extracellular,8760,O
levels,8760,O
of,8760,O
monoamines,8760,B-CHEMICAL
",",8760,O
and,8760,O
the,8760,O
expression,8760,O
of,8760,O
the,8760,O
neuronal,8760,O
activity,8760,O
marker,8760,O
Fos,8760,B-GENE-Y
in,8760,O
brain,8760,O
regions,8760,O
.,8760,O
Atomoxetine,8761,B-CHEMICAL
inhibited,8761,O
binding,8761,O
of,8761,O
radioligands,8761,O
to,8761,O
clonal,8761,O
cell,8761,O
lines,8761,O
transfected,8761,O
with,8761,O
human,8761,B-GENE-N
NE,8761,I-GENE-N
",",8761,I-GENE-N
serotonin,8761,I-GENE-N
(,8761,I-GENE-N
5-HT,8761,I-GENE-N
),8761,I-GENE-N
and,8761,I-GENE-N
dopamine,8761,I-GENE-N
(,8761,I-GENE-N
DA,8761,I-GENE-N
),8761,I-GENE-N
transporters,8761,I-GENE-N
with,8761,O
dissociation,8761,O
constants,8761,O
(,8761,O
K,8761,O
(,8761,O
i,8761,O
),8761,O
),8761,O
values,8761,O
of,8761,O
5,8761,O
",",8761,O
77,8761,O
and,8761,O
1451,8761,O
nM,8761,O
",",8761,O
respectively,8761,O
",",8761,O
demonstrating,8761,O
selectivity,8761,O
for,8761,O
NE,8761,B-GENE-Y
transporters,8761,I-GENE-Y
.,8761,O
In,8762,O
microdialysis,8762,O
studies,8762,O
",",8762,O
atomoxetine,8762,B-CHEMICAL
increased,8762,O
extracellular,8762,O
(,8762,O
EX,8762,O
),8762,O
levels,8762,O
of,8762,O
NE,8762,B-CHEMICAL
in,8762,O
prefrontal,8762,O
cortex,8762,O
(,8762,O
PFC,8762,O
),8762,O
3-fold,8762,O
",",8762,O
but,8762,O
did,8762,O
not,8762,O
alter,8762,O
5-HT,8762,O
(,8762,O
EX,8762,O
),8762,O
levels,8762,O
.,8762,O
Atomoxetine,8763,B-CHEMICAL
also,8763,O
increased,8763,O
DA,8763,O
(,8763,O
EX,8763,O
),8763,O
concentrations,8763,O
in,8763,O
PFC,8763,O
3-fold,8763,O
",",8763,O
but,8763,O
did,8763,O
not,8763,O
alter,8763,O
DA,8763,O
(,8763,O
EX,8763,O
),8763,O
in,8763,O
striatum,8763,O
or,8763,O
nucleus,8763,O
accumbens,8763,O
.,8763,O
In,8764,O
contrast,8764,O
",",8764,O
the,8764,O
psychostimulant,8764,O
methylphenidate,8764,B-CHEMICAL
",",8764,O
which,8764,O
is,8764,O
used,8764,O
in,8764,O
ADHD,8764,O
therapy,8764,O
",",8764,O
increased,8764,O
NE,8764,O
(,8764,O
EX,8764,O
),8764,O
and,8764,O
DA,8764,O
(,8764,O
EX,8764,O
),8764,O
equally,8764,O
in,8764,O
PFC,8764,O
",",8764,O
but,8764,O
also,8764,O
increased,8764,O
DA,8764,O
(,8764,O
EX,8764,O
),8764,O
in,8764,O
the,8764,O
striatum,8764,O
and,8764,O
nucleus,8764,O
accumbens,8764,O
to,8764,O
the,8764,O
same,8764,O
level,8764,O
.,8764,O
The,8765,O
expression,8765,O
of,8765,O
the,8765,O
neuronal,8765,O
activity,8765,O
marker,8765,O
Fos,8765,B-GENE-Y
was,8765,O
increased,8765,O
3.7-fold,8765,O
in,8765,O
PFC,8765,O
by,8765,O
atomoxetine,8765,B-CHEMICAL
administration,8765,O
",",8765,O
but,8765,O
was,8765,O
not,8765,O
increased,8765,O
in,8765,O
the,8765,O
striatum,8765,O
or,8765,O
nucleus,8765,O
accumbens,8765,O
",",8765,O
consistent,8765,O
with,8765,O
the,8765,O
regional,8765,O
distribution,8765,O
of,8765,O
increased,8765,O
DA,8765,O
(,8765,O
EX,8765,O
),8765,O
.,8765,O
We,8766,O
hypothesize,8766,O
that,8766,O
the,8766,O
atomoxetine-induced,8766,B-CHEMICAL
increase,8766,O
of,8766,O
catecholamines,8766,B-CHEMICAL
in,8766,O
PFC,8766,O
",",8766,O
a,8766,O
region,8766,O
involved,8766,O
in,8766,O
attention,8766,O
and,8766,O
memory,8766,O
",",8766,O
mediates,8766,O
the,8766,O
therapeutic,8766,O
effects,8766,O
of,8766,O
atomoxetine,8766,B-CHEMICAL
in,8766,O
ADHD,8766,O
.,8766,O
In,8767,O
contrast,8767,O
to,8767,O
methylphenidate,8767,B-CHEMICAL
",",8767,O
atomoxetine,8767,B-CHEMICAL
did,8767,O
not,8767,O
increase,8767,O
DA,8767,B-CHEMICAL
in,8767,O
striatum,8767,O
or,8767,O
nucleus,8767,O
accumbens,8767,O
",",8767,O
suggesting,8767,O
it,8767,O
would,8767,O
not,8767,O
have,8767,O
motoric,8767,O
or,8767,O
drug,8767,O
abuse,8767,O
liabilities,8767,O
.,8767,O
Locally,8768,O
administered,8768,O
prostaglandin,8768,B-CHEMICAL
E2,8768,I-CHEMICAL
prevents,8768,O
aeroallergen-induced,8768,O
airway,8768,O
sensitization,8768,O
in,8768,O
mice,8768,O
through,8768,O
immunomodulatory,8768,O
mechanisms,8768,O
.,8768,O
Prostaglandin,8769,B-CHEMICAL
E2,8769,I-CHEMICAL
attenuates,8769,O
airway,8769,O
pathology,8769,O
in,8769,O
asthmatic,8769,O
patients,8769,O
and,8769,O
exerts,8769,O
a,8769,O
protective,8769,O
effect,8769,O
in,8769,O
antigen-sensitized,8769,O
mice,8769,O
when,8769,O
administered,8769,O
systemically,8769,O
.,8769,O
We,8770,O
aimed,8770,O
to,8770,O
establish,8770,O
the,8770,O
consequences,8770,O
of,8770,O
intranasal,8770,O
PGE2,8770,B-CHEMICAL
administration,8770,O
on,8770,O
airway,8770,O
reactivity,8770,O
to,8770,O
aeroallergens,8770,O
in,8770,O
mice,8770,O
and,8770,O
reveal,8770,O
the,8770,O
underlying,8770,O
immunoinflammatory,8770,O
mechanisms,8770,O
.,8770,O
PGE2,8771,B-CHEMICAL
was,8771,O
administered,8771,O
either,8771,O
daily,8771,O
during,8771,O
a,8771,O
10-day,8771,O
exposure,8771,O
to,8771,O
house,8771,O
dust,8771,O
mite,8771,O
(,8771,O
HDM,8771,O
),8771,O
extracts,8771,O
or,8771,O
for,8771,O
limited,8771,O
intervals,8771,O
.,8771,O
Airway,8772,O
hyperreactivity,8772,O
was,8772,O
measured,8772,O
by,8772,O
whole-body,8772,O
and,8772,O
invasive,8772,O
plethysmography,8772,O
.,8772,O
The,8773,O
phenotypes,8773,O
of,8773,O
lung,8773,O
immune,8773,O
cells,8773,O
and,8773,O
cytokine,8773,B-GENE-N
production,8773,O
were,8773,O
analysed,8773,O
by,8773,O
flow,8773,O
cytometry,8773,O
and,8773,O
ELISA,8773,O
",",8773,O
respectively,8773,O
.,8773,O
Airway,8774,O
hyperreactivity,8774,O
was,8774,O
sustainably,8774,O
reduced,8774,O
only,8774,O
when,8774,O
PGE2,8774,B-CHEMICAL
administration,8774,O
was,8774,O
restricted,8774,O
to,8774,O
the,8774,O
initial,8774,O
5,8774,O
days,8774,O
of,8774,O
exposure,8774,O
to,8774,O
HDM,8774,O
.,8774,O
Lung,8775,O
inflammation,8775,O
",",8775,O
IL-4,8775,B-GENE-Y
production,8775,O
",",8775,O
and,8775,O
airway,8775,O
mast,8775,O
cell,8775,O
activity,8775,O
were,8775,O
also,8775,O
prevented,8775,O
under,8775,O
this,8775,O
early,8775,O
short-term,8775,O
treatment,8775,O
with,8775,O
PGE2,8775,B-CHEMICAL
.,8775,O
Interestingly,8776,O
",",8776,O
a,8776,O
Th2,8776,O
response,8776,O
was,8776,O
already,8776,O
committed,8776,O
on,8776,O
day,8776,O
5,8776,O
of,8776,O
exposure,8776,O
to,8776,O
HDM,8776,O
.,8776,O
This,8777,O
was,8777,O
paralleled,8777,O
by,8777,O
GM-CSF,8777,B-GENE-Y
and,8777,O
osteopontin,8777,B-GENE-Y
upregulation,8777,O
and,8777,O
a,8777,O
decreased,8777,O
number,8777,O
of,8777,O
plasmacytoid,8777,O
dendritic,8777,O
and,8777,O
T,8777,O
regulatory,8777,O
cells,8777,O
",",8777,O
as,8777,O
well,8777,O
as,8777,O
a,8777,O
trend,8777,O
towards,8777,O
reduced,8777,O
IL-10,8777,B-GENE-Y
expression,8777,O
.,8777,O
Local,8778,O
PGE2,8778,B-CHEMICAL
administration,8778,O
prevented,8778,O
the,8778,O
increase,8778,O
of,8778,O
airway,8778,O
IL-13,8778,B-GENE-Y
and,8778,O
osteopontin,8778,B-GENE-Y
and,8778,O
kept,8778,O
lung,8778,O
plasmacytoid,8778,O
dendritic,8778,O
cell,8778,O
counts,8778,O
close,8778,O
to,8778,O
baseline,8778,O
.,8778,O
GM-CSF,8779,B-GENE-Y
and,8779,O
Tregs,8779,O
were,8779,O
unaffected,8779,O
by,8779,O
the,8779,O
treatment,8779,O
.,8779,O
These,8780,O
findings,8780,O
suggest,8780,O
that,8780,O
the,8780,O
protection,8780,O
provided,8780,O
by,8780,O
PGE2,8780,B-CHEMICAL
is,8780,O
a,8780,O
result,8780,O
of,8780,O
the,8780,O
modulation,8780,O
of,8780,O
early,8780,O
lung,8780,O
immunomodulatory,8780,O
mechanisms,8780,O
",",8780,O
and,8780,O
possibly,8780,O
a,8780,O
shift,8780,O
in,8780,O
the,8780,O
balance,8780,O
of,8780,O
dendritic,8780,O
cells,8780,O
towards,8780,O
a,8780,O
tolerogenic,8780,O
profile,8780,O
.,8780,O
In,8781,O
vitro,8781,O
investigation,8781,O
of,8781,O
efficacy,8781,O
of,8781,O
new,8781,O
reactivators,8781,O
on,8781,O
OPC,8781,O
inhibited,8781,O
rat,8781,B-GENE-Y
brain,8781,I-GENE-Y
acetylcholinesterase,8781,I-GENE-Y
.,8781,O
Organophosphorus,8782,B-CHEMICAL
compounds,8782,O
(,8782,O
OPC,8782,O
),8782,O
were,8782,O
developed,8782,O
as,8782,O
warfare,8782,O
nerve,8782,O
agents,8782,O
.,8782,O
They,8783,O
are,8783,O
also,8783,O
widely,8783,O
used,8783,O
as,8783,O
pesticides,8783,O
.,8783,O
The,8784,O
drug,8784,O
therapy,8784,O
of,8784,O
intoxication,8784,O
with,8784,O
OPC,8784,O
includes,8784,O
mainly,8784,O
combination,8784,O
of,8784,O
cholinesterase,8784,B-GENE-Y
(,8784,O
ChE,8784,B-GENE-Y
),8784,O
reactivators,8784,O
and,8784,O
cholinolytics,8784,O
.,8784,O
There,8785,O
is,8785,O
no,8785,O
single,8785,O
ChE,8785,B-GENE-Y
reactivator,8785,O
having,8785,O
an,8785,O
ability,8785,O
to,8785,O
reactivate,8785,O
sufficiently,8785,O
the,8785,O
inhibited,8785,O
enzyme,8785,O
due,8785,O
to,8785,O
the,8785,O
high,8785,O
variability,8785,O
of,8785,O
chemical,8785,O
structure,8785,O
of,8785,O
the,8785,O
inhibitors,8785,O
.,8785,O
The,8786,O
difficulties,8786,O
in,8786,O
reactivation,8786,O
of,8786,O
ChE,8786,B-GENE-Y
activity,8786,O
and,8786,O
slight,8786,O
antidote,8786,O
effect,8786,O
regarding,8786,O
intoxication,8786,O
with,8786,O
some,8786,O
OPC,8786,O
are,8786,O
some,8786,O
of,8786,O
the,8786,O
reasons,8786,O
for,8786,O
continuous,8786,O
efforts,8786,O
to,8786,O
obtain,8786,O
new,8786,O
reactivators,8786,O
of,8786,O
ChE,8786,B-GENE-Y
.,8786,O
The,8787,O
aim,8787,O
of,8787,O
the,8787,O
present,8787,O
study,8787,O
was,8787,O
to,8787,O
evaluate,8787,O
the,8787,O
efficacy,8787,O
of,8787,O
some,8787,O
ChE,8787,B-GENE-Y
reactivators,8787,O
against,8787,O
OPC,8787,O
intoxication,8787,O
(,8787,O
tabun,8787,B-CHEMICAL
",",8787,O
paraoxon,8787,B-CHEMICAL
and,8787,O
dichlorvos,8787,B-CHEMICAL
),8787,O
in,8787,O
in,8787,O
vitro,8787,O
experiments,8787,O
and,8787,O
to,8787,O
compare,8787,O
their,8787,O
activity,8787,O
to,8787,O
that,8787,O
known,8787,O
for,8787,O
some,8787,O
currently,8787,O
used,8787,O
oximes,8787,B-CHEMICAL
(,8787,O
obidoxime,8787,B-CHEMICAL
",",8787,O
HI-6,8787,B-CHEMICAL
",",8787,O
2-PAM,8787,B-CHEMICAL
),8787,O
.,8787,O
Experiments,8788,O
were,8788,O
carried,8788,O
out,8788,O
using,8788,O
rat,8788,B-GENE-Y
brain,8788,I-GENE-Y
acetylcholinesterase,8788,I-GENE-Y
(,8788,O
AChE,8788,B-GENE-Y
),8788,O
.,8788,O
Reactivators,8789,O
showed,8789,O
different,8789,O
activity,8789,O
in,8789,O
the,8789,O
reactivation,8789,O
of,8789,O
rat,8789,B-GENE-Y
brain,8789,I-GENE-Y
AChE,8789,I-GENE-Y
after,8789,O
dichlorvos,8789,B-CHEMICAL
",",8789,O
paraoxon,8789,B-CHEMICAL
and,8789,O
tabun,8789,B-CHEMICAL
inhibition,8789,O
.,8789,O
AChE,8790,B-GENE-Y
was,8790,O
easier,8790,O
reactivated,8790,O
after,8790,O
paraoxon,8790,B-CHEMICAL
treatment,8790,O
.,8790,O
The,8791,O
best,8791,O
effect,8791,O
showed,8791,O
BT-07-4M,8791,B-CHEMICAL
",",8791,O
obidoxime,8791,B-CHEMICAL
",",8791,O
TMB-4,8791,B-CHEMICAL
and,8791,O
BT-08,8791,B-CHEMICAL
from,8791,O
the,8791,O
group,8791,O
of,8791,O
symmetric,8791,O
oximes,8791,B-CHEMICAL
",",8791,O
and,8791,O
Toxidin,8791,B-CHEMICAL
",",8791,O
BT-05,8791,B-CHEMICAL
and,8791,O
BT-03,8791,B-CHEMICAL
from,8791,O
asymmetric,8791,O
compounds,8791,O
.,8791,O
The,8792,O
reactivation,8792,O
of,8792,O
brain,8792,O
AChE,8792,B-GENE-Y
inhibited,8792,O
with,8792,O
tabun,8792,O
demonstrated,8792,O
better,8792,O
activity,8792,O
of,8792,O
new,8792,O
compound,8792,O
BT-07-4M,8792,B-CHEMICAL
",",8792,O
TMB-4,8792,B-CHEMICAL
and,8792,O
obidoxime,8792,B-CHEMICAL
from,8792,O
symmetric,8792,O
oximes,8792,B-CHEMICAL
",",8792,O
and,8792,O
BT-05,8792,B-CHEMICAL
and,8792,O
BT-03,8792,B-CHEMICAL
possessing,8792,O
asymmetric,8792,O
structure,8792,O
.,8792,O
All,8793,O
compounds,8793,O
showed,8793,O
low,8793,O
activity,8793,O
toward,8793,O
inhibition,8793,O
of,8793,O
AChE,8793,B-GENE-Y
caused,8793,O
by,8793,O
dichlorvos,8793,B-CHEMICAL
.,8793,O
Comparison,8794,O
of,8794,O
two,8794,O
main,8794,O
structure,8794,O
types,8794,O
(,8794,O
symmetric/asymmetric,8794,O
),8794,O
showed,8794,O
that,8794,O
the,8794,O
symmetric,8794,O
compounds,8794,O
reactivated,8794,O
better,8794,O
AChE,8794,B-GENE-Y
",",8794,O
inhibited,8794,O
with,8794,O
this,8794,O
OPC,8794,O
",",8794,O
than,8794,O
asymmetric,8794,O
ones,8794,O
.,8794,O
State-dependent,8795,O
mibefradil,8795,B-CHEMICAL
block,8795,O
of,8795,O
Na+,8795,B-GENE-N
channels,8795,I-GENE-N
.,8795,O
Mibefradil,8796,B-CHEMICAL
is,8796,O
a,8796,O
T-type,8796,B-GENE-N
Ca2+,8796,I-GENE-N
channel,8796,I-GENE-N
antagonist,8796,O
with,8796,O
reported,8796,O
cross-reactivity,8796,O
with,8796,O
other,8796,O
classes,8796,O
of,8796,O
ion,8796,O
channels,8796,O
",",8796,O
including,8796,O
K+,8796,B-GENE-N
",",8796,I-GENE-N
Cl-,8796,I-GENE-N
",",8796,I-GENE-N
and,8796,I-GENE-N
Na+,8796,I-GENE-N
channels,8796,I-GENE-N
.,8796,O
Using,8797,O
whole-cell,8797,O
voltage,8797,O
clamp,8797,O
",",8797,O
we,8797,O
examined,8797,O
mibefradil,8797,B-CHEMICAL
block,8797,O
of,8797,O
four,8797,O
Na+,8797,B-GENE-N
channel,8797,I-GENE-N
isoforms,8797,O
expressed,8797,O
in,8797,O
human,8797,O
embryonic,8797,O
kidney,8797,O
cells,8797,O
:,8797,O
Nav1.5,8797,B-GENE-Y
(,8797,O
cardiac,8797,O
),8797,O
",",8797,O
Nav1.4,8797,B-GENE-Y
(,8797,O
skeletal,8797,O
muscle,8797,O
),8797,O
",",8797,O
Nav1.2,8797,B-GENE-Y
(,8797,O
brain,8797,O
),8797,O
",",8797,O
and,8797,O
Nav1.7,8797,B-GENE-Y
(,8797,O
peripheral,8797,O
nerve,8797,O
),8797,O
.,8797,O
Mibefradil,8798,B-CHEMICAL
blocked,8798,O
Nav1.5,8798,B-GENE-Y
in,8798,O
a,8798,O
use/frequency-dependent,8798,O
manner,8798,O
",",8798,O
indicating,8798,O
preferential,8798,O
binding,8798,O
to,8798,O
states,8798,O
visited,8798,O
during,8798,O
depolarization,8798,O
.,8798,O
Mibefradil,8799,B-CHEMICAL
blocked,8799,O
currents,8799,O
of,8799,O
all,8799,O
Na+,8799,B-GENE-N
channel,8799,I-GENE-N
isoforms,8799,O
with,8799,O
similar,8799,O
affinity,8799,O
and,8799,O
a,8799,O
dependence,8799,O
on,8799,O
holding,8799,O
potential,8799,O
",",8799,O
and,8799,O
drug,8799,O
off-rate,8799,O
was,8799,O
slowed,8799,O
at,8799,O
depolarized,8799,O
potentials,8799,O
(,8799,O
k,8799,O
(,8799,O
off,8799,O
),8799,O
was,8799,O
0.024/s,8799,O
at,8799,O
-130,8799,O
mV,8799,O
and,8799,O
0.007/s,8799,O
at,8799,O
-100,8799,O
mV,8799,O
for,8799,O
Nav1.5,8799,B-GENE-Y
),8799,O
.,8799,O
We,8800,O
further,8800,O
probed,8800,O
the,8800,O
interaction,8800,O
of,8800,O
mibefradil,8800,B-CHEMICAL
with,8800,O
inactivated,8800,O
Nav1.5,8800,B-GENE-Y
channels,8800,O
.,8800,O
Neither,8801,O
the,8801,O
degree,8801,O
nor,8801,O
the,8801,O
time,8801,O
course,8801,O
of,8801,O
block,8801,O
was,8801,O
dependent,8801,O
on,8801,O
the,8801,O
stimulus,8801,O
duration,8801,O
",",8801,O
which,8801,O
dramatically,8801,O
changed,8801,O
the,8801,O
residency,8801,O
time,8801,O
of,8801,O
channels,8801,O
in,8801,O
the,8801,O
fast-inactivated,8801,O
state,8801,O
.,8801,O
In,8802,O
addition,8802,O
",",8802,O
inhibiting,8802,O
the,8802,O
binding,8802,O
of,8802,O
the,8802,O
fast,8802,O
inactivation,8802,O
lid,8802,O
(,8802,O
Nav1.5,8802,B-GENE-Y
ICM,8802,O
+,8802,O
MTSET,8802,O
),8802,O
did,8802,O
not,8802,O
alter,8802,O
mibefradil,8802,B-CHEMICAL
block,8802,O
",",8802,O
confirming,8802,O
that,8802,O
the,8802,O
drug,8802,O
does,8802,O
not,8802,O
preferentially,8802,O
interact,8802,O
with,8802,O
the,8802,O
fast-inactivated,8802,O
state,8802,O
.,8802,O
We,8803,O
also,8803,O
tested,8803,O
whether,8803,O
mibefradil,8803,B-CHEMICAL
interacted,8803,O
with,8803,O
slow-inactivated,8803,O
state,8803,O
(,8803,O
s,8803,O
),8803,O
.,8803,O
When,8804,O
selectively,8804,O
applied,8804,O
to,8804,O
channels,8804,O
after,8804,O
inducing,8804,O
slow,8804,O
inactivation,8804,O
with,8804,O
a,8804,O
60-s,8804,O
pulse,8804,O
to,8804,O
-10,8804,O
mV,8804,O
",",8804,O
mibefradil,8804,B-CHEMICAL
(,8804,O
1,8804,O
microM,8804,O
),8804,O
produced,8804,O
45,8804,O
%,8804,O
fractional,8804,O
block,8804,O
in,8804,O
Nav1.5,8804,B-GENE-Y
and,8804,O
greater,8804,O
block,8804,O
(,8804,O
88,8804,O
%,8804,O
),8804,O
in,8804,O
an,8804,O
isoform,8804,O
(,8804,O
Nav1.4,8804,B-GENE-Y
),8804,O
that,8804,O
slow-inactivates,8804,O
more,8804,O
completely,8804,O
.,8804,O
Our,8805,O
results,8805,O
suggest,8805,O
that,8805,O
mibefradil,8805,B-CHEMICAL
blocks,8805,O
Na+,8805,B-GENE-N
channels,8805,I-GENE-N
in,8805,O
a,8805,O
state-dependent,8805,O
manner,8805,O
that,8805,O
does,8805,O
not,8805,O
depend,8805,O
on,8805,O
fast,8805,O
inactivation,8805,O
but,8805,O
probably,8805,O
involves,8805,O
interaction,8805,O
with,8805,O
one,8805,O
or,8805,O
more,8805,O
slow-inactivated,8805,O
state,8805,O
(,8805,O
s,8805,O
),8805,O
.,8805,O
Enhanced,8806,O
heterodimerization,8806,O
of,8806,O
Bax,8806,B-GENE-Y
by,8806,O
Bcl-2,8806,B-GENE-Y
mutants,8806,O
improves,8806,O
irradiated,8806,O
cell,8806,O
survival,8806,O
.,8806,O
B,8807,B-GENE-Y
Cell,8807,I-GENE-Y
Lymphoma-2,8807,I-GENE-Y
(,8807,O
Bcl-2,8807,B-GENE-Y
),8807,O
protein,8807,O
suppresses,8807,O
ionizing,8807,O
radiation-induced,8807,O
apoptosis,8807,O
in,8807,O
hemato-lymphoid,8807,O
system,8807,O
.,8807,O
To,8808,O
enhance,8808,O
the,8808,O
survival,8808,O
of,8808,O
irradiated,8808,O
cells,8808,O
",",8808,O
we,8808,O
have,8808,O
compared,8808,O
the,8808,O
effects,8808,O
and,8808,O
mechanism,8808,O
of,8808,O
Bcl-2,8808,B-GENE-Y
and,8808,O
its,8808,O
functional,8808,O
variants,8808,O
",",8808,O
D34A,8808,B-GENE-N
(,8808,O
caspase-3,8808,B-GENE-Y
resistant,8808,O
),8808,O
and,8808,O
S70E,8808,B-GENE-N
(,8808,O
mimics,8808,O
phosphorylation,8808,O
on,8808,O
S70,8808,O
),8808,O
.,8808,O
Bcl-2,8809,B-GENE-Y
and,8809,O
its,8809,O
mutants,8809,O
were,8809,O
transfected,8809,O
into,8809,O
hematopoietic,8809,O
cell,8809,O
line,8809,O
and,8809,O
assessed,8809,O
for,8809,O
cell,8809,O
survival,8809,O
",",8809,O
clonogenicity,8809,O
and,8809,O
cell,8809,O
cycle,8809,O
perturbations,8809,O
upon,8809,O
exposure,8809,O
to,8809,O
ionizing,8809,O
radiation,8809,O
.,8809,O
The,8810,O
electrostatic,8810,O
potential,8810,O
of,8810,O
BH3,8810,B-GENE-N
cleft,8810,I-GENE-N
of,8810,O
Bcl-2/mutants,8810,B-GENE-Y
and,8810,O
their,8810,O
heterodimerization,8810,O
with,8810,O
Bcl-2,8810,B-GENE-Y
associated,8810,I-GENE-Y
X,8810,I-GENE-Y
protein,8810,I-GENE-Y
(,8810,O
Bax,8810,B-GENE-Y
),8810,O
were,8810,O
computationally,8810,O
evaluated,8810,O
.,8810,O
Correspondingly,8811,O
",",8811,O
these,8811,O
results,8811,O
were,8811,O
verified,8811,O
by,8811,O
co-immunoprecipitation,8811,O
and,8811,O
western,8811,O
blotting,8811,O
.,8811,O
The,8812,O
mutants,8812,O
afford,8812,O
higher,8812,O
radioprotective,8812,O
effect,8812,O
than,8812,O
Bcl-2,8812,B-GENE-Y
in,8812,O
apoptotic,8812,O
and,8812,O
clonogenic,8812,O
assays,8812,O
at,8812,O
D,8812,O
(,8812,O
0,8812,O
),8812,O
(,8812,O
radiation,8812,O
dose,8812,O
at,8812,O
which,8812,O
37,8812,O
%,8812,O
cell,8812,O
survival,8812,O
was,8812,O
observed,8812,O
),8812,O
.,8812,O
The,8813,O
computational,8813,O
and,8813,O
functional,8813,O
analysis,8813,O
indicates,8813,O
that,8813,O
mutants,8813,O
have,8813,O
higher,8813,O
propensity,8813,O
to,8813,O
neutralize,8813,O
Bax,8813,B-GENE-Y
protein,8813,O
by,8813,O
heterodimerization,8813,O
and,8813,O
have,8813,O
increased,8813,O
caspase-9,8813,B-GENE-Y
suppression,8813,O
capability,8813,O
",",8813,O
which,8813,O
is,8813,O
responsible,8813,O
for,8813,O
enhanced,8813,O
survival,8813,O
.,8813,O
This,8814,O
study,8814,O
implies,8814,O
potential,8814,O
of,8814,O
Bcl-2,8814,B-GENE-Y
mutants,8814,O
or,8814,O
their,8814,O
chemical/peptide,8814,O
mimics,8814,O
to,8814,O
elicit,8814,O
radioprotective,8814,O
effect,8814,O
in,8814,O
cells,8814,O
exposed,8814,O
to,8814,O
radiation,8814,O
.,8814,O
[,8815,O
Treatment,8815,O
of,8815,O
androgen-independent,8815,B-CHEMICAL
hormone,8815,O
refractory,8815,O
prostate,8815,O
cancer,8815,O
using,8815,O
docetaxel,8815,B-CHEMICAL
],8815,O
.,8815,O
Although,8816,O
prostate,8816,O
cancer,8816,O
patients,8816,O
with,8816,O
metastatic,8816,O
lesion,8816,O
initially,8816,O
respond,8816,O
to,8816,O
androgen,8816,B-CHEMICAL
ablation,8816,O
therapy,8816,O
",",8816,O
almost,8816,O
patients,8816,O
develop,8816,O
to,8816,O
hormone-refractory,8816,O
states,8816,O
.,8816,O
The,8817,O
optimal,8817,O
treatment,8817,O
for,8817,O
men,8817,O
with,8817,O
hormone,8817,O
refractory,8817,O
prostate,8817,O
cancer,8817,O
(,8817,O
HRPC,8817,O
),8817,O
has,8817,O
not,8817,O
been,8817,O
established,8817,O
.,8817,O
Docetaxel,8818,B-CHEMICAL
is,8818,O
a,8818,O
semisynthetic,8818,O
taxane,8818,B-CHEMICAL
that,8818,O
inhibit,8818,O
tumor,8818,O
growth,8818,O
by,8818,O
induction,8818,O
of,8818,O
microtubule,8818,O
stabilization,8818,O
and,8818,O
promotion,8818,O
of,8818,O
bcl-2,8818,B-GENE-Y
inactivation,8818,O
",",8818,O
which,8818,O
induce,8818,O
apoptosis,8818,O
.,8818,O
Docetaxel,8819,B-CHEMICAL
as,8819,O
single,8819,O
agent,8819,O
has,8819,O
significant,8819,O
anti-tumor,8819,O
effect,8819,O
in,8819,O
HRPC,8819,O
patients,8819,O
.,8819,O
Docetaxel,8820,B-CHEMICAL
combined,8820,O
with,8820,O
estramustine,8820,B-CHEMICAL
or,8820,O
other,8820,O
antimicrotubular,8820,O
agents,8820,O
have,8820,O
shown,8820,O
further,8820,O
significant,8820,O
cytotoxicity,8820,O
in,8820,O
HRPC,8820,O
patients,8820,O
.,8820,O
In,8821,O
the,8821,O
United,8821,O
States,8821,O
",",8821,O
Food,8821,O
and,8821,O
Drug,8821,O
Administration,8821,O
(,8821,O
FDA,8821,O
),8821,O
approved,8821,O
docetaxel,8821,B-CHEMICAL
",",8821,O
injection,8821,O
in,8821,O
combination,8821,O
with,8821,O
prednisone,8821,B-CHEMICAL
for,8821,O
the,8821,O
treatment,8821,O
of,8821,O
patients,8821,O
with,8821,O
advanced,8821,O
metastatic,8821,O
prostate,8821,O
cancer,8821,O
in,8821,O
2004,8821,O
.,8821,O
ABCB1,8822,B-GENE-Y
polymorphisms,8822,O
influence,8822,O
steady-state,8822,O
plasma,8822,O
levels,8822,O
of,8822,O
9-hydroxyrisperidone,8822,B-CHEMICAL
and,8822,O
risperidone,8822,B-CHEMICAL
active,8822,O
moiety,8822,O
.,8822,O
Risperidone,8823,B-CHEMICAL
is,8823,O
metabolized,8823,O
to,8823,O
its,8823,O
active,8823,O
metabolite,8823,O
",",8823,O
9-hydroxyrisperidone,8823,B-CHEMICAL
",",8823,O
mainly,8823,O
by,8823,O
the,8823,O
cytochrome,8823,B-GENE-N
P450,8823,I-GENE-N
enzymes,8823,O
CYP2D6,8823,B-GENE-N
and,8823,I-GENE-N
3A4,8823,I-GENE-N
.,8823,O
Its,8824,O
antipsychotic,8824,O
effect,8824,O
is,8824,O
assumed,8824,O
to,8824,O
be,8824,O
related,8824,O
to,8824,O
the,8824,O
active,8824,O
moiety,8824,O
",",8824,O
that,8824,O
is,8824,O
",",8824,O
the,8824,O
sum,8824,O
of,8824,O
risperidone,8824,B-CHEMICAL
and,8824,O
9-hydroxyrisperidone,8824,B-CHEMICAL
.,8824,O
Both,8825,O
risperidone,8825,B-CHEMICAL
and,8825,O
9-hydroxyrisperidone,8825,B-CHEMICAL
are,8825,O
substrates,8825,O
of,8825,O
P-glycoprotein,8825,B-GENE-N
(,8825,O
P-gp,8825,B-GENE-N
),8825,O
",",8825,O
a,8825,O
transport,8825,O
protein,8825,O
involved,8825,O
in,8825,O
drug,8825,O
absorption,8825,O
",",8825,O
distribution,8825,O
",",8825,O
and,8825,O
elimination,8825,O
.,8825,O
The,8826,O
aim,8826,O
of,8826,O
the,8826,O
present,8826,O
study,8826,O
was,8826,O
to,8826,O
evaluate,8826,O
the,8826,O
influence,8826,O
of,8826,O
polymorphisms,8826,O
in,8826,O
genes,8826,O
encoding,8826,O
CYP3A5,8826,B-GENE-Y
and,8826,O
P-gp,8826,B-GENE-N
(,8826,O
ABCB1,8826,B-GENE-Y
),8826,O
on,8826,O
the,8826,O
steady-state,8826,O
plasma,8826,O
levels,8826,O
of,8826,O
risperidone,8826,B-CHEMICAL
",",8826,O
9-hydroxyrisperidone,8826,B-CHEMICAL
",",8826,O
and,8826,O
the,8826,O
active,8826,O
moiety,8826,O
",",8826,O
taking,8826,O
CYP2D6,8826,B-GENE-Y
genotype,8826,O
status,8826,O
into,8826,O
account,8826,O
.,8826,O
Forty-six,8827,O
white,8827,O
patients,8827,O
with,8827,O
schizophrenia,8827,O
treated,8827,O
with,8827,O
risperidone,8827,B-CHEMICAL
(,8827,O
1-10,8827,O
mg/d,8827,O
),8827,O
in,8827,O
monotherapy,8827,O
for,8827,O
4-6,8827,O
weeks,8827,O
were,8827,O
genotyped,8827,O
",",8827,O
and,8827,O
their,8827,O
plasma,8827,O
concentrations,8827,O
of,8827,O
risperidone,8827,B-CHEMICAL
and,8827,O
9-hydroxyrisperidone,8827,B-CHEMICAL
were,8827,O
measured,8827,O
.,8827,O
Dose-corrected,8828,O
plasma,8828,O
concentrations,8828,O
(,8828,O
C/D,8828,O
),8828,O
of,8828,O
risperidone,8828,B-CHEMICAL
",",8828,O
9-hydroxyrisperidone,8828,B-CHEMICAL
",",8828,O
and,8828,O
active,8828,O
moiety,8828,O
showed,8828,O
up,8828,O
to,8828,O
68-,8828,O
",",8828,O
9-,8828,O
",",8828,O
and,8828,O
10-fold,8828,O
interindividual,8828,O
variation,8828,O
",",8828,O
respectively,8828,O
.,8828,O
Six,8829,O
patients,8829,O
carried,8829,O
1,8829,O
CYP3A5,8829,B-GENE-Y
*,8829,O
1,8829,O
allele,8829,O
and,8829,O
therefore,8829,O
were,8829,O
likely,8829,O
to,8829,O
express,8829,O
the,8829,O
CYP3A5,8829,B-GENE-Y
enzyme,8829,O
.,8829,O
The,8830,O
CYP3A5,8830,B-GENE-Y
genotype,8830,O
did,8830,O
not,8830,O
influence,8830,O
risperidone,8830,B-CHEMICAL
",",8830,O
9-hydroxyrisperidone,8830,B-CHEMICAL
",",8830,O
or,8830,O
active,8830,O
moiety,8830,O
C/Ds,8830,O
.,8830,O
The,8831,O
CYP2D6,8831,B-GENE-Y
genotype,8831,O
in,8831,O
these,8831,O
46,8831,O
patients,8831,O
was,8831,O
again,8831,O
associated,8831,O
with,8831,O
risperidone,8831,B-CHEMICAL
C/D,8831,O
(,8831,O
P,8831,O
=,8831,O
0.001,8831,O
),8831,O
but,8831,O
not,8831,O
with,8831,O
9-hydroxyrisperidone,8831,B-CHEMICAL
C/D,8831,O
or,8831,O
active,8831,O
moiety,8831,O
C/D,8831,O
",",8831,O
as,8831,O
previously,8831,O
shown,8831,O
by,8831,O
our,8831,O
group,8831,O
in,8831,O
37,8831,O
of,8831,O
these,8831,O
patients,8831,O
.,8831,O
Patients,8832,O
homozygous,8832,O
for,8832,O
the,8832,O
ABCB1,8832,B-GENE-Y
3435T/2677T/1236T,8832,O
haplotype,8832,O
had,8832,O
significantly,8832,O
lower,8832,O
C/Ds,8832,O
of,8832,O
9-hydroxyrisperidone,8832,B-CHEMICAL
(,8832,O
P,8832,O
=,8832,O
0.026,8832,O
),8832,O
and,8832,O
active,8832,O
moiety,8832,O
(,8832,O
P,8832,O
=,8832,O
0.028,8832,O
),8832,O
than,8832,O
patients,8832,O
carrying,8832,O
other,8832,O
ABCB1,8832,B-GENE-Y
genotypes,8832,O
.,8832,O
In,8833,O
conclusion,8833,O
",",8833,O
our,8833,O
results,8833,O
confirmed,8833,O
the,8833,O
significant,8833,O
effect,8833,O
of,8833,O
CYP2D6,8833,B-GENE-Y
genotype,8833,O
on,8833,O
the,8833,O
steady-state,8833,O
plasma,8833,O
levels,8833,O
of,8833,O
risperidone,8833,B-CHEMICAL
and,8833,O
showed,8833,O
that,8833,O
ABCB1,8833,B-GENE-Y
polymorphisms,8833,O
have,8833,O
a,8833,O
moderate,8833,O
effect,8833,O
on,8833,O
those,8833,O
of,8833,O
9-hydroxyrisperidone,8833,B-CHEMICAL
and,8833,O
the,8833,O
active,8833,O
moiety,8833,O
.,8833,O
Polyamine,8834,B-CHEMICAL
metabolism,8834,O
in,8834,O
a,8834,O
member,8834,O
of,8834,O
the,8834,O
phylum,8834,O
Microspora,8834,O
(,8834,O
Encephalitozoon,8834,O
cuniculi,8834,O
),8834,O
:,8834,O
effects,8834,O
of,8834,O
polyamine,8834,B-CHEMICAL
analogues,8834,O
.,8834,O
The,8835,O
uptake,8835,O
",",8835,O
biosynthesis,8835,O
and,8835,O
catabolism,8835,O
of,8835,O
polyamines,8835,B-CHEMICAL
in,8835,O
the,8835,O
microsporidian,8835,O
parasite,8835,O
Encephalitozoon,8835,O
cuniculi,8835,O
are,8835,O
detailed,8835,O
with,8835,O
reference,8835,O
to,8835,O
the,8835,O
effects,8835,O
of,8835,O
oligoamine,8835,B-CHEMICAL
and,8835,O
arylamine,8835,B-CHEMICAL
analogues,8835,O
of,8835,O
polyamines,8835,B-CHEMICAL
.,8835,O
Enc,8836,O
.,8836,O
cuniculi,8837,O
",",8837,O
an,8837,O
intracellular,8837,O
parasite,8837,O
of,8837,O
mammalian,8837,O
cells,8837,O
",",8837,O
has,8837,O
both,8837,O
biosynthetic,8837,O
and,8837,O
catabolic,8837,O
enzymes,8837,O
of,8837,O
polyamine,8837,B-CHEMICAL
metabolism,8837,O
",",8837,O
as,8837,O
demonstrated,8837,O
in,8837,O
cell-free,8837,O
extracts,8837,O
of,8837,O
mature,8837,O
spores,8837,O
.,8837,O
The,8838,O
uptake,8838,O
of,8838,O
polyamines,8838,B-CHEMICAL
was,8838,O
measured,8838,O
in,8838,O
immature,8838,O
",",8838,O
pre-emergent,8838,O
spores,8838,O
isolated,8838,O
from,8838,O
host,8838,O
cells,8838,O
by,8838,O
Percoll,8838,O
gradient,8838,O
.,8838,O
Spermine,8839,O
was,8839,O
rapidly,8839,O
taken,8839,O
up,8839,O
and,8839,O
metabolized,8839,O
to,8839,O
spermidine,8839,O
and,8839,O
an,8839,O
unknown,8839,O
",",8839,O
possibly,8839,O
acetamidopropanal,8839,O
",",8839,O
by,8839,O
spermidine/spermine,8839,B-GENE-N
N,8839,I-GENE-N
(,8839,I-GENE-N
1,8839,I-GENE-N
),8839,I-GENE-N
-acetyltransferase,8839,I-GENE-N
(,8839,O
SSAT,8839,B-GENE-N
),8839,O
and,8839,O
polyamine,8839,B-GENE-N
oxidase,8839,I-GENE-N
(,8839,O
PAO,8839,B-GENE-N
),8839,O
.,8839,O
Most,8840,O
of,8840,O
the,8840,O
spermidine,8840,B-CHEMICAL
and,8840,O
the,8840,O
unknown,8840,O
product,8840,O
were,8840,O
found,8840,O
in,8840,O
the,8840,O
cell,8840,O
incubation,8840,O
medium,8840,O
",",8840,O
indicating,8840,O
they,8840,O
were,8840,O
released,8840,O
from,8840,O
the,8840,O
cell,8840,O
.,8840,O
bis,8841,B-CHEMICAL
(,8841,I-CHEMICAL
Ethyl,8841,I-CHEMICAL
),8841,I-CHEMICAL
oligoamine,8841,I-CHEMICAL
analogues,8841,O
of,8841,O
polyamines,8841,B-CHEMICAL
",",8841,O
such,8841,O
as,8841,O
SL-11144,8841,B-CHEMICAL
and,8841,O
SL-11158,8841,B-CHEMICAL
",",8841,O
as,8841,O
well,8841,O
as,8841,O
arylamine,8841,B-CHEMICAL
analogues,8841,O
[,8841,O
BW-1,8841,B-CHEMICAL
",",8841,O
a,8841,O
bis,8841,B-CHEMICAL
(,8841,I-CHEMICAL
phenylbenzyl,8841,I-CHEMICAL
),8841,I-CHEMICAL
3-7-3,8841,O
analogue,8841,O
],8841,O
blocked,8841,O
uptake,8841,O
and,8841,O
interconversion,8841,O
of,8841,O
spermine,8841,B-CHEMICAL
at,8841,O
micromolar,8841,O
levels,8841,O
and,8841,O
",",8841,O
in,8841,O
the,8841,O
case,8841,O
of,8841,O
BW-1,8841,B-CHEMICAL
",",8841,O
acted,8841,O
as,8841,O
substrate,8841,O
for,8841,O
PAO,8841,B-GENE-N
.,8841,O
The,8842,O
Enc,8842,O
.,8842,O
cuniculi,8843,O
PAO,8843,O
activity,8843,O
differed,8843,O
from,8843,O
that,8843,O
found,8843,O
in,8843,O
mammalian,8843,O
cells,8843,O
with,8843,O
respect,8843,O
to,8843,O
pH,8843,O
optimum,8843,O
",",8843,O
substrate,8843,O
specificity,8843,O
and,8843,O
sensitivity,8843,O
to,8843,O
known,8843,O
PAO,8843,B-GENE-N
inhibitors,8843,O
.,8843,O
SL-11158,8844,B-CHEMICAL
inhibited,8844,O
SSAT,8844,B-GENE-N
activity,8844,O
with,8844,O
a,8844,O
mixed,8844,O
type,8844,O
of,8844,O
inhibition,8844,O
in,8844,O
which,8844,O
the,8844,O
analogue,8844,O
had,8844,O
a,8844,O
70-fold,8844,O
higher,8844,O
affinity,8844,O
for,8844,O
the,8844,O
enzyme,8844,O
than,8844,O
the,8844,O
natural,8844,O
substrate,8844,O
",",8844,O
spermine,8844,B-CHEMICAL
.,8844,O
The,8845,O
interest,8845,O
in,8845,O
Enc,8845,O
.,8845,O
cuniculi,8846,O
polyamine,8846,O
metabolism,8846,O
and,8846,O
the,8846,O
biochemical,8846,O
effects,8846,O
of,8846,O
these,8846,O
polyamine,8846,B-CHEMICAL
analogues,8846,O
is,8846,O
warranted,8846,O
since,8846,O
they,8846,O
cure,8846,O
model,8846,O
infections,8846,O
of,8846,O
Enc,8846,O
.,8846,O
cuniculi,8847,O
in,8847,O
mice,8847,O
and,8847,O
are,8847,O
potential,8847,O
candidates,8847,O
for,8847,O
human,8847,O
clinical,8847,O
trials,8847,O
.,8847,O
Synthesis,8848,O
and,8848,O
in,8848,O
vitro,8848,O
evaluation,8848,O
of,8848,O
N-Aryl,8848,B-CHEMICAL
pyrido-quinazolines,8848,I-CHEMICAL
derivatives,8848,O
as,8848,O
potent,8848,O
EGFR,8848,B-GENE-Y
inhibitors,8848,O
.,8848,O
A,8849,O
series,8849,O
of,8849,O
pyrido-quinazolines,8849,B-CHEMICAL
have,8849,O
been,8849,O
synthesised,8849,O
",",8849,O
characterised,8849,O
and,8849,O
tested,8849,O
for,8849,O
their,8849,O
in,8849,O
vitro,8849,O
EGFR,8849,B-GENE-Y
tyrosine,8849,B-GENE-N
kinase,8849,I-GENE-N
inhibitory,8849,O
activity,8849,O
.,8849,O
The,8850,O
compounds,8850,O
were,8850,O
prepared,8850,O
from,8850,O
Alkylideno/arylideno-bis-ureas,8850,B-CHEMICAL
.,8850,O
Their,8851,O
final,8851,O
structure,8851,O
of,8851,O
the,8851,O
compounds,8851,O
were,8851,O
elucidated,8851,O
on,8851,O
the,8851,O
basis,8851,O
of,8851,O
spectral,8851,O
studies,8851,O
(,8851,O
IR.,8851,O
",",8851,O
1H,8851,B-CHEMICAL
NMR,8851,O
",",8851,O
FT-IR,8851,O
and,8851,O
EI-MS,8851,O
),8851,O
.,8851,O
The,8852,O
cellular,8852,O
EGFR,8852,B-GENE-Y
internalization,8852,O
response,8852,O
of,8852,O
selected,8852,O
compounds,8852,O
was,8852,O
evaluated,8852,O
using,8852,O
HeLa,8852,O
cells,8852,O
.,8852,O
Most,8853,O
of,8853,O
the,8853,O
synthesized,8853,O
compounds,8853,O
displayed,8853,O
potent,8853,O
EGFR-TK,8853,B-GENE-Y
inhibitory,8853,O
activity,8853,O
and,8853,O
structurally,8853,O
halogenated,8853,O
derivatives,8853,O
had,8853,O
a,8853,O
pronounced,8853,O
effect,8853,O
in,8853,O
inhibiting,8853,O
EGFR,8853,B-GENE-Y
internalization,8853,O
.,8853,O
©,8854,O
2013,8854,O
John,8854,O
Wiley,8854,O
&,8854,O
Sons,8854,O
A/S,8854,O
.,8854,O
A,8855,O
fluorescent,8855,O
polymeric,8855,O
heparin,8855,O
sensor,8855,O
.,8855,O
Linear,8856,O
copolymers,8856,O
have,8856,O
been,8856,O
developed,8856,O
which,8856,O
carry,8856,O
binding,8856,O
sites,8856,O
tailored,8856,O
for,8856,O
sulfated,8856,O
sugars,8856,O
.,8856,O
All,8857,O
binding,8857,O
monomers,8857,O
are,8857,O
based,8857,O
on,8857,O
the,8857,O
methacrylamide,8857,B-CHEMICAL
skeleton,8857,O
and,8857,O
ensure,8857,O
statistical,8857,O
radical,8857,O
copolymerization,8857,O
.,8857,O
They,8858,O
are,8858,O
decorated,8858,O
with,8858,O
o-aminomethylphenylboronates,8858,B-CHEMICAL
for,8858,O
covalent,8858,O
ester,8858,O
formation,8858,O
and/or,8858,O
alkylammonium,8858,B-CHEMICAL
ions,8858,O
for,8858,O
noncovalent,8858,O
Coulomb,8858,O
attraction,8858,O
.,8858,O
Alcohol,8859,B-CHEMICAL
sidechains,8859,O
maintain,8859,O
a,8859,O
high,8859,O
water,8859,O
solubility,8859,O
;,8859,O
a,8859,O
dansyl,8859,B-CHEMICAL
monomer,8859,O
was,8859,O
constructed,8859,O
as,8859,O
a,8859,O
fluorescence,8859,O
label,8859,O
.,8859,O
Statistical,8860,O
copolymerization,8860,O
of,8860,O
comonomer,8860,O
mixtures,8860,O
with,8860,O
optimized,8860,O
ratios,8860,O
was,8860,O
started,8860,O
by,8860,O
AIBN,8860,B-CHEMICAL
(,8860,O
"AIBN=2,2'-azoisobutyronitrile",8860,B-CHEMICAL
),8860,O
and,8860,O
furnished,8860,O
water-soluble,8860,O
comonomers,8860,O
with,8860,O
an,8860,O
exceptionally,8860,O
high,8860,O
affinity,8860,O
for,8860,O
glucosaminoglucans,8860,O
.,8860,O
Heparin,8861,O
can,8861,O
be,8861,O
quantitatively,8861,O
detected,8861,O
with,8861,O
an,8861,O
unprecedented,8861,O
30,8861,O
nM,8861,O
sensitivity,8861,O
",",8861,O
and,8861,O
a,8861,O
neutral,8861,O
polymer,8861,O
without,8861,O
any,8861,O
ammonium,8861,B-CHEMICAL
cation,8861,I-CHEMICAL
is,8861,O
still,8861,O
able,8861,O
to,8861,O
bind,8861,O
the,8861,O
target,8861,O
with,8861,O
almost,8861,O
micromolar,8861,O
affinity,8861,O
.,8861,O
From,8862,O
this,8862,O
unexpected,8862,O
result,8862,O
",",8862,O
we,8862,O
propose,8862,O
a,8862,O
new,8862,O
binding,8862,O
scheme,8862,O
between,8862,O
the,8862,O
boronate,8862,B-CHEMICAL
and,8862,O
a,8862,O
sulfated,8862,O
ethylene,8862,B-CHEMICAL
glycol,8862,I-CHEMICAL
or,8862,O
aminoethanol,8862,B-CHEMICAL
unit,8862,O
.,8862,O
Although,8863,O
the,8863,O
mechanism,8863,O
of,8863,O
heparin,8863,O
binding,8863,O
involves,8863,O
covalent,8863,O
boronate,8863,B-CHEMICAL
ester,8863,I-CHEMICAL
formation,8863,O
",",8863,O
it,8863,O
can,8863,O
be,8863,O
completely,8863,O
reversed,8863,O
by,8863,O
protamine,8863,O
addition,8863,O
",",8863,O
similar,8863,O
to,8863,O
heparin,8863,O
's,8863,O
complex,8863,O
formation,8863,O
with,8863,O
antithrombin,8863,B-GENE-Y
III,8863,I-GENE-Y
.,8863,O
Impaired,8864,O
cliff,8864,O
avoidance,8864,O
reaction,8864,O
in,8864,O
dopamine,8864,B-GENE-Y
transporter,8864,I-GENE-Y
knockout,8864,O
mice,8864,O
.,8864,O
RATIONALE,8865,O
:,8865,O
Impulsivity,8865,O
is,8865,O
a,8865,O
key,8865,O
feature,8865,O
of,8865,O
disorders,8865,O
that,8865,O
include,8865,O
attention-deficit/hyperactivity,8865,O
disorder,8865,O
(,8865,O
ADHD,8865,O
),8865,O
.,8865,O
The,8866,O
cliff,8866,O
avoidance,8866,O
reaction,8866,O
(,8866,O
CAR,8866,O
),8866,O
assesses,8866,O
maladaptive,8866,O
impulsive,8866,O
rodent,8866,O
behavior,8866,O
.,8866,O
Dopamine,8867,B-GENE-Y
transporter,8867,I-GENE-Y
knockout,8867,O
(,8867,O
DAT-KO,8867,B-GENE-Y
),8867,O
mice,8867,O
display,8867,O
features,8867,O
of,8867,O
ADHD,8867,O
and,8867,O
are,8867,O
candidates,8867,O
in,8867,O
which,8867,O
to,8867,O
test,8867,O
other,8867,O
impulsive,8867,O
phenotypes,8867,O
.,8867,O
OBJECTIVES,8868,O
:,8868,O
Impulsivity,8868,O
of,8868,O
DAT-KO,8868,B-GENE-Y
mice,8868,O
was,8868,O
assessed,8868,O
in,8868,O
the,8868,O
CAR,8868,O
paradigm,8868,O
.,8868,O
For,8869,O
comparison,8869,O
",",8869,O
attentional,8869,O
deficits,8869,O
were,8869,O
also,8869,O
assessed,8869,O
in,8869,O
prepulse,8869,O
inhibition,8869,O
(,8869,O
PPI,8869,O
),8869,O
in,8869,O
which,8869,O
DAT-KO,8869,B-GENE-Y
mice,8869,O
have,8869,O
been,8869,O
shown,8869,O
to,8869,O
exhibit,8869,O
impaired,8869,O
sensorimotor,8869,O
gating,8869,O
.,8869,O
RESULTS,8870,O
:,8870,O
DAT-KO,8870,B-GENE-Y
mice,8870,O
exhibited,8870,O
a,8870,O
profound,8870,O
CAR,8870,O
impairment,8870,O
compared,8870,O
to,8870,O
wild-type,8870,O
(,8870,O
WT,8870,O
),8870,O
mice,8870,O
.,8870,O
As,8871,O
expected,8871,O
",",8871,O
DAT-KO,8871,B-GENE-Y
mice,8871,O
showed,8871,O
PPI,8871,O
deficits,8871,O
compared,8871,O
to,8871,O
WT,8871,O
mice,8871,O
.,8871,O
Furthermore,8872,O
",",8872,O
the,8872,O
DAT-KO,8872,B-GENE-Y
mice,8872,O
with,8872,O
the,8872,O
most,8872,O
impaired,8872,O
CAR,8872,O
exhibited,8872,O
the,8872,O
most,8872,O
severe,8872,O
PPI,8872,O
deficits,8872,O
.,8872,O
Treatment,8873,O
with,8873,O
methylphenidate,8873,B-CHEMICAL
or,8873,O
nisoxetine,8873,B-CHEMICAL
ameliorated,8873,O
CAR,8873,O
impairments,8873,O
in,8873,O
DAT-KO,8873,B-GENE-Y
mice,8873,O
.,8873,O
CONCLUSION,8874,O
:,8874,O
These,8874,O
results,8874,O
suggest,8874,O
that,8874,O
DAT-KO,8874,B-GENE-Y
mice,8874,O
exhibit,8874,O
impulsive,8874,O
CAR,8874,O
behavior,8874,O
that,8874,O
correlates,8874,O
with,8874,O
their,8874,O
PPI,8874,O
deficits,8874,O
.,8874,O
Blockade,8875,O
of,8875,O
monoamine,8875,B-GENE-N
transporters,8875,I-GENE-N
",",8875,O
especially,8875,O
the,8875,O
norepinephrine,8875,B-GENE-Y
transporter,8875,I-GENE-Y
(,8875,O
NET,8875,B-GENE-Y
),8875,O
in,8875,O
the,8875,O
prefrontal,8875,O
cortex,8875,O
(,8875,O
PFC,8875,O
),8875,O
",",8875,O
may,8875,O
contribute,8875,O
to,8875,O
pharmacological,8875,O
improvement,8875,O
of,8875,O
impulsivity,8875,O
in,8875,O
these,8875,O
mice,8875,O
.,8875,O
SPACRCAN,8876,B-GENE-N
",",8876,O
a,8876,O
novel,8876,O
human,8876,B-GENE-N
interphotoreceptor,8876,I-GENE-N
matrix,8876,I-GENE-N
hyaluronan-binding,8876,I-GENE-N
proteoglycan,8876,I-GENE-N
synthesized,8876,O
by,8876,O
photoreceptors,8876,O
and,8876,O
pinealocytes,8876,O
.,8876,O
The,8877,O
interphotoreceptor,8877,O
matrix,8877,O
is,8877,O
a,8877,O
unique,8877,O
extracellular,8877,O
complex,8877,O
occupying,8877,O
the,8877,O
interface,8877,O
between,8877,O
photoreceptors,8877,O
and,8877,O
the,8877,O
retinal,8877,O
pigment,8877,O
epithelium,8877,O
in,8877,O
the,8877,O
fundus,8877,O
of,8877,O
the,8877,O
eye,8877,O
.,8877,O
Because,8878,O
of,8878,O
the,8878,O
putative,8878,O
supportive,8878,O
role,8878,O
in,8878,O
photoreceptor,8878,O
maintenance,8878,O
",",8878,O
it,8878,O
is,8878,O
likely,8878,O
that,8878,O
constituent,8878,O
molecules,8878,O
play,8878,O
key,8878,O
roles,8878,O
in,8878,O
photoreceptor,8878,O
function,8878,O
and,8878,O
may,8878,O
be,8878,O
targets,8878,O
for,8878,O
inherited,8878,O
retinal,8878,B-CHEMICAL
disease,8878,O
.,8878,O
In,8879,O
this,8879,O
study,8879,O
we,8879,O
identify,8879,O
and,8879,O
characterize,8879,O
SPACRCAN,8879,B-GENE-N
",",8879,O
a,8879,O
novel,8879,O
chondroitin,8879,O
proteoglycan,8879,O
in,8879,O
this,8879,O
matrix,8879,O
.,8879,O
SPACRCAN,8880,B-GENE-N
was,8880,O
cloned,8880,O
from,8880,O
a,8880,O
human,8880,O
retinal,8880,B-CHEMICAL
cDNA,8880,O
library,8880,O
and,8880,O
the,8880,O
gene,8880,O
localized,8880,O
to,8880,O
chromosome,8880,O
3q11.2,8880,O
.,8880,O
Analysis,8881,O
of,8881,O
SPACRCAN,8881,B-GENE-N
mRNA,8881,O
and,8881,O
protein,8881,O
revealed,8881,O
that,8881,O
SPACRCAN,8881,B-GENE-N
is,8881,O
expressed,8881,O
exclusively,8881,O
by,8881,O
photoreceptors,8881,O
and,8881,O
pinealocytes,8881,O
.,8881,O
SPACRCAN,8882,B-GENE-N
synthesized,8882,O
by,8882,O
photoreceptors,8882,O
is,8882,O
localized,8882,O
to,8882,O
the,8882,O
interphotoreceptor,8882,O
matrix,8882,O
where,8882,O
it,8882,O
surrounds,8882,O
both,8882,O
rods,8882,O
and,8882,O
cones,8882,O
.,8882,O
The,8883,O
functional,8883,O
protein,8883,O
contains,8883,O
1160,8883,O
amino,8883,B-CHEMICAL
acids,8883,I-CHEMICAL
with,8883,O
a,8883,O
large,8883,O
central,8883,O
mucin,8883,B-GENE-N
domain,8883,I-GENE-N
",",8883,O
three,8883,O
consensus,8883,O
sites,8883,O
for,8883,O
glycosaminoglycan,8883,O
attachment,8883,O
",",8883,O
two,8883,O
epidermal,8883,O
growth,8883,O
factor-like,8883,O
repeats,8883,O
",",8883,O
a,8883,O
putative,8883,O
hyaluronan-binding,8883,B-GENE-N
motif,8883,I-GENE-N
",",8883,O
and,8883,O
a,8883,O
potential,8883,O
transmembrane,8883,O
domain,8883,O
near,8883,O
the,8883,O
C-terminal,8883,B-CHEMICAL
.,8883,O
Lectin,8884,B-GENE-N
and,8884,O
Western,8884,O
blotting,8884,O
indicate,8884,O
an,8884,O
M,8884,O
(,8884,O
r,8884,O
),8884,O
around,8884,O
"400,000",8884,O
before,8884,O
and,8884,O
"230,000",8884,O
after,8884,O
chondroitinase,8884,B-GENE-N
ABC,8884,I-GENE-N
digestion,8884,O
.,8884,O
Removal,8885,O
of,8885,O
N-,8885,B-CHEMICAL
and,8885,O
O-linked,8885,B-CHEMICAL
oligosaccharides,8885,O
reduces,8885,O
the,8885,O
M,8885,O
(,8885,O
r,8885,O
),8885,O
to,8885,O
approximately,8885,O
"160,000",8885,O
",",8885,O
suggesting,8885,O
that,8885,O
approximately,8885,O
60,8885,O
%,8885,O
of,8885,O
the,8885,O
mass,8885,O
of,8885,O
SPACRCAN,8885,B-GENE-N
is,8885,O
carbohydrate,8885,B-CHEMICAL
.,8885,O
Finally,8886,O
",",8886,O
we,8886,O
demonstrate,8886,O
that,8886,O
SPACRCAN,8886,B-GENE-N
binds,8886,O
hyaluronan,8886,B-GENE-N
and,8886,O
propose,8886,O
that,8886,O
associations,8886,O
between,8886,O
SPACRCAN,8886,B-GENE-N
and,8886,O
hyaluronan,8886,B-GENE-N
may,8886,O
be,8886,O
involved,8886,O
in,8886,O
organization,8886,O
of,8886,O
the,8886,O
insoluble,8886,O
interphotoreceptor,8886,O
matrix,8886,O
",",8886,O
particularly,8886,O
as,8886,O
SPACRCAN,8886,B-GENE-N
is,8886,O
the,8886,O
major,8886,O
proteoglycan,8886,O
present,8886,O
in,8886,O
this,8886,O
matrix,8886,O
.,8886,O
Validation,8887,O
of,8887,O
an,8887,O
in,8887,O
vitro,8887,O
exposure,8887,O
system,8887,O
for,8887,O
toxicity,8887,O
assessment,8887,O
of,8887,O
air-delivered,8887,O
nanomaterials,8887,O
.,8887,O
To,8888,O
overcome,8888,O
the,8888,O
limitations,8888,O
of,8888,O
in,8888,O
vitro,8888,O
exposure,8888,O
of,8888,O
submerged,8888,O
lung,8888,O
cells,8888,O
to,8888,O
nanoparticles,8888,O
(,8888,O
NPs,8888,O
),8888,O
",",8888,O
we,8888,O
validated,8888,O
an,8888,O
integrated,8888,O
low,8888,O
flow,8888,O
system,8888,O
capable,8888,O
of,8888,O
generating,8888,O
and,8888,O
depositing,8888,O
airborne,8888,O
NPs,8888,O
directly,8888,O
onto,8888,O
cells,8888,O
at,8888,O
an,8888,O
air-liquid,8888,O
interface,8888,O
(,8888,O
ALI,8888,O
),8888,O
.,8888,O
The,8889,O
in,8889,O
vitro,8889,O
exposure,8889,O
system,8889,O
was,8889,O
shown,8889,O
to,8889,O
provide,8889,O
uniform,8889,O
and,8889,O
controlled,8889,O
dosing,8889,O
of,8889,O
particles,8889,O
with,8889,O
70.3,8889,O
%,8889,O
efficiency,8889,O
to,8889,O
epithelial,8889,O
cells,8889,O
grown,8889,O
on,8889,O
transwells,8889,O
.,8889,O
This,8890,O
system,8890,O
delivered,8890,O
a,8890,O
continuous,8890,O
airborne,8890,O
exposure,8890,O
of,8890,O
NPs,8890,O
to,8890,O
lung,8890,O
cells,8890,O
without,8890,O
loss,8890,O
of,8890,O
cell,8890,O
viability,8890,O
in,8890,O
repeated,8890,O
4h,8890,O
exposure,8890,O
periods,8890,O
.,8890,O
We,8891,O
sequentially,8891,O
exposed,8891,O
cells,8891,O
to,8891,O
air-delivered,8891,O
copper,8891,B-CHEMICAL
(,8891,O
Cu,8891,B-CHEMICAL
),8891,O
NPs,8891,O
in,8891,O
vitro,8891,O
to,8891,O
compare,8891,O
toxicity,8891,O
results,8891,O
to,8891,O
our,8891,O
prior,8891,O
in,8891,O
vivo,8891,O
inhalation,8891,O
studies,8891,O
.,8891,O
The,8892,O
evaluation,8892,O
of,8892,O
cellular,8892,O
dosimetry,8892,O
indicated,8892,O
that,8892,O
a,8892,O
large,8892,O
amount,8892,O
of,8892,O
Cu,8892,B-CHEMICAL
was,8892,O
taken,8892,O
up,8892,O
",",8892,O
dissolved,8892,O
and,8892,O
released,8892,O
into,8892,O
the,8892,O
basolateral,8892,O
medium,8892,O
(,8892,O
62,8892,O
%,8892,O
of,8892,O
total,8892,O
mass,8892,O
),8892,O
.,8892,O
Exposure,8893,O
to,8893,O
Cu,8893,B-CHEMICAL
NPs,8893,O
decreased,8893,O
cell,8893,O
viability,8893,O
to,8893,O
73,8893,O
%,8893,O
(,8893,O
p,8893,O
<,8893,O
0.01,8893,O
),8893,O
and,8893,O
significantly,8893,O
(,8893,O
p,8893,O
<,8893,O
0.05,8893,O
),8893,O
elevated,8893,O
levels,8893,O
of,8893,O
lactate,8893,B-GENE-N
dehydrogenase,8893,I-GENE-N
",",8893,O
intracellular,8893,O
reactive,8893,O
oxygen,8893,B-CHEMICAL
species,8893,O
and,8893,O
interleukin-8,8893,B-GENE-Y
that,8893,O
mirrored,8893,O
our,8893,O
findings,8893,O
from,8893,O
subacute,8893,O
in,8893,O
vivo,8893,O
inhalation,8893,O
studies,8893,O
in,8893,O
mice,8893,O
.,8893,O
Our,8894,O
results,8894,O
show,8894,O
that,8894,O
this,8894,O
exposure,8894,O
system,8894,O
is,8894,O
useful,8894,O
for,8894,O
screening,8894,O
of,8894,O
NP,8894,O
toxicity,8894,O
in,8894,O
a,8894,O
manner,8894,O
that,8894,O
represents,8894,O
cellular,8894,O
responses,8894,O
of,8894,O
the,8894,O
pulmonary,8894,O
epithelium,8894,O
in,8894,O
vivo,8894,O
.,8894,O
Thioredoxin-mimetic,8895,B-GENE-Y
peptides,8895,O
(,8895,O
TXM,8895,O
),8895,O
reverse,8895,O
auranofin,8895,B-CHEMICAL
induced,8895,O
apoptosis,8895,O
and,8895,O
restore,8895,O
insulin,8895,B-GENE-N
secretion,8895,O
in,8895,O
insulinoma,8895,O
cells,8895,O
.,8895,O
The,8896,O
thioredoxin,8896,B-GENE-N
reductase/thioredoxin,8896,O
system,8896,O
(,8896,O
TrxR/Trx1,8896,B-GENE-N
),8896,O
plays,8896,O
a,8896,O
major,8896,O
role,8896,O
in,8896,O
protecting,8896,O
cells,8896,O
from,8896,O
oxidative,8896,O
stress,8896,O
.,8896,O
Disruption,8897,O
of,8897,O
the,8897,O
TrxR-Trx1,8897,B-GENE-N
system,8897,O
keeps,8897,O
Trx1,8897,B-GENE-Y
in,8897,O
the,8897,O
oxidized,8897,O
state,8897,O
leading,8897,O
to,8897,O
cell,8897,O
death,8897,O
through,8897,O
activation,8897,O
of,8897,O
the,8897,O
ASK1-Trx1,8897,B-GENE-Y
apoptotic,8897,O
pathway,8897,O
.,8897,O
The,8898,O
potential,8898,O
mechanism,8898,O
and,8898,O
ability,8898,O
of,8898,O
tri-,8898,O
and,8898,O
tetra-oligopeptides,8898,O
derived,8898,O
from,8898,O
the,8898,O
canonical,8898,O
-CxxC-,8898,O
motif,8898,I-GENE-N
of,8898,O
the,8898,O
Trx1-active,8898,B-GENE-Y
site,8898,O
to,8898,O
mimic,8898,O
and,8898,O
enhance,8898,O
Trx1,8898,B-GENE-Y
cellular,8898,O
activity,8898,O
was,8898,O
examined,8898,O
.,8898,O
The,8899,O
Trx,8899,B-GENE-Y
mimetics,8899,O
peptides,8899,O
(,8899,O
TXM,8899,O
),8899,O
protected,8899,O
insulinoma,8899,O
INS,8899,O
832/13,8899,O
cells,8899,O
from,8899,O
oxidative,8899,O
stress,8899,O
induced,8899,O
by,8899,O
selectively,8899,O
inhibiting,8899,O
TrxR,8899,B-GENE-N
with,8899,O
auranofin,8899,B-CHEMICAL
(,8899,O
AuF,8899,B-CHEMICAL
),8899,O
.,8899,O
TXM,8900,O
reversed,8900,O
the,8900,O
AuF-effects,8900,B-CHEMICAL
preventing,8900,O
apoptosis,8900,O
",",8900,O
and,8900,O
increasing,8900,O
cell-viability,8900,O
.,8900,O
The,8901,O
TXM,8901,O
peptides,8901,O
were,8901,O
effective,8901,O
in,8901,O
inhibiting,8901,O
AuF-induced,8901,B-CHEMICAL
MAPK,8901,B-GENE-N
",",8901,O
JNK,8901,B-GENE-N
and,8901,O
p38,8901,B-GENE-N
(,8901,O
MAPK,8901,B-GENE-N
),8901,O
phosphorylation,8901,O
",",8901,O
in,8901,O
correlation,8901,O
with,8901,O
preventing,8901,O
caspase-3,8901,B-GENE-Y
cleavage,8901,O
and,8901,O
thereby,8901,O
PARP-1,8901,B-GENE-Y
dissociation,8901,O
.,8901,O
The,8902,O
ability,8902,O
to,8902,O
form,8902,O
a,8902,O
disulfide-bridge-like,8902,B-CHEMICAL
conformation,8902,O
was,8902,O
estimated,8902,O
from,8902,O
molecular,8902,O
dynamics,8902,O
simulations,8902,O
.,8902,O
The,8903,O
TXM,8903,O
peptides,8903,O
restored,8903,O
insulin,8903,B-GENE-N
secretion,8903,O
and,8903,O
displayed,8903,O
Trx1,8903,B-GENE-Y
denitrosylase,8903,B-GENE-N
activity,8903,O
.,8903,O
Their,8904,O
potency,8904,O
was,8904,O
10-100-fold,8904,O
higher,8904,O
than,8904,O
redox,8904,O
reagents,8904,O
like,8904,O
NAC,8904,B-CHEMICAL
",",8904,O
AD4,8904,B-CHEMICAL
",",8904,O
or,8904,O
ascorbic,8904,B-CHEMICAL
acid,8904,I-CHEMICAL
.,8904,O
Unable,8905,O
to,8905,O
reverse,8905,O
ERK1/2,8905,B-GENE-N
phosphorylation,8905,O
",",8905,O
TXM-CB3,8905,O
(,8905,O
NAc-Cys-Pro-Cys,8905,B-CHEMICAL
amide,8905,I-CHEMICAL
),8905,O
appeared,8905,O
to,8905,O
function,8905,O
in,8905,O
part,8905,O
",",8905,O
through,8905,O
inhibiting,8905,O
ASK1-Trx,8905,B-GENE-Y
dissociation,8905,O
.,8905,O
These,8906,O
highly,8906,O
effective,8906,O
anti-apoptotic,8906,O
effects,8906,O
of,8906,O
Trx1,8906,B-GENE-Y
mimetic,8906,O
peptides,8906,O
exhibited,8906,O
in,8906,O
INS,8906,O
832/13,8906,O
cells,8906,O
could,8906,O
become,8906,O
valuable,8906,O
in,8906,O
treating,8906,O
adverse,8906,O
oxidative-stress,8906,O
related,8906,O
disorders,8906,O
such,8906,O
as,8906,O
diabetes,8906,O
.,8906,O
Preferential,8907,O
block,8907,O
of,8907,O
late,8907,O
sodium,8907,B-CHEMICAL
current,8907,O
in,8907,O
the,8907,O
LQT3,8907,B-GENE-Y
DeltaKPQ,8907,I-GENE-Y
mutant,8907,I-GENE-Y
by,8907,O
the,8907,O
class,8907,O
I,8907,O
(,8907,O
C,8907,O
),8907,O
antiarrhythmic,8907,O
flecainide,8907,B-CHEMICAL
.,8907,O
Flecainide,8908,B-CHEMICAL
block,8908,O
of,8908,O
Na,8908,B-CHEMICAL
(,8908,I-CHEMICAL
+,8908,I-CHEMICAL
),8908,I-CHEMICAL
current,8908,O
(,8908,O
I,8908,O
(,8908,O
Na,8908,B-CHEMICAL
),8908,O
),8908,O
was,8908,O
investigated,8908,O
in,8908,O
wild-type,8908,O
(,8908,O
WT,8908,O
),8908,O
or,8908,O
the,8908,O
long,8908,B-GENE-Y
QT,8908,I-GENE-Y
syndrome,8908,I-GENE-Y
3,8908,I-GENE-Y
(,8908,I-GENE-Y
LQT3,8908,I-GENE-Y
),8908,I-GENE-Y
sodium,8908,I-GENE-Y
channel,8908,I-GENE-Y
alpha,8908,I-GENE-Y
subunit,8908,O
mutation,8908,O
with,8908,O
three,8908,O
amino,8908,B-CHEMICAL
acids,8908,I-CHEMICAL
deleted,8908,O
(,8908,O
DeltaKPQ,8908,B-GENE-Y
),8908,O
stably,8908,O
transfected,8908,O
into,8908,O
human,8908,O
embryonic,8908,O
kidney,8908,O
293,8908,O
cells,8908,O
using,8908,O
whole-cell,8908,O
",",8908,O
patch-clamp,8908,O
recordings,8908,O
.,8908,O
Flecainide,8909,B-CHEMICAL
(,8909,O
1-300,8909,O
mM,8909,O
),8909,O
caused,8909,O
tonic,8909,O
and,8909,O
use-dependent,8909,O
block,8909,O
(,8909,O
UDB,8909,O
),8909,O
of,8909,O
I,8909,O
(,8909,O
Na,8909,B-CHEMICAL
),8909,O
in,8909,O
a,8909,O
concentration-dependent,8909,O
manner,8909,O
.,8909,O
Compared,8910,O
with,8910,O
WT,8910,O
",",8910,O
DeltaKPQ,8910,B-GENE-Y
I,8910,O
(,8910,O
Na,8910,B-CHEMICAL
),8910,O
was,8910,O
more,8910,O
sensitive,8910,O
to,8910,O
flecainide,8910,B-CHEMICAL
",",8910,O
and,8910,O
flecainide,8910,B-CHEMICAL
preferentially,8910,O
inhibited,8910,O
late,8910,O
I,8910,O
(,8910,O
Na,8910,B-CHEMICAL
),8910,O
(,8910,O
mean,8910,O
current,8910,O
between,8910,O
20,8910,O
and,8910,O
23.5,8910,O
ms,8910,O
after,8910,O
depolarization,8910,O
),8910,O
compared,8910,O
with,8910,O
peak,8910,O
I,8910,O
(,8910,O
Na,8910,B-CHEMICAL
),8910,O
.,8910,O
The,8911,O
IC,8911,O
(,8911,O
50,8911,O
),8911,O
value,8911,O
of,8911,O
peak,8911,O
and,8911,O
late,8911,O
I,8911,O
(,8911,O
Na,8911,B-CHEMICAL
),8911,O
for,8911,O
WT,8911,O
was,8911,O
127,8911,O
+/-,8911,O
6,8911,O
and,8911,O
44,8911,O
+/-,8911,O
2,8911,O
microM,8911,O
(,8911,O
n,8911,O
=,8911,O
20,8911,O
),8911,O
and,8911,O
for,8911,O
DeltaKPQ,8911,B-GENE-Y
was,8911,O
80,8911,O
+/-,8911,O
9,8911,O
and,8911,O
19,8911,O
+/-,8911,O
2,8911,O
microM,8911,O
(,8911,O
n,8911,O
=,8911,O
31,8911,O
),8911,O
respectively,8911,O
.,8911,O
UDB,8912,O
of,8912,O
peak,8912,O
I,8912,O
(,8912,O
Na,8912,B-CHEMICAL
),8912,O
was,8912,O
greater,8912,O
and,8912,O
developed,8912,O
more,8912,O
slowly,8912,O
during,8912,O
pulse,8912,O
trains,8912,O
for,8912,O
DeltaKPQ,8912,B-GENE-Y
than,8912,O
for,8912,O
WT,8912,O
.,8912,O
The,8913,O
IC,8913,O
(,8913,O
50,8913,O
),8913,O
value,8913,O
for,8913,O
UDB,8913,O
of,8913,O
peak,8913,O
I,8913,O
(,8913,O
Na,8913,O
),8913,O
for,8913,O
WT,8913,O
was,8913,O
29,8913,O
+/-,8913,O
4,8913,O
microM,8913,O
(,8913,O
n,8913,O
=,8913,O
20,8913,O
),8913,O
and,8913,O
for,8913,O
DeltaKPQ,8913,B-GENE-Y
was,8913,O
11,8913,O
+/-,8913,O
1,8913,O
microM,8913,O
(,8913,O
n,8913,O
=,8913,O
26,8913,O
),8913,O
.,8913,O
For,8914,O
DeltaKPQ,8914,B-GENE-Y
",",8914,O
UDB,8914,O
of,8914,O
late,8914,O
I,8914,O
(,8914,O
Na,8914,B-CHEMICAL
),8914,O
was,8914,O
greater,8914,O
than,8914,O
for,8914,O
peak,8914,O
I,8914,O
(,8914,O
Na,8914,B-CHEMICAL
),8914,O
.,8914,O
Recovery,8915,O
from,8915,O
block,8915,O
was,8915,O
slower,8915,O
for,8915,O
DeltaKPQ,8915,B-GENE-Y
than,8915,O
for,8915,O
WT,8915,O
.,8915,O
We,8916,O
conclude,8916,O
that,8916,O
DeltaKPQ,8916,B-GENE-Y
interacts,8916,O
differently,8916,O
with,8916,O
flecainide,8916,B-CHEMICAL
than,8916,O
with,8916,O
WT,8916,O
",",8916,O
leading,8916,O
to,8916,O
increased,8916,O
block,8916,O
and,8916,O
slowed,8916,O
recovery,8916,O
",",8916,O
especially,8916,O
for,8916,O
late,8916,O
I,8916,O
(,8916,O
Na,8916,B-CHEMICAL
),8916,O
.,8916,O
These,8917,O
data,8917,O
provide,8917,O
insights,8917,O
into,8917,O
mechanisms,8917,O
for,8917,O
flecainide,8917,B-CHEMICAL
block,8917,O
and,8917,O
provide,8917,O
a,8917,O
rationale,8917,O
at,8917,O
the,8917,O
cellular,8917,O
and,8917,O
molecular,8917,O
level,8917,O
that,8917,O
open,8917,O
channel,8917,O
block,8917,O
may,8917,O
be,8917,O
a,8917,O
useful,8917,O
pharmacological,8917,O
property,8917,O
for,8917,O
treatment,8917,O
of,8917,O
LQT3,8917,O
.,8917,O
In,8918,O
vivo,8918,O
and,8918,O
in,8918,O
vitro,8918,O
characterization,8918,O
of,8918,O
naltrindole-derived,8918,B-CHEMICAL
ligands,8918,O
at,8918,O
the,8918,O
κ-opioid,8918,B-GENE-Y
receptor,8918,I-GENE-Y
.,8918,O
Accumulating,8919,O
evidence,8919,O
supports,8919,O
a,8919,O
role,8919,O
for,8919,O
κ-opioid,8919,B-GENE-Y
receptor,8919,I-GENE-Y
antagonists,8919,O
in,8919,O
the,8919,O
treatment,8919,O
of,8919,O
mood,8919,O
disorders,8919,O
.,8919,O
Standard,8920,O
κ-antagonists,8920,O
have,8920,O
an,8920,O
unusual,8920,O
pharmacodynamic,8920,O
action,8920,O
",",8920,O
with,8920,O
a,8920,O
single,8920,O
injection,8920,O
blocking,8920,O
receptor,8920,O
signaling,8920,O
for,8920,O
several,8920,O
weeks,8920,O
.,8920,O
Here,8921,O
",",8921,O
we,8921,O
have,8921,O
characterized,8921,O
the,8921,O
κ-selective,8921,O
properties,8921,O
of,8921,O
two,8921,O
ligands,8921,O
",",8921,O
5'-,8921,B-CHEMICAL
(,8921,I-CHEMICAL
2-aminomethyl,8921,I-CHEMICAL
),8921,I-CHEMICAL
naltrindole,8921,I-CHEMICAL
(,8921,O
5'-AMN,8921,B-CHEMICAL
),8921,O
and,8921,O
N-,8921,B-CHEMICAL
(,8921,I-CHEMICAL
(,8921,I-CHEMICAL
Naltrindol-5-yl,8921,I-CHEMICAL
),8921,I-CHEMICAL
methyl,8921,I-CHEMICAL
),8921,I-CHEMICAL
pentanimidamide,8921,I-CHEMICAL
(,8921,O
5'-MABN,8921,B-CHEMICAL
),8921,O
",",8921,O
to,8921,O
identify,8921,O
whether,8921,O
modifications,8921,O
of,8921,O
the,8921,O
naltrindole,8921,B-CHEMICAL
side,8921,O
chain,8921,O
produces,8921,O
short-acting,8921,O
κ-antagonists,8921,O
.,8921,O
Opioid,8922,B-GENE-N
receptor,8922,I-GENE-N
binding,8922,O
affinity,8922,O
and,8922,O
activity,8922,O
were,8922,O
assessed,8922,O
using,8922,O
[,8922,B-CHEMICAL
(,8922,I-CHEMICAL
3,8922,I-CHEMICAL
),8922,I-CHEMICAL
H,8922,I-CHEMICAL
],8922,I-CHEMICAL
-diprenorphine,8922,I-CHEMICAL
binding,8922,O
",",8922,O
guanosine-5'-O-,8922,B-CHEMICAL
(,8922,I-CHEMICAL
3-,8922,I-CHEMICAL
[,8922,I-CHEMICAL
35S,8922,I-CHEMICAL
],8922,I-CHEMICAL
-thio,8922,I-CHEMICAL
),8922,I-CHEMICAL
triphosphate,8922,I-CHEMICAL
(,8922,O
[,8922,B-CHEMICAL
(,8922,I-CHEMICAL
35,8922,I-CHEMICAL
),8922,I-CHEMICAL
S,8922,I-CHEMICAL
],8922,I-CHEMICAL
-GTPγS,8922,I-CHEMICAL
),8922,O
binding,8922,O
and,8922,O
isolated,8922,O
guinea-pig,8922,O
ileum,8922,O
.,8922,O
Pharmacodynamic,8923,O
profiles,8923,O
of,8923,O
5'-AMN,8923,B-CHEMICAL
and,8923,O
5'-MABN,8923,B-CHEMICAL
(,8923,O
1-10,8923,O
mg/kg,8923,O
),8923,O
were,8923,O
investigated,8923,O
using,8923,O
the,8923,O
tail-withdrawal,8923,O
assay,8923,O
and,8923,O
diuresis,8923,O
.,8923,O
Efficacy,8924,O
was,8924,O
also,8924,O
determined,8924,O
in,8924,O
depression-,8924,O
and,8924,O
anxiety-related,8924,O
behavioral,8924,O
paradigms,8924,O
in,8924,O
CD-1,8924,O
mice,8924,O
.,8924,O
Both,8925,O
5'-AMN,8925,B-CHEMICAL
and,8925,O
5'-MABN,8925,B-CHEMICAL
had,8925,O
high,8925,O
affinity,8925,O
for,8925,O
κ-receptors,8925,B-GENE-Y
(,8925,O
K,8925,O
(,8925,O
i,8925,O
),8925,O
1.36,8925,O
±,8925,O
0.98,8925,O
and,8925,O
0.27,8925,O
±,8925,O
0.08,8925,O
",",8925,O
respectively,8925,O
),8925,O
and,8925,O
were,8925,O
revealed,8925,O
as,8925,O
potent,8925,O
κ-antagonists,8925,O
(,8925,O
pA,8925,O
(,8925,O
2,8925,O
),8925,O
7.43,8925,O
and,8925,O
8.18,8925,O
",",8925,O
respectively,8925,O
),8925,O
and,8925,O
μ-receptor,8925,B-GENE-Y
antagonists,8925,O
(,8925,O
pA,8925,O
(,8925,O
2,8925,O
),8925,O
7.62,8925,O
and,8925,O
7.85,8925,O
",",8925,O
respectively,8925,O
),8925,O
in,8925,O
the,8925,O
ileum,8925,O
.,8925,O
Contrary,8926,O
to,8926,O
our,8926,O
hypothesis,8926,O
",",8926,O
in,8926,O
vivo,8926,O
",",8926,O
5'-AMN,8926,B-CHEMICAL
and,8926,O
5'-MABN,8926,B-CHEMICAL
displayed,8926,O
long-lasting,8926,O
antagonist,8926,O
effects,8926,O
in,8926,O
mice,8926,O
",",8926,O
reducing,8926,O
the,8926,O
antinociceptive,8926,O
actions,8926,O
of,8926,O
"U50,488",8926,B-CHEMICAL
(,8926,O
10,8926,O
mg/kg,8926,O
),8926,O
at,8926,O
28,8926,O
and,8926,O
21,8926,O
days,8926,O
post-injection,8926,O
",",8926,O
respectively,8926,O
.,8926,O
Interestingly,8927,O
",",8927,O
while,8927,O
5'-AMN,8927,B-CHEMICAL
and,8927,O
5'-MABN,8927,B-CHEMICAL
were,8927,O
not,8927,O
κ-selective,8927,O
",",8927,O
both,8927,O
compounds,8927,O
did,8927,O
show,8927,O
significant,8927,O
antidepressant-,8927,O
and,8927,O
anxiolytic-like,8927,O
effects,8927,O
at,8927,O
7-14,8927,O
days,8927,O
post-injection,8927,O
in,8927,O
mice,8927,O
.,8927,O
Design,8928,O
and,8928,O
synthesis,8928,O
of,8928,O
highly,8928,O
selective,8928,O
",",8928,O
orally,8928,O
active,8928,O
Polo-like,8928,B-GENE-Y
kinase-2,8928,I-GENE-Y
(,8928,O
Plk-2,8928,B-GENE-Y
),8928,O
inhibitors,8928,O
.,8928,O
Polo-like,8929,B-GENE-Y
kinase-2,8929,I-GENE-Y
(,8929,O
Plk-2,8929,B-GENE-Y
),8929,O
is,8929,O
a,8929,O
potential,8929,O
therapeutic,8929,O
target,8929,O
for,8929,O
Parkinson,8929,O
's,8929,O
disease,8929,O
and,8929,O
this,8929,O
Letter,8929,O
describes,8929,O
the,8929,O
SAR,8929,O
of,8929,O
a,8929,O
series,8929,O
of,8929,O
dihydropteridinone,8929,B-CHEMICAL
based,8929,O
Plk-2,8929,B-GENE-Y
inhibitors,8929,O
.,8929,O
By,8930,O
optimizing,8930,O
both,8930,O
the,8930,O
N-8,8930,O
substituent,8930,O
and,8930,O
the,8930,O
biaryl,8930,O
region,8930,O
of,8930,O
the,8930,O
inhibitors,8930,O
we,8930,O
obtained,8930,O
single,8930,O
digit,8930,O
nanomolar,8930,O
compounds,8930,O
such,8930,O
as,8930,O
37,8930,O
with,8930,O
excellent,8930,O
selectivity,8930,O
for,8930,O
Plk-2,8930,B-GENE-Y
over,8930,O
Plk-1,8930,B-GENE-Y
.,8930,O
When,8931,O
dosed,8931,O
orally,8931,O
in,8931,O
rats,8931,O
",",8931,O
compound,8931,O
37,8931,O
demonstrated,8931,O
a,8931,O
41-45,8931,O
%,8931,O
reduction,8931,O
of,8931,O
pS129-α-synuclein,8931,B-GENE-Y
levels,8931,O
in,8931,O
the,8931,O
cerebral,8931,O
cortex,8931,O
.,8931,O
Effect,8932,O
of,8932,O
bioactive,8932,O
peptide,8932,O
of,8932,O
Carapax,8932,O
Trionycis,8932,O
on,8932,O
TGF-β1-induced,8932,B-GENE-Y
intracellular,8932,O
events,8932,O
in,8932,O
hepatic,8932,O
stellate,8932,O
cells,8932,O
.,8932,O
ETHNOPHARMACOLOGICAL,8933,O
RELEVANCE,8933,O
:,8933,O
In,8933,O
traditional,8933,O
Chinese,8933,O
medicines,8933,O
for,8933,O
hepatic,8933,O
fibrosis,8933,O
therapy,8933,O
",",8933,O
Carapax,8933,O
Trionycis,8933,O
is,8933,O
used,8933,O
usually,8933,O
as,8933,O
an,8933,O
indispensable,8933,O
component,8933,O
and,8933,O
has,8933,O
a,8933,O
long,8933,O
history,8933,O
of,8933,O
medical,8933,O
use,8933,O
in,8933,O
China,8933,O
.,8933,O
Previous,8934,O
studies,8934,O
have,8934,O
demonstrated,8934,O
that,8934,O
extracts,8934,O
of,8934,O
Carapax,8934,O
Trionycis,8934,O
were,8934,O
able,8934,O
to,8934,O
protect,8934,O
liver,8934,O
against,8934,O
fibrosis,8934,O
in,8934,O
CCl4,8934,O
animal,8934,O
models,8934,O
.,8934,O
AIM,8935,O
OF,8935,O
THE,8935,O
STUDY,8935,O
:,8935,O
The,8935,O
purpose,8935,O
of,8935,O
this,8935,O
study,8935,O
is,8935,O
to,8935,O
verify,8935,O
the,8935,O
inhibitory,8935,O
effect,8935,O
and,8935,O
the,8935,O
underlying,8935,O
mechanisms,8935,O
of,8935,O
Carapax,8935,O
Trionycis,8935,O
extract,8935,O
peptide,8935,O
(,8935,O
CTEP,8935,O
),8935,O
on,8935,O
activated,8935,O
hepatic,8935,O
stellate,8935,O
cells,8935,O
which,8935,O
play,8935,O
a,8935,O
central,8935,O
role,8935,O
in,8935,O
liver,8935,O
fibrogenesis,8935,O
.,8935,O
MATERIALS,8936,O
AND,8936,O
METHODS,8936,O
:,8936,O
Hepatic,8936,O
stellate,8936,O
cells,8936,O
induced,8936,O
by,8936,O
TGF-β1,8936,B-GENE-Y
were,8936,O
applied,8936,O
to,8936,O
evaluate,8936,O
the,8936,O
anti-fibrotic,8936,O
effect,8936,O
of,8936,O
CTEP,8936,O
in,8936,O
vitro,8936,O
.,8936,O
MTS,8937,B-CHEMICAL
assay,8937,O
",",8937,O
enzyme-linked,8937,O
immunosorbent,8937,O
assay,8937,O
and,8937,O
western,8937,O
blotting,8937,O
were,8937,O
then,8937,O
used,8937,O
to,8937,O
further,8937,O
investigate,8937,O
the,8937,O
molecular,8937,O
mechanisms,8937,O
.,8937,O
RESULTS,8938,O
:,8938,O
The,8938,O
results,8938,O
show,8938,O
that,8938,O
the,8938,O
contents,8938,O
of,8938,O
collagen,8938,B-GENE-N
I,8938,I-GENE-N
",",8938,O
collagen,8938,B-GENE-N
III,8938,I-GENE-N
and,8938,O
TIMP-1,8938,B-GENE-Y
were,8938,O
significantly,8938,O
inhibited,8938,O
and,8938,O
the,8938,O
level,8938,O
of,8938,O
collagen,8938,B-GENE-N
I,8938,I-GENE-N
",",8938,O
collagen,8938,B-GENE-N
III,8938,I-GENE-N
",",8938,O
p-Smad,8938,B-GENE-Y
3,8938,I-GENE-Y
",",8938,O
TIMP-1,8938,B-GENE-Y
and,8938,O
α-SMA,8938,B-GENE-Y
proteins,8938,O
decreased,8938,O
significantly,8938,O
in,8938,O
a,8938,O
concentration-dependence,8938,O
manner,8938,O
after,8938,O
treatment,8938,O
with,8938,O
CTEP,8938,O
.,8938,O
Interestingly,8939,O
",",8939,O
the,8939,O
level,8939,O
of,8939,O
Smad,8939,B-GENE-Y
3,8939,I-GENE-Y
protein,8939,O
was,8939,O
not,8939,O
different,8939,O
significantly,8939,O
.,8939,O
CONCLUSIONS,8940,O
:,8940,O
Our,8940,O
data,8940,O
indicate,8940,O
that,8940,O
CTEP,8940,O
efficiently,8940,O
inhibits,8940,O
cultured,8940,O
HSC-T6,8940,O
cell,8940,O
activation,8940,O
and,8940,O
proliferation,8940,O
via,8940,O
the,8940,O
TGF-β1/Smad,8940,B-GENE-Y
pathway,8940,O
as,8940,O
well,8940,O
as,8940,O
by,8940,O
the,8940,O
elimination,8940,O
of,8940,O
the,8940,O
extracellular,8940,O
matrix,8940,O
.,8940,O
Sphingosine-1-phosphate,8941,B-CHEMICAL
promotes,8941,O
the,8941,O
nuclear,8941,O
translocation,8941,O
of,8941,O
β-catenin,8941,B-GENE-N
and,8941,O
thereby,8941,O
induces,8941,O
osteoprotegerin,8941,B-GENE-N
gene,8941,O
expression,8941,O
in,8941,O
osteoblast-like,8941,O
cell,8941,O
lines,8941,O
.,8941,O
Sphingosine-1-phosphate,8942,B-CHEMICAL
(,8942,O
S1P,8942,B-CHEMICAL
),8942,O
is,8942,O
a,8942,O
well-known,8942,O
signaling,8942,O
sphingolipid,8942,B-CHEMICAL
and,8942,O
bioactive,8942,O
lipid,8942,O
mediator,8942,O
.,8942,O
Recently,8943,O
",",8943,O
it,8943,O
was,8943,O
reported,8943,O
that,8943,O
S1P,8943,B-CHEMICAL
inhibits,8943,O
osteoclast,8943,O
differentiation,8943,O
and,8943,O
bone,8943,O
resorption,8943,O
.,8943,O
On,8944,O
the,8944,O
other,8944,O
hand,8944,O
",",8944,O
S1P,8944,B-CHEMICAL
effects,8944,O
on,8944,O
osteoblasts,8944,O
and,8944,O
bone,8944,O
formation,8944,O
are,8944,O
little,8944,O
known,8944,O
.,8944,O
In,8945,O
this,8945,O
study,8945,O
",",8945,O
we,8945,O
investigated,8945,O
the,8945,O
effects,8945,O
of,8945,O
S1P,8945,B-CHEMICAL
on,8945,O
osteoblasts,8945,O
",",8945,O
using,8945,O
two,8945,O
osteoblast-like,8945,O
cell,8945,O
lines,8945,O
",",8945,O
SaOS-2,8945,O
and,8945,O
MC3T3-E1,8945,O
.,8945,O
S1P,8946,B-CHEMICAL
activated,8946,O
phosphatidylinositol,8946,B-GENE-N
3-kinase,8946,I-GENE-N
(,8946,O
PI3K,8946,B-GENE-N
),8946,O
/Akt,8946,O
signaling,8946,O
",",8946,O
leading,8946,O
to,8946,O
the,8946,O
inhibition,8946,O
of,8946,O
glycogen,8946,B-GENE-N
synthase,8946,I-GENE-N
kinase-3β,8946,I-GENE-N
and,8946,O
the,8946,O
nuclear,8946,O
translocation,8946,O
of,8946,O
β-catenin,8946,B-GENE-N
",",8946,O
followed,8946,O
by,8946,O
the,8946,O
increase,8946,O
of,8946,O
the,8946,O
transcriptional,8946,O
activity,8946,O
by,8946,O
β-catenin/T-cell,8946,B-GENE-N
factor,8946,I-GENE-N
complex,8946,O
formation,8946,O
in,8946,O
both,8946,O
SaOS-2,8946,O
cells,8946,O
and,8946,O
MC3T3-E1,8946,O
cells,8946,O
.,8946,O
The,8947,O
inhibitors,8947,O
of,8947,O
PI3K,8947,B-GENE-N
and,8947,O
Akt,8947,B-GENE-N
suppressed,8947,O
S1P-induced,8947,B-CHEMICAL
nuclear,8947,O
localization,8947,O
of,8947,O
β-catenin,8947,B-GENE-N
.,8947,O
We,8948,O
further,8948,O
investigated,8948,O
the,8948,O
effects,8948,O
of,8948,O
PI3K/Akt,8948,B-GENE-N
signaling,8948,O
on,8948,O
the,8948,O
Wnt/β-catenin,8948,B-GENE-N
signaling,8948,O
pathway,8948,O
",",8948,O
since,8948,O
β-catenin,8948,B-GENE-N
takes,8948,O
a,8948,O
central,8948,O
role,8948,O
in,8948,O
this,8948,O
signaling,8948,O
pathway,8948,O
.,8948,O
Both,8949,O
inhibitors,8949,O
for,8949,O
PI3K,8949,B-GENE-N
and,8949,O
Akt,8949,B-GENE-N
suppressed,8949,O
the,8949,O
nuclear,8949,O
localization,8949,O
of,8949,O
β-catenin,8949,B-GENE-N
and,8949,O
T-cell,8949,B-GENE-N
factor,8949,I-GENE-N
transcriptional,8949,O
activity,8949,O
induced,8949,O
by,8949,O
Wnt-3a,8949,B-GENE-N
.,8949,O
S1P,8950,B-CHEMICAL
increased,8950,O
the,8950,O
amount,8950,O
of,8950,O
osteoprotegerin,8950,B-GENE-N
at,8950,O
both,8950,O
mRNA,8950,O
and,8950,O
protein,8950,O
levels,8950,O
",",8950,O
and,8950,O
increased,8950,O
the,8950,O
activity,8950,O
of,8950,O
alkaline,8950,B-GENE-N
phosphatase,8950,I-GENE-N
",",8950,O
leading,8950,O
to,8950,O
the,8950,O
mineralization,8950,O
.,8950,O
These,8951,O
findings,8951,O
suggest,8951,O
that,8951,O
S1P,8951,B-CHEMICAL
activates,8951,O
the,8951,O
PI3K/Akt,8951,B-GENE-N
signaling,8951,O
pathway,8951,O
leading,8951,O
to,8951,O
the,8951,O
promotion,8951,O
of,8951,O
nuclear,8951,O
translocation,8951,O
of,8951,O
β-catenin,8951,B-GENE-N
in,8951,O
osteoblast-like,8951,O
cells,8951,O
",",8951,O
resulting,8951,O
in,8951,O
the,8951,O
upregulation,8951,O
of,8951,O
osteoptotegerin,8951,B-GENE-N
and,8951,O
osteoblast,8951,O
differentiation,8951,O
markers,8951,O
including,8951,O
alkaline,8951,B-GENE-N
phosphatase,8951,I-GENE-N
",",8951,O
probably,8951,O
relating,8951,O
to,8951,O
the,8951,O
inhibition,8951,O
of,8951,O
osteoclast,8951,O
formation,8951,O
and,8951,O
the,8951,O
mineralization,8951,O
",",8951,O
respectively,8951,O
.,8951,O
Plerixafor,8952,B-CHEMICAL
",",8952,O
a,8952,O
CXCR4,8952,B-GENE-Y
antagonist,8952,O
for,8952,O
the,8952,O
mobilization,8952,O
of,8952,O
hematopoietic,8952,O
stem,8952,O
cells,8952,O
.,8952,O
Stem,8953,O
cells,8953,O
harvested,8953,O
from,8953,O
peripheral,8953,O
blood,8953,O
are,8953,O
the,8953,O
most,8953,O
commonly,8953,O
used,8953,O
graft,8953,O
source,8953,O
in,8953,O
hematopoietic,8953,O
stem,8953,O
cell,8953,O
transplantation,8953,O
.,8953,O
While,8954,O
G-CSF,8954,B-GENE-Y
is,8954,O
the,8954,O
most,8954,O
frequently,8954,O
used,8954,O
agent,8954,O
for,8954,O
stem,8954,O
cell,8954,O
mobilization,8954,O
",",8954,O
the,8954,O
use,8954,O
of,8954,O
G-CSF,8954,B-GENE-Y
alone,8954,O
results,8954,O
in,8954,O
suboptimal,8954,O
stem,8954,O
cell,8954,O
yields,8954,O
in,8954,O
a,8954,O
significant,8954,O
proportion,8954,O
of,8954,O
patients,8954,O
undergoing,8954,O
autologous,8954,O
transplantation,8954,O
.,8954,O
Plerixafor,8955,B-CHEMICAL
(,8955,O
AMD3100,8955,B-CHEMICAL
",",8955,O
Genzyme,8955,O
Corporation,8955,O
),8955,O
is,8955,O
a,8955,O
bicyclam,8955,B-CHEMICAL
molecule,8955,O
that,8955,O
antagonizes,8955,O
the,8955,O
binding,8955,O
of,8955,O
the,8955,O
chemokine,8955,B-GENE-N
stromal,8955,B-GENE-Y
cell-derived,8955,I-GENE-Y
factor-1,8955,I-GENE-Y
(,8955,O
SDF-1,8955,B-GENE-Y
),8955,O
to,8955,O
its,8955,O
cognate,8955,O
receptor,8955,O
CXCR4,8955,B-GENE-Y
.,8955,O
Plerixafor,8956,B-CHEMICAL
results,8956,O
in,8956,O
the,8956,O
rapid,8956,O
and,8956,O
reversible,8956,O
mobilization,8956,O
of,8956,O
hematopoietic,8956,O
stem,8956,O
cells,8956,O
into,8956,O
the,8956,O
peripheral,8956,O
circulation,8956,O
and,8956,O
is,8956,O
synergistic,8956,O
when,8956,O
combined,8956,O
with,8956,O
G-CSF,8956,B-GENE-Y
.,8956,O
In,8957,O
clinical,8957,O
studies,8957,O
of,8957,O
autologous,8957,O
stem,8957,O
cell,8957,O
transplantation,8957,O
",",8957,O
the,8957,O
combination,8957,O
of,8957,O
plerixafor,8957,B-CHEMICAL
and,8957,O
G-CSF,8957,B-GENE-Y
allows,8957,O
the,8957,O
collection,8957,O
of,8957,O
large,8957,O
numbers,8957,O
of,8957,O
stem,8957,O
cells,8957,O
in,8957,O
fewer,8957,O
apheresis,8957,O
sessions,8957,O
and,8957,O
can,8957,O
salvage,8957,O
those,8957,O
who,8957,O
fail,8957,O
G-CSF,8957,B-GENE-Y
mobilization,8957,O
alone,8957,O
.,8957,O
Supra-normal,8958,O
stimulation,8958,O
of,8958,O
dopamine,8958,B-GENE-Y
D1,8958,I-GENE-Y
receptors,8958,I-GENE-Y
in,8958,O
the,8958,O
prelimbic,8958,O
cortex,8958,O
blocks,8958,O
behavioral,8958,O
expression,8958,O
of,8958,O
both,8958,O
aversive,8958,O
and,8958,O
rewarding,8958,O
associative,8958,O
memories,8958,O
through,8958,O
a,8958,O
cyclic-AMP-dependent,8958,B-CHEMICAL
signaling,8958,O
pathway,8958,O
.,8958,O
Dopamine,8959,B-GENE-N
(,8959,I-GENE-N
DA,8959,I-GENE-N
),8959,I-GENE-N
receptor,8959,I-GENE-N
transmission,8959,O
through,8959,O
either,8959,O
D,8959,B-GENE-Y
(,8959,I-GENE-Y
1,8959,I-GENE-Y
),8959,I-GENE-Y
or,8959,O
D,8959,B-GENE-Y
(,8959,I-GENE-Y
2,8959,I-GENE-Y
),8959,I-GENE-Y
-like,8959,O
subtypes,8959,O
is,8959,O
involved,8959,O
critically,8959,O
in,8959,O
the,8959,O
processing,8959,O
of,8959,O
emotional,8959,O
information,8959,O
within,8959,O
the,8959,O
medial,8959,O
prefrontal,8959,O
cortex,8959,O
(,8959,O
mPFC,8959,O
),8959,O
.,8959,O
However,8960,O
the,8960,O
functional,8960,O
role,8960,O
of,8960,O
specific,8960,O
DA,8960,B-GENE-Y
D,8960,I-GENE-Y
(,8960,I-GENE-Y
1,8960,I-GENE-Y
),8960,I-GENE-Y
-like,8960,I-GENE-Y
receptor,8960,I-GENE-Y
transmission,8960,O
in,8960,O
the,8960,O
expression,8960,O
of,8960,O
emotionally,8960,O
salient,8960,O
associative,8960,O
memories,8960,O
(,8960,O
either,8960,O
aversive,8960,O
or,8960,O
rewarding,8960,O
),8960,O
is,8960,O
not,8960,O
currently,8960,O
understood,8960,O
.,8960,O
Here,8961,O
we,8961,O
demonstrate,8961,O
that,8961,O
specific,8961,O
activation,8961,O
of,8961,O
DA,8961,B-GENE-Y
D,8961,I-GENE-Y
(,8961,I-GENE-Y
1,8961,I-GENE-Y
),8961,I-GENE-Y
receptors,8961,I-GENE-Y
in,8961,O
the,8961,O
prelimbic,8961,O
(,8961,O
PLC,8961,O
),8961,O
division,8961,O
of,8961,O
the,8961,O
mPFC,8961,O
causes,8961,O
a,8961,O
transient,8961,O
block,8961,O
in,8961,O
the,8961,O
behavioral,8961,O
expression,8961,O
of,8961,O
both,8961,O
aversive,8961,O
and,8961,O
rewarding,8961,O
associative,8961,O
memories,8961,O
.,8961,O
We,8962,O
report,8962,O
that,8962,O
intra-PLC,8962,O
microinfusions,8962,O
of,8962,O
a,8962,O
selective,8962,O
D,8962,B-GENE-Y
(,8962,I-GENE-Y
1,8962,I-GENE-Y
),8962,I-GENE-Y
receptor,8962,I-GENE-Y
agonist,8962,O
block,8962,O
the,8962,O
spontaneous,8962,O
expression,8962,O
of,8962,O
an,8962,O
associative,8962,O
olfactory,8962,O
fear,8962,O
memory,8962,O
",",8962,O
without,8962,O
altering,8962,O
the,8962,O
stability,8962,O
of,8962,O
the,8962,O
original,8962,O
memory,8962,O
trace,8962,O
.,8962,O
Furthermore,8963,O
",",8963,O
using,8963,O
an,8963,O
unbiased,8963,O
place,8963,O
conditioning,8963,O
procedure,8963,O
(,8963,O
CPP,8963,O
),8963,O
",",8963,O
intra-PLC,8963,O
D,8963,B-GENE-Y
(,8963,I-GENE-Y
1,8963,I-GENE-Y
),8963,I-GENE-Y
receptor,8963,I-GENE-Y
activation,8963,O
blocks,8963,O
the,8963,O
spontaneous,8963,O
expression,8963,O
of,8963,O
an,8963,O
associative,8963,O
morphine,8963,B-CHEMICAL
(,8963,O
5,8963,O
mg/kg,8963,O
;,8963,O
i.p,8963,O
.,8963,O
),8963,O
reward,8964,O
memory,8964,O
",",8964,O
while,8964,O
leaving,8964,O
morphine-primed,8964,B-CHEMICAL
memory,8964,O
expression,8964,O
intact,8964,O
.,8964,O
Interestingly,8965,O
",",8965,O
both,8965,O
intra-PLC,8965,O
D,8965,B-GENE-Y
(,8965,I-GENE-Y
1,8965,I-GENE-Y
),8965,I-GENE-Y
-receptor,8965,I-GENE-Y
mediated,8965,O
block,8965,O
of,8965,O
either,8965,O
fear-related,8965,O
or,8965,O
reward-related,8965,O
associative,8965,O
memories,8965,O
were,8965,O
dependent,8965,O
upon,8965,O
downstream,8965,O
cyclic-AMP,8965,B-CHEMICAL
(,8965,O
cAMP,8965,B-CHEMICAL
),8965,O
signaling,8965,O
as,8965,O
both,8965,O
effects,8965,O
were,8965,O
rescued,8965,O
by,8965,O
co-administration,8965,O
of,8965,O
a,8965,O
cAMP,8965,B-CHEMICAL
signaling,8965,O
inhibitor,8965,O
.,8965,O
The,8966,O
blockade,8966,O
of,8966,O
both,8966,O
rewarding,8966,O
and,8966,O
aversive,8966,O
associative,8966,O
memories,8966,O
is,8966,O
mediated,8966,O
through,8966,O
a,8966,O
D,8966,B-GENE-Y
(,8966,I-GENE-Y
1,8966,I-GENE-Y
),8966,I-GENE-Y
-specific,8966,O
signaling,8966,O
pathway,8966,O
",",8966,O
as,8966,O
neither,8966,O
forms,8966,O
of,8966,O
spontaneous,8966,O
memory,8966,O
expression,8966,O
were,8966,O
blocked,8966,O
by,8966,O
intra-PLC,8966,O
microinfusions,8966,O
of,8966,O
a,8966,O
D,8966,B-GENE-Y
(,8966,I-GENE-Y
2,8966,I-GENE-Y
),8966,I-GENE-Y
-like,8966,I-GENE-Y
receptor,8966,I-GENE-Y
agonist,8966,O
.,8966,O
Our,8967,O
results,8967,O
demonstrate,8967,O
that,8967,O
the,8967,O
spontaneous,8967,O
expression,8967,O
of,8967,O
either,8967,O
rewarding,8967,O
or,8967,O
aversive,8967,O
emotionally,8967,O
salient,8967,O
memories,8967,O
shares,8967,O
a,8967,O
common,8967,O
",",8967,O
D,8967,B-GENE-Y
(,8967,I-GENE-Y
1,8967,I-GENE-Y
),8967,I-GENE-Y
-receptor,8967,I-GENE-Y
mediated,8967,O
substrate,8967,O
within,8967,O
the,8967,O
mPFC,8967,O
.,8967,O
P21-activated,8968,B-GENE-Y
protein,8968,I-GENE-Y
kinase,8968,I-GENE-Y
1,8968,I-GENE-Y
(,8968,O
Pak1,8968,B-GENE-Y
),8968,O
mediates,8968,O
the,8968,O
cross,8968,O
talk,8968,O
between,8968,O
insulin,8968,B-GENE-N
and,8968,O
β-catenin,8968,B-GENE-Y
on,8968,O
proglucagon,8968,B-GENE-N
gene,8968,O
expression,8968,O
and,8968,O
its,8968,O
ablation,8968,O
affects,8968,O
glucose,8968,B-CHEMICAL
homeostasis,8968,O
in,8968,O
male,8968,O
C57BL/6,8968,O
mice,8968,O
.,8968,O
In,8969,O
gut,8969,O
endocrine,8969,O
L,8969,O
cells,8969,O
",",8969,O
the,8969,O
Wnt,8969,B-GENE-N
signaling,8969,O
pathway,8969,O
effector,8969,O
β-catenin,8969,B-GENE-Y
(,8969,O
β-cat,8969,B-GENE-Y
),8969,O
/transcription,8969,O
factor,8969,I-GENE-Y
7-like,8969,I-GENE-Y
2,8969,I-GENE-Y
mediates,8969,O
the,8969,O
stimulatory,8969,O
effect,8969,O
of,8969,O
insulin,8969,B-GENE-Y
on,8969,O
proglucagon,8969,B-GENE-N
(,8969,O
gcg,8969,B-GENE-Y
),8969,O
expression,8969,O
and,8969,O
glucagon-like,8969,B-GENE-Y
peptide-1,8969,I-GENE-Y
(,8969,O
GLP-1,8969,B-GENE-Y
),8969,O
production,8969,O
.,8969,O
In,8970,O
several,8970,O
other,8970,O
cell,8970,O
lineages,8970,O
",",8970,O
insulin,8970,B-GENE-N
is,8970,O
able,8970,O
to,8970,O
stimulate,8970,O
p21-activated,8970,B-GENE-Y
protein,8970,I-GENE-Y
kinase,8970,I-GENE-Y
1,8970,I-GENE-Y
(,8970,O
Pak1,8970,B-GENE-Y
),8970,O
.,8970,O
Here,8971,O
we,8971,O
determined,8971,O
the,8971,O
role,8971,O
of,8971,O
Pak1,8971,B-GENE-Y
in,8971,O
gcg,8971,B-GENE-Y
expression,8971,O
and,8971,O
the,8971,O
effect,8971,O
of,8971,O
Pak1,8971,B-GENE-Y
deletion,8971,O
on,8971,O
glucose,8971,B-CHEMICAL
homeostasis,8971,O
.,8971,O
Insulin,8972,B-GENE-N
stimulated,8972,O
Pak1,8972,B-GENE-Y
activation,8972,O
through,8972,O
increasing,8972,O
its,8972,O
Thr423,8972,B-CHEMICAL
phosphorylation,8972,O
in,8972,O
gut,8972,O
gcg-expressing,8972,B-GENE-Y
cell,8972,O
lines,8972,O
",",8972,O
associated,8972,O
with,8972,O
increased,8972,O
gcg,8972,B-GENE-Y
mRNA,8972,O
levels,8972,O
.,8972,O
This,8973,O
stimulation,8973,O
was,8973,O
attenuated,8973,O
by,8973,O
the,8973,O
Pak,8973,B-GENE-N
inhibitor,8973,O
"2,2'-dihydroxy-1,1'-dinaphthyldisulfide",8973,B-CHEMICAL
(,8973,O
IPA3,8973,B-CHEMICAL
),8973,O
or,8973,O
dominant-negative,8973,O
Pak1,8973,B-GENE-Y
.,8973,O
Both,8974,O
insulin,8974,B-GENE-N
and,8974,O
cAMP-promoting,8974,B-CHEMICAL
agents,8974,O
activated,8974,O
β-cat,8974,O
Ser675,8974,B-CHEMICAL
phosphorylation,8974,O
",",8974,O
which,8974,O
was,8974,O
attenuated,8974,O
by,8974,O
IPA3,8974,O
or,8974,O
protein,8974,B-GENE-N
kinase,8974,I-GENE-N
A,8974,I-GENE-N
inhibition,8974,O
",",8974,O
respectively,8974,O
.,8974,O
Gut,8975,O
gcg,8975,B-GENE-Y
levels,8975,O
were,8975,O
reduced,8975,O
in,8975,O
male,8975,O
Pak1,8975,B-GENE-Y
(,8975,O
-/-,8975,O
),8975,O
mice,8975,O
",",8975,O
associated,8975,O
with,8975,O
impaired,8975,O
glucose,8975,B-CHEMICAL
tolerance,8975,O
after,8975,O
an,8975,O
ip,8975,O
or,8975,O
oral,8975,O
glucose,8975,B-CHEMICAL
challenge,8975,O
.,8975,O
These,8976,O
mice,8976,O
had,8976,O
lower,8976,O
circulating,8976,O
active,8976,O
GLP-1,8976,B-GENE-Y
levels,8976,O
after,8976,O
a,8976,O
glucose,8976,B-CHEMICAL
challenge,8976,O
as,8976,O
well,8976,O
as,8976,O
reduced,8976,O
distal,8976,O
ileum,8976,O
GLP-1,8976,B-GENE-Y
content,8976,O
after,8976,O
insulin,8976,O
treatment,8976,O
.,8976,O
Finally,8977,O
",",8977,O
the,8977,O
Pak1,8977,B-GENE-Y
(,8977,O
-/-,8977,O
),8977,O
mice,8977,O
exhibited,8977,O
reduced,8977,O
brainstem,8977,O
gcg,8977,O
level,8977,O
and,8977,O
abolished,8977,O
β-cat,8977,B-GENE-Y
Ser675,8977,B-CHEMICAL
phosphorylation,8977,O
in,8977,O
brain,8977,O
neurons,8977,O
after,8977,O
insulin,8977,B-GENE-N
treatment,8977,O
.,8977,O
We,8978,O
suggest,8978,O
that,8978,O
Pak1,8978,B-GENE-Y
mediates,8978,O
the,8978,O
cross,8978,O
talk,8978,O
between,8978,O
insulin,8978,B-GENE-N
and,8978,O
Wnt,8978,B-GENE-N
signaling,8978,O
pathways,8978,O
on,8978,O
gut,8978,O
and,8978,O
brain,8978,O
gcg,8978,B-GENE-Y
expression,8978,O
",",8978,O
and,8978,O
its,8978,O
ablation,8978,O
impairs,8978,O
glucose,8978,B-CHEMICAL
homeostasis,8978,O
.,8978,O
Characterization,8979,O
of,8979,O
the,8979,O
regulation,8979,O
of,8979,O
renal,8979,B-GENE-N
Na+/H+,8979,I-GENE-N
exchanger,8979,I-GENE-N
NHE3,8979,B-GENE-Y
by,8979,O
insulin,8979,B-GENE-Y
.,8979,O
Insulin,8980,B-GENE-Y
receptors,8980,I-GENE-Y
are,8980,O
widely,8980,O
distributed,8980,O
in,8980,O
the,8980,O
kidney,8980,O
and,8980,O
affect,8980,O
multiple,8980,O
aspects,8980,O
of,8980,O
renal,8980,O
function,8980,O
.,8980,O
In,8981,O
the,8981,O
proximal,8981,O
tubule,8981,O
",",8981,O
insulin,8981,B-GENE-Y
regulates,8981,O
volume,8981,O
and,8981,O
acid-base,8981,O
regulation,8981,O
through,8981,O
stimulation,8981,O
of,8981,O
the,8981,O
Na,8981,B-GENE-N
(,8981,I-GENE-N
+,8981,I-GENE-N
),8981,I-GENE-N
/H,8981,I-GENE-N
(,8981,I-GENE-N
+,8981,I-GENE-N
),8981,I-GENE-N
exchanger,8981,I-GENE-N
NHE3,8981,B-GENE-Y
.,8981,O
This,8982,O
paper,8982,O
characterizes,8982,O
the,8982,O
signaling,8982,O
pathway,8982,O
by,8982,O
which,8982,O
insulin,8982,B-GENE-Y
stimulates,8982,O
NHE3,8982,B-GENE-Y
in,8982,O
a,8982,O
cell,8982,O
culture,8982,O
model,8982,O
[,8982,O
opossum,8982,O
kidney,8982,O
(,8982,O
OK,8982,O
),8982,O
cell,8982,O
],8982,O
.,8982,O
Insulin,8983,B-GENE-Y
has,8983,O
two,8983,O
distinct,8983,O
phases,8983,O
of,8983,O
action,8983,O
on,8983,O
NHE3,8983,B-GENE-Y
.,8983,O
Chronic,8984,O
insulin,8984,B-GENE-Y
(,8984,O
24,8984,O
h,8984,O
),8984,O
activates,8984,O
NHE3,8984,B-GENE-Y
through,8984,O
the,8984,O
classic,8984,O
phosphatidylinositol,8984,B-GENE-N
3-kinase-serum-,8984,O
and,8984,I-GENE-N
glucocorticoid-dependent,8984,I-GENE-N
kinase,8984,I-GENE-N
1,8984,I-GENE-N
(,8984,O
PI3K-SGK1,8984,B-GENE-N
),8984,O
pathway,8984,O
as,8984,O
insulin,8984,B-GENE-Y
stimulates,8984,O
SGK1,8984,B-GENE-N
phosphorylation,8984,O
and,8984,O
the,8984,O
insulin,8984,B-GENE-Y
effect,8984,O
can,8984,O
be,8984,O
blocked,8984,O
by,8984,O
the,8984,O
PI3K,8984,B-GENE-N
inhibitor,8984,O
wortmannin,8984,B-CHEMICAL
or,8984,O
a,8984,O
dominant-negative,8984,O
SGK1,8984,B-GENE-N
.,8984,O
We,8985,O
showed,8985,O
that,8985,O
SGK1,8985,B-GENE-N
transcript,8985,O
and,8985,O
protein,8985,O
are,8985,O
expressed,8985,O
in,8985,O
rat,8985,O
proximal,8985,O
tubule,8985,O
and,8985,O
OK,8985,O
cells,8985,O
.,8985,O
We,8986,O
previously,8986,O
showed,8986,O
that,8986,O
glucocorticoids,8986,O
augment,8986,O
the,8986,O
effect,8986,O
of,8986,O
insulin,8986,B-GENE-Y
on,8986,O
NHE3,8986,B-GENE-Y
(,8986,O
Klisic,8986,O
J,8986,O
",",8986,O
Hu,8986,O
MC,8986,O
",",8986,O
Nief,8986,O
V,8986,O
",",8986,O
Reyes,8986,O
L,8986,O
",",8986,O
Fuster,8986,O
D,8986,O
",",8986,O
Moe,8986,O
OW,8986,O
",",8986,O
Ambuhl,8986,O
PM,8986,O
.,8986,O
Am,8987,O
J,8987,O
Physiol,8987,O
Renal,8987,O
Physiol,8987,O
283,8987,O
:,8987,O
F532-F539,8987,O
",",8987,O
2002,8987,O
),8987,O
.,8987,O
Part,8988,O
of,8988,O
this,8988,O
can,8988,O
be,8988,O
mediated,8988,O
via,8988,O
induction,8988,O
of,8988,O
SGK1,8988,B-GENE-Y
by,8988,O
glucocorticoids,8988,O
",",8988,O
and,8988,O
indeed,8988,O
the,8988,O
insulin,8988,B-GENE-Y
effect,8988,O
on,8988,O
NHE3,8988,B-GENE-Y
can,8988,O
also,8988,O
be,8988,O
amplified,8988,O
by,8988,O
overexpression,8988,O
of,8988,O
SGK1,8988,B-GENE-Y
.,8988,O
We,8989,O
next,8989,O
addressed,8989,O
the,8989,O
acute,8989,O
effect,8989,O
of,8989,O
insulin,8989,B-GENE-Y
(,8989,O
1-2,8989,O
h,8989,O
),8989,O
on,8989,O
NHE3,8989,B-GENE-Y
by,8989,O
systematically,8989,O
examining,8989,O
the,8989,O
candidate,8989,O
signaling,8989,O
cascades,8989,O
and,8989,O
activation,8989,O
mechanisms,8989,O
of,8989,O
NHE3,8989,B-GENE-Y
.,8989,O
We,8990,O
ruled,8990,O
out,8990,O
the,8990,O
PI3K-SGK1-Akt,8990,B-GENE-N
and,8990,O
TC10,8990,B-GENE-N
pathways,8990,O
",",8990,O
increased,8990,O
surface,8990,O
NHE3,8990,B-GENE-Y
",",8990,O
NHE3,8990,B-GENE-Y
phosphorylation,8990,O
",",8990,O
NHE3,8990,B-GENE-Y
association,8990,O
with,8990,O
calcineurin,8990,B-GENE-N
homologous,8990,I-GENE-N
protein,8990,I-GENE-N
1,8990,I-GENE-N
or,8990,O
megalin,8990,B-GENE-Y
as,8990,O
mechanisms,8990,O
of,8990,O
acute,8990,O
activation,8990,O
of,8990,O
NHE3,8990,B-GENE-Y
by,8990,O
insulin,8990,B-GENE-Y
.,8990,O
In,8991,O
summary,8991,O
",",8991,O
insulin,8991,B-GENE-Y
stimulates,8991,O
NHE3,8991,B-GENE-Y
acutely,8991,O
via,8991,O
yet,8991,O
undefined,8991,O
pathways,8991,O
and,8991,O
mechanisms,8991,O
.,8991,O
The,8992,O
chronic,8992,O
effect,8992,O
of,8992,O
insulin,8992,B-GENE-Y
is,8992,O
mediated,8992,O
by,8992,O
the,8992,O
classic,8992,O
PI3K-SGK1,8992,B-GENE-N
route,8992,O
.,8992,O
The,8993,O
effects,8993,O
of,8993,O
adulthood,8993,O
olanzapine,8993,B-CHEMICAL
treatment,8993,O
on,8993,O
cognitive,8993,O
performance,8993,O
and,8993,O
neurotrophic,8993,B-GENE-N
factor,8993,I-GENE-N
content,8993,O
in,8993,O
male,8993,O
and,8993,O
female,8993,O
rats,8993,O
neonatally,8993,O
treated,8993,O
with,8993,O
quinpirole,8993,B-CHEMICAL
.,8993,O
Male,8994,O
and,8994,O
female,8994,O
Sprague-Dawley,8994,O
rats,8994,O
were,8994,O
administered,8994,O
quinpirole,8994,B-CHEMICAL
(,8994,O
1,8994,O
mg/kg,8994,O
",",8994,O
i.p,8994,O
.,8994,O
),8994,O
or,8995,O
saline,8995,O
once,8995,O
daily,8995,O
from,8995,O
postnatal,8995,O
day,8995,O
(,8995,O
P,8995,O
),8995,O
1,8995,O
to,8995,O
P21,8995,O
.,8995,O
This,8996,O
drug,8996,O
treatment,8996,O
has,8996,O
been,8996,O
shown,8996,O
to,8996,O
produce,8996,O
long-term,8996,O
priming,8996,O
of,8996,O
the,8996,O
D2,8996,B-GENE-Y
receptor,8996,I-GENE-Y
.,8996,O
Beginning,8997,O
on,8997,O
P62,8997,O
",",8997,O
rats,8997,O
were,8997,O
administered,8997,O
the,8997,O
atypical,8997,O
antipsychotic,8997,O
olanzapine,8997,B-CHEMICAL
(,8997,O
2.5,8997,O
mg/kg,8997,O
),8997,O
or,8997,O
saline,8997,O
twice,8997,O
daily,8997,O
(,8997,O
i.p,8997,O
.,8997,O
),8997,O
for,8998,O
28,8998,O
days,8998,O
.,8998,O
One,8999,O
day,8999,O
after,8999,O
olanzapine,8999,B-CHEMICAL
treatment,8999,O
ceased,8999,O
",",8999,O
rats,8999,O
were,8999,O
tested,8999,O
on,8999,O
the,8999,O
place,8999,O
and,8999,O
match-to-place,8999,O
versions,8999,O
of,8999,O
the,8999,O
Morris,8999,O
water,8999,O
maze,8999,O
(,8999,O
MWM,8999,O
),8999,O
for,8999,O
seven,8999,O
consecutive,8999,O
days,8999,O
.,8999,O
Dopamine,9000,B-GENE-Y
D2,9000,I-GENE-Y
receptor,9000,I-GENE-Y
priming,9000,O
was,9000,O
verified,9000,O
through,9000,O
a,9000,O
yawning,9000,O
behavioural,9000,O
test,9000,O
",",9000,O
a,9000,O
D2,9000,B-GENE-Y
receptor-mediated,9000,O
event,9000,O
",",9000,O
before,9000,O
olanzapine,9000,B-CHEMICAL
was,9000,O
administered,9000,O
as,9000,O
well,9000,O
as,9000,O
after,9000,O
olanzapine,9000,B-CHEMICAL
treatment,9000,O
and,9000,O
behavioural,9000,O
testing,9000,O
were,9000,O
complete,9000,O
.,9000,O
Results,9001,O
showed,9001,O
that,9001,O
neonatal,9001,O
quinpirole,9001,B-CHEMICAL
treatment,9001,O
induced,9001,O
D2,9001,B-GENE-Y
priming,9001,O
that,9001,O
was,9001,O
eliminated,9001,O
by,9001,O
olanzapine,9001,B-CHEMICAL
treatment,9001,O
.,9001,O
On,9002,O
the,9002,O
MWM,9002,O
place,9002,O
version,9002,O
",",9002,O
D2-primed,9002,B-GENE-Y
rats,9002,O
demonstrated,9002,O
a,9002,O
significant,9002,O
impairment,9002,O
that,9002,O
was,9002,O
eliminated,9002,O
by,9002,O
olanzapine,9002,B-CHEMICAL
treatment,9002,O
",",9002,O
but,9002,O
olanzapine,9002,B-CHEMICAL
treatment,9002,O
to,9002,O
animals,9002,O
neonatally,9002,O
treated,9002,O
with,9002,O
saline,9002,O
produced,9002,O
a,9002,O
significant,9002,O
deficit,9002,O
on,9002,O
the,9002,O
place,9002,O
version,9002,O
of,9002,O
the,9002,O
MWM,9002,O
.,9002,O
There,9003,O
were,9003,O
no,9003,O
significant,9003,O
deficits,9003,O
on,9003,O
the,9003,O
match-to-place,9003,O
version,9003,O
.,9003,O
Brain,9004,O
tissue,9004,O
analyses,9004,O
revealed,9004,O
that,9004,O
neonatal,9004,O
quinpirole,9004,B-CHEMICAL
treatment,9004,O
produced,9004,O
a,9004,O
significant,9004,O
decrease,9004,O
in,9004,O
hippocampal,9004,O
NGF,9004,B-GENE-Y
",",9004,O
BDNF,9004,B-GENE-Y
and,9004,O
ChAT,9004,B-GENE-Y
that,9004,O
was,9004,O
eliminated,9004,O
by,9004,O
olanzapine,9004,B-CHEMICAL
treatment,9004,O
.,9004,O
Neonatal,9005,O
quinpirole,9005,B-CHEMICAL
treatment,9005,O
produced,9005,O
a,9005,O
significant,9005,O
decrease,9005,O
in,9005,O
BDNF,9005,B-GENE-Y
and,9005,O
ChAT,9005,B-GENE-Y
in,9005,O
the,9005,O
frontal,9005,O
cortex,9005,O
that,9005,O
was,9005,O
unaffected,9005,O
by,9005,O
olanzapine,9005,B-CHEMICAL
treatment,9005,O
.,9005,O
These,9006,O
results,9006,O
show,9006,O
that,9006,O
olanzapine,9006,B-CHEMICAL
eliminates,9006,O
D2,9006,B-GENE-Y
receptor,9006,I-GENE-Y
priming,9006,O
and,9006,O
cognitive,9006,O
impairment,9006,O
and,9006,O
also,9006,O
alleviates,9006,O
decreases,9006,O
in,9006,O
neurotrophins,9006,O
and,9006,O
acetylcholinergic,9006,O
markers,9006,O
produced,9006,O
by,9006,O
D2,9006,B-GENE-Y
priming,9006,O
in,9006,O
the,9006,O
hippocampus,9006,O
.,9006,O
Temperature,9007,O
Effects,9007,O
of,9007,O
Sputtering,9007,O
of,9007,O
Langmuir-Blodgett,9007,O
Multilayers,9007,O
.,9007,O
Time-of-flight,9008,O
secondary,9008,O
ion,9008,O
mass,9008,O
spectrometry,9008,O
(,9008,O
TOF-SIMS,9008,O
),9008,O
and,9008,O
atomic,9008,O
force,9008,O
microscopy,9008,O
(,9008,O
AFM,9008,O
),9008,O
are,9008,O
employed,9008,O
to,9008,O
characterize,9008,O
a,9008,O
wedge-shaped,9008,O
crater,9008,O
eroded,9008,O
by,9008,O
a,9008,O
40,9008,O
keV,9008,O
C,9008,B-CHEMICAL
(,9008,I-CHEMICAL
60,9008,I-CHEMICAL
),9008,I-CHEMICAL
(,9008,I-CHEMICAL
+,9008,I-CHEMICAL
),9008,I-CHEMICAL
cluster,9008,O
ion,9008,O
beam,9008,O
on,9008,O
an,9008,O
organic,9008,O
thin,9008,O
film,9008,O
of,9008,O
402,9008,O
nm,9008,O
of,9008,O
barium,9008,B-CHEMICAL
arachidate,9008,I-CHEMICAL
(,9008,O
AA,9008,O
),9008,O
multilayers,9008,O
prepared,9008,O
by,9008,O
the,9008,O
Langmuir-Blodgett,9008,O
(,9008,O
LB,9008,O
),9008,O
technique,9008,O
.,9008,O
Sample,9009,O
cooling,9009,O
to,9009,O
90,9009,O
K,9009,O
was,9009,O
used,9009,O
to,9009,O
help,9009,O
reduce,9009,O
chemical,9009,O
damage,9009,O
",",9009,O
improve,9009,O
depth,9009,O
resolution,9009,O
and,9009,O
maintain,9009,O
constant,9009,O
erosion,9009,O
rate,9009,O
during,9009,O
depth,9009,O
profiling,9009,O
.,9009,O
The,9010,O
film,9010,O
was,9010,O
characterized,9010,O
at,9010,O
90,9010,O
K,9010,O
",",9010,O
135,9010,O
K,9010,O
",",9010,O
165,9010,O
K,9010,O
",",9010,O
205,9010,O
K,9010,O
",",9010,O
265,9010,O
K,9010,O
and,9010,O
300,9010,O
K.,9010,O
It,9010,O
is,9010,O
shown,9010,O
that,9010,O
sample,9010,O
cooling,9010,O
to,9010,O
205,9010,O
K,9010,O
or,9010,O
lower,9010,O
helps,9010,O
to,9010,O
inhibit,9010,O
erosion,9010,O
rate,9010,O
decay,9010,O
",",9010,O
whereas,9010,O
at,9010,O
300,9010,O
K,9010,O
and,9010,O
265,9010,O
K,9010,O
the,9010,O
erosion,9010,O
rate,9010,O
continues,9010,O
to,9010,O
drop,9010,O
after,9010,O
250,9010,O
nm,9010,O
of,9010,O
erosion,9010,O
",",9010,O
reaching,9010,O
about,9010,O
half,9010,O
of,9010,O
the,9010,O
initial,9010,O
value,9010,O
after,9010,O
removal,9010,O
of,9010,O
the,9010,O
entire,9010,O
film,9010,O
.,9010,O
Depth,9011,O
profiles,9011,O
are,9011,O
acquired,9011,O
from,9011,O
the,9011,O
SIMS,9011,O
images,9011,O
of,9011,O
the,9011,O
eroded,9011,O
wedge,9011,O
crater,9011,O
.,9011,O
The,9012,O
results,9012,O
suggest,9012,O
that,9012,O
sample,9012,O
cooling,9012,O
only,9012,O
slightly,9012,O
improves,9012,O
the,9012,O
altered,9012,O
layer,9012,O
thickness,9012,O
",",9012,O
but,9012,O
eliminates,9012,O
the,9012,O
decrease,9012,O
in,9012,O
erosion,9012,O
rate,9012,O
observed,9012,O
above,9012,O
265,9012,O
K,9012,O
.,9012,O
An,9013,O
engineered,9013,O
human,9013,B-GENE-Y
follistatin,9013,I-GENE-Y
variant,9013,O
:,9013,O
insights,9013,O
into,9013,O
the,9013,O
pharmacokinetic,9013,O
and,9013,O
pharmocodynamic,9013,O
relationships,9013,O
of,9013,O
a,9013,O
novel,9013,O
molecule,9013,O
with,9013,O
broad,9013,O
therapeutic,9013,O
potential,9013,O
.,9013,O
Human,9014,B-GENE-Y
follistatin,9014,I-GENE-Y
is,9014,O
a,9014,O
regulatory,9014,O
glycoprotein,9014,O
with,9014,O
widespread,9014,O
biologic,9014,O
functions,9014,O
",",9014,O
including,9014,O
antiinflammatory,9014,O
activities,9014,O
",",9014,O
wound-healing,9014,O
properties,9014,O
",",9014,O
and,9014,O
muscle-stimulating,9014,O
effects,9014,O
.,9014,O
The,9015,O
role,9015,O
of,9015,O
follistatin,9015,B-GENE-Y
in,9015,O
a,9015,O
wide,9015,O
range,9015,O
of,9015,O
biologic,9015,O
activities,9015,O
shows,9015,O
promise,9015,O
for,9015,O
potential,9015,O
clinical,9015,O
application,9015,O
",",9015,O
which,9015,O
has,9015,O
prompted,9015,O
considerable,9015,O
interest,9015,O
in,9015,O
the,9015,O
investigation,9015,O
of,9015,O
the,9015,O
protein,9015,O
as,9015,O
a,9015,O
potential,9015,O
disease-modifying,9015,O
agent,9015,O
.,9015,O
In,9016,O
spite,9016,O
of,9016,O
this,9016,O
potential,9016,O
",",9016,O
the,9016,O
development,9016,O
of,9016,O
follistatin,9016,B-GENE-Y
as,9016,O
a,9016,O
broad,9016,O
use,9016,O
biotherapeutic,9016,O
has,9016,O
been,9016,O
severely,9016,O
hindered,9016,O
by,9016,O
a,9016,O
poor,9016,O
understanding,9016,O
and,9016,O
characterization,9016,O
of,9016,O
its,9016,O
pharmacokinetic/pharmacodynamic,9016,O
(,9016,O
PK/PD,9016,O
),9016,O
relationships,9016,O
.,9016,O
Therefore,9017,O
",",9017,O
to,9017,O
better,9017,O
define,9017,O
these,9017,O
relationships,9017,O
",",9017,O
we,9017,O
performed,9017,O
in-depth,9017,O
analyses,9017,O
of,9017,O
the,9017,O
PK/PD,9017,O
relationships,9017,O
of,9017,O
native,9017,O
follistatin-315,9017,B-GENE-Y
(,9017,O
FST315,9017,B-GENE-Y
),9017,O
.,9017,O
Our,9018,O
data,9018,O
indicate,9018,O
that,9018,O
the,9018,O
intrinsic,9018,O
PK/PD,9018,O
properties,9018,O
of,9018,O
native,9018,O
FST315,9018,B-GENE-Y
are,9018,O
poorly,9018,O
suited,9018,O
for,9018,O
acting,9018,O
as,9018,O
a,9018,O
parentally,9018,O
administered,9018,O
biotherapeutic,9018,O
with,9018,O
broad,9018,O
systemic,9018,O
effects,9018,O
.,9018,O
Here,9019,O
",",9019,O
we,9019,O
leveraged,9019,O
protein,9019,O
engineering,9019,O
to,9019,O
modify,9019,O
the,9019,O
PK,9019,O
characteristics,9019,O
of,9019,O
the,9019,O
native,9019,O
molecule,9019,O
by,9019,O
fusing,9019,O
FST315,9019,B-GENE-Y
to,9019,O
a,9019,O
murine,9019,B-GENE-N
IgG,9019,I-GENE-N
(,9019,I-GENE-N
1,9019,I-GENE-N
),9019,I-GENE-N
Fc,9019,I-GENE-N
and,9019,O
removing,9019,O
the,9019,O
intrinsic,9019,O
heparan,9019,O
sulfate-binding,9019,B-CHEMICAL
activity,9019,O
of,9019,O
follistatin,9019,B-GENE-Y
.,9019,O
The,9020,O
engineered,9020,O
variant,9020,O
molecule,9020,O
had,9020,O
~100-,9020,O
and,9020,O
~1600-fold,9020,O
improvements,9020,O
in,9020,O
terminal,9020,O
half-life,9020,O
and,9020,O
exposure,9020,O
",",9020,O
respectively,9020,O
.,9020,O
In,9021,O
contrast,9021,O
to,9021,O
the,9021,O
native,9021,O
FST315,9021,B-GENE-Y
",",9021,O
the,9021,O
variant,9021,O
showed,9021,O
a,9021,O
robust,9021,O
",",9021,O
dose-dependent,9021,O
pharmacological,9021,O
effect,9021,O
when,9021,O
administered,9021,O
subcutaneously,9021,O
on,9021,O
a,9021,O
weekly,9021,O
basis,9021,O
in,9021,O
mouse,9021,O
models,9021,O
of,9021,O
muscle,9021,O
atrophy,9021,O
and,9021,O
degeneration,9021,O
.,9021,O
These,9022,O
studies,9022,O
highlight,9022,O
the,9022,O
underappreciated,9022,O
and,9022,O
critical,9022,O
relationship,9022,O
between,9022,O
optimizing,9022,O
multiple,9022,O
physical,9022,O
and,9022,O
chemical,9022,O
properties,9022,O
of,9022,O
follistatin,9022,B-GENE-Y
on,9022,O
its,9022,O
overall,9022,O
PK/PD,9022,O
profile,9022,O
.,9022,O
Moreover,9023,O
",",9023,O
our,9023,O
findings,9023,O
provide,9023,O
the,9023,O
first,9023,O
documented,9023,O
strategy,9023,O
toward,9023,O
the,9023,O
development,9023,O
of,9023,O
a,9023,O
follistatin,9023,B-GENE-Y
therapeutic,9023,O
with,9023,O
potential,9023,O
use,9023,O
in,9023,O
patients,9023,O
affected,9023,O
with,9023,O
skeletal,9023,O
muscle,9023,O
diseases,9023,O
.,9023,O
Suppression,9024,O
of,9024,O
Src/ERK,9024,B-GENE-Y
and,9024,O
GSK-3/β-catenin,9024,B-GENE-N
signaling,9024,O
by,9024,O
pinosylvin,9024,B-CHEMICAL
inhibits,9024,O
the,9024,O
growth,9024,O
of,9024,O
human,9024,O
colorectal,9024,O
cancer,9024,O
cells,9024,O
.,9024,O
Pinosylvin,9025,B-CHEMICAL
",",9025,O
a,9025,O
naturally,9025,O
occurring,9025,O
trans-stilbenoid,9025,B-CHEMICAL
mainly,9025,O
found,9025,O
in,9025,O
Pinus,9025,O
species,9025,O
",",9025,O
has,9025,O
exhibited,9025,O
a,9025,O
potential,9025,O
cancer,9025,O
chemopreventive,9025,O
activity,9025,O
.,9025,O
However,9026,O
",",9026,O
the,9026,O
growth,9026,O
inhibitory,9026,O
activity,9026,O
against,9026,O
cancer,9026,O
cells,9026,O
and,9026,O
the,9026,O
underlying,9026,O
molecular,9026,O
mechanisms,9026,O
remain,9026,O
to,9026,O
be,9026,O
elucidated,9026,O
.,9026,O
Therefore,9027,O
",",9027,O
the,9027,O
anti-proliferative,9027,O
activity,9027,O
of,9027,O
pinosylvin,9027,B-CHEMICAL
was,9027,O
investigated,9027,O
in,9027,O
human,9027,O
colorectal,9027,O
HCT,9027,O
116,9027,O
cancer,9027,O
cells,9027,O
.,9027,O
Pinosylvin,9028,B-CHEMICAL
inhibited,9028,O
the,9028,O
proliferation,9028,O
of,9028,O
HCT,9028,O
116,9028,O
cells,9028,O
by,9028,O
arresting,9028,O
transition,9028,O
of,9028,O
cell,9028,O
cycle,9028,O
from,9028,O
G1,9028,O
to,9028,O
S,9028,O
phase,9028,O
along,9028,O
with,9028,O
the,9028,O
downregulation,9028,O
of,9028,O
cyclin,9028,B-GENE-Y
D1,9028,I-GENE-Y
",",9028,O
cyclin,9028,B-GENE-Y
E,9028,I-GENE-Y
",",9028,O
cyclin,9028,B-GENE-Y
A,9028,I-GENE-Y
",",9028,O
cyclin,9028,B-GENE-Y
dependent,9028,I-GENE-Y
kinase,9028,I-GENE-Y
2,9028,I-GENE-Y
(,9028,O
CDK2,9028,B-GENE-Y
),9028,O
",",9028,O
CDK4,9028,B-GENE-Y
",",9028,O
c-Myc,9028,B-GENE-Y
",",9028,O
and,9028,O
retinoblastoma,9028,B-GENE-Y
protein,9028,I-GENE-Y
(,9028,O
pRb,9028,B-GENE-Y
),9028,O
",",9028,O
and,9028,O
the,9028,O
upregulation,9028,O
of,9028,O
p21,9028,B-GENE-Y
(,9028,O
WAF1/CIP1,9028,B-GENE-Y
),9028,O
and,9028,O
p53,9028,B-GENE-Y
.,9028,O
Pinosylvin,9029,B-CHEMICAL
was,9029,O
also,9029,O
found,9029,O
to,9029,O
attenuate,9029,O
the,9029,O
activation,9029,O
of,9029,O
proteins,9029,O
involved,9029,O
in,9029,O
focal,9029,O
adhesion,9029,I-GENE-Y
kinase,9029,I-GENE-Y
(,9029,O
FAK,9029,B-GENE-Y
),9029,O
/c-Src/extracellular,9029,O
signal-regulated,9029,I-GENE-N
kinase,9029,I-GENE-N
(,9029,O
ERK,9029,B-GENE-N
),9029,O
signaling,9029,O
",",9029,O
and,9029,O
phosphoinositide,9029,B-GENE-N
3-kinase,9029,I-GENE-N
(,9029,O
PI3K,9029,B-GENE-N
),9029,O
/Akt/,9029,O
glycogen,9029,B-GENE-Y
synthase,9029,I-GENE-Y
kinase,9029,I-GENE-Y
3β,9029,I-GENE-Y
(,9029,O
GSK-3β,9029,B-GENE-Y
),9029,O
signaling,9029,O
pathway,9029,O
.,9029,O
Subsequently,9030,O
",",9030,O
pinosylvin,9030,B-CHEMICAL
suppressed,9030,O
the,9030,O
nuclear,9030,O
translocation,9030,O
of,9030,O
β-catenin,9030,B-GENE-Y
",",9030,O
one,9030,O
of,9030,O
downstream,9030,O
molecules,9030,O
of,9030,O
PI3K/Akt/GSK-3β,9030,B-GENE-N
signaling,9030,O
",",9030,O
and,9030,O
these,9030,O
events,9030,O
led,9030,O
to,9030,O
the,9030,O
sequential,9030,O
downregulation,9030,O
of,9030,O
β-catenin-mediated,9030,B-GENE-Y
transcription,9030,O
of,9030,O
target,9030,O
genes,9030,O
including,9030,O
BMP4,9030,B-GENE-Y
",",9030,O
ID2,9030,B-GENE-Y
",",9030,O
survivin,9030,B-GENE-Y
",",9030,O
cyclin,9030,B-GENE-Y
D1,9030,I-GENE-Y
",",9030,O
MMP7,9030,B-GENE-Y
",",9030,O
and,9030,O
c-Myc,9030,B-GENE-Y
.,9030,O
These,9031,O
findings,9031,O
demonstrate,9031,O
that,9031,O
the,9031,O
anti-proliferative,9031,O
activity,9031,O
of,9031,O
pinosylvin,9031,B-CHEMICAL
might,9031,O
be,9031,O
associated,9031,O
with,9031,O
the,9031,O
cell,9031,O
cycle,9031,O
arrest,9031,O
and,9031,O
downregulation,9031,O
of,9031,O
cell,9031,O
proliferation,9031,O
regulating,9031,O
signaling,9031,O
pathways,9031,O
in,9031,O
human,9031,O
colorectal,9031,O
cancer,9031,O
cells,9031,O
.,9031,O
The,9032,O
Interaction,9032,O
of,9032,O
Adrenomedullin,9032,B-GENE-Y
and,9032,O
Macrophages,9032,O
Induces,9032,O
Ovarian,9032,O
Cancer,9032,O
Cell,9032,O
Migration,9032,O
via,9032,O
Activation,9032,O
of,9032,O
RhoA,9032,B-GENE-Y
Signaling,9032,O
Pathway,9032,O
.,9032,O
Tumor-associated,9033,O
macrophages,9033,O
(,9033,O
TAMs,9033,O
),9033,O
are,9033,O
correlated,9033,O
with,9033,O
poor,9033,O
prognosis,9033,O
in,9033,O
many,9033,O
human,9033,O
cancers,9033,O
;,9033,O
however,9033,O
",",9033,O
the,9033,O
mechanism,9033,O
by,9033,O
which,9033,O
TAMs,9033,O
facilitate,9033,O
ovarian,9033,O
cancer,9033,O
cell,9033,O
migration,9033,O
and,9033,O
invasion,9033,O
remains,9033,O
unknown,9033,O
.,9033,O
This,9034,O
study,9034,O
was,9034,O
aimed,9034,O
to,9034,O
examine,9034,O
the,9034,O
function,9034,O
of,9034,O
adrenomedullin,9034,B-GENE-Y
(,9034,O
ADM,9034,B-GENE-Y
),9034,O
in,9034,O
macrophage,9034,O
polarization,9034,O
and,9034,O
their,9034,O
further,9034,O
effects,9034,O
on,9034,O
the,9034,O
migration,9034,O
of,9034,O
ovarian,9034,O
cancer,9034,O
cells,9034,O
.,9034,O
Exogenous,9035,O
ADM,9035,B-GENE-Y
antagonist,9035,O
and,9035,O
small,9035,O
interfering,9035,O
RNA,9035,O
(,9035,O
siRNA,9035,O
),9035,O
specific,9035,O
for,9035,O
ADM,9035,B-GENE-Y
expression,9035,O
were,9035,O
treated,9035,O
to,9035,O
macrophages,9035,O
and,9035,O
EOC,9035,O
cell,9035,O
line,9035,O
HO8910,9035,O
",",9035,O
respectively,9035,O
.,9035,O
Then,9036,O
macrophages,9036,O
were,9036,O
cocultured,9036,O
with,9036,O
HO8910,9036,O
cells,9036,O
without,9036,O
direct,9036,O
contact,9036,O
.,9036,O
Flow,9037,O
cytometry,9037,O
",",9037,O
Western,9037,O
blot,9037,O
and,9037,O
real-time,9037,O
PCR,9037,O
were,9037,O
used,9037,O
to,9037,O
detect,9037,O
macrophage,9037,O
phenotype,9037,O
and,9037,O
cytokine,9037,B-GENE-N
production,9037,O
.,9037,O
The,9038,O
migration,9038,O
ability,9038,O
and,9038,O
cytoskeleton,9038,O
rearrangement,9038,O
of,9038,O
ovarian,9038,O
cancer,9038,O
cells,9038,O
were,9038,O
determined,9038,O
by,9038,O
Transwell,9038,O
migration,9038,O
assay,9038,O
and,9038,O
phalloidin,9038,B-CHEMICAL
staining,9038,O
.,9038,O
Western,9039,O
blot,9039,O
was,9039,O
performed,9039,O
to,9039,O
evaluate,9039,O
the,9039,O
activity,9039,O
status,9039,O
of,9039,O
signaling,9039,O
molecules,9039,O
in,9039,O
the,9039,O
process,9039,O
of,9039,O
ovarian,9039,O
cancer,9039,O
cell,9039,O
migration,9039,O
.,9039,O
The,9040,O
results,9040,O
showed,9040,O
that,9040,O
ADM,9040,B-GENE-Y
induced,9040,O
macrophage,9040,O
phenotype,9040,O
and,9040,O
cytokine,9040,B-GENE-N
production,9040,O
similar,9040,O
to,9040,O
TAMs,9040,O
.,9040,O
Macrophages,9041,O
polarized,9041,O
by,9041,O
ADM,9041,B-GENE-Y
promoted,9041,O
the,9041,O
migration,9041,O
and,9041,O
cytoskeleton,9041,O
rearrangement,9041,O
of,9041,O
HO8910,9041,O
cells,9041,O
.,9041,O
The,9042,O
expression,9042,O
of,9042,O
RhoA,9042,B-GENE-Y
and,9042,O
its,9042,O
downstream,9042,O
effector,9042,O
",",9042,O
cofilin,9042,B-GENE-N
",",9042,O
were,9042,O
upregulated,9042,O
in,9042,O
macrophage-induced,9042,O
migration,9042,O
of,9042,O
HO8910,9042,O
cells,9042,O
.,9042,O
In,9043,O
conclusion,9043,O
",",9043,O
ADM,9043,B-GENE-Y
could,9043,O
polarize,9043,O
macrophages,9043,O
similar,9043,O
to,9043,O
TAMs,9043,O
",",9043,O
and,9043,O
then,9043,O
polarized,9043,O
macrophages,9043,O
promote,9043,O
the,9043,O
migration,9043,O
of,9043,O
ovarian,9043,O
cancer,9043,O
cells,9043,O
via,9043,O
activation,9043,O
of,9043,O
RhoA,9043,B-GENE-Y
signaling,9043,O
pathway,9043,O
in,9043,O
vitro,9043,O
.,9043,O
Influence,9044,O
of,9044,O
nitrogen,9044,B-CHEMICAL
supply,9044,O
on,9044,O
the,9044,O
production,9044,O
of,9044,O
higher,9044,O
alcohols/esters,9044,B-CHEMICAL
and,9044,O
expression,9044,O
of,9044,O
flavour-related,9044,O
genes,9044,O
in,9044,O
cachaça,9044,O
fermentation,9044,O
.,9044,O
This,9045,O
study,9045,O
provides,9045,O
the,9045,O
first,9045,O
attempt,9045,O
to,9045,O
analyse,9045,O
the,9045,O
influence,9045,O
of,9045,O
ammonium,9045,B-CHEMICAL
supplements,9045,O
on,9045,O
sugar-cane,9045,B-CHEMICAL
juice,9045,O
fermentation,9045,O
and,9045,O
the,9045,O
flavour,9045,O
profile,9045,O
in,9045,O
a,9045,O
cachaça,9045,O
industrial,9045,O
process,9045,O
.,9045,O
The,9046,O
objective,9046,O
was,9046,O
to,9046,O
find,9046,O
a,9046,O
relationship,9046,O
between,9046,O
higher,9046,O
alcohol/ester,9046,B-CHEMICAL
content,9046,O
and,9046,O
the,9046,O
transcription,9046,O
levels,9046,O
of,9046,O
the,9046,O
main,9046,O
genes,9046,O
involved,9046,O
in,9046,O
production,9046,O
of,9046,O
these,9046,O
compounds,9046,O
under,9046,O
cachaça,9046,O
fermentation,9046,O
.,9046,O
Sugar-cane,9047,B-CHEMICAL
juice,9047,O
with,9047,O
a,9047,O
low,9047,O
amount,9047,O
of,9047,O
assimilable,9047,O
nitrogen,9047,B-CHEMICAL
(,9047,O
81,9047,O
mg,9047,O
N/L,9047,O
),9047,O
",",9047,O
was,9047,O
further,9047,O
supplemented,9047,O
with,9047,O
mid-range,9047,O
or,9047,O
high,9047,O
concentrations,9047,O
of,9047,O
ammonium,9047,B-CHEMICAL
sulfate,9047,I-CHEMICAL
.,9047,O
Overall,9048,O
",",9048,O
higher,9048,O
alcohol,9048,B-CHEMICAL
production,9048,O
was,9048,O
reduced,9048,O
by,9048,O
ammonium,9048,B-CHEMICAL
supplementation,9048,O
",",9048,O
and,9048,O
this,9048,O
can,9048,O
be,9048,O
correlated,9048,O
with,9048,O
a,9048,O
general,9048,O
downregulation,9048,O
of,9048,O
genes,9048,O
encoding,9048,O
decarboxylases,9048,B-GENE-N
and,9048,O
dehydrogenases,9048,B-GENE-N
of,9048,O
the,9048,O
Ehrlich,9048,B-GENE-N
pathway,9048,I-GENE-N
.,9048,O
The,9049,O
production,9049,O
of,9049,O
acetate,9049,B-CHEMICAL
esters,9049,I-CHEMICAL
was,9049,O
enhanced,9049,O
by,9049,O
mid-range,9049,O
ammonium,9049,B-CHEMICAL
supplementation,9049,O
and,9049,O
the,9049,O
production,9049,O
of,9049,O
acyl,9049,B-CHEMICAL
esters,9049,I-CHEMICAL
by,9049,O
high,9049,O
ammonium,9049,B-CHEMICAL
supplementation,9049,O
.,9049,O
The,9050,O
acyl,9050,B-CHEMICAL
esters,9050,I-CHEMICAL
could,9050,O
be,9050,O
correlated,9050,O
with,9050,O
expression,9050,O
of,9050,O
alcohol,9050,B-GENE-Y
acyl-transferase,9050,I-GENE-Y
EEB1,9050,I-GENE-Y
and,9050,O
the,9050,O
acyl,9050,B-GENE-Y
esterase,9050,I-GENE-Y
IAH1,9050,I-GENE-Y
.,9050,O
Novel,9051,O
analgesic/anti-inflammatory,9051,O
agents,9051,O
:,9051,O
"1,5-diarylpyrrole",9051,B-CHEMICAL
nitrooxyalkyl,9051,I-CHEMICAL
ethers,9051,I-CHEMICAL
and,9051,O
related,9051,O
compounds,9051,O
as,9051,O
cyclooxygenase-2,9051,B-GENE-Y
inhibiting,9051,O
nitric,9051,B-CHEMICAL
oxide,9051,I-CHEMICAL
donors,9051,O
.,9051,O
A,9052,O
series,9052,O
of,9052,O
3-substituted,9052,B-CHEMICAL
"1,5-diarylpyrroles",9052,I-CHEMICAL
bearing,9052,O
a,9052,O
nitrooxyalkyl,9052,B-CHEMICAL
side,9052,O
chain,9052,O
linked,9052,O
to,9052,O
different,9052,O
spacers,9052,O
were,9052,O
designed,9052,O
.,9052,O
New,9053,O
classes,9053,O
of,9053,O
pyrrole-derived,9053,B-CHEMICAL
nitrooxyalkyl,9053,B-CHEMICAL
inverse,9053,O
esters,9053,B-CHEMICAL
",",9053,O
carbonates,9053,B-CHEMICAL
",",9053,O
and,9053,O
ethers,9053,B-CHEMICAL
(,9053,O
7-10,9053,O
),9053,O
as,9053,O
COX-2,9053,B-GENE-Y
selective,9053,O
inhibitors,9053,O
and,9053,O
NO,9053,B-CHEMICAL
donors,9053,O
were,9053,O
synthesized,9053,O
and,9053,O
are,9053,O
herein,9053,O
reported,9053,O
.,9053,O
By,9054,O
taking,9054,O
into,9054,O
account,9054,O
the,9054,O
metabolic,9054,O
conversion,9054,O
of,9054,O
nitrooxyalkyl,9054,B-CHEMICAL
ethers,9054,I-CHEMICAL
(,9054,O
9,9054,O
",",9054,O
10,9054,O
),9054,O
into,9054,O
corresponding,9054,O
alcohols,9054,B-CHEMICAL
",",9054,O
derivatives,9054,O
17,9054,O
and,9054,O
18,9054,O
were,9054,O
also,9054,O
studied,9054,O
.,9054,O
Nitrooxy,9055,B-CHEMICAL
derivatives,9055,O
showed,9055,O
NO-dependent,9055,B-CHEMICAL
vasorelaxing,9055,O
properties,9055,O
",",9055,O
while,9055,O
most,9055,O
of,9055,O
the,9055,O
compounds,9055,O
proved,9055,O
to,9055,O
be,9055,O
very,9055,O
potent,9055,O
and,9055,O
selective,9055,O
COX-2,9055,B-GENE-Y
inhibitors,9055,O
in,9055,O
in,9055,O
vitro,9055,O
experimental,9055,O
models,9055,O
.,9055,O
Further,9056,O
in,9056,O
vivo,9056,O
studies,9056,O
on,9056,O
compounds,9056,O
9a,9056,O
",",9056,O
c,9056,O
and,9056,O
17a,9056,O
highlighted,9056,O
good,9056,O
anti-inflammatory,9056,O
and,9056,O
antinociceptive,9056,O
activities,9056,O
.,9056,O
Compound,9057,O
9c,9057,O
was,9057,O
able,9057,O
to,9057,O
inhibit,9057,O
glycosaminoglycan,9057,O
(,9057,O
GAG,9057,O
),9057,O
release,9057,O
induced,9057,O
by,9057,O
interleukin-1β,9057,B-GENE-Y
(,9057,O
IL-1β,9057,B-GENE-Y
),9057,O
",",9057,O
showing,9057,O
cartilage,9057,O
protective,9057,O
properties,9057,O
.,9057,O
Finally,9058,O
",",9058,O
molecular,9058,O
modeling,9058,O
and,9058,O
(,9058,B-CHEMICAL
1,9058,I-CHEMICAL
),9058,I-CHEMICAL
H-,9058,O
and,9058,O
(,9058,B-CHEMICAL
13,9058,I-CHEMICAL
),9058,I-CHEMICAL
C-NMR,9058,O
studies,9058,O
performed,9058,O
on,9058,O
compounds,9058,O
6c,9058,O
",",9058,O
d,9058,O
",",9058,O
9c,9058,O
",",9058,O
and,9058,O
10b,9058,O
allowed,9058,O
the,9058,O
right,9058,O
conformation,9058,O
of,9058,O
nitrooxyalkyl,9058,B-CHEMICAL
ester,9058,I-CHEMICAL
and,9058,I-CHEMICAL
ether,9058,I-CHEMICAL
side,9058,O
chain,9058,O
of,9058,O
these,9058,O
molecules,9058,O
within,9058,O
the,9058,O
COX-2,9058,B-GENE-Y
active,9058,O
site,9058,O
to,9058,O
be,9058,O
assessed,9058,O
.,9058,O
The,9059,O
clinical,9059,O
profile,9059,O
of,9059,O
the,9059,O
angiotensin,9059,B-GENE-N
II,9059,I-GENE-N
receptor,9059,I-GENE-N
blocker,9059,O
eprosartan,9059,B-CHEMICAL
.,9059,O
Angiotensin,9060,B-GENE-N
II,9060,I-GENE-N
receptor,9060,I-GENE-N
antagonists,9060,O
block,9060,O
angiotensin,9060,B-GENE-Y
II,9060,I-GENE-Y
type,9060,I-GENE-Y
1,9060,I-GENE-Y
(,9060,I-GENE-Y
AT1,9060,I-GENE-Y
),9060,I-GENE-Y
receptors,9060,I-GENE-Y
and,9060,O
reduce,9060,O
the,9060,O
pressor,9060,O
effects,9060,O
of,9060,O
angiotensin,9060,B-GENE-Y
in,9060,O
the,9060,O
vasculature,9060,O
.,9060,O
By,9061,O
this,9061,O
mechanism,9061,O
",",9061,O
they,9061,O
induce,9061,O
similar,9061,O
pharmacological,9061,O
effects,9061,O
to,9061,O
angiotensin-converting,9061,B-GENE-Y
enzyme,9061,I-GENE-Y
(,9061,O
ACE,9061,B-GENE-Y
),9061,O
inhibitors,9061,O
",",9061,O
resulting,9061,O
in,9061,O
a,9061,O
lowering,9061,O
of,9061,O
blood,9061,O
pressure,9061,O
(,9061,O
BP,9061,O
),9061,O
.,9061,O
However,9062,O
",",9062,O
AT1,9062,B-GENE-Y
antagonists,9062,O
differ,9062,O
from,9062,O
ACE,9062,B-GENE-Y
inhibitors,9062,O
with,9062,O
respect,9062,O
to,9062,O
side,9062,O
effects,9062,O
",",9062,O
and,9062,O
induce,9062,O
less,9062,O
cough,9062,O
",",9062,O
which,9062,O
is,9062,O
related,9062,O
to,9062,O
bradykinin,9062,B-GENE-Y
activation,9062,O
.,9062,O
Within,9063,O
the,9063,O
class,9063,O
of,9063,O
angiotensin,9063,B-GENE-Y
II,9063,I-GENE-Y
antagonists,9063,O
",",9063,O
eprosartan,9063,O
differs,9063,O
from,9063,O
other,9063,O
currently,9063,O
clinically,9063,O
available,9063,O
agents,9063,O
in,9063,O
terms,9063,O
of,9063,O
its,9063,O
chemical,9063,O
structure,9063,O
and,9063,O
its,9063,O
dual,9063,O
pharmacological,9063,O
mode,9063,O
of,9063,O
action,9063,O
.,9063,O
Eprosartan,9064,B-CHEMICAL
acts,9064,O
not,9064,O
only,9064,O
at,9064,O
vascular,9064,O
AT1,9064,B-GENE-Y
receptors,9064,O
but,9064,O
also,9064,O
at,9064,O
presynaptic,9064,O
AT1,9064,B-GENE-Y
receptors,9064,O
",",9064,O
causing,9064,O
inhibition,9064,O
of,9064,O
sympathetically,9064,O
stimulated,9064,O
noradrenaline,9064,B-CHEMICAL
release,9064,O
.,9064,O
Eprosartan,9065,B-CHEMICAL
is,9065,O
not,9065,O
metabolized,9065,O
by,9065,O
cytochrome,9065,B-GENE-N
P450,9065,I-GENE-N
enzymes,9065,O
and,9065,O
therefore,9065,O
has,9065,O
a,9065,O
low,9065,O
potential,9065,O
for,9065,O
metabolic,9065,O
drug,9065,O
interactions,9065,O
",",9065,O
which,9065,O
may,9065,O
be,9065,O
of,9065,O
importance,9065,O
when,9065,O
treating,9065,O
the,9065,O
elderly,9065,O
and,9065,O
patients,9065,O
on,9065,O
multiple,9065,O
drugs,9065,O
.,9065,O
In,9066,O
clinical,9066,O
trials,9066,O
eprosartan,9066,B-CHEMICAL
has,9066,O
proven,9066,O
to,9066,O
be,9066,O
at,9066,O
least,9066,O
as,9066,O
effective,9066,O
as,9066,O
the,9066,O
ACE,9066,B-GENE-Y
inhibitor,9066,O
enalapril,9066,O
in,9066,O
reducing,9066,O
BP,9066,O
",",9066,O
but,9066,O
with,9066,O
a,9066,O
significantly,9066,O
lower,9066,O
incidence,9066,O
of,9066,O
side,9066,O
effects,9066,O
.,9066,O
Eprosartan,9067,B-CHEMICAL
is,9067,O
safe,9067,O
",",9067,O
effective,9067,O
and,9067,O
well,9067,O
tolerated,9067,O
in,9067,O
long-term,9067,O
treatment,9067,O
",",9067,O
either,9067,O
as,9067,O
monotherapy,9067,O
or,9067,O
in,9067,O
combination,9067,O
with,9067,O
other,9067,O
antihypertensive,9067,O
drugs,9067,O
such,9067,O
as,9067,O
hydrochlorothiazide,9067,B-CHEMICAL
.,9067,O
Protective,9068,O
Effects,9068,O
of,9068,O
a,9068,O
Purified,9068,O
Saponin,9068,B-CHEMICAL
Mixture,9068,O
from,9068,O
Astragalus,9068,O
corniculatus,9068,O
Bieb.,9068,O
",",9068,O
in,9068,O
vivo,9068,O
Hepatotoxicity,9068,O
Models,9068,O
.,9068,O
In,9069,O
this,9069,O
study,9069,O
",",9069,O
the,9069,O
in,9069,O
vivo,9069,O
effects,9069,O
of,9069,O
a,9069,O
purified,9069,O
saponin,9069,B-CHEMICAL
mixture,9069,O
(,9069,O
PSM,9069,O
),9069,O
",",9069,O
obtained,9069,O
from,9069,O
Astragalus,9069,O
corniculatus,9069,O
Bieb.,9069,O
",",9069,O
were,9069,O
investigated,9069,O
using,9069,O
two,9069,O
in,9069,O
vivo,9069,O
hepatotoxicity,9069,O
models,9069,O
based,9069,O
on,9069,O
liver,9069,O
damage,9069,O
caused,9069,O
by,9069,O
paracetamol,9069,B-CHEMICAL
(,9069,O
PC,9069,O
),9069,O
and,9069,O
carbon,9069,B-CHEMICAL
tetrachloride,9069,I-CHEMICAL
(,9069,O
CCl4,9069,B-CHEMICAL
),9069,O
.,9069,O
The,9070,O
effects,9070,O
of,9070,O
PSM,9070,O
were,9070,O
compared,9070,O
with,9070,O
silymarin,9070,B-CHEMICAL
.,9070,O
Male,9071,O
Wistar,9071,O
rats,9071,O
were,9071,O
challenged,9071,O
orally,9071,O
with,9071,O
20,9071,O
%,9071,O
CCl4,9071,B-CHEMICAL
or,9071,O
PC,9071,O
(,9071,O
2,9071,O
g/kg,9071,O
),9071,O
four,9071,O
days,9071,O
after,9071,O
being,9071,O
pre-treated,9071,O
with,9071,O
PSM,9071,O
(,9071,O
100,9071,O
mg/kg,9071,O
),9071,O
or,9071,O
silymarin,9071,B-CHEMICAL
(,9071,O
200,9071,O
mg/kg,9071,O
),9071,O
.,9071,O
A,9072,O
significant,9072,O
decrease,9072,O
of,9072,O
aspartate,9072,B-GENE-Y
aminotransferase,9072,I-GENE-Y
",",9072,O
alanine,9072,B-GENE-N
aminotransferase,9072,I-GENE-N
",",9072,O
lactate,9072,B-GENE-N
dehydrogenase,9072,I-GENE-N
(,9072,O
LDH,9072,B-GENE-N
),9072,O
activities,9072,O
and,9072,O
glutathione,9072,B-CHEMICAL
(,9072,O
GSH,9072,B-CHEMICAL
),9072,O
levels,9072,O
and,9072,O
an,9072,O
increase,9072,O
of,9072,O
malondialdehyde,9072,B-CHEMICAL
(,9072,O
MDA,9072,B-CHEMICAL
),9072,O
quantity,9072,O
was,9072,O
observed,9072,O
after,9072,O
CCl4,9072,B-CHEMICAL
and,9072,O
PC,9072,O
administration,9072,O
alone,9072,O
.,9072,O
PSM,9073,O
pre-treatment,9073,O
decreased,9073,O
serum,9073,B-GENE-N
transaminases,9073,I-GENE-N
and,9073,O
LDH,9073,B-GENE-N
activities,9073,O
and,9073,O
MDA,9073,B-CHEMICAL
levels,9073,O
and,9073,O
increased,9073,O
the,9073,O
levels,9073,O
of,9073,O
cell,9073,O
protector,9073,O
GSH,9073,B-CHEMICAL
.,9073,O
Biotransformation,9074,O
phase,9074,O
I,9074,O
enzymes,9074,O
were,9074,O
also,9074,O
assessed,9074,O
in,9074,O
both,9074,O
models,9074,O
.,9074,O
In,9075,O
the,9075,O
CCl4,9075,B-CHEMICAL
hepatotoxicity,9075,O
model,9075,O
",",9075,O
pre-treatment,9075,O
with,9075,O
PSM,9075,O
or,9075,O
silymarin,9075,B-CHEMICAL
resulted,9075,O
in,9075,O
significantly,9075,O
increased,9075,O
activities,9075,O
of,9075,O
ethylmorphine-N-demethylase,9075,B-GENE-N
and,9075,O
aniline,9075,B-GENE-N
4-hydroxylase,9075,I-GENE-N
activity,9075,O
and,9075,O
cytochrome,9075,B-GENE-N
P450,9075,I-GENE-N
",",9075,O
compared,9075,O
to,9075,O
the,9075,O
CCl4,9075,B-CHEMICAL
only,9075,O
group,9075,O
.,9075,O
Neither,9076,O
silymarin,9076,B-CHEMICAL
nor,9076,O
PSM,9076,O
influenced,9076,O
PC,9076,O
biotransformation,9076,O
.,9076,O
Our,9077,O
results,9077,O
suggest,9077,O
that,9077,O
PSM,9077,O
",",9077,O
obtained,9077,O
from,9077,O
A.,9077,O
corniculatus,9077,O
",",9077,O
Bieb,9077,O
.,9077,O
showed,9078,O
in,9078,O
vivo,9078,O
hepatoprotective,9078,O
and,9078,O
antioxidant,9078,O
activities,9078,O
against,9078,O
CCl4,9078,B-CHEMICAL
and,9078,O
PC-induced,9078,O
liver,9078,O
damage,9078,O
comparable,9078,O
to,9078,O
that,9078,O
of,9078,O
silymarin,9078,B-CHEMICAL
.,9078,O
Copyright,9079,O
©,9079,O
2012,9079,O
John,9079,O
Wiley,9079,O
&,9079,O
Sons,9079,O
",",9079,O
Ltd,9079,O
.,9079,O
In,9080,O
vitro,9080,O
inhibition,9080,O
of,9080,O
diacylglycerol,9080,B-GENE-Y
acyltransferase,9080,I-GENE-Y
by,9080,O
prenylflavonoids,9080,B-CHEMICAL
from,9080,O
Sophora,9080,O
flavescens,9080,O
.,9080,O
Four,9081,O
prenylflavonoids,9081,B-CHEMICAL
",",9081,O
kurarinone,9081,B-CHEMICAL
(,9081,O
1,9081,O
),9081,O
",",9081,O
a,9081,O
chalcone,9081,B-CHEMICAL
of,9081,O
1,9081,O
",",9081,O
kuraridin,9081,B-CHEMICAL
(,9081,O
2,9081,O
),9081,O
",",9081,O
kurarinol,9081,B-CHEMICAL
(,9081,O
3,9081,O
),9081,O
",",9081,O
kushenol,9081,B-CHEMICAL
H,9081,I-CHEMICAL
(,9081,O
4,9081,O
),9081,O
and,9081,O
kushenol,9081,B-CHEMICAL
K,9081,I-CHEMICAL
(,9081,O
5,9081,O
),9081,O
isolated,9081,O
from,9081,O
the,9081,O
roots,9081,O
of,9081,O
Sophora,9081,O
flavescens,9081,O
were,9081,O
investigated,9081,O
for,9081,O
their,9081,O
inhibitory,9081,O
effects,9081,O
on,9081,O
diacylglycerol,9081,B-GENE-Y
acyltransferase,9081,I-GENE-Y
(,9081,O
DGAT,9081,B-GENE-Y
),9081,O
.,9081,O
The,9082,O
flavonoids,9082,B-CHEMICAL
inhibited,9082,O
DGAT,9082,B-GENE-Y
activity,9082,O
in,9082,O
a,9082,O
dose-dependent,9082,O
manner,9082,O
with,9082,O
IC50,9082,O
values,9082,O
of,9082,O
10.9,9082,O
microM,9082,O
(,9082,O
1,9082,O
),9082,O
",",9082,O
9.8,9082,O
microM,9082,O
(,9082,O
2,9082,O
),9082,O
",",9082,O
8.6,9082,O
microM,9082,O
(,9082,O
3,9082,O
),9082,O
",",9082,O
142.0,9082,O
microM,9082,O
(,9082,O
4,9082,O
),9082,O
and,9082,O
250,9082,O
microM,9082,O
(,9082,O
5,9082,O
),9082,O
.,9082,O
The,9083,O
prenylflavonoids,9083,B-CHEMICAL
without,9083,O
C3-OH,9083,B-CHEMICAL
(,9083,O
1,9083,O
",",9083,O
2,9083,O
",",9083,O
3,9083,O
),9083,O
showed,9083,O
stronger,9083,O
inhibition,9083,O
than,9083,O
those,9083,O
with,9083,O
C3-OH,9083,B-CHEMICAL
(,9083,O
4,9083,O
",",9083,O
5,9083,O
),9083,O
.,9083,O
On,9084,O
the,9084,O
other,9084,O
hand,9084,O
",",9084,O
flavonoids,9084,B-CHEMICAL
without,9084,O
side,9084,O
chains,9084,O
(,9084,O
hesperetin,9084,B-CHEMICAL
",",9084,O
naringenin,9084,B-CHEMICAL
",",9084,O
quercetin,9084,B-CHEMICAL
and,9084,O
kaempferol,9084,B-CHEMICAL
),9084,O
did,9084,O
not,9084,O
inhibit,9084,O
the,9084,O
enzyme,9084,O
activity,9084,O
at,9084,O
a,9084,O
final,9084,O
concentration,9084,O
of,9084,O
800,9084,O
microM,9084,O
.,9084,O
These,9085,O
data,9085,O
suggest,9085,O
that,9085,O
the,9085,O
lavandulyl,9085,B-CHEMICAL
side,9085,O
chain,9085,O
and,9085,O
the,9085,O
position,9085,O
of,9085,O
the,9085,O
hydroxy,9085,B-CHEMICAL
group,9085,O
are,9085,O
important,9085,O
for,9085,O
high,9085,O
DGAT,9085,B-GENE-Y
inhibitory,9085,O
activity,9085,O
.,9085,O
Compound,9086,O
1,9086,O
also,9086,O
inhibited,9086,O
de,9086,O
novo,9086,O
synthesis,9086,O
of,9086,O
triacylglycerol,9086,B-CHEMICAL
(,9086,O
TG,9086,B-CHEMICAL
),9086,O
in,9086,O
Raji,9086,O
cells,9086,O
.,9086,O
IL-4,9087,B-GENE-Y
stimulates,9087,O
the,9087,O
expression,9087,O
of,9087,O
CXCL-8,9087,B-GENE-Y
",",9087,O
E-selectin,9087,B-GENE-Y
",",9087,O
VEGF,9087,B-GENE-Y
",",9087,O
and,9087,O
inducible,9087,B-GENE-Y
nitric,9087,I-GENE-Y
oxide,9087,I-GENE-Y
synthase,9087,I-GENE-Y
mRNA,9087,O
by,9087,O
equine,9087,O
pulmonary,9087,O
artery,9087,O
endothelial,9087,O
cells,9087,O
.,9087,O
Little,9088,O
is,9088,O
known,9088,O
concerning,9088,O
the,9088,O
possible,9088,O
contribution,9088,O
of,9088,O
T,9088,O
helper,9088,O
2,9088,O
(,9088,O
Th2,9088,O
),9088,O
-type,9088,O
cytokines,9088,B-GENE-N
to,9088,O
the,9088,O
recruitment,9088,O
of,9088,O
neutrophils,9088,O
into,9088,O
the,9088,O
lung,9088,O
tissue,9088,O
.,9088,O
In,9089,O
the,9089,O
present,9089,O
study,9089,O
",",9089,O
endothelial,9089,O
cells,9089,O
from,9089,O
equine,9089,O
pulmonary,9089,O
arteries,9089,O
were,9089,O
cultured,9089,O
in,9089,O
the,9089,O
presence,9089,O
of,9089,O
recombinant,9089,O
equine,9089,B-GENE-Y
(,9089,I-GENE-Y
re,9089,I-GENE-Y
),9089,I-GENE-Y
IL-4,9089,I-GENE-Y
and,9089,O
reIL-5,9089,B-GENE-Y
",",9089,O
and,9089,O
the,9089,O
cytokine,9089,B-GENE-N
mRNA,9089,O
expression,9089,O
of,9089,O
molecules,9089,O
implicated,9089,O
in,9089,O
the,9089,O
chemotaxis,9089,O
and,9089,O
migration,9089,O
of,9089,O
neutrophils,9089,O
was,9089,O
studied,9089,O
using,9089,O
real-time,9089,O
RT-PCR,9089,O
.,9089,O
The,9090,O
functional,9090,O
response,9090,O
of,9090,O
reIL-4-induced,9090,B-GENE-Y
endothelial,9090,O
cell,9090,O
stimulation,9090,O
on,9090,O
neutrophil,9090,O
migration,9090,O
was,9090,O
also,9090,O
studied,9090,O
using,9090,O
a,9090,O
chemotaxis,9090,O
chamber,9090,O
.,9090,O
ReIL-4,9091,B-GENE-Y
either,9091,O
increased,9091,O
the,9091,O
expression,9091,O
of,9091,O
CXCL-8,9091,B-GENE-Y
",",9091,O
E-selectin,9091,B-GENE-Y
",",9091,O
vascular,9091,B-GENE-Y
endothelial,9091,I-GENE-Y
growth,9091,I-GENE-Y
factor,9091,I-GENE-Y
(,9091,O
VEGF,9091,B-GENE-Y
),9091,O
",",9091,O
and,9091,O
inducible,9091,B-GENE-Y
nitric,9091,I-GENE-Y
oxide,9091,I-GENE-Y
synthase,9091,I-GENE-Y
(,9091,O
iNOS,9091,B-GENE-Y
),9091,O
",",9091,O
or,9091,O
potentiated,9091,O
the,9091,O
coeffects,9091,O
of,9091,O
lipopolysaccharide,9091,O
(,9091,O
LPS,9091,O
),9091,O
and,9091,O
tumor,9091,B-GENE-Y
necrosis,9091,I-GENE-Y
factor-alpha,9091,I-GENE-Y
(,9091,O
TNF-alpha,9091,B-GENE-Y
),9091,O
on,9091,O
CXCL-8,9091,B-GENE-Y
.,9091,O
Supernatants,9092,O
collected,9092,O
from,9092,O
cultured,9092,O
endothelial,9092,O
cells,9092,O
stimulated,9092,O
with,9092,O
reIL-4,9092,B-GENE-Y
significantly,9092,O
promoted,9092,O
neutrophil,9092,O
migration,9092,O
in,9092,O
a,9092,O
dose-dependent,9092,O
manner,9092,O
.,9092,O
Dexamethasone,9093,B-CHEMICAL
(,9093,O
DXM,9093,B-CHEMICAL
),9093,O
decreased,9093,O
the,9093,O
expression,9093,O
of,9093,O
CXCL-8,9093,B-GENE-Y
",",9093,O
VEGF,9093,B-GENE-Y
",",9093,O
and,9093,O
iNOS,9093,B-GENE-Y
induced,9093,O
by,9093,O
reIL-4,9093,B-GENE-Y
",",9093,O
while,9093,O
1400W,9093,B-CHEMICAL
dihydrochloride,9093,I-CHEMICAL
(,9093,O
1400W,9093,B-CHEMICAL
),9093,O
",",9093,O
a,9093,O
selective,9093,O
inhibitor,9093,O
of,9093,O
iNOS,9093,B-GENE-Y
",",9093,O
decreased,9093,O
the,9093,O
expression,9093,O
of,9093,O
E-selectin,9093,B-GENE-Y
",",9093,O
VEGF,9093,B-GENE-Y
",",9093,O
and,9093,O
iNOS,9093,B-GENE-Y
.,9093,O
DXM,9094,B-CHEMICAL
and,9094,O
1400W,9094,B-CHEMICAL
attenuated,9094,O
the,9094,O
mRNA,9094,O
expression,9094,O
of,9094,O
E-selectin,9094,B-GENE-Y
and,9094,O
iNOS,9094,B-GENE-Y
induced,9094,O
by,9094,O
the,9094,O
costimulation,9094,O
of,9094,O
reIL-4,9094,B-GENE-Y
",",9094,O
reTNF-alpha,9094,B-GENE-Y
",",9094,O
and,9094,O
LPS,9094,O
.,9094,O
Neither,9095,O
equine,9095,B-GENE-N
nor,9095,I-GENE-N
human,9095,I-GENE-N
recombinant,9095,I-GENE-N
IL-5,9095,I-GENE-N
influenced,9095,O
the,9095,O
mRNA,9095,O
expression,9095,O
of,9095,O
CXCL-8,9095,B-GENE-Y
",",9095,O
E-selectin,9095,B-GENE-Y
",",9095,O
or,9095,O
VEGF,9095,B-GENE-Y
.,9095,O
These,9096,O
findings,9096,O
suggest,9096,O
that,9096,O
Th2-type,9096,O
cytokines,9096,B-GENE-N
may,9096,O
contribute,9096,O
to,9096,O
pulmonary,9096,O
neutrophilia,9096,O
during,9096,O
allergic,9096,O
inflammation,9096,O
by,9096,O
the,9096,O
increased,9096,O
expression,9096,O
of,9096,O
neutrophil,9096,O
chemokines,9096,B-GENE-N
and,9096,O
adhesion,9096,B-GENE-N
molecules,9096,I-GENE-N
by,9096,O
endothelial,9096,O
cells,9096,O
.,9096,O
DXM,9097,B-CHEMICAL
and,9097,O
the,9097,O
iNOS,9097,B-GENE-Y
inhibitors,9097,O
may,9097,O
decrease,9097,O
pulmonary,9097,O
neutrophilia,9097,O
due,9097,O
",",9097,O
in,9097,O
part,9097,O
",",9097,O
to,9097,O
a,9097,O
direct,9097,O
inhibition,9097,O
of,9097,O
some,9097,O
of,9097,O
these,9097,O
factors,9097,O
.,9097,O
Hydroxy-terminated,9098,B-CHEMICAL
conjugated,9098,O
polymer,9098,O
nanoparticles,9098,O
have,9098,O
near-unity,9098,O
bright,9098,O
fraction,9098,O
and,9098,O
reveal,9098,O
cholesterol-dependence,9098,B-CHEMICAL
of,9098,O
IGF1R,9098,B-GENE-N
nanodomains,9098,I-GENE-N
.,9098,O
Fluorescent,9099,O
nanoparticles,9099,O
have,9099,O
enabled,9099,O
many,9099,O
discoveries,9099,O
regarding,9099,O
how,9099,O
molecular,9099,O
machines,9099,O
function,9099,O
.,9099,O
Quantum,9100,O
dots,9100,O
have,9100,O
been,9100,O
the,9100,O
dominant,9100,O
class,9100,O
of,9100,O
fluorescent,9100,O
nanoparticles,9100,O
but,9100,O
suffer,9100,O
from,9100,O
blinking,9100,O
and,9100,O
from,9100,O
a,9100,O
substantial,9100,O
dark,9100,O
fraction,9100,O
--,9100,O
particles,9100,O
where,9100,O
the,9100,O
fluorescence,9100,O
is,9100,O
never,9100,O
seen,9100,O
--,9100,O
complicating,9100,O
any,9100,O
analysis,9100,O
of,9100,O
biological,9100,O
function,9100,O
.,9100,O
Nanoparticles,9101,O
composed,9101,O
of,9101,O
conjugated,9101,O
fluorescent,9101,O
polymers,9101,O
(,9101,O
Pdots,9101,O
),9101,O
have,9101,O
recently,9101,O
been,9101,O
shown,9101,O
to,9101,O
have,9101,O
high,9101,O
brightness,9101,O
and,9101,O
no,9101,O
blinking,9101,O
.,9101,O
Here,9102,O
we,9102,O
develop,9102,O
a,9102,O
robust,9102,O
and,9102,O
efficient,9102,O
means,9102,O
to,9102,O
measure,9102,O
the,9102,O
dark,9102,O
fraction,9102,O
of,9102,O
Pdots,9102,O
",",9102,O
conjugating,9102,O
Atto,9102,O
dyes,9102,O
to,9102,O
the,9102,O
nanoparticles,9102,O
and,9102,O
testing,9102,O
fluorescence,9102,O
colocalization,9102,O
of,9102,O
dye,9102,O
and,9102,O
Pdot,9102,O
puncta,9102,O
.,9102,O
This,9103,O
established,9103,O
that,9103,O
the,9103,O
Pdots,9103,O
we,9103,O
generated,9103,O
had,9103,O
minimal,9103,O
dark,9103,O
fraction,9103,O
:,9103,O
∼3,9103,O
%,9103,O
.,9103,O
The,9104,O
application,9104,O
of,9104,O
nanoparticles,9104,O
in,9104,O
biological,9104,O
environments,9104,O
is,9104,O
highly,9104,O
sensitive,9104,O
to,9104,O
surface,9104,O
functionalization,9104,O
.,9104,O
For,9105,O
Pdots,9105,O
we,9105,O
found,9105,O
that,9105,O
passivation,9105,O
with,9105,O
uncharged,9105,O
hydroxy-terminated,9105,B-CHEMICAL
polyethylene,9105,B-CHEMICAL
glycol,9105,I-CHEMICAL
caused,9105,O
a,9105,O
dramatic,9105,O
reduction,9105,O
in,9105,O
nonspecific,9105,O
cell,9105,O
binding,9105,O
and,9105,O
aggregation,9105,O
compared,9105,O
to,9105,O
a,9105,O
charged,9105,O
coating,9105,O
.,9105,O
Using,9106,O
carbonyl,9106,B-CHEMICAL
di-imidazole,9106,I-CHEMICAL
the,9106,O
hydroxy-Pdots,9106,B-CHEMICAL
were,9106,O
functionalized,9106,O
efficiently,9106,O
with,9106,O
streptavidin,9106,O
for,9106,O
high,9106,O
stability,9106,O
targeting,9106,O
",",9106,O
allowing,9106,O
specific,9106,O
labeling,9106,O
of,9106,O
mammalian,9106,O
cells,9106,O
.,9106,O
Type,9107,B-GENE-Y
I,9107,I-GENE-Y
insulin-like,9107,I-GENE-Y
growth,9107,I-GENE-Y
factor,9107,I-GENE-Y
receptor,9107,I-GENE-Y
(,9107,O
IGF1R,9107,B-GENE-Y
),9107,O
regulates,9107,O
cell,9107,O
survival,9107,O
and,9107,O
development,9107,O
",",9107,O
with,9107,O
roles,9107,O
in,9107,O
aging,9107,O
",",9107,O
heart,9107,O
disease,9107,O
",",9107,O
and,9107,O
cancer,9107,O
.,9107,O
We,9108,O
used,9108,O
hydroxy-Pdots,9108,B-CHEMICAL
to,9108,O
track,9108,O
the,9108,O
dynamics,9108,O
of,9108,O
IGF1R,9108,B-GENE-Y
on,9108,O
a,9108,O
breast,9108,O
cancer,9108,O
cell-line,9108,O
",",9108,O
determining,9108,O
the,9108,O
diffusion,9108,O
characteristics,9108,O
and,9108,O
showing,9108,O
cholesterol-containing,9108,B-CHEMICAL
membrane,9108,O
nanodomains,9108,O
were,9108,O
important,9108,O
for,9108,O
receptor,9108,O
mobility,9108,O
at,9108,O
the,9108,O
plasma,9108,O
membrane,9108,O
.,9108,O
The,9109,O
near-unity,9109,O
bright,9109,O
fraction,9109,O
and,9109,O
low,9109,O
nonspecific,9109,O
binding,9109,O
of,9109,O
hydroxy-Pdots,9109,B-CHEMICAL
",",9109,O
combined,9109,O
with,9109,O
Pdot,9109,O
photostability,9109,O
and,9109,O
lack,9109,O
of,9109,O
blinking,9109,O
",",9109,O
provides,9109,O
many,9109,O
advantages,9109,O
for,9109,O
investigations,9109,O
at,9109,O
the,9109,O
single,9109,O
molecule,9109,O
level,9109,O
.,9109,O
Medroxyprogesterone,9110,B-CHEMICAL
acetate,9110,I-CHEMICAL
but,9110,O
not,9110,O
drospirenone,9110,B-CHEMICAL
ablates,9110,O
the,9110,O
protective,9110,O
function,9110,O
of,9110,O
17,9110,B-CHEMICAL
beta-estradiol,9110,I-CHEMICAL
in,9110,O
aldosterone,9110,B-CHEMICAL
salt-treated,9110,O
rats,9110,O
.,9110,O
Controversial,9111,O
results,9111,O
obtained,9111,O
from,9111,O
human,9111,O
and,9111,O
animal,9111,O
studies,9111,O
on,9111,O
the,9111,O
prevention,9111,O
of,9111,O
heart,9111,O
disease,9111,O
by,9111,O
estrogens,9111,B-CHEMICAL
and,9111,O
progestins,9111,B-CHEMICAL
warrant,9111,O
a,9111,O
better,9111,O
understanding,9111,O
of,9111,O
nuclear,9111,B-GENE-N
hormone,9111,I-GENE-N
receptor,9111,I-GENE-N
function,9111,O
and,9111,O
interaction,9111,O
.,9111,O
To,9112,O
address,9112,O
this,9112,O
issue,9112,O
and,9112,O
taking,9112,O
into,9112,O
account,9112,O
that,9112,O
effects,9112,O
of,9112,O
synthetic,9112,O
progestins,9112,B-CHEMICAL
are,9112,O
not,9112,O
only,9112,O
referable,9112,O
to,9112,O
action,9112,O
through,9112,O
the,9112,O
progesterone,9112,B-GENE-Y
receptor,9112,I-GENE-Y
but,9112,O
may,9112,O
also,9112,O
be,9112,O
mediated,9112,O
by,9112,O
other,9112,O
steroid,9112,B-GENE-N
receptors,9112,I-GENE-N
",",9112,O
we,9112,O
characterized,9112,O
cardiovascular,9112,O
function,9112,O
and,9112,O
inflammatory,9112,O
gene,9112,O
expression,9112,O
in,9112,O
aldosterone,9112,B-CHEMICAL
salt-treated,9112,O
rats,9112,O
on,9112,O
long-term,9112,O
administration,9112,O
of,9112,O
17beta-estradiol,9112,B-CHEMICAL
",",9112,O
medroxyprogesterone,9112,B-CHEMICAL
acetate,9112,I-CHEMICAL
",",9112,O
and,9112,O
drospirenone,9112,B-CHEMICAL
",",9112,O
a,9112,O
new,9112,O
progestogen,9112,B-CHEMICAL
exhibiting,9112,O
antimineralocorticoid,9112,O
activity,9112,O
.,9112,O
The,9113,O
complex,9113,O
pattern,9113,O
of,9113,O
cardiovascular,9113,O
injury,9113,O
in,9113,O
ovariectomized,9113,O
Wistar,9113,O
rats,9113,O
induced,9113,O
by,9113,O
chronic,9113,O
aldosterone,9113,B-CHEMICAL
infusion,9113,O
plus,9113,O
a,9113,O
high-salt,9113,O
diet,9113,O
was,9113,O
significantly,9113,O
attenuated,9113,O
in,9113,O
sham-ovariectomized,9113,O
rats,9113,O
and,9113,O
by,9113,O
coadministration,9113,O
of,9113,O
17beta-estradiol,9113,B-CHEMICAL
in,9113,O
ovariectomized,9113,O
animals,9113,O
after,9113,O
8,9113,O
weeks,9113,O
of,9113,O
continuous,9113,O
treatment,9113,O
.,9113,O
The,9114,O
beneficial,9114,O
role,9114,O
of,9114,O
17beta-estradiol,9114,B-CHEMICAL
on,9114,O
blood,9114,O
pressure,9114,O
",",9114,O
cardiac,9114,O
hypertrophy,9114,O
",",9114,O
vascular,9114,O
osteopontin,9114,B-GENE-Y
expression,9114,O
",",9114,O
perivascular,9114,O
fibrosis,9114,O
",",9114,O
and,9114,O
impaired,9114,O
NO-dependent,9114,B-CHEMICAL
relaxation,9114,O
of,9114,O
isolated,9114,O
aortic,9114,O
rings,9114,O
was,9114,O
completely,9114,O
abrogated,9114,O
by,9114,O
coadministration,9114,O
of,9114,O
medroxyprogesterone,9114,B-CHEMICAL
acetate,9114,I-CHEMICAL
.,9114,O
In,9115,O
contrast,9115,O
",",9115,O
drospirenone,9115,B-CHEMICAL
was,9115,O
either,9115,O
neutral,9115,O
or,9115,O
additive,9115,O
to,9115,O
17beta-estradiol,9115,B-CHEMICAL
in,9115,O
protecting,9115,O
against,9115,O
aldosterone,9115,B-CHEMICAL
salt-induced,9115,O
cardiovascular,9115,O
injury,9115,O
and,9115,O
inflammation,9115,O
.,9115,O
The,9116,O
current,9116,O
results,9116,O
support,9116,O
the,9116,O
hypothesis,9116,O
of,9116,O
complex,9116,O
interactions,9116,O
among,9116,O
estrogen,9116,B-GENE-N
",",9116,I-GENE-N
progesterone,9116,I-GENE-N
",",9116,I-GENE-N
glucocorticoid,9116,I-GENE-N
",",9116,I-GENE-N
androgen,9116,I-GENE-N
",",9116,I-GENE-N
and,9116,I-GENE-N
mineralocorticoid,9116,I-GENE-N
receptor,9116,I-GENE-N
signaling,9116,O
in,9116,O
cardiovascular,9116,O
injury,9116,O
and,9116,O
inflammation,9116,O
.,9116,O
Novel,9117,O
progestins,9117,B-CHEMICAL
",",9117,O
such,9117,O
as,9117,O
drospirenone,9117,B-CHEMICAL
",",9117,O
confer,9117,O
superior,9117,O
effects,9117,O
compared,9117,O
with,9117,O
medroxyprogesterone,9117,B-CHEMICAL
acetate,9117,I-CHEMICAL
in,9117,O
a,9117,O
model,9117,O
of,9117,O
aldosterone-induced,9117,B-CHEMICAL
heart,9117,O
disease,9117,O
because,9117,O
of,9117,O
its,9117,O
antimineralocorticoid,9117,O
properties,9117,O
.,9117,O
Effect,9118,O
of,9118,O
ifenprodil,9118,B-CHEMICAL
on,9118,O
GluN1/GluN2B,9118,B-GENE-Y
N-methyl-D-aspartate,9118,B-GENE-N
receptor,9118,I-GENE-N
gating,9118,O
.,9118,O
Ifenprodil,9119,B-CHEMICAL
is,9119,O
an,9119,O
allosteric,9119,O
inhibitor,9119,O
of,9119,O
GluN1/GluN2B,9119,B-GENE-Y
N-methyl-D-aspartate,9119,B-GENE-N
receptors,9119,I-GENE-N
.,9119,O
Despite,9120,O
its,9120,O
widespread,9120,O
use,9120,O
as,9120,O
a,9120,O
prototype,9120,O
for,9120,O
drug,9120,O
development,9120,O
and,9120,O
a,9120,O
subtype-selective,9120,O
tool,9120,O
for,9120,O
physiologic,9120,O
experiments,9120,O
",",9120,O
its,9120,O
precise,9120,O
effect,9120,O
on,9120,O
GluN1/GluN2B,9120,B-GENE-Y
gating,9120,O
is,9120,O
yet,9120,O
to,9120,O
be,9120,O
fully,9120,O
understood,9120,O
.,9120,O
Interestingly,9121,O
",",9121,O
recent,9121,O
crystallographic,9121,O
evidence,9121,O
identified,9121,O
that,9121,O
ifenprodil,9121,B-CHEMICAL
",",9121,I-CHEMICAL
unlike,9121,O
zinc,9121,B-CHEMICAL
",",9121,O
binds,9121,O
at,9121,O
the,9121,O
interface,9121,O
of,9121,O
the,9121,O
GluN1/GluN2B,9121,B-GENE-Y
amino,9121,B-CHEMICAL
terminal,9121,O
domain,9121,O
dimer,9121,O
by,9121,O
an,9121,O
induced-fit,9121,O
mechanism,9121,O
.,9121,O
To,9122,O
delineate,9122,O
the,9122,O
effect,9122,O
of,9122,O
this,9122,O
unique,9122,O
binding,9122,O
on,9122,O
GluN1/GluN2B,9122,B-GENE-Y
receptor,9122,O
gating,9122,O
",",9122,O
we,9122,O
recorded,9122,O
steady-state,9122,O
currents,9122,O
from,9122,O
cell-attached,9122,O
and,9122,O
outside-out,9122,O
patches,9122,O
.,9122,O
At,9123,O
pH,9123,O
7.9,9123,O
in,9123,O
cell-attached,9123,O
patches,9123,O
",",9123,O
ifenprodil,9123,B-CHEMICAL
increased,9123,O
the,9123,O
occupancy,9123,O
of,9123,O
the,9123,O
long-lived,9123,O
shut,9123,O
conformations,9123,O
",",9123,O
thereby,9123,O
reducing,9123,O
the,9123,O
open,9123,O
probability,9123,O
of,9123,O
the,9123,O
receptor,9123,O
with,9123,O
no,9123,O
change,9123,O
in,9123,O
the,9123,O
mean,9123,O
open,9123,O
time,9123,O
.,9123,O
In,9124,O
addition,9124,O
",",9124,O
ifenprodil,9124,B-CHEMICAL
selectively,9124,O
affected,9124,O
the,9124,O
area,9124,O
of,9124,O
shut,9124,O
time,9124,O
constants,9124,O
",",9124,O
but,9124,O
not,9124,O
the,9124,O
time,9124,O
constants,9124,O
themselves,9124,O
.,9124,O
Kinetic,9125,O
analyses,9125,O
suggested,9125,O
that,9125,O
ifenprodil,9125,B-CHEMICAL
prevents,9125,O
the,9125,O
transition,9125,O
of,9125,O
the,9125,O
receptor,9125,O
to,9125,O
an,9125,O
open,9125,O
state,9125,O
and,9125,O
increases,9125,O
its,9125,O
dwell,9125,O
time,9125,O
in,9125,O
an,9125,O
intrinsically,9125,O
occurring,9125,O
closed,9125,O
conformation,9125,O
or,9125,O
desensitized,9125,O
state,9125,O
.,9125,O
We,9126,O
found,9126,O
distinct,9126,O
differences,9126,O
in,9126,O
the,9126,O
action,9126,O
of,9126,O
ifenprodil,9126,B-CHEMICAL
at,9126,O
GluN1/GluN2B,9126,B-GENE-Y
in,9126,O
comparison,9126,O
with,9126,O
previous,9126,O
studies,9126,O
on,9126,O
the,9126,O
effect,9126,O
of,9126,O
zinc,9126,B-CHEMICAL
on,9126,O
GluN1/GluN2A,9126,B-GENE-Y
gating,9126,O
",",9126,O
which,9126,O
may,9126,O
arise,9126,O
due,9126,O
to,9126,O
their,9126,O
unique,9126,O
binding,9126,O
sites,9126,O
.,9126,O
Our,9127,O
data,9127,O
also,9127,O
uncover,9127,O
the,9127,O
potential,9127,O
pH-dependent,9127,O
action,9127,O
of,9127,O
ifenprodil,9127,B-CHEMICAL
on,9127,O
gating,9127,O
.,9127,O
At,9128,O
a,9128,O
low,9128,O
pH,9128,O
(,9128,O
pH,9128,O
7.4,9128,O
),9128,O
",",9128,O
but,9128,O
not,9128,O
pH,9128,O
7.9,9128,O
",",9128,O
ifenprodil,9128,B-CHEMICAL
reduces,9128,O
the,9128,O
mean,9128,O
open,9128,O
time,9128,O
of,9128,O
GluN1/GluN2B,9128,B-GENE-Y
receptors,9128,O
",",9128,O
which,9128,O
may,9128,O
be,9128,O
responsible,9128,O
for,9128,O
its,9128,O
usefulness,9128,O
as,9128,O
a,9128,O
context-dependent,9128,O
inhibitor,9128,O
in,9128,O
conditions,9128,O
like,9128,O
ischemia,9128,O
and,9128,O
stroke,9128,O
",",9128,O
when,9128,O
the,9128,O
pH,9128,O
of,9128,O
the,9128,O
extracellular,9128,O
milieu,9128,O
becomes,9128,O
acidic,9128,O
.,9128,O
mTOR,9129,B-GENE-Y
Regulates,9129,O
Nox4-Mediated,9129,B-GENE-Y
Podocyte,9129,O
Depletion,9129,O
in,9129,O
Diabetic,9129,O
Renal,9129,O
Injury,9129,O
.,9129,O
Podocyte,9130,O
apoptosis,9130,O
is,9130,O
a,9130,O
critical,9130,O
mechanism,9130,O
for,9130,O
excessive,9130,O
loss,9130,O
of,9130,O
urinary,9130,O
albumin,9130,B-GENE-Y
that,9130,O
eventuates,9130,O
in,9130,O
kidney,9130,O
fibrosis,9130,O
.,9130,O
Pharmacological,9131,O
doses,9131,O
of,9131,O
the,9131,O
mTOR,9131,B-GENE-Y
inhibitor,9131,O
rapamycin,9131,B-CHEMICAL
reduce,9131,O
albuminura,9131,O
in,9131,O
diabetes,9131,O
.,9131,O
We,9132,O
explored,9132,O
the,9132,O
hypothesis,9132,O
that,9132,O
mTOR,9132,B-GENE-Y
mediates,9132,O
podocyte,9132,O
injury,9132,O
in,9132,O
diabetes,9132,O
.,9132,O
High,9133,O
glucose,9133,B-CHEMICAL
(,9133,O
HG,9133,O
),9133,O
induces,9133,O
apoptosis,9133,O
of,9133,O
podocytes,9133,O
",",9133,O
inhibits,9133,O
AMPK,9133,B-GENE-N
activation,9133,O
",",9133,O
inactivates,9133,O
tuberin,9133,B-GENE-Y
and,9133,O
activates,9133,O
mTOR,9133,B-GENE-Y
.,9133,O
HG,9134,O
also,9134,O
increases,9134,O
the,9134,O
levels,9134,O
of,9134,O
Nox4,9134,B-GENE-Y
and,9134,O
Nox1,9134,B-GENE-Y
and,9134,O
NADPH,9134,B-GENE-N
oxidase,9134,I-GENE-N
activity,9134,O
.,9134,O
Inhibition,9135,O
of,9135,O
mTOR,9135,B-GENE-Y
by,9135,O
low,9135,O
dose,9135,O
rapamycin,9135,B-CHEMICAL
decreases,9135,O
HG-induced,9135,O
Nox4,9135,B-GENE-Y
and,9135,O
Nox1,9135,B-GENE-Y
",",9135,O
NADPH,9135,B-GENE-N
oxidase,9135,I-GENE-N
activity,9135,O
and,9135,O
podocyte,9135,O
apoptosis,9135,O
.,9135,O
Inhibition,9136,O
of,9136,O
mTOR,9136,B-GENE-Y
had,9136,O
no,9136,O
effect,9136,O
on,9136,O
AMPK,9136,B-GENE-N
or,9136,O
tuberin,9136,B-GENE-Y
phosphorylation,9136,O
indicating,9136,O
that,9136,O
mTOR,9136,B-GENE-Y
is,9136,O
downstream,9136,O
of,9136,O
these,9136,O
signaling,9136,O
molecules,9136,O
.,9136,O
In,9137,O
isolated,9137,O
glomeruli,9137,O
of,9137,O
OVE26,9137,O
mice,9137,O
",",9137,O
there,9137,O
is,9137,O
similar,9137,O
decrease,9137,O
in,9137,O
the,9137,O
activation,9137,O
of,9137,O
AMPK,9137,B-GENE-N
and,9137,O
tuberin,9137,B-GENE-Y
and,9137,O
activation,9137,O
of,9137,O
mTOR,9137,B-GENE-Y
with,9137,O
increase,9137,O
in,9137,O
Nox4,9137,B-GENE-Y
and,9137,O
NADPH,9137,B-GENE-N
oxidase,9137,I-GENE-N
activity,9137,O
.,9137,O
Inhibition,9138,O
of,9138,O
mTOR,9138,B-GENE-Y
by,9138,O
small,9138,O
dose,9138,O
of,9138,O
rapamycin,9138,B-CHEMICAL
reduces,9138,O
podocyte,9138,O
apoptosis,9138,O
",",9138,O
attenuates,9138,O
glomerular,9138,O
injury,9138,O
and,9138,O
albuminuria,9138,O
.,9138,O
Our,9139,O
data,9139,O
provide,9139,O
evidence,9139,O
for,9139,O
a,9139,O
novel,9139,O
function,9139,O
of,9139,O
mTOR,9139,B-GENE-Y
in,9139,O
Nox4-derived,9139,B-GENE-Y
ROS,9139,O
generation,9139,O
and,9139,O
podocyte,9139,O
apoptosis,9139,O
that,9139,O
contributes,9139,O
to,9139,O
urinary,9139,O
albumin,9139,B-GENE-Y
excretion,9139,O
in,9139,O
type,9139,O
1,9139,O
diabetes,9139,O
.,9139,O
Thus,9140,O
mTOR,9140,B-GENE-Y
and,9140,O
or,9140,O
NADPH,9140,B-GENE-N
oxidase,9140,I-GENE-N
inhibition,9140,O
may,9140,O
represent,9140,O
a,9140,O
therapeutic,9140,O
modality,9140,O
of,9140,O
diabetic,9140,O
kidney,9140,O
disease,9140,O
.,9140,O
Cavity,9141,O
Ringdown,9141,O
Spectroscopy,9141,O
of,9141,O
the,9141,O
Hydroxy-Methyl-Peroxy,9141,B-CHEMICAL
Radical,9141,O
.,9141,O
We,9142,O
report,9142,O
vibrational,9142,O
and,9142,O
electronic,9142,O
spectra,9142,O
of,9142,O
the,9142,O
hydroxyl-methyl-peroxy,9142,B-CHEMICAL
radical,9142,O
(,9142,O
HOCH2OO,9142,B-CHEMICAL
",",9142,O
or,9142,O
HMP,9142,B-CHEMICAL
),9142,O
",",9142,O
the,9142,O
primary,9142,O
product,9142,O
of,9142,O
the,9142,O
reaction,9142,O
of,9142,O
the,9142,O
hydroperoxy,9142,B-CHEMICAL
radical,9142,O
",",9142,O
HO2,9142,B-CHEMICAL
",",9142,O
and,9142,O
formaldehyde,9142,B-CHEMICAL
",",9142,O
HCHO,9142,B-CHEMICAL
.,9142,O
The,9143,O
ν1,9143,O
vibrational,9143,O
(,9143,O
OH,9143,B-CHEMICAL
stretch,9143,O
),9143,O
spectrum,9143,O
and,9143,O
the,9143,O
Ã-X,9143,O
electronic,9143,O
spectrum,9143,O
of,9143,O
HMP,9143,B-CHEMICAL
were,9143,O
detected,9143,O
by,9143,O
Infrared,9143,O
Cavity,9143,O
Ringdown,9143,O
Spectroscopy,9143,O
(,9143,O
IR-CRDS,9143,O
),9143,O
",",9143,O
and,9143,O
assignments,9143,O
were,9143,O
verified,9143,O
with,9143,O
density,9143,O
functional,9143,O
calculations,9143,O
.,9143,O
The,9144,O
HMP,9144,B-CHEMICAL
radical,9144,O
was,9144,O
generated,9144,O
in,9144,O
reactions,9144,O
of,9144,O
HCHO,9144,B-CHEMICAL
with,9144,O
HO2,9144,B-CHEMICAL
.,9144,O
Free,9145,O
radical,9145,O
reactions,9145,O
were,9145,O
initiated,9145,O
by,9145,O
pulsed,9145,O
laser,9145,O
photolysis,9145,O
(,9145,O
PLP,9145,O
),9145,O
of,9145,O
Cl2,9145,B-CHEMICAL
in,9145,O
the,9145,O
presence,9145,O
of,9145,O
HCHO,9145,B-CHEMICAL
and,9145,O
O2,9145,B-CHEMICAL
in,9145,O
a,9145,O
flow,9145,O
reactor,9145,O
at,9145,O
300-330,9145,O
Torr,9145,O
and,9145,O
295K,9145,O
.,9145,O
IR-CRDS,9146,O
spectra,9146,O
were,9146,O
measured,9146,O
in,9146,O
mid-IR,9146,O
and,9146,O
near-IR,9146,O
regions,9146,O
over,9146,O
the,9146,O
ranges,9146,O
3525-3700,9146,O
cm,9146,O
(,9146,O
-1,9146,O
),9146,O
(,9146,O
ν1,9146,O
),9146,O
and,9146,O
7250-7800,9146,O
cm,9146,O
(,9146,O
-1,9146,O
),9146,O
(,9146,O
Ã-X,9146,O
),9146,O
(,9146,O
respectively,9146,O
",",9146,O
at,9146,O
a,9146,O
delay,9146,O
time,9146,O
100,9146,O
µs,9146,O
after,9146,O
photolysis,9146,O
.,9146,O
The,9147,O
ν1,9147,O
spectrum,9147,O
had,9147,O
an,9147,O
origin,9147,O
at,9147,O
3622,9147,O
cm,9147,O
(,9147,O
-1,9147,O
),9147,O
and,9147,O
exhibited,9147,O
partially,9147,O
resolved,9147,O
P-,9147,O
and,9147,O
R-branch,9147,O
contours,9147,O
and,9147,O
a,9147,O
small,9147,O
Q,9147,O
branch,9147,O
.,9147,O
At,9148,O
these,9148,O
short,9148,O
delay,9148,O
times,9148,O
",",9148,O
spectral,9148,O
interference,9148,O
from,9148,O
HOOH,9148,B-CHEMICAL
and,9148,O
HCOOH,9148,B-CHEMICAL
was,9148,O
minimal,9148,O
",",9148,O
and,9148,O
could,9148,O
be,9148,O
subtracted,9148,O
.,9148,O
From,9149,O
B3LYP/6-31G+,9149,O
(,9149,O
d,9149,O
",",9149,O
p,9149,O
),9149,O
calculations,9149,O
",",9149,O
we,9149,O
found,9149,O
that,9149,O
the,9149,O
anharmonic,9149,O
vibrational,9149,O
frequency,9149,O
and,9149,O
band,9149,O
contour,9149,O
predicted,9149,O
for,9149,O
the,9149,O
lowest,9149,O
energy,9149,O
conformer,9149,O
",",9149,O
HMP-A,9149,B-CHEMICAL
",",9149,O
The,9149,O
calculated,9149,O
anharmonic,9149,O
vibrational,9149,O
frequency,9149,O
and,9149,O
band,9149,O
contour,9149,O
computed,9149,O
using,9149,O
B3LYP/63-1G,9149,O
(,9149,O
d,9149,O
",",9149,O
p,9149,O
),9149,O
level,9149,O
were,9149,O
in,9149,O
good,9149,O
agreement,9149,O
with,9149,O
the,9149,O
observed,9149,O
spectrum,9149,O
.,9149,O
In,9150,O
the,9150,O
near-IR,9150,O
",",9150,O
we,9150,O
observed,9150,O
four,9150,O
well,9150,O
spaced,9150,O
vibronic,9150,O
bands,9150,O
",",9150,O
each,9150,O
with,9150,O
partially,9150,O
resolved,9150,O
rotational,9150,O
contours,9150,O
.,9150,O
We,9151,O
assigned,9151,O
the,9151,O
apparent,9151,O
origin,9151,O
of,9151,O
the,9151,O
electronic,9151,O
spectrum,9151,O
of,9151,O
HMP,9151,B-CHEMICAL
at,9151,O
7392,9151,O
cm,9151,O
(,9151,O
-1,9151,O
),9151,O
and,9151,O
two,9151,O
bands,9151,O
to,9151,O
the,9151,O
blue,9151,O
to,9151,O
a,9151,O
progression,9151,O
in,9151,O
ν15,9151,O
',9151,O
",",9151,O
the,9151,O
lowest,9151,O
torsional,9151,O
mode,9151,O
of,9151,O
the,9151,O
state,9151,O
(,9151,O
ν15'=,9151,O
171,9151,O
cm,9151,O
(,9151,O
-1,9151,O
),9151,O
),9151,O
.,9151,O
The,9152,O
band,9152,O
furthest,9152,O
to,9152,O
the,9152,O
red,9152,O
was,9152,O
assigned,9152,O
as,9152,O
a,9152,O
hot,9152,O
band,9152,O
in,9152,O
ν15,9152,O
'',9152,O
",",9152,O
leading,9152,O
to,9152,O
a,9152,O
ground,9152,O
state,9152,O
torsional,9152,O
frequency,9152,O
of,9152,O
(,9152,O
ν15,9152,O
'',9152,O
=,9152,O
122,9152,O
cm,9152,O
(,9152,O
-1,9152,O
),9152,O
),9152,O
.,9152,O
We,9153,O
simulated,9153,O
the,9153,O
spectrum,9153,O
using,9153,O
second,9153,O
order,9153,O
vibrational,9153,O
perturbation,9153,O
theory,9153,O
(,9153,O
VPT2,9153,O
),9153,O
with,9153,O
B3LYP/6-31+G,9153,O
(,9153,O
d,9153,O
",",9153,O
p,9153,O
),9153,O
calculations,9153,O
at,9153,O
the,9153,O
minimum,9153,O
energy,9153,O
geometries,9153,O
of,9153,O
the,9153,O
HMP-A,9153,B-CHEMICAL
conformer,9153,O
on,9153,O
the,9153,O
X,9153,O
̃,9153,O
and,9153,O
A,9153,O
̃,9153,O
states,9153,O
.,9153,O
The,9154,O
predictions,9154,O
of,9154,O
the,9154,O
electronic,9154,O
origin,9154,O
frequency,9154,O
",",9154,O
torsional,9154,O
frequencies,9154,O
",",9154,O
anharmonicities,9154,O
and,9154,O
rotational,9154,O
band,9154,O
contours,9154,O
matched,9154,O
the,9154,O
observed,9154,O
spectrum,9154,O
.,9154,O
We,9155,O
investigated,9155,O
the,9155,O
torsional,9155,O
modes,9155,O
more,9155,O
explicitly,9155,O
by,9155,O
computing,9155,O
potential,9155,O
energy,9155,O
surfaces,9155,O
of,9155,O
HMP,9155,B-CHEMICAL
as,9155,O
a,9155,O
function,9155,O
of,9155,O
the,9155,O
two,9155,O
dihedral,9155,O
angles,9155,O
τOCOH,9155,O
and,9155,O
τOOCO,9155,O
.,9155,O
Wave,9156,O
functions,9156,O
and,9156,O
energy,9156,O
levels,9156,O
were,9156,O
calculated,9156,O
based,9156,O
on,9156,O
this,9156,O
potential,9156,O
surface,9156,O
;,9156,O
these,9156,O
results,9156,O
were,9156,O
used,9156,O
to,9156,O
calculate,9156,O
the,9156,O
Franck-Condon,9156,O
factors,9156,O
",",9156,O
which,9156,O
reproduced,9156,O
the,9156,O
vibronic,9156,O
band,9156,O
intensities,9156,O
in,9156,O
the,9156,O
observed,9156,O
electronic,9156,O
spectrum,9156,O
.,9156,O
The,9157,O
transitions,9157,O
that,9157,O
we,9157,O
observed,9157,O
all,9157,O
involved,9157,O
states,9157,O
with,9157,O
wave,9157,O
functions,9157,O
localized,9157,O
on,9157,O
the,9157,O
minimum,9157,O
energy,9157,O
conformer,9157,O
",",9157,O
HMP-A,9157,B-CHEMICAL
.,9157,O
Our,9158,O
calculations,9158,O
indicated,9158,O
that,9158,O
the,9158,O
observed,9158,O
near-IR,9158,O
spectrum,9158,O
was,9158,O
that,9158,O
of,9158,O
the,9158,O
minimum,9158,O
energy,9158,O
conformer,9158,O
HMP-A,9158,B-CHEMICAL
",",9158,O
but,9158,O
that,9158,O
this,9158,O
conformer,9158,O
is,9158,O
not,9158,O
the,9158,O
lowest,9158,O
energy,9158,O
conformer,9158,O
in,9158,O
the,9158,O
state,9158,O
",",9158,O
which,9158,O
remains,9158,O
unobserved,9158,O
.,9158,O
We,9159,O
estimated,9159,O
that,9159,O
the,9159,O
energy,9159,O
of,9159,O
this,9159,O
lowest,9159,O
conformer,9159,O
(,9159,O
HMP-B,9159,B-CHEMICAL
),9159,O
of,9159,O
the,9159,O
Ã,9159,O
state,9159,O
to,9159,O
be,9159,O
T0,9159,O
(,9159,O
Ã,9159,O
),9159,O
≈,9159,O
7200,9159,O
cm,9159,O
(,9159,O
-1,9159,O
),9159,O
",",9159,O
based,9159,O
on,9159,O
the,9159,O
energy,9159,O
difference,9159,O
E0,9159,O
(,9159,O
HMP-B,9159,B-CHEMICAL
),9159,O
-,9159,O
E0,9159,O
(,9159,O
HMP-A,9159,B-CHEMICAL
),9159,O
on,9159,O
the,9159,O
Ã,9159,O
state,9159,O
computed,9159,O
at,9159,O
the,9159,O
B3LYP/6-31+G,9159,O
(,9159,O
d,9159,O
",",9159,O
p,9159,O
),9159,O
level,9159,O
.,9159,O
Systemic,9160,O
administration,9160,O
of,9160,O
beta2-adrenoceptor,9160,B-GENE-Y
agonists,9160,O
",",9160,O
formoterol,9160,B-CHEMICAL
and,9160,O
salmeterol,9160,B-CHEMICAL
",",9160,O
elicit,9160,O
skeletal,9160,O
muscle,9160,O
hypertrophy,9160,O
in,9160,O
rats,9160,O
at,9160,O
micromolar,9160,O
doses,9160,O
.,9160,O
beta,9161,B-GENE-Y
(,9161,I-GENE-Y
2,9161,I-GENE-Y
),9161,I-GENE-Y
-Adrenoceptor,9161,I-GENE-Y
agonists,9161,O
provide,9161,O
a,9161,O
potential,9161,O
therapy,9161,O
for,9161,O
muscle,9161,O
wasting,9161,O
and,9161,O
weakness,9161,O
",",9161,O
but,9161,O
their,9161,O
use,9161,O
may,9161,O
be,9161,O
limited,9161,O
by,9161,O
adverse,9161,O
effects,9161,O
on,9161,O
the,9161,O
heart,9161,O
",",9161,O
mediated,9161,O
in,9161,O
part,9161,O
",",9161,O
by,9161,O
beta,9161,B-GENE-Y
(,9161,I-GENE-Y
1,9161,I-GENE-Y
),9161,I-GENE-Y
-adrenoceptor,9161,I-GENE-Y
activation,9161,O
.,9161,O
Two,9162,O
beta,9162,O
(,9162,O
2,9162,O
),9162,O
-agonists,9162,O
",",9162,O
formoterol,9162,B-CHEMICAL
and,9162,O
salmeterol,9162,B-CHEMICAL
",",9162,O
are,9162,O
approved,9162,O
for,9162,O
treating,9162,O
asthma,9162,O
and,9162,O
have,9162,O
an,9162,O
extended,9162,O
duration,9162,O
of,9162,O
action,9162,O
and,9162,O
increased,9162,O
safety,9162,O
",",9162,O
associated,9162,O
with,9162,O
greater,9162,O
beta,9162,B-GENE-Y
(,9162,I-GENE-Y
2,9162,I-GENE-Y
),9162,I-GENE-Y
-adrenoceptor,9162,I-GENE-Y
selectivity,9162,O
.,9162,O
The,9163,O
pharmacological,9163,O
profiles,9163,O
of,9163,O
formoterol,9163,B-CHEMICAL
and,9163,O
salmeterol,9163,B-CHEMICAL
and,9163,O
their,9163,O
effects,9163,O
on,9163,O
skeletal,9163,O
and,9163,O
cardiac,9163,O
muscle,9163,O
mass,9163,O
were,9163,O
investigated,9163,O
in,9163,O
12-week-old,9163,O
",",9163,O
male,9163,O
F344,9163,O
rats,9163,O
.,9163,O
Formoterol,9164,B-CHEMICAL
and,9164,O
salmeterol,9164,B-CHEMICAL
were,9164,O
each,9164,O
administered,9164,O
via,9164,O
daily,9164,O
i.p,9164,O
.,9164,O
injection,9165,O
at,9165,O
one,9165,O
of,9165,O
seven,9165,O
doses,9165,O
(,9165,O
ranging,9165,O
from,9165,O
1,9165,O
to,9165,O
"2,000",9165,O
microg,9165,O
kg,9165,O
(,9165,O
-1,9165,O
),9165,O
day,9165,O
(,9165,O
-1,9165,O
),9165,O
),9165,O
",",9165,O
for,9165,O
4,9165,O
weeks,9165,O
.,9165,O
Rats,9166,O
were,9166,O
anaesthetised,9166,O
and,9166,O
the,9166,O
EDL,9166,O
and,9166,O
soleus,9166,O
muscles,9166,O
and,9166,O
the,9166,O
heart,9166,O
were,9166,O
excised,9166,O
and,9166,O
weighed,9166,O
.,9166,O
Dose-response,9167,O
curves,9167,O
were,9167,O
constructed,9167,O
based,9167,O
on,9167,O
skeletal,9167,O
and,9167,O
cardiac,9167,O
muscle,9167,O
hypertrophy,9167,O
.,9167,O
Formoterol,9168,B-CHEMICAL
was,9168,O
more,9168,O
potent,9168,O
than,9168,O
salmeterol,9168,B-CHEMICAL
",",9168,O
with,9168,O
a,9168,O
significantly,9168,O
lower,9168,O
ED,9168,O
(,9168,O
50,9168,O
),9168,O
in,9168,O
EDL,9168,O
muscles,9168,O
(,9168,O
1,9168,O
and,9168,O
130,9168,O
microg,9168,O
kg,9168,O
(,9168,O
-1,9168,O
),9168,O
day,9168,O
(,9168,O
-1,9168,O
),9168,O
",",9168,O
P,9168,O
<,9168,O
0.05,9168,O
),9168,O
",",9168,O
whereas,9168,O
salmeterol,9168,B-CHEMICAL
had,9168,O
greater,9168,O
intrinsic,9168,O
activity,9168,O
than,9168,O
formoterol,9168,B-CHEMICAL
in,9168,O
both,9168,O
EDL,9168,O
and,9168,O
soleus,9168,O
muscles,9168,O
(,9168,O
12,9168,O
%,9168,O
greater,9168,O
hypertrophy,9168,O
than,9168,O
formoterol,9168,B-CHEMICAL
),9168,O
.,9168,O
The,9169,O
drugs,9169,O
had,9169,O
similar,9169,O
potency,9169,O
and,9169,O
intrinsic,9169,O
activity,9169,O
in,9169,O
the,9169,O
heart,9169,O
",",9169,O
with,9169,O
a,9169,O
smaller,9169,O
leftward,9169,O
shift,9169,O
for,9169,O
formoterol,9169,B-CHEMICAL
than,9169,O
seen,9169,O
in,9169,O
skeletal,9169,O
muscle,9169,O
.,9169,O
A,9170,O
dose,9170,O
of,9170,O
25,9170,O
microg,9170,O
kg,9170,O
(,9170,O
-1,9170,O
),9170,O
day,9170,O
(,9170,O
-1,9170,O
),9170,O
of,9170,O
formoterol,9170,B-CHEMICAL
elicited,9170,O
greater,9170,O
EDL,9170,O
and,9170,O
soleus,9170,O
hypertrophy,9170,O
than,9170,O
salmeterol,9170,B-CHEMICAL
",",9170,O
but,9170,O
resulted,9170,O
in,9170,O
similar,9170,O
beta-adrenoceptor,9170,B-GENE-N
downregulation,9170,O
.,9170,O
These,9171,O
results,9171,O
show,9171,O
that,9171,O
doses,9171,O
as,9171,O
low,9171,O
as,9171,O
1,9171,O
microg,9171,O
kg,9171,O
(,9171,O
-1,9171,O
),9171,O
day,9171,O
(,9171,O
-1,9171,O
),9171,O
of,9171,O
formoterol,9171,B-CHEMICAL
can,9171,O
elicit,9171,O
significant,9171,O
muscle,9171,O
hypertrophy,9171,O
with,9171,O
minimal,9171,O
cardiac,9171,O
hypertrophy,9171,O
and,9171,O
provide,9171,O
important,9171,O
information,9171,O
regarding,9171,O
the,9171,O
potential,9171,O
therapeutic,9171,O
use,9171,O
of,9171,O
formoterol,9171,B-CHEMICAL
and,9171,O
salmeterol,9171,B-CHEMICAL
for,9171,O
muscle,9171,O
wasting,9171,O
.,9171,O
Clinical,9172,O
utility,9172,O
of,9172,O
acarbose,9172,B-CHEMICAL
",",9172,O
an,9172,O
alpha-glucosidase,9172,B-GENE-Y
inhibitor,9172,O
in,9172,O
cardiometabolic,9172,O
disorders,9172,O
.,9172,O
Diabetes,9173,O
is,9173,O
associated,9173,O
with,9173,O
an,9173,O
increase,9173,O
risk,9173,O
for,9173,O
cardiovascular,9173,O
disease,9173,O
(,9173,O
CVD,9173,O
),9173,O
.,9173,O
Recently,9174,O
",",9174,O
macrovascular,9174,O
complications,9174,O
of,9174,O
diabetes,9174,O
have,9174,O
been,9174,O
shown,9174,O
to,9174,O
start,9174,O
before,9174,O
the,9174,O
development,9174,O
of,9174,O
diabetes,9174,O
.,9174,O
Indeed,9175,O
",",9175,O
several,9175,O
clinical,9175,O
studies,9175,O
have,9175,O
confirmed,9175,O
the,9175,O
increased,9175,O
risk,9175,O
of,9175,O
CVD,9175,O
in,9175,O
patients,9175,O
with,9175,O
impaired,9175,O
glucose,9175,B-CHEMICAL
tolerance,9175,O
(,9175,O
IGT,9175,O
),9175,O
.,9175,O
Since,9176,O
postprandial,9176,O
hyperglycemia,9176,O
and,9176,O
insulin,9176,B-GENE-Y
resistance,9176,O
are,9176,O
thought,9176,O
to,9176,O
play,9176,O
a,9176,O
central,9176,O
role,9176,O
in,9176,O
the,9176,O
development,9176,O
and,9176,O
progression,9176,O
of,9176,O
CVD,9176,O
in,9176,O
patients,9176,O
with,9176,O
IGT,9176,O
",",9176,O
amelioration,9176,O
of,9176,O
postprandial,9176,O
hyperglycemia,9176,O
as,9176,O
well,9176,O
as,9176,O
insulin,9176,B-GENE-Y
resistance,9176,O
is,9176,O
a,9176,O
therapeutic,9176,O
target,9176,O
for,9176,O
the,9176,O
prevention,9176,O
of,9176,O
CVD,9176,O
in,9176,O
these,9176,O
high-risk,9176,O
patients,9176,O
.,9176,O
Acarbose,9177,B-CHEMICAL
",",9177,O
an,9177,O
alpha-glucosidase,9177,B-GENE-Y
inhibitor,9177,O
",",9177,O
delays,9177,O
the,9177,O
absorption,9177,O
of,9177,O
carbohydrate,9177,B-CHEMICAL
from,9177,O
the,9177,O
small,9177,O
intestine,9177,O
",",9177,O
thereby,9177,O
reducing,9177,O
postprandial,9177,O
hyperglycemia,9177,O
.,9177,O
Further,9178,O
",",9178,O
recently,9178,O
",",9178,O
acarbose,9178,B-CHEMICAL
has,9178,I-CHEMICAL
been,9178,I-CHEMICAL
shown,9178,I-CHEMICAL
to,9178,I-CHEMICAL
improve,9178,I-CHEMICAL
insulin,9178,I-CHEMICAL
resistance,9178,I-CHEMICAL
in,9178,I-CHEMICAL
vivo,9178,I-CHEMICAL
.,9178,O
These,9179,O
findings,9179,O
suggest,9179,O
that,9179,O
acarbose,9179,B-CHEMICAL
is,9179,O
a,9179,O
promising,9179,O
metabolic,9179,O
modifier,9179,O
that,9179,O
could,9179,O
reduce,9179,O
the,9179,O
risk,9179,O
of,9179,O
CVD,9179,O
in,9179,O
patients,9179,O
with,9179,O
the,9179,O
metabolic,9179,O
syndrome,9179,O
.,9179,O
In,9180,O
this,9180,O
paper,9180,O
",",9180,O
we,9180,O
review,9180,O
the,9180,O
clinical,9180,O
utility,9180,O
of,9180,O
acarbose,9180,B-CHEMICAL
in,9180,O
various,9180,O
cardiometabolic,9180,O
disorders,9180,O
.,9180,O
Hematologic,9181,O
and,9181,O
hepatic,9181,O
responses,9181,O
of,9181,O
the,9181,O
freshwater,9181,O
fish,9181,O
Hoplias,9181,O
malabaricus,9181,O
after,9181,O
saxitoxin,9181,B-CHEMICAL
exposure,9181,O
.,9181,O
The,9182,O
bioaccumulation,9182,O
of,9182,O
saxitoxins,9182,B-CHEMICAL
(,9182,O
STX,9182,B-CHEMICAL
),9182,O
in,9182,O
the,9182,O
trophic,9182,O
chain,9182,O
",",9182,O
mainly,9182,O
in,9182,O
freshwater,9182,O
",",9182,O
are,9182,O
not,9182,O
completely,9182,O
known,9182,O
.,9182,O
This,9183,O
work,9183,O
aimed,9183,O
to,9183,O
elucidate,9183,O
the,9183,O
effects,9183,O
of,9183,O
STX,9183,B-CHEMICAL
on,9183,O
Hoplias,9183,O
malabaricus,9183,O
through,9183,O
trophic,9183,O
bioassay,9183,O
.,9183,O
The,9184,O
fish,9184,O
were,9184,O
fed,9184,O
once,9184,O
every,9184,O
five,9184,O
days,9184,O
with,9184,O
Astyanax,9184,O
sp,9184,O
.,9184,O
before,9185,O
being,9185,O
subjected,9185,O
to,9185,O
an,9185,O
intraperitoneal,9185,O
inoculation,9185,O
with,9185,O
the,9185,O
lysate,9185,O
of,9185,O
Cylindrospermopsis,9185,O
raciborskii,9185,O
culture,9185,O
containing,9185,O
97,9185,O
%,9185,O
STX,9185,B-CHEMICAL
and,9185,O
3,9185,O
%,9185,O
by,9185,O
neosaxitoxin,9185,B-CHEMICAL
and,9185,O
gonyautoxin,9185,B-CHEMICAL
during,9185,O
20,9185,O
days,9185,O
.,9185,O
The,9186,O
animal,9186,O
's,9186,O
liver,9186,O
was,9186,O
assessed,9186,O
using,9186,O
biomarkers,9186,O
as,9186,O
activities,9186,O
of,9186,O
superoxide,9186,B-GENE-N
dismutase,9186,I-GENE-N
(,9186,O
SOD,9186,B-GENE-N
),9186,O
",",9186,O
catalase,9186,B-GENE-N
(,9186,O
CAT,9186,B-GENE-N
),9186,O
",",9186,O
glutathione,9186,B-GENE-N
S-transferase,9186,I-GENE-N
(,9186,O
GST,9186,B-GENE-N
),9186,O
",",9186,O
and,9186,O
glutathione,9186,B-GENE-N
peroxidase,9186,I-GENE-N
(,9186,O
GPx,9186,B-GENE-N
),9186,O
",",9186,O
and,9186,O
concentrations,9186,O
of,9186,O
reduced,9186,B-CHEMICAL
glutathione,9186,I-CHEMICAL
(,9186,O
GSH,9186,B-CHEMICAL
),9186,O
and,9186,O
lipoperoxidation,9186,O
(,9186,O
LPO,9186,O
),9186,O
and,9186,O
protein,9186,O
carbonylation,9186,O
(,9186,O
PCO,9186,O
),9186,O
.,9186,O
In,9187,O
the,9187,O
blood,9187,O
was,9187,O
analyzed,9187,O
the,9187,O
genotoxic,9187,O
and,9187,O
hematological,9187,O
parameters,9187,O
.,9187,O
The,9188,O
hepatosomatic,9188,O
index,9188,O
and,9188,O
the,9188,O
relative,9188,O
condition,9188,O
factor,9188,O
did,9188,O
not,9188,O
show,9188,O
a,9188,O
significant,9188,O
difference,9188,O
between,9188,O
the,9188,O
exposed,9188,O
and,9188,O
control,9188,O
groups,9188,O
.,9188,O
The,9189,O
values,9189,O
of,9189,O
mean,9189,O
corpuscular,9189,O
hemoglobin,9189,B-GENE-N
concentration,9189,O
and,9189,O
mean,9189,O
corpuscular,9189,O
hemoglobin,9189,B-GENE-N
increased,9189,O
in,9189,O
the,9189,O
STX,9189,B-CHEMICAL
group,9189,O
.,9189,O
The,9190,O
hepatic,9190,O
tissue,9190,O
from,9190,O
both,9190,O
groups,9190,O
exhibited,9190,O
a,9190,O
typical,9190,O
pattern,9190,O
that,9190,O
have,9190,O
been,9190,O
already,9190,O
described,9190,O
for,9190,O
most,9190,O
teleost,9190,O
fish,9190,O
.,9190,O
The,9191,O
results,9191,O
suggested,9191,O
the,9191,O
generation,9191,O
of,9191,O
reactive,9191,O
oxygen,9191,B-CHEMICAL
species,9191,O
",",9191,O
with,9191,O
increased,9191,O
activity,9191,O
of,9191,O
GPx,9191,B-GENE-N
and,9191,O
concentrations,9191,O
of,9191,O
LPO,9191,O
and,9191,O
GSH,9191,B-CHEMICAL
;,9191,O
whereas,9191,O
the,9191,O
specific,9191,O
activity,9191,O
of,9191,O
SOD,9191,B-GENE-N
decreased,9191,O
.,9191,O
However,9192,O
",",9192,O
no,9192,O
changes,9192,O
were,9192,O
observed,9192,O
in,9192,O
the,9192,O
CAT,9192,B-GENE-N
",",9192,O
PCO,9192,O
",",9192,O
and,9192,O
DNA,9192,O
damage,9192,O
.,9192,O
Although,9193,O
the,9193,O
STX,9193,B-CHEMICAL
effects,9193,O
are,9193,O
known,9193,O
as,9193,O
neurotoxic,9193,O
",",9193,O
this,9193,O
cyanotoxin,9193,O
caused,9193,O
liver,9193,O
biochemical,9193,O
alterations,9193,O
that,9193,O
can,9193,O
be,9193,O
considered,9193,O
ecologically,9193,O
relevant,9193,O
.,9193,O
The,9194,O
Protective,9194,O
Effects,9194,O
of,9194,O
α-Lipoic,9194,B-CHEMICAL
Acid,9194,I-CHEMICAL
on,9194,O
Kidneys,9194,O
in,9194,O
Type,9194,O
2,9194,O
Diabetic,9194,O
Goto-Kakisaki,9194,O
Rats,9194,O
via,9194,O
Reducing,9194,O
Oxidative,9194,O
Stress,9194,O
.,9194,O
To,9195,O
evaluate,9195,O
the,9195,O
protective,9195,O
effects,9195,O
of,9195,O
α-lipoic,9195,B-CHEMICAL
acid,9195,I-CHEMICAL
on,9195,O
the,9195,O
kidneys,9195,O
of,9195,O
Goto-Kakisaki,9195,O
(,9195,O
GK,9195,O
),9195,O
diabetic,9195,O
rats,9195,O
",",9195,O
ten,9195,O
GK,9195,O
diabetic,9195,O
rats,9195,O
were,9195,O
randomly,9195,O
divided,9195,O
into,9195,O
a,9195,O
diabetic,9195,O
control,9195,O
group,9195,O
and,9195,O
a,9195,O
lipoic,9195,B-CHEMICAL
acid-treated,9195,O
diabetic,9195,O
group,9195,O
with,9195,O
α-lipoic,9195,B-CHEMICAL
acid,9195,I-CHEMICAL
35,9195,O
mg·Kg-1,9195,O
intraperitoneal,9195,O
injections,9195,O
.,9195,O
Four,9196,O
healthy,9196,O
Wistar,9196,O
rats,9196,O
served,9196,O
as,9196,O
normal,9196,O
controls,9196,O
.,9196,O
Malonaldehyde,9197,B-CHEMICAL
(,9197,O
MDA,9197,B-CHEMICAL
),9197,O
",",9197,O
ascorbic,9197,B-CHEMICAL
acid,9197,I-CHEMICAL
(,9197,O
vitamin,9197,B-CHEMICAL
C,9197,I-CHEMICAL
),9197,O
",",9197,O
vitamin,9197,B-CHEMICAL
E,9197,I-CHEMICAL
",",9197,O
glutathione,9197,B-CHEMICAL
(,9197,O
GSH,9197,B-CHEMICAL
),9197,O
and,9197,O
superoxide,9197,B-GENE-N
dismutase,9197,I-GENE-N
(,9197,O
SOD,9197,B-GENE-N
),9197,O
levels,9197,O
in,9197,O
renal,9197,O
homogenate,9197,O
",",9197,O
and,9197,O
urine,9197,O
protein,9197,O
excretion,9197,O
were,9197,O
measured,9197,O
.,9197,O
The,9198,O
expression,9198,O
of,9198,O
mRNA,9198,O
for,9198,O
NF-κB,9198,B-GENE-N
",",9198,O
NADPH,9198,B-GENE-N
oxidase,9198,I-GENE-N
subunits,9198,O
p22phox,9198,B-GENE-Y
and,9198,O
p47phox,9198,B-GENE-Y
in,9198,O
renal,9198,O
tissue,9198,O
was,9198,O
examined,9198,O
by,9198,O
realtime,9198,O
PCR,9198,O
.,9198,O
Pathological,9199,O
changes,9199,O
in,9199,O
renal,9199,O
tissue,9199,O
were,9199,O
evaluated,9199,O
by,9199,O
light,9199,O
and,9199,O
electron,9199,O
microscopy,9199,O
.,9199,O
There,9200,O
were,9200,O
significant,9200,O
increases,9200,O
in,9200,O
urine,9200,O
protein,9200,O
excretion,9200,O
",",9200,O
MDA,9200,B-CHEMICAL
levels,9200,O
and,9200,O
the,9200,O
expression,9200,O
of,9200,O
mRNA,9200,O
of,9200,O
NF-κB,9200,B-GENE-N
",",9200,O
p22phox,9200,B-GENE-Y
and,9200,O
p47phox,9200,B-GENE-Y
",",9200,O
and,9200,O
significant,9200,O
decreases,9200,O
in,9200,O
GSH,9200,B-CHEMICAL
",",9200,O
SOD,9200,B-GENE-N
",",9200,O
vitamin,9200,B-CHEMICAL
C,9200,I-CHEMICAL
and,9200,O
vitamin,9200,B-CHEMICAL
E,9200,I-CHEMICAL
levels,9200,O
in,9200,O
the,9200,O
diabetic,9200,O
control,9200,O
group,9200,O
compared,9200,O
with,9200,O
the,9200,O
normal,9200,O
control,9200,O
group,9200,O
.,9200,O
Pathological,9201,O
changes,9201,O
of,9201,O
renal,9201,O
tissue,9201,O
were,9201,O
more,9201,O
progressive,9201,O
in,9201,O
the,9201,O
diabetic,9201,O
control,9201,O
group,9201,O
than,9201,O
in,9201,O
the,9201,O
normal,9201,O
control,9201,O
group,9201,O
.,9201,O
All,9202,O
the,9202,O
parameters,9202,O
above,9202,O
were,9202,O
improved,9202,O
in,9202,O
the,9202,O
α-lipoic,9202,B-CHEMICAL
acid-treated,9202,O
diabetic,9202,O
group,9202,O
.,9202,O
Oxidative,9203,O
stress,9203,O
is,9203,O
increased,9203,O
in,9203,O
the,9203,O
kidney,9203,O
of,9203,O
type,9203,O
2,9203,O
diabetic,9203,O
GK,9203,O
rats,9203,O
.,9203,O
It,9204,O
is,9204,O
associated,9204,O
with,9204,O
the,9204,O
progression,9204,O
of,9204,O
diabetic,9204,O
nephropathy,9204,O
.,9204,O
α-lipoic,9205,B-CHEMICAL
acid,9205,I-CHEMICAL
can,9205,O
protect,9205,O
renal,9205,O
function,9205,O
in,9205,O
diabetic,9205,O
rats,9205,O
via,9205,O
its,9205,O
antioxidant,9205,O
activity,9205,O
.,9205,O
Alcohol,9206,O
intoxications,9206,O
during,9206,O
adolescence,9206,O
increase,9206,O
motivation,9206,O
for,9206,O
alcohol,9206,O
in,9206,O
adult,9206,O
rats,9206,O
and,9206,O
induce,9206,O
neuroadaptations,9206,O
in,9206,O
the,9206,O
nucleus,9206,O
accumbens,9206,O
.,9206,O
Adolescent,9207,O
alcohol,9207,O
binge,9207,O
drinking,9207,O
constitutes,9207,O
a,9207,O
major,9207,O
vulnerability,9207,O
factor,9207,O
to,9207,O
develop,9207,O
alcoholism,9207,O
.,9207,O
However,9208,O
",",9208,O
mechanisms,9208,O
underlying,9208,O
this,9208,O
susceptibility,9208,O
remain,9208,O
unknown,9208,O
.,9208,O
We,9209,O
evaluated,9209,O
the,9209,O
effect,9209,O
of,9209,O
adolescent,9209,O
binge-like,9209,O
ethanol,9209,B-CHEMICAL
intoxication,9209,O
on,9209,O
vulnerability,9209,O
to,9209,O
alcohol,9209,O
abuse,9209,O
in,9209,O
Sprague-Dawley,9209,O
rats,9209,O
.,9209,O
To,9210,O
model,9210,O
binge-like,9210,O
ethanol,9210,B-CHEMICAL
intoxication,9210,O
",",9210,O
every,9210,O
2,9210,O
days,9210,O
",",9210,O
rats,9210,O
received,9210,O
an,9210,O
ethanol,9210,B-CHEMICAL
injection,9210,O
(,9210,O
3.0,9210,O
g/kg,9210,O
),9210,O
for,9210,O
2,9210,O
consecutive,9210,O
days,9210,O
across,9210,O
14,9210,O
days,9210,O
either,9210,O
from,9210,O
postnatal,9210,O
day,9210,O
30,9210,O
(,9210,O
PND30,9210,O
),9210,O
to,9210,O
43,9210,O
(,9210,O
early,9210,O
adolescence,9210,O
),9210,O
or,9210,O
from,9210,O
PND,9210,O
45,9210,O
to,9210,O
PND,9210,O
58,9210,O
(,9210,O
late,9210,O
adolescence,9210,O
),9210,O
.,9210,O
In,9211,O
young,9211,O
adult,9211,O
animals,9211,O
",",9211,O
we,9211,O
measured,9211,O
free,9211,O
ethanol,9211,B-CHEMICAL
consumption,9211,O
in,9211,O
the,9211,O
two-bottle,9211,O
choice,9211,O
paradigm,9211,O
",",9211,O
motivation,9211,O
for,9211,O
ethanol,9211,B-CHEMICAL
in,9211,O
the,9211,O
operant,9211,O
self-administration,9211,O
task,9211,O
and,9211,O
both,9211,O
ethanol,9211,B-CHEMICAL
's,9211,O
rewarding,9211,O
and,9211,O
aversive,9211,O
properties,9211,O
in,9211,O
the,9211,O
conditioned,9211,O
place,9211,O
preference,9211,O
(,9211,O
CPP,9211,O
),9211,O
and,9211,O
taste,9211,O
aversion,9211,O
(,9211,O
CTA,9211,O
),9211,O
paradigms,9211,O
.,9211,O
While,9212,O
intermittent,9212,O
ethanol,9212,B-CHEMICAL
intoxications,9212,O
(,9212,O
IEI,9212,O
),9212,O
during,9212,O
late,9212,O
adolescence,9212,O
had,9212,O
no,9212,O
effect,9212,O
on,9212,O
free-choice,9212,O
10,9212,O
%,9212,O
ethanol,9212,B-CHEMICAL
consumption,9212,O
",",9212,O
we,9212,O
found,9212,O
that,9212,O
IEI,9212,O
during,9212,O
early,9212,O
adolescence,9212,O
promoted,9212,O
free-choice,9212,O
10,9212,O
%,9212,O
ethanol,9212,B-CHEMICAL
consumption,9212,O
",",9212,O
enhanced,9212,O
motivation,9212,O
for,9212,O
ethanol,9212,B-CHEMICAL
in,9212,O
the,9212,O
self-administration,9212,O
paradigm,9212,O
and,9212,O
induced,9212,O
a,9212,O
loss,9212,O
of,9212,O
both,9212,O
ethanol-induced,9212,B-CHEMICAL
CPP,9212,O
and,9212,O
CTA,9212,O
in,9212,O
young,9212,O
adults,9212,O
.,9212,O
No,9213,O
modification,9213,O
in,9213,O
either,9213,O
sucrose,9213,B-CHEMICAL
self-administration,9213,O
or,9213,O
amphetamine-induced,9213,B-CHEMICAL
CPP,9213,O
was,9213,O
observed,9213,O
.,9213,O
As,9214,O
the,9214,O
nucleus,9214,O
accumbens,9214,O
(,9214,O
Nac,9214,O
),9214,O
is,9214,O
particularly,9214,O
involved,9214,O
in,9214,O
addictive,9214,O
behavior,9214,O
",",9214,O
we,9214,O
analyzed,9214,O
IEI-induced,9214,O
long-term,9214,O
neuroadaptations,9214,O
in,9214,O
the,9214,O
Nac,9214,O
using,9214,O
c-Fos,9214,B-GENE-Y
immunohistochemistry,9214,O
and,9214,O
an,9214,O
array,9214,O
of,9214,O
neurotransmission-related,9214,O
genes,9214,O
.,9214,O
This,9215,O
vulnerability,9215,O
to,9215,O
ethanol,9215,B-CHEMICAL
abuse,9215,O
was,9215,O
associated,9215,O
with,9215,O
a,9215,O
lower,9215,O
c-Fos,9215,B-GENE-Y
immunoreactivity,9215,O
in,9215,O
the,9215,O
Nac,9215,O
and,9215,O
enduring,9215,O
alterations,9215,O
of,9215,O
the,9215,O
expression,9215,O
of,9215,O
Penk,9215,B-GENE-Y
and,9215,O
Slc6a4,9215,B-GENE-Y
",",9215,O
2,9215,O
neurotransmission-related,9215,O
genes,9215,O
that,9215,O
have,9215,O
been,9215,O
shown,9215,O
to,9215,O
play,9215,O
critical,9215,O
roles,9215,O
in,9215,O
the,9215,O
behavioral,9215,O
effects,9215,O
of,9215,O
ethanol,9215,B-CHEMICAL
and,9215,O
alcoholism,9215,O
.,9215,O
Gliotransmission,9216,O
and,9216,O
brain,9216,O
glucose,9216,B-CHEMICAL
sensing,9216,O
:,9216,O
critical,9216,O
role,9216,O
of,9216,O
endozepines,9216,B-GENE-N
.,9216,O
Hypothalamic,9217,O
glucose,9217,B-CHEMICAL
sensing,9217,O
is,9217,O
involved,9217,O
in,9217,O
the,9217,O
control,9217,O
of,9217,O
feeding,9217,O
behavior,9217,O
and,9217,O
peripheral,9217,O
glucose,9217,B-CHEMICAL
homeostasis,9217,O
",",9217,O
and,9217,O
glial,9217,O
cells,9217,O
are,9217,O
suggested,9217,O
to,9217,O
play,9217,O
an,9217,O
important,9217,O
role,9217,O
in,9217,O
this,9217,O
process,9217,O
.,9217,O
Diazepam-binding,9218,B-GENE-Y
inhibitor,9218,I-GENE-Y
(,9218,O
DBI,9218,B-GENE-Y
),9218,O
and,9218,O
its,9218,O
processing,9218,O
product,9218,O
the,9218,O
octadecaneuropeptide,9218,B-GENE-N
(,9218,O
ODN,9218,B-GENE-N
),9218,O
",",9218,O
collectively,9218,O
named,9218,O
endozepines,9218,B-GENE-N
",",9218,O
are,9218,O
secreted,9218,O
by,9218,O
astroglia,9218,O
",",9218,O
and,9218,O
ODN,9218,B-GENE-N
is,9218,O
a,9218,O
potent,9218,O
anorexigenic,9218,O
factor,9218,O
.,9218,O
Therefore,9219,O
",",9219,O
we,9219,O
investigated,9219,O
the,9219,O
involvement,9219,O
of,9219,O
endozepines,9219,O
in,9219,O
brain,9219,O
glucose,9219,B-CHEMICAL
sensing,9219,O
.,9219,O
First,9220,O
",",9220,O
we,9220,O
showed,9220,O
that,9220,O
intracerebroventricular,9220,O
administration,9220,O
of,9220,O
glucose,9220,B-CHEMICAL
in,9220,O
rats,9220,O
increases,9220,O
DBI,9220,B-GENE-Y
expression,9220,O
in,9220,O
hypothalamic,9220,O
glial-like,9220,O
tanycytes,9220,O
.,9220,O
We,9221,O
then,9221,O
demonstrated,9221,O
that,9221,O
glucose,9221,B-CHEMICAL
stimulates,9221,O
endozepine,9221,O
secretion,9221,O
from,9221,O
hypothalamic,9221,O
explants,9221,O
.,9221,O
Feeding,9222,O
experiments,9222,O
indicate,9222,O
that,9222,O
the,9222,O
anorexigenic,9222,O
effect,9222,O
of,9222,O
central,9222,O
administration,9222,O
of,9222,O
glucose,9222,B-CHEMICAL
was,9222,O
blunted,9222,O
by,9222,O
coinjection,9222,O
of,9222,O
an,9222,O
ODN,9222,B-GENE-N
antagonist,9222,O
.,9222,O
Conversely,9223,O
",",9223,O
the,9223,O
hyperphagic,9223,O
response,9223,O
elicited,9223,O
by,9223,O
central,9223,O
glucoprivation,9223,O
was,9223,O
suppressed,9223,O
by,9223,O
an,9223,O
ODN,9223,B-GENE-N
agonist,9223,O
.,9223,O
The,9224,O
anorexigenic,9224,O
effects,9224,O
of,9224,O
centrally,9224,O
injected,9224,O
glucose,9224,B-CHEMICAL
or,9224,O
ODN,9224,B-GENE-N
agonist,9224,O
were,9224,O
suppressed,9224,O
by,9224,O
blockade,9224,O
of,9224,O
the,9224,O
melanocortin-3/4,9224,B-GENE-N
receptors,9224,I-GENE-N
",",9224,O
suggesting,9224,O
that,9224,O
glucose,9224,B-CHEMICAL
sensing,9224,O
involves,9224,O
endozepinergic,9224,O
control,9224,O
of,9224,O
the,9224,O
melanocortin,9224,B-GENE-N
pathway,9224,O
.,9224,O
Finally,9225,O
",",9225,O
we,9225,O
found,9225,O
that,9225,O
brain,9225,O
endozepines,9225,B-GENE-N
modulate,9225,O
blood,9225,O
glucose,9225,B-CHEMICAL
levels,9225,O
",",9225,O
suggesting,9225,O
their,9225,O
involvement,9225,O
in,9225,O
a,9225,O
feedback,9225,O
loop,9225,O
controlling,9225,O
whole-body,9225,O
glucose,9225,B-CHEMICAL
homeostasis,9225,O
.,9225,O
Collectively,9226,O
",",9226,O
these,9226,O
data,9226,O
indicate,9226,O
that,9226,O
endozepines,9226,B-GENE-N
are,9226,O
a,9226,O
critical,9226,O
relay,9226,O
in,9226,O
brain,9226,O
glucose,9226,B-CHEMICAL
sensing,9226,O
and,9226,O
potentially,9226,O
new,9226,O
targets,9226,O
in,9226,O
treatment,9226,O
of,9226,O
metabolic,9226,O
disorders,9226,O
.,9226,O
Tyrosine,9227,B-GENE-Y
hydroxylase,9227,I-GENE-Y
binds,9227,O
tetrahydrobiopterin,9227,B-CHEMICAL
cofactor,9227,O
with,9227,O
negative,9227,O
cooperativity,9227,O
",",9227,O
as,9227,O
shown,9227,O
by,9227,O
kinetic,9227,O
analyses,9227,O
and,9227,O
surface,9227,O
plasmon,9227,O
resonance,9227,O
detection,9227,O
.,9227,O
Kinetic,9228,O
studies,9228,O
of,9228,O
tetrameric,9228,O
recombinant,9228,O
human,9228,B-GENE-Y
tyrosine,9228,I-GENE-Y
hydroxylase,9228,I-GENE-Y
isoform,9228,I-GENE-Y
1,9228,I-GENE-Y
(,9228,O
hTH1,9228,B-GENE-Y
),9228,O
have,9228,O
revealed,9228,O
properties,9228,O
so,9228,O
far,9228,O
not,9228,O
reported,9228,O
for,9228,O
this,9228,O
enzyme,9228,O
.,9228,O
Firstly,9229,O
",",9229,O
with,9229,O
the,9229,O
natural,9229,O
cofactor,9229,O
(,9229,B-CHEMICAL
6R,9229,I-CHEMICAL
),9229,I-CHEMICAL
"-Lerythro-5,6,7",9229,I-CHEMICAL
",",9229,I-CHEMICAL
8-tetrahydrobiopterin,9229,I-CHEMICAL
(,9229,O
H4biopterin,9229,B-CHEMICAL
),9229,O
a,9229,O
time-dependent,9229,O
change,9229,O
(,9229,O
burst,9229,O
),9229,O
in,9229,O
enzyme,9229,O
activity,9229,O
was,9229,O
observed,9229,O
",",9229,O
with,9229,O
a,9229,O
half-time,9229,O
of,9229,O
about,9229,O
20,9229,O
s,9229,O
for,9229,O
the,9229,O
kinetic,9229,O
transient,9229,O
.,9229,O
Secondly,9230,O
",",9230,O
nonhyperbolic,9230,O
saturation,9230,O
behaviour,9230,O
was,9230,O
found,9230,O
for,9230,O
H4biopterin,9230,B-CHEMICAL
with,9230,O
a,9230,O
pronounced,9230,O
negative,9230,O
cooperativity,9230,O
(,9230,O
0.39,9230,O
<,9230,O
h,9230,O
<,9230,O
0.58,9230,O
;,9230,O
[,9230,O
S,9230,O
],9230,O
0.5,9230,O
=,9230,O
24,9230,O
+/-,9230,O
4,9230,O
microM,9230,O
),9230,O
.,9230,O
On,9231,O
phosphorylation,9231,O
of,9231,O
Ser40,9231,B-CHEMICAL
by,9231,O
protein,9231,B-GENE-N
kinase,9231,I-GENE-N
A,9231,I-GENE-N
",",9231,O
the,9231,O
affinity,9231,O
for,9231,O
H4biopterin,9231,B-CHEMICAL
increased,9231,O
(,9231,O
[,9231,O
S,9231,O
],9231,O
0.5,9231,O
=,9231,O
11,9231,O
+/-,9231,O
2,9231,O
microM,9231,O
),9231,O
and,9231,O
the,9231,O
negative,9231,O
cooperativity,9231,O
was,9231,O
amplified,9231,O
(,9231,O
h,9231,O
=,9231,O
0.27,9231,O
+/-,9231,O
0.03,9231,O
),9231,O
.,9231,O
The,9232,O
dimeric,9232,O
C-terminal,9232,B-CHEMICAL
deletion,9232,O
mutant,9232,O
(,9232,O
Delta473-528,9232,O
),9232,O
of,9232,O
hTH1,9232,B-GENE-Y
also,9232,O
showed,9232,O
negative,9232,O
cooperativity,9232,O
of,9232,O
H4biopterin,9232,B-CHEMICAL
binding,9232,O
(,9232,O
h,9232,O
=,9232,O
0.4,9232,O
),9232,O
.,9232,O
Cooperativity,9233,O
was,9233,O
not,9233,O
observed,9233,O
with,9233,O
the,9233,O
cofactor,9233,O
analogues,9233,O
"6-methyl-5,6,7,8-tetrahydropterin",9233,B-CHEMICAL
(,9233,O
h,9233,O
=,9233,O
0.9,9233,O
+/-,9233,O
0.1,9233,O
;,9233,O
Km,9233,O
=,9233,O
62.7,9233,O
+/-,9233,O
5.7,9233,O
microM,9233,O
),9233,O
and,9233,O
"3-methyl-5,6,7",9233,B-CHEMICAL
",",9233,I-CHEMICAL
8-tetrahydropterin,9233,I-CHEMICAL
(,9233,O
H43-methyl-pterin,9233,B-CHEMICAL
),9233,O
(,9233,O
h,9233,O
=,9233,O
1.0,9233,O
+/-,9233,O
0.1,9233,O
;,9233,O
Km,9233,O
=,9233,O
687,9233,O
+/-,9233,O
50,9233,O
microM,9233,O
),9233,O
.,9233,O
In,9234,O
the,9234,O
presence,9234,O
of,9234,O
1,9234,O
mM,9234,O
H43-methyl-pterin,9234,B-CHEMICAL
",",9234,O
used,9234,O
as,9234,O
a,9234,O
competitive,9234,O
cofactor,9234,O
analogue,9234,O
to,9234,O
BH4,9234,O
",",9234,O
hyperbolic,9234,O
saturation,9234,O
curves,9234,O
were,9234,O
also,9234,O
found,9234,O
for,9234,O
H4biopterin,9234,B-CHEMICAL
(,9234,O
h,9234,O
=,9234,O
1.0,9234,O
),9234,O
",",9234,O
thus,9234,O
confirming,9234,O
the,9234,O
genuine,9234,O
nature,9234,O
of,9234,O
the,9234,O
kinetic,9234,O
negative,9234,O
cooperativity,9234,O
.,9234,O
This,9235,O
cooperativity,9235,O
was,9235,O
confirmed,9235,O
by,9235,O
real-time,9235,O
biospecific,9235,O
interaction,9235,O
analysis,9235,O
by,9235,O
surface,9235,O
plasmon,9235,O
resonance,9235,O
detection,9235,O
.,9235,O
The,9236,O
equilibrium,9236,O
binding,9236,O
of,9236,O
H4biopterin,9236,B-CHEMICAL
to,9236,O
the,9236,O
immobilized,9236,O
iron-free,9236,O
apoenzyme,9236,O
results,9236,O
in,9236,O
a,9236,O
saturable,9236,O
positive,9236,O
resonance,9236,O
unit,9236,O
(,9236,O
DeltaRU,9236,O
),9236,O
response,9236,O
with,9236,O
negative,9236,O
cooperativity,9236,O
(,9236,O
h,9236,O
=,9236,O
0.52-0.56,9236,O
),9236,O
.,9236,O
Infrared,9237,O
spectroscopic,9237,O
studies,9237,O
revealed,9237,O
a,9237,O
reduced,9237,O
thermal,9237,O
stability,9237,O
both,9237,O
of,9237,O
the,9237,O
apo-and,9237,O
the,9237,O
holo-hTH1,9237,O
on,9237,O
binding,9237,O
of,9237,O
H4biopterin,9237,B-CHEMICAL
and,9237,O
Lerythro-dihydrobiopterin,9237,B-CHEMICAL
(,9237,O
H2biopterin,9237,B-CHEMICAL
),9237,O
.,9237,O
Moreover,9238,O
",",9238,O
the,9238,O
ligand-bound,9238,O
forms,9238,O
of,9238,O
the,9238,O
enzyme,9238,O
also,9238,O
showed,9238,O
a,9238,O
decreased,9238,O
resistance,9238,O
to,9238,O
limited,9238,O
tryptic,9238,O
proteolysis,9238,O
.,9238,O
These,9239,O
findings,9239,O
indicate,9239,O
that,9239,O
the,9239,O
binding,9239,O
of,9239,O
H4biopterin,9239,B-CHEMICAL
at,9239,O
the,9239,O
active,9239,O
site,9239,O
induces,9239,O
a,9239,O
destabilizing,9239,O
conformational,9239,O
change,9239,O
in,9239,O
the,9239,O
enzyme,9239,O
which,9239,O
could,9239,O
be,9239,O
related,9239,O
to,9239,O
the,9239,O
observed,9239,O
negative,9239,O
cooperativity,9239,O
.,9239,O
Thus,9240,O
",",9240,O
our,9240,O
studies,9240,O
provide,9240,O
new,9240,O
insight,9240,O
into,9240,O
the,9240,O
regulation,9240,O
of,9240,O
TH,9240,B-GENE-Y
by,9240,O
the,9240,O
concentration,9240,O
of,9240,O
H4biopterin,9240,B-CHEMICAL
which,9240,O
may,9240,O
have,9240,O
significant,9240,O
implications,9240,O
for,9240,O
the,9240,O
physiological,9240,O
regulation,9240,O
of,9240,O
catecholamine,9240,B-CHEMICAL
biosynthesis,9240,O
in,9240,O
neuroendocrine,9240,O
cells,9240,O
.,9240,O
Disposition,9241,O
of,9241,O
a,9241,O
specific,9241,O
cyclooxygenase-2,9241,B-GENE-Y
inhibitor,9241,O
",",9241,O
valdecoxib,9241,B-CHEMICAL
",",9241,O
in,9241,O
human,9241,O
.,9241,O
Valdecoxib,9242,B-CHEMICAL
is,9242,O
a,9242,O
potent,9242,O
and,9242,O
specific,9242,O
inhibitor,9242,O
of,9242,O
cyclooxygenase-2,9242,B-GENE-Y
",",9242,O
which,9242,O
is,9242,O
used,9242,O
for,9242,O
the,9242,O
treatment,9242,O
of,9242,O
rheumatoid,9242,O
arthritis,9242,O
",",9242,O
osteoarthritis,9242,O
",",9242,O
and,9242,O
the,9242,O
dysmenorrhea,9242,O
pain,9242,O
.,9242,O
Eight,9243,O
male,9243,O
human,9243,O
subjects,9243,O
each,9243,O
received,9243,O
a,9243,O
single,9243,O
50-mg,9243,O
oral,9243,O
dose,9243,O
of,9243,O
[,9243,B-CHEMICAL
(,9243,I-CHEMICAL
14,9243,I-CHEMICAL
),9243,I-CHEMICAL
C,9243,I-CHEMICAL
],9243,I-CHEMICAL
valdecoxib,9243,I-CHEMICAL
.,9243,O
Urine,9244,O
",",9244,O
feces,9244,O
",",9244,O
and,9244,O
blood,9244,O
samples,9244,O
were,9244,O
collected,9244,O
after,9244,O
administration,9244,O
of,9244,O
the,9244,O
radioactive,9244,O
dose,9244,O
.,9244,O
Most,9245,O
of,9245,O
the,9245,O
radioactivity,9245,O
in,9245,O
plasma,9245,O
was,9245,O
associated,9245,O
with,9245,O
valdecoxib,9245,B-CHEMICAL
and,9245,O
the,9245,O
hydroxylated,9245,O
metabolite,9245,O
of,9245,O
valdecoxib,9245,B-CHEMICAL
(,9245,O
M1,9245,O
),9245,O
.,9245,O
The,9246,O
estimated,9246,O
terminal,9246,O
half-life,9246,O
for,9246,O
valdecoxib,9246,B-CHEMICAL
was,9246,O
about,9246,O
7,9246,O
h.,9246,O
About,9246,O
76.1,9246,O
%,9246,O
of,9246,O
the,9246,O
radioactive,9246,O
dose,9246,O
was,9246,O
recovered,9246,O
in,9246,O
urine,9246,O
and,9246,O
18,9246,O
%,9246,O
of,9246,O
the,9246,O
radioactive,9246,O
dose,9246,O
was,9246,O
recovered,9246,O
in,9246,O
feces,9246,O
.,9246,O
Valdecoxib,9247,B-CHEMICAL
was,9247,O
extensively,9247,O
metabolized,9247,O
in,9247,O
human,9247,O
",",9247,O
and,9247,O
nine,9247,O
phase,9247,O
I,9247,O
metabolites,9247,O
were,9247,O
identified,9247,O
.,9247,O
The,9248,O
primary,9248,O
oxidative,9248,O
metabolic,9248,O
pathways,9248,O
of,9248,O
valdecoxib,9248,B-CHEMICAL
involved,9248,O
hydroxylation,9248,O
at,9248,O
either,9248,O
the,9248,O
methyl,9248,B-CHEMICAL
group,9248,O
to,9248,O
form,9248,O
M1,9248,O
or,9248,O
N-hydroxylation,9248,B-CHEMICAL
at,9248,O
the,9248,O
sulfonamide,9248,B-CHEMICAL
moiety,9248,O
to,9248,O
form,9248,O
M2,9248,O
.,9248,O
Further,9249,O
oxidation,9249,O
of,9249,O
M1,9249,O
led,9249,O
to,9249,O
the,9249,O
formation,9249,O
of,9249,O
several,9249,O
other,9249,O
phase,9249,O
I,9249,O
metabolites,9249,O
.,9249,O
Oxidative,9250,O
breakdown,9250,O
of,9250,O
the,9250,O
N-hydroxy,9250,B-CHEMICAL
sulfonamide,9250,I-CHEMICAL
function,9250,O
group,9250,O
in,9250,O
M2,9250,O
led,9250,O
to,9250,O
the,9250,O
formation,9250,O
of,9250,O
corresponding,9250,O
sulfinic,9250,B-CHEMICAL
acid,9250,I-CHEMICAL
and,9250,O
sulfonic,9250,B-CHEMICAL
acid,9250,I-CHEMICAL
metabolites,9250,O
.,9250,O
The,9251,O
O-glucuronide,9251,B-CHEMICAL
conjugate,9251,O
of,9251,O
M1,9251,O
and,9251,O
N-glucuronide,9251,B-CHEMICAL
conjugate,9251,O
of,9251,O
valdecoxib,9251,B-CHEMICAL
were,9251,O
the,9251,O
major,9251,O
urinary,9251,O
metabolites,9251,O
",",9251,O
which,9251,O
accounted,9251,O
for,9251,O
23.3,9251,O
and,9251,O
19.5,9251,O
%,9251,O
of,9251,O
the,9251,O
total,9251,O
administered,9251,O
dose,9251,O
",",9251,O
respectively,9251,O
.,9251,O
The,9252,O
remaining,9252,O
urinary,9252,O
metabolites,9252,O
were,9252,O
glucuronide,9252,O
conjugates,9252,O
of,9252,O
other,9252,O
phase,9252,O
I,9252,O
metabolites,9252,O
.,9252,O
Only,9253,O
3,9253,O
%,9253,O
of,9253,O
the,9253,O
administered,9253,O
dose,9253,O
was,9253,O
recovered,9253,O
in,9253,O
urine,9253,O
as,9253,O
unchanged,9253,O
parent,9253,O
",",9253,O
suggesting,9253,O
that,9253,O
renal,9253,O
clearance,9253,O
is,9253,O
insignificant,9253,O
for,9253,O
valdecoxib,9253,B-CHEMICAL
.,9253,O
Absorption,9254,O
of,9254,O
valdecoxib,9254,B-CHEMICAL
was,9254,O
excellent,9254,O
since,9254,O
the,9254,O
recovery,9254,O
of,9254,O
unchanged,9254,O
valdecoxib,9254,B-CHEMICAL
in,9254,O
feces,9254,O
was,9254,O
<,9254,O
1,9254,O
%,9254,O
of,9254,O
the,9254,O
administered,9254,O
dose,9254,O
.,9254,O
Defective,9255,O
DNA,9255,O
damage,9255,O
response,9255,O
and,9255,O
repair,9255,O
in,9255,O
liver,9255,O
cells,9255,O
expressing,9255,O
hepatitis,9255,B-GENE-Y
B,9255,I-GENE-Y
virus,9255,I-GENE-Y
surface,9255,I-GENE-Y
antigen,9255,I-GENE-Y
.,9255,O
Hepatitis,9256,O
B,9256,O
virus,9256,O
(,9256,O
HBV,9256,O
),9256,O
is,9256,O
implicated,9256,O
in,9256,O
liver,9256,O
cancer,9256,O
.,9256,O
The,9257,O
aim,9257,O
of,9257,O
this,9257,O
study,9257,O
was,9257,O
to,9257,O
find,9257,O
out,9257,O
whether,9257,O
HBV,9257,O
or,9257,O
its,9257,O
components,9257,O
[,9257,O
HBV,9257,B-GENE-Y
surface,9257,I-GENE-Y
antigen,9257,I-GENE-Y
(,9257,O
HBsAg,9257,B-GENE-Y
),9257,O
",",9257,O
HBV,9257,B-GENE-Y
core,9257,I-GENE-Y
protein,9257,I-GENE-Y
(,9257,O
HBc,9257,B-GENE-Y
),9257,O
",",9257,O
and,9257,O
HBV,9257,B-GENE-Y
X,9257,I-GENE-Y
protein,9257,I-GENE-Y
(,9257,O
HBx,9257,B-GENE-Y
),9257,O
],9257,O
could,9257,O
interfere,9257,O
with,9257,O
the,9257,O
host,9257,O
DNA,9257,O
damage,9257,O
response,9257,O
and,9257,O
repair,9257,O
pathway,9257,O
.,9257,O
The,9258,O
full,9258,O
HBV,9258,O
genome,9258,O
or,9258,O
individual,9258,O
HBV,9258,B-GENE-N
open-reading,9258,I-GENE-N
frame,9258,I-GENE-N
(,9258,O
ORF,9258,B-GENE-N
),9258,O
was,9258,O
introduced,9258,O
into,9258,O
HepG2,9258,O
cells,9258,O
to,9258,O
examine,9258,O
the,9258,O
effect,9258,O
on,9258,O
host,9258,O
genomic,9258,O
stability,9258,O
",",9258,O
DNA,9258,O
repair,9258,O
efficacy,9258,O
in,9258,O
response,9258,O
to,9258,O
double-strand,9258,O
DNA,9258,O
damage,9258,O
",",9258,O
and,9258,O
DNA,9258,O
damage-induced,9258,O
cell,9258,O
death,9258,O
.,9258,O
Responses,9259,O
to,9259,O
apoptosis,9259,O
induction,9259,O
in,9259,O
the,9259,O
HBV,9259,B-GENE-N
ORF-transfected,9259,O
HepG2,9259,O
cells,9259,O
were,9259,O
also,9259,O
compared,9259,O
with,9259,O
those,9259,O
in,9259,O
HBV-positive,9259,O
and,9259,O
HBV-negative,9259,O
human,9259,O
hepatocellular,9259,O
carcinoma,9259,O
(,9259,O
HCC,9259,O
),9259,O
cells,9259,O
.,9259,O
In,9260,O
the,9260,O
absence,9260,O
of,9260,O
HBV,9260,O
replication,9260,O
",",9260,O
accumulation,9260,O
of,9260,O
HBsAg,9260,B-GENE-Y
in,9260,O
liver,9260,O
cells,9260,O
without,9260,O
other,9260,O
HBV,9260,O
proteins,9260,O
enhanced,9260,O
DNA,9260,O
repair,9260,O
protein,9260,O
and,9260,O
tumor,9260,O
suppressor,9260,O
promyelocytic,9260,B-GENE-Y
leukemia,9260,I-GENE-Y
(,9260,O
PML,9260,B-GENE-Y
),9260,O
degradation,9260,O
",",9260,O
which,9260,O
resulted,9260,O
in,9260,O
resistance,9260,O
to,9260,O
apoptosis,9260,O
induction,9260,O
and,9260,O
deficient,9260,O
double-strand,9260,O
DNA,9260,O
repair,9260,O
.,9260,O
However,9261,O
",",9261,O
HBsAg-positive,9261,B-GENE-Y
cells,9261,O
exhibited,9261,O
increased,9261,O
cell,9261,O
death,9261,O
with,9261,O
exposure,9261,O
to,9261,O
the,9261,O
poly,9261,B-GENE-N
(,9261,I-GENE-N
ADP-ribose,9261,I-GENE-N
),9261,I-GENE-N
polymerase,9261,I-GENE-N
inhibitor,9261,O
that,9261,O
blocks,9261,O
single-strand,9261,O
DNA,9261,O
repair,9261,O
.,9261,O
These,9262,O
results,9262,O
indicate,9262,O
that,9262,O
suppression,9262,O
of,9262,O
PML,9262,B-GENE-Y
by,9262,O
HBsAg,9262,B-GENE-Y
disrupts,9262,O
cellular,9262,O
mechanisms,9262,O
that,9262,O
respond,9262,O
to,9262,O
double-strand,9262,O
DNA,9262,O
damage,9262,O
for,9262,O
DNA,9262,O
repair,9262,O
or,9262,O
apoptosis,9262,O
induction,9262,O
",",9262,O
which,9262,O
may,9262,O
facilitate,9262,O
hepatocarcinogenesis,9262,O
and,9262,O
open,9262,O
up,9262,O
a,9262,O
synthetic,9262,O
lethality,9262,O
strategy,9262,O
for,9262,O
HBsAg-positive,9262,B-GENE-Y
HCC,9262,O
treatment.-Chung,9262,O
",",9262,O
Y.-L,9262,O
.,9262,O
Defective,9263,O
DNA,9263,O
damage,9263,O
response,9263,O
and,9263,O
repair,9263,O
in,9263,O
liver,9263,O
cells,9263,O
expressing,9263,O
hepatitis,9263,B-GENE-Y
B,9263,I-GENE-Y
virus,9263,I-GENE-Y
surface,9263,I-GENE-Y
antigen,9263,I-GENE-Y
.,9263,O
Effects,9264,O
of,9264,O
labor,9264,O
and,9264,O
delivery,9264,O
on,9264,O
fibrinolysis,9264,O
.,9264,O
Because,9265,O
timing,9265,O
of,9265,O
sampling,9265,O
is,9265,O
crucial,9265,O
in,9265,O
an,9265,O
investigation,9265,O
of,9265,O
the,9265,O
effects,9265,O
of,9265,O
labor,9265,O
and,9265,O
delivery,9265,O
on,9265,O
fibrinolysis,9265,O
we,9265,O
conducted,9265,O
a,9265,O
study,9265,O
of,9265,O
fibrinolytic,9265,O
markers,9265,O
in,9265,O
plasma,9265,O
of,9265,O
10,9265,O
healthy,9265,O
multiparous,9265,O
women,9265,O
in,9265,O
whom,9265,O
labor,9265,O
was,9265,O
induced,9265,O
",",9265,O
which,9265,O
allowed,9265,O
standardization,9265,O
of,9265,O
sampling,9265,O
times,9265,O
in,9265,O
relation,9265,O
to,9265,O
the,9265,O
course,9265,O
of,9265,O
labor,9265,O
and,9265,O
delivery,9265,O
.,9265,O
Blood,9266,O
samples,9266,O
were,9266,O
taken,9266,O
5,9266,O
min,9266,O
before,9266,O
the,9266,O
start,9266,O
of,9266,O
oxytocin,9266,B-GENE-Y
infusion,9266,O
",",9266,O
at,9266,O
full,9266,O
cervical,9266,O
dilatation,9266,O
",",9266,O
and,9266,O
within,9266,O
5,9266,O
min,9266,O
after,9266,O
delivery,9266,O
of,9266,O
the,9266,O
placenta,9266,O
.,9266,O
A,9267,O
sample,9267,O
of,9267,O
mixed,9267,O
free,9267,O
flowing,9267,O
cord,9267,O
blood,9267,O
was,9267,O
obtained,9267,O
after,9267,O
delivery,9267,O
with,9267,O
the,9267,O
placenta,9267,O
in,9267,O
situ,9267,O
.,9267,O
Variables,9268,O
determined,9268,O
were,9268,O
tissue-type,9268,B-GENE-Y
plasminogen-activator,9268,I-GENE-Y
(,9268,O
t-PA,9268,B-GENE-Y
),9268,O
and,9268,O
the,9268,O
plasminogen,9268,B-GENE-Y
activator,9268,I-GENE-Y
inhibitors,9268,I-GENE-Y
type,9268,I-GENE-Y
1,9268,I-GENE-Y
(,9268,O
PAI-1,9268,B-GENE-Y
),9268,O
and,9268,O
type,9268,O
2,9268,O
(,9268,O
PAI-2,9268,B-GENE-Y
),9268,O
.,9268,O
The,9269,O
only,9269,O
significant,9269,O
change,9269,O
between,9269,O
the,9269,O
beginning,9269,O
of,9269,O
the,9269,O
induction,9269,O
of,9269,O
labor,9269,O
and,9269,O
the,9269,O
end,9269,O
of,9269,O
the,9269,O
first,9269,O
stage,9269,O
of,9269,O
labor,9269,O
was,9269,O
a,9269,O
rise,9269,O
in,9269,O
t-PA,9269,B-GENE-Y
antigen,9269,O
(,9269,O
P,9269,O
=,9269,O
0.01,9269,O
),9269,O
.,9269,O
All,9270,O
variables,9270,O
",",9270,O
except,9270,O
PAI-2,9270,B-GENE-Y
antigen,9270,O
",",9270,O
changed,9270,O
significantly,9270,O
after,9270,O
delivery,9270,O
of,9270,O
the,9270,O
placenta,9270,O
:,9270,O
t-PA,9270,B-GENE-Y
antigen,9270,O
and,9270,O
activity,9270,O
showed,9270,O
a,9270,O
rise,9270,O
(,9270,O
P,9270,O
<,9270,O
0.05,9270,O
),9270,O
",",9270,O
accompanied,9270,O
by,9270,O
a,9270,O
fall,9270,O
in,9270,O
PAI-1,9270,B-GENE-Y
antigen,9270,O
and,9270,O
activity,9270,O
(,9270,O
P,9270,O
<,9270,O
0.01,9270,O
),9270,O
.,9270,O
T-PA,9271,B-GENE-Y
activity,9271,O
in,9271,O
cord,9271,O
plasma,9271,O
was,9271,O
higher,9271,O
(,9271,O
P,9271,O
<,9271,O
0.01,9271,O
),9271,O
in,9271,O
comparison,9271,O
with,9271,O
maternal,9271,O
plasma,9271,O
concentrations,9271,O
at,9271,O
the,9271,O
end,9271,O
of,9271,O
the,9271,O
first,9271,O
stage,9271,O
of,9271,O
labor,9271,O
",",9271,O
t-PA,9271,B-GENE-Y
antigen,9271,O
levels,9271,O
were,9271,O
similar,9271,O
",",9271,O
and,9271,O
PAI-1,9271,B-GENE-Y
antigen,9271,O
and,9271,O
activity,9271,O
and,9271,O
PAI-2,9271,B-GENE-Y
antigen,9271,O
were,9271,O
lower,9271,O
in,9271,O
cord,9271,O
plasma,9271,O
(,9271,O
P,9271,O
<,9271,O
0.001,9271,O
),9271,O
.,9271,O
Our,9272,O
study,9272,O
shows,9272,O
that,9272,O
activation,9272,O
of,9272,O
the,9272,O
maternal,9272,O
fibrinolytic,9272,O
system,9272,O
can,9272,O
already,9272,O
be,9272,O
detected,9272,O
during,9272,O
labor,9272,O
",",9272,O
with,9272,O
a,9272,O
marked,9272,O
further,9272,O
increase,9272,O
in,9272,O
fibrinolytic,9272,O
potential,9272,O
after,9272,O
placental,9272,O
separation,9272,O
.,9272,O
Toxicity,9273,O
and,9273,O
toxicokinetics,9273,O
of,9273,O
binary,9273,O
combinations,9273,O
of,9273,O
petroleum,9273,B-CHEMICAL
hydrocarbon,9273,I-CHEMICAL
distillates,9273,O
with,9273,O
the,9273,O
earthworm,9273,O
Eisenia,9273,O
andrei,9273,O
.,9273,O
Petroleum,9274,B-CHEMICAL
hydrocarbons,9274,I-CHEMICAL
(,9274,O
PHCs,9274,B-CHEMICAL
),9274,O
act,9274,O
via,9274,O
narcosis,9274,O
and,9274,O
are,9274,O
expected,9274,O
to,9274,O
have,9274,O
additive,9274,O
toxicity,9274,O
.,9274,O
However,9275,O
",",9275,O
previous,9275,O
work,9275,O
has,9275,O
demonstrated,9275,O
less-than-additive,9275,O
toxicity,9275,O
with,9275,O
PHC,9275,B-CHEMICAL
distillates,9275,O
and,9275,O
earthworms,9275,O
.,9275,O
A,9276,O
study,9276,O
was,9276,O
initiated,9276,O
to,9276,O
investigate,9276,O
this,9276,O
through,9276,O
toxicity,9276,O
and,9276,O
toxicokinetic,9276,O
studies,9276,O
with,9276,O
the,9276,O
earthworm,9276,O
Eisenia,9276,O
andrei,9276,O
.,9276,O
Three,9277,O
petroleum,9277,O
distillate,9277,O
fractions,9277,O
",",9277,O
F2,9277,O
(,9277,O
>,9277,O
C10-C16,9277,B-CHEMICAL
),9277,O
",",9277,O
F3a,9277,O
(,9277,O
>,9277,O
C16-C23,9277,B-CHEMICAL
),9277,O
",",9277,O
and,9277,O
F3b,9277,O
(,9277,O
>,9277,O
C23-C34,9277,B-CHEMICAL
),9277,O
",",9277,O
were,9277,O
used,9277,O
in,9277,O
two,9277,O
binary,9277,O
combinations,9277,O
",",9277,O
F2F3a,9277,O
and,9277,O
F3aF3b,9277,O
.,9277,O
In,9278,O
the,9278,O
toxicity,9278,O
study,9278,O
",",9278,O
clean,9278,O
soil,9278,O
was,9278,O
spiked,9278,O
with,9278,O
equitoxic,9278,O
combinations,9278,O
of,9278,O
the,9278,O
two,9278,O
distillates,9278,O
ranging,9278,O
from,9278,O
0.5,9278,O
to,9278,O
2.5,9278,O
toxic,9278,O
units,9278,O
.,9278,O
In,9279,O
the,9279,O
toxicokinetic,9279,O
study,9279,O
",",9279,O
a,9279,O
binary,9279,O
combination,9279,O
consisting,9279,O
of,9279,O
one,9279,O
concentration,9279,O
of,9279,O
each,9279,O
distillate,9279,O
was,9279,O
used,9279,O
.,9279,O
On,9280,O
a,9280,O
soil,9280,O
concentration,9280,O
basis,9280,O
",",9280,O
the,9280,O
toxicity,9280,O
of,9280,O
the,9280,O
binary,9280,O
combinations,9280,O
of,9280,O
distillates,9280,O
was,9280,O
less,9280,O
than,9280,O
additive,9280,O
.,9280,O
Accumulation,9281,O
of,9281,O
the,9281,O
individual,9281,O
distillates,9281,O
",",9281,O
however,9281,O
",",9281,O
was,9281,O
generally,9281,O
reduced,9281,O
when,9281,O
a,9281,O
second,9281,O
distillate,9281,O
was,9281,O
present,9281,O
",",9281,O
resulting,9281,O
in,9281,O
lower,9281,O
body,9281,O
burden,9281,O
.,9281,O
This,9282,O
is,9282,O
thought,9282,O
to,9282,O
be,9282,O
due,9282,O
to,9282,O
the,9282,O
presence,9282,O
of,9282,O
a,9282,O
nonaqueous-phase,9282,O
liquid,9282,O
at,9282,O
the,9282,O
soil,9282,O
concentrations,9282,O
used,9282,O
.,9282,O
On,9283,O
a,9283,O
tissue,9283,O
concentration,9283,O
basis,9283,O
",",9283,O
toxicity,9283,O
was,9283,O
closer,9283,O
to,9283,O
additive,9283,O
.,9283,O
The,9284,O
results,9284,O
demonstrate,9284,O
that,9284,O
tissue,9284,O
concentrations,9284,O
are,9284,O
the,9284,O
preferred,9284,O
metric,9284,O
for,9284,O
toxicity,9284,O
for,9284,O
earthworms,9284,O
.,9284,O
They,9285,O
also,9285,O
demonstrate,9285,O
that,9285,O
the,9285,O
Canada-wide,9285,O
soil,9285,O
standards,9285,O
based,9285,O
on,9285,O
individual,9285,O
distillates,9285,O
are,9285,O
likely,9285,O
protective,9285,O
.,9285,O
Environ,9286,O
.,9286,O
Toxicol,9287,O
.,9287,O
Chem,9288,O
.,9288,O
2013,9289,O
;,9289,O
32:1016-1026,9289,O
.,9289,O
©,9290,O
2013,9290,O
SETAC,9290,O
.,9290,O
Pharmacogenetics,9291,O
of,9291,O
Allopurinol-Making,9291,B-CHEMICAL
an,9291,O
Old,9291,O
Drug,9291,O
Safer,9291,O
.,9291,O
Allopurinol,9292,B-CHEMICAL
is,9292,O
a,9292,O
drug,9292,O
that,9292,O
has,9292,O
been,9292,O
used,9292,O
for,9292,O
decades,9292,O
to,9292,O
lower,9292,O
serum,9292,O
urate,9292,O
levels,9292,O
in,9292,O
patients,9292,O
with,9292,O
gout,9292,O
or,9292,O
chronic,9292,O
renal,9292,O
failure,9292,O
and,9292,O
in,9292,O
cancer,9292,O
patients,9292,O
undergoing,9292,O
chemotherapy,9292,O
at,9292,O
risk,9292,O
of,9292,O
tumor,9292,O
lysis,9292,O
syndrome,9292,O
.,9292,O
Patients,9293,O
may,9293,O
develop,9293,O
cutaneous,9293,O
hypersensitivity,9293,O
reactions,9293,O
",",9293,O
ranging,9293,O
from,9293,O
mild,9293,O
rashes,9293,O
to,9293,O
potentially,9293,O
fatal,9293,O
severe,9293,O
cutaneous,9293,O
adverse,9293,O
reactions,9293,O
(,9293,O
SCARs,9293,O
),9293,O
namely,9293,O
drug,9293,O
hypersensitivity,9293,O
syndrome,9293,O
",",9293,O
Stevens-Johnson,9293,O
syndrome,9293,O
(,9293,O
SJS,9293,O
),9293,O
",",9293,O
and,9293,O
toxic,9293,O
epidermal,9293,O
necrolysis,9293,O
(,9293,O
TEN,9293,O
),9293,O
.,9293,O
Recent,9294,O
studies,9294,O
have,9294,O
demonstrated,9294,O
the,9294,O
association,9294,O
between,9294,O
human,9294,B-GENE-Y
leukocyte,9294,I-GENE-Y
antigen,9294,I-GENE-Y
(,9294,I-GENE-Y
HLA,9294,I-GENE-Y
),9294,I-GENE-Y
B,9294,I-GENE-Y
*,9294,O
58:01,9294,O
allele,9294,O
and,9294,O
allopurinol-induced,9294,B-CHEMICAL
SCARs,9294,O
",",9294,O
which,9294,O
might,9294,O
explain,9294,O
ethnic,9294,O
differences,9294,O
in,9294,O
their,9294,O
incidences,9294,O
.,9294,O
Genotyping,9295,O
is,9295,O
now,9295,O
required,9295,O
before,9295,O
starting,9295,O
abacavir,9295,B-CHEMICAL
and,9295,O
carbamazepine,9295,B-CHEMICAL
so,9295,O
as,9295,O
to,9295,O
identify,9295,O
individuals,9295,O
susceptible,9295,O
to,9295,O
SJS,9295,O
.,9295,O
However,9296,O
",",9296,O
no,9296,O
genetic,9296,O
screening,9296,O
is,9296,O
advocated,9296,O
before,9296,O
commencement,9296,O
of,9296,O
allopurinol,9296,B-CHEMICAL
.,9296,O
The,9297,O
lack,9297,O
of,9297,O
availability,9297,O
of,9297,O
a,9297,O
rapid,9297,O
and,9297,O
inexpensive,9297,O
screening,9297,O
test,9297,O
for,9297,O
the,9297,O
HLA-B,9297,B-GENE-Y
*,9297,O
58:01,9297,O
allele,9297,O
is,9297,O
one,9297,O
of,9297,O
the,9297,O
obstacles,9297,O
to,9297,O
such,9297,O
screening,9297,O
.,9297,O
Development,9298,O
of,9298,O
a,9298,O
test,9298,O
that,9298,O
is,9298,O
quick,9298,O
",",9298,O
accurate,9298,O
",",9298,O
and,9298,O
cost-effective,9298,O
is,9298,O
warranted,9298,O
.,9298,O
Silibinin,9299,B-CHEMICAL
triggers,9299,O
apoptosis,9299,O
and,9299,O
cell-cycle,9299,O
arrest,9299,O
of,9299,O
SGC7901,9299,O
cells,9299,O
.,9299,O
Silibinin,9300,B-CHEMICAL
",",9300,O
a,9300,O
flavonoid,9300,B-CHEMICAL
compound,9300,O
",",9300,O
has,9300,O
shown,9300,O
to,9300,O
be,9300,O
of,9300,O
chemopreventive,9300,O
potential,9300,O
against,9300,O
many,9300,O
cancers,9300,O
.,9300,O
However,9301,O
",",9301,O
its,9301,O
efficacy,9301,O
against,9301,O
gastric,9301,O
cancer,9301,O
has,9301,O
not,9301,O
been,9301,O
well,9301,O
elucidated,9301,O
.,9301,O
Here,9302,O
",",9302,O
we,9302,O
assessed,9302,O
the,9302,O
activity,9302,O
of,9302,O
Silibinin,9302,B-CHEMICAL
on,9302,O
apoptosis,9302,O
and,9302,O
cell-cycle,9302,O
arrest,9302,O
in,9302,O
human,9302,O
gastric,9302,O
cells,9302,O
culture,9302,O
system,9302,O
using,9302,O
SGC-7901,9302,O
as,9302,O
the,9302,O
model,9302,O
.,9302,O
Silibinin,9303,B-CHEMICAL
treatment,9303,O
could,9303,O
inhibit,9303,O
the,9303,O
cell,9303,O
growth,9303,O
and,9303,O
cause,9303,O
a,9303,O
prominent,9303,O
G2,9303,O
phase,9303,O
arrest,9303,O
and,9303,O
apoptosis,9303,O
in,9303,O
dose-,9303,O
and,9303,O
time-dependent,9303,O
manner,9303,O
.,9303,O
In,9304,O
mechanistic,9304,O
studies,9304,O
",",9304,O
Silibinin,9304,B-CHEMICAL
decreased,9304,O
the,9304,O
protein,9304,O
level,9304,O
of,9304,O
p34cdc2,9304,B-GENE-Y
",",9304,O
which,9304,O
might,9304,O
be,9304,O
the,9304,O
possible,9304,O
molecular,9304,O
mechanism,9304,O
of,9304,O
Silibinin,9304,B-CHEMICAL
efficacy,9304,O
on,9304,O
the,9304,O
growth,9304,O
inhibition,9304,O
in,9304,O
SGC-7901,9304,O
cells,9304,O
.,9304,O
In,9305,O
addition,9305,O
",",9305,O
Silibinin,9305,B-CHEMICAL
caused,9305,O
an,9305,O
increase,9305,O
in,9305,O
p53,9305,B-GENE-Y
and,9305,O
p21,9305,B-GENE-Y
protein,9305,O
level,9305,O
as,9305,O
well,9305,O
as,9305,O
mRNA,9305,O
levels,9305,O
.,9305,O
Interestingly,9306,O
",",9306,O
Silibinin-induced,9306,B-CHEMICAL
apoptosis,9306,O
in,9306,O
SGC-7901,9306,O
cells,9306,O
was,9306,O
independent,9306,O
of,9306,O
caspases,9306,O
activation,9306,O
.,9306,O
These,9307,O
results,9307,O
indicated,9307,O
that,9307,O
Silibinin,9307,B-CHEMICAL
is,9307,O
a,9307,O
cell-cycle,9307,O
regulator,9307,O
and,9307,O
apoptosis,9307,O
inducer,9307,O
in,9307,O
human,9307,O
gastric,9307,O
carcinoma,9307,O
SGC-7901,9307,O
cells,9307,O
and,9307,O
might,9307,O
be,9307,O
used,9307,O
as,9307,O
a,9307,O
candidate,9307,O
chemopreventive,9307,O
agent,9307,O
for,9307,O
gastric,9307,O
carcinoma,9307,O
prevention,9307,O
and,9307,O
intervention,9307,O
.,9307,O
Copyright,9308,O
©,9308,O
2012,9308,O
John,9308,O
Wiley,9308,O
&,9308,O
Sons,9308,O
",",9308,O
Ltd,9308,O
.,9308,O
Influence,9309,O
of,9309,O
developmental,9309,O
lead,9309,O
exposure,9309,O
on,9309,O
expression,9309,O
of,9309,O
DNA,9309,B-GENE-N
methyltransferases,9309,I-GENE-N
and,9309,O
methyl,9309,B-GENE-N
cytosine-binding,9309,I-GENE-N
proteins,9309,I-GENE-N
in,9309,O
hippocampus,9309,O
.,9309,O
Developmental,9310,O
exposure,9310,O
to,9310,O
lead,9310,O
(,9310,O
Pb,9310,B-CHEMICAL
),9310,O
has,9310,O
adverse,9310,O
effects,9310,O
on,9310,O
cognitive,9310,O
functioning,9310,O
and,9310,O
behavior,9310,O
that,9310,O
can,9310,O
persist,9310,O
into,9310,O
adulthood,9310,O
.,9310,O
Exposures,9311,O
that,9311,O
occur,9311,O
during,9311,O
fetal,9311,O
or,9311,O
early,9311,O
life,9311,O
periods,9311,O
may,9311,O
produce,9311,O
changes,9311,O
in,9311,O
brain,9311,O
related,9311,O
to,9311,O
physiological,9311,O
re-programming,9311,O
from,9311,O
an,9311,O
epigenetic,9311,O
influence,9311,O
such,9311,O
as,9311,O
altered,9311,O
DNA,9311,O
methylation,9311,O
status,9311,O
.,9311,O
Since,9312,O
DNA,9312,O
methylation,9312,O
is,9312,O
regulated,9312,O
by,9312,O
DNA,9312,B-GENE-N
methyltransferases,9312,I-GENE-N
and,9312,O
methyl,9312,B-GENE-N
cytosine-binding,9312,I-GENE-N
proteins,9312,I-GENE-N
",",9312,O
this,9312,O
study,9312,O
assessed,9312,O
the,9312,O
extent,9312,O
to,9312,O
which,9312,O
developmental,9312,O
Pb,9312,B-CHEMICAL
exposure,9312,O
might,9312,O
affect,9312,O
expression,9312,O
of,9312,O
these,9312,O
proteins,9312,O
in,9312,O
the,9312,O
hippocampus,9312,O
.,9312,O
Long,9313,O
Evans,9313,O
dams,9313,O
were,9313,O
fed,9313,O
chow,9313,O
with,9313,O
or,9313,O
without,9313,O
added,9313,O
Pb,9313,B-CHEMICAL
acetate,9313,I-CHEMICAL
(,9313,O
0,9313,O
",",9313,O
150,9313,O
",",9313,O
375,9313,O
",",9313,O
750,9313,O
ppm,9313,O
),9313,O
prior,9313,O
to,9313,O
breeding,9313,O
and,9313,O
remained,9313,O
on,9313,O
the,9313,O
same,9313,O
diet,9313,O
through,9313,O
weaning,9313,O
(,9313,O
perinatal,9313,O
exposure,9313,O
group,9313,O
),9313,O
.,9313,O
Other,9314,O
animals,9314,O
were,9314,O
exposed,9314,O
to,9314,O
the,9314,O
same,9314,O
doses,9314,O
of,9314,O
Pb,9314,B-CHEMICAL
but,9314,O
exposure,9314,O
started,9314,O
on,9314,O
postnatal,9314,O
day,9314,O
1,9314,O
and,9314,O
continued,9314,O
through,9314,O
weaning,9314,O
(,9314,O
early,9314,O
postnatal,9314,O
exposure,9314,O
group,9314,O
),9314,O
.,9314,O
All,9315,O
animals,9315,O
were,9315,O
euthanized,9315,O
on,9315,O
day,9315,O
55,9315,O
and,9315,O
hippocampi,9315,O
were,9315,O
removed,9315,O
.,9315,O
Western,9316,O
blot,9316,O
analyses,9316,O
showed,9316,O
significant,9316,O
effects,9316,O
of,9316,O
Pb,9316,B-CHEMICAL
exposure,9316,O
on,9316,O
DNMT1,9316,B-GENE-Y
",",9316,O
DNMT3a,9316,B-GENE-Y
",",9316,O
and,9316,O
MeCP2,9316,B-GENE-Y
expression,9316,O
",",9316,O
with,9316,O
effects,9316,O
often,9316,O
seen,9316,O
at,9316,O
the,9316,O
lowest,9316,O
level,9316,O
of,9316,O
exposure,9316,O
and,9316,O
modified,9316,O
by,9316,O
sex,9316,O
and,9316,O
developmental,9316,O
window,9316,O
of,9316,O
Pb,9316,B-CHEMICAL
exposure,9316,O
.,9316,O
These,9317,O
data,9317,O
suggest,9317,O
potential,9317,O
epigenetic,9317,O
effects,9317,O
of,9317,O
developmental,9317,O
Pb,9317,B-CHEMICAL
exposure,9317,O
on,9317,O
DNA,9317,O
methylation,9317,O
mediated,9317,O
at,9317,O
least,9317,O
in,9317,O
part,9317,O
through,9317,O
dysregulation,9317,O
of,9317,O
methyltransferases,9317,B-GENE-N
.,9317,O
Synergy,9318,O
between,9318,O
pairs,9318,O
of,9318,O
competitive,9318,O
antagonists,9318,O
at,9318,O
adult,9318,O
human,9318,B-GENE-N
muscle,9318,I-GENE-N
acetylcholine,9318,I-GENE-N
receptors,9318,I-GENE-N
.,9318,O
BACKGROUND,9319,O
:,9319,O
Synergistic,9319,O
neuromuscular,9319,O
blocking,9319,O
effects,9319,O
have,9319,O
been,9319,O
observed,9319,O
clinically,9319,O
with,9319,O
certain,9319,O
pairs,9319,O
of,9319,O
nicotinic,9319,B-GENE-N
acetylcholine,9319,I-GENE-N
receptor,9319,I-GENE-N
(,9319,O
nAChR,9319,B-GENE-N
),9319,O
competitive,9319,O
antagonists,9319,O
.,9319,O
The,9320,O
mechanism,9320,O
for,9320,O
synergy,9320,O
has,9320,O
not,9320,O
been,9320,O
elucidated,9320,O
.,9320,O
We,9321,O
tested,9321,O
the,9321,O
hypothesis,9321,O
that,9321,O
synergy,9321,O
arises,9321,O
from,9321,O
a,9321,O
differential,9321,O
selectivity,9321,O
of,9321,O
antagonists,9321,O
for,9321,O
the,9321,O
two,9321,O
ligand,9321,O
binding,9321,O
sites,9321,O
on,9321,O
adult,9321,O
human,9321,B-GENE-N
nAChR,9321,I-GENE-N
.,9321,O
METHODS,9322,O
:,9322,O
We,9322,O
expressed,9322,O
nAChR,9322,B-GENE-N
in,9322,O
BOSC23,9322,O
cells,9322,O
.,9322,O
We,9323,O
applied,9323,O
ACh,9323,O
with,9323,O
or,9323,O
without,9323,O
antagonists,9323,O
to,9323,O
outside-out,9323,O
patches,9323,O
and,9323,O
measured,9323,O
macroscopic,9323,O
currents,9323,O
at,9323,O
room,9323,O
temperature,9323,O
.,9323,O
We,9324,O
determined,9324,O
the,9324,O
IC,9324,O
(,9324,O
90,9324,O
),9324,O
for,9324,O
(,9324,B-CHEMICAL
+,9324,I-CHEMICAL
),9324,I-CHEMICAL
-tubocurarine,9324,I-CHEMICAL
",",9324,O
metocurine,9324,B-CHEMICAL
",",9324,O
pancuronium,9324,B-CHEMICAL
",",9324,O
vecuronium,9324,B-CHEMICAL
",",9324,O
cisatracurium,9324,B-CHEMICAL
",",9324,O
rocuronium,9324,B-CHEMICAL
",",9324,O
and,9324,O
atracurium,9324,B-CHEMICAL
.,9324,O
For,9325,O
15,9325,O
combinations,9325,O
of,9325,O
two,9325,O
antagonists,9325,O
",",9325,O
we,9325,O
determined,9325,O
the,9325,O
IC,9325,O
(,9325,O
90,9325,O
),9325,O
for,9325,O
one,9325,O
antagonist,9325,O
in,9325,O
the,9325,O
presence,9325,O
of,9325,O
the,9325,O
IC,9325,O
(,9325,O
70,9325,O
),9325,O
of,9325,O
a,9325,O
second,9325,O
antagonist,9325,O
.,9325,O
We,9326,O
constructed,9326,O
isobolograms,9326,O
for,9326,O
90,9326,O
%,9326,O
inhibition,9326,O
.,9326,O
For,9327,O
single,9327,O
antagonists,9327,O
",",9327,O
we,9327,O
measured,9327,O
inhibition,9327,O
of,9327,O
receptors,9327,O
containing,9327,O
mutations,9327,O
in,9327,O
the,9327,O
epsilon-,9327,O
and,9327,O
delta-subunits,9327,O
to,9327,O
determine,9327,O
site,9327,O
selectivity,9327,O
.,9327,O
RESULTS,9328,O
:,9328,O
Two,9328,O
pairs,9328,O
of,9328,O
antagonists,9328,O
",",9328,O
metocurine+cisatracurium,9328,B-CHEMICAL
and,9328,O
cisatracurium+,9328,B-CHEMICAL
atracurium,9328,B-CHEMICAL
exhibited,9328,O
additive,9328,O
inhibition,9328,O
.,9328,O
Ten,9329,O
combinations,9329,O
",",9329,O
including,9329,O
(,9329,B-CHEMICAL
+,9329,I-CHEMICAL
),9329,I-CHEMICAL
-tubocurarine+,9329,O
pancuronium,9329,B-CHEMICAL
and,9329,O
pancuronium+vecuronium,9329,B-CHEMICAL
",",9329,O
were,9329,O
highly,9329,O
synergistic,9329,O
such,9329,O
that,9329,O
the,9329,O
combination,9329,O
was,9329,O
two,9329,O
to,9329,O
three,9329,O
times,9329,O
more,9329,O
effective,9329,O
than,9329,O
expected,9329,O
for,9329,O
additivity,9329,O
.,9329,O
Three,9330,O
combinations,9330,O
were,9330,O
1.5-1.6,9330,O
times,9330,O
more,9330,O
effective,9330,O
than,9330,O
expected,9330,O
for,9330,O
additivity,9330,O
.,9330,O
Inhibition,9331,O
by,9331,O
(,9331,B-CHEMICAL
+,9331,I-CHEMICAL
),9331,I-CHEMICAL
-tubocurarine,9331,I-CHEMICAL
and,9331,O
metocurine,9331,B-CHEMICAL
was,9331,O
sensitive,9331,O
to,9331,O
mutations,9331,O
in,9331,O
the,9331,O
epsilon-subunit,9331,O
only,9331,O
.,9331,O
Vecuronium,9332,B-CHEMICAL
was,9332,O
affected,9332,O
by,9332,O
the,9332,O
delta-subunit,9332,O
mutation,9332,O
only,9332,O
.,9332,O
Inhibition,9333,O
by,9333,O
other,9333,O
antagonists,9333,O
was,9333,O
decreased,9333,O
by,9333,O
mutations,9333,O
in,9333,O
either,9333,O
subunit,9333,O
.,9333,O
CONCLUSIONS,9334,O
:,9334,O
Many,9334,O
combinations,9334,O
of,9334,O
antagonists,9334,O
exhibited,9334,O
synergistic,9334,O
effects,9334,O
on,9334,O
adult,9334,O
human,9334,B-GENE-N
nAChR,9334,I-GENE-N
.,9334,O
Synergy,9335,O
was,9335,O
observed,9335,O
with,9335,O
structurally,9335,O
similar,9335,O
and,9335,O
dissimilar,9335,O
antagonists,9335,O
.,9335,O
The,9336,O
degree,9336,O
of,9336,O
synergy,9336,O
did,9336,O
not,9336,O
always,9336,O
correlate,9336,O
well,9336,O
with,9336,O
site,9336,O
specificity,9336,O
assayed,9336,O
with,9336,O
mutants,9336,O
.,9336,O
In,9337,O
some,9337,O
",",9337,O
but,9337,O
not,9337,O
all,9337,O
cases,9337,O
",",9337,O
the,9337,O
synergy,9337,O
at,9337,O
the,9337,O
receptor,9337,O
level,9337,O
correlated,9337,O
with,9337,O
clinical,9337,O
determinations,9337,O
of,9337,O
synergy,9337,O
.,9337,O
We,9338,O
conclude,9338,O
that,9338,O
the,9338,O
synergistic,9338,O
actions,9338,O
of,9338,O
muscle,9338,O
relaxants,9338,O
can,9338,O
be,9338,O
partially,9338,O
explained,9338,O
by,9338,O
direct,9338,O
interactions,9338,O
with,9338,O
adult,9338,O
human,9338,B-GENE-N
nAChR,9338,I-GENE-N
.,9338,O
The,9339,O
interaction,9339,O
between,9339,O
mGluR1,9339,B-GENE-Y
and,9339,O
the,9339,O
calcium,9339,B-GENE-N
channel,9339,I-GENE-N
Cav₂.₁,9339,B-GENE-Y
preserves,9339,O
coupling,9339,O
in,9339,O
the,9339,O
presence,9339,O
of,9339,O
long,9339,B-GENE-N
Homer,9339,I-GENE-N
proteins,9339,I-GENE-N
.,9339,O
Group,9340,B-GENE-N
I,9340,I-GENE-N
metabotropic,9340,I-GENE-N
glutamate,9340,I-GENE-N
receptors,9340,I-GENE-N
(,9340,O
mGluR1,9340,B-GENE-N
and,9340,I-GENE-N
5,9340,I-GENE-N
),9340,O
are,9340,O
G,9340,B-GENE-N
protein,9340,I-GENE-N
coupled,9340,I-GENE-N
receptors,9340,I-GENE-N
that,9340,O
regulate,9340,O
neuronal,9340,O
activity,9340,O
in,9340,O
a,9340,O
number,9340,O
of,9340,O
ways,9340,O
.,9340,O
Some,9341,O
of,9341,O
the,9341,O
most,9341,O
well,9341,O
studied,9341,O
functions,9341,O
of,9341,O
group,9341,B-GENE-N
I,9341,I-GENE-N
mGluRs,9341,I-GENE-N
",",9341,O
such,9341,O
as,9341,O
initiation,9341,O
of,9341,O
multiple,9341,O
forms,9341,O
of,9341,O
mGluR-dependent,9341,B-GENE-N
long-term,9341,O
depression,9341,O
",",9341,O
require,9341,O
receptor,9341,O
localization,9341,O
near,9341,O
the,9341,O
post-synaptic,9341,O
density,9341,O
(,9341,O
PSD,9341,O
),9341,O
.,9341,O
This,9342,O
localization,9342,O
is,9342,O
in,9342,O
turn,9342,O
dependent,9342,O
on,9342,O
the,9342,O
Homer,9342,B-GENE-N
family,9342,O
of,9342,O
scaffolding,9342,O
proteins,9342,O
which,9342,O
bind,9342,O
to,9342,O
a,9342,O
small,9342,O
motif,9342,O
on,9342,O
the,9342,O
distal,9342,O
C-termini,9342,B-CHEMICAL
of,9342,O
mGluR1,9342,B-GENE-N
and,9342,I-GENE-N
5,9342,I-GENE-N
",",9342,O
localize,9342,O
the,9342,O
receptors,9342,O
near,9342,O
the,9342,O
PSD,9342,O
",",9342,O
strengthen,9342,O
coupling,9342,O
to,9342,O
post-synaptic,9342,O
effectors,9342,O
and,9342,O
simultaneously,9342,O
uncouple,9342,O
the,9342,O
mGluRs,9342,B-GENE-N
from,9342,O
extra-synaptic,9342,O
effectors,9342,O
such,9342,O
as,9342,O
voltage,9342,B-GENE-N
dependent,9342,I-GENE-N
ion,9342,I-GENE-N
channels,9342,I-GENE-N
.,9342,O
Here,9343,O
the,9343,O
selectivity,9343,O
of,9343,O
this,9343,O
uncoupling,9343,O
process,9343,O
was,9343,O
examined,9343,O
by,9343,O
testing,9343,O
the,9343,O
ability,9343,O
of,9343,O
Homer-2b,9343,B-GENE-Y
to,9343,O
uncouple,9343,O
mGluR1,9343,B-GENE-Y
from,9343,O
multiple,9343,O
voltage,9343,B-GENE-N
dependent,9343,I-GENE-N
calcium,9343,I-GENE-N
channels,9343,I-GENE-N
including,9343,O
Ca,9343,B-GENE-Y
(,9343,I-GENE-Y
V2.2,9343,I-GENE-Y
),9343,I-GENE-Y
(,9343,O
N-type,9343,B-GENE-N
),9343,O
",",9343,O
Ca,9343,B-GENE-Y
(,9343,I-GENE-Y
V3.2,9343,I-GENE-Y
),9343,I-GENE-Y
(,9343,O
T-type,9343,B-GENE-N
),9343,I-GENE-N
",",9343,O
and,9343,O
Ca,9343,B-GENE-Y
(,9343,I-GENE-Y
V2.1,9343,I-GENE-Y
),9343,I-GENE-Y
(,9343,O
P/Q-type,9343,B-GENE-N
),9343,O
expressed,9343,O
in,9343,O
rat,9343,O
sympathetic,9343,O
neurons,9343,O
from,9343,O
the,9343,O
superior,9343,O
cervical,9343,O
ganglion,9343,O
(,9343,O
SCG,9343,O
),9343,O
.,9343,O
Of,9344,O
these,9344,O
",",9344,O
only,9344,O
the,9344,O
mGluR1-Ca,9344,B-GENE-Y
(,9344,I-GENE-Y
V2.1,9344,I-GENE-Y
),9344,I-GENE-Y
modulatory,9344,O
pathway,9344,O
was,9344,O
insensitive,9344,O
to,9344,O
Homer-2b,9344,B-GENE-Y
expression,9344,O
.,9344,O
Uncoupling,9345,O
from,9345,O
this,9345,O
channel,9345,O
was,9345,O
achieved,9345,O
by,9345,O
co-expression,9345,O
of,9345,O
an,9345,O
mGluR1,9345,B-GENE-Y
C-terminal,9345,B-CHEMICAL
protein,9345,O
designed,9345,O
to,9345,O
disrupt,9345,O
a,9345,O
previously,9345,O
described,9345,O
direct,9345,O
interaction,9345,O
between,9345,O
these,9345,O
two,9345,O
proteins,9345,O
",",9345,O
suggesting,9345,O
that,9345,O
this,9345,O
interaction,9345,O
allows,9345,O
incorporation,9345,O
of,9345,O
Ca,9345,B-GENE-Y
(,9345,I-GENE-Y
V2.1,9345,I-GENE-Y
),9345,I-GENE-Y
into,9345,O
the,9345,O
mGluR1/Homer,9345,B-GENE-Y
signaling,9345,O
complex,9345,O
",",9345,O
thereby,9345,O
preserving,9345,O
modulation,9345,O
in,9345,O
the,9345,O
presence,9345,O
of,9345,O
scaffolding,9345,O
Homer,9345,B-GENE-N
proteins,9345,I-GENE-N
.,9345,O
This,9346,O
article,9346,O
is,9346,O
part,9346,O
of,9346,O
a,9346,O
Special,9346,O
Issue,9346,O
entitled,9346,O
'Metabotropic,9346,O
Glutamate,9346,I-GENE-N
Receptors,9346,I-GENE-N
',9346,O
.,9346,O
Transfection,9347,O
of,9347,O
HepG2,9347,O
cells,9347,O
with,9347,O
hGSTA4,9347,B-GENE-Y
provides,9347,O
protection,9347,O
against,9347,O
4-hydroxynonenal-mediated,9347,B-CHEMICAL
oxidative,9347,O
injury,9347,O
.,9347,O
4-Hydroxynonenal,9348,B-CHEMICAL
(,9348,O
4-HNE,9348,B-CHEMICAL
),9348,O
is,9348,O
a,9348,O
mutagenic,9348,O
alpha,9348,B-CHEMICAL
",",9348,I-CHEMICAL
beta-unsaturated,9348,I-CHEMICAL
aldehyde,9348,I-CHEMICAL
produced,9348,O
during,9348,O
oxidative,9348,O
injury,9348,O
that,9348,O
is,9348,O
conjugated,9348,O
by,9348,O
several,9348,O
glutathione,9348,B-GENE-N
S-transferase,9348,I-GENE-N
(,9348,O
GST,9348,B-GENE-N
),9348,O
isoforms,9348,O
.,9348,O
The,9349,O
alpha,9349,O
class,9349,O
human,9349,B-GENE-Y
GSTA4-4,9349,I-GENE-Y
enzyme,9349,O
(,9349,O
hGSTA4-4,9349,B-GENE-Y
),9349,O
has,9349,O
a,9349,O
particularly,9349,O
high,9349,O
catalytic,9349,O
efficiency,9349,O
toward,9349,O
4-HNE,9349,B-CHEMICAL
conjugation,9349,O
.,9349,O
However,9350,O
",",9350,O
hGST4-4,9350,B-GENE-Y
expression,9350,O
is,9350,O
low,9350,O
in,9350,O
most,9350,O
human,9350,O
cells,9350,O
and,9350,O
there,9350,O
are,9350,O
other,9350,O
aldehyde,9350,B-CHEMICAL
metabolizing,9350,O
enzymes,9350,O
that,9350,O
detoxify,9350,O
4-HNE,9350,B-CHEMICAL
.,9350,O
In,9351,O
the,9351,O
current,9351,O
study,9351,O
",",9351,O
we,9351,O
determined,9351,O
the,9351,O
effect,9351,O
of,9351,O
over-expression,9351,O
of,9351,O
hGSTA4,9351,B-GENE-Y
mRNA,9351,O
on,9351,O
the,9351,O
sensitivity,9351,O
of,9351,O
HepG2,9351,O
cells,9351,O
to,9351,O
4-HNE,9351,B-CHEMICAL
injury,9351,O
.,9351,O
HepG2,9352,O
cells,9352,O
transfected,9352,O
with,9352,O
an,9352,O
hGSTA4,9352,B-GENE-Y
vector,9352,O
construct,9352,O
exhibited,9352,O
high,9352,O
steady-state,9352,O
hGSTA4,9352,B-GENE-Y
mRNA,9352,O
",",9352,O
high,9352,O
GST-4-HNE,9352,B-GENE-Y
catalytic,9352,O
activities,9352,O
",",9352,O
but,9352,O
lower,9352,O
basal,9352,O
glutathione,9352,B-CHEMICAL
(,9352,O
GSH,9352,B-CHEMICAL
),9352,O
concentrations,9352,O
relative,9352,O
to,9352,O
insert-free,9352,O
vector,9352,O
(,9352,O
control,9352,O
),9352,O
cells,9352,O
.,9352,O
Exposure,9353,O
to,9353,O
4-HNE,9353,B-CHEMICAL
elicited,9353,O
an,9353,O
increase,9353,O
in,9353,O
GSH,9353,B-CHEMICAL
concentrations,9353,O
in,9353,O
the,9353,O
control,9353,O
and,9353,O
hGSTA4,9353,B-GENE-Y
cells,9353,O
",",9353,O
although,9353,O
the,9353,O
dose-response,9353,O
of,9353,O
GSH,9353,B-CHEMICAL
induction,9353,O
differed,9353,O
among,9353,O
the,9353,O
two,9353,O
cell,9353,O
types,9353,O
.,9353,O
Specifically,9354,O
",",9354,O
hGSTA4,9354,B-GENE-Y
cells,9354,O
had,9354,O
significantly,9354,O
higher,9354,O
GSH,9354,B-CHEMICAL
concentrations,9354,O
when,9354,O
exposed,9354,O
to,9354,O
5-15,9354,O
microM,9354,O
4-HNE,9354,B-CHEMICAL
",",9354,O
but,9354,O
not,9354,O
at,9354,O
20,9354,O
microM,9354,O
4-HNE,9354,B-CHEMICAL
",",9354,O
suggesting,9354,O
extensive,9354,O
GSH,9354,B-CHEMICAL
utilization,9354,O
at,9354,O
high,9354,O
concentrations,9354,O
of,9354,O
4-HNE,9354,B-CHEMICAL
.,9354,O
The,9355,O
hGSTA4,9355,B-GENE-Y
cells,9355,O
exhibited,9355,O
a,9355,O
significant,9355,O
growth,9355,O
advantage,9355,O
relative,9355,O
to,9355,O
control,9355,O
cells,9355,O
in,9355,O
the,9355,O
absence,9355,O
of,9355,O
4-HNE,9355,B-CHEMICAL
",",9355,O
and,9355,O
a,9355,O
trend,9355,O
towards,9355,O
increased,9355,O
growth,9355,O
at,9355,O
low,9355,O
dose,9355,O
exposures,9355,O
to,9355,O
4-HNE,9355,B-CHEMICAL
.,9355,O
However,9356,O
",",9356,O
the,9356,O
hGSTA4,9356,B-GENE-Y
cells,9356,O
did,9356,O
not,9356,O
exhibit,9356,O
a,9356,O
growth,9356,O
advantage,9356,O
relative,9356,O
to,9356,O
control,9356,O
cells,9356,O
at,9356,O
higher,9356,O
4-HNE,9356,B-CHEMICAL
exposures,9356,O
associated,9356,O
with,9356,O
increased,9356,O
GSH,9356,B-CHEMICAL
utilization,9356,O
.,9356,O
As,9357,O
expected,9357,O
",",9357,O
the,9357,O
hGSTA4,9357,B-GENE-Y
cells,9357,O
showed,9357,O
resistance,9357,O
to,9357,O
4-HNE,9357,B-CHEMICAL
stimulated,9357,O
lipid,9357,O
peroxidation,9357,O
at,9357,O
all,9357,O
4-HNE,9357,B-CHEMICAL
doses,9357,O
.,9357,O
In,9358,O
summary,9358,O
",",9358,O
our,9358,O
data,9358,O
indicates,9358,O
that,9358,O
over-expression,9358,O
of,9358,O
hGSTA4,9358,B-GENE-Y
at,9358,O
levels,9358,O
conferring,9358,O
high,9358,O
GST-4-HNE,9358,B-GENE-N
conjugating,9358,O
activity,9358,O
confers,9358,O
a,9358,O
partial,9358,O
growth,9358,O
advantage,9358,O
to,9358,O
HepG2,9358,O
cells,9358,O
and,9358,O
protects,9358,O
against,9358,O
4-HNE,9358,B-CHEMICAL
oxidative,9358,O
injury,9358,O
.,9358,O
However,9359,O
",",9359,O
the,9359,O
loss,9359,O
of,9359,O
proliferative,9359,O
capacity,9359,O
of,9359,O
hGSTA4,9359,B-GENE-Y
cells,9359,O
challenged,9359,O
with,9359,O
levels,9359,O
of,9359,O
4-HNE,9359,B-CHEMICAL
associated,9359,O
with,9359,O
severe,9359,O
oxidative,9359,O
stress,9359,O
indicates,9359,O
a,9359,O
role,9359,O
of,9359,O
other,9359,O
aldehyde,9359,B-CHEMICAL
metabolizing,9359,O
enzymes,9359,O
",",9359,O
and/or,9359,O
GSH-electrophile,9359,B-CHEMICAL
transporter,9359,O
proteins,9359,O
",",9359,O
in,9359,O
providing,9359,O
full,9359,O
cellular,9359,O
protection,9359,O
against,9359,O
4-HNE,9359,B-CHEMICAL
toxicity,9359,O
.,9359,O
DRF,9360,B-CHEMICAL
2655,9360,I-CHEMICAL
:,9360,O
a,9360,O
unique,9360,O
molecule,9360,O
that,9360,O
reduces,9360,O
body,9360,O
weight,9360,O
and,9360,O
ameliorates,9360,O
metabolic,9360,O
abnormalities,9360,O
.,9360,O
OBJECTIVE,9361,O
:,9361,O
Preclinical,9361,O
evaluation,9361,O
of,9361,O
DRF,9361,B-CHEMICAL
2655,9361,I-CHEMICAL
",",9361,O
a,9361,O
peroxisome,9361,B-GENE-Y
proliferator-activated,9361,I-GENE-Y
receptor,9361,I-GENE-Y
alpha,9361,I-GENE-Y
(,9361,O
PPARalpha,9361,B-GENE-Y
),9361,O
and,9361,O
PPARgamma,9361,B-GENE-Y
agonist,9361,O
",",9361,O
as,9361,O
a,9361,O
body-weight,9361,O
lowering,9361,O
",",9361,O
hypolipidemic,9361,O
and,9361,O
euglycemic,9361,O
agent,9361,O
.,9361,O
RESEARCH,9362,O
METHODS,9362,O
AND,9362,O
PROCEDURES,9362,O
:,9362,O
DRF,9362,B-CHEMICAL
2655,9362,I-CHEMICAL
was,9362,O
studied,9362,O
in,9362,O
different,9362,O
genetic,9362,O
",",9362,O
normal,9362,O
",",9362,O
and,9362,O
hyperlipidemic,9362,O
animal,9362,O
models,9362,O
.,9362,O
HEK,9363,O
293,9363,O
cells,9363,O
were,9363,O
used,9363,O
to,9363,O
conduct,9363,O
the,9363,O
reporter-based,9363,O
transactivation,9363,O
of,9363,O
PPARalpha,9363,B-GENE-Y
and,9363,O
PPARgamma,9363,B-GENE-Y
.,9363,O
To,9364,O
understand,9364,O
the,9364,O
biochemical,9364,O
mechanism,9364,O
of,9364,O
lipid-,9364,O
",",9364,O
body-weight-,9364,O
",",9364,O
and,9364,O
glucose-lowering,9364,B-CHEMICAL
effects,9364,O
",",9364,O
activities,9364,O
of,9364,O
key,9364,O
beta-oxidation,9364,O
and,9364,O
lipid,9364,O
catabolism,9364,O
enzymes,9364,O
and,9364,O
gluconeogenic,9364,O
enzymes,9364,O
were,9364,O
studied,9364,O
in,9364,O
db/db,9364,O
mice,9364,O
treated,9364,O
with,9364,O
DRF,9364,B-CHEMICAL
2655,9364,I-CHEMICAL
.,9364,O
3T3L1,9365,O
cells,9365,O
were,9365,O
used,9365,O
for,9365,O
adipogenesis,9365,O
study,9365,O
",",9365,O
and,9365,O
HepG2,9365,O
cells,9365,O
were,9365,O
used,9365,O
to,9365,O
study,9365,O
the,9365,O
effect,9365,O
of,9365,O
DRF,9365,B-CHEMICAL
2655,9365,I-CHEMICAL
on,9365,O
total,9365,O
cholesterol,9365,B-CHEMICAL
and,9365,O
triglyceride,9365,B-CHEMICAL
synthesis,9365,O
using,9365,O
[,9365,B-CHEMICAL
(,9365,I-CHEMICAL
14,9365,I-CHEMICAL
),9365,I-CHEMICAL
C,9365,I-CHEMICAL
],9365,I-CHEMICAL
acetate,9365,I-CHEMICAL
and,9365,O
[,9365,B-CHEMICAL
(,9365,I-CHEMICAL
3,9365,I-CHEMICAL
),9365,I-CHEMICAL
H,9365,I-CHEMICAL
],9365,I-CHEMICAL
glycerol,9365,I-CHEMICAL
.,9365,O
RESULTS,9366,O
:,9366,O
DRF,9366,B-CHEMICAL
2655,9366,I-CHEMICAL
showed,9366,O
concentration-dependent,9366,O
transactivation,9366,O
of,9366,O
PPARalpha,9366,B-GENE-Y
and,9366,O
PPARgamma,9366,B-GENE-Y
.,9366,O
In,9367,O
the,9367,O
3T3L1,9367,O
cell-differentiation,9367,O
study,9367,O
",",9367,O
DRF,9367,B-CHEMICAL
2655,9367,I-CHEMICAL
and,9367,O
rosiglitazone,9367,B-CHEMICAL
showed,9367,O
369,9367,O
%,9367,O
and,9367,O
471,9367,O
%,9367,O
increases,9367,O
",",9367,O
respectively,9367,O
",",9367,O
in,9367,O
triglyceride,9367,B-CHEMICAL
accumulation,9367,O
.,9367,O
DRF,9368,B-CHEMICAL
2655,9368,I-CHEMICAL
showed,9368,O
body-weight,9368,O
lowering,9368,O
and,9368,O
euglycemic,9368,O
and,9368,O
hypolipidemic,9368,O
effects,9368,O
in,9368,O
various,9368,O
animal,9368,O
models,9368,O
.,9368,O
db/db,9369,O
mice,9369,O
treated,9369,O
with,9369,O
DRF,9369,B-CHEMICAL
2655,9369,I-CHEMICAL
showed,9369,O
5-,9369,O
and,9369,O
3.6-fold,9369,O
inhibition,9369,O
in,9369,O
phosphoenolpyruvate,9369,B-GENE-Y
carboxykinase,9369,I-GENE-Y
and,9369,O
glucose,9369,B-GENE-Y
6-phosphatase,9369,I-GENE-Y
activity,9369,O
and,9369,O
651,9369,O
%,9369,O
and,9369,O
77,9369,O
%,9369,O
increases,9369,O
in,9369,O
the,9369,O
beta-oxidation,9369,O
enzymes,9369,O
carnitine,9369,B-GENE-N
palmitoyltransferase,9369,I-GENE-N
and,9369,O
carnitine,9369,B-GENE-Y
acetyltransferase,9369,I-GENE-Y
",",9369,O
respectively,9369,O
.,9369,O
HepG2,9370,O
cells,9370,O
treated,9370,O
with,9370,O
DRF,9370,B-CHEMICAL
2655,9370,I-CHEMICAL
showed,9370,O
significant,9370,O
reduction,9370,O
in,9370,O
lipid,9370,O
synthesis,9370,O
.,9370,O
DISCUSSION,9371,O
:,9371,O
DRF,9371,B-CHEMICAL
2655,9371,I-CHEMICAL
showed,9371,O
excellent,9371,O
euglycemic,9371,O
and,9371,O
hypolipidemic,9371,O
activities,9371,O
in,9371,O
different,9371,O
animal,9371,O
models,9371,O
.,9371,O
An,9372,O
exciting,9372,O
finding,9372,O
is,9372,O
its,9372,O
body-weight,9372,O
lowering,9372,O
effect,9372,O
in,9372,O
these,9372,O
models,9372,O
",",9372,O
which,9372,O
might,9372,O
be,9372,O
mediated,9372,O
by,9372,O
the,9372,O
induction,9372,O
of,9372,O
target,9372,O
enzymes,9372,O
involved,9372,O
in,9372,O
hepatic,9372,O
lipid,9372,O
catabolism,9372,O
through,9372,O
PPARalpha,9372,B-GENE-Y
activation,9372,O
.,9372,O
Expression,9373,O
and,9373,O
selective,9373,O
inhibition,9373,O
of,9373,O
the,9373,O
constitutive,9373,B-GENE-N
and,9373,I-GENE-N
inducible,9373,I-GENE-N
forms,9373,I-GENE-N
of,9373,I-GENE-N
human,9373,I-GENE-N
cyclo-oxygenase,9373,I-GENE-N
.,9373,O
The,9374,O
enzyme,9374,O
cyclo-oxygenase,9374,B-GENE-N
catalyses,9374,O
the,9374,O
oxygenation,9374,O
of,9374,O
arachidonic,9374,B-CHEMICAL
acid,9374,I-CHEMICAL
",",9374,O
leading,9374,O
to,9374,O
the,9374,O
formation,9374,O
of,9374,O
prostaglandins,9374,B-CHEMICAL
.,9374,O
Recently,9375,O
two,9375,O
forms,9375,O
of,9375,O
cyclo-oxygenase,9375,B-GENE-N
have,9375,O
been,9375,O
described,9375,O
:,9375,O
a,9375,O
constitutive,9375,O
(,9375,O
COX-1,9375,B-GENE-Y
),9375,O
enzyme,9375,O
present,9375,O
in,9375,O
most,9375,O
cells,9375,O
and,9375,O
tissues,9375,O
",",9375,O
and,9375,O
an,9375,O
inducible,9375,O
(,9375,O
COX-2,9375,B-GENE-Y
),9375,O
isoenzyme,9375,O
observed,9375,O
in,9375,O
many,9375,O
cells,9375,O
in,9375,O
response,9375,O
to,9375,O
pro-inflammatory,9375,O
cytokines,9375,B-GENE-N
.,9375,O
Constitutive,9376,B-GENE-N
and,9376,I-GENE-N
inducible,9376,I-GENE-N
forms,9376,I-GENE-N
of,9376,I-GENE-N
human,9376,I-GENE-N
cyclo-oxygenase,9376,I-GENE-N
(,9376,O
hCOX-1,9376,B-GENE-Y
and,9376,O
hCOX-2,9376,B-GENE-Y
),9376,O
were,9376,O
cloned,9376,O
and,9376,O
expressed,9376,O
in,9376,O
insect,9376,O
cells,9376,O
",",9376,O
utilizing,9376,O
a,9376,O
baculovirus,9376,O
expression,9376,O
system,9376,O
.,9376,O
hCOX-1,9377,B-GENE-Y
had,9377,O
a,9377,O
specific,9377,O
activity,9377,O
of,9377,O
18.8,9377,O
mumol,9377,O
of,9377,O
O2/mg,9377,B-CHEMICAL
with,9377,O
a,9377,O
Km,9377,O
of,9377,O
13.8,9377,O
microM,9377,O
for,9377,O
arachidonate,9377,B-CHEMICAL
and,9377,O
Vmax,9377,O
.,9377,O
of,9378,O
1500,9378,O
nmol,9378,O
of,9378,O
O2/nmol,9378,O
of,9378,O
enzyme,9378,O
",",9378,O
whereas,9378,O
hCOX-2,9378,B-GENE-Y
had,9378,O
a,9378,O
specific,9378,O
activity,9378,O
of,9378,O
12.2,9378,O
mumol,9378,O
of,9378,O
O2/mg,9378,B-CHEMICAL
with,9378,O
a,9378,O
Km,9378,O
of,9378,O
8.7,9378,O
microM,9378,O
for,9378,O
arachidonate,9378,B-CHEMICAL
and,9378,O
a,9378,O
Vmax,9378,O
.,9378,O
of,9379,O
1090,9379,O
nmol,9379,O
of,9379,O
O2/nmol,9379,B-CHEMICAL
of,9379,O
enzyme,9379,O
.,9379,O
Indomethacin,9380,B-CHEMICAL
inhibited,9380,O
both,9380,O
hCOX-1,9380,B-GENE-Y
and,9380,O
hCOX-2,9380,B-GENE-Y
",",9380,O
whereas,9380,O
NS-398,9380,B-CHEMICAL
and,9380,O
Dup-697,9380,B-CHEMICAL
selectively,9380,O
inhibited,9380,O
hCOX-2,9380,B-GENE-Y
.,9380,O
Both,9381,O
NS-398,9381,B-CHEMICAL
and,9381,O
Dup-697,9381,B-CHEMICAL
exhibited,9381,O
time-dependent,9381,O
inactivation,9381,O
of,9381,O
hCOX-2,9381,B-GENE-Y
",",9381,O
as,9381,O
did,9381,O
indomethacin,9381,B-CHEMICAL
on,9381,O
both,9381,O
enzymes,9381,O
.,9381,O
The,9382,O
competitive,9382,O
inhibitor,9382,O
of,9382,O
hCOX-1,9382,B-GENE-Y
",",9382,O
mefenamic,9382,B-CHEMICAL
acid,9382,I-CHEMICAL
",",9382,O
also,9382,O
displayed,9382,O
competitive,9382,O
inhibition,9382,O
of,9382,O
hCOX-2,9382,B-GENE-Y
.,9382,O
These,9383,O
results,9383,O
demonstrate,9383,O
the,9383,O
ability,9383,O
to,9383,O
generate,9383,O
selective,9383,O
non-steroidal,9383,O
anti-inflammatory,9383,O
drugs,9383,O
(,9383,O
NSAIDs,9383,O
),9383,O
",",9383,O
which,9383,O
could,9383,O
provide,9383,O
useful,9383,O
improvement,9383,O
therapeutically,9383,O
in,9383,O
the,9383,O
treatment,9383,O
of,9383,O
chronic,9383,O
inflammatory,9383,O
disease,9383,O
.,9383,O
Dose-response,9384,O
effect,9384,O
of,9384,O
tetracyclines,9384,B-CHEMICAL
on,9384,O
cerebral,9384,O
matrix,9384,B-GENE-Y
metalloproteinase-9,9384,I-GENE-Y
after,9384,O
vascular,9384,B-GENE-Y
endothelial,9384,I-GENE-Y
growth,9384,I-GENE-Y
factor,9384,I-GENE-Y
hyperstimulation,9384,O
.,9384,O
Brain,9385,O
arteriovenous,9385,O
malformations,9385,O
(,9385,O
BAVMs,9385,O
),9385,O
are,9385,O
a,9385,O
potentially,9385,O
life-threatening,9385,O
disorder,9385,O
.,9385,O
Matrix,9386,B-GENE-Y
metalloproteinase,9386,I-GENE-Y
(,9386,I-GENE-Y
MMP,9386,I-GENE-Y
),9386,I-GENE-Y
-9,9386,I-GENE-Y
activity,9386,O
was,9386,O
greatly,9386,O
increased,9386,O
in,9386,O
BAVM,9386,O
tissue,9386,O
specimens,9386,O
.,9386,O
Doxycycline,9387,B-CHEMICAL
was,9387,O
shown,9387,O
to,9387,O
decrease,9387,O
cerebral,9387,O
MMP-9,9387,B-GENE-Y
activities,9387,O
and,9387,O
angiogenesis,9387,O
induced,9387,O
by,9387,O
vascular,9387,B-GENE-Y
endothelial,9387,I-GENE-Y
growth,9387,I-GENE-Y
factor,9387,I-GENE-Y
(,9387,O
VEGF,9387,B-GENE-Y
),9387,O
.,9387,O
In,9388,O
the,9388,O
present,9388,O
study,9388,O
",",9388,O
we,9388,O
determined,9388,O
the,9388,O
dose-response,9388,O
effects,9388,O
of,9388,O
doxycycline,9388,B-CHEMICAL
and,9388,O
minocycline,9388,B-CHEMICAL
on,9388,O
cerebral,9388,O
MMP-9,9388,B-GENE-Y
using,9388,O
our,9388,O
mouse,9388,O
model,9388,O
with,9388,O
VEGF,9388,B-GENE-Y
focal,9388,O
hyperstimulation,9388,O
delivered,9388,O
with,9388,O
adenoviral,9388,O
vector,9388,O
(,9388,O
AdVEGF,9388,O
),9388,O
in,9388,O
the,9388,O
brain,9388,O
.,9388,O
Mice,9389,O
were,9389,O
treated,9389,O
with,9389,O
doxycycline,9389,B-CHEMICAL
or,9389,O
minocycline,9389,B-CHEMICAL
",",9389,O
respectively,9389,O
",",9389,O
at,9389,O
1,9389,O
",",9389,O
5,9389,O
",",9389,O
10,9389,O
",",9389,O
30,9389,O
",",9389,O
50,9389,O
",",9389,O
or,9389,O
100,9389,O
mg/kg/day,9389,O
through,9389,O
drinking,9389,O
water,9389,O
for,9389,O
1,9389,O
week,9389,O
.,9389,O
Our,9390,O
results,9390,O
have,9390,O
shown,9390,O
that,9390,O
MMP-9,9390,B-GENE-Y
messenger,9390,O
ribonucleic,9390,O
acid,9390,O
(,9390,O
mRNA,9390,O
),9390,O
expression,9390,O
was,9390,O
inhibited,9390,O
by,9390,O
doxycycline,9390,B-CHEMICAL
starting,9390,O
at,9390,O
10,9390,O
mg/kg/day,9390,O
(,9390,O
P,9390,O
<,9390,O
0.02,9390,O
),9390,O
.,9390,O
Minocycline,9391,B-CHEMICAL
showed,9391,O
more,9391,O
potent,9391,O
inhibition,9391,O
on,9391,O
MMP-9,9391,B-GENE-Y
mRNA,9391,O
expression,9391,O
",",9391,O
starting,9391,O
at,9391,O
1,9391,O
(,9391,O
P,9391,O
<,9391,O
0.005,9391,O
),9391,O
and,9391,O
further,9391,O
at,9391,O
more,9391,O
than,9391,O
30,9391,O
(,9391,O
P,9391,O
<,9391,O
0.001,9391,O
),9391,O
mg/kg/day,9391,O
.,9391,O
At,9392,O
the,9392,O
enzymatic,9392,O
activity,9392,O
level,9392,O
",",9392,O
doxycycline,9392,B-CHEMICAL
started,9392,O
to,9392,O
suppress,9392,O
MMP-9,9392,B-GENE-Y
activity,9392,O
at,9392,O
5,9392,O
mg/kg/day,9392,O
(,9392,O
P,9392,O
<,9392,O
0.001,9392,O
),9392,O
",",9392,O
while,9392,O
minocycline,9392,B-CHEMICAL
had,9392,O
an,9392,O
effect,9392,O
at,9392,O
a,9392,O
lower,9392,O
dose,9392,O
",",9392,O
1,9392,O
mg/kg/day,9392,O
(,9392,O
P,9392,O
<,9392,O
0.02,9392,O
),9392,O
.,9392,O
The,9393,O
inhibition,9393,O
of,9393,O
cerebral,9393,O
MMP-9,9393,B-GENE-Y
mRNA,9393,O
and,9393,O
activity,9393,O
were,9393,O
highly,9393,O
correlated,9393,O
with,9393,O
drug,9393,O
levels,9393,O
in,9393,O
the,9393,O
brain,9393,O
tissue,9393,O
.,9393,O
We,9394,O
also,9394,O
assessed,9394,O
the,9394,O
potential,9394,O
relevant,9394,O
signaling,9394,O
pathway,9394,O
in,9394,O
vitro,9394,O
to,9394,O
elucidate,9394,O
the,9394,O
mechanisms,9394,O
underlying,9394,O
the,9394,O
MMP-9,9394,B-GENE-Y
inhibition,9394,O
by,9394,O
tetracyclines,9394,B-CHEMICAL
.,9394,O
In,9395,O
vitro,9395,O
",",9395,O
minocycline,9395,B-CHEMICAL
",",9395,O
but,9395,O
not,9395,O
doxycycline,9395,B-CHEMICAL
",",9395,O
inhibits,9395,O
MMP-9,9395,B-GENE-Y
",",9395,O
at,9395,O
least,9395,O
in,9395,O
part,9395,O
",",9395,O
via,9395,O
the,9395,O
extracellular,9395,B-GENE-N
signaling-related,9395,I-GENE-N
kinase,9395,I-GENE-N
1/2,9395,I-GENE-N
(,9395,O
ERK1/2,9395,B-GENE-N
),9395,O
-mediated,9395,O
pathway,9395,O
.,9395,O
This,9396,O
study,9396,O
provided,9396,O
the,9396,O
evidence,9396,O
that,9396,O
the,9396,O
tetracyclines,9396,B-CHEMICAL
inhibit,9396,O
stimulated,9396,O
cerebral,9396,O
MMP-9,9396,B-GENE-Y
at,9396,O
multiple,9396,O
levels,9396,O
and,9396,O
are,9396,O
effective,9396,O
at,9396,O
very,9396,O
low,9396,O
doses,9396,O
",",9396,O
offering,9396,O
great,9396,O
potential,9396,O
for,9396,O
therapeutic,9396,O
use,9396,O
.,9396,O
Investigating,9397,O
the,9397,O
regulation,9397,O
of,9397,O
one-carbon,9397,O
metabolism,9397,O
in,9397,O
Arabidopsis,9397,O
thaliana,9397,O
.,9397,O
Serine,9398,B-CHEMICAL
(,9398,O
Ser,9398,B-CHEMICAL
),9398,O
biosynthesis,9398,O
in,9398,O
C,9398,O
(,9398,O
3,9398,O
),9398,O
plants,9398,O
can,9398,O
occur,9398,O
via,9398,O
several,9398,O
pathways,9398,O
.,9398,O
One,9399,O
major,9399,O
route,9399,O
involves,9399,O
the,9399,O
tetrahydrofolate,9399,B-CHEMICAL
(,9399,O
THF,9399,B-CHEMICAL
),9399,O
-dependent,9399,O
activities,9399,O
of,9399,O
the,9399,O
glycine,9399,B-GENE-N
decarboxylase,9399,I-GENE-N
complex,9399,I-GENE-N
(,9399,O
GDC,9399,B-GENE-N
",",9399,O
EC,9399,B-GENE-Y
2.1.1.10,9399,I-GENE-Y
),9399,O
and,9399,O
serine,9399,B-GENE-N
hydroxymethyltransferase,9399,I-GENE-N
(,9399,O
SHMT,9399,B-GENE-N
",",9399,O
EC,9399,B-GENE-Y
2.1.2.1,9399,I-GENE-Y
),9399,O
with,9399,O
glycine,9399,B-CHEMICAL
(,9399,O
Gly,9399,B-CHEMICAL
),9399,O
as,9399,O
one-carbon,9399,O
(,9399,O
1-C,9399,B-CHEMICAL
),9399,O
source,9399,O
.,9399,O
An,9400,O
alternative,9400,O
THF-dependent,9400,B-CHEMICAL
pathway,9400,O
involves,9400,O
the,9400,O
C1-THF,9400,B-GENE-Y
synthase/SHMT,9400,O
activities,9400,O
with,9400,O
formate,9400,B-CHEMICAL
as,9400,O
1-C,9400,B-CHEMICAL
source,9400,O
.,9400,O
Here,9401,O
",",9401,O
we,9401,O
have,9401,O
investigated,9401,O
aspects,9401,O
of,9401,O
the,9401,O
regulation,9401,O
of,9401,O
these,9401,O
two,9401,O
folate-mediated,9401,O
pathways,9401,O
in,9401,O
Arabidopsis,9401,O
thaliana,9401,O
(,9401,O
L.,9401,O
),9401,O
Heynh,9401,O
.,9401,O
Columbia,9402,O
using,9402,O
two,9402,O
approaches,9402,O
.,9402,O
Firstly,9403,O
",",9403,O
transgenic,9403,O
plants,9403,O
overexpressing,9403,O
formate,9403,B-GENE-Y
dehydrogenase,9403,I-GENE-Y
(,9403,O
FDH,9403,B-GENE-Y
",",9403,O
EC,9403,B-GENE-Y
1.2.1.2,9403,I-GENE-Y
),9403,O
were,9403,O
used,9403,O
to,9403,O
continue,9403,O
our,9403,O
previous,9403,O
studies,9403,O
on,9403,O
the,9403,O
function,9403,O
of,9403,O
FDH,9403,B-GENE-Y
in,9403,O
formate,9403,B-CHEMICAL
metabolism,9403,O
.,9403,O
The,9404,O
formate,9404,B-CHEMICAL
pool,9404,O
size,9404,O
was,9404,O
approximately,9404,O
73,9404,O
nmol,9404,O
(,9404,O
g,9404,O
FW,9404,O
),9404,O
(,9404,O
-1,9404,O
),9404,O
in,9404,O
wild,9404,O
type,9404,O
(,9404,O
WT,9404,O
),9404,O
Arabidopsis,9404,O
plants,9404,O
;,9404,O
three,9404,O
independent,9404,O
transgenic,9404,O
lines,9404,O
had,9404,O
similar-sized,9404,O
pools,9404,O
of,9404,O
formate,9404,B-CHEMICAL
.,9404,O
Transgenic,9405,O
plants,9405,O
produced,9405,O
more,9405,O
(,9405,B-CHEMICAL
13,9405,I-CHEMICAL
),9405,I-CHEMICAL
CO,9405,I-CHEMICAL
(,9405,I-CHEMICAL
2,9405,I-CHEMICAL
),9405,I-CHEMICAL
from,9405,O
supplied,9405,O
[,9405,B-CHEMICAL
(,9405,I-CHEMICAL
13,9405,I-CHEMICAL
),9405,I-CHEMICAL
C,9405,I-CHEMICAL
],9405,I-CHEMICAL
formate,9405,I-CHEMICAL
than,9405,O
did,9405,O
WT,9405,O
plants,9405,O
but,9405,O
were,9405,O
not,9405,O
significantly,9405,O
different,9405,O
from,9405,O
WT,9405,O
plants,9405,O
in,9405,O
their,9405,O
synthesis,9405,O
of,9405,O
Ser,9405,B-CHEMICAL
.,9405,O
We,9406,O
concluded,9406,O
that,9406,O
FDH,9406,B-GENE-Y
has,9406,O
no,9406,O
direct,9406,O
role,9406,O
in,9406,O
the,9406,O
regulation,9406,O
of,9406,O
the,9406,O
above,9406,O
two,9406,O
pathways,9406,O
of,9406,O
Ser,9406,B-CHEMICAL
synthesis,9406,O
;,9406,O
the,9406,O
breakdown,9406,O
of,9406,O
formate,9406,B-CHEMICAL
to,9406,O
CO,9406,B-CHEMICAL
(,9406,I-CHEMICAL
2,9406,I-CHEMICAL
),9406,I-CHEMICAL
by,9406,O
the,9406,O
FDH,9406,B-GENE-Y
reaction,9406,O
is,9406,O
the,9406,O
primary,9406,O
and,9406,O
preferred,9406,O
fate,9406,O
of,9406,O
the,9406,O
organic,9406,O
acid,9406,O
in,9406,O
Arabidopsis,9406,O
.,9406,O
The,9407,O
ratio,9407,O
between,9407,O
the,9407,O
GDC/SHMT,9407,B-GENE-N
and,9407,O
C1-THF,9407,B-GENE-Y
synthase/SHMT,9407,O
pathways,9407,O
of,9407,O
Ser,9407,B-CHEMICAL
synthesis,9407,O
from,9407,O
[,9407,B-CHEMICAL
alpha-,9407,I-CHEMICAL
(,9407,I-CHEMICAL
13,9407,I-CHEMICAL
),9407,I-CHEMICAL
C,9407,I-CHEMICAL
],9407,I-CHEMICAL
Gly,9407,I-CHEMICAL
and,9407,O
[,9407,B-CHEMICAL
(,9407,I-CHEMICAL
13,9407,I-CHEMICAL
),9407,I-CHEMICAL
C,9407,I-CHEMICAL
],9407,I-CHEMICAL
formate,9407,I-CHEMICAL
",",9407,O
respectively,9407,O
",",9407,O
in,9407,O
Arabidopsis,9407,O
shoots,9407,O
was,9407,O
21,9407,O
:,9407,O
1,9407,O
;,9407,O
in,9407,O
roots,9407,O
",",9407,O
9,9407,O
:,9407,O
1,9407,O
.,9407,O
In,9408,O
shoots,9408,O
",",9408,O
therefore,9408,O
",",9408,O
the,9408,O
pathway,9408,O
from,9408,O
formate,9408,B-CHEMICAL
plays,9408,O
only,9408,O
a,9408,O
small,9408,O
role,9408,O
in,9408,O
Ser,9408,B-CHEMICAL
synthesis,9408,O
;,9408,O
in,9408,O
the,9408,O
case,9408,O
of,9408,O
roots,9408,O
",",9408,O
results,9408,O
indicated,9408,O
that,9408,O
the,9408,O
9,9408,O
:,9408,O
1,9408,O
ratio,9408,O
was,9408,O
as,9408,O
a,9408,O
result,9408,O
of,9408,O
greater,9408,O
fluxes,9408,O
of,9408,O
(,9408,B-CHEMICAL
13,9408,I-CHEMICAL
),9408,I-CHEMICAL
C,9408,I-CHEMICAL
through,9408,O
both,9408,O
pathways,9408,O
together,9408,O
with,9408,O
a,9408,O
relatively,9408,O
higher,9408,O
contribution,9408,O
from,9408,O
the,9408,O
C1-THF,9408,B-GENE-Y
synthase/SHMT,9408,O
route,9408,O
than,9408,O
in,9408,O
shoots,9408,O
.,9408,O
We,9409,O
also,9409,O
examined,9409,O
the,9409,O
synthesis,9409,O
of,9409,O
Ser,9409,B-CHEMICAL
in,9409,O
a,9409,O
GDC-deficient,9409,B-GENE-N
mutant,9409,O
of,9409,O
Arabidopsis,9409,O
(,9409,O
glyD,9409,B-CHEMICAL
),9409,O
where,9409,O
the,9409,O
GDC/SHMT,9409,B-GENE-N
pathway,9409,O
was,9409,O
impaired,9409,O
.,9409,O
Compared,9410,O
with,9410,O
WT,9410,O
",",9410,O
glyD,9410,B-CHEMICAL
plants,9410,O
accumulated,9410,O
5-fold,9410,O
more,9410,O
Gly,9410,B-CHEMICAL
than,9410,O
WT,9410,O
after,9410,O
supplying,9410,O
[,9410,B-CHEMICAL
alpha-,9410,I-CHEMICAL
(,9410,I-CHEMICAL
13,9410,I-CHEMICAL
),9410,I-CHEMICAL
C,9410,I-CHEMICAL
],9410,I-CHEMICAL
Gly,9410,I-CHEMICAL
for,9410,O
24,9410,O
h,9410,O
;,9410,O
the,9410,O
accumulation,9410,O
of,9410,O
Ser,9410,B-CHEMICAL
from,9410,O
[,9410,B-CHEMICAL
alpha-,9410,I-CHEMICAL
(,9410,I-CHEMICAL
13,9410,I-CHEMICAL
),9410,I-CHEMICAL
C,9410,I-CHEMICAL
],9410,I-CHEMICAL
Gly,9410,I-CHEMICAL
was,9410,O
reduced,9410,O
by,9410,O
25,9410,O
%,9410,O
in,9410,O
the,9410,O
same,9410,O
time,9410,O
period,9410,O
.,9410,O
On,9411,O
the,9411,O
other,9411,O
hand,9411,O
",",9411,O
the,9411,O
accumulation,9411,O
of,9411,O
Ser,9411,B-CHEMICAL
through,9411,O
the,9411,O
C1-THF,9411,B-GENE-Y
synthase/SHMT,9411,O
pathway,9411,O
in,9411,O
glyD,9411,B-CHEMICAL
plants,9411,O
was,9411,O
2.5-fold,9411,O
greater,9411,O
than,9411,O
that,9411,O
in,9411,O
WT,9411,O
plants,9411,O
.,9411,O
Our,9412,O
experiments,9412,O
confirmed,9412,O
that,9412,O
the,9412,O
GDC/SHMT,9412,B-GENE-N
and,9412,O
C1-THF,9412,B-GENE-Y
synthase/SHMT,9412,O
pathways,9412,O
normally,9412,O
operate,9412,O
independently,9412,O
in,9412,O
Arabidopsis,9412,O
plants,9412,O
but,9412,O
that,9412,O
when,9412,O
the,9412,O
primary,9412,O
GDC/SHMT,9412,B-GENE-N
pathway,9412,O
is,9412,O
impaired,9412,O
the,9412,O
alternative,9412,O
C1-THF,9412,B-GENE-Y
synthase/SHMT,9412,O
pathway,9412,O
can,9412,O
partially,9412,O
compensate,9412,O
for,9412,O
deficiencies,9412,O
in,9412,O
the,9412,O
synthesis,9412,O
of,9412,O
Ser,9412,B-CHEMICAL
.,9412,O
Studies,9413,O
of,9413,O
the,9413,O
biogenic,9413,B-GENE-N
amine,9413,I-GENE-N
transporters,9413,I-GENE-N
.,9413,O
13,9414,O
.,9414,O
Identification,9415,O
of,9415,O
``,9415,O
agonist,9415,O
'',9415,O
and,9415,O
``,9415,O
antagonist,9415,O
'',9415,O
allosteric,9415,O
modulators,9415,O
of,9415,O
amphetamine-induced,9415,B-CHEMICAL
dopamine,9415,B-CHEMICAL
release,9415,O
.,9415,O
Recent,9416,O
studies,9416,O
identified,9416,O
novel,9416,O
allosteric,9416,O
modulators,9416,O
of,9416,O
the,9416,O
dopamine,9416,B-GENE-Y
(,9416,I-GENE-Y
DA,9416,I-GENE-Y
),9416,I-GENE-Y
transporter,9416,I-GENE-Y
(,9416,O
DAT,9416,B-GENE-Y
),9416,O
.,9416,O
N-,9417,B-CHEMICAL
(,9417,I-CHEMICAL
Diphenylmethyl,9417,I-CHEMICAL
),9417,I-CHEMICAL
-2-phenyl-4-quinazolinamine,9417,I-CHEMICAL
(,9417,O
SoRI-9804,9417,B-CHEMICAL
),9417,O
",",9417,O
N-,9417,B-CHEMICAL
(,9417,I-CHEMICAL
"2,2-diphenylethyl",9417,I-CHEMICAL
),9417,I-CHEMICAL
-2-phenyl-4-quinazolinamine,9417,I-CHEMICAL
(,9417,O
SoRI-20040,9417,B-CHEMICAL
),9417,O
",",9417,O
and,9417,O
N-,9417,B-CHEMICAL
(,9417,I-CHEMICAL
"3,3-diphenylpropyl",9417,I-CHEMICAL
),9417,I-CHEMICAL
-2-phenyl-4-quinazolinamine,9417,I-CHEMICAL
(,9417,O
SoRI-20041,9417,B-CHEMICAL
),9417,O
partially,9417,O
inhibited,9417,O
[,9417,B-CHEMICAL
(,9417,I-CHEMICAL
125,9417,I-CHEMICAL
),9417,I-CHEMICAL
I,9417,I-CHEMICAL
],9417,I-CHEMICAL
3beta-,9417,I-CHEMICAL
(,9417,I-CHEMICAL
4'-iodophenyl,9417,I-CHEMICAL
),9417,I-CHEMICAL
tropan-2beta-carboxylic,9417,I-CHEMICAL
acid,9417,I-CHEMICAL
methyl,9417,I-CHEMICAL
ester,9417,I-CHEMICAL
(,9417,O
RTI-55,9417,B-CHEMICAL
),9417,O
binding,9417,O
",",9417,O
slowed,9417,O
the,9417,O
dissociation,9417,O
rate,9417,O
of,9417,O
[,9417,B-CHEMICAL
(,9417,I-CHEMICAL
125,9417,I-CHEMICAL
),9417,I-CHEMICAL
I,9417,I-CHEMICAL
],9417,I-CHEMICAL
RTI-55,9417,I-CHEMICAL
from,9417,O
the,9417,O
DAT,9417,B-GENE-Y
",",9417,O
and,9417,O
partially,9417,O
inhibited,9417,O
[,9417,B-CHEMICAL
(,9417,I-CHEMICAL
3,9417,I-CHEMICAL
),9417,I-CHEMICAL
H,9417,I-CHEMICAL
],9417,I-CHEMICAL
dopamine,9417,I-CHEMICAL
uptake,9417,O
.,9417,O
In,9418,O
the,9418,O
present,9418,O
study,9418,O
",",9418,O
we,9418,O
report,9418,O
that,9418,O
SoRI-9804,9418,B-CHEMICAL
and,9418,O
SoRI-20040,9418,B-CHEMICAL
",",9418,O
at,9418,O
doses,9418,O
that,9418,O
do,9418,O
not,9418,O
alter,9418,O
release,9418,O
",",9418,O
partially,9418,O
inhibited,9418,O
d-amphetamine-induced,9418,B-CHEMICAL
DAT-mediated,9418,B-GENE-Y
release,9418,O
of,9418,O
[,9418,B-CHEMICAL
(,9418,I-CHEMICAL
3,9418,I-CHEMICAL
),9418,I-CHEMICAL
H,9418,I-CHEMICAL
],9418,I-CHEMICAL
1-methyl-4-phenylpyridinium,9418,I-CHEMICAL
(,9418,O
MPP,9418,B-CHEMICAL
(,9418,I-CHEMICAL
+,9418,I-CHEMICAL
),9418,I-CHEMICAL
),9418,O
or,9418,O
[,9418,B-CHEMICAL
(,9418,I-CHEMICAL
3,9418,I-CHEMICAL
),9418,I-CHEMICAL
H,9418,I-CHEMICAL
],9418,I-CHEMICAL
dopamine,9418,I-CHEMICAL
from,9418,O
striatal,9418,O
synaptosomes,9418,O
(,9418,O
``,9418,O
DAT-mediated,9418,B-GENE-Y
DA,9418,B-GENE-Y
release,9418,O
'',9418,O
),9418,I-CHEMICAL
in,9418,I-CHEMICAL
a,9418,I-CHEMICAL
dose-dependent,9418,O
manner,9418,O
.,9418,O
SoRI-20041,9419,B-CHEMICAL
",",9419,O
which,9419,O
does,9419,O
not,9419,O
alter,9419,O
DAT-mediated,9419,B-GENE-Y
DA,9419,B-CHEMICAL
release,9419,O
measured,9419,O
with,9419,O
[,9419,B-CHEMICAL
(,9419,I-CHEMICAL
3,9419,I-CHEMICAL
),9419,I-CHEMICAL
H,9419,I-CHEMICAL
],9419,I-CHEMICAL
DA,9419,I-CHEMICAL
",",9419,O
reversed,9419,O
the,9419,O
effect,9419,O
of,9419,O
SoRI-20040,9419,B-CHEMICAL
.,9419,O
SoRI-20040,9420,B-CHEMICAL
and,9420,O
SoRI-9804,9420,B-CHEMICAL
also,9420,O
partially,9420,O
inhibited,9420,O
DAT-mediated,9420,B-GENE-Y
DA,9420,B-CHEMICAL
release,9420,O
induced,9420,O
by,9420,O
DA,9420,B-CHEMICAL
or,9420,O
(,9420,B-CHEMICAL
+/-,9420,I-CHEMICAL
),9420,I-CHEMICAL
"-3,4-methylenedioxyamphetamine",9420,I-CHEMICAL
",",9420,O
demonstrating,9420,O
that,9420,O
the,9420,O
observed,9420,O
partial,9420,O
inhibition,9420,O
is,9420,O
not,9420,O
specific,9420,O
for,9420,O
a,9420,O
particular,9420,O
DAT,9420,B-GENE-Y
substrate,9420,O
.,9420,O
SoRI-9804,9421,B-CHEMICAL
and,9421,O
SoRI-20040,9421,B-CHEMICAL
did,9421,O
not,9421,O
attenuate,9421,O
D-amphetamine-induced,9421,B-CHEMICAL
release,9421,O
of,9421,O
[,9421,B-CHEMICAL
(,9421,I-CHEMICAL
3,9421,I-CHEMICAL
),9421,I-CHEMICAL
H,9421,I-CHEMICAL
],9421,I-CHEMICAL
5-hydroxytryptamine,9421,I-CHEMICAL
from,9421,O
serotonergic,9421,O
",",9421,O
or,9421,O
[,9421,B-CHEMICAL
(,9421,I-CHEMICAL
3,9421,I-CHEMICAL
),9421,I-CHEMICAL
H,9421,I-CHEMICAL
],9421,I-CHEMICAL
MPP,9421,I-CHEMICAL
(,9421,I-CHEMICAL
+,9421,I-CHEMICAL
),9421,I-CHEMICAL
from,9421,O
noradrenergic,9421,O
",",9421,O
nerve,9421,O
terminals,9421,O
.,9421,O
Kinetic,9422,O
experiments,9422,O
demonstrated,9422,O
that,9422,O
SoRI-9804,9422,B-CHEMICAL
",",9422,O
in,9422,O
contrast,9422,O
to,9422,O
cocaine,9422,B-CHEMICAL
",",9422,O
slowed,9422,O
D-amphetamine-induced,9422,B-CHEMICAL
release,9422,O
of,9422,O
[,9422,B-CHEMICAL
(,9422,I-CHEMICAL
3,9422,I-CHEMICAL
),9422,I-CHEMICAL
H,9422,I-CHEMICAL
],9422,I-CHEMICAL
MPP,9422,I-CHEMICAL
(,9422,I-CHEMICAL
+,9422,I-CHEMICAL
),9422,I-CHEMICAL
from,9422,O
dopaminergic,9422,O
nerve,9422,O
terminals,9422,O
without,9422,O
altering,9422,O
the,9422,O
apparent,9422,O
rate,9422,O
constants,9422,O
.,9422,O
The,9423,O
two,9423,O
major,9423,O
findings,9423,O
of,9423,O
this,9423,O
study,9423,O
are,9423,O
1,9423,O
),9423,O
the,9423,O
identification,9423,O
of,9423,O
both,9423,O
``,9423,O
agonist,9423,O
'',9423,O
(,9423,O
SoRI-9804,9423,B-CHEMICAL
and,9423,O
SoRI-20040,9423,B-CHEMICAL
),9423,O
and,9423,O
``,9423,O
antagonist,9423,O
'',9423,O
(,9423,O
SoRI-20041,9423,B-CHEMICAL
),9423,O
allosteric,9423,O
modulators,9423,O
of,9423,O
D-amphetamine-induced,9423,B-CHEMICAL
DAT-mediated,9423,B-GENE-Y
DA,9423,B-CHEMICAL
release,9423,O
and,9423,O
2,9423,O
),9423,O
[,9423,B-CHEMICAL
(,9423,I-CHEMICAL
3,9423,I-CHEMICAL
),9423,I-CHEMICAL
H,9423,I-CHEMICAL
],9423,I-CHEMICAL
DA,9423,I-CHEMICAL
uptake,9423,O
and,9423,O
d-amphetamine-induced,9423,B-CHEMICAL
DAT-mediated,9423,B-GENE-Y
efflux,9423,O
can,9423,O
be,9423,O
separately,9423,O
modulated,9423,O
.,9423,O
Such,9424,O
agents,9424,O
may,9424,O
have,9424,O
therapeutic,9424,O
potential,9424,O
for,9424,O
the,9424,O
treatment,9424,O
of,9424,O
stimulant,9424,O
addiction,9424,O
",",9424,O
Parkinson,9424,O
's,9424,O
disease,9424,O
",",9424,O
and,9424,O
other,9424,O
psychiatric,9424,O
disorders,9424,O
.,9424,O
Enhanced,9425,O
beta2-adrenergic,9425,B-GENE-Y
receptor,9425,I-GENE-Y
(,9425,O
beta2AR,9425,B-GENE-Y
),9425,O
signaling,9425,O
by,9425,O
adeno-associated,9425,O
viral,9425,O
(,9425,O
AAV,9425,O
),9425,O
-mediated,9425,O
gene,9425,O
transfer,9425,O
.,9425,O
BACKGROUND,9426,O
:,9426,O
Beta2-adrenergic,9426,B-GENE-Y
receptors,9426,I-GENE-Y
(,9426,O
beta2AR,9426,B-GENE-Y
),9426,O
play,9426,O
important,9426,O
regulatory,9426,O
roles,9426,O
in,9426,O
a,9426,O
variety,9426,O
of,9426,O
cells,9426,O
and,9426,O
organ,9426,O
systems,9426,O
and,9426,O
are,9426,O
important,9426,O
therapeutic,9426,O
targets,9426,O
in,9426,O
the,9426,O
treatment,9426,O
of,9426,O
airway,9426,O
and,9426,O
cardiovascular,9426,O
disease,9426,O
.,9426,O
Prolonged,9427,O
use,9427,O
of,9427,O
beta-agonists,9427,O
results,9427,O
in,9427,O
tolerance,9427,O
secondary,9427,O
to,9427,O
receptor,9427,O
down-regulation,9427,O
resulting,9427,O
in,9427,O
reduced,9427,O
therapeutic,9427,O
efficiency,9427,O
.,9427,O
The,9428,O
purpose,9428,O
of,9428,O
this,9428,O
work,9428,O
is,9428,O
to,9428,O
evaluate,9428,O
the,9428,O
signaling,9428,O
capabilities,9428,O
of,9428,O
the,9428,O
beta2AR,9428,B-GENE-Y
expressed,9428,O
by,9428,O
a,9428,O
recombinant,9428,O
adeno-associated,9428,O
viral,9428,O
(,9428,O
AAV,9428,O
),9428,O
vector,9428,O
that,9428,O
also,9428,O
included,9428,O
an,9428,O
enhanced,9428,O
green,9428,O
fluorescent,9428,O
protein,9428,O
(,9428,O
EGFP,9428,O
),9428,O
gene,9428,O
(,9428,O
AAV-beta2AR/EGFP,9428,O
),9428,O
.,9428,O
RESULTS,9429,O
:,9429,O
By,9429,O
epifluorescence,9429,O
microscopy,9429,O
",",9429,O
approximately,9429,O
40,9429,O
%,9429,O
of,9429,O
infected,9429,O
HEK,9429,O
293,9429,O
cells,9429,O
demonstrated,9429,O
EGFP,9429,O
expression,9429,O
.,9429,O
beta2AR,9430,B-GENE-Y
density,9430,O
measured,9430,O
with,9430,O
[,9430,B-CHEMICAL
3H,9430,I-CHEMICAL
],9430,I-CHEMICAL
dihydroalprenolol,9430,I-CHEMICAL
(,9430,O
[,9430,B-CHEMICAL
3H,9430,I-CHEMICAL
],9430,I-CHEMICAL
DHA,9430,I-CHEMICAL
),9430,O
increased,9430,O
either,9430,O
13-,9430,O
or,9430,O
77-fold,9430,O
in,9430,O
infected,9430,O
cells,9430,O
compared,9430,O
to,9430,O
mock,9430,O
infected,9430,O
controls,9430,O
depending,9430,O
on,9430,O
the,9430,O
culture,9430,O
conditions,9430,O
used,9430,O
.,9430,O
The,9431,O
[,9431,B-CHEMICAL
3H,9431,I-CHEMICAL
],9431,I-CHEMICAL
DHA,9431,I-CHEMICAL
binding,9431,O
was,9431,O
to,9431,O
a,9431,O
single,9431,O
receptor,9431,O
population,9431,O
with,9431,O
a,9431,O
dissociation,9431,O
constant,9431,O
of,9431,O
0.42,9431,O
nM,9431,O
",",9431,O
as,9431,O
would,9431,O
be,9431,O
expected,9431,O
for,9431,O
wild-type,9431,O
beta2AR,9431,B-GENE-Y
.,9431,O
Agonist,9432,O
competition,9432,O
assays,9432,O
with,9432,O
[,9432,B-CHEMICAL
3H,9432,I-CHEMICAL
],9432,I-CHEMICAL
DHA,9432,I-CHEMICAL
showed,9432,O
the,9432,O
following,9432,O
rank,9432,O
order,9432,O
of,9432,O
potency,9432,O
:,9432,O
isoproterenol,9432,B-CHEMICAL
>,9432,O
epinephrine,9432,B-CHEMICAL
>,9432,O
norepinephrine,9432,B-CHEMICAL
",",9432,O
consistent,9432,O
with,9432,O
beta2AR,9432,B-GENE-Y
interaction,9432,O
.,9432,O
Isoproterenol-stimulated,9433,B-CHEMICAL
cyclic,9433,B-CHEMICAL
AMP,9433,I-CHEMICAL
levels,9433,O
were,9433,O
5-fold,9433,O
higher,9433,O
in,9433,O
infected,9433,O
cells,9433,O
compared,9433,O
to,9433,O
controls,9433,O
(,9433,O
314,9433,O
+/-,9433,O
43,9433,O
vs.,9433,O
63.4,9433,O
+/-,9433,O
9.6,9433,O
nmol/dish,9433,O
;,9433,O
n,9433,O
=,9433,O
3,9433,O
),9433,O
.,9433,O
Receptor,9434,O
trafficking,9434,O
demonstrated,9434,O
surface,9434,O
expression,9434,O
of,9434,O
beta2AR,9434,B-GENE-Y
with,9434,O
vehicle,9434,O
treatment,9434,O
and,9434,O
internalization,9434,O
following,9434,O
isoproterenol,9434,B-CHEMICAL
treatment,9434,O
.,9434,O
CONCLUSIONS,9435,O
:,9435,O
We,9435,O
conclude,9435,O
that,9435,O
HEK,9435,O
293,9435,O
cells,9435,O
infected,9435,O
with,9435,O
AAV-beta2AR/EGFP,9435,O
effectively,9435,O
express,9435,O
beta2AR,9435,B-GENE-Y
and,9435,O
that,9435,O
increased,9435,O
expression,9435,O
of,9435,O
these,9435,O
receptors,9435,O
results,9435,O
in,9435,O
enhanced,9435,O
beta2AR,9435,B-GENE-Y
signaling,9435,O
.,9435,O
This,9436,O
method,9436,O
of,9436,O
gene,9436,O
transfer,9436,O
may,9436,O
provide,9436,O
an,9436,O
important,9436,O
means,9436,O
to,9436,O
enhance,9436,O
function,9436,O
in,9436,O
in,9436,O
vivo,9436,O
systems,9436,O
.,9436,O
Update,9437,O
on,9437,O
rivastigmine,9437,B-CHEMICAL
.,9437,O
BACKGROUND,9438,O
:,9438,O
Rivastigmine,9438,B-CHEMICAL
is,9438,O
a,9438,O
carbamate,9438,B-CHEMICAL
drug,9438,O
designed,9438,O
to,9438,O
inhibit,9438,O
both,9438,O
acetylcholinesterase,9438,B-GENE-Y
and,9438,O
butyrylcholinesterase,9438,B-GENE-Y
by,9438,O
reversibly,9438,O
covalently,9438,O
bonding,9438,O
to,9438,O
these,9438,O
enzymes,9438,O
.,9438,O
Butyrylcholinesterase,9439,B-GENE-Y
in-creases,9439,O
as,9439,O
Alzheimer,9439,O
disease,9439,O
progresses,9439,O
",",9439,O
so,9439,O
its,9439,O
inhibition,9439,O
may,9439,O
become,9439,O
more,9439,O
important,9439,O
as,9439,O
the,9439,O
disease,9439,O
worsens,9439,O
.,9439,O
Metabolism,9440,O
of,9440,O
rivastigmine,9440,B-CHEMICAL
occurs,9440,O
at,9440,O
the,9440,O
synapse,9440,O
rather,9440,O
than,9440,O
at,9440,O
the,9440,O
liver,9440,O
and,9440,O
previous,9440,O
studies,9440,O
have,9440,O
demonstrated,9440,O
no,9440,O
drug-drug,9440,O
interactions,9440,O
.,9440,O
Rivastigmine,9441,B-CHEMICAL
has,9441,O
a,9441,O
half-life,9441,O
at,9441,O
the,9441,O
synapse,9441,O
of,9441,O
9,9441,O
hours,9441,O
allowing,9441,O
for,9441,O
bid,9441,O
dosing,9441,O
.,9441,O
REVIEW,9442,O
SUMMARY,9442,O
:,9442,O
Effective,9442,O
therapy,9442,O
requires,9442,O
up-titration,9442,O
from,9442,O
initial,9442,O
dosage,9442,O
of,9442,O
3,9442,O
mg/d,9442,O
to,9442,O
6,9442,O
mg/d,9442,O
with,9442,O
additional,9442,O
increases,9442,O
to,9442,O
9,9442,O
mg,9442,O
or,9442,O
12,9442,O
mg/d,9442,O
giving,9442,O
additional,9442,O
benefits,9442,O
in,9442,O
some,9442,O
patients,9442,O
.,9442,O
Beneficial,9443,O
effects,9443,O
with,9443,O
rivastigmine,9443,B-CHEMICAL
therapy,9443,O
in,9443,O
the,9443,O
functioning,9443,O
of,9443,O
activities,9443,O
of,9443,O
daily,9443,O
living,9443,O
",",9443,O
behavior,9443,O
",",9443,O
cognition,9443,O
",",9443,O
and,9443,O
global,9443,O
functioning,9443,O
have,9443,O
been,9443,O
demonstrated,9443,O
in,9443,O
patients,9443,O
with,9443,O
mild,9443,O
to,9443,O
moderate,9443,O
Alzheimer,9443,O
disease,9443,O
in,9443,O
4,9443,O
large,9443,O
double-blind,9443,O
",",9443,O
placebo-controlled,9443,O
multicenter,9443,O
clinical,9443,O
trials,9443,O
.,9443,O
Potential,9444,O
adverse,9444,O
effects,9444,O
of,9444,O
nausea,9444,O
",",9444,O
vomiting,9444,O
",",9444,O
or,9444,O
diarrhea,9444,O
in,9444,O
these,9444,O
original,9444,O
Alzheimer,9444,O
trials,9444,O
with,9444,O
rapid,9444,O
(,9444,O
every,9444,O
week,9444,O
),9444,O
dosage,9444,O
increases,9444,O
occurred,9444,O
in,9444,O
up,9444,O
to,9444,O
34,9444,O
%,9444,O
of,9444,O
patients,9444,O
and,9444,O
can,9444,O
be,9444,O
minimized,9444,O
by,9444,O
slower,9444,O
monthly,9444,O
up-titrations,9444,O
.,9444,O
Rivastigmine,9445,B-CHEMICAL
also,9445,O
was,9445,O
proven,9445,O
effective,9445,O
in,9445,O
decreasing,9445,O
psychiatric,9445,O
symptoms,9445,O
and,9445,O
cognitive,9445,O
deficits,9445,O
in,9445,O
a,9445,O
large,9445,O
double-blind,9445,O
",",9445,O
placebo-controlled,9445,O
trial,9445,O
in,9445,O
patients,9445,O
with,9445,O
diffuse,9445,O
Lewy,9445,O
body,9445,O
disease,9445,O
.,9445,O
Other,9446,O
studies,9446,O
have,9446,O
suggested,9446,O
that,9446,O
rivastigmine,9446,B-CHEMICAL
improves,9446,O
symptoms,9446,O
in,9446,O
nursing,9446,O
home,9446,O
patients,9446,O
with,9446,O
more,9446,O
severe,9446,O
stage,9446,O
Alzheimer,9446,O
disease,9446,O
",",9446,O
Parkinson,9446,O
dementia,9446,O
",",9446,O
and,9446,O
subcortical,9446,O
dementia,9446,O
.,9446,O
Follow-up,9447,O
studies,9447,O
have,9447,O
suggested,9447,O
that,9447,O
rivastigmine,9447,B-CHEMICAL
may,9447,O
delay,9447,O
disease,9447,O
progression,9447,O
and,9447,O
",",9447,O
in,9447,O
patients,9447,O
discontinuing,9447,O
the,9447,O
drug,9447,O
",",9447,O
no,9447,O
withdrawal,9447,O
effects,9447,O
were,9447,O
seen,9447,O
.,9447,O
CONCLUSION,9448,O
:,9448,O
Rivastigmine,9448,B-CHEMICAL
is,9448,O
an,9448,O
effective,9448,O
therapeutic,9448,O
agent,9448,O
for,9448,O
treating,9448,O
cognitive,9448,O
and,9448,O
behavioral,9448,O
symptoms,9448,O
in,9448,O
Alzheimer,9448,O
disease,9448,O
and,9448,O
diffuse,9448,O
Lewy,9448,O
body,9448,O
disease,9448,O
and,9448,O
may,9448,O
also,9448,O
have,9448,O
beneficial,9448,O
effects,9448,O
in,9448,O
vascular,9448,O
and,9448,O
Parkinson,9448,O
dementias,9448,O
.,9448,O
The,9449,O
therapeutic,9449,O
potential,9449,O
of,9449,O
allosteric,9449,O
ligands,9449,O
for,9449,O
free,9449,O
fatty,9449,B-CHEMICAL
acid,9449,I-CHEMICAL
sensitive,9449,O
GPCRs,9449,B-GENE-N
.,9449,O
G,9450,B-GENE-N
protein,9450,I-GENE-N
coupled,9450,I-GENE-N
receptors,9450,I-GENE-N
(,9450,O
GPCRs,9450,B-GENE-N
),9450,O
are,9450,O
the,9450,O
most,9450,O
historically,9450,O
successful,9450,O
therapeutic,9450,O
targets,9450,O
.,9450,O
Despite,9451,O
this,9451,O
success,9451,O
there,9451,O
are,9451,O
many,9451,O
important,9451,O
aspects,9451,O
of,9451,O
GPCR,9451,B-GENE-N
pharmacology,9451,O
and,9451,O
function,9451,O
that,9451,O
have,9451,O
yet,9451,O
to,9451,O
be,9451,O
exploited,9451,O
to,9451,O
their,9451,O
full,9451,O
therapeutic,9451,O
potential,9451,O
.,9451,O
One,9452,O
in,9452,O
particular,9452,O
that,9452,O
has,9452,O
been,9452,O
gaining,9452,O
attention,9452,O
in,9452,O
recent,9452,O
times,9452,O
is,9452,O
that,9452,O
of,9452,O
GPCR,9452,B-GENE-N
ligands,9452,O
that,9452,O
bind,9452,O
to,9452,O
allosteric,9452,O
sites,9452,O
on,9452,O
the,9452,O
receptor,9452,O
distinct,9452,O
from,9452,O
the,9452,O
orthosteric,9452,O
site,9452,O
of,9452,O
the,9452,O
endogenous,9452,O
ligand,9452,O
.,9452,O
As,9453,O
therapeutics,9453,O
",",9453,O
allosteric,9453,O
ligands,9453,O
possess,9453,O
many,9453,O
theoretical,9453,O
advantages,9453,O
over,9453,O
their,9453,O
orthosteric,9453,O
counterparts,9453,O
",",9453,O
including,9453,O
more,9453,O
complex,9453,O
modes,9453,O
of,9453,O
action,9453,O
",",9453,O
improved,9453,O
safety,9453,O
",",9453,O
more,9453,O
physiologically,9453,O
appropriate,9453,O
responses,9453,O
",",9453,O
better,9453,O
target,9453,O
selectivity,9453,O
",",9453,O
and,9453,O
reduced,9453,O
likelihood,9453,O
of,9453,O
desensitisation,9453,O
and,9453,O
tachyphylaxis,9453,O
.,9453,O
Despite,9454,O
these,9454,O
advantages,9454,O
",",9454,O
the,9454,O
development,9454,O
of,9454,O
allosteric,9454,O
ligands,9454,O
is,9454,O
often,9454,O
difficult,9454,O
from,9454,O
a,9454,O
medicinal,9454,O
chemistry,9454,O
standpoint,9454,O
due,9454,O
to,9454,O
the,9454,O
more,9454,O
complex,9454,O
challenge,9454,O
of,9454,O
identifying,9454,O
allosteric,9454,O
leads,9454,O
and,9454,O
their,9454,O
often,9454,O
flat,9454,O
or,9454,O
confusing,9454,O
SAR,9454,O
.,9454,O
The,9455,O
present,9455,O
review,9455,O
will,9455,O
consider,9455,O
the,9455,O
advantages,9455,O
and,9455,O
challenges,9455,O
associated,9455,O
with,9455,O
allosteric,9455,O
GPCR,9455,B-GENE-N
ligands,9455,O
",",9455,O
and,9455,O
examine,9455,O
how,9455,O
the,9455,O
particular,9455,O
properties,9455,O
of,9455,O
these,9455,O
ligands,9455,O
may,9455,O
be,9455,O
exploited,9455,O
to,9455,O
uncover,9455,O
the,9455,O
therapeutic,9455,O
potential,9455,O
for,9455,O
free,9455,O
fatty,9455,B-CHEMICAL
acid,9455,I-CHEMICAL
sensitive,9455,O
GPCRs,9455,B-GENE-N
.,9455,O
Chemokine,9456,B-GENE-N
expression,9456,O
is,9456,O
upregulated,9456,O
in,9456,O
chondrocytes,9456,O
in,9456,O
diabetic,9456,O
fracture,9456,O
healing,9456,O
.,9456,O
Chemokines,9457,B-GENE-N
are,9457,O
thought,9457,O
to,9457,O
play,9457,O
an,9457,O
important,9457,O
role,9457,O
in,9457,O
several,9457,O
aspects,9457,O
of,9457,O
bone,9457,O
metabolism,9457,O
including,9457,O
the,9457,O
recruitment,9457,O
of,9457,O
leukocytes,9457,O
and,9457,O
the,9457,O
formation,9457,O
of,9457,O
osteoclasts,9457,O
.,9457,O
We,9458,O
investigated,9458,O
the,9458,O
impact,9458,O
of,9458,O
diabetes,9458,O
on,9458,O
chemokine,9458,B-GENE-N
expression,9458,O
in,9458,O
normal,9458,O
and,9458,O
diabetic,9458,O
fracture,9458,O
healing,9458,O
.,9458,O
Fracture,9459,O
of,9459,O
the,9459,O
femur,9459,O
was,9459,O
performed,9459,O
in,9459,O
streptozotocin-induced,9459,B-CHEMICAL
diabetic,9459,O
and,9459,O
matched,9459,O
normoglycemic,9459,O
control,9459,O
mice,9459,O
.,9459,O
Microarray,9460,O
analysis,9460,O
was,9460,O
carried,9460,O
out,9460,O
and,9460,O
chemokine,9460,B-GENE-N
mRNA,9460,O
levels,9460,O
in,9460,O
vivo,9460,O
were,9460,O
assessed,9460,O
.,9460,O
CCL4,9461,B-GENE-Y
were,9461,O
examined,9461,O
in,9461,O
fracture,9461,O
calluses,9461,O
by,9461,O
immunohistochemistry,9461,O
and,9461,O
the,9461,O
role,9461,O
of,9461,O
TNF,9461,B-GENE-N
in,9461,O
diabetes-enhanced,9461,O
expression,9461,O
was,9461,O
investigated,9461,O
by,9461,O
treatment,9461,O
of,9461,O
animals,9461,O
with,9461,O
the,9461,O
TNF-specific,9461,B-GENE-N
inhibitor,9461,O
",",9461,O
pegsunercept,9461,O
.,9461,O
In,9462,O
vitro,9462,O
studies,9462,O
were,9462,O
conducted,9462,O
with,9462,O
ATDC5,9462,O
chondrocytes,9462,O
.,9462,O
Diabetes,9463,O
significantly,9463,O
upregulated,9463,O
mRNA,9463,O
levels,9463,O
of,9463,O
several,9463,O
chemokines,9463,B-GENE-N
in,9463,O
vivo,9463,O
including,9463,O
CCL4,9463,B-GENE-Y
",",9463,O
CCL8,9463,B-GENE-Y
",",9463,O
CCL6,9463,B-GENE-Y
",",9463,O
CCL11,9463,B-GENE-Y
",",9463,O
CCL20,9463,B-GENE-Y
",",9463,O
CCL24,9463,B-GENE-Y
",",9463,O
CXCL2,9463,B-GENE-Y
",",9463,O
CXCL5,9463,B-GENE-Y
and,9463,O
chemokine,9463,B-GENE-N
receptors,9463,I-GENE-N
CCR5,9463,B-GENE-Y
and,9463,O
CXCR4,9463,B-GENE-Y
.,9463,O
Chondrocytes,9464,O
were,9464,O
identified,9464,O
as,9464,O
a,9464,O
significant,9464,O
source,9464,O
of,9464,O
CCL4,9464,B-GENE-Y
and,9464,O
its,9464,O
expression,9464,O
in,9464,O
diabetic,9464,O
fractures,9464,O
was,9464,O
dependent,9464,O
on,9464,O
TNF,9464,B-GENE-N
(,9464,O
P,9464,O
<,9464,O
0.05,9464,O
),9464,O
.,9464,O
TNF-α,9465,B-GENE-Y
significantly,9465,O
increased,9465,O
mRNA,9465,O
levels,9465,O
of,9465,O
several,9465,O
chemokines,9465,B-GENE-N
in,9465,O
vitro,9465,O
which,9465,O
were,9465,O
knocked,9465,O
down,9465,O
with,9465,O
FOXO1,9465,B-GENE-Y
siRNA,9465,O
(,9465,O
P,9465,O
<,9465,O
0.05,9465,O
),9465,O
.,9465,O
CCL4,9466,B-GENE-Y
expression,9466,O
at,9466,O
the,9466,O
mRNA,9466,O
and,9466,O
proteins,9466,O
levels,9466,O
was,9466,O
induced,9466,O
by,9466,O
FOXO1,9466,B-GENE-Y
over-expression,9466,O
and,9466,O
reduced,9466,O
by,9466,O
FOXO1,9466,B-GENE-Y
knockdown,9466,O
.,9466,O
The,9467,O
current,9467,O
studies,9467,O
point,9467,O
to,9467,O
the,9467,O
importance,9467,O
of,9467,O
TNF-α,9467,B-GENE-Y
as,9467,O
a,9467,O
mechanism,9467,O
for,9467,O
diabetes,9467,O
enhanced,9467,O
chemokine,9467,B-GENE-N
expression,9467,O
by,9467,O
chondrocytes,9467,O
",",9467,O
which,9467,O
may,9467,O
contribute,9467,O
to,9467,O
the,9467,O
accelerated,9467,O
loss,9467,O
of,9467,O
cartilage,9467,O
observed,9467,O
in,9467,O
diabetic,9467,O
fracture,9467,O
healing,9467,O
.,9467,O
Moreover,9468,O
",",9468,O
in,9468,O
vitro,9468,O
results,9468,O
point,9468,O
to,9468,O
FOXO1,9468,B-GENE-Y
as,9468,O
a,9468,O
potentially,9468,O
important,9468,O
transcription,9468,O
factor,9468,O
in,9468,O
mediating,9468,O
this,9468,O
effect,9468,O
.,9468,O
Allelopathic,9469,O
activity,9469,O
studies,9469,O
of,9469,O
Mikania,9469,O
scandens,9469,O
.,9469,O
Preliminary,9470,O
investigation,9470,O
of,9470,O
a,9470,O
number,9470,O
of,9470,O
plant,9470,O
extracts,9470,O
for,9470,O
allelopathic,9470,O
activity,9470,O
using,9470,O
seed,9470,O
germination,9470,O
inhibition,9470,O
bioassay,9470,O
showed,9470,O
a,9470,O
promising,9470,O
activity,9470,O
of,9470,O
the,9470,O
water,9470,O
extract,9470,O
of,9470,O
the,9470,O
aerial,9470,O
parts,9470,O
of,9470,O
Mikania,9470,O
scandens,9470,O
.,9470,O
Activity-guided,9471,O
fractionation,9471,O
of,9471,O
the,9471,O
M.,9471,O
scandens,9471,O
extract,9471,O
led,9471,O
to,9471,O
the,9471,O
isolation,9471,O
of,9471,O
the,9471,O
highly,9471,O
allelopathic,9471,O
active,9471,O
compound,9471,O
mikanolide,9471,B-CHEMICAL
",",9471,O
with,9471,O
minimum,9471,O
inhibitory,9471,O
concentration,9471,O
of,9471,O
0.083,9471,O
µM,9471,O
mL,9471,O
(,9471,O
-1,9471,O
),9471,O
.,9471,O
As,9472,O
M.,9472,O
scandens,9472,O
is,9472,O
a,9472,O
highly,9472,O
abundant,9472,O
invasive,9472,O
plant,9472,O
in,9472,O
Sri,9472,O
Lanka,9472,O
and,9472,O
other,9472,O
South,9472,O
Asian,9472,O
countries,9472,O
",",9472,O
this,9472,O
plant,9472,O
could,9472,O
be,9472,O
developed,9472,O
as,9472,O
an,9472,O
environment,9472,O
friendly,9472,O
natural,9472,O
herbicide,9472,O
",",9472,O
either,9472,O
in,9472,O
crude,9472,O
form,9472,O
as,9472,O
shredded,9472,O
plant,9472,O
material,9472,O
or,9472,O
as,9472,O
pure,9472,O
mikanolide,9472,B-CHEMICAL
",",9472,O
which,9472,O
is,9472,O
the,9472,O
major,9472,O
constituent,9472,O
(,9472,O
∼0.02,9472,O
%,9472,O
),9472,O
in,9472,O
the,9472,O
plant,9472,O
.,9472,O
Glioma,9473,O
cell,9473,O
sensitivity,9473,O
to,9473,O
topotecan,9473,B-CHEMICAL
:,9473,O
the,9473,O
role,9473,O
of,9473,O
p53,9473,B-GENE-Y
and,9473,O
topotecan-induced,9473,B-CHEMICAL
DNA,9473,O
damage,9473,O
.,9473,O
Topotecan,9474,B-CHEMICAL
is,9474,O
a,9474,O
topoisomerase,9474,B-GENE-Y
I,9474,I-GENE-Y
inhibitor,9474,O
which,9474,O
is,9474,O
currently,9474,O
evaluated,9474,O
as,9474,O
an,9474,O
adjuvant,9474,O
agent,9474,O
for,9474,O
malignant,9474,O
glioma,9474,O
.,9474,O
Here,9475,O
",",9475,O
we,9475,O
analysed,9475,O
the,9475,O
effects,9475,O
of,9475,O
topotecan,9475,B-CHEMICAL
on,9475,O
12,9475,O
human,9475,O
malignant,9475,O
glioma,9475,O
cell,9475,O
lines,9475,O
in,9475,O
vitro,9475,O
.,9475,O
All,9476,O
cell,9476,O
lines,9476,O
expressed,9476,O
topoisomerase,9476,B-GENE-Y
I,9476,I-GENE-Y
mRNA,9476,O
.,9476,O
High,9477,O
p53,9477,B-GENE-Y
protein,9477,O
levels,9477,O
",",9477,O
but,9477,O
not,9477,O
genetic,9477,O
or,9477,O
functional,9477,O
p53,9477,B-GENE-Y
status,9477,O
",",9477,O
were,9477,O
associated,9477,O
with,9477,O
increased,9477,O
topotecan-induced,9477,B-CHEMICAL
DNA/topoisomerase,9477,O
I,9477,I-GENE-Y
complex,9477,O
formation,9477,O
.,9477,O
Neither,9478,O
functional,9478,O
p53,9478,B-GENE-Y
status,9478,O
",",9478,O
nor,9478,O
p53,9478,B-GENE-Y
protein,9478,O
levels,9478,O
",",9478,O
nor,9478,O
complex,9478,O
formation,9478,O
predicted,9478,O
topotecan-induced,9478,B-CHEMICAL
growth,9478,O
inhibition,9478,O
.,9478,O
We,9479,O
thus,9479,O
confirm,9479,O
a,9479,O
possible,9479,O
role,9479,O
for,9479,O
p53,9479,B-GENE-Y
protein,9479,O
in,9479,O
modulating,9479,O
topoisomerase,9479,B-GENE-Y
I,9479,I-GENE-Y
activity,9479,O
but,9479,O
conclude,9479,O
that,9479,O
the,9479,O
major,9479,O
molecular,9479,O
determinants,9479,O
of,9479,O
topotecan,9479,B-CHEMICAL
sensitivity,9479,O
in,9479,O
glioma,9479,O
cells,9479,O
await,9479,O
identification,9479,O
.,9479,O
Binding,9480,O
site,9480,O
of,9480,O
amiloride,9480,B-CHEMICAL
to,9480,O
urokinase,9480,B-GENE-Y
plasminogen,9480,I-GENE-Y
activator,9480,I-GENE-Y
depends,9480,O
on,9480,O
species,9480,O
.,9480,O
A,9481,O
novel,9481,O
drug,9481,O
candidate,9481,O
is,9481,O
checked,9481,O
on,9481,O
its,9481,O
potency,9481,O
on,9481,O
animal,9481,O
models,9481,O
before,9481,O
it,9481,O
can,9481,O
advance,9481,O
to,9481,O
human,9481,O
phase,9481,O
of,9481,O
the,9481,O
research,9481,O
.,9481,O
Usually,9482,O
negative,9482,O
results,9482,O
on,9482,O
animal,9482,O
phase,9482,O
disqualify,9482,O
it,9482,O
.,9482,O
Targeting,9483,O
specific,9483,O
enzymes,9483,O
by,9483,O
small,9483,O
chemicals,9483,O
raises,9483,O
the,9483,O
question,9483,O
about,9483,O
the,9483,O
appropriateness,9483,O
of,9483,O
this,9483,O
approach,9483,O
.,9483,O
As,9484,O
an,9484,O
example,9484,O
",",9484,O
the,9484,O
urokinase,9484,B-GENE-Y
(,9484,O
uPA,9484,B-GENE-Y
),9484,O
is,9484,O
recognized,9484,O
as,9484,O
an,9484,O
important,9484,O
enzyme,9484,O
responsible,9484,O
for,9484,O
cancer,9484,O
metastasis,9484,O
and,9484,O
angiogenesis,9484,O
.,9484,O
It,9485,O
is,9485,O
therefore,9485,O
important,9485,O
to,9485,O
ask,9485,O
the,9485,O
question,9485,O
if,9485,O
a,9485,O
small,9485,O
chemical,9485,O
will,9485,O
inhibit,9485,O
uPA,9485,B-GENE-N
of,9485,O
different,9485,O
species,9485,O
with,9485,O
the,9485,O
same,9485,O
or,9485,O
different,9485,O
potency,9485,O
.,9485,O
Using,9486,O
DNA,9486,O
sequence,9486,O
and,9486,O
known,9486,O
structure,9486,O
of,9486,O
uPA,9486,B-GENE-N
we,9486,O
have,9486,O
modeled,9486,O
3D,9486,O
structures,9486,O
of,9486,O
uPAs,9486,B-GENE-N
for,9486,O
several,9486,O
different,9486,O
species,9486,O
.,9486,O
By,9487,O
theoretical,9487,O
calculations,9487,O
we,9487,O
have,9487,O
determined,9487,O
most,9487,O
probable,9487,O
structure,9487,O
of,9487,O
amiloride/uPAs,9487,B-CHEMICAL
complexes,9487,O
.,9487,O
Catalytic,9488,O
triad,9488,O
(,9488,O
B57,9488,O
",",9488,O
B102,9488,O
",",9488,O
B195,9488,O
),9488,O
and,9488,O
specificity,9488,O
pocket,9488,O
(,9488,O
B187-B197,9488,O
",",9488,O
B212-B229,9488,O
),9488,O
are,9488,O
highly,9488,O
conserved,9488,O
in,9488,O
all,9488,O
cases,9488,O
",",9488,O
and,9488,O
are,9488,O
the,9488,O
regions,9488,O
responsible,9488,O
for,9488,O
proteolytic,9488,O
activity,9488,O
and,9488,O
recognition,9488,O
of,9488,O
the,9488,O
substrate,9488,O
.,9488,O
Significant,9489,O
differences,9489,O
were,9489,O
observed,9489,O
in,9489,O
a,9489,O
different,9489,O
region,9489,O
(,9489,O
loop,9489,O
B93-B101,9489,O
),9489,O
",",9489,O
that,9489,O
we,9489,O
identified,9489,O
as,9489,O
binding,9489,O
site,9489,O
of,9489,O
amiloride,9489,B-CHEMICAL
to,9489,O
the,9489,O
tissue,9489,B-GENE-Y
plasminogen,9489,I-GENE-Y
activator,9489,I-GENE-Y
(,9489,O
tPA,9489,B-GENE-Y
),9489,O
.,9489,O
Although,9490,O
tPA,9490,B-GENE-Y
shares,9490,O
the,9490,O
same,9490,O
function,9490,O
of,9490,O
activating,9490,O
plasminogen,9490,O
and,9490,O
it,9490,O
is,9490,O
structurally,9490,O
similar,9490,O
to,9490,O
uPA,9490,B-GENE-Y
.,9490,O
Amiloride,9491,B-CHEMICAL
is,9491,O
a,9491,O
specific,9491,O
inhibitor,9491,O
of,9491,O
uPA,9491,B-GENE-N
but,9491,O
does,9491,O
not,9491,O
inhibit,9491,O
tPA,9491,B-GENE-Y
.,9491,O
Our,9492,O
study,9492,O
shows,9492,O
that,9492,O
predicted,9492,O
position,9492,O
of,9492,O
amiloride,9492,B-CHEMICAL
depends,9492,O
on,9492,O
species,9492,O
and,9492,O
in,9492,O
some,9492,O
cases,9492,O
was,9492,O
located,9492,O
",",9492,O
as,9492,O
expected,9492,O
",",9492,O
in,9492,O
the,9492,O
specificity,9492,O
pocket,9492,O
",",9492,O
but,9492,O
in,9492,O
the,9492,O
other,9492,O
cases,9492,O
close,9492,O
to,9492,O
the,9492,O
loop,9492,O
B93-B101,9492,O
.,9492,O
This,9493,O
location,9493,O
could,9493,O
weaken,9493,O
affinity,9493,O
of,9493,O
binding,9493,O
or,9493,O
prevent,9493,O
inhibition,9493,O
of,9493,O
uPA,9493,B-GENE-Y
.,9493,O
Therefore,9494,O
",",9494,O
drug,9494,O
screening,9494,O
and,9494,O
elimination,9494,O
process,9494,O
based,9494,O
solely,9494,O
on,9494,O
animal,9494,O
study,9494,O
",",9494,O
without,9494,O
careful,9494,O
structural,9494,O
analysis,9494,O
",",9494,O
could,9494,O
lead,9494,O
to,9494,O
the,9494,O
elimination,9494,O
of,9494,O
potential,9494,O
drugs,9494,O
for,9494,O
humans,9494,O
.,9494,O
Threshold,9495,O
concentrations,9495,O
of,9495,O
endothelin-1,9495,B-GENE-Y
:,9495,O
the,9495,O
effects,9495,O
on,9495,O
contractions,9495,O
induced,9495,O
by,9495,O
5-hydroxytryptamine,9495,B-CHEMICAL
in,9495,O
isolated,9495,O
rat,9495,O
cerebral,9495,O
and,9495,O
mesenteric,9495,O
arteries,9495,O
.,9495,O
This,9496,O
study,9496,O
compares,9496,O
the,9496,O
effects,9496,O
of,9496,O
threshold,9496,O
concentrations,9496,O
of,9496,O
endothelin-1,9496,B-GENE-Y
in,9496,O
isolated,9496,O
rat,9496,O
basilar,9496,O
arteries,9496,O
with,9496,O
those,9496,O
in,9496,O
mesenteric,9496,O
arterial,9496,O
branches,9496,O
and,9496,O
investigates,9496,O
the,9496,O
mechanisms,9496,O
of,9496,O
inhibitory,9496,O
and,9496,O
potentiating,9496,O
endothelin-1-effects,9496,B-GENE-Y
.,9496,O
In,9497,O
basilar,9497,O
arteries,9497,O
",",9497,O
endothelin-1,9497,B-GENE-Y
reduces,9497,O
the,9497,O
contractions,9497,O
induced,9497,O
by,9497,O
5-hydroxytryptamine,9497,B-CHEMICAL
(,9497,O
5-HT,9497,B-CHEMICAL
),9497,O
",",9497,O
by,9497,O
the,9497,O
thromboxane,9497,B-CHEMICAL
A2,9497,I-CHEMICAL
agonist,9497,O
U46619,9497,B-CHEMICAL
",",9497,O
and,9497,O
by,9497,O
vasopressin,9497,B-GENE-Y
.,9497,O
The,9498,O
inhibitory,9498,O
effect,9498,O
of,9498,O
endothelin-1,9498,B-GENE-Y
on,9498,O
the,9498,O
contraction,9498,O
induced,9498,O
by,9498,O
5-HT,9498,B-CHEMICAL
is,9498,O
abolished,9498,O
by,9498,O
deendothelialization,9498,O
",",9498,O
by,9498,O
the,9498,O
endothelin,9498,B-GENE-Y
ET,9498,I-GENE-Y
(,9498,I-GENE-Y
B,9498,I-GENE-Y
),9498,I-GENE-Y
receptor,9498,I-GENE-Y
antagonist,9498,O
RES,9498,B-CHEMICAL
701-1,9498,I-CHEMICAL
",",9498,O
by,9498,O
indomethacin,9498,B-CHEMICAL
",",9498,O
or,9498,O
by,9498,O
glibenclamide,9498,B-CHEMICAL
.,9498,O
In,9499,O
mesenteric,9499,O
arteries,9499,O
",",9499,O
endothelin-1,9499,B-GENE-Y
potentiates,9499,O
the,9499,O
contractile,9499,O
effects,9499,O
of,9499,O
5-HT,9499,B-CHEMICAL
",",9499,O
U46619,9499,B-CHEMICAL
",",9499,O
and,9499,O
vasopressin,9499,B-GENE-Y
.,9499,O
The,9500,O
potentiation,9500,O
of,9500,O
the,9500,O
contractile,9500,O
effect,9500,O
induced,9500,O
by,9500,O
5-HT,9500,B-CHEMICAL
is,9500,O
only,9500,O
somewhat,9500,O
modified,9500,O
by,9500,O
deendothelialization,9500,O
",",9500,O
but,9500,O
abolished,9500,O
by,9500,O
the,9500,O
thromboxane,9500,B-GENE-Y
A2,9500,I-GENE-Y
receptor,9500,I-GENE-Y
antagonists,9500,O
GR32191,9500,B-CHEMICAL
and,9500,O
ridogrel,9500,B-CHEMICAL
.,9500,O
U46619,9501,B-CHEMICAL
potentiates,9501,O
the,9501,O
5-HT-effect,9501,B-CHEMICAL
in,9501,O
mesenteric,9501,O
arteries,9501,O
.,9501,O
Thus,9502,O
",",9502,O
though,9502,O
the,9502,O
contractile,9502,O
endothelin,9502,B-GENE-N
ET,9502,I-GENE-N
(,9502,I-GENE-N
A,9502,I-GENE-N
),9502,I-GENE-N
receptors,9502,I-GENE-N
were,9502,O
not,9502,O
blocked,9502,O
",",9502,O
threshold,9502,O
concentrations,9502,O
of,9502,O
endothelin-1,9502,B-GENE-N
inhibited,9502,O
contractile,9502,O
effects,9502,O
in,9502,O
the,9502,O
rat,9502,O
basilar,9502,O
artery,9502,O
via,9502,O
activation,9502,O
of,9502,O
endothelial,9502,B-GENE-Y
ET,9502,I-GENE-Y
(,9502,I-GENE-Y
B,9502,I-GENE-Y
),9502,I-GENE-Y
receptors,9502,I-GENE-Y
.,9502,O
Prostaglandins,9503,B-CHEMICAL
and,9503,O
ATP-sensitive,9503,B-GENE-N
K+,9503,I-GENE-N
channels,9503,I-GENE-N
are,9503,O
involved,9503,O
in,9503,O
this,9503,O
inhibitory,9503,O
action,9503,O
.,9503,O
In,9504,O
contrast,9504,O
",",9504,O
endothelin-1,9504,B-GENE-N
potentiates,9504,O
contractile,9504,O
actions,9504,O
in,9504,O
mesenteric,9504,O
arteries,9504,O
via,9504,O
the,9504,O
release,9504,O
of,9504,O
endogeneous,9504,O
thromboxane,9504,B-CHEMICAL
A2,9504,I-CHEMICAL
from,9504,O
non-endothelial,9504,O
cells,9504,O
.,9504,O
The,9505,O
study,9505,O
points,9505,O
out,9505,O
the,9505,O
completely,9505,O
different,9505,O
role,9505,O
of,9505,O
the,9505,O
endothelium,9505,O
in,9505,O
combined,9505,O
effects,9505,O
of,9505,O
endothelin-1,9505,B-GENE-Y
between,9505,O
cerebral,9505,O
and,9505,O
mesenteric,9505,O
arteries,9505,O
.,9505,O
ABCA1,9506,B-GENE-Y
single,9506,O
nucleotide,9506,B-CHEMICAL
polymorphisms,9506,O
on,9506,O
high-density,9506,B-GENE-N
lipoprotein-cholesterol,9506,O
and,9506,O
overweight,9506,O
:,9506,O
the,9506,O
D.E.S.I.R,9506,O
.,9506,O
study,9507,O
.,9507,O
The,9508,O
adenosine,9508,B-GENE-Y
triphosphate-binding,9508,I-GENE-Y
cassette,9508,I-GENE-Y
A1,9508,I-GENE-Y
(,9508,O
ABCA1,9508,B-GENE-Y
),9508,O
gene,9508,O
plays,9508,O
a,9508,O
key,9508,O
role,9508,O
in,9508,O
reverse,9508,O
cholesterol,9508,B-CHEMICAL
transport,9508,O
.,9508,O
Some,9509,O
ABCA1,9509,B-GENE-Y
gene,9509,O
polymorphisms,9509,O
have,9509,O
been,9509,O
associated,9509,O
with,9509,O
high-density,9509,B-GENE-N
lipoprotein-cholesterol,9509,O
(,9509,O
HDL-C,9509,B-GENE-N
),9509,O
concentrations,9509,O
.,9509,O
The,9510,O
aim,9510,O
of,9510,O
this,9510,O
study,9510,O
was,9510,O
to,9510,O
assess,9510,O
the,9510,O
effect,9510,O
of,9510,O
three,9510,O
polymorphisms,9510,O
",",9510,O
C69T,9510,B-GENE-N
",",9510,O
G378C,9510,B-GENE-N
",",9510,O
and,9510,O
G1051A,9510,B-GENE-N
(,9510,O
R219K,9510,B-GENE-N
),9510,O
",",9510,O
on,9510,O
HDL-C,9510,B-GENE-N
levels,9510,O
and,9510,O
their,9510,O
interaction,9510,O
with,9510,O
BMI,9510,O
in,9510,O
more,9510,O
than,9510,O
5000,9510,O
French,9510,O
whites,9510,O
from,9510,O
the,9510,O
D.E.S.I.R,9510,O
.,9510,O
(,9511,O
Data,9511,O
from,9511,O
an,9511,O
Epidemiological,9511,O
Study,9511,O
on,9511,O
the,9511,O
Insulin,9511,B-GENE-Y
Resistance,9511,O
syndrome,9511,O
),9511,O
cohort,9511,O
study,9511,O
.,9511,O
The,9512,O
T,9512,O
allele,9512,O
of,9512,O
the,9512,O
C69T,9512,B-GENE-N
single,9512,O
nucleotide,9512,O
polymorphism,9512,O
(,9512,O
SNP,9512,O
),9512,O
was,9512,O
associated,9512,O
with,9512,O
higher,9512,O
HDL-C,9512,B-GENE-N
levels,9512,O
in,9512,O
normal-weight,9512,O
men,9512,O
(,9512,O
BMI,9512,O
<,9512,O
25,9512,O
kg/m,9512,O
(,9512,O
2,9512,O
),9512,O
),9512,O
.,9512,O
The,9513,O
C,9513,O
allele,9513,O
of,9513,O
the,9513,O
G378C,9513,B-GENE-N
SNP,9513,O
was,9513,O
associated,9513,O
with,9513,O
lower,9513,O
HDL-C,9513,B-GENE-N
in,9513,O
overweight,9513,O
subjects,9513,O
(,9513,O
BMI,9513,O
>,9513,O
or,9513,O
=25,9513,O
kg/m,9513,O
(,9513,O
2,9513,O
),9513,O
),9513,O
.,9513,O
For,9514,O
the,9514,O
G1051A,9514,B-GENE-N
SNP,9514,O
",",9514,O
in,9514,O
the,9514,O
normal-weight,9514,O
group,9514,O
",",9514,O
the,9514,O
minor,9514,O
A,9514,O
allele,9514,O
was,9514,O
significantly,9514,O
associated,9514,O
with,9514,O
higher,9514,O
HDL-C,9514,B-GENE-N
levels,9514,O
.,9514,O
In,9515,O
contrast,9515,O
",",9515,O
in,9515,O
overweight,9515,O
people,9515,O
",",9515,O
the,9515,O
minor,9515,O
allele,9515,O
was,9515,O
associated,9515,O
with,9515,O
lower,9515,O
HDL-C,9515,B-GENE-N
levels,9515,O
.,9515,O
After,9516,O
accounting,9516,O
for,9516,O
multiple,9516,O
testing,9516,O
",",9516,O
empiric,9516,O
p,9516,O
values,9516,O
remained,9516,O
significant,9516,O
for,9516,O
the,9516,O
associations,9516,O
between,9516,O
G378C,9516,B-GENE-N
SNP,9516,O
and,9516,O
HDL-C,9516,B-GENE-N
in,9516,O
the,9516,O
overweight,9516,O
group,9516,O
and,9516,O
between,9516,O
G1051A,9516,B-GENE-N
SNP,9516,O
and,9516,O
HDL-C,9516,B-GENE-N
in,9516,O
the,9516,O
normal-weight,9516,O
group,9516,O
.,9516,O
This,9517,O
study,9517,O
suggests,9517,O
that,9517,O
ABCA1,9517,B-GENE-Y
gene,9517,O
polymorphisms,9517,O
modulate,9517,O
HDL-C,9517,B-GENE-N
concentrations,9517,O
",",9517,O
in,9517,O
interaction,9517,O
with,9517,O
BMI,9517,O
",",9517,O
and,9517,O
",",9517,O
thus,9517,O
",",9517,O
they,9517,O
might,9517,O
influence,9517,O
cardiovascular,9517,O
risk,9517,O
in,9517,O
the,9517,O
general,9517,O
population,9517,O
.,9517,O
Metformin,9518,B-CHEMICAL
and,9518,O
Sulfonylureas,9518,B-CHEMICAL
in,9518,O
Relation,9518,O
to,9518,O
Cancer,9518,O
Risk,9518,O
in,9518,O
Type,9518,O
II,9518,O
Diabetes,9518,O
Patients,9518,O
:,9518,O
A,9518,O
Meta-analysis,9518,O
using,9518,O
primary,9518,O
data,9518,O
of,9518,O
published,9518,O
studies,9518,O
.,9518,O
INTRODUCTION,9519,O
:,9519,O
Accumulating,9519,O
evidence,9519,O
suggests,9519,O
that,9519,O
patients,9519,O
with,9519,O
type,9519,O
2,9519,O
diabetes,9519,O
mellitus,9519,O
(,9519,O
T2DM,9519,O
),9519,O
and,9519,O
hyperinsulinemia,9519,O
are,9519,O
at,9519,O
increased,9519,O
risk,9519,O
for,9519,O
developing,9519,O
malignancies,9519,O
.,9519,O
It,9520,O
remains,9520,O
to,9520,O
be,9520,O
fully,9520,O
elucidated,9520,O
whether,9520,O
use,9520,O
of,9520,O
metformin,9520,B-CHEMICAL
",",9520,O
an,9520,O
insulin,9520,B-GENE-Y
sensitizer,9520,O
",",9520,O
and/or,9520,O
sulfonylureas,9520,B-CHEMICAL
",",9520,O
insulin,9520,B-GENE-Y
secretagogues,9520,O
",",9520,O
affect,9520,O
cancer,9520,O
incidence,9520,O
in,9520,O
subjects,9520,O
with,9520,O
T2DM,9520,O
.,9520,O
MATERIAL,9521,O
&,9521,O
METHODS,9521,O
:,9521,O
We,9521,O
performed,9521,O
a,9521,O
meta-analysis,9521,O
using,9521,O
PubMed,9521,O
",",9521,O
of,9521,O
randomized,9521,O
control,9521,O
trials,9521,O
(,9521,O
RCTs,9521,O
),9521,O
",",9521,O
cohorts,9521,O
",",9521,O
and,9521,O
case-control,9521,O
studies,9521,O
published,9521,O
through,9521,O
July,9521,O
2012,9521,O
that,9521,O
assess,9521,O
effects,9521,O
of,9521,O
metformin,9521,B-CHEMICAL
and/or,9521,O
sulfonylurea,9521,B-CHEMICAL
sulfonylureas,9521,B-CHEMICAL
on,9521,O
cancer,9521,O
risk,9521,O
at,9521,O
any,9521,O
site,9521,O
",",9521,O
in,9521,O
subjects,9521,O
with,9521,O
T2DM,9521,O
.,9521,O
Fixed,9522,O
and,9522,O
random,9522,O
effects,9522,O
meta-analysis,9522,O
models,9522,O
were,9522,O
used,9522,O
",",9522,O
and,9522,O
the,9522,O
effect,9522,O
size,9522,O
was,9522,O
summarized,9522,O
as,9522,O
relative,9522,O
risk,9522,O
(,9522,O
RR,9522,O
),9522,O
for,9522,O
RCTs/cohorts,9522,O
and,9522,O
as,9522,O
odds,9522,O
ratio,9522,O
(,9522,O
OR,9522,O
),9522,O
for,9522,O
the,9522,O
case-control,9522,O
studies,9522,O
.,9522,O
RESULTS,9523,O
:,9523,O
Analysis,9523,O
of,9523,O
24,9523,O
metformin,9523,B-CHEMICAL
studies,9523,O
in,9523,O
subjects,9523,O
with,9523,O
T2DM,9523,O
showed,9523,O
that,9523,O
metformin,9523,B-CHEMICAL
use,9523,O
is,9523,O
associated,9523,O
with,9523,O
reduced,9523,O
risk,9523,O
for,9523,O
the,9523,O
development,9523,O
of,9523,O
cancer,9523,O
",",9523,O
in,9523,O
both,9523,O
cohort,9523,O
(,9523,O
RR=0.70,9523,O
[,9523,O
95,9523,O
%,9523,O
CI=0.67-0.73,9523,O
],9523,O
),9523,O
and,9523,O
case-control,9523,O
studies,9523,O
(,9523,O
OR=0.90,9523,O
[,9523,O
95,9523,O
%,9523,O
CI=0.84-0.98,9523,O
],9523,O
),9523,O
",",9523,O
but,9523,O
this,9523,O
finding,9523,O
was,9523,O
not,9523,O
supported,9523,O
by,9523,O
RCTs,9523,O
(,9523,O
RR=1.01,9523,O
[,9523,O
95,9523,O
%,9523,O
CI=0.81-1.26,9523,O
],9523,O
),9523,O
.,9523,O
Data,9524,O
from,9524,O
18,9524,O
sulfonylurea,9524,B-CHEMICAL
studies,9524,O
in,9524,O
subjects,9524,O
with,9524,O
T2DM,9524,O
showed,9524,O
that,9524,O
sulfonylurea,9524,B-CHEMICAL
use,9524,O
is,9524,O
associated,9524,O
with,9524,O
an,9524,O
increase,9524,O
in,9524,O
all-cancer,9524,O
risk,9524,O
",",9524,O
in,9524,O
cohort,9524,O
studies,9524,O
(,9524,O
RR=1.55,9524,O
[,9524,O
95,9524,O
%,9524,O
CI=1.48,9524,O
-1.63,9524,O
],9524,O
),9524,O
",",9524,O
though,9524,O
data,9524,O
from,9524,O
RCTs,9524,O
(,9524,O
RR=1.17,9524,O
[,9524,O
95,9524,O
%,9524,O
CI=0.95-1.45,9524,O
],9524,O
),9524,O
and,9524,O
case-control,9524,O
studies,9524,O
(,9524,O
OR=1.02,9524,O
[,9524,O
95,9524,O
%,9524,O
CI=0.93-1.13,9524,O
],9524,O
),9524,O
failed,9524,O
to,9524,O
demonstrate,9524,O
a,9524,O
statistically,9524,O
significant,9524,O
effect,9524,O
.,9524,O
CONCLUSIONS,9525,O
:,9525,O
This,9525,O
analysis,9525,O
using,9525,O
pooled,9525,O
primary,9525,O
data,9525,O
demonstrates,9525,O
that,9525,O
metformin,9525,B-CHEMICAL
use,9525,O
reduces,9525,O
",",9525,O
while,9525,O
sulfonylurea,9525,B-CHEMICAL
use,9525,O
may,9525,O
be,9525,O
associated,9525,O
with,9525,O
an,9525,O
increased,9525,O
cancer,9525,O
risk,9525,O
in,9525,O
subjects,9525,O
with,9525,O
T2DM,9525,O
.,9525,O
These,9526,O
findings,9526,O
need,9526,O
to,9526,O
be,9526,O
confirmed,9526,O
in,9526,O
large-scale,9526,O
RCTs,9526,O
before,9526,O
they,9526,O
are,9526,O
translated,9526,O
into,9526,O
clinical,9526,O
practice,9526,O
.,9526,O
Discovery,9527,O
and,9527,O
structure-activity,9527,O
relationships,9527,O
of,9527,O
small,9527,O
molecules,9527,O
that,9527,O
block,9527,O
the,9527,O
human,9527,B-GENE-N
immunoglobulin,9527,I-GENE-N
G-human,9527,O
neonatal,9527,I-GENE-Y
Fc,9527,I-GENE-Y
receptor,9527,I-GENE-Y
(,9527,O
hIgG-hFcRn,9527,B-GENE-N
),9527,O
protein-protein,9527,O
interaction,9527,O
.,9527,O
The,9528,O
neonatal,9528,B-GENE-Y
Fc,9528,I-GENE-Y
receptor,9528,I-GENE-Y
",",9528,O
FcRn,9528,B-GENE-Y
",",9528,O
prolongs,9528,O
the,9528,O
half-life,9528,O
of,9528,O
IgG,9528,B-GENE-N
in,9528,O
the,9528,O
serum,9528,O
and,9528,O
represents,9528,O
a,9528,O
potential,9528,O
therapeutic,9528,O
target,9528,O
for,9528,O
the,9528,O
treatment,9528,O
of,9528,O
autoimmune,9528,O
disease,9528,O
.,9528,O
Small,9529,O
molecules,9529,O
that,9529,O
block,9529,O
the,9529,O
protein-protein,9529,O
interactions,9529,O
of,9529,O
human,9529,B-GENE-N
IgG-human,9529,O
FcRn,9529,I-GENE-Y
may,9529,O
lower,9529,O
pathogenic,9529,O
autoantibodies,9529,O
and,9529,O
provide,9529,O
effective,9529,O
treatment,9529,O
.,9529,O
A,9530,O
novel,9530,O
class,9530,O
of,9530,O
quinoxalines,9530,B-CHEMICAL
has,9530,O
been,9530,O
discovered,9530,O
as,9530,O
antagonists,9530,O
of,9530,O
the,9530,O
IgG,9530,B-GENE-N
:,9530,O
FcRn,9530,B-GENE-Y
protein-protein,9530,O
interaction,9530,O
through,9530,O
optimization,9530,O
of,9530,O
a,9530,O
hit,9530,O
derived,9530,O
from,9530,O
a,9530,O
virtual,9530,O
ligand-based,9530,O
screen,9530,O
.,9530,O
Comparative,9531,O
formation,9531,O
of,9531,O
2-amino-1-methyl-6-phenylimidazo,9531,B-CHEMICAL
[,9531,I-CHEMICAL
"4,5-b",9531,I-CHEMICAL
],9531,I-CHEMICAL
pyridine,9531,I-CHEMICAL
(,9531,O
PhIP,9531,B-CHEMICAL
),9531,O
in,9531,O
creatinine/phenylalanine,9531,B-CHEMICAL
and,9531,O
creatinine/phenylalanine/4-oxo-2-nonenal,9531,B-CHEMICAL
reaction,9531,O
mixtures,9531,O
.,9531,O
The,9532,O
comparative,9532,O
formation,9532,O
of,9532,O
the,9532,O
heterocyclic,9532,O
aromatic,9532,O
amine,9532,O
2-amino-1-methyl-6-phenylimidazo,9532,B-CHEMICAL
[,9532,I-CHEMICAL
"4,5-b",9532,I-CHEMICAL
],9532,I-CHEMICAL
pyridine,9532,I-CHEMICAL
(,9532,O
PhIP,9532,B-CHEMICAL
),9532,O
in,9532,O
both,9532,O
creatinine/phenylalanine,9532,B-CHEMICAL
(,9532,O
CRN/Phe,9532,B-CHEMICAL
),9532,O
and,9532,O
creatinine/phenylalanine/4-oxo-2-nonenal,9532,B-CHEMICAL
(,9532,O
CRN/Phe/ON,9532,B-CHEMICAL
),9532,O
systems,9532,O
was,9532,O
studied,9532,O
to,9532,O
analyse,9532,O
the,9532,O
ability,9532,O
of,9532,O
lipid-derived,9532,O
reactive,9532,O
carbonyls,9532,B-CHEMICAL
to,9532,O
promote,9532,O
PhIP,9532,B-CHEMICAL
formation,9532,O
.,9532,O
Although,9533,O
PhIP,9533,B-CHEMICAL
was,9533,O
produced,9533,O
to,9533,O
some,9533,O
extent,9533,O
in,9533,O
the,9533,O
CRN/Phe,9533,B-CHEMICAL
system,9533,O
",",9533,O
the,9533,O
presence,9533,O
of,9533,O
the,9533,O
oxidized,9533,O
lipid,9533,O
increased,9533,O
considerably,9533,O
the,9533,O
amount,9533,O
of,9533,O
PhIP,9533,B-CHEMICAL
produced,9533,O
.,9533,O
This,9534,O
increase,9534,O
seemed,9534,O
to,9534,O
be,9534,O
a,9534,O
consequence,9534,O
of,9534,O
the,9534,O
decrease,9534,O
in,9534,O
the,9534,O
E,9534,O
(,9534,O
a,9534,O
),9534,O
of,9534,O
the,9534,O
reaction,9534,O
when,9534,O
the,9534,O
lipid,9534,O
was,9534,O
present,9534,O
",",9534,O
which,9534,O
diminished,9534,O
from,9534,O
112.9,9534,O
to,9534,O
80.9,9534,O
kJ/mol,9534,O
.,9534,O
On,9535,O
the,9535,O
other,9535,O
hand,9535,O
",",9535,O
the,9535,O
addition,9535,O
of,9535,O
the,9535,O
lipid,9535,O
did,9535,O
not,9535,O
seem,9535,O
to,9535,O
produce,9535,O
PhIP,9535,B-CHEMICAL
by,9535,O
an,9535,O
alternative,9535,O
mechanism,9535,O
because,9535,O
PhIP,9535,B-CHEMICAL
was,9535,O
formed,9535,O
analogously,9535,O
in,9535,O
both,9535,O
CRN/Phe,9535,B-CHEMICAL
and,9535,O
CRN/Phe/ON,9535,B-CHEMICAL
systems,9535,O
as,9535,O
a,9535,O
function,9535,O
of,9535,O
pH,9535,O
",",9535,O
creatinine,9535,B-CHEMICAL
concentration,9535,O
",",9535,O
phenylalanine,9535,B-CHEMICAL
concentration,9535,O
",",9535,O
time,9535,O
",",9535,O
temperature,9535,O
",",9535,O
oxygen,9535,B-CHEMICAL
concentration,9535,O
in,9535,O
the,9535,O
reaction,9535,O
atmosphere,9535,O
",",9535,O
and,9535,O
the,9535,O
addition,9535,O
of,9535,O
different,9535,O
amounts,9535,O
of,9535,O
ammonia,9535,B-CHEMICAL
.,9535,O
All,9536,O
these,9536,O
results,9536,O
suggest,9536,O
that,9536,O
the,9536,O
ability,9536,O
of,9536,O
lipid,9536,O
oxidation,9536,O
products,9536,O
to,9536,O
produce,9536,O
PhIP,9536,B-CHEMICAL
is,9536,O
related,9536,O
to,9536,O
their,9536,O
capacity,9536,O
to,9536,O
induce,9536,O
the,9536,O
Strecker,9536,O
degradation,9536,O
of,9536,O
phenylalanine,9536,B-CHEMICAL
to,9536,O
phenylacetaldehyde,9536,B-CHEMICAL
.,9536,O
Therefore,9537,O
",",9537,O
any,9537,O
other,9537,O
reactive,9537,O
carbonyl,9537,B-CHEMICAL
compound,9537,O
that,9537,O
can,9537,O
produce,9537,O
the,9537,O
Strecker,9537,O
degradation,9537,O
of,9537,O
phenylalanine,9537,B-CHEMICAL
should,9537,O
also,9537,O
be,9537,O
considered,9537,O
as,9537,O
a,9537,O
potential,9537,O
inducer,9537,O
of,9537,O
PhIP,9537,B-CHEMICAL
formation,9537,O
under,9537,O
appropriate,9537,O
conditions,9537,O
.,9537,O
Agmatine,9538,B-CHEMICAL
:,9538,O
an,9538,O
endogenous,9538,O
clonidine-displacing,9538,B-CHEMICAL
substance,9538,O
in,9538,O
the,9538,O
brain,9538,O
.,9538,O
Clonidine,9539,B-CHEMICAL
",",9539,O
an,9539,O
antihypertensive,9539,O
drug,9539,O
",",9539,O
binds,9539,O
to,9539,O
alpha,9539,B-GENE-N
2-adrenergic,9539,I-GENE-N
and,9539,I-GENE-N
imidazoline,9539,I-GENE-N
receptors,9539,I-GENE-N
.,9539,O
The,9540,O
endogenous,9540,O
ligand,9540,O
for,9540,O
imidazoline,9540,B-GENE-N
receptors,9540,I-GENE-N
may,9540,O
be,9540,O
a,9540,O
clonidine-displacing,9540,B-CHEMICAL
substance,9540,O
",",9540,O
a,9540,O
small,9540,O
molecule,9540,O
isolated,9540,O
from,9540,O
bovine,9540,O
brain,9540,O
.,9540,O
This,9541,O
clonidine-displacing,9541,B-CHEMICAL
substance,9541,O
was,9541,O
purified,9541,O
and,9541,O
determined,9541,O
by,9541,O
mass,9541,O
spectroscopy,9541,O
to,9541,O
be,9541,O
agmatine,9541,B-CHEMICAL
(,9541,O
decarboxylated,9541,B-CHEMICAL
arginine,9541,I-CHEMICAL
),9541,O
",",9541,O
heretofore,9541,O
not,9541,O
detected,9541,O
in,9541,O
brain,9541,O
.,9541,O
Agmatine,9542,B-CHEMICAL
binds,9542,O
to,9542,O
alpha,9542,B-GENE-N
2-adrenergic,9542,I-GENE-N
and,9542,I-GENE-N
imidazoline,9542,I-GENE-N
receptors,9542,I-GENE-N
and,9542,O
stimulates,9542,O
release,9542,O
of,9542,O
catecholamines,9542,B-CHEMICAL
from,9542,O
adrenal,9542,O
chromaffin,9542,O
cells,9542,O
.,9542,O
Its,9543,O
biosynthetic,9543,O
enzyme,9543,O
",",9543,O
arginine,9543,B-GENE-Y
decarboxylase,9543,I-GENE-Y
",",9543,O
is,9543,O
present,9543,O
in,9543,O
brain,9543,O
.,9543,O
Agmatine,9544,B-CHEMICAL
",",9544,O
locally,9544,O
synthesized,9544,O
",",9544,O
is,9544,O
an,9544,O
endogenous,9544,O
agonist,9544,O
at,9544,O
imidazoline,9544,B-GENE-N
receptors,9544,I-GENE-N
",",9544,O
a,9544,O
noncatecholamine,9544,B-CHEMICAL
ligand,9544,O
at,9544,O
alpha,9544,B-GENE-N
2-adrenergic,9544,I-GENE-N
receptors,9544,I-GENE-N
and,9544,O
may,9544,O
act,9544,O
as,9544,O
a,9544,O
neurotransmitter,9544,O
.,9544,O
Amino,9545,B-CHEMICAL
acids,9545,I-CHEMICAL
as,9545,O
co-amorphous,9545,O
stabilizers,9545,O
for,9545,O
poorly,9545,O
water,9545,O
soluble,9545,O
drugs,9545,O
-,9545,O
Part,9545,O
1,9545,O
:,9545,O
Preparation,9545,O
",",9545,O
stability,9545,O
and,9545,O
dissolution,9545,O
enhancement,9545,O
.,9545,O
Poor,9546,O
aqueous,9546,O
solubility,9546,O
of,9546,O
an,9546,O
active,9546,O
pharmaceutical,9546,O
ingredient,9546,O
(,9546,O
API,9546,O
),9546,O
is,9546,O
one,9546,O
of,9546,O
the,9546,O
most,9546,O
pressing,9546,O
problems,9546,O
in,9546,O
pharmaceutical,9546,O
research,9546,O
and,9546,O
development,9546,O
because,9546,O
up,9546,O
to,9546,O
90,9546,O
%,9546,O
of,9546,O
new,9546,O
API,9546,O
candidates,9546,O
under,9546,O
development,9546,O
are,9546,O
poorly,9546,O
water,9546,O
soluble,9546,O
.,9546,O
These,9547,O
drugs,9547,O
usually,9547,O
have,9547,O
a,9547,O
low,9547,O
and,9547,O
variable,9547,O
oral,9547,O
bioavailability,9547,O
",",9547,O
and,9547,O
therefore,9547,O
an,9547,O
unsatisfactory,9547,O
therapeutic,9547,O
effect,9547,O
.,9547,O
One,9548,O
of,9548,O
the,9548,O
most,9548,O
promising,9548,O
approaches,9548,O
to,9548,O
increase,9548,O
dissolution,9548,O
rate,9548,O
and,9548,O
solubility,9548,O
of,9548,O
these,9548,O
drugs,9548,O
is,9548,O
the,9548,O
conversion,9548,O
of,9548,O
a,9548,O
crystalline,9548,O
form,9548,O
of,9548,O
the,9548,O
drug,9548,O
into,9548,O
its,9548,O
respective,9548,O
amorphous,9548,O
form,9548,O
",",9548,O
usually,9548,O
by,9548,O
incorporation,9548,O
into,9548,O
hydrophilic,9548,O
polymers,9548,O
",",9548,O
forming,9548,O
glass,9548,O
solutions,9548,O
.,9548,O
However,9549,O
",",9549,O
this,9549,O
strategy,9549,O
only,9549,O
led,9549,O
to,9549,O
a,9549,O
small,9549,O
number,9549,O
of,9549,O
marketed,9549,O
products,9549,O
usually,9549,O
because,9549,O
of,9549,O
inadequate,9549,O
physical,9549,O
stability,9549,O
of,9549,O
the,9549,O
drug,9549,O
(,9549,O
crystallization,9549,O
),9549,O
.,9549,O
In,9550,O
this,9550,O
study,9550,O
",",9550,O
we,9550,O
investigated,9550,O
a,9550,O
fundamentally,9550,O
different,9550,O
approach,9550,O
to,9550,O
stabilize,9550,O
the,9550,O
amorphous,9550,O
form,9550,O
of,9550,O
drugs,9550,O
",",9550,O
namely,9550,O
the,9550,O
use,9550,O
of,9550,O
amino,9550,B-CHEMICAL
acids,9550,I-CHEMICAL
as,9550,O
small,9550,O
molecular,9550,O
weight,9550,O
excipients,9550,O
that,9550,O
form,9550,O
specific,9550,O
molecular,9550,O
interactions,9550,O
with,9550,O
the,9550,O
drug,9550,O
resulting,9550,O
in,9550,O
co-amorphous,9550,O
forms,9550,O
.,9550,O
The,9551,O
two,9551,O
poorly,9551,O
water,9551,O
soluble,9551,O
drugs,9551,O
carbamazepine,9551,B-CHEMICAL
and,9551,O
indomethacin,9551,B-CHEMICAL
were,9551,O
combined,9551,O
with,9551,O
amino,9551,B-CHEMICAL
acids,9551,I-CHEMICAL
from,9551,O
the,9551,O
binding,9551,O
sites,9551,O
of,9551,O
the,9551,O
biological,9551,O
receptors,9551,O
of,9551,O
these,9551,O
drugs,9551,O
.,9551,O
Mixtures,9552,O
of,9552,O
drug,9552,O
and,9552,O
the,9552,O
amino,9552,B-CHEMICAL
acids,9552,I-CHEMICAL
arginine,9552,B-CHEMICAL
",",9552,O
phenylalanine,9552,B-CHEMICAL
",",9552,O
tryptophan,9552,B-CHEMICAL
and,9552,O
tyrosine,9552,B-CHEMICAL
were,9552,O
prepared,9552,O
by,9552,O
vibrational,9552,O
ball,9552,O
milling,9552,O
.,9552,O
Solid-state,9553,O
characterization,9553,O
with,9553,O
X-ray,9553,O
powder,9553,O
diffraction,9553,O
(,9553,O
XRPD,9553,O
),9553,O
and,9553,O
differential,9553,O
scanning,9553,O
calorimetry,9553,O
(,9553,O
DSC,9553,O
),9553,O
revealed,9553,O
that,9553,O
the,9553,O
various,9553,O
blends,9553,O
could,9553,O
be,9553,O
prepared,9553,O
as,9553,O
homogeneous,9553,O
",",9553,O
single,9553,O
phase,9553,O
co-amorphous,9553,O
formulations,9553,O
indicated,9553,O
by,9553,O
the,9553,O
appearance,9553,O
of,9553,O
an,9553,O
amorphous,9553,O
halo,9553,O
in,9553,O
the,9553,O
XRPD,9553,O
diffractograms,9553,O
and,9553,O
a,9553,O
single,9553,O
glass,9553,O
transition,9553,O
temperature,9553,O
(,9553,O
Tg,9553,O
),9553,O
in,9553,O
the,9553,O
DSC,9553,O
measurements,9553,O
.,9553,O
In,9554,O
addition,9554,O
",",9554,O
the,9554,O
Tgs,9554,O
of,9554,O
the,9554,O
co-amorphous,9554,O
mixtures,9554,O
were,9554,O
significantly,9554,O
increased,9554,O
over,9554,O
those,9554,O
of,9554,O
the,9554,O
individual,9554,O
drugs,9554,O
.,9554,O
The,9555,O
drugs,9555,O
remained,9555,O
chemically,9555,O
stable,9555,O
during,9555,O
the,9555,O
milling,9555,O
process,9555,O
and,9555,O
the,9555,O
co-amorphous,9555,O
formulations,9555,O
were,9555,O
generally,9555,O
physically,9555,O
stable,9555,O
over,9555,O
at,9555,O
least,9555,O
6months,9555,O
at,9555,O
40°C,9555,O
under,9555,O
dry,9555,O
conditions,9555,O
.,9555,O
The,9556,O
dissolution,9556,O
rate,9556,O
of,9556,O
all,9556,O
co-amorphous,9556,O
drug-amino,9556,O
acid,9556,I-CHEMICAL
mixtures,9556,O
was,9556,O
significantly,9556,O
increased,9556,O
over,9556,O
that,9556,O
of,9556,O
the,9556,O
respective,9556,O
crystalline,9556,O
and,9556,O
amorphous,9556,O
pure,9556,O
drugs,9556,O
.,9556,O
Amino,9557,B-CHEMICAL
acids,9557,I-CHEMICAL
thus,9557,O
appear,9557,O
as,9557,O
promising,9557,O
excipients,9557,O
to,9557,O
solve,9557,O
challenges,9557,O
connected,9557,O
with,9557,O
the,9557,O
stability,9557,O
and,9557,O
dissolution,9557,O
of,9557,O
amorphous,9557,O
drugs,9557,O
.,9557,O
Disposition,9558,O
and,9558,O
Metabolism,9558,O
of,9558,O
GSK2251052,9558,B-CHEMICAL
in,9558,O
Humans,9558,O
:,9558,O
A,9558,O
Novel,9558,O
Boron-Containing,9558,B-CHEMICAL
Antibiotic,9558,O
.,9558,O
(,9559,B-CHEMICAL
S,9559,I-CHEMICAL
),9559,I-CHEMICAL
-3-,9559,I-CHEMICAL
(,9559,I-CHEMICAL
Aminomethyl,9559,I-CHEMICAL
),9559,I-CHEMICAL
-7-,9559,I-CHEMICAL
(,9559,I-CHEMICAL
3-hydroxypropoxy,9559,I-CHEMICAL
),9559,I-CHEMICAL
"-1-hydroxy-1,3-dihydro-2,1-benzoxaborole",9559,I-CHEMICAL
(,9559,O
GSK2251052,9559,B-CHEMICAL
),9559,O
is,9559,O
a,9559,O
novel,9559,O
boron-containing,9559,B-CHEMICAL
antibiotic,9559,O
that,9559,O
inhibits,9559,O
bacterial,9559,B-GENE-N
leucyl,9559,I-GENE-N
tRNA,9559,I-GENE-N
synthetase,9559,I-GENE-N
",",9559,O
and,9559,O
that,9559,O
has,9559,O
been,9559,O
in,9559,O
development,9559,O
for,9559,O
the,9559,O
treatment,9559,O
of,9559,O
serious,9559,O
Gram-negative,9559,O
infections,9559,O
.,9559,O
In,9560,O
this,9560,O
study,9560,O
",",9560,O
six,9560,O
healthy,9560,O
adult,9560,O
male,9560,O
subjects,9560,O
received,9560,O
a,9560,O
single,9560,O
i.v,9560,O
.,9560,O
dose,9561,O
of,9561,O
[,9561,B-CHEMICAL
(,9561,I-CHEMICAL
14,9561,I-CHEMICAL
),9561,I-CHEMICAL
C,9561,I-CHEMICAL
],9561,I-CHEMICAL
GSK2251052,9561,I-CHEMICAL
",",9561,O
1500,9561,O
mg,9561,O
infused,9561,O
over,9561,O
1,9561,O
hour,9561,O
.,9561,O
Blood,9562,O
",",9562,O
urine,9562,O
",",9562,O
and,9562,O
feces,9562,O
were,9562,O
collected,9562,O
over,9562,O
an,9562,O
extended,9562,O
period,9562,O
of,9562,O
14,9562,O
days,9562,O
",",9562,O
and,9562,O
accelerator,9562,O
mass,9562,O
spectrometry,9562,O
was,9562,O
used,9562,O
to,9562,O
quantify,9562,O
low,9562,O
levels,9562,O
of,9562,O
radioactivity,9562,O
in,9562,O
plasma,9562,O
at,9562,O
later,9562,O
time,9562,O
points,9562,O
to,9562,O
supplement,9562,O
the,9562,O
less-sensitive,9562,O
liquid,9562,O
scintillation,9562,O
counting,9562,O
technique,9562,O
.,9562,O
An,9563,O
excellent,9563,O
mass,9563,O
balance,9563,O
recovery,9563,O
was,9563,O
achieved,9563,O
representing,9563,O
a,9563,O
mean,9563,O
total,9563,O
of,9563,O
98.2,9563,O
%,9563,O
of,9563,O
the,9563,O
dose,9563,O
",",9563,O
including,9563,O
90.5,9563,O
%,9563,O
recovered,9563,O
in,9563,O
the,9563,O
urine,9563,O
.,9563,O
Pharmacokinetic,9564,O
analysis,9564,O
demonstrated,9564,O
that,9564,O
radioactivity,9564,O
was,9564,O
moderately,9564,O
associated,9564,O
with,9564,O
the,9564,O
blood,9564,O
cellular,9564,O
components,9564,O
",",9564,O
and,9564,O
together,9564,O
with,9564,O
GSK2251052,9564,B-CHEMICAL
",",9564,O
both,9564,O
were,9564,O
highly,9564,O
distributed,9564,O
into,9564,O
tissues,9564,O
.,9564,O
The,9565,O
parent,9565,O
compound,9565,O
had,9565,O
a,9565,O
much,9565,O
shorter,9565,O
half-life,9565,O
than,9565,O
total,9565,O
radioactivity,9565,O
in,9565,O
plasma,9565,O
",",9565,O
approximately,9565,O
11.6,9565,O
hours,9565,O
compared,9565,O
with,9565,O
96,9565,O
hours,9565,O
.,9565,O
GSK2251052,9566,B-CHEMICAL
and,9566,O
its,9566,O
major,9566,O
metabolite,9566,O
M3,9566,O
",",9566,O
which,9566,O
resulted,9566,O
from,9566,O
oxidation,9566,O
of,9566,O
the,9566,O
propanol,9566,B-CHEMICAL
side,9566,O
chain,9566,O
to,9566,O
the,9566,O
corresponding,9566,O
carboxylic,9566,B-CHEMICAL
acid,9566,I-CHEMICAL
",",9566,O
comprised,9566,O
the,9566,O
majority,9566,O
of,9566,O
the,9566,O
plasma,9566,O
radioactivity,9566,O
",",9566,O
37,9566,O
and,9566,O
53,9566,O
%,9566,O
of,9566,O
the,9566,O
area,9566,O
under,9566,O
the,9566,O
plasma,9566,O
versus,9566,O
time,9566,O
concentration,9566,O
curve,9566,O
from,9566,O
time,9566,O
zero,9566,O
to,9566,O
infinity,9566,O
",",9566,O
respectively,9566,O
.,9566,O
Additionally,9567,O
",",9567,O
M3,9567,O
was,9567,O
eliminated,9567,O
renally,9567,O
",",9567,O
and,9567,O
was,9567,O
demonstrated,9567,O
to,9567,O
be,9567,O
responsible,9567,O
for,9567,O
the,9567,O
long,9567,O
plasma,9567,O
radioactivity,9567,O
elimination,9567,O
half-life,9567,O
.,9567,O
A,9568,O
combination,9568,O
of,9568,O
in,9568,O
vitro,9568,O
metabolism,9568,O
experiments,9568,O
and,9568,O
a,9568,O
pharmacokinetic,9568,O
study,9568,O
in,9568,O
monkeys,9568,O
with,9568,O
the,9568,O
inhibitor,9568,O
4-methylpyrazole,9568,B-CHEMICAL
provided,9568,O
strong,9568,O
evidence,9568,O
that,9568,O
alcohol,9568,B-GENE-N
dehydrogenase,9568,I-GENE-N
",",9568,O
potentially,9568,O
in,9568,O
association,9568,O
with,9568,O
aldehyde,9568,B-GENE-N
dehydrogenase,9568,I-GENE-N
",",9568,O
is,9568,O
the,9568,O
primary,9568,O
enzyme,9568,O
involved,9568,O
in,9568,O
the,9568,O
formation,9568,O
of,9568,O
the,9568,O
M3,9568,O
metabolite,9568,O
.,9568,O
Identification,9569,O
of,9569,O
a,9569,O
novel,9569,O
polymorphism,9569,O
in,9569,O
the,9569,O
3'UTR,9569,O
of,9569,O
the,9569,O
L-arginine,9569,B-GENE-N
transporter,9569,I-GENE-N
gene,9569,O
SLC7A1,9569,B-GENE-Y
:,9569,O
contribution,9569,O
to,9569,O
hypertension,9569,O
and,9569,O
endothelial,9569,O
dysfunction,9569,O
.,9569,O
BACKGROUND,9570,O
:,9570,O
Endothelial,9570,O
dysfunction,9570,O
because,9570,O
of,9570,O
reduced,9570,O
nitric,9570,B-CHEMICAL
oxide,9570,I-CHEMICAL
bioavailability,9570,O
is,9570,O
a,9570,O
key,9570,O
feature,9570,O
of,9570,O
essential,9570,O
hypertension,9570,O
.,9570,O
We,9571,O
have,9571,O
found,9571,O
that,9571,O
normotensive,9571,O
siblings,9571,O
of,9571,O
subjects,9571,O
with,9571,O
essential,9571,O
hypertension,9571,O
have,9571,O
impaired,9571,O
endothelial,9571,O
function,9571,O
accompanied,9571,O
by,9571,O
altered,9571,O
arginine,9571,B-CHEMICAL
metabolism,9571,O
.,9571,O
METHODS,9572,O
AND,9572,O
RESULTS,9572,O
:,9572,O
We,9572,O
have,9572,O
identified,9572,O
a,9572,O
novel,9572,O
C/T,9572,O
polymorphism,9572,O
in,9572,O
the,9572,O
3'UTR,9572,O
of,9572,O
the,9572,O
principal,9572,O
arginine,9572,B-GENE-N
transporter,9572,I-GENE-N
",",9572,I-GENE-N
solute,9572,I-GENE-N
carrier,9572,I-GENE-N
family,9572,I-GENE-N
7,9572,I-GENE-N
(,9572,I-GENE-N
cationic,9572,I-GENE-N
amino,9572,I-GENE-N
acid,9572,I-GENE-N
transporter,9572,I-GENE-N
",",9572,I-GENE-N
y+,9572,I-GENE-N
system,9572,I-GENE-N
),9572,I-GENE-N
",",9572,I-GENE-N
member,9572,I-GENE-N
1,9572,I-GENE-N
gene,9572,I-GENE-N
(,9572,O
SLC7A1,9572,B-GENE-Y
),9572,O
.,9572,O
The,9573,O
minor,9573,O
T,9573,O
allele,9573,O
significantly,9573,O
attenuates,9573,O
reporter,9573,O
gene,9573,O
expression,9573,O
(,9573,O
P,9573,O
<,9573,O
0.01,9573,O
),9573,O
and,9573,O
is,9573,O
impaired,9573,O
in,9573,O
its,9573,O
capacity,9573,O
to,9573,O
form,9573,O
DNA-protein,9573,O
complexes,9573,O
(,9573,O
P,9573,O
<,9573,O
0.05,9573,O
),9573,O
.,9573,O
In,9574,O
278,9574,O
hypertensive,9574,O
subjects,9574,O
the,9574,O
frequency,9574,O
of,9574,O
the,9574,O
T,9574,O
allele,9574,O
was,9574,O
13.3,9574,O
%,9574,O
compared,9574,O
with,9574,O
7.6,9574,O
%,9574,O
in,9574,O
498,9574,O
normotensive,9574,O
subjects,9574,O
(,9574,O
P,9574,O
<,9574,O
0.001,9574,O
),9574,O
.,9574,O
Moreover,9575,O
",",9575,O
the,9575,O
overall,9575,O
genotype,9575,O
distribution,9575,O
observed,9575,O
in,9575,O
hypertensives,9575,O
differed,9575,O
significantly,9575,O
from,9575,O
that,9575,O
in,9575,O
normotensives,9575,O
(,9575,O
P,9575,O
<,9575,O
0.001,9575,O
),9575,O
.,9575,O
To,9576,O
complement,9576,O
these,9576,O
studies,9576,O
",",9576,O
we,9576,O
generated,9576,O
an,9576,O
endothelial-specific,9576,O
transgenic,9576,O
mouse,9576,O
overexpressing,9576,O
L-arginine,9576,B-GENE-N
transporter,9576,I-GENE-N
SLC7A1,9576,B-GENE-Y
.,9576,O
The,9577,O
Slc7A1,9577,B-GENE-Y
transgenic,9577,O
mice,9577,O
exhibited,9577,O
significantly,9577,O
enhanced,9577,O
responses,9577,O
to,9577,O
the,9577,O
endothelium-dependent,9577,O
vasodilator,9577,O
acetylcholine,9577,B-CHEMICAL
(,9577,O
-log,9577,O
EC50,9577,O
for,9577,O
wild-type,9577,O
versus,9577,O
Slc7A1,9577,B-GENE-Y
transgenic,9577,O
:,9577,O
6.87+/-0.10,9577,O
versus,9577,O
7.56+/-0.13,9577,O
;,9577,O
P,9577,O
<,9577,O
0.001,9577,O
),9577,O
.,9577,O
This,9578,O
was,9578,O
accompanied,9578,O
by,9578,O
elevated,9578,O
production,9578,O
of,9578,O
nitric,9578,B-CHEMICAL
oxide,9578,I-CHEMICAL
by,9578,O
isolated,9578,O
aortic,9578,O
endothelial,9578,O
cells,9578,O
.,9578,O
CONCLUSIONS,9579,O
:,9579,O
The,9579,O
present,9579,O
study,9579,O
identifies,9579,O
a,9579,O
key,9579,O
",",9579,O
functionally,9579,O
active,9579,O
polymorphism,9579,O
in,9579,O
the,9579,O
3'UTR,9579,O
of,9579,O
SLC7A1,9579,B-GENE-Y
.,9579,O
As,9580,O
such,9580,O
",",9580,O
this,9580,O
polymorphism,9580,O
may,9580,O
account,9580,O
for,9580,O
the,9580,O
apparent,9580,O
link,9580,O
between,9580,O
altered,9580,O
endothelial,9580,O
function,9580,O
",",9580,O
L-arginine,9580,B-CHEMICAL
",",9580,O
and,9580,O
nitric,9580,B-CHEMICAL
oxide,9580,I-CHEMICAL
metabolism,9580,O
and,9580,O
predisposition,9580,O
to,9580,O
essential,9580,O
hypertension,9580,O
.,9580,O
Identification,9581,O
of,9581,O
an,9581,O
Allosteric,9581,O
Modulator,9581,O
of,9581,O
Serotonin,9581,B-GENE-Y
Transporter,9581,I-GENE-Y
with,9581,O
Novel,9581,O
Mechanism,9581,O
of,9581,O
Action,9581,O
.,9581,O
Serotonin,9582,B-GENE-Y
transporters,9582,I-GENE-Y
(,9582,O
SERT,9582,B-GENE-Y
),9582,O
play,9582,O
an,9582,O
essential,9582,O
role,9582,O
in,9582,O
the,9582,O
termination,9582,O
and,9582,O
regulation,9582,O
of,9582,O
serotonin,9582,B-CHEMICAL
signaling,9582,O
in,9582,O
the,9582,O
brain,9582,O
.,9582,O
SERT,9583,B-GENE-Y
is,9583,O
also,9583,O
the,9583,O
target,9583,O
of,9583,O
antidepressants,9583,O
and,9583,O
psychostimulants,9583,O
.,9583,O
Molecules,9584,O
with,9584,O
novel,9584,O
activities,9584,O
and,9584,O
modes,9584,O
of,9584,O
interaction,9584,O
with,9584,O
regard,9584,O
to,9584,O
SERT,9584,B-GENE-Y
function,9584,O
are,9584,O
of,9584,O
great,9584,O
scientific,9584,O
and,9584,O
clinical,9584,O
interest,9584,O
.,9584,O
We,9585,O
explored,9585,O
structural,9585,O
regions,9585,O
outside,9585,O
the,9585,O
putative,9585,O
serotonin,9585,B-CHEMICAL
translocation,9585,O
pathway,9585,O
to,9585,O
identify,9585,O
potential,9585,O
binding,9585,O
sites,9585,O
for,9585,O
allosteric,9585,O
transporter,9585,O
modulators,9585,O
(,9585,O
ATMs,9585,O
),9585,O
.,9585,O
Mutational,9586,O
studies,9586,O
revealed,9586,O
a,9586,O
pocket,9586,O
of,9586,O
amino,9586,B-CHEMICAL
acids,9586,I-CHEMICAL
outside,9586,O
the,9586,O
orthosteric,9586,O
substrate,9586,O
binding,9586,O
sites,9586,O
located,9586,O
in,9586,O
the,9586,O
interface,9586,O
between,9586,O
extracellular,9586,O
loops,9586,O
1,9586,O
and,9586,O
3,9586,O
that,9586,O
when,9586,O
mutated,9586,O
affect,9586,O
transporter,9586,O
function,9586,O
.,9586,O
Using,9587,O
the,9587,O
structure,9587,O
of,9587,O
the,9587,O
bacterial,9587,O
transporter,9587,O
homologue,9587,O
leucine,9587,B-GENE-N
transporter,9587,I-GENE-N
as,9587,O
a,9587,O
template,9587,O
",",9587,O
we,9587,O
developed,9587,O
a,9587,O
structural,9587,O
model,9587,O
of,9587,O
SERT,9587,B-GENE-Y
.,9587,O
We,9588,O
performed,9588,O
molecular,9588,O
dynamics,9588,O
simulations,9588,O
to,9588,O
further,9588,O
characterize,9588,O
the,9588,O
allosteric,9588,O
pocket,9588,O
that,9588,O
was,9588,O
identified,9588,O
by,9588,O
site-directed,9588,O
mutagenesis,9588,O
studies,9588,O
and,9588,O
employed,9588,O
this,9588,O
pocket,9588,O
in,9588,O
a,9588,O
virtual,9588,O
screen,9588,O
for,9588,O
small-molecule,9588,O
modulators,9588,O
of,9588,O
SERT,9588,B-GENE-Y
function,9588,O
.,9588,O
In,9589,O
functional,9589,O
transport,9589,O
assays,9589,O
",",9589,O
we,9589,O
found,9589,O
that,9589,O
one,9589,O
of,9589,O
the,9589,O
identified,9589,O
molecules,9589,O
",",9589,O
ATM7,9589,O
",",9589,O
increased,9589,O
the,9589,O
reuptake,9589,O
of,9589,O
serotonin,9589,B-CHEMICAL
",",9589,O
possibly,9589,O
by,9589,O
facilitating,9589,O
the,9589,O
interaction,9589,O
of,9589,O
serotonin,9589,B-CHEMICAL
with,9589,O
transport-ready,9589,O
conformations,9589,O
of,9589,O
SERT,9589,B-GENE-Y
when,9589,O
concentrations,9589,O
of,9589,O
serotonin,9589,B-CHEMICAL
were,9589,O
low,9589,O
and,9589,O
rate,9589,O
limiting,9589,O
.,9589,O
In,9590,O
addition,9590,O
",",9590,O
ATM7,9590,O
potentiates,9590,O
"3,4-methylenedioxy-N-methylamphetamine",9590,B-CHEMICAL
(,9590,O
MDMA,9590,B-CHEMICAL
",",9590,O
``,9590,O
Ecstasy,9590,O
'',9590,O
),9590,O
-induced,9590,O
reversed,9590,O
transport,9590,O
by,9590,O
SERT,9590,B-GENE-Y
.,9590,O
Taking,9591,O
advantage,9591,O
of,9591,O
a,9591,O
conformationally,9591,O
sensitive,9591,O
residue,9591,O
in,9591,O
transmembrane,9591,O
domain,9591,O
6,9591,O
",",9591,O
we,9591,O
demonstrate,9591,O
that,9591,O
ATM7,9591,O
mechanistically,9591,O
stabilizes,9591,O
an,9591,O
outward-facing,9591,O
conformation,9591,O
of,9591,O
SERT,9591,B-GENE-Y
.,9591,O
Taken,9592,O
together,9592,O
these,9592,O
observations,9592,O
demonstrate,9592,O
that,9592,O
ATM7,9592,O
acts,9592,O
through,9592,O
a,9592,O
novel,9592,O
mechanism,9592,O
that,9592,O
involves,9592,O
allosteric,9592,O
modulation,9592,O
of,9592,O
SERT,9592,B-GENE-Y
function,9592,O
.,9592,O
Structural,9593,O
basis,9593,O
for,9593,O
the,9593,O
altered,9593,O
drug,9593,O
sensitivities,9593,O
of,9593,O
non-small,9593,O
cell,9593,O
lung,9593,O
cancer-associated,9593,O
mutants,9593,O
of,9593,O
human,9593,B-GENE-Y
epidermal,9593,I-GENE-Y
growth,9593,I-GENE-Y
factor,9593,I-GENE-Y
receptor,9593,I-GENE-Y
.,9593,O
The,9594,O
epidermal,9594,B-GENE-Y
growth,9594,I-GENE-Y
factor,9594,I-GENE-Y
receptor,9594,I-GENE-Y
(,9594,O
EGFR,9594,B-GENE-Y
),9594,O
has,9594,O
an,9594,O
essential,9594,O
role,9594,O
in,9594,O
multiple,9594,O
signaling,9594,O
pathways,9594,O
",",9594,O
including,9594,O
cell,9594,O
proliferation,9594,O
and,9594,O
migration,9594,O
",",9594,O
through,9594,O
extracellular,9594,O
ligand,9594,O
binding,9594,O
and,9594,O
subsequent,9594,O
activation,9594,O
of,9594,O
its,9594,O
intracellular,9594,O
tyrosine,9594,B-GENE-N
kinase,9594,I-GENE-N
(,9594,I-GENE-N
TK,9594,I-GENE-N
),9594,I-GENE-N
domain,9594,I-GENE-N
.,9594,O
The,9595,O
non-small,9595,O
cell,9595,O
lung,9595,O
cancer,9595,O
(,9595,O
NSCLC,9595,O
),9595,O
-associated,9595,O
EGFR,9595,B-GENE-Y
mutants,9595,O
",",9595,O
L858R,9595,B-GENE-N
and,9595,O
G719S,9595,B-GENE-N
",",9595,O
are,9595,O
constitutively,9595,O
active,9595,O
and,9595,O
oncogenic,9595,O
.,9595,O
They,9596,O
display,9596,O
sensitivity,9596,O
to,9596,O
TK,9596,B-GENE-N
inhibitors,9596,O
",",9596,O
including,9596,O
gefitinib,9596,B-CHEMICAL
and,9596,O
erlotinib,9596,B-CHEMICAL
.,9596,O
In,9597,O
contrast,9597,O
",",9597,O
the,9597,O
secondary,9597,O
mutation,9597,O
of,9597,O
the,9597,O
gatekeeper,9597,O
residue,9597,O
",",9597,O
T790M,9597,B-GENE-N
",",9597,O
reportedly,9597,O
confers,9597,O
inhibitor,9597,O
resistance,9597,O
on,9597,O
the,9597,O
oncogenic,9597,O
EGFR,9597,B-GENE-Y
mutants,9597,O
.,9597,O
In,9598,O
this,9598,O
study,9598,O
",",9598,O
our,9598,O
biochemical,9598,O
analyses,9598,O
revealed,9598,O
that,9598,O
the,9598,O
introduction,9598,O
of,9598,O
the,9598,O
T790M,9598,B-GENE-N
mutation,9598,O
confers,9598,O
gefitinib,9598,B-CHEMICAL
resistance,9598,O
on,9598,O
the,9598,O
G719S,9598,B-GENE-N
mutant,9598,O
.,9598,O
The,9599,O
G719S/T790M,9599,B-GENE-N
double,9599,O
mutant,9599,O
has,9599,O
enhanced,9599,O
activity,9599,O
and,9599,O
retains,9599,O
high,9599,O
gefitinib-binding,9599,B-CHEMICAL
affinity,9599,O
.,9599,O
The,9600,O
T790M,9600,B-GENE-N
mutation,9600,O
increases,9600,O
the,9600,O
ATP,9600,B-CHEMICAL
affinity,9600,O
of,9600,O
the,9600,O
G719S,9600,B-GENE-N
mutant,9600,O
",",9600,O
explaining,9600,O
the,9600,O
acquired,9600,O
drug,9600,O
resistance,9600,O
of,9600,O
the,9600,O
double,9600,O
mutant,9600,O
.,9600,O
Structural,9601,O
analyses,9601,O
of,9601,O
the,9601,O
G719S/T790M,9601,B-GENE-N
double,9601,O
mutant,9601,O
",",9601,O
as,9601,O
well,9601,O
as,9601,O
the,9601,O
wild,9601,O
type,9601,O
and,9601,O
the,9601,O
G719S,9601,B-GENE-N
and,9601,O
L858R,9601,B-GENE-N
mutants,9601,O
",",9601,O
revealed,9601,O
that,9601,O
the,9601,O
T790M,9601,B-GENE-N
mutation,9601,O
stabilizes,9601,O
the,9601,O
hydrophobic,9601,O
spine,9601,O
of,9601,O
the,9601,O
active,9601,O
EGFR-TK,9601,B-GENE-Y
conformation,9601,O
.,9601,O
The,9602,O
Met790,9602,B-CHEMICAL
side,9602,O
chain,9602,O
of,9602,O
the,9602,O
G719S/T790M,9602,B-GENE-N
double,9602,O
mutant,9602,O
",",9602,O
in,9602,O
the,9602,O
apo,9602,O
form,9602,O
and,9602,O
gefitinib-,9602,B-CHEMICAL
and,9602,O
AMPPNP-bound,9602,O
forms,9602,O
",",9602,O
adopts,9602,O
different,9602,O
conformations,9602,O
that,9602,O
explain,9602,O
the,9602,O
accommodation,9602,O
of,9602,O
these,9602,O
ligands,9602,O
.,9602,O
In,9603,O
the,9603,O
L858R,9603,B-GENE-N
mutant,9603,O
structure,9603,O
",",9603,O
the,9603,O
active-site,9603,O
cleft,9603,O
is,9603,O
expanded,9603,O
by,9603,O
the,9603,O
repositioning,9603,O
of,9603,O
Phe723,9603,B-CHEMICAL
within,9603,O
the,9603,O
P-loop,9603,O
.,9603,O
Notably,9604,O
",",9604,O
the,9604,O
introduction,9604,O
of,9604,O
the,9604,O
F723A,9604,B-GENE-N
mutation,9604,O
greatly,9604,O
enhanced,9604,O
the,9604,O
gefitinib,9604,B-CHEMICAL
sensitivity,9604,O
of,9604,O
the,9604,O
wild-type,9604,O
EGFR,9604,B-GENE-Y
in,9604,O
vivo,9604,O
",",9604,O
supporting,9604,O
our,9604,O
hypothesis,9604,O
that,9604,O
the,9604,O
expansion,9604,O
of,9604,O
the,9604,O
active-site,9604,O
cleft,9604,O
results,9604,O
in,9604,O
enhanced,9604,O
gefitinib,9604,B-CHEMICAL
sensitivity,9604,O
.,9604,O
Taken,9605,O
together,9605,O
",",9605,O
our,9605,O
results,9605,O
provide,9605,O
a,9605,O
structural,9605,O
basis,9605,O
for,9605,O
the,9605,O
altered,9605,O
drug,9605,O
sensitivities,9605,O
caused,9605,O
by,9605,O
distinct,9605,O
NSCLC-associated,9605,O
EGFR,9605,B-GENE-Y
mutations,9605,O
.,9605,O
Chemopreventive,9606,O
effects,9606,O
of,9606,O
Ginkgo,9606,O
biloba,9606,O
extract,9606,O
in,9606,O
estrogen-negative,9606,B-CHEMICAL
human,9606,O
breast,9606,O
cancer,9606,O
cells,9606,O
.,9606,O
Excessive,9607,O
level,9607,O
of,9607,O
estrogen,9607,B-CHEMICAL
is,9607,O
considered,9607,O
as,9607,O
a,9607,O
main,9607,O
cause,9607,O
of,9607,O
breast,9607,O
cancer,9607,O
",",9607,O
therefore,9607,O
",",9607,O
many,9607,O
studies,9607,O
have,9607,O
focused,9607,O
on,9607,O
estrogen,9607,B-GENE-Y
receptor,9607,I-GENE-Y
(,9607,O
ER,9607,B-GENE-Y
),9607,O
-positive,9607,O
breast,9607,O
cancer,9607,O
",",9607,O
even,9607,O
though,9607,O
ER-negative,9607,B-GENE-Y
cancer,9607,O
has,9607,O
a,9607,O
poor,9607,O
prognosis,9607,O
than,9607,O
ER-positive,9607,B-GENE-Y
breast,9607,O
cancer,9607,O
.,9607,O
We,9608,O
evaluated,9608,O
the,9608,O
anti-cancer,9608,O
effects,9608,O
of,9608,O
Ginkgo,9608,O
biloba,9608,O
extract,9608,O
(,9608,O
GBE,9608,O
),9608,O
in,9608,O
estrogen-independent,9608,B-CHEMICAL
breast,9608,O
cancer,9608,O
.,9608,O
GBE,9609,O
has,9609,O
been,9609,O
traditionally,9609,O
used,9609,O
as,9609,O
a,9609,O
platelet,9609,O
activating,9609,O
factor,9609,O
",",9609,O
a,9609,O
circulatory,9609,O
stimulant,9609,O
",",9609,O
a,9609,O
tonic,9609,O
",",9609,O
and,9609,O
anti-asthmatic,9609,O
drug,9609,O
",",9609,O
and,9609,O
anti-cancer,9609,O
agent,9609,O
.,9609,O
However,9610,O
",",9610,O
anti-cancer,9610,O
effects,9610,O
of,9610,O
GBE,9610,O
on,9610,O
ER-negative,9610,B-GENE-Y
breast,9610,O
cancer,9610,O
have,9610,O
not,9610,O
been,9610,O
proved,9610,O
yet,9610,O
.,9610,O
In,9611,O
this,9611,O
study,9611,O
",",9611,O
we,9611,O
tested,9611,O
chemotherapeutic,9611,O
potential,9611,O
of,9611,O
GBE,9611,O
in,9611,O
the,9611,O
MDA-MB-231,9611,O
(,9611,O
ER-negative,9611,B-GENE-Y
),9611,O
human,9611,O
breast,9611,O
cancer,9611,O
cell,9611,O
line,9611,O
.,9611,O
Our,9612,O
results,9612,O
showed,9612,O
that,9612,O
cytotoxicity,9612,O
effects,9612,O
of,9612,O
GBE,9612,O
in,9612,O
MDA-MB-231,9612,O
lead,9612,O
to,9612,O
DNA,9612,O
fragmentation,9612,O
at,9612,O
high,9612,O
concentrations,9612,O
(,9612,O
500,9612,O
and,9612,O
"1,000",9612,O
μg/ml,9612,O
),9612,O
.,9612,O
Caspase-3,9613,B-GENE-Y
was,9613,O
significantly,9613,O
activated,9613,O
and,9613,O
mRNA,9613,O
levels,9613,O
of,9613,O
apoptosis-related,9613,O
genes,9613,O
(,9613,O
Bcl-2,9613,B-GENE-Y
and,9613,O
Bax,9613,B-GENE-Y
),9613,O
were,9613,O
altered,9613,O
.,9613,O
These,9614,O
results,9614,O
indicate,9614,O
that,9614,O
GBE,9614,O
induces,9614,O
apoptosis,9614,O
in,9614,O
MDA-MB-231,9614,O
cells,9614,O
.,9614,O
It,9615,O
is,9615,O
presumed,9615,O
that,9615,O
GBE,9615,O
has,9615,O
chemopreventive,9615,O
effects,9615,O
in,9615,O
ER-independent,9615,B-GENE-Y
breast,9615,O
cancer,9615,O
through,9615,O
anti-proliferation,9615,O
and,9615,O
apoptosis-inducing,9615,O
activities,9615,O
.,9615,O
Biosynthesis,9616,O
of,9616,O
iron-sulphur,9616,B-CHEMICAL
clusters,9616,O
is,9616,O
a,9616,O
complex,9616,O
and,9616,O
highly,9616,O
conserved,9616,O
process,9616,O
.,9616,O
Iron-sulphur,9617,B-CHEMICAL
(,9617,O
[,9617,O
Fe-S,9617,B-CHEMICAL
],9617,O
),9617,O
clusters,9617,O
are,9617,O
simple,9617,O
inorganic,9617,O
prosthetic,9617,O
groups,9617,O
that,9617,O
are,9617,O
contained,9617,O
in,9617,O
a,9617,O
variety,9617,O
of,9617,O
proteins,9617,O
having,9617,O
functions,9617,O
related,9617,O
to,9617,O
electron,9617,O
transfer,9617,O
",",9617,O
gene,9617,O
regulation,9617,O
",",9617,O
environmental,9617,O
sensing,9617,O
and,9617,O
substrate,9617,O
activation,9617,O
.,9617,O
In,9618,O
spite,9618,O
of,9618,O
their,9618,O
simple,9618,O
structures,9618,O
",",9618,O
biological,9618,O
[,9618,O
Fe-S,9618,B-CHEMICAL
],9618,O
clusters,9618,O
are,9618,O
not,9618,O
formed,9618,O
spontaneously,9618,O
.,9618,O
Rather,9619,O
",",9619,O
a,9619,O
consortium,9619,O
of,9619,O
highly,9619,O
conserved,9619,O
proteins,9619,O
is,9619,O
required,9619,O
for,9619,O
both,9619,O
the,9619,O
formation,9619,O
of,9619,O
[,9619,O
Fe-S,9619,B-CHEMICAL
],9619,O
clusters,9619,O
and,9619,O
their,9619,O
insertion,9619,O
into,9619,O
various,9619,O
protein,9619,O
partners,9619,O
.,9619,O
Among,9620,O
the,9620,O
[,9620,O
Fe-S,9620,B-CHEMICAL
],9620,O
cluster,9620,O
biosynthetic,9620,O
proteins,9620,O
are,9620,O
included,9620,O
a,9620,O
pyridoxal,9620,B-CHEMICAL
phosphate-dependent,9620,O
enzyme,9620,O
(,9620,O
NifS,9620,B-GENE-Y
),9620,O
that,9620,O
is,9620,O
involved,9620,O
in,9620,O
the,9620,O
activation,9620,O
of,9620,O
sulphur,9620,B-CHEMICAL
from,9620,O
l-cysteine,9620,B-CHEMICAL
",",9620,O
and,9620,O
a,9620,O
molecular,9620,O
scaffold,9620,O
protein,9620,O
(,9620,O
NifU,9620,B-GENE-N
),9620,O
upon,9620,O
which,9620,O
[,9620,O
Fe-S,9620,B-CHEMICAL
],9620,O
cluster,9620,O
precursors,9620,O
are,9620,O
formed,9620,O
.,9620,O
The,9621,O
formation,9621,O
or,9621,O
transfer,9621,O
of,9621,O
[,9621,O
Fe-S,9621,B-CHEMICAL
],9621,O
clusters,9621,O
appears,9621,O
to,9621,O
require,9621,O
an,9621,O
electron-transfer,9621,O
step,9621,O
.,9621,O
Another,9622,O
complexity,9622,O
is,9622,O
that,9622,O
molecular,9622,O
chaperones,9622,O
homologous,9622,O
to,9622,O
DnaJ,9622,O
and,9622,O
DnaK,9622,O
are,9622,O
involved,9622,O
in,9622,O
some,9622,O
aspect,9622,O
of,9622,O
the,9622,O
maturation,9622,O
of,9622,O
[,9622,O
Fe-S,9622,B-CHEMICAL
],9622,O
-cluster-containing,9622,O
proteins,9622,O
.,9622,O
It,9623,O
appears,9623,O
that,9623,O
the,9623,O
basic,9623,O
biochemical,9623,O
features,9623,O
of,9623,O
[,9623,O
Fe-S,9623,B-CHEMICAL
],9623,O
cluster,9623,O
formation,9623,O
are,9623,O
strongly,9623,O
conserved,9623,O
in,9623,O
Nature,9623,O
",",9623,O
since,9623,O
organisms,9623,O
from,9623,O
all,9623,O
three,9623,O
life,9623,O
Kingdoms,9623,O
contain,9623,O
the,9623,O
same,9623,O
consortium,9623,O
of,9623,O
homologous,9623,O
proteins,9623,O
required,9623,O
for,9623,O
[,9623,O
Fe-S,9623,B-CHEMICAL
],9623,O
cluster,9623,O
formation,9623,O
that,9623,O
were,9623,O
discovered,9623,O
in,9623,O
the,9623,O
eubacteria,9623,O
.,9623,O
Copolymerization,9624,O
of,9624,O
"2-methylene-1,3-dioxepane",9624,B-CHEMICAL
and,9624,O
glycidyl,9624,B-CHEMICAL
methacrylate,9624,I-CHEMICAL
",",9624,O
a,9624,O
well-defined,9624,O
and,9624,O
efficient,9624,O
process,9624,O
for,9624,O
achieving,9624,O
functionalized,9624,O
polyesters,9624,B-CHEMICAL
for,9624,O
covalent,9624,O
binding,9624,O
of,9624,O
bioactive,9624,O
molecules,9624,O
.,9624,O
The,9625,O
understanding,9625,O
of,9625,O
cell-material,9625,O
interactions,9625,O
is,9625,O
important,9625,O
for,9625,O
creating,9625,O
personalized,9625,O
implants,9625,O
for,9625,O
tissue,9625,O
engineering,9625,O
.,9625,O
This,9626,O
has,9626,O
resulted,9626,O
in,9626,O
an,9626,O
interest,9626,O
in,9626,O
developing,9626,O
polymers,9626,O
with,9626,O
functional,9626,O
groups,9626,O
with,9626,O
the,9626,O
possibility,9626,O
of,9626,O
controlling,9626,O
the,9626,O
macromolecular,9626,O
surface,9626,O
.,9626,O
We,9627,O
have,9627,O
in,9627,O
a,9627,O
one-pot,9627,O
reaction,9627,O
synthesized,9627,O
a,9627,O
series,9627,O
of,9627,O
amorphous,9627,O
and,9627,O
degradable,9627,O
polyester-based,9627,B-CHEMICAL
copolymers,9627,O
with,9627,O
active,9627,O
functional,9627,O
groups,9627,O
by,9627,O
copolymerization,9627,O
of,9627,O
"2-methylene-1,3-dioxepane",9627,B-CHEMICAL
and,9627,O
glycidyl,9627,B-CHEMICAL
methacrylate,9627,I-CHEMICAL
.,9627,O
The,9628,O
properties,9628,O
of,9628,O
the,9628,O
final,9628,O
polymers,9628,O
were,9628,O
varied,9628,O
by,9628,O
varying,9628,O
the,9628,O
feed,9628,O
ratios,9628,O
of,9628,O
the,9628,O
monomers,9628,O
and,9628,O
it,9628,O
was,9628,O
seen,9628,O
that,9628,O
it,9628,O
was,9628,O
possible,9628,O
to,9628,O
control,9628,O
the,9628,O
amount,9628,O
of,9628,O
active,9628,O
functional,9628,O
groups,9628,O
.,9628,O
The,9629,O
resulting,9629,O
epoxy-functionalized,9629,B-CHEMICAL
polyester,9629,I-CHEMICAL
was,9629,O
further,9629,O
modified,9629,O
by,9629,O
covalent,9629,O
immobilization,9629,O
of,9629,O
heparin,9629,O
.,9629,O
The,9630,O
heparinization,9630,O
was,9630,O
done,9630,O
in,9630,O
order,9630,O
",",9630,O
in,9630,O
a,9630,O
future,9630,O
aspect,9630,O
",",9630,O
to,9630,O
enhance,9630,O
the,9630,O
osteogenic,9630,O
differentiation,9630,O
of,9630,O
mesenchymal,9630,O
stem,9630,O
cells,9630,O
.,9630,O
Heparin,9631,O
binds,9631,O
directly,9631,O
with,9631,O
the,9631,O
growth,9631,O
factor,9631,O
bone,9631,B-GENE-Y
morphogenetic,9631,I-GENE-Y
protein-2,9631,I-GENE-Y
and,9631,O
helps,9631,O
to,9631,O
retain,9631,O
its,9631,O
activity,9631,O
.,9631,O
The,9632,O
molecular,9632,O
structure,9632,O
of,9632,O
the,9632,O
copolymers,9632,O
was,9632,O
characterized,9632,O
by,9632,O
nuclear,9632,O
magnetic,9632,O
resonance,9632,O
",",9632,O
size,9632,O
exclusion,9632,O
chromatography,9632,O
",",9632,O
and,9632,O
fourier,9632,O
transform,9632,O
infrared,9632,O
spectroscopy,9632,O
.,9632,O
Differential,9633,O
scanning,9633,O
calorimetry,9633,O
and,9633,O
tensile,9633,O
testing,9633,O
showed,9633,O
that,9633,O
the,9633,O
monomer,9633,O
feed,9633,O
ratio,9633,O
had,9633,O
a,9633,O
great,9633,O
influence,9633,O
on,9633,O
the,9633,O
properties,9633,O
of,9633,O
the,9633,O
final,9633,O
polymer,9633,O
and,9633,O
that,9633,O
it,9633,O
thus,9633,O
was,9633,O
possible,9633,O
to,9633,O
control,9633,O
the,9633,O
mechanical,9633,O
properties,9633,O
to,9633,O
suit,9633,O
an,9633,O
intended,9633,O
application,9633,O
.,9633,O
The,9634,O
presence,9634,O
of,9634,O
heparin,9634,O
was,9634,O
verified,9634,O
by,9634,O
toluidine,9634,B-CHEMICAL
blue,9634,I-CHEMICAL
staining,9634,O
and,9634,O
all,9634,O
the,9634,O
films,9634,O
tested,9634,O
showed,9634,O
positive,9634,O
signals,9634,O
for,9634,O
heparin,9634,O
.,9634,O
DNA,9635,B-GENE-Y
polymerase,9635,I-GENE-Y
POLQ,9635,I-GENE-Y
and,9635,O
cellular,9635,O
defense,9635,O
against,9635,O
DNA,9635,O
damage,9635,O
.,9635,O
In,9636,O
mammalian,9636,O
cells,9636,O
",",9636,O
POLQ,9636,B-GENE-Y
(,9636,O
pol,9636,B-GENE-Y
θ,9636,I-GENE-Y
),9636,O
is,9636,O
an,9636,O
unusual,9636,O
specialized,9636,O
DNA,9636,B-GENE-N
polymerase,9636,I-GENE-N
whose,9636,O
in,9636,O
vivo,9636,O
function,9636,O
is,9636,O
under,9636,O
active,9636,O
investigation,9636,O
.,9636,O
POLQ,9637,B-GENE-Y
has,9637,O
been,9637,O
implicated,9637,O
by,9637,O
different,9637,O
experiments,9637,O
to,9637,O
play,9637,O
a,9637,O
role,9637,O
in,9637,O
resistance,9637,O
to,9637,O
ionizing,9637,O
radiation,9637,O
and,9637,O
defense,9637,O
against,9637,O
genomic,9637,O
instability,9637,O
",",9637,O
in,9637,O
base,9637,O
excision,9637,O
repair,9637,O
",",9637,O
and,9637,O
in,9637,O
immunological,9637,O
diversification,9637,O
.,9637,O
The,9638,O
protein,9638,O
is,9638,O
formed,9638,O
by,9638,O
an,9638,O
N-terminal,9638,B-GENE-N
helicase-like,9638,I-GENE-N
domain,9638,I-GENE-N
",",9638,O
a,9638,O
C-terminal,9638,B-GENE-N
DNA,9638,I-GENE-N
polymerase,9638,I-GENE-N
domain,9638,I-GENE-N
",",9638,O
and,9638,O
a,9638,O
large,9638,B-GENE-N
central,9638,I-GENE-N
domain,9638,I-GENE-N
that,9638,O
spans,9638,O
between,9638,O
the,9638,O
two,9638,O
.,9638,O
This,9639,O
arrangement,9639,O
is,9639,O
also,9639,O
found,9639,O
in,9639,O
the,9639,O
Drosophila,9639,B-GENE-Y
Mus308,9639,I-GENE-Y
protein,9639,O
",",9639,O
which,9639,O
functions,9639,O
in,9639,O
resistance,9639,O
to,9639,O
DNA,9639,O
interstrand,9639,O
crosslinking,9639,O
agents,9639,O
.,9639,O
Homologs,9640,O
of,9640,O
POLQ,9640,B-GENE-Y
and,9640,O
Mus308,9640,B-GENE-Y
are,9640,O
found,9640,O
in,9640,O
multicellular,9640,O
eukaryotes,9640,O
",",9640,O
including,9640,O
plants,9640,O
",",9640,O
but,9640,O
a,9640,O
comparison,9640,O
of,9640,O
phenotypes,9640,O
suggests,9640,O
that,9640,O
not,9640,O
all,9640,O
of,9640,O
these,9640,O
genes,9640,O
are,9640,O
functional,9640,O
orthologs,9640,O
.,9640,O
Flies,9641,O
defective,9641,O
in,9641,O
Mus308,9641,B-GENE-Y
are,9641,O
sensitive,9641,O
to,9641,O
DNA,9641,O
interstrand,9641,O
crosslinking,9641,O
agents,9641,O
",",9641,O
while,9641,O
mammalian,9641,O
cells,9641,O
defective,9641,O
in,9641,O
POLQ,9641,B-GENE-Y
are,9641,O
primarily,9641,O
sensitive,9641,O
to,9641,O
DNA,9641,O
double-strand,9641,O
breaking,9641,O
agents,9641,O
.,9641,O
Cells,9642,O
from,9642,O
Polq,9642,B-GENE-Y
(,9642,O
-/-,9642,O
),9642,O
mice,9642,O
are,9642,O
hypersensitive,9642,O
to,9642,O
radiation,9642,O
and,9642,O
peripheral,9642,O
blood,9642,O
cells,9642,O
display,9642,O
increased,9642,O
spontaneous,9642,O
and,9642,O
ionizing,9642,O
radiation-induced,9642,O
levels,9642,O
of,9642,O
micronuclei,9642,O
(,9642,O
a,9642,O
hallmark,9642,O
of,9642,O
gross,9642,O
chromosomal,9642,O
aberrations,9642,O
),9642,O
",",9642,O
though,9642,O
mice,9642,O
apparently,9642,O
develop,9642,O
normally,9642,O
.,9642,O
Loss,9643,O
of,9643,O
POLQ,9643,B-GENE-N
in,9643,O
human,9643,O
and,9643,O
mouse,9643,O
cells,9643,O
causes,9643,O
sensitivity,9643,O
to,9643,O
ionizing,9643,O
radiation,9643,O
and,9643,O
other,9643,O
double,9643,O
strand,9643,O
breaking,9643,O
agents,9643,O
and,9643,O
increased,9643,O
DNA,9643,O
damage,9643,O
signaling,9643,O
.,9643,O
Retrospective,9644,O
studies,9644,O
of,9644,O
clinical,9644,O
samples,9644,O
show,9644,O
that,9644,O
higher,9644,O
levels,9644,O
of,9644,O
POLQ,9644,B-GENE-Y
gene,9644,O
expression,9644,O
in,9644,O
breast,9644,O
and,9644,O
colorectal,9644,O
cancer,9644,O
are,9644,O
correlated,9644,O
with,9644,O
poorer,9644,O
outcomes,9644,O
for,9644,O
patients,9644,O
.,9644,O
A,9645,O
clear,9645,O
understanding,9645,O
of,9645,O
the,9645,O
mechanism,9645,O
of,9645,O
action,9645,O
and,9645,O
physiologic,9645,O
function,9645,O
of,9645,O
POLQ,9645,B-GENE-Y
in,9645,O
the,9645,O
cell,9645,O
is,9645,O
likely,9645,O
to,9645,O
bear,9645,O
clinical,9645,O
relevance,9645,O
.,9645,O
Impaired,9646,O
in,9646,O
vivo,9646,O
binding,9646,O
of,9646,O
MeCP2,9646,B-GENE-Y
to,9646,O
chromatin,9646,O
in,9646,O
the,9646,O
absence,9646,O
of,9646,O
its,9646,O
DNA,9646,B-GENE-N
methyl-binding,9646,I-GENE-N
domain,9646,I-GENE-N
.,9646,O
MeCP2,9647,B-GENE-Y
is,9647,O
a,9647,O
methyl-CpG-binding,9647,B-GENE-N
protein,9647,I-GENE-N
that,9647,O
is,9647,O
a,9647,O
main,9647,O
component,9647,O
of,9647,O
brain,9647,O
chromatin,9647,O
in,9647,O
vertebrates,9647,O
.,9647,O
In,9648,O
vitro,9648,O
studies,9648,O
have,9648,O
determined,9648,O
that,9648,O
in,9648,O
addition,9648,O
to,9648,O
its,9648,O
specific,9648,O
methyl-CpG-binding,9648,B-GENE-N
domain,9648,I-GENE-N
(,9648,O
MBD,9648,B-GENE-N
),9648,O
MeCP2,9648,B-GENE-Y
also,9648,O
has,9648,O
several,9648,O
chromatin,9648,B-GENE-N
association,9648,I-GENE-N
domains,9648,I-GENE-N
.,9648,O
However,9649,O
",",9649,O
the,9649,O
specific,9649,O
interactions,9649,O
of,9649,O
MeCP2,9649,B-GENE-Y
with,9649,O
methylated,9649,O
or,9649,O
non-methylated,9649,O
chromatin,9649,O
regions,9649,O
and,9649,O
the,9649,O
structural,9649,O
characteristics,9649,O
of,9649,O
the,9649,O
resulting,9649,O
DNA,9649,O
associations,9649,O
in,9649,O
vivo,9649,O
remain,9649,O
poorly,9649,O
understood,9649,O
.,9649,O
We,9650,O
analysed,9650,O
the,9650,O
role,9650,O
of,9650,O
the,9650,O
MBD,9650,B-GENE-N
in,9650,O
MeCP2-chromatin,9650,B-GENE-Y
associations,9650,O
in,9650,O
vivo,9650,O
using,9650,O
an,9650,O
MeCP2,9650,B-GENE-Y
mutant,9650,O
Rett,9650,O
syndrome,9650,O
mouse,9650,O
model,9650,O
(,9650,O
Mecp2,9650,B-GENE-Y
(,9650,O
tm,9650,O
),9650,O
(,9650,O
1,9650,O
),9650,O
(,9650,O
.,9650,O
),9651,O
(,9651,O
1,9651,O
),9651,O
(,9651,O
Jae,9651,O
),9651,O
),9651,O
in,9651,O
which,9651,O
exon,9651,O
3,9651,O
deletion,9651,O
results,9651,O
in,9651,O
an,9651,O
N-terminal,9651,O
truncation,9651,O
of,9651,O
the,9651,O
protein,9651,O
",",9651,O
including,9651,O
most,9651,O
of,9651,O
the,9651,O
MBD,9651,O
.,9651,O
Our,9652,O
results,9652,O
show,9652,O
that,9652,O
in,9652,O
mutant,9652,O
mice,9652,O
",",9652,O
the,9652,O
truncated,9652,O
form,9652,O
of,9652,O
MeCP2,9652,O
(,9652,B-GENE-Y
ΔMeCP2,9652,O
),9652,O
is,9652,O
expressed,9652,O
in,9652,O
different,9652,O
regions,9652,O
of,9652,O
the,9652,O
brain,9652,O
and,9652,O
liver,9652,O
",",9652,O
albeit,9652,O
at,9652,O
50,9652,O
%,9652,O
of,9652,O
its,9652,O
wild-type,9652,O
(,9652,O
wt,9652,O
),9652,O
counterpart,9652,O
.,9652,O
In,9653,O
contrast,9653,O
to,9653,O
the,9653,O
punctate,9653,O
nuclear,9653,O
distribution,9653,O
characteristic,9653,O
of,9653,O
wt,9653,O
MeCP2,9653,O
",",9653,O
ΔMeCP2,9653,O
exhibits,9653,O
both,9653,O
diffuse,9653,O
nuclear,9653,O
localization,9653,O
and,9653,O
a,9653,O
substantial,9653,O
retention,9653,O
in,9653,O
the,9653,O
cytoplasm,9653,O
",",9653,O
suggesting,9653,O
a,9653,O
dysfunction,9653,O
of,9653,O
nuclear,9653,O
transport,9653,O
.,9653,O
In,9654,O
mutant,9654,O
brain,9654,O
tissue,9654,O
",",9654,O
neuronal,9654,O
nuclei,9654,O
are,9654,O
smaller,9654,O
",",9654,O
and,9654,O
ΔMeCP2,9654,O
chromatin,9654,O
is,9654,O
digested,9654,O
faster,9654,O
by,9654,O
nucleases,9654,O
",",9654,O
producing,9654,O
a,9654,O
characteristic,9654,O
nuclease-resistant,9654,O
dinucleosome,9654,O
.,9654,O
Although,9655,O
a,9655,O
fraction,9655,O
of,9655,O
ΔMeCP2,9655,O
is,9655,O
found,9655,O
associated,9655,O
with,9655,O
nucleosomes,9655,O
",",9655,O
its,9655,O
interaction,9655,O
with,9655,O
chromatin,9655,O
is,9655,O
transient,9655,O
and,9655,O
weak,9655,O
.,9655,O
Thus,9656,O
",",9656,O
our,9656,O
results,9656,O
unequivocally,9656,O
demonstrate,9656,O
that,9656,O
in,9656,O
vivo,9656,O
the,9656,O
MBD,9656,O
of,9656,O
MeCP2,9656,O
together,9656,O
with,9656,O
its,9656,O
adjacent,9656,O
region,9656,O
in,9656,O
the,9656,O
N-terminal,9656,O
domain,9656,O
are,9656,O
critical,9656,O
for,9656,O
the,9656,O
proper,9656,O
interaction,9656,O
of,9656,O
the,9656,O
protein,9656,O
with,9656,O
chromatin,9656,O
",",9656,O
which,9656,O
can,9656,O
not,9656,O
be,9656,O
replaced,9656,O
by,9656,O
any,9656,O
other,9656,O
of,9656,O
its,9656,O
protein,9656,O
domains,9656,O
.,9656,O
Pseudohypoaldosteronism,9657,O
type,9657,O
1,9657,O
and,9657,O
the,9657,O
genes,9657,O
encoding,9657,O
prostasin,9657,B-GENE-Y
",",9657,O
alpha-spectrin,9657,B-GENE-Y
",",9657,O
and,9657,O
Nedd4,9657,B-GENE-Y
.,9657,O
Pseudohypoaldosteronism,9658,O
type,9658,O
1,9658,O
(,9658,O
PHA1,9658,O
),9658,O
",",9658,O
a,9658,O
rare,9658,O
disorder,9658,O
of,9658,O
infancy,9658,O
",",9658,O
presents,9658,O
with,9658,O
potential,9658,O
life-threatening,9658,O
salt,9658,O
wasting,9658,O
and,9658,O
failure,9658,O
to,9658,O
thrive,9658,O
.,9658,O
Thus,9659,O
far,9659,O
",",9659,O
PHA1,9659,O
has,9659,O
been,9659,O
attributed,9659,O
to,9659,O
mutations,9659,O
affecting,9659,O
the,9659,O
mineralocorticoid,9659,B-GENE-Y
receptor,9659,I-GENE-Y
or,9659,O
any,9659,O
of,9659,O
the,9659,O
three,9659,O
subunits,9659,O
assembling,9659,O
the,9659,O
amiloride-sensitive,9659,B-GENE-N
epithelial,9659,I-GENE-N
sodium,9659,I-GENE-N
channel,9659,I-GENE-N
(,9659,O
ENaC,9659,B-GENE-N
),9659,O
.,9659,O
However,9660,O
",",9660,O
a,9660,O
lot,9660,O
of,9660,O
patients,9660,O
with,9660,O
a,9660,O
phenotype,9660,O
resembling,9660,O
PHA1,9660,O
",",9660,O
show,9660,O
no,9660,O
defects,9660,O
in,9660,O
these,9660,O
proteins,9660,O
",",9660,O
making,9660,O
it,9660,O
likely,9660,O
that,9660,O
further,9660,O
genes,9660,O
are,9660,O
involved,9660,O
in,9660,O
the,9660,O
aetiology,9660,O
of,9660,O
this,9660,O
disease,9660,O
.,9660,O
Recent,9661,O
studies,9661,O
have,9661,O
elucidated,9661,O
additional,9661,O
participants,9661,O
(,9661,O
alpha-spectrin,9661,B-GENE-Y
and,9661,O
members,9661,O
of,9661,O
the,9661,O
families,9661,O
of,9661,O
transmembrane,9661,B-GENE-N
serine,9661,I-GENE-N
proteases,9661,I-GENE-N
",",9661,O
ubiquitin-protein,9661,B-GENE-N
ligases,9661,I-GENE-N
",",9661,O
and,9661,O
serum-,9661,B-GENE-N
and,9661,I-GENE-N
glucocorticoid-regulated,9661,I-GENE-N
kinases,9661,I-GENE-N
",",9661,O
respectively,9661,O
),9661,O
regulating,9661,O
and/or,9661,O
interacting,9661,O
in,9661,O
the,9661,O
complex,9661,O
pathway,9661,O
of,9661,O
sodium,9661,B-CHEMICAL
retention,9661,O
in,9661,O
the,9661,O
amiloride-sensitive,9661,B-CHEMICAL
distal,9661,O
nephron,9661,O
.,9661,O
This,9662,O
led,9662,O
us,9662,O
to,9662,O
investigate,9662,O
whether,9662,O
PHA1,9662,O
can,9662,O
also,9662,O
be,9662,O
associated,9662,O
with,9662,O
mutations,9662,O
in,9662,O
some,9662,O
of,9662,O
these,9662,O
genes,9662,O
.,9662,O
Our,9663,O
data,9663,O
suggest,9663,O
that,9663,O
at,9663,O
least,9663,O
the,9663,O
prostasin,9663,B-GENE-Y
gene,9663,O
might,9663,O
be,9663,O
excluded,9663,O
as,9663,O
a,9663,O
causative,9663,O
locus,9663,O
.,9663,O
Cerebral,9664,O
and,9664,O
extracerebral,9664,O
cholesterol,9664,B-CHEMICAL
metabolism,9664,O
and,9664,O
CSF,9664,O
markers,9664,O
of,9664,O
Alzheimer,9664,O
's,9664,O
disease,9664,O
.,9664,O
The,9665,O
disturbances,9665,O
of,9665,O
the,9665,O
cholesterol,9665,B-CHEMICAL
synthesis,9665,O
and,9665,O
metabolism,9665,O
described,9665,O
in,9665,O
Alzheimer,9665,O
's,9665,O
disease,9665,O
(,9665,O
AD,9665,O
),9665,O
may,9665,O
be,9665,O
both,9665,O
a,9665,O
consequence,9665,O
of,9665,O
the,9665,O
neurodegenerative,9665,O
process,9665,O
and,9665,O
a,9665,O
contributor,9665,O
to,9665,O
the,9665,O
pathogenesis,9665,O
.,9665,O
These,9666,O
putative,9666,O
relationships,9666,O
and,9666,O
their,9666,O
underlying,9666,O
mechanisms,9666,O
are,9666,O
not,9666,O
well,9666,O
understood,9666,O
.,9666,O
The,9667,O
aim,9667,O
of,9667,O
this,9667,O
study,9667,O
was,9667,O
to,9667,O
evaluate,9667,O
the,9667,O
relationship,9667,O
between,9667,O
the,9667,O
cerebral,9667,O
and,9667,O
extracerebral,9667,O
cholesterol,9667,B-CHEMICAL
synthesis,9667,O
and,9667,O
metabolism,9667,O
",",9667,O
and,9667,O
the,9667,O
AD,9667,O
pathology,9667,O
as,9667,O
reflected,9667,O
by,9667,O
CSF,9667,O
markers,9667,O
in,9667,O
humans,9667,O
.,9667,O
We,9668,O
evaluated,9668,O
the,9668,O
relationships,9668,O
between,9668,O
the,9668,O
plasma,9668,O
and,9668,O
the,9668,O
cerebrospinal,9668,O
fluid,9668,O
(,9668,O
CSF,9668,O
),9668,O
concentrations,9668,O
of,9668,O
cholesterol,9668,B-CHEMICAL
",",9668,O
the,9668,O
cholesterol,9668,B-CHEMICAL
precursors,9668,O
lanosterol,9668,B-CHEMICAL
",",9668,O
lathosterol,9668,B-CHEMICAL
and,9668,O
desmosterol,9668,B-CHEMICAL
",",9668,O
and,9668,O
the,9668,O
cholesterol,9668,B-CHEMICAL
elimination,9668,O
products,9668,O
24S-hydroxycholesterol,9668,B-CHEMICAL
and,9668,O
27-hydroxycholesterol,9668,B-CHEMICAL
",",9668,O
and,9668,O
the,9668,O
CSF,9668,O
markers,9668,O
for,9668,O
AD,9668,O
pathology,9668,O
Aβ1-42,9668,B-GENE-Y
and,9668,O
p-tau181,9668,B-GENE-Y
in,9668,O
86,9668,O
subjects,9668,O
with,9668,O
normal,9668,O
cognition,9668,O
and,9668,O
in,9668,O
107,9668,O
AD,9668,O
patients,9668,O
.,9668,O
CSF,9669,O
desmosterol,9669,B-CHEMICAL
",",9669,O
cholesterol,9669,B-CHEMICAL
and,9669,O
24S-hydroxycholesterol,9669,B-CHEMICAL
in,9669,O
the,9669,O
AD,9669,O
group,9669,O
",",9669,O
and,9669,O
CSF,9669,O
24S-hydroxycholesterol,9669,B-CHEMICAL
in,9669,O
the,9669,O
control,9669,O
group,9669,O
correlated,9669,O
with,9669,O
the,9669,O
p-tau181,9669,B-GENE-Y
levels,9669,O
.,9669,O
Neither,9670,O
CSF,9670,O
nor,9670,O
plasma,9670,O
concentrations,9670,O
of,9670,O
the,9670,O
included,9670,O
compounds,9670,O
correlated,9670,O
with,9670,O
the,9670,O
CSF,9670,O
Aβ1-42,9670,B-GENE-Y
levels,9670,O
.,9670,O
In,9671,O
multivariate,9671,O
regression,9671,O
tests,9671,O
including,9671,O
age,9671,O
",",9671,O
gender,9671,O
",",9671,O
albumin,9671,O
ratio,9671,O
",",9671,O
number,9671,O
of,9671,O
the,9671,O
APOEɛ4,9671,B-GENE-Y
alleles,9671,O
",",9671,O
and,9671,O
diagnosis,9671,O
",",9671,O
p-tau181,9671,B-GENE-Y
levels,9671,O
independently,9671,O
predicted,9671,O
the,9671,O
CSF,9671,O
desmosterol,9671,B-CHEMICAL
",",9671,O
cholesterol,9671,B-CHEMICAL
and,9671,O
24S-hydroxycholesterol,9671,B-CHEMICAL
concentrations,9671,O
.,9671,O
The,9672,O
associations,9672,O
remained,9672,O
significant,9672,O
for,9672,O
CSF,9672,O
cholesterol,9672,B-CHEMICAL
and,9672,O
24S-hydroxycholesterol,9672,B-CHEMICAL
when,9672,O
analyses,9672,O
were,9672,O
separately,9672,O
performed,9672,O
in,9672,O
the,9672,O
AD,9672,O
group,9672,O
.,9672,O
The,9673,O
results,9673,O
suggest,9673,O
that,9673,O
alterations,9673,O
of,9673,O
CNS,9673,O
cholesterol,9673,B-CHEMICAL
de,9673,O
novo,9673,O
genesis,9673,O
and,9673,O
metabolism,9673,O
are,9673,O
related,9673,O
to,9673,O
neurodegeneration,9673,O
and,9673,O
in,9673,O
particular,9673,O
to,9673,O
the,9673,O
cerebral,9673,O
accumulation,9673,O
of,9673,O
phosphorylated,9673,B-GENE-Y
tau,9673,I-GENE-Y
.,9673,O
In,9674,O
vivo,9674,O
genotoxicity,9674,O
of,9674,O
methyleugenol,9674,B-CHEMICAL
in,9674,O
gpt,9674,B-GENE-Y
delta,9674,O
transgenic,9674,O
rats,9674,O
following,9674,O
medium-term,9674,O
exposure,9674,O
.,9674,O
Methyleugenol,9675,B-CHEMICAL
(,9675,O
MEG,9675,B-CHEMICAL
),9675,O
",",9675,O
which,9675,O
is,9675,O
commonly,9675,O
used,9675,O
as,9675,O
a,9675,O
fragrance,9675,O
and,9675,O
flavoring,9675,O
agent,9675,O
",",9675,O
has,9675,O
been,9675,O
shown,9675,O
to,9675,O
induce,9675,O
hepatocellular,9675,O
tumors,9675,O
in,9675,O
rodents,9675,O
.,9675,O
However,9676,O
",",9676,O
the,9676,O
role,9676,O
of,9676,O
genotoxicity,9676,O
as,9676,O
a,9676,O
possible,9676,O
mechanism,9676,O
of,9676,O
action,9676,O
is,9676,O
not,9676,O
fully,9676,O
understood,9676,O
even,9676,O
though,9676,O
the,9676,O
DNA-reactive,9676,O
metabolite,9676,O
of,9676,O
MEG,9676,B-CHEMICAL
has,9676,O
been,9676,O
identified,9676,O
.,9676,O
In,9677,O
this,9677,O
study,9677,O
",",9677,O
a,9677,O
gpt,9677,B-GENE-Y
delta,9677,O
transgenic,9677,O
rat,9677,O
model,9677,O
was,9677,O
used,9677,O
to,9677,O
clarify,9677,O
whether,9677,O
genotoxic,9677,O
mechanisms,9677,O
are,9677,O
involved,9677,O
in,9677,O
MEG-induced,9677,B-CHEMICAL
hepatocarcinogenesis,9677,O
following,9677,O
medium-term,9677,O
exposure,9677,O
.,9677,O
F344,9678,O
gpt,9678,B-GENE-Y
delta,9678,O
rats,9678,O
were,9678,O
subjected,9678,O
to,9678,O
repeated,9678,O
oral,9678,O
administration,9678,O
of,9678,O
MEG,9678,B-CHEMICAL
at,9678,O
dosages,9678,O
of,9678,O
0,9678,O
",",9678,O
10,9678,O
",",9678,O
30,9678,O
",",9678,O
or,9678,O
100mg/kg,9678,O
(,9678,O
a,9678,O
carcinogenic,9678,O
dose,9678,O
),9678,O
for,9678,O
13,9678,O
weeks,9678,O
.,9678,O
The,9679,O
relative,9679,O
weight,9679,O
of,9679,O
the,9679,O
liver,9679,O
of,9679,O
the,9679,O
male,9679,O
and,9679,O
female,9679,O
rats,9679,O
that,9679,O
were,9679,O
administered,9679,O
100mg/kg,9679,O
MEG,9679,B-CHEMICAL
and,9679,O
the,9679,O
absolute,9679,O
weight,9679,O
of,9679,O
the,9679,O
liver,9679,O
of,9679,O
the,9679,O
male,9679,O
rats,9679,O
that,9679,O
were,9679,O
administered,9679,O
100mg/kg,9679,O
MEG,9679,B-CHEMICAL
were,9679,O
significantly,9679,O
increased,9679,O
.,9679,O
In,9680,O
addition,9680,O
",",9680,O
the,9680,O
number,9680,O
and,9680,O
area,9680,O
of,9680,O
glutathione,9680,B-GENE-N
S-transferase,9680,I-GENE-N
placental,9680,I-GENE-N
form,9680,I-GENE-N
(,9680,O
GST-P,9680,B-GENE-N
),9680,O
positive,9680,O
foci,9680,O
and,9680,O
proliferating,9680,B-GENE-Y
cell,9680,I-GENE-Y
nuclear,9680,I-GENE-Y
antigen,9680,I-GENE-Y
(,9680,O
PCNA,9680,B-GENE-Y
),9680,O
positive,9680,O
cell,9680,O
ratios,9680,O
in,9680,O
the,9680,O
hepatocytes,9680,O
were,9680,O
significantly,9680,O
increased,9680,O
in,9680,O
the,9680,O
male,9680,O
and,9680,O
female,9680,O
rats,9680,O
that,9680,O
were,9680,O
administered,9680,O
100mg/kg,9680,O
MEG,9680,B-CHEMICAL
compared,9680,O
with,9680,O
the,9680,O
control,9680,O
animals,9680,O
.,9680,O
In,9681,O
the,9681,O
in,9681,O
vivo,9681,O
mutation,9681,O
assays,9681,O
",",9681,O
a,9681,O
significant,9681,O
increase,9681,O
in,9681,O
the,9681,O
gpt,9681,B-GENE-Y
and,9681,O
Spi,9681,B-GENE-N
(,9681,O
-,9681,O
),9681,O
mutant,9681,O
frequencies,9681,O
was,9681,O
observed,9681,O
in,9681,O
both,9681,O
sexes,9681,O
at,9681,O
the,9681,O
carcinogenic,9681,O
dose,9681,O
.,9681,O
These,9682,O
results,9682,O
suggest,9682,O
the,9682,O
possible,9682,O
participation,9682,O
of,9682,O
genotoxic,9682,O
mechanisms,9682,O
in,9682,O
MEG-induced,9682,B-CHEMICAL
hepatocarcinogenesis,9682,O
.,9682,O
Structural,9683,O
Investigation,9683,O
and,9683,O
Biological,9683,O
Activity,9683,O
of,9683,O
Sesquiterpene,9683,B-CHEMICAL
Lactones,9683,I-CHEMICAL
from,9683,O
the,9683,O
Traditional,9683,O
Chinese,9683,O
Herb,9683,O
Inula,9683,O
racemosa,9683,O
.,9683,O
Five,9684,O
new,9684,O
sesquiterpene,9684,B-CHEMICAL
lactones,9684,I-CHEMICAL
",",9684,O
racemosalactones,9684,B-CHEMICAL
A-E,9684,I-CHEMICAL
(,9684,O
1-5,9684,O
),9684,O
",",9684,O
along,9684,O
with,9684,O
19,9684,O
known,9684,O
sesquiterpene,9684,B-CHEMICAL
latones,9684,I-CHEMICAL
(,9684,O
6-24,9684,O
),9684,O
",",9684,O
were,9684,O
isolated,9684,O
from,9684,O
the,9684,O
roots,9684,O
of,9684,O
Inula,9684,O
racemosa,9684,O
.,9684,O
Their,9685,O
structures,9685,O
were,9685,O
elucidated,9685,O
by,9685,O
extensive,9685,O
spectroscopic,9685,O
analysis,9685,O
",",9685,O
and,9685,O
the,9685,O
absolute,9685,O
configuration,9685,O
of,9685,O
2,9685,O
was,9685,O
deduced,9685,O
from,9685,O
X-ray,9685,O
diffraction,9685,O
analysis,9685,O
.,9685,O
Compounds,9686,O
1,9686,O
",",9686,O
6,9686,O
",",9686,O
8,9686,O
",",9686,O
10,9686,O
",",9686,O
12,9686,O
",",9686,O
14,9686,O
",",9686,O
and,9686,O
17,9686,O
exhibited,9686,O
antiproliferative,9686,O
activities,9686,O
with,9686,O
IC50,9686,O
values,9686,O
ranging,9686,O
from,9686,O
0.38,9686,O
to,9686,O
4.19,9686,O
μg/mL,9686,O
against,9686,O
human,9686,O
non-small-cell,9686,O
lung,9686,O
cancer,9686,O
A549,9686,O
",",9686,O
hepatocellular,9686,O
carcinoma,9686,O
HepG2,9686,O
",",9686,O
and,9686,O
human,9686,O
fibrosarcoma,9686,O
HT1080,9686,O
cells,9686,O
.,9686,O
Compounds,9687,O
6,9687,O
and,9687,O
8,9687,O
exhibited,9687,O
antiproliferative,9687,O
activities,9687,O
against,9687,O
endothelial,9687,O
cells,9687,O
with,9687,O
IC50,9687,O
values,9687,O
of,9687,O
2.4,9687,O
and,9687,O
2.5,9687,O
μg/mL,9687,O
",",9687,O
respectively,9687,O
.,9687,O
Furthermore,9688,O
",",9688,O
compounds,9688,O
6,9688,O
and,9688,O
8,9688,O
both,9688,O
inhibited,9688,O
endothelial,9688,O
cell,9688,O
tube,9688,O
formation,9688,O
at,9688,O
1.0,9688,O
μg/mL,9688,O
.,9688,O
A,9689,O
method,9689,O
for,9689,O
the,9689,O
rapid,9689,O
and,9689,O
straightforward,9689,O
preparative-scale,9689,O
isolation,9689,O
of,9689,O
compound,9689,O
6,9689,O
from,9689,O
alantolides,9689,B-CHEMICAL
is,9689,O
described,9689,O
.,9689,O
Narirutin,9690,B-CHEMICAL
fraction,9690,O
from,9690,O
citrus,9690,O
peels,9690,O
attenuates,9690,O
alcoholic,9690,O
liver,9690,O
disease,9690,O
in,9690,O
mice,9690,O
.,9690,O
This,9691,O
study,9691,O
aimed,9691,O
to,9691,O
demonstrate,9691,O
protective,9691,O
activities,9691,O
of,9691,O
the,9691,O
narirutin,9691,B-CHEMICAL
fraction,9691,O
from,9691,O
peels,9691,O
of,9691,O
Citrus,9691,O
unshiu,9691,O
against,9691,O
ethanol-induced,9691,B-CHEMICAL
hepatic,9691,O
damage,9691,O
through,9691,O
an,9691,O
animal,9691,O
study,9691,O
.,9691,O
Citrus,9692,O
narirutin,9692,B-CHEMICAL
fraction,9692,O
(,9692,O
CNF,9692,O
),9692,O
",",9692,O
contained,9692,O
75,9692,O
%,9692,O
of,9692,O
narirutin,9692,B-CHEMICAL
",",9692,O
was,9692,O
obtained,9692,O
by,9692,O
an,9692,O
ultra-sonicated,9692,O
extraction,9692,O
and,9692,O
further,9692,O
purification,9692,O
.,9692,O
ICR,9693,O
mice,9693,O
were,9693,O
divided,9693,O
into,9693,O
four,9693,O
groups,9693,O
;,9693,O
normaldiet,9693,O
control,9693,O
",",9693,O
ethanol,9693,B-CHEMICAL
control,9693,O
(,9693,O
6.5g,9693,O
ethanol/kg,9693,B-CHEMICAL
),9693,O
",",9693,O
low-CNF,9693,O
(,9693,O
ethanol+150mg,9693,B-CHEMICAL
CNF/kg,9693,O
),9693,O
and,9693,O
high-CNF,9693,O
(,9693,O
ethanol+300mg,9693,B-CHEMICAL
CNF/kg,9693,O
),9693,O
groups,9693,O
.,9693,O
Consumption,9694,O
of,9694,O
alcohol,9694,B-CHEMICAL
for,9694,O
8weeks,9694,O
induced,9694,O
severe,9694,O
liver,9694,O
damage,9694,O
with,9694,O
increases,9694,O
in,9694,O
prognostic,9694,O
indicators,9694,O
such,9694,O
as,9694,O
aspartate,9694,B-GENE-N
transaminase,9694,I-GENE-N
",",9694,O
alanine,9694,B-GENE-N
transaminase,9694,I-GENE-N
in,9694,O
serum,9694,O
whereas,9694,O
co-administration,9694,O
of,9694,O
CNF,9694,O
suppressed,9694,O
their,9694,O
increases,9694,O
.,9694,O
Excessive,9695,O
accumulations,9695,O
in,9695,O
liver,9695,O
TG,9695,O
and,9695,O
TC,9695,O
in,9695,O
ethanol,9695,B-CHEMICAL
control,9695,O
group,9695,O
were,9695,O
also,9695,O
suppressed,9695,O
by,9695,O
co-administration,9695,O
of,9695,O
CNF,9695,O
.,9695,O
Co-administration,9696,O
of,9696,O
CNF,9696,O
maintained,9696,O
SOD,9696,B-GENE-N
activity,9696,O
",",9696,O
GSH,9696,B-CHEMICAL
and,9696,O
malondialdehyde,9696,B-CHEMICAL
levels,9696,O
close,9696,O
to,9696,O
those,9696,O
of,9696,O
the,9696,O
normal,9696,O
diet,9696,O
group,9696,O
.,9696,O
Chronic,9697,O
consumption,9697,O
of,9697,O
alcohol,9697,B-CHEMICAL
also,9697,O
stimulated,9697,O
abrupt,9697,O
increases,9697,O
in,9697,O
pro-inflammatory,9697,O
cytokines,9697,O
such,9697,O
as,9697,O
nuclear,9697,B-GENE-N
factor,9697,I-GENE-N
(,9697,I-GENE-N
NF,9697,I-GENE-N
),9697,I-GENE-N
-κB,9697,I-GENE-N
",",9697,O
tumor,9697,B-GENE-Y
necrosis,9697,I-GENE-Y
factor,9697,I-GENE-Y
(,9697,I-GENE-Y
TNF,9697,I-GENE-Y
),9697,I-GENE-Y
-α,9697,I-GENE-Y
and,9697,O
interleukin,9697,B-GENE-Y
(,9697,I-GENE-Y
IL,9697,I-GENE-Y
),9697,I-GENE-Y
-1β,9697,I-GENE-Y
in,9697,O
liver,9697,O
otherwise,9697,O
co-administration,9697,O
of,9697,O
CNF,9697,O
effectively,9697,O
suppressed,9697,O
production,9697,O
of,9697,O
these,9697,O
cytokines,9697,B-GENE-N
dose-dependently,9697,O
.,9697,O
These,9698,O
results,9698,O
indicate,9698,O
that,9698,O
co-administration,9698,O
of,9698,O
CNF,9698,O
with,9698,O
alcohol,9698,B-CHEMICAL
can,9698,O
alleviate,9698,O
alcohol,9698,B-CHEMICAL
induced,9698,O
liver,9698,O
damage,9698,O
through,9698,O
preventing,9698,O
lipid,9698,O
formation,9698,O
",",9698,O
protecting,9698,O
antioxidant,9698,O
system,9698,O
and,9698,O
suppressing,9698,O
productions,9698,O
of,9698,O
pro-inflammatory,9698,O
cytokines,9698,B-GENE-N
.,9698,O
Impaired,9699,O
local,9699,O
production,9699,O
of,9699,O
pro-resolving,9699,O
lipid,9699,O
mediators,9699,O
in,9699,O
obesity,9699,O
and,9699,O
17-HDHA,9699,B-CHEMICAL
as,9699,O
a,9699,O
potential,9699,O
treatment,9699,O
for,9699,O
obesity-associated,9699,O
inflammation,9699,O
.,9699,O
Obesity-induced,9700,O
chronic,9700,O
low-grade,9700,O
inflammation,9700,O
originates,9700,O
from,9700,O
adipose,9700,O
tissue,9700,O
and,9700,O
is,9700,O
crucial,9700,O
for,9700,O
obesity-driven,9700,O
metabolic,9700,O
deterioration,9700,O
including,9700,O
insulin,9700,B-GENE-Y
resistance,9700,O
and,9700,O
type,9700,O
2,9700,O
diabetes.Chronic,9700,O
inflammation,9700,O
may,9700,O
be,9700,O
a,9700,O
consequence,9700,O
of,9700,O
a,9700,O
failure,9700,O
to,9700,O
actively,9700,O
resolve,9700,O
inflammation,9700,O
",",9700,O
and,9700,O
could,9700,O
result,9700,O
from,9700,O
a,9700,O
lack,9700,O
of,9700,O
local,9700,O
specialized,9700,O
pro-resolving,9700,O
lipid,9700,O
mediators,9700,O
(,9700,O
SPM,9700,O
),9700,O
such,9700,O
as,9700,O
resolvins,9700,B-CHEMICAL
and,9700,O
protectins,9700,O
",",9700,O
which,9700,O
derive,9700,O
from,9700,O
the,9700,O
n-3,9700,O
polyunsaturated,9700,B-CHEMICAL
fatty,9700,I-CHEMICAL
acids,9700,I-CHEMICAL
eicosapentaenoic,9700,B-CHEMICAL
acid,9700,I-CHEMICAL
(,9700,O
EPA,9700,B-CHEMICAL
),9700,O
and,9700,O
docosahexaenoic,9700,B-CHEMICAL
acid,9700,I-CHEMICAL
(,9700,O
DHA,9700,B-CHEMICAL
),9700,O
.,9700,O
We,9701,O
assessed,9701,O
obesity-induced,9701,O
changes,9701,O
of,9701,O
n-3-derived,9701,O
SPM,9701,O
in,9701,O
adipose,9701,O
tissue,9701,O
and,9701,O
effects,9701,O
of,9701,O
dietary,9701,O
EPA/DHA,9701,B-CHEMICAL
thereon.Moreover,9701,O
",",9701,O
we,9701,O
treated,9701,O
obese,9701,O
mice,9701,O
with,9701,O
SPM,9701,O
precursors,9701,O
and,9701,O
investigated,9701,O
effects,9701,O
on,9701,O
inflammation,9701,O
and,9701,O
metabolic,9701,O
dysregulation,9701,O
.,9701,O
Obesity,9702,O
significantly,9702,O
decreased,9702,O
DHA-derived,9702,B-CHEMICAL
17-hydroxydocosahexaenoic,9702,B-CHEMICAL
acid,9702,I-CHEMICAL
(,9702,O
17-HDHA,9702,B-CHEMICAL
",",9702,O
resolvin,9702,B-CHEMICAL
D1,9702,I-CHEMICAL
precursor,9702,O
),9702,O
and,9702,O
protectin,9702,B-CHEMICAL
D1,9702,I-CHEMICAL
levels,9702,O
in,9702,O
murine,9702,O
adipose,9702,O
tissue,9702,O
.,9702,O
Dietary,9703,O
EPA/DHA,9703,B-CHEMICAL
treatment,9703,O
restored,9703,O
endogenous,9703,O
biosynthesis,9703,O
of,9703,O
n-3,9703,O
derived,9703,O
lipid,9703,O
mediators,9703,O
in,9703,O
obesity,9703,O
while,9703,O
attenuating,9703,O
adipose,9703,O
tissue,9703,O
inflammation,9703,O
and,9703,O
improving,9703,O
insulin,9703,B-GENE-N
sensitivity,9703,O
.,9703,O
Notably,9704,O
",",9704,O
17-HDHA,9704,B-CHEMICAL
treatment,9704,O
reduced,9704,O
adipose,9704,O
tissue,9704,O
expression,9704,O
of,9704,O
inflammatory,9704,O
cytokines,9704,B-GENE-N
",",9704,O
increased,9704,O
adiponectin,9704,B-GENE-Y
expression,9704,O
and,9704,O
improved,9704,O
glucose,9704,B-CHEMICAL
tolerance,9704,O
parallel,9704,O
to,9704,O
insulin,9704,B-GENE-N
sensitivity,9704,O
in,9704,O
obese,9704,O
mice,9704,O
.,9704,O
These,9705,O
findings,9705,O
indicate,9705,O
that,9705,O
impaired,9705,O
biosynthesis,9705,O
of,9705,O
certain,9705,O
SPM,9705,O
and,9705,O
SPM,9705,O
precursors,9705,O
including,9705,O
17-HDHA,9705,B-CHEMICAL
and,9705,O
protectin,9705,B-CHEMICAL
D1,9705,I-CHEMICAL
contributes,9705,O
to,9705,O
adipose,9705,O
tissue,9705,O
inflammation,9705,O
in,9705,O
obesity,9705,O
and,9705,O
suggest,9705,O
17-HDHA,9705,B-CHEMICAL
as,9705,O
a,9705,O
novel,9705,O
treatment,9705,O
option,9705,O
for,9705,O
obesity-associated,9705,O
complications,9705,O
.,9705,O
The,9706,O
glycogen,9706,B-GENE-Y
synthase,9706,I-GENE-Y
kinase-3β/nuclear,9706,O
factor-kappa,9706,I-GENE-N
B,9706,I-GENE-N
pathway,9706,O
is,9706,O
involved,9706,O
in,9706,O
cinobufagin-induced,9706,B-CHEMICAL
apoptosis,9706,O
in,9706,O
cultured,9706,O
osteosarcoma,9706,O
cells,9706,O
.,9706,O
Cinobufagin,9707,B-CHEMICAL
",",9707,O
a,9707,O
major,9707,O
component,9707,O
of,9707,O
cinobufacini,9707,O
(,9707,O
huachansu,9707,O
),9707,O
",",9707,O
is,9707,O
an,9707,O
important,9707,O
cardenolidal,9707,B-CHEMICAL
steroid,9707,I-CHEMICAL
.,9707,O
Several,9708,O
studies,9708,O
have,9708,O
suggested,9708,O
that,9708,O
cinobufagin,9708,B-CHEMICAL
has,9708,O
potent,9708,O
anti-cancer,9708,O
effects,9708,O
.,9708,O
The,9709,O
present,9709,O
study,9709,O
examines,9709,O
the,9709,O
apoptosis-inducing,9709,O
activity,9709,O
and,9709,O
the,9709,O
underlying,9709,O
mechanism,9709,O
of,9709,O
action,9709,O
of,9709,O
cinobufagin,9709,B-CHEMICAL
in,9709,O
osteosarcoma,9709,O
(,9709,O
OS,9709,O
),9709,O
cells,9709,O
.,9709,O
Our,9710,O
results,9710,O
showed,9710,O
that,9710,O
cinobufagin,9710,B-CHEMICAL
potently,9710,O
inhibited,9710,O
the,9710,O
proliferation,9710,O
of,9710,O
U2OS,9710,O
",",9710,O
MG63,9710,O
and,9710,O
SaOS-2,9710,O
cells,9710,O
.,9710,O
Significant,9711,O
increases,9711,O
in,9711,O
G2/M,9711,O
cell-cycle,9711,O
arrest,9711,O
and,9711,O
apoptosis,9711,O
in,9711,O
OS,9711,O
cells,9711,O
were,9711,O
also,9711,O
observed,9711,O
.,9711,O
The,9712,O
expression,9712,O
levels,9712,O
of,9712,O
several,9712,O
apoptotic,9712,O
proteins,9712,O
were,9712,O
assessed,9712,O
after,9712,O
cinobufagin,9712,B-CHEMICAL
treatment,9712,O
in,9712,O
U2OS,9712,O
cells,9712,O
.,9712,O
Among,9713,O
them,9713,O
",",9713,O
xIAP,9713,B-GENE-Y
",",9713,O
cIAP-1,9713,B-GENE-Y
",",9713,O
survivin,9713,B-GENE-Y
and,9713,O
Bcl-2,9713,B-GENE-Y
levels,9713,O
decreased,9713,O
remarkably,9713,O
",",9713,O
while,9713,O
the,9713,O
levels,9713,O
of,9713,O
Bax,9713,B-GENE-Y
and,9713,O
cleaved-PARP,9713,O
increased,9713,O
.,9713,O
Furthermore,9714,O
",",9714,O
we,9714,O
validated,9714,O
the,9714,O
inhibition,9714,O
of,9714,O
GSK-3β/NF-κB,9714,B-GENE-Y
signaling,9714,O
following,9714,O
cinobufagin,9714,B-CHEMICAL
treatment,9714,O
.,9714,O
Western,9715,O
blots,9715,O
showed,9715,O
a,9715,O
decrease,9715,O
in,9715,O
nuclear,9715,O
p65,9715,B-GENE-Y
protein,9715,O
expression,9715,O
after,9715,O
exposure,9715,O
to,9715,O
different,9715,O
concentrations,9715,O
of,9715,O
cinobufagin,9715,B-CHEMICAL
",",9715,O
while,9715,O
the,9715,O
phosphorylation,9715,O
of,9715,O
GSK-3β,9715,B-GENE-Y
was,9715,O
simultaneously,9715,O
increased,9715,O
.,9715,O
Transduction,9716,O
with,9716,O
constitutively,9716,O
active,9716,O
forms,9716,O
of,9716,O
GSK-3β,9716,B-GENE-Y
could,9716,O
protect,9716,O
against,9716,O
the,9716,O
downregulation,9716,O
of,9716,O
p65,9716,B-GENE-Y
and,9716,O
upregulation,9716,O
of,9716,O
cleaved-PARP,9716,O
that,9716,O
are,9716,O
induced,9716,O
by,9716,O
cinobufagin,9716,B-CHEMICAL
treatment,9716,O
.,9716,O
However,9717,O
",",9717,O
combined,9717,O
treatment,9717,O
with,9717,O
cinobufagin,9717,B-CHEMICAL
and,9717,O
SB216367,9717,B-CHEMICAL
resulted,9717,O
in,9717,O
a,9717,O
significant,9717,O
reduction,9717,O
in,9717,O
p65,9717,B-GENE-Y
and,9717,O
an,9717,O
increase,9717,O
in,9717,O
cleaved-PARP,9717,O
in,9717,O
U2OS,9717,O
cells,9717,O
.,9717,O
Altogether,9718,O
",",9718,O
these,9718,O
results,9718,O
show,9718,O
that,9718,O
cinobufagin,9718,B-CHEMICAL
is,9718,O
a,9718,O
promising,9718,O
agent,9718,O
for,9718,O
the,9718,O
treatment,9718,O
of,9718,O
OS,9718,O
.,9718,O
These,9719,O
studies,9719,O
are,9719,O
the,9719,O
first,9719,O
to,9719,O
reveal,9719,O
the,9719,O
involvement,9719,O
of,9719,O
the,9719,O
GSK-3β/NF-κB,9719,B-GENE-Y
pathway,9719,O
in,9719,O
cinobufagin-induced,9719,B-CHEMICAL
apoptosis,9719,O
.,9719,O
Arsenic,9720,B-CHEMICAL
activates,9720,O
endothelin-1,9720,B-GENE-Y
Gi,9720,B-GENE-N
protein-coupled,9720,I-GENE-N
receptor,9720,I-GENE-N
signaling,9720,O
to,9720,O
inhibit,9720,O
stem,9720,O
cell,9720,O
differentiation,9720,O
in,9720,O
adipogenesis,9720,O
.,9720,O
Dysfunctional,9721,O
lipid,9721,O
and,9721,O
glucose,9721,B-CHEMICAL
metabolism,9721,O
contribute,9721,O
to,9721,O
metabolic,9721,O
syndrome-a,9721,O
major,9721,O
public,9721,O
health,9721,O
concern,9721,O
that,9721,O
enhances,9721,O
cardiovascular,9721,O
disease,9721,O
risk,9721,O
.,9721,O
Arsenic,9722,B-CHEMICAL
(,9722,O
As,9722,B-CHEMICAL
(,9722,I-CHEMICAL
III,9722,I-CHEMICAL
),9722,I-CHEMICAL
),9722,O
exposure,9722,O
may,9722,O
increase,9722,O
metabolic,9722,O
syndrome,9722,O
and,9722,O
cardiovascular,9722,O
disease,9722,O
risk,9722,O
by,9722,O
impairing,9722,O
adipose,9722,O
tissue,9722,O
differentiation,9722,O
",",9722,O
function,9722,O
",",9722,O
and,9722,O
insulin,9722,O
sensitivity,9722,O
through,9722,O
pathogenic,9722,O
mechanisms,9722,O
that,9722,O
remain,9722,O
unclear,9722,O
.,9722,O
We,9723,O
hypothesized,9723,O
that,9723,O
As,9723,B-CHEMICAL
(,9723,I-CHEMICAL
III,9723,I-CHEMICAL
),9723,I-CHEMICAL
signals,9723,O
through,9723,O
the,9723,O
Pertussis,9723,B-GENE-N
toxin,9723,I-GENE-N
(,9723,O
Ptx,9723,B-GENE-N
),9723,O
sensitive,9723,O
",",9723,O
Gi,9723,B-GENE-N
protein-coupled,9723,I-GENE-N
receptor,9723,I-GENE-N
(,9723,O
GPCR,9723,B-GENE-N
),9723,O
to,9723,O
impair,9723,O
adipogenesis,9723,O
",",9723,O
as,9723,O
previously,9723,O
demonstrated,9723,O
for,9723,O
its,9723,O
stimulation,9723,O
of,9723,O
vascular,9723,O
oxidant,9723,O
generation,9723,O
",",9723,O
angiogenesis,9723,O
",",9723,O
and,9723,O
remodeling,9723,O
.,9723,O
Because,9724,O
both,9724,O
As,9724,B-CHEMICAL
(,9724,I-CHEMICAL
III,9724,I-CHEMICAL
),9724,I-CHEMICAL
and,9724,O
GPCR,9724,B-GENE-N
ligands,9724,O
inhibit,9724,O
progenitor,9724,O
cell,9724,O
differentiation,9724,O
into,9724,O
adipocytes,9724,O
",",9724,O
we,9724,O
investigated,9724,O
the,9724,O
hypothesis,9724,O
in,9724,O
a,9724,O
model,9724,O
of,9724,O
low-passage,9724,O
human,9724,O
mesenchymal,9724,O
stem,9724,O
cells,9724,O
(,9724,O
hMSC,9724,O
),9724,O
.,9724,O
As,9725,B-CHEMICAL
(,9725,I-CHEMICAL
III,9725,I-CHEMICAL
),9725,I-CHEMICAL
(,9725,O
0.1-1.0,9725,O
µM,9725,O
),9725,O
suppressed,9725,O
dexamethasone/insulin-induced,9725,B-CHEMICAL
hMSC,9725,O
adipogenesis,9725,O
",",9725,O
as,9725,O
indicated,9725,O
by,9725,O
decreased,9725,O
transcriptional,9725,O
promoters,9725,O
of,9725,O
differentiation,9725,O
",",9725,O
decreased,9725,O
fat,9725,O
droplet,9725,O
formation,9725,O
",",9725,O
and,9725,O
decreased,9725,O
expression,9725,O
of,9725,O
differentiated,9725,O
adipocyte,9725,O
markers,9725,O
",",9725,O
such,9725,O
as,9725,O
adiponectin,9725,B-GENE-Y
and,9725,O
perilipin,9725,B-GENE-Y
.,9725,O
Preincubating,9726,O
hMSC,9726,O
with,9726,O
Ptx,9726,B-GENE-N
prevented,9726,O
90,9726,O
%,9726,O
of,9726,O
the,9726,O
suppressive,9726,O
effect,9726,O
of,9726,O
As,9726,B-CHEMICAL
(,9726,I-CHEMICAL
III,9726,I-CHEMICAL
),9726,I-CHEMICAL
.,9726,O
Selective,9727,O
competitive,9727,O
antagonists,9727,O
of,9727,O
Gi-coupled,9727,B-GENE-N
endothelin-1,9727,B-GENE-N
type,9727,I-GENE-N
A,9727,I-GENE-N
and,9727,I-GENE-N
B,9727,I-GENE-N
receptors,9727,I-GENE-N
were,9727,O
~60,9727,O
%,9727,O
effective,9727,O
in,9727,O
blocking,9727,O
As,9727,B-CHEMICAL
(,9727,I-CHEMICAL
III,9727,I-CHEMICAL
),9727,I-CHEMICAL
inhibition,9727,O
and,9727,O
combination,9727,O
of,9727,O
antagonists,9727,O
to,9727,O
both,9727,O
receptors,9727,O
were,9727,O
85,9727,O
%,9727,O
effective,9727,O
.,9727,O
In,9728,O
contrast,9728,O
",",9728,O
antagonists,9728,O
to,9728,O
the,9728,O
sphingosine-1-phosphate,9728,B-GENE-Y
type,9728,I-GENE-Y
1,9728,I-GENE-Y
receptor,9728,I-GENE-Y
(,9728,O
previously,9728,O
shown,9728,O
to,9728,O
mediate,9728,O
As,9728,B-CHEMICAL
(,9728,I-CHEMICAL
III,9728,I-CHEMICAL
),9728,I-CHEMICAL
vascular,9728,O
effects,9728,O
),9728,O
or,9728,O
the,9728,O
angiotensin,9728,B-GENE-Y
II,9728,I-GENE-Y
type,9728,I-GENE-Y
1,9728,I-GENE-Y
receptor,9728,I-GENE-Y
were,9728,O
ineffective,9728,O
in,9728,O
blocking,9728,O
As,9728,B-CHEMICAL
(,9728,I-CHEMICAL
III,9728,I-CHEMICAL
),9728,I-CHEMICAL
effects,9728,O
.,9728,O
These,9729,O
studies,9729,O
suggest,9729,O
a,9729,O
majority,9729,O
of,9729,O
arsenic-inhibited,9729,B-CHEMICAL
adipocyte,9729,O
differentiation,9729,O
",",9729,O
and,9729,O
metabolism,9729,O
requires,9729,O
endothelin-1,9729,B-GENE-Y
GPCRs,9729,B-GENE-N
and,9729,O
that,9729,O
As,9729,B-CHEMICAL
(,9729,I-CHEMICAL
III,9729,I-CHEMICAL
),9729,I-CHEMICAL
effects,9729,O
on,9729,O
GPCR,9729,B-GENE-N
signaling,9729,O
are,9729,O
tissue,9729,O
and,9729,O
context,9729,O
specific,9729,O
.,9729,O
This,9730,O
may,9730,O
represent,9730,O
a,9730,O
significant,9730,O
mechanism,9730,O
for,9730,O
the,9730,O
contribution,9730,O
of,9730,O
arsenic,9730,B-CHEMICAL
exposure,9730,O
to,9730,O
increased,9730,O
metabolic,9730,O
and,9730,O
cardiovascular,9730,O
diseases,9730,O
.,9730,O
Activation-dependent,9731,O
exposure,9731,O
of,9731,O
the,9731,O
inter-EGF,9731,B-GENE-N
sequence,9731,I-GENE-N
Leu83-Leu88,9731,B-GENE-N
in,9731,O
factor,9731,B-GENE-Y
Xa,9731,I-GENE-Y
mediates,9731,O
ligand,9731,O
binding,9731,O
to,9731,O
effector,9731,B-GENE-Y
cell,9731,I-GENE-Y
protease,9731,I-GENE-Y
receptor-1,9731,I-GENE-Y
.,9731,O
Binding,9732,O
of,9732,O
factor,9732,B-GENE-Y
Xa,9732,I-GENE-Y
to,9732,O
human,9732,O
umbilical,9732,O
vein,9732,O
endothelial,9732,O
cells,9732,O
(,9732,O
HUVEC,9732,O
),9732,O
is,9732,O
contributed,9732,O
by,9732,O
effector,9732,B-GENE-Y
cell,9732,I-GENE-Y
protease,9732,I-GENE-Y
receptor-1,9732,I-GENE-Y
(,9732,O
EPR-1,9732,B-GENE-Y
),9732,O
.,9732,O
The,9733,O
structural,9733,O
requirements,9733,O
of,9733,O
this,9733,O
recognition,9733,O
were,9733,O
investigated,9733,O
.,9733,O
Factor,9734,B-GENE-Y
Xa,9734,I-GENE-Y
or,9734,O
catalytically,9734,O
inactive,9734,O
5-dimethylaminonaphthalene-1sulfonyl,9734,B-CHEMICAL
(,9734,I-CHEMICAL
dansyl,9734,I-CHEMICAL
),9734,I-CHEMICAL
Glu-Gly-Arg-,9734,I-CHEMICAL
(,9734,I-CHEMICAL
DEGR,9734,I-CHEMICAL
),9734,I-CHEMICAL
-chloromethylketone-factor,9734,O
Xa,9734,I-GENE-Y
bound,9734,O
indistinguishably,9734,O
to,9734,O
HUVEC,9734,O
and,9734,O
EPR-1,9734,B-GENE-Y
transfectants,9734,O
",",9734,O
and,9734,O
inhibited,9734,O
equally,9734,O
well,9734,O
the,9734,O
binding,9734,O
of,9734,O
125I-factor,9734,O
Xa,9734,I-GENE-Y
to,9734,O
these,9734,O
cells,9734,O
.,9734,O
Similarly,9735,O
",",9735,O
factor,9735,B-GENE-Y
Xa,9735,I-GENE-Y
active,9735,O
site,9735,O
inhibitors,9735,O
TAP,9735,O
or,9735,O
NAP5,9735,O
did,9735,O
not,9735,O
reduce,9735,O
ligand,9735,O
binding,9735,O
to,9735,O
EPR-1,9735,B-GENE-Y
.,9735,O
A,9736,O
factor,9736,B-GENE-Y
X,9736,I-GENE-Y
peptide,9736,O
duplicating,9736,O
the,9736,O
inter-EGF,9736,B-GENE-N
sequence,9736,I-GENE-N
Leu83-Phe84-Thr85-Arg86-Lys87-Leu88-,9736,B-GENE-N
(,9736,I-GENE-N
Gly,9736,I-GENE-N
),9736,I-GENE-N
inhibited,9736,O
factor,9736,B-GENE-Y
V/Va-independent,9736,O
prothrombin,9736,B-GENE-Y
activation,9736,O
by,9736,O
HUVEC,9736,O
and,9736,O
blocked,9736,O
binding,9736,O
of,9736,O
125I-factor,9736,B-CHEMICAL
Xa,9736,I-GENE-Y
to,9736,O
these,9736,O
cells,9736,O
in,9736,O
a,9736,O
dose-dependent,9736,O
manner,9736,O
(,9736,O
IC50,9736,O
approximately,9736,O
20-40,9736,O
microM,9736,O
),9736,O
.,9736,O
In,9737,O
contrast,9737,O
",",9737,O
none,9737,O
of,9737,O
the,9737,O
other,9737,O
factor,9737,B-GENE-Y
X,9737,I-GENE-Y
peptides,9737,O
tested,9737,O
or,9737,O
a,9737,O
control,9737,O
peptide,9737,O
with,9737,O
the,9737,O
inter-EGF,9737,B-GENE-N
sequence,9737,I-GENE-N
in,9737,O
scrambled,9737,O
order,9737,O
was,9737,O
effective,9737,O
.,9737,O
A,9738,O
recombinant,9738,O
chimeric,9738,O
molecule,9738,O
expressing,9738,O
the,9738,O
factor,9738,B-GENE-Y
X,9738,I-GENE-Y
sequence,9738,O
Leu83-Leu88,9738,B-GENE-N
within,9738,O
a,9738,O
factor,9738,B-GENE-Y
IX,9738,I-GENE-Y
backbone,9738,O
inhibited,9738,O
binding,9738,O
of,9738,O
125I-factor,9738,B-CHEMICAL
Xa,9738,I-GENE-Y
to,9738,O
HUVEC,9738,O
and,9738,O
EPR-1,9738,B-GENE-Y
transfectants,9738,O
in,9738,O
a,9738,O
dose-dependent,9738,O
fashion,9738,O
",",9738,O
while,9738,O
recombinant,9738,O
factor,9738,B-GENE-Y
IX,9738,I-GENE-Y
or,9738,O
plasma,9738,O
IXa,9738,B-GENE-Y
had,9738,O
no,9738,O
effect,9738,O
.,9738,O
An,9739,O
antibody,9739,O
generated,9739,O
against,9739,O
the,9739,O
factor,9739,B-GENE-Y
X,9739,I-GENE-Y
peptide,9739,O
83-88,9739,O
",",9739,O
and,9739,O
designated,9739,O
JC15,9739,O
",",9739,O
inhibited,9739,O
125I-factor,9739,O
Xa,9739,I-GENE-Y
binding,9739,O
to,9739,O
HUVEC,9739,O
.,9739,O
The,9740,O
JC15,9740,O
antibody,9740,O
bound,9740,O
to,9740,O
factor,9740,B-GENE-Y
Xa,9740,I-GENE-Y
and,9740,O
the,9740,O
recombinant,9740,O
IX/X83-88,9740,O
chimera,9740,O
in,9740,O
a,9740,O
concentration,9740,O
dependent,9740,O
manner,9740,O
",",9740,O
while,9740,O
no,9740,O
specific,9740,O
reactivity,9740,O
with,9740,O
factors,9740,B-GENE-N
X,9740,I-GENE-N
or,9740,I-GENE-N
IXa,9740,I-GENE-N
was,9740,O
observed,9740,O
.,9740,O
Furthermore,9741,O
",",9741,O
binding,9741,O
of,9741,O
125I-factor,9741,B-CHEMICAL
Xa,9741,I-GENE-Y
to,9741,O
immobilized,9741,O
JC15,9741,O
was,9741,O
inhibited,9741,O
by,9741,O
molar,9741,O
excess,9741,O
of,9741,O
unlabeled,9741,O
factor,9741,B-GENE-Y
Xa,9741,I-GENE-Y
",",9741,O
but,9741,O
not,9741,O
by,9741,O
comparable,9741,O
concentrations,9741,O
of,9741,O
factors,9741,B-GENE-N
X,9741,I-GENE-N
or,9741,I-GENE-N
IXa,9741,I-GENE-N
.,9741,O
These,9742,O
findings,9742,O
identify,9742,O
the,9742,O
inter-EGF,9742,B-GENE-N
sequence,9742,I-GENE-N
Leu83-Leu88,9742,B-GENE-N
in,9742,O
factor,9742,B-GENE-Y
Xa,9742,I-GENE-Y
as,9742,O
a,9742,O
novel,9742,O
recognition,9742,O
site,9742,O
for,9742,O
EPR-1,9742,B-GENE-Y
",",9742,O
and,9742,O
suggest,9742,O
its,9742,O
potential,9742,O
role,9742,O
as,9742,O
a,9742,O
protease,9742,O
activation-dependent,9742,O
neo-epitope,9742,O
.,9742,O
This,9743,O
interacting,9743,O
motif,9743,O
may,9743,O
help,9743,O
elucidate,9743,O
the,9743,O
contribution,9743,O
of,9743,O
factor,9743,B-GENE-Y
Xa,9743,I-GENE-Y
to,9743,O
cellular,9743,O
assembly,9743,O
of,9743,O
coagulation,9743,O
and,9743,O
vascular,9743,O
injury,9743,O
.,9743,O
[,9744,B-CHEMICAL
6,9744,I-CHEMICAL
],9744,I-CHEMICAL
-gingerol,9744,I-CHEMICAL
:,9744,O
a,9744,O
novel,9744,O
AT₁,9744,B-GENE-Y
antagonist,9744,O
for,9744,O
the,9744,O
treatment,9744,O
of,9744,O
cardiovascular,9744,O
disease,9744,O
.,9744,O
Considering,9745,O
the,9745,O
prevalence,9745,O
of,9745,O
cardiovascular,9745,O
disease,9745,O
in,9745,O
public,9745,O
health,9745,O
and,9745,O
the,9745,O
limited,9745,O
validated,9745,O
therapeutic,9745,O
options,9745,O
",",9745,O
this,9745,O
study,9745,O
aimed,9745,O
to,9745,O
find,9745,O
novel,9745,O
compounds,9745,O
targeting,9745,O
the,9745,O
angiotensin,9745,B-GENE-Y
II,9745,I-GENE-Y
type,9745,I-GENE-Y
1,9745,I-GENE-Y
receptor,9745,I-GENE-Y
",",9745,O
accepted,9745,O
as,9745,O
a,9745,O
therapeutic,9745,O
target,9745,O
in,9745,O
cardiovascular,9745,O
disease,9745,O
.,9745,O
A,9746,O
small,9746,O
library,9746,O
consisting,9746,O
of,9746,O
89,9746,O
compounds,9746,O
from,9746,O
39,9746,O
Chinese,9746,O
herbs,9746,O
was,9746,O
profiled,9746,O
using,9746,O
a,9746,O
cell-based,9746,O
calcium,9746,O
mobilization,9746,O
assay,9746,O
which,9746,O
was,9746,O
developed,9746,O
and,9746,O
characterized,9746,O
for,9746,O
high-throughput,9746,O
screening,9746,O
.,9746,O
[,9747,B-CHEMICAL
6,9747,I-CHEMICAL
],9747,I-CHEMICAL
-Gingerol,9747,I-CHEMICAL
derived,9747,O
from,9747,O
Zingiber,9747,O
officinale,9747,O
Roscoe,9747,O
(,9747,O
ginger,9747,O
),9747,O
was,9747,O
identified,9747,O
as,9747,O
a,9747,O
novel,9747,O
angiotensin,9747,B-GENE-Y
II,9747,I-GENE-Y
type,9747,I-GENE-Y
1,9747,I-GENE-Y
receptor,9747,I-GENE-Y
antagonist,9747,O
",",9747,O
with,9747,O
an,9747,O
IC50,9747,O
value,9747,O
of,9747,O
8.173,9747,O
µM,9747,O
.,9747,O
The,9748,O
hit,9748,O
was,9748,O
further,9748,O
tested,9748,O
by,9748,O
a,9748,O
specificity,9748,O
assay,9748,O
indicating,9748,O
that,9748,O
it,9748,O
had,9748,O
no,9748,O
antagonistic,9748,O
effects,9748,O
on,9748,O
other,9748,O
evaluated,9748,O
GPCRs,9748,B-GENE-N
",",9748,O
such,9748,O
as,9748,O
endothelin,9748,B-GENE-N
receptors,9748,I-GENE-N
.,9748,O
The,9749,O
major,9749,O
ingredient,9749,O
of,9749,O
ginger,9749,O
",",9749,O
[,9749,B-CHEMICAL
6,9749,I-CHEMICAL
],9749,I-CHEMICAL
-gingerol,9749,I-CHEMICAL
",",9749,O
could,9749,O
inhibit,9749,O
angiotensin,9749,B-GENE-Y
II,9749,I-GENE-Y
type,9749,I-GENE-Y
1,9749,I-GENE-Y
receptor,9749,I-GENE-Y
activation,9749,O
",",9749,O
which,9749,O
partially,9749,O
clarified,9749,O
the,9749,O
mechanism,9749,O
of,9749,O
ginger,9749,O
regulating,9749,O
blood,9749,O
pressure,9749,O
and,9749,O
strengthening,9749,O
heart,9749,O
in,9749,O
the,9749,O
cardiovascular,9749,O
system,9749,O
.,9749,O
Osteochondral,9750,O
tissue,9750,O
regeneration,9750,O
using,9750,O
a,9750,O
bilayered,9750,O
composite,9750,O
hydrogel,9750,O
with,9750,O
modulating,9750,O
dual,9750,O
growth,9750,O
factor,9750,O
release,9750,O
kinetics,9750,O
in,9750,O
a,9750,O
rabbit,9750,O
model,9750,O
.,9750,O
Biodegradable,9751,O
oligo,9751,B-CHEMICAL
(,9751,I-CHEMICAL
poly,9751,I-CHEMICAL
(,9751,I-CHEMICAL
ethylene,9751,I-CHEMICAL
glycol,9751,I-CHEMICAL
),9751,I-CHEMICAL
fumarate,9751,I-CHEMICAL
),9751,I-CHEMICAL
(,9751,O
OPF,9751,B-CHEMICAL
),9751,O
composite,9751,O
hydrogels,9751,O
have,9751,O
been,9751,O
investigated,9751,O
for,9751,O
the,9751,O
delivery,9751,O
of,9751,O
growth,9751,O
factors,9751,O
(,9751,O
GFs,9751,O
),9751,O
with,9751,O
the,9751,O
aid,9751,O
of,9751,O
gelatin,9751,O
microparticles,9751,O
(,9751,O
GMPs,9751,O
),9751,O
and,9751,O
stem,9751,O
cell,9751,O
populations,9751,O
for,9751,O
osteochondral,9751,O
tissue,9751,O
regeneration,9751,O
.,9751,O
In,9752,O
this,9752,O
study,9752,O
",",9752,O
a,9752,O
bilayered,9752,O
OPF,9752,B-CHEMICAL
composite,9752,O
hydrogel,9752,O
that,9752,O
mimics,9752,O
the,9752,O
distinctive,9752,O
hierarchical,9752,O
structure,9752,O
of,9752,O
native,9752,O
osteochondral,9752,O
tissue,9752,O
was,9752,O
utilized,9752,O
to,9752,O
investigate,9752,O
the,9752,O
effect,9752,O
of,9752,O
transforming,9752,B-GENE-Y
growth,9752,I-GENE-Y
factor-β3,9752,I-GENE-Y
(,9752,O
TGF-β3,9752,B-GENE-Y
),9752,O
with,9752,O
varying,9752,O
release,9752,O
kinetics,9752,O
and/or,9752,O
insulin-like,9752,B-GENE-Y
growth,9752,I-GENE-Y
factor-1,9752,I-GENE-Y
(,9752,O
IGF-1,9752,B-GENE-Y
),9752,O
on,9752,O
osteochondral,9752,O
tissue,9752,O
regeneration,9752,O
in,9752,O
a,9752,O
rabbit,9752,O
full-thickness,9752,O
osteochondral,9752,O
defect,9752,O
model,9752,O
.,9752,O
The,9753,O
four,9753,O
groups,9753,O
investigated,9753,O
included,9753,O
(,9753,O
i,9753,O
),9753,O
a,9753,O
blank,9753,O
control,9753,O
(,9753,O
no,9753,O
GFs,9753,O
),9753,O
",",9753,O
(,9753,O
ii,9753,O
),9753,O
GMP-loaded,9753,O
IGF-1,9753,B-GENE-Y
alone,9753,O
",",9753,O
(,9753,O
iii,9753,O
),9753,O
GMP-loaded,9753,O
IGF-1,9753,B-GENE-Y
and,9753,O
gel-loaded,9753,O
TGF-β3,9753,B-GENE-Y
",",9753,O
and,9753,O
(,9753,O
iv,9753,O
),9753,O
GMP-loaded,9753,O
IGF-1,9753,B-GENE-Y
and,9753,O
GMP-loaded,9753,O
TGF-β3,9753,B-GENE-Y
in,9753,O
OPF,9753,B-CHEMICAL
composite,9753,O
hydrogels,9753,O
.,9753,O
The,9754,O
results,9754,O
of,9754,O
an,9754,O
in,9754,O
vitro,9754,O
release,9754,O
study,9754,O
demonstrated,9754,O
that,9754,O
TGF-β3,9754,B-GENE-Y
release,9754,O
kinetics,9754,O
could,9754,O
be,9754,O
modulated,9754,O
by,9754,O
the,9754,O
GF,9754,O
incorporation,9754,O
method,9754,O
.,9754,O
At,9755,O
12weeks,9755,O
post-implantation,9755,O
",",9755,O
the,9755,O
quality,9755,O
of,9755,O
tissue,9755,O
repair,9755,O
in,9755,O
both,9755,O
chondral,9755,O
and,9755,O
subchondral,9755,O
layers,9755,O
was,9755,O
analyzed,9755,O
based,9755,O
on,9755,O
quantitative,9755,O
histological,9755,O
scoring,9755,O
.,9755,O
All,9756,O
groups,9756,O
incorporating,9756,O
GFs,9756,O
resulted,9756,O
in,9756,O
a,9756,O
significant,9756,O
improvement,9756,O
in,9756,O
cartilage,9756,O
morphology,9756,O
compared,9756,O
to,9756,O
the,9756,O
control,9756,O
.,9756,O
Single,9757,O
delivery,9757,O
of,9757,O
IGF-1,9757,B-GENE-Y
showed,9757,O
higher,9757,O
scores,9757,O
in,9757,O
subchondral,9757,O
bone,9757,O
morphology,9757,O
as,9757,O
well,9757,O
as,9757,O
chondrocyte,9757,O
and,9757,O
glycosaminoglycan,9757,O
amount,9757,O
in,9757,O
adjacent,9757,O
cartilage,9757,O
tissue,9757,O
when,9757,O
compared,9757,O
to,9757,O
a,9757,O
dual,9757,O
delivery,9757,O
of,9757,O
IGF-1,9757,B-GENE-Y
and,9757,O
TGF-β3,9757,B-GENE-Y
",",9757,O
independent,9757,O
of,9757,O
the,9757,O
TGF-β3,9757,B-GENE-Y
release,9757,O
kinetics,9757,O
.,9757,O
The,9758,O
results,9758,O
suggest,9758,O
that,9758,O
although,9758,O
the,9758,O
dual,9758,O
delivery,9758,O
of,9758,O
TGF-β3,9758,B-GENE-Y
and,9758,O
IGF-1,9758,B-GENE-Y
may,9758,O
not,9758,O
synergistically,9758,O
enhance,9758,O
the,9758,O
quality,9758,O
of,9758,O
engineered,9758,O
tissue,9758,O
",",9758,O
the,9758,O
delivery,9758,O
of,9758,O
IGF-1,9758,B-GENE-Y
alone,9758,O
from,9758,O
bilayered,9758,O
composite,9758,O
hydrogels,9758,O
positively,9758,O
affects,9758,O
osteochondral,9758,O
tissue,9758,O
repair,9758,O
and,9758,O
holds,9758,O
promise,9758,O
for,9758,O
osteochondral,9758,O
tissue,9758,O
engineering,9758,O
applications,9758,O
.,9758,O
LDL,9759,B-GENE-N
Cholesterol,9759,B-CHEMICAL
Goals,9759,O
in,9759,O
High-Risk,9759,O
Patients,9759,O
:,9759,O
How,9759,O
Low,9759,O
Do,9759,O
We,9759,O
Go,9759,O
and,9759,O
How,9759,O
Do,9759,O
We,9759,O
Get,9759,O
There,9759,O
?,9759,O
It,9760,O
is,9760,O
widely,9760,O
recognised,9760,O
that,9760,O
low-density,9760,B-GENE-N
lipoprotein,9760,I-GENE-N
cholesterol,9760,B-CHEMICAL
(,9760,O
LDL-C,9760,B-GENE-N
),9760,O
is,9760,O
one,9760,O
of,9760,O
the,9760,O
most,9760,O
important,9760,O
and,9760,O
modifiable,9760,O
risk,9760,O
factors,9760,O
for,9760,O
cardiovascular,9760,O
disease,9760,O
(,9760,O
CVD,9760,O
),9760,O
.,9760,O
Statins,9761,O
(,9761,O
HMG-CoA,9761,B-GENE-Y
reductase,9761,I-GENE-Y
inhibitors,9761,O
),9761,O
have,9761,O
consistently,9761,O
been,9761,O
shown,9761,O
to,9761,O
decrease,9761,O
both,9761,O
LDL-C,9761,B-GENE-N
and,9761,O
CVD,9761,O
risk,9761,O
in,9761,O
almost,9761,O
all,9761,O
patient,9761,O
categories,9761,O
",",9761,O
with,9761,O
the,9761,O
exception,9761,O
of,9761,O
heart,9761,O
and,9761,O
kidney,9761,O
failure,9761,O
as,9761,O
well,9761,O
as,9761,O
advanced,9761,O
aortic,9761,O
stenosis,9761,O
.,9761,O
As,9762,O
a,9762,O
consequence,9762,O
",",9762,O
statins,9762,O
have,9762,O
become,9762,O
the,9762,O
cornerstone,9762,O
in,9762,O
current,9762,O
prevention,9762,O
guidelines,9762,O
.,9762,O
In,9763,O
patients,9763,O
who,9763,O
do,9763,O
not,9763,O
reach,9763,O
the,9763,O
LDL-C,9763,B-GENE-N
target,9763,O
",",9763,O
combination,9763,O
therapy,9763,O
with,9763,O
additional,9763,O
LDL-C,9763,B-GENE-N
lowering,9763,O
drugs,9763,O
(,9763,O
e.g,9763,O
.,9763,O
ezetimibe,9764,B-CHEMICAL
",",9764,O
bile,9764,B-CHEMICAL
acid,9764,I-CHEMICAL
sequestrants,9764,O
or,9764,O
fibrates,9764,B-CHEMICAL
),9764,O
should,9764,O
be,9764,O
considered,9764,O
.,9764,O
Guidelines,9765,O
provide,9765,O
different,9765,O
LDL-C,9765,B-GENE-N
levels,9765,O
to,9765,O
strive,9765,O
for,9765,O
",",9765,O
depending,9765,O
on,9765,O
the,9765,O
CVD,9765,O
risk,9765,O
.,9765,O
In,9766,O
this,9766,O
review,9766,O
",",9766,O
we,9766,O
describe,9766,O
the,9766,O
rationale,9766,O
for,9766,O
these,9766,O
LDL-C,9766,B-GENE-N
targets,9766,O
and,9766,O
how,9766,O
these,9766,O
goals,9766,O
might,9766,O
be,9766,O
reached,9766,O
by,9766,O
current,9766,O
and,9766,O
future,9766,O
therapies,9766,O
.,9766,O
Contrasting,9767,O
effects,9767,O
of,9767,O
N5-substituted,9767,B-CHEMICAL
tetrahydrobiopterin,9767,I-CHEMICAL
derivatives,9767,O
on,9767,O
phenylalanine,9767,B-GENE-Y
hydroxylase,9767,I-GENE-Y
",",9767,O
dihydropteridine,9767,B-GENE-Y
reductase,9767,I-GENE-Y
and,9767,O
nitric,9767,B-GENE-N
oxide,9767,I-GENE-N
synthase,9767,I-GENE-N
.,9767,O
Tetrahydrobiopterin,9768,B-CHEMICAL
[,9768,O
(,9768,B-CHEMICAL
6R,9768,I-CHEMICAL
),9768,I-CHEMICAL
"-5,6,7,8-tetrahydro-L-biopterin",9768,I-CHEMICAL
",",9768,O
H,9768,B-CHEMICAL
(,9768,I-CHEMICAL
4,9768,I-CHEMICAL
),9768,I-CHEMICAL
biopterin,9768,I-CHEMICAL
],9768,O
is,9768,O
one,9768,O
of,9768,O
several,9768,O
cofactors,9768,O
of,9768,O
nitric,9768,B-GENE-N
oxide,9768,I-GENE-N
synthases,9768,I-GENE-N
(,9768,O
EC,9768,B-GENE-Y
1.14.13.39,9768,I-GENE-Y
),9768,O
.,9768,O
Here,9769,O
we,9769,O
compared,9769,O
the,9769,O
action,9769,O
of,9769,O
N,9769,B-CHEMICAL
(,9769,I-CHEMICAL
5,9769,I-CHEMICAL
),9769,I-CHEMICAL
-substituted,9769,O
derivatives,9769,O
on,9769,O
recombinant,9769,O
rat,9769,B-GENE-Y
neuronal,9769,I-GENE-Y
nitric,9769,I-GENE-Y
oxide,9769,I-GENE-Y
synthase,9769,I-GENE-Y
with,9769,O
their,9769,O
effects,9769,O
on,9769,O
dihydropteridine,9769,B-GENE-Y
reductase,9769,I-GENE-Y
(,9769,O
EC,9769,B-GENE-Y
1.6.99.7,9769,I-GENE-Y
),9769,O
and,9769,O
phenylalanine,9769,B-GENE-Y
hydroxylase,9769,I-GENE-Y
(,9769,O
EC,9769,B-GENE-Y
1.14.16.1,9769,I-GENE-Y
),9769,O
",",9769,O
the,9769,O
well-studied,9769,O
classical,9769,O
H,9769,B-CHEMICAL
(,9769,I-CHEMICAL
4,9769,I-CHEMICAL
),9769,I-CHEMICAL
biopterin-dependent,9769,O
reactions,9769,O
.,9769,O
H,9770,B-CHEMICAL
(,9770,I-CHEMICAL
4,9770,I-CHEMICAL
),9770,I-CHEMICAL
biopterin,9770,I-CHEMICAL
substituted,9770,O
at,9770,O
N,9770,B-CHEMICAL
(,9770,I-CHEMICAL
5,9770,I-CHEMICAL
),9770,I-CHEMICAL
with,9770,O
methyl,9770,B-CHEMICAL
",",9770,O
hydroxymethyl,9770,B-CHEMICAL
",",9770,O
formyl,9770,B-CHEMICAL
and,9770,O
acetyl,9770,B-CHEMICAL
groups,9770,O
were,9770,O
used,9770,O
.,9770,O
Substitution,9771,O
at,9771,O
N,9771,B-CHEMICAL
(,9771,I-CHEMICAL
5,9771,I-CHEMICAL
),9771,I-CHEMICAL
occurs,9771,O
at,9771,O
a,9771,O
position,9771,O
critical,9771,O
to,9771,O
the,9771,O
redox,9771,O
cycle,9771,O
of,9771,O
the,9771,O
cofactor,9771,O
in,9771,O
phenylalanine,9771,B-GENE-Y
hydroxylase/dihydropteridine,9771,O
reductase,9771,I-GENE-Y
.,9771,O
We,9772,O
also,9772,O
included,9772,O
N,9772,B-CHEMICAL
(,9772,I-CHEMICAL
2,9772,I-CHEMICAL
),9772,I-CHEMICAL
'-methyl,9772,I-CHEMICAL
H,9772,I-CHEMICAL
(,9772,I-CHEMICAL
4,9772,I-CHEMICAL
),9772,I-CHEMICAL
biopterin,9772,I-CHEMICAL
",",9772,O
a,9772,O
derivative,9772,O
substituted,9772,O
at,9772,O
a,9772,O
position,9772,O
not,9772,O
directly,9772,O
involved,9772,O
in,9772,O
redox,9772,O
cycling,9772,O
",",9772,O
as,9772,O
a,9772,O
control,9772,O
.,9772,O
As,9773,O
compared,9773,O
with,9773,O
N,9773,B-CHEMICAL
(,9773,I-CHEMICAL
5,9773,I-CHEMICAL
),9773,I-CHEMICAL
-methyl,9773,I-CHEMICAL
H,9773,I-CHEMICAL
(,9773,I-CHEMICAL
4,9773,I-CHEMICAL
),9773,I-CHEMICAL
biopterin,9773,I-CHEMICAL
",",9773,O
N,9773,B-CHEMICAL
(,9773,I-CHEMICAL
5,9773,I-CHEMICAL
),9773,I-CHEMICAL
-formyl,9773,I-CHEMICAL
H,9773,I-CHEMICAL
(,9773,I-CHEMICAL
4,9773,I-CHEMICAL
),9773,I-CHEMICAL
biopterin,9773,I-CHEMICAL
bound,9773,O
with,9773,O
twice,9773,O
the,9773,O
capacity,9773,O
but,9773,O
stimulated,9773,O
nitric,9773,B-GENE-N
oxide,9773,I-GENE-N
synthase,9773,I-GENE-N
to,9773,O
a,9773,O
lesser,9773,O
extent,9773,O
.,9773,O
Depending,9774,O
on,9774,O
the,9774,O
substituent,9774,O
used,9774,O
",",9774,O
N,9774,B-CHEMICAL
(,9774,I-CHEMICAL
5,9774,I-CHEMICAL
),9774,I-CHEMICAL
-substituted,9774,O
derivatives,9774,O
were,9774,O
redox-active,9774,O
:,9774,O
N,9774,B-CHEMICAL
(,9774,I-CHEMICAL
5,9774,I-CHEMICAL
),9774,I-CHEMICAL
-methyl-,9774,O
and,9774,O
N,9774,B-CHEMICAL
(,9774,I-CHEMICAL
5,9774,I-CHEMICAL
),9774,I-CHEMICAL
-hydroxyl,9774,I-CHEMICAL
methyl,9774,I-CHEMICAL
H,9774,I-CHEMICAL
(,9774,I-CHEMICAL
4,9774,I-CHEMICAL
),9774,I-CHEMICAL
biopterin,9774,I-CHEMICAL
",",9774,O
but,9774,O
not,9774,O
N,9774,B-CHEMICAL
(,9774,I-CHEMICAL
5,9774,I-CHEMICAL
),9774,I-CHEMICAL
-formyl-,9774,O
and,9774,O
N,9774,B-CHEMICAL
(,9774,I-CHEMICAL
5,9774,I-CHEMICAL
),9774,I-CHEMICAL
-acetyl,9774,I-CHEMICAL
H,9774,I-CHEMICAL
(,9774,I-CHEMICAL
4,9774,I-CHEMICAL
),9774,I-CHEMICAL
biopterin,9774,I-CHEMICAL
",",9774,O
reduced,9774,O
"2,6-dichlorophenol",9774,B-CHEMICAL
indophenol,9774,I-CHEMICAL
.,9774,O
N,9775,B-CHEMICAL
(,9775,I-CHEMICAL
5,9775,I-CHEMICAL
),9775,I-CHEMICAL
-Substituted,9775,I-CHEMICAL
H,9775,I-CHEMICAL
(,9775,I-CHEMICAL
4,9775,I-CHEMICAL
),9775,I-CHEMICAL
biopterin,9775,I-CHEMICAL
derivatives,9775,O
were,9775,O
not,9775,O
oxidized,9775,O
to,9775,O
products,9775,O
serving,9775,O
as,9775,O
substrates,9775,O
for,9775,O
dihydropteridine,9775,B-GENE-Y
reductase,9775,I-GENE-Y
and,9775,O
",",9775,O
depending,9775,O
on,9775,O
the,9775,O
substituent,9775,O
",",9775,O
were,9775,O
competitive,9775,O
inhibitors,9775,O
of,9775,O
phenylalanine,9775,B-GENE-Y
hydroxylase,9775,I-GENE-Y
:,9775,O
N,9775,B-CHEMICAL
(,9775,I-CHEMICAL
5,9775,I-CHEMICAL
),9775,I-CHEMICAL
-methyl-,9775,O
and,9775,O
N,9775,B-CHEMICAL
(,9775,I-CHEMICAL
5,9775,I-CHEMICAL
),9775,I-CHEMICAL
-hydroxymethyl,9775,I-CHEMICAL
H,9775,I-CHEMICAL
(,9775,I-CHEMICAL
4,9775,I-CHEMICAL
),9775,I-CHEMICAL
biopterin,9775,I-CHEMICAL
inhibited,9775,O
phenylalanine,9775,B-GENE-Y
hydroxylase,9775,I-GENE-Y
",",9775,O
whereas,9775,O
N,9775,B-CHEMICAL
(,9775,I-CHEMICAL
5,9775,I-CHEMICAL
),9775,I-CHEMICAL
-formyl-,9775,O
and,9775,O
N,9775,B-CHEMICAL
(,9775,I-CHEMICAL
5,9775,I-CHEMICAL
),9775,I-CHEMICAL
-acetyl,9775,I-CHEMICAL
H,9775,I-CHEMICAL
(,9775,I-CHEMICAL
4,9775,I-CHEMICAL
),9775,I-CHEMICAL
biopterin,9775,I-CHEMICAL
had,9775,O
no,9775,O
effect,9775,O
.,9775,O
Our,9776,O
data,9776,O
demonstrate,9776,O
differences,9776,O
in,9776,O
the,9776,O
mechanism,9776,O
of,9776,O
stimulation,9776,O
of,9776,O
phenylalanine,9776,B-GENE-Y
hydroxylase,9776,I-GENE-Y
and,9776,O
nitric,9776,B-GENE-N
oxide,9776,I-GENE-N
synthase,9776,I-GENE-N
by,9776,O
H,9776,B-CHEMICAL
(,9776,I-CHEMICAL
4,9776,I-CHEMICAL
),9776,I-CHEMICAL
biopterin,9776,I-CHEMICAL
.,9776,O
They,9777,O
are,9777,O
compatible,9777,O
with,9777,O
a,9777,O
novel,9777,O
",",9777,O
non-classical,9777,O
",",9777,O
redox-active,9777,O
contribution,9777,O
of,9777,O
H,9777,B-CHEMICAL
(,9777,I-CHEMICAL
4,9777,I-CHEMICAL
),9777,I-CHEMICAL
biopterin,9777,I-CHEMICAL
to,9777,O
the,9777,O
catalysis,9777,O
of,9777,O
the,9777,O
nitric,9777,B-GENE-N
oxide,9777,I-GENE-N
synthase,9777,I-GENE-N
reaction,9777,O
.,9777,O
Vesicular,9778,B-GENE-Y
monoamine,9778,I-GENE-Y
transporter-1,9778,I-GENE-Y
(,9778,O
VMAT-1,9778,B-GENE-Y
),9778,O
mRNA,9778,O
and,9778,O
immunoreactive,9778,O
proteins,9778,O
in,9778,O
mouse,9778,O
brain,9778,O
.,9778,O
OBJECTIVE,9779,O
:,9779,O
Vesicular,9779,B-GENE-Y
monoamine,9779,I-GENE-Y
transporter,9779,I-GENE-Y
1,9779,I-GENE-Y
(,9779,O
VMAT-1,9779,B-GENE-Y
),9779,O
mRNA,9779,O
and,9779,O
protein,9779,O
were,9779,O
examined,9779,O
(,9779,O
1,9779,O
),9779,O
to,9779,O
determine,9779,O
whether,9779,O
adult,9779,O
mouse,9779,O
brain,9779,O
expresses,9779,O
full-length,9779,O
VMAT-1,9779,B-GENE-Y
mRNA,9779,O
that,9779,O
can,9779,O
be,9779,O
translated,9779,O
to,9779,O
functional,9779,O
transporter,9779,O
protein,9779,O
and,9779,O
(,9779,O
2,9779,O
),9779,O
to,9779,O
compare,9779,O
immunoreactive,9779,O
VMAT-1,9779,B-GENE-Y
proteins,9779,O
in,9779,O
brain,9779,O
and,9779,O
adrenal,9779,O
.,9779,O
METHODS,9780,O
:,9780,O
VMAT-1,9780,B-GENE-Y
mRNA,9780,O
was,9780,O
detected,9780,O
in,9780,O
mouse,9780,O
brain,9780,O
with,9780,O
RT-PCR,9780,O
.,9780,O
The,9781,O
cDNA,9781,O
was,9781,O
sequenced,9781,O
",",9781,O
cloned,9781,O
into,9781,O
an,9781,O
expression,9781,O
vector,9781,O
",",9781,O
transfected,9781,O
into,9781,O
COS-1,9781,O
cells,9781,O
",",9781,O
and,9781,O
cell,9781,O
protein,9781,O
was,9781,O
assayed,9781,O
for,9781,O
VMAT-1,9781,B-GENE-Y
activity,9781,O
.,9781,O
Immunoreactive,9782,O
proteins,9782,O
were,9782,O
examined,9782,O
on,9782,O
western,9782,O
blots,9782,O
probed,9782,O
with,9782,O
four,9782,O
different,9782,O
antibodies,9782,O
to,9782,O
VMAT-1,9782,B-GENE-Y
.,9782,O
RESULTS,9783,O
:,9783,O
Sequencing,9783,O
confirmed,9783,O
identity,9783,O
of,9783,O
the,9783,O
entire,9783,O
coding,9783,O
sequences,9783,O
of,9783,O
VMAT-1,9783,B-GENE-Y
cDNA,9783,O
from,9783,O
mouse,9783,O
medulla,9783,O
oblongata/pons,9783,O
and,9783,O
adrenal,9783,O
to,9783,O
a,9783,O
Gen-Bank,9783,O
reference,9783,O
sequence,9783,O
.,9783,O
Transfection,9784,O
of,9784,O
the,9784,O
brain,9784,O
cDNA,9784,O
into,9784,O
COS-1,9784,O
cells,9784,O
resulted,9784,O
in,9784,O
transporter,9784,O
activity,9784,O
that,9784,O
was,9784,O
blocked,9784,O
by,9784,O
the,9784,O
VMAT,9784,B-GENE-N
inhibitor,9784,O
reserpine,9784,B-CHEMICAL
and,9784,O
a,9784,O
proton,9784,O
ionophore,9784,O
",",9784,O
but,9784,O
not,9784,O
by,9784,O
tetrabenazine,9784,B-CHEMICAL
",",9784,O
which,9784,O
has,9784,O
a,9784,O
high,9784,O
affinity,9784,O
for,9784,O
VMAT-2,9784,B-GENE-Y
.,9784,O
Antibodies,9785,O
to,9785,O
either,9785,O
the,9785,O
C-,9785,B-CHEMICAL
or,9785,O
N-,9785,B-CHEMICAL
terminus,9785,O
of,9785,O
VMAT-1,9785,B-GENE-Y
detected,9785,O
two,9785,O
proteins,9785,O
(,9785,O
73,9785,O
and,9785,O
55,9785,O
kD,9785,O
),9785,O
in,9785,O
transfected,9785,O
COS-1,9785,O
cells,9785,O
.,9785,O
The,9786,O
C-terminal,9786,B-CHEMICAL
antibodies,9786,O
detected,9786,O
both,9786,O
proteins,9786,O
in,9786,O
extracts,9786,O
of,9786,O
mouse,9786,O
medulla/pons,9786,O
",",9786,O
cortex,9786,O
",",9786,O
hypothalamus,9786,O
",",9786,O
and,9786,O
cerebellum,9786,O
but,9786,O
only,9786,O
the,9786,O
73,9786,O
kD,9786,O
protein,9786,O
and,9786,O
higher,9786,O
molecular,9786,O
weight,9786,O
immunoreactive,9786,O
proteins,9786,O
in,9786,O
mouse,9786,O
adrenal,9786,O
and,9786,O
rat,9786,O
PC12,9786,O
cells,9786,O
",",9786,O
which,9786,O
are,9786,O
positive,9786,O
controls,9786,O
for,9786,O
rodent,9786,B-GENE-Y
VMAT-1,9786,I-GENE-Y
.,9786,O
CONCLUSIONS,9787,O
:,9787,O
These,9787,O
findings,9787,O
demonstrate,9787,O
that,9787,O
a,9787,O
functional,9787,O
VMAT-1,9787,B-GENE-Y
mRNA,9787,O
coding,9787,O
sequence,9787,O
is,9787,O
expressed,9787,O
in,9787,O
mouse,9787,O
brain,9787,O
and,9787,O
suggest,9787,O
processing,9787,O
of,9787,O
VMAT-1,9787,B-GENE-Y
protein,9787,O
differs,9787,O
in,9787,O
mouse,9787,O
adrenal,9787,O
and,9787,O
brain,9787,O
.,9787,O
Chloride,9788,B-GENE-N
channels,9788,I-GENE-N
in,9788,O
renal,9788,O
disease,9788,O
.,9788,O
Recent,9789,O
studies,9789,O
of,9789,O
hereditary,9789,O
renal,9789,O
tubular,9789,O
disorders,9789,O
have,9789,O
facilitated,9789,O
the,9789,O
identification,9789,O
and,9789,O
roles,9789,O
of,9789,O
chloride,9789,B-GENE-N
channels,9789,I-GENE-N
and,9789,I-GENE-N
cotransporters,9789,I-GENE-N
in,9789,O
the,9789,O
regulation,9789,O
of,9789,O
the,9789,O
most,9789,O
abundant,9789,O
anion,9789,O
",",9789,O
Cl-,9789,B-CHEMICAL
",",9789,O
in,9789,O
the,9789,O
ECF,9789,O
.,9789,O
Thus,9790,O
",",9790,O
mutations,9790,O
that,9790,O
result,9790,O
in,9790,O
a,9790,O
loss,9790,O
of,9790,O
function,9790,O
of,9790,O
the,9790,O
voltage-gated,9790,B-GENE-N
chloride,9790,I-GENE-N
channel,9790,I-GENE-N
",",9790,O
CLC-5,9790,B-GENE-Y
",",9790,O
are,9790,O
associated,9790,O
with,9790,O
Dent,9790,O
's,9790,O
disease,9790,O
",",9790,O
which,9790,O
is,9790,O
characterized,9790,O
by,9790,O
low-molecular,9790,O
weight,9790,O
proteinuria,9790,O
",",9790,O
hypercalciuria,9790,O
",",9790,O
nephrolithiasis,9790,O
",",9790,O
and,9790,O
renal,9790,O
failure,9790,O
.,9790,O
Mutations,9791,O
of,9791,O
another,9791,O
voltage-gated,9791,B-GENE-N
chloride,9791,I-GENE-N
channel,9791,I-GENE-N
",",9791,O
CLC-Kb,9791,B-GENE-Y
",",9791,O
are,9791,O
associated,9791,O
with,9791,O
a,9791,O
form,9791,O
of,9791,O
Bartter,9791,O
's,9791,O
syndrome,9791,O
",",9791,O
whereas,9791,O
other,9791,O
forms,9791,O
of,9791,O
Bartter,9791,O
's,9791,O
syndrome,9791,O
are,9791,O
caused,9791,O
by,9791,O
mutations,9791,O
in,9791,O
the,9791,O
bumetanide-sensitive,9791,B-GENE-N
sodium-potassium-chloride,9791,I-GENE-N
cotransporter,9791,I-GENE-N
(,9791,O
NKCC2,9791,B-GENE-Y
),9791,O
and,9791,O
the,9791,O
potassium,9791,B-GENE-N
channel,9791,I-GENE-N
",",9791,O
ROMK,9791,B-GENE-Y
.,9791,O
Finally,9792,O
",",9792,O
mutations,9792,O
of,9792,O
the,9792,O
thiazide-sensitive,9792,B-GENE-Y
sodium-chloride,9792,I-GENE-Y
cotransporter,9792,I-GENE-Y
(,9792,O
NCCT,9792,B-GENE-Y
),9792,O
are,9792,O
associated,9792,O
with,9792,O
Gitelman,9792,O
's,9792,O
syndrome,9792,O
.,9792,O
These,9793,O
studies,9793,O
have,9793,O
helped,9793,O
to,9793,O
elucidate,9793,O
some,9793,O
of,9793,O
the,9793,O
renal,9793,O
tubular,9793,O
mechanisms,9793,O
regulating,9793,O
mineral,9793,O
homeostasis,9793,O
and,9793,O
the,9793,O
role,9793,O
of,9793,O
chloride,9793,B-GENE-N
channels,9793,I-GENE-N
.,9793,O
Mitochondrial,9794,B-GENE-Y
arginase,9794,I-GENE-Y
II,9794,I-GENE-Y
modulates,9794,O
nitric-oxide,9794,B-CHEMICAL
synthesis,9794,O
through,9794,O
nonfreely,9794,O
exchangeable,9794,O
L-arginine,9794,B-CHEMICAL
pools,9794,O
in,9794,O
human,9794,O
endothelial,9794,O
cells,9794,O
.,9794,O
Reduced,9795,O
synthesis,9795,O
of,9795,O
nitric,9795,B-CHEMICAL
oxide,9795,I-CHEMICAL
(,9795,O
NO,9795,B-CHEMICAL
),9795,O
contributes,9795,O
to,9795,O
the,9795,O
endothelial,9795,O
dysfunction,9795,O
and,9795,O
may,9795,O
be,9795,O
related,9795,O
to,9795,O
limited,9795,O
availability,9795,O
of,9795,O
L-arginine,9795,B-CHEMICAL
",",9795,O
the,9795,O
common,9795,O
substrate,9795,O
of,9795,O
constitutive,9795,B-GENE-Y
nitric-oxide,9795,I-GENE-Y
synthase,9795,I-GENE-Y
(,9795,O
NOS,9795,B-GENE-N
),9795,O
and,9795,O
cytosolic,9795,O
arginase,9795,B-GENE-Y
I,9795,I-GENE-Y
and,9795,O
mitochondrial,9795,B-GENE-Y
arginase,9795,I-GENE-Y
II,9795,I-GENE-Y
.,9795,O
To,9796,O
determine,9796,O
whether,9796,O
arginases,9796,B-GENE-N
modulate,9796,O
the,9796,O
endothelial,9796,O
NO,9796,B-CHEMICAL
synthesis,9796,O
",",9796,O
we,9796,O
investigated,9796,O
the,9796,O
effects,9796,O
of,9796,O
the,9796,O
competitive,9796,O
arginase,9796,B-GENE-N
inhibitor,9796,O
N,9796,B-CHEMICAL
(,9796,I-CHEMICAL
omega,9796,I-CHEMICAL
),9796,I-CHEMICAL
-hydroxy-nor-L-arginine,9796,I-CHEMICAL
(,9796,O
Nor-NOHA,9796,B-CHEMICAL
),9796,O
on,9796,O
the,9796,O
activity,9796,O
of,9796,O
NOS,9796,B-GENE-N
",",9796,O
arginases,9796,B-GENE-N
",",9796,O
and,9796,O
L-arginine,9796,B-GENE-N
transporter,9796,I-GENE-N
and,9796,O
on,9796,O
NO,9796,B-CHEMICAL
release,9796,O
at,9796,O
surface,9796,O
of,9796,O
human,9796,O
umbilical,9796,O
vein,9796,O
endothelial,9796,O
cells,9796,O
(,9796,O
HUVECs,9796,O
),9796,O
.,9796,O
In,9797,O
unstimulated,9797,O
cells,9797,O
",",9797,O
Nor-NOHA,9797,B-CHEMICAL
dose-dependently,9797,O
reduced,9797,O
the,9797,O
arginase,9797,B-GENE-N
activity,9797,O
with,9797,O
maximal,9797,O
inhibition,9797,O
at,9797,O
20,9797,O
microM,9797,O
.,9797,O
When,9798,O
HUVECs,9798,O
were,9798,O
stimulated,9798,O
by,9798,O
thrombin,9798,B-GENE-Y
without,9798,O
extracellular,9798,O
L-arginine,9798,B-CHEMICAL
",",9798,O
Nor-NOHA,9798,B-CHEMICAL
dose-dependently,9798,O
increased,9798,O
the,9798,O
NOS,9798,B-GENE-N
activity,9798,O
and,9798,O
the,9798,O
NO,9798,B-CHEMICAL
release,9798,O
with,9798,O
maximal,9798,O
effects,9798,O
at,9798,O
20,9798,O
microM,9798,O
.,9798,O
Extracellular,9799,O
L-arginine,9799,B-CHEMICAL
also,9799,O
dose-dependently,9799,O
increased,9799,O
NO,9799,B-CHEMICAL
release,9799,O
and,9799,O
arginase,9799,B-GENE-N
activity,9799,O
.,9799,O
When,9800,O
HUVECs,9800,O
were,9800,O
stimulated,9800,O
by,9800,O
thrombin,9800,B-GENE-Y
in,9800,O
the,9800,O
presence,9800,O
of,9800,O
100,9800,O
microM,9800,O
L-arginine,9800,B-CHEMICAL
",",9800,O
NOS,9800,B-GENE-N
activity,9800,O
and,9800,O
NO,9800,B-CHEMICAL
release,9800,O
were,9800,O
similar,9800,O
in,9800,O
untreated,9800,O
and,9800,O
Nor-NOHA-treated,9800,B-CHEMICAL
cells,9800,O
.,9800,O
However,9801,O
",",9801,O
despite,9801,O
activation,9801,O
of,9801,O
L-arginine,9801,B-CHEMICAL
uptake,9801,O
",",9801,O
the,9801,O
inhibition,9801,O
of,9801,O
arginase,9801,B-GENE-N
activity,9801,O
by,9801,O
Nor-NOHA,9801,B-CHEMICAL
was,9801,O
still,9801,O
significant,9801,O
.,9801,O
The,9802,O
depletion,9802,O
of,9802,O
freely,9802,O
exchangeable,9802,O
L-arginine,9802,B-CHEMICAL
pools,9802,O
with,9802,O
extracellular,9802,O
L-lysine,9802,B-CHEMICAL
did,9802,O
not,9802,O
prevent,9802,O
Nor-NOHA,9802,B-CHEMICAL
from,9802,O
increasing,9802,O
the,9802,O
NO,9802,B-CHEMICAL
release,9802,O
.,9802,O
This,9803,O
indicates,9803,O
the,9803,O
presence,9803,O
of,9803,O
pools,9803,O
",",9803,O
which,9803,O
are,9803,O
accessible,9803,O
to,9803,O
NOS,9803,B-GENE-N
and,9803,O
arginase,9803,B-GENE-N
",",9803,O
but,9803,O
not,9803,O
exchangeable,9803,O
.,9803,O
Interestingly,9804,O
",",9804,O
the,9804,O
mitochondrial,9804,B-GENE-Y
arginase,9804,I-GENE-Y
II,9804,I-GENE-Y
was,9804,O
constitutively,9804,O
expressed,9804,O
",",9804,O
whereas,9804,O
the,9804,O
cytosolic,9804,O
arginase,9804,B-GENE-Y
I,9804,I-GENE-Y
was,9804,O
barely,9804,O
detectable,9804,O
in,9804,O
HUVECs,9804,O
.,9804,O
These,9805,O
data,9805,O
suggest,9805,O
that,9805,O
endothelial,9805,O
NO,9805,B-CHEMICAL
synthesis,9805,O
depends,9805,O
on,9805,O
the,9805,O
activity,9805,O
of,9805,O
arginase,9805,B-GENE-Y
II,9805,I-GENE-Y
in,9805,O
mitochondria,9805,O
and,9805,O
l-arginine,9805,B-CHEMICAL
carriers,9805,O
in,9805,O
cell,9805,O
membrane,9805,O
.,9805,O
The,9806,O
role,9806,O
of,9806,O
late,9806,O
I,9806,O
and,9806,O
antiarrhythmic,9806,O
drugs,9806,O
in,9806,O
EAD,9806,O
formation,9806,O
and,9806,O
termination,9806,O
in,9806,O
Purkinje,9806,O
fibers,9806,O
.,9806,O
Multiple,9807,O
components,9807,O
of,9807,O
cardiac,9807,O
Na,9807,B-CHEMICAL
current,9807,O
play,9807,O
a,9807,O
role,9807,O
in,9807,O
determining,9807,O
electrical,9807,O
excitation,9807,O
in,9807,O
the,9807,O
heart,9807,O
.,9807,O
Recently,9808,O
",",9808,O
the,9808,O
role,9808,O
of,9808,O
nonequilibrium,9808,O
components,9808,O
in,9808,O
controlling,9808,O
cardiac,9808,O
action,9808,O
potential,9808,O
plateau,9808,O
duration,9808,O
",",9808,O
and,9808,O
their,9808,O
importance,9808,O
in,9808,O
regulating,9808,O
the,9808,O
occurrence,9808,O
of,9808,O
afterdepolarizations,9808,O
and,9808,O
arrhythmias,9808,O
have,9808,O
garnered,9808,O
more,9808,O
attention,9808,O
.,9808,O
In,9809,O
particular,9809,O
",",9809,O
late,9809,O
Na,9809,B-CHEMICAL
current,9809,O
(,9809,O
late,9809,O
I,9809,O
(,9809,O
Na,9809,B-CHEMICAL
),9809,O
),9809,O
has,9809,O
been,9809,O
shown,9809,O
to,9809,O
be,9809,O
important,9809,O
in,9809,O
LQT2,9809,O
and,9809,O
LQT3,9809,O
arrhythmias,9809,O
.,9809,O
Class,9810,O
III,9810,O
agents,9810,O
like,9810,O
dofetilide,9810,B-CHEMICAL
",",9810,O
clofilium,9810,B-CHEMICAL
",",9810,O
and,9810,O
sotalol,9810,B-CHEMICAL
",",9810,O
which,9810,O
can,9810,O
all,9810,O
cause,9810,O
a,9810,O
drug-induced,9810,O
form,9810,O
of,9810,O
LQT2,9810,O
",",9810,O
significantly,9810,O
lengthen,9810,O
action,9810,O
potential,9810,O
duration,9810,O
at,9810,O
50,9810,O
%,9810,O
and,9810,O
90,9810,O
%,9810,O
repolarization,9810,O
in,9810,O
isolated,9810,O
rabbit,9810,O
Purkinje,9810,O
fibers,9810,O
",",9810,O
and,9810,O
can,9810,O
initiate,9810,O
the,9810,O
formation,9810,O
of,9810,O
early,9810,O
afterdepolarizations,9810,O
",",9810,O
and,9810,O
extra,9810,O
beats,9810,O
.,9810,O
These,9811,O
actions,9811,O
can,9811,O
lead,9811,O
to,9811,O
the,9811,O
development,9811,O
of,9811,O
a,9811,O
serious,9811,O
ventricular,9811,O
tachycardia,9811,O
",",9811,O
torsades,9811,O
de,9811,O
pointes,9811,O
",",9811,O
in,9811,O
animal,9811,O
models,9811,O
and,9811,O
patients,9811,O
.,9811,O
However,9812,O
",",9812,O
pretreatment,9812,O
with,9812,O
agents,9812,O
that,9812,O
block,9812,O
late,9812,O
I,9812,O
(,9812,O
Na,9812,B-CHEMICAL
),9812,O
",",9812,O
like,9812,O
lidocaine,9812,B-CHEMICAL
",",9812,O
mexiletine,9812,B-CHEMICAL
",",9812,O
and,9812,O
RSD1235,9812,B-CHEMICAL
",",9812,O
a,9812,O
novel,9812,O
mixed,9812,O
ion,9812,B-GENE-N
channel,9812,I-GENE-N
blocker,9812,O
for,9812,O
the,9812,O
rapid,9812,O
pharmacologic,9812,O
conversion,9812,O
of,9812,O
atrial,9812,O
fibrillation,9812,O
",",9812,O
significantly,9812,O
attenuates,9812,O
the,9812,O
prolonging,9812,O
effects,9812,O
of,9812,O
Class,9812,O
III,9812,O
agents,9812,O
or,9812,O
those,9812,O
induced,9812,O
by,9812,O
ATX-II,9812,O
",",9812,O
a,9812,O
specific,9812,O
toxin,9812,O
that,9812,O
delays,9812,O
Na,9812,B-GENE-N
channel,9812,I-GENE-N
inactivation,9812,O
and,9812,O
amplifies,9812,O
late,9812,O
I,9812,O
(,9812,O
Na,9812,B-CHEMICAL
),9812,O
greatly,9812,O
",",9812,O
mimicking,9812,O
LQT3,9812,O
.,9812,O
The,9813,O
Na,9813,B-GENE-N
channel,9813,I-GENE-N
block,9813,O
caused,9813,O
by,9813,O
lidocaine,9813,B-CHEMICAL
and,9813,O
RSD1235,9813,B-CHEMICAL
can,9813,O
be,9813,O
through,9813,O
the,9813,O
open,9813,O
or,9813,O
inactivated,9813,O
states,9813,O
of,9813,O
the,9813,O
channel,9813,O
",",9813,O
but,9813,O
both,9813,O
equivalently,9813,O
inhibit,9813,O
a,9813,O
late,9813,O
component,9813,O
of,9813,O
Na,9813,B-CHEMICAL
current,9813,O
(,9813,O
I,9813,O
(,9813,O
Na,9813,B-CHEMICAL
),9813,O
),9813,O
",",9813,O
recorded,9813,O
at,9813,O
22,9813,O
degrees,9813,O
C,9813,O
using,9813,O
whole-cell,9813,O
patch,9813,O
clamp,9813,O
of,9813,O
Nav,9813,B-GENE-Y
1.5,9813,I-GENE-Y
expressed,9813,O
in,9813,O
HEK,9813,O
cells,9813,O
.,9813,O
These,9814,O
protective,9814,O
actions,9814,O
of,9814,O
lidocaine,9814,B-CHEMICAL
",",9814,O
mexiletine,9814,B-CHEMICAL
",",9814,O
and,9814,O
RSD1235,9814,B-CHEMICAL
may,9814,O
result,9814,O
",",9814,O
at,9814,O
least,9814,O
in,9814,O
part,9814,O
",",9814,O
from,9814,O
their,9814,O
ability,9814,O
to,9814,O
inhibit,9814,O
late,9814,O
I,9814,O
(,9814,O
Na,9814,B-CHEMICAL
),9814,O
during,9814,O
action,9814,O
potential,9814,O
repolarization,9814,O
",",9814,O
and,9814,O
inhibition,9814,O
of,9814,O
the,9814,O
inward,9814,O
currents,9814,O
contributing,9814,O
to,9814,O
EAD,9814,O
and,9814,O
arrhythmia,9814,O
formation,9814,O
.,9814,O
Polyamine,9815,B-CHEMICAL
depletion,9815,O
delays,9815,O
apoptosis,9815,O
of,9815,O
rat,9815,O
intestinal,9815,O
epithelial,9815,O
cells,9815,O
.,9815,O
The,9816,O
polyamines,9816,B-CHEMICAL
spermidine,9816,B-CHEMICAL
",",9816,O
spermine,9816,B-CHEMICAL
",",9816,O
and,9816,O
their,9816,O
precursor,9816,O
putrescine,9816,B-CHEMICAL
are,9816,O
essential,9816,O
for,9816,O
cell,9816,O
growth,9816,O
and,9816,O
the,9816,O
regulation,9816,O
of,9816,O
the,9816,O
cell,9816,O
cycle,9816,O
.,9816,O
Recent,9817,O
studies,9817,O
suggest,9817,O
that,9817,O
excessive,9817,O
accumulation,9817,O
of,9817,O
polyamines,9817,B-CHEMICAL
favors,9817,O
either,9817,O
malignant,9817,O
transformation,9817,O
or,9817,O
apoptosis,9817,O
",",9817,O
depending,9817,O
on,9817,O
the,9817,O
cell,9817,O
type,9817,O
and,9817,O
the,9817,O
stimulus,9817,O
.,9817,O
This,9818,O
study,9818,O
examines,9818,O
the,9818,O
involvement,9818,O
of,9818,O
polyamines,9818,B-CHEMICAL
in,9818,O
the,9818,O
induction,9818,O
of,9818,O
apoptosis,9818,O
by,9818,O
the,9818,O
DNA,9818,B-GENE-Y
topoisomerase,9818,I-GENE-Y
I,9818,I-GENE-Y
inhibitor,9818,O
",",9818,O
camptothecin,9818,O
.,9818,O
In,9819,O
IEC-6,9819,O
cells,9819,O
",",9819,O
camptothecin,9819,B-CHEMICAL
induced,9819,O
apoptosis,9819,O
within,9819,O
6,9819,O
h,9819,O
",",9819,O
accompanied,9819,O
by,9819,O
detachment,9819,O
of,9819,O
cells,9819,O
.,9819,O
Detached,9820,O
cells,9820,O
showed,9820,O
DNA,9820,O
laddering,9820,O
and,9820,O
caspase,9820,B-GENE-Y
3,9820,I-GENE-Y
induction,9820,O
",",9820,O
characteristic,9820,O
features,9820,O
of,9820,O
apoptosis,9820,O
.,9820,O
Depletion,9821,O
of,9821,O
putrescine,9821,B-CHEMICAL
",",9821,O
spermidine,9821,B-CHEMICAL
",",9821,O
and,9821,O
spermine,9821,B-CHEMICAL
by,9821,O
DL-alpha-difluoromethylornithine,9821,B-CHEMICAL
(,9821,O
DFMO,9821,B-CHEMICAL
),9821,O
",",9821,O
a,9821,O
specific,9821,O
inhibitor,9821,O
of,9821,O
ornithine,9821,B-GENE-Y
decarboxylase,9821,I-GENE-Y
(,9821,O
ODC,9821,B-GENE-Y
),9821,O
that,9821,O
is,9821,O
the,9821,O
first,9821,O
rate-limiting,9821,O
enzyme,9821,O
for,9821,O
polyamine,9821,B-CHEMICAL
biosynthesis,9821,O
",",9821,O
decreased,9821,O
the,9821,O
apoptotic,9821,O
index,9821,O
.,9821,O
Delayed,9822,O
apoptosis,9822,O
was,9822,O
accompanied,9822,O
by,9822,O
a,9822,O
decrease,9822,O
in,9822,O
caspase,9822,B-GENE-Y
3,9822,I-GENE-Y
activity,9822,O
in,9822,O
polyamine-depleted,9822,B-CHEMICAL
cells,9822,O
.,9822,O
Addition,9823,O
of,9823,O
putrescine,9823,B-CHEMICAL
restored,9823,O
the,9823,O
induction,9823,O
of,9823,O
apoptosis,9823,O
as,9823,O
indicated,9823,O
by,9823,O
an,9823,O
increase,9823,O
in,9823,O
the,9823,O
number,9823,O
of,9823,O
detached,9823,O
cells,9823,O
and,9823,O
caspase,9823,B-GENE-Y
3,9823,I-GENE-Y
activity,9823,O
.,9823,O
Polyamine,9824,B-CHEMICAL
depletion,9824,O
did,9824,O
not,9824,O
change,9824,O
the,9824,O
level,9824,O
of,9824,O
caspase,9824,B-GENE-Y
3,9824,I-GENE-Y
protein,9824,O
.,9824,O
Inhibition,9825,O
of,9825,O
S-adenosylmethionine,9825,B-GENE-Y
decarboxylase,9825,I-GENE-Y
by,9825,O
a,9825,O
specific,9825,O
inhibitor,9825,O
[,9825,O
diethylglyoxal,9825,B-CHEMICAL
bis-,9825,I-CHEMICAL
(,9825,I-CHEMICAL
guanylhydrazone,9825,I-CHEMICAL
),9825,I-CHEMICAL
;,9825,O
DEGBG,9825,B-CHEMICAL
],9825,O
led,9825,O
to,9825,O
depletion,9825,O
of,9825,O
spermidine,9825,B-CHEMICAL
and,9825,O
spermine,9825,B-CHEMICAL
with,9825,O
a,9825,O
significant,9825,O
accumulation,9825,O
of,9825,O
putrescine,9825,B-CHEMICAL
and,9825,O
induction,9825,O
of,9825,O
ODC,9825,B-GENE-Y
.,9825,O
The,9826,O
DEGBG-treated,9826,B-CHEMICAL
cells,9826,O
showed,9826,O
an,9826,O
increase,9826,O
in,9826,O
apoptosis,9826,O
",",9826,O
suggesting,9826,O
the,9826,O
importance,9826,O
of,9826,O
putrescine,9826,B-CHEMICAL
in,9826,O
the,9826,O
apoptotic,9826,O
process,9826,O
.,9826,O
Addition,9827,O
of,9827,O
putrescine,9827,B-CHEMICAL
to,9827,O
DFMO-treated,9827,B-CHEMICAL
cell,9827,O
extracts,9827,O
did,9827,O
not,9827,O
increase,9827,O
caspase,9827,B-GENE-Y
3,9827,I-GENE-Y
activity,9827,O
.,9827,O
The,9828,O
above,9828,O
results,9828,O
indicate,9828,O
that,9828,O
polyamine,9828,B-CHEMICAL
depletion,9828,O
delays,9828,O
the,9828,O
onset,9828,O
of,9828,O
apoptosis,9828,O
in,9828,O
IEC-6,9828,O
cells,9828,O
and,9828,O
confers,9828,O
protection,9828,O
against,9828,O
DNA,9828,O
damaging,9828,O
agents,9828,O
",",9828,O
suggesting,9828,O
that,9828,O
polyamines,9828,B-CHEMICAL
might,9828,O
be,9828,O
involved,9828,O
in,9828,O
the,9828,O
caspase,9828,B-GENE-N
activating,9828,O
signal,9828,O
cascade,9828,O
.,9828,O
Profile,9829,O
of,9829,O
certolizumab,9829,O
and,9829,O
its,9829,O
potential,9829,O
in,9829,O
the,9829,O
treatment,9829,O
of,9829,O
psoriatic,9829,O
arthritis,9829,O
.,9829,O
Psoriatic,9830,O
arthritis,9830,O
(,9830,O
PsA,9830,O
),9830,O
is,9830,O
a,9830,O
chronic,9830,O
inflammatory,9830,O
arthropathy,9830,O
associated,9830,O
with,9830,O
psoriasis,9830,O
(,9830,O
PsO,9830,O
),9830,O
.,9830,O
PsA,9831,O
could,9831,O
be,9831,O
considered,9831,O
an,9831,O
enthesal,9831,O
disease,9831,O
because,9831,O
of,9831,O
the,9831,O
link,9831,O
between,9831,O
mechanical,9831,O
stress,9831,O
(,9831,O
entheses,9831,O
),9831,O
and,9831,O
immunologically,9831,O
active,9831,O
tissue,9831,O
(,9831,O
synovium,9831,O
),9831,O
.,9831,O
Evidence,9832,O
of,9832,O
efficacy,9832,O
of,9832,O
anti-tumor,9832,O
necrosis,9832,I-GENE-Y
factor,9832,I-GENE-Y
alpha,9832,I-GENE-Y
(,9832,O
TNF-alpha,9832,B-GENE-Y
),9832,O
is,9832,O
supported,9832,O
by,9832,O
reduction,9832,O
of,9832,O
histological,9832,O
vascularity,9832,O
and,9832,O
immune,9832,O
cell,9832,O
infiltrates,9832,O
in,9832,O
synovial,9832,O
tissue,9832,O
after,9832,O
treatment,9832,O
.,9832,O
Certolizumab,9833,O
pegol,9833,O
(,9833,O
CZP,9833,O
),9833,O
is,9833,O
a,9833,O
polyethylene,9833,O
glycolylated,9833,O
(,9833,O
PEGylated,9833,O
),9833,O
Fab,9833,B-GENE-N
',9833,O
fragment,9833,O
of,9833,O
a,9833,O
humanized,9833,O
monoclonal,9833,O
antibody,9833,O
that,9833,O
binds,9833,O
and,9833,O
neutralizes,9833,O
human,9833,B-GENE-Y
TNF-alpha,9833,I-GENE-Y
.,9833,O
The,9834,O
PEG,9834,B-CHEMICAL
moiety,9834,O
of,9834,O
the,9834,O
Fab,9834,B-GENE-N
fragment,9834,O
",",9834,O
markedly,9834,O
increases,9834,O
the,9834,O
half-life,9834,O
of,9834,O
CZP,9834,O
and,9834,O
confers,9834,O
to,9834,O
the,9834,O
drug,9834,O
a,9834,O
unique,9834,O
structure,9834,O
that,9834,O
differs,9834,O
from,9834,O
the,9834,O
other,9834,O
anti-TNF-alpha,9834,O
agents,9834,O
tested,9834,O
for,9834,O
the,9834,O
treatment,9834,O
of,9834,O
Crohn,9834,O
's,9834,O
disease,9834,O
",",9834,O
rheumatoid,9834,O
arthritis,9834,O
",",9834,O
ankylosing,9834,O
spondylitis,9834,O
",",9834,O
axial,9834,O
spondyloarthritis,9834,O
",",9834,O
nonradiographic,9834,O
spondyloarthritis,9834,O
",",9834,O
PsO,9834,O
",",9834,O
and,9834,O
PsA,9834,O
.,9834,O
In,9835,O
contrast,9835,O
to,9835,O
other,9835,O
anti-TNF-alpha,9835,O
agents,9835,O
",",9835,O
CZP,9835,O
did,9835,O
not,9835,O
mediate,9835,O
increased,9835,O
levels,9835,O
of,9835,O
apoptosis,9835,O
",",9835,O
suggesting,9835,O
that,9835,O
these,9835,O
mechanisms,9835,O
are,9835,O
not,9835,O
essential,9835,O
for,9835,O
the,9835,O
anti-TNF-alpha,9835,O
efficacy,9835,O
in,9835,O
Crohn,9835,O
's,9835,O
disease,9835,O
.,9835,O
As,9836,O
CZP,9836,O
",",9836,O
infliximab,9836,O
",",9836,O
and,9836,O
adalimumab,9836,O
",",9836,O
but,9836,O
not,9836,O
etanercept,9836,O
",",9836,O
almost,9836,O
completely,9836,O
inhibited,9836,O
lipopolysaccharide-induced,9836,O
interleukin-1,9836,B-GENE-Y
beta,9836,I-GENE-Y
release,9836,O
from,9836,O
monocytes,9836,O
",",9836,O
this,9836,O
cytokine-production,9836,B-GENE-N
inhibition,9836,O
may,9836,O
be,9836,O
relevant,9836,O
for,9836,O
drug,9836,O
efficacy,9836,O
.,9836,O
Due,9837,O
to,9837,O
these,9837,O
characteristics,9837,O
",",9837,O
it,9837,O
has,9837,O
been,9837,O
demonstrated,9837,O
in,9837,O
clinical,9837,O
studies,9837,O
that,9837,O
CZP,9837,O
effectively,9837,O
improves,9837,O
signs,9837,O
and,9837,O
symptoms,9837,O
of,9837,O
arthritis,9837,O
and,9837,O
physical,9837,O
function,9837,O
and,9837,O
skin,9837,O
manifestations,9837,O
of,9837,O
PsO,9837,O
",",9837,O
with,9837,O
a,9837,O
safety,9837,O
profile,9837,O
similar,9837,O
to,9837,O
rheumatoid,9837,O
arthritis,9837,O
.,9837,O
This,9838,O
drug,9838,O
can,9838,O
be,9838,O
considered,9838,O
as,9838,O
a,9838,O
valid,9838,O
treatment,9838,O
in,9838,O
patients,9838,O
affected,9838,O
by,9838,O
PsA,9838,O
.,9838,O
The,9839,O
efficacy,9839,O
and,9839,O
tolerability,9839,O
profiles,9839,O
suggest,9839,O
CZP,9839,O
as,9839,O
a,9839,O
suitable,9839,O
antipsoriatic,9839,O
drug,9839,O
in,9839,O
the,9839,O
treatment,9839,O
of,9839,O
PsA,9839,O
.,9839,O
Predictive,9840,O
modeling,9840,O
of,9840,O
insulin,9840,B-GENE-Y
release,9840,O
profile,9840,O
from,9840,O
cross-linked,9840,O
chitosan,9840,O
microspheres,9840,O
.,9840,O
Insulin-loaded,9841,B-GENE-Y
microspheres,9841,O
composed,9841,O
of,9841,O
chitosan,9841,O
3,9841,O
%,9841,O
(,9841,O
w/v,9841,O
),9841,O
",",9841,O
and,9841,O
loading,9841,O
120,9841,O
IU,9841,O
insulin,9841,B-GENE-Y
were,9841,O
produced,9841,O
by,9841,O
emulsion,9841,O
cross-linking,9841,O
method,9841,O
.,9841,O
Cross-linking,9842,O
time,9842,O
was,9842,O
5,9842,O
h,9842,O
and,9842,O
glutaraldehyde,9842,B-CHEMICAL
3.5,9842,O
%,9842,O
(,9842,O
v/v,9842,O
),9842,O
was,9842,O
used,9842,O
as,9842,O
cross-linker,9842,O
.,9842,O
Swelling,9843,O
ratio,9843,O
studies,9843,O
were,9843,O
evaluated,9843,O
to,9843,O
predict,9843,O
release,9843,O
of,9843,O
insulin,9843,B-GENE-Y
from,9843,O
chitosan,9843,O
microspheres,9843,O
.,9843,O
Bacitracin,9844,B-CHEMICAL
and,9844,O
sodium,9844,B-CHEMICAL
taurocholate,9844,I-CHEMICAL
were,9844,O
incorporated,9844,O
in,9844,O
the,9844,O
formulations,9844,O
as,9844,O
proteolytic,9844,O
enzyme,9844,O
inhibitor,9844,O
and,9844,O
absorption,9844,O
enhancer,9844,O
",",9844,O
respectively,9844,O
.,9844,O
In,9845,O
vitro,9845,O
insulin,9845,B-GENE-Y
release,9845,O
studies,9845,O
were,9845,O
performed,9845,O
in,9845,O
phosphate,9845,B-CHEMICAL
buffer,9845,O
pH,9845,O
7.4,9845,O
and,9845,O
also,9845,O
in,9845,O
HCl,9845,B-CHEMICAL
pH,9845,O
2,9845,O
with,9845,O
and,9845,O
without,9845,O
trypsin,9845,B-GENE-N
.,9845,O
Activity,9846,O
of,9846,O
bacitracin,9846,B-CHEMICAL
was,9846,O
also,9846,O
evaluated,9846,O
.,9846,O
In,9847,O
vitro,9847,O
release,9847,O
showed,9847,O
a,9847,O
controlled,9847,O
profile,9847,O
up,9847,O
to,9847,O
12,9847,O
h,9847,O
and,9847,O
the,9847,O
formulation,9847,O
containing,9847,O
0.15,9847,O
%,9847,O
(,9847,O
w/v,9847,O
),9847,O
of,9847,O
bacitracin,9847,B-CHEMICAL
revealed,9847,O
a,9847,O
maximum,9847,O
biological,9847,O
activity,9847,O
of,9847,O
about,9847,O
49.1,9847,O
±,9847,O
4.1,9847,O
%,9847,O
.,9847,O
Mathematical,9848,O
modeling,9848,O
using,9848,O
Higuchi,9848,O
and,9848,O
Korsmeyer-Peppas,9848,O
suggested,9848,O
a,9848,O
non-Fickian,9848,O
diffusion,9848,O
as,9848,O
the,9848,O
mechanism,9848,O
of,9848,O
insulin,9848,B-GENE-Y
release,9848,O
.,9848,O
Insulin-loaded,9849,B-GENE-Y
chitosan,9849,O
microspheres,9849,O
for,9849,O
oral,9849,O
delivery,9849,O
showed,9849,O
to,9849,O
be,9849,O
an,9849,O
innovative,9849,O
and,9849,O
reliable,9849,O
delivery,9849,O
system,9849,O
to,9849,O
overcome,9849,O
conventional,9849,O
insulin,9849,B-GENE-Y
therapy,9849,O
.,9849,O
Serum,9850,O
carvedilol,9850,B-CHEMICAL
concentration,9850,O
and,9850,O
its,9850,O
relation,9850,O
to,9850,O
change,9850,O
in,9850,O
plasma,9850,O
brain,9850,B-GENE-Y
natriuretic,9850,I-GENE-Y
peptide,9850,I-GENE-Y
level,9850,O
in,9850,O
the,9850,O
treatment,9850,O
of,9850,O
heart,9850,O
failure,9850,O
:,9850,O
a,9850,O
preliminary,9850,O
study,9850,O
.,9850,O
OBJECTIVE,9851,O
:,9851,O
To,9851,O
examine,9851,O
the,9851,O
influence,9851,O
of,9851,O
carvedilol,9851,B-CHEMICAL
dose,9851,O
and,9851,O
concentration,9851,O
in,9851,O
serum,9851,O
on,9851,O
plasma,9851,O
brain,9851,B-GENE-Y
natriuretic,9851,I-GENE-Y
peptide,9851,I-GENE-Y
(,9851,O
BNP,9851,B-GENE-Y
),9851,O
",",9851,O
a,9851,O
measure,9851,O
of,9851,O
heart,9851,O
failure,9851,O
progression,9851,O
.,9851,O
METHODS,9852,O
:,9852,O
12,9852,O
patients,9852,O
with,9852,O
New,9852,O
York,9852,O
Heart,9852,O
Association,9852,O
(,9852,O
NYHA,9852,O
),9852,O
functional,9852,O
class,9852,O
II-III,9852,O
chronic,9852,O
heart,9852,O
failure,9852,O
were,9852,O
enrolled,9852,O
in,9852,O
the,9852,O
study,9852,O
.,9852,O
They,9853,O
received,9853,O
carvedilol,9853,B-CHEMICAL
at,9853,O
daily,9853,O
doses,9853,O
of,9853,O
1-20,9853,O
mg,9853,O
with,9853,O
a,9853,O
1-2,9853,O
weekly,9853,O
adjustment,9853,O
.,9853,O
Serum,9854,O
carvedilol,9854,B-CHEMICAL
trough,9854,O
concentrations,9854,O
were,9854,O
measured,9854,O
in,9854,O
steady-state,9854,O
using,9854,O
a,9854,O
specific,9854,O
fluorescence,9854,O
HPLC,9854,O
method,9854,O
.,9854,O
The,9855,O
degree,9855,O
of,9855,O
improvement,9855,O
in,9855,O
heart,9855,O
failure,9855,O
was,9855,O
assessed,9855,O
from,9855,O
the,9855,O
ratio,9855,O
of,9855,O
change,9855,O
in,9855,O
the,9855,O
plasma,9855,O
BNP,9855,B-GENE-Y
concentration,9855,O
",",9855,O
2,9855,O
weeks,9855,O
",",9855,O
1,9855,O
month,9855,O
and,9855,O
3,9855,O
months,9855,O
after,9855,O
the,9855,O
commencement,9855,O
of,9855,O
carvedilol,9855,B-CHEMICAL
administration,9855,O
.,9855,O
RESULTS,9856,O
:,9856,O
From,9856,O
the,9856,O
pharmacokinetic,9856,O
aspect,9856,O
",",9856,O
there,9856,O
was,9856,O
no,9856,O
valid,9856,O
correlation,9856,O
between,9856,O
the,9856,O
trough,9856,O
serum,9856,O
carvedilol,9856,B-CHEMICAL
concentration,9856,O
(,9856,O
Cmin,9856,O
),9856,O
and,9856,O
daily,9856,O
dose,9856,O
per,9856,O
body,9856,O
weight,9856,O
(,9856,O
Dd/BW,9856,O
),9856,O
",",9856,O
indicating,9856,O
that,9856,O
there,9856,O
was,9856,O
a,9856,O
wide,9856,O
difference,9856,O
in,9856,O
the,9856,O
carvedilol,9856,B-CHEMICAL
elimination,9856,O
capacity,9856,O
among,9856,O
individuals,9856,O
.,9856,O
A,9857,O
significant,9857,O
decrease,9857,O
in,9857,O
the,9857,O
BNP,9857,B-GENE-Y
was,9857,O
observed,9857,O
at,9857,O
the,9857,O
3rd,9857,O
month,9857,O
in,9857,O
patients,9857,O
treated,9857,O
with,9857,O
the,9857,O
high,9857,O
dose,9857,O
(,9857,O
>,9857,O
750,9857,O
mg/3,9857,O
months,9857,O
),9857,O
.,9857,O
On,9858,O
the,9858,O
other,9858,O
hand,9858,O
",",9858,O
in,9858,O
patients,9858,O
with,9858,O
a,9858,O
mean,9858,O
serum,9858,O
carvedilol,9858,B-CHEMICAL
level,9858,O
(,9858,O
Cmin,9858,O
),9858,O
of,9858,O
less,9858,O
than,9858,O
2.5,9858,O
nmol/l,9858,O
up,9858,O
to,9858,O
2,9858,O
weeks,9858,O
after,9858,O
the,9858,O
start,9858,O
ofcarvedilol,9858,O
therapy,9858,O
",",9858,O
the,9858,O
degree,9858,O
of,9858,O
reduction,9858,O
in,9858,O
the,9858,O
BNP,9858,B-GENE-Y
value,9858,O
after,9858,O
the,9858,O
3rd,9858,O
month,9858,O
was,9858,O
significantly,9858,O
larger,9858,O
",",9858,O
relative,9858,O
to,9858,O
the,9858,O
patient,9858,O
group,9858,O
with,9858,O
Cmin,9858,O
over,9858,O
2.5,9858,O
nmol/l,9858,O
.,9858,O
CONCLUSIONS,9859,O
:,9859,O
The,9859,O
total,9859,O
carvedilol,9859,B-CHEMICAL
dose,9859,O
was,9859,O
confirmed,9859,O
to,9859,O
be,9859,O
one,9859,O
of,9859,O
the,9859,O
determinants,9859,O
for,9859,O
improvement,9859,O
in,9859,O
heart,9859,O
failure,9859,O
",",9859,O
and,9859,O
it,9859,O
was,9859,O
suggested,9859,O
that,9859,O
the,9859,O
initial,9859,O
serum,9859,O
level,9859,O
also,9859,O
plays,9859,O
an,9859,O
important,9859,O
role,9859,O
in,9859,O
therapeutic,9859,O
outcome,9859,O
.,9859,O
Therefore,9860,O
",",9860,O
it,9860,O
may,9860,O
be,9860,O
important,9860,O
to,9860,O
monitor,9860,O
the,9860,O
serum,9860,O
carvedilol,9860,B-CHEMICAL
level,9860,O
at,9860,O
the,9860,O
introductory,9860,O
period,9860,O
to,9860,O
determine,9860,O
the,9860,O
daily,9860,O
dose,9860,O
requirements,9860,O
because,9860,O
of,9860,O
the,9860,O
wide,9860,O
inter-individual,9860,O
variability,9860,O
in,9860,O
its,9860,O
metabolic,9860,O
clearance,9860,O
.,9860,O
Mechanism,9861,O
of,9861,O
action,9861,O
of,9861,O
leflunomide,9861,B-CHEMICAL
in,9861,O
rheumatoid,9861,O
arthritis,9861,O
.,9861,O
Leflunomide,9862,B-CHEMICAL
",",9862,O
a,9862,O
novel,9862,O
drug,9862,O
with,9862,O
proven,9862,O
efficacy,9862,O
in,9862,O
rheumatoid,9862,O
arthritis,9862,O
",",9862,O
is,9862,O
an,9862,O
isoxazol,9862,B-CHEMICAL
derivative,9862,O
structurally,9862,O
unrelated,9862,O
to,9862,O
other,9862,O
immunomodulatory,9862,O
drugs,9862,O
.,9862,O
Leflunomide,9863,B-CHEMICAL
is,9863,O
rapidly,9863,O
metabolized,9863,O
to,9863,O
its,9863,O
active,9863,O
form,9863,O
",",9863,O
A77,9863,B-CHEMICAL
1726,9863,I-CHEMICAL
.,9863,O
Two,9864,O
mechanisms,9864,O
of,9864,O
action,9864,O
have,9864,O
been,9864,O
identified,9864,O
for,9864,O
A77,9864,B-CHEMICAL
1726,9864,I-CHEMICAL
:,9864,O
inhibition,9864,O
of,9864,O
dihydroorotate,9864,B-GENE-Y
dehydrogenase,9864,I-GENE-Y
(,9864,O
DHODH,9864,B-GENE-Y
),9864,O
and,9864,O
inhibition,9864,O
of,9864,O
tyrosine,9864,B-GENE-N
kinases,9864,I-GENE-N
.,9864,O
DHODH,9865,B-GENE-Y
inhibition,9865,O
occurs,9865,O
at,9865,O
lower,9865,O
concentrations,9865,O
of,9865,O
A77,9865,B-CHEMICAL
1726,9865,I-CHEMICAL
than,9865,O
that,9865,O
of,9865,O
tyrosine,9865,B-GENE-N
kinases,9865,I-GENE-N
and,9865,O
is,9865,O
currently,9865,O
considered,9865,O
the,9865,O
major,9865,O
mode,9865,O
of,9865,O
action,9865,O
.,9865,O
Stimulated,9866,O
lymphocytes,9866,O
must,9866,O
increase,9866,O
ribonucleotide,9866,O
levels,9866,O
from,9866,O
8,9866,O
to,9866,O
16-fold,9866,O
before,9866,O
proceeding,9866,O
from,9866,O
the,9866,O
G1,9866,O
into,9866,O
the,9866,O
S,9866,O
phase,9866,O
.,9866,O
Increased,9867,O
levels,9867,O
of,9867,O
ribonucleotides,9867,O
can,9867,O
only,9867,O
be,9867,O
met,9867,O
by,9867,O
de,9867,O
novo,9867,O
ribonucleotide,9867,O
synthesis,9867,O
.,9867,O
At,9868,O
low,9868,O
levels,9868,O
of,9868,O
ribonucleotides,9868,O
",",9868,O
p53,9868,B-GENE-Y
",",9868,O
a,9868,O
``,9868,O
sensor,9868,O
'',9868,O
molecule,9868,O
",",9868,O
gets,9868,O
activated,9868,O
and,9868,O
prevents,9868,O
progression,9868,O
through,9868,O
the,9868,O
cell,9868,O
cycle,9868,O
.,9868,O
Therefore,9869,O
",",9869,O
an,9869,O
inhibitor,9869,O
of,9869,O
de,9869,O
novo,9869,O
uridine,9869,B-CHEMICAL
monophosphate,9869,I-CHEMICAL
synthesis,9869,O
would,9869,O
predictably,9869,O
arrest,9869,O
stimulated,9869,O
cells,9869,O
at,9869,O
the,9869,O
G1,9869,O
phase,9869,O
.,9869,O
In,9870,O
support,9870,O
of,9870,O
this,9870,O
mechanism,9870,O
of,9870,O
action,9870,O
",",9870,O
in,9870,O
vitro,9870,O
mitogen,9870,O
stimulated,9870,O
human,9870,O
peripheral,9870,O
blood,9870,O
lymphocytes,9870,O
treated,9870,O
with,9870,O
A77,9870,B-CHEMICAL
1726,9870,I-CHEMICAL
undergo,9870,O
arrest,9870,O
at,9870,O
the,9870,O
G1,9870,O
phase,9870,O
;,9870,O
this,9870,O
inhibition,9870,O
is,9870,O
reversed,9870,O
by,9870,O
uridine,9870,B-CHEMICAL
.,9870,O
L-proline,9871,B-CHEMICAL
accumulation,9871,O
and,9871,O
freeze,9871,O
tolerance,9871,O
of,9871,O
Saccharomyces,9871,O
cerevisiae,9871,O
are,9871,O
caused,9871,O
by,9871,O
a,9871,O
mutation,9871,O
in,9871,O
the,9871,O
PRO1,9871,B-GENE-Y
gene,9871,O
encoding,9871,O
gamma-glutamyl,9871,B-GENE-Y
kinase,9871,I-GENE-Y
.,9871,O
We,9872,O
previously,9872,O
isolated,9872,O
a,9872,O
mutant,9872,O
which,9872,O
showed,9872,O
a,9872,O
high,9872,O
tolerance,9872,O
to,9872,O
freezing,9872,O
that,9872,O
correlated,9872,O
with,9872,O
higher,9872,O
levels,9872,O
of,9872,O
intracellular,9872,O
L-proline,9872,B-CHEMICAL
derived,9872,O
from,9872,O
L-proline,9872,B-CHEMICAL
analogue-resistant,9872,O
mutants,9872,O
.,9872,O
The,9873,O
mutation,9873,O
responsible,9873,O
for,9873,O
the,9873,O
analogue,9873,O
resistance,9873,O
and,9873,O
L-proline,9873,B-CHEMICAL
accumulation,9873,O
was,9873,O
a,9873,O
single,9873,O
nuclear,9873,O
dominant,9873,O
mutation,9873,O
.,9873,O
By,9874,O
introducing,9874,O
the,9874,O
mutant-derived,9874,O
genomic,9874,O
library,9874,O
into,9874,O
a,9874,O
non-L-proline-utilizing,9874,O
strain,9874,O
",",9874,O
the,9874,O
mutant,9874,O
was,9874,O
found,9874,O
to,9874,O
carry,9874,O
an,9874,O
allele,9874,O
of,9874,O
the,9874,O
wild-type,9874,O
PRO1,9874,B-GENE-Y
gene,9874,O
encoding,9874,O
gamma-glutamyl,9874,B-GENE-Y
kinase,9874,I-GENE-Y
",",9874,O
which,9874,O
resulted,9874,O
in,9874,O
a,9874,O
single,9874,O
amino,9874,B-CHEMICAL
acid,9874,I-CHEMICAL
replacement,9874,O
;,9874,O
Asp,9874,B-CHEMICAL
(,9874,O
GAC,9874,B-GENE-N
),9874,O
at,9874,O
position,9874,O
154,9874,O
was,9874,O
replaced,9874,O
by,9874,O
Asn,9874,B-CHEMICAL
(,9874,O
AAC,9874,B-GENE-N
),9874,O
.,9874,O
Interestingly,9875,O
",",9875,O
the,9875,O
allele,9875,O
of,9875,O
PRO1,9875,B-GENE-Y
was,9875,O
shown,9875,O
to,9875,O
enhance,9875,O
the,9875,O
activities,9875,O
of,9875,O
gamma-glutamyl,9875,B-GENE-Y
kinase,9875,I-GENE-Y
and,9875,O
gamma-glutamyl,9875,B-GENE-Y
phosphate,9875,I-GENE-Y
reductase,9875,I-GENE-Y
",",9875,O
both,9875,O
of,9875,O
which,9875,O
catalyze,9875,O
the,9875,O
first,9875,O
two,9875,O
steps,9875,O
of,9875,O
L-proline,9875,B-CHEMICAL
synthesis,9875,O
from,9875,O
L-glutamate,9875,B-CHEMICAL
and,9875,O
which,9875,O
together,9875,O
may,9875,O
form,9875,O
a,9875,O
complex,9875,O
in,9875,O
vivo,9875,O
.,9875,O
When,9876,O
cultured,9876,O
in,9876,O
liquid,9876,O
minimal,9876,O
medium,9876,O
",",9876,O
yeast,9876,O
cells,9876,O
expressing,9876,O
the,9876,O
mutated,9876,O
gamma-glutamyl,9876,B-GENE-Y
kinase,9876,I-GENE-Y
were,9876,O
found,9876,O
to,9876,O
accumulate,9876,O
intracellular,9876,O
L-proline,9876,B-CHEMICAL
and,9876,O
showed,9876,O
a,9876,O
prominent,9876,O
increase,9876,O
in,9876,O
cell,9876,O
viability,9876,O
after,9876,O
freezing,9876,O
at,9876,O
-20,9876,O
degrees,9876,O
C,9876,O
compared,9876,O
to,9876,O
the,9876,O
viability,9876,O
of,9876,O
cells,9876,O
harboring,9876,O
the,9876,O
wild-type,9876,O
PRO1,9876,B-GENE-Y
gene,9876,O
.,9876,O
These,9877,O
results,9877,O
suggest,9877,O
that,9877,O
the,9877,O
altered,9877,O
gamma-glutamyl,9877,B-GENE-Y
kinase,9877,I-GENE-Y
results,9877,O
in,9877,O
stabilization,9877,O
of,9877,O
the,9877,O
complex,9877,O
or,9877,O
has,9877,O
an,9877,O
indirect,9877,O
effect,9877,O
on,9877,O
gamma-glutamyl,9877,B-GENE-Y
phosphate,9877,I-GENE-Y
reductase,9877,I-GENE-Y
activity,9877,O
",",9877,O
which,9877,O
leads,9877,O
to,9877,O
an,9877,O
increase,9877,O
in,9877,O
L-proline,9877,B-CHEMICAL
production,9877,O
in,9877,O
Saccharomyces,9877,O
cerevisiae,9877,O
.,9877,O
The,9878,O
approach,9878,O
described,9878,O
in,9878,O
this,9878,O
paper,9878,O
could,9878,O
be,9878,O
a,9878,O
practical,9878,O
method,9878,O
for,9878,O
breeding,9878,O
novel,9878,O
freeze-tolerant,9878,O
yeast,9878,O
strains,9878,O
.,9878,O
Structural,9879,O
optimization,9879,O
of,9879,O
"2,5-thiophene",9879,B-CHEMICAL
amides,9879,I-CHEMICAL
as,9879,O
highly,9879,O
potent,9879,O
and,9879,O
selective,9879,O
17β-hydroxysteroid,9879,B-GENE-Y
dehydrogenase,9879,I-GENE-Y
type,9879,I-GENE-Y
2,9879,I-GENE-Y
inhibitors,9879,O
for,9879,O
the,9879,O
treatment,9879,O
of,9879,O
osteoporosis,9879,O
.,9879,O
Inhibition,9880,O
of,9880,O
17β-HSD2,9880,B-GENE-Y
is,9880,O
an,9880,O
attractive,9880,O
mechanism,9880,O
for,9880,O
the,9880,O
treatment,9880,O
of,9880,O
osteoporosis,9880,O
.,9880,O
We,9881,O
report,9881,O
here,9881,O
the,9881,O
optimization,9881,O
of,9881,O
human,9881,B-GENE-Y
17β-HSD2,9881,I-GENE-Y
inhibitors,9881,O
in,9881,O
the,9881,O
"2,5-thiophene",9881,B-CHEMICAL
amide,9881,I-CHEMICAL
class,9881,O
by,9881,O
varying,9881,O
the,9881,O
size,9881,O
of,9881,O
the,9881,O
linker,9881,O
(,9881,O
n,9881,O
equals,9881,O
0,9881,O
and,9881,O
2,9881,O
),9881,O
between,9881,O
the,9881,O
amide,9881,B-CHEMICAL
moiety,9881,O
and,9881,O
the,9881,O
phenyl,9881,B-CHEMICAL
group,9881,O
.,9881,O
While,9882,O
none,9882,O
of,9882,O
the,9882,O
phenethylamides,9882,B-CHEMICAL
(,9882,O
n,9882,O
=,9882,O
2,9882,O
),9882,O
were,9882,O
active,9882,O
",",9882,O
most,9882,O
of,9882,O
the,9882,O
anilides,9882,B-CHEMICAL
(,9882,O
n,9882,O
=,9882,O
0,9882,O
),9882,O
turned,9882,O
out,9882,O
to,9882,O
moderately,9882,O
or,9882,O
strongly,9882,O
inhibit,9882,O
17β-HSD2,9882,B-GENE-Y
.,9882,O
The,9883,O
four,9883,O
most,9883,O
active,9883,O
compounds,9883,O
showed,9883,O
an,9883,O
IC₅₀,9883,O
of,9883,O
around,9883,O
60,9883,O
nM,9883,O
and,9883,O
a,9883,O
very,9883,O
good,9883,O
selectivity,9883,O
toward,9883,O
17β-HSD1,9883,B-GENE-Y
",",9883,O
17β-HSD4,9883,B-GENE-Y
",",9883,O
17β-HSD5,9883,B-GENE-Y
",",9883,O
11β-HSD1,9883,B-GENE-Y
",",9883,O
11β-HSD2,9883,B-GENE-Y
and,9883,O
the,9883,O
estrogen,9883,B-GENE-N
receptors,9883,I-GENE-N
α,9883,I-GENE-N
and,9883,I-GENE-N
β,9883,I-GENE-N
.,9883,O
The,9884,O
investigated,9884,O
compounds,9884,O
inhibited,9884,O
monkey,9884,O
17β-HSD2,9884,B-GENE-Y
moderately,9884,O
",",9884,O
and,9884,O
one,9884,O
of,9884,O
them,9884,O
showed,9884,O
good,9884,O
inhibitory,9884,O
activity,9884,O
on,9884,O
mouse,9884,B-GENE-Y
17β-HSD2,9884,I-GENE-Y
.,9884,O
SAR,9885,O
studies,9885,O
allowed,9885,O
a,9885,O
first,9885,O
characterization,9885,O
of,9885,O
the,9885,O
human,9885,B-GENE-Y
17β-HSD2,9885,I-GENE-Y
active,9885,O
site,9885,O
",",9885,O
which,9885,O
is,9885,O
predicted,9885,O
to,9885,O
be,9885,O
considerably,9885,O
larger,9885,O
than,9885,O
that,9885,O
of,9885,O
17β-HSD1,9885,B-GENE-Y
.,9885,O
Changes,9886,O
in,9886,O
submaxillary,9886,O
gland,9886,O
gene,9886,O
expression,9886,O
in,9886,O
F344,9886,O
rats,9886,O
by,9886,O
multiple,9886,O
dosing,9886,O
of,9886,O
theophylline,9886,B-CHEMICAL
.,9886,O
Multiple,9887,O
exposure,9887,O
to,9887,O
theophylline,9887,B-CHEMICAL
",",9887,O
a,9887,O
phosphodiesterase,9887,B-GENE-N
(,9887,O
PDE,9887,B-GENE-N
),9887,O
inhibitor,9887,O
",",9887,O
induces,9887,O
acinar,9887,O
hypertrophy,9887,O
in,9887,O
the,9887,O
salivary,9887,O
gland,9887,O
.,9887,O
This,9888,O
study,9888,O
examined,9888,O
the,9888,O
effect,9888,O
of,9888,O
theophylline,9888,B-CHEMICAL
on,9888,O
the,9888,O
gene,9888,O
expression,9888,O
of,9888,O
secretory,9888,O
proteins,9888,O
and,9888,O
phosphodiesterases,9888,B-GENE-N
in,9888,O
the,9888,O
submaxillary,9888,O
gland,9888,O
.,9888,O
Male,9889,O
F344,9889,O
rats,9889,O
received,9889,O
saline,9889,O
or,9889,O
theophylline,9889,B-CHEMICAL
(,9889,O
50,9889,O
mg/kg,9889,O
),9889,O
intraperitoneally,9889,O
for,9889,O
4,9889,O
days,9889,O
.,9889,O
The,9890,O
gene,9890,O
expressions,9890,O
for,9890,O
the,9890,O
secretory,9890,O
protein,9890,O
",",9890,O
cystatin,9890,B-GENE-Y
S,9890,I-GENE-Y
(,9890,O
CysS,9890,B-GENE-Y
),9890,O
",",9890,O
and,9890,O
PDE,9890,B-GENE-N
subfamilies,9890,I-GENE-N
3A,9890,I-GENE-N
and,9890,I-GENE-N
4D,9890,I-GENE-N
in,9890,O
the,9890,O
submaxillary,9890,O
gland,9890,O
were,9890,O
quantified,9890,O
using,9890,O
RT-PCR,9890,O
.,9890,O
Theophylline,9891,B-CHEMICAL
exposure,9891,O
resulted,9891,O
in,9891,O
a,9891,O
sustained,9891,O
increase,9891,O
in,9891,O
mRNA,9891,O
expression,9891,O
for,9891,O
CysS,9891,B-GENE-Y
and,9891,O
PDE3A,9891,B-GENE-Y
",",9891,O
but,9891,O
PDE4D,9891,B-GENE-Y
gene,9891,O
expression,9891,O
was,9891,O
unchanged,9891,O
.,9891,O
Our,9892,O
results,9892,O
suggest,9892,O
that,9892,O
submaxillary,9892,O
hypertrophy,9892,O
is,9892,O
primarily,9892,O
caused,9892,O
by,9892,O
the,9892,O
enhanced,9892,O
transcription,9892,O
of,9892,O
CysS,9892,B-GENE-Y
",",9892,O
and,9892,O
that,9892,O
the,9892,O
transcription,9892,O
of,9892,O
each,9892,O
PDE,9892,B-GENE-N
subfamily,9892,O
gene,9892,O
is,9892,O
regulated,9892,O
differently,9892,O
.,9892,O
eIF4F,9893,B-GENE-Y
suppression,9893,O
in,9893,O
breast,9893,O
cancer,9893,O
affects,9893,O
maintenance,9893,O
and,9893,O
progression,9893,O
.,9893,O
Levels,9894,O
of,9894,O
eukaryotic,9894,B-GENE-Y
initiation,9894,I-GENE-Y
factor,9894,I-GENE-Y
4E,9894,I-GENE-Y
(,9894,O
eIF4E,9894,B-GENE-Y
),9894,O
are,9894,O
frequently,9894,O
elevated,9894,O
in,9894,O
human,9894,O
cancers,9894,O
and,9894,O
in,9894,O
some,9894,O
instances,9894,O
have,9894,O
been,9894,O
associated,9894,O
with,9894,O
poor,9894,O
prognosis,9894,O
and,9894,O
outcome,9894,O
.,9894,O
Here,9895,O
we,9895,O
utilize,9895,O
transgenic,9895,O
and,9895,O
allograft,9895,O
breast,9895,O
cancer,9895,O
models,9895,O
to,9895,O
demonstrate,9895,O
that,9895,O
increased,9895,O
mammalian,9895,B-GENE-Y
target,9895,I-GENE-Y
of,9895,I-GENE-Y
rapamycin,9895,I-GENE-Y
(,9895,O
mTOR,9895,B-GENE-Y
),9895,O
signalling,9895,O
can,9895,O
be,9895,O
a,9895,O
significant,9895,O
contributor,9895,O
to,9895,O
breast,9895,O
cancer,9895,O
progression,9895,O
in,9895,O
vivo,9895,O
.,9895,O
Suppressing,9896,O
mTOR,9896,B-GENE-Y
activity,9896,O
",",9896,O
as,9896,O
well,9896,O
as,9896,O
levels,9896,O
and,9896,O
activity,9896,O
of,9896,O
the,9896,O
downstream,9896,O
translation,9896,O
regulators,9896,O
",",9896,O
eIF4E,9896,B-GENE-Y
and,9896,O
eIF4A,9896,B-GENE-Y
",",9896,O
delayed,9896,O
breast,9896,O
cancer,9896,O
progression,9896,O
",",9896,O
onset,9896,O
of,9896,O
associated,9896,O
pulmonary,9896,O
metastasis,9896,O
in,9896,O
vivo,9896,O
and,9896,O
breast,9896,O
cancer,9896,O
cell,9896,O
invasion,9896,O
and,9896,O
migration,9896,O
in,9896,O
vitro,9896,O
.,9896,O
Translation,9897,O
of,9897,O
vascular,9897,B-GENE-Y
endothelial,9897,I-GENE-Y
growth,9897,I-GENE-Y
factor,9897,I-GENE-Y
(,9897,O
VEGF,9897,B-GENE-Y
),9897,O
",",9897,O
matrix,9897,B-GENE-Y
metallopeptidase,9897,I-GENE-Y
9,9897,I-GENE-Y
(,9897,O
MMP9,9897,B-GENE-Y
),9897,O
and,9897,O
cyclin,9897,B-GENE-Y
D1,9897,I-GENE-Y
mRNAs,9897,O
",",9897,O
which,9897,O
encode,9897,O
products,9897,O
associated,9897,O
with,9897,O
the,9897,O
metastatic,9897,O
phenotype,9897,O
",",9897,O
is,9897,O
inhibited,9897,O
upon,9897,O
eIF4E,9897,B-GENE-Y
suppression,9897,O
.,9897,O
Our,9898,O
results,9898,O
indicate,9898,O
that,9898,O
the,9898,O
mTOR/eIF4F,9898,B-GENE-Y
axis,9898,O
is,9898,O
an,9898,O
important,9898,O
contributor,9898,O
to,9898,O
tumor,9898,O
maintenance,9898,O
and,9898,O
progression,9898,O
programs,9898,O
in,9898,O
breast,9898,O
cancer,9898,O
.,9898,O
Targeting,9899,O
this,9899,O
pathway,9899,O
may,9899,O
be,9899,O
of,9899,O
therapeutic,9899,O
benefit,9899,O
.,9899,O
[,9900,O
Psychopharmacological,9900,O
profile,9900,O
of,9900,O
venlafaxine,9900,B-CHEMICAL
],9900,O
.,9900,O
Venlafaxine,9901,B-CHEMICAL
is,9901,O
an,9901,O
antidepressant,9901,O
which,9901,O
blocks,9901,O
reuptake,9901,O
of,9901,O
noradrenaline,9901,B-CHEMICAL
and,9901,O
serotonin,9901,B-CHEMICAL
and,9901,O
",",9901,O
to,9901,O
a,9901,O
lesser,9901,O
extent,9901,O
",",9901,O
dopamine,9901,B-CHEMICAL
.,9901,O
These,9902,O
data,9902,O
have,9902,O
been,9902,O
confirmed,9902,O
by,9902,O
behavioral,9902,O
tests,9902,O
.,9902,O
It,9903,O
has,9903,O
been,9903,O
shown,9903,O
that,9903,O
by,9903,O
decreasing,9903,O
the,9903,O
overall,9903,O
cerebral,9903,O
quantity,9903,O
of,9903,O
5-HT,9903,B-CHEMICAL
and,9903,O
NA,9903,B-CHEMICAL
",",9903,O
venlafaxine,9903,B-CHEMICAL
continued,9903,O
to,9903,O
have,9903,O
an,9903,O
antidepressant,9903,O
action,9903,O
in,9903,O
animal,9903,O
models,9903,O
.,9903,O
In,9904,O
addition,9904,O
",",9904,O
the,9904,O
drug,9904,O
has,9904,O
been,9904,O
shown,9904,O
to,9904,O
act,9904,O
preferentially,9904,O
on,9904,O
5-HT1A,9904,B-GENE-Y
and,9904,O
5-HT1B,9904,B-GENE-Y
receptors,9904,O
.,9904,O
Transcriptome,9905,O
alterations,9905,O
following,9905,O
developmental,9905,O
atrazine,9905,B-CHEMICAL
exposure,9905,O
in,9905,O
zebrafish,9905,O
are,9905,O
associated,9905,O
with,9905,O
disruption,9905,O
of,9905,O
neuroendocrine,9905,O
and,9905,O
reproductive,9905,O
system,9905,O
function,9905,O
",",9905,O
cell,9905,O
cycle,9905,O
",",9905,O
and,9905,O
carcinogenesis,9905,O
.,9905,O
Atrazine,9906,B-CHEMICAL
",",9906,O
a,9906,O
herbicide,9906,O
commonly,9906,O
applied,9906,O
to,9906,O
agricultural,9906,O
areas,9906,O
and,9906,O
a,9906,O
common,9906,O
contaminant,9906,O
of,9906,O
potable,9906,O
water,9906,O
supplies,9906,O
",",9906,O
is,9906,O
implicated,9906,O
as,9906,O
an,9906,O
endocrine-disrupting,9906,O
chemical,9906,O
(,9906,O
EDC,9906,O
),9906,O
and,9906,O
potential,9906,O
carcinogen,9906,O
.,9906,O
Studies,9907,O
show,9907,O
that,9907,O
EDCs,9907,O
can,9907,O
cause,9907,O
irreversible,9907,O
changes,9907,O
in,9907,O
tissue,9907,O
formation,9907,O
",",9907,O
decreased,9907,O
reproductive,9907,O
potential,9907,O
",",9907,O
obesity,9907,O
",",9907,O
and,9907,O
cancer,9907,O
.,9907,O
The,9908,O
U.S.,9908,O
Environmental,9908,O
Protection,9908,O
Agency,9908,O
considers,9908,O
an,9908,O
atrazine,9908,B-CHEMICAL
concentration,9908,O
of,9908,O
≤,9908,O
3,9908,O
ppb,9908,O
in,9908,O
drinking,9908,O
water,9908,O
safe,9908,O
for,9908,O
consumption,9908,O
.,9908,O
The,9909,O
specific,9909,O
adverse,9909,O
human,9909,O
health,9909,O
effects,9909,O
associated,9909,O
with,9909,O
a,9909,O
developmental,9909,O
atrazine,9909,B-CHEMICAL
exposure,9909,O
and,9909,O
the,9909,O
underlying,9909,O
genetic,9909,O
mechanisms,9909,O
of,9909,O
these,9909,O
effects,9909,O
are,9909,O
not,9909,O
well,9909,O
defined,9909,O
.,9909,O
In,9910,O
this,9910,O
study,9910,O
",",9910,O
zebrafish,9910,O
embryos,9910,O
were,9910,O
exposed,9910,O
to,9910,O
a,9910,O
range,9910,O
of,9910,O
atrazine,9910,B-CHEMICAL
concentrations,9910,O
to,9910,O
establish,9910,O
toxicity,9910,O
.,9910,O
Morphological,9911,O
",",9911,O
transcriptomic,9911,O
",",9911,O
and,9911,O
protein,9911,O
alterations,9911,O
were,9911,O
then,9911,O
assessed,9911,O
at,9911,O
72h,9911,O
postfertilization,9911,O
following,9911,O
developmental,9911,O
atrazine,9911,B-CHEMICAL
exposure,9911,O
at,9911,O
0,9911,O
",",9911,O
0.3,9911,O
",",9911,O
3,9911,O
",",9911,O
or,9911,O
30,9911,O
ppb,9911,O
.,9911,O
A,9912,O
significant,9912,O
increase,9912,O
in,9912,O
head,9912,O
length,9912,O
was,9912,O
observed,9912,O
in,9912,O
all,9912,O
three,9912,O
atrazine,9912,B-CHEMICAL
treatments,9912,O
.,9912,O
Transcriptomic,9913,O
profiles,9913,O
revealed,9913,O
21,9913,O
",",9913,O
62,9913,O
",",9913,O
and,9913,O
64,9913,O
genes,9913,O
with,9913,O
altered,9913,O
expression,9913,O
in,9913,O
the,9913,O
0.3,9913,O
",",9913,O
3,9913,O
",",9913,O
and,9913,O
30,9913,O
ppb,9913,O
atrazine,9913,B-CHEMICAL
treatments,9913,O
",",9913,O
respectively,9913,O
.,9913,O
Altered,9914,O
genes,9914,O
were,9914,O
associated,9914,O
with,9914,O
neuroendocrine,9914,O
and,9914,O
reproductive,9914,O
system,9914,O
development,9914,O
",",9914,O
function,9914,O
",",9914,O
and,9914,O
disease,9914,O
;,9914,O
cell,9914,O
cycle,9914,O
control,9914,O
;,9914,O
and,9914,O
carcinogenesis,9914,O
.,9914,O
There,9915,O
was,9915,O
a,9915,O
significant,9915,O
overlap,9915,O
(,9915,O
42,9915,O
genes,9915,O
),9915,O
between,9915,O
the,9915,O
3,9915,O
and,9915,O
30,9915,O
ppb,9915,O
differentially,9915,O
expressed,9915,O
gene,9915,O
lists,9915,O
",",9915,O
with,9915,O
two,9915,O
of,9915,O
these,9915,O
genes,9915,O
(,9915,O
CYP17A1,9915,B-GENE-Y
and,9915,O
SAMHD1,9915,B-GENE-Y
),9915,O
present,9915,O
in,9915,O
all,9915,O
three,9915,O
atrazine,9915,B-CHEMICAL
treatments,9915,O
.,9915,O
Increased,9916,O
transcript,9916,O
levels,9916,O
were,9916,O
translated,9916,O
to,9916,O
significant,9916,O
upregulation,9916,O
in,9916,O
protein,9916,O
expression,9916,O
.,9916,O
Overall,9917,O
",",9917,O
this,9917,O
study,9917,O
identifies,9917,O
genetic,9917,O
and,9917,O
molecular,9917,O
targets,9917,O
altered,9917,O
in,9917,O
response,9917,O
to,9917,O
a,9917,O
developmental,9917,O
atrazine,9917,B-CHEMICAL
exposure,9917,O
to,9917,O
further,9917,O
define,9917,O
the,9917,O
biological,9917,O
pathways,9917,O
and,9917,O
mechanisms,9917,O
of,9917,O
toxicity,9917,O
.,9917,O
Effects,9918,O
of,9918,O
bambuterol,9918,B-CHEMICAL
and,9918,O
terbutaline,9918,B-CHEMICAL
on,9918,O
isolated,9918,O
rat,9918,O
's,9918,O
tracheal,9918,O
smooth,9918,O
muscle,9918,O
.,9918,O
Terbutaline,9919,B-CHEMICAL
(,9919,O
Bricanyl,9919,B-CHEMICAL
),9919,O
and,9919,O
its,9919,O
prodrug,9919,O
Bambuterol,9919,B-CHEMICAL
(,9919,O
Bambec,9919,B-CHEMICAL
),9919,O
are,9919,O
highly,9919,O
potent,9919,O
beta,9919,B-GENE-Y
(,9919,I-GENE-Y
2,9919,I-GENE-Y
),9919,I-GENE-Y
-adrenoceptor,9919,I-GENE-Y
agonists,9919,O
often,9919,O
used,9919,O
in,9919,O
asthma,9919,O
patients,9919,O
.,9919,O
Terbutaline,9920,B-CHEMICAL
in,9920,O
the,9920,O
form,9920,O
of,9920,O
inhaled,9920,O
short-acting,9920,O
bronchodilator,9920,O
relieves,9920,O
asthmatic,9920,O
symptoms,9920,O
.,9920,O
However,9921,O
",",9921,O
the,9921,O
effects,9921,O
of,9921,O
bambuterol,9921,B-CHEMICAL
given,9921,O
intratracheally,9921,O
have,9921,O
rarely,9921,O
been,9921,O
explored,9921,O
.,9921,O
To,9922,O
verify,9922,O
the,9922,O
effect,9922,O
of,9922,O
bambuterol,9922,B-CHEMICAL
and,9922,O
terbutaline,9922,B-CHEMICAL
",",9922,O
which,9922,O
act,9922,O
on,9922,O
the,9922,O
tracheal,9922,O
smooth,9922,O
muscle,9922,O
directly,9922,O
in,9922,O
vitro,9922,O
",",9922,O
we,9922,O
used,9922,O
our,9922,O
preparation,9922,O
to,9922,O
test,9922,O
the,9922,O
effects,9922,O
of,9922,O
bambuterol,9922,B-CHEMICAL
on,9922,O
isolated,9922,O
rat,9922,O
's,9922,O
tracheal,9922,O
smooth,9922,O
muscle,9922,O
compared,9922,O
with,9922,O
terbutaline,9922,B-CHEMICAL
.,9922,O
The,9923,O
following,9923,O
assessments,9923,O
of,9923,O
bambuterol,9923,B-CHEMICAL
and,9923,O
terbutaline,9923,B-CHEMICAL
were,9923,O
performed,9923,O
:,9923,O
(,9923,O
1,9923,O
),9923,O
effect,9923,O
on,9923,O
tracheal,9923,O
smooth,9923,O
muscle,9923,O
resting,9923,O
tension,9923,O
;,9923,O
(,9923,O
2,9923,O
),9923,O
effect,9923,O
on,9923,O
contraction,9923,O
caused,9923,O
by,9923,O
10,9923,O
(,9923,O
-6,9923,O
),9923,O
M,9923,O
methacholine,9923,B-CHEMICAL
as,9923,O
a,9923,O
parasympathetic,9923,O
mimetic,9923,O
;,9923,O
(,9923,O
3,9923,O
),9923,O
effect,9923,O
of,9923,O
the,9923,O
drugs,9923,O
on,9923,O
electrically,9923,O
induced,9923,O
tracheal,9923,O
smooth,9923,O
muscle,9923,O
contractions,9923,O
.,9923,O
The,9924,O
results,9924,O
indicated,9924,O
that,9924,O
adding,9924,O
bambuterol,9924,B-CHEMICAL
induced,9924,O
a,9924,O
significant,9924,O
further,9924,O
contraction,9924,O
to,9924,O
10,9924,O
(,9924,O
-6,9924,O
),9924,O
M,9924,O
methacholine-induced,9924,B-CHEMICAL
contraction,9924,O
when,9924,O
the,9924,O
preparation,9924,O
was,9924,O
increased,9924,O
to,9924,O
10,9924,O
(,9924,O
-4,9924,O
),9924,O
M.,9924,O
But,9924,O
terbutaline,9924,B-CHEMICAL
elicited,9924,O
a,9924,O
relaxation,9924,O
response,9924,O
at,9924,O
a,9924,O
dose,9924,O
of,9924,O
10,9924,O
(,9924,O
-6,9924,O
),9924,O
M,9924,O
or,9924,O
more,9924,O
.,9924,O
Both,9925,O
bambuterol,9925,B-CHEMICAL
and,9925,O
terbutaline,9925,B-CHEMICAL
could,9925,O
inhibit,9925,O
electrical,9925,O
field,9925,O
stimulation,9925,O
(,9925,O
EFS,9925,O
),9925,O
induced,9925,O
spike,9925,O
contraction,9925,O
.,9925,O
Terbutaline,9926,B-CHEMICAL
had,9926,O
an,9926,O
anti-cholinergic,9926,O
effect,9926,O
that,9926,O
could,9926,O
relieve,9926,O
asthmatic,9926,O
symptoms,9926,O
.,9926,O
But,9927,O
the,9927,O
effect,9927,O
of,9927,O
bambuterol,9927,O
acting,9927,O
on,9927,O
tracheal,9927,O
smooth,9927,O
muscle,9927,O
directly,9927,O
was,9927,O
controversial,9927,O
.,9927,O
(,9928,B-CHEMICAL
+/-,9928,I-CHEMICAL
),9928,I-CHEMICAL
-tamsulosin,9928,I-CHEMICAL
",",9928,O
an,9928,O
alpha,9928,B-GENE-Y
1A-adrenoceptor,9928,I-GENE-Y
antagonist,9928,O
",",9928,O
inhibits,9928,O
the,9928,O
positive,9928,O
inotropic,9928,O
effect,9928,O
but,9928,O
not,9928,O
the,9928,O
accumulation,9928,O
of,9928,O
inositol,9928,B-CHEMICAL
phosphates,9928,I-CHEMICAL
in,9928,O
rabbit,9928,O
heart,9928,O
.,9928,O
The,9929,O
influence,9929,O
of,9929,O
(,9929,B-CHEMICAL
+/-,9929,I-CHEMICAL
),9929,I-CHEMICAL
-tamsulosin,9929,I-CHEMICAL
",",9929,O
a,9929,O
selective,9929,O
alpha,9929,B-GENE-Y
1A-adrenoceptor,9929,I-GENE-Y
antagonist,9929,O
",",9929,O
on,9929,O
the,9929,O
positive,9929,O
inotropic,9929,O
effect,9929,O
and,9929,O
the,9929,O
accumulation,9929,O
of,9929,O
inositol,9929,B-CHEMICAL
phosphates,9929,I-CHEMICAL
that,9929,O
are,9929,O
induced,9929,O
via,9929,O
alpha,9929,B-GENE-N
1-adrenoceptors,9929,I-GENE-N
was,9929,O
studied,9929,O
in,9929,O
comparison,9929,O
with,9929,O
that,9929,O
of,9929,O
another,9929,O
alpha,9929,B-GENE-Y
1A-adrenoceptor,9929,I-GENE-Y
ligand,9929,O
oxymetazoline,9929,B-CHEMICAL
in,9929,O
the,9929,O
rabbit,9929,O
ventricular,9929,O
myocardium,9929,O
.,9929,O
Phenylephrine,9930,B-CHEMICAL
elicited,9930,O
a,9930,O
concentration-dependent,9930,O
positive,9930,O
inotropic,9930,O
effect,9930,O
via,9930,O
alpha,9930,B-GENE-N
1-adrenoceptors,9930,I-GENE-N
in,9930,O
the,9930,O
presence,9930,O
of,9930,O
either,9930,O
(,9930,B-CHEMICAL
+/-,9930,I-CHEMICAL
),9930,I-CHEMICAL
-bupranolol,9930,I-CHEMICAL
or,9930,O
S,9930,B-CHEMICAL
(,9930,I-CHEMICAL
-,9930,I-CHEMICAL
),9930,I-CHEMICAL
-timolol,9930,I-CHEMICAL
.,9930,O
The,9931,O
mode,9931,O
of,9931,O
antagonism,9931,O
induced,9931,O
by,9931,O
(,9931,B-CHEMICAL
+/-,9931,I-CHEMICAL
),9931,I-CHEMICAL
-tamsulosin,9931,I-CHEMICAL
on,9931,O
the,9931,O
effect,9931,O
of,9931,O
phenylephrine,9931,B-CHEMICAL
was,9931,O
dependent,9931,O
or,9931,O
the,9931,O
concentration,9931,O
applied,9931,O
:,9931,O
(,9931,B-CHEMICAL
+/-,9931,I-CHEMICAL
),9931,I-CHEMICAL
-tamsulosin,9931,I-CHEMICAL
at,9931,O
1,9931,O
and,9931,O
3,9931,O
nM,9931,O
acted,9931,O
in,9931,O
a,9931,O
competitive,9931,O
manner,9931,O
",",9931,O
the,9931,O
slope,9931,O
of,9931,O
the,9931,O
regression,9931,O
line,9931,O
of,9931,O
the,9931,O
Schild,9931,O
plot,9931,O
being,9931,O
unity,9931,O
and,9931,O
the,9931,O
pA2,9931,O
value,9931,O
being,9931,O
9.12,9931,O
;,9931,O
at,9931,O
10,9931,O
nM,9931,O
",",9931,O
it,9931,O
shifted,9931,O
further,9931,O
the,9931,O
concentration-response,9931,O
curve,9931,O
to,9931,O
the,9931,O
right,9931,O
without,9931,O
affecting,9931,O
the,9931,O
maximal,9931,O
response,9931,O
but,9931,O
the,9931,O
slope,9931,O
became,9931,O
less,9931,O
than,9931,O
unity,9931,O
.,9931,O
At,9932,O
100,9932,O
nM,9932,O
and,9932,O
higher,9932,O
",",9932,O
it,9932,O
suppressed,9932,O
the,9932,O
maximal,9932,O
response,9932,O
to,9932,O
phenylephrine,9932,B-CHEMICAL
.,9932,O
(,9933,B-CHEMICAL
+/-,9933,I-CHEMICAL
),9933,I-CHEMICAL
-Tamsulosin,9933,I-CHEMICAL
effectively,9933,O
antagonized,9933,O
the,9933,O
positive,9933,O
inotropic,9933,O
effect,9933,O
of,9933,O
phenylephrine,9933,B-CHEMICAL
even,9933,O
after,9933,O
inactivation,9933,O
of,9933,O
alpha,9933,B-GENE-Y
1B-adrenoceptors,9933,I-GENE-Y
by,9933,O
treatment,9933,O
with,9933,O
chlorethylclonidine,9933,B-CHEMICAL
",",9933,O
which,9933,O
is,9933,O
an,9933,O
indication,9933,O
that,9933,O
the,9933,O
(,9933,B-CHEMICAL
+/-,9933,I-CHEMICAL
),9933,I-CHEMICAL
-tamsulosin-sensitive,9933,O
subtype,9933,O
belongs,9933,O
to,9933,O
a,9933,O
class,9933,O
resistant,9933,O
to,9933,O
chlorethylclonidine,9933,B-CHEMICAL
.,9933,O
(,9934,B-CHEMICAL
+/-,9934,I-CHEMICAL
),9934,I-CHEMICAL
-Tamsulosin,9934,I-CHEMICAL
",",9934,O
over,9934,O
the,9934,O
range,9934,O
of,9934,O
concentrations,9934,O
at,9934,O
which,9934,O
it,9934,O
antagonized,9934,O
the,9934,O
positive,9934,O
inotropic,9934,O
effect,9934,O
mediated,9934,O
by,9934,O
alpha,9934,B-GENE-N
1-adrenoceptors,9934,I-GENE-N
",",9934,O
did,9934,O
not,9934,O
affect,9934,O
the,9934,O
accumulation,9934,O
of,9934,O
[,9934,B-CHEMICAL
3H,9934,I-CHEMICAL
],9934,I-CHEMICAL
inositol,9934,I-CHEMICAL
phosphates,9934,I-CHEMICAL
that,9934,O
was,9934,O
induced,9934,O
by,9934,O
10,9934,O
microM,9934,O
phenylephrine,9934,B-CHEMICAL
.,9934,O
Oxymetazoline,9935,B-CHEMICAL
antagonized,9935,O
the,9935,O
positive,9935,O
inotropic,9935,O
effect,9935,O
of,9935,O
phenylephrine,9935,B-CHEMICAL
in,9935,O
a,9935,O
competitive,9935,O
manner,9935,O
without,9935,O
affecting,9935,O
the,9935,O
accumulation,9935,O
of,9935,O
inositol,9935,B-CHEMICAL
monophosphate,9935,I-CHEMICAL
induced,9935,O
by,9935,O
phenylephrine,9935,B-CHEMICAL
.,9935,O
These,9936,O
results,9936,O
indicate,9936,O
that,9936,O
the,9936,O
positive,9936,O
inotropic,9936,O
effect,9936,O
",",9936,O
mediated,9936,O
via,9936,O
(,9936,B-CHEMICAL
+/-,9936,I-CHEMICAL
),9936,I-CHEMICAL
-tamsulosin-,9936,O
and,9936,O
oxymetazoline-sensitive,9936,B-CHEMICAL
subtype,9936,O
of,9936,O
alpha,9936,B-GENE-N
1-adrenoceptors,9936,I-GENE-N
",",9936,O
is,9936,O
exerted,9936,O
by,9936,O
a,9936,O
subcellular,9936,O
mechanism,9936,O
that,9936,O
is,9936,O
independent,9936,O
of,9936,O
the,9936,O
accumulation,9936,O
of,9936,O
inositol,9936,B-CHEMICAL
phosphates,9936,I-CHEMICAL
.,9936,O
Pterostilbene,9937,B-CHEMICAL
exerts,9937,O
antitumor,9937,O
activity,9937,O
against,9937,O
human,9937,O
osteosarcoma,9937,O
cells,9937,O
by,9937,O
inhibiting,9937,O
the,9937,O
JAK2/STAT3,9937,B-GENE-Y
signaling,9937,O
pathway,9937,O
.,9937,O
Osteosarcoma,9938,O
is,9938,O
a,9938,O
high-grade,9938,O
malignant,9938,O
bone,9938,O
tumor,9938,O
.,9938,O
Pterostilbene,9939,B-CHEMICAL
(,9939,O
PTE,9939,B-CHEMICAL
),9939,O
is,9939,O
a,9939,O
natural,9939,O
",",9939,O
dimethylated,9939,O
analog,9939,O
of,9939,O
resveratrol,9939,B-CHEMICAL
with,9939,O
higher,9939,O
bioavailability,9939,O
.,9939,O
While,9940,O
PTE,9940,B-CHEMICAL
has,9940,O
been,9940,O
shown,9940,O
to,9940,O
have,9940,O
potent,9940,O
antitumor,9940,O
activity,9940,O
against,9940,O
various,9940,O
types,9940,O
of,9940,O
cancer,9940,O
",",9940,O
the,9940,O
molecular,9940,O
mechanisms,9940,O
underlying,9940,O
the,9940,O
effects,9940,O
of,9940,O
PTE,9940,B-CHEMICAL
remain,9940,O
largely,9940,O
unknown,9940,O
.,9940,O
The,9941,O
Janus,9941,B-GENE-Y
kinase,9941,I-GENE-Y
2/Signal,9941,O
Transducer,9941,I-GENE-Y
and,9941,I-GENE-Y
Activator,9941,I-GENE-Y
of,9941,I-GENE-Y
Transcription,9941,I-GENE-Y
3,9941,I-GENE-Y
(,9941,O
JAK2/STAT3,9941,B-GENE-Y
),9941,O
signaling,9941,O
pathway,9941,O
plays,9941,O
a,9941,O
crucial,9941,O
role,9941,O
in,9941,O
tumorigenesis,9941,O
and,9941,O
immune,9941,O
development,9941,O
.,9941,O
In,9942,O
this,9942,O
study,9942,O
",",9942,O
we,9942,O
assessed,9942,O
the,9942,O
antitumor,9942,O
activity,9942,O
of,9942,O
PTE,9942,B-CHEMICAL
against,9942,O
human,9942,O
osteosarcoma,9942,O
cells,9942,O
and,9942,O
explored,9942,O
the,9942,O
role,9942,O
of,9942,O
JAK2/STAT3,9942,B-GENE-Y
and,9942,O
apoptosis-related,9942,O
signaling,9942,O
pathways,9942,O
on,9942,O
the,9942,O
activity,9942,O
of,9942,O
PTE,9942,B-CHEMICAL
.,9942,O
PTE,9943,B-CHEMICAL
treatment,9943,O
resulted,9943,O
in,9943,O
a,9943,O
dose-,9943,O
and,9943,O
time-dependent,9943,O
inhibition,9943,O
of,9943,O
osteosarcoma,9943,O
cell,9943,O
viability,9943,O
.,9943,O
Additionally,9944,O
",",9944,O
PTE,9944,B-CHEMICAL
exhibited,9944,O
strong,9944,O
antitumor,9944,O
activity,9944,O
",",9944,O
as,9944,O
evidenced,9944,O
not,9944,O
only,9944,O
by,9944,O
reductions,9944,O
in,9944,O
tumor,9944,O
cell,9944,O
adhesion,9944,O
",",9944,O
migration,9944,O
and,9944,O
mitochondrial,9944,O
membrane,9944,O
potential,9944,O
(,9944,O
MMP,9944,O
),9944,O
but,9944,O
also,9944,O
by,9944,O
increases,9944,O
in,9944,O
the,9944,O
apoptotic,9944,O
index,9944,O
",",9944,O
reactive,9944,O
oxygen,9944,B-CHEMICAL
species,9944,O
(,9944,O
ROS,9944,O
),9944,O
and,9944,O
several,9944,O
biochemical,9944,O
parameters,9944,O
.,9944,O
Furthermore,9945,O
",",9945,O
PTE,9945,B-CHEMICAL
treatment,9945,O
directly,9945,O
inhibited,9945,O
the,9945,O
phosphorylation,9945,O
of,9945,O
JAK2,9945,B-GENE-Y
at,9945,O
Tyr,9945,B-CHEMICAL
1007,9945,O
and,9945,O
the,9945,O
downstream,9945,O
activation,9945,O
of,9945,O
STAT3,9945,B-GENE-Y
.,9945,O
PTE,9946,B-CHEMICAL
also,9946,O
down-regulated,9946,O
the,9946,O
expression,9946,O
of,9946,O
STAT3,9946,B-GENE-Y
target,9946,O
genes,9946,O
",",9946,O
including,9946,O
the,9946,O
anti-apoptotic,9946,O
proteins,9946,O
Bcl-xL,9946,B-GENE-Y
and,9946,O
Mcl-1,9946,B-GENE-Y
",",9946,O
leading,9946,O
to,9946,O
the,9946,O
up-regulation,9946,O
of,9946,O
mitochondrial,9946,O
apoptosis,9946,O
pathway-related,9946,O
proteins,9946,O
(,9946,O
Bax,9946,B-GENE-Y
",",9946,O
Bak,9946,B-GENE-Y
",",9946,O
cytosolic,9946,O
Cytochrome,9946,B-GENE-Y
c,9946,I-GENE-Y
",",9946,O
and,9946,O
cleaved,9946,O
Caspase3,9946,B-GENE-Y
),9946,O
and,9946,O
cyclin-dependent,9946,B-GENE-N
kinase,9946,I-GENE-N
inhibitors,9946,O
such,9946,O
as,9946,O
p21,9946,B-GENE-Y
and,9946,O
p27,9946,B-GENE-Y
.,9946,O
PTE,9947,B-CHEMICAL
",",9947,O
used,9947,O
in,9947,O
combination,9947,O
with,9947,O
a,9947,O
known,9947,O
JAK2/STAT3,9947,B-GENE-Y
inhibitor,9947,O
",",9947,O
AG490,9947,B-CHEMICAL
",",9947,O
further,9947,O
decreased,9947,O
the,9947,O
viability,9947,O
of,9947,O
osteosarcoma,9947,O
cells,9947,O
.,9947,O
Taken,9948,O
together,9948,O
",",9948,O
PTE,9948,B-CHEMICAL
is,9948,O
a,9948,O
potent,9948,O
inhibitor,9948,O
of,9948,O
osteosarcoma,9948,O
cell,9948,O
growth,9948,O
that,9948,O
targets,9948,O
the,9948,O
JAK2/STAT3,9948,B-GENE-Y
signaling,9948,O
pathway,9948,O
.,9948,O
These,9949,O
data,9949,O
suggest,9949,O
that,9949,O
inhibition,9949,O
of,9949,O
JAK2/STAT3,9949,B-GENE-Y
signaling,9949,O
is,9949,O
a,9949,O
novel,9949,O
mechanism,9949,O
of,9949,O
action,9949,O
for,9949,O
PTE,9949,B-CHEMICAL
during,9949,O
therapeutic,9949,O
intervention,9949,O
in,9949,O
osteosarcoma,9949,O
cancers,9949,O
.,9949,O
Effect,9950,O
of,9950,O
sinapic,9950,B-CHEMICAL
acid,9950,I-CHEMICAL
against,9950,O
dimethylnitrosamine-induced,9950,B-CHEMICAL
hepatic,9950,O
fibrosis,9950,O
in,9950,O
rats,9950,O
.,9950,O
Sinapic,9951,B-CHEMICAL
acid,9951,I-CHEMICAL
is,9951,O
a,9951,O
member,9951,O
of,9951,O
the,9951,O
phenylpropanoid,9951,B-CHEMICAL
family,9951,O
and,9951,O
is,9951,O
abundant,9951,O
in,9951,O
cereals,9951,O
",",9951,O
nuts,9951,O
",",9951,O
oil,9951,O
seeds,9951,O
",",9951,O
and,9951,O
berries,9951,O
.,9951,O
It,9952,O
exhibits,9952,O
a,9952,O
wide,9952,O
range,9952,O
of,9952,O
pharmacological,9952,O
properties,9952,O
.,9952,O
In,9953,O
this,9953,O
study,9953,O
",",9953,O
we,9953,O
investigated,9953,O
the,9953,O
hepatoprotective,9953,O
and,9953,O
antifibrotic,9953,O
effects,9953,O
of,9953,O
sinapic,9953,B-CHEMICAL
acid,9953,I-CHEMICAL
on,9953,O
dimethylnitrosamine,9953,B-CHEMICAL
(,9953,O
DMN,9953,B-CHEMICAL
),9953,O
-induced,9953,O
chronic,9953,O
liver,9953,O
injury,9953,O
in,9953,O
rats,9953,O
.,9953,O
Sinapic,9954,B-CHEMICAL
acid,9954,I-CHEMICAL
remarkably,9954,O
prevented,9954,O
DMN-induced,9954,B-CHEMICAL
loss,9954,O
of,9954,O
body,9954,O
weight,9954,O
.,9954,O
This,9955,O
was,9955,O
accompanied,9955,O
by,9955,O
a,9955,O
significant,9955,O
increase,9955,O
in,9955,O
levels,9955,O
of,9955,O
serum,9955,O
alanine,9955,B-GENE-N
transaminase,9955,I-GENE-N
",",9955,O
aspartate,9955,B-GENE-Y
transaminase,9955,I-GENE-Y
",",9955,O
and,9955,O
liver,9955,O
malondialdehyde,9955,B-CHEMICAL
content,9955,O
.,9955,O
Furthermore,9956,O
",",9956,O
sinapic,9956,B-CHEMICAL
acid,9956,I-CHEMICAL
reduced,9956,O
hepatic,9956,O
hydroxyproline,9956,B-CHEMICAL
content,9956,O
",",9956,O
which,9956,O
correlated,9956,O
with,9956,O
a,9956,O
reduction,9956,O
in,9956,O
the,9956,O
expression,9956,O
of,9956,O
type,9956,B-GENE-N
I,9956,I-GENE-N
collagen,9956,I-GENE-N
mRNA,9956,O
and,9956,O
histological,9956,O
analysis,9956,O
of,9956,O
collagen,9956,B-GENE-N
in,9956,O
liver,9956,O
tissue,9956,O
.,9956,O
Additionally,9957,O
",",9957,O
the,9957,O
expression,9957,O
of,9957,O
hepatic,9957,O
fibrosis-related,9957,O
factors,9957,O
such,9957,O
as,9957,O
α-smooth,9957,B-GENE-Y
muscle,9957,I-GENE-Y
actin,9957,I-GENE-Y
and,9957,O
transforming,9957,B-GENE-Y
growth,9957,I-GENE-Y
factor-β1,9957,I-GENE-Y
(,9957,O
TGF-β1,9957,B-GENE-Y
),9957,O
",",9957,O
were,9957,O
reduced,9957,O
in,9957,O
rats,9957,O
treated,9957,O
with,9957,O
sinapic,9957,B-CHEMICAL
acid,9957,I-CHEMICAL
.,9957,O
Sinapic,9958,B-CHEMICAL
acid,9958,I-CHEMICAL
exhibited,9958,O
strong,9958,O
scavenging,9958,O
activity,9958,O
.,9958,O
In,9959,O
conclusion,9959,O
",",9959,O
we,9959,O
find,9959,O
that,9959,O
sinapic,9959,B-CHEMICAL
acid,9959,I-CHEMICAL
exhibits,9959,O
hepatoprotective,9959,O
and,9959,O
antifibrotic,9959,O
effects,9959,O
against,9959,O
DMN-induced,9959,B-CHEMICAL
liver,9959,O
injury,9959,O
",",9959,O
most,9959,O
likely,9959,O
due,9959,O
to,9959,O
its,9959,O
antioxidant,9959,O
activities,9959,O
of,9959,O
scavenging,9959,O
radicals,9959,O
",",9959,O
its,9959,O
capacity,9959,O
to,9959,O
suppress,9959,O
TGF-β1,9959,B-GENE-Y
and,9959,O
its,9959,O
ability,9959,O
to,9959,O
attenuate,9959,O
activation,9959,O
of,9959,O
hepatic,9959,O
stellate,9959,O
cells,9959,O
.,9959,O
This,9960,O
suggests,9960,O
that,9960,O
sinapic,9960,B-CHEMICAL
acid,9960,I-CHEMICAL
is,9960,O
a,9960,O
potentially,9960,O
useful,9960,O
agent,9960,O
for,9960,O
the,9960,O
protection,9960,O
against,9960,O
liver,9960,O
fibrosis,9960,O
and,9960,O
cirrhosis,9960,O
.,9960,O
Glutathione,9961,B-GENE-N
S-transferase,9961,I-GENE-N
M1,9961,I-GENE-N
and,9961,I-GENE-N
P1,9961,I-GENE-N
polymorphisms,9961,O
and,9961,O
risk,9961,O
of,9961,O
breast,9961,O
cancer,9961,O
and,9961,O
fibrocystic,9961,O
breast,9961,O
conditions,9961,O
in,9961,O
Chinese,9961,O
women,9961,O
.,9961,O
Enzymes,9962,O
encoded,9962,O
by,9962,O
the,9962,O
glutathione,9962,B-GENE-Y
S-tranferase,9962,I-GENE-Y
mu,9962,I-GENE-Y
1,9962,I-GENE-Y
(,9962,O
GSTM1,9962,B-GENE-Y
),9962,O
and,9962,O
pi,9962,B-GENE-Y
1,9962,I-GENE-Y
(,9962,O
GSTP1,9962,B-GENE-Y
),9962,O
genes,9962,O
",",9962,O
which,9962,O
are,9962,O
expressed,9962,O
in,9962,O
breast,9962,O
tissue,9962,O
",",9962,O
catalyze,9962,O
the,9962,O
detoxification,9962,O
of,9962,O
endogenous,9962,O
and,9962,O
exogenous,9962,O
electrophiles,9962,O
.,9962,O
Reduced,9963,O
enzyme,9963,O
activity,9963,O
",",9963,O
due,9963,O
to,9963,O
carriage,9963,O
of,9963,O
the,9963,O
GSTM1,9963,B-GENE-Y
deletion,9963,O
or,9963,O
the,9963,O
GSTP1,9963,B-GENE-Y
Ile105Val,9963,O
Val,9963,O
allele,9963,O
",",9963,O
may,9963,O
therefore,9963,O
affect,9963,O
susceptibility,9963,O
to,9963,O
breast,9963,O
cancer,9963,O
and,9963,O
related,9963,O
conditions,9963,O
.,9963,O
In,9964,O
a,9964,O
case-control,9964,O
study,9964,O
of,9964,O
Chinese,9964,O
women,9964,O
",",9964,O
we,9964,O
examined,9964,O
whether,9964,O
these,9964,O
polymorphisms,9964,O
were,9964,O
associated,9964,O
with,9964,O
risk,9964,O
of,9964,O
breast,9964,O
cancer,9964,O
and,9964,O
fibrocystic,9964,O
breast,9964,O
conditions,9964,O
.,9964,O
Women,9965,O
diagnosed,9965,O
with,9965,O
breast,9965,O
cancer,9965,O
(,9965,O
n=615,9965,O
),9965,O
or,9965,O
fibrocystic,9965,O
breast,9965,O
conditions,9965,O
(,9965,O
n=467,9965,O
),9965,O
were,9965,O
compared,9965,O
to,9965,O
women,9965,O
without,9965,O
clinical,9965,O
breast,9965,O
disease,9965,O
(,9965,O
n=878,9965,O
),9965,O
.,9965,O
We,9966,O
also,9966,O
examined,9966,O
whether,9966,O
these,9966,O
associations,9966,O
differed,9966,O
by,9966,O
menopausal,9966,O
status,9966,O
or,9966,O
by,9966,O
presence,9966,O
of,9966,O
proliferation,9966,O
in,9966,O
the,9966,O
extra-tumoral,9966,O
epithelium,9966,O
among,9966,O
women,9966,O
with,9966,O
breast,9966,O
cancer,9966,O
and,9966,O
in,9966,O
lesions,9966,O
among,9966,O
women,9966,O
with,9966,O
fibrocystic,9966,O
conditions,9966,O
.,9966,O
No,9967,O
overall,9967,O
association,9967,O
of,9967,O
either,9967,O
GST,9967,B-GENE-N
polymorphism,9967,O
with,9967,O
risk,9967,O
of,9967,O
breast,9967,O
cancer,9967,O
or,9967,O
fibrocystic,9967,O
breast,9967,O
conditions,9967,O
was,9967,O
observed,9967,O
.,9967,O
There,9968,O
was,9968,O
some,9968,O
evidence,9968,O
of,9968,O
slightly,9968,O
elevated,9968,O
cancer,9968,O
risk,9968,O
associated,9968,O
with,9968,O
carriage,9968,O
of,9968,O
the,9968,O
GSTM1,9968,B-GENE-Y
null,9968,O
genotype,9968,O
and,9968,O
at,9968,O
least,9968,O
one,9968,O
GSTP1,9968,B-GENE-Y
105-Val,9968,O
allele,9968,O
(,9968,O
OR=1.33,9968,O
",",9968,O
95,9968,O
%,9968,O
CI,9968,O
",",9968,O
0.99-1.80,9968,O
),9968,O
",",9968,O
compared,9968,O
to,9968,O
carriage,9968,O
of,9968,O
the,9968,O
GSTM1,9968,B-GENE-Y
non-null,9968,O
and,9968,O
GSTP1,9968,B-GENE-Y
Ile/Ile,9968,O
genotypes,9968,O
.,9968,O
This,9969,O
relationship,9969,O
was,9969,O
stronger,9969,O
in,9969,O
women,9969,O
who,9969,O
had,9969,O
breast,9969,O
cancer,9969,O
with,9969,O
extra-tumoral,9969,O
tissue,9969,O
proliferation,9969,O
(,9969,O
OR=1.77,9969,O
",",9969,O
95,9969,O
%,9969,O
CI,9969,O
",",9969,O
1.03-3.04,9969,O
),9969,O
.,9969,O
Our,9970,O
results,9970,O
suggest,9970,O
that,9970,O
GSTM1,9970,B-GENE-Y
and,9970,O
GSTP1,9970,B-GENE-Y
genotypes,9970,O
do,9970,O
not,9970,O
individually,9970,O
influence,9970,O
susceptibility,9970,O
to,9970,O
breast,9970,O
cancer,9970,O
or,9970,O
fibrocystic,9970,O
breast,9970,O
conditions,9970,O
.,9970,O
The,9971,O
observed,9971,O
increased,9971,O
risk,9971,O
of,9971,O
breast,9971,O
cancer,9971,O
associated,9971,O
with,9971,O
joint,9971,O
carriage,9971,O
of,9971,O
the,9971,O
GSTM1,9971,B-GENE-Y
null,9971,O
genotype,9971,O
and,9971,O
GSTP1,9971,B-GENE-Y
105-Val,9971,O
allele,9971,O
needs,9971,O
confirmation,9971,O
in,9971,O
other,9971,O
studies,9971,O
.,9971,O
Candesartan,9972,B-CHEMICAL
cilexetil,9972,I-CHEMICAL
--,9972,O
a,9972,O
review,9972,O
of,9972,O
effects,9972,O
on,9972,O
cardiovascular,9972,O
complications,9972,O
in,9972,O
hypertension,9972,O
and,9972,O
chronic,9972,O
heart,9972,O
failure,9972,O
.,9972,O
UNLABELLED,9973,O
:,9973,O
Therapeutic,9973,O
interventions,9973,O
that,9973,O
block,9973,O
the,9973,O
renin-angiotensin-aldosterone,9973,B-GENE-Y
system,9973,O
(,9973,O
RAAS,9973,O
),9973,O
have,9973,O
an,9973,O
important,9973,O
role,9973,O
in,9973,O
slowing,9973,O
the,9973,O
progression,9973,O
of,9973,O
cardiovascular,9973,O
risk,9973,O
actors,9973,O
to,9973,O
established,9973,O
cardiovascular,9973,O
diseases,9973,O
.,9973,O
In,9974,O
recent,9974,O
years,9974,O
",",9974,O
angiotensin,9974,B-GENE-N
receptor,9974,I-GENE-N
blockers,9974,O
(,9974,O
ARBs,9974,O
),9974,O
have,9974,O
emerged,9974,O
as,9974,O
effective,9974,O
and,9974,O
well-tolerated,9974,O
alternatives,9974,O
to,9974,O
an,9974,O
angiotensin-converting,9974,B-GENE-Y
enzyme,9974,I-GENE-Y
inhibitor,9974,O
(,9974,O
ACEi,9974,O
),9974,O
for,9974,O
RAAS,9974,O
blockade,9974,O
.,9974,O
The,9975,O
ARB,9975,O
candesartan,9975,B-CHEMICAL
was,9975,O
initially,9975,O
established,9975,O
as,9975,O
an,9975,O
effective,9975,O
once-daily,9975,O
antihypertensive,9975,O
treatment,9975,O
",",9975,O
providing,9975,O
24-h,9975,O
blood,9975,O
pressure,9975,O
(,9975,O
BP,9975,O
),9975,O
control,9975,O
with,9975,O
a,9975,O
trough,9975,O
:,9975,O
peak,9975,O
ratio,9975,O
close,9975,O
to,9975,O
100,9975,O
%,9975,O
.,9975,O
SCOPE,9976,O
:,9976,O
A,9976,O
Medline,9976,O
literature,9976,O
search,9976,O
was,9976,O
undertaken,9976,O
to,9976,O
identify,9976,O
randomised,9976,O
",",9976,O
controlled,9976,O
trials,9976,O
that,9976,O
examined,9976,O
the,9976,O
efficacy,9976,O
and,9976,O
cardiovascular,9976,O
outcomes,9976,O
associated,9976,O
with,9976,O
candesartan,9976,B-CHEMICAL
cilexetil,9976,I-CHEMICAL
in,9976,O
hypertension,9976,O
and,9976,O
chronic,9976,O
heart,9976,O
failure,9976,O
(,9976,O
CHF,9976,O
),9976,O
.,9976,O
FINDINGS,9977,O
:,9977,O
Compared,9977,O
with,9977,O
other,9977,O
ARBs,9977,O
",",9977,O
candesartan,9977,B-CHEMICAL
demonstrates,9977,O
the,9977,O
strongest,9977,O
binding,9977,O
affinity,9977,O
to,9977,O
the,9977,O
angiotensin,9977,B-GENE-Y
II,9977,I-GENE-Y
type,9977,I-GENE-Y
1,9977,I-GENE-Y
receptor,9977,I-GENE-Y
.,9977,O
Clinical,9978,O
trials,9978,O
have,9978,O
demonstrated,9978,O
that,9978,O
candesartan,9978,B-CHEMICAL
is,9978,O
well,9978,O
tolerated,9978,O
in,9978,O
combination,9978,O
with,9978,O
diuretics,9978,O
or,9978,O
calcium,9978,B-GENE-N
channel,9978,I-GENE-N
blockers,9978,O
(,9978,O
CCBs,9978,O
),9978,O
",",9978,O
making,9978,O
it,9978,O
a,9978,O
suitable,9978,O
treatment,9978,O
option,9978,O
for,9978,O
patients,9978,O
whose,9978,O
hypertension,9978,O
is,9978,O
not,9978,O
adequately,9978,O
controlled,9978,O
by,9978,O
monotherapy,9978,O
.,9978,O
Subsequently,9979,O
",",9979,O
candesartan,9979,B-CHEMICAL
became,9979,O
the,9979,O
only,9979,O
ARB,9979,O
licensed,9979,O
in,9979,O
the,9979,O
UK,9979,O
to,9979,O
treat,9979,O
patients,9979,O
with,9979,O
CHF,9979,O
and,9979,O
left,9979,O
ventricular,9979,O
ejection,9979,O
fraction,9979,O
<,9979,O
or,9979,O
=,9979,O
40,9979,O
%,9979,O
as,9979,O
add-on,9979,O
therapy,9979,O
to,9979,O
an,9979,O
ACEi,9979,O
or,9979,O
when,9979,O
an,9979,O
ACEi,9979,O
is,9979,O
not,9979,O
tolerated,9979,O
.,9979,O
Studies,9980,O
in,9980,O
patients,9980,O
with,9980,O
symptomatic,9980,O
HF,9980,O
have,9980,O
indicated,9980,O
that,9980,O
candesartan,9980,B-CHEMICAL
treatment,9980,O
was,9980,O
associated,9980,O
with,9980,O
significant,9980,O
relative,9980,O
risk,9980,O
reductions,9980,O
in,9980,O
cardiovascular,9980,O
mortality,9980,O
and,9980,O
hospitalisation,9980,O
due,9980,O
to,9980,O
CHF,9980,O
.,9980,O
CONCLUSIONS,9981,O
:,9981,O
There,9981,O
are,9981,O
clear,9981,O
indications,9981,O
that,9981,O
the,9981,O
clinical,9981,O
benefits,9981,O
of,9981,O
candesartan,9981,B-CHEMICAL
may,9981,O
extend,9981,O
beyond,9981,O
its,9981,O
proven,9981,O
antihypertensive,9981,O
effects,9981,O
to,9981,O
a,9981,O
wider,9981,O
range,9981,O
of,9981,O
complications,9981,O
across,9981,O
the,9981,O
cardiovascular,9981,O
continuum,9981,O
",",9981,O
including,9981,O
diabetes,9981,O
",",9981,O
left,9981,O
ventricular,9981,O
hypertrophy,9981,O
",",9981,O
atherosclerosis,9981,O
and,9981,O
stroke,9981,O
.,9981,O
Such,9982,O
results,9982,O
suggest,9982,O
that,9982,O
candesartan,9982,B-CHEMICAL
treatment,9982,O
may,9982,O
offer,9982,O
significant,9982,O
patient,9982,O
benefits,9982,O
as,9982,O
well,9982,O
as,9982,O
practical,9982,O
advantages,9982,O
over,9982,O
conventional,9982,O
treatment,9982,O
.,9982,O
Interacting,9983,O
Glutamate,9983,B-GENE-N
Receptor-Like,9983,O
Proteins,9983,O
in,9983,O
Phloem,9983,O
Regulate,9983,O
Lateral,9983,O
Root,9983,O
Initiation,9983,O
in,9983,O
Arabidopsis,9983,O
.,9983,O
Molecular,9984,O
",",9984,O
genetic,9984,O
",",9984,O
and,9984,O
electrophysiological,9984,O
evidence,9984,O
indicates,9984,O
that,9984,O
at,9984,O
least,9984,O
one,9984,O
of,9984,O
the,9984,O
plant,9984,O
Glu,9984,B-GENE-N
receptor-like,9984,O
molecules,9984,O
",",9984,O
GLR3.4,9984,B-GENE-N
",",9984,O
functions,9984,O
as,9984,O
an,9984,O
amino,9984,B-GENE-N
acid-gated,9984,I-GENE-N
Ca,9984,I-GENE-N
(,9984,I-GENE-N
2+,9984,I-GENE-N
),9984,I-GENE-N
channel,9984,I-GENE-N
at,9984,O
the,9984,O
plasma,9984,O
membrane,9984,O
.,9984,O
The,9985,O
aspect,9985,O
of,9985,O
plant,9985,O
physiology,9985,O
",",9985,O
growth,9985,O
",",9985,O
or,9985,O
development,9985,O
to,9985,O
which,9985,O
GLR3.4,9985,B-GENE-N
contributes,9985,O
is,9985,O
an,9985,O
open,9985,O
question,9985,O
.,9985,O
Protein,9986,O
localization,9986,O
studies,9986,O
performed,9986,O
here,9986,O
provide,9986,O
important,9986,O
information,9986,O
.,9986,O
In,9987,O
roots,9987,O
",",9987,O
GLR3.4,9987,B-GENE-N
and,9987,O
the,9987,O
related,9987,O
GLR3.2,9987,B-GENE-N
protein,9987,O
were,9987,O
present,9987,O
primarily,9987,O
in,9987,O
the,9987,O
phloem,9987,O
",",9987,O
especially,9987,O
in,9987,O
the,9987,O
vicinity,9987,O
of,9987,O
the,9987,O
sieve,9987,O
plates,9987,O
.,9987,O
GLR3.3,9988,B-GENE-N
was,9988,O
expressed,9988,O
in,9988,O
most,9988,O
cells,9988,O
of,9988,O
the,9988,O
growing,9988,O
primary,9988,O
root,9988,O
but,9988,O
was,9988,O
not,9988,O
enriched,9988,O
in,9988,O
the,9988,O
phloem,9988,O
",",9988,O
including,9988,O
the,9988,O
sieve,9988,O
plate,9988,O
area,9988,O
.,9988,O
GLR3.2,9989,B-GENE-N
and,9989,O
GLR3.4,9989,B-GENE-N
physically,9989,O
interacted,9989,O
with,9989,O
each,9989,O
other,9989,O
better,9989,O
than,9989,O
with,9989,O
themselves,9989,O
as,9989,O
evidenced,9989,O
by,9989,O
a,9989,O
biophotonic,9989,O
assay,9989,O
performed,9989,O
in,9989,O
human,9989,O
embryonic,9989,O
kidney,9989,O
cells,9989,O
and,9989,O
Nicotiana,9989,O
benthamiana,9989,O
leaf,9989,O
cells,9989,O
.,9989,O
GLR3.3,9990,B-GENE-N
interacted,9990,O
poorly,9990,O
with,9990,O
itself,9990,O
or,9990,O
the,9990,O
other,9990,O
two,9990,O
GLRs,9990,B-GENE-N
.,9990,O
Mutations,9991,O
in,9991,O
GLR3.2,9991,B-GENE-N
",",9991,O
GLR3.4,9991,B-GENE-N
",",9991,O
or,9991,O
GLR3.2,9991,B-GENE-N
and,9991,O
GLR3.4,9991,B-GENE-N
caused,9991,O
the,9991,O
same,9991,O
and,9991,O
equally,9991,O
severe,9991,O
phenotype,9991,O
",",9991,O
namely,9991,O
",",9991,O
a,9991,O
large,9991,O
overproduction,9991,O
and,9991,O
aberrant,9991,O
placement,9991,O
of,9991,O
lateral,9991,O
root,9991,O
primordia,9991,O
.,9991,O
Loss,9992,O
of,9992,O
GLR3.3,9992,B-GENE-N
did,9992,O
not,9992,O
affect,9992,O
lateral,9992,O
root,9992,O
primordia,9992,O
.,9992,O
These,9993,O
results,9993,O
support,9993,O
the,9993,O
hypothesis,9993,O
that,9993,O
apoplastic,9993,O
amino,9993,B-CHEMICAL
acids,9993,I-CHEMICAL
acting,9993,O
through,9993,O
heteromeric,9993,O
GLR3.2/GLR3.4,9993,B-GENE-N
channels,9993,O
affect,9993,O
lateral,9993,O
root,9993,O
development,9993,O
via,9993,O
Ca,9993,B-CHEMICAL
(,9993,I-CHEMICAL
2+,9993,I-CHEMICAL
),9993,I-CHEMICAL
signaling,9993,O
in,9993,O
the,9993,O
phloem,9993,O
.,9993,O
Purification,9994,O
and,9994,O
structural,9994,O
characterisation,9994,O
of,9994,O
phospholipase,9994,B-GENE-N
A1,9994,I-GENE-N
(,9994,O
Vespapase,9994,B-GENE-N
",",9994,O
Ves,9994,B-GENE-N
a,9994,I-GENE-N
1,9994,I-GENE-N
),9994,O
from,9994,O
Thai,9994,O
banded,9994,O
tiger,9994,O
wasp,9994,O
(,9994,O
Vespa,9994,O
affinis,9994,O
),9994,O
venom,9994,O
.,9994,O
The,9995,O
Thai,9995,O
banded,9995,O
tiger,9995,O
wasp,9995,O
(,9995,O
Vespa,9995,O
affinis,9995,O
),9995,O
is,9995,O
one,9995,O
of,9995,O
the,9995,O
most,9995,O
dangerous,9995,O
vespid,9995,O
species,9995,O
in,9995,O
Southeast,9995,O
Asia,9995,O
",",9995,O
and,9995,O
stinging,9995,O
accidents,9995,O
involving,9995,O
this,9995,O
species,9995,O
still,9995,O
cause,9995,O
fatalities,9995,O
.,9995,O
In,9996,O
the,9996,O
present,9996,O
study,9996,O
",",9996,O
four,9996,O
forms,9996,O
of,9996,O
V.,9996,B-GENE-N
affinis,9996,I-GENE-N
phospholipase,9996,I-GENE-N
A,9996,I-GENE-N
(,9996,I-GENE-N
1,9996,I-GENE-N
),9996,I-GENE-N
were,9996,O
identified,9996,O
through,9996,O
a,9996,O
proteomics,9996,O
approach,9996,O
.,9996,O
Two,9997,O
of,9997,O
these,9997,O
enzymes,9997,O
were,9997,O
purified,9997,O
by,9997,O
reverse-phase,9997,O
chromatography,9997,O
",",9997,O
and,9997,O
their,9997,O
biochemical,9997,O
properties,9997,O
were,9997,O
characterised,9997,O
.,9997,O
These,9998,O
enzymes,9998,O
",",9998,O
designated,9998,O
Ves,9998,B-GENE-N
a,9998,I-GENE-N
1s,9998,I-GENE-N
",",9998,O
are,9998,O
not,9998,O
glycoproteins,9998,O
and,9998,O
exist,9998,O
as,9998,O
33441.5,9998,O
and,9998,O
33474.4,9998,O
Da,9998,O
proteins,9998,O
",",9998,O
which,9998,O
corresponded,9998,O
with,9998,O
the,9998,O
34-kDa,9998,O
band,9998,O
observed,9998,O
via,9998,O
SDS-PAGE,9998,O
.,9998,O
The,9999,O
thermal,9999,O
stabilities,9999,O
of,9999,O
these,9999,O
enzymes,9999,O
were,9999,O
stronger,9999,O
than,9999,O
snake,9999,O
venom,9999,O
.,9999,O
Using,10000,O
an,10000,O
in,10000,O
vivo,10000,O
assay,10000,O
",",10000,O
no,10000,O
difference,10000,O
was,10000,O
found,10000,O
in,10000,O
the,10000,O
toxicities,10000,O
of,10000,O
the,10000,O
different,10000,O
isoforms,10000,O
.,10000,O
Furthermore,10001,O
",",10001,O
the,10001,O
toxicity,10001,O
of,10001,O
these,10001,O
enzymes,10001,O
does,10001,O
not,10001,O
appear,10001,O
to,10001,O
be,10001,O
correlated,10001,O
with,10001,O
their,10001,O
PLA,10001,B-GENE-N
(,10001,I-GENE-N
1,10001,I-GENE-N
),10001,I-GENE-N
activity,10001,O
.,10001,O
The,10002,O
cDNAs,10002,O
of,10002,O
the,10002,O
full-length,10002,O
version,10002,O
of,10002,O
Ves,10002,B-GENE-N
a,10002,I-GENE-N
1s,10002,I-GENE-N
revealed,10002,O
that,10002,O
the,10002,O
Ves,10002,B-GENE-N
a,10002,I-GENE-N
1,10002,I-GENE-N
gene,10002,O
consists,10002,O
of,10002,O
a,10002,O
1005-bp,10002,O
ORF,10002,O
",",10002,O
which,10002,O
encodes,10002,O
334,10002,O
amino,10002,B-CHEMICAL
acid,10002,I-CHEMICAL
residues,10002,O
",",10002,O
and,10002,O
67-,10002,O
and,10002,O
227-bp,10002,O
5,10002,O
',10002,O
and,10002,O
3,10002,O
',10002,O
UTRs,10002,O
",",10002,O
respectively,10002,O
.,10002,O
The,10003,O
two,10003,O
isoforms,10003,O
are,10003,O
different,10003,O
by,10003,O
three,10003,O
nucleotide,10003,B-CHEMICAL
substitutions,10003,O
",",10003,O
resulting,10003,O
in,10003,O
the,10003,O
replacement,10003,O
of,10003,O
two,10003,O
amino,10003,B-CHEMICAL
acids,10003,I-CHEMICAL
.,10003,O
Through,10004,O
sequence,10004,O
alignment,10004,O
",",10004,O
these,10004,O
enzymes,10004,O
were,10004,O
classified,10004,O
as,10004,O
members,10004,O
of,10004,O
the,10004,O
pancreatic,10004,B-GENE-N
lipase,10004,I-GENE-N
family,10004,O
.,10004,O
The,10005,O
structural,10005,O
modelling,10005,O
of,10005,O
Ves,10005,B-GENE-N
a,10005,I-GENE-N
1,10005,I-GENE-N
used,10005,O
the,10005,O
rat,10005,B-GENE-Y
pancreatic,10005,I-GENE-Y
lipase-related,10005,I-GENE-Y
protein,10005,I-GENE-Y
2,10005,I-GENE-Y
(,10005,O
1bu8A,10005,B-GENE-Y
),10005,O
as,10005,O
a,10005,O
template,10005,O
because,10005,O
it,10005,O
has,10005,O
PLA,10005,B-GENE-N
(,10005,I-GENE-N
1,10005,I-GENE-N
),10005,I-GENE-N
activity,10005,O
",",10005,O
which,10005,O
demonstrated,10005,O
that,10005,O
this,10005,O
enzyme,10005,O
belongs,10005,O
to,10005,O
the,10005,O
α/β,10005,B-GENE-N
hydrolase,10005,I-GENE-N
fold,10005,O
family,10005,O
.,10005,O
The,10006,O
Ves,10006,B-GENE-N
a,10006,I-GENE-N
1,10006,I-GENE-N
structure,10006,O
",",10006,O
which,10006,O
is,10006,O
composed,10006,O
of,10006,O
seven,10006,O
α-helixes,10006,O
and,10006,O
eleven,10006,O
β-strands,10006,O
",",10006,O
contains,10006,O
the,10006,O
β-strand/ɛSer/α-helix,10006,O
structural,10006,O
motif,10006,O
",",10006,O
which,10006,O
contains,10006,O
the,10006,O
Gly-X-Ser-X-Gly,10006,B-GENE-N
consensus,10006,O
sequence,10006,O
.,10006,O
The,10007,O
typical,10007,O
surface,10007,O
structures,10007,O
that,10007,O
play,10007,O
important,10007,O
roles,10007,O
in,10007,O
substrate,10007,O
selectivity,10007,O
(,10007,O
the,10007,O
lid,10007,O
domain,10007,O
and,10007,O
the,10007,O
β9,10007,O
loop,10007,O
),10007,O
were,10007,O
shortened,10007,O
in,10007,O
the,10007,O
Ves,10007,B-GENE-N
a,10007,I-GENE-N
1,10007,I-GENE-N
structure,10007,O
",",10007,O
which,10007,O
suggests,10007,O
that,10007,O
this,10007,O
enzyme,10007,O
may,10007,O
only,10007,O
exhibit,10007,O
phospholipase,10007,B-GENE-N
activity,10007,O
.,10007,O
Moreover,10008,O
",",10008,O
the,10008,O
observed,10008,O
insertion,10008,O
of,10008,O
proline,10008,B-CHEMICAL
into,10008,O
the,10008,O
lid,10008,O
domain,10008,O
of,10008,O
the,10008,O
Ves,10008,B-GENE-N
a,10008,I-GENE-N
1,10008,I-GENE-N
structure,10008,O
is,10008,O
rare,10008,O
.,10008,O
We,10009,O
therefore,10009,O
propose,10009,O
that,10009,O
this,10009,O
proline,10009,B-CHEMICAL
residue,10009,O
might,10009,O
be,10009,O
involved,10009,O
in,10009,O
the,10009,O
stability,10009,O
and,10009,O
activity,10009,O
of,10009,O
Ves,10009,B-GENE-N
a,10009,I-GENE-N
1s,10009,I-GENE-N
.,10009,O
Thalidomide,10010,B-CHEMICAL
inhibits,10010,O
growth,10010,O
of,10010,O
tumors,10010,O
through,10010,O
COX-2,10010,B-GENE-Y
degradation,10010,O
independent,10010,O
of,10010,O
antiangiogenesis,10010,O
.,10010,O
Thalidomide,10011,B-CHEMICAL
is,10011,O
an,10011,O
antiangiogenic,10011,O
drug,10011,O
and,10011,O
is,10011,O
clinically,10011,O
useful,10011,O
in,10011,O
a,10011,O
number,10011,O
of,10011,O
cancers,10011,O
.,10011,O
However,10012,O
",",10012,O
the,10012,O
molecular,10012,O
mechanism,10012,O
by,10012,O
which,10012,O
thalidomide,10012,B-CHEMICAL
exerts,10012,O
its,10012,O
antitumor,10012,O
effects,10012,O
is,10012,O
poorly,10012,O
understood,10012,O
.,10012,O
This,10013,O
study,10013,O
was,10013,O
designed,10013,O
to,10013,O
clarify,10013,O
the,10013,O
relationship,10013,O
between,10013,O
antiangiogenesis,10013,O
and,10013,O
antitumor,10013,O
effects,10013,O
of,10013,O
thalidomide,10013,B-CHEMICAL
and,10013,O
to,10013,O
explore,10013,O
the,10013,O
molecular,10013,O
mechanism,10013,O
for,10013,O
its,10013,O
antitumor,10013,O
activity,10013,O
.,10013,O
We,10014,O
evaluated,10014,O
the,10014,O
effects,10014,O
of,10014,O
thalidomide,10014,B-CHEMICAL
on,10014,O
the,10014,O
growth,10014,O
of,10014,O
human,10014,O
tumor,10014,O
cells,10014,O
expressing,10014,O
(,10014,O
MCF-7,10014,O
and,10014,O
HL-60,10014,O
),10014,O
or,10014,O
not,10014,O
expressing,10014,O
(,10014,O
HeLa,10014,O
and,10014,O
K562,10014,O
),10014,O
COX-2,10014,B-GENE-Y
in,10014,O
vitro,10014,O
.,10014,O
We,10015,O
also,10015,O
studied,10015,O
the,10015,O
effects,10015,O
of,10015,O
thalidomide,10015,B-CHEMICAL
on,10015,O
COX-1,10015,B-GENE-Y
",",10015,O
COX-2,10015,B-GENE-Y
or,10015,O
bcl-2,10015,B-GENE-Y
expression,10015,O
",",10015,O
TNFalpha,10015,B-GENE-Y
",",10015,O
VEGF,10015,B-GENE-Y
",",10015,O
GSH,10015,O
and,10015,O
cytochrome,10015,B-GENE-Y
c,10015,I-GENE-Y
in,10015,O
these,10015,O
cells,10015,O
.,10015,O
Thalidomide,10016,B-CHEMICAL
could,10016,O
inhibit,10016,O
tumor,10016,O
growth,10016,O
in,10016,O
a,10016,O
concentration-dependent,10016,O
manner,10016,O
in,10016,O
MCF-7,10016,O
and,10016,O
HL-60,10016,O
;,10016,O
its,10016,O
IC50s,10016,O
for,10016,O
them,10016,O
were,10016,O
18.36+/-2.34,10016,O
and,10016,O
22.14+/-2.15,10016,O
microM,10016,O
",",10016,O
respectively,10016,O
",",10016,O
while,10016,O
this,10016,O
effect,10016,O
was,10016,O
not,10016,O
observed,10016,O
in,10016,O
HeLa,10016,O
and,10016,O
K562,10016,O
.,10016,O
Thalidomide,10017,B-CHEMICAL
reduced,10017,O
COX-2,10017,B-GENE-Y
expression,10017,O
accompanied,10017,O
by,10017,O
a,10017,O
decrease,10017,O
of,10017,O
bcl-2,10017,B-GENE-Y
protein,10017,O
",",10017,O
TNFalpha,10017,B-GENE-Y
",",10017,O
VEGF,10017,B-GENE-Y
",",10017,O
GSH,10017,O
and,10017,O
an,10017,O
increased,10017,O
cytochrome,10017,B-GENE-Y
c,10017,I-GENE-Y
",",10017,O
but,10017,O
had,10017,O
no,10017,O
effect,10017,O
on,10017,O
that,10017,O
of,10017,O
COX-1,10017,B-GENE-Y
",",10017,O
in,10017,O
MCF-7,10017,O
and,10017,O
HL-60,10017,O
.,10017,O
Moreover,10018,O
",",10018,O
cells,10018,O
not,10018,O
expressing,10018,O
COX-2,10018,B-GENE-Y
were,10018,O
insensitive,10018,O
to,10018,O
the,10018,O
growth-inhibitory,10018,O
and,10018,O
effects,10018,O
on,10018,O
cytokines,10018,B-GENE-N
of,10018,O
thalidomide,10018,B-CHEMICAL
.,10018,O
In,10019,O
our,10019,O
mouse,10019,O
xenograft,10019,O
model,10019,O
of,10019,O
OVCAR-3,10019,O
and,10019,O
HCT-8,10019,O
",",10019,O
we,10019,O
found,10019,O
that,10019,O
thalidomide,10019,B-CHEMICAL
could,10019,O
decrease,10019,O
intratumoral,10019,O
microvessel,10019,O
density,10019,O
in,10019,O
both,10019,O
tumors,10019,O
;,10019,O
it,10019,O
exerted,10019,O
antitumor,10019,O
effects,10019,O
only,10019,O
on,10019,O
OVCAR-3,10019,O
expressing,10019,O
COX-2,10019,B-GENE-Y
but,10019,O
did,10019,O
not,10019,O
on,10019,O
HCT-8,10019,O
not,10019,O
expressing,10019,O
COX-2,10019,B-GENE-Y
.,10019,O
Effect,10020,O
of,10020,O
thalidomide,10020,B-CHEMICAL
on,10020,O
COX-1,10020,B-GENE-Y
and,10020,O
COX-2,10020,B-GENE-Y
in,10020,O
vivo,10020,O
was,10020,O
consistent,10020,O
with,10020,O
that,10020,O
of,10020,O
in,10020,O
vitro,10020,O
.,10020,O
These,10021,O
results,10021,O
demonstrated,10021,O
that,10021,O
thalidomide,10021,B-CHEMICAL
might,10021,O
inhibit,10021,O
growth,10021,O
of,10021,O
tumors,10021,O
through,10021,O
COX-2,10021,B-GENE-Y
degradation,10021,O
independent,10021,O
of,10021,O
antiangiogenesis,10021,O
.,10021,O
Toxicological,10022,O
impact,10022,O
of,10022,O
inhaled,10022,O
electric,10022,O
mosquito-repellent,10022,O
liquid,10022,O
on,10022,O
the,10022,O
rat,10022,O
:,10022,O
a,10022,O
hematological,10022,O
",",10022,O
cytokine,10022,B-GENE-N
indications,10022,O
",",10022,O
oxidative,10022,O
stress,10022,O
and,10022,O
tumor,10022,O
markers,10022,O
.,10022,O
Abstract,10023,O
Context,10023,O
:,10023,O
High,10023,O
malaria,10023,O
burden,10023,O
has,10023,O
led,10023,O
to,10023,O
the,10023,O
increased,10023,O
use,10023,O
of,10023,O
insecticides,10023,O
in,10023,O
the,10023,O
tropics,10023,O
and,10023,O
subtropics,10023,O
.,10023,O
This,10024,O
study,10024,O
thus,10024,O
aimed,10024,O
at,10024,O
assessing,10024,O
the,10024,O
hematological,10024,O
effects,10024,O
alteration,10024,O
of,10024,O
pyrethroid,10024,B-CHEMICAL
insecticide,10024,O
exposure,10024,O
using,10024,O
the,10024,O
experimental,10024,O
animal,10024,O
model,10024,O
.,10024,O
Objective,10025,O
:,10025,O
A,10025,O
commonly,10025,O
available,10025,O
Electric,10025,O
Mosquito-Repellent,10025,O
Liquid,10025,O
pyrethroid,10025,B-CHEMICAL
insecticide,10025,O
containing,10025,O
prallethrin,10025,B-CHEMICAL
1.6,10025,O
%,10025,O
w/w,10025,O
is,10025,O
widely,10025,O
used,10025,O
for,10025,O
mosquito,10025,O
control,10025,O
in,10025,O
Saudi,10025,O
Arabia,10025,O
.,10025,O
The,10026,O
immunotoxic,10026,O
effects,10026,O
after,10026,O
inhalation,10026,O
exposures,10026,O
to,10026,O
the,10026,O
preparation,10026,O
for,10026,O
a,10026,O
continuous,10026,O
period,10026,O
of,10026,O
24,10026,O
",",10026,O
48,10026,O
",",10026,O
and,10026,O
72,10026,O
h,10026,O
were,10026,O
investigated,10026,O
in,10026,O
rats,10026,O
.,10026,O
Methods,10027,O
and,10027,O
materials,10027,O
:,10027,O
Rats,10027,O
were,10027,O
exposed,10027,O
to,10027,O
prallethrin,10027,B-CHEMICAL
1.6,10027,O
%,10027,O
w/w,10027,O
by,10027,O
inhalation,10027,O
for,10027,O
72,10027,O
consecutive,10027,O
hours,10027,O
.,10027,O
Total,10028,O
blood,10028,O
count,10028,O
",",10028,O
blood,10028,O
indices,10028,O
of,10028,O
creatine,10028,B-GENE-N
kinase,10028,I-GENE-N
(,10028,O
CK,10028,B-GENE-N
),10028,O
",",10028,O
gamma-glutamyltranspeptidase,10028,B-GENE-Y
(,10028,O
γ-GT,10028,B-GENE-Y
),10028,O
",",10028,O
superoxide,10028,B-GENE-N
dismutase,10028,I-GENE-N
(,10028,O
SOD,10028,B-GENE-N
),10028,O
",",10028,O
nitric,10028,B-CHEMICAL
oxide,10028,I-CHEMICAL
(,10028,O
NO,10028,B-CHEMICAL
),10028,O
",",10028,O
malondialdehyde,10028,B-CHEMICAL
(,10028,O
MDA,10028,B-CHEMICAL
),10028,O
",",10028,O
interleukin,10028,B-GENE-Y
(,10028,I-GENE-Y
IL,10028,I-GENE-Y
),10028,I-GENE-Y
-2,10028,I-GENE-Y
",",10028,O
tumor,10028,B-GENE-Y
necrosis,10028,I-GENE-Y
factors,10028,I-GENE-Y
(,10028,I-GENE-Y
TNF,10028,I-GENE-Y
),10028,I-GENE-Y
α,10028,I-GENE-Y
",",10028,O
alpha-fetoprotein,10028,B-GENE-Y
(,10028,O
AFP,10028,B-GENE-Y
),10028,O
",",10028,O
carbohydrate,10028,B-GENE-N
antigen,10028,I-GENE-N
(,10028,I-GENE-N
CA,10028,I-GENE-N
),10028,I-GENE-N
19.9,10028,I-GENE-N
and,10028,O
carcinoembrionic,10028,B-GENE-N
antigen,10028,I-GENE-N
(,10028,O
CEA,10028,B-GENE-N
),10028,O
were,10028,O
assayed,10028,O
.,10028,O
Results,10029,O
:,10029,O
The,10029,O
administration,10029,O
of,10029,O
prallethrin,10029,B-CHEMICAL
1.6,10029,O
%,10029,O
w/w,10029,O
created,10029,O
significant,10029,O
increased,10029,O
changes,10029,O
in,10029,O
the,10029,O
levels,10029,O
of,10029,O
total,10029,O
WBC,10029,O
",",10029,O
lymphocytes,10029,O
",",10029,O
RBC,10029,O
",",10029,O
hemoglobin,10029,B-GENE-N
",",10029,O
packed,10029,O
cell,10029,O
volume,10029,O
",",10029,O
platelets,10029,O
",",10029,O
mean,10029,O
corpuscular,10029,O
volume,10029,O
",",10029,O
and,10029,O
mean,10029,O
corpuscular,10029,O
hemoglobin,10029,B-GENE-N
in,10029,O
rats,10029,O
after,10029,O
24,10029,O
",",10029,O
48,10029,O
",",10029,O
and,10029,O
72,10029,O
h,10029,O
of,10029,O
continuous,10029,O
inhalation,10029,O
;,10029,O
however,10029,O
",",10029,O
there,10029,O
was,10029,O
a,10029,O
significant,10029,O
reduction,10029,O
in,10029,O
neutrophils,10029,O
at,10029,O
transient,10029,O
reduction,10029,O
in,10029,O
the,10029,O
monocytes,10029,O
after,10029,O
24,10029,O
and,10029,O
48,10029,O
h,10029,O
to,10029,O
return,10029,O
to,10029,O
normal,10029,O
after,10029,O
72,10029,O
h.,10029,O
Significant,10029,O
increases,10029,O
in,10029,O
the,10029,O
levels,10029,O
of,10029,O
CK,10029,B-GENE-N
",",10029,O
γ-GT,10029,B-GENE-Y
",",10029,O
SOD,10029,B-GENE-N
",",10029,O
NO,10029,B-CHEMICAL
",",10029,O
MDA,10029,B-CHEMICAL
",",10029,O
AFP,10029,B-GENE-Y
",",10029,O
IL-2,10029,B-GENE-Y
",",10029,O
and,10029,O
TNFα,10029,B-GENE-Y
were,10029,O
recorded,10029,O
.,10029,O
CA,10030,B-GENE-N
and,10030,O
CEA,10030,B-GENE-N
did,10030,O
not,10030,O
exhibit,10030,O
any,10030,O
change,10030,O
.,10030,O
Conclusions,10031,O
:,10031,O
Continuous,10031,O
inhalation,10031,O
to,10031,O
prallethrin,10031,B-CHEMICAL
1.6,10031,O
%,10031,O
insecticides,10031,O
poses,10031,O
toxicity,10031,O
on,10031,O
hematological,10031,O
variables,10031,O
.,10031,O
It,10032,O
is,10032,O
also,10032,O
concluded,10032,O
that,10032,O
pyrethroid,10032,B-CHEMICAL
group,10032,O
of,10032,O
insecticide,10032,O
may,10032,O
cause,10032,O
hematological,10032,O
",",10032,O
biochemical,10032,O
",",10032,O
cytokine,10032,B-GENE-N
disturbances,10032,O
and,10032,O
possible,10032,O
mutagenic,10032,O
damage,10032,O
to,10032,O
the,10032,O
tissues,10032,O
.,10032,O
Contribution,10033,O
of,10033,O
the,10033,O
m1,10033,O
transmembrane,10033,O
helix,10033,O
and,10033,O
pre-m1,10033,O
region,10033,O
to,10033,O
positive,10033,O
allosteric,10033,O
modulation,10033,O
and,10033,O
gating,10033,O
of,10033,O
N-methyl-d-aspartate,10033,B-GENE-N
receptors,10033,I-GENE-N
.,10033,O
N-methyl-d-aspartate,10034,B-GENE-N
(,10034,I-GENE-N
NMDA,10034,I-GENE-N
),10034,I-GENE-N
receptors,10034,I-GENE-N
are,10034,O
glutamate-gated,10034,B-GENE-N
ion,10034,I-GENE-N
channels,10034,I-GENE-N
whose,10034,O
function,10034,O
is,10034,O
critical,10034,O
for,10034,O
normal,10034,O
excitatory,10034,O
synaptic,10034,O
transmission,10034,O
in,10034,O
the,10034,O
brain,10034,O
and,10034,O
whose,10034,O
dysfunction,10034,O
has,10034,O
been,10034,O
implicated,10034,O
in,10034,O
several,10034,O
neurologic,10034,O
conditions,10034,O
.,10034,O
NMDA,10035,B-GENE-N
receptor,10035,I-GENE-N
function,10035,O
is,10035,O
subject,10035,O
to,10035,O
extensive,10035,O
allosteric,10035,O
regulation,10035,O
both,10035,O
by,10035,O
endogenous,10035,O
compounds,10035,O
and,10035,O
by,10035,O
exogenous,10035,O
small,10035,O
molecules,10035,O
.,10035,O
Elucidating,10036,O
the,10036,O
structural,10036,O
determinants,10036,O
and,10036,O
mechanism,10036,O
of,10036,O
action,10036,O
by,10036,O
which,10036,O
allosteric,10036,O
regulators,10036,O
control,10036,O
gating,10036,O
will,10036,O
enhance,10036,O
our,10036,O
understanding,10036,O
of,10036,O
NMDA,10036,B-GENE-N
receptor,10036,I-GENE-N
activation,10036,O
and,10036,O
facilitate,10036,O
the,10036,O
development,10036,O
of,10036,O
novel,10036,O
therapeutics,10036,O
.,10036,O
Here,10037,O
",",10037,O
we,10037,O
investigated,10037,O
the,10037,O
structural,10037,O
determinants,10037,O
for,10037,O
(,10037,B-CHEMICAL
3-chlorophenyl,10037,I-CHEMICAL
),10037,I-CHEMICAL
(,10037,I-CHEMICAL
"6,7-dimethoxy-1-",10037,I-CHEMICAL
(,10037,I-CHEMICAL
(,10037,I-CHEMICAL
4-methoxyphenoxy,10037,I-CHEMICAL
),10037,I-CHEMICAL
methyl,10037,I-CHEMICAL
),10037,I-CHEMICAL
"-3,4-dihydroisoquinolin-2",10037,I-CHEMICAL
(,10037,I-CHEMICAL
1H,10037,I-CHEMICAL
),10037,I-CHEMICAL
-yl,10037,I-CHEMICAL
),10037,I-CHEMICAL
methanone,10037,I-CHEMICAL
(,10037,O
CIQ,10037,B-CHEMICAL
),10037,O
",",10037,O
a,10037,O
GluN2C/2D-selective,10037,O
positive,10037,O
allosteric,10037,O
modulator,10037,O
.,10037,O
We,10038,O
show,10038,O
that,10038,O
CIQ,10038,B-CHEMICAL
does,10038,O
not,10038,O
bind,10038,O
to,10038,O
the,10038,O
amino-terminal,10038,B-CHEMICAL
domain,10038,O
of,10038,O
the,10038,O
NMDA,10038,B-GENE-N
receptor,10038,I-GENE-N
and,10038,O
does,10038,O
not,10038,O
share,10038,O
structural,10038,O
determinants,10038,O
with,10038,O
modulators,10038,O
acting,10038,O
at,10038,O
the,10038,O
agonist-binding,10038,O
domain,10038,O
dimer,10038,O
interface,10038,O
or,10038,O
ion,10038,B-GENE-N
channel,10038,I-GENE-N
pore,10038,O
.,10038,O
Rather,10039,O
",",10039,O
we,10039,O
identified,10039,O
critical,10039,O
determinants,10039,O
of,10039,O
CIQ,10039,B-CHEMICAL
modulation,10039,O
in,10039,O
the,10039,O
region,10039,O
near,10039,O
the,10039,O
first,10039,O
transmembrane,10039,O
helix,10039,O
of,10039,O
GluN2D,10039,O
",",10039,O
including,10039,O
in,10039,O
a,10039,O
putative,10039,O
pre-M1,10039,O
cuff,10039,O
helix,10039,O
that,10039,O
may,10039,O
influence,10039,O
channel,10039,O
gating,10039,O
.,10039,O
We,10040,O
also,10040,O
show,10040,O
that,10040,O
mutations,10040,O
within,10040,O
the,10040,O
GluN2D,10040,O
pre-M1,10040,O
region,10040,O
alter,10040,O
open,10040,O
probability,10040,O
of,10040,O
the,10040,O
NMDA,10040,B-GENE-N
receptor,10040,I-GENE-N
.,10040,O
These,10041,O
results,10041,O
suggest,10041,O
a,10041,O
novel,10041,O
site,10041,O
of,10041,O
action,10041,O
for,10041,O
potentiation,10041,O
of,10041,O
NMDA,10041,B-GENE-N
receptors,10041,I-GENE-N
by,10041,O
small,10041,O
molecules,10041,O
and,10041,O
implicate,10041,O
the,10041,O
pre-M1,10041,O
region,10041,O
in,10041,O
NMDA,10041,B-GENE-N
receptor,10041,I-GENE-N
gating,10041,O
.,10041,O
Association,10042,O
of,10042,O
ATP-binding,10042,B-GENE-N
cassette,10042,I-GENE-N
transporter,10042,I-GENE-N
variants,10042,O
with,10042,O
the,10042,O
risk,10042,O
of,10042,O
Alzheimer,10042,O
's,10042,O
disease,10042,O
.,10042,O
Aim,10043,O
:,10043,O
A,10043,O
number,10043,O
of,10043,O
studies,10043,O
have,10043,O
demonstrated,10043,O
that,10043,O
ABCB1,10043,B-GENE-Y
and,10043,O
BCRP,10043,B-GENE-Y
(,10043,O
ABCG2,10043,B-GENE-Y
),10043,O
actively,10043,O
transport,10043,O
Aβ,10043,B-GENE-Y
.,10043,O
We,10044,O
aimed,10044,O
to,10044,O
investigate,10044,O
the,10044,O
association,10044,O
of,10044,O
genetic,10044,O
variants,10044,O
of,10044,O
selected,10044,O
multidrug,10044,B-GENE-N
transporters,10044,I-GENE-N
with,10044,O
Alzheimer,10044,O
's,10044,O
disease,10044,O
(,10044,O
AD,10044,O
),10044,O
in,10044,O
histopathologically,10044,O
confirmed,10044,O
AD,10044,O
cases,10044,O
and,10044,O
controls,10044,O
.,10044,O
Materials,10045,O
&,10045,O
methods,10045,O
:,10045,O
DNA,10045,O
from,10045,O
brain,10045,O
tissue,10045,O
of,10045,O
71,10045,O
AD,10045,O
cases,10045,O
with,10045,O
Consortium,10045,O
to,10045,O
Establish,10045,O
a,10045,O
Registry,10045,O
for,10045,O
Alzheimer,10045,O
's,10045,O
Disease,10045,O
(,10045,O
CERAD,10045,O
),10045,O
neuropathological,10045,O
stages,10045,O
B/C,10045,O
and,10045,O
81,10045,O
controls,10045,O
was,10045,O
genotyped,10045,O
for,10045,O
selected,10045,O
variants,10045,O
in,10045,O
ABCA1,10045,B-GENE-Y
",",10045,O
ABCA7,10045,B-GENE-Y
",",10045,O
ABCB1,10045,B-GENE-Y
",",10045,O
ABCC2,10045,B-GENE-Y
and,10045,O
ABCG2,10045,B-GENE-Y
.,10045,O
In,10046,O
addition,10046,O
",",10046,O
the,10046,O
APOE4,10046,B-GENE-Y
status,10046,O
was,10046,O
analyzed,10046,O
.,10046,O
Results,10047,O
:,10047,O
The,10047,O
novel,10047,O
ABCA7,10047,B-GENE-Y
SNP,10047,O
",",10047,O
rs3752246,10047,O
",",10047,O
tended,10047,O
to,10047,O
be,10047,O
associated,10047,O
with,10047,O
AD,10047,O
in,10047,O
our,10047,O
study,10047,O
.,10047,O
Variants,10048,O
in,10048,O
ABCB1,10048,B-GENE-Y
were,10048,O
significantly,10048,O
less,10048,O
frequent,10048,O
in,10048,O
AD,10048,O
cases,10048,O
older,10048,O
than,10048,O
65,10048,O
years,10048,O
of,10048,O
age,10048,O
and,10048,O
among,10048,O
females,10048,O
.,10048,O
This,10049,O
association,10049,O
of,10049,O
ABCB1,10049,B-GENE-Y
2677G,10049,B-GENE-N
>,10049,I-GENE-N
T,10049,I-GENE-N
(,10049,O
rs2032582,10049,O
),10049,O
was,10049,O
more,10049,O
pronounced,10049,O
in,10049,O
APOE4-negative,10049,B-GENE-Y
cases,10049,O
(,10049,O
p,10049,O
=,10049,O
0.005,10049,O
),10049,O
.,10049,O
However,10050,O
",",10050,O
only,10050,O
ABCC2,10050,B-GENE-Y
3972C,10050,B-GENE-N
>,10050,I-GENE-N
T,10050,I-GENE-N
(,10050,O
rs3740066,10050,O
),10050,O
was,10050,O
significantly,10050,O
associated,10050,O
with,10050,O
AD,10050,O
risk,10050,O
after,10050,O
logistic,10050,O
regression,10050,O
analysis,10050,O
including,10050,O
all,10050,O
variants,10050,O
.,10050,O
Other,10051,O
transporters,10051,O
showed,10051,O
a,10051,O
lack,10051,O
of,10051,O
association,10051,O
.,10051,O
Conclusion,10052,O
:,10052,O
Our,10052,O
results,10052,O
support,10052,O
the,10052,O
hypothesis,10052,O
that,10052,O
ABCB1,10052,B-GENE-Y
and,10052,O
possibly,10052,O
other,10052,O
ABC-transporters,10052,B-GENE-N
are,10052,O
involved,10052,O
in,10052,O
the,10052,O
process,10052,O
of,10052,O
Aβ,10052,B-GENE-Y
accumulation,10052,O
in,10052,O
the,10052,O
aging,10052,O
brain,10052,O
and,10052,O
may,10052,O
modulate,10052,O
the,10052,O
risk,10052,O
for,10052,O
AD,10052,O
in,10052,O
an,10052,O
allele-specific,10052,O
manner,10052,O
",",10052,O
and,10052,O
thus,10052,O
might,10052,O
represent,10052,O
a,10052,O
new,10052,O
target,10052,O
for,10052,O
prevention,10052,O
and,10052,O
treatment,10052,O
of,10052,O
AD,10052,O
.,10052,O
Original,10053,O
submitted,10053,O
8,10053,O
October,10053,O
2012,10053,O
;,10053,O
Revision,10053,O
submitted,10053,O
22,10053,O
January,10053,O
2013,10053,O
.,10053,O
Dandelion,10054,O
leaf,10054,O
extract,10054,O
protects,10054,O
against,10054,O
liver,10054,O
injury,10054,O
induced,10054,O
by,10054,O
methionine-,10054,B-CHEMICAL
and,10054,O
choline-deficient,10054,B-CHEMICAL
diet,10054,O
in,10054,O
mice,10054,O
.,10054,O
We,10055,O
investigated,10055,O
the,10055,O
hepatoprotective,10055,O
effects,10055,O
of,10055,O
the,10055,O
extract,10055,O
of,10055,O
dandelion,10055,O
leaves,10055,O
(,10055,O
EDL,10055,O
),10055,O
on,10055,O
a,10055,O
murine,10055,O
model,10055,O
of,10055,O
methionine-,10055,B-CHEMICAL
and,10055,O
choline-deficient,10055,B-CHEMICAL
(,10055,O
MCD,10055,O
),10055,O
diet-induced,10055,O
nonalcoholic,10055,O
steatohepatitis,10055,O
(,10055,O
NASH,10055,O
),10055,O
.,10055,O
C57BL/6,10056,O
mice,10056,O
were,10056,O
fed,10056,O
for,10056,O
4,10056,O
weeks,10056,O
with,10056,O
one,10056,O
of,10056,O
the,10056,O
following,10056,O
diets,10056,O
:,10056,O
control,10056,O
diet,10056,O
(,10056,O
Cont,10056,O
),10056,O
",",10056,O
MCD,10056,O
diet,10056,O
(,10056,O
MCD,10056,O
),10056,O
",",10056,O
MCD,10056,O
diet,10056,O
supplemented,10056,O
with,10056,O
EDL,10056,O
at,10056,O
200,10056,O
mg/kg,10056,O
body,10056,O
weight·daily,10056,O
(,10056,O
MCD+D200,10056,O
),10056,O
",",10056,O
and,10056,O
MCD,10056,O
diet,10056,O
supplemented,10056,O
with,10056,O
EDL,10056,O
at,10056,O
500,10056,O
mg/kg,10056,O
body,10056,O
weight·daily,10056,O
(,10056,O
MCD+D500,10056,O
),10056,O
.,10056,O
Hepatic,10057,O
function,10057,O
was,10057,O
assessed,10057,O
by,10057,O
evaluating,10057,O
the,10057,O
following,10057,O
parameters,10057,O
:,10057,O
liver,10057,O
histology,10057,O
;,10057,O
plasma,10057,O
levels,10057,O
of,10057,O
alanine,10057,B-GENE-N
aminotransferase,10057,I-GENE-N
(,10057,O
ALT,10057,B-GENE-N
),10057,O
",",10057,O
triglyceride,10057,B-CHEMICAL
(,10057,O
TG,10057,O
),10057,O
",",10057,O
malondialdehyde,10057,B-CHEMICAL
(,10057,O
MDA,10057,B-CHEMICAL
),10057,O
",",10057,O
and,10057,O
reduced,10057,B-CHEMICAL
glutathione,10057,I-CHEMICAL
(,10057,O
GSH,10057,B-CHEMICAL
),10057,O
;,10057,O
expression,10057,O
levels,10057,O
of,10057,O
TNF-α,10057,B-GENE-Y
and,10057,O
IL-6,10057,B-GENE-Y
;,10057,O
and,10057,O
levels,10057,O
of,10057,O
caspase-3,10057,B-GENE-Y
and,10057,O
pJNK/JNK,10057,B-GENE-N
protein,10057,O
.,10057,O
Histopathological,10058,O
evaluations,10058,O
revealed,10058,O
that,10058,O
addition,10058,O
of,10058,O
EDL,10058,O
to,10058,O
the,10058,O
MCD,10058,O
diet,10058,O
dampens,10058,O
the,10058,O
severity,10058,O
of,10058,O
the,10058,O
clinical,10058,O
signs,10058,O
of,10058,O
NASH,10058,O
.,10058,O
Moreover,10059,O
",",10059,O
EDL,10059,O
led,10059,O
to,10059,O
a,10059,O
significant,10059,O
decrease,10059,O
in,10059,O
the,10059,O
serum,10059,O
levels,10059,O
of,10059,O
ALT,10059,B-GENE-N
",",10059,O
hepatic,10059,O
TG,10059,O
",",10059,O
and,10059,O
MDA,10059,B-CHEMICAL
",",10059,O
and,10059,O
in,10059,O
the,10059,O
expression,10059,O
levels,10059,O
of,10059,O
TNF-α,10059,B-GENE-Y
",",10059,O
and,10059,O
IL-6,10059,B-GENE-Y
;,10059,O
on,10059,O
the,10059,O
contrary,10059,O
",",10059,O
the,10059,O
levels,10059,O
of,10059,O
reduced,10059,B-CHEMICAL
GSH,10059,I-CHEMICAL
increased,10059,O
.,10059,O
At,10060,O
the,10060,O
post-transcriptional,10060,O
level,10060,O
",",10060,O
EDL,10060,O
significantly,10060,O
decreased,10060,O
the,10060,O
activation,10060,O
of,10060,O
procaspase-3,10060,B-GENE-Y
to,10060,O
active,10060,O
caspase-3,10060,B-GENE-Y
",",10060,O
and,10060,O
the,10060,O
phosphorylation,10060,O
of,10060,O
JNK,10060,B-GENE-N
.,10060,O
These,10061,O
results,10061,O
suggest,10061,O
that,10061,O
the,10061,O
beneficial,10061,O
effects,10061,O
of,10061,O
EDL,10061,O
on,10061,O
NASH,10061,O
are,10061,O
mainly,10061,O
due,10061,O
to,10061,O
its,10061,O
antioxidant,10061,O
and,10061,O
anti-inflammatory,10061,O
activities,10061,O
.,10061,O
A,10062,O
novel,10062,O
tyrosine,10062,B-GENE-N
kinase,10062,I-GENE-N
switch,10062,O
is,10062,O
a,10062,O
mechanism,10062,O
of,10062,O
imatinib,10062,B-CHEMICAL
resistance,10062,O
in,10062,O
gastrointestinal,10062,O
stromal,10062,O
tumors,10062,O
.,10062,O
KIT,10063,B-GENE-Y
or,10063,O
alpha-platelet-derived,10063,B-GENE-Y
growth,10063,I-GENE-Y
factor,10063,I-GENE-Y
receptor,10063,I-GENE-Y
(,10063,O
alpha-PDGFR,10063,B-GENE-Y
),10063,O
activating,10063,O
mutations,10063,O
are,10063,O
the,10063,O
pathogenic,10063,O
mechanisms,10063,O
that,10063,O
characterize,10063,O
gastrointestinal,10063,O
stromal,10063,O
tumors,10063,O
(,10063,O
GIST,10063,O
),10063,O
.,10063,O
Despite,10064,O
excellent,10064,O
responses,10064,O
to,10064,O
imatinib,10064,B-CHEMICAL
mesylate,10064,I-CHEMICAL
(,10064,O
IM,10064,B-CHEMICAL
),10064,O
",",10064,O
patients,10064,O
are,10064,O
relapsing,10064,O
.,10064,O
We,10065,O
developed,10065,O
an,10065,O
IM-resistant,10065,B-CHEMICAL
GIST,10065,O
cell,10065,O
line,10065,O
(,10065,O
GIST-R,10065,O
),10065,O
from,10065,O
the,10065,O
IM-sensitive,10065,B-CHEMICAL
GIST882,10065,O
cell,10065,O
line,10065,O
(,10065,O
GIST-S,10065,O
),10065,O
by,10065,O
growing,10065,O
these,10065,O
cells,10065,O
in,10065,O
IM,10065,B-CHEMICAL
.,10065,O
Gene,10066,O
expression,10066,O
profiling,10066,O
(,10066,O
GEP,10066,O
),10066,O
of,10066,O
GIST-S,10066,O
",",10066,O
GIST-R,10066,O
cells,10066,O
and,10066,O
two,10066,O
IM,10066,B-CHEMICAL
resistant,10066,O
GIST,10066,O
patients,10066,O
demonstrated,10066,O
that,10066,O
KIT,10066,B-GENE-Y
is,10066,O
downregulated,10066,O
implying,10066,O
a,10066,O
major,10066,O
role,10066,O
in,10066,O
IM,10066,B-CHEMICAL
resistance,10066,O
.,10066,O
Instead,10067,O
",",10067,O
GIST-R,10067,O
cells,10067,O
have,10067,O
acquired,10067,O
IM,10067,B-CHEMICAL
resistance,10067,O
by,10067,O
overexpressing,10067,O
the,10067,O
oncogenic,10067,B-GENE-N
receptor,10067,I-GENE-N
tyrosine,10067,I-GENE-N
kinase,10067,I-GENE-N
-,10067,O
AXL,10067,B-GENE-Y
-,10067,O
in,10067,O
a,10067,O
'kinase,10067,O
switch,10067,O
',10067,O
.,10067,O
Further,10068,O
",",10068,O
the,10068,O
two,10068,O
IM,10068,B-CHEMICAL
resistant,10068,O
GIST,10068,O
patients,10068,O
express,10068,O
AXL,10068,B-GENE-Y
and,10068,O
not,10068,O
c-Kit,10068,B-GENE-Y
",",10068,O
seen,10068,O
by,10068,O
immunohistochemistry,10068,O
(,10068,O
IHC,10068,O
),10068,O
.,10068,O
Real,10069,O
time,10069,O
reverse,10069,O
transcriptase-polymerase,10069,O
chain,10069,O
reaction,10069,O
and,10069,O
Western,10069,O
blotting,10069,O
of,10069,O
the,10069,O
GIST-S,10069,O
and,10069,O
GIST-R,10069,O
cells,10069,O
confirmed,10069,O
the,10069,O
switch,10069,O
from,10069,O
Kit,10069,B-GENE-Y
to,10069,O
AXL,10069,B-GENE-Y
.,10069,O
In,10070,O
GIST-R,10070,O
",",10070,O
AXL,10070,B-GENE-Y
is,10070,O
tyrosine,10070,B-CHEMICAL
phosphorylated,10070,O
and,10070,O
its,10070,O
ligand,10070,O
growth-arrest-specific,10070,B-GENE-Y
gene,10070,I-GENE-Y
6,10070,I-GENE-Y
is,10070,O
overexpressed,10070,O
implying,10070,O
autocrine,10070,O
activation,10070,O
.,10070,O
The,10071,O
kinase,10071,B-GENE-N
switch,10071,O
is,10071,O
associated,10071,O
with,10071,O
a,10071,O
morphological,10071,O
change,10071,O
from,10071,O
spindle,10071,O
to,10071,O
epithelioid,10071,O
.,10071,O
Molecular,10072,O
modeling,10072,O
of,10072,O
the,10072,O
kinase,10072,B-GENE-N
domain,10072,I-GENE-N
of,10072,O
mutant,10072,O
c-Kit,10072,B-GENE-Y
(,10072,O
V654A,10072,B-GENE-N
),10072,O
and,10072,O
AXL,10072,B-GENE-Y
showed,10072,O
no,10072,O
binding,10072,O
to,10072,O
IM,10072,B-CHEMICAL
but,10072,O
efficient,10072,O
binding,10072,O
to,10072,O
MP470,10072,B-CHEMICAL
",",10072,O
a,10072,O
novel,10072,O
c-Kit/AXL,10072,B-GENE-Y
kinase,10072,B-GENE-N
inhibitor,10072,O
.,10072,O
MP470,10073,B-CHEMICAL
synergizes,10073,O
with,10073,O
docetaxel,10073,B-CHEMICAL
(,10073,O
taxotere,10073,B-CHEMICAL
),10073,O
and,10073,O
is,10073,O
cytotoxic,10073,O
to,10073,O
GIST,10073,O
cells,10073,O
.,10073,O
Differential,10074,O
interactions,10074,O
of,10074,O
heparin,10074,O
and,10074,O
heparan,10074,O
sulfate,10074,O
glycosaminoglycans,10074,O
with,10074,O
the,10074,O
selectins,10074,B-GENE-N
.,10074,O
Implications,10075,O
for,10075,O
the,10075,O
use,10075,O
of,10075,O
unfractionated,10075,O
and,10075,O
low,10075,O
molecular,10075,O
weight,10075,O
heparins,10075,O
as,10075,O
therapeutic,10075,O
agents,10075,O
.,10075,O
The,10076,O
selectins,10076,B-GENE-N
are,10076,O
calcium-dependent,10076,B-CHEMICAL
C-type,10076,B-GENE-N
lectins,10076,I-GENE-N
that,10076,O
bind,10076,O
certain,10076,O
sialylated,10076,O
",",10076,O
fucosylated,10076,O
",",10076,O
sulfated,10076,O
glycoprotein,10076,O
ligands,10076,O
.,10076,O
L-selectin,10077,B-GENE-Y
also,10077,O
recognizes,10077,O
endothelial,10077,O
proteoglycans,10077,O
in,10077,O
a,10077,O
calcium-dependent,10077,B-CHEMICAL
manner,10077,O
",",10077,O
via,10077,O
heparan,10077,O
sulfate,10077,O
(,10077,O
HS,10077,O
),10077,O
glycosaminoglycan,10077,O
chains,10077,O
enriched,10077,O
in,10077,O
unsubstituted,10077,O
glucosamine,10077,B-CHEMICAL
units,10077,O
.,10077,O
We,10078,O
now,10078,O
show,10078,O
that,10078,O
these,10078,O
HS,10078,O
chains,10078,O
can,10078,O
also,10078,O
bind,10078,O
P-selectin,10078,B-GENE-Y
",",10078,O
but,10078,O
not,10078,O
E-selectin,10078,B-GENE-Y
.,10078,O
However,10079,O
",",10079,O
while,10079,O
L-selectin,10079,B-GENE-Y
binding,10079,O
requires,10079,O
micromolar,10079,O
levels,10079,O
of,10079,O
free,10079,O
calcium,10079,O
",",10079,O
P-selectin,10079,B-GENE-Y
recognition,10079,O
is,10079,O
largely,10079,O
divalent,10079,O
cation-independent,10079,O
.,10079,O
Despite,10080,O
this,10080,O
",",10080,O
HS,10080,O
chains,10080,O
bound,10080,O
to,10080,O
P-selectin,10080,B-GENE-Y
are,10080,O
eluted,10080,O
by,10080,O
ethylenediamine,10080,B-CHEMICAL
tetraacetic,10080,I-CHEMICAL
acid,10080,I-CHEMICAL
(,10080,O
EDTA,10080,B-CHEMICAL
),10080,O
",",10080,O
but,10080,O
only,10080,O
at,10080,O
high,10080,O
concentrations,10080,O
.,10080,O
Porcine,10081,O
intestinal,10081,O
mucosal,10081,O
(,10081,O
mast,10081,O
cell-derived,10081,O
),10081,O
heparin,10081,O
(,10081,O
PIM-heparin,10081,O
),10081,O
shows,10081,O
similar,10081,O
properties,10081,O
",",10081,O
with,10081,O
no,10081,O
binding,10081,O
to,10081,O
E-selectin,10081,B-GENE-Y
",",10081,O
calcium-dependent,10081,B-CHEMICAL
binding,10081,O
of,10081,O
a,10081,O
subfraction,10081,O
to,10081,O
L-selectin,10081,B-GENE-Y
and,10081,O
to,10081,O
P-selectin,10081,B-GENE-Y
",",10081,O
and,10081,O
calcium-independent,10081,B-CHEMICAL
binding,10081,O
of,10081,O
a,10081,O
larger,10081,O
fraction,10081,O
to,10081,O
P-selectin,10081,B-GENE-Y
",",10081,O
the,10081,O
latter,10081,O
being,10081,O
disrupted,10081,O
by,10081,O
high,10081,O
EDTA,10081,B-CHEMICAL
concentrations,10081,O
.,10081,O
Analysis,10082,O
of,10082,O
defined,10082,O
heparin,10082,O
fragment,10082,O
pools,10082,O
shows,10082,O
a,10082,O
size,10082,O
dependence,10082,O
for,10082,O
interaction,10082,O
",",10082,O
with,10082,O
tetradecasaccharides,10082,B-CHEMICAL
showing,10082,O
easily,10082,O
detectable,10082,O
binding,10082,O
to,10082,O
L-,10082,B-GENE-N
and,10082,I-GENE-N
P-selectin,10082,I-GENE-N
affinity,10082,O
columns,10082,O
.,10082,O
L-selectin,10083,B-GENE-Y
binding,10083,O
fragments,10083,O
include,10083,O
more,10083,O
heavily,10083,O
sulfated,10083,O
and,10083,O
epimerized,10083,O
regions,10083,O
and,10083,O
",",10083,O
as,10083,O
with,10083,O
the,10083,O
endothelial,10083,O
HS,10083,O
chains,10083,O
",",10083,O
they,10083,O
are,10083,O
enriched,10083,O
in,10083,O
free,10083,B-CHEMICAL
amino,10083,I-CHEMICAL
groups,10083,O
.,10083,O
The,10084,O
P-selectin,10084,B-GENE-Y
binding,10084,O
component,10084,O
includes,10084,O
this,10084,O
fraction,10084,O
as,10084,O
well,10084,O
as,10084,O
some,10084,O
less,10084,O
highly,10084,O
modified,10084,O
regions,10084,O
.,10084,O
Thus,10085,O
",",10085,O
endothelium-derived,10085,O
HS,10085,O
chains,10085,O
and,10085,O
mast,10085,O
cell-derived,10085,O
heparins,10085,O
could,10085,O
play,10085,O
a,10085,O
role,10085,O
in,10085,O
modulating,10085,O
the,10085,O
biology,10085,O
of,10085,O
selectins,10085,B-GENE-N
in,10085,O
vivo,10085,O
.,10085,O
Notably,10086,O
",",10086,O
P-,10086,B-GENE-N
and,10086,I-GENE-N
L-selectin,10086,I-GENE-N
binding,10086,O
to,10086,O
sialyl-Lewisx,10086,O
and,10086,O
to,10086,O
HL-60,10086,O
cells,10086,O
(,10086,O
which,10086,O
are,10086,O
known,10086,O
to,10086,O
carry,10086,O
the,10086,O
native,10086,O
ligand,10086,O
PSGL-1,10086,B-GENE-Y
),10086,O
is,10086,O
inhibited,10086,O
by,10086,O
unfractionated,10086,O
pharmaceutical,10086,O
heparin,10086,O
preparations,10086,O
at,10086,O
concentrations,10086,O
12-50-fold,10086,O
lower,10086,O
than,10086,O
those,10086,O
recommended,10086,O
for,10086,O
effective,10086,O
anticoagulation,10086,O
in,10086,O
vivo,10086,O
.,10086,O
In,10087,O
contrast,10087,O
",",10087,O
two,10087,O
low,10087,O
molecular,10087,O
weight,10087,O
heparins,10087,O
currently,10087,O
considered,10087,O
as,10087,O
clinical,10087,O
replacements,10087,O
for,10087,O
unfractionated,10087,O
heparin,10087,O
are,10087,O
much,10087,O
poorer,10087,O
inhibitors,10087,O
.,10087,O
Thus,10088,O
",",10088,O
patients,10088,O
undergoing,10088,O
heparin,10088,O
therapy,10088,O
for,10088,O
other,10088,O
reasons,10088,O
may,10088,O
be,10088,O
experiencing,10088,O
clinically,10088,O
significant,10088,O
inhibition,10088,O
of,10088,O
L-,10088,B-GENE-N
and,10088,I-GENE-N
P-selectin,10088,I-GENE-N
function,10088,O
",",10088,O
and,10088,O
the,10088,O
current,10088,O
switchover,10088,O
to,10088,O
low-molecular,10088,O
weight,10088,O
heparins,10088,O
may,10088,O
come,10088,O
at,10088,O
some,10088,O
loss,10088,O
of,10088,O
this,10088,O
effect,10088,O
.,10088,O
Low-dose,10089,O
unfractionated,10089,O
heparin,10089,O
should,10089,O
be,10089,O
investigated,10089,O
as,10089,O
a,10089,O
treatment,10089,O
option,10089,O
for,10089,O
acute,10089,O
and,10089,O
chronic,10089,O
diseases,10089,O
in,10089,O
which,10089,O
P-,10089,B-GENE-N
and,10089,I-GENE-N
L-selectin,10089,I-GENE-N
play,10089,O
pathological,10089,O
roles,10089,O
.,10089,O
Differentiation,10090,O
of,10090,O
opioid,10090,O
drug,10090,O
effects,10090,O
by,10090,O
hierarchical,10090,O
multi-site,10090,O
phosphorylation,10090,O
.,10090,O
Differences,10091,O
in,10091,O
the,10091,O
ability,10091,O
of,10091,O
opioid,10091,O
drugs,10091,O
to,10091,O
promote,10091,O
regulated,10091,O
endocytosis,10091,O
of,10091,O
μ-opioid,10091,B-GENE-Y
receptors,10091,I-GENE-Y
are,10091,O
related,10091,O
to,10091,O
their,10091,O
tendency,10091,O
to,10091,O
produce,10091,O
drug,10091,O
tolerance,10091,O
and,10091,O
dependence,10091,O
.,10091,O
Here,10092,O
we,10092,O
show,10092,O
that,10092,O
drug-specific,10092,O
differences,10092,O
in,10092,O
receptor,10092,O
internalization,10092,O
are,10092,O
determined,10092,O
by,10092,O
a,10092,O
conserved,10092,O
",",10092,O
10-residue,10092,O
sequence,10092,O
in,10092,O
the,10092,O
receptor,10092,O
's,10092,O
carboxyl-terminal,10092,B-GENE-N
cytoplasmic,10092,I-GENE-N
tail,10092,I-GENE-N
.,10092,O
Diverse,10093,O
opioids,10093,O
induce,10093,O
receptor,10093,O
phosphorylation,10093,O
at,10093,O
serine,10093,B-CHEMICAL
(,10093,O
S,10093,O
),10093,O
375,10093,O
",",10093,O
present,10093,O
in,10093,O
the,10093,O
middle,10093,O
of,10093,O
this,10093,O
sequence,10093,O
",",10093,O
but,10093,O
opioids,10093,O
differ,10093,O
markedly,10093,O
in,10093,O
their,10093,O
ability,10093,O
to,10093,O
drive,10093,O
higher-order,10093,O
phosphorylation,10093,O
on,10093,O
flanking,10093,O
residues,10093,O
[,10093,O
threonine,10093,B-CHEMICAL
(,10093,O
T,10093,O
),10093,O
370,10093,O
",",10093,O
T376,10093,O
",",10093,O
and,10093,O
T379,10093,O
],10093,O
.,10093,O
Multi-phosphorylation,10094,O
is,10094,O
required,10094,O
for,10094,O
the,10094,O
endocytosis-promoting,10094,O
activity,10094,O
of,10094,O
this,10094,O
sequence,10094,O
and,10094,O
occurs,10094,O
both,10094,O
sequentially,10094,O
and,10094,O
hierarchically,10094,O
",",10094,O
with,10094,O
S375,10094,O
representing,10094,O
the,10094,O
initiating,10094,O
site,10094,O
.,10094,O
Higher-order,10095,O
phosphorylation,10095,O
involving,10095,O
T370,10095,O
",",10095,O
T376,10095,O
",",10095,O
and,10095,O
T379,10095,O
specifically,10095,O
requires,10095,O
GRK2/3,10095,B-GENE-N
isoforms,10095,O
",",10095,O
and,10095,O
the,10095,O
same,10095,O
sequence,10095,O
controls,10095,O
opioid,10095,B-GENE-N
receptor,10095,I-GENE-N
internalization,10095,O
in,10095,O
neurons,10095,O
.,10095,O
These,10096,O
results,10096,O
reveal,10096,O
a,10096,O
biochemical,10096,O
mechanism,10096,O
differentiating,10096,O
the,10096,O
endocytic,10096,O
activity,10096,O
of,10096,O
opioid,10096,O
drugs,10096,O
.,10096,O
Effects,10097,O
of,10097,O
changeover,10097,O
from,10097,O
voglibose,10097,B-CHEMICAL
to,10097,O
acarbose,10097,B-CHEMICAL
on,10097,O
postprandial,10097,O
triglycerides,10097,B-CHEMICAL
in,10097,O
type,10097,O
2,10097,O
diabetes,10097,O
mellitus,10097,O
patients,10097,O
.,10097,O
INTRODUCTION,10098,O
:,10098,O
In,10098,O
this,10098,O
study,10098,O
",",10098,O
we,10098,O
examined,10098,O
the,10098,O
effects,10098,O
of,10098,O
the,10098,O
alpha-glucosidase,10098,B-GENE-N
inhibitors,10098,O
acarbose,10098,B-CHEMICAL
and,10098,O
voglibose,10098,B-CHEMICAL
on,10098,O
postprandial,10098,O
plasma,10098,O
glucose,10098,B-CHEMICAL
and,10098,O
serum,10098,O
triglyceride,10098,O
levels,10098,O
in,10098,O
patients,10098,O
with,10098,O
type,10098,O
2,10098,O
diabetes,10098,O
mellitus,10098,O
.,10098,O
METHODS,10099,O
:,10099,O
Twenty-one,10099,O
Japanese,10099,O
patients,10099,O
with,10099,O
type,10099,O
2,10099,O
diabetes,10099,O
were,10099,O
enrolled,10099,O
in,10099,O
this,10099,O
study,10099,O
.,10099,O
Subjects,10100,O
had,10100,O
been,10100,O
treated,10100,O
with,10100,O
voglibose,10100,B-CHEMICAL
for,10100,O
at,10100,O
least,10100,O
3,10100,O
months,10100,O
.,10100,O
They,10101,O
underwent,10101,O
a,10101,O
400,10101,O
kcal,10101,O
balanced,10101,O
food,10101,O
meal,10101,O
tolerance,10101,O
test,10101,O
before,10101,O
and,10101,O
8,10101,O
weeks,10101,O
after,10101,O
the,10101,O
changeover,10101,O
from,10101,O
voglibose,10101,B-CHEMICAL
to,10101,O
acarbose,10101,B-CHEMICAL
.,10101,O
Subjects,10102,O
were,10102,O
divided,10102,O
into,10102,O
two,10102,O
groups,10102,O
:,10102,O
the,10102,O
first,10102,O
group,10102,O
(,10102,O
low-dose,10102,O
group,10102,O
;,10102,O
n=11,10102,O
),10102,O
was,10102,O
changed,10102,O
over,10102,O
from,10102,O
0.6,10102,O
mg/day,10102,O
voglibose,10102,B-CHEMICAL
to,10102,O
150,10102,O
mg/day,10102,O
acarbose,10102,B-CHEMICAL
",",10102,O
and,10102,O
the,10102,O
other,10102,O
(,10102,O
high-dose,10102,O
group,10102,O
;,10102,O
n=10,10102,O
),10102,O
from,10102,O
0.9,10102,O
mg/day,10102,O
voglibose,10102,B-CHEMICAL
to,10102,O
300,10102,O
mg/day,10102,O
acarbose,10102,O
.,10102,O
RESULTS,10103,O
:,10103,O
The,10103,O
increment,10103,O
rate,10103,O
of,10103,O
postprandial,10103,O
plasma,10103,O
glucose,10103,B-CHEMICAL
(,10103,O
[,10103,O
plasma,10103,O
glucose,10103,B-CHEMICAL
2,10103,O
hours,10103,O
after,10103,O
test,10103,O
meal,10103,O
-,10103,O
fasting,10103,O
glucose,10103,B-CHEMICAL
],10103,O
/fasting,10103,O
glucose,10103,B-CHEMICAL
),10103,O
decreased,10103,O
from,10103,O
34.7,10103,O
%,10103,O
+/-23.9,10103,O
%,10103,O
to,10103,O
25.0,10103,O
%,10103,O
+/-24.6,10103,O
%,10103,O
(,10103,O
P=0.13,10103,O
),10103,O
in,10103,O
the,10103,O
low-dose,10103,O
group,10103,O
",",10103,O
and,10103,O
decreased,10103,O
significantly,10103,O
from,10103,O
56.1,10103,O
%,10103,O
+/-53.1,10103,O
%,10103,O
to,10103,O
31.5,10103,O
%,10103,O
+/-36.0,10103,O
%,10103,O
(,10103,O
P=0.03,10103,O
),10103,O
in,10103,O
the,10103,O
high-dose,10103,O
group,10103,O
after,10103,O
changeover,10103,O
.,10103,O
However,10104,O
",",10104,O
there,10104,O
were,10104,O
no,10104,O
significant,10104,O
changes,10104,O
in,10104,O
blood,10104,O
glycated,10104,B-GENE-Y
hemoglobin,10104,I-GENE-Y
(,10104,O
HbA,10104,B-GENE-Y
(,10104,I-GENE-Y
1c,10104,I-GENE-Y
),10104,I-GENE-Y
),10104,O
levels,10104,O
before,10104,O
and,10104,O
after,10104,O
changeover,10104,O
in,10104,O
either,10104,O
group,10104,O
.,10104,O
The,10105,O
increment,10105,O
rate,10105,O
of,10105,O
postprandial,10105,O
serum,10105,O
triglyceride,10105,B-CHEMICAL
(,10105,O
TG,10105,B-CHEMICAL
),10105,O
(,10105,O
[,10105,O
serum,10105,O
TG,10105,B-CHEMICAL
2,10105,O
hours,10105,O
after,10105,O
test,10105,O
meal,10105,O
-,10105,O
fasting,10105,O
TG,10105,B-CHEMICAL
],10105,O
/fasting,10105,O
TG,10105,B-CHEMICAL
),10105,O
decreased,10105,O
significantly,10105,O
only,10105,O
in,10105,O
the,10105,O
high-dose,10105,O
group,10105,O
(,10105,O
52.4,10105,O
%,10105,O
+/-60.0,10105,O
%,10105,O
to,10105,O
24.3,10105,O
%,10105,O
+/-16.6,10105,O
%,10105,O
),10105,O
(,10105,O
P=0.05,10105,O
),10105,O
.,10105,O
No,10106,O
significant,10106,O
changes,10106,O
in,10106,O
serum,10106,O
high-density,10106,O
lipoprotein,10106,O
cholesterol,10106,B-CHEMICAL
levels,10106,O
were,10106,O
observed,10106,O
in,10106,O
either,10106,O
group,10106,O
",",10106,O
whereas,10106,O
serum,10106,O
low-density,10106,B-GENE-N
lipoprotein,10106,I-GENE-N
cholesterol,10106,B-CHEMICAL
levels,10106,O
decreased,10106,O
significantly,10106,O
from,10106,O
3.20+/-0.25,10106,O
to,10106,O
2.65+/-0.18,10106,O
mmol/L,10106,O
(,10106,O
P=0.04,10106,O
),10106,O
",",10106,O
only,10106,O
in,10106,O
the,10106,O
high-dose,10106,O
group,10106,O
.,10106,O
CONCLUSIONS,10107,O
:,10107,O
In,10107,O
patients,10107,O
with,10107,O
type,10107,O
2,10107,O
diabetes,10107,O
our,10107,O
findings,10107,O
suggest,10107,O
that,10107,O
acarbose,10107,B-CHEMICAL
300,10107,O
mg/day,10107,O
is,10107,O
superior,10107,O
to,10107,O
voglibose,10107,B-CHEMICAL
0.9,10107,O
mg/day,10107,O
in,10107,O
improving,10107,O
postprandial,10107,O
hyperglycemia,10107,O
and,10107,O
hypertriglyceridemia,10107,O
.,10107,O
Modulation,10108,O
of,10108,O
the,10108,O
JAK/ERK/STAT,10108,B-GENE-N
signaling,10108,O
in,10108,O
melanocortin-induced,10108,B-GENE-Y
inhibition,10108,O
of,10108,O
local,10108,O
and,10108,O
systemic,10108,O
responses,10108,O
to,10108,O
myocardial,10108,O
ischemia/reperfusion,10108,O
.,10108,O
The,10109,O
janus,10109,B-GENE-N
kinases,10109,I-GENE-N
(,10109,O
JAK,10109,B-GENE-N
),10109,O
",",10109,O
extracellular,10109,B-GENE-N
signal-regulated,10109,I-GENE-N
kinases,10109,I-GENE-N
(,10109,O
ERK,10109,B-GENE-N
),10109,O
and,10109,O
signal,10109,B-GENE-N
transducers,10109,I-GENE-N
and,10109,I-GENE-N
activators,10109,I-GENE-N
of,10109,I-GENE-N
transcription,10109,I-GENE-N
(,10109,O
STAT,10109,B-GENE-N
),10109,O
pathways,10109,O
have,10109,O
been,10109,O
shown,10109,O
to,10109,O
play,10109,O
a,10109,O
cardioprotective,10109,O
role,10109,O
.,10109,O
We,10110,O
previously,10110,O
gave,10110,O
evidence,10110,O
that,10110,O
melanocortins,10110,B-GENE-Y
afford,10110,O
cardioprotection,10110,O
in,10110,O
conditions,10110,O
of,10110,O
myocardial,10110,O
ischemia/reperfusion,10110,O
.,10110,O
Here,10111,O
we,10111,O
aimed,10111,O
to,10111,O
investigate,10111,O
the,10111,O
influence,10111,O
of,10111,O
melanocortins,10111,B-GENE-Y
on,10111,O
the,10111,O
JAK/ERK/STAT,10111,B-GENE-N
signaling,10111,O
in,10111,O
cardiac,10111,O
and,10111,O
systemic,10111,O
responses,10111,O
to,10111,O
prolonged,10111,O
myocardial,10111,O
ischemia/reperfusion,10111,O
.,10111,O
Ischemia,10112,O
was,10112,O
produced,10112,O
in,10112,O
rats,10112,O
by,10112,O
ligature,10112,O
of,10112,O
the,10112,O
left,10112,O
anterior,10112,O
descending,10112,O
coronary,10112,O
artery,10112,O
for,10112,O
30min,10112,O
.,10112,O
At,10113,O
the,10113,O
end,10113,O
of,10113,O
the,10113,O
2-h,10113,O
reperfusion,10113,O
",",10113,O
western,10113,O
blot,10113,O
analysis,10113,O
of,10113,O
the,10113,O
cardioprotective,10113,O
transcription,10113,O
factors,10113,O
pJAK2,10113,B-GENE-Y
",",10113,O
pERK1/2,10113,B-GENE-N
",",10113,O
pTyr-STAT3,10113,B-GENE-Y
and,10113,O
pSer-STAT3,10113,B-GENE-Y
",",10113,O
the,10113,O
inflammatory,10113,O
mediator,10113,O
tumor,10113,B-GENE-Y
necrosis,10113,I-GENE-Y
factor-α,10113,I-GENE-Y
(,10113,O
TNF-α,10113,B-GENE-Y
),10113,O
",",10113,O
the,10113,O
pro-apoptotic,10113,O
factors,10113,O
BAX,10113,B-GENE-Y
and,10113,O
c-jun,10113,B-GENE-N
N-terminal,10113,I-GENE-N
kinases,10113,I-GENE-N
(,10113,O
pJNK,10113,B-GENE-N
),10113,O
",",10113,O
the,10113,O
anti-apoptotic,10113,O
protein,10113,O
Bcl-XL,10113,B-GENE-Y
",",10113,O
as,10113,O
well,10113,O
as,10113,O
of,10113,O
the,10113,O
cardioprotective,10113,O
enzyme,10113,O
heme,10113,B-GENE-Y
oxygenase-1,10113,I-GENE-Y
(,10113,O
HO-1,10113,B-GENE-Y
),10113,O
",",10113,O
was,10113,O
performed,10113,O
in,10113,O
the,10113,O
left,10113,O
ventricle,10113,O
and,10113,O
spleen,10113,O
.,10113,O
Intravenous,10114,O
treatment,10114,O
",",10114,O
during,10114,O
coronary,10114,O
artery,10114,O
occlusion,10114,O
",",10114,O
with,10114,O
the,10114,O
melanocortin,10114,B-GENE-Y
analogs,10114,O
[,10114,O
Nle,10114,B-CHEMICAL
(,10114,O
4,10114,O
),10114,O
",",10114,O
D-Phe,10114,B-CHEMICAL
(,10114,O
7,10114,O
),10114,O
],10114,O
α-melanocyte-stimulating,10114,B-GENE-Y
hormone,10114,I-GENE-Y
(,10114,O
NDP-α-MSH,10114,O
),10114,O
and,10114,O
adrenocorticotropic,10114,B-GENE-Y
hormone,10114,I-GENE-Y
1-24,10114,I-GENE-Y
[,10114,O
ACTH-,10114,B-GENE-Y
(,10114,I-GENE-Y
1-24,10114,I-GENE-Y
),10114,I-GENE-Y
],10114,O
",",10114,O
induced,10114,O
a,10114,O
left,10114,O
ventricle,10114,O
up-regulation,10114,O
of,10114,O
pJAK2,10114,B-GENE-Y
",",10114,O
pERK1/2,10114,B-GENE-N
and,10114,O
pTyr-STAT3,10114,B-GENE-Y
(,10114,O
JAK-dependent,10114,B-GENE-N
),10114,O
",",10114,O
and,10114,O
a,10114,O
reduction,10114,O
in,10114,O
pJNK,10114,B-GENE-N
and,10114,O
TNF-α,10114,B-GENE-Y
levels,10114,O
;,10114,O
these,10114,O
effects,10114,O
of,10114,O
NDP-α-MSH,10114,O
and,10114,O
ACTH-,10114,B-GENE-Y
(,10114,I-GENE-Y
1-24,10114,I-GENE-Y
),10114,I-GENE-Y
were,10114,O
associated,10114,O
with,10114,O
over-expression,10114,O
of,10114,O
the,10114,O
pro-survival,10114,O
proteins,10114,O
HO-1,10114,B-GENE-Y
and,10114,O
Bcl-XL,10114,B-GENE-Y
",",10114,O
and,10114,O
marked,10114,O
decrease,10114,O
of,10114,O
the,10114,O
myocardial,10114,O
infarct,10114,O
size,10114,O
.,10114,O
Melanocortin,10115,B-GENE-Y
treatment,10115,O
did,10115,O
not,10115,O
affect,10115,O
left,10115,O
ventricle,10115,O
pSer-STAT3,10115,B-GENE-Y
(,10115,O
ERK1/2-dependent,10115,B-GENE-N
),10115,O
and,10115,O
BAX,10115,B-GENE-Y
levels,10115,O
.,10115,O
In,10116,O
the,10116,O
spleen,10116,O
",",10116,O
NDP-α-MSH,10116,O
and,10116,O
ACTH-,10116,B-GENE-Y
(,10116,I-GENE-Y
1-24,10116,I-GENE-Y
),10116,I-GENE-Y
induced,10116,O
similar,10116,O
effects,10116,O
on,10116,O
the,10116,O
expression,10116,O
of,10116,O
the,10116,O
above,10116,O
transcription,10116,O
factors/proteins,10116,O
",",10116,O
except,10116,O
for,10116,O
pERK1/2,10116,B-GENE-N
(,10116,O
down-regulated,10116,O
),10116,O
and,10116,O
HO-1,10116,B-GENE-Y
(,10116,O
unaffected,10116,O
),10116,O
.,10116,O
Blockade,10117,O
of,10117,O
JAK,10117,B-GENE-N
and,10117,O
ERK,10117,B-GENE-N
pathways,10117,O
with,10117,O
AG490,10117,B-CHEMICAL
and,10117,O
U0126,10117,B-CHEMICAL
",",10117,O
respectively,10117,O
",",10117,O
abrogated,10117,O
the,10117,O
myocardial,10117,O
infarct,10117,O
size,10117,O
reduction,10117,O
by,10117,O
NDP-α-MSH,10117,O
.,10117,O
These,10118,O
results,10118,O
indicate,10118,O
that,10118,O
melanocortins,10118,B-GENE-Y
inhibit,10118,O
local,10118,O
and,10118,O
systemic,10118,O
inflammatory,10118,O
and,10118,O
apoptotic,10118,O
cascades,10118,O
triggered,10118,O
by,10118,O
prolonged,10118,O
myocardial,10118,O
ischemia/reperfusion,10118,O
",",10118,O
with,10118,O
consequent,10118,O
reduction,10118,O
in,10118,O
myocardium,10118,O
infarct,10118,O
size,10118,O
",",10118,O
seemingly,10118,O
via,10118,O
activation,10118,O
of,10118,O
the,10118,O
JAK/STAT,10118,B-GENE-N
signaling,10118,O
and,10118,O
with,10118,O
modulation,10118,O
of,10118,O
an,10118,O
ERK,10118,B-GENE-N
(,10118,O
STAT,10118,B-GENE-N
unrelated,10118,O
),10118,O
signaling,10118,O
pathway,10118,O
.,10118,O
Cyclooxygenase,10119,B-GENE-N
and,10119,O
5-lipoxygenase,10119,B-GENE-Y
inhibitors,10119,O
protect,10119,O
against,10119,O
mononuclear,10119,O
phagocyte,10119,O
neurotoxicity,10119,O
.,10119,O
Neuroinflammation,10120,O
and,10120,O
oxidative,10120,O
stress,10120,O
are,10120,O
believed,10120,O
to,10120,O
be,10120,O
contributing,10120,O
factors,10120,O
to,10120,O
neurodegeneration,10120,O
in,10120,O
normal,10120,O
aging,10120,O
",",10120,O
as,10120,O
well,10120,O
as,10120,O
in,10120,O
age-related,10120,O
neurological,10120,O
disorders,10120,O
.,10120,O
Reactive,10121,O
microglia,10121,O
are,10121,O
found,10121,O
in,10121,O
increased,10121,O
numbers,10121,O
in,10121,O
aging,10121,O
brain,10121,O
and,10121,O
are,10121,O
prominently,10121,O
associated,10121,O
with,10121,O
lesions,10121,O
in,10121,O
such,10121,O
age-related,10121,O
degenerative,10121,O
conditions,10121,O
as,10121,O
Alzheimer,10121,O
's,10121,O
disease,10121,O
(,10121,O
AD,10121,O
),10121,O
",",10121,O
Parkinson,10121,O
's,10121,O
disease,10121,O
(,10121,O
PD,10121,O
),10121,O
and,10121,O
amyotrophic,10121,O
lateral,10121,O
sclerosis,10121,O
(,10121,O
ALS,10121,O
),10121,O
.,10121,O
In,10122,O
vitro,10122,O
",",10122,O
stimulated,10122,O
microglia,10122,O
or,10122,O
microglial-like,10122,O
cells,10122,O
secrete,10122,O
neurotoxic,10122,O
materials,10122,O
and,10122,O
are,10122,O
generators,10122,O
of,10122,O
free,10122,O
radicals,10122,O
through,10122,O
their,10122,O
respiratory,10122,O
burst,10122,O
system,10122,O
.,10122,O
Agents,10123,O
that,10123,O
suppress,10123,O
microglial,10123,O
activation,10123,O
are,10123,O
therefore,10123,O
candidates,10123,O
for,10123,O
neuroprotection,10123,O
.,10123,O
We,10124,O
have,10124,O
developed,10124,O
quantitative,10124,O
in,10124,O
vitro,10124,O
assays,10124,O
for,10124,O
measuring,10124,O
neurotoxicity,10124,O
of,10124,O
microglia,10124,O
or,10124,O
other,10124,O
mononuclear,10124,O
phagocytes,10124,O
.,10124,O
Neuronal,10125,O
like,10125,O
SH-SY5Y,10125,O
cells,10125,O
are,10125,O
cultured,10125,O
in,10125,O
supernatants,10125,O
from,10125,O
activated,10125,O
cells,10125,O
of,10125,O
the,10125,O
human,10125,O
monocytic,10125,O
THP-1,10125,O
line,10125,O
and,10125,O
their,10125,O
survival,10125,O
is,10125,O
followed,10125,O
.,10125,O
Respiratory,10126,O
burst,10126,O
is,10126,O
directly,10126,O
measured,10126,O
on,10126,O
the,10126,O
activated,10126,O
cells,10126,O
.,10126,O
We,10127,O
tested,10127,O
inhibitors,10127,O
of,10127,O
the,10127,O
cyclooxygenase,10127,B-GENE-N
(,10127,O
COX,10127,B-GENE-N
),10127,O
or,10127,O
the,10127,O
5-lipoxygenase,10127,B-GENE-Y
(,10127,O
5-LOX,10127,B-GENE-Y
),10127,O
pathways,10127,O
as,10127,O
possible,10127,O
neuroprotective,10127,O
agents,10127,O
.,10127,O
The,10128,O
COX,10128,B-GENE-N
pathway,10128,O
generates,10128,O
inflammatory,10128,O
prostaglandins,10128,B-CHEMICAL
",",10128,O
while,10128,O
the,10128,O
5-LOX,10128,B-GENE-Y
pathway,10128,O
generates,10128,O
inflammatory,10128,O
leukotrienes,10128,B-CHEMICAL
.,10128,O
We,10129,O
found,10129,O
that,10129,O
inhibitors,10129,O
of,10129,O
both,10129,O
these,10129,O
pathways,10129,O
suppressed,10129,O
neurotoxicity,10129,O
in,10129,O
a,10129,O
dose-dependent,10129,O
fashion,10129,O
.,10129,O
They,10130,O
included,10130,O
the,10130,O
COX-1,10130,B-GENE-Y
inhibitor,10130,O
indomethacin,10130,O
;,10130,O
the,10130,O
COX-2,10130,B-GENE-Y
inhibitor,10130,O
NS-398,10130,B-CHEMICAL
;,10130,O
the,10130,O
mixed,10130,O
COX-1/COX-2,10130,B-GENE-Y
inhibitor,10130,O
ibuprofen,10130,B-CHEMICAL
;,10130,O
the,10130,O
nitric,10130,B-CHEMICAL
oxide,10130,I-CHEMICAL
(,10130,O
NO,10130,B-CHEMICAL
),10130,O
derivatives,10130,O
of,10130,O
indomethacin,10130,B-CHEMICAL
",",10130,O
ibuprofen,10130,B-CHEMICAL
and,10130,O
flurbiprofen,10130,B-CHEMICAL
;,10130,O
the,10130,O
5-LOX,10130,B-GENE-Y
inhibitor,10130,O
REV,10130,B-CHEMICAL
5901,10130,I-CHEMICAL
;,10130,O
and,10130,O
the,10130,O
5-LOX,10130,B-GENE-Y
activating,10130,I-GENE-Y
protein,10130,I-GENE-Y
(,10130,O
FLAP,10130,B-GENE-Y
),10130,O
inhibitor,10130,O
MK-886,10130,B-CHEMICAL
.,10130,O
The,10131,O
FLAP,10131,B-GENE-Y
inhibitor,10131,O
also,10131,O
reduced,10131,O
respiratory,10131,O
burst,10131,O
activity,10131,O
in,10131,O
a,10131,O
more,10131,O
potent,10131,O
manner,10131,O
than,10131,O
indomethacin,10131,O
.,10131,O
Combinations,10132,O
of,10132,O
COX,10132,B-GENE-N
and,10132,O
5-LOX,10132,B-GENE-Y
inhibitors,10132,O
were,10132,O
more,10132,O
effective,10132,O
than,10132,O
single,10132,O
inhibitors,10132,O
.,10132,O
The,10133,O
data,10133,O
suggest,10133,O
that,10133,O
both,10133,O
COX,10133,B-GENE-N
inhibitors,10133,O
and,10133,O
5-LOX,10133,B-GENE-Y
inhibitors,10133,O
may,10133,O
be,10133,O
neuroprotective,10133,O
in,10133,O
vivo,10133,O
by,10133,O
suppressing,10133,O
toxic,10133,O
actions,10133,O
of,10133,O
microglia/macrophages,10133,O
",",10133,O
and,10133,O
that,10133,O
combinations,10133,O
of,10133,O
the,10133,O
two,10133,O
might,10133,O
have,10133,O
greater,10133,O
therapeutic,10133,O
potential,10133,O
than,10133,O
single,10133,O
inhibitors,10133,O
of,10133,O
either,10133,O
class,10133,O
.,10133,O
Cyperi,10134,O
Rhizoma,10134,O
inhibits,10134,O
the,10134,O
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced",10134,B-CHEMICAL
reduction,10134,O
in,10134,O
nigrostriatal,10134,O
dopaminergenic,10134,O
neurons,10134,O
in,10134,O
estrogen-deprived,10134,B-CHEMICAL
mice,10134,O
.,10134,O
ETHNOPHARMACOLOGICAL,10135,O
RELEVANCE,10135,O
:,10135,O
Cyperi,10135,O
Rhizoma,10135,O
has,10135,O
commonly,10135,O
been,10135,O
used,10135,O
for,10135,O
the,10135,O
treatment,10135,O
of,10135,O
gynecological,10135,O
and,10135,O
neuropsychiatric,10135,O
disorders,10135,O
in,10135,O
traditional,10135,O
medicine,10135,O
.,10135,O
The,10136,O
aim,10136,O
of,10136,O
this,10136,O
study,10136,O
was,10136,O
to,10136,O
evaluate,10136,O
the,10136,O
estrogenic,10136,O
properties,10136,O
and,10136,O
neuroprotective,10136,O
effects,10136,O
of,10136,O
Cyperi,10136,O
Rhizoma,10136,O
under,10136,O
estrogen-deprived,10136,B-CHEMICAL
condition,10136,O
in,10136,O
female,10136,O
mice,10136,O
.,10136,O
MATERIALS,10137,O
AND,10137,O
METHODS,10137,O
:,10137,O
To,10137,O
determine,10137,O
the,10137,O
estrogen-like,10137,B-CHEMICAL
effect,10137,O
of,10137,O
Cyperi,10137,O
Rhizoma,10137,O
extract,10137,O
(,10137,O
CRE,10137,O
),10137,O
",",10137,O
we,10137,O
measured,10137,O
luciferase,10137,O
expression,10137,O
after,10137,O
transfection,10137,O
of,10137,O
a,10137,O
promoter,10137,O
construct,10137,O
containing,10137,O
an,10137,O
estrogen,10137,B-GENE-N
response,10137,I-GENE-N
element,10137,I-GENE-N
(,10137,O
ERE,10137,B-GENE-N
),10137,O
and,10137,O
treatment,10137,O
of,10137,O
CRE,10137,O
.,10137,O
To,10138,O
evaluate,10138,O
the,10138,O
neuroprotective,10138,O
effect,10138,O
of,10138,O
CRE,10138,O
",",10138,O
we,10138,O
measured,10138,O
striatal,10138,O
dopamine,10138,B-CHEMICAL
",",10138,O
movement,10138,O
ability,10138,O
",",10138,O
tyrosine,10138,B-GENE-Y
hydroxylase,10138,I-GENE-Y
(,10138,O
TH,10138,B-GENE-Y
),10138,O
immunoreactivity,10138,O
",",10138,O
and,10138,O
apoptosis-related,10138,O
protein,10138,O
expression,10138,O
levels,10138,O
after,10138,O
treatment,10138,O
of,10138,O
CRE,10138,O
either,10138,O
with,10138,O
or,10138,O
without,10138,O
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",10138,B-CHEMICAL
(,10138,O
MPTP,10138,B-CHEMICAL
),10138,O
in,10138,O
ovariectomized,10138,O
female,10138,O
mice,10138,O
.,10138,O
RESULTS,10139,O
:,10139,O
CRE,10139,O
significantly,10139,O
induced,10139,O
the,10139,O
luciferase,10139,O
expression,10139,O
driven,10139,O
by,10139,O
an,10139,O
ERE,10139,B-GENE-N
in,10139,O
PC12,10139,O
cells,10139,O
",",10139,O
a,10139,O
dopaminergic,10139,O
cell,10139,O
line,10139,O
",",10139,O
in,10139,O
a,10139,O
dose-dependent,10139,O
manner,10139,O
.,10139,O
In,10140,O
mice,10140,O
",",10140,O
MPTP,10140,B-CHEMICAL
significantly,10140,O
decreased,10140,O
the,10140,O
levels,10140,O
of,10140,O
dopamine,10140,B-CHEMICAL
in,10140,O
the,10140,O
striatum,10140,O
and,10140,O
behavior,10140,O
performance,10140,O
;,10140,O
in,10140,O
contrast,10140,O
",",10140,O
both,10140,O
CRE,10140,O
and,10140,O
17β-estradiol,10140,B-CHEMICAL
benzoate,10140,I-CHEMICAL
(,10140,O
EB,10140,O
),10140,O
recovered,10140,O
these,10140,O
parameters,10140,O
to,10140,O
normal,10140,O
levels,10140,O
.,10140,O
CRE,10141,O
and,10141,O
EB,10141,O
treatment,10141,O
also,10141,O
recovered,10141,O
TH,10141,B-GENE-Y
immunopositive,10141,O
fibers,10141,O
and,10141,O
cells,10141,O
",",10141,O
respectively,10141,O
",",10141,O
from,10141,O
MPTP,10141,B-CHEMICAL
toxicity,10141,O
.,10141,O
Additionally,10142,O
",",10142,O
MPTP,10142,B-CHEMICAL
significantly,10142,O
down-regulated,10142,O
Bcl-2,10142,B-GENE-Y
expression,10142,O
in,10142,O
the,10142,O
mitochondria,10142,O
of,10142,O
dopaminergic,10142,O
cells,10142,O
in,10142,O
the,10142,O
SN,10142,O
",",10142,O
followed,10142,O
by,10142,O
an,10142,O
increase,10142,O
in,10142,O
Bax,10142,B-GENE-Y
expression,10142,O
",",10142,O
cytochrome,10142,B-GENE-Y
C,10142,I-GENE-Y
translocation,10142,O
to,10142,O
the,10142,O
cytosol,10142,O
",",10142,O
andcleaved-caspase-3,10142,O
expression,10142,O
",",10142,O
whereas,10142,O
these,10142,O
were,10142,O
inhibited,10142,O
by,10142,O
CRE,10142,O
or,10142,O
EB,10142,O
treatment,10142,O
.,10142,O
CONCLUSIONS,10143,O
:,10143,O
These,10143,O
findings,10143,O
provide,10143,O
the,10143,O
first,10143,O
evidence,10143,O
that,10143,O
CRE,10143,O
has,10143,O
estrogen-like,10143,B-CHEMICAL
and,10143,O
neuroprotective,10143,O
effects,10143,O
on,10143,O
dopaminergic,10143,O
neurons,10143,O
in,10143,O
estrogen-deprived,10143,B-CHEMICAL
mice,10143,O
treated,10143,O
with,10143,O
MPTP-toxin,10143,B-CHEMICAL
.,10143,O
New,10144,O
progestagens,10144,B-CHEMICAL
for,10144,O
contraceptive,10144,O
use,10144,O
.,10144,O
The,10145,O
progestins,10145,B-CHEMICAL
have,10145,O
different,10145,O
pharmacologic,10145,O
properties,10145,O
depending,10145,O
upon,10145,O
the,10145,O
parent,10145,O
molecule,10145,O
",",10145,O
usually,10145,O
testosterone,10145,B-CHEMICAL
or,10145,O
progesterone,10145,B-CHEMICAL
(,10145,O
P,10145,O
),10145,O
",",10145,O
from,10145,O
which,10145,O
they,10145,O
are,10145,O
derived,10145,O
.,10145,O
Very,10146,O
small,10146,O
structural,10146,O
changes,10146,O
in,10146,O
the,10146,O
parent,10146,O
molecule,10146,O
may,10146,O
induce,10146,O
considerable,10146,O
differences,10146,O
in,10146,O
the,10146,O
activity,10146,O
of,10146,O
the,10146,O
derivative,10146,O
.,10146,O
In,10147,O
hormonal,10147,O
contraceptives,10147,O
",",10147,O
progestins,10147,O
represent,10147,O
the,10147,O
major,10147,O
agent,10147,O
designed,10147,O
for,10147,O
suppressing,10147,O
ovulation,10147,O
and,10147,O
are,10147,O
used,10147,O
in,10147,O
combination,10147,O
with,10147,O
estrogen,10147,B-CHEMICAL
(,10147,O
E,10147,O
),10147,O
usually,10147,O
ethinyl-estradiol,10147,B-CHEMICAL
(,10147,O
EE,10147,B-CHEMICAL
),10147,O
.,10147,O
The,10148,O
development,10148,O
of,10148,O
new,10148,O
generations,10148,O
of,10148,O
progestins,10148,B-CHEMICAL
with,10148,O
improved,10148,O
selectivity,10148,O
profiles,10148,O
has,10148,O
been,10148,O
a,10148,O
great,10148,O
challenge,10148,O
.,10148,O
Steroidal,10149,B-CHEMICAL
and,10149,O
nonsteroidal,10149,O
progesterone,10149,B-GENE-Y
receptor,10149,I-GENE-Y
(,10149,O
PR,10149,B-GENE-Y
),10149,O
agonists,10149,O
have,10149,O
been,10149,O
synthesized,10149,O
as,10149,O
well,10149,O
",",10149,O
although,10149,O
the,10149,O
latter,10149,O
are,10149,O
still,10149,O
in,10149,O
a,10149,O
very,10149,O
early,10149,O
stage,10149,O
of,10149,O
development,10149,O
.,10149,O
Several,10150,O
new,10150,O
progestins,10150,B-CHEMICAL
",",10150,O
have,10150,O
been,10150,O
synthesized,10150,O
in,10150,O
the,10150,O
last,10150,O
two,10150,O
decades,10150,O
.,10150,O
These,10151,O
include,10151,O
dienogest,10151,B-CHEMICAL
(,10151,O
DNG,10151,B-CHEMICAL
),10151,O
",",10151,O
drospirenone,10151,B-CHEMICAL
(,10151,O
DRSP,10151,B-CHEMICAL
),10151,O
",",10151,O
Nestorone,10151,B-CHEMICAL
(,10151,O
NES,10151,B-CHEMICAL
),10151,O
",",10151,O
nomegestrol,10151,B-CHEMICAL
acetate,10151,I-CHEMICAL
(,10151,O
NOMAc,10151,B-CHEMICAL
),10151,O
and,10151,O
trimegestone,10151,B-CHEMICAL
(,10151,O
TMG,10151,B-CHEMICAL
),10151,O
.,10151,O
These,10152,O
new,10152,O
progestins,10152,B-CHEMICAL
have,10152,O
been,10152,O
designed,10152,O
to,10152,O
have,10152,O
no,10152,O
androgenic,10152,O
or,10152,O
estrogenic,10152,O
actions,10152,O
and,10152,O
to,10152,O
be,10152,O
closer,10152,O
in,10152,O
activity,10152,O
to,10152,O
the,10152,O
physiological,10152,O
hormone,10152,O
P.,10152,O
DRSP,10152,B-CHEMICAL
differs,10152,O
from,10152,O
the,10152,O
classic,10152,O
progestins,10152,B-CHEMICAL
as,10152,O
it,10152,O
is,10152,O
derived,10152,O
from,10152,O
spirolactone,10152,B-CHEMICAL
.,10152,O
It,10153,O
is,10153,O
essentially,10153,O
an,10153,O
antimineralocorticoid,10153,O
steroid,10153,B-CHEMICAL
with,10153,O
no,10153,O
androgenic,10153,O
effect,10153,O
but,10153,O
a,10153,O
partial,10153,O
antiandrogenic,10153,O
effect,10153,O
.,10153,O
The,10154,O
antiovulatory,10154,O
potency,10154,O
of,10154,O
the,10154,O
different,10154,O
progestins,10154,B-CHEMICAL
varies,10154,O
.,10154,O
TMG,10155,B-CHEMICAL
and,10155,O
NES,10155,B-CHEMICAL
are,10155,O
the,10155,O
most,10155,O
potent,10155,O
progestins,10155,B-CHEMICAL
synthesized,10155,O
to,10155,O
date,10155,O
",",10155,O
followed,10155,O
by,10155,O
two,10155,O
of,10155,O
the,10155,O
older,10155,O
progestins,10155,B-CHEMICAL
",",10155,O
keto-desogestrel,10155,B-CHEMICAL
(,10155,O
keto-DSG,10155,B-CHEMICAL
),10155,O
and,10155,O
levonorgestrel,10155,B-CHEMICAL
(,10155,O
LNG,10155,B-CHEMICAL
),10155,O
.,10155,O
The,10156,O
new,10156,O
molecules,10156,O
TMG,10156,B-CHEMICAL
",",10156,O
DRSP,10156,B-CHEMICAL
and,10156,O
DNG,10156,B-CHEMICAL
also,10156,O
have,10156,O
antiandrogenic,10156,O
activity,10156,O
.,10156,O
Striking,10157,O
differences,10157,O
exist,10157,O
regarding,10157,O
the,10157,O
side,10157,O
effects,10157,O
among,10157,O
the,10157,O
progestins,10157,B-CHEMICAL
and,10157,O
the,10157,O
combination,10157,O
with,10157,O
EE,10157,B-CHEMICAL
leads,10157,O
to,10157,O
other,10157,O
reactions,10157,O
related,10157,O
to,10157,O
the,10157,O
E,10157,O
itself,10157,O
and,10157,O
whether,10157,O
the,10157,O
associated,10157,O
progestin,10157,B-CHEMICAL
counterbalances,10157,O
",",10157,O
more,10157,O
or,10157,O
less,10157,O
",",10157,O
the,10157,O
estrogenic,10157,O
action,10157,O
.,10157,O
The,10158,O
19-norprogesterone,10158,B-CHEMICAL
molecules,10158,O
and,10158,O
the,10158,O
new,10158,O
molecules,10158,O
DRSP,10158,B-CHEMICAL
and,10158,O
DNG,10158,B-CHEMICAL
are,10158,O
not,10158,O
androgenic,10158,O
and,10158,O
",",10158,O
therefore,10158,O
",",10158,O
have,10158,O
no,10158,O
negative,10158,O
effect,10158,O
on,10158,O
the,10158,O
lipid,10158,O
profile,10158,O
.,10158,O
Given,10159,O
their,10159,O
pharmacological,10159,O
properties,10159,O
",",10159,O
it,10159,O
is,10159,O
likely,10159,O
that,10159,O
the,10159,O
new,10159,O
progestins,10159,B-CHEMICAL
may,10159,O
have,10159,O
neutral,10159,O
effects,10159,O
on,10159,O
metabolic,10159,O
or,10159,O
vascular,10159,O
risks,10159,O
.,10159,O
However,10160,O
",",10160,O
this,10160,O
hypothesis,10160,O
must,10160,O
be,10160,O
confirmed,10160,O
in,10160,O
large,10160,O
clinical,10160,O
trials,10160,O
.,10160,O
Add-on,10161,O
therapy,10161,O
with,10161,O
the,10161,O
DPP-4,10161,B-GENE-Y
inhibitor,10161,O
sitagliptin,10161,B-CHEMICAL
improves,10161,O
glycemic,10161,O
control,10161,O
in,10161,O
insulin-treated,10161,B-GENE-Y
Japanese,10161,O
patients,10161,O
with,10161,O
type,10161,O
2,10161,O
diabetes,10161,O
mellitus,10161,O
.,10161,O
The,10162,O
effect,10162,O
of,10162,O
add-on,10162,O
therapy,10162,O
with,10162,O
sitagliptin,10162,B-CHEMICAL
on,10162,O
glycemic,10162,O
control,10162,O
was,10162,O
prospectively,10162,O
investigated,10162,O
in,10162,O
patients,10162,O
with,10162,O
type,10162,O
2,10162,O
diabetes,10162,O
mellitus,10162,O
(,10162,O
T2DM,10162,O
),10162,O
receiving,10162,O
insulin,10162,B-GENE-Y
alone,10162,O
or,10162,O
insulin,10162,B-GENE-N
combined,10162,O
with,10162,O
oral,10162,O
antidiabetic,10162,O
drugs,10162,O
.,10162,O
Seventy-one,10163,O
patients,10163,O
were,10163,O
evaluated,10163,O
(,10163,O
38,10163,O
men,10163,O
and,10163,O
33,10163,O
women,10163,O
aged,10163,O
63.9±10.2,10163,O
years,10163,O
),10163,O
.,10163,O
They,10164,O
were,10164,O
divided,10164,O
into,10164,O
three,10164,O
groups,10164,O
",",10164,O
which,10164,O
were,10164,O
45,10164,O
patients,10164,O
receiving,10164,O
premixed,10164,O
insulin,10164,B-GENE-Y
twice,10164,O
daily,10164,O
",",10164,O
15,10164,O
patients,10164,O
receiving,10164,O
multiple,10164,O
daily,10164,O
insulin,10164,B-GENE-Y
injections,10164,O
",",10164,O
and,10164,O
11,10164,O
patients,10164,O
receiving,10164,O
basal,10164,O
insulin,10164,B-GENE-Y
with,10164,O
oral,10164,O
antidiabetic,10164,O
drugs,10164,O
(,10164,O
basal,10164,O
insulin,10164,B-GENE-Y
therapy,10164,O
),10164,O
.,10164,O
Concomitant,10165,O
oral,10165,O
drugs,10165,O
included,10165,O
sulfonylureas,10165,B-CHEMICAL
",",10165,O
α-glucosidase,10165,B-GENE-N
inhibitors,10165,O
and,10165,O
metformin,10165,B-CHEMICAL
.,10165,O
The,10166,O
hemoglobin,10166,B-GENE-Y
A1c,10166,I-GENE-Y
(,10166,O
HbA1c,10166,B-GENE-Y
),10166,O
of,10166,O
all,10166,O
patients,10166,O
improved,10166,O
significantly,10166,O
from,10166,O
8.1±1.2,10166,O
%,10166,O
to,10166,O
7.6±1.1,10166,O
%,10166,O
after,10166,O
12,10166,O
weeks,10166,O
of,10166,O
add-on,10166,O
therapy,10166,O
with,10166,O
sitagliptin,10166,B-CHEMICAL
(,10166,O
p,10166,O
<,10166,O
0.01,10166,O
),10166,O
",",10166,O
and,10166,O
the,10166,O
insulin,10166,B-GENE-Y
dosage,10166,O
was,10166,O
reduced,10166,O
from,10166,O
27.3±15.8,10166,O
U/day,10166,O
to,10166,O
24.5±16.5,10166,O
U/day,10166,O
(,10166,O
p,10166,O
<,10166,O
0.001,10166,O
),10166,O
.,10166,O
Body,10167,O
weight,10167,O
did,10167,O
not,10167,O
change,10167,O
after,10167,O
the,10167,O
start,10167,O
of,10167,O
concomitant,10167,O
therapy,10167,O
and,10167,O
severe,10167,O
hypoglycemia,10167,O
was,10167,O
not,10167,O
observed,10167,O
.,10167,O
The,10168,O
baseline,10168,O
HbA1c,10168,B-GENE-Y
and,10168,O
glycated,10168,B-GENE-Y
albumin,10168,I-GENE-Y
levels,10168,O
were,10168,O
identified,10168,O
as,10168,O
factors,10168,O
that,10168,O
predicted,10168,O
the,10168,O
response,10168,O
to,10168,O
add-on,10168,O
therapy,10168,O
with,10168,O
sitagliptin,10168,B-CHEMICAL
.,10168,O
These,10169,O
findings,10169,O
suggest,10169,O
that,10169,O
add-on,10169,O
therapy,10169,O
with,10169,O
sitagliptin,10169,B-CHEMICAL
can,10169,O
be,10169,O
expected,10169,O
to,10169,O
achieve,10169,O
improvement,10169,O
of,10169,O
poor,10169,O
glycemic,10169,O
control,10169,O
irrespective,10169,O
of,10169,O
a,10169,O
patient,10169,O
's,10169,O
demographic,10169,O
profile,10169,O
.,10169,O
Stratified,10170,O
analysis,10170,O
based,10170,O
on,10170,O
the,10170,O
insulin,10170,B-GENE-Y
regimen,10170,O
revealed,10170,O
a,10170,O
stronger,10170,O
antidiabetic,10170,O
effect,10170,O
and,10170,O
a,10170,O
high,10170,O
efficacy,10170,O
of,10170,O
sitagliptin,10170,B-CHEMICAL
when,10170,O
it,10170,O
was,10170,O
added,10170,O
to,10170,O
basal,10170,O
insulin,10170,B-GENE-Y
therapy,10170,O
.,10170,O
The,10171,O
results,10171,O
of,10171,O
this,10171,O
investigation,10171,O
confirmed,10171,O
that,10171,O
add-on,10171,O
therapy,10171,O
with,10171,O
sitagliptin,10171,B-CHEMICAL
to,10171,O
various,10171,O
insulin,10171,B-GENE-Y
regimens,10171,O
could,10171,O
improve,10171,O
glycemic,10171,O
control,10171,O
without,10171,O
severe,10171,O
hypoglycemia,10171,O
and/or,10171,O
weight,10171,O
gain,10171,O
.,10171,O
Effect,10172,O
of,10172,O
blood-retinal,10172,O
barrier,10172,O
development,10172,O
on,10172,O
formation,10172,O
of,10172,O
selenite,10172,B-CHEMICAL
nuclear,10172,O
cataract,10172,O
in,10172,O
rat,10172,O
.,10172,O
Selenite,10173,B-CHEMICAL
cataract,10173,O
",",10173,O
as,10173,O
an,10173,O
experimental,10173,O
animal,10173,O
model,10173,O
of,10173,O
nuclear,10173,O
cataract,10173,O
to,10173,O
mimic,10173,O
human,10173,O
senile,10173,O
cataract,10173,O
",",10173,O
is,10173,O
produced,10173,O
only,10173,O
when,10173,O
overdose,10173,O
selenite,10173,B-CHEMICAL
is,10173,O
injected,10173,O
to,10173,O
neonatal,10173,O
rats,10173,O
before,10173,O
eyelid,10173,O
opening,10173,O
.,10173,O
To,10174,O
clarify,10174,O
the,10174,O
cause,10174,O
of,10174,O
age,10174,O
differences,10174,O
on,10174,O
selenite,10174,B-CHEMICAL
cataract,10174,O
formation,10174,O
in,10174,O
rats,10174,O
",",10174,O
mRNA,10174,O
expression,10174,O
of,10174,O
GPx1,10174,B-GENE-Y
",",10174,O
MsrA,10174,B-GENE-Y
and,10174,O
MsrB1,10174,B-GENE-Y
",",10174,O
as,10174,O
well,10174,O
as,10174,O
GPx,10174,B-GENE-N
activity,10174,O
in,10174,O
Wistar,10174,O
rat,10174,O
lens,10174,O
at,10174,O
different,10174,O
ages,10174,O
were,10174,O
assayed,10174,O
",",10174,O
level,10174,O
of,10174,O
lipid,10174,O
peroxidation,10174,O
",",10174,O
extent,10174,O
of,10174,O
lens,10174,O
damage,10174,O
induced,10174,O
by,10174,O
sodium,10174,B-CHEMICAL
selenite,10174,I-CHEMICAL
and,10174,O
barricade,10174,O
function,10174,O
of,10174,O
blood-retinal,10174,O
barrier,10174,O
(,10174,O
BRB,10174,O
),10174,O
were,10174,O
investigated,10174,O
.,10174,O
The,10175,O
results,10175,O
showed,10175,O
that,10175,O
mRNA,10175,O
expressions,10175,O
and,10175,O
activity,10175,O
of,10175,O
antioxidant,10175,O
enzymes,10175,O
in,10175,O
neonatal,10175,O
rat,10175,O
lens,10175,O
before,10175,O
eyelid,10175,O
opening,10175,O
were,10175,O
the,10175,O
highest,10175,O
and,10175,O
then,10175,O
decreased,10175,O
with,10175,O
age,10175,O
",",10175,O
and,10175,O
revealed,10175,O
by,10175,O
transmission,10175,O
electron,10175,O
microscopy,10175,O
(,10175,O
TEM,10175,O
),10175,O
using,10175,O
lanthanum,10175,B-CHEMICAL
hydroxide,10175,I-CHEMICAL
as,10175,O
tracer,10175,O
that,10175,O
higher,10175,O
selenite,10175,B-CHEMICAL
content,10175,O
entering,10175,O
eyes,10175,O
injured,10175,O
lens,10175,O
and,10175,O
resulted,10175,O
in,10175,O
cataract,10175,O
formation,10175,O
for,10175,O
immature,10175,O
BRB,10175,O
before,10175,O
eyelid,10175,O
opening,10175,O
",",10175,O
moreover,10175,O
",",10175,O
a,10175,O
little,10175,O
selenite,10175,B-CHEMICAL
content,10175,O
entering,10175,O
eyes,10175,O
was,10175,O
not,10175,O
enough,10175,O
to,10175,O
induce,10175,O
cataract,10175,O
formation,10175,O
after,10175,O
eyelid,10175,O
opening,10175,O
because,10175,O
of,10175,O
mature,10175,O
BRB,10175,O
.,10175,O
Lowering,10176,O
interleukin-1,10176,B-GENE-N
activity,10176,O
with,10176,O
anakinra,10176,O
improves,10176,O
myocardial,10176,O
deformation,10176,O
in,10176,O
rheumatoid,10176,O
arthritis,10176,O
.,10176,O
OBJECTIVE,10177,O
:,10177,O
Inhibition,10177,O
of,10177,O
interleukin-1,10177,B-GENE-N
activity,10177,O
improves,10177,O
nitro-oxidative,10177,B-CHEMICAL
stress,10177,O
",",10177,O
endothelial,10177,O
and,10177,O
coronary,10177,O
function,10177,O
.,10177,O
The,10178,O
authors,10178,O
investigated,10178,O
(,10178,O
a,10178,O
),10178,O
the,10178,O
association,10178,O
of,10178,O
nitro-oxidative,10178,B-CHEMICAL
stress,10178,O
and,10178,O
endothelial,10178,O
function,10178,O
with,10178,O
myocardial,10178,O
deformation,10178,O
",",10178,O
(,10178,O
b,10178,O
),10178,O
the,10178,O
effects,10178,O
of,10178,O
anakinra,10178,O
",",10178,O
an,10178,O
interleukin-1a,10178,B-GENE-Y
receptor,10178,I-GENE-Y
antagonist,10178,O
on,10178,O
myocardial,10178,O
deformation,10178,O
in,10178,O
patients,10178,O
with,10178,O
rheumatoid,10178,O
arthritis,10178,O
(,10178,O
RA,10178,O
),10178,O
.,10178,O
METHODS,10179,O
:,10179,O
The,10179,O
authors,10179,O
compared,10179,O
46,10179,O
RA,10179,O
patients,10179,O
to,10179,O
23,10179,O
normal,10179,O
controls,10179,O
.,10179,O
23,10180,O
patients,10180,O
received,10180,O
anakinra,10180,O
(,10180,O
150,10180,O
mg,10180,O
subcutaneously,10180,O
once,10180,O
daily,10180,O
),10180,O
and,10180,O
23,10180,O
patients,10180,O
a,10180,O
5-mg,10180,O
increase,10180,O
of,10180,O
prednisolone,10180,B-CHEMICAL
dose,10180,O
for,10180,O
30,10180,O
days,10180,O
.,10180,O
At,10181,O
baseline,10181,O
and,10181,O
post-treatment,10181,O
this,10181,O
study,10181,O
assessed,10181,O
(,10181,O
a,10181,O
),10181,O
the,10181,O
left,10181,O
ventricular,10181,O
(,10181,O
LV,10181,O
),10181,O
longitudinal,10181,O
",",10181,O
circumferential,10181,O
and,10181,O
radial,10181,O
strain,10181,O
and,10181,O
strain,10181,O
rate,10181,O
",",10181,O
using,10181,O
speckle,10181,O
tracking,10181,O
echocardiography,10181,O
",",10181,O
(,10181,O
b,10181,O
),10181,O
the,10181,O
coronary,10181,O
flow,10181,O
reserve,10181,O
(,10181,O
CFR,10181,O
),10181,O
",",10181,O
(,10181,O
c,10181,O
),10181,O
the,10181,O
flow-mediated,10181,O
endothelial-dependent,10181,O
dilation,10181,O
of,10181,O
the,10181,O
brachial,10181,O
artery,10181,O
(,10181,O
FMD,10181,O
),10181,O
and,10181,O
(,10181,O
d,10181,O
),10181,O
nitrotyrosine,10181,B-CHEMICAL
(,10181,O
NT,10181,B-CHEMICAL
),10181,O
and,10181,O
malondialdehyde,10181,B-CHEMICAL
blood,10181,O
levels,10181,O
.,10181,O
RESULTS,10182,O
:,10182,O
Patients,10182,O
had,10182,O
impaired,10182,O
baseline,10182,O
myocardial,10182,O
deformation,10182,O
indices,10182,O
compared,10182,O
to,10182,O
controls,10182,O
(,10182,O
p,10182,O
<,10182,O
0.05,10182,O
),10182,O
.,10182,O
CFR,10183,O
and,10183,O
NT,10183,B-CHEMICAL
levels,10183,O
were,10183,O
related,10183,O
to,10183,O
longitudinal,10183,O
strain,10183,O
",",10183,O
systolic,10183,O
and,10183,O
diastolic,10183,O
strain,10183,O
rate,10183,O
",",10183,O
circumferential,10183,O
strain,10183,O
and,10183,O
systolic,10183,O
strain,10183,O
rate,10183,O
(,10183,O
p,10183,O
<,10183,O
0.05,10183,O
),10183,O
.,10183,O
FMD,10184,O
was,10184,O
related,10184,O
to,10184,O
longitudinal,10184,O
and,10184,O
circumferential,10184,O
diastolic,10184,O
strain,10184,O
rate,10184,O
(,10184,O
p,10184,O
<,10184,O
0.01,10184,O
),10184,O
.,10184,O
Compared,10185,O
to,10185,O
baseline,10185,O
",",10185,O
anakinra-treated,10185,O
patients,10185,O
increased,10185,O
the,10185,O
longitudinal,10185,O
strain,10185,O
(,10185,O
-17.8,10185,O
%,10185,O
(,10185,O
3.7,10185,O
%,10185,O
),10185,O
vs,10185,O
-22.1,10185,O
%,10185,O
(,10185,O
3.5,10185,O
%,10185,O
),10185,O
),10185,O
",",10185,O
systolic,10185,O
(,10185,O
-1.02,10185,O
(,10185,O
0.23,10185,O
),10185,O
l/s,10185,O
vs,10185,O
-1.25,10185,O
(,10185,O
0.23,10185,O
),10185,O
l/s,10185,O
),10185,O
and,10185,O
diastolic,10185,O
(,10185,O
0.96,10185,O
(,10185,O
0.37,10185,O
),10185,O
l/s,10185,O
vs,10185,O
1.20,10185,O
(,10185,O
0.39,10185,O
),10185,O
l/s,10185,O
),10185,O
longitudinal,10185,O
strain,10185,O
rate,10185,O
",",10185,O
circumferential,10185,O
strain,10185,O
and,10185,O
strain,10185,O
rate,10185,O
(,10185,O
p,10185,O
<,10185,O
0.05,10185,O
for,10185,O
all,10185,O
comparisons,10185,O
),10185,O
.,10185,O
No,10186,O
significant,10186,O
changes,10186,O
were,10186,O
observed,10186,O
among,10186,O
prednisolone-treated,10186,B-CHEMICAL
patients,10186,O
CONCLUSIONS,10186,O
:,10186,O
Myocardial,10186,O
deformation,10186,O
is,10186,O
impaired,10186,O
in,10186,O
RA,10186,O
patients,10186,O
and,10186,O
is,10186,O
related,10186,O
to,10186,O
nitro-oxidative,10186,B-CHEMICAL
stress,10186,O
and,10186,O
endothelial,10186,O
dysfunction,10186,O
.,10186,O
Chronic,10187,O
inhibition,10187,O
of,10187,O
IL-1,10187,B-GENE-N
improves,10187,O
LV,10187,O
deformation,10187,O
in,10187,O
parallel,10187,O
with,10187,O
endothelial,10187,O
function,10187,O
and,10187,O
nitro-oxidative,10187,B-CHEMICAL
stress,10187,O
.,10187,O
A,10188,O
molecular,10188,O
mechanism,10188,O
of,10188,O
pyruvate,10188,B-CHEMICAL
protection,10188,O
against,10188,O
cytotoxicity,10188,O
of,10188,O
reactive,10188,O
oxygen,10188,B-CHEMICAL
species,10188,O
in,10188,O
osteoblasts,10188,O
.,10188,O
We,10189,O
demonstrated,10189,O
previously,10189,O
that,10189,O
exogenous,10189,O
pyruvate,10189,B-CHEMICAL
has,10189,O
a,10189,O
protective,10189,O
action,10189,O
against,10189,O
cell,10189,O
death,10189,O
by,10189,O
hydrogen,10189,B-CHEMICAL
peroxide,10189,I-CHEMICAL
in,10189,O
cultured,10189,O
osteoblasts,10189,O
through,10189,O
a,10189,O
mechanism,10189,O
associated,10189,O
with,10189,O
its,10189,O
antioxidative,10189,O
property,10189,O
.,10189,O
In,10190,O
the,10190,O
present,10190,O
study,10190,O
",",10190,O
we,10190,O
have,10190,O
evaluated,10190,O
possible,10190,O
participation,10190,O
of,10190,O
monocarboxylate,10190,B-GENE-N
transporters,10190,I-GENE-N
(,10190,O
MCTs,10190,B-GENE-N
),10190,O
responsible,10190,O
for,10190,O
the,10190,O
bidirectional,10190,O
membrane,10190,O
transport,10190,O
of,10190,O
pyruvate,10190,B-CHEMICAL
in,10190,O
the,10190,O
cytoprotective,10190,O
property,10190,O
in,10190,O
osteoblasts,10190,O
.,10190,O
Expression,10191,O
of,10191,O
the,10191,O
MCT2,10191,B-GENE-Y
isoform,10191,O
was,10191,O
found,10191,O
in,10191,O
cultured,10191,O
rat,10191,O
calvarial,10191,O
osteoblasts,10191,O
and,10191,O
in,10191,O
osteoblasts,10191,O
located,10191,O
on,10191,O
mouse,10191,O
tibia,10191,O
at,10191,O
both,10191,O
mRNA,10191,O
and,10191,O
protein,10191,O
levels,10191,O
.,10191,O
The,10192,O
accumulation,10192,O
of,10192,O
[,10192,B-CHEMICAL
14C,10192,I-CHEMICAL
],10192,I-CHEMICAL
pyruvate,10192,I-CHEMICAL
occurred,10192,O
in,10192,O
a,10192,O
temperature-,10192,O
and,10192,O
pH-dependent,10192,O
manner,10192,O
in,10192,O
osteoblasts,10192,O
cultured,10192,O
for,10192,O
7,10192,O
days,10192,O
with,10192,O
high,10192,O
sensitivity,10192,O
to,10192,O
a,10192,O
specific,10192,O
MCT,10192,B-GENE-N
inhibitor,10192,O
",",10192,O
whereas,10192,O
pyruvate,10192,B-CHEMICAL
was,10192,O
released,10192,O
into,10192,O
extracellular,10192,O
spaces,10192,O
from,10192,O
cultured,10192,O
osteoblasts,10192,O
in,10192,O
a,10192,O
fashion,10192,O
sensitive,10192,O
to,10192,O
the,10192,O
MCT,10192,B-GENE-N
inhibitor,10192,O
.,10192,O
Transient,10193,O
overexpression,10193,O
of,10193,O
the,10193,O
MCT2,10193,B-GENE-Y
isoform,10193,O
led,10193,O
to,10193,O
reduced,10193,O
vulnerability,10193,O
to,10193,O
the,10193,O
cytotoxicity,10193,O
of,10193,O
hydrogen,10193,B-CHEMICAL
peroxide,10193,I-CHEMICAL
with,10193,O
an,10193,O
increased,10193,O
activity,10193,O
of,10193,O
[,10193,B-CHEMICAL
14C,10193,I-CHEMICAL
],10193,I-CHEMICAL
pyruvate,10193,I-CHEMICAL
accumulation,10193,O
in,10193,O
murine,10193,O
osteoblastic,10193,O
MC3T3-E1,10193,O
cells,10193,O
.,10193,O
Ovariectomy,10194,O
significantly,10194,O
decreased,10194,O
the,10194,O
content,10194,O
of,10194,O
pyruvate,10194,B-CHEMICAL
in,10194,O
femoral,10194,O
bone,10194,O
marrows,10194,O
in,10194,O
mice,10194,O
in,10194,O
vivo,10194,O
",",10194,O
whereas,10194,O
daily,10194,O
i.p,10194,O
.,10194,O
administration,10195,O
of,10195,O
pyruvate,10195,B-CHEMICAL
at,10195,O
0.25,10195,O
g/kg,10195,O
significantly,10195,O
prevented,10195,O
alterations,10195,O
of,10195,O
several,10195,O
histomorphometric,10195,O
parameters,10195,O
as,10195,O
well,10195,O
as,10195,O
cancellous,10195,O
bone,10195,O
loss,10195,O
in,10195,O
femurs,10195,O
by,10195,O
ovariectomy,10195,O
on,10195,O
28,10195,O
days,10195,O
after,10195,O
the,10195,O
operation,10195,O
.,10195,O
These,10196,O
results,10196,O
suggest,10196,O
that,10196,O
MCTs,10196,B-GENE-N
may,10196,O
be,10196,O
functionally,10196,O
expressed,10196,O
by,10196,O
osteoblasts,10196,O
to,10196,O
play,10196,O
a,10196,O
pivotal,10196,O
role,10196,O
in,10196,O
mechanisms,10196,O
related,10196,O
to,10196,O
the,10196,O
cytoprotective,10196,O
property,10196,O
of,10196,O
pyruvate,10196,B-CHEMICAL
.,10196,O
Lower,10197,O
Adiponectin,10197,B-GENE-Y
Levels,10197,O
at,10197,O
First,10197,O
Trimester,10197,O
of,10197,O
Pregnancy,10197,O
Are,10197,O
Associated,10197,O
With,10197,O
Increased,10197,O
Insulin,10197,B-GENE-Y
Resistance,10197,O
and,10197,O
Higher,10197,O
Risk,10197,O
of,10197,O
Developing,10197,O
Gestational,10197,O
Diabetes,10197,O
Mellitus,10197,O
.,10197,O
OBJECTIVETo,10198,O
evaluate,10198,O
the,10198,O
associations,10198,O
between,10198,O
adiponectin,10198,B-GENE-Y
levels,10198,O
and,10198,O
1,10198,O
),10198,O
the,10198,O
risk,10198,O
of,10198,O
developing,10198,O
gestational,10198,O
diabetes,10198,O
mellitus,10198,O
(,10198,O
GDM,10198,O
),10198,O
",",10198,O
and,10198,O
2,10198,O
),10198,O
insulin,10198,B-GENE-Y
resistance/sensitivity,10198,O
",",10198,O
β-cell,10198,O
function,10198,O
",",10198,O
and,10198,O
compensation,10198,O
indices,10198,O
in,10198,O
a,10198,O
prospective,10198,O
cohort,10198,O
representative,10198,O
of,10198,O
the,10198,O
general,10198,O
population,10198,O
of,10198,O
pregnant,10198,O
women.RESEARCH,10198,O
DESIGN,10198,O
AND,10198,O
METHODSWe,10198,O
performed,10198,O
anthropometric,10198,O
measurements,10198,O
and,10198,O
collected,10198,O
blood,10198,O
samples,10198,O
at,10198,O
1st,10198,O
(,10198,O
6-13,10198,O
weeks,10198,O
),10198,O
and,10198,O
2nd,10198,O
(,10198,O
24-28,10198,O
weeks,10198,O
),10198,O
trimesters,10198,O
.,10198,O
Diagnosis,10199,O
of,10199,O
GDM,10199,O
was,10199,O
made,10199,O
at,10199,O
2nd,10199,O
trimester,10199,O
",",10199,O
based,10199,O
on,10199,O
a,10199,O
75-g,10199,O
oral,10199,O
glucose,10199,B-CHEMICAL
tolerance,10199,O
test,10199,O
(,10199,O
International,10199,O
Association,10199,O
of,10199,O
Diabetes,10199,O
and,10199,O
Pregnancy,10199,O
Study,10199,O
Group,10199,O
criteria,10199,O
),10199,O
.,10199,O
Insulin,10200,B-GENE-Y
was,10200,O
measured,10200,O
(,10200,O
ELISA,10200,O
;,10200,O
Luminex,10200,O
),10200,O
to,10200,O
estimate,10200,O
homeostasis,10200,O
model,10200,O
assessment,10200,O
of,10200,O
insulin,10200,B-GENE-Y
resistance,10200,O
(,10200,O
HOMA-IR,10200,O
),10200,O
",",10200,O
β-cell,10200,O
function,10200,O
(,10200,O
HOMA-B,10200,O
),10200,O
",",10200,O
insulin,10200,B-GENE-Y
sensitivity,10200,O
(,10200,O
Matsuda,10200,O
index,10200,O
),10200,O
",",10200,O
insulin,10200,B-GENE-Y
secretion,10200,O
(,10200,O
AUC,10200,O
(,10200,O
insulin/glucose,10200,B-GENE-Y
),10200,O
),10200,O
",",10200,O
and,10200,O
β-cell,10200,O
compensation,10200,O
(,10200,O
insulin,10200,B-GENE-Y
secretion,10200,O
sensitivity,10200,O
index-2,10200,O
),10200,O
.,10200,O
Adiponectin,10201,B-GENE-Y
was,10201,O
measured,10201,O
by,10201,O
radioimmunoassay.RESULTSAmong,10201,O
the,10201,O
445,10201,O
participants,10201,O
included,10201,O
in,10201,O
this,10201,O
study,10201,O
",",10201,O
38,10201,O
women,10201,O
developed,10201,O
GDM,10201,O
.,10201,O
Women,10202,O
who,10202,O
developed,10202,O
GDM,10202,O
had,10202,O
lower,10202,O
1st-trimester,10202,O
adiponectin,10202,B-GENE-Y
levels,10202,O
(,10202,O
9.67,10202,O
±,10202,O
3.84,10202,O
vs.,10202,O
11.92,10202,O
±,10202,O
4.59,10202,O
µg/mL,10202,O
in,10202,O
women,10202,O
with,10202,O
normal,10202,O
glucose,10202,B-CHEMICAL
tolerance,10202,O
),10202,O
.,10202,O
Lower,10203,O
adiponectin,10203,B-GENE-Y
levels,10203,O
were,10203,O
associated,10203,O
with,10203,O
higher,10203,O
risk,10203,O
of,10203,O
developing,10203,O
GDM,10203,O
(,10203,O
OR,10203,O
",",10203,O
1.12,10203,O
per,10203,O
1,10203,O
µg/mL,10203,O
decrease,10203,O
of,10203,O
adiponectin,10203,B-GENE-Y
levels,10203,O
;,10203,O
P,10203,O
=,10203,O
0.02,10203,O
",",10203,O
adjusted,10203,O
for,10203,O
BMI,10203,O
and,10203,O
HbA,10203,O
(,10203,O
1c,10203,O
),10203,O
at,10203,O
1st,10203,O
trimester,10203,O
),10203,O
.,10203,O
Adiponectin,10204,B-GENE-Y
levels,10204,O
at,10204,O
1st,10204,O
and,10204,O
2nd,10204,O
trimesters,10204,O
were,10204,O
associated,10204,O
with,10204,O
HOMA-IR,10204,O
(,10204,O
both,10204,O
:,10204,O
r,10204,O
=,10204,O
-0.22,10204,O
",",10204,O
P,10204,O
<,10204,O
0.0001,10204,O
),10204,O
and,10204,O
Matsuda,10204,O
index,10204,O
(,10204,O
r,10204,O
=,10204,O
0.28,10204,O
",",10204,O
P,10204,O
<,10204,O
0.0001,10204,O
",",10204,O
and,10204,O
r,10204,O
=,10204,O
0.29,10204,O
",",10204,O
P,10204,O
<,10204,O
0.0001,10204,O
),10204,O
.,10204,O
After,10205,O
adjustment,10205,O
for,10205,O
confounding,10205,O
factors,10205,O
",",10205,O
we,10205,O
found,10205,O
no,10205,O
significant,10205,O
association,10205,O
with,10205,O
HOMA-B,10205,O
and,10205,O
AUC,10205,O
(,10205,O
insulin/glucose,10205,B-GENE-Y
),10205,O
.CONCLUSIONSPregnant,10205,O
women,10205,O
with,10205,O
lower,10205,O
adiponectin,10205,B-GENE-Y
levels,10205,O
at,10205,O
1st,10205,O
trimester,10205,O
have,10205,O
higher,10205,O
levels,10205,O
of,10205,O
insulin,10205,B-GENE-Y
resistance,10205,O
and,10205,O
are,10205,O
more,10205,O
likely,10205,O
to,10205,O
develop,10205,O
GDM,10205,O
independently,10205,O
of,10205,O
adiposity,10205,O
or,10205,O
glycemic,10205,O
measurements,10205,O
.,10205,O
Reduced,10206,O
plasma,10206,O
oxytocin,10206,B-GENE-Y
levels,10206,O
in,10206,O
female,10206,O
patients,10206,O
with,10206,O
borderline,10206,O
personality,10206,O
disorder,10206,O
.,10206,O
The,10207,O
neuropeptide,10207,O
oxytocin,10207,B-GENE-Y
is,10207,O
involved,10207,O
in,10207,O
social,10207,O
cognition,10207,O
and,10207,O
interaction,10207,O
across,10207,O
species,10207,O
and,10207,O
plays,10207,O
a,10207,O
crucial,10207,O
role,10207,O
in,10207,O
the,10207,O
regulation,10207,O
of,10207,O
affiliative,10207,O
behaviors,10207,O
.,10207,O
Oxytocin,10208,B-GENE-Y
levels,10208,O
in,10208,O
cerebrospinal,10208,O
fluid,10208,O
(,10208,O
CSF,10208,O
),10208,O
",",10208,O
but,10208,O
also,10208,O
in,10208,O
plasma,10208,O
or,10208,O
urine,10208,O
",",10208,O
have,10208,O
been,10208,O
shown,10208,O
to,10208,O
be,10208,O
negatively,10208,O
associated,10208,O
with,10208,O
childhood,10208,O
traumata,10208,O
",",10208,O
aggressive,10208,O
behavior,10208,O
",",10208,O
and,10208,O
suicide,10208,O
attempts,10208,O
.,10208,O
Recently,10209,O
",",10209,O
an,10209,O
altered,10209,O
activity,10209,O
of,10209,O
the,10209,O
oxytocin,10209,B-GENE-Y
system,10209,O
has,10209,O
been,10209,O
discussed,10209,O
to,10209,O
play,10209,O
a,10209,O
prominent,10209,O
role,10209,O
in,10209,O
borderline,10209,O
personality,10209,O
disorder,10209,O
(,10209,O
BPD,10209,O
),10209,O
",",10209,O
which,10209,O
is,10209,O
thought,10209,O
to,10209,O
be,10209,O
closely,10209,O
related,10209,O
to,10209,O
traumatic,10209,O
experiences,10209,O
in,10209,O
childhood,10209,O
and,10209,O
is,10209,O
characterized,10209,O
by,10209,O
(,10209,O
para,10209,O
),10209,O
suicidal,10209,O
behaviors,10209,O
as,10209,O
well,10209,O
as,10209,O
aggressive,10209,O
outbursts,10209,O
.,10209,O
In,10210,O
the,10210,O
present,10210,O
study,10210,O
",",10210,O
we,10210,O
compared,10210,O
plasma,10210,O
oxytocin,10210,B-GENE-Y
levels,10210,O
of,10210,O
women,10210,O
with,10210,O
and,10210,O
without,10210,O
BPD,10210,O
in,10210,O
the,10210,O
follicular,10210,O
phase,10210,O
and,10210,O
assessed,10210,O
the,10210,O
relationship,10210,O
between,10210,O
oxytocin,10210,B-GENE-Y
concentrations,10210,O
and,10210,O
childhood,10210,O
traumata,10210,O
.,10210,O
Women,10211,O
diagnosed,10211,O
with,10211,O
BPD,10211,O
had,10211,O
significantly,10211,O
reduced,10211,O
oxytocin,10211,B-GENE-Y
concentrations,10211,O
",",10211,O
even,10211,O
after,10211,O
controlling,10211,O
for,10211,O
estrogen,10211,B-CHEMICAL
",",10211,O
progesterone,10211,B-CHEMICAL
",",10211,O
and,10211,O
contraceptive,10211,O
intake,10211,O
.,10211,O
In,10212,O
addition,10212,O
",",10212,O
plasma,10212,O
oxytocin,10212,B-GENE-Y
correlated,10212,O
negatively,10212,O
with,10212,O
experiences,10212,O
of,10212,O
childhood,10212,O
traumata,10212,O
",",10212,O
in,10212,O
particular,10212,O
with,10212,O
emotional,10212,O
neglect,10212,O
and,10212,O
abuse,10212,O
.,10212,O
The,10213,O
results,10213,O
of,10213,O
mediation,10213,O
analyses,10213,O
do,10213,O
not,10213,O
support,10213,O
a,10213,O
model,10213,O
of,10213,O
oxytocin,10213,B-GENE-Y
being,10213,O
a,10213,O
prominent,10213,O
mediator,10213,O
in,10213,O
the,10213,O
link,10213,O
between,10213,O
childhood,10213,O
trauma,10213,O
and,10213,O
BPD,10213,O
.,10213,O
Thus,10214,O
",",10214,O
the,10214,O
findings,10214,O
indicate,10214,O
dysregulations,10214,O
in,10214,O
the,10214,O
oxytocin,10214,B-GENE-Y
system,10214,O
of,10214,O
patients,10214,O
diagnosed,10214,O
with,10214,O
BPD,10214,O
with,10214,O
more,10214,O
longitudinal,10214,O
research,10214,O
being,10214,O
necessary,10214,O
to,10214,O
disentangle,10214,O
the,10214,O
relationship,10214,O
between,10214,O
childhood,10214,O
adversities,10214,O
",",10214,O
oxytocin,10214,B-GENE-Y
system,10214,O
",",10214,O
and,10214,O
psychopathology,10214,O
.,10214,O
Interferon-gamma,10215,B-GENE-Y
is,10215,O
causatively,10215,O
involved,10215,O
in,10215,O
experimental,10215,O
inflammatory,10215,O
bowel,10215,O
disease,10215,O
in,10215,O
mice,10215,O
.,10215,O
Cytokines,10216,B-GENE-N
may,10216,O
be,10216,O
crucially,10216,O
involved,10216,O
in,10216,O
the,10216,O
pathogenesis,10216,O
of,10216,O
inflammatory,10216,O
bowel,10216,O
diseases,10216,O
(,10216,O
IBD,10216,O
),10216,O
",",10216,O
but,10216,O
it,10216,O
remains,10216,O
controversial,10216,O
whether,10216,O
interferon,10216,B-GENE-Y
(,10216,I-GENE-Y
IFN,10216,I-GENE-Y
),10216,I-GENE-Y
-gamma,10216,I-GENE-Y
",",10216,O
a,10216,O
typical,10216,O
proinflammatory,10216,O
cytokine,10216,B-GENE-N
",",10216,O
is,10216,O
an,10216,O
essential,10216,O
mediator,10216,O
to,10216,O
cause,10216,O
the,10216,O
disorders,10216,O
.,10216,O
In,10217,O
the,10217,O
present,10217,O
study,10217,O
",",10217,O
IFN-gamma,10217,B-GENE-Y
(,10217,O
-/-,10217,O
),10217,O
and,10217,O
wild-type,10217,O
(,10217,O
WT,10217,O
),10217,O
C57BL/6,10217,O
mice,10217,O
were,10217,O
fed,10217,O
2.5,10217,O
%,10217,O
dextran,10217,O
sodium,10217,O
sulphate,10217,O
(,10217,O
DSS,10217,O
),10217,O
in,10217,O
drinking,10217,O
water,10217,O
for,10217,O
7,10217,O
days,10217,O
",",10217,O
in,10217,O
order,10217,O
to,10217,O
investigate,10217,O
DSS-induced,10217,O
intestinal,10217,O
inflammation,10217,O
.,10217,O
The,10218,O
DSS-treated,10218,O
WT,10218,O
mice,10218,O
exhibited,10218,O
a,10218,O
robust,10218,O
production,10218,O
of,10218,O
IFN-gamma,10218,B-GENE-Y
in,10218,O
the,10218,O
gut,10218,O
",",10218,O
a,10218,O
remarkable,10218,O
loss,10218,O
of,10218,O
body,10218,O
weight,10218,O
",",10218,O
as,10218,O
well,10218,O
as,10218,O
high,10218,O
rate,10218,O
of,10218,O
mortality,10218,O
(,10218,O
60,10218,O
%,10218,O
),10218,O
.,10218,O
In,10219,O
striking,10219,O
contrast,10219,O
",",10219,O
IFN-gamma,10219,B-GENE-Y
deficient,10219,O
mice,10219,O
did,10219,O
not,10219,O
develop,10219,O
DSS-induced,10219,O
colitis,10219,O
",",10219,O
as,10219,O
indicated,10219,O
by,10219,O
the,10219,O
maintenance,10219,O
of,10219,O
body,10219,O
weight,10219,O
and,10219,O
survival,10219,O
rate,10219,O
of,10219,O
100,10219,O
%,10219,O
.,10219,O
Severe,10220,O
intestinal,10220,O
inflammation,10220,O
was,10220,O
demonstrated,10220,O
exclusively,10220,O
in,10220,O
WT,10220,O
animals,10220,O
in,10220,O
terms,10220,O
of,10220,O
the,10220,O
shortening,10220,O
of,10220,O
the,10220,O
bowel,10220,O
as,10220,O
well,10220,O
as,10220,O
the,10220,O
elevation,10220,O
of,10220,O
the,10220,O
disease,10220,O
activity,10220,O
index,10220,O
",",10220,O
myeloperoxidase,10220,B-GENE-Y
(,10220,O
MPO,10220,B-GENE-Y
),10220,O
activity,10220,O
and,10220,O
serum,10220,B-GENE-Y
haptoglobin,10220,I-GENE-Y
level,10220,O
.,10220,O
Histological,10221,O
study,10221,O
of,10221,O
DSS-treated,10221,O
WT,10221,O
intestine,10221,O
revealed,10221,O
disruption,10221,O
of,10221,O
mucosal,10221,O
epithelium,10221,O
and,10221,O
massive,10221,O
infiltration,10221,O
of,10221,O
inflammatory,10221,O
cells,10221,O
",",10221,O
while,10221,O
the,10221,O
organ,10221,O
from,10221,O
IFN-gamma,10221,B-GENE-Y
(,10221,O
-/-,10221,O
),10221,O
mice,10221,O
remained,10221,O
virtually,10221,O
normal,10221,O
in,10221,O
appearance,10221,O
.,10221,O
Enzyme-linked,10222,O
immunosorbent,10222,O
assay,10222,O
(,10222,O
ELISA,10222,O
),10222,O
analyses,10222,O
indicated,10222,O
abundant,10222,O
production,10222,O
of,10222,O
three,10222,O
chemokines,10222,B-GENE-N
",",10222,O
i.e,10222,O
.,10222,O
monokine,10223,B-GENE-Y
induced,10223,I-GENE-Y
by,10223,I-GENE-Y
interferon-gamma,10223,I-GENE-Y
(,10223,O
MIG,10223,B-GENE-Y
),10223,O
",",10223,O
interferon-inducible,10223,B-GENE-Y
protein,10223,I-GENE-Y
10,10223,I-GENE-Y
(,10223,O
IP-10,10223,B-GENE-Y
),10223,O
and,10223,O
monocyte,10223,B-GENE-Y
chemoattractant,10223,I-GENE-Y
protein-1,10223,I-GENE-Y
(,10223,O
MCP-1,10223,B-GENE-Y
),10223,O
",",10223,O
in,10223,O
the,10223,O
DSS-irritated,10223,O
intestine,10223,O
of,10223,O
WT,10223,O
but,10223,O
not,10223,O
of,10223,O
IFN-gamma,10223,B-GENE-Y
(,10223,O
-/-,10223,O
),10223,O
mice,10223,O
.,10223,O
The,10224,O
present,10224,O
results,10224,O
demonstrate,10224,O
clearly,10224,O
that,10224,O
IFN-gamma,10224,B-GENE-Y
plays,10224,O
indispensable,10224,O
roles,10224,O
in,10224,O
the,10224,O
initiation,10224,O
of,10224,O
DSS,10224,O
colitis,10224,O
",",10224,O
and,10224,O
some,10224,O
chemokines,10224,B-GENE-N
are,10224,O
produced,10224,O
in,10224,O
an,10224,O
IFN-gamma-dependent,10224,B-GENE-Y
fashion,10224,O
.,10224,O
Formoterol,10225,B-CHEMICAL
in,10225,O
the,10225,O
management,10225,O
of,10225,O
chronic,10225,O
obstructive,10225,O
pulmonary,10225,O
disease,10225,O
.,10225,O
Bronchodilators,10226,O
represent,10226,O
the,10226,O
hallmark,10226,O
of,10226,O
symptomatic,10226,O
treatment,10226,O
of,10226,O
Chronic,10226,O
Obstructive,10226,O
Pulmonary,10226,O
Disease,10226,O
(,10226,O
COPD,10226,O
),10226,O
.,10226,O
There,10227,O
are,10227,O
four,10227,O
categories,10227,O
of,10227,O
bronchodilators,10227,O
:,10227,O
anticholinergics,10227,O
",",10227,O
methylxanthines,10227,B-CHEMICAL
",",10227,O
short-acting,10227,O
beta2-agonists,10227,O
",",10227,O
and,10227,O
long-acting,10227,O
beta2-agonists,10227,O
such,10227,O
as,10227,O
formoterol,10227,B-CHEMICAL
.,10227,O
Significant,10228,O
research,10228,O
has,10228,O
been,10228,O
performed,10228,O
to,10228,O
investigate,10228,O
the,10228,O
efficacy,10228,O
",",10228,O
safety,10228,O
and,10228,O
tolerability,10228,O
of,10228,O
formoterol,10228,B-CHEMICAL
in,10228,O
the,10228,O
therapeutic,10228,O
field,10228,O
of,10228,O
COPD,10228,O
.,10228,O
Formoterol,10229,B-CHEMICAL
exhibits,10229,O
a,10229,O
rapid,10229,O
onset,10229,O
of,10229,O
bronchodilation,10229,O
similar,10229,O
to,10229,O
that,10229,O
observed,10229,O
with,10229,O
salbutamol,10229,B-CHEMICAL
",",10229,O
yet,10229,O
its,10229,O
long,10229,O
bronchodilatory,10229,O
duration,10229,O
is,10229,O
comparable,10229,O
to,10229,O
salmeterol,10229,B-CHEMICAL
.,10229,O
In,10230,O
addition,10230,O
",",10230,O
formoterol,10230,B-CHEMICAL
presents,10230,O
with,10230,O
a,10230,O
clear,10230,O
superiority,10230,O
in,10230,O
lung,10230,O
function,10230,O
improvement,10230,O
compared,10230,O
with,10230,O
either,10230,O
ipratropium,10230,B-CHEMICAL
bromide,10230,I-CHEMICAL
or,10230,O
oral,10230,O
theophylline,10230,B-CHEMICAL
",",10230,O
while,10230,O
its,10230,O
efficacy,10230,O
improves,10230,O
when,10230,O
administered,10230,O
in,10230,O
combination,10230,O
with,10230,O
ipratropium,10230,B-CHEMICAL
.,10230,O
Formoterol,10231,B-CHEMICAL
has,10231,O
been,10231,O
shown,10231,O
to,10231,O
better,10231,O
reduce,10231,O
dynamic,10231,O
hyperinflation,10231,O
",",10231,O
which,10231,O
is,10231,O
responsible,10231,O
for,10231,O
exercise,10231,O
intolerance,10231,O
and,10231,O
dyspnea,10231,O
in,10231,O
COPD,10231,O
patients,10231,O
",",10231,O
compared,10231,O
with,10231,O
other,10231,O
bronchodilators,10231,O
",",10231,O
whereas,10231,O
it,10231,O
exerts,10231,O
synergistic,10231,O
effect,10231,O
with,10231,O
tiotropium,10231,O
.,10231,O
Moreover,10232,O
",",10232,O
formoterol,10232,B-CHEMICAL
reduces,10232,O
exacerbations,10232,O
",",10232,O
increases,10232,O
days,10232,O
free,10232,O
of,10232,O
use,10232,O
of,10232,O
rescue,10232,O
medication,10232,O
and,10232,O
improves,10232,O
patients,10232,O
',10232,O
quality,10232,O
of,10232,O
life,10232,O
and,10232,O
disease,10232,O
symptoms,10232,O
.,10232,O
Formoterol,10233,B-CHEMICAL
has,10233,O
a,10233,O
favorable,10233,O
safety,10233,O
profile,10233,O
and,10233,O
is,10233,O
better,10233,O
tolerated,10233,O
than,10233,O
theophylline,10233,B-CHEMICAL
.,10233,O
Collectively,10234,O
",",10234,O
data,10234,O
extracted,10234,O
from,10234,O
multicenter,10234,O
clinical,10234,O
trials,10234,O
support,10234,O
formoterol,10234,B-CHEMICAL
as,10234,O
a,10234,O
valid,10234,O
therapeutic,10234,O
option,10234,O
in,10234,O
the,10234,O
treatment,10234,O
of,10234,O
COPD,10234,O
.,10234,O
Comparative,10235,O
genomics,10235,O
",",10235,O
molecular,10235,O
evolution,10235,O
and,10235,O
computational,10235,O
modeling,10235,O
of,10235,O
ALDH1B1,10235,B-GENE-Y
and,10235,O
ALDH2,10235,B-GENE-Y
.,10235,O
Vertebrate,10236,B-GENE-Y
ALDH2,10236,I-GENE-Y
genes,10236,O
encode,10236,O
mitochondrial,10236,O
enzymes,10236,O
capable,10236,O
of,10236,O
metabolizing,10236,O
acetaldehyde,10236,B-CHEMICAL
and,10236,O
other,10236,O
biological,10236,O
aldehydes,10236,B-CHEMICAL
in,10236,O
the,10236,O
body,10236,O
.,10236,O
Mammalian,10237,B-GENE-Y
ALDH1B1,10237,I-GENE-Y
",",10237,O
another,10237,O
mitochondrial,10237,O
enzyme,10237,O
sharing,10237,O
72,10237,O
%,10237,O
identity,10237,O
with,10237,O
ALDH2,10237,B-GENE-Y
",",10237,O
is,10237,O
also,10237,O
capable,10237,O
of,10237,O
metabolizing,10237,O
acetaldehyde,10237,B-CHEMICAL
but,10237,O
has,10237,O
a,10237,O
tissue,10237,O
distribution,10237,O
and,10237,O
pattern,10237,O
of,10237,O
activity,10237,O
distinct,10237,O
from,10237,O
that,10237,O
of,10237,O
ALDH2,10237,B-GENE-Y
.,10237,O
Bioinformatic,10238,O
analyses,10238,O
of,10238,O
several,10238,O
vertebrate,10238,O
genomes,10238,O
were,10238,O
undertaken,10238,O
using,10238,O
known,10238,O
ALDH2,10238,B-GENE-Y
and,10238,O
ALDH1B1,10238,B-GENE-Y
amino,10238,B-CHEMICAL
acid,10238,I-CHEMICAL
sequences,10238,O
.,10238,O
Phylogenetic,10239,O
analysis,10239,O
of,10239,O
many,10239,O
representative,10239,O
vertebrate,10239,O
species,10239,O
(,10239,O
including,10239,O
fish,10239,O
",",10239,O
amphibians,10239,O
",",10239,O
birds,10239,O
and,10239,O
mammals,10239,O
),10239,O
indicated,10239,O
the,10239,O
presence,10239,O
of,10239,O
ALDH1B1,10239,B-GENE-Y
in,10239,O
many,10239,O
mammalian,10239,O
species,10239,O
and,10239,O
in,10239,O
frogs,10239,O
(,10239,O
Xenopus,10239,O
tropicalis,10239,O
),10239,O
;,10239,O
no,10239,O
evidence,10239,O
was,10239,O
found,10239,O
for,10239,O
ALDH1B1,10239,B-GENE-Y
in,10239,O
the,10239,O
genomes,10239,O
of,10239,O
birds,10239,O
",",10239,O
reptiles,10239,O
or,10239,O
fish,10239,O
.,10239,O
Predicted,10240,O
vertebrate,10240,B-GENE-Y
ALDH2,10240,I-GENE-Y
and,10240,O
ALDH1B1,10240,B-GENE-Y
subunit,10240,O
sequences,10240,O
and,10240,O
structures,10240,O
were,10240,O
highly,10240,O
conserved,10240,O
",",10240,O
including,10240,O
residues,10240,O
previously,10240,O
shown,10240,O
to,10240,O
be,10240,O
involved,10240,O
in,10240,O
catalysis,10240,O
and,10240,O
coenzyme,10240,O
binding,10240,O
for,10240,O
human,10240,B-GENE-Y
ALDH2,10240,I-GENE-Y
.,10240,O
Studies,10241,O
of,10241,O
ALDH1B1,10241,B-GENE-Y
sequences,10241,O
supported,10241,O
the,10241,O
hypothesis,10241,O
that,10241,O
the,10241,O
ALDH1B1,10241,B-GENE-N
gene,10241,O
originated,10241,O
in,10241,O
early,10241,O
vertebrates,10241,O
from,10241,O
a,10241,O
retrotransposition,10241,O
of,10241,O
the,10241,O
vertebrate,10241,O
ALDH2,10241,B-GENE-Y
gene,10241,O
.,10241,O
Given,10242,O
the,10242,O
high,10242,O
degree,10242,O
of,10242,O
similarity,10242,O
between,10242,O
ALDH2,10242,B-GENE-Y
and,10242,O
ALDH1B1,10242,B-GENE-Y
",",10242,O
it,10242,O
is,10242,O
surprising,10242,O
that,10242,O
individuals,10242,O
with,10242,O
an,10242,O
inactivating,10242,O
mutation,10242,O
in,10242,O
ALDH2,10242,B-GENE-Y
(,10242,O
ALDH2,10242,B-GENE-Y
*,10242,O
2,10242,O
),10242,O
do,10242,O
not,10242,O
exhibit,10242,O
a,10242,O
compensatory,10242,O
increase,10242,O
in,10242,O
ALDH1B1,10242,B-GENE-Y
activity,10242,O
.,10242,O
We,10243,O
hypothesized,10243,O
that,10243,O
the,10243,O
similarity,10243,O
between,10243,O
the,10243,O
two,10243,O
ALDHs,10243,B-GENE-N
would,10243,O
allow,10243,O
for,10243,O
dominant,10243,O
negative,10243,O
heterotetramerization,10243,O
between,10243,O
the,10243,O
inactive,10243,O
ALDH2,10243,B-GENE-Y
mutants,10243,O
and,10243,O
ALDH1B1,10243,B-GENE-Y
.,10243,O
Computational-based,10244,O
molecular,10244,O
modeling,10244,O
studies,10244,O
examining,10244,O
predicted,10244,O
protein-protein,10244,O
interactions,10244,O
indicated,10244,O
that,10244,O
heterotetramerization,10244,O
between,10244,O
ALDH2,10244,B-GENE-Y
and,10244,O
ALDH1B1,10244,B-GENE-Y
subunits,10244,O
was,10244,O
highly,10244,O
probable,10244,O
and,10244,O
may,10244,O
partially,10244,O
explain,10244,O
a,10244,O
lack,10244,O
of,10244,O
compensation,10244,O
by,10244,O
ALDH1B1,10244,B-GENE-Y
in,10244,O
ALDH2,10244,B-GENE-Y
(,10244,O
∗,10244,O
),10244,O
2,10244,O
individuals,10244,O
.,10244,O
Influence,10245,O
of,10245,O
chain,10245,O
length,10245,O
and,10245,O
double,10245,O
bond,10245,O
on,10245,O
the,10245,O
aqueous,10245,O
behavior,10245,O
of,10245,O
choline,10245,B-CHEMICAL
carboxylate,10245,I-CHEMICAL
soaps,10245,O
.,10245,O
In,10246,O
preceding,10246,O
studies,10246,O
",",10246,O
we,10246,O
demonstrated,10246,O
that,10246,O
choline,10246,B-CHEMICAL
carboxylates,10246,I-CHEMICAL
ChC,10246,B-CHEMICAL
(,10246,I-CHEMICAL
m,10246,I-CHEMICAL
),10246,I-CHEMICAL
with,10246,O
alkyl,10246,B-CHEMICAL
chain,10246,O
lengths,10246,O
of,10246,O
m,10246,O
=,10246,O
12,10246,O
-,10246,O
18,10246,O
are,10246,O
highly,10246,O
water-soluble,10246,O
(,10246,O
for,10246,O
m,10246,O
=,10246,O
12,10246,O
",",10246,O
soluble,10246,O
up,10246,O
to,10246,O
93,10246,O
wt,10246,O
%,10246,O
soap,10246,O
and,10246,O
0,10246,O
°C,10246,O
),10246,O
.,10246,O
In,10247,O
addition,10247,O
",",10247,O
choline,10247,B-CHEMICAL
soaps,10247,O
are,10247,O
featured,10247,O
by,10247,O
an,10247,O
extraordinary,10247,O
lyotropic,10247,O
phase,10247,O
behavior,10247,O
.,10247,O
With,10248,O
decreasing,10248,O
water,10248,O
concentration,10248,O
",",10248,O
the,10248,O
following,10248,O
phases,10248,O
were,10248,O
found,10248,O
:,10248,O
micellar,10248,O
phase,10248,O
(,10248,O
L,10248,O
(,10248,O
1,10248,O
),10248,O
),10248,O
",",10248,O
discontinuous,10248,O
cubic,10248,O
phase,10248,O
(,10248,O
I,10248,O
(,10248,O
1,10248,O
),10248,O
',10248,O
and,10248,O
I,10248,O
(,10248,O
1,10248,O
),10248,O
'',10248,O
),10248,O
",",10248,O
hexagonal,10248,O
phase,10248,O
(,10248,O
H,10248,O
(,10248,O
1,10248,O
),10248,O
),10248,O
",",10248,O
bicontinuous,10248,O
cubic,10248,O
phase,10248,O
(,10248,O
V,10248,O
(,10248,O
1,10248,O
),10248,O
),10248,O
",",10248,O
and,10248,O
lamellar,10248,O
phase,10248,O
(,10248,O
L,10248,O
(,10248,O
α,10248,O
),10248,O
),10248,O
.,10248,O
The,10249,O
present,10249,O
work,10249,O
is,10249,O
also,10249,O
focused,10249,O
on,10249,O
the,10249,O
lyotropic,10249,O
phase,10249,O
behavior,10249,O
of,10249,O
choline,10249,B-CHEMICAL
soaps,10249,O
but,10249,O
with,10249,O
shorter,10249,O
alkyl,10249,B-CHEMICAL
chains,10249,O
or,10249,O
different,10249,O
alkyl,10249,B-CHEMICAL
chain,10249,O
properties,10249,O
.,10249,O
We,10250,O
have,10250,O
investigated,10250,O
the,10250,O
aqueous,10250,O
phase,10250,O
behavior,10250,O
of,10250,O
choline,10250,B-CHEMICAL
soaps,10250,O
with,10250,O
C,10250,B-CHEMICAL
(,10250,I-CHEMICAL
8,10250,I-CHEMICAL
),10250,I-CHEMICAL
and,10250,O
C,10250,B-CHEMICAL
(,10250,I-CHEMICAL
10,10250,I-CHEMICAL
),10250,I-CHEMICAL
chain-lengths,10250,O
(,10250,O
choline,10250,B-CHEMICAL
octanoate,10250,I-CHEMICAL
and,10250,O
choline,10250,B-CHEMICAL
decanoate,10250,I-CHEMICAL
),10250,O
and,10250,O
with,10250,O
a,10250,O
C,10250,B-CHEMICAL
(,10250,I-CHEMICAL
18,10250,I-CHEMICAL
),10250,I-CHEMICAL
chain-length,10250,O
with,10250,O
a,10250,O
cis-double,10250,O
bond,10250,O
(,10250,O
choline,10250,B-CHEMICAL
oleate,10250,I-CHEMICAL
),10250,O
.,10250,O
We,10251,O
found,10251,O
that,10251,O
choline,10251,B-CHEMICAL
decanoate,10251,I-CHEMICAL
follows,10251,O
the,10251,O
lyotropic,10251,O
phase,10251,O
behavior,10251,O
of,10251,O
the,10251,O
longer-chain,10251,O
homologues,10251,O
mentioned,10251,O
above,10251,O
.,10251,O
Choline,10252,B-CHEMICAL
octanoate,10252,I-CHEMICAL
in,10252,O
water,10252,O
shows,10252,O
no,10252,O
discontinuous,10252,O
cubic,10252,O
phases,10252,O
",",10252,O
but,10252,O
an,10252,O
extended,10252,O
",",10252,O
isotropic,10252,O
micellar,10252,O
solution,10252,O
phase,10252,O
.,10252,O
In,10253,O
addition,10253,O
",",10253,O
choline,10253,B-CHEMICAL
octanoate,10253,I-CHEMICAL
is,10253,O
at,10253,O
the,10253,O
limit,10253,O
between,10253,O
a,10253,O
surfactant,10253,O
and,10253,O
a,10253,O
hydrotrope,10253,O
.,10253,O
The,10254,O
double,10254,O
bond,10254,O
in,10254,O
choline,10254,B-CHEMICAL
oleate,10254,I-CHEMICAL
leads,10254,O
also,10254,O
to,10254,O
a,10254,O
better,10254,O
solubility,10254,O
in,10254,O
water,10254,O
and,10254,O
a,10254,O
decrease,10254,O
of,10254,O
the,10254,O
solubilization,10254,O
temperature,10254,O
.,10254,O
It,10255,O
also,10255,O
influences,10255,O
the,10255,O
Gaussian,10255,O
curvature,10255,O
of,10255,O
the,10255,O
aggregates,10255,O
which,10255,O
results,10255,O
in,10255,O
a,10255,O
loss,10255,O
of,10255,O
discontinuous,10255,O
cubic,10255,O
phases,10255,O
in,10255,O
the,10255,O
binary,10255,O
phase,10255,O
diagram,10255,O
.,10255,O
The,10256,O
different,10256,O
lyotropic,10256,O
mesophases,10256,O
were,10256,O
identified,10256,O
by,10256,O
the,10256,O
penetration,10256,O
scan,10256,O
technique,10256,O
with,10256,O
polarizing,10256,O
light,10256,O
microscope,10256,O
and,10256,O
visual,10256,O
observations,10256,O
.,10256,O
To,10257,O
clarify,10257,O
the,10257,O
structural,10257,O
behavior,10257,O
small,10257,O
(,10257,O
SAXS,10257,O
),10257,O
and,10257,O
wide,10257,O
(,10257,O
WAXS,10257,O
),10257,O
angle,10257,O
X-ray,10257,O
scattering,10257,O
were,10257,O
performed,10257,O
.,10257,O
To,10258,O
further,10258,O
characterize,10258,O
the,10258,O
extended,10258,O
",",10258,O
isotropic,10258,O
micellar,10258,O
solution,10258,O
phase,10258,O
in,10258,O
the,10258,O
binary,10258,O
phase,10258,O
diagram,10258,O
of,10258,O
choline,10258,B-CHEMICAL
octanoate,10258,I-CHEMICAL
viscosity,10258,O
and,10258,O
conductivity,10258,O
measurements,10258,O
were,10258,O
also,10258,O
carried,10258,O
out,10258,O
.,10258,O
Loss,10259,O
of,10259,O
Kruppel-like,10259,B-GENE-Y
Factor,10259,I-GENE-Y
3,10259,I-GENE-Y
(,10259,O
KLF3/BKLF,10259,B-GENE-Y
),10259,O
leads,10259,O
to,10259,O
upregulation,10259,O
of,10259,O
the,10259,O
insulin-sensitizing,10259,B-GENE-Y
factor,10259,I-GENE-Y
adipolin,10259,I-GENE-Y
(,10259,O
FAM132A/CTRP12/C1qdc2,10259,B-GENE-Y
),10259,O
.,10259,O
Krüppel-like,10260,B-GENE-Y
Factor,10260,I-GENE-Y
3,10260,I-GENE-Y
(,10260,O
KLF3,10260,B-GENE-Y
),10260,O
is,10260,O
a,10260,O
transcriptional,10260,O
regulator,10260,O
that,10260,O
we,10260,O
have,10260,O
shown,10260,O
to,10260,O
be,10260,O
involved,10260,O
in,10260,O
the,10260,O
regulation,10260,O
of,10260,O
adipogenesis,10260,O
in,10260,O
vitro,10260,O
.,10260,O
Here,10261,O
we,10261,O
report,10261,O
that,10261,O
KLF3,10261,B-GENE-Y
null,10261,O
mice,10261,O
are,10261,O
lean,10261,O
and,10261,O
protected,10261,O
from,10261,O
diet-induced,10261,O
obesity,10261,O
and,10261,O
glucose,10261,B-CHEMICAL
intolerance,10261,O
.,10261,O
On,10262,O
a,10262,O
chow,10262,O
diet,10262,O
",",10262,O
plasma,10262,O
levels,10262,O
of,10262,O
leptin,10262,B-GENE-Y
are,10262,O
decreased,10262,O
",",10262,O
and,10262,O
adiponectin,10262,B-GENE-Y
is,10262,O
increased,10262,O
.,10262,O
Despite,10263,O
significant,10263,O
reductions,10263,O
in,10263,O
body,10263,O
weight,10263,O
and,10263,O
adiposity,10263,O
",",10263,O
wildtype,10263,O
and,10263,O
knockout,10263,O
animals,10263,O
show,10263,O
equivalent,10263,O
energy,10263,O
intake,10263,O
",",10263,O
expenditure,10263,O
and,10263,O
excretion,10263,O
.,10263,O
To,10264,O
investigate,10264,O
the,10264,O
molecular,10264,O
events,10264,O
underlying,10264,O
these,10264,O
observations,10264,O
",",10264,O
we,10264,O
used,10264,O
microarray,10264,O
analysis,10264,O
to,10264,O
compare,10264,O
gene,10264,O
expression,10264,O
in,10264,O
Klf3,10264,B-GENE-Y
(,10264,O
+/+,10264,O
),10264,O
and,10264,O
Klf3,10264,B-GENE-Y
(,10264,O
-/-,10264,O
),10264,O
tissues,10264,O
.,10264,O
We,10265,O
found,10265,O
that,10265,O
mRNA,10265,O
expression,10265,O
of,10265,O
Fam132a,10265,B-GENE-Y
",",10265,O
which,10265,O
encodes,10265,O
a,10265,O
newly,10265,O
identified,10265,O
insulin-sensitizing,10265,B-GENE-N
adipokine,10265,B-GENE-N
",",10265,O
adipolin,10265,B-GENE-Y
",",10265,O
is,10265,O
significantly,10265,O
upregulated,10265,O
in,10265,O
the,10265,O
absence,10265,O
of,10265,O
KLF3,10265,B-GENE-Y
.,10265,O
We,10266,O
confirmed,10266,O
that,10266,O
KLF3,10266,B-GENE-Y
binds,10266,O
the,10266,O
Fam132a,10266,B-GENE-N
promoter,10266,I-GENE-N
in,10266,O
vitro,10266,O
and,10266,O
in,10266,O
vivo,10266,O
and,10266,O
that,10266,O
this,10266,O
leads,10266,O
to,10266,O
repression,10266,O
of,10266,O
promoter,10266,O
activity,10266,O
.,10266,O
Further,10267,O
",",10267,O
plasma,10267,O
adipolin,10267,B-GENE-Y
levels,10267,O
were,10267,O
significantly,10267,O
increased,10267,O
in,10267,O
Klf3,10267,B-GENE-Y
(,10267,O
-/-,10267,O
),10267,O
mice,10267,O
compared,10267,O
to,10267,O
wild-type,10267,O
littermates,10267,O
.,10267,O
Boosting,10268,O
levels,10268,O
of,10268,O
adipolin,10268,B-GENE-Y
via,10268,O
targeting,10268,O
of,10268,O
KLF3,10268,B-GENE-Y
offers,10268,O
a,10268,O
novel,10268,O
potential,10268,O
therapeutic,10268,O
strategy,10268,O
for,10268,O
the,10268,O
treatment,10268,O
of,10268,O
insulin,10268,B-GENE-N
resistance,10268,O
.,10268,O
Salicylate,10269,B-CHEMICAL
pre-treatment,10269,O
attenuates,10269,O
intensity,10269,O
of,10269,O
bronchial,10269,O
and,10269,O
nasal,10269,O
symptoms,10269,O
precipitated,10269,O
by,10269,O
aspirin,10269,B-CHEMICAL
in,10269,O
aspirin-intolerant,10269,B-CHEMICAL
patients,10269,O
.,10269,O
Aspirin,10270,B-CHEMICAL
(,10270,O
ASA,10270,B-CHEMICAL
),10270,O
and,10270,O
other,10270,O
non-steroidal,10270,O
anti-inflammatory,10270,O
drugs,10270,O
",",10270,O
which,10270,O
are,10270,O
cyclooxygenase,10270,B-GENE-N
(,10270,O
COX,10270,B-GENE-N
),10270,O
inhibitors,10270,O
",",10270,O
precipitate,10270,O
asthmatic,10270,O
attacks,10270,O
in,10270,O
ASA-intolerant,10270,B-CHEMICAL
patients,10270,O
",",10270,O
while,10270,O
sodium,10270,B-CHEMICAL
salicylate,10270,I-CHEMICAL
",",10270,O
hardly,10270,O
active,10270,O
on,10270,O
COX,10270,B-GENE-N
by,10270,O
itself,10270,O
",",10270,O
is,10270,O
well,10270,O
tolerated,10270,O
by,10270,O
these,10270,O
patients,10270,O
.,10270,O
However,10271,O
",",10271,O
salicylate,10271,B-CHEMICAL
moiety,10271,O
appears,10271,O
to,10271,O
interfere,10271,O
with,10271,O
aspirin,10271,B-CHEMICAL
inhibitory,10271,O
action,10271,O
on,10271,O
platelets,10271,O
and,10271,O
vascular,10271,O
COX,10271,B-GENE-N
.,10271,O
Such,10272,O
interaction,10272,O
",",10272,O
if,10272,O
present,10272,O
at,10272,O
the,10272,O
level,10272,O
of,10272,O
respiratory,10272,O
tract,10272,O
",",10272,O
may,10272,O
be,10272,O
of,10272,O
interest,10272,O
to,10272,O
pathogenesis,10272,O
of,10272,O
ASA-induced,10272,B-CHEMICAL
asthma,10272,O
.,10272,O
We,10273,O
performed,10273,O
a,10273,O
double-blind,10273,O
",",10273,O
placebo-controlled,10273,O
",",10273,O
randomized,10273,O
cross-over,10273,O
study,10273,O
on,10273,O
the,10273,O
effect,10273,O
of,10273,O
choline,10273,B-CHEMICAL
magnesium,10273,I-CHEMICAL
trisalicylate,10273,I-CHEMICAL
(,10273,O
CMT,10273,B-CHEMICAL
",",10273,O
trilisate,10273,B-CHEMICAL
),10273,O
pre-treatment,10273,O
on,10273,O
ASA-induced,10273,B-CHEMICAL
adverse,10273,O
reactions,10273,O
in,10273,O
nine,10273,O
patients,10273,O
.,10273,O
Pulmonary,10274,O
function,10274,O
tests,10274,O
",",10274,O
nasal,10274,O
symptoms,10274,O
score,10274,O
",",10274,O
PNIF,10274,O
and,10274,O
serum,10274,O
salicylate,10274,B-CHEMICAL
levels,10274,O
were,10274,O
monitored,10274,O
following,10274,O
challenges,10274,O
with,10274,O
threshold,10274,O
doses,10274,O
of,10274,O
ASA,10274,B-CHEMICAL
.,10274,O
Trilisate,10275,B-CHEMICAL
administered,10275,O
at,10275,O
a,10275,O
dose,10275,O
of,10275,O
3000,10275,O
mg,10275,O
daily,10275,O
for,10275,O
3,10275,O
days,10275,O
",",10275,O
offered,10275,O
a,10275,O
moderate,10275,O
protection,10275,O
against,10275,O
ASA-induced,10275,B-CHEMICAL
symptoms,10275,O
;,10275,O
it,10275,O
diminished,10275,O
the,10275,O
severity,10275,O
and/or,10275,O
delayed,10275,O
the,10275,O
appearance,10275,O
of,10275,O
FEV1,10275,O
fall,10275,O
.,10275,O
Maximal,10276,O
decreases,10276,O
in,10276,O
FEV1,10276,O
as,10276,O
well,10276,O
as,10276,O
reaction,10276,O
intensity,10276,O
indexes,10276,O
were,10276,O
significantly,10276,O
lower,10276,O
(,10276,O
P,10276,O
less,10276,O
than,10276,O
0.02,10276,O
and,10276,O
P,10276,O
less,10276,O
than,10276,O
0.002,10276,O
",",10276,O
respectively,10276,O
),10276,O
after,10276,O
trilisate,10276,B-CHEMICAL
pre-treatment,10276,O
as,10276,O
compared,10276,O
to,10276,O
placebo,10276,O
.,10276,O
Trilisate,10277,B-CHEMICAL
also,10277,O
attenuated,10277,O
nasal,10277,O
symptoms,10277,O
in,10277,O
three,10277,O
out,10277,O
of,10277,O
five,10277,O
patients,10277,O
.,10277,O
Although,10278,O
the,10278,O
precise,10278,O
mechanism,10278,O
of,10278,O
the,10278,O
protective,10278,O
action,10278,O
of,10278,O
trilisate,10278,B-CHEMICAL
is,10278,O
unknown,10278,O
",",10278,O
our,10278,O
data,10278,O
support,10278,O
the,10278,O
possibility,10278,O
of,10278,O
interaction,10278,O
between,10278,O
salicylate,10278,B-CHEMICAL
and,10278,O
ASA,10278,B-CHEMICAL
on,10278,O
cyclo-oxygenase,10278,B-GENE-N
locus,10278,O
in,10278,O
the,10278,O
respiratory,10278,O
tract,10278,O
in,10278,O
ASA-intolerant,10278,B-CHEMICAL
patients,10278,O
.,10278,O
Minocycline,10279,B-CHEMICAL
inhibits,10279,O
cytochrome,10279,B-GENE-Y
c,10279,I-GENE-Y
release,10279,O
and,10279,O
delays,10279,O
progression,10279,O
of,10279,O
amyotrophic,10279,O
lateral,10279,O
sclerosis,10279,O
in,10279,O
mice,10279,O
.,10279,O
Minocycline,10280,B-CHEMICAL
mediates,10280,O
neuroprotection,10280,O
in,10280,O
experimental,10280,O
models,10280,O
of,10280,O
neurodegeneration,10280,O
.,10280,O
It,10281,O
inhibits,10281,O
the,10281,O
activity,10281,O
of,10281,O
caspase-1,10281,B-GENE-Y
",",10281,O
caspase-3,10281,B-GENE-Y
",",10281,O
inducible,10281,B-GENE-Y
form,10281,I-GENE-Y
of,10281,I-GENE-Y
nitric,10281,I-GENE-Y
oxide,10281,I-GENE-Y
synthetase,10281,I-GENE-Y
(,10281,O
iNOS,10281,B-GENE-Y
),10281,O
and,10281,O
p38,10281,B-GENE-N
mitogen-activated,10281,B-GENE-N
protein,10281,I-GENE-N
kinase,10281,I-GENE-N
(,10281,O
MAPK,10281,B-GENE-N
),10281,O
.,10281,O
Although,10282,O
minocycline,10282,B-CHEMICAL
does,10282,O
not,10282,O
directly,10282,O
inhibit,10282,O
these,10282,O
enzymes,10282,O
",",10282,O
the,10282,O
effects,10282,O
may,10282,O
result,10282,O
from,10282,O
interference,10282,O
with,10282,O
upstream,10282,O
mechanisms,10282,O
resulting,10282,O
in,10282,O
their,10282,O
secondary,10282,O
activation,10282,O
.,10282,O
Because,10283,O
the,10283,O
above-mentioned,10283,O
factors,10283,O
are,10283,O
important,10283,O
in,10283,O
amyotrophic,10283,O
lateral,10283,O
sclerosis,10283,O
(,10283,O
ALS,10283,O
),10283,O
",",10283,O
we,10283,O
tested,10283,O
minocycline,10283,B-CHEMICAL
in,10283,O
mice,10283,O
with,10283,O
ALS,10283,O
.,10283,O
Here,10284,O
we,10284,O
report,10284,O
that,10284,O
minocycline,10284,B-CHEMICAL
delays,10284,O
disease,10284,O
onset,10284,O
and,10284,O
extends,10284,O
survival,10284,O
in,10284,O
ALS,10284,O
mice,10284,O
.,10284,O
Given,10285,O
the,10285,O
broad,10285,O
efficacy,10285,O
of,10285,O
minocycline,10285,B-CHEMICAL
",",10285,O
understanding,10285,O
its,10285,O
mechanisms,10285,O
of,10285,O
action,10285,O
is,10285,O
of,10285,O
great,10285,O
importance,10285,O
.,10285,O
We,10286,O
find,10286,O
that,10286,O
minocycline,10286,B-CHEMICAL
inhibits,10286,O
mitochondrial,10286,O
permeability-transition-mediated,10286,O
cytochrome,10286,B-GENE-Y
c,10286,I-GENE-Y
release,10286,O
.,10286,O
Minocycline-mediated,10287,B-CHEMICAL
inhibition,10287,O
of,10287,O
cytochrome,10287,B-GENE-Y
c,10287,I-GENE-Y
release,10287,O
is,10287,O
demonstrated,10287,O
in,10287,O
vivo,10287,O
",",10287,O
in,10287,O
cells,10287,O
",",10287,O
and,10287,O
in,10287,O
isolated,10287,O
mitochondria,10287,O
.,10287,O
Understanding,10288,O
the,10288,O
mechanism,10288,O
of,10288,O
action,10288,O
of,10288,O
minocycline,10288,B-CHEMICAL
will,10288,O
assist,10288,O
in,10288,O
the,10288,O
development,10288,O
and,10288,O
testing,10288,O
of,10288,O
more,10288,O
powerful,10288,O
and,10288,O
effective,10288,O
analogues,10288,O
.,10288,O
Because,10289,O
of,10289,O
the,10289,O
safety,10289,O
record,10289,O
of,10289,O
minocycline,10289,B-CHEMICAL
",",10289,O
and,10289,O
its,10289,O
ability,10289,O
to,10289,O
penetrate,10289,O
the,10289,O
blood-brain,10289,O
barrier,10289,O
",",10289,O
this,10289,O
drug,10289,O
may,10289,O
be,10289,O
a,10289,O
novel,10289,O
therapy,10289,O
for,10289,O
ALS,10289,O
.,10289,O
Use,10290,O
of,10290,O
the,10290,O
Combination,10290,O
Index,10290,O
to,10290,O
determine,10290,O
interactions,10290,O
between,10290,O
plant-derived,10290,O
phenolic,10290,B-CHEMICAL
acids,10290,I-CHEMICAL
on,10290,O
hepatotoxicity,10290,O
endpoints,10290,O
in,10290,O
human,10290,O
and,10290,O
rat,10290,O
hepatoma,10290,O
cells,10290,O
.,10290,O
The,10291,O
beneficial,10291,O
or,10291,O
adverse,10291,O
effects,10291,O
of,10291,O
isolated,10291,O
phytochemicals,10291,O
are,10291,O
not,10291,O
always,10291,O
concordant,10291,O
with,10291,O
effects,10291,O
of,10291,O
the,10291,O
botanical,10291,O
dietary,10291,O
supplements,10291,O
from,10291,O
which,10291,O
they,10291,O
were,10291,O
derived,10291,O
.,10291,O
This,10292,O
disparity,10292,O
could,10292,O
be,10292,O
due,10292,O
to,10292,O
interactions,10292,O
between,10292,O
the,10292,O
various,10292,O
phytochemicals,10292,O
present,10292,O
in,10292,O
the,10292,O
whole,10292,O
plant,10292,O
.,10292,O
The,10293,O
phenolic,10293,B-CHEMICAL
acids,10293,I-CHEMICAL
",",10293,O
rosmarinic,10293,B-CHEMICAL
acid,10293,I-CHEMICAL
(,10293,O
RA,10293,O
),10293,O
",",10293,O
caffeic,10293,B-CHEMICAL
acid,10293,I-CHEMICAL
(,10293,O
CA,10293,O
),10293,O
and,10293,O
ferulic,10293,B-CHEMICAL
acid,10293,I-CHEMICAL
(,10293,O
FA,10293,O
),10293,O
are,10293,O
widely,10293,O
present,10293,O
in,10293,O
foods,10293,O
and,10293,O
dietary,10293,O
supplements,10293,O
",",10293,O
and,10293,O
they,10293,O
are,10293,O
assumed,10293,O
to,10293,O
exert,10293,O
various,10293,O
beneficial,10293,O
biological,10293,O
effects,10293,O
.,10293,O
However,10294,O
",",10294,O
there,10294,O
is,10294,O
little,10294,O
data,10294,O
on,10294,O
the,10294,O
potential,10294,O
biological,10294,O
interactions,10294,O
of,10294,O
these,10294,O
three,10294,O
phenolic,10294,B-CHEMICAL
acids,10294,I-CHEMICAL
which,10294,O
commonly,10294,O
occur,10294,O
together,10294,O
and,10294,O
are,10294,O
linked,10294,O
metabolically,10294,O
.,10294,O
In,10295,O
the,10295,O
present,10295,O
study,10295,O
",",10295,O
liver,10295,O
toxicity,10295,O
of,10295,O
the,10295,O
three,10295,O
phenolic,10295,B-CHEMICAL
acids,10295,I-CHEMICAL
was,10295,O
assessed,10295,O
on,10295,O
the,10295,O
three,10295,O
compounds,10295,O
singly,10295,O
and,10295,O
in,10295,O
various,10295,O
binary,10295,O
and,10295,O
one,10295,O
ternary,10295,O
combinations,10295,O
.,10295,O
A,10296,O
series,10296,O
of,10296,O
in,10296,O
vitro,10296,O
endpoints,10296,O
relevant,10296,O
to,10296,O
liver,10296,O
toxicity,10296,O
were,10296,O
evaluated,10296,O
in,10296,O
both,10296,O
a,10296,O
human,10296,O
(,10296,O
HepG2/C3A,10296,O
),10296,O
and,10296,O
rat,10296,O
(,10296,O
MH1C1,10296,O
),10296,O
hepatocyte,10296,O
cell,10296,O
line,10296,O
.,10296,O
The,10297,O
Combination,10297,O
Index,10297,O
(,10297,O
CI,10297,O
),10297,O
was,10297,O
calculated,10297,O
for,10297,O
each,10297,O
endpoint,10297,O
from,10297,O
both,10297,O
the,10297,O
concentration,10297,O
responses,10297,O
of,10297,O
the,10297,O
single,10297,O
compounds,10297,O
and,10297,O
the,10297,O
responses,10297,O
of,10297,O
the,10297,O
various,10297,O
binary,10297,O
and,10297,O
ternary,10297,O
mixtures,10297,O
.,10297,O
Both,10298,O
synergistic,10298,O
and,10298,O
antagonistic,10298,O
interactions,10298,O
were,10298,O
observed,10298,O
for,10298,O
some,10298,O
endpoints,10298,O
and,10298,O
some,10298,O
combinations,10298,O
of,10298,O
test,10298,O
agents,10298,O
.,10298,O
Interactions,10299,O
were,10299,O
most,10299,O
prevalent,10299,O
in,10299,O
measures,10299,O
of,10299,O
oxidative,10299,O
stress,10299,O
and,10299,O
cytochrome,10299,B-GENE-N
P450,10299,I-GENE-N
activities,10299,O
in,10299,O
both,10299,O
cell,10299,O
types,10299,O
.,10299,O
There,10300,O
was,10300,O
only,10300,O
a,10300,O
53,10300,O
%,10300,O
concordance,10300,O
between,10300,O
the,10300,O
rat,10300,O
and,10300,O
human,10300,O
cells,10300,O
which,10300,O
may,10300,O
be,10300,O
suggestive,10300,O
of,10300,O
species,10300,O
differences,10300,O
.,10300,O
The,10301,O
data,10301,O
suggest,10301,O
an,10301,O
approach,10301,O
for,10301,O
better,10301,O
characterizing,10301,O
the,10301,O
beneficial,10301,O
or,10301,O
adverse,10301,O
effects,10301,O
of,10301,O
complex,10301,O
botanical,10301,O
products,10301,O
through,10301,O
evaluation,10301,O
of,10301,O
interactions,10301,O
between,10301,O
individual,10301,O
phytochemical,10301,O
components,10301,O
.,10301,O
Heterogeneous,10302,O
expression,10302,O
and,10302,O
polymorphic,10302,O
genotype,10302,O
of,10302,O
glutathione,10302,B-GENE-N
S-transferases,10302,I-GENE-N
in,10302,O
human,10302,O
lung,10302,O
.,10302,O
BACKGROUND,10303,O
:,10303,O
Glutathione,10303,B-GENE-N
S-transferases,10303,I-GENE-N
(,10303,O
GSTs,10303,B-GENE-N
),10303,O
are,10303,O
involved,10303,O
in,10303,O
the,10303,O
detoxification,10303,O
of,10303,O
xenobiotics,10303,O
by,10303,O
conjugation,10303,O
with,10303,O
glutathione,10303,B-CHEMICAL
.,10303,O
One,10304,O
of,10304,O
the,10304,O
mu,10304,O
class,10304,O
genes,10304,O
of,10304,O
this,10304,O
superfamily,10304,O
of,10304,O
enzymes,10304,O
",",10304,O
GSTM1,10304,B-GENE-Y
",",10304,O
is,10304,O
polymorphic,10304,O
because,10304,O
of,10304,O
a,10304,O
partial,10304,O
gene,10304,O
deletion,10304,O
.,10304,O
This,10305,O
results,10305,O
in,10305,O
a,10305,O
failure,10305,O
to,10305,O
express,10305,O
GSTM1,10305,B-GENE-Y
in,10305,O
approximately,10305,O
50,10305,O
%,10305,O
of,10305,O
individuals,10305,O
.,10305,O
Several,10306,O
studies,10306,O
have,10306,O
linked,10306,O
GSTM1,10306,B-GENE-Y
null,10306,O
status,10306,O
to,10306,O
an,10306,O
increased,10306,O
risk,10306,O
of,10306,O
lung,10306,O
carcinoma,10306,O
.,10306,O
This,10307,O
study,10307,O
investigated,10307,O
the,10307,O
expression,10307,O
and,10307,O
distribution,10307,O
of,10307,O
GST,10307,B-GENE-N
isoenzymes,10307,O
in,10307,O
human,10307,O
lung,10307,O
",",10307,O
and,10307,O
developed,10307,O
a,10307,O
polymerase,10307,O
chain,10307,O
reaction,10307,O
(,10307,O
PCR,10307,O
),10307,O
assay,10307,O
which,10307,O
would,10307,O
allow,10307,O
genotyping,10307,O
of,10307,O
archival,10307,O
",",10307,O
paraffin,10307,O
embedded,10307,O
lung,10307,O
tissue,10307,O
.,10307,O
METHODS,10308,O
:,10308,O
Distribution,10308,O
was,10308,O
examined,10308,O
using,10308,O
a,10308,O
panel,10308,O
of,10308,O
polyclonal,10308,O
anti-GST,10308,O
antibodies,10308,O
for,10308,O
immunohistochemistry,10308,O
in,10308,O
normal,10308,O
tissue,10308,O
of,10308,O
21,10308,O
tumour-bearing,10308,O
lungs,10308,O
.,10308,O
DNA,10309,O
for,10309,O
PCR,10309,O
was,10309,O
extracted,10309,O
from,10309,O
paraffin,10309,O
blocks,10309,O
and,10309,O
a,10309,O
control,10309,O
group,10309,O
of,10309,O
350,10309,O
blood,10309,O
lysates,10309,O
.,10309,O
As,10310,O
a,10310,O
positive,10310,O
control,10310,O
each,10310,O
assay,10310,O
amplified,10310,O
part,10310,O
of,10310,O
GSTM4,10310,B-GENE-Y
",",10310,O
a,10310,O
mu,10310,O
class,10310,O
gene,10310,O
which,10310,O
is,10310,O
not,10310,O
polymorphic,10310,O
but,10310,O
which,10310,O
shows,10310,O
strong,10310,O
sequence,10310,O
homology,10310,O
to,10310,O
GSTM1,10310,B-GENE-Y
.,10310,O
The,10311,O
presence,10311,O
of,10311,O
GST,10311,B-GENE-N
in,10311,O
bronchoalveolar,10311,O
lavage,10311,O
fluid,10311,O
was,10311,O
sought,10311,O
by,10311,O
Western,10311,O
analysis,10311,O
.,10311,O
RESULTS,10312,O
:,10312,O
Proximal,10312,O
airways,10312,O
contained,10312,O
pi,10312,B-GENE-Y
class,10312,I-GENE-Y
GST,10312,I-GENE-Y
",",10312,O
alpha,10312,B-GENE-N
class,10312,I-GENE-N
GST,10312,I-GENE-N
",",10312,O
and,10312,O
mu,10312,B-GENE-N
class,10312,I-GENE-N
GST,10312,I-GENE-N
with,10312,O
expression,10312,O
concentrated,10312,O
in,10312,O
the,10312,O
brush,10312,O
border,10312,O
.,10312,O
In,10313,O
distal,10313,O
airspaces,10313,O
no,10313,O
alpha,10313,B-GENE-N
GST,10313,I-GENE-N
was,10313,O
expressed,10313,O
but,10313,O
pi,10313,B-GENE-Y
GST,10313,I-GENE-Y
and,10313,O
mu,10313,B-GENE-N
GST,10313,I-GENE-N
were,10313,O
present,10313,O
in,10313,O
alveolar,10313,O
cells,10313,O
and,10313,O
also,10313,O
alveolar,10313,O
macrophages,10313,O
.,10313,O
Pi,10314,B-GENE-Y
class,10314,I-GENE-Y
GST,10314,I-GENE-Y
was,10314,O
present,10314,O
in,10314,O
bronchoalveolar,10314,O
lavage,10314,O
fluid,10314,O
.,10314,O
The,10315,O
PCR,10315,O
assay,10315,O
enabled,10315,O
genotypic,10315,O
determination,10315,O
using,10315,O
DNA,10315,O
extracted,10315,O
from,10315,O
archival,10315,O
material,10315,O
.,10315,O
Of,10316,O
the,10316,O
control,10316,O
group,10316,O
56,10316,O
%,10316,O
were,10316,O
null,10316,O
at,10316,O
the,10316,O
GSTM1,10316,B-GENE-Y
locus,10316,O
.,10316,O
CONCLUSIONS,10317,O
:,10317,O
The,10317,O
distribution,10317,O
of,10317,O
GST,10317,B-GENE-N
isoenzymes,10317,O
in,10317,O
the,10317,O
lung,10317,O
is,10317,O
heterogeneous,10317,O
with,10317,O
an,10317,O
apparent,10317,O
decrease,10317,O
in,10317,O
GST,10317,B-GENE-N
in,10317,O
distal,10317,O
lung,10317,O
.,10317,O
Since,10318,O
GSTM1,10318,B-GENE-Y
status,10318,O
has,10318,O
already,10318,O
been,10318,O
associated,10318,O
with,10318,O
susceptibility,10318,O
to,10318,O
disease,10318,O
",",10318,O
the,10318,O
PCR,10318,O
assay,10318,O
developed,10318,O
will,10318,O
allow,10318,O
further,10318,O
studies,10318,O
of,10318,O
the,10318,O
relation,10318,O
between,10318,O
genotype,10318,O
and,10318,O
structural,10318,O
disorders,10318,O
in,10318,O
the,10318,O
lung,10318,O
using,10318,O
archival,10318,O
pathological,10318,O
material,10318,O
.,10318,O
Monoacylglycerol,10319,B-GENE-Y
lipase,10319,I-GENE-Y
inhibition-induced,10319,O
changes,10319,O
in,10319,O
plasma,10319,O
corticosterone,10319,B-CHEMICAL
levels,10319,O
",",10319,O
anxiety,10319,O
and,10319,O
locomotor,10319,O
activity,10319,O
in,10319,O
male,10319,O
CD1,10319,O
mice,10319,O
.,10319,O
The,10320,O
hypothalamus-pituitary-adrenal-axis,10320,O
is,10320,O
strongly,10320,O
controlled,10320,O
by,10320,O
the,10320,O
endocannabinoid,10320,O
system,10320,O
.,10320,O
The,10321,O
specific,10321,O
impact,10321,O
of,10321,O
enhanced,10321,O
2-arachidonoylglycerol,10321,B-CHEMICAL
signaling,10321,O
on,10321,O
corticosterone,10321,B-CHEMICAL
plasma,10321,O
levels,10321,O
",",10321,O
however,10321,O
",",10321,O
was,10321,O
not,10321,O
investigated,10321,O
so,10321,O
far,10321,O
.,10321,O
Here,10322,O
we,10322,O
studied,10322,O
the,10322,O
effects,10322,O
of,10322,O
the,10322,O
recently,10322,O
developed,10322,O
monoacylglycerol,10322,B-GENE-Y
lipase,10322,I-GENE-Y
inhibitor,10322,O
JZL184,10322,B-CHEMICAL
on,10322,O
basal,10322,O
and,10322,O
stress-induced,10322,O
corticosterone,10322,B-CHEMICAL
levels,10322,O
in,10322,O
male,10322,O
CD1,10322,O
mice,10322,O
",",10322,O
and,10322,O
found,10322,O
that,10322,O
this,10322,O
compound,10322,O
dramatically,10322,O
increased,10322,O
basal,10322,O
levels,10322,O
without,10322,O
affecting,10322,O
stress,10322,O
responses,10322,O
.,10322,O
Since,10323,O
acute,10323,O
changes,10323,O
in,10323,O
corticosterone,10323,B-CHEMICAL
levels,10323,O
can,10323,O
affect,10323,O
behavior,10323,O
",",10323,O
JZL184,10323,B-CHEMICAL
was,10323,O
administered,10323,O
concurrently,10323,O
with,10323,O
the,10323,O
corticosterone,10323,B-CHEMICAL
synthesis,10323,O
inhibitor,10323,O
metyrapone,10323,B-CHEMICAL
",",10323,O
to,10323,O
investigate,10323,O
whether,10323,O
the,10323,O
previously,10323,O
shown,10323,O
behavioral,10323,O
effects,10323,O
of,10323,O
JZL184,10323,B-CHEMICAL
are,10323,O
dependent,10323,O
on,10323,O
corticosterone,10323,B-CHEMICAL
.,10323,O
We,10324,O
found,10324,O
that,10324,O
in,10324,O
the,10324,O
elevated,10324,O
plus-maze,10324,O
",",10324,O
the,10324,O
effects,10324,O
of,10324,O
JZL184,10324,B-CHEMICAL
on,10324,O
``,10324,O
classical,10324,O
'',10324,O
anxiety-related,10324,O
measures,10324,O
were,10324,O
abolished,10324,O
by,10324,O
corticosterone,10324,B-CHEMICAL
synthesis,10324,O
blockade,10324,O
.,10324,O
By,10325,O
contrast,10325,O
",",10325,O
effects,10325,O
on,10325,O
the,10325,O
``,10325,O
ethological,10325,O
'',10325,O
measures,10325,O
of,10325,O
anxiety,10325,O
(,10325,O
i.e,10325,O
.,10325,O
risk,10326,O
assessment,10326,O
),10326,O
were,10326,O
not,10326,O
affected,10326,O
by,10326,O
metyrapone,10326,B-CHEMICAL
.,10326,O
In,10327,O
the,10327,O
open-field,10327,O
",",10327,O
the,10327,O
locomotion-enhancing,10327,O
effects,10327,O
of,10327,O
the,10327,O
compound,10327,O
were,10327,O
not,10327,O
changed,10327,O
either,10327,O
.,10327,O
These,10328,O
findings,10328,O
show,10328,O
that,10328,O
monoacylglycerol,10328,B-GENE-Y
lipase,10328,I-GENE-Y
inhibition,10328,O
dramatically,10328,O
increases,10328,O
basal,10328,O
levels,10328,O
of,10328,O
corticosterone,10328,B-CHEMICAL
.,10328,O
This,10329,O
endocrine,10329,O
effect,10329,O
partly,10329,O
affects,10329,O
the,10329,O
anxiolytic,10329,O
",",10329,O
but,10329,O
not,10329,O
the,10329,O
locomotion-enhancing,10329,O
effects,10329,O
of,10329,O
monoacylglycerol,10329,B-GENE-Y
lipase,10329,I-GENE-Y
blockade,10329,O
.,10329,O
Induction,10330,O
of,10330,O
the,10330,O
liver,10330,O
cancer-down-regulated,10330,O
long,10330,O
noncoding,10330,O
RNA,10330,O
uc002mbe.2,10330,B-GENE-Y
mediates,10330,O
trichostatin-induced,10330,B-CHEMICAL
apoptosis,10330,O
of,10330,O
liver,10330,O
cancer,10330,O
cells,10330,O
.,10330,O
Differential,10331,O
expression,10331,O
of,10331,O
long,10331,O
non-coding,10331,O
RNAs,10331,O
(,10331,O
lncRNAs,10331,O
),10331,O
plays,10331,O
critical,10331,O
roles,10331,O
in,10331,O
hepatocarcinogenesis,10331,O
.,10331,O
Considerable,10332,O
attention,10332,O
has,10332,O
focused,10332,O
on,10332,O
the,10332,O
antitumor,10332,O
effect,10332,O
of,10332,O
histone,10332,B-GENE-N
deacetylase,10332,I-GENE-N
inhibitor,10332,O
(,10332,O
Trichostatin,10332,B-CHEMICAL
A,10332,I-CHEMICAL
",",10332,O
TSA,10332,B-CHEMICAL
),10332,O
as,10332,O
well,10332,O
as,10332,O
the,10332,O
coding,10332,O
gene,10332,O
expression-induced,10332,O
apoptosis,10332,O
of,10332,O
cancer,10332,O
cells,10332,O
.,10332,O
However,10333,O
",",10333,O
it,10333,O
is,10333,O
not,10333,O
known,10333,O
whether,10333,O
lncRNA,10333,O
has,10333,O
a,10333,O
role,10333,O
in,10333,O
TSA-induced,10333,B-CHEMICAL
apoptosis,10333,O
of,10333,O
human,10333,O
hepatocellular,10333,O
carcinoma,10333,O
(,10333,O
HCC,10333,O
),10333,O
cells,10333,O
.,10333,O
The,10334,O
global,10334,O
expression,10334,O
of,10334,O
lncRNAs,10334,O
and,10334,O
coding,10334,O
genes,10334,O
was,10334,O
analyzed,10334,O
with,10334,O
the,10334,O
Human,10334,O
LncRNA,10334,O
Array,10334,O
V2.0,10334,O
after,10334,O
24h,10334,O
treatment,10334,O
.,10334,O
Expression,10335,O
was,10335,O
verified,10335,O
in,10335,O
cell,10335,O
lines,10335,O
and,10335,O
tissues,10335,O
by,10335,O
quantitative,10335,O
real-time,10335,O
PCR,10335,O
.,10335,O
The,10336,O
data,10336,O
showed,10336,O
that,10336,O
4.8,10336,O
%,10336,O
(,10336,O
959,10336,O
),10336,O
of,10336,O
lncRNA,10336,O
and,10336,O
6.1,10336,O
%,10336,O
(,10336,O
1849,10336,O
),10336,O
of,10336,O
protein,10336,O
coding,10336,O
gene,10336,O
were,10336,O
significantly,10336,O
differentially,10336,O
expressed,10336,O
.,10336,O
The,10337,O
differential,10337,O
expressions,10337,O
of,10337,O
lncRNA,10337,O
and,10337,O
protein,10337,O
coding,10337,O
genes,10337,O
had,10337,O
distinguishable,10337,O
hierarchical,10337,O
clustering,10337,O
expression,10337,O
profiling,10337,O
pattern,10337,O
.,10337,O
Among,10338,O
these,10338,O
differentially,10338,O
expressed,10338,O
lncRNAs,10338,O
",",10338,O
the,10338,O
greatest,10338,O
change,10338,O
was,10338,O
noted,10338,O
for,10338,O
uc002mbe.2,10338,B-GENE-Y
",",10338,O
which,10338,O
had,10338,O
more,10338,O
than,10338,O
300,10338,O
folds,10338,O
induction,10338,O
upon,10338,O
TSA,10338,B-CHEMICAL
treatment,10338,O
.,10338,O
TSA,10339,B-CHEMICAL
selectively,10339,O
induced,10339,O
uc002mbe.2,10339,B-GENE-Y
in,10339,O
four,10339,O
studied,10339,O
HCC,10339,O
cell,10339,O
lines,10339,O
.,10339,O
Compared,10340,O
with,10340,O
normal,10340,O
human,10340,O
hepatocytes,10340,O
and,10340,O
adjacent,10340,O
noncancerous,10340,O
tissues,10340,O
",",10340,O
uc002mbe.2,10340,B-GENE-Y
expression,10340,O
level,10340,O
was,10340,O
significantly,10340,O
lower,10340,O
in,10340,O
the,10340,O
HCC,10340,O
cell,10340,O
lines,10340,O
and,10340,O
liver,10340,O
cancer,10340,O
tissues,10340,O
.,10340,O
The,10341,O
TSA-induced,10341,B-CHEMICAL
uc002mbe.2,10341,B-GENE-Y
expression,10341,O
was,10341,O
positively,10341,O
correlated,10341,O
with,10341,O
the,10341,O
apoptotic,10341,O
effect,10341,O
of,10341,O
TSA,10341,B-CHEMICAL
in,10341,O
HCC,10341,O
cells,10341,O
.,10341,O
In,10342,O
addition,10342,O
",",10342,O
knockdown,10342,O
the,10342,O
expression,10342,O
of,10342,O
uc002mbe.2,10342,B-GENE-Y
significantly,10342,O
reduced,10342,O
TSA-induced,10342,B-CHEMICAL
apoptosis,10342,O
of,10342,O
Huh7cells,10342,O
.,10342,O
Therefore,10343,O
",",10343,O
TSA-induced,10343,B-CHEMICAL
apoptosis,10343,O
of,10343,O
HCC,10343,O
cells,10343,O
is,10343,O
uc002mbe.2,10343,B-GENE-Y
dependent,10343,O
and,10343,O
reduced,10343,O
expression,10343,O
of,10343,O
uc002mbe.2,10343,B-GENE-Y
may,10343,O
be,10343,O
associated,10343,O
with,10343,O
liver,10343,O
carcinogenesis,10343,O
.,10343,O
The,10344,O
mannose,10344,B-CHEMICAL
6-phosphate-binding,10344,O
sites,10344,O
of,10344,O
M6P/IGF2R,10344,B-CHEMICAL
determine,10344,O
its,10344,O
capacity,10344,O
to,10344,O
suppress,10344,O
matrix,10344,O
invasion,10344,O
by,10344,O
squamous,10344,O
cell,10344,O
carcinoma,10344,O
cells,10344,O
.,10344,O
The,10345,O
M6P,10345,B-CHEMICAL
(,10345,O
mannose,10345,B-CHEMICAL
6-phosphate,10345,I-CHEMICAL
),10345,O
/IGF2R,10345,O
(,10345,O
insulin-like,10345,B-GENE-Y
growth,10345,I-GENE-Y
factor,10345,I-GENE-Y
II,10345,I-GENE-Y
receptor,10345,I-GENE-Y
),10345,O
interacts,10345,O
with,10345,O
a,10345,O
variety,10345,O
of,10345,O
factors,10345,O
that,10345,O
impinge,10345,O
on,10345,O
tumour,10345,O
invasion,10345,O
and,10345,O
metastasis,10345,O
.,10345,O
It,10346,O
has,10346,O
been,10346,O
shown,10346,O
that,10346,O
expression,10346,O
of,10346,O
wild-type,10346,O
M6P/IGF2R,10346,B-CHEMICAL
reduces,10346,O
the,10346,O
tumorigenic,10346,O
and,10346,O
invasive,10346,O
properties,10346,O
of,10346,O
receptor-deficient,10346,O
SCC-VII,10346,O
squamous,10346,O
cell,10346,O
carcinoma,10346,O
cells,10346,O
.,10346,O
We,10347,O
have,10347,O
now,10347,O
used,10347,O
mutant,10347,O
forms,10347,O
of,10347,O
M6P/IGF2R,10347,B-CHEMICAL
to,10347,O
assess,10347,O
the,10347,O
relevance,10347,O
of,10347,O
the,10347,O
different,10347,O
ligand-binding,10347,O
sites,10347,O
of,10347,O
the,10347,O
receptor,10347,O
for,10347,O
its,10347,O
biological,10347,O
activities,10347,O
in,10347,O
this,10347,O
cellular,10347,O
system,10347,O
.,10347,O
The,10348,O
results,10348,O
of,10348,O
the,10348,O
present,10348,O
study,10348,O
demonstrate,10348,O
that,10348,O
M6P/IGF2R,10348,B-CHEMICAL
does,10348,O
not,10348,O
require,10348,O
a,10348,O
functional,10348,O
binding,10348,O
site,10348,O
for,10348,O
insulin-like,10348,B-GENE-Y
growth,10348,I-GENE-Y
factor,10348,I-GENE-Y
II,10348,I-GENE-Y
for,10348,O
inhibition,10348,O
of,10348,O
anchorage-independent,10348,O
growth,10348,O
and,10348,O
matrix,10348,O
invasion,10348,O
by,10348,O
SCC-VII,10348,O
cells,10348,O
.,10348,O
In,10349,O
contrast,10349,O
",",10349,O
the,10349,O
simultaneous,10349,O
mutation,10349,O
of,10349,O
both,10349,O
M6P-binding,10349,B-CHEMICAL
sites,10349,O
is,10349,O
sufficient,10349,O
to,10349,O
impair,10349,O
all,10349,O
cellular,10349,O
functions,10349,O
of,10349,O
the,10349,O
receptor,10349,O
tested,10349,O
.,10349,O
These,10350,O
findings,10350,O
highlight,10350,O
that,10350,O
the,10350,O
interaction,10350,O
between,10350,O
M6P/IGF2R,10350,B-CHEMICAL
and,10350,O
M6P-modified,10350,B-CHEMICAL
ligands,10350,O
is,10350,O
not,10350,O
only,10350,O
important,10350,O
for,10350,O
intracellular,10350,O
accumulation,10350,O
of,10350,O
lysosomal,10350,O
enzymes,10350,O
and,10350,O
formation,10350,O
of,10350,O
dense,10350,O
lysosomes,10350,O
",",10350,O
but,10350,O
is,10350,O
also,10350,O
crucial,10350,O
for,10350,O
the,10350,O
ability,10350,O
of,10350,O
the,10350,O
receptor,10350,O
to,10350,O
suppress,10350,O
SCC-VII,10350,O
growth,10350,O
and,10350,O
invasion,10350,O
.,10350,O
The,10351,O
present,10351,O
study,10351,O
also,10351,O
shows,10351,O
that,10351,O
some,10351,O
of,10351,O
the,10351,O
biological,10351,O
activities,10351,O
of,10351,O
M6P/IGF2R,10351,B-CHEMICAL
in,10351,O
SCC-VII,10351,O
cells,10351,O
strongly,10351,O
depend,10351,O
on,10351,O
a,10351,O
functional,10351,O
M6P-binding,10351,B-CHEMICAL
site,10351,O
within,10351,O
domain,10351,O
3,10351,O
",",10351,O
thus,10351,O
providing,10351,O
further,10351,O
evidence,10351,O
for,10351,O
the,10351,O
non-redundant,10351,O
cellular,10351,O
functions,10351,O
of,10351,O
the,10351,O
individual,10351,O
carbohydrate-binding,10351,B-CHEMICAL
domains,10351,O
of,10351,O
the,10351,O
receptor,10351,O
.,10351,O
Orlistat,10352,B-CHEMICAL
",",10352,O
a,10352,O
new,10352,O
lipase,10352,B-GENE-N
inhibitor,10352,O
for,10352,O
the,10352,O
management,10352,O
of,10352,O
obesity,10352,O
.,10352,O
Orlistat,10353,B-CHEMICAL
",",10353,O
a,10353,O
weight-loss,10353,O
agent,10353,O
with,10353,O
a,10353,O
novel,10353,O
mechanism,10353,O
of,10353,O
action,10353,O
",",10353,O
recently,10353,O
was,10353,O
approved,10353,O
by,10353,O
the,10353,O
Food,10353,O
and,10353,O
Drug,10353,O
Administration,10353,O
for,10353,O
the,10353,O
treatment,10353,O
of,10353,O
obesity,10353,O
.,10353,O
It,10354,O
inhibits,10354,O
gastric,10354,B-GENE-N
and,10354,I-GENE-N
pancreatic,10354,I-GENE-N
lipases,10354,I-GENE-N
in,10354,O
the,10354,O
lumen,10354,O
of,10354,O
the,10354,O
gastrointestinal,10354,O
tract,10354,O
to,10354,O
decrease,10354,O
systemic,10354,O
absorption,10354,O
of,10354,O
dietary,10354,O
fat,10354,O
.,10354,O
In,10355,O
several,10355,O
trials,10355,O
lasting,10355,O
up,10355,O
to,10355,O
2,10355,O
years,10355,O
",",10355,O
orlistat,10355,B-CHEMICAL
was,10355,O
more,10355,O
effective,10355,O
than,10355,O
diet,10355,O
alone,10355,O
for,10355,O
weight,10355,O
reduction,10355,O
and,10355,O
maintenance,10355,O
of,10355,O
lost,10355,O
weight,10355,O
.,10355,O
Orlistat,10356,B-CHEMICAL
treatment,10356,O
also,10356,O
results,10356,O
in,10356,O
modest,10356,O
improvements,10356,O
in,10356,O
total,10356,O
cholesterol,10356,B-CHEMICAL
",",10356,O
low-density,10356,B-GENE-N
lipoprotein,10356,I-GENE-N
",",10356,O
blood,10356,O
pressure,10356,O
",",10356,O
and,10356,O
fasting,10356,O
glucose,10356,B-CHEMICAL
and,10356,O
insulin,10356,B-GENE-Y
concentrations,10356,O
.,10356,O
The,10357,O
major,10357,O
adverse,10357,O
effects,10357,O
are,10357,O
gastrointestinal,10357,O
",",10357,O
usually,10357,O
occur,10357,O
early,10357,O
in,10357,O
therapy,10357,O
",",10357,O
and,10357,O
tend,10357,O
to,10357,O
decrease,10357,O
with,10357,O
continued,10357,O
treatment,10357,O
.,10357,O
Because,10358,O
orlistat,10358,B-CHEMICAL
may,10358,O
decrease,10358,O
the,10358,O
absorption,10358,O
of,10358,O
fat-soluble,10358,O
vitamins,10358,B-CHEMICAL
",",10358,O
a,10358,O
standard,10358,O
multiple-vitamin,10358,O
supplement,10358,O
is,10358,O
recommended,10358,O
daily,10358,O
during,10358,O
therapy,10358,O
to,10358,O
prevent,10358,O
abnormalities,10358,O
in,10358,O
vitamin,10358,B-CHEMICAL
serum,10358,O
concentrations,10358,O
.,10358,O
The,10359,O
potential,10359,O
for,10359,O
severe,10359,O
gastrointestinal,10359,O
discomfort,10359,O
and,10359,O
the,10359,O
modest,10359,O
degree,10359,O
of,10359,O
weight,10359,O
loss,10359,O
may,10359,O
limit,10359,O
the,10359,O
agent,10359,O
's,10359,O
clinical,10359,O
utility,10359,O
.,10359,O
Its,10360,O
long-term,10360,O
safety,10360,O
and,10360,O
effectiveness,10360,O
for,10360,O
weight,10360,O
maintenance,10360,O
",",10360,O
cost-effectiveness,10360,O
of,10360,O
treatment,10360,O
",",10360,O
and,10360,O
overall,10360,O
reduction,10360,O
in,10360,O
obesity-related,10360,O
morbidity,10360,O
and,10360,O
mortality,10360,O
remain,10360,O
to,10360,O
be,10360,O
determined,10360,O
.,10360,O
The,10361,O
Atrial,10361,B-GENE-Y
Natriuretic,10361,I-GENE-Y
Peptide,10361,I-GENE-Y
Genetic,10361,O
Variant,10361,O
Rs5068,10361,B-GENE-Y
Is,10361,O
Associated,10361,O
With,10361,O
a,10361,O
Favorable,10361,O
Cardiometabolic,10361,O
Phenotype,10361,O
in,10361,O
a,10361,O
Mediterranean,10361,O
Population,10361,O
.,10361,O
OBJECTIVEWe,10362,O
hypothesized,10362,O
that,10362,O
the,10362,O
minor,10362,O
allele,10362,O
of,10362,O
the,10362,O
atrial,10362,B-GENE-Y
natriuretic,10362,I-GENE-Y
peptide,10362,I-GENE-Y
(,10362,O
ANP,10362,B-GENE-Y
),10362,O
genetic,10362,O
variant,10362,O
rs5068,10362,B-GENE-Y
is,10362,O
associated,10362,O
with,10362,O
a,10362,O
favorable,10362,O
cardiometabolic,10362,O
phenotype,10362,O
in,10362,O
a,10362,O
general,10362,O
Mediterranean,10362,O
population.RESEARCH,10362,O
DESIGN,10362,O
AND,10362,O
METHODSWe,10362,O
genotyped,10362,O
a,10362,O
random,10362,O
sample,10362,O
of,10362,O
the,10362,O
residents,10362,O
of,10362,O
Ventimiglia,10362,O
di,10362,O
Sicilia,10362,O
",",10362,O
Sicily,10362,O
",",10362,O
for,10362,O
rs5068.RESULTSGenotype,10362,B-GENE-Y
frequencies,10362,O
of,10362,O
rs5068,10362,B-GENE-Y
are,10362,O
AA,10362,O
",",10362,O
93.5,10362,O
%,10362,O
;,10362,O
AG,10362,O
",",10362,O
6.4,10362,O
%,10362,O
;,10362,O
and,10362,O
GG,10362,O
",",10362,O
0.1,10362,O
%,10362,O
.,10362,O
All,10363,O
subsequent,10363,O
analyses,10363,O
are,10363,O
AA,10363,O
versus,10363,O
AG+GG,10363,O
.,10363,O
After,10364,O
adjusting,10364,O
for,10364,O
age,10364,O
and,10364,O
sex,10364,O
",",10364,O
the,10364,O
minor,10364,O
G,10364,O
allele,10364,O
is,10364,O
associated,10364,O
with,10364,O
lower,10364,O
BMI,10364,O
(,10364,O
estimate,10364,O
[,10364,O
SE,10364,O
],10364,O
:,10364,O
-1.7,10364,O
kg/m,10364,O
(,10364,O
2,10364,O
),10364,O
[,10364,O
0.8,10364,O
],10364,O
",",10364,O
P,10364,O
=,10364,O
0.04,10364,O
),10364,O
.,10364,O
In,10365,O
the,10365,O
AG+GG,10365,O
group,10365,O
",",10365,O
males,10365,O
with,10365,O
HDL,10365,B-GENE-N
cholesterol,10365,B-CHEMICAL
levels,10365,O
<,10365,O
40,10365,O
mg/dL,10365,O
are,10365,O
less,10365,O
frequent,10365,O
(,10365,O
P,10365,O
=,10365,O
0.05,10365,O
),10365,O
and,10365,O
obesity,10365,O
tends,10365,O
to,10365,O
be,10365,O
less,10365,O
prevalent,10365,O
(,10365,O
P,10365,O
=,10365,O
0.07,10365,O
),10365,O
.,10365,O
Importantly,10366,O
",",10366,O
the,10366,O
G,10366,O
allele,10366,O
is,10366,O
associated,10366,O
with,10366,O
a,10366,O
lower,10366,O
prevalence,10366,O
of,10366,O
metabolic,10366,O
syndrome,10366,O
(,10366,O
P,10366,O
=,10366,O
0.02,10366,O
),10366,O
.,10366,O
After,10367,O
adjusting,10367,O
for,10367,O
BMI,10367,O
",",10367,O
the,10367,O
above,10367,O
associations,10367,O
were,10367,O
attenuated,10367,O
.,10367,O
Independently,10368,O
of,10368,O
age,10368,O
",",10368,O
sex,10368,O
",",10368,O
and,10368,O
BMI,10368,O
",",10368,O
the,10368,O
minor,10368,O
allele,10368,O
is,10368,O
also,10368,O
associated,10368,O
with,10368,O
lower,10368,O
systolic,10368,O
blood,10368,O
pressure,10368,O
(,10368,O
-6.0,10368,O
mmHg,10368,O
[,10368,O
2.5,10368,O
],10368,O
",",10368,O
P,10368,O
=,10368,O
0.02,10368,O
),10368,O
and,10368,O
lower,10368,O
prevalence,10368,O
of,10368,O
hypertension,10368,O
(,10368,O
odds,10368,O
ratio,10368,O
0.41,10368,O
[,10368,O
95,10368,O
%,10368,O
CI,10368,O
0.20-0.83,10368,O
],10368,O
",",10368,O
P,10368,O
=,10368,O
0.01,10368,O
),10368,O
.CONCLUSIONSThe,10368,O
association,10368,O
between,10368,O
the,10368,O
minor,10368,O
allele,10368,O
of,10368,O
rs5068,10368,B-GENE-Y
and,10368,O
a,10368,O
favorable,10368,O
cardiometabolic,10368,O
phenotype,10368,O
that,10368,O
we,10368,O
previously,10368,O
reported,10368,O
in,10368,O
a,10368,O
U.S.,10368,O
population,10368,O
is,10368,O
now,10368,O
replicated,10368,O
in,10368,O
a,10368,O
Mediterranean,10368,O
population,10368,O
in,10368,O
which,10368,O
the,10368,O
G,10368,O
allele,10368,O
of,10368,O
rs5068,10368,B-GENE-Y
is,10368,O
associated,10368,O
with,10368,O
lower,10368,O
blood,10368,O
pressure,10368,O
",",10368,O
BMI,10368,O
",",10368,O
and,10368,O
prevalence,10368,O
of,10368,O
hypertension,10368,O
and,10368,O
metabolic,10368,O
syndrome,10368,O
.,10368,O
These,10369,O
findings,10369,O
may,10369,O
lead,10369,O
to,10369,O
a,10369,O
diagnostic,10369,O
strategy,10369,O
to,10369,O
assess,10369,O
cardiometabolic,10369,O
risk,10369,O
and,10369,O
lay,10369,O
the,10369,O
foundation,10369,O
for,10369,O
the,10369,O
future,10369,O
development,10369,O
of,10369,O
an,10369,O
ANP,10369,B-GENE-Y
or,10369,O
ANP-like,10369,B-GENE-Y
therapy,10369,O
for,10369,O
metabolic,10369,O
syndrome,10369,O
.,10369,O
The,10370,O
microsomal/peroxidase,10370,B-GENE-Y
antigen,10370,I-GENE-Y
:,10370,O
modulation,10370,O
of,10370,O
its,10370,O
expression,10370,O
in,10370,O
thyroid,10370,O
cells,10370,O
.,10370,O
Evidence,10371,O
has,10371,O
accumulated,10371,O
in,10371,O
the,10371,O
last,10371,O
few,10371,O
years,10371,O
that,10371,O
the,10371,O
expression,10371,O
of,10371,O
the,10371,O
microsomal/peroxidase,10371,B-GENE-Y
antigen,10371,I-GENE-Y
(,10371,O
M/TPO-Ag,10371,B-GENE-Y
),10371,O
in,10371,O
thyroid,10371,O
cells,10371,O
is,10371,O
induced,10371,O
by,10371,O
TSH,10371,B-GENE-N
",",10371,O
through,10371,O
pathways,10371,O
which,10371,O
involve,10371,O
intracellular,10371,O
cAMP,10371,B-CHEMICAL
accumulation,10371,O
and,10371,O
protein,10371,O
synthesis,10371,O
.,10371,O
These,10372,O
data,10372,O
have,10372,O
been,10372,O
found,10372,O
true,10372,O
in,10372,O
any,10372,O
thyroid,10372,O
system,10372,O
studied,10372,O
so,10372,O
far,10372,O
",",10372,O
both,10372,O
in,10372,O
terms,10372,O
of,10372,O
immunologic,10372,O
and,10372,O
enzymatic,10372,O
activity,10372,O
of,10372,O
TPO,10372,B-GENE-Y
.,10372,O
TSH,10373,B-GENE-N
and,10373,O
cAMP,10373,B-CHEMICAL
also,10373,O
increase,10373,O
the,10373,O
levels,10373,O
of,10373,O
the,10373,O
specific,10373,O
mRNA,10373,O
for,10373,O
TPO,10373,B-GENE-Y
in,10373,O
thyroid,10373,O
cells,10373,O
from,10373,O
different,10373,O
species,10373,O
.,10373,O
Whether,10374,O
this,10374,O
phenomenon,10374,O
is,10374,O
due,10374,O
to,10374,O
a,10374,O
direct,10374,O
transcriptional,10374,O
regulation,10374,O
of,10374,O
the,10374,O
TPO,10374,B-GENE-Y
gene,10374,O
",",10374,O
as,10374,O
shown,10374,O
in,10374,O
dog,10374,O
thyroid,10374,O
cells,10374,O
",",10374,O
or,10374,O
to,10374,O
posttranscriptional,10374,O
effects,10374,O
",",10374,O
as,10374,O
it,10374,O
would,10374,O
appear,10374,O
in,10374,O
FRTL-5,10374,O
cells,10374,O
",",10374,O
remains,10374,O
to,10374,O
be,10374,O
clarified,10374,O
by,10374,O
future,10374,O
experiments,10374,O
.,10374,O
Thyroid,10375,B-GENE-N
stimulating,10375,I-GENE-N
antibody,10375,I-GENE-N
(,10375,O
TSAb,10375,B-GENE-N
),10375,O
of,10375,O
Graves,10375,O
',10375,O
disease,10375,O
also,10375,O
stimulates,10375,O
the,10375,O
expression,10375,O
of,10375,O
M/TPO-Ag,10375,B-GENE-Y
.,10375,O
This,10376,O
finding,10376,O
gives,10376,O
further,10376,O
support,10376,O
to,10376,O
the,10376,O
relevance,10376,O
of,10376,O
TSAb,10376,B-GENE-N
in,10376,O
the,10376,O
pathogenesis,10376,O
of,10376,O
hyperthyroidism,10376,O
and,10376,O
explains,10376,O
the,10376,O
well,10376,O
known,10376,O
observation,10376,O
that,10376,O
the,10376,O
``,10376,O
microsomal,10376,O
'',10376,O
antigen,10376,O
is,10376,O
particularly,10376,O
abundant,10376,O
in,10376,O
glands,10376,O
of,10376,O
Graves,10376,O
',10376,O
patients,10376,O
.,10376,O
The,10377,O
modulation,10377,O
of,10377,O
M/TPO-Ag,10377,B-GENE-Y
surface,10377,O
expression,10377,O
by,10377,O
TSH,10377,B-GENE-N
can,10377,O
explain,10377,O
the,10377,O
decrease,10377,O
of,10377,O
circulating,10377,O
anti-MAb,10377,O
observed,10377,O
during,10377,O
L-thyroxine,10377,B-CHEMICAL
therapy,10377,O
in,10377,O
hypothyroid,10377,O
patients,10377,O
with,10377,O
Hashimoto,10377,O
's,10377,O
thyroiditis,10377,O
.,10377,O
Other,10378,O
agents,10378,O
",",10378,O
such,10378,O
as,10378,O
methimazole,10378,B-CHEMICAL
and,10378,O
sodium,10378,B-CHEMICAL
iodide,10378,I-CHEMICAL
",",10378,O
which,10378,O
influence,10378,O
thyroid,10378,O
cell,10378,O
function,10378,O
",",10378,O
do,10378,O
not,10378,O
directly,10378,O
interfere,10378,O
with,10378,O
the,10378,O
expression,10378,O
of,10378,O
M/TPO-Ag,10378,B-GENE-Y
.,10378,O
Cytokines,10379,B-GENE-N
",",10379,O
such,10379,O
as,10379,O
gamma-interferon,10379,B-GENE-Y
",",10379,O
interleukin-1,10379,B-GENE-N
",",10379,O
and,10379,O
interleukin-6,10379,B-GENE-Y
have,10379,O
been,10379,O
shown,10379,O
to,10379,O
inhibit,10379,O
the,10379,O
TSH-induced,10379,B-GENE-N
increase,10379,O
of,10379,O
TPO,10379,B-GENE-Y
mRNA,10379,O
",",10379,O
but,10379,O
further,10379,O
investigations,10379,O
are,10379,O
required,10379,O
to,10379,O
elucidate,10379,O
the,10379,O
exact,10379,O
role,10379,O
of,10379,O
cytokines,10379,B-GENE-N
in,10379,O
the,10379,O
regulation,10379,O
of,10379,O
M/TPO-Ag,10379,B-GENE-Y
expression,10379,O
.,10379,O
Structural,10380,O
and,10380,O
functional,10380,O
characterization,10380,O
of,10380,O
a,10380,O
phosphatase,10380,B-GENE-N
domain,10380,I-GENE-N
within,10380,O
yeast,10380,O
general,10380,O
transcription,10380,O
factor,10380,O
TFIIIC,10380,B-GENE-Y
.,10380,O
Saccharomyces,10381,B-GENE-Y
cerevisiae,10381,I-GENE-Y
τ55,10381,I-GENE-Y
",",10381,O
a,10381,O
subunit,10381,O
of,10381,O
the,10381,O
RNA,10381,B-GENE-N
polymerase,10381,I-GENE-N
III-specific,10381,O
general,10381,O
transcription,10381,O
factor,10381,O
TFIIIC,10381,B-GENE-Y
",",10381,O
comprises,10381,O
an,10381,O
N-terminal,10381,B-GENE-N
histidine,10381,I-GENE-N
phosphatase,10381,I-GENE-N
domain,10381,I-GENE-N
(,10381,O
τ55-HPD,10381,B-GENE-Y
),10381,O
whose,10381,O
catalytic,10381,O
activity,10381,O
and,10381,O
cellular,10381,O
function,10381,O
is,10381,O
poorly,10381,O
understood,10381,O
.,10381,O
We,10382,O
solved,10382,O
the,10382,O
crystal,10382,O
structures,10382,O
of,10382,O
τ55-HPD,10382,B-GENE-Y
and,10382,O
its,10382,O
closely,10382,O
related,10382,O
paralogue,10382,O
Huf,10382,B-GENE-N
and,10382,O
used,10382,O
in,10382,O
silico,10382,O
docking,10382,O
methods,10382,O
to,10382,O
identify,10382,O
phospho-serine,10382,B-CHEMICAL
and,10382,O
phospho-tyrosine,10382,B-CHEMICAL
containing,10382,O
peptides,10382,O
as,10382,O
possible,10382,O
substrates,10382,O
that,10382,O
were,10382,O
subsequently,10382,O
validated,10382,O
using,10382,O
in,10382,O
vitro,10382,O
phosphatase,10382,B-GENE-N
assays,10382,O
.,10382,O
A,10383,O
comparative,10383,O
phospho-proteomic,10383,B-CHEMICAL
study,10383,O
identified,10383,O
additional,10383,O
phosphopeptides,10383,O
as,10383,O
possible,10383,O
targets,10383,O
",",10383,O
which,10383,O
show,10383,O
the,10383,O
involvement,10383,O
of,10383,O
these,10383,O
two,10383,O
phosphatases,10383,B-GENE-N
in,10383,O
the,10383,O
regulation,10383,O
of,10383,O
a,10383,O
variety,10383,O
of,10383,O
cellular,10383,O
functions,10383,O
.,10383,O
Our,10384,O
results,10384,O
identify,10384,O
τ55-HPD,10384,B-GENE-Y
and,10384,O
Huf,10384,O
as,10384,O
bona,10384,O
fide,10384,O
protein,10384,B-GENE-N
phosphatases,10384,I-GENE-N
",",10384,O
characterize,10384,O
their,10384,O
substrate,10384,O
specificities,10384,O
and,10384,O
provide,10384,O
a,10384,O
small,10384,O
set,10384,O
of,10384,O
regulated,10384,O
phosphosite,10384,O
targets,10384,O
in,10384,O
vivo,10384,O
.,10384,O
A,10385,O
novel,10385,O
benzo,10385,B-CHEMICAL
[,10385,I-CHEMICAL
d,10385,I-CHEMICAL
],10385,I-CHEMICAL
imidazole,10385,I-CHEMICAL
derivate,10385,O
prevents,10385,O
the,10385,O
development,10385,O
of,10385,O
dextran,10385,O
sulfate,10385,O
sodium-induced,10385,B-CHEMICAL
murine,10385,O
experimental,10385,O
colitis,10385,O
via,10385,O
inhibition,10385,O
of,10385,O
NLRP3,10385,B-GENE-Y
inflammasome,10385,O
.,10385,O
NLRP3,10386,B-GENE-Y
inflammasome,10386,O
has,10386,O
been,10386,O
reported,10386,O
to,10386,O
be,10386,O
associated,10386,O
with,10386,O
various,10386,O
kinds,10386,O
of,10386,O
immunological,10386,O
diseases,10386,O
including,10386,O
colitis,10386,O
.,10386,O
However,10387,O
",",10387,O
there,10387,O
are,10387,O
few,10387,O
drug,10387,O
candidates,10387,O
targeting,10387,O
inflammasomes,10387,O
for,10387,O
the,10387,O
treatment,10387,O
of,10387,O
colitis,10387,O
.,10387,O
In,10388,O
the,10388,O
present,10388,O
study,10388,O
",",10388,O
we,10388,O
aimed,10388,O
at,10388,O
examining,10388,O
the,10388,O
effect,10388,O
of,10388,O
1-ethyl-5-methyl-2-phenyl-1H-benzo,10388,B-CHEMICAL
[,10388,I-CHEMICAL
d,10388,I-CHEMICAL
],10388,I-CHEMICAL
imidazole,10388,I-CHEMICAL
",",10388,O
a,10388,O
synthetic,10388,O
small,10388,O
molecular,10388,O
compound,10388,O
also,10388,O
named,10388,O
Fc11a-2,10388,B-CHEMICAL
",",10388,O
for,10388,O
the,10388,O
treatment,10388,O
of,10388,O
dextran,10388,O
sulfate,10388,B-CHEMICAL
sodium,10388,B-CHEMICAL
(,10388,O
DSS,10388,O
),10388,O
-induced,10388,O
experimental,10388,O
colitis,10388,O
in,10388,O
mice,10388,O
via,10388,O
targeting,10388,O
NLRP3,10388,B-GENE-Y
inflammasome,10388,O
.,10388,O
Treatment,10389,O
with,10389,O
Fc11a-2,10389,O
dose-dependently,10389,O
attenuated,10389,O
the,10389,O
loss,10389,O
of,10389,O
body,10389,O
weight,10389,O
and,10389,O
shortening,10389,O
of,10389,O
colon,10389,O
length,10389,O
induced,10389,O
by,10389,O
DSS,10389,O
.,10389,O
In,10390,O
addition,10390,O
",",10390,O
the,10390,O
disease,10390,O
activity,10390,O
index,10390,O
",",10390,O
histopathologic,10390,O
scores,10390,O
and,10390,O
myeloperoxidase,10390,B-GENE-N
activity,10390,O
were,10390,O
also,10390,O
significantly,10390,O
reduced,10390,O
by,10390,O
Fc11a-2,10390,B-CHEMICAL
treatment,10390,O
.,10390,O
Moreover,10391,O
",",10391,O
protein,10391,O
and,10391,O
mRNA,10391,O
levels,10391,O
of,10391,O
DSS-induced,10391,O
proinflammatory,10391,O
cytokines,10391,B-GENE-N
in,10391,O
colon,10391,O
",",10391,O
including,10391,O
TNF-α,10391,B-GENE-Y
",",10391,O
IL-1β,10391,B-GENE-Y
",",10391,O
IL-18,10391,B-GENE-Y
",",10391,O
IL-17A,10391,B-GENE-Y
and,10391,O
IFN-γ,10391,B-GENE-Y
",",10391,O
were,10391,O
markedly,10391,O
suppressed,10391,O
by,10391,O
Fc11a-2,10391,B-CHEMICAL
.,10391,O
Furthermore,10392,O
",",10392,O
a,10392,O
decreased,10392,O
CD11c,10392,O
(,10392,O
+,10392,O
),10392,O
macrophage,10392,O
infiltration,10392,O
in,10392,O
colons,10392,O
and,10392,O
inactivation,10392,O
of,10392,O
caspase-1,10392,B-GENE-Y
in,10392,O
peritoneal,10392,O
macrophages,10392,O
were,10392,O
detected,10392,O
in,10392,O
Fc11a-2-treated,10392,B-CHEMICAL
mice,10392,O
.,10392,O
The,10393,O
mechanism,10393,O
of,10393,O
action,10393,O
of,10393,O
Fc11a-2,10393,B-CHEMICAL
was,10393,O
related,10393,O
to,10393,O
the,10393,O
inhibition,10393,O
of,10393,O
the,10393,O
cleavage,10393,O
of,10393,O
pro-caspase-1,10393,B-GENE-Y
",",10393,O
pro-IL-1β,10393,B-GENE-Y
and,10393,O
pro-IL-18,10393,B-GENE-Y
which,10393,O
in,10393,O
turn,10393,O
suppressed,10393,O
the,10393,O
activation,10393,O
of,10393,O
NLRP3,10393,B-GENE-Y
inflammasome,10393,O
.,10393,O
Taken,10394,O
together,10394,O
",",10394,O
our,10394,O
results,10394,O
demonstrate,10394,O
the,10394,O
ability,10394,O
of,10394,O
Fc11a-2,10394,B-CHEMICAL
to,10394,O
inhibit,10394,O
NLRP3,10394,B-GENE-Y
inflammasome,10394,O
activation,10394,O
and,10394,O
its,10394,O
potential,10394,O
use,10394,O
in,10394,O
the,10394,O
treatment,10394,O
of,10394,O
inflammatory,10394,O
bowel,10394,O
diseases,10394,O
.,10394,O
Methylphenidate,10395,B-CHEMICAL
administration,10395,O
to,10395,O
juvenile,10395,O
rats,10395,O
alters,10395,O
brain,10395,O
areas,10395,O
involved,10395,O
in,10395,O
cognition,10395,O
",",10395,O
motivated,10395,O
behaviors,10395,O
",",10395,O
appetite,10395,O
",",10395,O
and,10395,O
stress,10395,O
.,10395,O
Thousands,10396,O
of,10396,O
children,10396,O
receive,10396,O
methylphenidate,10396,B-CHEMICAL
(,10396,O
MPH,10396,B-CHEMICAL
;,10396,O
Ritalin,10396,B-CHEMICAL
),10396,O
for,10396,O
attention,10396,O
deficit/hyperactivity,10396,O
disorder,10396,O
(,10396,O
ADHD,10396,O
),10396,O
",",10396,O
yet,10396,O
the,10396,O
long-term,10396,O
neurochemical,10396,O
consequences,10396,O
of,10396,O
MPH,10396,B-CHEMICAL
treatment,10396,O
are,10396,O
unknown,10396,O
.,10396,O
To,10397,O
mimic,10397,O
clinical,10397,O
Ritalin,10397,B-CHEMICAL
treatment,10397,O
in,10397,O
children,10397,O
",",10397,O
male,10397,O
rats,10397,O
were,10397,O
injected,10397,O
with,10397,O
MPH,10397,B-CHEMICAL
(,10397,O
5,10397,O
mg/kg,10397,O
),10397,O
or,10397,O
vehicle,10397,O
twice,10397,O
daily,10397,O
from,10397,O
postnatal,10397,O
day,10397,O
7,10397,O
(,10397,O
PND7,10397,O
),10397,O
-PND35,10397,O
.,10397,O
At,10398,O
the,10398,O
end,10398,O
of,10398,O
administration,10398,O
(,10398,O
PND35,10398,O
),10398,O
or,10398,O
in,10398,O
adulthood,10398,O
(,10398,O
PND135,10398,O
),10398,O
",",10398,O
brain,10398,O
sections,10398,O
from,10398,O
littermate,10398,O
pairs,10398,O
were,10398,O
immunocytochemically,10398,O
labeled,10398,O
for,10398,O
neurotransmitters,10398,O
and,10398,O
cytological,10398,O
markers,10398,O
in,10398,O
16,10398,O
regions,10398,O
implicated,10398,O
in,10398,O
MPH,10398,B-CHEMICAL
effects,10398,O
and/or,10398,O
ADHD,10398,O
etiology,10398,O
.,10398,O
At,10399,O
PND35,10399,O
",",10399,O
the,10399,O
medial,10399,O
prefrontal,10399,O
cortex,10399,O
(,10399,O
mPFC,10399,O
),10399,O
of,10399,O
rats,10399,O
given,10399,O
MPH,10399,B-CHEMICAL
showed,10399,O
55,10399,O
%,10399,O
greater,10399,O
immunoreactivity,10399,O
(,10399,O
-ir,10399,O
),10399,O
for,10399,O
the,10399,O
catecholamine,10399,B-CHEMICAL
marker,10399,O
tyrosine,10399,B-GENE-Y
hydroxylase,10399,I-GENE-Y
(,10399,O
TH,10399,B-GENE-Y
),10399,O
",",10399,O
60,10399,O
%,10399,O
more,10399,O
Nissl-stained,10399,O
cells,10399,O
",",10399,O
and,10399,O
40,10399,O
%,10399,O
less,10399,O
norepinephrine,10399,B-GENE-Y
transporter,10399,I-GENE-Y
(,10399,O
NET,10399,B-GENE-Y
),10399,O
-ir,10399,O
density,10399,O
.,10399,O
In,10400,O
hippocampal,10400,O
dentate,10400,O
gyrus,10400,O
",",10400,O
MPH-receiving,10400,B-CHEMICAL
rats,10400,O
showed,10400,O
a,10400,O
51,10400,O
%,10400,O
decrease,10400,O
in,10400,O
NET-ir,10400,B-GENE-Y
density,10400,O
and,10400,O
a,10400,O
61,10400,O
%,10400,O
expanded,10400,O
distribution,10400,O
of,10400,O
the,10400,O
new-cell,10400,O
marker,10400,O
PSA-NCAM,10400,O
(,10400,O
polysialylated,10400,O
form,10400,O
of,10400,O
neural,10400,B-GENE-Y
cell,10400,I-GENE-Y
adhesion,10400,I-GENE-Y
molecule,10400,I-GENE-Y
),10400,O
.,10400,O
In,10401,O
medial,10401,O
striatum,10401,O
",",10401,O
TH-ir,10401,B-GENE-Y
decreased,10401,O
by,10401,O
21,10401,O
%,10401,O
",",10401,O
and,10401,O
in,10401,O
hypothalamus,10401,O
neuropeptide,10401,B-GENE-Y
Y-ir,10401,O
increased,10401,O
by,10401,O
10,10401,O
%,10401,O
in,10401,O
MPH-exposed,10401,B-CHEMICAL
rats,10401,O
.,10401,O
At,10402,O
PND135,10402,O
",",10402,O
MPH-exposed,10402,O
rats,10402,O
exhibited,10402,O
decreased,10402,O
anxiety,10402,O
in,10402,O
the,10402,O
elevated,10402,O
plus-maze,10402,O
and,10402,O
a,10402,O
trend,10402,O
for,10402,O
decreased,10402,O
TH-ir,10402,B-GENE-Y
in,10402,O
the,10402,O
mPFC,10402,O
.,10402,O
Neither,10403,O
PND35,10403,O
nor,10403,O
PND135,10403,O
rats,10403,O
showed,10403,O
major,10403,O
structural,10403,O
differences,10403,O
with,10403,O
MPH,10403,B-CHEMICAL
exposure,10403,O
.,10403,O
These,10404,O
findings,10404,O
suggest,10404,O
that,10404,O
developmental,10404,O
exposure,10404,O
to,10404,O
high,10404,O
therapeutic,10404,O
doses,10404,O
of,10404,O
MPH,10404,B-CHEMICAL
has,10404,O
short-term,10404,O
effects,10404,O
on,10404,O
select,10404,O
neurotransmitters,10404,O
in,10404,O
brain,10404,O
regions,10404,O
involved,10404,O
in,10404,O
motivated,10404,O
behaviors,10404,O
",",10404,O
cognition,10404,O
",",10404,O
appetite,10404,O
",",10404,O
and,10404,O
stress,10404,O
.,10404,O
Although,10405,O
the,10405,O
observed,10405,O
neuroanatomical,10405,O
changes,10405,O
largely,10405,O
resolve,10405,O
with,10405,O
time,10405,O
",",10405,O
chronic,10405,O
modulation,10405,O
of,10405,O
young,10405,O
brains,10405,O
with,10405,O
MPH,10405,B-CHEMICAL
may,10405,O
exert,10405,O
effects,10405,O
on,10405,O
brain,10405,O
neurochemistry,10405,O
that,10405,O
modify,10405,O
some,10405,O
behaviors,10405,O
even,10405,O
in,10405,O
adulthood,10405,O
.,10405,O
